Mammalian Phenotype Ontology Annotations

Mammalian Phenotype Ontology Annotations
Query Results - Summary

16314 genotypes with 53048 annotations displayed of selected term and subterms
Searched Term: immune system phenotype
Allelic Composition (Genetic Background)	Annotated Term	Reference
\1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (C.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan})	abnormal CD8-positive, alpha-beta T cell differentiation	J:93488
	abnormal T cell activation	J:93488
	decreased CD8-positive, alpha-beta T cell number	J:93488
	decreased cytotoxic T cell cytolysis	J:93488
	decreased dendritic cell number	J:93488
	increased neutrophil cell number	J:194800
\1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (B6.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/J)	abnormal NK cell physiology	J:96123
	abnormal NK T cell physiology	J:96123
	decreased circulating interferon-gamma level	J:96123
	decreased circulating interleukin-12 level	J:96123
	decreased dendritic cell number	J:100867, J:113232, J:96123
	decreased interferon-gamma secretion	J:96123
	decreased interleukin-4 secretion	J:96123
	decreased interleukin-12b secretion	J:125611
	immune system phenotype	J:122114, J:96123
	impaired natural killer cell mediated cytotoxicity	J:125611
	sepsis	J:113232
\1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (C.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/J)	abnormal NK cell physiology	J:96123
	decreased circulating interferon-gamma level	J:96123
	decreased circulating interleukin-12 level	J:96123
	decreased dendritic cell number	J:96123
	decreased interferon-gamma secretion	J:96123
	immune system phenotype	J:96123
\1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (involves: C57BL/6 * FVB/N)	abnormal alveolar macrophage morphology	J:137452
	decreased dendritic cell number	J:137452
	decreased interferon-gamma secretion	J:137452
	increased susceptibility to Orthomyxoviridae infection	J:137452
\1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (NOD.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/Jdk)	abnormal professional antigen presenting cell physiology	J:137009
	decreased dendritic cell number	J:137009
	decreased macrophage cell number	J:137009
	decreased NK T cell number	J:137009
	decreased susceptibility to autoimmune diabetes	J:137009
	increased interferon-gamma secretion	J:137009
	increased tumor necrosis factor secretion	J:137009
	insulitis	J:137009
\1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (involves: FVB/N)	abnormal response to infection	J:189122
	decreased gamma-delta T cell number	J:193548
	decreased interleukin-17 secretion	J:193548
	decreased leukocyte cell number	J:193548
	decreased neutrophil cell number	J:193548
	decreased susceptibility to bacterial infection	J:210086
	decreased T cell number	J:193548
\1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (B6.FVB-1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan})	abnormal circulating cytokine level	J:194800
	abnormal susceptibility to infection	J:194800
	decreased dendritic cell number	J:194800
	decreased neutrophil cell number	J:194800
	impaired neutrophil recruitment	J:194800
	increased monocyte cell number	J:194800
	increased neutrophil cell number	J:194800
	increased susceptibility to bacterial infection	J:194800
\1700019D03Rik^{tm1.1(NCOM)Mfgc}/\1700019D03Rik^{tm1.1(NCOM)Mfgc} (C57BL/6N-1700019D03Rik^{tm1.1(NCOM)Mfgc}/Tcp)	enlarged lymph nodes	J:211773
\1700025G04Rik^em1(IMPC)Mbp/\1700025G04Rik^em1(IMPC)Mbp (C57BL/6NCrl-1700025G04Rik^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\1700034E13Rik^em1(IMPC)Mbp/\1700034E13Rik^em1(IMPC)Mbp (C57BL/6NCrl-1700034E13Rik^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\1700067K01Rik^{tm2a(KOMP)Wtsi}/\1700067K01Rik^{tm2a(KOMP)Wtsi} (C57BL/6N-1700067K01Rik^{tm2a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\1700069L16Rik^em1(IMPC)Mbp/\1700069L16Rik^em1(IMPC)Mbp (C57BL/6NCrl-1700069L16Rik^em1(IMPC)Mbp/Mmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\2310022B05Rik^{tm1a(EUCOMM)Hmgu}/\2310022B05Rik^{tm1a(EUCOMM)Hmgu} (C57BL/6N-2310022B05Rik^{tm1a(EUCOMM)Hmgu}/H)	increased B cell number	J:165965
	increased leukocyte cell number	J:165965
\2810408A11Rik^{tm1a(EUCOMM)Wtsi}/\2810408A11Rik^{tm1a(EUCOMM)Wtsi} (C57BL/6N-2810408A11Rik^{tm1a(EUCOMM)Wtsi}/H)	decreased NK cell number	J:165965
	increased CD4-positive, alpha-beta T cell number	J:165965
	increased NK cell number	J:165965
\3425401B19Rik^{em2(IMPC)Ccpcz}/\3425401B19Rik^{em2(IMPC)Ccpcz} (C57BL/6NCrl-3425401B19Rik^{em2(IMPC)Ccpcz}/Ph)	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
\4930444P10Rik^em1(IMPC)Tcp/\4930444P10Rik⁺ (C57BL/6NCrl-4930444P10Rik^em1(IMPC)Tcp/Cmmr)	decreased eosinophil cell number	J:211773
\4931422A03Rik^{tm1b(EUCOMM)Wtsi}/\4931422A03Rik^{tm1b(EUCOMM)Wtsi} (C57BL/6N-4931422A03Rik^{tm1b(EUCOMM)Wtsi}/Bay)	decreased leukocyte cell number	J:211773
\4933434E20Rik^{tm1a(EUCOMM)Wtsi}/\4933434E20Rik^{tm1a(EUCOMM)Wtsi} (C57BL/6N-4933434E20Rik^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
\5730403I07Rik^em8Gpt/\5730403I07Rik^em8Gpt (involves: C57BL/6JGpt)	abnormal regulatory T cell physiology	J:329871
	abnormal T cell number	J:329871
	abnormal T cell physiology	J:329871
	increased inflammatory response	J:329871
	increased interferon-gamma secretion	J:329871
\6430548M08Rik^em1(IMPC)Mbp/\6430548M08Rik^em1(IMPC)Mbp (C57BL/6N-6430548M08Rik^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\9030622O22Rik^em1Eem/\9030622O22Rik⁺ \Foxa2^tm1.1Khk/\Foxa2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	respiratory system inflammation	J:284174
\9030622O22Rik^em1Eem/\9030622O22Rik^em1Eem (involves: C57BL/6 * CD-1)	lung inflammation	J:284174
\9430015G10Rik^tm1Lex/\9430015G10Rik^tm1Lex (B6;129S5-9430015G10Rik^tm1Lex/Mmucd)	decreased CD4-positive, alpha-beta T cell number	J:171883
	increased B cell number	J:171883
\A1cf^{Tg(Myh6-cre/Esr1)1Jmk}/\A1cf⁺ \Tg(Myh6-2A)#Know/0 (involves: BALB/c C57BL/6 * FVB/N)	heart inflammation	J:128060
\A2ml1^em1(IMPC)Tcp/\A2ml1⁺ (C57BL/6N-A2ml1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\A2ml1^em1(IMPC)Tcp/\A2ml1^em1(IMPC)Tcp (C57BL/6N-A2ml1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\A3galt2^tm1.1Hjg/\A3galt2^tm1.1Hjg (involves: 129P2/OlaHsd * BALB/cJ)	immune system phenotype	J:120323
\A4galt^tm1.1Poru/\A4galt^tm1.1Poru \Gla^tm1Kul/\Gla^tm1Kul (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	immune system phenotype	J:189359
\A4gnt^tm1Jnaka/\A4gnt^tm1Jnaka (B6.129S6-A4gnt^tm1Jnaka)	stomach inflammation	J:184485
\A930024E05Rik^em2Zfa/\A930024E05Rik^em2Zfa \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:259392
\A930024E05Rik^em2Zfa/\A930024E05Rik^em2Zfa \Satb1^em1Zfa/\Satb1^em1Zfa \Tg(Rorc-cre)1Litt/0 (involves: C57BL/6 * FVB)	increased susceptibility to bacterial infection	J:259392
	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
\A930024E05Rik^em2Zfa/\A930024E05Rik^em2Zfa \Tg(Rorc-cre)1Litt/0 (involves: C57BL/6 * FVB)	abnormal interleukin secretion	J:259392
	increased susceptibility to bacterial infection	J:259392
	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
\A^tm1Brd/\A^tm1Brd \Ypel4^{tm1a(EUCOMM)Wtsi}/\Ypel4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-A^tm1Brd Ypel4^{tm1a(EUCOMM)Wtsi}/WtsiIeg)	immune system phenotype	J:313842
\A^y/\a \Apoe^tm1Unc/\Apoe^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J * KK/TaJcl)	abnormal inflammatory response	J:177084
	increased monocyte cell number	J:177084
\AA467197^em1Nyam/\AA467197^em1Nyam (C57BL/6J-AA467197^em1Nyam)	abnormal thymus cortex morphology	J:347271
	abnormal thymus medulla morphology	J:347271
	decreased CD4-positive, alpha-beta T cell number	J:347271
	increased IgG level	J:347271
	kidney inflammation	J:347271
	liver inflammation	J:347271
	lung inflammation	J:347271
\AA467197^em1Nyam/\AA467197^em1Nyam (C.B6-AA467197^em1Nyam)	increased susceptibility to autoimmune disorder	J:347271
\Aabpr^NZB/Slc/? (involves: NZB/Slc * NZW/Slc)	increased B cell proliferation	J:87690
\Aadac^em1(IMPC)Mbp/\Aadac^em1(IMPC)Mbp (C57BL/6NCrl-Aadac^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	small thymus	J:211773
\Aadacl4^{em1(IMPC)Ccpcz}/\Aadacl4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Aadacl4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Aars2^{tm1(KOMP)Wtsi}/\Aars2⁺ (C57BL/6N-Aars2^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Aass^em1(IMPC)Tcp/\Aass^em1(IMPC)Tcp (C57BL/6NCrl-Aass^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
\Abat^{tm1c(EUCOMM)Hmgu}/\Abat^{tm1c(EUCOMM)Hmgu} \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)	abnormal CD4-positive T cell differentiation	J:333883
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:333883
	abnormal T-helper 1 cell differentiation	J:333883
	abnormal T-helper 17 cell differentiation	J:333883
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:333883
	decreased T cell proliferation	J:333883
	immune system phenotype	J:333883
\Abca1^tm1Jdm/\Abca1^tm1Jdm (DBA/1LacJ-Abca1^tm1Jdm)	enlarged spleen	J:60210
\Abca1^tm1Jdm/\Abca1^tm1Jdm (DBA/1LacJ-Abca1^tm1Jdm)	impaired macrophage phagocytosis	J:63265
\Abca1^tm1Jdm/\Abca1^tm1Jdm (involves: C57BL/6 * DBA/1LacJ)	abnormal thymus morphology	J:132254
\Abca1^tm1Jdm/\Abca1^tm1Jdm (involves: C57BL/6 * DBA/1LacJ)	impaired macrophage phagocytosis	J:132254
\Abca1^tm1Jdm/\Abca1^tm1Jdm \Abcg1^tm1Dgen/\Abcg1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6 * DBA/1LacJ)	abnormal chemokine secretion	J:130777
	abnormal cytokine secretion	J:130777
\Abca1^tm1Jdm/\Abca1^tm1Jdm \Abcg1^tm1Dgen/\Abcg1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6 * DBA * DBA/1LacJ)	decreased monocyte cell number	J:190966
	increased monocyte cell number	J:190966
	increased neutrophil cell number	J:190966
\Abca1^tm1Jdm/\Abca1^tm1Jdm \Tgm2^tm1Gml/\Tgm2^tm1Gml (involves: C57BL/6 * DBA/1LacJ)	abnormal thymus morphology	J:132254
	impaired macrophage phagocytosis	J:132254
\Abca1^tm1Jp/\Abca1^tm1Jp \Abcg1^tm1Tall/\Abcg1^tm1Tall \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	increased interleukin-17 secretion	J:190966
	increased interleukin-23 secretion	J:190966
\Abca1^tm1Jp/\Abca1^tm1Jp \Abcg1^tm1Tall/\Abcg1^tm1Tall \Tg(Itgax-cre,-EGFP)4097Ach/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J)	increased interleukin-17 secretion	J:190966
	increased interleukin-23 secretion	J:190966
\Abca1^tm1Wpfl/\Abca1^tm1Wpfl (involves: 129P2/OlaHsd * C57BL/6J)	abnormal thymus morphology	J:64390
	glomerulonephritis	J:64390
	uterus inflammation	J:64390
\Abca5^{em1(IMPC)Ccpcz}/\Abca5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Abca5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Abcb1a^mds/\Abcb1a^mds (involves: CF-1)	increased eosinophil cell number	J:64725
\Abcb1a^tm1Bor/\Abcb1a^tm1Bor (FVBTac.129P2-Abcb1a^tm1Bor)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:102640
\Abcb1a^tm1Bor/\Abcb1a^tm1Bor (FVBTac.129P2-Abcb1a^tm1Bor)	decreased gamma-delta intraepithelial T cell number	J:102640
\Abcb1a^tm1Bor/\Abcb1a^tm1Bor (FVB.129P2-Abcb1a^tm1Bor/TacImx)	abnormal lymphocyte physiology	J:51190
	colitis	J:51190
	increased IgA level	J:51190
	increased IgE level	J:51190
	increased IgG1 level	J:51190
	increased IgG2 level	J:51190
	increased IgG2a level	J:51190
	increased IgG2b level	J:51190
	increased IgG3 level	J:51190
	increased IgM level	J:51190
	increased immunoglobulin level	J:51190
	large intestinal inflammation	J:51190
\Abcb1a^tm1Bor/\Abcb1a^tm1Bor \Abcb1b^tm1Bor/\Abcb1b^tm1Bor (FVBTac.129P2-Abcb1b^tm1Bor Abcb1a^tm1Bor)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:102640
	abnormal T cell physiology	J:102640
	decreased gamma-delta intraepithelial T cell number	J:102640
	increased double-positive T cell number	J:102640
	increased interferon-gamma secretion	J:102640
	increased interleukin-2 secretion	J:102640
\Abcb4^em1(IMPC)H/\Abcb4^em1(IMPC)H (C57BL/6NTac-Abcb4^em1(IMPC)H/H)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Abcb4^tm1Bor/\Abcb4^tm1Bor (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))	bile duct inflammation	J:15531, J:21232
	liver inflammation	J:15531
\Abcb4^tm1Bor/\Abcb4^tm1Bor (involves: 129P2/OlaHsd * FVB/N)	bile duct inflammation	J:175015
	liver inflammation	J:175015
\Abcb4^tm1Bor/\Abcb4^tm1Bor (FVB.129P2-Abcb4^tm1Bor/J)	bile duct inflammation	J:105357
\Abcb4^tm1Bor/\Abcb4^tm1Bor (FVB.129P2-Abcb4^tm1Bor/J)	enlarged spleen	J:217802
\Abcb4^tm1Bor/\Abcb4^tm1Bor (involves: 129P2/OlaHsd * BALB/c)	bile duct inflammation	J:168123
\Abcb4^tm1Bor/\Abcb4^tm1Bor (CAnNCrl.12P2(FVB)-Abcb4^tm1Bor)	enlarged spleen	J:217802
\Abcb9^{tm1b(KOMP)Wtsi}/\Abcb9^{tm1b(KOMP)Wtsi} (C57BL/6N-Abcb9^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
\Abcc1^tm1Bor/\Abcc1^tm1Bor (involves: 129P2/OlaHsd * FVB)	abnormal mast cell physiology	J:44110
\Abcc1^tm1Bor/\Abcc1^tm1Bor (involves: 129P2/OlaHsd * FVB)	decreased inflammatory response	J:44110
\Abcc1^tm1Bor/\Abcc1^tm1Bor \Tg(Thy1-APPSw,Thy1-PSEN1L166P)21Jckr/0 (FVB.Cg-Abcc1^tm1Bor Tg(Thy1-APPSw,Thy1-PSEN1L166P)21Jckr)	microgliosis	J:178230
\Abcc2^{tm2b(KOMP)Wtsi}/\Abcc2^{tm2b(KOMP)Wtsi} (C57BL/6N-Abcc2^{tm2b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Abcc4^tm1Kruh/\Abcc4^tm1Kruh (B6.129-Abcc4^tm1Kruh)	abnormal spleen B cell follicle morphology	J:117326
	abnormal spleen red pulp morphology	J:117326
	decreased spleen B cell follicle number	J:117326
	decreased spleen B cell follicle size	J:117326
	increased susceptibility to induced colitis	J:117326
	intestinal inflammation	J:117326
	small intestinal inflammation	J:117326
	small spleen	J:117326
	thymus cortex hypoplasia	J:117326
\Abcc5^em1(IMPC)H/\Abcc5^em1(IMPC)H (C57BL/6N-Abcc5^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Abcc9^em1(IMPC)H/\Abcc9⁺ (C57BL/6N-Abcc9^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
\Abcc9^em1(IMPC)H/\Abcc9⁺ (C57BL/6N-Abcc9^em1(IMPC)H/H)	increased monocyte cell number	J:211773
\Abcc10^tm1Eah/\Abcc10^tm1Eah (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen red pulp morphology	J:172648
	decreased leukocyte cell number	J:172648
	decreased spleen germinal center number	J:172648
	decreased spleen germinal center size	J:172648
	decreased spleen white pulp amount	J:172648
	small spleen	J:172648
	thymus cortex hypoplasia	J:172648
\Abcd1^tm1Kds/Y (involves: 129S4/SvJae * C57BL/6J)	abnormal microglial cell morphology	J:94583
\Abcd1^tm1Kds/Y \Abcd2^tm1Apuj/\Abcd2^tm1Apuj (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)	abnormal microglial cell morphology	J:94583
	increased inflammatory response	J:94583
\Abcd2^tm1Apuj/\Abcd2^tm1Apuj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal microglial cell morphology	J:94583
\Abce1^{tm1.1(KOMP)Vlcg}/\Abce1⁺ (C57BL/6N-Abce1^{tm1.1(KOMP)Vlcg}/Tcp)	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
\Abce1^{tm1b(EUCOMM)Hmgu}/\Abce1⁺ (C57BL/6N-Abce1^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
\Abcg1^tm1Dgen/\Abcg1^tm1Dgen (B6.129P2-Abcg1^tm1Dgen)	abnormal macrophage physiology	J:117028
\Abcg1^tm1Dgen/\Abcg1^tm1Dgen (B6.129P2-Abcg1^tm1Dgen)	increased macrophage derived foam cell number	J:117028
\Abcg1^tm1Dgen/\Abcg1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:130777
	abnormal cytokine secretion	J:130777
	abnormal leukocyte morphology	J:132952
	abnormal macrophage morphology	J:132952
	abnormal monocyte differentiation	J:132952
	increased B cell number	J:132952
	increased CD4-positive, alpha-beta T cell number	J:132952
	increased CD8-positive, alpha-beta T cell number	J:132952
	increased dendritic cell number	J:132952
	increased eosinophil cell number	J:132952
	increased monocyte cell number	J:132952
	increased neutrophil cell number	J:132952
	lung inflammation	J:132952
\Abcg2^tm1.1Ssf/\Abcg2^tm1.1Ssf (involves: 129 * C57BL/6 * FVB)	liver inflammation	J:201884
\Abcg5^trac/\Abcg5^trac (A/J-Abcg5^trac)	abnormal neutrophil morphology	J:157223
\Abcg5^trac/\Abcg5^trac (A/J-Abcg5^trac)	decreased leukocyte cell number	J:157223
\Abcg8^{tm1b(KOMP)Wtsi}/\Abcg8^{tm1b(KOMP)Wtsi} (C57BL/6N-Abcg8^{tm1b(KOMP)Wtsi}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD4-negative NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T cell number	J:211773
	enlarged spleen	J:211773
	immune system phenotype	J:211773
\Abhd5^tm1.1Lqyu/\Abhd5^tm1.1Lqyu \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * DBA)	liver inflammation	J:199570
\Abhd5^tm1.1Rze/\Abhd5^tm1.1Rze (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:160725
\Abhd10^em1(IMPC)Mbp/\Abhd10^em1(IMPC)Mbp (C57BL/6NCrl-Abhd10^em1(IMPC)Mbp/Mmucd)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Abhd12^tm1Crv/\Abhd12^tm1Crv (involves: C57BL/6)	microgliosis	J:193716
\Abhd13^em1(IMPC)Mbp/\Abhd13^em1(IMPC)Mbp (C57BL/6NCrl-Abhd13^em1(IMPC)Mbp/Mmucd)	decreased spleen weight	J:211773
\Abhd16a^{tm1a(EUCOMM)Wtsi}/\Abhd16a^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal macrophage physiology	J:232688
	decreased interleukin-1 beta secretion	J:232688
	decreased interleukin-6 secretion	J:232688
	decreased macrophage cytokine production	J:232688
	decreased tumor necrosis factor secretion	J:232688
\Abhd17c^em1(IMPC)Mbp/\Abhd17c^em1(IMPC)Mbp (C57BL/6N-Abhd17c^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Abi1^tm1Pen/\Abi1⁺ \Abi2^tm1Pen/\Abi2^tm1Pen (Not Specified)	decreased interleukin-2 secretion	J:104623
	decreased T cell proliferation	J:104623
	immune system phenotype	J:104623
\Abl1^m1/\Abl1^m1 (either: 129S/SvEv-Abl1^m1 or (involves: 129S/SvEv * CD-1) or (involves: 129S/SvEv * C57BL/6 * DBA/2))	abnormal B cell differentiation	J:14644
	abnormal immune system cell morphology	J:14644
	abnormal immune system organ morphology	J:14644
	abnormal spleen germinal center morphology	J:14644
	abnormal spleen morphology	J:14644
	abnormal spleen white pulp morphology	J:14644
	abnormal T cell number	J:14644
	abnormal thymus morphology	J:14644
	decreased immature B cell number	J:14644
	decreased pre-B cell number	J:14644
	decreased pro-B cell number	J:14644
	decreased single-positive T cell number	J:14644
	decreased thymocyte number	J:14644
	increased single-positive T cell number	J:14644
	increased susceptibility to infection	J:14644
	spleen hypoplasia	J:14644
	thymus cortex hypoplasia	J:14644
	thymus hypoplasia	J:14644
\Abl1^m1/\Abl1^m1 (involves: 129S/SvEv)	abnormal B cell differentiation	J:28795
	abnormal immune system cell morphology	J:34903
	abnormal splenocyte physiology	J:34903
	decreased mature B cell number	J:28795
	decreased pre-B cell number	J:28795
	decreased pro-B cell number	J:28795
\Abl1^m1/\Abl1^m1 (involves: 129S/SvEv * C57BL/6)	abnormal B cell calcium ion homeostasis	J:148105
	abnormal lymphopoiesis	J:148105
	decreased pro-B cell number	J:148105
\Abl1^tm1Mlg/\Abl1^tm1Mlg (involves: 129S/SvEv * C57BL/6J)	decreased B cell number	J:72875
	decreased lymphocyte cell number	J:72875
	decreased T cell number	J:72875
	decreased thymocyte number	J:72875
	lung inflammation	J:72875
	spleen atrophy	J:72875
	thymus atrophy	J:72875
\Abl1^tm1Mlg/\Abl1^tm1Mlg (involves: 129S/SvEv * C57BL/6J * CBA)	abnormal spleen morphology	J:34643
	increased susceptibility to infection	J:34643
\Abl1^tm1Mlg/\Abl1^tm1Mlg \Tg(ACTB-Abl1K290R)1Spg/0 (involves: 129S/SvEv C57BL/6J * CBA)	abnormal spleen morphology	J:34643
	increased susceptibility to infection	J:34643
\Abl1^tm2.2Goff/\Abl1^tm2.2Goff (involves: 129P2/OlaHsd * C57BL/6J * FVB/N)	spleen atrophy	J:166211
	thymus atrophy	J:166211
\Ablim3^em1(IMPC)Tcp/\Ablim3^em1(IMPC)Tcp (C57BL/6N-Ablim3^em1(IMPC)Tcp/Tcp)	decreased basophil cell number	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
\Abmm^DBA/2J/? (involves: BALB/cByJ * DBA/2J)	myocarditis	J:52296
\Abraxas2^tm1.2Bwng/\Abraxas2⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl)	enlarged spleen	J:245949
\Abraxas2^tm1.2Bwng/\Abraxas2^tm1.2Bwng (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl)	enlarged spleen	J:245949
	increased inflammatory response	J:245949
\Abtb1^{em1(IMPC)Ccpcz}/\Abtb1^{em1(IMPC)Ccpcz} (C57BL/6N-Abtb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Abtb2^{tm1a(KOMP)Wtsi}/\Abtb2^{tm1a(KOMP)Wtsi} (C57BL/6N-A^tm1Brd Abtb2^{tm1a(KOMP)Wtsi}/WtsiH)	decreased leukocyte cell number	J:211773
\Acaca^tm1Dejs/\Acaca^tm1Dejs \Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	abnormal T cell physiology	J:209886
	decreased memory T cell number	J:209886
	decreased T cell number	J:209886
	immune system phenotype	J:209886
\Acaca^tm1Dejs/\Acaca^tm1Dejs \Tg(Cd4-cre)1Cwi/? \Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * DBA/2)	increased T cell proliferation	J:209886
\Acad10^em1(IMPC)Tcp/\Acad10^em1(IMPC)Tcp (C57BL/6N-Acad10^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Acan^{tm1b(EUCOMM)Hmgu}/\Acan⁺ (C57BL/6N-Acan^{tm1b(EUCOMM)Hmgu}/H)	increased basophil cell number	J:211773
\Acan^tm2Afos/\Acan^tm2Afos (involves: C57BL/6)	decreased susceptibility to induced arthritis	J:122102
\Acbd5^{tm1a(EUCOMM)Wtsi}/\Acbd5^{tm1a(EUCOMM)Wtsi} (C57BL/6N-A^tm1Brd Acbd5^{tm1a(EUCOMM)Wtsi}/WtsiCnbc)	abnormal microglial cell morphology	J:299448
	brain inflammation	J:299448
\Ace2^{em1(ACE2)Yowa}/\Ace2^{em1(ACE2)Yowa} (C57BL/6-Ace2^{em1(ACE2)Yowa})	abnormal circulating cytokine level	J:288243
	increased circulating interferon-gamma level	J:288243
	increased circulating interleukin-9 level	J:288243
	increased susceptibility to Coronaviridae infection	J:288243
	interstitial pneumonia	J:288243
\Ace2^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Ace2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Ace2^{em1(IMPC)Ccpcz}/\Ace2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ace2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Ace2^em1Cya/Y (C57BL/6J-Ace2^em1Cya/Cya)	increased susceptibility to induced colitis	J:299383
\Ace2^em1Cya/Y (C57BL/6J-Ace2^em1Cya/Cya)	intestinal inflammation	J:299383
\Ace2^em2(ACE2)Gpt/Y (C57BL/6JGpt-Ace2^em2(ACE2)Gpt/Gpt)	increased susceptibility to Coronaviridae infection	J:302150
\Ace2^em2(ACE2)Gpt/Y (C57BL/6JGpt-Ace2^em2(ACE2)Gpt/Gpt)	lung inflammation	J:302150
\Ace2^em#Yngh/Y (involves: Kunming)	increased susceptibility to induced colitis	J:221616
\Ace2^{tm1a(KOMP)Wtsi}/Y \Tg(FOXJ1-cre)F26Htzm/0 (involves: C57BL/6N * C57BL/6NTac)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139
\Ace2^{tm1a(KOMP)Wtsi}/\Ace2^{tm1a(KOMP)Wtsi} \Tg(FOXJ1-cre)F26Htzm/0 (involves: C57BL/6N * C57BL/6NTac)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139
\Ace2^tm1Cof/\Ace2^tm1Cof (involves: 129S6/SvEvTac * C57BL/6)	increased incidence of corneal inflammation	J:289503
\Ace2^tm1Lex/\Ace2^tm1Lex (B6;129S5-Ace2^tm1Lex/Mmucd)	lung inflammation	J:264991
\Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:124548
\Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd * C57BL/6)	heart inflammation	J:124548
\Ace2^tm1Pngr/Y (B6.129P2-Ace2^tm1Pngr/J)	decreased susceptibility to Coronaviridae infection	J:286299
\Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139, J:100334
\Ace2^tm1Pngr/Y (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:277074
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:277074
	lung inflammation	J:277074
\Ace2^tm1Pngr/\Ace2^tm1Pngr (involves: 129P2/OlaHsd)	increased neutrophil cell number	J:282139
	increased susceptibility to bacterial infection	J:282139
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282139
	lung inflammation	J:282139, J:100334
\Ace2^tm1Pngr/\Ace2^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:277074
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:277074
	lung inflammation	J:277074
\Ace2^tm1Pngr/\Ace2^tm1Pngr (B6.129P2-Ace2^tm1Pngr/J)	decreased susceptibility to Coronaviridae infection	J:286299
\Ace^{tm1.1(KOMP)Vlcg}/\Ace⁺ (C57BL/6N-Ace^{tm1.1(KOMP)Vlcg}/MbpMmucd)	increased basophil cell number	J:211773
\Ace^tm1Keb/\Ace^tm1Keb (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	kidney inflammation	J:33018
\Ace^tm1Mcf/\Ace^tm1Mcf (Not Specified)	kidney inflammation	J:32114
\Ace^tm1Mcf/\Ace^tm1Mcf (Not Specified)	tubulointerstitial nephritis	J:32114
\Ace^tm1Unc/\Ace^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	kidney inflammation	J:25284
\Ace^tm6Keb/\Ace^tm6Keb (involves: 129 * C57BL/6)	abnormal interleukin level	J:122178
\Ace^tm6Keb/\Ace^tm6Keb (involves: 129 * C57BL/6)	increased T cell number	J:122178
\Ace^tm9Keb/\Ace^tm9Keb (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	kidney inflammation	J:185888
\Acer1^{tm1a(EUCOMM)Wtsi}/\Acer1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Acer1^{tm1a(EUCOMM)Wtsi})	increased eosinophil cell number	J:235775
	skin inflammation	J:235775
\Ache^em1(IMPC)Mbp/\Ache⁺ (C57BL/6N-Ache^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Ackr1^tm1Scp/\Ackr1^tm1Scp (involves: 129P2/OlaHsd * C57BL/6)	increased inflammatory response	J:64222
\Ackr1^tm1Scp/\Ackr1^tm1Scp (involves: 129P2/OlaHsd)	abnormal circulating chemokine level	J:162629
\Ackr1^tm1Skmz/\Ackr1^tm1Skmz (involves: 129P2/OlaHsd * C57BL/6J)	abnormal chemokine level	J:82938
\Ackr2^tm1Gjg/\Ackr2^tm1Gjg (involves: 129/Sv * C57BL/6)	dermatitis	J:97607
\Ackr2^tm1Gjg/\Ackr2^tm1Gjg (involves: 129/Sv * C57BL/6)	increased inflammatory response	J:97806
\Ackr3^tm1.1Fma/\Ackr3^tm1.1Fma (involves: BALB/cJ * C57BL/6)	decreased marginal zone B cell number	J:124878
\Ackr3^tm1.1Rodb/\Ackr3^tm1.1Rodb (involves: 129S6/SvEvTac * BALB/cJ * C57BL/6)	immune system phenotype	J:165184
\Ackr3^tm1Jgo/\Ackr3⁺ (involves: 129S/SvEvBrd * C57BL/6)	lung inflammation	J:136246
\Ackr3^tm1Jgo/\Ackr3^tm1Jgo (involves: 129S/SvEvBrd * C57BL/6)	lung inflammation	J:136246
\Ackr4^tm1.1Rjbn/\Ackr4^tm1.1Rjbn (B6.129S6-Ackr4^tm1.1Rjbn)	abnormal CD4-positive, alpha-beta T cell number	J:166490
	abnormal CD4-positive, alpha-beta T cell physiology	J:166490
	abnormal chemokine level	J:166490
	abnormal circulating chemokine level	J:166490
	abnormal T-helper 17 cell differentiation	J:166490
	decreased T cell proliferation	J:166490
	increased interleukin-23 secretion	J:166490
	increased susceptibility to experimental autoimmune encephalomyelitis	J:166490
	increased T-helper 17 cell number	J:166490
	spleen hyperplasia	J:166490
\Acla1^BXSB/Slc/\Acla1^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Acla1^NZW/Slc/\Acla1^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Acla2^BXSB/Slc/\Acla2^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Acla2^NZW/Slc/\Acla2^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Acod1^{tm1a(KOMP)Wtsi}/\Acod1^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	abnormal macrophage physiology	J:235002
\Acot11^tm1Deco/\Acot11^tm1Deco (involves: 129S6/SvEvTac * C57BL/6)	decreased inflammatory response	J:182660
\Acox1^lampe1/\Acox1^lampe1 (involves: C57BL/6J)	liver inflammation	J:174942
\Acox2^em1Jynz/\Acox2^em1Jynz (involves: C57BL/6N)	liver inflammation	J:323193
\Acoxl^em1(IMPC)Mbp/\Acoxl^em1(IMPC)Mbp (C57BL/6NCrl-Acoxl^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Acp1^tm1Lex/\Acp1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased interleukin-6 secretion	J:171883
\Acp2^{tm1a(EUCOMM)Wtsi}/\Acp2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Acp2^{tm1a(EUCOMM)Wtsi}/H)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
	increased B cell number	J:165965
\Acp2^tm1Psa/\Acp2^tm1Psa (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)	abnormal microglial cell morphology	J:41986
\Acp5^tm1Ahdm/\Acp5^tm1Ahdm (involves: 129S/SvEv)	abnormal osteoclast physiology	J:36232
\Acsl3^{Gt(OST148301)Lex}/\Acsl3^{Gt(OST148301)Lex} (B6;129S5-Acsl3^{Gt(OST148301)Lex}/Orl)	abnormal humoral immune response	J:82809
	decreased B cell number	J:82809
	increased CD4-positive, alpha-beta T cell number	J:82809
\Acsl5^{tm1.1(KOMP)Vlcg}/\Acsl5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Acsl5^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
\Acsl6^tm1.1Jeme/\Acsl6^tm1.1Jeme (involves: BALB/cJ * C57BL/6)	abnormal microglial cell activation	J:267563
\Acsm1^{em1(IMPC)Mhzh}/\Acsm1^{em1(IMPC)Mhzh} (C57BL/6N-Acsm1^{em1(IMPC)Mhzh}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Acsns1^A/J/\Acsns1^A/J (involves: A/J * SM/J)	decreased susceptibility to parasitic infection	J:75549
\Acsns2^SM/J/\Acsns2^SM/J (involves: A/J * SM/J)	increased susceptibility to parasitic infection	J:75549
\Acsns2^SM/J/\Acsns2^SM/J \Acsns3^SM/J/\Acsns3^SM/J (involves: A/J * SM/J)	increased susceptibility to parasitic infection	J:75549
\Acsns3^SM/J/\Acsns3^SM/J (involves: A/J * SM/J)	increased susceptibility to parasitic infection	J:75549
\Acss2^em22Gpt/\Acss2^em22Gpt (C57BL/6JGpt-Acss2^em22Gpt/Gpt)	decreased interleukin-1 beta secretion	J:346990
	decreased susceptibility to endotoxin shock	J:346990
\Acss3^{em1(IMPC)Ccpcz}/\Acss3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Acss3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
\Acta2^em1(IMPC)H/\Acta2^em1(IMPC)H (C57BL/6NTac-Acta2^em1(IMPC)H/H)	decreased basophil cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Actb^{tm4(cre/ERT2)Npa}/\Actb⁺ \Sgpl1^tm1.1Npa/\Sgpl1^tm1.1Npa (involves: BALB/cJ * C57BL/6)	abnormal lymph node morphology	J:199525
	abnormal regulatory T cell number	J:199525
	abnormal type IV hypersensitivity reaction	J:199525
	decreased follicular B cell number	J:199525
	decreased marginal zone B cell number	J:199525
	decreased single-positive T cell number	J:199525
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199525
	increased thymocyte number	J:199525
	spleen hypoplasia	J:199525
\Actl6a^tm1.1Grc/\Actl6a⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6J * CBA)	decreased granulocyte number	J:192124
	decreased macrophage cell number	J:192124
\Actl6a^tm1.1Grc/\Actl6a^tm1.1Grc \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6J * CBA)	decreased B cell number	J:192124
	decreased granulocyte number	J:192124
	decreased leukocyte cell number	J:192124
	decreased lymphocyte cell number	J:192124
	decreased macrophage cell number	J:192124
	decreased monocyte cell number	J:192124
\Actn4^{tm1a(EUCOMM)Wtsi}/\Actn4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Actn4^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Actn4^tm1Mrpk/\Actn4^tm1Mrpk (involves: 129 * C57BL/6)	abnormal lymphocyte chemotaxis	J:83911
\Acvr1^tm1Emsh/\Acvr1⁺ (chimera involves: BALB/c * C57BL/6 * CD-1)	increased inflammatory response	J:194134
\Acvr1b^{tm1.1(KOMP)Vlcg}/\Acvr1b⁺ (C57BL/6N-Acvr1b^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
\Acvr2a^{tm1.1(KOMP)Vlcg}/\Acvr2a⁺ (C57BL/6N-Acvr2a^{tm1.1(KOMP)Vlcg}/Ucd)	decreased eosinophil cell number	J:211773
	decreased neutrophil cell number	J:211773
\Acvr2b^tm1Enl/\Acvr2b^tm1Enl (either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * C57BL/6J))	abnormal spleen morphology	J:42018
	small spleen	J:42018
\Ada^tm1Mw/\Ada^tm1Mw (involves: 129S7/SvEvBrd * C57BL/6)	decreased T cell number	J:25085
\Ada^tm1Mw/\Ada^tm1Mw (involves: 129S7/SvEvBrd)	abnormal dendritic cell physiology	J:138722
\Ada^tm1Mw/\Ada^tm1Mw (involves: 129S7/SvEvBrd)	increased dendritic cell number	J:138722
\Ada^tm1Mw/\Ada^tm1Mw \Tg(PLADA)4118Rkmb/0 (involves: 129S7/SvEvBrd * C57BL/6)	abnormal spleen red pulp morphology	J:73418
	abnormal thymus corticomedullary boundary morphology	J:73418
	decreased double-positive T cell number	J:73418
	decreased immunoglobulin level	J:73418
	decreased leukocyte cell number	J:73418
	increased double-negative T cell number	J:73418
	increased eosinophil cell number	J:73418
	increased granulocyte number	J:73418
	increased macrophage cell number	J:73418
	lung inflammation	J:73418
	small spleen	J:73418
	small thymus	J:73418
	spleen hypoplasia	J:73418
\Adam7^tm1Tigm/\Adam7^tm1Tigm (involves: C57BL/6)	spermatic granuloma	J:226260
\Adam8^tm1.1Mdz/\Adam8^tm1.1Mdz (DBA/1LacJ-Adam8^tm1.1Mdz)	decreased susceptibility to induced arthritis	J:155243
\Adam8^tm1.1Mdz/\Adam8^tm1.1Mdz (DBA/1LacJ-Adam8^tm1.1Mdz)	immune system phenotype	J:155243
\Adam8^tm1.1Rood/\Adam8^tm1.1Rood (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal osteoclast differentiation	J:172936
\Adam10^tm1.1Dhc/\Adam10^tm1.1Dhc \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)	abnormal B cell differentiation	J:158127
	absent marginal zone B cells	J:158127
	decreased transitional stage T2 B cell number	J:158127
	increased follicular B cell number	J:158127
	increased transitional stage T1 B cell number	J:158127
\Adam10^tm1.1Khr/\Adam10^tm1.1Khr \Csf3r^tm1Link/\Csf3r^tm1Link \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6N)	abnormal granulocyte differentiation	J:179060
	enlarged spleen	J:179060
	myeloid hyperplasia	J:179060
	spleen hyperplasia	J:179060
\Adam10^tm1.1Khr/\Adam10^tm1.1Khr \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6N)	abnormal granulocyte differentiation	J:179060
	abnormal spleen morphology	J:179060
	abnormal T cell differentiation	J:179060
	decreased CD4-positive, alpha-beta T cell number	J:179060
	decreased CD8-positive, alpha-beta T cell number	J:179060
	decreased double-positive T cell number	J:179060
	decreased T cell number	J:179060
	enlarged spleen	J:179060
	increased leukocyte cell number	J:179060
	increased neutrophil cell number	J:179060
	increased spleen red pulp amount	J:179060
	increased spleen weight	J:179060
	myeloid hyperplasia	J:179060
	small thymus	J:179060
	spleen hyperplasia	J:179060
	thymus hypoplasia	J:179060
\Adam10^tm1Zhu/\Adam10^tm1.1Zhu \Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL * SJL/J)	abnormal T cell differentiation	J:139042
	decreased CD4-positive, alpha-beta T cell number	J:139042
	decreased double-positive T cell number	J:139042
	thymus hypoplasia	J:139042
\Adam10^tm1Zhu/\Adam10^tm1Zhu \Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL/J)	abnormal T cell differentiation	J:139042
	decreased CD4-positive, alpha-beta T cell number	J:139042
	decreased double-positive T cell number	J:139042
	thymus hypoplasia	J:139042
\Adam17^m1Btlr/\Adam17^m1Btlr (C57BL/6J-Adam17^m1Btlr)	decreased circulating tumor necrosis factor level	J:166602
\Adam17^m1Btlr/\Adam17^m1Btlr (C57BL/6J-Adam17^m1Btlr)	increased susceptibility to induced colitis	J:166602
\Adam17^tm1.1Srj/\Adam17^tm1.1Srj (involves: 129S/SvEv * C57BL/6 * SJL)	abnormal chemokine level	J:163380
	abnormal interleukin secretion	J:163380
	increased interleukin-10 secretion	J:163380
	increased susceptibility to induced colitis	J:163380
	skin inflammation	J:163380
\Adam17^tm1.2Bbl/\Adam17^tm1.2Bbl \Il17a^tm1Yiw/\Il17a^tm1Yiw \Sox9^tm3(cre)Crm/\Sox9⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)	dermatitis	J:229771
\Adam17^tm1.2Bbl/\Adam17^tm1.2Bbl \Il23a^tm1Dnax/\Il23a^tm1Dnax \Sox9^tm3(cre)Crm/\Sox9⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)	dermatitis	J:229771
\Adam17^tm1.2Bbl/\Adam17^tm1.2Bbl \Sox9^tm3(cre)Crm/\Sox9⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:144795
	decreased B cell number	J:144795
	decreased lymphocyte cell number	J:144795
	decreased T cell number	J:144795
	enlarged spleen	J:144795
	increased circulating interleukin-17 level	J:144795
	increased interleukin-17 secretion	J:144795
	increased leukocyte cell number	J:144795
	increased macrophage cell number	J:144795
	increased neutrophil cell number	J:144795
	increased spleen red pulp amount	J:144795
\Adam17^tm1.2Bbl/\Adam17^tm1.2Bbl \Sox9^tm3(cre)Crm/\Sox9⁺ (B6.129(SJL)-Sox9^tm3(cre)Crm Adam17^tm1.2Bbl)	abnormal circulating chemokine level	J:229771
	dermatitis	J:229771
	increased IgE level	J:229771
	increased T-helper 1 cell number	J:229771
	increased T-helper 2 cell number	J:229771
	increased T-helper 17 cell number	J:229771
\Adam17^{tm1a(EUCOMM)Wtsi}/\Adam17⁺ (involves: C57BL/6 * C57BL/6N)	myeloid hyperplasia	J:213427
\Adam17^tm1Bbl/\Adam17^tm1Bbl \Lyz2^tm1(cre)Ifo/0 (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:139846
	decreased circulating tumor necrosis factor level	J:139846
	decreased susceptibility to endotoxin shock	J:139846
\Adam17^tm1Bbl/\Adam17^tm1Bbl \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased circulating tumor necrosis factor level	J:139846
	decreased susceptibility to endotoxin shock	J:139846
\Adam17^tm1Ckww/\Adam17^tm1Ckww (Not Specified)	abnormal dendritic cell physiology	J:138782
\Adam17^tm1Imx/\Adam17^tm1Imx (involves: 129 * C57BL/6)	increased incidence of corneal inflammation	J:51053
\Adam17^tm1Imx/\Adam17^tm1Imx (B6.129-Adam17^tm1Imx)	enhanced leukocyte tethering or rolling	J:174865
\Adam17^tm1Rain/\Adam17^tm1Rain (involves: C57BL/6)	enhanced leukocyte tethering or rolling	J:174865
\Adam17^woe/\Adam17^woe (C57BL/6-Adam17^woe)	dermatitis	J:160781
\Adam17^woe/\Adam17^woe (C57BL/6-Adam17^woe)	increased incidence of corneal inflammation	J:160781
\Adam28^tm1.2Dica/\Adam28^tm1.2Dica (B6JRj.129-Adam28^tm1.2Dica)	abnormal alpha-beta T cell morphology	J:298188
	abnormal lymphocyte morphology	J:298188
	decreased CD8-positive, alpha-beta T cell number	J:298188
\Adam28^tm1.2Dica/\Adam28^tm1.2Dica (CJRj.129-Adam28^tm1.2Dica)	decreased CD8-positive, alpha-beta T cell number	J:298188
\Adam29^em1Otin/\Adam29^em1Otin (C57BL/6-Adam29^em1Otin)	increased inflammatory response	J:353244
\Adamdec1^tm1Dgen/\Adamdec1⁺ (B6.129P2-Adamdec1^tm1Dgen)	increased susceptibility to induced colitis	J:301741
\Adamdec1^tm1Dgen/\Adamdec1^tm1Dgen (B6.129P2-Adamdec1^tm1Dgen)	decreased circulating interleukin-10 level	J:301741
	increased circulating interleukin-1 beta level	J:301741
	increased circulating interleukin-6 level	J:301741
	increased neutrophil cell number	J:301741
	increased susceptibility to bacterial infection	J:301741
	increased susceptibility to bacterial infection induced morbidity/mortality	J:301741
	increased susceptibility to colitis induced morbidity/mortality	J:301741
	increased susceptibility to induced colitis	J:301741
	intestinal inflammation	J:301741
\Adamts1^em1(IMPC)Mbp/\Adamts1⁺ (C57BL/6N-Adamts1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Adamts2^tm1Prc/\Adamts2^tm1Prc (involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)	increased interferon-gamma secretion	J:271185
\Adamts3^tm1.2Itl/\Adamts3^tm1.2Itl (involves: BALB/cJ * C57BL/6NTac * SJL)	abnormal lymphangiogenesis	J:245044
	absent lymphatic vessels	J:245044
\Adamts5^tm1.1Eam/\Adamts5⁺ (involves: 129S5/SvEvBrd)	decreased susceptibility to induced arthritis	J:97590
\Adamts5^tm1.1Eam/\Adamts5^tm1.1Eam (involves: 129S5/SvEvBrd)	decreased susceptibility to induced arthritis	J:97590
\Adamts5^tm1Lex/\Adamts5^tm1Lex \Tg(CMV-cre)1Cgn/0 (involves: 129S5/SvEvBrd * BALB/cJ)	osteoarthritis	J:105138
\Adamts5^tm2.2Lex/\Adamts5^tm2.2Lex (B6.129S5-Adamts5^tm2.2Lex)	decreased susceptibility to induced arthritis	J:175366
\Adamts6^b2b1879.1Clo/\Adamts6^b2b1879.1Clo (C57BL/6J-Adamts6^b2b1879.1Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2029Clo/\Adamts6^b2b2029Clo (C57BL/6J-Adamts6^b2b2029Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2182Clo/\Adamts6^b2b2182Clo (C57BL/6J-Adamts6^b2b2182Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2187.1Clo/\Adamts6^b2b2187.1Clo (C57BL/6J-Adamts6^b2b2187.1Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2228Clo/\Adamts6^b2b2228Clo (C57BL/6J-Adamts6^b2b2228Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2405Clo/\Adamts6^b2b2405Clo (C57BL/6J-Adamts6^b2b2405Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2407Clo/\Adamts6^b2b2407Clo (C57BL/6J-Adamts6^b2b2407Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2744Clo/\Adamts6^b2b2744Clo (C57BL/6J-Adamts6^b2b2744Clo)	thymus hypoplasia	J:175213
\Adamts6^b2b2966.2Clo/\Adamts6^b2b2966.2Clo (C57BL/6J-Adamts6^b2b2966.2Clo)	thymus hypoplasia	J:175213
\Adamts9^{tm1b(KOMP)Wtsi}/\Adamts9⁺ (C57BL/6N-Adamts9^{tm1b(KOMP)Wtsi}/MbpMmucd)	abnormal lymph node morphology	J:211773
\Adamts13^tm1Dgi/\Adamts13^tm1Dgi (involves: 129X1/SvJ * C57BL/6J * CASA/Rk)	immune system phenotype	J:101752
	increased susceptibility to bacterial infection	J:101752
\Adamts14^{Gt(511E11)Cmhd}/\Adamts14^{Gt(511E11)Cmhd} (involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)	increased interferon-gamma secretion	J:271185
	increased interleukin-2 secretion	J:271185
\Adamts14^{Gt(511E11)Cmhd}/\Adamts14^{Gt(511E11)Cmhd} \Adamts2^tm1Prc/\Adamts2^tm1Prc (involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell activation	J:271185
	cutaneous mastocytosis	J:271185
	decreased B cell number	J:271185
	decreased CD8-positive, alpha-beta T cell number	J:271185
	dermatitis	J:271185
	increased CD4-positive, alpha-beta T cell number	J:271185
	increased interferon-gamma secretion	J:271185
	increased interleukin-2 secretion	J:271185
	increased T cell proliferation	J:271185
\Adamts16^em1(IMPC)H/\Adamts16^em1(IMPC)H (C57BL/6N-Adamts16^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased neutrophil cell number	J:211773
\Adamts18^tm1.1Wzha/\Adamts18^tm1.1Wzha (involves: 129 * C57BL/6)	increased acute inflammation	J:258487
	increased susceptibility to induced colitis	J:258487
\Adamtsl3^em1(IMPC)Tcp/\Adamtsl3^em1(IMPC)Tcp (C57BL/6N-Adamtsl3^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Adap1^{tm1a(EUCOMM)Wtsi}/\Adap1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Adap1^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased memory-marker NK cell number	J:211773
	increased NK cell number	J:211773
\Adar^em1Stsn/\Adar^tm1Olds (involves: 129S/SvEv * C57BL/6J)	abnormal spleen morphology	J:308678
\Adar^em2Qwan/\Adar^em2Qwan (Not Specified)	immune system phenotype	J:325221
\Adar^em3Qwan/\Adar^em3Qwan (Not Specified)	abnormal chemokine level	J:325221
	immune system phenotype	J:325221
	increased circulating interleukin-1 level	J:325221
	increased circulating interleukin-6 level	J:325221
	increased circulating interleukin-17 level	J:325221
	increased CXCL10 level	J:325221
\Adar^tm1Olds/\Adar^tm1Olds (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:169014
	increased susceptibility to Paramyxoviridae infection	J:169014
\Adar^tm2Phs/\Adar^tm2Phs (B6.Cg-Adar^tm2Phs)	abnormal circulating interferon-beta level	J:142338
\Adar^tm2Phs/\Adar^tm2Phs (B6.Cg-Adar^tm2Phs)	increased circulating interferon-alpha level	J:142338
\Adarb2^em1(IMPC)Tcp/\Adarb2^em1(IMPC)Tcp (C57BL/6NCrl-Adarb2^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Adaz1^NZM2328/J/\Adaz1^NZM2328/J (involves: C57L/J * NZM2328/J)	increased anti-double stranded DNA antibody level	J:71397
\Adck1^em2(IMPC)Tcp/\Adck1^em2(IMPC)Tcp (C57BL/6NCrl-Adck1^em2(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Adcy1^{tm1b(EUCOMM)Wtsi}/\Adcy1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Adcy1^{tm1b(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
\Adcy7^tm1.1Pcst/\Adcy7^tm1.1Pcst \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased tumor necrosis factor secretion	J:191067
	peritoneal inflammation	J:191067
\Adcy9^{Gt(OST193739)Lex}/\Adcy9^{Gt(OST193739)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	increased IgG1 level	J:103485
\Adcy9^{tm1b(EUCOMM)Wtsi}/\Adcy9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Adcy9^{tm1b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Adcyap1^tm1Clw/\Adcyap1^tm1Clw (B6.129S4-Adcyap1^tm1Clw)	abnormal regulatory T cell physiology	J:194151
	abnormal T cell activation	J:194151
	increased microglial cell activation	J:194151
	increased T-helper 17 cell number	J:194151
\Adcyap1r1^tm1Bbt/\Adcyap1r1^tm1Bbt (involves: 129 * C57BL/6J)	increased susceptibility to bacterial infection	J:73990
\Add2^tm1Feb/\Add2^tm1Feb (B6.129-Add2^tm1Feb)	increased spleen weight	J:63047
\Add2^tm1Llp/\Add2^tm1Llp (involves: 129S4/SvJae * C57BL/6J)	enlarged spleen	J:71029
	increased spleen iron level	J:71029
\Adgb^em1(IMPC)Mbp/\Adgb⁺ (C57BL/6NCrl-Adgb^em1(IMPC)Mbp/Mmucd)	increased eosinophil cell number	J:211773
\Adgrb1^{tm2a(EUCOMM)Wtsi}/\Adgrb1⁺ (C57BL/6N-Adgrb1^{tm2a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Adgrd1^{tm1b(EUCOMM)Wtsi}/\Adgrd1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Adgrd1^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\Adgre1^m1Btlr/\Adgre1^m1Btlr (C57BL/6J-Adgre1^m1Btlr)	immune system phenotype	J:135219
\Adgre1^m2Btlr/\Adgre1^m2Btlr (C57BL/6J-Adgre1^m2Btlr)	abnormal macrophage physiology	J:195410
\Adgre1^m2Btlr/\Adgre1^m2Btlr (C57BL/6J-Adgre1^m2Btlr)	decreased macrophage cell number	J:195410
\Adgre1^m3Btlr/\Adgre1^m3Btlr (C57BL/6J-Adgre1^m3Btlr)	abnormal macrophage physiology	J:234244
\Adgre1^m3Btlr/\Adgre1^m3Btlr (C57BL/6J-Adgre1^m3Btlr)	decreased macrophage cell number	J:234244
\Adgre1^M4Btlr/\Adgre1⁺ (C57BL/6J-Adgre1^M4Btlr)	decreased macrophage cell number	J:255001
\Adgre1^M4Btlr/\Adgre1^M4Btlr (C57BL/6J-Adgre1^M4Btlr)	decreased macrophage cell number	J:255001
\Adgre1^tm1Stst/\Adgre1^tm1Stst (B6.129S1-Emr1^tm1Stst)	abnormal immune tolerance	J:99213
\Adgre1^tm1Stst/\Adgre1^tm1Stst (B6.129S1-Emr1^tm1Stst)	abnormal regulatory T cell physiology	J:99213
\Adgre5^tm1.1Joha/\Adgre5^tm1.1Joha (involves: 129P2/OlaHsd * C57BL/6J * FVB/N)	immune system phenotype	J:140713
	increased granulocyte number	J:140713
\Adgre5^tm1Kake/\Adgre5^tm1Kake (B6.129S6-Adgre5^tm1Kake)	decreased susceptibility to bacterial infection	J:118705
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:118705
	immune system phenotype	J:118705
	increased granulocyte number	J:118705
\Adgrf1^{em1(IMPC)Ccpcz}/\Adgrf1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Adgrf1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Adgrf5^tm1.2Bstc/\Adgrf5^tm1.2Bstc (involves: 129S4/SvJae * C57BL/6J)	increased macrophage derived foam cell number	J:196943
\Adgrf5^tm1.2Jpbs/\Adgrf5^tm1.2Jpbs (BALB/c-Adgrf5^tm1.2Jpbs)	abnormal alveolar macrophage morphology	J:221769
\Adgrf5^{tm1b(KOMP)Wtsi}/\Adgrf5^{tm1b(KOMP)Wtsi} (C57BL/6N-Adgrf5^{tm1b(KOMP)Wtsi}/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
\Adgrf5^tm1Shiro/\Adgrf5^tm1Shiro (B6.Cg-Adgrf5^tm1Shiro)	abnormal alveolar macrophage morphology	J:204701
\Adgrf5^tm1Shiro/\Adgrf5^tm1Shiro (B6.Cg-Adgrf5^tm1Shiro)	increased macrophage cell number	J:204701
\Adgrg3^tm1Fwa/\Adgrg3^tm1Fwa (129S4/SvJae-Adgrg3^tm1Fwa)	immune system phenotype	J:62512
\Adgrg3^tm1Zgwg/\Adgrg3^tm1Zgwg (involves: 129 * C57BL/6)	abnormal B cell morphology	J:222670
	abnormal IgG1 level	J:222670
	abnormal IgG2 level	J:222670
	abnormal IgG level	J:222670
	abnormal immune system morphology	J:222670
	abnormal immune system physiology	J:222670
	abnormal immunoglobulin level	J:222670
	abnormal spleen B cell follicle morphology	J:222670
	abnormal spleen B cell follicle shape	J:222670
	abnormal spleen marginal zone morphology	J:222670
	abnormal spleen morphology	J:222670
	decreased follicular B cell number	J:222670
	decreased IgA level	J:222670
	decreased IgG1 level	J:222670
	decreased IgG2b level	J:222670
	decreased IgG3 level	J:222670
	decreased IgM level	J:222670
	decreased mature B cell number	J:222670
	decreased transitional stage T1 B cell number	J:222670
	immune system phenotype	J:222670
	increased B cell apoptosis	J:222670
	increased IgG1 level	J:222670
	increased IgG2a level	J:222670
	increased marginal zone B cell number	J:222670
	increased transitional stage T2 B cell number	J:222670
\Adgrl4^em1(IMPC)Mbp/\Adgrl4^em1(IMPC)Mbp (C57BL/6N-Adgrl4^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Adh5^tm1.1Llli/\Adh5^tm1.1Llli \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (B6.Cg-Adh5^tm1.1Llli Speer6-ps1^{Tg(Alb-cre)21Mgn})	increased susceptibility to bacterial infection induced morbidity/mortality	J:173666
\Adh5^tm1Stam/\Adh5^tm1Stam (B6.129-Adh5^tm1Stam)	increased susceptibility to bacterial infection	J:88337
\Adh5^tm1Stam/\Adh5^tm1Stam (B6.129-Adh5^tm1Stam)	increased susceptibility to bacterial infection induced morbidity/mortality	J:88337
\Adip1^LG/J/? \Capn10^tm1Chev/\Capn10⁺ ((B6.129-Capn10^tm1Chev x LG/J)F1)	increased spleen weight	J:153477
\Adipoq^tm1Chan/\Adipoq⁺ (B6.129-Adipoq^tm1Chan)	abnormal leukocyte physiology	J:122020
\Adipoq^tm1Chan/\Adipoq⁺ (B6.129-Adipoq^tm1Chan)	increased leukocyte cell number	J:122020
\Adipoq^tm1Chan/\Adipoq^tm1Chan (B6.129-Adipoq^tm1Chan)	abnormal leukocyte physiology	J:122020
\Adipoq^tm1Chan/\Adipoq^tm1Chan (B6.129-Adipoq^tm1Chan)	increased leukocyte cell number	J:122020
\Adipoq^tm1Ish/\Adipoq^tm1Ish (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal osteoclast morphology	J:199264
\Adipor1^{tm1b(EUCOMM)Hmgu}/\Adipor1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Adipor1^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Adipor2^{tm1b(EUCOMM)Hmgu}/\Adipor2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Adipor2^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Adk^{em1(IMPC)Ccpcz}/\Adk⁺ (C57BL/6N-Adk^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Adm2^em1Zhan/\Adm2^em1Zhan (Not Specified)	increased inflammatory response	J:266495
	increased Ly6C high monocyte number	J:266495
	increased susceptibility to infection	J:266495
	liver inflammation	J:266495
\Adm^tm1Kmca/\Adm^tm1Kmca (B6.129P2-Adm^tm1Kmca)	increased uterine NK cell number	J:201446
\Adm^tm1Tfjt/\Adm⁺ (involves: C57BL/6 * CBA)	blood vessel inflammation	J:102946
\Adm^tm1Unc/\Adm^tm1Unc (involves: 129S6/SvEvTac)	decreased uterine NK cell number	J:201446
\Adm^tm1Unc/\Adm^tm1Unc (129S6/SvEvTac-Adm^tm1Unc)	abnormal lymph organ development	J:130930
\Adnp2^em3(IMPC)Tcp/\Adnp2⁺ (C57BL/6NCrl-Adnp2^em3(IMPC)Tcp/Tcp)	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Adora2a^em1(IMPC)H/\Adora2a^em1(IMPC)H (C57BL/6N-Adora2a^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Adora2a^tm1Map/\Adora2a^tm1Map (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased interleukin-10 secretion	J:147023
\Adora2b^tm1.1Msit/\Adora2b^tm1.1Msit (either: (involves: C57BL/6) or (involves: C57BL/6 * CD-1 * ICR))	abnormal macrophage physiology	J:169155
	increased interleukin-6 secretion	J:169155
	increased tumor necrosis factor secretion	J:169155
\Adora2b^tm1Dgen/\Adora2b^tm1Dgen (B6.129P2-Adora2b^tm1Dgen)	abnormal dendritic cell physiology	J:138722
	decreased interleukin-10 secretion	J:147023
\Adora2b^tm1Kra/\Adora2b^tm1Kra (involves: 129 * C57BL/6J)	abnormal cytokine level	J:111715
	abnormal inflammatory response	J:111715
	abnormal interleukin level	J:111715
	abnormal leukocyte adhesion	J:111715
	abnormal leukocyte migration	J:111715
	abnormal tumor necrosis factor level	J:111715
	decreased interleukin-10 secretion	J:111715
	enhanced leukocyte tethering or rolling	J:111715
	increased circulating interleukin-6 level	J:111715
\Adora2b^tm1Till/\Adora2b^tm1Till (B6.129P2-Adora2b^tm1Till)	abnormal cellular extravasation	J:125297
	increased interleukin-6 secretion	J:125297
	increased susceptibility to type I hypersensitivity reaction	J:125297
\Adora3^{tm1(ADORA3)Msth}/\Adora3^{tm1(ADORA3)Msth} (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal mast cell physiology	J:104494
	decreased mast cell degranulation	J:104494
\Adora3^tm1Jbsn/\Adora3^tm1Jbsn (either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal mast cell physiology	J:60293
	decreased tumor necrosis factor secretion	J:60293
\Adora3^tm1Jbsn/\Adora3^tm1Jbsn (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased acute inflammation	J:120442
\Adora3^tm1Jbsn/\Adora3^tm1Jbsn (B6.129P2-Adora3^tm1Jbsn)	abnormal mast cell degranulation	J:123463
\Adora3^tm1Jbsn/\Adora3^tm1Jbsn (B6.129P2-Adora3^tm1Jbsn)	impaired neutrophil recruitment	J:123463
\Adprh^tm1Jlms/\Adprh^tm1Jlms (involves: 129X1/SvJ * C57BL/6J)	increased susceptibility to infection	J:123619
\Adrb2^em1(IMPC)Mbp/\Adrb2^em1(IMPC)Mbp (C57BL/6N-Adrb2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Adrb2^tm1Bkk/\Adrb2⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:97566
\Adrb2^tm1Bkk/\Adrb2^tm1Bkk (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:97566
	abnormal osteoclast morphology	J:97566
	abnormal osteoclast physiology	J:97566
\Adrb2^tm1Bkk/\Adrb2^tm1Bkk (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * FVB/N)	increased tumor necrosis factor secretion	J:204379
\Adrb3^em1(IMPC)Krb/\Adrb3^em1(IMPC)Krb (C57BL/6NTac-Adrb3^em1(IMPC)Krb/Krb)	increased CD4-negative, CD25-positive NK T cell number	J:211773
\Adrm1^{Gt(OST128063)Lex}/\Adrm1^{Gt(OST128063)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal single-positive T cell number	J:166694
	enlarged thymus	J:166694
	immune system phenotype	J:166694
	increased CD4-positive, alpha-beta T cell number	J:166694
	increased CD8-positive, alpha-beta T cell number	J:166694
	thymus hyperplasia	J:166694
\Ads1^NZB/\Ads1^NZB (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7239, J:7111
\Ads1^NZB/\Ads1^NZB (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
\Ads1^NZB/\Ads1^NZW (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7111
\Ads1^NZB/\Ads1^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
\Ads2^NZB/\Ads2^NZB (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7111
\Ads2^NZB/\Ads2^NZB (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
\Ads2^NZB/\Ads2^NZW (involves: NZB * NZW)	increased anti-double stranded DNA antibody level	J:7111
\Ads2^NZB/\Ads2^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
\Ads3^NZB/\Ads3^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
\Ads3^NZB/\Ads3^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
\Ads3^NZW/\Ads3^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
	increased anti-double stranded DNA antibody level	J:7239
	increased susceptibility to autoimmune disorder	J:7111
\Ads4^NZB/\Ads4^NZB (involves: NZB * NZW)	decreased anti-double stranded DNA antibody level	J:11074
\Ads4^NZB/\Ads4^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
\Ads4^NZB/\Ads4^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
\Ads4^NZW/\Ads4^NZW (involves: NZB * NZW)	abnormal immunoglobulin level	J:7111
\Ads4^NZW/\Ads4^NZW (involves: NZB * NZW)	increased susceptibility to autoimmune disorder	J:7111
\Adss2^{tm1b(EUCOMM)Wtsi}/\Adss2⁺ (C57BL/6N-Adss2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased eosinophil cell number	J:211773
\Adtrp^tm1.1Clu/\Adtrp^tm1.1Clu (involves: 129S4/SvJaeSor * C57BL/6)	increased inflammatory response	J:295059
	increased mast cell number	J:295059
\Aec1^NOD/Uf/\Aec1^NOD/Uf \Aec2^NOD/Uf/\Aec2^NOD/Uf (B6.NOD-Aec2^NOD/Uf Aec1^NOD/Uf)	increased anti-nuclear antigen antibody level	J:129282
	increased susceptibility to autoimmune disorder	J:128900
	lacrimal gland inflammation	J:129282
	salivary gland inflammation	J:129282
\Aem1^C57BL/6/\Aem1^NZB (involves: C57BL/6 * NZB)	decreased autoantibody level	J:7191
\Aem2^C57BL/6/\Aem2^C57BL/6 (involves: C57BL/6 * NZB)	decreased autoantibody level	J:59427
\Aem2^C57BL/6/\Aem2^NZB (involves: C57BL/6 * NZB)	decreased autoantibody level	J:59427
\Aem2^C57BL/6/\Aem2^NZB \Aem3^C57BL/6/\Aem3^NZB (involves: C57BL/6 * NZB)	decreased autoantibody level	J:59427
\Aem3^C57BL/6/? (involves: C57BL/6 * NZB)	abnormal immune system physiology	J:59427
\Afap1l2^{tm1b(KOMP)Wtsi}/\Afap1l2^{tm1b(KOMP)Wtsi} (C57BL/6N-Afap1l2^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	increased neutrophil cell number	J:211773
\Afdn^em1(IMPC)Mbp/\Afdn⁺ (C57BL/6N-Afdn^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Aff1^Rob/\Aff1⁺ (involves: BALB/cAnNCrl * C3H/HeN)	abnormal double-negative T cell morphology	J:82265
	decreased thymus weight	J:82265
	thymus hypoplasia	J:82265
\Aff1^tm1Cim/\Aff1^tm1Cim (involves: 129P2/OlaHsd * BALB/c)	abnormal immune system cell morphology	J:63253
	abnormal immune system organ morphology	J:63253
	abnormal T cell differentiation	J:63253
	decreased B cell number	J:63253
	decreased double-positive T cell number	J:63253
	decreased mature B cell number	J:63253
	decreased pre-B cell number	J:63253
	decreased single-positive T cell number	J:63253
	thymus hypoplasia	J:63253
\Afg2b^em1(IMPC)Bay/\Afg2b⁺ (C57BL/6N-Afg2b^em1(IMPC)Bay/BayMmucd)	enlarged lymph nodes	J:211773
\Afg3l1^tm1.1Arte/\Afg3l1^tm1.1Arte \Afg3l2^tm1Arte/\Afg3l2^tm1Arte \Tg(Plp1-cre/ERT)3Pop/0 (involves: C57BL/6J * C57BL/6N)	microgliosis	J:237410
\Afg3l2^tm1Arte/\Afg3l2^tm1Arte \Tg(Pcp2-cre)2Mpin/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	microgliosis	J:193564
\Agbl1^em1Zfa/\Agbl1^em1Zfa (Not Specified)	immune system phenotype	J:231311
\Agbl2^em1Zfa/\Agbl2^em1Zfa (Not Specified)	immune system phenotype	J:231311
\Agbl3^em1Zfa/\Agbl3^em1Zfa (Not Specified)	immune system phenotype	J:231311
\Agbl4^em1(IMPC)Mbp/\Agbl4^em1(IMPC)Mbp (C57BL/6NCrl-Agbl4^em1(IMPC)Mbp/Mmucd)	increased monocyte cell number	J:211773
\Agbl4^{Tn(pb-Act-RFP)1.080115015-HRAZhu}/\Agbl4^{Tn(pb-Act-RFP)1.080115015-HRAZhu} (involves: FVB/N)	abnormal spleen morphology	J:233744
	increased spleen weight	J:233744
	increased susceptibility to Herpesvirales infection	J:231311
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:231311
	increased susceptibility to Poxviridae infection	J:231311
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:231311
\Agbl5^em1Zfa/\Agbl5^em1Zfa (Not Specified)	increased susceptibility to Herpesvirales infection	J:231311
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:231311
	increased susceptibility to Poxviridae infection	J:231311
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:231311
\Ager^tm1.1Arnd/\Ager^tm1.1Arnd (B6.129P2-Ager^tm1.1Arnd)	decreased circulating interleukin-6 level	J:104998
\Ager^tm1.1Arnd/\Ager^tm1.1Arnd (B6.129P2-Ager^tm1.1Arnd)	decreased osteoclast cell number	J:104998
\Ager^tm1.1Arnd/\Ager^tm1.1Arnd (involves: 129P2/OlaHsd)	abnormal immune system physiology	J:113376
\Ager^tm1Arnd/\Ager⁺ \Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased dendritic cell number	J:194800
	decreased plasmacytoid dendritic cell number	J:194800
\Agk^em1Qiz/\Agk^em1Qiz (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:282052
	abnormal CD8-positive, alpha-beta T cell physiology	J:282052
	decreased effector memory CD8-positive, alpha-beta T cell number	J:282052
\Agk^tm1.1Smoc/\Agk^tm1.1Smoc (Not Specified)	decreased effector memory CD8-positive, alpha-beta T cell number	J:282052
\Agk^tm1.1Smoc/\Agk^tm1.1Smoc (Not Specified)	immune system phenotype	J:282052
\Aglna/? (C57BL/6-Aglna/Anu)	abnormal spleen marginal zone morphology	J:169366
\Aglna/? (C57BL/6-Aglna/Anu)	increased activated T cell number	J:169366
\Agnm1^MRL/MpJ/\Agnm1^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
\Agnm2^C3H/HeJ/\Agnm2^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
\Agnm2^MRL/MpJ/\Agnm2^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
\Agnm3^C3H/HeJ/\Agnm3^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
\Agnm3^MRL/MpJ/\Agnm3^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:97786
	increased susceptibility to systemic lupus erythematosus	J:97786
\Ago2^tm1.1Tara/\Ago2^tm1.1Tara \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)	enlarged spleen	J:165967
\Agp1^NZB/\Agp1^NZB (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
\Agp1^NZB/\Agp1^NZW (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
\Agp2^NZB/\Agp2^NZW (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
\Agp2^NZW/\Agp2^NZW (involves: NZB * NZW)	increased susceptibility to type III hypersensitivity reaction	J:6920
\Agpat2^{em1(IMPC)Ccpcz}/\Agpat2⁺ (C57BL/6NCrl-Agpat2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Agpat2^{Gt(OST438470)Lex}/\Agpat2^{Gt(OST438470)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	brown adipose tissue inflammation	J:186035
	granulomatous inflammation	J:186035
	liver inflammation	J:186035
\Agpat2^tm1Garg/\Agpat2^tm1Garg (involves: 129S6/SvEvTac)	increased spleen weight	J:146649
\Agpat5^{em1(IMPC)Ccpcz}/\Agpat5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Agpat5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Agr2^tm1.1Lpkn/\Agr2^tm1.1Lpkn \Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/\Gt(ROSA)26Sor⁺ (involves: 129 * 129S6/SvEvTac * C57BL/6)	colitis	J:156704
\Agr2^tm1.2Erle/\Agr2^tm1.2Erle (involves: 129S4/SvJae * FVB/N)	increased mast cell number	J:148339
	increased susceptibility to induced colitis	J:148339
\Agr2^tm1.2Lpkn/\Agr2^tm1.2Lpkn (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal Peyer's patch follicle morphology	J:156704
	colitis	J:156704
	ileum inflammation	J:156704
\Agt^tm1Afu/\Agt^tm1Afu (involves: C57BL/6 * CBA)	tubulointerstitial nephritis	J:46506
\Agt^tm1Unc/\Agt^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	tubulointerstitial nephritis	J:24156
\Agtpbp1^atms/\Agtpbp1^atms (MRL/Mp-Agtpbp1^atms Fas^lpr)	decreased spleen weight	J:103944
\Agtpbp1^atms/\Agtpbp1^atms (MRL/Mp-Agtpbp1^atms)	abnormal lymphocyte cell number	J:103944
	abnormal spleen morphology	J:103944
	abnormal T cell differentiation	J:103944
	abnormal T cell physiology	J:103944
	abnormal T cell subpopulation ratio	J:103944
	decreased B cell number	J:103944
	decreased spleen weight	J:103944
	increased CD4-positive, alpha-beta T cell number	J:103944
	increased CD8-positive, alpha-beta T cell number	J:103944
	spleen hypoplasia	J:103944
\Agtpbp1^atms/\Agtpbp1^atms \Fas^lpr/\Fas^lpr (MRL/Mp-Agtpbp1^atms Fas^lpr)	enlarged lymph nodes	J:103944
	enlarged spleen	J:103944
\Agtpbp1^pcd-3J/\Agtpbp1^pcd-3J (involves: BALB/cByJ)	immune system phenotype	J:231311
\Agtr1a^{em1(IMPC)Rbrc}/\Agtr1a^{em1(IMPC)Rbrc} (C57BL/6NJcl-Agtr1a^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Agtr1a^tm1Unc/\Agtr1a^tm1Unc \Agtr1b^tm1Cof/\Agtr1b^tm1Cof (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:137944
\Agtrap^em1(IMPC)Mbp/\Agtrap^em1(IMPC)Mbp (C57BL/6NCrl-Agtrap^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Agtrap^tm1Tamk/\Agtrap^tm1Tamk (involves: C57BL/6N)	abnormal macrophage morphology	J:263253
\Ahcy^{tm1b(EUCOMM)Hmgu}/\Ahcy⁺ (C57BL/6N-Ahcy^{tm1b(EUCOMM)Hmgu}/Tcp)	increased basophil cell number	J:211773
\Ahi1^tm1Jgg/\Ahi1^tm1Jgg \Tg(TCF/Lef1-lacZ)34Efu/0 (involves: 129S1/Sv * 129X1/SvJ)	kidney inflammation	J:154321
\Ahnak^{tm1b(KOMP)Mbp}/\Ahnak⁺ (C57BL/6N-Ahnak^{tm1b(KOMP)Mbp}/H)	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
\Ahnak^tm1Vtm/\Ahnak^tm1Vtm (involves: 129S1/Sv * C57BL/6)	abnormal T cell activation	J:131148
	abnormal T-helper 1 physiology	J:131148
	decreased interferon-gamma secretion	J:131148
	decreased interleukin-2 secretion	J:131148
	decreased T cell proliferation	J:131148
	increased interleukin-4 secretion	J:131148
	increased susceptibility to parasitic infection	J:131148
\Ahr^b-1/\Ahr^b-1 (C57BL/6J)	increased inflammatory response	J:5244, J:5387
\Ahr^b-1/\Ahr^b-1 (involves: C57BL/6J * DBA/2J)	abnormal immune system physiology	J:5387
\Ahr^tm1Bra/\Ahr^tm1Bra (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:148870
	abnormal Langerhans cell morphology	J:148870
	abnormal Langerhans cell physiology	J:148870
	decreased spleen germinal center size	J:33827
	decreased susceptibility to type IV hypersensitivity reaction	J:148870
	enlarged spleen	J:33827
\Ahr^tm1Bra/\Ahr^tm1Bra (B6.129-Ahr^tm1Bra/J)	abnormal chemokine level	J:118646
	abnormal cytokine level	J:118646
	abnormal interleukin level	J:118646
	abnormal macrophage physiology	J:118646
	abnormal tumor necrosis factor level	J:118646
	increased susceptibility to bacterial infection	J:118646
	lung inflammation	J:118646, J:100359
\Ahr^tm1Gonz/\Ahr^tm1Gonz (involves: 129S4/SvJae * C57BL/6N)	abnormal spleen morphology	J:44690
	abnormal spleen red pulp morphology	J:44690
	bile duct inflammation	J:25048
	colitis	J:44690
	decreased spleen white pulp amount	J:44690
	enlarged spleen	J:44690
	folliculitis	J:44690
	heart inflammation	J:44690
	increased inflammatory response	J:25048
	small spleen	J:25048
	spleen hypoplasia	J:25048
\Ahr^tm1Yfk/\Ahr^tm1Yfk (involves: 129S/SvEv * C57BL/6J)	urinary bladder inflammation	J:179919
\Ahr^tm2Bra/\Ahr^tm2Bra (involves: 129/Sv * C57BL/6)	increased spleen weight	J:83597
\Ahr^tm4.1Bra/\Ahr^tm4.1Bra (involves: 129/Sv * C57BL/6)	enlarged spleen	J:141978
\Ahsp^tm1.1Mjwe/\Ahsp^tm1.1Mjwe (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:94421
\Ahsp^tm1Mjwe/\Ahsp^tm1Mjwe (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:94421
\Aia1^NZB/Omr/\Aia1^NZB/Omr (involves: NZB/Omr * NZC/Omr)	increased susceptibility to autoimmune hemolytic anemia	J:6517
\Aia1^NZB/Omr/\Aia1^NZC/Omr (involves: NZB/Omr * NZC/Omr)	increased susceptibility to autoimmune hemolytic anemia	J:6517
\Aicda^em1Jaych/\Aicda^em1Jaych (involves: C57BL/6J)	abnormal class switch recombination	J:305843
	abnormal lymph node cell ratio	J:305843
	abnormal Peyer's patch germinal center morphology	J:305843
	abnormal splenic cell ratio	J:305843
	increased IgM level	J:305843
\Aicda^m1Btlr/\Aicda^m1Btlr (C57BL/6J-Aicda^m1Btlr)	abnormal humoral immune response	J:265155
	decreased IgE level	J:265155
	increased IgM level	J:265155
\Aicda^m2Btlr/\Aicda^m2Btlr (C57BL/6J-Aicda^m2Btlr)	abnormal humoral immune response	J:265156
	decreased IgE level	J:265156
	increased IgM level	J:265156
\Aicda^tm1(cre)Mnz/\Aicda⁺ \Gt(ROSA)26Sor^{tm2(sb11)Njen}/\Gt(ROSA)26Sor⁺ \TgTn(sb-T2/Onc2)6070Njen/0 (involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)	increased T cell derived lymphoma incidence	J:153656
\Aicda^tm1(cre)Mnz/\Aicda⁺ \Igh^tm3Mnz/\Igh⁺ \Myc^tm37Mnz/\Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:145691
\Aicda^tm1(cre)Mnz/\Aicda⁺ \Igh^tm3Mnz/\Igh⁺ \Myc^tm39Mnz/\Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:145691
\Aicda^tm1.1Fwa/\Aicda^tm1.1Fwa (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:209271
	abnormal somatic hypermutation frequency	J:209271
	immune system phenotype	J:209271
\Aicda^{tm1b(EUCOMM)Hmgu}/\Aicda^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Aicda^{tm1b(EUCOMM)Hmgu}/Wtsi)	decreased follicular B cell number	J:211773
	decreased late germinal center B cell number	J:211773
	increased early germinal center B cell number	J:211773
	increased germinal center B cell number	J:211773
	increased leukocyte cell number	J:211773
\Aicda^tm1Hon/\Aicda⁺ (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:136224, J:141427
	abnormal somatic hypermutation frequency	J:141427
	immune system phenotype	J:136224
\Aicda^tm1Hon/\Aicda^tm1.1Fwa (involves: 129S/SvEv * C57BL/6NCrlj * CBA/JNCrlj)	abnormal class switch recombination	J:209271
	immune system phenotype	J:209271
\Aicda^tm1Hon/\Aicda^tm1Hon (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427, J:73659, J:120658
	abnormal somatic hypermutation frequency	J:136224, J:141427
	decreased IgA level	J:169227
	decreased IgG1 level	J:169227, J:73659
	decreased IgG2a level	J:73659
	decreased IgG2b level	J:169227
	decreased IgG3 level	J:169227
	decreased IgG level	J:169227
	increased germinal center B cell number	J:169227
	increased IgM level	J:169227, J:73659
	increased susceptibility to bacterial infection induced morbidity/mortality	J:169227
\Aicda^tm1Hon/\Aicda^tm1Hon \Bcl6^tm1.1Jwan/\Bcl6^tm1.1Jwan (involves: 129S6/SvEvTac * C57BL/6NCrlj * CBA/JNCrlj)	abnormal somatic hypermutation frequency	J:190534
\Aicda^tm1Hon/\Aicda^tm1Hon \Blm^tm3Brd/\Blm^tm3Brd \Igh^tm4.1Mnz/\Igh⁺ \Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	immune system phenotype	J:194603
\Aicda^tm1Hon/\Aicda^tm1Hon \Exo1^tm1Wed/\Exo1^tm1Wed \Igh^tm4.1Mnz/\Igh⁺ (involves: C57BL/6 * CBA/JNCrlj * SJL)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
\Aicda^tm1Hon/\Aicda^tm1Hon \Exo1^tm1Wed/\Exo1^tm1Wed \Igh^tm4.1Mnz/\Igh⁺ \Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc (involves: 129 * C57BL/6 * CBA/JNCrlj * SJL)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
\Aicda^tm1Hon/\Aicda^tm1Hon \Igh^tm3Mnz/\Igh^tm4.1Mnz \Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc (involves: 129 * C57BL/6 * CBA)	abnormal class switch recombination	J:159173
\Aicda^tm1Hon/\Aicda^tm1Hon \Igh^tm4.1Mnz/\Igh⁺ (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
\Aicda^tm1Hon/\Aicda^tm1Hon \Igh^tm4.1Mnz/\Igh⁺ \Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc (involves: 129 * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal immunoglobulin heavy chain V(D)J recombination	J:194603
\Aicda^tm1Hon/\Aicda^tm1Hon \Ighm^{tm1.1(IGH-2)Cog}/\Ighm⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)	abnormal B cell physiology	J:157575
\Aicda^tm1Hon/\Aicda^tm1Hon \Tg(Igkv3-5-MYC)#Plbe/0 (involves: C57BL/6 C57BL/6NCrlj * CBA/JNCrlj)	immune system phenotype	J:131912
\Aicda^tm1Hon/\Aicda^tm2Mnz (involves: C57BL/6 * CBA)	immune system phenotype	J:136224
\Aicda^tm1Hon/\Aicda^tm3Mnz (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
\Aicda^tm1Hon/\Aicda^tm3Mnz (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
\Aicda^tm1Hon/\Aicda^tm4Mnz (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
\Aicda^tm1Hon/\Aicda^tm4Mnz (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
\Aicda^tm2.1Hon/\Aicda^tm2.1Hon (C57BL/6-Aicda^tm2.1Hon)	abnormal somatic hypermutation frequency	J:169227
	decreased IgG1 level	J:169227
	immune system phenotype	J:169227
	increased germinal center B cell number	J:169227
	increased susceptibility to bacterial infection	J:169227
	increased susceptibility to bacterial infection induced morbidity/mortality	J:169227
\Aicda^tm2.1Hon/\Aicda^tm2.1Hon (involves: BALB/c * C57BL/6)	increased germinal center B cell number	J:169227
\Aicda^tm2Mnz/\Aicda^tm2Mnz (B6.Cg-Aicda^tm2Mnz)	immune system phenotype	J:136224
\Aicda^tm3.1Mnz/\Aicda^tm3.1Mnz (involves: C57BL/6)	abnormal class switch recombination	J:147109
\Aicda^tm3.1Mnz/\Aicda^tm3.1Mnz (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:147109
\Aicda^tm3Mnz/\Aicda⁺ (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
\Aicda^tm3Mnz/\Aicda⁺ (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
\Aicda^tm4.1Mnz/\Aicda^tm4.1Mnz (involves: C57BL/6)	abnormal class switch recombination	J:147109
\Aicda^tm4.1Mnz/\Aicda^tm4.1Mnz (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:147109
\Aicda^tm4Mnz/\Aicda⁺ (involves: C57BL/6 * CBA)	abnormal class switch recombination	J:141427
\Aicda^tm4Mnz/\Aicda⁺ (involves: C57BL/6 * CBA)	abnormal somatic hypermutation frequency	J:141427
\Aif1^tm1Nsib/\Aif1^tm1Nsib (involves: 129S/SvEv * C57BL/6)	decreased spleen weight	J:204462
\Aif1^tm1Nsib/\Aif1^tm1Nsib (involves: 129S/SvEv * C57BL/6)	decreased susceptibility to induced arthritis	J:204462
\Aif1l^{tm1b(EUCOMM)Wtsi}/\Aif1l^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Aif1l^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
\Aim2^{em1(IMPC)Ccpcz}/\Aim2^{em1(IMPC)Ccpcz} (C57BL/6N-Aim2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Aim2^{Gt(CSG445)Byg}/\Aim2^{Gt(CSG445)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:158969
	decreased circulating interleukin-18 level	J:158969
	decreased interleukin-1 beta secretion	J:158969
	decreased interleukin-18 secretion	J:158969
	decreased NK cell number	J:158969
	increased interferon-beta secretion	J:158969
	increased susceptibility to bacterial infection	J:158969
	increased susceptibility to Herpesvirales infection	J:158969
	increased susceptibility to Poxviridae infection	J:158969
\Aim2^{Gt(CSG445)Byg}/\Aim2^{Gt(CSG445)Byg} (involves: 129P2/OlaHsd)	immune system phenotype	J:173245
\Aim2^{Gt(CSG445)Byg}/\Aim2^{Gt(CSG445)Byg} (B6.129P2-Aim2^{Gt(CSG445)Byg}/J)	abnormal interferon secretion	J:234263
	decreased interleukin-1 beta secretion	J:234263
	decreased macrophage apoptosis	J:234263
\Aim2^tm1.1Vmd/\Aim2^tm1.1Vmd (C57BL/6-Aim2^tm1.1Vmd)	abnormal cytokine secretion	J:160545
	abnormal macrophage physiology	J:160545
	decreased interleukin-1 beta secretion	J:160545
	decreased interleukin-18 secretion	J:160545
	increased interferon-beta secretion	J:160545
	increased susceptibility to bacterial infection	J:160545
	increased tumor necrosis factor secretion	J:160545
\Aim2^tm1.2Arte/\Aim2^tm1.2Arte \Dnase2a^tm1Osa/\Dnase2a^tm1Osa \Ifnar1^tm1Agt/\Ifnar1^tm1Agt (involves: 129 * BALB/c * C57BL/6 * C57BL/6J)	abnormal spleen morphology	J:238323
	enlarged spleen	J:238323
	increased autoantibody level	J:238323
	increased circulating interleukin-10 level	J:238323
	increased circulating tumor necrosis factor level	J:238323
	increased spleen weight	J:238323
	rheumatoid arthritis	J:238323
\Aim2^tm1Ktak/\Aim2^tm1Ktak (involves: 129S4/SvJae * C57BL/6)	decreased circulating interleukin-18 level	J:188013
	decreased interferon-gamma secretion	J:188013
	decreased interleukin-1 beta secretion	J:188013
	decreased interleukin-18 secretion	J:188013
	increased susceptibility to bacterial infection	J:188013
	increased susceptibility to bacterial infection induced morbidity/mortality	J:188013
\Aimp1^em1(IMPC)Tcp/\Aimp1^em1(IMPC)Tcp (C57BL/6NCrl-Aimp1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
\Aimp1^{Gt(OST58507)Lex}/\Aimp1^{Gt(OST58507)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased inflammatory response	J:95974
\Aire^{tm1.1(cre)Ghr}/\Aire^{tm1.1(cre)Ghr} (Not Specified)	decreased dendritic cell number	J:176844
	decreased regulatory T cell number	J:176844
	increased dendritic cell number	J:176844
\Aire^{tm1.1(NCOM)Mfgc}/\Aire^{tm1.1(NCOM)Mfgc} (C57BL/6N-Aire^{tm1.1(NCOM)Mfgc}/Tcp)	increased monocyte cell number	J:211773
\Aire^tm1.1Doi/\Aire^tm1.1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal thymus medulla morphology	J:83422
	increased autoantibody level	J:119475
	increased susceptibility to autoimmune disorder	J:83422
	increased T cell number	J:83422
	stomach inflammation	J:119475
\Aire^tm1.1Doi/\Aire^tm1.1Doi (B6.129S2-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	increased incidence of corneal inflammation	J:107432
	lung inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
\Aire^tm1.1Doi/\Aire^tm1.1Doi (NOD.129S2(B6)-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	increased incidence of corneal inflammation	J:107432
	liver inflammation	J:107432
	lung inflammation	J:107432
	ovary inflammation	J:107432
	pancreas inflammation	J:107432
	prostate gland inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
	thyroid gland inflammation	J:107432
\Aire^tm1.1Doi/\Aire^tm1.1Doi (C.129S2-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	increased incidence of corneal inflammation	J:107432
	liver inflammation	J:107432
	lung inflammation	J:107432
	ovary inflammation	J:107432
	prostate gland inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
\Aire^tm1.1Doi/\Aire^tm1.1Doi (SJL.129S2-Aire^tm1.1Doi/Doi)	increased autoantibody level	J:107432
	liver inflammation	J:107432
	lung inflammation	J:107432
	ovary inflammation	J:107432
	pancreas inflammation	J:107432
	prostate gland inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
\Aire^tm1.1Doi/\Aire^tm1.1Doi (involves: 129S2/SvPas * C57BL/6 * NOD)	liver inflammation	J:107432
	lung inflammation	J:107432
	pancreas inflammation	J:107432
	salivary gland inflammation	J:107432
	stomach inflammation	J:107432
\Aire^tm1.1Doi/\Aire^tm1.1Doi (NOD.129S2-Aire^tm1.1Doi)	abnormal CD4-positive, alpha-beta T cell physiology	J:135154
	chronic pancreas inflammation	J:135154
	insulitis	J:135154
	lacrimal gland inflammation	J:135154
	lung inflammation	J:135154
	salivary gland inflammation	J:135154
	stomach inflammation	J:135154
	thyroid gland inflammation	J:135154
	uveitis	J:135154
\Aire^tm1.1Doi/\Aire^tm1.1Doi \H2^b/\H2^b (NOD.Cg-Aire^tm1.1Doi H2^b/Doi)	stomach inflammation	J:107432
\Aire^tm1.1Doi/\Aire^tm1.1Doi \Idd3^C57BL/6/\Idd3^C57BL/6 \Idd5^C57BL/10SnJ/\Idd5^C57BL/10SnJ (NOD.Cg-Idd3^C57BL/6 Idd5^C57BL/10SnJ Aire^tm1.1Doi/Doi)	stomach inflammation	J:107432
\Aire^tm1.1Doi/\Aire^tm1.1Doi \Il1r1^tm1Imx/\Il1r1⁺ (involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)	keratoconjunctivitis	J:163691
	lacrimal gland inflammation	J:163691
\Aire^tm1.1Doi/\Aire^tm1.1Doi \Il1r1^tm1Imx/\Il1r1^tm1Imx (involves: 129S2/SvPas * 129S7/SvEvBrd * NOD)	keratoconjunctivitis	J:163691
	lacrimal gland inflammation	J:163691
\Aire^tm1.1Doi/\Aire^tm1.1Doi \Tg(Ins2-TFRC/OVA)296Wehi/0 \Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:135154
	decreased CD4-positive, alpha-beta T cell number	J:135154
\Aire^tm1Mand/\Aire⁺ (involves: 129P2/OlaHsd * C57BL/6)	lacrimal gland inflammation	J:135154
\Aire^tm1Mand/\Aire⁺ (involves: 129P2/OlaHsd * C57BL/6)	salivary gland inflammation	J:135154
\Aire^tm1Mand/\Aire⁺ (NOD.129P2-Aire^tm1Mand)	abnormal CD4-positive, alpha-beta T cell physiology	J:135154, J:188686
	abnormal chemokine level	J:188686
	chronic pancreas inflammation	J:135154
	CNS inflammation	J:135154
	increased autoantibody level	J:188686
	increased CXCL10 level	J:188686
	increased inflammatory response	J:188686
	increased susceptibility to autoimmune diabetes	J:135154, J:188686
	insulitis	J:135154
	lacrimal gland inflammation	J:135154
	salivary gland inflammation	J:135154
	thyroid gland inflammation	J:135154
\Aire^tm1Mand/\Aire⁺ \Tg(Ins2-TFRC/OVA)296Wehi/0 \Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:135154
\Aire^tm1Mand/\Aire^tm1.1Doi (NOD.129-Aire^tm1Mand/Aire^tm1.1Doi)	abnormal CD4-positive, alpha-beta T cell physiology	J:135154
	chronic pancreas inflammation	J:135154
	insulitis	J:135154
	lacrimal gland inflammation	J:135154
	lung inflammation	J:135154
	salivary gland inflammation	J:135154
	stomach inflammation	J:135154
	thyroid gland inflammation	J:135154
	uveitis	J:135154
\Aire^tm1Mand/\Aire^tm1Mand (involves: 129P2/OlaHsd * C57BL/6)	eye inflammation	J:135154
	lacrimal gland inflammation	J:135154
	salivary gland inflammation	J:135154
\Aire^tm1Mmat/\Aire^tm1Mmat (involves: C57BL/6 * CBA)	autoimmune response	J:96580
	lacrimal gland inflammation	J:96580
	pancreas inflammation	J:96580
	parotid gland inflammation	J:96580
	stomach inflammation	J:96580
	submandibular gland inflammation	J:96580
\Aire^tm1Mmat/\Aire^tm1Mmat (C.Cg-Aire^tm1Mmat)	increased autoantibody level	J:96580
\Aire^tm1Mmat/\Aire^tm1Mmat (C.Cg-Aire^tm1Mmat)	stomach inflammation	J:96580
\Aire^tm1Mmat/\Aire^tm1Mmat (B6.Cg-Aire^tm1Mmat)	autoimmune response	J:96580
\Aire^tm1Mmat/\Aire^tm1Mmat (B6.Cg-Aire^tm1Mmat)	salivary gland inflammation	J:96580
\Aire^tm1Mmat/\Aire^tm2Mmat (involves: C57BL/6 * CBA)	abnormal thymus morphology	J:141379
\Aire^tm1Mmat/\Aire^tm2Mmat (involves: C57BL/6 * CBA)	autoimmune response	J:141379
\Aire^tm1Mmat/\Aire^tm2Mmat \Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6 * CBA)	abnormal thymus morphology	J:141379
	immune system phenotype	J:141379
\Aire^tm1Pltn/\Aire^tm1Pltn (involves: 129S4/SvJae * C57BL/6)	abnormal T cell morphology	J:77873
	increased autoantibody level	J:77873
	increased T cell proliferation	J:77873
	liver inflammation	J:77873
	thymus atrophy	J:77873
\Aire^tm1Pltn/\Aire^tm1Pltn (B6.129S4-Aire^tm1Pltn)	abnormal metallophilic macrophage morphology	J:115076
	abnormal myelopoiesis	J:115076
	abnormal spleen marginal zone morphology	J:115076
	decreased follicular B cell number	J:115076
	enlarged spleen	J:115076
	immune system phenotype	J:115076
	increased B cell number	J:115076
	increased marginal zone B cell number	J:115076
	increased monocyte cell number	J:115076
	increased spleen weight	J:115076
	liver inflammation	J:115076
\Aire^tm1Ptsn/\Aire^tm1Ptsn (C57BL/6-Aire^tm1Ptsn)	abnormal T cell activation	J:145910
	abnormal thymus medulla morphology	J:145910
	increased autoantibody level	J:145910
	parotid gland inflammation	J:145910
	sublingual gland inflammation	J:145910
	uveitis	J:145910
	vitreous body inflammation	J:145910
\Aire^tm1Ptsn/\Aire^tm1Ptsn (C.B6-Aire^tm1Ptsn)	abnormal adaptive immunity	J:174653
	abnormal cytokine level	J:174653
	abnormal regulatory T cell physiology	J:174653
	abnormal T-helper 1 physiology	J:174653
	abnormal T-helper 17 cell physiology	J:174653
	decreased susceptibility to fungal infection	J:174653
	increased interleukin-6 secretion	J:174653
	increased interleukin-12 secretion	J:174653
	increased interleukin-23 secretion	J:174653
	increased susceptibility to autoimmune disorder	J:174653
	increased susceptibility to fungal infection	J:174653
	increased tumor necrosis factor secretion	J:174653
	stomach inflammation	J:174653
\Aire^tm2Mmat/\Aire^tm2Mmat (involves: C57BL/6 * CBA)	abnormal thymus morphology	J:141379
	abnormal thymus physiology	J:141379
	absent Hassall's corpuscle	J:141379
	autoimmune response	J:141379
\Ajuba^em1(IMPC)H/\Ajuba^em1(IMPC)H (C57BL/6N-Ajuba^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Ak7^{em1(IMPC)Ccpcz}/\Ak7⁺ (C57BL/6NCrl-Ak7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Ak7^{Gt(OST434404)Lex}/\Ak7^{Gt(OST434404)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	rhinosinusitis	J:185566
\Ak7^{Tg(tetO-Hmox1)67Sami}/\Ak7^{Tg(tetO-Hmox1)67Sami} (FVB/N-Ak7^{Tg(tetO-Hmox1)67Sami})	respiratory system inflammation	J:186062
	rhinitis	J:186062
\Akap9^{tm1a(KOMP)Wtsi}/\Akap9⁺ (involves: C57BL/6 * C57BL/6N)	decreased B cell number	J:213427
	decreased mature B cell number	J:213427
	increased CD4-positive, alpha-beta T cell number	J:213427
	increased CD8-positive, alpha-beta T cell number	J:213427
	increased T cell number	J:213427
\Akap11^{tm1b(EUCOMM)Hmgu}/\Akap11^{tm1b(EUCOMM)Hmgu} (B6N(Cg)-Akap11^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
\Akap12^tm1Ihg/\Akap12^tm1Ihg (involves: 129S4/SvJae * C57BL/6)	increased spleen red pulp amount	J:138882
	liver inflammation	J:138882
\Akap13^em1(IMPC)Mbp/\Akap13^em1(IMPC)Mbp (C57BL/6N-Akap13^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Akap13^tm1Segj/\Akap13⁺ (involves: 129)	abnormal lymphocyte physiology	J:111574
	abnormal splenocyte physiology	J:181088
	decreased B cell number	J:181088
	decreased IgG1 level	J:181088
	decreased spleen B cell follicle size	J:181088
	decreased spleen weight	J:181088
	decreased splenocyte number	J:181088
	decreased transitional stage T2 B cell number	J:181088
	increased transitional stage T1 B cell number	J:181088
	small spleen	J:181088
	spleen hypoplasia	J:181088
\Akip1^em1Cya/\Akip1^em1Cya (C57BL/6N-Akip1^em1Cya)	decreased susceptibility to endotoxin shock	J:326919
\Akip1^em1Cya/\Akip1^em1Cya (C57BL/6N-Akip1^em1Cya)	decreased susceptibility to viral infection	J:326919
\Akna^tm1Mak/\Akna^tm1Mak (B6.129P2-Akna^tm1Mak)	alveolitis	J:233952
	increased acute inflammation	J:233952
	increased neutrophil cell number	J:233952
	increased susceptibility to fungal infection	J:233952
	lung inflammation	J:233952
\Akna^tm2Mak/\Akna^tm2Mak (B6.129-Akna^tm2Mak)	increased susceptibility to fungal infection	J:233952
\Akr1a1^{Gt(OST222400)Lex}/\Akr1a1^{Gt(OST222400)Lex} (B6.129S5-Akr1a1^{Gt(OST222400)Lex})	abnormal osteoclast physiology	J:164548
	increased osteoclast cell number	J:164548
\Akr1b8^tm1Dgen/\Akr1b8^tm1Dgen (Not Specified)	abnormal interferon level	J:301852
	abnormal interleukin level	J:301852
	increased susceptibility to induced colitis	J:301852
\Akr1c21^em1Wany/\Akr1c21^em1Wany (involves: C57BL/6)	increased acute inflammation	J:322353
	increased interleukin level	J:322353
	lung inflammation	J:322353
\Akt1^tm1Nhy/\Akt1^tm1Nhy (involves: 129/Sv * C57BL/6)	abnormal thymus morphology	J:71404
\Akt1^tm1Pnt/\Akt1^tm1Pnt \Akt2^tm1.1Mbb/\Akt2^tm1.1Mbb \Akt3^tm1Mbb/\Akt3^tm1Mbb \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd)	arrested T cell differentiation	J:135903
	decreased double-positive T cell number	J:135903
	increased double-negative T cell number	J:135903
	increased T cell apoptosis	J:135903
	thymus hypoplasia	J:135903
\Akt1^tm1Pnt/\Akt1^tm1Pnt \Akt2^tm1.1Mbb/\Akt2^tm1.1Mbb \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd)	arrested T cell differentiation	J:135903
	decreased double-positive T cell number	J:135903
	increased double-negative T cell number	J:135903
	increased T cell apoptosis	J:135903
	thymus hypoplasia	J:135903
\Akt1^tm1Pnt/\Akt1^tm1Pnt \Akt3^tm1Mbb/\Akt3^tm1Mbb \Tg(Lck-cre)1Cwi/0 (Not Specified)	decreased double-positive T cell number	J:135903
	thymus hypoplasia	J:135903
\Akt2^tm1.1Mbb/\Akt2^tm1.1Mbb (involves: 129P2/OlaHsd)	immune system phenotype	J:135903
\Akt3^tm1Mbb/\Akt3^tm1Mbb (Not Specified)	immune system phenotype	J:135903
\Aktip^{tm1a(EUCOMM)Hmgu}/\Aktip^{tm1a(EUCOMM)Hmgu} \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6N)	kidney inflammation	J:276210
	liver inflammation	J:276210
	lung inflammation	J:276210
	peritoneal inflammation	J:276210
\Alad^em1(IMPC)Tcp/\Alad⁺ (C57BL/6NCrl-Alad^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Alan2^B10.O20/Dem/\Alan2^B10.O20/Dem (involves: B10.O20/Dem * O20/A)	abnormal immune system physiology	J:67657
\Alan2^B10.O20/Dem/\Alan2^O20/A (involves: B10.O20/Dem * O20/A)	abnormal immune system physiology	J:67657
\Aldh1a2^tm1Dll/\Aldh1a2^tm1Ipc (involves: CD-1)	athymia	J:81969
\Aldh1a2^tm1Dll/\Aldh1a2^tm1Ipc (involves: CD-1)	thymus hypoplasia	J:81969
\Aldh1l2^{em1(IMPC)Kmpc}/\Aldh1l2^{em1(IMPC)Kmpc} (C57BL/6NTac-Aldh1l2^{em1(IMPC)Kmpc}/Kmpc)	increased B-1a cell number	J:211773
	increased CD8-positive, CD25-positive alpha-beta T cell number	J:211773
\Aldh1l2^{tm2e(KOMP)Wtsi}/\Aldh1l2^{tm2e(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	immune system phenotype	J:299012
\Aldh2^tm1.1Mak/\Aldh2⁺ (involves: 129S6/SvEvTac * C57BL/6J)	decreased leukocyte cell number	J:223796
\Aldh2^tm1.1Mak/\Aldh2^tm1.1Mak (involves: 129S6/SvEvTac * C57BL/6J)	decreased leukocyte cell number	J:223796
\Aldh2^{tm1a(EUCOMM)Wtsi}/\Aldh2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Aldh2^{tm1a(EUCOMM)Wtsi}/Ieg)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
\Aldh2^{tm1a(EUCOMM)Wtsi}/\Aldh2^{tm1a(EUCOMM)Wtsi} \Fancd2^tm1Hou/\Fancd2^tm1Hou (involves: 129S4/SvJae * C57BL/6J * C57BL/6N)	abnormal lymphopoiesis	J:193232
	abnormal spleen morphology	J:188123
	abnormal thymus morphology	J:188123
	decreased leukocyte cell number	J:188123
	enlarged spleen	J:193232
	increased CD8-positive, alpha-beta T cell number	J:193232
	increased double-positive T cell number	J:193232
	increased T cell derived lymphoma incidence	J:193232
\Aldh18a1^{tm1a(KOMP)Wtsi}/\Aldh18a1⁺ (C57BL/6N-Aldh18a1^{tm1a(KOMP)Wtsi}/Wtsi)	skin inflammation	J:232539
\Aldoa^{tm1.1(KOMP)Wtsi}/\Aldoa⁺ (C57BL/6N-Aldoa^{tm1.1(KOMP)Wtsi}/Bay)	decreased leukocyte cell number	J:211773
\Aldob^{tm1(KOMP)Vlcg}/\Aldob^{tm1(KOMP)Vlcg} (C57BL/6NTac-Aldob^{tm1(KOMP)Vlcg})	liver inflammation	J:220330
\Alg1^{tm1b(KOMP)Wtsi}/\Alg1⁺ (C57BL/6N-Alg1^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Alg6^em1(IMPC)Tcp/\Alg6⁺ (C57BL/6N-Alg6^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
\Alg13^{tm1a(KOMP)Wtsi}/\Alg13^{tm1a(KOMP)Wtsi} (C57BL/6N-Alg13^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Alkbh1^{tm1b(EUCOMM)Hmgu}/\Alkbh1⁺ (C57BL/6N-Alkbh1^{tm1b(EUCOMM)Hmgu}/Ieg)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Alms1^Gt(XH152)Byg/\Alms1^Gt(XH152)Byg (involves: 129P2/OlaHsd * C57BL/6J)	tubulointerstitial nephritis	J:100403
\Alo1/\Alo1 (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
\Alo1/\Alo1⁺ (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
\Alo2/\Alo2 (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
\Alo2/\Alo2⁺ (involves: C3H/HeJ * C57BL/6J)	abnormal lymph node morphology	J:109802
	enlarged lymph nodes	J:109802
	enlarged spleen	J:109802
	lymph node necrosis	J:109802
\Alox5^{em1(IMPC)Ccpcz}/\Alox5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Alox5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Alox5^tm1Bhk/\Alox5^tm1Bhk (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))	abnormal inflammatory response	J:68714
	abnormal neutrophil physiology	J:68714
	decreased acute inflammation	J:68714
	decreased susceptibility to type I hypersensitivity reaction	J:68714
	impaired neutrophil chemotaxis	J:68714
	impaired neutrophil recruitment	J:68714
\Alox5^tm1Fun/\Alox5^tm1Fun (involves: 129S2/SvPas * C57BL/6)	abnormal immune system physiology	J:21372
	decreased inflammatory response	J:21372, J:75371
	immune system phenotype	J:21372
	small spleen	J:21372
\Alox5^tm1Fun/\Alox5^tm1Fun (B6.129S2-Alox5^tm1Fun)	immune system phenotype	J:89268
\Alox5^tm1Fun/\Alox5^tm1Fun (B6.129S2-Alox5^tm1Fun/J)	decreased susceptibility to experimental autoimmune uveoretinitis	J:108446
\Alox5ap^tm1Bhk/\Alox5ap^tm1Bhk (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased susceptibility to type I hypersensitivity reaction	J:39229
\Alox5ap^tm1Bhk/\Alox5ap^tm1Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	decreased acute inflammation	J:39229
	impaired neutrophil recruitment	J:39229
\Alox5ap^tm1Jdm/\Alox5ap⁺ (DBA/1LacJ-Alox5ap^tm1Jdm)	decreased susceptibility to induced arthritis	J:100736
\Alox5ap^tm1Jdm/\Alox5ap⁺ (DBA/1LacJ-Alox5ap^tm1Jdm)	immune system phenotype	J:100736
\Alox5ap^tm1Jdm/\Alox5ap^tm1Jdm (DBA/1LacJ-Alox5ap^tm1Jdm)	decreased inflammatory response	J:100736
	decreased susceptibility to induced arthritis	J:100736
	immune system phenotype	J:100736
\Alox8^{tm1a(KOMP)Wtsi}/\Alox8^{tm1a(KOMP)Wtsi} (C57BL/6N-Alox8^{tm1a(KOMP)Wtsi}/MbpMmucd)	abnormal susceptibility to Orthomyxoviridae infection	J:277623
	increased interleukin-6 secretion	J:277623
	lung inflammation	J:277623
\Alox12^tm1Fun/\Alox12^tm1Fun (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:55741
\Alox15^tm1Fun/\Alox15^tm1Fun (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:44778
\Alox15^tm1Fun/\Alox15^tm1Fun (B6.129S2-Alox15^tm1Fun/J)	abnormal lymph node morphology	J:119405
	abnormal myelopoiesis	J:119405
	abnormal spleen red pulp morphology	J:119405
	abnormal spleen white pulp morphology	J:119405
	decreased spleen B cell follicle number	J:119405
	dermatitis	J:119405
	increased basophil cell number	J:119405
	increased leukocyte cell number	J:119405
	increased spleen weight	J:119405
	intermingled spleen red and white pulp	J:119405
\Alox15^tm1Fun/\Alox15^tm1Fun (B6.129S2-Alox15^tm1Fun)	immune system phenotype	J:197334
\Aloxe3^em1(IMPC)Mbp/\Aloxe3⁺ (C57BL/6N-Aloxe3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Alpk1^em1Dlka/\Alpk1^em1Dlka \Crb1^rd8/\Crb1^rd8 (involves: C57BL/6N)	abnormal circulating chemokine level	J:344848
	immune system phenotype	J:344848
	increased circulating CXCL10 level	J:344848
\Alpl^{em1(IMPC)Ccpcz}/\Alpl⁺ (C57BL/6NCrl-Alpl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Alpl^tm1Jlm/\Alpl^tm1Jlm (either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * C57BL/6J))	abnormal spleen morphology	J:39015
	abnormal thymus cortex morphology	J:39015
	decreased leukocyte cell number	J:39015
	pale spleen	J:39015
	small spleen	J:39015
\Als2^tm1Jei/\Als2^tm1Jei (involves: 129P2/OlaHsd * C57BL/6J)	CNS inflammation	J:104446
\Altre^tm1.1Hbgl/\Altre^tm1.1Hbgl \Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal regulatory T cell physiology	J:342907
	decreased regulatory T cell number	J:342907
	decreased T cell number	J:342907
	increased CD8-positive, alpha-beta T cell number	J:342907
	increased interleukin-17 secretion	J:342907
	increased memory T cell number	J:342907
	increased regulatory T cell apoptosis	J:342907
\amd^A/J/\amd^A/J (involves: A/J * C57BL/6J)	myocarditis	J:2843, J:11025
\amd^DBA/2J/\amd^DBA/2J (B10.D2-H8^b/(57N)SnJ)	myocarditis	J:11025
\Amdhd1^{tm2b(EUCOMM)Hmgu}/\Amdhd1^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Amdhd1^{tm2b(EUCOMM)Hmgu}/BayMmucd)	increased lymphocyte cell number	J:211773
\Amelx^{em1(IMPC)Ccpcz}/Y (C57BL/6N-Amelx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Amelx^{em1(IMPC)Ccpcz}/\Amelx⁺ (C57BL/6N-Amelx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased eosinophil cell number	J:211773
\Amelx^{em1(IMPC)Ccpcz}/\Amelx^{em1(IMPC)Ccpcz} (C57BL/6N-Amelx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Amer1^tm1.2Nbar/Y (involves: 129S4/SvJae * C57BL/6 * CD-1 * SJL)	spleen hypoplasia	J:173242
\Amfr^{Gt(IST12797A11)Tigm}/\Amfr^{Gt(IST12797A11)Tigm} (C57BL/6-Amfr^{Gt(IST12797A11)Tigm})	liver inflammation	J:221247
\Amhr2^tm3(cre)Bhr/\Amhr2⁺ \Pten^tm1Hwu/\Pten^tm1Hwu (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)	decreased uterine NK cell number	J:170203
\Amotl2^em1(IMPC)Mbp/\Amotl2^em1(IMPC)Mbp (C57BL/6NCrl-Amotl2^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
\Ampd1^{tm1b(KOMP)Wtsi}/\Ampd1⁺ (C57BL/6N-Ampd1^{tm1b(KOMP)Wtsi}/Ucd)	decreased neutrophil cell number	J:211773
\Ampd1^{tm1b(KOMP)Wtsi}/\Ampd1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ampd1^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
\Ampd2^tm1Tm/\Ampd2^tm1Tm (involves: 129S2/SvPas)	immune system phenotype	J:201211
\Ampd3^tm1Tm/\Ampd3^tm1Tm (Not Specified)	lung inflammation	J:201211
\Ampd3^tm1Tm/\Ampd3^tm1Tm \Pklr^slc/\Pklr^slc (involves: CBA/NSlc)	enlarged spleen	J:203909
\Ampd3^{tm2a(KOMP)Wtsi}/\Ampd3^{tm2a(KOMP)Wtsi} (B6JTyr;B6N-Ampd3^{tm2a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:165965
\Amt^em1(IMPC)Tcp/\Amt⁺ (C57BL/6N-Amt^em1(IMPC)Tcp/Cmmr)	decreased lymphocyte cell number	J:211773
\Amtn^em1(IMPC)Mbp/\Amtn^em1(IMPC)Mbp (C57BL/6N-Amtn^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\anan/\anan (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
\anan/\anan⁺ (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
\anaya/\anaya (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
\andra/\andra (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	increased anti-nuclear antigen antibody level	J:169366
\anem/\anem (BALB/c-anem)	increased leukocyte cell number	J:227974
\Ang^{tm1.1(KOMP)Vlcg}/\Ang^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ang^{tm1.1(KOMP)Vlcg}/Ucd)	increased eosinophil cell number	J:211773
\Ang^tm1Dats/\Ang^tm1Dats (Not Specified)	decreased leukocyte cell number	J:236081
\Ang^tm1Dats/\Ang^tm1Dats (Not Specified)	increased lymphocyte cell number	J:236081
\Angpt1^tm1.1Seq/\Angpt1^tm1.1Seq \Angpt2^{tm1c(KOMP)Seq}/\Angpt2^{tm1c(KOMP)Seq} \Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/? \Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6NCr)	abnormal lymphatic vessel morphology	J:217296
\Angpt2^em1(IMPC)Mbp/\Angpt2⁺ (C57BL/6NCrl-Angpt2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Angpt2^em1(IMPC)Mbp/\Angpt2^em1(IMPC)Mbp (C57BL/6NCrl-Angpt2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	small thymus	J:211773
\Angpt2^tm1Gdy/\Angpt2^tm1Gdy (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphatic vessel morphology	J:89618
\Angpt2^{tm2(Angpt1)Gdy}/\Angpt2^{tm2(Angpt1)Gdy} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:89618
\Angptl2^tm1Yo/\Angptl2^tm1Yo (B6.Cg-Angptl2^tm1Yo)	impaired macrophage chemotaxis	J:152387
\Angptl3^{tm2b(KOMP)Wtsi}/\Angptl3^{tm2b(KOMP)Wtsi} (C57BL/6N-Angptl3^{tm2b(KOMP)Wtsi}/Ccpcz)	enlarged lymph nodes	J:211773
\Angptl4^{Gt(OST352973)Lex}/\Angptl4^{Gt(OST352973)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:122968
	abnormal mesenteric lymph node morphology	J:122968
\Angptl4^tm1Lex/\Angptl4^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:122968
	abnormal mesenteric lymph node morphology	J:122968
\Ank1^ity16/\Ank1⁺ (involves: 129S1/Sv * 129X1/SvJ * DBA/2J)	increased susceptibility to bacterial infection	J:199427
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
\Ank1^ity16/\Ank1^ity16 (involves: 129S1/Sv * 129X1/SvJ * DBA/2J)	decreased spleen iron level	J:199427
	enlarged spleen	J:199427
	glomerulonephritis	J:199427
	increased leukocyte cell number	J:199427
	increased lymphocyte cell number	J:199427
	increased neutrophil cell number	J:199427
	increased susceptibility to bacterial infection	J:199427
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
\Ank1^M1Btlr/\Ank1^M1Btlr (C57BL/6J-Ank1^m1Btlr)	abnormal spleen morphology	J:203831
	enlarged spleen	J:203831
	increased spleen iron level	J:203831
\Ank1^M1Wlst/\Ank1⁺ (involves: 129S1/SvImJ * C3H/HeJ * C57BL/6)	enlarged spleen	J:170562
\Ank1^M1Wlst/\Ank1^M1Wlst (involves: C3H/HeJ * C57BL/6)	abnormal leukocyte cell number	J:170562
\Ank1^M1Wlst/\Ank1^M1Wlst (involves: 129S1/SvImJ * C3H/HeJ * C57BL/6)	abnormal myelopoiesis	J:170562
	enlarged spleen	J:170562
\Ank1^MRI23420/\Ank1⁺ (SJL/J-Ank1^MRI23420)	abnormal spleen morphology	J:187820
	decreased susceptibility to parasitic infection	J:187820
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:187820
	enlarged spleen	J:187820
	increased spleen iron level	J:187820
	increased spleen weight	J:187820
\Ank1^MRI23420/\Ank1^MRI23420 (SJL/J-Ank1^MRI23420)	enlarged spleen	J:187820
\Ank1^MRI23420/\Ank1^MRI23420 (SJL/J-Ank1^MRI23420)	increased spleen weight	J:187820
\Ank1^nb/\Ank1⁺ (involves: C57BL/6J * WB/Re)	decreased susceptibility to parasitic infection	J:111131
\Ank1^nb/\Ank1^nb (either: (involves: non-inbred stock) or (involves: C57BL/6) or (involves: WB/Re))	abnormal thymus development	J:30699
	enlarged lymph nodes	J:30699
	enlarged spleen	J:30699
	increased leukocyte cell number	J:30699
\Ank1^nb/\Ank1^nb (involves: C57BL/6J * WB/Re)	decreased susceptibility to parasitic infection	J:111131
\Ank1^nb/\Ank1^nb ((WB.Cg-Ank1^nb/BrkJ x B6.Cg-Ank1^nb/BrkJ)F1)	enlarged spleen	J:162532
\Ank1^Rbc2/\Ank1⁺ (involves: 129S1/Sv * BALB/c)	decreased susceptibility to parasitic infection	J:148127
\Ank1^Rbc2/\Ank1^Rbc2 (involves: 129S1/Sv * BALB/c)	enlarged spleen	J:148127
\Ank^ank/\Ank^ank (involves: C3HeB/FeJ * C57BL/6J * JGBF/LeJ)	autoimmune arthritis	J:63420
\Ank^tm1.1Ejr/\Ank⁺ (B6.129-Ank^tm1.1Ejr)	abnormal osteoclast differentiation	J:168526
\Ank^tm1.1Ejr/\Ank^tm1.1Ejr (B6.129-Ank^tm1.1Ejr)	abnormal osteoclast differentiation	J:168526
\Ankfy1^{tm1b(KOMP)Mbp}/\Ankfy1⁺ (C57BL/6N-Ankfy1^{tm1b(KOMP)Mbp}/Tcp)	increased monocyte cell number	J:211773
\Ankrd2^tm1Krc/\Ankrd2^tm1Krc (involves: 129 * Black Swiss)	abnormal inflammatory response	J:214867
\Ankrd11^{tm1c(EUCOMM)Wtsi}/\Ankrd11^{tm1c(EUCOMM)Wtsi} \E2f1^{Tg(Wnt1-cre)2Sor}/\E2f1⁺ (involves: C3H * C57BL/6 * C57BL/6N)	decreased osteoclast cell number	J:306391
\Ankrd11^Yod/\Ankrd11⁺ (involves: BALB/cAnNCrl * C3H/HeH)	decreased osteoclast cell number	J:136455
\Ankrd31^{em1(IMPC)Hmgu}/\Ankrd31^{em1(IMPC)Hmgu} (C57BL/6NCrl-Ankrd31^{em1(IMPC)Hmgu}/Ieg)	abnormal spleen morphology	J:211773
\Ankrd46^em1(IMPC)Mbp/\Ankrd46^em1(IMPC)Mbp (C57BL/6NCrl-Ankrd46^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
\Ankrd49^em1(IMPC)Tcp/\Ankrd49⁺ (C57BL/6NCrl-Ankrd49^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Ankrd52^em1(IMPC)J/\Ankrd52⁺ (C57BL/6NJ-Ankrd52^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ankrd60^em1(IMPC)J/\Ankrd60^em1(IMPC)J (C57BL/6NJ-Ankrd60^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Ano2^{em1(IMPC)Ccpcz}/\Ano2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ano2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Ano5^em1Huyi/\Ano5^em1Huyi (C57BL/6N-Ano5^em1Huyi)	periodontium inflammation	J:294237
\Ano5^em2Huyi/\Ano5^em2Huyi (C57BL/6-Ano5^em2Huyi)	abnormal osteoclast physiology	J:336715
	decreased osteoclast cell number	J:336715
	osteomyelitis	J:336715
\Ano6^em3(IMPC)Tcp/\Ano6⁺ (C57BL/6NCrl-Ano6^em3(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Anpep^tm1.1Lsha/\Anpep^tm1.1Lsha (B6.Cg-Anpep^tm1.1Lsha)	abnormal macrophage physiology	J:163945
	immune system phenotype	J:163945
	increased CD4-positive, alpha-beta T cell number	J:163945
\Anta/\Anta⁺ (involves: C57BL/6 * C57BL/10 * C57BR/cd)	glomerulonephritis	J:169366
\Anta/\Anta⁺ (involves: C57BL/6 * C57BL/10 * C57BR/cd)	increased anti-nuclear antigen antibody level	J:169366
\Anth2^CBA/J/? (involves: A/J * CBA/J)	decreased susceptibility to bacterial infection	J:9501
\Anth^C3H/HeNCrj/\Anth^C3H/HeNCrj (involves: C3H/HeNCrj * C57BL/6NCrj)	decreased susceptibility to bacterial infection	J:11149
\Anth^C3H/HeNCrj/\Anth^C57BL/6NCrj (involves: C3H/HeNCrj * C57BL/6NCrj)	decreased susceptibility to bacterial infection	J:11149
\Antxr1^tm1.2Lepp/\Antxr1^tm1.2Lepp (involves: 129 * C57BL/6)	immune system phenotype	J:150952
\Antxr2^tm1.1Jkit/\Antxr2^tm1.1Jkit (involves: 129 * C57BL/6)	lymphangiectasis	J:187210
\Antxr2^tm1.2Lepp/\Antxr2^tm1.2Lepp (involves: C57BL/6)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:150952
\anx/\anx (B6C3Fe a/a-anx/J)	abnormal inflammatory response	J:103396
	decreased spleen weight	J:7689
	increased thymus weight	J:7689
	pale spleen	J:7689
	small spleen	J:7689
\anx/\anx (involves: DW/J * M. m. domesticus poschiavinus * Swiss)	abnormal spleen morphology	J:13936
	small spleen	J:13936
\Anxa1^{em1(IMPC)Ccpcz}/\Anxa1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Anxa1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Anxa1^tm1Rjf/\Anxa1⁺ (Not Specified)	increased inflammatory response	J:81498
\Anxa1^tm1Rjf/\Anxa1^tm1Rjf (Not Specified)	abnormal leukocyte physiology	J:81498
	impaired macrophage phagocytosis	J:81498
	increased inflammatory response	J:81498
\Anxa1^tm1Rjf/\Anxa1^tm1Rjf (involves: BALB/c)	increased susceptibility to induced colitis	J:142735
\Anxa5^tm1Epo/\Anxa5^tm1Epo (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:117249
	abnormal inflammatory response	J:117249
	decreased susceptibility to type IV hypersensitivity reaction	J:117249
\Anxa5^tm1Epo/\Anxa5^tm1Epo \Anxa6^tm1Moss/\Anxa6^tm1Moss (involves: 129P2/OlaHsd * C57BL/6)	decreased dendritic cell number	J:193886
	increased B cell number	J:193886
\Anxa5^tm1Epo/\Anxa5^tm1Epo \Anxa6^tm1Moss/\Anxa6^tm1Moss \Col10a1^tm1Ksec/\Col10a1^tm1Ksec (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased dendritic cell number	J:193886
	increased B cell number	J:193886
	increased T-helper cell number	J:193886
\Anxa6^tm1Moss/\Anxa6^tm1Moss (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:58609
\Anxa7^tm1Pll/\Anxa7⁺ (Not Specified)	pancreas inflammation	J:58572
\Anxa8^tm1Resc/\Anxa8^tm1Resc \Tg(Pgk1-cre)1Lni/0 (involves: 129 * C57BL/6J * BALB/c)	impaired leukocyte tethering or rolling	J:225224
\Aoah^tm1Rsm/\Aoah^tm1Rsm (involves: 129S6/SvEvTac)	abnormal humoral immune response	J:90493
\Aoc3^tm1Salm/\Aoc3^tm1Salm (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	abnormal cellular extravasation	J:95656
	abnormal leukocyte adhesion	J:95656
	abnormal leukocyte migration	J:95656
	decreased inflammatory response	J:95656
	impaired leukocyte tethering or rolling	J:95656
\Aod1a^A/J/? (involves: A/J * C57BL/6J)	ovary inflammation	J:83714
\Aod1b^C57BL/6J/? (involves: A/J * C57BL/6J)	ovary inflammation	J:83714
\Aod3^A/J/? (A/J)	ovary inflammation	J:78005
\aol/\aol (involves: C3H * C57BL/6)	osteoarthritis	J:115238
\Ap1b1^b2b1660Clo/\Ap1b1^b2b1660Clo (C57BL/6J-Ap1b1^b2b1660Clo)	absent spleen	J:175213
	spleen hypoplasia	J:175213
\Ap1g1^tm1Schu/\Ap1g1⁺ (either: (involves: 129P2/OlaHsd * 129X1/SvJ) or (involves: 129P2/OlaHsd * C57BL/6J))	decreased CD4-positive, alpha-beta T cell number	J:53252
\Ap2b1^b2b2321Clo/\Ap2b1^b2b2321Clo (C57BL/6J-Ap2b1^b2b2321Clo)	thymus hypoplasia	J:175213
\Ap3b1^m1Btlr/\Ap3b1^m1Btlr (C57BL/6J-Ap3b1^m1Btlr)	increased susceptibility to Herpesvirales infection	J:132673
\Ap3b1^pe/\Ap3b1^pe \Hps1^ep/\Hps1^ep (involves: C3H/He * C3HeB/FeJ * C57BL/6J)	abnormal monocyte morphology	J:85431
	lung inflammation	J:85431
\Ap4e1^{tm1b(KOMP)Wtsi}/\Ap4e1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ap4e1^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Ap4e1^{tm1b(KOMP)Wtsi}/\Ap4e1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ap4e1^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
\Ap4e1^{tm1b(KOMP)Wtsi}/\Ap4e1^{tm1b(KOMP)Wtsi} (C57BL/6N-Ap4e1^{tm1b(KOMP)Wtsi}/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Ap4m1^{tm1b(EUCOMM)Wtsi}/\Ap4m1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ap4m1^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Ap5m1^em1(IMPC)Mbp/\Ap5m1^em1(IMPC)Mbp (C57BL/6N-Ap5m1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Apaf1^tm1Mak/\Apaf1^tm1Mak (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CD-1))	immune system phenotype	J:49841
\Apba3^tm1.1Ski/\Apba3^tm1.1Ski \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.129-Apba3^tm1.1Ski Lyz2^tm1(cre)Ifo)	decreased susceptibility to endotoxin shock	J:176742
\Apba3^tm1.2Ski/\Apba3^tm1.2Ski (B6.129-Apba3^tm1.2Ski)	abnormal macrophage physiology	J:176742
	decreased circulating interleukin-12 level	J:176742
	decreased circulating tumor necrosis factor level	J:176742
	decreased interleukin-12 secretion	J:176742
	decreased susceptibility to endotoxin shock	J:176742
	decreased tumor necrosis factor secretion	J:176742
\Apbb1ip^{em1(IMPC)Ccpcz}/\Apbb1ip^{em1(IMPC)Ccpcz} (C57BL/6N-Apbb1ip^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Apc^Min/\Apc⁺ (C57BL/6J-Apc^Min)	decreased macrophage cell number	J:85142
\Apc^Min/\Apc⁺ (involves: 129 * C57BL/6)	decreased NK cell number	J:156864
	decreased splenocyte number	J:156864
	decreased T cell number	J:156864
\Apc^Min/\Apc⁺ (C57BL/6J-Apc^Min/J)	abnormal interleukin secretion	J:305794
\Apc^Min/\Apc⁺ \Elp3^tm1.1Tac/\Elp3^tm1.1Tac \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6 * C57BL/6J * C57BL/6NTac * SJL)	immune system phenotype	J:227334
\Apc^Min/\Apc⁺ \Esr2^tm1Mma/\Esr2^tm1Mma (involves: 129S2/SvPas * C57BL/6J)	colitis	J:118600
\Apc^Min/\Apc⁺ \Mapkapk2^tm1.2Gkl/\Mapkapk2^tm1.2Gkl (involves: BALB/cJ * C57BL/6J)	abnormal chemokine secretion	J:262876
	decreased interleukin-6 secretion	J:262876
\Apc^Min/\Apc⁺ \Tg(Rorc-EGFP)1Ebe/? (involves: C57BL/6)	abnormal effector T cell morphology	J:137020
	enlarged mesenteric lymph nodes	J:137020
	lymph node hyperplasia	J:137020
\Apc^tm1Kk/\Apc^tm1Kk \Tg(Lck-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:100461
	arrested T cell differentiation	J:100461
	increased circulating tumor necrosis factor level	J:128606
	increased double-negative T cell number	J:100461
	increased mast cell number	J:128606
	small thymus	J:100461
	thymus hypoplasia	J:100461
\Apc^tm1Rak/\Apc⁺ \Smad4^E6sad/\Smad4⁺ (B6.129P2-Apc^tm1Rak Smad4^E6sad/+ +)	enlarged spleen	J:107273
\Apc^tm1Tno/\Apc⁺ \Pten^tm2Mak/\Pten^tm2Mak \Tg(Cyp1a1-cre/ERT)1Dwi/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)	peritoneal inflammation	J:143082
\Apc^tm2.1Cip/\Apc⁺ \Atg7^tm1Tchi/\Atg7^tm1Tchi \Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)	abnormal immune system physiology	J:227287
	increased CD8-positive, alpha-beta T cell number	J:227287
	increased CD103-positive CD11b-low dendritic cell number	J:227287
	increased interleukin-1 beta secretion	J:227287
	increased interleukin-10 secretion	J:227287
	increased regulatory T cell number	J:227287
\Apc^tm2.1Cip/\Apc^tm2.1Cip \Lect2^tm1Ymg/\Lect2^tm1Ymg \Tg(Ttr-cre/Esr1)1Vco/0 (B6.Cg-Lect2^tm1Ymg Apc^tm2.1Cip Tg(Ttr-cre/Esr1)1Vco)	abnormal chemokine level	J:184496
	abnormal neutrophil physiology	J:184496
	abnormal NK T cell physiology	J:184496
	decreased interferon-gamma secretion	J:184496
	increased interleukin-4 secretion	J:184496
	increased NK T cell number	J:184496
	liver inflammation	J:184496
\Apc^tm2.1Cip/\Apc^tm2.1Cip \Tg(Ttr-cre/Esr1)1Vco/0 (B6.Cg-Apc^tm2.1Cip Tg(Ttr-cre/Esr1)1Vco)	abnormal NK T cell physiology	J:184496
	decreased NK T cell number	J:184496
	increased interferon-gamma secretion	J:184496
	increased interleukin-4 secretion	J:184496
	liver inflammation	J:184496
\Apc^tm2Rak/\Apc⁺ \Trp53^tm1Brn/\Trp53^tm1Brn \Tg(Pdx1-cre)6Tuv/0 (involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)	abnormal cytokine level	J:234310
\Apc^tm2Rak/\Apc^tm2Rak \Tg(KRT14-cre)8Brn/0 (involves: 129/Sv * C57BL/6J * FVB/N * SJL)	abnormal Hassall's corpuscle morphology	J:114152
	abnormal thymus morphology	J:114152
	decreased thymocyte number	J:114152
	small thymus	J:114152
\Apcs^tm1Mpe/\Apcs⁺ (B6.Cg-Apcs^tm1Mpe)	abnormal spleen red pulp morphology	J:90502
	abnormal spleen white pulp morphology	J:90502
	glomerulonephritis	J:90502
	increased autoantibody level	J:90502
	increased spleen white pulp amount	J:90502
\Apcs^tm1Mpe/\Apcs^tm1Mpe (B6.Cg-Apcs^tm1Mpe)	abnormal spleen morphology	J:90502
	abnormal spleen red pulp morphology	J:90502
	abnormal spleen white pulp morphology	J:90502
	decreased susceptibility to bacterial infection	J:125473
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:125473
	glomerulonephritis	J:90502
	increased autoantibody level	J:90502
	increased spleen white pulp amount	J:90502
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125473
\Apcs^tm1Mpe/\Apcs^tm1Mpe (129.Cg-Apcs^tm1Mpe)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:125473
	glomerulonephritis	J:90502
	immune system phenotype	J:90502
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125473
\Apcs^tm1Smae/\Apcs^tm1Smae (involves: 129S/SvEv * C57BL/6)	decreased susceptibility to endotoxin shock	J:71194
\Apcs^tm1Smae/\Apcs^tm1Smae (involves: 129S/SvEv * C57BL/6)	increased autoantibody level	J:71194
\Apex1^tm1Cur/\Apex1⁺ (involves: 129S1/Sv)	increased circulating interleukin-1 alpha level	J:119957
\Apex1^tm1Cur/\Apex1⁺ (involves: 129S1/Sv)	increased circulating interleukin-10 level	J:119957
\Apex1^tm1Ecf/\Apex1⁺ (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	heart inflammation	J:70397
	myocarditis	J:70397
	pericarditis	J:70397
\Apex2^em1(IMPC)H/\Apex2^em1(IMPC)H (C57BL/6NTac-Apex2^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Apex2^tm1Yun/Y (B6.129S-Apex2^tm1Yun)	decreased B cell number	J:95267
	decreased leukocyte cell number	J:95267
	decreased splenocyte proliferation	J:95267
	decreased T cell number	J:95267
	decreased thymocyte number	J:95267
	thymus atrophy	J:95267
\Aplf^{Gt(RRF189)Byg}/\Aplf^{Gt(RRF189)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal class switch recombination	J:168260
\Apoa4^tm1Bres/\Apoa4^tm1Bres (B6.129S4-Apoa4^tm1Bres)	increased susceptibility to induced colitis	J:91357
\Apob^tm2Sgy/\Apob^tm2Sgy \Ldlr^tm1Her/\Ldlr^tm1Her \Tg(Ins-Igf2)1Fbos/? (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J * SJL)	aortitis	J:227165
\Apobec1^{em1(IMPC)Ccpcz}/\Apobec1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Apobec1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Apobec3^Gt(XN450)Byg/\Apobec3^Gt(XN450)Byg (B6.Cg-Apobec3^Gt(XN450)Byg)	increased susceptibility to Retroviridae infection	J:118597
\Apobec3^Gt(XN450)Byg/\Apobec3^Gt(XN450)Byg (B6.129P2-Apobec3^Gt(XN450)Byg)	abnormal immunoglobulin level	J:138778
	increased susceptibility to Retroviridae infection	J:138778
\Apobec3^Gt(XN450)Byg/\Apobec3^Gt(XN450)Byg (129P2/OlaHsd-Apobec3^Gt(XN450)Byg)	abnormal immunoglobulin level	J:138778
	increased susceptibility to Retroviridae infection	J:138778
\Apobec3^Gt(XN450)Byg/\Apobec3^Rfv3-s \H2^b/\H2^b (involves: A.BY * C57BL/6)	abnormal immunoglobulin level	J:138778
\Apobec3^Gt(XN450)Byg/\Apobec3^Rfv3-s \H2^b/\H2^d (involves: BALB/c * C57BL/6)	abnormal immunoglobulin level	J:138778
	increased susceptibility to Retroviridae infection	J:138778
	increased susceptibility to Retroviridae infection induced morbidity/mortality	J:138778
\Apobec3^Rfv3-r/\Apobec3⁺ ((B10.A x A)F1)	decreased susceptibility to Retroviridae infection	J:6147
\Apobec3^Rfv3-r/\Apobec3⁺ ((B10.A x A)F1)	immune system phenotype	J:41946, J:6261, J:6147
\Apoc4^{tm1.1(KOMP)Mbp}/\Apoc4^{tm1.1(KOMP)Mbp} (C57BL/6N-Apoc4^{tm1.1(KOMP)Mbp}/Ieg)	increased leukocyte cell number	J:211773
\Apoe^tm1.1Mae/\Apoe^tm1.1Mae \Tg(Fabp4-cre)1Rev/0 (B6.Cg-Apoe^tm1.1Mae Tg(Fabp4-cre)1Rev)	decreased macrophage cell number	J:219838
	increased macrophage cell number	J:219838
\Apoe^tm1Bres/\Apoe^tm1Bres \Bcl2^tm1Irt/\Bcl2^tm1Irt \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased macrophage apoptosis	J:144243
\Apoe^tm1Bres/\Apoe^tm1Bres \Cx3cr1^tm1Ifc/\Cx3cr1^tm1Ifc (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:81822
\Apoe^tm1Bres/\Apoe^tm1Bres \Mapk9^tm1Flv/\Mapk9^tm1Flv (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal macrophage morphology	J:94044
	abnormal macrophage physiology	J:94044
	increased macrophage derived foam cell number	J:94044
\Apoe^tm1Khw/\Apoe^tm1Khw \Tg(Mx1-cre)29-4Her/0 (B6.Cg-Apoe^tm1Khw Tg(Mx1-cre)29-4Her)	immune system phenotype	J:196923
\Apoe^tm1Rraf/\Apoe^tm1Rraf \Tg(Mx1-cre)29-4Her/0 (B6.Cg-Apoe^tm1Rraf Tg(Mx1-cre)29-4Her)	immune system phenotype	J:196923
\Apoe^tm1Unc/\Apoe^tm1Unc (B6.129P2-Apoe^tm1Unc/J)	abnormal B cell activation	J:133606
	abnormal CD4-positive, alpha-beta T cell number	J:108154, J:47027
	abnormal immune serum protein physiology	J:61564
	abnormal immune system morphology	J:47027
	abnormal immune system physiology	J:61564
	abnormal T cell number	J:47027
	blood vessel inflammation	J:91058
	decreased follicular B cell number	J:133606
	decreased interferon-gamma secretion	J:47027
	decreased marginal zone B cell number	J:133606
	decreased susceptibility to type IV hypersensitivity reaction	J:61564
	increased anti-double stranded DNA antibody level	J:133606
	increased anti-nuclear antigen antibody level	J:133606
	increased autoantibody level	J:133606
	increased B cell number	J:133606
	increased IgM level	J:61564
	increased immunoglobulin level	J:133606
	increased marginal zone B cell number	J:133606
	increased spleen weight	J:61564
	increased susceptibility to systemic lupus erythematosus	J:133606
	increased T-helper 2 cell number	J:47027
\Apoe^tm1Unc/\Apoe^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	lung inflammation	J:83615
\Apoe^tm1Unc/\Apoe^tm1Unc (B6.129P2-Apoe^tm1Unc)	abnormal cell-mediated immunity	J:125366
	abnormal dendritic cell physiology	J:125366
	increased CD4-positive, alpha-beta T cell number	J:125366
	increased susceptibility to parasitic infection	J:125366
\Apoe^tm1Unc/\Apoe^tm1Unc (B6.Cg-Apoe^tm1Unc Fas^lpr)	increased anti-double stranded DNA antibody level	J:133606
	increased anti-nuclear antigen antibody level	J:133606
	increased immunoglobulin level	J:133606
	increased susceptibility to systemic lupus erythematosus	J:133606
\Apoe^tm1Unc/\Apoe^tm1Unc \Cbs^tm1Unc/\Cbs^tm1Unc \Tg(Mt1-CBS)25Waku/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	increased circulating tumor necrosis factor level	J:168131
	increased Ly6C high monocyte number	J:168131
	increased monocyte cell number	J:168131
\Apoe^tm1Unc/\Apoe^tm1Unc \Ccr1^tm1Gao/\Ccr1^tm1Gao (involves: 129P2/OlaHsd * 129S4/SvJae)	increased interferon-gamma secretion	J:128063
\Apoe^tm1Unc/\Apoe^tm1Unc \Ccr2^tm1Ifc/\Ccr2^tm1Ifc (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:111471
\Apoe^tm1Unc/\Apoe^tm1Unc \Ccr2^tm1Ifc/\Ccr2^tm1Ifc (B6.Cg-Apoe^tm1Unc Ccr2^tm1Ifc)	decreased monocyte cell number	J:153310
\Apoe^tm1Unc/\Apoe^tm1Unc \Ccr2^tm1Ifc/\Ccr2^tm1Ifc \Cx3cl1^tm1Lira/\Cx3cl1^tm1Lira (B6.Cg-Apoe^tm1Unc Cx3cl1^tm1Lira Ccr2^tm1Ifc)	decreased monocyte cell number	J:153310
\Apoe^tm1Unc/\Apoe^tm1Unc \Ccr5^tm1Blck/\Ccr5^tm1Blck (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:128063
	abnormal lymphocyte physiology	J:128063
	abnormal mononuclear phagocyte morphology	J:128063
	decreased interferon-gamma secretion	J:128063
	decreased T cell number	J:128063
	increased interleukin-10 secretion	J:128063
\Apoe^tm1Unc/\Apoe^tm1Unc \Ccr5^tm1Kuz/\Ccr5^tm1Kuz (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:128063
	abnormal lymphocyte physiology	J:128063
	abnormal mononuclear phagocyte morphology	J:128063
	decreased interferon-gamma secretion	J:128063
	decreased T cell number	J:128063
	increased interleukin-10 secretion	J:128063
\Apoe^tm1Unc/\Apoe^tm1Unc \Cd36^tm1Mfe/\Cd36^tm1Mfe (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	abnormal macrophage derived foam cell morphology	J:61672
	abnormal macrophage physiology	J:61672
\Apoe^tm1Unc/\Apoe^tm1Unc \Cx3cl1^tm1Sgs/\Cx3cl1^tm1Sgs (B6.129-Apoe^tm1Unc Cx3cl1^tm1Sgs)	impaired macrophage chemotaxis	J:95279
	increased macrophage derived foam cell number	J:95279
\Apoe^tm1Unc/\Apoe^tm1Unc \Cxcl10^tm1Adl/\Cxcl10^tm1Adl (B6.129-Cxcl10^tm1Adl Apoe^tm1Unc)	decreased CD4-positive, alpha-beta T cell number	J:166204
	impaired macrophage chemotaxis	J:166204
\Apoe^tm1Unc/\Apoe^tm1Unc \Cyp4f13^{Gt(OST14770)Lex}/\Cyp4f13^{Gt(OST14770)Lex} (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)	abnormal macrophage chemotaxis	J:289999
\Apoe^tm1Unc/\Apoe^tm1Unc \Cyp19a1^tm1Esi/\Cyp19a1^tm1Esi (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	increased circulating C-reactive protein level	J:184647
	increased circulating interleukin-6 level	J:184647
	increased circulating tumor necrosis factor level	J:184647
\Apoe^tm1Unc/\Apoe^tm1Unc \Fas^lpr/\Fas^lpr (MRL.Cg-Apoe^tm1Unc Fas^lpr)	increased anti-double stranded DNA antibody level	J:133606
	increased anti-nuclear antigen antibody level	J:133606
	increased autoantibody level	J:133606
	increased immunoglobulin level	J:133606
	increased susceptibility to systemic lupus erythematosus	J:133606
\Apoe^tm1Unc/\Apoe^tm1Unc \Fas^lpr/\Fas^lpr (B6.Cg-Apoe^tm1Unc Fas^lpr)	decreased autoantibody level	J:121671
	decreased CD4-positive, alpha-beta T cell number	J:121671
	decreased CD8-positive, alpha-beta T cell number	J:121671
	enlarged lymph nodes	J:121671
	enlarged spleen	J:121671
	enlarged thymus	J:121671
	glomerulonephritis	J:121671
	increased anti-double stranded DNA antibody level	J:121671
	increased autoantibody level	J:121671
	increased IgG level	J:121671
\Apoe^tm1Unc/\Apoe^tm1Unc \Fasl^gld/\Fasl^gld (B6.Cg-Fasl^gld Apoe^tm1Unc)	abnormal lymph node morphology	J:91058
	blood vessel inflammation	J:91058
	enlarged lymph nodes	J:200141, J:91058
	enlarged spleen	J:91058
	impaired macrophage phagocytosis	J:91058
	increased anti-nuclear antigen antibody level	J:200141, J:91058
	increased autoantibody level	J:91058
	increased IgG level	J:91058
	increased spleen weight	J:200141, J:91058
	increased T cell number	J:91058
	kidney inflammation	J:200141
\Apoe^tm1Unc/\Apoe^tm1Unc \Gja5^tm1Mchn/\Gja5^tm1Mchn \Tg(TIE2-lacZ)182Sato/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal neutrophil physiology	J:162224
	alveolitis	J:162224
\Apoe^tm1Unc/\Apoe^tm1Unc \Glg1^{Gt(RST092)Byg}/\Glg1⁺ (B6J.129P2-Apoe^tm1Unc Glg1^{Gt(RST092)Byg})	decreased macrophage cell number	J:226586
	impaired macrophage chemotaxis	J:226586
\Apoe^tm1Unc/\Apoe^tm1Unc \Hp^tm1Alev/\Hp^tm1Alev (involves: 129)	abnormal macrophage chemotaxis	J:134942
\Apoe^tm1Unc/\Apoe^tm1Unc \Hsd11b1^tm1Lex/\Hsd11b1^tm1Lex (B6.129-Hsd11b1^tm1Lex Apoe^tm1Unc)	abnormal cytokine secretion	J:199430
	abnormal macrophage derived foam cell morphology	J:199430
	decreased macrophage cell number	J:199430
	decreased tumor necrosis factor secretion	J:199430
	immune system phenotype	J:199430
\Apoe^tm1Unc/\Apoe^tm1Unc \Il1r1^tm1Imx/\Il1r1^tm1Imx (B6.129-Il1r1^tm1Imx Apoe^tm1Unc)	decreased circulating interleukin-6 level	J:148173
\Apoe^tm1Unc/\Apoe^tm1Unc \Il1rn^tm1Dih/\Il1rn^tm1Dih (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	abnormal macrophage chemotaxis	J:132570
\Apoe^tm1Unc/\Apoe^tm1Unc \Il10^tm1Cgn/\Il10^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal circulating cytokine level	J:105858
	increased circulating interferon-gamma level	J:105858
	increased circulating interleukin-12 level	J:105858
\Apoe^tm1Unc/\Apoe^tm1Unc \Itgb3^tm1Hyn/\Itgb3^tm1Hyn (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	lung inflammation	J:83615
\Apoe^tm1Unc/\Apoe^tm1Unc \Klf15^tm2Jain/\Klf15^tm2Jain \Tg(Tagln-cre)1Jjl/0 (involves: 129P2/OlaHsd * FVB/N)	blood vessel inflammation	J:203920
	increased macrophage cell number	J:203920
\Apoe^tm1Unc/\Apoe^tm1Unc \Mmp9^tm1Tvu/\Mmp9^tm1Tvu (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased macrophage cell number	J:110044
\Apoe^tm1Unc/\Apoe^tm1Unc \Ncf1^tm1Shl/\Ncf1^tm1Shl (involves: 129P2/OlaHsd * 129S2/SvPas)	decreased acute inflammation	J:123854
\Apoe^tm1Unc/\Apoe^tm1Unc \Nck1^tm1Paw/\Nck1^tm1Paw \Nck2^tm3Paw/\Nck2^tm3Paw \Tg(Cdh5-cre/ERT2)1Rha/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:326659
\Apoe^tm1Unc/\Apoe^tm1Unc \Nfe2l2^tm1Mym/\Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:143903
\Apoe^tm1Unc/\Apoe^tm1Unc \Pla2g15^tm1Ytan/\Pla2g15^tm1Ytan (involves: 129S/SvEv * B6.129P2-Apoe^tm1Unc/J)	abnormal macrophage morphology	J:97471
\Apoe^tm1Unc/\Apoe^tm1Unc \Soat1^tm1Far/\Soat1^tm1Far (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)	skin inflammation	J:61147
\Apoe^tm1Unc/\Apoe^tm1Unc \Spp1^tm1Blh/\Spp1^tm1Blh (involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6J)	abnormal macrophage physiology	J:86531
\Apoe^tm1Unc/\Apoe^tm1Unc \Tg(CAG-IL1RN)1Cga/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)	decreased circulating serum amyloid protein level	J:132570
\Apoe^tm1Unc/\Apoe^tm1Unc \Tg(CAG-IL1RN)2Cga/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/1 * FVB)	decreased circulating serum amyloid protein level	J:132570
\Apoe^tm1Unc/\Apoe^tm1Unc \Tg(MSR1-Plau)1Ddi/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	heart inflammation	J:101486
\Apoe^tm1Unc/\Apoe^tm1Unc \Thbs4^tm1Olsa/\Thbs4^tm1Olsa (involves: 129P2/OlaHsd * C57BL/6J)	increased chemokine level	J:345752
	increased circulating interleukin-10 level	J:345752
	increased circulating tumor necrosis factor level	J:345752
	increased macrophage cell number	J:345752
\Apoe^{tm2(APOE3)Mae}/\Apoe^{tm2(APOE3)Mae} (involves: 129P2/OlaHsd * C57BL/6J)	decreased interleukin-6 secretion	J:86768
	decreased tumor necrosis factor secretion	J:86768
\Apoe^{tm2(APOE3)Mae}/\Apoe^{tm2(APOE3)Mae} \Tg(Thy1-APPSwDutIowa)BWevn/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal microglial cell morphology	J:136318
\Apoe^{tm3(APOE4)Mae}/\Apoe^{tm3(APOE4)Mae} (involves: 129P2/OlaHsd * C57BL/6)	abnormal response to infection	J:138241
	increased interleukin-6 secretion	J:86768
	increased tumor necrosis factor secretion	J:86768
\Apoe^{tm3(APOE4)Mae}/\Apoe^{tm3(APOE4)Mae} \Tg(Thy1-APPSwDutIowa)BWevn/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal microglial cell morphology	J:136318
\Apof^{tm1.1(KOMP)Vlcg}/\Apof^{tm1.1(KOMP)Vlcg} (C57BL/6N-Apof^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
\Apol6^em1Hsul/\Apol6^em1Hsul (Not Specified)	decreased inflammatory response	J:344362
\Apol7c^em4Gpt/\Apol7c^em4Gpt (C57BL/6JGpt-Apol7c^em4Gpt/Gpt)	abnormal dendritic cell antigen presentation	J:362930
	abnormal dendritic cell physiology	J:362930
\App^{tm1b(KOMP)Wtsi}/\App⁺ (C57BL/6N-App^{tm1b(KOMP)Wtsi}/Ics)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\App^tm1Ck/\App^tm1Ck \Tg(PDGFB-PSEN1M146L)2Jhd/0 (involves: 129 * Black Swiss * C57BL/6 * DBA/2 * SW)	abnormal microglial cell morphology	J:102542
\App^tm2.1Ldad/\App^tm2.1Ldad (involves: 129 * C57BL/6J)	myositis	J:166989
\App^tm2.1Tcs/\App^tm2.1Tcs (involves: C57BL/6)	microgliosis	J:212758
\App^tm2.1Tcs/\App^tm2.1Tcs \Cast^tm1Tcs/\Cast^tm1Tcs (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:212758
\App^tm3.1Tcs/\App^tm3.1Tcs (involves: C57BL/6)	microgliosis	J:212758
\App^tm3.1Tcs/\App^tm3.1Tcs \Mapt^{tm1.1(MAPT)Tcs}/\Mapt^{tm1.1(MAPT)Tcs} (involves: 129S/SvEv * C57BL/6)	CNS inflammation	J:278451
\Appl1^Gt(XM073)Byg/\Appl1^Gt(XM073)Byg (B6.129P2-Appl1^Gt(XM073)Byg)	immune system phenotype	J:164696
	increased T cell proliferation	J:164696
\Appl1^tm1.2Test/\Appl1^tm1.2Test (involves: 129X1/SvJ)	increased T cell proliferation	J:164696
\Aprt^tm1Dwm/\Aprt^tm1Dwm (129P2/OlaHsd-Aprt^tm1Dwm)	pyelonephritis	J:38450
\Aprt^tm1Jat/\Aprt^tm1Jat (involves: 129S2/SvPas * Black Swiss)	kidney inflammation	J:33255
\Aprt^tm1Jat/\Aprt^tm1Jat (involves: 129S2/SvPas * C57BL/6J)	kidney inflammation	J:33255
\Aprt^tm1Vri/\Aprt^tm1Vri (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:50874
\Aptx^tm1Pmc/\Aptx^tm1Pmc \Atm^tm2.1Mfgc/\Atm^tm2.1Mfgc (involves: 129 * C57BL/6)	abnormal CD4-positive helper T cell morphology	J:316365
	abnormal T cell differentiation	J:316365
	decreased T cell number	J:316365
	increased CD8-positive, alpha-beta T cell number	J:316365
\Aqp1^{tm1b(EUCOMM)Wtsi}/\Aqp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Aqp1^{tm1b(EUCOMM)Wtsi}/H)	increased neutrophil cell number	J:211773
\Aqp3^m1Btlr/\Aqp3^m1Btlr (C57BL/6J-Aqp3^m1Btlr)	abnormal gut-associated lymphoid tissue morphology	J:153279
\Aqp3^m1Btlr/\Aqp3^m1Btlr (C57BL/6J-Aqp3^m1Btlr)	increased susceptibility to induced colitis	J:153279
\Aqp4^tm1.1Lmno/\Aqp4^tm1.1Lmno (B6.Cg-Aqp4^tm1.1Lmno)	increased susceptibility to parasitic infection	J:193622
\Aqp4^tm1.1Lmno/\Aqp4^tm1.1Lmno (B6.Cg-Aqp4^tm1.1Lmno)	increased susceptibility to parasitic infection induced morbidity/mortality	J:193622
\Aqp4^tm1.1Mysi/\Aqp4^tm1.1Mysi (involves: C57BL/6JJcl * C57BL/6NCrlj * CBA/JNCrlj)	abnormal microglial cell physiology	J:214906
\Aqp9^tm1Nlsn/\Aqp9^tm1Nlsn (involves: 129S1/Sv)	decreased susceptibility to parasitic infection	J:123305
\Aqp11^{tm1.1(KOMP)Vlcg}/\Aqp11⁺ (B6N(Cg)-Aqp11^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Aqp12^tm1Rai/\Aqp12^tm1Rai (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased susceptibility to induced pancreatitis	J:155920
\Ar^Tfm/Y (involves: STOCK Eda^Ta Atp7a^Mo-blo)	abnormal myeloid leukocyte morphology	J:110923
\Ar^Tfm/Y (involves: STOCK Eda^Ta Atp7a^Mo-blo)	increased immature B cell number	J:110923
\Ar^tm1Chc/Y \Tmem163^{Tg(ACTB-cre)2Mrt}/0 (involves: 129S/SvEv * C57BL/6J * FVB/N)	increased osteoclast cell number	J:81789
\Ar^tm1Chc/\Ar^tm1.1Chc \Tmem163^{Tg(ACTB-cre)2Mrt}/0 (involves: 129S/SvEv * C57BL/6J * FVB/N)	enlarged thymus	J:87193
\Ar^tm1Verh/Y \Rnase10^tm1(cre)Hht/\Rnase10⁺ (involves: 129S7/SvEvBrd * C57BL/6)	testis inflammation	J:173897
\Araf^tm1Mmc/Y (involves: 129P2/OlaHsd * C57BL/6)	small thymus	J:33951
\Araf^tm1Mmc/\Araf^tm1Mmc (involves: 129P2/OlaHsd * C57BL/6)	small thymus	J:33951
\Arb2a^{em2(IMPC)Ccpcz}/\Arb2a^{em2(IMPC)Ccpcz} (C57BL/6NCrl-Arb2a^{em2(IMPC)Ccpcz}/Ph)	abnormal thymus morphology	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	enlarged thymus	J:211773
\Arb2a^{Tg(Tyr)TpNpln}/\Arb2a^{Tg(Tyr)TpNpln} (involves: FVB/N)	thymus hypoplasia	J:260599
\Areg^tm1Dle/\Areg^tm1Dle \Egf^tm1Dle/\Egf^tm1Dle \Tgfa^tm1Unc/\Tgfa^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	dermatitis	J:54980
\Areg^{tm2c(EUCOMM)Hmgu}/\Areg^{tm2c(EUCOMM)Hmgu} \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	immune system phenotype	J:224904
	increased susceptibility to Orthomyxoviridae infection	J:224904
\Areg^{tm2c(EUCOMM)Hmgu}/\Areg^{tm2c(EUCOMM)Hmgu} \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:224904
	increased susceptibility to Orthomyxoviridae infection	J:224904
\Arel1^em1Bbc/\Arel1⁺ (C57BL/6J-Arel1^em1Bbc)	decreased acute inflammation	J:280563
\Arel1^em1Bbc/\Arel1⁺ (C57BL/6J-Arel1^em1Bbc)	decreased response to antigen	J:280563
\Arel1^em1Bbc/\Arel1^em1Bbc (C57BL/6J-Arel1^em1Bbc)	decreased acute inflammation	J:280563
\Arel1^em1Bbc/\Arel1^em1Bbc (C57BL/6J-Arel1^em1Bbc)	decreased response to antigen	J:280563
\Arf4^{tm1b(KOMP)Wtsi}/\Arf4⁺ (C57BL/6N-Arf4^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Arfgap2^{tm1c(EUCOMM)Hmgu}/\Arfgap2^{tm1c(EUCOMM)Hmgu} \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S4/SvJae * C57BL/6J * C57BL/6N * C57BL/10 * CBA/Ca)	immune system phenotype	J:363611
\Arfgap2^{tm1c(EUCOMM)Hmgu}/\Arfgap2^{tm1c(EUCOMM)Hmgu} \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * C57BL/6N)	immune system phenotype	J:363611
\Arfgap2^{tm1c(EUCOMM)Hmgu}/\Arfgap2^{tm1c(EUCOMM)Hmgu} \Sting1^em1Jmin/\Sting1^em1Jmin \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (Not Specified)	abnormal splenic cell ratio	J:363611
	decreased CD8-positive, alpha-beta T cell number	J:363611
	decreased effector memory CD4-positive, alpha-beta T cell number	J:363611
	decreased interferon-gamma secretion	J:363611
	decreased interleukin-1 beta secretion	J:363611
	decreased susceptibility to autoimmune disorder	J:363611
	increased CD4-positive, alpha-beta memory T cell number	J:363611
	increased CD4-positive, alpha-beta T cell number	J:363611
	increased regulatory T cell number	J:363611
\Arfgap2^{tm1c(EUCOMM)Hmgu}/\Arfgap2^{tm1c(EUCOMM)Hmgu} \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S4/SvJae C57BL/6J * C57BL/6N)	abnormal macrophage activation involved in immune response	J:363611
	decreased interferon-beta secretion	J:363611
	decreased interleukin-6 secretion	J:363611
	decreased level of surface class I molecules	J:363611
	decreased level of surface class II molecules	J:363611
	decreased macrophage cytokine production	J:363611
	immune system phenotype	J:363611
\Arfgap2^{tm1c(EUCOMM)Hmgu}/\Arfgap2^{tm1c(EUCOMM)Hmgu} \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6J * C57BL/6N)	immune system phenotype	J:363611
\Arfip1^em1(IMPC)Mbp/\Arfip1^em1(IMPC)Mbp (C57BL/6N-Arfip1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Arg1^tm1.1Lky/\Arg1⁺ \Tg(Sftpc-Chia)#Lky/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)	decreased macrophage cell number	J:122735
\Arg1^tm1.1Pmu/\Arg1^tm1.1Pmu (involves: C57BL/6 * NZB)	increased macrophage nitric oxide production	J:143229
\Arg1^tm1Ekoe/\Arg1^tm1Ekoe (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:183882
\Arg1^tm1Pmu/\Arg1^tm1Pmu \Lyz2^tm1(cre)Ifo/? (B6.Cg-Arg1^tm1Pmu Lyz2^tm1(cre)Ifo)	decreased susceptibility to parasitic infection	J:143229
\Arg1^tm1Pmu/\Arg1^tm1Pmu \Tg(Tek-cre)1Ywa/? (B6.Cg-Tg(Tek-cre)1Ywa Arg1^tm1Pmu)	abnormal macrophage physiology	J:143229
	decreased susceptibility to bacterial infection	J:143229
	increased macrophage nitric oxide production	J:143229
\Arg2^{em1(IMPC)Ccpcz}/\Arg2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Arg2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Arhgap1^tm1Yizh/\Arhgap1^tm1Yizh (involves: 129S6/SvEvTac)	spleen hypoplasia	J:101418
\Arhgap1^tm1Yizh/\Arhgap1^tm1Yizh (involves: 129S6/SvEvTac)	thymus hypoplasia	J:101418
\Arhgap1^tm1Yizh/\Arhgap1^tm1Yizh (involves: 129S6/SvEvTac * C57BL/6)	decreased spleen white pulp amount	J:119516
	spleen hypoplasia	J:119516
\Arhgap5^tm1Jset/\Arhgap5^tm1Jset (involves: 129S2/SvPas * C57BL/6J)	small thymus	J:76484
\Arhgap10^em1(IMPC)Tcp/\Arhgap10^em1(IMPC)Tcp (C57BL/6NCrl-Arhgap10^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
\Arhgap15^tm1Ehi/\Arhgap15^tm1Ehi (B6.129-Arhgap15^tm1Ehi)	abnormal leukocyte cell number	J:174896
	abnormal leukocyte morphology	J:174896
	abnormal macrophage morphology	J:174896
	abnormal neutrophil physiology	J:174896
	decreased lymphocyte cell number	J:174896
	decreased macrophage cell number	J:174896
	decreased monocyte cell number	J:174896
	decreased neutrophil cell number	J:174896
	decreased susceptibility to bacterial infection	J:174896
	immune system phenotype	J:174896
\Arhgap17^{Gt(RRN062)Byg}/\Arhgap17^{Gt(RRN062)Byg} (B6.129P2-Arhgap17^{Gt(RRN062)Byg})	increased susceptibility to induced colitis	J:277297
	increased tumor necrosis factor secretion	J:277297
\Arhgap17^{tm1b(EUCOMM)Wtsi}/\Arhgap17^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Arhgap17^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased B-1a cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased mature B cell number	J:211773
	increased transitional stage T1 B cell number	J:211773
\Arhgap21^{Gt(RRR629)Byg}/\Arhgap21⁺ (B6.129P2-Arhgap21^{Gt(RRR629)Byg})	increased leukocyte cell number	J:262703
	increased neutrophil cell number	J:262703
\Arhgap25^{tm1a(KOMP)Wtsi}/\Arhgap25^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	abnormal cellular extravasation	J:240521
	abnormal neutrophil physiology	J:240521
	enhanced leukocyte migration	J:240521
	enhanced leukocyte tethering or rolling	J:240521
	increased acute inflammation	J:240521
	increased neutrophil cell number	J:240521
\Arhgap26^{tm1b(EUCOMM)Hmgu}/\Arhgap26^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Arhgap26^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Arhgap28^em1(IMPC)Mbp/\Arhgap28^em1(IMPC)Mbp (C57BL/6NCrl-Arhgap28^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
\Arhgap30^{tm1a(EUCOMM)Wtsi}/\Arhgap30^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Arhgap30^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Arhgap45^em1Ciphe/\Arhgap45^em1Ciphe (C57BL/6-Arhgap45^em1Ciphe)	decreased B cell number	J:309971
	decreased CD4-positive, alpha-beta T cell number	J:309971
	decreased CD8-positive, alpha-beta T cell number	J:309971
	decreased CD8-positive, naive alpha-beta T cell number	J:309971
	decreased DN1 thymic pro-T cell number	J:309971
	decreased lymphocyte chemotaxis	J:309971
	decreased naive B cell number	J:309971
	decreased T cell number	J:309971
	immune system phenotype	J:309971
	lymph node hypoplasia	J:309971
\Arhgdia^tm1Ytk/\Arhgdia^tm1Ytk (involves: 129S/SvEv * C57BL/6 * DBA)	decreased T cell number	J:140671
	tubulointerstitial nephritis	J:57995
\Arhgdia^tm1Ytk/\Arhgdia^tm1Ytk \Arhgdib^tm1Miyo/\Arhgdib^tm1Miyo (involves: 129S/SvEv)	abnormal leukocyte cell number	J:140671
	abnormal lymph node B cell domain morphology	J:140671
	abnormal mesenteric lymph node morphology	J:140671
	abnormal T cell physiology	J:140671
	abnormal thymus medulla morphology	J:140671
	decreased double-positive T cell number	J:140671
	decreased follicular B cell number	J:140671
	decreased immature B cell number	J:140671
	decreased marginal zone B cell number	J:140671
	decreased mature B cell number	J:140671
	decreased pre-B cell number	J:140671
	decreased T cell number	J:140671
	decreased T cell proliferation	J:140671
	decreased transitional stage B cell number	J:140671
	disorganized spleen B cell follicle	J:140671
	enhanced B cell migration	J:140671
	increased B cell proliferation	J:140671
	increased circulating interleukin-5 level	J:140671
	increased eosinophil cell number	J:140671
	increased single-positive T cell number	J:140671
	spleen hypoplasia	J:140671
\Arhgdib^tm1Len/\Arhgdib^tm1Len (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:42604
	increased B cell proliferation	J:42604
\Arhgdib^tm1Miyo/\Arhgdib^tm1Miyo (involves: 129S/SvEv)	decreased B cell number	J:140671
\Arhgdib^tm1Miyo/\Arhgdib^tm1Miyo (involves: 129S/SvEv)	decreased T cell number	J:140671
\Arhgef1^tm1.1Rmt/\Arhgef1^tm1.1Rmt (C57BL/6-Arhgef1^tm1.1Rmt)	abnormal marginal zone B cell physiology	J:113295
	decreased B cell number	J:113295
	decreased B-1 B cell number	J:113295
	decreased follicular B cell number	J:113295
	decreased IgM level	J:113295
	decreased marginal zone B cell number	J:113295
\Arhgef1^{tm1a(EUCOMM)Wtsi}/\Arhgef1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Arhgef1^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased dendritic cell number	J:211773
	decreased immature NK cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased marginal zone B cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased memory-marker gamma-delta T cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta memory T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
	increased mature NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
\Arhgef1^tm1Djle/\Arhgef1^tm1Djle (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil physiology	J:129331
	enlarged spleen	J:129331
	increased leukocyte cell number	J:129331
\Arhgef1^tm1Djle/\Arhgef1^tm1Djle (involves: 129S4/SvJae)	increased germinal center B cell number	J:174313
\Arhgef1^tm1Kdf/\Arhgef1^tm1Kdf (involves: 129S1/Sv * 129X1/SvJ)	abnormal humoral immune response	J:99463
	abnormal lymphocyte cell number	J:99463
	abnormal lymphocyte physiology	J:99463
	decreased B cell number	J:99463
	decreased B cell proliferation	J:99463
	decreased IgG level	J:99463
	decreased IgM level	J:99463
	decreased marginal zone B cell number	J:99463
	increased T cell proliferation	J:99463
\Arhgef2^em1(IMPC)Mbp/\Arhgef2^em1(IMPC)Mbp (C57BL/6N-Arhgef2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Arhgef2^{Gt(IST13976A8)Tigm}/\Arhgef2^{Gt(IST13976A8)Tigm} (involves: C57BL/6N)	abnormal macrophage physiology	J:209086
	decreased interferon-beta secretion	J:209086
	immune system phenotype	J:209086
	increased susceptibility to Orthomyxoviridae infection	J:209086
\Arhgef4^{tm1a(KOMP)Wtsi}/\Arhgef4^{tm1a(KOMP)Wtsi} (C57BL/6N-Arhgef4^{tm1a(KOMP)Wtsi}/Wtsi)	decreased IgE level	J:165965
	decreased IgG1 level	J:165965
	decreased T cell number	J:165965
	increased mature B cell number	J:165965
\Arhgef5^tm1.1Dwu/\Arhgef5^tm1.1Dwu (involves: 129S1/Sv * 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:157812
	abnormal dendritic cell physiology	J:157812
	decreased eosinophil cell number	J:157812
	decreased interleukin-4 secretion	J:157812
	immune system phenotype	J:157812
\Arhgef6^tm1Kdf/\Arhgef6^tm1Kdf (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:137269
	abnormal humoral immune response	J:137269
	abnormal T cell physiology	J:137269
	decreased B cell proliferation	J:137269
	decreased CD4-positive, alpha-beta T cell number	J:137269
	decreased CD8-positive, alpha-beta T cell number	J:137269
	decreased interleukin-2 secretion	J:137269
	decreased lymphocyte cell number	J:137269
	decreased mature B cell number	J:137269
	decreased T cell proliferation	J:137269
	enhanced B cell migration	J:137269
\Arhgef6^{tm2e.1(EUCOMM)Wtsi}/Y (C57BL/6N-Arhgef6^{tm2e.1(EUCOMM)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
\Arhgef6^{tm2e.1(EUCOMM)Wtsi}/\Arhgef6^{tm2e.1(EUCOMM)Wtsi} (C57BL/6N-Arhgef6^{tm2e.1(EUCOMM)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
\Arhgef12^tm1.1Wet/\Arhgef12^tm1.1Wet \Tg(Lck-cre)548Jxm/0 (involves: 129 * C57BL/6 * CBA)	abnormal T cell proliferation	J:149560
\Arhgef16^em1(IMPC)Mbp/\Arhgef16^em1(IMPC)Mbp (C57BL/6NCrl-Arhgef16^em1(IMPC)Mbp/Mmucd)	increased monocyte cell number	J:211773
\Arid1a^tm1.1Mag/\Arid1a^tm1.1Mag \Gt(ROSA)26Sor^{tm1(Pik3caH1047R)Egan}/\Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac CD-1)	increased interleukin-6 secretion	J:219794
\Arid1b^em1(IMPC)Tcp/\Arid1b⁺ (C57BL/6NCrl-Arid1b^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Arid2^{tm1a(EUCOMM)Wtsi}/\Arid2^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	immune system phenotype	J:223458
\Arid3a^tm1Pwt/\Arid3a^tm1Pwt (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:169178
	abnormal class switch recombination	J:169178
	decreased B cell number	J:169178
	decreased B-1 B cell number	J:169178
	decreased B-1a cell number	J:169178
	decreased B-2 B cell number	J:169178
	decreased IgG1 level	J:169178
	decreased IgM level	J:169178
	decreased marginal zone B cell number	J:169178
	decreased pre-B cell number	J:169178
	decreased pro-B cell number	J:169178
	decreased transitional stage B cell number	J:169178
	decreased transitional stage T1 B cell number	J:169178
	decreased transitional stage T2 B cell number	J:169178
\Arid3b^{tm1c(KOMP)Wtsi}/\Arid3b^{tm1c(KOMP)Wtsi} \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6N * SJL)	abnormal B cell differentiation	J:236980
	decreased B cell number	J:236980
	decreased B-1b cell number	J:236980
	decreased CD4-positive, alpha-beta T cell number	J:236980
	decreased immature B cell number	J:236980
	decreased pre-B cell number	J:236980
	decreased pre-pro B cell number	J:236980
	decreased pro-B cell number	J:236980
	decreased transitional stage B cell number	J:236980
	increased B-1a cell number	J:236980
	increased follicular B cell number	J:236980
\Arid3c^em1(IMPC)J/\Arid3c^em1(IMPC)J (C57BL/6NJ-Arid3c^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Arid4a^tm1Alb/\Arid4a^tm1Alb (involves: 129S7/SvEvBrd)	abnormal mononuclear cell differentiation	J:141004
	decreased B cell number	J:141004
	decreased leukocyte cell number	J:141004
	decreased lymphocyte cell number	J:141004
	decreased monocyte cell number	J:141004
	decreased neutrophil cell number	J:141004
	decreased T cell number	J:141004
	enlarged spleen	J:141004
	increased leukocyte cell number	J:141004
	increased T cell number	J:141004
\Arid4a^tm1Alb/\Arid4a^tm1Alb \Arid4b^tm1Alb/\Arid4b⁺ (involves: 129S7/SvEvBrd)	abnormal leukopoiesis	J:141004
	decreased B cell number	J:141004
	decreased lymphocyte cell number	J:141004
	decreased T cell number	J:141004
	enlarged spleen	J:141004
	hemophagocytosis	J:141004
	increased leukocyte cell number	J:141004
	increased monocyte cell number	J:141004
	increased neutrophil cell number	J:141004
	increased T cell number	J:141004
\Arid5a^tm1Rnis/\Arid5a^tm1Rnis (B6.Cg-Arid5a^tm1Rnis)	decreased circulating interleukin-6 level	J:197418
	decreased circulating tumor necrosis factor level	J:197418
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:197418
	decreased T-helper 17 cell number	J:197418
	increased T cell number	J:197418
\Arid5b^{Gt(ROSA)75Sor}/\Arid5b^{Gt(ROSA)75Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
\Arid5b^tm1Pjh/\Arid5b^tm1Pjh (involves: 129S4/SvJae * BALB/c)	abnormal immune system organ morphology	J:70658
	abnormal lymphopoiesis	J:70658
	decreased double-positive T cell number	J:70658
	decreased pro-B cell number	J:70658
	increased single-positive T cell number	J:70658
	spleen hypoplasia	J:70658
	thymus cortex hypoplasia	J:70658
	thymus hypoplasia	J:70658
\Arigg1^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg2^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg3^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg4^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg5^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg6^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg7^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg8^BALB/cByJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg9^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigg10^BALB/cByJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased anti-erythrocyte antigen antibody level	J:93737
\Arigm1^BALB/cByJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
\Arigm2^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
\Arigm3^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
\Arigm4^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
\Arigm5^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
\Arigm6^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
\Arigm7^NZB/BlNJ/? (involves: BALB/cByJ * NZB/BlNJ)	increased IgM level	J:93737
\Arih1^em3Gpt/\Arih1^em3Gpt \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C57BL/6JGpt)	decreased interferon-beta secretion	J:330879
	decreased interleukin-6 secretion	J:330879
	increased susceptibility to Herpesvirales infection	J:330879
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:330879
\Arih1^em3Gpt/\Arih1^em3Gpt \Lyz2^em1(icre)Gpt/\Lyz2⁺ (C57BL/6JGpt-Arih1^em3Gpt Lyz2^em1(icre)Gpt)	decreased circulating interferon-beta level	J:330879
	decreased circulating interleukin-6 level	J:330879
	decreased interferon-beta secretion	J:330879
	decreased interleukin-6 secretion	J:330879
	immune system phenotype	J:330879
	increased susceptibility to Herpesvirales infection	J:330879
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:330879
\Arih1^em3Gpt/\Arih1^em3Gpt \Lyz2^em1(icre)Gpt/\Lyz2⁺ \Trex1^em1Gpt/\Trex1^em1Gpt (C57BL/6JGpt-Arih1^em3Gpt Trex1^em1Gpt Lyz2^em1(icre)Gpt)	immune system phenotype	J:330879
\Arih2^tm1Mak/\Arih2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	dermatitis	J:191066
	heart inflammation	J:191066
	increased inflammatory response	J:191066
	liver inflammation	J:191066
	lung inflammation	J:191066
\Arih2^tm1Mak/\Arih2^tm1Mak (B6.129P2-Arih2^tm1Mak)	abnormal dendritic cell physiology	J:191066
\Arih2^tm1Mak/\Arih2^tm1Mak (B6.129P2-Arih2^tm1Mak)	increased inflammatory response	J:191066
\Arl3^{Gt(OST263303)Lex}/\Arl3^{Gt(OST263303)Lex} (involves: 129S5/SvEvBrd)	bile duct inflammation	J:107331
\Arl6ip5^tm1.2Jwzh/\Arl6ip5^tm1.2Jwzh (B6.129X1-Arl6ip5^tm1.2Jwzh)	abnormal immune system organ morphology	J:187133
\Arl16^{em1(IMPC)Ccpcz}/\Arl16^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Arl16^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Arln^em1(IMPC)Mbp/\Arln^em1(IMPC)Mbp (C57BL/6NCrl-Arln^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
\Armc2^{tm1b(EUCOMM)Hmgu}/\Armc2⁺ (C57BL/6N-Armc2^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
\Armcx1^em1(IMPC)Mbp/Y (C57BL/6N-Armcx1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Armh4^em1(IMPC)H/\Armh4^em1(IMPC)H (C57BL/6N-Armh4^em1(IMPC)H/H)	enlarged spleen	J:211773
\Arnt^tm1.1Gonz/\Arnt^tm1.2Gonz \Tg(Lck-cre)I57Jxm/0 (involves: 129X1/SvJ * ICR)	abnormal immune system physiology	J:85934
\Arp^BALB/c/\Arp^BALB/c (involves: B10.D2 * BALB/c)	abnormal lymph node morphology	J:7273
	abnormal Peyer's patch morphology	J:6549
	lymph node hypoplasia	J:6549
	spleen hyperplasia	J:6549
	thymus hyperplasia	J:6549
\Arp^BALB/c/\Arp^BALB/c \Lus^C57BL/10/\Lus^C57BL/10 (involves: B10.D2 * BALB/c)	abnormal lymph node morphology	J:7273
\Arpc1b^{tm1a(EUCOMM)Wtsi}/\Arpc1b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Arpc1b^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	decreased marginal zone precursor B cell number	J:211773
	decreased mature NK cell number	J:211773
	decreased NK cell number	J:211773
	decreased transitional stage T2 B cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD103-positive CD11b-low dendritic cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased immature NK cell number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased leukocyte cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased plasma cell number	J:211773
\Arpc4^{tm1a(EUCOMM)Wtsi}/\Arpc4⁺ (B6JTyr;B6N-Arpc4^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:165965
\Arpc4^{tm1c(EUCOMM)Wtsi}/\Arpc4^{tm1c(EUCOMM)Wtsi} \Krt14^tm1(cre)Wbm/\Krt14⁺ (B6.Cg-Arpc4^{tm1c(EUCOMM)Wtsi} Krt14^tm1(cre)Wbm)	dermatitis	J:253986
\Arrb2^tm1Rjl/\Arrb2^tm1Rjl (involves: 129X1/SvJ * C57BL/6)	abnormal circulating tumor necrosis factor level	J:112607
	abnormal lymphocyte physiology	J:76872
	increased acute inflammation	J:112607
	increased circulating interleukin-6 level	J:112607
	increased interleukin-6 secretion	J:112607
	increased interleukin-12b secretion	J:112607
	increased susceptibility to endotoxin shock	J:112607
	increased tumor necrosis factor secretion	J:112607
\Arrdc4^em1(IMPC)Tcp/\Arrdc4^em1(IMPC)Tcp (C57BL/6NCrl-Arrdc4^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
\Arsa^tm1Gie/\Arsa^tm1Gie (involves: 129P2/OlaHsd * C57BL/6J)	abnormal microglial cell morphology	J:37978
\Arsg^tm1Tdi/\Arsg^tm1Tdi (involves: 129S2/SvPas * C57BL/6)	abnormal macrophage morphology	J:185592
	abnormal microglial cell morphology	J:185592
	abnormal perivascular macrophage morphology	J:185592
	microgliosis	J:185592, J:254592
\Art1^{tm1b(EUCOMM)Wtsi}/\Art1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Art1^{tm1b(EUCOMM)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
\Art2a^tm1Fkn/\Art2a^tm1Fkn \Art2b^tm1Fkn/\Art2b^tm1Fkn (NOD.129S4(B6)-Art2a^tm1Fkn Art2b^tm1Fkn/Lt)	decreased T cell apoptosis	J:108097
\Art2a^tm1Fkn/\Art2a^tm1Fkn \Art2b^tm1Fkn/\Art2b^tm1Fkn \Cd38^tm1Lnd/\Cd38^tm1Lnd (NOD.129(B6)-Cd38^tm1Lnd Art2a^tm1Fkn Art2b^tm1Fkn/Lt)	decreased susceptibility to autoimmune diabetes	J:108097
\Arti1^C57BL/6J/\Arti1^C57BL/6J \Arti2^C57BL/6J/\Arti2^C57BL/6J (involves: C57BL/6J * DBA/2J)	abnormal thymus involution	J:85261
\Arti1^DBA/2J/\Arti1^DBA/2J \Arti2^DBA/2J/\Arti2^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal thymus involution	J:85261
\Arvm2^MRL/MpJ/\Arvm2^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	abnormal immune system physiology	J:63511
\asa/\asa (either: A/J or BALB/c or DBA/2J)	increased autoantibody level	J:2843
\asa/\asa (either: A/J or BALB/c or DBA/2J)	myocarditis	J:2843
\Asah1^tm1.2Geno/\Asah1^tm1.2Geno (involves: C57BL/6)	abnormal circulating cytokine level	J:285931
	abnormal lymph node morphology	J:285931
	abnormal thymus morphology	J:285931
	decreased B cell number	J:285931
	decreased CD4-positive, alpha-beta T cell number	J:285931
	decreased CD8-positive, alpha-beta T cell number	J:285931
	decreased double-positive T cell number	J:285931
	decreased leukocyte cell number	J:285931
	decreased lymphocyte cell number	J:285931
	decreased splenocyte number	J:285931
	decreased T cell number	J:285931
	enlarged spleen	J:285931
	increased circulating CXCL10 level	J:285931
	increased granulocyte number	J:285931
	increased macrophage cell number	J:285931
	increased macrophage derived foam cell number	J:285931
	increased monocyte cell number	J:285931
	lung inflammation	J:285931
\Asah1^tm1Medin/\Asah1^tm1Medin (involves: 129S6/SvEvTac * CD-1)	abnormal chemokine secretion	J:232306
	abnormal circulating chemokine level	J:232306
	enlarged lymph nodes	J:232306
	enlarged spleen	J:232306
	enlarged thymus	J:232306
	increased circulating interleukin-12b level	J:232306
	increased eosinophil cell number	J:232306
	increased leukocyte cell number	J:232306
	increased macrophage derived foam cell number	J:232306
	increased monocyte cell number	J:232306
	increased neutrophil cell number	J:232306
	increased spleen weight	J:232306
	pale spleen	J:232306
\Asb1^{em1(IMPC)Ccpcz}/\Asb1^{em1(IMPC)Ccpcz} (C57BL/6N-Asb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Asb1^tm1Wehi/\Asb1^tm1Wehi (involves: C57BL/6)	small spleen	J:71266
\Asb1^tm1Wehi/\Asb1^tm1Wehi (involves: C57BL/6)	spleen hypoplasia	J:71266
\Asb2^tm1.1Lutz/\Asb2^tm1.1Lutz \Tg(Mx1-cre)1Cgn/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	abnormal dendritic cell physiology	J:200966
\Asb2^{tm2b(KOMP)Wtsi}/\Asb2⁺ (C57BL/6N-Asb2^{tm2b(KOMP)Wtsi}/Kmpc)	decreased Ly6C-positive immature NK cell number	J:211773
	increased Ly6C-positive immature NK cell number	J:211773
	increased T cell number	J:211773
\Asb4^{em1(IMPC)Ccpcz}/\Asb4^{em1(IMPC)Ccpcz} (C57BL/6N-Asb4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Asb5^{em1(IMPC)Ccpcz}/\Asb5^{em1(IMPC)Ccpcz} (C57BL/6N-Asb5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Asb7^{em1(IMPC)Ccpcz}/\Asb7^{em1(IMPC)Ccpcz} (C57BL/6N-Asb7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	enlarged spleen	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Asb16^{em1(IMPC)Ccpcz}/\Asb16^{em1(IMPC)Ccpcz} (C57BL/6N-Asb16^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Asbb1^BALB/c/\Asbb1^BALB/c (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
\Asbb2^BALB/c/\Asbb2^C57BL/6J (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
\Asbb2^C57BL/6J/\Asbb2^C57BL/6J (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
\Asbb3^C57BL/6J/\Asbb3^C57BL/6J (involves: BALB/c * C57BL/6J)	increased susceptibility to systemic lupus erythematosus	J:76486
\Ascc2^{tm1a(EUCOMM)Wtsi}/\Ascc2⁺ (C57BL/6N-Ascc2^{tm1a(EUCOMM)Wtsi}/Bay)	enlarged spleen	J:211773
\Ascl4^em1(IMPC)J/\Ascl4^em1(IMPC)J (C57BL/6NJ-Ascl4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ascl5^{em1(IMPC)Ccpcz}/\Ascl5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ascl5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Asf1b^m1Btlr/\Asf1b^m1Btlr (C57BL/6J-Asf1b^m1Btlr)	increased IgE level	J:267479
\Asgr1^tm1Sau/\Asgr1^tm1Sau (B6.129S4-Asgr1^tm1Sau)	increased susceptibility to bacterial infection	J:136946
\Asgr2^tm1Her/\Asgr2^tm1Her (B6.129S7-Asgr2^tm1Her)	increased susceptibility to bacterial infection	J:136946
\Ash1l^{Gt(AL0395)Wtsi}/\Ash1l^{Gt(AL0395)Wtsi} (involves: 129P2/OlaHsd * C57BL/6J)	blepharitis	J:227516
\Ash1l^{tm2b(EUCOMM)Hmgu}/\Ash1l⁺ (C57BL/6N-Ash1l^{tm2b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu}/\Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu} (B6.FVB-Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu})	glomerulonephritis	J:208213
	immune system phenotype	J:208213
	increased autoantibody level	J:208213
	increased circulating interleukin-6 level	J:208213
	increased circulating tumor necrosis factor level	J:208213
	increased IgA level	J:208213
	increased IgG1 level	J:208213
	increased IgG2a level	J:208213
	increased IgG2b level	J:208213
	increased IgM level	J:208213
	increased interleukin-6 secretion	J:208213
	increased susceptibility to autoimmune disorder	J:208213
	increased susceptibility to bacterial infection	J:208213
	increased susceptibility to bacterial infection induced morbidity/mortality	J:208213
	increased susceptibility to endotoxin shock	J:208213
	increased susceptibility to induced arthritis	J:208213
	increased tumor necrosis factor secretion	J:208213
\Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu}/\Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu} \Il6^tm1Kopf/\Il6^tm1Kopf (B6.Cg-Ash1l^{Tn(pb-Act-RFP)1.AF0-180T25Zhu} Il6^tm1Kopf)	abnormal inflammatory response	J:208213
	increased susceptibility to induced arthritis	J:208213
\Asic2^em1(IMPC)Mbp/\Asic2^em1(IMPC)Mbp (C57BL/6N-Asic2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Asic3^em1(IMPC)Mbp/\Asic3^em1(IMPC)Mbp (C57BL/6NCrl-Asic3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Asl^tm1Brle/\Asl^tm1Brle (involves: 129S7/SvEvBrd)	decreased lymphocyte cell number	J:180208
	decreased spleen germinal center number	J:180208
	increased macrophage cell number	J:180208
	increased spleen red pulp amount	J:180208
	thymus cortex hypoplasia	J:180208
\Asm1^MRL/MpJ/? (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	abnormal immune system physiology	J:66459
\Asm2^MRL/MpJ/? (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	salivary gland inflammation	J:66459
\Asphd1^{em1(IMPC)Ccpcz}/\Asphd1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Asphd1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Aspscr1^em1(IMPC)Tcp/\Aspscr1^em1(IMPC)Tcp (C57BL/6NCrl-Aspscr1^em1(IMPC)Tcp/Tcp)	decreased neutrophil cell number	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
\Asq1^IQI/\Asq1^IQI (involves: IQI * C57BL/6CrSlc)	salivary gland inflammation	J:127310
\Ass1^tm1.1Ekoe/\Ass1^tm1.1Ekoe \Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	immune system phenotype	J:203474
\Aste1^{tm1a(KOMP)Wtsi}/\Aste1^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Aste1^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Asxl1^tm1.1Iaai/\Asxl1^tm1.1Iaai \Tet2^tm1.1Iaai/\Tet2^tm1.1Iaai \Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA)	abnormal myelopoiesis	J:208092
\Asxl1^tm1.1Iaai/\Asxl1^tm1.1Iaai \Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA)	abnormal myelopoiesis	J:208092
	decreased leukocyte cell number	J:208092
	decreased mature B cell number	J:208092
	decreased monocyte cell number	J:208092
	decreased neutrophil cell number	J:208092
\Asxl1^tm1.1Iaai/\Asxl1^tm1.1Iaai \Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	abnormal myelopoiesis	J:208092
	decreased leukocyte cell number	J:208092
	decreased mature B cell number	J:208092
	decreased monocyte cell number	J:208092
	decreased neutrophil cell number	J:208092
	decreased splenocyte number	J:208092
\Asxl1^tm1.1Mjxu/\Asxl1⁺ (involves: 129 * C57BL/6)	abnormal leukocyte morphology	J:208085
	abnormal myelopoiesis	J:208085
	abnormal neutrophil morphology	J:208085
	abnormal neutrophil physiology	J:208085
	abnormal spleen morphology	J:208085
	decreased B cell number	J:208085
	decreased leukocyte cell number	J:208085
	decreased neutrophil cell number	J:208085
	enlarged spleen	J:208085
	increased leukocyte cell number	J:208085
	increased monocyte cell number	J:208085
\Asxl1^tm1.1Mjxu/\Asxl1^tm1.1Mjxu (involves: 129 * C57BL/6)	abnormal leukocyte morphology	J:208085
	abnormal neutrophil morphology	J:208085
	abnormal spleen white pulp morphology	J:208085
	decreased B cell number	J:208085
	decreased leukocyte cell number	J:208085
	decreased lymphocyte cell number	J:208085
	decreased spleen red pulp amount	J:208085
	decreased spleen weight	J:208085
	increased monocyte cell number	J:208085
	increased single-positive T cell number	J:208085
	myeloid hyperplasia	J:208085
	small spleen	J:208085
	spleen atrophy	J:208085
\Asxl1^{tm1a(EUCOMM)Wtsi}/\Asxl1⁺ (B6Dnk;B6Brd;B6N-Asxl1^{tm1a(EUCOMM)Wtsi} Tyr^c-Brd/WtsiH)	decreased leukocyte cell number	J:175295
\Asxl1^{tm1a(EUCOMM)Wtsi}/\Asxl1⁺ (C57BL/6N-Asxl1^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased B cell number	J:165965
\Asxl1^tm1Bc/\Asxl1^tm1Bc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal immune system cell morphology	J:155898
	abnormal immune system organ morphology	J:155898
	abnormal lymphopoiesis	J:155898
	abnormal thymus morphology	J:155898
	decreased B cell number	J:155898
	decreased CD4-positive, alpha-beta T cell number	J:155898
	decreased pre-B cell number	J:155898
	decreased T cell number	J:155898
	increased double-negative T cell number	J:155898
	spleen hyperplasia	J:155898
\Atad2b^{tm1b(EUCOMM)Hmgu}/\Atad2b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Atad2b^{tm1b(EUCOMM)Hmgu}/Ics)	decreased NK T cell number	J:211773
\Atad5^{Gt(RRF055)Byg}/\Atad5⁺ (involves: 129P2/OlaHsd)	increased T cell derived lymphoma incidence	J:176672
\Atcay^ji/\Atcay^ji (Not Specified)	abnormal thymus cortex morphology	J:14903
	abnormal thymus medulla morphology	J:14903
	abnormal thymus morphology	J:14903
\Atf1^tm1.1Arte/\Atf1^tm1.1Arte (involves: C57BL/6)	immune system phenotype	J:191723
\Atf2^{Tg(Gzma-Klra1)7Wum}/\Atf2⁺ (involves: C57BL/6)	abnormal NK cell physiology	J:61178
	decreased circulating interferon-gamma level	J:61178
	decreased NK cell number	J:61178
	decreased NK T cell number	J:61178
	immune system phenotype	J:61178
\Atf2^{tm1b(EUCOMM)Hmgu}/\Atf2⁺ (C57BL/6N-Atf2^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
\Atf2^tm1Glm/\Atf2^tm1Glm (involves: 129S2/SvPas)	eye inflammation	J:30611
\Atf2^tm1Glm/\Atf2^tm1Glm (involves: 129S2/SvPas)	increased susceptibility to bacterial infection	J:30611
\Atf2^tm1Glm/\Atf2^tm1Glm (C.Cg-Atf2^tm1Glm)	abnormal cytokine secretion	J:67176
	immune system phenotype	J:67176
	increased susceptibility to endotoxin shock	J:67176
	increased susceptibility to Herpesvirales infection	J:67176
	increased susceptibility to Picornaviridae infection	J:67176
\Atf3^tm1Dron/\Atf3^tm1Dron (involves: 129X1/SvJ * C57BL/6)	abnormal T-helper 2 physiology	J:140112
	decreased IgG2a level	J:140112
	increased interleukin-4 secretion	J:140112
	increased interleukin-5 secretion	J:140112
	increased interleukin-13 secretion	J:140112
	lung inflammation	J:140112
\Atf4^tm1(KOMP)Mbp/\Atf4⁺ (C57BL/6NCrl-Atf4^tm1(KOMP)Mbp/MbpMmucd)	decreased monocyte cell number	J:211773
\Atg3^tm1.1Ywh/\Atg3^tm1.1Ywh \Fnip1^m1Btlr/\Fnip1^m1Btlr \Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/\Gt(ROSA)26Sor⁺ (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J)	absent B cells	J:234285
\Atg3^tm1.1Ywh/\Atg3^tm1.1Ywh \Gt(ROSA)26Sor^{tm1(cre/ERT)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJaeSor * C57BL/6)	abnormal T cell morphology	J:172749
	increased T cell apoptosis	J:172749
\Atg3^tm1.1Ywh/\Atg3^tm1.1Ywh \Tg(Lck-cre)548Jxm/0 (involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * CBA)	abnormal T cell morphology	J:172749
	decreased CD4-positive, alpha-beta T cell number	J:172749
	decreased CD8-positive, alpha-beta T cell number	J:172749
	decreased T cell proliferation	J:172749
	increased T cell apoptosis	J:172749
	spleen hypoplasia	J:172749
	thymus hypoplasia	J:172749
\Atg4b^{tm1b(EUCOMM)Hmgu}/\Atg4b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Atg4b^{tm1b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Atg5^tm1Myok/\Atg5^tm1Myok \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
\Atg5^tm1Nmz/\Atg5^tm1Nmz (involves: 129 * BALB/c * C57BL/6)	abnormal thymus cortex morphology	J:140583
\Atg5^tm1Nmz/\Atg5^tm1Nmz \Tg(CAG-EGFP/Map1lc3b)53Nmz/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal thymus morphology	J:140583
	abnormal thymus physiology	J:140583
\Atg5^tm1Nmz/\Atg5^tm1Nmz \Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell morphology	J:211733
	abnormal T cell physiology	J:211733
	abnormal T cell subpopulation ratio	J:211733
	decreased CD4-positive, alpha-beta T cell number	J:211733
	decreased CD8-positive, alpha-beta T cell number	J:211733
	decreased T cell number	J:211733
	decreased T cell proliferation	J:211733
\Atg7^tm1Tchi/\Atg7^tm1Tchi \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj)	abnormal leukocyte morphology	J:176843
	decreased B cell number	J:176843
	decreased leukocyte cell number	J:176843
	decreased NK cell number	J:176843
	decreased T cell number	J:176843
\Atg7^tm1Tchi/\Atg7^tm1Tchi \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
\Atg7^tm1Tchi/\Atg7^tm1Tchi \Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Tg(CAG-EGFP/Map1lc3b)53Nmz/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
\Atg7^tm1Tchi/\Atg7^tm1Tchi \Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Defa6-icre)1Rsb/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	small intestinal inflammation	J:206084
\Atg7^tm1Tchi/\Atg7^tm1Tchi \Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)	ileum inflammation	J:206084
	intestinal inflammation	J:206084
\Atg9a^tm1Aki/\Atg9a^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal innate immunity	J:155552
	increased interferon-beta secretion	J:155552
	increased interleukin-6 secretion	J:155552
\Atg16l1^tm1.1Mvlc/\Atg16l1^tm1.1Mvlc (C57BL/6-Atg16l1^tm1.1Mvlc)	abnormal macrophage physiology	J:206931
	immune system phenotype	J:206931
	increased circulating interleukin-1 beta level	J:206931
	increased macrophage cytokine production	J:206931
	increased susceptibility to bacterial infection	J:206931
\Atg16l1^{tm1a(EUCOMM)Wtsi}/\Atg16l1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Atg16l1^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
\Atg16l1^tm1Aki/\Atg16l1^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:141420
	increased interleukin-1 beta secretion	J:141420
	increased interleukin-18 secretion	J:141420
	increased susceptibility to induced colitis	J:141420
\Atg16l1^{tm1c(EUCOMM)Wtsi}/\Atg16l1^{tm1c(EUCOMM)Wtsi} \Tcrd^tm1Mom/\Tcrd^tm1Mom \Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N * SJL)	abnormal cytokine level	J:340266
	increased susceptibility to colitis induced morbidity/mortality	J:340266
\Atg16l1^{tm1c(EUCOMM)Wtsi}/\Atg16l1^{tm1c(EUCOMM)Wtsi} \Tg(Defa6-icre)1Rsb/0 (involves: C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:340266
	increased susceptibility to induced colitis	J:340266
\Atg16l1^{tm1c(EUCOMM)Wtsi}/\Atg16l1^{tm1c(EUCOMM)Wtsi} \Tg(Itgax-cre)1-1Reiz/? (involves: C57BL/6 * C57BL/6N * CBA)	immune system phenotype	J:221019
\Atg16l1^{tm1c(EUCOMM)Wtsi}/\Atg16l1^{tm1c(EUCOMM)Wtsi} \Tg(Vil1-cre)997Gum/? (involves: C57BL/6J * C57BL/6N * SJL)	abnormal chemokine level	J:221019
	abnormal circulating interleukin level	J:221019
	abnormal cytokine level	J:221019
	cecum inflammation	J:221019
	increased circulating interleukin-1 beta level	J:221019
	increased circulating interleukin-6 level	J:221019
	increased macrophage cell number	J:221019
	increased susceptibility to bacterial infection	J:221019
\Atg16l1^tm1Kuv/\Atg16l1^tm1Kuv \Tg(Vil1-cre)997Gum/0 (B6.Cg-Atg16l1^tm1Kuv Tg(Vil1-cre)997Gum)	increased susceptibility to induced colitis	J:269933
	small intestinal inflammation	J:269933
\Atg16l1^tm1Kuv/\Atg16l1^tm1Kuv \Tg(Vil1-cre)997Gum/0 \Xbp1^tm2Glm/\Xbp1^tm2Glm (B6.Cg-Atg16l1^tm1Kuv Xbp1^tm2Glm Tg(Vil1-cre)997Gum)	small intestinal inflammation	J:269933
\Atg16l1^tm1Kuv/\Atg16l1^tm1Kuv \Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	ileum inflammation	J:206084
	intestinal inflammation	J:206084
\Atg16l2^m1Anu/\Atg16l2^m1Anu (C57BL/6NCrlAnu-Atg16l2^m1Anu)	decreased lymphocyte cell number	J:104190
\Atl1^tm1.2Cbla/\Atl1^tm1.2Cbla \Reep1^{Gt(OST398247)Lex}/\Reep1^{Gt(OST398247)Lex} (B6.Cg-Reep1^{Gt(OST398247)Lex} Atl1^tm1.2Cbla)	increased susceptibility to otitis media	J:334532
\Atl2^{tm2b(EUCOMM)Hmgu}/\Atl2⁺ (C57BL/6N-Atl2^{tm2b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
	decreased spleen weight	J:211773
	increased lymphocyte cell number	J:211773
\Atl3^em1(IMPC)Tcp/\Atl3^em1(IMPC)Tcp (C57BL/6N-Atl3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Atm^m1Btlr/\Atm^m1Btlr (C57BL/6J-Atm^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265252
	decreased CD8-positive, alpha-beta T cell number	J:265252
	decreased response to antigen	J:265252
	decreased single-positive T cell number	J:265252
	decreased T cell number	J:265252
	impaired humoral immune response	J:265252
	increased IgM level	J:265252
\Atm^m2Btlr/\Atm^m2Btlr (C57BL/6J-Atm^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265253
	decreased CD8-positive, naive alpha-beta T cell number	J:265253
	decreased single-positive T cell number	J:265253
	increased central memory CD8 positive, alpha-beta T cell number	J:265253
	increased effector memory CD4-positive, alpha-beta T cell number	J:265253
\Atm^m3Btlr/\Atm^m3Btlr (C57BL/6J-Atm^m3Btlr)	increased B-1a cell number	J:272820
\Atm^m3Btlr/\Atm^m3Btlr (C57BL/6J-Atm^m3Btlr)	increased macrophage cell number	J:272820
\Atm^M4Btlr/\Atm^M4Btlr (C57BL/6J-Atm^M4Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272821
\Atm^m5Btlr/\Atm^m5Btlr (C57BL/6J-Atm^m5Btlr)	abnormal lymphocyte morphology	J:272824
	decreased interleukin-1 beta secretion	J:272824
	impaired macrophage phagocytosis	J:272824
	increased B-1 B cell number	J:272824
\Atm^m6Btlr/\Atm^m6Btlr (C57BL/6J-Atm^m6Btlr)	abnormal CD4-positive T cell differentiation	J:274964
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274964
	abnormal T cell differentiation	J:274964
	decreased CD4-positive, alpha-beta T cell number	J:274964
	decreased CD8-positive, naive alpha-beta T cell number	J:274964
	decreased T cell number	J:274964
	increased CD8-positive, alpha-beta memory T cell number	J:274964
	increased central memory CD4-positive, alpha-beta T cell number	J:274964
	increased central memory CD8 positive, alpha-beta T cell number	J:274964
	increased effector memory CD4-positive, alpha-beta T cell number	J:274964
\Atm^tm1.1Mmpl/\Atm^tm1.1Mmpl (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)	decreased T cell number	J:226414
	increased B cell number	J:226414
	increased T cell derived lymphoma incidence	J:226414
\Atm^tm1Awb/\Atm⁺ \Rad50^tm2Jpt/\Rad50^tm2Jpt (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	decreased macrophage cell number	J:103922
\Atm^tm1Awb/\Atm^tm1Awb (either: 129S6/SvEvTac-Atm^tm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))	decreased activated T cell number	J:34193
	decreased double-positive T cell number	J:34193
	decreased T cell number	J:34193
	immune system phenotype	J:34193
	increased double-positive T cell number	J:34193
	increased T cell derived lymphoma incidence	J:34193
\Atm^tm1Awb/\Atm^tm1Awb (involves: 129S6/SvEvTac * C57BL/6)	increased T cell derived lymphoma incidence	J:103922
\Atm^tm1Awb/\Atm^tm1Awb (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:150435
	decreased CD4-positive, alpha-beta T cell number	J:90941
	decreased CD8-positive, alpha-beta T cell number	J:90941
	immune system phenotype	J:126920
	increased T cell derived lymphoma incidence	J:90941
\Atm^tm1Awb/\Atm^tm1Awb (CByJ.129S6-Atm^tm1Awb)	increased T cell derived lymphoma incidence	J:208539
\Atm^tm1Awb/\Atm^tm1Awb (129S6/SvEvTac-Atm^tm1Awb)	increased T cell derived lymphoma incidence	J:208539
\Atm^tm1Awb/\Atm^tm1Awb (either: (129S6/SvEvTac-Atm^tm1Awb x B6.129S6-Atm^tm1Awb)F1 or (B6.129S6-Atm^tm1Awb x 129S6/SvEvTac-Atm^tm1Awb)F1)	increased T cell derived lymphoma incidence	J:208539
\Atm^tm1Awb/\Atm^tm1Awb (either: (129S6/SvEvTac-Atm^tm1Awb x A.129S6-Atm^tm1Awb)F1 or (A.129S6-Atm^tm1Awb x 129S6/SvEvTac-Atm^tm1Awb)F1)	increased T cell derived lymphoma incidence	J:208539
\Atm^tm1Awb/\Atm^tm1Awb (129S6/SvEvTac-Atm^tm1Awb/J)	decreased single-positive T cell number	J:226414
	decreased T cell number	J:226414
	increased B cell number	J:226414
	increased double-positive T cell number	J:226414
	increased T cell derived lymphoma incidence	J:226414
\Atm^tm1Awb/\Atm^tm1Awb \Paxx^em1Spj/\Paxx^em1Spj (involves: A/J * C57BL/6NTac)	abnormal class switch recombination	J:236776
	decreased B cell number	J:236776
	decreased splenocyte number	J:236776
	decreased T cell number	J:236776
\Atm^tm1Awb/\Atm^tm1Awb \Rad52^tm1Aps/\Rad52^tm1Aps (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased CD4-positive, alpha-beta T cell number	J:90941
	decreased CD8-positive, alpha-beta T cell number	J:90941
	increased T cell derived lymphoma incidence	J:90941
\Atm^tm1Bal/\Atm^tm1Bal (involves: 129S4/SvJae)	abnormal microglial cell physiology	J:44190
	abnormal T cell physiology	J:35914
	decreased IgG2a level	J:35914
	decreased IgG2b level	J:35914
	decreased IgG3 level	J:35914
	decreased IgG level	J:35914
	decreased pre-B cell number	J:35914
	decreased thymocyte number	J:35914
	increased T cell derived lymphoma incidence	J:35914
	small thymus	J:35914
\Atm^tm1Fwa/\Atm^tm1Fwa (involves: 129S4/SvJae * C57BL/6)	decreased immature B cell number	J:61201
	decreased lymphocyte cell number	J:61201
	decreased pre-B cell number	J:61201
	decreased splenocyte number	J:61201
	decreased T cell number	J:61201
	decreased thymocyte number	J:61201
	increased T cell derived lymphoma incidence	J:61201
\Atm^tm1Fwa/\Atm^tm1Fwa (involves: 129S4/SvJae)	abnormal class switch recombination	J:191288
\Atm^tm1Led/\Atm^tm1Led (involves: 129S6/SvEvTac * Black Swiss)	abnormal T cell differentiation	J:36561
	decreased CD4-positive, alpha-beta T cell number	J:36561
	increased double-positive T cell number	J:36561
	increased T cell derived lymphoma incidence	J:69726
	small thymus	J:36561
	thymus cortex hypoplasia	J:36561
\Atm^tm1Mfl/\Atm^tm1Mfl (involves: 129T2/SvEms * C57BL/6J)	abnormal immune system cell morphology	J:69726
	abnormal immune system organ morphology	J:69726
	abnormal T cell differentiation	J:69726
	decreased thymocyte number	J:69726
	enlarged spleen	J:69726
	increased double-negative T cell number	J:69726
	increased single-positive T cell number	J:69726
	increased T cell derived lymphoma incidence	J:69726
	small lymph nodes	J:69726
	small spleen	J:69726
	small thymus	J:69726
\Atm^tm1Pmc/\Atm^tm1Pmc \Trp73^tm2Mak/\Trp73^tm2Mak (involves: 129P2/OlaHsd * C57BL/6J)	decreased thymocyte apoptosis	J:157905
\Atm^tm1Shzh/\Atm^tm2.1Fwa \Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/\Gt(ROSA)26Sor⁺ (involves: 129 * 129S6/SvEvTac)	abnormal class switch recombination	J:191288
\Atm^tm2.1Fwa/\Atm^tm2.1Fwa \Tg(VAV1-cre)1Graf/0 (involves: 129S6/SvEvTac)	decreased B cell number	J:277750
	decreased T cell number	J:277750
	decreased thymocyte number	J:277750
	increased T cell derived lymphoma incidence	J:277750
\Atm^tm2.1Mfgc/\Atm^tm2.1Mfgc (C57BL/6-Atm^tm2.1Mfgc)	abnormal T cell differentiation	J:316365
\Atm^tm2.1Mfgc/\Atm^tm2.1Mfgc (C57BL/6-Atm^tm2.1Mfgc)	decreased T cell number	J:316365
\Atmin^tm1.1Jhh/\Atmin^tm1.1Jhh (C57BL/6-Atmin^tm1.1Jhh)	thymus hypoplasia	J:167544
\Atmin^tm1.1Jhh/\Atmin^tm1.1Jhh \Cd79a^tm1(cre)Reth/\Cd79a⁺ (B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh)	decreased B cell number	J:230105
	decreased IgG1 level	J:230105
	decreased immature B cell number	J:230105
	increased B cell apoptosis	J:230105
\Atmin^tm1.1Jhh/\Atmin^tm1.1Jhh \Cd79a^tm1(cre)Reth/\Cd79a⁺ \Tg(IghMyc)22Bri/0 (B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri)	decreased B cell number	J:230105
	decreased immature B cell number	J:230105
	increased B cell apoptosis	J:230105
\Atmin^tm1.2Jhh/\Atmin^tm1.2Jhh \Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S1/Sv * BALB/c * C57BL/6)	enlarged spleen	J:191832
	immune system phenotype	J:191832
	increased B cell number	J:191832
	increased immature B cell number	J:191832
	increased pre-B cell number	J:191832
	increased spleen weight	J:191832
\Atmin^tm1.2Jhh/\Atmin^tm1.2Jhh \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell differentiation	J:191832
	abnormal B cell physiology	J:191832
	decreased immature B cell number	J:191832
	decreased mature B cell number	J:191832
	decreased pre-B cell number	J:191832
	decreased spleen weight	J:191832
	small spleen	J:191832
\Atmin^tm1.2Jhh/\Atmin^tm1.2Jhh \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased B cell number	J:191832
	decreased lymphocyte cell number	J:191832
	decreased mature B cell number	J:191832
	decreased pre-B cell number	J:191832
	immune system phenotype	J:191832
\Atmin^tm1.2Jhh/\Atmin^tm1.2Jhh \Trp53^tm1Brn/\Trp53^tm1Brn \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased B cell number	J:191832
	decreased immature B cell number	J:191832
\Atn1^{tm1b(EUCOMM)Wtsi}/\Atn1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Atn1^{tm1b(EUCOMM)Wtsi}/Cnrm)	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Atp1a1^{em1(IMPC)Ccpcz}/\Atp1a1⁺ (C57BL/6NCrl-Atp1a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Atp1a3^Myk/\Atp1a3⁺ (involves: 129S1/SvImJ * C57BL/6J * C57BL/6NCr * FVB/NCr)	microgliosis	J:151948
\Atp2a2^tm1Ges/\Atp2a2⁺ (involves: 129X1/SvJ)	abnormal osteoclast differentiation	J:198051
\Atp2b4^tm1Ges/\Atp2b4^tm1Ges (involves: 129X1/SvJ * Black Swiss)	enlarged submandibular lymph nodes	J:91844
\Atp2c2^em1(IMPC)Tcp/\Atp2c2^em1(IMPC)Tcp (C57BL/6NCrl-Atp2c2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Atp4a^m1Btlr/\Atp4a^m1Btlr (involves: C57BL/6J)	abnormal spleen morphology	J:179090
\Atp4a^m1Btlr/\Atp4a^m1Btlr (involves: C57BL/6J)	enlarged spleen	J:179090
\Atp5if1^em1Jpy/\Atp5if1^em1Jpy (C57BL/6J-Atp5if1^em1Jpy)	decreased neutrophil cell number	J:312819
\Atp5if1^em1Jpy/\Atp5if1^em1Jpy (C57BL/6J-Atp5if1^em1Jpy)	decreased susceptibility to colitis induced morbidity/mortality	J:312819
\Atp5mg^{tm1b(EUCOMM)Hmgu}/\Atp5mg⁺ (C57BL/6N-Atp5mg^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
	enlarged spleen	J:211773
\Atp5mk^{tm1b(EUCOMM)Wtsi}/\Atp5mk^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Atp5mk^{tm1b(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Atp6v0a2^tm1Kdb/\Atp6v0a2^tm1Kdb \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:274048
	decreased alpha-beta T cell number	J:274048
	decreased CD4-positive, alpha-beta T cell number	J:274048
	decreased T cell number	J:274048
\Atp6v0d1^{tm1b(EUCOMM)Hmgu}/\Atp6v0d1⁺ (C57BL/6N-Atp6v0d1^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Atp6v0d2^tm1Ywc/\Atp6v0d2^tm1Ywc (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:117744
	abnormal osteoclast morphology	J:117744
\Atp6v1b2^{tm1b(KOMP)Wtsi}/\Atp6v1b2⁺ (C57BL/6N-Atp6v1b2^{tm1b(KOMP)Wtsi}/Tcp)	small lymph nodes	J:211773
\Atp6v1c1^{tm1b(NCOM)Mfgc}/\Atp6v1c1⁺ (C57BL/6N-Atp6v1c1^{tm1b(NCOM)Mfgc}/Tcp)	increased leukocyte cell number	J:211773
\Atp6v1h^em1Xhd/\Atp6v1h⁺ (involves: C57BL/6)	abnormal osteoclast differentiation	J:239439
\Atp6v1h^em1Xhd/\Atp6v1h⁺ (involves: C57BL/6)	abnormal osteoclast physiology	J:239439
\Atp7a^Mo-3Btlr/Y (C57BL/6J-Atp7a^Mo-3Btlr)	decreased susceptibility to prion infection	J:188598
\Atp7a^Mo-blo/Y (B6.Cg-Atp7a^Mo-blo/J)	osteoarthritis	J:36378
\Atp7a^Mo-ml/Y (involves: C3Hf/He)	decreased spleen weight	J:12745
\Atp7b^tx-J/\Atp7b^tx-J (C3H/HeJ-Atp7b^tx-J/J)	increased eosinophil cell number	J:24233
\Atp8b1^em1(IMPC)Tcp/\Atp8b1^em1(IMPC)Tcp (C57BL/6NCrl-Atp8b1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
\Atp10a^m1Anu/\Atp10a^m1Anu (C57BL/6NCrlAnu-Atp10a^m1Anu)	immune system phenotype	J:104190
\Atp11a^{tm1a(KOMP)Wtsi}/\Atp11a^{tm1a(KOMP)Wtsi} (C57BL/6N-Atp11a^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
\Atp11c^ambr/Y (C57BL/6-Atp11c^ambr)	abnormal B cell differentiation	J:171924
	abnormal humoral immune response	J:171924
	decreased B cell number	J:171924
	decreased B-1 B cell number	J:171924
	decreased B-1a cell number	J:171924
	decreased B-1b cell number	J:171924
	decreased B-2 B cell number	J:171924
	decreased follicular B cell number	J:171924
	decreased immature B cell number	J:171924
	decreased leukocyte cell number	J:171924
	decreased lymphocyte cell number	J:171924
	decreased mature B cell number	J:171924
	decreased pre-B cell number	J:171924
	decreased pro-B cell number	J:171924
	decreased T cell number	J:171924
\Atp11c^ambr/Y \Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6 * C57BL/6JApb * DBA/2)	decreased B cell number	J:171924
\Atp11c^ambr/Y \Tg(IghelMD4)4Ccg/0 (involves: C57BL/6 * C57BL/6JApb)	decreased immature B cell number	J:171924
	decreased pro-B cell number	J:171924
\Atp11c^ambr/Y \Tg(Vav-BCL2)69Jad/0 (involves: C57BL/6 * C57BL/6J * C57BL/6JApb)	decreased B cell number	J:171924
	decreased immature B cell number	J:171924
	decreased pre-B cell number	J:171924
\Atp11c^em1(IMPC)J/Y (C57BL/6NJ-Atp11c^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Atp11c^em1(IMPC)J/\Atp11c^em1(IMPC)J (C57BL/6NJ-Atp11c^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Atp11c^m1Btlr/Y (involves: C57BL/6J)	absent follicular B cells	J:171925
	arrested B cell differentiation	J:171925
	decreased B cell number	J:185495, J:171925
	decreased B-1 B cell number	J:171925
	decreased B-2 B cell number	J:171925
	decreased IgA level	J:171925
	decreased IgG1 level	J:171925
	decreased IgM level	J:171925
	decreased immature B cell number	J:171925
	decreased transitional stage B cell number	J:171925
	decreased transitional stage T1 B cell number	J:171925
	decreased transitional stage T2 B cell number	J:171925
	decreased transitional stage T3 B cell number	J:171925
	immune system phenotype	J:185495, J:171925
\Atp11c^m1Btlr/Y \Tg(BCL2)22Wehi/0 (involves: C57BL/6J * C57BL/6JWehi * SJL/Wehi)	decreased B cell number	J:171925
	decreased follicular B cell number	J:171925
	decreased mature B cell number	J:171925
	increased marginal zone B cell number	J:171925
\Atp11c^m1Btlr/Y \Tg(IghmHyHEL10,IgkHyHEL10)4Ccg/0 (involves: C57BL/6 * C57BL/6J * C57BL/6JSfdAnu)	decreased B cell number	J:171925
\Atp11c^m1Btlr/\Atp11c^m1Btlr (involves: C57BL/6J)	decreased B cell number	J:185495
\Atp11c^m1Btlr/\Atp11c^m1Btlr (involves: C57BL/6J)	immune system phenotype	J:185495, J:171925
\Atp11c^m1Btlr/\Atp11c^m2Btlr (involves: C57BL/6J)	decreased B cell number	J:171925
\Atp11c^m2Anu/Y (C57BL/6JAnu-Atp11c^m2Anu/AnuApb)	decreased B cell number	J:171924
\Atp11c^m2Btlr/Y (involves: C57BL/6J)	decreased B cell number	J:185495, J:171925
\Atp11c^m2Btlr/Y (involves: C57BL/6J)	immune system phenotype	J:185495
\Atp11c^m2Btlr/\Atp11c^m2Btlr (involves: C57BL/6J)	decreased B cell number	J:185495
\Atp11c^m2Btlr/\Atp11c^m2Btlr (involves: C57BL/6J)	immune system phenotype	J:185495
\Atp13a3^em1(IMPC)J/\Atp13a3^em1(IMPC)J (C57BL/6NJ-Atp13a3^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Atp13a5^tm1Lex/\Atp13a5^tm1Lex (B6;129S5-Atp13a5^tm1Lex/Mmucd)	decreased NK cell number	J:171883
\Atr^tm1Bal/\Atr^tm2Bal \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal thymus involution	J:123200
	decreased thymocyte number	J:123200
	kidney inflammation	J:123200
\Atr^tm1Ofc/\Atr^tm1Ofc (Not Specified)	decreased spleen weight	J:151542
\Atr^tm1Ofc/\Atr^tm1Ofc (Not Specified)	decreased thymus weight	J:151542
\Atxn3^{tm1a(KOMP)Wtsi}/\Atxn3^{tm1a(KOMP)Wtsi} (C57BL/6N-Atxn3^{tm1a(KOMP)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\AU040320^em1Janc/\AU040320^em2Janc (FVB/N-AU040320^em1Janc AU040320^em2Janc)	decreased susceptibility to Parvoviridae infection	J:229089
\Auh^em1(IMPC)Tcp/\Auh^em1(IMPC)Tcp (C57BL/6NCrl-Auh^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
\Aurka^{tm1b(EUCOMM)Hmgu}/\Aurka⁺ (B6N(Cg)-Aurka^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
\Avil^tm2(cre)Fawa/\Avil^tm2(cre)Fawa (B6J.129P2-Avil^tm2(cre)Fawa)	increased susceptibility to experimental autoimmune encephalomyelitis	J:265529
\Avp^{tm1b(EUCOMM)Wtsi}/\Avp⁺ (C57BL/6N-Avp^{tm1b(EUCOMM)Wtsi}/H)	decreased large unstained cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Avpr1a^tm1Sbhu/\Avpr1a^tm1Sbhu (involves: C57BL/6)	abnormal B cell differentiation	J:105892
	abnormal immunoglobulin level	J:105892
	decreased IgG2b level	J:105892
	increased B-1a cell number	J:105892
	increased IgG2a level	J:105892
\AW112010^em2Flv/\AW112010^em2Flv (involves: C57BL/6N)	decreased circulating interleukin-6 level	J:267975
	decreased circulating interleukin-12b level	J:267975
	decreased interleukin-6 secretion	J:267975
	decreased interleukin-12b secretion	J:267975
	decreased susceptibility to induced colitis	J:267975
	increased susceptibility to bacterial infection	J:267975
	increased susceptibility to bacterial infection induced morbidity/mortality	J:267975
\Awat2^em1(IMPC)Mbp/Y (C57BL/6NCrl-Awat2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
\Awat2^tm1.2Golc/Y (involves: 129 * C57BL/6 * C57BL/6J)	abnormal lymphangiogenesis	J:308387
	blepharitis	J:308387
	eye inflammation	J:308387
\Awat2^tm1.2Golc/\Awat2^tm1.2Golc (involves: 129 * C57BL/6 * C57BL/6J)	abnormal lymphangiogenesis	J:308387
	blepharitis	J:308387
	eye inflammation	J:308387
\awg^{Tg(GBts1env)832Pkw}/\awg^{Tg(GBts1env)832Pkw} (involves: C57BL/6J * SJL)	thymus atrophy	J:43273
\Axl^tm1Grl/\Axl^tm1Grl \Mertk^tm1Grl/\Mertk^tm1Grl (involves: C57BL/6J)	increased anti-double stranded DNA antibody level	J:70420
\Axl^tm1Grl/\Axl^tm1Grl \Mertk^tm1Grl/\Mertk^tm1Grl \Tyro3^tm1Grl/\Tyro3^tm1Grl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal B cell activation	J:70420
	abnormal macrophage physiology	J:70420
	abnormal professional antigen presenting cell physiology	J:70420
	abnormal susceptibility to autoimmune disorder	J:70420
	abnormal T cell activation	J:70420
	enlarged lymph nodes	J:70420
	enlarged spleen	J:54681, J:70420
	increased anti-double stranded DNA antibody level	J:70420
	increased autoantibody level	J:70420
	increased B cell proliferation	J:70420
	increased circulating tumor necrosis factor level	J:70420
	increased lymphocyte cell number	J:70420
	increased splenocyte apoptosis	J:54681
	increased T cell proliferation	J:70420
	joint inflammation	J:70420
\Axl^tm1Grl/\Axl^tm1Grl \Tyro3^tm1Grl/\Tyro3^tm1Grl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	increased anti-double stranded DNA antibody level	J:70420
\Azgp1^tm1.1Sbah/\Azgp1^tm1.1Sbah (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:118213
\Azi2^tm1Aki/\Azi2^tm1Aki (Not Specified)	abnormal dendritic cell differentiation	J:204786
	abnormal dendritic cell physiology	J:204786
	decreased interferon-alpha secretion	J:204786
	decreased interleukin-6 secretion	J:204786
	decreased tumor necrosis factor secretion	J:204786
	immune system phenotype	J:204786
\Azi2^tm1Aki/\Azi2^tm1Aki \Tbkbp1^tm1Aki/\Tbkbp1^tm1Aki (Not Specified)	abnormal dendritic cell physiology	J:204786
	decreased interferon-alpha secretion	J:204786
	decreased interleukin-6 secretion	J:204786
	decreased tumor necrosis factor secretion	J:204786
	immune system phenotype	J:204786
\b2b227Clo/\b2b227Clo (C57BL/6J-b2b227Clo)	spleen hypoplasia	J:175213
\b2b386.1Clo/\b2b386.1Clo (C57BL/6J-b2b386.1Clo)	absent spleen	J:175213
\b2b386Clo/\b2b386Clo (C57BL/6J-b2b386Clo)	absent spleen	J:175213
\b2b954Clo/\b2b954Clo (C57BL/6J-b2b954Clo)	thymus hypoplasia	J:175213
\b2b1249Clo/\b2b1249Clo (C57BL/6J-b2b1249Clo)	thymus hypoplasia	J:175213
\b2b1702Clo/\b2b1702Clo (C57BL/6J-b2b1702Clo)	spleen hypoplasia	J:175213
\b2b1702Clo/\b2b1702Clo (C57BL/6J-b2b1702Clo)	thymus hypoplasia	J:175213
\b2b1941Clo/\b2b1941Clo (C57BL/6J-b2b1941Clo)	athymia	J:175213
\b2b2025Clo/\b2b2025Clo (C57BL/6J-b2b2025Clo)	absent spleen	J:175213
\b2b2025Clo/\b2b2025Clo (C57BL/6J-b2b2025Clo)	spleen hypoplasia	J:175213
\b2b2059Clo/\b2b2059Clo (C57BL/6J-b2b2059Clo)	spleen hypoplasia	J:175213
\b2b2140Clo/\b2b2140Clo (C57BL/6J-b2b2140Clo)	spleen hypoplasia	J:175213
\b2b2187Clo/\b2b2187Clo (C57BL/6J-b2b2187Clo)	thymus hypoplasia	J:175213
\b2b2463Clo/\b2b2463Clo (C57BL/6J-b2b2463Clo)	thymus hypoplasia	J:175213
\b2b2588Clo/\b2b2588Clo (C57BL/6J-b2b2588Clo)	thymus hypoplasia	J:175213
\b2b2696.1Clo/\b2b2696.1Clo (C57BL/6J-b2b2696.1Clo)	absent spleen	J:175213
\b2b2696.2Clo/\b2b2696.2Clo (C57BL/6J-b2b2696.2Clo)	thymus hypoplasia	J:175213
\b2b2696Clo/\b2b2696Clo (C57BL/6J-b2b2696Clo)	absent spleen	J:175213
\b2b2736.2Clo/\b2b2736.2Clo (C57BL/6J-b2b2736.2Clo)	thymus hypoplasia	J:175213
\b2b2736Clo/\b2b2736Clo (C57BL/6J-b2b2736Clo)	accessory spleen	J:175213
	spleen hypoplasia	J:175213
	thymus hypoplasia	J:175213
\b2b2821Clo/\b2b2821Clo (C57BL/6J-b2b2821Clo)	thymus hypoplasia	J:175213
\b2b2966Clo/\b2b2966Clo (C57BL/6J-b2b2966Clo)	thymus hypoplasia	J:175213
\b2b3077.2Clo/\b2b3077.2Clo (C57BL/6J-b2b3077.2Clo)	thymus hypoplasia	J:175213
\b2b3077Clo/\b2b3077Clo (C57BL/6J-b2b3077Clo)	thymus hypoplasia	J:175213
\b2b3121Clo/\b2b3121Clo (C57BL/6J-b2b3121Clo)	thymus hypoplasia	J:175213
\b2b3260.2Clo/\b2b3260.2Clo (C57BL/6J-b2b3260.2Clo)	abnormal thymus morphology	J:175213
\b2b3260.2Clo/\b2b3260.2Clo (C57BL/6J-b2b3260.2Clo)	thymus hypoplasia	J:175213
\b2b3260Clo/\b2b3260Clo (C57BL/6J-b2b3260Clo)	abnormal thymus morphology	J:175213
\b2b3260Clo/\b2b3260Clo (C57BL/6J-b2b3260Clo)	thymus hypoplasia	J:175213
\B2m^tm1Jae/\B2m^tm1Jae (involves: 129S2/SvPas * C57BL/6J)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:80910
	abnormal cytotoxic T cell physiology	J:80910
	decreased CD8-positive, alpha-beta T cell number	J:80910, J:744
	increased gamma-delta intraepithelial T cell number	J:744
	increased gamma-delta T cell number	J:744
\B2m^tm1Jae/\B2m^tm1Jae (involves: 129S2/SvPas)	decreased CD8-positive, alpha-beta T cell number	J:166104
\B2m^tm1Jae/\B2m^tm1Jae (B6.129S2-B2m^tm1Jae)	decreased interleukin-4 secretion	J:64283
	decreased susceptibility to parasitic infection	J:64283
	increased interleukin-3 secretion	J:64283
	increased tumor necrosis factor secretion	J:64283
\B2m^tm1Jae/\B2m^tm1Jae \Cd4^tm1Jrp/\Cd4^tm1Jrp (involves: 129S2/SvPas * C57BL/6)	increased CD8-positive, alpha-beta T cell number	J:45168
\B2m^tm1Jae/\B2m^tm1Jae \Foxp3^sf\Otc^spf/Y (involves: 129/Rl * 129S2/SvPas)	abnormal immune system organ morphology	J:20865
	abnormal interleukin level	J:20865
	abnormal lymph node morphology	J:20865
	abnormal tumor necrosis factor level	J:20865
	dermatitis	J:20865
	enlarged lymph nodes	J:20865
	enlarged spleen	J:20865
	increased CD4-positive, alpha-beta T cell number	J:20865
	increased IgG level	J:20865
	increased IgM level	J:20865
	increased immunoglobulin level	J:20865
	increased plasma cell number	J:20865
\B2m^tm1Jae/\B2m^tm1Jae \Rr94^tm3.2Litt/\Rr94^tm3.2Litt (involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
	increased T cell proliferation	J:158962
\B2m^tm1Jae/\B2m^tm1Jae \Rr96^tm1.1Yzo/\Rr96^tm1.1Yzo (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal T cell differentiation	J:130559
\B2m^tm1Jae/\B2m^tm1Jae \Tg(H2-K-Cd86)27All/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	absent B cells	J:112475
\B2m^tm1Jae/\B2m^tm1Jae \Tg(LckNotch1)9Erob/? (involves: 129S2/SvPas * C57BL/6 * CBA)	increased CD8-positive, alpha-beta T cell number	J:93005
	lymph node hypoplasia	J:93005
\B2m^tm1Jae/\B2m^tm1Jae \Themis^tm1Lov/\Themis^tm1Lov (involves: 129)	abnormal CD8-positive, alpha-beta T cell differentiation	J:151075
\B2m^tm1Jae/\B2m^tm1Jae \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	small intestinal inflammation	J:108572
\B2m^tm1Jae/\B2m^tm1Jae \Tox^tm1.1Kay/\Tox^tm1.1Kay (involves: 129S6/SvEvTac * 129S2/SvPas)	abnormal CD8-positive, alpha-beta T cell number	J:131287
\B2m^tm1Jae/\B2m^tm1Jae \Zbtb7b^tm1Litt/\Zbtb7b^tm1.2Litt (involves: 129S2/SvPas * C57BL/6)	abnormal CD8-positive, alpha-beta T cell differentiation	J:141144
	abnormal double-positive T cell morphology	J:141144
\B2m^tm1Unc/\B2m⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:64451
\B2m^tm1Unc/\B2m⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased level of surface class I molecules	J:64451
\B2m^tm1Unc/\B2m^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell number	J:113083
	absent CD8-positive, alpha-beta T cells	J:64451
	decreased level of surface class I molecules	J:64451
\B2m^tm1Unc/\B2m^tm1Unc (NOD.129P2-B2m^tm1Unc)	absent CD8-positive, alpha-beta T cells	J:121685
\B2m^tm1Unc/\B2m^tm1Unc (NOD.129P2-B2m^tm1Unc)	decreased susceptibility to autoimmune diabetes	J:121685, J:17000
\B2m^tm1Unc/\B2m^tm1Unc (involves: 129P2/OlaHsd * NOD/Lt)	insulitis	J:93557
\B2m^tm1Unc/\B2m^tm1Unc (B6.129P2-B2m^tm1Unc/DcrJ)	abnormal interleukin level	J:123934
	abnormal tumor necrosis factor level	J:123934
	decreased CD8-positive, alpha-beta T cell number	J:123934
	decreased IgG level	J:110885
	decreased susceptibility to autoimmune diabetes	J:135214
	decreased susceptibility to bacterial infection	J:123934
	increased IgM level	J:110885
	increased susceptibility to infection induced morbidity/mortality	J:123934
	increased T-helper 1 cell number	J:123934
\B2m^tm1Unc/\B2m^tm1Unc \Cd4^tm1Mak/\Cd4^tm1Mak \Cd8a^{tm2.1(Cd4)Asin}/\Cd8a^{tm2.1(Cd4)Asin} (involves: 129 * C57BL/6)	abnormal T cell physiology	J:180236
\B2m^tm1Unc/\B2m^tm1Unc \Ciita^tm1Ccum/\Ciita^tm1Ccum (NOD.Cg-B2m^tm1Unc Ciita^tm1Ccum)	decreased single-positive T cell number	J:107051
	decreased susceptibility to autoimmune diabetes	J:107051
\B2m^tm1Unc/\B2m^tm1Unc \Emv30^b/\Emv30^b \Prkdc^scid/\Prkdc^scid \Tg(B2M)55Hpl/? \Mcph1^{Tg(HLA-A2.1)1Enge}/? (NOD.Cg-B2m^tm1Unc Mcph1^{Tg(HLA-A2.1)1Enge} Emv30^b Prkdc^scid Tg(B2M)55Hpl/Dvs)	decreased susceptibility to autoimmune diabetes	J:109851
\B2m^tm1Unc/\B2m^tm1Unc \H2-Ab1^b-tm1Doi/\H2-Ab1^b-tm1Doi \Lat^tm1.1Mal/\Lat^tm1.1Mal (involves: 129P2/OlaHsd * 129S2/SvPas)	absent CD4-positive, alpha-beta T cells	J:77098
	absent CD8-positive, alpha-beta T cells	J:77098
	immune system phenotype	J:77098
\B2m^tm1Unc/\B2m^tm1Unc \H2-D1^b-tm1Bpe/\H2-D1^b-tm1Bpe (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:41077
\B2m^tm1Unc/\B2m^tm1Unc \Il2^tm1Hor/\Il2^tm1Hor (involves: 129 * C57BL/6)	abnormal CD4-positive T cell differentiation	J:39981
	abnormal CD4-positive, alpha-beta T cell physiology	J:51450
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:39981
	abnormal CD8-positive, alpha beta T cell morphology	J:51450
	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:39981
	colitis	J:39981, J:51450
\B2m^tm1Unc/\B2m^tm1Unc \Il2rg^tm1.1Asin/\Il2rg^tm1Wjl \Tg(Cd8a-cre)B8Asin/0 (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
\B2m^tm1Unc/\B2m^tm1Unc \Il7r^tm1.1Asin/\Il7r^tm1Imx \Tg(Cd8a-cre)B8Asin/0 (involves: 129P2/OlaHsd 129S7/SvEvBrd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
\B2m^tm1Unc/\B2m^tm1Unc \Lat^tm1.1Mal/\Lat^tm1.1Mal (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal immune system morphology	J:77098
\B2m^tm1Unc/\B2m^tm1Unc \Prkdc^scid/\Prkdc^scid (NOD.Cg-B2m^tm1Unc Prkdc^scid)	abnormal NK cell physiology	J:102141
	abnormal response to transplant	J:102141
	absent lymphocyte	J:102141
	arrested B cell differentiation	J:102141
	arrested T cell differentiation	J:102141
	decreased level of surface class I molecules	J:102141
	increased macrophage cell number	J:102141
	increased T cell derived lymphoma incidence	J:102141
\B2m^tm1Unc/\B2m^tm1Unc \Rr381^em2Kap/\Rr381^em2Kap (involves: 129P2/OlaHsd * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
\B2m^tm1Unc/\B2m^tm1Unc \Tespa1^tm1Smoc/\Tespa1^tm1Smoc (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:186446
\B2m^tm1Unc/\B2m^tm1Unc \Tg(B2M)55Hpl/0 (NOD.Cg-B2m^tm1Unc Tg(B2M)55Hpl/Dvs)	decreased susceptibility to autoimmune diabetes	J:71837
	immune system phenotype	J:71837
\B2m^tm1Unc/\B2m^tm1Unc \Tg(B2M)55Hpl/\Tg(B2M)55Hpl \Mcph1^{Tg(HLA-A2.1)1Enge}/\Mcph1^{Tg(HLA-A2.1)1Enge} (NOD.Cg-B2m^tm1Unc Mcph1^{Tg(HLA-A2.1)1Enge} Tg(B2M)55Hpl)	increased susceptibility to autoimmune diabetes	J:109851
\B2m^tm1Unc/\B2m^tm1Unc \Tg(GFAP-B2m)9Mdos/? (involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)	absent CD8-positive, alpha-beta T cells	J:135214
	decreased susceptibility to autoimmune diabetes	J:135214
\B2m^tm1Unc/\B2m^tm1Unc \Tg(GFAP-B2m)#Mdos/? (involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)	absent CD8-positive, alpha-beta T cells	J:135214
	decreased susceptibility to autoimmune diabetes	J:135214
\B2m^tm1Unc/\B2m^tm1Unc \Tg(HLA-A/H2-D/B2M)1Dvs/0 (NOD.Cg-B2m^tm1Unc Tg(HLA-A/H2-D/B2M)1Dvs)	abnormal CD8-positive, alpha-beta T cell physiology	J:121685
	abnormal cell-mediated immunity	J:121685
	abnormal cytotoxic T cell physiology	J:121685
	decreased CD8-positive, alpha-beta T cell number	J:121685
	increased susceptibility to autoimmune diabetes	J:121685
\B2m^tm1Unc/\B2m^tm1Unc \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0 (NOD.Cg-B2m^tm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	abnormal CD8-positive, alpha beta T cell morphology	J:93553
	decreased susceptibility to autoimmune diabetes	J:93553
\B2m^tm1Unc/\B2m^tm1Unc X/\Yaa (BXSB.129P2(B6)-B2m^tm1Unc/Dcr)	increased anti-nuclear antigen antibody level	J:179430
	increased susceptibility to systemic lupus erythematosus	J:179430
\B2m^tm1Unc/\B2m^tm1Unc \Zbtb7b^tm4.1Itan/\Zbtb7b^tm4.1Itan (involves: 129P2/OlaHsd)	increased CD8-positive, alpha-beta T cell number	J:193321
\B3galt2^{tm1.1(KOMP)Vlcg}/\B3galt2⁺ (C57BL/6N-B3galt2^{tm1.1(KOMP)Vlcg}/Tcp)	decreased lymphocyte cell number	J:211773
\B3gnt2^{Gt(OST237555)Lex}/\B3gnt2^{Gt(OST237555)Lex} (involves: 129S5/SvEvBrd * C57BL/6N)	abnormal macrophage physiology	J:125556
	increased interleukin-1 beta secretion	J:125556
	increased interleukin-6 secretion	J:125556
	increased T cell proliferation	J:125556
	increased tumor necrosis factor secretion	J:125556
\B3gnt5^tm1Big/\B3gnt5^tm1Big (C57BL/6-B3gnt5^tm1Big)	abnormal spleen germinal center morphology	J:166763
	abnormal spleen morphology	J:166763
	absent spleen marginal zone	J:166763
	decreased B cell number	J:166763
	enlarged lymph nodes	J:166763
	enlarged spleen	J:166763
	increased spleen white pulp amount	J:166763
	intermingled spleen red and white pulp	J:166763
\B3gnt5^tm1Nari/\B3gnt5^tm1Nari (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:161366
	increased IgG2a level	J:161366
	increased IgG2b level	J:161366
	increased IgG level	J:161366
\B3gnt5^tm2.1Big/\B3gnt5^tm2.1Big (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal spleen germinal center morphology	J:166763
	abnormal spleen morphology	J:166763
	absent spleen marginal zone	J:166763
	decreased B cell number	J:166763
	enlarged lymph nodes	J:166763
	enlarged spleen	J:166763
	increased spleen white pulp amount	J:166763
	intermingled spleen red and white pulp	J:166763
\B3gnt6^tm1Lx/\B3gnt6^tm1Lx (involves: 129S1/Sv * C57BL/6J)	increased interferon-gamma secretion	J:123826
	increased interleukin-2 secretion	J:123826
	increased macrophage cell number	J:123826
	increased monocyte cell number	J:123826
	increased susceptibility to induced colitis	J:123826
	increased T cell number	J:123826
	increased tumor necrosis factor secretion	J:123826
\B3gnt6^tm1Lx/\B3gnt6^tm1Lx \C1galt1^tm1.1Rpmc/\C1galt1^tm1.1Rpmc \Tg(Vil1-cre)997Gum/0 (involves: 129S1/Sv * C57BL/6J * SJL)	small intestinal inflammation	J:239765
\B3gnt7^{tm1e.1(KOMP)Wtsi}/\B3gnt7^{tm1e.1(KOMP)Wtsi} (C57BL/6N-B3gnt7^{tm1e.1(KOMP)Wtsi}/Ucd)	enlarged spleen	J:211773
\B4galnt1^tm1Rlp/\B4galnt1^tm1Rlp \Hexb^tm1Rlp/\Hexb^tm1Rlp (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:53080
\B4galnt2^tm1Jbl/\B4galnt2^tm1Jbl (involves: 129S1/Sv)	abnormal B cell number	J:217719
\B4galnt2^tm1Jbl/\B4galnt2^tm1Jbl (involves: 129S1/Sv)	increased neutrophil cell number	J:217719
\B4galnt3^{tm1a(EUCOMM)Wtsi}/\B4galnt3^{tm1a(EUCOMM)Wtsi} (C57BL/6N-B4galnt3^{tm1a(EUCOMM)Wtsi}/Ics)	increased CD8-positive, alpha-beta T cell number	J:165965
\B4galt1^tm1Yiw/\B4galt1^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal leukocyte physiology	J:106669
	abnormal neutrophil physiology	J:106669
	decreased acute inflammation	J:106669
	decreased susceptibility to type IV hypersensitivity reaction	J:106669
	enlarged spleen	J:106669
	impaired macrophage chemotaxis	J:89125
	impaired neutrophil recruitment	J:89125
	increased leukocyte cell number	J:106669
	increased lymphocyte cell number	J:106669
	increased neutrophil cell number	J:106669
\B4galt1^tm1Yiw/\B4galt1^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal IgM level	J:117891
	glomerulonephritis	J:117891
	increased IgA level	J:117891
\B4galt3^em1Masn/\B4galt3^em1Masn (C57BL/6-B4galt3^em1Masn)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:343168
	decreased regulatory T cell number	J:343168
	increased CD8-positive, alpha-beta T cell number	J:343168
\B4galt4^em1(IMPC)J/\B4galt4^em1(IMPC)J (C57BL/6NJ-B4galt4^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\B4galt5^em1(IMPC)Tcp/\B4galt5⁺ (C57BL/6NCrl-B4galt5^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\B4gat1^tm1Mifu/\B4gat1^tm1Mifu (B6.Cg-B4gat1^tm1Mifu)	abnormal lymph node cell ratio	J:120722
	immune system phenotype	J:120722
	impaired leukocyte tethering or rolling	J:120722
\B4gat1^tm1Mifu/\B4gat1^tm1Mifu \Gcnt1^tm1Jxm/\Gcnt1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:120722
	abnormal lymph node cell ratio	J:120722
	decreased susceptibility to type IV hypersensitivity reaction	J:120722
	impaired leukocyte tethering or rolling	J:120722
\B9d2/Tgfb1^tm1Flv/\B9d2/Tgfb1^tm1Flv \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal regulatory T cell physiology	J:204761
\B9d2/Tgfb1^tm1Flv/\B9d2/Tgfb1^tm1Flv \Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
\B9d2/Tgfb1^tm1Flv/\Tgfb1^tm2Flv \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	immune system phenotype	J:169839
	increased regulatory T cell number	J:169839
\B9d2/Tgfb1^tm1Flv/\Tgfb1^tm2Flv \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal inflammatory response	J:123547
	abnormal interferon level	J:123547
	abnormal interleukin level	J:123547
	abnormal T cell activation	J:123547
	abnormal T cell differentiation	J:123547
	abnormal T-helper 17 cell differentiation	J:169839
	colitis	J:123547
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:123547
	increased anti-double stranded DNA antibody level	J:123547
	increased anti-nuclear antigen antibody level	J:123547
	increased T cell proliferation	J:123547
\B9d2/Tgfb1^tm1Flv/\Tgfb1^tm2Flv \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal T cell differentiation	J:169839
	colitis	J:169839
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:169839
	decreased T-helper 17 cell number	J:169839
	increased regulatory T cell number	J:169839
	increased T-helper 1 cell number	J:169839
	liver inflammation	J:169839
	lung inflammation	J:169839
\B9d2/Tgfb1^tm1Flv/\B9d2/Tgfb1^tm1Flv \Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal inflammatory response	J:123547
\B9d2/Tgfb1^tm1Flv/\B9d2/Tgfb1^tm1Flv \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal regulatory T cell physiology	J:204761
\B9d2/Tgfb1^tm1Flv/\B9d2/Tgfb1^tm1Flv \Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
\B9d2/Tgfb1^tm1Flv/\B9d2⁺ \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	immune system phenotype	J:169839
	increased regulatory T cell number	J:169839
\B9d2/Tgfb1^tm1Flv/\B9d2⁺ \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T-helper 17 cell differentiation	J:169839
\B9d2/Tgfb1^tm1Flv/\B9d2⁺ \Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
\B9d2/Tgfb1^tm1Flv/\B9d2⁺ \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal T cell differentiation	J:169839
	colitis	J:169839
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:169839
	decreased T-helper 17 cell number	J:169839
	increased regulatory T cell number	J:169839
	increased T-helper 1 cell number	J:169839
	liver inflammation	J:169839
	lung inflammation	J:169839
\B9d2^{tm1a(EUCOMM)Wtsi}/\B9d2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-B9d2^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	accessory spleen	J:239583
	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
	small spleen	J:239583
\Baa1^BALB/cJ/\Baa1^NZW/LacJ (involves: BALB/cJ * NZW/LacJ)	increased IgM level	J:35434
\Baa2^BALB/cJ/\Baa2^NZW/LacJ (involves: BALB/cJ * NZW/LacJ)	increased IgM level	J:35434
\Baat^em1(IMPC)Mbp/\Baat^em1(IMPC)Mbp (C57BL/6NCrl-Baat^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
\Babam1^{em1(IMPC)Ccpcz}/\Babam1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Babam1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
\Bach2^M1Btlr/\Bach2^M1Btlr (C57BL/6J-Bach2^M1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:272023
\Bach2^M1Btlr/\Bach2^M1Btlr (C57BL/6J-Bach2^M1Btlr)	increased B-1 B cell number	J:272023
\Bach2^m1Ccg/\Bach2^m1Ccg (C57BL/6-Bach2^m1Ccg)	decreased B cell number	J:94077
	decreased marginal zone B cell number	J:94077
	myeloid hyperplasia	J:94077
\Bach2^m2Anu/\Bach2^m2Anu (C57BL/6NCrlAnu-Bach2^m2Anu)	decreased mature B cell number	J:104190
	increased IgM level	J:104190
	increased immature B cell number	J:104190
\Bach2^{tm1a(EUCOMM)Wtsi}/\Bach2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Bach2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased mature B cell number	J:211773
	decreased memory-marker NK cell number	J:211773
	decreased regulatory T cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD8-positive, alpha-beta memory T cell number	J:211773
	increased CD11b-low dendritic cell number	J:211773
	increased CD103-positive CD11b-low dendritic cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased immature B cell number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-negative NK T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive gamma-delta T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased macrophage cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
\Bach2^{tm1b(EUCOMM)Wtsi}/\Bach2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Bach2^{tm1b(EUCOMM)Wtsi}/Ieg)	decreased B cell number	J:211773
	decreased B-1a cell number	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD4-negative NK T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased marginal zone B cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased transitional stage B cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased eosinophil cell number	J:211773
	increased granulocyte number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased monocyte cell number	J:211773
	increased NK T cell number	J:211773
\Bach2^tm1Igar/\Bach2^tm1Igar (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:91110
	abnormal B cell physiology	J:91110
	abnormal class switch recombination	J:91110
	abnormal somatic hypermutation frequency	J:91110
	absent germinal center B cells	J:91110
	decreased B cell number	J:91110
	decreased IgA level	J:91110
	decreased IgG1 level	J:91110
	decreased IgG2a level	J:91110
	decreased IgG2b level	J:91110
	decreased IgG3 level	J:91110
	decreased IgG level	J:91110
	decreased mature B cell number	J:91110
	increased IgM level	J:91110
	spleen hypoplasia	J:91110
\Bad^tm1Meg/\Bad^tm1Meg (involves: 129S4/SvJae)	abnormal B cell differentiation	J:88139
	abnormal T cell differentiation	J:88139
	decreased mature B cell number	J:88139
	decreased pro-B cell number	J:88139
	decreased thymus weight	J:88139
	small thymus	J:88139
	thymus hypoplasia	J:88139
\Bad^tm1Sjk/\Bad^tm1Sjk (either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6))	abnormal B cell physiology	J:84987
	abnormal immune system cell morphology	J:84987
	abnormal T cell physiology	J:84987
\Bad^tm1Sjk/\Bad^tm1Sjk (involves: 129X1/SvJ)	immune system phenotype	J:132819
\Bag3^tm1.1Jhl/\Bag3^tm1.1Jhl (B6.129S2-Bag3^tm1.1Jhl)	decreased leukocyte cell number	J:144416
	decreased lymphocyte cell number	J:144416
	decreased neutrophil cell number	J:144416
	decreased spleen weight	J:144416
	decreased thymus weight	J:144416
	spleen hypoplasia	J:144416
	thymus hypoplasia	J:144416
\Bag4^tm1Yeh/\Bag4^tm1Yeh (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:83559
	increased circulating interleukin-6 level	J:83559
	increased inflammatory response	J:83559
	increased interleukin-6 secretion	J:83559
	spleen hypoplasia	J:83559
	thymus hypoplasia	J:83559
\Bahd1^tm1.1Ics/\Bahd1⁺ (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:169470
\Bahd1^{tm2b(KOMP)Wtsi}/\Bahd1⁺ (C57BL/6N-Bahd1^{tm2b(KOMP)Wtsi}/Ics)	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
	increased NK T cell number	J:211773
	increased T cell number	J:211773
\Bak1^tm1Thsn/\Bak1^tm1Thsn \Bax^tm1Sjk/\Bax^tm1Sjk (involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * C57BL/6)	abnormal B cell morphology	J:66872
	abnormal splenocyte physiology	J:66872
	abnormal T cell morphology	J:66872
	enlarged lymph nodes	J:66872
	enlarged spleen	J:66872
	increased leukocyte cell number	J:66872
	increased lymphocyte cell number	J:66872
	increased spleen red pulp amount	J:66872
	increased spleen white pulp amount	J:66872
\Bak1^tm1Thsn/\Bak1^tm1Thsn \Bax^tm1Sjk/\Bax^tm2Sjk \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal B cell number	J:100463
	abnormal B cell physiology	J:100463
	decreased marginal zone B cell number	J:100463
	increased B cell number	J:100463
	increased B-2 B cell number	J:100463
	increased follicular B cell number	J:100463
	increased IgA level	J:100463
	increased IgG level	J:100463
	increased IgM level	J:100463
	increased immunoglobulin level	J:100463
	increased pre-B cell number	J:100463
	increased pro-B cell number	J:100463
	increased transitional stage B cell number	J:100463
\Bak1^tm1Thsn/\Bak1^tm1Thsn \Bax^tm1Sjk/\Bax^tm2Sjk \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal T cell differentiation	J:100463
	autoimmune arthritis	J:100463
	glomerulonephritis	J:100463
	increased anti-double stranded DNA antibody level	J:100463
	increased B cell number	J:100463
	increased leukocyte cell number	J:100463
	increased lymphocyte cell number	J:100463
	increased susceptibility to autoimmune disorder	J:100463
\Bak1^tm1Thsn/\Bak1^tm1Thsn \Bax^tm2Sjk/\Bax^tm2Sjk \Tg(Lck-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte apoptosis	J:220951
\Bak1^tm1Thsn/\Bak1^tm1Thsn \Bax^tm2Sjk/\Bax^tm2Sjk \Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased regulatory T cell number	J:208318
\Bank1^tm1Kuro/\Bank1^tm1Kuro (Not Specified)	abnormal B cell physiology	J:113321
	abnormal lymphocyte physiology	J:113321
	abnormal spleen germinal center morphology	J:113321
	abnormal splenic cell ratio	J:113321
	increased B cell proliferation	J:113321
	increased B-1a cell number	J:113321
	increased IgG2a level	J:113321
	increased IgM level	J:113321
	increased mature B cell number	J:113321
	increased spleen germinal center number	J:113321
	increased spleen germinal center size	J:113321
\Bank1^tm1Kuro/\Bank1^tm1Kuro \Cd40^tm1Kik/\Cd40^tm1Kik (involves: 129P2/OlaHsd)	immune system phenotype	J:113321
\Bap1^tm1.1Geno/\Bap1^tm1.1Geno \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal granulocyte morphology	J:187380
	abnormal myelopoiesis	J:187380
	abnormal neutrophil morphology	J:187380
	enlarged spleen	J:187380
	heart inflammation	J:187380
	increased leukocyte cell number	J:187380
	increased monocyte cell number	J:187380
	increased neutrophil cell number	J:187380
	myeloid hyperplasia	J:187380
\Batf2^tm1Kmm/\Batf2^tm1Kmm (129S6/SvEvTac-Batf2^tm1Kmm)	increased susceptibility to parasitic infection induced morbidity/mortality	J:101977
\Batf3^tm1Kmm/\Batf3^tm1Kmm (involves: 129S6/SvEvTac * BALB/cJ)	abnormal cytotoxic T cell physiology	J:141064
	abnormal dendritic cell antigen presentation	J:141064
	abnormal dendritic cell differentiation	J:141064
	abnormal dendritic cell physiology	J:141064
	abnormal immune system physiology	J:141064
	decreased cytotoxic T cell cytolysis	J:141064
	decreased memory T cell number	J:141064
	decreased myeloid dendritic cell number	J:141064
\Batf3^tm1Kmm/\Batf3^tm1Kmm (involves: 129S6/SvEvTac)	abnormal cytotoxic T cell physiology	J:181366
	abnormal dendritic cell antigen presentation	J:362930
	immune system phenotype	J:181366
\Batf3^tm1Kmm/\Batf3^tm1Kmm \Id2^tm1Gtbz/\Id2^tm1Gtbz (B6.Cg-Batf3^tm1Kmm Id2^tm1Gtbz)	abnormal dendritic cell physiology	J:194760
\Batf^tm1.1Ejt/\Batf^tm1.1Ejt (involves: 129S/Sv * C57BL/6 * FVB/N)	abnormal class switch recombination	J:160935
	abnormal T-helper 2 cell differentiation	J:160935
	absent germinal center B cells	J:160935
	decreased CD4-positive, alpha-beta T cell number	J:160935
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:160935
	decreased IgA level	J:160935
	decreased IgE level	J:160935
	decreased IgG1 level	J:160935
	decreased IgG2c level	J:160935
	decreased IgM level	J:160935
	decreased interleukin-4 secretion	J:160935
	decreased interleukin-17 secretion	J:160935
	decreased T follicular helper cell number	J:160935
	decreased T-helper 17 cell number	J:160935
\Batf^tm1.1Kmm/\Batf^tm1.1Kmm (129S6/SvEvTac-Batf^tm1.1Kmm)	abnormal CD4-positive T cell differentiation	J:150643
	decreased interleukin-17 secretion	J:150643
	decreased interleukin-21 secretion	J:150643
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:150643
\Bax^tm1Sjk/\Bax^tm1Sjk (involves: 129X1/SvJ)	enlarged spleen	J:29253
	increased B cell number	J:29253
	increased thymocyte number	J:29253
\Baz2a^em1(IMPC)Tcp/\Baz2a^em1(IMPC)Tcp (C57BL/6NCrl-Baz2a^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Baz2b^{em1(IMPC)Wtsi}/\Baz2b^{em1(IMPC)Wtsi} (C57BL/6N-Baz2b^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Bbaa1^C3H/HeNCr/\Bbaa1^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:52017
\Bbaa1^C3H/HeNCr/\Bbaa1^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:52017
\Bbaa2^C3H/HeNCr/\Bbaa2^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal immune system physiology	J:52017
\Bbaa3^C3H/HeNCr/\Bbaa3^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:73060
\Bbaa3^C3H/HeNCr/\Bbaa3^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal inflammatory response	J:52017
\Bbaa5^C57BL/6NCr/\Bbaa5^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	increased IgM level	J:52017
\Bbaa9^C57BL/6NCr/\Bbaa9^C3H/HeNCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal immunoglobulin level	J:52017
\Bbaa9^C57BL/6NCr/\Bbaa9^C57BL/6NCr (involves: C3H/HeNCr * C57BL/6NCr)	abnormal immunoglobulin level	J:52017
\Bbaa10^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa11^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa12^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa13^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa14^C3H/HeJ/? (involves: C3H/HeN * C57BL/6N)	increased IgG level	J:73060
\Bbaa14^C3H/HeJ/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa15^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased IgG level	J:73060
\Bbaa16^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa17^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa18^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa19^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased IgG level	J:73060
\Bbaa20^C3H/HeJ/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa21^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased susceptibility to bacterial infection	J:73060
\Bbaa22^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbaa23^C3H/HeN/? (involves: C3H/HeN * C57BL/6N)	increased inflammatory response	J:73060
\Bbc3^tm1Ast/\Bbc3^tm1Ast (involves: C57BL/6 * NZB)	abnormal CD8-positive, alpha-beta T cell physiology	J:132819
	abnormal splenic cell ratio	J:132819
	immune system phenotype	J:132819
	increased CD8-positive, alpha-beta T cell number	J:132819
	increased leukocyte cell number	J:132819
\Bbc3^tm1Gpz/\Bbc3^tm1Gpz \Trp53^tm1Brd/\Trp53^tm8Xu (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	decreased thymocyte number	J:170216
\Bbln^{tm1(KOMP)Wtsi}/\Bbln⁺ (involves: C57BL/6N)	abnormal osteoclast differentiation	J:296689
\Bbln^{tm1(KOMP)Wtsi}/\Bbln^{tm1(KOMP)Wtsi} (involves: C57BL/6N)	abnormal osteoclast differentiation	J:296689
	increased osteoclast cell number	J:296689
\Bbs4^Gt1Nk/\Bbs4^Gt1Nk (involves: 129S7/SvEvBrd)	increased immunoglobulin level	J:134093
\Bbs5^{tm1b(EUCOMM)Wtsi}/\Bbs5^{tm1b(EUCOMM)Wtsi} (C57BL/6NTac-Bbs5^{tm1b(EUCOMM)Wtsi}/H)	decreased spleen weight	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Bbs9^em1(IMPC)Bay/\Bbs9⁺ (C57BL/6N-Bbs9^em1(IMPC)Bay/Bay)	increased leukocyte cell number	J:211773
\Bbs12^{em1(IMPC)Ccpcz}/\Bbs12⁺ (C57BL/6NCrl-Bbs12^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Bbs12^tm1.1Vmar/\Bbs12^tm1.1Vmar (involves: 129S6/SvEvTac * C57BL/6)	decreased circulating interleukin-6 level	J:189019
	decreased circulating tumor necrosis factor level	J:189019
	decreased inflammatory response	J:189019
\Bbx^{tm1a(EUCOMM)Wtsi}/\Bbx^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased IgA level	J:213427
\Bcap31^tm1.1Bwang/\Bcap31^tm1.1Bwang \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased inflammatory response	J:292505
	increased interleukin-1 beta secretion	J:292505
	increased microglial cell activation	J:292505
	increased tumor necrosis factor secretion	J:292505
\Bcap31^tm1.1Bwang/\Bcap31^tm1.1Bwang \Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal T cell activation	J:274469
	decreased CD8-positive, naive alpha-beta T cell number	J:274469
	decreased interferon-gamma secretion	J:274469
	decreased interleukin-2 secretion	J:274469
	decreased single-positive T cell number	J:274469
	decreased T cell proliferation	J:274469
	decreased thymocyte number	J:274469
	decreased thymus weight	J:274469
	increased effector memory T-helper cell number	J:274469
	increased thymocyte apoptosis	J:274469
	small thymus	J:274469
	thymus hypoplasia	J:274469
\Bcar3^em1(IMPC)Mbp/\Bcar3^em1(IMPC)Mbp (C57BL/6N-Bcar3^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
\Bcas1^tm1Himo/\Bcas1^tm1Himo (C57BL/6-Bcas1^tm1Himo)	brain inflammation	J:242041
\Bcat1^tm1.2Eaa/\Bcat1^tm1.2Eaa (involves: C57BL/6)	abnormal T cell physiology	J:216027
\Bckdha^em1(IMPC)Tcp/\Bckdha⁺ (C57BL/6NCrl-Bckdha^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:73660
	decreased CD8-positive, alpha-beta T cell number	J:73660
	decreased lymphocyte cell number	J:73660
	decreased mature B cell number	J:73660
	decreased pre-B cell number	J:73660
	decreased thymocyte number	J:73660
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo (B6.129P2-Bcl2^tm1Dlo)	abnormal leukopoiesis	J:73316
	abnormal lymphocyte physiology	J:104487, J:73316
	decreased spleen weight	J:153846
	decreased spleen white pulp amount	J:153846
	increased B cell apoptosis	J:73316
	increased splenocyte apoptosis	J:153846
	increased T cell apoptosis	J:73316
	spleen atrophy	J:153846
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm1.1Ast/\Bcl2l11⁺ (B6.129-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	abnormal lymphocyte physiology	J:73316
	increased T cell apoptosis	J:73316
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm1.1Ast/\Bcl2l11⁺ (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast (B6.129-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	abnormal leukopoiesis	J:73316
	abnormal lymphocyte physiology	J:73316
	decreased B cell apoptosis	J:73316
	increased T cell apoptosis	J:73316
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Ast)	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm1.1Boui/\Bcl2l11^tm1.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Boui)	immune system phenotype	J:153846
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm1.1Boui/\Bcl2l11^tm2.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm1.1Boui/Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm2.1Boui/\Bcl2l11^tm2.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bcl2l11^tm3.1Boui/\Bcl2l11^tm3.1Boui (B6.Cg-Bcl2^tm1Dlo Bcl2l11^tm3.1Boui)	decreased splenocyte apoptosis	J:153846
	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2^tm1Dlo/\Bcl2^tm1Dlo \Bik^tm1Ast/\Bik^tm1Ast (B6.Cg-Bcl2^tm1Dlo Bik^tm1Ast)	abnormal lymphocyte physiology	J:104487
\Bcl2^tm1Irt/\Bcl2^tm1Irt \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased macrophage apoptosis	J:144243
\Bcl2^tm1Lbox/\Bcl2^tm1Lbox (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal B cell activation	J:114637
	abnormal B cell differentiation	J:114637
	decreased B cell number	J:114637
	decreased B cell proliferation	J:114637
	decreased immature B cell number	J:114637
	decreased mature B cell number	J:114637
	decreased pre-B cell number	J:114637
	increased B cell apoptosis	J:114637
\Bcl2^tm1Sjk/\Bcl2^tm1Sjk (involves: 129S2/SvPas * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:15224
	abnormal CD8-positive, alpha beta T cell morphology	J:15224
	abnormal immune system organ morphology	J:15224
	abnormal spleen morphology	J:15224
	abnormal spleen red pulp morphology	J:15224
	abnormal spleen white pulp morphology	J:15224
	abnormal thymus involution	J:15224
	abnormal thymus morphology	J:15224
	decreased B cell number	J:15224
	decreased double-positive T cell number	J:15224
	decreased lymphocyte cell number	J:15224
	decreased T cell number	J:15224
	increased double-negative T cell number	J:15224
	increased T cell apoptosis	J:15224
	small spleen	J:15224
	small thymus	J:15224
\Bcl2^tm1Tsu/\Bcl2^tm1Tsu (involves: 129P2/OlaHsd * ICR)	abnormal lymphocyte morphology	J:22391
	abnormal T cell physiology	J:22391
	small spleen	J:22391
	small thymus	J:22391
	spleen atrophy	J:22391
	thymus atrophy	J:22391
\Bcl2^tm2.1Lbox/\Bcl2⁺ (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal B cell physiology	J:175730
	enlarged lymph nodes	J:175730
	enlarged spleen	J:175730
	increased B cell number	J:175730
	increased immature B cell number	J:175730
	increased mature B cell number	J:175730
	increased pre-B cell number	J:175730
\Bcl2^tm2.1Lbox/\Bcl2^tm2.1Lbox (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal B cell physiology	J:175730
	enlarged lymph nodes	J:175730
	enlarged spleen	J:175730
	increased B cell number	J:175730
	increased immature B cell number	J:175730
	increased mature B cell number	J:175730
	increased pre-B cell number	J:175730
\Bcl2a1a^tm1.1Tac/\Bcl2a1a^tm1.1Tac \Bcl2a1b^tm1.1Tac/\Bcl2a1b^tm1.1Tac \Bcl2a1d^tm1.1Tac/\Bcl2a1d^tm1.1Tac (involves: BALB/cJ * C57BL/6NTac)	abnormal dendritic cell physiology	J:258915
	decreased CD4-positive, alpha-beta memory T cell number	J:258915
	decreased central memory CD4-positive, alpha-beta T cell number	J:258915
	decreased dendritic cell number	J:258915
	decreased effector memory CD4-positive, alpha-beta T cell number	J:258915
	decreased gamma-delta T cell number	J:258915
	decreased regulatory T cell number	J:258915
	immune system phenotype	J:258915
\Bcl2a1a^tm1Prys/\Bcl2a1a^tm1Prys (involves: 129/Sv * C57BL/6J * SJL)	abnormal neutrophil physiology	J:74478
	decreased inflammatory response	J:74478
	decreased susceptibility to parasitic infection	J:74478
\Bcl2a1a^tm1Sen/\Bcl2a1a^tm1Sen (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:52127
\Bcl2l1^tm1Cant/\Bcl2l1^tm1Cant (involves: 129S6/SvEvTac)	abnormal memory T cell physiology	J:77507
	abnormal T cell physiology	J:77507
	decreased interleukin-2 secretion	J:77507
	decreased memory T cell number	J:77507
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:77507
	decreased T cell proliferation	J:77507
\Bcl2l1^tm1Dlo/\Bcl2l1^tm1.1Mam \Tg(Aicda-cre)9Mbu/0 (B6.Cg-Bcl2l1^tm1Dlo/Bcl2l1^tm1.1Mam Tg(Aicda-cre)9Mbu)	decreased IgG1 level	J:166069
	immune system phenotype	J:166069
\Bcl2l1^tm1Ywh/\Bcl2l1^tm1Ywh \Mcl1^tm1Ywh/\Mcl1^tm1Ywh \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	absent CD4-positive, alpha-beta T cells	J:137400
	absent CD8-positive, alpha-beta T cells	J:137400
	decreased double-positive T cell number	J:137400
\Bcl2l1^tm1Ywh/\Bcl2l1^tm1Ywh \Tg(Lck-cre)548Jxm/? (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA)	decreased double-positive T cell number	J:99012
	decreased thymocyte number	J:99012
\Bcl2l11^em1(IMPC)H/\Bcl2l11^em1(IMPC)H (C57BL/6NTac-Bcl2l11^em1(IMPC)H/H)	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased spleen weight	J:211773
\Bcl2l11^em1Flv/\Bcl2l11⁺ \Morrbid⁺/\Morrbid^em1Flv (C57BL/6N-Bcl2l11^em1Flv +/+ Morrbid^em1Flv)	decreased eosinophil cell number	J:236609
	decreased Ly6C high monocyte number	J:236609
	decreased neutrophil cell number	J:236609
\Bcl2l11^em1Flv/\Bcl2l11⁺ \Morrbid^em1Flv/\Morrbid⁺ (C57BL/6N-Bcl2l11^em1Flv Morrbid^em1Flv /+ +)	immune system phenotype	J:236609
\Bcl2l11^tm1.1Ast/\Bcl2l11⁺ (involves: 129S1/Sv * C57BL/6)	abnormal lymphocyte physiology	J:58641
	glomerulonephritis	J:58641
	increased IgA level	J:58641
	increased IgG level	J:58641
	increased IgM level	J:58641
	increased susceptibility to autoimmune disorder	J:58641
\Bcl2l11^tm1.1Ast/\Bcl2l11⁺ (B6.129S1-Bcl2l11^tm1.1Ast)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2l11^tm1.1Ast/\Bcl2l11⁺ \Pten^tm1Hwu/\Pten⁺ \Tg(CD2-icre)4Kio/0 (involves: 129S1/Sv * 129S4/SvJae * C57BL/10 * CBA/Ca)	abnormal T cell number	J:133215
	increased germinal center B cell number	J:133215
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast (involves: 129S1/Sv * C57BL/6)	abnormal B cell proliferation	J:90963
	abnormal lymphocyte physiology	J:58641
	abnormal plasma cell morphology	J:58641
	abnormal spleen morphology	J:58641
	abnormal splenic cell ratio	J:132217
	decreased B cell apoptosis	J:90963
	decreased double-positive T cell number	J:58641
	enlarged spleen	J:58641
	glomerulonephritis	J:58641
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased B cell number	J:58641
	increased CD4-positive, alpha-beta T cell number	J:58641
	increased CD8-positive, alpha-beta T cell number	J:58641
	increased double-negative T cell number	J:58641
	increased follicular B cell number	J:132217
	increased granulocyte number	J:58641
	increased IgA level	J:58641
	increased IgG level	J:58641
	increased IgM level	J:58641
	increased immature B cell number	J:132217
	increased inflammatory response	J:58641
	increased leukocyte cell number	J:58641
	increased marginal zone B cell number	J:132217
	increased monocyte cell number	J:58641
	increased splenocyte number	J:132217
	increased susceptibility to autoimmune disorder	J:58641
	increased T cell number	J:58641
	increased transitional stage B cell number	J:132217
	spleen hyperplasia	J:58641
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast (B6.129S1-Bcl2l11^tm1.1Ast)	abnormal B cell morphology	J:133084
	abnormal leukopoiesis	J:73316
	abnormal lymphocyte physiology	J:73316
	abnormal NK cell morphology	J:123409
	abnormal response to infection	J:123409
	decreased B cell apoptosis	J:73316
	decreased T cell apoptosis	J:73316, J:133084
	immune system phenotype	J:153846
	increased immature B cell number	J:133084
	increased leukocyte cell number	J:153846
	increased mature B cell number	J:133084
	increased NK cell number	J:123409
	increased regulatory T cell number	J:208318
	increased spleen weight	J:153846
	increased transitional stage B cell number	J:133084
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast (B6.129-Bcl2l11^tm1.1Ast/J)	decreased lymphocyte cell number	J:137609
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast (involves: 129S1/Sv)	abnormal CD4-positive, alpha-beta T cell number	J:132819
	abnormal CD8-positive, alpha-beta T cell physiology	J:132819
	abnormal splenic cell ratio	J:132819
	decreased splenocyte apoptosis	J:266833
	decreased thymocyte apoptosis	J:266833
	increased B cell number	J:132819
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast (B6.129S1-Bcl2l11^tm1.1Ast/J)	decreased T cell apoptosis	J:153652
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Bik^tm1Ast/\Bik^tm1Ast (B6.Cg-Bcl2l11^tm1.1Ast Bik^tm1Ast)	abnormal B cell differentiation	J:103605
	abnormal lymphocyte physiology	J:103605
	abnormal T cell differentiation	J:103605
	decreased immature B cell number	J:103605
	decreased pre-B cell number	J:103605
	decreased pro-B cell number	J:103605
	enlarged spleen	J:103605
	increased B cell number	J:103605
	increased granulocyte number	J:103605
	increased mature B cell number	J:103605
	increased monocyte cell number	J:103605
	increased T cell number	J:103605
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Bmf^tm1Rjd/\Bmf^tm1Rjd (B6.129S-Bcl2l11^tm1.1Ast Bmf^tm1Rjd)	decreased T cell apoptosis	J:153652
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
	increased thymocyte number	J:153652
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Bmf^tm2.1Rjd/\Bmf^tm2.1Rjd (B6.129S-Bcl2l11^tm1.1Ast Bmf^tm2.1Rjd)	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Bnip3l^{Gt(XT0573)Wtsi}/\Bnip3l^{Gt(XT0573)Wtsi} (involves: 129S1/Sv * C57BL/6)	decreased lymphocyte cell number	J:137609
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Dicer1^tm1Mmk/\Dicer1^tm1Mmk \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S1/Sv * BALB/c)	decreased B cell number	J:135783
	decreased mature B cell number	J:135783
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Fas^lpr/\Fas^lpr (B6.Cg-Bcl2l11^tm1.1Ast Fas^lpr)	abnormal effector T cell morphology	J:132217
	abnormal lymph node cell ratio	J:132217
	abnormal splenic cell ratio	J:132217
	abnormal T cell number	J:132217
	abnormal T cell subpopulation ratio	J:132217
	decreased B cell number	J:132217
	decreased spleen red pulp amount	J:132217
	enlarged lymph nodes	J:132217
	enlarged spleen	J:132217
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased dendritic cell number	J:132217
	increased follicular B cell number	J:132217
	increased immature B cell number	J:132217
	increased leukocyte cell number	J:132217
	increased macrophage cell number	J:132217
	increased marginal zone B cell number	J:132217
	increased memory T cell number	J:132217
	increased spleen white pulp amount	J:132217
	increased susceptibility to autoimmune disorder	J:132217
	increased transitional stage B cell number	J:132217
	lymph node hyperplasia	J:132217
	spleen hyperplasia	J:132217
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Il15^tm1Imx/\Il15^tm1Imx (involves: C57BL/6)	immune system phenotype	J:208318
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Mirc14^tm1.2Flv/\Mirc14^tm1.2Flv (involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N * SJL)	decreased NK T cell number	J:203157
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Mlf1^tm1Swm/\Mlf1^tm1Swm (involves: 129S1/Sv * C57BL/6)	decreased splenocyte apoptosis	J:266833
	decreased thymocyte apoptosis	J:266833
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Pmaip1^tm1Ast/\Pmaip1^tm1Ast (involves: 129S1/Sv * C57BL/6)	abnormal NK cell morphology	J:123409
\Bcl2l11^tm1.1Ast/\Bcl2l11^tm1.1Ast \Zbtb1^m1Btlr/\Zbtb1^m1Btlr (involves: 129S1/Sv * C3H/HeN * C57BL/6 * C57BL/6J)	absent T cells	J:178820
\Bcl2l11^tm1.1Boui/\Bcl2l11⁺ \Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
	increased T cell derived lymphoma incidence	J:186117
\Bcl2l11^tm1.1Boui/\Bcl2l11^tm1.1Boui (C57BL/6-Bcl2l11^tm1.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2l11^tm1.1Boui/\Bcl2l11^tm1.1Boui \Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
\Bcl2l11^tm1.1Boui/\Bcl2l11^tm2.1Boui (C57BL/6-Bcl2l11^tm1.1Boui/Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2l11^tm1Ast/\Bcl2l11^tm1Ast \Dicer1^tm1Bdh/\Dicer1^tm1Bdh \Aicda^tm1(cre)Njen/\Aicda⁺ (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:181782
	decreased germinal center B cell number	J:181782
	decreased plasma cell number	J:181782
\Bcl2l11^tm1Sjk/\Bcl2l11^tm1Sjk (involves: 129X1/SvJ)	abnormal B cell physiology	J:100463
	abnormal spleen marginal zone morphology	J:100463
	increased B cell number	J:100463
	increased B-2 B cell number	J:100463
	increased follicular B cell number	J:100463
	increased immunoglobulin level	J:100463
	increased transitional stage B cell number	J:100463
\Bcl2l11^tm2.1Boui/\Bcl2l11⁺ \Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
\Bcl2l11^tm2.1Boui/\Bcl2l11^tm2.1Boui (C57BL/6-Bcl2l11^tm2.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2l11^tm2.1Boui/\Bcl2l11^tm2.1Boui \Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:186117
\Bcl2l11^tm3.1Boui/\Bcl2l11^tm3.1Boui (C57BL/6-Bcl2l11^tm3.1Boui)	immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
\Bcl2l11^tm3Rjd/\Bcl2l11^tm3Rjd (B6.129S6-Bcl2l11^tm3Rjd)	decreased thymocyte apoptosis	J:137061
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
\Bcl2l11^tm3Rjd/\Bcl2l11^tm3Rjd \Bmf^tm3.1Rjd/\Bmf^tm3.1Rjd (B6.129S6-Bcl2l11^tm3Rjd Bmf^tm3.1Rjd)	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
\Bcl2l11^tm4Boul/\Bcl2l11^tm4Boul (involves: C57BL/6)	immune system phenotype	J:203181
\Bcl2l11^tm4Rjd/\Bcl2l11^tm4Rjd (involves: 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:203181
\Bcl2l11^tm5Boul/\Bcl2l11^tm5Boul (involves: C57BL/6)	immune system phenotype	J:203181
\Bcl2l11^tm6.1Boui/\Bcl2l11^tm6.1Boui \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased regulatory T cell number	J:208318
\Bcl2l12^{tm1.1(KOMP)Vlcg}/\Bcl2l12^{tm1.1(KOMP)Vlcg} (C57BL/6N-Bcl2l12^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Bcl2l14^tm1.1Boui/\Bcl2l14^tm1.1Boui (involves: C57BL/6)	abnormal susceptibility to induced colitis	J:296081
\Bcl3^m1Btlr/\Bcl3⁺ (C57BL/6J-Bcl3^m1Btlr)	decreased B cell number	J:255184
	decreased B-1b cell number	J:255184
	increased CD8-positive, alpha-beta T cell number	J:255184
	increased macrophage cell number	J:255184
\Bcl3^m1Btlr/\Bcl3^m1Btlr (C57BL/6J-Bcl3^m1Btlr)	abnormal humoral immune response	J:255184
	decreased B cell number	J:255184
	decreased B-1b cell number	J:255184
	decreased IgE level	J:255184
	decreased IgG level	J:255184
	increased B-1 B cell number	J:255184
	increased CD8-positive, alpha-beta T cell number	J:255184
	increased central memory CD4-positive, alpha-beta T cell number	J:255184
	increased macrophage cell number	J:255184
\Bcl3^m2Btlr/\Bcl3^m2Btlr (C57BL/6J-Bcl3^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:264818
	decreased IgD level	J:264818
	increased B-1 B cell number	J:264818
	increased CD8-positive, alpha-beta memory T cell number	J:264818
	increased IgM level	J:264818
\Bcl3^m3Btlr/\Bcl3^m3Btlr (C57BL/6J-Bcl3^m3Btlr)	decreased central memory CD8 positive, alpha-beta T cell number	J:274858
\Bcl3^{tm1b(EUCOMM)Wtsi}/\Bcl3^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Bcl3^{tm1b(EUCOMM)Wtsi}/H)	increased spleen weight	J:211773
\Bcl3^tm1Rie/\Bcl3^tm1Rie (involves: 129)	abnormal dendritic cell number	J:77049
	abnormal follicular dendritic cell morphology	J:77049
	abnormal myeloid dendritic cell morphology	J:77049
	abnormal Peyer's patch follicle morphology	J:77049
	abnormal Peyer's patch germinal center morphology	J:77049
	abnormal Peyer's patch morphology	J:77049
	abnormal Peyer's patch T cell area morphology	J:77049
	decreased B cell number	J:77049
	decreased Peyer's patch number	J:77049
	increased plasmacytoid dendritic cell number	J:77049
	small Peyer's patches	J:77049
\Bcl3^tm1Rsch/\Bcl3^tm1Rsch (involves: 129P2/OlaHsd * CD-1)	abnormal cytokine secretion	J:116724
	abnormal innate immunity	J:116724
	increased susceptibility to bacterial infection	J:116724
\Bcl3^tm1Rsch/\Bcl3^tm1Rsch (B6.Cg-Bcl3^tm1Rsch)	abnormal cytokine secretion	J:116724
\Bcl3^tm1Rsch/\Bcl3^tm1Rsch (B6.Cg-Bcl3^tm1Rsch)	abnormal macrophage physiology	J:116724
\Bcl3^tm1Sbn/\Bcl3^tm1Sbn (involves: 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:39747
	abnormal class switch recombination	J:39747
	abnormal cytotoxic T cell physiology	J:39747
	abnormal lymph node B cell domain morphology	J:39747
	abnormal lymphocyte morphology	J:39747
	abnormal metallophilic macrophage morphology	J:39747
	abnormal spleen marginal zone macrophage morphology	J:39747
	absent spleen germinal center	J:39747
	decreased B cell number	J:39747
	decreased IgG2a level	J:39747
	decreased interferon-gamma secretion	J:39747
	decreased interleukin-12 secretion	J:39747
	decreased macrophage cell number	J:39747
	decreased spleen germinal center size	J:39747
	disorganized spleen B cell follicle	J:39747
	increased susceptibility to parasitic infection	J:39747
	intermingled spleen red and white pulp	J:39747
	lymph node hypoplasia	J:39747
\Bcl3^tm1Sbn/\Bcl3^tm1Sbn (involves: 129S4/SvJae)	abnormal B cell physiology	J:207111
	decreased B cell proliferation	J:207111
	decreased follicular B cell number	J:207111
	decreased transitional stage T1 B cell number	J:207111
	decreased transitional stage T2 B cell number	J:207111
	increased B cell proliferation	J:207111
	increased marginal zone B cell number	J:207111
\Bcl3^tm1Ver/\Bcl3^tm1Ver (involves: 129P2/OlaHsd * FVB/NJ)	abnormal humoral immune response	J:38092
	absent spleen germinal center	J:38092
	immune system phenotype	J:38092
	increased susceptibility to bacterial infection	J:38092
\Bcl6^tm1.1Dent/\Bcl6^tm1.1Dent \Tg(Cd4-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * DBA/2 * FVB/N)	abnormal T follicular helper cell differentiation	J:202372
	decreased germinal center B cell number	J:202372
	decreased IgG level	J:202372
	decreased interleukin-4 secretion	J:202372
	decreased T follicular helper cell number	J:202372
	increased interleukin-10 secretion	J:202372
\Bcl6^tm1.1Jwan/\Bcl6^tm1.1Jwan (involves: 129S6/SvEvTac)	abnormal somatic hypermutation frequency	J:190534
\Bcl6^tm1.1Jwan/\Bcl6^tm1.1Jwan (involves: 129S6/SvEvTac)	immune system phenotype	J:190534
\Bcl6^tm1.1Meln/\Bcl6^tm1.1Meln (involves: 129 * C57BL/6 * FVB/N)	abnormal adaptive immunity	J:194821
	abnormal germinal center B cell physiology	J:194821
	abnormal immune system organ morphology	J:194821
	abnormal Peyer's patch germinal center morphology	J:194821
	abnormal professional antigen presenting cell physiology	J:194821
	abnormal spleen germinal center morphology	J:194821
	decreased IgG1 level	J:194821
	decreased IgG2a level	J:194821
	decreased IgG level	J:194821
	decreased spleen germinal center number	J:194821
	decreased T follicular helper cell number	J:194821
	immune system phenotype	J:194821
\Bcl6^tm1.1Mtto/\Bcl6^tm1.1Mtto \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6 * C57BL/6JJcl)	abnormal humoral immune response	J:190943
	abnormal memory B cell morphology	J:190943
	abnormal memory B cell physiology	J:190943
	abnormal somatic hypermutation frequency	J:190943
	decreased germinal center B cell number	J:190943
\Bcl6^tm1.1Mtto/\Bcl6^tm1.1Mtto \Cd79a^tm1(cre)Reth/\Cd79a⁺ \Tg(Cd4-cre)1Cwi/0 (involves: BALB/c * C57BL/6 * C57BL/6JJcl * DBA/2)	decreased germinal center B cell number	J:190943
	immune system phenotype	J:190943
\Bcl6^tm1.1Mtto/\Bcl6^tm1.1Mtto \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JJcl)	decreased germinal center B cell number	J:190943
	immune system phenotype	J:190943
\Bcl6^tm1.1Mtto/\Bcl6^tm1.1Mtto \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6JJcl * DBA/2)	abnormal humoral immune response	J:190943
	abnormal somatic hypermutation frequency	J:190943
	absent germinal center B cells	J:190943
	decreased germinal center B cell number	J:190943
	decreased T follicular helper cell number	J:190943
\Bcl6^tm1.1Toka/\Bcl6⁺ \Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6 * NZB)	decreased T cell proliferation	J:174014
\Bcl6^tm1.1Toka/\Bcl6^tm1.1Toka (involves: C57BL/6 * NZB)	abnormal Peyer's patch morphology	J:174014
	decreased germinal center B cell number	J:174014
	decreased T follicular helper cell number	J:174014
	immune system phenotype	J:174014
\Bcl6^tm1.1Toka/\Bcl6^tm1.1Toka \Tg(IghelMD4)4Ccg/0 (involves: C57BL/6 * NZB)	abnormal germinal center B cell physiology	J:174014
	increased activation-induced B cell apoptosis	J:174014
\Bcl6^tm1Gdba/\Bcl6^tm1Gdba \Tg(Adipoq-cre)1Evdr/0 (involves: C57BL/6 * FVB/NJ)	white adipose tissue inflammation	J:271078
\Bcl6^tm1Htno/\Bcl6^tm1Htno (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:55952
	lung inflammation	J:55952
	myocarditis	J:55952
\Bcl6^tm1Rdf/\Bcl6^tm1Rdf (involves: 129S1/Sv)	abnormal B cell physiology	J:40769
	abnormal humoral immune response	J:40769
	abnormal immune system morphology	J:40769
	abnormal immune system physiology	J:40769
	abnormal Peyer's patch germinal center morphology	J:40769
	abnormal T-helper 2 physiology	J:40769
	absent lymph node germinal center	J:40769
	absent spleen germinal center	J:40769
	decreased IgG level	J:40769
	decreased IgM level	J:40769
	heart inflammation	J:40769
	increased eosinophil cell number	J:40769
	increased inflammatory response	J:40769
	increased susceptibility to bacterial infection	J:40769
	liver inflammation	J:40769
	lung inflammation	J:40769
	small thymus	J:40769
	spleen hyperplasia	J:40769
\Bcl6^tm1Sdt/\Bcl6^tm1Sdt (involves: 129/Sv * C57BL/6)	abnormal chemokine level	J:123621
	abnormal immune system physiology	J:123621
	spleen hypoplasia	J:123621
\Bcl6^tm1Sdt/\Bcl6^tm1Sdt \Bcl6b^tm2Dent/\Bcl6b^tm2Dent (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:123621
\Bcl6^tm2Rdf/\Bcl6^tm2Rdf (involves: 129S1/Sv)	abnormal B cell physiology	J:40769
	abnormal humoral immune response	J:40769
	abnormal immune system morphology	J:40769
	abnormal immune system physiology	J:40769
	abnormal Peyer's patch germinal center morphology	J:40769
	abnormal T-helper 2 physiology	J:40769
	absent lymph node germinal center	J:40769
	absent spleen germinal center	J:40769
	decreased B cell proliferation	J:40769
	decreased IgG level	J:40769
	decreased IgM level	J:40769
	heart inflammation	J:40769
	increased eosinophil cell number	J:40769
	increased inflammatory response	J:40769
	increased susceptibility to bacterial infection	J:40769
	liver inflammation	J:40769
	lung inflammation	J:40769
	small thymus	J:40769
	spleen hyperplasia	J:40769
\Bcl6^tm2Rdf/\Bcl6^tm2Rdf \Ighm^tm1(Bcl6)Rdf/? (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal immune system morphology	J:98937
	abnormal spleen germinal center morphology	J:98937
\Bcl6b^tm1Dtf/\Bcl6b^tm1Dtf (involves: 129P2/OlaHsd)	abnormal response to infection	J:99818
	decreased memory T cell number	J:99818
	decreased T cell proliferation	J:99818
\Bcl6b^tm1Tto/\Bcl6b^tm1Tto (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:93656
	abnormal CD8-positive, alpha beta T cell morphology	J:93656
\Bcl6b^tm2Dent/\Bcl6b^tm2Dent (involves: 129/Sv * C57BL/6)	decreased neutrophil cell number	J:123621
\Bcl6b^tm2Dent/\Bcl6b^tm2Dent (involves: 129/Sv * C57BL/6)	increased monocyte cell number	J:123621
\Bcl6b^tm2Dent/\Bcl6b^tm2Dent \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6)	decreased lymphocyte cell number	J:123621
\Bcl10^m1Btlr/\Bcl10^m1Btlr (C57BL/6J-Bcl10^m1Btlr)	abnormal humoral immune response	J:265122
	decreased B-1 B cell number	J:265122
	decreased IgG level	J:265122
	increased CD4-positive, alpha-beta T cell number	J:265122
	increased IgE level	J:265122
	increased IgM level	J:265122
	increased single-positive T cell number	J:265122
	increased T cell number	J:265122
\Bcl10^tm1Mak/\Bcl10^tm1Mak (involves: 129P2/OlaHsd)	abnormal cytotoxic T cell physiology	J:67297
	abnormal dendritic cell physiology	J:111706
	abnormal immune cell physiology	J:67297
	abnormal response to infection	J:67297
	abnormal T cell activation	J:67297
	abnormal T cell differentiation	J:67297
	decreased activated T cell number	J:67297
	decreased B cell proliferation	J:109545, J:67297
	decreased double-positive T cell number	J:67297
	decreased IgG level	J:67297
	decreased IgM level	J:67297
	decreased immunoglobulin level	J:67297
	decreased T cell proliferation	J:109545, J:67297
	decreased thymocyte number	J:67297
	increased double-negative T cell number	J:67297
	increased susceptibility to infection	J:67297
\Bcl10^tm1Mak/\Bcl10^tm1Mak \Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:228288
\Bcl10^tm1Swm/\Bcl10^tm1Swm (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:85147
	abnormal humoral immune response	J:85147
	abnormal marginal zone B cell physiology	J:85147
	decreased B cell number	J:85147
	decreased B cell proliferation	J:85147
	decreased B-1 B cell number	J:85147
	decreased follicular B cell number	J:85147
	decreased marginal zone B cell number	J:85147
	decreased mature B cell number	J:85147
	increased susceptibility to bacterial infection	J:85147
\Bcl10^tm1Swm/\Bcl10^tm1Swm (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:122394
	abnormal dendritic cell physiology	J:122394
\Bcl11a^tm1Ngc/\Bcl11a⁺ (involves: 129S1/Sv)	abnormal T cell differentiation	J:194616
	decreased DN2 thymocyte number	J:194616
	decreased lymphocyte cell number	J:207383
\Bcl11a^tm1Ngc/\Bcl11a^tm1Ngc (involves: 129S1/Sv * C57BL/6J)	abnormal dendritic cell differentiation	J:207383
	abnormal immunoglobulin heavy chain V(D)J recombination	J:83646
	absent B cells	J:207383, J:83646
	absent CD4-positive, alpha-beta T cells	J:83646
	absent lymphocyte	J:207383
	decreased plasmacytoid dendritic cell number	J:207383
	decreased T cell number	J:83646
	increased CD8-positive, alpha-beta T cell number	J:83646
	increased double-negative T cell number	J:83646
	increased gamma-delta T cell number	J:83646
	small thymus	J:83646
	thymus hypoplasia	J:83646
\Bcl11a^tm1Pwt/\Bcl11a^tm1Pwt \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	decreased B cell number	J:207383
	decreased circulating interferon-alpha level	J:207383
	decreased plasmacytoid dendritic cell number	J:207383
\Bcl11a^tm1Pwt/\Bcl11a^tm1Pwt \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal dendritic cell differentiation	J:207383
	decreased B cell number	J:207383
	decreased dendritic cell number	J:207383
	decreased plasmacytoid dendritic cell number	J:207383
\Bcl11a^tm1Pwt/\Bcl11a^tm1Pwt \Kdm1a^tm1.1Sho/\Kdm1a^tm1.1Sho \Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	decreased leukocyte cell number	J:196140
\Bcl11a^tm1Pwt/\Bcl11a^tm1Pwt \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased leukocyte cell number	J:196140
\Bcl11a^tm2.1Peli/\Bcl11a^tm2.1Peli \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal immune system morphology	J:194616
	abnormal T cell differentiation	J:194616
	decreased B cell number	J:194616
	decreased DN2 thymocyte number	J:194616
	decreased immature B cell number	J:194616
	decreased pre-B cell number	J:194616
	decreased pro-B cell number	J:194616
	increased B cell apoptosis	J:194616
\Bcl11a^tm2.1Peli/\Bcl11a^tm2.1Peli \Trp53^tm1Brn/\Trp53^tm1Brn \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	immune system phenotype	J:194616
\Bcl11b^tm1.2Leid/\Bcl11b^tm1.2Leid (involves: C57BL/6 * SJL)	absent T cells	J:147182
	thymus hypoplasia	J:147182
\Bcl11b^tm1Avram/\Bcl11b^tm1Avram \Tcra^tm1Mom/\Tcra^tm1Mom \Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:128515
	decreased double-positive T cell number	J:128515
	thymus hypoplasia	J:128515
\Bcl11b^tm1Avram/\Bcl11b^tm1Avram \Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal leukocyte morphology	J:128515
	abnormal positive T cell selection	J:128515
	abnormal thymocyte activation	J:128515
	decreased CD4-positive, alpha-beta T cell number	J:128515
	decreased CD8-positive, alpha-beta T cell number	J:128515
	decreased double-negative T cell number	J:128515
	decreased double-positive T cell number	J:128515
	enlarged mesenteric lymph nodes	J:128515
	increased B cell number	J:128515
	increased dendritic cell number	J:128515
	increased gamma-delta T cell number	J:128515
	increased NK cell number	J:128515
	increased spleen weight	J:128515
	spleen hyperplasia	J:128515
	thymus hypoplasia	J:128515
\Bcl11b^tm1Avram/\Bcl11b^tm1Avram \Tg(Cd4-cre)1Cwi/? \Tg(LCKprBCL2)36Sjk/? (involves: 129 * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:128515
	decreased CD4-positive, alpha-beta T cell number	J:128515
	decreased CD8-positive, alpha-beta T cell number	J:128515
	decreased double-positive T cell number	J:128515
	thymus hypoplasia	J:128515
\Bcl11b^tm1Jpk/\Bcl11b^tm1Jpk (involves: BALB/c * C57BL/6 * CBA)	abnormal T cell differentiation	J:83651
	abnormal T cell morphology	J:83651
	abnormal T cell receptor beta chain V(D)J recombination	J:83651
	abnormal thymus cortex morphology	J:83651
	abnormal thymus medulla morphology	J:83651
	absent thymus corticomedullary boundary	J:83651
	decreased double-positive T cell number	J:83651
	increased CD8-positive, alpha-beta T cell number	J:83651
	increased double-negative T cell number	J:83651
	increased thymocyte apoptosis	J:83651
	thymus hypoplasia	J:83651
\Bcl11b^tm1Peli/\Bcl11b^tm1Peli \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J)	abnormal NK cell differentiation	J:161373
\Bcl11b^tm2.1Jpk/\Bcl11b⁺ \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6J * DBA/2)	immune system phenotype	J:210122
\Bcl11b^tm2.1Jpk/\Bcl11b⁺ \Tg(Lck-cre)1Jtak/0 (involves: C57BL/6)	abnormal T cell number	J:210122
	decreased CD4-positive, alpha-beta T cell number	J:210122
	decreased CD8-positive, alpha-beta T cell number	J:210122
	decreased double-positive T cell number	J:210122
	decreased thymocyte number	J:210122
	increased double-negative T cell number	J:210122
\Bclaf1^tm1Raz/\Bclaf1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased T cell proliferation	J:158087
\Bclaf1^tm1Raz/\Bclaf1^tm1Raz (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:158087
	decreased T cell proliferation	J:158087
	increased B cell number	J:158087
\Bcmd2^CAST/EiJ/\Bcmd2^CAST/EiJ (AW.CAST-Bcmd2)	increased mast cell number	J:75340
\Bco2^tm1Dnp/\Bco2^tm1Dnp (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:166153
	increased spleen weight	J:166153
\Bcor^tm1.1Vjba/Y \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S1/Sv * C57BL/6 * CBA/Ca)	increased neutrophil cell number	J:231455
\Bcr^{tm1(BCR/ABL)Tsr}/\Bcr⁺ \Runx1^tm3Dow/\Runx1⁺ \Tg(Vav1-cre)#Cgp/0 (involves: C57BL/6)	decreased lymphocyte cell number	J:203111
	increased monocyte cell number	J:203111
	increased neutrophil cell number	J:203111
\Bcr^tm1Hkp/\Bcr^tm1Hkp (involves: 129S2/SvPas)	abnormal neutrophil physiology	J:23804
	increased leukocyte cell number	J:23804
	increased neutrophil cell number	J:23804
	increased susceptibility to endotoxin shock	J:23804
	sepsis	J:23804
\Bcs1l^tm1.1Levp/\Bcs1l^tm1.1Levp (B6.129-Bcs1l^tm1.1Levp)	abnormal macrophage morphology	J:273501
	increased macrophage cell number	J:273501
	increased neutrophil cell number	J:273501
	liver inflammation	J:273501
\Bdkrb1^tm1Bdr/\Bdkrb1^tm1Bdr (involves: 129P2/OlaHsd)	abnormal acute inflammation	J:63271
\Bdkrb1^tm1Bdr/\Bdkrb1^tm1Bdr (involves: 129P2/OlaHsd)	decreased susceptibility to endotoxin shock	J:135789
\Bdkrb1^tm2Bdr/\Bdkrb1^tm2Bdr \Bdkrb2^tm1Jfh/\Bdkrb2^tm1Jfh (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to endotoxin shock	J:135789
\Bdp1^em1(IMPC)Tcp/\Bdp1⁺ (C57BL/6N-Bdp1^em1(IMPC)Tcp/Cmmr)	abnormal spleen morphology	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Bean1^em1(IMPC)H/\Bean1^em1(IMPC)H (C57BL/6N-Bean1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Becn1^tm1.1Bflu/\Becn1^tm1.1Bflu \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:203090
	decreased CD4-positive, alpha-beta T cell number	J:203090
	decreased CD8-positive, alpha-beta T cell number	J:203090
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:203090
	decreased T cell proliferation	J:203090
	increased T cell apoptosis	J:203090
\Becn1^{tm1b(KOMP)Wtsi}/\Becn1⁺ (C57BL/6N-Becn1^{tm1b(KOMP)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
\Becn1^tm1Blev/\Becn1⁺ (involves: 129X1/SvJ * C57BL/6J)	abnormal immune system morphology	J:86953
	increased spleen germinal center number	J:86953
	increased spleen germinal center size	J:86953
\Becn1^tm1Ebr/\Becn1^tm1Ebr \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	abnormal spleen morphology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
\Becn1^tm1Smoc/\Becn1^tm1Smoc \Foxp3^{tm4(YFP/icre)Ayr}/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:306129
\Becn1^tm1Smoc/\Becn1^tm1Smoc \Zfp91^tm1Smoc/\Zfp91^tm1Smoc \Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:306129
\Belr1^BALB/cJ/\Belr1^BALB/cJ (involves: BALB/cJ * C57BL/6J)	decreased susceptibility to parasitic infection	J:133125
\Belr1^BALB/cJ/\Belr1^BALB/cJ (B6.C-H2^d/bByJ)	decreased susceptibility to parasitic infection	J:133125
\Berr1^WLA/Pas/? (involves: C57BL/6JRj * WLA/Pas)	decreased susceptibility to parasitic infection	J:78027
\Berr2^WLA/Pas/? (involves: C57BL/6JRj * WLA/Pas)	decreased susceptibility to parasitic infection	J:78027
\Best3^tm1.1Zhoj/\Best3^tm1.1Zhoj \Tg(Tagln-cre)1Her/0 (involves: C57BL/6 * SJL)	aortitis	J:338981
\Bex2^{tm1b(EUCOMM)Hmgu}/\Bex2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bex2^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Bex6^{tm1.1(KOMP)Vlcg}/\Bex6^{tm1.1(KOMP)Vlcg} (B6N(Cg)-Bex6^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
\Bgn^tm1Mfy/Y (involves: 129S4/SvJae * C57BL/6)	osteoarthritis	J:76203
\Bgn^tm1Mfy/Y \Fmod^tm1Aol/\Fmod^tm1Aol (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)	osteoarthritis	J:76203
\Bgn^tm1Mfy/Y \Fmod^tm1Aol/\Fmod^tm1Aol (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	accelerated temporomandibular joint osteoarthritis	J:112779, J:117908
\Bgn^tm1Mfy/\Bgn^tm1Mfy (involves: 129S4/SvJae)	osteoarthritis	J:222369
\Bgn^tm1Mfy/\Bgn^tm1Mfy \Epyc^tm1Mhok/\Epyc^tm1Mhok (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)	osteoarthritis	J:222369
\Bgn^tm1Mfy/\Bgn^tm1Mfy \Fmod^tm1Aol/\Fmod^tm1Aol (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	accelerated temporomandibular joint osteoarthritis	J:117908
\bhe/\bhe (Not Specified)	chronic inflammation	J:85113
\Bhlhe40^tm1Tan/\Bhlhe40^tm1Tan (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal CD4-positive T cell differentiation	J:72651
	abnormal CD4-positive, alpha-beta T cell physiology	J:72651
	abnormal immune system cell morphology	J:72651
	abnormal immune system physiology	J:72651
	abnormal lymph node germinal center morphology	J:72651
	abnormal susceptibility to autoimmune disorder	J:72651
	abnormal T cell activation	J:72651
	decreased double-positive T cell number	J:72651
	decreased interleukin-2 secretion	J:72651
	decreased T cell proliferation	J:72651
	increased anti-nuclear antigen antibody level	J:72651
	increased CD4-positive, alpha-beta T cell number	J:72651
	increased CD8-positive, alpha-beta T cell number	J:72651
	increased double-negative T cell number	J:72651
	increased IgE level	J:72651
	increased IgG1 level	J:72651
	increased spleen germinal center number	J:72651
	increased spleen white pulp amount	J:72651
	lymph node hyperplasia	J:72651
	spleen hyperplasia	J:72651
	thymus hyperplasia	J:72651
\Bhlhe41^tm1.2Cdon/\Bhlhe41^tm1.2Cdon (B6.129S6-Bhlhe41^tm1.2Cdon)	abnormal lymphocyte cell number	J:157740
	abnormal T-helper 2 cell differentiation	J:157740
	decreased eosinophil cell number	J:157740
	decreased interferon-gamma secretion	J:157740
	decreased interleukin-2 secretion	J:157740
	decreased interleukin-5 secretion	J:157740
	decreased interleukin-13 secretion	J:157740
	decreased macrophage cell number	J:157740
	decreased neutrophil cell number	J:157740
	decreased T cell proliferation	J:157740
	increased interleukin-4 secretion	J:157740
	increased interleukin-17 secretion	J:157740
\Bhmt^{tm1b(EUCOMM)Hmgu}/\Bhmt^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bhmt^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
\Bicdl1^{tm2b(EUCOMM)Wtsi}/\Bicdl1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Bicdl1^{tm2b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Bicdl2^em1(IMPC)Mbp/\Bicdl2^em1(IMPC)Mbp (C57BL/6N-Bicdl2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Bid^tm1Sjk/\Bid^tm1Sjk (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to endotoxin shock	J:117693
\Bin1^tm1Gcp/\Bin1^tm1Gcp (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:83753
\Bin1^tm1Gcp/\Bin1^tm2Gcp \Tg(Wap-cre)11738Mam/0 (involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)	endometrium inflammation	J:117330
\Bin3^tm1Gcp/\Bin3^tm1Gcp (involves: 129 * C57BL/6)	enlarged spleen	J:133313
	liver inflammation	J:133313
	lung inflammation	J:133313
\Birc2^tm1Jda/\Birc2^tm1Jda (B6.129P2-Birc2^tm1Jda)	decreased lymphocyte cell number	J:97656
\Birc2^tm1Rbr/\Birc2^tm1Rbr \Birc3^tm1.1Rbr/\Birc3^tm1.1Rbr (involves: C57BL/6 * NZB)	immune system phenotype	J:172843
\Birc2^tm1Rbr/\Birc2^tm1Rbr \Birc3^tm1.1Rbr/\Birc3^tm1.1Rbr \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * NZB)	decreased B cell apoptosis	J:172843
	decreased germinal center B cell number	J:172843
	decreased spleen germinal center size	J:172843
	enlarged lymph nodes	J:172843
	enlarged spleen	J:172843
	increased B cell number	J:172843
	increased follicular B cell number	J:172843
	increased marginal zone B cell number	J:172843
\Birc2^tm1Rbr/\Birc2^tm1Rbr \Birc3^tm1.1Rbr/\Birc3^tm1.1Rbr \Cd19^tm1(cre)Cgn/\Cd19⁺ \Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6 * NZB)	immune system phenotype	J:172843
\Birc2^tm1Rbr/\Birc2^tm1Rbr \Birc3^tm1Rbr/\Birc3^tm1Rbr \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * NZB)	immune system phenotype	J:172843
\Birc2^tm2.1Jda/\Birc2^tm2.1Jda (B6.Cg-Birc2^tm2.1Jda)	immune system phenotype	J:199221
	increased interferon-gamma secretion	J:199221
	increased T cell proliferation	J:199221
\Birc3^tm1Jda/\Birc3^tm1Jda (B6.Cg-Birc3^tm1Jda)	abnormal gut-associated lymphoid tissue morphology	J:166899
	abnormal lymphocyte cell number	J:166899
	decreased B cell apoptosis	J:166899
	decreased follicular B cell number	J:166899
	decreased IgG1 level	J:166899
	decreased immature B cell number	J:166899
	enlarged mesenteric lymph nodes	J:166899
	increased B cell number	J:166899
	increased B cell proliferation	J:166899
	increased IgA level	J:166899
	increased IgG3 level	J:166899
	increased IgM level	J:166899
	increased marginal zone B cell number	J:166899
	increased T cell number	J:166899
	lymph node hyperplasia	J:166899
\Birc3^tm1Jda/\Birc3^tm1Jda (involves: 129 * C57BL/6)	increased interferon-gamma secretion	J:199221
\Birc3^tm1Jda/\Birc3^tm1Jda (involves: 129 * C57BL/6)	increased T cell proliferation	J:199221
\Birc3^tm1Rgk/\Birc3^tm1Rgk (B6.129X1-Birc3^tm1Rgk)	abnormal cytokine secretion	J:144012
	abnormal immune cell physiology	J:144012
	abnormal interleukin-1 beta secretion	J:144012
	abnormal interleukin-12 secretion	J:144012
	abnormal leukocyte cell number	J:144012
	abnormal macrophage physiology	J:144012
	abnormal T cell physiology	J:144012
	abnormal tumor necrosis factor secretion	J:144012
	decreased macrophage cell number	J:144012
	decreased susceptibility to endotoxin shock	J:144012
\Birc5^tm1Mak/\Birc5^tm1Mak \Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd)	abnormal T cell morphology	J:90892
	abnormal thymus corticomedullary boundary morphology	J:90892
	decreased double-negative T cell number	J:90892
	decreased thymocyte number	J:90892
	increased T cell apoptosis	J:90892
	small thymus	J:90892
\Birc5^tm1Wnt/\Birc5^tm1Emc \Tg(Cd4-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:87435
\Birc5^tm1Wnt/\Birc5^tm1Emc \Tg(Lck-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	decreased double-positive T cell number	J:87435
	decreased T cell number	J:87435
	increased double-negative T cell number	J:87435
	small lymph nodes	J:87435
	thymus hypoplasia	J:87435
\Birc6^tm1Nai/\Birc6^tm1Nai (involves: 129S4/SvJae * C57BL/6J)	increased thymocyte apoptosis	J:96768
\Bld/\Bld⁺ (involves: BALB/cCi)	increased incidence of corneal inflammation	J:5076
\Blk^m1Btlr/\Blk^m1Btlr (C57BL/6J-Blk^m1Btlr)	increased IgE level	J:255004
\Blk^m1Btlr/\Blk^m1Btlr (C57BL/6J-Blk^m1Btlr)	increased interleukin-1 beta secretion	J:255004
\Blk^tm1Tara/\Blk^tm1Tara \Fyn^tm1Sor/\Fyn^tm1Sor \Lyn^tm1Ard/\Lyn^tm1Ard (either: B6.129-Lyn^tm1Ard Fyn^tm1Sor Blk^tm1Tara or (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6))	abnormal B cell differentiation	J:115080
	abnormal pro-B cell differentiation	J:115080
	arrested B cell differentiation	J:115080
	decreased B cell number	J:115080
	decreased immature B cell number	J:115080
	decreased pre-B cell number	J:115080
\Blm^tm3Brd/\Blm^tm3Brd (involves: 129S7/SvEvBrd * C57BL/6)	decreased IgM level	J:66261
\Blm^tm4Ches/\Blm^tm4Ches \Cd19^tm1(cre)Cgn/\Cd19⁺ \Nsmce2^tm2.1Ofc/\Nsmce2^tm2.1Ofc (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal B cell morphology	J:227197
	abnormal B cell physiology	J:227197
	decreased B cell number	J:227197
	small spleen	J:227197
\Blm^tm4Ches/\Blm^tm4Ches \Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal class switch recombination	J:194603
\Blmh^tm1Geh/\Blmh^tm1Geh (either: (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	dermatitis	J:54585
\Blnk^em1(IMPC)H/\Blnk^em1(IMPC)H (C57BL/6N-Blnk^em1(IMPC)H/H)	decreased basophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
	small spleen	J:211773
\Blnk^m1Btlr/\Blnk^m1Btlr (C57BL/6J-Blnk^m1Btlr)	arrested B cell differentiation	J:159439
	decreased IgG level	J:159439
	decreased IgM level	J:159439
	decreased mature B cell number	J:159439
	increased CD4-positive, alpha-beta T cell number	J:159439
	increased CD8-positive, alpha-beta T cell number	J:159439
\Blnk^m1Btlr/\Blnk^m1Btlr (involves: C57BL/6J)	arrested B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
\Blnk^tm1Achn/\Blnk⁺ (involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)	decreased B cell proliferation	J:82430
\Blnk^tm1Achn/\Blnk⁺ \Btk^tm1Wk/\Btk^tm1Wk \Tg(IGH-Btk)1Witt/0 (involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)	abnormal B cell physiology	J:82430
	decreased B cell proliferation	J:82430
\Blnk^tm1Achn/\Blnk^tm1Achn (involves: 129X1/SvJ)	abnormal B cell differentiation	J:58805
	abnormal mature B cell morphology	J:58805
	absent B-1b cells	J:58805
	arrested B cell differentiation	J:58805
	decreased B-1a cell number	J:58805
	decreased immunoglobulin level	J:58805
	decreased mature B cell number	J:58805
	decreased splenocyte number	J:58805
	increased pro-B cell number	J:58805
\Blnk^tm1Dkit/\Blnk^tm1Dkit (involves: C57BL/6)	abnormal B cell apoptosis	J:143854
	abnormal B cell differentiation	J:84040
	abnormal immature B cell morphology	J:94297
	abnormal plasma cell differentiation	J:143854
	abnormal pre-B cell morphology	J:84040
	arrested B cell differentiation	J:143854
	decreased follicular B cell number	J:143854
	decreased IgG3 level	J:143854
	decreased IgM level	J:143854
	decreased immature B cell number	J:84040
	decreased marginal zone B cell number	J:143854
	decreased mature B cell number	J:84040
	decreased transitional stage B cell number	J:143854
	increased anti-double stranded DNA antibody level	J:94297
	increased B cell apoptosis	J:143854
\Blnk^tm1Dkit/\Blnk^tm1Dkit \Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn (involves: 129P2/OlaHsd * C57BL/6 * NZB)	abnormal pre-B cell morphology	J:84040
	absent immature B cells	J:84040
	absent mature B cells	J:84040
	arrested B cell differentiation	J:84040
	decreased pre-B cell number	J:84040
	enlarged lymph nodes	J:84040
	enlarged spleen	J:84040
\Blnk^tm1Dkit/\Blnk^tm1Dkit \Igh-J^{tm1(3H9-VDJ)Mwg}/\Igh-J⁺ (involves: C57BL/6 * NZB)	abnormal immature B cell morphology	J:94297
\Blnk^tm1Dkit/\Blnk^tm1Dkit \Igh-J^{tm1(3H9-VDJ)Mwg}/\Igh-J⁺ \Igk-J^tm1Mwg/\Igk-J⁺ (involves: C57BL/6 * NZB)	abnormal immature B cell morphology	J:94297
\Blnk^tm1Dkit/\Blnk^tm1Dkit \Prkcd^tm1Kin/\Prkcd^tm1Kin (involves: 129P2/OlaHsd * C57BL/6 * NZB)	abnormal B cell proliferation	J:143854
	abnormal immunoglobulin level	J:143854
	abnormal plasma cell differentiation	J:143854
	arrested B cell differentiation	J:143854
	decreased B-1 B cell number	J:143854
	decreased B-2 B cell number	J:143854
	decreased follicular B cell number	J:143854
	decreased marginal zone B cell number	J:143854
	increased B cell apoptosis	J:143854
	increased IgA level	J:143854
	increased IgG1 level	J:143854
	increased IgG2b level	J:143854
	increased IgG3 level	J:143854
	increased IgM level	J:143854
\Blnk^tm1Kplm/\Blnk^tm1Kplm (involves: 129P2/OlaHsd)	abnormal B cell activation	J:61130, J:131161
	abnormal B cell differentiation	J:61130, J:131161
	absent B-1a cells	J:61130
	decreased B cell number	J:61130, J:131161
	decreased B cell proliferation	J:61130
	decreased immature B cell number	J:61130
	decreased mature B cell number	J:61130
	decreased pre-B cell number	J:61130, J:120460
	increased B cell apoptosis	J:131161
	increased pro-B cell number	J:61130, J:131161
	spleen hypoplasia	J:131161
\Blnk^tm1Kplm/\Blnk^tm1Kplm \Igh^tm4Cgn/\Igh⁺ \Igk^tm1Rsky/\Igk⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:120460
	decreased B cell number	J:120460
	increased pre-B cell number	J:120460
	increased transitional stage B cell number	J:120460
\Blnk^tm1Kplm/\Blnk^tm1Kplm \Plcg2^tm1.1Kuro/\Plcg2⁺ (involves: 129P2/OlaHsd)	abnormal B cell activation	J:131161
	decreased B cell number	J:131161
	increased B cell apoptosis	J:131161
\Blnk^tm1Kplm/\Blnk^tm1Kplm \Plcg2^tm1.1Kuro/\Plcg2^tm1.1Kuro (involves: 129P2/OlaHsd)	decreased B cell number	J:131161
	increased B cell apoptosis	J:131161
	spleen hypoplasia	J:131161
\Blnk^tm1Pjln/\Blnk^tm1Pjln (involves: BALB/c)	abnormal pre-B cell morphology	J:58740
	arrested B cell differentiation	J:58740
	decreased IgG3 level	J:58740
	decreased IgM level	J:58740
	decreased mature B cell number	J:58740
	enlarged spleen	J:80332
	increased mature B cell number	J:157575
	increased pre-B cell number	J:58740, J:80332
\Blnk^tm1Pjln/\Blnk^tm1Pjln \Btk^tm1Gsv/Y (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell differentiation	J:94768
	decreased IgG3 level	J:94768
	decreased IgM level	J:94768
	decreased immature B cell number	J:94768
	decreased immunoglobulin level	J:94768
	decreased mature B cell number	J:94768
\Blnk^tm1Pjln/\Blnk^tm1Pjln \Btk^tm1Gsv/Y \Tg(CD19-BTKK430R)XK24Rwhe/? (involves: 129P2/OlaHsd BALB/c * C57BL/6 * FVB)	abnormal B cell differentiation	J:94768
	decreased IgG3 level	J:94768
	decreased IgM level	J:94768
	decreased immunoglobulin level	J:94768
\Blnk^tm1Pjln/\Blnk^tm1Pjln \Btk^tm1Wk/\Btk^tm1Wk (involves: 129S4/SvJae * BALB/c * C57BL/6)	arrested B cell differentiation	J:70406
\Bloc1s3^rp/\Bloc1s3^rp (involves: C57BL/10ScSn * C57BL/Tb)	abnormal NK cell physiology	J:6801
\Bloc1s4^em1(IMPC)Mbp/\Bloc1s4^em1(IMPC)Mbp (C57BL/6NCrl-Bloc1s4^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
\Bloc1s5^mu-Btlr/\Bloc1s5^mu-Btlr (C57BL/6J-Bloc1s5^mu-Btlr)	immune system phenotype	J:137494
\Bloc1s6^em1(IMPC)Mbp/\Bloc1s6^em1(IMPC)Mbp (C57BL/6N-Bloc1s6^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
\Bloc1s6^pa/\Bloc1s6^pa (B6.Cg-Bloc1s6^pa/J)	abnormal NK cell physiology	J:6801
\Bloc1s6^pa/\Bloc1s6^pa (B6.Cg-Bloc1s6^pa/J)	lung inflammation	J:4098
\Bmal1^em1Bwu/\Bmal1^em1Bwu (C57BL/6-Bmal1^em1Bwu)	abnormal macrophage physiology	J:340220
\Bmal1^tm1Bra/\Bmal1^tm1Bra (B6.129-Bmal1^tm1Bra)	decreased basophil cell number	J:191844
	decreased leukocyte cell number	J:110697
	decreased lymphocyte cell number	J:110697
	decreased spleen weight	J:110697
	impaired leukocyte tethering or rolling	J:191844
	increased circulating fibrinogen level	J:191844
	increased eosinophil cell number	J:191844
	increased incidence of corneal inflammation	J:110697
	increased leukocyte cell number	J:191844
	increased lymphocyte cell number	J:191844
	increased monocyte cell number	J:110697
	increased neutrophil cell number	J:110697, J:191844
\Bmal1^tm1Bra/\Bmal1^tm1Bra (involves: 129/Sv * C57BL/6)	abnormal B cell differentiation	J:118522
	abnormal T cell subpopulation ratio	J:118522
	decreased B cell number	J:135933, J:118522
	decreased follicular B cell number	J:118522
	decreased IgG1 level	J:118522
	decreased lymphocyte cell number	J:135933, J:118522
	decreased transitional stage B cell number	J:118522
	increased neutrophil cell number	J:135933
\Bmf^tm1.1Ast/\Bmf^tm1.1Ast (B6.Cg-Bmf^tm1.1Anst)	abnormal B cell morphology	J:133084
	abnormal immune system cell morphology	J:133084
	abnormal spleen morphology	J:133084
	decreased B cell apoptosis	J:133084
	decreased T cell apoptosis	J:133084
	enlarged spleen	J:133084
	increased follicular B cell number	J:133084
	increased immature B cell number	J:133084
	increased immunoglobulin level	J:133084
	increased mature B cell number	J:133084
	increased pre-B cell number	J:133084
	increased T cell derived lymphoma incidence	J:133084
	increased transitional stage B cell number	J:133084
	spleen hyperplasia	J:133084
\Bmf^tm1Rjd/\Bmf^tm1Rjd (B6.129S6-Bmf^tm1Rjd)	decreased T cell apoptosis	J:153652
	enlarged spleen	J:153652
	increased B cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
\Bmf^tm3.1Rjd/\Bmf^tm3.1Rjd (B6.129S6-Bmf^tm3.1Rjd)	decreased CD4-positive, alpha-beta T cell number	J:153652
\Bmgr2^C57BL/6J/? \Prf1^tm1Sdz/\Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
\Bmgr3^{129S6/SvEvTac}/\Bmgr3^{129S6/SvEvTac} \Prf1^tm1Sdz/\Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
\Bmgr4^C57BL/6J/? \Ebmgr1^{129S6/SvEvTac}/\Ebmgr1^{129S6/SvEvTac} \Prf1^tm1Sdz/\Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
\Bmgr4^C57BL/6J/? \Prf1^tm1Sdz/\Prf1^tm1Sdz (involves: 129S6/SvEvTac * C57BL/6J)	abnormal response to transplant	J:116666
\Bmi1^tm1Brn/\Bmi1^tm1Brn (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))	abnormal double-negative T cell morphology	J:17712
	abnormal spleen red pulp morphology	J:17712
	abnormal spleen white pulp morphology	J:17712
	abnormal thymus involution	J:17712
	decreased IgM level	J:17712
	decreased immature B cell number	J:17712
	decreased mature B cell number	J:17712
	decreased splenocyte proliferation	J:17712
	decreased thymocyte number	J:17712
	lung inflammation	J:17712
	small spleen	J:17712
	thymus cortex hypoplasia	J:17712
\Bmi1^tm1Brn/\Bmi1^tm1Brn (involves: 129P2/OlaHsd)	decreased double-positive T cell number	J:134271
\Bmi1^tm1Brn/\Bmi1^tm1Brn \E2f6^tm1Lees/\E2f6^tm1Lees (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased double-positive T cell number	J:134271
\Bmi1^tm1Sgon/\Bmi1^tm1Sgon \Commd10^{Tg(Vav1-icre)A2Kio}/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)	abnormal immune system cell morphology	J:221849
	abnormal immune system organ morphology	J:221849
	abnormal spleen morphology	J:221849
	abnormal spleen periarteriolar lymphoid sheath morphology	J:221849
	abnormal spleen white pulp morphology	J:221849
	abnormal thymus morphology	J:221849
	absent spleen germinal center	J:221849
	decreased B cell number	J:221849
	decreased spleen red pulp amount	J:221849
	decreased spleen white pulp amount	J:221849
	decreased T cell number	J:221849
	small spleen	J:221849
	small thymus	J:221849
	thymus atrophy	J:221849
\Bmi1^tm1Sgon/\Bmi1^tm1Sgon \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/? (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	decreased lymphocyte cell number	J:221849
	decreased spleen weight	J:221849
	immune system phenotype	J:221849
\Bmp1^tm1.1Dgr/\Bmp1^tm1.1Dgr \Tll1^tm2.1Dgr/\Tll1^tm2.1Dgr \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * SJL)	increased osteoclast cell number	J:210366
\Bmp2^tm1.1Mis/\Bmp2^tm1.2Mis \Tg(Col1a1-cre)1Bek/0 (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * CD-1)	decreased osteoclast cell number	J:210409
\Bmp2^tm1Cjt/\Bmp2^tm1Cjt \Bmp4^tm1Jfm/\Bmp4^tm1Jfm \Tg(Prrx1-cre)1Cjt/0 (involves: 129S4/SvJaeSor * C57BL/6 * SJL)	abnormal bone marrow development	J:118257
\Bmp5^se-Ca/\Bmp5⁺ (SEACGn.CB-Bmp5^se-Ca)	granulomatous inflammation	J:5086
\Bmp5^se-Ca/\Bmp5^se-Ca (CBA/Ca-Bmp5^se-Ca)	granulomatous inflammation	J:5086
\Bmp5^se-Ca/\Bmp5^se-Ca (SEACGn.CB-Bmp5^se-Ca)	granulomatous inflammation	J:5086
\Bmp5^se/\Bmp5^se (SEC/1Gn)	granulomatous inflammation	J:5086
\Bmp5^se/\Bmp5^se (SEAC/Gn)	granulomatous inflammation	J:5086
\Bmp7^tm1.1Dgra/\Bmp7^tm1.1Dgra \Tg(Prrx1-cre)1Cjt/0 (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac * SJL/J)	joint inflammation	J:221175
	osteoarthritis	J:221175
\Bmp7^{tm1a(EUCOMM)Hmgu}/\Bmp7⁺ (C57BL/6N-Bmp7^{tm1a(EUCOMM)Hmgu}/H)	increased monocyte cell number	J:165965
\Bmp7^tm1Rob/\Bmp7⁺ \Bmp8a^tm1Blh/\Bmp8a^tm1Blh (involves: 129S/SvEv * 129S6/SvEvTac * Black Swiss * C57BL/6)	granulomatous inflammation	J:78867
\Bmp8a^tm1Blh/\Bmp8a⁺ \Bmp8b^tm1Blh/\Bmp8b⁺ (involves: 129/Sv * 129S6/SvEvTac * Black Swiss)	granulomatous inflammation	J:46927
\Bmp8a^tm1Blh/\Bmp8a^tm1Blh (involves: 129S6/SvEvTac * Black Swiss)	granulomatous inflammation	J:46927
\Bmp10^b2b2711Clo/\Bmp10^b2b2711Clo (C57BL/6J-Bmp10^b2b2711Clo)	thymus hypoplasia	J:175213
\Bmpr1a^tm2.1Bhr/\Bmpr1a^tm2.1Bhr \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S7/SvEvBrd C57BL/6 * CBA)	stomach inflammation	J:163367
\Bmpr1a^tm2.1Bhr/\Bmpr1a^tm2.1Bhr \Tg(Col1a1-cre/Esr1*)1Mis/0 (involves: 129S7/SvEvBrd)	abnormal osteoclast differentiation	J:143588
	abnormal osteoclast physiology	J:143588
	decreased osteoclast cell number	J:143588
\Bmpr1a^tm2.1Bhr/\Bmpr1a^tm2.2Bhr \Tg(Gdf5-cre,-ALPP)1Kng/0 (involves: 129 * C57BL/6 * FVB/N-Tg(Gdf5-cre-ALPP)1Kng)	osteoarthritis	J:97780
\Bmpr2^tm1Kmi/\Bmpr2⁺ (involves: 129S4/SvJae * C57BL/6J)	abnormal leukocyte physiology	J:117167
\Bmx^tm1Ali/\Bmx^tm1Ali (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to induced arthritis	J:173099
\Bnc1^em1(IMPC)H/\Bnc1^em1(IMPC)H (C57BL/6NTac-Bnc1^em1(IMPC)H/H)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Bnip1^{tm2b(KOMP)Wtsi}/\Bnip1⁺ (C57BL/6N-Bnip1^{tm2b(KOMP)Wtsi}/Nju)	increased eosinophil cell number	J:211773
\Bnip3l^tm1.1Gwd/\Bnip3l^tm1.1Gwd (involves: 129 * C57BL/6)	abnormal spleen morphology	J:141583
	abnormal thrombopoiesis	J:141583
	enlarged spleen	J:141583
	increased spleen red pulp amount	J:141583
\Bnip3l^tm1Ney/\Bnip3l^tm1Ney (Not Specified)	enlarged spleen	J:141545
\Bnip3l^tm1Ney/\Bnip3l^tm1Ney (Not Specified)	spleen hyperplasia	J:141545
\Bnip5^{tm1.1(KOMP)Vlcg}/\Bnip5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Bnip5^{tm1.1(KOMP)Vlcg}/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Boc^{tm1b(KOMP)Wtsi}/\Boc^{tm1b(KOMP)Wtsi} (C57BL/6N-Boc^{tm1b(KOMP)Wtsi}/H)	increased basophil cell number	J:211773
\Bod1^{tm1b(KOMP)Wtsi}/\Bod1⁺ (C57BL/6N-Bod1^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Bod1l^em1Bltn/\Bod1l^em1Bltn \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6J)	decreased IgG1 level	J:337726
	decreased IgG level	J:337726
\Bod1l^em1Bltn/\Bod1l^em1Bltn \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6J * C57BL/6NTac)	abnormal class switch recombination	J:337726
	decreased IgG1 level	J:337726
\Bok^tm1.1Ast/\Bok^tm1.1Ast (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:203179
	increased spleen weight	J:203179
	increased thymus weight	J:203179
\Bok^{tm1b(EUCOMM)Hmgu}/\Bok^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bok^{tm1b(EUCOMM)Hmgu}/Tcp)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Bomb1^NSF/N/\Bomb1^NSF/N (involves: NFS/N * SL/Kh)	increased pre-B cell number	J:55364
\Bomb1^SL/Kh/\Bomb1^SL/Kh (involves: NFS/N * SL/Kh)	increased pre-B cell number	J:55364
\Bpgm^m1Pgrs/\Bpgm^m1Pgrs (involves: C57BL/6 * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:301620
	enlarged spleen	J:301620
	immune system phenotype	J:301620
\Bpgm^m1Pgrs/\Bpgm^m1Pgrs (involves: A/J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:301620
\Bpi^tm1.1Buls/\Bpi^tm1.1Buls (involves: BALB/cJ * C57BL/6J)	abnormal circulating interleukin level	J:346703
	abnormal immune cell physiology	J:346703
	abnormal interleukin secretion	J:346703
	decreased circulating interferon-gamma level	J:346703
	enlarged mesenteric lymph nodes	J:346703
	immune system phenotype	J:346703
	increased susceptibility to induced colitis	J:346703
	increased T cell number	J:346703
\Bpifa1^m1Ingm/\Bpifa1^m1Ingm (involves: C3HeB/FeJ)	increased interleukin-1 alpha secretion	J:195535
	increased interleukin-1 beta secretion	J:195535
	increased susceptibility to bacterial infection	J:195535
	increased susceptibility to otitis media	J:221346
	increased tumor necrosis factor secretion	J:195535
	lung inflammation	J:195535
\Bpifa1^{tm1(KOMP)Vlcg}/\Bpifa1^{tm1(KOMP)Vlcg} (involves: C57BL/6J * C57BL/6NTac)	increased susceptibility to bacterial infection	J:171589
\Bpifa1^tm1.1Jpst/\Bpifa1^tm1.1Jpst \Scgb1a1^{tm1(cre/ERT)Blh}/\Scgb1a1^{tm1(cre/ERT)Blh} (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)	increased susceptibility to Orthomyxoviridae infection	J:265391
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:265391
\Bpifa1^tm1.2Jpst/\Bpifa1^tm1.2Jpst (involves: BALB/cJ * C57BL/6 * C57BL/6J * SJL)	increased susceptibility to Orthomyxoviridae infection	J:265391
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:265391
\Bptf^em1Zfa/\Bptf^em1Zfa \Tg(Rorc-cre)1Litt/0 (involves: C57BL/6 * FVB)	increased susceptibility to bacterial infection	J:259392
	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
\Bptf^tm1.1Cwu/\Bptf^tm1.1Cwu \Emx1^tm1(cre)Krj/\Emx1⁺ (involves: 129S1/Sv * 129S2/SvPas * C57BL/6)	microgliosis	J:334252
\Braf^tm1(ARAF)Urr/\Braf^tm1(ARAF)Urr (involves: 129S1/Sv * C57BL/6 * CD-1)	decreased spleen weight	J:112971
	decreased thymus weight	J:112971
\Braf^tm1Bbd/\Braf⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal immune system physiology	J:170095
	abnormal thymus morphology	J:170095
	decreased thymocyte number	J:170095
	increased splenocyte apoptosis	J:170095
	increased thymocyte apoptosis	J:170095
	thymus atrophy	J:170095
\Braf^tm1Bbd/\Braf⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)	abnormal immune system physiology	J:170095
	abnormal thymus morphology	J:170095
	decreased thymocyte number	J:170095
	increased splenocyte apoptosis	J:170095
	increased thymocyte apoptosis	J:170095
	thymus atrophy	J:170095
\Braf^tm1Bbd/\Braf⁺ (B6.129-Braf^tm1Bbd)	abnormal immune system physiology	J:170095
	abnormal thymus morphology	J:170095
	decreased thymocyte number	J:170095
	increased splenocyte apoptosis	J:170095
	increased thymocyte apoptosis	J:170095
	thymus atrophy	J:170095
\Braf^tm1Cpri/\Braf⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased leukocyte cell number	J:104375
	enlarged spleen	J:104375
\Braf^tm1Mmcm/\Braf^tm1Mmcm \Cd207^{tm2.1(cre)Bjec}/\Cd207⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	increased dendritic cell number	J:211690
	liver inflammation	J:211690
	lung inflammation	J:211690
\Braf^tm1Mmcm/\Braf^tm1Mmcm \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	cytokine storm	J:211690
	enlarged lymph nodes	J:211690
	granulomatous inflammation	J:211690
	hepatosplenomegaly	J:211690
	increased dendritic cell number	J:211690
	increased inflammatory response	J:211690
\Braf^tm1Tumg/\Braf⁺ \Tg(CAG-cre)2Osb/0 (involves: C57BL * C57BL/6J * DBA)	abnormal lymph organ development	J:216228
\Braf^tm1Wds/\Braf^tm1Wds \Raf1^tm2Bacc/\Raf1^tm2Bacc \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129P2/OlaHsd * C57BL/6J * CBA/J)	small thymus	J:144862
\Braf^tm2Cpri/\Braf⁺ \Tg(CMV-cre)1Cgn/0 (B6.Cg-Braf^tm2Cpri Tg(CMV-cre)1Cgn)	enlarged spleen	J:187371
	increased spleen weight	J:187371
	lymphoid hyperplasia	J:187371
\Brap^em1(IMPC)Mbp/\Brap⁺ (C57BL/6NCrl-Brap^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Brca1^tm2.1Cxd/\Brca1^tm2.1Cxd \Shld1^em1Nus/\Shld1^em1Nus (involves: 129S6/SvEvTac * C57BL/6NCrl)	abnormal class switch recombination	J:307190
\Brca1^tm2.1Cxd/\Brca1^tm2.1Cxd \Trp53^tm1Brd/\Trp53⁺ (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	enlarged thymus	J:81541
	increased T cell derived lymphoma incidence	J:81541
\Brca1^tm2.1Cxd/\Brca1^tm2.1Cxd \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:81541
\Brca1^tm2.1Cxd/\Brca1^tm2.1Cxd \Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc (involves: 129 * 129S6/SvEvTac)	abnormal class switch recombination	J:307190
\Brca1^tm2Mak/\Brca1^tm2Mak \Cdkn1a^tm1Tyj/\Cdkn1a^tm1Tyj \Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased thymocyte number	J:63282
	immune system phenotype	J:63282
\Brca1^tm2Mak/\Brca1^tm2Mak \Chek2^tm1Mak/\Chek2^tm1Mak \Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:90512
	increased T cell derived lymphoma incidence	J:90512
\Brca1^tm2Mak/\Brca1^tm2Mak \Tg(BCL2)36Wehi/? \Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:63282
\Brca1^tm2Mak/\Brca1^tm2Mak \Tg(Lck-cre)548Jxm/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal immune system organ morphology	J:63282
	abnormal T cell number	J:63282
	decreased double-positive T cell number	J:63282
	decreased single-positive T cell number	J:63282
	decreased T cell proliferation	J:63282
	decreased thymocyte number	J:63282
	increased double-negative T cell number	J:63282
\Brca1^tm2Mak/\Brca1^tm2Mak \Tg(Lck-cre)548Jxm/? \Tg(TcrLCMV)327Sdz/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell number	J:63282
	decreased double-positive T cell number	J:63282
	decreased T cell proliferation	J:63282
	decreased thymocyte number	J:63282
	increased double-negative T cell number	J:63282
\Brca1^tm2Mak/\Brca1^tm2Mak \Tg(Lck-cre)548Jxm/? \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:63282
	increased T cell derived lymphoma incidence	J:90512
\Brca1^tm5.1Cxd/\Brca1^tm5.1Cxd (involves: 129S6/SvEvTac * FVB/N)	dermatitis	J:155810
	increased T cell derived lymphoma incidence	J:155810
\Brca2^tm1Cam/\Brca2^tm1Cam (involves: 129S/SvEv * MF1)	increased T cell derived lymphoma incidence	J:46812
\Brca2^tm1Cam/\Brca2^tm1Cam (involves: 129S/SvEv * MF1)	increased thymus weight	J:46812
\Brca2^tm1Cbl/\Brca2^tm1Cbl (either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))	increased T cell derived lymphoma incidence	J:44386
\Brca2^tm1Hst/\Brca2^tm1Hst (involves: 129S7/SvEvBrd * C57BL/6)	sepsis	J:82434
\Brca2^tm1Kamc/\Brca2^tm1Kamc (involves: 129P2/OlaHsd * BALB/c)	spleen hypoplasia	J:144998
\Brca2^tm1Mak/\Brca2^tm2Mak \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:79697
	increased T cell apoptosis	J:79697
\Brca2^tm1Mak/\Brca2^tm2Mak \Trp53^tm1Brd/\Trp53^tm1Brd \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)	immune system phenotype	J:79697
	increased activated T cell number	J:79697
\Brd2^{em1(IMPC)Wtsi}/\Brd2⁺ (C57BL/6N-Brd2^{em1(IMPC)Wtsi}/WtsiIeg)	decreased CD8-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
\Brd2^{em1(IMPC)Wtsi}/\Brd2^{em1(IMPC)Wtsi} (C57BL/6N-Brd2^{em1(IMPC)Wtsi}/WtsiIeg)	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
	small thymus	J:239583
\Brd2^{Gt(RRT234)Byg}/\Brd2⁺ (B6.129P2-Brd2^{Gt(RRT234)Byg})	increased circulating interleukin-1 beta level	J:159964
	increased circulating tumor necrosis factor level	J:159964
\Brd9^em1(IMPC)Tcp/\Brd9⁺ (C57BL/6N-Brd9^em1(IMPC)Tcp/Cmmr)	increased neutrophil cell number	J:211773
\Brf1^tm1Arte/\Brf1^tm1Arte \Tg(Cyp1a1-cre)1Dwi/0 (involves: C57BL/6 * CBA)	liver inflammation	J:285667
\Brix1^{tm1b(KOMP)Mbp}/\Brix1⁺ (C57BL/6N-Brix1^{tm1b(KOMP)Mbp}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Brpf1^{tm1a(EUCOMM)Wtsi}/\Brpf1⁺ (Not Specified)	decreased T cell number	J:165965
\Brpf1^{tm1a(EUCOMM)Wtsi}/\Brpf1⁺ (Not Specified)	increased monocyte cell number	J:165965
\Brwd1^em1(IMPC)Tcp/\Brwd1^em1(IMPC)Tcp (C57BL/6N-Brwd1^em1(IMPC)Tcp/Cmmr)	abnormal spleen morphology	J:211773
\Bscl2^tm1.1Lchan/\Bscl2^tm1.1Lchan (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	enlarged spleen	J:183701
\Bscl2^tm1.2Gliu/\Bscl2^tm1.2Gliu (involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB/N)	enlarged spleen	J:173404
\Bscl2^{tm1b(EUCOMM)Hmgu}/\Bscl2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Bscl2^{tm1b(EUCOMM)Hmgu}/Ics)	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Bsg^tm1.1Znc/\Bsg^tm1.1Znc \Tg(Lck-cre)19Hhan/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	abnormal T cell activation	J:207886
	decreased double-positive T cell number	J:207886
	decreased single-positive T cell number	J:207886
	decreased thymocyte number	J:207886
	decreased thymus weight	J:207886
	immune system phenotype	J:207886
	increased T cell proliferation	J:207886
\Bsg^tm1Tmu/\Bsg^tm1Tmu (involves: 129S2/SvPas * C57BL/6J)	interstitial pneumonia	J:46376
\Bsg^tm1Tmu/\Bsg^tm1Tmu (involves: 129/Sv * 129S2/SvPas)	interstitial pneumonia	J:46376
\Bsg^tm1Tmu/\Bsg^tm1Tmu (involves: 129S2/SvPas)	decreased circulating complement protein level	J:287636
	glomerulonephritis	J:287636
	increased spleen weight	J:287636
	increased splenocyte number	J:287636
	increased susceptibility to systemic lupus erythematosus	J:287636
	increased T-helper 17 cell number	J:287636
\Bsp/\Bsp (C57BL/6By)	abnormal spleen morphology	J:6856
\Bsp/\Bsp⁺ (C57BL/6By)	abnormal spleen morphology	J:6856
\Bst1^tm1Thir/\Bst1^tm1Thir (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:111424
	abnormal humoral immune response	J:111424
	decreased B-1 B cell number	J:111424
	decreased IgA level	J:111424
	decreased IgG3 level	J:111424
	decreased immature B cell number	J:111424
	immune system phenotype	J:111424
	increased B cell number	J:111424
\Bst2^tm1.1Bsz/\Bst2^tm1.1Bsz (involves: C57BL/6)	enlarged lymph nodes	J:180252
	enlarged spleen	J:180252
	increased susceptibility to Retroviridae infection	J:180252
\Btbd1^{tm1a(KOMP)Wtsi}/\Btbd1^{tm1a(KOMP)Wtsi} (C57BL/6N-Btbd1^{tm1a(KOMP)Wtsi}/Wtsi)	increased CD8-positive, naive alpha-beta T cell number	J:211773
\Btbd2^em1(IMPC)Mbp/\Btbd2^em1(IMPC)Mbp (C57BL/6N-Btbd2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Btbd3^{tm1b(EUCOMM)Hmgu}/\Btbd3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Btbd3^{tm1b(EUCOMM)Hmgu}/Ccpcz)	increased CD8-positive, CD25-positive alpha-beta T cell number	J:211773
\Btbd7^{em1(IMPC)Ccpcz}/\Btbd7^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Btbd7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Btbd8^em1Lych/\Btbd8^em1Lych (involves: C57BL/6)	decreased macrophage cytokine production	J:349252
\Btbd8^em1Lych/\Btbd8^em1Lych (involves: C57BL/6)	decreased susceptibility to induced colitis	J:349252
\Btbd16^{tm2b(EUCOMM)Hmgu}/\Btbd16^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Btbd16^{tm2b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Btbd18^{em1(IMPC)Ccpcz}/\Btbd18^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Btbd18^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Btc^em1(IMPC)Mbp/\Btc^em1(IMPC)Mbp (C57BL/6N-Btc^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
\Btf3^em1(IMPC)Tcp/\Btf3⁺ (C57BL/6NCrl-Btf3^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
\Btg1^em1(IMPC)Mbp/\Btg1^em1(IMPC)Mbp (C57BL/6NCrl-Btg1^em1(IMPC)Mbp/Mmucd)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Btk^m1Anu/\Btk^m1Anu (involves: BXSB/MpJ * C57BL/6JAnu * SB/Le)	decreased B cell number	J:104190
\Btk^m1Anu/\Btk^m1Anu X/\Yaa (involves: BXSB/MpJ * C57BL/6JAnu * SB/Le)	decreased B cell number	J:104190
\Btk^m2Anu/\Btk^m2Anu (C57BL/6NCrlAnu-Btk^m2Anu)	increased IgM level	J:104190
\Btk^m2Anu/\Btk^m2Anu (C57BL/6NCrlAnu-Btk^m2Anu)	increased immature B cell number	J:104190
\Btk^{tm1a(EUCOMM)Hmgu}/Y (C57BL/6N-Btk^{tm1a(EUCOMM)Hmgu}/Ics)	increased CD4-positive, alpha-beta T cell number	J:165965
\Btk^tm1Gsv/Y (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell calcium ion homeostasis	J:94768
	abnormal B cell differentiation	J:35769
	abnormal humoral immune response	J:120989
	abnormal immune system physiology	J:35769
	absent B-1a cells	J:35769
	absent mature B cells	J:35769
	decreased B cell number	J:35769
	decreased IgG3 level	J:35769
	decreased IgM level	J:35769
	decreased immature B cell number	J:35769
	decreased immunoglobulin level	J:120989
\Btk^tm1Gsv/Y \Tg(CD19-BTKK430R)XK24Rwhe/? (involves: 129P2/OlaHsd C57BL/6 * FVB)	abnormal lymphocyte cell number	J:120989
	abnormal pre-B cell morphology	J:120989
	absent B-1a cells	J:120989
	decreased B cell apoptosis	J:120989
	decreased B cell number	J:120989
	decreased immunoglobulin level	J:120989
	immune system phenotype	J:94768
\Btk^tm1Gsv/\Btk⁺ (involves: 129P2/OlaHsd * C57BL/6)	absent B-1a cells	J:35769
	decreased B cell number	J:35769
	decreased mature B cell number	J:35769
\Btk^tm1Witt/\Btk^tm1Wk (involves: 129S4/SvJae * 129X1/SvJ)	immune system phenotype	J:104167
\Btk^tm1Wk/\Btk^tm1Wk (involves: 129S4/SvJae * C57BL/6)	abnormal B cell activation	J:28968
	abnormal B cell differentiation	J:28968
	abnormal lymph node germinal center morphology	J:82298
	decreased B cell proliferation	J:82298
	decreased IgG3 level	J:28968, J:82298
	decreased IgM level	J:28968, J:82298
	decreased mature B cell number	J:28968, J:82298
	decreased spleen germinal center number	J:82298
	decreased spleen germinal center size	J:82298
	increased pro-B cell number	J:28968
\Btk^tm1Wk/\Btk^tm1Wk \Cd40^tm1Geha/\Cd40^tm1Geha (involves: 129S4/SvJae * C57BL/6)	abnormal humoral immune response	J:82298
	absent lymph node germinal center	J:82298
	absent spleen germinal center	J:82298
	decreased B cell number	J:82298
	decreased B cell proliferation	J:82298
	decreased IgA level	J:82298
	decreased IgG2a level	J:82298
	decreased IgG2b level	J:82298
	decreased IgG3 level	J:82298
	decreased IgM level	J:82298
	decreased mature B cell number	J:82298
\Btk^tm1Wk/\Btk^tm1Wk \Tec^tm1Welm/\Tec^tm1Welm (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:66080
	abnormal humoral immune response	J:66080
	abnormal spleen marginal zone morphology	J:66080
	abnormal spleen morphology	J:66080
	abnormal spleen white pulp morphology	J:66080
	decreased B cell number	J:66080
	decreased B cell proliferation	J:66080
	decreased IgG2a level	J:66080
	decreased IgG3 level	J:66080
	decreased IgM level	J:66080
	decreased immunoglobulin level	J:66080
	increased pre-B cell number	J:66080
\Btk^tm1Wk/\Btk^tm1Wk \Tg(IGH-Btk)1Witt/0 (involves: 129S4/SvJae * 129X1/SvJ * BALB/c * C3H * C57BL/6)	decreased B cell proliferation	J:82430
\Btk^vila/\Btk^vila (C57BL/6JAnu-Btk^vila/AnuApb)	abnormal leukocyte morphology	J:104190
	decreased B cell number	J:104190
	decreased IgD level	J:104190
	increased IgE level	J:104190
	increased IgG level	J:104190
\Btk^xid/Y (CBA/HN-Btk^xid)	decreased B cell number	J:81429
	decreased B cell proliferation	J:81429
	decreased splenocyte number	J:81429
\Btk^xid/Y (involves: CBA/HN * DBA/2N)	decreased B cell number	J:81429
	decreased B cell proliferation	J:81429
	spleen hypoplasia	J:81429
\Btk^xid/? (involves: BALB/c * CBA/N)	decreased B cell proliferation	J:108696
	decreased B-1 B cell number	J:108696
	decreased IgG3 level	J:108696
	decreased IgM level	J:108696
	decreased mature B cell number	J:108696
\Btk^xid/Y \Ikzf3^tm1Kge/\Ikzf3^tm1Kge (involves: 129S4/SvJae * CBA/CaHN)	decreased follicular B cell number	J:69477
\Btk^xid/? \Ptpn6^me/\Ptpn6^me (involves: C57BL/6J * CBA/N * NFS)	increased autoantibody level	J:30994
	increased IgM level	J:30994
	increased splenocyte proliferation	J:30994
\Btk^xid/? \Tg(IGH-Btk)1Witt/0 (involves: BALB/c * C3H * C57BL/6 * CBA/N)	decreased B cell proliferation	J:108696
	decreased B-1 B cell number	J:108696
	decreased IgG3 level	J:108696
	decreased IgM level	J:108696
\Btk^xid/? \Tg(IGH-Btk)1Witt/\Tg(IGH-Btk)1Witt (involves: BALB/c * C3H * C57BL/6 * CBA/N)	decreased B cell proliferation	J:108696
	decreased B-1 B cell number	J:108696
	decreased IgG3 level	J:108696
	decreased IgM level	J:108696
\Btk^xid/\Btk^xid (CBA/CaHN-Btk^xid/J)	abnormal macrophage physiology	J:92639
	abnormal neutrophil physiology	J:92639
	decreased acute inflammation	J:92639
	decreased follicular B cell number	J:69477
	decreased neutrophil cell number	J:92639
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:92639
	impaired myelopoiesis	J:92639
	impaired neutrophil phagocytosis	J:92639
	increased susceptibility to bacterial infection induced morbidity/mortality	J:128518
	increased susceptibility to induced colitis	J:92639
\Btk^xid/\Btk^xid (involves: CBA/HN * DBA/2N)	abnormal B cell physiology	J:81429
	abnormal B cell proliferation	J:81429
	decreased B cell number	J:81429
	spleen hypoplasia	J:81429
\Btk^xid/\Btk^xid (CBA/HN-Btk^xid)	abnormal lymphopoiesis	J:7981
	abnormal pre-B cell morphology	J:7981
	autoimmune response	J:125114
	decreased B cell number	J:81429
	decreased B cell proliferation	J:81429
	decreased splenocyte number	J:81429
\Btk^xid/\Btk^xid (involves: C57BL/6 * CBA)	immune system phenotype	J:113083
\Btk^xid/\Btk^xid (B6.CBA-Btk^xid)	decreased transitional stage B cell number	J:145687
\Btk^xid/\Btk^xid \Ikzf3^tm1Kge/\Ikzf3^tm1Kge (involves: 129S4/SvJae * CBA/CaHN)	decreased follicular B cell number	J:69477
\Btla^tm1Dgra/\Btla^tm1Dgra (involves: C57BL/6)	abnormal peripheral T cell anergy	J:147751
\Btla^tm1Dgra/\Btla^tm1Dgra (involves: C57BL/6)	abnormal T cell activation	J:147751
\Btla^tm1Dgra/\Btla^tm1Dgra \Tg(TcraTcrb)425Cbn/? (involves: C57BL/6)	abnormal peripheral T cell anergy	J:147751
\Btla^tm1Dgra/\Btla^tm1Dgra \Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal peripheral T cell anergy	J:147751
\Btla^tm1Kay/\Btla^tm1Kay (involves: 129S6/SvEvTac * C57BL/6J)	abnormal T cell activation	J:89864
\Btla^tm1Kmm/\Btla^tm1Kmm (involves: 129S/SvEv)	abnormal humoral immune response	J:84084
	increased B cell proliferation	J:84084
	increased IgG1 level	J:84084
	increased IgG2a level	J:84084
	increased IgG2b level	J:84084
	increased susceptibility to experimental autoimmune encephalomyelitis	J:84084
	increased T cell proliferation	J:84084
\Btla^tm1Kmm/\Btla^tm1Kmm (B6.129S-Btla^tm1Kmm)	abnormal T cell activation	J:119356
	decreased interferon-gamma secretion	J:119356
	decreased interleukin-2 secretion	J:119356
	decreased T cell proliferation	J:119356
	increased length of allograft survival	J:119356
	increased T cell proliferation	J:119356
\Btla^tm1Kmm/\Btla^tm1Kmm \Pdcd1^tm1Hon/\Pdcd1^tm1Hon (B6.129S-Pdcd1^tm1Hon Btla^tm1Kmm)	decreased length of allograft survival	J:119356
	increased T cell proliferation	J:119356
\Btla^tm1Kmm/\Btla^tm1Kmm \Tg(DO11.10)10Dlo/? (involves: 129S/SvEv * BALB/c * C3H * C57BL/6)	increased T cell proliferation	J:84084
\Btn2a2^tm1.2Wrth/\Btn2a2^tm1.2Wrth (C57BL/6-Btn2a2^tm1.2Wrth)	abnormal T-helper 1 physiology	J:232636
	abnormal T-helper 2 physiology	J:232636
	increased anti-nuclear antigen antibody level	J:232636
	increased IgG1 level	J:232636
	increased IgG2c level	J:232636
	increased IgG level	J:232636
	increased response to antigen	J:232636
	increased susceptibility to experimental autoimmune encephalomyelitis	J:232636
\Btnl1^em1Ahay/\Btnl1^em1Ahay (Not Specified)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:236526
\Btnl1^em1Ahay/\Btnl1^em1Ahay (Not Specified)	decreased gamma-delta intraepithelial T cell number	J:236526
\Btnl1^em3Ahay/\Btnl1^em3Ahay \Btnl6^em2Ahay/\Btnl6^em2Ahay \Tg(Vil1-cre/ERT2)23Syr/0 (involves: BALB/c * C57BL/6J * DBA/2)	immune system phenotype	J:291989
\Btnl1^em4Ahay/\Btnl1^em4Ahay \Tg(Vil1-cre/ERT2)23Syr/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:291989
\Btnl1^tm1(KOMP)Mbp/\Btnl1^tm1(KOMP)Mbp (C57BL/6N-Btnl1^tm1(KOMP)Mbp)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:236526
	decreased gamma-delta intraepithelial T cell number	J:236526
\Btnl1^tm1(KOMP)Mbp/\Btnl1^tm1(KOMP)Mbp \Foxn1^nu/\Foxn1^nu (involves: albino stock * C57BL/6N)	decreased gamma-delta intraepithelial T cell number	J:236526
\Btnl1^tm1(KOMP)Mbp/\Btnl1^tm1(KOMP)Mbp \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/0 \Tg(tetO-Btnl1)#Ahay/0 (involves: 129S4/SvJae C57BL/6 * C57BL/6N)	decreased gamma-delta intraepithelial T cell number	J:236526
\Btnl1^tm1(KOMP)Mbp/\Btnl1^tm1(KOMP)Mbp \Tg(tetO-Btnl1)#Ahay/0 \Tg(Vil-rtTA2M2)1Rsmi/0 (involves: C57BL/6N FVB/N)	decreased gamma-delta intraepithelial T cell number	J:236526
\Btnl2^em1Wche/\Btnl2^em1Wche (C57BL/6-Btnl2^em1Wche)	abnormal cytokine level	J:321348
	abnormal gamma-delta T cell morphology	J:321348
	large intestinal inflammation	J:321348
\Btnl4^em1(IMPC)Tcp/\Btnl4^em1(IMPC)Tcp (C57BL/6N-Btnl4^em1(IMPC)Tcp/1Cmmr)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Btnl4^tm1(KOMP)Mbp/\Btnl4^tm1(KOMP)Mbp (C57BL/6N-Btnl4^tm1(KOMP)Mbp)	immune system phenotype	J:291989
\Btnl6^em1.1Ahay/\Btnl6^em1.1Ahay (Not Specified)	decreased CD4-positive, gamma-delta intraepithelial T cell number	J:291989
\Btnl6^em1Ahay/\Btnl6^em1Ahay \Tg(Vil1-cre)20Syr/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, gamma-delta intraepithelial T cell number	J:291989
\Btrc^{tm1b(KOMP)Wtsi}/\Btrc^{tm1b(KOMP)Wtsi} (C57BL/6N-Btrc^{tm1b(KOMP)Wtsi}/H)	increased monocyte cell number	J:211773
\Btrc^tm1Kin/\Btrc^tm1Kin (involves: C57BL/6)	abnormal lymphocyte morphology	J:84639
\Btrc^tm1Paga/\Btrc^tm1Paga \Fbxw11^tm1Ybn/\Fbxw11^tm1Ybn \Tg(Vil1-cre/ERT2)23Syr/? (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	increased circulating interleukin-1 beta level	J:206654
	intestinal inflammation	J:206654
\Bub1^tm1.1Tvd/\Bub1^tm1.1Tvd (B6.129P2-Bub1^tm1.1Tvd)	increased leukocyte cell number	J:143035
\Bub1b^{Gt(neo-btk)1Dai}/\Bub1b⁺ (involves: 129S4/SvJae * C57BL/6)	enlarged spleen	J:88223
\Bub1b^tm1.1Hsl/\Bub1b⁺ (involves: 129 * C57BL/6)	enlarged spleen	J:201641
	increased B cell proliferation	J:201641
	increased spleen white pulp amount	J:201641
\Bud13^{em1(IMPC)Ccpcz}/\Bud13⁺ (C57BL/6NCrl-Bud13^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Bxs6^BXSB/MpJ/\Bxs6^BXSB/MpJ (involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)	autoimmune response	J:145903
	glomerulonephritis	J:145903
	increased autoantibody level	J:145903
\Bxs6^BXSB/MpJ/\Bxs6^BXSB/MpJ (B10.BXSB-(D13Mit3-D13Mit78))	autoimmune response	J:145049
	increased anti-double stranded DNA antibody level	J:145049
	increased anti-single stranded DNA antibody level	J:145049
	increased autoantibody level	J:145049
\Bxs6^BXSB/MpJ/\Bxs6^BXSB/MpJ \Gpab1^C57BL/6J/? (involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)	autoimmune response	J:145903
	increased autoantibody level	J:145903
\Bxs6^BXSB/MpJ/\Bxs6^BXSB/MpJ X/\Yaa (B10.BXSB-(D13Mit3-D13Mit78) Yaa)	autoimmune response	J:145049
	enlarged spleen	J:145049
	glomerulonephritis	J:145049
	increased anti-double stranded DNA antibody level	J:145049
	increased anti-single stranded DNA antibody level	J:145049
	increased autoantibody level	J:145049
\C1galt1^ptl1/\C1galt1^ptl1 (C57BL/6-C1galt1^ptl1)	abnormal thrombopoiesis	J:115272
	glomerulonephritis	J:115272
	kidney inflammation	J:115272
\C1galt1^ptl1/\C1galt1^ptl1 \Rag1^tm1Bal/\Rag1^tm1Bal (involves: 129S4/SvJae * C57BL/6)	kidney inflammation	J:115272
\C1qa^tm1Mjw/\C1qa^tm1Mjw (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	glomerulonephritis	J:47315
	increased anti-histone antibody level	J:47315
	increased anti-nuclear antigen antibody level	J:47315
	increased susceptibility to bacterial infection	J:83712
\C1qa^tm1Mjw/\C1qa^tm1Mjw (involves: 129P2/Ola * 129S/SvEv)	immune system phenotype	J:47315
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle16^{129S6/SvEvTac}/\Sle16^{129S6/SvEvTac} (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle16^{129S6/SvEvTac}/\Sle16^C57BL/6 (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle18^C57BL/6/\Sle18^C57BL/6 (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle18^C57BL/6/\Sle18^C57BL/6 (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle19^C57BL/6/? (involves: 129S/SvEv * 129X1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle19^C57BL/6/? (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle21^129P2/Ola/? \Sle18^C57BL/6/\Sle18^C57BL/6 (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-nuclear antigen antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle21^129P2/Ola/\Sle21^129P2/Ola (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1qa^tm1Mjw/\C1qa^tm1Mjw \Sle21^129P2/Ola/\Sle21^C57BL/6 (involves: 129P2/Ola * 129S/SvEv * C57BL/6)	increased anti-chromatin antibody level	J:118645
	increased anti-double stranded DNA antibody level	J:118645
	increased anti-nuclear antigen antibody level	J:118645
	increased anti-single stranded DNA antibody level	J:118645
	increased susceptibility to systemic lupus erythematosus	J:118645
\C1ql2^em1(IMPC)Mbp/\C1ql2^em1(IMPC)Mbp (C57BL/6N-C1ql2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\C1ql3^em1(IMPC)H/\C1ql3^em1(IMPC)H (C57BL/6NTac-C1ql3^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
\C1ql4^tm1Lex/\C1ql4^tm1Lex (B6.129S5-C1ql4^tm1Lex)	decreased leukocyte cell number	J:344722
\C1ql4^tm1Lex/\C1ql4^tm1Lex (B6.129S5-C1ql4^tm1Lex)	decreased lymphocyte cell number	J:344722
\C1qtnf1^em1(IMPC)Mbp/\C1qtnf1^em1(IMPC)Mbp (C57BL/6N-C1qtnf1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\C1qtnf3^tm1Yiw/\C1qtnf3^tm1Yiw (involves: C57BL/6NSlc)	immune system phenotype	J:211893
	increased IgG level	J:211893
	increased susceptibility to induced arthritis	J:211893
	joint inflammation	J:211893
\C1qtnf4^em1Smoc/\C1qtnf4^em1Smoc (C57BL/6JSmoc-C1qtnf4^em1Smoc/Smoc)	abnormal macrophage differentiation	J:302282
	increased circulating interleukin-6 level	J:302282
	increased circulating interleukin-18 level	J:302282
	increased circulating tumor necrosis factor level	J:302282
	increased susceptibility to endotoxin shock	J:302282
	increased tumor necrosis factor secretion	J:302282
\C1qtnf6^tm1Yiw/\C1qtnf6^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:227217
	increased anti-nuclear antigen antibody level	J:227217
	increased autoantibody level	J:227217
\C1qtnf6^tm1Yiw/\C1qtnf6^tm1Yiw (B6.129P2-C1qtnf6^tm1Yiw)	abnormal complement pathway	J:227217
	abnormal complement protein level	J:227217
	immune system phenotype	J:227217
	increased B cell number	J:227217
	increased circulating complement protein level	J:227217
	increased IgG level	J:227217
	increased susceptibility to experimental autoimmune encephalomyelitis	J:227217
	increased susceptibility to induced arthritis	J:227217
	increased susceptibility to type III hypersensitivity reaction	J:227217
\C1qtnf7^{tm1(KOMP)Vlcg}/\C1qtnf7^{tm1(KOMP)Vlcg} (C57BL/6N-C1qtnf7^{tm1(KOMP)Vlcg})	increased macrophage cell number	J:244352
\C2cd3^em1(IMPC)Tcp/\C2cd3⁺ (C57BL/6N-C2cd3^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\C3^tm1Crr/\C3^tm1Crr (involves: 129S4/SvJae * C57BL/6)	abnormal cell-mediated immunity	J:30152
	abnormal humoral immune response	J:64282
	abnormal immune system morphology	J:44240
	abnormal immune system physiology	J:44240
	abnormal mast cell physiology	J:44240
	abnormal spleen germinal center morphology	J:64282
	abnormal tumor necrosis factor level	J:44240
	decreased circulating interleukin-6 level	J:166640, J:152533
	decreased circulating tumor necrosis factor level	J:152533
	decreased mast cell number	J:44240
	decreased neutrophil cell number	J:44240
	decreased osteoclast cell number	J:166640
	decreased spleen germinal center number	J:64282
	decreased spleen germinal center size	J:64282
	immune system phenotype	J:64282
	increased susceptibility to bacterial infection	J:44240, J:30152
	increased susceptibility to bacterial infection induced morbidity/mortality	J:205353
	liver inflammation	J:30152
\C3^tm1Crr/\C3^tm1Crr (B6.129S4-C3^tm1Crr)	abnormal inflammatory response	J:113463
	abnormal neutrophil morphology	J:113463
	brain inflammation	J:123658
	decreased susceptibility to autoimmune hemolytic anemia	J:145432
\C3^tm1Crr/\C3^tm1Crr (B6;129S4-C3^tm1Crr/J)	decreased susceptibility to Coronaviridae infection	J:286325
\C3^tm1Crr/\C3^tm1Crr (B6;129S4-C3^tm1Crr/J)	increased susceptibility to bacterial infection	J:136745
\C3^tm1Crr/\C3^tm1Crr (involves: 129S4/SvJae)	glomerulonephritis	J:44715
\C3^tm1Crr/\C3^tm1Crr \C4b^tm1Crr/\C4b^tm1Crr \Fas^lpr/\Fas^lpr (involves: 129S4/SvJae * C57BL/6 * MRL)	abnormal immune system physiology	J:127292
	enlarged cervical lymph nodes	J:127292
	enlarged spleen	J:127292
	increased anti-double stranded DNA antibody level	J:127292
	increased anti-nuclear antigen antibody level	J:127292
\C3^tm1Crr/\C3^tm1Crr \Cd59a^tm1Bpm/\Cd59a^tm1Bpm (B6.129-Cd59a^tm1Bpm C3^tm1Crr)	increased T cell proliferation	J:122201
\C3^tm1Crr/\C3^tm1Crr \Fas^lpr/\Fas^lpr (involves: 129S4/SvJae * C57BL/6 * MRL)	decreased susceptibility to autoimmune disorder	J:127292
	immune system phenotype	J:127292
\C3^tm1Crr/\C3^tm1Crr \Fcer1g^tm1Rav/\Fcer1g^tm1Rav \Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:122114
\C3^tm1Crr/\C3^tm1Crr \Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129S4/SvJae * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:122114
	increased interferon-gamma secretion	J:122114
	increased T cell proliferation	J:122114
	insulitis	J:122114
\C3^tm1Crr/\C3^tm1Crr \Zbtb20^{Tg(PDGFB-APPSwInd)20Lms}/? (involves: 129S4/SvJae * C57BL/6)	increased microglial cell activation	J:135902
\C3^tm1Hrc/\C3^tm1Hrc (either: (involves: 129S2/SvPas * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))	increased susceptibility to bacterial infection	J:56193
\C3^tm1Hrc/\C3^tm1Hrc (B6.129-C3^tm1Hrc)	impaired complement alternative pathway	J:177350
\C3^tm1Hrc/\C3^tm1Hrc \Cr1l^tm1Hmo/\Cr1l^tm1Hmo (involves: 129/Sv * 129X1/SvJ * C57BL/6)	abnormal complement pathway	J:76578
\C3^tm1Hrc/\C3^tm1Hrc \Lama2^dy/\Lama2^dy (either: (involves: 129S2/SvPas * 129P1/ReJ) or (involves: 129X1/SvJ * 129P1/ReJ))	decreased IgM level	J:102959
	increased IgG level	J:102959
	increased IgM level	J:102959
\C3^tm1Hrc/\C3^tm1Hrc \Vsig4^tm1Gne/\Vsig4^tm1Gne (involves: 129/Sv * C57BL/6N)	immune system phenotype	J:138691
\C3^tm1Pkna/\C3^tm1Pkna (D1.129P2-C3^tm1Pkna)	decreased susceptibility to induced arthritis	J:88872
\C3ar1^tm1Cge/\C3ar1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	decreased circulating interleukin-6 level	J:166640
	decreased osteoclast cell number	J:166640
\C3ar1^tm1Raw/\C3ar1⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal immune system physiology	J:68807
\C3ar1^tm1Raw/\C3ar1^tm1Raw (involves: 129X1/SvJ * C57BL/6)	increased circulating interleukin-1 beta level	J:68807
\C3ar1^tm1Raw/\C3ar1^tm1Raw (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to endotoxin shock	J:68807
\C3ar1^tm1Raw/\C3ar1^tm1Raw (B6.129X1(B6)-C3ar1^tm1Raw)	abnormal adaptive immunity	J:80071
	abnormal eosinophil physiology	J:80071
	abnormal interleukin level	J:80071
	abnormal T-helper 2 cell differentiation	J:80071
	abnormal T-helper 2 physiology	J:80071
	decreased eosinophil cell number	J:80071
	decreased IgE level	J:80071
	decreased IgG1 level	J:80071
	decreased interleukin-4 secretion	J:80071
	decreased lymphocyte cell number	J:80071
	decreased neutrophil cell number	J:80071
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:93791
	impaired neutrophil recruitment	J:80071
	increased circulating interleukin-1 beta level	J:93791
	increased susceptibility to type I hypersensitivity reaction	J:80071
\C3ar1^tm1Raw/\C3ar1^tm1Raw \Cpn1^tm1Raw/\Cpn1^tm1Raw (B6.129-C3ar1^tm1Raw Cpn1^tm1Raw)	increased acute inflammation	J:148315
\C4b^tm1Crr/\C4b^tm1Crr (involves: 129S4/SvJae * C57BL/6)	abnormal humoral immune response	J:64282
	abnormal spleen germinal center morphology	J:64282
	decreased spleen germinal center number	J:64282
	decreased spleen germinal center size	J:64282
	decreased susceptibility to bacterial infection	J:30152
	immune system phenotype	J:64282, J:30152
	increased susceptibility to bacterial infection induced morbidity/mortality	J:30152
	liver inflammation	J:30152
\C4b^tm1Crr/\C4b^tm1Crr (involves: 129S4/SvJae * C57BL/6J)	abnormal immune system physiology	J:111811
	glomerulonephritis	J:111811
	increased anti-double stranded DNA antibody level	J:111811
	increased anti-nuclear antigen antibody level	J:111811
	increased anti-single stranded DNA antibody level	J:111811
	increased macrophage cell number	J:111811
	increased neutrophil cell number	J:111811
	increased spleen germinal center number	J:111811
	increased spleen weight	J:111811
\C4b^tm1Crr/\C4b^tm1Crr (involves: 129S4/SvJae)	decreased susceptibility to Coronaviridae infection	J:286325
\C4b^tm1Crr/\C4b^tm1Crr (involves: 129S4/SvJae)	glomerulonephritis	J:44715
\C4b^tm1Crr/\C4b^tm1Crr \Fas^lpr/\Fas^lpr (involves: 129S4/SvJae * C57BL/6 * MRL)	abnormal immune system physiology	J:127292
	enlarged cervical lymph nodes	J:127292
	enlarged spleen	J:127292
	increased anti-double stranded DNA antibody level	J:127292
	increased anti-nuclear antigen antibody level	J:127292
\C4bp^tm1Raw/\C4bp^tm1Raw (B6.129-C4bp^tm1Raw)	increased circulating interleukin-6 level	J:244020
\C5ar1^tm1Cge/\C5ar1^tm1Cge (involves: 129S4/SvJae)	abnormal humoral immune response	J:35529
	impaired neutrophil recruitment	J:69177
	increased susceptibility to bacterial infection	J:69177
\C5ar1^tm1Cge/\C5ar1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	decreased circulating interleukin-6 level	J:166640
	decreased osteoclast cell number	J:166640
\C5ar1^tm1Raw/\C5ar1^tm1Raw (B6.Cg-C5ar1^tm1Raw)	immune system phenotype	J:139786
\C5ar1^tm1Raw/\C5ar1^tm1Raw (B6.Cg-C5ar1^tm1Raw)	increased spleen germinal center number	J:139786
\C5ar1^tm1Song/\C5ar1^tm1Song (involves: 129S6/SvEvTac * C57BL/6)	abnormal neutrophil physiology	J:184056
\C5ar2^em1(IMPC)H/\C5ar2^em1(IMPC)H (C57BL/6NTac-C5ar2^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\C5ar2^tm1Cge/\C5ar2^tm1Cge (B6.129S1-C5ar2^tm1Cge)	abnormal immune cell physiology	J:104092
\C5ar2^tm1Cge/\C5ar2^tm1Cge (B6.129S1-C5ar2^tm1Cge)	increased inflammatory response	J:104092
\C8a^{tm1b(EUCOMM)Hmgu}/\C8a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-C8a^{tm1b(EUCOMM)Hmgu}/Tcp)	increased lymphocyte cell number	J:211773
\C9^em1Sjlg/\C9⁺ (C57BL/6-C9^em1Sjlg)	impaired complement classical pathway	J:301607
\C9^em1Sjlg/\C9^em1Sjlg (C57BL/6-C9^em1Sjlg)	decreased interleukin-1 beta secretion	J:301607
	decreased susceptibility to endotoxin shock	J:301607
	impaired complement classical pathway	J:301607
\C9orf72^em1Eggn/\C9orf72^em1Eggn (involves: C57BL/6)	enlarged cervical lymph nodes	J:240357
	enlarged spleen	J:240357
	increased anti-double stranded DNA antibody level	J:240357
\C9orf72^em5Lutzy/\C9orf72^em5Lutzy (C57BL/6-C9orf72^em5Lutzy)	abnormal macrophage physiology	J:101977
	abnormal microglial cell physiology	J:101977
	enlarged lymph nodes	J:101977
	enlarged spleen	J:101977
\C9orf72^{tm1.1(KOMP)Mbp}/\C9orf72^{tm1.1(KOMP)Mbp} (C57BL/6N-C9orf72^{tm1.1(KOMP)Mbp}/Ucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\C9orf72^tm1.1Eggn/\C9orf72⁺ (involves: C57BL/6 * C57BL/6N)	abnormal circulating interleukin level	J:240357
	decreased circulating interleukin-2 level	J:240357
	dermatitis	J:240357
	increased autoantibody level	J:240357
	increased IgG level	J:240357
	increased IgM level	J:240357
\C9orf72^tm1.1Eggn/\C9orf72^tm1.1Eggn (involves: C57BL/6 * C57BL/6N)	abnormal circulating cytokine level	J:240357
	abnormal lymphocyte morphology	J:240357
	abnormal spleen morphology	J:240357
	brain inflammation	J:240357
	dermatitis	J:240357
	enlarged spleen	J:240357
	increased anti-double stranded DNA antibody level	J:240357
	increased autoantibody level	J:240357
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:240357
	increased IgG level	J:240357
	increased IgM level	J:240357
	increased leukocyte cell number	J:240357
	increased neutrophil cell number	J:240357
	increased splenocyte number	J:240357
	increased susceptibility to autoimmune disorder	J:240357
	liver inflammation	J:240357
\C9orf72^tm1Eggn/\C9orf72⁺ (involves: C57BL/6 * C57BL/6N)	dermatitis	J:240357
\C9orf72^tm1Eggn/\C9orf72^tm1Eggn (involves: C57BL/6 * C57BL/6N)	abnormal circulating cytokine level	J:240357
	abnormal lymphocyte morphology	J:240357
	dermatitis	J:240357
	enlarged cervical lymph nodes	J:240357
	enlarged spleen	J:240357
	increased anti-double stranded DNA antibody level	J:240357
	increased leukocyte cell number	J:240357
	increased neutrophil cell number	J:240357
	increased susceptibility to autoimmune disorder	J:240357
\C9orf72^tm1Lagi/\C9orf72^tm1Lagi (involves: C57BL/6 * C57BL/6N)	abnormal celiac lymph node morphology	J:232242
	abnormal cervical lymph node morphology	J:232242
	abnormal lymph node cell ratio	J:232242
	decreased lymphocyte cell number	J:232242
	enlarged cervical lymph nodes	J:232242
	enlarged spleen	J:232242
	increased neutrophil cell number	J:232242
\Cab39^em1(IMPC)Tcp/\Cab39⁺ (C57BL/6NCrl-Cab39^em1(IMPC)Tcp/Cmmr)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Cabin1^{em1(IMPC)Ccpcz}/\Cabin1⁺ (C57BL/6NCrl-Cabin1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Cabin1^tm1.1Che/\Cabin1^tm1.1Che (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:72760
	abnormal humoral immune response	J:72760
	immune system phenotype	J:72760
	increased IgE level	J:72760
	increased IgG1 level	J:72760
	increased IgG2b level	J:72760
\Cabp1^{tm1b(EUCOMM)Wtsi}/\Cabp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cabp1^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Cacna1a^tg-6J/\Cacna1a^tg-6J (involves: BALB/cByJ * C57BL/6J)	abnormal spleen red pulp morphology	J:82238
	thymus atrophy	J:82238
\Cacna1c^tm2Itl/\Cacna1c⁺ (involves: 129S6/SvEvTac * C57BL/6NTac)	dermatitis	J:201506
\Cacna1g^em1(IMPC)Mbp/\Cacna1g^em1(IMPC)Mbp (C57BL/6N-Cacna1g^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Cacna1i^{tm1b(KOMP)Wtsi}/\Cacna1i^{tm1b(KOMP)Wtsi} (C57BL/6N-Cacna1i^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Cacna2d1^em1(IMPC)Mbp/\Cacna2d1^em1(IMPC)Mbp (C57BL/6N-Cacna2d1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
\Cacna2d2^du-td/\Cacna2d2^du-td (involves: DBA/2J)	abnormal thymus involution	J:12166
\Cacna2d2^em1(IMPC)Mbp/\Cacna2d2⁺ (C57BL/6N-Cacna2d2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Cacna2d2^em1(IMPC)Mbp/\Cacna2d2^em1(IMPC)Mbp (C57BL/6N-Cacna2d2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Cacna2d2^tm1Svi/\Cacna2d2^tm1Svi (involves: 129S1/Sv * C57BL/6J)	rhinitis	J:92396
	thymus hypoplasia	J:92396
\Cacna2d3^{Tn(pb-Act-RFP)1.1Zhu}/\Cacna2d3^{Tn(pb-Act-RFP)1.1Zhu} (FVB/NJ-Cacna2d3^{Tn(pb-Act-RFP)1.1Zhu})	abnormal macrophage physiology	J:267961
	increased susceptibility to bacterial infection	J:267961
\Cacnb3^tm1Acv/\Cacnb3^tm1Acv (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD4-positive, alpha-beta T cell physiology	J:115345
	abnormal interleukin secretion	J:115345
	decreased interferon-gamma secretion	J:115345
\Cacnb4^lh/\Cacnb4^lh (B6EiC3Sn a/A-Cacnb4^lh/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:115345
	abnormal interleukin secretion	J:115345
	abnormal lymph node morphology	J:5281
	abnormal Peyer's patch germinal center morphology	J:5281
	abnormal thymus involution	J:5281
	absent thymus corticomedullary boundary	J:5281
	decreased double-positive T cell number	J:115345
	decreased interferon-gamma secretion	J:115345
	decreased interleukin-2 secretion	J:115345
	decreased lymphocyte cell number	J:5281
	decreased Peyer's patch number	J:5281
	enlarged lymph nodes	J:5281
	small Peyer's patches	J:5281
	small spleen	J:5281
	small thymus	J:5281
\Cacnb4^lh/\Cacnb4^lh (BALB/cGn-Cacnb4^lh)	abnormal thymus involution	J:12166
\Cacnb4^lh/\Cacnb4^lh (BALB/cGn-Cacnb4^lh)	increased length of allograft survival	J:5766
\Cacnb4^lh/\Cacnb4^lh (involves: BALB/cGn)	increased IgG1 level	J:5883
\Cactin^{em1(IMPC)Ccpcz}/\Cactin⁺ (C57BL/6NCrl-Cactin^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Cacybp^{GT(OST39970)Lex}/\Cacybp^{GT(OST39970)Lex} (involves: 129S5/SvEvBrd)	abnormal spleen white pulp morphology	J:110899
	abnormal T cell morphology	J:110899
	decreased thymocyte number	J:110899
	small thymus medulla	J:110899
	spleen hypoplasia	J:110899
	thymus hypoplasia	J:110899
\Cacybp^{tm1b(EUCOMM)Wtsi}/\Cacybp⁺ (C57BL/6N-Cacybp^{tm1b(EUCOMM)Wtsi}/Tcp)	increased neutrophil cell number	J:211773
\Cadm1^{Gt(Ayu21-W34)Imeg}/\Cadm1^{Gt(Ayu21-W34)Imeg} (involves: C57BL/6 * CBA/JNCrlj)	abnormal T cell differentiation	J:178612
	abnormal T cell receptor V(D)J recombination	J:178612
	decreased CD4-positive, alpha-beta T cell number	J:178612
	decreased CD8-positive, alpha-beta T cell number	J:178612
	decreased interferon-gamma secretion	J:178612
	decreased interleukin-2 secretion	J:178612
	decreased interleukin-4 secretion	J:178612
	decreased T cell proliferation	J:178612
	increased double-positive T cell number	J:178612
\Cadps2^{em1(IMPC)Rbrc}/\Cadps2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Cadps2^{em1(IMPC)Rbrc}/Rbrc)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Calb1^{em1(IMPC)Ccpcz}/\Calb1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Calb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Calcr^tm1Dgal/\Calcr⁺ \Iapp^tm1Sgm/\Iapp⁺ (involves: 129P2/OlaHsd)	increased osteoclast cell number	J:88964
\Calcr^tm1Rda/\Calcr^tm1Rda \Tg(CMV-cre)1Cgn/0 (B6.Cg-Calcr^tm1Rda Tg(CMV-cre)1Cgn)	abnormal osteoclast physiology	J:150982
\Calcrl^tm1Kmca/\Calcrl^tm1Kmca (129S6/SvEvTac-Calcrl^tm1Kmca)	abnormal lymph organ development	J:130930
\Calcrl^tm1Kmca/\Calcrl^tm1Kmca (involves: 129S6/SvEvTac)	decreased uterine NK cell number	J:201446
\Calu^em1(IMPC)Tcp/\Calu⁺ (C57BL/6N-Calu^em1(IMPC)Tcp/Tcp)	small lymph nodes	J:211773
\Camk1d^em1(IMPC)Mbp/\Camk1d^em1(IMPC)Mbp (C57BL/6NCrl-Camk1d^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Camk2g^tm1.1Irt/\Camk2g^tm1.1Irt (involves: C57BL/6 * C57BL/6J)	decreased macrophage apoptosis	J:154647
\Camk2g^tm1.1Irt/\Camk2g^tm1.1Irt (involves: C57BL/6J)	increased susceptibility to colitis induced morbidity/mortality	J:243363
\Camk2g^tm1.1Irt/\Camk2g^tm1.1Irt (involves: C57BL/6J)	increased susceptibility to induced colitis	J:243363
\Camk4^{em1(IMPC)Ccpcz}/\Camk4^{em1(IMPC)Ccpcz} (C57BL/6N-Camk4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Camk4^tm1Tch/\Camk4^tm1Tch (B6.129X1-Camk4^tm1Tch)	abnormal osteoclast differentiation	J:129599
\Camk4^tm1Tch/\Camk4^tm1Tch (B6.129X1-Camk4^tm1Tch)	decreased osteoclast cell number	J:129599
\Caml^tm1Rjb/\Caml^tm2Rjb \Tg(Lck-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased single-positive T cell number	J:100536
	decreased thymocyte number	J:100536
	increased T cell apoptosis	J:100536
\Caml^tm1Rjb/\Caml^tm2Rjb \Tg(Lck-cre)1Cwi/0 \Tg(TcraTcrb)1100Mjb/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal negative T cell selection	J:100536
	abnormal positive T cell selection	J:100536
	decreased thymocyte number	J:100536
\Camp^tm1.1Jimw/\Camp^tm1.1Jimw (involves: C57BL/6)	decreased dendritic cell number	J:199611
\Camp^tm1Rlg/\Camp⁺ (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to bacterial infection	J:72924
\Camp^tm1Rlg/\Camp^tm1Rlg (involves: 129X1/SvJ * C57BL/6)	increased incidence of corneal inflammation	J:199719
	increased neutrophil cell number	J:199719
	increased susceptibility to bacterial infection	J:72924
	increased susceptibility to fungal infection	J:199719
\Camp^tm1Rlg/\Camp^tm1Rlg (129X1(B6)-Camp^tm1Rlg/Kini)	increased susceptibility to bacterial infection	J:109553
\Camp^tm1Rlg/\Camp^tm1Rlg (129X1(B6)-Camp^tm1Rlg/Kini)	increased susceptibility to bacterial infection induced morbidity/mortality	J:109553
\Camsap3^{tm1a(EUCOMM)Wtsi}/\Camsap3^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Camsap3^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased gamma-delta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cand1^em1(IMPC)Mbp/\Cand1⁺ (C57BL/6NCrl-Cand1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Canx^{em1(IMPC)Ccpcz}/\Canx⁺ (C57BL/6NCrl-Canx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Canx^{em1(IMPC)Ccpcz}/\Canx^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Canx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Canx^{Gt(KST286)Byg}/\Canx^{Gt(KST286)Byg} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:164553
\Cap2^{tm1a(EUCOMM)Wtsi}/\Cap2^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	eye inflammation	J:234044
	increased susceptibility to infection	J:234044
\Capg^tm1Djk/\Capg^tm1Djk (involves: 129S4/SvJae)	abnormal macrophage physiology	J:86517
\Capg^tm1Djk/\Capg^tm1Djk (involves: 129S4/SvJae)	impaired macrophage phagocytosis	J:86517
\Capg^tm1Djk/\Capg^tm1Djk (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal dendritic cell physiology	J:86277
	impaired macrophage phagocytosis	J:86277
	impaired neutrophil chemotaxis	J:86277
	increased susceptibility to bacterial infection	J:86277
\Capg^tm1Djk/\Capg^tm1Djk \Gsn^tm1Djk/\Gsn^tm1Djk (involves: 129S4/SvJae)	abnormal macrophage physiology	J:86517
	impaired macrophage phagocytosis	J:86517
\Capn1^tm1Dgen/\Capn1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:183585
\Capn5^tm1Nde/\Capn5^tm1Nde (involves: 129X1/SvJ * C57BL/6J)	immune system phenotype	J:87678
\Capop^NOD/\Capop^NOD (involves: C57BL/6 * NOD)	decreased T cell apoptosis	J:68151
\Capza1^em1(IMPC)Tcp/\Capza1^em1(IMPC)Tcp (C57BL/6NCrl-Capza1^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Capza2^{tm1b(KOMP)Wtsi}/\Capza2^{tm1b(KOMP)Wtsi} (C57BL/6N-Capza2^{tm1b(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Car2^{tm1(KOMP)Vlcg}/\Car2^{tm1(KOMP)Vlcg} (involves: C57BL/6 * C57BL/6NTac)	increased susceptibility to bacterial infection	J:216402
	pyelonephritis	J:216402
\Car6^{em1(IMPC)Ccpcz}/\Car6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Car6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased NK cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
\Car6^tm1Pwp/\Car6^tm1Pwp (B6.129S6-Car6^tm1Pwp)	abnormal Peyer's patch follicle morphology	J:172854
\Car9^tm1Lex/\Car9^tm1Lex (B6;129S5-Car9^tm1Lex/Mmucd)	increased mature B cell number	J:171883
\Card6^tm1.1Aldu/\Card6^tm1.1Aldu (B6.129P2-Card6^tm1.1Aldu)	immune system phenotype	J:132634
\Card9^tm1Jrld/\Card9^tm1Jrld (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:111706
\Card9^tm1Jrld/\Card9^tm1Jrld (involves: 129P2/OlaHsd)	increased susceptibility to fungal infection	J:111706
\Card9^tm1Tks/\Card9^tm1Tks (B6.129-Card9^tm1Tks)	abnormal chemokine secretion	J:141143
	abnormal cytokine secretion	J:122394
	abnormal dendritic cell physiology	J:122394
	abnormal macrophage physiology	J:141143, J:122394
	decreased interleukin-6 secretion	J:160680
	decreased interleukin-10 secretion	J:160680
	decreased interleukin-12b secretion	J:160680
	decreased interleukin-23 secretion	J:160680
	decreased tumor necrosis factor secretion	J:160680
	immune system phenotype	J:122394
	increased susceptibility to bacterial infection	J:122394
\Card9^tm1Xlin/\Card9^tm1Xlin (involves: 129/Sv * C57BL/6)	abnormal cytokine level	J:117799
	abnormal innate immunity	J:117799
	abnormal macrophage physiology	J:117799
	increased susceptibility to bacterial infection	J:117799
\Card11^{em1(IMPC)Ccpcz}/\Card11^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Card11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
	small spleen	J:211773
\Card11^em1Welu/\Card11⁺ (involves: C57BL/6)	decreased marginal zone B cell number	J:292926
	decreased transitional stage T1 B cell number	J:292926
	decreased transitional stage T3 B cell number	J:292926
	impaired humoral immune response	J:292926
	increased transitional stage T2 B cell number	J:292926
\Card11^em1Welu/\Card11^em1Welu (involves: C57BL/6)	abnormal B cell differentiation	J:292926
	abnormal germinal center B cell morphology	J:292926
	abnormal plasma cell differentiation	J:292926
	decreased B cell proliferation	J:292926
	decreased B-1 B cell number	J:292926
	decreased B-1a cell number	J:292926
	decreased germinal center B cell number	J:292926
	decreased IgG level	J:292926
	decreased IgM level	J:292926
	decreased marginal zone B cell number	J:292926
	decreased pre-B cell number	J:292926
	decreased transitional stage T1 B cell number	J:292926
	decreased transitional stage T3 B cell number	J:292926
	impaired humoral immune response	J:292926
	increased follicular B cell number	J:292926
	increased transitional stage T2 B cell number	J:292926
\Card11^em2Welu/\Card11⁺ (involves: C57BL/6)	increased B-1 B cell number	J:292926
\Card11^em2Welu/\Card11⁺ (involves: C57BL/6)	increased marginal zone B cell number	J:292926
\Card11^em2Welu/\Card11^em2Welu (involves: C57BL/6)	abnormal plasma cell differentiation	J:292926
	decreased mature B cell number	J:292926
	enlarged spleen	J:292926
	increased B cell proliferation	J:292926
	increased B-1a cell number	J:292926
	increased B-1b cell number	J:292926
	increased germinal center B cell number	J:292926
	increased marginal zone B cell number	J:292926
	increased pre-B cell number	J:292926
	increased transitional stage T2 B cell number	J:292926
\Card11^em3Welu/\Card11^em3Welu (Not Specified)	decreased B-1 B cell number	J:292926
\Card11^em3Welu/\Card11^em3Welu (Not Specified)	decreased marginal zone B cell number	J:292926
\Card11^m1Btlr/\Card11^m1Btlr (C57BL/6J-Card11^m1Btlr)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:149767
	abnormal cytokine secretion	J:149767
	abnormal cytotoxic T cell physiology	J:139069
	abnormal double-negative T cell morphology	J:149767, J:139069
	abnormal NK cell physiology	J:139069
	abnormal T cell activation	J:139069
	decreased B cell proliferation	J:149767, J:139069
	decreased B-1 B cell number	J:149767, J:139069
	decreased gamma-delta T cell number	J:149767, J:139069
	decreased IgG1 level	J:149767, J:139069
	decreased IgG2a level	J:149767, J:139069
	decreased IgG2b level	J:149767, J:139069
	decreased IgG2c level	J:149767
	decreased IgG3 level	J:149767, J:139069
	decreased IgM level	J:149767, J:139069
	decreased immunoglobulin level	J:139069
	decreased interferon-gamma secretion	J:139069
	decreased interleukin-2 secretion	J:139069
	decreased mature B cell number	J:149767, J:139069
	decreased memory T cell number	J:149767, J:139069
	decreased NK cell number	J:149767, J:139069
	decreased NK T cell number	J:149767, J:139069
	decreased regulatory T cell number	J:149767
	decreased T cell proliferation	J:149767, J:139069
	dermatitis	J:149767, J:139069
	immune system phenotype	J:139069
\Card11^M2Btlr/\Card11^M2Btlr (involves: C57BL/6J)	decreased IgM level	J:198555
\Card11^m3Btlr/\Card11^m3Btlr (C57BL/6J-Card11^m3Btlr)	increased B-1a cell number	J:221487
\Card11^M4Btlr/\Card11⁺ (C57BL/6J-Card11^M4Btlr)	decreased B-1a cell number	J:254856
\Card11^M4Btlr/\Card11⁺ (C57BL/6J-Card11^M4Btlr)	increased B-1b cell number	J:254856
\Card11^M4Btlr/\Card11^M4Btlr (C57BL/6J-Card11^M4Btlr)	decreased B-1a cell number	J:254856
	decreased IgM level	J:254856
	impaired humoral immune response	J:254856
	increased B-1b cell number	J:254856
\Card11^M5Btlr/\Card11⁺ (C57BL/6J-Card11^M5Btlr)	decreased IgM level	J:254879
	impaired humoral immune response	J:254879
	increased B-1 B cell number	J:254879
	increased B-1a cell number	J:254879
\Card11^M5Btlr/\Card11^M5Btlr (C57BL/6J-Card11^M5Btlr)	decreased IgM level	J:254879
	impaired humoral immune response	J:254879
	increased B-1 B cell number	J:254879
	increased B-1a cell number	J:254879
\Card11^M6Btlr/\Card11^M6Btlr (C57BL/6J-Card11^M6Btlr)	increased alpha-beta T cell number	J:272116
\Card11^M7Btlr/\Card11^M7Btlr (C57BL/6J-Card11^M7Btlr)	abnormal T cell differentiation	J:274762
	decreased B cell number	J:274762
	decreased B-1 B cell number	J:274762
	decreased central memory CD4-positive, alpha-beta T cell number	J:274762
	decreased effector memory CD4-positive, alpha-beta T cell number	J:274762
	decreased effector memory CD8-positive, alpha-beta T cell number	J:274762
	increased CD4-positive, alpha-beta T cell number	J:274762
	increased CD8-positive, alpha-beta T cell number	J:274762
	increased T cell number	J:274762
\Card11^m8Btlr/\Card11^m8Btlr (C57BL/6J-Card11^m8Btlr)	abnormal B cell differentiation	J:274940
	decreased B cell number	J:274940
	decreased B-1a cell number	J:274940
	decreased effector memory CD8-positive, alpha-beta T cell number	J:274940
	decreased IgG level	J:274940
	decreased IgM level	J:274940
	decreased response to antigen	J:274940
	impaired humoral immune response	J:274940
	increased B-1b cell number	J:274940
	increased CD4-positive, alpha-beta T cell number	J:274940
	increased CD8-positive, alpha-beta T cell number	J:274940
	increased NK T cell number	J:274940
	increased T cell number	J:274940
\Card11^tm1.1Litt/\Card11^tm1.1Litt \Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/\Gt(ROSA)26Sor⁺ \Tg(TcraTcrb)425Cbn/? (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal T cell activation	J:180410
\Card11^tm1.1Litt/\Card11^tm1.1Litt \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal T cell activation	J:180410
	immune system phenotype	J:180410
	respiratory system inflammation	J:180410
\Card11^tm1Litt/\Card11^tm1Litt (involves: 129P2/OlaHsd)	abnormal B cell proliferation	J:89322
	abnormal double-negative T cell morphology	J:89322
	abnormal T cell activation	J:89322
	abnormal T cell differentiation	J:89322
	abnormal T cell proliferation	J:89322
	absent B-1a cells	J:89322
	decreased IgA level	J:89322
	decreased IgG1 level	J:89322
	decreased IgG2b level	J:89322
	decreased IgG3 level	J:89322
	decreased IgM level	J:89322
	decreased immunoglobulin level	J:89322
\Card11^tm1Pngr/\Card11^tm1Pngr (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:84036
	abnormal B cell physiology	J:84036
	abnormal interleukin-2 secretion	J:84036
	abnormal lymphocyte morphology	J:84036
	abnormal T cell activation	J:84036
	absent B-1a cells	J:84036
	decreased B cell proliferation	J:84036
	decreased IgA level	J:84036
	decreased IgE level	J:84036
	decreased IgG1 level	J:84036
	decreased IgG2a level	J:84036
	decreased IgG2b level	J:84036
	decreased IgG3 level	J:84036
	decreased IgG level	J:84036
	decreased IgM level	J:84036
	decreased immunoglobulin level	J:84036
	decreased NK cell number	J:84036
\Card11^tm1Pngr/\Card11^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:122394
\Card11^tm1Vmd/\Card11⁺ (involves: 129S6/SvEvTac * C57BL/6N)	decreased B cell proliferation	J:95800
\Card11^tm1Vmd/\Card11^tm1Vmd (involves: 129S6/SvEvTac * C57BL/6N)	abnormal B cell physiology	J:95800
	absent immature B cells	J:95800
	decreased B cell proliferation	J:95800
	decreased IgA level	J:95800
	decreased IgG1 level	J:95800
	decreased IgG2a level	J:95800
	decreased IgG2b level	J:95800
	decreased IgG3 level	J:95800
	decreased IgG level	J:95800
	decreased IgM level	J:95800
	decreased T cell proliferation	J:95800
\Card11^tm1Xav/\Card11^tm1Xav (involves: 129 * C57BL/6)	abnormal T cell activation	J:132226
	abnormal T-helper 2 cell differentiation	J:132226
	decreased circulating interleukin-4 level	J:132226
	decreased circulating interleukin-5 level	J:132226
	decreased IgE level	J:132226
	increased CD4-positive, alpha-beta T cell number	J:132226
	increased CD8-positive, alpha-beta T cell number	J:132226
	lung inflammation	J:132226
\Card11^unm/\Card11^unm (C57BL/6JSfdAnu-Card11^unm/Anu)	abnormal B cell differentiation	J:84042
	abnormal immune system physiology	J:84042
	abnormal T cell activation	J:84042
	decreased B-1 B cell number	J:84042
	decreased IgG3 level	J:84042
	decreased IgM level	J:84042
	decreased immunoglobulin level	J:84042
	dermatitis	J:84042
	erythroderma	J:84042
	increased IgE level	J:84042
	increased immunoglobulin level	J:84042
	increased inflammatory response	J:84042
	lymph node hyperplasia	J:84042
	spleen hyperplasia	J:84042
\Card14^{em1(IMPC)Ccpcz}/\Card14^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Card14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Card14^em1Maak/\Card14^em1Maak (C57BL/6JJmsSlc-Card14^em1Maak)	skin inflammation	J:360877
\Card14^em1Tshu/\Card14^em1Tshu (C57BL/6-Card14^em1Tshu)	decreased susceptibility to chemically induced skin inflammation	J:289239
\Card14^em2Tshu/\Card14⁺ (involves: C57BL/6)	abnormal gamma-delta T cell number	J:289239
	increased alpha-beta T cell number	J:289239
	skin inflammation	J:289239
\Card14^em3Tshu/\Card14⁺ (involves: C57BL/6)	skin inflammation	J:289239
\Card14^em3Tshu/\Card14⁺ \Il17a^tm1Cdon/\Il17a^tm1Cdon (involves: C57BL/6)	decreased inflammatory response	J:289239
\Card14^em9Lutzy/\Card14⁺ (C57BL/6J-Card14^em9Lutzy/J)	skin inflammation	J:262723
\Card14^tm1Lex/\Card14^tm1Lex (B6.129S-Card14^tm1Lex)	decreased susceptibility to chemically induced skin inflammation	J:253409
\Card19^tm1Rwen/\Card19^tm1Rwen (involves: 129P2/OlaHsd * C57BL/6)	decreased autoantibody level	J:336763
	immune system phenotype	J:336763
\Card19^tm1Rwen/\Card19^tm1Rwen \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:336763
\Card19^tm1Rwen/\Card19^tm1Rwen \Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JSfd)	decreased B cell number	J:336763
	decreased B cell proliferation	J:336763
	increased B cell apoptosis	J:336763
	increased B cell number	J:336763
\Carm1^{tm1b(EUCOMM)Hmgu}/\Carm1⁺ (C57BL/6N-Carm1^{tm1b(EUCOMM)Hmgu}/Nju)	decreased lymphocyte cell number	J:211773
\Carm1^tm1Mtb/\Carm1^tm1Mtb (involves: 129S6/SvEvTac)	arrested T cell differentiation	J:159958
\Carm1^tm2.1Mtb/\Carm1^tm2.1Mtb (involves: 129S4/SvJaeSor * 129S6/SvEvTac * Black Swiss)	arrested T cell differentiation	J:159958
	thymus hypoplasia	J:159958
\carmelo/\carmelo (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:220661
\Carmil2^bas/\Carmil2^bas (involves: C3HeB/FeJ * C57BL/6)	decreased interferon-gamma secretion	J:205441
	decreased interleukin-2 secretion	J:205441
	decreased regulatory T cell number	J:205441
	decreased T cell proliferation	J:205441
	enlarged thymus	J:205441
	immune system phenotype	J:205441
\Carmil2^bas/\Carmil2^{tm1a(KOMP)Mbp} (involves: C3HeB/FeJ * C57BL/6 * C57BL/6N)	decreased interleukin-2 secretion	J:205441
	decreased regulatory T cell number	J:205441
	decreased T cell proliferation	J:205441
\Carmil3^em1(IMPC)Mbp/\Carmil3^em1(IMPC)Mbp (C57BL/6N-Carmil3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Cartpt^tm1Hmh/\Cartpt^tm1Hmh (Not Specified)	abnormal osteoclast morphology	J:97566
\Cartpt^tm1Hmh/\Cartpt^tm1Hmh (Not Specified)	increased osteoclast cell number	J:97566
\Casp1^tm1Flv/\Casp1^tm1Flv \Casp4^del/\Casp4^del (involves: 129S2/SvPas * C57BL/6)	abnormal cytokine secretion	J:24258
	decreased circulating interferon-gamma level	J:115310
	decreased interferon-gamma secretion	J:115310
	decreased interleukin-1 alpha secretion	J:24258
	decreased interleukin-1 beta secretion	J:24258
	decreased interleukin-6 secretion	J:24258
	decreased interleukin-18 secretion	J:115310
	decreased susceptibility to endotoxin shock	J:43088
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:57101
	decreased thymocyte apoptosis	J:24258
	decreased tumor necrosis factor secretion	J:24258
	impaired neutrophil chemotaxis	J:124226
	increased susceptibility to bacterial infection	J:117251
\Casp1^tm1Flv/\Casp1^tm1Flv \Casp4^del/\Casp4^del (B6.129S2-Casp1^tm1Flv)	decreased interleukin-1 beta secretion	J:160545
	increased susceptibility to induced colitis	J:173245
\Casp1^tm1Flv/\Casp1^tm1Flv \Casp4^del/\Casp4^del \Il1r1^tm1Imx/\Il1r1^tm1Imx (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to endotoxin shock	J:43088
\Casp1^tm1Flv/\Casp1^tm1Flv \Casp4^del/\Casp4^del \Slc11a1^r/\Slc11a1^r (involves: 129S2/SvPas)	increased susceptibility to bacterial infection	J:124378
\Casp1^tm1Flv/\Casp1^tm1Flv \Casp4^del/\Casp4^del \Slc11a1^s/\Slc11a1^s (B6.129S2-Casp1^tm1Flv)	cecum inflammation	J:124378
	increased susceptibility to bacterial infection	J:124378
\Casp1^tm1Sesh/\Casp1⁺ \Casp4^del/\Casp4⁺ (involves: 129S2/SvPas * C57BL/6)	decreased interleukin-1 beta secretion	J:22964
\Casp1^tm1Sesh/\Casp1⁺ \Casp4^del/\Casp4⁺ (involves: 129S1/SvImJ * 129S2/SvPas * NOD)	abnormal macrophage physiology	J:99748
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del (involves: 129S2/SvPas * C57BL/6)	abnormal inflammatory response	J:80568
	abnormal macrophage physiology	J:22964
	abnormal neutrophil physiology	J:80568
	decreased circulating interleukin-1 alpha level	J:22964
	decreased circulating interleukin-1 beta level	J:22964
	decreased circulating interleukin-6 level	J:22964
	decreased circulating tumor necrosis factor level	J:22964
	decreased interleukin-1 alpha secretion	J:22964
	decreased interleukin-1 beta secretion	J:88212, J:22964
	decreased susceptibility to endotoxin shock	J:22964, J:40691
	decreased T cell apoptosis	J:40691
	immune system phenotype	J:40691
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del (NOD.129S2(B6)-Casp1^tm1Sesh Casp4^del/LtJ)	decreased interleukin-1 alpha secretion	J:87250
	decreased interleukin-1 beta secretion	J:87250
	decreased interleukin-18 secretion	J:87250
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del (C3N.129S2-Casp1^tm1Sesh Casp4^del)	abnormal response to infection	J:86761
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del (B10.Cg-Casp1^tm1Sesh Casp4^del H2^r H2-T18^b)	decreased inflammatory response	J:63488
	decreased susceptibility to bacterial infection	J:63488
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:63488
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del (involves: 129 * 129S2/SvPas * C57BL/6)	decreased interleukin-1 beta secretion	J:50775
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del (C3.129S2-Casp1^tm1Sesh Casp4^del)	abnormal macrophage physiology	J:136368
	decreased interleukin-1 beta secretion	J:136368
	increased susceptibility to bacterial infection	J:136368
	increased susceptibility to bacterial infection induced morbidity/mortality	J:136368
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del (B6.129S2(NOD)-Casp1^tm1Sesh Casp4^del)	decreased circulating interleukin-1 alpha level	J:193522
	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 alpha secretion	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased interleukin-18 secretion	J:193522
	decreased macrophage apoptosis	J:193522
	decreased susceptibility to endotoxin shock	J:193522
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del \Slc11a1^r/\Slc11a1^s (involves: 129/Sv * 129S2/SvPas * C57BL/6)	increased susceptibility to bacterial infection	J:112400
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del \Slc11a1^s/\Slc11a1^s (B6.129S2-Casp1^tm1Sesh Casp4^del)	abnormal macrophage physiology	J:112400
	increased susceptibility to bacterial infection	J:112400
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Casp4^del/\Casp4^del \Tg(Casp4)#Gne/0 (involves: 129S2/SvPas * C57BL/6 * NOD/ShiLtJ)	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 alpha secretion	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased interleukin-18 secretion	J:193522
	decreased macrophage apoptosis	J:193522
	decreased susceptibility to endotoxin shock	J:193522
\Casp1^tm1Sesh/\Casp1^tm1Sesh \Nlrp1a^Neut1/\Nlrp1a^Neut1 (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:191055
	increased circulating interleukin-18 level	J:191055
\Casp2^tm1Vaux/\Casp2^tm1Vaux \Casp9^tm1Flv/\Casp9^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal T cell physiology	J:91156
\Casp2^tm1Yuan/\Casp2^tm1Yuan (involves: 129S4/SvJae * C57BL/6J * DBA/2)	abnormal B cell apoptosis	J:47601
\Casp3^tm1Flv/\Casp3^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal bone marrow development	J:94703
	abnormal osteoclast physiology	J:94703
	decreased thymocyte number	J:36821
	immune system phenotype	J:36821
\Casp3^tm1Flv/\Casp3^tm1Flv \Casp7^tm1Flv/\Casp7⁺ (B6.129S-Casp3^tm1Flv Casp7^tm1Flv)	decreased thymocyte apoptosis	J:105496
\Casp3^tm1Flv/\Casp3^tm1Flv \Casp7^tm1Flv/\Casp7^tm1Flv (B6.129S-Casp3^tm1Flv Casp7^tm1Flv)	decreased thymocyte apoptosis	J:105496
\Casp3^tm1Flv/\Casp3^tm1Flv \Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0 (involves: 129S1/Sv * C57BL/6 * CBA)	increased lymphocyte cell number	J:100854
	increased macrophage cell number	J:100854
	increased neutrophil cell number	J:100854
\Casp3^tm1Mak/\Casp3^tm1Mak (B6.129P2-Casp3^tm1Mak)	decreased inflammatory response	J:97650, J:179279
\Casp3^tm1Mak/\Casp3^tm1Mak \Tg(TcrLCMV)327Sdz/0 (B6.Cg-Casp3^tm1Mak Tg(TcrLCMV)327Sdz)	abnormal CD8-positive, alpha beta T cell morphology	J:97650
\Casp4^tm1.1Vmd/\Casp4^tm1.1Vmd (involves: C57BL/6)	decreased circulating interleukin-1 alpha level	J:193522
	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 alpha secretion	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased macrophage apoptosis	J:193522
	decreased susceptibility to endotoxin shock	J:193522
\Casp4^tm1Yuan/\Casp4^tm1Yuan (involves: 129S4/SvJae * C57BL/6J * DBA/2)	decreased circulating interleukin-1 alpha level	J:46167
	decreased circulating interleukin-1 beta level	J:46167
	decreased susceptibility to endotoxin shock	J:46167
\Casp4^tm1Yuan/\Casp4^tm1Yuan (B6.129S4(D2)-Casp4^tm1Yuan/J)	decreased interleukin-1 beta secretion	J:270123
	decreased interleukin-18 secretion	J:270123
\Casp7^tm1.1Acau/\Casp7^tm1.1Acau (B6.Cg-Casp7^tm1.1Acau)	immune system phenotype	J:179279
\Casp7^tm1Flv/\Casp7^tm1Flv (B6.129S6-Casp7^tm1Flv)	immune system phenotype	J:105496
\Casp8^em1Hbz/\Casp8^em1Hbz (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:342732
\Casp8^em1Hbz/\Casp8^em1Hbz (involves: C57BL/6)	enlarged spleen	J:342732
\Casp8^em1Hbz/\Casp8^em1Hbz \Mlkl^em1Hbz/\Mlkl^em1Hbz (involves: C57BL/6)	decreased B cell number	J:342732
	decreased leukocyte cell number	J:342732
	decreased lymphocyte cell number	J:342732
	decreased mature B cell number	J:342732
	decreased T cell number	J:342732
	enlarged spleen	J:342732
	increased CD11b-high dendritic cell number	J:342732
	increased granulocyte number	J:342732
	increased macrophage cell number	J:342732
\Casp8^em1Hbz/\Casp8^em1Hbz \Ripk1^em1Hbz/\Ripk1^em1Hbz \Ripk3^tm1Xidw/\Ripk3^tm1Xidw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased leukocyte cell number	J:342732
	decreased lymphocyte cell number	J:342732
	decreased mature B cell number	J:342732
	decreased T cell number	J:342732
\Casp8^em1Hbz/\Casp8^em1Hbz \Ripk3^tm1Xidw/\Ripk3^tm1Xidw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased B cell number	J:342732
	decreased leukocyte cell number	J:342732
	decreased lymphocyte cell number	J:342732
	decreased mature B cell number	J:342732
	decreased T cell number	J:342732
	enlarged spleen	J:342732
	increased CD11b-high dendritic cell number	J:342732
	increased granulocyte number	J:342732
	increased macrophage cell number	J:342732
\Casp8^m1Btlr/\Casp8^m1Btlr (C57BL/6J-Casp8^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:255007
	decreased CD8-positive, naive alpha-beta T cell number	J:255007
	decreased T cell number	J:255007
	increased CD8-positive, alpha-beta T cell number	J:255007
	increased effector memory CD4-positive, alpha-beta T cell number	J:255007
\Casp8^M2Btlr/\Casp8^M2Btlr (C57BL/6J-Casp8^M2Btlr)	increased effector memory CD8-positive, alpha-beta T cell number	J:272851
\Casp8^tm1.1Raz/\Casp8^tm1.1Raz \Otulin^em1Gvl/\Otulin^em1Gvl \Ripk3^tm1Vmd/\Ripk3^tm1Vmd (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	enlarged lymph nodes	J:312394
	immune system phenotype	J:312394
\Casp8^tm1.1Raz/\Casp8^tm1.1Raz \Ripk3^tm1Vmd/\Ripk3^tm1Vmd (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:170815
	decreased macrophage apoptosis	J:170815
	decreased thymocyte apoptosis	J:170814
	enlarged axillary lymph nodes	J:170815
	enlarged cervical lymph nodes	J:170815
	enlarged lymph nodes	J:170814
	enlarged spleen	J:170815, J:170814
	enlarged thymus	J:170814
	immune system phenotype	J:170815
	increased B cell number	J:170815
	increased inflammatory response	J:170815
	increased leukocyte cell number	J:170815
	increased spleen white pulp amount	J:170815
	increased T cell number	J:170815, J:170814
	large lymphoid organs	J:170814
	lymph node hyperplasia	J:170815
\Casp8^tm1.1Vmd/\Casp8^tm1.1Vmd \Ripk3^tm2Vmd/\Ripk3^tm2Vmd (involves: C57BL/6N)	enlarged lymph nodes	J:209137
	enlarged spleen	J:209137
	increased T cell number	J:209137
\Casp8^tm1Clie/\Casp8^tm1Clie \Tg(Alb1-cre)7Gsc/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	liver inflammation	J:218665
\Casp8^tm1Hed/\Casp8^tm1Hed \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd)	abnormal adaptive immunity	J:116713
	abnormal immunoglobulin level	J:116713
	decreased B cell number	J:116713
	decreased B cell proliferation	J:116713
	decreased B-1 B cell number	J:116713
	decreased marginal zone B cell number	J:116713
	spleen hypoplasia	J:116713
\Casp8^tm1Hed/\Casp8^tm1Hed \Tg(KRT14-cre)1Efu/0 (Not Specified)	abnormal T cell physiology	J:167299
	dermatitis	J:167299
	increased IgE level	J:167299
	increased IgG1 level	J:167299
	increased mast cell number	J:167299
\Casp8^tm1Raz/\Casp8^tm1Raz \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal CD8-positive, alpha-beta T cell physiology	J:82759
	abnormal lymphocyte morphology	J:107455
	abnormal T cell activation	J:107455
	abnormal T cell morphology	J:82759
	abnormal T cell physiology	J:107455
	abnormal T cell proliferation	J:107455
	abnormal T cell subpopulation ratio	J:107455, J:82759
	decreased CD4-positive, alpha-beta T cell number	J:82759
	decreased CD8-positive, alpha-beta T cell number	J:82759
	decreased leukocyte cell number	J:107455
	decreased T cell apoptosis	J:82759
	decreased T cell number	J:82759
	decreased T cell proliferation	J:82759
	enlarged lymph nodes	J:107455
	enlarged spleen	J:107455
	increased B cell number	J:107455
	increased lymphocyte cell number	J:107455
	increased T cell number	J:107455
	lymphoid hyperplasia	J:107455
\Casp8^tm1Wll/\Casp8^tm1.1Yuan \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129S1/Sv * 129X1/SvJ * MF1)	abnormal macrophage differentiation	J:92722
\Casp9^tm1Flv/\Casp9^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal thymocyte apoptosis	J:49088
	decreased T cell apoptosis	J:91156
	immune system phenotype	J:49088
\Casp9^tm1Mak/\Casp9^tm1Mak (either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * CD-1))	abnormal splenocyte apoptosis	J:49087
	abnormal thymocyte apoptosis	J:49087
	immune system phenotype	J:49087
\Casp12^tm1Dwni/\Casp12^tm1Dwni (involves: 129S1/SvImJ * C57BL/6)	decreased susceptibility to bacterial infection	J:144912
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:144912
	increased circulating interleukin-18 level	J:144912
	increased interferon-gamma secretion	J:144912
	increased interleukin-1 beta secretion	J:144912
	increased susceptibility to endotoxin shock	J:144912
\Casp14^{em1(IMPC)Ccpcz}/\Casp14^{em1(IMPC)Ccpcz} (C57BL/6N-Casp14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Casr^Nuf/\Casr^Nuf (involves: 102/El * C3H/He)	tongue inflammation	J:92612
\Casz1^{Gt(CJ0565)Wtsi}/\Casz1^{Gt(CJ0565)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphatic vessel morphology	J:242127
	enlarged lymphatic vessel	J:242127
\Cav1^tm1Mls/\Cav1^tm1Mls (involves: 129/Sv * C57BL/6 * SJL)	abnormal chemokine secretion	J:115914
	abnormal cytokine level	J:115914
	abnormal macrophage physiology	J:115914
	abnormal neutrophil physiology	J:139304
	abnormal osteoclast morphology	J:141361
	decreased susceptibility to endotoxin shock	J:139304
	impaired neutrophil recruitment	J:115914
	increased circulating CXCL10 level	J:115914
	increased circulating interferon-gamma level	J:115914
	increased circulating interleukin-6 level	J:115914
	increased circulating tumor necrosis factor level	J:115914
	increased susceptibility to bacterial infection	J:115914
	increased susceptibility to bacterial infection induced morbidity/mortality	J:115914
	lung inflammation	J:87282
\Cav1^tm1Mls/\Cav1^tm1Mls \Cav3^tm1Mls/\Cav3^tm1Mls (involves: 129/Sv * C57BL/6J * SJL)	heart inflammation	J:77372
\Cbfa2t2^tm1Swh/\Cbfa2t2^tm1Swh (either: B6.129S6-Cbfa2t2^tm1Swh or (involves: 129S6/SvEvTac * C57BL/6))	small intestinal inflammation	J:102172
\Cbfa2t3^tm1.1Swh/\Cbfa2t3^tm1.1Swh (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal myelopoiesis	J:140967
	decreased immature B cell number	J:140967
	enlarged spleen	J:140967
\Cbfb^tm1Itan/\Cbfb^tm1Itan \Rr94^tm3.1Litt/\Rr94^tm3.1Litt \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal double-positive T cell morphology	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased double-positive T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
	increased double-positive T cell number	J:158962
\Cbfb^tm1Itan/\Cbfb^tm1Itan \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:158962, J:125953
	abnormal CD8-positive, alpha-beta T cell number	J:125953
	abnormal T cell differentiation	J:125953
	abnormal T-helper 1 cell differentiation	J:125953
	decreased CD8-positive, alpha-beta T cell number	J:158962
	increased double-positive T cell number	J:158962
	increased IgA level	J:125953
	increased IgE level	J:125953
	increased IgG1 level	J:125953
	increased immunoglobulin level	J:125953
	lung inflammation	J:125953
\Cbfb^tm1Itan/\Cbfb^tm1Itan \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd)	abnormal CD4-positive T cell differentiation	J:125953
	abnormal CD8-positive, alpha-beta T cell differentiation	J:125953
	abnormal double-positive T cell morphology	J:125953
	abnormal T-helper 1 cell differentiation	J:125953
	decreased thymocyte number	J:125953
\Cbfb^tm1Itan/\Cbfb^tm1Itan \Zbtb7b^tm2Litt/\Zbtb7b⁺ \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
\Cbfb^tm1Itan/\Cbfb^tm1Itan \Zbtb7b^tm2Litt/\Zbtb7b^tm1.2Litt \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
\Cbfb^tm1Lhc/\Cbfb^tm1Lhc \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal myelopoiesis	J:105040
	abnormal spleen morphology	J:105040
	enlarged spleen	J:105040
	increased leukocyte cell number	J:105040
\Cbfb^tm1Spe/\Cbfb^tm1Spe \Tg(Tek-GFP/Cbfb)1Spe/0 (either: (involves: 129S4/SvJae * BALB/c * CD-1) or (involves: 129S4/SvJae * C57BL/6 * CD-1))	abnormal myelopoiesis	J:80670
	abnormal splenic cell ratio	J:80670
	increased CD4-positive, alpha-beta T cell number	J:80670
	small thymus	J:80670
	spleen hypoplasia	J:80670
\Cbfb^tm1Spe/\Cbfb^tm1Spe \Tg(Tek-GFP/Cbfb)2Spe/0 (either: (involves: 129S4/SvJae * BALB/c * CD-1 * Swiss Webster) or (involves: 129S4/SvJae * C57BL/6 * CD-1 * Swiss Webster))	abnormal myelopoiesis	J:80670
	abnormal splenic cell ratio	J:80670
	increased CD4-positive, alpha-beta T cell number	J:80670
	small thymus	J:80670
	spleen hypoplasia	J:80670
\Cbfb^tm1Spe/\Cbfb^tm2.1Spe (involves: 129S4/SvJae)	abnormal splenic cell ratio	J:124224
	abnormal T cell differentiation	J:124224
	abnormal thymus cell ratio	J:124224
	abnormal thymus morphology	J:124224
	decreased double-positive T cell number	J:124224
	increased CD4-positive, alpha-beta T cell number	J:124224
	thymus hypoplasia	J:124224
\Cbfb^tm1Tok/\Cbfb^tm1Tok \Tg(Gata1-Cbfb)1Tok/0 (involves: 129P2/OlaHsd * C57BL/6J)	absent T cells	J:80668
	decreased lymphocyte cell number	J:80668
	small spleen	J:80668
	small thymus	J:80668
\Cbfb^tm2.1Spe/\Cbfb^tm2.1Spe (involves: 129S4/SvJae)	abnormal splenic cell ratio	J:124224
	abnormal T cell differentiation	J:124224
	abnormal thymus cell ratio	J:124224
	abnormal thymus morphology	J:124224
	decreased double-positive T cell number	J:124224
	increased CD4-positive, alpha-beta T cell number	J:124224
	thymus hypoplasia	J:124224
\Cbfb^tm2Itan/\Cbfb^tm2Itan (Not Specified)	abnormal lymph organ development	J:168918
	abnormal peripheral lymph node morphology	J:168918
	absent Peyer's patches	J:168918
	decreased Peyer's patch number	J:168918
\Cbfb^tm5Ppl/\Cbfb⁺ (Not Specified)	abnormal mononuclear cell differentiation	J:193140
\Cbfb^tm5Ppl/\Cbfb⁺ (Not Specified)	myeloid hyperplasia	J:193140
\Cbfb^tm6Ppl/\Cbfb⁺ (involves: 129S/SvEv * C57BL/6)	decreased B cell number	J:252447
\Cbl^tm1.1Hua/\Cbl^tm1.1Hua \Lat^tm1Les/\Lat^tm1Les (involves: 129P2/OlaHsd)	abnormal thymus development	J:91369
	increased CD4-positive, alpha-beta T cell number	J:91369
	liver inflammation	J:91369
	lung inflammation	J:91369
	thymus hypoplasia	J:91369
\Cbl^tm1.1Hua/\Cbl^tm1.1Hua \Lcp2^tm1Gak/\Lcp2^tm1Gak (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal cytokine secretion	J:91369
	abnormal T cell differentiation	J:91369
	enlarged spleen	J:91369
	increased CD4-positive, alpha-beta T cell number	J:91369
	liver inflammation	J:91369
	lung inflammation	J:91369
\Cbl^tm1.1Hua/\Cbl^tm1.1Hua \Lcp2^tm1Gak/\Lcp2^tm1Gak \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv * 129S1/Sv * 129X1/SvJ)	abnormal T cell differentiation	J:91369
\Cbl^tm1Ddlb/\Cbl^tm1Ddlb (involves: 129S1/Sv * C57BL/6J)	abnormal lymph node cell ratio	J:76895
	abnormal spleen morphology	J:76895
	abnormal splenic cell ratio	J:76895
	abnormal thymus cell ratio	J:76895
	enlarged lymph nodes	J:76895
	enlarged spleen	J:76895
\Cbl^tm1Ddlb/\Cbl^tm1Ddlb (involves: 129S1/Sv)	abnormal T cell physiology	J:81965
	enlarged spleen	J:81965
	increased spleen red pulp amount	J:81965
	spleen hyperplasia	J:81965
\Cbl^tm1Ddlb/\Cbl^tm1Ddlb (involves: 129S1/Sv * C57BL/6)	enlarged spleen	J:103366
	increased spleen red pulp amount	J:103366
	spleen hyperplasia	J:103366
\Cbl^tm1Ddlb/\Cbl^tm2Wlan (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal double-negative T cell morphology	J:103366
	abnormal lymph node cell ratio	J:103366
	abnormal spleen morphology	J:103366
	abnormal splenic cell ratio	J:103366
	abnormal T cell activation	J:103366
	abnormal T cell differentiation	J:103366
	abnormal T cell physiology	J:103366
	abnormal thymus morphology	J:103366
	abnormal thymus size	J:103366
	decreased single-positive T cell number	J:103366
	enlarged spleen	J:103366
	increased spleen red pulp amount	J:103366
	spleen hyperplasia	J:103366
	thymus hypoplasia	J:103366
\Cbl^tm1Soga/\Cbl^tm1Soga (Not Specified)	enlarged spleen	J:151543
\Cbl^tm1Soga/\Cbl^tm1Soga \Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6 * DBA/2)	enlarged lymph nodes	J:151543
\Cbl^tm1Wlan/\Cbl^tm1Wlan (involves: 129S1/Sv * C57BL/6)	abnormal T cell physiology	J:81965
	enlarged spleen	J:81965
	increased spleen red pulp amount	J:81965
	myeloid hyperplasia	J:81965
	spleen hyperplasia	J:81965
\Cbl^tm2Hua/\Cbl^tm2Hua \Cblb^tm1Hua/\Cblb^tm1Hua \Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * ICR)	abnormal immune system physiology	J:80427
	abnormal T cell morphology	J:80427
	dermatitis	J:80427
	enlarged spleen	J:80427
	increased T cell proliferation	J:80427
\Cbl^tm2Wlan/\Cbl^tm2Wlan (involves: 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:103366
	abnormal thymus morphology	J:103366
	abnormal thymus size	J:103366
	enlarged spleen	J:103366
	increased spleen red pulp amount	J:103366
	spleen hyperplasia	J:103366
	thymus hypoplasia	J:103366
\Cblb^tm1Hua/\Cblb^tm1Hua (Not Specified)	increased T cell proliferation	J:89761
\Cblb^tm1Hua/\Cblb^tm1Hua (B6.129P2-Cblb^tm1Hua)	increased interleukin-2 secretion	J:94685
	increased susceptibility to experimental autoimmune encephalomyelitis	J:94685
	increased T cell proliferation	J:94685
\Cblb^tm1Hua/\Cblb^tm1Hua \Ubash3b^tm1Jni/\Ubash3b^tm1Jni \Ubash3a^tm1Jni/\Ubash3a^tm1Jni (Not Specified)	increased susceptibility to experimental autoimmune encephalomyelitis	J:89761
	increased T cell proliferation	J:89761
\Cblb^tm1Pngr/\Cblb^tm1Pngr (involves: 129 * C57BL/6)	abnormal mast cell physiology	J:126361
	increased interleukin-6 secretion	J:126361
	increased tumor necrosis factor secretion	J:126361
\Cblb^tm1Pngr/\Cblb^tm1Pngr (B6.129P2-Cblb^tm1Pngr)	increased T cell proliferation	J:141390
\Cblb^tm1Pngr/\Cblb^tm1Pngr \Itk^tm1Litt/\Itk^tm1Litt (B6.129-Itk^tm1Litt Cblb^tm1Pngr)	abnormal T cell morphology	J:141390
	abnormal T-helper 2 cell differentiation	J:141390
	decreased interleukin-2 secretion	J:141390
	decreased T cell number	J:141390
	immune system phenotype	J:141390
\Cblb^tm1Pngr/\Cblb^tm1Pngr \Vav1^tm1Tyb/\Vav1^tm1Tyb \Was^tm1Sbs/\Was^tm1Sbs (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)	abnormal T cell physiology	J:79550
\Cblb^tm1Pngr/\Cblb^tm1Pngr \Was^tm1Sbs/\Was^tm1Sbs (Not Specified)	abnormal T cell physiology	J:79550
\Cblb^tm1Wlan/\Cblb^tm1Wlan (involves: 129X1/SvJ * C57BL/6)	abnormal mast cell physiology	J:126361
	increased interleukin-6 secretion	J:126361
	increased tumor necrosis factor secretion	J:126361
\Cblif^{tm1a(KOMP)Wtsi}/\Cblif^{tm1a(KOMP)Wtsi} (C57BL/6N-Cblif^{tm1a(KOMP)Wtsi})	increased CD4-positive, alpha-beta T cell number	J:236022
	increased susceptibility to bacterial infection	J:236022
	increased susceptibility to bacterial infection induced morbidity/mortality	J:236022
	increased T cell number	J:236022
\Cbs^tm1Unc/\Cbs^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal interleukin level	J:101303
	abnormal tumor necrosis factor level	J:101303
	absent uterine NK cells	J:190486
	decreased uterine NK cell number	J:190486
	liver inflammation	J:101303
\Cbs^tm1Unc/\Cbs^tm1Unc \Tg(Mt1-CBSS466L)EB86Waku/0 (involves: 129P2/OlaHsd C3H * C57BL/6)	increased Ly6C high monocyte number	J:168131
	increased monocyte cell number	J:168131
\Cbx1^{em1(IMPC)Ccpcz}/\Cbx1⁺ (C57BL/6NCrl-Cbx1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Cbx2^tm1Cim/\Cbx2^tm1Cim (involves: 129P2/OlaHsd * BALB/c)	arrested T cell differentiation	J:38487
\Cbx2^tm1Cim/\Cbx2^tm1Cim (involves: 129P2/OlaHsd * BALB/c)	decreased splenocyte proliferation	J:38487
\Cbx3^tm1Ics/\Cbx3^tm1Ics (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:186702
\Cbx4^tm1.1Gxu/\Cbx4^tm1.2Gxu \Tg(Foxn1-cre)1Tbo/0 (involves: 129S2/SvPas * C57BL/6J)	abnormal lymphopoiesis	J:194053
	abnormal thymus development	J:194053
	abnormal thymus physiology	J:194053
	decreased double-positive T cell number	J:194053
	decreased T cell number	J:194053
	thymus atrophy	J:194053
	thymus hypoplasia	J:194053
\Cbx4^tm1.2Gxu/\Cbx4^tm1.2Gxu (involves: 129S2/SvPas * C57BL/6J)	abnormal thymus development	J:194053
	abnormal thymus physiology	J:194053
	thymus hypoplasia	J:194053
\Cbx5^{em1(IMPC)Ccpcz}/\Cbx5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cbx5^{em1(IMPC)Ccpcz}/Ccpcz)	increased monocyte cell number	J:211773
\Cbx5^tm1.1Ics/\Cbx5^tm1.1Ics (involves: 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:186702
	immune system phenotype	J:186702
\Cbx6^{tm1a(EUCOMM)Wtsi}/\Cbx6^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cbx6^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Cby1^tm1Ktkm/\Cby1^tm1Ktkm (B6.129-Cby1^tm1Ktkm)	increased susceptibility to bacterial infection	J:147413
	increased susceptibility to otitis media	J:147413
	sinus inflammation	J:147413
\Cc2d1a^{tm1a(KOMP)Wtsi}/\Cc2d1a^{tm1a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased interferon-beta secretion	J:190401
	decreased interleukin-6 secretion	J:190401
\Ccar2^Gt(XN876)Byg/\Ccar2^Gt(XN876)Byg (involves: 129P2/OlaHsd * C57BL/6)	decreased tumor necrosis factor secretion	J:156677
\Ccbe1^tm1Lex/\Ccbe1^tm1Lex (involves: 129S5/SvEvBrd)	abnormal lymphangiogenesis	J:186594
\Ccbe1^tm1Lex/\Ccbe1^tm1Lex (involves: 129S5/SvEvBrd)	absent lymphatic vessels	J:186594
\Ccbe1^tm1Mlkn/\Ccbe1^tm1Mlkn (either: B6.129-Ccbe1^tm1Mlkn or (involves: 129 * C57BL/6))	abnormal macrophage physiology	J:196696
	absent lymphatic vessels	J:196696
	decreased macrophage cell number	J:196696
\Ccdc18^{em1(IMPC)Ccpcz}/\Ccdc18^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccdc18^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Ccdc25^em1(IMPC)Mbp/\Ccdc25⁺ (C57BL/6N-Ccdc25^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Ccdc32^em1(IMPC)J/\Ccdc32⁺ (C57BL/6NJ-Ccdc32^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Ccdc39^b2b2025.1Clo/\Ccdc39^b2b2025.1Clo (C57BL/6J-Ccdc39^b2b2025.1Clo)	absent spleen	J:175213
	spleen hypoplasia	J:175213
\Ccdc40^em1(IMPC)J/\Ccdc40^em1(IMPC)J (C57BL/6NJ-Ccdc40^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ccdc50^em2Gpt/\Ccdc50^em2Gpt (C57BL/6J-Ccdc50^em2Gpt)	decreased susceptibility to Herpesvirales infection	J:345495
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:345495
	increased circulating interferon-beta level	J:345495
	increased interferon-beta secretion	J:345495
\Ccdc86^tm1Hfuj/\Ccdc86⁺ (involves: C57BL/6NTac)	abnormal T cell morphology	J:151722
\Ccdc86^tm1Hfuj/\Ccdc86⁺ (involves: C57BL/6NTac)	decreased T cell apoptosis	J:151722
\Ccdc88b^em1(IMPC)Tcp/\Ccdc88b^em1(IMPC)Tcp (C57BL/6NCrl-Ccdc88b^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
\Ccdc88b^m1Pgrs/\Ccdc88b^m1Pgrs (involves: C57BL/6J * C57BL/10J)	decreased CD8-positive, alpha-beta T cell number	J:230618
	decreased interferon-gamma secretion	J:230618
	decreased susceptibility to parasitic infection	J:230618
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:230618
	decreased T cell proliferation	J:230618
	decreased tumor necrosis factor secretion	J:230618
	immune system phenotype	J:230618
\Ccdc88b^m1Pgrs/\Ccdc88b^m1Pgrs (involves: 129S1/SvImJ * C57BL/6J * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:230618
\Ccdc92^{tm1a(KOMP)Mbp}/\Ccdc92^{tm1a(KOMP)Mbp} (C57BL/6N-Ccdc92^{tm1a(KOMP)Mbp})	decreased circulating interleukin-1 beta level	J:332421
	decreased circulating interleukin-18 level	J:332421
	decreased inflammatory response	J:332421
	decreased macrophage cell number	J:332421
\Ccdc110^{em1(IMPC)Ccpcz}/\Ccdc110^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccdc110^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Ccdc124^{tm1b(KOMP)Wtsi}/\Ccdc124^{tm1b(KOMP)Wtsi} (C57BL/6N-Ccdc124^{tm1b(KOMP)Wtsi}/Nju)	small spleen	J:211773
\Ccdc127^{tm1b(EUCOMM)Wtsi}/\Ccdc127^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ccdc127^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Ccdc154^ntl/\Ccdc154^ntl (involves: 129S7/SvEvBrd * C57BL/6J)	enlarged spleen	J:226596
\Ccdc166^em1(IMPC)J/\Ccdc166^em1(IMPC)J (C57BL/6NJ-Ccdc166^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Ccdc171^m1Anu/\Ccdc171⁺ (C57BL/NCrlAnu-Ccdc171^m1Anu/Anu)	decreased IgD level	J:104190
	decreased mature B cell number	J:104190
	increased IgM level	J:104190
\Ccdc171^m1Anu/\Ccdc171^m1Anu (C57BL/NCrlAnu-Ccdc171^m1Anu/Anu)	decreased IgD level	J:104190
	decreased mature B cell number	J:104190
	increased IgM level	J:104190
\Ccdc183^{em1(IMPC)Hmgu}/\Ccdc183^{em1(IMPC)Hmgu} (C57BL/6NCrl-Ccdc183^{em1(IMPC)Hmgu}/Ieg)	increased neutrophil cell number	J:211773
\Ccdc198^{em1(IMPC)Ccpcz}/\Ccdc198^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccdc198^{em1(IMPC)Ccpcz}/Ph)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased eosinophil cell number	J:337480
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Cchcr1^em1Aoka/\Cchcr1⁺ (C57BL/6NJcl-Cchcr1^em1Aoka)	immune system phenotype	J:309941
\Cchcr1^em1Aoka/\Cchcr1^em1Aoka (C57BL/6NJcl-Cchcr1^em1Aoka)	immune system phenotype	J:309941
\Cckbr^tm1Tom/\Cckbr^tm1Tom (involves: 129S4/SvJae * C57BL/6J)	decreased susceptibility to endotoxin shock	J:143853
\Ccl1^tm1Sman/\Ccl1^tm1Sman (B6.129-Ccl1^tm1Sman)	abnormal inflammatory response	J:138942
\Ccl1^tm1Sman/\Ccl1^tm1Sman (B6.129-Ccl1^tm1Sman)	abnormal regulatory T cell physiology	J:138942
\Ccl2^tm1.1Pame/\Ccl2^tm1.1Pame \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:171379
\Ccl2^tm1.1Pame/\Ccl2^tm1.1Pame \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: C57BL/6 * DBA)	immune system phenotype	J:171379
\Ccl2^tm1.1Pame/\Ccl2^tm1.1Pame \Tg(Nes-cre)1Kln/0 (involves: C57BL/6 * SJL)	abnormal leukocyte migration	J:171379
	increased susceptibility to bacterial infection	J:171379
\Ccl2^tm1.1Pame/\Ccl2^tm1.1Pame \Tg(Tek-cre)12Flv/0 (involves: C3H * C57BL/6)	abnormal leukocyte migration	J:171379
	increased susceptibility to bacterial infection	J:171379
\Ccl2^tm1.1Tyos/\Ccl2^tm1.1Tyos (involves: 129S1/Sv * C57BL/6)	abnormal chemokine level	J:151874
	abnormal chemokine secretion	J:151874
	abnormal neutrophil physiology	J:151874
	impaired macrophage chemotaxis	J:151874
\Ccl2^tm1.1Tyos/\Ccl2^tm1.1Tyos (involves: 129S1/Sv)	abnormal dendritic cell chemotaxis	J:199611
	abnormal dendritic cell physiology	J:199611
	decreased dendritic cell number	J:199611
\Ccl2^tm1Lex/\Ccl2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	impaired macrophage chemotaxis	J:191510
\Ccl2^tm1Rol/\Ccl2⁺ \Mpz^tm1Msch/\Mpz⁺ (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal macrophage derived foam cell morphology	J:133028
	decreased macrophage cell number	J:133028
\Ccl2^tm1Rol/\Ccl2⁺ \Tg(PMP22)C61Clh/0 (involves: 129S4/SvJae * C57BL/6J * CBA/Ca)	increased macrophage cell number	J:158350
\Ccl2^tm1Rol/\Ccl2^tm1Rol (involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)	abnormal monocyte morphology	J:45920
	decreased interferon-gamma secretion	J:45920
	decreased interleukin-4 secretion	J:45920
	decreased interleukin-5 secretion	J:45920
	decreased susceptibility to type IV hypersensitivity reaction	J:45920
	impaired macrophage chemotaxis	J:45920
\Ccl2^tm1Rol/\Ccl2^tm1Rol (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage chemotaxis	J:116878
	abnormal T cell physiology	J:116878
	decreased interferon-gamma secretion	J:116878
	decreased interleukin-1 beta secretion	J:116878
	decreased interleukin-12b secretion	J:116878
	decreased susceptibility to induced colitis	J:116878
	impaired macrophage chemotaxis	J:108533
\Ccl2^tm1Rol/\Ccl2^tm1Rol (involves: 129S4/SvJae)	abnormal macrophage physiology	J:155025
	abnormal monocyte morphology	J:121281
	decreased inflammatory response	J:155025
	decreased lymphocyte cell number	J:147697
	decreased macrophage cell number	J:147697
	impaired macrophage chemotaxis	J:147697
	increased circulating interferon-gamma level	J:155025
	increased circulating interleukin-10 level	J:155025
	increased circulating tumor necrosis factor level	J:155025
	increased susceptibility to infection induced morbidity/mortality	J:155025
	increased susceptibility to parasitic infection	J:155025
\Ccl2^tm1Rol/\Ccl2^tm1Rol (B6.129S4-Ccl2^tm1Rol)	abnormal chemokine level	J:151874, J:118606
	abnormal chemokine secretion	J:151874
	abnormal cytokine secretion	J:68145
	abnormal macrophage chemotaxis	J:109290
	abnormal neutrophil physiology	J:151874
	decreased interferon-gamma secretion	J:68145
	decreased leukocyte cell number	J:68145
	decreased macrophage cell number	J:147328
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:68145
	impaired macrophage chemotaxis	J:151874, J:68145, J:118606
	increased CD4-positive, alpha-beta T cell number	J:68145
	increased IgG1 level	J:68145
	increased IgG level	J:147328
	increased interleukin-10 secretion	J:68145
	increased neutrophil cell number	J:118606
	increased osteoclast cell number	J:109290
\Ccl2^tm1Rol/\Ccl2^tm1Rol (SJL.129S4-Ccl2^tm1Rol)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:68145
\Ccl2^tm1Rol/\Ccl2^tm1Rol ((129S4/SvJae x C57BL/6)F1)	decreased macrophage cell number	J:119615
\Ccl2^tm1Rol/\Ccl2^tm1Rol (B6.129S4-Ccl2^tm1Rol/J)	abnormal microglial cell physiology	J:141739
\Ccl2^tm1Rol/\Ccl2^tm1Rol \Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)	abnormal macrophage physiology	J:200877
	abnormal microglial cell morphology	J:200877
	increased microglial cell activation	J:200877
\Ccl2^tm1Rol/\Ccl2^tm1Rol \Mpz^tm1Msch/\Mpz⁺ (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal cytokine level	J:133028
	decreased macrophage cell number	J:133028
	increased macrophage cell number	J:133028
\Ccl2^tm1Rol/\Ccl2^tm1Rol \Tg(Ccr2-EGFP)8Pame/0 (involves: 129S4/SvJae * C57BL/6J)	abnormal leukocyte migration	J:171379
\Ccl2^tm1Rol/\Ccl2^tm1Rol \Tg(PMP22)C61Clh/0 (involves: 129S4/SvJae * C57BL/6J * CBA/Ca)	increased macrophage cell number	J:158350
\Ccl2^tm1Tyos/\Ccl2^tm1Tyos (involves: 129S1/Sv * C57BL/6)	abnormal chemokine level	J:151874
\Ccl2^tm1Tyos/\Ccl2^tm1Tyos (involves: 129S1/Sv * C57BL/6)	abnormal chemokine secretion	J:151874
\Ccl3^tm1Unc/\Ccl3^tm1Unc (involves: 129P2/OlaHsd)	abnormal susceptibility to Orthomyxoviridae infection	J:107677
	cecum inflammation	J:107677
	decreased susceptibility to bacterial infection	J:107677
	decreased susceptibility to Orthomyxoviridae infection	J:107677
	decreased susceptibility to Picornaviridae infection	J:28704
\Ccl3^tm1Unc/\Ccl3^tm1Unc (B6.129P2-Ccl3^tm1Unc/J)	decreased neutrophil cell number	J:94599
\Ccl3^tm1Unc/\Ccl3^tm1Unc (B6.129P2-Ccl3^tm1Unc/J)	decreased susceptibility to type III hypersensitivity reaction	J:94599
\Ccl3^tm1Unc/\Ccl3^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	decreased microglial cell activation	J:153059
\Ccl3^tm1Unc/\Ccl3^tm1Unc \Hexb^tm1Rlp/\Hexb^tm1Rlp (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal tumor necrosis factor level	J:90687
	CNS inflammation	J:90687
\Ccl4^em1Narl/\Ccl4^em1Narl (C57BL/6JNarl-Ccl4^em1Narl)	decreased inflammatory response	J:346348
\Ccl4^em1Narl/\Ccl4^em1Narl (C57BL/6JNarl-Ccl4^em1Narl)	decreased susceptibility to autoimmune diabetes	J:346348
\Ccl5^tm1Hso/\Ccl5^tm1Hso (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:75842
	decreased interferon-gamma secretion	J:75842
	decreased interleukin-2 secretion	J:75842
	decreased susceptibility to type IV hypersensitivity reaction	J:75842
	decreased T cell proliferation	J:75842
\Ccl7^tm1Ifc/\Ccl7^tm1Ifc (involves: 129S4/SvJae)	abnormal monocyte morphology	J:121281
\Ccl11^tm1Mer/\Ccl11^tm1Mer (involves: 129S6/SvEvTac * NIH Black Swiss)	decreased eosinophil cell number	J:38945
	impaired eosinophil recruitment	J:38945
\Ccl11^tm1Mer/\Ccl11^tm1Mer (129S.129S6-Ccl11^tm1Mer)	decreased eosinophil cell number	J:102034
\Ccl11^tm1Mer/\Ccl11^tm1Mer \Ccl24^tm1Mer/\Ccl24^tm1Mer (129S.129S6(Cg)-Ccl24^tm1Mer Ccl11^tm1Mer)	abnormal immune system physiology	J:102034
	abnormal inflammatory response	J:102034
\Ccl11^tm1Mer/\Ccl11^tm1Mer \Ccl24^tm1Mer/\Ccl24^tm1Mer (involves: 129S6/SvEvTac)	decreased eosinophil cell number	J:115273
\Ccl12^tm1.1Ifc/\Ccl12^tm1.1Ifc (involves: 129S4/SvJae)	immune system phenotype	J:121281
\Ccl12^tm1Ifc/\Ccl12^tm1Ifc (involves: 129S4/SvJae)	immune system phenotype	J:121281
\Ccl17^em1(IMPC)H/\Ccl17^em1(IMPC)H (C57BL/6N-Ccl17^em1(IMPC)H/H)	increased spleen weight	J:211773
\Ccl17^tm1.1Ifo/\Ccl17^tm1.1Ifo (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to type IV hypersensitivity reaction	J:159098
	increased length of allograft survival	J:159098
\Ccl17^{tm2.1(cre)Ifo}/\Ccl17⁺ \Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal dendritic cell number	J:187773
	abnormal interleukin-1 beta secretion	J:187773
	abnormal leukocyte migration	J:187773
	abnormal tumor necrosis factor secretion	J:187773
	immune system phenotype	J:187773
\Ccl19^tm1Cys/\Ccl19^tm1Cys (B6.129X1-Ccl19^tm1Cys)	abnormal immune system morphology	J:126345
\Ccl19^tm1Cys/\Ccl19^tm1Cys (B6.129X1-Ccl19^tm1Cys)	decreased T cell number	J:126345
\Ccl19^tm1Cys/\Ccl19^tm1Cys (involves: 129X1/SvJ)	immune system phenotype	J:244640
\Ccl21a^tm1Yout/\Ccl21a^tm1Yout (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal negative T cell selection	J:244640
	abnormal spleen morphology	J:244640
	decreased alpha-beta T cell number	J:244640
	decreased B cell number	J:244640
	decreased thymocyte number	J:244640
	immune system phenotype	J:244640
	lacrimal gland inflammation	J:244640
	small thymus medulla	J:244640
\Ccl22^{tm1(KOMP)Vlcg}/\Ccl22^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal dendritic cell physiology	J:236051
\Ccl24^tm1Mer/\Ccl24^tm1Mer (129S.129S6-Ccl24^tm1Mer)	abnormal immune system physiology	J:98708, J:102034
\Ccl24^tm1Mer/\Ccl24^tm1Mer (involves: 129S6/SvEvTac * C57BL/6J)	abnormal immune system physiology	J:98708
\Ccl25^em1(IMPC)H/\Ccl25^em1(IMPC)H (C57BL/6N-Ccl25^em1(IMPC)H/H)	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Ccl25^tm1.1Mal/\Ccl25^tm1.1Mal (B6.129S2-Ccl25^tm1.1Mal)	abnormal gamma-delta T cell number	J:136944
	abnormal mesenteric lymph node morphology	J:136944
	abnormal T cell subpopulation ratio	J:136944
	decreased gamma-delta intraepithelial T cell number	J:136944
\Ccl25^tm1.1Mal/\Ccl25^tm1.1Mal \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:136667
	abnormal T cell subpopulation ratio	J:136667
	decreased gamma-delta intraepithelial T cell number	J:136667
	intestinal inflammation	J:136667
\Ccl27a^em1Nax/\Ccl27a^em1Nax \Ccl27al^em1Nax/\Ccl27al^em1Nax \Ccl27b^em1Nax/\Ccl27b^em1Nax (involves: C57BL/6)	impaired leukocyte migration	J:330550
	increased interleukin-17 secretion	J:330550
	increased susceptibility to chemically induced skin inflammation	J:330550
\Ccl27a^em1Nax/\Ccl27a^em1Nax \Ccl27al^em1Nax/\Ccl27al^em1Nax \Ccl27b^em1Nax/\Ccl27b^em1Nax \Ccr10^tm1.1Nax/\Ccr10⁺ (involves: C57BL/6)	impaired leukocyte migration	J:330550
	increased interleukin-10 secretion	J:330550
	uterus inflammation	J:330550
\Ccl27a^{tm1.1(KOMP)Vlcg}/\Ccl27a^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ccl27a^{tm1.1(KOMP)Vlcg}/MbpMmucd)	decreased regulatory T cell number	J:330550
	immune system phenotype	J:330550
\Ccl27a^{tm1.1(KOMP)Vlcg}/\Ccl27a^{tm1.1(KOMP)Vlcg} \Ccr10^tm1.1Nax/\Ccr10⁺ (B6.Cg-Ccl27a^{tm1.1(KOMP)Vlcg} Ccr10^tm1.1Nax)	immune system phenotype	J:330550
\Ccl28^{em1(IMPC)Ccpcz}/\Ccl28^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccl28^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Ccl28^tm1Takna/\Ccl28^tm1Takna (C57BL/6J-Ccl28^tm1Takna)	abnormal immune system cell morphology	J:256896
	decreased IgA level	J:256896
	increased IgG level	J:256896
	increased susceptibility to induced colitis	J:256896
\Ccm2^tm1Kwhi/\Ccm2^tm1.1Kwhi \Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/? (involves: C57BL/6 * CBA)	CNS inflammation	J:173947
\Ccm2^tm2.1Sbn/\Ccm2^tm2.1Sbn \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	microgliosis	J:174085
\Ccn3^em1(IMPC)Mbp/\Ccn3^em1(IMPC)Mbp (C57BL/6N-Ccn3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Ccn3^tm1.1Ecan/\Ccn3^tm1.1Ecan (B6.Cg-Ccn3^tm1.1Ecan)	abnormal osteoclast differentiation	J:158478
\Ccn3^tm1.1Ecan/\Ccn3^tm1.1Ecan (B6.Cg-Ccn3^tm1.1Ecan)	abnormal osteoclast physiology	J:158478
\Ccna1^tm1Djw/\Ccna1^tm1Djw \Ccna2^tm1.1Pisc/\Ccna2^tm1.1Pisc \Tg(Mx1-cre)1Cgn/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	decreased leukocyte cell number	J:155178
\Ccnb1ip1^em1(IMPC)Tcp/\Ccnb1ip1^em1(IMPC)Tcp (C57BL/6NCrl-Ccnb1ip1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Ccnb2^tm1Thnt/\Ccnb2^tm1Thnt (involves: 129P2/OlaHsd * C57BL/6)	increased double-negative T cell number	J:47430
	small thymus	J:47430
\Ccnc^tm1.1Pisc/\Ccnc^tm1.1Pisc \Tg(Lck-LMO1)11Sjk/0 \Tg(Mx1-cre)1Cgn/0 (Not Specified)	increased T cell derived lymphoma incidence	J:217695
\Ccnd1^tm1Dsn/\Ccnd1^tm1Dsn \Ccnd2^tm1Wbg/\Ccnd2^tm1Wbg \Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal lymphopoiesis	J:92563
\Ccnd1^tm1Dsn/\Ccnd1^tm1Dsn \Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf (involves: 129 * C57BL/6)	enlarged spleen	J:66707
	enlarged thymus	J:66707
	thymus hyperplasia	J:66707
\Ccnd3^{tm1.1(Ccnd2)Iaai}/\Ccnd3^{tm1.1(Ccnd2)Iaai} (involves: 129S6/SvEvTac)	decreased B cell proliferation	J:192031
	decreased double-positive T cell number	J:192031
	decreased pre-B cell number	J:192031
	decreased T cell proliferation	J:192031
	small thymus	J:192031
	thymus hypoplasia	J:192031
\Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc (Not Specified)	decreased B cell proliferation	J:192031
	decreased double-positive T cell number	J:88120, J:192031
	decreased lymphocyte cell number	J:88120
	decreased pre-B cell number	J:192031
	decreased T cell proliferation	J:88120, J:192031
	increased double-negative T cell number	J:88120
	small thymus	J:192031
	thymus hypoplasia	J:88120, J:192031
\Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc \Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf (involves: 129S4/SvJaeSor)	decreased double-positive T cell number	J:192031
	decreased T cell proliferation	J:192031
	thymus hypoplasia	J:192031
\Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc \Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf \Rb1^tm2Brn/\Rb1^tm2Brn \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	immune system phenotype	J:192031
\Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv)	increased T cell proliferation	J:88120
\Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc \Rb1^tm2Brn/\Rb1^tm2Brn \Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	decreased double-positive T cell number	J:192031
	decreased T cell proliferation	J:192031
	thymus hypoplasia	J:192031
\Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc \Tg(Lck)4220Rmp/0 (involves: C57BL/6J * DBA/2)	increased T cell derived lymphoma incidence	J:88120
\Ccnd3^tm1Pisc/\Ccnd3^tm1Pisc \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas)	increased T cell derived lymphoma incidence	J:88120
\Ccnd3^tm2.1Pisc/\Ccnd3^tm2.1Pisc \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased double-positive T cell number	J:192032
	decreased leukocyte cell number	J:192032
	small thymus	J:192032
\Ccne1^tm1Clur/\Ccne1^tm1Clur (involves: 129S4/SvJae)	abnormal myeloid leukocyte morphology	J:136692
	abnormal spleen red pulp morphology	J:136692
	enlarged spleen	J:136692
	immune system phenotype	J:136692
	spleen hyperplasia	J:136692
\Ccne1^tm1Jro/\Ccne1^tm1Jro (either: 129-Ccne1^tm1Jro or B6.129-Ccne1^tm1Jro)	increased spleen weight	J:99695
	increased splenocyte proliferation	J:99695
\Ccne1^tm1Pisc/\Ccne1^tm1Pisc \Ccne2^tm1Pisc/\Ccne2^tm1Pisc (involves: 129S2/SvPas)	abnormal thrombopoiesis	J:85224
\Ccno^{tm1b(EUCOMM)Wtsi}/\Ccno^{tm1b(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N * CBA)	immune system phenotype	J:220709
\Ccnt1^em1(IMPC)J/\Ccnt1⁺ (C57BL/6NJ-Ccnt1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ccnt1^em1(IMPC)J/\Ccnt1^em1(IMPC)J (C57BL/6NJ-Ccnt1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ccnt1^{Gt(RRR115)Byg}/\Ccnt1^{Gt(RRR115)Byg} (involves: 129P2/OlaHsd)	abnormal thymus physiology	J:130071
	autoimmune response	J:130071
	immune system phenotype	J:130071
	lacrimal gland inflammation	J:130071
	salivary gland inflammation	J:130071
\Ccpg1^{tm1a(EUCOMM)Hmgu}/\Ccpg1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Ccpg1^{tm1a(EUCOMM)Hmgu})	pancreas inflammation	J:256708
\Ccr1^tm1Cge/\Ccr1^tm1Cge (involves: 129S4/SvJae)	decreased tumor necrosis factor secretion	J:43569
	glomerulonephritis	J:115119
	immune system phenotype	J:115119
	impaired neutrophil recruitment	J:43569
	increased IgG2a level	J:115119
	increased interferon-gamma secretion	J:115119
	increased susceptibility to type IV hypersensitivity reaction	J:115119
	increased tumor necrosis factor secretion	J:115119
	lung inflammation	J:43569
\Ccr1^tm1Cge/\Ccr1^tm1Cge (involves: 129S4/SvJae * C57BL/6)	cecum inflammation	J:107677
	decreased susceptibility to bacterial infection	J:107677
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:63952
	immune system phenotype	J:63952
	increased length of allograft survival	J:59235
\Ccr1^tm1Cge/\Ccr1^tm1Cge (involves: 129S4/SvJae * BALB/c)	abnormal chemokine secretion	J:169909
	abnormal circulating chemokine level	J:169909
	abnormal macrophage physiology	J:169909
	decreased circulating interferon-gamma level	J:169909
	decreased interleukin-10 secretion	J:169909
	decreased susceptibility to bacterial infection	J:169909
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:169909
	decreased tumor necrosis factor secretion	J:169909
	increased interleukin-12 secretion	J:169909
	increased macrophage nitric oxide production	J:169909
	increased tumor necrosis factor secretion	J:169909
\Ccr1^tm1Cge/\Ccr1^tm1Cge (C.129S4-Ccr1^tm1Cge)	decreased CD4-positive, alpha-beta T cell number	J:95242
	decreased CD8-positive, alpha-beta T cell number	J:95242
	decreased interleukin-13 secretion	J:95242
	decreased susceptibility to Riboviria infection	J:95242
\Ccr1^tm1Gao/\Ccr1^tm1Gao (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil physiology	J:41324
	granulomatous inflammation	J:41324
	immune system phenotype	J:41324
	increased susceptibility to fungal infection	J:41324
	increased susceptibility to parasitic infection	J:41324
\Ccr1^tm1Gao/\Ccr1^tm1Gao (involves: C57BL/6)	decreased mast cell number	J:94599
\Ccr1^tm1Gao/\Ccr1^tm1Gao (involves: C57BL/6)	decreased susceptibility to type III hypersensitivity reaction	J:94599
\Ccr1^tm1Gao/\Ccr1^tm1Gao (B6.129S4-Ccr1^tm1Gao)	abnormal cellular extravasation	J:104744
	abnormal leukocyte adhesion	J:104744
	bronchiolitis	J:162707
	increased susceptibility to Coronaviridae infection	J:162707
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:162707
\Ccr1^tm1Gao/\Ccr1^tm1Gao (involves: 129S4/SvJae)	abnormal Kupffer cell morphology	J:152548
\Ccr1l1^em1Semp/\Ccr1l1^em1Semp (C57BL/6NTac-Ccr1l1^em1Semp)	immune system phenotype	J:304824
\Ccr1l1^em2Semp/\Ccr1l1^em2Semp (C57BL/6NTac-Ccr1l1^em2Semp)	immune system phenotype	J:304824
\Ccr2^em1(IMPC)H/\Ccr2^em1(IMPC)H (C57BL/6N-Ccr2^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Ccr2^{tm1.1(CCR2)Rodb}/\Ccr2^{tm1.1(CCR2)Rodb} (involves: C57BL/6)	abnormal macrophage morphology	J:203000
	immune system phenotype	J:203000
\Ccr2^tm1.1Dnc/\Ccr2^tm1.1Dnc (Not Specified)	abnormal dendritic cell chemotaxis	J:223508
	decreased CD11b-high dendritic cell number	J:223508
	increased CD11b-high dendritic cell number	J:223508
	increased dendritic cell number	J:223508
\Ccr2^tm1.1Mpa/\Ccr2^tm1.1Mpa (involves: BALB/cJ * C57BL/6)	decreased macrophage cell number	J:189044
\Ccr2^tm1.1Mpa/\Ccr2^tm1.1Mpa (involves: BALB/cJ * C57BL/6)	decreased monocyte cell number	J:189044
\Ccr2^tm1Blck/\Ccr2^tm1Blck (B6.129P2-Ccr2^tm1Blck)	abnormal cellular extravasation	J:104744
\Ccr2^tm1Blck/\Ccr2^tm1Blck (B6.129P2-Ccr2^tm1Blck)	abnormal leukocyte adhesion	J:104744
\Ccr2^tm1Blck/\Ccr2^tm1Blck \Fas^lpr/\Fas^lpr (MRL.Cg-Ccr2^tm1Blck Fas^lpr)	abnormal immune system organ morphology	J:113343
	abnormal interferon level	J:113343
	abnormal lymphocyte cell number	J:113343
	abnormal tumor necrosis factor level	J:113343
	enlarged lymph nodes	J:113343
	enlarged spleen	J:113343
	glomerulonephritis	J:113343
	kidney inflammation	J:113343
\Ccr2^tm1Brv/\Ccr2^tm1Brv (involves: 129S1/Sv * ICR)	abnormal spleen morphology	J:111517
	enlarged spleen	J:111517
	impaired macrophage chemotaxis	J:111517
	increased eosinophil cell number	J:111517
	increased susceptibility to bacterial infection	J:111517
	liver inflammation	J:111517
\Ccr2^tm1Ifc/\Ccr2⁺ (involves: 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:121703
\Ccr2^tm1Ifc/\Ccr2^tm1Ifc (B6.129S4-Ccr2^tm1Ifc/J)	abnormal leukocyte migration	J:106738
	abnormal leukocyte physiology	J:122119
	abnormal microglial cell physiology	J:106738
	abnormal osteoclast cell number	J:149360
	abnormal osteoclast differentiation	J:149360
	abnormal osteoclast physiology	J:149360
	decreased acute inflammation	J:106738
	decreased interferon-gamma secretion	J:106738
	decreased osteoclast cell number	J:149360
	increased susceptibility to Coronaviridae infection	J:106738
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:106738
\Ccr2^tm1Ifc/\Ccr2^tm1Ifc (involves: 129S4/SvJae)	abnormal monocyte morphology	J:121281
\Ccr2^tm1Ifc/\Ccr2^tm1Ifc (involves: 129S4/SvJae * C57BL/6)	abnormal immune serum protein physiology	J:118971
	abnormal Langerhans cell physiology	J:112594
	abnormal macrophage chemotaxis	J:44345
	abnormal microglial cell physiology	J:121703
	decreased inflammatory response	J:44345
	decreased interferon-gamma secretion	J:75838, J:44345
	decreased interleukin-2 secretion	J:44345
	decreased interleukin-6 secretion	J:75838
	decreased splenocyte proliferation	J:75838
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:75838
	decreased susceptibility to type I hypersensitivity reaction	J:118971
	decreased T cell proliferation	J:75838
	impaired macrophage chemotaxis	J:81363, J:44345, J:121703
	increased interferon-gamma secretion	J:61542
	increased tumor necrosis factor secretion	J:61542
\Ccr2^tm1Ifc/\Ccr2^tm1Ifc (B6.129S4-Ccr2^tm1Ifc)	decreased susceptibility to induced colitis	J:161138
	immune system phenotype	J:154558
	impaired leukocyte tethering or rolling	J:154558
\Ccr2^tm1Ifc/\Ccr2^tm1Ifc \Tg(APPSWE)2576Kha/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal microglial cell physiology	J:121703
\Ccr2^tm1Mae/\Ccr2^tm1Mae (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine secretion	J:110814
	decreased CD4-positive, alpha-beta T cell number	J:110814
	decreased inflammatory response	J:110814
	increased B cell number	J:110814
	increased CD8-positive, alpha-beta T cell number	J:110814
	increased susceptibility to induced colitis	J:110814
\Ccr2^tm1Mae/\Ccr2^tm1Mae (B6.129P2-Ccr2^tm1Mae)	bronchiolitis	J:162707
	decreased macrophage cell number	J:147328
	increased IgG level	J:147328
	increased susceptibility to Coronaviridae infection	J:162707
\Ccr2^tm1Mae/\Ccr2^tm1Mae (involves: 129P2/OlaHsd)	abnormal chemokine secretion	J:151874
	abnormal leukocyte migration	J:171379
	impaired macrophage chemotaxis	J:191510, J:151874
\Ccr2^tm1Mae/\Ccr2^tm1Mae (involves: 129P2/OlaHsd * BALB/c)	abnormal leukocyte physiology	J:162714
	decreased neutrophil cell number	J:162714
	impaired macrophage chemotaxis	J:162714
\Ccr2^tm1Mpa/\Ccr2^tm1Mpa \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased macrophage cell number	J:189044
\Ccr2^tm2.1Ifc/\Ccr2^tm2.1Ifc \Cx3cr1^tm1Litt/\Cx3cr1⁺ (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal leukocyte physiology	J:166664
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:166664
\Ccr2^tm2.1Ifc/\Ccr2^tm2.1Ifc \Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal leukocyte physiology	J:166664
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:166664
\Ccr3^{em1(IMPC)Ccpcz}/\Ccr3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ccr3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Ccr3^tm1Cge/\Ccr3^tm1Cge (involves: 129S4/SvJae * BALB/c)	abnormal eosinophil cell number	J:74509
	abnormal eosinophil physiology	J:74509, J:75347
	abnormal mast cell physiology	J:74509
	decreased circulating interleukin-4 level	J:115273
	decreased eosinophil cell number	J:115273, J:74509, J:75347
	decreased monocyte cell number	J:115273
	impaired eosinophil chemotaxis	J:74509
	impaired eosinophil recruitment	J:74509, J:75347
	increased eosinophil cell number	J:74509
	increased mast cell degranulation	J:74509
\Ccr4^tm1Pwr/\Ccr4^tm1Pwr (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:70088
	abnormal cytokine secretion	J:120221
	abnormal splenocyte physiology	J:70088
	decreased eosinophil cell number	J:120221
	decreased IgE level	J:120221
	decreased interleukin-1 beta secretion	J:70088
	decreased interleukin-4 secretion	J:120221
	decreased interleukin-5 secretion	J:120221
	decreased interleukin-10 secretion	J:120221
	decreased interleukin-13 secretion	J:120221
	decreased lymphocyte cell number	J:70088
	decreased macrophage cell number	J:70088
	decreased susceptibility to endotoxin shock	J:70088
	decreased susceptibility to fungal infection	J:120221
	decreased tumor necrosis factor secretion	J:70088
	immune system phenotype	J:70088
	increased IgE level	J:120221
	increased IgG1 level	J:120221
	increased interferon-gamma secretion	J:120221
	increased interleukin-4 secretion	J:120221
	increased interleukin-5 secretion	J:120221
	increased interleukin-10 secretion	J:120221
	increased macrophage cell number	J:120221
	increased neutrophil cell number	J:120221
	increased tumor necrosis factor secretion	J:120221
\Ccr4^tm1Pwr/\Ccr4^tm1Pwr (B6.129P2-Ccr4^tm1Pwr)	increased CD8-positive, alpha-beta T cell number	J:95239
	increased length of allograft survival	J:95239
	increased NK T cell number	J:95239
\Ccr5^tm1Blck/\Ccr5^tm1Blck (B6.129P2-Ccr5^tm1Blck)	abnormal cellular extravasation	J:104744
	abnormal leukocyte adhesion	J:104744
	increased length of allograft survival	J:105072
\Ccr5^tm1Brv/\Ccr5^tm1Brv (either: (involves: 129S1/Sv * ICR) or (involves: 129S1/Sv * 129X1/SvJ * ICR))	abnormal cytokine secretion	J:46941
	decreased interleukin-1 beta secretion	J:46941
	decreased interleukin-6 secretion	J:46941
	decreased susceptibility to endotoxin shock	J:46941
	increased IgG1 level	J:46941
	increased interferon-gamma secretion	J:46941
	increased interleukin-4 secretion	J:46941
	increased susceptibility to bacterial infection	J:46941
	increased susceptibility to type IV hypersensitivity reaction	J:46941
\Ccr5^tm1Kuz/\Ccr5^tm1Kuz (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:110814
	abnormal CD8-positive, alpha beta T cell morphology	J:110814
	abnormal cytokine level	J:110814
	abnormal Kupffer cell morphology	J:152548
	abnormal NK T cell physiology	J:100869
	decreased microglial cell activation	J:153059
	decreased NK cell number	J:135308
	decreased susceptibility to induced colitis	J:110814
	decreased susceptibility to Retroviridae infection	J:132342
	impaired macrophage chemotaxis	J:153059, J:84243, J:64293
	increased NK T cell number	J:110814
	increased susceptibility to fungal infection	J:64293
\Ccr5^tm1Kuz/\Ccr5^tm1Kuz (B6.129P2-Ccr5^tm1Kuz)	bronchiolitis	J:162707
\Ccr5^tm1Kuz/\Ccr5^tm1Kuz (B6.129P2-Ccr5^tm1Kuz)	increased susceptibility to Coronaviridae infection	J:162707
\Ccr5^tm1Kuz/\Ccr5^tm1Kuz (involves: 129P2/OlaHsd)	decreased inflammatory response	J:227458
\Ccr5^tm1Kuz/\Ccr5^tm1Kuz \Cxcr4^tm1Qma/\Cxcr4^tm1Qma (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	decreased susceptibility to Retroviridae infection	J:132342
\Ccr5^tm1Sush/\Ccr5^tm1Sush (B6.129P2-Ccr5^tm1Sush)	abnormal leukocyte physiology	J:94937
\Ccr5^tm1Sush/\Ccr5^tm1Sush (B6.129P2-Ccr5^tm1Sush)	decreased T cell proliferation	J:94937
\Ccr6^tm1(EGFP)Irw/\Ccr6^tm1(EGFP)Irw (involves: 129S6/SvEvTac * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:85086
	abnormal B cell physiology	J:120122
	abnormal CD4-positive, alpha-beta intraepithelial T cell morphology	J:85086
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:85086
	abnormal follicular dendritic cell physiology	J:113363
	abnormal gut-associated lymphoid tissue morphology	J:113363, J:120122
	abnormal Peyer's patch morphology	J:120122
	abnormal T cell physiology	J:85086
	decreased B cell number	J:120122
	decreased Peyer's patch number	J:120122
	impaired B cell migration	J:120122
	increased T cell proliferation	J:85086
\Ccr6^tm1(EGFP)Irw/\Ccr6^tm1(EGFP)Irw (B6.129S6-Ccr6^tm1(EGFP)Irw)	decreased interleukin-4 secretion	J:132012
	decreased interleukin-12 secretion	J:132012
	decreased susceptibility to bacterial infection	J:132012
	decreased tumor necrosis factor secretion	J:132012
	increased interferon-gamma secretion	J:132012
\Ccr6^{tm1.1(KOMP)Vlcg}/\Ccr6^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ccr6^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
\Ccr6^tm1.1Jmf/\Ccr6^tm1.1Jmf (B6.129-Ccr6^tm1.1Jmf)	abnormal CD4-positive, alpha-beta T cell physiology	J:152716
	abnormal dendritic cell physiology	J:152716
	abnormal interleukin secretion	J:152716
	decreased inflammatory response	J:152716
\Ccr6^tm1Gma/\Ccr6^tm1Gma (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:68191
	abnormal myeloid dendritic cell morphology	J:68191
	abnormal Peyer's patch follicle morphology	J:68191
	abnormal Peyer's patch morphology	J:68191
	decreased inflammatory response	J:68191
	decreased leukocyte cell number	J:68191
	increased leukocyte cell number	J:68191
\Ccr6^tm1Gma/\Ccr6^tm1Gma \Tg(Rorc-EGFP)1Ebe/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal effector T cell morphology	J:137020
\Ccr6^tm1Lira/\Ccr6^tm1Lira (involves: 129)	abnormal follicular dendritic cell antigen presentation	J:113363
	abnormal Peyer's patch T cell area morphology	J:113363
	abnormal T cell physiology	J:123150
\Ccr6^tm1Lira/\Ccr6^tm1Lira (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:148286
	abnormal CD4-positive, alpha-beta T cell physiology	J:148286
	abnormal gut-associated lymphoid tissue morphology	J:76461
	abnormal intraepithelial T cell number	J:76461
	abnormal lymphocyte morphology	J:148286
	abnormal macrophage physiology	J:124358
	abnormal myeloid dendritic cell morphology	J:124358
	abnormal peritoneal macrophage morphology	J:124358
	abnormal Peyer's patch germinal center morphology	J:76461
	abnormal Peyer's patch morphology	J:76461
	decreased B cell number	J:148286
	decreased CD4-positive, alpha-beta T cell number	J:148286
	decreased CD8-positive, alpha-beta T cell number	J:148286
	decreased IgA level	J:76461
	decreased IgG3 level	J:76461
	decreased inflammatory response	J:124358
	decreased interleukin-10 secretion	J:124358
	decreased interleukin-12 secretion	J:124358
	decreased macrophage cytokine production	J:124358
	decreased macrophage nitric oxide production	J:124358
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:148286
	decreased tumor necrosis factor secretion	J:124358
	increased activated T cell number	J:76461
	increased B-1 B cell number	J:124358
	increased double-positive T cell number	J:76461
	increased IgM level	J:76461
	increased susceptibility to Riboviria infection	J:76461
	increased T cell number	J:76461
\Ccr6^tm1Lira/\Ccr6^tm1Lira (B6.129-Ccr6^tm1Lira)	decreased IgE level	J:71096
	decreased interleukin-5 secretion	J:71096
	decreased susceptibility to type I hypersensitivity reaction	J:71096
	impaired eosinophil recruitment	J:71096
\Ccr7^m1Btlr/\Ccr7⁺ (C57BL/6J-Ccr7^m1Btlr)	decreased macrophage cell number	J:221477
\Ccr7^m1Btlr/\Ccr7^m1Btlr (C57BL/6J-Ccr7^m1Btlr)	decreased macrophage cell number	J:221477
\Ccr7^m1Btlr/\Ccr7^m1Btlr (C57BL/6J-Ccr7^m1Btlr)	increased single-positive T cell number	J:221477
\Ccr7^tm1Dgen/\Ccr7^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	chronic inflammation	J:101679
\Ccr7^tm1Rfor/\Ccr7^tm1Rfor (involves: 129P2/OlaHsd * BALB/c)	abnormal B cell activation	J:57976
	abnormal class switch recombination	J:57976
	abnormal dendritic cell physiology	J:57976
	abnormal humoral immune response	J:57976
	abnormal leukocyte migration	J:57976
	abnormal lymph node cortex morphology	J:57976
	abnormal lymph node germinal center morphology	J:57976
	abnormal lymph node T cell domain morphology	J:57976
	abnormal Peyer's patch T cell area morphology	J:57976
	abnormal spleen marginal sinus morphology	J:57976
	abnormal spleen periarteriolar lymphoid sheath morphology	J:57976
	abnormal spleen red pulp morphology	J:57976
	abnormal T cell physiology	J:57976
	decreased CD4-positive, alpha-beta T cell number	J:57976
	decreased dendritic cell number	J:57976
	decreased IgG3 level	J:57976
	decreased susceptibility to type IV hypersensitivity reaction	J:57976
	decreased T cell number	J:57976
	enlarged spleen	J:57976
	impaired B cell migration	J:57976
	increased CD4-positive, alpha-beta T cell number	J:57976
	increased IgE level	J:57976
	increased IgG1 level	J:57976
	increased IgG2a level	J:57976
	increased T cell number	J:57976
	small lymph nodes	J:57976
	small Peyer's patches	J:57976
\Ccr7^tm1Rfor/\Ccr7^tm1Rfor (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:134784
\Ccr7^tm1Rfor/\Ccr7^tm1Rfor (B6.129P2-Ccr7^tm1Rfor)	abnormal dendritic cell physiology	J:183989
	abnormal leukocyte migration	J:93960, J:110910
	abnormal thymus cortex morphology	J:93960
	immune system phenotype	J:93960
	increased inflammatory response	J:110910
	increased susceptibility to autoimmune disorder	J:110910
	lacrimal gland inflammation	J:110910
	parotid gland inflammation	J:110910
	salivary gland inflammation	J:110910
	small thymus medulla	J:93960
	submandibular gland inflammation	J:110910
\Ccr7^tm1Rfor/\Ccr7^tm1Rfor (B6.129P2(C)-Ccr7^tm1Rfor/J)	decreased susceptibility to bacterial infection	J:210086
\Ccr7^tm1Rfor/\Ccr7^tm1Rfor (involves: 129P2/OlaHsd)	abnormal dendritic cell chemotaxis	J:223508
	decreased CD11b-high dendritic cell number	J:223508
	decreased CD103-positive CD11b-low dendritic cell number	J:223508
\Ccr7^tm1Rfor/\Ccr7^tm1Rfor \Tg(DO11.10)10Dlo/? (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	abnormal leukocyte migration	J:123482
	abnormal regulatory T cell physiology	J:123482
\Ccr8^tm1Lira/\Ccr8^tm1Lira (involves: 129S/SvEv * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:118417
\Ccr9^tm1.1Mal/\Ccr9^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte cell number	J:72386
	abnormal T cell differentiation	J:72386
	decreased double-positive T cell number	J:72386
	decreased pro-B cell number	J:72386
	decreased T cell number	J:72386
	increased T cell number	J:72386
\Ccr9^tm1.1Mal/\Ccr9^tm1.1Mal (involves: 129S2/SvPas)	abnormal gamma-delta T cell number	J:136944
	abnormal mesenteric lymph node morphology	J:136944
	abnormal T cell subpopulation ratio	J:136944
	decreased gamma-delta intraepithelial T cell number	J:136944
\Ccr9^tm1.1Mal/\Ccr9^tm1.1Mal \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:136667
	abnormal T cell subpopulation ratio	J:136667
	decreased gamma-delta intraepithelial T cell number	J:136667
	intestinal inflammation	J:136667
\Ccr9^tm1Ccb/\Ccr9^tm1Ccb (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:94596
	decreased thymocyte number	J:94596
\Ccr9^tm1Lov/\Ccr9^tm1Lov (involves: 129)	abnormal gamma-delta intraepithelial T cell morphology	J:110846
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:110846
	decreased lymphocyte cell number	J:110846
	increased gamma-delta T cell number	J:110846
\Ccr10^tm1.1Nax/\Ccr10^tm1.1Nax (B6.129S4(Cg)-Ccr10^tm1.1Nax)	decreased gamma-delta intraepithelial T cell number	J:165323
\Ccr10^tm1Cge/\Ccr10^tm1Cge (C.129S4-Ccr10^tm1Cge)	abnormal leukocyte migration	J:140728
	abnormal plasma cell morphology	J:140728
	decreased IgA level	J:140728
\Ccrl2^tm1Lex/\Ccrl2^tm1Lex (involves: 129S/SvEvBrd * C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:140110
\Ccrl2^tm1Ssoz/\Ccrl2^tm1Ssoz (B6.129-Ccrl2^tm1Ssoz)	abnormal dendritic cell chemotaxis	J:165873
	abnormal hypersensitivity reaction	J:165873
	abnormal T-helper 2 physiology	J:165873
	decreased interleukin-4 secretion	J:165873
	decreased interleukin-5 secretion	J:165873
	decreased interleukin-13 secretion	J:165873
	lymph node hypoplasia	J:165873
\Cd1^tm1Gru/\Cd1^tm1Gru (involves: 129S2/SvPas * BALB/c)	abnormal eosinophil cell number	J:84720
	absent NK T cells	J:47769
	decreased CD4-positive, alpha-beta T cell number	J:126220
	decreased interleukin-4 secretion	J:47769
	decreased susceptibility to infection induced morbidity/mortality	J:126220
	immune system phenotype	J:47769
	myocarditis	J:126220
\Cd1d1^em1(IMPC)H/\Cd1d1^em1(IMPC)H (C57BL/6NTac-Cd1d1^em1(IMPC)H/H)	increased basophil cell number	J:211773
\Cd1d1^tm1.1Aben/\Cd1d1^tm1.1Aben \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.Cg-Cd1d1^tm1.1Aben Lyz2^tm1(cre)Ifo)	decreased interferon-gamma secretion	J:183087
	decreased interleukin-4 secretion	J:183087
	immune system phenotype	J:183087
\Cd1d1^tm1.1Aben/\Cd1d1^tm1.1Aben \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Cd1d1^tm1.1Aben Tg(Cd4-cre)1Cwi)	decreased NK T cell number	J:183087
\Cd1d1^tm1.1Aben/\Cd1d1^tm1.1Aben \Tg(Itgax-cre,-EGFP)4097Ach/0 (C57BL/6-Cd1d1^tm1.1Aben Tg(Itgax-cre,-EGFP)4097Ach)	decreased interferon-gamma secretion	J:183087
	decreased interleukin-4 secretion	J:183087
	immune system phenotype	J:183087
\Cd1d1^tm1.1Boes/\Cd1d1^tm1.1Boes (involves: C57BL/6)	abnormal dendritic cell antigen presentation	J:151699
	abnormal interleukin-4 secretion	J:151699
	abnormal NK T cell morphology	J:151699
	abnormal NK T cell physiology	J:151699
	decreased interleukin-2 secretion	J:151699
	decreased NK T cell number	J:151699
\Cd1d1^tm1.1Boes/\Cd1d1^tm1.1Boes \Cd74^tm1Doi/\Cd74^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal dendritic cell antigen presentation	J:151699
\Cd1d1^tm1.2Aben/\Cd1d1^tm1.2Aben (B6(C)-Cd1d1^tm1.2Aben/J)	abnormal CD4-positive T cell differentiation	J:177038
	abnormal T cell activation	J:177038
	increased susceptibility to bacterial infection	J:177038
	increased susceptibility to bacterial infection induced morbidity/mortality	J:177038
	lung inflammation	J:177038
\Cd1d1^tm1Crw/\Cd1d1^tm1Crw (involves: 129S4/SvJae * C57BL/6)	decreased NK T cell number	J:76976
\Cd1d1^tm1Crw/\Cd1d1^tm1Crw (B6.129S4-Cd1d1^tm1Crw)	decreased IgG level	J:99107
\Cd1d1^tm1Crw/\Cd1d1^tm1Crw (B6.129S4-Cd1d1^tm1Crw)	decreased susceptibility to induced arthritis	J:99107
\Cd1d1^tm1Luc/\Cd1d1^tm1Luc (B6.129S6-Cd1d1^tm1Luc)	autoimmune response	J:122245
\Cd1d1^tm1Luc/\Cd1d1^tm1Luc (B6.129S6-Cd1d1^tm1Luc)	decreased regulatory T cell number	J:122245
\Cd1d1^tm1Luc/\Cd1d1^tm1Luc (involves: 129S6/SvEvTac * C57BL/6)	arrested T cell differentiation	J:125679
	decreased acute inflammation	J:93915
	decreased interferon-gamma secretion	J:93915, J:39748
	decreased interleukin-4 secretion	J:39748
	decreased NK T cell number	J:39748
	decreased tumor necrosis factor secretion	J:93915
\Cd1d1^tm1Luc/\Cd1d1^tm1Luc (C.129S6-Cd1d1^tm1Luc)	decreased interleukin-4 secretion	J:121187
	glomerulonephritis	J:121187
	increased anti-double stranded DNA antibody level	J:121187
	increased anti-nuclear antigen antibody level	J:121187
	increased IgG3 level	J:121187
	kidney inflammation	J:121187
\Cd1d1^tm1Luc/\Cd1d1^tm1Luc \Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt (B6.129-Cd1d1^tm1Luc Cx3cr1^tm1Litt)	decreased NK cell number	J:129712
	increased susceptibility to experimental autoimmune encephalomyelitis	J:129712
\Cd1d1^tm2Aben/\Del(3Cd1d2-Cd1d1)1Crw (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal antigen presentation	J:174337
\Cd1d1^tm2Aben/\Cd1d1^tm2Aben (B6.129P2-Cd1d1^tm2Aben)	abnormal antigen presentation	J:174337
\Cd1d1^tm2Aben/\Cd1d1^tm2Aben (B6.129P2-Cd1d1^tm2Aben)	decreased NK T cell number	J:174337
\Cd1d1^tm2Aben/\Cd1d1^tm2Aben (involves: 129P2/OlaHsd * C57BL/6)	abnormal antigen presentation	J:174337
	decreased NK T cell number	J:174337
\Cd2ap^em1Irgu/\Cd2ap^em1Irgu (C57BL/6-Cd2ap^em1Irgu)	kidney inflammation	J:294238
\Cd2ap^tm1Shaw/\Cd2ap^tm1Shaw (involves: 129X1/SvJ)	decreased T cell proliferation	J:57971
	spleen atrophy	J:57971
	thymus atrophy	J:57971
\Cd2bp2^tm1.1Tbh/\Cd2bp2^tm1.1Tbh \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J)	impaired macrophage phagocytosis	J:283435
\Cd3d^tm1Kap/\Cd3d^tm1Kap (C57BL/6-Cd3d^tm1Kap)	arrested T cell differentiation	J:39925
	decreased CD4-positive, alpha-beta T cell number	J:39925
	decreased CD8-positive, alpha-beta T cell number	J:39925
\Cd3e^m1Btlr/\Cd3e^m1Btlr (C57BL/6J-Cd3e^m1Btlr)	abnormal thymus morphology	J:132486
	absent T cells	J:132486
	arrested T cell differentiation	J:132486
	increased T cell apoptosis	J:132486
	small thymus	J:132486
\Cd3e^m1Btlr/\Cd3e^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
\Cd3e^m2Btlr/\Cd3e^m2Btlr (C57BL/6J-Cd3e^m2Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:274934
	abnormal T cell differentiation	J:274934
	decreased CD4-positive, alpha-beta T cell number	J:274934
	decreased CD8-positive, naive alpha-beta T cell number	J:274934
	increased CD8-positive, alpha-beta T cell number	J:274934
	increased central memory CD8 positive, alpha-beta T cell number	J:274934
\Cd3e^tm1.1Geno/\Cd3e^tm1.1Geno (involves: C57BL/6)	abnormal double-positive T cell morphology	J:192604
	abnormal T cell differentiation	J:192604
	abnormal T cell number	J:192604
	increased DN3 thymocyte number	J:192604
\Cd3e^tm1.1Geno/\Cd3e^tm1.1Geno \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:192604
	abnormal positive T cell selection	J:192604
	increased DN3 thymocyte number	J:192604
\Cd3e^tm1.1Geno/\Cd3e^tm1.1Geno \Tg(TcrAND)53Hed/0 (involves: C57BL/6 * SJL)	abnormal CD4-positive T cell differentiation	J:192604
	abnormal positive T cell selection	J:192604
	increased DN3 thymocyte number	J:192604
\Cd3e^tm1.1Geno/\Cd3e^tm1.1Geno \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	abnormal positive T cell selection	J:192604
	abnormal T cell differentiation	J:192604
	abnormal thymus cell ratio	J:192604
	decreased double-positive T cell number	J:192604
	decreased T cell number	J:192604
	increased DN3 thymocyte number	J:192604
\Cd3e^tm1.1Lov/\Cd3e^tm1.1Lov (Not Specified)	abnormal T cell morphology	J:72144
	arrested T cell differentiation	J:72144
	decreased double-positive T cell number	J:72144
	increased double-negative T cell number	J:72144
\Cd3e^tm1.1Lov/\Cd3e^tm1.1Lov \Trdc^tm1Mal/\Trdc^tm1Mal (involves: C57BL/6)	abnormal double-negative T cell morphology	J:112658
\Cd3e^tm1Cpt/\Cd3e^tm1Cpt (involves: 129S4/SvJae * C57BL/6)	absent T cells	J:54756
	decreased double-positive T cell number	J:54756
	thymus hypoplasia	J:54756
\Cd3e^tm1Cpt/\Cd3e^tm1Cpt \Tg(CD3E)26Cpt/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	decreased double-positive T cell number	J:54756
	decreased T cell number	J:54756
	thymus hypoplasia	J:54756
\Cd3e^tm1Lov/\Cd3e^tm1Lov (involves: 129S1/Sv * 129X1/SvJ)	abnormal T cell morphology	J:72144
	arrested T cell differentiation	J:72144
	decreased double-positive T cell number	J:72144
	increased double-negative T cell number	J:72144
\Cd3e^tm1Mal/\Cd3e^tm1Mal (involves: C57BL/6)	absent CD4-positive, alpha-beta T cells	J:77098
	absent CD8-positive, alpha-beta T cells	J:77098
	arrested T cell differentiation	J:77098
\Cd3e^tm1Mal/\Cd3e^tm1Mal (C57BL/6-Cd3e^tm1Mal)	abnormal B cell morphology	J:81133
	abnormal double-negative T cell morphology	J:81133
	abnormal regulatory T cell physiology	J:125748
	absent T cells	J:131351
	arrested T cell differentiation	J:81133
\Cd3e^tm1Mal/\Cd3e^tm1Mal \Lat^tm1.1Mal/\Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:77098
	absent CD8-positive, alpha-beta T cells	J:77098
	arrested T cell differentiation	J:77098
	immune system phenotype	J:77098
\Cd3e^tm1Mal/\Cd3e^tm1Mal \Nlrp1a^Neut1/\Nlrp1a^Neut1 (involves: C57BL/6)	increased neutrophil cell number	J:191055
	increased susceptibility to infection induced morbidity/mortality	J:191055
	skin inflammation	J:191055
\Cd3g^tm1.1Cage/\Cd3g^tm1.1Cage (B6.129P2-Cd3g^tm1.1Cage)	abnormal response to infection	J:153813
	decreased CD8-positive, alpha-beta T cell number	J:153813
	decreased thymocyte number	J:153813
	increased T cell apoptosis	J:153813
	spleen hypoplasia	J:153813
\Cd3g^tm1.1Cage/\Cd3g^tm1.1Cage \Tg(TcrLCMV)318Sdz/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal response to infection	J:142387
	abnormal T cell physiology	J:142387
	immune system phenotype	J:142387
\Cd3g^tm1Amk/\Cd3g^tm1Amk (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell physiology	J:77504
	abnormal T cell activation	J:77504
	abnormal T cell differentiation	J:77504
	abnormal T cell physiology	J:77504
	abnormal T cell proliferation	J:77504
	decreased cytotoxic T cell cytolysis	J:77504
	decreased thymocyte number	J:114561
	lymph node hypoplasia	J:77504
	thymus hypoplasia	J:77504
\Cd3g^tm1Amk/\Cd3g^tm1Amk \Tg(Igh-Pim1)1Brn/0 (involves: 129P2/OlaHsd * C57BL/6LiA * CBA)	decreased thymocyte number	J:114561
\Cd3g^tm2Amk/\Cd3g^tm2Amk (involves: 129P2/OlaHsd * FVB)	immune system phenotype	J:77504
\Cd4^del/\Cd4^del (C57BR/cdJ-Cd4^del)	abnormal immune system organ morphology	J:46692
	abnormal lymph node T cell domain morphology	J:46692
	abnormal spleen morphology	J:46692
	absent CD4-positive, alpha-beta T cells	J:46692
	decreased IgG level	J:46692
	decreased IgM level	J:46692
	decreased immunoglobulin level	J:46692
	increased CD8-positive, alpha-beta T cell number	J:46692
\Cd4^em1Litt/\Cd4^em1Litt (involves: C57BL/6J)	immune system phenotype	J:333574
\Cd4^em1Litt/\Cd4^em1Litt \Rr386^em1Pdi/\Rr386^em1Pdi (involves: C57BL/6J)	abnormal lymphocyte activation involved in immune response	J:333574
	decreased T helper 1 cell number	J:333574
	immune system phenotype	J:333574
\Cd4^m1Btlr/\Cd4^m1Btlr (C57BL/6J-Cd4^m1Btlr)	absent CD4-positive, alpha-beta T cells	J:212900
\Cd4^m1Btlr/\Cd4^m1Btlr (C57BL/6J-Cd4^m1Btlr)	impaired humoral immune response	J:212900
\Cd4^maat/\Cd4^maat (C57BL/6JAnu-Cd4^maat/Apb)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
	abnormal double-positive T cell morphology	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
	increased CD8-positive, alpha-beta T cell number	J:104190
\Cd4^sesh/\Cd4^sesh (C57BL/6JAnu-Cd4^sesh/AnuApb)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
	abnormal double-positive T cell morphology	J:104190
	decreased T cell number	J:104190
\Cd4^thth/\Cd4^thth (C57BL/6JSfdAnu-Cd4^thth)	absent CD4-positive, alpha-beta T cells	J:104190
\Cd4^{tm1(cre/ERT2)Thbu}/\Cd4⁺ \Gfm1^{tm1c(EUCOMM)Wtsi}/\Gfm1^{tm1c(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N * SJL)	abnormal T-helper 17 cell differentiation	J:302272
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:302272
	increased CD8-positive, alpha-beta T cell number	J:302272
	increased single-positive T cell number	J:302272
\Cd4^{tm1(cre/ERT2)Thbu}/\Cd4⁺ \Tgfbr2^tm1Karl/\Tgfbr2^tm1Karl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:204579
	increased memory T cell number	J:204579
	increased regulatory T cell number	J:204579
\Cd4^tm1Doi/\Cd4^tm1Doi \Lag3^tm1Doi/\Lag3^tm1Doi (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:33272
	increased double-negative T cell number	J:33272
\Cd4^tm1Doi/\Cd4^tm1Litt \Lag3^tm1Doi/\Lag3⁺ (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:33272
	increased double-negative T cell number	J:33272
\Cd4^tm1Jrp/\Cd4^tm1Jrp (either: B6.129S2-Cd4^tm1Jrp or B10.Cg-Cd4^tm1Jrp)	abnormal T cell differentiation	J:45168
	decreased CD4-positive, alpha-beta T cell number	J:45168
	decreased double-positive T cell number	J:45168
	increased CD8-positive, alpha-beta T cell number	J:45168
\Cd4^tm1Jrp/\Cd4^tm1Jrp \Tg(TcrAND)53Hed/0 (either: (involves: 129S2/SvPas * C57BL/6 * SJL) or (involves: 129S2/SvPas * C57BL/6 * C57BL/10 * SJL))	abnormal T cell number	J:45168
	thymus hyperplasia	J:45168
\Cd4^tm1Knw/\Cd4^tm1Knw (B6.129S-Cd4^tm1Knw/J)	decreased CD4-positive, alpha-beta T cell number	J:87828
	increased CD8-positive, alpha-beta T cell number	J:87828
	increased susceptibility to parasitic infection	J:87828
\Cd4^tm1Knw/\Cd4^tm1Knw (NOD.Cg-Cd4^tm1Knw)	decreased susceptibility to autoimmune diabetes	J:93553
\Cd4^tm1Knw/\Cd4^tm1Knw \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0 (NOD.Cg-Cd4^tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	increased susceptibility to autoimmune diabetes	J:93553
\Cd4^tm1Litt/\Cd4^tm1Litt (involves: 129S2/SvPas)	abnormal CD4-positive, alpha-beta T cell physiology	J:50435
	absent CD4-positive, alpha-beta T cells	J:50435
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased T cell proliferation	J:50435
	increased CD8-positive, alpha-beta T cell number	J:158962, J:50435
\Cd4^tm1Litt/\Cd4^tm1Litt \Foxp3^sf\Otc^spf/Y (involves: 129/Rl * 129S2/SvPas)	abnormal CD8-positive, alpha beta T cell morphology	J:20865
	abnormal cytokine secretion	J:20865
	abnormal immune system organ morphology	J:20865
	enlarged lymph nodes	J:20865
	increased IgG level	J:20865
	increased IgM level	J:20865
	increased interleukin-4 secretion	J:20865
	increased interleukin-6 secretion	J:20865
	increased tumor necrosis factor secretion	J:20865
\Cd4^tm1Litt/\Cd4^tm1Litt \Tg(Cd4-CD4)2362Litt/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:50435
\Cd4^tm1Litt/\Cd4^tm1Nik \Tg(Lck-cre)3778Nik/0 (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:73479
	abnormal interleukin-4 secretion	J:73479
	abnormal T-helper 2 physiology	J:73479
	decreased T cell proliferation	J:73479
\Cd4^tm1Litt/\Cd4^tm1Nik \Tg(Lck-cre)3785Nik/0 (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:73479
	decreased CD4-positive, alpha-beta T cell number	J:73479
	increased CD8-positive, alpha-beta T cell number	J:73479
	increased T cell apoptosis	J:73479
	increased T cell proliferation	J:73479
\Cd4^tm1Litt/\Cd4^tm1Nik \Tg(Lck-icre)3779Nik/0 (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:73479
	decreased T cell proliferation	J:73479
\Cd4^tm1Mak/\Cd4^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:68957
	increased CD8-positive, alpha-beta T cell number	J:68957
	increased susceptibility to Picornaviridae infection	J:92227
\Cd4^tm1Mak/\Cd4^tm1Mak (PL.129S2(B6)-Cd4^tm1Mak/Rdgz)	brain inflammation	J:92227
\Cd4^tm1Mak/\Cd4^tm1Mak (PL.129S2(B6)-Cd4^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
\Cd4^tm1Mak/\Cd4^tm1Mak (SJL.129S2(B6)-Cd4^tm1Mak/Rdgz)	brain inflammation	J:92227
\Cd4^tm1Mak/\Cd4^tm1Mak (SJL.129S2(B6)-Cd4^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
\Cd4^tm1Mak/\Cd4^tm1Mak (involves: 129S2/SvPas)	immune system phenotype	J:110749
\Cd4^tm1Mak/\Cd4^tm1Mak (B6.129S2-Cd4^tm1Mak/J)	absent plasma cells	J:133047
\Cd4^tm1Mak/\Cd4^tm1Mak (B6.129S2-Cd4^tm1Mak/J)	immune system phenotype	J:133047
\Cd4^tm1Mak/\Cd4^tm1Mak \Cd8a^tm1Mak/\Cd8a^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal double-negative T cell morphology	J:12572
	abnormal gamma-delta T cell number	J:12572
	abnormal T cell differentiation	J:12572
	abnormal T cell number	J:12572
	decreased cytotoxic T cell cytolysis	J:12572
	decreased double-positive T cell number	J:12572
	increased length of allograft survival	J:12572
	small thymus medulla	J:12572
\Cd4^tm1Mak/\Cd4^tm1Mak \Cd8a^tm1Mak/\Cd8a^tm1Mak (involves: 129S2/SvPas)	increased susceptibility to viral infection	J:110749
\Cd4^tm1Mak/\Cd4^tm1Mak \Igh-J^{tm2(3H9-VDJ)Mwg}/\Igh-J⁺ (B6.Cg-Cd4^tm1Mak Igh-J^{tm2(3H9-VDJ)Mwg})	increased anti-double stranded DNA antibody level	J:142389
\Cd4^tm1Mak/\Cd4^tm1Mak \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	small intestinal inflammation	J:108572
\Cd4^tm1Nik/\Cd4^tm1Nik \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129X1/SvJ)	abnormal regulatory T cell physiology	J:152472
\Cd4ts1^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd4ts2^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd4ts3^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd4ts4^C3H/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd4ts5^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd4ts5^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
\Cd4ts6^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd4vts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd5^{tm1.1(KOMP)Mbp}/\Cd5^{tm1.1(KOMP)Mbp} (C57BL/6N-Cd5^{tm1.1(KOMP)Mbp}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Cd5^tm1.1Chra/\Cd5^tm1.1Chra (involves: C57BL/6 * FVB/N)	abnormal T cell anergy	J:189919
	abnormal T cell physiology	J:189919
	decreased B cell number	J:189919
	decreased CD4-positive, alpha-beta T cell number	J:189919
	decreased double-positive T cell number	J:189919
	decreased follicular B cell number	J:189919
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:189919
	decreased T cell proliferation	J:189919
	decreased T-helper 17 cell number	J:189919
	increased double-negative T cell number	J:189919
	increased T cell proliferation	J:189919
\Cd5^tm1.1Chra/\Cd5^tm1.1Chra \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: C57BL/6 * FVB/N)	decreased interferon-gamma secretion	J:189919
	decreased interleukin-2 secretion	J:189919
	decreased T cell proliferation	J:189919
	decreased T helper 1 cell number	J:189919
	increased interferon-gamma secretion	J:189919
	increased interleukin-6 secretion	J:189919
	increased interleukin-17 secretion	J:189919
\Cd5^tm1Cgn/\Cd5^tm1Cgn (B6.129P2-Cd5^tm1Cgn)	abnormal T cell anergy	J:189919
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:189919
	increased regulatory T cell number	J:189919
	increased T cell proliferation	J:189919
\Cd5l^tm1Nto/\Cd5l^tm1Nto (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-positive T cell morphology	J:52195
	decreased thymocyte number	J:52195
	immune system phenotype	J:52195
	increased susceptibility to bacterial infection	J:82352
\Cd6^tm1Linf/\Cd6^tm1Linf (D1.Cg-Cd6^tm1Linf)	abnormal B cell physiology	J:238478
	decreased B cell proliferation	J:238478
	decreased B-1 B cell number	J:238478
	decreased B-1a cell number	J:238478
	decreased IgM level	J:238478
	decreased interleukin-6 secretion	J:238478
	increased B-1a cell number	J:238478
	increased B-1b cell number	J:238478
\Cd7^tm1Bfh/\Cd7^tm1Bfh (involves: 129 * C57BL/6)	immune system phenotype	J:48758
	increased double-positive T cell number	J:48758
	increased thymocyte number	J:48758
\Cd7^tm1Bfh/\Cd7^tm1Bfh (B6.129-Cd7^tm1Bfh)	decreased cytotoxic T cell cytolysis	J:48758
	decreased interferon-gamma secretion	J:48758
	immune system phenotype	J:48758
	increased double-positive T cell number	J:48758
	increased thymocyte number	J:48758
\Cd7^tm1Fabo/\Cd7^tm1Fabo (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:45026
\Cd8a^m1Btlr/\Cd8a^m1Btlr (C57BL/6J-Cd8a^m1Btlr)	abnormal CD4-positive T cell differentiation	J:221492
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221492
	increased susceptibility to Herpesvirales infection	J:221492
\Cd8a^m2Btlr/\Cd8a^m2Btlr (C57BL/6J-Cd8a^m2Btlr)	abnormal CD8-positive, alpha-beta T cell physiology	J:236677
\Cd8a^m2Btlr/\Cd8a^m2Btlr (C57BL/6J-Cd8a^m2Btlr)	increased CD8-positive, alpha-beta memory T cell proliferation	J:236677
\Cd8a^{tm1.1(cre)Koni}/\Cd8a^{tm1.1(cre)Koni} (involves: C57BL/6J * C57BL/6NHsd * SJL)	decreased CD8-positive, alpha-beta T cell number	J:177182
\Cd8a^tm1.1Kio/\Cd8a^tm1.1Kio (involves: 129S4/SvJae * C57BL/10 * CBA/Ca)	abnormal CD4-positive T cell differentiation	J:76799
\Cd8a^tm1.1Litt/\Cd8a^tm1.1Litt (either: (involves: 129P2/OlaHsd * AKR) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal CD8-positive, alpha beta T cell morphology	J:50624
\Cd8a^tm1.1Welm/\Cd8a^tm1.1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:113136
\Cd8a^tm1Asin/\Cd8a^tm1Asin (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal double-positive T cell morphology	J:126026
\Cd8a^tm1Asin/\Cd8a^tm1Asin \Cd8b1^tm1Litt/\Cd8b1^tm1Litt \H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru (involves: 129 * FVB/N)	decreased CD4-positive, alpha-beta T cell number	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
\Cd8a^tm1Asin/\Cd8a^tm1Asin \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
\Cd8a^tm1Asin/\Cd8a^tm1Asin \Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N)	abnormal positive T cell selection	J:126026
	decreased CD4-positive, alpha-beta T cell number	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
\Cd8a^tm1Asin/\Cd8a^tm1Mak (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * FVB/N)	abnormal positive T cell selection	J:126026
	abnormal T cell subpopulation ratio	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
\Cd8a^tm1Mak/\Cd8a^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:68956
	absent CD8-positive, alpha-beta T cells	J:68956
	increased susceptibility to Picornaviridae infection	J:92227
\Cd8a^tm1Mak/\Cd8a^tm1Mak (PL.129S2(B6)-Cd8a^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
\Cd8a^tm1Mak/\Cd8a^tm1Mak (SJL.129S2(B6)-Cd8a^tm1Mak/Rdgz)	increased susceptibility to Picornaviridae infection	J:92227
\Cd8a^tm1Mak/\Cd8a^tm1Mak (B6.129S2-Cd8a^tm1Mak)	abnormal response to transplant	J:91742
\Cd8a^tm1Mak/\Cd8a^tm1Mak (involves: 129S2/SvPas)	immune system phenotype	J:110749
\Cd8a^tm1Mak/\Cd8a^tm1Mak \Il15^tm1Imx/\Il15^tm1Imx X/\Yaa (BXSB.Cg-Cd8a^tm1Mak Il15^tm1Imx/Dcr)	abnormal spleen B cell follicle morphology	J:179430
	increased anti-nuclear antigen antibody level	J:179430
	increased IgG1 level	J:179430
	increased IgG2a level	J:179430
	increased IgG2b level	J:179430
	increased monocyte cell number	J:179430
	increased splenocyte number	J:179430
	increased susceptibility to systemic lupus erythematosus	J:179430
\Cd8a^tm1Mak/\Cd8a^tm1Mak X/\Yaa (BXSB.129S2(B6)-Cd8a^tm1Mak/4Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
\Cd8a^tm1Mak/\Cd8a^tm1Mak \Zbtb7b^hd/\Zbtb7b^hd (involves: B6.129S2-Cd8a^tm1Mak * B6.Cg-Thpok^hd)	absent CD4-positive, alpha-beta T cells	J:95867
\Cd8b1^M1Btlr/\Cd8b1⁺ (C57BL/6J-Cd8b1^M1Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:255009
\Cd8b1^M1Btlr/\Cd8b1⁺ (C57BL/6J-Cd8b1^M1Btlr)	increased CD4-positive, alpha-beta T cell number	J:255009
\Cd8b1^M1Btlr/\Cd8b1^M1Btlr (C57BL/6J-Cd8b1^M1Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:255009
	enhanced humoral immune response	J:255009
	increased CD4-positive, alpha-beta T cell number	J:255009
	increased IgG level	J:255009
\Cd8b1^m2Btlr/\Cd8b1^m2Btlr (C57BL/6J-Cd8b1^m2Btlr)	abnormal B cell differentiation	J:274761
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274761
	decreased CD8-positive, alpha-beta T cell number	J:274761
	decreased CD8-positive, naive alpha-beta T cell number	J:274761
	decreased T cell number	J:274761
	increased CD4-positive, alpha-beta T cell number	J:274761
	increased central memory CD8 positive, alpha-beta T cell number	J:274761
	increased effector memory CD8-positive, alpha-beta T cell number	J:274761
\Cd8b1^tm1Litt/\Cd8b1⁺ \Tg(Cd8b1)46Erob/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal T cell subpopulation ratio	J:110916
	decreased T cell number	J:110916
	decreased thymocyte number	J:110916
\Cd8b1^tm1Litt/\Cd8b1⁺ \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S4/SvJae * C57BL/6J * DBA/2)	decreased double-positive T cell number	J:112551
\Cd8b1^tm1Litt/\Cd8b1^tm1Litt (involves: 129S4/SvJae * C57BL/6J)	abnormal cytotoxic T cell physiology	J:112551
	abnormal T cell subpopulation ratio	J:110916
	decreased CD8-positive, alpha-beta T cell number	J:112551, J:110916
	decreased thymocyte number	J:110916
\Cd8b1^tm1Litt/\Cd8b1^tm1Litt \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S4/SvJae * C57BL/6J * DBA/2)	abnormal lymph node cell ratio	J:112551
	abnormal negative T cell selection	J:112551
	abnormal positive T cell selection	J:112551
	decreased CD8-positive, alpha-beta T cell number	J:112551
	increased CD4-positive, alpha-beta T cell number	J:112551
\Cd8b1^tm1Wpfl/\Cd8b1^tm1Wpfl (involves: 129S2/SvPas)	abnormal CD8-positive, alpha beta T cell morphology	J:19928
	abnormal CD8-positive, alpha-beta T cell differentiation	J:19928
	abnormal T cell subpopulation ratio	J:19928
	decreased CD8-positive, alpha-beta T cell number	J:19928
	decreased thymocyte number	J:19928
	immune system phenotype	J:19928
\Cd8mts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
\Cd8mts2^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
\Cd8mts3^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
\Cd8mts4^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
\Cd8mts5^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd8mts5^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased memory T cell number	J:83220
\Cd8mts6^C3H/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
\Cd8ts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
\Cd8ts2^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
\Cd8ts3^C3H/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
\Cd8ts3^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Cd14^hdl/\Cd14^hdl (C57BL/6-Cd14^hdl)	abnormal interferon secretion	J:98908
	decreased susceptibility to endotoxin shock	J:98908
	decreased tumor necrosis factor secretion	J:98908
	increased susceptibility to Riboviria infection	J:98908
\Cd14^tm1Frm/\Cd14⁺ (involves: 129S4/SvJae * C57BL/6J)	abnormal cytokine secretion	J:65107
	decreased interleukin-6 secretion	J:65107
	decreased tumor necrosis factor secretion	J:65107
\Cd14^tm1Frm/\Cd14^tm1Frm (involves: 129S4/SvJae * C57BL/6J)	abnormal cytokine secretion	J:65107
	decreased interleukin-6 secretion	J:65107
	decreased tumor necrosis factor secretion	J:65107
\Cd14^tm1Frm/\Cd14^tm1Frm (involves: 129S4/SvJae)	abnormal interferon secretion	J:98908
	decreased susceptibility to endotoxin shock	J:98908
	increased susceptibility to Riboviria infection	J:98908
\Cd14^tm1Frm/\Cd14^tm1Frm (B6.129S4-Cd14^tm1Frm)	abnormal cytokine level	J:96680
	abnormal interleukin level	J:96680
	abnormal tumor necrosis factor level	J:96680
\Cd14^tm1Smg/\Cd14^tm1Smg (involves: 129S1/Sv * C57BL/6)	decreased circulating interleukin-6 level	J:32729
	decreased circulating tumor necrosis factor level	J:32729
	decreased interleukin-6 secretion	J:32729
	decreased susceptibility to bacterial infection	J:32729
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:32729
	decreased susceptibility to endotoxin shock	J:32729
	decreased tumor necrosis factor secretion	J:32729
\Cd14^tm1Smg/\Cd14^tm1Smg (C.129S1-CD14^tm1Smg)	abnormal macrophage physiology	J:116691
	abnormal neutrophil physiology	J:127072
	decreased susceptibility to bacterial infection	J:127072
	decreased tumor necrosis factor secretion	J:116691
\Cd14^tm1Smg/\Cd14^tm1Smg (B6.129S1-CD14^tm1Smg)	decreased susceptibility to bacterial infection	J:127072
\Cd14^tm1Smg/\Cd14^tm1Smg (involves: 129S1/Sv)	abnormal tumor necrosis factor level	J:103464
\Cd14^tm1Smg/\Cd14^tm1Smg \Tlr4^Lps-d/\Tlr4^Lps-d (C3.129S1-CD14^tm1Smg)	abnormal macrophage physiology	J:116691
	decreased tumor necrosis factor secretion	J:116691
\Cd19^em2(IMPC)Ics/\Cd19^em2(IMPC)Ics (C57BL/6N-Cd19^em2(IMPC)Ics/Ics)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Cd19^tm1(cre)Cgn/? \Gt(ROSA)26Sor^{tm1(HBEGF)Awai}/\Gt(ROSA)26Sor^{tm1(HBEGF)Awai} (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:131076
	abnormal lymph node cell ratio	J:131076
	abnormal lymphocyte cell number	J:131076
	abnormal lymphocyte morphology	J:131076
	abnormal splenic cell ratio	J:131076
	absent immature B cells	J:131076
	absent mature B cells	J:131076
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Cd1d1^tm1.1Aben/\Cd1d1^tm1.1Aben (B6.Cg-Cd1d1^tm1.1Aben Cd19^tm1(cre)Cgn)	immune system phenotype	J:183087
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ctnnbl1^tm1.1Crad/\Ctnnbl1^tm1.1Crad (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased B cell proliferation	J:232010
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Cxcr4^tm1Tng/\Cxcr4^tm2Tng (involves: 129P2/OlaHsd * C57BL/6)	decreased plasma cell number	J:109147
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Derl2^tm1.1Hpl/\Derl2^tm1.1Hpl (involves: 129P2/OlaHsd)	immune system phenotype	J:170650
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ell2^tm1.1Cmil/\Ell2^tm1.1Cmil (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased IgA level	J:234692
	decreased IgG1 level	J:234692
	decreased IgM level	J:234692
	decreased immunoglobulin level	J:234692
	decreased mature B cell number	J:234692
	decreased plasma cell number	J:234692
	decreased transitional stage T1 B cell number	J:234692
	decreased transitional stage T2 B cell number	J:234692
	decreased transitional stage T3 B cell number	J:234692
	impaired humoral immune response	J:234692
	increased follicular B cell number	J:234692
	increased immature B cell number	J:234692
	increased pre-B cell number	J:234692
	increased pro-B cell number	J:234692
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ell2^tm2.1Cmil/\Ell2^tm2.1Cmil (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased IgA level	J:234692
	decreased IgG1 level	J:234692
	decreased IgM level	J:234692
	decreased immunoglobulin level	J:234692
	decreased mature B cell number	J:234692
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ep300^tm2Reck/\Ep300⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal adaptive immunity	J:147840
	abnormal B cell differentiation	J:147840
	abnormal humoral immune response	J:147840
	abnormal spleen marginal zone macrophage morphology	J:147840
	abnormal transitional stage B cell morphology	J:147840
	arteritis	J:147840
	decreased B cell proliferation	J:147840
	decreased marginal zone B cell number	J:147840
	enlarged lymph nodes	J:147840
	enlarged spleen	J:147840
	glomerulonephritis	J:147840
	increased activated T cell number	J:147840
	increased anti-double stranded DNA antibody level	J:147840
	increased B cell apoptosis	J:147840
	increased B cell number	J:147840
	increased IgG2b level	J:147840
	increased immunoglobulin level	J:147840
	increased spleen weight	J:147840
	increased susceptibility to systemic lupus erythematosus	J:147840
	intermingled spleen red and white pulp	J:147840
	kidney inflammation	J:147840
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ep300^tm2Reck/\Ep300⁺ (involves: 129/Sv * 129P2/OlaHsd * FVB/N)	increased susceptibility to systemic lupus erythematosus	J:147840
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Fas^lpr/\Fas^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6 * MRL)	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Fas^lpr/\Fas^tm1Cgn \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL)	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
	increased double-negative T cell number	J:114948
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Fas^tm1Ach/\Fas^tm1Ach (involves: 129P2/OlaHsd * BALB/c)	enlarged spleen	J:123556
	increased anti-nuclear antigen antibody level	J:123556
	increased immunoglobulin level	J:123556
	increased lymphocyte cell number	J:123556
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Fas^tm1Cgn/\Fas^tm1Cgn (B6.Cg-Cd19^tm1(cre)Cgn Fas^tm1Cgn)	increased anti-single stranded DNA antibody level	J:114948
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gna12^tm1Citb/\Gna12^tm1Citb \Gna13^tm2.1Soff/\Gna13^tm2.1Soff (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N)	abnormal B cell physiology	J:117663
	decreased marginal zone B cell number	J:117663
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl}/\Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl} (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:112660
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^tm1(DTA)Riet/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	decreased B cell number	J:92789
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm1(ITK/SYK)Jrld}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	abnormal T cell activation	J:160931
	enlarged spleen	J:160931
	increased T cell derived lymphoma incidence	J:160931
	increased T cell proliferation	J:160931
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^tm1Uzs/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:130768
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	abnormal B cell activation	J:228288
	abnormal plasmablast number	J:228288
	abnormal spleen morphology	J:228288
	enlarged lymph nodes	J:228288
	enlarged spleen	J:228288
	increased B cell number	J:228288
	increased B cell proliferation	J:228288
	increased plasma cell number	J:228288
	spleen hyperplasia	J:228288
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm2(CARD11*L225LI)Jrld}/\Gt(ROSA)26Sor⁺ \Malt1^tm1Mak/\Malt1^tm1Mak (involves: 129P2/OlaHsd)	immune system phenotype	J:228288
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm2(Cd74/MOG)Awai}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:140751
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm2(Cd74/MOG)Awai}/\Gt(ROSA)26Sor⁺ \Il10^tm1Roer/\Il10^tm1Roer (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:140751
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:113365
	abnormal splenic cell ratio	J:113365
	decreased B cell apoptosis	J:113365
	increased B cell number	J:113365
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/\Gt(ROSA)26Sor⁺ \Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:113365
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}/\Gt(ROSA)26Sor^{tm5(Map3k14)Rsky} (involves: 129P2/OlaHsd * C57BL/6)	enlarged lymph nodes	J:139293
	enlarged spleen	J:139293
	increased marginal zone B cell number	J:139293
	increased mature B cell number	J:139293
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm5(Map3k14)Rsky}/\Gt(ROSA)26Sor^{tm5(Map3k14)Rsky} \Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	decreased lymphocyte cell number	J:139293
	decreased mature B cell number	J:139293
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm6(Map3k14)Rsky}/\Gt(ROSA)26Sor^{tm6(Map3k14)Rsky} (involves: 129P2/OlaHsd * C57BL/6)	abnormal Peyer's patch morphology	J:139293
	abnormal spleen B cell follicle morphology	J:139293
	decreased B-1 B cell number	J:139293
	enlarged lymph nodes	J:139293
	enlarged spleen	J:139293
	increased mature B cell number	J:139293
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Gt(ROSA)26Sor^{tm6(Map3k14)Rsky}/\Gt(ROSA)26Sor^{tm6(Map3k14)Rsky} \Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	increased lymphocyte cell number	J:139293
	increased mature B cell number	J:139293
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ifnar1^tm1Uka/\Ifnar1^tm1Uka (B6.129P2-Cd19^tm1(cre)Cgn Ifnar1^tm1Uka)	decreased IgG1 level	J:129128
	decreased IgG2a level	J:129128
	decreased IgG3 level	J:129128
	decreased IgM level	J:129128
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Igbp1^tm1Imku/Y (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:74619
	abnormal somatic hypermutation frequency	J:74619
	abnormal spleen germinal center morphology	J:74619
	decreased B cell number	J:74619
	decreased B cell proliferation	J:74619
	decreased follicular B cell number	J:74619
	decreased immunoglobulin level	J:74619
	decreased pre-B cell number	J:74619
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ikbkb^tm1Cgn/\Ikbkb^tm1.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	decreased B-1 B cell number	J:79132
	decreased follicular B cell number	J:79132
	decreased immature B cell number	J:79132
	decreased marginal zone B cell number	J:79132
	decreased mature B cell number	J:79132
	increased B cell proliferation	J:79132
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ikbkb^tm2Cgn/\Ikbkb^tm2.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	decreased B-1 B cell number	J:79132
	decreased follicular B cell number	J:79132
	decreased marginal zone B cell number	J:79132
	decreased mature B cell number	J:79132
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ikbkb^tm2Mka/\Ikbkb^tm2Mka (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:82995
	decreased B cell number	J:82995
	decreased B cell proliferation	J:82995
	decreased B-1 B cell number	J:82995
	decreased IgG level	J:82995
	decreased IgM level	J:82995
	decreased marginal zone B cell number	J:82995
	increased B cell apoptosis	J:82995
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ikbkg^tm1.1Mpa/Y (involves: 129P2/OlaHsd * C57BL/6)	decreased B-1 B cell number	J:79132
	decreased follicular B cell number	J:79132
	decreased immature B cell number	J:79132
	decreased marginal zone B cell number	J:79132
	decreased mature B cell number	J:79132
	increased B cell proliferation	J:79132
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Il10^tm1Roer/\Il10^tm1Roer (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell physiology	J:151551
	abnormal myeloid leukocyte morphology	J:151551
	decreased circulating interleukin-10 level	J:151551
	increased B cell number	J:151551
	increased CD4-positive, alpha-beta T cell number	J:151551
	increased plasma cell number	J:151551
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Il10ra^tm1.1Jack/\Il10ra^tm1.1Jack (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	immune system phenotype	J:157787
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Inpp5d^tm1Rav/\Inpp5d^tm1Rav \Pten^tm1Hwu/\Pten^tm1Hwu (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal B cell morphology	J:166155
	abnormal B cell physiology	J:166155
	abnormal myeloid leukocyte morphology	J:166155
	decreased B cell number	J:166155
	enlarged spleen	J:166155
	increased B cell number	J:166155
	increased B cell proliferation	J:166155
	increased spleen white pulp amount	J:166155
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Irf8^tm1.1Hm/\Irf8^tm1.1Hm (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen marginal zone morphology	J:168923
	decreased follicular B cell number	J:168923
	immune system phenotype	J:168923
	increased B cell number	J:168923
	increased B-2 B cell number	J:168923
	increased follicular B cell number	J:168923
	increased marginal zone B cell number	J:168923
	increased transitional stage B cell number	J:168923
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Klhl6^tm2Sato/\Klhl6^tm2Sato (either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1))	abnormal B cell differentiation	J:101363
	abnormal lymph node germinal center morphology	J:101363
	decreased B cell number	J:101363
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Kmt2a^tm1.1Erns/\Kmt2a^tm1.1Erns (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:147265
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ltb^tm1Avt/\Ltb^tm1Avt (involves: 129P2/OlaHsd * C57BL/6)	abnormal adaptive immunity	J:79129
	abnormal spleen B cell follicle morphology	J:79129
	abnormal spleen follicular dendritic cell network	J:79129
	decreased marginal zone B cell number	J:79129
	decreased spleen germinal center number	J:79129
	decreased spleen germinal center size	J:79129
	small Peyer's patches	J:79129
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ltb^tm1Avt/\Ltb^tm1Avt \Tg(Lck-cre)1Jtak/? (involves: 129P2/OlaHsd * C57BL/6)	absent follicular dendritic cells	J:79129
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ltbr^tm1Avt/\Ltbr^tm1Avt (involves: 129P2/OlaHsd)	immune system phenotype	J:158663
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ltbr^tm1Avt/\Ltbr^tm1Avt \Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd)	immune system phenotype	J:158663
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Map3k7^tm1Aki/\Map3k7^tm1.1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:112597
	decreased B cell proliferation	J:112597
	decreased B-1 B cell number	J:112597
	decreased IgG1 level	J:112597
	decreased IgG3 level	J:112597
	decreased IgG level	J:112597
	decreased immunoglobulin level	J:112597
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Mcl1^tm2Sjk/\Mcl1^tm3Sjk (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal B cell differentiation	J:86906
	absent early pro-B cells	J:86906
	absent late pro-B cells	J:86906
	absent pre-B cells	J:86906
	arrested B cell differentiation	J:86906
	decreased B cell number	J:86906
	increased B cell apoptosis	J:86906
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Mirc30^tm1.1Rdf/\Mirc30^tm1.1Rdf (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Myd88^em1.1Rsky/\Myd88⁺ (involves: C57BL/6NTac)	abnormal splenic cell ratio	J:308792
	enlarged spleen	J:308792
	increased germinal center B cell number	J:308792
	increased IgM level	J:308792
	increased plasma cell number	J:308792
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Myd88^em1.1Rsky/\Myd88^em1.1Rsky (involves: C57BL/6NTac)	increased B cell proliferation	J:308792
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Notch2^tm1.1Hhi/\Notch2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased marginal zone B cell number	J:83476
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Notch2^tm2Hhi/\Notch2^tm1.1Hhi (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal spleen marginal zone morphology	J:83476
	absent marginal zone B cells	J:83476
	decreased transitional stage B cell number	J:83476
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Pax5^tm1Mbu/\Pax5^tm3Mbu (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal B cell differentiation	J:75504
	abnormal class switch recombination	J:75504
	decreased IgG1 level	J:75504
	decreased IgG3 level	J:75504
	decreased IgG level	J:75504
	decreased immature B cell number	J:75504
	decreased immunoglobulin level	J:75504
	decreased mature B cell number	J:75504
	decreased pre-B cell number	J:75504
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Pdia3^tm1Gjh/\Pdia3^tm1Gjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:112606
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Prdm1^tm1Clme/\Prdm1^tm1Clme (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal B cell differentiation	J:101890
	abnormal memory B cell number	J:101890
	abnormal plasma cell differentiation	J:101890
	abnormal plasma cell morphology	J:101890, J:114881
	decreased IgG level	J:101890
	decreased IgM level	J:101890
	decreased immunoglobulin level	J:101890
	decreased plasma cell number	J:101890
	increased spleen germinal center number	J:101890
	increased spleen germinal center size	J:101890
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Pten^tm1Hwu/\Pten^tm1Hwu (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal B cell negative selection	J:155314
	abnormal B cell physiology	J:83213
	abnormal class switch recombination	J:114881
	abnormal plasma cell morphology	J:114881
	decreased IgG level	J:114881
	decreased spleen germinal center number	J:83213
	increased B cell apoptosis	J:83213
	increased B cell number	J:83213
	increased B cell proliferation	J:155314, J:83213
	increased B-1 B cell number	J:83213
	increased IgM level	J:114881
	increased marginal zone B cell number	J:83213
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Pten^tm1Hwu/\Pten^tm1Hwu \Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal peripheral B cell anergy	J:155314
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ptpn6^tm1Rsky/\Ptpn6^tm1Rsky (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:123568
	abnormal immune system physiology	J:123568
	abnormal leukocyte cell number	J:123568
	abnormal lymph organ size	J:123568
	decreased B cell proliferation	J:123568
	decreased follicular B cell number	J:123568
	decreased marginal zone B cell number	J:123568
	enlarged lymph nodes	J:123568
	enlarged spleen	J:123568
	increased B cell number	J:123568
	increased B-1a cell number	J:123568
	increased granulocyte number	J:123568
	increased macrophage cell number	J:123568
	increased plasma cell number	J:123568
	increased susceptibility to systemic lupus erythematosus	J:123568
	increased T cell number	J:123568
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Rac1^tm1Tyb/\Rac1^tm1Tyb (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	immune system phenotype	J:86765
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Rac1^tm1Tyb/\Rac1^tm1Tyb \Rac2^tm1Mddw/\Rac2^tm1Mddw (involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6)	arrested B cell differentiation	J:86765
	decreased B cell number	J:86765
	decreased B-1 B cell number	J:86765
	decreased follicular B cell number	J:86765
	decreased marginal zone B cell number	J:86765
	decreased transitional stage B cell number	J:86765
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Rapgef2^tm1.1Hous/\Rapgef2^tm1.1Hous (involves: 129P2/OlaHsd * 129S1/Sv)	immune system phenotype	J:165879
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Rbpj^tm1Hon/\Rbpj^tm1Hon (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:76240
	decreased marginal zone B cell number	J:121523, J:76240
	increased follicular B cell number	J:121523, J:76240
	increased IgG3 level	J:76240
	increased susceptibility to bacterial infection	J:76240
	increased susceptibility to bacterial infection induced morbidity/mortality	J:76240
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Rbpj^tm1Hon/\Rbpj^tm1Hon \Spen^tm2.1Hon/\Spen^tm2.1Hon (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased marginal zone B cell number	J:121523
	increased follicular B cell number	J:121523
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Slc3a2^tm1.1Mgin/\Slc3a2^tm1.1Mgin (involves: 129 * C57BL/6 * SJL)	abnormal B cell activation	J:148000
	abnormal B cell physiology	J:148000
	abnormal class switch recombination	J:148000
	abnormal plasma cell differentiation	J:148000
	decreased B cell proliferation	J:148000
	decreased germinal center B cell number	J:148000
	decreased IgG level	J:148000
	decreased IgM level	J:148000
	immune system phenotype	J:148000
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Slc3a2^tm1.1Mgin/\Slc3a2^tm1Yai (involves: 129 * C57BL/6 * SJL)	decreased IgG3 level	J:148000
	decreased IgM level	J:148000
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Spen^tm2.1Hon/\Spen^tm2.1Hon (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased follicular B cell number	J:121523
	increased marginal zone B cell number	J:121523
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Srsf3^tm1Pjln/\Srsf3^tm1Pjln (involves: 129P2/OlaHsd * BALB/c)	decreased B cell number	J:113645
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tbl1xr1^{tm1c(EUCOMM)Hmgu}/\Tbl1xr1^{tm1c(EUCOMM)Hmgu} \Tg(Vav-BCL2)69Jad/0 (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)	abnormal B cell differentiation	J:292118
	abnormal lymphocyte morphology	J:292118
	abnormal spleen morphology	J:292118
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tcf3^tm1Mbu/\Tcf3^tm1.2Mbu (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased B cell number	J:137719
	decreased immature B cell number	J:137719
	decreased mature B cell number	J:137719
	decreased pre-B cell number	J:137719
	decreased pro-B cell number	J:137719
	decreased transitional stage B cell number	J:137719
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tcf3^tm1Mbu/\Tcf3^tm1.2Mbu \Tg(Vav-BCL2)69Jad/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)	decreased pre-B cell number	J:137719
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tgfbr2^tm1Roes/\Tgfbr2^tm1Roes (involves: 129P2/OlaHsd * BALB/c)	abnormal B cell physiology	J:90558
	abnormal B-1 B cell morphology	J:90558
	abnormal B-1 B cell number	J:90558
	absent plasma cells	J:90558
	decreased IgA level	J:90558
	enlarged Peyer's patches	J:90558
	increased IgG level	J:90558
	increased IgM level	J:90558
	increased leukocyte cell number	J:90558
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tnf^tm2.1Gkl/\Tnf^tm2.1Gkl (involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:108572
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tnfaip3^tm1.1Awai/\Tnfaip3^tm1.1Awai (involves: 129P2/OlaHsd)	decreased B-1a cell number	J:175422
	decreased B-1b cell number	J:175422
	decreased marginal zone B cell number	J:175422
	decreased mature B cell number	J:175422
	enlarged spleen	J:175422
	increased anti-nuclear antigen antibody level	J:175422
	increased B cell number	J:175422
	increased B cell proliferation	J:175422
	increased follicular B cell number	J:175422
	increased germinal center B cell number	J:175422
	increased IgA level	J:175422
	increased IgG2a level	J:175422
	increased IgM level	J:175422
	increased splenocyte number	J:175422
	increased T cell number	J:175422
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tnfaip3^tm2Ama/\Tnfaip3⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell apoptosis	J:163917
	increased autoantibody level	J:163917
	increased germinal center B cell number	J:163917
	increased immunoglobulin level	J:163917
	increased plasma cell number	J:163917
	increased susceptibility to autoimmune disorder	J:163917
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:172843
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Tnfsf13b^tm1Msc/\Tnfsf13b^tm1Msc \Traf2^tm1Rbr/\Traf2^tm1Rbr (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased follicular B cell number	J:132877
	increased marginal zone B cell number	J:132877
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Traf2^tm1Rbr/\Traf2^tm1Rbr (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:132877
	increased follicular B cell number	J:132877
	increased marginal zone B cell number	J:132877
	lymph node hyperplasia	J:132877
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Traf2^tm1Rbr/\Traf2^tm1Rbr \Traf3^tm1Rbr/\Traf3^tm1Rbr (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal B cell physiology	J:132877
	increased marginal zone B cell number	J:132877
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Traf3^tm1Rbr/\Traf3^tm1Rbr (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal B cell physiology	J:132877
	increased follicular B cell number	J:132877
	increased marginal zone B cell number	J:132877
	lymph node hyperplasia	J:132877
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Ube2n^tm1Aki/\Ube2n^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:112287
	abnormal humoral immune response	J:112287
	abnormal spleen marginal zone morphology	J:112287
	decreased B cell number	J:112287
	decreased B cell proliferation	J:112287
	decreased immunoglobulin level	J:112287
	decreased marginal zone B cell number	J:112287
	increased B cell apoptosis	J:112287
\Cd19^tm1(cre)Cgn/\Cd19⁺ \Wac^em2Cya/\Wac^em2Cya (B6.Cg-Cd19^tm1(cre)Cgn Wac^em2Cya)	abnormal plasma cell differentiation	J:345327
	decreased B cell proliferation	J:345327
	decreased IgG1 level	J:345327
	decreased IgG2b level	J:345327
	decreased IgG3 level	J:345327
	decreased IgM level	J:345327
	decreased plasma cell number	J:345327
	impaired humoral immune response	J:345327
\Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:27463
	abnormal B cell physiology	J:27463
	abnormal immunoglobulin level	J:27463
	absent spleen germinal center	J:83213, J:27463
	decreased B-1 B cell number	J:83213, J:27463
	decreased IgE level	J:27463
	decreased IgG1 level	J:27463
	decreased IgM level	J:27463
\Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn \Igh^tm1Mnz/\Igh^tm1Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:75653
\Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn \Igh^tm2Mnz/\Igh^tm2Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:75653
\Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn \Pten^tm1Hwu/\Pten^tm1Hwu (involves: 129P2/OlaHsd * 129S4/SvJae)	immune system phenotype	J:83213
\Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:155314
	immune system phenotype	J:155314
\Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn \Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:155314
	immune system phenotype	J:155314
\Cd19^{tm1(cre/ERT2)Rsky}/\Cd19⁺ \Myd88^em1.1Rsky/\Myd88⁺ (involves: 129P2/OlaHsd * C57BL/6NTac)	increased IgM level	J:308792
	increased plasma cell number	J:308792
\Cd19^tm1Tft/\Cd19^tm1Tft (Not Specified)	abnormal B cell physiology	J:27236
	decreased B cell number	J:27236
	decreased B cell proliferation	J:27236
	decreased B-1 B cell number	J:27236
	decreased IgA level	J:27236
	decreased IgG1 level	J:27236
	decreased IgG2a level	J:27236
	decreased IgG2b level	J:27236
	decreased IgG3 level	J:27236
	decreased IgM level	J:27236
\Cd19^tm1Tft/\Cd19^tm1Tft (involves: 129/Sv * C57BL/6)	decreased neutrophil cell number	J:66111
\Cd19^tm1Tft/\Cd19^tm1Tft (involves: 129/Sv * C57BL/6)	decreased tumor necrosis factor secretion	J:66111
\Cd19^tm1Tft/\Cd19^tm1Tft (involves: 129 * C57BL/6)	abnormal humoral immune response	J:71174
	decreased B cell number	J:71174
	decreased B cell proliferation	J:71174
	decreased B-1 B cell number	J:71174
	decreased IgA level	J:71174
	decreased IgG1 level	J:71174
	decreased IgG2b level	J:71174
	decreased IgM level	J:71174
\Cd19^tm1Tft/\Cd19^tm1Tft (B6.Cg-Cd19^tm1Tft)	abnormal B cell physiology	J:136210
	decreased anti-double stranded DNA antibody level	J:136210
	decreased anti-nuclear antigen antibody level	J:136210
	decreased circulating interferon-gamma level	J:136210
	decreased circulating interleukin-4 level	J:136210
	decreased circulating interleukin-6 level	J:136210
	decreased circulating interleukin-10 level	J:136210
	decreased circulating tumor necrosis factor level	J:136210
	decreased IgA level	J:136210
	decreased IgG1 level	J:136210
	decreased IgG2a level	J:136210
	decreased IgG2b level	J:136210
	decreased IgG3 level	J:136210
	decreased IgM level	J:136210
	decreased interleukin-10 secretion	J:106487
	increased CD8-positive, alpha-beta T cell number	J:106487
	increased interferon-gamma secretion	J:106487
	increased susceptibility to experimental autoimmune encephalomyelitis	J:106487
\Cd19^tm1Tft/\Cd19^tm1Tft \Lyn^tm1Sor/\Lyn^tm1Sor (involves: 129S4/SvJaeSor * C57BL/6)	abnormal humoral immune response	J:71174
	decreased anti-double stranded DNA antibody level	J:71174
	decreased B cell number	J:71174
	decreased B cell proliferation	J:71174
	decreased B-1 B cell number	J:71174
	decreased mature B cell number	J:71174
	decreased susceptibility to systemic lupus erythematosus	J:71174
	enlarged spleen	J:71174
	immune system phenotype	J:71174
\Cd22^m1Anu/\Cd22^m1Anu (C57BL/6JAnu-Cd22^m1Anu/AnuApb)	arrested B cell differentiation	J:104190
\Cd22^m1Anu/\Cd22^m1Anu (C57BL/6JAnu-Cd22^m1Anu/AnuApb)	decreased B cell number	J:104190
\Cd22^m1Btlr/\Cd22^m1Btlr (C57BL/6J-Cd22^m1Btlr)	abnormal B cell differentiation	J:173079
\Cd22^m1Btlr/\Cd22^m1Btlr (C57BL/6J-Cd22^m1Btlr)	abnormal humoral immune response	J:173079
\Cd22^m1Btlr/\Cd22^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
\Cd22^m2Btlr/\Cd22^m2Btlr (C57BL/6J-Cd22^m2Btlr)	abnormal B cell differentiation	J:215821
\Cd22^m2Btlr/\Cd22^m2Btlr (C57BL/6J-Cd22^m2Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:215821
\Cd22^m3Btlr/\Cd22^m3Btlr (C57BL/6J-Cd22^m3Btlr)	decreased B cell number	J:220066
\Cd22^m3Btlr/\Cd22^m3Btlr (C57BL/6J-Cd22^m3Btlr)	increased B-1a cell number	J:220066
\Cd22^m4Btlr/\Cd22^m4Btlr (C57BL/6J-Cd22^m4Btlr)	decreased B cell number	J:224660
	decreased B-2 B cell number	J:224660
	decreased memory B cell number	J:224660
	increased B-1a cell number	J:224660
\Cd22^m5Btlr/\Cd22^m5Btlr (C57BL/6J-Cd22^m5Btlr)	decreased B cell number	J:254827
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254827
	increased CD8-positive, alpha-beta memory T cell number	J:254827
\Cd22^{tm1.1(CD22)Lnit}/\Cd22^{tm1.1(CD22)Lnit} (involves: 129S4/SvJae)	abnormal B cell calcium ion homeostasis	J:189017
	abnormal B cell physiology	J:189017
	decreased B cell number	J:189017
	decreased marginal zone B cell number	J:189017
	decreased transitional stage T1 B cell number	J:189017
	decreased transitional stage T2 B cell number	J:189017
	immune system phenotype	J:189017
	impaired B cell migration	J:189017
\Cd22^{tm1b(EUCOMM)Wtsi}/\Cd22^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cd22^{tm1b(EUCOMM)Wtsi}/Tcp)	increased monocyte cell number	J:211773
\Cd22^tm1Eac/\Cd22⁺ \Lyn^tm1Ard/\Lyn⁺ \Ptpn6^me-v/\Ptpn6⁺ \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
	increased IgM level	J:110531
\Cd22^tm1Eac/\Cd22⁺ \Lyn^tm1Ard/\Lyn⁺ \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
\Cd22^tm1Eac/\Cd22⁺ \Ptpn6^me-v/\Ptpn6⁺ \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
\Cd22^tm1Eac/\Cd22⁺ \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
\Cd22^tm1Eac/\Cd22^tm1Eac (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:37451
	abnormal B cell proliferation	J:37451, J:132991
	abnormal mature B cell morphology	J:37451
	abnormal transitional stage B cell morphology	J:132991
	decreased IgG1 level	J:37451
	decreased IgG3 level	J:37451
	decreased IgM level	J:37451
	decreased marginal zone B cell number	J:132991
	decreased mature B cell number	J:37451, J:132991
	decreased memory B cell number	J:37451
	increased B cell apoptosis	J:132991
\Cd22^tm1Lam/\Cd22^tm1Lam (involves: 129 * C57BL/6)	abnormal B cell activation	J:125719
	decreased marginal zone B cell number	J:125719
	decreased mature B cell number	J:125719
\Cd22^tm1Lam/\Cd22^tm1Lam \Igh^tm1.2Rsky/\Igh⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal class switch recombination	J:125719
\Cd22^tm1Lam/\Cd22^tm1Lam \Igh^tm1.2Rsky/\Igh^tm1.2Rsky (involves: 129 * BALB/c * C57BL/6)	abnormal B cell activation	J:125719
	decreased B-1a cell number	J:125719
\Cd22^tm1Lnit/\Cd22^tm1Lnit (involves: 129P2/OlaHsd * C57BL/6)	decreased marginal zone B cell number	J:198790
	immune system phenotype	J:198790
\Cd22^tm1Msn/\Cd22^tm1Msn (either: (involves: 129S/SvEv * BALB/c) or (involves: 129S/SvEv * C57BL/6J))	abnormal B cell activation	J:76974
	abnormal B cell calcium ion homeostasis	J:76974
	abnormal immune system physiology	J:76974
	abnormal immunoglobulin level	J:76974
	abnormal mature B cell morphology	J:76974
	increased anti-double stranded DNA antibody level	J:76974, J:76975
	increased B-1 B cell number	J:76974
	increased IgG2a level	J:76975
	increased IgG level	J:76975
	increased IgM level	J:76974
\Cd22^tm1Tft/\Cd22^tm1Tft (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:92736
	decreased marginal zone B cell number	J:92736
	decreased mature B cell number	J:92736
	increased B cell proliferation	J:92736
\Cd22^tm2Lnit/\Cd22^tm2Lnit (involves: 129P2/OlaHsd * C57BL/6)	absent mature B cells	J:198790
	autoimmune response	J:198790
	decreased marginal zone B cell number	J:198790
	immune system phenotype	J:198790
\Cd22^tm2Tft/\Cd22^tm2Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased B cell number	J:92736
	decreased B cell proliferation	J:92736
	increased B cell proliferation	J:92736
\Cd22^tm2Tft/\Cd22^tm2Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal peripheral B cell anergy	J:208364
	decreased B cell number	J:208364
	decreased B cell proliferation	J:208364
	increased activation-induced B cell apoptosis	J:208364
\Cd22^tm2Tft/\Cd22^tm2Tft \Endou^tm1Tft/\Endou^tm1Tft (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:208364
\Cd22^tm3Lnit/\Cd22^tm3Lnit (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:198790
	abnormal immune system morphology	J:198790
	abnormal immune system physiology	J:198790
	absent mature B cells	J:198790
	autoimmune response	J:198790
	decreased B cell number	J:198790
	decreased marginal zone B cell number	J:198790
	decreased transitional stage B cell number	J:198790
	immune system phenotype	J:198790
	increased B cell apoptosis	J:198790
	increased IgG1 level	J:198790
\Cd22^tm3Tft/\Cd22^tm3Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased B cell number	J:92736
	decreased B cell proliferation	J:92736
	increased B cell proliferation	J:92736
\Cd24a^tm1Pjln/\Cd24a^tm1Pjln (C57BL/6-Cd24a^tm1Pjln)	abnormal B cell differentiation	J:76695
	dark spleen	J:76695
	decreased immature B cell number	J:76695
	decreased pre-B cell number	J:76695
	immune system phenotype	J:76695
	increased susceptibility to parasitic infection	J:76695
\Cd27^{em1(IMPC)Ccpcz}/\Cd27^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd27^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
\Cd27^tm1Jbo/\Cd27^tm1Jbo (either: B6.129P2-CD27^tm1Jbo or 129P2/OlaHsd-Tnfrsf7^tm1Jbo)	abnormal CD4-positive, alpha-beta T cell physiology	J:65516
	abnormal cytotoxic T cell physiology	J:65516
	abnormal T cell physiology	J:65516
\Cd27^tm1Jbo/\Cd27^tm1Jbo (B6.129P2-Cd27^tm1Jbo)	abnormal leukopoiesis	J:97606
	decreased regulatory T cell number	J:198200
	immune system phenotype	J:198200
	increased leukocyte cell number	J:97606
	increased T cell apoptosis	J:198200
\Cd27^tm1Jbo/\Cd27^tm1Jbo \Tg(CD19-Tnfsf7)#Rvl/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:88620
\Cd28^tm1.1Huen/\Cd28^tm1.1Huen \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal regulatory T cell physiology	J:191101
	decreased regulatory T cell number	J:191101
\Cd28^{tm1a(EUCOMM)Hmgu}/\Cd28^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Cd28^{tm1a(EUCOMM)Hmgu}/H)	decreased T cell number	J:165965
	increased CD4-positive, alpha-beta T cell number	J:165965
	increased leukocyte cell number	J:165965
\Cd28^tm1Jmg/\Cd28^tm1Jmg (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:124570
	abnormal germinal center B cell physiology	J:124570
	abnormal lymphopoiesis	J:124570
	decreased immunoglobulin level	J:124570
	decreased interleukin-2 secretion	J:124570
\Cd28^tm1Jmg/\Cd28^tm1Jmg (B6.129X1-Cd28^tm1Jmg)	decreased interleukin-2 secretion	J:149888
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:149888
	increased susceptibility to type I hypersensitivity reaction	J:149888
\Cd28^tm1Jmg/\Cd28^tm1Mak (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:124570
	abnormal germinal center B cell physiology	J:124570
	abnormal lymphopoiesis	J:124570
	decreased immunoglobulin level	J:124570
	decreased interleukin-2 secretion	J:124570
	decreased T cell proliferation	J:149888, J:124570
\Cd28^tm1Ltu/\Cd28^tm1Ltu \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased regulatory T cell number	J:194503
	decreased T cell proliferation	J:194503
	enlarged lymph nodes	J:194503
	enlarged spleen	J:194503
	increased activated T cell number	J:194503
	increased B cell number	J:194503
	increased susceptibility to autoimmune disorder	J:194503
	increased susceptibility to experimental autoimmune encephalomyelitis	J:194503
	skin inflammation	J:194503
\Cd28^tm1Mak/\Cd28⁺ \Cd5^tm1Cgn/\Cd5^tm1Cgn (either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))	abnormal T cell clonal deletion	J:110925
\Cd28^tm1Mak/\Cd28^tm1Mak (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:14194
	abnormal class switch recombination	J:14194
	decreased IgG1 level	J:14194
	decreased IgG2b level	J:14194
	decreased immunoglobulin level	J:14194
	decreased interleukin-2 secretion	J:14194
	decreased T cell proliferation	J:14194
	increased IgG2a level	J:14194
\Cd28^tm1Mak/\Cd28^tm1Mak (NOD.129S2-Cd28^tm1Mak)	abnormal CD4-positive, alpha-beta T cell physiology	J:61905
	abnormal response to transplant	J:61905
	increased susceptibility to autoimmune diabetes	J:93421
	increased T cell proliferation	J:93421
\Cd28^tm1Mak/\Cd28^tm1Mak (involves: 129S2/SvPas)	abnormal class switch recombination	J:123989
	abnormal regulatory T cell physiology	J:191101
	decreased interferon-gamma secretion	J:205441
	decreased interleukin-2 secretion	J:205441, J:130882
	decreased regulatory T cell number	J:191101, J:205441
	decreased spleen germinal center number	J:123989
	decreased T cell proliferation	J:205441, J:130882, J:123989
	enlarged thymus	J:205441
\Cd28^tm1Mak/\Cd28^tm1Mak (involves: 129S2/SvPas * NOD)	abnormal T-helper 1 physiology	J:35353
	abnormal T-helper 2 physiology	J:35353
	decreased IgG2a level	J:35353
	decreased interleukin-2 secretion	J:35353
	decreased interleukin-4 secretion	J:35353
	decreased T cell proliferation	J:35353
	increased interferon-gamma secretion	J:35353
	increased susceptibility to autoimmune diabetes	J:35353
\Cd28^tm1Mak/\Cd28^tm1Mak (involves: 129S2/SvPas * C57BL/6)	abnormal NK cell physiology	J:95353
	decreased circulating interferon-gamma level	J:95353
	decreased circulating interleukin-4 level	J:95353
	decreased interleukin-2 secretion	J:149888
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:149888
	decreased T cell proliferation	J:149888
	increased susceptibility to type I hypersensitivity reaction	J:149888
	increased T cell apoptosis	J:149888
\Cd28^tm1Mak/\Cd28^tm1Mak (B6.129S2-Cd28^tm1Mak)	abnormal cytotoxic T cell physiology	J:76373
\Cd28^tm1Mak/\Cd28^tm1Mak (B6.129S2-Cd28^tm1Mak/J)	brain inflammation	J:57613
\Cd28^tm1Mak/\Cd28^tm1Mak (B6.129S2-Cd28^tm1Mak/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:57613
\Cd28^tm1Mak/\Cd28^tm1Mak \Cd5^tm1Cgn/\Cd5⁺ (either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))	abnormal T cell clonal deletion	J:110925
\Cd28^tm1Mak/\Cd28^tm1Mak \Cd5^tm1Cgn/\Cd5^tm1Cgn (either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP))	abnormal T cell clonal deletion	J:110925
	increased CD4-positive, alpha-beta T cell number	J:110925
	increased CD8-positive, alpha-beta T cell number	J:110925
\Cd28^tm1Mak/\Cd28^tm1Mak \Cd40lg^tm1Flv/\Cd40lg^tm1Flv (NOD.Cg-Cd40lg^tm1Flv Cd28^tm1Mak)	decreased regulatory T cell number	J:93421
	increased susceptibility to autoimmune diabetes	J:93421
	insulitis	J:93421
\Cd28^tm1Mak/\Cd28^tm1Mak \Ndfip1^{Gt(RRD002)Byg}/\Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd * 129S2/SvPas)	esophageal inflammation	J:205692
	increased eosinophil cell number	J:205692
	increased interleukin-2 secretion	J:205692
	increased interleukin-4 secretion	J:205692
\Cd28^tm1Mak/\Cd28^tm1Mak \Rc3h1^san/\Rc3h1⁺ (involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)	increased T cell derived lymphoma incidence	J:189087
\Cd28^tm1Mak/\Cd28^tm1Mak \Stat6^tm1Gru/\Stat6^tm1Gru (C.129S2(B6)-Cd28^tm1Mak Stat6^tm1Gru)	increased susceptibility to parasitic infection	J:90987
\Cd28^tm1Mak/\Cd28^tm1Mak \Tg(Cd4-cre)1Cwi/? \Traf6^tm2Ywc/\Traf6^tm2Ywc (involves: 129S2/SvPas * C57BL/6 * DBA/2)	decreased interleukin-2 secretion	J:130882
	decreased T cell proliferation	J:130882
	increased activated T cell number	J:130882
	increased memory T cell number	J:130882
\Cd28^tm1Mak/\Cd28^tm1Mak \Tg(H2-K-Cd86)7All/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal T cell differentiation	J:112266
\Cd28^tm1Mak/\Cd28^tm1Mak \Tg(TcrLCMV)327Sdz/0 (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal T cell anergy	J:123989
	decreased cytotoxic T cell cytolysis	J:123989
	decreased splenocyte proliferation	J:123989
	decreased T cell proliferation	J:123989
\Cd28^tm1Mak/\Cd28^tm1Mak \Tnfsf9^tm1Thw/\Tnfsf9^tm1Thw (involves: 129 * 129S2/SvPas * C57BL/6)	abnormal cytotoxic T cell physiology	J:76373
	increased length of allograft survival	J:76373
\Cd28^tm1Mak/\Cd28^tm1Mak \Tnfsf14^tm1Kpf/\Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased length of allograft survival	J:77250
\Cd28^tm1Pjl/\Cd28^tm1Pjl (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:83722
	abnormal cytotoxic T cell physiology	J:83722
	abnormal immunoglobulin level	J:83722
	decreased IgG1 level	J:83722
	decreased IgG2a level	J:83722
	decreased IgM level	J:83722
	decreased interleukin-12 secretion	J:83722
	decreased susceptibility to type IV hypersensitivity reaction	J:83722
	increased splenocyte proliferation	J:83722
\Cd28^tm1Pjl/\Cd28^tm1Pjl \Tg(DO11.10)10Dlo/0 (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	abnormal T cell activation	J:25536
	abnormal T cell proliferation	J:25536
	abnormal thymocyte activation	J:25536
	decreased interleukin-2 secretion	J:25536
\Cd28^tm1Pjl/\Cd28^tm1Pjl \Tg(H2-K-Cd86)27All/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased B cell number	J:112475
\Cd28^tm1Pjl/\Cd28^tm1Pjl \Tnfrsf9^tm1Byk/\Tnfrsf9^tm1Byk (either: B6.Cg-Cd28^tm1Pjl Tnfrsf9^tm1Byk or C.Cg-Cd28^tm1Pjl Tnfrsf9^tm1Byk)	abnormal class switch recombination	J:83722
	abnormal cytotoxic T cell physiology	J:83722
	decreased IgG1 level	J:83722
	decreased IgG2a level	J:83722
	decreased IgM level	J:83722
	decreased interleukin-12 secretion	J:83722
	decreased splenocyte proliferation	J:83722
	decreased susceptibility to type IV hypersensitivity reaction	J:83722
\Cd28^tm1Shr/\Cd28^tm1Shr (involves: 129S4/SvJae * BALB/c * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:68642
	decreased interleukin-2 secretion	J:68642
	decreased T cell proliferation	J:68642
\Cd28^tm1Shr/\Cd28^tm1Shr \Ctla4^tm1Shr/\Ctla4⁺ (C.129S4-Cd28^tm1Shr Ctla4^tm1Shr)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	increased susceptibility to autoimmune disorder	J:125259
\Cd28^tm1Shr/\Cd28^tm1Shr \Ctla4^tm1Shr/\Ctla4^tm1Shr (C.129S4-Cd28^tm1Shr Ctla4^tm1Shr)	abnormal interferon level	J:68642
	abnormal interleukin secretion	J:68642
	decreased CD4-positive, alpha-beta T cell number	J:68642
	decreased T cell proliferation	J:68642
	increased length of allograft survival	J:68642
\Cd33^tm1Avrk/\Cd33^tm1Avrk (involves: 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:83728
\Cd34^tm1Lal/\Cd34^tm1Lal (involves: 129S2/SvPas)	decreased splenocyte number	J:30621
\Cd34^tm1Szk/\Cd34^tm1Szk (involves: 129P2/OlaHsd * C57BL/6J)	decreased eosinophil cell number	J:32799
	immune system phenotype	J:32799
\Cd36^em1(IMPC)Mbp/\Cd36^em1(IMPC)Mbp (C57BL/6N-Cd36^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Cd36^obl/\Cd36^obl (C57BL/6-Cd36^obl)	abnormal cell-mediated immunity	J:96018
	abnormal macrophage physiology	J:96018
	endophthalmitis	J:96018
	increased susceptibility to bacterial infection	J:96018
\Cd36^tm1Frm/\Cd36^tm1Frm (involves: 129S4/SvJae)	abnormal microglial cell physiology	J:140907
\Cd36^tm1Frm/\Cd36^tm1Frm (involves: 129S4/SvJae * C57BL/6J)	abnormal chemokine level	J:80658
	abnormal macrophage physiology	J:80658
\Cd36^tm1Frm/\Cd36^tm1Frm (B6.129S4-Cd36^tm1Frm)	abnormal response to infection	J:100140
	decreased interleukin-6 secretion	J:100140
	decreased interleukin-12 secretion	J:100140
	decreased tumor necrosis factor secretion	J:100140
	impaired macrophage phagocytosis	J:100140
	increased susceptibility to bacterial infection induced morbidity/mortality	J:100140
	sepsis	J:100140
\Cd36^tm1Mfe/\Cd36^tm1Mfe (B6.129S1-Cd36^tm1Mfe)	abnormal B cell morphology	J:130897
	abnormal plasma cell differentiation	J:130897
	decreased IgG1 level	J:130897
	decreased IgG2a level	J:130897
	decreased IgG2c level	J:130897
	decreased IgG level	J:130897
	decreased IgM level	J:130897
	decreased immunoglobulin level	J:130897
	increased transitional stage B cell number	J:130897
\Cd36^tm1Mfe/\Cd36^tm1Mfe (involves: 129S1/Sv)	abnormal macrophage chemotaxis	J:89664
\Cd37^tm1Hor/\Cd37^tm1Hor (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:63315
	abnormal humoral immune response	J:63315
	abnormal lymph node germinal center morphology	J:63315
	decreased IgG1 level	J:63315
	decreased spleen germinal center number	J:63315
	decreased spleen germinal center size	J:63315
	immune system phenotype	J:63315
\Cd38^{em1(IMPC)Ccpcz}/\Cd38^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd38^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased NK cell number	J:211773
\Cd38^tm1Lnd/\Cd38^tm1Lnd (involves: 129P2/OlaHsd * C57BL/6J)	abnormal humoral immune response	J:49170
\Cd38^tm1Lnd/\Cd38^tm1Lnd (NOD.129P2(B6)-Cd38^tm1Lnd/LtJ)	increased susceptibility to autoimmune diabetes	J:108097
	increased T cell apoptosis	J:108097
	insulitis	J:108097
\Cd40^m1Btlr/\Cd40^m1Btlr (C57BL/6J-Cd40^m1Btlr)	impaired humoral immune response	J:221482
\Cd40^m2Btlr/\Cd40^m2Btlr (C57BL/6J-Cd40^m2Btlr)	abnormal humoral immune response	J:254828
\Cd40^m2Btlr/\Cd40^m2Btlr (C57BL/6J-Cd40^m2Btlr)	decreased IgG level	J:254828
\Cd40^tm1Arah/\Cd40^tm1Arah (B6.129S1-Cd40^tm1Arah)	abnormal immunoglobulin level	J:120512
	abnormal response to transplant	J:120512
	absent spleen germinal center	J:120512
	decreased IgE level	J:120512
	decreased IgG1 level	J:120512
	decreased IgG2b level	J:120512
	decreased IgG level	J:120512
	decreased IgM level	J:120512
	increased IgG3 level	J:120512
	increased IgM level	J:120512
\Cd40^tm1Geha/\Cd40^tm1Geha (involves: 129S4/SvJae * C57BL/6)	abnormal lymph node germinal center morphology	J:82298
	decreased IgA level	J:82298
	decreased IgG1 level	J:82298
	decreased IgG2a level	J:82298
	decreased IgG2b level	J:82298
	decreased spleen germinal center number	J:82298
	decreased spleen germinal center size	J:82298
\Cd40^tm1Kik/\Cd40⁺ \Mir146^tm1.1Lfl/\Mir146^tm1.1Lfl \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:266124
	increased T follicular helper cell number	J:266124
\Cd40^tm1Kik/\Cd40^tm1Kik (B6.129P2-Cd40^tm1Kik/J)	abnormal dendritic cell physiology	J:86998
\Cd40^tm1Kik/\Cd40^tm1Kik (B6.129P2-Cd40^tm1Kik/J)	increased susceptibility to bacterial infection	J:86998
\Cd40^tm1Kik/\Cd40^tm1Kik (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:25007
	absent spleen germinal center	J:25007
	decreased IgA level	J:25007
	decreased IgE level	J:25007
	decreased IgG1 level	J:25007
	decreased IgG2a level	J:25007
	decreased IgG2b level	J:25007
	decreased IgG3 level	J:25007
	decreased immunoglobulin level	J:25007
	decreased neutrophil cell number	J:25007
	decreased susceptibility to type II hypersensitivity reaction	J:61673
	immune system phenotype	J:25007
\Cd40^tm1Kik/\Cd40^tm1Kik (involves: 129P2/OlaHsd)	absent germinal center B cells	J:190943
	decreased B cell number	J:190943
	immune system phenotype	J:173115
\Cd40^tm1Kik/\Cd40^tm1Kik \Ltbr^tm1Mmat/\Ltbr^tm1Mmat (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal thymus epithelium morphology	J:173115
	abnormal thymus medulla morphology	J:173115
	immune system phenotype	J:173115
\Cd40^tm1Kik/\Cd40^tm1Kik \Tg(Tnfsf13b)1Fma/? (B6.Cg-Cd40^tm1Kik Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	abnormal class switch recombination	J:113556
	absent spleen germinal center	J:113556
	glomerulonephritis	J:113556
	increased anti-double stranded DNA antibody level	J:113556
	increased marginal zone B cell number	J:113556
\Cd40^tm1Kik/\Cd40^tm1Kik \Tnfsf11^tm1Pngr/\Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd)	abnormal thymus epithelium morphology	J:173115
\Cd40^tm1Kik/\Cd40^tm1Kik \Traf3ip2^tm1.1Lix/\Traf3ip2^tm1.1Lix (involves: 129 * 129P2/OlaHsd * BALB/c)	abnormal B cell physiology	J:138560
	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	immune system phenotype	J:138560
	increased follicular B cell number	J:138560
	increased marginal zone B cell number	J:138560
	increased transitional stage B cell number	J:138560
\Cd40lg^m1Btlr/Y (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	immune system phenotype	J:185495
\Cd40lg^m1Btlr/\Cd40lg^m1Btlr (C57BL/6J-Cd40lg^m1Btlr)	decreased IgG level	J:162147
\Cd40lg^m1Btlr/\Cd40lg^m1Btlr (C57BL/6J-Cd40lg^m1Btlr)	immune system phenotype	J:162147
\Cd40lg^m1Btlr/\Cd40lg^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	immune system phenotype	J:185495
\Cd40lg^tm1Flv/Y \Fas^lpr/\Fas^lpr (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	decreased IgG level	J:38492
	decreased immunoglobulin level	J:38492
\Cd40lg^tm1Flv/Y \Fas^lpr/\Fas^lpr \Tcra^tm1Mjo/\Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	increased anti-double stranded DNA antibody level	J:38492
\Cd40lg^tm1Flv/\Cd40lg^tm1Flv (involves: 129S2/SvPas * C57BL/6)	abnormal adaptive immunity	J:25010
	abnormal class switch recombination	J:25010
	abnormal immune system morphology	J:25010
	abnormal immune system physiology	J:25010
	abnormal osteoclast differentiation	J:120087
	abnormal T cell differentiation	J:25010
	abnormal T-helper 2 physiology	J:25010
	absent spleen germinal center	J:25010
	decreased double-positive T cell number	J:25010
	decreased IgA level	J:25010
	decreased IgD level	J:25010
	decreased IgE level	J:25010
	decreased IgG1 level	J:25010
	decreased IgG3 level	J:25010
	decreased immunoglobulin level	J:25010
	increased CD4-positive, alpha-beta T cell number	J:25010
\Cd40lg^tm1Flv/\Cd40lg^tm1Flv (NOD.129S2-Cd40lg^tm1Flv)	decreased regulatory T cell number	J:93421
\Cd40lg^tm1Flv/\Cd40lg^tm1Flv (NOD.129S2-Cd40lg^tm1Flv)	decreased susceptibility to autoimmune diabetes	J:93421
\Cd40lg^tm1Flv/\Cd40lg^tm1Flv \Fas^lpr/\Fas^lpr (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	decreased IgG level	J:38492
	decreased immunoglobulin level	J:38492
\Cd40lg^tm1Flv/\Cd40lg^tm1Flv \Fas^lpr/\Fas^lpr \Tcra^tm1Mjo/\Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	increased anti-double stranded DNA antibody level	J:38492
\Cd40lg^tm1Imx/Y (involves: 129S2/SvPas * C57BL/6)	abnormal antigen presentation	J:21137
	abnormal class switch recombination	J:21137
	abnormal immune system organ morphology	J:21137
	abnormal immune system physiology	J:21137
	abnormal lymph node morphology	J:21137
	absent lymph node germinal center	J:21137
	absent spleen germinal center	J:21137
	decreased IgA level	J:21137
	decreased IgE level	J:21137
	decreased IgG1 level	J:21137
	decreased IgG2b level	J:21137
	decreased immunoglobulin level	J:21137
	immune system phenotype	J:21137
	lymph node hypoplasia	J:21137
\Cd40lg^tm1Imx/Y (B6.129S2-Cd40lg^tm1Imx/J)	abnormal leukocyte adhesion	J:108988
\Cd40lg^tm1Imx/\Cd40lg^tm1Imx (involves: 129S2/SvPas * C57BL/6J * BALB/c)	abnormal T cell clonal deletion	J:110925
\Cd40lg^tm1Imx/\Cd40lg^tm1Imx (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to prion infection	J:115487
	microgliosis	J:115487
\Cd40lg^tm1Parl/Y \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased IgM level	J:213459
	increased IgG1 level	J:213459
\Cd40lg^tm1Parl/Y \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	immune system phenotype	J:213459
\Cd40lg^tm1Parl/Y \Tg(Tek-cre)1Ywa/0 (involves: 129 * C57BL/6 * CD-1 * SJL)	decreased IgA level	J:213459
	decreased IgG1 level	J:213459
	decreased IgG2a level	J:213459
	decreased IgG3 level	J:213459
	decreased IgM level	J:213459
\Cd40lg^tm1Parl/\Cd40lg^tm1Parl \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased IgM level	J:213459
	increased IgG1 level	J:213459
\Cd40lg^tm1Parl/\Cd40lg^tm1Parl \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	immune system phenotype	J:213459
\Cd40lg^tm1Parl/\Cd40lg^tm1Parl \Tg(Tek-cre)1Ywa/0 (involves: 129 * C57BL/6 * CD-1 * SJL)	decreased IgA level	J:213459
	decreased IgG1 level	J:213459
	decreased IgG2a level	J:213459
	decreased IgG3 level	J:213459
	decreased IgM level	J:213459
\Cd44^M1Btlr/\Cd44^M1Btlr (C57BL/6J-Cd44^M1Btlr)	decreased alpha-beta T cell number	J:267483
	decreased CD4-positive, alpha-beta T cell number	J:267483
	decreased CD8-positive, alpha-beta T cell number	J:267483
	decreased central memory CD4-positive, alpha-beta T cell number	J:267483
	decreased central memory CD8 positive, alpha-beta T cell number	J:267483
	decreased effector memory CD4-positive, alpha-beta T cell number	J:267483
\Cd44^tm1.1Ugu/\Cd44^tm1.1Ugu (involves: 129/Sv * C57BL/6)	abnormal T-helper 1 physiology	J:62867
	abnormal T-helper 2 physiology	J:62867
	immune system phenotype	J:62867
\Cd44^tm1.1Ugu/\Cd44^tm1.1Ugu (B6.129(Cg)-Cd44^tm1.1Ugu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199279
\Cd44^tm1.1Ugu/\Cd44^tm1.1Ugu (SJL.129(Cg)-Cd44^tm1.1Ugu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199279
\Cd44^tm1.1Ugu/\Cd44^tm1.1Ugu (SJL.129(Cg)-Cd44^tm1.1Ugu)	decreased T cell proliferation	J:199279
\Cd44^tm1.1Ugu/\Cd44^tm1.1Ugu \Il10^tm1Cgn/\Il10^tm1Cgn (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:62867
\Cd44^tm1Hbg/\Cd44⁺ \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)	ileum inflammation	J:145626
\Cd44^tm1Hbg/\Cd44^tm1Hbg (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:68069
	abnormal CD8-positive, alpha beta T cell morphology	J:68069
	abnormal leukocyte migration	J:68069
	abnormal neutrophil physiology	J:94850
\Cd44^tm1Hbg/\Cd44^tm1Hbg (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:101563
	abnormal response to infection	J:86947
	increased acute inflammation	J:131974
\Cd44^tm1Hbg/\Cd44^tm1Hbg (B6.129-Cd44^tm1Hbg)	decreased mast cell histamine storage	J:146846
\Cd44^tm1Hbg/\Cd44^tm1Hbg (B6.129-Cd44^tm1Hbg)	decreased mast cell number	J:146846
\Cd44^tm1Hbg/\Cd44^tm1Hbg \Tg(TNF)197Gkl/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal osteoclast differentiation	J:97992
	abnormal osteoclast morphology	J:97992
	autoimmune arthritis	J:97992
	increased circulating interleukin-1 level	J:97992
	increased circulating interleukin-6 level	J:97992
	increased interleukin-1 secretion	J:97992
	increased interleukin-6 secretion	J:97992
	increased osteoclast cell number	J:97992
\Cd44^tm1Hbg/\Cd44^tm1Hbg \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:145626
\Cd44^tm1Mak/\Cd44⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal leukocyte migration	J:99032
\Cd44^tm1Mak/\Cd44^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	abnormal leukocyte migration	J:99032
	immune system phenotype	J:72658
	increased susceptibility to parasitic infection	J:72658
\Cd44^tm1Mak/\Cd44^tm1Mak (B6.129P2-Cd44^tm1Mak)	abnormal circulating cytokine level	J:69351
	abnormal leukocyte migration	J:108245
	decreased activation-induced cell death of T cells	J:69351
	impaired macrophage phagocytosis	J:111216
	impaired natural killer cell mediated cytotoxicity	J:110889
	increased circulating interferon-gamma level	J:69351
	increased circulating interleukin-2 level	J:69351
	increased circulating tumor necrosis factor level	J:69351
	liver inflammation	J:69351
	lung inflammation	J:111216, J:108245
\Cd44^tm1Mak/\Cd44^tm1Mak (D1.129P2-Cd44^tm1Mak)	increased susceptibility to induced arthritis	J:95275
\Cd44^tm1Mak/\Cd44^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:155691
	abnormal circulating chemokine level	J:155691
	abnormal interleukin secretion	J:155691
	decreased acute inflammation	J:114341
	decreased circulating tumor necrosis factor level	J:155691
	increased interleukin-1 beta secretion	J:155691
	increased interleukin-6 secretion	J:155691
	increased interleukin-10 secretion	J:155691
	increased tumor necrosis factor secretion	J:155691
	peritoneal inflammation	J:155691
\Cd44^tm1Mak/\Cd44^tm1Mak \Itgal^tm1Mak/\Itgal^tm1Mak (B6.129P2-Cd44^tm1Mak Itgal^tm1Mak)	impaired natural killer cell mediated cytotoxicity	J:110889
\Cd44^tm1Ugu/\Cd44^tm1Ugu (involves: 129/Sv * C57BL/6)	abnormal T-helper 1 physiology	J:62867
	abnormal T-helper 2 physiology	J:62867
	immune system phenotype	J:62867
\Cd44^tm2.1Ugu/\Cd44^tm2.1Ugu (B6.129-Cd44^tm2.1Ugu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:199279
\Cd44^tm2.1Ugu/\Cd44^tm2.1Ugu (B6.129-Cd44^tm2.1Ugu)	decreased T cell proliferation	J:199279
\Cd44^tm2Kmz/\Cd44^tm2Kmz (DBA/1LacJ-Cd44^tm2Kmz)	decreased susceptibility to induced arthritis	J:74268
\Cd44^tm2Kmz/\Cd44^tm2Kmz (involves: BALB/c * DBA/1)	abnormal CD4-positive, alpha-beta T cell physiology	J:114317
	abnormal leukocyte adhesion	J:114317
	decreased susceptibility to type IV hypersensitivity reaction	J:114317
	impaired leukocyte tethering or rolling	J:114317
	impaired neutrophil recruitment	J:114317
\Cd44^tm2Kmz/\Cd44^tm2Kmz \Sell^tm2Hyn/\Sell^tm2Hyn (involves: 129S2/SvPas * BALB/c * DBA/1)	abnormal CD4-positive, alpha-beta T cell physiology	J:114317
	abnormal leukocyte adhesion	J:114317
	decreased susceptibility to type IV hypersensitivity reaction	J:114317
	impaired leukocyte tethering or rolling	J:114317
	impaired neutrophil recruitment	J:114317
\Cd47^tm1Fpl/\Cd47⁺ (B6.129S7-Cd47^tm1Fpl)	increased susceptibility to bacterial infection induced morbidity/mortality	J:36489
\Cd47^tm1Fpl/\Cd47^tm1Fpl (involves: 129S7/SvEvBrd)	decreased T cell number	J:36489
\Cd47^tm1Fpl/\Cd47^tm1Fpl (involves: 129S7/SvEvBrd)	impaired neutrophil recruitment	J:148196
\Cd47^tm1Fpl/\Cd47^tm1Fpl (B6.129S7-Cd47^tm1Fpl)	abnormal neutrophil physiology	J:36489
	decreased osteoclast cell number	J:116609
	impaired granulocyte bactericidal activity	J:36489
	impaired neutrophil chemotaxis	J:36489
	impaired neutrophil phagocytosis	J:36489
	increased susceptibility to bacterial infection	J:36489
	increased susceptibility to bacterial infection induced morbidity/mortality	J:36489
\Cd47^tm1Fpl/\Cd47^tm1Fpl (C.129S7-Cd47^tm1Fpl)	decreased osteoclast cell number	J:116609
\Cd47^tm1Fpl/\Cd47^tm1Fpl (NOD.129S7-Cd47^tm1Fpl)	abnormal spleen morphology	J:76580
	abnormal splenic cell ratio	J:76580
	enlarged spleen	J:76580
\Cd47^tm1Fpl/\Cd47^tm1Fpl (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine level	J:134866
	abnormal osteoclast differentiation	J:147367
	abnormal tumor necrosis factor level	J:134866
	decreased leukocyte cell number	J:134866
	decreased neutrophil cell number	J:134866
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:134866
	increased susceptibility to bacterial infection	J:134866
\Cd48^tm1Rsr/\Cd48^tm1Rsr (B6.129S4-Cd48^tm1Rsr)	abnormal T cell activation	J:53718
	decreased T cell proliferation	J:53718
	increased CD4-positive, alpha-beta T cell number	J:53718
\Cd52^{em1(IMPC)Ccpcz}/\Cd52^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd52^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK T cell number	J:211773
\Cd53^tm1.1Nmg/\Cd53^tm1.1Nmg (involves: C57BL/6J)	abnormal B cell physiology	J:260065
\Cd55^tm1Mme/\Cd55^tm1Mme (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to experimental autoimmune myasthenia gravis	J:80116
\Cd55^tm1Song/\Cd55^tm1Song (involves: 129S6/SvEvTac * C57BL/6)	abnormal complement pathway	J:52968
	immune system phenotype	J:52968
	impaired complement alternative pathway	J:52968
	impaired complement classical pathway	J:52968
\Cd55^tm1Song/\Cd55^tm1Song (involves: 129S6/SvEvTac)	abnormal complement pathway	J:76578
\Cd55^tm1Song/\Cd55^tm1Song (B6.129S6-Cd55^tm1Song)	increased susceptibility to experimental autoimmune myasthenia gravis	J:113567
\Cd55^tm1Song/\Cd55^tm1Song \Cd59a^tm1Bpm/\Cd59a^tm1Bpm (B6.129-Cd55^tm1Song Cd59a^tm1Bpm)	abnormal complement pathway	J:113567
	increased susceptibility to experimental autoimmune myasthenia gravis	J:113567
	myositis	J:113567
\Cd59a^tm1Bpm/\Cd59a^tm1Bpm (involves: 129 * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:89014
\Cd59a^tm1Bpm/\Cd59a^tm1Bpm (involves: 129)	abnormal complement pathway	J:148367
	increased macrophage cell number	J:148367
	increased susceptibility to induced arthritis	J:146711
\Cd59a^tm1Bpm/\Cd59a^tm1Bpm (B6.129-Cd59a^tm1Bpm)	abnormal CD4-positive, alpha-beta T cell physiology	J:119703, J:123582
	abnormal complement pathway	J:92414
	abnormal humoral immune response	J:119703
	decreased B cell proliferation	J:119703
	decreased IgG level	J:119703
	decreased plasma cell number	J:119703
	decreased susceptibility to Poxviridae infection	J:122201
	increased CD4-positive, alpha-beta T cell number	J:123582
	increased double-positive T cell number	J:123582
	increased neutrophil cell number	J:123582
	increased susceptibility to experimental autoimmune myasthenia gravis	J:113567
	increased susceptibility to Orthomyxoviridae infection	J:123582
	increased T cell proliferation	J:122201
	lung inflammation	J:123582
	myositis	J:113567
\Cd59a^tm1Bpm/\Cd59a^tm1Bpm (involves: 129 * BALB/c)	increased susceptibility to Orthomyxoviridae infection	J:123582
\Cd59a^tm1Song/\Cd59a^tm1Song (involves: 129S6/SvEvTac)	abnormal complement pathway	J:76578
\Cd59a^tm1Song/\Cd59a^tm1Song \Cd55^tm1Song/\Cd55^tm1Song (involves: 129S6/SvEvTac * C57BL/6)	abnormal complement pathway	J:76578
\Cd68^tm1Shnd/\Cd68^tm1Shnd (either: B6.129-Cd68^tm1Shnd or (involves: 129S1/Sv * 129X1/SvJ))	abnormal dendritic cell antigen presentation	J:175275
\Cd68^tm1Xfen/\Cd68^tm1Xfen (C57BL/6J-Cd68^tm1Xfen)	abnormal osteoclast morphology	J:178120
\Cd68^tm1Xfen/\Cd68^tm1Xfen (C57BL/6J-Cd68^tm1Xfen)	abnormal osteoclast physiology	J:178120
\Cd69^tm1Fsm/\Cd69^tm1Fsm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:61329
	abnormal humoral immune response	J:61329
	immune system phenotype	J:61329
	increased IgG2a level	J:61329
	increased IgM level	J:61329
	increased immature B cell number	J:61329
	increased pre-B cell number	J:61329
\Cd69^tm1Naka/\Cd69^tm1Naka (C.129P2-Cd69^tm1Naka)	decreased susceptibility to induced arthritis	J:84940
	impaired neutrophil chemotaxis	J:84940
	impaired neutrophil recruitment	J:84940
\Cd69^tm1Naka/\Cd69^tm1Naka (B6.129P2-Cd69^tm1Naka)	abnormal CD4-positive, alpha-beta T cell physiology	J:184704
	abnormal humoral immune response	J:184704
	abnormal memory T cell physiology	J:184704
	abnormal T cell physiology	J:184704
	decreased CD4-positive, alpha-beta T cell number	J:184704
	decreased interferon-gamma secretion	J:184704
	decreased tumor necrosis factor secretion	J:184704
\Cd70^tm1(cre)Jbo/\Cd70^tm1(cre)Jbo (B6.129P2-Cd70^tm1(cre)Jbo)	decreased regulatory T cell number	J:198200
	immune system phenotype	J:198200
\Cd70^tm1.1Jda/\Cd70^tm1.1Jda (B6.Cg-Cd70^tm1.1Jda)	abnormal CD8-positive, alpha-beta T cell physiology	J:193042
	abnormal immune system physiology	J:193042
	abnormal T cell physiology	J:193042
	decreased CD8-positive, alpha-beta T cell number	J:193042
	immune system phenotype	J:193042
	increased susceptibility to Riboviria infection	J:193042
\Cd72^b/\Cd72^b \Fas^lpr/\Fas^lpr (involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)	abnormal B cell number	J:204782
	abnormal T cell number	J:204782
	autoimmune response	J:204782
	decreased anti-double stranded DNA antibody level	J:204782
	decreased anti-nuclear antigen antibody level	J:204782
	decreased IgG level	J:204782
	decreased spleen weight	J:204782
	decreased susceptibility to autoimmune disorder	J:204782
\Cd72^c/\Cd72^c (involves: C57BL/6 * MRL)	immune system phenotype	J:204782
\Cd72^c/\Cd72^c (involves: C57BL/6 * MRL)	increased B cell proliferation	J:204782
\Cd72^c/\Cd72^c \Fas^lpr/\Fas^lpr (involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)	abnormal B cell number	J:204782
	abnormal T cell number	J:204782
	autoimmune response	J:204782
	enlarged lymph nodes	J:204782
	increased anti-chromatin antibody level	J:204782
	increased anti-double stranded DNA antibody level	J:204782
	increased anti-single stranded DNA antibody level	J:204782
	increased IgG level	J:204782
	increased spleen weight	J:204782
	increased susceptibility to systemic lupus erythematosus	J:204782
	liver inflammation	J:204782
	lung inflammation	J:204782
\Cd72^tm1Jrp/\Cd72^tm1Jrp (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal B cell activation	J:76990
	abnormal B cell calcium ion homeostasis	J:76990
	abnormal B cell differentiation	J:76990
	decreased B cell number	J:76990
	decreased B-2 B cell number	J:76990
	decreased follicular B cell number	J:76990
	decreased mature B cell number	J:76990
	increased B cell proliferation	J:76990
	increased B-1 B cell number	J:76990
	increased B-1a cell number	J:76990
	increased IgM level	J:76990
	increased immature B cell number	J:76990
	increased marginal zone B cell number	J:76990
	increased pre-B cell number	J:76990
	increased pro-B cell number	J:76990
\Cd72^tm1Jrp/\Cd72^tm1Jrp \Tg(BCL2)22Wehi/0 (either: (involves: 129P2/OlaHsd * C57BL/6JWehi * SJL/JWehi) or (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6JWehi * SJL/JWehi))	abnormal B cell physiology	J:76990
	decreased mature B cell number	J:76990
	increased immature B cell number	J:76990
\Cd72^tm1Tsub/\Cd72^tm1Tsub (involves: C57BL/6J)	glomerulonephritis	J:204782
	immune system phenotype	J:204782
	increased anti-chromatin antibody level	J:204782
	increased anti-double stranded DNA antibody level	J:204782
	increased anti-single stranded DNA antibody level	J:204782
	increased B cell proliferation	J:204782
	increased spleen weight	J:204782
	lung inflammation	J:204782
\Cd72^tm1Tsub/\Cd72^tm1Tsub \Fas^lpr/\Fas^lpr (involves: C57BL/6J * C57BL/6JJmsSlc * MRL/Mp)	abnormal B cell number	J:204782
	abnormal T cell number	J:204782
	autoimmune response	J:204782
	enlarged lymph nodes	J:204782
	glomerulonephritis	J:204782
	increased anti-chromatin antibody level	J:204782
	increased anti-double stranded DNA antibody level	J:204782
	increased anti-single stranded DNA antibody level	J:204782
	increased spleen weight	J:204782
	liver inflammation	J:204782
	lung inflammation	J:204782
\Cd74^em1(IMPC)H/\Cd74^em1(IMPC)H (C57BL/6N-Cd74^em1(IMPC)H/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cd74^tm1Doi/\Cd74^tm1Doi (either: (involves: 129/Sv * B10.BR) or (involves: 129/Sv * C57BL/6))	abnormal antigen presentation	J:4119
	abnormal level of surface class II molecules	J:45185
	decreased CD4-positive, alpha-beta T cell number	J:4119, J:45185
	increased CD8-positive, alpha-beta T cell number	J:4119
\Cd74^tm1Doi/\Cd74^tm1Doi (involves: 129S2/SvPas)	abnormal dendritic cell antigen presentation	J:151699
\Cd74^tm1Doi/\Cd74^tm1Doi \H2-DMa^tm1Doi/\H2-DMa^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal professional antigen presenting cell physiology	J:42482
	decreased CD4-positive, alpha-beta T cell number	J:42482
	increased CD8-positive, alpha-beta T cell number	J:42482
\Cd74^tm1Doi/\Cd74^tm1Doi \Tap1^tm1Arp/\Tap1^tm1Arp (involves: 129S2/SvPas * C57BL/6)	abnormal T cell number	J:113083
\Cd74^tm1Eae/\Cd74^tm1Eae (involves: 129S2/SvPas)	abnormal level of surface class II molecules	J:65917
	decreased B cell proliferation	J:113050, J:132865
	decreased CD4-positive, alpha-beta T cell number	J:113050
	decreased IgM level	J:113050
\Cd74^tm1Eae/\Cd74^tm1Eae (B6.129S2-Cd74^tm1Eae)	abnormal lymph node cell ratio	J:112084
\Cd74^tm1Eae/\Cd74^tm1Eae (B6.129S2-Cd74^tm1Eae)	arrested B cell differentiation	J:112084
\Cd74^tm1Liz/\Cd74^tm1Liz (involves: 129S/SvEv * C57BL/6J)	abnormal antigen presentation	J:72243
	abnormal antigen presentation via MHC class II	J:65918
	abnormal level of surface class II molecules	J:65918
	decreased CD4-positive, alpha-beta T cell number	J:65918
	decreased interferon-gamma secretion	J:72243
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:72243
	decreased T cell proliferation	J:72243
	defective assembly of class II molecules	J:65918
\Cd74^tm1Liz/\Cd74^tm1Liz (B6.129S-Cd74^tm1Liz)	abnormal antigen presentation	J:125654
	abnormal antigen presentation via MHC class II	J:28966
	abnormal level of surface class II molecules	J:28966
	abnormal T-helper 1 physiology	J:125654
	decreased CD4-positive, alpha-beta T cell number	J:28966
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:125654
	decreased susceptibility to type IV hypersensitivity reaction	J:125654
	decreased T cell proliferation	J:28966
	defective assembly of class II molecules	J:28966
\Cd74^tm1Liz/\Cd74^tm1Liz (involves: 129S/SvEv * C57BL/6)	abnormal antigen presentation via MHC class II	J:111565
\Cd74^tm1Liz/\Cd74^tm1Liz (involves: 129S/SvEv * BALB/cAn)	abnormal antigen presentation via MHC class II	J:110927, J:113714
	abnormal B cell differentiation	J:110927
	abnormal dendritic cell antigen presentation	J:110927
	abnormal professional antigen presenting cell physiology	J:113714
	decreased CD4-positive, alpha-beta T cell number	J:110927, J:113714
	increased immature B cell number	J:110927
\Cd74^tm1Liz/\Cd74^tm1Liz (involves: 129S/SvEv * BALB/c * C57BL)	abnormal antigen presentation via MHC class II	J:110927
	abnormal B cell differentiation	J:110927
	abnormal dendritic cell antigen presentation	J:110927
	abnormal T cell proliferation	J:110927
	increased immature B cell number	J:110927
\Cd74^tm1Liz/\Cd74^tm1Liz (involves: 129S/SvEv * C57BL * C57BL/10 * C57BR)	abnormal antigen presentation via MHC class II	J:110927
	abnormal B cell differentiation	J:110927
	abnormal dendritic cell antigen presentation	J:110927
	abnormal T cell proliferation	J:110927
	increased immature B cell number	J:110927
\Cd74^tm1Liz/\Cd74^tm1Liz (involves: 129S/SvEv)	abnormal positive T cell selection	J:125548
\Cd74^tm1Liz/\Cd74^tm1Liz (B6.129S-Cd74^tm1Liz/J)	decreased B cell number	J:194664
\Cd74^tm1Liz/\Cd74^tm1Liz \H2-DMa^tm1Liz/\H2-DMa^tm1Liz (involves: 129S/SvEv * BALB/c)	decreased CD4-positive, alpha-beta T cell number	J:113714
\Cd74^tm1Liz/\Cd74^tm1Liz \H2-DMa^tm1Luc/\H2-DMa^tm1Luc \Tg(CD74)AR194Ayr/? (involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * DBA/2J)	abnormal antigen presentation via MHC class II	J:88717
	decreased CD4-positive, alpha-beta T cell number	J:88717
\Cd74^tm1Liz/\Cd74^tm1Liz \H2-DMa^tm1Luc/\H2-DMa^tm1Luc \Tg(CD74)1Ayr/0 (involves: 129S/SvEv 129S4/SvJae * C57BL/6J * DBA/2J)	abnormal antigen presentation via MHC class II	J:88717
	decreased CD4-positive, alpha-beta T cell number	J:88717
\Cd74^tm1Liz/\Cd74^tm1Liz \Sppl2a^tm1Basc/\Sppl2a^tm1Basc (B6.129-Sppl2a^tm1Basc Cd74^tm1Liz)	decreased B cell number	J:194664
	decreased Peyer's patch number	J:194664
	immune system phenotype	J:194664
\Cd74^tm1Liz/\Cd74^tm1Liz \Sppl2a^tm1Dgen/\Sppl2a^tm1Dgen (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased follicular B cell number	J:194595
	immune system phenotype	J:194595
\Cd74^tm2Liz/\Cd74^tm1Liz (involves: 129S/SvEv * C57BL/6)	abnormal antigen presentation via MHC class II	J:28966
	immune system phenotype	J:28966
	increased T cell proliferation	J:28966
\Cd74^tm2Liz/\Cd74^tm2Liz (involves: 129S/SvEv * C57BL/6)	decreased interleukin-2 secretion	J:72243
\Cd74^tm2Liz/\Cd74^tm2Liz (involves: 129S/SvEv * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:72243
\Cd74^tm3Liz/\Cd74^tm3Liz (involves: 129S/SvEv * C57BL/6)	abnormal antigen presentation via MHC class II	J:82880
	abnormal level of surface class II molecules	J:82880
	decreased interleukin-2 secretion	J:72243
	defective assembly of class II molecules	J:82880
	immune system phenotype	J:82880
	increased susceptibility to experimental autoimmune encephalomyelitis	J:72243
\Cd79a^m1Anu/\Cd79a^m1Anu (involves: C57BL/6JSfdAnu * C57BL/10Sg * C57BR/cd)	absent pre-B cells	J:104190
	decreased IgG level	J:104190
\Cd79a^m1Anu/\Cd79a^m1Anu (C57BL/6-Cd79a^m1Anu)	absent pre-B cells	J:171924
\Cd79a^m1Anu/\Cd79a^m1Anu \Rasgrp1^m1Anu/\Rasgrp1^m1Anu (involves: C57BL/6JSfdAnu * CBA/J)	immune system phenotype	J:207898
\Cd79a^m1Btlr/\Cd79a^m1Btlr (involves: C57BL/6J * C57BL/10J)	abnormal humoral immune response	J:174338
	decreased B cell number	J:174338
	decreased IgG level	J:174338
	decreased IgM level	J:174338
\Cd79a^m1Btlr/\Cd79a^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
\Cd79a^m2Btlr/\Cd79a^m2Btlr (C57BL/6J-Cd79a^m2Btlr)	decreased B-1 B cell number	J:254836
	decreased IgM level	J:254836
	impaired humoral immune response	J:254836
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Commd3^tm1.1Ksuz/\Commd3^tm1.1Ksuz (involves: BALB/c * C57BL/6NSlc * SJL)	abnormal follicular B cell physiology	J:278399
	abnormal plasmablast number	J:278399
	abnormal spleen B cell follicle morphology	J:278399
	decreased follicular B cell number	J:278399
	decreased IgG1 level	J:278399
	decreased IgG2b level	J:278399
	decreased IgG2c level	J:278399
	decreased IgM level	J:278399
	decreased mature B cell number	J:278399
	decreased spleen germinal center number	J:278399
	immune system phenotype	J:278399
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Commd8^tm1.1Ksuz/\Commd8^tm1.1Ksuz (involves: BALB/c * C57BL/6NSlc * SJL)	abnormal follicular B cell physiology	J:278399
	abnormal plasmablast number	J:278399
	abnormal spleen B cell follicle morphology	J:278399
	decreased follicular B cell number	J:278399
	decreased IgG1 level	J:278399
	decreased IgG2b level	J:278399
	decreased IgG2c level	J:278399
	decreased IgG3 level	J:278399
	decreased IgM level	J:278399
	decreased mature B cell number	J:278399
	decreased spleen germinal center number	J:278399
	immune system phenotype	J:278399
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Ctnnbl1^tm1.1Crad/\Ctnnbl1^tm1.1Crad (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	abnormal B cell proliferation	J:232010
	abnormal class switch recombination	J:232010
	decreased B cell proliferation	J:232010
	immune system phenotype	J:232010
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Dicer1^tm1Mmk/\Dicer1^tm1Mmk \Tg(BCL2)22Wehi/0 (involves: BALB/c * C57BL/6JWehi * SJL/JWehi)	decreased B cell number	J:135783
	decreased mature B cell number	J:135783
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Dynll1^tm1.1Jhh/\Dynll1^tm1.1Jhh (B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth)	abnormal B cell morphology	J:230105
	decreased immature B cell number	J:230105
	decreased mature B cell number	J:230105
	decreased pre-B cell number	J:230105
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Dynll1^tm1.1Jhh/\Dynll1^tm1.1Jhh \Tg(IghMyc)22Bri/0 (B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth Tg(IghMyc)22Bri)	decreased immature B cell number	J:230105
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Eif4a1^tm1.1Bea/\Eif4a1^tm1.1Bea (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased B cell number	J:344730
	decreased pro-B cell number	J:344730
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Eif4b^tm1.1Tnr/\Eif4b^tm1.1Tnr \Eif4h^{tm1c(EUCOMM)Wtsi}/\Eif4h^{tm1c(EUCOMM)Wtsi} (involves: BALB/c * C57BL/6 * C57BL/6N)	decreased IgG1 level	J:344730
	decreased mature B cell number	J:344730
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Huwe1^tm1.1Mak/Y (B6.Cg-Cd79a^tm1(cre)Reth Huwe1^tm1.1Mak)	abnormal B cell differentiation	J:181705
	abnormal class switch recombination	J:181705
	abnormal humoral immune response	J:181705
	absent B-1a cells	J:181705
	decreased B cell proliferation	J:181705
	decreased follicular B cell number	J:181705
	decreased IgA level	J:181705
	decreased IgG1 level	J:181705
	decreased IgG2a level	J:181705
	decreased IgG3 level	J:181705
	decreased IgM level	J:181705
	decreased marginal zone B cell number	J:181705
	decreased mature B cell number	J:181705
	decreased pre-B cell number	J:181705
	decreased transitional stage B cell number	J:181705
	increased B cell apoptosis	J:181705
	increased susceptibility to Riboviria infection	J:181705
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Huwe1^tm1.1Mak/Y \Trp53^tm1Brn/\Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal class switch recombination	J:181705
	absent B-1a cells	J:181705
	decreased IgG1 level	J:181705
	decreased IgM level	J:181705
	immune system phenotype	J:181705
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Ikzf1^tm3.1Mbu/\Ikzf1^tm3.1Mbu (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	abnormal B cell differentiation	J:209928
	abnormal B cell number	J:209928
	decreased pre-B cell number	J:209928
	increased pro-B cell number	J:209928
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Inpp5d^tm1Rav/\Inpp5d^tm1Rav (involves: 129 * BALB/c * C57BL/6)	increased anti-chromatin antibody level	J:178833
	increased anti-double stranded DNA antibody level	J:178833
	increased anti-nuclear antigen antibody level	J:178833
	increased anti-single stranded DNA antibody level	J:178833
	increased autoantibody level	J:178833
	increased IgG level	J:178833
	increased susceptibility to systemic lupus erythematosus	J:178833
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Nfkbiz^tm1.1Muta/\Nfkbiz^tm1.1Muta (involves: BALB/c * C57BL/6)	immune system phenotype	J:194832
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Nr4a1^tm1Pcn/\Nr4a1^tm1Pcn (involves: 129 * BALB/c)	increased B cell proliferation	J:306652
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Nr4a1^tm1Pcn/\Nr4a1^tm1Pcn \Nr4a3^em1Juz/\Nr4a3^em1Juz (involves: 129 * BALB/c * C57BL/6)	decreased B cell apoptosis	J:306652
	immune system phenotype	J:306652
	increased B cell proliferation	J:306652
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Orai1^tm1Smua/\Orai1^tm1Smua (involves: BALB/c * C57BL/6J)	abnormal B cell activation	J:345485
	abnormal B cell physiology	J:345485
	immune system phenotype	J:345485
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Orai1^tm1Smua/\Orai1^tm1Smua \Orai3^em1.1Treb/\Orai3^em1.1Treb (involves: BALB/c * C57BL/6J * C57BL/6N)	abnormal B cell activation	J:345485
	abnormal B cell physiology	J:345485
	decreased B cell proliferation	J:345485
	immune system phenotype	J:345485
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Orai3^em1.1Treb/\Orai3^em1.1Treb (involves: BALB/c * C57BL/6J * C57BL/6N)	abnormal B cell activation	J:345485
	immune system phenotype	J:345485
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Phf5a^tm1.1Oux/\Phf5a^tm1.1Oux (involves: BALB/c * C57BL/6J)	abnormal B cell physiology	J:345807
	abnormal B cell receptor editing	J:345807
	abnormal immunoglobulin heavy chain V(D)J recombination	J:345807
	decreased B cell number	J:345807
	decreased early pro-B cell number	J:345807
	decreased immature B cell number	J:345807
	decreased late pro-B cell number	J:345807
	decreased mature B cell number	J:345807
	decreased pre-B cell number	J:345807
	increased pre-pro B cell number	J:345807
	small spleen	J:345807
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Phf5a^tm1.1Oux/\Phf5a^tm1.1Oux \Tg(IghelMD4)4Ccg/0 (involves: BALB/c * C57BL/6 * C57BL/6J)	abnormal B cell number	J:345807
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Slc39a10^tm1.1Tfk/\Slc39a10^tm1.1Tfk (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)	decreased B cell number	J:213935
	decreased IgA level	J:213935
	decreased IgE level	J:213935
	decreased IgG1 level	J:213935
	decreased IgG2b level	J:213935
	decreased IgG2c level	J:213935
	decreased IgG3 level	J:213935
	decreased IgM level	J:213935
	decreased immunoglobulin level	J:213935
	decreased pro-B cell number	J:213935
	spleen atrophy	J:213935
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Was^tm1.1Ldn/Y (involves: BALB/c * C57BL/6)	abnormal B cell physiology	J:182528
	decreased B cell number	J:182528
	decreased follicular B cell number	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Was^tm1.1Ldn/\Was⁺ (involves: BALB/c * C57BL/6)	abnormal B cell number	J:182528
	abnormal B cell proliferation	J:182528
\Cd79a^tm1(cre)Reth/\Cd79a⁺ \Was^tm1.1Ldn/\Was^tm1.1Ldn (involves: BALB/c * C57BL/6)	abnormal B cell physiology	J:182528
	decreased B cell number	J:182528
	decreased follicular B cell number	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
\Cd79a^tm1(cre)Reth/\Cd79a^tm1(cre)Reth \Mzb1^tm1.1Rug/\Mzb1^tm1.1Rug (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	abnormal B cell number	J:211639
	decreased pre-B cell number	J:211639
	increased late pro-B cell number	J:211639
	increased pro-B cell number	J:211639
	small spleen	J:211639
\Cd79a^{tm1.1(BAP31N-EGFP)Pld}/\Cd79a^{tm1.1(BAP31N-EGFP)Pld} (Not Specified)	abnormal immune system cell morphology	J:75114
\Cd79a^tm1.1Cgn/\Cd79a⁺ \Cd79b^tm1Gzmn/\Cd79b^tm1Gzmn (involves: 129P2/OlaHsd)	decreased B cell number	J:179254
	decreased pre-B cell number	J:179254
	increased pro-B cell number	J:179254
\Cd79a^tm1.1Cgn/\Cd79a^tm1.1Cgn (involves: 129P2/OlaHsd)	decreased B-1a cell number	J:124400
\Cd79a^tm1.1Cgn/\Cd79a^tm1.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:71100
	decreased B-1 B cell number	J:71100
	decreased IgG1 level	J:71100
	decreased marginal zone B cell number	J:71100
	decreased mature B cell number	J:71100
\Cd79a^tm1.1Cgn/\Cd79a^tm1.1Cgn \Cd79b^tm1Gzmn/\Cd79b⁺ (involves: 129P2/OlaHsd)	decreased B cell number	J:179254
	decreased pre-B cell number	J:179254
	increased pro-B cell number	J:179254
\Cd79a^tm1.1Cgn/\Cd79a^tm1.1Cgn \Cd79b^tm1Gzmn/\Cd79b^tm1Gzmn (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:124400
\Cd79a^tm1.1Cgn/\Cd79a^tm1.1Cgn \Cd79b^tm1Gzmn/\Cd79b^tm1Gzmn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:179254
	absent pre-B cells	J:179254
	decreased B cell number	J:179254
	increased pro-B cell number	J:179254
\Cd79a^tm1.1Cgn/\Cd79a^tm1.1Cgn \Cd79b^tm2.1Mnz/\Cd79b^tm2.1Mnz (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	absent mature B cells	J:71100
	arrested B cell differentiation	J:71100
\Cd79a^tm1.1Cgn/\Cd79a^tm1.1Cgn \Cd79b^tm3Mnz/\Cd79b^tm3Mnz (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:128768
\Cd79a^tm1.1Rsky/\Cd79a^tm1.1Rsky (involves: C57BL/6)	abnormal humoral immune response	J:179254
	decreased IgG2b level	J:179254
	decreased IgG2c level	J:179254
	decreased IgG3 level	J:179254
	decreased marginal zone B cell number	J:179254
	decreased mature B cell number	J:179254
	immune system phenotype	J:179254
	increased anti-single stranded DNA antibody level	J:179254
	increased IgG2b level	J:179254
	increased IgG2c level	J:179254
	increased immature B cell number	J:179254
	increased pre-B cell number	J:179254
	increased transitional stage B cell number	J:179254
	increased transitional stage T1 B cell number	J:179254
	increased transitional stage T2 B cell number	J:179254
	increased transitional stage T3 B cell number	J:179254
\Cd79a^{tm2(cre/Esr1*)Reth}/\Cd79a⁺ \Rag1^tm1.1Sadu/\Rag1^tm1.1Sadu (involves: BALB/c)	arrested B cell differentiation	J:155473
\Cd79a^{tm2(cre/Esr1*)Reth}/\Cd79a⁺ \Rag1^tm1.1Sadu/\Rag1^tm1.1Sadu (involves: BALB/c)	immune system phenotype	J:155473
\Cd79a^tm2Cgn/\Cd79a^tm2Cgn (involves: C57BL/6 * C.B-20)	decreased B cell number	J:80885
	decreased immunoglobulin level	J:80885
	decreased mature B cell number	J:80885
\Cd79a^tm2Cgn/\Cd79a^tm2Cgn (involves: C57BL/6)	decreased mature B cell number	J:71100, J:66840
	decreased pre-B cell number	J:71100, J:66840
	increased pro-B cell number	J:66840
\Cd79a^tm2Cgn/\Cd79a^tm2Cgn \Cd79b^tm2.1Mnz/\Cd79b^tm2.1Mnz (involves: 129/Sv * C57BL/6)	arrested B cell differentiation	J:66840
	decreased transitional stage B cell number	J:66840
\Cd79a^tm2Pld/\Cd79a^tm2Pld (BALB/c-Cd79a^tm2Pld)	abnormal B cell differentiation	J:87492
	abnormal T cell differentiation	J:87492
	absent mature B cells	J:87492
	decreased double-positive T cell number	J:87492
\Cd79a^tm2Pld/\Cd79a^tm2Pld \Cd79b^tm1Mnz/\Cd79b^tm1Mnz (involves: 129S1/Sv * BALB/c)	absent pre-B cells	J:87492
\Cd79a^tm3Cgn/\Cd79a^tm3Cgn \Tg(Mx1-cre)1Cgn/? (involves: C57BL/6 * CBA)	abnormal metallophilic macrophage morphology	J:88620
	abnormal spleen marginal zone macrophage morphology	J:88620
	abnormal spleen red pulp morphology	J:88620
	decreased B cell number	J:88620
\Cd79a^tm3Cgn/\Cd79a^tm4.1Cgn (involves: C57BL/6 * CBA)	immune system phenotype	J:88620
\Cd79a^tm4.1Cgn/\Cd79a^tm4.1Cgn (involves: C57BL/6)	abnormal B cell differentiation	J:91091
\Cd79a^tm4.1Cgn/\Cd79a^tm4.1Cgn \Igh^tm1.2Rsky/\Igh⁺ (involves: BALB/c * C57BL/6)	abnormal pro-B cell differentiation	J:125719
\Cd79a^tm4Cgn/\Cd79a^tm4.1Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:91091
	decreased IgD level	J:91091
	decreased IgM level	J:91091
\Cd79a^tm4Cgn/\Cd79a^tm4.1Cgn \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	absent immature B cells	J:91091
	arrested B cell differentiation	J:91091
	decreased B cell number	J:91091
	decreased follicular B cell number	J:91091
	decreased marginal zone B cell number	J:91091
\Cd79a^tm5.1Cgn/\Cd79a⁺ \Igh^tm1.2Rsky/\Igh⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal class switch recombination	J:125719
\Cd79a^tm5.1Cgn/\Cd79a^tm5.1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:91091
\Cd79a^tm5.1Cgn/\Cd79a^tm5.1Cgn (involves: 129 * C57BL/6)	abnormal B cell morphology	J:125719
	decreased B-1a cell number	J:125719
	decreased immature B cell number	J:125719
	decreased mature B cell number	J:125719
	decreased pre-B cell number	J:125719
	decreased T cell number	J:125719
	increased pro-B cell number	J:125719
\Cd79a^tm5.1Cgn/\Cd79a^tm5.1Cgn \Igh^tm1.2Rsky/\Igh⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal class switch recombination	J:125719
\Cd79a^tm5.1Cgn/\Cd79a^tm5.1Cgn \Igh^tm1.2Rsky/\Igh^tm1.2Rsky (involves: 129 * BALB/c * C57BL/6)	abnormal B cell morphology	J:125719
	abnormal class switch recombination	J:125719
	decreased immature B cell number	J:125719
	decreased mature B cell number	J:125719
	decreased pre-B cell number	J:125719
	decreased T cell number	J:125719
	increased B-1b cell number	J:125719
	increased pro-B cell number	J:125719
\Cd79a^tm5Cgn/\Cd79a^tm5.1Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:91091
\Cd79a^tm5Cgn/\Cd79a^tm5.1Cgn \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	absent immature B cells	J:91091
	arrested B cell differentiation	J:91091
	decreased B cell number	J:91091
\Cd79a^tm6Cgn/\Cd79a^tm6Cgn (involves: C57BL/6)	abnormal B cell number	J:113407
	abnormal B cell physiology	J:113407
	abnormal humoral immune response	J:113407
	abnormal immunoglobulin level	J:113407
	decreased B cell proliferation	J:113407
	decreased B-1a cell number	J:113407
	decreased IgG2a level	J:113407
	decreased IgG3 level	J:113407
	decreased IgM level	J:113407
	immune system phenotype	J:113407
	increased transitional stage B cell number	J:113407
\Cd79a^tm7Cgn/\Cd79a^tm7Cgn (involves: C57BL/6)	abnormal immune system physiology	J:113407
\Cd79b^m1Btlr/\Cd79b^m1Btlr (C57BL/6J-Cd79b^m1Btlr)	decreased B cell number	J:267537
	decreased B-1 B cell number	J:267537
	decreased NK cell number	J:267537
	increased alpha-beta T cell number	J:267537
	increased CD4-positive, alpha-beta T cell number	J:267537
	increased CD8-positive, alpha-beta T cell number	J:267537
\Cd79b^m1Ghost/\Cd79b^m1Ghost (B10.Cg-Ptprc^a Cd79b^m1Ghost H2^a)	abnormal B cell differentiation	J:157450
	absent B cells	J:157450
	absent Peyer's patches	J:157450
	arrested B cell differentiation	J:157450
	decreased IgA level	J:157450
	decreased IgG level	J:157450
\Cd79b^M2Btlr/\Cd79b^M2Btlr (C57BL/6J-Cd79b^M2Btlr)	abnormal lymphocyte morphology	J:272863
	decreased B cell number	J:272863
	decreased B-1 B cell number	J:272863
\Cd79b^tm1Gzmn/\Cd79b^tm1Gzmn (involves: 129/Sv * C57BL/6)	abnormal immune system physiology	J:124400
	decreased B-1a cell number	J:124400
	decreased IgG1 level	J:124400
	increased IgD level	J:124400
	increased IgM level	J:124400
\Cd79b^tm1Mnz/\Cd79b^tm1Mnz (involves: 129S1/Sv)	abnormal pro-B cell differentiation	J:78601
	abnormal pro-B cell morphology	J:78601
	arrested B cell differentiation	J:78601
\Cd79b^tm1Mnz/\Cd79b^tm1Mnz \Tg(BCL2)22Wehi/0 \Tg(IghelMD4)4Ccg/0 \Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv * C57BL/6 * C57BL/6JWehi * SJL/JWehi)	arrested B cell differentiation	J:78601
\Cd79b^tm1Mnz/\Cd79b^tm1Mnz \Tg(BCL2)22Wehi/0 \Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv * C57BL/6JWehi * SJL/JWehi)	arrested B cell differentiation	J:78601
\Cd79b^tm1Mnz/\Cd79b^tm1Mnz \Tg(IghelMD4)4Ccg/0 \Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv * C57BL/6)	abnormal immature B cell morphology	J:78601
	arrested B cell differentiation	J:78601
\Cd79b^tm1Mnz/\Cd79b^tm1Mnz \Tg(Rag2-Igb)1Mnz/0 (involves: 129S1/Sv)	abnormal pre-B cell morphology	J:78601
	arrested B cell differentiation	J:78601
\Cd79b^tm2.1Mnz/\Cd79b^tm2.1Mnz (involves: 129 * C57BL/6)	decreased mature B cell number	J:71100
\Cd79b^tm2.1Mnz/\Cd79b^tm2.1Mnz (involves: 129/Sv * C57BL/6)	abnormal B cell activation	J:66840
	arrested B cell differentiation	J:66840
	decreased mature B cell number	J:66840
	decreased pre-B cell number	J:66840
	decreased transitional stage B cell number	J:66840
	increased pro-B cell number	J:66840
\Cd79b^tm3Mnz/\Cd79b^tm3Mnz (involves: 129/Sv * C57BL/6)	abnormal B cell physiology	J:128768
	abnormal immature B cell morphology	J:128768
	abnormal immune system physiology	J:128768
	decreased B cell number	J:128768
	decreased B cell proliferation	J:128768
	decreased B-1a cell number	J:128768
	decreased immature B cell number	J:128768
	decreased mature B cell number	J:128768
	increased marginal zone B cell number	J:128768
	increased pro-B cell number	J:128768
\Cd80^tm1Lbgn/\Cd80^tm1Lbgn (C3.Cg-Cd80^tm1Lbgn)	abnormal T cell physiology	J:110947
\Cd80^tm1Shr/\Cd80^tm1Shr (involves: 129S4/SvJae)	abnormal immunoglobulin level	J:39089
\Cd80^tm1Shr/\Cd80^tm1Shr (involves: 129S4/SvJae)	decreased B cell proliferation	J:74662
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm1Shr/\Cd86^tm1Shr (B6.129S4-Cd80^tm1Shr Cd86^tm1Shr)	brain inflammation	J:57613
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:57613
	decreased T cell proliferation	J:57613
	increased interferon-gamma secretion	J:57613
	increased tumor necrosis factor secretion	J:57613
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm2Shr/\Cd86^tm2Shr (involves: 129S4/SvJae)	abnormal lymph node B cell domain morphology	J:39089
	abnormal spleen morphology	J:39089
	abnormal T cell physiology	J:57090
	abnormal T cell proliferation	J:57090
	decreased IgG1 level	J:39089
	decreased IgG2a level	J:39089
	decreased IgG level	J:39089
	decreased regulatory T cell number	J:205441, J:113109
	increased IgG3 level	J:39089
	increased IgM level	J:39089
	increased susceptibility to autoimmune diabetes	J:113109
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm2Shr/\Cd86^tm2Shr (involves: 129S4/SvJae * NOD)	abnormal CD4-positive, alpha-beta T cell physiology	J:61905
	abnormal cytokine secretion	J:61905
	increased susceptibility to autoimmune diabetes	J:61905
	insulitis	J:61905
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm2Shr/\Cd86^tm2Shr (129.SJL-Cd86^tm2Shr)	decreased interleukin-2 secretion	J:78992
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:78992
	increased susceptibility to experimental autoimmune encephalomyelitis	J:78992
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm2Shr/\Cd86^tm2Shr (involves: 129S4/SvJae * C57BL/6J * SJL)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:78992
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm2Shr/\Cd86^tm2Shr (involves: 129S4/SvJae * BALB/c)	abnormal T cell number	J:112266
	decreased double-positive T cell number	J:112266
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm2Shr/\Cd86^tm2Shr \Ctla4^tm1Shr/\Ctla4^tm1Shr (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:57090
	abnormal T cell physiology	J:57090
	increased T cell proliferation	J:57090
\Cd80^tm1Shr/\Cd80^tm1Shr \Cd86^tm2Shr/\Cd86^tm2Shr \Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (involves: 129S4/SvJae * FVB/N * NOD)	decreased regulatory T cell number	J:113109
	decreased susceptibility to autoimmune diabetes	J:113109
	insulitis	J:113109
\Cd81^tm1Geha/\Cd81^tm1Geha (involves: 129S4/SvJae * C57BL/6)	abnormal B cell morphology	J:43975
	decreased B-1 B cell number	J:43975
	decreased B-1a cell number	J:43975
	increased B cell proliferation	J:43975
	increased IgA level	J:43975
	increased IgG3 level	J:43975
	increased IgM level	J:43975
\Cd81^tm1Lvy/\Cd81^tm1Lvy (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell morphology	J:40394
	abnormal T-helper 2 physiology	J:40394
	decreased IgG1 level	J:40394
	decreased IgG level	J:40394
	decreased susceptibility to parasitic infection	J:126000
\Cd81^tm1Lvy/\Cd81^tm1Lvy (CByJ.129-Cd81^tm1Lvy)	abnormal T-helper 2 physiology	J:46171
\Cd81^tm1Lvy/\Cd81^tm1Lvy (CByJ.129-Cd81^tm1Lvy)	decreased susceptibility to type I hypersensitivity reaction	J:46171
\Cd81^tm1Lvy/\Cd81^tm1Lvy (either: (B6ByJ.129-Cd81^tm1Lvy x CByJ.129-Cd81^tm1Lvy)F1 or (CByJ.129-Cd81^tm1Lvy x B6ByJ.129-Cd81^tm1Lvy)F1)	abnormal microglial cell morphology	J:79426
\Cd81^tm1Tmiy/\Cd81^tm1Tmiy (involves: 129/Sv * C57BL/6)	abnormal B cell differentiation	J:41830
	abnormal immune system cell morphology	J:41830
	abnormal macrophage physiology	J:83795
	abnormal T cell proliferation	J:41830
	decreased B cell proliferation	J:41830
	decreased B-1 B cell number	J:41830
	increased B cell proliferation	J:41830
\Cd81^tm1Tmiy/\Cd81^tm1Tmiy \Cd9^tm1Mek/\Cd9^tm1Mek (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:83795
	increased osteoclast cell number	J:83795
\Cd82^tm1Kjbr/\Cd82^tm1Kjbr (Not Specified)	abnormal cellular extravasation	J:326451
	abnormal macrophage differentiation	J:326451
	abnormal neutrophil physiology	J:326451
	impaired leukocyte tethering or rolling	J:326451
	increased macrophage cell number	J:326451
	increased neutrophil cell number	J:326451
	increased susceptibility to bacterial infection	J:326451
\Cd83^anu/\Cd83^anu (involves: C57BL/6JAnu * CBA/CaJAnu)	abnormal B cell morphology	J:104190
	abnormal dendritic cell morphology	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
\Cd83^lcd4/\Cd83^lcd4 (involves: C57BL/6J)	abnormal CD4-positive T cell differentiation	J:92721
	abnormal CD4-positive, alpha-beta T cell physiology	J:92721
	decreased susceptibility to type IV hypersensitivity reaction	J:92721
	decreased T cell proliferation	J:92721
\Cd83^tm1.1Lnjt/\Cd83^tm1.1Lnjt (involves: C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:236611
\Cd83^tm1.1Lnjt/\Cd83^tm1.1Lnjt \H2-Ab1^b-tm2Hpl/\H2-Ab1^b-tm2Hpl (involves: 129S4/SvJae * C57BL/6 * C57BL/6N)	immune system phenotype	J:236611
\Cd83^tm1.1Lnjt/\Cd83^tm1.1Lnjt \Marchf1^tm1.1Sish/\Marchf1^tm1.1Sish (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:236611
\Cd83^tm1.1Lnjt/\Cd83^tm1.1Lnjt \Marchf8^tm1.1Lkle/\Marchf8^tm1.1Lkle (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N)	immune system phenotype	J:236611
\Cd83^tm1Tft/\Cd83^tm1Tft (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive T cell differentiation	J:75700
	abnormal humoral immune response	J:75700
	arrested T cell differentiation	J:75700
	decreased CD4-positive, alpha-beta T cell number	J:75700
	decreased IgA level	J:75700
	decreased IgG1 level	J:75700
	decreased IgG2a level	J:75700
	decreased IgG2b level	J:75700
	decreased IgG3 level	J:75700
	decreased IgM level	J:75700
	decreased susceptibility to type IV hypersensitivity reaction	J:75700
\Cd84^tm1Pls/\Cd84^tm1Pls (C57BL/6J-Cd84^tm1Pls)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
	abnormal long lived plasma cell morphology	J:157915
	decreased CD4-positive, alpha-beta T cell number	J:157915
	decreased germinal center B cell number	J:157915
	decreased IgG level	J:157915
	decreased interleukin-21 secretion	J:157915
	decreased spleen germinal center size	J:157915
\Cd84^tm1Pls/\Cd84^tm1Pls \Tg(TcraTcrb)425Cbn/? (B6.Cg-Cd84^tm1Pls Tg(TcraTcrb)425Cbn)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
\Cd86^tm1Shr/\Cd86^tm1Shr (NOD.129S4-Cd86^tm1Shr)	abnormal T cell proliferation	J:142046
	decreased regulatory T cell number	J:93421
	decreased susceptibility to autoimmune diabetes	J:71352
	decreased T cell proliferation	J:93421
	increased autoantibody level	J:142046
	increased interferon-gamma secretion	J:142046
	increased susceptibility to autoimmune diabetes	J:93421
\Cd86^tm1Shr/\Cd86^tm1Shr (involves: 129S4/SvJae)	abnormal humoral immune response	J:39089
	absent spleen germinal center	J:39089
	decreased IgG level	J:39089
\Cd86^tm1Shr/\Cd86^tm1Shr (B6.129S4-Cd86^tm1Shr)	decreased T cell proliferation	J:57613
\Cd86^tm1Shr/\Cd86^tm1Shr (B6.129S4-Cd86^tm1Shr)	increased interferon-gamma secretion	J:57613
\Cd86^tm1Shr/\Cd86^tm1Shr \Marchf1^tm1.1Sish/\Marchf1^tm1.1Sish (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	decreased interleukin-12 secretion	J:157516
	decreased tumor necrosis factor secretion	J:157516
\Cd86^tm2Shr/\Cd86^tm2Shr \Icos^tm1Flv/\Icos^tm1Flv (involves: 129S1/Sv * 129S4/SvJaeSor)	abnormal cytokine level	J:112600
\Cd93^tm1Mbo/\Cd93^tm1Mbo (either: 129/Sv or B6.129-Cd93^tm1Mbo or (involves: 129/Sv * C57BL/6))	impaired macrophage phagocytosis	J:88610
\Cd96^{em1(IMPC)Wtsi}/\Cd96^{em1(IMPC)Wtsi} (C57BL/6N-Cd96^{em1(IMPC)Wtsi}/WtsiOulu)	increased leukocyte cell number	J:211773
\Cd96^tm1.1Mjs/\Cd96^tm1.1Mjs (B6.129P2(Cg)-Cd96^tm1.1Mjs)	abnormal NK cell physiology	J:209990
	immune system phenotype	J:209990
	increased inflammatory response	J:209990
	increased susceptibility to endotoxin shock	J:209990
\Cd99^{Gt(Ayu21-B6T44)Imeg}/\Cd99^{Gt(Ayu21-B6T44)Imeg} (involves: C57BL/6)	immune system phenotype	J:207031
\Cd99^{Gt(Ayu21-B6T44)Imeg}/\Cd99^{Gt(Ayu21-B6T44)Imeg} (involves: C57BL/6 * C57BL/6NSlc)	abnormal splenocyte physiology	J:212222
\Cd99l2^tm1.1Dvst/\Cd99l2^tm1.1Dvst \Tg(Tek-cre)1Ywa/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal cellular extravasation	J:193021
	decreased susceptibility to type IV hypersensitivity reaction	J:193021
\Cd99l2^tm1.2Dvst/\Cd99l2^tm1.2Dvst (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal cellular extravasation	J:193021
\Cd101^tm1.1Dil/\Cd101^tm1.1Dil (involves: BALB/cJ * C57BL/6 * C57BL/6NTac)	decreased granulocyte number	J:175943
\Cd109^tm1Mat/\Cd109^tm1Mat (involves: 129S6/SvEvTac * C57BL/6J)	skin inflammation	J:188696
\Cd151^tm1Lka/\Cd151^tm1Lka (C57BL/6-Cd151^tm1Lka)	abnormal T cell proliferation	J:91605
\Cd151^tm1Nki/\Cd151^tm1Nki (involves: 129P2/OlaHsd * FVB/N)	tubulointerstitial nephritis	J:114988
\Cd160^tm1Yxf/\Cd160^tm1Yxf (C57BL/6-Cd160^tm1Yxf)	decreased interferon-gamma secretion	J:222131
\Cd160^tm1Yxf/\Cd160^tm1Yxf \Rag1^tm1Mom/\Rag1^tm1Mom (B6.Cg-Rag1^tm1Mom Cd160^tm1Yxf)	decreased interferon-gamma secretion	J:222131
\Cd163^{tm1(KOMP)Vlcg}/\Cd163^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal circulating cytokine level	J:224919
	abnormal macrophage chemotaxis	J:224919
\Cd163^{tm1(KOMP)Vlcg}/\Cd163^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	lung inflammation	J:233977
\Cd177^{tm1(KOMP)Vlcg}/\Cd177^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal neutrophil physiology	J:225335
	decreased monocyte cell number	J:225335
	decreased neutrophil cell number	J:225335
	immune system phenotype	J:225335
\Cd180^tm1Kmiy/\Cd180^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:63145
	decreased IgG2b level	J:137066
	decreased IgG3 level	J:137066
\Cd180^tm1Kmiy/\Cd180^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6 * NZB * NZW)	decreased IgG2a level	J:137066
	decreased IgG3 level	J:137066
\Cd180^tm1Kmiy/\Cd180^tm1Kmiy \Fas^lpr/\Fas^lpr (MRL.Cg-Cd180^tm1Kmiy Fas^lpr)	blood vessel inflammation	J:137066
	decreased B cell number	J:137066
	decreased CD8-positive, alpha-beta T cell number	J:137066
	decreased IgG2a level	J:137066
	decreased IgG3 level	J:137066
	enlarged lymph nodes	J:137066
	enlarged spleen	J:137066
	glomerulonephritis	J:137066
	increased anti-nuclear antigen antibody level	J:137066
	increased autoantibody level	J:137066
	increased double-negative T cell number	J:137066
\Cd200^tm1Jods/\Cd200^tm1Jods (C57BL/6-Cd200^tm1Jods)	abnormal cytokine level	J:95862
	abnormal immune system organ morphology	J:65982
	abnormal immune system physiology	J:65982
	abnormal lymph node morphology	J:65982
	abnormal macrophage physiology	J:65982
	abnormal microglial cell morphology	J:65982
	abnormal microglial cell physiology	J:65982
	enlarged lymph nodes	J:65982
	increased macrophage cell number	J:79906, J:65982
	increased spleen red pulp amount	J:65982
	increased susceptibility to experimental autoimmune encephalomyelitis	J:65982
	increased susceptibility to experimental autoimmune uveoretinitis	J:79906
	increased susceptibility to induced arthritis	J:65982
\Cd200r1^tm1.1Rmgo/\Cd200r1^tm1.1Rmgo (C57BL/6-Cd200r1^tm1.1Rmgo)	abnormal dendritic cell physiology	J:134313
	abnormal professional antigen presenting cell physiology	J:135069
	abnormal response to transplant	J:135069
	increased interleukin-12b secretion	J:135069
	increased tumor necrosis factor secretion	J:135069
\Cd200r1^tm1.1Rmgo/\Cd200r1^tm1.1Rmgo \Tg(tetO/CMV-CD200)1Rmgo/\Tg(tetO/CMV-CD200)1Rmgo (involves: C57BL/6)	abnormal dendritic cell physiology	J:134313
\Cd200r1^tm1Eakj/\Cd200r1^tm1Eakj (Not Specified)	abnormal macrophage physiology	J:326965
	decreased interferon-beta secretion	J:192198
	decreased interleukin-1 beta secretion	J:192198
	decreased interleukin-6 secretion	J:192198
	decreased susceptibility to Herpesvirales infection	J:192198
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:192198
\Cd207^{tm1(Hbegf/EGFP)Bjec}/\Cd207⁺ (involves: C57BL/6 * SJL)	absent Langerhans cell	J:137517
	decreased dendritic cell number	J:137452
	decreased susceptibility to type IV hypersensitivity reaction	J:137517
	increased susceptibility to Orthomyxoviridae infection	J:137452
\Cd207^{tm1(Hbegf/EGFP)Bjec}/\Cd207⁺ (involves: C57BL/6)	abnormal type IV hypersensitivity reaction	J:179630
\Cd207^tm1.1Cfg/\Cd207^tm1.1Cfg (involves: C57BL/6)	abnormal Peyer's patch morphology	J:217719
	decreased IgA level	J:217719
	decreased IgG1 level	J:217719
	decreased IgG2a level	J:217719
	decreased IgG3 level	J:217719
	decreased IgM level	J:217719
\Cd207^tm1Mal/\Cd207^tm1Mal (B6.129S2-Cd207^tm1Mal)	abnormal Langerhans cell morphology	J:95147
\Cd207^{tm2.1(cre)Bjec}/\Cd207⁺ (B6.Cg-CD207^{tm2.1(cre)Bjec})	immune system phenotype	J:179630
\Cd207^{tm2.1(cre)Bjec}/\Cd207⁺ \Tgfbr1^tm1.1Karl/\Tgfbr1^tm1.1Karl (involves: 129S4/SvJaeSor * C57BL/6)	abnormal type IV hypersensitivity reaction	J:179630
	decreased dendritic cell number	J:179630
\Cd207^tm2.1Mal/\Cd207^{tm3.1(HBEGF/EGFP)Mal} (involves: 129S2/SvPas)	abnormal Langerhans cell morphology	J:99114
	absent Langerhans cell	J:99114
	decreased Langerhans cell number	J:99114
\Cd209a^tm1.1Cfg/\Cd209a^tm1.1Cfg (involves: C57BL/6)	decreased IgG2b level	J:217719
	increased inflammatory response	J:217719
	increased lymphocyte cell number	J:217719
	increased mature B cell number	J:217719
	increased monocyte cell number	J:217719
	increased plasma cell number	J:217719
	increased spleen germinal center size	J:217719
	increased T cell proliferation	J:217719
\Cd209a^tm1.1Cfg/\Cd209a^tm1.1Cfg (B6.Cg-Cd209a^tm1.1Cfg/Mmucd)	immune system phenotype	J:194602
\Cd209a^tm1Olne/\Cd209a^tm1Olne (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:153503
\Cd209b^tm1.1Cfg/\Cd209b^tm1.1Cfg (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:153503
\Cd209b^tm1.1Cfg/\Cd209b^tm1.1Cfg (involves: C57BL/6)	decreased mature B cell number	J:217719
	impaired macrophage phagocytosis	J:288225
	increased eosinophil cell number	J:288225
	increased IgG2b level	J:217719
	increased IgG3 level	J:217719
	increased IgM level	J:217719
	increased macrophage cell number	J:217719
	increased susceptibility to bacterial infection	J:288225
	urinary bladder inflammation	J:288225
\Cd209b^tm1Anjm/\Cd209b^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:94698
	impaired macrophage phagocytosis	J:94698
	increased susceptibility to bacterial infection	J:94698
	increased susceptibility to bacterial infection induced morbidity/mortality	J:94698
\Cd209b^tm1Anjm/\Cd209b^tm1Anjm (B6.129P2-Cd209b^tm1Anjm)	decreased interleukin-1 beta secretion	J:159646
	decreased interleukin-18 secretion	J:159646
	decreased susceptibility to endotoxin shock	J:159646
	decreased susceptibility to induced colitis	J:159646
	increased susceptibility to bacterial infection induced morbidity/mortality	J:94698
\Cd209b^tm1Anjm/\Cd209b^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:209808
\Cd209b^tm1Anjm/\Cd209b^tm1Anjm (C.129P2-Cd209b^tm1Anjm)	immune system phenotype	J:143766
\Cd209c^{em1(IMPC)Ccpcz}/\Cd209c^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cd209c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Cd209d^tm1.1Cfg/\Cd209d^tm1.1Cfg (involves: C57BL/6 * C57BL/6J)	increased circulating tumor necrosis factor level	J:153503
	increased susceptibility to bacterial infection	J:153503
\Cd209d^tm1.1Cfg/\Cd209d^tm1.1Cfg (involves: C57BL/6)	increased B cell number	J:217719
\Cd209d^tm1.1Cfg/\Cd209d^tm1.1Cfg (involves: C57BL/6)	increased B cell proliferation	J:217719
\Cd226^tm1.1Cln/\Cd226^tm1.1Cln (B6.129P2-Cd226^tm1.1Cln)	decreased inflammatory response	J:209990
	decreased T cell proliferation	J:159749
	impaired natural killer cell mediated cytotoxicity	J:159749
\Cd226^tm1.1Cln/\Cd226^tm1.1Cln \Tg(TcraTcrb)1100Mjb/0 (B6.Cg-Cd226^tm1.1Cln Tg(TcraTcrb)1100Mjb)	abnormal T cell activation	J:159749
	decreased cytotoxic T cell cytolysis	J:159749
	decreased interferon-gamma secretion	J:159749
	decreased T cell proliferation	J:159749
\Cd226^tm1Shib/\Cd226^tm1Shib (involves: BALB/c)	abnormal immune system physiology	J:165704
	decreased cytotoxic T cell cytolysis	J:165704
	impaired natural killer cell mediated cytotoxicity	J:165704
\Cd244a^Chip/\Cd244a⁺ (C57BL/6J-Cd244a^Chip)	abnormal NK cell physiology	J:196519
\Cd244a^Chip/\Cd244a⁺ (C57BL/6J-Cd244a^Chip)	impaired natural killer cell mediated cytotoxicity	J:196519
\Cd244a^Chip/\Cd244a^Chip (C57BL/6J-Cd244a^Chip)	abnormal NK cell physiology	J:196519
\Cd244a^Chip/\Cd244a^Chip (C57BL/6J-Cd244a^Chip)	impaired natural killer cell mediated cytotoxicity	J:196519
\Cd244a^tm1Kmle/\Cd244a^tm1Kmle (involves: C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:166054
\Cd244a^tm1Kmle/\Cd244a^tm1Kmle (involves: C57BL/6)	increased natural killer cell mediated cytotoxicity	J:92740
\Cd247^m1Btlr/\Cd247^m1Btlr (C57BL/6J-Cd247^m1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:158794
\Cd247^tm1Lov/\Cd247^tm1Lov (involves: 129S4/SvJae)	abnormal single-positive T cell number	J:14170
	abnormal T-helper 1 cell morphology	J:14170
	abnormal T-helper 1 physiology	J:46914
	absent gamma-delta intraepithelial T cell	J:46914
	decreased CD4-positive, alpha-beta T cell number	J:14170
	decreased double-positive T cell number	J:14170
	decreased thymocyte number	J:14170
\Cd247^tm1Lov/\Cd247^tm1Lov \Fcer1g^tm1Rav/\Fcer1g^tm1Rav (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal effector T cell morphology	J:46914
	abnormal T cell activation	J:46914
	abnormal T-helper 1 physiology	J:46914
	absent gamma-delta intraepithelial T cell	J:46914
	decreased thymocyte number	J:46914
	impaired natural killer cell mediated cytotoxicity	J:64764
\Cd247^tm1Lov/\Cd247^tm2.1Lov (involves: 129S4/SvJae)	immune system phenotype	J:192915
\Cd247^tm1Mal/\Cd247^tm1Mal (either: C57BL/6-Cd247^tm1Mal or (involves: BALB/c * C57BL/6))	abnormal intraepithelial T cell morphology	J:15272
	abnormal T cell differentiation	J:15272
	decreased CD4-positive, alpha-beta T cell number	J:15272
	decreased CD8-positive, alpha-beta T cell number	J:15272
	decreased double-positive T cell number	J:15272
	decreased single-positive T cell number	J:15272
	decreased thymocyte number	J:15272
	increased double-negative T cell number	J:15272
\Cd247^tm1Mal/\Cd247^tm1Mal (involves: C57BL/6)	abnormal double-negative T cell morphology	J:112990, J:110847
	abnormal T cell differentiation	J:112990
	abnormal T cell morphology	J:110847
	abnormal thymocyte activation	J:110847
	decreased double-positive T cell number	J:110847
\Cd247^tm1Mal/\Cd247^tm1Mal \Lck^tm1Mak/\Lck^tm1Mak (involves: 129S2/SvPas * C57BL/6)	abnormal double-negative T cell morphology	J:110847
	abnormal T cell differentiation	J:110847
	abnormal T cell morphology	J:110847
	abnormal thymocyte activation	J:110847
	decreased double-positive T cell number	J:110847
\Cd247^tm1Mhu/\Cd247^tm1Mhu (involves: 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:15579
	decreased CD4-positive, alpha-beta T cell number	J:15579
	decreased CD8-positive, alpha-beta T cell number	J:15579
	decreased double-positive T cell number	J:15579
	decreased splenocyte proliferation	J:15579
	decreased T cell proliferation	J:15579
	decreased thymocyte number	J:15579
	enlarged lymph nodes	J:15579
	enlarged spleen	J:15579
	enlarged thymus cortex	J:15579
	immune system phenotype	J:15579
	increased double-negative T cell number	J:15579
	small thymus	J:15579
	small thymus medulla	J:15579
	thymus hypoplasia	J:15579
\Cd247^tm1Mhu/\Cd247^tm1Mhu \Fcer1g^tm1Rav/\Fcer1g^tm1Rav (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	decreased uterine NK cell number	J:100668
\Cd247^tm1Tks/\Cd247^tm1Tks (involves: 129P2/OlaHsd * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:15271
	abnormal T cell proliferation	J:15271
	decreased CD4-positive, alpha-beta T cell number	J:15271
	decreased CD8-positive, alpha-beta T cell number	J:15271
	decreased double-positive T cell number	J:15271
	decreased single-positive T cell number	J:15271
	decreased thymocyte number	J:15271
	small thymus medulla	J:15271
\Cd247^tm1Tks/\Cd247^tm1Tks (B6.129P2-Cd247^tm1Tks)	abnormal NK cell morphology	J:66403
	abnormal NK cell physiology	J:66403
	decreased NK T cell number	J:28282
	increased interferon-gamma secretion	J:66403
	increased natural killer cell mediated cytotoxicity	J:66403
\Cd247^tm2.1Lov/\Cd247^tm2.1Lov (Not Specified)	abnormal gamma-delta T cell differentiation	J:192915
	abnormal NK T cell morphology	J:192915
	abnormal regulatory T cell physiology	J:192915
	abnormal T cell differentiation	J:192915
	abnormal T cell physiology	J:192915
	abnormal T-helper 1 cell differentiation	J:192915
	decreased CD4-positive, alpha-beta T cell number	J:192915
	decreased CD8-positive, alpha-beta T cell number	J:192915
	decreased thymocyte apoptosis	J:192915
	decreased thymocyte number	J:192915
	immune system phenotype	J:192915
	increased regulatory T cell number	J:192915
\Cd247^tm2.1Lov/\Cd247^tm2.1Lov (B6.Cg-Cd247^tm2.1Lov)	increased susceptibility to experimental autoimmune encephalomyelitis	J:192915
\Cd247^tm2.1Lov/\Cd247^tm2.1Lov \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:192915
\Cd248^tm1Huso/\Cd248^tm1Huso (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:107172
\Cd274^tm1.1Lex/\Cd274^tm1.1Lex (involves: 129S5/SvEvBrd)	abnormal cytokine secretion	J:126829
	decreased CD8-positive, alpha-beta T cell number	J:126829
	increased susceptibility to experimental autoimmune encephalomyelitis	J:126829
\Cd274^tm1Igu/\Cd274^tm1Igu \Vsir^tm1Lex/\Vsir^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal T cell activation	J:222944
\Cd274^tm1Lpc/\Cd274^tm1Lpc (B6.129S-Cd274^tm1Lpc)	abnormal CD8-positive, alpha-beta T cell physiology	J:89781
	decreased T cell apoptosis	J:89781
	increased activated T cell number	J:89781
	increased CD8-positive, alpha-beta T cell number	J:89781
	increased susceptibility to autoimmune disorder	J:89781
\Cd274^tm1Lpc/\Cd274^tm1Lpc (involves: 129S/SvEv)	abnormal chemokine secretion	J:158023
\Cd274^tm1Lpc/\Cd274^tm1Lpc (involves: 129S/SvEv)	increased tumor necrosis factor secretion	J:158023
\Cd274^tm1Lpc/\Cd274^tm1Lpc (involves: 129S/SvEv * C57BL/6)	abnormal dendritic cell physiology	J:152305
	abnormal T cell morphology	J:136330
	abnormal T-helper 1 cell differentiation	J:162539
	decreased susceptibility to Riboviria infection	J:136330
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:136330
	decreased T cell apoptosis	J:136330
	decreased T helper 1 cell number	J:162539
	increased CD8-positive, alpha-beta T cell number	J:152305
	increased IgG1 level	J:162539
	increased IgG2c level	J:162539
	increased susceptibility to bacterial infection	J:162539
	increased susceptibility to bacterial infection induced morbidity/mortality	J:162539
	increased susceptibility to experimental autoimmune encephalomyelitis	J:142815
	increased T cell number	J:142815
\Cd274^tm1Lpc/\Cd274^tm1Lpc (C.129S-Cd274^tm1Lpc)	abnormal regulatory T cell physiology	J:165841
	abnormal T follicular helper cell physiology	J:165841
	decreased germinal center B cell number	J:165841
	decreased IgG1 level	J:165841
	decreased IgG2a level	J:165841
	decreased interleukin-17 secretion	J:165841
	decreased plasma cell number	J:165841
	decreased T-helper 17 cell number	J:165841
	immune system phenotype	J:165841
	increased interferon-gamma secretion	J:165841
	increased interleukin-4 secretion	J:165841
	increased susceptibility to induced arthritis	J:165841
	increased T cell proliferation	J:165841
\Cd274^tm1Shr/\Cd274^tm1Shr (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:91480
\Cd274^tm1Shr/\Cd274^tm1Shr (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:91480
\Cd274^tm1Shr/\Cd274^tm1Shr (C.B6-Cd274^tm1Shr)	abnormal interleukin secretion	J:123785
	increased interferon-gamma secretion	J:123785
	increased susceptibility to autoimmune diabetes	J:123785
\Cd274^tm1Shr/\Cd274^tm1Shr \Pdcd1lg2^tm3Shr/\Pdcd1lg2^tm3Shr (C.B6-Cd274^tm1Shr Pdcd1lg2^tm3Shr)	abnormal dendritic cell physiology	J:123785
	decreased interleukin-4 secretion	J:123785
	increased interferon-gamma secretion	J:123785
	increased interleukin-2 secretion	J:123785
\Cd274^tm1Shr/\Cd274^tm1Shr \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	increased susceptibility to autoimmune diabetes	J:153040
\Cd274^tm2Shr/\Cd274^tm2Shr (involves: 129/Sv * 129S4/SvJae)	abnormal cytokine secretion	J:113851
	decreased susceptibility to parasitic infection	J:113851
\Cd274^tm2Shr/\Cd274^tm2Shr \Pdcd1lg2^tm4Shr/\Pdcd1lg2^tm4Shr (involves: 129S4/SvJae)	abnormal immune system physiology	J:160970
\Cd276^tm1Lpc/\Cd276^tm1Lpc (B6.129-Cd276^tm1Lpc)	abnormal T-helper 1 physiology	J:237700
	abnormal T-helper 2 physiology	J:237700
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:237700
	increased susceptibility to type I hypersensitivity reaction	J:237700
\Cd276^tm1Lpc/\Cd276^tm1Lpc (D1J.129-Cd276^tm1Lpc)	abnormal T-helper 1 physiology	J:237700
	abnormal T-helper 17 cell physiology	J:237700
	decreased susceptibility to induced arthritis	J:237700
\Cd276^tm1Mak/\Cd276^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 physiology	J:84973
	immune system phenotype	J:84973
	increased anti-single stranded DNA antibody level	J:84973
	increased inflammatory response	J:84973
	increased susceptibility to experimental autoimmune encephalomyelitis	J:84973
	increased T cell proliferation	J:84973
\Cd276^tm1Mak/\Cd276^tm1Mak (C.129P2-Cd276^tm1Mak)	abnormal T-helper 1 physiology	J:84973
	increased inflammatory response	J:84973
	increased interferon-gamma secretion	J:84973
\Cd276^tm1Wwh/\Cd276^tm1Wwh (B6.Cg-B7h3^tm1Wwh)	abnormal cytokine secretion	J:95550
\Cd276^tm1Wwh/\Cd276^tm1Wwh (B6.Cg-B7h3^tm1Wwh)	abnormal response to transplant	J:95550
\Cd300a^{tm1b(EUCOMM)Hmgu}/\Cd300a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cd300a^{tm1b(EUCOMM)Hmgu}/Bay)	decreased eosinophil cell number	J:211773
\Cd300a^tm1Shib/\Cd300a^tm1Shib (B6JJcl.C-Cd300a^tm1Shib)	abnormal chemokine secretion	J:189144
	abnormal mast cell physiology	J:189144
	increased interleukin-10 secretion	J:189144
	increased interleukin-13 secretion	J:189144
	increased neutrophil cell number	J:189144
	increased tumor necrosis factor secretion	J:189144
\Cd300c2^tm1Shib/\Cd300c2^tm1Shib (B6.Cg-Cd300c2^tm1Shib)	increased B cell proliferation	J:177613
\Cd300c^{em1(IMPC)Wtsi}/\Cd300c^{em1(IMPC)Wtsi} (C57BL/6N-Cd300c^{em1(IMPC)Wtsi}/WtsiOulu)	increased leukocyte cell number	J:211773
\Cd300lb^tm1Toki/\Cd300lb^tm1Toki (B6.Cg-Cd300lb^tm1Toki)	immune system phenotype	J:163402
\Cd300lf^tm1Gne/\Cd300lf^tm1Gne (involves: C57BL/6N)	immune system phenotype	J:156819
	increased interleukin-1 alpha secretion	J:156819
	increased interleukin-1 beta secretion	J:156819
	increased interleukin-12 secretion	J:156819
	increased susceptibility to experimental autoimmune encephalomyelitis	J:156819
\Cd300lf^tm1Toki/\Cd300lf^tm1Toki (Not Specified)	abnormal interleukin secretion	J:190979
	abnormal mast cell physiology	J:190979
	immune system phenotype	J:190979
	increased interleukin-4 secretion	J:190979
	increased interleukin-5 secretion	J:190979
	increased interleukin-13 secretion	J:190979
	increased susceptibility to type I hypersensitivity reaction	J:190979
	respiratory system inflammation	J:190979
\Cd302^tm1.1Dnjh/\Cd302^tm1.1Dnjh (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:301848
	abnormal dendritic cell physiology	J:301848
	decreased dendritic cell number	J:301848
	immune system phenotype	J:301848
\Cd320^{Gt(CC0426)Wtsi}/\Cd320^{Gt(CC0426)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:199961
\Cdc7^{tm1.1(KOMP)Vlcg}/\Cdc7⁺ (C57BL/6N-Cdc7^{tm1.1(KOMP)Vlcg}/Tcp)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Cdc7^tm1Hmas/\Cdc7^tm1Hmas \Tg(EF1A-Cdc7)DKO28Hmas/0 (involves: 129S/Sv * C57BL/6)	immune system phenotype	J:85942
\Cdc42^{tm1b(EUCOMM)Hmgu}/\Cdc42⁺ (C57BL/6N-Cdc42^{tm1b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cdc42ep5^{tm1(KOMP)Wtsi}/\Cdc42ep5^{tm1(KOMP)Wtsi} (C57BL/6N-Cdc42ep5^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Cdc73^tm1Btt/\Cdc73^tm1Btt \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S4/SvJae C57BL/6 * CBA)	small spleen	J:135255
\Cdca7l^em1(IMPC)Mbp/\Cdca7l^em1(IMPC)Mbp (C57BL/6NCrl-Cdca7l^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Cdcp2^em1(IMPC)Mbp/\Cdcp2^em1(IMPC)Mbp (C57BL/6N-Cdcp2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Cdcs1^C3H/HeJBir/\Cdcs1^C3H/HeJBir (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	abnormal immune system physiology	J:72978
\Cdcs1^C3H/HeJBir/\Cdcs1^C57BL/6J (involves: C3H/HeJBir-Il10^tm1Cgn * C57BL/6J-Il10^tm1Cgn)	colitis	J:72978
\Cdcs2^C3H/HeJBir/\Cdcs2^C3H/HeJBir (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
\Cdcs2^C3H/HeJBir/\Cdcs2^C57BL/6J (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
\Cdcs3^C3H/HeJBir/\Cdcs3^C3H/HeJBir (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
\Cdcs4^C3H/HeJBir/\Cdcs4^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:72978
\Cdcs4^C57BL/6J/\Cdcs4^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:72978
\Cdcs5^C57BL/6J/\Cdcs5^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:72978
\Cdcs6^C57BL/6J/? (involves: B6.129P2-Il10^tm1Cgn/Lt * C3Bir.129P2(B6)-Il10^tm1Cgn/Lt)	intestinal inflammation	J:72978
\Cdcs7^C3H/HeJBir/\Cdcs7^C3H/HeJBir (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
\Cdcs8^C57BL/6J/\Cdcs8^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
\Cdcs9^C3H/HeJBir/\Cdcs9^C3H/HeJBir (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
\Cdcs9^C3H/HeJBir/\Cdcs9^C57BL/6J (involves: C3H/HeJBir * C57BL/6J)	intestinal inflammation	J:78917
\Cdcs10^C3H/HeJBir/\Cdcs10^C3H/HeJBir (involves: C3H/HeJBir-Il10^tm1Cgn * C57BL/6J-Il10^tm1Cgn)	intestinal inflammation	J:78917
\Cdcs10^C3H/HeJBir/\Cdcs10^C57BL/6J (involves: C3H/HeJBir-Il10^tm1Cgn * C57BL/6J-Il10^tm1Cgn)	intestinal inflammation	J:72978
\Cdh1^tm1Mlec/\Cdh1^tm1Mlec (involves: 129S2/SvPas)	increased susceptibility to bacterial infection	J:142843
\Cdh5^{tm3(Cdh5/Ctnna1)Dvst}/\Cdh5^{tm3(Cdh5/Ctnna1)Dvst} (involves: 129 * C57BL/6)	abnormal cellular extravasation	J:177191
	abnormal leukocyte migration	J:177191
	abnormal lymphatic vessel endothelial cell morphology	J:213676
	immune system phenotype	J:213676
	increased leukocyte cell number	J:177191
	increased neutrophil cell number	J:177191
\Cdh5^{tm3(Cdh5/Ctnna1)Dvst}/\Cdh5^{tm3(Cdh5/Ctnna1)Dvst} (B6.Cg-Cdh5^{tm3(Cdh5/Ctnna1)Dvst})	abnormal lymphatic vessel endothelium morphology	J:213676
	abnormal lymphatic vessel morphology	J:213676
\Cdh5^{tm4(Cdh5/Fkbp,Ptprb/Mtor)Dvst}/\Cdh5^{tm4(Cdh5/Fkbp,Ptprb/Mtor)Dvst} (involves: C57BL/6)	abnormal cellular extravasation	J:178759
	impaired neutrophil recruitment	J:178759
\Cdh5^tm5Dvst/\Cdh5^tm5Dvst (B6.Cg-Cdh5^tm5Dvst)	abnormal cellular extravasation	J:209801
\Cdh5^tm6Dvst/\Cdh5^tm6Dvst (B6.Cg-Cdh5^tm6Dvst)	abnormal cellular extravasation	J:209801
\Cdh10^{tm2b(KOMP)Wtsi}/\Cdh10^{tm2b(KOMP)Wtsi} (C57BL/6N-Cdh10^{tm2b(KOMP)Wtsi}/Ucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cdh17^M1Btlr/\Cdh17^M1Btlr (C57BL/6J-Cdh17^M1Btlr)	increased susceptibility to induced colitis	J:272090
\Cdh17^tm1Ohn/\Cdh17^tm1Ohn (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen marginal zone morphology	J:96738
	decreased B cell number	J:96738
	decreased B-1a cell number	J:96738
	decreased germinal center B cell number	J:96738
	decreased IgG level	J:96738
	decreased marginal zone B cell number	J:96738
	decreased mature B cell number	J:96738
	decreased spleen germinal center size	J:96738
	increased pre-B cell number	J:96738
	increased pro-B cell number	J:96738
\Cdh23^{tm2b(EUCOMM)Wtsi}/\Cdh23^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Cdh23^{tm2b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Cdhr3^{em1(IMPC)Wtsi}/\Cdhr3^{em1(IMPC)Wtsi} (C57BL/6NCrl-Cdhr3^{em1(IMPC)Wtsi}/Wtsi)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cdk2^tm2Sgo/\Cdk2^tm2Sgo \Cdk4^tm2.1Bbd/\Cdk4^tm2.1Bbd \Polr2a^{tm1(cre/ERT2)Bbd}/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased susceptibility to autoimmune diabetes	J:125217
\Cdk4⁺/\Cdk4⁺ \Tg(Mt1-Hgf)#Lmb/0 (B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb)	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
\Cdk4^tm1.1Bbd/\Cdk4⁺ \Tg(Mt1-Hgf)#Lmb/0 (B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb)	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
	enlarged axillary lymph nodes	J:111992
	enlarged inguinal lymph nodes	J:111992
\Cdk4^tm1.1Bbd/\Cdk4^tm1.1Bbd \Tg(Mt1-Hgf)#Lmb/0 (B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb)	abnormal axillary lymph node morphology	J:111992
	abnormal inguinal lymph node morphology	J:111992
	enlarged axillary lymph nodes	J:111992
	enlarged inguinal lymph nodes	J:111992
\Cdk4^tm1Kiyo/\Cdk4⁺ \Lin9^tm1Orc/\Lin9⁺ (involves: 129S1/Sv)	decreased susceptibility to autoimmune diabetes	J:111333
\Cdk5rap2^an/\Cdk5rap2^an (Not Specified)	decreased leukocyte cell number	J:5439
\Cdk5rap2^{Gt(RRO242)Byg}/\Cdk5rap2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	decreased leukocyte cell number	J:160533
\Cdk5rap2^{Gt(RRO242)Byg}/\Cdk5rap2^an (involves: 129P2/OlaHsd * C57BL/6J)	decreased leukocyte cell number	J:160533
\Cdk5rap2^{tm1a(EUCOMM)Wtsi}/\Cdk5rap2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cdk5rap2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Cdk6^tm1.1Phin/\Cdk6^tm1.1Phin (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:144975
\Cdk6^tm1Bbd/\Cdk6^tm1Bbd (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal spleen morphology	J:92529
	abnormal spleen red pulp morphology	J:92529
	abnormal thymus morphology	J:92529
	decreased leukocyte cell number	J:92529
	decreased T cell proliferation	J:92529
	increased single-positive T cell number	J:92529
	small spleen	J:92529
	spleen hypoplasia	J:92529
	thymus cortex atrophy	J:92529
	thymus hypoplasia	J:92529
\Cdk6^tm1Phin/\Cdk6⁺ \Tg(Lck-Akt1*E40K)E-3Pnt/0 (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:144975
\Cdk6^tm1Phin/\Cdk6^tm1Phin (involves: 129S4/SvJae)	abnormal lymphopoiesis	J:144975
	abnormal T cell differentiation	J:144975
	abnormal thymocyte activation	J:144975
	decreased CD8-positive, alpha-beta T cell number	J:144975
	decreased double-negative T cell number	J:144975
	decreased double-positive T cell number	J:144975
	decreased thymocyte apoptosis	J:144975
	decreased thymocyte number	J:144975
	thymus atrophy	J:144975
	thymus hypoplasia	J:144975
\Cdk6^tm1Phin/\Cdk6^tm1Phin (involves: 129S4/SvJae * C57BL/6)	decreased DN1 thymic pro-T cell number	J:174697
	decreased DN2 thymocyte number	J:174697
	decreased double-positive T cell number	J:174697
	immune system phenotype	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
	increased DN3 thymocyte number	J:174697
\Cdk6^tm1Phin/\Cdk6^tm1Phin \Tg(Lck-Akt1*E40K)E-3Pnt/0 (involves: 129S4/SvJae)	abnormal T cell differentiation	J:144975
\Cdk6^tm2.1Phin/\Cdk6^tm2.1Phin (involves: 129 * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:174697
	decreased DN1 thymic pro-T cell number	J:174697
	decreased DN2 thymocyte number	J:174697
	decreased DN4 thymocyte number	J:174697
	decreased double-positive T cell number	J:174697
	decreased thymocyte number	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
	increased DN3 thymocyte number	J:174697
	increased double-negative T cell number	J:174697
	small thymus	J:174697
\Cdk6^tm2.1Phin/\Cdk6^tm2.1Phin \Il2ra^tm1Dw/\Il2ra^tm1Dw (involves: 129S4/SvJae * C57BL/6 * FVB/N)	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
\Cdk6^tm3.1Phin/\Cdk6^tm3.1Phin (involves: 129 * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:174697
	enlarged thymus	J:174697
	immune system phenotype	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased DN1 thymic pro-T cell number	J:174697
	increased T cell apoptosis	J:174697
	increased thymocyte number	J:174697
\Cdk6^tm4.1Phin/\Cdk6^tm4.1Phin (involves: 129 * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:174697
	decreased DN1 thymic pro-T cell number	J:174697
	decreased DN2 thymocyte number	J:174697
	decreased DN4 thymocyte number	J:174697
	decreased double-positive T cell number	J:174697
	decreased thymocyte number	J:174697
	immune system phenotype	J:174697
	increased CD4-positive, alpha-beta T cell number	J:174697
	increased CD8-positive, alpha-beta T cell number	J:174697
	increased DN3 thymocyte number	J:174697
	small thymus	J:174697
\Cdk10^tm1.2Kald/\Cdk10^tm1.2Kald (involves: 129 * C57BL/6 * FVB/N)	abnormal spleen morphology	J:262333
\Cdk12^em1(IMPC)Tcp/\Cdk12⁺ (C57BL/6NCrl-Cdk12^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Cdkl2^{tm1b(EUCOMM)Hmgu}/\Cdkl2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cdkl2^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Cdkn1a^{tm1.1(KOMP)Vlcg}/\Cdkn1a^{tm1.1(KOMP)Vlcg} (C57BL/6N-Cdkn1a^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Cdkn1a^tm1Led/\Cdkn1a^tm1Led (involves: 129S6/SvEvTac)	increased anti-double stranded DNA antibody level	J:76041
	increased anti-histone antibody level	J:76041
	increased anti-single stranded DNA antibody level	J:76041
	increased autoantibody level	J:76041
	increased T cell proliferation	J:76041
\Cdkn1a^tm1Led/\Cdkn1a^tm1Led \Gadd45a^tm1Ajf/\Gadd45a^tm1Ajf (either: (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6))	abnormal lymphopoiesis	J:76041
	abnormal T cell activation	J:76041
	decreased basophil cell number	J:76041
	decreased eosinophil cell number	J:76041
	decreased leukocyte cell number	J:76041
	decreased lymphocyte cell number	J:76041
	glomerulonephritis	J:76041
	increased anti-double stranded DNA antibody level	J:76041
	increased anti-histone antibody level	J:76041
	increased anti-single stranded DNA antibody level	J:76041
	increased autoantibody level	J:76041
	increased IgG1 level	J:76041
	increased IgM level	J:76041
	increased inflammatory response	J:76041
	increased T cell proliferation	J:76041
\Cdkn1a^tm1Led/\Cdkn1a^tm1Led \Zbtb17^tm1Cksn/\Zbtb17^tm1Cksn \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (B6.Cg-Zbtb17^tm1Cksn Cdkn1a^tm1Led Commd10^{Tg(Vav1-icre)A2Kio})	arrested T cell differentiation	J:170508
\Cdkn1a^tm1Tyj/\Cdkn1a^tm1Tyj (B6;129S2-Cdkn1a^tm1Tyj/J)	decreased monocyte cell number	J:108569
	decreased susceptibility to induced arthritis	J:108569
	impaired macrophage chemotaxis	J:108569
\Cdkn1a^tm1Tyj/\Cdkn1a^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:60292
	abnormal self tolerance	J:60292
	abnormal thymus physiology	J:70894
	enlarged cervical lymph nodes	J:60292
	enlarged lymph nodes	J:60292
	enlarged spleen	J:60292
	glomerulonephritis	J:60292, J:70894
	immune system phenotype	J:60292
	increased anti-double stranded DNA antibody level	J:60292
	increased anti-histone antibody level	J:60292
	increased anti-nuclear antigen antibody level	J:60292
	increased B cell number	J:60292
	increased IgG1 level	J:60292
	increased memory T cell number	J:60292
	increased spleen weight	J:60292
	increased T cell derived lymphoma incidence	J:70894
	increased T cell proliferation	J:60292
	lymph node hyperplasia	J:60292
	spleen hyperplasia	J:60292
\Cdkn1a^tm1Tyj/\Cdkn1a^tm1Tyj \Tg(MMTV-vHaras)SH1Led/0 (involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)	enlarged spleen	J:66183
\Cdkn1b^tm1Ako/\Cdkn1b^tm1Ako (involves: 129S1/Sv * C57BL/6)	increased spleen weight	J:33401
	increased thymocyte number	J:33401
	increased thymus weight	J:33401
\Cdkn1b^tm1Ako/\Cdkn1b^tm1Ako \Cdkn2c^tm1Yxi/\Cdkn2c^tm1Yxi (involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)	enlarged spleen	J:50053
	enlarged thymus	J:50053
\Cdkn1b^tm1Jro/\Cdkn1b^tm1Jro (involves: 129S4/SvJaeSor * C57BL/6)	decreased T cell proliferation	J:71780
\Cdkn1b^tm1Kin/\Cdkn1b^tm1Kin (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:33402
	enlarged thymus	J:33402
	increased T cell number	J:33402
	thymus hyperplasia	J:33402
\Cdkn1b^tm1Kin/\Cdkn1b^tm1Kin \Skp2^tm1Kin/\Skp2^tm1Kin (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:74265
\Cdkn1b^tm1Mlf/\Cdkn1b⁺ \Crebbp^tm1Jvd/\Crebbp^tm1Jvd \Tg(MMTV-cre)4Mam/0 (involves: 129 * C57BL/6 * CBA * FVB)	increased T cell derived lymphoma incidence	J:88323
\Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf (involves: 129S4/SvJaeSor * C57BL/6J)	abnormal spleen morphology	J:33400
	abnormal thymus morphology	J:33400
	enlarged spleen	J:33400
	enlarged thymus	J:33400
	increased T cell proliferation	J:33400
	spleen hyperplasia	J:33400
	thymus hyperplasia	J:33400
\Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf (involves: 129S4/SvJaeSor)	enlarged spleen	J:107588
	enlarged thymus	J:107588
	spleen hypoplasia	J:107588
\Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf \Myc^tm1Atp/\Myc⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	decreased T cell proliferation	J:73369
\Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf \Tg(KRT5-CDK4)2303Mlrp/0 (involves: 129S4/SvJae * C57BL/6 * FVB * SENCAR * SSIN)	enlarged thymus	J:107588
	thymus hyperplasia	J:107588
\Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf \Trp53^tm1Brd/\Trp53^tm1Brd (involves: C3H * C57BL/6J * NIH)	increased T cell derived lymphoma incidence	J:87536
\Cdkn1b^tm1Mlf/\Cdkn1b^tm1Mlf \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)	increased T cell derived lymphoma incidence	J:87536
\Cdkn1b^tm2Kin/\Cdkn1b^tm2Kin \Rassf5^tm1Kina/\Rassf5^tm1Kina (involves: C57BL/6 * CBA)	immune system phenotype	J:168749
\Cdkn1b^tm3Jro/\Cdkn1b^tm3Jro (involves: 129S4/SvJaeSor)	enlarged spleen	J:103819
\Cdkn1b^tm3Jro/\Cdkn1b^tm3Jro (involves: 129S4/SvJaeSor)	enlarged thymus	J:103819
\Cdkn1c^tm1Kat/\Cdkn1c^tm1Kat (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen white pulp morphology	J:61190
\Cdkn2a^tm1Cjs/\Cdkn2a^tm1Cjs (involves: 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:44427
\Cdkn2a^tm1Cjs/\Cdkn2a^tm1Cjs \Nop53^tm2.1Asuz/\Nop53^tm2.1Asuz \Tg(Lck-cre)#Jxm/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	decreased thymocyte number	J:241062
\Cdkn2a^tm1Rdp/\Cdkn2a^tm1Rdp (involves: 129/Sv * C57BL/6 * SJL)	abnormal spleen morphology	J:53805
	abnormal spleen red pulp morphology	J:53805
	increased spleen white pulp amount	J:53805
\Cdkn2a^tm1Rdp/\Cdkn2a^tm1Rdp \Rnf2^tm1Mvi/\Rnf2^tm1Mvi \Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL)	enlarged spleen	J:130397
\Cdkn2a^tm1Rdp/\Cdkn2a^tm1Rdp \Tg(Tyr-NRASQ61K)1Bee/? (involves: 129/Sv C57BL/6 * DBA/2 * SJL)	enlarged lymph nodes	J:98545
\Cdkn2a^tm2.1Rdp/\Cdkn2a^tm2.1Rdp (involves: 129S6/SvEvTac * FVB/N)	increased CD4-positive, alpha-beta T cell number	J:71394
	increased CD8-positive, alpha-beta T cell number	J:71394
	increased double-positive T cell number	J:71394
	increased splenocyte proliferation	J:71394
	increased thymus weight	J:71394
	thymus hyperplasia	J:71394
\Cdkn2b^tm1Bbd/\Cdkn2b^tm1Bbd (involves: 129S1/Sv * C57BL/6)	abnormal lymph node germinal center morphology	J:63299
	abnormal lymph node secondary follicle morphology	J:63299
	abnormal lymphocyte morphology	J:63299
	abnormal spleen marginal zone morphology	J:63299
	abnormal spleen morphology	J:63299
	increased mature B cell number	J:63299
	lymph node hyperplasia	J:63299
	lymphoid hyperplasia	J:63299
	spleen hyperplasia	J:63299
\Cdkn2b^tm1Bbd/\Cdkn2b^tm1Bbd \Cdkn2c^tm1Bbd/\Cdkn2c^tm1Bbd (involves: 129S1/Sv * C57BL/6)	abnormal Langerhans cell morphology	J:63299
	abnormal lymphocyte morphology	J:63299
	enlarged spleen	J:63299
	lymph node hyperplasia	J:63299
	lymphoid hyperplasia	J:63299
\Cdkn2b^tm1Bbd/\Cdkn2b^tm1Bbd \Pbx1^tm1Koss/\Pbx1^tm1Koss \Nkx2-5^tm2(cre)Rph/\Nkx2-5⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal spleen mesenchyme morphology	J:184521
	abnormal spleen morphology	J:184521
\Cdkn2b^tm1Wff/\Cdkn2b^tm1Wff \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	increased monocyte cell number	J:163498
	myeloid hyperplasia	J:163498
\Cdkn2c^tm1Bbd/\Cdkn2c^tm1Bbd (involves: 129S1/Sv * C57BL/6)	abnormal lymph node medulla morphology	J:63299
	enlarged lymph nodes	J:63299
	enlarged spleen	J:63299
	increased spleen white pulp amount	J:63299
	increased T cell derived lymphoma incidence	J:63299
	lymphoid hyperplasia	J:63299
\Cdkn2c^tm1Yxi/\Cdkn2c^tm1Yxi (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal T cell physiology	J:50053
	abnormal thymus size	J:50053
	enlarged spleen	J:50053
	increased B cell number	J:50053
	increased T cell number	J:50053
	spleen hyperplasia	J:50053
	thymus hyperplasia	J:50053
\Cds2^{Gt(OST184358)Lex}/\Cds2⁺ (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:103485
	increased T cell number	J:103485
\Cdsn^tm1.1Ics/\Cdsn^tm1.1Ics \Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S2/SvPas)	skin inflammation	J:153292
\Ceacam1^Hv2-r/\Ceacam1^Hv2-r (SJL/J)	decreased susceptibility to Coronaviridae infection	J:92495
\Ceacam1^Hv2-r/\Ceacam1^Hv2-r (SJL/J)	decreased susceptibility to viral infection	J:25438
\Ceacam1^Hv2-s/\Ceacam1^Hv2-s (Not Specified)	immune system phenotype	J:92495
\Ceacam1^tm1.1Fta/\Ceacam1^tm1.1Fta (C57BL/6(FVB)-Ceacam1^tm1.1Fta)	decreased susceptibility to Coronaviridae infection	J:198335
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:198335
\Ceacam1^tm1Bcn/\Ceacam1^tm1Bcn (either: (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:70815
\Ceacam1^tm1Rsb/\Ceacam1^tm1Rsb \Tg(Lck-cre)1Cwi/0 (involves: 129)	abnormal cytokine secretion	J:116136
	increased interferon-gamma secretion	J:116136
	increased interleukin-2 secretion	J:116136
	increased T cell proliferation	J:116136
\Ceacam1^tm2Bcn/\Ceacam1^tm2Bcn (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:92376
\Ceacam3^em1Btlr/\Ceacam3^em1Btlr (C57BL/6J-Ceacam3^em1Btlr)	immune system phenotype	J:354285
\Ceacam5^{em1(IMPC)Wtsi}/\Ceacam5^{em1(IMPC)Wtsi} (C57BL/6N-Ceacam5^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Ceat1^CBA/J/\Ceat1^NOD (involves: CBA/J * NOD-H2^k)	increased susceptibility to experimental autoimmune thyroiditis	J:77545
\Ceat1^NOD/\Ceat1^NOD (involves: CBA/J * NOD-H2^k)	increased susceptibility to experimental autoimmune thyroiditis	J:77545
\Cebpa^{tm1.1(Cebpb)Ylee}/\Cebpa^{tm1.1(Cebpb)Ylee} (involves: 129X1/SvJ * C57BL/6 * FVB/N)	immune system phenotype	J:77646
\Cebpa^tm1Dgt/\Cebpa^tm1Dgt \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal myelopoiesis	J:94682
	decreased granulocyte number	J:94682
	failure of myelopoiesis	J:94682
	sepsis	J:94682
\Cebpa^tm1Gjd/\Cebpa^tm1Gjd (B6.129S7-Cebpa^tm1Gjd)	failure of myelopoiesis	J:94682
\Cebpa^tm1Nerl/\Cebpa^tm1Nerl (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:72330
\Cebpa^tm2Btp/\Cebpa^tm2Btp (B6.129P2-Cebpa^tm2Btp)	abnormal myelopoiesis	J:187834
	decreased neutrophil cell number	J:187834
	enlarged spleen	J:187834
\Cebpa^tm2Nerl/\Cebpa^tm2Nerl (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:72330
	decreased granulocyte number	J:72330
	immune system phenotype	J:72330
\Cebpa^tm3Nerl/\Cebpa^tm3Nerl (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:72330
\Cebpa^tm4Nerl/\Cebpa^tm4Nerl (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:72330
	decreased granulocyte number	J:72330
	immune system phenotype	J:72330
\Cebpa^tm8.1Nerl/\Cebpa^tm8.1Nerl (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal granulocyte morphology	J:136134
	abnormal leukocyte morphology	J:136134
	abnormal myeloid leukocyte morphology	J:136134
	decreased granulocyte number	J:136134
	decreased monocyte cell number	J:136134
	decreased neutrophil cell number	J:136134
	enlarged spleen	J:136134
	liver inflammation	J:136134
\Cebpb^tm1.1Acle/\Cebpb^tm1.1Acle (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal osteoclast differentiation	J:150006
	abnormal osteoclast morphology	J:150006
	abnormal osteoclast physiology	J:150006
\Cebpb^tm1.1Elgaz/\Cebpb^tm1.1Elgaz \Lyz2^{em1.1(cre)Elgaz}/\Lyz2⁺ (BALB/cJ-Cebpb^tm1.1Elgaz Lyz2^em1.1Elgaz/Elgaz)	decreased circulating interleukin-10 level	J:247885
	decreased susceptibility to bacterial infection	J:247885
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:247885
	increased circulating interleukin-6 level	J:247885
	increased circulating tumor necrosis factor level	J:247885
\Cebpb^tm1Aki/\Cebpb^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:153025
	abnormal T-helper 1 physiology	J:153025
	decreased susceptibility to endotoxin shock	J:153025
	granulomatous inflammation	J:153025
	increased susceptibility to bacterial infection	J:153025
\Cebpb^tm1Kish/\Cebpb^tm1Kish (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:77003
	impaired macrophage phagocytosis	J:77003
	increased interleukin-12 secretion	J:126085
	increased susceptibility to bacterial infection	J:77003
\Cebpb^tm1Pfj/\Cebpb^tm1Pfj (involves: 129S1/Sv * C57BL/6)	abnormal osteoclast differentiation	J:150006
	abnormal osteoclast morphology	J:150006
	abnormal osteoclast physiology	J:150006
	abnormal tumor necrosis factor level	J:192313
\Cebpb^tm1Vpo/\Cebpb^tm1Vpo (involves: 129S/SvEv * MF1)	abnormal cell-mediated immunity	J:25215
	abnormal humoral immune response	J:25215
	abnormal innate immunity	J:25215
	abnormal lymph node B cell domain morphology	J:25215
	abnormal lymph node cortex morphology	J:25215
	abnormal lymph node medulla morphology	J:25215
	abnormal lymph node medullary cord morphology	J:25215
	abnormal lymph node secondary follicle morphology	J:25215
	abnormal lymph node T cell domain morphology	J:25215
	abnormal macrophage physiology	J:25215
	abnormal mucosa-associated lymphoid tissue morphology	J:25215
	abnormal plasma cell morphology	J:25215
	abnormal spleen red pulp morphology	J:25215
	abnormal spleen secondary B follicle morphology	J:25215
	abnormal spleen white pulp morphology	J:25215
	abnormal T-helper 1 physiology	J:25215
	abnormal T-helper 2 physiology	J:25215
	decreased circulating interleukin-12 level	J:25215
	decreased susceptibility to type IV hypersensitivity reaction	J:25215
	enlarged axillary lymph nodes	J:25215
	enlarged inguinal lymph nodes	J:25215
	enlarged lymph nodes	J:25215
	enlarged mesenteric lymph nodes	J:25215
	enlarged spleen	J:25215
	enlarged submandibular lymph nodes	J:25215
	glomerulonephritis	J:25215
	increased circulating interleukin-6 level	J:25215
	increased IgG level	J:25215
	increased susceptibility to fungal infection	J:25215
\Cebpb^tm2.1Acle/\Cebpb^tm2.1Acle (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal osteoclast morphology	J:155795
	decreased osteoclast cell number	J:155795
	increased circulating interleukin-6 level	J:155795
\Cebpb^tm3Nerl/\Cebpb^tm3Nerl (either: B6.129P2-Cebpb^tm3Nerl or (involves: 129P2/OlaHsd * C57BL/6))	myositis	J:153686
\Cebpd^tm1Pfj/\Cebpd^tm1Pfj (involves: 129S1/Sv * C57BL/6)	abnormal cytokine level	J:192313
\Cebpd^tm1Pfj/\Cebpd^tm1Pfj (involves: 129S1/Sv * C57BL/6)	decreased inflammatory response	J:192313
\Cebpe^tm1Kgx/\Cebpe^tm1Kgx (involves: 129S6/SvEvTac * NIH Black Swiss)	abnormal eosinophil differentiation	J:76024
	abnormal granulocyte differentiation	J:76024
	abnormal myelopoiesis	J:76024
	abnormal neutrophil differentiation	J:76024
	abnormal neutrophil morphology	J:76024
	abnormal neutrophil physiology	J:76024
	colitis	J:76024
	conjunctivitis	J:76024
	decreased eosinophil cell number	J:76024
	decreased granulocyte number	J:76024
	enlarged lymph nodes	J:76024
	impaired myelopoiesis	J:76024
	increased inflammatory response	J:76024
	increased plasma cell number	J:76024
	increased susceptibility to bacterial infection	J:76024
	lung inflammation	J:76024
	osteomyelitis	J:76024
	peritoneal inflammation	J:76024
	rhinitis	J:76024
\Cebpe^tm1Kgx/\Cebpe^tm1Kgx (involves: 129S6/SvEvTac)	abnormal eosinophil differentiation	J:76024
	abnormal granulocyte differentiation	J:76024
	abnormal myelopoiesis	J:76024
	abnormal neutrophil differentiation	J:76024
	abnormal neutrophil morphology	J:76024
	abnormal neutrophil physiology	J:76024
	colitis	J:76024
	conjunctivitis	J:76024
	decreased eosinophil cell number	J:76024
	decreased granulocyte number	J:76024
	enlarged lymph nodes	J:76024
	impaired myelopoiesis	J:76024
	increased inflammatory response	J:76024
	increased plasma cell number	J:76024
	increased susceptibility to bacterial infection	J:76024
	lung inflammation	J:76024
	osteomyelitis	J:76024
	peritoneal inflammation	J:76024
	pleuritis	J:76024
	rhinitis	J:76024
\Cebpg^tm1Aki/\Cebpg^tm1Aki (involves: 129P2/OlaHsd)	abnormal NK cell physiology	J:58801
\Cebpg^tm1Aki/\Cebpg^tm1Aki (involves: 129P2/OlaHsd)	impaired natural killer cell mediated cytotoxicity	J:58801
\Cecr2^{tm2b(EUCOMM)Hmgu}/\Cecr2⁺ (C57BL/6N-Cecr2^{tm2b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
\Celf4^{tm1a(EUCOMM)Wtsi}/\Celf4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Celf4^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Celsr1^ctb-2J/\Celsr1^ctb-2J (STOCK Celsr1^ctb-2J/GrsrJ)	increased susceptibility to otitis media	J:229303
\Celsr1^ctb/\Celsr1^ctb (CByJ.Cg-Celsr1^ctb/GrsrJ)	increased susceptibility to otitis media	J:229303
\Cemip2^tm1.1Cya/\Cemip2^tm1.1Cya \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	abnormal lymph node morphology	J:317425
\Cemip^tm1.1Okda/\Cemip^tm1.1Okda (involves: C57BL/6NCrlj * CBA/JNCrlj)	decreased osteoclast cell number	J:241936
\Cep68^em1(IMPC)J/\Cep68^em1(IMPC)J (C57BL/6NJ-Cep68^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Cep76^{tm1b(EUCOMM)Hmgu}/\Cep76^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cep76^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Cep85l^em1(IMPC)Mbp/\Cep85l^em1(IMPC)Mbp (C57BL/6N-Cep85l^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Cep290^b2b1454Clo/\Cep290^b2b1454Clo (C57BL/6J-Cep290^b2b1454Clo)	accessory spleen	J:175213
	spleen hypoplasia	J:175213
\Cep290^b2b1752Clo/\Cep290^b2b1752Clo (C57BL/6J-Cep290^b2b1752Clo)	spleen hypoplasia	J:175213
\Cer1^{em1(IMPC)Ccpcz}/\Cer1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cer1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Cerk^tm1Fbor/\Cerk^tm1Fbor (involves: BALB/c)	decreased granulocyte number	J:131522
	decreased neutrophil cell number	J:131522
	immune system phenotype	J:131522
	increased leukocyte cell number	J:131522
	increased susceptibility to bacterial infection	J:131522
\Cers1^{tm1b(EUCOMM)Hmgu}/\Cers1⁺ (C57BL/6N-Cers1^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
\Cers3^tm1.1Rsnd/\Cers3^tm1.1Rsnd (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to fungal infection	J:179754
\Cers6^tm1.1Arte/\Cers6^tm1.1Arte (involves: BALB/cJ * C57BL/6N)	decreased inflammatory response	J:215519
\Cers6^tm1.1Kwi/\Cers6^tm1.1Kwi (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:201327
\Ces1c^{em1(IMPC)Ccpcz}/\Ces1c^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ces1c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Ces2a^{tm1(KOMP)Vlcg}/\Ces2a^{tm1(KOMP)Vlcg} (C57BL6/N-Ces2a^{tm1(KOMP)Vlcg})	liver inflammation	J:335459
\Cfap20dc^em1(IMPC)J/\Cfap20dc^em1(IMPC)J (C57BL/6NJ-Cfap20dc^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Cfap47^{em1(IMPC)Hmgu}/\Cfap47^{em1(IMPC)Hmgu} (C57BL/6NCrl-Cfap47^{em1(IMPC)Hmgu}/Ieg)	decreased spleen weight	J:211773
\Cfap53^{em1(IMPC)Wtsi}/\Cfap53^{em1(IMPC)Wtsi} (C57BL/6N-Cfap53^{em1(IMPC)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
	small spleen	J:239583
\Cfap161^{em1(IMPC)Ccpcz}/\Cfap161^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cfap161^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Cfb^tm1Hrc/\Cfb⁺ \Cfh^tm1Mbo/\Cfh^tm1Mbo (involves: 129S/Sv * C57BL/6)	decreased circulating complement protein level	J:78193
\Cfb^tm1Hrc/\Cfb^tm1Hrc (involves: 129S/Sv * C57BL/6)	abnormal complement pathway	J:42679
\Cfb^tm1Hrc/\Cfb^tm1Hrc (involves: 129S/Sv * C57BL/6)	impaired complement alternative pathway	J:42679
\Cfb^tm1Hrc/\Cfb^tm1Hrc (involves: 129S/Sv)	decreased susceptibility to Coronaviridae infection	J:286325
\Cfb^tm1Hrc/\Cfb^tm1Hrc (involves: 129S/Sv)	impaired complement classical pathway	J:130108
\Cfb^tm1Mbo/\Cfb^tm1Mbo (involves: 129/Sv * C57BL/6)	increased susceptibility to bacterial infection	J:83712
\Cfb^tm1Pkna/\Cfb^tm1Pkna (D1.129P2-Cfb^tm1Pkna)	decreased susceptibility to induced arthritis	J:88872
\Cfc1^b2b2736.1Clo/\Cfc1^b2b2736.1Clo (C57BL/6J-Cfc1^b2b2736.1Clo)	accessory spleen	J:175213
	spleen hypoplasia	J:175213
\Cfc1^tm1Cbm/\Cfc1^tm1Cbm (Not Specified)	small spleen	J:58530
\Cfc1^tm1Cbm/\Cfc1^tm1Cbm (Not Specified)	spleen hypoplasia	J:58530
\Cfc1^tm1Mms/\Cfc1^tm1Mms (either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J))	absent spleen	J:58104
\Cfd^tm1Yxu/\Cfd^tm1Yxu (involves: 129P2/OlaHsd * C57BL/6J)	impaired complement alternative pathway	J:73125
\Cfd^tm1Yxu/\Cfd^tm1Yxu (B6.129P2-Cfd^tm1Yxu)	impaired complement alternative pathway	J:94855
\Cfd^tm1Yxu/\Cfd^tm1Yxu (B6.129P2-Cfd^tm1Yxu)	increased susceptibility to bacterial infection	J:94855
\Cfh^tm1.1Song/\Cfh^tm1.1Song (involves: C57BL/6)	decreased circulating complement protein level	J:240426
	decreased complement C5 level	J:240426
	decreased serum complement activity	J:240426
\Cfh^tm1Mbo/\Cfh⁺ (involves: 129/Sv * C57BL/6)	decreased circulating complement protein level	J:78193
\Cfh^tm1Mbo/\Cfh^tm1Mbo (involves: 129/Sv * C57BL/6)	decreased circulating complement protein level	J:78193
	glomerulonephritis	J:78193
	increased susceptibility to type III hypersensitivity reaction	J:78193
\Cfh^tm1Mbo/\Cfh^tm1Mbo (involves: 129)	abnormal complement protein level	J:125860
	decreased circulating complement protein level	J:125860, J:131403
	glomerulonephritis	J:131403
\Cfh^tm1Mbo/\Cfh^tm1Mbo \Tg(CAG-Cfh)#Mcp/0 (involves: 129/Sv C57BL/6 * CBA)	abnormal circulating complement protein level	J:125860
	abnormal complement protein level	J:125860
\Cfi^em1Jiwe/\Cfi^em1Jiwe (involves: C57BL/6J)	abnormal complement protein level	J:308307
\Cfi^em1Jiwe/\Cfi^em1Jiwe (involves: C57BL/6J)	impaired complement alternative pathway	J:308307
\Cfi^tm1Mcp/\Cfi^tm1Mcp (involves: 129/Sv * C57BL/6)	decreased circulating complement protein level	J:131403
\Cflar^tm1.1Pope/\Cflar^tm1.2Pope \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal abdominal lymph node morphology	J:167430
	abnormal B cell number	J:167430
	abnormal CD4-positive, alpha-beta T cell number	J:167430
	abnormal CD8-positive, alpha-beta T cell number	J:167430
	abnormal lymphocyte cell number	J:167430
	abnormal myelopoiesis	J:167430
	abnormal spleen B cell follicle morphology	J:167430
	abnormal spleen marginal zone morphology	J:167430
	abnormal spleen morphology	J:167430
	abnormal spleen red pulp morphology	J:167430
	abnormal thymus corticomedullary boundary morphology	J:167430
	abnormal thymus morphology	J:167430
	decreased macrophage cell number	J:167430
	enlarged spleen	J:167430
	increased CD8-positive, alpha-beta T cell number	J:167430
	increased eosinophil cell number	J:167430
	increased granulocyte number	J:167430
	increased leukocyte cell number	J:167430
	increased monocyte cell number	J:167430
	increased neutrophil cell number	J:167430
\Cflar^tm1Ywh/\Cflar^tm1Ywh \Tg(Lck-cre)548Jxm/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA)	decreased single-positive T cell number	J:100558
	increased thymocyte apoptosis	J:100558
\Cfmq1^129X1/SvJ/\Cfmq1^C57BL/6J \Cftr^tm1Unc/\Cftr^tm1Unc (involves: 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:101842
\Cfmq2^129X1/SvJ/\Cfmq2^129X1/SvJ \Cftr^tm1Unc/\Cftr^tm1Unc (involves: 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:101842
\Cfmq3^129X1/SvJ/\Cfmq3^C57BL/6J \Cftr^tm1Unc/\Cftr^tm1Unc (involves: 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:101842
\Cfp^tm1Cmst/\Cfp^tm1Cmst (B6.129P2-Cfp^tm1Cmst)	sepsis	J:131526
\Cfp^tm1Song/Y (involves: 129 * C57BL/6)	abnormal complement pathway	J:130108
	impaired complement alternative pathway	J:130108
	impaired complement classical pathway	J:130108
\Cfp^tm1Song/\Cfp^tm1Song (involves: 129 * C57BL/6)	decreased susceptibility to induced arthritis	J:165497
\Cfp^tm1Song/\Cfp^tm1Song (involves: 129 * C57BL/6)	impaired complement alternative pathway	J:165497
\Cfp^tm2.1Song/\Cfp^tm2.1Song \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)	decreased susceptibility to induced arthritis	J:165497
	impaired complement alternative pathway	J:165497
\Cfp^tm2.1Song/\Cfp^tm2.1Song \Tg(EIIa-cre)C5379Lmgd/0 (involves: 129 * C57BL/6 * FVB/N * SJL)	impaired complement alternative pathway	J:165497
\Cftr^tm1Bay/\Cftr^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	acute pancreas inflammation	J:15244
\Cftr^tm1Cam/\Cftr^tm1Cam (involves: 129S/SvEv)	increased susceptibility to infection	J:23850
\Cftr^tm1Cam/\Cftr^tm1Cam (involves: 129S/SvEv)	peritoneal inflammation	J:23850
\Cftr^tm1Hgu/\Cftr^tm1Hgu (involves: 129P2/OlaHsd)	increased susceptibility to bacterial infection	J:24119
\Cftr^tm1Hgu/\Cftr^tm1Hgu (involves: 129P2/OlaHsd)	lung inflammation	J:24119
\Cftr^tm1Kth/\Cftr^tm1Kth (involves: 129S7/SvEvBrd * C57BL/6J)	peritoneal inflammation	J:29074
\Cftr^tm1Kth/\Cftr^tm1Kth (B6.129S7-Cftr^tm1Kth)	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
\Cftr^tm1Kth/\Cftr^tm1Kth (B6.129S7-Cftr^tm1Kth)	lung inflammation	J:112450
\Cftr^tm1Unc/\Cftr^tm1Unc (B6.129P2-Cftr^tm1Unc/J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
\Cftr^tm1Unc/\Cftr^tm1Unc (B6.129P2-Cftr^tm1Unc/J)	lung inflammation	J:58571, J:112450
\Cftr^tm1Unc/\Cftr^tm1Unc (involves: 129P2/OlaHsd)	abnormal thymus involution	J:2079
	peritoneal inflammation	J:2079
	spleen hyperplasia	J:2079
\Cftr^tm1Unc/\Cftr^tm1Unc (B6.129P2-Cftr^tm1Unc)	lung inflammation	J:44904
\Cftr^tm1Unc/\Cftr^tm1Unc \Tg(FABPCFTR)1Jaw/0 \Tg(Scgb1a1-Scnn1b)6608Bouc/0 (involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)	respiratory system inflammation	J:191673
\Cftr^tm2Cam/\Cftr^tm2Cam (involves: 129S/SvEv)	peritoneal inflammation	J:27734
\Cftr^tm2Mrc/\Cftr^tm2Mrc (B6.129S6-Cftr^tm2Mrc)	abnormal alveolar macrophage morphology	J:112450
	decreased neutrophil cell number	J:112450
	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
	lung inflammation	J:112450
\Cftr^tm3Hgu/\Cftr^tm3Hgu (involves: 129P2/OlaHsd)	gallbladder inflammation	J:32766
\Cftr^tm3Hgu/\Cftr^tm3Hgu (involves: 129P2/OlaHsd)	peritoneal inflammation	J:32766
\Cftr^tm3Mrc/\Cftr^tm3Mrc (B6.129S6-Cftr^tm3Mrc)	increased susceptibility to bacterial infection induced morbidity/mortality	J:112450
\Cftr^tm3Mrc/\Cftr^tm3Mrc (B6.129S6-Cftr^tm3Mrc)	lung inflammation	J:112450
\Cgas^{tm1a(EUCOMM)Hmgu}/\Cgas^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Cgas^{tm1a(EUCOMM)Hmgu})	abnormal dendritic cell physiology	J:201167
	abnormal immune cell physiology	J:201167
	abnormal macrophage physiology	J:201167
	abnormal plasmacytoid dendritic cell physiology	J:201167
	decreased circulating interferon-alpha level	J:201167
	decreased circulating interferon-beta level	J:201167
	increased susceptibility to Herpesvirales infection	J:201167
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:201167
\Cgas^{tm1a(EUCOMM)Hmgu}/\Cgas^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal interferon secretion	J:234263
\Cgas^{tm1a(EUCOMM)Hmgu}/\Cgas^{tm1a(EUCOMM)Hmgu} \Rnaseh2a^tm1Crh/\Rnaseh2a^tm1Crh (involves: C57BL/6N)	immune system phenotype	J:232933
\Cgas^{tm1a(EUCOMM)Hmgu}/\Cgas^{tm1a(EUCOMM)Hmgu} \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6N)	increased susceptibility to Retroviridae infection	J:234263
\Cgas^{tm1d(EUCOMM)Hmgu}/\Cgas^{tm1d(EUCOMM)Hmgu} (involves: BALB/c * C57BL/6JJcl * C57BL/6N)	increased susceptibility to Flaviviridae infection	J:207826
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:207826
	increased susceptibility to Herpesvirales infection	J:207826
	increased susceptibility to Poxviridae infection	J:207826
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:207826
\Cgas^{tm1d(EUCOMM)Hmgu}/\Cgas^{tm1d(EUCOMM)Hmgu} (involves: C57BL/6N)	immune system phenotype	J:265023
	increased susceptibility to Retroviridae infection	J:265023
\Cgnz1^NZM2328/J/\Cgnz1^NZM2328/J (involves: C57L/J * NZM2328/J)	increased susceptibility to systemic lupus erythematosus	J:71397
	kidney inflammation	J:71397
\Cgref1^em1(IMPC)J/\Cgref1^em1(IMPC)J (C57BL/6NJ-Cgref1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Cgrrf1^{tm1b(KOMP)Wtsi}/\Cgrrf1^{tm1b(KOMP)Wtsi} (C57BL/6N-Cgrrf1^{tm1b(KOMP)Wtsi}/Wtsi)	increased CD5-positive gamma-delta T cell number	J:211773
	increased gamma-delta T cell number	J:211773
\Ch25h^tm1Rus/\Ch25h^tm1Rus (B6.129S6-Ch25h^tm1Rus)	increased IgA level	J:170807
	increased IgG2a level	J:170807
	increased IgG2b level	J:170807
	increased IgG3 level	J:170807
\Chaf1b^{tm2c(EUCOMM)Hmgu}/\Chaf1b⁺ \Kras^tm4Tyj/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6J * C57BL/6N * CBA/J)	increased leukocyte cell number	J:266848
\Champ1^em1(IMPC)Mbp/\Champ1⁺ (C57BL/6NCrl-Champ1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Char2a^C3H/HeJ/\Char2a^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to parasitic infection	J:117548
\Char2b^C3H/HeJ/\Char2b^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to parasitic infection	J:117548
\Char3^C3H/He/\Char3^C57BL/6 (involves: C3H/He * C57BL/6)	decreased susceptibility to parasitic infection	J:72455
\Char3^C57BL/6/\Char3^C57BL/6 (involves: C3H/He * C57BL/6)	decreased susceptibility to parasitic infection	J:72455
\Char4^C57BL/6J/\Char4^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:71471
\Char9^A/J/\Char9^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:122131
\Char9^C57BL/6J/\Char9^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:122131
\Char11^A/J/\Char11^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:106220
\Char11^C57BL/6J/\Char11^C57BL/6J (involves: A/J * C57BL/6J)	decreased susceptibility to parasitic infection	J:106220
\Chchd7^em3(IMPC)Tcp/\Chchd7^em3(IMPC)Tcp (C57BL/6NCrl-Chchd7^em3(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Chchd10^em8Lutzy/\Chchd10⁺ (C57BL/6NJ-Chchd10^em8Lutzy/J)	increased susceptibility to otitis media	J:272524
\Chd2^{Gt(RRBO46)Byg}/\Chd2⁺ (involves: 129P2/OlaHsd * C57BL/6)	arteritis	J:146176
	dark spleen	J:146743
	decreased lymphocyte cell number	J:146176
	enlarged lymph nodes	J:146743
	enlarged spleen	J:146743
	heart inflammation	J:146176
	increased CD4-positive, alpha-beta T cell number	J:146176
	increased spleen red pulp amount	J:146743
	increased T cell derived lymphoma incidence	J:146176
	interstitial pneumonia	J:146743
	liver inflammation	J:146743
	lymphoid hyperplasia	J:146176
	myocarditis	J:146743
\Chd4^tm1.1Kge/\Chd4^tm1.1Kge \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:109547
	abnormal T cell physiology	J:109547
	arrested T cell differentiation	J:109547
	decreased double-positive T cell number	J:109547
	increased CD8-positive, alpha-beta T cell number	J:109547
	lymph node hypoplasia	J:109547
	spleen hypoplasia	J:109547
\Chd4^tm1.1Kge/\Chd4^tm1.2Kge \Tg(CAG-Bgeo/GFP)21Lbe/0 \Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	decreased T cell proliferation	J:109547
\Chd4^tm1.1Kge/\Chd4^tm1.2Kge \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * SJL)	thymus hypoplasia	J:109547
\Chd4^tm1.2Kge/\Chd4^tm1.2Kge \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal T cell differentiation	J:109547
	decreased double-positive T cell number	J:109547
	decreased T cell proliferation	J:109547
	increased CD8-positive, alpha-beta T cell number	J:109547
	increased double-negative T cell number	J:109547
	thymus hypoplasia	J:109547
\Chd5^em1(IMPC)Mbp/\Chd5^em1(IMPC)Mbp (C57BL/6NCrl-Chd5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Chd7^Flo/\Chd7⁺ (involves: C3HeB/FeJ)	keratoconjunctivitis sicca	J:104123
\Chd7^{Gt(RRR136)Byg}/\Chd7⁺ (involves: 129P2/OlaHsd * C57BL/6)	ectopic thymus	J:154590
	small thymus	J:154590
	thymus hypoplasia	J:154590
\Chd7^Gt(XK403)Byg/\Chd7⁺ \Tbx1^tm1Bld/\Tbx1⁺ (either: (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6) or (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CD-1))	ectopic thymus	J:154590
\Chd7^Looper/\Chd7⁺ (BALB/c-Chd7^Looper)	blepharitis	J:252089
\Chd7^Looper/\Chd7⁺ (BALB/c-Chd7^Looper)	conjunctivitis	J:252089
\Chd7^Ome/\Chd7⁺ (involves: BALB/cByJ * C57BL/6J)	increased susceptibility to otitis media	J:187200
\Chd7^{tm2a(EUCOMM)Wtsi}/\Chd7⁺ (involves: 129S5/SvEvBrd * C57BL/6N)	decreased leukocyte cell number	J:330596
	decreased monocyte cell number	J:330596
	increased NK T cell number	J:330596
\Chd7^Trooper/\Chd7⁺ (BALB/c-Chd7^Trooper)	blepharitis	J:262283
\Chd7^Trooper/\Chd7⁺ (BALB/c-Chd7^Trooper)	conjunctivitis	J:262283
\Chd7^Whi/\Chd7⁺ (C3HeB/FeJ-Chd7^Whi)	decreased monocyte cell number	J:330596
\Chd7^Whi/\Chd7⁺ (C3HeB/FeJ-Chd7^Whi)	increased NK T cell number	J:330596
\Chd7^Whi/\Chd7⁺ (involves: C3HeB/FeJ)	keratoconjunctivitis sicca	J:104123
\Chd8^em1(IMPC)Mbp/\Chd8⁺ (C57BL/6N-Chd8^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
\Chd9^{tm1a(EUCOMM)Wtsi}/\Chd9^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Chd9^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased Langerhans cell number	J:211773
\Chek2^tm1Mak/\Chek2⁺ \Rad50^tm2Jpt/\Rad50^tm2Jpt (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal pro-B cell morphology	J:103922
	decreased double-negative T cell number	J:103922
	decreased macrophage cell number	J:103922
\Chfr^{tm1a(KOMP)Wtsi}/\Chfr^{tm1a(KOMP)Wtsi} (C57BL/6NCrl-Chfr^{tm1a(KOMP)Wtsi}/Ccpcz)	abnormal spleen morphology	J:211773
\Chi3l1^tm1Eli/\Chi3l1^tm1Eli (B6.Cg-Chi3l1^tm1Eli)	abnormal dendritic cell physiology	J:148490
	abnormal macrophage morphology	J:148490
	abnormal plasmacytoid dendritic cell physiology	J:148490
	abnormal T-helper 2 physiology	J:148490
	decreased IgE level	J:148490
	decreased interleukin-4 secretion	J:148490
	decreased interleukin-13 secretion	J:148490
	decreased splenocyte proliferation	J:148490
	decreased T-helper 2 cell number	J:148490
	impaired eosinophil recruitment	J:148490
	impaired neutrophil recruitment	J:148490
	increased T cell apoptosis	J:148490
\Chi3l1^tm1Eli/\Chi3l1^tm1Eli \Tg(Scgb1a1-rtTA,-tTS,tetO-CHI3L1)1Eli/0 (involves: 129 * C57BL/6)	immune system phenotype	J:148490
\Chi3l1^tm1Eli/\Chi3l1^tm1Eli \Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * CBA)	abnormal T-helper 2 cell number	J:148490
	abnormal T-helper 2 physiology	J:148490
\Chia1^tm1.1Lof/\Chia1^tm1.1Lof (C57BL/6-Chia1^tm1.1Lof)	decreased interleukin-13 secretion	J:257728
	immune system phenotype	J:257728
	increased lymphocyte cell number	J:257728
	increased neutrophil cell number	J:257728
\Chic2^{tm1b(EUCOMM)Wtsi}/\Chic2⁺ (C57BL/6N-Chic2^{tm1b(EUCOMM)Wtsi}/H)	enlarged spleen	J:211773
\Chit1^tm1Eli/\Chit1^tm1Eli (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:189872
\Chit1^tm1Eli/\Chit1^tm1Eli \Tg(Scgb1a1-Il13)2Eli/0 (involves: C57BL/6 * CBA)	decreased susceptibility to bacterial infection	J:189872
\Chit1^tm1Eli/\Chit1^tm1Eli \Tg(Scgb1a1-rtTA,tetO-CHIT1)#Eli/0 (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:189872
\Chmp2b^em1(IMPC)Mbp/\Chmp2b⁺ (C57BL/6NCrl-Chmp2b^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Chmp4c^{tm1b(EUCOMM)Wtsi}/\Chmp4c^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Chmp4c^{tm1b(EUCOMM)Wtsi}/H)	decreased basophil cell number	J:211773
\Chordc1^em1(IMPC)Mbp/\Chordc1⁺ (C57BL/6N-Chordc1^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Chordc1^tm1Mbra/\Chordc1⁺ (involves: 129 * C57BL/6)	abnormal myelopoiesis	J:222040
	abnormal spleen morphology	J:222040
	enlarged spleen	J:222040
	increased leukocyte cell number	J:222040
\Chrd^tm1Emdr/\Chrd^tm1Emdr (either: B6SJL.129-Chrd^tm1Emdr or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL/J))	athymia	J:83662
\Chrd^tm1Emdr/\Chrd^tm1Emdr (129S6.129-Chrd^tm1Emdr)	athymia	J:146769
\Chrd^tm1Emdr/\Chrd^tm1Emdr \Tbx1^m1Jlk/\Tbx1^m1Jlk (129/Sv-Tbx1^m1Jlk Chrd^tm1Emdr)	athymia	J:146769
\Chrm1^tm1Jwe/\Chrm1^tm1Jwe (involves: 129S6/SvEvTac * CF-1)	decreased cytotoxic T cell cytolysis	J:106393
\Chrna3^tm1Bay/\Chrna3^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	increased susceptibility to bacterial infection	J:54994
	urinary bladder inflammation	J:54994
\Chrna4^tm1Jpc/\Chrna4^tm1Jpc (involves: C57BL/6)	decreased IgG level	J:103908
	decreased immunoglobulin level	J:103908
	immune system phenotype	J:103908
	increased IgG level	J:103908
\Chrna5^em1(IMPC)H/\Chrna5^em1(IMPC)H (C57BL/6N-Chrna5^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Chrna7^tm1Bay/\Chrna7^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	decreased neutrophil cell number	J:140280
	increased lymphocyte cell number	J:140280
\Chrna7^tm1Bay/\Chrna7^tm1Bay (B6.Cg-Chrna7^tm1Bay)	abnormal interleukin level	J:89610
\Chrna7^tm1Bay/\Chrna7^tm1Bay (B6.Cg-Chrna7^tm1Bay)	abnormal tumor necrosis factor level	J:89610
\Chrna7^tm1Bay/\Chrna7^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased IgG level	J:103908
	decreased immunoglobulin level	J:103908
	immune system phenotype	J:103908
\Chrnb2^tm1Jpc/\Chrnb2^tm1Jpc (B6.129P2-Chrnb2^tm1Jpc)	decreased B cell number	J:112766
\Chrnb2^tm1Jpc/\Chrnb2^tm1Jpc (involves: 129P2/OlaHsd * C57BL/6J)	myeloid hyperplasia	J:140280
\Chrnb2^tm1Jpc/\Chrnb2^tm1Jpc (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:103908
	abnormal immunoglobulin level	J:103908
	decreased B cell number	J:103908
	decreased immunoglobulin level	J:103908
	immune system phenotype	J:103908
	increased B cell proliferation	J:103908
	increased IgG level	J:103908
\Chrnb2^tm1Mdb/\Chrnb2^tm1Mdb \Chrnb4^tm1Mdb/\Chrnb4^tm1Mdb (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to bacterial infection	J:73590
	urinary bladder inflammation	J:73590
\Chst1^{tm1(KOMP)Vlcg}/\Chst1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased B cell number	J:204813
	immune system phenotype	J:204813
	increased T cell number	J:204813
\Chst1^{tm1(KOMP)Vlcg}/\Chst1^{tm1(KOMP)Vlcg} \Chst2^tm1Tmu/\Chst2^tm1Tmu \Chst4^tm1Sdr/\Chst4^tm1Sdr (involves: 129S2/SvPas * C57BL/6NTac)	abnormal leukocyte migration	J:204813
\Chst2^em1(IMPC)Mbp/\Chst2^em1(IMPC)Mbp (C57BL/6N-Chst2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Chst2^tm1Tmu/\Chst2^tm1Tmu (involves: 129S2/SvPas * C57BL/6J)	abnormal leukocyte migration	J:92231
	abnormal leukocyte physiology	J:92231
\Chst2^tm1Tmu/\Chst2^tm1Tmu \Chst4^tm1Sdr/\Chst4^tm1Sdr (involves: 129S2/SvPas)	abnormal leukocyte migration	J:204813
\Chst3^tm1Tmu/\Chst3^tm1Tmu (involves: 129S2/SvPas * 129X1/SvJ)	decreased T cell number	J:73698
\Chst3^tm1Tmu/\Chst3^tm1Tmu (involves: 129S2/SvPas)	decreased neutrophil cell number	J:217719
	increased T cell proliferation	J:217719
	lymph node hypoplasia	J:217719
\Chst4^tm1Mifu/\Chst4^tm1Mifu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:113195
	impaired leukocyte tethering or rolling	J:113195
\Chst4^tm1Mifu/\Chst4^tm1Mifu \Gcnt1^tm1Jxm/\Gcnt1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:113195
	impaired leukocyte tethering or rolling	J:113195
\Chst4^tm1Sdr/\Chst4^tm1Sdr (involves: C57BL/6)	abnormal leukocyte adhesion	J:86759
	abnormal leukocyte migration	J:86759
	abnormal lymph node morphology	J:86759
	abnormal lymph node primary follicle morphology	J:86759
\Chst10^{em1(IMPC)Hmgu}/\Chst10^{em1(IMPC)Hmgu} (C57BL/6NCrl-Chst10^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
\Chst11^{tm1a(KOMP)Wtsi}/\Chst11^{tm1a(KOMP)Wtsi} (C57BL/6N-Chst11^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
\Chst15^tm1Oh/\Chst15^tm1Oh (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:165927
\Chsy1^em1(IMPC)Mbp/\Chsy1^em1(IMPC)Mbp (C57BL/6NCrl-Chsy1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Chsy1^skt/\Chsy1^skt \Pde6b⁺/\Pde6b⁺ (mixed)	decreased macrophage cell number	J:286529
	decreased neutrophil cell number	J:286529
	kidney inflammation	J:286529
	microgliosis	J:286529
\Chsy1^skt/\Chsy1^tm1Lex (mixed)	microgliosis	J:286529
\Chsy1^tm1Lex/\Chsy1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	autoimmune arthritis	J:171883
	microgliosis	J:286529
\Chtop^{tm1a(EUCOMM)Wtsi}/\Chtop^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Chtop^{tm1a(EUCOMM)Wtsi}/Wtsi)	absent spleen	J:239583
	spleen hypoplasia	J:239583
\Chuk^{em1(IMPC)Ccpcz}/\Chuk⁺ (C57BL/6NCrl-Chuk^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Chuk^tm1Lex/\Chuk^tm1Lex \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEvBrd)	impaired macrophage chemotaxis	J:159873
	impaired neutrophil chemotaxis	J:159873
	impaired neutrophil recruitment	J:159873
\Chuk^tm1Mka/\Chuk^tm1Mka (B6.129-Chuk^tm1Mka)	abnormal B cell physiology	J:113556
\Chuk^tm1Mpa/\Chuk^tm1Mpa \Ikbkb^tm2Cgn/\Ikbkb^tm2Cgn \Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	increased susceptibility to endotoxin shock	J:137861
\Chuk^tm2Mka/\Chuk^tm2Mka (B6.Cg-Chuk^tm2Mka)	abnormal B cell physiology	J:113556
\Chuk^tm2Mka/\Chuk^tm2Mka \Tg(Tnfsf13b)1Fma/? (B6.Cg-Chuk^tm2Mka Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	absent spleen marginal zone	J:113556
	decreased marginal zone B cell number	J:113556
	increased anti-double stranded DNA antibody level	J:113556
	increased transitional stage B cell number	J:113556
\Chuk^tm2Yhu/\Chuk^tm2Yhu (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	skin inflammation	J:197037
\Chuk^tm2Yhu/\Chuk^tm2Yhu \Tg(Lor-CHUK)8Yhu/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	absent lymph nodes	J:197037
\Chuk^tm2Yhu/\Chuk^tm2Yhu \Tg(Lor-CHUK)8Yhu/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	increased CD4-positive, alpha-beta T cell number	J:197037
	increased CD8-positive, alpha-beta T cell number	J:197037
	increased macrophage cell number	J:197037
	increased neutrophil cell number	J:197037
	lung inflammation	J:197037
\Churc1^{tm1b(EUCOMM)Wtsi}/\Churc1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Churc1^{tm1b(EUCOMM)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory T-helper cell number	J:211773
\Cia2^DBA/1J/\Cia2^DBA/1J (involves: DBA/1J * SWR/J)	abnormal immune system physiology	J:53356
\Cia2^DBA/1J/\Cia2^DBA/1J (involves: DBA/1J * FVB/N)	increased susceptibility to induced arthritis	J:116665
\Cia2^DBA/1J/\Cia2^SWR/J (involves: DBA/1J * SWR/J)	abnormal immune system physiology	J:53356
\Cia5^C57BL/10/\Cia5^C57BL/10 (involves: B10.RIII * RIIIS/J)	abnormal inflammatory response	J:50472
\Cia5b^RIIIS/J/? (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
\Cia5b^RIIIS/J/\Cia5b^RIIIS/J \Cia32^B10.RIII/\Cia32^RIIIS/J (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
\Cia5c^RIIIS/J/? (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
\Cia6^C57BL/10SnSg/\Cia6^C57BL/10SnSg (involves: B10.Q * DBA/1)	abnormal inflammatory response	J:57012
\Cia6^C57BL/10SnSg/\Cia6^DBA/1J (involves: B10.Q * DBA/1)	abnormal inflammatory response	J:57012
\Cia6^DBA/1J/\Cia6^DBA/1J (involves: B10.Q * DBA/1)	decreased inflammatory response	J:57012
\Cia7^DBA/1J/\Cia7^C57BL/10SnSg (involves: B10.Q * DBA/1)	increased inflammatory response	J:57012
\Cia7^DBA/1J/\Cia7^DBA/1J (involves: B10.Q * DBA/1)	increased inflammatory response	J:57012
\Cia7^DBA/1J/\Cia7^DBA/1J (involves: B10.Q * DBA/1)	increased susceptibility to induced arthritis	J:122130
\Cia8^DBA/1J/\Cia8^DBA/1J (involves: B10.Q * DBA/1)	increased inflammatory response	J:57012
\Cia9^C57BL/10SnSg/\Cia9^NOD/ShiLtJ (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	increased inflammatory response	J:69981
\Cia9^NOD/ShiLtJ/\Cia9^NOD/ShiLtJ (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	abnormal immune system physiology	J:69981
\Cia10^C57BL/10/\Cia10^C57BL/10 (involves: C57BL/10 * RIIIS/J)	abnormal inflammatory response	J:50472
\Cia10^C57BL/10/\Cia10^C57BL/10 \Cia5^C57BL/10/\Cia5^C57BL/10 (involves: C57BL/10 * RIIIS/J)	abnormal inflammatory response	J:50472
\Cia23^C57BL/10SnSg/\Cia23^C57BL/10SnSg (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	abnormal inflammatory response	J:69981
\Cia23^C57BL/10SnSg/\Cia23^NOD/ShiLtJ (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	abnormal inflammatory response	J:69981
\Cia23^C57BL/10SnSg/\Cia23^NOD/ShiLtJ \Cia9^C57BL/10SnSg/\Cia9^C57BL/10SnSg (involves: B10.D1-H2^q/SgJ * NOD.C3-H2^q/Rhd)	decreased inflammatory response	J:69981
\Cia26^RIIIS/J/\Cia26^RIIIS/J \Cia30^B10.RIII/? (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
\Cia27^DBA/1J/? (involves: DBA/1J * FVB/N)	increased IgG level	J:116665, J:94347
\Cia30^RIIIS/J/\Cia30^RIIIS/J \Cia5^B10.RIII/\Cia5^B10.RIII (involves: B10.RIII * RIIIS/J)	decreased susceptibility to induced arthritis	J:95848
\Cia31^B10.RIII/\Cia31^RIIIS/J \Cia5^B10.RIII/\Cia5^B10.RIII (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
\Cia31^B10.RIII/\Cia31^RIIIS/J \Cia5^RIIIS/J/\Cia5^RIIIS/J (involves: C57BL/10 * RIIIS/J)	decreased susceptibility to induced arthritis	J:101767
\Cia32^B10.RIII/\Cia32^RIIIS/J \Cia5^B10.RIII/\Cia5^B10.RIII (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
\Cia34^DBA/1J/\Cia34^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased autoantibody level	J:122130
\Cia34^DBA/1J/\Cia34^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased susceptibility to induced arthritis	J:122130
\Cia35^C57BL/10SnSg/\Cia35^C57BL/10SnSg \Cia42^DBA/1J/\Cia42^DBA/1J (involves: B10.Q * DBA/1)	decreased susceptibility to induced arthritis	J:122130
\Cia35^C57BL/10SnSg/\Cia35^DBA/1J (involves: C57BL/10 * DBA/1J)	increased autoantibody level	J:122130
	increased susceptibility to induced arthritis	J:122130
\Cia35^C57BL/10SnSg/\Cia35^DBA/1J \Cia42^DBA/1J/\Cia42^DBA/1J (involves: B10.Q * DBA/1)	decreased susceptibility to induced arthritis	J:122130
\Cia35^DBA/1J/\Cia35^DBA/1J \Cia42^DBA/1J/\Cia42^DBA/1J (involves: B10.Q * DBA/1)	decreased susceptibility to induced arthritis	J:122130
\Cia36^DBA/1J/\Cia36^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased autoantibody level	J:122130
\Cia36^DBA/1J/\Cia36^DBA/1J (involves: C57BL/10 * DBA/1J)	decreased susceptibility to induced arthritis	J:122130
\Cia37^C57BL/10SnSg/\Cia37^DBA/1J (involves: C57BL/10 * DBA/1J)	increased autoantibody level	J:122130
	increased susceptibility to induced arthritis	J:122130
\Cia38^DBA/1J/\Cia38^DBA/1J (involves: C57BL/10 * DBA/1J)	increased autoantibody level	J:122130
\Cia38^DBA/1J/\Cia38^DBA/1J (involves: C57BL/10 * DBA/1J)	increased susceptibility to induced arthritis	J:122130
\Cia39^C57BL/10Sn/\Cia39^C57BL/10Sn (involves: B10.Q/Lund-H2^q * B10.RIII/Lund-H2^r)	decreased susceptibility to induced arthritis	J:97801
\Cia39^RIII/WySn/\Cia39^RIII/WySn (involves: B10.Q/Lund-H2^q * B10.RIII/Lund-H2^r)	autoimmune arthritis	J:97801
\Cia40^C57BL/10SnSg/\Cia40^C57BL/10SnSg (involves: C57BL/10SnSg * DBA/1J * NFS/N)	increased susceptibility to induced arthritis	J:106522
\Cia43^DBA/1J/\Cia43^FVB/N (involves: DBA/1J * FVB/N)	increased susceptibility to induced arthritis	J:146242
\Cia43^FVB/N/\Cia43^FVB/N (involves: DBA/1J * FVB/N)	increased susceptibility to induced arthritis	J:146242
\Ciaaq1^DBA/1J/\Ciaaq1^DBA/1J (involves: DBA/1J * FVB/NJ)	increased autoantibody level	J:122919
\Ciaaq1^DBA/1J/\Ciaaq1^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased autoantibody level	J:122919
\Ciao2b^{em1(IMPC)Ccpcz}/\Ciao2b⁺ (C57BL/6N-Ciao2b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Cib1^{tm1b(EUCOMM)Hmgu}/\Cib1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cib1^{tm1b(EUCOMM)Hmgu}/Bay)	decreased neutrophil cell number	J:211773
\Cib2^{tm1b(EUCOMM)Wtsi}/\Cib2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cib2^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
\Cibar1^{tm1b(KOMP)Wtsi}/\Cibar1^{tm1b(KOMP)Wtsi} (C57BL/6N-Cibar1^{tm1b(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:274784, J:211773
\Cideb^tm1Pli/\Cideb^tm1Pli (Not Specified)	decreased spleen weight	J:126556
\Cigs2^tm1.1Anse/\Cigs2⁺ \Il4^tm1(CD2)Mmrs/\Il4⁺ (involves: 129 * BALB/cJ * C57BL/6)	decreased basophil cell number	J:181313
	decreased IgE level	J:181313
	decreased IgG1 level	J:181313
	decreased interleukin-4 secretion	J:181313
	immune system phenotype	J:181313
\Cigs2^tm1.1Anse/\Cigs2^tm1.1Anse (involves: BALB/cJ * C57BL/6)	abnormal class switch recombination	J:181313
	abnormal humoral immune response	J:181313
	abnormal susceptibility to infection	J:181313
	decreased IgE level	J:181313
	decreased IgG1 level	J:181313
	decreased interleukin-4 secretion	J:181313
	decreased interleukin-13 secretion	J:181313
	increased IgG2b level	J:181313
\Cigs2^tm1.1Kubo/\Cigs2^tm1.1Kubo (B6.Cg-Cigs2^tm1.1Kubo)	abnormal interleukin secretion	J:129048
	abnormal mast cell physiology	J:129048
	abnormal neutrophil physiology	J:129048
	decreased interleukin-4 secretion	J:167446, J:129048
	decreased interleukin-13 secretion	J:129048
\Ciita^m1Btlr/\Ciita^m1Btlr (C57BL/6J-Ciita^m1Btlr)	abnormal CD4-positive T cell differentiation	J:221483
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221483
	impaired humoral immune response	J:221483
\Ciita^tm1.1Dim/\Ciita^tm1.1Dim (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal level of surface class II molecules	J:51885
	decreased CD4-positive, alpha-beta T cell number	J:51885
	decreased dendritic cell number	J:51885
\Ciita^tm1Adm/\Ciita⁺ (involves: 129S1/Sv * C57BL/6)	abnormal immune system physiology	J:117111
\Ciita^tm1Adm/\Ciita^tm1Adm (involves: 129S1/Sv * C57BL/6)	abnormal immune system physiology	J:117111
\Ciita^tm1Ccum/\Ciita^tm1Ccum (involves: 129S2/SvPas * C57BL/6J)	abnormal B cell physiology	J:96421
	abnormal CD4-positive, alpha-beta T cell physiology	J:31601
	abnormal cytokine secretion	J:64283
	abnormal dendritic cell physiology	J:96421
	abnormal level of surface class II molecules	J:31601, J:96421
	abnormal lymphocyte physiology	J:96421
	abnormal MHC II cell surface expression on macrophages	J:31601
	abnormal popliteal lymph node morphology	J:64283
	abnormal susceptibility to infection	J:64283
	abnormal T cell differentiation	J:64283
	abnormal T cell physiology	J:31601
	decreased CD4-positive, alpha-beta T cell number	J:31601
	decreased susceptibility to parasitic infection	J:64283
	decreased T cell proliferation	J:31601
	increased CD4-positive, alpha-beta T cell number	J:64283
	increased CD8-positive, alpha-beta T cell number	J:64283
	increased susceptibility to parasitic infection	J:64283
\Ciita^tm1Ccum/\Ciita^tm1Ccum (NOD.129S2(B6)-Ciita^tm1Ccum)	abnormal inflammatory response	J:106081
	abnormal level of surface class II molecules	J:106081
	abnormal T cell differentiation	J:106081
	decreased CD4-positive, alpha-beta T cell number	J:106081
	decreased susceptibility to autoimmune diabetes	J:107051
	increased CD8-positive, alpha-beta T cell number	J:106081
	insulitis	J:107051
	pancreas inflammation	J:106081
	periinsulitis	J:106081
\Ciita^tm1Ccum/\Ciita^tm1Ccum (involves: 129S2/SvPas * C57BL/6)	abnormal level of surface class II molecules	J:67941
\Ciita^tm1Jpyt/\Ciita^tm1Jpyt (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell subpopulation ratio	J:57100
	decreased CD4-positive, alpha-beta T cell number	J:57100
	decreased IgG level	J:57100
	increased CD8-positive, alpha-beta T cell number	J:57100
	increased double-positive T cell number	J:57100
	increased IgM level	J:57100
\Ciita^tm1Jpyt/\Ciita^tm1Jpyt (B6.129P2-Ciita^tm1Jpyt)	abnormal T-helper 1 physiology	J:125654
\Ciita^tm1Jpyt/\Ciita^tm1Jpyt (B6.129P2-Ciita^tm1Jpyt)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:125654
\Ciita^tm1Wrth/\Ciita^tm1Wrth (B6.129P2-Ciita^tm1Wrth)	immune system phenotype	J:117111
\Ciita^tm1Wrth/\Ciita^tm1Wrth (involves: 129P2/OlaHsd * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:233241
	increased osteoclast cell number	J:233241
\Ciita^tm2Wrth/\Ciita^tm2Wrth (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:92170
	decreased CD4-positive, alpha-beta T cell number	J:92170
\Ciita^tm2Wrth/\Ciita^tm2Wrth (B6.129P2-Ciita^tm2Wrth)	immune system phenotype	J:117111
\Cilk1^{tm1b(KOMP)Mbp}/\Cilk1^{tm1b(KOMP)Mbp} (C57BL/6N-Cilk1^{tm1b(KOMP)Mbp}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Cimap1b^{em1(IMPC)Ccpcz}/\Cimap1b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cimap1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Cimap2^Retro/\Cimap2⁺ (involves: C57BL/6J)	increased CD8-positive, alpha-beta T cell number	J:223336
\Cimap2^Retro/\Cimap2⁺ (involves: C57BL/6J)	increased cytotoxic T cell cytolysis	J:223336
\Cimap2^Retro/\Cimap2^Retro (involves: C57BL/6J)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:223336
	increased activated T cell number	J:223336
	increased CD8-positive, alpha-beta T cell number	J:223336
	increased central memory CD8 positive, alpha-beta T cell number	J:223336
	increased cytotoxic T cell cytolysis	J:223336
	increased interferon-gamma secretion	J:223336
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:223336
	increased T cell proliferation	J:223336
\Cimap2^{tm1a(KOMP)Wtsi}/\Cimap2⁺ (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:223336
\Cimap2^{tm1a(KOMP)Wtsi}/\Cimap2⁺ (involves: C57BL/6)	decreased cytotoxic T cell cytolysis	J:223336
\Cimip2b^{tm1(KOMP)Wtsi}/\Cimip2b^{tm1(KOMP)Wtsi} (C57BL/6N-Cimip2b^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Cinda1^BALB/c/? (involves: BALB/c * CcS-4/Dem)	increased T cell proliferation	J:40728
\Cinda2^STS/A/? (involves: BALB/c * CcS-4/Dem)	increased T cell proliferation	J:40728
\Cinda3^O20/A/\Cinda3^O20/A (involves: O20/A * OcB-9/Dem)	decreased T cell proliferation	J:95917
\Cinda3^OcB9/Dem/\Cinda3^O20/A (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
\Cinda4^OcB9/Dem/\Cinda4^O20/A (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
\Cinda4^OcB9/Dem/\Cinda4^OcB9/Dem (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
\Cinda5^OcB9/Dem/\Cinda5^O20/A (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
\Cinda5^OcB9/Dem/\Cinda5^OcB9/Dem (involves: O20/A * OcB-9/Dem)	increased T cell proliferation	J:95917
\Ciroz^b2b1167Clo/\Ciroz^b2b1167Clo (C57BL/6J-Ciroz^b2b1167Clo)	spleen hypoplasia	J:175213
\Cish^tm1.1Cdon/\Cish^tm1.1Cdon \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:204829
\Cish^tm1.1Cdon/\Cish^tm1.1Cdon \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T-helper 2 cell differentiation	J:204829
	increased eosinophil cell number	J:204829
	increased interleukin-4 secretion	J:204829
	increased interleukin-5 secretion	J:204829
	increased interleukin-10 secretion	J:204829
	increased interleukin-13 secretion	J:204829
	increased susceptibility to type I hypersensitivity reaction	J:204829
\Cish^tm1.2Cdon/\Cish^tm1.2Cdon (B6.129S6(Cg)-Cish^tm1.2Cdon)	abnormal CD4-positive T cell differentiation	J:204829
	abnormal immune system morphology	J:204829
	abnormal immune system physiology	J:204829
	abnormal T-helper 2 cell differentiation	J:204829
	immune system phenotype	J:204829
	increased eosinophil cell number	J:204829
	increased interleukin-4 secretion	J:204829
	increased interleukin-5 secretion	J:204829
	increased interleukin-9 secretion	J:204829
	increased interleukin-13 secretion	J:204829
	increased lymphocyte cell number	J:204829
	increased susceptibility to type I hypersensitivity reaction	J:204829
	increased T cell proliferation	J:204829
	lung inflammation	J:204829
	lymph node hyperplasia	J:204829
	spleen hyperplasia	J:204829
	thymus hyperplasia	J:204829
\Cited2^tm1Bha/\Cited2^tm1Bha (involves: 129P2/OlaHsd * C57BL/6J)	small spleen	J:92872
\Cited2^tm1Bha/\Cited2^tm1Bha (B6.129P2-Cited2^tm1Bha)	small spleen	J:92872
\Ciz1^{Gt(IST13830B6)Tigm}/\Ciz1^{Gt(IST13830B6)Tigm} (B6J.B6N-Ciz1^{Gt(IST13830B6)Tigm})	increased monocyte cell number	J:231433
	increased neutrophil cell number	J:231433
\Ciz1^tm1.1Homy/\Ciz1^tm1.1Homy (involves: 129P2/OlaHsd * C57BL/6 * DBA)	enlarged spleen	J:198470
	lymph node hyperplasia	J:198470
	thymus hyperplasia	J:198470
\Ckb^{tm1.1(KOMP)Wtsi}/\Ckb^{tm1.1(KOMP)Wtsi} (C57BL/6N-Ckb^{tm1.1(KOMP)Wtsi}/Ucd)	increased lymphocyte cell number	J:211773
\Cks1b^tm1Sir/\Cks1b^tm1Sir \Tg(IghMyc)22Bri/? (involves: C57BL * C57BL/6 * SJL)	decreased B cell proliferation	J:121564
	decreased leukocyte cell number	J:121564
	decreased lymphocyte cell number	J:121564
	decreased spleen weight	J:121564
\Clasp1^em1(IMPC)Mbp/\Clasp1⁺ (C57BL/6NCrl-Clasp1^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Clca1^tm1.1Lex/\Clca1^tm1.1Lex (involves: 129S/SvEvBrd)	abnormal chemokine level	J:125158
	increased inflammatory response	J:125158
	increased neutrophil cell number	J:125158
	lung inflammation	J:125158
\Clca1^tm1Dgen/\Clca1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal inflammatory response	J:112942
\Clcf1^{tm1.1(KOMP)Vlcg}/\Clcf1⁺ (C57BL/6N-Clcf1^{tm1.1(KOMP)Vlcg}/Ucd)	decreased leukocyte cell number	J:211773
\Clcn1^em1(IMPC)Mbp/\Clcn1^em1(IMPC)Mbp (C57BL/6NCrl-Clcn1^em1(IMPC)Mbp/MbpMmucd)	increased eosinophil cell number	J:211773
\Clcn2^tm1Tjj/\Clcn2^tm1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal microglial cell physiology	J:122365
\Clcn3^tm1Lamb/\Clcn3^tm1Lamb (involves: 129S1/Sv * 129X1/SvJ)	abnormal neutrophil physiology	J:112692
	impaired neutrophil phagocytosis	J:112692
	sepsis	J:112692
\Clcn3^tm1Tjj/\Clcn3^tm1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal microglial cell physiology	J:77635
\Clcn7^tm1.1Lex/\Clcn7^tm1.1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	microgliosis	J:186049
\Clcn7^tm1.1Mawa/\Clcn7⁺ (involves: C57BL/6J * C57BL/6N * CD-1)	increased osteoclast cell number	J:254787
\Clcn7^tm1.1Teti/\Clcn7⁺ (involves: 129S2/SvPas * C57BL/6)	abnormal osteoclast physiology	J:203761
\Clcn7^tm1.1Teti/\Clcn7⁺ (involves: 129S2/SvPas * C57BL/6)	increased osteoclast cell number	J:203761
\Clcn7^tm1Tjj/\Clcn7^tm1Tjj (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast morphology	J:67273
	abnormal osteoclast physiology	J:67273
\Clcn7^tm2Tjj/\Clcn7^tm2Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast morphology	J:67273, J:217031
	abnormal osteoclast physiology	J:67273
\Clcn7^tm2Tjj/\Clcn7^tm2Tjj (involves: 129S1/Sv * 129X1/SvJ)	microgliosis	J:155176
\Clcn7^tm3.1Tjj/\Clcn7^tm3.1Tjj \Emx1^{tm1.1(cre)Ito}/\Emx1⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)	microgliosis	J:155176
\Clcn7^tm4.1Tjj/\Clcn7^tm4.1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast morphology	J:160702, J:217031
	abnormal osteoclast physiology	J:160702
\Clcn7^tm5.1Tjj/\Clcn7^tm5.1Tjj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast morphology	J:217031
\Clcnka^m1Btlr/\Clcnka^m1Btlr (C57BL/6J-Clcnka^m1Btlr)	increased susceptibility to induced colitis	J:271974
\Clcnkb^em1(IMPC)Mbp/\Clcnkb^em1(IMPC)Mbp (C57BL/6NCrl-Clcnkb^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Cldn3^em1(IMPC)H/\Cldn3^em1(IMPC)H (C57BL/6N-Cldn3^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cldn9^em1(IMPC)H/\Cldn9^em1(IMPC)H (C57BL/6NTac-Cldn9^em1(IMPC)H/H)	increased basophil cell number	J:211773
\Cldn12^{tm1.1(KOMP)Vlcg}/\Cldn12^{tm1.1(KOMP)Vlcg} (B6J.B6N-Cldn12^{tm1.1(KOMP)Vlcg})	immune system phenotype	J:279934
	increased leukocyte cell number	J:279934
	increased spleen weight	J:279934
\Cldn18^tm1Lex/\Cldn18^tm1Lex (involves: 129S5/SvEvBrd)	abnormal osteoclast differentiation	J:195931
\Cldn18^tm1Lex/\Cldn18^tm1Lex (involves: 129S5/SvEvBrd)	increased osteoclast cell number	J:195931
\Clec1a^tm1Yiw/\Clec1a^tm1Yiw (involves: C57BL/6J * C57BL/6NSlc)	abnormal dendritic cell antigen presentation	J:329240
	decreased CD8-positive, alpha-beta memory T cell proliferation	J:329240
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:329240
	immune system phenotype	J:329240
\Clec1b^tm1.1Arte/\Clec1b^tm1.1Arte \Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	abnormal lymphatic vessel endothelial cell morphology	J:181715
	abnormal lymphatic vessel morphology	J:181715
\Clec1b^tm1.1Ksi/\Clec1b^tm1.1Ksi (involves: C57BL/6)	abnormal lymphatic system physiology	J:165898
\Clec1b^tm1.1Ksi/\Clec1b^tm1.1Ksi (involves: C57BL/6)	abnormal lymphatic vessel morphology	J:165898
\Clec1b^tm1.2Arte/\Clec1b^tm1.2Arte (Not Specified)	abnormal lymphatic vessel morphology	J:181715
\Clec1b^tm1.2Arte/\Clec1b^tm1.2Arte (Not Specified)	decreased lymphatic vessel endothelial cell number	J:181715
\Clec1b^tm1Ksi/\Clec1b^tm1Ksi \Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	abnormal lymphatic vessel morphology	J:187533
\Clec1b^tm1Lex/\Clec1b^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal mononuclear cell morphology	J:161922
\Clec1b^tm1Mlkn/\Clec1b^tm1Mlkn (involves: 129S4/SvJae * C57BL/6)	abnormal lymphatic vessel morphology	J:162815
\Clec1b^tm2Mlkn/\Clec1b^tm2Mlkn \Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6 * SJL)	lymph node hemorrhage	J:205423
\Clec2d^tm1.1Mgil/\Clec2d^tm1.1Mgil (C57BL/6-Clec2d^tm1.1Mgil)	abnormal osteoclast differentiation	J:143122
	increased osteoclast cell number	J:143122
\Clec2d^tm1.1Mgil/\Clec2d^tm1.1Mgil (involves: C57BL/6)	immune system phenotype	J:222057
\Clec2h^tm1.1Apma/\Clec2h^tm1.1Apma (B6(Cg)-Clec2h^tm1.1Apma)	kidney inflammation	J:322835
\Clec2h^tm1.1Apma/\Clec2h^tm1.1Apma \Rag1^tm1Mom/\Rag1^tm1Mom (B6.Cg-Rag1^tm1Mom Clec2h^tm1.1Apma)	kidney inflammation	J:322835
\Clec4a2^tm1.1Cfg/\Clec4a2^tm1.1Cfg (involves: C57BL/6)	enlarged lymph nodes	J:217719
	immune system phenotype	J:217719
	increased B cell proliferation	J:217719
	increased IgG2a level	J:217719
	increased IgG2b level	J:217719
	increased IgG3 level	J:217719
	increased inflammatory response	J:217719
\Clec4a2^tm1Yiw/\Clec4a2^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6J)	abnormal circulating interleukin level	J:217720
	abnormal immune system morphology	J:217720
	abnormal immune system physiology	J:217720
	enthesitis	J:217720
	increased anti-nuclear antigen antibody level	J:217720
	increased autoantibody level	J:217720
	increased circulating interleukin-4 level	J:217720
	increased circulating interleukin-10 level	J:217720
	increased circulating interleukin-17 level	J:217720
	increased circulating interleukin-23 level	J:217720
	increased dendritic cell number	J:217720
	increased IgG1 level	J:217720
	increased IgG3 level	J:217720
	increased IgG level	J:217720
	increased inflammatory response	J:217720
	increased single-positive T cell number	J:217720
	increased susceptibility to induced arthritis	J:217720
	joint inflammation	J:217720
	salivary gland inflammation	J:217720
\Clec4b1^em#Tsak/\Clec4b1^em#Tsak (involves: C57BL/6N)	abnormal adaptive immunity	J:258645
	abnormal cytokine level	J:258645
	abnormal cytokine secretion	J:258645
	decreased interferon-gamma secretion	J:258645
	decreased interleukin-12 secretion	J:258645
	increased susceptibility to bacterial infection	J:258645
\Clec4d^tm1.1Cfg/\Clec4d^tm1.1Cfg (involves: C57BL/6)	decreased B cell proliferation	J:217719
	decreased T cell proliferation	J:217719
	immune system phenotype	J:203221
	increased B cell number	J:217719
	increased interferon-gamma secretion	J:203221
	increased interleukin-6 secretion	J:203221
	increased interleukin-10 secretion	J:203221
	increased interleukin-17 secretion	J:203221
	increased mature B cell number	J:217719
	increased susceptibility to bacterial infection	J:203221
	increased susceptibility to bacterial infection induced morbidity/mortality	J:203221
	increased tumor necrosis factor secretion	J:203221
	lung inflammation	J:203221
\Clec4d^tm1.1Shoy/\Clec4d^tm1.1Shoy (involves: 129P2/OlaHsd * C57BL/6)	abnormal antigen presentation	J:203159
	abnormal chemokine secretion	J:203159
	abnormal immune serum protein physiology	J:203159
	abnormal immune system physiology	J:203159
	abnormal interferon-gamma secretion	J:203159
	abnormal interleukin-17 secretion	J:203159
	abnormal response to infection	J:203159
	abnormal thymus morphology	J:203159
	decreased circulating interleukin-17 level	J:203159
	decreased dendritic cell number	J:203159
	decreased IgG level	J:203159
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:203159
	decreased susceptibility to type IV hypersensitivity reaction	J:203159
	decreased tumor necrosis factor secretion	J:203159
	granulomatous inflammation	J:203159
	lung inflammation	J:203159
\Clec4e^tm1.1Cfg/\Clec4e^tm1.1Cfg (B6.Cg-Clec4e^tm1.1Cfg)	abnormal macrophage physiology	J:136334
	decreased lymphocyte cell number	J:136334
	decreased monocyte cell number	J:136334
	decreased neutrophil cell number	J:136334
	decreased tumor necrosis factor secretion	J:136334
	increased susceptibility to fungal infection	J:136334
\Clec4e^tm1Tks/\Clec4e^tm1Tks (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal chemokine secretion	J:172959
	decreased interleukin-6 secretion	J:172959
	decreased interleukin-10 secretion	J:172959
	decreased neutrophil cell number	J:172959
	decreased susceptibility to fungal infection	J:172959
	decreased tumor necrosis factor secretion	J:172959
\Clec4e^tm1Tks/\Clec4e^tm1Tks (involves: 129S1/Sv * 129X1/SvJ)	abnormal chemokine secretion	J:203159
	abnormal immune serum protein physiology	J:203159
	abnormal interferon-gamma secretion	J:203159
	abnormal interleukin-17 secretion	J:203159
	abnormal response to infection	J:203159
	decreased circulating interleukin-17 level	J:203159
	decreased dendritic cell number	J:203159
	decreased IgG level	J:203159
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:203159
	decreased susceptibility to type IV hypersensitivity reaction	J:203159
	decreased tumor necrosis factor secretion	J:203159
\Clec4f^tm1Ymed/\Clec4f^tm1Ymed (B6.129S7-Clec4f^tm1Ymed)	abnormal macrophage cytokine production	J:203199
	decreased interferon-gamma secretion	J:203199
	immune system phenotype	J:203199
\Clec4g^tm1.1Cfg/\Clec4g^tm1.1Cfg (involves: C57BL/6)	increased lymphocyte cell number	J:217719
\Clec4g^tm1.1Cfg/\Clec4g^tm1.1Cfg (involves: C57BL/6)	increased monocyte cell number	J:217719
\Clec4g^tm1.1Fhe/\Clec4g^tm1.1Fhe (B6.129-Clec4g^tm1.1Fhe)	abnormal immune system cell morphology	J:200968
	abnormal immune system physiology	J:200968
	decreased susceptibility to Adenoviridae infection	J:194891
	immune system phenotype	J:200968
	increased activated T cell number	J:200968
	increased CD4-positive, alpha-beta T cell number	J:200968
	increased CD8-positive, alpha-beta T cell number	J:200968, J:194891
	liver inflammation	J:200968
\Clec4n^tm1.2Mgne/\Clec4n^tm1.2Mgne (involves: C57BL/6 * C57BL/6J)	abnormal chemokine secretion	J:209284
	abnormal interferon secretion	J:209284
	abnormal interleukin secretion	J:209284
	abnormal macrophage physiology	J:209284
	abnormal neutrophil physiology	J:209284
	abnormal susceptibility to fungal infection	J:209284
	abnormal tumor necrosis factor secretion	J:209284
	decreased interferon-gamma secretion	J:209284
	decreased interleukin-17 secretion	J:209284
	decreased tumor necrosis factor secretion	J:209284
	impaired macrophage phagocytosis	J:209284
	impaired neutrophil phagocytosis	J:209284
	increased interferon-gamma secretion	J:209284
	increased interleukin-1 alpha secretion	J:209284
	increased interleukin-1 beta secretion	J:209284
	increased interleukin-6 secretion	J:209284
	increased interleukin-17 secretion	J:209284
	increased susceptibility to fungal infection	J:209284
	increased tumor necrosis factor secretion	J:209284
\Clec4n^tm1Yiw/\Clec4n^tm1Yiw (B6.129P2-Clec4n^tm1Yiw)	abnormal CD4-positive T cell differentiation	J:160680
	decreased interferon-gamma secretion	J:160680
	decreased interleukin-6 secretion	J:160680
	decreased interleukin-10 secretion	J:160680
	decreased interleukin-12b secretion	J:160680
	decreased interleukin-17 secretion	J:160680
	decreased interleukin-23 secretion	J:160680
	decreased tumor necrosis factor secretion	J:160680
	increased susceptibility to infection induced morbidity/mortality	J:160680
\Clec4n^tm1Yiw/\Clec4n^tm1Yiw (involves: 129P2/OlaHsd)	increased susceptibility to fungal infection	J:209284
\Clec5a^em1(IMPC)Mbp/\Clec5a^em1(IMPC)Mbp (C57BL/6NCrl-Clec5a^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Clec5a^tm1Cua/\Clec5a^tm1Cua (involves: C57BL/6)	decreased susceptibility to induced arthritis	J:158811
\Clec7a^tm1.1Bpip/\Clec7a^tm1.1Bpip \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:203908
	decreased tumor necrosis factor secretion	J:203908
	impaired macrophage phagocytosis	J:203908
	increased susceptibility to fungal infection	J:203908
\Clec7a^tm1Gdb/\Clec7a^tm1Gdb (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytokine secretion	J:116669
	abnormal inflammatory response	J:116669
	abnormal macrophage physiology	J:116669
	abnormal neutrophil physiology	J:116669
	increased susceptibility to fungal infection	J:116669
\Clec7a^tm1Gdb/\Clec7a^tm1Gdb (B6.129S6-Clec7a^tm1Gdb)	abnormal circulating interleukin level	J:179011
	decreased circulating interleukin-17 level	J:179011
	increased susceptibility to fungal infection	J:179011
	lung inflammation	J:179011
\Clec7a^tm1Yiw/\Clec7a^tm1Yiw (C.129P2-Clec7a^tm1Yiw)	abnormal cytokine secretion	J:116670
	abnormal dendritic cell physiology	J:116670
	abnormal macrophage physiology	J:116670
	increased susceptibility to fungal infection	J:116670
\Clec7a^tm1Yiw/\Clec7a^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:122394
	immune system phenotype	J:122394
\Clec7a^tm1Yiw/\Clec7a^tm1Yiw \Myd88^tm1Aki/\Myd88^tm1Aki (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	abnormal cytokine secretion	J:116670
	abnormal dendritic cell physiology	J:116670
\Clec9a^tm1.1Crs/\Clec9a^tm1.1Crs (C57BL/6-Clec9a^tm1.1Crs)	abnormal dendritic cell antigen presentation	J:178441
\Clec9a^tm1.1Kens/\Clec9a^tm1.1Kens (involves: C57BL/6)	abnormal humoral immune response	J:181366
\Clec9a^tm1Crs/\Clec9a^tm1Crs (involves: 129S6/SvEvTac * C57BL/6)	abnormal dendritic cell antigen presentation	J:147472
\Clec10a^m1/\Clec10a^m1 (NC/Nga)	dermatitis	J:283174
	immune system phenotype	J:283174
	increased neutrophil cell number	J:283174
\Clec10a^tm1Hed/\Clec10a⁺ \St3gal1^tm1Jxm/\St3gal1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased CD8-positive, alpha-beta T cell number	J:78035
\Clec10a^tm1Hed/\Clec10a^tm1Hed (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	dermatitis	J:283174
	immune system phenotype	J:78035, J:283174
	increased neutrophil cell number	J:283174
\Clec10a^tm1Hed/\Clec10a^tm1Hed \St3gal1^tm1Jxm/\St3gal1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased CD8-positive, alpha-beta T cell number	J:78035
\Clec12a^tm1Gdb/\Clec12a^tm1Gdb (involves: C57BL/6)	increased susceptibility to bacterial infection	J:224869
\Clec12a^tm1Gdb/\Clec12a^tm1Gdb (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:224869
\Clec12a^tm1Jrld/\Clec12a^tm1Jrld (B6J.129-Clec12a^tm1Jrld)	abnormal chemokine secretion	J:210326
	abnormal neutrophil physiology	J:210326
	immune system phenotype	J:210326
	increased inflammatory response	J:210326
	increased tumor necrosis factor secretion	J:210326
\Clic4^tm1.1Aidi/\Clic4^tm1.1Aidi (involves: C57BL/6 * C57BL/6J)	abnormal chemokine secretion	J:175404
	decreased circulating interleukin-6 level	J:175404
	decreased circulating tumor necrosis factor level	J:175404
	decreased interleukin-6 secretion	J:175404
	decreased interleukin-12 secretion	J:175404
	decreased susceptibility to endotoxin shock	J:175404
	decreased tumor necrosis factor secretion	J:175404
	increased susceptibility to bacterial infection	J:175404
\Clic4^tm1.1Yus/\Clic4^tm1.1Yus (involves: 129S4/SvJae * C57BL/6J)	impaired macrophage phagocytosis	J:183611
\Clic5^jbg/\Clic5^jbg (involves: C3H/HeJ * C57BL/6)	decreased eosinophil cell number	J:160186
	decreased monocyte cell number	J:160186
	decreased neutrophil cell number	J:160186
\Clip2^{em1(IMPC)Ccpcz}/\Clip2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Clip2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Clk1^{tm1a(EUCOMM)Wtsi}/\Clk1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Clk1^{tm1a(EUCOMM)Wtsi}/Ics)	decreased granulocyte number	J:165965
\Cln3^em1Dprc/\Cln3^em1Dprc (C57BL/6-Cln3^em1Dprc)	increased microglial cell activation	J:294634
\Cln3^tm1Nbm/\Cln3^tm1Nbm (involves: 129S6/SvEvTac * C57BL/6J)	abnormal dendritic cell physiology	J:233445
	abnormal macrophage physiology	J:233445
	abnormal professional antigen presenting cell morphology	J:233445
	decreased macrophage cytokine production	J:233445
\Cln8^em1(IMPC)Mbp/\Cln8^em1(IMPC)Mbp (C57BL/6N-Cln8^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Clnk^{em1(IMPC)Ccpcz}/\Clnk^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Clnk^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Clnk^tm1Rygo/\Clnk^tm1Rygo (B6.129P2-Clnk^tm1Rygo)	abnormal interferon-gamma secretion	J:131738
	abnormal NK T cell physiology	J:131738
	decreased interleukin-4 secretion	J:131738
	immune system phenotype	J:131738
	increased natural killer cell mediated cytotoxicity	J:131738
\Clnk^tm1Rygo/\Clnk^tm1Rygo (involves: 129P2/OlaHsd * BALB/c)	immune system phenotype	J:131621
	increased interferon-gamma secretion	J:131621
	increased natural killer cell mediated cytotoxicity	J:131621
\Clnk^tm1Rygo/\Clnk^tm1Rygo \Lcp2^tm1Geha/\Lcp2^tm1Geha (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c)	decreased interferon-gamma secretion	J:131621
	impaired natural killer cell mediated cytotoxicity	J:131621
	increased NK cell number	J:131621
\Clnk^tm1Vei/\Clnk^tm1Vei (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal mast cell physiology	J:91590
	immune system phenotype	J:91590
	increased natural killer cell mediated cytotoxicity	J:91590
\Clock^{em1(IMPC)Ccpcz}/\Clock^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Clock^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased T-helper cell number	J:211773
\Clp1^tm1.1Pngr/\Clp1^tm1.1Pngr (CBA.Cg-Clp1^tm1.1Pngr)	abnormal microglial cell morphology	J:209564
\Clpp^{Gt(IST11134F10)Tigm}/\Clpp^{Gt(IST11134F10)Tigm} (involves: C57BL/6N)	abnormal T cell activation	J:203140
	dermatitis	J:203140
\Clpp^{Gt(IST13563G11)Tigm}/\Clpp^{Gt(IST13563G11)Tigm} (involves: C57BL/6N)	abnormal T cell activation	J:203140
	dermatitis	J:203140
\Clpp^{tm1a(EUCOMM)Wtsi}/\Clpp^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Clpp^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive NK T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased gamma-delta T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	increased B cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased mature B cell number	J:211773
	increased monocyte cell number	J:211773
\Clptm1^em1(IMPC)Tcp/\Clptm1⁺ (C57BL/6N-Clptm1^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
\Clptm1l^{tm1d(EUCOMM)Wtsi}/\Clptm1l⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)	abnormal class switch recombination	J:265892
\Clptm1l^{tm1d(EUCOMM)Wtsi}/\Clptm1l^{tm1d(EUCOMM)Wtsi} (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)	immune system phenotype	J:265892
\Clptm1l^{tm1d(EUCOMM)Wtsi}/\Clptm1l^{tm1d(EUCOMM)Wtsi} \Prdm1^tm1Nutt/\Prdm1⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6N)	immune system phenotype	J:265892
\Clptq1^NZB/BlNJ/\Clptq1^NZB/BlNJ (B6.NZB-(D4Mit193-D4Mit33))	enlarged spleen	J:143646
	enlarged thymus	J:143646
	increased B-1a cell number	J:143646
	increased NK T cell number	J:143646
\Clrn1^{tm1.1(KOMP)Vlcg}/\Clrn1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Clrn1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
\cls/\cls (involves: DBA/1Lac)	immune system phenotype	J:15088
\Clspn^{tm1(KOMP)Vlcg}/\Clspn⁺ (C57BL/6N-Clspn^{tm1(KOMP)Vlcg})	increased B cell number	J:332163
	lymphoid hyperplasia	J:332163
\Clstn1^{tm1b(EUCOMM)Hmgu}/\Clstn1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Clstn1^{tm1b(EUCOMM)Hmgu}/H)	increased basophil cell number	J:211773
\Clta^tm1.2Fmb/\Clta^tm1.2Fmb (involves: C57BL/6)	abnormal class switch recombination	J:235591
\Clta^tm1.2Fmb/\Clta^tm1.2Fmb (involves: C57BL/6)	decreased germinal center B cell number	J:235591
\Clu^tm1Jakh/\Clu^tm1Jakh (involves: Black Swiss * FVB/N)	heart inflammation	J:65660
\Clu^tm1Jakh/\Clu^tm1Jakh (involves: Black Swiss * FVB/N)	myocarditis	J:65660
\Cluh^{em1(IMPC)Ccpcz}/\Cluh⁺ (C57BL/6N-Cluh^{em1(IMPC)Ccpcz}/Ccpcz)	increased Ly6C-positive mature NK cell number	J:211773
\Cma1^tm1Mfg/\Cma1^tm1Mfg (either: (involves: 129 * C57BL/6) or (involves: 129 * BALB/c))	abnormal mast cell physiology	J:98963
\Cmah^tm1Avrk/\Cmah^tm1Avrk \Dmd^mdx/\Dmd^mdx (involves: 129X1/SvJ * C57BL/10ScSn)	increased macrophage cell number	J:164594
	increased monocyte cell number	J:164594
\Cmah^tm1Avrk/\Cmah^tm1Avrk \Dock2^m1Hsd/\Dock2^m1Hsd (B6NHsd.Cg-Dock2^m1Hsd Cmah^tm1Avrk)	abnormal B cell activation	J:144035
	decreased follicular B cell number	J:144035
	decreased marginal zone B cell number	J:144035
\Cmah^tm1Avrk/\Cmah^tm1Avrk \Dock2^m1Hsd/\Dock2^m1Hsd \Siae^tm1.2Avrk/\Siae^tm1.2Avrk (B6NHsd.Cg-Siae^tm1.2Avrk Dock2^m1Hsd Cmah^tm1Avrk)	abnormal B cell activation	J:144035
	decreased follicular B cell number	J:144035
	decreased marginal zone B cell number	J:144035
\Cmah^tm1Ykoz/\Cmah^tm1Ykoz (B6.129P2-Cmah^tm1Ykoz)	abnormal B cell physiology	J:121365
	abnormal humoral immune response	J:121365
	abnormal interleukin secretion	J:121365
	abnormal T cell physiology	J:121365
	decreased interferon-gamma secretion	J:121365
	immune system phenotype	J:121365
	increased B cell proliferation	J:121365
	increased IgG1 level	J:121365
\Cmas^tm1.1Bwei/\Cmas^tm1.1Bwei \Tg(NPHS2-cre)295Lbh/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	tubular nephritis	J:286022
\Cmcs^CBA/N/? (involves: CBA/N * DBA/2)	abnormal immune system physiology	J:94127
\Cmcs^DBA/2/? (involves: CBA/N * DBA/2)	abnormal immune system physiology	J:94127
\Cmip^{tm1a(EUCOMM)Wtsi}/\Cmip^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cmip^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal lymphatic vessel morphology	J:239583
\Cmklr1^tm1Dgen/\Cmklr1^tm1Dgen (B6.Cg-Cmklr1^tm1Dgen)	abnormal alveolar macrophage morphology	J:157190
	abnormal dendritic cell physiology	J:157190
	abnormal immune system morphology	J:157190
	abnormal macrophage chemotaxis	J:157190
	abnormal professional antigen presenting cell physiology	J:157190
	increased neutrophil cell number	J:157190
	increased susceptibility to endotoxin shock	J:157190
	lung inflammation	J:157190
\Cmklr1^tm1Drg/\Cmklr1^tm1Drg (Not Specified)	impaired macrophage chemotaxis	J:133968
\Cmklr1^tm1Drg/\Cmklr1^tm1Drg (Not Specified)	impaired neutrophil recruitment	J:133968
\Cms1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	decreased susceptibility to fungal infection	J:55132
\Cms2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	decreased susceptibility to infection	J:55132
\Cmtm4^{tm1d(EUCOMM)Wtsi}/\Cmtm4^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased CD8-positive, alpha-beta T cell number	J:333836
	decreased inflammatory response	J:333836
	decreased susceptibility to chemically induced skin inflammation	J:333836
	immune system phenotype	J:333836
	increased B cell number	J:333836
\Cmtm5^{tm1c(KOMP)Wtsi}/\Cmtm5^{tm1c(KOMP)Wtsi} \Cnp^tm1(cre)Kan/\Cnp⁺ (B6.Cg-Cnp^tm1(cre)Kan Cmtm5^{tm1c(KOMP)Wtsi})	microgliosis	J:327261
\Cmtm7^{tm2a(EUCOMM)Hmgu}/\Cmtm7⁺ \Rag1^tm1Fwa/\Rag1^tm1Fwa (chimera involves: C57BL/6 * C57BL/6N)	abnormal B cell physiology	J:207033
	abnormal B-1a B cell morphology	J:207033
	decreased B cell proliferation	J:207033
	decreased B-1a cell number	J:207033
	decreased IgG2b level	J:207033
	decreased IgM level	J:207033
	decreased plasma cell number	J:207033
\Cmtr1^{tm1b(EUCOMM)Hmgu}/\Cmtr1^{tm1b(EUCOMM)Hmgu} \Emx1^tm1(cre)Krj/\Emx1⁺ \Tg(Thy1-YFP)HJrs/0 (involves: 129S2/SvPas * C57BL/6J * C57BL/6N * CBA)	abnormal susceptibility to Riboviria infection	J:300305
\Cndp2^em1(IMPC)Mbp/\Cndp2^em1(IMPC)Mbp (C57BL/6NCrl-Cndp2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Cnga3^{tm1.1(KOMP)Vlcg}/\Cnga3⁺ (C57BL/6N-Cnga3^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged spleen	J:211773
\Cngb3^{em1(IMPC)Ccpcz}/\Cngb3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cngb3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Cnmd^tm1Ska/\Cnmd^tm1Ska (involves: C57BL/6 * CBA)	abnormal osteoclast physiology	J:81137
\Cnn2^tm1.1Jin/\Cnn2^tm1.1Jin \Cnn3^tm1.1Hjum/\Cnn3^tm1.1Hjum \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S6/SvEvTac * 129X1/SvJ * BALB/c)	immune system phenotype	J:237712
\Cnn2^tm1.2Jin/\Cnn2^tm1.2Jin (B6.129X1-Cnn2^tm1.2Jin)	abnormal immune system cell morphology	J:141867
	abnormal macrophage chemotaxis	J:141867
	abnormal macrophage physiology	J:141867
	decreased granulocyte number	J:141867
	decreased monocyte cell number	J:141867
	decreased neutrophil cell number	J:141867
	immune system phenotype	J:141867
	increased macrophage cell number	J:141867
\Cnn2^tm1Jin/\Cnn2^tm1Jin (B6.129X1-Cnn2^tm1Jin)	decreased monocyte cell number	J:141867
	decreased neutrophil cell number	J:141867
	immune system phenotype	J:141867
\Cnn3^tm1.1Hjum/\Cnn3^tm1.1Hjum \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S6/SvEvTac * BALB/c)	immune system phenotype	J:237712
\Cnot3^tm1.1Tya/\Cnot3⁺ (B6.129P2(Cg)-Cnot3^tm1.1Tya)	abnormal osteoclast differentiation	J:206802
\Cnot3^tm1.1Tya/\Cnot3⁺ (B6.129P2(Cg)-Cnot3^tm1.1Tya)	increased osteoclast cell number	J:206802
\Cnot4^{tm1b(EUCOMM)Wtsi}/\Cnot4⁺ (C57BL/6N-Cnot4^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased KLRG1-positive NK cell number	J:211773
\Cnppd1^{tm1.1(KOMP)Vlcg}/\Cnppd1^{tm1.1(KOMP)Vlcg} (B6N(Cg)-Cnppd1^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
\Cnpy2^{em1(IMPC)Wtsi}/\Cnpy2⁺ (C57BL/6N-Cnpy2^{em1(IMPC)Wtsi}/Wtsi)	increased effector memory T-helper cell number	J:211773
\Cnpy3^tm1Kmiy/\Cnpy3^tm1Kmiy (involves: C57BL/6)	abnormal lymphocyte physiology	J:128513
	abnormal macrophage physiology	J:128513
	decreased interleukin-6 secretion	J:128513
	decreased tumor necrosis factor secretion	J:128513
\Cnr2^tm1Zim/\Cnr2^tm1Zim (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:62417
\Cnr2^tm1Zim/\Cnr2^tm1Zim (involves: 129 * C57BL/6)	immune system phenotype	J:62417
\Cntf^tm1Mpin/\Cntf^tm1Mpin (involves: 129S2/SvPas)	abnormal microglial cell morphology	J:15313
\Cntf^tm1Mpin/\Cntf^tm1Mpin (B6.129S2-Cntf^tm1Mpin)	increased susceptibility to experimental autoimmune encephalomyelitis	J:126852
\Cntn5^em1(IMPC)Mbp/\Cntn5^em1(IMPC)Mbp (C57BL/6N-Cntn5^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Coasy^em1(IMPC)H/\Coasy⁺ (C57BL/6NTac-Coasy^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Cobl^{em1(IMPC)Ccpcz}/\Cobl^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cobl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased effector memory T-helper cell number	J:211773
\Cobll1^{em1(IMPC)Ccpcz}/\Cobll1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cobll1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Cog5^{em1(IMPC)Ccpcz}/\Cog5⁺ (C57BL/6NCrl-Cog5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Cog6^{tm1a(EUCOMM)Wtsi}/\Cog6^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cog6^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased marginal zone B cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased memory-marker gamma-delta T cell number	J:211773
	decreased memory-marker NK cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T cell number	J:211773
	decreased T-helper cell number	J:211773
	decreased transitional stage T2 B cell number	J:211773
	increased anti-nuclear antigen antibody level	J:211773
	increased B-2 B cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD5-positive gamma-delta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased follicular B cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased plasma cell number	J:211773
\Col1a1^Aga2/\Col1a1⁺ (C3HeB/FeJ-Col1a1^Aga2)	lung inflammation	J:185988
\Col1a1^M1Jrt/\Col1a1⁺ (involves: C3H/HeJ * C57BL/6J * FVB/NJ)	osteoarthritis	J:216423
\Col1a1^M1Jrt/\Col1a1⁺ (involves: C57BL/6 * FVB/N)	autoimmune arthritis	J:228439
\Col1a1^{tm1(CAG-Ezh2)Meln}/\Col1a1⁺ \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	immune system phenotype	J:199122
	increased germinal center B cell number	J:199122
	increased spleen germinal center number	J:199122
	increased spleen germinal center size	J:199122
\Col1a1^{tm1(CAG-Mir22)Ppp}/\Col1a1^{tm1(CAG-Mir22)Ppp} \Tg(Mx1-cre)1Cgn/0 (Not Specified)	decreased leukocyte cell number	J:199366
	enlarged spleen	J:199366
	increased myeloid dendritic cell number	J:199366
	increased T cell derived lymphoma incidence	J:199366
\Col1a1^{tm1(tetO-Cyp26b1)Mfra}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	abnormal lymphatic vessel morphology	J:206581
\Col1a1^{tm1(tetO-Fos)Wag}/\Col1a1⁺ \Tg(KRT5-rtTA)T2D6Sgkd/0 (involves: 129S4/SvJae * C57BL/6 * FVB/N)	immune system phenotype	J:201145
	increased CD4-positive, alpha-beta T cell number	J:201145
	increased granulocyte number	J:201145
	skin inflammation	J:201145
\Col1a1^{tm1(tetO-GFP/RNAi:Rad21)Iaai}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	decreased B cell number	J:229031
\Col1a1^{tm1(tetO-Irf4)Sing}/\Col1a1^{tm1(tetO-Irf4)Sing} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ \Irf4^tm1Mak/\Irf4⁺ (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:203903
	abnormal plasma cell differentiation	J:203903
\Col1a1^{tm1(tetO-Irf4)Sing}/\Col1a1^{tm1(tetO-Irf4)Sing} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ \Irf4^tm1Mak/\Irf4^tm1Mak (involves: 129P2/OlaHsd 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:203903
	abnormal plasma cell differentiation	J:203903
\Col1a1^{tm1(tetO-RNAi:Rps19)Karl}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
\Col1a1^{tm1(tetO-RNAi:Rps19)Karl}/\Col1a1^{tm1(tetO-RNAi:Rps19)Karl} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
	decreased neutrophil cell number	J:179085
\Col1a1^{tm1(tetO-Stat1)Biat}/\Col1a1^{tm1(tetO-Stat1)Biat} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} \Stat1^tm1Dlv/\Stat1^tm1Dlv (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	abnormal susceptibility to infection induced morbidity/mortality	J:212694
\Col1a1^{tm1(tetO-Tcfap2c)Hsc}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	immune system phenotype	J:174049
\Col1a1^{tm1(tetO-Yod1)Hpl}/\Col1a1^{tm1(tetO-Yod1)Hpl} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:194608
	abnormal professional antigen presenting cell physiology	J:194608
	immune system phenotype	J:194608
\Col1a1^{tm1(tetO-Yod1)Hpl}/\Col1a1^{tm1(tetO-Yod1)Hpl} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} \Tap1^tm1Arp/\Tap1^tm1Arp (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal professional antigen presenting cell physiology	J:194608
\Col1a1^tm1Jae/\Col1a1^tm1Jae (involves: 129S4/SvJae * C57BL/6)	abnormal osteoclast physiology	J:53079
\Col1a1^{tm2(tetO-Fosl2,-DsRed)Wag}/\Col1a1⁺ \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129S4/SvJae * C57BL/6 * CD-1)	abnormal osteoclast morphology	J:211215
\Col1a1^{tm2(tetO-GFP/RNAi:Smc1a)Iaai}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	decreased B cell number	J:229031
	enlarged spleen	J:229031
	increased neutrophil cell number	J:229031
	increased spleen red pulp amount	J:229031
	myeloid hyperplasia	J:229031
	myeloid metaplasia	J:229031
\Col1a1^{tm2(tetO-GFP/RNAi:Smc1a)Iaai}/\Col1a1^{tm3(tetO-GFP/RNAi:Stag2)Iaai} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	abnormal spleen morphology	J:229031
	decreased B cell number	J:229031
	enlarged spleen	J:229031
	myeloid hyperplasia	J:229031
\Col1a1^{tm2(tetO-IDH2R140Q)Ppp}/\Col1a1^{tm2(tetO-IDH2R140Q)Ppp} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/? (involves: 129S4/SvJae C57BL/6)	enlarged spleen	J:210097
\Col1a1^{tm2(tetO-Pou5f1)Jae}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	spleen atrophy	J:98920
	thymus atrophy	J:98920
\Col1a1^{tm2(tetO-RNAi:Rps19)Karl}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
\Col1a1^{tm2(tetO-RNAi:Rps19)Karl}/\Col1a1^{tm2(tetO-RNAi:Rps19)Karl} \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129S4/SvJae * C57BL/6)	decreased lymphocyte cell number	J:179085
	decreased neutrophil cell number	J:179085
\Col1a1^{tm3(tetO-Fosl1,-DsRed)Wag}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	enlarged spleen	J:213764
\Col1a1^{tm3(tetO-Fosl1,-DsRed)Wag}/\Col1a1⁺ \Tg(Cebpb-tTA)5Bjd/0 (involves: 129S4/SvJae * C57BL/6 * NMRI)	decreased circulating interleukin-6 level	J:210545
	liver inflammation	J:210545
\Col1a1^{tm3(tetO-GFP/RNAi:Apc)Slowe}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	increased T cell derived lymphoma incidence	J:171191
\Col1a1^{tm3(tetO-GFP/RNAi:Stag2)Iaai}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	decreased B cell number	J:229031
\Col1a1^{tm4(tetO-GFP/RNAi:Apc)Slowe}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	increased T cell derived lymphoma incidence	J:171191
\Col1a1^{tm6(tetO-MSI2)Jae}/\Col1a1⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae C57BL/6)	abnormal leukocyte morphology	J:163322
	abnormal myelopoiesis	J:163322
	decreased lymphocyte cell number	J:163322
	decreased neutrophil cell number	J:163322
	enlarged spleen	J:163322
	increased leukocyte cell number	J:163322
	increased spleen weight	J:163322
	spleen hyperplasia	J:163322
\Col1a2^{tm1b(EUCOMM)Wtsi}/\Col1a2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Col1a2^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Col2a1^{em1(IMPC)Ccpcz}/\Col2a1⁺ (C57BL/6NCrl-Col2a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased monocyte cell number	J:211773
\Col2a1^tm1Prc/\Col2a1⁺ \Col9a1^tm1Jae/\Col9a1^tm1Jae (involves: 129/Sv * 129S2/SvPas)	osteoarthritis	J:117910
\Col2a1^tm1Prc/\Col2a1^tm1Prc (involves: 129/Sv * C57BL/6)	immune system phenotype	J:30041
\Col3a1^m1Btlr/\Col3a1^m1Btlr (C57BL/6J-Col3a1^m1Btlr)	increased alpha-beta T cell number	J:271973
	increased CD4-positive, alpha-beta T cell number	J:271973
	increased CD8-positive, alpha-beta T cell number	J:271973
	increased susceptibility to induced colitis	J:271973
\Col3a1^Tsk2/\Col3a1⁺ (C3H101H-Col3a1^Tsk2/H)	adipose tissue inflammation	J:31216
\Col3a1^Tsk2/\Col3a1⁺ (C3H101H-Col3a1^Tsk2/H)	skin inflammation	J:31216
\Col4a1^tm1.1Ics/\Col4a1⁺ (involves: 129S2/SvPas * C57BL/6)	kidney inflammation	J:240798
\Col4a1^tm1.1Ics/\Col4a1^tm1.1Ics (involves: 129S2/SvPas * C57BL/6)	kidney inflammation	J:240798
\Col4a2^{em1(IMPC)Wtsi}/\Col4a2^{em1(IMPC)Wtsi} (C57BL/6N-Col4a2^{em1(IMPC)Wtsi}/WtsiOulu)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
	small thymus	J:239583
\Col4a3^tm1.1Rkl/\Col4a3⁺ (involves: C57BL/6)	glomerulonephritis	J:167404
\Col4a3^{tm1b(EUCOMM)Wtsi}/\Col4a3^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Col4a3^{tm1b(EUCOMM)Wtsi}/H)	decreased basophil cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
\Col4a3^tm1Dec/\Col4a3^tm1Dec (involves: 129X1/SvJ * C57BL/6)	glomerulonephritis	J:37963
\Col4a3^tm1Dec/\Col4a3^tm1Dec (129-Col4a3^tm1Dec/J)	glomerulonephritis	J:158731
\Col4a3^tm1Dec/\Col4a3^tm1Dec (B6.129X1-Col4a3^tm1Dec)	glomerulonephritis	J:167404
\Col4a3^tm1Dec/\Col4a3^tm1Dec \Itga1^tm1Gdnr/\Itga1^tm1Gdnr (involves: 129S4/SvJae * 129X1/SvJ * BALB/c)	tubular nephritis	J:71378
\Col4a3^tm1Dec/\Col4a3^tm1Dec \Sostdc1^tm1Myan/\Sostdc1^tm1Myan (involves: 129X1/SvJ)	glomerulonephritis	J:158731
\Col4a3^tm1Jhm/\Col4a3^tm1Jhm (involves: 129S1/Sv * 129X1/SvJ)	glomerulonephritis	J:37017
\Col4a3^tm1Jhm/\Col4a3^tm1Jhm \Mmp9^tm1Tvu/\Mmp9^tm1Tvu (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	glomerulonephritis	J:63137
\Col4a4^bwk/\Col4a4^bwk (NON;NZO-Col4a4^bwk/J)	kidney inflammation	J:223185
\Col4a4^bwk/\Col4a4^bwk (NON;NZO-Col4a4^bwk/J)	tubulointerstitial nephritis	J:223185
\Col4a4^bwk/\Col4a4^bwk (D2.NON(NZO)-Col4a4^bwk/GrsrJ)	kidney inflammation	J:223185
\Col4a4^bwk/\Col4a4^bwk (129S1.NON(NZO)-Col4a4^bwk/PgnJ)	kidney inflammation	J:223185
\Col4a4^m1H/\Col4a4^m1H (involves: C3H/HeH * C57BL/6J)	increased leukocyte cell number	J:285510
\Col4a5^{tm1b(EUCOMM)Wtsi}/Y (C57BL/6N-Col4a5^{tm1b(EUCOMM)Wtsi}/Cnrm)	increased leukocyte cell number	J:211773
\Col4a5^{tm1b(EUCOMM)Wtsi}/\Col4a5^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Col4a5^{tm1b(EUCOMM)Wtsi}/Cnrm)	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Col4a5^tm1Yseg/Y (B6.Cg-Col4a5^tm1Yseg)	tubulointerstitial nephritis	J:102306
\Col5a2^{em1(IMPC)Ccpcz}/\Col5a2⁺ (C57BL/6NCrl-Col5a2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Col6a3^em1(IMPC)Tcp/\Col6a3^em1(IMPC)Tcp (C57BL/6N-Col6a3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Col7a1^em#Jtol/\Col7a1^em#Jtol (involves: 129S4/SvJae * BALB/c * C57BL/Ka * NOD)	absent B cells	J:280214
	absent NK T cells	J:280214
	absent T cells	J:280214
\Col9a1^tm1Jae/\Col9a1^tm1Jae (either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL))	osteoarthritis	J:18628
\Col9a1^tm1Jae/\Col9a1^tm1Jae (involves: 129S2/SvPas)	osteoarthritis	J:117910
\Col9a3^em1(IMPC)Tcp/\Col9a3^em1(IMPC)Tcp (C57BL/6N-Col9a3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Col10a1^tm1.1Rpbh/\Col10a1^tm1.1Rpbh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased osteoclast cell number	J:154052
\Col10a1^tm1Bhr/\Col10a1^tm1Bhr (involves: 129S7/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:62230
	absent lymph nodes	J:62230
	decreased B cell number	J:62230
	decreased double-positive T cell number	J:62230
	decreased spleen red pulp amount	J:62230
	decreased spleen weight	J:62230
	decreased thymocyte number	J:62230
	decreased thymus weight	J:62230
	increased CD4-positive, alpha-beta T cell number	J:62230
	increased double-negative T cell number	J:62230
	increased single-positive T cell number	J:62230
	small spleen	J:62230
	small thymus	J:62230
	spleen hypoplasia	J:62230
	thymus hypoplasia	J:62230
\Col10a1^tm1Ksec/\Col10a1^tm1Ksec (involves: 129S/SvEv * C57BL/6)	abnormal T-helper 2 cell differentiation	J:193886
	decreased dendritic cell number	J:193886
	decreased interleukin-2 secretion	J:193886
	decreased interleukin-4 secretion	J:193886
	decreased interleukin-10 secretion	J:193886
	decreased interleukin-17 secretion	J:193886
	increased B cell number	J:193886
	increased interleukin-4 secretion	J:193886
	increased T-helper cell number	J:193886
\Col11a1^cho/\Col11a1⁺ (involves: C57BL/6Fr)	osteoarthritis	J:106282
\Col13a1^tm1Pih/\Col13a1^tm1Pih (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	myositis	J:71939
\Col17a1^em1Dcr/\Col17a1^em1Dcr \Lamc2^jeb/\Lamc2^jeb (B6.Cg-Lamc2^jeb Col17a1^em1Dcr/Dcr)	ear inflammation	J:352187
\Col17a1^em2Dcr/\Col17a1^em2Dcr \Lamc2^jeb/\Lamc2^jeb (C57BL/6J-Col17a1^em2Dcr/Dcr)	ear inflammation	J:352187
\Col17a1^{tm1.1(COL17A1)Zliu}/\Col17a1^{tm1.1(COL17A1)Zliu} (involves: 129P2/OlaHsd * C57BL/6J)	increased mast cell degranulation	J:261781
	increased neutrophil cell number	J:261781
\Col17a1^tm1Shzu/\Col17a1^tm1Shzu \Tg(KRT14-COL17A1)1Shzu/0 (involves: 129S/SvEv * C57BL/6J * C57BL/6Ncr)	decreased autoantibody level	J:121695
\Col17a1^tm1Tiin/\Col17a1^tm1Tiin (involves: C57BL/6)	increased autoantibody level	J:220622
	increased basophil cell number	J:220622
	increased eosinophil cell number	J:220622
	increased IgE level	J:220622
	increased monocyte cell number	J:220622
	increased neutrophil cell number	J:220622
	skin inflammation	J:220622
\Col26a1^em3(IMPC)Tcp/\Col26a1^em3(IMPC)Tcp (C57BL/6NCrl-Col26a1^em3(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Col27a1^em1(IMPC)Mbp/\Col27a1⁺ (C57BL/6N-Col27a1^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
\Colec11^tm1Lex/\Colec11^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal complement protein level	J:234934
\Colec12^em1(IMPC)Mbp/\Colec12^em1(IMPC)Mbp (C57BL/6N-Colec12^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Colgalt2^tm1.1Hwei/\Colgalt2^tm1.1Hwei (involves: C57BL/6J)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:310468
	abnormal regulatory T cell morphology	J:310468
	increased circulating interleukin-1 beta level	J:310468
	increased circulating interleukin-4 level	J:310468
	increased circulating interleukin-6 level	J:310468
	increased circulating interleukin-9 level	J:310468
	increased T cell apoptosis	J:310468
\Commd8^tm1.1Ksuz/\Commd8^tm1.1Ksuz \Igh^tm1Mnz/\Igh⁺ \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6NSlc * SJL)	abnormal spleen B cell follicle morphology	J:278399
\Commd9^{tm1b(KOMP)Wtsi}/\Commd9⁺ (C57BL/6N-Commd9^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Commd10^{Tg(Vav1-icre)A2Kio}/0 \Map3k7^tm1.1Arte/\Map3k7^tm1.1Arte (involves: C57BL/10 * C57BL/6J * C57BL/6NTac * CBA/Ca)	decreased interleukin-6 secretion	J:332172
	decreased interleukin-10 secretion	J:332172
	decreased interleukin-12b secretion	J:332172
	decreased macrophage cell number	J:332172
	decreased tumor necrosis factor secretion	J:332172
	enlarged axillary lymph nodes	J:332172
	enlarged inguinal lymph nodes	J:332172
	enlarged spleen	J:332172
	increased B cell number	J:332172
	increased lymphocyte cell number	J:332172
	increased neutrophil cell number	J:332172
	increased splenocyte number	J:332172
\Commd10^{Tg(Vav1-icre)A2Kio}/0 \Nfil3^tm1.2Kubo/\Nfil3^tm1.2Kubo (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased dendritic cell number	J:334296
\Commd10^{Tg(Vav1-icre)A2Kio}/? \Tnfrsf14^tm1.1Kro/\Tnfrsf14^tm1.1Kro (involves: C57BL/6NCrl * C57BL/10 * CBA * SJL)	decreased susceptibility to Herpesvirales infection	J:243038
\Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ \Zbtb11^tm1.1Lieg/\Zbtb11^tm1.1Lieg (involves: C57BL/6J * C57BL/10 * CBA/Ca)	abnormal lymphopoiesis	J:343208
	abnormal myelopoiesis	J:343208
\Comp^tm1Mbri/\Comp^tm1Mbri (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	osteoarthritis	J:125086
\Comt^tm1Kara/\Comt^tm1Kara (involves: 129S4/SvJaeSor)	increased interferon-gamma secretion	J:137276
\Comt^tm1Kara/\Comt^tm1Kara (involves: 129S4/SvJaeSor)	increased uterine NK cell number	J:137276
\Cop1^{Gt(XR0653)1.1Wtsi}/\Cop1^{Gt(XR0653)1.1Wtsi} (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:178271
\Copa^tm1.1Shum/\Copa⁺ (B6(CBA)-Copa^tm1.1Shum)	abnormal B cell morphology	J:288425
	abnormal T cell activation	J:288425
	bronchiolitis	J:288425
	decreased double-positive T cell number	J:288425
	increased effector memory T-helper cell number	J:288425
	increased single-positive T cell number	J:288425
	lung inflammation	J:288425
\Copg1^em1Geha/\Copg1^em1Geha (involves: C57BL/6)	abnormal B cell physiology	J:345528
	abnormal IgG level	J:345528
	decreased circulating interferon-gamma level	J:345528
	immune system phenotype	J:345528
	increased susceptibility to bacterial infection induced morbidity/mortality	J:345528
	increased T cell apoptosis	J:345528
\Cops5^tm1Rpar/\Cops5^tm1Rpar \Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)	decreased double-positive T cell number	J:132114
	decreased single-positive T cell number	J:132114
	decreased thymocyte number	J:132114
	increased T cell apoptosis	J:132114
	thymus medulla hypoplasia	J:132114
\Cops5^tm1Rpar/\Cops5^tm1Rpar \Tg(Lck-cre)548Jxm/0 \Tg(TcraTcrb)425Cbn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)	decreased thymocyte number	J:132114
\Cops5^tm1Rpar/\Cops5^tm1Rpar \Tg(Lck-cre)548Jxm/0 \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129 * C57BL/6 * CBA * SJL)	decreased thymocyte number	J:132114
\Cops6^{Gt(RRI087)Byg}/\Cops6⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased thymocyte apoptosis	J:172038
\Cops7a^{tm1b(KOMP)Mbp}/\Cops7a^{tm1b(KOMP)Mbp} (C57BL/6N-Cops7a^{tm1b(KOMP)Mbp}/Ucd)	increased monocyte cell number	J:211773
\Cops8^{em1(IMPC)Ccpcz}/\Cops8⁺ (C57BL/6NCrl-Cops8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Cops8^tm1Nwe/\Cops8^tm1.1Nwe \Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:126339
	abnormal T cell activation	J:126339
	decreased interleukin-2 secretion	J:126339
	decreased T cell number	J:126339
	decreased T cell proliferation	J:126339
\Coq6^em1Shcm/\Coq6^em1Shcm (C57BL/6-Coq6^em1Shcm)	increased susceptibility to bacterial infection	J:360514
\Coq6^em1Shcm/\Coq6^em1Shcm (C57BL/6-Coq6^em1Shcm)	increased susceptibility to bacterial infection induced morbidity/mortality	J:360514
\Cora1^BALB/c/\Cora1^BALB/c (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
\Cora1^STS/A/\Cora1^STS/A (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
\Coro1a^koy/\Coro1a^koy (C57BL/6-Coro1a^koy)	abnormal T cell physiology	J:141431
	decreased CD4-positive, alpha-beta T cell number	J:141431
	decreased CD8-positive, alpha-beta T cell number	J:141431
	decreased thymocyte number	J:141431
\Coro1a^{Lmb3-C57BL/6Scr}/\Coro1a^{Lmb3-C57BL/6Scr} (MRL.Cg-Coro1a^C57BL/6Scr Fas^lpr)	decreased autoantibody level	J:125557
	decreased spleen weight	J:125557
	decreased susceptibility to systemic lupus erythematosus	J:125557
	glomerulonephritis	J:125557
	small lymph nodes	J:125557
\Coro1a^{Lmb3-MRL/MpScr}/\Coro1a^{Lmb3-MRL/MpScr} (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
\Coro1a^{Lmb3-MRL/MpScr}/\Coro1a^{Lmb3-MRL/MpScr} (B6.MRL-Coro1a^MRL/MpScr Fas^lpr)	enlarged lymph nodes	J:125557
	increased spleen weight	J:125557
	increased susceptibility to systemic lupus erythematosus	J:125557
\Coro1a^ptcd/\Coro1a^ptcd (B6.CTS-Coro1a^ptcd)	abnormal effector T cell morphology	J:141431
	abnormal T cell activation	J:141431
	abnormal T cell physiology	J:141431
	decreased CD4-positive, alpha-beta T cell number	J:141431
	decreased CD8-positive, alpha-beta T cell number	J:141431
	increased T cell apoptosis	J:141431
	increased thymocyte number	J:141431
\Coro1a^ptcd/\Coro1a^tm1Achn (B6.Cg-Coro1a^ptcd Coro1a^tm1Achn)	abnormal effector T cell morphology	J:141431
	abnormal T cell activation	J:141431
	abnormal T cell physiology	J:141431
	decreased CD4-positive, alpha-beta T cell number	J:141431
	decreased CD8-positive, alpha-beta T cell number	J:141431
	increased thymocyte number	J:141431
\Coro1a^tm1Achn/\Coro1a^tm1Achn (involves: 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:111593
	decreased CD4-positive, alpha-beta T cell number	J:111593
	decreased CD8-positive, alpha-beta T cell number	J:111593
	decreased memory T cell number	J:111593
	decreased T cell number	J:111593
\Coro1a^tm1Achn/\Coro1a^tm1Achn (B6.129X1-Coro1a^tm1Achn)	decreased thymocyte number	J:141431
\Coro1a^tm1Achn/\Coro1a^tm1Achn (B6.129X1-Coro1a^tm1Achn)	increased T cell apoptosis	J:141431
\Coro1a^tm1Achn/\Coro1a^tm1Achn (involves: 129X1/SvJ)	decreased interleukin-6 secretion	J:177785
	decreased tumor necrosis factor secretion	J:177785
	increased mast cell degranulation	J:177785
\Coro1a^tm1Achn/\Coro1a^tm1Achn \Coro1b^tm1.1Nfoe/\Coro1b^tm1.1Nfoe (involves: 129X1/SvJ * C57BL/6N)	decreased interleukin-6 secretion	J:177785
	decreased tumor necrosis factor secretion	J:177785
	increased mast cell degranulation	J:177785
	increased susceptibility to type I hypersensitivity reaction	J:177785
\Coro1a^tm1Jpie/\Coro1a^tm1Jpie (involves: 129 * C57BL/6)	abnormal T cell activation	J:133258
	abnormal thymocyte activation	J:133258
	decreased B cell number	J:133258
	decreased CD4-positive, alpha-beta T cell number	J:133258
	decreased CD8-positive, alpha-beta T cell number	J:133258
	decreased interleukin-2 secretion	J:133258
	decreased monocyte cell number	J:133258
	decreased susceptibility to bacterial infection	J:133404
	decreased T cell proliferation	J:133258
	impaired macrophage phagocytosis	J:133404
\Coro1b^tm1.1Nfoe/\Coro1b^tm1.1Nfoe (B6N.129X1-Coro1b^tm1.1Nfoe)	immune system phenotype	J:177785
\Coro1c^{tm1a(KOMP)Wtsi}/\Coro1c^{tm1a(KOMP)Wtsi} (C57BL/6N-Coro1c^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Cotl1^{tm1b(EUCOMM)Hmgu}/\Cotl1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cotl1^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Cox4i2^tm1Hutt/\Cox4i2⁺ (B6.129-Cox4i2^tm1Hutt)	lung inflammation	J:187640
\Cox4i2^tm1Hutt/\Cox4i2^tm1Hutt (B6.129-Cox4i2^tm1Hutt)	immune system phenotype	J:233986
\Cox4i2^tm1Hutt/\Cox4i2^tm1Hutt (B6.129-Cox4i2^tm1Hutt)	lung inflammation	J:187640
\Cox6b1^em1(IMPC)Tcp/\Cox6b1⁺ (C57BL/6NCrl-Cox6b1^em1(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
\Cox10^tm1Ctm/\Cox10^tm1Ctm \Slc6a3^{tm1.1(cre)Bkmn}/? (B6.Cg-Cox10^tm1Ctm Slc6a3^{tm1.1(cre)Bkmn})	abnormal chemokine secretion	J:231810
	increased interleukin-1 beta secretion	J:231810
	increased microglial cell activation	J:231810
	microgliosis	J:231810
\Cox19^{tm1b(EUCOMM)Hmgu}/\Cox19⁺ (C57BL/6N-Cox19^{tm1b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
\Cp^tm1Hrs/\Cp^tm1Hrs (involves: 129X1/SvJ * Black Swiss)	increased spleen iron level	J:57730
\Cp^tm1Hrs/\Cp^tm1Hrs \Heph^sla/Y (involves: 129X1/SvJ * C57BL/6)	eye inflammation	J:136925
\Cp^tm1Yos/\Cp^tm1Yos (involves: 129P2/OlaHsd * BALB/c)	abnormal Kupffer cell morphology	J:79916
\Cpa1^tm1.1Satom/\Cpa1^tm1.1Satom (involves: C57BL/6NCrl * FVB/N)	pancreas inflammation	J:300042
\Cpa3^tm1Hrr/\Cpa3^tm1Hrr (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:99367
\Cpa3^tm3(icre)Hrr/\Cpa3⁺ (B6.129P2-Cpa3^tm3(icre)Hrr)	abnormal inflammatory response	J:178942
	absent mast cells	J:178942
	decreased basophil cell number	J:178942
	immune system phenotype	J:178942
\Cpa3^tm3(icre)Hrr/\Cpa3⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:178942
\Cpa3^tm3(icre)Hrr/\Cpa3⁺ \Fgfr1^tm1Upir/\Fgfr1^tm1Upir \Fgfr2^tm1Dor/\Fgfr2^tm1Dor \Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)	absent mast cells	J:221184
	skin inflammation	J:221184
\Cpa3^tm3(icre)Hrr/\Cpa3⁺ \Gt(ROSA)26Sor^tm1Hjf/? \Notch1^tm1Agt/\Notch1^tm1Agt (involves: 129 * C57BL/6)	abnormal dendritic cell differentiation	J:143731
	abnormal T cell receptor beta chain V(D)J recombination	J:143731
\Cpa3^tm3(icre)Hrr/\Cpa3⁺ \Notch1^tm1Agt/\Notch1^tm1Agt (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:143731
	abnormal B cell morphology	J:143731
	abnormal T cell receptor beta chain V(D)J recombination	J:143731
	decreased double-negative T cell number	J:143731
	decreased double-positive T cell number	J:143731
	increased single-positive T cell number	J:143731
	thymus hypoplasia	J:143731
\Cpap^{tm1a(EUCOMM)Wtsi}/\Cpap^{tm1a(EUCOMM)Wtsi} (B6Brd;B6N-Tyr^c-Brd Cpap^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased CD8-positive, alpha-beta T cell number	J:194085
	increased T cell number	J:194085
\Cpb2^tm1Efp/\Cpb2⁺ \Plg^tm1Dco/\Plg⁺ (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
\Cpb2^tm1Efp/\Cpb2^tm1Efp \Plg^tm1Dco/\Plg⁺ (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
\Cpb2^tm1Mng/\Cpb2^tm1Mng (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal chemokine level	J:107340
	abnormal tumor necrosis factor level	J:107340
\Cpb2^tm1Nok/\Cpb2^tm1Nok (involves: 129P2/OlaHsd * BALB/c)	impaired complement alternative pathway	J:93733
\Cpb2^tm1Nok/\Cpb2^tm1Nok (involves: 129P2/OlaHsd * BALB/c)	increased inflammatory response	J:93733
\Cpe^{tm1b(EUCOMM)Hmgu}/\Cpe^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cpe^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Cpgi5563^{tm1.1(NCC)Wcs}/\Cpgi5563^{tm1.1(NCC)Wcs} (C57BL/6N-Cpgi5563^{tm1.1(NCC)Wcs}/Wtsi)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:277622
	decreased CD8-positive, alpha-beta T cell number	J:277622
	decreased effector memory CD4-positive, alpha-beta T cell number	J:277622
	decreased gamma-delta T cell number	J:277622
\Cplane2^b2b2827Clo/\Cplane2^b2b2827Clo (C57BL/6J-Cplane2^b2b2827Clo)	thymus hypoplasia	J:175213
\Cpm^{em1(IMPC)Ccpcz}/\Cpm^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Cpm^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD8-positive, alpha-beta T cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
\Cpn1^tm1Raw/\Cpn1^tm1Raw (B6.129S1-Cpn1^tm1Raw)	abnormal complement pathway	J:148315
\Cpn1^tm1Raw/\Cpn1^tm1Raw (B6.129S1-Cpn1^tm1Raw)	increased acute inflammation	J:148315
\Cpne5^{tm2b(EUCOMM)Hmgu}/\Cpne5^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Cpne5^{tm2b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Cpox^Rbc16/\Cpox⁺ (involves: C57BL/6)	enlarged spleen	J:244493
\Cpox^Rbc16/\Cpox⁺ (involves: C57BL/6)	increased spleen red pulp amount	J:244493
\Cpq^em1(IMPC)Tcp/\Cpq^em1(IMPC)Tcp (C57BL/6N-Cpq^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Cps1^em1(IMPC)H/\Cps1⁺ (C57BL/6NTac-Cps1^em1(IMPC)H/H)	decreased neutrophil cell number	J:211773
\Cps1^em1(IMPC)H/\Cps1⁺ (C57BL/6NTac-Cps1^em1(IMPC)H/H)	increased lymphocyte cell number	J:211773
\Cpsf6^em1Bcgen/\Cpsf6⁺ (Not Specified)	decreased susceptibility to Riboviria infection	J:346988
\Cpsf6^em1Bcgen/\Cpsf6⁺ (Not Specified)	increased interferon-beta secretion	J:346988
\Cpt1c^Gt(XL823)Byg/\Cpt1c⁺ \Nf1^tm1Tyj/\Nf1⁺ \Trp53^tm1Tyj/\Trp53⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	spleen hyperplasia	J:228258
\Cpt2^{tm1b(KOMP)Wtsi}/\Cpt2^{tm1b(KOMP)Wtsi} (C57BL/6N-Cpt2^{tm1b(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Cpvl^em1(IMPC)Tcp/\Cpvl^em1(IMPC)Tcp (C57BL/6NCrl-Cpvl^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Cpxm1^em1(IMPC)Tcp/\Cpxm1^em1(IMPC)Tcp (C57BL/6N-Cpxm1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
\Cr1l^tm1.1Song/\Cr1l^tm1.1Song \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:146538
	decreased CD8-positive, alpha-beta T cell number	J:146538
	decreased lymphocyte cell number	J:146538
	increased B cell number	J:146538
	lymph node hypoplasia	J:146538
\Cr1l^tm1.1Song/\Cr1l^tm1.1Song \Tg(Lck-cre)548Jxm/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:146538
	decreased CD8-positive, alpha-beta T cell number	J:146538
	decreased lymphocyte cell number	J:146538
	increased B cell number	J:146538
	lymph node hypoplasia	J:146538
\Cr1l^tm1.1Song/\Cr1l^tm1.1Song \Vsig4^tm1Gne/\Vsig4^tm1Gne \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6N * DBA/2 * SJL)	decreased lymphocyte cell number	J:146538
\Cr1l^tm1Hmo/\Cr1l^tm1Hmo (involves: 129X1/SvJ)	increased inflammatory response	J:59432
\Cr2^M1Btlr/\Cr2^M1Btlr (C57BL/6J-Cr2^M1Btlr)	decreased IgG level	J:267527
\Cr2^M1Btlr/\Cr2^M1Btlr (C57BL/6J-Cr2^M1Btlr)	impaired humoral immune response	J:267527
\Cr2^tm1.1Jhws/\Cr2^tm1.1Jhws (B6.Cg-Cr2^tm1.1Jhws)	immune system phenotype	J:155241
\Cr2^tm1.1Jhws/\Cr2^tm1.1Jhws (Not Specified)	abnormal germinal center B cell physiology	J:205353
	decreased B-1a cell number	J:205353
	decreased IgG2b level	J:205353
	decreased IgG2c level	J:205353
	decreased IgG3 level	J:205353
	decreased IgM level	J:205353
	immune system phenotype	J:205353
	increased susceptibility to bacterial infection induced morbidity/mortality	J:205353
\Cr2^tm1Crr/\Cr2^tm1Crr (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B-1 B cell morphology	J:31942
	abnormal humoral immune response	J:31942, J:69452
	abnormal immune system morphology	J:69452
	abnormal spleen germinal center morphology	J:31942
	decreased B cell number	J:31942
	decreased B-1a cell number	J:69452
	decreased IgG2a level	J:31942
	decreased IgG2b level	J:31942
	decreased IgG3 level	J:31942
	decreased IgG level	J:31942, J:69452
	decreased IgM level	J:69452
	decreased immunoglobulin level	J:69452
	decreased neutrophil cell number	J:66111
	decreased spleen germinal center number	J:31942, J:69452
	decreased spleen germinal center size	J:31942
	decreased tumor necrosis factor secretion	J:66111
	immune system phenotype	J:31942
\Cr2^tm1Crr/\Cr2^tm1Crr (involves: 129S7/SvEvBrd * C57BL/6J)	increased anti-double stranded DNA antibody level	J:111811
\Cr2^tm1Crr/\Cr2^tm1Crr (involves: 129S7/SvEvBrd)	decreased follicular B cell number	J:69477
\Cr2^tm1Crr/\Cr2^tm1Crr (involves: 129S7/SvEvBrd)	increased marginal zone B cell number	J:69477
\Cr2^tm1Crr/\Cr2^tm1Crr \Ggta1^tm1Jbl/\Ggta1^tm1Jbl (involves: 129S2/SvPas * 129S7/SvEvBrd)	abnormal humoral immune response	J:113488
\Cr2^tm1Hmo/\Cr2^tm1Hmo (involves: 129S7/SvEvBrd)	decreased IgG level	J:35112
\Cr2^tm1Hmo/\Cr2^tm1Hmo (involves: 129S7/SvEvBrd)	decreased IgM level	J:35112
\Cr2^tm1Hmo/\Cr2^tm1Hmo (B6.129S7-Cr2^tm1Hmo)	increased susceptibility to bacterial infection	J:94855
\Cr2^tm1Hmo/\Cr2^tm1Hmo (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell activation	J:151991
	abnormal B cell physiology	J:151991
	abnormal class switch recombination	J:151991
	abnormal memory B cell differentiation	J:151991
\Cr2^tm1Tft/\Cr2^tm1Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal adaptive immunity	J:95979
	decreased IgG1 level	J:95979
	decreased IgG2b level	J:95979
	decreased IgG3 level	J:95979
	decreased IgG level	J:95979
	decreased IgM level	J:95979
	decreased spleen germinal center number	J:95979
	increased susceptibility to bacterial infection	J:95979
\Cr2^{tm2.1(HLA-A)Crr}/\Cr2^{tm2.1(HLA-A)Crr} (involves: C57BL/6)	abnormal B cell physiology	J:151991
	abnormal class switch recombination	J:151991
	abnormal memory B cell differentiation	J:151991
\Cr2^{tm2.1(HLA-A)Crr}/\Cr2^{tm2.1(HLA-A)Crr} \Tg(IghelMD4)4Ccg/? (involves: C57BL/6)	abnormal B cell activation	J:151991
\Cr2^tm2.1Jhws/\Cr2^tm2.1Jhws (B6.129-Cr2^tm2.1Jhws)	abnormal germinal center B cell physiology	J:205353
	decreased IgG3 level	J:205353
	decreased IgM level	J:205353
	immune system phenotype	J:205353
	increased IgM level	J:205353
\Crabp1^{tm1b(EUCOMM)Wtsi}/\Crabp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Crabp1^{tm1b(EUCOMM)Wtsi}/Tcp)	increased monocyte cell number	J:211773
\Cracr2a^tm1.1Ygwa/\Cracr2a^tm1.1Ygwa \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Cracr2a^tm1.1Ygwa Tg(Cd4-cre)1Cwi)	abnormal CD4-positive, alpha-beta T cell physiology	J:259523
	decreased interleukin-2 secretion	J:259523
\Crat^em1(IMPC)Bay/\Crat^em1(IMPC)Bay (C57BL/6N-Crat^em1(IMPC)Bay/Bay)	small lymph nodes	J:211773
\Crb1^rd8+em1Boc/\Crb1^rd8+em1Boc \Jak3^m1J/\Jak3^m1J (B6.Cg-Crb1^rd8+em1Boc Jak3^m1J/Boc)	small spleen	J:265859
	small thymus	J:265859
\Crb1^rd8/\Crb1^rd8 \Jak3^m1J/\Jak3^m1J (B6.Cg-Crb1^rd8 Jak3^m1J/BocJ)	decreased spleen weight	J:265859
	small spleen	J:265859
	small thymus	J:265859
\Crbn^tm1.1Ble/\Crbn^tm1.1Ble (involves: C57BL/6)	decreased B cell number	J:267091
	decreased granulocyte number	J:267091
	decreased leukocyte cell number	J:267091
	decreased T cell number	J:267091
\Creb3l2^{em1(IMPC)Ccpcz}/\Creb3l2⁺ (C57BL/6NCrl-Creb3l2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Creb3l3^tm1.1Sad/\Creb3l3^tm1.1Sad (involves: 129 * C57BL/6 * FVB/N)	decreased acute inflammation	J:140018
	decreased circulating serum amyloid protein level	J:140018
\Crebbp^{Gt(U-San)112Imeg}/\Crebbp⁺ (involves: C57BL/6 * CBA)	abnormal tumor necrosis factor level	J:75361
\Crebbp^tm1Dli/\Crebbp⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal granulocyte morphology	J:191503
	abnormal leukocyte morphology	J:191503
	absent pre-B cells	J:60630
	decreased B cell number	J:60630
	decreased lymphocyte cell number	J:191503
	enlarged spleen	J:191503, J:60630
	increased granulocyte number	J:191503
\Crebbp^tm1Jvd/\Crebbp^tm1Jvd \Ep300^tm2Pkb/\Ep300^tm2Pkb \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell number	J:105505
	decreased double-positive T cell number	J:105505
	increased double-negative T cell number	J:105505
\Crebbp^tm1Jvd/\Crebbp^tm1Jvd \Tg(Lck-cre)548Jxm/0 (involves: 129 * C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:105505
	decreased T cell number	J:105505
	decreased thymocyte number	J:105505
	increased double-positive T cell number	J:105505
	increased T cell derived lymphoma incidence	J:105505
	small thymus	J:105505
\Crebbp^tm1Jvd/\Crebbp^tm1Jvd \Tg(MMTV-cre)4Mam/0 (involves: 129 * C57BL/6 * FVB)	decreased double-positive T cell number	J:88323
	increased CD8-positive, alpha-beta T cell number	J:88323
	increased T cell derived lymphoma incidence	J:88323
\Crebbp^tm1Pkb/\Crebbp^tm1Pkb (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:98329
\Crh^tm1Maj/\Crh^tm1Maj (involves: 129S2/SvPas * C57BL/6)	abnormal cell-mediated immunity	J:98419
	abnormal cytokine secretion	J:98419
	abnormal inflammatory response	J:98419
	abnormal professional antigen presenting cell physiology	J:98419
	decreased inflammatory response	J:90690, J:72196
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:98419
	decreased T cell proliferation	J:98419
	increased circulating interleukin-6 level	J:72196
	increased splenocyte number	J:98419
\Crhr2^tm1Mpsp/\Crhr2^tm1Mpsp (involves: 129X1/SvJ * C57BL/6J)	immune system phenotype	J:61510
\cri/\cri (involves: DBA/2J)	decreased leukocyte cell number	J:6327
\cri/\cri (involves: DBA/2J)	decreased neutrophil cell number	J:6327
\Crim1^{em1(IMPC)Wtsi}/\Crim1^{em1(IMPC)Wtsi} (C57BL/6N-Crim1^{em1(IMPC)Wtsi}/WtsiOrl)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
\Crim1^{Gt(KST264)Byg}/\Crim1^{Gt(KST264)Byg} (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	kidney inflammation	J:172334
\Crip3^tm1Mjb/\Crip3^tm1Mjb (either: (involves: 129S/Sv) or (involves: 129S/Sv * C57BL/6))	decreased thymocyte number	J:72942
	small thymus	J:72942
	thymus hypoplasia	J:72942
\Crispld2^tm1Lex/\Crispld2^tm1Lex (B6;129S5-Crispld2^tm1Lex/Mmucd)	abnormal immune system morphology	J:171883
	abnormal immune system physiology	J:171883
\Crkl^tm1Imo/\Crkl^tm1Imo (involves: 129S4/SvJaeSor * C57BL/6J)	abnormal thymus development	J:67826
\Crl1^A/WySnJ/\Crl1^A/WySnJ (B10.A-H2^a/SgSnJ)	abnormal B cell physiology	J:5442
\Crl1^AKR/J/\Crl1^AKR/J (involves: AKR/J * DBA/2J)	abnormal B cell physiology	J:5442
\Crl1^DBA/2J/\Crl1^DBA/2J (involves: AKR/J * DBA/2J)	abnormal B cell physiology	J:5442
\Crlf2^em1(IMPC)Mbp/\Crlf2^em1(IMPC)Mbp (C57BL/6N-Crlf2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Crlf2^tm1Jni/\Crlf2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:89031
\Crlf2^tm1Jni/\Crlf2^tm1Jni (involves: 129P2/OlaHsd)	respiratory system inflammation	J:187770
\Crlf2^tm1Wjl/\Crlf2^tm1Wjl (involves: 129 * C57BL/6)	abnormal lymphopoiesis	J:108209
	decreased B cell number	J:108209
	decreased single-positive T cell number	J:108209
\Crlf2^tm1Wjl/\Crlf2^tm1Wjl (involves: BALB/c)	abnormal cytokine secretion	J:107431
	abnormal T cell proliferation	J:107431
	decreased immunoglobulin level	J:107431
	decreased splenocyte proliferation	J:107431
	lung inflammation	J:107431
\Crlf2^tm1Wjl/\Crlf2^tm1Wjl (Not Specified)	colitis	J:175844
\Crocc2^{em1(IMPC)Ccpcz}/\Crocc2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Crocc2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Crocc^tm1Tili/\Crocc^tm1Tili (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	lung inflammation	J:98885
\Crot^em1Akw/\Crot^em1Akw \Ldlr^tm1Her/\Ldlr^tm1Her (B6.Cg-Crot^em1Akw Ldlr^tm1Her)	blood vessel inflammation	J:331161
\Crp^tm1Hjf/\Crp⁺ (C57BL/6-Crp^tm1Hjf)	decreased circulating C-reactive protein level	J:170409
\Crp^tm1Hjf/\Crp^tm1Hjf (C57BL/6-Crp^tm1Hjf)	decreased circulating C-reactive protein level	J:170409
\Crppa^em1(IMPC)H/\Crppa⁺ (C57BL/6NTac-Crppa^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Crsl/\Crsl⁺ (involves: C3HeB/FeJ)	keratoconjunctivitis sicca	J:104123
\Crtam^tm1Achn/\Crtam^tm1Achn (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:145314
	abnormal interleukin secretion	J:145314
	abnormal T cell activation	J:145314
	abnormal T-helper 1 physiology	J:145314
	decreased interferon-gamma secretion	J:145314
	decreased interleukin-17 secretion	J:145314
	increased CD4-positive, alpha-beta T cell number	J:145314
	increased CD8-positive, alpha-beta T cell number	J:145314
	increased susceptibility to bacterial infection	J:145314
	increased T cell proliferation	J:145314
\Crtam^tm1Tks/\Crtam^tm1Tks (B6.Cg-Crtam^tm1Tks)	abnormal response to infection	J:152770
\Crtam^tm1Tks/\Crtam^tm1Tks (B6.Cg-Crtam^tm1Tks)	immune system phenotype	J:152770
\Crtc1^{tm1a(EUCOMM)Wtsi}/\Crtc1⁺ (C57BL/6N-Crtc1^{tm1a(EUCOMM)Wtsi}/Ics)	increased IgG2b level	J:165965
\Crx^{em1(IMPC)Ccpcz}/\Crx^{em1(IMPC)Ccpcz} (C57BL/6N-Crx^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased NK cell number	J:211773
	small thymus	J:211773
\Cry1^em1(IMPC)H/\Cry1^em1(IMPC)H (C57BL/6N-Cry1^em1(IMPC)H/H)	increased leukocyte cell number	J:211773
\Cry1^tm1Jhjh/\Cry1^tm1Jhjh \Cry2^tm1Jhjh/\Cry2^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell activation	J:159504
	increased circulating interleukin-1 beta level	J:159504
	increased circulating interleukin-6 level	J:159504
	increased circulating tumor necrosis factor level	J:159504
	increased susceptibility to induced arthritis	J:159504
	increased tumor necrosis factor secretion	J:159504
\Cry2^tm1Jhjh/\Cry2^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast physiology	J:163112
\Csf1^op/\Csf1^op (C57BL/6J-Csf1^op)	abnormal osteoclast morphology	J:5634
	abnormal spleen red pulp morphology	J:5634
	decreased macrophage cell number	J:110981
	decreased osteoclast cell number	J:5634
\Csf1^op/\Csf1^op (B6C3Fe a/a-Csf1^op/J)	abnormal Kupffer cell morphology	J:26978
	abnormal Langerhans cell morphology	J:112594
	abnormal Langerhans cell physiology	J:112594
	abnormal microglial cell morphology	J:49613
	abnormal osteoclast differentiation	J:19549, J:4732
	abnormal osteoclast morphology	J:26978
	abnormal perivascular macrophage morphology	J:49613
	abnormal spleen red pulp morphology	J:26978
	abnormal splenic cell ratio	J:104139
	abnormal splenocyte physiology	J:19549
	absent Langerhans cell	J:112594
	decreased leukocyte cell number	J:104139
	decreased macrophage cell number	J:26978, J:104139
	decreased monocyte cell number	J:104139
	decreased osteoclast cell number	J:73663
	thymus cortex hypoplasia	J:26978
	thymus medulla atrophy	J:26978
\Csf1^op/\Csf1^op (involves: C3HeB/FeJ * C57BL/6J)	abnormal osteoclast cell number	J:33189
	abnormal osteoclast differentiation	J:38039
	decreased osteoclast cell number	J:33189
\Csf1^op/\Csf1^op (B6;C3Fe a/a-Csf1^op/J)	abnormal microglial cell morphology	J:170081
	decreased macrophage cell number	J:30863, J:147697
	impaired macrophage chemotaxis	J:147697
\Csf1^op/\Csf1^op \Csf2^tm1Ard/\Csf2^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:19089
	increased neutrophil cell number	J:19089
	interstitial pneumonia	J:19089
	lung inflammation	J:19089
\Csf1^op/\Csf1^op \Galc^twi/\Galc^twi (involves: C3HeB/Fe * C57BL/6J * CE/J)	impaired macrophage chemotaxis	J:170081
\Csf1^op/\Csf1^op \Mpz^tm1Msch/\Mpz⁺ (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:67581
\Csf1^op/\Csf1^op \Sh3bp2^tm1Bjro/\Sh3bp2^tm1Bjro (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal lymph node cell ratio	J:117880
	increased circulating tumor necrosis factor level	J:117880
	liver inflammation	J:117880
\Csf1^{tm1.1(CSF1)Flv}/\Csf1^{tm1.1(CSF1)Flv} \Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/\Csf2/Il3^{tm1.1(CSF2,IL3)Flv} \Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Rag2^tm1.1Flv/\Rag2^tm1.1Flv \Tg(SIRPA)1Flv/0 \Thpo^{tm1.1(TPO)Flv}/\Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
\Csf1^{tm1.1(CSF1)Flv}/\Csf1^{tm1.1(CSF1)Flv} \Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/\Csf2/Il3^{tm1.1(CSF2,IL3)Flv} \Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Rag2^tm1.1Flv/\Rag2^tm1.1Flv \Thpo^{tm1.1(TPO)Flv}/\Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
\Csf1^{tm1.1(CSF1)Flv}/\Csf1^{tm1.1(CSF1)Flv} \Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/\Csf2/Il3^{tm1.1(CSF2,IL3)Flv} \Rag2^tm1.1Flv/\Rag2^tm1.1Flv \Tg(SIRPA)1Flv/0 \Thpo^{tm1.1(TPO)Flv}/\Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
\Csf1^{tm1.1(CSF1)Flv}/\Csf1^{tm1.1(CSF1)Flv} \Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/\Csf2/Il3^{tm1.1(CSF2,IL3)Flv} \Rag2^tm1.1Flv/\Rag2^tm1.1Flv \Thpo^{tm1.1(TPO)Flv}/\Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:207289
\Csf1^{tm1.1(CSF1)Flv}/\Csf1^{tm1.1(CSF1)Flv} \Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Rag2^tm1.1Flv/\Rag2^tm1.1Flv (involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * BALB/cAnNTac)	abnormal immune system physiology	J:177073
	immune system phenotype	J:177073
\Csf1^tm1.2Sabw/\Csf1^tm1.2Sabw (involves: 129S4/SvJaeSor * C57BL/6)	abnormal Kupffer cell morphology	J:180199
	abnormal myeloid leukocyte morphology	J:180199
	decreased B cell number	J:180199
	decreased lymphocyte cell number	J:180199
	decreased macrophage cell number	J:180199
	decreased monocyte cell number	J:180199
	decreased osteoclast cell number	J:180199
	decreased spleen weight	J:180199
	increased granulocyte number	J:180199
	increased T cell number	J:180199
	small spleen	J:180199
\Csf1r^tm1Ers/\Csf1r⁺ (B6.129X1-Csf1r^tm1Ers)	microgliosis	J:219294
\Csf1r^tm1Ers/\Csf1r^tm1Ers (involves: 129X1/SvJ * C3Heb/FeJ * C57BL/6J)	abnormal circulating cytokine level	J:73663
	abnormal leukocyte cell number	J:73663
	abnormal osteoclast differentiation	J:73663
	abnormal spleen morphology	J:73663
	decreased Langerhans cell number	J:73663
	decreased lymphocyte cell number	J:73663
	decreased macrophage cell number	J:73663
	decreased monocyte cell number	J:73663
	increased granulocyte number	J:73663
	increased spleen weight	J:73663
\Csf1r^tm1Ers/\Csf1r^tm1Ers (FVB.129X1-Csf1r^tm1Ers)	abnormal Langerhans cell physiology	J:112594
	abnormal macrophage differentiation	J:112594
	abnormal osteoclast morphology	J:111489
	absent Langerhans cell	J:112594
\Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/\Csf2/Il3^{tm1.1(CSF2,IL3)Flv} \Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Rag2^tm1.1Flv/\Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)	abnormal response to transplant	J:168302
\Csf2^tm1Ard/\Csf2^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	abnormal alveolar macrophage morphology	J:18747
	abnormal leukocyte physiology	J:86386
	abnormal MHC II cell surface expression on macrophages	J:86386
	abnormal spleen size	J:67766
	impaired macrophage chemotaxis	J:86386
	increased susceptibility to bacterial infection	J:18747, J:53659
	increased susceptibility to fungal infection	J:18747
	increased susceptibility to parasitic infection	J:67766
	lung inflammation	J:18747
	lymphoid hyperplasia	J:18747
\Csf2^tm1Dran/\Csf2^tm1Dran \Ifng^tm1Ts/\Ifng^tm1Ts \Il3^tm1Glli/\Il3^tm1Glli (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)	increased eosinophil cell number	J:83086
	increased IgE level	J:83086
	increased IgG1 level	J:83086
	increased immunoglobulin level	J:83086
	increased inflammatory response	J:83086
\Csf2^tm1Dran/\Csf2^tm1Dran \Il3^tm1Glli/\Il3^tm1Glli (B6.129S2-Csf2^tm1Dran Il3^tm1Glli)	abnormal leukocyte physiology	J:83086
	decreased susceptibility to type IV hypersensitivity reaction	J:67404
	glomerulonephritis	J:83086
	increased anti-double stranded DNA antibody level	J:83086
	increased eosinophil cell number	J:67404
	lung inflammation	J:67404
\Csf2^tm1Dran/\Csf2^tm1Dran \Il3^tm1Glli/\Il3^tm1Glli (C.129S2-Csf2^tm1Dran Il3^tm1Glli)	decreased susceptibility to type IV hypersensitivity reaction	J:67404
	increased eosinophil cell number	J:67404
	lung inflammation	J:67404
\Csf2^tm1Mlg/\Csf2^tm1Mlg (involves: 129S2/SvPas)	abnormal alveolar macrophage morphology	J:17978
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:148120
	lymphoid hyperplasia	J:17978
\Csf2ra^em1Szut/\Csf2ra^em1Szut (C57BL/6-Csf2ra^em1Szut)	abnormal alveolar macrophage morphology	J:322934
	impaired macrophage phagocytosis	J:322934
	increased lymphocyte cell number	J:322934
	lung inflammation	J:322934
\Csf2rb^tm1Cgb/\Csf2rb^tm1Cgb (involves: 129S1/Sv * C57BL/6)	decreased eosinophil cell number	J:29737
	lung inflammation	J:29737
\Csf2rb^tm1Clsc/\Csf2rb^tm1Clsc \Csf2rb2^tm1Cgb/\Csf2rb2^tm1Cgb (C.129S1-Csf2rb2^tm1Cgb Csf2rb^tm1Clsc)	abnormal dendritic cell physiology	J:130939
	abnormal interleukin secretion	J:130939
	abnormal plasmacytoid dendritic cell physiology	J:130939
	abnormal T cell activation	J:130939
	abnormal T cell physiology	J:130939
	decreased interleukin-4 secretion	J:130939
	decreased interleukin-5 secretion	J:130939
	decreased interleukin-13 secretion	J:130939
	decreased susceptibility to type I hypersensitivity reaction	J:130939
	decreased T cell proliferation	J:130939
	impaired eosinophil recruitment	J:130939
	increased IgG1 level	J:130939
	lymph node hyperplasia	J:130939
\Csf2rb^tm1Mur/\Csf2rb^tm1Mur (involves: 129P2/OlaHsd * C57BL/6)	abnormal eosinophil physiology	J:35829
	decreased eosinophil cell number	J:35829
	lung inflammation	J:35829
\Csf2rb^tm1Mur/\Csf2rb^tm1Mur (involves: 129P2/OlaHsd)	abnormal eosinophil physiology	J:24122
	decreased eosinophil cell number	J:24122
	increased susceptibility to infection	J:24122
	lung inflammation	J:24122
\Csf2rb^tm1Mur/\Csf2rb^tm1Mur \Il3^tm1Tyb/\Il3^tm1Tyb (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal eosinophil physiology	J:35829
	decreased eosinophil cell number	J:35829
	lung inflammation	J:35829
\Csf2rb^{tm2b(EUCOMM)Hmgu}/\Csf2rb⁺ (C57BL/6N-Csf2rb^{tm2b(EUCOMM)Hmgu}/Orl)	increased eosinophil cell number	J:211773
\Csf3^em1(IMPC)H/\Csf3^em1(IMPC)H (C57BL/6NTac-Csf3^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Csf3^tm1Ard/\Csf3⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased neutrophil cell number	J:20400
\Csf3^tm1Ard/\Csf3^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:20400
	decreased leukocyte cell number	J:20400
	decreased monocyte cell number	J:20400
	decreased neutrophil cell number	J:20400
	impaired myelopoiesis	J:20400
	increased susceptibility to bacterial infection	J:20400
\Csf3^tm1Ard/\Csf3^tm1Ard \Junb^tm3Wag/\Junb^tm3Wag \Tg(KRT5-cre)1Tak/0 (involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)	increased susceptibility to systemic lupus erythematosus	J:155575
\Csf3r^tm1Eur/\Csf3r^tm1Eur (involves: 129P2/OlaHsd * C57BL/6 * FVB)	abnormal neutrophil differentiation	J:48503
	decreased neutrophil cell number	J:48503
\Csf3r^tm1Link/\Csf3r^tm1Link (involves: 129X1/SvJ * NIH Black Swiss)	abnormal monocyte morphology	J:37618
	decreased monocyte cell number	J:37618
	decreased neutrophil cell number	J:37618
\Csf3r^tm1Link/\Csf3r^tm1Link (involves: 129X1/SvJ)	impaired neutrophil chemotaxis	J:79825
\Csf3r^tm1Link/\Csf3r^tm1Link (B6.129X1-Csf3r^tm1Link)	impaired neutrophil chemotaxis	J:79567
\Csf3r^tm2Eur/\Csf3r^tm2Eur (involves: 129P2/OlaHsd * FVB)	decreased neutrophil cell number	J:185115
\Csf3r^tm2Link/\Csf3r⁺ \Elane^tm1Link/\Elane⁺ (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:131496
\Csf3r^tm2Link/\Csf3r^tm2Link (B6.129X1-Csf3r^tm2Link)	abnormal neutrophil physiology	J:79567
\Csf3r^tm3Link/\Csf3r^tm3Link (B6.129X1-Csf3r^tm3Link)	immune system phenotype	J:79567
\Csf3r^tm3Link/\Csf3r^tm3Link (involves: 129X1/SvJ * C57BL/6)	decreased neutrophil cell number	J:67612
\Csf3r^{tm4(Epor)Link}/\Csf3r^{tm4(Epor)Link} (involves: 129X1/SvJ * C57BL/6)	decreased granulocyte number	J:79825
	decreased neutrophil cell number	J:79825
	impaired neutrophil chemotaxis	J:79825
\Csf3r^{tm4(Epor)Link}/\Csf3r^{tm4(Epor)Link} (B6.129X1-Csf3r^{tm4(Epor)Link})	decreased neutrophil cell number	J:79567
	impaired neutrophil chemotaxis	J:79567
\Csgalnact1^tm1.1Migar/\Csgalnact1^tm1.1Migar (involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)	periodontium inflammation	J:269621
\Csk^tm1Sor/\Csk⁺ \Ptprc^ltng/\Ptprc^ltng (involves: 129S7/SvEvBrd * C57BL/6)	thymus hypoplasia	J:158876
\Csk^tm1Sor/\Csk⁺ \Ptprc^ltng/\Ptprc^tm1Mak (involves: 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:158876
	thymus hypoplasia	J:158876
\Csk^tm1Tara/\Csk^tm1Tara \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CB20 * CBA)	abnormal CD4-positive T cell differentiation	J:49654
	absent CD8-positive, alpha-beta T cells	J:49654
	enlarged thymus	J:49654
\Csk^tm1Tara/\Csk^tm2Tara \Elane^tm1(cre)Roes/\Elane⁺ (involves: 129P2/OlaHsd * CB20 * C57BL/6)	abnormal granulocyte physiology	J:89716
	abnormal myelopoiesis	J:89716
	increased acute inflammation	J:89716
	increased susceptibility to bacterial infection	J:89716
\Csmd3^em1(IMPC)Mbp/\Csmd3^em1(IMPC)Mbp (C57BL/6NCrl-Csmd3^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Csnk1a1^{tm1c(KOMP)Wtsi}/\Csnk1a1^{tm1c(KOMP)Wtsi} \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * CBA)	abnormal spleen red pulp morphology	J:216977
	bone marrow failure	J:216977
\Csnk1g1^em1(IMPC)J/\Csnk1g1^em1(IMPC)J (C57BL/6NJ-Csnk1g1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Csnk2a2^em1(IMPC)Mbp/\Csnk2a2^em1(IMPC)Mbp (C57BL/6N-Csnk2a2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Cspg4^tm1Wbst/\Cspg4^tm1Wbst (involves: 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:184220
\Cspt^C57BL/6/\Cspt^C57BL/6 (involves: C57BL/6 * NOD/ShLtDoi * SJL)	increased CD8-positive, alpha-beta T cell number	J:97046
\Cspt^C57BL/6/\Cspt^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	increased CD8-positive, alpha-beta T cell number	J:97046
\Csrnp1^tm1Jni/\Csrnp1^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
\Csrnp1^tm1Jni/\Csrnp1^tm1Jni \Csrnp2^tm1Jni/\Csrnp2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
\Csrnp2^tm1Jni/\Csrnp2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
\Csrnp3^tm1Jni/\Csrnp3^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:129366
\Cst6^{em1(IMPC)Ccpcz}/\Cst6⁺ (C57BL/6NCrl-Cst6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Cst7^tm1.2Arte/\Cst7^tm1.2Arte (involves: C57BL/6)	abnormal eosinophil morphology	J:258944
	abnormal eosinophil physiology	J:258944
	abnormal hypersensitivity reaction	J:258944
	decreased eosinophil cell number	J:258944
	increased susceptibility to parasitic infection	J:258944
\Cstb^{tm1b(EUCOMM)Wtsi}/\Cstb^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cstb^{tm1b(EUCOMM)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Cstb^tm1Rm/\Cstb^tm1Rm (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	increased incidence of corneal inflammation	J:50587
	uveitis	J:50587
\Ct55^em1Xdzg/\Ct55^em1Xdzg (involves: C57BL/6)	decreased susceptibility to induced colitis	J:280149
\Ctbs^tm1Tbec/\Ctbs^tm1Tbec (involves: 129S2/SvPas * C57BL/6N)	abnormal Kupffer cell morphology	J:185162
\Ctc1^tm1.1Schg/\Ctc1^tm1.1Schg (involves: 129S7/SvEvBrd * C57BL/6)	decreased splenocyte proliferation	J:184809
	small spleen	J:184809
	small thymus	J:184809
\Ctcf^tm2Gal/\Ctcf⁺ \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased CD8-positive, alpha-beta T cell number	J:143271
	thymus hypoplasia	J:143271
\Ctcf^tm2Gal/\Ctcf^tm2Gal \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6 * C57BL/10)	decreased double-positive T cell number	J:143271
\Ctcf^tm2Gal/\Ctcf^tm2Gal \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:143271
	abnormal T cell morphology	J:143271
	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased CD8-positive, alpha-beta T cell number	J:143271
	decreased double-positive T cell number	J:143271
	decreased single-positive T cell number	J:143271
	increased double-negative T cell number	J:143271
	increased single-positive T cell number	J:143271
	thymus hypoplasia	J:143271
\Ctcf^tm2Gal/\Ctcf^tm2Gal \Tg(Lck-cre)1Cwi/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * DBA/2J)	abnormal T cell differentiation	J:143271
	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased CD8-positive, alpha-beta T cell number	J:143271
	decreased double-positive T cell number	J:143271
\Ctcf^tm2Gal/\Ctcf^tm2Gal \Tg(Lck-cre)1Cwi/0 \Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:143271
	decreased CD4-positive, alpha-beta T cell number	J:143271
	decreased double-positive T cell number	J:143271
	decreased T cell number	J:143271
	increased double-negative T cell number	J:143271
	increased single-positive T cell number	J:143271
\Ctdspl2^{tm2b(KOMP)Wtsi}/\Ctdspl2⁺ (C57BL/6N-Ctdspl2^{tm2b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
\ctl/\ctl (A/WySnJ-ctl/GrsrJ)	autoimmune arthritis	J:91389
\Ctl1^NZB/BlN/\Ctl1^C57BL/10 (involves: C57BL/10 * NZB/BlN)	abnormal T cell physiology	J:6736
\Ctla4^m1Btlr/\Ctla4^m1Btlr (C57BL/6J-Ctla4^m1Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:265263
	increased effector memory CD4-positive, alpha-beta T cell number	J:265263
	increased effector memory CD8-positive, alpha-beta T cell number	J:265263
\Ctla4^tm1All/\Ctla4^tm1All (involves: 129S1/Sv * 129X1/SvJ)	abnormal thymus morphology	J:42481
	decreased double-positive T cell number	J:42481
	decreased T cell number	J:42481
	increased double-negative T cell number	J:42481
	lymph node hypoplasia	J:42481
\Ctla4^tm1All/\Ctla4^tm1All (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD)	increased acute inflammation	J:109887
\Ctla4^tm1All/\Ctla4^tm1All \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcrAND)53Hed/0 (involves: 129S/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal T cell activation	J:119845
	increased interleukin-4 secretion	J:119845
	increased T cell proliferation	J:119845
\Ctla4^tm1All/\Ctla4^tm1All \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraTcrb)8Rest/0 (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)	immune system phenotype	J:140448
\Ctla4^tm1All/\Ctla4^tm1All \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD * SJL)	abnormal splenocyte physiology	J:109887
	enlarged spleen	J:109887
	increased acute inflammation	J:109887
	insulitis	J:109887
\Ctla4^tm1All/\Ctla4^tm1All \Tg(TcrAND)53Hed/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal lymphopoiesis	J:119845
	abnormal T cell activation	J:119845
	abnormal T cell subpopulation ratio	J:119845
	increased CD4-positive, alpha-beta T cell number	J:119845
	increased CD8-positive, alpha-beta T cell number	J:119845
\Ctla4^tm1All/\Ctla4^tm1All \Tg(TcraTcrb)8Rest/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:140448
	increased CD4-positive, alpha-beta T cell number	J:140448
	increased interferon-gamma secretion	J:140448
\Ctla4^tm1Mak/\Ctla4^tm1Mak (involves: 129P2/OlaHsd * BALB/c)	increased interferon-gamma secretion	J:140085
	increased interleukin-2 secretion	J:140085
	increased interleukin-4 secretion	J:140085
	increased interleukin-17 secretion	J:140085
\Ctla4^tm1Saka/\Ctla4^tm1Saka \Foxp3^tm1(cre)Saka/Y (involves: BALB/c)	abnormal immunoglobulin level	J:140085
	abnormal regulatory T cell physiology	J:140085
	abnormal splenic cell ratio	J:140085
	increased autoantibody level	J:140085
	increased IgE level	J:140085
	increased IgG level	J:140085
	increased inflammatory response	J:140085
	increased interferon-gamma secretion	J:140085
	increased interleukin-2 secretion	J:140085
	increased interleukin-4 secretion	J:140085
	increased regulatory T cell number	J:140085
	lung inflammation	J:140085
	lymph node hyperplasia	J:140085
	myocarditis	J:140085
	salivary gland inflammation	J:140085
	spleen hyperplasia	J:140085
	stomach inflammation	J:140085
\Ctla4^tm1Shr/\Ctla4^tm1Shr (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	abnormal cytokine secretion	J:30393
	abnormal lymph node cell ratio	J:30393
	abnormal splenic cell ratio	J:30393
	abnormal T cell differentiation	J:30393
	abnormal T cell morphology	J:30393
	decreased double-positive T cell number	J:30393
	enlarged lymph nodes	J:30393
	enlarged spleen	J:30393
	increased double-negative T cell number	J:30393
	increased T cell number	J:30393
	increased T cell proliferation	J:30393
	joint inflammation	J:30393
	lung inflammation	J:30393
	myocarditis	J:30393
	pancreas inflammation	J:30393
	salivary gland inflammation	J:30393
\Ctla4^tm1Shr/\Ctla4^tm1Shr (B6.129S4-Ctla4^tm1Shr)	abnormal regulatory T cell physiology	J:146644
	abnormal T cell physiology	J:146644
	autoimmune response	J:146644
\Ctla4^tm1Shr/\Ctla4^tm1Shr \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(DO11.10)10Dlo/0 (involves: 129S/Sv * BALB/c * C3H * C57BL/6)	abnormal cytokine secretion	J:110446
	abnormal T cell physiology	J:110446
	immune system phenotype	J:110446
\Ctla4^tm1Shr/\Ctla4^tm1Shr \Tg(DO11.10)10Dlo/0 (involves: 129S4/SvJae * BALB/c * C3H * C57BL/6)	abnormal T cell physiology	J:57090
	enlarged lymph nodes	J:57090
	enlarged spleen	J:57090
	increased T cell proliferation	J:57090
\Ctnnb1^{tm1(Nfkbia)Rsu}/\Ctnnb1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal cervical lymph node morphology	J:71744
	abnormal macrophage physiology	J:71744
	abnormal peripheral lymph node morphology	J:71744
	absent peripheral lymph nodes	J:71744
	absent Peyer's patches	J:71744
	absent popliteal lymph nodes	J:71744
	conjunctivitis	J:71744
	decreased Peyer's patch number	J:71744
	increased granulocyte number	J:71744
	increased inflammatory response	J:71744
	increased leukocyte cell number	J:71744
	increased susceptibility to otitis media	J:71744
	increased susceptibility to parasitic infection	J:71744
	keratoconjunctivitis sicca	J:71744
	small axillary lymph nodes	J:71744
	small brachial lymph nodes	J:71744
	small Peyer's patches	J:71744
\Ctnnb1^tm1Mmt/\Ctnnb1⁺ \Ctsk^tm1(cre)Ska/\Ctsk⁺ (involves: 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast differentiation	J:178340
\Ctnnb1^tm1Mmt/\Ctnnb1⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal osteoclast differentiation	J:178340
\Ctnnb1^tm1Mmt/\Ctnnb1⁺ \Pparg^{tm1.1(tTA)Jmgr}/\Pparg⁺ \Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:178340
	decreased osteoclast cell number	J:178340
	increased splenocyte number	J:178340
\Ctnnb1^tm1Mmt/\Ctnnb1⁺ \Tg(Col1a1-cre)1Kry/0 (involves: 129X1/SvJ * FVB)	decreased osteoclast cell number	J:98430
\Ctnnb1^tm1Mmt/\Ctnnb1⁺ \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129X1/SvJ * CD-1)	abnormal osteoclast differentiation	J:114494
\Ctnnb1^{tm2(Nfkbia)Rsu}/\Ctnnb1⁺ \Tg(CMV-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal lymph node morphology	J:71744
	abnormal macrophage physiology	J:71744
	abnormal Peyer's patch morphology	J:71744
	increased granulocyte number	J:71744
	increased inflammatory response	J:71744
	increased leukocyte cell number	J:71744
	increased susceptibility to otitis media	J:71744
	keratoconjunctivitis sicca	J:71744
\Ctnnb1^tm2Kem/\Ctnnb1⁺ \Ctsk^tm1(cre)Ska/\Ctsk⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)	increased osteoclast cell number	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	increased osteoclast cell number	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1⁺ \Pparg^{tm1.1(tTA)Jmgr}/\Pparg⁺ \Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:178340
	increased osteoclast cell number	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1⁺ \Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased osteoclast cell number	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1^tm2Kem \Ctsk^tm1(cre)Ska/\Ctsk⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrlj * CBA/JNCrlj)	increased osteoclast cell number	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1^tm2Kem \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	increased osteoclast cell number	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1^tm2Kem \Pparg^{tm1.1(tTA)Jmgr}/\Pparg⁺ \Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:178340
	decreased osteoclast cell number	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1^tm2Kem \Pparg^{tm1.1(tTA)Jmgr}/\Pparg⁺ \Tg(tetO-cre)1Jaw/0 \Tg(tetO-HIST1H2BJ/GFP)47Efu/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	abnormal osteoclast differentiation	J:178340
\Ctnnb1^tm2Kem/\Ctnnb1^tm2Kem \Tg(Col1a1-cre)1Kry/0 (involves: 129S1/Sv * 129X1/SvJ * FVB)	increased osteoclast cell number	J:98430
\Ctnnb1^tm2Kem/\Ctnnb1^tm2Kem \Tg(KRT14-cre/ERT)20Efu/0 (involves: 129S1/Sv * 129X1/SvJ * CD-1)	cutaneous mastocytosis	J:204142
\Ctnnb1^tm2Kem/\Ctnnb1^tm2Kem \Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	decreased osteoclast cell number	J:178340
\Ctnnb1^tm4Wbm/\Ctnnb1^tm4Wbm \Krt14^tm1(cre)Wbm/\Krt14⁺ (involves: 129P2/OlaHsd)	decreased gamma-delta T cell number	J:202499
	increased neutrophil cell number	J:202499
\Ctnnb1^tm4Wbm/\Ctnnb1^tm4Wbm \Tg(Pdx1-cre)6Tuv/0 (involves: 129P2/OlaHsd * FVB/N)	pancreas inflammation	J:119908
\Ctps1^em1(IMPC)Tcp/\Ctps1⁺ (C57BL/6N-Ctps1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Ctps1^{tm1c(KOMP)Wtsi}/\Ctps1^{tm1c(KOMP)Wtsi} \Commd10^{Tg(Vav1-icre)A2Kio}/0 (B6.Cg-Ctps1^{tm1c(KOMP)Wtsi} Commd10^{Tg(Vav1-icre)A2Kio})	abnormal spleen morphology	J:348981
	decreased B cell number	J:348981
	decreased double-positive T cell number	J:348981
	decreased NK cell number	J:348981
	decreased T cell number	J:348981
	decreased T cell proliferation	J:348981
	increased CD4-positive, alpha-beta T cell number	J:348981
	increased CD8-positive, alpha-beta T cell number	J:348981
	small thymus	J:348981
	thymus hypoplasia	J:348981
\Ctps1^{tm1c(KOMP)Wtsi}/\Ctps1^{tm1c(KOMP)Wtsi} \Ctps2^{tm1c(EUCOMM)Hmgu}/\Ctps2⁺ \Tg(Cd4-cre)1Cwi/0 (involves: 129S/Sv * C57BL/6 * DBA/2)	decreased T cell proliferation	J:348981
\Ctps1^{tm1c(KOMP)Wtsi}/\Ctps1^{tm1c(KOMP)Wtsi} \Ctps2^{tm1c(EUCOMM)Hmgu}/\Ctps2^{tm1c(EUCOMM)Hmgu} \Tg(Cd4-cre)1Cwi/0 (involves: 129S/Sv * C57BL/6 * DBA/2)	decreased T cell number	J:348981
	decreased T cell proliferation	J:348981
\Ctps1^{tm1c(KOMP)Wtsi}/\Ctps1^{tm1c(KOMP)Wtsi} \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ (B6.Cg-Ctps1^{tm1c(KOMP)Wtsi} Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj})	abnormal spleen morphology	J:348981
	abnormal thymus physiology	J:348981
	decreased germinal center B cell number	J:348981
	decreased IgM level	J:348981
	decreased lymphocyte cell number	J:348981
	decreased T cell proliferation	J:348981
	decreased T follicular helper cell number	J:348981
	impaired humoral immune response	J:348981
	increased CD8-positive, alpha-beta T cell number	J:348981
	small thymus	J:348981
	thymus hypoplasia	J:348981
\Ctps1^{tm1c(KOMP)Wtsi}/\Ctps1^{tm1c(KOMP)Wtsi} \Tg(Cd4-cre)1Cwi/0 (involves: 129S/Sv * C57BL/6 * DBA/2)	decreased effector memory T-helper cell number	J:348981
	decreased T cell proliferation	J:348981
	increased CD8-positive, naive alpha-beta T cell number	J:348981
\Ctps1^{tm1c(KOMP)Wtsi}/\Ctps1^{tm1c(KOMP)Wtsi} \Tg(Cd4-cre)1Cwi/0 \Foxp3^sf/Y \Rag1^tm1Mom/\Rag1⁺ (mixed)	decreased inflammatory response	J:348981
	decreased regulatory T cell number	J:348981
	decreased T cell proliferation	J:348981
	enlarged spleen	J:348981
	thymus hypoplasia	J:348981
\Ctps1^{tm1c(KOMP)Wtsi}/\Ctps1^{tm1c(KOMP)Wtsi} \Tg(Cd8a-cre)1Itan/0 (B6(129S4)-Ctps1^{tm1c(KOMP)Wtsi} Tg(Cd8a-cre)1Itan)	decreased T cell proliferation	J:348981
\Ctrb1^em1Toth/\Ctrb1^em1Toth (C57BL/6N-Ctrb1^em1Toth)	increased susceptibility to induced pancreatitis	J:294171, J:294035
\Ctrc^m1/\Ctrc^m1 (C57BL/6-Ctrc^m1)	increased susceptibility to induced pancreatitis	J:291240
\Ctrq1^C3H/HeJ/\Ctrq1^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:106111
\Ctrq2^C3H/HeJ/\Ctrq2^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:106111
\Ctrq2^C3H/HeJ/\Ctrq2^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:106111
\Ctrq3^C3H/HeJ/\Ctrq3^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:106111
\Ctrq3^C3H/HeJ/\Ctrq3^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:106111
\Ctsa^tm1Adz/\Ctsa^tm1Adz (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/NJ))	enlarged spleen	J:29674
\Ctsa^{tm2b(EUCOMM)Hmgu}/\Ctsa^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Ctsa^{tm2b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
\Ctsb^tm1Jde/\Ctsb⁺ (NOD.129P2-Ctsb^tm1Jde)	decreased susceptibility to autoimmune diabetes	J:153355
\Ctsb^tm1Jde/\Ctsb⁺ (NOD.129P2-Ctsb^tm1Jde)	insulitis	J:153355
\Ctsb^tm1Jde/\Ctsb^tm1Jde (either: (involves: 129P2/OlaHsd * 129/Sv) or (involves: 129P2/OlaHsd * C57BL/6))	immune system phenotype	J:47432
\Ctsb^tm1Jde/\Ctsb^tm1Jde (NOD.129P2-Ctsb^tm1Jde)	decreased susceptibility to autoimmune diabetes	J:153355
	insulitis	J:153355
	salivary gland inflammation	J:153355
\Ctsb^tm1Jde/\Ctsb^tm1Jde \Serpina3g^tm1.1Arp/\Serpina3g^tm1.1Arp (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:189782
\Ctsc^tm1Ley/\Ctsc^tm1Ley (either: 129X1/SvJ-Ctsc^tm1Ley or (involves: 129X1/SvJ * C57BL/6))	abnormal cytotoxic T cell physiology	J:77312
	abnormal T cell physiology	J:77312
\Ctsc^tm1Ley/\Ctsc^tm1Ley (B6.129X1-Ctsc^tm1Ley)	abnormal chemokine level	J:131520
	abnormal leukocyte migration	J:131520
	abnormal response to infection	J:131520
	decreased circulating interleukin-6 level	J:131520
	impaired neutrophil recruitment	J:131520
	increased circulating interleukin-6 level	J:88160
	sepsis	J:88160
\Ctsc^tm1Ley/\Ctsc^tm1Ley \Il6^tm1Kopf/\Il6^tm1Kopf (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	immune system phenotype	J:88160
\Ctsd^m1J/\Ctsd^m1J (C3HeB/FeJ-Ctsd^m1J/GrsrJ)	thymus atrophy	J:229377
\Ctsd^tm1.1Thre/\Ctsd^tm1.1Thre \Edil3^{Tg(Sox2-cre)1Amc}/\Edil3⁺ (involves: C57BL/6 * C57BL/6N * CBA * SJL)	decreased double-positive T cell number	J:227618
	microgliosis	J:227618
	thymus atrophy	J:227618
\Ctsd^tm1.1Thre/\Ctsd^tm1.1Thre \Tg(Nes-cre)1Kln/0 (involves: C57BL/6 * C57BL/6N * SJL)	abnormal thymus morphology	J:227618
	decreased double-positive T cell number	J:227618
	microgliosis	J:227618
\Ctsd^tm1Cptr/\Ctsd^tm1Cptr (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd))	abnormal antigen presentation	J:47432
	abnormal microglial cell morphology	J:71688
	abnormal spleen B cell follicle morphology	J:28201
	abnormal spleen white pulp morphology	J:28201
	decreased double-positive T cell number	J:28201
	decreased lymphocyte cell number	J:28201
	thymus hypoplasia	J:28201
\Ctse^{C57BL/6JOlaHsd}/\Ctse^{C57BL/6JOlaHsd} (involves: 129S2/SvPasHsd * C57BL/6JOlaHsd)	abnormal dendritic cell antigen presentation	J:128538
	abnormal dendritic cell physiology	J:128538
	abnormal immune system physiology	J:128538
\Ctse^tm1Kjy/\Ctse⁺ (involves: C57BL/6)	increased IgE level	J:108745
\Ctse^tm1Kjy/\Ctse^tm1Kjy (involves: C57BL/6)	dermatitis	J:108745
	increased circulating interleukin-1 beta level	J:108745
	increased circulating interleukin-18 level	J:108745
	increased double-positive T cell number	J:108745
	increased eosinophil cell number	J:108745
	increased IgE level	J:108745
	increased interleukin-4 secretion	J:108745
	increased interleukin-5 secretion	J:108745
\Ctsg^tm1.1Roes/\Ctsg^tm1.1Roes (involves: 129P2/OlaHsd)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:77597
\Ctsg^tm1.1Roes/\Ctsg^tm1.1Roes (involves: 129P2/OlaHsd)	increased susceptibility to infection induced morbidity/mortality	J:77597
\Ctsg^tm1.1Roes/\Ctsg^tm1.1Roes \Elane^tm1(cre)Roes/\Elane^tm1(cre)Roes (involves: 129P2/OlaHsd)	decreased susceptibility to endotoxin shock	J:77597
	increased susceptibility to fungal infection	J:77597
\Ctsg^tm1Ley/\Ctsg^tm1Ley (either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ))	immune system phenotype	J:59006
\Ctsg^tm1Ley/\Ctsg^tm1Ley \Elane^tm1Sds/\Elane^tm1Sds (involves: 129X1/SvJ)	immune system phenotype	J:131496
\Ctsg^tm1Ley/\Ctsg^tm1Ley \Elane^tm1Sds/\Elane^tm1Sds (B6.129X1-Elane^tm1Sds Ctsg^tm1Ley)	immune system phenotype	J:131520
\Ctsg^{tm2.1(PML/RARA)Ley}/\Ctsg⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal myelopoiesis	J:84230, J:86458
	enlarged spleen	J:84230
	increased leukocyte cell number	J:84230
\Ctsg^{tm2.1(PML/RARA)Ley}/\Ctsg⁺ (involves: 129 * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:166479
	enlarged spleen	J:166479
	increased spleen weight	J:166479
\Ctsg^{tm2.1(PML/RARA)Ley}/\Ctsg⁺ \Elane^tm1Sds/\Elane^tm1Sds (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	abnormal myelopoiesis	J:86458
\Ctsg^{tm3.1(PML/RARA)Ley}/\Ctsg⁺ (involves: 129 * C57BL/6)	abnormal spleen morphology	J:166479
	enlarged spleen	J:166479
	increased spleen weight	J:166479
\Ctsk^tm1(cre)Ska/\Ctsk⁺ \Esr1^tm1Mma/\Esr1^tm1Mma (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal osteoclast physiology	J:127179
	increased osteoclast cell number	J:127179
\Ctsk^tm1(cre)Ska/\Ctsk⁺ \Plekhm1^tm1.1Hzhao/\Plekhm1^tm1.1Hzhao (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast morphology	J:236517
	abnormal osteoclast physiology	J:236517
\Ctsk^tm1(cre)Ska/\Ctsk⁺ \Snx10^{tm1c(EUCOMM)Raba}/\Snx10^{tm1c(EUCOMM)Raba} (involves: 129S4/SvJae * C57BL/6 * C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast physiology	J:224711
\Ctsk^tm1.1Rbar/\Ctsk^tm1.1Rbar \Tg(Itgam-cre)AJva/0 (involves: C57BL/6)	increased osteoclast cell number	J:194492
\Ctsk^tm1.1Rbar/\Ctsk^tm1.1Rbar \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:194492
	abnormal osteoclast physiology	J:194492
	increased osteoclast cell number	J:194492
\Ctsk^tm1Mbs/\Ctsk^tm1Mbs (B6.129-Ctsk^tm1Mbs)	abnormal osteoclast physiology	J:128098
\Ctsk^tm1Mbs/\Ctsk^tm1Mbs (B6.129-Ctsk^tm1Mbs)	increased osteoclast cell number	J:128098
\Ctsk^tm1Psa/\Ctsk^tm1Psa (involves: 129X1/SvJ * C57BL/6J)	abnormal osteoclast physiology	J:50934
\Ctsk^tm1Vuo/\Ctsk^tm1Vuo (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal osteoclast morphology	J:95525
	increased osteoclast cell number	J:95525
\Ctsk^tm1Ypl/\Ctsk^tm1Ypl (B6.129S4-Ctsk^tm1Ypl)	increased osteoclast cell number	J:117870
\Ctsk^tm1Ypl/\Ctsk^tm1Ypl (129S4/SvJae-Ctsk^tm1Ypl)	increased osteoclast cell number	J:117870
\Ctsl^m1Btlr/\Ctsl^m1Btlr (C57BL/6J-Ctsl^m1Btlr)	abnormal CD4-positive T cell differentiation	J:272869
	abnormal CD8-positive, alpha beta T cell morphology	J:272869
	abnormal CD8-positive, alpha-beta T cell differentiation	J:272869
	abnormal T cell differentiation	J:272869
	decreased alpha-beta T cell number	J:272869
	decreased CD4-positive, alpha-beta T cell number	J:272869
	increased alpha-beta T cell number	J:272869
	increased CD8-positive, alpha-beta T cell number	J:272869
	increased central memory CD4-positive, alpha-beta T cell number	J:272869
	increased central memory CD8 positive, alpha-beta T cell number	J:272869
	increased effector memory CD4-positive, alpha-beta T cell number	J:272869
\Ctsl^nkt/\Ctsl^nkt (either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6) or (involves: 129S2/SvPas * DBA/2))	abnormal immune system organ morphology	J:54856
	decreased CD4-positive, alpha-beta T cell number	J:54856
	dermatitis	J:54856
	increased inflammatory response	J:54856
	liver inflammation	J:54856
	lymph node hyperplasia	J:54856
	lymph node inflammation	J:54856
	thymus atrophy	J:54856
\Ctsl^nkt/\Ctsl^nkt (B6.Cg-Ctsl^nkt)	dermatitis	J:78460
\Ctsl^nkt/\Ctsl^nkt (B6.Cg-Ctsl^nkt)	enlarged lymph nodes	J:78460
\Ctsl^nkt/\Ctsl^nkt (C.Cg-Ctsl^nkt)	abnormal immune system organ morphology	J:78460
	abnormal leukocyte cell number	J:99009
	abnormal lymph node cortex morphology	J:99009
	abnormal lymph node morphology	J:99009
	abnormal thymus corticomedullary boundary morphology	J:99009
	abnormal thymus lobule morphology	J:99009
	abnormal thymus morphology	J:99009
	decreased CD4-positive, alpha-beta T cell number	J:99009
	dermatitis	J:78460
	dilated lymph node medullary sinus	J:99009
	enlarged lymph nodes	J:78460, J:99009
	enlarged thymus cortex	J:99009
	increased CD8-positive, alpha-beta T cell number	J:99009
\Ctsl^tm1.2Thre/\Ctsl^tm1.2Thre (involves: C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:216506
\Ctsl^tm1Alpk/\Ctsl^tm1Alpk (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast physiology	J:99755
	decreased osteoclast cell number	J:99755
	dermatitis	J:99755
	folliculitis	J:99755
	granulomatous inflammation	J:99755
\Ctsl^tm1Alpk/\Ctsl^tm1Alpk (B6.129P2-Ctsl^tm1Alpk)	granulomatous inflammation	J:99755
\Ctsl^tm1Cptr/\Ctsl⁺ (NOD.129P2-Ctsl^tm1Cptr)	decreased susceptibility to autoimmune diabetes	J:153355
\Ctsl^tm1Cptr/\Ctsl⁺ (NOD.129P2-Ctsl^tm1Cptr)	insulitis	J:153355
\Ctsl^tm1Cptr/\Ctsl^tm1Cptr (involves: 129P2/OlaHsd * C57BL/6J)	increased regulatory T cell number	J:153355
\Ctsl^tm1Cptr/\Ctsl^tm1Cptr (NOD.129P2-Ctsl^tm1Cptr)	decreased CD4-positive, alpha-beta T cell number	J:153355
	decreased susceptibility to autoimmune diabetes	J:153355
	increased regulatory T cell number	J:153355
	salivary gland inflammation	J:153355
\Ctsl^tm1Cptr/\Ctsl^tm1Cptr (involves: 129P2/OlaHsd)	decreased CD4-positive, alpha-beta T cell number	J:216506
\Ctsm^{tm1(KOMP)Wtsi}/\Ctsm^{tm1(KOMP)Wtsi} (C57BL/6N-Ctsm^{tm1(KOMP)Wtsi}/Nju)	increased monocyte cell number	J:211773
\Ctss^em1(IMPC)H/\Ctss^em1(IMPC)H (C57BL/6NTac-Ctss^em1(IMPC)H/H)	decreased spleen weight	J:211773
\Ctss^m1Btlr/\Ctss^m1Btlr (C57BL/6J-Ctss^m1Btlr)	decreased IgG level	J:267491
\Ctss^m1Btlr/\Ctss^m1Btlr (C57BL/6J-Ctss^m1Btlr)	impaired humoral immune response	J:267491
\Ctss^tm1Eae/\Ctss⁺ (NOD.D1-Ctss^tm1Eae)	insulitis	J:153355
\Ctss^tm1Eae/\Ctss^tm1Eae (involves: C57BL/6 * DBA/1LacJ)	abnormal B lymphocyte antigen presentation	J:53399
\Ctss^tm1Eae/\Ctss^tm1Eae (involves: C57BL/6 * DBA/1LacJ)	decreased susceptibility to induced arthritis	J:53399
\Ctss^tm1Eae/\Ctss^tm1Eae (NOD.D1-Ctss^tm1Eae)	decreased susceptibility to autoimmune diabetes	J:153355
	insulitis	J:153355
	salivary gland inflammation	J:153355
\Ctss^tm1Hap/\Ctss^tm1Hap (B6.129S2-Ctss^tm1Hap)	abnormal B cell physiology	J:96401
	abnormal cytokine secretion	J:96401
	abnormal humoral immune response	J:96401
	abnormal interleukin secretion	J:96401
	abnormal professional antigen presenting cell physiology	J:96401
	abnormal T cell physiology	J:96401
	decreased IgG level	J:96401
	decreased IgM level	J:96401
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:96401
\Ctss^tm1Hap/\Ctss^tm1Hap \Ldlr^tm1Her/\Ldlr^tm1Her (B6.129S-Ctss^tm1Hap Ldlr^tm1Her)	abnormal leukocyte migration	J:82520
\Ctss^tm1Hap/\Ctss^tm1Hap \Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	increased lymphocyte cell number	J:100854
	increased macrophage cell number	J:100854
	increased neutrophil cell number	J:100854
\Ctsw^tm1Ctnp/\Ctsw^tm1Ctnp (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:91265
\Cttn^tm1.2Dvst/\Cttn^tm1.2Dvst (either: B6.Cg-Cttn^tm1.2Dvst or (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2 * SJL))	abnormal cellular extravasation	J:177602
	abnormal leukocyte adhesion	J:177602
	abnormal leukocyte migration	J:177602
	abnormal neutrophil physiology	J:177602
\Cttnbp2^{tm1b(KOMP)Wtsi}/\Cttnbp2^{tm1b(KOMP)Wtsi} (C57BL/6N-Cttnbp2^{tm1b(KOMP)Wtsi}/Wtsi)	decreased transitional stage T1 B cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased plasma cell number	J:211773
\Ctu2^{tm1(KOMP)Wtsi}/\Ctu2⁺ (C57BL/6N-Ctu2^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Cuedc2^tm1Qxia/\Cuedc2^tm1Qxia (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	abnormal macrophage physiology	J:211782
	increased macrophage cytokine production	J:211782
	increased susceptibility to induced colitis	J:211782
\Cul4a/Pcid2^tm2Ktc/\Cul4a/Pcid2^tm2Ktc \Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)	abnormal leukocyte morphology	J:138468
	abnormal spleen capsule morphology	J:138468
	abnormal spleen morphology	J:138468
	decreased lymphocyte cell number	J:138468
	decreased monocyte cell number	J:138468
	decreased neutrophil cell number	J:138468
	decreased spleen red pulp amount	J:138468
	decreased spleen weight	J:138468
	decreased spleen white pulp amount	J:138468
	small thymus	J:138468
	spleen hypoplasia	J:138468
\Cul4a/Pcid2^tm2Ktc/\Cul4a/Pcid2^tm2Ktc \Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)	abnormal leukocyte morphology	J:138468
	abnormal spleen capsule morphology	J:138468
	abnormal spleen morphology	J:138468
	decreased lymphocyte cell number	J:138468
	decreased monocyte cell number	J:138468
	decreased neutrophil cell number	J:138468
	decreased spleen red pulp amount	J:138468
	decreased spleen weight	J:138468
	decreased spleen white pulp amount	J:138468
	small thymus	J:138468
	spleen hypoplasia	J:138468
\Cul4a^{tm1b(EUCOMM)Hmgu}/\Cul4a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cul4a^{tm1b(EUCOMM)Hmgu}/Ccpcz)	decreased spleen weight	J:211773
\Cul5^{tm1.1(KOMP)Vlcg}/\Cul5⁺ (involves: C57BL/6NTac)	decreased interleukin-1 alpha secretion	J:244502
	decreased interleukin-6 secretion	J:244502
	decreased tumor necrosis factor secretion	J:244502
\Cul5^{tm1.1(KOMP)Vlcg}/\Cul5⁺ (C57BL/6N-Cul5^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Cul9^{em1(IMPC)Ccpcz}/\Cul9^{em1(IMPC)Ccpcz} (C57BL/6N-Cul9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Cux1^tm1Rhsc/\Cux1^tm1Rhsc (involves: 129S1/Sv * C57BL/6J)	abnormal myelopoiesis	J:100055
	abnormal T cell differentiation	J:100055
	abnormal tumor necrosis factor level	J:100055
	decreased B cell number	J:100055
	decreased double-positive T cell number	J:100055
	decreased thymocyte number	J:100055
	small thymus	J:100055
	thymus cortex hypoplasia	J:100055
	thymus hypoplasia	J:100055
\Cux1^tm2Ejn/\Cux1^tm2Ejn (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to bacterial infection	J:74660
\Cux1^tm2Ejn/\Cux1^tm2Ejn (involves: 129S4/SvJae * C57BL/6)	rhinitis	J:74660
\Cuzd1^tm1Ljm/\Cuzd1^tm1Ljm (involves: 129S6/SvEvTac * Black Swiss)	increased susceptibility to induced pancreatitis	J:80980
\Cwc22^em1(IMPC)Mbp/\Cwc22⁺ (C57BL/6NCrl-Cwc22^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
\Cwc27^tm1Lex/\Cwc27^tm1Lex (B6;129S5-Cwc27^tm1Lex/Mmucd)	abnormal immune system physiology	J:171883
\Cx3cl1^tm1.1Yono/\Cx3cl1^tm1.1Yono (involves: C57BL/6J)	abnormal dendritic cell physiology	J:271242
\Cx3cl1^tm1.1Yono/\Cx3cl1^tm1.1Yono (involves: C57BL/6J)	decreased inflammatory response	J:271242
\Cx3cl1^tm1Lira/\Cx3cl1^tm1Lira (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:68831
\Cx3cl1^tm1Lira/\Cx3cl1^tm1Lira (involves: C57BL/6)	decreased monocyte cell number	J:145036
\Cx3cl1^tm1Sgs/\Cx3cl1^tm1Sgs \Ldlr^tm1Her/\Ldlr^tm1Her (involves: B6.129S4-Cx3cl1^tm1Sgs * B6.129S7-Ldlr^tm1Her/J)	impaired macrophage chemotaxis	J:95279
\Cx3cr1^tm1Ifc/\Cx3cr1^tm1Ifc (involves: 129S4/SvJae * C57BL/6)	abnormal NK cell physiology	J:82033
	abnormal response to transplant	J:82033
	immune system phenotype	J:82033
	impaired macrophage chemotaxis	J:82033
\Cx3cr1^tm1Litt/\Cx3cr1⁺ (B6.129P2-Cx3cr1^tm1Litt)	increased susceptibility to experimental autoimmune encephalomyelitis	J:129712
\Cx3cr1^tm1Litt/\Cx3cr1⁺ (B6.129P2-Cx3cr1^tm1Litt)	microgliosis	J:110266
\Cx3cr1^tm1Litt/\Cx3cr1⁺ \Psen1^tm1Mpm/\Psen1^tm1Mpm \Tg(APPSwe,tauP301L)1Lfa/0 \Tg(Thy1-YFP)HJrs/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal microglial cell morphology	J:159680
	abnormal microglial cell physiology	J:159680
\Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte physiology	J:162714
	decreased monocyte cell number	J:145036
	immune system phenotype	J:84544
	impaired macrophage chemotaxis	J:162714
\Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt (C.129P2-Cx3cr1^tm1Litt)	immune system phenotype	J:84544
\Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:271242, J:95694
	decreased inflammatory response	J:271242
	increased dendritic cell number	J:210086
	increased susceptibility to bacterial infection induced morbidity/mortality	J:95694
\Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt (B6.129P2-Cx3cr1^tm1Litt)	abnormal leukocyte physiology	J:124722
	abnormal microglial cell morphology	J:265696
	abnormal microglial cell physiology	J:110266, J:265696
	abnormal NK cell physiology	J:129712
	brain inflammation	J:129712
	decreased NK cell number	J:129712
	immune system phenotype	J:129712
	increased susceptibility to experimental autoimmune encephalomyelitis	J:129712
	microgliosis	J:110266
\Cx3cr1^tm1Litt/\Cx3cr1^tm1Litt \H2-Ab1^b-tm1Hpl/\H2-Ab1⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal response to infection	J:95694
\Cx3cr1^tm1Zm/\Cx3cr1^tm1Zm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal splenocyte physiology	J:103047
\Cx3cr1^{tm2.1(cre/ERT2)Litt}/\Cx3cr1⁺ \Vps35^{Gt(RRK261)Byg}/\Vps35^{Gt(RRK261)Byg} (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-1 beta secretion	J:292365
	decreased interleukin-6 secretion	J:292365
	decreased tumor necrosis factor secretion	J:292365
	increased interleukin-4 secretion	J:292365
	increased interleukin-10 secretion	J:292365
	increased macrophage cell number	J:292365
	microgliosis	J:292365
\Cx3cr1^{tm3(Hbegf)Litt}/\Cx3cr1^{tm3(Hbegf)Litt} \Tg(Itgax-cre)1-1Reiz/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased susceptibility to bacterial infection	J:210086
\Cxadr^em1(IMPC)Mbp/\Cxadr⁺ (C57BL/6N-Cxadr^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Cxadr^tm1.1Ics/\Cxadr^tm1.1Ics \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S2/SvPas C57BL/6 * C57BL/6J * CBA)	enlarged thymus	J:174138
	increased thymocyte number	J:174138
\Cxcl1^em1(IMPC)Mbp/\Cxcl1^em1(IMPC)Mbp (C57BL/6N-Cxcl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
\Cxcl5^tm1.1Mkch/\Cxcl5^tm1.1Mkch (B6.129P2-Cxcl5^tm1.1Mkch)	decreased interferon-alpha secretion	J:208901
	decreased interleukin-1 alpha secretion	J:208901
	decreased interleukin-6 secretion	J:208901
	decreased neutrophil cell number	J:208901
	decreased susceptibility to bacterial infection	J:208901
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:208901
	decreased tumor necrosis factor secretion	J:208901
	immune system phenotype	J:208901
\Cxcl5^tm1Gscw/\Cxcl5^tm1Gscw (involves: 129)	abnormal circulating chemokine level	J:162629
	abnormal neutrophil physiology	J:162629
	decreased circulating interleukin-6 level	J:162629
	decreased susceptibility to bacterial infection	J:162629
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:162629
	decreased susceptibility to endotoxin shock	J:162629
	increased granulocyte number	J:162629
\Cxcl5^tm1Gscw/\Cxcl5^tm1Gscw \Ackr1^tm1Scp/\Ackr1^tm1Scp (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal circulating chemokine level	J:162629
\Cxcl9^{tm1b(EUCOMM)Wtsi}/\Cxcl9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cxcl9^{tm1b(EUCOMM)Wtsi}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Cxcl9^tm1Jmf/\Cxcl9^tm1Jmf (either: B6.129S4-Cxcl9^tm1Jmf or (involves: 129S4/SvJae * C57BL/6))	decreased IgG level	J:121818
	decreased immunoglobulin level	J:121818
	immune system phenotype	J:121818
\Cxcl9^tm1Jmf/\Cxcl9^tm1Jmf (B6.129S4-Cxcl9^tm1Jmf)	abnormal cytokine secretion	J:120743
\Cxcl9^tm1Jmf/\Cxcl9^tm1Jmf (B6.129S4-Cxcl9^tm1Jmf)	decreased inflammatory response	J:120743
\Cxcl10^tm1Adl/\Cxcl10^tm1Adl (involves: 129S4/SvJae * 129X1/SvJ)	decreased IgG2a level	J:75584
	decreased interferon-gamma secretion	J:75584
	decreased splenocyte proliferation	J:75584
	decreased susceptibility to type IV hypersensitivity reaction	J:75584
\Cxcl10^tm1Adl/\Cxcl10^tm1Adl (involves: 129S4/SvJae * C57BL/6)	abnormal interferon level	J:75584
	abnormal T cell physiology	J:75584
	decreased CD8-positive, alpha-beta T cell number	J:75584
	increased susceptibility to Hepadnaviridae infection	J:75584
\Cxcl10^tm1Adl/\Cxcl10^tm1Adl (B6.129S4-Cxcl10^tm1Adl)	abnormal cytokine secretion	J:120743
	CNS inflammation	J:87076
	increased susceptibility to experimental autoimmune encephalomyelitis	J:87076
	increased susceptibility to Herpesvirales infection	J:120743
\Cxcl11^em1Groj/\Cxcl11^em1Groj (C57BL/6J-Cxcl11^em1Groj)	abnormal B cell morphology	J:345391
	immune system phenotype	J:345391
	increased CD8-positive, alpha-beta T cell number	J:345391
\Cxcl12^tm1.1Sjm/\Cxcl12^tm1.1Sjm \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/? (involves: 129S/SvEv * C57BL/6)	decreased leukocyte cell number	J:194748
	decreased lymphocyte cell number	J:194748
\Cxcl12^tm1.1Sjm/\Cxcl12^tm1.1Sjm \Tg(Prrx1-cre)1Cjt/? (involves: C57BL/6 * SJL/J)	abnormal B cell differentiation	J:194748
\Cxcl12^tm1.1Ystz/\Cxcl12^tm1.2Ystz \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129X1/SvJ C57BL/6 * CBA * FVB/N)	decreased pro-B cell number	J:168434
	increased neutrophil cell number	J:168434
\Cxcl12^tm1Tng/\Cxcl12^tm1.1Link \Tg(BGLAP-cre)1Clem/0 (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac * FVB/N)	decreased B cell number	J:193594
\Cxcl12^tm1Tng/\Cxcl12^tm1.1Link \Tg(Prrx1-cre)1Cjt/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL/J)	decreased B cell number	J:193594
	decreased pre-pro B cell number	J:193594
\Cxcl12^tm1Tng/\Cxcl12^tm1.1Link \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * FVB/N)	decreased B cell number	J:193594
	decreased pre-pro B cell number	J:193594
\Cxcl12^tm1Tng/\Cxcl12^tm1Tng (involves: 129P2/OlaHsd)	decreased pre-B cell number	J:34750
	decreased pro-B cell number	J:34750
	impaired myelopoiesis	J:49070
\Cxcl12^{tm3.1(HBEGF/EGFP)Tng}/\Cxcl12⁺ (B6.Cg-Cxcl12^{tm3.1(HBEGF/EGFP)Tng})	decreased pro-B cell number	J:164657
	increased B cell apoptosis	J:164657
\Cxcl13^em2(IMPC)H/\Cxcl13^em2(IMPC)H (C57BL/6NTac-Cxcl13^em2(IMPC)H/H)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Cxcl13^m1Btlr/\Cxcl13^m1Btlr (C57BL/6J-Cxcl13^m1Btlr)	increased B-1 B cell number	J:221480
\Cxcl13^tm1Cys/\Cxcl13^tm1Cys (involves: 129X1/SvJ * C57BL/6)	abnormal B cell physiology	J:78282
	abnormal lymph node germinal center morphology	J:78282
	abnormal Peyer's patch morphology	J:78282
	abnormal spleen B cell follicle morphology	J:78282
	abnormal spleen marginal zone morphology	J:78282
	absent axillary lymph nodes	J:78282
	absent brachial lymph nodes	J:78282
	absent follicular dendritic cells	J:78282
	absent inguinal lymph nodes	J:78282
	decreased lymph node number	J:78282
	decreased Peyer's patch number	J:78282
	decreased spleen germinal center size	J:78282
	small Peyer's patches	J:78282
\Cxcl13^tm1Cys/\Cxcl13^tm1Cys (B6.129X1-Cxcl13^tm1Cys)	impaired B cell migration	J:118931
\Cxcl13^tm1Mmi/\Cxcl13^tm1Mmi (involves: C57BL/6)	abnormal B cell physiology	J:84804
	abnormal leukocyte adhesion	J:84804
	abnormal leukocyte migration	J:84804
\Cxcl14^tm1Bmsr/\Cxcl14^tm1Bmsr (involves: 129/Sv * C57BL/6)	immune system phenotype	J:118303
\Cxcl14^tm1Tha/\Cxcl14^tm1Tha (involves: C57BL/6 * CBA)	decreased macrophage cell number	J:126841
\Cxcl15^tm1Lira/\Cxcl15^tm1Lira (involves: 129 * C57BL/6J)	decreased neutrophil cell number	J:67605
	immune system phenotype	J:67605
	increased susceptibility to bacterial infection	J:67605
\Cxcl16^tm1Syon/\Cxcl16^tm1Syon (B6.129P2-Cxcl16^tm1Syon)	decreased circulating interferon-gamma level	J:155199
	decreased circulating interleukin-4 level	J:155199
	decreased interferon-gamma secretion	J:155199
	decreased interleukin-4 secretion	J:155199
	decreased NK T cell number	J:155199
	decreased susceptibility to bacterial infection	J:155199
\Cxcr2^{tm1(IL8RB)Dktr}/\Cxcr2^{tm1(IL8RB)Dktr} (involves: 129S2/SvPas * C57BL/6)	decreased spleen weight	J:113489
	immune system phenotype	J:113489
	increased granulocyte number	J:113489
	increased leukocyte cell number	J:113489
\Cxcr2^{tm1a(EUCOMM)Wtsi}/\Cxcr2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cxcr2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased immature B cell number	J:211773
	decreased mature B cell number	J:211773
	decreased pre-B cell number	J:211773
	decreased pre-pro B cell number	J:211773
	decreased T cell number	J:211773
	increased anti-nuclear antigen antibody level	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD8-positive, alpha-beta memory T cell number	J:211773
	increased CD103-positive CD11b-low dendritic cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1+ CD4 alpha-beta T cell number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cxcr2^tm1Mwm/\Cxcr2⁺ (C.129S2(B6)-Cxcr2^tm1Mwm/J)	impaired neutrophil recruitment	J:63935
\Cxcr2^tm1Mwm/\Cxcr2^tm1Mwm (involves: 129S2/SvPas * C57BL/6J)	abnormal granulocyte differentiation	J:19570
	abnormal myelopoiesis	J:19570
	abnormal spleen white pulp morphology	J:19570
	enlarged cervical lymph nodes	J:19570
	enlarged lymph nodes	J:19570
	enlarged spleen	J:19570
	impaired neutrophil chemotaxis	J:19570
	increased B cell number	J:19570
	increased circulating interleukin-6 level	J:19570
	increased neutrophil cell number	J:19570
	lymph node medullary cord hyperplasia	J:19570
	myeloid hyperplasia	J:19570
\Cxcr2^tm1Mwm/\Cxcr2^tm1Mwm (C.129S2(B6)-Cxcr2^tm1Mwm/J)	abnormal chemokine level	J:73947
	abnormal cytokine secretion	J:72824
	abnormal eosinophil physiology	J:73947
	abnormal interleukin level	J:73947, J:87365
	abnormal leukocyte physiology	J:94170
	abnormal neutrophil physiology	J:93946, J:73947
	abnormal NK T cell physiology	J:66399
	abnormal T cell physiology	J:73947
	abnormal T-helper 1 physiology	J:73947
	abnormal T-helper 2 physiology	J:73947
	decreased susceptibility to fungal infection	J:73947
	decreased susceptibility to induced arthritis	J:142880
	impaired neutrophil chemotaxis	J:65905, J:72824
	impaired neutrophil recruitment	J:65425, J:63935, J:93116
	increased IgE level	J:73947
	increased susceptibility to bacterial infection	J:65905
	increased susceptibility to Herpesvirales infection	J:87365
	increased susceptibility to parasitic infection	J:72824
\Cxcr2^tm1Mwm/\Cxcr2^tm1Mwm (involves: 129S2/SvPas * BALB/c)	abnormal myelopoiesis	J:113489
	abnormal neutrophil physiology	J:113489
	decreased thymus weight	J:113489
	increased granulocyte number	J:113489
	increased spleen weight	J:113489
\Cxcr2^tm1Mwm/\Cxcr2^tm1Mwm (involves: 129S2/SvPas)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:208901
\Cxcr2^tm1Rmra/\Cxcr2^tm1Rmra \Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * CBA)	abnormal neutrophil physiology	J:204482
\Cxcr3^tm1Raks/\Cxcr3^tm1Raks (B6.129P2-Cxcr3^tm1Raks)	kidney inflammation	J:152790
\Cxcr3^tm1Wwh/Y (B6.Cg-Cxcr3^tm1Wwh)	abnormal cellular extravasation	J:107646
	abnormal interferon level	J:91359
	impaired macrophage chemotaxis	J:107646
	increased length of allograft survival	J:65916
	lung inflammation	J:91359
\Cxcr3^tm1Wwh/\Cxcr3^tm1Wwh (B6.Cg-Cxcr3^tm1Wwh)	abnormal cellular extravasation	J:96905, J:107646
	abnormal interferon level	J:91359
	decreased susceptibility to Riboviria infection	J:96905
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:96905
	impaired macrophage chemotaxis	J:107646
	increased length of allograft survival	J:65916
	lung inflammation	J:91359
\Cxcr4^em1(IMPC)Mbp/\Cxcr4⁺ (C57BL/6NCrl-Cxcr4^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Cxcr4^tm1.1Bala/\Cxcr4⁺ (B6.129S2-Cxcr4^tm1.1Bala)	abnormal CD4-positive, alpha-beta T cell number	J:186735
	abnormal immune system cell morphology	J:186735
	abnormal immune system morphology	J:186735
	abnormal immune system organ morphology	J:186735
	abnormal immune system physiology	J:186735
	abnormal lymph node B cell domain morphology	J:186735
	abnormal lymph node morphology	J:186735
	abnormal neutrophil morphology	J:186735
	abnormal NK cell physiology	J:178789
	abnormal spleen morphology	J:186735
	abnormal spleen white pulp morphology	J:186735
	abnormal thymus morphology	J:186735
	decreased B cell apoptosis	J:186735
	decreased B cell number	J:186735
	decreased immature B cell number	J:186735
	decreased leukocyte cell number	J:186735
	decreased NK cell number	J:178789
	decreased spleen weight	J:186735
	decreased T cell number	J:186735
	increased IgG level	J:186735
	increased IgM level	J:186735
	increased immunoglobulin level	J:186735
	increased mature B cell number	J:186735
	increased NK cell number	J:178789
\Cxcr4^tm1Qma/\Cxcr4^tm1Qma (involves: 129X1/SvJ)	decreased pro-B cell number	J:49070
\Cxcr4^tm1Qma/\Cxcr4^tm1Qma (involves: 129X1/SvJ)	impaired myelopoiesis	J:49070
\Cxcr4^tm1Qma/\Cxcr4^tm1Qma (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Retroviridae infection	J:132342
\Cxcr4^tm1Qma/\Cxcr4^tm1Qma (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to Retroviridae infection induced morbidity/mortality	J:132342
\Cxcr4^tm1Tng/\Cxcr4^tm1Tng (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:69256
\Cxcr4^tm1Tng/\Cxcr4^tm1Tng (involves: 129P2/OlaHsd)	failure of myelopoiesis	J:69256
\Cxcr4^tm1Tng/\Cxcr4^tm1Tng (B6.Cg-Cxcr4^tm1Tng)	abnormal T cell differentiation	J:82996
\Cxcr4^tm1Tng/\Cxcr4^tm1Tng (B6.Cg-Cxcr4^tm1Tng)	decreased double-positive T cell number	J:82996
\Cxcr4^tm1Yiw/\Cxcr4^tm1Yiw \Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd)	abnormal leukocyte migration	J:164872
	decreased susceptibility to induced arthritis	J:164872
	decreased thymocyte number	J:164872
\Cxcr4^tm1Yzo/\Cxcr4^tm1Yzo (Not Specified)	abnormal B cell differentiation	J:167314
	abnormal B cell physiology	J:167314
	abnormal leukopoiesis	J:69255
	abnormal lymphopoiesis	J:69255
	impaired myelopoiesis	J:69255
\Cxcr4^tm2Yzo/\Cxcr4^tm2Yzo \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:94911
	abnormal Peyer's patch follicle morphology	J:94911
	decreased B-1 B cell number	J:94911
	decreased B-2 B cell number	J:94911
	decreased immunoglobulin level	J:94911
	decreased mature B cell number	J:94911
	decreased plasma cell number	J:94911
\Cxcr4^tm2Yzo/\Cxcr4^tm2Yzo \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased lymphocyte cell number	J:217569
	increased monocyte cell number	J:217569
	increased neutrophil cell number	J:217569
\Cxcr4^tm2Yzo/\Cxcr4^tm2Yzo \Tg(Fabp4-cre)1Rev/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage cell number	J:217569
	decreased B cell number	J:217569
	decreased CD4-positive, alpha-beta T cell number	J:217569
	increased CD8-positive, alpha-beta T cell number	J:217569
\Cxcr4^tm2Yzo/\Cxcr4^tm3.1Yzo \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:167314
\Cxcr4^tm3.1Yzo/\Cxcr4^tm3.1Yzo (Not Specified)	abnormal B cell physiology	J:167314
	decreased pro-B cell number	J:167314
	impaired myelopoiesis	J:167314
\Cxcr5^tm1.1Namt/\Cxcr5^tm1.1Namt \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6J * CBA)	abnormal dendritic cell chemotaxis	J:241561
	decreased follicular dendritic cell number	J:241561
	decreased susceptibility to prion infection	J:241561
	immune system phenotype	J:241561
\Cxcr5^tm1.1Namt/\Cxcr5^tm1.1Namt \Tg(Itgax-cre)1-1Reiz/0 \Tg(Prnp)a20Cwe/0 (involves: C57BL/6 * C57BL/6J * CBA)	decreased susceptibility to prion infection	J:241561
\Cxcr5^tm1Lipp/\Cxcr5^tm1Lipp (involves: 129S2/SvPas * CD-1)	abnormal leukocyte migration	J:37126
	abnormal Peyer's patch morphology	J:37126
	abnormal spleen primary B follicle morphology	J:37126
	abnormal spleen secondary B follicle morphology	J:37126
	absent axillary lymph nodes	J:78282
	absent brachial lymph nodes	J:78282
	absent cervical lymph nodes	J:78282
	absent follicular dendritic cells	J:78282
	absent inguinal lymph nodes	J:78282, J:37126
	absent lymph nodes	J:78282
	absent Peyer's patches	J:37126
	absent spleen germinal center	J:37126
	increased B cell number	J:37126
\Cxv1^F/St/\Cxv1^F/St (involves: AKR/J * F/St)	abnormal immune cell physiology	J:7030
\Cxv2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	abnormal immune cell physiology	J:6143
\Cyb5d1^{tm1.1(KOMP)Vlcg}/\Cyb5d1^{tm1.1(KOMP)Vlcg} (B6N(Cg)-Cyb5d1^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
\Cyb5r3^{tm1c(KOMP)Wtsi}/\Cyb5r3^{tm1c(KOMP)Wtsi} \Tg(Myh11-icre/ERT2)1Soff/0 (B6.Cg-Cyb5r3^{tm1c(KOMP)Wtsi} Tg(Myh11-icre/ERT2)1Soff)	decreased monocyte cell number	J:280543
\Cyb561d2^{tm1b(EUCOMM)Wtsi}/\Cyb561d2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cyb561d2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Cyba^nmf333/\Cyba^nmf333 (A.B6 Tyr⁺-Cyba^nmf333/J)	abnormal neutrophil physiology	J:132359
	increased inflammatory response	J:132359
	increased susceptibility to bacterial infection	J:132359
	lung inflammation	J:132359
	sepsis	J:132359
\Cyba^{tm1a(EUCOMM)Wtsi}/\Cyba^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Cyba^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Cyba^tm1Dgh/\Cyba^tm1Dgh (B6.Cg-Cyba^tm1Dgh)	abnormal T cell activation	J:231269
\Cyba^tm1Dgh/\Cyba^tm1Dgh (B6.Cg-Cyba^tm1Dgh)	decreased inflammatory response	J:231269
\Cybb^tm1.1Abk/\Cybb^tm1.1Abk \Lyz2^tm1(cre)Ifo/? (B6.Cg-Lyz2^tm1(cre)Ifo Cybb^tm1.1Abk)	abnormal macrophage chemotaxis	J:245699
	enlarged spleen	J:245699
\Cybb^tm1Din/Y (involves: 129S/SvEv * C57BL/6)	abnormal immune system physiology	J:22868
	abnormal macrophage physiology	J:22868
	abnormal neutrophil physiology	J:22868
	increased inflammatory response	J:22868
	increased susceptibility to bacterial infection	J:22868
	increased susceptibility to infection	J:22868
\Cybb^tm1Din/\Cybb^tm1Din (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:64232
\Cybb^tm1Din/\Cybb^tm1Din (B6.129S-Cybb^tm1Din)	granulomatous inflammation	J:146231
	immune system phenotype	J:113463
	increased acute inflammation	J:110181
\Cybb^tm1Din/\Cybb^tm1Din (B6.129S-Cybb^tm1Din/J)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
\Cybb^tm1Din/\Cybb^tm1Din \Nrros^tm1Lex/\Nrros^tm1Lex (B6.129S-Nrros^tm1Lex Cybb^tm1Din)	immune system phenotype	J:209569
\Cybb^{tm2b(KOMP)Wtsi}/\Cybb^{tm2b(KOMP)Wtsi} (C57BL/6N-Cybb^{tm2b(KOMP)Wtsi}/H)	increased spleen weight	J:211773
\Cycs^tm1Mak/\Cycs^tm1Mak (involves: C57BL/6)	absent pre-B cells	J:98949
	decreased B cell number	J:98949
	decreased leukocyte cell number	J:98949
	decreased T cell number	J:98949
	increased spleen weight	J:98949
	spleen hyperplasia	J:98949
	thymus atrophy	J:98949
	thymus hypoplasia	J:98949
\Cyld^tm1.1Awai/\Cyld^tm1.1Awai (Not Specified)	abnormal B cell differentiation	J:126113
	abnormal B cell morphology	J:126113
	abnormal B cell physiology	J:126113
	abnormal class switch recombination	J:126113
	abnormal humoral immune response	J:126113
	abnormal Peyer's patch germinal center morphology	J:126113
	abnormal spleen marginal zone morphology	J:126113
	abnormal spleen morphology	J:126113
	decreased B-1 B cell number	J:126113
	decreased IgG3 level	J:126113
	decreased IgM level	J:126113
	decreased immature B cell number	J:126113
	enlarged lymph nodes	J:126113
	enlarged Peyer's patches	J:126113
	enlarged spleen	J:126113
	increased B cell number	J:126113
	increased follicular B cell number	J:126113
	increased IgA level	J:126113
	increased IgG1 level	J:126113
	increased IgG2a level	J:126113
	increased IgG2b level	J:126113
	increased marginal zone B cell number	J:126113
	increased pro-B cell number	J:126113
\Cyld^tm1.1Mpa/\Cyld^tm1.1Mpa \Fadd^tm1Mpa/\Fadd^tm1Mpa \Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Cyld^tm1.1Mpa Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
\Cyld^tm1.1Mpa/\Cyld^tm1.1Mpa \Ikbkg^tm1.1Mpa/Y \Tg(Vil1-cre)997Gum/0 (B6.Cg-Cyld^tm1.1Mpa Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
\Cyld^tm1.1Mpa/\Cyld^tm1.1Mpa \Ikbkg^tm1.1Mpa/\Ikbkg^tm1.1Mpa \Tg(Vil1-cre)997Gum/0 (B6.Cg-Cyld^tm1.1Mpa Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
\Cyld^tm1Awai/\Cyld^tm1Awai \Tg(CD19-cre/ERT2)1Cgn/? (Not Specified)	abnormal mature B cell morphology	J:126113
	decreased B-1 B cell number	J:126113
	decreased immature B cell number	J:126113
	enlarged lymph nodes	J:126113
	enlarged Peyer's patches	J:126113
	enlarged spleen	J:126113
	increased B cell number	J:126113
\Cyld^tm1Jdgl/\Cyld^tm1Jdgl (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:124327
\Cyld^tm1Jdgl/\Cyld^tm1Jdgl (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:124327
\Cyld^tm1Lex/\Cyld^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal inflammatory response	J:114972
	immune system phenotype	J:114972
	increased susceptibility to induced colitis	J:114972
	thymus hyperplasia	J:114972
\Cyld^tm1Ref/\Cyld^tm1Ref (Not Specified)	immune system phenotype	J:126113
\Cyld^tm1Scs/\Cyld^tm1Scs (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell differentiation	J:112392
	abnormal T cell number	J:112392
	decreased CD4-positive, alpha-beta T cell number	J:112392
	decreased CD8-positive, alpha-beta T cell number	J:112392
	increased double-positive T cell number	J:112392
\Cyp1a1^tm1.1Dwn/\Cyp1a1^tm1.1Dwn (B6.129P2-Cyp1a1^tm1.1Dwn)	decreased lymphocyte cell number	J:163973
	decreased spleen weight	J:163973
	decreased thymus weight	J:163973
	increased neutrophil cell number	J:163973
\Cyp1a1^tm1.1Dwn/\Cyp1a1^tm1.1Dwn (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:122409
	small spleen	J:122409
	small thymus	J:122409
\Cyp1a1^tm4.1Dwn/\Cyp1a1^tm4.1Dwn (B6.129X1-Cyp1a1^tm4.1Dwn)	decreased lymphocyte cell number	J:163973
	decreased spleen weight	J:163973
	decreased thymus weight	J:163973
	increased neutrophil cell number	J:163973
\Cyp1a^tm1Dwn/\Cyp1a^tm1Dwn (B6.129-Cyp1a^tm1Dwn)	decreased leukocyte cell number	J:122409
	small spleen	J:122409
	small thymus	J:122409
\Cyp2ab1^{tm1b(KOMP)Wtsi}/\Cyp2ab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Cyp2ab1^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Cyp2c70^em1Sjka/\Cyp2c70^em1Sjka (C57BL/6-Cyp2c70^em1Sjka)	increased spleen weight	J:330641
\Cyp2c70^em1Sjka/\Cyp2c70^em1Sjka (C57BL/6-Cyp2c70^em1Sjka)	liver inflammation	J:330641
\Cyp2c70^em1Utr/\Cyp2c70^em1Utr (C57BL/6J-Cyp2c70^em1Utr)	liver inflammation	J:302190
\Cyp2c^tm1104Arte/\Cyp2c^tm1104Arte (B6NTac(Cg)-Cyp2c^tm1104Arte/Arte)	liver inflammation	J:241121
\Cyp2c^{tm1897.1(Alb-CYP2C9)Arte}/\Cyp2c^{tm1897.1(Alb-CYP2C9)Arte} (B6(Cg)-Cyp2c^{tm1897.1(Alb-CYP2C9)Arte}/Arte)	liver inflammation	J:241121
\Cyp2d22^em1(IMPC)Tcp/\Cyp2d22^em1(IMPC)Tcp (C57BL/6NCrl-Cyp2d22^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Cyp2f2^em1(IMPC)H/\Cyp2f2^em1(IMPC)H (C57BL/6N-Cyp2f2^em1(IMPC)H/H)	enlarged spleen	J:211773
\Cyp2g1^{tm1(rtTA)Lane}/\Cyp2g1⁺ \Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0 (involves: 129 * C57BL/6 * SJL)	increased macrophage cell number	J:157842
	rhinitis	J:157842
\Cyp4v3^em1Xsu/\Cyp4v3^em1Xsu (C57BL/6J-Cyp4v3^em1Xsu)	increased microglial cell activation	J:321817
\Cyp7a1^{tm1b(EUCOMM)Wtsi}/\Cyp7a1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Cyp7a1^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
\Cyp7b1^tm1Rus/\Cyp7b1^tm1Rus (involves: 129S/SvEv * C57BL/6J)	decreased IgA level	J:170807
\Cyp11a1^tm2Bcc/\Cyp11a1^tm2Bcc (Not Specified)	decreased T cell apoptosis	J:133007
\Cyp11b1^tm1Chjk/\Cyp11b1^tm1Chjk (involves: 129P2/OlaHsd * C57BL/6J)	decreased thymus weight	J:147610
\Cyp19a1^{tm1b(EUCOMM)Hmgu}/\Cyp19a1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cyp19a1^{tm1b(EUCOMM)Hmgu}/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Cyp19a1^tm1Esi/\Cyp19a1^tm1Esi (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen germinal center morphology	J:92438
	enlarged mesenteric lymph nodes	J:92438
	enlarged spleen	J:92438
	increased autoantibody level	J:92438
	increased B cell number	J:92438
	increased granulocyte number	J:92438
	increased IgG level	J:92438
	increased leukocyte cell number	J:92438
	increased lymphocyte cell number	J:92438
	increased mature B cell number	J:92438
	kidney inflammation	J:92438
	salivary gland inflammation	J:92438
	spleen hyperplasia	J:92438
\Cyp19a1^tm1Sih/\Cyp19a1^tm1Sih (involves: 129S/SvEv)	increased anti-single stranded DNA antibody level	J:216958
	increased autoantibody level	J:216958
	increased dendritic cell number	J:216958
	increased macrophage cell number	J:216958
	increased susceptibility to autoimmune disorder	J:216958
	lacrimal gland inflammation	J:216958
	salivary gland inflammation	J:216958
\Cyp19a1^tm1Toda/\Cyp19a1^tm1Toda (involves: 129P2/OlaHsd * C57BL/6J)	increased osteoclast cell number	J:114305
\Cyp21a1^em1(IMPC)Tcp/\Cyp21a1⁺ (C57BL/6NCrl-Cyp21a1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
\Cyp26b1^tm1Hmd/\Cyp26b1^tm1Hmd (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphatic vessel endothelial cell morphology	J:206581
\Cyp26b1^tm1Hmd/\Cyp26b1^tm1Hmd \Tg(Prox1-EGFP)KY221Gsat/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/NTac)	abnormal lymphatic vessel endothelial cell morphology	J:206581
	abnormal lymphatic vessel morphology	J:206581
\Cyp27b1^{tm1b(EUCOMM)Hmgu}/\Cyp27b1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cyp27b1^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Cyp27b1^tm1Dgo/\Cyp27b1^tm1Dgo (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	decreased osteoclast cell number	J:70030
	decreased T cell number	J:70030
	enlarged lymph nodes	J:70030
\Cyp51^tm1.1Bfro/\Cyp51^tm1.1Bfro (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphatic vessel morphology	J:173366
	abnormal lymphatic vessel smooth muscle morphology	J:173366
\Cypr1^STS/A/? (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
\Cypr2^BALB/c/? (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
\Cypr3^BALB/c/? (involves: BALB/c * STS/A)	abnormal cytokine secretion	J:52119
\Cyren^em1Vokh/\Cyren^em1Vokh (C57BL/6-Cyren^em1Vokh)	abnormal class switch recombination	J:306598
\Cyren^{tm1.1(KOMP)Vlcg}/\Cyren^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal class switch recombination	J:265834
\Cyrib^m1Ivdi/\Cyrib^m1Ivdi (involves: 129S1/Sv * 129X1/SvJ * DBA/2J)	abnormal spleen morphology	J:282597
	abnormal spleen white pulp morphology	J:282597
	increased circulating interleukin-6 level	J:282597
	increased circulating interleukin-10 level	J:282597
	increased circulating tumor necrosis factor level	J:282597
	increased neutrophil cell number	J:282597
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282597
\Cyrib^{tm1c(KOMP)Wtsi}/\Cyrib^{tm1d(KOMP)Wtsi} \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BcA17/Skmn * C57BL/6N)	abnormal circulating chemokine level	J:282597
	abnormal neutrophil physiology	J:282597
	increased circulating CXCL10 level	J:282597
	increased circulating interleukin-6 level	J:282597
	increased circulating interleukin-10 level	J:282597
	increased circulating tumor necrosis factor level	J:282597
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282597
\Cys1^cpk/\Cys1^cpk (involves: C57BL/6J * CD-1)	spleen hypoplasia	J:33739
\Cys1^cpk/\Cys1^cpk (involves: C57BL/6J * CD-1)	thymus hypoplasia	J:33739
\Cys1^cpk/\Cys1^cpk (129.B6-Cys1^cpk)	liver inflammation	J:116210
\Cysltr1^tm1Ykn/\Cysltr1^tm1Ykn (involves: C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:77087
\Cysltr1^tm1Ykn/\Cysltr1^tm1Ykn (involves: C57BL/6)	respiratory system inflammation	J:88647
\Cysltr1^tm1Ykn/\Cysltr1^tm1Ykn (C.B6-Cysltr1^tm1Ykn)	immune system phenotype	J:182213
\Cysltr1^tm1Ykn/\Cysltr1^tm1Ykn \Cysltr2^tm1Ykn/\Cysltr2^tm1Ykn (involves: BALB/c * C57BL/6)	abnormal immune system physiology	J:198383
\Cysltr1^tm1Ykn/\Cysltr1^tm1Ykn \Cysltr2^tm1Ykn/\Cysltr2^tm1Ykn \Oxgr1^{tm1(KOMP)Vlcg}/\Oxgr1^{tm1(KOMP)Vlcg} (involves: BALB/c * C57BL/6 * C57BL/6NTac)	abnormal immune system physiology	J:198383
\Cysltr2^tm1Ykn/\Cysltr2^tm1Ykn (C57BL/6-Cysltr2^tm1Ykn)	decreased susceptibility to type I hypersensitivity reaction	J:94488
\Cysltr2^tm1Ykn/\Cysltr2^tm1Ykn (C.B6-Cysltr2^tm1Ykn)	autoimmune response	J:182213
\Cystm1^{tm1b(EUCOMM)Hmgu}/\Cystm1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Cystm1^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Cyth2^{tm1d(EUCOMM)Wtsi}/\Cyth2^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N)	decreased eosinophil cell number	J:307633
	decreased susceptibility to type I hypersensitivity reaction	J:307633
\Cytip^tm1Tes/\Cytip^tm1Tes (involves: 129S1/Sv * FVB/N)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:110320
	abnormal cellular extravasation	J:110320
	abnormal leukocyte migration	J:110320
	decreased leukocyte cell number	J:110320
	decreased lymphocyte cell number	J:110320
	lymph node hypoplasia	J:110320
\Cytip^tm1Wtw/\Cytip^tm1Wtw (involves: 129S6/SvEvTac * C57BL/6)	abnormal response to transplant	J:112168
	immune system phenotype	J:112168
\Cytl1^tm1Chun/\Cytl1^tm1Chun (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to induced arthritis	J:175377
\D6Wsu163e^{tm1b(EUCOMM)Wtsi}/\D6Wsu163e^{tm1b(EUCOMM)Wtsi} (C57BL/6N-D6Wsu163e^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased memory-marker NK cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
\D630045J12Rik^{tm1b(KOMP)Wtsi}/\D630045J12Rik^{tm1b(KOMP)Wtsi} (C57BL/6N-D630045J12Rik^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
\Daam2^{tm1b(KOMP)Wtsi}/\Daam2^{tm1b(KOMP)Wtsi} (C57BL/6N-Daam2^{tm1b(KOMP)Wtsi}/Wtsi)	increased large unstained cell number	J:211773
\Dab1^scm-4J/\Dab1^scm-4J (CBA/J-Dab1^scm-4J/GrsrJ)	thymus atrophy	J:153275
\Dach2^{em1(IMPC)Ccpcz}/\Dach2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Dach2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	small lymph nodes	J:211773
	small spleen	J:211773
\Dact2^{tm1b(EUCOMM)Wtsi}/\Dact2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dact2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Dad1^tm1Kni/\Dad1⁺ (involves: 129S/SvEv)	decreased thymus weight	J:99897
\Dagla^{tm1a(EUCOMM)Wtsi}/\Dagla^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Dagla^{tm1a(EUCOMM)Wtsi}/Nju)	small spleen	J:211773
	small thymus	J:211773
\Dapp1^{Gt(OST111213)Lex}/\Dapp1^{Gt(OST111213)Lex} (B6.Cg-Dapp1^{Gt(OST111213)Lex})	abnormal humoral immune response	J:110009
	decreased B cell proliferation	J:110009
	decreased IgG3 level	J:110009
	increased susceptibility to bacterial infection	J:110009
\Dapp1^tm1Mnz/\Dapp1^tm1Mnz (B6.129P2-Dapp1^tm1Mnz)	abnormal B cell activation	J:86182
	decreased B cell proliferation	J:86182
	decreased B-1a cell number	J:86182
	decreased IgG3 level	J:86182
	decreased IgM level	J:86182
\Daw1^b2b1116Clo/\Daw1^b2b1116Clo (C57BL/6J-Daw1^b2b1116Clo)	spleen hypoplasia	J:175213
\Daw1^b2b1584Clo/\Daw1^b2b1584Clo (C57BL/6J-Daw1^b2b1584Clo)	absent spleen	J:175213
\Dbacl^C57BL/6Jcl/\Dbacl^C57BL/6Jcl (NOD.B6-(D4Mit193-D4Mit17))	increased susceptibility to autoimmune diabetes	J:144964
	insulitis	J:144964
\Dbn1^{tm1a(KOMP)Wtsi}/\Dbn1⁺ (C57BL/6N-Dbn1^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Dbn1^{tm1b(KOMP)Wtsi}/\Dbn1⁺ (C57BL/6N-Dbn1^{tm1b(KOMP)Wtsi}/Wtsi)	increased CD8-positive, alpha-beta T cell number	J:211773
\Dbnl^{Gt(betageo)11Byg}/\Dbnl^{Gt(betageo)11Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell activation	J:119847
	abnormal T cell physiology	J:119847
	decreased IgG1 level	J:119847
	decreased IgM level	J:119847
	decreased immunoglobulin level	J:119847
	decreased interleukin-2 secretion	J:119847
	decreased T cell proliferation	J:119847
	immune system phenotype	J:119847
\Dbnl^tm1Jwnd/\Dbnl⁺ (involves: BALB/c)	increased spleen weight	J:109363
\Dbnl^tm1Jwnd/\Dbnl^tm1Jwnd (involves: BALB/c)	increased spleen weight	J:109363
\Dbr1^{Gt(YTA280)Byg}/\Dbr1⁺ (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:223318
\Dcaf5^{em1(IMPC)Ccpcz}/\Dcaf5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Dcaf5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased NK cell number	J:211773
	increased spleen weight	J:211773
	small spleen	J:211773
\Dcaf8^{em1(IMPC)Ccpcz}/\Dcaf8^{em1(IMPC)Ccpcz} (C57BL/6N-Dcaf8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Dcaf12^{em1(IMPC)Ccpcz}/\Dcaf12^{em1(IMPC)Ccpcz} (C57BL/6N-Dcaf12^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
\Dcaf15^{tm1a(EUCOMM)Hmgu}/\Dcaf15^{tm1a(EUCOMM)Hmgu} (C57BL/6NCrl-Dcaf15^{tm1a(EUCOMM)Hmgu}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased NK cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
\Dcbld2^{tm1a(KOMP)Wtsi}/\Dcbld2^{tm1a(KOMP)Wtsi} (C57BL/6N-Dcbld2^{tm1a(KOMP)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\Dcc^{Tg(H2-Kb-Jak2V617F)1Shmd}/\Dcc⁺ (involves: C57BL/6 DBA/2)	abnormal neutrophil morphology	J:130189
	abnormal spleen morphology	J:130189
	decreased spleen white pulp amount	J:130189
	enlarged spleen	J:130189
	increased granulocyte number	J:130189
	increased leukocyte cell number	J:130189
	increased spleen red pulp amount	J:130189
	increased spleen weight	J:130189
	myeloid hyperplasia	J:130189
\Dcc^{tm1b(NCOM)Mfgc}/\Dcc⁺ (C57BL/6N-Dcc^{tm1b(NCOM)Mfgc}/Tcp)	increased neutrophil cell number	J:211773
\Dck^m1Btlr/\Dck⁺ (C57BL/6J-Dck^m1Btlr)	decreased B cell number	J:236696
\Dck^m1Btlr/\Dck^m1Btlr (C57BL/6J-Dck^m1Btlr)	decreased B cell number	J:236696
	decreased CD4-positive, alpha-beta T cell number	J:236696
	decreased IgG level	J:236696
	decreased response to antigen	J:236696
	increased CD8-positive, alpha-beta T cell number	J:236696
	increased IgE level	J:236696
	increased macrophage cell number	J:236696
\Dck^memi/\Dck^memi (C57BL/6J-Dck^memi)	abnormal myeloid leukocyte morphology	J:184080
	abnormal response to infection	J:184080
	abnormal T cell differentiation	J:184080
	decreased B cell number	J:184080
	decreased CD4-positive, alpha-beta T cell number	J:184080
	enlarged spleen	J:184080
	increased effector memory CD4-positive, alpha-beta T cell number	J:184080
	increased effector memory CD8-positive, alpha-beta T cell number	J:184080
	increased T cell apoptosis	J:184080
	increased T cell proliferation	J:184080
	small thymus	J:184080
	thymus hypoplasia	J:184080
\Dck^tm1.1Radu/\Dck^tm1.1Radu (involves: 129S4/SvJae * BALB/cJ * C57BL/6 * C57BL/6J)	abnormal double-negative T cell morphology	J:158373
	abnormal peripheral lymph node morphology	J:158373
	abnormal spleen morphology	J:158373
	abnormal T cell differentiation	J:158373
	abnormal thymus morphology	J:158373
	absent spleen white pulp	J:158373
	decreased B cell number	J:158373
	decreased double-positive T cell number	J:158373
	decreased pre-B cell number	J:158373
	decreased T cell number	J:158373
	increased double-negative T cell number	J:158373
	increased pro-B cell number	J:158373
	increased spleen weight	J:158373
	thymus hypoplasia	J:158373
\Dclk1^{tm1a(EUCOMM)Wtsi}/\Dclk1⁺ (C57BL/6N-Dclk1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\Dclk1^{tm1a(EUCOMM)Wtsi}/\Dclk1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Dclk1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\Dclre1a^tm1Rleg/\Dclre1a^tm1Rleg (involves: 129S7/SvEvBrd)	immune system phenotype	J:102381
\Dclre1a^tm1Rleg/\Dclre1a^tm1Rleg (involves: 129S7/SvEvBrd)	increased susceptibility to bacterial infection	J:102381
\Dclre1a^tm1Rleg/\Dclre1a^tm1Rleg \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:102381
\Dclre1c^m1Brck/\Dclre1c^m1Brck (involves: C3H * C57BL/6)	absent B cells	J:207533
\Dclre1c^m1Brck/\Dclre1c^m1Brck (involves: C3H * C57BL/6)	absent T cells	J:207533
\Dclre1c^m1Brck/\Dclre1c^m1Brck (involves: C57BL/6)	absent B cells	J:207533
	absent CD4-positive, alpha-beta T cells	J:207533
	absent CD8-positive, alpha-beta T cells	J:207533
	decreased DN1 thymic pro-T cell number	J:207533
	decreased DN4 thymocyte number	J:207533
	decreased double-positive T cell number	J:207533
	decreased pre-B cell number	J:207533
	immune system phenotype	J:207533
\Dclre1c^m1Btlr/\Dclre1c^m1Btlr (C57BL/6J-Dclre1c^m1Btlr)	decreased B cell number	J:217790
	decreased IgM level	J:217790
	decreased response to antigen	J:217790
	decreased single-positive T cell number	J:217790
	decreased T cell number	J:217790
	impaired humoral immune response	J:217790
	increased macrophage cell number	J:217790
	increased neutrophil cell number	J:217790
	increased NK cell number	J:217790
\Dclre1c^M2Btlr/\Dclre1c^M2Btlr (C57BL/6J-Dclre1c^M2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265131
	decreased CD8-positive, naive alpha-beta T cell number	J:265131
	decreased single-positive T cell number	J:265131
	decreased T cell number	J:265131
	increased central memory CD8 positive, alpha-beta T cell number	J:265131
	increased effector memory CD4-positive, alpha-beta T cell number	J:265131
	increased effector memory CD8-positive, alpha-beta T cell number	J:265131
\Dclre1c^m3Btlr/\Dclre1c^m3Btlr (C57BL/6J-Dclre1c^m3Btlr)	decreased B cell number	J:265132
	decreased B-1 B cell number	J:265132
	decreased CD4-positive, alpha-beta T cell number	J:265132
	decreased CD8-positive, alpha-beta T cell number	J:265132
	decreased CD8-positive, naive alpha-beta T cell number	J:265132
	decreased NK T cell number	J:265132
	decreased single-positive T cell number	J:265132
	decreased T cell number	J:265132
	increased central memory CD4-positive, alpha-beta T cell number	J:265132
	increased effector memory CD4-positive, alpha-beta T cell number	J:265132
	increased effector memory CD8-positive, alpha-beta T cell number	J:265132
\Dclre1c^tm1.1Fwa/\Dclre1c^tm1.1Fwa (involves: 129S6/SvEvTac * C57BL/6)	arrested B cell differentiation	J:80995
	arrested T cell differentiation	J:80995
\Dclre1c^tm1.1Jpdv/\Dclre1c^tm1.1Jpdv (involves: 129P1/ReJ)	abnormal B cell differentiation	J:137743
	abnormal T cell receptor V(D)J recombination	J:194422
	arrested T cell differentiation	J:137712
\Dclre1c^tm1Fwa/\Dclre1c^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	absent immature B cells	J:80995
	arrested B cell differentiation	J:80995
	arrested T cell differentiation	J:80995
	decreased thymocyte number	J:80995
\Dclre1c^tm1Fwa/\Dclre1c^tm1Fwa (involves: 129S6/SvEvTac)	abnormal T cell receptor beta chain V(D)J recombination	J:147864
	absent B cells	J:147864
	arrested B cell differentiation	J:147864
	decreased CD4-positive, alpha-beta T cell number	J:147864
	decreased CD8-positive, alpha-beta T cell number	J:147864
	decreased double-positive T cell number	J:147864
	decreased thymocyte number	J:147864
	spleen hypoplasia	J:147864
\Dclre1c^tm1Jsek/\Dclre1c^tm1Jsek (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:147864
	abnormal T cell receptor beta chain V(D)J recombination	J:147864
	decreased B cell number	J:147864
	decreased CD4-positive, alpha-beta T cell number	J:147864
	decreased CD8-positive, alpha-beta T cell number	J:147864
	decreased double-positive T cell number	J:147864
	decreased pre-B cell number	J:147864
	decreased thymocyte number	J:147864
	increased pro-B cell number	J:147864
	spleen hypoplasia	J:147864
\Dclre1c^tm2.1Jpdv/\Dclre1c^tm2.2Jpdv \Tg(Cr2-cre)3Cgn/0 (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:153841
	immune system phenotype	J:153841
\Dclre1c^tm2.2Jpdv/\Dclre1c^tm2.2Jpdv (B6.129S2-Dclre1c^tm2.2Jpdv)	abnormal mononuclear cell morphology	J:153841
	absent immature B cells	J:153841
	arrested B cell differentiation	J:153841
	arrested T cell differentiation	J:153841
	decreased CD4-positive, alpha-beta T cell number	J:153841
	decreased CD8-positive, alpha-beta T cell number	J:153841
	decreased double-positive T cell number	J:153841
	decreased mature B cell number	J:153841
	decreased splenocyte number	J:153841
	decreased thymocyte number	J:153841
\Dclre1c^tm2Mcow/\Dclre1c^tm2Mcow (involves: 129/Sv * C57BL/6)	abnormal leukocyte physiology	J:96535
	abnormal lymph node morphology	J:96535
	abnormal spleen B cell follicle morphology	J:96535
	absent thymus cortex	J:96535
	arrested B cell differentiation	J:96535
	arrested T cell differentiation	J:96535
	decreased B cell proliferation	J:96535
	decreased lymphocyte cell number	J:96535
	decreased T cell proliferation	J:96535
	decreased thymocyte number	J:96535
	decreased thymus weight	J:96535
	small lymph nodes	J:96535
	small spleen	J:96535
\Dcn^tm1Ioz/\Dcn⁺ (either: C.Cg-Dcn^tm1Ioz or C3.Cg-Dcn^tm1Ioz)	decreased susceptibility to bacterial infection	J:68640
\Dcn^tm1Ioz/\Dcn⁺ \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129/Sv * Black Swiss * C57BL/6)	increased T cell derived lymphoma incidence	J:53511
\Dcn^tm1Ioz/\Dcn^tm1Ioz (involves: 129S1/Sv * 129X1/SvJ * Black Swiss)	immune system phenotype	J:39212
	tubular nephritis	J:75298
\Dcn^tm1Ioz/\Dcn^tm1Ioz (either: C.Cg-Dcn^tm1Ioz or C3.Cg-Dcn^tm1Ioz)	decreased susceptibility to bacterial infection	J:68640
\Dcn^tm1Ioz/\Dcn^tm1Ioz (C.129(Cg)-Dcn^tm1Ioz)	abnormal humoral immune response	J:92428
\Dcn^tm1Ioz/\Dcn^tm1Ioz \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129/Sv * Black Swiss * C57BL/6)	enlarged thymus	J:53511
	increased T cell derived lymphoma incidence	J:53511
	thymus hyperplasia	J:53511
\Dcstamp^tm1Suda/\Dcstamp^tm1Suda (Not Specified)	abnormal macrophage physiology	J:100555
	abnormal osteoclast differentiation	J:100555
	abnormal osteoclast physiology	J:100555
\Dctn1^tm2.1Cai/\Dctn1^tm2.1Cai \Tg(Thy1-cre)1Vln/? (involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB/N)	microgliosis	J:264431
\Dcun1d1^{Gt(RRR261)Byg}/\Dcun1d1^{Gt(RRR261)Byg} (involves: 129P2/OlaHsd)	lymphoid hypoplasia	J:262901
	spleen hypoplasia	J:262901
\Ddb1^{em1(IMPC)Ccpcz}/\Ddb1⁺ (C57BL/6N-Ddb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Ddc^tm1.1Rhrs/\Ddc^tm1.1Rhrs \Tg(Ggt1-cre)M3Egn/0 (involves: 129 * C57BL/6 * SJL)	tubulointerstitial nephritis	J:175630
\Ddc^tm1.1Rhrs/\Ddc^tm1.1Rhrs \Tg(Ggt1-cre)M3Egn/0 (129.Cg-Ddc^tm1.1Rhrs Tg(Ggt1-cre)M3Egn)	tubulointerstitial nephritis	J:175630
\Ddit3^tm1Dron/\Ddit3^tm1Dron (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	decreased susceptibility to Retroviridae infection	J:112354
\Ddit3^tm1Dron/\Ddit3^tm1Dron (B6.129-Ddit3^tm1Dron)	abnormal macrophage activation involved in immune response	J:153833
\Ddit3^tm1Dron/\Ddit3^tm1Dron (B6.129-Ddit3^tm1Dron)	decreased macrophage apoptosis	J:153833
\Ddit3^tm1Dron/\Ddit3^tm1Dron \Tg(Col2a1-rtTA,tetO-COMP)2Jath/0 (involves: 129X1/SvJ 129S1/Sv * C57BL/6)	decreased inflammatory response	J:233238
\Ddit3^tm2.1Dron/\Ddit3^tm2.1Dron (B6.129S(Cg)-Ddit3^tm2.1Dron/J)	abnormal T cell morphology	J:214136
	white adipose tissue inflammation	J:214136
\Ddost^{tm1.1(KOMP)Vlcg}/\Ddost⁺ (C57BL/6N-Ddost^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Ddr1^tm1Wfv/\Ddr1^tm1Wfv \Ldlr^tm1Her/\Ldlr^tm1Her (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ)	decreased macrophage cell number	J:149015
\Ddrgk1^{tm1c(EUCOMM)Hmgu}/\Ddrgk1^{tm1c(EUCOMM)Hmgu} \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N)	decreased granulocyte number	J:231701
	decreased lymphocyte cell number	J:231701
	decreased monocyte cell number	J:231701
\Ddx19b^em1Chaw/\Ddx19b⁺ (C57BL/6-Ddx19b^em1Chaw)	increased interferon-alpha secretion	J:289833
\Ddx19b^em1Chaw/\Ddx19b⁺ (C57BL/6-Ddx19b^em1Chaw)	increased interferon-beta secretion	J:289833
\Ddx23^{em1(IMPC)Wtsi}/\Ddx23⁺ (C57BL/6N-Ddx23^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Ddx41^tm1.1Arte/\Ddx41^tm1.1Arte \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:265023
	increased susceptibility to Retroviridae infection	J:265023
\Ddx41^tm1.1Arte/\Ddx41^tm1.1Arte \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6N * CBA)	immune system phenotype	J:265023
	increased susceptibility to Retroviridae infection	J:265023
\Ddx46^em1(IMPC)Tcp/\Ddx46⁺ (C57BL/6N-Ddx46^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
\Ddx46^em1Caox/\Ddx46⁺ (involves: C57BL/6J)	abnormal innate immunity	J:271836
	abnormal macrophage physiology	J:271836
	decreased susceptibility to Riboviria infection	J:271836
	increased circulating interferon-beta level	J:271836
	increased interferon-beta secretion	J:271836
	increased interleukin-1 beta secretion	J:271836
	increased interleukin-6 secretion	J:271836
	increased macrophage cytokine production	J:271836
	increased tumor necrosis factor secretion	J:271836
\Ddx52^{tm1a(EUCOMM)Wtsi}/\Ddx52⁺ (C57BL/6N-Ddx52^{tm1a(EUCOMM)Wtsi}/Ics)	decreased NK cell number	J:165965
\Ddx60^{tm1b(EUCOMM)Wtsi}/\Ddx60^{tm1b(EUCOMM)Wtsi} (involves: C57BL/6N)	decreased circulating interferon-beta level	J:228452
	increased circulating interferon-alpha level	J:228452
	increased susceptibility to Riboviria infection	J:228452
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:228452
\Ddx60^{tm1b(EUCOMM)Wtsi}/\Ddx60^{tm1b(EUCOMM)Wtsi} \Mavs^tm1Tsse/\Mavs^tm1Tsse (involves: 129 * C57BL/6N)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:228452
\Dedd^tm1Tmiy/\Dedd^tm1Tmiy (B6.Cg-Dedd^tm1Tmiy)	decreased spleen weight	J:119734
\Def6^{Gt(OST307148)Lex}/\Def6^{Gt(OST307148)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:106469
	abnormal spleen germinal center morphology	J:106469
	decreased T cell apoptosis	J:106469
	enlarged lymph nodes	J:106469
	enlarged spleen	J:106469
	increased anti-nuclear antigen antibody level	J:106469
	increased IgG level	J:106469
	increased immature B cell number	J:106469
	increased immunoglobulin level	J:106469
	increased memory T cell number	J:106469
	increased T cell number	J:106469
\Defb1^tm1Hgu/\Defb1^tm1Hgu (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:76528
\Defb1^tm1Jmw/\Defb1⁺ (B6.129S5-Defb1^tm1Jmw)	increased susceptibility to bacterial infection	J:76529
\Defb1^tm1Jmw/\Defb1^tm1Jmw (B6.129S5-Defb1^tm1Jmw)	increased susceptibility to bacterial infection	J:76529
\Defb3^tm1Lex/\Defb3^tm1Lex (B6;129S5-Defb3^tm1Lex/Mmucd)	increased susceptibility to bacterial infection	J:168725
\Defb3^tm1Xen/\Defb3^tm1Xen (involves: C57BL/6)	increased incidence of corneal inflammation	J:199719
	increased neutrophil cell number	J:199719
	increased susceptibility to fungal infection	J:199719
\Defb14^tm1Wme/\Defb14^tm1Wme (B6.129P2-Defb14^tm1Wme)	immune system phenotype	J:180788
\Del(1)1Brk/\Del(1)1Brk (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	abnormal spleen morphology	J:100202
	abnormal spleen white pulp morphology	J:100202
	enlarged spleen	J:100202
	increased leukocyte cell number	J:100202
	increased spleen red pulp amount	J:100202
\Del(1Aim2-Ifi205)1Stsn/\+ \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	heart inflammation	J:234263
	increased autoantibody level	J:234263
	increased inflammatory response	J:234263
	kidney inflammation	J:234263
	myositis	J:234263
	stomach inflammation	J:234263
\Del(1Aim2-Ifi205)1Stsn/\Del(1Aim2-Ifi205)1Stsn (B6(129S4)-Del(1Aim2-Ifi205)1Stsn)	abnormal interferon secretion	J:234263
	decreased interleukin-1 beta secretion	J:234263
	decreased macrophage apoptosis	J:234263
\Del(1Aim2-Ifi205)1Stsn/\Del(1Aim2-Ifi205)1Stsn (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	stomach inflammation	J:234263
\Del(1Aim2-Ifi205)1Stsn/\Del(1Aim2-Ifi205)1Stsn \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	heart inflammation	J:234263
	increased autoantibody level	J:234263
	increased inflammatory response	J:234263
	kidney inflammation	J:234263
	myositis	J:234263
	stomach inflammation	J:234263
\Del(2Duoxa2-Duoxa1)1Sref/\Del(2Duoxa2-Duoxa1)1Sref (involves: 129S6/SvEvTac * C57BL/6J)	decreased spleen weight	J:205165
\Del(3Bglap2-Bglap)2Kry/\Del(3Bglap2-Bglap)2Kry (involves: 129S7/SvEvBrd * C57BL/6)	increased osteoclast cell number	J:34440
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw (involves: 129S4/SvJae * C57BL/6)	abnormal antigen presentation	J:174337
	abnormal NK T cell physiology	J:112657
	decreased CD4-positive, alpha-beta T cell number	J:174337
	decreased interleukin-4 secretion	J:39749
	decreased NK T cell number	J:112657, J:174337, J:39749, J:76976
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw \Tcra^Ln1Ogu/\Tcra⁺ (involves: 129/Sv * C57BL/6)	abnormal NK T cell morphology	J:152041
\Del(3Cd1d2-Cd1d1)1Crw/\Del(3Cd1d2-Cd1d1)1Crw \Tg(TcraAV19AJ33)1Shima/0 (involves: 129S4/SvJae * C57BL/6)	abnormal NK T cell morphology	J:112657
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:112657
	increased interleukin-10 secretion	J:112657
\Del(3Cd1d2-Cd1d1)1Sbp/\Del(3Cd1d2-Cd1d1)1Sbp (either: B6NTac.129S6-Del(3Cd1d2-Cd1d1)1Sbp or (involves: 129S6/SvEvTac * C57BL/6NTac))	abnormal immune tolerance	J:58315
\Del(3Cd1d2-Cd1d1)1Sbp/\Del(3Cd1d2-Cd1d1)1Sbp (involves: 129S6/SvEvTac)	abnormal dendritic cell antigen presentation	J:151699
	decreased NK T cell number	J:151699
\Del(3Gbp2-ps-Gbp5)1Ktak/\Del(3Gbp2-ps-Gbp5)1Ktak (involves: C57BL/6)	immune system phenotype	J:187397
	increased susceptibility to parasitic infection	J:187397
	increased susceptibility to parasitic infection induced morbidity/mortality	J:187397
\Del(4C4-C5)1Lap/\+ (involves: 129S6/SvEvTac)	enlarged spleen	J:158126
\Del(4C4-C5)1Lap/\Del(4C4-C5)1Lap (involves: 129S6/SvEvTac)	enlarged spleen	J:158126
\Del(4D4Mit190-D4Mit51)2Aam/\+ (involves: 129S7/SvEvBrd)	spleen hyperplasia	J:121726
\Del(6Ephb6-Trpv6)1Mhed/\+ (involves: 129S/SvEv)	dermatitis	J:133151
\Del(6Ephb6-Trpv6)1Mhed/\Del(6Ephb6-Trpv6)1Mhed (involves: 129S/SvEv)	dermatitis	J:133151
\Del(6Gimap5-Gimap3)1Yout/\Del(6Gimap5-Gimap3)1Yout (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal T cell physiology	J:209926
	decreased B cell number	J:209926
	decreased NK cell number	J:209926
	decreased T cell number	J:209926
\Del(6Snca)1Slab/\Del(6Snca)1Slab \Tg(Th-SNCA)1Mgsp/0 (involves: C57BL/6J C57BL/6JOlaHsd * CBA/Ca)	abnormal microglial cell morphology	J:108310
	brain inflammation	J:108310
\Del(7)Tyr^c-3H/\Del(7)Tyr^c-3H (involves: 101/H * C3H/HeH)	abnormal thymus morphology	J:5063
\Del(7Ifitm5-Ifitm6)1Masu/\+ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:137940
\Del(7Mrgpra2a-Mrgpra2b)1Xzd/\Del(7Mrgpra2a-Mrgpra2b)1Xzd (C57BL/6J-Del(7Mrgpra2a-Mrgpra2b)1Xzd)	abnormal neutrophil physiology	J:332494
	decreased interleukin-1 beta secretion	J:332494
	increased susceptibility to bacterial infection	J:332494
\Del(7Pira1-Lilra6)1Fgla/\Del(7Pira1-Lilra6)1Fgla (involves: C57BL/6)	decreased susceptibility to graft versus host disease	J:290663
\Del(7Pira1-Lilra6)1Fgla/\Del(7Pira1-Lilra6)1Fgla \Il2rg^tm1Wjl/\Il2rg^tm1Wjl \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: C57BL/6J * C57BL/6NTac)	abnormal response to transplant	J:290663
\Del(8A4-B3)7H/\+ (involves: 101/H * C3H/HeH)	abnormal lymphatic vessel morphology	J:123074
\Del(8Ddx19a-Ddx19b)1Chaw/\+ (C57BL/6-Del(8Ddx19a-Ddx19b)1Chaw)	decreased susceptibility to Picornaviridae infection	J:289833
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:289833
	increased interferon-alpha secretion	J:289833
	increased interferon-beta secretion	J:289833
\Del(8Ddx19a-Ddx19b)2Chaw/\+ (C57BL/6-Del(8Ddx19a-Ddx19b)2Chaw)	increased interferon-alpha secretion	J:289833
	increased interferon-beta secretion	J:289833
\Del(8Defa1-Def)2Xzd/\Del(8Defa1-Def)2Xzd \Tg(KRT14-cre)1Amc/0 (involves: C57BL/6J * CBA)	increased susceptibility to bacterial infection	J:332494
\Del(8Defb1-Defb13)1Jrdo/\Del(8Defb1-Defb13)1Jrdo (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:204187
\Del(9Apoa1-Apoa4)1Hmez/\Del(9Apoa1-Apoa4)1Hmez (involves: 129P2/OlaHsd * C57BL/6)	increased macrophage derived foam cell number	J:109005
\Del(9Casp1-Casp4)1Bhk/\Del(9Casp1-Casp4)1Bhk (129-Del(9Casp1-Casp4)1Bhk)	abnormal macrophage physiology	J:189777
	decreased interleukin-1 alpha secretion	J:189777
	decreased interleukin-1 beta secretion	J:189777
\Del(9Cd3g-Cd3d)1Cpt/\Del(9Cd3g-Cd3d)1Cpt (involves: 129S4/SvJae * C57BL/6)	absent gamma-delta T cells	J:76991
	arrested T cell differentiation	J:76991
	decreased alpha-beta T cell number	J:76991
	thymus hypoplasia	J:76991
\Del(9Hspb2-Cryab)1Wawr/\Del(9Hspb2-Cryab)1Wawr (involves: 129S4/SvJae)	osteoarthritis	J:72926
\Del(10Prmt2-Col6a1)1Yah/\+ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal cytokine level	J:167506
	abnormal macrophage physiology	J:167506
	lung inflammation	J:167506
	respiratory system inflammation	J:167506
\Del(10Prtn3-Elane)1Deje/\Del(10Prtn3-Elane)1Deje (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	abnormal neutrophil physiology	J:137674
	immune system phenotype	J:137674
	impaired neutrophil recruitment	J:137674
\Del(11Cxcl16-Zmynd15)1Ifc/\Del(11Cxcl16-Zmynd15)1Ifc (B6.129S-Ldlr^tm1Her Del(11Cxcl16-Zmynd15)1Ifc)	abnormal macrophage physiology	J:123851
\Del(11Hoxb3-Hoxb4)1Karl/\Del(11Hoxb3-Hoxb4)1Karl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal spleen morphology	J:83563
	decreased spleen weight	J:83563
	spleen hypoplasia	J:83563
\Del(11Hoxb3-Hoxb4)1Karl/\Del(11Hoxb3-Hoxb4)1Karl \Hoxa9^tm1Mrc/\Hoxa9^tm1Mrc (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)	decreased spleen weight	J:126371
	spleen hypoplasia	J:126371
\Del(11Jmjd6-Mettl23)1Ysfk/\Del(11Jmjd6-Mettl23)1Ysfk (involves: C57BL/6)	abnormal thymus development	J:90288
	impaired macrophage chemotaxis	J:90288
	impaired macrophage phagocytosis	J:90288
	thymus hypoplasia	J:90288
\Del(11Nlrp1a-Nlrp1c-ps)1Smas/\Del(11Nlrp1a-Nlrp1c-ps)1Smas (Not Specified)	decreased neutrophil cell number	J:191055
	increased susceptibility to Riboviria infection	J:191055
\Del(11Stat5a-Stat5b)1Mam/\Del(11Stat5a-Stat5b)1Mam (involves: 129 * 129S6/SvEvTac * C57BL/6)	absent gamma-delta T cells	J:122463
	arrested B cell differentiation	J:122463
	decreased B cell number	J:122463
	decreased CD8-positive, alpha-beta T cell number	J:122463
	small lymph nodes	J:122463
	small spleen	J:122463
	small thymus	J:122463
\Del(13Naip1-Naip5)1Vnce/\Del(13Naip1-Naip5)1Vnce (involves: C57BL/6)	decreased inflammatory response	J:294930
\Del(13Naip1-Naip5)1Vnce/\Del(13Naip1-Naip5)1Vnce \Nlrc4^em2Vnce/\Nlrc4^em2Vnce (involves: C57BL/6)	decreased inflammatory response	J:294930
\Del(13Naip1-Naip5)1Vnce/\Del(13Naip1-Naip5)1Vnce \Nlrp3^tm1Vmd/\Nlrp3^tm1Vmd (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:294930
\Del(14Ltb4r2-Ltb4r1)1Bodd/\+ (involves: 129S4/SvJaeSor * C57BL/6)	decreased susceptibility to induced arthritis	J:131779
\Del(14Ltb4r2-Ltb4r1)1Bodd/\Del(14Ltb4r2-Ltb4r1)1Bodd (involves: 129S4/SvJaeSor * C57BL/6)	decreased susceptibility to induced arthritis	J:131779
	immune system phenotype	J:131779
	impaired neutrophil chemotaxis	J:163271
\Del(14Trim13-Dleu2)4Rdf/\Del(14Trim13-Dleu2)4Rdf (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal B cell proliferation	J:156946
	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
\Del(14Trim13-Rnaseh2b)6Rdf/\+ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal lymphopoiesis	J:179879
	increased B cell number	J:179879
\Del(15Rr357-Rr303293)2Jta/\Del(15Rr357-Rr303293)2Jta (involves: C57BL/6)	immune system phenotype	J:257088
\Del(15Rr316124-Rr313939)2Fsp/\+ \Myc^tm1Atp/\Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:257739
	decreased granulocyte number	J:257739
\Del(15Rr316124-Rr313939)2Fsp/\+ \Rr331^em1Fsp/\Rr331⁺ (involves: C57BL/6)	decreased B cell number	J:257739
	increased pre-B cell number	J:257739
\Del(15Rr316124-Rr313939)2Fsp/\+ \Rr307328^em1Fsp/\Rr307328⁺ (involves: C57BL/6)	decreased B cell number	J:257739
	increased pre-B cell number	J:257739
\Del(15Rr316124-Rr313939)2Fsp/\Del(15Rr316124-Rr313939)2Fsp (Not Specified)	decreased B cell number	J:257739
	decreased granulocyte number	J:257739
\Del(16Dgcr2-Hira)1Rak/\+ (involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)	immune system phenotype	J:67796
\Del(16Es2el-Ufd1l)217Bld/\+ (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:57757
\Del(16Pi4ka-Hira)1Atai/\+ (C57BL/6N-Del(16Pi4ka-Hira)1Atai)	thymus hypoplasia	J:285407
\Del(17Btnl1-Btnl6)1Ahay/\Del(17Btnl1-Btnl6)1Ahay (involves: BALB/c * C57BL/6J)	decreased CD4-positive, gamma-delta intraepithelial T cell number	J:291989
\Del(17Trem1-Trem3)1Jkt/\Del(17Trem1-Trem3)1Jkt (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal chemokine level	J:194295
	abnormal circulating chemokine level	J:194295
	abnormal cytokine level	J:194295
	abnormal cytokine secretion	J:194295
	impaired neutrophil chemotaxis	J:194295
	increased circulating interleukin-1 alpha level	J:194295
	increased circulating interleukin-6 level	J:194295
	increased circulating interleukin-10 level	J:194295
	increased circulating tumor necrosis factor level	J:194295
	increased interleukin-1 alpha secretion	J:194295
	increased interleukin-1 beta secretion	J:194295
	increased interleukin-6 secretion	J:194295
	increased interleukin-10 secretion	J:194295
	increased interleukin-17 secretion	J:194295
	increased susceptibility to bacterial infection	J:194295
	increased susceptibility to bacterial infection induced morbidity/mortality	J:194295
\Del(18Pcdhg)1Xzw/\Del(18Pcdhg)1Xzw (Not Specified)	microgliosis	J:188341
\Del(19Poll-Dcpd)1Nmt/\Del(19Poll-Dcpd)1Nmt (involves: 129P2/OlaHsd)	sinus inflammation	J:75779
\Dennd1b^tm1.1Achn/\Dennd1b^tm1.1Achn \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	lymph node hyperplasia	J:229307
\Dennd1b^tm1.2Achn/\Dennd1b^tm1.2Achn (involves: C57BL/6)	abnormal interleukin secretion	J:229307
	abnormal T cell number	J:229307
	abnormal T-helper 2 physiology	J:229307
	immune system phenotype	J:229307
	lymph node hyperplasia	J:229307
\Dennd5b^em1(IMPC)Tcp/\Dennd5b^em1(IMPC)Tcp (C57BL/6N-Dennd5b^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Dennd5b^m1Anu/\Dennd5b^m1Anu (C57BL/6NCrlAnu-Dennd5b^m1Anu)	immune system phenotype	J:104190
\Dennd10^{em1(IMPC)Ccpcz}/\Dennd10^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Dennd10^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Derm1^NC/Nga/\Derm1^NC/Nga (involves: MSM/Ms * NC/Nga)	dermatitis	J:68698
\Derms^BALB/cByJ/? (involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)	dermatitis	J:80574
\Derms^DBA/2J/? (involves: BALB/cByJ * C3H/HeJ * C57BL/6J * DBA/2J)	dermatitis	J:80574
\Dexi^em1Kslr/\Dexi^em1Kslr (NOD/ShiLtJ-Dexi^em1Kslr)	immune system phenotype	J:285312
\Dffb^{em1(IMPC)Wtsi}/\Dffb^{em1(IMPC)Wtsi} (C57BL/6N-Dffb^{em1(IMPC)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\Dffb^tm1Osa/\Dffb^tm1Osa \Dnase2a^tm1Osa/\Dnase2a^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:81474
	abnormal thymus morphology	J:81474
	decreased double-positive T cell number	J:81474
	increased double-negative T cell number	J:81474
	small thymus	J:81474
	thymus hypoplasia	J:81474
\Dgcr2^{tm1b(EUCOMM)Wtsi}/\Dgcr2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dgcr2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Dgka^tm1Xpz/\Dgka^tm1Xpz (involves: 129 * C57BL/6)	abnormal lymphocyte anergy	J:113564
	increased interleukin-2 secretion	J:113564
	increased T cell number	J:113564
\Dgka^tm1Xpz/\Dgka^tm1Xpz \Dgkz^tm1Gak/\Dgkz^tm1Gak (involves: 129 * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:113564
	abnormal thymocyte activation	J:113564
\Dgkz^tm1Gak/\Dgkz^tm1Gak (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine level	J:293120
	abnormal cytokine secretion	J:293120
	abnormal inflammatory response	J:293120
	abnormal interferon level	J:85149
	abnormal macrophage physiology	J:293120
	abnormal T cell activation	J:85149
	abnormal T cell physiology	J:85149
	decreased CD4-positive, alpha-beta T cell number	J:85149
	decreased CD8-positive, alpha-beta T cell number	J:85149
	decreased interleukin-6 secretion	J:293120
	decreased susceptibility to induced arthritis	J:293120
	decreased susceptibility to Riboviria infection	J:85149
	increased B cell number	J:85149
	increased T cell proliferation	J:85149
\Dgkz^tm1Gak/\Dgkz^tm1Gak (B6.129X1-Dgkz^tm1Gak)	abnormal interleukin-2 secretion	J:113564
	abnormal lymphocyte anergy	J:113564
	increased T cell number	J:113564
\Dh/\Dh (Not Specified)	absent spleen	J:152370, J:112
\Dh/\Dh⁺ (Not Specified)	absent spleen	J:152370, J:112
	enlarged lymph nodes	J:30753
	increased granulocyte number	J:30753
	increased lymphocyte cell number	J:30753
\Dh/\Dh⁺ (B6.CBA-Dh)	abnormal T cell differentiation	J:5834
	absent spleen	J:5834
	decreased immunoglobulin level	J:5834
\Dh/\Dh⁺ \Foxn1^nu/\Foxn1^nu (involves: N:NIH(S))	abnormal Peyer's patch morphology	J:6062
	absent spleen	J:6062
	athymia	J:6062
	decreased leukocyte cell number	J:6062
	increased IgA level	J:6062
\Dh/\Dh⁺ \H2^d/\H2^d (NZB.Cg-Dh)	absent spleen	J:12036
	decreased B cell proliferation	J:12036
	decreased IgG1 level	J:12036
	decreased IgG level	J:12036
	decreased IgM level	J:12036
	decreased susceptibility to graft versus host disease	J:12036
	glomerulonephritis	J:12036
	increased anti-erythrocyte antigen antibody level	J:12036
	increased anti-nuclear antigen antibody level	J:12036
	increased anti-single stranded DNA antibody level	J:12036
	increased autoantibody level	J:12036
	increased T cell proliferation	J:12036
\Dhcr7^em1(IMPC)Mbp/\Dhcr7⁺ (C57BL/6N-Dhcr7^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Dhfr^orana/\Dhfr⁺ (involves: C57BL/6JAnu)	enlarged spleen	J:236197
\Dhps^{tm2c(EUCOMM)Wtsi}/\Dhps^{tm2c(EUCOMM)Wtsi} \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6J C57BL/6N * CBA * SJL)	decreased spleen red pulp amount	J:236582
	spleen hypoplasia	J:236582
\Dhrs4^tm1Lex/\Dhrs4^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal humoral immune response	J:171883
	decreased IgG2a level	J:171883
\Dhrs7b^{Gt(OST255410)Lex}/\Dhrs7b^{Gt(OST255410)Lex} (B6;129S5-Dhrs7b^{Gt(OST255410)Lex}/Mmucd)	thymus atrophy	J:171883
\Dhx8^em1(IMPC)Mbp/\Dhx8⁺ (C57BL/6NCrl-Dhx8^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged thymus	J:211773
\Dhx9^{Tn(pb-Act-RFP)1.071225026-HRAZhu}/\Dhx9⁺ (involves: FVB/NJ)	immune system phenotype	J:207361
\Dhx9^{Tn(pb-Act-RFP)1.071225026-HRAZhu}/\Dhx9⁺ \Igs12^tm1Zhu/\Igs12^tm1Zhu \Ptprc^a/\Ptprc^b \Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * FVB/NJ * SJL/J)	abnormal T cell differentiation	J:207361
\Dhx15^{tm1c(EUCOMM)Wtsi}/\Dhx15^{tm1c(EUCOMM)Wtsi} \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C3H * C57BL/6N)	abnormal B cell differentiation	J:284624
	decreased B cell number	J:284624
	decreased B cell proliferation	J:284624
	decreased pre-B cell number	J:284624
	decreased spleen weight	J:284624
	spleen hypoplasia	J:284624
\Dhx15^{tm1c(EUCOMM)Wtsi}/\Dhx15^{tm1c(EUCOMM)Wtsi} \Tg(Cd4-cre)1Cwi/0 (involves: C3H * C57BL/6N * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:284624
	decreased CD8-positive, alpha-beta T cell number	J:284624
\Dhx35^{tm1b(EUCOMM)Wtsi}/\Dhx35^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dhx35^{tm1b(EUCOMM)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
\Dhx36^tm1.2Pmt/\Dhx36^tm1.2Pmt \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129P2/Ola * 129S4/SvJaeSor * C57BL/6 * C57BL/10 * CBA/Ca)	enlarged spleen	J:185179
	intermingled spleen red and white pulp	J:185179
	thymus hypoplasia	J:185179
\Dhx36^tm1.2Pmt/\Dhx36^tm1.2Pmt \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/Ola * 129S4/SvJaeSor * C57BL/6 * CBA)	abnormal leukopoiesis	J:185179
\Dhx40^{tm1b(KOMP)Wtsi}/\Dhx40^{tm1b(KOMP)Wtsi} (C57BL/6N-Dhx40^{tm1b(KOMP)Wtsi}/Wtsi)	increased spleen weight	J:211773
\Dhx58^tm1Aki/\Dhx58^tm1Aki (involves: 129/Sv * C57BL/6)	decreased circulating interferon-beta level	J:156867
	decreased interferon-beta secretion	J:156867
	decreased interleukin-6 secretion	J:156867
	increased susceptibility to Picornaviridae infection	J:156867
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:156867
\Dhx58^tm1Gnb/\Dhx58^tm1Gnb (involves: 129P2/OlaHsd * C57BL/6J)	abnormal interferon secretion	J:146113
	abnormal susceptibility to Riboviria infection	J:146113
	decreased interferon-alpha secretion	J:146113
	decreased interferon-beta secretion	J:146113
	decreased susceptibility to Riboviria infection	J:146113
	increased circulating interferon-gamma level	J:146113
	increased circulating interleukin-12 level	J:146113
	increased interferon-alpha secretion	J:146113
	increased interferon-beta secretion	J:146113
	increased susceptibility to Picornaviridae infection	J:146113
\Dhx58^tm1Itl/\Dhx58^tm1Itl (C57BL/6-Dhx58^tm1Itl)	decreased interferon-beta secretion	J:187386
	decreased interferon-gamma secretion	J:187386
	decreased tumor necrosis factor secretion	J:187386
	increased susceptibility to Flaviviridae infection	J:187386
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:187386
	increased T cell apoptosis	J:187386
\Dhx58^tm2.1Aki/\Dhx58^tm2.1Aki (involves: 129/Sv * C57BL/6)	decreased interferon-beta secretion	J:156867
	decreased interleukin-6 secretion	J:156867
	increased susceptibility to Picornaviridae infection	J:156867
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:156867
\Diaph1^M1Btlr/\Diaph1⁺ (C57BL/6J-Diaph1^M1Btlr)	abnormal CD4-positive, alpha-beta T cell number	J:254820
	abnormal CD8-positive, alpha-beta T cell number	J:254820
	decreased IgE level	J:254820
	increased central memory CD4-positive, alpha-beta T cell number	J:254820
	increased central memory CD8 positive, alpha-beta T cell number	J:254820
\Diaph1^M1Btlr/\Diaph1^M1Btlr (C57BL/6J-Diaph1^M1Btlr)	abnormal CD4-positive, alpha-beta T cell number	J:254820
	abnormal CD8-positive, alpha-beta T cell number	J:254820
	decreased effector memory CD8-positive, alpha-beta T cell number	J:254820
	decreased IgE level	J:254820
	increased central memory CD4-positive, alpha-beta T cell number	J:254820
	increased central memory CD8 positive, alpha-beta T cell number	J:254820
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:254820
\Diaph1^M2Btlr/\Diaph1⁺ (C57BL/6J-Diaph1^M2Btlr)	decreased B-1 B cell number	J:254819
\Diaph1^M2Btlr/\Diaph1^M2Btlr (C57BL/6J-Diaph1^M2Btlr)	decreased B-1 B cell number	J:254819
\Diaph1^M2Btlr/\Diaph1^M2Btlr (C57BL/6J-Diaph1^M2Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254819
\Diaph1^m3Btlr/\Diaph1^m3Btlr (C57BL/6J-Diaph1^m3Btlr)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254818
	decreased CD8-positive, naive alpha-beta T cell number	J:254818
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254818
	increased CD8-positive, alpha-beta memory T cell number	J:254818
	increased central memory CD4-positive, alpha-beta T cell number	J:254818
	increased central memory CD8 positive, alpha-beta T cell number	J:254818
	increased effector memory CD4-positive, alpha-beta T cell number	J:254818
	increased effector memory CD8-positive, alpha-beta T cell number	J:254818
\Diaph1^tm1.1Sna/\Diaph1^tm1.1Sna (B6.Cg-Diaph1^tm1.1Sna)	abnormal humoral immune response	J:126090
	abnormal leukocyte migration	J:126090
	decreased CD4-positive, alpha-beta T cell number	J:126090
	decreased CD8-positive, alpha-beta T cell number	J:126090
	decreased T cell number	J:126090
	decreased T cell proliferation	J:126090
	increased single-positive T cell number	J:126090
\Diaph1^tm1Asal/\Diaph1^tm1Asal (involves: 129S1/Sv * C57BL/6)	abnormal lymph node morphology	J:124319
	abnormal spleen germinal center morphology	J:124319
	abnormal spleen morphology	J:124319
	absent spleen white pulp	J:124319
	decreased lymphocyte cell number	J:124319
	dermatitis	J:124319
	increased granulocyte number	J:124319
	increased leukocyte cell number	J:124319
	increased monocyte cell number	J:124319
	increased neutrophil cell number	J:124319
	increased spleen weight	J:124319
\Diaph3^tm1.1Pji/\Diaph3^tm1.1Pji \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * CBA/J)	enlarged spleen	J:293763
\Dice1b^C57BL/10Sn/\Dice1b^C57BL/10Sn (involves: B10.D2-H2^d/oSnJ * BALB/cAnN)	decreased susceptibility to parasitic infection	J:95337
\Dicer1^{Gt(RRF266)Byg}/\Dicer1^{Gt(RRF266)Byg} (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to Riboviria infection	J:123635
	increased susceptibility to Herpesvirales infection	J:123635
	increased susceptibility to Riboviria infection	J:123635
\Dicer1^m1Btlr/\Dicer1^m1Btlr (C57BL/6J-Dicer1^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265172
	decreased CD8-positive, alpha-beta T cell number	J:265172
	decreased CD8-positive, naive alpha-beta T cell number	J:265172
	decreased single-positive T cell number	J:265172
	decreased T cell number	J:265172
	increased B-1 B cell number	J:265172
	increased central memory CD8 positive, alpha-beta T cell number	J:265172
	increased effector memory CD4-positive, alpha-beta T cell number	J:265172
	increased effector memory CD8-positive, alpha-beta T cell number	J:265172
\Dicer1^{tm1b(EUCOMM)Wtsi}/\Dicer1⁺ (C57BL/6N-Dicer1^{tm1b(EUCOMM)Wtsi}/H)	absent spleen	J:211773
	decreased neutrophil cell number	J:211773
	decreased spleen weight	J:211773
\Dicer1^tm1Bdh/\Dicer1⁺ \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129 * C57BL/6 * CBA/J)	abnormal thymus development	J:166758
\Dicer1^tm1Bdh/\Dicer1^tm1Bdh \Aicda^tm1(cre)Njen/\Aicda⁺ (involves: 129 * C57BL/6)	abnormal germinal center B cell physiology	J:181782
	abnormal humoral immune response	J:181782
	absent memory B cells	J:181782
	absent plasma cells	J:181782
	decreased germinal center B cell number	J:181782
	decreased immunoglobulin level	J:181782
	immune system phenotype	J:181782
\Dicer1^tm1Bdh/\Dicer1^tm1Bdh \Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ)	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
\Dicer1^tm1Bdh/\Dicer1^tm1Bdh \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3^{tm4(YFP/icre)Ayr} (involves: 129S1/Sv * 129X1/SvJ)	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
\Dicer1^tm1Bdh/\Dicer1^tm1Bdh \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129 * C57BL/6 * CBA/J)	athymia	J:166758
\Dicer1^tm1Bdh/\Dicer1^tm1Bdh \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased regulatory T cell number	J:138683
\Dicer1^tm1Bdh/\Dicer1^tm1Bdh \Tg(Foxp3-EGFP/icre)1aJbs/0 (involves: 129 * NOD/ShiLt)	abnormal CD4-positive, alpha-beta T cell physiology	J:138808
	abnormal effector T cell morphology	J:138808
	abnormal lymph node cell ratio	J:138808
	abnormal regulatory T cell morphology	J:138808
	abnormal regulatory T cell physiology	J:138808
	abnormal splenic cell ratio	J:138808
	decreased regulatory T cell number	J:138808
	enlarged lymph nodes	J:138808
	enlarged spleen	J:138808
	liver inflammation	J:138808
	lung inflammation	J:138808
\Dicer1^tm1Dli/\Dicer1^tm1Dli \Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:100546
	abnormal T-helper 1 physiology	J:100546
	abnormal T-helper 2 physiology	J:100546
	decreased T cell number	J:100546
	decreased T cell proliferation	J:100546
	immune system phenotype	J:100546
	increased T cell apoptosis	J:100546
\Dicer1^tm1Mmk/\Dicer1^tm1.1Mmk \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c)	abnormal immunoglobulin V(D)J recombination	J:135783
	decreased B cell number	J:135783
\Dicer1^tm1Mmk/\Dicer1^tm1Mmk \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c)	arrested B cell differentiation	J:135783
	decreased immature B cell number	J:135783
	decreased mature B cell number	J:135783
	decreased pre-B cell number	J:135783
	increased pro-B cell number	J:135783
\Dicer1^tm1Mmk/\Dicer1^tm1Mmk \Tg(IghelMD4)4Ccg/0 \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c)	decreased B cell number	J:135783
	decreased mature B cell number	J:135783
\Dicer1^tm1Mmk/\Dicer1^tm1Mmk \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased T cell number	J:98192
	decreased thymocyte number	J:98192
	increased gamma-delta T cell number	J:98192
\Dicer1^tm1Mmk/\Dicer1^tm1Mmk \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129 * C57BL/6 * CD-1)	abnormal granulocyte differentiation	J:158901
	abnormal myeloid leukocyte morphology	J:158901
	abnormal neutrophil morphology	J:158901
	decreased B cell number	J:158901
	decreased leukocyte cell number	J:158901
	enlarged spleen	J:158901
\Dicer1^tm1Tara/\Dicer1^tm1Tara \Foxn1^tm3(cre)Nrm/\Foxn1⁺ (involves: 129P2/OlaHsd * C57BL/6NHsd)	abnormal positive T cell selection	J:180783
	abnormal thymus cortex morphology	J:180783
	abnormal thymus epithelium morphology	J:180783
	abnormal thymus involution	J:180783
	abnormal thymus medulla morphology	J:180783
	abnormal thymus morphology	J:180783
	abnormal thymus physiology	J:180783
	decreased CD4-positive, alpha-beta T cell number	J:180783
	decreased CD8-positive, alpha-beta T cell number	J:180783
	increased susceptibility to induced arthritis	J:180783
\Dido1^tm1Cmar/\Dido1⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal splenic cell ratio	J:101201
	abnormal splenocyte morphology	J:101201
	increased granulocyte number	J:101201
	increased monocyte cell number	J:101201
	increased spleen weight	J:101201
	spleen hyperplasia	J:101201
\Dido1^tm1Cmar/\Dido1^tm1Cmar (involves: 129S1/Sv * 129X1/SvJ)	abnormal splenic cell ratio	J:101201
	abnormal splenocyte morphology	J:101201
	immune system phenotype	J:101201
	increased granulocyte number	J:101201
	increased monocyte cell number	J:101201
	increased spleen weight	J:101201
	increased spleen white pulp amount	J:101201
	spleen hyperplasia	J:101201
\Dido1^tm3Cmar/\Dido1^tm3.1Cmar \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/\Ndor1⁺ (involves: 129S/SvEv * C57BL/6)	liver inflammation	J:328215
\Dip2b^{tm1a(EUCOMM)Wtsi}/\Dip2b⁺ (B6JTyr;B6N-Dip2b^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Dip2c^em1(IMPC)Tcp/\Dip2c⁺ (C57BL/6N-Dip2c^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
	small thymus	J:211773
\Dipk2b^em1(IMPC)Mbp/\Dipk2b^em1(IMPC)Mbp (C57BL/6N-Dipk2b^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Dis3^tm1.1Uba/\Dis3^tm1.1Uba \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	abnormal B cell morphology	J:302856
	abnormal class switch recombination	J:302856
\Dis3l^{em1(IMPC)Ccpcz}/\Dis3l⁺ (C57BL/6NCrl-Dis3l^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased eosinophil cell number	J:211773
\Disc1^em1(IMPC)Mbp/\Disc1^em1(IMPC)Mbp (C57BL/6N-Disc1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\Disp3^em1(IMPC)Mbp/\Disp3^em1(IMPC)Mbp (C57BL/6N-Disp3^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Dkc1^tm1.1Pjma/Y (B6.129X1(FVB)-Dkc1^tm1.1Pjma)	decreased B cell number	J:217050
\Dkc1^tm1.1Pjma/Y (B6.129X1(FVB)-Dkc1^tm1.1Pjma)	decreased T cell number	J:217050
\Dkc1^tm1Ppp/Y (involves: 129S1/Sv)	abnormal spleen morphology	J:81054
	decreased B cell number	J:81054
	decreased leukocyte cell number	J:81054
	decreased lymphocyte cell number	J:81054
	decreased pre-B cell number	J:81054
	decreased spleen red pulp amount	J:81054
	decreased spleen white pulp amount	J:81054
	enlarged spleen	J:81054
	lung inflammation	J:81054
\Dkc1^tm1Ppp/\Dkc1⁺ (involves: 129S1/Sv)	abnormal immune system cell morphology	J:81054
\Dkc1^tm1Ppp/\Dkc1⁺ (involves: 129S1/Sv)	abnormal immune system organ morphology	J:81054
\Dkk2^tm1Dwu/\Dkk2^tm1Dwu (involves: 129)	abnormal osteoclast differentiation	J:100858
\Dkk2^tm1Dwu/\Dkk2^tm1Dwu (involves: 129)	increased osteoclast cell number	J:100858
\Dkk3^tm1Cni/\Dkk3^tm1Cni (involves: 129X1/SvJ * C57BL/6)	decreased NK cell number	J:106922
\Dkk3^tm1Cni/\Dkk3^tm1Cni (involves: 129X1/SvJ * C57BL/6)	increased IgM level	J:106922
\Dlg1^tm1Rlh/\Dlg1^tm1Rlh \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:191788
	abnormal cytokine secretion	J:191788
	abnormal T-helper 1 physiology	J:191788
	abnormal T-helper 2 physiology	J:191788
	decreased interferon-gamma secretion	J:191788
	decreased interleukin-2 secretion	J:191788
	decreased tumor necrosis factor secretion	J:191788
	increased interleukin-4 secretion	J:191788
	increased interleukin-5 secretion	J:191788
\Dlgap2^{em1(IMPC)Mhzh}/\Dlgap2^{em1(IMPC)Mhzh} (C57BL/6N-Dlgap2^{em1(IMPC)Mhzh}/Mhzh)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Dlk1^tm1.1Jvs/\Dlk1⁺ \Myf5^tm3(cre)Sor/\Myf5⁺ (involves: 129P2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)	increased inflammatory response	J:167124
\Dlk1^tm1Srba/\Dlk1^tm1Srba (involves: 129X1/SvJ * C57BL/6)	abnormal B cell number	J:145076
	abnormal spleen B cell follicle morphology	J:145076
	abnormal spleen marginal zone morphology	J:145076
	decreased immature B cell number	J:145076
	decreased mature B cell number	J:145076
	increased IgG1 level	J:145076
	increased IgG2a level	J:145076
	increased IgG2b level	J:145076
	increased IgG2c level	J:145076
	increased IgG3 level	J:145076
	increased IgM level	J:145076
	increased immature B cell number	J:145076
	increased immunoglobulin level	J:145076
	increased marginal zone B cell number	J:145076
	increased transitional stage B cell number	J:145076
\Dll1^m1Mhda/\Dll1⁺ (C3HeB/FeJ-Dll1^m1Mhda)	immune system phenotype	J:150183
\Dll1^tm1Gos/\Dll1⁺ (C3Fe.129-Dll1^tm1Gos)	decreased B-1 B cell number	J:150183
	decreased CD4-positive, alpha-beta T cell number	J:150183
	decreased CD8-positive, alpha-beta T cell number	J:150183
	decreased IgA level	J:150183
	decreased IgG1 level	J:150183
	decreased IgG2b level	J:150183
	decreased IgG3 level	J:150183
	increased B cell number	J:150183
	increased CD8-positive, alpha-beta T cell number	J:150183
\Dll1^tm1Gos/\Dll1⁺ (involves: 129S1/Sv * 129X1/SvJ)	decreased CD4-positive, alpha-beta T cell number	J:150183
\Dll1^tm1Gos/\Dll1⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased B cell number	J:150183
\Dll1^tm1Mjo/\Dll1^tm1Mjo \Tg(KRT5-cre)1Tak/? \Tg(Mx1-cre)1Cgn/? (involves: 129 * C3H * C57BL/6 * CBA)	immune system phenotype	J:90630
\Dll1^tm1Mjo/\Dll1^tm1Mjo \Tg(Mx1-cre)1Cgn/? (involves: 129 * C57BL/6 * CBA)	absent marginal zone B cells	J:90630
\Dll1^tm3.1Gos/\Dll1^tm3.1Gos (Not Specified)	immune system phenotype	J:213529
\Dll4^tm1Frad/\Dll4^tm1Frad \Foxn1^tm3(cre)Nrm/\Foxn1⁺ (B6.Cg-Dll4^tm1Frad Foxn1^tm3(cre)Nrm)	abnormal T cell differentiation	J:143472
	abnormal thymus cell ratio	J:143472
	decreased CD4-positive, alpha-beta T cell number	J:143472
	decreased CD8-positive, alpha-beta T cell number	J:143472
	decreased double-positive T cell number	J:143472
	decreased thymocyte number	J:143472
	increased immature B cell number	J:143472
\Dll4^tm1Frad/\Dll4^tm1Frad \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Dll4^tm1Frad Tg(Mx1-cre)1Cgn)	immune system phenotype	J:143472
\Dll4^tm1Kaho/\Dll4^tm1Kaho \Tg(Foxn1-cre)8Ghr/0 (involves: C57BL/6 * DBA/2)	abnormal lymphopoiesis	J:143473
	absent CD4-positive, alpha-beta T cells	J:143473
	absent CD8-positive, alpha-beta T cells	J:143473
	decreased double-positive T cell number	J:143473
	thymus hypoplasia	J:143473
\Dmbt1^tm1Janm/\Dmbt1^tm1Janm (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to induced colitis	J:130258
\Dmd^em1Cmusr/Y (BALB/c-Dmd^em1Cmusr)	enlarged spleen	J:353371
\Dmd^em1Eno/Y (involves: C57BL/6J)	myositis	J:253191
\Dmd^em4Eno/Y (C57BL/6-Dmd^em4Eno)	myositis	J:285447
\Dmd^em4Eno/\Dmd^em4Eno (C57BL/6-Dmd^em4Eno)	myositis	J:285447
\Dmd^mdx/Y (C57BL/10ScSn-Dmd^mdx/J)	increased interferon-gamma secretion	J:150572
	increased interleukin-2 secretion	J:150572
	increased interleukin-4 secretion	J:150572
	increased interleukin-6 secretion	J:150572
	increased interleukin-12 secretion	J:150572
	increased tumor necrosis factor secretion	J:150572
\Dmd^mdx/Y (involves: C57BL/10ScSn)	diaphragmitis	J:140282
\Dmd^mdx/Y (involves: C57BL/10ScSn)	myositis	J:140282
\Dmd^mdx/Y \Spp1^tm1Blh/\Spp1^tm1Blh (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * C57BL/10ScSn)	decreased granulocyte number	J:150572
	decreased neutrophil cell number	J:150572
	decreased T cell number	J:150572
	increased regulatory T cell number	J:150572
	increased T cell number	J:150572
\Dmd^mdx/Y \Terc^tm1Rdp/\Terc^tm1Rdp (involves: 129/Sv * C57BL/6J * C57BL/10ScSn * SJL)	myositis	J:167294
\Dmd^mdx/Y \Tg(DMD)#Spc/0 (involves: 129P2/OlaHsd C57BL/10ScSn * DBA/2)	myositis	J:280218
\Dmd^mdx/Y \Utrn^tm1Jrs/\Utrn⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/10ScSn)	diaphragmitis	J:140282
	myositis	J:140282
\Dmd^mdx/\Dmd^mdx (C57BL/10ScSn-Dmd^mdx/J)	increased interferon-gamma secretion	J:150572
	increased interleukin-2 secretion	J:150572
	increased interleukin-4 secretion	J:150572
	increased interleukin-6 secretion	J:150572
	increased interleukin-12 secretion	J:150572
	increased tumor necrosis factor secretion	J:150572
	myositis	J:226314
\Dmd^mdx/\Dmd^mdx (D2.B10-Dmd^mdx/J)	heart inflammation	J:226314
\Dmd^mdx/\Dmd^mdx (D2.B10-Dmd^mdx/J)	myositis	J:226314
\Dmd^mdx/\Dmd^mdx \Dusp1^tm1Brv/\Dusp1^tm1Brv (involves: 129S2/SvPas * C57BL/6 * C57BL/10ScSn)	myositis	J:162340
\Dmd^mdx/\Dmd^mdx \Mmp9^tm1Tvu/\Mmp9⁺ (B10.Cg-Mmp9^tm1Tvu Dmd^mdx)	decreased macrophage cell number	J:150030
\Dmd^mdx/\Dmd^mdx \Mmp9^tm1Tvu/\Mmp9^tm1Tvu (B10.Cg-Mmp9^tm1Tvu Dmd^mdx)	decreased macrophage cell number	J:150030
\Dmd^mdx/\Dmd^mdx \Prkdc^scid/\Prkdc^scid (involves: BALB/c * C57BL/10ScSn * C57BL/Ka)	absent CD4-positive, alpha-beta T cells	J:125527
	absent CD8-positive, alpha-beta T cells	J:125527
	decreased B cell number	J:125527
\Dmd^mdx/\Dmd^mdx \Spp1^tm1Blh/\Spp1^tm1Blh (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * C57BL/10ScSn)	decreased granulocyte number	J:150572
	decreased neutrophil cell number	J:150572
	decreased T cell number	J:150572
	increased regulatory T cell number	J:150572
	increased T cell number	J:150572
\Dmd^tm1.1Know/\Dmd^tm1.1Know (involves: C3H)	decreased susceptibility to Picornaviridae infection	J:207775
\Dmd^tm1.1Know/\Dmd^tm1.1Know (involves: C3H)	myocarditis	J:207775
\Dmd^tm1Kmf/Y (involves: C57BL/6)	myositis	J:233298
\Dmp1^tm1Mis/\Dmp1^tm1Mis (involves: 129S7/SvEvBrd * C57BL/6)	increased susceptibility to bacterial infection	J:241769
\Dmp1^tm1Mis/\Dmp1^tm1Mis (involves: 129S7/SvEvBrd * CD-1)	abnormal bone marrow development	J:184352
\Dmp1^tm1Mis/\Dmp1^tm1Mis (involves: 129S7/SvEvBrd * CD-1)	decreased osteoclast cell number	J:184352
\Dmtf1^tm1Cjs/\Dmtf1⁺ \Kras^tm2Tyj/\Kras⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
\Dmtf1^tm1Cjs/\Dmtf1⁺ \Kras^tm3Tyj/\Kras⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
\Dmtf1^tm1Cjs/\Dmtf1^tm1Cjs (involves: 129/Sv * C57BL/6)	abnormal T cell physiology	J:63444
\Dmtf1^tm1Cjs/\Dmtf1^tm1Cjs (involves: 129/Sv * C57BL/6)	decreased thymocyte number	J:63444
\Dmtf1^tm1Cjs/\Dmtf1^tm1Cjs \Kras^tm2Tyj/\Kras⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
\Dmtf1^tm1Cjs/\Dmtf1^tm1Cjs \Kras^tm3Tyj/\Kras⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:126002
\Dmxl2^{tm1a(EUCOMM)Wtsi}/\Dmxl2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-A^tm1Brd Dmxl2^{tm1a(EUCOMM)Wtsi}/WtsiH)	blood in lymph vessels	J:239583
\Dnaaf4^b2b811.1Clo/\Dnaaf4^b2b811.1Clo (C57BL/6J-Dnaaf4^b2b811.1Clo)	abnormal spleen morphology	J:205312
\Dnaaf4^tm1.2Jjlo/\Dnaaf4^tm1.2Jjlo (involves: 129S1/Sv * 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)	abnormal spleen morphology	J:205312
\Dnaaf5^em1Slb/\Dnaaf5^em1Slb (C57BL/6-Dnaaf5^em1Slb)	sinus inflammation	J:342770
\Dnaaf5^em1Slb/\Dnaaf5^em2Slb (C57BL/6-Dnaaf5^em1Slb Dnaaf5^em2Slb)	sinus inflammation	J:342770
\Dnaaf9^{tm1b(EUCOMM)Hmgu}/\Dnaaf9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Dnaaf9^{tm1b(EUCOMM)Hmgu}/Tcp)	increased neutrophil cell number	J:211773
\Dnah2^em1(IMPC)Tcp/\Dnah2^em1(IMPC)Tcp (C57BL/6N-Dnah2^em1(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
\Dnah5^b2b2451Clo/\Dnah5^b2b2451Clo (C57BL/6J-Dnah5^b2b2451Clo)	abnormal spleen morphology	J:175213
\Dnah5^b2b2925Clo/\Dnah5^b2b2925Clo (C57BL/6J-Dnah5^b2b2925Clo)	absent spleen	J:175213
\Dnah5^hlb612/\Dnah5^hlb612 (involves: C57BL/6J)	abnormal spleen morphology	J:130755
\Dnah5^hlb612/\Dnah5^hlb612 (involves: C57BL/6J)	absent spleen	J:130755
\Dnah5^Tg1Htz/\Dnah5^Tg1Htz (involves: C57BL/6 * CBA/J)	increased susceptibility to otitis media	J:76189
\Dnah5^Tg1Htz/\Dnah5^Tg1Htz (involves: C57BL/6 * CBA/J)	sinus inflammation	J:76189
\Dnah11^b2b1289Clo/\Dnah11^b2b1289Clo (C57BL/6J-Dnah11^b2b1289Clo)	accessory spleen	J:175213
\Dnah11^b2b1727Clo/\Dnah11^b2b1727Clo (C57BL/6J-Dnah11^b2b1727Clo)	spleen hypoplasia	J:175213
\Dnah11^b2b1775Clo/\Dnah11^b2b1775Clo (C57BL/6J-Dnah11^b2b1775Clo)	spleen hypoplasia	J:175213
\Dnah11^iv/\Dnah11^iv (SI/Col Tyrp1^b Dnah11^iv/J)	abnormal spleen morphology	J:4058
\Dnai1^b2b1526Clo/\Dnai1^b2b1526Clo (C57BL/6J-Dnai1^b2b1526Clo)	spleen hypoplasia	J:175213
\Dnai1^tm1.1Leo/\Dnai1^tm1.1Leo \Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/\Gt(ROSA)26Sor⁺ (involves: 129 * C57BL/6)	rhinosinusitis	J:155730
\Dnai2^em1(IMPC)Tcp/\Dnai2⁺ (C57BL/6NCrl-Dnai2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Dnajc2^em1(IMPC)J/\Dnajc2⁺ (C57BL/6NJ-Dnajc2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Dnajc3^m1Btlr/\Dnajc3^m1Btlr (C57BL/6J-Dnajc3^m1Btlr)	increased CD4-positive, alpha-beta T cell number	J:265248
	increased CD8-positive, alpha-beta memory T cell number	J:265248
	increased single-positive T cell number	J:265248
	increased susceptibility to induced colitis	J:265248
	increased T cell number	J:265248
\Dnajc11^spc/\Dnajc11^spc (B6.Cg-Dnajc11^spc)	decreased B cell number	J:221543
	decreased double-positive T cell number	J:221543
	decreased leukocyte cell number	J:221543
	decreased thymus weight	J:221543
	enlarged thymus medulla	J:221543
	increased CD4-positive, alpha-beta T cell number	J:221543
	increased CD8-positive, alpha-beta T cell number	J:221543
	increased DN1 thymic pro-T cell number	J:221543
	increased double-negative T cell number	J:221543
	spleen hypoplasia	J:221543
	thymus cortex atrophy	J:221543
	thymus hypoplasia	J:221543
\Dnajc15^{Gt(RRN226)Byg}/\Dnajc15^{Gt(RRN226)Byg} (B6.129P2-Dnajc15^{Gt(RRN226)Byg})	abnormal CD8-positive, alpha beta T cell morphology	J:204025
	immune system phenotype	J:204025
\Dnajc15^{tm1b(KOMP)Wtsi}/\Dnajc15^{tm1b(KOMP)Wtsi} (C57BL/6N-Dnajc15^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Dnal1^{tm1.1(KOMP)Vlcg}/\Dnal1⁺ (C57BL/6N-Dnal1^{tm1.1(KOMP)Vlcg}/Ucd)	decreased eosinophil cell number	J:211773
\Dnase1^tm1Tmo/\Dnase1⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:62549
	glomerulonephritis	J:62549
	increased anti-nuclear antigen antibody level	J:62549
	kidney inflammation	J:62549
\Dnase1^tm1Tmo/\Dnase1^tm1Tmo (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:62549
	glomerulonephritis	J:62549
	increased anti-nuclear antigen antibody level	J:62549
	increased susceptibility to systemic lupus erythematosus	J:62549
	kidney inflammation	J:62549
\Dnase1^tm1Tmo/\Dnase1^tm1Tmo (involves: 129P2/OlaHsd * CD-1)	decreased susceptibility to systemic lupus erythematosus	J:110060
\Dnase1^tm2092.1Arte/\Dnase1^tm2092.1Arte (involves: C57BL/6)	glomerulonephritis	J:277126
	increased anti-double stranded DNA antibody level	J:277126
	increased anti-histone antibody level	J:277126
	increased anti-nuclear antigen antibody level	J:277126
	increased autoantibody level	J:277126
	increased susceptibility to systemic lupus erythematosus	J:277126
\Dnase1l2^em1(IMPC)Bay/\Dnase1l2^em1(IMPC)Bay (C57BL/6N-Dnase1l2^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Dnase1l2^{tm1.1(KOMP)Wtsi}/\Dnase1l2^{tm1.1(KOMP)Wtsi} (C57BL/6N-Dnase1l2^{tm1.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Dnase1l3^em1(IMPC)Mbp/\Dnase1l3^em1(IMPC)Mbp (C57BL/6NCrl-Dnase1l3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Dnase2a^tm1Osa/\Dnase2a^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal thymus morphology	J:81474
	small thymus	J:81474
	thymus hypoplasia	J:81474
\Dnase2a^tm1Osa/\Dnase2a^tm1Osa \Ifnar1^tm1Agt/\Ifnar1^tm1Agt (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal cytokine level	J:114982
	abnormal macrophage morphology	J:114982
	abnormal spleen morphology	J:238323
	enlarged spleen	J:238323, J:114982
	increased anti-double stranded DNA antibody level	J:114982
	increased autoantibody level	J:238323
	increased circulating interleukin-10 level	J:238323
	increased circulating interleukin-18 level	J:114982
	increased circulating tumor necrosis factor level	J:238323, J:114982
	increased spleen red pulp amount	J:114982
	increased spleen weight	J:238323
	joint inflammation	J:238323, J:114982
	rheumatoid arthritis	J:238323, J:114982
\Dnase2a^tm1Osa/\Dnase2a^tm2Osa \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)	abnormal cytokine level	J:114982
	abnormal macrophage morphology	J:114982
	increased circulating interleukin-18 level	J:114982
	increased circulating tumor necrosis factor level	J:114982
	joint inflammation	J:114982
	rheumatoid arthritis	J:114982
\Dnm2^tm2.1Ics/\Dnm2⁺ (involves: C57BL/6J)	immune system phenotype	J:288372
\Dnm2^tm2.1Ics/\Dnm2⁺ (involves: C57BL/6J)	increased macrophage cell number	J:288372
\Dnmbp^em1(IMPC)Mbp/\Dnmbp^em1(IMPC)Mbp (C57BL/6N-Dnmbp^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Dnmt1^{tm1(tetO-BCL2)Sjk}/\Dnmt1⁺ \Tg(IghMyc)22Bri/0 \Tg(MMTVtTA)1Mam/0 (involves: 129S4/SvJae * C57BL/6)	enlarged spleen	J:93549
\Dnmt1^tm2Jae/\Dnmt1^tm2Jae \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal B cell differentiation	J:113645
	decreased pro-B cell number	J:113645
\Dnmt3b^tm1Enl/\Dnmt3b^tm6Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
\Dnmt3b^tm1Enl/\Dnmt3b^tm7Enl (involves: 129S4/SvJae * C57BL/6)	decreased double-positive T cell number	J:106540
	decreased thymocyte number	J:106540
	increased double-negative T cell number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
\Dnmt3b^tm6Enl/\Dnmt3b^tm6Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
\Dnmt3b^tm6Enl/\Dnmt3b^tm7Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
\Dnmt3b^tm7Enl/\Dnmt3b^tm7Enl (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte number	J:106540
	increased thymocyte apoptosis	J:106540
	small thymus	J:106540
\Dntt^tm1Fwa/\Dntt^tm1Fwa (chimera involves: 129S/SvEv)	abnormal immune system morphology	J:75921
\Dntt^tm1Gfn/\Dntt^tm1Gfn \Fas^lpr/\Fas^lpr (involves: 129S2/SvPas * C57BL/6 * MRL/MpJ)	decreased autoantibody level	J:110248
\Dntt^tm1Gfn/\Dntt^tm1Gfn \Polm^tm1Crey/\Polm^tm1Crey (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal immunoglobulin light chain V-J recombination	J:113406
	immune system phenotype	J:113406
\Dntt^tm1Tok/\Dntt^tm1Tok (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphocyte cell number	J:61801
	abnormal T cell morphology	J:61801
	decreased gamma-delta T cell number	J:61801
\Dnttip1^em1Shmc/\Dnttip1^em1Shmc (C57BL/6J-Dnttip1^em1Shmc)	immune system phenotype	J:291786
\Dock1^b2b3190Clo/\Dock1^b2b3190Clo (C57BL/6J-Dock1^b2b3190Clo)	thymus hypoplasia	J:175213
\Dock2^m1Anu/\Dock2^m1Anu (C57BL/6JAnu-Dock2^m1Anu)	decreased B cell number	J:104190
\Dock2^m1Anu/\Dock2^m1Anu (C57BL/6JAnu-Dock2^m1Anu)	decreased T cell number	J:104190
\Dock2^m1Btlr/\Dock2^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:173592
	abnormal class switch recombination	J:185495
	abnormal humoral immune response	J:173592
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:185495
\Dock2^m1Hsd/\Dock2^m1Hsd \Irf5^tm1Ttg/\Irf5^tm1Ttg (B6NHsd.Cg-Irf5^tm1Ttg Dock2^m1Hsd)	abnormal B cell differentiation	J:182658
	abnormal response to infection	J:182658
	absent marginal zone B cells	J:182658
	decreased follicular B cell number	J:182658
	decreased interferon-alpha secretion	J:182658
	decreased plasmacytoid dendritic cell number	J:182658
	decreased splenocyte number	J:182658
	increased B cell number	J:182658
	increased immature B cell number	J:182658
	increased plasmacytoid dendritic cell number	J:182658
\Dock2^m1Hsd/\Dock2^m1Hsd \Siae^tm1.2Avrk/\Siae^tm1.2Avrk (B6NHsd.Cg-Siae^tm1.2Avrk Dock2^m1Hsd)	abnormal B cell activation	J:144035
	abnormal immunoglobulin level	J:144035
	decreased B-1a cell number	J:144035
	decreased follicular B cell number	J:144035
	decreased marginal zone B cell number	J:231437, J:144035
	decreased T cell number	J:144035
	glomerulonephritis	J:144035
	increased anti-double stranded DNA antibody level	J:144035
	increased anti-histone antibody level	J:144035
	increased anti-single stranded DNA antibody level	J:144035
	increased B cell proliferation	J:144035
	increased B-1b cell number	J:144035
	increased CD4-positive, alpha-beta memory T cell number	J:231437
	increased IgE level	J:144035
	increased IgG1 level	J:144035
	increased IgG2a level	J:144035
	increased IgG2b level	J:144035
	increased IgG3 level	J:144035
	increased IgM level	J:144035
	spleen hypoplasia	J:144035
\Dock2^m2Anu/\Dock2^m2Anu (C57BL/6JAnu-Dock2^m2Anu)	abnormal T cell morphology	J:104190
	decreased mature B cell number	J:104190
	decreased T cell number	J:104190
\Dock2^m2Btlr/\Dock2^m2Btlr (C57BL/6J-Dock2^m2Btlr)	abnormal humoral immune response	J:173670
	decreased B cell number	J:173670
	decreased CD4-positive, alpha-beta T cell number	J:173670
	decreased CD8-positive, alpha-beta T cell number	J:173670
\Dock2^m2Btlr/\Dock2^m2Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	abnormal class switch recombination	J:185495
	abnormal humoral immune response	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:185495
\Dock2^m3Anu/\Dock2^m3Anu (C57BL/6NCrlAnu-Dock2^m3Anu)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
	abnormal CD8-positive, alpha beta T cell morphology	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
\Dock2^m3Btlr/\Dock2^m3Btlr (C57BL/6J-Dock2^m3Btlr)	abnormal CD4-positive T cell differentiation	J:191187
	abnormal CD8-positive, alpha-beta T cell differentiation	J:191187
	abnormal humoral immune response	J:191187
	abnormal immune system physiology	J:191187
	decreased CD4-positive, alpha-beta T cell number	J:191187
	decreased CD8-positive, alpha-beta T cell number	J:191187
\Dock2^m4Btlr/\Dock2^m4Btlr (C57BL/6J-Dock2^m4Btlr)	abnormal B cell differentiation	J:221486
	abnormal CD4-positive T cell differentiation	J:221486
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221486
\Dock2^m5Btlr/\Dock2⁺ (C57BL/6J-Dock2^m5Btlr)	abnormal CD4-positive T cell differentiation	J:225938
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225938
	decreased CD4-positive, alpha-beta T cell number	J:225938
	decreased single-positive T cell number	J:225938
	increased CD8-positive, alpha-beta T cell number	J:225938
	increased single-positive T cell number	J:225938
\Dock2^m5Btlr/\Dock2^m5Btlr (C57BL/6J-Dock2^m5Btlr)	abnormal B cell differentiation	J:225938
	abnormal CD4-positive T cell differentiation	J:225938
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225938
	decreased CD4-positive, alpha-beta T cell number	J:225938
	decreased single-positive T cell number	J:225938
	increased B cell number	J:225938
	increased CD8-positive, alpha-beta T cell number	J:225938
	increased single-positive T cell number	J:225938
\Dock2^m6Btlr/\Dock2^m6Btlr (C57BL/6J-Dock2^m6Btlr)	decreased IgE level	J:236689
\Dock2^m6Btlr/\Dock2^m6Btlr (C57BL/6J-Dock2^m6Btlr)	decreased response to antigen	J:236689
\Dock2^m7Btlr/\Dock2⁺ (C57BL/6J-Dock2^m7Btlr)	decreased B cell number	J:255181
	increased macrophage cell number	J:255181
	increased neutrophil cell number	J:255181
\Dock2^m7Btlr/\Dock2^m7Btlr (C57BL/6J-Dock2^m7Btlr)	decreased B cell number	J:255181
	increased IgE level	J:255181
	increased macrophage cell number	J:255181
	increased neutrophil cell number	J:255181
	increased NK cell number	J:255181
\Dock2^m8Btlr/\Dock2^m8Btlr (C57BL/6J-Dock2^m8Btlr)	decreased CD4-positive, alpha-beta T cell number	J:272402
\Dock2^m8Btlr/\Dock2^m8Btlr (C57BL/6J-Dock2^m8Btlr)	increased CD8-positive, alpha-beta T cell number	J:272402
\Dock2^M9Btlr/\Dock2^M9Btlr (C57BL/6J-Dock2^M9Btlr)	increased CD8-positive, alpha-beta T cell number	J:272403
\Dock2^m10Btlr/\Dock2^m10Btlr (C57BL/6J-Dock2^m10Btlr)	decreased B-1b cell number	J:272404
\Dock2^m10Btlr/\Dock2^m10Btlr (C57BL/6J-Dock2^m10Btlr)	increased NK cell number	J:272404
\Dock2^m11Btlr/\Dock2^m11Btlr (C57BL/6J-Dock2^m11Btlr)	abnormal B cell differentiation	J:272405
	abnormal CD4-positive T cell differentiation	J:272405
	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:272405
	decreased B cell number	J:272405
	decreased CD4-positive, alpha-beta T cell number	J:272405
	decreased CD8-positive, naive alpha-beta T cell number	J:272405
	decreased NK cell number	J:272405
	increased B-1 B cell number	J:272405
	increased CD8-positive, alpha-beta T cell number	J:272405
	increased central memory CD4-positive, alpha-beta T cell number	J:272405
	increased central memory CD8 positive, alpha-beta T cell number	J:272405
	increased effector memory CD4-positive, alpha-beta T cell number	J:272405
\Dock2^M12Btlr/\Dock2^M12Btlr (C57BL/6J-Dock2^M12Btlr)	decreased B-1a cell number	J:272406
\Dock2^m13Btlr/\Dock2^m13Btlr (C57BL/6J-Dock2^m13Btlr)	increased alpha-beta T cell number	J:272437
\Dock2^m13Btlr/\Dock2^m13Btlr (C57BL/6J-Dock2^m13Btlr)	increased CD8-positive, alpha-beta T cell number	J:272437
\Dock2^M14Btlr/\Dock2^M14Btlr (C57BL/6J-Dock2^M14Btlr)	abnormal lymphocyte morphology	J:272438
\Dock2^M14Btlr/\Dock2^M14Btlr (C57BL/6J-Dock2^M14Btlr)	increased CD8-positive, alpha-beta T cell number	J:272438
\Dock2^m15Btlr/\Dock2^m15Btlr (C57BL/6J-Dock2^m15Btlr)	decreased B cell number	J:274942
	decreased CD4-positive, alpha-beta T cell number	J:274942
	decreased CD8-positive, naive alpha-beta T cell number	J:274942
	decreased T cell number	J:274942
	increased B-1 B cell number	J:274942
	increased CD8-positive, alpha-beta T cell number	J:274942
	increased central memory CD8 positive, alpha-beta T cell number	J:274942
	increased NK cell number	J:274942
\Dock2^M16Btlr/\Dock2^M16Btlr (C57BL/6J-Dock2^M16Btlr)	abnormal CD8-positive, alpha-beta T cell number	J:274971
\Dock2^{tm1b(EUCOMM)Wtsi}/\Dock2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dock2^{tm1b(EUCOMM)Wtsi}/BayMmucd)	increased spleen weight	J:211773
\Dock2^tm1Tsas/\Dock2^tm1Tsas (involves: C57BL/6)	abnormal immune system morphology	J:71005
	abnormal leukocyte migration	J:71005
	abnormal Peyer's patch morphology	J:71005
	abnormal spleen morphology	J:71005
	abnormal spleen white pulp morphology	J:71005
	decreased marginal zone B cell number	J:71005
	lymph node hypoplasia	J:71005
	spleen hypoplasia	J:71005
\Dock2^tm1Tsas/\Dock2^tm1Tsas (B6.Cg-Dock2^tm1Tsas)	decreased lymphocyte cell number	J:130919
	decreased mature B cell number	J:130919
	decreased T cell number	J:130919
	impaired neutrophil chemotaxis	J:113266
\Dock2^tm1Tsas/\Dock2^tm1Tsas \Tg(Tcra2B4)1Mmd/? \Tg(Tcrb2B4)1Mmd/? (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:84581
	abnormal T cell physiology	J:84581
	decreased double-positive T cell number	J:84581
\Dock3^tm1Dasc/\Dock3^tm1Dasc (B6.Cg-Dock3^tm1Dasc)	abnormal microglial cell physiology	J:144341
\Dock7^mnlt/\Dock7^mnlt (C57BL/6J-Dock7^mnlt)	immune system phenotype	J:146458
\Dock8^cpm/\Dock8^cpm (C57BL/6JSfdAnu-Dock8^cpm)	abnormal humoral immune response	J:155516
	decreased marginal zone B cell number	J:155516
	decreased spleen germinal center size	J:155516
	decreased T cell number	J:155516
\Dock8^cpm/\Dock8^pri (C57BL/6J-Dock8^cpm/Dock8^pri)	decreased marginal zone B cell number	J:155516
\Dock8^cpm/\Dock8^pri (C57BL/6J-Dock8^cpm/Dock8^pri)	decreased T cell number	J:155516
\Dock8^m1Anu/\Dock8^m1Anu (C57BL/6NCrlAnu-Dock8^m1Anu)	decreased activated T cell number	J:104190
	decreased IgM level	J:104190
	decreased T cell number	J:104190
\Dock8^m1Btlr/\Dock8^m1Btlr (C57BL/6J-Dock8^m1Btlr)	decreased IgG level	J:234247
\Dock8^m1Btlr/\Dock8^m1Btlr (C57BL/6J-Dock8^m1Btlr)	impaired humoral immune response	J:234247
\Dock8^m2Anu/\Dock8^m2Anu (C57BL/6NCrlAnu-Dock8^m2Anu)	absent marginal zone B cells	J:104190
	decreased activated T cell number	J:104190
	decreased IgM level	J:104190
	decreased T cell number	J:104190
\Dock8^M2Btlr/\Dock8^M2Btlr (C57BL/6J-Dock8^M2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272530
\Dock8^M3Btlr/\Dock8^M3Btlr (C57BL/6J-Dock8^M3Btlr)	decreased IgG level	J:272531
\Dock8^M3Btlr/\Dock8^M3Btlr (C57BL/6J-Dock8^M3Btlr)	impaired humoral immune response	J:272531
\Dock8^m4Btlr/\Dock8^m4Btlr (C57BL/6J-Dock8^m4Btlr)	abnormal B cell differentiation	J:274856
	abnormal CD4-positive T cell differentiation	J:274856
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274856
	abnormal T cell differentiation	J:274856
	decreased B-1 B cell number	J:274856
	decreased CD4-positive, alpha-beta T cell number	J:274856
	decreased CD8-positive, alpha-beta T cell number	J:274856
	decreased CD8-positive, naive alpha-beta T cell number	J:274856
	decreased T cell number	J:274856
	increased CD4-positive, alpha-beta T cell number	J:274856
	increased central memory CD4-positive, alpha-beta T cell number	J:274856
	increased central memory CD8 positive, alpha-beta T cell number	J:274856
	increased effector memory CD4-positive, alpha-beta T cell number	J:274856
	increased effector memory CD8-positive, alpha-beta T cell number	J:274856
\Dock8^pri/\Dock8^pri (C57BL/6JAnu-Dock8^pri)	abnormal humoral immune response	J:155516
	decreased B-1 B cell number	J:155516
	decreased germinal center B cell number	J:155516
	decreased marginal zone B cell number	J:155516
	decreased spleen germinal center size	J:155516
	decreased T cell number	J:155516
\Dock8^pri/\Dock8^pri (involves: C57BL/6JAnu)	abnormal cellular extravasation	J:238772
\Dock8^pri/\Dock8^pri (involves: C57BL/6JAnu)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:238772
\Dock8^tm1Ysfk/\Dock8^tm1Ysfk (B6.Cg-Dock8^tm1Ysfk)	abnormal dendritic cell physiology	J:185165
	decreased CD4-positive, alpha-beta T cell number	J:185165
	decreased CD8-positive, alpha-beta T cell number	J:185165
	decreased follicular dendritic cell number	J:185165
	decreased IgG level	J:185165
	decreased marginal zone B cell number	J:185165
	decreased T cell proliferation	J:185165
\Dock8^tm1Ysfk/\Dock8^tm1Ysfk \Tg(TcrAND)53Hed/0 (involves: C57BL/6 * SJL)	dermatitis	J:305132
\Dock9^tm1Thar/\Dock9^tm1Thar (involves: C57BL/6)	immune system phenotype	J:300632
\Dock10^{tm1a(EUCOMM)Hmgu}/\Dock10^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Dock10^{tm1a(EUCOMM)Hmgu}/Ieg)	abnormal B cell physiology	J:236911
	abnormal follicular B cell physiology	J:236911
	abnormal spleen marginal zone morphology	J:238172
	abnormal thymus cell ratio	J:238172
	arrested B cell differentiation	J:236911
	decreased B cell number	J:236911
	decreased follicular B cell number	J:236911
	decreased marginal zone B cell number	J:236911
	immune system phenotype	J:238172
	increased single-positive T cell number	J:236911
	increased T cell number	J:236911
\Dock10^tm1Thar/\Dock10^tm1Thar (involves: C57BL/6)	abnormal microglial cell chemotaxis	J:300632
	decreased B cell number	J:300632
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:300632
	impaired macrophage chemotaxis	J:300632
\Dock11^tm1.1Mmar/\Dock11^tm1.1Mmar (Not Specified)	abnormal metallophilic macrophage morphology	J:238172
	abnormal spleen marginal zone morphology	J:238172
	abnormal thymus cell ratio	J:238172
	decreased marginal zone B cell number	J:238172
	immune system phenotype	J:238172
\Dock11^tm1Thar/\Dock11^tm1Thar (involves: C57BL/6)	immune system phenotype	J:300632
\Dock11^tm1Thar/\Dock11^tm1Thar (involves: C57BL/6)	impaired macrophage chemotaxis	J:300632
\Dohh^tm1.2Sbal/\Dohh⁺ (B6.129(Cg)-Dohh^tm1.2Sbal)	abnormal spleen morphology	J:214321
\Dok1^tm1Ppp/\Dok1^tm1Ppp (129S1/Sv-Dok1^tm1Ppp)	abnormal T cell proliferation	J:95640
\Dok1^tm1Ppp/\Dok1^tm1Ppp \Dok2^tm1Ppp/\Dok2^tm1Ppp (129S1/Sv-Dok1^tm1Ppp Dok2^tm1Ppp)	abnormal leukocyte physiology	J:95334
	enlarged spleen	J:95334
	increased leukocyte cell number	J:95334
	increased monocyte cell number	J:95334
	increased neutrophil cell number	J:95334
\Dok1^tm1Ppp/\Dok1^tm1Ppp \Dok2^tm1Ppp/\Dok2^tm1Ppp \Dok3^tm1Ppp/\Dok3^tm1Ppp (129S1/Sv-Dok1^tm1Ppp Dok2^tm1Ppp Dok3^tm1Ppp)	increased leukocyte cell number	J:158011
\Dok1^tm1Yyam/\Dok1^tm1Yyam (involves: 129S4/SvJae * C57BL/6)	decreased IgM level	J:95641
	increased B cell proliferation	J:95641
\Dok1^tm1Yyam/\Dok1^tm1Yyam \Dok2^tm1Yyam/\Dok2^tm1Yyam (B6.129-Dok1^tm1Yyam Dok2^tm1Yyam)	abnormal leukocyte physiology	J:95335
	abnormal myelopoiesis	J:95335
	enlarged spleen	J:95335
	increased leukocyte cell number	J:95335
	increased monocyte cell number	J:95335
	increased neutrophil cell number	J:95335
\Dok1^tm1Yyam/\Dok1^tm1Yyam \Dok2^tm1Yyam/\Dok2^tm1Yyam (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:163407
\Dok1^tm1Yyam/\Dok1^tm1Yyam \Dok2^tm1Yyam/\Dok2^tm1Yyam \Dok3^tm1Brs/\Dok3^tm1Brs (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:163407
	increased macrophage cell number	J:163407
\Dok1^tm1Yyam/\Dok1^tm1Yyam \Dok2^tm1Yyam/\Dok2^tm1Yyam \Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6)	enlarged lymph nodes	J:95335
	enlarged thymus	J:95335
\Dok1^tm1Yyam/\Dok1^tm1Yyam \Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6)	enlarged lymph nodes	J:95335
	enlarged thymus	J:95335
\Dok2^tm1Ppp/\Dok2^tm1Ppp (129S1/Sv-Dok2^tm1Ppp)	abnormal granulocyte physiology	J:95334
\Dok2^tm1Yyam/\Dok2^tm1Yyam \Tg(Tec-BCR/ABL1)5Hhi/0 (involves: C57BL/6)	enlarged lymph nodes	J:95335
	enlarged thymus	J:95335
\Dok3^tm1Brs/\Dok3^tm1Brs (involves: C57BL/6)	increased macrophage cell number	J:163407
\Dok3^tm1Kplm/\Dok3^tm1Kplm (involves: 129P2/OlaHsd)	abnormal B cell calcium ion homeostasis	J:280795
	abnormal B cell physiology	J:280795
	enhanced humoral immune response	J:280795
	increased B cell proliferation	J:280795
	increased IgG3 level	J:280795
	increased IgM level	J:280795
\Dok7^{tm1.1(KOMP)Vlcg}/\Dok7⁺ (C57BL/6N-Dok7^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Dop1b^{tm1a(EUCOMM)Wtsi}/\Dop1b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Dop1b^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Dot1l^tm1.1Saam/\Dot1l^tm1.1Saam \Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv * C57BL/6)	abnormal leukopoiesis	J:193161
	decreased lymphocyte cell number	J:193161
	decreased neutrophil cell number	J:193161
\Dp(11Cops3-Rnf112)1Jrl/0 (involves: 129S7/SvEvBrd * C57BL/6)	decreased spleen weight	J:83302
\Dp(16Cbr1-Fam3b)1Rhr/0 \Gata1^tm8.2Sho/Y (involves: 129S1/Sv * 129S6/SvEvTac)	enlarged spleen	J:184564
	increased monocyte cell number	J:184564
\Dp(17Nfkbil1-Or2h1)1Cogr/0 (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:190754
\Dpcd/Poll^{Gt(OST280355)Lex}/\Dpcd/Poll^{Gt(OST280355)Lex} (involves: 129S5/SvEvBrd * C57BL/6Brd)	increased susceptibility to otitis media	J:185566
\Dph6^{tm1a(KOMP)Wtsi}/\Dph6^{tm1a(KOMP)Wtsi} (C57BL/6N-Dph6^{tm1a(KOMP)Wtsi}/Wtsi)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased mature B cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD5-positive gamma-delta T cell number	J:211773
	increased CD11b-low dendritic cell number	J:211773
	increased dendritic cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased marginal zone B cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased monocyte cell number	J:211773
	increased plasma cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
\Dpp3^{tm1d(EUCOMM)Hmgu}/\Dpp3^{tm1d(EUCOMM)Hmgu} (involves: BALB/c * C57BL/6 * C57BL/6J * C57BL/6N * SJL)	abnormal interferon-gamma secretion	J:294242
	increased interleukin-1 beta secretion	J:294242
	increased interleukin-6 secretion	J:294242
	increased interleukin-10 secretion	J:294242
	increased osteoclast cell number	J:294242
	increased tumor necrosis factor secretion	J:294242
\Dpp4^em1Rba/\Dpp4⁺ (C57BL/6J-Dpp4^em1Rba)	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:279834
	increased susceptibility to Coronaviridae infection	J:279834
	lung inflammation	J:279834
\Dpp4^em1Rba/\Dpp4^em1Rba (C57BL/6J-Dpp4^em1Rba)	decreased lymphocyte cell number	J:279723
	increased monocyte cell number	J:279723
	increased neutrophil cell number	J:279723
	increased susceptibility to Coronaviridae infection	J:279723, J:279834
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:279834
	lung inflammation	J:279834
\Dpp4^em3Gpt/\Dpp4^em3Gpt (C57BL/6JGpt-Dpp4^em3Gpt)	immune system phenotype	J:324112
\Dpp4^{tm1(DPP4)Vlcg}/? (involves: 129S6/SvEvTac * C57BL/6NTac)	increased susceptibility to Coronaviridae infection	J:223728
	interstitial pneumonia	J:223728
	lung inflammation	J:223728
\Dpp4^{tm1(DPP4)Vlcg}/? (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased CD4-positive, alpha-beta T cell number	J:238079
	increased CD8-positive, alpha-beta T cell number	J:238079
	increased macrophage cell number	J:238079
	increased neutrophil cell number	J:238079
	increased susceptibility to Coronaviridae infection	J:238079
	lung inflammation	J:238079
	pleuritis	J:238079
\Dpp4^{tm1.1(DPP4)Pbmj}/\Dpp4^{tm1.1(DPP4)Pbmj} (involves: C57BL/6 * C57BL/6NTac)	increased susceptibility to Coronaviridae infection	J:242025
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:242025
	lung inflammation	J:242025
\Dpp4^{tm1b(EUCOMM)Wtsi}/\Dpp4^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Dpp4^{tm1b(EUCOMM)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
\Dpp9^{em1(IMPC)Ccpcz}/\Dpp9⁺ (C57BL/6NCrl-Dpp9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Dppa1^{tm1b(KOMP)Wtsi}/\Dppa1⁺ (C57BL/6N-Dppa1^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Dpy19l4^em1(IMPC)J/\Dpy19l4^em1(IMPC)J (C57BL/6NJ-Dpy19l4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Drc1^b2b1654Clo/\Drc1^b2b1654Clo (C57BL/6J-Drc1^b2b1654Clo)	absent spleen	J:175213
\Drd1^tm1Jcd/\Drd1^tm1Jcd \Drd2^tm1Ebo/\Drd2⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	small intestinal inflammation	J:91781
\Drd1^tm2Jcd/\Drd1⁺ \Tg(Camk2a-cre)2Gsc/0 (involves: 129S4/SvJae * FVB/N)	abnormal microglial cell physiology	J:120070
\Drd2^tm1Low/\Drd2^tm1Low (B6.129S2-Drd2^tm1Low/J)	decreased spleen weight	J:106832
	increased interleukin-1 beta secretion	J:194407
	microgliosis	J:194407
\Drd3^em1(IMPC)Mbp/\Drd3^em1(IMPC)Mbp (C57BL/6N-Drd3^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Drgx^em1(IMPC)Mbp/\Drgx⁺ (C57BL/6N-Drgx^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Drosha^tm1Litt/\Drosha^tm1.1Litt \Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal interferon-gamma secretion	J:138683
	abnormal interleukin-4 secretion	J:138683
	abnormal T cell activation	J:138683
	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	increased CD8-positive, alpha-beta T cell number	J:138683
	increased leukocyte cell number	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
\Drosha^tm1Litt/\Drosha^tm1.1Litt \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3^{tm4(YFP/icre)Ayr} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal interferon-gamma secretion	J:138683
	abnormal interleukin-4 secretion	J:138683
	abnormal regulatory T cell morphology	J:138683
	abnormal T cell activation	J:138683
	blood vessel inflammation	J:138683
	enlarged lymph nodes	J:138683
	enlarged spleen	J:138683
	increased CD8-positive, alpha-beta T cell number	J:138683
	increased leukocyte cell number	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
\Drosha^tm1Litt/\Drosha^tm1.1Litt \Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/\Gt(ROSA)26Sor⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal interferon-gamma secretion	J:138683
\Drosha^tm1Litt/\Drosha^tm1.1Litt \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal immune system physiology	J:138683
	decreased CD8-positive, alpha-beta T cell number	J:138683
	decreased double-positive T cell number	J:138683
	decreased lymphocyte cell number	J:138683
	decreased regulatory T cell number	J:138683
	decreased thymocyte number	J:138683
	immune system phenotype	J:138683
	increased activated T cell number	J:138683
	increased gamma-delta T cell number	J:138683
	increased granulocyte number	J:138683
	intestinal inflammation	J:138683
	liver inflammation	J:138683
	lung inflammation	J:138683
\Dsc1^tm1Dga/\Dsc1^tm1Dga (involves: C57BL/6J)	dermatitis	J:73102
\Dsc2^tm1.1Leu/\Dsc2^tm1.1Leu \Tg(Vil1-cre)20Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	immune system phenotype	J:302333
\Dsg2^m1Btlr/\Dsg2^m1Btlr (C57BL/6J-Dsg2^m1Btlr)	increased susceptibility to induced colitis	J:271975
\Dsg2^m2Btlr/\Dsg2^m2Btlr (C57BL/6J-Dsg2^m2Btlr)	increased susceptibility to induced colitis	J:271976
\Dsg2^m3Btlr/\Dsg2^m3Btlr (C57BL/6J-Dsg2^m3Btlr)	increased susceptibility to induced colitis	J:271977
\Dsg2^{tm1d(EUCOMM)Wtsi}/\Dsg2^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	heart inflammation	J:235770
\Dsg2^tm3.1Leu/\Dsg2^tm3.1Leu \Tg(Vil1-cre)20Syr/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:302333
	increased susceptibility to induced colitis	J:302333
\Dsg3^bal/\Dsg3^bal (C57BL/6J-Dsg3^bal/J)	cutaneous mastocytosis	J:18223
\Dsg3^bal/\Dsg3^bal (C57BL/6J-Dsg3^bal/J)	increased IgE level	J:18223
\Dsg3^sqk/\Dsg3^sqk (C57BL/6-Dsg3^sqk)	conjunctivitis	J:219200
	decreased B cell number	J:219200
	decreased double-positive T cell number	J:219200
	decreased immature B cell number	J:219200
	decreased lymphocyte cell number	J:219200
	decreased pre-B cell number	J:219200
	decreased single-positive T cell number	J:219200
	decreased transitional stage B cell number	J:219200
	increased neutrophil cell number	J:219200
	increased susceptibility to infection	J:219200
\Dsg3^tm1Stan/\Dsg3^tm1Stan (involves: 129X1/SvJ * C57BL/6J)	conjunctivitis	J:40804
\Dsg4^hage/\Dsg4^hage \Fas^lpr/\Fas^lpr X/\Yaa (EOD-Dsg4^hage)	abnormal effector T cell morphology	J:140028
	abnormal mast cell morphology	J:140028
\Dsg4^lah-J/\Dsg4^lah-J (involves: DBA/1LacJ)	abnormal peripheral lymph node morphology	J:83117
	dermatitis	J:83117
	increased IgE level	J:83117
\Dsg4^lah/\Dsg4^lah (LAH/Pas)	dermatitis	J:33849
\Dsp^em1(IMPC)Mbp/\Dsp⁺ (C57BL/6N-Dsp^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Dspp^tm1Kul/\Dspp^tm1Kul (B6;129-Dspp^tm1Kul/Mmnc)	periodontium inflammation	J:241990
\Dssc1^C3H/HeJ/\Dssc1^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
\Dssc1^C57BL/6J/\Dssc1^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
\Dssc2^C3H/HeJ/\Dssc2^C3H/HeJ (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
\Dssc2^C3H/HeJ/\Dssc2^C57BL/6J (involves: C3H/HeJ * C57BL/6J)	colitis	J:52852
\Dst^Tg4/\Dst^Tg4 (involves: C57BL/6 * CD-1)	conjunctivitis	J:209161
\Dstn^corn1/\Dstn^corn1 (A.BY-H2^bc H2-T18^f/SnJ)	abnormal lymphangiogenesis	J:98465
\Dstn^corn1/\Dstn^corn1 (A.BY-H2^bc H2-T18^f/SnJ)	immune system phenotype	J:98465
\Dstn^corn1/\Dstn^corn1 (A.BY-H2^bc H2-T18^f/SnJ-Dstn^corn1/J)	immune system phenotype	J:139239
\Dtnbp1^sdy-Btlr/\Dtnbp1^sdy-Btlr (C57BL/6J-Dtnbp1^sdy-Btlr)	impaired natural killer cell mediated cytotoxicity	J:133620
	increased susceptibility to Herpesvirales infection	J:133620
\Dtnbp1^{tm1b(EUCOMM)Hmgu}/\Dtnbp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Dtnbp1^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased lymphocyte cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Dtx1^tm1.1Mzl/\Dtx1^tm1.1Mzl \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal thymocyte activation	J:151605
	increased anti-double stranded DNA antibody level	J:151605
	increased anti-histone antibody level	J:151605
	increased autoantibody level	J:151605
	increased interleukin-2 secretion	J:151605
	increased T cell proliferation	J:151605
\Dtx1^tm1.2Mzl/\Dtx1^tm1.2Mzl (B6.129-Dtx1^tm1.2Mzl)	abnormal lymphocyte morphology	J:151605
	abnormal lymphocyte physiology	J:151605
	abnormal regulatory T cell physiology	J:151605
	abnormal T cell anergy	J:151605
	abnormal thymocyte activation	J:151605
	decreased marginal zone B cell number	J:151605
	decreased thymocyte apoptosis	J:151605
	glomerulonephritis	J:151605
	increased anti-double stranded DNA antibody level	J:151605
	increased anti-histone antibody level	J:151605
	increased B cell proliferation	J:151605
	increased interferon-gamma secretion	J:151605
	increased interleukin-2 secretion	J:151605
	increased interleukin-4 secretion	J:151605
	increased T cell proliferation	J:151605
	liver inflammation	J:151605
	lung inflammation	J:151605
	spleen hyperplasia	J:151605
\Dtx1^tm1Mjb/\Dtx1^tm1Mjb (either: B6.129S6-Dtx1^tm1Mjb or (involves: 129S6/SvEvTac * C57BL/6))	immune system phenotype	J:114658
\Dtx1^tm1Mjb/\Dtx1^tm1Mjb \Dtx2^tm1Mjb/\Dtx2^tm1Mjb (involves: 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:114658
\Dtx2^tm1Mjb/\Dtx2^tm1Mjb (involves: 129S6/SvEvTac)	immune system phenotype	J:114658
\Dtx4^{em1(IMPC)Ccpcz}/\Dtx4⁺ (C57BL/6N-Dtx4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Ducm1^129X1/SvJ/\Ducm1^129X1/SvJ (involves: 129X1/SvJ * C57BL/6J)	abnormal professional antigen presenting cell physiology	J:86617
\Ducm1^129X1/SvJ/\Ducm1^C57BL/6J (involves: 129X1/SvJ * C57BL/6J)	abnormal professional antigen presenting cell physiology	J:86617
\Duox2^em1(IMPC)Mbp/\Duox2^em1(IMPC)Mbp (C57BL/6N-Duox2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	small spleen	J:211773
\Duoxa2^{tm1b(KOMP)Wtsi}/\Duoxa2^{tm1b(KOMP)Wtsi} (C57BL/6N-Duoxa2^{tm1b(KOMP)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased follicular B cell number	J:211773
	decreased immature B cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased Ly6C low monocyte number	J:211773
	decreased mature B cell number	J:211773
	decreased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased memory-marker gamma-delta T cell number	J:211773
	decreased NK cell number	J:211773
	decreased transitional stage T1 B cell number	J:211773
	increased alpha-beta T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
\Dusp1^tm1Brv/\Dusp1^tm1Brv (involves: 129S2/SvPas)	abnormal cytokine secretion	J:118832
\Dusp1^tm1Brv/\Dusp1^tm1Brv (involves: 129S2/SvPas)	lung inflammation	J:118832
\Dusp1^tm1Brv/\Dusp1^tm1Brv (involves: 129S2/SvPas * C57BL/6)	increased circulating interleukin-6 level	J:118833
	increased circulating interleukin-10 level	J:118833
	increased circulating tumor necrosis factor level	J:118833
	increased interleukin-6 secretion	J:118833
	increased susceptibility to endotoxin shock	J:118833
	increased tumor necrosis factor secretion	J:118833
\Dusp1^tm1Brv/\Dusp1^tm1Brv (involves: 129S2/SvPas * various)	immune system phenotype	J:125919
	increased mast cell degranulation	J:125919
	increased susceptibility to type I hypersensitivity reaction	J:125919
\Dusp1^tm1Brv/\Dusp1^tm1Brv (C3.129S2-Dusp1^tm1Brv)	abnormal chemokine secretion	J:164929
	increased granulocyte number	J:164929
	increased interleukin-1 beta secretion	J:164929
	increased interleukin-6 secretion	J:164929
	increased susceptibility to bacterial infection	J:164929
	lung inflammation	J:164929
\Dusp1^tm1Lex/\Dusp1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal chemokine level	J:126383
	abnormal innate immunity	J:126383
	abnormal interleukin level	J:126383
	increased circulating interferon-gamma level	J:126383
	increased circulating interleukin-6 level	J:126383
	increased circulating interleukin-10 level	J:126383
	increased circulating tumor necrosis factor level	J:126383
	increased susceptibility to endotoxin shock	J:126383
	increased susceptibility to induced arthritis	J:126383
\Dusp2^tm1Cmac/\Dusp2^tm1Cmac (B6.Cg-Dusp2^tm1Cmac)	abnormal cytokine secretion	J:112609
	abnormal macrophage activation involved in immune response	J:112609
	abnormal mast cell physiology	J:112609
	decreased susceptibility to induced arthritis	J:112609
\Dusp4^Gt(XG164)Byg/\Dusp4^Gt(XG164)Byg (B6.129P2-Dusp4^Gt(XG164)Byg)	immune system phenotype	J:180366
	increased CD4-positive, alpha-beta T cell number	J:180366
	increased interleukin-10 secretion	J:180366
	increased T cell proliferation	J:180366
\Dusp4^tm1Jmol/\Dusp4^tm1Jmol (involves: 129)	decreased B cell apoptosis	J:140567
\Dusp4^tm1Plev/\Dusp4^tm1Plev (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:170774
	decreased IgG2a level	J:170774
	decreased interferon-gamma secretion	J:170774
	decreased interleukin-10 secretion	J:170774
	increased IgG1 level	J:170774
	increased interleukin-4 secretion	J:170774
	increased interleukin-6 secretion	J:170774
	increased interleukin-12 secretion	J:170774
	increased interleukin-13 secretion	J:170774
	increased susceptibility to parasitic infection	J:170774
	increased tumor necrosis factor secretion	J:170774
\Dusp5^tm1.1Achn/\Dusp5^tm1.1Achn (involves: C57BL/6NCrl)	abnormal susceptibility to parasitic infection	J:218203
	immune system phenotype	J:218203
	increased T cell proliferation	J:218203
	increased thymocyte number	J:218203
\Dusp5^tm1.1Achn/\Dusp5^tm1.1Achn \Rag2^tm1.1Cgn/\Rag2^tm1.1Cgn (involves: C57BL/6NCrl)	abnormal eosinophil physiology	J:218203
	abnormal susceptibility to parasitic infection	J:218203
	increased eosinophil cell number	J:218203
\Dusp5^{tm1a(KOMP)Wtsi}/\Dusp5^{tm1a(KOMP)Wtsi} (C57BL/6-Dusp5^{tm1a(KOMP)Wtsi})	abnormal CD8-positive, alpha beta T cell morphology	J:240637
	abnormal T cell physiology	J:240637
	increased effector memory CD8-positive, alpha-beta T cell number	J:240637
	increased T cell apoptosis	J:240637
	increased T cell proliferation	J:240637
\Dusp5^{tm1d(KOMP)Wtsi}/\Dusp5^{tm1d(KOMP)Wtsi} (B6(Cg)-Dusp5^{tm1d(KOMP)Wtsi})	increased T cell apoptosis	J:240637
\Dusp6^tm1Jmol/\Dusp6^tm1Jmol (involves: 129 * C57BL/6)	increased spleen weight	J:142966
\Dusp10^tm1Flv/\Dusp10^tm1Flv (involves: 129S6/SvEvTac)	abnormal adaptive immunity	J:92104
	abnormal cytokine secretion	J:92104
	abnormal interleukin secretion	J:92104
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:92104
	decreased T cell proliferation	J:92104
	increased activated T cell number	J:92104
	increased interferon-gamma secretion	J:92104
	increased susceptibility to type I hypersensitivity reaction	J:92104
	increased tumor necrosis factor secretion	J:92104
\Dusp11^{Gt(BB0198)Wtsi}/\Dusp11^{Gt(BB0198)Wtsi} (B6.129P2-Dusp11^{Gt(BB0198)Wtsi})	abnormal macrophage activation involved in immune response	J:301503
	immune system phenotype	J:301503
	increased circulating interleukin-1 beta level	J:301503
	increased circulating interleukin-6 level	J:301503
	increased circulating tumor necrosis factor level	J:301503
	increased macrophage cytokine production	J:301503
	increased susceptibility to endotoxin shock	J:301503
\Dusp12^em1(IMPC)Mbp/\Dusp12⁺ (C57BL/6N-Dusp12^em1(IMPC)Mbp/Ucd)	increased basophil cell number	J:211773
\Dusp14^{Gt(OST210117)Lex}/\Dusp14^{Gt(OST210117)Lex} (B6.129S5-Dusp14^{Gt(OST210117)Lex})	abnormal cytokine secretion	J:209403
	abnormal humoral immune response	J:209403
	abnormal T cell activation	J:209403
	immune system phenotype	J:209403
	increased susceptibility to experimental autoimmune encephalomyelitis	J:209403
	increased T cell proliferation	J:209403
	increased T-helper 1 cell number	J:209403
	increased T-helper 17 cell number	J:209403
\Dusp16^em1(IMPC)Tcp/\Dusp16^em1(IMPC)Tcp (C57BL/6NCrl-Dusp16^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Dusp22^tm1Tht/\Dusp22^tm1Tht (B6.129S7-Dusp22^tm1Tht)	abnormal B cell activation	J:213253
	abnormal cytokine level	J:213253
	abnormal T cell activation	J:213253
	decreased B cell proliferation	J:213253
	decreased IgG3 level	J:213253
	decreased IgM level	J:213253
	decreased immunoglobulin level	J:213253
	enlarged spleen	J:213253
	increased circulating interferon-gamma level	J:213253
	increased circulating interleukin-6 level	J:213253
	increased circulating interleukin-17 level	J:213253
	increased circulating tumor necrosis factor level	J:213253
	increased inflammatory response	J:213253
	increased interferon-gamma secretion	J:213253
	increased interleukin-2 secretion	J:213253
	increased interleukin-4 secretion	J:213253
	increased interleukin-17 secretion	J:213253
	increased spleen white pulp amount	J:213253
	increased susceptibility to autoimmune disorder	J:213253
	increased susceptibility to experimental autoimmune encephalomyelitis	J:213253
	increased T cell proliferation	J:213253
	kidney inflammation	J:213253
	liver inflammation	J:213253
	lung inflammation	J:213253
\Dvl3^b2b2866Clo/\Dvl3^b2b2866Clo (C57BL/6J-Dvl3^b2b2866Clo)	thymus hypoplasia	J:175213
\Dync1li1^em1(IMPC)Tcp/\Dync1li1⁺ (C57BL/6NCrl-Dync1li1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Dyrk1a^tm1Jdc/\Dyrk1a^tm1Jdc \Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6J * C57BL/6NTac * CBA/J)	decreased B cell number	J:223138
	decreased double-positive T cell number	J:223138
	decreased immature B cell number	J:223138
	decreased mature B cell number	J:223138
	decreased pre-B cell number	J:223138
	decreased thymocyte number	J:223138
	increased T cell apoptosis	J:223138
\Dyrk1b^{tm1b(EUCOMM)Wtsi}/\Dyrk1b⁺ (C57BL/6N-Dyrk1b^{tm1b(EUCOMM)Wtsi}/Ics)	decreased large unstained cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Dyrk2^em1(IMPC)Ics/\Dyrk2⁺ (C57BL/6N-Dyrk2^em1(IMPC)Ics/Ics)	decreased large unstained cell number	J:211773
\Dysf^im/\Dysf⁺ \Large1^myd/\Large1^myd (involves: C57BL/6 * SJL/J)	myositis	J:221523
\Dysf^im/\Dysf^im \Fktn^tm1Ttd/\Fktn^tm2(FCMD)Ttd (involves: 129S7/SvEvBrd * C57BL/6 * SJL/J)	myositis	J:221523
\Dysf^im/\Dysf^im \Large1^myd/\Large1^myd (involves: C57BL/6 * SJL/J)	myositis	J:221523
\Dysf^tm1Kcam/\Dysf^tm1Kcam (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	myositis	J:171870
\Dytn^em1(IMPC)J/\Dytn^em1(IMPC)J (C57BL/6NJ-Dytn^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\E2f1^{Tg(Wnt1-cre)2Sor}/\E2f1⁺ \Snrpb^em1Lajm/\Snrpb⁺ (involves: C3H * C57BL/6 * C57BL/6J * CD1)	athymia	J:326544
\E2f1^tm1Meg/\E2f1^tm1Meg (either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))	abnormal double-positive T cell morphology	J:33100
	enlarged thymus	J:33100
	increased CD4-positive, alpha-beta T cell number	J:33100
	increased CD8-positive, alpha-beta T cell number	J:33100
	increased T cell derived lymphoma incidence	J:33100
	increased thymocyte number	J:33100
	increased thymus weight	J:33100
\E2f1^tm1Meg/\E2f1^tm1Meg (NOD.Cg-E2f1^tm1Meg)	abnormal CD4-positive, alpha beta T cell morphology	J:93708
	abnormal CD8-positive, alpha beta T cell morphology	J:93708
	abnormal double-positive T cell morphology	J:93708
	decreased double-positive T cell number	J:93708
	decreased regulatory T cell number	J:93708
	enlarged thymus	J:93708
	increased interferon-gamma secretion	J:93708
	increased interleukin-4 secretion	J:93708
	increased susceptibility to autoimmune diabetes	J:93708
	increased T cell number	J:93708
	increased thymocyte number	J:93708
	insulitis	J:93708
	salivary gland inflammation	J:93708
\E2f1^tm1Meg/\E2f1^tm1Meg (involves: 129S4/SvJae * C57BL/6)	decreased T cell proliferation	J:76318
\E2f2^tm1Zubi/\E2f2^tm1Zubi (involves: 129S1/Sv * C57BL/6)	abnormal immune system morphology	J:76318
	abnormal immune system physiology	J:76318
	abnormal spleen white pulp morphology	J:76318
	abnormal T cell differentiation	J:76318
	abnormal T cell subpopulation ratio	J:76318
	enlarged spleen	J:76318
	glomerulonephritis	J:76318
	increased anti-double stranded DNA antibody level	J:76318
	increased inflammatory response	J:76318
	increased memory T cell number	J:76318
	increased spleen weight	J:76318
	increased susceptibility to autoimmune disorder	J:76318
	increased T cell proliferation	J:76318
	liver inflammation	J:76318
	lung inflammation	J:76318
\E2f2^tm1Zubi/\E2f2^tm1Zubi \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J)	abnormal immune system morphology	J:76318
	abnormal immune system physiology	J:76318
	enlarged spleen	J:76318
	increased CD8-positive, alpha-beta T cell number	J:76318
	increased inflammatory response	J:76318
	increased susceptibility to autoimmune disorder	J:76318
	increased T cell proliferation	J:76318
	thymus hypoplasia	J:76318
\E2f3^tm1Lees/\E2f3^tm1Lees (involves: 129S2/SvPas * C57BL/6)	lung inflammation	J:75765
\E2f4^tm1Jrn/\E2f4^tm1Jrn (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:64192
	decreased double-positive T cell number	J:64192
	decreased granulocyte number	J:64192
	decreased thymocyte number	J:64192
	increased double-negative T cell number	J:64192
	increased NK cell number	J:64192
	thymus hypoplasia	J:64192
\E2f4^tm1Lees/\E2f4^tm1Lees (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to bacterial infection	J:64193
	increased susceptibility to otitis media	J:64193
	rhinitis	J:64193
\E2f4^tm1Lees/\E2f4^tm1Lees \Rb1^tm1Tyj/\Rb1⁺ (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to infection	J:81082
\E2f6^{em1(IMPC)Ccpcz}/\E2f6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-E2f6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	small spleen	J:211773
	small thymus	J:211773
\Eae1^A/J/\Eae1^A/J (involves: A/J * C57BL/10SnJ)	increased susceptibility to experimental autoimmune encephalomyelitis	J:30574
\Eae1^PL/J/\Eae1^PL/J (involves: C57BL/10SnJ * PL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:30574
\Eae2^B10.RIII/\Eae2^RIIIS/J (involves: B10.RIII * RIIIS/J)	autoimmune arthritis	J:95848
\Eae2^RIIIS/J/\Eae2^RIIIS/J (involves: B10.RIII * RIIIS/J)	decreased susceptibility to induced arthritis	J:95848
\Eae2b^C57BL/10SnSg/\Eae2b^C57BL/10SnSg (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
\Eae4^ABH/? (involves: ABH * NOD)	increased susceptibility to experimental autoimmune encephalomyelitis	J:29171
\Eae5^B10.S/DvTe/\Eae5^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae5^SJL/J/\Eae5^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae7^B10.S/DvTe/\Eae7^B10.S/DvTe (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae7^B10.S/DvTe/\Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
\Eae7^B10.S/DvTe/\Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae7^SJL/J/\Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
\Eae7^SJL/J/\Eae7^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae9^B10.S/DvTe/\Eae9^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae10^SJL/J/\Eae10^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae11^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
\Eae12^SJL/J/\Eae12^SJL/J (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
\Eae13^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
\Eae14^C57BL/10/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:69083
\Eae16^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
\Eae17^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:69083
\Eae18^NOD/\Eae18^NOD (involves: ABH * NOD)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:29171
\Eae21^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
\Eae22^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
\Eae23^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:67840
\Eae25^SJL/J/? (involves: B10.S/DvTe * SJL/J)	increased inflammatory response	J:69083
\Eae26^B10.RIII/\Eae26^B10.RIII (involves: B10.RIII * RIIIS/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:73850
\Eae26^B10.RIII/\Eae26^RIIIS/J (involves: B10.RIII * RIIIS/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:73850
\Eae27^C57BL/10SnSg/\Eae27^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
\Eae27^RIIIS/J/\Eae27^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
\Eae33^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:99793
\Eae34^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:99793
\Eae35^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:99793
\Eae36^SJL/J/? (involves: B10.S * SJL/J)	increased susceptibility to autoimmune disorder	J:99793
\Eae37^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to autoimmune disorder	J:99793
\Eae38^C57BL/10SnSg/? (involves: B10.S * SJL/J)	increased susceptibility to autoimmune disorder	J:99793
\Eae39^C57BL/10SnSg/\Eae39^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
\Eae39^RIIIS/J/\Eae39^RIIIS/J (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
\Eae41^C57BL/10SnSg/\Eae41^C57BL/10SnSg (involves: B10.RIII * RIIIS/J)	CNS inflammation	J:96204
\Eae42^C57BL/10SnSg/? (involves: B10.S * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:34892
\Eae42^SJL/J/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:34892
\Eae43^B10.S/DvTe/? (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:53193
\Eae43^B10.S/DvTe/\Eae43^B10.S/DvTe (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Eae44a^B10.S/DvTe/\Eae44a^B10.S/DvTe (involves: B10.S/DvTe * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:56752
\Eae44a^B10.S/DvTe/\Eae44a^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
\Eae44a^SJL/J/\Eae44a^SJL/J (involves: B10.S/DvTe * SJL/J)	brain inflammation	J:49054
\Eae44b^B10.S/DvTe/\Eae44b^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:56752
\Eae44b^SJL/J/\Eae44b^SJL/J (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:56752
\Eaf1^tm1.1Zhow/\Eaf1^tm1.1Zhow \Eaf2^tm1Zhow/\Eaf2^tm1Zhow \Tg(Pbsn-cre)4Prb/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)	prostate gland inflammation	J:288972
\Eaf1^tm1.1Zhow/\Eaf1^tm1.1Zhow \Tg(Pbsn-cre)4Prb/0 (B6(Cg)-Eaf1^tm1.1Zhow Tg(Pbsn-cre)4Prb)	prostate gland inflammation	J:288972
\Eaf2^tm1Zhow/\Eaf2^tm1Zhow (involves: 129P2/OlaHsd)	prostate gland inflammation	J:288972
\Eamcd1^A/WySn/\Eamcd1^A/WySn (B10.A-(D1Mit65-D1Mit334))	myocarditis	J:145043
\Eamcd2^A/WySn/\Eamcd2^A/WySn (involves: A.SW-H2^s/J * B10.S-H2^s/J)	myocarditis	J:96562
\Ebag9^tm1Rehm/\Ebag9^tm1Rehm (either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal CD8-positive, alpha beta T cell morphology	J:152534
	abnormal cytotoxic T cell physiology	J:152534
	abnormal memory T cell physiology	J:152534
	decreased susceptibility to bacterial infection	J:152534
\Ebf1^em1(IMPC)Mbp/\Ebf1⁺ (C57BL/6N-Ebf1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Ebf1^m1Btlr/\Ebf1^m1Btlr (C57BL/6J-Ebf1^m1Btlr)	decreased B cell number	J:265157
	decreased IgD level	J:265157
	increased CD4-positive, alpha-beta T cell number	J:265157
	increased single-positive T cell number	J:265157
	increased T cell number	J:265157
\Ebf1^m2Btlr/\Ebf1^m2Btlr (C57BL/6J-Ebf1^m2Btlr)	abnormal humoral immune response	J:265158
	decreased B cell number	J:265158
	decreased B-1 B cell number	J:265158
	decreased B-2 B cell number	J:265158
	decreased IgD level	J:265158
	decreased IgM level	J:265158
	increased B-1a cell number	J:265158
	increased B-1b cell number	J:265158
	increased CD4-positive, alpha-beta T cell number	J:265158
	increased IgM level	J:265158
	increased single-positive T cell number	J:265158
	increased T cell number	J:265158
	increased tumor necrosis factor secretion	J:265158
\Ebf1^M3Btlr/\Ebf1^M3Btlr (C57BL/6J-Ebf1^M3Btlr)	decreased B-1 B cell number	J:265160
	increased CD4-positive, alpha-beta T cell number	J:265160
	increased single-positive T cell number	J:265160
	increased T cell number	J:265160
\Ebf1^M4Btlr/\Ebf1^M4Btlr (C57BL/6J-Ebf1^M4Btlr)	decreased B cell number	J:267560
	decreased NK cell number	J:267560
	increased alpha-beta T cell number	J:267560
	increased CD4-positive, alpha-beta T cell number	J:267560
	increased CD8-positive, alpha-beta T cell number	J:267560
\Ebf1^M5Btlr/\Ebf1^M5Btlr (C57BL/6J-Ebf1^M5Btlr)	abnormal lymphocyte morphology	J:272841
	decreased B cell number	J:272841
	decreased B-1 B cell number	J:272841
\Ebf1^m6Btlr/\Ebf1^m6Btlr (C57BL/6J-Ebf1^m6Btlr)	abnormal lymphocyte morphology	J:272842
	decreased B cell number	J:272842
	decreased B-1 B cell number	J:272842
	decreased effector memory CD4-positive, alpha-beta T cell number	J:272842
	decreased IgD level	J:272842
	increased alpha-beta T cell number	J:272842
	increased CD4-positive, alpha-beta T cell number	J:272842
	increased CD8-positive, alpha-beta T cell number	J:272842
\Ebf1^Serv/\Ebf1⁺ (C57BL/6JAnu-Ebf1^Serv)	decreased B cell number	J:104190
\Ebf1^tm1.1Rug/\Ebf1^tm1.1Rug \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased B-1 B cell number	J:182210
	decreased marginal zone B cell number	J:182210
\Ebf1^tm1.1Rug/\Ebf1^tm1.1Rug \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6 * SJL)	arrested B cell differentiation	J:182210
\Ebf1^tm1.1Rug/\Ebf1^tm1.1Rug \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased germinal center B cell number	J:182210
\Ebf1^tm1.1Rug/\Ebf1^tm1.1Rug \Polr2a^{tm1(cre/ERT2)Bbd}/\Polr2a⁺ (involves: C57BL/6 * SJL)	abnormal germinal center B cell physiology	J:182210
	arrested B cell differentiation	J:182210
	decreased B cell proliferation	J:182210
	decreased germinal center B cell number	J:182210
	decreased IgG1 level	J:182210
	decreased IgG3 level	J:182210
	decreased immature B cell number	J:182210
	decreased marginal zone B cell number	J:182210
	decreased pre-B cell number	J:182210
	decreased spleen germinal center number	J:182210
	decreased transitional stage B cell number	J:182210
	immune system phenotype	J:182210
	increased B cell apoptosis	J:182210
	increased B cell number	J:182210
\Ebf1^tm1.1Rug/\Ebf1^tm1.1Rug \Polr2a^{tm1(cre/ERT2)Bbd}/\Polr2a⁺ \Tg(BCL2)#Wehi/0 (involves: C57BL/6 * C57BL/6JWehi * SJL * SJL/JWehi)	decreased immature B cell number	J:182210
	decreased pre-B cell number	J:182210
\Ebf1^tm1.1Rug/\Ebf1^tm1.1Rug \Tg(Cr2-cre)3Cgn/0 (involves: C57BL/6 * SJL)	decreased B-1 B cell number	J:182210
	decreased marginal zone B cell number	J:182210
\Ebf1^tm1Rug/\Ebf1^tm1Rug (involves: 129S2/SvPas)	abnormal B cell morphology	J:52607
	absent B-1 B cells	J:52607
	absent mature B cells	J:52607
	arrested B cell differentiation	J:52607
	decreased IgM level	J:52607
	decreased pro-B cell number	J:52607
\Ebf1^tm1Rug/\Ebf1^tm1Rug (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	increased osteoclast cell number	J:147179
\Ebf2^em1(IMPC)Mbp/\Ebf2⁺ (C57BL/6N-Ebf2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Ebi3^Gt716Lex/\Ebi3^Gt716Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:286951
	abnormal T cell activation	J:286951
	brain inflammation	J:286951
	decreased interleukin-10 secretion	J:286951
	increased CD8-positive, alpha-beta T cell number	J:286951
	increased interferon-gamma secretion	J:286951
	increased macrophage cell number	J:286951
	increased susceptibility to Coronaviridae infection	J:286951
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286951
\Ebi3^Gt716Lex/\Ebi3^Gt716Lex \Tg(DO11.10)10Dlo/0 (involves: 129S5/SvEvBrd * BALB/c * C3H * C57BL/6)	abnormal circulating interleukin level	J:134148
	abnormal T cell differentiation	J:134148
	decreased susceptibility to bacterial infection	J:134148
	increased circulating interleukin-17 level	J:134148
	increased interleukin-17 secretion	J:134148
\Ebi3^tm1Nkma/\Ebi3^tm1Nkma \Fas^lpr/\Fas^lpr (MRL.Cg-Ebi3^tm1Nkma Fas^lpr)	abnormal cytokine level	J:181669
	decreased circulating interferon-gamma level	J:181669
	increased circulating interleukin-4 level	J:181669
	increased IgE level	J:181669
	increased IgG1 level	J:181669
	increased IgG level	J:181669
	increased immunoglobulin level	J:181669
\Ebi3^tm1Rsb/\Ebi3^tm1Rsb (involves: 129X1/SvJ * C57BL/6)	abnormal immune system morphology	J:81014
	abnormal immune system physiology	J:81014
	abnormal T-helper 1 cell morphology	J:97822
	abnormal T-helper 2 cell morphology	J:97822
	decreased interleukin-4 secretion	J:81014
	decreased NK cell number	J:81014
	decreased susceptibility to induced colitis	J:81014
	decreased T-helper 2 cell number	J:81014
	increased interferon-gamma secretion	J:81014
	increased susceptibility to parasitic infection	J:97822
\Ebna1bp2^em1(IMPC)Tcp/\Ebna1bp2⁺ (C57BL/6N-Ebna1bp2^em1(IMPC)Tcp/Cmmr)	enlarged spleen	J:211773
\Ece1^tm1Reh/\Ece1^tm1Reh (involves: 129S6/SvEvTac * C57BL/6)	persistent cervical thymus	J:46640
\Ecm1^{tm1b(EUCOMM)Hmgu}/\Ecm1⁺ (C57BL/6N-Ecm1^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
\Ecm1^tm1Bsun/\Ecm1^tm1Bsun (involves: 129 * C57BL/6)	abnormal T-helper 2 physiology	J:168252
	decreased IgE level	J:168252
	decreased susceptibility to type I hypersensitivity reaction	J:168252
	immune system phenotype	J:168252
	increased susceptibility to autoimmune disorder	J:168252
\Ecrg4^{tm1b(EUCOMM)Hmgu}/\Ecrg4^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ecrg4^{tm1b(EUCOMM)Hmgu}/Orl)	decreased large unstained cell number	J:211773
\Ecscr^{tm1.1(KOMP)Vlcg}/\Ecscr^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ecscr^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal thymus morphology	J:211773
	small thymus	J:211773
\Eda^Ta-6J/Y (C57BL/6J A^w-J-Eda^Ta-6J/J)	blepharitis	J:99510
	conjunctivitis	J:99510
	corneal limbitis	J:99510
	eye inflammation	J:99510
	increased incidence of corneal inflammation	J:99510
\Eda^Ta-6J/Y \Tg(MMTVtTA)1Mam/0 \Tg(tetO-Eda*A1)1Dsch/0 (involves: C57BL/6J)	immune system phenotype	J:99510
\Edc3^em1(IMPC)Tcp/\Edc3⁺ (C57BL/6NCrl-Edc3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Edc3^em1(IMPC)Tcp/\Edc3^em1(IMPC)Tcp (C57BL/6NCrl-Edc3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Eddm3b^{tm1b(KOMP)Wtsi}/\Eddm3b^{tm1b(KOMP)Wtsi} (C57BL/6N-Eddm3b^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Edil3^Tg(lacZ)1Tq/\Edil3^Tg(lacZ)1Tq (Not Specified)	increased susceptibility to induced arthritis	J:254384
\Edil3^tm1Tq/\Edil3^tm1Tq (B6.129S6-Edil3^tm1Tq)	abnormal cellular extravasation	J:141063
	abnormal leukocyte adhesion	J:141063
	abnormal neutrophil physiology	J:141063
	enhanced leukocyte tethering or rolling	J:141063
\Edil3^tm1Tq/\Edil3^tm1Tq \Itgal^tm1Bll/\Itgal^tm1Bll (involves: 129 * C57BL/6)	abnormal cellular extravasation	J:141063
	abnormal neutrophil physiology	J:141063
\Ednra^tm1Ywa/\Ednra^tm1Ywa (129S/SvEv-Ednra^tm1Ywa)	ectopic thymus	J:46639
\Ednra^tm1Ywa/\Ednra^tm1Ywa (129S/SvEv-Ednra^tm1Ywa)	thymus hypoplasia	J:46639
\Ednrb^tm1Nrd/\Ednrb^tm1Nrd \Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze}/\Gt(ROSA)26Sor⁺ \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * CBA/J)	abnormal mature B cell number	J:233811
	abnormal Peyer's patch morphology	J:233811
	abnormal spleen morphology	J:233811
	abnormal splenic cell ratio	J:233811
	decreased B cell number	J:233811
	decreased germinal center B cell number	J:233811
	decreased IgA level	J:233811
	decreased marginal zone B cell number	J:233811
	decreased spleen red pulp amount	J:233811
	decreased spleen weight	J:233811
	decreased spleen white pulp amount	J:233811
	large intestinal inflammation	J:233811
	small Peyer's patches	J:233811
	small spleen	J:233811
\Ednrb^tm1Ywa/\Ednrb⁺ (involves: 129S/SvEvBrd)	decreased acute inflammation	J:103977
\Ednrb^tm1Ywa/\Ednrb^tm1Ywa (involves: 129S5/SvEvBrd)	decreased acute inflammation	J:103977
\Eef1a1^tm2Arge/\Eef1a1⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal double-positive T cell morphology	J:197167
\Eef1a2^wst/\Eef1a2^wst (B6C3Fe a/a-Eef1a2^wst/J)	decreased plasma cell number	J:7903
	decreased spleen weight	J:6766
	decreased susceptibility to type IV hypersensitivity reaction	J:6766
	decreased thymus weight	J:6766
	lymphoid hypoplasia	J:6766
	small lymph nodes	J:6766
\Eef1a2^wst/\Eef1a2^wst (Not Specified)	thymus atrophy	J:50410
\Eef1d^em1(IMPC)Mbp/\Eef1d⁺ (C57BL/6NCrl-Eef1d^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Eef1e1^{Gt(OST377244)Lex}/\Eef1e1⁺ (involves: 129S5/SvEvBrd * C57BL/6)	decreased splenocyte apoptosis	J:96923
	increased splenocyte proliferation	J:96923
\Efemp1^tm2Lmar/\Efemp1^tm2Lmar (involves: 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:132043
	decreased spleen weight	J:132043
\Efhd2^{tm1(KOMP)Vlcg}/\Efhd2^{tm1(KOMP)Vlcg} (C57BL/6-Efhd2^{tm1(KOMP)Vlcg})	abnormal response to infection	J:228565
	immune system phenotype	J:228565
	increased germinal center B cell number	J:228565
	increased IgE level	J:228565
	increased IgG1 level	J:228565
	increased IgG2a level	J:228565
	increased IgM level	J:228565
	increased plasma cell number	J:228565
	increased spleen germinal center size	J:228565
\Efnb1^tm1.1Jwu/\Efnb1^tm1.1Jwu \Efnb2^tm1.1Jwu/\Efnb2^tm1.1Jwu \Tg(Lck-cre)I540Jxm/0 (B6.Cg-Efnb2^tm1.1Jwu Efnb1^tm1.1Jwu Tg(Lck-cre)I540Jxm)	abnormal T cell differentiation	J:178148
	abnormal T-helper 1 cell differentiation	J:178148
	abnormal T-helper 17 cell differentiation	J:178148
	decreased CD4-positive, alpha-beta T cell number	J:178148
	decreased CD8-positive, alpha-beta T cell number	J:178148
	decreased DN4 thymocyte number	J:178148
	decreased double-positive T cell number	J:178148
	decreased spleen weight	J:178148
	decreased T cell number	J:178148
	decreased thymus weight	J:178148
	increased DN3 thymocyte number	J:178148
	increased double-negative T cell number	J:178148
	increased length of allograft survival	J:178148
	increased susceptibility to Riboviria infection	J:178148
	increased thymocyte apoptosis	J:178148
	small spleen	J:178148
	small thymus	J:178148
	spleen hypoplasia	J:178148
	thymus hypoplasia	J:178148
\Efnb1^tm1.1Jwu/\Efnb1^tm1.1Jwu \Tg(Lck-cre)I540Jxm/0 (B6.Cg-Efnb1^tm1.1Jwu Tg(Lck-cre)I540Jxm)	immune system phenotype	J:178148
\Efnb2^tm1.1Jwu/\Efnb2^tm1.1Jwu \Tg(Lck-cre)I540Jxm/0 (B6.Cg-Efnb2^tm1.1Jwu Tg(Lck-cre)I540Jxm)	immune system phenotype	J:178148
\Efnb2^tm5.1Kln/\Efnb2^tm5.1Kln (involves: C57BL/6)	abnormal afferent lymphatic vessel morphology	J:95885
	abnormal lymph circulation	J:95885
	abnormal lymphatic vessel morphology	J:95885
\Efnb2^tm5.1Kln/\Efnb2^tm5.1Kln (involves: CD-1)	abnormal lymphatic vessel morphology	J:95885
\Efnb2^tm5.1Kln/\Efnb2^tm5.1Kln \Flt4^tm1Ali/\Flt4⁺ (involves: C57BL/6)	abnormal afferent lymphatic vessel morphology	J:95885
	abnormal lymphatic vessel morphology	J:95885
\Efnb2^tm6Kln/\Efnb2^tm6Kln (involves: C57BL/6)	abnormal lymph circulation	J:95885
\Efnb2^tm6Kln/\Efnb2^tm6Kln (involves: C57BL/6)	abnormal lymphatic vessel morphology	J:95885
\Efs^tm1Kale/\Efs⁺ (either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))	increased IgA level	J:103757
	increased IgG level	J:103757
	increased inflammatory response	J:103757
	small intestinal inflammation	J:103757
\Efs^tm1Kale/\Efs^tm1Kale (either: (involves: 129X1/SvJ) or (involves: 129X1/SvJ * C57BL/6J))	abnormal interleukin secretion	J:103757
	abnormal T cell physiology	J:103757
	increased IgA level	J:103757
	increased IgG level	J:103757
	increased immunoglobulin level	J:103757
	increased inflammatory response	J:103757
	increased interferon-gamma secretion	J:103757
	kidney inflammation	J:103757
	liver inflammation	J:103757
	lung inflammation	J:103757
	small intestinal inflammation	J:103757
\Eftud2^{tm1b(KOMP)Wtsi}/\Eftud2⁺ (C57BL/6N-Eftud2^{tm1b(KOMP)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Egfr^Mhdadsk5/\Egfr⁺ (involves: 129S1/SvImJ * C3HeB/FeJ)	increased susceptibility to Coronaviridae infection	J:243599
\Egfr^Mhdadsk5/\Egfr⁺ (involves: 129S1/SvImJ * C3HeB/FeJ)	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:243599
\Egfr^{tm1a(EUCOMM)Wtsi}/\Egfr⁺ (C57BL/6N-Egfr^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Egfr^tm1Dwt/\Egfr^tm1Dwt \Sox9^tm3(cre)Crm/\Sox9⁺ (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	dermatitis	J:229771
	increased IgE level	J:229771
	increased T-helper 1 cell number	J:229771
	increased T-helper 2 cell number	J:229771
	increased T-helper 17 cell number	J:229771
\Egfr^tm1Msi/\Egfr^tm1Msi \Tg(Alb1-cre)7Gsc/? (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	increased circulating tumor necrosis factor level	J:125912
\Egfr^tm1Msi/\Egfr^tm1Msi \Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased circulating tumor necrosis factor level	J:125912
\Egln1^tm1.1Brei/\Egln1^tm1.1Brei \Tg(CD68-icre)1Bwlx/0 (involves: C57BL/6)	abnormal lymphocyte cell number	J:194598
	abnormal spleen morphology	J:194598
	enlarged spleen	J:194598
	increased spleen weight	J:194598
\Egln1^tm1.1Fsl/\Egln1⁺ (C57BL/6-Egln1^tm1.1Fsl)	increased spleen weight	J:202737
\Egln1^tm1Fong/\Egln1^tm1Fong (involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)	abnormal lymph organ development	J:114669
\Egln1^tm2.1Fsl/\Egln1^tm2.1Fsl \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (B6.Cg-Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} Egln1^tm2.1Fsl)	increased spleen weight	J:202737
\Egln1^tm2.1Fsl/\Egln1^tm2.1Fsl \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ \Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo (B6.Cg-Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} Egln1^tm2.1Fsl Hif1a^tm3Rsjo)	increased spleen weight	J:202737
\Egln1^tm2.1Fsl/\Egln1^tm2.1Fsl \Pax3^tm1(cre)Joe/\Pax3⁺ (involves: 129 * C57BL/6)	increased spleen weight	J:202737
\Egln1^tm2.2Fsl/\Egln1⁺ (B6.Cg-Egln1^tm2.2Fsl)	increased spleen weight	J:202737
\Egln1^tm2Fong/\Egln1^tm2Fong \Gt(ROSA)26Sor^{tm1(cre/ERT2)Alj}/\Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal splenic cell ratio	J:132720
	enlarged spleen	J:132720
	increased leukocyte cell number	J:132720
\Egln2^tm1Fong/\Egln2^tm1Fong \Egln3^tm1Fong/\Egln3^tm1Fong (involves: 129S6/SvEvTac * C57BL/6)	abnormal splenic cell ratio	J:132720
	enlarged spleen	J:132720
\Egr1^{tm1b(NCOM)Mfgc}/\Egr1⁺ (C57BL/6N-Egr1^{tm1b(NCOM)Mfgc}/Tcp)	increased lymphocyte cell number	J:211773
\Egr1^tm1Jmi/\Egr1^tm1Jmi (B6.129-Egr1^tm1Jmi)	abnormal circulating tumor necrosis factor level	J:128421
	increased osteoclast cell number	J:51107
	liver inflammation	J:128421
\Egr1^tm1Jmi/\Egr1^tm1Jmi (involves: 129 * C57BL/6)	abnormal leukocyte cell number	J:123870
	abnormal leukocyte morphology	J:123870
	abnormal microglial cell physiology	J:135238
	abnormal neutrophil morphology	J:123870
	abnormal tumor necrosis factor level	J:105638
	decreased inflammatory response	J:152898
	immune system phenotype	J:105638
	increased lymphocyte cell number	J:123870
	increased spleen weight	J:123870
	increased T cell derived lymphoma incidence	J:123870
\Egr1^tm1Jmi/\Egr1^tm1Jmi \Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1)1Eli/? (involves: 129 C57BL/6)	lung inflammation	J:92469
\Ehbp1l1^{tm1a(EUCOMM)Wtsi}/\Ehbp1l1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Ehbp1l1^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Ehmt1^{tm1b(EUCOMM)Hmgu}/\Ehmt1⁺ (C57BL/6N-Ehmt1^{tm1b(EUCOMM)Hmgu}/Nju)	increased neutrophil cell number	J:211773
\Ehmt2^tm1.1Cza/\Ehmt2^tm1.1Cza \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	decreased IgG1 level	J:160938
	decreased interleukin-4 secretion	J:160938
	increased IgG2a level	J:160938
	increased interferon-gamma secretion	J:160938
	increased susceptibility to parasitic infection	J:160938
\Ehmt2^tm1.1Cza/\Ehmt2^tm1.1Cza \Tg(VAV1-cre)1Graf/0 (involves: C57BL/6 * SJL)	decreased interleukin-4 secretion	J:160938
	decreased interleukin-5 secretion	J:160938
	decreased interleukin-13 secretion	J:160938
	increased interferon-gamma secretion	J:160938
	increased interleukin-17 secretion	J:160938
	increased susceptibility to parasitic infection	J:160938
\Eid2b^em1(IMPC)J/\Eid2b⁺ (C57BL/6NJ-Eid2b^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Eif1ad^{tm1b(EUCOMM)Hmgu}/\Eif1ad⁺ (C57BL/6N-Eif1ad^{tm1b(EUCOMM)Hmgu}/Bay)	increased large unstained cell number	J:211773
\Eif2a^em1(IMPC)Mbp/\Eif2a^em1(IMPC)Mbp (C57BL/6N-Eif2a^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Eif2ak1^em1(IMPC)Bay/\Eif2ak1^em1(IMPC)Bay (C57BL/6N-Eif2ak1^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
\Eif2ak2^em1(IMPC)Mbp/\Eif2ak2^em1(IMPC)Mbp (C57BL/6N-Eif2ak2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Eif2ak2^em1Btlr/\Eif2ak2^em1Btlr (C57BL/6J-Eif2ak2^em1Btlr)	immune system phenotype	J:354285
\Eif2ak2^em1Btlr/\Eif2ak2^em1Btlr \Zfp574^em1Btlr/\Zfp574^em1Btlr (C57BL/6J-Zfp574^em1Btlr Eif2ak2^em1Btlr)	abnormal B cell physiology	J:354285
	abnormal class switch recombination	J:354285
	abnormal humoral immune response	J:354285
	decreased lymphocyte cell number	J:354285
\Eif2ak2^tm1Cwe/\Eif2ak2^tm1Cwe (involves: 129S/SvEv * C57BL/6)	increased interleukin-4 secretion	J:66112
	increased susceptibility to Picornaviridae infection	J:30617
	increased susceptibility to type IV hypersensitivity reaction	J:66112
	increased T cell proliferation	J:66112
\Eif2ak2^tm1Cwe/\Eif2ak2^tm1Cwe (involves: 129)	immune system phenotype	J:114555
\Eif2ak2^tm1Cwe/\Eif2ak2^tm1Cwe \Rnasel^tm1Slvm/\Rnasel^tm1Slvm (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	increased susceptibility to Picornaviridae infection	J:55974
\Eif2ak2^tm1Jcbe/\Eif2ak2^tm1Jcbe (involves: 129S4/SvJae * BALB/c)	immune system phenotype	J:53258
\Eif2ak2^tm1Jcbe/\Eif2ak2^tm1Jcbe (involves: 129S4/SvJae)	immune system phenotype	J:63671
	increased susceptibility to Orthomyxoviridae infection	J:63671
	increased susceptibility to Riboviria infection	J:167126, J:63671
\Eif2ak3^tm1.1Drc/\Eif2ak3^tm1.1Drc \Tg(Ela1-cre)16Eps/0 (involves: 129S6/SvEvTac)	acute pancreas inflammation	J:129974
\Eif2ak4^m1Btlr/\Eif2ak4^m1Btlr (C57BL/6J-Eif2ak4^m1Btlr)	abnormal macrophage physiology	J:173669
	increased susceptibility to Adenoviridae infection	J:173669
	increased susceptibility to Herpesvirales infection	J:173669
\Eif2ak4^tm1.2Dron/\Eif2ak4^tm1.2Dron (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal cytokine secretion	J:120813
	abnormal dendritic cell physiology	J:120813
\Eif2b5^tm1Itl/\Eif2b5^tm1Itl (involves: 129S/SvEv)	abnormal microglial cell physiology	J:192103
\Eif2d^em1(IMPC)Mbp/\Eif2d^em1(IMPC)Mbp (C57BL/6N-Eif2d^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Eif2s2^em3(IMPC)Bay/\Eif2s2⁺ (C57BL/6N-Eif2s2^em3(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Eif4a1^tm1.1Bea/\Eif4a1^tm1.1Bea \Tg(Fcer2a-cre)5Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased B cell proliferation	J:344730
	decreased germinal center B cell number	J:344730
	decreased IgG1 level	J:344730
\Eif4b^tm1.1Smoc/\Eif4b⁺ \Tg(SFTPC-rtTA)5Jaw/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	increased susceptibility to Riboviria infection	J:311140
\Eif4b^tm1.1Smoc/\Eif4b^tm1.1Smoc \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/\Ndor1⁺ (involves: 129 * C57BL/6)	decreased leukocyte cell number	J:311140
	decreased lymphocyte cell number	J:311140
	decreased NK cell number	J:311140
	increased macrophage cell number	J:311140
	increased neutrophil cell number	J:311140
	increased susceptibility to induced colitis	J:311140
	increased susceptibility to Orthomyxoviridae infection	J:311140
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:311140
	lung inflammation	J:311140
	small spleen	J:311140
	small thymus	J:311140
\Eif4b^tm1.1Smoc/\Eif4b^tm1.1Smoc \Tg(SFTPC-rtTA)5Jaw/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	increased susceptibility to Orthomyxoviridae infection	J:311140
\Eif4g1^{em1(IMPC)Hmgu}/\Eif4g1⁺ (C57BL/6NCrl-Eif4g1^{em1(IMPC)Hmgu}/Ieg)	decreased spleen weight	J:211773
\Elac2^em1Afi/\Elac2^em1Afi (C57BL/6N-Elac2^em1Afi)	prostate gland inflammation	J:336403
\Elane^M1Btlr/\Elane^M1Btlr (C57BL/6J-Elane^M1Btlr)	decreased tumor necrosis factor secretion	J:218967
\Elane^tm1(cre)Roes/\Elane^tm1(cre)Roes (involves: 129)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:77597
\Elane^tm1(cre)Roes/\Elane^tm1(cre)Roes (involves: 129)	increased susceptibility to infection induced morbidity/mortality	J:77597
\Elane^tm1(cre)Roes/\Elane^tm1(cre)Roes (involves: 129S6/SvEvTac)	impaired neutrophil recruitment	J:137674
\Elane^tm1Link/\Elane^tm1Link (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:131496
\Elane^tm1Sds/\Elane^tm1Sds (129X1/SvJ-Elane^tm1Sds)	abnormal neutrophil physiology	J:47420
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:47420
	increased susceptibility to bacterial infection	J:47420
	increased susceptibility to bacterial infection induced morbidity/mortality	J:47420
\Elane^tm1Sds/\Elane^tm1Sds (involves: 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:113463
\Elapor1^{tm1b(EUCOMM)Hmgu}/\Elapor1⁺ (C57BL/6N-Elapor1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
\Elavl1^tm1.1Atas/\Elavl1^tm1.1Atas \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:207013
	decreased T cell proliferation	J:207013
	decreased T-helper 17 cell number	J:207013
\Elavl1^tm1.1Dkon/\Elavl1^tm1.1Dkon \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.129P2-Elavl1^tm1.1Dkon Lyz2^tm1(cre)Ifo)	abnormal macrophage chemotaxis	J:184388
	immune system phenotype	J:184388
	increased circulating interleukin-1 beta level	J:184388
	increased circulating interleukin-6 level	J:184388
	increased circulating interleukin-12 level	J:184388
	increased circulating tumor necrosis factor level	J:184388
	increased macrophage cell number	J:184388
	increased monocyte cell number	J:184388
	increased susceptibility to endotoxin shock	J:184388
	increased susceptibility to induced colitis	J:184388
\Elavl1^tm1.1Dkon/\Elavl1^tm1.1Dkon \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:184388
	increased circulating interleukin-1 beta level	J:184388
	increased circulating interleukin-6 level	J:184388
	increased circulating interleukin-12 level	J:184388
	increased circulating tumor necrosis factor level	J:184388
	increased susceptibility to endotoxin shock	J:184388
\Elavl1^tm1.1Thla/\Elavl1⁺ (involves: 129S1/Sv)	spleen hypoplasia	J:155109
\Elavl1^tm1.1Thla/\Elavl1⁺ (involves: 129S1/Sv)	thymus hypoplasia	J:155109
\Elavl1^tm1Dkon/\Elavl1^tm1Dkon \Edil3^{Tg(Sox2-cre)1Amc}/\Edil3⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal spleen development	J:149149
	absent spleen	J:149149
\Elavl1^tm1Dkon/\Elavl1^tm1Dkon \Tg(Lck-cre)I57Jxm/0 (B6.Cg-Elavl1^tm1Dkon Tg(Lck-cre)I57Jxm)	abnormal positive T cell selection	J:148866
	abnormal T cell physiology	J:148866
	abnormal thymocyte activation	J:148866
	decreased CD4-positive, alpha-beta T cell number	J:148866
	decreased CD8-positive, alpha-beta T cell number	J:148866
	increased double-negative T cell number	J:148866
	increased double-positive T cell number	J:148866
	increased single-positive T cell number	J:148866
\Elavl1^tm1Dkon/\Elavl1^tm1Dkon \Tg(Lck-cre)I57Jxm/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (B6.Cg-Elavl1^tm1Dkon Tg(Lck-cre)I57Jxm Tg(TcraH-Y,TcrbH-Y)71Vbo)	abnormal negative T cell selection	J:148866
	increased thymocyte number	J:148866
\Elavl1^tm1Lix/\Elavl1^tm1Lix \Tg(Scgb1a1-rtTA)2Jaw/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	decreased inflammatory response	J:204952
	lung inflammation	J:204952
\Elavl1^tm1Thla/\Elavl1^tm1Thla \Gt(ROSA)26Sor^{tm1(cre/ERT2)Alj}/\Gt(ROSA)26Sor⁺ (involves: 129)	abnormal B cell physiology	J:155109
	abnormal myeloid leukocyte morphology	J:155109
	decreased B cell apoptosis	J:155109
	decreased double-positive T cell number	J:155109
	decreased granulocyte number	J:155109
	decreased leukocyte cell number	J:155109
	increased granulocyte number	J:155109
	increased T cell apoptosis	J:155109
	lymph node hypoplasia	J:155109
	spleen hypoplasia	J:155109
	thymus hypoplasia	J:155109
\Elf1^tm1Jml/\Elf1^tm1Jml (Not Specified)	abnormal B cell differentiation	J:100734
\Elf1^tm1Jml/\Elf1^tm1Jml (Not Specified)	abnormal B cell physiology	J:100734
\Elf4^em1Hdu/\Elf4^em1Hdu (C57BL/6-Elf4^em1Hdu)	abnormal CD4-positive T cell differentiation	J:328935
	abnormal interferon level	J:328935
	abnormal interleukin level	J:328935
	abnormal macrophage physiology	J:328935
	abnormal tumor necrosis factor level	J:328935
	increased susceptibility to viral infection	J:328935
\Elf4^tm1Nim/\Elf4^tm1Nim (B6.129S1-Elf4^tm1Nim)	abnormal inflammatory response	J:79568
	abnormal lymphocyte morphology	J:79568
	abnormal lymphocyte physiology	J:79568
	abnormal NK cell physiology	J:79568
	abnormal T cell differentiation	J:79568
	decreased cytotoxic T cell cytolysis	J:79568
	decreased NK cell number	J:79568
	decreased NK T cell number	J:79568
	impaired natural killer cell mediated cytotoxicity	J:79568
	increased B cell number	J:79568
	increased B cell proliferation	J:79568
	increased T cell proliferation	J:79568
	large lymphoid organs	J:79568
\Elfn2^{tm1.1(KOMP)Vlcg}/\Elfn2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Elfn2^{tm1.1(KOMP)Vlcg}/Ucd)	increased eosinophil cell number	J:211773
\Elk1^tm1Nor/Y (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:87597
\Elk3^tm1Wlyk/\Elk3^tm1Wlyk (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	lymphangiectasis	J:71816
\Elk4^{tm1a(EUCOMM)Wtsi}/\Elk4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Elk4^{tm1a(EUCOMM)Wtsi}/H)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased mature B cell number	J:165965
	decreased T cell number	J:165965
	increased B cell number	J:165965
	increased T cell number	J:165965
\Elk4^tm1Rtr/\Elk4^tm1Rtr (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	abnormal positive T cell selection	J:88515
	abnormal T cell selection	J:88515
	decreased CD4-positive, alpha-beta T cell number	J:88515
	decreased CD8-positive, alpha-beta T cell number	J:88515
	decreased single-positive T cell number	J:88515
	decreased T cell number	J:88515
	decreased thymocyte number	J:88515
\Elk4^tm1Rtr/\Elk4^tm1Rtr \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129/Sv * C57BL/6 * DBA/2J)	abnormal positive T cell selection	J:88515
	decreased CD8-positive, alpha-beta T cell number	J:88515
\Elk4^tm1Rtr/\Elk4^tm1Rtr \Tg(TcraTcrb)425Cbn/? (involves: 129/Sv * C57BL/6)	abnormal positive T cell selection	J:88515
	abnormal splenic cell ratio	J:88515
	decreased CD4-positive, alpha-beta T cell number	J:88515
\Elk4^tm1Rtr/\Elk4^tm1Rtr \Tg(TcrLCMV)327Sdz/? (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:88515
	decreased CD8-positive, alpha-beta T cell number	J:88515
\Elmo1^M1Btlr/\Elmo1^M1Btlr (C57BL/6J-Elmo1^M1Btlr)	decreased B cell number	J:265231
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265231
	decreased IgM level	J:265231
	impaired humoral immune response	J:265231
	increased B-1 B cell number	J:265231
	increased CD8-positive, alpha-beta memory T cell number	J:265231
\Elmo1^m2Btlr/\Elmo1^m2Btlr (C57BL/6J-Elmo1^m2Btlr)	decreased B cell number	J:265232
\Elmo1^m3Btlr/\Elmo1^m3Btlr (C57BL/6J-Elmo1^m3Btlr)	decreased central memory CD8 positive, alpha-beta T cell number	J:271894
	decreased NK cell number	J:271894
	increased CD8-positive, alpha-beta T cell number	J:271894
\Elmo1^M4Btlr/\Elmo1^M4Btlr (C57BL/6J-Elmo1^M4Btlr)	abnormal B cell morphology	J:271969
	abnormal T cell morphology	J:271969
	decreased CD4-positive, alpha-beta T cell number	J:271969
	increased B-1 B cell number	J:271969
	increased CD8-positive, alpha-beta T cell number	J:271969
\Elmo1^{tm1a(EUCOMM)Wtsi}/\Elmo1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Elmo1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Elmod1^{tm1a(EUCOMM)Hmgu}/\Elmod1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Elmod1^{tm1a(EUCOMM)Hmgu}/H)	decreased B cell number	J:165965
	decreased leukocyte cell number	J:165965
\Elmod1^{tm1b(EUCOMM)Hmgu}/\Elmod1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Elmod1^{tm1b(EUCOMM)Hmgu}/H)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Elovl3^tm1Jaco/\Elovl3^tm1Jaco (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	dermatitis	J:88477
\Elp1^tm1.1Id/\Elp1^tm1.2Id (involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)	conjunctivitis	J:188923
\Elp1^tm1.2Id/\Elp1^tm1.2Id (involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA)	conjunctivitis	J:188923
\Elsgp1^C57BL/6J/\Elsgp1^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
\Elsgp1^NZB/BlNJ/\Elsgp1^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
\Elsgp1^NZB/BlNJ/\Elsgp1^NZB/BlNJ \Elsgp2^NZB/BlNJ/\Elsgp2^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
\Elsgp2^C57BL/6J/\Elsgp2^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
\Elsgp2^NZB/BlNJ/\Elsgp2^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
\Elsgp3^C57BL/6J/\Elsgp3^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
\Elsgp3^NZB/BlNJ/\Elsgp3^NZB/BlNJ (involves: C57BL/6J * NZB/BlNJ)	abnormal immune serum protein physiology	J:63674
\Elsgp4^NZB/BlNJ/\Elsgp4^NZB/BlNJ (involves: BALB/cByJ * NZB/BlNJ)	abnormal immune serum protein physiology	J:89134
\Elsgp4^NZW/LacJ/? (involves: BALB/cByJ * NZW/LacJ)	abnormal immune serum protein physiology	J:89134
\Emc4^{tm1(KOMP)Wtsi}/\Emc4⁺ (C57BL/6N-Emc4^{tm1(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Emc8^{tm1b(EUCOMM)Hmgu}/\Emc8⁺ (C57BL/6N-Emc8^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
\Eme1^{tm1.1(KOMP)Wtsi}/\Eme1^{tm1.1(KOMP)Wtsi} (C57BL/6N-Eme1^{tm1.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Eml3^em1(IMPC)J/\Eml3⁺ (C57BL/6NJ-Eml3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Emp2^tm1.1Tac/\Emp2^tm1.1Tac \Tg(Zp3-cre)93Knw/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N)	increased leukocyte cell number	J:243365
	increased uterine NK cell number	J:243365
\Emsy^{em1(IMPC)Ccpcz}/\Emsy⁺ (C57BL/6NCrl-Emsy^{em1(IMPC)Ccpcz}/Ccpcz)	increased NK cell number	J:211773
\Emv30^b/\Emv30^b \Prkdc^scid/\Prkdc^scid (NOD.Cg-Emv30^b Prkdc^scid/Dvs)	increased T cell derived lymphoma incidence	J:29951
\Emv72^a/\Emv72^a (involves: BALB/cAnNCr * C57BL/6NCr)	abnormal cytotoxic T cell physiology	J:194735
\Emv72^b/\Emv72^b (CAnNCr.B6NCr-Emv72^b)	abnormal cytotoxic T cell physiology	J:194735
\Emv72^b/\Emv72^b (CAnNCr.B6NCr-Emv72^b)	abnormal T cell morphology	J:194735
\Emv72^b/\Emv72^b (involves: BALB/cAnNCr * C57BL/6NCr)	abnormal cytotoxic T cell physiology	J:194735
\En1^tm1(Tnf)Fpit/\En1^tm1(Tnf)Fpit (involves: C57BL/6)	increased monocyte cell number	J:170743
\En1^tm1(Tnf)Fpit/\En1^tm1(Tnf)Fpit (involves: C57BL/6)	microgliosis	J:170743
\Endou^tm1Tft/\Endou^tm1Tft (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:208364
\Endou^tm1Tft/\Endou^tm1Tft \Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd)	decreased activation-induced B cell apoptosis	J:208364
	immune system phenotype	J:208364
	increased autoantibody level	J:208364
\Eng^em1(IMPC)Mbp/\Eng⁺ (C57BL/6N-Eng^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Enkur^tm1Hmf/\Enkur^tm1Hmf (involves: 129 * C57BL/6J)	abnormal spleen morphology	J:253966
\Enkur^tm1Hmf/\Enkur^tm1Hmf (involves: 129 * C57BL/6J)	absent spleen	J:253966
\Enpep^tm1Mdc/\Enpep^tm1Mdc (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:47424
\Enpp1^asj/\Enpp1^asj (C57BL/6J-Enpp1^asj/GrsrJ)	increased susceptibility to otitis media	J:251638
	joint inflammation	J:174912
	osteoarthritis	J:174912
	osteomyelitis	J:174912
\Enpp1^{em1(IMPC)Ccpcz}/\Enpp1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Enpp1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	small thymus	J:211773
\Enpp1^ttw/\Enpp1^ttw (involves: ICR)	osteoarthritis	J:19124, J:37369
\Enpp2^tm1Lex/\Enpp2⁺ (involves: 129S/SvEvBrd * C57BL/6J)	abnormal chemokine level	J:103485
	decreased circulating interleukin-6 level	J:103485
	decreased circulating tumor necrosis factor level	J:103485
	decreased susceptibility to endotoxin shock	J:103485
\Enpp3^tm1Ktak/\Enpp3^tm1Ktak (either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c * C57BL/6))	abnormal basophil physiology	J:223825
	abnormal mast cell physiology	J:223825
	immune system phenotype	J:223825
	increased basophil cell number	J:223825
	increased IgE level	J:223825
	increased interleukin-4 secretion	J:223825
	increased mast cell number	J:223825
	increased susceptibility to type I hypersensitivity reaction	J:223825
	intestinal inflammation	J:223825
	lung inflammation	J:223825
\Enpp3^tm1Ktak/\Enpp3^tm1Ktak \P2rx7^tm1Gab/\P2rx7^tm1Gab (either: (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6) or (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6))	immune system phenotype	J:223825
	increased basophil cell number	J:223825
	increased mast cell number	J:223825
\Entpd1^{tm1a(EUCOMM)Wtsi}/\Entpd1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Entpd1^{tm1a(EUCOMM)Wtsi}/Ieg)	increased T cell number	J:165965
\Entpd1^tm1Rdr/\Entpd1^tm1Rdr (involves: 129S2/SvPas)	abnormal neutrophil physiology	J:129091
\Entpd1^tm1Rdr/\Entpd1^tm1Rdr (involves: 129S2/SvPas)	spleen fibrosis	J:57505
\Entpd5^tm1Rre/\Entpd5^tm1Rre (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal Kupffer cell morphology	J:163795
	liver inflammation	J:163795
\Entpd7^tm1Ktak/\Entpd7^tm1Ktak (B6.Cg-Entpd7^tm1Ktak)	abnormal CD4-positive, alpha-beta T cell number	J:191188
	decreased susceptibility to bacterial infection	J:191188
	increased susceptibility to experimental autoimmune encephalomyelitis	J:191188
	increased T-helper 17 cell number	J:191188
\Entpd8^tm1Ktak/\Entpd8^tm1Ktak (C.Cg-Entpd8^tm1Ktak)	increased susceptibility to induced colitis	J:311564
\Entpd8^tm1Ktak/\Entpd8^tm1Ktak \P2rx4^tm1Ando/\P2rx4^tm1Ando (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal susceptibility to induced colitis	J:311564
\Eomes^tm1.1Bflu/\Eomes^tm1.1Bflu \Tbx21^tm1Glm/\Tbx21^tm1Glm \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * SJL)	abnormal leukocyte migration	J:163822
	decreased CD4-positive, alpha-beta T cell number	J:163822
	decreased CD8-positive, alpha-beta T cell number	J:163822
	decreased interferon-gamma secretion	J:163822
	decreased memory T cell number	J:163822
	increased interleukin-4 secretion	J:163822
	increased interleukin-17 secretion	J:163822
\Eomes^tm1.1Bflu/\Eomes^tm1.1Bflu \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal leukocyte migration	J:163822
	decreased memory T cell number	J:163822
\Eomes^tm1.1Twa/? \Il15^tm1Imx/\Il15^tm1Imx (involves: C57BL/6 * C57BL/6N)	abnormal NK cell differentiation	J:210160
\Eomes^tm1.1Twa/? \Tbx21^tm1Glm/\Tbx21^tm1Glm (involves: 129S6/SvEvTac * C57BL/6N)	abnormal NK cell differentiation	J:210160
\Eomes^tm1.1Twa/? \Tg(CD2-Tbx21)#Staka/? (involves: C57BL/6N)	abnormal NK cell differentiation	J:210160
\Eomes^tm1.1Twa/? \Tg(Itgax-TGFBR2)1Flv/? (involves: C3H * C57BL/6 * C57BL/6N)	abnormal NK cell differentiation	J:210160
\Eomes^tm1Apr/\Eomes⁺ (involves: C57BL/6)	decreased memory T cell number	J:112679
\Eomes^tm1Apr/\Eomes⁺ (involves: C57BL/6)	decreased NK cell number	J:112679
\Eomes^tm1Apr/\Eomes⁺ \Tbx21^tm1Srnr/\Tbx21^tm1Srnr (involves: C57BL/6)	decreased interferon-gamma secretion	J:112679
	decreased memory T cell number	J:112679
	decreased NK cell number	J:112679
	decreased NK T cell number	J:112679
\Eomes^tm1Srnr/\Eomes^tm1Srnr \Tbx21^tm1Srnr/\Tbx21^tm1Srnr \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:137655
	abnormal immune system physiology	J:137655
	abnormal interleukin level	J:137655
	abnormal leukocyte physiology	J:137655
	abnormal T cell morphology	J:137655
	decreased CD8-positive, alpha-beta T cell number	J:137655
	decreased memory T cell number	J:137655
	increased neutrophil cell number	J:137655
	increased susceptibility to Riboviria infection	J:137655
\Eomes^tm1Srnr/\Eomes^tm1Srnr \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased memory T cell number	J:137655
	immune system phenotype	J:137655
\Ep300^Plt6/\Ep300⁺ \Mpl^tm1Wsa/\Mpl^tm1Wsa (involves: 129S1/Sv * C57BL/6)	increased eosinophil cell number	J:140200
\Ep300^Plt6/\Ep300^Plt6 (involves: 129S1/Sv * C57BL/6)	decreased B cell number	J:140200
	decreased eosinophil cell number	J:140200
	decreased leukocyte cell number	J:140200
	decreased lymphocyte cell number	J:140200
\Ep300^tm1Pkb/\Ep300⁺ \Myb^tm1Ssp/\Myb⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased thymocyte number	J:98329
\Ep300^tm1Pkb/\Ep300^tm1Pkb (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:98329
\Ep300^tm2Pkb/\Ep300^tm2Pkb \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased single-positive T cell number	J:105505
	decreased thymocyte number	J:105505
	increased double-positive T cell number	J:105505
	small thymus	J:105505
\Epas1^tm1.1Fsl/\Epas1⁺ (involves: C57BL/6 * C57BL/6NTac)	increased leukocyte cell number	J:199595
	increased lymphocyte cell number	J:199595
	increased monocyte cell number	J:199595
\Epas1^tm1.1Fsl/\Epas1^tm1.1Fsl (involves: C57BL/6 * C57BL/6NTac)	increased leukocyte cell number	J:199595
	increased monocyte cell number	J:199595
	increased spleen weight	J:199595
\Epas1^tm1Mcs/\Epas1^tm1.1Mcs \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129X1/SvJ * FVB/N)	enlarged spleen	J:119731
\Epb41^tm1Cnby/\Epb41^tm1Cnby (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ)	decreased spleen iron level	J:77852
	enlarged spleen	J:77852
	increased spleen red pulp amount	J:77852
\Epb42^tm1Llp/\Epb42^tm1Llp (involves: 129P2/OlaHsd * C57BL/6J)	increased spleen iron level	J:67412
	increased spleen weight	J:67412
\Epc1^{tm1a(EUCOMM)Wtsi}/\Epc1⁺ (Not Specified)	decreased leukocyte cell number	J:175295
\Epcam^tm1.1Mcu/\Epcam^tm1.1Mcu \Tg(CD207-cre)1Dhka/0 (involves: 129 * C57BL/6 * C57BL/6J * SJL/J)	abnormal Langerhans cell morphology	J:182665
	abnormal Langerhans cell physiology	J:182665
	increased susceptibility to type IV hypersensitivity reaction	J:182665
\Epcam^tm1.2Msiv/\Epcam^tm1.2Msiv (involves: C57BL/6 * FVB/N * SJL)	small intestinal inflammation	J:210901
\Epdr1^{tm1b(NCOM)Mfgc}/\Epdr1^{tm1b(NCOM)Mfgc} (C57BL/6N-Epdr1^{tm1b(NCOM)Mfgc}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Epg5^em1(IMPC)H/\Epg5^em1(IMPC)H (C57BL/6NTac-Epg5^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Epg5^tm1Ygz/\Epg5^tm1Ygz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	microgliosis	J:196603
\Epgn^tm1.1Msdr/\Epgn^tm1.1Msdr (involves: 129P2/OlaHsd * C57BL/6N)	increased spleen weight	J:194427
\Epha1^tm1Sld/\Epha1^tm1Sld (involves: 129 * C57BL/6J)	endometrium inflammation	J:142722
\Epha1^tm1Sld/\Epha1^tm1Sld (involves: 129 * C57BL/6J)	vaginal inflammation	J:142722
\Epha2^em1(IMPC)Mbp/\Epha2^em1(IMPC)Mbp (C57BL/6N-Epha2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Epha3^em1(IMPC)Mbp/\Epha3^em1(IMPC)Mbp (C57BL/6N-Epha3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Epha6^{tm1b(KOMP)Wtsi}/\Epha6^{tm1b(KOMP)Wtsi} (C57BL/6N-Epha6^{tm1b(KOMP)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
\Ephb1^em1(IMPC)Mbp/\Ephb1^em1(IMPC)Mbp (C57BL/6N-Ephb1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Ephb2^em1(IMPC)Mbp/\Ephb2^em1(IMPC)Mbp (C57BL/6N-Ephb2^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
\Ephb4^tm1.1Jwu/\Ephb4^tm1.1Jwu \Tg(KRT5-cre)1Tak/0 (involves: 129 * C3H * C57BL/6)	immune system phenotype	J:206160
\Ephb6^tm1Jwu/\Ephb6^tm1Jwu (involves: 129)	abnormal cytokine secretion	J:94701
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:94701
	decreased susceptibility to type IV hypersensitivity reaction	J:94701
	decreased T cell proliferation	J:94701
\Ephb6^tm1Tom/\Ephb6^tm1Tom (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:79747
\Ephb6^tm2Tom/\Ephb6^tm2Tom (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:79747
\epi/? (involves: CBA/J)	decreased leukocyte cell number	J:27487
	decreased lymphocyte cell number	J:27487
	increased neutrophil cell number	J:27487
\Epm2a^{Tg(TcraK,TcrbK)TG-BFlv}/\Epm2a⁺ (involves: C57BL/6J * CBA/J)	increased CD8-positive, alpha-beta T cell number	J:107545
\Epm2a^{Tg(TcraK,TcrbK)TG-BFlv}/\Epm2a⁺ (involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J)	increased T cell derived lymphoma incidence	J:112696
\Epm2a^{Tg(TcraK,TcrbK)TG-BFlv}/\Epm2a⁺ \Tg(Ela1-TAg)18Bri/0 (involves: C57BL/6 * CBA/J * SJL)	pancreas inflammation	J:107545
\Epo^{Tg(TAg/Epo)134.3LCPjr}/\Epo^{Tg(TAg/Epo)134.3LCPjr} (involves: C57BL/6 * CBA)	increased spleen weight	J:79374
\Epor^{tm1.2(EPOR)Jtp}/\Epor^{tm1.2(EPOR)Jtp} (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen weight	J:67205
\Eppin^em1(IMPC)Mbp/\Eppin^em1(IMPC)Mbp (C57BL/6N-Eppin^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Eps8l2^{tm1b(EUCOMM)Wtsi}/\Eps8l2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Eps8l2^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
\Eps15^{tm1a(KOMP)Wtsi}/\Eps15^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Eps15^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:165965
\Eps15^{tm1a(KOMP)Wtsi}/\Eps15^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	dermatitis	J:213427
\Eps15^tm1Noff/\Eps15^tm1Noff (B6.129-Eps15^tm1Noff)	abnormal spleen B cell follicle morphology	J:195689
	abnormal spleen marginal zone morphology	J:195689
	abnormal spleen white pulp morphology	J:195689
	decreased B cell number	J:195689
	decreased leukocyte cell number	J:195689
	decreased lymphocyte cell number	J:195689
	immune system phenotype	J:195689
	increased marginal zone B cell number	J:195689
\Eps15^tm1Noff/\Eps15^tm1Noff (involves: 129 * C57BL/6)	abnormal marginal zone B cell morphology	J:195689
	increased marginal zone B cell number	J:195689
	increased transitional stage T1 B cell number	J:195689
\Epsti1^em1Mjnh/\Epsti1^em1Mjnh (Not Specified)	abnormal macrophage differentiation	J:272013
\Epsti1^em1Mjnh/\Epsti1^em1Mjnh (Not Specified)	decreased macrophage cell number	J:272013
\Epx^{tm1.1(cre)Jlee}/\Epx⁺ \Gt(ROSA)26Sor^tm1(DTA)Lky/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased eosinophil cell number	J:198489
\Epx^{tm1.1(cre)Jlee}/\Epx^{tm1.1(cre)Jlee} (B6.Cg-Epx^{tm1.1(cre)Jlee}/Jlee)	immune system phenotype	J:198489
\Epx^{tm1b(EUCOMM)Wtsi}/\Epx^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Epx^{tm1b(EUCOMM)Wtsi}/Orl)	increased monocyte cell number	J:211773
\Epx^tm1Nal/\Epx^tm1Nal (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal eosinophil morphology	J:70567
	immune system phenotype	J:70567
\Epyc^tm1Mhok/\Epyc^tm1Mhok (involves: 129S7/SvEvBrd * C57BL/6J)	osteoarthritis	J:222369
\Erap1^tm1.1Gnie/\Erap1^tm1.1Gnie (involves: 129S6/SvEvTac * C57BL/6)	abnormal antigen presentation	J:143988
	abnormal cytotoxic T cell physiology	J:143988
	abnormal response to infection	J:143988
	decreased interferon-gamma secretion	J:143988
	decreased level of surface class I molecules	J:143988
	decreased T cell proliferation	J:143988
\Erap1^tm1Dgen/\Erap1^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:101679
	thymus hyperplasia	J:101679
\Erap1^tm1Iay/\Erap1^tm1Iay (involves: C57BL/6)	abnormal cytotoxic T cell physiology	J:111047
\Erap1^tm1Iay/\Erap1^tm1Iay (involves: C57BL/6)	decreased level of surface class I molecules	J:111047
\Erap1^tm1Luc/\Erap1⁺ (involves: 129S6/SvEvTac)	abnormal antigen presentation	J:122479
\Erap1^tm1Luc/\Erap1⁺ (involves: 129S6/SvEvTac)	decreased level of surface class I molecules	J:122479
\Erap1^tm1Luc/\Erap1^tm1Luc (involves: 129S6/SvEvTac)	abnormal antigen presentation	J:122479
	abnormal CD8-positive, alpha-beta T cell physiology	J:122479
	abnormal lymphocyte physiology	J:122479
	decreased level of surface class I molecules	J:122479
	immune system phenotype	J:122479
	increased level of surface class I molecules	J:122479
\Erap1^tm1Luc/\Erap1^tm1Luc \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcrLCMV)327Sdz/\Tg(TcrLCMV)327Sdz (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * C57BL/10SgSnAi * DBA/2)	immune system phenotype	J:122479
\Erap1^tm1Nsha/\Erap1^tm1Nsha (B6.129S6-Erap1^tm1Nsha)	abnormal antigen presentation via MHC class I	J:112389, J:116606
	abnormal CD8-positive, alpha-beta T cell physiology	J:112389, J:116606
	abnormal cytokine secretion	J:116606
	decreased level of surface class I molecules	J:112389
\Erap1^tm1Nsha/\Erap1^tm1Nsha \Tap1^tm1Arp/\Tap1^tm1Arp (B6.129-Erap1^tm1Nsha Tap1^tm1Arp)	abnormal antigen presentation via MHC class I	J:112389
\Erap1^tm1Nsha/\Erap1^tm1Nsha \Tap1^tm1Arp/\Tap1^tm1Arp (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/10 * DBA/2)	abnormal antigen presentation via MHC class I	J:116606
\Erars1^DBA/2J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	increased anti-nuclear antigen antibody level	J:96064
\Erars1^DBA/2J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	increased immunoglobulin level	J:96064
\Erars2^C57BL/6J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	abnormal humoral immune response	J:96064
\Erars2^C57BL/6J/? (involves: BXD2/TyJ * C57BL/6J * DBA/2J)	increased immunoglobulin level	J:96064
\Erbb3^tm1.1Dwt/\Erbb3^tm2.1Dwt \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	increased susceptibility to induced colitis	J:152703
\Erbb4^tm1Grl/\Erbb4^tm1Grl \Tg(Myh6-ERBB4)HT2Gass/0 (involves: 129S1/Sv * 129X1/SvJ)	increased granulocyte number	J:132190
	lung inflammation	J:132190
\Ercc1^tm1Jhjh/\Ercc1^tm1Jhjh (involves: C57BL/6 * FVB/N)	abnormal class switch recombination	J:92471
	decreased B cell proliferation	J:92471
	spleen hypoplasia	J:92471
\Ercc1^tm2Jhjh/\Ercc1^tm2Jhjh (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:41161
\Ercc2^{tm2(ERCC2)Jhjh}/\Ercc2^{tm2(ERCC2)Jhjh} (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:76608
\Ercc2^{tm2(ERCC2)Jhjh}/\Ercc2^{tm2(ERCC2)Jhjh} (involves: 129P2/OlaHsd)	immune system phenotype	J:47993
\Ercc2^tm3Jhjh/\Ercc2^tm3Jhjh (involves: 129 * C57BL/6J)	microgliosis	J:179808
\Ercc5^tm1Shm/\Ercc5^tm1Shm (involves: 129S2/SvPas * C57BL/6J)	decreased spleen weight	J:53756
\Ercc6^tm1Gvh/\Ercc6^tm1Gvh (involves: 129P2/OlaHsd * C57BL/6J)	microgliosis	J:179808
\Ercc6^tm1Gvh/\Ercc6^tm1Gvh \Xpa^tm1Gvh/\Xpa^tm1Hvs \Tg(Camk2a-cre)1Szi/0 (involves: 129P2/OlaHsd * C57BL/6J * CBA)	microgliosis	J:179808
\Ercc6^tm1Gvh/\Ercc6^tm1Gvh \Xpa^tm1Gvh/\Xpa^tm1Hvs \Tg(Pcp2-cre)2Mpin/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	microgliosis	J:179808
\Ercc6l2^em1Mengf/\Ercc6l2^em1Mengf (Not Specified)	abnormal class switch recombination	J:311900
	decreased IgA level	J:311900
	decreased IgG1 level	J:311900
	decreased IgG2b level	J:311900
	decreased IgG3 level	J:311900
	decreased IgG level	J:311900
	decreased T cell number	J:311900
	immune system phenotype	J:311900
\Ercc6l2^em1Mengf/\Ercc6l2^em1Mengf \Nhej1^em1Mengf/\Nhej1^em1Mengf (Not Specified)	abnormal T cell receptor V(D)J recombination	J:311900
\Ercc6l2^em2Mengf/\Ercc6l2^em2Mengf (Not Specified)	abnormal class switch recombination	J:311900
\Ercc6l2^em2Mengf/\Ercc6l2^em2Mengf (Not Specified)	immune system phenotype	J:311900
\Ercc8^tm1Jhjh/\Ercc8^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6J)	microgliosis	J:179808
\Ereg^tm1Dwt/\Ereg^tm1Dwt (129S6/SvEvTac-Ereg^tm1Dwt)	increased susceptibility to induced colitis	J:93327
\Ereg^tm1Sawa/\Ereg^tm1Sawa (involves: 129X1/SvJ * C57BL/6J)	dermatitis	J:92618
\Erg^em1(IMPC)Bay/\Erg⁺ (C57BL/6N-Erg^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Erg^em1(IMPC)Bay/\Erg⁺ (C57BL/6N-Erg^em1(IMPC)Bay/Bay)	decreased leukocyte cell number	J:211773
\Erg^mld2/\Erg⁺ (involves: 129S1/Sv * C57BL/6)	decreased transitional stage B cell number	J:137835
\Erg^mld2/\Erg⁺ \Mpl^tm1Wsa/\Mpl^tm1Wsa (B6.Cg-Mpl^tm1Wsa Erg^mld2)	decreased leukocyte cell number	J:137835
\Erg^tm1.1Iwamo/\Erg^tm1.1Iwamo \Tg(Gdf5-cre,-ALPP)1Kng/? (involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)	increased susceptibility to induced arthritis	J:243715
	osteoarthritis	J:243715
\Erlec1^em1(IMPC)Mbp/\Erlec1^em1(IMPC)Mbp (C57BL/6N-Erlec1^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Erlin1^em1(IMPC)Tcp/\Erlin1^em1(IMPC)Tcp (C57BL/6N-Erlin1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Ermp1^em1Gjom/\Ermp1⁺ (Not Specified)	kidney inflammation	J:361886
\Ern1^tm1Rjk/\Ern1^tm1Rjk (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal pro-B cell morphology	J:106975
\Ern1^tm2.1Tiw/\Ern1^tm2.1Tiw \Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Vil1-cre)997Gum/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * SJL)	small intestinal inflammation	J:206084
\Ern2^m1Btlr/\Ern2^m1Btlr (C57BL/6J-Ern2^m1Btlr)	increased susceptibility to induced colitis	J:216045
\Ern2^M2Btlr/\Ern2^M2Btlr (C57BL/6J-Ern2^M2Btlr)	increased susceptibility to induced colitis	J:234237
\Ern2^m3Btlr/\Ern2^m3Btlr (C57BL/6J-Ern2^m3Btlr)	increased susceptibility to induced colitis	J:236686
\Ern2^tm1Dron/\Ern2^tm1Dron (either: 129S6/SvEvTac-Ern2^tm1Dron or B6.129S6-Ern2^tm1Dron)	increased susceptibility to induced colitis	J:67934
\Ero1a^{Gt(XST171)Byg}/\Ero1a^{Gt(XST171)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:153833
	decreased macrophage apoptosis	J:153833
\Errfi1^tm1Gvw/\Errfi1^tm1Gvw (Not Specified)	accelerated temporomandibular joint osteoarthritis	J:100927
	enlarged thymus	J:100927
	osteoarthritis	J:100927
\Errfi1^tm1Gvw/\Errfi1^tm1Gvw \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv)	osteoarthritis	J:100927
\Errfi1^tm3.1Gvw/\Errfi1^tm3.1Gvw \Tg(CMV-cre)1Cgn/0 (involves: 129 * 129S4/SvJaeSor * BALB/cJ)	osteoarthritis	J:206807
\Errfi1^tm3.1Gvw/\Errfi1^tm3.1Gvw \Tg(Col2a1-cre)1Asz/0 (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6 * CBA)	osteoarthritis	J:206807
\Esam^tm1Dvst/\Esam^tm1Dvst (B6.129-Esam1^tm1Dvst)	abnormal cellular extravasation	J:124397
\Esam^tm1Dvst/\Esam^tm1Dvst (B6.129-Esam1^tm1Dvst)	abnormal leukocyte migration	J:124397
\Esm1^tm1.1Rha/\Esm1^tm1.1Rha (involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6NTac)	abnormal cellular extravasation	J:246778
\Esmr^DBA/2NCrj/\Esmr^DBA/2NCrj (involves: C57BL/6NCrj * DBA/2NCrj)	decreased susceptibility to parasitic infection	J:74563
\Espl1^Gt(XL058)Byg/\Espl1⁺ \Trp53^tm1Tyj/\Trp53^tm1Tyj (B6.129-Trp53^tm1Tyj Espl1^Gt(XL058)Byg)	abnormal splenocyte morphology	J:174926
	increased splenocyte proliferation	J:174926
\Espn^je/? \f/\f \Hps6^ru/\Hps6^ru (JE/LeJ)	abnormal mast cell degranulation	J:37255
\Esr1^tm1.1Lja/\Esr1^tm1.1Mma (involves: 129P2/OlaHsd * 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:128135
\Esr1^tm1.1Mma/\Esr1^tm1.1Mma (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:171276
	abnormal thymus physiology	J:171276
\Esr1^tm1.1Ohl/\Esr1^tm1.1Ohl (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:171276
	abnormal thymus physiology	J:171276
\Esr1^tm1.1Scma/\Esr1^tm1.1Scma \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal osteoclast physiology	J:156947
	increased osteoclast cell number	J:156947
\Esr1^tm1Arnal/\Esr1^tm1Arnal (involves: C57BL/6)	abnormal immunoglobulin level	J:171276
\Esr1^tm1Arnal/\Esr1^tm1Arnal (involves: C57BL/6)	increased osteoclast cell number	J:171276
\Esr1^tm1Ksk/\Esr1^tm1Ksk (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell number	J:82423
	abnormal class switch recombination	J:82423
	abnormal immunoglobulin level	J:82423
	abnormal lymph node cell ratio	J:88156
	abnormal spleen physiology	J:88156
	decreased CD4-positive, alpha-beta T cell number	J:110416
	decreased CD8-positive, alpha-beta T cell number	J:110416
	glomerulonephritis	J:88156
	increased anti-double stranded DNA antibody level	J:88156
	increased double-positive T cell number	J:110416
	increased IgG3 level	J:88156
	increased plasma cell number	J:88156
	increased spleen germinal center number	J:88156
	thymus hypoplasia	J:110416
\Esr1^tm1Ksk/\Esr1^tm1Ksk (involves: 129P2/OlaHsd)	decreased immature B cell number	J:110923
	decreased mature B cell number	J:110923
	spermatic granuloma	J:60490
\Esr1^tm1Ksk/\Esr1^tm1Ksk (involves: 129P2/OlaHsd * C57BL/6N)	abnormal B cell differentiation	J:63462
	abnormal thymus physiology	J:111590
	decreased B cell number	J:63462
	decreased immature B cell number	J:63462
	decreased mature B cell number	J:63462
	decreased thymocyte number	J:111590
	decreased thymus weight	J:111590
\Esr1^tm1Ksk/\Esr1^tm1Ksk \Esr2^tm1Unc/\Esr2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell number	J:82423
	abnormal class switch recombination	J:82423
	abnormal immunoglobulin level	J:82423
	decreased CD4-positive, alpha-beta T cell number	J:110416
	decreased CD8-positive, alpha-beta T cell number	J:110416
	decreased spleen weight	J:110416
	increased double-positive T cell number	J:110416
	thymus hypoplasia	J:110416
\Esr1^tm1Ksk/\Esr1^tm1Ksk \Inha^tm1Bay/\Inha^tm1Bay (involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)	liver inflammation	J:84989
\Esr2^tm1.2Pcn/\Esr2^tm1.2Pcn (involves: 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:132171
\Esr2^tm1Mma/\Esr2^tm1Mma (involves: 129S2/SvPas)	increased neutrophil cell number	J:165719
\Esr2^tm1Unc/\Esr2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell number	J:82423
	abnormal leukopoiesis	J:83617
	abnormal lymphopoiesis	J:83617
	enlarged lymph nodes	J:83617
	enlarged spleen	J:83617
	increased granulocyte number	J:83617
	increased leukocyte cell number	J:83617
	increased monocyte cell number	J:83617
	increased neutrophil cell number	J:83617
	increased pre-B cell number	J:83617
	increased pro-B cell number	J:83617
	spleen hyperplasia	J:83617
	spleen hypoplasia	J:110416
\Esr2^tm1Unc/\Esr2^tm1Unc (involves: 129P2/OlaHsd)	colitis	J:107308
\Esr2^tm1Unc/\Esr2^tm1Unc (involves: 129P2/OlaHsd)	urinary bladder inflammation	J:122274
\Esrp2^em1(IMPC)Tcp/\Esrp2^em1(IMPC)Tcp (C57BL/6NCrl-Esrp2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Esrra^tm1Vgi/\Esrra^tm1Vgi (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast differentiation	J:160910
	decreased osteoclast cell number	J:160910
	increased splenocyte number	J:160910
\Ess2^tm1.1Nbioc/\Ess2^tm1.1Nbioc \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6N * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:339504
	decreased CD4-positive, alpha-beta T cell number	J:339504
	decreased CD8-positive, alpha-beta T cell number	J:339504
	decreased CD8-positive, naive alpha-beta T cell number	J:339504
	decreased memory T cell number	J:339504
	immune system phenotype	J:339504
	increased gamma-delta T cell number	J:339504
	increased NK T cell number	J:339504
\Esyt2^{tm2b(KOMP)Wtsi}/\Esyt2⁺ (C57BL/6N-Esyt2^{tm2b(KOMP)Wtsi}/Bay)	enlarged spleen	J:211773
\Etfb^{em1(IMPC)Hmgu}/\Etfb⁺ (C57BL/6NCrl-Etfb^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
\Etnk1^{tm1b(EUCOMM)Wtsi}/\Etnk1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Etnk1^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Ets1^m1Anu/\Ets1^m1Anu (C57BL/6NCrlAnu-Ets1^m1Anu)	immune system phenotype	J:104190
\Ets1^tm1.1Dds/\Ets1⁺ (129S6/SvEvTac-Ets1^tm1.1Dds)	abnormal thymus morphology	J:121460
	decreased memory T cell number	J:121460
	decreased thymocyte apoptosis	J:121460
	enlarged thymus	J:121460
	increased splenocyte apoptosis	J:121460
	increased thymus weight	J:121460
\Ets1^tm1.1Dds/\Ets1^tm1.1Dds (129S6/SvEvTac-Ets1^tm1.1Dds)	abnormal CD8-positive, alpha beta T cell morphology	J:121460
	abnormal lymphopoiesis	J:121460
	abnormal spleen morphology	J:121460
	abnormal spleen red pulp morphology	J:121460
	abnormal thymus cortex morphology	J:121460
	abnormal thymus morphology	J:121460
	abnormal thymus subcapsular epithelium morphology	J:121460
	decreased B cell number	J:121460
	decreased CD4-positive, alpha-beta T cell number	J:121460
	decreased leukocyte cell number	J:121460
	decreased memory T cell number	J:121460
	decreased spleen weight	J:121460
	decreased thymocyte apoptosis	J:121460
	enlarged thymus	J:121460
	increased double-positive T cell number	J:121460
	increased splenocyte apoptosis	J:121460
	increased thymus weight	J:121460
	small spleen	J:121460
\Ets1^tm1Fwa/\Ets1^tm1Fwa (B6.129S4-Ets1^tm1Fwa)	abnormal B cell differentiation	J:93845
	absent B-1a cells	J:93845
	decreased B cell number	J:93845
	decreased B cell proliferation	J:93845
	decreased mature B cell number	J:93845
	decreased pro-B cell number	J:93845
	immune system phenotype	J:93845
	increased B cell apoptosis	J:93845
	increased pro-B cell number	J:93845
\Ets1^tm1Jml/\Ets1^tm1Jml (involves: 129S/SvEv * C57BL/6)	abnormal CD8-positive, alpha-beta T cell differentiation	J:125056
	decreased CD4-positive, alpha-beta T cell number	J:125056
	decreased CD8-positive, alpha-beta T cell number	J:125056
	increased double-negative T cell number	J:125056
	thymus hypoplasia	J:125056
\Ets1^tm1Jml/\Ets1^tm1Jml \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6J * DBA/2J)	decreased CD8-positive, alpha-beta T cell number	J:125056
	immune system phenotype	J:125056
	increased double-negative T cell number	J:125056
\Ets1^tm2Jml/\Ets1^tm2Jml (involves: 129X1/SvJ * C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:50627
	abnormal leukocyte physiology	J:50627
	abnormal NK cell physiology	J:50627
	abnormal T cell activation	J:50627
	decreased NK cell number	J:50627
	decreased T cell number	J:50627
	decreased T cell proliferation	J:50627
	decreased thymocyte number	J:50627
	impaired natural killer cell mediated cytotoxicity	J:50627
	increased plasma cell number	J:50627
\Etv2^tm1Dlim/\Etv2^tm2.1Dlim \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	decreased leukocyte cell number	J:172687
	impaired myelopoiesis	J:172687
	spleen hypoplasia	J:172687
\Etv6^{em1(IMPC)Rbrc}/\Etv6⁺ (C57BL/6NJcl-Etv6^{em1(IMPC)Rbrc}/Rbrc)	increased large unstained cell number	J:211773
	increased spleen weight	J:211773
\Etv6^em3Knic/\Etv6⁺ (involves: C57BL/6J)	abnormal B cell number	J:342774
\Etv6^{tm1(RUNX1)Haho}/\Etv6⁺ \Tg(CD2-icre)4Kio/0 (involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:151639
\Etv6^{tm1(RUNX1)Haho}/\Etv6⁺ \Tg(Gata1-cre)1Sho/0 (involves: 129S1/Sv * C57BL/6 * CD-1 * Swiss Webster)	abnormal B cell differentiation	J:151639
	immune system phenotype	J:151639
\Etv6^{tm1(RUNX1)Haho}/\Etv6⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal lymphopoiesis	J:151639
	decreased B cell number	J:151639
	decreased lymphocyte cell number	J:151639
	decreased neutrophil cell number	J:151639
	immune system phenotype	J:151639
	myeloid hyperplasia	J:151639
\Etv6^{tm1(RUNX1)Haho}/\Etv6⁺ \Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv * C57BL/6)	arrested B cell differentiation	J:151639
	decreased B cell number	J:151639
	decreased pre-B cell number	J:151639
	decreased pro-B cell number	J:151639
\Etv6^tm2Sho/\Etv6^tm2Sho \Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * C57BL/6 * CBA)	decreased neutrophil cell number	J:93052
\Evc2^em1(IMPC)Mbp/\Evc2^em1(IMPC)Mbp (C57BL/6N-Evc2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Evl^tm1Lfr/\Evl^tm1Lfr (involves: 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:94077
\Ewsr1^tm1(ERG)Thr/\Ewsr1⁺ \Rag1^tm1(cre)Thr/\Rag1⁺ (involves: 129S/SvEv)	increased lymphocyte cell number	J:98679
	increased T cell derived lymphoma incidence	J:98679
\Ewsr1^{tm1b(EUCOMM)Wtsi}/\Ewsr1⁺ (C57BL/6N-Ewsr1^{tm1b(EUCOMM)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Ewsr1^tm1Sblee/\Ewsr1^tm1Sblee (involves: 129S6/SvEvTac * Black Swiss)	decreased double-positive T cell number	J:122058
	decreased immature B cell number	J:122058
	decreased leukocyte cell number	J:122058
	decreased mature B cell number	J:122058
	decreased pre-B cell number	J:122058
	spleen hypoplasia	J:122058
	thymus hypoplasia	J:122058
\exf/\exf (involves: C3H/HeN(MTV^-))	conjunctivitis	J:5649
\exf/\exf (involves: C3H/HeN(MTV^-))	increased susceptibility to bacterial infection	J:5649
\Exo1^tm2Wed/\Exo1^tm2Wed (involves: 129 * C57BL/6)	abnormal class switch recombination	J:198719
\Exo1^tm2Wed/\Exo1^tm2Wed (involves: 129 * C57BL/6)	abnormal somatic hypermutation frequency	J:198719
\Exo1^tm3.1Wed/\Exo1^tm3.1Wed (involves: 129 * C57BL/6)	immune system phenotype	J:198719
\Exoc6^hbd/\Exoc6^hbd (AB.Cg-Exoc6^hbd)	decreased spleen iron level	J:8251
\Exoc6^hbd/\Exoc6^hbd (AB.Cg-Exoc6^hbd)	enlarged spleen	J:8251
\Exph5^tm1Tiz/\Exph5^tm1Tiz (B6NJcl.Cg-Exph5^tm1Tiz/Tiz)	abnormal interleukin secretion	J:313415
	abnormal T-helper 2 physiology	J:313415
	increased interleukin-5 secretion	J:313415
	increased interleukin-13 secretion	J:313415
	increased susceptibility to type I hypersensitivity reaction	J:313415
\Extl1^em1Caox/\Extl1^em1Caox \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * CBA)	abnormal dendritic cell chemotaxis	J:333437
	abnormal dendritic cell migration	J:333437
	abnormal dendritic cell physiology	J:333437
	abnormal regulatory T cell morphology	J:333437
	chronic inflammation	J:333437
	decreased acute inflammation	J:333437
	decreased dendritic cell number	J:333437
	decreased T helper 1 cell number	J:333437
	enlarged lymph nodes	J:333437
	enlarged spleen	J:333437
	immune system phenotype	J:333437
	increased B cell number	J:333437
	increased circulating interleukin-6 level	J:333437
	increased circulating interleukin-17 level	J:333437
	increased circulating tumor necrosis factor level	J:333437
	increased IgG level	J:333437
	increased immunoglobulin level	J:333437
	increased interleukin-6 secretion	J:333437
	increased Ly6C high monocyte number	J:333437
	increased susceptibility to autoimmune disorder	J:333437
	increased susceptibility to bacterial infection induced morbidity/mortality	J:333437
	increased T cell number	J:333437
	increased T-helper 17 cell number	J:333437
\Extl3^em1(IMPC)Mbp/\Extl3⁺ (C57BL/6N-Extl3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Eya1^tm1Rilm/\Eya1^tm1Rilm (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	athymia	J:79848, J:57313
\Eya2^em1(IMPC)Mbp/\Eya2^em1(IMPC)Mbp (C57BL/6N-Eya2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Eya2^tm2Px/\Eya2^tm2Px (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	small thymus	J:311538
\Eya4^tm1Jse/\Eya4^tm1Jse (involves: 129S6/SvEvTac * CBA/J)	increased susceptibility to otitis media	J:131873
\Ezh1^tm1Sgon/\Ezh1^tm1Sgon \Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal myeloid leukocyte morphology	J:193722
	absent spleen germinal center	J:193722
	decreased B cell number	J:193722
	decreased immature B cell number	J:193722
	decreased pro-B cell number	J:193722
	decreased spleen red pulp amount	J:193722
	decreased spleen white pulp amount	J:193722
	lymphoid hypoplasia	J:193722
	small spleen	J:193722
\Ezh2^em1Jbn/\Ezh2⁺ (C57BL/6J-Ezh2^em1Jbn)	increased spleen weight	J:267184
\Ezh2^tm1.1Nesh/\Ezh2⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:239472
	abnormal spleen white pulp morphology	J:239472
	enlarged lymph nodes	J:239472
	enlarged spleen	J:239472
\Ezh2^tm1.1Nesh/\Ezh2^tm1.1Nesh \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	enlarged lymph nodes	J:239472
	enlarged spleen	J:239472
\Ezh2^tm1Tara/\Ezh2^tm1Tara \Cd19^tm1(cre)Cgn/? (involves: 129P2/OlaHsd)	immune system phenotype	J:83216
\Ezh2^tm1Tara/\Ezh2^tm1Tara \Igh^tm2Cgn/? \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:83216
\Ezh2^tm1Tara/\Ezh2^tm1Tara \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd)	decreased B cell proliferation	J:199122
	decreased germinal center B cell number	J:199122
	decreased IgG1 level	J:199122
	decreased IgG2b level	J:199122
	decreased IgG3 level	J:199122
	decreased spleen germinal center number	J:199122
	decreased spleen germinal center size	J:199122
	immune system phenotype	J:199122
\Ezh2^tm1Tara/\Ezh2^tm1Tara \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:83216
	abnormal immunoglobulin V(D)J recombination	J:83216
	abnormal pro-B cell morphology	J:83216
	decreased immature B cell number	J:83216
	decreased pre-B cell number	J:83216
\Ezh2^tm2Sho/\Ezh2^tm2.1Sho \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	decreased double-positive T cell number	J:182211
	decreased thymocyte number	J:182211
	enlarged lymph nodes	J:182211
	enlarged spleen	J:182211
	increased double-negative T cell number	J:182211
\Ezh2^tm2Sho/\Ezh2^tm2Sho \Pgr^tm2(cre)Lyd/\Pgr⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased uterine NK cell number	J:290765
\Ezh2^tm2Sho/\Ezh2^tm2Sho \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	decreased double-positive T cell number	J:182211
	decreased thymocyte number	J:182211
	enlarged lymph nodes	J:182211
	enlarged spleen	J:182211
	increased double-negative T cell number	J:182211
\Ezr^tm2Aim/\Ezr^tm2Aim \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	decreased interleukin-2 secretion	J:143487
\F2^tm1Jld/\F2^tm1Jld \Tg(Mx1-cre)1Cgn/0 (B6.Cg-F2^tm1Jld Tg(Mx1-cre)1Cgn)	increased susceptibility to bacterial infection	J:144572
\F2^tm2Jld/\F2⁺ (B6.129P2-F2^tm2Jld)	decreased susceptibility to endotoxin shock	J:174629
\F2^tm2Jld/\F2⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)	decreased susceptibility to induced arthritis	J:174629
\F2r^tm1Ajc/\F2r^tm1Ajc (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:132733
\F2r^tm1Ajc/\F2r^tm1Ajc \F2rl1^tm1Cgh/\F2rl1^tm1Cgh (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to endotoxin shock	J:132733
\F2r^tm1Pago/\F2r^tm1Pago (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:124648
	decreased susceptibility to induced colitis	J:94420
\F2r^tm1Pago/\F2r^tm1Pago (B6.129P2-F2r^tm1Pago)	immune system phenotype	J:88245
\F2r^tm1Pago/\F2r^tm1Pago (involves: 129P2/OlaHsd)	abnormal cytokine level	J:133917
	abnormal lymph node morphology	J:133917
	decreased susceptibility to endotoxin shock	J:133917
	enlarged mesenteric lymph nodes	J:133917
\F2rl1^tm1Bpd/\F2rl1^tm1Bpd (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:124648
	increased inflammatory response	J:96196
	increased susceptibility to induced pancreatitis	J:96196
\F2rl1^tm1Bpd/\F2rl1^tm1Bpd (B6.129P2-F2rl1^tm1Bpd)	decreased susceptibility to endotoxin shock	J:88245
\F2rl1^tm1Bpd/\F2rl1^tm1Bpd (B6.129P2-F2rl1^tm1Bpd)	immune system phenotype	J:88245
\F2rl1^tm1Cgh/\F2rl1^tm1Cgh (involves: 129S4/SvJae * C57BL/6)	glomerulonephritis	J:124303
	immune system phenotype	J:132733
	impaired leukocyte tethering or rolling	J:76626
\F2rl1^tm1Cgh/\F2rl1^tm1Cgh (B6.129S4-F2rl1^tm1Cgh)	decreased dendritic cell number	J:113591
\F2rl1^tm1Jkaw/\F2rl1^tm1Jkaw (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to type IV hypersensitivity reaction	J:106127
\F2rl1^tm1Mslb/\F2rl1^tm1Mslb (involves: 129X1/SvJ * C57BL/6)	decreased IgE level	J:79757
	decreased inflammatory response	J:79757
\F2rl1^tm1Wrf/\F2rl1^tm1Wrf (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to induced arthritis	J:81119
\F2rl1^tm1Wrf/\F2rl1^tm1Wrf (involves: 129P2/OlaHsd)	decreased circulating interleukin-18 level	J:102762
\F2rl1^tm1Wrf/\F2rl1^tm1Wrf (involves: 129P2/OlaHsd)	liver inflammation	J:102762
\F2rl3^tm1Cgh/\F2rl3^tm1Cgh (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:132733
\F3^tm1.1Dwr/\F3^tm1.1Dwr (involves: 129S1/Sv * 129X1/SvJ * MF1 * Swiss)	abnormal cellular extravasation	J:91165
	abnormal leukocyte adhesion	J:91165
	decreased B cell number	J:91165
	decreased circulating interleukin-1 beta level	J:91165
	decreased circulating interleukin-6 level	J:91165
	decreased circulating tumor necrosis factor level	J:91165
	decreased leukocyte cell number	J:91165
	decreased neutrophil cell number	J:91165
	decreased susceptibility to endotoxin shock	J:91165
	impaired leukocyte tethering or rolling	J:91165
\F3^tm1Dco/\F3^tm1Dco \Tg(F3)1Nmk/0 (B6.Cg-F3^tm1Dco Tg(F3)1Nmk)	abnormal interleukin level	J:88245
	decreased susceptibility to endotoxin shock	J:88245
\F3^tm1Gjb/\F3⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal chemokine secretion	J:128891
	abnormal macrophage physiology	J:128891
	decreased interleukin-6 secretion	J:128891
	immune system phenotype	J:128891
\F8^tm1.1Len/Y (B6.Cg-F8^tm1.1Len)	abnormal immune tolerance	J:266699
\F8^tm1Kaz/Y (involves: 129S4/SvJae * C57BL/6)	abnormal immune tolerance	J:266699, J:178969
\F8^tm1Kaz/Y \Tg(Alb-F8R593C)T4Mcal/0 (involves: 129S4/SvJae C57BL/6 * FVB/N)	immune system phenotype	J:178969
\F9^tm1Dws/Y (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:44497
\F11^tm1Gjb/\F11^tm1Gjb \Proc^tm1Fjc/\Proc^tm1Fjc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymph circulation	J:67398
	abnormal lymph node cortex morphology	J:67398
	abnormal lymph node morphology	J:67398
	abnormal neutrophil morphology	J:67398
	decreased leukocyte cell number	J:67398
	decreased neutrophil cell number	J:67398
	enlarged lymph nodes	J:67398
	lung inflammation	J:67398
	lymph node hemorrhage	J:67398
\F11r^tm1.1Dej/\F11r^tm1.1Dej (Not Specified)	abnormal dendritic cell physiology	J:92592
\F11r^tm1.1Dej/\F11r^tm1.1Dej (Not Specified)	increased susceptibility to type IV hypersensitivity reaction	J:92592
\F11r^tm1Dej/\F11r^tm1.1Dej \Tg(Tek-cre)1Ywa/0 (Not Specified)	immune system phenotype	J:92592
\Fa2h^em1(IMPC)Mbp/\Fa2h^em1(IMPC)Mbp (C57BL/6NCrl-Fa2h^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Fabp1^{tm1b(EUCOMM)Hmgu}/\Fabp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fabp1^{tm1b(EUCOMM)Hmgu}/Cnrm)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
\Fabp2^{em1(IMPC)Hmgu}/\Fabp2^{em1(IMPC)Hmgu} (C57BL/6N-Fabp2^{em1(IMPC)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
\Fabp5^tm1Kdo/\Fabp5^tm1Kdo (involves: C57BL/6)	immune system phenotype	J:75715
\Fadd^tm1Mpa/\Fadd^tm1Mpa \Ikbkg^tm1.1Mpa/\Ikbkg^tm1.1Mpa \Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	liver inflammation	J:118336
\Fadd^tm1Mpa/\Fadd^tm1Mpa \Mlkl^tm1.1Wsa/\Mlkl^tm1.1Wsa \Otulin^{tm1c(EUCOMM)Hmgu}/\Otulin^{tm1c(EUCOMM)Hmgu} \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:312394
\Fadd^tm1Mpa/\Fadd^tm1Mpa \Mog^tm1(cre)Gkl/\Mog⁺ (involves: C57BL/6 * SJL)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:167475
	immune system phenotype	J:167475
\Fadd^tm1Mpa/\Fadd^tm1Mpa \Myd88^tm1Aki/\Myd88^tm1Aki \Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Myd88^tm1Aki Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
\Fadd^tm1Mpa/\Fadd^tm1Mpa \Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
	colitis	J:175865
\Fadd^tm1Mpa/\Fadd^tm1Mpa \Tnf^tm1Gkl/\Tnf^tm1Gkl \Tg(Vil1-cre)997Gum/0 (B6.Cg-Fadd^tm1Mpa Tnf^tm1Gkl Tg(Vil1-cre)997Gum)	cecum inflammation	J:175865
	colitis	J:175865
\Fadd^tm1Wnt/\Fadd^tm1Wnt \Tg(Fadd)33Wnt/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	immune system phenotype	J:69617
\Fadd^tm1Wnt/\Fadd^tm1Wnt \Tg(Fadd)33Wnt/0 \Tg(Lck-cre)I57Jxm/0 (involves: 129S4/SvJae * C57BL/6 * CBA * ICR)	abnormal T cell differentiation	J:69617
	decreased CD4-positive, alpha-beta T cell number	J:69617
	decreased CD8-positive, alpha-beta T cell number	J:69617
	decreased double-positive T cell number	J:69617
	increased B cell number	J:69617
	increased double-negative T cell number	J:69617
	thymus hypoplasia	J:69617
\Fadd^tm1Wnt/\Fadd^tm1Wnt \Tg(Fadd)33Wnt/0 \Tg(Lck-cre)I57Jxm/0 \Tg(Tcra2C,Tcrb2C)1Dlo/0 (involves: 129S4/SvJae * C57BL/6 * C57L * CBA * ICR * SJL)	increased double-negative T cell number	J:69617
	thymus hypoplasia	J:69617
\Fadd^tm1Wnt/\Fadd^tm1Wnt \Tg(Fadd/EGFP)#Jizh/? \Tg(Cd4-cre)1Cwi/? (involves: 129S4/SvJae * C57BL/6 * DBA/2)	decreased activated T cell number	J:113207
	decreased single-positive T cell number	J:113207
	immune system phenotype	J:113207
	increased B cell number	J:113207
\Fadd^tm1Wnt/\Fadd^tm1Wnt \Tg(Fadd/EGFP)#Jizh/? \Tg(Lck-cre)1Cwi/? (involves: 129S4/SvJae)	decreased activated T cell number	J:113207
	decreased single-positive T cell number	J:113207
	immune system phenotype	J:113207
	increased B cell number	J:113207
\Fadd^tm1Wnt/\Fadd^tm1Wnt \Tg(Fadd/EGFP)#Jizh/? \Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJae * C57BL/6 * CBA)	spleen hypoplasia	J:168722
	thymus hypoplasia	J:168722
\Fadd^tm2.1Wnt/\Fadd^tm2.1Wnt \Tg(Cd4-cre)1Cwi/? (B6.Cg-Tg(Cd4-cre)1Cwi Fadd^tm2.1Wnt)	abnormal T cell proliferation	J:162312
	abnormal T cell subpopulation ratio	J:162312
	abnormal thymocyte apoptosis	J:162312
	enlarged lymph nodes	J:162312
	enlarged spleen	J:162312
	increased B cell number	J:162312
	increased susceptibility to parasitic infection	J:162312
\Fads1^{Gt(IST11525H2)Tigm}/\Fads1⁺ (C57BL/6-Fads1^{Gt(IST11525H2)Tigm})	decreased interferon-gamma secretion	J:186265
	decreased tumor necrosis factor secretion	J:186265
\Fads1^{Gt(IST11525H2)Tigm}/\Fads1^{Gt(IST11525H2)Tigm} (C57BL/6-Fads1^{Gt(IST11525H2)Tigm})	abnormal mononuclear cell morphology	J:186265
	decreased interferon-gamma secretion	J:186265
	decreased regulatory T cell number	J:186265
	decreased tumor necrosis factor secretion	J:186265
\Fads2^tm1Mtna/\Fads2^tm1Mtna (involves: 129S6/SvEvTac * C57BL/6J)	abnormal spleen white pulp morphology	J:153293
	abnormal thymus cortex morphology	J:153293
	dermatitis	J:153293
	enlarged spleen	J:153293
	increased spleen red pulp amount	J:153293
	lymphoid hypoplasia	J:153293
	small thymus	J:153293
\Fads2^tm1Wst/\Fads2^tm1Wst (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:140341
\Fah^em1(IMPC)Mbp/\Fah⁺ (C57BL/6N-Fah^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Fah^tm1Mgo/\Fah^tm1Mgo (involves: 129S7/SvEvBrd * PT)	kidney inflammation	J:77295
\Fah^tm1Mgo/\Fah^tm1Mgo (involves: 129S7/SvEvBrd * C57BL)	liver inflammation	J:27735
\Fah^tm1Mgo/\Fah^tm1Mgo \Hgd^aku/\Hgd⁺ (involves: 129S7/SvEvBrd * NB)	kidney inflammation	J:77295
\Faim2^{em1(IMPC)Ccpcz}/\Faim2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Faim2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Faim^tm1Kplm/\Faim^tm1Kplm (involves: 129P2/OlaHsd * C57BL/6)	increased B cell apoptosis	J:164184
	increased thymocyte apoptosis	J:164184
	liver inflammation	J:164184
\Fam3a^em1Cya/\Fam3a^em1Cya (involves: C57BL/6)	increased macrophage cell number	J:295206
	increased NK T cell number	J:295206
	increased T cell number	J:295206
\Fam3d^em1Wko/\Fam3d^em1Wko (C57BL/6-Fam3d^em1Wko)	abnormal cytokine level	J:300819
	abnormal neutrophil physiology	J:304594
	colitis	J:300819
	decreased Ly6C high monocyte number	J:304594
	decreased macrophage cell number	J:304594
	decreased neutrophil cell number	J:304594
	enlarged spleen	J:300819
	increased leukocyte cell number	J:300819
	increased neutrophil cell number	J:304594, J:300819
	increased susceptibility to colitis induced morbidity/mortality	J:300819
	increased susceptibility to induced colitis	J:300819
\Fam13a^{tm1e(KOMP)Wtsi}/\Fam13a^{tm1e(KOMP)Wtsi} (C57BL/6N-Fam13a^{tm1e(KOMP)Wtsi})	white adipose tissue inflammation	J:258290
\Fam20c^tm1.1Cqi/\Fam20c^tm1.1Cqi \Tg(Col1a1-cre)2Bek/0 (involves: 129S6/SvEvTac * CD-1)	dental pulp inflammation	J:225679
	periodontium inflammation	J:225679
\Fam53a^{em1(IMPC)Ccpcz}/\Fam53a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam53a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Fam72a^{tm1.1(KOMP)Vlcg}/\Fam72a^{tm1.1(KOMP)Vlcg} (C57BL/6NTac-Fam72a^{tm1.1(KOMP)Vlcg})	abnormal class switch recombination	J:326431
	abnormal somatic hypermutation frequency	J:326431
	increased B cell apoptosis	J:326431
	increased germinal center B cell number	J:326431
\Fam72a^{tm1.1(KOMP)Vlcg}/\Fam72a^{tm1.1(KOMP)Vlcg} \Msh2^tm1Mak/\Msh2^tm1Mak (C57BL/6NTac-Fam72a^{tm1.1(KOMP)Vlcg} Msh2^tm1Mak)	abnormal class switch recombination	J:326431
	abnormal somatic hypermutation frequency	J:326431
\Fam76b^{Gt(IST14004H1)Tigm}/\Fam76b^{Gt(IST14004H1)Tigm} (C57BL/6-Fam76b^{Gt(IST14004H1)Tigm})	abnormal macrophage physiology	J:358021
	abnormal spleen germinal center morphology	J:358021
	abnormal spleen white pulp morphology	J:358021
	abnormal splenic cell ratio	J:358021
	decreased B cell number	J:358021
	enlarged spleen	J:358021
	increased inflammatory response	J:358021
	increased interleukin-6 secretion	J:358021
	increased microglial cell activation	J:358021
	increased spleen weight	J:358021
	increased tumor necrosis factor secretion	J:358021
	microgliosis	J:358021
\Fam81a^{em1(IMPC)Ccpcz}/\Fam81a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam81a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fam83d^{em1(IMPC)Ccpcz}/\Fam83d^{em1(IMPC)Ccpcz} (C57BL/6N-Fam83d^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Fam83h^{em1(IMPC)Ccpcz}/\Fam83h^{em1(IMPC)Ccpcz} (C57BL/6N-Fam83h^{em1(IMPC)Ccpcz}/Ccpcz)	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
\Fam83h^{em2(IMPC)Ccpcz}/\Fam83h⁺ (C57BL/6NCrl-Fam83h^{em2(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Fam110b^{tm1a(EUCOMM)Wtsi}/\Fam110b⁺ (C57BL/6N-Fam110b^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased mature B cell number	J:165965
	increased leukocyte cell number	J:165965
\Fam120c^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Fam120c^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK cell number	J:211773
\Fam120c^{em1(IMPC)Ccpcz}/\Fam120c^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fam120c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fam124a^{em1(IMPC)Ccpcz}/\Fam124a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam124a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fam151b^{tm1b(EUCOMM)Hmgu}/\Fam151b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fam151b^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
\Fam161a^{Gt(462E7)Cmhd}/\Fam161a^{Gt(462E7)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	microgliosis	J:214319
\Fam161b^{em1(IMPC)Ccpcz}/\Fam161b^{em1(IMPC)Ccpcz} (C57BL/6N-Fam161b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fam163a^{tm2b(KOMP)Wtsi}/\Fam163a^{tm2b(KOMP)Wtsi} (C57BL/6N-Fam163a^{tm2b(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Fam167a^{em1(IMPC)Ccpcz}/\Fam167a^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fam167a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fam185a^{em1(IMPC)Ccpcz}/\Fam185a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam185a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Fam209^{tm1b(KOMP)Wtsi}/\Fam209^{tm1b(KOMP)Wtsi} (C57BL/6N-Fam209^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Fam210a^{tm1b(EUCOMM)Wtsi}/\Fam210a⁺ (involves: BALB/cJ * C57BL/6N)	increased osteoclast cell number	J:261817
\Fam210a^{tm1c(EUCOMM)Wtsi}/\Fam210a^{tm1c(EUCOMM)Wtsi} \Tg(ACTA1-cre/Esr1)2Kesr/0 (involves: C3H C57BL/6N * SJL)	increased osteoclast cell number	J:261817
\Fam210a^{tm1c(EUCOMM)Wtsi}/\Fam210a^{tm1c(EUCOMM)Wtsi} \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6N CBA * SJL)	increased osteoclast cell number	J:261817
\Fam210b^em1Cya/\Fam210b^em1Cya (involves: C57BL/6N)	abnormal splenocyte physiology	J:351618
	enlarged spleen	J:351618
	glomerulonephritis	J:351618
	increased anti-double stranded DNA antibody level	J:351618
	increased anti-nuclear antigen antibody level	J:351618
	increased IgG level	J:351618
	increased splenocyte number	J:351618
\Fam210b^{tm1b(KOMP)Mbp}/\Fam210b^{tm1b(KOMP)Mbp} (C57BL/6N-Fam210b^{tm1b(KOMP)Mbp}/Ucd)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Fam219a^{em1(IMPC)Ccpcz}/\Fam219a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam219a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Fam221a^{em1(IMPC)Ccpcz}/\Fam221a^{em1(IMPC)Ccpcz} (C57BL/6N-Fam221a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
\Fam227b^{em1(IMPC)Ccpcz}/\Fam227b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fam227b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fam229b^em1(IMPC)Mbp/\Fam229b^em1(IMPC)Mbp (C57BL/6NCrl-Fam229b^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
\Fam234b^{tm1a(EUCOMM)Wtsi}/\Fam234b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fam234b^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased CD8-positive, alpha-beta T cell number	J:165965
\Fan1^{tm1a(KOMP)Wtsi}/\Fan1^{tm1a(KOMP)Wtsi} (129S1.B6-Fan1^{tm1a(KOMP)Wtsi})	tubulointerstitial nephritis	J:242198
\Fancc^tm1Mab/\Fancc^tm1Mab \Sod1^tm1Cep/\Sod1^tm1Cep (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphocyte morphology	J:71134
	decreased leukocyte cell number	J:71134
	decreased lymphocyte cell number	J:71134
	decreased neutrophil cell number	J:71134
\Fancd2^em1Tzh/\Fancd2^em1Tzh (C57BL/6-Fancd2^em1Tzh)	enlarged spleen	J:284566
\Fancl^{tm1b(EUCOMM)Hmgu}/\Fancl^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fancl^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Farp2^tm1Akum/\Farp2^tm1Akum (B6.Cg-Farp2^tm1Akum)	abnormal osteoclast physiology	J:166376
	decreased osteoclast cell number	J:166376
	increased osteoclast cell number	J:166376
\Farsa^{tm2a(EUCOMM)Wtsi}/\Farsa⁺ (C57BL/6N-Farsa^{tm2a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Fas^lpr-cg/\Fas^lpr-cg (CBA/KlJms-Fas^lpr-cg/J)	abnormal hypersensitivity reaction	J:24805, J:81770
	abnormal lymph organ size	J:24805
	abnormal T cell differentiation	J:24805
	autoimmune response	J:24805, J:81770
	enlarged lymph nodes	J:24805, J:81770
	enlarged spleen	J:24805
	increased anti-nuclear antigen antibody level	J:24805
	increased autoantibody level	J:81770
	increased IgG level	J:24805, J:81770
	increased IgM level	J:24805, J:81770
	increased immunoglobulin level	J:24805
	increased spleen weight	J:81770
\Fas^lpr/\Fas⁺ \Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * MRL/Mp)	liver inflammation	J:72817
\Fas^lpr/\Fas^lpr (MRL/Mp-Fas^lpr)	abnormal B cell morphology	J:108760
	abnormal B cell receptor editing	J:131138
	abnormal cytotoxic T cell physiology	J:7488
	abnormal immune system organ morphology	J:28885
	abnormal immune system physiology	J:28885
	abnormal interleukin level	J:8267
	abnormal lymph node cell ratio	J:6257
	abnormal lymph node morphology	J:27634
	abnormal marginal zone B cell morphology	J:131138
	abnormal T cell morphology	J:108760, J:8267
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
	abnormal T-helper 2 physiology	J:6257
	abnormal thymus medulla morphology	J:28885
	abnormal type III hypersensitivity reaction	J:28885
	blood vessel inflammation	J:28885
	decreased interleukin-2 secretion	J:6638, J:7488
	enlarged lymph nodes	J:27634, J:108760, J:13757, J:28885
	enlarged Peyer's patches	J:28885
	enlarged spleen	J:28885
	enlarged thymus	J:13757
	glomerulonephritis	J:27634, J:13757, J:28885
	increased anti-double stranded DNA antibody level	J:27634, J:131138, J:6257
	increased anti-erythrocyte antigen antibody level	J:27634
	increased anti-nuclear antigen antibody level	J:27634, J:28885
	increased anti-single stranded DNA antibody level	J:27634
	increased autoantibody level	J:28885
	increased IgA level	J:28885
	increased IgG1 level	J:13757, J:28885
	increased IgG2a level	J:13757, J:28885
	increased IgG2b level	J:28885
	increased IgG level	J:27634
	increased IgM level	J:28885
	increased immunoglobulin level	J:13757, J:28885, J:6257
	increased susceptibility to autoimmune disorder	J:108760
	increased thymus weight	J:28885
	lacrimal gland inflammation	J:18512
	lymph node hemorrhage	J:27634
	lymph node hyperplasia	J:27634
	lymph node necrosis	J:27634
	salivary gland inflammation	J:18512
	submandibular gland inflammation	J:21965
	thymus atrophy	J:27634
	thymus cortex atrophy	J:13757, J:28885
	thyroid gland inflammation	J:28171
\Fas^lpr/\Fas^lpr (MRL/Mp-Agtpbp1^atms Fas^lpr)	enlarged lymph nodes	J:103944
	enlarged spleen	J:103944
	enlarged thymus	J:103944
\Fas^lpr/\Fas^lpr (NOD.MRL(B6)-Fas^lpr)	decreased susceptibility to autoimmune diabetes	J:64051
\Fas^lpr/\Fas^lpr (MRL/MpJ-Fas^lpr/J)	abnormal immunoglobulin level	J:122315
	CNS inflammation	J:14151
	conjunctivitis	J:123192
	decreased IgG level	J:122315
	decreased immature B cell number	J:122315
	decreased marginal zone B cell number	J:122315
	decreased mature B cell number	J:122315
	decreased spleen germinal center number	J:122315
	decreased transitional stage B cell number	J:122315
	enlarged lymph nodes	J:92084, J:7454
	glomerulonephritis	J:92084, J:122315, J:127199, J:7454
	increased anti-double stranded DNA antibody level	J:92084, J:122315, J:7454
	increased anti-nuclear antigen antibody level	J:111811, J:92084, J:14151, J:7454
	increased autoantibody level	J:92084, J:14151
	increased IgG level	J:92084
	increased immunoglobulin level	J:122315, J:7454
	increased neutrophil cell number	J:127199
	increased plasma cell number	J:122315
	increased susceptibility to systemic lupus erythematosus	J:92084
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
	salivary gland inflammation	J:92084
\Fas^lpr/\Fas^lpr (NOD.MRL-Fas^lpr)	decreased susceptibility to autoimmune diabetes	J:78679
\Fas^lpr/\Fas^lpr (involves: C3H * MRL/Mp)	autoimmune response	J:1060
	increased anti-nuclear antigen antibody level	J:34296
	increased spleen weight	J:34296
	increased susceptibility to systemic lupus erythematosus	J:34296
	increased susceptibility to type III hypersensitivity reaction	J:34296
\Fas^lpr/\Fas^lpr (B6.MRL-Fas^lpr/J)	abnormal NK cell physiology	J:115033
	abnormal splenic cell ratio	J:132217
	brain inflammation	J:120427
	CNS inflammation	J:120427
	decreased B cell apoptosis	J:135830
	enlarged lymph nodes	J:119584
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased follicular B cell number	J:132217
	increased immature B cell number	J:132217
	increased marginal zone B cell number	J:132217
	increased splenocyte number	J:132217
	increased susceptibility to bacterial infection	J:136745
	increased susceptibility to Picornaviridae infection	J:120427
	increased transitional stage B cell number	J:132217
	lymph node hyperplasia	J:132217
\Fas^lpr/\Fas^lpr (MRL-Fas^lpr)	abnormal T-helper 2 physiology	J:6257
	enlarged lymph nodes	J:126261
	glomerulonephritis	J:126261
	increased anti-double stranded DNA antibody level	J:126261
	increased anti-nuclear antigen antibody level	J:126261
	increased IgG level	J:126261
	increased IgM level	J:126261
	increased immunoglobulin level	J:6257
	increased spleen weight	J:126261
\Fas^lpr/\Fas^lpr (MRL.Cg-Irf1^tm1Mak Fas^lpr)	glomerulonephritis	J:114771
\Fas^lpr/\Fas^lpr (MRL.Cg-Irf1^tm1Mak Fas^lpr)	increased anti-double stranded DNA antibody level	J:114771
\Fas^lpr/\Fas^lpr (C3.MRL-Fas^lpr/J)	abnormal B cell activation	J:7454
	abnormal T cell morphology	J:7454
	decreased eosinophil cell number	J:106288
	decreased interleukin-2 secretion	J:7454
	enlarged lymph nodes	J:7454
	glomerulonephritis	J:7454
	immune system phenotype	J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:7454
	increased autoantibody level	J:7454
	increased immunoglobulin level	J:7454
	lymph node hemorrhage	J:7454
	lymph node hyperplasia	J:7454
	lymph node necrosis	J:7454
\Fas^lpr/\Fas^lpr (B6.MRL-Fas^lpr)	decreased interleukin-2 secretion	J:6638
	enlarged lymph nodes	J:6638, J:135036, J:7454
	enlarged spleen	J:135036
	glomerulonephritis	J:135036, J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:6638, J:135036
	increased autoantibody level	J:135036, J:7454
	increased double-negative T cell number	J:135036
	increased immunoglobulin level	J:7454
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
\Fas^lpr/\Fas^lpr (AK.MRL-Fas^lpr)	enlarged lymph nodes	J:7454
	glomerulonephritis	J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:7454
	increased autoantibody level	J:7454
	increased immunoglobulin level	J:7454
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
\Fas^lpr/\Fas^lpr (C3.MRL-Fas^lpr)	abnormal interleukin level	J:8267
	abnormal T cell morphology	J:8267
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
	lacrimal gland inflammation	J:1028
	salivary gland inflammation	J:1028
\Fas^lpr/\Fas^lpr (MRL/MpJ-Fas^lpr)	abnormal leukocyte adhesion	J:126009
	abnormal leukocyte morphology	J:126009
	autoimmune response	J:125114
	blood vessel inflammation	J:137066
	decreased activated T cell number	J:137066
	decreased B cell number	J:137066
	decreased CD4-positive, alpha-beta T cell number	J:137066
	decreased CD8-positive, alpha-beta T cell number	J:137066
	enlarged lymph nodes	J:137066
	enlarged spleen	J:137066
	glomerulonephritis	J:125114, J:132514, J:137066
	impaired leukocyte tethering or rolling	J:126009
	increased anti-nuclear antigen antibody level	J:137066
	increased autoantibody level	J:137066
	increased double-negative T cell number	J:137066
	increased immunoglobulin level	J:125114
\Fas^lpr/\Fas^lpr (involves: MRL/Mp)	decreased macrophage apoptosis	J:154647
\Fas^lpr/\Fas^lpr (involves: MRL/Mp)	increased susceptibility to bacterial infection	J:50903
\Fas^lpr/\Fas^lpr (involves: C57BL/6 * MRL/Mp)	enlarged spleen	J:73396
	increased anti-double stranded DNA antibody level	J:73396
	increased anti-single stranded DNA antibody level	J:73396
	increased IgA level	J:73396
	increased IgG1 level	J:73396
	increased IgG2a level	J:73396
	increased IgG2b level	J:73396
	increased IgG3 level	J:73396
	increased IgM level	J:73396
	lymph node hyperplasia	J:73396
\Fas^lpr/\Fas^lpr (involves: 129P2/OlaHsd * MRL)	enlarged lymph nodes	J:26250
	glomerulonephritis	J:45448
	increased double-negative T cell number	J:26250
	increased gamma-delta T cell number	J:26250
	kidney inflammation	J:45448
\Fas^lpr/\Fas^lpr \Fcer1g^tm1Tks/\Fcer1g^tm1Tks (MRL.Cg-Fcer1g^tm1Tks Fas^lpr)	arteritis	J:106188
	decreased susceptibility to type III hypersensitivity reaction	J:106188
	glomerulonephritis	J:106188
	immune system phenotype	J:106188
	increased anti-double stranded DNA antibody level	J:106188
	increased double-negative T cell number	J:106188
	increased IgG level	J:106188
	increased spleen weight	J:106188
\Fas^lpr/\Fas^lpr \Havcr1^tm1Kuch/\Havcr1^tm1Kuch (B6.Cg-Havcr1^tm1Kuch Fas^lpr)	abnormal immunoglobulin level	J:186484
	enlarged lymph nodes	J:186484
	enlarged spleen	J:186484
	increased activated T cell number	J:186484
	increased anti-double stranded DNA antibody level	J:186484
	increased autoantibody level	J:186484
	increased B cell number	J:186484
	increased CD4-positive, alpha-beta T cell number	J:186484
	increased CD8-positive, alpha-beta T cell number	J:186484
	increased double-negative T cell number	J:186484
	increased IgG1 level	J:186484
	increased IgG2a level	J:186484
	increased IgG2b level	J:186484
	increased IgG3 level	J:186484
	increased susceptibility to systemic lupus erythematosus	J:186484
	increased T cell number	J:186484
\Fas^lpr/\Fas^lpr \Hspa13^tm1.1Smoc/\Hspa13^tm1.1Smoc \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp)	decreased autoantibody level	J:303927
	decreased susceptibility to systemic lupus erythematosus	J:303927
\Fas^lpr/\Fas^lpr \Ifnar1^tm1Agt/\Ifnar1^tm1Agt (MRL.Cg-Ifnar1^tm1Agt Fas^lpr)	enlarged lymph nodes	J:92084
	glomerulonephritis	J:92084
	increased anti-nuclear antigen antibody level	J:92084
	increased autoantibody level	J:92084
	increased IgA level	J:92084
	increased IgG2b level	J:92084
	increased IgG3 level	J:92084
	increased IgG level	J:92084
	increased IgM level	J:92084
	increased susceptibility to systemic lupus erythematosus	J:92084
	salivary gland inflammation	J:92084
\Fas^lpr/\Fas^lpr \Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Ifngr1^tm1Agt/\Ifngr1^tm1Agt (MRL.Cg-Ifngr1^tm1Agt Ifnar1^tm1Agt Fas^lpr)	decreased anti-nuclear antigen antibody level	J:92084
	decreased autoantibody level	J:92084
	decreased IgG level	J:92084
	decreased susceptibility to systemic lupus erythematosus	J:92084
	glomerulonephritis	J:92084
	increased IgG level	J:92084
	increased susceptibility to systemic lupus erythematosus	J:92084
	salivary gland inflammation	J:92084
	small lymph nodes	J:92084
\Fas^lpr/\Fas^lpr \Ifng^tm1Ts/\Ifng⁺ (MRL.Cg-Ifng^tm1Ts Fas^lpr)	abnormal macrophage chemotaxis	J:123834
	glomerulonephritis	J:123834
	increased autoantibody level	J:123834
\Fas^lpr/\Fas^lpr \Ifng^tm1Ts/\Ifng^tm1Ts (MRL.Cg-Ifng^tm1Ts Fas^lpr)	abnormal macrophage chemotaxis	J:123834
	immune system phenotype	J:123834
	kidney inflammation	J:123834
	lung inflammation	J:123834
\Fas^lpr/\Fas^lpr \Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)	abnormal lymph node size	J:39600
	abnormal spleen size	J:39600
	decreased anti-double stranded DNA antibody level	J:39600
	decreased anti-nuclear antigen antibody level	J:39600
	decreased autoantibody level	J:39600
	decreased double-negative T cell number	J:39600
	decreased IgA level	J:39600
	decreased IgG2a level	J:39600
	decreased IgG2b level	J:39600
	decreased IgM level	J:39600
	decreased immunoglobulin level	J:39600
	decreased susceptibility to systemic lupus erythematosus	J:39600
	enlarged lymph nodes	J:39600
	enlarged spleen	J:39600
\Fas^lpr/\Fas^lpr \Ifngr1^tm1Agt/\Ifngr1^tm1Agt (MRL.Cg-Ifngr1^tm1Agt Fas^lpr)	decreased anti-nuclear antigen antibody level	J:92084
	decreased autoantibody level	J:92084
	decreased IgA level	J:92084
	decreased IgG2a level	J:92084
	decreased IgG2b level	J:92084
	decreased IgG3 level	J:92084
	decreased IgM level	J:92084
	decreased susceptibility to systemic lupus erythematosus	J:92084
	glomerulonephritis	J:92084
	increased IgG1 level	J:92084
	increased IgG level	J:92084
	small lymph nodes	J:92084
\Fas^lpr/\Fas^lpr \Igh-J^{tm2(3H9-VDJ)Mwg}/\Igh-J⁺ (MRL.Cg-Fas^lpr Igh-J^{tm2(3H9-VDJ)Mwg})	abnormal B cell receptor editing	J:131138
	abnormal marginal zone B cell morphology	J:131138
	increased anti-double stranded DNA antibody level	J:131138
\Fas^lpr/\Fas^lpr \Ighm^tm1Cgn/\Ighm^tm1Cgn (involves: 129S2/SvPas * C57BL/6 * MRL/Mp)	abnormal humoral immune response	J:119584
	abnormal immunoglobulin level	J:119584
	arrested B cell differentiation	J:119584
	decreased IgM level	J:119584
	decreased mature B cell number	J:119584
	enlarged lymph nodes	J:119584
	increased autoantibody level	J:119584
	increased T cell number	J:119584
\Fas^lpr/\Fas^lpr \Il2ra^tm1Dw/\Il2ra^tm1Dw \Tg(CD2-Ccdc86)1Hfuj/? (B6.Cg-Il2ra^tm1Dw Fas^lpr Tg(CD2-Ccdc86)1Hfuj)	enlarged spleen	J:151722
\Fas^lpr/\Fas^lpr \Il4^tm1Cgn/\Il4^tm1Cgn (MRL.Cg-Il4^tm1Cgn Fas^lpr)	glomerulonephritis	J:132514
	lacrimal gland inflammation	J:132514
\Fas^lpr/\Fas^lpr \Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)	abnormal lymph node size	J:39600
	abnormal spleen size	J:39600
	decreased anti-nuclear antigen antibody level	J:39600
	decreased IgA level	J:39600
	decreased IgE level	J:39600
	decreased IgG1 level	J:39600
	decreased IgG3 level	J:39600
	decreased immunoglobulin level	J:39600
	decreased susceptibility to systemic lupus erythematosus	J:39600
	enlarged spleen	J:39600
	increased spleen weight	J:39600
	spleen hyperplasia	J:39600
\Fas^lpr/\Fas^lpr \Il27ra^tm1Mak/\Il27ra^tm1Mak (MRL.Cg-Il27ra^tm1Mak Fas^lpr)	abnormal T-helper 2 physiology	J:122148
	decreased anti-double stranded DNA antibody level	J:122148
	decreased IgG2a level	J:122148
	decreased interferon-gamma secretion	J:122148
	decreased susceptibility to systemic lupus erythematosus	J:122148
	glomerulonephritis	J:122148
	immune system phenotype	J:122148
	increased circulating interleukin-4 level	J:122148
	increased circulating interleukin-5 level	J:122148
	increased IgE level	J:122148
	increased IgG1 level	J:122148
\Fas^lpr/\Fas^lpr \Irf1^tm1Mak/\Irf1⁺ (MRL.Cg-Irf1^tm1Mak Fas^lpr)	glomerulonephritis	J:114771
	immune system phenotype	J:114771
	increased anti-double stranded DNA antibody level	J:114771
	increased CD4-positive, alpha-beta T cell number	J:114771
\Fas^lpr/\Fas^lpr \Irf1^tm1Mak/\Irf1^tm1Mak (MRL.Cg-Irf1^tm1Mak Fas^lpr)	abnormal cytokine secretion	J:114771
	decreased anti-double stranded DNA antibody level	J:114771
	glomerulonephritis	J:114771
	immune system phenotype	J:114771
	increased CD4-positive, alpha-beta T cell number	J:114771
\Fas^lpr/\Fas^lpr \Itfg2^{Gt(OST215121)Lex}/\Itfg2^{Gt(OST215121)Lex} (involves: 129S5/SvEvBrd * C57BL/6J * MRL/Mp)	decreased B cell number	J:205951
	enlarged lymph nodes	J:205951
	enlarged spleen	J:205951
	increased anti-double stranded DNA antibody level	J:205951
	increased anti-nuclear antigen antibody level	J:205951
	increased double-negative T cell number	J:205951
	increased IgG2a level	J:205951
	increased IgM level	J:205951
	increased susceptibility to systemic lupus erythematosus	J:205951
\Fas^lpr/\Fas^lpr \Kdelr1^m1Btlr/\Kdelr1^m1Btlr (involves: C57BL/6J * MRL/Mp)	immune system phenotype	J:224970
\Fas^lpr/\Fas^lpr \Nos2^tm1Mrl/\Nos2^tm1Mrl (involves: 129S7/SvEvBrd * MRL)	abnormal immunoglobulin level	J:42666
	decreased IgG level	J:42666
	decreased IgM level	J:42666
	immune system phenotype	J:42666
\Fas^lpr/\Fas^lpr \Pou2af1^tm1Pmt/\Pou2af1^tm1Pmt (involves: 129P2/OlaHsd * C57BL/6 * MRL)	abnormal T cell number	J:125114
	autoimmune response	J:125114
	decreased immunoglobulin level	J:125114
	decreased plasma cell number	J:125114
	increased B cell number	J:125114
\Fas^lpr/\Fas^lpr \Selp^tm1Bay/\Selp^tm1Bay (MRL.Cg-Selp^tm1Bay Fas^lpr)	abnormal chemokine secretion	J:127199
	abnormal leukocyte adhesion	J:126009
	dermatitis	J:127199
	glomerulonephritis	J:127199
	impaired leukocyte tethering or rolling	J:126009
	increased neutrophil cell number	J:127199
\Fas^lpr/\Fas^lpr \Selplg^tm1Fur/\Selplg^tm1Fur (MRL.Cg-Selplg^tm1Fur Fas^lpr)	abnormal chemokine level	J:127199
	dermatitis	J:127199
	glomerulonephritis	J:127199
\Fas^lpr/\Fas^lpr \Sh2d1a^rpl/\Sh2d1a^rpl (MRL/Mp-Fas^lpr Sh2d1a^rpl)	abnormal immune system physiology	J:126261
	increased anti-nuclear antigen antibody level	J:126261
\Fas^lpr/\Fas^lpr \Spp1^tm1Rit/\Spp1^tm1Rit (involves: 129S7/SvEvBrd * C57BL/6 * MRL/Mp)	enlarged spleen	J:73396
	increased anti-double stranded DNA antibody level	J:73396
	increased anti-single stranded DNA antibody level	J:73396
	increased IgA level	J:73396
	increased IgG1 level	J:73396
	increased IgG2a level	J:73396
	increased IgG2b level	J:73396
	increased IgG3 level	J:73396
	increased IgM level	J:73396
	kidney inflammation	J:73396
	lymph node hyperplasia	J:73396
\Fas^lpr/\Fas^lpr \Tcra^tm1Mjo/\Tcra⁺ (MRL.Cg-Tcra^tm1Mjo Fas^lpr)	immune system phenotype	J:108590
\Fas^lpr/\Fas^lpr \Tcra^tm1Mjo/\Tcra^tm1Mjo (involves: 129P2/OlaHsd * MRL)	immune system phenotype	J:26250
	increased gamma-delta intraepithelial T cell number	J:26250
	increased gamma-delta T cell number	J:26250
	increased T cell number	J:26250
	kidney inflammation	J:45448
\Fas^lpr/\Fas^lpr \Tcra^tm1Mjo/\Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S2/SvPas * MRL)	decreased autoantibody level	J:38492
	decreased immunoglobulin level	J:38492
\Fas^lpr/\Fas^lpr \Tg(CD2-Foxj1)#Stlp/0 (MRL.Cg-Fas^lpr Tg(CD2-Foxj1)#Stlp)	abnormal T cell physiology	J:122222
	decreased CD4-positive, alpha-beta T cell number	J:122222
	decreased susceptibility to systemic lupus erythematosus	J:122222
	enlarged lymph nodes	J:122222
	enlarged spleen	J:122222
	increased anti-nuclear antigen antibody level	J:122222
	increased double-negative T cell number	J:122222
	kidney inflammation	J:122222
	liver inflammation	J:122222
	lung inflammation	J:122222
	salivary gland inflammation	J:122222
\Fas^lpr/\Fas^lpr \Tg(H2-K-Cd86)27All/0 (involves: C57BL/6 * CBA * MRL/MpJ)	decreased B cell number	J:112475
\Fas^lpr/\Fas^lpr \Tg(Ins2-Fasl)24Ach/0 (NOD.Cg-Fas^lpr Tg(Ins2-Fasl)24Ach)	decreased susceptibility to autoimmune diabetes	J:81416
\Fas^lpr/\Fas^lpr \Tg(INS-Il10)#Sar/0 (NOD.Cg-Fas^lpr Tg(INS-Il10)#Sar)	increased susceptibility to autoimmune diabetes	J:64051
	insulitis	J:64051
\Fas^lpr/\Fas^lpr \Tlr7^tm1Flv/Y (involves: 129S1/Sv * C57BL/6 * MRL/Mp)	abnormal B cell activation	J:113557
	abnormal CD4-positive, alpha beta T cell morphology	J:113557
	abnormal lymph node size	J:113557
	abnormal plasmacytoid dendritic cell physiology	J:113557
	decreased autoantibody level	J:113557
	decreased double-negative T cell number	J:113557
	decreased IgG2a level	J:113557
	decreased IgG3 level	J:113557
	decreased spleen weight	J:113557
	decreased susceptibility to systemic lupus erythematosus	J:113557
	increased anti-chromatin antibody level	J:113557
	increased autoantibody level	J:113557
\Fas^lpr/\Fas^lpr \Tlr9^tm1Aki/\Tlr9^tm1Aki (B6.Cg-Tlr9^tm1Aki Fas^lpr)	autoimmune response	J:135036
	decreased IgM level	J:135036
	enlarged lymph nodes	J:135036
	enlarged spleen	J:135036
	glomerulonephritis	J:135036
	increased double-negative T cell number	J:135036
	increased IgG level	J:135036
\Fas^lpr/\Fas^lpr \Tlr9^tm1Aki/\Tlr9^tm1Aki (MRL.Cg-Tlr9^tm1Aki Fas^lpr)	abnormal B cell activation	J:113557
	abnormal plasmacytoid dendritic cell physiology	J:113557
	decreased autoantibody level	J:113557
	enlarged lymph nodes	J:113557
	enlarged spleen	J:113557
	glomerulonephritis	J:113557
	increased autoantibody level	J:113557
	increased CD4-positive, alpha-beta T cell number	J:113557
	increased circulating interferon-alpha level	J:113557
	increased double-negative T cell number	J:113557
	increased IgG2a level	J:113557
	increased IgG3 level	J:113557
	increased IgG level	J:113557
	increased susceptibility to systemic lupus erythematosus	J:113557
	kidney inflammation	J:113557
\Fas^lpr/\Fas^lpr \Tnfrsf1a^tm1.1Gkl/\Tnfrsf1a^tm1.1Gkl (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
\Fas^lpr/\Fas^lpr \Tnfrsf9^tm1Byk/\Tnfrsf9^tm1Byk (MRL.Cg-Tnfrsf9^tm1Byk Fas^lpr)	enlarged lymph nodes	J:127197
	enlarged spleen	J:127197
	increased anti-nuclear antigen antibody level	J:127197
	increased B-1 B cell number	J:127197
	increased B-2 B cell number	J:127197
	increased CD4-positive, alpha-beta T cell number	J:127197, J:126929
	increased double-negative T cell number	J:127197, J:126929
	increased immunoglobulin level	J:127197
	increased interleukin-4 secretion	J:126929
	increased spleen germinal center number	J:127197
	increased susceptibility to systemic lupus erythematosus	J:127197
	lacrimal gland inflammation	J:126929
\Fas^lpr/\Fas^lpr \Tnfrsf13c^Bcmd1/\Tnfrsf13c⁺ (MRL.Cg-Tnfrsf13c^Bcmd1 Fas^lpr)	decreased B cell number	J:122315
	decreased marginal zone B cell number	J:122315
\Fas^lpr/\Fas^tm1.1Cgn (involves: C57BL/6 * MRL)	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
\Fas^lpr/\Fas^tm1Cgn \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * MRL)	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
	increased double-negative T cell number	J:114948
\Fas^m1Btlr/\Fas^m1Btlr (C57BL/6J-Fas^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:216052
	decreased CD8-positive, alpha-beta T cell number	J:216052
	increased neutrophil cell number	J:216052
	increased NK cell number	J:216052
\Fas^m2Btlr/\Fas^m2Btlr (C57BL/6J-Fas^m2Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:271891
\Fas^m2Btlr/\Fas^m2Btlr (C57BL/6J-Fas^m2Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:271891
\Fas^theo/\Fas^theo (either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu))	enlarged lymph nodes	J:104190
	increased anti-nuclear antigen antibody level	J:104190
\Fas^tm1.1Cgn/\Fas^tm1.1Cgn (involves: C57BL/6)	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
\Fas^tm1Ach/\Fas^tm1Ach \Tg(GZMB-cre)1Jcb/? (involves: C57BL/6 * FVB/N)	increased anti-nuclear antigen antibody level	J:123556
	increased double-positive T cell number	J:123556
\Fas^tm1Ach/\Fas^tm1Ach \Tg(Itgax-cre,-EGFP)4097Ach/? (Not Specified)	abnormal spleen morphology	J:123556
	abnormal spleen periarteriolar lymphoid sheath morphology	J:123556
	enlarged spleen	J:123556
	increased anti-nuclear antigen antibody level	J:123556
	increased dendritic cell number	J:123556
	increased IgG level	J:123556
	increased IgM level	J:123556
	increased immunoglobulin level	J:123556
\Fas^tm1Ach/\Fas^tm1Ach \Tg(Lck-cre)548Jxm/? (involves: C57BL/6 * CBA)	increased anti-nuclear antigen antibody level	J:123556
	increased double-positive T cell number	J:123556
\Fas^tm1Cgn/\Fas^tm1Cgn (C57BL/6-Fas^tm1Cgn)	immune system phenotype	J:114948
\Fas^tm1Cgn/\Fas^tm1Cgn \Cd19^tm1(cre)Cgn/\Cd19⁺ \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Cd19^tm1(cre)Cgn Fas^tm1Cgn)	increased anti-single stranded DNA antibody level	J:114948
\Fas^tm1Cgn/\Fas^tm1Cgn \Mog^tm1(cre)Gkl/\Mog⁺ (involves: C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114741
	immune system phenotype	J:114741
\Fas^tm1Cgn/\Fas^tm1Cgn \Mog^tm1(cre)Gkl/\Mog⁺ \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114741
	immune system phenotype	J:114741
\Fas^tm1Cgn/\Fas^tm1Cgn \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Fas^tm1Cgn)	abnormal immune system cell morphology	J:114948
	abnormal immune system organ morphology	J:114948
	abnormal thymus involution	J:114948
	alveolitis	J:114948
	decreased B cell number	J:114948
	decreased T cell number	J:114948
	enlarged spleen	J:114948
	increased activated T cell number	J:114948
	increased anti-single stranded DNA antibody level	J:114948
	increased double-negative T cell number	J:114948
	increased inflammatory response	J:114948
	increased memory T cell number	J:114948
	increased T cell apoptosis	J:114948
	kidney inflammation	J:114948
	liver inflammation	J:114948
	lung inflammation	J:114948
	lymph node hypoplasia	J:114948
	spleen hypoplasia	J:114948
\Fas^tm1Cgn/\Fas^tm1Cgn \Tg(Lck-cre)I57Jxm/0 (B6.Cg-Fas^tm1Cgn Tg(Lck-cre)I57Jxm)	lymph node hypoplasia	J:114948
\Fas^tm1Cgn/\Fas^tm1Cgn \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Fas^tm1Cgn Tg(Mx1-cre)1Cgn)	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
\Fas^tm1Cgn/\Fas^tm1Cgn \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114741
\Fas^tm1Dlo/\Fas^tm1Dlo (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus involution	J:90750
	enlarged lymph nodes	J:31847
	enlarged spleen	J:31847
	increased immunoglobulin level	J:31847
\Fas^tm1Osa/\Fas^tm1Osa (involves: 129P2/OlaHsd * C57BL/6)	abnormal hypersensitivity reaction	J:64296, J:32125
	abnormal lymph organ size	J:64296
	abnormal T cell clonal deletion	J:32125
	enlarged lymph nodes	J:64296, J:32125
	enlarged spleen	J:64296, J:32125
	increased anti-double stranded DNA antibody level	J:32125
	increased anti-single stranded DNA antibody level	J:32125
	increased autoantibody level	J:32125
	increased B cell number	J:32125
	increased IgG1 level	J:32125
	increased IgG2a level	J:32125
	increased IgG2b level	J:32125
	increased IgG3 level	J:32125
	increased IgG level	J:32125
	increased leukocyte cell number	J:32125
	increased lymphocyte cell number	J:64296, J:32125
	increased susceptibility to parasitic infection	J:81397
	lymphoid hyperplasia	J:64296
\Fas^tm1Osa/\Fas^tm1Osa \Gzma^tm1Simn/\Gzma^tm1Simn \Gzmb^tm1Ley/\Gzmb^tm1Ley (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased susceptibility to parasitic infection	J:81397
\Fas^tm1Vbo/\Fas^tm1Vbo \Tg(Ins2-cre)25Mgn/0 \Tg(Ins2-HA)165Bri/0 \Tg(Tcra/Tcrb)1Vbo/0 (Not Specified)	increased susceptibility to autoimmune diabetes	J:85985
\Fasl^del1Hong/\Fasl^del1Hong (either: (involves: 129 * BALB/c * C57BL/6) or (involves: 129X1/SvJ * C3H/HeJ * C57BL/6))	abnormal thymus cell ratio	J:112563
	enlarged lymph nodes	J:112563
	enlarged spleen	J:112563
	enlarged thymus	J:112563
	increased IgG level	J:112563
	increased IgM level	J:112563
\Fasl^gld/\Fasl^gld (C3H/HeJ-Fasl^gld/J)	abnormal lymph node morphology	J:7306
	abnormal T cell differentiation	J:12002, J:8267
	decreased B cell number	J:29572
	decreased cytotoxic T cell cytolysis	J:17698
	enlarged lymph nodes	J:7306, J:29572
	enlarged spleen	J:7306, J:29572
	increased anti-double stranded DNA antibody level	J:7306
	increased anti-nuclear antigen antibody level	J:7306, J:29572
	increased autoantibody level	J:7306
	increased IgA level	J:7306, J:29572
	increased IgG1 level	J:7306
	increased IgG2a level	J:7306
	increased IgG2b level	J:7306
	increased IgG level	J:29572
	increased IgM level	J:7306, J:29572
	increased immunoglobulin level	J:7306, J:29572
	increased leukocyte cell number	J:7306
	increased lymphocyte cell number	J:7306, J:29572
	increased neutrophil cell number	J:7306
	increased T cell number	J:29572
	interstitial pneumonia	J:7306
\Fasl^gld/\Fasl^gld (B6Smn.C3-Fasl^gld/J)	abnormal NK cell physiology	J:115033
	abnormal osteoclast physiology	J:127179
	brain inflammation	J:120427
	CNS inflammation	J:120427
	decreased granulocyte number	J:136745
	eye inflammation	J:136745
	increased susceptibility to bacterial infection	J:136745
	increased susceptibility to Picornaviridae infection	J:120427
	liver inflammation	J:135830
\Fasl^gld/\Fasl^gld (C3H/HeJ-Fasl^gld)	abnormal interleukin level	J:8267
	abnormal T cell morphology	J:8267
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
\Fasl^gld/\Fasl^gld (involves: C3H/HeJ * C57BL/6)	dermatitis	J:153501
	enlarged lymph nodes	J:153501
	enlarged spleen	J:153501
	immune system phenotype	J:153501
	increased anti-nuclear antigen antibody level	J:153501
	increased circulating tumor necrosis factor level	J:153501
	increased IgE level	J:153501
	increased IgG1 level	J:153501
	increased IgG2a level	J:153501
	increased IgG2b level	J:153501
	increased IgG level	J:153501
	increased susceptibility to systemic lupus erythematosus	J:153501
	increased T cell number	J:153501
\Fasl^gld/\Fasl^gld (involves: C3H/HeJ)	abnormal osteoclast physiology	J:156947
	enlarged lymph nodes	J:171440
	enlarged spleen	J:171440
	increased spleen weight	J:171440
\Fasl^gld/\Fasl^gld (B6.C3-Fasl^gld)	abnormal lymph node morphology	J:91058
	enlarged lymph nodes	J:91058
	enlarged spleen	J:91058
	impaired macrophage phagocytosis	J:91058
	increased anti-nuclear antigen antibody level	J:91058
	increased autoantibody level	J:91058
	increased spleen weight	J:91058
\Fasl^gld/\Fasl^gld \Ighm^tm1Cgn/\Ighm^tm1Cgn (involves: 129S2/SvPas * C3H/HeJ * C57BL/6)	immune system phenotype	J:119584
\Fasl^m1Btlr/\Fasl^m1Btlr (C57BL/6J-Fasl^m1Btlr)	abnormal humoral immune response	J:212067
\Fasl^m2Btlr/\Fasl^m2Btlr (C57BL/6J-Fasl^m2Btlr)	decreased IgG level	J:224659
\Fasl^m2Btlr/\Fasl^m2Btlr (C57BL/6J-Fasl^m2Btlr)	impaired humoral immune response	J:224659
\Fasl^tm1.1Ast/\Fasl^tm1.1Ast (involves: BALB/cJ * C57BL/6)	decreased cytotoxic T cell cytolysis	J:153501
	dermatitis	J:153501
	enlarged lymph nodes	J:153501
	enlarged spleen	J:153501
	glomerulonephritis	J:153501
	immune system phenotype	J:153501
	increased anti-double stranded DNA antibody level	J:153501
	increased anti-nuclear antigen antibody level	J:153501
	increased circulating tumor necrosis factor level	J:153501
	increased IgA level	J:153501
	increased IgE level	J:153501
	increased IgG1 level	J:153501
	increased IgG2a level	J:153501
	increased IgG2b level	J:153501
	increased IgG level	J:153501
	increased IgM level	J:153501
	increased immunoglobulin level	J:153501
	increased susceptibility to systemic lupus erythematosus	J:153501
\Fasl^tm1.1Bksa/\Fasl^tm1.1Bksa (involves: 129)	enlarged lymph nodes	J:171440
	enlarged spleen	J:171440
	increased spleen weight	J:171440
\Fasl^tm1.1Cgm/\Fasl^tm1.1Cgm (involves: 129S2/SvPas * C57BL/6 * C57BL/6N)	immune system phenotype	J:168406
	increased B cell proliferation	J:168406
	increased germinal center B cell number	J:168406
	increased IgM level	J:168406
	increased plasma cell number	J:168406
	increased T cell proliferation	J:168406
\Fasl^tm1.1Lest/\Fasl^tm1.1Lest (involves: 129 * C57BL/6)	abnormal double-negative T cell morphology	J:87990
	abnormal lymph node morphology	J:87990
	autoimmune response	J:87990
	enlarged lymph nodes	J:87990
	enlarged spleen	J:87990
	glomerulonephritis	J:87990
	increased IgG level	J:87990
	lymphoid hyperplasia	J:87990
\Fasl^tm1.1Lest/\Fasl^tm1.1Lest (B6.129-Fasl^tm1.1Lest)	glomerulonephritis	J:87990
\Fasl^tm2.1Ast/\Fasl^tm2.1Ast (involves: BALB/cJ * C57BL/6)	abnormal cytotoxic T cell physiology	J:153501
\Fastk^tm1.1Andp/\Fastk^tm1.1Andp (B6.129S6-Fastk^tm1.1Andp)	abnormal chemokine secretion	J:160443
	abnormal neutrophil physiology	J:160443
	decreased interleukin-6 secretion	J:160443
	decreased interleukin-23 secretion	J:160443
	decreased neutrophil cell number	J:160443
	decreased tumor necrosis factor secretion	J:160443
\Fastkd2^{tm1b(EUCOMM)Wtsi}/\Fastkd2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Fastkd2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased spleen weight	J:211773
\Fat1^{Gt(KST249)Byg}/\Fat1^{Gt(KST249)Byg} \Tg(Myl1-lacZ)1Ibdml/0 (involves: 129P2/OlaHsd)	lymphangiectasis	J:199157
	myositis	J:199157
\Fat1^tm1.2Fhel/\Fat1^tm1.2Fhel \Tg(Myl1-lacZ)1Ibdml/0 (involves: 129S6/SvEvTac * BALB/cJ * C57BL/6J * SJL)	myositis	J:199157
\Fat3^{em1(IMPC)Ccpcz}/\Fat3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fat3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fbf1^{tm1a(EUCOMM)Wtsi}/\Fbf1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fbf1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Fblim1^tm1.1Chen/\Fblim1^tm1.1Chen (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	abnormal osteoclast differentiation	J:186501
	abnormal osteoclast physiology	J:186501
	increased osteoclast cell number	J:186501
\Fbln1^{Gt(XST011)Byg}/\Fbln1^{Gt(XST011)Byg} (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:137690
\Fbln1^tm1Tmpl/\Fbln1^tm1Tmpl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	thymus hypoplasia	J:137690
\Fbn1^em1(IMPC)H/\Fbn1⁺ (C57BL/6NTac-Fbn1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Fbn1^tm1Lper/\Fbn1⁺ (involves: 129/Sv * CD-1)	lung inflammation	J:167276
\Fbn1^tm2.1Hcd/\Fbn1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)	abnormal interleukin secretion	J:206074
	abnormal T-helper 1 cell morphology	J:206074
	increased anti-nuclear antigen antibody level	J:206074
	increased autoantibody level	J:206074
	increased B cell number	J:206074
	increased interleukin-9 secretion	J:206074
	increased interleukin-13 secretion	J:206074
	increased plasma cell number	J:206074
\Fbn1^tm2Rmz/\Fbn1^tm2Rmz (involves: 129S1/Sv * 129X1/SvJ)	aortitis	J:54081
\Fbn1^tm2Rmz/\Fbn1^tm2Rmz (involves: 129S1/Sv * 129X1/SvJ)	lung inflammation	J:91815
\Fbn1^tm3.1Hcd/\Fbn1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)	abnormal interleukin secretion	J:206074
	abnormal T-helper 1 cell morphology	J:206074
	increased anti-nuclear antigen antibody level	J:206074
	increased autoantibody level	J:206074
	increased B cell number	J:206074
	increased interleukin-9 secretion	J:206074
	increased interleukin-13 secretion	J:206074
	increased plasma cell number	J:206074
\Fbn1^Tsk/\Fbn1⁺ (B6.Cg-Fbn1^Tsk)	abnormal uterine NK cell morphology	J:1377
	alveolitis	J:15018, J:30961, J:6566
	increased autoantibody level	J:21987, J:14166
	increased mast cell number	J:8047
	increased susceptibility to type IV hypersensitivity reaction	J:7185
	lung inflammation	J:30961, J:6566
\Fbn1^Tsk/\Fbn1⁺ \Il4^tm1Nnt/\Il4^tm1Nnt (involves: C57BL/6 * C57BL/10 * DBA/2)	decreased interleukin-4 secretion	J:57957
\Fbn1^Tsk/\Fbn1⁺ \Il4ra^tm1Sz/\Il4ra⁺ (involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)	increased autoantibody level	J:68448
\Fbn1^Tsk/\Fbn1⁺ \Il4ra^tm1Sz/\Il4ra^tm1Sz (involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)	immune system phenotype	J:68448
\Fbn1^Tsk/\Fbn1⁺ \Kit^W/\Kit^W-v (involves: C57BL/6 * C57BL/10 * DBA/2 * WB/ReJ)	absent mast cells	J:24076
\Fbn1^Tsk/\Fbn1⁺ \Stat6^tm1Gru/\Stat6^tm1Gru (involves: 129S2/SvPas * C57BL/10 * DBA/2)	decreased interleukin-4 secretion	J:57957
\Fbn1^Tsk/\Fbn1⁺ \Tgfb1^tm1N/\Tgfb1⁺ (involves: 129S/SvEv * C57BL/6J * C57BL/10 * DBA/2)	immune system phenotype	J:68448
\Fbp2^{tm2b(EUCOMM)Hmgu}/\Fbp2⁺ (C57BL/6N-Fbp2^{tm2b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Fbrsl1^em1(IMPC)Tcp/\Fbrsl1^em1(IMPC)Tcp (C57BL/6N-Fbrsl1^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
	small thymus	J:211773
\Fbxl3^{em1(IMPC)Ccpcz}/\Fbxl3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fbxl3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
\Fbxl4^tm1.2Lrsn/\Fbxl4^tm1.2Lrsn (involves: C57BL/6N)	liver inflammation	J:303084
\Fbxl5^{Gt(OST386421)Lex}/\Fbxl5⁺ (involves: 129S5/SvEvBrd * C57BL/6)	increased spleen iron level	J:193752
\Fbxl5^tm2.1Kei/\Fbxl5^tm2.1Kei \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: C57BL/6 * DBA)	liver inflammation	J:176655
\Fbxl18^{tm1b(EUCOMM)Hmgu}/\Fbxl18^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fbxl18^{tm1b(EUCOMM)Hmgu}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Fbxl19^{tm1b(EUCOMM)Wtsi}/\Fbxl19⁺ (C57BL/6N-Fbxl19^{tm1b(EUCOMM)Wtsi}/Nju)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Fbxo4^tm1.1Jadi/\Fbxo4⁺ (Not Specified)	myeloid hyperplasia	J:178645
\Fbxo4^tm1.1Jadi/\Fbxo4^tm1.1Jadi (Not Specified)	myeloid hyperplasia	J:178645
\Fbxo7^{tm1a(EUCOMM)Hmgu}/\Fbxo7^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	increased pro-B cell number	J:183053
\Fbxo7^{tm1a(EUCOMM)Wtsi}/\Fbxo7^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fbxo7^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Fbxo7^{tm1a(EUCOMM)Wtsi}/\Fbxo7^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal effector T cell number	J:272313
	abnormal T cell differentiation	J:272313
	decreased CD4-positive, alpha-beta T cell number	J:272313
	decreased CD8-positive, alpha-beta T cell number	J:272313
	decreased T cell number	J:272313
	enlarged spleen	J:272313
	increased activated T cell number	J:272313
	increased double-negative T cell number	J:272313
	increased effector memory CD4-positive, alpha-beta T cell number	J:272313
	increased effector memory CD8-positive, alpha-beta T cell number	J:272313
	increased memory T cell number	J:272313
	increased spleen weight	J:272313
	increased susceptibility to bacterial infection	J:272313
	increased susceptibility to bacterial infection induced morbidity/mortality	J:272313
	thymus atrophy	J:272313
	thymus hypoplasia	J:272313
\Fbxo7^{tm1c(EUCOMM)Wtsi}/\Fbxo7^{tm1c(EUCOMM)Wtsi} \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6J * C57BL/6N)	decreased CD8-positive, alpha-beta T cell number	J:272313
	decreased T cell number	J:272313
	immune system phenotype	J:272313
\Fbxo9^{tm1b(EUCOMM)Hmgu}/\Fbxo9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fbxo9^{tm1b(EUCOMM)Hmgu}/Tcp)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Fbxo10^{tm1b(KOMP)Wtsi}/\Fbxo10^{tm1b(KOMP)Wtsi} (C57BL/6N-Fbxo10^{tm1b(KOMP)Wtsi}/Nju)	decreased neutrophil cell number	J:211773
\Fbxo11^Jf/\Fbxo11⁺ (involves: BALB/cAnNCrl * C3H/HeN)	abnormal cytokine secretion	J:85263
\Fbxo11^Jf/\Fbxo11⁺ (involves: BALB/cAnNCrl * C3H/HeN)	increased susceptibility to otitis media	J:85263
\Fbxo11^Jf/\Fbxo11⁺ (involves: BALB/cAnNCrl * C3H/HeN * C57BL/6J)	increased susceptibility to otitis media	J:114851
\Fbxo11^Jf/\Fbxo11⁺ (involves: BALB/cAnNCrl)	increased susceptibility to otitis media	J:250208
\Fbxo11^Jf/\Fbxo11^Mutt (involves: BALB/c * C3H/HeN)	increased susceptibility to otitis media	J:114851
\Fbxo21^em1Smbk/\Fbxo21^em1Smbk \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (B6.Cg-Fbxo21^em1Smbk Commd10^{Tg(Vav1-icre)A2Kio})	decreased spleen weight	J:333469
	increased T cell number	J:333469
\Fbxo25^{em1(IMPC)Ccpcz}/\Fbxo25^{em1(IMPC)Ccpcz} (C57BL/6N-Fbxo25^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fbxo28^{em1(IMPC)Mhzh}/\Fbxo28⁺ (C57BL/6N-Fbxo28^{em1(IMPC)Mhzh}/Mhzh)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Fbxo36^{tm1b(KOMP)Wtsi}/\Fbxo36^{tm1b(KOMP)Wtsi} (C57BL/6N-Fbxo36^{tm1b(KOMP)Wtsi}/Nju)	decreased monocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Fbxw2^{tm1b(EUCOMM)Hmgu}/\Fbxw2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fbxw2^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
\Fbxw7^tm1Iaai/\Fbxw7^tm1Iaai \Tg(Lck-cre)1Cwi/0 (involves: 129/Sv * C57BL/6)	immune system phenotype	J:137138
	increased T cell derived lymphoma incidence	J:137138
\Fbxw7^tm1Iaai/\Fbxw7^tm1Iaai \Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * CBA)	abnormal T cell differentiation	J:137138
	decreased double-negative T cell number	J:137138
	thymus hypoplasia	J:137138
\Fbxw7^tm1Iaai/\Fbxw7^tm1Iaai \Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	abnormal T cell differentiation	J:200006
\Fbxw7^tm1Kei/\Fbxw7^tm1Kei \Myc^tm2Fwa/\Myc^tm2Fwa \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:128523
\Fbxw7^tm1Kei/\Fbxw7^tm1Kei \Rbpj^tm1Hon/\Rbpj^tm1Hon \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	increased double-positive T cell number	J:128523
\Fbxw7^tm1Kei/\Fbxw7^tm1Kei \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6)	increased double-positive T cell number	J:128523
\Fbxw7^tm1Kei/\Fbxw7^tm1Kei \Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell activation	J:128523
	arrested T cell differentiation	J:128523
	decreased single-positive T cell number	J:128523
	enlarged thymus	J:128523
	increased double-positive T cell number	J:128523
	increased T cell apoptosis	J:128523
\Fbxw7^tm1Kei/\Fbxw7^tm1Kei \Trp53^tm1Tyj/\Trp53^tm1Tyj \Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	immune system phenotype	J:128523
	increased T cell derived lymphoma incidence	J:128523
\Fbxw7^tm2Iaai/\Fbxw7⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:200006
\Fbxw8^{tm1b(EUCOMM)Hmgu}/\Fbxw8⁺ (C57BL/6N-Fbxw8^{tm1b(EUCOMM)Hmgu}/Nju)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Fbxw9^{tm1a(EUCOMM)Wtsi}/\Fbxw9⁺ (C57BL/6N-Fbxw9^{tm1a(EUCOMM)Wtsi}/Bay)	absent spleen	J:211773
\Fbxw9^{tm1a(EUCOMM)Wtsi}/\Fbxw9^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Fbxw9^{tm1a(EUCOMM)Wtsi}/Bay)	absent lymph nodes	J:211773
\Fbxw9^{tm1b(EUCOMM)Wtsi}/\Fbxw9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Fbxw9^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Fbxw10^em1(IMPC)Tcp/\Fbxw10^em1(IMPC)Tcp (C57BL/6N-Fbxw10^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Fbxw16^{em1(IMPC)Ccpcz}/\Fbxw16⁺ (C57BL/6N-Fbxw16^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	small thymus	J:211773
\Fbxw18^{em1(IMPC)Ccpcz}/\Fbxw18⁺ (C57BL/6N-Fbxw18^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Fbxw20^{em1(IMPC)Ccpcz}/\Fbxw20^{em1(IMPC)Ccpcz} (C57BL/6N-Fbxw20^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fbxw25^{em1(IMPC)Ccpcz}/\Fbxw25^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fbxw25^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Fbxw26^{tm1b(KOMP)Wtsi}/\Fbxw26^{tm1b(KOMP)Wtsi} (C57BL/6N-Fbxw26^{tm1b(KOMP)Wtsi}/Wtsi)	decreased memory-marker NK cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased NK cell number	J:211773
\Fcamr^tm1Shib/\Fcamr^tm1Shib (involves: 129P2/OlaHsd * C57BL/6)	abnormal follicular dendritic cell antigen presentation	J:150824
	abnormal marginal zone B cell physiology	J:150824
	abnormal memory B cell differentiation	J:150824
	abnormal somatic hypermutation frequency	J:150824
	abnormal spleen germinal center morphology	J:150824
	increased spleen germinal center number	J:150824
	increased spleen germinal center size	J:150824
\Fcamr^tm2Shib/\Fcamr^tm2Shib (BALB/c-Fcamr^tm2Shib)	abnormal follicular dendritic cell antigen presentation	J:150824
	abnormal marginal zone B cell physiology	J:150824
	increased spleen germinal center number	J:150824
	increased spleen germinal center size	J:150824
\Fcer1a^tm1Ftl/\Fcer1a^tm1Ftl (CBy.129S2-Fcer1a^tm1Ftl)	abnormal humoral immune response	J:120702
	abnormal mast cell physiology	J:120702
	decreased circulating interleukin-4 level	J:120702
	decreased eosinophil cell number	J:120702
\Fcer1a^tm1Knt/\Fcer1a^tm1Knt (either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))	abnormal mast cell physiology	J:39250
	decreased susceptibility to type I hypersensitivity reaction	J:113572, J:39250
\Fcer1a^tm1Knt/\Fcer1a^tm1Knt (involves: 129 * BALB/c)	abnormal mast cell physiology	J:78659
\Fcer1a^tm1Knt/\Fcer1a^tm1Knt (involves: 129 * BALB/c)	increased susceptibility to type I hypersensitivity reaction	J:78659
\Fcer1a^tm1Knt/\Fcer1a^tm1Knt \Fcer2a^tm1Max/\Fcer2a^tm1Max (B6.Cg-Fcer1a^tm1Knt Fcer2a^tm1Max)	abnormal mast cell physiology	J:144620
\Fcer1a^tm1Knt/\Fcer1a^tm1Knt \Fcer2a^tm1Max/\Fcer2a^tm1Max \Fcgr1^tm1Jsv/\Fcgr1^tm1Jsv \Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Fcgr3^tm1Jsv/\Fcgr3^tm1Jsv (B6.Cg-Fcgr2b^tm1Ttk Fcgr3^tm1Jsv Fcer1a^tm1Knt Fcgr1^tm1Jsv Fcer2a^tm1Max)	abnormal macrophage physiology	J:144620
	abnormal mast cell physiology	J:144620
	increased susceptibility to type I hypersensitivity reaction	J:144620
\Fcer1a^tm1Knt/\Fcer1a^tm1Knt \Tg(FCER1A)1Bhk/? (B6.129-Fcer1a^tm1Knt Tg(FCER1A)1Bhk)	abnormal macrophage physiology	J:144620
	increased tumor necrosis factor secretion	J:144620
\Fcer1a^tm1Knt/\Fcer1a^tm1Knt \Tg(SV40/HTLV-FCER1A)1Bhk/0 (either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * DBA/2))	abnormal type I hypersensitivity reaction	J:113572
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell antigen presentation	J:83995
	abnormal immune cell physiology	J:39248
	abnormal immunoglobulin level	J:78659
	abnormal mast cell physiology	J:39248
	abnormal NK cell physiology	J:39248
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:126520
	decreased susceptibility to type I hypersensitivity reaction	J:78659, J:39248
	immune system phenotype	J:28282
	impaired macrophage phagocytosis	J:39248
	increased IgE level	J:78659
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav (B6.129P2-Fcer1g^tm1Rav)	decreased interleukin-1 beta secretion	J:160680
	decreased interleukin-6 secretion	J:160680
	decreased interleukin-10 secretion	J:160680
	decreased interleukin-12b secretion	J:160680
	decreased interleukin-23 secretion	J:160680
	decreased tumor necrosis factor secretion	J:160680
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav (involves: 129P2/OlaHsd)	increased susceptibility to parasitic infection	J:163761
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav \Del(7Tyrobp-Hcst)1Ttk/\Del(7Tyrobp-Hcst)1Ttk (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:147155
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav \Hexb^tm1Rlp/\Hexb^tm1Rlp (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	increased immunoglobulin level	J:87617
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav \Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:122114
	decreased T cell proliferation	J:122114
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav \Tyrobp^tm1.1Viv/\Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * C57BL/6)	decreased interferon-gamma secretion	J:100668
	decreased uterine NK cell number	J:100668
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav \Tyrobp^tm1Lll/\Tyrobp^tm1Lll (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:89583
\Fcer1g^tm1Rav/\Fcer1g^tm1Rav \Tyrobp^tm1Lll/\Tyrobp^tm1Lll (involves: 129P2/OlaHsd)	abnormal osteoclast physiology	J:147155
\Fcer1g^tm1Tks/\Fcer1g^tm1Tks (involves: C57BL/6)	abnormal antigen presentation	J:112160
	abnormal CD4-positive, alpha-beta T cell physiology	J:112160
	abnormal chemokine secretion	J:141143
	abnormal cytokine level	J:258645
	abnormal macrophage physiology	J:141143
	abnormal NK cell physiology	J:111365
	abnormal NK T cell physiology	J:111365
	decreased IgG1 level	J:112160
	decreased IgG2a level	J:112160
	decreased IgG2b level	J:112160
	decreased IgG3 level	J:112160
	decreased IgG level	J:112160
	decreased inflammatory response	J:50023
	decreased interferon-gamma secretion	J:111365, J:112160
	decreased interleukin-2 secretion	J:112160
	decreased susceptibility to type IV hypersensitivity reaction	J:112160
	decreased T cell proliferation	J:112160
	impaired macrophage phagocytosis	J:50023
	impaired natural killer cell mediated cytotoxicity	J:111365
\Fcer1g^tm1Tks/\Fcer1g^tm1Tks (C57BL/6-Fcer1g^tm1Tks)	decreased susceptibility to autoimmune hemolytic anemia	J:145432
\Fcer1g^tm1Tks/\Fcer1g^tm1Tks (involves: C57BL/6J)	abnormal chemokine secretion	J:203159
	abnormal interferon-gamma secretion	J:203159
	abnormal interleukin-17 secretion	J:203159
	decreased dendritic cell number	J:203159
	decreased tumor necrosis factor secretion	J:203159
\Fcer2a^Hie/\Fcer2a^Hie (NZB)	increased IgE level	J:93999
\Fcer2a^tm1Kik/\Fcer2a^tm1Kik (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:129296
	abnormal humoral immune response	J:19437
	abnormal immune system physiology	J:129296
	increased immunoglobulin level	J:129296
\Fcer2a^tm1Max/\Fcer2a^tm1Max (involves: C57BL/6)	abnormal macrophage chemotaxis	J:57738
	decreased IgG1 level	J:18952
	decreased IgG2b level	J:18952
	impaired eosinophil recruitment	J:57738
	increased IgE level	J:57738, J:18952, J:107857
	increased IgM level	J:18952
	increased susceptibility to type I hypersensitivity reaction	J:57738
\Fcer2a^tm1Max/\Fcer2a^tm1Max \Ighg1^tm1.1Pyu/\Ighg1⁺ (involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)	decreased IgG1 level	J:198154
	decreased IgG2c level	J:198154
	decreased IgG level	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
\Fcer2a^tm1Max/\Fcer2a^tm1Max \Ighg1^tm1.1Pyu/\Ighg1^tm1.1Pyu (involves: 129 * BALB/cJ * C57BL/6 * C57BL/6J)	abnormal immunoglobulin level	J:198154
	decreased IgG2c level	J:198154
	decreased IgG level	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
\Fcer2a^tm1Putt/\Fcer2a⁺ (involves: 129S/SvEv * C57BL/6)	increased IgE level	J:69547
\Fcer2a^tm1Putt/\Fcer2a^tm1Putt (involves: 129S/SvEv * C57BL/6)	abnormal B cell proliferation	J:69547
\Fcgr1^tm1Hoga/\Fcgr1^tm1Hoga (involves: 129S1/Sv * 129X1/SvJ)	abnormal cell-mediated immunity	J:86281
	abnormal macrophage antigen presentation	J:86281
	decreased inflammatory response	J:86281
	impaired macrophage phagocytosis	J:86281
	increased IgG level	J:86281
\Fcgr1^tm1Jgjw/\Fcgr1^tm1Jgjw (involves: 129 * C57BL/6)	abnormal dendritic cell antigen presentation	J:112436
\Fcgr1^tm1Jgjw/\Fcgr1^tm1Jgjw (involves: 129 * C57BL/6)	abnormal dendritic cell differentiation	J:112436
\Fcgr1^tm1Jsv/\Fcgr1^tm1Jsv (involves: 129P2/OlaHsd * BALB/c)	abnormal dendritic cell antigen presentation	J:83995
	abnormal macrophage physiology	J:83995
	abnormal type I hypersensitivity reaction	J:83995
	decreased susceptibility to autoimmune hemolytic anemia	J:83995
	decreased susceptibility to induced arthritis	J:83995
	increased susceptibility to bacterial infection	J:83995
\Fcgr1^tm1Jsv/\Fcgr1^tm1Jsv \Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Fcgr3^tm1Jsv/\Fcgr3^tm1Jsv (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)	impaired macrophage phagocytosis	J:83995
\Fcgr2b^tm1.2Jsv/\Fcgr2b⁺ X/\Yaa (involves: C57BL/6 * FVB/N * SB/Le)	enlarged spleen	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased monocyte cell number	J:179175
	increased susceptibility to systemic lupus erythematosus	J:179175
\Fcgr2b^tm1.2Jsv/\Fcgr2b^tm1.2Jsv \Sle16^C57BL/6/\Sle16^C57BL/6 (involves: C57BL/6 * FVB/N)	abnormal adaptive immunity	J:179175
	immune system phenotype	J:179175
	increased immunoglobulin level	J:179175
	increased susceptibility to induced arthritis	J:179175
	kidney inflammation	J:179175
\Fcgr2b^tm1Kgcs/\Fcgr2b⁺ (involves: C57BL/6)	decreased B cell apoptosis	J:190890
	increased anti-chromatin antibody level	J:190890
	increased anti-double stranded DNA antibody level	J:190890
	increased germinal center B cell number	J:190890
	increased IgG1 level	J:190890
	increased IgG3 level	J:190890
	increased IgM level	J:190890
	increased susceptibility to induced arthritis	J:190890
\Fcgr2b^tm1Ttk/\Fcgr2b⁺ X/\Yaa (involves: 129S4/SvJae * C57BL/6 * SB/Le)	increased monocyte cell number	J:129409
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1.2Jsv \Sle21^129P2/Ola/\Sle21^C57BL/6 (involves: 129P2/Ola * 129S4/SvJae * C57BL/6 * FVB/N)	enlarged spleen	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased anti-histone antibody level	J:179175
	increased anti-single stranded DNA antibody level	J:179175
	increased spleen weight	J:179175
	increased susceptibility to systemic lupus erythematosus	J:179175
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk (involves: 129S4/SvJae)	abnormal mast cell physiology	J:31133
	increased IgA level	J:31133
	increased IgG1 level	J:31133
	increased IgG2a level	J:31133
	increased IgG2b level	J:31133
	increased IgG3 level	J:31133
	increased IgG level	J:31133
	increased IgM level	J:31133
	increased susceptibility to type I hypersensitivity reaction	J:31133
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk (C.129S4-Fcgr2b^tm1Ttk)	decreased susceptibility to parasitic infection	J:120905
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk (B6.129S4-Fcgr2b^tm1Ttk)	abnormal hypersensitivity reaction	J:64152
	enlarged lymph nodes	J:64152
	enlarged spleen	J:64152
	glomerulonephritis	J:64152
	increased immunoglobulin level	J:64152
	increased inflammatory response	J:64152
	kidney inflammation	J:64152
	liver inflammation	J:64152
	lung inflammation	J:64152
	pancreas inflammation	J:64152
	salivary gland inflammation	J:64152
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk (Not Specified)	increased susceptibility to induced arthritis	J:106191
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Il17a^tm1Yiw/\Il17a⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	glomerulonephritis	J:191090
	increased plasma cell number	J:191090
	increased spleen germinal center number	J:191090
	kidney inflammation	J:191090
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Il17a^tm1Yiw/\Il17a^tm1Yiw (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased susceptibility to systemic lupus erythematosus	J:191090
	increased anti-double stranded DNA antibody level	J:191090
	increased anti-nuclear antigen antibody level	J:191090
	increased double-negative T cell number	J:191090
	increased plasma cell number	J:191090
	increased spleen germinal center number	J:191090
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Pdcd1^tm1Hon/\Pdcd1^tm1Hon (involves: 129S2/SvPas * 129S4/SvJae * BALB/c)	abnormal cytokine level	J:207275
	abnormal urine cytokine level	J:207275
	increased autoantibody level	J:207275
	urinary bladder inflammation	J:207275
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Sle21^129P2/Ola/\Sle21^129P2/Ola (B6.129S4-Fcgr2b^tm1Ttk)	abnormal adaptive immunity	J:179175
	enlarged spleen	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased anti-histone antibody level	J:179175
	increased anti-single stranded DNA antibody level	J:179175
	increased autoantibody level	J:179175
	increased IgG2a level	J:179175
	increased immunoglobulin level	J:179175
	increased spleen weight	J:179175
	increased susceptibility to induced arthritis	J:179175
	increased susceptibility to systemic lupus erythematosus	J:179175
	kidney inflammation	J:179175
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to autoimmune diabetes	J:122114
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Tlr7^tm1Flv/Y X/\Yaa (B6.Cg-Fcgr2b^tm1Ttk Tlr7^tm1Flv Yaa)	abnormal splenocyte physiology	J:127600
	autoimmune response	J:127600
	enlarged spleen	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased susceptibility to systemic lupus erythematosus	J:127600
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Traf3ip2^tm1Sbn/\Traf3ip2⁺ (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal neutrophil morphology	J:191090
	abnormal T cell morphology	J:191090
	increased anti-double stranded DNA antibody level	J:191090
	increased anti-nuclear antigen antibody level	J:191090
	increased autoantibody level	J:191090
	increased double-negative T cell number	J:191090
	increased IgG level	J:191090
	increased memory T cell number	J:191090
	increased monocyte cell number	J:191090
	increased myeloid dendritic cell number	J:191090
	increased neutrophil cell number	J:191090
	increased plasma cell number	J:191090
	increased plasmacytoid dendritic cell number	J:191090
	increased single-positive T cell number	J:191090
	increased spleen germinal center number	J:191090
	increased susceptibility to systemic lupus erythematosus	J:191090
	kidney inflammation	J:191090
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Traf3ip2^tm1Sbn/\Traf3ip2^tm1Sbn (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal T cell morphology	J:191090
	decreased susceptibility to systemic lupus erythematosus	J:191090
	increased anti-double stranded DNA antibody level	J:191090
	increased anti-nuclear antigen antibody level	J:191090
	increased autoantibody level	J:191090
	increased double-negative T cell number	J:191090
	increased IgG level	J:191090
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Traf3ip2^tm2Sbn/\Traf3ip2⁺ (involves: 129S4/SvJae * BALB/c * C57BL/6)	enlarged spleen	J:191090
	increased germinal center B cell number	J:191090
	increased plasma cell number	J:191090
	increased spleen weight	J:191090
	spleen hyperplasia	J:191090
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk \Traf3ip2^tm2Sbn/\Traf3ip2^tm2Sbn \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S4/SvJae * BALB/c * C57BL/6)	glomerulonephritis	J:191090
	increased germinal center B cell number	J:191090
	increased plasma cell number	J:191090
\Fcgr2b^tm1Ttk/\Fcgr2b^tm1Ttk X/\Yaa (B6.Cg-Fcgr2b^tm1Ttk Yaa)	autoimmune response	J:127600
	enlarged spleen	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased susceptibility to systemic lupus erythematosus	J:127600
\Fcgr3^tm1Jsv/\Fcgr3^tm1Jsv (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell antigen presentation	J:83995
	abnormal type I hypersensitivity reaction	J:83995
	decreased mast cell degranulation	J:35057
	decreased susceptibility to autoimmune hemolytic anemia	J:83995
	decreased susceptibility to type II hypersensitivity reaction	J:35057
	impaired macrophage phagocytosis	J:35057
	impaired natural killer cell mediated cytotoxicity	J:35057
\Fcgr3^tm1Jsv/\Fcgr3^tm1Jsv (B6.129P2-Fcgr3^tm1Jsv/J)	abnormal leukocyte cell number	J:78297
	abnormal neutrophil physiology	J:78297
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:126520
	decreased susceptibility to induced arthritis	J:106191
	impaired neutrophil recruitment	J:78297
	increased neutrophil cell number	J:78297
\Fcgr3^tm1Jsv/\Fcgr3^tm1Jsv \Sle21^129P2/Ola/\Sle21^129P2/Ola (B6.129P2-Fcgr3^tm1Jsv)	enlarged spleen	J:179175
	increased activated T cell number	J:179175
	increased anti-chromatin antibody level	J:179175
	increased anti-double stranded DNA antibody level	J:179175
	increased anti-histone antibody level	J:179175
	increased anti-single stranded DNA antibody level	J:179175
	increased B cell number	J:179175
	increased spleen weight	J:179175
\Fcgr3^tm1Ttk/\Fcgr3^tm1Ttk (involves: 129X1/SvJ)	decreased susceptibility to type I hypersensitivity reaction	J:107371
\Fcgr4^tm1.1Rav/\Fcgr4^tm1.1Rav (involves: C57BL/6)	decreased susceptibility to induced arthritis	J:167375
\Fcgr4^tm1.1Rav/\Fcgr4^tm1.1Rav (involves: C57BL/6)	immune system phenotype	J:167375
\Fcgr4^tm1Rav/\Fcgr4^tm1Rav \Tg(Ctsk-cre)1Rda/0 (involves: C57BL/6)	autoimmune arthritis	J:197378
	decreased osteoclast cell number	J:197378
\Fcgrt^tm1Dcr/\Fcgrt^tm1Dcr (either: 129 or (involves: 129 * C57BL/6))	decreased IgG level	J:94189
\Fcgrt^tm1Dcr/\Fcgrt^tm1Dcr (B6.129X1-Fcgrt^tm1Dcr/DcrJ)	decreased IgG level	J:110885
\Fcgrt^tm1Dcr/\Fcgrt^tm1Dcr \Tg(CAG-FCGRT)276Dcr/0 (involves: 129X1/SvJ * C57BL/6 * C57BL/6J)	immune system phenotype	J:110885
\Fcgrt^tm1Esw/\Fcgrt^tm1Esw \Tg(Tek-cre)1Ywa/0 (B6.Cg-Tg(Tek-cre)1Ywa Fcgrt^tm1Esw)	abnormal humoral immune response	J:146640
	decreased IgG1 level	J:146640
\Fcmr^tm1.2Khl/\Fcmr^tm1.2Khl (involves: C57BL/6)	abnormal granulocyte physiology	J:194323
	decreased B cell number	J:174871
	immune system phenotype	J:174871
	increased T cell apoptosis	J:174871
\Fcmr^tm1Mak/\Fcmr^tm1Mak (B6.129S2-Fcmr^tm1Mak)	abnormal cytokine secretion	J:194323
	abnormal granulocyte physiology	J:194323
	decreased interleukin-6 secretion	J:194323
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:194323
	decreased tumor necrosis factor secretion	J:194323
	impaired granulocyte bactericidal activity	J:194323
	increased susceptibility to bacterial infection	J:194323
	increased susceptibility to bacterial infection induced morbidity/mortality	J:194323
\Fcmr^tm1Ohno/\Fcmr^tm1Ohno (B6.129-Fcmr^tm1Ohno)	abnormal B cell morphology	J:190117
	abnormal immunoglobulin level	J:190117
	abnormal response to infection	J:190117
	decreased IgG1 level	J:190117
	decreased IgM level	J:190117
	decreased marginal zone B cell number	J:190117
	increased anti-chromatin antibody level	J:190117
	increased anti-double stranded DNA antibody level	J:190117
	increased B-1 B cell number	J:190117
	increased IgG3 level	J:190117
	increased IgM level	J:190117
	increased T cell number	J:190117
\Fcna^tm1Tefu/\Fcna^tm1Tefu (involves: 129S4/SvJae)	immune system phenotype	J:177350
\Fcna^tm1Tefu/\Fcna^tm1Tefu (B6.129-Fcna^tm1Tefu)	impaired lectin complement pathway	J:190858
	increased susceptibility to bacterial infection	J:190858
	increased susceptibility to bacterial infection induced morbidity/mortality	J:190858
\Fcna^tm1Tefu/\Fcna^tm1Tefu \Fcnb^tm1Tefu/\Fcnb^tm1Tefu (B6.129-Fcna^tm1Tefu Fcnb^tm1Yend)	impaired lectin complement pathway	J:190858
	increased susceptibility to bacterial infection	J:190858
	increased susceptibility to bacterial infection induced morbidity/mortality	J:190858
\Fcna^tm1Tefu/\Fcna^tm1Tefu \Mbl1^tm1Kata/\Mbl1^tm1Kata \Mbl2^tm1Kata/\Mbl2^tm1Kata (involves: 129S4/SvJae)	immune system phenotype	J:177350
\Fcnb^tm1Tefu/\Fcnb^tm1Tefu (B6.129-Fcnb^tm1Yend)	increased susceptibility to bacterial infection	J:190858
\Fcnb^tm1Tefu/\Fcnb^tm1Tefu (B6.129-Fcnb^tm1Yend)	increased susceptibility to bacterial infection induced morbidity/mortality	J:190858
\Fcrl2^tm1Lex/\Fcrl2^tm1Lex (B6;129S5-Fcrl2^tm1Lex/Mmucd)	decreased CD8-positive, alpha-beta T cell number	J:171883
\Fcrla^tm1.1Cln/\Fcrla^tm1.1Cln (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:163261
	immune system phenotype	J:163261
	increased IgG1 level	J:163261
\Fcrla^{tm1b(KOMP)Wtsi}/\Fcrla^{tm1b(KOMP)Wtsi} (C57BL/6N-Fcrla^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Fcrlb^tm1Pdb/\Fcrlb^tm1Pdb (B6.129-Fcrlb^tm1Pdb)	increased anti-nuclear antigen antibody level	J:165408
\Fcrlb^tm1Pdb/\Fcrlb^tm1Pdb (B6.129-Fcrlb^tm1Pdb)	increased IgG1 level	J:165408
\Fdx2^{em1(IMPC)Rbrc}/\Fdx2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Fdx2^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased large unstained cell number	J:211773
	increased spleen weight	J:211773
\Fdxr^tm1Xch/\Fdxr⁺ (B6.Cg-Fdxr^tm1Xch)	chronic liver inflammation	J:244082
\Fdxr^tm1Xch/\Fdxr⁺ (B6.Cg-Fdxr^tm1Xch)	increased T cell derived lymphoma incidence	J:244082
\Fech^m1Pas/\Fech^m1Pas (involves: 129/Sv * BALB/c)	increased spleen weight	J:2021
\Fech^m1Pas/\Fech^{tm1.1(FECH)Emi} (involves: 129 BALB/cJ * C57BL/6J)	decreased eosinophil cell number	J:239515
	enlarged spleen	J:239515
\Fem1a^tm1Seno/\Fem1a^tm1Seno (C57BL/6-Fem1a^tm1Seno)	increased susceptibility to colitis induced morbidity/mortality	J:228893
\Fem1a^tm1Seno/\Fem1a^tm1Seno (C57BL/6-Fem1a^tm1Seno)	increased susceptibility to induced colitis	J:228893
\Fen1^tm1Bhsh/\Fen1^tm1Bhsh (involves: 129S1/Sv)	pale spleen	J:121378
\Fen1^tm1Rak/\Fen1⁺ (involves: 129/Sv * C57BL/6 * SJL/J)	thymus atrophy	J:77962
\Fen1^tm2.1Bhsh/\Fen1^tm2.1Bhsh (involves: 129S1/Sv)	increased thymus tumor incidence	J:218627
\Fen1^tm2Klng/\Fen1^tm2Klng (involves: 129X1/SvJ * C57BL/6)	abnormal spleen B cell follicle morphology	J:138901
	abnormal spleen marginal zone morphology	J:138901
	enlarged spleen	J:138901
	immune system phenotype	J:138901
	increased spleen B cell follicle number	J:138901
	increased spleen B cell follicle size	J:138901
	lymphoid hyperplasia	J:138901
\Fen1^tm3.1Bhsh/\Fen1⁺ (Not Specified)	chronic inflammation	J:231218
	enlarged spleen	J:231218
	glomerulonephritis	J:231218
	increased anti-double stranded DNA antibody level	J:231218
	increased anti-nuclear antigen antibody level	J:231218
	increased plasma cell number	J:231218
	increased susceptibility to autoimmune disorder	J:231218
	interstitial pneumonia	J:231218
	lung inflammation	J:231218
	lymphoid hyperplasia	J:231218
\Fen1^tm3.1Bhsh/\Fen1^tm3.1Bhsh (Not Specified)	chronic inflammation	J:231218
	enlarged spleen	J:231218
	glomerulonephritis	J:231218
	increased anti-double stranded DNA antibody level	J:231218
	increased anti-nuclear antigen antibody level	J:231218
	increased plasma cell number	J:231218
	increased susceptibility to autoimmune disorder	J:231218
	interstitial pneumonia	J:231218
	lung inflammation	J:231218
	lymphoid hyperplasia	J:231218
\Fer^em1(IMPC)Tcp/\Fer⁺ (C57BL/6N-Fer^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Fer^em1(IMPC)Tcp/\Fer⁺ (C57BL/6N-Fer^em1(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
\Fer^em1(IMPC)Tcp/\Fer^em1(IMPC)Tcp (C57BL/6N-Fer^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
\Fermt1^tm1Ref/\Fermt1^tm1Ref (involves: 129S1/Sv * 129X1/SvJ)	ileum inflammation	J:142913
	large intestinal inflammation	J:142913
\Fermt3^tm1.1Efp/\Fermt3^tm1.1Efp (involves: C57BL/6)	increased leukocyte cell number	J:227094
\Fermt3^tm2.1Ref/\Fermt3^tm2.1Ref \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal effector T cell morphology	J:203436
	abnormal T cell physiology	J:203436
\Fes^tm1Mcs/\Fes^tm1Mcs (involves: 129X1/SvJ)	abnormal leukocyte cell number	J:64748
	abnormal macrophage physiology	J:64748
	conjunctivitis	J:64748
	decreased B cell number	J:64748
	increased granulocyte number	J:64748
	increased monocyte cell number	J:64748
	increased neutrophil cell number	J:64748
	increased susceptibility to bacterial infection	J:64748
	thymus hypoplasia	J:64748
\Fes^tm2Pag/\Fes^tm2Pag (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal myelopoiesis	J:98590
	decreased B cell number	J:98590
	increased pre-B cell number	J:98590
	increased pro-B cell number	J:98590
	increased susceptibility to endotoxin shock	J:98590
\Fezf2^{em1(IMPC)Hmgu}/\Fezf2^{em1(IMPC)Hmgu} (C57BL/6NCrl-Fezf2^{em1(IMPC)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Ffar2^tm1Dgen/\Ffar2^tm1Dgen (involves: C57BL/6)	abnormal granulocyte physiology	J:153951
	abnormal neutrophil physiology	J:153951
	impaired neutrophil chemotaxis	J:153951
	impaired neutrophil phagocytosis	J:153951
	increased susceptibility to induced arthritis	J:153951
	increased susceptibility to induced colitis	J:153951
	increased T cell number	J:153951
	lung inflammation	J:153951
\Ffar2^tm2Lex/\Ffar2^tm2Lex (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine level	J:157383
	abnormal inflammatory response	J:157383
	abnormal neutrophil morphology	J:157383
	decreased circulating tumor necrosis factor level	J:157383
	decreased susceptibility to induced colitis	J:157383
	decreased tumor necrosis factor secretion	J:157383
	impaired neutrophil chemotaxis	J:157383
	increased circulating tumor necrosis factor level	J:157383
	large intestinal inflammation	J:157383
	sepsis	J:157383
\Fga^tm1Jld/\Fga^tm1Jld (involves: 129P2/OlaHsd * CF-1)	decreased circulating fibrinogen level	J:28436
\Fga^tm1Jld/\Fga^tm1Jld (B6.129P2-Fga^tm1Jld)	decreased circulating fibrinogen level	J:28436
\Fga^tm1Jld/\Fga^tm1Jld \Plg^tm1Jld/\Plg^tm1Jld (involves: 129P2/OlaHsd * Black Swiss * CF-1)	immune system phenotype	J:36591
\Fgd1^em1(IMPC)Tcp/\Fgd1⁺ (C57BL/6NCrl-Fgd1^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
\Fgd3^{em1(IMPC)Ccpcz}/\Fgd3^{em1(IMPC)Ccpcz} (C57BL/6N-Fgd3^{em1(IMPC)Ccpcz}/Ccpcz)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Fgd5^em1(IMPC)Mbp/\Fgd5⁺ (C57BL/6NCrl-Fgd5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Fgf3^{tm4b(EUCOMM)Hmgu}/\Fgf3⁺ (C57BL/6N-Fgf3^{tm4b(EUCOMM)Hmgu}/Bay)	enlarged lymph nodes	J:211773
\Fgf7^tm1Efu/\Fgf7^tm1Efu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune system physiology	J:129368
	abnormal response to transplant	J:129368
	immune system phenotype	J:129368
	spleen hypoplasia	J:129368
\Fgf8^tm1.3Mrt/\Fgf8^tm1.4Mrt \Tg(Tbx1-cre)1Joe/0 (involves: 129P2/OlaHsd)	abnormal thymus morphology	J:88814
	small thymus	J:88814
\Fgf8^tm1.4Mrt/\Fgf8⁺ \Tbx1^tm1Bld/\Tbx1⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * ICR)	thymus hypoplasia	J:78686
\Fgf8^tm1Mrc/\Fgf8^tm1Moon \Hoxa3^tm1(cre)Moon/\Hoxa3⁺ (involves: 129/Sv * C57BL/6)	ectopic thymus	J:87304
	thymus hypoplasia	J:87304
\Fgf8^tm1Mrc/\Fgf8^tm2Mrc \Hoxa3^tm1(cre)Moon/\Hoxa3⁺ (involves: 129/Sv * C57BL/6)	ectopic thymus	J:87304
	thymus hypoplasia	J:87304
\Fgf10^{tm1b(EUCOMM)Wtsi}/\Fgf10⁺ (C57BL/6N-Fgf10^{tm1b(EUCOMM)Wtsi}/H)	decreased leukocyte cell number	J:211773
\Fgf10^tm1Ska/\Fgf10^tm1Ska (involves: C57BL/6 * CBA)	small thymus	J:114183
\Fgf14^{em1(IMPC)Ccpcz}/\Fgf14^{em1(IMPC)Ccpcz} (C57BL/6N-Fgf14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Fgf20^{em1(IMPC)Ccpcz}/\Fgf20^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fgf20^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fgf23^{em1(IMPC)Ccpcz}/\Fgf23⁺ (C57BL/6NCrl-Fgf23^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Fgf23^tm1Blan/\Fgf23^tm1Blan (involves: 129/Sv * C57BL/6)	small spleen	J:121006
\Fgf23^tm1Tyam/\Fgf23^tm1Tyam (involves: C57BL/6 * CBA)	decreased lymphocyte cell number	J:88172
	spleen hypoplasia	J:88172
	thymus atrophy	J:88172
\Fgfbp3^{tm1.1(KOMP)Wtsi}/\Fgfbp3^{tm1.1(KOMP)Wtsi} (C57BL/6N-Fgfbp3^{tm1.1(KOMP)Wtsi}/Ucd)	increased neutrophil cell number	J:211773
\Fgfr1^Hspy/\Fgfr1⁺ (C3HeB/FeJ-Hspy)	increased susceptibility to otitis media	J:95895
\Fgfr1^tm1Upir/\Fgfr1^tm1Upir \Fgfr2^tm1Dor/\Fgfr2^tm1Dor \Tg(KRT5-cre)5132Jlj/0 (involves: 129X1/SvJ * C57BL/6 * C57BL/6J * DBA/2J)	abnormal chemokine level	J:221184
	abnormal mast cell morphology	J:221184
	dermatitis	J:221184
	increased IgE level	J:158802
	increased IgG1 level	J:158802
	increased IgG2a level	J:158802
	increased mast cell number	J:221184
	skin inflammation	J:158802, J:221184
\Fgfr2^tm1Dor/\Fgfr2^tm1.1Dor \Twist2^tm1(cre)Dor/\Twist2⁺ (involves: 129X1/SvJ)	abnormal osteoclast differentiation	J:90391
\Fgfr2^tm1Dsn/\Fgfr2^tm1Dsn \Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	adipose tissue inflammation	J:119723
	increased gamma-delta T cell number	J:119723
	skin inflammation	J:119723
\Fgfr2^tm1Ewj/\Fgfr2⁺ \Tg(EIIa-cre)C5379Lmgd/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)	abnormal thymus morphology	J:101174
	bronchiolectasis	J:101174
	decreased osteoclast cell number	J:101174
\Fgfr2^tm3Dsn/\Fgfr2^tm3Dsn (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus development	J:67731
\Fgfr3^{tm1.1(FGFR3*)Ytc}/\Fgfr3⁺ (involves: 129)	decreased osteoclast cell number	J:287271
\Fgfr3^{tm1.1(FGFR3)Ytc}/\Fgfr3^{tm1.1(FGFR3)Ytc} (involves: 129)	decreased osteoclast cell number	J:287271
\Fgfr3^tm1Led/\Fgfr3^tm1Led (involves: 129S6/SvEvTac)	increased osteoclast cell number	J:32105
\Fgfr3^tm2Llm/\Fgfr3⁺ \Tg(CMV-cre)1Ipc/? (involves: 129S2/SvPas * C57BL/6 * SJL)	increased osteoclast cell number	J:183772
\Fgfr3^tm2Llm/\Fgfr3⁺ \Tg(Col2a1-cre)1Bhr/? (involves: 129S2/SvPas * C57BL/6 * SJL)	increased osteoclast cell number	J:183772
\Fgfr3^tm3.1Cxd/\Fgfr3^tm3.1Cxd (involves: 129S6/SvEvTac)	abnormal osteoclast physiology	J:69849
\Fgfr4^M1Btlr/\Fgfr4^M1Btlr (C57BL/6J-Fgfr4^M1Btlr)	decreased B-1a cell number	J:265097
\Fgg^tm1Lord/\Fgg⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating fibrinogen level	J:129828
\Fgg^tm1Lord/\Fgg^tm1Lord (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating fibrinogen level	J:129828
	increased leukocyte cell number	J:129828
\Fgg^tm2Jld/\Fgg^tm2Jld (involves: 129P2/OlaHsd * Black Swiss * C57BL/6)	abnormal neutrophil physiology	J:90908
	increased susceptibility to bacterial infection	J:90908
\Fgl1^{tm1b(EUCOMM)Hmgu}/\Fgl1^{tm1b(EUCOMM)Hmgu} (involves: BALB/cJ * C57BL/6N)	decreased B cell number	J:269578
	dermatitis	J:269578
	increased anti-double stranded DNA antibody level	J:269578
	increased central memory CD8 positive, alpha-beta T cell number	J:269578
\Fgl2^tm1Pam/\Fgl2⁺ (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:99453
\Fgl2^tm1Pam/\Fgl2^tm1Pam (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:99453
\Fgl2^tm1Pam/\Fgl2^tm1Pam (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:99453
\Fgl2^tm1Pam/\Fgl2^tm1Pam (B6.129X1-Fgl2^tm1Pam)	abnormal B cell physiology	J:130895
	abnormal dendritic cell physiology	J:130895
	abnormal Peyer's patch follicle morphology	J:130895
	abnormal regulatory T cell physiology	J:130895
	abnormal T cell physiology	J:130895
	decreased dendritic cell apoptosis	J:130895
	decreased Peyer's patch number	J:130895
	decreased susceptibility to Coronaviridae infection	J:99453
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:99453
	enlarged spleen	J:130895
	glomerulonephritis	J:130895
	increased dendritic cell number	J:130895
	increased IgA level	J:130895
	increased IgG level	J:130895
	increased IgM level	J:130895
	increased regulatory T cell number	J:130895
	increased T cell proliferation	J:130895
\Fgl2^tm1Pam/\Fgl2^tm1Pam (involves: 129X1/SvJ * C57BL/6J)	increased length of allograft survival	J:98997
\Fgl2^tm1Stsm/\Fgl2^tm1Stsm (C57BL/6-Fgl2^tm1Stsm)	immune system phenotype	J:88648
\Fgr^Mhdaali18/\Fgr⁺ (C3HeB/FeJ-Fgr^Mhdaali18)	dermatitis	J:112868
\Fgr^Mhdaali18/\Fgr⁺ (C3HeB/FeJ-Fgr^Mhdaali18)	increased inflammatory response	J:112868
\Fgr^Mhdaali18/\Fgr^Mhdaali18 (C3HeB/FeJ-Fgr^Mhdaali18)	autoimmune arthritis	J:112868
\Fgr^Mhdaali18/\Fgr^Mhdaali18 (C3HeB/FeJ-Fgr^Mhdaali18)	dermatitis	J:112868
\Fgr^tm1Hev/\Fgr^tm1Hev (involves: 129S7/SvEvBrd * C57BL/6)	abnormal interferon-gamma secretion	J:131738
\Fgr^tm1Hev/\Fgr^tm1Hev (B6.129S7-Fgr^tm1Hev)	abnormal inflammatory response	J:113463
\Fgr^tm1Hev/\Fgr^tm1Hev \Hck^tm1Hev/\Hck^tm1Hev (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal macrophage morphology	J:59037
	abnormal macrophage physiology	J:59037
	impaired macrophage phagocytosis	J:16994
	increased susceptibility to bacterial infection	J:16994
\Fgr^tm1Hev/\Fgr^tm1Hev \Hck^tm1Hev/\Hck^tm1Hev \Lyn^tm1Sor/\Lyn^tm1Sor (B6.Cg-Hck^tm1Hev Fgr^tm1Hev Lyn^tm1Sor)	abnormal inflammatory response	J:113463
	abnormal neutrophil physiology	J:113463
\Fhip1b^em1(IMPC)Tcp/\Fhip1b^em1(IMPC)Tcp (C57BL/6NCrl-Fhip1b^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Fhip2b^{em1(IMPC)Ccpcz}/\Fhip2b^{em1(IMPC)Ccpcz} (C57BL/6N-Fhip2b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fhip2b^em1Wwan/\Fhip2b^em1Wwan (involves: C57BL/6)	abnormal cytokine level	J:302658, J:285283
	enlarged spleen	J:285283
	increased leukocyte cell number	J:285283
	increased susceptibility to induced colitis	J:285283
	liver inflammation	J:302658
\Fhit^tm1Hbn/\Fhit⁺ (involves: 129X1/SvJ * C57BL/6)	decreased granulocyte number	J:71303
\Fhit^tm1Hbn/\Fhit⁺ (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to infection	J:71303
\Fhit^tm1Hbn/\Fhit^tm1Hbn (involves: 129X1/SvJ * C57BL/6)	decreased granulocyte number	J:71303
\Fhit^tm1Hbn/\Fhit^tm1Hbn (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to infection	J:71303
\Fibcd1^tm1Spte/\Fibcd1^tm1Spte (B6.129S1-Fibcd1^tm1Spte)	abnormal interferon secretion	J:340107
	abnormal tumor necrosis factor level	J:340107
	decreased cytokine level	J:340107
	decreased lymphocyte cell number	J:340107
	decreased susceptibility to fungal infection	J:340107
	decreased susceptibility to infection induced morbidity/mortality	J:340107
	increased cytokine level	J:340107
\Fig4^plt1/\Fig4^plt1 (involves: 129P2/OlaHsd * C3H * C57BL/6 * CAST/Ei * SJL)	spleen hypoplasia	J:122737
\Fign^fi/\Fign^fi (mixed)	conjunctivitis	J:13035
\Fign^fi/\Fign^fi (mixed)	eye inflammation	J:13035
\Fis1^tm1.1Itl/\Fis1^tm1.1Itl \Tg(Ckmm-cre)5Khn/0 (involves: C57BL/6NTac * FVB)	increased circulating interferon-beta level	J:290485
	increased circulating interleukin-6 level	J:290485
	increased circulating interleukin-12b level	J:290485
	increased circulating interleukin-13 level	J:290485
\Fitm2^tm1.1Dls/\Fitm2^tm1.1Dls \Tg(Fabp4-cre)1Rev/? (involves: 129S6/SvEvTac * C57BL/6J)	increased circulating tumor necrosis factor level	J:212437
\Fkbp4^em1(IMPC)Mbp/\Fkbp4^em1(IMPC)Mbp (C57BL/6N-Fkbp4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Fkbp5^{tm1b(KOMP)Wtsi}/\Fkbp5^{tm1b(KOMP)Wtsi} (C57BL/6N-Fkbp5^{tm1b(KOMP)Wtsi}/MbpMmucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Fkbp11^em1(IMPC)Mbp/\Fkbp11^em1(IMPC)Mbp (C57BL/6N-Fkbp11^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Fkbp11^{Gt(OST298786)Lex}/\Fkbp11^{Gt(OST298786)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	increased immunoglobulin level	J:103485
	increased inflammatory response	J:103485
\Fkrp^tm1Scbr/\Fkrp^tm1Scbr \Sox1^tm1(cre)Take/\Sox1⁺ (involves: C57BL/6NCrlj * CBA/JNCrlj)	myositis	J:207119
\Fkrp^tm1Scbr/\Fkrp^tm1Scbr \Sox1^tm1(cre)Take/\Sox1⁺ \Tg(CAG-LARGE)126Fmu/0 (involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj)	myositis	J:207119
\Flcn^tm1Baba/\Flcn^tm1.1Lss \Tg(CAG-cre/Esr1)1Lbe/0 (involves: 129S1/Sv 129X1/SvJ)	arrested B cell differentiation	J:189078
	decreased B cell number	J:189078
\Flg^ft/\Flg^ft (involves: C57BL/6)	skin inflammation	J:151110
\Flg^ft/\Flg^ft (B6.Cg-Flg^ft)	immune system phenotype	J:202453, J:151110
	increased IgE level	J:202453, J:151110
	increased IgG1 level	J:151110
	increased IgG2a level	J:151110
	increased IgG level	J:151110
	increased interferon-gamma secretion	J:151110
	increased interleukin-4 secretion	J:151110
	increased interleukin-5 secretion	J:151110
	increased interleukin-10 secretion	J:151110
	increased interleukin-13 secretion	J:151110
	increased interleukin-17 secretion	J:151110
	increased splenocyte proliferation	J:151110
\Flg^ft/\Flg^ft (Not Specified)	dermatitis	J:198332
\Flg^ft/\Flg^ft (STOCK a/a Tmem79^ma Flg^ft/J)	abnormal cytokine level	J:204304
\Flg^ft/\Flg^ft (STOCK a/a Tmem79^ma Flg^ft/J)	dermatitis	J:204304
\Flg^ft/\Flg^ft \Tmem79^ma/\Tmem79^ma (involves: CBA/CaGr)	blepharitis	J:202453
	increased IgE level	J:202453
	skin inflammation	J:202453
\Flg^tm1Amag/\Flg^tm1Amag (involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac)	abnormal humoral immune response	J:198332
	dermatitis	J:198332
	increased IgE level	J:198332
	increased IgG1 level	J:198332
	increased inflammatory response	J:229771
	increased susceptibility to type IV hypersensitivity reaction	J:198332
\Flg^tm1Amag/\Flg^tm1Amag \Tg(CD207-Dta)312Dhka/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6NTac * FVB)	decreased inflammatory response	J:229771
\Fli1^tm1.1Dkw/\Fli1⁺ (B6.129S6-Fli1^tm1.1Dkw)	decreased B cell number	J:137876
\Fli1^tm1.1Dkw/\Fli1^tm1.1Dkw (B6.129S6-Fli1^tm1.1Dkw)	abnormal B cell differentiation	J:137876
	abnormal class switch recombination	J:137876
	abnormal humoral immune response	J:137876
	abnormal splenic cell ratio	J:137876
	decreased B cell number	J:137876
	decreased B cell proliferation	J:137876
	decreased follicular B cell number	J:137876
	decreased IgG1 level	J:137876
	decreased IgG3 level	J:137876
	increased marginal zone B cell number	J:137876
	increased transitional stage B cell number	J:137876
	spleen hyperplasia	J:137876
\Fli1^tm1Ber/\Fli1^tm1Ber (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1))	decreased thymocyte number	J:33052
\Fli1^tm1Ber/\Fli1^tm1Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	enlarged spleen	J:33052
\Fli1^tm1Morl/\Fli1^tm1Morl \Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * CBA)	abnormal leukocyte morphology	J:167426
	abnormal thrombopoiesis	J:167426
	decreased granulocyte number	J:167426
	increased monocyte cell number	J:167426
	increased NK cell number	J:167426
\Flicr^em1Doi/\Flicr^em1Doi (NOD/ShiLtDoi-Flicr^em1Doi)	decreased susceptibility to autoimmune diabetes	J:241346
\Flicr^em1Doi/\Flicr^em1Doi (NOD/ShiLtDoi-Flicr^em1Doi)	insulitis	J:241346
\Flna^tm1.2Caw/\Flna⁺ (involves: 129S4/SvJae * C57BL/6)	increased leukocyte cell number	J:118252
\Flnb^{tm1b(KOMP)Wtsi}/\Flnb⁺ (C57BL/6N-Flnb^{tm1b(KOMP)Wtsi}/H)	decreased neutrophil cell number	J:211773
\Flot1^tm1.1Arte/\Flot1^tm1.1Arte (involves: C57BL/6J)	abnormal leukocyte physiology	J:166672
	impaired neutrophil chemotaxis	J:166672
	impaired neutrophil recruitment	J:166672
\Flt1^tm1.1Fong/\Flt1^tm1.1Fong \Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/\Gt(ROSA)26Sor⁺ (involves: 129S6/SvEvTac * C57BL/6NCr * CD-1)	increased macrophage cell number	J:202202
\Flt1^tm1Msh/\Flt1^tm1Msh (involves: 129S4/SvJae * C57BL/6J)	impaired macrophage chemotaxis	J:49507
\Flt3^{em1(IMPC)Ccpcz}/\Flt3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Flt3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased NK cell number	J:211773
\Flt3^m1Btlr/\Flt3^m1Btlr (C57BL/6J-Flt3^m1Btlr)	abnormal dendritic cell antigen presentation	J:159599
	abnormal dendritic cell physiology	J:159599
	abnormal macrophage physiology	J:105543
	abnormal NK cell physiology	J:159599
	decreased circulating interferon-alpha level	J:159599
	decreased circulating interferon-gamma level	J:159599
	decreased circulating interleukin-12 level	J:159599
	decreased dendritic cell number	J:159599
	decreased interferon-alpha secretion	J:159599
	decreased interferon-gamma secretion	J:159599
	decreased interleukin-12 secretion	J:159599
	decreased NK cell number	J:159599
	decreased plasmacytoid dendritic cell number	J:159599
	decreased splenocyte number	J:159599
	increased circulating interleukin-6 level	J:159599
	increased circulating tumor necrosis factor level	J:159599
	increased susceptibility to Herpesvirales infection	J:105543
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:159599
	increased susceptibility to Riboviria infection	J:105543
	small lymph nodes	J:159599
\Flt3^tm1.1Dosm/\Flt3⁺ (B6.129(C)-Flt3^tm1.1Dosm)	abnormal spleen morphology	J:205200
	arrested B cell differentiation	J:205200
	enlarged spleen	J:205200
	increased spleen white pulp amount	J:205200
\Flt3^tm1Dgg/\Flt3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:126003
	decreased B cell number	J:126003
	decreased mature B cell number	J:126003
	decreased T cell number	J:126003
	enlarged spleen	J:126003
	increased granulocyte number	J:126003
	increased leukocyte cell number	J:126003
	increased monocyte cell number	J:126003
	increased spleen red pulp amount	J:126003
	increased spleen white pulp amount	J:126003
\Flt3^tm1Dgg/\Flt3⁺ \Kmt2a^tm1Clgr/\Kmt2a⁺ (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)	enlarged spleen	J:189096
	increased leukocyte cell number	J:189096
\Flt3^tm1Dgg/\Flt3^tm1Dgg (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:126003
	decreased B cell number	J:126003
	decreased mature B cell number	J:126003
	decreased T cell number	J:126003
	enlarged spleen	J:126003
	increased granulocyte number	J:126003
	increased leukocyte cell number	J:126003
	increased monocyte cell number	J:126003
	increased spleen red pulp amount	J:126003
	increased spleen white pulp amount	J:126003
\Flt3^tm1Dgg/\Flt3^tm1Dgg \Kmt2a^tm1Clgr/\Kmt2a⁺ (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)	enlarged spleen	J:189096
	increased leukocyte cell number	J:189096
\Flt3^tm1Dosm/\Flt3⁺ \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Flt3^tm1Dosm Tg(Mx1-cre)1Cgn)	abnormal spleen white pulp morphology	J:133528
	arrested B cell differentiation	J:133528
	decreased B cell number	J:133528
	decreased leukocyte cell number	J:133528
	decreased lymphocyte cell number	J:133528
	decreased neutrophil cell number	J:133528
	decreased pre-B cell number	J:133528
	enlarged spleen	J:133528
	increased dendritic cell number	J:133528
	increased granulocyte number	J:133528
	increased leukocyte cell number	J:133528
	increased monocyte cell number	J:133528
	increased neutrophil cell number	J:133528
	increased pro-B cell number	J:133528
	intermingled spleen red and white pulp	J:133528
\Flt3^tm1Irl/\Flt3^tm1Irl (either: 129S/SvEv-Flt3^tm1Irl or (involves: 129S/SvEv * C57BL/6J))	abnormal B cell differentiation	J:27238, J:99149
	decreased pre-B cell number	J:27238
	decreased pro-B cell number	J:27238
\Flt3^tm1Irl/\Flt3^tm1Irl \Kit^W/\Kit^W-v (involves: 129S/SvEv * C57BL/6)	abnormal leukocyte morphology	J:27238
	abnormal myelopoiesis	J:27238
	abnormal T cell number	J:27238
	decreased B cell number	J:27238
	decreased double-negative T cell number	J:27238
	decreased double-positive T cell number	J:27238
	decreased lymphocyte cell number	J:27238
	decreased pre-B cell number	J:27238
	decreased pro-B cell number	J:27238
	thymus hypoplasia	J:27238
\Flt3^tm2.1Dosm/\Flt3⁺ (B6.129(C)-Flt3^tm2.1Dosm)	abnormal B cell morphology	J:205200
	abnormal myelopoiesis	J:205200
	abnormal spleen morphology	J:205200
	enlarged spleen	J:205200
	increased leukocyte cell number	J:205200
	increased pre-pro B cell number	J:205200
	increased pro-B cell number	J:205200
	increased spleen white pulp amount	J:205200
	intermingled spleen red and white pulp	J:205200
	myeloid hyperplasia	J:205200
\Flt3l^tm1Imx/\Flt3l^tm1Imx (C57BL/6-Flt3l^tm1Imx)	abnormal dendritic cell morphology	J:62536, J:89868
	abnormal immature B cell morphology	J:62536
	abnormal immune system cell morphology	J:62536
	abnormal immune system organ morphology	J:62536
	abnormal leukocyte morphology	J:62536
	decreased B cell number	J:79569
	decreased double-negative T cell number	J:79569
	decreased leukocyte cell number	J:62536
	decreased lymphocyte cell number	J:62536
	decreased myeloid dendritic cell number	J:62536, J:89868
	decreased NK cell number	J:62536
	decreased plasmacytoid dendritic cell number	J:62536, J:89868
	decreased pre-B cell number	J:79569
	decreased pro-B cell number	J:79569, J:62536
	impaired myelopoiesis	J:62536
	increased IgM level	J:62536
	increased length of allograft survival	J:89868
	increased neutrophil cell number	J:62536
	lymph node hypoplasia	J:62536
	spleen hypoplasia	J:62536
\Flt3l^tm1Imx/\Flt3l^tm1Imx (involves: C57BL/6)	abnormal dendritic cell antigen presentation	J:223508
	abnormal dendritic cell chemotaxis	J:223508
	abnormal memory T cell physiology	J:189122
	abnormal T-helper 1 physiology	J:189122
	decreased CD11b-high dendritic cell number	J:223508
	decreased CD103-positive CD11b-low dendritic cell number	J:223508
	decreased dendritic cell number	J:189122
	decreased macrophage cell number	J:189122
	decreased monocyte cell number	J:189122
	decreased NK cell number	J:189122
	decreased plasmacytoid dendritic cell number	J:189122
	increased neutrophil cell number	J:189122
	increased susceptibility to parasitic infection	J:189122
\Flt4^Chy/\Flt4⁺ (involves: C3H)	abnormal lymph circulation	J:72387
	abnormal lymphangiogenesis	J:177405
	abnormal lymphatic vessel morphology	J:72387
\Flt4^Chy/\Flt4^Chy (involves: C3H)	abnormal lymphangiogenesis	J:177405
\Flt4^Chy/\Flt4^Chy (involves: C3H)	absent lymphatic vessels	J:177405
\Flt4^tm1.1Ichi/\Flt4⁺ \Kras^tm1Mok/\Kras⁺ (involves: 129S/SvEv * C57BL/6)	lymphatic vessel hypoplasia	J:159024
\Flt4^tm1.1Ichi/\Flt4⁺ \Kras^tm1Mok/\Kras⁺ \Tg(HRAS)2Jic/0 (involves: 129S/SvEv * BALB/c * C57BL/6 * DBA/2)	lymphatic vessel hypoplasia	J:159024
\Flt4^tm1.2Yhe/\Flt4^tm1.2Yhe (involves: 129/Sv * C57BL/6J * FVB/N)	abnormal lymphangiogenesis	J:177405
	absent lymphatic vessels	J:177405
\Flt4^tm1Ali/\Flt4⁺ \Nrp2^tm1Ddg/\Nrp2⁺ (involves: C57BL/6)	abnormal lymphangiogenesis	J:156869
\Flt4^tm1Ali/\Flt4⁺ \Nrp2^tm1Ddg/\Nrp2^tm1Ddg (involves: C57BL/6)	abnormal lymphangiogenesis	J:156869
\Flt4^tm1Ali/\Flt4⁺ \Tmem204^tm1.1Ali/\Tmem204^tm1.1Ali (involves: BALB/c * C57BL/6)	abnormal lymphatic vessel smooth muscle morphology	J:159519
	enlarged lymphatic vessel	J:159519
\Flt4^tm1Ali/\Flt4^tm2Ali (involves: 129S1/Sv * 129X1/SvJ * ICR)	absent lymphatic vessels	J:137909
\Flt4^tm2Ali/\Flt4⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymph circulation	J:137909
\Flt4^tm2Ali/\Flt4⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymphatic vessel morphology	J:137909
\Flt4^tm2Ali/\Flt4^tm2Ali (involves: 129S1/Sv * 129X1/SvJ * ICR)	absent lymphatic vessels	J:137909
\Flvcr1^tm1.1Jlab/\Flvcr1^tm1.1Jlab (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal spleen morphology	J:132057
	enlarged spleen	J:132057
\Flvcr2^tm1.2Tda/\Flvcr2^tm1.2Tda (involves: C57BL/6J)	brain inflammation	J:287134
\Flvcr2^{tm1a(EUCOMM)Hmgu}/\Flvcr2^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Flvcr2^{tm1a(EUCOMM)Hmgu}/Wtsi)	blood in lymph vessels	J:239583
\fm/\fm (involves: CBA/H)	abnormal lymph node morphology	J:275
	abnormal Peyer's patch morphology	J:275
	abnormal spleen morphology	J:5417, J:275
	abnormal thymus morphology	J:275
\Fmnl1^tm1.2Sdb/\Fmnl1^tm1.2Sdb \Lyz2^tm1(cre)Ifo/\Lyz2^tm1(cre)Ifo (involves: C3H * C57BL/6 * FVB/N)	abnormal Kupffer cell morphology	J:250144
	abnormal macrophage morphology	J:250144
	abnormal macrophage physiology	J:250144
	decreased macrophage cell number	J:250144
	impaired macrophage chemotaxis	J:250144
\Fmo1^em1Anz/\Fmo1^em1Anz (involves: C57BL/6N)	increased cytokine level	J:312983
\Fmo3^em1(IMPC)Mbp/\Fmo3^em1(IMPC)Mbp (C57BL/6N-Fmo3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Fmo5^em1(IMPC)Mbp/\Fmo5^em1(IMPC)Mbp (C57BL/6N-Fmo5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Fmod^tm1Aol/\Fmod^tm1Aol (involves: 129S1/Sv * 129X1/SvJ * CD-1)	osteoarthritis	J:79115
\Fmod^tm1Aol/\Fmod^tm1Aol \Lum^tm1Chak/\Lum^tm1Chak (involves: 129S1/Sv * 129X1/SvJ * CD-1)	osteoarthritis	J:79115
\Fn1^tm1Bwg/\Fn1^tm1Bwg (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:90917
\Fndc3a^em1(IMPC)Tcp/\Fndc3a^em1(IMPC)Tcp (C57BL/6N-Fndc3a^em1(IMPC)Tcp/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Fndc4^tm1.1Mabo/\Fndc4^tm1.1Mabo (involves: C57BL/6 * BALB/c)	increased susceptibility to induced colitis	J:236896
\Fndc9^{tm1.1(KOMP)Vlcg}/\Fndc9^{tm1.1(KOMP)Vlcg} (C57BL/6N-Fndc9^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Fnip1^{em1(IMPC)Ccpcz}/\Fnip1⁺ (C57BL/6NCrl-Fnip1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	small thymus	J:211773
\Fnip1^{em1(IMPC)Ccpcz}/\Fnip1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Fnip1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased spleen weight	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
	small spleen	J:211773
\Fnip1^{Gt(RRM154)Byg}/\Fnip1^{Gt(RRM154)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	arrested B cell differentiation	J:189078
	decreased B cell number	J:189078
	decreased B-1 B cell number	J:189078
	decreased mature B cell number	J:189078
	decreased pre-B cell number	J:189078
	decreased transitional stage B cell number	J:189078
	increased B cell apoptosis	J:189078
	increased pro-B cell number	J:189078
	small spleen	J:189078
\Fnip1^{Gt(RRM154)Byg}/\Fnip1^{Gt(RRM154)Byg} \Igh^tm2Cgn/\Igh^tm2Cgn (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
\Fnip1^{Gt(RRM154)Byg}/\Fnip1^{Gt(RRM154)Byg} \Tg(BCL2)22Wehi/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	increased B cell number	J:189078
\Fnip1^{Gt(RRM154)Byg}/\Fnip1^{Gt(RRM154)Byg} \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
	increased immature B cell number	J:189078
\Fnip1^LPAB.1/\Fnip1^LPAB.1 (C57BL/6J-Fnip1^LPAB.1)	abnormal B cell physiology	J:187318
	absent B cells	J:187318
	arrested B cell differentiation	J:187318
	decreased B-1 B cell number	J:187318
	decreased IgE level	J:187318
	decreased IgG1 level	J:187318
	decreased IgG2a level	J:187318
	decreased IgG level	J:187318
	decreased IgM level	J:187318
	increased B cell apoptosis	J:187318
\Fnip1^LPAB.1/\Fnip1^LPAB.1 \Tg(IghMyc)22Bri/0 (involves: C57BL * C57BL/6J * SJL)	increased B cell apoptosis	J:187318
\Fnip1^m1Btlr/\Fnip1^m1Btlr (C57BL/6J-Fnip1^m1Btlr)	abnormal splenocyte morphology	J:234285
	absent B cells	J:234285
	decreased IgM level	J:234285
	decreased marginal zone B cell number	J:234285
\Fnip1^m2Btlr/\Fnip1^m2Btlr (C57BL/6J-Fnip1^m2Btlr)	decreased B cell number	J:265134
	increased B-1 B cell number	J:265134
	increased CD4-positive, alpha-beta T cell number	J:265134
	increased single-positive T cell number	J:265134
	increased T cell number	J:265134
\Fnip1^M3Btlr/\Fnip1^M3Btlr (C57BL/6J-Fnip1^M3Btlr)	abnormal B cell differentiation	J:272802
\Fnip1^tm1.2Baba/\Fnip1^tm1.2Baba (involves: C57BL/6 * C57BL/6J * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	arrested B cell differentiation	J:189078
	decreased B cell number	J:189078
	decreased B-1 B cell number	J:189078
	decreased mature B cell number	J:189078
	decreased pre-B cell number	J:189078
	decreased transitional stage B cell number	J:189078
	increased B cell apoptosis	J:189078
	increased pro-B cell number	J:189078
	small spleen	J:189078
\Fnip1^tm1.2Baba/\Fnip1^tm1.2Baba \Igh^tm2Cgn/\Igh^tm2Cgn (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
\Fnip1^tm1.2Baba/\Fnip1^tm1.2Baba \Tg(BCL2)22Wehi/0 (involves: C57BL/6 * FVB/N * SJL)	increased B cell number	J:189078
\Fnip1^tm1.2Baba/\Fnip1^tm1.2Baba \Tg(IghelMD4)4Ccg/0 (involves: C57BL/6 * C57BL/6J * FVB/N * SJL)	absent B cells	J:189078
	absent B-2 B cells	J:189078
	decreased B-1 B cell number	J:189078
	increased immature B cell number	J:189078
\Fntb^tm1Bbd/\Fntb^tm1.1Bbd \Polr2a^{tm1(cre/ERT2)Bbd}/\Polr2a^{tm1(cre/ERT2)Bbd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)	small spleen	J:98944
\Fntb^tm1Bbd/\Fntb^tm1Bbd \Polr2a^{tm1(cre/ERT2)Bbd}/\Polr2a^{tm1(cre/ERT2)Bbd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)	small spleen	J:98944
\Focad^em1(IMPC)Bay/\Focad⁺ (C57BL/6N-Focad^em1(IMPC)Bay/BayMmucd)	decreased spleen weight	J:211773
\Fos^tm1Pa/\Fos^tm1Pa (involves: 129X1/SvJ * C57BL/6J)	abnormal lymphopoiesis	J:3233
\Fos^tm1Wag/\Fos^tm1Wag (involves: 129S2/SvPas)	decreased osteoclast cell number	J:65766
\Fos^tm1Wag/\Fos^tm1Wag (involves: 129S2/SvPas * C57BL/6)	abnormal cytokine secretion	J:118693
	abnormal macrophage physiology	J:118693
	abnormal spleen morphology	J:3493
	abnormal spleen white pulp morphology	J:3493
	abnormal thymus size	J:3493
	decreased B cell number	J:3493
	decreased double-positive T cell number	J:3493
	decreased splenocyte number	J:3493
	decreased thymocyte number	J:3493
	increased macrophage apoptosis	J:118693
	increased macrophage cytokine production	J:118693
	increased susceptibility to bacterial infection	J:118693
	increased T cell number	J:3493
\Fos^tm1Wag/\Fos^{tm2(Fosl1)Wag} (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased osteoclast cell number	J:65766
\Fos^tm3.1Wag/\Fos^tm3.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased interleukin-10 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
\Fos^tm4.1Wag/\Fos^tm4.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased interleukin-10 secretion	J:175064
	increased interleukin-6 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
\Fos^tm5.1Wag/\Fos^tm5.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:175064
	decreased interleukin-10 secretion	J:175064
	decreased osteoclast cell number	J:175064
	increased circulating tumor necrosis factor level	J:175064
	increased interleukin-6 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
\Fos^tm6.1Wag/\Fos^tm6.1Wag (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:175064
	increased circulating interleukin-6 level	J:175064
	increased circulating interleukin-10 level	J:175064
	increased circulating tumor necrosis factor level	J:175064
	increased susceptibility to endotoxin shock	J:175064
\Fos^tm7Wag/\Fos^tm7Wag \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-10 secretion	J:175064
	increased circulating interleukin-6 level	J:175064
	increased circulating interleukin-10 level	J:175064
	increased circulating tumor necrosis factor level	J:175064
	increased interleukin-6 secretion	J:175064
	increased susceptibility to endotoxin shock	J:175064
	increased tumor necrosis factor secretion	J:175064
\Fos^tm7Wag/\Fos^tm7Wag \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:190150
\Fosl2^tm2.1Wag/\Fosl2^tm2.1Wag (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:137646
	abnormal osteoclast morphology	J:137646
	abnormal osteoclast physiology	J:137646
	increased osteoclast cell number	J:137646
\Fosl2^tm2Wag/\Fosl2^tm2Wag \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:137646
\Fosl2^tm2Wag/\Fosl2^tm2Wag \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	abnormal osteoclast morphology	J:211215
\Foxa1^tm1(cre)Sew/\Foxa1⁺ \Mst1r^tm1Sew/\Mst1r^tm1Sew (involves: 129P2/OlaHsd * CD-1 * NIH Black Swiss)	decreased susceptibility to bacterial infection	J:105979
\Foxa2^tm1.1Khk/\Foxa2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	respiratory system inflammation	J:284174
\Foxa2^tm1Khk/\Foxa2^tm1Khk \Tg(Scgb1a1-rtTA)1Jaw/0 \Tg(tetO-cre)1Jaw/0 (Not Specified)	immune system phenotype	J:88601
\Foxa2^tm1Khk/\Foxa2^tm1Khk \Tg(SFTPC-rtTA)5Jaw/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 * 129P2/OlaHsd * C57BL/6)	increased macrophage cell number	J:88601
	increased neutrophil cell number	J:88601
\Foxc2^tm1.1Miu/\Foxc2^tm1.1Miu \Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * C57BL/6J * SJL)	abnormal lymphatic vessel morphology	J:316530
\Foxc2^tm1Miu/\Foxc2⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)	abnormal lymph circulation	J:83436
	abnormal thoracic duct morphology	J:83436
	enlarged lymph nodes	J:83436
	increased lymph node number	J:83436
	lymphangiectasis	J:83436
	lymphatic vessel hyperplasia	J:83436
\Foxf1^em1Vvk/\Foxf1⁺ (involves: C57BL/6 * DBA/2)	lung inflammation	J:296328
\Foxh1^b2b2662Clo/\Foxh1^b2b2662Clo (C57BL/6J-Foxh1^b2b2662Clo)	absent spleen	J:175213
	thymus hypoplasia	J:175213
\Foxh1^tm1Hmd/\Foxh1^tm1.1Hmd \Tg(Leftb-cre)1Hmd/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6Cr)	spleen hypoplasia	J:82311
\Foxi3^em3Akg/\Foxi3^tm1.2Akg (involves: 129X1/SvJ * C57BL/6)	athymia	J:336768
\Foxj3^{tm1b(EUCOMM)Wtsi}/\Foxj3⁺ (C57BL/6N-Foxj3^{tm1b(EUCOMM)Wtsi}/Bay)	increased leukocyte cell number	J:211773
\Foxm1^tm1Rhc/\Foxm1^tm1Rhc \Tg(Tek-cre)1Ywa/0 (involves: 129X1/SvJ * C57BL/6 * SJL)	lung inflammation	J:167773
\Foxn1^nu-2J/\Foxn1^nu-2J (B6(SJL)-Foxn1^nu-2J/GrsrJ)	athymia	J:192383
\Foxn1^nu-StL/\Foxn1^nu-StL (involves: C57BL/6)	absent T cells	J:63313
\Foxn1^nu-StL/\Foxn1^nu-StL (involves: C57BL/6)	athymia	J:63313
\Foxn1^nu-StL/\Foxn1^tm1Tbo (involves: 129S1/Sv * C57BL/6)	abnormal thymus development	J:63313
\Foxn1^nu-StL/\Foxn1^tm1Tbo (involves: 129S1/Sv * C57BL/6)	athymia	J:63313
\Foxn1^nu-str/\Foxn1^nu-str (AKR/J-Foxn1^nu-str/J)	abnormal humoral immune response	J:30715
	abnormal immune system cell morphology	J:30715
	abnormal immune system morphology	J:24755
	abnormal immune system organ morphology	J:30715
	abnormal immune system physiology	J:30715
	abnormal Peyer's patch germinal center morphology	J:30715
	abnormal Peyer's patch morphology	J:30715
	athymia	J:24755
	decreased immunoglobulin level	J:30715
	decreased lymphocyte cell number	J:30715
	decreased T cell number	J:30715
	increased eosinophil cell number	J:30715
	increased granulocyte number	J:30715
	increased length of allograft survival	J:30715
	increased neutrophil cell number	J:30715
	lymph node hypoplasia	J:30715
	spleen hypoplasia	J:30715
\Foxn1^nu-Y/\Foxn1^nu-Y (101/HY-Foxn1^nu-Y)	abnormal thymus development	J:4060
	absent T cells	J:4060
	athymia	J:4060, J:29022
\Foxn1^nu/\Foxn1⁺ (C.Cg-Foxn1^nu)	small thymus	J:7330
\Foxn1^nu/\Foxn1⁺ (involves: BALB/c)	blepharitis	J:12543
	increased incidence of corneal inflammation	J:12543
	increased susceptibility to Herpesvirales infection	J:12543
\Foxn1^nu/\Foxn1⁺ (NFS.Cg-Foxn1^nu)	abnormal thymus morphology	J:7330
\Foxn1^nu/\Foxn1⁺ (NFS.Cg-Foxn1^nu)	small thymus	J:7330
\Foxn1^nu/\Foxn1⁺ (B6N.Cg-Foxn1^nu)	small thymus	J:7330
\Foxn1^nu/\Foxn1⁺ (C3N.Cg-Foxn1^nu)	small thymus	J:7330
\Foxn1^nu/\Foxn1^nu (involves: NMRI)	abnormal thymus development	J:6363
\Foxn1^nu/\Foxn1^nu (Not Specified)	abnormal lymph node T cell domain morphology	J:202296
	abnormal Peyer's patch germinal center morphology	J:202296
	abnormal spleen morphology	J:202296
	abnormal splenic cell ratio	J:202296
	abnormal thymus morphology	J:202297
	athymia	J:202296, J:5059
	decreased leukocyte cell number	J:5059
	small spleen	J:202296
\Foxn1^nu/\Foxn1^nu (B6NTac.Cg-Foxn1^nu/Tac)	decreased susceptibility to parasitic infection	J:64283
\Foxn1^nu/\Foxn1^nu (involves: BALB/c)	abnormal circulating cytokine level	J:50903
	blepharitis	J:12543
	decreased circulating interleukin-2 level	J:50903
	decreased circulating interleukin-6 level	J:50903
	decreased circulating tumor necrosis factor level	J:50903
	decreased interferon-gamma secretion	J:50903
	decreased susceptibility to bacterial infection	J:50903
	increased susceptibility to Herpesvirales infection	J:12543
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:12543
\Foxn1^nu/\Foxn1^nu (involves: C57BL/10Sn * C57BR/cd)	abnormal thymus development	J:7898
\Foxn1^nu/\Foxn1^nu (involves: CD-1)	athymia	J:106251
\Foxn1^nu/\Foxn1^nu (involves: CBA)	abnormal lymph node morphology	J:202808
	abnormal spleen physiology	J:202299
	abnormal T cell activation	J:202299
	decreased leukocyte cell number	J:202299
	decreased lymphocyte cell number	J:202299
	decreased T cell number	J:202808
	increased length of allograft survival	J:202299
\Foxn1^nu/\Foxn1^nu \Fv4^r/\Fv4^r (involves: BALB/c)	decreased susceptibility to Retroviridae infection	J:5714, J:5684
\Foxn1^nu/\Foxn1^nu \Map3k14^aly/\Map3k14^aly (involves: BALB/cAJcl * C57BL/6J)	absent B cells	J:96579
	absent lymph nodes	J:96579
	absent Peyer's patches	J:96579
	athymia	J:96579
	decreased gamma-delta intraepithelial T cell number	J:96579
	decreased T cell number	J:96579
\Foxn1^nu/\Foxn1^nu \Tg(Foxn1)E1Hon/0 (involves: CD-1)	athymia	J:33866
\Foxn1^nu/\Foxn1^nu \Tgfb1^tm1Doe/\Tgfb1^tm1Doe (involves: 129S2/SvPas * BALB/c * CF-1)	abnormal T cell physiology	J:99033
	decreased inflammatory response	J:99033
\Foxn1^nu/\Foxn1^tm1.1Dmsu \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129/Sv C57BL/6 * CBA * SJL)	abnormal thymus epithelium morphology	J:159773
	decreased thymocyte number	J:159773
	increased thymocyte apoptosis	J:159773
\Foxn1^sepe/\Foxn1^sepe (BALB/c-Foxn1^sepe)	athymia	J:227974
\Foxn1^{tm1.1(KOMP)Vlcg}/\Foxn1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Foxn1^{tm1.1(KOMP)Vlcg}/Tcp)	abnormal thymus morphology	J:211773
	athymia	J:211773
\Foxn1^tm1.1Cbln/\Foxn1⁺ (involves: 129P2/OlaHsd * C57BL/6)	thymus hyperplasia	J:177992
\Foxn1^tm1.1Cbln/\Foxn1⁺ \Tg(Zp3-cre)3Mrt/? (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * FVB/N)	immune system phenotype	J:177992
\Foxn1^tm1.1Cbln/\Foxn1^tm1.1Cbln (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphocyte cell number	J:177992
	decreased single-positive T cell number	J:177992
	increased DN1 thymic pro-T cell number	J:177992
	increased double-positive T cell number	J:177992
	thymus hypoplasia	J:177992
\Foxn1^tm1.1Cbln/\Foxn1^tm1Tbo (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	absent T cells	J:177992
	small thymus	J:177992
\Foxn1^tm1.1Cbln/\Foxn1^tm1Tbo \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	immune system phenotype	J:177992
\Foxn1^tm1.1Dmsu/\Foxn1^tm1.1Dmsu \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129/Sv C57BL/6 * CBA * SJL)	abnormal thymus morphology	J:159773
	decreased double-positive T cell number	J:159773
	decreased thymocyte number	J:159773
	small thymus	J:159773
	thymus atrophy	J:159773
\Foxn1^tm1.1Dmsu/\Foxn1^tm1.1Dmsu \Tg(KRT5-cre/ERT2)2Ipc/0 (involves: 129/Sv * C57BL/6 * SJL)	abnormal thymus corticomedullary boundary morphology	J:159773
	abnormal thymus medulla morphology	J:159773
	decreased thymocyte number	J:159773
	small thymus	J:159773
	thymus atrophy	J:159773
\Foxn1^tm1.1Dmsu/\Foxn1^tm1.1Dmsu \Tg(KRT18-cre/ERT2)1Rgo/0 (involves: 129/Sv * C57BL/6 * FVB/N * SJL)	immune system phenotype	J:159773
\Foxn1^tm1Dmsu/\Foxn1^tm1Dmsu (involves: 129/Sv * C57BL/6)	athymia	J:159773
\Foxn1^tm1Nrm/\Foxn1^tm1Nrm (involves: 129X1/SvJ * C57BL/6J)	abnormal CD4-positive, alpha beta T cell morphology	J:86255
	abnormal CD8-positive, alpha beta T cell morphology	J:86255
	abnormal T cell differentiation	J:86255
	abnormal thymus development	J:86255
	abnormal thymus epithelium morphology	J:86255
	absent thymus cortex	J:86255
	absent thymus medulla	J:86255
	decreased CD4-positive, alpha-beta T cell number	J:86255
	decreased double-negative T cell number	J:86255
	decreased double-positive T cell number	J:86255
	decreased T cell number	J:86255
	decreased thymocyte number	J:86255
	small thymus	J:86255
	thymus cyst	J:86255
\Foxn1^tm1Tbo/\Foxn1^tm1Tbo (involves: 129S1/Sv)	abnormal leukocyte cell number	J:33796
	abnormal thymus development	J:33796
	abnormal thymus epithelium morphology	J:177992
	abnormal thymus morphology	J:33796
	absent T cells	J:33796
	athymia	J:33796
	increased B cell number	J:33796
\Foxn1^tm2Nrm/\Foxn1^tm2Nrm (either: (involves: 129/Sv) or (involves: C57BL/6))	immune system phenotype	J:125817
\Foxn1^tm2Tbo/\Foxn1^tm2Tbo \Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased T cell number	J:110046
\Foxn1^tm3(cre)Nrm/\Foxn1⁺ \Gt(ROSA)26Sor^{tm1(Tbx1)Rche}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NHsd)	abnormal thymus development	J:214094
	abnormal thymus epithelium morphology	J:214094
	decreased thymocyte number	J:214094
	thymus hypoplasia	J:214094
\Foxn1^tm3(cre)Nrm/\Foxn1⁺ \Mir205hg^tm1Oers/\Mir205hg^tm1Oers (B6(Cg)-Mir205hg^tm1Oers Foxn1^tm3(cre)Nrm)	decreased thymocyte number	J:278363
	decreased thymus weight	J:278363
	thymus hypoplasia	J:278363
\Foxn1^tm3(cre)Nrm/\Foxn1^tm3(cre)Nrm (either: (involves: 129/Sv) or (involves: C57BL/6))	immune system phenotype	J:125817
\Foxn4^{em1(IMPC)Ccpcz}/\Foxn4⁺ (C57BL/6NCrl-Foxn4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
\Foxo1^tm1.1Rdp/\Foxo1⁺ \Igh-J^tm1Cgn/\Igh^tm4Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv)	increased B cell number	J:157297
\Foxo1^tm1.1Stlp/\Foxo1^tm1.1Stlp \Tg(Lck-cre)1Cwi/0 (involves: 129S4/SvJae)	abnormal single-positive T cell number	J:154205
	decreased CD8-positive, alpha-beta T cell number	J:154205
	decreased double-positive T cell number	J:154205
	decreased T cell number	J:154205
	decreased T cell proliferation	J:154205
	decreased thymocyte apoptosis	J:154205
	increased CD4-positive, alpha-beta T cell number	J:154205
	increased CD8-positive, alpha-beta T cell number	J:154205
	small lymphoid organs	J:154205
	small spleen	J:154205
\Foxo1^tm1Flv/\Foxo1^tm1Flv \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ)	abnormal inflammatory response	J:189962
	abnormal regulatory T cell physiology	J:189962
	enlarged lymph nodes	J:189962
	enlarged spleen	J:189962
	increased CD4-positive, alpha-beta T cell number	J:189962
	increased CD8-positive, alpha-beta T cell number	J:189962
	increased interferon-gamma secretion	J:189962
	increased regulatory T cell number	J:189962
	increased T cell number	J:189962
	increased T cell proliferation	J:189962
\Foxo1^tm1Flv/\Foxo1^tm1Flv \Gt(ROSA)26Sor^{tm1(CAG-FOXO1,GFP)Moli}/\Gt(ROSA)26Sor⁺ \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	immune system phenotype	J:189962
\Foxo1^tm1Flv/\Foxo1^tm1Flv \Ifng^tm1Ts/\Ifng^tm1Ts \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129S6/SvEvTac * 129S7/SvEvBrd * 129X1/SvJ)	immune system phenotype	J:189962
	increased CD4-positive, alpha-beta T cell number	J:189962
	increased CD8-positive, alpha-beta T cell number	J:189962
\Foxo1^tm1Flv/\Foxo1^tm1Flv \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)	increased interferon-gamma secretion	J:189962
\Foxo1^tm1Flv/\Foxo1^tm1Flv \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(CD2-Il7r)1Asin/? \Tg(Cd4-cre)1Cwi/? \Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2)	decreased T cell number	J:147057
\Foxo1^tm1Flv/\Foxo1^tm1Flv \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(Cd4-cre)1Cwi/? \Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2)	decreased T cell number	J:147057
\Foxo1^tm1Flv/\Foxo1^tm1Flv \Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:147057
	abnormal CD8-positive, alpha-beta T cell physiology	J:147057
	abnormal T cell activation	J:147057
	abnormal T cell physiology	J:147057
	enlarged lymph nodes	J:147057
	increased anti-double stranded DNA antibody level	J:147057
	increased anti-nuclear antigen antibody level	J:147057
	increased single-positive T cell number	J:147057
	increased susceptibility to induced colitis	J:147057
	increased T cell proliferation	J:147057
\Foxo1^tm1Rdp/\Foxo1^tm1.1Rdp \Igh-J^tm1Cgn/\Igh^tm4Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv)	absent marginal zone B cells	J:157297
	increased B cell number	J:157297
\Foxo1^tm1Rdp/\Foxo1^tm1Rdp \Foxo3^tm1Rdp/\Foxo3^tm1Rdp \Foxo4^tm1Rdp/\Foxo4^tm1Rdp \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)	increased T cell derived lymphoma incidence	J:118179
\Foxo1^tm2.1Dac/\Foxo1^tm2.1Dac (B6.Cg-Foxo1^tm2.1Dac)	decreased circulating tumor necrosis factor level	J:179687
\Foxo3^Gt(XAO26)Byg/\Foxo3^Gt(XAO26)Byg (involves: 129P2/OlaHsd)	abnormal immune system organ morphology	J:93593
	abnormal T cell activation	J:93593
	abnormal T cell physiology	J:93593
	enlarged lymph nodes	J:93593
	enlarged spleen	J:93593
	increased inflammatory response	J:93593
	increased T cell proliferation	J:93593
	kidney inflammation	J:93593
	lung inflammation	J:93593
	lymphoid hyperplasia	J:93593
	salivary gland inflammation	J:93593
	spleen hyperplasia	J:93593
\Foxo3^tm1.1Rdp/\Foxo3^tm1.1Rdp (involves: 129S6/SvEvTac * FVB/N)	dermatitis	J:118179
\Foxo3^tm1Nmt/\Foxo3^tm1Nmt (B6.Cg-Foxo3^tm1Nmt)	abnormal NK cell morphology	J:123409
\Foxo3^tm1Nmt/\Foxo3^tm1Nmt (B6.Cg-Foxo3^tm1Nmt)	increased NK cell number	J:123409
\Foxo6^{tm1(KOMP)Vlcg}/\Foxo6^{tm1(KOMP)Vlcg} (B6J.B6NTac-Foxo6^{tm1(KOMP)Vlcg})	abnormal Kupffer cell morphology	J:236585
	impaired macrophage chemotaxis	J:236585
\Foxp1^tm1.1Pwt/\Foxp1^tm1.1Pwt \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal T cell activation	J:156832
	decreased CD4-positive, alpha-beta T cell number	J:156832
	decreased CD8-positive, alpha-beta T cell number	J:156832
	immune system phenotype	J:156832
	increased T cell apoptosis	J:156832
\Foxp1^tm1Rao/\Foxp1^tm1Rao (B6.129-Foxp1^tm1Rao)	abnormal B cell differentiation	J:112644
	abnormal B cell physiology	J:112644
	arrested B cell differentiation	J:112644
	decreased mature B cell number	J:112644
\Foxp2^tm2.2Woen/\Foxp2⁺ (involves: C57BL/6 * C57BL/6J)	increased CD4-positive, alpha-beta T cell number	J:150425
\Foxp2^tm2.2Woen/\Foxp2⁺ (involves: C57BL/6 * C57BL/6J)	increased CD8-positive, alpha-beta T cell number	J:150425
\Foxp3^sf/Y (either: 129Rl.Cg-Foxp3^sf or (involves: 101/Rl * C3Hf/Rl * STOCK MR))	abnormal B cell physiology	J:11262
	abnormal lymph node B cell domain morphology	J:11262
	abnormal lymph node medullary cord morphology	J:11262
	abnormal lymph node morphology	J:11262
	abnormal lymph node T cell domain morphology	J:11262
	abnormal lymphocyte morphology	J:11262
	abnormal macrophage morphology	J:11262
	abnormal spleen morphology	J:11262
	abnormal spleen white pulp morphology	J:11262
	abnormal thymus cortex morphology	J:11262
	abnormal thymus morphology	J:11262
	absent spleen marginal zone	J:11262
	blepharitis	J:11262
	decreased spleen B cell follicle number	J:11262
	dermatitis	J:11262
	enlarged lymph nodes	J:11262
	increased IgG level	J:11262
	increased IgM level	J:11262
	increased inflammatory response	J:11262
	increased leukocyte cell number	J:11262
	increased spleen red pulp amount	J:11262
	increased spleen weight	J:11262
	liver inflammation	J:11262
	small thymus	J:11262
\Foxp3^sf/Y (involves: 101/H * C3H/HeH * STOCK MR)	abnormal spleen morphology	J:10398
	conjunctivitis	J:10398
	increased leukocyte cell number	J:10398
	increased spleen red pulp amount	J:10398
	increased spleen weight	J:10398
	increased spleen white pulp amount	J:10398
	intermingled spleen red and white pulp	J:10398
\Foxp3^sf/? (Not Specified)	liver inflammation	J:138808
\Foxp3^sf/? (Not Specified)	lung inflammation	J:138808
\Foxp3^sf/Y (B6.Cg-Foxp3^sf)	abnormal CD4-positive, alpha beta T cell morphology	J:82560
	abnormal CD4-positive, alpha-beta T cell physiology	J:82560
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:82560
\Foxp3^sf/Y (B6.Cg-Foxp3^sf/J)	lung inflammation	J:125129
	salivary gland inflammation	J:125129
	skin inflammation	J:125129
\Foxp3^sf\Otc^spf/Y (involves: 129/Rl)	enlarged lymph nodes	J:20865
	enlarged spleen	J:20865
	increased CD4-positive, alpha-beta T cell number	J:20865
\Foxp3^sf/\Foxp3^sf \Tg(Rorc-EGFP)1Ebe/? (involves: C57BL/6)	abnormal effector T cell morphology	J:137020
\Foxp3^{tm1(CD2/CD52)Shori}/\Foxp3^{tm1(CD2/CD52)Shori} (involves: C57BL/6)	decreased regulatory T cell number	J:171378
	increased susceptibility to type IV hypersensitivity reaction	J:171378
\Foxp3^tm1(cre)Saka/Y (involves: BALB/c)	increased autoantibody level	J:140085
\Foxp3^tm1(cre)Saka/Y (involves: BALB/c)	stomach inflammation	J:140085
\Foxp3^tm1.1Ayr/Y (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD4-positive, alpha beta T cell morphology	J:82560
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:82560
	enlarged lymph nodes	J:82560
	enlarged spleen	J:82560
	increased susceptibility to autoimmune disorder	J:82560
	skin inflammation	J:82560
\Foxp3^tm1.1Ayr/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	dermatitis	J:117743
	enlarged spleen	J:117743
	increased susceptibility to autoimmune disorder	J:117743
	liver inflammation	J:117743
	lung inflammation	J:117743
	lymph node inflammation	J:117743
\Foxp3^tm1.1Ayr/Y \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraTcrb)425Cbn/0 (Not Specified)	immune system phenotype	J:97029
\Foxp3^tm1.1Ayr/\Foxp3^tm1.1Ayr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:125405
	decreased double-positive T cell number	J:125405
	dermatitis	J:117743
	enlarged spleen	J:117743
	increased susceptibility to autoimmune disorder	J:117743
	liver inflammation	J:117743
	lung inflammation	J:117743
	lymph node inflammation	J:117743
	thymus hypoplasia	J:125405
\Foxp3^tm1.1Ayr/\Foxp3^tm1.1Ayr \Mir146^tm1.1Bal/\Mir146^tm1.1Bal (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphocyte physiology	J:167922
	blepharitis	J:167922
	conjunctivitis	J:167922
	decreased interferon-gamma secretion	J:167922
	dermatitis	J:167922
	increased regulatory T cell number	J:167922
\Foxp3^tm1.1Mal/\Foxp3^tm1.1Mal \Lat^tm1.1Mal/\Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal regulatory T cell physiology	J:131351
	decreased regulatory T cell number	J:131351
	thymus hypoplasia	J:131351
\Foxp3^tm1Ayr/Y \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	dermatitis	J:97029
	enlarged lymph nodes	J:97029
	enlarged spleen	J:97029
	increased susceptibility to autoimmune disorder	J:97029
\Foxp3^tm1Ayr/\Foxp3^tm1Ayr \Foxn1^tm3(cre)Nrm/\Foxn1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:125405
\Foxp3^tm1Ayr/\Foxp3^tm1Ayr \Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:125405
	decreased double-positive T cell number	J:125405
	thymus hypoplasia	J:125405
\Foxp3^tm1Flv/\Foxp3⁺ \B9d2/Tgfb1^tm1Flv/\Tgfb1^tm2Flv \Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	increased regulatory T cell number	J:123547
\Foxp3^tm1Kuch/? \Il6^tm1Kopf/\Il6^tm1Kopf (involves: 129S2/SvPas * C57BL/6)	abnormal CD4-positive T cell differentiation	J:123352
	decreased circulating interleukin-6 level	J:123352
	decreased interleukin-17 secretion	J:123352
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:123352
	increased regulatory T cell number	J:123352
\Foxp3^tm1Tch/Y (C.129X1-Foxp3^tm1Tch)	abnormal chemokine level	J:117165
	abnormal cytokine secretion	J:117165
	abnormal inflammatory response	J:117165
	abnormal lymphocyte physiology	J:117165
	absent regulatory T cells	J:117165
	dermatitis	J:117165
	enlarged spleen	J:117165
	increased activated T cell number	J:117165
	increased CD4-positive, alpha-beta T cell number	J:117165
	increased CD8-positive, alpha-beta T cell number	J:117165
	increased circulating interferon-gamma level	J:117165
	increased circulating interleukin-4 level	J:117165
	increased circulating interleukin-5 level	J:117165
	increased circulating interleukin-6 level	J:117165
	increased circulating interleukin-10 level	J:117165
	increased circulating tumor necrosis factor level	J:117165
	increased eosinophil cell number	J:117165
	increased IgE level	J:117165
	increased IgG1 level	J:117165
	increased leukocyte cell number	J:117165
	increased lymphocyte cell number	J:117165
	increased monocyte cell number	J:117165
	respiratory system inflammation	J:117165
\Foxp3^tm1Tch/Y (B6.129X1-Foxp3^tm1Tch)	abnormal inflammatory response	J:117165
	dermatitis	J:117165
	increased eosinophil cell number	J:117165
	increased IgE level	J:117165
	increased leukocyte cell number	J:117165
	increased lymphocyte cell number	J:117165
	increased monocyte cell number	J:117165
	respiratory system inflammation	J:117165
\Foxp3^tm1Tch/Y \Stat6^tm1Gru/\Stat6^tm1Gru (C.129-Stat6^tm1Gru Foxp3^tm1Tch)	abnormal cytokine secretion	J:117165
	immune system phenotype	J:117165
	increased circulating interferon-gamma level	J:117165
	increased eosinophil cell number	J:117165
\Foxp3^{tm2.1(EGFP/cre)Shori}/Y (involves: 129 * C57BL/6)	decreased regulatory T cell number	J:234397
\Foxp3^{tm2.1(EGFP/cre)Shori}/Y \Pdcd1^tm1Hon/\Pdcd1^tm1Hon (involves: 129 * 129S2/SvPas * C57BL/6)	enlarged lymph nodes	J:234397
	enlarged spleen	J:234397
	increased effector memory T-helper cell number	J:234397
	increased susceptibility to autoimmune disorder	J:234397
	lymph node hyperplasia	J:234397
	pancreas inflammation	J:234397
	spleen hyperplasia	J:234397
\Foxp3^tm2Ayr/Y (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:97029
\Foxp3^tm2Ayr/? \Zap70^rps/\Zap70^rps (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:211510
	abnormal double-positive T cell morphology	J:211510
	abnormal regulatory T cell number	J:211510
	abnormal T cell differentiation	J:211510
	decreased CD4-positive, alpha-beta T cell number	J:211510
	decreased CD8-positive, alpha-beta T cell number	J:211510
	immune system phenotype	J:211510
\Foxp3^tm2Ayr/\Foxp3⁺ \Rnf128^tm1Cdon/\Rnf128^tm1Cdon (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:160681
\Foxp3^tm2Ayr/\Foxp3^tm2Ayr (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:97029
\Foxp3^tm2Flv/Y (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:118631
	abnormal CD8-positive, alpha-beta T cell physiology	J:118631
	abnormal immune system physiology	J:118631
	blepharitis	J:118631
	enlarged lymph nodes	J:118631
	enlarged spleen	J:118631
	increased autoantibody level	J:118631
\Foxp3^tm2Tch/Y (C.129X1-Foxp3^tm2Tch)	immune system phenotype	J:120713
\Foxp3^tm2Tch/\Foxp3⁺ (C.129X1-Foxp3^tm2Tch)	immune system phenotype	J:120713
\Foxp3^{tm3(HBEGF/GFP)Ayr}/\Foxp3⁺ \Gpr174^tm1Cys/\Gpr174⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:222307
\Foxp3^{tm3(HBEGF/GFP)Ayr}/\Foxp3^{tm3(HBEGF/GFP)Ayr} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:117743
	abnormal dendritic cell physiology	J:117743
	conjunctivitis	J:117743
	decreased T cell number	J:117743
	dermatitis	J:117743
	enlarged spleen	J:117743
	increased dendritic cell number	J:117743
	increased susceptibility to autoimmune disorder	J:117743
	liver inflammation	J:117743
	lung inflammation	J:117743
	lymph node inflammation	J:117743
\Foxp3^tm3Tch/Y (C.129X1-Foxp3^tm3Tch)	abnormal CD4-positive, alpha beta T cell morphology	J:120636
	abnormal CD4-positive, alpha-beta T cell physiology	J:120636
	abnormal cytokine secretion	J:120636
	abnormal immune system organ morphology	J:120636
	abnormal lymphocyte physiology	J:120636
	abnormal regulatory T cell physiology	J:120636
	abnormal T cell subpopulation ratio	J:120636
	colitis	J:120636
	enlarged lymph nodes	J:120636
	enlarged spleen	J:120636
	increased T cell proliferation	J:120636
	thymus hypoplasia	J:120636
\Foxp3^tm3Tch/\Foxp3⁺ (C.129X1-Foxp3^tm3Tch)	abnormal CD4-positive, alpha-beta T cell physiology	J:120636
	decreased T cell number	J:120636
	decreased thymocyte number	J:120636
	increased T cell apoptosis	J:120636
\Foxp3^{tm4(YFP/icre)Ayr}/Y \Zfp91^tm1Smoc/\Zfp91^tm1Smoc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:306129
	decreased regulatory T cell number	J:306129
	increased CD8-positive, alpha-beta T cell number	J:306129
	increased susceptibility to autoimmune disorder	J:306129
	increased susceptibility to induced colitis	J:306129
\Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ \Nr4a2^tm1.1Pcn/\Nr4a2^tm1.1Pcn (involves: 129S1/Sv * 129X1/SvJ)	abnormal regulatory T cell morphology	J:205658
	abnormal regulatory T cell physiology	J:205658
\Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3^{tm4(YFP/icre)Ayr} \Ikzf4^tm1Djr/\Ikzf4^tm1Djr (involves: 129S1/Sv * 129X1/SvJ)	chronic inflammation	J:294549
	decreased regulatory T cell number	J:294549
	enlarged lymph nodes	J:294549
	enlarged spleen	J:294549
	glomerulonephritis	J:294549
	granulomatous inflammation	J:294549
	increased germinal center B cell number	J:294549
	increased immunoglobulin level	J:294549
	increased spleen B cell follicle number	J:294549
	increased spleen germinal center number	J:294549
	increased susceptibility to experimental autoimmune encephalomyelitis	J:294549
	increased T cell number	J:294549
	increased T follicular helper cell number	J:294549
	small intestinal inflammation	J:294549
\Foxp3^tm5.2Ayr/\Foxp3^tm5.2Ayr (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	abnormal gut-associated lymphoid tissue morphology	J:156942
	abnormal intraepithelial T cell morphology	J:156942
	abnormal mesenteric lymph node morphology	J:156942
	abnormal Peyer's patch morphology	J:156942
	abnormal T cell differentiation	J:156942
	decreased regulatory T cell number	J:156942
	increased T cell number	J:156942
\Foxp3^tm6.2Ayr/\Foxp3^tm6.2Ayr (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	decreased regulatory T cell number	J:156942
\Foxp3^tm7.2Ayr/\Foxp3⁺ (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	decreased regulatory T cell number	J:156942
\Foxp3^tm7.2Ayr/\Foxp3^tm7.2Ayr (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	abnormal regulatory T cell morphology	J:156942
	decreased regulatory T cell number	J:156942
\Foxp3^tm8Ayr/Y (B6.129-Foxp3^tm8Ayr)	autoimmune response	J:157377
\Foxp3^{tm9(EGFP/cre/ERT2)Ayr}/\Foxp3⁺ \Il1r2^tm1.1Epi/\Il1r2^tm1.1Epi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)	abnormal adaptive immunity	J:347877
	abnormal alpha-beta T cell number	J:347877
	increased CD4-positive, alpha-beta T cell number	J:347877
	increased IgG level	J:347877
	increased spleen germinal center size	J:347877
	increased T follicular helper cell number	J:347877
\Foxq1^sa-e1/\Foxq1^sa-e1 (involves: 101/Rl * C3H/Rl)	abnormal lymphocyte cell number	J:75422
\Foxq1^sa/\Foxq1^sa (involves: 101/Rl * C3H/Rl)	impaired natural killer cell mediated cytotoxicity	J:7649
\Foxq1^sa/\Foxq1^sa \Lyst^bg/\Lyst^bg (involves: 101/Rl * C3H/Rl * C57BL/6J * C57BL10/Rl)	enlarged lymph nodes	J:5311
	increased susceptibility to infection	J:5311
	interstitial pneumonia	J:15166, J:5311
\Foxq1^sa/\Foxq1^sa \Lyst^bg/\Lyst^bg (involves: 101/Rl * C3H/Rl * C57BL10/Rl)	enlarged spleen	J:5311
	interstitial pneumonia	J:5311
	lung inflammation	J:5311
\Foxr1^em1(IMPC)Tcp/\Foxr1⁺ (C57BL/6NCrl-Foxr1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Foxr1^em1(IMPC)Tcp/\Foxr1^em1(IMPC)Tcp (C57BL/6NCrl-Foxr1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Foxred1^em1(IMPC)Bay/\Foxred1⁺ (C57BL/6N-Foxred1^em1(IMPC)Bay/Bay)	increased spleen weight	J:211773
\Fpr1^tm1Gao/\Fpr1^tm1Gao (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal innate immunity	J:53354
	impaired neutrophil chemotaxis	J:53354
	increased susceptibility to bacterial infection	J:53354
	increased susceptibility to bacterial infection induced morbidity/mortality	J:53354
\Fpr2^tm1.1Jimw/\Fpr2^tm1.1Jimw \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	decreased susceptibility to induced colitis	J:197568
\Fpr2^tm1.2Jimw/\Fpr2^tm1.2Jimw (B6.129X1-Fpr2^tm1.2Jimw)	abnormal cytokine secretion	J:160074
	abnormal dendritic cell physiology	J:160074
	abnormal innate immunity	J:160074
	decreased dendritic cell number	J:160074
	decreased IgE level	J:160074
	decreased IgG1 level	J:160074
	decreased IgG2b level	J:160074
	decreased immunoglobulin level	J:160074
	decreased inflammatory response	J:160074
	decreased interferon-gamma secretion	J:160074
	decreased interleukin-2 secretion	J:160074
	decreased interleukin-4 secretion	J:160074
	decreased interleukin-5 secretion	J:160074
	decreased interleukin-13 secretion	J:160074
	impaired macrophage chemotaxis	J:160074
	impaired neutrophil chemotaxis	J:160074
	small lymph nodes	J:160074
\Fpr2^tm1.2Jimw/\Fpr2^tm1.2Jimw (involves: 129X1/SvJ)	abnormal dendritic cell chemotaxis	J:199611
	abnormal dendritic cell physiology	J:199611
	colitis	J:197568
	decreased acute inflammation	J:197568
	decreased dendritic cell number	J:199611
\Fpr2^tm1Rjf/\Fpr2^tm1Rjf (involves: 129S/SvEv * C57BL/6)	abnormal neutrophil physiology	J:159658
	impaired macrophage chemotaxis	J:159658
	increased acute inflammation	J:159658
	increased susceptibility to induced arthritis	J:159658
\fpw/\fpw (involves: C3H/HeJ * C57BL/6J)	decreased circulating interferon-gamma level	J:151726
	decreased circulating interleukin-1 alpha level	J:151726
	decreased circulating interleukin-6 level	J:151726
	increased circulating interleukin-10 level	J:151726
	increased circulating tumor necrosis factor level	J:151726
\Fras1^{em1(IMPC)Ccpcz}/\Fras1⁺ (C57BL/6NCrl-Fras1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Frmd3^em1(IMPC)J/\Frmd3^em1(IMPC)J (C57BL/6NJ-Frmd3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Frmd8^em2Smoc/\Frmd8^em2Smoc \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	increased spleen weight	J:338904
	increased susceptibility to colitis induced morbidity/mortality	J:338904
	increased susceptibility to induced colitis	J:338904
\Fryl^{Gt(Ayu21-T312)Imeg}/\Fryl^{Gt(Ayu21-T312)Imeg} (B6J.Cg-Fryl^{Gt(Ayu21-T312)Imeg})	kidney inflammation	J:260667
\Fscn1^{Gt(OST124903)Lex}/\Fscn1^{Gt(OST124903)Lex} (B6.129S5-Fscn1^{Gt(OST124903)Lex})	abnormal dendritic cell chemotaxis	J:169408
	abnormal dendritic cell physiology	J:169408
	abnormal Langerhans cell physiology	J:169408
\Fsd2^em1(IMPC)Mbp/\Fsd2^em1(IMPC)Mbp (C57BL/6N-Fsd2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Fshr^tm1Saco/\Fshr^tm1Saco (involves: 129)	enlarged spleen	J:70933
\Fshr^tm1Saco/\Fshr^tm1Saco (involves: 129)	increased pre-B cell number	J:65577
\Fstl1^{tm1b(EUCOMM)Hmgu}/\Fstl1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Fstl1^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Fth1^tm1.1Lck/\Fth1^tm1.1Lck \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Fth1^tm1.1Lck Tg(Mx1-cre)1Cgn)	decreased spleen iron level	J:166515
	liver inflammation	J:166515
\Ftl1^tm1.1Ruvi/\Ftl1^tm1.1Ruvi (involves: 129 * C57BL/6)	abnormal mononuclear phagocyte morphology	J:244236
\Fto^tm1.2Pzg/\Fto^tm1.2Pzg (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	dermatitis	J:166984
\Fto^tm1.3Pzg/\Fto^tm1.3Pzg (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	dermatitis	J:166984
\Fts/\Fts⁺ (involves: C57BL/6 * SJL)	thymus hyperplasia	J:20159
\Fts/\Fts⁺ (B6.Cg-Fts)	abnormal CD4-positive T cell differentiation	J:108193
	abnormal T cell morphology	J:108193
	abnormal T cell physiology	J:108193
	increased thymocyte number	J:108193
	thymus hyperplasia	J:108193
\Fubp1^em1(IMPC)Mbp/\Fubp1⁺ (C57BL/6N-Fubp1^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Fubp1^tm1.1Dlev/\Fubp1^tm1.1Dlev (involves: 129 * C57BL/6)	decreased B cell number	J:229985
	lymphoid hypoplasia	J:229985
	spleen hypoplasia	J:229985
	thymus hypoplasia	J:229985
\Fundc2^tm1Qim/\Fundc2^tm1Qim (involves: C57BL/6)	immune system phenotype	J:301633
\Furin^tm1Jwmc/\Furin^tm1Jwmc \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal regulatory T cell physiology	J:204761
\Fus^{Gt(U3NeoSV1)HO14Ggh}/\Fus^{Gt(U3NeoSV1)HO14Ggh} (B6.129S2-Fus^{Gt(U3NeoSV1)HO14Ggh})	abnormal immunoglobulin level	J:60213
	decreased B cell number	J:60213
	decreased lymphocyte cell number	J:60213
	lymphoid hypoplasia	J:60213
	small thymus	J:60213
\Fut2^tm1Sdo/\Fut2^tm1Sdo (B6.129X1-Fut2^tm1Sdo)	increased susceptibility to fungal infection	J:90993
\Fut4^tm1Jbl/\Fut4^tm1Jbl (B6.129S2-Fut4^tm1Jbl)	impaired leukocyte tethering or rolling	J:79397
	increased eosinophil cell number	J:79397
	increased granulocyte number	J:79397
	increased monocyte cell number	J:79397
	increased neutrophil cell number	J:79397
\Fut4^tm1Jbl/\Fut4^tm1Jbl \Fut7^tm1Jbl/\Fut7^tm1Jbl (B6.129S2-Fut7^tm1Jbl Fut4^tm1Jbl)	abnormal immune system organ morphology	J:79397
	abnormal leukocyte migration	J:79397
	abnormal leukocyte physiology	J:79397
	abnormal lymph node primary follicle morphology	J:79397
	abnormal neutrophil physiology	J:79397
	decreased susceptibility to bacterial infection	J:115682
	decreased susceptibility to type IV hypersensitivity reaction	J:79388
	impaired leukocyte tethering or rolling	J:79397
	increased leukocyte cell number	J:79397
	increased neutrophil cell number	J:79397
	lymph node hypoplasia	J:79388, J:79397
	small lymph nodes	J:79397
\Fut7^tm1Brs/\Fut7^tm1Brs (involves: 129 * C57BL/6)	immune system phenotype	J:64232
\Fut7^tm1Jbl/\Fut7^tm1Jbl (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal granulocyte physiology	J:35023
	abnormal immune system physiology	J:35023
	abnormal leukocyte adhesion	J:35023
	abnormal leukocyte migration	J:35023
	abnormal leukocyte physiology	J:35023
	abnormal leukocyte tethering or rolling	J:35023
	abnormal lymph node primary follicle morphology	J:35023
	impaired neutrophil recruitment	J:35023
\Fut7^tm1Jbl/\Fut7^tm1Jbl (B6.129S2-Fut7^tm1Jbl)	decreased susceptibility to type IV hypersensitivity reaction	J:79388, J:74776
\Fut7^tm1Jbl/\Fut7^tm1Jbl (B6.129S2-Fut7^tm1Jbl)	impaired neutrophil recruitment	J:79397
\Fut8^{em1(IMPC)Wtsi}/\Fut8^{em1(IMPC)Wtsi} (C57BL/6N-Fut8^{em1(IMPC)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Fv4^r/\Fv4⁺ (involves: AKR/J * BALB/c * FRG)	decreased susceptibility to Retroviridae infection	J:5714, J:5684
\Fxn^tm1Mkn/\Fxn^tm1Mkn \Tg(FXN)YG8Pook/0 (involves: 129/Sv * C57BL/6 * CBA)	brain inflammation	J:216422
\Fxn^tm1Mkn/\Fxn^tm1Pand (involves: 129/Sv * C57BL/6)	brain inflammation	J:216422
\Fxr1^tm1Dln/\Fxr1^tm1Dln (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:91191
\Fyb1^tm1Gak/\Fyb1^tm1Gak (B6.129-Fyb1^tm1Gak)	immune system phenotype	J:112087
\Fyb1^tm1Gak/\Fyb1^tm1Gak (involves: 129S1/Sv * 129X1/SvJ)	abnormal leukocyte adhesion	J:111368
	abnormal T cell physiology	J:126545
	decreased interleukin-2 secretion	J:111368, J:126545
	decreased T cell proliferation	J:111368, J:126545
	decreased thymocyte number	J:111368
\Fyn^tm1Rmp/\Fyn^tm1Rmp (involves: 129S2/SvPas * C57BL/6)	abnormal T cell activation	J:70886
	abnormal thymocyte activation	J:70886
	decreased T cell proliferation	J:70886
\Fyn^tm1Rmp/\Fyn^tm1Rmp (involves: 129S2/SvPas)	decreased gamma-delta T cell number	J:37062
\Fyn^tm1Rmp/\Fyn^tm1Rmp (involves: 129S2/SvPas)	decreased T cell number	J:37062
\Fyn^tm1Rmp/\Fyn^tm1Rmp (B6.129S2-Fyn^tm1Rmp)	abnormal eosinophil physiology	J:114287
	abnormal interleukin-4 secretion	J:114287
	decreased IgE level	J:114287
	decreased interleukin-2 secretion	J:114287
	increased interleukin-5 secretion	J:114287
	increased susceptibility to type I hypersensitivity reaction	J:114287
\Fyn^tm1Rmp/\Fyn^tm1Rmp \Lck^tm1Mak/\Lck^tm1Mak (involves: 129S2/SvPas)	abnormal alpha-beta intraepithelial T cell morphology	J:112977
	abnormal NK T cell number	J:37940
	absent CD4-positive, alpha-beta T cells	J:37940
	absent CD8-positive, alpha-beta T cells	J:37940
	absent T cells	J:37062
	arrested T cell differentiation	J:37062, J:37940
	decreased double-positive T cell number	J:37940
	decreased gamma-delta intraepithelial T cell number	J:112977, J:37940
	thymus hypoplasia	J:37062, J:37940
\Fyn^tm1Sor/\Fyn^tm1Sor (either: 129S7/SvEvBrd-Fyn^tm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))	abnormal immune cell physiology	J:2242
	abnormal T cell clonal deletion	J:2242
	abnormal T cell physiology	J:2242
	abnormal thymocyte activation	J:2242
	decreased interleukin-2 secretion	J:2242
	decreased T cell proliferation	J:2242
	increased IgG2a level	J:2242
	increased IgM level	J:2242
\Fyn^tm1Sor/\Fyn^tm1Sor (B6.129S7-Fyn^tm1Sor)	abnormal CD4-positive, alpha-beta T cell physiology	J:93886
	abnormal NK cell physiology	J:187430
	abnormal T cell proliferation	J:93886
	decreased IgE level	J:93886
	decreased interferon-gamma secretion	J:187430
\Fyn^tm1Sor/\Fyn^tm1Sor (involves: 129S7/SvEvBrd)	abnormal chemokine level	J:80658
\Fyn^tm1Sor/\Fyn^tm1Sor (involves: 129S7/SvEvBrd)	abnormal macrophage physiology	J:80658
\Fyn^tm1Sor/\Fyn^tm1Sor \Lck^tm1Litt/\Lck^tm1.1Litt \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129S7/SvEvBrd * 129X1/SvJ)	abnormal regulatory T cell physiology	J:152472
	decreased regulatory T cell number	J:152472
	decreased T cell proliferation	J:152472
	enlarged lymph nodes	J:152472
	increased regulatory T cell number	J:152472
	increased T cell number	J:152472
\Fyn^tm1Sor/\Fyn^tm1Sor \Yes1^tm1Sor/\Yes1^tm1Sor (involves: 129S7/SvEvBrd)	enlarged spleen	J:20346
	increased spleen white pulp amount	J:20346
	myeloid hyperplasia	J:20346
\Fyn^tm1Yik/\Fyn^tm1Yik (involves: C57BL/6 * CBA)	abnormal cytokine secretion	J:99347
	abnormal interleukin secretion	J:99347
	increased susceptibility to experimental autoimmune uveoretinitis	J:99347
	increased tumor necrosis factor secretion	J:99347
\Fyn^tm1Yik/\Fyn^tm1Yik \Ptk2^tm1Lfr/\Ptk2⁺ (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal T cell differentiation	J:110771
	decreased double-positive T cell number	J:110771
	decreased thymocyte number	J:110771
	thymus cortex atrophy	J:110771
\Fzd1^em1(IMPC)Mbp/\Fzd1^em1(IMPC)Mbp (C57BL/6N-Fzd1^em1(IMPC)Mbp/MbpMmucd)	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Fzd9^tm1Uta/\Fzd9^tm1Uta (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal lymph node medullary cord morphology	J:98133
	abnormal lymph node morphology	J:98133
	abnormal spleen marginal zone morphology	J:98133
	abnormal spleen red pulp morphology	J:98133
	decreased B cell number	J:98133
	decreased pre-B cell number	J:98133
	decreased pro-B cell number	J:98133
	enlarged lymph nodes	J:98133
	enlarged spleen	J:98133
	increased eosinophil cell number	J:98133
	increased leukocyte cell number	J:98133
	increased monocyte cell number	J:98133
	increased neutrophil cell number	J:98133
	thymus atrophy	J:98133
\G2e3^em1(IMPC)Tcp/\G2e3^em1(IMPC)Tcp (C57BL/6NCrl-G2e3^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\G6pc2^tm1.1Pesa/\G6pc2^tm1.1Pesa (NOD.129S2-G6pc2^tm1.1Pesa)	abnormal CD8-positive, alpha beta T cell morphology	J:160286
	abnormal CD8-positive, alpha-beta T cell physiology	J:160286
	decreased interferon-gamma secretion	J:160286
	decreased T cell proliferation	J:160286
	immune system phenotype	J:160286
\G6pc3^tm1Jyc/\G6pc3^tm1Jyc (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil physiology	J:120741
	decreased neutrophil cell number	J:120741
	impaired granulocyte bactericidal activity	J:120741
	increased granulocyte number	J:120741
	increased susceptibility to bacterial infection	J:120741
\G6pd2^em1(IMPC)Tcp/\G6pd2^em1(IMPC)Tcp (C57BL/6NCrl-G6pd2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Gab2^tm1Gsf/\Gab2^tm1Gsf (involves: BALB/c)	abnormal response to infection	J:122213
\Gab2^tm1Gsf/\Gab2^tm1Gsf (involves: BALB/c)	decreased susceptibility to Retroviridae infection	J:122429
\Gab2^tm1Hhg/\Gab2^tm1Hhg (involves: 129S4/SvJae)	decreased mast cell degranulation	J:70424
	decreased mast cell number	J:70424
	decreased susceptibility to type I hypersensitivity reaction	J:70424
	immune system phenotype	J:70424
\Gab2^tm1Pngr/\Gab2^tm1Pngr (B6.Cg-Gab2^tm1Pngr)	abnormal osteoclast differentiation	J:97515
	abnormal osteoclast morphology	J:97515
	decreased osteoclast cell number	J:97515
\Gab2^tm1Thir/\Gab2^tm1Thir (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal mast cell differentiation	J:75092
	abnormal mast cell physiology	J:75092
	decreased mast cell number	J:75092
\Gab2^tm2.1Thir/\Gab2^tm2.1Thir (involves: 129T/SvJcl * C57BL/6Jcl)	immune system phenotype	J:178045
\Gab2^tm3.1Thir/\Gab2^tm3.1Thir (involves: 129T/SvJcl * C57BL/6Jcl)	decreased mast cell degranulation	J:178045
	decreased mast cell number	J:178045
	decreased susceptibility to type I hypersensitivity reaction	J:178045
	immune system phenotype	J:178045
\Gab2^tm4.1Thir/\Gab2^tm4.1Thir (involves: 129T/SvJcl * C57BL/6Jcl)	decreased mast cell degranulation	J:178045
	decreased mast cell number	J:178045
	decreased susceptibility to type I hypersensitivity reaction	J:178045
	immune system phenotype	J:178045
\Gab3^em1Khoe/\Gab3^em1Khoe (C57BL/6-Gab3^em1Khoe)	abnormal mature NK cell morphology	J:291290
	abnormal NK cell physiology	J:291290
	abnormal uterine NK cell morphology	J:291290
	decreased NK cell number	J:291290
	immune system phenotype	J:291290
\Gab3^m1Khoe/\Gab3^m1Khoe (C57BL/6-Gab3^m1Khoe)	abnormal mature NK cell morphology	J:291290
	abnormal NK cell physiology	J:291290
	abnormal uterine NK cell morphology	J:291290
	decreased NK cell number	J:291290
	immune system phenotype	J:291290
\Gabarapl2^{tm1b(EUCOMM)Hmgu}/\Gabarapl2⁺ (C57BL/6N-Gabarapl2^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Gabpa^Gt(XH074)Byg/\Gabpa^Gt(XH074)Byg (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:92671
	small thymus	J:92671
\Gabpb1^tm1Hhx/\Gabpb1^tm1Hhx (involves: 129 * C57BL/6)	immune system phenotype	J:137300
\Gabpb2^{Gt(RRJ488)Byg}/\Gabpb2^{Gt(RRJ488)Byg} (involves: 129P2/OlaHsd)	increased B cell proliferation	J:141846
	increased IgG1 level	J:141846
	increased IgM level	J:141846
	increased spleen germinal center number	J:141846
\Gabra5^{em1(IMPC)Ccpcz}/\Gabra5^{em1(IMPC)Ccpcz} (C57BL/6N-Gabra5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Gabrb3^tm2.1Geh/\Gabrb3^tm2.1Geh \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:333883
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:333883
	abnormal T-helper 17 cell differentiation	J:333883
	immune system phenotype	J:333883
	increased susceptibility to experimental autoimmune encephalomyelitis	J:333883
\Gabrg1^{em1(IMPC)Ccpcz}/\Gabrg1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gabrg1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Gad2^tm1Miya/\Gad2^tm1Miya (NOD.129P2-Gad2^tm1Miya)	pancreas inflammation	J:88785
\Gadd45a^tm1Ajf/\Gadd45a^tm1Ajf (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))	abnormal lymphopoiesis	J:76041
	decreased basophil cell number	J:76041
	decreased eosinophil cell number	J:76041
	decreased leukocyte cell number	J:76041
	decreased lymphocyte cell number	J:76041
	glomerulonephritis	J:76041
	increased anti-double stranded DNA antibody level	J:76041
	increased anti-histone antibody level	J:76041
	increased anti-single stranded DNA antibody level	J:76041
	increased autoantibody level	J:76041
	increased IgG1 level	J:76041
	increased IgM level	J:76041
	increased inflammatory response	J:76041
	increased T cell number	J:76041
	increased T cell proliferation	J:76041
	increased thymocyte number	J:57882
	increased thymus weight	J:57882
\Gadd45b^tm1Flv/\Gadd45b^tm1Flv (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:87396
	abnormal dendritic cell physiology	J:87396
	abnormal T-helper 1 cell differentiation	J:87396
	abnormal T-helper 1 physiology	J:87396
	abnormal T-helper 2 physiology	J:87396
	decreased interferon-gamma secretion	J:87396
	decreased interleukin-2 secretion	J:87396
	decreased interleukin-4 secretion	J:87396
	decreased interleukin-6 secretion	J:87396
	decreased interleukin-12 secretion	J:87396
\Gadd45b^tm1Flv/\Gadd45b^tm1Flv (B6.129S6-Gadd45b^tm1Flv)	abnormal T-helper 1 physiology	J:118837
	glomerulonephritis	J:118837
	increased interferon-gamma secretion	J:118837
	increased susceptibility to experimental autoimmune encephalomyelitis	J:118837
	increased T cell proliferation	J:118837
	spleen hyperplasia	J:118837
\Gadd45b^tm1Flv/\Gadd45b^tm1Flv \Gadd45g^tm1Flv/\Gadd45g^tm1Flv (involves: 129S1/Sv * 129S6/SvEvTac)	abnormal T-helper 1 cell differentiation	J:87396
\Gadd45b^tm1Flv/\Gadd45b^tm1Flv \Gadd45g^tm1Flv/\Gadd45g^tm1Flv (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)	glomerulonephritis	J:118837
	increased anti-double stranded DNA antibody level	J:118837
	increased anti-histone antibody level	J:118837
	increased IgG1 level	J:118837
	increased IgM level	J:118837
	increased mature B cell number	J:118837
	increased memory T cell number	J:118837
	spleen hyperplasia	J:118837
\Gadd45g^tm1Flv/\Gadd45g^tm1Flv (involves: 129S1/Sv)	abnormal NK cell physiology	J:87396
	abnormal T-helper 1 cell differentiation	J:87396
	abnormal T-helper 1 physiology	J:69475
	abnormal type IV hypersensitivity reaction	J:69475
	decreased interferon-gamma secretion	J:87396, J:69475
\Gadd45g^tm1Jni/\Gadd45g^tm1Jni (involves: 129P2/OlaHsd)	immune system phenotype	J:68832
\Gak^{em1(IMPC)Ccpcz}/\Gak⁺ (C57BL/6NCrl-Gak^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Galc^tm1Wngr/\Galc^tm1Wngr (involves: 129S2/SvPas)	abnormal immune system physiology	J:78691
\Galc^twi-5J/\Galc^twi-5J (BXD32/TyJ-Galc^twi-5J/J)	abnormal leukocyte morphology	J:199132
\Galc^twi/\Galc^twi (B6.CE-Galc^twi/J)	abnormal microglial cell morphology	J:108359
\Galc^twi/\Galc^twi (B6.CE-Galc^twi/J)	abnormal osteoclast physiology	J:165361
\Galc^twi/\Galc^twi (involves: C57BL/6J * CE/J)	abnormal macrophage morphology	J:6390
\Galc^twi/\Galc^twi (involves: CE/J)	CNS inflammation	J:78223
\Galc^twi/\Galc^twi \Glb1^tm1Adz/\Glb1⁺ (involves: 129P2/OlaHsd * C57BL/6J * CE/J)	immune system phenotype	J:63197
\Galc^twi/\Galc^twi \Glb1^tm1Adz/\Glb1^tm1Adz (involves: 129P2/OlaHsd * C57BL/6J * CE/J)	abnormal macrophage physiology	J:63197
	enlarged spleen	J:63197
\Galc^twi/\Galc^twi \Il6⁺/? (involves: 129S2/SvPas * C57BL/6J * CE/J)	abnormal tumor necrosis factor level	J:56656
\Galc^twi/\Galc^twi \Il6^tm1Kopf/\Il6^tm1Kopf (involves: 129S2/SvPas * C57BL/6J * CE/J)	abnormal tumor necrosis factor level	J:56656
\Galnt1^tm1.1Jxm/\Galnt1^tm1.1Jxm (B6NHsd.Cg-Galnt1^tm1.1Jxm)	abnormal immune system physiology	J:128982
	decreased B cell number	J:128982
	decreased basophil cell number	J:128982
	decreased eosinophil cell number	J:128982
	decreased germinal center B cell number	J:128982
	decreased IgG level	J:128982
	decreased leukocyte cell number	J:128982
	decreased plasma cell number	J:128982
	decreased spleen germinal center number	J:128982
	decreased T cell number	J:128982
	impaired leukocyte tethering or rolling	J:128982
	increased lymphocyte cell number	J:128982
	lymph node hypoplasia	J:128982
\Galnt3^{em1(IMPC)Ccpcz}/\Galnt3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Galnt3^{em1(IMPC)Ccpcz}/Ccpcz)	increased eosinophil cell number	J:211773
\Galnt3^tm1.1Cfg/\Galnt3^tm1.1Cfg (involves: C57BL/6)	decreased monocyte cell number	J:217719
\Galnt13^em1(IMPC)Mbp/\Galnt13^em1(IMPC)Mbp (C57BL/6N-Galnt13^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Galnt18^{tm1b(KOMP)Wtsi}/\Galnt18^{tm1b(KOMP)Wtsi} (C57BL/6N-Galnt18^{tm1b(KOMP)Wtsi}/Wtsi)	increased NK cell number	J:211773
\Galr1^em1(IMPC)H/\Galr1^em1(IMPC)H (C57BL/6N-Galr1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
\Galr2^{Gt(OST105469)Lex}/\Galr2^{Gt(OST105469)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:103485
	increased T cell number	J:103485
\Galt^{Gt(E285B04)Wrst}/\Galt^{Gt(E285B04)Wrst} (involves: 129P2/OlaHsd * C57BL/6J)	brain inflammation	J:234753
	liver inflammation	J:234753
\Gapt^tm1.1Wz/\Gapt^tm1.1Wz (Not Specified)	immune system phenotype	J:138146
	increased B cell proliferation	J:138146
	increased IgG2b level	J:138146
	increased IgG3 level	J:138146
	increased IgM level	J:138146
	increased marginal zone B cell number	J:138146
\Gapvd1^em1(IMPC)Mbp/\Gapvd1⁺ (C57BL/6N-Gapvd1^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Garem1^em1(IMPC)Mbp/\Garem1^em1(IMPC)Mbp (C57BL/6N-Garem1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Garin1a^{em1(IMPC)Ccpcz}/\Garin1a^{em1(IMPC)Ccpcz} (C57BL/6N-Garin1a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Garin1b^{em1(IMPC)Ccpcz}/\Garin1b^{em1(IMPC)Ccpcz} (C57BL/6N-Garin1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Garin2^{em1(IMPC)Ccpcz}/\Garin2^{em1(IMPC)Ccpcz} (C57BL/6N-Garin2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Gars1^em1(IMPC)Tcp/\Gars1⁺ (C57BL/6NCrl-Gars1^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
\Gas2l2^{tm1a(KOMP)Wtsi}/\Gas2l2^{tm1a(KOMP)Wtsi} (C57BL/6N-Gas2l2^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
\Gas6^tm1Hiar/\Gas6^tm1Hiar (B6.129P2-Gas6^tm1Hiar)	immune system phenotype	J:112430
\Gasa1^BALB/cCrSlc/\Gasa1^BALB/cCrSlc (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
\Gasa1^BALB/cCrSlc/\Gasa1^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
\Gasa2^BALB/cCrSlc/\Gasa2^BALB/cCrSlc (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
\Gasa2^BALB/cCrSlc/\Gasa2^BALB/cCrSlc \Gasa4^BALB/cCrSlc/\Gasa4^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:75277
\Gasa2^BALB/cCrSlc/\Gasa2^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:54699
\Gasa3^BALB/cCrSlc/\Gasa3^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:75277
\Gasa4^BALB/cCrSlc/\Gasa4^C57BL/6 (involves: BALB/cCrSlc * C57BL/6)	stomach inflammation	J:75277
\Gast^tm1Lcs/\Gast^tm1Lcs (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	stomach inflammation	J:97527
\Gata1^Plt13/\Gata1⁺ (BALB/c-Gata1^Plt13)	abnormal myelopoiesis	J:113720
	abnormal thrombopoiesis	J:113720
	enlarged spleen	J:113720
	increased spleen weight	J:113720
\Gata1^tm1Mym/Y \Tg(Gata1)#Mym/0 (involves: 129P2/OlaHsd C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
\Gata1^tm1Mym/Y \Tg(Gata1V205G)1Mym/0 (involves: C57BL/6 DBA/2)	abnormal mononuclear cell morphology	J:89054
	abnormal thrombopoiesis	J:89054
\Gata1^tm1Mym/\Gata1⁺ (involves: 129P2/OlaHsd)	decreased spleen red pulp amount	J:88685
	decreased spleen white pulp amount	J:88685
	enlarged spleen	J:88685
	pale spleen	J:88685
\Gata1^tm1Mym/\Gata1^tm1Mym \Tg(Gata1)#Mym/0 (involves: 129P2/OlaHsd C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
\Gata1^tm1Sho/Y \Tg(Gata1)#Mym/0 (involves: 129S4/SvJae C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
\Gata1^tm1Sho/\Gata1⁺ (involves: 129S4/SvJae * C57BL/6)	decreased eosinophil cell number	J:88711
\Gata1^tm1Sho/\Gata1^tm1Sho \Tg(Gata1)#Mym/0 (involves: 129S4/SvJae C57BL/6 * DBA/2J)	increased leukocyte cell number	J:158252
\Gata1^tm2Sho/Y (involves: 129S4/SvJae * C57BL/6 * CD-1)	abnormal spleen morphology	J:78348
	abnormal spleen red pulp morphology	J:78540
	decreased lymphocyte cell number	J:78348
	enlarged spleen	J:78348, J:78540
	increased neutrophil cell number	J:78348
	increased splenocyte number	J:78540
\Gata1^tm2Sho/\Gata1^tm2Sho (involves: 129S4/SvJae * C57BL/6 * CD-1)	abnormal spleen morphology	J:78348
	abnormal spleen red pulp morphology	J:78540
	decreased lymphocyte cell number	J:78348
	enlarged spleen	J:78348, J:78540
	increased neutrophil cell number	J:78348
	increased splenocyte number	J:78540
\Gata1^tm2Sho/\Gata1^tm2Sho (involves: 129S4/SvJae)	increased osteoclast cell number	J:111270
\Gata1^tm6Sho/Y (involves: 129S1/Sv)	decreased eosinophil cell number	J:88711
\Gata1^tm6Sho/Y (involves: 129S1/Sv)	enlarged spleen	J:88711
\Gata1^tm6Sho/\Gata1^tm6Sho (involves: 129S1/Sv)	decreased eosinophil cell number	J:88711
\Gata1^tm6Sho/\Gata1^tm6Sho (involves: 129S1/Sv * BALB/c)	abnormal leukocyte cell number	J:115273
	decreased circulating interleukin-4 level	J:115273
	decreased circulating interleukin-13 level	J:115273
	decreased eosinophil cell number	J:115273
	decreased lymphocyte cell number	J:115273
	increased neutrophil cell number	J:115273
\Gata1^tm6Sho/\Gata1^tm6Sho (C.129S1-Gata1^tm6Sho)	autoimmune response	J:182213
\Gata3^tm1.1Mbu/\Gata3^tm1.1Mbu (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal humoral immune response	J:123631
	decreased interleukin-4 secretion	J:123631
	increased interferon-gamma secretion	J:123631
\Gata3^tm1Iho/\Gata3^tm1Iho \Il13^{tm1(YFP/cre)Lky}/\Il13⁺ (involves: 129S4/SvJae)	decreased eosinophil cell number	J:178986
	increased susceptibility to parasitic infection	J:178986
\Gata3^tm1Iho/\Gata3^tm1Iho \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T cell differentiation	J:86996
	decreased CD4-positive, alpha-beta T cell number	J:86996
\Gata3^tm1Iho/\Gata3^tm1Iho \Tg(Cd4-cre)1Cwi/0 \Tg(DO11.10)10Dlo/0 (involves: BALB/c * C3H * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:86996
\Gata3^tm1Iho/\Gata3^tm1Iho \Tg(DO11.10)10Dlo/0 \Tg(Lck-cre)1Cwi/0 (involves: BALB/c * C3H * C57BL/6)	arrested T cell differentiation	J:86996
	decreased CD4-positive, alpha-beta T cell number	J:86996
	decreased CD8-positive, alpha-beta T cell number	J:86996
	decreased double-positive T cell number	J:86996
	small thymus	J:86996
\Gata3^tm1Iho/\Gata3^tm1Iho \Tg(Lck-cre)1Cwi/0 (involves: BALB/c)	abnormal CD8-positive, alpha-beta T cell number	J:86996
	abnormal T cell subpopulation ratio	J:86996
	arrested T cell differentiation	J:86996
	decreased CD4-positive, alpha-beta T cell number	J:86996
	decreased double-positive T cell number	J:86996
	decreased thymocyte number	J:86996
	increased T cell apoptosis	J:86996
	small thymus	J:86996
\Gata3^tm1Jeng/\Gata3^tm1Jeng (involves: 129S7/SvEvBrd)	abnormal immune system organ morphology	J:62552
\Gata3^tm1Jfz/\Gata3^tm1Jfz \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Cd4-cre)1Cwi/0 \Tg(Tcra5CC7,Tcrb5CC7)IWep/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:141145
\Gata3^tm1Jfz/\Gata3^tm1Jfz \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:93538
	abnormal T cell differentiation	J:141145
	decreased CD4-positive, alpha-beta T cell number	J:141145
	decreased interleukin-13 secretion	J:172134
\Gata3^tm1Jfz/\Gata3^tm1Jfz \Tg(Tnfrsf4-cre)1Nik/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:93538
	decreased IgE level	J:93538
	decreased T-helper 2 cell number	J:93538
	increased susceptibility to parasitic infection	J:93538
	increased T-helper 1 cell number	J:93538
\Gata3^tm1Jml/\Gata3^tm1Jml (involves: 129S/SvEv * C57BL/6)	abnormal immune system cell morphology	J:37093
\Gata3^tm2Jeng/\Gata3^tm2Jeng (Not Specified)	abnormal double-positive T cell morphology	J:155686
	abnormal T cell differentiation	J:155686
	abnormal T cell number	J:155686
	decreased double-negative T cell number	J:155686
	decreased gamma-delta T cell number	J:155686
	decreased thymocyte number	J:155686
\Gata3^tm3Gsv/\Gata3^tm3Gsv \Tg(KRT14-cre)8Brn/0 (involves: 129P2/OlaHsd * FVB/N)	decreased T cell number	J:117058
\Gata5^tm1.2Nemr/\Gata5^tm1.2Nemr (Not Specified)	kidney inflammation	J:227997
\Gata5^tm1Eno/\Gata5^tm1Eno (involves: 129S6/SvEvTac * C57BL/6)	urethritis	J:63036
	vaginal inflammation	J:63036
\Gatad2b^{tm1b(EUCOMM)Hmgu}/\Gatad2b⁺ (C57BL/6N-Gatad2b^{tm1b(EUCOMM)Hmgu}/Ics)	increased monocyte cell number	J:211773
\Gatm^em1Btlr/\Gatm^em1Btlr (C57BL/6J-Gatm^em1Btlr)	immune system phenotype	J:252049
\Gatm^em1Btlr/\Gatm^em1Btlr (C57BL/6J-Gatm^em1Btlr)	increased susceptibility to induced colitis	J:252049
\Gatm^em1Btlr/\Gatm^m1Btlr (C57BL/6J-Gatm^em1Btlr/Gatm^m1Btlr)	increased susceptibility to induced colitis	J:252049
\Gatm^m1Btlr/\Gatm⁺ (C57BL/6J-Gatm^m1Btlr)	increased susceptibility to induced colitis	J:252049
\Gatm^m1Btlr/\Gatm^m1Btlr (C57BL/6J-Gatm^m1Btlr)	increased susceptibility to induced colitis	J:252049
\Gba1^tm1.1Pmis/\Gba1^tm1.1Pmis \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal circulating chemokine level	J:167081
	abnormal circulating cytokine level	J:167081
	abnormal T cell differentiation	J:167081
	abnormal thymus morphology	J:167081
	decreased circulating interleukin-1 alpha level	J:167081
	decreased circulating interleukin-1 beta level	J:167081
	decreased circulating interleukin-6 level	J:167081
	decreased circulating tumor necrosis factor level	J:167081
	decreased double-positive T cell number	J:167081
	enlarged spleen	J:167081
	increased circulating interferon-gamma level	J:167081
	increased circulating interleukin-2 level	J:167081
	increased circulating interleukin-3 level	J:167081
	increased circulating interleukin-9 level	J:167081
	increased circulating interleukin-10 level	J:167081
	increased circulating interleukin-13 level	J:167081
	spleen hyperplasia	J:167081
\Gba1^tm1.1Pmis/\Gba1^tm1.2Pmis \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal circulating chemokine level	J:167081
	abnormal circulating cytokine level	J:167081
	abnormal T cell differentiation	J:167081
	abnormal thymus morphology	J:167081
	decreased circulating interleukin-1 alpha level	J:167081
	decreased circulating interleukin-1 beta level	J:167081
	decreased circulating interleukin-6 level	J:167081
	decreased circulating tumor necrosis factor level	J:167081
	decreased double-positive T cell number	J:167081
	enlarged spleen	J:167081
	increased circulating interferon-gamma level	J:167081
	increased circulating interleukin-2 level	J:167081
	increased circulating interleukin-3 level	J:167081
	increased circulating interleukin-9 level	J:167081
	increased circulating interleukin-10 level	J:167081
	increased circulating interleukin-13 level	J:167081
	spleen hyperplasia	J:167081
\Gba1^tm1Clk/\Gba1^tm1.1Clk \Tg(Tek-cre)12Flv/0 (involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6J)	abnormal macrophage morphology	J:117763
	abnormal spleen morphology	J:117763
	increased spleen weight	J:117763
\Gba1^tm1Karl/\Gba1^tm1.1Karl \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal immune system organ morphology	J:113751
	abnormal response to transplant	J:113751
	abnormal spleen morphology	J:113751
	enlarged spleen	J:113751
	intermingled spleen red and white pulp	J:113751
\Gba1^tm1Karl/\Gba1^tm1Karl \Tg(Nes-cre)1Kln/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal microglial cell morphology	J:127108
\Gba1^tm1Nsb/\Gba1^tm1Nsb (involves: 129S/SvEv * C57BL/6)	abnormal macrophage morphology	J:1100
\Gba1^tm1Rlp/\Gba1^tm1Rlp (involves: 129S4/SvJae * C57BL/6)	abnormal inflammatory response	J:76409
	abnormal Kupffer cell morphology	J:76409
	abnormal lymph node morphology	J:76409
	abnormal macrophage morphology	J:76409
	abnormal spleen physiology	J:76409
	decreased leukocyte cell number	J:76409
	increased IgG level	J:76409
	increased spleen weight	J:76409
	liver inflammation	J:76409
	lung inflammation	J:76409
	lymph node inflammation	J:76409
	skin inflammation	J:76409
\Gba1^tm2Ggb/\Gba1^tm1Nsb (involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
\Gba1^tm2Ggb/\Gba1^tm2Ggb (involves: 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
\Gba1^tm2Karl/\Gba1^tm2Karl \Tg(KRT14-cre)8Brn/? (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal macrophage morphology	J:127108
\Gba1^tm3Ggb/\Gba1^tm1Nsb (involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
\Gba1^tm3Ggb/\Gba1^tm3Ggb (involves: 129S5/SvEvBrd)	abnormal spleen morphology	J:86334
\Gba1^tm4Ggb/\Gba1^tm1Nsb (involves: 129S/SvEv * 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
\Gba1^tm4Ggb/\Gba1^tm4Ggb (involves: 129S5/SvEvBrd * C57BL/6)	abnormal spleen morphology	J:86334
\Gbp2-ps^tm1.1Ktak/\Gbp2-ps^tm1.1Ktak (involves: C57BL/6)	immune system phenotype	J:187397
\Gbp2-ps^tm1.1Ktak/\Gbp2-ps^tm1.1Ktak \Gbp5^tm1Ktak/\Gbp5^tm1Ktak (involves: C57BL/6)	immune system phenotype	J:187397
\Gbp2^tm1.1Kpf/\Gbp2^tm1.1Kpf (involves: 129P2/OlaHsd)	immune system phenotype	J:192526
	increased susceptibility to parasitic infection	J:192526
	increased susceptibility to parasitic infection induced morbidity/mortality	J:192526
\Gbp2b^tm1Tigm/\Gbp2b^tm1Tigm (B6.129S5-Gbp2b^tm1Tigm/Jdmm)	abnormal macrophage physiology	J:172364
	immune system phenotype	J:172364
	increased susceptibility to bacterial infection	J:172364
	increased susceptibility to bacterial infection induced morbidity/mortality	J:172364
\Gbp5^tm1Tigm/\Gbp5^tm1Tigm (B6.Cg-Gbp5^tm1Tigm)	decreased circulating interleukin-1 beta level	J:183942
	decreased circulating interleukin-18 level	J:183942
	decreased interleukin-1 beta secretion	J:183942
	decreased interleukin-18 secretion	J:183942
	impaired neutrophil recruitment	J:183942
	increased susceptibility to bacterial infection	J:183942
\Gbp7^tm1Ddgd/\Gbp7^tm1Ddgd (B6.129P2-Gbp7^tm1Ddgd)	increased susceptibility to bacterial infection	J:314959
\Gbp7^tm1Ddgd/\Gbp7^tm1Ddgd (B6.129P2-Gbp7^tm1Ddgd)	increased susceptibility to bacterial infection induced morbidity/mortality	J:314959
\Gbx2^tm1.1Mrt/\Gbx2^tm1.1Mrt \Fgf8^tm1.4Mrt/\Fgf8⁺ (B6.129-Gbx2^tm1.1Mrt Fgf8^tm1.4Mrt)	abnormal thymus development	J:100584
\Gca^tm1Roes/\Gca^tm1Roes (involves: 129P2/OlaHsd * 129S2/SvPas)	decreased susceptibility to endotoxin shock	J:81436
\Gcc2^em1Cya/\Gcc2^em1Cya (C57BL/6J-Gcc2^em1Cya)	increased autoantibody level	J:346915
\Gcnt1^{em1(IMPC)Ccpcz}/\Gcnt1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gcnt1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Gcnt1^tm1Jxm/\Gcnt1^tm1Jxm (involves: 129/Sv * C57BL/6)	abnormal acute inflammation	J:86387
	abnormal B cell differentiation	J:86387
	abnormal immune system cell morphology	J:86387
	abnormal immune system physiology	J:86387
	abnormal inflammatory response	J:86387
	increased leukocyte cell number	J:86387
	increased neutrophil cell number	J:86387
\Gcnt1^tm1Jxm/\Gcnt1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:113195
	impaired leukocyte tethering or rolling	J:113195
\Gcnt2^tm1Tmu/\Gcnt2^tm1Tmu (involves: 129S2/SvPas * C57BL/6)	decreased B cell number	J:100533
\Gcnt3^tm1.1Jxm/\Gcnt3^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased IgA level	J:149909
	decreased IgG1 level	J:149909
	decreased IgG2a level	J:149909
	decreased IgG2b level	J:149909
	increased susceptibility to induced colitis	J:149909
\Gcnt4^tm1.1Jxm/\Gcnt4^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased neutrophil cell number	J:149909
\Gcsam^tm1.1Rsky/\Gcsam^tm1.1Rsky (involves: BALB/cJ * C57BL/6)	decreased Peyer's patch number	J:125784
	immune system phenotype	J:125784
	small Peyer's patches	J:125784
\Gcsfis^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	enlarged spleen	J:61462
\Gcsfis^C57BL/6J/\Gcsfis^C57BL/6J (B6.SJL-Ptprc^a Pepc^b/BoyJ)	enlarged spleen	J:61462
\Gcsh^em1(IMPC)H/\Gcsh⁺ (C57BL/6N-Gcsh^em1(IMPC)H/H)	increased basophil cell number	J:211773
\Gda^{tm1a(KOMP)Wtsi}/\Gda^{tm1a(KOMP)Wtsi} (C57BL/6N-Gda^{tm1a(KOMP)Wtsi}/Wtsi)	decreased T-helper cell number	J:211773
	increased effector memory T-helper cell number	J:211773
\Gdap1^{tm2b(KOMP)Wtsi}/\Gdap1^{tm2b(KOMP)Wtsi} (C57BL/6N-Gdap1^{tm2b(KOMP)Wtsi}/Ucd)	abnormal thymus morphology	J:211773
	small thymus	J:211773
\Gdf1^tm1Sjl/\Gdf1^tm1Sjl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:60755
\Gdf2^tm1Lex/\Gdf2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:222016
	lymphangiectasis	J:222016
\Gdf5^em1(IMPC)H/\Gdf5^em1(IMPC)H (C57BL/6NTac-Gdf5^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
\Gdf6^{em1(IMPC)Ccpcz}/\Gdf6⁺ (C57BL/6NCrl-Gdf6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Gdf11^tm1Sjl/\Gdf11^tm1Sjl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal spleen morphology	J:94455
\Gdi2^{Gt(S1-11F1)Sor}/\Gdi2⁺ (B6.129S4-Gdi2^{Gt(S1-11F1)Sor})	immune system phenotype	J:326029
\Gdnf^tm1Lmgd/\Gdnf⁺ (B6.129-Gdnf^tm1Lmgd)	tubulointerstitial nephritis	J:103081
\Gdnf^tm1Rosl/\Gdnf^tm1Rosl (involves: 129S2/SvPas)	abnormal spleen red pulp morphology	J:33808
\Gdpd3^m1Anu/\Gdpd3^m1Anu (C57BL/6NCrlAnu-Gdpd3^m1Anu)	immune system phenotype	J:104190
\Gdpd5^{tm1b(EUCOMM)Hmgu}/\Gdpd5⁺ (C57BL/6N-Gdpd5^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Gfap^tm1Pkny/\Gfap^tm1Pkny \Ppt1^tm1Hof/\Ppt1^tm1Hof \Vim^tm1Cba/\Vim^tm1Cba (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	abnormal cytokine level	J:177265
	brain inflammation	J:177265
\Gfap^tm1Pkny/\Gfap^tm1Pkny \Vim^tm1Cba/\Vim^tm1Cba (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	decreased inflammatory response	J:123278
\Gfer^tm1.1Crg/\Gfer^tm1.1Crg \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129 * C57BL/6 * DBA)	liver inflammation	J:227242
\Gfi1^Gen/\Gfi1⁺ (C57BL/6J-Gfi1^Gen)	abnormal myelopoiesis	J:182679
	abnormal NK cell differentiation	J:182679
	abnormal NK cell physiology	J:182679
	absent neutrophils	J:182679
	decreased NK cell degranulation	J:182679
	immune system phenotype	J:182679
\Gfi1^tm1.1Wep/\Gfi1^tm1.1Wep (B6.129-Gfi1^tm1.1Wep)	arrested T cell differentiation	J:117105
	decreased B cell number	J:117105
	small thymus	J:117105
	thymus hypoplasia	J:117105
\Gfi1^tm1Tmo/\Gfi1^tm1Tmo (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:75143
	abnormal granulocyte differentiation	J:75143
	abnormal monocyte differentiation	J:75143
	abnormal myelopoiesis	J:75143
	abnormal T cell differentiation	J:75143
	decreased B cell number	J:75143
	decreased granulocyte number	J:75143
	decreased lymphocyte cell number	J:75143
	decreased neutrophil cell number	J:75143
	decreased T cell number	J:75143
	decreased thymocyte number	J:75143
	increased interleukin-1 beta secretion	J:75143
	increased interleukin-10 secretion	J:75143
	increased susceptibility to endotoxin shock	J:75143
	increased tumor necrosis factor secretion	J:75143
\Gfi1^tm1Tmo/\Gfi1^tm1Tmo (involves: 129S1/Sv * 129X1/SvJ)	decreased B cell number	J:192927
	decreased granulocyte number	J:192927
	decreased neutrophil cell number	J:192927
	decreased thymocyte number	J:192927
	increased monocyte cell number	J:192927
\Gfi1^tm1Wep/\Gfi1^tm1Wep (B6.129-Gfi1^tm1Wep)	abnormal T cell proliferation	J:117105
\Gfi1^tm1Wep/\Gfi1^tm1Wep \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell proliferation	J:117105
	abnormal T cell subpopulation ratio	J:117105
	abnormal T-helper 2 physiology	J:117105
\Gfi1^tm2Tmo/\Gfi1^tm2Tmo (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:93337
	decreased neutrophil cell number	J:93337
	decreased thymocyte number	J:93337
\Gfi1^{tm3(Gfib1)Tmo}/\Gfi1^{tm3(Gfib1)Tmo} (involves: 129S1/Sv * 129X1/SvJ)	abnormal monocyte morphology	J:116870
	decreased granulocyte number	J:116870
\Gfi1^tm4Tmo/\Gfi1^tm4Tmo (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphopoiesis	J:116870
	abnormal monocyte morphology	J:116870
	abnormal neutrophil morphology	J:116870
	abnormal T cell differentiation	J:116870
	decreased double-negative T cell number	J:116870
	decreased lymphocyte cell number	J:116870
	decreased neutrophil cell number	J:116870
	decreased thymocyte number	J:116870
\Gfi1^{tm5.1(GFI1)Tmo}/\Gfi1⁺ \Kras^tm4Tyj/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)	myeloid hyperplasia	J:192927
\Gfi1^{tm5.1(GFI1)Tmo}/\Gfi1^{tm5.1(GFI1)Tmo} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased monocyte cell number	J:192927
\Gfi1^{tm5.1(GFI1)Tmo}/\Gfi1^{tm5.1(GFI1)Tmo} \Kras^tm4Tyj/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)	myeloid hyperplasia	J:192927
\Gfi1^{tm6.1(GFI1)Tmo}/\Gfi1^{tm6.1(GFI1)Tmo} \Kras^tm4Tyj/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)	myeloid hyperplasia	J:192927
\Gfi1b^{em1(IMPC)Ccpcz}/\Gfi1b⁺ (C57BL/6NCrl-Gfi1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Gfi1b^{tm1b(EUCOMM)Hmgu}/\Gfi1b⁺ (C57BL/6N-Gfi1b^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Gfi1b^tm2Tmo/\Gfi1b^tm2Tmo \Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased splenocyte number	J:167416
\Gfra1^tm1Rosl/\Gfra1^tm1Rosl (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))	decreased Peyer's patch number	J:120816
\Gfus^tm1Jbl/\Gfus^tm1Jbl (involves: 129S2/SvPas * C57BL/6J)	increased leukocyte cell number	J:82239
	increased neutrophil cell number	J:82239
	large intestinal inflammation	J:82239
\Ggct^em1.2Smoc/\Ggct^em1.2Smoc (involves: C57BL/6J)	enlarged spleen	J:322242
\Ggct^em1.2Smoc/\Ggct^em1.2Smoc (involves: C57BL/6J)	increased spleen red pulp amount	J:322242
\Ggh^em1(IMPC)Tcp/\Ggh^em1(IMPC)Tcp (C57BL/6N-Ggh^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\ggld/\ggld (MRL/MpJ-Fas^lpr/J-ggld)	decreased IgG1 level	J:14258
\Ggps1^{tm1b(EUCOMM)Wtsi}/\Ggps1⁺ (C57BL/6N-Ggps1^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
\Ggt1^dwg/\Ggt1^dwg ((STOCK Pou1f1^dw x T(8;16)17H)F1)	decreased spleen red pulp amount	J:14281
\Ggt1^dwg/\Ggt1^dwg ((STOCK Pou1f1^dw x T(8;16)17H)F1)	increased osteoclast cell number	J:14281
\Ggt5^tm1Mwl/\Ggt5^tm1Mwl (involves: 129S7/SvEvBrd * C57BL/6J)	decreased acute inflammation	J:77691
\Ggta1^tm1Jbl/\Ggta1⁺ \Igh^tm1Jiac/\Igh⁺ \Igk^tm1Jiac/\Igk^tm1Jiac (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	decreased mature B cell number	J:133032
\Ggta1^tm1Jbl/\Ggta1⁺ \Igh^tm1Jiac/\Igh^tm1Jiac \Igk^tm1Jiac/\Igk⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	decreased mature B cell number	J:133032
\Ggta1^tm1Jbl/\Ggta1⁺ \Igh^tm1Jiac/\Igh^tm1Jiac \Igk^tm1Jiac/\Igk^tm1Jiac (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:133032
	abnormal B cell selection	J:133032
	decreased mature B cell number	J:133032
\Ggta1^tm1Jbl/\Ggta1^tm1Jbl (involves: 129S2/SvPas)	abnormal humoral immune response	J:113488, J:90851
	abnormal immunoglobulin level	J:113488
	abnormal response to transplant	J:90851
	decreased IgG level	J:90851
	increased IgM level	J:90851
\Gh^{tm1.1(KOMP)Vlcg}/\Gh^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gh^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	decreased spleen weight	J:211773
	small spleen	J:211773
\Ghr^tm1Arge/\Ghr^tm1Arge (involves: 129S/SvEv * C57BL/6J)	small spleen	J:66913
\Ghr^{tm1c(KOMP)Wtsi}/\Ghr^{tm1c(KOMP)Wtsi} \Tg(Fabp4-cre)1Rev/0 (involves: C57BL/6N)	decreased spleen weight	J:206358
	increased circulating interleukin-6 level	J:206358
\Ghr^tm1Jjk/\Ghr^tm1Jjk (involves: 129P2/OlaHsd * BALB/c)	decreased spleen weight	J:60207
\Ghr^tm1Jjk/\Ghr^tm1Jjk (involves: 129P2/OlaHsd * BALB/c)	decreased susceptibility to autoimmune diabetes	J:59132
\Ghr^tm2Mwat/\Ghr^tm2Mwat (involves: 129X1/SvJ * C57BL)	small spleen	J:95149
\Ghrh^tm1Salv/\Ghrh^tm1Salv (involves: 129 * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177054
\Ghrhr^lit/\Ghrhr^lit (C57BL/6J-Ghrhr^lit)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:85381
\Gigyf2^{tm1b(EUCOMM)Wtsi}/\Gigyf2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Gigyf2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased eosinophil cell number	J:211773
	increased spleen weight	J:211773
\Gimap1^m1Btlr/\Gimap1^m1Btlr (C57BL/6J-Gimap1^m1Btlr)	decreased B cell number	J:267546
	decreased B-1 B cell number	J:267546
	decreased CD8-positive, alpha-beta T cell number	J:267546
	decreased IgD level	J:267546
	increased CD4-positive, alpha-beta T cell number	J:267546
	increased IgM level	J:267546
\Gimap1^tm1.1Gwb/\Gimap1^tm1.1Gwb \Tg(CD2-icre)4Kio/0 (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal CD4-positive, alpha-beta T cell physiology	J:160782
	abnormal CD8-positive, alpha-beta T cell physiology	J:160782
	decreased B cell number	J:160782
	decreased B-1a cell number	J:160782
	decreased B-1b cell number	J:160782
	decreased B-2 B cell number	J:160782
	decreased CD4-positive, alpha-beta T cell number	J:160782
	decreased CD8-positive, alpha-beta T cell number	J:160782
	decreased follicular B cell number	J:160782
	decreased lymphocyte cell number	J:160782
	decreased marginal zone B cell number	J:160782
	decreased T cell number	J:160782
	decreased thymocyte number	J:160782
	decreased transitional stage T2 B cell number	J:160782
\Gimap3^tm1.1Yout/\Gimap3^tm1.1Yout (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	decreased T cell number	J:209926
	decreased thymocyte number	J:209926
\Gimap4^tm1Jcbs/\Gimap4^tm1Jcbs (B6.129P2-Gimap4^tm1Jcbs)	abnormal T cell physiology	J:135744
\Gimap5^m1Btlr/\Gimap5^m1Btlr (involves: C57BL/6J)	abnormal B cell physiology	J:160090
	abnormal B cell proliferation	J:160090
	abnormal NK T cell physiology	J:160090
	abnormal response to transplant	J:160090
	abnormal spleen B cell follicle morphology	J:160090
	colitis	J:160090
	decreased B cell number	J:160090
	decreased B cell proliferation	J:160090
	decreased B-1 B cell number	J:160090
	decreased CD8-positive, alpha-beta T cell number	J:160090
	decreased circulating interferon-gamma level	J:160090
	decreased circulating interleukin-4 level	J:160090
	decreased IgG1 level	J:160090
	decreased IgG2a level	J:160090
	decreased IgG2b level	J:160090
	decreased IgG3 level	J:160090
	decreased IgG level	J:160090
	decreased IgM level	J:160090
	decreased interferon-gamma secretion	J:160090
	decreased interleukin-4 secretion	J:160090
	decreased lymphocyte cell number	J:160090
	decreased mature B cell number	J:160090
	decreased NK cell number	J:160090
	decreased NK T cell number	J:160090
	decreased spleen B cell follicle number	J:160090
	decreased spleen B cell follicle size	J:160090
	decreased tumor necrosis factor secretion	J:160090
	increased granulocyte number	J:160090
	increased neutrophil cell number	J:160090
	intestinal inflammation	J:160090
	thymus atrophy	J:160090
\Gimap5^m1Btlr/\Gimap5^m1Btlr \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6J * DBA/2J)	decreased CD8-positive, alpha-beta T cell number	J:160090
	decreased thymocyte number	J:160090
\Gimap5^tm1Wlr/\Gimap5^tm1Wlr (either: B6.129-Gimap5^tm1Wlr or C.129-Gimap5^tm1Wlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:143620
	abnormal leukocyte morphology	J:143620
	abnormal lymphocyte cell number	J:143620
	abnormal response to transplant	J:143620
	abnormal spleen morphology	J:143620
	decreased B cell number	J:143620
	decreased CD4-positive, alpha-beta T cell number	J:143620
	decreased CD8-positive, alpha-beta T cell number	J:143620
	decreased NK cell number	J:143620
	decreased NK T cell number	J:143620
	decreased T cell number	J:143620
	increased granulocyte number	J:143620
	small lymph nodes	J:143620
	spleen hypoplasia	J:143620
\Gimap5^tm1Yout/\Gimap5^tm1Yout (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	decreased T cell number	J:209926
\Gimap6^tm1.1Gwb/\Gimap6^tm1.1Gwb \Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal leukocyte morphology	J:262059
	abnormal T cell physiology	J:262059
	decreased B cell number	J:262059
	decreased T cell number	J:262059
	increased B cell number	J:262059
	increased T cell apoptosis	J:262059
\Gimap6^{tm1a(KOMP)Wtsi}/\Gimap6^{tm1a(KOMP)Wtsi} (C57BL/6N-Gimap6^{tm1a(KOMP)Wtsi}/Wtsi)	decreased CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased monocyte cell number	J:211773
\Gin1^em1(IMPC)Mbp/\Gin1^em1(IMPC)Mbp (C57BL/6N-Gin1^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Git2^Gt(XG510)Byg/\Git2^Gt(XG510)Byg (B6.129P2-Git2^Gt(XG510)Byg)	decreased marginal zone B cell number	J:160613
\Git2^Gt(XG510)Byg/\Git2^Gt(XG510)Byg (C.129P2-Git2^Gt(XG510)Byg)	decreased marginal zone B cell number	J:160613
\Git2^Gt(XG510)Byg/\Git2^Gt(XG510)Byg \Tg(DO11.10)10Dlo/0 (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:160613
\Git2^Gt(XG510)Byg/\Git2^Gt(XG510)Byg \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha-beta T cell physiology	J:160613
	abnormal CD8-positive, alpha-beta T cell physiology	J:160613
	abnormal positive T cell selection	J:160613
	decreased CD8-positive, alpha-beta T cell number	J:160613
\Git2^Gt(XG510)Byg/\Git2^Gt(XG510)Byg \Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:160613
\Git2^tm1Hsb/\Git2^tm1Hsb (involves: C57BL/6 * CBA)	abnormal neutrophil differentiation	J:112663
	abnormal neutrophil physiology	J:112663
	enlarged spleen	J:112663
	impaired neutrophil chemotaxis	J:112663
	increased susceptibility to fungal infection	J:112663
	lung inflammation	J:112663
\Gja1^{em1(IMPC)Ccpcz}/\Gja1⁺ (C57BL/6NCrl-Gja1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Gja1^M1Jrt/\Gja1⁺ (involves: C3H/HeJ * C57BL/6J)	heart inflammation	J:101733
\Gja1^tm1.1Kwi/\Gja1⁺ (involves: 129P2/OlaHsd)	abnormal neutrophil physiology	J:129091
\Gja1^tm1Kwi/\Gja1⁺ \Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal lymphatic vessel morphology	J:188626
	absent lymphatic vessels	J:188626
\Gja1^tm1Kwi/\Gja1^{tm5(cre/ERT)Kwi} (involves: 129P2/OlaHsd)	abnormal neutrophil physiology	J:129091
\Gjb1^tm1Kwi/Y \Gjc2^tm1(EGFP)Kwi/\Gjc2^tm1(EGFP)Kwi (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	microgliosis	J:219594
	optic nerve inflammation	J:219594
	spinal cord inflammation	J:219594
\Gjb2^{tm3.1(Gjb1)Kwi}/\Gjb2⁺ \Tg(KRT5-cre)5132Jlj/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J * SJL)	abnormal lymphatic vessel morphology	J:188626
\Gjb2^{tm3.2(Gjb1)Kwi}/\Gjb2⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	abnormal lymphatic vessel morphology	J:188626
	absent lymphatic vessels	J:188626
\Gjb4^{tm1.1(KOMP)Vlcg}/\Gjb4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gjb4^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Gjb6^tm1Kwi/\Gjb6^tm1Kwi (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:85065
\Gjc2^tm1(EGFP)Kwi/\Gjc2^tm1(EGFP)Kwi (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:174197
\Gjc2^tm1(EGFP)Kwi/\Gjc2^tm1(EGFP)Kwi \Gjb1^tm1Kwi/\Gjb1^tm1Kwi (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	microgliosis	J:219594
	optic nerve inflammation	J:219594
	spinal cord inflammation	J:219594
\Gjc2^tm2.1Kwi/\Gjc2⁺ (involves: C57BL/6 * SJL)	microgliosis	J:174197
\Gjc2^tm2.1Kwi/\Gjc2^tm2.1Kwi (involves: C57BL/6 * SJL)	microgliosis	J:174197
\Gjd4^tm1.1Malt/\Gjd4^tm1.1Malt (involves: 129S2/SvPas * C57BL/6 * SJL)	decreased macrophage cell number	J:172698
\Gk5^m5Btlr/\Gk5^m5Btlr (C57BL/6J-Gk5^m5Btlr)	increased alpha-beta T cell number	J:265118
	increased CD8-positive, alpha-beta memory T cell number	J:265118
	increased central memory CD8 positive, alpha-beta T cell number	J:265118
\Gkn2^{tm1.1(KOMP)Vlcg}/\Gkn2^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal chemokine level	J:234656
	abnormal cytokine level	J:234656
	abnormal innate immunity	J:234656
	abnormal interleukin level	J:234656
	abnormal susceptibility to bacterial infection	J:234656
	abnormal T-helper 1 physiology	J:234656
	abnormal tumor necrosis factor level	J:234656
	increased susceptibility to bacterial infection	J:234656
	stomach inflammation	J:234656
\Glb1^tm1Jmat/\Glb1^tm1Jmat (involves: C57BL/6 * CBA * ICR)	abnormal lymphopoiesis	J:43534
	abnormal macrophage chemotaxis	J:102576
	small spleen	J:43534
\Glb1l2^tm1Lex/\Glb1l2^tm1Lex (B6;129S5-Glb1l2^tm1Lex/Mmucd)	decreased leukocyte cell number	J:171883
	decreased lymphocyte cell number	J:171883
	decreased NK cell number	J:171883
\Glg1^{Gt(RST092)Byg}/\Glg1⁺ (B6J.129P2-Glg1^{Gt(RST092)Byg})	abnormal cellular extravasation	J:226586
	abnormal leukocyte adhesion	J:226586
	enhanced leukocyte tethering or rolling	J:226586
\Glis2^tm1Amj/\Glis2^tm1Amj (involves: 129P2/OlaHsd * C57BL/6)	glomerulonephritis	J:134208
\Glmp^{Gt(P084H04)Wrst}/\Glmp^{Gt(P084H04)Wrst} (involves: 129S2/SvPas * C57BL/6)	abnormal Kupffer cell morphology	J:208774
	increased spleen weight	J:208774
	liver inflammation	J:208774
\Glmp^tm1Lex/\Glmp^tm1Lex (B6;129S5-Glmp^tm1Lex/Mmucd)	abnormal immune system physiology	J:171883
\Glmp^tm1Lex/\Glmp^tm1Lex (B6;129S5-Glmp^tm1Lex/Mmucd)	liver inflammation	J:171883
\Glra1^nmf11/\Glra1^nmf11 (C57BL/6J-Glra1^nmf11/J)	small spleen	J:78134
\Glra1^nmf11/\Glra1^nmf11 (C57BL/6J-Glra1^nmf11/J)	thymus atrophy	J:78134
\Glra2^{tm1b(KOMP)Wtsi}/Y (C57BL/6N-Glra2^{tm1b(KOMP)Wtsi}/H)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Glrb^em1(IMPC)Tcp/\Glrb⁺ (C57BL/6NCrl-Glrb^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Gls2^em1(IMPC)Tcp/\Gls2^em1(IMPC)Tcp (C57BL/6N-Gls2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Glt8d2^tm1Lex/\Glt8d2^tm1Lex (B6;129S5-Glt8d2^tm1Lex/Mmucd)	abnormal adaptive immunity	J:171883
	decreased IgG1 level	J:171883
	decreased IgG2a level	J:171883
\Glyr1^em1(IMPC)Tcp/\Glyr1^em1(IMPC)Tcp (C57BL/6N-Glyr1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Gm614^tm1.1Cya/\Gm614^tm1.1Cya \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	decreased susceptibility to systemic lupus erythematosus	J:307345
	immune system phenotype	J:307345
	increased B cell apoptosis	J:307345
\Gm4922^em1(IMPC)Tcp/\Gm4922^em1(IMPC)Tcp (C57BL/6NCrl-Gm4922^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Gm5148^{em1(IMPC)Ccpcz}/\Gm5148⁺ (C57BL/6NCrl-Gm5148^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Gm5148^{em1(IMPC)Ccpcz}/\Gm5148^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gm5148^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Gm5544^{tm1a(KOMP)Wtsi}/\Gm5544⁺ (C57BL/6N-Gm5544^{tm1a(KOMP)Wtsi}/Wtsi)	decreased marginal zone B cell number	J:211773
\Gm5544^{tm1a(KOMP)Wtsi}/\Gm5544^{tm1a(KOMP)Wtsi} (C57BL/6N-Gm5544^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Gm7694^em1(IMPC)J/\Gm7694^em1(IMPC)J (C57BL/6NJ-Gm7694^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Gm10800^em1(IMPC)Mbp/\Gm10800^em1(IMPC)Mbp (C57BL/6N-Gm10800^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Gm10851^{em1(IMPC)Ccpcz}/\Gm10851^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gm10851^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Gm15551^{em1(IMPC)Ccpcz}/\Gm15551^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gm15551^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Gm16685^em1Osb/\Gm16685^em1Osb (C57BL/6N-Gm16685^em1Osb)	decreased susceptibility to colitis induced morbidity/mortality	J:303079
\Gm26330^em1Liuq/\Gm26330^em1Liuq (C57BL/6-Gm26330^em1Liuq)	decreased NK cell number	J:341056
\Gm36723^em1Flv/\Gm36723^em1Flv (C57BL/6-Gm36723^em1Flv)	abnormal lymphopoiesis	J:258967
	abnormal NK cell physiology	J:258967
	decreased interferon-gamma secretion	J:258967
	decreased lymphocyte cell number	J:258967
	decreased mature NK cell number	J:258967
	decreased NK cell number	J:258967
	decreased susceptibility to bacterial infection	J:258967
	immune system phenotype	J:258967
	impaired natural killer cell mediated cytotoxicity	J:258967
	increased immature NK cell number	J:258967
\Gm36723^em2Flv/\Gm36723^em2Flv (C57BL/6-Gm36723^em2Flv)	immune system phenotype	J:258967
\Gm36723^em3Flv/\Gm36723^em3Flv (C57BL/6-Gm36723^em3Flv)	decreased mature NK cell number	J:258967
\Gm40600^em1Cya/\Gm40600^em1Cya (C57BL/6-Gm40600^em1Cya)	abnormal plasmablast number	J:311878
	decreased B cell number	J:311878
	decreased IgA level	J:311878
	decreased IgE level	J:311878
	decreased IgG1 level	J:311878
	decreased IgG2b level	J:311878
	decreased IgG2c level	J:311878
	decreased IgG3 level	J:311878
	decreased IgG level	J:311878
	decreased IgM level	J:311878
	decreased plasma cell number	J:311878
	immune system phenotype	J:311878
	increased B cell number	J:311878
	increased IgA level	J:311878
	increased IgE level	J:311878
	increased IgG1 level	J:311878
	increased IgG2b level	J:311878
	increased IgG2c level	J:311878
	increased IgG3 level	J:311878
	increased IgG level	J:311878
	increased IgM level	J:311878
	increased plasma cell number	J:311878
\Gm41610^em1Scrp/\Gm41610^em1Scrp (C57BL/6-Gm41610^em1Scrp)	decreased susceptibility to endotoxin shock	J:302605
	immune system phenotype	J:302605
	increased circulating interleukin-5 level	J:302605
	increased circulating interleukin-13 level	J:302605
\Gmds^{tm1a(KOMP)Wtsi}/\Gmds^{tm1a(KOMP)Wtsi} (C57BL/6N-Gmds^{tm1a(KOMP)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased dendritic cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased KLRG1+ CD8 alpha-beta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	decreased mature NK cell number	J:211773
	decreased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased plasmacytoid dendritic cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T-helper cell number	J:211773
	decreased transitional stage T2 B cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased gamma-delta T cell number	J:211773
	increased granulocyte number	J:211773
	increased immature NK cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK T cell number	J:211773
\Gmfg^tm1Jyw/\Gmfg^tm1Jyw (B6.Cg-Gmfg^tm1Jyw)	abnormal marginal zone B cell physiology	J:345500
	decreased lymphocyte chemotaxis	J:345500
	impaired B cell migration	J:345500
	increased IgM level	J:345500
\Gmnn^tm1.1Kio/\Gmnn^tm1.2Kio \Tg(CD2-icre)4Kio/0 (involves: 129S4/SvJae * C57BL/10 * CBA/Ca)	decreased CD4-positive, alpha-beta T cell number	J:159657
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:159657
	decreased CD8-positive, alpha-beta T cell number	J:159657
	decreased DN1 thymic pro-T cell number	J:159657
	decreased DN4 thymocyte number	J:159657
	decreased double-positive T cell number	J:159657
	decreased memory T cell number	J:159657
	decreased T cell proliferation	J:159657
	decreased thymocyte number	J:159657
\Gmnn^tm1Tjm/\Gmnn^tm1Tjm \Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * C57BL/6J * CBA)	abnormal spleen red pulp morphology	J:171741
	decreased granulocyte number	J:171741
	decreased leukocyte cell number	J:171741
	decreased neutrophil cell number	J:171741
\Gmppa^em1(IMPC)Tcp/\Gmppa^em1(IMPC)Tcp (C57BL/6N-Gmppa^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Gmps^em1(IMPC)Tcp/\Gmps⁺ (C57BL/6NCrl-Gmps^em1(IMPC)Tcp/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Gna11^tm1Soff/\Gna11^tm1Soff (involves: 129S7/SvEvBrd)	decreased susceptibility to type I hypersensitivity reaction	J:146132
\Gna11^tm1Soff/\Gna11^tm1Soff \Gnaq^tm2Soff/\Gnaq^tm2Soff \Tg(Tek-icre/ERT2)1Soff/? (involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)	decreased susceptibility to type I hypersensitivity reaction	J:146132
	immune system phenotype	J:146132
\Gna12^tm1.1Cgh/\Gna12^tm1.1Cgh \Gna13^tm2Cgh/\Gna13^tm2Cgh \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal germinal center B cell morphology	J:174313
	decreased B cell apoptosis	J:174313
	increased germinal center B cell number	J:174313
\Gna12^tm1Citb/\Gna12^tm1Citb \Gna13^tm2.1Soff/\Gna13^tm2.1Soff \Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal CD4-positive, alpha-beta T cell physiology	J:149560
	increased CD4-positive, alpha-beta T cell number	J:149560
	increased CD8-positive, alpha-beta T cell number	J:149560
	increased interleukin-2 secretion	J:149560
	increased susceptibility to autoimmune diabetes	J:149560
	increased susceptibility to type IV hypersensitivity reaction	J:149560
	increased T cell proliferation	J:149560
	lymph node hyperplasia	J:149560
	thymus hyperplasia	J:149560
\Gnai1^{tm1b(EUCOMM)Wtsi}/\Gnai1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Gnai1^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Gnai1^tm1Drs/\Gnai1^tm1Drs \Gnai3^tm1Lbi/\Gnai3^tm1Lbi (involves: 129S/SvEv)	decreased interleukin-10 secretion	J:104683
	increased tumor necrosis factor secretion	J:104683
\Gnai2^tm1Lbi/\Gnai2^tm1Lbi (involves: 129S7/SvEvBrd * C57BL/6J)	colitis	J:24434
\Gnai2^tm1Lbi/\Gnai2^tm1Lbi (involves: 129S7/SvEvBrd)	abnormal cytokine level	J:121471
	abnormal cytokine secretion	J:30507
	abnormal immune system morphology	J:30507
	abnormal immune system physiology	J:30507
	abnormal neutrophil physiology	J:121471
	colitis	J:24434
	increased circulating interferon-gamma level	J:121471
	increased circulating interleukin-4 level	J:121471
	increased circulating interleukin-5 level	J:121471
	increased granulocyte number	J:30507
	increased IgA level	J:30507
	increased IgG level	J:30507
	increased immunoglobulin level	J:30507
	increased inflammatory response	J:30507
	increased interferon-gamma secretion	J:30507
	increased interleukin-2 secretion	J:30507
	increased single-positive T cell number	J:30507
	increased susceptibility to parasitic infection	J:121471
	increased T cell number	J:30507
	increased T cell proliferation	J:30507
	increased tumor necrosis factor secretion	J:30507
	large intestinal inflammation	J:30507
	peritoneal inflammation	J:30507
\Gnai2^tm1Lbi/\Gnai2^tm1Lbi (either: 129 or (involves: 129S7/SvEvBrd * C57BL/6J))	abnormal cytokine secretion	J:24434
	increased granulocyte number	J:24434
	increased IgG level	J:24434
	increased IgM level	J:24434
	increased thymocyte number	J:24434
\Gnai2^tm1Lbi/\Gnai2^tm1Lbi (129-Gnai2^tm1Lbi)	abnormal cytokine secretion	J:91100
	immune system phenotype	J:91100
	increased interleukin-1 beta secretion	J:91100
	increased tumor necrosis factor secretion	J:91100
\Gnai2^tm1Lbi/\Gnai2^tm1Lbi (B6.129S7-Gnai2^tm1Lbi)	abnormal cellular extravasation	J:120069
	abnormal eosinophil physiology	J:120069
	abnormal leukocyte adhesion	J:120069
	abnormal leukocyte cell number	J:121161
	abnormal T cell physiology	J:121161
	decreased eosinophil cell number	J:120069
	increased eosinophil cell number	J:120069
	increased lymphocyte cell number	J:120069
	increased monocyte cell number	J:120069
	increased neutrophil cell number	J:120069
\Gnai2^tm1Lbi/\Gnai2^tm1Lbi (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:91100
	colitis	J:91100
	increased interleukin-1 beta secretion	J:91100
	increased tumor necrosis factor secretion	J:91100
\Gnai2^tm2.1Lbi/\Gnai2^tm2.1Lbi \Tg(Cd4-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA)	decreased T-helper 17 cell number	J:194587
	increased susceptibility to induced colitis	J:194587
\Gnai3^tm1Lbi/\Gnai3^tm1Lbi (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:120069
\Gnai3^tm1Lbi/\Gnai3^tm1Lbi (B6.129S-Gnai3^tm1Lbi)	abnormal T cell physiology	J:121161
\Gnao1^{tm1b(EUCOMM)Hmgu}/\Gnao1⁺ (C57BL/6N-Gnao1^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
\Gnas^Oedsml/\Gnas⁺ (involves: 101/H * C3H/HeH)	abnormal inflammatory response	J:65007
\Gnas^tm1Lsw/\Gnas⁺ (involves: 129S4/SvJae * CD-1)	thymus cortex atrophy	J:49340
\Gnb1l^em1(IMPC)Tcp/\Gnb1l⁺ (C57BL/6NCrl-Gnb1l^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
\Gnb1l^{Gt(OST35527)Lex}/\Gnb1l⁺ (B6;129S5-Gnb1l^{Gt(OST35527)Lex}/Orl)	abnormal spleen B cell follicle morphology	J:82809
	glomerulonephritis	J:82809
\Gnb2^em1(IMPC)J/\Gnb2^em1(IMPC)J (C57BL/6NJ-Gnb2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Gnb4^em1(IMPC)H/\Gnb4^em1(IMPC)H (C57BL/6NTac-Gnb4^em1(IMPC)H/H)	enlarged spleen	J:211773
\Gne^tm1.1Masn/\Gne^tm1.1Masn (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:184315
\Gngt2^em1(IMPC)Bay/\Gngt2^em1(IMPC)Bay (C57BL/6N-Gngt2^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
\Gnl2^{em1(IMPC)Ccpcz}/\Gnl2⁺ (C57BL/6NCrl-Gnl2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Gnmt^tm1Ymac/\Gnmt^tm1Ymac (involves: 129 * C57BL/6)	decreased leukocyte cell number	J:147857
	decreased monocyte cell number	J:147857
	decreased neutrophil cell number	J:147857
\Gnpda1^{tm1b(KOMP)Mbp}/\Gnpda1⁺ (C57BL/6N-Gnpda1^{tm1b(KOMP)Mbp}/Tcp)	increased neutrophil cell number	J:211773
\Gnptab^em1(IMPC)Mbp/\Gnptab⁺ (C57BL/6N-Gnptab^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Gnptab^nym/\Gnptab^nym (involves: BALB/cAnNHsd * C3H/HeNHsd)	brain inflammation	J:218156
\Gnptab^tm1Dkji/\Gnptab^tm1Dkji (involves: 129 * C57BL/6)	increased interleukin-6 secretion	J:231531
\Gnptab^tm1Kkol/\Gnptab^tm1Kkol (involves: 129 * C57BL/6)	abnormal osteoclast physiology	J:202751
\Gnptab^tm1Kkol/\Gnptab^tm1Kkol (involves: 129 * C57BL/6)	increased osteoclast cell number	J:202751
\Gnrh1^hpg/\Gnrh1^hpg (HPG/BmJ)	abnormal splenic cell ratio	J:19436
	increased B cell number	J:19436
	increased immature B cell number	J:19436
	increased mature B cell number	J:19436
\Gns^{tm1e(EUCOMM)Hmgu}/\Gns^{tm1e(EUCOMM)Hmgu} (C57BL/6N-A^tm1Brd Gns^{tm1e(EUCOMM)Hmgu})	microgliosis	J:242250
\Golga2^{tm1(KOMP)Vlcg}/\Golga2^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	increased alveolar macrophage number	J:270564
\Golm1^{Gt(KST273)Byg}/\Golm1^{Gt(KST273)Byg} (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:151282
	liver inflammation	J:151282
\Golph3^em1(IMPC)Tcp/\Golph3⁺ (C57BL/6NCrl-Golph3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Golph3^em1(IMPC)Tcp/\Golph3^em1(IMPC)Tcp (C57BL/6NCrl-Golph3^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged thymus	J:211773
\Golt1b^{tm1b(EUCOMM)Wtsi}/\Golt1b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Golt1b^{tm1b(EUCOMM)Wtsi}/Ieg)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Gon4l^justy/\Gon4l^justy (C3HeB/FeJ-Gon4l^justy)	abnormal humoral immune response	J:163412
	absent B cells	J:163412
	arrested B cell differentiation	J:163412
	decreased B cell number	J:163412
	decreased immature B cell number	J:163412
	decreased immunoglobulin level	J:163412
	decreased pro-B cell number	J:163412
	decreased spleen white pulp amount	J:163412
	decreased T cell number	J:163412
	small spleen	J:163412
	spleen hypoplasia	J:163412
\Got1^{tm1b(EUCOMM)Hmgu}/\Got1⁺ (C57BL/6N-Got1^{tm1b(EUCOMM)Hmgu}/H)	decreased basophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Got2^em1(IMPC)Mbp/\Got2⁺ (C57BL/6N-Got2^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
\Gp2^em1(IMPC)Mbp/\Gp2^em1(IMPC)Mbp (C57BL/6N-Gp2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Gp6^tm1Beni/\Gp6^tm1Beni \Clec1b^tm1.1Arte/\Clec1b^tm1.1Arte \Tg(Pf4-icre)Q3Rsko/0 (involves: 129 * C57BL/6)	abnormal lymphatic vessel morphology	J:217963
\Gp6^{tm2b(EUCOMM)Hmgu}/\Gp6^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Gp6^{tm2b(EUCOMM)Hmgu}/Orl)	increased lymphocyte cell number	J:211773
\Gp9^{tm1.1(KOMP)Vlcg}/\Gp9^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gp9^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
\Gpa33^tm1Jkhh/\Gpa33^tm1Jkhh (B6.129-Gpa33^tm1Jkhh)	abnormal immune tolerance	J:224768
	increased dendritic cell number	J:224768
	increased susceptibility to induced colitis	J:224768
	increased susceptibility to type IV hypersensitivity reaction	J:224768
\Gpa33^tm1Jkhh/\Gpa33^tm1Jkhh (involves: 129 * C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:231808
\Gpa33^tm1Jkhh/\Gpa33^tm1Jkhh (involves: 129 * C57BL/6)	increased susceptibility to induced colitis	J:231808
\Gpatch2^em1Boui/\Gpatch2^em1Boui (C57BL/6-Gpatch2^em1Boui)	decreased B cell number	J:336774
\Gpatch2^em1Boui/\Gpatch2^em1Boui (C57BL/6-Gpatch2^em1Boui)	immune system phenotype	J:336774
\Gpatch3^em1(IMPC)Mbp/\Gpatch3^em1(IMPC)Mbp (C57BL/6N-Gpatch3^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Gpatch4^{em1(IMPC)Ccpcz}/\Gpatch4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gpatch4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	immune system phenotype	J:211773
	small spleen	J:211773
\Gpbar1^{tm1.1(KOMP)Vlcg}/\Gpbar1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gpbar1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal lymph node morphology	J:211773
\Gpc1^em1(IMPC)Mbp/\Gpc1^em1(IMPC)Mbp (C57BL/6N-Gpc1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Gpc3^tm1Arge/Y (either: (involves: 129S/SvEv * 129S1/Sv) or (involves: 129S1/Sv * C57BL/6J))	decreased spleen weight	J:75054
	increased spleen B cell follicle size	J:75054
	small spleen	J:75054
\Gpc3^tm1Fil/Y (B6.Cg-Gpc3^tm1Fil)	increased susceptibility to bacterial infection	J:73877
	lung inflammation	J:73877
	rhinitis	J:73877
\Gpc3^tm1Fil/\Gpc3^tm1Fil (B6.Cg-Gpc3^tm1Fil)	increased susceptibility to bacterial infection	J:73877
\Gpc3^tm1Fil/\Gpc3^tm1Fil (B6.Cg-Gpc3^tm1Fil)	lung inflammation	J:73877
\Gpc3^tm1Snd/Y (involves: 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:104555
\Gpcpd1^em1(IMPC)Tcp/\Gpcpd1⁺ (C57BL/6N-Gpcpd1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Gpdc1^C3H/HeN/\Gpdc1^C3H/HeN (involves: C3H/HeN-Gnai2^tm1Uru * C57BL/6J-Gna2^tm1Uru)	colitis	J:95140
\Gpdc2^C3H/HeN/\Gpdc2^C3H/HeN (involves: C3H/HeN-Gnai2^tm1Uru * C57BL/6J-Gna2^tm1Uru)	colitis	J:95140
\Gpdc3^C3H/HeN/? (involves: C3H/HeN-Gnai2^tm1Uru * C57BL/6J-Gna2^tm1Uru)	colitis	J:95140
\Gper1^tm1Dgen/\Gper1^tm1Dgen (B6.129-Gper1^tm1Dgen)	decreased CD4-positive, alpha-beta T cell number	J:151816
	decreased CD8-positive, alpha-beta T cell number	J:151816
	decreased T cell number	J:151816
\Gpi1^b-m1Neu/\Gpi1^b-m1Neu (C3.Cg-Gpi1^b-m1Neu)	increased spleen weight	J:35956
\Gpi1^b-m2Neu/\Gpi1^b-m2Neu (C3.Cg-Gpi1^b-m2Neu)	increased spleen weight	J:35956
\Gpld1^{tm1.1(KOMP)Vlcg}/\Gpld1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gpld1^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
\Gpm6b^tm1Kan\Plp1^tm1Kan/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	microgliosis	J:193310
\Gpnmb^tm1Ari/\Gpnmb^tm1Ari (C57BL/6-Gpnmb^tm1Ari)	abnormal dendritic cell physiology	J:215931
\Gpr15^tm1.1Litt/\Gpr15^tm1.1Litt (B6.129P2-Gpr15^tm1.1Litt)	abnormal regulatory T cell physiology	J:199126
	decreased CD4-positive, alpha-beta T cell number	J:199126
	decreased double-negative T cell number	J:199126
	decreased regulatory T cell number	J:199126
	immune system phenotype	J:199126
	increased CD8-positive, alpha-beta T cell number	J:199126
	increased susceptibility to bacterial infection	J:199126
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199126
	increased susceptibility to induced colitis	J:199126
\Gpr15^tm1.1Litt/\Gpr15^tm1.1Litt (involves: 129P2/OlaHsd * C57BL/6)	decreased regulatory T cell number	J:199126
	increased interferon-gamma secretion	J:199126
	increased interleukin-17 secretion	J:199126
\Gpr15^tm1.1Litt/\Gpr15^tm1.1Litt \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6)	abnormal immune system physiology	J:199126
\Gpr15lg^tm1Lex/\Gpr15lg^tm1Lex (B6;129S5-Gpr15lg^tm1Lex/Mmucd)	increased IgG2a level	J:171883
\Gpr17^{tm1b(KOMP)Mbp}/\Gpr17^{tm1b(KOMP)Mbp} (C57BL/6N-Gpr17^{tm1b(KOMP)Mbp}/Tcp)	increased neutrophil cell number	J:211773
\Gpr18^tm1.1Cys/\Gpr18^tm1.1Cys (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:219661
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:219661
	immune system phenotype	J:219661
\Gpr18^tm1Lex/\Gpr18^tm1Lex (involves: 129S/SvEv * C57BL/6)	increased susceptibility to bacterial infection	J:226433
\Gpr21^tm1Dgen/\Gpr21^tm1Dgen (B6.129P2-Gpr21^tm1Dgen)	abnormal circulating chemokine level	J:181127
\Gpr21^tm1Dgen/\Gpr21^tm1Dgen (B6.129P2-Gpr21^tm1Dgen)	decreased circulating serum amyloid protein level	J:181127
\Gpr31b^tm1Ktak/\Gpr31b^tm1Ktak (B6.Cg-Gpr31b^tm1Ktak)	abnormal dendritic cell physiology	J:271242
	decreased inflammatory response	J:271242
	increased susceptibility to bacterial infection	J:271242
\Gpr34^tm1.1Shbg/\Gpr34^tm1.1Shbg (B6.Cg-Gpr34^tm1.1Shbg)	abnormal chemokine secretion	J:168120
	abnormal cytokine secretion	J:168120
	abnormal leukocyte migration	J:168120
	increased interferon-gamma secretion	J:168120
	increased interleukin-2 secretion	J:168120
	increased interleukin-4 secretion	J:168120
	increased interleukin-5 secretion	J:168120
	increased interleukin-10 secretion	J:168120
	increased interleukin-12 secretion	J:168120
	increased susceptibility to fungal infection	J:168120
	increased susceptibility to type IV hypersensitivity reaction	J:168120
	increased tumor necrosis factor secretion	J:168120
\Gpr35^em1Niess/\Gpr35^em1Niess (C57BL/6N-Gpr35^em1Niess)	immune system phenotype	J:300275
\Gpr35^em1Niess/\Gpr35^em1Niess (C57BL/6N-Gpr35^em1Niess)	increased susceptibility to induced colitis	J:300275
\Gpr35^em2Niess/\Gpr35^em2Niess \Cx3cr1^{tm2.1(cre/ERT2)Litt}/\Cx3cr1⁺ (involves: 129P2/OlaHsd * C57BL/6N)	increased susceptibility to induced colitis	J:300275
\Gpr35^{tm1(KOMP)Vlcg}/\Gpr35^{tm1(KOMP)Vlcg} (C57BL/6N-Gpr35^{tm1(KOMP)Vlcg}/MbpMmucd)	abnormal chemokine level	J:306520
	abnormal interleukin level	J:306520
	decreased susceptibility to colitis induced morbidity/mortality	J:306520
	decreased susceptibility to induced colitis	J:306520
\Gpr55^tm1.1Mijr/\Gpr55^tm1.1Mijr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:153225
	abnormal osteoclast morphology	J:153225
	abnormal osteoclast physiology	J:153225
	decreased osteoclast cell number	J:153225
	increased osteoclast cell number	J:153225
\Gpr65^tm1Witt/\Gpr65^tm1Witt (B6.Cg-Gpr65^tm1Witt)	abnormal immune cell physiology	J:96112
\Gpr65^tm1Witt/\Gpr65^tm1Witt (B6.Cg-Gpr65^tm1Witt)	abnormal leukocyte physiology	J:96112
\Gpr65^tm1Witt/\Gpr65^tm1Witt (C.Cg-Gpr65^tm1Witt)	abnormal leukocyte physiology	J:96112
\Gpr65^{Tn(sb-lacZ,GFP)T1.88Jtak}/\Gpr65^{Tn(sb-lacZ,GFP)T1.88Jtak} (B6.Cg-Gpr65^{Tn(sb-lacZ,GFP)T1.88Jtak})	abnormal interleukin-1 beta secretion	J:208788
	abnormal macrophage physiology	J:146233
	decreased tumor necrosis factor secretion	J:146233
\Gpr68^em1(IMPC)Bay/\Gpr68^em1(IMPC)Bay (C57BL/6N-Gpr68^em1(IMPC)Bay/Bay)	decreased leukocyte cell number	J:211773
\Gpr68^tm1.1Yaxu/\Gpr68^tm1.1Yaxu (B6.Cg-Gpr68^tm1.1Yaxu)	abnormal osteoclast differentiation	J:149315
	abnormal osteoclast physiology	J:149315
	immune system phenotype	J:149315
\Gpr68^tm1.1Yaxu/\Gpr68^tm1.1Yaxu (involves: 129S4/SvJae * C57BL/6 * FVB/N)	abnormal macrophage physiology	J:149315
	abnormal osteoclast differentiation	J:149315
	abnormal osteoclast physiology	J:149315
	decreased macrophage cell number	J:149315
	increased monocyte cell number	J:149315
\Gpr68^tm1Aha/\Gpr68^tm1Aha (B6.129-Gpr68^tm1Aha)	immune system phenotype	J:146233
\Gpr68^tm1Yaxu/\Gpr68^tm1Yaxu (involves: C57BL/6)	abnormal macrophage physiology	J:149315
	abnormal osteoclast differentiation	J:149315
	abnormal osteoclast physiology	J:149315
	decreased monocyte cell number	J:149315
\Gpr83^{em1(IMPC)Ccpcz}/\Gpr83^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gpr83^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Gpr83^tm1.1Fpow/\Gpr83^tm1.1Fpow (C.129-Gpr83^tm1.1Fpow)	decreased CD4-positive, alpha-beta T cell number	J:144445
	immune system phenotype	J:144445
	spleen hyperplasia	J:144445
\Gpr84^tm1Lex/\Gpr84^tm1Lex (involves: 129S/SvEvBrd * C57BL/6)	abnormal T-helper 2 physiology	J:186985
	immune system phenotype	J:186985
	increased interleukin-4 secretion	J:186985
	increased interleukin-5 secretion	J:186985
	increased interleukin-13 secretion	J:186985
\Gpr89^ex/\Gpr89^ex (C57BL/6J-Gpr89^ex)	abnormal T cell morphology	J:287198
\Gpr89^ex/\Gpr89^ex (C57BL/6J-Gpr89^ex)	abnormal T cell number	J:287198
\Gpr89^tm1.1Ymae/\Gpr89^tm1.1Ymae \Tg(KRT5-cre)1Tak/0 (involves: C3H * C57BL/6)	dermatitis	J:189574
\Gpr101^em7036Tac/Y (C57BL/6NTac-Gpr101^em7036Tac)	abnormal microglial cell activation	J:347398
	abnormal microglial cell morphology	J:347398
	increased circulating tumor necrosis factor level	J:347398
	increased inflammatory response	J:347398
	increased monocyte cell number	J:347398
\Gpr108^tm1.1Brs/\Gpr108^tm1.1Brs (involves: 129S6/SvEvTac)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:266821
	decreased tumor necrosis factor secretion	J:266821
	increased interleukin-6 secretion	J:266821
	increased susceptibility to endotoxin shock	J:266821
	increased tumor necrosis factor secretion	J:266821
\Gpr132^tm1Witt/\Gpr132^tm1Witt (B6.129X1-Gpr132^tm1Witt)	impaired macrophage chemotaxis	J:96613
\Gpr132^tm1Witt/\Gpr132^tm1Witt (involves: 129X1/SvJ * BALB/c)	abnormal immune system organ morphology	J:69473
	abnormal lymph node morphology	J:69473
	abnormal lymphocyte physiology	J:69473
	enlarged inguinal lymph nodes	J:69473
	enlarged spleen	J:69473
	increased anti-nuclear antigen antibody level	J:69473
	increased B cell proliferation	J:69473
	increased IgA level	J:69473
	increased IgG1 level	J:69473
	increased immunoglobulin level	J:69473
	increased inflammatory response	J:69473
	increased T cell proliferation	J:69473
	kidney inflammation	J:69473
	liver inflammation	J:69473
	lung inflammation	J:69473
\Gpr132^tm1Witt/\Gpr132^tm1Witt \Ldlr^tm1Her/\Ldlr^tm1Her (B6.129-Ldlr^tm1Her Gpr132^tm1Witt)	decreased macrophage apoptosis	J:100498
\Gpr137b^{tm1b(KOMP)Wtsi}/\Gpr137b^{tm1b(KOMP)Wtsi} (C57BL/6N-Gpr137b^{tm1b(KOMP)Wtsi}/H)	increased neutrophil cell number	J:211773
\Gpr146^em1(IMPC)H/\Gpr146^em1(IMPC)H (C57BL/6NTac-Gpr146^em1(IMPC)H/H)	increased spleen weight	J:211773
\Gpr146^em1Bdu/\Gpr146^em1Bdu (C57BL/6-Gpr146^em1Bdu)	immune system phenotype	J:247263
\Gpr155^em1(IMPC)Mbp/\Gpr155^em1(IMPC)Mbp (C57BL/6N-Gpr155^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Gpr174^tm1Cys/Y (B6.129-Gpr174^tm1Cys)	abnormal regulatory T cell physiology	J:222307
	abnormal T-helper 1 cell differentiation	J:222307
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:222307
	immune system phenotype	J:222307
	increased single-positive T cell number	J:222307
	increased T cell proliferation	J:222307
\Gpr174^tm1Cys/\Gpr174⁺ (B6.129-Gpr174^tm1Cys)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:222307
\Gpr182^{tm2b(KOMP)Wtsi}/\Gpr182^{tm2b(KOMP)Wtsi} (C57BL/6N-Gpr182^{tm2b(KOMP)Wtsi}/Ucd)	increased spleen weight	J:211773
\Gpr182^{tm2c(KOMP)Wtsi}/\Gpr182^{tm2c(KOMP)Wtsi} \Tg(Cdh5-cre/ERT2)1Rha/0 (B6.Cg-Gpr182^{tm2c(KOMP)Wtsi} Tg(Cdh5-cre/ERT2)1Rha)	abnormal circulating chemokine level	J:305796
	increased circulating CXCL10 level	J:305796
	increased monocyte cell number	J:305796
	increased neutrophil cell number	J:305796
\Gpr183^tm1.1Cys/\Gpr183^tm1.1Cys (B6.129P2-Gpr183^tm1.1Cys)	abnormal follicular B cell physiology	J:151077
\Gpr183^tm1.2Rbr/\Gpr183^tm1.2Rbr (involves: C57BL/6 * FVB/N * SJL)	abnormal B cell physiology	J:151883
	decreased plasma cell number	J:151883
\Gpr183^tm1.2Rbr/\Gpr183^tm1.2Rbr \Igh^tm1Rbr/\Igh^tm1Rbr \Tg(IgkHyHEL10)1Rbr/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal B cell physiology	J:151883
	abnormal B cell proliferation	J:151883
	decreased B cell number	J:151883
	decreased IgG1 level	J:151883
	decreased IgM level	J:151883
	decreased plasma cell number	J:151883
	impaired B cell migration	J:151883
\Gpr183^tm1Lex/\Gpr183^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal circulating interferon-beta level	J:211122
	decreased myeloid dendritic cell number	J:211122
	decreased plasmacytoid dendritic cell number	J:211122
	increased circulating interferon-alpha level	J:211122
	increased circulating interferon-gamma level	J:211122
\Gprc5a^tm1Rlo/\Gprc5a^tm1Rlo (involves: 129 * C57BL/6)	lung inflammation	J:127821
\Gprc5c^tm1Yhir/\Gprc5c^tm1Yhir (B6.Cg-Gprc5c^tm1Yhir)	increased basophil cell number	J:176063
\Gprc6a^{tm1.1(KOMP)Vlcg}/\Gprc6a^{tm1.1(KOMP)Vlcg} (C57BL/6N-Gprc6a^{tm1.1(KOMP)Vlcg}/Ucd)	increased thymus weight	J:211773
\Gpsm3^{Gt(IST12408A1)Tigm}/\Gpsm3^{Gt(IST12408A1)Tigm} (involves: C57BL/6N)	abnormal leukocyte migration	J:193270
	abnormal leukocyte physiology	J:193270
	decreased monocyte cell number	J:193270
	decreased susceptibility to induced arthritis	J:193270
\Gpx1^tm1Kola/\Gpx1^tm1Kola (involves: 129S2/SvPas * BALB/c * CF-1)	increased inflammatory response	J:79183
\Gpx1^tm1Kola/\Gpx1^tm1Kola (B6.129S2(CF1)-Gpx1^tm1Kola)	immune system phenotype	J:100436
\Gpx1^tm1Ysh/\Gpx1⁺ \Gpx2^tm2Coh/\Gpx2^tm2Coh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:71506
\Gpx1^tm1Ysh/\Gpx1^tm1Ysh \Gpx2^tm2Coh/\Gpx2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	intestinal inflammation	J:71506
\Gpx1^tm1Ysh/\Gpx1^tm1Ysh \Gpx2^tm2Coh/\Gpx2^tm2Coh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	colitis	J:71506
	intestinal inflammation	J:71506
	small intestinal inflammation	J:71506
\Gpx7^tm1Whle/\Gpx7^tm1Whle (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:193993
	enlarged spleen	J:193993
	glomerulonephritis	J:193993
	increased anti-nuclear antigen antibody level	J:193993
\Gpx8^tm1Lex/\Gpx8^tm1Lex (B6;129S5-Gpx8^tm1Lex/Mmucd)	dermatitis	J:171883
\Gramd2a^em1(IMPC)Tcp/\Gramd2a^em1(IMPC)Tcp (C57BL/6NCrl-Gramd2a^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Grap2^tm1Amch/\Grap2^tm1Amch (involves: 129S1/Sv * 129X1/SvJ)	arrested T cell differentiation	J:76696
	decreased CD4-positive, alpha-beta T cell number	J:76696
	decreased CD8-positive, alpha-beta T cell number	J:76696
	decreased thymocyte number	J:76696
	increased double-negative T cell number	J:76696
\Grap2^tm1Amch/\Grap2^tm1Amch \Lcp2^tm1.1Wz/\Lcp2^tm1.1Wz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:150304
	decreased CD4-positive, alpha-beta T cell number	J:150304
	decreased CD8-positive, alpha-beta T cell number	J:150304
	decreased double-positive T cell number	J:150304
	decreased single-positive T cell number	J:150304
\Grap2^tm1Eac/\Grap2^tm1Eac (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:92023
	abnormal double-negative T cell morphology	J:92023
	decreased T cell number	J:92023
	decreased thymocyte number	J:92023
	increased activated T cell number	J:92023
	increased memory T cell number	J:92023
\Grap^tm1Gsf/\Grap^tm1Gsf (B6.129-Grap^tm1Gsf)	increased CD4-positive, alpha-beta T cell number	J:76243
\Grap^tm1Gsf/\Grap^tm1Gsf (B6.129-Grap^tm1Gsf)	increased T cell proliferation	J:76243
\Grass1^C57BL/6J/\Grass1^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:134374
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:134374
	sepsis	J:134374
\Grass1^C57BL/6J/\Grass1^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to bacterial infection	J:134374
	sepsis	J:134374
\Grass1^DBA/2J/\Grass1^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to bacterial infection	J:134374
\Grass1^DBA/2J/\Grass1^DBA/2J (involves: C57BL/6J * DBA/2J)	sepsis	J:134374
\Grb2^tm1.1Hua/\Grb2^tm1.1Hua \Tg(DO11.10)10Dlo/0 \Tg(Lck-cre)1Jtak/0 (involves: 129 * BALB/c * C3H * C57BL/6)	abnormal T cell differentiation	J:161294
	decreased CD4-positive, alpha-beta T cell number	J:161294
\Grb2^tm1.1Hua/\Grb2^tm1.1Hua \Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6)	abnormal T cell differentiation	J:161294
	decreased CD4-positive, alpha-beta T cell number	J:161294
	decreased CD8-positive, alpha-beta T cell number	J:161294
	decreased double-positive T cell number	J:161294
	decreased thymocyte number	J:161294
\Grb2^tm1.1Hua/\Grb2^tm1.1Hua \Tg(Lck-cre)1Jtak/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6 * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:161294
	decreased CD4-positive, alpha-beta T cell number	J:161294
	decreased CD8-positive, alpha-beta T cell number	J:161294
	increased CD8-positive, alpha-beta T cell number	J:161294
	increased double-positive T cell number	J:161294
\Grb2^tm1Lnit/\Grb2^tm1Lnit \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * BALB/cJ)	abnormal B cell differentiation	J:171222
	abnormal B cell physiology	J:171222
	abnormal memory B cell physiology	J:171222
	decreased B cell number	J:171222
	decreased follicular B cell number	J:171222
	decreased IgG3 level	J:171222
	decreased IgG level	J:171222
	decreased mature B cell number	J:171222
	decreased spleen germinal center number	J:171222
	decreased spleen germinal center size	J:171222
	decreased transitional stage T1 B cell number	J:171222
	decreased transitional stage T2 B cell number	J:171222
	increased B cell apoptosis	J:171222
	increased B cell proliferation	J:171222
	increased IgM level	J:171222
	increased plasma cell number	J:171222
\Grb2^tm1Paw/\Grb2⁺ (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	decreased susceptibility to Retroviridae infection	J:122429
\Grb2^tm1Paw/\Grb2⁺ \Pten^tm2Mak/\Pten^tm2Mak \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:93530
\Grb14^tm1Daly/\Grb14^tm1Daly (involves: 129X1/SvJ * C57BL/6)	decreased spleen weight	J:87892
\Greb1^em1Rkom/\Greb1^em1Rkom (C57BL/6NJ-Greb1^em1Rkom)	abnormal response to transplant	J:346713
\Grem2^em1Stpg/\Grem2^em1Stpg (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6J)	ovary inflammation	J:318711
\Grem2^tm1Akh/\Grem2^tm1Akh (involves: 129/Sv * C57BL/6)	abnormal chemokine level	J:250034
	increased inflammatory response	J:250034
	increased interleukin-10 secretion	J:250034
	increased leukocyte cell number	J:250034
\Grem2^tm1Lex/\Grem2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:227246
\Grhl3^{tm1a(EUCOMM)Wtsi}/\Grhl3⁺ (C57BL/6N-Grhl3^{tm1a(EUCOMM)Wtsi}/Ics)	decreased IgE level	J:165965
\Grhpr^{Gt(OST383093)Lex}/\Grhpr^{Gt(OST383093)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	urinary bladder inflammation	J:181969
\Grik3^em1(IMPC)Mbp/\Grik3^em1(IMPC)Mbp (C57BL/6N-Grik3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\Grk2^tm1Gwd/\Grk2^tm1Gwd \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129 * BALB/c * C57BL/6)	abnormal B cell physiology	J:176118
	decreased B cell number	J:176118
	increased B cell number	J:176118
	increased CD4-positive, alpha-beta T cell number	J:176118
	increased CD8-positive, alpha-beta T cell number	J:176118
	increased follicular B cell number	J:176118
	increased marginal zone B cell number	J:176118
\Grk2^tm1Gwd/\Grk2^tm1Mca \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal T cell physiology	J:176118
	decreased CD4-positive, alpha-beta T cell number	J:176118
	decreased CD8-positive, alpha-beta T cell number	J:176118
	decreased T cell number	J:176118
	impaired leukocyte tethering or rolling	J:176118
	increased B cell number	J:176118
\Grk6^tm1.1Mca/\Grk6^tm1.1Mca (involves: 129S4/SvJae * C57BL/6J)	abnormal B cell physiology	J:76872
	abnormal T cell physiology	J:76872
\Grk6^tm1.1Mca/\Grk6^tm1.1Mca (B6.129S4-Grk6^tm1.1Mca)	abnormal T cell subpopulation ratio	J:225063
	decreased CD8-positive, alpha-beta T cell number	J:225063
	decreased CD8-positive, naive alpha-beta T cell number	J:225063
	enlarged spleen	J:225063
	glomerulonephritis	J:225063
	impaired macrophage phagocytosis	J:225063
	increased anti-double stranded DNA antibody level	J:225063
	increased IgG level	J:225063
	increased memory T cell number	J:225063
	increased spleen iron level	J:225063
	increased spleen weight	J:225063
	increased spleen white pulp amount	J:225063
	increased splenocyte number	J:225063
\Grn^tm1.1Aidi/\Grn^tm1.1Aidi (involves: C57BL/6 * C57BL/6J)	abnormal chemokine secretion	J:156824
	abnormal macrophage physiology	J:156824
	abnormal microglial cell physiology	J:156824
	increased interleukin-6 secretion	J:156824
	increased interleukin-12 secretion	J:156824
	increased susceptibility to bacterial infection	J:156824
	increased tumor necrosis factor secretion	J:156824
	microgliosis	J:156824
\Grn^tm1.1Aidi/\Grn^tm1.1Aidi (involves: C57BL/6J)	kidney inflammation	J:268827
\Grn^tm1.1Far/\Grn^tm1.1Far (involves: 129S4/SvJae * FVB/N)	abnormal macrophage physiology	J:170823
\Grn^tm1.1Far/\Grn^tm1.1Far (involves: 129S4/SvJae * C57BL/6J * FVB/N)	increased interleukin-1 beta secretion	J:188324
	increased interleukin-6 secretion	J:188324
	increased interleukin-10 secretion	J:188324
	increased tumor necrosis factor secretion	J:188324
	microgliosis	J:188324
\Grn^tm1.1Geno/\Grn^tm1.1Geno (involves: 129 * C57BL/6J)	microgliosis	J:188420
\Grn^tm1Blrl/\Grn^tm1Blrl (involves: C57BL/6J)	microgliosis	J:182051
\Grn^tm1Far/\Grn^tm1Far \Tg(ITGAM-cre)2781Gkl/0 (involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)	microgliosis	J:188324
\Grn^tm2.1Far/\Grn^tm2.1Far (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:259651
	microgliosis	J:259651
\Grp^em1(IMPC)H/\Grp^em1(IMPC)H (C57BL/6NTac-Grp^em1(IMPC)H/H)	decreased monocyte cell number	J:211773
\Grsf1^{tm1b(EUCOMM)Wtsi}/\Grsf1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Grsf1^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Gsdma3^Ae/\Gsdma3⁺ (involves: C57BL/6J * CAST/Ei)	enlarged lymph nodes	J:180149
	enlarged spleen	J:180149
	enlarged thymus	J:180149
	skin inflammation	J:180149
\Gsdma3^M2Btlr/\Gsdma3^M2Btlr (involves: C57BL/6J)	dermatitis	J:209203
\Gsdma3^{tm1(KOMP)Vlcg}/\Gsdma3^{tm1(KOMP)Vlcg} (C57BL/6N-Gsdma3^{tm1(KOMP)Vlcg}/Nju)	increased lymphocyte cell number	J:211773
\Gsdma^em1Cya/\Gsdma^em1Cya (C57BL/6J-Gsdma^em1Cya)	increased susceptibility to bacterial infection	J:326434
\Gsdma^em1Cya/\Gsdma^em1Cya (C57BL/6J-Gsdma^em1Cya)	increased susceptibility to bacterial infection induced morbidity/mortality	J:326434
\Gsdmc^em1(IMPC)Tcp/\Gsdmc^em1(IMPC)Tcp (C57BL/6NCrl-Gsdmc^em1(IMPC)Tcp/TcpMmucd)	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
\Gsdmd^em1Fcw/\Gsdmd^em2Fcw (involves: C57BL/6)	abnormal macrophage apoptosis	J:226781
\Gsdmd^em1Fcw/\Gsdmd^em2Fcw (involves: C57BL/6)	decreased interleukin-1 beta secretion	J:226781
\Gsdmd^em1Flv/\Gsdmd^em1Flv (C57BL/6N-Gsdmd^em1Flv)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:243487
\Gsdmd^em3Fcw/\Gsdmd^em3Fcw (involves: C57BL/6)	abnormal macrophage apoptosis	J:226781
\Gsdmd^em3Fcw/\Gsdmd^em3Fcw (involves: C57BL/6)	decreased interleukin-1 beta secretion	J:226781
\Gsdmd^em4Fcw/\Gsdmd^em4Fcw (C57BL/6N-Gsdmd^em4Fcw/J)	abnormal macrophage apoptosis	J:101977
\Gsdmd^em4Fcw/\Gsdmd^em4Fcw (C57BL/6N-Gsdmd^em4Fcw/J)	abnormal susceptibility to bacterial infection	J:101977
\Gsdmd^m1Btlr/\Gsdmd^m1Btlr (C57BL/6J-Gsdmd^m1Btlr)	decreased interleukin-1 beta secretion	J:267555
\Gsk3a^tm1Dral/\Gsk3a^tm1Dral \Gsk3b^tm1Dral/\Gsk3b^tm1Dral (involves: 129P2/OlaHsd)	increased circulating interleukin-6 level	J:200517
\Gsn^tm1Djk/\Gsn^tm1Djk (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	abnormal immune system physiology	J:24346
	abnormal osteoclast differentiation	J:60625
	abnormal osteoclast physiology	J:60625
	decreased inflammatory response	J:24346
	impaired neutrophil chemotaxis	J:24346
	impaired neutrophil recruitment	J:24346
	increased leukocyte cell number	J:24346
	increased neutrophil cell number	J:24346
\Gsta4^tm1Pzim/\Gsta4⁺ (involves: 129S1/Sv * 129S6/SvEvTac)	increased susceptibility to bacterial infection	J:87983
\Gsta4^tm1Pzim/\Gsta4^tm1Pzim (involves: 129S1/Sv * 129S6/SvEvTac)	abnormal bone marrow development	J:87983
	increased susceptibility to bacterial infection	J:87983
\Gstcd^{tm1b(EUCOMM)Wtsi}/\Gstcd^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Gstcd^{tm1b(EUCOMM)Wtsi}/Bay)	enlarged spleen	J:211773
\Gstcd^{tm1b(EUCOMM)Wtsi}/\Gstcd^{tm1b(EUCOMM)Wtsi} (C57BL/6-Gstcd^{tm1b(EUCOMM)Wtsi})	increased tumor necrosis factor secretion	J:279480
\Gstk1^tm1Pgb/\Gstk1^tm1Pgb (BALB/c-Gstk1^tm1Pgb)	decreased spleen red pulp amount	J:177201
	decreased spleen weight	J:177201
	glomerulonephritis	J:177201
	urethritis	J:177201
	urinary bladder inflammation	J:177201
\Gstm4^{tm2b(EUCOMM)Hmgu}/\Gstm4^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Gstm4^{tm2b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Gstt2^em1Rmah/\Gstt2^em1Rmah (Not Specified)	decreased interleukin-12 secretion	J:358834
	decreased tumor necrosis factor secretion	J:358834
	increased inflammatory response	J:358834
	increased interleukin-6 secretion	J:358834
	increased interleukin-10 secretion	J:358834
	increased interleukin-12 secretion	J:358834
	increased tumor necrosis factor secretion	J:358834
\Gstz1^tm1Pgb/\Gstz1^tm1Pgb (BALB/c-Gstz1^tm1Pgb/AnuApb)	chronic inflammation	J:91519
	decreased leukocyte cell number	J:91519
	decreased spleen weight	J:91519
	liver inflammation	J:91519
\Gsx1^tm1Ssp/\Gsx1^tm1Ssp (involves: 129P2/OlaHsd)	decreased leukocyte cell number	J:31764
	decreased lymphocyte cell number	J:31764
	decreased neutrophil cell number	J:31764
\Gt(ROSA)26Sor^{em1(DPP4)Yowa}/\Gt(ROSA)26Sor^{em1(DPP4)Yowa} (C57BL/6-Gt(ROSA)26Sor^{em1(DPP4)Yowa})	increased susceptibility to Coronaviridae infection	J:279060
\Gt(ROSA)26Sor^{em1(Ube2s)Chaw}/? (involves: C57BL/6)	decreased interferon level	J:306461
\Gt(ROSA)26Sor^{em1(Ube2s)Chaw}/? (involves: C57BL/6)	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:306461
\Gt(ROSA)26Sor^{tm1(B4galt1)Clib}/\Gt(ROSA)26Sor^{tm1(B4galt1)Clib} \Tg(Nes-cre)Wme/? (involves: 129S6/SvEvTac * C57BL/6 * CBA)	decreased acute inflammation	J:209737
	decreased circulating interleukin-6 level	J:209737
	decreased susceptibility to induced colitis	J:209737
\Gt(ROSA)26Sor^{tm1(CAG-Bcl3,-EGFP)Hoev}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:208980
	abnormal B-2 B cell morphology	J:208980
	abnormal class switch recombination	J:208980
	abnormal follicular B cell morphology	J:208980
	abnormal Peyer's patch germinal center morphology	J:208980
	abnormal transitional stage T3 B cell morphology	J:208980
	absent marginal zone B cells	J:208980
	decreased B cell apoptosis	J:208980
	decreased B cell proliferation	J:208980
	decreased B-1 B cell number	J:208980
	decreased B-1a cell number	J:208980
	decreased IgG1 level	J:208980
	decreased IgG2b level	J:208980
	decreased IgG3 level	J:208980
	decreased IgM level	J:208980
	decreased immature B cell number	J:208980
	decreased marginal zone B cell number	J:208980
	decreased transitional stage T1 B cell number	J:208980
	enlarged spleen	J:208980
	increased lymphocyte cell number	J:208980
\Gt(ROSA)26Sor^{tm1(CAG-CAMK2GT287D,-EGFP)Whua}/\Gt(ROSA)26Sor⁺ \Tg(Vil1-cre)997Gum/0 (involves: 129 C57BL/6)	decreased susceptibility to induced colitis	J:243363
\Gt(ROSA)26Sor^{tm1(CAG-Foxn1/ERT2,-GFP)Cbln}/\Gt(ROSA)26Sor⁺ \Foxn1^tm3(cre)Nrm/\Foxn1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus involution	J:208852
	increased T cell number	J:208852
\Gt(ROSA)26Sor^{tm1(CAG-FOXO1,GFP)Moli}/\Gt(ROSA)26Sor⁺ \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:189962
\Gt(ROSA)26Sor^{tm1(CAG-NPM1)Geno}/\Gt(ROSA)26Sor⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	enlarged spleen	J:196690
	myeloid hyperplasia	J:196690
\Gt(ROSA)26Sor^{tm1(CAG-NPM1)Geno}/\Gt(ROSA)26Sor^{tm1(CAG-NPM1)Geno} \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	enlarged spleen	J:196690
\Gt(ROSA)26Sor^{tm1(CAG-SETBP1G870S,-EGFP)Ase}/\Gt(ROSA)26Sor⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6N C57BL/10 * CBA/Ca)	abnormal spleen morphology	J:363041
	decreased lymphocyte cell number	J:363041
	hepatosplenomegaly	J:363041
	increased leukocyte cell number	J:363041
	myeloid hyperplasia	J:363041
\Gt(ROSA)26Sor^{tm1(CAG-SETBP1G870S,-EGFP)Ase}/\Gt(ROSA)26Sor^{tm1(CAG-SETBP1G870S,-EGFP)Ase} \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6N * C57BL/10 * CBA/Ca)	abnormal myelopoiesis	J:363041
	decreased leukocyte cell number	J:363041
	increased neutrophil cell number	J:363041
\Gt(ROSA)26Sor^{tm1(CAG-Slc39a14*L438R)Wvh}/\Gt(ROSA)26Sor⁺ \Tg(Runx2-icre)1Jtuc/0 (involves: FVB/N)	increased osteoclast cell number	J:261326
\Gt(ROSA)26Sor^{tm1(CARD14)Ribt}/\Gt(ROSA)26Sor⁺ \Malt1^{tm1c(EUCOMM)Hmgu}/\Malt1^{tm1c(EUCOMM)Hmgu} \Tg(KRT14-cre/ERT)20Efu/0 (involves: 129S6/SvEvTac C57BL/6NCrl * CD-1)	increased dendritic cell number	J:292094
	increased neutrophil cell number	J:292094
	skin inflammation	J:292094
\Gt(ROSA)26Sor^{tm1(CARD14)Ribt}/\Gt(ROSA)26Sor⁺ \Tg(KRT14-cre/ERT)20Efu/0 (involves: 129S6/SvEvTac C57BL/6NCrl * CD-1)	increased dendritic cell number	J:292094
	increased neutrophil cell number	J:292094
	skin inflammation	J:292094
\Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/\Gt(ROSA)26Sor⁺ \Mcl1^tm1Ywh/\Mcl1^tm1Ywh (involves: 129/Sv * 129S6/SvEvTac * C57BL/6)	increased T cell apoptosis	J:137400
\Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/\Gt(ROSA)26Sor^{tm1(Tcfe2a/Tal1)Xhsu} (involves: 129/Sv * C57BL/6)	abnormal lymphopoiesis	J:144569
	abnormal myelopoiesis	J:144569
\Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ \Tacc3^tm1.1Tno/\Tacc3⁺ \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:179414
\Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ \Tacc3^tm1.1Tno/\Tacc3^tm1.2Tno \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:179414
\Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor^tm1(Pyy)Paba (involves: 129S4/SvJae)	abnormal osteoclast morphology	J:189512
	increased osteoclast cell number	J:189512
\Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/\Gt(ROSA)26Sor⁺ \Il1r2^tm1.1Epi/\Il1r2^tm1.1Epi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac)	abnormal adaptive immunity	J:347877
	increased IgG level	J:347877
	increased spleen germinal center size	J:347877
	increased T follicular helper cell number	J:347877
\Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/\Gt(ROSA)26Sor⁺ \Pten^tm1Hwu/\Pten^tm1Hwu (involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)	increased T cell derived lymphoma incidence	J:130367
\Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl}/\Gt(ROSA)26Sor^{tm1(CTNNB1)Nerl} \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	arrested T cell differentiation	J:112660
	decreased double-negative T cell number	J:112660
	decreased granulocyte number	J:112660
	decreased leukocyte cell number	J:112660
	impaired myelopoiesis	J:112660
	thymus hypoplasia	J:112660
\Gt(ROSA)26Sor^tm1(DTA)Jpmb/\Gt(ROSA)26Sor⁺ \Tg(Plp1-cre/ERT)3Pop/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	autoimmune response	J:234435
	CNS inflammation	J:234435
	increased activated T cell number	J:234435
	lymph node inflammation	J:234435
\Gt(ROSA)26Sor^tm1(DTA)Jpmb/\Gt(ROSA)26Sor⁺ \Tg(Trpv1-cre)1Hoon/0 (involves: 129S1/Sv)	decreased inflammatory response	J:169256
\Gt(ROSA)26Sor^tm1(DTA)Lky/? \Il5^{tm1.1(icre)Lky}/\Il5⁺ \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal immune system physiology	J:206097
\Gt(ROSA)26Sor^tm1(DTA)Lky/\Gt(ROSA)26Sor⁺ \Il13^{tm1(YFP/cre)Lky}/\Il13^{tm1(YFP/cre)Lky} (involves: 129P2/OlaHsd * 129S4/SvJae)	decreased eosinophil cell number	J:178986
	decreased IgG1 level	J:178986
	decreased interleukin-5 secretion	J:178986
	decreased interleukin-13 secretion	J:178986
	increased susceptibility to parasitic infection	J:178986
\Gt(ROSA)26Sor^tm1(DTA)Lky/\Gt(ROSA)26Sor^tm1(DTA)Lky \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:133382
	abnormal CD8-positive, alpha-beta T cell differentiation	J:133382
	abnormal lymph node T cell domain morphology	J:133382
	abnormal spleen morphology	J:133382
	abnormal T cell receptor V(D)J recombination	J:133382
	decreased CD4-positive, alpha-beta T cell number	J:133382
	decreased CD8-positive, alpha-beta T cell number	J:133382
	decreased double-positive T cell number	J:133382
	decreased lymphocyte cell number	J:133382
	decreased NK T cell number	J:133382
	decreased regulatory T cell number	J:133382
	immune system phenotype	J:133382
	increased susceptibility to parasitic infection	J:133382
\Gt(ROSA)26Sor^tm1(DTA)Riet/\Gt(ROSA)26Sor^tm1(DTA)Riet \Tg(Rorc-cre)1Litt/? (involves: 129P2/OlaHsd)	abnormal effector T cell morphology	J:137020
\Gt(ROSA)26Sor^tm1(DUX4)Sqh/\Gt(ROSA)26Sor⁺ \Tg(ACTA1-cre/Esr1)2Kesr/0 (involves: 129S6/SvEvTac C3H * C57BL/6)	abnormal acute inflammation	J:268959
\Gt(ROSA)26Sor^{tm1(ETV6/SYK)Hjum}/\Gt(ROSA)26Sor⁺ \Cd79a^{tm3(cre/ERT2)Reth}/\Cd79a⁺ (involves: 129S6/SvEvTac * BALB/c)	abnormal circulating chemokine level	J:208904
	abnormal cytokine level	J:208904
	abnormal plasma cell differentiation	J:208904
	enlarged lymph nodes	J:208904
	enlarged spleen	J:208904
	increased B cell apoptosis	J:208904
	increased B cell number	J:208904
	increased B cell proliferation	J:208904
	increased circulating interferon-gamma level	J:208904
	increased circulating interleukin-6 level	J:208904
	increased circulating interleukin-10 level	J:208904
	increased circulating tumor necrosis factor level	J:208904
	increased IgM level	J:208904
	increased interferon-gamma secretion	J:208904
	increased interleukin-10 secretion	J:208904
	increased tumor necrosis factor secretion	J:208904
\Gt(ROSA)26Sor^{tm1(ETV6/SYK)Hjum}/\Gt(ROSA)26Sor⁺ \Cd79a^{tm3(cre/ERT2)Reth}/\Cd79a⁺ \Tg(BCL2)22Wehi/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6JWehi * SJL/JWehi)	abnormal B cell physiology	J:208904
	abnormal plasma cell differentiation	J:208904
	enlarged lymph nodes	J:208904
	enlarged spleen	J:208904
\Gt(ROSA)26Sor^{tm1(EWSR1/FLI1)Sbk}/\Gt(ROSA)26Sor⁺ \Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal lymph node B cell domain morphology	J:129039
	abnormal myelopoiesis	J:129039
	enlarged spleen	J:129039
	increased leukocyte cell number	J:129039
	increased spleen red pulp amount	J:129039
\Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Ighg1^tm1(cre)Cgn/\Ighg1⁺ \Prdm1^tm2Masu/\Prdm1^tm2Masu (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal germinal center B cell physiology	J:167612
	abnormal plasma cell differentiation	J:167612
	decreased IgG1 level	J:167612
	enlarged lymph nodes	J:167612
	enlarged spleen	J:167612
	increased germinal center B cell number	J:167612
\Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Il22^{tm1.1(icre)Stck}/\Il22⁺ (involves: 129X1/SvJ * C57BL/6N)	abnormal susceptibility to bacterial infection	J:220074
\Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Kras^tm4Tyj/\Kras⁺ \Tg(Pdx1-cre)89.1Dam/0 (involves: 129 * C57BL/6 * CBA)	increased susceptibility to induced pancreatitis	J:289183
\Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Plcg1^tm1Gcrp/\Plcg1^tm1Rwen \Tg(Cd4-cre)1Cwi/0 (involves: 129X1/SvJ * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:157757
	abnormal CD8-positive, alpha-beta T cell differentiation	J:157757
	abnormal regulatory T cell physiology	J:157757
	abnormal T cell activation	J:157757
	decreased CD4-positive, alpha-beta T cell number	J:157757
	decreased CD8-positive, alpha-beta T cell number	J:157757
	decreased interferon-gamma secretion	J:157757
	decreased interleukin-2 secretion	J:157757
	decreased single-positive T cell number	J:157757
	decreased T cell number	J:157757
	decreased T cell proliferation	J:157757
	dermatitis	J:157757
	increased double-positive T cell number	J:157757
	increased T cell apoptosis	J:157757
\Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ \Rev3l^tm1.1Diaz/\Rev3l^tm1.1Diaz (involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac)	abnormal class switch recombination	J:188723
	abnormal somatic hypermutation frequency	J:188723
	decreased B cell proliferation	J:188723
	immune system phenotype	J:188723
\Gt(ROSA)26Sor^{tm1(GNAQ)Cvrk}/\Gt(ROSA)26Sor⁺ \Tg(Mitf-cre)7114Gsb/0 (C3FeJ.Cg-Gt(ROSA)26Sor^{tm1(GNAQ)Cvkr} Tg(Mitf-cre)7114Gsb/Cvrk)	enlarged lymph nodes	J:225597
\Gt(ROSA)26Sor^{tm1(gp80)Eces}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))	abnormal class switch recombination	J:172031
	absent spleen germinal center	J:172031
	decreased B cell apoptosis	J:172031
	decreased B cell number	J:172031
	decreased germinal center B cell number	J:172031
	decreased IgA level	J:172031
	decreased IgG1 level	J:172031
	decreased IgG2a level	J:172031
	decreased IgG3 level	J:172031
	decreased plasma cell number	J:172031
	enlarged spleen	J:172031
	increased B cell number	J:172031
	increased IgE level	J:172031
	increased macrophage cell number	J:172031
	increased marginal zone B cell number	J:172031
	increased spleen weight	J:172031
	increased T cell number	J:172031
\Gt(ROSA)26Sor^{tm1(gp80)Eces}/\Gt(ROSA)26Sor⁺ \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))	abnormal class switch recombination	J:172031
	absent spleen germinal center	J:172031
	decreased B cell number	J:172031
	decreased follicular B cell number	J:172031
	decreased germinal center B cell number	J:172031
	decreased IgA level	J:172031
	decreased IgG1 level	J:172031
	decreased IgG2a level	J:172031
	decreased IgG2b level	J:172031
	decreased IgG3 level	J:172031
	decreased plasma cell number	J:172031
	enlarged spleen	J:172031
	increased B cell number	J:172031
	increased IgE level	J:172031
	increased macrophage cell number	J:172031
	increased marginal zone B cell number	J:172031
	increased spleen weight	J:172031
\Gt(ROSA)26Sor^{tm1(H1/tetO-RNAi:Pdpk1)Mrl}/\Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} \Pten^tm1Hwu/\Pten^tm1Hwu (involves: 129S4/SvJae * C57BL/6)	decreased B cell number	J:170965
	enlarged lymph nodes	J:170965
	enlarged spleen	J:170965
	increased memory B cell number	J:170965
	increased spleen weight	J:170965
\Gt(ROSA)26Sor^tm1(HA)Libl/\Gt(ROSA)26Sor^tm1(HA)Libl \Mog^tm1(cre)Gkl/? (involves: 129/Sv * C57BL/6)	immune system phenotype	J:137838
\Gt(ROSA)26Sor^tm1(HA)Libl/\Gt(ROSA)26Sor^tm1(HA)Libl \Mog^tm1(cre)Gkl/? \Tg(TcraCl4,TcrbCl4)1Shrm/0 (involves: 129/Sv * BALB/c * C57BL/6)	brain inflammation	J:137838
	optic nerve inflammation	J:137838
	spinal cord inflammation	J:137838
\Gt(ROSA)26Sor^{tm1(HBEGF)Awai}/\Gt(ROSA)26Sor^{tm1(HBEGF)Awai} \Mog^tm1(cre)Gkl/? (involves: C57BL/6)	abnormal immune system physiology	J:131076
\Gt(ROSA)26Sor^{tm1(HBEGF)Awai}/\Gt(ROSA)26Sor^{tm1(HBEGF)Awai} \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal lymphocyte cell number	J:131076
	decreased single-positive T cell number	J:131076
\Gt(ROSA)26Sor^{tm1(ITK/SYK)Jrld}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal spleen morphology	J:160931
	abnormal T cell activation	J:160931
	abnormal T cell differentiation	J:160931
	decreased double-positive T cell number	J:160931
	decreased single-positive T cell number	J:160931
	decreased T cell number	J:160931
	enlarged spleen	J:160931
	immune system phenotype	J:160931
	increased T cell derived lymphoma incidence	J:160931
	increased T cell proliferation	J:160931
\Gt(ROSA)26Sor^{tm1(MAML1)Wsp}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Gt(ROSA)26Sor^{tm1(MAML1)Wsp})	abnormal immunoglobulin level	J:113262
	abnormal T-helper 1 physiology	J:113262
	abnormal T-helper 2 physiology	J:113262
	decreased susceptibility to parasitic infection	J:113262
	increased susceptibility to parasitic infection	J:113262
\Gt(ROSA)26Sor^{tm1(MAML1)Wsp}/\Gt(ROSA)26Sor⁺ \Tg(KRT14-rtTA)F42Efu/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6 * FVB)	conjunctivitis	J:194073
\Gt(ROSA)26Sor^{tm1(Mirn155)Rsky}/\Gt(ROSA)26Sor^{tm1(Mirn155)Rsky} (involves: BALB/c * C57BL/6)	abnormal humoral immune response	J:121084
	increased germinal center B cell number	J:121084
\Gt(ROSA)26Sor^{tm1(Nfatc2)Rao}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 DBA/2)	abnormal interferon level	J:148341
	abnormal T cell activation	J:148341
\Gt(ROSA)26Sor^{tm1(Notch1)Dam}/\Gt(ROSA)26Sor⁺ \Hes1^tm1.1Frad/\Hes1^tm1.1Frad \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	decreased B cell number	J:167000
\Gt(ROSA)26Sor^{tm1(Notch1)Dam}/\Gt(ROSA)26Sor⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	decreased B cell number	J:167000
	enlarged spleen	J:167000
	increased leukocyte cell number	J:167000
\Gt(ROSA)26Sor^{tm1(NOTCH1/GFP)Xhsu}/\Gt(ROSA)26Sor⁺ \Tg(Lck-cre)548Jxm/0 (B6.Cg-Gt(ROSA)26Sor^{tm1(NOTCH1/GFP)Xhsu} Tg(Lck-cre)548Jxm)	increased T cell derived lymphoma incidence	J:185287
\Gt(ROSA)26Sor^tm1(Ntn4)Dyl/\Gt(ROSA)26Sor⁺ \Tg(KRT14-cre)1Amc/0 (involves: 129/Sv * C57BL/6 * CBA)	abnormal lymphangiogenesis	J:162807
	abnormal lymphatic vessel morphology	J:162807
	lymphatic vessel hyperplasia	J:162807
\Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/\Gt(ROSA)26Sor⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal circulating cytokine level	J:260047
	decreased B cell number	J:260047
	decreased lymphocyte cell number	J:260047
	enlarged lymph nodes	J:260047
	enlarged spleen	J:260047
	glomerulonephritis	J:260047
	increased inflammatory response	J:260047
	increased monocyte cell number	J:260047
	increased neutrophil cell number	J:260047
	increased T cell number	J:260047
	joint inflammation	J:260047
	small intestinal inflammation	J:260047
\Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/\Gt(ROSA)26Sor⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Nlrc4^tm1Vmd/\Nlrc4^tm1Vmd (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NCrl)	immune system phenotype	J:260047
\Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/\Gt(ROSA)26Sor⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Pycard^tm1Vmd/\Pycard^tm1Vmd (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	immune system phenotype	J:260047
	increased circulating interferon-gamma level	J:260047
	increased circulating interleukin-6 level	J:260047
	increased circulating tumor necrosis factor level	J:260047
\Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/\Gt(ROSA)26Sor⁺ \Tg(Itgax-cre)1-1Reiz/0 (involves: C3H * C57BL/6 * C57BL/6J)	increased monocyte cell number	J:260047
	increased neutrophil cell number	J:260047
\Gt(ROSA)26Sor^{tm1(OVAL/fla,GFP)Vnce}/\Gt(ROSA)26Sor⁺ \Tg(S100A8-cre,-EGFP)1Ilw/0 (involves: C3H * C57BL/6 * C57BL/6J)	abnormal circulating cytokine level	J:260047
	increased circulating interleukin-18 level	J:260047
	increased monocyte cell number	J:260047
	increased neutrophil cell number	J:260047
\Gt(ROSA)26Sor^{tm1(Pik3caH1047R)Egan}/\Gt(ROSA)26Sor⁺ \Tg(MMTV-cre)#Tfln/0 \Trp53^tm1Brn/\Trp53⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:170898
\Gt(ROSA)26Sor^{tm1(Pik3caH1047R)Egan}/\Gt(ROSA)26Sor⁺ \Trp53^tm1Brn/\Trp53^tm1Brn \Tg(MMTV-cre)#Tfln/0 (involves: 129P2/OlaHsd 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:170898
\Gt(ROSA)26Sor^{tm1(Ptpn22)Draw}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd C57BL/6)	enlarged spleen	J:201448
	glomerulonephritis	J:201448
	increased anti-double stranded DNA antibody level	J:201448
	increased autoantibody level	J:201448
	increased B cell number	J:201448
	increased germinal center B cell number	J:201448
	spleen hyperplasia	J:201448
\Gt(ROSA)26Sor^{tm1(RNAi:Bmpr2)Dliu}/\Gt(ROSA)26Sor⁺ (involves: 129 * C57BL/6J)	abnormal spleen morphology	J:145514
	abnormal spleen white pulp morphology	J:145514
	enlarged spleen	J:145514
\Gt(ROSA)26Sor^tm1(rtTA)Awu/\Gt(ROSA)26Sor^tm1(rtTA)Awu \Xist^tm1Awu/Y (involves: 129S4/SvJae)	abnormal B cell differentiation	J:112954
	abnormal myelopoiesis	J:112954
	abnormal T cell differentiation	J:112954
	abnormal thymus morphology	J:112954
	absent pre-B cells	J:112954
	decreased double-positive T cell number	J:112954
	decreased granulocyte number	J:112954
	decreased immature B cell number	J:112954
	decreased macrophage cell number	J:112954
	decreased pro-B cell number	J:112954
	decreased thymocyte number	J:112954
	small thymus	J:112954
	thymus hypoplasia	J:112954
\Gt(ROSA)26Sor^tm1(rtTA)Awu/\Gt(ROSA)26Sor^tm1(rtTA)Awu \Xist^tm1Awu/\Xist^tm1Awu (involves: 129S4/SvJae)	small thymus	J:112954
\Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/\Gt(ROSA)26Sor⁺ \Tg(CAG-cre)1Nagy/0 \Tg(tetO-Vegfa)90Ala/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR)	enlarged lymph nodes	J:99607
	thymus atrophy	J:99607
\Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/\Gt(ROSA)26Sor⁺ \Tg(Col2a1-cre)1Bhr/0 \Tg(tetO-Vegfa)90Ala/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL)	decreased osteoclast cell number	J:156474
	enlarged spleen	J:156474
\Gt(ROSA)26Sor^{tm1(sb11)Njen}/\Gt(ROSA)26Sor⁺ \TgTn(sb-T2/Onc2)6057Njen/0 (involves: C3H * C57BL/6)	increased T cell derived lymphoma incidence	J:102234
\Gt(ROSA)26Sor^{tm1(sb11)Njen}/\Gt(ROSA)26Sor⁺ \TgTn(sb-T2/Onc2)6070Njen/0 (involves: C3H * C57BL/6)	increased T cell derived lymphoma incidence	J:102234
\Gt(ROSA)26Sor^{tm1(sb11)Njen}/\Gt(ROSA)26Sor⁺ \TgTn(sb-T2/Onc2)6113Njen/0 (involves: C3H * C57BL/6)	increased T cell derived lymphoma incidence	J:102234
\Gt(ROSA)26Sor^{tm1(sb11)Njen}/\Gt(ROSA)26Sor⁺ \TgTn(sb-T2/Onc3)12740Njen/0 (involves: C3H * C57BL/6J)	increased T cell derived lymphoma incidence	J:153656
\Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv}/\Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv} (involves: C57BL/6)	abnormal T-helper 17 cell differentiation	J:205858
\Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv}/\Gt(ROSA)26Sor^{tm1(Stat3A661CN663C)Sbkv} \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	increased circulating interleukin-17 level	J:205858
	increased interleukin-17 secretion	J:205858
	increased regulatory T cell number	J:205858
	increased T-helper 1 cell number	J:205858
	increased T-helper 17 cell number	J:205858
	lung inflammation	J:205858
\Gt(ROSA)26Sor^{tm1(Tbx1/GFP)Bem}/\Gt(ROSA)26Sor⁺ \Foxg1^tm1(cre)Skm/\Foxg1⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	athymia	J:204435
\Gt(ROSA)26Sor^{tm1(tTA,tetO-Mir21)Fjsl}/\Gt(ROSA)26Sor⁺ \Tg(Nes-cre)1Wmz/0 (involves: C57BL/6 * C57BL/6J * SJL/J)	abnormal spleen morphology	J:163919
	abnormal thymus corticomedullary boundary morphology	J:163919
	abnormal thymus morphology	J:163919
	decreased leukocyte cell number	J:163919
	enlarged lymph nodes	J:163919
	enlarged spleen	J:163919
	enlarged thymus	J:163919
	intermingled spleen red and white pulp	J:163919
\Gt(ROSA)26Sor^{tm1(tTA,tetO-Mir155)Fjsl}/\Gt(ROSA)26Sor⁺ \Tg(Nes-cre)1Wmz/0 (involves: 129 * C57BL/6 * FVB/N * SJL/J)	abnormal immune system morphology	J:185598
	enlarged lymph nodes	J:185598
	enlarged spleen	J:185598
	increased spleen weight	J:185598
	increased spleen white pulp amount	J:185598
	thymus hyperplasia	J:185598
\Gt(ROSA)26Sor^{tm1.1(Aco1)Mwh}/\Gt(ROSA)26Sor^{tm1.1(Aco1)Mwh} (B6.129P2(129S1)-Gt(ROSA)26Sor^{tm1.1(Aco1*)Mwh})	increased spleen iron level	J:196374
\Gt(ROSA)26Sor^{tm1.1(CAG-PSTPIP1)Dtg}/\Gt(ROSA)26Sor⁺ (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:196002
\Gt(ROSA)26Sor^{tm1.1(CAG-Trp53,-EGFP)Medz}/\Gt(ROSA)26Sor^{tm1.1(CAG-Trp53,-EGFP)Medz} (involves: C57BL/6)	decreased thymocyte apoptosis	J:158953
\Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/\Gt(ROSA)26Sor⁺ (B6(Cg)-Gt(ROSA)26Sor^{tm1.1(DUX4)Plj})	enlarged lymph nodes	J:256652
	enlarged popliteal lymph nodes	J:256652
\Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/\Gt(ROSA)26Sor⁺ \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv C57BL/6)	enlarged lymph nodes	J:256652
	enlarged popliteal lymph nodes	J:256652
\Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/\Gt(ROSA)26Sor⁺ \Tg(ACTA1-cre/Esr1)2Kesr/0 (involves: C3H * C57BL/6)	increased acute inflammation	J:256652
\Gt(ROSA)26Sor^{tm1.1(DUX4)Plj}/\Gt(ROSA)26Sor^{tm1.1(DUX4)Plj} (B6(Cg)-Gt(ROSA)26Sor^{tm1.1(DUX4*)Plj})	preputial gland inflammation	J:256652
\Gt(ROSA)26Sor^{tm1.1(Loxl2)Acan}/\Gt(ROSA)26Sor^{tm1.1(Loxl2)Acan} (Not Specified)	epididymis inflammation	J:220689
	increased inflammatory response	J:220689
\Gt(ROSA)26Sor^{tm1.1(Ubc-BCL3)Sbn}/\Gt(ROSA)26Sor⁺ \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6)	decreased B cell proliferation	J:207111
	decreased follicular B cell number	J:207111
	decreased marginal zone B cell number	J:207111
	increased follicular B cell number	J:207111
\Gt(ROSA)26Sor^{tm1.1(Wls/YFP)Mbtr}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6)	decreased neutrophil cell number	J:202499
\Gt(ROSA)26Sor^{tm1.2(CAG-PLS3,-GFP)Bwir}/\Gt(ROSA)26Sor⁺ (B6N.Cg-Gt(ROSA)26Sor^{tm1.1(CAG-PLS3,-GFP)Bwir})	decreased osteoclast cell number	J:267292
\Gt(ROSA)26Sor^tm1Fia/\Gt(ROSA)26Sor⁺ \Nf1^tm1Fcr/\Nf1^tm1Par \Tg(Tek-cre)1Ywa/0 (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal spleen morphology	J:114455
\Gt(ROSA)26Sor^tm1Jus/\Gt(ROSA)26Sor⁺ \Tg(Lck-icre)3779Nik/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)	immune system phenotype	J:202090
\Gt(ROSA)26Sor^tm1Jus/\Gt(ROSA)26Sor⁺ \Tg(MMTV-cre)4Mam/0 (involves: C57BL/6J * C57BL/6N * FVB/N)	abnormal leukocyte morphology	J:202090
	abnormal thymus physiology	J:202090
	arrested B cell differentiation	J:202090
	decreased B cell number	J:202090
	decreased double-positive T cell number	J:202090
	decreased mature B cell number	J:202090
	decreased pre-B cell number	J:202090
	decreased pro-B cell number	J:202090
	enlarged lymph nodes	J:202090
	enlarged spleen	J:202090
	enlarged thymus	J:202090
	increased CD8-positive, alpha-beta T cell number	J:202090
	increased inflammatory response	J:202090
	increased large unstained cell number	J:202090
	increased leukocyte cell number	J:202090
	increased single-positive T cell number	J:202090
	intermingled spleen red and white pulp	J:202090
	intestinal inflammation	J:202090
	kidney inflammation	J:202090
	liver inflammation	J:202090
	meningitis	J:202090
	stomach inflammation	J:202090
\Gt(ROSA)26Sor^tm1Jus/\Gt(ROSA)26Sor⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)	abnormal leukocyte morphology	J:202090
	abnormal thymus physiology	J:202090
	arrested B cell differentiation	J:202090
	decreased B cell number	J:202090
	decreased double-positive T cell number	J:202090
	decreased mature B cell number	J:202090
	decreased pre-B cell number	J:202090
	decreased pro-B cell number	J:202090
	enlarged lymph nodes	J:202090
	enlarged spleen	J:202090
	enlarged thymus	J:202090
	increased CD8-positive, alpha-beta T cell number	J:202090
	increased inflammatory response	J:202090
	increased large unstained cell number	J:202090
	increased leukocyte cell number	J:202090
	increased single-positive T cell number	J:202090
	intermingled spleen red and white pulp	J:202090
	intestinal inflammation	J:202090
	kidney inflammation	J:202090
	liver inflammation	J:202090
	meningitis	J:202090
	stomach inflammation	J:202090
\Gt(ROSA)26Sor^tm1Sor/\Gt(ROSA)26Sor⁺ \Id3^tm2.1Zhu/\Id3^tm2.1Zhu \Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * SJL)	decreased T cell number	J:172701
\Gt(ROSA)26Sor^tm1Sor/\Gt(ROSA)26Sor⁺ \Nr2f2^tm2.1Tsa/\Nr2f2^tm2.1Tsa \Prox1^{tm3(cre/ERT2)Gco}/\Prox1⁺ (involves: 129S1/Sv * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:158959
\Gt(ROSA)26Sor^tm1Sor/\Gt(ROSA)26Sor⁺ \Tbx1^tm3.1Bld/\Tbx1^tm6(cre)Bld (involves: 129S4/SvJaeSor * 129S7/SvEvBrd)	abnormal lymphatic vessel morphology	J:159824
\Gt(ROSA)26Sor^{tm2(CAG-Notch2)Uzs}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6J)	abnormal B cell differentiation	J:179036
	abnormal marginal zone B cell physiology	J:179036
	abnormal spleen marginal zone morphology	J:179036
	decreased B cell number	J:179036
	decreased B-1a cell number	J:179036
	decreased B-2 B cell number	J:179036
	decreased follicular B cell number	J:179036
	decreased IgG1 level	J:179036
	decreased IgG3 level	J:179036
	decreased IgM level	J:179036
	decreased spleen B cell follicle size	J:179036
	decreased spleen germinal center number	J:179036
	decreased transitional stage T2 B cell number	J:179036
	increased B cell proliferation	J:179036
	increased marginal zone B cell number	J:179036
	increased spleen weight	J:179036
	increased T cell number	J:179036
	increased transitional stage T1 B cell number	J:179036
\Gt(ROSA)26Sor^{tm2(CAG-Notch2)Uzs}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19^tm1(cre)Cgn (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6J)	abnormal B cell differentiation	J:179036
	abnormal spleen marginal zone morphology	J:179036
	decreased follicular B cell number	J:179036
	decreased mature B cell number	J:179036
	decreased pre-B cell number	J:179036
	decreased transitional stage T2 B cell number	J:179036
	increased marginal zone B cell number	J:179036
	increased transitional stage T1 B cell number	J:179036
\Gt(ROSA)26Sor^{tm2(CAG-Notch2)Uzs}/\Gt(ROSA)26Sor⁺ \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S6/SvEvTac BALB/c * C57BL/6J)	arrested B cell differentiation	J:179036
	decreased B cell number	J:179036
	decreased splenocyte number	J:179036
	increased T cell number	J:179036
\Gt(ROSA)26Sor^{tm2(CAG-Nr5a1)Fjd}/\Gt(ROSA)26Sor⁺ \Pgr^tm2(cre)Lyd/\Pgr⁺ (involves: 129S1/Sv * 129X1/SvJ)	uterus inflammation	J:269597
\Gt(ROSA)26Sor^{tm2(CAG-PSTPIP1)Dtg}/\Gt(ROSA)26Sor⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 C57BL/10 * CBA/Ca)	immune system phenotype	J:196002
\Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/0 \Tg(Sftpc-Grem1)105Mmyl/0 (involves: 129P2/OlaHsd * C57BL/6N)	lung inflammation	J:82809
\Gt(ROSA)26Sor^{tm2(H1/tetO-RNAi:Kdm1a)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6)	abnormal granulocyte differentiation	J:192055
	abnormal monocyte differentiation	J:192055
	enlarged spleen	J:192055
	increased leukocyte cell number	J:192055
\Gt(ROSA)26Sor^{tm2(ITK/Syk)Hjum}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal circulating cytokine level	J:207306
	abnormal cytokine secretion	J:207306
	abnormal immunoglobulin level	J:207306
	abnormal spleen morphology	J:207306
	enlarged spleen	J:207306
	immune system phenotype	J:207306
	increased activated T cell number	J:207306
	increased CD4-positive, alpha-beta T cell number	J:207306
	increased circulating interferon-gamma level	J:207306
	increased circulating interleukin-2 level	J:207306
	increased circulating interleukin-4 level	J:207306
	increased circulating interleukin-6 level	J:207306
	increased circulating interleukin-10 level	J:207306
	increased circulating tumor necrosis factor level	J:207306
	increased IgA level	J:207306
	increased IgG level	J:207306
	increased IgM level	J:207306
	increased inflammatory response	J:207306
	increased interferon-gamma secretion	J:207306
	increased interleukin-2 secretion	J:207306
	increased interleukin-4 secretion	J:207306
	increased interleukin-6 secretion	J:207306
	increased interleukin-10 secretion	J:207306
	increased mature B cell number	J:207306
	increased plasma cell number	J:207306
	increased tumor necrosis factor secretion	J:207306
\Gt(ROSA)26Sor^{tm2(ITK/Syk)Hjum}/\Gt(ROSA)26Sor⁺ \Tg(Lck-cre)I57Jxm/0 (involves: 129S6/SvEvTac * ICR)	abnormal circulating cytokine level	J:207306
	abnormal cytokine secretion	J:207306
	abnormal immunoglobulin level	J:207306
	abnormal spleen morphology	J:207306
	enlarged spleen	J:207306
	immune system phenotype	J:207306
	increased activated T cell number	J:207306
	increased CD4-positive, alpha-beta T cell number	J:207306
	increased circulating interferon-gamma level	J:207306
	increased circulating interleukin-2 level	J:207306
	increased circulating interleukin-4 level	J:207306
	increased circulating interleukin-6 level	J:207306
	increased circulating interleukin-10 level	J:207306
	increased circulating tumor necrosis factor level	J:207306
	increased IgA level	J:207306
	increased IgG level	J:207306
	increased IgM level	J:207306
	increased inflammatory response	J:207306
	increased interferon-gamma secretion	J:207306
	increased interleukin-2 secretion	J:207306
	increased interleukin-4 secretion	J:207306
	increased interleukin-6 secretion	J:207306
	increased interleukin-10 secretion	J:207306
	increased mature B cell number	J:207306
	increased plasma cell number	J:207306
	increased tumor necrosis factor secretion	J:207306
\Gt(ROSA)26Sor^{tm2(Lmp1/CD40)Uzs}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell activation	J:137122
	abnormal B cell physiology	J:137122
	abnormal class switch recombination	J:137122
	abnormal humoral immune response	J:137122
	abnormal T cell activation	J:137122
	enlarged inguinal lymph nodes	J:137122
	enlarged spleen	J:137122
	increased B cell number	J:137122
	increased B cell proliferation	J:137122
	increased follicular B cell number	J:137122
	increased marginal zone B cell number	J:137122
	increased spleen B cell follicle size	J:137122
	increased spleen weight	J:137122
	increased T cell number	J:137122
\Gt(ROSA)26Sor^{tm2(Lmp1/CD40)Uzs}/\Gt(ROSA)26Sor⁺ \Tg(Cr2-cre)3Cgn/0 (involves: BALB/c * C57BL/6)	abnormal immune system morphology	J:137122
	abnormal immune system physiology	J:137122
\Gt(ROSA)26Sor^{tm2(Mirn150)Rsky}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * SJL/J)	decreased mature B cell number	J:127234
\Gt(ROSA)26Sor^{tm2(Mirn150)Rsky}/\Gt(ROSA)26Sor^{tm2(Mirn150)Rsky} (involves: C57BL/6 * SJL/J)	decreased B-1 B cell number	J:127234
	decreased B-2 B cell number	J:127234
	decreased CD4-positive, alpha-beta T cell number	J:127234
	decreased CD8-positive, alpha-beta T cell number	J:127234
	increased B cell apoptosis	J:127234
\Gt(ROSA)26Sor^{tm2(Nfatc2)Rao}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 DBA/2)	abnormal interferon level	J:148341
	abnormal T cell activation	J:148341
\Gt(ROSA)26Sor^{tm2(sb11)Njen}/\Gt(ROSA)26Sor⁺ \TgTn(sb-T2/Onc2)6070Njen/0 (involves: 129 * C57BL/6 * C57BL/6J)	increased susceptibility to infection	J:153656
\Gt(ROSA)26Sor^{tm2.1(CAG-PSTPIP1)Dtg}/\Gt(ROSA)26Sor⁺ (involves: BALB/cJ C57BL/6)	increased circulating interleukin-1 alpha level	J:196002
	increased circulating interleukin-1 beta level	J:196002
	increased circulating tumor necrosis factor level	J:196002
\Gt(ROSA)26Sor^{tm2.1(Cd74/MOG)Awai}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * BALB/cJ)	abnormal humoral immune response	J:140751
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
\Gt(ROSA)26Sor^{tm2.1(Mirn150)Rsky}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * SJL/J)	decreased mature B cell number	J:127234
\Gt(ROSA)26Sor^{tm2.1(Mirn150)Rsky}/\Gt(ROSA)26Sor^{tm2.1(Mirn150)Rsky} (involves: C57BL/6 * SJL/J)	arrested B cell differentiation	J:127234
	arrested T cell differentiation	J:127234
	decreased B-1 B cell number	J:127234
	decreased B-2 B cell number	J:127234
	decreased lymphocyte cell number	J:127234
	increased B cell apoptosis	J:127234
\Gt(ROSA)26Sor^{tm2.1(sb11)Njen}/\Gt(ROSA)26Sor⁺ \TgTn(sb-T2/Onc2)6070Njen/0 (involves: 129 * C57BL/6 * C57BL/6J)	increased T cell derived lymphoma incidence	J:153656
\Gt(ROSA)26Sor^tm2Sho/\Gt(ROSA)26Sor⁺ \Lef1^tm1Hhx/\Lef1^tm1Hhx \Tg(GZMB-cre)1Jcb/0 (involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal memory T cell physiology	J:189838
	decreased CD8-positive, alpha-beta T cell number	J:189838
\Gt(ROSA)26Sor^{tm3(CAG-EYFP)Hze}/\Gt(ROSA)26Sor⁺ \Stat5a^tm2Mam \Stat5b^tm1Mam/\Del(11Stat5a-Stat5b)1Mam \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA)	abnormal CD4-positive T cell differentiation	J:204829
\Gt(ROSA)26Sor^{tm3(CAG-Il17a)Awai}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal immune system physiology	J:144710
	abnormal neutrophil physiology	J:144710
	increased circulating interleukin-17 level	J:144710
	increased granulocyte number	J:144710
	increased interleukin-17 secretion	J:144710
\Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/\Gt(ROSA)26Sor⁺ \Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	decreased marginal zone B cell number	J:133215
	increased B-1a cell number	J:133215
\Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/\Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky} \Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal B cell activation	J:133215
	abnormal B cell morphology	J:133215
	abnormal CD4-positive, alpha beta T cell morphology	J:133215
	abnormal CD4-positive, alpha-beta T cell physiology	J:133215
	abnormal immune system morphology	J:133215
	abnormal immune system physiology	J:133215
	abnormal immunoglobulin level	J:133215
	abnormal spleen marginal zone morphology	J:133215
	abnormal T cell activation	J:133215
	abnormal T cell differentiation	J:133215
	decreased marginal zone B cell number	J:133215
	decreased spleen red pulp amount	J:133215
	enlarged lymph nodes	J:133215
	immune system phenotype	J:133215
	increased anti-double stranded DNA antibody level	J:133215
	increased anti-single stranded DNA antibody level	J:133215
	increased B cell number	J:133215
	increased B cell proliferation	J:133215
	increased B-1a cell number	J:133215
	increased CD4-positive, alpha-beta T cell number	J:133215
	increased CD8-positive, alpha-beta T cell number	J:133215
	increased germinal center B cell number	J:133215
	increased IgG2a level	J:133215
	increased IgG2b level	J:133215
	increased IgG3 level	J:133215
	increased IgM level	J:133215
	increased lymphocyte cell number	J:133215
	increased spleen weight	J:133215
	increased spleen white pulp amount	J:133215
	intermingled spleen red and white pulp	J:133215
	lymph node hyperplasia	J:133215
	spleen hyperplasia	J:133215
\Gt(ROSA)26Sor^{tm3.1(CAG-Il17a)Awai}/\Gt(ROSA)26Sor⁺ (involves: BALB/c * C57BL/6)	increased granulocyte number	J:144710
	increased interleukin-17 secretion	J:144710
	skin inflammation	J:144710
\Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/\Gt(ROSA)26Sor⁺ \Hnrnpl^tm1.1Tmo/\Hnrnpl^tm1.1Tmo \Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal T cell differentiation	J:188749
\Gt(ROSA)26Sor^{tm4(CAG-hsb5)Nki}/\Gt(ROSA)26Sor⁺ \Tg(Mx1-cre)1Cgn/0 \Tg(Tal1-tTA)19Dgt/0 \Tg(tetO-BCR/ABL1)2Dgt/0 \TgTn(pb-sb-GrOnc)#aGsva/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N)	increased basophil cell number	J:227558
	increased granulocyte number	J:227558
	increased leukocyte cell number	J:227558
	increased spleen weight	J:227558
\Gt(ROSA)26Sor^{tm4(H1/tetO-RNAi:Ezh2)Arte}/\Gt(ROSA)26Sor⁺ (C57BL/6-Gt(ROSA)26Sor^{tm4(H1/tetO-RNAi:Ezh2)Arte})	small lymph nodes	J:202724
\Gt(ROSA)26Sor^{tm4(HIF2A)Kael}/\Gt(ROSA)26Sor^{tm4(HIF2A)Kael} \Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:307422
\Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/\Gt(ROSA)26Sor⁺ \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:167612
	decreased germinal center B cell number	J:167612
	enlarged spleen	J:167612
	increased B cell number	J:167612
	increased IgG1 level	J:167612
	increased IgM level	J:167612
	increased plasma cell number	J:167612
\Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/\Gt(ROSA)26Sor⁺ \Ighg1^tm1(cre)Cgn/\Ighg1⁺ \Prdm1^tm2Masu/\Prdm1^tm2Masu (involves: 129P2/OlaHsd * C57BL/6)	abnormal germinal center B cell physiology	J:167612
	abnormal plasma cell differentiation	J:167612
	decreased IgG1 level	J:167612
	increased germinal center B cell number	J:167612
\Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/\Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky} \Igh-J^tm1Cgn/\Igh^tm4Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	increased B cell number	J:157297
\Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/\Gt(ROSA)26Sor⁺ \Tg(Col1a1-cre)1Ack/0 (involves: FVB/N)	decreased osteoclast cell number	J:208766
	enlarged spleen	J:208766
	increased spleen weight	J:208766
\Gt(ROSA)26Sor^{tm4(Wnt7b)Flng}/\Gt(ROSA)26Sor⁺ \Tg(Runx2-rtTAM2)#Flng/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 C57BL/6)	decreased osteoclast cell number	J:208766
\Gt(ROSA)26Sor^{tm5(H1/tetO-RNAi:Ezh2)Arte}/\Gt(ROSA)26Sor⁺ (C57BL/6-Gt(ROSA)26Sor^{tm5(H1/tetO-RNAi:Ezh2)Arte})	small lymph nodes	J:202724
\Gt(ROSA)26Sor^{tm7(Pik3ca,-EGFP)Rsky}/\Gt(ROSA)26Sor⁺ \Tg(CAG-cre/Esr1)5Amc/0 (B6.Cg-Gt(ROSA)26Sor^{tm7(Pik3ca,-EGFP)Rsky} Tg(CAG-cre/Esr1)5Amc)	abnormal spleen morphology	J:264410
	enlarged lymphatic vessel	J:264410
\Gt(ROSA)26Sor^{tm7(Pik3ca,-EGFP)Rsky}/\Gt(ROSA)26Sor^{tm13(CAG-MYC,-CD2)Rsky} \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:191824
	increased germinal center B cell number	J:191824
\Gt(ROSA)26Sor^{tm8(Map2k1,-EGFP)Rsky}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 \Traf3ip3^{tm1c(KOMP)Wtsi}/\Traf3ip3^{tm1c(KOMP)Wtsi} (involves: C57BL/6 C57BL/6N * DBA/2)	immune system phenotype	J:226431
\Gt(ROSA)26Sor^{tm8(Map2k1,-EGFP)Rsky}/\Gt(ROSA)26Sor^{tm8(Map2k1,-EGFP)Rsky} \Igh-J^tm1Cgn/\Igh^tm4Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:157297
\Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/? \Tnfaip3^tm1Homy/\Tnfaip3^tm1Homy (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)	abnormal circulating cytokine level	J:212681
	abnormal circulating interleukin level	J:212681
	increased circulating interferon-gamma level	J:212681
	increased circulating interleukin-1 beta level	J:212681
	increased circulating interleukin-6 level	J:212681
	increased circulating tumor necrosis factor level	J:212681
	pale spleen	J:212681
	thymus atrophy	J:212681
\Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ \Map3k14^tm1.1Gne/\Map3k14^tm1.1Gne (B6(Cg)-Map3k14^tm1.1Gne Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte})	abnormal immunoglobulin level	J:240453
	decreased B cell number	J:240453
	decreased B cell proliferation	J:240453
	decreased germinal center B cell number	J:240453
	decreased IgA level	J:240453
	decreased IgG1 level	J:240453
	decreased IgM level	J:240453
	decreased Peyer's patch number	J:240453
	immune system phenotype	J:240453
\Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ \Pten^tm1Hwu/\Pten^tm1Hwu (involves: 129S4/SvJae * C57BL/6)	enlarged lymph nodes	J:170965
	enlarged spleen	J:170965
	increased spleen weight	J:170965
\Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ \Ripk3^tm1Arte/\Ripk3^tm1Arte (involves: C57BL/6NTac)	abnormal lymphocyte morphology	J:209137
	intestinal inflammation	J:209137
	thymus atrophy	J:209137
\Gt(ROSA)26Sor^{tm9(Rac1,-EGFP)Rsky}/\Gt(ROSA)26Sor^{tm9(Rac1,-EGFP)Rsky} \Igh-J^tm1Cgn/\Igh^tm4Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:157297
\Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ (involves: BALB/cJ)	abnormal B cell morphology	J:181546
	increased B cell proliferation	J:181546
\Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * BALB/cJ)	abnormal B cell differentiation	J:181546
	abnormal CD8-positive, alpha-beta T cell physiology	J:181546
	abnormal immune system physiology	J:181546
	decreased B cell number	J:181546
	decreased mature B cell number	J:181546
	decreased pre-B cell number	J:181546
	enlarged spleen	J:181546
	increased B cell number	J:181546
	increased B cell proliferation	J:181546
	increased CD4-positive, alpha-beta T cell number	J:181546
	increased CD8-positive, alpha-beta T cell number	J:181546
	increased pro-B cell number	J:181546
\Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ \Tcrb^tm1Mom/\Tcrb⁺ \Tcrd^tm1Mom/\Tcrd^tm1Mom \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)	enlarged spleen	J:181546
	increased B cell number	J:181546
\Gt(ROSA)26Sor^{tm10(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ \Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)	enlarged spleen	J:181546
	increased B cell number	J:181546
\Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6)	abnormal B cell morphology	J:181546
	increased B cell proliferation	J:181546
\Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:181546
	abnormal CD4-positive, alpha-beta T cell physiology	J:181546
	abnormal CD8-positive, alpha-beta T cell physiology	J:181546
	abnormal immune system physiology	J:181546
	decreased B cell number	J:181546
	decreased mature B cell number	J:181546
	decreased pre-B cell number	J:181546
	enlarged spleen	J:181546
	increased B cell number	J:181546
	increased B cell proliferation	J:181546
	increased CD4-positive, alpha-beta T cell number	J:181546
	increased CD8-positive, alpha-beta T cell number	J:181546
	increased interferon-gamma secretion	J:181546
	increased pro-B cell number	J:181546
	increased tumor necrosis factor secretion	J:181546
\Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ \Cd19^{tm1(cre/ERT2)Rsky}/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell physiology	J:217520
	enlarged spleen	J:217520
	increased activated T cell number	J:217520
	increased B cell number	J:217520
	increased CD4-positive, alpha-beta T cell number	J:217520
	increased CD8-positive, alpha-beta T cell number	J:217520
\Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ \Tcrb^tm1Mom/\Tcrb⁺ \Tcrd^tm1Mom/\Tcrd^tm1Mom \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	enlarged spleen	J:181546
	increased B cell number	J:181546
\Gt(ROSA)26Sor^{tm11(Lmp1)Rsky}/\Gt(ROSA)26Sor⁺ \Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	enlarged spleen	J:181546
	increased B cell number	J:181546
\Gt(ROSA)26Sor^{tm12(CD2)Rsky}/\Gt(ROSA)26Sor⁺ \Myc^tm2Fwa/\Myc^tm2Fwa \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6)	decreased spleen germinal center size	J:188564
\Gt(ROSA)26Sor^{tm13(CAG-MYC,-CD2)Rsky}/\Gt(ROSA)26Sor⁺ \Myc^tm2Fwa/\Myc^tm2Fwa \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:188564
\Gt(ROSA)26Sor^{tm18(Zeb2)Jhai}/\Gt(ROSA)26Sor⁺ \Tg(Tek-cre)1Ywa/0 \Trp53^tm1Brn/\Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)	increased T cell derived lymphoma incidence	J:263520
\Gt(ROSA)26Sor^{tm18(Zeb2)Jhai}/\Gt(ROSA)26Sor^{tm18(Zeb2)Jhai} \Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * CD-1 * SJL)	increased thymus tumor incidence	J:263520
\Gt(ROSA)26Sor^{tm18(Zeb2)Jhai}/\Gt(ROSA)26Sor^{tm18(Zeb2)Jhai} \Tg(Tek-cre)1Ywa/0 \Trp53^tm1Brn/\Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)	increased T cell derived lymphoma incidence	J:263520
\Gtf2a1l^em1(IMPC)J/\Gtf2a1l^em1(IMPC)J (C57BL/6NJ-Gtf2a1l^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Gtf2ird1^{em1(IMPC)Ccpcz}/\Gtf2ird1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gtf2ird1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Gtpbp2^{tm1b(KOMP)Mbp}/\Gtpbp2⁺ (C57BL/6N-Gtpbp2^{tm1b(KOMP)Mbp}/Ucd)	enlarged lymph nodes	J:211773
\Gtpbp2^{tm1b(KOMP)Mbp}/\Gtpbp2^{tm1b(KOMP)Mbp} (C57BL/6N-Gtpbp2^{tm1b(KOMP)Mbp}/Ucd)	enlarged lymph nodes	J:211773
\Gtsf1l^em1(IMPC)J/\Gtsf1l^em1(IMPC)J (C57BL/6NJ-Gtsf1l^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Guca2a^em1(IMPC)Mbp/\Guca2a^em1(IMPC)Mbp (C57BL/6N-Guca2a^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Gucy1b1^tm1.1Frb/\Gucy1b1^tm1.1Frb (involves: 129 * C57BL/6 * FVB/N)	peritoneal inflammation	J:121321
\Gucy2c^tm1Gar/\Gucy2c^tm1Gar (either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J))	decreased susceptibility to bacterial infection	J:43046
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:43046
\Gucy2c^tm1Gian/\Gucy2c^tm1Gian (involves: 129P2/OlaHsd * Black Swiss)	decreased susceptibility to infection	J:43682
\Guk1^em1(IMPC)J/\Guk1⁺ (C57BL/6NJ-Guk1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Gulo^{em1(IMPC)Ccpcz}/\Gulo^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Gulo^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Gulo^sfx/\Gulo^sfx (BALB/cBy-Gulo^sfx/J)	abnormal osteoclast differentiation	J:66648
	small spleen	J:66648
	small thymus	J:66648
\Gulp1^tm1.2Kimj/\Gulp1^tm1.2Kimj (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:340688
	abnormal osteoclast morphology	J:340688
	abnormal osteoclast physiology	J:340688
	increased osteoclast cell number	J:340688
\Gvhd1^C57BL/10J/\Gvhd1^C57BL/10J (involves: B10.D2-H2^d * C57BL/10J)	increased susceptibility to graft versus host disease	J:52834
\Gvhd1^C57BL/10J/\Gvhd1^C57BL/10J \Gvhd2^C57BL/10J/\Gvhd2^C57BL/10J (involves: B10.D2-H2^d * C57BL/10J)	increased susceptibility to graft versus host disease	J:52834
\Gvhd2^C57BL/10J/\Gvhd2^C57BL/10J (involves: B10.D2-H2^d * DBA/2J)	increased susceptibility to graft versus host disease	J:52834
\Gvhd4^DBA/2J/\Gvhd4^DBA/2J (involves: C57BL/10 * DBA/2J)	increased anti-single stranded DNA antibody level	J:66655
\Gvhd4^DBA/2J/\Gvhd4^DBA/2J \Gvhd5^DBA/2J/\Gvhd5^DBA/2J (involves: C57BL/10 * DBA/2J)	increased anti-single stranded DNA antibody level	J:66655
\Gvhd5^DBA/2J/\Gvhd5^DBA/2J (involves: C57BL/10 * DBA/2J)	increased anti-single stranded DNA antibody level	J:66655
\Gy/Y (involves: 101/H * C3H/HeH)	blepharitis	J:8335
\Gzma^tm1Ley/\Gzma^tm1Ley (involves: 129X1/SvJ * C57BL/6)	decreased cytotoxic T cell cytolysis	J:49361
\Gzma^tm1Simn/\Gzma^tm1Simn (B6.Cg-Gzma^tm1Simn)	immune system phenotype	J:92718, J:28773
\Gzma^tm1Simn/\Gzma^tm1Simn \Gzmb^tm1Ley/\Gzmb^tm1Ley (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte physiology	J:44204
	immune system phenotype	J:44204
\Gzma^tm1Simn/\Gzma^tm1Simn \Gzmb^tm1Ley/\Gzmb^tm1Ley (B6.Cg-Gzma^tm1Simn Gzmb^tm1Ley)	immune system phenotype	J:92718
	increased susceptibility to Flaviviridae infection	J:90852
	increased susceptibility to parasitic infection	J:81397
\Gzma^tm1Simn/\Gzma^tm1Simn \Gzmb^tm1Ley/\Gzmb^tm1Ley \Prf1^tm1Sdz/\Prf1^tm1Sdz (B6.Cg-Gzma^tm1Simn Gzmb^tm1Ley Prf1^tm1Sdz)	immune system phenotype	J:92718
	increased susceptibility to Flaviviridae infection	J:90852
	increased susceptibility to parasitic infection	J:81397
\Gzmb^tm1Asmv/\Gzmb^tm1Asmv (involves: C57BL/6)	immune system phenotype	J:203720
\Gzmb^tm1Ley/\Gzmb^tm1Ley (involves: 129S2/SvPas * C57BL/6J)	decreased cytotoxic T cell cytolysis	J:23560
\Gzmb^tm1Ley/\Gzmb^tm1Ley (B6.129S2-Gzmb^tm1Ley)	impaired natural killer cell mediated cytotoxicity	J:113213
\Gzmb^tm1Ley/\Gzmb^tm1Ley (involves: 129X1/SvJ)	abnormal NK cell physiology	J:126114
\Gzmb^tm1Ley/\Gzmb^tm1Ley (involves: 129X1/SvJ)	decreased T cell apoptosis	J:126114
\Gzmb^tm1Ley/\Gzmb^tm1Ley \Serpinb9^tm1.1Pib/\Serpinb9^tm1.1Pib (involves: 129S2/SvPas * BALB/cJ * C57BL/6J)	decreased cytotoxic T cell apoptosis	J:252016
\Gzmb^tm1Ley/\Gzmb^tm1Ley \Serpinb9^tm1Arp/\Serpinb9^tm1Arp (involves: 129S2/SvPas * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:113349
	abnormal cytotoxic T cell physiology	J:113349
\Gzmb^tm2.1Ley/\Gzmb^tm2.1Ley (129X1/SvJ-Gzmb^tm2.1Ley)	decreased cytotoxic T cell cytolysis	J:96538
\Gzmb^tm2Ley/\Gzmb^tm2Ley (129X1/SvJ-Gzmb^tm2Ley)	abnormal immune system physiology	J:96538
\Gzmb^tm2Ley/\Gzmb^tm2Ley (129X1/SvJ-Gzmb^tm2Ley)	decreased cytotoxic T cell cytolysis	J:96538
\Gzmk^tm1.1Pib/\Gzmk^tm1.1Pib (B6(Cg)-Gzmk^tm1.1Pib)	immune system phenotype	J:302067
\Gzmm^tm1(cre)Mjs/\Gzmm^tm1(cre)Mjs (C57BL/6-Gzmm^tm1(cre)Mjs)	increased susceptibility to Herpesvirales infection	J:113213
\H1f0^tm1Ais/\H1f0^tm1Ais \H1f2^tm2Ais/\H1f2^tm2Ais \H1f4^tm2Ais/\H1f4^tm2Ais (involves: 129/Sv * C57BL/6 * SJL)	small thymus	J:83954
\H1f2^tm2Ais/\H1f2^tm2Ais \H1f3^tm2Ais/\H1f3⁺ \H1f4^tm2Ais/\H1f4^tm2Ais (involves: 129/Sv * C57BL/6 * SJL)	small thymus	J:83954
\H2-Aa^b-tm1Blt/\H2-Aa^b-tm1Blt (C57BL/6-H2-Aa^b-tm1Blt)	abnormal MHC II cell surface expression on macrophages	J:67924
	abnormal splenocyte physiology	J:16372
	abnormal T cell morphology	J:16372
	decreased CD4-positive, alpha-beta T cell number	J:16372
	enlarged lymph nodes	J:16372
	enlarged thymus	J:16372
	increased CD8-positive, alpha-beta T cell number	J:16372
	thymus hyperplasia	J:16372
\H2-Ab1^b-tm1.1Jssh/\H2-Ab1^b-tm1.1Jssh (C57BL/6-H2-Ab1^b-tm1.1Jssh)	abnormal dendritic cell antigen presentation	J:201198
	abnormal T cell differentiation	J:201198
	decreased regulatory T cell number	J:201198
\H2-Ab1^b-tm1.1Sish/\H2-Ab1^b-tm1.1Sish (involves: 129S1/Sv * 129X1/SvJ)	abnormal dendritic cell physiology	J:157516
	decreased interleukin-12 secretion	J:157516
	decreased tumor necrosis factor secretion	J:157516
\H2-Ab1^b-tm1Doi/\H2-Ab1⁺ (involves: 129S2/SvPas * C57BL/6 * NOD/Lt)	insulitis	J:93557
\H2-Ab1^b-tm1Doi/\H2-Ab1^b-tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal B cell physiology	J:65736
	abnormal CD4-positive, alpha beta T cell morphology	J:65736
	abnormal CD4-positive, alpha-beta T cell physiology	J:65736
	abnormal cytokine secretion	J:64283
	abnormal immune system cell morphology	J:65736
	abnormal immune system morphology	J:65736
	abnormal immune system organ morphology	J:65736
	abnormal immune system physiology	J:65736
	abnormal lymph node cell ratio	J:65736
	abnormal spleen B cell follicle morphology	J:65736
	abnormal spleen marginal zone morphology	J:65736
	abnormal spleen morphology	J:65736
	abnormal spleen periarteriolar lymphoid sheath morphology	J:65736
	abnormal T cell physiology	J:65736
	absent spleen germinal center	J:65736
	decreased CD4-positive, alpha-beta T cell number	J:51885, J:65736
	decreased IgG1 level	J:65736
	decreased susceptibility to parasitic infection	J:64283
	increased CD4-positive, alpha-beta T cell number	J:64283
	increased CD8-positive, alpha-beta T cell number	J:65736, J:64283
	increased susceptibility to parasitic infection	J:64283
\H2-Ab1^b-tm1Doi/\H2-Ab1^b-tm1Doi (involves: 129S2/SvPas * C57BL/6 * NOD/Lt)	insulitis	J:93557
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru (involves: 129S2/SvPas * C57BL/6J)	abnormal humoral immune response	J:74418
	abnormal response to transplant	J:91742
	decreased CD4-positive, alpha-beta T cell number	J:74418
	decreased IgG level	J:74418
	increased CD8-positive, alpha-beta T cell number	J:74418
	increased IgM level	J:74418
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru (NOD.129S2-H2-Ab1^b-tm1Gru)	immune system phenotype	J:86540
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru (B6.129S2-H2-Ab1^b-tm1Gru)	abnormal B cell physiology	J:91341
	abnormal lymphocyte physiology	J:91341
	decreased CD4-positive, alpha-beta T cell number	J:91341
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru (involves: 129S2/SvPas * C57BL/6)	abnormal level of surface class II molecules	J:67941
	decreased CD4-positive, alpha-beta T cell number	J:67941
	decreased IgG1 level	J:67941
	decreased IgM level	J:67941
	decreased single-positive T cell number	J:67941
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Ighm^tm1Cgn/\Ighm^tm1Cgn \Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD.Cg-Ighm^tm1Cgn H2-Ab1^b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	heart inflammation	J:113267
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD.Cg-Rag1^tm1Mom H2-Ab1^b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	abnormal response to transplant	J:113267
	heart inflammation	J:113267
	increased autoantibody level	J:113267
	myocarditis	J:113267
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(HLA-DQA1,HLA-DQB1)73Myl/0 (NOD.Cg-Rag1^tm1Mom H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)	abnormal response to transplant	J:88055
	myocarditis	J:88055
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Runx1^tm1Toku/\Runx1^tm1Toku \Runx3^tm1Itan/\Runx3^tm1Itan \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/2)	abnormal interferon secretion	J:131081
	increased CD4-positive, alpha-beta T cell number	J:131081
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tespa1^tm1Smoc/\Tespa1^tm1Smoc (involves: 129 * 129S2/SvPas * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(Ab1TL)1Gru/0 (B6.Cg-H2-Ab1^b-tm1Gru Tg(Ab1TL)1Gru)	abnormal CD4-positive T cell differentiation	J:91341
	abnormal macrophage antigen presentation	J:91341
	abnormal professional antigen presenting cell physiology	J:91341
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD.Cg-H2-Ab1^b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	autoimmune response	J:87013, J:86540
	decreased susceptibility to autoimmune disorder	J:87013
	heart inflammation	J:87013, J:86540
	immune system phenotype	J:87013
	increased autoantibody level	J:113267
	lung inflammation	J:86540
	myositis	J:86540
	salivary gland inflammation	J:86540
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/\Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell (NOD.Cg-H2-Ab1^b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell)	immune system phenotype	J:113267
	increased autoantibody level	J:113509
	thyroid gland inflammation	J:113509
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(HLA-DRB1)31Dmz/0 \Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:68641
	abnormal CD8-positive, alpha beta T cell morphology	J:68641
	decreased susceptibility to autoimmune diabetes	J:68641
	salivary gland inflammation	J:68641
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(Ins2-CD80)3B7Flv/0 (B6.Cg-H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)	increased susceptibility to autoimmune diabetes	J:59245
	salivary gland inflammation	J:59245
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA)	decreased interleukin-6 secretion	J:68641
	increased interferon-gamma secretion	J:68641
	increased susceptibility to autoimmune diabetes	J:68641
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)70Myl/0 (NOD.Cg-H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl)	heart inflammation	J:88055
	increased autoantibody level	J:88055
	insulitis	J:88055
	myocarditis	J:88055
	salivary gland inflammation	J:88055
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(HLA-DQA1,HLA-DQB1)73Myl/0 (NOD.Cg-H2-Ab1^b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)	heart inflammation	J:88055
	increased autoantibody level	J:88055
	insulitis	J:88055
	myocarditis	J:88055
	salivary gland inflammation	J:88055
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(HLA-DRB1)31Dmz/0 \Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * CBA * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:68641
	abnormal CD8-positive, alpha beta T cell morphology	J:68641
	decreased susceptibility to autoimmune diabetes	J:68641
	salivary gland inflammation	J:68641
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Tg(Ins2-CD80)3B7Flv/0 (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased susceptibility to autoimmune diabetes	J:68641
\H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru \Themis^tm1Lov/\Themis^tm1Lov (involves: 129)	abnormal negative T cell selection	J:151075
\H2-Ab1^b-tm1Koni/\H2-Ab1^b-tm1.1Koni \Tg(Tek-cre)12Flv/0 (involves: 129X1/SvJ * C3H * C57BL/6 * C57BL/6J)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:131774
	abnormal T cell activation	J:131774
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:131774
	decreased level of surface class II molecules	J:131774
	immune system phenotype	J:131774
	increased CD4-positive, alpha-beta T cell number	J:131774
\H2-Ab1^b-tm1Wug/\H2-Ab1^b-tm1Wug (involves: C57BL/6)	abnormal B cell physiology	J:204951
	abnormal dendritic cell physiology	J:204951
	absent CD4-positive, alpha-beta T cells	J:204951
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:204951
\H2-Ab1^b-tm1Wug/\H2-Ab1^b-tm1Wug \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129S2/SvPas * C57BL/6)	abnormal B cell physiology	J:204951
	abnormal dendritic cell physiology	J:204951
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:204951
	immune system phenotype	J:204951
\H2-Ab1^bm12/\H2-Ab1^bm12 (B6(C)-H2-Ab1^bm12/KhEgJ)	abnormal level of surface class II molecules	J:100194
	abnormal T cell physiology	J:100123
	decreased susceptibility to autoimmune disorder	J:100123
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:100213
	decreased susceptibility to parasitic infection	J:48242
\H2-Ab1^bm12/\H2-Ab1^bm12 (NZB.B6(C)-H2-Ab1^bm12)	abnormal immunoglobulin level	J:104189
	abnormal level of surface class II molecules	J:104189
	autoimmune response	J:4554
	decreased CD8-positive, alpha-beta T cell number	J:4554
	increased anti-double stranded DNA antibody level	J:104189
	increased anti-erythrocyte antigen antibody level	J:4554
	increased anti-single stranded DNA antibody level	J:104189
	increased B cell number	J:104189
	increased CD4-positive, alpha-beta T cell number	J:4554
	increased double-negative T cell number	J:4554
\H2-Ab1^g7-em1Dvs/\H2-Ab1^g7-em1Dvs \H2-D1^b-em5Dvs/\H2-D1^b-em5Dvs \H2-K1^d-em1Dvs/\H2-K1^d-em1Dvs (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-Ab1^g7-em1Dvs H2-D1^em5Dvs/Dvs)	abnormal T cell subpopulation ratio	J:257229
	decreased alpha-beta T cell number	J:257229
	decreased CD4-positive, alpha-beta T cell number	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-Ab1^g7-em1Ygch/\H2-Ab1^g7-em1Ygch (NOD/ShiLtJ-H2-Ab1^g7-em1Ygch)	decreased CD4-positive, alpha-beta T cell number	J:101977
\H2-D1^b-em1Dvs/\H2-D1^b-em1Dvs (NOD/ShiLtDvs-H2-D1^b-em1Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-D1^b-em2Dvs/\H2-D1^b-em2Dvs (NOD/ShiLtDvs-H2-D1^b-em2Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-D1^b-em3Dvs/\H2-D1^b-em3Dvs (NOD/ShiLtDvs-H2-D1^b-em3Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-D1^b-em4Dvs/\H2-D1^b-em4Dvs (NOD/ShiLtDvs-H2-D1^b-em4Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-D1^b-em5Dvs/\H2-D1^b-em5Dvs \H2-K1^d-em1Dvs/\H2-K1^d-em1Dvs (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-D1^b-em5Dvs/Dvs)	abnormal T cell subpopulation ratio	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-D1^b-em5Dvs/\H2-D1^b-em5Dvs \H2-K1^d-em1Dvs/\H2-K1^d-em1Dvs \Tg(HLA-A/H2-D/B2M)1Dvs/? (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-D1^b-em5Dvs Tg(HLA-A/H2-D/B2M)1Dvs/Dvs)	autoimmune response	J:257229
	increased susceptibility to autoimmune diabetes	J:257229
	insulitis	J:257229
\H2-D1^b-em5Dvs/\H2-D1^b-em5Dvs \H2-K1^d-em1Dvs/\H2-K1^d-em1Dvs \Tg(HLA-B39/H2-D/B2m)2Dvs/? (NOD/ShiLtDvs-H2-K1^d-em1Dvs H2-D1^b-em5Dvs Tg(HLA-B39/H2-D/B2M)2Dvs/Dvs)	autoimmune response	J:257229
	increased susceptibility to autoimmune diabetes	J:257229
	insulitis	J:257229
\H2-D1^b-tm1Bpe/\H2-D1^b-tm1Bpe \H2-K1^b-tm1Bpe/\H2-K1^b-tm1Bpe (involves: 129P2/OlaHsd * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:57703
	decreased CD8-positive, alpha-beta T cell number	J:54709
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:54709
	increased CD4-positive, alpha-beta T cell number	J:54709
\H2-D1^b-tm1Bpe/\H2-D1^b-tm1Bpe \H2-K1^b-tm1Bpe/\H2-K1^b-tm1Bpe (B6.129P-H2-D1^b-tm1Bpe H2-K1^b-tm1Bpe)	abnormal cytotoxic T cell physiology	J:118960
\H2-D1^b-tm1Bpe/\H2-D1^b-tm1Bpe \H2-K1^b-tm1Bpe/\H2-K1^b-tm1Bpe \Klra1^tm1.1Wyok/\Klra1^tm1.1Wyok \Tg(H2-D^d)28Bee/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6NTac * DBA/2)	abnormal NK cell physiology	J:252851
\H2-D1^b-tm1Bpe/\H2-D1^b-tm1Bpe \H2-K1^b-tm1Bpe/\H2-K1^b-tm1Bpe X/\Yaa (BXSB.129P2(B6)-H2-K1^b-tm1Bpe H2-D1^b-tm1Bpe/Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
\H2-D1^bm14/\H2-D1^bm14 (C57BL/6)	abnormal T cell activation	J:97717
\H2-D1^bm14/\H2-D1^bm14 (C57BL/6)	spinal cord inflammation	J:97717
\H2-DMa^tm1Doi/\H2-DMa^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal professional antigen presenting cell physiology	J:31624
	immune system phenotype	J:31624
\H2-DMa^tm1Liz/\H2-DMa^tm1Liz (involves: BALB/cJ)	abnormal antigen presentation via MHC class II	J:113714
	abnormal CD4-positive, alpha beta T cell morphology	J:113714
	abnormal professional antigen presenting cell physiology	J:111565, J:113714
	defective assembly of class II molecules	J:113714
\H2-DMa^tm1Lkrl/\H2-DMa^tm1Lkrl (involves: 129P2/OlaHsd)	abnormal antigen presentation	J:31786
	abnormal CD4-positive, alpha-beta T cell physiology	J:31786
	abnormal positive T cell selection	J:31786
	abnormal professional antigen presenting cell physiology	J:31786
	decreased CD4-positive, alpha-beta T cell number	J:31786
\H2-DMa^tm1Luc/\H2-DMa^tm1Luc (involves: 129S4/SvJae)	abnormal antigen presentation via MHC class II	J:31625
	abnormal CD4-positive, alpha-beta T cell physiology	J:31625
	abnormal level of surface class II molecules	J:45185
	abnormal positive T cell selection	J:125548
	decreased CD4-positive, alpha-beta T cell number	J:31625, J:45185
	decreased interferon-gamma secretion	J:45185
	increased susceptibility to bacterial infection	J:45185
\H2-DMa^tm1Luc/\H2-DMa^tm1Luc (involves: 129S4/SvJae * C57BL/6)	abnormal antigen presentation	J:72243
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:72243
\H2-DMa^tm1Luc/\H2-DMa^tm1Luc (B6.129S4-H2-Dma^tm1Luc)	abnormal antigen presentation	J:125654
	abnormal T-helper 1 physiology	J:125654
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:125654
	decreased susceptibility to type IV hypersensitivity reaction	J:125654
\H2-DMa^tm1Luc/\H2-DMa^tm1Luc \Cd74^tm1Doi/\Cd74^tm1Doi (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal level of surface class II molecules	J:45185
	increased susceptibility to parasitic infection	J:45185
\H2-DMa^tm2Liz/\H2-DMa^tm2Liz (involves: C57BL/6 * C57BL/10 * C57BR * CBA)	abnormal antigen presentation via MHC class II	J:111565
	abnormal professional antigen presenting cell physiology	J:111565
	decreased T cell proliferation	J:111565
\H2-K1^b-tm1Bpe/\H2-K1^b-tm1Bpe (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:54709
	increased CD4-positive, alpha-beta T cell number	J:54709
\H2-K1^d-em4Dvs/\H2-K1^d-em4Dvs (NOD/ShiLtDvs-H2-K1^d-em4Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-K1^d-em5Dvs/\H2-K1^d-em5Dvs (NOD/ShiLtDvs-H2-K1^d-em5Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-K1^d-em7Dvs/\H2-K1^d-em7Dvs (NOD/ShiLtDvs-H2-K1^d-em7Dvs/Dvs)	abnormal immune system physiology	J:257229
	decreased susceptibility to autoimmune diabetes	J:257229
\H2-K^bm1/\H2-K^bm1 \Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal positive T cell selection	J:92867
\H2-K^bm5/\H2-K^bm5 \Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal positive T cell selection	J:133645
\H2-K^dm4/\H2-K^dm4 (involves: BALB/cKh * C57BL/6Kh)	immune system phenotype	J:109272
\H2-K^dm5/\H2-K^dm5 (involves: BALB/cKh * C57BL/6Kh)	immune system phenotype	J:109272
\H2-M3^tm1Crw/\H2-M3^tm1Crw (B6.129-H2-M3^tm1Crw)	abnormal CD8-positive, alpha beta T cell morphology	J:118960
	abnormal cytotoxic T cell physiology	J:118960
	abnormal innate immunity	J:118960
	decreased activated T cell number	J:118960
	decreased interferon-gamma secretion	J:118960
	decreased macrophage nitric oxide production	J:118960
	impaired natural killer cell mediated cytotoxicity	J:118960
	increased susceptibility to bacterial infection	J:118960
\H2-Oa^tm1Dma/\H2-Oa^tm1Dma (involves: 129/Sv * C57BL/6)	abnormal antigen presentation via MHC class II	J:65235
\H2-Oa^tm1Dma/\H2-Oa^tm1Dma (involves: 129/Sv * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:65235
\H2-Oa^tm1Lkar/\H2-Oa^tm1Lkar (involves: 129P2/OlaHsd)	abnormal antigen presentation via MHC class II	J:85084
	immune system phenotype	J:85084
	increased IgG1 level	J:85084
\H2-Ob^em1Tvg/\H2-Ob^em1Tvg (C57BL/6J-H2-Ob^em1Tvg/Tvg)	decreased susceptibility to Retroviridae infection	J:254532
	defective assembly of class II molecules	J:254532
	immune system phenotype	J:254532
\H2-Ob^vic1/\H2-Ob^vic1 (I/LnJ)	decreased susceptibility to Retroviridae infection	J:163153
\H2-Ob^vic1/\H2-Ob^vic1 (I/LnJ)	decreased susceptibility to viral infection	J:81554, J:60602
\H2-Ob^vic1/\H2-Ob^vic1 (C3N.I-H2-Ob^vic1)	decreased susceptibility to Retroviridae infection	J:254532
\H2-Ob^vic1/\H2-Ob^vic1 (B6.I-H2-Ob^vic1)	decreased susceptibility to Retroviridae infection	J:254532
\H2-Ob^vic1/\H2-Ob^vic1 (C.I-H2-Ob^vic1)	decreased susceptibility to Retroviridae infection	J:254532
\H2-Q10^{tm1.1(KOMP)Mbp}/\H2-Q10^{tm1.1(KOMP)Mbp} (involves: C57BL/6 * C57BL/6N)	decreased gamma-delta T cell number	J:294888
	decreased immature NK cell number	J:294888
	decreased mature NK cell number	J:294888
	decreased NK cell number	J:294888
	increased NK cell number	J:294888
\H2-T18^b/\H2-T18^b \H2-T3^tm1Luc/\H2-T3^tm1Luc (C57BL/6-H2-T3^tm1Luc)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:142515
	abnormal CD8-positive, gamma-delta intraepithelial T cell morphology	J:142515
	abnormal intraepithelial T cell morphology	J:142515
	increased interferon-gamma secretion	J:142515
\H2-T18^b/\H2-T18^b \H2-T3^tm1Luc/\H2-T3^tm1Luc \Tcra^tm1Mom/\Tcra^tm1Mom (B6.Cg-Tcra^tm1Mom H2-T3^tm1Luc)	abnormal intraepithelial T cell number	J:142515
	colitis	J:142515
	enlarged mesenteric lymph nodes	J:142515
	increased interleukin-4 secretion	J:142515
\H2-T23^tm1Cant/\H2-T23^tm1Cant (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087, J:123555
	abnormal memory T cell physiology	J:123555
	increased susceptibility to bacterial infection	J:89808
	increased susceptibility to experimental autoimmune encephalomyelitis	J:89808
	increased susceptibility to Herpesvirales infection	J:89808
\H2-T23^tm2Cant/\H2-T23^tm2Cant (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:123555
\H2-T23^tm2Cant/\H2-T23^tm2Cant (B6.129S6-H2-T23^tm2Cant)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
\H2-T23^tm2Cant/\H2-T23^tm2Cant (B6.129S6-H2-T23^tm2Cant)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:142087
\H2-T23^tm2Cant/\H2-T23^tm2Cant \Tg(Tcra2D2,Tcrb2D2)1Kuch/? (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
	increased susceptibility to experimental autoimmune encephalomyelitis	J:142087
\H2-T23^tm3Cant/\H2-T23^tm3Cant (B6.129S6-H2-T23^tm3Cant)	increased susceptibility to experimental autoimmune encephalomyelitis	J:142087
\H2-T23^tm3Cant/\H2-T23^tm3Cant \Tg(Tcra2D2,Tcrb2D2)1Kuch/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
\H2-T23^tm3Cant/\H2-T23^tm3Cant \Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:142087
\H2-T24^{em1(IMPC)Wtsi}/\H2-T24^{em1(IMPC)Wtsi} (C57BL/6N-H2-T24^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\H2^b/\H2^b (NOD.B10SnJ-H2^b)	decreased susceptibility to autoimmune diabetes	J:14178
\H2^b/\H2^b (NOD.B10SnJ-H2^b)	periinsulitis	J:14178
\H2^b/\H2^b \Itk^tm1Ljb/\Itk^tm1Ljb \Tg(TcrAND)53Hed/? (involves: C3H/HeJ * C57BL/6 * C57BL/10)	abnormal positive T cell selection	J:123795
	decreased CD4-positive, alpha-beta T cell number	J:123795
\H2^b/\H2^b \Nfkbid^tm1Clay/\Nfkbid^tm1Clay \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraN15,TcrbN15)L2Elre/? (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6)	abnormal thymocyte activation	J:132071
	decreased interleukin-2 secretion	J:132071
	decreased T cell proliferation	J:132071
\H2^b/\H2^b \Ptcra^tm1Vbo/\Ptcra^tm1Vbo (involves: 129P2/OlaHsd)	decreased double-positive T cell number	J:131357
	decreased thymocyte number	J:131357
	spleen hypoplasia	J:131357
\H2^b/\H2^b \Ptcra^tm1Vbo/\Ptcra^tm1Vbo \Tcra^tm1Mom/\Tcra/Tcrd^{tm1.1(Tcra)Rsky} \Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
	decreased thymocyte number	J:131357
\H2^b/\H2^b \Ptcra^tm1Vbo/\Ptcra^tm1Vbo \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
\H2^b/\H2^b \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(Tcra19,Tcrb19)#Stl/0 (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:19795
\H2^b/\H2^b \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraN15,TcrbN15)L2Elre/? (involves: 129S/SvEv * C57BL/6)	abnormal cytotoxic T cell physiology	J:133112
	arrested T cell differentiation	J:133112
	decreased CD4-positive, alpha-beta T cell number	J:133112
	increased CD8-positive, alpha-beta T cell number	J:133112
	increased T cell proliferation	J:133112
\H2^b/\H2^b \Tcra/Tcrd^{tm1.1(Tcra)Rsky}/\Tcra/Tcrd^{tm1.1(Tcra)Rsky} \Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
\H2^b/\H2^b \Tcra/Tcrd^{tm1.1(Tcra)Rsky}/\Tcra/Tcrd^{tm1.1(Tcra)Rsky} \Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
\H2^b/\H2^b \Tcra^tm1Mom/\Tcra/Tcrd^{tm1.1(Tcra)Rsky} \Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal double-negative T cell morphology	J:131357
	abnormal double-positive T cell morphology	J:81564
	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
	decreased double-positive T cell number	J:131357
	decreased thymocyte number	J:131357
\H2^b/\H2^d ((C57BL/6 x DBA/2)F1)	abnormal cytokine secretion	J:106141
	abnormal T cell differentiation	J:106141
	decreased susceptibility to parasitic infection	J:106141
	increased autoantibody level	J:106141
\H2^b/\H2^d \Tg(Ins2-E3)1Dvs/0 (involves: BALB/c * C57BL/6 * DBA/2J)	increased length of allograft survival	J:109763
\H2^b/\H2^d \Tg(TcraTcrb)1100Mjb/? (involves: BALB/c * C57BL/6)	abnormal negative T cell selection	J:133645
	decreased CD8-positive, alpha-beta T cell number	J:133645
	small thymus	J:133645
\H2^b/\H2^d \Themis^tm1Gasc/\Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * DBA/2)	abnormal negative T cell selection	J:151074
\H2^b/\H2^g7 (NOD.B10SnJ-H2^b)	decreased susceptibility to autoimmune diabetes	J:14178
\H2^b/\H2^g7 \Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * NOD * SJL)	mitral valve inflammation	J:275827
	rheumatoid arthritis	J:36815, J:275827
\H2^b/\H2^k \Itk^tm1Ljb/\Itk^tm1Ljb \Tg(TcrAND)53Hed/? (involves: C3H/HeJ * C57BL/6 * C57BL/10)	abnormal positive T cell selection	J:123795
	decreased CD4-positive, alpha-beta T cell number	J:123795
\H2^b/\H2^k \Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * C57BL/10Sg * C57BR/c)	abnormal negative T cell selection	J:133645
	decreased CD8-positive, alpha-beta T cell number	J:133645
	small thymus	J:133645
\H2^b/\H2^s \Tg(TcraTcrb)1100Mjb/? (involves: A/WySn * C57BL/6 * C57BL/10Sg * Swiss)	abnormal negative T cell selection	J:133645
	decreased CD8-positive, alpha-beta T cell number	J:133645
	small thymus	J:133645
\H2^d/\H2^d (DBA/2)	abnormal cytokine secretion	J:106141
	abnormal T cell differentiation	J:106141
	decreased susceptibility to parasitic infection	J:106141
	increased autoantibody level	J:106141
\H2^d/\H2^d \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraN15,TcrbN15)L2Elre/? (involves: 129S/SvEv * C57BL/6)	arrested T cell differentiation	J:133112
	decreased CD4-positive, alpha-beta T cell number	J:133112
	decreased CD8-positive, alpha-beta T cell number	J:133112
\H2^d/\H2^d \Tcra/Tcrd^{tm1.1(Tcra)Rsky}/\Tcra/Tcrd^{tm1.1(Tcra)Rsky} \Tg(Tcrb)93Vbo/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
	decreased thymocyte number	J:131357
\H2^d/\H2^d \Tg(TcraP1.5,TcrbP1.5)29Amsv/0 \Trap1a^tm1.1Jvde/Y (involves: 129 * BALB/cJ * C57BL/10 * DBA/2)	abnormal T cell clonal deletion	J:180807
\H2^d/\H2^d \Trap1a^tm1.1Jvde/Y (involves: 129 * BALB/cJ * C57BL/10 * DBA/2)	abnormal CD8-positive, alpha-beta T cell physiology	J:180807
	abnormal immune tolerance	J:180807
\H2^dlAb1-Ea/\H2^dlAb1-Ea (B6.129S2-H2^dlAb1-Ea/J)	increased susceptibility to bacterial infection	J:123934
\H2^dlAb1-Ea/\H2^dlAb1-Ea (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:57484
	abnormal T cell number	J:57484
	decreased CD4-positive, alpha-beta T cell number	J:57484
	decreased IgG1 level	J:57484
	decreased IgG2a level	J:57484
	immune system phenotype	J:157516
	increased CD8-positive, alpha-beta T cell number	J:57484
	increased IgM level	J:57484
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Marchf1^tm1.1Sish/\Marchf1^tm1.1Sish (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	immune system phenotype	J:157516
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Psmb11^{tm1(Psmb8)Khog}/\Psmb11^{tm1(Psmb8)Khog} (involves: 129S2/SvPas * C57BL/6)	abnormal T cell differentiation	J:196156
	decreased CD8-positive, alpha-beta T cell number	J:196156
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(HLA-DRA,HLA-DRB50101)hiKito/0 \Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas 129S7/SvEvBrd * C57BL/6)	brain inflammation	J:189816
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(HLA-DRA,HLA-DRB50101)loKito/0 \Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas 129S7/SvEvBrd * C57BL/6)	brain inflammation	J:189816
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Rr381^em2Kap/\Rr381^em2Kap (involves: 129S2/SvPas * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:333471
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Rr381^em4Kap/\Rr381^em4Kap (involves: 129S2/SvPas * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Rr381^em5Kap/\Rr381^em5Kap (involves: 129S2/SvPas * C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Tg(HLA-DRA,HLA-DRB50101)hiKito/0 \Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas C57BL/6)	abnormal cytokine secretion	J:189816
	brain inflammation	J:189816
	CNS inflammation	J:189816
	increased CD4-positive, alpha-beta T cell number	J:189816
	increased inflammatory response	J:189816
	increased interferon-gamma secretion	J:189816
	increased interleukin-17 secretion	J:189816
	increased susceptibility to experimental autoimmune encephalomyelitis	J:189816
	increased T-helper 1 cell number	J:189816
	increased T-helper 17 cell number	J:189816
\H2^dlAb1-Ea/\H2^dlAb1-Ea \Tg(HLA-DRA,HLA-DRB50101)loKito/0 \Tg(TRATL3A6,TRBTL3A6)#Kito/0 (involves: 129S2/SvPas C57BL/6)	brain inflammation	J:189816
	increased susceptibility to experimental autoimmune encephalomyelitis	J:189816
\H2^g7/\H2^g7 \Ins2^tm1Jja/\Ins2^tm1Jja \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	increased susceptibility to autoimmune diabetes	J:111874
\H2^g7/\H2^g7 \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	increased susceptibility to autoimmune diabetes	J:111874
	insulitis	J:111874
\H2^g7/\H2^g7 \Tg(Ins2-Vtcn1)#Xxz/0 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: C57BL/6 * NOD * SJL)	decreased interferon-gamma secretion	J:177612
	decreased interleukin-17 secretion	J:177612
	decreased regulatory T cell number	J:177612
	decreased susceptibility to autoimmune diabetes	J:177612
\H2^g7/\H2^g7 \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0 (B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	increased susceptibility to autoimmune diabetes	J:167508
\H2^g7/\H2^g7 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (B6.Cg-H2^g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased susceptibility to autoimmune diabetes	J:86926
\H2^g7/\H2^g7 \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased susceptibility to autoimmune diabetes	J:111874
	insulitis	J:111874
\H2^g7/\H2^q \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	increased susceptibility to autoimmune diabetes	J:111874
\H2^h2/\H2^g7 (NOD.Cg-H2^h2)	decreased susceptibility to autoimmune diabetes	J:14178
\H2^h2/\H2^h2 (NOD.Cg-H2^h2)	decreased susceptibility to autoimmune diabetes	J:14178
	insulitis	J:14178
	periinsulitis	J:14178
\H2^h4/\H2^g7 (NOD.Cg-H2^h4)	decreased susceptibility to autoimmune diabetes	J:14178
\H2^h4/\H2^h4 (NOD.Cg-H2^h4)	abnormal cytokine secretion	J:54563
	decreased susceptibility to autoimmune diabetes	J:14178
	insulitis	J:14178
	periinsulitis	J:14178
	thyroid gland inflammation	J:54563
\H2ⁱ⁵/\H2^g7 (NOD.Cg-H2ⁱ⁵)	decreased susceptibility to autoimmune diabetes	J:14178
\H2ⁱ⁵/\H2ⁱ⁵ (NOD.Cg-H2ⁱ⁵)	decreased susceptibility to autoimmune diabetes	J:14178
\H2ⁱ⁵/\H2ⁱ⁵ (NOD.Cg-H2ⁱ⁵)	periinsulitis	J:14178
\H2ⁱ⁷/\H2^g7 (NOD.Cg-H2ⁱ⁷)	decreased susceptibility to autoimmune diabetes	J:14178
\H2ⁱ⁷/\H2^g7 ((NOD x NOD.Cg-H2ⁱ⁷)F1)	insulitis	J:14178
\H2ⁱ⁷/\H2ⁱ⁷ (NOD.Cg-H2ⁱ⁷)	decreased susceptibility to autoimmune diabetes	J:14178
\H2ⁱ⁷/\H2ⁱ⁷ (NOD.Cg-H2ⁱ⁷)	periinsulitis	J:14178
\H2^k/\H2^g7 (NOD.Cg-H2^k)	decreased susceptibility to autoimmune diabetes	J:14178
\H2^k/\H2^k (NOD.Cg-H2^k)	increased susceptibility to autoimmune diabetes	J:14178
\H2^k/\H2^k (NOD.Cg-H2^k)	periinsulitis	J:14178
\H2^k/\H2^k \Tg(TcraTcrbAD10)1Hed/? (involves: C57BL/6 * SJL)	increased CD4-positive, alpha-beta T cell number	J:124701
\H2^q/? \Ncf1^m1J/\Ncf1^m1J (B6.Cg-Ncf1^m1J H2^q)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:92437
	increased susceptibility to experimental autoimmune encephalomyelitis	J:92437
	increased susceptibility to induced arthritis	J:92437
	increased susceptibility to type IV hypersensitivity reaction	J:92437
	rheumatoid arthritis	J:92437
\H2^q/\H2^q \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased susceptibility to autoimmune diabetes	J:111874
\H2^u/\H2^u \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(Tcra19,Tcrb19)#Stl/0 (either: (involves: 129S7/SvEvBrd * C57BL/6 * PL/J) or (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * PL/J))	increased susceptibility to autoimmune disorder	J:19795
\H2^u/\H2^u \Tg(Tcra19,Tcrb19)#Stl/0 (either: (involves: C57BL/6 * PL/J) or (involves: C57BL/6 * C57BL/10 * PL/J))	increased susceptibility to autoimmune disorder	J:19795
	increased susceptibility to experimental autoimmune encephalomyelitis	J:19795
\H2^u/\H2^u \Tg(TCRA)B1Jg/0 (B10.PL-H2^u H2-T18^a/(73NS)Sn-Tg(TCRA)B1Jg/J)	abnormal thymus cell ratio	J:92992
	decreased CD4-positive, alpha-beta T cell number	J:92992
	decreased double-positive T cell number	J:92992
	decreased thymocyte number	J:92992
	increased double-negative T cell number	J:92992
	increased T cell derived lymphoma incidence	J:92992
\H2^u/\H2^u \Tg(TCRA)B1Jg/? \Tg(TCRB)C14Jg/? (involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:92991
	abnormal effector T cell morphology	J:92991
	decreased CD8-positive, alpha-beta T cell number	J:92991
	decreased double-positive T cell number	J:92991
	increased autoantibody level	J:92991
	increased CD4-positive, alpha-beta T cell number	J:92991
	increased susceptibility to experimental autoimmune encephalomyelitis	J:92991
\H2^u/\H2^u \Tg(TCRA)B1Jg/0 \Tg(TCRB)C14Jg/0 (B10.PL-H2^u H2-T18^a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg)	abnormal double-negative T cell morphology	J:92992
	abnormal double-positive T cell morphology	J:92992
	abnormal thymus cell ratio	J:92992
	absent gamma-delta T cells	J:92992
	decreased double-positive T cell number	J:92992
	increased CD4-positive, alpha-beta T cell number	J:92992
	increased double-negative T cell number	J:92992
	increased T cell derived lymphoma incidence	J:92992
\H2^u/\H2^u \Tg(TCRB)C14Jg/0 (B10.PL-H2^u H2-T18^a/(73NS)Sn-Tg(TCRB)C14Jg/J)	abnormal double-negative T cell morphology	J:92992
	abnormal double-positive T cell morphology	J:92992
	absent gamma-delta T cells	J:92992
\H2ax^tm1Fwa/\H2ax⁺ \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:84879
\H2ax^tm1Fwa/\H2ax^tm1Fwa (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:84879
	decreased lymphocyte cell number	J:84879
	increased T cell derived lymphoma incidence	J:84879
\H2ax^tm1Fwa/\H2ax^tm1Fwa \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:84879
\H2ax^tm1Nus/\H2ax^tm1Nus (Not Specified)	abnormal class switch recombination	J:194603, J:120658
	decreased B cell number	J:76360
	decreased IgG level	J:73342
	decreased T cell number	J:76360
\H2ax^tm1Nus/\H2ax^tm1Nus \Igh^tm1Mnz/\Igh^tm1Mnz (involves: 129P2/OlaHsd)	immune system phenotype	J:120658
\H2ax^tm1Nus/\H2ax^tm1Nus \Igh^tm2Mnz/\Igh^tm2Mnz (involves: 129P2/OlaHsd)	immune system phenotype	J:120658
\H2bc4^em1(IMPC)Tcp/\H2bc4^em1(IMPC)Tcp (C57BL/6N-H2bc4^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
\H4c1^{em1(IMPC)Ccpcz}/\H4c1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-H4c1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\H4c16^em1(IMPC)Mbp/\H4c16^em1(IMPC)Mbp (C57BL/6N-H4c16^em1(IMPC)Mbp/MbpMmucd)	enlarged thymus	J:211773
\H13^{tm1b(KOMP)Wtsi}/\H13^{tm1b(KOMP)Wtsi} (C57BL/6N-H13^{tm1b(KOMP)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
\Habp2^tm1Lex/\Habp2^tm1Lex (involves: 129S7/SvEvBrd * BALB/c * C57BL/6)	liver inflammation	J:207454
\Hace1^tm1Pngr/\Hace1^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:125183
\Hamp^tm1Svl/\Hamp^tm1Svl (involves: 129S2/SvPas * C57BL/6)	decreased spleen iron level	J:119004
\Hamp^tm1Svl/\Hamp^tm1Svl (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
\Hand2^tm1Cse/\Hand2⁺ \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129S1/Sv * C57BL/6J * CBA/J)	abnormal thymus development	J:155265
\Hapln3^{em1(IMPC)Hmgu}/\Hapln3^{em1(IMPC)Hmgu} (C57BL/6NCrl-Hapln3^{em1(IMPC)Hmgu}/Ieg)	increased eosinophil cell number	J:211773
\Hapstr1^tm1.1Menm/\Hapstr1^tm1.1Menm \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 C57BL/6J * CBA)	large intestinal inflammation	J:348964
\Has1^{tm1b(KOMP)Wtsi}/\Has1^{tm1b(KOMP)Wtsi} (C57BL/6N-Has1^{tm1b(KOMP)Wtsi}/H)	decreased eosinophil cell number	J:211773
	increased basophil cell number	J:211773
\Havcr1^tm1Kuch/\Havcr1^tm1Kuch (B6.Cg-Havcr1^tm1Kuch)	abnormal B cell physiology	J:186484
	abnormal CD4-positive, alpha-beta T cell physiology	J:186484
	abnormal dendritic cell physiology	J:186484
	abnormal T cell differentiation	J:186484
	autoimmune response	J:186484
	enlarged spleen	J:186484
	increased activated T cell number	J:186484
	increased anti-double stranded DNA antibody level	J:186484
	increased CD4-positive, alpha-beta T cell number	J:186484
	increased CD8-positive, alpha-beta T cell number	J:186484
	increased double-negative T cell number	J:186484
	increased T cell number	J:186484
\Havcr1^tm1Shw/\Havcr1^tm1Shw (C.129P2-Havcr1^tm1Shw)	immune system phenotype	J:166400
\Havcr1^tm1Vlcg/\Havcr1^tm1Vlcg (B6.129-Havcr1^tm1Vlcg)	immune system phenotype	J:187793
	increased interleukin-5 secretion	J:187793
	increased interleukin-13 secretion	J:187793
\Havcr1^tm1Vlcg/\Havcr1^tm1Vlcg (C.129-Havcr1^tm1Vlcg)	abnormal cytokine secretion	J:187793
	immune system phenotype	J:187793
	increased interleukin-4 secretion	J:187793
	increased interleukin-5 secretion	J:187793
	increased interleukin-10 secretion	J:187793
	increased interleukin-13 secretion	J:187793
	increased interleukin-17 secretion	J:187793
	respiratory system inflammation	J:187793
\Havcr2^{tm1b(KOMP)Wtsi}/\Havcr2^{tm1b(KOMP)Wtsi} (C57BL/6N-Havcr2^{tm1b(KOMP)Wtsi}/Ucd)	increased spleen weight	J:211773
\Havcr2^tm1Bmed/\Havcr2^tm1Bmed (B6.Cg-Havcr2^tm1Bmed)	abnormal CD8-positive, alpha-beta T cell physiology	J:189839
	decreased activation-induced cell death of T cells	J:189839
	decreased interferon-gamma secretion	J:189839
	decreased susceptibility to Orthomyxoviridae infection	J:189839
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:189839
	decreased T cell proliferation	J:189839
\Havcr2^tm1Tbs/\Havcr2^tm1Tbs (C.Cg-Havcr2^tm1Tbs)	immune system phenotype	J:86260
\Havcr2^tm1Vlcg/\Havcr2^tm1Vlcg (B6.129-Havcr2^tm1Vlcg)	decreased interferon-gamma secretion	J:209885
\Havcr2^tm1Vlcg/\Havcr2^tm1Vlcg (B6.129-Havcr2^tm1Vlcg)	decreased T cell number	J:209885
\Havcr2^tm1Vlcg/\Havcr2^tm1Vlcg \Tg(TcraTcrb)1100Mjb/? (B6.Cg-Havcr2^tm1Vlcg Tg(TcraTcrb)1100Mjb)	decreased interferon-gamma secretion	J:209885
	decreased T cell number	J:209885
\Hax1^tm1.1Gach/\Hax1^tm1.1Gach (involves: BALB/c)	abnormal B cell number	J:174159
	abnormal lymphocyte morphology	J:174159
	abnormal T cell number	J:174159
	decreased B cell number	J:174159
	decreased B-1a cell number	J:174159
	decreased CD4-positive, alpha-beta T cell number	J:174159
	decreased CD8-positive, alpha-beta T cell number	J:174159
	decreased double-positive T cell number	J:174159
	decreased IgG2a level	J:174159
	decreased immature B cell number	J:174159
	decreased marginal zone B cell number	J:174159
	decreased mature B cell number	J:174159
	decreased pre-B cell number	J:174159
	decreased pro-B cell number	J:174159
	decreased thymocyte number	J:174159
	decreased transitional stage T1 B cell number	J:174159
	decreased transitional stage T2 B cell number	J:174159
	increased follicular B cell number	J:174159
	spleen hypoplasia	J:174159
	thymus hypoplasia	J:174159
\Hax1^tm1Jni/\Hax1^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	decreased double-positive T cell number	J:132627
	decreased immature B cell number	J:132627
	decreased leukocyte cell number	J:132627
	decreased lymphocyte cell number	J:132627
	decreased neutrophil cell number	J:132627
	decreased single-positive T cell number	J:132627
	decreased T cell number	J:132627
\Hba^b2(th)/\Hba⁺ (either: (involves: 101 * SEC) or (involves: 101 * C57BL * SEC))	increased leukocyte cell number	J:123943
\Hba^tm1(HBA)Tow/\Hba^tm1(HBA)Tow \Hbb^{tm2(HBG1,HBB)Tow}/\Hbb^{tm2(HBG1,HBB)Tow} (Not Specified)	abnormal Kupffer cell morphology	J:134980
	abnormal spleen white pulp morphology	J:134980
	enlarged spleen	J:134980
	increased spleen red pulp amount	J:134980
	spleen vascular congestion	J:134980
\Hba^tm1(HBA)Tow/\Hba^tm1(HBA)Tow \Hbb^{tm2(HBG1,HBB)Tow}/\Hbb^{tm2(HBG1,HBB)Tow} \Slc12a4^Rbc10/\Slc12a4⁺ (involves: 129 * BALB/c * C57BL/6J)	enlarged spleen	J:227339
	liver inflammation	J:227339
\Hba^tm1(HBA)Tow/\Hba^tm1(HBA)Tow \Hbb^{tm2(HBG1,HBD,HBB)Ryan}/\Hbb^{tm2(HBG1,HBD,HBB)Ryan} (Not Specified)	intermingled spleen red and white pulp	J:148521
	spleen hyperplasia	J:148521
\Hba^tm1(HBA)Tow/\Hba^tm1(HBA)Tow \Hbb^{tm2(HBG1,HBD,HBB*)Ryan}/\Hbb^{tm3(HBG1,HBB)Tow} (Not Specified)	spleen hyperplasia	J:148521
\Hba^tm1Paz/\Hba^tm1Paz \Hbb^tm1Tow/\Hbb^tm1Tow \Tg(HBA-HBBs)41Paz/? (involves: 129S2/SvPas * 129S7/SvEvBrd * Black Swiss * C57BL/6 * DBA/2* FVB/N)	increased spleen weight	J:44161
	spleen vascular congestion	J:44161
\Hbb-b1^MommeD7/\Hbb-b1⁺ (involves: FVB/N)	enlarged spleen	J:142335, J:190446
\Hbb-b1^MommeD7/\Hbb-b1⁺ (involves: FVB/N)	increased spleen red pulp amount	J:190446
\Hbb-b1^Rbc13/\Hbb-b1⁺ (involves: BALB/c * C57BL/6)	enlarged spleen	J:190446
\Hbb-b1^Rbc13/\Hbb-b1⁺ (involves: BALB/c * C57BL/6)	increased spleen red pulp amount	J:190446
\Hbb-b1^tm1Shs/\Hbb-b1^tm1Shs (involves: C57BL/6)	enlarged spleen	J:78271
\Hbb-b1^tm1Shs/\Hbb-b1^tm1Shs (involves: C57BL/6)	increased spleen iron level	J:78271
\Hbb-b1^tm1Unc/\Hbb-b1⁺ \Hbb-b2^tm1Unc/\Hbb-b2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal spleen morphology	J:88672, J:30155
	decreased spleen white pulp amount	J:30155
	increased spleen weight	J:30155
	intermingled spleen red and white pulp	J:30155
\Hbb-b1^tm1Unc/\Hbb-b1⁺ \Hbb-b2^tm1Unc/\Hbb-b2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	enlarged spleen	J:185154
	increased spleen iron level	J:185154
\Hbb-b1^tm1Unc/\Hbb-b1⁺ \Hbb-b2^tm1Unc/\Hbb-b2⁺ (B6;129-Hbb-b1^tm1Unc Hbb-b2^tm1Unc/J)	abnormal spleen morphology	J:211331
\Hbb-b1^tm1Unc/\Hbb-b1⁺ \Hbb-b2^tm1Unc/\Hbb-b2⁺ (involves: 129P2/OlaHsd)	enlarged spleen	J:97548
\Hbb-b1^tm1Unc/\Hbb-b1⁺ \Hbb-b2^tm1Unc/\Hbb-b2⁺ \Tg(HBB)L2Pai/0 (involves: 129P2/OlaHsd C57BL/6)	enlarged spleen	J:97548
\Hbb-b1^tm1Unc/\Hbb-b1⁺ \Hbb-b2^tm1Unc/\Hbb-b2⁺ \Tmprss6^tm1Otin/\Tmprss6⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal spleen iron level	J:185154
	abnormal spleen size	J:185154
\Hbb-b1^tm1Unc/\Hbb-b1⁺ \Hbb-b2^tm1Unc/\Hbb-b2⁺ \Tmprss6^tm1Otin/\Tmprss6^tm1Otin (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal spleen size	J:185154
\Hbb^d3th/\Hbb⁺ \Tg(LCR-HBA1,LCR-HBB)1Tow/0 (involves: C57BL/6 DBA/2J * SJL)	enlarged spleen	J:127701
\Hbb^d3th/\Hbb⁺ \Tg(LCR-HBA2,LCR-HBB)1Cos/0 (involves: C57BL/6J CBA/J * DBA/2J)	enlarged spleen	J:94193
\Hbb^d3th/\Hbb^d3th \Tg(HBB-AR-HBA2,-HBB)58Rub/0 \Tg(LCR-HBA2,LCR-HBB)11Cos/0 (involves: FVB/N Swiss Webster)	abnormal spleen morphology	J:94190
	enlarged spleen	J:94190
	increased spleen red pulp amount	J:94190
	spleen fibrosis	J:94190
	spleen vascular congestion	J:94190
\Hbb^d4/\Hbb^d4 (involves: 101/H)	abnormal macrophage morphology	J:7972
	enlarged spleen	J:7972
	increased spleen red pulp amount	J:7972
\Hbb^{tm1.1(HBG1,HBB*)Ryan}/\Hbb⁺ (involves: C57BL/6J)	abnormal spleen morphology	J:147906
	enlarged spleen	J:147906
	increased spleen iron level	J:147906
	increased spleen red pulp amount	J:147906
	intermingled spleen red and white pulp	J:147906
\Hbb^tm1Tow/\Hbb⁺ (involves: 129S2/SvPas * C57BL/6)	enlarged spleen	J:29087
\Hbb^tm1Tow/\Hbb⁺ (involves: 129S2/SvPas * C57BL/6)	increased spleen weight	J:29087
\Hbb^tm2Unc/\Hbb⁺ (involves: 129P2/OlaHsd * C57BL/6J)	enlarged spleen	J:64295
\Hbb^tm2Unc/\Hbb⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased spleen iron level	J:64295
\Hbnr1^CBA/\Hbnr1^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:82261, J:85787
\Hbnr1^SWR/\Hbnr1^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:82261, J:110034, J:85787
\Hbnr2^CBA/\Hbnr2^SWR (involves: CBA * SWR)	granulomatous inflammation	J:85787
\Hbnr2^SWR/? (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:82261
\Hbnr2^SWR/\Hbnr2^SWR (involves: CBA * SWR)	decreased IgE level	J:85787
	decreased susceptibility to parasitic infection	J:110034
	granulomatous inflammation	J:85787
\Hbnr3^CBA/\Hbnr3^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
\Hbnr3^CBA/\Hbnr3^SWR (involves: CBA * SWR)	increased susceptibility to parasitic infection	J:82261
\Hbnr3^SWR/\Hbnr3^SWR (involves: CBA * SWR)	increased susceptibility to parasitic infection	J:82261, J:85787
\Hbnr4^SWR/\Hbnr4^SWR (involves: CBA * SWR)	abnormal immune serum protein physiology	J:85787
\Hbnr5^CBA/\Hbnr5^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
\Hbnr5^SWR/\Hbnr5^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
\Hbnr6^SWR/\Hbnr6^SWR (involves: CBA * SWR)	increased IgE level	J:85787
\Hbnr7^CBA/\Hbnr7^SWR (involves: CBA * SWR)	decreased IgG1 level	J:85787
\Hbnr7^SWR/\Hbnr7^SWR (involves: CBA * SWR)	decreased IgG2b level	J:85787
\Hbnr8^CBA/\Hbnr8^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
\Hbnr8^SWR/\Hbnr8^SWR (involves: CBA * SWR)	decreased susceptibility to parasitic infection	J:85787
\Hbs1l^{tm1a(KOMP)Wtsi}/\Hbs1l^{tm1a(KOMP)Wtsi} (C57BL/6N-Hbs1l^{tm1a(KOMP)Wtsi}/Wtsi)	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased Langerhans cell number	J:211773
	decreased mature B cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased T-helper cell number	J:211773
	increased CD4-positive, alpha-beta memory T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD5-positive gamma-delta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased leukocyte cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased regulatory T cell number	J:211773
\Hc⁰/\Hc⁰ (involves: C57BL/10SnJ)	increased susceptibility to bacterial infection	J:44240
\Hc⁰/\Hc⁰ \Tg(TcrbBL17)1Lmor/0 (involves: DBA/1J * SWR/J)	decreased susceptibility to induced arthritis	J:134111
\Hc¹/? \Tg(TcrbBL17)1Lmor/0 (involves: DBA/1J * SWR/J)	increased susceptibility to induced arthritis	J:134111
\Hcar1^{em1(IMPC)Ccpcz}/\Hcar1^{em1(IMPC)Ccpcz} (C57BL/6N-Hcar1^{em1(IMPC)Ccpcz}/Ccpcz)	decreased effector memory T-helper cell number	J:211773
\Hcfc2^em1Btlr/\Hcfc2^em1Btlr (C57BL/6J-Hcfc2^em1Btlr)	decreased tumor necrosis factor secretion	J:251008
\Hcfc2^fkls/\Hcfc2⁺ (involves: C57BL/6J)	decreased interferon-beta secretion	J:251008
\Hcfc2^fkls/\Hcfc2⁺ (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:251008
\Hcfc2^fkls/\Hcfc2^fkls (C57BL/6J-Hcfc2^fkls)	abnormal innate immunity	J:94077
\Hcfc2^fkls/\Hcfc2^fkls (involves: C57BL/6J)	decreased circulating interferon-alpha level	J:251008
	decreased circulating interferon-beta level	J:251008
	decreased interferon-beta secretion	J:251008
	decreased tumor necrosis factor secretion	J:251008
	increased susceptibility to Herpesvirales infection	J:251008
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:251008
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:251008
\Hcfc2^fkls/\Hcfc2^min (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:251008
\Hcfc2^fkls/\Hcfc2^sca (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:251008
\Hck^tm1Ern/\Hck^tm1Ern (involves: 129S1/Sv * C57BL/6)	abnormal alveolar macrophage morphology	J:111432
	abnormal immune system physiology	J:111432
	abnormal macrophage physiology	J:111432
	increased circulating tumor necrosis factor level	J:111432
	increased eosinophil cell number	J:111432
	increased interleukin-5 secretion	J:111432
	lung inflammation	J:111432
\Hck^tm1Hev/\Hck^tm1Hev (involves: 129S7/SvEvBrd * C57BL/6J)	impaired macrophage phagocytosis	J:16994
\Hck^tm1Hev/\Hck^tm1Hev (B6.129S7-Hck^tm1Hev)	abnormal inflammatory response	J:113463
\Hck^tm1Hev/\Hck^tm1Hev (B6.129S7-Hck^tm1Hev)	abnormal neutrophil physiology	J:113463
\Hck^tm1Hev/\Hck^tm1Hev \Src^tm1Sor/\Src^tm1Sor (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal immune system organ morphology	J:31647
	abnormal spleen germinal center morphology	J:31647
	abnormal spleen morphology	J:31647
	abnormal splenic cell ratio	J:31647
	decreased leukocyte cell number	J:31647
	increased macrophage cell number	J:31647
	lymph node hypoplasia	J:31647
	thymus hypoplasia	J:31647
\Hcls1^{em1(IMPC)Ccpcz}/\Hcls1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Hcls1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Hcls1^tm1Wtn/\Hcls1^tm1Wtn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:28146
	abnormal humoral immune response	J:28146
	decreased B cell number	J:28146
	decreased T cell proliferation	J:28146
\Hcls1^tm1Wtn/\Hcls1^tm1Wtn \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:28146
	decreased double-positive T cell number	J:28146
\Hcls1^tm2Wtn/\Hcls1^tm2Wtn (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:28146
	abnormal humoral immune response	J:28146
	decreased B cell number	J:28146
	decreased T cell proliferation	J:28146
\Hcn2^m1Btlr/\Hcn2^m1Btlr (C57BL/6J-Hcn2^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255187
\Hcn2^m1Btlr/\Hcn2^m1Btlr (C57BL/6J-Hcn2^m1Btlr)	increased CD4-positive, alpha-beta T cell number	J:255187
\Hcrt^{tm1.1(KOMP)Vlcg}/\Hcrt^{tm1.1(KOMP)Vlcg} (C57BL/6N-Hcrt^{tm1.1(KOMP)Vlcg}/Ucd)	increased lymphocyte cell number	J:211773
\Hcst^tm1.1Cln/\Hcst^tm1.1Cln (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:80426
	immune system phenotype	J:80426
	impaired natural killer cell mediated cytotoxicity	J:80426
\Hcst^tm1.1Cln/\Hcst^tm1.1Cln (involves: 129P2/OlaHsd * C57BL/6)	decreased interferon-gamma secretion	J:100668
	decreased uterine NK cell number	J:100668
\Hcst^tm1.1Cln/\Hcst^tm1.1Cln (B6.129P2-Hcst^tm1.1Cln)	abnormal osteoclast differentiation	J:147155
	abnormal osteoclast physiology	J:147155
	decreased osteoclast cell number	J:147155
\Hcst^tm1.1Cln/\Hcst^tm1.1Cln \Tyrobp^tm1Lll/\Tyrobp^tm1Lll (B6.Cg-Hcst^tm1.1Cln Tyrobp^tm1Lll)	abnormal NK T cell physiology	J:147867
	abnormal response to infection	J:147867
\Hcst^tm1.1Dnax/\Hcst^tm1.1Dnax (involves: C57BL/6)	abnormal NK T cell physiology	J:147867, J:148086
	abnormal response to infection	J:147867
	decreased interferon-gamma secretion	J:147867
	immune system phenotype	J:148086
	impaired natural killer cell mediated cytotoxicity	J:148086
	increased interferon-gamma secretion	J:148086
	increased interleukin-4 secretion	J:148086
	increased spleen weight	J:148086
	increased susceptibility to experimental autoimmune encephalomyelitis	J:148086
\Hdac1^tm1.1Pmt/\Hdac1^tm1.1Pmt \Hdac2^tm1.1Pmt/\Hdac2^tm1.1Pmt \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N)	abnormal spleen morphology	J:157903
	arrested B cell differentiation	J:157903
	decreased B cell number	J:157903
	decreased pre-B cell number	J:157903
	decreased pro-B cell number	J:157903
	increased B cell apoptosis	J:157903
\Hdac1^tm1.1Pmt/\Hdac1^tm1.1Pmt \Hdac2^tm1.1Pmt/\Hdac2^tm1.1Pmt \Tg(Fcer2a-cre)5Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N)	decreased B cell proliferation	J:157903
	increased B cell apoptosis	J:157903
\Hdac1^tm1.1Shmc/\Hdac1⁺ \Hdac2^tm1.1Shmc/\Hdac2^tm1.1Shmc \Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	immune system phenotype	J:194769
\Hdac1^tm1.1Shmc/\Hdac1^tm1.1Shmc \Hdac2^tm1.1Shmc/\Hdac2⁺ \Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	arrested T cell differentiation	J:194769
	decreased CD4-positive, alpha-beta T cell number	J:194769
	decreased CD8-positive, alpha-beta T cell number	J:194769
	decreased double-positive T cell number	J:194769
	enlarged spleen	J:194769
	enlarged thymus	J:194769
	increased double-negative T cell number	J:194769
	increased double-positive T cell number	J:194769
	increased single-positive T cell number	J:194769
	thymus hypoplasia	J:194769
\Hdac1^tm1.1Shmc/\Hdac1^tm1.1Shmc \Hdac2^tm1.1Shmc/\Hdac2^tm1.1Shmc \Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	abnormal thymus corticomedullary boundary morphology	J:194769
	arrested T cell differentiation	J:194769
	decreased double-positive T cell number	J:194769
	decreased thymocyte number	J:194769
	enlarged spleen	J:194769
	enlarged thymus	J:194769
	increased double-positive T cell number	J:194769
	increased single-positive T cell number	J:194769
	increased T cell derived lymphoma incidence	J:194769
	increased T cell proliferation	J:194769
	increased thymocyte apoptosis	J:194769
	increased thymocyte number	J:194769
\Hdac1^tm1.1Shmc/\Hdac1^tm1.1Shmc \Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	immune system phenotype	J:194769
\Hdac2^tm1.1Shmc/\Hdac2^tm1.1Shmc \Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	immune system phenotype	J:194769
\Hdac4^{em1(IMPC)Ccpcz}/\Hdac4⁺ (C57BL/6N-Hdac4^{em1(IMPC)Ccpcz}/Ccpcz)	increased NK cell number	J:211773
\Hdac6^tm1.1Pmt/Y (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG level	J:132629
	decreased IgM level	J:132629
	immune system phenotype	J:132629
\Hdac6^tm1.1Pmt/\Hdac6^tm1.1Pmt (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG level	J:132629
	decreased IgM level	J:132629
	immune system phenotype	J:132629
\Hdac6^tm1.1Pmt/\Hdac6^tm1.1Pmt (involves: 129P2/OlaHsd)	decreased circulating interleukin-10 level	J:228570
\Hdac6^tm1.1Pmt/\Hdac6^tm1.1Pmt (involves: 129P2/OlaHsd)	decreased interleukin-10 secretion	J:228570
\Hdac11^tm1.2Mrl/\Hdac11^tm1.2Mrl (involves: C57BL/6NTac)	decreased interferon-gamma secretion	J:222335
\Hdac11^tm1.2Mrl/\Hdac11^tm1.2Mrl (involves: C57BL/6NTac)	increased interleukin-10 secretion	J:228570
\Hdc^tm1Nagy/\Hdc^tm1Nagy (involves: 129S1/Sv * 129X1/SvJ)	abnormal mast cell morphology	J:70702
	decreased mast cell histamine storage	J:70702
	decreased mast cell number	J:70702
	decreased mast cell protease storage	J:70702
\Hddc2^em1(IMPC)H/\Hddc2^em1(IMPC)H (C57BL/6NTac-Hddc2^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Hddc3^{tm1.1(KOMP)Vlcg}/\Hddc3^{tm1.1(KOMP)Vlcg} (C57BL/6N-Hddc3^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Hectd1^{tm1b(EUCOMM)Hmgu}/\Hectd1⁺ (C57BL/6N-Hectd1^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Hectd3^{tm1(NCOM)Cmhd}/\Hectd3^{tm1(NCOM)Cmhd} (C57BL/6N-Hectd3^{tm1(NCOM)Cmhd}/Nju)	small spleen	J:211773
	small thymus	J:211773
\Hectd3^tm1Lex/\Hectd3^tm1Lex (FVB.129S5(B6)-Hectd3^tm1Lex)	decreased circulating interferon-beta level	J:266602
	decreased circulating interleukin-1 beta level	J:266602
	decreased circulating interleukin-6 level	J:266602
	decreased circulating tumor necrosis factor level	J:266602
	decreased susceptibility to bacterial infection	J:266602
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:266602
\Heg1^tm1Mlkn/\Heg1^tm1Mlkn (either: B6.129-Heg1^tm1Mlkn or (involves: 129 * C57BL/6))	abnormal lymph circulation	J:146528
	abnormal lymphatic vessel endothelium morphology	J:146528
	lymphangiectasis	J:146528
\Helb^{tm1(KOMP)Vlcg}/\Helb^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	immune system phenotype	J:231089
\Hells^{tm1a(EUCOMM)Wtsi}/\Hells^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Hells^{tm1a(EUCOMM)Wtsi}/Ieg)	decreased granulocyte number	J:165965
	decreased IgG1 level	J:165965
\Hells^tm1Kmu/\Hells^tm1Kmu (involves: 129S1/Sv)	decreased B cell number	J:61948
	increased CD8-positive, alpha-beta T cell number	J:61948
	increased double-negative T cell number	J:61948
	small spleen	J:61948
	small thymus	J:61948
\Hells^tm1Rarc/\Hells^tm1Rarc (involves: 129X1/SvJ * C57BL/6J)	small thymus	J:107145
	thymus hypoplasia	J:107145
\hem1/\hem1 (Not Specified)	decreased leukocyte cell number	J:85113
\hem2/\hem2 (Not Specified)	decreased leukocyte cell number	J:85113
\Heph^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Heph^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Heph^{em1(IMPC)Ccpcz}/\Heph^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Heph^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Hephl1^cw-thd/\Hephl1^cw-thd (SJL/J)	abnormal humoral immune response	J:15004
\Hephl1^cw/\Hephl1^cw (CWD/LeJ)	abnormal immune system morphology	J:24875
	abnormal lymph node morphology	J:24875
	abnormal spleen morphology	J:24875
	enlarged spleen	J:24875
	enlarged thymus	J:24875
\Herc1^{em3(IMPC)Wtsi}/\Herc1^{em3(IMPC)Wtsi} (C57BL/6N-Herc1^{em3(IMPC)Wtsi}/Wtsi)	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased monocyte cell number	J:211773
\Herc4^{tm1b(KOMP)Wtsi}/\Herc4^{tm1b(KOMP)Wtsi} (C57BL/6N-Herc4^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Herc6^{tm1b(EUCOMM)Hmgu}/\Herc6^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Herc6^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Herc6^tm1Kshim/\Herc6^tm1Kshim (either: B6.Cg-Herc6^tm1Kshim or (involves: C57BL/6NCrlj * CBA/JNCrlj))	immune system phenotype	J:330459
\Hes1^tm1.1Frad/\Hes1^tm1.1Frad \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:167000
\Hes1^tm1.1Frad/\Hes1^tm1.1Frad \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6)	immune system phenotype	J:167000
\Hes1^tm1.1Frad/\Hes1^tm1.1Frad \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal T cell differentiation	J:167000
	decreased DN1 thymic pro-T cell number	J:167000
	decreased DN2 thymocyte number	J:167000
	decreased DN3 thymocyte number	J:167000
	decreased DN4 thymocyte number	J:167000
	decreased double-positive T cell number	J:167000
	decreased gamma-delta T cell number	J:167000
	increased DN1 thymic pro-T cell number	J:167000
	increased immature B cell number	J:167000
	thymus hypoplasia	J:167000
\Hexb^{tm1b(EUCOMM)Hmgu}/\Hexb^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hexb^{tm1b(EUCOMM)Hmgu}/H)	increased monocyte cell number	J:211773
\Hexb^tm1Rlp/\Hexb^tm1Rlp (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	CNS inflammation	J:90687
	increased circulating interleukin-4 level	J:87617
	increased immunoglobulin level	J:87617
\Hexb^tm1Rlp/\Hexb^tm1Rlp \Tg(Hexb-tTA2S,tetO-Hexb)#Tjsa/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	microgliosis	J:190450
\Hexb^tm1Rlp/\Hexb^tm1Rlp \Tg(SYN1-tTA2S,tetO-Hexb)#Tjsa/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	microgliosis	J:190450
\Hfe^tm1.1Wsr/\Hfe^tm1.1Wsr (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen iron level	J:132134
\Hfe^tm1Gfn/\Hfe^tm1Gfn (involves: 129P2/OlaHsd * C57BL/6)	increased osteoclast cell number	J:262906
\Hfe^tm1Gfn/\Hfe^tm1Gfn (involves: 129P2/OlaHsd * C57BL/6)	increased spleen iron level	J:68025
\Hfe^tm1Wsr/\Hfe^tm1Wsr \Tg(Alb1-cre)7Gsc/? (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	decreased spleen iron level	J:132134
\Hfe^tm2Nca/\Hfe^tm2Nca (involves: 129S6/SvEvTac)	decreased spleen iron level	J:78536
\Hfe^tm2Nca/\Hfe^tm2Nca (involves: 129S6/SvEvTac * C57BL/6J)	decreased spleen iron level	J:78536
\Hfgi1^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	abnormal lymphopoiesis	J:123483
\Hfgi1^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	stomach inflammation	J:123483
\Hfgi2^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	abnormal lymphopoiesis	J:123483
\Hfgi2^C57BL/6Ola/? (involves: C57BL/6Ola * BALB/cOla)	stomach inflammation	J:123483
\Hgsnat^em4(IMPC)Tcp/\Hgsnat^em4(IMPC)Tcp (C57BL/6NCrl-Hgsnat^em4(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Hgsnat^{tm1a(EUCOMM)Wtsi}/\Hgsnat^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal Kupffer cell morphology	J:235361
	enlarged spleen	J:235361
	increased spleen weight	J:235361
	microgliosis	J:235361
\Hhat^{em1(IMPC)Ccpcz}/\Hhat⁺ (C57BL/6NCrl-Hhat^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
\Hhex^tm1Ngu/\Hhex^tm1Ngu (involves: 129/Sv * C57BL/6)	abnormal monocyte differentiation	J:65105
\Hhip^tm1Amc/\Hhip^tm1Amc (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:85472
\Hhip^tm1Amc/\Hhip^tm1Amc (involves: 129S1/Sv * 129X1/SvJ)	small spleen	J:85472
\Hic1^tm1Sbb/\Hic1⁺ (involves: 129S4/SvJae * C57BL/6)	dermatitis	J:81448
\Hif1a^tm1Kats/\Hif1a^tm1Kats (involves: 129 * C57BL/6)	abnormal cytokine level	J:117857
	abnormal interleukin secretion	J:117857
	increased interferon-gamma secretion	J:117857
	increased tumor necrosis factor secretion	J:117857
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Gt(ROSA)26Sor^tm1Sor/\Gt(ROSA)26Sor⁺ \Hprt1^{tm1(Pck1-cre)Vhh}/Y (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)	kidney inflammation	J:130751
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Hprt1^{tm1(Pck1-cre)Vhh}/Y \Vhl^tm1Jae/\Vhl^tm1Jae (involves: 129 * BALB/c * C57BL/6)	kidney inflammation	J:106705
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal leukocyte physiology	J:117348
	abnormal macrophage physiology	J:107682
	decreased inflammatory response	J:107682
	decreased susceptibility to induced arthritis	J:107682
	decreased tumor necrosis factor secretion	J:107682
	impaired macrophage chemotaxis	J:107682
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased interleukin-1 alpha secretion	J:148597
	decreased interleukin-1 beta secretion	J:148597
	decreased interleukin-6 secretion	J:148597
	decreased interleukin-12 secretion	J:148597
	decreased susceptibility to endotoxin shock	J:148597
	decreased tumor necrosis factor secretion	J:148597
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:119731
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Tg(Fabp1-cre)1Jig/0 (involves: 129S1/Sv * 129X1/SvJ * BALB/c * FVB/N)	increased susceptibility to induced colitis	J:93476
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Tg(Itgax-cre)1-1Reiz/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal dendritic cell number	J:187773
	abnormal leukocyte migration	J:187773
	immune system phenotype	J:187773
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Tg(Lck-cre)1Jtak/0 (involves: 129S1/Sv * 129X1/SvJ)	increased interferon-gamma secretion	J:117857
\Hif1a^tm3Rsjo/\Hif1a^tm3Rsjo \Tg(Tal1-cre/ERT)42-056Jrg/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:192126
	abnormal T cell differentiation	J:192126
\Hif1an^em1(IMPC)Mbp/\Hif1an^em1(IMPC)Mbp (C57BL/6N-Hif1an^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Hip1^tm4Tsr/\Hip1⁺ \Runx1^tm3Dow/\Runx1⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal myelopoiesis	J:151974
	abnormal spleen B cell follicle morphology	J:151974
	abnormal spleen morphology	J:151974
	enlarged spleen	J:151974
	increased granulocyte number	J:151974
	increased leukocyte cell number	J:151974
	increased neutrophil cell number	J:151974
	increased spleen red pulp amount	J:151974
	increased spleen weight	J:151974
	spleen hyperplasia	J:151974
\Hip1^tm4Tsr/\Hip1⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal myelopoiesis	J:151974
	abnormal spleen morphology	J:151974
	enlarged spleen	J:151974
	increased spleen red pulp amount	J:151974
	increased T cell derived lymphoma incidence	J:151974
\Hira^{tm1a(EUCOMM)Wtsi}/\Hira⁺ (C57BL/6N-Hira^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Hirip3^{tm1.1(KOMP)Mbp}/\Hirip3^{tm1.1(KOMP)Mbp} (C57BL/6N-Hirip3^{tm1.1(KOMP)Mbp}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Hivep2^tm1Sis/\Hivep2⁺ (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj)	decreased CD8-positive, alpha-beta T cell number	J:72249
	decreased single-positive T cell number	J:72249
\Hivep2^tm1Sis/\Hivep2^tm1Sis (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj)	abnormal immune system cell morphology	J:72249
	abnormal thymus cortex morphology	J:72249
	abnormal thymus lobule morphology	J:72249
	abnormal thymus medulla morphology	J:72249
	decreased single-positive T cell number	J:72249
	enlarged thymus cortex	J:72249
\Hivep2^tm1Sis/\Hivep2^tm1Sis (C.Cg-Hivep2^tm1Sis)	abnormal T-helper 2 cell morphology	J:96024
\Hivep2^tm1Sis/\Hivep2^tm1Sis (either: (involves: BALB/cA * C57BL/6NCrlj * CBA/JNCrlj) or (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj))	CNS inflammation	J:263351
\Hivep2^tm1Sis/\Hivep2^tm1Sis \Tg(DO11.10)10Dlo/? (involves: BALB/cA * C3H * C57BL/6NCrlj * CBA/JNCrlj)	abnormal positive T cell selection	J:96024
	abnormal T-helper 2 cell morphology	J:96024
	decreased single-positive T cell number	J:72249
\Hivep3^tm1Glm/\Hivep3^tm1Glm (involves: 129 * C57BL/6)	decreased interleukin-2 secretion	J:100058
\Hivep3^tm1Glm/\Hivep3^tm1Glm (Not Specified)	abnormal osteoclast differentiation	J:184764
	abnormal osteoclast physiology	J:184764
	decreased osteoclast cell number	J:184764
\Hivep3^tm1Lcw/\Hivep3^tm1Lcw (chimera involves: 129S/SvEv * 129X1/SvJ)	decreased double-positive T cell number	J:79652
\Hjv^tm1Arbr/\Hjv^tm1Arbr (involves: 129S4/SvJae * 129X1/SvJ)	decreased spleen iron level	J:100173
\Hjv^tm1Kpan/\Hjv^tm1Kpan \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:231428
	decreased spleen iron level	J:231428
\Hjv^tm1Nca/\Hjv^tm1Nca (involves: 129S4/SvJae * 129S6/SvEvTac)	decreased spleen iron level	J:100178
\Hjv^tm1Nca/\Hjv^tm1Nca (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:160248
	decreased spleen iron level	J:160248
\Hjv^tm1Nca/\Hjv^tm1Nca \Tmprss6^tm1Dgen/\Tmprss6⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:160248
	decreased spleen iron level	J:160248
\Hjv^tm1Nca/\Hjv^tm1Nca \Tmprss6^tm1Dgen/\Tmprss6^tm1Dgen (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:160248
	decreased spleen iron level	J:160248
\Hk1^dea/\Hk1^dea (A/J-Hk1^dea/J)	abnormal spleen morphology	J:72146
	increased spleen red pulp amount	J:72146
	increased spleen weight	J:72146
\Hk3^em1(IMPC)Tcp/\Hk3^em1(IMPC)Tcp (C57BL/6N-Hk3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Hlb18/? (C57BL/6J-Hlb18)	increased leukocyte cell number	J:82961
\Hlb95/? (C57BL/6J-Hlb95)	increased leukocyte cell number	J:82961
\Hlb141/? (C57BL/6J-Hlb141)	decreased leukocyte cell number	J:82961
\Hlb141/? (C57BL/6J-Hlb141)	decreased neutrophil cell number	J:82961
\hlb145/? (C57BL/6J-hlb145/J)	decreased leukocyte cell number	J:82961
\hlb156/? (C57BL/6J-hlb156/J)	decreased neutrophil cell number	J:82961
\hlb258/? (involves: 129S4/SvJae * C57BL/6J)	decreased circulating fibrinogen level	J:82961
\hlb385/? (C57BL/6J-hlb385/J)	decreased leukocyte cell number	J:82961
\Hltf^tm1.1Hdin/\Hltf^tm1.1Hdin \Shprh^{Gt(RRJ453)Byg}/\Shprh^{Gt(RRJ453)Byg} (involves: 129 * C57BL/6 * SJL)	immune system phenotype	J:177630
\Hltf^tm1.1Hdin/\Hltf^tm1.1Hdin \Shprh^tm1Jhjh/\Shprh^tm1Jhjh (involves: 129 * C57BL/6 * SJL)	immune system phenotype	J:177630
\Hmbox1^em1(IMPC)Tcp/\Hmbox1^em1(IMPC)Tcp (C57BL/6N-Hmbox1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
\Hmga1^tm1Afus/\Hmga1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	enlarged spleen	J:106702
\Hmga1^tm1Afus/\Hmga1^tm1Afus (involves: 129S7/SvEvBrd * C57BL/6)	enlarged spleen	J:106702
	lymphoid hyperplasia	J:106702
	myeloid hyperplasia	J:106702
\Hmgb1^tm1.1Dltg/\Hmgb1^tm1.1Dltg \Tg(Pdx1-cre)6Tuv/0 (involves: C57BL/6 * FVB/N)	increased circulating interleukin-6 level	J:225260
	increased circulating tumor necrosis factor level	J:225260
	increased susceptibility to induced pancreatitis	J:225260
\Hmgb1^tm1.1Ttg/\Hmgb1^tm1.1Ttg \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:205499
	decreased macrophage cell number	J:205499
	impaired macrophage phagocytosis	J:205499
	increased circulating interleukin-1 beta level	J:205499
	increased circulating interleukin-18 level	J:205499
	increased interleukin-1 beta secretion	J:205499
	increased interleukin-18 secretion	J:205499
	increased macrophage apoptosis	J:205499
	increased susceptibility to bacterial infection	J:205499
	increased susceptibility to endotoxin shock	J:205499
\Hmgb1^tm1.1Ttg/\Hmgb1^tm1.1Ttg \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA)	increased circulating interleukin-1 beta level	J:205499
	increased circulating interleukin-18 level	J:205499
\Hmgb1^tm1.1Ttg/\Hmgb1^tm1.1Ttg \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased circulating interleukin-1 beta level	J:205499
	increased circulating interleukin-18 level	J:205499
\Hmgb3^tm1Dmb/Y (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal leukopoiesis	J:96514
\Hmgn5^tm1.2Mbus/Y (involves: 129S4/SvJae * C57BL/6J)	decreased granulocyte number	J:199604
	decreased IgE level	J:199604
	increased CD8-positive, alpha-beta T cell number	J:199604
	increased IgA level	J:199604
\Hmgn5^tm1.2Mbus/\Hmgn5^tm1.2Mbus (involves: 129S4/SvJae * C57BL/6J)	decreased granulocyte number	J:199604
	decreased IgE level	J:199604
	increased CD8-positive, alpha-beta T cell number	J:199604
	increased IgA level	J:199604
\Hmgxb3^{tm1a(EUCOMM)Wtsi}/\Hmgxb3^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Hmgxb3^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Hmgxb4^tm1.2Zhji/\Hmgxb4^tm1.2Zhji (B6(Cg)-Hmgxb4^tm1.2Zhji)	decreased macrophage nitric oxide production	J:302603
	decreased susceptibility to endotoxin shock	J:302603
\Hmox1^tm1.1Gkl/\Hmox1^tm1.1Gkl \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased interferon-beta secretion	J:148498
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:148498
	decreased susceptibility to Paramyxoviridae infection	J:148498
	increased B cell number	J:148498
	increased CD4-positive, alpha-beta T cell number	J:148498
	increased CD8-positive, alpha-beta T cell number	J:148498
	increased circulating tumor necrosis factor level	J:148498
	increased granulocyte number	J:148498
	increased interferon-gamma secretion	J:148498
	increased macrophage cell number	J:148498
	increased splenocyte proliferation	J:148498
	increased susceptibility to experimental autoimmune encephalomyelitis	J:148498
\Hmox1^tm1.1Hes/\Hmox1^tm1.1Hes \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)	decreased inflammatory response	J:214639
	decreased interleukin-1 beta secretion	J:214639
	decreased interleukin-6 secretion	J:214639
	decreased tumor necrosis factor secretion	J:214639
\Hmox1^tm1.2Gkl/\Hmox1^tm1.2Gkl (involves: 129 * BALB/cJ * C57BL/6)	enlarged spleen	J:148498
	increased inflammatory response	J:148498
	liver inflammation	J:148498
\Hmox1^tm1Mlee/\Hmox1^tm1Mlee (involves: 129S2/SvPas * BALB/c)	increased susceptibility to parasitic infection	J:153083
	increased susceptibility to parasitic infection induced morbidity/mortality	J:153083
\Hmox1^tm1Poss/\Hmox1⁺ \Slc48a1^em1Ih/\Slc48a1^em1Ih (involves: 129 * 129S2/SvPas * C57BL/6J)	decreased macrophage cell number	J:282829
\Hmox1^tm1Poss/\Hmox1^tm1Poss (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte cell number	J:79254
	abnormal lymph node cell ratio	J:79254
	abnormal splenic cell ratio	J:79254
	chronic inflammation	J:79254
	enlarged lymph nodes	J:79254
	enlarged spleen	J:79254
	glomerulonephritis	J:79254
	liver inflammation	J:79254
	lung inflammation	J:79254
	spleen hyperplasia	J:79254
\Hmox1^tm1Poss/\Hmox1^tm1Poss (involves: 129 * 129S2/SvPas * C57BL/6J)	decreased macrophage cell number	J:282829
\Hmox1^tm1Poss/\Hmox1^tm1Poss \Slc48a1^em1Ih/\Slc48a1^em1Ih (involves: 129 * 129S2/SvPas * C57BL/6J)	decreased macrophage cell number	J:282829
\Hmox1^tm1Poss/\Hmox1^tm1Poss \Spic^tm2Kmm/\Spic^tm2Kmm (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * FVB/N)	decreased macrophage cell number	J:210804
\Hmox2^{tm1b(EUCOMM)Hmgu}/\Hmox2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hmox2^{tm1b(EUCOMM)Hmgu}/H)	decreased monocyte cell number	J:211773
	increased spleen weight	J:211773
\Hnf1b^tm1Mya/\Hnf1b^tm3Mya \Tg(Alb1-cre)7Gsc/0 (involves: 129S2/SvPas * C57BL/6 * FVB/N)	liver inflammation	J:75935
\Hnf1b^tm2Ics/\Hnf1b⁺ (involves: 129 * C57BL/6N)	chronic pancreas inflammation	J:306082
\Hnrnpa2b1^tm1.1Caox/\Hnrnpa2b1^tm1.1Caox \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal interferon level	J:283622
	decreased circulating interferon-beta level	J:283622
	decreased interferon-beta secretion	J:283622
	immune system phenotype	J:283622
	increased susceptibility to Herpesvirales infection	J:283622
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:283622
\Hnrnpd^{tm1b(KOMP)Wtsi}/\Hnrnpd⁺ (C57BL/6N-Hnrnpd^{tm1b(KOMP)Wtsi}/Nju)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Hnrnpd^tm1Rjsc/\Hnrnpd^tm1Rjsc (involves: 129S6/SvEvTac * C57BL/6J)	abnormal macrophage physiology	J:116112
	increased circulating tumor necrosis factor level	J:116112
	increased susceptibility to bacterial infection	J:116112
	increased susceptibility to endotoxin shock	J:116112
\Hnrnph1^{tm1b(KOMP)Wtsi}/\Hnrnph1⁺ (C57BL/6N-Hnrnph1^{tm1b(KOMP)Wtsi}/Nju)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Hnrnpl^tm1.1Tmo/\Hnrnpl^tm1.1Tmo \Tg(Lck-cre)548Jxm/0 (B6.Cg-Hnrnpl^tm1.1Tmo Tg(Lck-cre)548Jxm)	abnormal T cell differentiation	J:188749
	decreased CD4-positive, alpha-beta T cell number	J:188749
	decreased CD8-positive, alpha-beta T cell number	J:188749
	decreased double-positive T cell number	J:188749
	decreased T cell number	J:188749
	increased double-negative T cell number	J:188749
	increased T cell proliferation	J:188749
	thymus hypoplasia	J:188749
\Hnrnpll^thdr/\Hnrnpll^thdr (C57BL/6JSfdAnu-Hnrnpll^thdr/Anu)	abnormal memory T cell morphology	J:142641
	abnormal memory T cell physiology	J:142641
	abnormal T cell differentiation	J:142641
	decreased CD4-positive, alpha-beta T cell number	J:142641
\Hook1^em1(IMPC)Tcp/\Hook1^em1(IMPC)Tcp (C57BL/6NCrl-Hook1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Hook2^em1(IMPC)Tcp/\Hook2^em1(IMPC)Tcp (C57BL/6N-Hook2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Hook3^{tm1b(NCOM)Mfgc}/\Hook3^{tm1b(NCOM)Mfgc} (C57BL/6N-Hook3^{tm1b(NCOM)Mfgc}/Tcp)	increased basophil cell number	J:211773
\Hormad2^{em1(IMPC)Ccpcz}/\Hormad2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Hormad2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Hoxa1^tm3.1Mrc/\Hoxa1^tm3.1Mrc (involves: 129S1/Sv * 129X1/SvJ)	thymus hypoplasia	J:178887
\Hoxa1^tm3.1Mrc/\Hoxa1^tm3.1Mrc \Hoxb1^tm3Mrc/\Hoxb1⁺ (involves: 129S1/Sv * 129X1/SvJ)	small thymus	J:41540
\Hoxa1^tm3.1Mrc/\Hoxa1^tm3.1Mrc \Hoxb1^tm3Mrc/\Hoxb1^tm3Mrc (involves: 129S1/Sv * 129X1/SvJ)	athymia	J:41540
\Hoxa3^tm1Kth/\Hoxa3^tm1Kth (involves: 129S1/Sv * 129X1/SvJ)	athymia	J:60296
\Hoxa3^tm1Kth/\Hoxa3^tm1Kth \Hoxd3^{tm3(Hoxa3)Mrc}/\Hoxd3⁺ (involves: 129S1/Sv * 129X1/SvJ)	athymia	J:60296
\Hoxa3^tm1Kth/\Hoxa3^{tm2(Hoxd3)Mrc} (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:60296
\Hoxa3^tm1Mrc/\Hoxa3⁺ \Hoxb3^tm1Mrc/\Hoxb3^tm1Mrc (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)	ectopic thymus	J:46523
\Hoxa3^tm1Mrc/\Hoxa3⁺ \Hoxd3^tm1Mrc/\Hoxd3^tm1Mrc (involves: 129S7/SvEvBrd * C57BL/6J)	ectopic thymus	J:46523
\Hoxa3^tm1Mrc/\Hoxa3^tm1Mrc (involves: 129S7/SvEvBrd)	athymia	J:17753, J:161296
\Hoxa3^tm1Mrc/\Hoxa3^tm1Mrc \Hoxd3^tm1Mrc/\Hoxd3^tm1Mrc (involves: 129S7/SvEvBrd * C57BL/6J)	athymia	J:19447
\Hoxa3^tm1Mrc/\Hoxa3^tm2Nrm (involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
\Hoxa3^tm1Mrc/\Hoxa3^tm3.1Nrm \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129S7/SvEvBrd * C57BL/6J * CBA/J)	ectopic thymus	J:161296
\Hoxa3^tm1Nrm/\Hoxa3^tm1Mrc (involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
\Hoxa3^tm1Nrm/\Hoxa3^tm1Nrm (involves: C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
\Hoxa3^{tm2(Hoxd3)Mrc}/\Hoxa3^{tm2(Hoxd3)Mrc} (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:60296
\Hoxa3^tm2Nrm/\Hoxa3^tm2Nrm (involves: C3H * C57BL/6 * C57BL/6NHsd)	athymia	J:161296
\Hoxa3^tm2Nrm/\Hoxa3^tm3.1Nrm \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: C3H * C57BL/6 * CBA/J)	ectopic thymus	J:161296
\Hoxa5^tm1Rob/\Hoxa5^tm1Rob (involves: 129S/SvEv * C57BL/6 * MF1)	abnormal alveolar macrophage morphology	J:113378
	lung inflammation	J:113378
\Hoxa7^tm1Mrc/\Hoxa7^tm1Mrc \Hoxb7^tm1Mrc/\Hoxb7^tm1Mrc (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ)	small thymus	J:50942
\Hoxa9^tm1Mrc/\Hoxa9^tm1Mrc (B6.129S7-Hoxa9^tm1Mrc)	decreased spleen weight	J:126371
\Hoxa9^tm1Mrc/\Hoxa9^tm1Mrc (B6.129S7-Hoxa9^tm1Mrc)	spleen hypoplasia	J:126371
\Hoxa11os^em1Kaf/\Hoxa11os^em1Kaf (C57BL/6-Hoxa11os^em1Kaf)	abnormal cytokine secretion	J:344661
	increased susceptibility to induced colitis	J:344661
	intestinal inflammation	J:344661
\Hoxb4^tm1.1Karl/\Hoxb4^tm1.1Karl (involves: 129 * C57BL/6J)	spleen hypoplasia	J:90976
\Hoxb6^tm1Cka/\Hoxb6^tm1Cka (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:133561
\Hoxb8^tm1.1Mrc/\Hoxb8^tm1.1Mrc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal microglial cell morphology	J:162102
\Hoxb9^tm1Mrc/\Hoxb9^tm1Mrc (involves: 129S7/SvEvBrd)	small thymus	J:37847
\Hoxc4^tm2.1Mrc/\Hoxc4^tm2.1Mrc (involves: 129S/SvEv * C57BL/6)	abnormal class switch recombination	J:148278
	abnormal somatic hypermutation frequency	J:148278
	decreased IgA level	J:148278
	decreased IgE level	J:148278
	decreased IgG1 level	J:148278
	decreased IgG2a level	J:148278
	decreased IgG2b level	J:148278
	decreased IgG3 level	J:148278
	decreased IgM level	J:148278
	immune system phenotype	J:148278
\Hp^tm1Skl/\Hp^tm1Skl \Hpx^tm1Altr/\Hpx^tm1Altr (involves: 129/Sv * 129P2/OlaHsd * C57BL/6J)	enlarged spleen	J:80539
	increased spleen red pulp amount	J:80539
	liver inflammation	J:80539
\Hpgds^tm1Urad/\Hpgds^tm1Urad (B6.129-Hpgds^tm1Urad)	abnormal cytokine secretion	J:107651
	abnormal lymph node morphology	J:107651
	increased acute inflammation	J:107651
	increased inflammatory response	J:107651
	increased susceptibility to type I hypersensitivity reaction	J:197334
\Hpi1^C57BL/6J/? (involves: A/J * C57BL/6J)	abnormal inflammatory response	J:69153
\Hpi1^C57BL/6J/\Hpi1^C57BL/6J \Hpi2^C57BL/6J/\Hpi2^C57BL/6J (involves: A/J * C57BL/6J)	abnormal inflammatory response	J:69153
\Hpi2^C57BL/6J/? (involves: A/J * C57BL/6J)	abnormal inflammatory response	J:69153
\Hprt1^b-m3/Y \Impdh1^tm1Bmi/\Impdh1^tm1Bmi (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphopoiesis	J:85443
	decreased cytotoxic T cell cytolysis	J:85443
	decreased interleukin-4 secretion	J:85443
	decreased splenocyte proliferation	J:85443
	decreased T cell proliferation	J:85443
\Hprt1^b-m3/Y \Impdh2^tm1Bmi/\Impdh2⁺ (involves: 129P2/OlaHsd)	abnormal cytotoxic T cell physiology	J:86045
	abnormal lymphocyte cell number	J:86045
\Hprt1^{tm1(CAG-Tgfbr1)Lba}/Y \Tg(Cd4-cre)1Cwi/0 (involves: 129 C57BL/6 * DBA/2)	abnormal T cell activation	J:148747
\Hprt1^{tm1(CAG-Tgfbr1)Lba}/Y \Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(Cd4-cre)1Cwi/0 (involves: 129 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:148747
\Hprt1^{tm1(CAG-Tgfbr1)Lba}/\Hprt1^{tm1(CAG-Tgfbr1)Lba} \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	abnormal T cell activation	J:148747
\Hprt1^{tm1(CAG-Tgfbr1)Lba}/\Hprt1^{tm1(CAG-Tgfbr1)Lba} \Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(Cd4-cre)1Cwi/0 (involves: 129 * 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:148747
\Hprt1^{tm1(CUX1)Anep}/\Hprt1⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB))	abnormal spleen white pulp morphology	J:113393
	abnormal splenic cell ratio	J:113393
	decreased B cell number	J:113393
	enlarged lymph nodes	J:113393
	enlarged spleen	J:113393
	increased leukocyte cell number	J:113393
	increased neutrophil cell number	J:113393
	myeloid hyperplasia	J:113393
	spleen hyperplasia	J:113393
\Hprt1^{tm1(Pck1-cre)Vhh}/Y \Vhl^tm1Jae/\Vhl^tm1Jae (involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)	kidney inflammation	J:106705
\Hprt1^{tm2(CUX1)Anep}/\Hprt1⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * FVB))	immune system phenotype	J:113393
\Hps1^ep/\Hps1^ep (involves: C3HeB/FeJ * C57BL/6J)	abnormal macrophage physiology	J:7869
\Hps1^ep/\Hps1^ep (B6.C3Fe-Hps1^ep/J)	abnormal NK cell physiology	J:6801
\Hps1^ep/\Hps1^ep (B6.C3Fe-Hps1^ep/J)	alveolitis	J:110157
\Hps3^coa-Btlr/\Hps3^coa-Btlr (C57BL/6J-Hps3^coa-Btlr)	immune system phenotype	J:137495
\Hps5^ru2-2Btlr/\Hps5^ru2-2Btlr (C57BL/6J-Hps5^ru2-2Btlr)	immune system phenotype	J:135220
\Hps5^ru2-Btlr/\Hps5^ru2-Btlr (C57BL/6J-Hps5^ru2-Btlr)	increased susceptibility to bacterial infection	J:133272
\Hps5^ru2-Btlr/\Hps5^ru2-Btlr (C57BL/6J-Hps5^ru2-Btlr)	increased susceptibility to Herpesvirales infection	J:133272
\Hps6^em1(IMPC)Tcp/\Hps6^em1(IMPC)Tcp (C57BL/6N-Hps6^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
	small thymus	J:211773
\Hps6^ru-2J/\Hps6^ru-2J (C57BL/10J-Hps6^ru-2J)	immune system phenotype	J:6485
\Hps6^ru-Btlr/\Hps6^ru-Btlr (C57BL/6J-Hps6^ru-Btlr)	immune system phenotype	J:137496
\Hpse^tm1.2Mdh/\Hpse^tm1.2Mdh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal dendritic cell chemotaxis	J:209913
	abnormal Langerhans cell morphology	J:209913
	decreased acute inflammation	J:209913
	decreased leukocyte cell number	J:209913
	impaired eosinophil recruitment	J:209913
	increased eosinophil cell number	J:209913
\Hr^em1(IMPC)H/\Hr^em1(IMPC)H (C57BL/6NTac-Hr^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
\Hr^em1(IMPC)H/\Hr^em1(IMPC)H (C57BL/6NTac-Hr^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Hr^hr/\Hr^hr (HRS/J)	decreased T cell number	J:6087
	decreased T cell proliferation	J:6375
	increased macrophage cell number	J:150402
\Hr^hr/\Hr^hr \Tg(CD2-Stat6V625AT626A)78Mhk/0 (involves: C3H * SKH1)	blepharitis	J:230018
	eye inflammation	J:230018
	Meibomian gland inflammation	J:230018
	uveitis	J:230018
\Hr^m1Btlr/\Hr^m1Btlr (C57BL/6J-Hr^m1Btlr)	immune system phenotype	J:138686
\Hr^m1Enu/\Hr^m1Enu (BALB/cJ-Hr^m1Enu)	granulomatous inflammation	J:108173
\Hr^rh-bmh/\Hr^rh-bmh (involves: C57BL/6JRj * CBA/JRj)	immune system phenotype	J:89321
\Hr^rh-R/\Hr^rh-R (involves: 101 * C3H/Rl * C57BL/RlEl * C57BL/10Rl * SEC/El)	decreased thymus weight	J:156542
\Hr^rh/\Hr^rh (Not Specified)	eye inflammation	J:16021
\Hr^rh/\Hr^rh (RHJ/LeJ)	thymus atrophy	J:57947
\Hr^rhsl/\Hr^rhsl (involves: BALB/c)	thymus atrophy	J:98859
\Hr^USP/\Hr^USP (either: (involves: A/J * BALB/c) or (involves: BALB/c * C57BL/6) or (involves: BALB/c * DBA/2))	abnormal immunoglobulin level	J:21316
	abnormal lymph node secondary follicle morphology	J:21316
	abnormal thymus involution	J:21316
	decreased IgM level	J:21316
	enlarged inguinal lymph nodes	J:21316
	enlarged popliteal lymph nodes	J:21316
	glomerulonephritis	J:21316
	increased IgG level	J:21316
	increased susceptibility to autoimmune disorder	J:21316
	lymph node inflammation	J:21316
	lymph node medullary cord hyperplasia	J:21316
	thymus cortex atrophy	J:21316
\Hrg^tm1Wja/\Hrg^tm1Wja (involves: 129P2/OlaHsd * C57BL/6)	increased circulating fibrinogen level	J:134621
\Hrg^tm1Wja/\Hrg^tm1Wja (involves: 129P2/OlaHsd * C57BL/6)	increased monocyte cell number	J:134621
\Hrh1^Bphs-r/\Hrh1^Bphs-r (C3H/HeJ)	immune system phenotype	J:4933, J:77938
\Hrh1^Bphs-r/\Hrh1^Bphs-s ((C3H/HeJ x SJL/J)F1)	abnormal immune system physiology	J:77938
	abnormal response to infection	J:77938
	increased susceptibility to bacterial infection	J:77938
	increased susceptibility to bacterial infection induced morbidity/mortality	J:77938
\Hrh1^Bphs-s/\Hrh1^Bphs-s (C3.SJL-Hrh1^Bphs-s)	abnormal response to infection	J:77938
	increased susceptibility to bacterial infection	J:77938
	increased susceptibility to bacterial infection induced morbidity/mortality	J:77938
\Hrh1^tm1Wtn/\Hrh1^tm1Wtn (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell proliferation	J:111704
	decreased IgG3 level	J:111704
	decreased IgM level	J:111704
	decreased interferon-gamma secretion	J:111704
	decreased interleukin-2 secretion	J:111704
	decreased T cell number	J:111704
	decreased T cell proliferation	J:111704
	increased interleukin-4 secretion	J:111704
\Hrh1^tm1Wtn/\Hrh1^tm1Wtn (B6.129P2-Hrh1^tm1Wtn)	decreased inflammatory response	J:110367
	decreased interferon-gamma secretion	J:110367
	decreased interleukin-5 secretion	J:110367
	decreased interleukin-13 secretion	J:110367
	increased IgG level	J:110367
	increased IgM level	J:110367
\Hrh3^Eae8-r/? (B10.S-H2^s/SgMcdJ)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:34892
\Hrh3^Eae8-r/\Hrh3^Eae8-r (involves: B10.S/DvTe * SJL/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Hrh3^Eae8-s/? (involves: B10.S * SJL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:49054
\Hrh3^tm1Twl/\Hrh3^tm1Twl (involves: 129P2/OlaHsd)	immune system phenotype	J:132140
\Hrh3^tm1Twl/\Hrh3^tm1Twl (B6.129X1-Hrh3^tm1Twl)	increased susceptibility to experimental autoimmune encephalomyelitis	J:122269
\Hrh4^tm1Lex/\Hrh4⁺ (involves: 129S/SvEv * C57BL/6)	abnormal mast cell physiology	J:132140
\Hrh4^tm1Lex/\Hrh4^tm1Lex (involves: 129S/SvEv * C57BL/6)	abnormal mast cell physiology	J:131785
\Hrh4^tm1Lex/\Hrh4^tm1Lex (involves: 129S/SvEv * BALB/c)	abnormal chemokine level	J:131785
	abnormal dendritic cell physiology	J:131785
	abnormal interleukin level	J:131785
	decreased IgE level	J:131785
	decreased IgG1 level	J:131785
	decreased inflammatory response	J:131785
\Hrl^{129S6/SvEvTac}/\Hrl^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to Herpesvirales infection	J:86189
\Hrl^C57BL/6J/\Hrl^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to Herpesvirales infection	J:86189
\Hs1bp3^em1(IMPC)J/\Hs1bp3^em1(IMPC)J (C57BL/6NJ-Hs1bp3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Hs3st3b1^em2(IMPC)Mbp/\Hs3st3b1^em2(IMPC)Mbp (C57BL/6N-Hs3st3b1^em2(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Hsd17b3^tm1.2Mpo/\Hsd17b3^tm1.2Mpo (involves: 129S6/SvEvTac * C57BL/6N * C57BL/6NCrl)	increased spleen weight	J:301756
\Hsd17b4^em1(IMPC)Tcp/\Hsd17b4^em1(IMPC)Tcp (C57BL/6NCrl-Hsd17b4^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Hsd17b4^tm1Baes/\Hsd17b4^tm1Baes (involves: 129S1/Sv * 129X1/SvJ)	microgliosis	J:201698
\Hsd17b4^tm2Baes/\Hsd17b4^tm2Baes \Tg(Nes-cre)1Kln/0 (involves: 129 * C57BL/6 * SJL)	microgliosis	J:201698
\Hsd17b11^{Gt(OST237628)Lex}/\Hsd17b11^{Gt(OST237628)Lex} (B6;129S5-Hsd17b11^{Gt(OST237628)Lex}/Mmucd)	increased IgG2a level	J:171883
	increased immature B cell number	J:171883
\Hsd17b13^tm1Lex/\Hsd17b13^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6N)	liver inflammation	J:273927
\Hsd17b14^tm1Lex/\Hsd17b14^tm1Lex (B6;129S5-Hsd17b14^tm1Lex/Mmucd)	increased IgG2a level	J:171883
\Hsf1^tm1Ijb/\Hsf1^tm1Ijb (either: (involves: 129S6/SvEvTac * 129X1/SvJ) or (involves: 129S6/SvEvTac * BALB/c) or (involves: 129S6/SvEvTac * C57BL/6J) or (involves: 129S6/SvEvTac * ICR))	increased susceptibility to bacterial infection	J:58383
	increased tumor necrosis factor secretion	J:58383
\Hsf1^tm1Ijb/\Hsf1^tm1Ijb \Tg(TTR-V30M)15Imeg/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	increased interleukin-1 beta secretion	J:156658
	increased tumor necrosis factor secretion	J:156658
\Hsf2bp^{tm1b(EUCOMM)Hmgu}/\Hsf2bp^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hsf2bp^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
\Hsfy2^em1(IMPC)J/\Hsfy2^em1(IMPC)J (C57BL/6NJ-Hsfy2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Hsh2d^tm1Viss/\Hsh2d^tm1Viss (B6.129-Hsh2d^tm1Viss)	immune system phenotype	J:111408
	increased interleukin-2 secretion	J:111408
	increased T cell proliferation	J:111408
\Hsh2d^tm1Viss/\Hsh2d^tm1Viss (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:111408
	abnormal CD8-positive, alpha-beta T cell physiology	J:111408
	increased spleen weight	J:111408
\Hsp90aa1^tm1.1Udon/\Hsp90aa1^tm1.1Udon (involves: C57BL/6)	abnormal dendritic cell antigen presentation	J:177143
	abnormal dendritic cell physiology	J:177143
	decreased interferon-gamma secretion	J:177143
\Hsp90b1^tm1Zhli/\Hsp90b1^tm1.1Zhli \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal cytokine secretion	J:118427
	abnormal inflammatory response	J:118427
	abnormal macrophage physiology	J:118427
	increased susceptibility to bacterial infection	J:118427
\Hspa1b^tm1Clib/\Hspa1b^tm1Clib (involves: 129P2/OlaHsd * C57BL/6J)	increased interleukin-6 secretion	J:76801
\Hspa9^{Gt(IST14901H6)Tigm}/\Hspa9⁺ (involves: C57BL/6N)	decreased pre-B cell number	J:227164
\Hspa12a^tm1.1Zdi/\Hspa12a^tm1.1Zdi (involves: 129 * C57BL/6)	abnormal macrophage morphology	J:302786
	increased susceptibility to endotoxin shock	J:302787
\Hspa13^tm1.1Smoc/\Hspa13^tm1.1Smoc \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S * C57BL/6)	abnormal class switch recombination	J:303927
	abnormal humoral immune response	J:303927
	abnormal plasmablast number	J:303927
	abnormal somatic hypermutation frequency	J:303927
	decreased autoantibody level	J:303927
	decreased IgA level	J:303927
	decreased IgE level	J:303927
	decreased IgG1 level	J:303927
	decreased IgG2b level	J:303927
	decreased IgG2c level	J:303927
	decreased IgG3 level	J:303927
	decreased IgG level	J:303927
	decreased IgM level	J:303927
	decreased plasma cell number	J:303927
\Hspb1^tm1.1Jdn/\Hspb1^tm1.1Jdn (B6.129S2(Cg)-Hspb1^tm1.1Jdn)	abnormal chemokine secretion	J:209117
	abnormal macrophage physiology	J:209117
	abnormal neutrophil physiology	J:209117
	increased inflammatory response	J:209117
	increased interleukin-6 secretion	J:209117
\Hspb8^em1(IMPC)J/\Hspb8^em1(IMPC)J (C57BL/6NJ-Hspb8^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Hspb8^tm1.1Depr/\Hspb8^tm1.1Depr (B.129-Hspb8^tm1.1Depr)	decreased circulating interleukin-6 level	J:186292
\Hspbap1^{tm1b(EUCOMM)Hmgu}/\Hspbap1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Hspbap1^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
\Hspg2^tm1Rdgr/\Hspg2^tm1Rdgr (involves: 129S1/Sv * 129X1/SvJ)	abnormal osteoclast morphology	J:121855
	increased osteoclast cell number	J:121855
	osteoarthritis	J:121855
\Htr2c^tm1Jul/Y (B6.129S-Htr2c^tm1Jul)	abnormal tumor necrosis factor level	J:50262
\Htr3a^tm1Ckn/\Htr3a^tm1Ckn (involves: 129S1/Sv * C57BL/6J * DBA/2)	decreased lymphocyte cell number	J:90942
	kidney inflammation	J:90942
	prostate gland inflammation	J:90942
	pyelonephritis	J:90942
	seminal vesiculitis	J:90942
	tubulointerstitial nephritis	J:90942
\Htra2^mnd2/\Htra2^mnd2 (involves: C3H/HeJ * C57BL/6J * CAST/Ei)	abnormal thymus morphology	J:12780
	spleen atrophy	J:12780
\Htra2^mnd2/\Htra2^mnd2 (B6.Cg-Htra2^mnd2)	abnormal interleukin level	J:76481
\Htra2^mnd2/\Htra2^mnd2 (B6.Cg-Htra2^mnd2)	abnormal tumor necrosis factor level	J:76481
\Htra2^mnd2/\Htra2^mnd2 (involves: C57BL/6J)	abnormal immune system morphology	J:132627
	decreased double-positive T cell number	J:132627
	decreased pre-B cell number	J:132627
	decreased pro-B cell number	J:132627
	decreased single-positive T cell number	J:132627
\Htra2^tm1.1Hohj/\Htra2^tm1.1Hohj \Tg(Nes-cre)1Kln/0 (involves: C57BL/6J)	spleen atrophy	J:225666
	thymus atrophy	J:225666
\Htra2^tm1.2Hohj/\Htra2^tm1.2Hohj (involves: C57BL/6 * C57BL/6J)	decreased lymphocyte cell number	J:225666
	spleen atrophy	J:225666
	thymus atrophy	J:225666
\Htra2^tm1Jdo/\Htra2^tm1Jdo (involves: 129P/Ola * C57BL/6)	small spleen	J:94227
\Htra2^tm1Jdo/\Htra2^tm1Jdo (involves: 129P/Ola * C57BL/6)	small thymus	J:94227
\Htt^tm2Detl/\Htt⁺ (B6J.129P2-Htt^tm2Detl)	microgliosis	J:220868
\hubb/\hubb (involves: ICR)	increased spleen weight	J:8170
\Hvcn1^{Gt(RRN293)Byg}/\Hvcn1^{Gt(RRN293)Byg} (B6.129P2-Hvcn1^{Gt(RRN293)Byg})	abnormal macrophage physiology	J:148032
	abnormal neutrophil physiology	J:148032
\hvlk/\hvlk (C57BL/6J-hvlk)	increased susceptibility to Herpesvirales infection	J:105543
\Hyal1^tm1Stn/\Hyal1^tm1Stn (involves: 129X1/SvJ * C57BL/6J)	osteoarthritis	J:136860
\Hyal2^tm1.1Bfla/\Hyal2^tm1.1Bfla (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	increased spleen iron level	J:146040
\Hycc1^{em1(IMPC)Ccpcz}/\Hycc1^{em1(IMPC)Ccpcz} (C57BL/6N-Hycc1^{em1(IMPC)Ccpcz}/Ccpcz)	enlarged thymus	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Hydin^hyrh/\Hydin^hyrh (involves: C57BL/6J * C57BL/10J * RIII)	rhinitis	J:137815
	thymus atrophy	J:137815
\Iapp^tm1Sgm/\Iapp⁺ (involves: 129P2/OlaHsd)	increased osteoclast cell number	J:88964
\Iapp^tm1Sgm/\Iapp^tm1Sgm (involves: 129P2/OlaHsd)	increased osteoclast cell number	J:88964
\Ibdq1^C57BL/6J/\Ibdq1^SAMP1/YitFcs (involves: C57BL/6J * SAMP1/YitFc)	ileum inflammation	J:84661
\Ibdq1^SAMP1/YitFcs/\Ibdq1^SAMP1/YitFcs (involves: C57BL/6J * SAMP1/YitFc)	ileum inflammation	J:84661
\Ibdq2^SAMP1/YitFcs/\Ibdq2^SAMP1/YitFcs (involves: AKR/J * SAMP1/YitFcs)	small intestinal inflammation	J:105411
\Ibsp^tm1Jeau/\Ibsp^tm1Jeau (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal osteoclast morphology	J:228156, J:136223
	decreased osteoclast cell number	J:136223
	increased osteoclast cell number	J:228156
\Ibtk^Gt(XF224)Byg/\Ibtk^Gt(XF224)Byg (involves: 129P2/OlaHsd * C57BL/6)	abnormal splenocyte physiology	J:174707
	immune system phenotype	J:174707
\Ica1^{tm1b(EUCOMM)Wtsi}/\Ica1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ica1^{tm1b(EUCOMM)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Ica1^tm1Mdos/\Ica1^tm1Mdos (NOD.129-Ica1^tm1Mdos)	abnormal T cell physiology	J:83526
\Ica1^tm1Mdos/\Ica1^tm1Mdos (NOD.129-Ica1^tm1Mdos)	decreased susceptibility to autoimmune diabetes	J:83526
\Icam1^tm1Alb/\Icam1^tm1Alb (B6.Cg-Icam1^tm1Alb)	abnormal leukocyte adhesion	J:100242
	abnormal leukocyte tethering or rolling	J:100242
	increased leukocyte cell number	J:100242
	increased neutrophil cell number	J:100242
\Icam1^tm1Bay/\Icam1^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal cellular extravasation	J:14565
	abnormal immune system physiology	J:14565
	decreased susceptibility to type IV hypersensitivity reaction	J:14565
	increased neutrophil cell number	J:14565
\Icam1^tm1Bay/\Icam1^tm1Bay (B6.129S7-Icam1^tm1Bay)	abnormal cellular extravasation	J:48271
	abnormal leukocyte migration	J:24239
	abnormal leukocyte tethering or rolling	J:48271
	decreased susceptibility to endotoxin shock	J:123460
	increased eosinophil cell number	J:48271
	increased lymphocyte cell number	J:48271
	increased monocyte cell number	J:48271
	increased neutrophil cell number	J:48271, J:24239
\Icam1^tm1Bay/\Icam1^tm1Bay (either: B6.129S7-Icam1^tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal leukocyte tethering or rolling	J:31374
	increased leukocyte cell number	J:31374
\Icam1^tm1Bay/\Icam1^tm1Bay (B6.129S7-Icam1^tm1Bay/J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:193592
\Icam1^tm1Bay/\Icam1^tm1Bay (B6.129S7-Icam1^tm1Bay/J)	immune system phenotype	J:193592
\Icam1^tm1Bay/\Icam1^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to induced colitis	J:111227
	impaired neutrophil recruitment	J:112286
	increased neutrophil cell number	J:112286
	large intestinal inflammation	J:111227
\Icam1^tm1Bay/\Icam1^tm1Bay \Sele^tm2Alb/\Sele^tm2Alb \Selp^tm1Bay/\Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased acute inflammation	J:112286
	impaired neutrophil chemotaxis	J:112286
	increased neutrophil cell number	J:112286
\Icam1^tm1Bay/\Icam1^tm1Bay \Sell^tm1Tft/\Sell^tm1Tft (B6.129-Sell^tm1Tft Icam1^tm1Bay)	abnormal cellular extravasation	J:48271
	abnormal inflammatory response	J:124291
	abnormal leukocyte tethering or rolling	J:48271
	abnormal macrophage physiology	J:124291
	abnormal mast cell physiology	J:124291
	impaired macrophage chemotaxis	J:124291
	increased eosinophil cell number	J:48271
	increased lymphocyte cell number	J:48271
	increased monocyte cell number	J:48271
	increased neutrophil cell number	J:48271
\Icam1^tm1Bay/\Icam1^tm1Bay \Selp^tm1Bay/\Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal leukocyte migration	J:24239
	increased neutrophil cell number	J:24239
\Icam1^tm1Bay/\Icam1^tm1Bay \Selp^tm1Bay/\Selp^tm1Bay (either: B6.129S7-Selp^tm1Bay Icam1^tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))	impaired leukocyte tethering or rolling	J:31374
\Icam1^tm1Bay/\Icam1^tm1Bay \Selp^tm1Bay/\Selp^tm1Bay (B6.129S7-Icam1^tm1Bay Selp^tm1Bay/J)	immune system phenotype	J:119906
\Icam1^tm1Cws/\Icam1^tm1Cws (involves: C57BL/6)	abnormal macrophage morphology	J:100353
\Icam1^tm1Jcgr/\Icam1^tm1Jcgr (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal interleukin level	J:18743
	abnormal T cell physiology	J:18743
	abnormal tumor necrosis factor level	J:18743
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:18743
	decreased susceptibility to type IV hypersensitivity reaction	J:18743
	increased lymphocyte cell number	J:18743
	increased neutrophil cell number	J:18743
\Icam1^tm1Jcgr/\Icam1^tm1Jcgr (B6.129S4-Icam1^tm1Jcgr)	immune system phenotype	J:113463
\Icam1^tm1Jcgr/\Icam1^tm1Jcgr \Ldlr^tm1Her/\Ldlr^tm1Her (involves: 129S4/SvJae * 129S7/SvEvBrd)	increased neutrophil cell number	J:69597
\Icam1^tm1Jcgr/\Icam1^tm1Jcgr \Ldlr^tm1Her/\Ldlr^tm1Her \Vcam1^tm1Dmil/\Vcam1^tm1Dmil (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)	increased leukocyte cell number	J:69597
	increased lymphocyte cell number	J:69597
	increased monocyte cell number	J:69597
	increased neutrophil cell number	J:69597
\Icam1^tm1Jcgr/\Icam1^tm1Jcgr \Tg(INS-Il10)#Sar/0 (NOD.Cg-Icam1^tm1Jcgr Tg(INS-Il10)#Sar)	decreased susceptibility to autoimmune diabetes	J:66103
	periinsulitis	J:66103
\Icam1^tm1Jcgr/\Icam1^tm1Jcgr \Vcam1^tm1Dmil/\Vcam1^tm1Dmil (involves: 129S4/SvJae * C57BL/6)	impaired macrophage chemotaxis	J:227109
\Icam2^tm1Jcgr/\Icam2^tm1Jcgr (involves: 129S4/SvJae * C57BL/6)	abnormal eosinophil physiology	J:54748
\Ichs^C57BL/6J/\Ichs^C57BL/6J (involves: A/J * C57BL/6J * C57BL/6JOlaHsd)	abnormal type I hypersensitivity reaction	J:63737
\Ichs^{C57BL/6JOlaHsd}/\Ichs^{C57BL/6JOlaHsd} (involves: A/J * C57BL/6J * C57BL/6JOlaHsd)	abnormal type I hypersensitivity reaction	J:63737
\Icos^tm1.1Wks/\Icos^tm1.1Wks (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell number	J:155586
	abnormal B cell physiology	J:155586
	abnormal B cell selection	J:155586
	abnormal class switch recombination	J:155586
	abnormal immune system physiology	J:155586
	abnormal Peyer's patch germinal center morphology	J:155586
	abnormal spleen morphology	J:155586
	decreased CD4-positive, alpha-beta T cell number	J:155586
	decreased IgA level	J:155586
	decreased IgG1 level	J:155586
	decreased IgG2b level	J:155586
	decreased IgG2c level	J:155586
	decreased interleukin-4 secretion	J:155586
	decreased interleukin-21 secretion	J:155586
	decreased spleen germinal center number	J:155586
	small Peyer's patches	J:155586
\Icos^tm1Dgry/\Icos^tm1Dgry (B6.129P2-Icos^tm1Dgry)	abnormal CD4-positive, alpha-beta T cell physiology	J:123477
	abnormal immune system physiology	J:123477
	abnormal interleukin secretion	J:123477
	abnormal leukocyte cell number	J:123477
	abnormal memory B cell number	J:123477
	abnormal response to infection	J:123477
	abnormal T cell physiology	J:123477
	decreased germinal center B cell number	J:123477
	decreased IgG level	J:123477
	decreased interleukin-4 secretion	J:123477
	decreased interleukin-5 secretion	J:123477
	decreased plasma cell number	J:123477
	increased plasma cell number	J:123477
\Icos^tm1Flv/\Icos⁺ (NOD.129S1-Icos^tm1Flv)	insulitis	J:131529
\Icos^tm1Flv/\Icos^tm1Flv (involves: 129/Sv * C57BL/6)	abnormal immunoglobulin level	J:87123
	abnormal interferon level	J:87123
	abnormal interleukin level	J:87123
	abnormal T-helper 2 physiology	J:87123
	decreased IgE level	J:87123
	decreased IgG1 level	J:87123
	immune system phenotype	J:87123
	increased susceptibility to experimental autoimmune encephalomyelitis	J:87123
	small lymph nodes	J:87123
\Icos^tm1Flv/\Icos^tm1Flv (NOD.129S1-Icos^tm1Flv)	decreased anti-insulin autoantibody level	J:131529
	decreased autoantibody level	J:131529
	decreased IgG level	J:131529
	decreased interferon-gamma secretion	J:131529
	decreased susceptibility to autoimmune diabetes	J:131529
	decreased T cell number	J:131529
	immune system phenotype	J:131529
	insulitis	J:131529
\Icos^tm1Flv/\Icos^tm1Flv (involves: 129S1/Sv)	abnormal cytokine secretion	J:112600
\Icos^tm1Flv/\Icos^tm1Flv \Rc3h1^san/\Rc3h1⁺ (involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu)	increased T cell derived lymphoma incidence	J:189087
\Icos^tm1Flv/\Icos^tm1Flv \Tg(Cd4-Maf)6666Glm/0 (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:112600
\Icos^tm1Flv/\Icos^tm1Flv \Tg(TcraTcrb)425Cbn/0 (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:112600
\Icos^tm1Mak/\Icos^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:155586
	abnormal B cell physiology	J:66702
	abnormal class switch recombination	J:66702
	abnormal immune system physiology	J:66702
	abnormal Peyer's patch germinal center morphology	J:155586
	abnormal spleen morphology	J:66702
	abnormal T cell physiology	J:66702
	decreased CD4-positive, alpha-beta T cell number	J:155586
	decreased IgA level	J:155586
	decreased IgE level	J:66702
	decreased IgG1 level	J:66702, J:155586
	decreased IgG2b level	J:155586
	decreased IgG2c level	J:155586
	decreased interleukin-21 secretion	J:155586
	decreased spleen germinal center number	J:66702, J:155586
	decreased spleen germinal center size	J:66702
	decreased T cell proliferation	J:66702
	small Peyer's patches	J:155586
\Icos^tm1Shr/\Icos^tm1Shr (Not Specified)	abnormal CD4-positive, alpha-beta T cell physiology	J:87124
	abnormal immunoglobulin level	J:87124
	abnormal interleukin level	J:87124
	abnormal spleen germinal center morphology	J:87124
	abnormal T cell differentiation	J:87124
	decreased IgE level	J:87124
	decreased IgG1 level	J:87124
	decreased IgG2a level	J:87124
	decreased IgG level	J:87124
	increased IgG3 level	J:87124
\Icos^tm1Tkan/\Icos^tm1Tkan (involves: 129S7/SvEvBrd * C57BL/6)	abnormal NK cell physiology	J:95353
	abnormal Peyer's patch germinal center morphology	J:95728
	decreased circulating interferon-gamma level	J:95353
	decreased circulating interleukin-4 level	J:95353
	small Peyer's patches	J:95728
\Icosl^tm1Cdon/\Icosl^tm1Cdon (involves: 129S6/SvEvTac)	abnormal immunoglobulin level	J:86697
	abnormal interferon level	J:86697
	abnormal interleukin secretion	J:86697
	abnormal T cell differentiation	J:86697
	abnormal T-helper 2 physiology	J:86697
	decreased IgE level	J:86697
	decreased IgG1 level	J:86697
	decreased IgG2a level	J:86697
	decreased IgG level	J:86697
	decreased IgM level	J:86697
	small spleen	J:86697
\Icosl^tm1Kplm/\Icosl^tm1Kplm (involves: 129P2/OlaHsd)	abnormal humoral immune response	J:84893
	abnormal immune serum protein physiology	J:84893
	abnormal spleen germinal center morphology	J:84893
	decreased IgA level	J:84893
	decreased IgG2a level	J:84893
	decreased IgG2b level	J:84893
	decreased interleukin-4 secretion	J:84893
	decreased interleukin-10 secretion	J:84893
	increased interferon-gamma secretion	J:84893
\Icosl^tm1Mak/\Icosl^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:84668
	abnormal immune system physiology	J:84668
	abnormal spleen morphology	J:84668
	abnormal T-helper 2 cell differentiation	J:84668
	decreased IgG1 level	J:84668
	decreased inflammatory response	J:84668
	decreased spleen germinal center number	J:84668
	decreased spleen germinal center size	J:84668
	immune system phenotype	J:84668
\Id1^tm1Zhu/\Id1⁺ \Id3^tm1Zhu/\Id3^tm1Zhu (involves: 129S1/Sv * 129S4/SvJaeSor)	increased susceptibility to otitis media	J:311050
\Id1^tm1Zhu/\Id1^tm1Zhu (involves: 129S1/Sv * C57BL/6)	abnormal myelopoiesis	J:155384
	abnormal osteoclast differentiation	J:155384
	decreased lymphocyte cell number	J:119519
	increased monocyte cell number	J:155384
	increased neutrophil cell number	J:155384
	increased osteoclast cell number	J:155384
	myeloid hyperplasia	J:155384
\Id1^tm1Zhu/\Id1^tm1Zhu \Id3^tm1Zhu/\Id3⁺ (involves: 129S1/Sv * 129S4/SvJaeSor)	increased susceptibility to otitis media	J:311050
\Id1^tm1Zhu/\Id1^tm1Zhu \Tcf3^tm1Wein/\Tcf3^tm1Wein (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:44278
	absent B cells	J:44278
	arrested B cell differentiation	J:44278
	decreased lymphocyte cell number	J:44278
	increased T cell derived lymphoma incidence	J:44278
	intermingled spleen red and white pulp	J:44278
\Id2^tm1Ago/\Id2^tm1Ago (B6.129-Id2^tm1Ago)	absent lymph nodes	J:116119
	absent NK cells	J:116119
	decreased CD8-positive, alpha-beta T cell number	J:116119
\Id2^tm1Ago/\Id2^tm1Ago \Tg(TcraTcrb)1100Mjb/0 (B6.Cg-Id2^tm1Ago Tg(TcraTcrb)1100Mjb)	abnormal T cell activation	J:116119
\Id2^tm1Gtbz/\Id2^tm1Gtbz \Nfil3^tm1.1Brad/\Nfil3^tm1.1Brad (involves: C57BL/6)	immune system phenotype	J:194760
\Id2^tm1Mais/\Id2^tm1Mais (involves: 129X1/SvJ * C57BL/6)	abnormal immune system physiology	J:146624
\Id2^tm1Yyk/\Id2^tm1Yyk (involves: 129S1/Sv * 129X1/SvJ)	abnormal oropharyngeal lymphoid tissue morphology	J:78101
	absent Peyer's patches	J:53267
	decreased lymph node number	J:53267
	decreased NK cell number	J:53267
\Id2^tm1Yyk/\Id2^tm1Yyk (involves: 129S1/Sv * 129X1/SvJ * NMRI)	abnormal oropharyngeal lymphoid tissue morphology	J:78101
	absent Peyer's patches	J:53267
	decreased lymph node number	J:53267
	decreased NK cell number	J:53267
\Id2^tm1Yyk/\Id2^tm1Yyk (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * FVB/NJ))	absent lymph nodes	J:125739
	absent Peyer's patches	J:125739
	decreased NK T cell number	J:125739
\Id2^tm1Yyk/\Id2^tm1Yyk \Rorc^tm2Litt/\Rorc⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal gut-associated lymphoid tissue morphology	J:87395
	abnormal immune system cell morphology	J:87395
	abnormal lymph organ development	J:87395
\Id2^tm1Yyk/\Id2^tm1Yyk \Tcf3^tm1Cmu/\Tcf3⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	absent axillary lymph nodes	J:125739
	absent brachial lymph nodes	J:125739
	absent inguinal lymph nodes	J:125739
	decreased NK T cell number	J:125739
\Id2^tm1Yyk/\Id2^tm1Yyk \Tcf3^tm1Cmu/\Tcf3^tm1Cmu (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	decreased B cell number	J:125739
	decreased NK T cell number	J:125739
	immune system phenotype	J:125739
	small lymph nodes	J:125739
\Id2^tm2.1Ago/\Id2⁺ \Id3^tm2.1Cmu/\Id3⁺ (involves: C57BL/6)	immune system phenotype	J:179006
\Id2^tm2.1Gtbz/\Id2^tm2.1Gtbz \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:194760
\Id3^em1(IMPC)Mbp/\Id3^em1(IMPC)Mbp (C57BL/6N-Id3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Id3^tm1Cmu/\Id3^tm1Cmu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal double-positive T cell morphology	J:59969
	abnormal T cell differentiation	J:59969
\Id3^tm1Zhu/\Id3^tm1Zhu (involves: 129/Sv * C57BL/6)	abnormal T cell physiology	J:56950
	decreased B cell proliferation	J:56950
	decreased immunoglobulin level	J:56950
	immune system phenotype	J:56950
\Id3^tm1Zhu/\Id3^tm1Zhu (involves: 129S4/SvJaeSor * C57BL/6)	abnormal T cell differentiation	J:144696
\Id3^tm1Zhu/\Id3^tm1Zhu (involves: 129S4/SvJaeSor)	immune system phenotype	J:93916
	increased autoantibody level	J:93916
	lacrimal gland inflammation	J:93916
	salivary gland inflammation	J:93916
\Id3^tm2.1Cmu/\Id3^tm2.1Cmu (Not Specified)	decreased thymocyte number	J:176462
	increased B cell number	J:176462
	increased gamma-delta T cell number	J:176462
	increased T follicular helper cell number	J:176462
\Id3^tm2.1Cmu/\Id3^tm2.1Cmu \Tcf3^tm4Zhu/\Tcf3^tm4Zhu \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6 * DBA/2)	decreased thymocyte number	J:176462
	immune system phenotype	J:176462
\Id3^tm2.1Zhu/\Id3^tm2.1Zhu \Tg(Lck-cre)#Zhu/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL * SJL/J)	abnormal T cell differentiation	J:172701
	decreased CD4-positive, alpha-beta T cell number	J:172701
	decreased CD8-positive, alpha-beta T cell number	J:172701
	decreased T cell number	J:172701
	increased CD4-positive, alpha-beta memory T cell number	J:172701
	increased CD8-positive, alpha-beta memory T cell number	J:172701
	increased gamma-delta T cell number	J:172701
	parotid gland inflammation	J:172701
	submandibular gland inflammation	J:172701
\Idc/\Idc⁺ (involves: 101 * C3H)	blepharitis	J:6686
\Idd1^NOD/Uf/\Idd1^NOD/Uf (involves: C57BL/6 * NOD/Uf)	periinsulitis	J:33172
\Idd1^NOD/Uf/\Idd1^NOD/Uf (B6.NOD-(D17Mit164-D17Mit152))	increased CD4-positive, alpha-beta T cell number	J:92304
\Idd2^NOD/Smrf/\Idd2^NOD/Smrf (involves: NON/Lt * NOD/Smrf)	increased CD4-positive, alpha-beta T cell number	J:30526
\Idd3^A/J/\Idd3^A/J (NOD.A-Idd3^A/J)	increased susceptibility to autoimmune diabetes	J:120349
\Idd3^C57BL/6/\Idd3^C57BL/6 (NOD.B6-Idd3^C57BL/6)	decreased susceptibility to autoimmune diabetes	J:120349
\Idd3^C57BL/10SnJ/\Idd3^C57BL/10SnJ \Idd5.2^C57BL/10SnJ/\Idd5.2^C57BL/10SnJ (involves: C57BL/10SnJ * NOD/MrkTac)	insulitis	J:143549
\Idd3^C57BL/10SnJ/\Idd3^C57BL/10SnJ \Idd5^C57BL/10SnJ/\Idd5^C57BL/10SnJ (involves: C57BL/10 * NOD/MrkTac)	pancreas inflammation	J:88667
\Idd3^CAST/EiJ/\Idd3^CAST/EiJ (NOD.CAST-Idd3^CAST/EiJ)	increased susceptibility to autoimmune diabetes	J:120349
\Idd3^CZECHI/EiJ/\Idd3^CZECHI/EiJ (NOD.CZECH-Idd3^CZECHI/EiJ)	decreased susceptibility to autoimmune diabetes	J:120349
\Idd3^NOD/? (involves: C57BL/10 * NOD)	pancreas inflammation	J:17906
\Idd3^SWR/J/\Idd3^SWR/J (NOD.SWR-Idd3^SWR/J)	increased susceptibility to autoimmune diabetes	J:120349
\Idd4.3^C57L/\Idd4.3^C57L (involves: C57L/J * NOD)	abnormal cytokine secretion	J:118951
	abnormal macrophage physiology	J:118951
	increased susceptibility to autoimmune diabetes	J:118951
\Idd4^C57BL/6/\Idd4^C57BL/6 (involves: C57BL/6 * DBA/2)	increased T cell proliferation	J:25969
\Idd4^C57BL/6/\Idd4^C57BL/6 (involves: C57BL/6 * NOD)	increased T cell proliferation	J:25969
\Idd4^C57BL/6J/? (involves: C57BL/6J * NOD)	pancreas inflammation	J:73763
\Idd4^NOD/Jsd/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
\Idd4^NOD/Jsd/\Idd4^NOD/Jsd \Idd9^NOD/Jsd/\Idd9^NOD/Jsd (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
\Idd4^NOD/\Idd4^NOD (B6.NOD-Idd4)	abnormal cytokine secretion	J:85823
\Idd4^NOD/\Idd4^NOD (B6.NOD-Idd4)	decreased NK T cell number	J:85823
\Idd4^NOR/LtJ/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
\Idd5^NOD/Uf/\Idd5^NOD/Uf (involves: C57BL/6 * NOD/Uf)	periinsulitis	J:33172
\Idd6.1^C3H/HeJ/\Idd6.1^C3H/HeJ (involves: C3H/HeJ * NOD)	decreased susceptibility to autoimmune diabetes	J:115021
\Idd6.2^C3H/HeJ/\Idd6.2^C3H/HeJ (involves: C3H/HeJ * NOD)	decreased susceptibility to autoimmune diabetes	J:115021
\Idd6.2^C3H/HeJ/\Idd6.2^C3H/HeJ (NOD.C3-Idd6.2^C3H/HeJ)	decreased NK cell number	J:137837
\Idd6.2^NOD/\Idd6.2^NOD (B6.NOD-(D6Mit259-D6Mit304))	abnormal T cell differentiation	J:120148
\Idd6.3^C3H/HeJ/\Idd6.3^C3H/HeJ (involves: C3H/HeJ * NOD)	decreased susceptibility to autoimmune diabetes	J:115021
\Idd6^C3H/HeJ/\Idd6^C3H/HeJ (NOD.C3-Idd6^C3H/HeJ)	decreased interferon-gamma secretion	J:137837
	decreased interleukin-4 secretion	J:137837
	decreased NK cell number	J:137837
\Idd6^C57BL/6/\Idd6^NOD (involves: C57BL/6 * NOD)	decreased T cell proliferation	J:72360
\Idd6^NOD/\Idd6^NOD (involves: C57BL/6 * NOD)	decreased T cell proliferation	J:72360
\Idd6^NOD/\Idd6^NOD (B6.NOD-Idd6)	abnormal NK cell physiology	J:85823
\Idd7^NOD/ShiLt/\Idd7^NOD/ShiLt (involves: C57BL/6 * NOD/ShiLt)	abnormal T cell clonal deletion	J:131557
\Idd9.1^C57BL/10SnJ/\Idd9.1^C57BL/10SnJ (NOD.B10-Idd9.1^C57BL/10SnJ)	increased NK T cell number	J:85823
\Idd9^NOD/Jsd/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
\Idd9^NOR/LtJ/? (involves: NOD/Jsd * NOR/LtJ)	pancreas inflammation	J:99002
\Idd10^NOD/ShiLt/\Idd10^NOD/ShiLt \Idd3^NOD/\Idd3^NOD (B6.NOD-Idd3^NOD Idd10^NOD/Lt)	abnormal cytokine secretion	J:85823
	abnormal NK T cell physiology	J:85823
\Idd13^NOD/ShiLt/\Idd13^NOD/ShiLt (B6.NOD-Idd13)	abnormal cytokine secretion	J:85823
\Idd13^NOD/ShiLt/\Idd13^NOD/ShiLt (B6.NOD-Idd13)	abnormal NK T cell physiology	J:85823
\Idd16.1^ALR/LtJ/\Idd16.1^ALR/LtJ (involves: ALR/LtJ * NOD/LtJ)	pancreas inflammation	J:98187
\Idh1^tm1Mak/\Idh1^tm1Mak \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:186700
	decreased B cell number	J:186700
	decreased CD4-positive, alpha-beta T cell number	J:186700
	decreased CD8-positive, alpha-beta T cell number	J:186700
	enlarged spleen	J:186700
	increased CD4-positive, alpha-beta T cell number	J:186700
\Idh1^tm2Mak/\Idh1^tm2Mak \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:186700
	decreased B cell number	J:186700
	decreased CD4-positive, alpha-beta T cell number	J:186700
	decreased CD8-positive, alpha-beta T cell number	J:186700
	enlarged spleen	J:186700
	increased CD4-positive, alpha-beta T cell number	J:186700
\Idh2^tm1Jwpk/\Idh2^tm1Jwpk (involves: 129S4/SvJae * C57BL/6)	increased osteoclast cell number	J:272241
\Idh3g^em1(IMPC)Bay/\Idh3g^em1(IMPC)Bay (C57BL/6N-Idh3g^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Ido1^tm1Alm/\Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal cytokine secretion	J:120813
	abnormal dendritic cell physiology	J:120813
\Ido1^tm1Alm/\Ido1^tm1Alm (involves: 129X1/SvJ * BALB/c)	abnormal cytokine level	J:170565
	decreased leukocyte cell number	J:170565
	epididymis inflammation	J:170565
\Ido1^tm1Alm/\Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6J * FVB/N)	decreased susceptibility to type IV hypersensitivity reaction	J:211949
	increased interferon-gamma secretion	J:211949
	increased interleukin-6 secretion	J:211949
	increased tumor necrosis factor secretion	J:211949
\Ido1^tm1Alm/\Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6J)	abnormal macrophage morphology	J:282516
\Ido1^tm1Alm/\Ido1^tm1Alm (involves: 129X1/SvJ * C57BL/6J)	abnormal macrophage physiology	J:282516
\Ido2^em1Lamn/\Ido2^em1Lamn (involves: BALB/c * C57BL/6J)	decreased susceptibility to type IV hypersensitivity reaction	J:342726
\Ido2^em1Lamn/\Ido2^em1Lamn \Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * C57BL/6J * SJL)	autoimmune arthritis	J:342726
\Ido2^em2Lamn/\Ido2^em2Lamn (involves: BALB/c * C57BL/6J)	decreased susceptibility to type IV hypersensitivity reaction	J:342726
\Ido2^em2Lamn/\Ido2^em2Lamn \Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * C57BL/6J * SJL)	autoimmune arthritis	J:342726
\Ido2^tm1.2Gcp/\Ido2^tm1.2Gcp (involves: C57BL/6J * FVB/N)	abnormal chemokine secretion	J:211949
	abnormal regulatory T cell physiology	J:211949
	decreased interferon-gamma secretion	J:211949
	decreased interleukin-6 secretion	J:211949
	decreased susceptibility to type IV hypersensitivity reaction	J:211949
	decreased tumor necrosis factor secretion	J:211949
\Ids^tm1Muen/Y (Not Specified)	abnormal lymph node morphology	J:108761
\Ids^tm1Muen/Y (involves: C57BL/6)	increased spleen weight	J:259752
\Idua^tm1Efn/\Idua^tm1Efn (involves: C57BL/6)	abnormal microglial cell morphology	J:81974
	abnormal microglial cell physiology	J:81974
	increased susceptibility to otitis media	J:123676
\Ier3^tm1Mxw/\Ier3^tm1Mxw (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:157504
	abnormal interleukin level	J:157504
	abnormal macrophage physiology	J:157504
	abnormal response to infection	J:157504
	abnormal tumor necrosis factor level	J:157504
	abnormal tumor necrosis factor secretion	J:157504
	decreased regulatory T cell number	J:157504
	impaired macrophage phagocytosis	J:157504
	increased granulocyte number	J:157504
	increased neutrophil cell number	J:157504
	increased susceptibility to parasitic infection	J:157504
\Ier3^tm1Mxw/\Ier3^tm1Mxw (involves: C57BL/6)	decreased susceptibility to induced colitis	J:194587
\Ier3^tm1Mxw/\Ier3^tm1Mxw (involves: C57BL/6)	increased T-helper 17 cell number	J:194587
\Ier3^tm1Mxw/\Ier3^tm1Mxw \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to induced colitis	J:194587
\If1^l/\If1^l (involves: BALB/c)	abnormal circulating interferon level	J:5113
\If1^l/\If1^l (involves: BALB/c)	abnormal response to infection	J:38004
\If1^l/\If1^l (B6.C-Ifi44l^H28-c If1^l/(HW81)aByJ)	abnormal response to infection	J:38004
\Ifi27l2a^{tm1(KOMP)Vlcg}/\Ifi27l2a^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	immune system phenotype	J:221531
\Ifi30^tm1Cres/\Ifi30^tm1Cres (involves: 129S1/Sv * C57BL/6)	abnormal professional antigen presenting cell physiology	J:72708
\Ifi35^em1Hhl/\Ifi35^em1Hhl (C57BL/6-Ifi35^em1Hhl)	decreased circulating interleukin-6 level	J:298909
	decreased circulating tumor necrosis factor level	J:298909
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:298909
	decreased susceptibility to endotoxin shock	J:298909
\Ifi44^{tm1b(KOMP)Wtsi}/\Ifi44^{tm1b(KOMP)Wtsi} (C57BL/6N-Ifi44^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Ifi44^{tm1b(KOMP)Wtsi}/\Ifi44^{tm1b(KOMP)Wtsi} (involves: C57BL/6N)	decreased CXCL10 secretion	J:297991
	decreased interleukin-1 beta secretion	J:297991
	increased CD8-positive, alpha-beta T cell number	J:297991
	increased susceptibility to Riboviria infection	J:297991
\Ifi47^tm1Gat/\Ifi47^tm1Gat (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:87535
	increased susceptibility to parasitic infection	J:87535
\Ifi204^tm1.1Cjul/\Ifi204^tm1.1Cjul (B6.129(Cg)-Ifi204^tm1.1Cjul)	decreased circulating interferon-beta level	J:270123
	decreased circulating interleukin-1 beta level	J:270123
	decreased circulating interleukin-6 level	J:270123
	decreased circulating tumor necrosis factor level	J:270123
	decreased interferon-beta secretion	J:270123
	decreased interleukin-6 secretion	J:270123
	decreased susceptibility to endotoxin shock	J:270123
	decreased tumor necrosis factor secretion	J:270123
\Ifi204^{tm1b(KOMP)Wtsi}/\Ifi204^{tm1b(KOMP)Wtsi} (involves: BALB/cJ * C57BL/6J * C57BL/6N)	immune system phenotype	J:354143
\Ifi207^{em1(IMPC)Wtsi}/\Ifi207⁺ (C57BL/6N-Ifi207^{em1(IMPC)Wtsi})	increased susceptibility to Retroviridae infection	J:354143
\Ifi207^{em1(IMPC)Wtsi}/\Ifi207^{em1(IMPC)Wtsi} (C57BL/6N-Ifi207^{em1(IMPC)Wtsi})	decreased interferon-beta secretion	J:354143
	immune system phenotype	J:354143
	increased susceptibility to Retroviridae infection	J:354143
\Ifi208^em1(IMPC)Mbp/\Ifi208^em1(IMPC)Mbp (C57BL/6N-Ifi208^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Ifih1^Rgsc422/\Ifih1⁺ (D2JJcl.B6JJcl-Ifih1^Rgsc422)	abnormal chemokine level	J:209917
	abnormal cytokine level	J:209917
	abnormal dendritic cell antigen presentation	J:209917
	abnormal leukocyte cell number	J:209917
	abnormal macrophage activation involved in immune response	J:209917
	abnormal T cell activation	J:209917
	autoimmune response	J:209917
	chronic liver inflammation	J:209917
	glomerulonephritis	J:209917
	increased anti-double stranded DNA antibody level	J:209917
	increased anti-nuclear antigen antibody level	J:209917
	increased dendritic cell number	J:209917
	increased granulocyte number	J:209917
	increased IgA level	J:209917
	increased IgG level	J:209917
	increased IgM level	J:209917
	increased immunoglobulin level	J:209917
	increased inflammatory response	J:209917
	increased macrophage cell number	J:209917
	increased plasma cell number	J:209917
	increased susceptibility to systemic lupus erythematosus	J:209917
	skin inflammation	J:209917
\Ifih1^Rgsc422/\Ifih1⁺ \Ifnar1^tm1Agt/\Ifnar1⁺ (involves: 129S2/SvPas * C57BL/6JJcl * DBA/2JJcl)	glomerulonephritis	J:209917
\Ifih1^Rgsc422/\Ifih1⁺ \Mavs^tm1Aki/\Mavs⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	glomerulonephritis	J:209917
\Ifih1^Rgsc422/\Ifih1⁺ \Mavs^tm1Aki/\Mavs^tm1Aki (involves: C57BL/6JJcl * DBA/2JJcl)	immune system phenotype	J:209917
\Ifih1^Rgsc422/\Ifih1^Rgsc422 (D2JJcl.B6JJcl-Ifih1^Rgsc422)	glomerulonephritis	J:209917
\Ifih1^Rgsc422/\Ifih1^Rgsc422 (D2JJcl.B6JJcl-Ifih1^Rgsc422)	increased susceptibility to systemic lupus erythematosus	J:209917
\Ifih1^tm1.1Cln/\Ifih1^tm1.1Cln (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:110201
	decreased interferon-alpha secretion	J:110201
	decreased interleukin-6 secretion	J:110201
	increased susceptibility to Picornaviridae infection	J:110201
\Ifih1^tm1.1Cln/\Ifih1^tm1.1Cln (involves: 129X1/SvJ)	decreased interferon-beta secretion	J:240099
\Ifih1^tm1Aki/\Ifih1^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:137522
	abnormal interferon level	J:137522
	abnormal interleukin level	J:137522
	increased susceptibility to Picornaviridae infection	J:137522
\Ifih1^tm1Aki/\Ifih1^tm1Aki \Ticam1^tm1Aki/\Ticam1^tm1Aki (involves: 129P2/OlaHsd)	abnormal interferon level	J:137522
	abnormal interleukin level	J:137522
\Ifit1^{tm1(KOMP)Vlcg}/\Ifit1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	increased susceptibility to Riboviria infection	J:187549
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:187549
\Ifit1^{tm1(KOMP)Vlcg}/\Ifit1^{tm1(KOMP)Vlcg} (involves: C57BL/6 * C57BL/6NTac)	abnormal interferon level	J:205203
	abnormal T cell physiology	J:205203
	brain inflammation	J:205203
	increased susceptibility to Coronaviridae infection	J:205203
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:205203
\Ifit2^tm1.1Ebsb/\Ifit2^tm1.1Ebsb (B6NCrl.129P2(C)-Ifit2^tm1.1Ebsb)	decreased circulating interleukin-1 beta level	J:199862
	decreased circulating interleukin-6 level	J:199862
	decreased circulating interleukin-12b level	J:199862
	decreased circulating tumor necrosis factor level	J:199862
	decreased interleukin-6 secretion	J:199862
	decreased tumor necrosis factor secretion	J:199862
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199862
\Ifit2^tm1.1Ebsb/\Ifit2^tm1.1Ebsb (B6.129P2(C)-Ifit2^tm1.1Ebsb)	enhanced humoral immune response	J:233986
	increased IgE level	J:233986
	increased IgG1 level	J:233986
	increased IgG3 level	J:233986
	increased IgM level	J:233986
\Ifit2^tm1.1Gcs/\Ifit2⁺ (involves: C57BL/6)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:195382
\Ifit2^tm1.1Gcs/\Ifit2^tm1.1Gcs (involves: C57BL/6)	increased susceptibility to Riboviria infection	J:195382
\Ifit2^tm1.1Gcs/\Ifit2^tm1.1Gcs (involves: C57BL/6)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:195382
\Ifitm1^tm1.1Ieg/\Ifitm1^tm1.1Ieg (B6.129P2-Ifitm1^tm1.1Ieg)	decreased granulocyte number	J:192287
	decreased T cell number	J:192287
	immune system phenotype	J:192287
	increased IgE level	J:192287
\Ifitm3^tm1Masu/\Ifitm3^tm1Masu (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to Orthomyxoviridae infection	J:183865
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:183865
	increased susceptibility to Riboviria infection	J:209781
\Ifitm5^em1Pmof/\Ifitm5⁺ (involves: CD-1)	abnormal osteoclast morphology	J:255349
\Ifna6^tm1Aki/\Ifna6⁺ \Myd88^tm1Aki/\Myd88^tm1Aki (involves: 129P2/OlaHsd)	abnormal plasmacytoid dendritic cell morphology	J:124340
	decreased interferon-alpha secretion	J:124340
\Ifnar1^m1Btlr/\Ifnar1^m1Btlr (C57BL/6J-Ifnar1^m1Btlr)	abnormal macrophage physiology	J:142790
	decreased interferon-alpha secretion	J:142790
	decreased interferon-beta secretion	J:142790
	immune system phenotype	J:142790
	increased susceptibility to Adenoviridae infection	J:142790
	increased susceptibility to Herpesvirales infection	J:142790
	increased susceptibility to Orthomyxoviridae infection	J:142790
	increased susceptibility to Riboviria infection	J:142790
\Ifnar1^m2Btlr/\Ifnar1^m2Btlr (involves: C57BL/6J)	decreased interferon-beta secretion	J:198556
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt (involves: 129S2/SvPas)	abnormal cytokine secretion	J:114555
	abnormal dendritic cell physiology	J:114555
	abnormal immunoglobulin level	J:101427
	abnormal inflammatory response	J:114555
	abnormal NK cell physiology	J:79552, J:139001
	immune system phenotype	J:286237
	impaired natural killer cell mediated cytotoxicity	J:79552
	increased susceptibility to Coronaviridae infection	J:144400
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:144400
	increased susceptibility to Herpesvirales infection	J:197569, J:81243
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:115139
	increased susceptibility to Paramyxoviridae infection	J:160878
	increased susceptibility to Paramyxoviridae infection induced morbidity/mortality	J:160878
	increased susceptibility to Picornaviridae infection	J:137522
	increased susceptibility to Poxviridae infection	J:101427
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt (involves: 129S2/SvPas * C57BL/6)	abnormal susceptibility to infection	J:120938
	immune system phenotype	J:238323
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt (B6.129S2-Ifnar1^tm1Agt)	abnormal osteoclast morphology	J:76097
	abnormal response to infection	J:116703
	decreased interferon-alpha secretion	J:125611
	decreased interferon-beta secretion	J:125611
	decreased interleukin-6 secretion	J:199862
	decreased tumor necrosis factor secretion	J:199862
	impaired natural killer cell mediated cytotoxicity	J:118750
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199862
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	increased susceptibility to Orthomyxoviridae infection	J:119783
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt (involves: 129S2/SvPas * 129S6/SvEvTac)	abnormal CD8-positive, alpha-beta T cell physiology	J:54482
	abnormal interferon-gamma secretion	J:54482
	increased circulating interleukin-12 level	J:54482
	increased susceptibility to Riboviria infection	J:54482
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt (involves: 129S2/SvPas * BALB/c)	abnormal cytokine level	J:291874
	abnormal mononuclear phagocyte morphology	J:291874
	decreased Ly6C high monocyte number	J:291874
	decreased susceptibility to Coronaviridae infection	J:291874
	decreased T cell apoptosis	J:291874
	increased CD4-positive, alpha-beta T cell number	J:291874
	increased CD8-positive, alpha-beta T cell number	J:291874
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:291874
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:291874
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Ifngr1^tm1Agt/\Ifngr1^tm1Agt (involves: 129S2/SvPas * 129S7/SvEvBrd)	abnormal immunoglobulin level	J:101427
	immune system phenotype	J:286237
	increased susceptibility to Herpesvirales infection	J:81243
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:115139
	increased susceptibility to Poxviridae infection	J:101427
	increased susceptibility to Togaviridae infection	J:81243
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Myd88^tm1Aki/\Myd88⁺ (B6.129-Myd88^tm1Aki Ifnar1^tm1Agt)	increased susceptibility to parasitic infection	J:140485
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Myd88^tm1Aki/\Myd88^tm1Aki (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal leukocyte migration	J:171379
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Myd88^tm1Aki/\Myd88^tm1Aki (B6.129-Myd88^tm1Aki Ifnar1^tm1Agt)	increased susceptibility to parasitic infection	J:140485
	increased susceptibility to parasitic infection induced morbidity/mortality	J:140485
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Otulin^{tm1c(EUCOMM)Hmgu}/\Otulin^{tm1c(EUCOMM)Hmgu} \Tg(KRT14-cre)1Cgn/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/6N * DBA/2)	dermatitis	J:312394
	immune system phenotype	J:312394
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Slamf1^tm1Oono/\Slamf1^tm1Oono (B6.129-Slamf1^tm1Oono Ifnar1^tm1Agt)	abnormal lymphopoiesis	J:117810
	increased susceptibility to Paramyxoviridae infection	J:117810
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Sp140^em1Vnce/\Sp140^em1Vnce (B6.Cg-Sp140^em1Vnce Ifnar1^tm1Agt)	immune system phenotype	J:313901
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Tg(CD46)373Zbz/\Tg(CD46)373Zbz (involves: 129S2/SvPas * C3H/He * C57BL/6)	brain inflammation	J:160878
	increased susceptibility to Paramyxoviridae infection	J:160878
	increased susceptibility to Paramyxoviridae infection induced morbidity/mortality	J:160878
	lung inflammation	J:160878
	meningitis	J:160878
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Tg(Hmgcr-MX1)LStae/\Tg(Hmgcr-MX1)LStae (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	decreased susceptibility to Orthomyxoviridae infection	J:119783
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:119783
\Ifnar1^tm1Agt/\Ifnar1^tm1Agt \Ythdf3^em1Caox/\Ythdf3^em1Caox (involves: C57BL/6J)	abnormal macrophage physiology	J:276397
\Ifnar1^tm1Pjh/\Ifnar1^tm1Pjh (involves: 129S2/SvPas * BALB/c)	abnormal macrophage physiology	J:36004
	increased leukocyte cell number	J:36004
	increased susceptibility to Picornaviridae infection	J:36004
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:36004
	increased susceptibility to Togaviridae infection	J:36004
	increased susceptibility to Togaviridae infection induced morbidity/mortality	J:36004
\Ifnar1^tm1Pjh/\Ifnar1^tm1Pjh (B6.129S2-Ifnar1^tm1Pjh)	decreased NK cell number	J:125812
\Ifnar1^tm1Pjh/\Ifnar1^tm1Pjh (B6.129S2-Ifnar1^tm1Pjh)	impaired natural killer cell mediated cytotoxicity	J:125812
\Ifnar2^m1Btlr/\Ifnar2^m1Btlr (C57BL/6J-Ifnar2^m1Btlr)	abnormal macrophage physiology	J:147329
	decreased interferon-alpha secretion	J:147329
	decreased interferon-beta secretion	J:147329
	increased susceptibility to Adenoviridae infection	J:147329
	increased susceptibility to Herpesvirales infection	J:147329
	increased susceptibility to Orthomyxoviridae infection	J:147329
	increased susceptibility to Riboviria infection	J:147329
\Ifnar2^tm1Pjh/\Ifnar2^tm1Pjh (B6.Cg-Ifnar2^tm1Pjh)	decreased NK cell number	J:125812
\Ifnar2^tm1Pjh/\Ifnar2^tm1Pjh (B6.Cg-Ifnar2^tm1Pjh)	impaired natural killer cell mediated cytotoxicity	J:125812
\Ifnar2^tm1Pjh/\Ifnar2^tm1Pjh (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:132662
	abnormal cytotoxic T cell physiology	J:132662
	decreased IgG1 level	J:132662
	decreased IgG2a level	J:132662
	decreased IgG level	J:132662
	decreased interferon-gamma secretion	J:132662
\Ifnar2^tm1Pjh/\Ifnar2^tm1Pjh \Il6st^tm1Ern/\Il6st^tm1Ern (involves: 129S1/Sv)	increased circulating interleukin-6 level	J:168781
	increased susceptibility to endotoxin shock	J:168781
\Ifnb1^tm1Acgp/\Ifnb1^tm1Acgp (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interferon-beta level	J:61048
	increased susceptibility to Poxviridae infection	J:61048
\Ifnb1^tm1Acgp/\Ifnb1^tm1Acgp (involves: 129P2/OlaHsd)	abnormal spleen primary B follicle morphology	J:86527
	decreased macrophage cell number	J:86527
	decreased mature B cell number	J:86527
	decreased monocyte cell number	J:86527
	decreased neutrophil cell number	J:86527
	decreased pro-B cell number	J:86527
	decreased tumor necrosis factor secretion	J:86527
	increased T cell proliferation	J:86527
\Ifnb1^tm1Acgp/\Ifnb1^tm1Acgp (B6.129P2-Ifnb1^tm1Acgp)	abnormal macrophage physiology	J:136368
\Ifnb1^tm1Acgp/\Ifnb1^tm1Acgp (B6.129P2-Ifnb1^tm1Acgp)	decreased interleukin-1 beta secretion	J:136368
\Ifnb1^tm1Tl/\Ifnb1^tm1Tl (B10.129P2-Ifnb1^tm1Tl)	abnormal macrophage physiology	J:83021
	abnormal microglial cell physiology	J:83021
	CNS inflammation	J:83021
	increased interferon-gamma secretion	J:83021
	increased interleukin-4 secretion	J:83021
	increased susceptibility to experimental autoimmune encephalomyelitis	J:83021
	increased tumor necrosis factor secretion	J:83021
\Ifnb1^tm1Tl/\Ifnb1^tm1Tl (B6.129P2-Ifnb1^tm1Tl)	decreased circulating interferon-alpha level	J:172226
	decreased circulating interferon-beta level	J:172226
	decreased susceptibility to bacterial infection	J:172226
\Ifnb1^tm1Ttg/\Ifnb1^tm1Ttg (B6.Cg-Ifnb1^tm1Ttg)	abnormal osteoclast morphology	J:76097
\Ifnb1^tm1Ttg/\Ifnb1^tm1Ttg (involves: C57BL/6)	abnormal response to infection	J:116703
\Ifnb1^tm2.1Lien/\Ifnb1^tm2.1Lien \Tg(Itgax-cre)1-1Reiz/0 \Tyr^c-2J/\Tyr^c-2J (involves: C57BL/6 * CBA)	immune system phenotype	J:172226
\Ifnb1^tm2.1Lien/\Ifnb1^tm2.1Lien \Tyr^c-2J/\Tyr^c-2J (involves: C57BL/6)	immune system phenotype	J:172226
\Ifnb1^tm2.1Lien/\Ifnb1^tm2.1Lien \Tyr^c-2J/\Tyr^c-2J \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interferon-alpha level	J:172226
	decreased circulating interferon-beta level	J:172226
	decreased susceptibility to bacterial infection	J:172226
\Ifne^tm1.2Pjh/\Ifne^tm1.2Pjh (involves: C57BL/6)	decreased NK cell number	J:197569
	increased susceptibility to bacterial infection	J:197569
	increased susceptibility to Herpesvirales infection	J:197569
\Ifng^tm1.1Hayg/\Ifng^tm1.1Hayg (involves: 129S4/SvJae * C57BL/6J)	abnormal B cell differentiation	J:220784
	abnormal circulating cytokine level	J:220784
	abnormal cytokine level	J:220784
	abnormal lymph node morphology	J:220784
	abnormal T cell activation	J:220784
	decreased leukocyte cell number	J:220784
	decreased mature B cell number	J:220784
	decreased pre-B cell number	J:220784
	increased T cell number	J:220784
	spleen atrophy	J:220784
	thymus atrophy	J:220784
\Ifng^tm1Lky/\Ifng^tm1Lky (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:189794
\Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:66802
	abnormal MHC II cell surface expression on macrophages	J:66802
	abnormal NK cell physiology	J:66802, J:115033
	abnormal type IV hypersensitivity reaction	J:55740
	decreased length of allograft survival	J:44346
	decreased susceptibility to parasitic infection	J:189794
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:189794
	immune system phenotype	J:119206
	increased splenocyte proliferation	J:66802
	increased susceptibility to bacterial infection	J:66802
\Ifng^tm1Ts/\Ifng^tm1Ts (NOD.129S7-Ifng^tm1Ts)	abnormal susceptibility to autoimmune disorder	J:33427
\Ifng^tm1Ts/\Ifng^tm1Ts (NOD.129S7-Ifng^tm1Ts)	decreased susceptibility to autoimmune diabetes	J:95105
\Ifng^tm1Ts/\Ifng^tm1Ts (NOD.Cg-Ifng^tm1Ts Prkdc^scid)	decreased susceptibility to autoimmune diabetes	J:72818
\Ifng^tm1Ts/\Ifng^tm1Ts (NOD.129S7(B6)-Ifng^tm1Ts/DvsJ)	abnormal cytotoxic T cell physiology	J:72818
	abnormal diapedesis	J:72818
	decreased susceptibility to autoimmune diabetes	J:72818
\Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd)	abnormal cytokine level	J:112600
	abnormal immunoglobulin level	J:29170
	abnormal response to infection	J:110721, J:29170
	decreased susceptibility to type IV hypersensitivity reaction	J:29170
	impaired natural killer cell mediated cytotoxicity	J:73948
	increased IgG1 level	J:110721
	increased interleukin-17 secretion	J:132905
	increased susceptibility to bacterial infection	J:110856
	increased susceptibility to bacterial infection induced morbidity/mortality	J:110856
	increased susceptibility to Herpesvirales infection	J:29170
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:29170
\Ifng^tm1Ts/\Ifng^tm1Ts (B6.129S7-Ifng^tm1Ts/J)	abnormal circulating cytokine level	J:47459
	abnormal cytokine secretion	J:120556
	abnormal dendritic cell antigen presentation	J:134949
	abnormal dendritic cell chemotaxis	J:134949
	abnormal dendritic cell physiology	J:134949
	abnormal humoral immune response	J:45665
	abnormal immune tolerance	J:45665
	abnormal immunoglobulin level	J:45665
	abnormal Langerhans cell physiology	J:134949
	abnormal macrophage chemotaxis	J:136628
	abnormal spleen morphology	J:47459
	abnormal spleen red pulp morphology	J:47459
	abnormal spleen white pulp morphology	J:47459
	abnormal type IV hypersensitivity reaction	J:45665
	decreased interferon-gamma secretion	J:120556
	decreased interleukin-10 secretion	J:120556, J:134949
	decreased length of allograft survival	J:44346
	enlarged mesenteric lymph nodes	J:50832
	enlarged spleen	J:47459
	glomerulonephritis	J:118730
	immune system phenotype	J:114783
	increased circulating interleukin-6 level	J:47459
	increased granulocyte number	J:47459
	increased interleukin-4 secretion	J:120556
	increased interleukin-12 secretion	J:134949
	increased leukocyte cell number	J:47459
	increased monocyte cell number	J:47459
	increased NK T cell number	J:122801
	increased susceptibility to bacterial infection	J:47459
	increased susceptibility to bacterial infection induced morbidity/mortality	J:47459
	increased susceptibility to parasitic infection	J:50832
	increased susceptibility to parasitic infection induced morbidity/mortality	J:50832
	increased susceptibility to type IV hypersensitivity reaction	J:118730
	pale spleen	J:47459
	stomach inflammation	J:120556
\Ifng^tm1Ts/\Ifng^tm1Ts (B6.129S7-Ifng^tm1Ts)	abnormal B cell physiology	J:112084
	abnormal cytokine secretion	J:18801, J:110826
	abnormal immunoglobulin level	J:18801
	abnormal lymph node cell ratio	J:112084
	abnormal response to infection	J:18801, J:110826
	abnormal response to transplant	J:42090
	decreased IgG2a level	J:18801
	decreased IgG3 level	J:18801
	increased CD8-positive, alpha-beta T cell number	J:112048
	increased IgE level	J:18801
	increased IgG1 level	J:18801, J:112048
	increased interleukin-2 secretion	J:112048
	increased interleukin-5 secretion	J:112048
	increased interleukin-10 secretion	J:112048
	increased susceptibility to Coronaviridae infection	J:112048
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:112048
	increased susceptibility to parasitic infection	J:18801
	increased susceptibility to parasitic infection induced morbidity/mortality	J:18801, J:110826
	increased T cell derived lymphoma incidence	J:77491
\Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to bacterial infection	J:15723
	increased susceptibility to bacterial infection induced morbidity/mortality	J:15723
\Ifng^tm1Ts/\Ifng^tm1Ts (C.129S7-Ifng^tm1Ts)	abnormal cytokine secretion	J:110826
	abnormal humoral immune response	J:45665
	abnormal immune tolerance	J:45665
	abnormal immunoglobulin level	J:45665
	abnormal response to infection	J:110826
	increased interleukin-5 secretion	J:110826
	increased susceptibility to bacterial infection induced morbidity/mortality	J:83180
	increased susceptibility to experimental autoimmune encephalomyelitis	J:34161
	increased susceptibility to parasitic infection	J:110826
	increased susceptibility to parasitic infection induced morbidity/mortality	J:110826
\Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd * NOD)	immune system phenotype	J:33427
\Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd * BALB/c)	abnormal susceptibility to infection	J:39478
	decreased IgE level	J:114213
	decreased inflammatory response	J:114213
	immune system phenotype	J:39881
\Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)	decreased anti-double stranded DNA antibody level	J:39600
	decreased anti-nuclear antigen antibody level	J:39600
	decreased autoantibody level	J:39600
	decreased IgA level	J:39600
	decreased IgG2a level	J:39600
	decreased IgG2b level	J:39600
	decreased IgG3 level	J:39600
	decreased IgM level	J:39600
	decreased immunoglobulin level	J:39600
	decreased susceptibility to autoimmune disorder	J:39600
\Ifng^tm1Ts/\Ifng^tm1Ts (C.129S7(B6)-Ifng^tm1Ts/J)	abnormal adaptive immunity	J:115144
	abnormal circulating cytokine level	J:47459
	abnormal cytokine secretion	J:115144
	abnormal cytotoxic T cell physiology	J:115144
	abnormal inflammatory response	J:115144
	abnormal macrophage physiology	J:115144
	abnormal NK cell physiology	J:115144
	abnormal spleen morphology	J:115144
	abnormal spleen red pulp morphology	J:47459
	abnormal spleen white pulp morphology	J:47459
	abnormal uterine NK cell morphology	J:56503
	abnormal uterine NK cell physiology	J:56503
	decreased susceptibility to parasitic infection	J:50832
	enlarged spleen	J:47459
	increased circulating interleukin-6 level	J:47459
	increased granulocyte number	J:47459
	increased leukocyte cell number	J:47459
	increased monocyte cell number	J:47459
	increased susceptibility to bacterial infection	J:47459
	increased susceptibility to bacterial infection induced morbidity/mortality	J:47459
	increased uterine NK cell number	J:56503
	pale spleen	J:47459
\Ifng^tm1Ts/\Ifng^tm1Ts (involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss)	decreased IgG2a level	J:119207
	decreased IgG level	J:119207
	decreased susceptibility to autoimmune disorder	J:119207
	increased IgG1 level	J:119207
\Ifng^tm1Ts/\Ifng^tm1Ts \Ldlr^tm1Her/\Ldlr^tm1Her (B6.129S7-Ldlr^tm1Her Ifng^tm1Ts)	increased T cell number	J:103072
\Ifng^tm1Ts/\Ifng^tm1Ts \Nlrp1a^Neut1/\Nlrp1a^Neut1 (involves: 129S7/SvEvBrd * C57BL/6)	brain inflammation	J:191055
	immune system phenotype	J:191055
\Ifng^tm1Ts/\Ifng^tm1Ts \Pld4^tm1.2Nemz/\Pld4^tm1.2Nemz (involves: 129 * 129S7/SvEvBrd * C57BL/6J * FVB/N)	decreased NK T cell number	J:281205
\Ifng^tm1Ts/\Ifng^tm1Ts \Socs1^tm1Jni/\Socs1^tm1Jni (involves: 129S7/SvEvBrd)	increased interleukin-17 secretion	J:132905
\Ifng^tm1Ts/\Ifng^tm1Ts \Socs1^tm1Wehi/\Socs1^tm1Wehi (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6)	enlarged thymus medulla	J:57474
\Ifng^tm1Ts/\Ifng^tm1Ts \Tg(SFTPC-Il18)AThos/0 (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N * DBA/2)	lung inflammation	J:147547
\Ifng^tm1Ts/\Ifng^tm1Ts \Tgfb1^tm1Doe/\Tgfb1^tm1Doe (C.129-Ifng^tm1Ts Tgfb1^tm1Doe)	liver inflammation	J:69346
\Ifng^tm1Ts/\Ifng^tm1Ts \Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)	immune system phenotype	J:196160
\Ifng^tm1Ts/\Ifng^tm1Ts \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6J)	small intestinal inflammation	J:108572
\Ifng^tm1Ts/\Ifng^tm1Ts \Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm1Blt \Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129P2/OlaHsd * 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)	abnormal lymph node cortex morphology	J:119206
	abnormal lymph node primary follicle morphology	J:119206
	abnormal lymph node secondary follicle morphology	J:119206
	absent lymph node germinal center	J:119206
	absent spleen germinal center	J:119206
	increased eosinophil cell number	J:119206
	increased leukocyte cell number	J:119206
	increased lymphocyte cell number	J:119206
	increased susceptibility to fungal infection	J:119206
	lung inflammation	J:119206
	small Peyer's patches	J:119206
\Ifng^tm1Yiw/\Ifng^tm1Yiw (involves: 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:41632, J:88226
\Ifng^tm1Yiw/\Ifng^tm1Yiw (B6.129X1-Ifng^tm1Yiw)	abnormal circulating interferon level	J:91691
	increased susceptibility to Coronaviridae infection	J:91691, J:50405
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:91691, J:50405
	liver inflammation	J:50405
	peritoneal inflammation	J:50405
\Ifng^tm1Yiw/\Ifng^tm1Yiw (C.129X1-Ifng^tm1Yiw)	abnormal circulating interferon level	J:91691
	increased susceptibility to Coronaviridae infection	J:91691
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:91691
\Ifngr1^m1Btlr/\Ifngr1^m1Btlr (C57BL/6J-Ifngr1^m1Btlr)	decreased macrophage cell number	J:236694
	decreased tumor necrosis factor secretion	J:236694
	increased B cell number	J:236694
\Ifngr1^tm1.1Rds/\Ifngr1^tm1.1Rds \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (B6NTac.Cg-Ifngr1^tm1.1Rds Commd10^{Tg(Vav1-icre)A2Kio})	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
\Ifngr1^tm1.1Rds/\Ifngr1^tm1.1Rds \Tg(Itgax-cre,-EGFP)4097Ach/0 (B6NTac.Cg-Ifngr1^tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach)	decreased interferon-gamma secretion	J:206257
	decreased interleukin-12b secretion	J:206257
	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
\Ifngr1^tm1.1Rost/\Ifngr1^tm1.1Rost (involves: BALB/cJ * C57BL/6)	abnormal chemokine level	J:152785
	decreased circulating interferon-gamma level	J:152785
	decreased circulating interleukin-12 level	J:152785
	immune system phenotype	J:152785
\Ifngr1^tm1.2Rds/\Ifngr1^tm1.2Rds (C57BL/6NTac-Ifngr1^tm1.2Rds)	decreased interleukin-12b secretion	J:206257
	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
\Ifngr1^tm1Agt/\Ifngr1^tm1Agt (involves: 129S7/SvEvBrd)	abnormal immunoglobulin level	J:38363, J:101427
	abnormal response to infection	J:115139
	abnormal uterine NK cell morphology	J:56503
	abnormal uterine NK cell physiology	J:56503
	aortitis	J:115139
	arteritis	J:115139
	decreased circulating tumor necrosis factor level	J:17878
	decreased IgG2a level	J:38363
	decreased susceptibility to endotoxin shock	J:17878
	increased circulating interferon-gamma level	J:314959
	increased circulating interleukin-1 beta level	J:314959
	increased circulating interleukin-6 level	J:174397
	increased interferon-gamma secretion	J:38363
	increased susceptibility to bacterial infection	J:314959, J:174397
	increased susceptibility to bacterial infection induced morbidity/mortality	J:314959, J:174397
	increased susceptibility to experimental autoimmune encephalomyelitis	J:38363
	increased susceptibility to Herpesvirales infection	J:81243
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:115139
	increased susceptibility to parasitic infection	J:114203
	increased susceptibility to Poxviridae infection	J:101427
	increased tumor necrosis factor secretion	J:38363
	increased uterine NK cell number	J:56503
\Ifngr1^tm1Agt/\Ifngr1^tm1Agt (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytotoxic T cell physiology	J:63815
	decreased IgG2a level	J:63815
	decreased IgG3 level	J:63815
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:53577
	increased interferon-gamma secretion	J:99347
	increased interleukin-6 secretion	J:99347
	increased splenocyte proliferation	J:99347
	increased susceptibility to bacterial infection	J:63815
	increased susceptibility to experimental autoimmune uveoretinitis	J:99347
	increased susceptibility to Riboviria infection	J:63815
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:63815
\Ifngr1^tm1Agt/\Ifngr1^tm1Agt (B6.129S7-Ifngr1^tm1Agt/J)	abnormal circulating chemokine level	J:152785
	abnormal lymphopoiesis	J:138728
	abnormal osteoclast differentiation	J:233116
	decreased CD4-positive, alpha-beta T cell number	J:138728
	decreased CD8-positive, alpha-beta T cell number	J:138728
	decreased circulating interleukin-12 level	J:152785
	decreased lymphocyte cell number	J:138728
	decreased susceptibility to bacterial infection	J:147443
	increased interferon-gamma secretion	J:138728
	increased susceptibility to graft versus host disease	J:138728
	spleen hypoplasia	J:138728
\Ifngr1^tm1Agt/\Ifngr1^tm1Agt (involves: 129S7/SvEvBrd * DBA/1OlaHsd)	decreased IgG2a level	J:40634
	increased susceptibility to induced arthritis	J:40634
\Ifngr1^tm1Agt/\Ifngr1^tm1Agt (129-Ifngr1^tm1Agt/J)	immune system phenotype	J:286237
\Ifngr1^tm1Agt/\Ifngr1^tm1Agt \Tg(GZMB-Tax)#Lera/0 (involves: 129S7/SvEvBrd * C57BL/6)	abnormal osteoclast differentiation	J:147601
	abnormal osteoclast physiology	J:147601
	increased osteoclast cell number	J:147601
\Ifngr1^tm1Dmer/\Ifngr1^tm1Dmer (B6.Cg-Ifngr1^tm1Dmer)	abnormal response to infection	J:202844
\Ifngr1^tm1Dmer/\Ifngr1^tm1Dmer \Tg(Thy1-cre)1Vln/0 (B6.Cg-Ifngr1^tm1Dmer Tg(Thy1-cre)1Vln)	abnormal response to infection	J:202844
\Ifngr2^tm1Pbro/\Ifngr2^tm1Pbro (involves: 129S1/Sv)	abnormal class switch recombination	J:48016
	abnormal T-helper 1 cell differentiation	J:48016
	decreased susceptibility to type IV hypersensitivity reaction	J:48016
	increased susceptibility to bacterial infection	J:48016
\Ifngr2^tm1Pbro/\Ifngr2^tm1Pbro (NOD.129S1-Ifngr2^tm1Pbro)	abnormal cytotoxic T cell physiology	J:72818
	abnormal diapedesis	J:72818
	abnormal T-helper 2 physiology	J:65986
	decreased susceptibility to autoimmune diabetes	J:72818
\Ifnk^{tm1.1(KOMP)Vlcg}/\Ifnk^{tm1.1(KOMP)Vlcg} (C57BL/6NTac-Ifnk^{tm1.1(KOMP)Vlcg})	decreased susceptibility to chemically induced skin inflammation	J:322130
	enlarged spleen	J:322130
\Ifnl3^em1Mtba/\Ifnl3^em1Mtba (involves: C57BL/6)	abnormal circulating interferon level	J:287260
	increased susceptibility to Orthomyxoviridae infection	J:287260
	increased susceptibility to Riboviria infection	J:287260
	increased susceptibility to viral infection	J:287260
\Ifnlr1^{tm1b(EUCOMM)Wtsi}/\Ifnlr1^{tm1b(EUCOMM)Wtsi} (B6(Cg)-Ifnlr1^{tm1b(EUCOMM)Wtsi})	increased susceptibility to Orthomyxoviridae infection	J:287260
	increased susceptibility to Riboviria infection	J:287260
	increased susceptibility to viral infection	J:287260
\Ifnlr1^tm1Palu/\Ifnlr1^tm1Palu (B6.Cg-Ifnlr1^tm1Palu)	abnormal susceptibility to infection	J:131989
\Ifnlr1^tm1Palu/\Ifnlr1^tm1Palu (involves: BALB/c * C57BL/6)	immune system phenotype	J:286237
\Ift70b^em1(IMPC)Bay/\Ift70b^em1(IMPC)Bay (C57BL/6N-Ift70b^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Ift140^b2b1283Clo/\Ift140^b2b1283Clo (C57BL/6J-Ift140^b2b1283Clo)	absent spleen	J:175213
\Iftap^tm1Mnz/\Iftap^tm1Mnz (Not Specified)	immune system phenotype	J:254587
\Igbp1^tm1Cbt/Y \Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte number	J:93221
\Igbp1^tm1Cbt/\Igbp1⁺ \Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte number	J:93221
\Igbp1^tm1Imku/Y \Tg(Lck-cre)I57Jxm/? (involves: 129P2/OlaHsd * ICR)	abnormal thymus cortex morphology	J:84395
	abnormal thymus corticomedullary boundary morphology	J:84395
	decreased double-negative T cell number	J:84395
	decreased T cell number	J:84395
	decreased thymocyte number	J:84395
\Igdcc4^em1Bcgen/\Igdcc4^em1Bcgen (involves: C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection	J:320015
\Igdcc4^em1Bcgen/\Igdcc4^em1Bcgen (involves: C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:320015
\Igf1^tm1.1Dlr/\Igf1^tm1.1Dlr \Tg(Ttr-IGF1)1Sykr/0 (FVB.Cg-Igf1^tm1.1Dlr Tg(Ttr-IGF1)1Sykr)	increased spleen weight	J:157350
\Igf1r^tm1Jcbr/\Igf1r^tm1Jcbr \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (B6.Cg-Ndor1^{Tg(UBC-cre/ERT2)1Ejb} Igf1r^tm1Jcbr)	decreased susceptibility to type I hypersensitivity reaction	J:241924
\Igf1r^tm2Arge/\Igf1r^tm2Arge \Tg(BGLAP-cre)1Clem/0 (involves: 129 * FVB/N)	abnormal osteoclast physiology	J:80190
	decreased osteoclast cell number	J:80190
\Igf1sl2^C3H/HeJ/\Igf1sl2^C3H/HeJ (B6.C3H-Igf1sl2^C3H/HeJ)	increased osteoclast cell number	J:111677
\Igf2^tm1Snha/\Igf2⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal osteoclast differentiation	J:167738
\Igf2bp1^{Gt(OST33739)Lex}/\Igf2bp1^{Gt(OST33739)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	spleen hypoplasia	J:89882
\Igfbp1^tm1Taub/\Igfbp1^tm1Taub (involves: 129X1/SvJ * C57BL/6)	liver inflammation	J:81123
\Igfbp2^tm1Jep/\Igfbp2^tm1Jep (either: (involves: 129P1/ReJ * 129S/SvEv) or (involves: 129S/SvEv * C57BL/6))	small spleen	J:64338
\Igh-7^tm1.1Lam/\Igh-7^tm1.1Lam (involves: BALB/c)	decreased IgE level	J:146733
\Igh-7^tm1.1Lam/\Igh-7^tm1.1Lam (involves: BALB/c)	decreased mature B cell number	J:146733
\Igh-7^tm1Gach/\Igh-7^tm1Gach (BALB/c-Igh-7^tm1Gach)	abnormal B cell number	J:143266
	enhanced B cell migration	J:143266
	increased IgE level	J:143266
	increased memory B cell number	J:143266
	increased plasma cell number	J:143266
\Igh-7^tm1Lam/\Igh-7^tm1Lam (involves: BALB/c)	decreased IgE level	J:146733
\Igh-7^tm1Lam/\Igh-7^tm1Lam (involves: BALB/c)	decreased mature B cell number	J:146733
\Igh-7^tm1Lcwu/\Igh-7^tm1Lcwu (involves: C57BL/6)	decreased IgE level	J:161452
\Igh-7^tm1Lcwu/\Igh-7^tm1Lcwu (involves: C57BL/6)	decreased mature B cell number	J:161452
\Igh-7^tm1Led/\Igh-7^tm1Led (involves: 129S4/SvJae * Black Swiss)	immune system phenotype	J:19552
\Igh-7^tm1Led/\Igh-7^tm1Led (C.129S4-Igh-7^tm1Led)	impaired eosinophil recruitment	J:133373
\Igh-7^tm1Led/\Igh-7^tm1Led \Lyn^tm1Ard/\Lyn^tm1Ard (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal circulating complement protein level	J:161523
	decreased B cell number	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgM level	J:161523
\Igh-8^tm1.1Aak/\Igh-8^tm1.1Aak (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:171251
\Igh-8^tm1Aak/\Igh-8^tm1Aak (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:107063
\Igh-8^tm1Schr/\Igh-8^tm1Schr (involves: 129P2/OlaHsd * Black Swiss)	increased IgM level	J:49847
\Igh-8^tm1Schr/\Igh-8^tm1Schr (C.129P2(BKSW)-Igh-8^tm1Schr)	increased IgG level	J:75577
	increased IgM level	J:75577
	increased susceptibility to bacterial infection	J:75577
\Igh-8^{tm2(Ighg1)Aak}/\Igh-8^{tm2(Ighg1)Aak} (involves: 129S2/SvPas)	abnormal class switch recombination	J:130574
	decreased IgG3 level	J:130574
\Igh-8^tm2.1Aak/\Igh-8^tm2.1Aak (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:171251
\Igh-J^{tm1(3H9-VDJ)Mwg}/\Igh-J^{tm1(3H9-VDJ)Mwg} (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell receptor editing	J:126940
\Igh-J^{tm1(CB20)Riho}/\Igh-J⁺ (involves: C57BL/10 * DBA/1)	abnormal B cell differentiation	J:179456
	decreased pre-B cell number	J:179456
	increased immature B cell number	J:179456
	increased marginal zone B cell number	J:179456
	increased mature B cell number	J:179456
	increased susceptibility to induced arthritis	J:179456
\Igh-J^{tm1(CB20)Riho}/\Igh-J^{tm1(CB20)Riho} (involves: C57BL/10 * DBA/1)	abnormal B cell differentiation	J:179456
	decreased pre-B cell number	J:179456
	increased immature B cell number	J:179456
	increased marginal zone B cell number	J:179456
	increased mature B cell number	J:179456
	increased susceptibility to induced arthritis	J:179456
\Igh-J^{tm1(Ighel)Cys}/\Igh-J^{tm1(Ighel)Cys} \Myd88^tm1Aki/\Myd88^tm1Aki \Igkj1^{tm1(IgkHyHEL10)Mnz}/0 (involves: 129P2/OlaHsd)	increased IgM level	J:115059
\Igh-J^{tm1(VDJ-KL25)Zbz}/\Igh-J⁺ (involves: C57BL/6 * C57BL/6J * BALB/cJ)	increased IgG level	J:86411
	increased IgM level	J:86411
\Igh-J^{tm1(VDJ-VI10)Zbz}/\Igh-J⁺ (involves: C57BL/6 * C57BL/6J * BALB/cJ)	abnormal immune serum protein physiology	J:86411
\Igh-J^tm1.1Lave/\Igh-J⁺ (Not Specified)	abnormal B cell differentiation	J:155798
	decreased B cell number	J:155798
	decreased immature B cell number	J:155798
	decreased mature B cell number	J:155798
	decreased spleen weight	J:155798
	decreased T cell number	J:155798
	decreased transitional stage B cell number	J:155798
	decreased transitional stage T1 B cell number	J:155798
	decreased transitional stage T2 B cell number	J:155798
	increased pre-B cell number	J:155798
	increased pro-B cell number	J:155798
\Igh-J^tm1.1Lave/\Igh-J^tm1.1Lave (Not Specified)	abnormal B cell differentiation	J:155798
	abnormal immunoglobulin level	J:179317
	arrested B cell differentiation	J:179317
	decreased B cell number	J:155798, J:179317
	decreased IgM level	J:155798
	decreased immature B cell number	J:155798
	decreased mature B cell number	J:155798
	decreased spleen weight	J:155798
	decreased T cell number	J:155798
	decreased transitional stage B cell number	J:155798
	decreased transitional stage T1 B cell number	J:155798
	decreased transitional stage T2 B cell number	J:155798
	increased IgG level	J:155798
	increased pre-B cell number	J:155798
	increased pro-B cell number	J:155798
\Igh-J^tm1.1Lave/\Igh-J^tm1.1Lave \Igk-J^tm1.1Lave/\Igk-J^tm1.1Lave (Not Specified)	abnormal B cell clonal deletion	J:179317
	abnormal B cell differentiation	J:205708
	abnormal B cell physiology	J:205708
	abnormal immunoglobulin level	J:179317
	arrested B cell differentiation	J:205708, J:179317
	decreased B cell number	J:205708, J:179317
	decreased immature B cell number	J:205708
	decreased mature B cell number	J:205708
\Igh-J^tm1.1Lave/\Igh-J^tm1.1Lave \Igk-J^tm1.1Lave/\Igk-J^tm1.1Lave \Tg(BCL2)22Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell differentiation	J:179317
\Igh-J^tm1Aigl/\Igh-J⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell morphology	J:111543
	decreased B cell number	J:111543
	decreased B-1 B cell number	J:111543
	increased susceptibility to experimental autoimmune encephalomyelitis	J:111543
\Igh-J^tm1Aigl/\Igh-J⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	increased susceptibility to experimental autoimmune encephalomyelitis	J:111543
\Igh-J^tm1Aigl/\Igh-J⁺ \Mog^tm1Dpd/\Mog^tm1Dpd \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)	CNS inflammation	J:151335
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
\Igh-J^tm1Aigl/\Igh-J⁺ \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	CNS inflammation	J:151335
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
\Igh-J^tm1Aigl/\Igh-J^tm1Aigl \Tg(H2-K^b-Tcra,-Tcrb)1640Kurs/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J)	increased autoantibody level	J:149511
	increased susceptibility to experimental autoimmune encephalomyelitis	J:149511
\Igh-J^tm1Cgn/\Igh^tm4Cgn \Tg(Cr2-cre)3Cgn/0 (Not Specified)	decreased B cell number	J:79299
	decreased follicular B cell number	J:79299
	decreased marginal zone B cell number	J:79299
\Igh-J^tm1Cgn/\Igh^tm4Cgn \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd)	decreased mature B cell number	J:157297
\Igh-J^tm1Cgn/\Igh^tm11.1Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:113434
\Igh-J^tm1Cgn/\Igh-J⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:64285
\Igh-J^tm1Cgn/\Igh^tm1Leck (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin light chain V-J recombination	J:144033
\Igh-J^tm1Cgn/\Igh-J^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	absent mature B cells	J:64285
	arrested B cell differentiation	J:64285
\Igh-J^tm1Dhu/\Igh^tm3Tim (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
\Igh-J^tm1Dhu/\Igh^tm3Tim (involves: 129 * C57BL/6)	decreased B cell number	J:102308
\Igh-J^tm1Dhu/\Igh^tm1Tim (involves: 129X1/SvJ * C57BL/6)	abnormal B cell differentiation	J:88410
	abnormal B cell morphology	J:87624
	abnormal immune system organ morphology	J:87624
	abnormal spleen marginal zone morphology	J:87624
	abnormal spleen morphology	J:87624
\Igh-J^tm1Dhu/\Igh^tm2Tim (involves: 129X1/SvJ * C57BL/6)	abnormal lymph node morphology	J:87624
	abnormal spleen morphology	J:87624
	decreased marginal zone B cell number	J:87624
\Igh-J^tm1Dhu/\Igh-J⁺ \Il2^tm1Hor/\Il2^tm1Hor (involves: 129/Sv * C57BL/6)	colitis	J:29999
	enlarged mesenteric lymph nodes	J:29999
\Igh-J^tm1Dhu/\Igh-J^{tm1(VDJ-17.2.25)Wabl} \Igk^tm1Dhu/\Igk^tm1Dhu (Not Specified)	abnormal B cell differentiation	J:33628
	abnormal immature B cell morphology	J:89757
\Igh-J^tm1Dhu/\Igh-J^tm1Dhu \Il2^tm1Hor/\Il2^tm1Hor (involves: 129/Sv * C57BL/6)	colitis	J:29999
	enlarged mesenteric lymph nodes	J:29999
\Igh-J^tm1Dhu/\Igh-J^tm1Dhu \Wdr1^rede/\Wdr1^rede (involves: 129S7/SvEvBrd * BALB/c * C57BL/6)	abnormal immune system physiology	J:134092
\Igh-J^tm1Dim/\Igh-J⁺ \Igk-J^tm1Dim/\Igk-J⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:107241
	increased IgG level	J:107241
	increased IgM level	J:107241
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell number	J:113083
	absent B cells	J:70038
	decreased IgM level	J:70038
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv (involves: 129P2/OlaHsd)	absent mature B cells	J:137738
	arrested B cell differentiation	J:137738
	increased late pro-B cell number	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv (involves: 129P2/OlaHsd)	absent B cells	J:23827
	absent mature B cells	J:137738, J:70620
	arrested B cell differentiation	J:137738, J:23827
	increased late pro-B cell number	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH1)2BJkbv/0 \Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
	increased mature B cell number	J:23827
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH1)2BJkbv/0 \Tg(IGK@yK1)9.2CJkbv/\Tg(IGK@yK1)9.2CJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH1)2BJkbv/\Tg(IGH@yH1)2BJkbv \Tg(IGK@yK1)9.2CJkbv/\Tg(IGK@yK1)9.2CJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH1)2BJkbv/\Tg(IGH@yH1)2BJkbv \Tg(IGK@yK2)J23.1Jkbv/\Tg(IGK@yK2)J23.1Jkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH2)J9.2Jkbv/0 \Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell morphology	J:70620
	abnormal immunoglobulin heavy chain V(D)J recombination	J:70620
	abnormal immunoglobulin level	J:70620
	abnormal immunoglobulin light chain V-J recombination	J:70620
	increased mature B cell number	J:70620
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH2)J9.2Jkbv/0 \Tg(IGK@yK2)J23.1Jkbv/\Tg(IGK@yK2)J23.1Jkbv (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	immune system phenotype	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH2BM)7Amgn/0 \Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
	decreased B cell number	J:139792
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yH2CM)2Amgn/0 \Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
	decreased B cell number	J:139792
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yHG1/2)1Amgn/0 \Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGH@yHG4)1Amgn/0 \Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:139792
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Tg(IGH@*)SALed/0 (involves: 129P2/OlaHsd)	decreased mature B cell number	J:137738
	immune system phenotype	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Tg(IGH@yH1)2BJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Tg(IGH@yH1)2BJkbv/0 \Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
	increased late pro-B cell number	J:23827
	increased mature B cell number	J:23827
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Tg(IGH@yH1)2BJkbv/\Tg(IGH@yH1)2BJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	decreased pre-B cell number	J:137738
	increased late pro-B cell number	J:137738
\Igh-J^tm1Jkbv/\Igh-J^tm1Jkbv \Tg(IGH@yH2)J9.2Jkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:137738
	decreased mature B cell number	J:137738
	immune system phenotype	J:137738
\Igh-J^tm1Khyk/\Igh-J⁺ (CB17.129X1-Igh-J^tm1Khyk)	increased B-1 B cell number	J:109979
\Igh-J^tm1Mcdl/\Igh-J^tm1Mcdl \Igk-J^tm1Mcdl/\Igk-J^tm1Mcdl \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(DO11.10)10Dlo/? (involves: 129S/Sv * BALB/c * C3H * C57BL/6)	abnormal spleen germinal center morphology	J:100072
	abnormal T cell differentiation	J:100072
	increased IgE level	J:100072
	increased IgG level	J:100072
\Igh-J^{tm2(3H9-VDJ)Mwg}/\Igh-J⁺ (involves: 129P2/OlaHsd BALB/c * C57BL/6)	abnormal B cell receptor editing	J:126940
	increased anti-double stranded DNA antibody level	J:126940
\Igh-J^{tm2(3H9-VDJ)Mwg}/\Igh-J⁺ (involves: 129P2/OlaHsd BALB/c)	abnormal B cell receptor editing	J:131138
	abnormal marginal zone B cell morphology	J:131138
	increased anti-double stranded DNA antibody level	J:131138
\Igh-J^{tm2(3H9-VDJ)Mwg}/\Igh-J⁺ (B6.129P2-Igh-J^{tm2(3H9-VDJ)Mwg})	decreased B cell number	J:142389
	increased anti-double stranded DNA antibody level	J:142389
	increased marginal zone B cell number	J:142389
	spleen hypoplasia	J:142389
\Igh-J^{tm2.1(4E10)Lave}/\Igh-J^{tm2.1(4E10)Lave} (involves: C57BL/6)	arrested B cell differentiation	J:205708
	decreased B-1a cell number	J:205708
	decreased IgG1 level	J:205708
	decreased IgG2b level	J:205708
	decreased IgG3 level	J:205708
	decreased IgG level	J:205708
	decreased IgM level	J:205708
\Igh-J^{tm2.1(4E10)Lave}/\Igh-J^{tm2.1(4E10)Lave} \Igk-J^{tm2.1(4E10)Lave}/\Igk-J^{tm2.1(4E10)Lave} (involves: C57BL/6)	abnormal B cell differentiation	J:205708
	abnormal B cell physiology	J:205708
	arrested B cell differentiation	J:205708
	decreased immature B cell number	J:205708
	decreased mature B cell number	J:205708
\Igh-J^{tm3(3H9-VDJ)Mwg}/\Igh-J^{tm3(3H9-VDJ)Mwg} (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell receptor editing	J:126940
	increased anti-double stranded DNA antibody level	J:126940
\Igh-J^{tm3.1(48d)Lave}/\Igh-J^{tm3.1(48d)Lave} (involves: C57BL/6)	decreased B-1a cell number	J:205708
	decreased IgG1 level	J:205708
	decreased IgG2b level	J:205708
	decreased IgM level	J:205708
	immune system phenotype	J:205708
\Igh-V7183^tm1Cgn/\Igh-V7183^tm1Cgn (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	immune system phenotype	J:112978
\Igh-V^{tm1(Igh-Vx24)Hmb}/\Igh-V^{tm1(Igh-Vx24)Hmb} (involves: 129/Sv * C57BL/6)	increased T cell derived lymphoma incidence	J:54380
\Igh-V^tm1Jjk/\Igh-V^tm1Jjk (involves: 129S4/SvJae * C57BL/6)	abnormal adaptive immunity	J:62284
	increased susceptibility to bacterial infection	J:62284
\Igh^deltaD/\Igh⁺ (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:95981
	decreased B cell number	J:95981
	decreased immunoglobulin level	J:95981
\Igh^deltaD/\Igh^deltaD (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:95981
	abnormal immunoglobulin level	J:95981
	abnormal spleen morphology	J:95981
	arrested B cell differentiation	J:95981
	decreased B cell number	J:95981
	decreased follicular B cell number	J:95981
	decreased IgG1 level	J:95981
	increased IgA level	J:95981
	increased marginal zone B cell number	J:95981
\Igh^deltaD/\Igh^tm11.1Cgn (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:113434
\Igh^tm1(IGH)Vlcg/\Igh^tm1(IGH)Vlcg \Igk^tm1(IGK)Vlcg/\Igk^tm1(IGK)Vlcg (involves: 129S6/SvEvTac * C57BL/6N)	immune system phenotype	J:208620
\Igh^{tm1(Ighppc1-5)Cche}/\Igh⁺ (B6.Cg-Igh^{tm1(Ighppc1-5)Cche})	immune system phenotype	J:138356
	increased autoantibody level	J:138356
\Igh^tm1(Myc)Janz/\Igh⁺ (involves: 129X1/SvJ * C57BL/6)	enlarged lymph nodes	J:96785
	enlarged spleen	J:96785
	increased B cell apoptosis	J:96785
	increased B cell proliferation	J:96785
	lymphoid hyperplasia	J:96785
\Igh^tm1(Myc)Janz/\Igh⁺ \Mdm4^tm1.1Wahl/\Mdm4^tm1.1Wahl (involves: 129S/Sv * C57BL/6)	enlarged lymph nodes	J:150341
	enlarged spleen	J:150341
	increased splenocyte proliferation	J:150341
\Igh^tm1(PAX5)Mbu/\Igh⁺ (B6.Cg-Igh^tm1(PAX5)Mbu)	abnormal lymph node morphology	J:118111
	abnormal spleen morphology	J:118111
	abnormal T cell differentiation	J:118111
	abnormal thymus morphology	J:118111
	decreased double-negative T cell number	J:118111
	decreased double-positive T cell number	J:118111
	enlarged lymph nodes	J:118111
	enlarged spleen	J:118111
	enlarged thymus	J:118111
	increased pro-B cell number	J:118111
	increased T cell derived lymphoma incidence	J:118111
	thymus hypoplasia	J:118111
\Igh^tm1(PAX5)Mbu/\Igh⁺ \Pax5^tm1Mbu/\Pax5^tm1Mbu (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)	abnormal B cell differentiation	J:118111
	decreased B cell number	J:118111
	immune system phenotype	J:118111
\Igh^tm1(PAX5)Mbu/\Igh^tm1(PAX5)Mbu (B6.Cg-Igh^tm1(PAX5)Mbu)	abnormal lymph node morphology	J:118111
	abnormal spleen morphology	J:118111
	abnormal T cell differentiation	J:118111
	abnormal thymus morphology	J:118111
	decreased double-negative T cell number	J:118111
	decreased double-positive T cell number	J:118111
	enlarged lymph nodes	J:118111
	enlarged spleen	J:118111
	enlarged thymus	J:118111
	increased pro-B cell number	J:118111
	increased T cell derived lymphoma incidence	J:118111
	thymus hypoplasia	J:118111
\Igh^{tm1(VH558)Mss}/\Igh⁺ (involves: FVB/N)	abnormal B cell differentiation	J:130421
\Igh^{tm1(VH558)Mss}/\Igh^{tm1(VH558)Mss} (involves: FVB/N)	abnormal B cell differentiation	J:130421
\Igh^{tm1.1(b12)Nemz}/\Igh^{tm1.1(b12)Nemz} (involves: C57BL/6N * FVB/N)	decreased IgM level	J:205766
	decreased immature B cell number	J:205766
	increased B cell number	J:205766
\Igh^{tm1.1(b12)Nemz}/\Igh^{tm1.1(b12)Nemz} \Igk^{tm1.1(b12)Nemz}/\Igk^{tm1.1(b12)Nemz} (involves: C57BL/6N * C57BL/6NTac * FVB/N)	decreased IgM level	J:205766
	decreased immature B cell number	J:205766
	immune system phenotype	J:205766
	increased B cell number	J:205766
\Igh^{tm1.1(Igh564)Tik}/\Igh^{tm1.1(Igh564)Tik} \Igk^{tm1(Igk564)Tik}/\Igk^{tm1(Igk564)Tik} (B6.129S4-Igk^{tm1(Igk564)Tik} Igh^{tm1(Igh564)Tik})	glomerulonephritis	J:113555
\Igh^{tm1.1(Rr361-HBB)Aak}/\Igh^{tm1.1(Rr361-HBB)Aak} (129.129S2(Cg)-Igh^{tm1.1(Rr361-HBB)Aak})	abnormal class switch recombination	J:333279
	decreased IgA level	J:333279
	decreased IgE level	J:333279
	decreased IgG1 level	J:333279
	decreased IgG2a level	J:333279
	decreased IgG2b level	J:333279
\Igh^{tm1.1(Tag)Rwhe}/\Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:150315
	enlarged spleen	J:150315
	increased B cell number	J:150315
	lymph node hyperplasia	J:150315
\Igh^tm1.1Hmj/\Igh^tm1.1Hmj (involves: 129S6/SvEvTac * C57BL/6J * FVB/N)	abnormal B cell differentiation	J:140486
	abnormal immunoglobulin heavy chain V(D)J recombination	J:140486
	decreased mature B cell number	J:140486
	immune system phenotype	J:140486
	spleen hypoplasia	J:140486
\Igh^tm1.1Hws/\Igh^tm1.1Hws (BALB/cJ-Igh^tm1.1Hws)	decreased IgM level	J:119391
	decreased immature B cell number	J:119391
	decreased immunoglobulin level	J:119391
	decreased pre-B cell number	J:119391
	increased late pro-B cell number	J:119391
\Igh^tm1.1Hws/\Igh^tm1.1Hws (involves: BALB/c)	decreased immature B cell number	J:142069
	decreased late pro-B cell number	J:142069
	increased early pro-B cell number	J:142069
	increased IgG3 level	J:142069
	increased IgM level	J:142069
\Igh^tm1.1Lnit/\Igh⁺ (involves: BALB/c * C57BL/6)	abnormal B cell differentiation	J:119484
\Igh^tm1.1Rsky/\Igh^tm1.1Rsky (BALB/c-Igh^tm1.1Rsky)	abnormal class switch recombination	J:125719
\Igh^tm1.1Rsky/\Igh^tm1.1Rsky (BALB/c-Igh^tm1.1Rsky)	decreased IgM level	J:125719
\Igh^tm1.1Twin/\Igh⁺ (involves: 129 * 129S4/SvJae * C57BL/6)	decreased pre-B cell number	J:174233
	increased pro-B cell number	J:174233
\Igh^tm1.1Twin/\Igh^tm1.1Twin (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:174233
	abnormal B cell morphology	J:174233
	abnormal B cell number	J:174233
	abnormal marginal zone B cell morphology	J:174233
	abnormal marginal zone B cell physiology	J:174233
	absent plasma cells	J:174233
	decreased B cell number	J:174233
	decreased B-1a cell number	J:174233
	decreased follicular B cell number	J:174233
	decreased IgG3 level	J:174233
	decreased IgG level	J:174233
	decreased IgM level	J:174233
	decreased immature B cell number	J:174233
	decreased mature B cell number	J:174233
	decreased transitional stage T2 B cell number	J:174233
	immune system phenotype	J:174233
\Igh^tm1.1Twin/\Igh^tm1.1Twin \Plcg2^Ali5/\Plcg2⁺ (involves: 129 * 129S4/SvJae * C3HeB/FeJ * C57BL/6)	immune system phenotype	J:174233
	increased B-1a cell number	J:174233
\Igh^tm1.1Twin/\Igh^tm1.1Twin \Siglecg^tm1Lnit/\Siglecg^tm1Lnit (involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)	immune system phenotype	J:174233
\Igh^tm1.1Vmd/\Igh⁺ (involves: C57BL/6)	abnormal class switch recombination	J:201147
\Igh^tm1.1Vmd/\Igh^tm1.1Vmd (involves: C57BL/6)	abnormal class switch recombination	J:201147
	decreased IgG1 level	J:201147
	decreased IgG3 level	J:201147
	immune system phenotype	J:201147
	increased IgE level	J:201147
\Igh^tm1.2Rsky/\Igh⁺ (BALB/c-Igh^tm1.2Rsky)	increased IgG1 level	J:125719
\Igh^tm1.2Rsky/\Igh⁺ \Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: BALB/c * C57BL/6)	decreased mature B cell number	J:125719
\Igh^tm1.2Rsky/\Igh^tm1.2Rsky (BALB/c-Igh^tm1.2Rsky)	abnormal B cell activation	J:125719
	abnormal B cell morphology	J:125719
	abnormal B cell proliferation	J:125719
	abnormal mature B cell morphology	J:125719
	decreased B-1a cell number	J:125719
	decreased IgA level	J:125719
	decreased IgD level	J:125719
	decreased IgE level	J:125719
	decreased IgM level	J:125719
	decreased immunoglobulin level	J:125719
	decreased pre-B cell number	J:125719
	decreased transitional stage B cell number	J:125719
	increased marginal zone B cell number	J:125719
	increased pro-B cell number	J:125719
\Igh^tm1.2Rsky/\Igh^tm1.2Rsky \Tg(CD19-cre/ERT2)1Cgn/? (involves: BALB/c)	abnormal B cell activation	J:125719
	abnormal class switch recombination	J:125719
\Igh^tm1Aak/\Igh^tm1Aak (Not Specified)	abnormal B cell differentiation	J:158402
	decreased B cell number	J:158402
	decreased pre-B cell number	J:158402
	increased pro-B cell number	J:158402
\Igh^tm1Cgn/\Igh⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:79556
\Igh^tm1Cgn/\Igh^tm2Cgn (involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)	abnormal B cell differentiation	J:79556
\Igh^tm1Cog/\Igh^tm1Cog (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:80654
	absent B cells	J:80654
	arrested B cell differentiation	J:80654
	decreased IgA level	J:80654
	decreased IgE level	J:80654
	decreased IgG1 level	J:80654
	decreased IgG2a level	J:80654
	decreased IgG2b level	J:80654
	decreased IgG3 level	J:80654
	decreased IgM level	J:80654
	decreased immunoglobulin level	J:80654
\Igh^tm1Cys/\Igh⁺ \Tg(Igk)5Cys/0 (B6.Cg-Igh^tm1Cys Tg(Igk)5Cys)	abnormal B cell physiology	J:118931
	immune system phenotype	J:118931
\Igh^tm1Cys/\Igh⁺ \Tg(Igk)5Cys/0 \Tg(UBC-GFP)30Scha/\Tg(UBC-GFP)30Scha (involves: 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:118931
\Igh^tm1Emo/\Igh^tm1Emo (involves: 129S1/Sv * C57BL/6 * FVB/N)	immune system phenotype	J:108098
\Igh^tm1Kplm/\Igh⁺ (involves: A/WySnJ * BALB/c)	abnormal B-1 B cell morphology	J:115788
\Igh^tm1Kplm/\Igh⁺ (Not Specified)	abnormal B cell differentiation	J:115292
\Igh^tm1Kplm/\Igh⁺ (Not Specified)	increased B cell number	J:115292
\Igh^tm1Kplm/\Igh⁺ \Tg(Igk-V4CH27)1-2Shc/0 (involves: C57BL/6 * SJL)	increased B cell number	J:115292
\Igh^tm1Kplm/\Igh^tm3Cgn (involves: C57BL/6)	abnormal B cell differentiation	J:115292
\Igh^tm1Kplm/\Igh^tm3Cgn (involves: C57BL/6)	abnormal B cell number	J:115292
\Igh^tm1Kplm/\Igh^tm4Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:115292
	abnormal B cell number	J:115292
	abnormal B-1 B cell morphology	J:115292
\Igh^tm1Kplm/\Igh^tm4Cgn \Tg(Igk-V4CH27)1-2Shc/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	increased B cell number	J:115292
\Igh^tm1Ktom/\Igh^tm1Ktom (involves: ICR)	abnormal B cell physiology	J:59894
	abnormal immunoglobulin level	J:178635
	absent mature B cells	J:178635
\Igh^tm1Ktom/\Igh^tm1Ktom \Igk^tm1Ktom/\Igk^tm1Ktom \Tc(HSA14)SC20Ktom/0 \Tc(HSA2)W23Ktom/0 (involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)	abnormal B cell physiology	J:59894
\Igh^tm1Ktom/\Igh^tm1Ktom \Tc(HSA2)W23Ktom/0 (involves: C57BL/6NCrlj * CBA/JNCrlj * ICR)	abnormal B cell physiology	J:59894
\Igh^tm1Leck/\Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:144033
	abnormal B-1a B cell morphology	J:144033
	abnormal immature B cell morphology	J:144033
	abnormal immunoglobulin light chain V-J recombination	J:144033
	abnormal mature B cell morphology	J:144033
\Igh^tm1Leck/\Igh^tm1Leck (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:144033
\Igh^tm1Mnz/\Igh^tm1Mnz (B6.129P2-Igh^tm1Mnz)	abnormal B cell physiology	J:75653
	increased B cell apoptosis	J:75653
	increased B cell proliferation	J:75653
	increased IgG level	J:75653
	increased IgM level	J:75653
\Igh^tm1Mnz/\Igh^tm1Mnz \Dis3^tm1.1Uba/\Dis3^tm1.1Uba \Aicda^tm1(cre)Uba/\Aicda⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	abnormal somatic hypermutation frequency	J:302856
\Igh^tm1Mnz/\Igh^tm1Mnz \Lyn^tm1Sor/\Lyn^tm1Sor (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal B cell physiology	J:75653
	increased B cell proliferation	J:75653
\Igh^tm1Rbr/\Igh⁺ (C57BL/6-Igh^tm1Rbr)	abnormal B cell morphology	J:132538
\Igh^tm1Rbr/\Igh⁺ \Tg(IgkHyHEL10)1Rbr/0 (involves: C57BL/6)	abnormal B cell morphology	J:132538
	abnormal B-2 B cell morphology	J:132538
	increased IgA level	J:132538
	increased IgG1 level	J:132538
	increased IgG2a level	J:132538
	increased IgG2b level	J:132538
	increased IgG3 level	J:132538
	increased IgM level	J:132538
	increased immature B cell number	J:132538
	increased immunoglobulin level	J:132538
\Igh^tm1Rbr/\Igh⁺ \Tg(IgkHyHEL10)1Rbr/0 \Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6 * C57BL/6JSfd)	abnormal B cell anergy	J:132538
	abnormal B cell morphology	J:132538
	decreased follicular B cell number	J:132538
	decreased marginal zone B cell number	J:132538
	increased immature B cell number	J:132538
\Igh^tm2(IGH)Vlcg/\Igh^tm2(IGH)Vlcg \Igk^tm2(IGK)Vlcg/\Igk^tm2(IGK)Vlcg (involves: 129S6/SvEvTac * C57BL/6N)	immune system phenotype	J:208620
\Igh^{tm2.1(4E10)Nemz}/\Igh^{tm2.1(4E10)Nemz} \Igk^{tm2.1(4E10)Nemz}/\Igk^{tm2.1(4E10)Nemz} (involves: C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)	decreased B cell number	J:101977
	decreased IgG level	J:101977
	decreased IgM level	J:101977
\Igh^{tm2.1(Tag)Rwhe}/\Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:150315
	enlarged spleen	J:150315
	increased B cell number	J:150315
	lymph node hyperplasia	J:150315
\Igh^tm2.1Fwa/\Igh^tm2.1Fwa (involves: 129S/SvEv * C57BL/6)	abnormal class switch recombination	J:161437
	abnormal somatic hypermutation frequency	J:161437
	decreased IgG1 level	J:161437
	decreased mature B cell number	J:161437
	immune system phenotype	J:161437
	increased IgE level	J:161437
\Igh^tm2.1Hws/\Igh^tm2.1Hws (involves: BALB/c * C57BL/6NCrl * DBA/2NCrl)	abnormal humoral immune response	J:124421
	decreased B cell number	J:124421
	decreased B-1a cell number	J:124421
	decreased B-1b cell number	J:124421
	decreased follicular B cell number	J:124421
	decreased IgG level	J:124421
	decreased IgM level	J:124421
	decreased pre-B cell number	J:124421
	decreased transitional stage B cell number	J:124421
	increased early pro-B cell number	J:124421
	increased marginal zone B cell number	J:124421
\Igh^tm2.1Hws/\Igh^tm2.1Hws (involves: BALB/c)	abnormal B cell differentiation	J:142069
	decreased B-1a cell number	J:142069
	decreased follicular B cell number	J:142069
	decreased IgM level	J:142069
	decreased immature B cell number	J:142069
	decreased late pro-B cell number	J:142069
	decreased mature B cell number	J:142069
	decreased transitional stage B cell number	J:142069
	increased anti-nuclear antigen antibody level	J:142069
	increased early pro-B cell number	J:142069
	increased marginal zone B cell number	J:142069
\Igh^tm2Cgn/\Igh⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)	abnormal B cell differentiation	J:79556
\Igh^tm2Cgn/\Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin light chain V-J recombination	J:144033
\Igh^tm2Cgn/\Igh⁺ \Igk^tm1Rsky/\Igk⁺ (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))	abnormal B cell differentiation	J:111431
	absent pre-B cells	J:111431
\Igh^tm2Cgn/\Igh⁺ \Igk^tm2Rsky/\Igk⁺ (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:150435
\Igh^tm2Cgn/\Igh⁺ \Igk^tm2Rsky/\Igk⁺ \Prkdc^scid/\Prkdc^scid (involves: 129P2/OlaHsd * BALB/c * C57BL/Ka)	abnormal class switch recombination	J:150435
\Igh^tm2Cgn/\Igh⁺ \Rr158^tm1Cgn/\Rr158^tm1Cgn \Arhgef1^tm1.1Rmt/\Arhgef1^tm1.1Rmt (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell migration	J:113295
\Igh^tm2Cgn/\Igh⁺ \Xrcc6^tm1Fwa/\Xrcc6^tm1Fwa (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:44361
\Igh^tm2Cgn/\Igh^tm2Cgn \Igk^tm1Rsky/\Igk^tm1Rsky \Lig4^tm1Fwa/\Lig4^tm1Fwa \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)	abnormal class switch recombination	J:126758
\Igh^tm2Cgn/\Igh^tm2Cgn \Igk^tm1Rsky/\Igk^tm1Rsky \Trp53^tm1Tyj/\Trp53^tm1Tyj \Xrcc4^tm1Fwa/\Xrcc4^tm1Fwa (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac)	abnormal class switch recombination	J:126758
\Igh^tm2Cgn/\Igh^tm3Cgn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/Ka)	abnormal B cell differentiation	J:79556
\Igh^tm2Cgn/\Igh^tm4.1Fwa (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal immunoglobulin V(D)J recombination	J:176649
\Igh^tm2Emo/\Igh^tm2Emo (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:108098
	absent pre-B cells	J:108098
\Igh^tm2Mnz/\Igh^tm2Mnz (B6.129P2-Igh^tm2Mnz)	increased B cell proliferation	J:75653
	increased IgG level	J:75653
	increased IgM level	J:75653
\Igh^tm2Mnz/\Igh^tm2Mnz \Lyn^tm1Sor/\Lyn^tm1Sor (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal B cell physiology	J:75653
	increased B cell proliferation	J:75653
\Igh^tm2Rsky/\Igh⁺ \Igk^tm1Rsky/\Igk⁺ (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))	abnormal B cell differentiation	J:111431
\Igh^tm2Rsky/\Igh⁺ \Igk^tm2Rsky/\Igk⁺ (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * BALB/c))	abnormal B cell differentiation	J:111431
\Igh^{tm3.1(IGH)Vlcg}/\Igh^{tm3.1(IGH)Vlcg} \Igk^{tm3.1(IGK)Vlcg}/\Igk^{tm3.1(IGK)Vlcg} (involves: 129S6/SvEvTac * C57BL/6N)	immune system phenotype	J:208620
\Igh^tm3.1Tim/\Igh⁺ (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
\Igh^tm3.1Tim/\Igh⁺ (involves: 129 * C57BL/6)	abnormal spleen B cell follicle morphology	J:102308
\Igh^tm3Cgn/\Igh⁺ (involves: C57BL/6)	abnormal B cell differentiation	J:79556, J:115292
\Igh^tm3Cgn/\Igh^tm3Cgn (involves: C57BL/6)	abnormal immune system physiology	J:76117
\Igh^tm3Cgn/\Igh^tm3Cgn (involves: C57BL/6)	decreased immature B cell number	J:76117
\Igh^tm3Hws/\Igh^tm3Hws (BALB/c-Igh^tm3Hws)	abnormal immunoglobulin heavy chain V(D)J recombination	J:142068
\Igh^tm3Hws/\Igh^tm3Hws (involves: BALB/c)	abnormal immunoglobulin level	J:142069
	decreased B cell number	J:142069
	decreased follicular B cell number	J:142069
	decreased IgG1 level	J:142069
	decreased IgG2a level	J:142069
	decreased IgG2b level	J:142069
	decreased IgM level	J:142069
	decreased immature B cell number	J:142069
	decreased late pro-B cell number	J:142069
	decreased mature B cell number	J:142069
	decreased transitional stage B cell number	J:142069
	increased IgM level	J:142069
	spleen hypoplasia	J:142069
\Igh^tm3Mnz/\Igh^tm4.1Mnz (involves: C57BL/6)	immune system phenotype	J:159173
\Igh^tm3Tim/\Igh⁺ (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
\Igh^tm3Tim/\Igh⁺ (involves: 129 * C57BL/6)	abnormal spleen B cell follicle morphology	J:102308
\Igh^tm4.1Cog/\Igh^tm4.1Cog (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal class switch recombination	J:184094
	decreased IgA level	J:184094
	immune system phenotype	J:184094
	increased IgM level	J:184094
\Igh^tm4.1Fwa/\Igh⁺ (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
\Igh^tm4.1Fwa/\Igh⁺ (involves: 129S6/SvEvTac)	abnormal immunoglobulin V(D)J recombination	J:176649
\Igh^tm4.1Fwa/\Igh^tm4.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
\Igh^tm4.1Fwa/\Igh^tm4.1Fwa (involves: 129S6/SvEvTac)	abnormal immunoglobulin V(D)J recombination	J:176649
\Igh^tm4Cgn/\Igh⁺ (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:115292
\Igh^tm4Cog/\Igh⁺ (involves: 129S2/SvPas * C57BL/6)	decreased IgM level	J:109988
\Igh^tm4Cog/\Igh⁺ (involves: 129S2/SvPas * C57BL/6)	increased IgA level	J:109988
\Igh^tm4Cog/\Igh^tm4Cog (involves: 129S2/SvPas * C57BL/6)	absent Peyer's patches	J:109988
	absent spleen germinal center	J:109988
	small spleen	J:109988
\Igh^tm5.1Cgn/\Igh^tm5.1Cgn (BALB/c-Igh^tm5.1Cgn)	abnormal B cell activation	J:88472
	abnormal B cell differentiation	J:88472
	abnormal gut-associated lymphoid tissue morphology	J:88472
	abnormal lymph node germinal center morphology	J:88472
	abnormal mature B cell morphology	J:88472
	abnormal Peyer's patch germinal center morphology	J:88472
	absent B-1 B cells	J:88472
	absent B-1a cells	J:88472
	absent B-1b cells	J:88472
	absent spleen germinal center	J:88472
	decreased B cell number	J:88472
	decreased immature B cell number	J:88472
	decreased marginal zone B cell number	J:88472
	increased pro-B cell number	J:88472
\Igh^tm5.1Fwa/\Igh⁺ (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
	decreased pre-B cell number	J:176649
	immune system phenotype	J:176649
\Igh^tm5.1Fwa/\Igh^tm5.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:176649
	decreased pre-B cell number	J:176649
	immune system phenotype	J:176649
\Igh^tm5Cgn/\Igh^tm5Cgn (involves: BALB/c)	absent B cells	J:88472
\Igh^tm5Cgn/\Igh^tm5Cgn (involves: BALB/c)	arrested B cell differentiation	J:88472
\Igh^tm5Cgn/\Igh^tm5Cgn \Tg(CD19-cre/ERT2)1Cgn/0 (C.Cg-Igh^tm5Cgn Tg(CD19-cre/ERT2)1Cgn)	abnormal B cell differentiation	J:88472
	abnormal mature B cell morphology	J:88472
	abnormal Peyer's patch germinal center morphology	J:88472
	absent follicular B cells	J:88472
	absent marginal zone B cells	J:88472
	increased B cell number	J:88472
	increased pro-B cell number	J:88472
\Igh^tm6Fwa/\Igh^tm6Fwa (Not Specified)	immune system phenotype	J:176649
\Igh^{tm7(VHB1-8)Cgn}/\Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:48835
\Igh^tm7.1Fwa/\Igh^tm7.1Fwa (Not Specified)	immune system phenotype	J:176649
\Igh^{tm8(VHB1-8)Cgn}/\Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:48835
\Igh^{tm9(VHB1-8)Cgn}/\Igh⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:48835
\Igh^tm11.1Cgn/\Igh^tm11.1Cgn (Not Specified)	abnormal B cell differentiation	J:113434
	decreased B cell number	J:113434
	decreased immature B cell number	J:113434
	decreased mature B cell number	J:113434
	increased pro-B cell number	J:113434
\Igh^tm12Cgn/\Igh^tm12Cgn (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:66031
\Igha^tm1(Myc)Janz/\Igha⁺ (involves: 129S1/Sv * C57BL/6)	increased B cell apoptosis	J:90901
	increased B cell proliferation	J:90901
	increased plasma cell number	J:90901
\Igha^tm1(Myc)Janz/\Igha⁺ \Tg(Igk-V21-Bax)1967Bvn/0 (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal B cell apoptosis	J:90901
	abnormal plasma cell morphology	J:90901
	enlarged spleen	J:90901
	increased IgG level	J:90901
	increased IgM level	J:90901
	increased plasma cell number	J:90901
\Igha^tm1(Myc)Janz/\Igha⁺ \Tg(Tnfsf13b)1Fma/0 (involves: 129S1/Sv * C57BL/6 * DBA/2J)	enlarged spleen	J:166158
	increased B cell number	J:166158
	increased lymphocyte cell number	J:166158
	increased mature B cell number	J:166158
	increased spleen white pulp amount	J:166158
\Igha^tm1Grh/\Igha^tm1Grh (involves: 129S7/SvEvBrd * C57BL/6)	abnormal dendritic cell physiology	J:125472
	abnormal immunoglobulin level	J:125472
	abnormal memory T cell physiology	J:125472
	abnormal T cell activation	J:53217
	decreased IgA level	J:53217, J:125472
	decreased IgE level	J:53217
	decreased IgG3 level	J:53217
	decreased interferon-gamma secretion	J:53217
	decreased T cell proliferation	J:125472
	immune system phenotype	J:53218
	increased IgG1 level	J:53217, J:125472
	increased IgG2a level	J:53217
	increased IgG2b level	J:53217
	increased IgG level	J:53217
	increased IgM level	J:53217, J:125472
	increased interferon-gamma secretion	J:125472
	increased interleukin-4 secretion	J:53217
	increased susceptibility to Orthomyxoviridae infection	J:125472
\Igha^tm1Grh/\Igha^tm1Grh (involves: 129 * C57BL/6)	increased susceptibility to parasitic infection	J:140515, J:74568
\Igha^tm1Grh/\Igha^tm1Grh \Tg(Tnfsf13b)1Fma/\Tg(Tnfsf13b)1Fma (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	immune system phenotype	J:178227
\Igha^tm2Grh/\Igha^tm2Grh (involves: 129S7/SvEvBrd * C57BL/6)	abnormal class switch recombination	J:72521
\Ighd^dmit/\Ighd^dmit (C57BL/6JAnu-Ighd^dmit/AnuApb)	abnormal immunoglobulin level	J:104190
\Ighd^M1Btlr/\Ighd⁺ (C57BL/6J-Ighd^M1Btlr)	decreased B cell number	J:255202
\Ighd^M1Btlr/\Ighd^M1Btlr (C57BL/6J-Ighd^M1Btlr)	decreased B cell number	J:255202
\Ighd^M1Btlr/\Ighd^M1Btlr (C57BL/6J-Ighd^M1Btlr)	decreased IgD level	J:255202
\Ighd^m2Btlr/\Ighd⁺ (C57BL/6J-Ighd^m2Btlr)	decreased B cell number	J:255203
\Ighd^m2Btlr/\Ighd^m2Btlr (C57BL/6J-Ighd^m2Btlr)	decreased B cell number	J:255203
\Ighd^m2Btlr/\Ighd^m2Btlr (C57BL/6J-Ighd^m2Btlr)	decreased IgD level	J:255203
\Ighd^tm1Cgn/\Ighd^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:64281
	decreased IgE level	J:64281
\Ighd^tm1Lam/\Ighd⁺ (involves: 129S2/SvPas * C57BL/6)	decreased B cell number	J:111020
\Ighd^tm1Lam/\Ighd^tm1Lam (involves: 129S2/SvPas * C57BL/6)	abnormal B cell physiology	J:111020
	abnormal leukopoiesis	J:111020
	decreased IgG2b level	J:111020
	increased IgA level	J:111020
\Ighe^M1Btlr/\Ighe^M1Btlr (C57BL/6J-Ighe^M1Btlr)	decreased IgE level	J:267480
\Ighg1^em1Wliu/\Ighg1^em1Wliu (C57BL/6-Ighg1^em1Wliu)	abnormal plasma cell differentiation	J:266937
	enhanced humoral immune response	J:266937
	increased anti-double stranded DNA antibody level	J:266937
	increased anti-nuclear antigen antibody level	J:266937
	increased autoantibody level	J:266937
	increased germinal center B cell number	J:266937
	increased IgG1 level	J:266937
	increased plasma cell number	J:266937
\Ighg1^tm1(cre)Cgn/0 \Mef2b^tm1.1Rdf/\Mef2b⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased germinal center B cell number	J:265465
\Ighg1^tm1(cre)Cgn/0 \Mef2b^tm1.1Rdf/\Mef2b^tm1.1Rdf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:265465
	decreased germinal center B cell number	J:265465
\Ighg1^tm1(cre)Cgn/0 \Mef2b^tm1.1Rdf/\Mef2b^tm1.1Rdf \Mef2c^tm2Eno/\Mef2c^tm2Eno (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased germinal center B cell number	J:265465
\Ighg1^tm1(cre)Cgn/0 \Mef2b^tm2Rdf/\Mef2b⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:265465
	increased germinal center B cell number	J:265465
\Ighg1^tm1(cre)Cgn/0 \Mef2b^tm2Rdf/\Mef2b^tm1.1Rdf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:265465
	increased germinal center B cell number	J:265465
\Ighg1^tm1(cre)Cgn/0 \Mef2c^tm2Eno/\Mef2c^tm2Eno (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased germinal center B cell number	J:265465
\Ighg1^tm1(cre)Cgn/\Ighg1⁺ \Irf4^tm1Rdf/\Irf4^tm1.1Rdf (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal class switch recombination	J:112643
	abnormal memory B cell morphology	J:112643
	absent plasma cells	J:112643
	decreased IgG1 level	J:112643
	immune system phenotype	J:112643
\Ighg1^tm1(cre)Cgn/\Ighg1⁺ \Myd88^em1.1Rsky/\Myd88⁺ (involves: 129P2/OlaHsd * C57BL/6NTac)	abnormal somatic hypermutation frequency	J:308792
	abnormal splenic cell ratio	J:308792
	increased germinal center B cell number	J:308792
	increased IgM level	J:308792
	increased plasma cell number	J:308792
\Ighg1^tm1(cre)Cgn/\Ighg1⁺ \Tbl1xr1^tm1.1Meln/\Tbl1xr1⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:292118
	abnormal spleen morphology	J:292118
\Ighg1^tm1(cre)Cgn/\Ighg1⁺ \Tbl1xr1^{tm1c(EUCOMM)Hmgu}/\Tbl1xr1^{tm1c(EUCOMM)Hmgu} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:292118
	abnormal spleen morphology	J:292118
\Ighg1^tm1.1Ksho/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
\Ighg1^tm1.1Ksho/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG1 level	J:39568
\Ighg1^tm1.1Ksho/\Ighg1^tm1.1Ksho (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
	decreased IgG1 level	J:39568
\Ighg1^tm1.1Pyu/\Ighg1⁺ (B6.C(Cg)-Ighg1^tm1.1Pyu)	decreased IgG1 level	J:198154
	decreased IgG2c level	J:198154
	immune system phenotype	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
\Ighg1^tm1.1Pyu/\Ighg1^tm1.1Pyu (B6.C(Cg)-Ighg1^tm1.1Pyu)	decreased IgG1 level	J:198154
	decreased IgG2c level	J:198154
	immune system phenotype	J:198154
	increased IgE level	J:198154
	increased IgG2a level	J:198154
	increased IgG2b level	J:198154
	increased susceptibility to type I hypersensitivity reaction	J:198154
\Ighg1^tm1Ksho/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
\Ighg1^tm1Ksho/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased IgG1 level	J:39568
\Ighg1^tm1Ksho/\Ighg1^tm1Ksho (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:39568
	absent memory B cells	J:39568
	decreased IgG1 level	J:39568
\Ighg1^tm2Cgn/\Ighg1⁺ ((C57BL/6 x 129P2/OlaHsd)F1)	abnormal class switch recombination	J:146428
\Ighg1^tm2Cgn/\Ighg1⁺ ((C57BL/6 x 129P2/OlaHsd)F1)	decreased IgG1 level	J:146428
\Ighg1^tm3Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal class switch recombination	J:166887
	decreased IgG1 level	J:166887
\Ighg1^tm4Cgn/\Ighg1^tm4Cgn (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:166887
\Ighg2c^em1Wliu/\Ighg2c^em1Wliu (C57BL/6J-Ighg2c^em1Wliu)	abnormal dendritic cell physiology	J:322180
	abnormal macrophage activation involved in immune response	J:322180
	abnormal macrophage physiology	J:322180
	abnormal plasma cell differentiation	J:322180
	decreased susceptibility to induced colitis	J:322180
	increased CD8-positive, alpha-beta T cell number	J:322180
	increased CD103-positive CD11b-low dendritic cell number	J:322180
	increased effector memory CD8-positive, alpha-beta T cell number	J:322180
	increased germinal center B cell number	J:322180
	increased IgG2c level	J:322180
	increased memory B cell number	J:322180
\Ighg2c^em2Wliu/\Ighg2c^em2Wliu (C57BL/6J-Ighg2c^em2Wliu)	abnormal macrophage activation involved in immune response	J:322180
	abnormal plasma cell differentiation	J:322180
	decreased germinal center B cell number	J:322180
	decreased IgG2c level	J:322180
	decreased memory B cell number	J:322180
	impaired macrophage phagocytosis	J:322180
\Ighm^tm1(Bcl6)Rdf/? (involves: 129/Sv * C57BL/6)	abnormal B cell proliferation	J:98937
	abnormal spleen B cell follicle morphology	J:98937
	abnormal spleen morphology	J:98937
	decreased immunoglobulin level	J:98937
	decreased plasma cell number	J:98937
	enlarged spleen	J:98937
	increased spleen germinal center number	J:98937
	increased spleen white pulp amount	J:98937
\Ighm^{tm1.1(IGH-2)Cog}/\Ighm^{tm1.1(IGH-2)Cog} (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:157575
	abnormal plasma cell differentiation	J:157575
	decreased B cell number	J:157575
	decreased B cell proliferation	J:157575
	decreased B-1 B cell number	J:157575
	decreased follicular B cell number	J:157575
	decreased IgA level	J:157575
	decreased IgG1 level	J:157575
	decreased IgG2a level	J:157575
	decreased IgG3 level	J:157575
	decreased IgG level	J:157575
	decreased IgM level	J:157575
	decreased marginal zone B cell number	J:157575
	decreased mature B cell number	J:157575
	decreased Peyer's patch number	J:157575
	decreased pre-B cell number	J:157575
	decreased transitional stage B cell number	J:157575
	immune system phenotype	J:157575
	increased B cell number	J:157575
	increased B cell proliferation	J:157575
	increased plasma cell number	J:157575
	increased pro-B cell number	J:157575
	small lymph nodes	J:157575
	small Peyer's patches	J:157575
\Ighm^tm1.1Aak/\Ighm^tm1.1Aak (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:171251
	decreased B cell number	J:171251
	decreased pre-B cell number	J:171251
	immune system phenotype	J:171251
	increased pro-B cell number	J:171251
\Ighm^tm1Bhe/\Ighm^tm1Bhe (C.Cg-Ighm^tm1Bhe)	abnormal complement pathway	J:177421
	abnormal immune serum protein physiology	J:177421
	impaired complement classical pathway	J:177421
\Ighm^tm1Cgn/\Igh^tm3Tim (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:102308
\Ighm^tm1Cgn/\Igh^tm3Tim (involves: 129 * C57BL/6)	decreased B cell number	J:102308
\Ighm^tm1Cgn/\Ighm⁺ (NOD.129S2-Ighm^tm1Cgn)	increased susceptibility to autoimmune diabetes	J:37287
\Ighm^tm1Cgn/\Ighm⁺ (involves: 129S2/SvPas * C57BL/6)	arrested B cell differentiation	J:70398
\Ighm^tm1Cgn/\Ighm⁺ \Tg(Igh-6/Igh-V125)2Jwt/0 \Tg(Igk-C/Igk-V125)1Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)	increased susceptibility to autoimmune diabetes	J:91865
	insulitis	J:91865
\Ighm^tm1Cgn/\Ighm⁺ \Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V281)3Jwt)	insulitis	J:91865
\Ighm^tm1Cgn/\Ighm⁺ \Tgfb1^tm1Doe/\Tgfb1^tm1Doe (involves: 129S2/SvPas * C57BL/6 * CF-1)	thymus hypoplasia	J:99033
\Ighm^tm1Cgn/\Ighm^tm1Cgn (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:64298, J:70398
	abnormal lymphatic vessel morphology	J:119344
	abnormal response to infection	J:119344
	absent immature B cells	J:64298
	absent mature B cells	J:64298
	arrested B cell differentiation	J:64298
	decreased IgM level	J:64298
	immune system phenotype	J:113083
\Ighm^tm1Cgn/\Ighm^tm1Cgn (NODCaj.129S2-Ighm^tm1Cgn)	insulitis	J:93190
\Ighm^tm1Cgn/\Ighm^tm1Cgn (NOD.129S2-Ighm^tm1Cgn)	decreased susceptibility to autoimmune diabetes	J:37287
\Ighm^tm1Cgn/\Ighm^tm1Cgn (B6.129S2-Ighm^tm1Cgn/J)	abnormal cytokine secretion	J:118565
	abnormal humoral immune response	J:119584
	abnormal spleen morphology	J:73100
	arrested B cell differentiation	J:119584
	decreased CD4-positive, alpha-beta T cell number	J:73100, J:118565
	decreased CD8-positive, alpha-beta T cell number	J:73100
	decreased dendritic cell number	J:73100
	decreased IgE level	J:125656
	decreased IgG1 level	J:125656
	decreased IgG level	J:119584, J:125656
	decreased immunoglobulin level	J:119584
	decreased spleen weight	J:73100
	immune system phenotype	J:73100, J:118565
	increased susceptibility to parasitic infection	J:74568
\Ighm^tm1Cgn/\Ighm^tm1Cgn (involves: 129S2/SvPas)	abnormal antigen presentation	J:112160
	abnormal CD4-positive, alpha-beta T cell physiology	J:112160
	abnormal metallophilic macrophage morphology	J:88620
	abnormal spleen marginal sinus morphology	J:88620
	abnormal spleen marginal zone macrophage morphology	J:88620
	absent follicular dendritic cells	J:88620
	absent mature B cells	J:118453
	arrested B cell differentiation	J:118453
	decreased IgA level	J:157450
	decreased IgG level	J:157450
	decreased susceptibility to type IV hypersensitivity reaction	J:112160
	decreased T cell proliferation	J:112160
	increased osteoclast cell number	J:157619
	increased susceptibility to induced arthritis	J:157619
	increased susceptibility to parasitic infection	J:163761
\Ighm^tm1Cgn/\Ighm^tm1Cgn (B6.129S2-Ighm^tm1Cgn)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:126867
\Ighm^tm1Cgn/\Ighm^tm1Cgn (NOD.129S2-Ighm^tm1Cgn/DvsJ)	abnormal T cell number	J:80859
	abnormal T cell proliferation	J:80859
	absent B cells	J:80859
	decreased spleen B cell follicle number	J:80859
	decreased susceptibility to autoimmune diabetes	J:80859
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Igkc^tm1Bgmn/\Igkc^tm1Bgmn \Igl^tm2.1Bgmn/\Igl^tm2.1Bgmn (involves: 129)	decreased IgG level	J:130864
	decreased IgM level	J:130864
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Nlrp1a^Neut1/\Nlrp1a^Neut1 (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:191055
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Tg(Igh-6/Igh-V125)2Jwt/0 \Tg(Igk-C/Igk-V125)1Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)	insulitis	J:91865
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.Cg-Ighm^tm1Cgn Tg(Igh-6/Igh-V281)3Jwt)	insulitis	J:91865
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Tg(Igh-VB1-8/Igh-6m)1Mjsk/? (NODCaj.Cg-Ighm^tm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/FswJ)	increased susceptibility to autoimmune diabetes	J:93190
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg (NOD.Cg-Ighm^tm1Cgn Tg(IghelMD4)4Ccg/DvsJ)	abnormal B lymphocyte antigen presentation	J:80859
	abnormal mature B cell morphology	J:80859
	abnormal T cell proliferation	J:80859
	decreased CD8-positive, alpha-beta T cell number	J:80859
	decreased susceptibility to autoimmune diabetes	J:80859
	insulitis	J:80859
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Tg(TcraR28,TcrbR28)KRNDim/0 (involves: 129S2/SvPas * C57BL/6 * NOD * SJL)	immune system phenotype	J:36815
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Tgfb1^tm1Doe/\Tgfb1^tm1Doe (involves: 129S2/SvPas * C57BL/6 * CF-1)	abnormal inflammatory response	J:99033
	thymus hypoplasia	J:99033
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	small intestinal inflammation	J:108572
\Ighm^tm1Cgn/\Ighm^tm1Cgn \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased inflammatory response	J:181257
	kidney inflammation	J:181257
	myocarditis	J:181257
	tubular nephritis	J:181257
\Ighm^tm1Cgn/\Ighm^tm1Cgn X/\Yaa (BXSB.129S2(B6)-Ighm^tm1Cgn/Dcr)	decreased susceptibility to systemic lupus erythematosus	J:206236
\Ighm^tm1Che/\Ighm^tm1Che (involves: 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:47425
	abnormal follicular dendritic cell antigen presentation	J:47425
	abnormal humoral immune response	J:47425
	abnormal immune system physiology	J:47425
	abnormal metallophilic macrophage morphology	J:125338
	abnormal spleen B cell follicle morphology	J:125338
	abnormal spleen germinal center morphology	J:47425
	abnormal spleen marginal zone morphology	J:125338
	abnormal spleen morphology	J:125338
	abnormal spleen periarteriolar lymphoid sheath morphology	J:125338
	abnormal spleen white pulp morphology	J:125338
	decreased IgG1 level	J:47425
	decreased IgG2b level	J:47425
	decreased IgM level	J:47425
	increased B-1 B cell number	J:47425
	increased IgA level	J:47425
	increased IgG2a level	J:47425
	increased IgG3 level	J:47425
\Ighm^tm1Che/\Ighm^tm1Che (involves: 129 * C57BL/6)	increased susceptibility to parasitic infection	J:74568
\Ighm^tm1Fbb/\Ighm^tm1Fbb (involves: BALB/cJ)	immune system phenotype	J:57600
\Ighm^tm1Fbb/\Ighm^tm1Fbb (involves: BALB/cJ)	increased susceptibility to Riboviria infection	J:57600
\Ighm^tm1Msn/\Ighm⁺ (involves: 129S/SvEv)	decreased IgM level	J:49405
\Ighm^tm1Msn/\Ighm^tm1Msn (involves: 129S/SvEv)	abnormal B-1a B cell morphology	J:49405
	abnormal immature B cell morphology	J:49405
	abnormal mature B cell morphology	J:49405
	decreased IgG1 level	J:49405
	decreased IgM level	J:49405
	increased IgG3 level	J:49405
\Ighm^tm1Msn/\Ighm^tm1Msn (involves: 129S/SvEv * C57BL/6)	increased anti-double stranded DNA antibody level	J:111817
	increased autoantibody level	J:111817
	kidney inflammation	J:111817
\Ighm^tm1Msn/\Ighm^tm1Msn (B6.129S-Ighm^tm1Msn)	abnormal B-1a B cell morphology	J:80656
	abnormal splenic cell ratio	J:80656
	decreased follicular B cell number	J:80656
	decreased IgM level	J:80656
	increased marginal zone B cell number	J:80656
\Ighm^tm1Msn/\Ighm^tm1Msn \Tg(Igh-6)1Msn/? (B6.129S-Ighm^tm1Msn)	abnormal B-1a B cell morphology	J:80656
	abnormal splenic cell ratio	J:80656
	decreased follicular B cell number	J:80656
	decreased IgM level	J:80656
	increased marginal zone B cell number	J:80656
\Ighm^tm1Sls/\Ighm^tm1Sls (Not Specified)	abnormal class switch recombination	J:99465
	decreased IgG1 level	J:99465
	decreased IgG2b level	J:99465
	decreased IgG3 level	J:99465
	decreased IgG level	J:99465
	increased IgM level	J:99465
\Ighm^tm2.1Bgmn/\Ighm^tm2.1Bgmn (involves: 129/Sv * C57BL/6 * CBA)	abnormal immune system physiology	J:118453
	absent mature B cells	J:118453
	arrested B cell differentiation	J:118453
	decreased immunoglobulin level	J:118453
\Ighm^tm3Bgmn/\Ighm^tm3Bgmn (involves: 129)	abnormal B cell activation	J:131633
	decreased B cell proliferation	J:131633
	decreased IgM level	J:131633
	decreased immature B cell number	J:131633
	decreased mature B cell number	J:131633
	increased B-1 B cell number	J:131633
\Ighm^tm3Bgmn/\Ighm^tm3Bgmn \Igkc^tm1Bgmn/\Igkc^tm1Bgmn \Igl^tm2.1Bgmn/\Igl^tm2.1Bgmn (involves: 129P2/OlaHsd * 129/Sv)	abnormal B cell differentiation	J:130864
	decreased IgG level	J:130864
	decreased IgM level	J:130864
\Ighm^tm4Bgmn/\Ighm^tm4Bgmn (involves: 129)	abnormal B cell activation	J:131633
	decreased B cell proliferation	J:131633
	decreased IgM level	J:131633
	decreased immature B cell number	J:131633
	decreased mature B cell number	J:131633
	increased B-1 B cell number	J:131633
\Igk-J^tm1.1Lave/\Igk-J^tm1.1Lave (Not Specified)	immune system phenotype	J:179317
\Igk-J^tm1Cog/\Igk-J^tm1.1Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:110100
	abnormal plasma cell morphology	J:110100
	decreased B cell number	J:110100
	decreased naive B cell number	J:110100
	immune system phenotype	J:110100
	increased plasma cell number	J:110100
	increased pre-B cell number	J:110100
\Igk-J^tm1Cog/\Igk-J^tm1Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:110100
	decreased B cell number	J:110100
\Igk-J^tm1Mwg/\Igk^tm1Dhu (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:76116
\Igk-J^tm2Mwg/\Igk^tm1Dhu (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	immune system phenotype	J:76116
\Igk^{tm1.1(b12)Nemz}/\Igk^{tm1.1(b12)Nemz} (involves: C57BL/6NTac * FVB/N)	immune system phenotype	J:205766
\Igk^tm1Dhu/\Igk^tm1Dhu \Iglc1^tm1.1Ust/\Iglc1⁺ (involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)	decreased B cell number	J:68144
\Igk^tm1Dhu/\Igk^tm1Dhu \Iglc1^tm1.1Ust/\Iglc1^tm1.1Ust (involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)	decreased B cell number	J:68144
\Igk^tm1Dhu/\Igk^tm1Dhu \Iglc1^tm1Ust/\Iglc1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell differentiation	J:68144
	increased B cell number	J:68144
\Igk^tm1Dhu/\Igk^tm1Dhu \Iglc1^tm1Ust/\Iglc1^tm1Ust (involves: 129S7/SvEvBrd * C57BL/6)	increased B cell number	J:68144
\Igk^tm1Dhu/\Igk^tm1Dhu \Iglc1^tm2Ust/\Iglc1^tm2Ust (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal B cell differentiation	J:74717
	decreased B cell number	J:74717
	decreased immature B cell number	J:74717
	decreased marginal zone B cell number	J:74717
	decreased mature B cell number	J:74717
	decreased transitional stage T1 B cell number	J:74717
	decreased transitional stage T2 B cell number	J:74717
\Igk^tm1Dhu/\Igk^tm1Dhu \Iglc1^tm2Ust/\Iglc1^tm2Ust (involves: 129S7/SvEvBrd)	increased B-1a cell number	J:113218
\Igk^tm1Dhu/\Igk^tm1Dhu \Tg(H2-Ea-HA)HACIIAjca/0 \Tg(Tcra/Tcrb)1Vbo/0 (C.Cg-Igk^tm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)	autoimmune arthritis	J:209872
\Igk^tm1Dhu/\Igk^tm1Dhu \Tg(H2-Ea-HA)HACIIAjca/0 \Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0 (C.Cg-Igk^tm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)	abnormal CD4-positive, alpha beta T cell morphology	J:209872
	abnormal lymph node morphology	J:209872
	abnormal spleen morphology	J:209872
	absent B cells	J:209872
	decreased susceptibility to autoimmune disorder	J:209872
	increased CD4-positive, alpha-beta T cell number	J:209872
\Igk^tm1Rsky/\Igk⁺ \Igll1^tm1Cgn/\Igll1^tm1Cgn (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)	abnormal B cell differentiation	J:35357
	decreased B cell number	J:35357
	decreased immature B cell number	J:35357
	decreased mature B cell number	J:35357
	decreased pre-B cell number	J:35357
\Igk^tm2Ybgn/\Igk^tm2Ybgn (Not Specified)	decreased pre-B cell number	J:123344
\Igk^tm2Ybgn/\Igk^tm2Ybgn (Not Specified)	increased immature B cell number	J:123344
\Igkc^tm1(IGKC)Mnz/\Igkc⁺ \Igk-J^tm1(CD4*)Mss/\Igk-J⁺ (involves: 129S4/SvJae)	abnormal immunoglobulin light chain V-J recombination	J:143876
\Igkc^tm1(IGKC)Mnz/\Igkc⁺ \Rr158^tm1(Igh)Xu/\Rr158⁺ (Not Specified)	abnormal immune system morphology	J:124407
	decreased B cell number	J:124407
\Igkc^tm1(IGKC)Mnz/\Rr166^tm4.1Wtg (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:193015
	abnormal immunoglobulin level	J:193015
\Igkc^tm1Bgmn/\Igkc^tm1Bgmn (involves: 129P2/OlaHsd)	abnormal B cell number	J:28868, J:118712
	abnormal humoral immune response	J:28868
	abnormal Peyer's patch germinal center morphology	J:28868
	abnormal Peyer's patch morphology	J:28868
\Igkc^tm1Bgmn/\Igkc^tm1Bgmn \Igl^tm1.1Bgmn/\Igl^tm1.1Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	abnormal immature B cell morphology	J:118712
	absent B cells	J:118712
	absent B-1 B cells	J:118712
	absent B-2 B cells	J:118712
	decreased B cell number	J:118712
	spleen hypoplasia	J:118712
\Igkc^tm1Bgmn/\Igkc^tm1Bgmn \Igl^tm1Bgmn/\Igl^tm1Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	abnormal immature B cell morphology	J:118712
	absent B-1 B cells	J:118712
	absent B-2 B cells	J:118712
	absent mature B cells	J:118712
	decreased B cell number	J:118712
	spleen hypoplasia	J:118712
\Igkc^tm1Bgmn/\Igkc^tm1Bgmn \Igl^tm2.1Bgmn/\Igl^tm2.1Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	absent B cells	J:118712
	arrested B cell differentiation	J:118712
\Igkc^tm1Bgmn/\Igkc^tm1Bgmn \Igl^tm2.1Bgmn/\Igl^tm2.1Bgmn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:130864
	abnormal immunoglobulin heavy chain V(D)J recombination	J:130864
	abnormal plasma cell morphology	J:130864
	decreased IgG level	J:130864
	decreased IgM level	J:130864
\Igkc^tm1Bgmn/\Igkc^tm1Bgmn \Igl^tm2Bgmn/\Igl^tm2Bgmn (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA)	absent B cells	J:118712
	arrested B cell differentiation	J:118712
\Igkc^tm1Cgn/\Igkc⁺ (involves: C57BL/6)	increased mature B cell number	J:64287
\Igkc^tm1Cgn/\Igkc^tm1Cgn (involves: C57BL/6)	abnormal B cell differentiation	J:64287
	decreased mature B cell number	J:64287
	increased immature B cell number	J:64287
	increased mature B cell number	J:64287
	spleen hypoplasia	J:64287
\Igkc^tm1Jkbv/\Igkc^tm1Jkbv (Not Specified)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	abnormal immunoglobulin light chain V-J recombination	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	increased pre-B cell number	J:137738
\Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	increased pre-B cell number	J:137738
\Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGK@yK1)9.2CJkbv/\Tg(IGK@yK1)9.2CJkbv (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:137738
	abnormal immunoglobulin level	J:137738
	decreased immature B cell number	J:137738
	decreased mature B cell number	J:137738
	increased pre-B cell number	J:137738
\Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGK@yK2)J23.1Jkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:137738
	abnormal immunoglobulin level	J:137738
	immune system phenotype	J:137738
\Igkc^tm1Jkbv/\Igkc^tm1Jkbv \Tg(IGK@yK2)J23.1Jkbv/\Tg(IGK@yK2)J23.1Jkbv (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:137738
	immune system phenotype	J:137738
\Igkc^tm2(IGKC)Cgn/\Igkc^tm2(IGKC)Cgn (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:113008
	immune system phenotype	J:113008
\Igkc^tm2(IGKC)Cgn/\Igkc^tm2(IGKC)Cgn \Ighg1^{tm1(IGHG1)Rsky}/\Ighg1^{tm1(IGHG1)Rsky} (involves: 129P2/OlaHsd)	immune system phenotype	J:127217
\Igkrs^tm1Nemz/\Igkrs^tm1Nemz (B6.129-Igkrs^tm1Nemz)	abnormal immunoglobulin light chain V-J recombination	J:132125
	decreased immature B cell number	J:132125
	decreased mature B cell number	J:132125
\Igkrs^tm1Nemz/\Igkrs^tm1Nemz \Tg(BCL2)22Wehi/? (involves: 129 * C57BL)	increased anti-double stranded DNA antibody level	J:132125
\Igkrs^tm1Nemz/\Igkrs^tm1Nemz \Tg(UBC-scFv)2Nemz/? (involves: 129 * C57BL/6 * DBA/2)	abnormal B cell clonal deletion	J:132125
	decreased immature B cell number	J:132125
	decreased mature B cell number	J:132125
\Igl^tm1Cgn/\Igl^tm1Cgn (involves: C57BL/6)	immune system phenotype	J:83289
\Iglc1^tm1Ust/\Iglc1^tm1Ust (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell number	J:68144
	increased lymphocyte cell number	J:68144
\Iglc1^tm2Ust/\Iglc1⁺ (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal immunoglobulin light chain V-J recombination	J:74717
\Iglc1^tm2Ust/\Iglc1^tm2Ust (involves: 129S7/SvEvBrd)	decreased B cell number	J:113218
\Iglc1^tm2Ust/\Iglc1^tm2Ust \Ptpn6^me-v/\Ptpn6^me-v (involves: 129S7/SvEvBrd * C57BL/6J)	decreased B cell number	J:113218
\Igll1^tm1Cgn/\Igll1^tm1Cgn (involves: 129S2/SvPas * C57BL/6)	abnormal B cell morphology	J:64284
	abnormal B-1 B cell number	J:64284
	abnormal lymphopoiesis	J:64284
	abnormal pre-B cell morphology	J:64284
	decreased B cell number	J:64284, J:35357
	decreased IgG1 level	J:64284
	decreased IgG2b level	J:64284
	decreased IgG3 level	J:64284
	decreased IgG level	J:64284
	increased pro-B cell number	J:64284
	spleen hypoplasia	J:64284
\Igll1^tm1Cgn/\Igll1^tm1Cgn \Tg(Igk-V4CH27)1-2Shc/0 (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	abnormal B cell differentiation	J:35357
	decreased pre-B cell number	J:35357
\Igll1^tm1Shim/\Igll1^tm1Shim \Vpreb1a^tm1Shim/\Vpreb1a^tm1Shim \Vpreb1b^tm1Shim/\Vpreb1b^tm1Shim (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:76947
	decreased B cell number	J:76947
	decreased B-1a cell number	J:76947
	decreased immature B cell number	J:76947
	decreased mature B cell number	J:76947
	decreased pre-B cell number	J:76947
	immune system phenotype	J:76947
	increased late pro-B cell number	J:76947
\Iglon5^em1(IMPC)Mbp/\Iglon5^em1(IMPC)Mbp (C57BL/6NCrl-Iglon5^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Ignpq1^BALB/cAJcl/\Ignpq1^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
\Ignpq1^HIGA/Nsc/\Ignpq1^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
\Ignpq2^BALB/cAJcl/\Ignpq2^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
\Ignpq2^HIGA/Nsc/\Ignpq2^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	increased IgA level	J:116904
\Ignpq3^BALB/cAJcl/\Ignpq3^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	glomerulonephritis	J:116904
\Ignpq3^HIGA/Nsc/\Ignpq3^HIGA/Nsc (involves: BALB/cAJcl * HIGA/Nsc)	glomerulonephritis	J:116904
\Igs2^{em1(Alb-Golm1)Jdon}/\Igs2⁺ (involves: C57BL/6N)	decreased CD8-positive, alpha-beta T cell number	J:306528
\Igs2^{tm1(CAG-Ptgs2os)Scrp}/\Igs2^{tm1(CAG-Ptgs2os)Scrp} (involves: C57BL/6)	abnormal circulating cytokine level	J:325487
	increased circulating interleukin-10 level	J:325487
\Igs2^{tm1(CAG-Ptgs2os)Scrp}/\Igs2^{tm1(CAG-Ptgs2os)Scrp} \Ptgs2os^em1Scrp/\Ptgs2os^em1Scrp (involves: C57BL/6)	immune system phenotype	J:325487
\Igtp^em1Myam/\Igtp^em1Myam \Irgm1^em1Myam/\Irgm1^em1Myam (C57BL/6-Irgm1^em1Myam Igtp^em1Myam)	increased susceptibility to parasitic infection	J:308470
\Igtp^em1Myam/\Igtp^em1Myam \Irgm1^em1Myam/\Irgm1^em1Myam \Irgm2^em2Myam/\Irgm2^em2Myam (C57BL/6-Irgm1^em1Myam Igtp^em1Myam Irgm2^em2Myam)	increased susceptibility to parasitic infection	J:308470
\Igtp^tm1Gvw/\Igtp^tm1Gvw (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:59891
	increased circulating interferon-gamma level	J:59891
	increased circulating interleukin-12b level	J:59891
	increased susceptibility to parasitic infection	J:99144, J:59891
\Iigp1^tm1.1Jcho/\Iigp1^tm1.1Jcho (involves: C57BL/6)	increased susceptibility to parasitic infection	J:135070
\Iigp1c^{em1(IMPC)Hmgu}/\Iigp1c^{em1(IMPC)Hmgu} (C57BL/6N-Iigp1c^{em1(IMPC)Hmgu}/Ieg)	abnormal lymph node morphology	J:211773
\Ikbip^em1Bcgen/\Ikbip^em1Bcgen \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	abnormal cytokine level	J:282971
	decreased macrophage cytokine production	J:282971
	increased circulating interleukin-6 level	J:282971
	increased circulating tumor necrosis factor level	J:282971
	increased susceptibility to bacterial infection induced morbidity/mortality	J:282971
	increased susceptibility to induced colitis	J:282971
	lung inflammation	J:282971
\Ikbkb^em1Macc/\Ikbkb⁺ (involves: C57BL/6NCrl)	abnormal effector T cell number	J:290616
	abnormal T cell activation	J:290616
	decreased B cell number	J:290616
	decreased CD4-positive, alpha-beta T cell number	J:290616
	decreased CD8-positive, alpha-beta T cell number	J:290616
	decreased memory B cell number	J:290616
	decreased T cell number	J:290616
	increased regulatory T cell number	J:290616
\Ikbkb^em1Macc/\Ikbkb^em1Macc (involves: C57BL/6NCrl)	abnormal effector T cell number	J:290616
	abnormal T cell activation	J:290616
	decreased B cell number	J:290616
	decreased CD4-positive, alpha-beta T cell number	J:290616
	decreased CD8-positive, alpha-beta T cell number	J:290616
	decreased memory B cell number	J:290616
	decreased T cell number	J:290616
	increased regulatory T cell number	J:290616
\Ikbkb^em1Smoc/\Ikbkb^em1Smoc (C57BL/6J-Ikbkb^em1Smoc)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:309163
\Ikbkb^M1Btlr/\Ikbkb⁺ (C57BL/6J-Ikbkb^M1Btlr)	abnormal B cell physiology	J:225271
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225271
	abnormal response to infection	J:225271
	increased response to antigen	J:225271
\Ikbkb^M1Btlr/\Ikbkb^M1Btlr (C57BL/6J-Ikbkb^M1Btlr)	abnormal B cell physiology	J:225271
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225271
	increased susceptibility to viral infection	J:225271
\Ikbkb^M2Btlr/\Ikbkb^M2Btlr (C57BL/6J-Ikbkb^M2Btlr)	decreased central memory CD4-positive, alpha-beta T cell number	J:274802
\Ikbkb^tm1.1Cgn/\Ikbkb^tm1.1Cgn (involves: C57BL/6)	decreased interleukin-6 secretion	J:79132, J:85810
\Ikbkb^tm1Cgn/\Ikbkb^tm1.1Cgn \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
	decreased single-positive T cell number	J:85810
	decreased T cell number	J:85810
\Ikbkb^tm1Cgn/\Ikbkb^tm1Cgn \Il20ra^tm1Rsab/\Il20ra^tm1Rsab \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
\Ikbkb^tm1Cgn/\Ikbkb^tm1Cgn \Il22^tm1Jcrd/\Il22^tm1Jcrd \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
\Ikbkb^tm1Cgn/\Ikbkb^tm1Cgn \Il22ra1^tm1Rsab/\Il22ra1^tm1Rsab \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
\Ikbkb^tm1Cgn/\Ikbkb^tm1Cgn \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * DBA/2)	skin inflammation	J:208995
\Ikbkb^tm1Cgn/\Ikbkb^tm1Cgn \Tg(Lck-cre)I57Jxm/0 (involves: C57BL/6 * ICR)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
\Ikbkb^tm1Cgn/\Ikbkb^tm1Cgn \Tnfrsf1a^tm2Gkl/\Tnfrsf1a^tm2Gkl \Tg(KRT14-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	skin inflammation	J:208995
\Ikbkb^tm1Lex/\Ikbkb^tm1Lex \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEvBrd)	impaired macrophage chemotaxis	J:159873
	impaired neutrophil chemotaxis	J:159873
	impaired neutrophil recruitment	J:159873
\Ikbkb^tm2.1Cgn/\Ikbkb^tm2.1Cgn (involves: C57BL/6)	decreased interleukin-6 secretion	J:79132
\Ikbkb^tm2Cgn/\Ikbkb^tm2.1Cgn \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal humoral immune response	J:85810
	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
	decreased IgE level	J:85810
\Ikbkb^tm2Cgn/\Ikbkb^tm2Cgn \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased memory T cell number	J:85810
	decreased regulatory T cell number	J:85810
\Ikbkb^tm2Mka/\Ikbkb^tm2.1Mka \Tg(Vil-cre)1Mka/0 (involves: 129/Sv * C57BL/6)	decreased acute inflammation	J:83313
	decreased circulating tumor necrosis factor level	J:83313
	impaired neutrophil recruitment	J:83313
\Ikbkb^tm2Mka/\Ikbkb^tm2Mka \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd)	increased macrophage apoptosis	J:80159
\Ikbke^tm1Tman/\Ikbke^tm1Tman (B6.Cg-Ikbke^tm1Tman)	increased susceptibility to Orthomyxoviridae infection	J:119791
\Ikbke^tm1Tman/\Ikbke^tm1Tman (B6.Cg-Ikbke^tm1Tman)	lung inflammation	J:119791
\Ikbkg^m1Btlr/Y (C57BL/6J-Ikbkg^m1Btlr)	decreased regulatory T cell number	J:139558
	decreased tumor necrosis factor secretion	J:139558
	immune system phenotype	J:139558
\Ikbkg^tm1.1Chtr/Y \Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal NK cell physiology	J:151485
	abnormal NK T cell physiology	J:151485
	decreased NK cell number	J:151485
	decreased NK T cell number	J:151485
	increased interferon-gamma secretion	J:151485
	liver inflammation	J:151485
\Ikbkg^tm1.1Chtr/\Ikbkg^tm1.1Chtr \Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal NK cell physiology	J:151485
	abnormal NK T cell physiology	J:151485
	decreased NK cell number	J:151485
	decreased NK T cell number	J:151485
	increased circulating tumor necrosis factor level	J:151485
	increased interferon-gamma secretion	J:151485
	liver inflammation	J:151485
\Ikbkg^tm1.1Dwat/Y \Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	immune system phenotype	J:202106
	liver inflammation	J:202106
\Ikbkg^tm1.1Dwat/\Ikbkg⁺ (B6.Cg-Ikbkg^tm1.1Dwat)	decreased B cell number	J:202106
\Ikbkg^tm1.1Dwat/\Ikbkg⁺ (B6.Cg-Ikbkg^tm1.1Dwat)	enlarged spleen	J:202106
\Ikbkg^tm1.1Mpa/Y \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:85810
	decreased CD8-positive, alpha-beta T cell number	J:85810
	decreased single-positive T cell number	J:85810
	decreased T cell number	J:85810
	increased T cell apoptosis	J:85810
\Ikbkg^tm1.1Mpa/Y \Tg(Vil1-cre)997Gum/0 (B6.Cg-Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
\Ikbkg^tm1.1Mpa/\Ikbkg^tm1.1Mpa \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell differentiation	J:113365
	decreased B cell number	J:113365
	decreased mature B cell number	J:113365
\Ikbkg^tm1.1Mpa/\Ikbkg^tm1.1Mpa \Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	abnormal cytokine secretion	J:118336
	abnormal inflammatory response	J:118336
	increased susceptibility to endotoxin shock	J:137861
	liver inflammation	J:118336
\Ikbkg^tm1.1Mpa/\Ikbkg^tm1.1Mpa \Tg(Vil1-cre)997Gum/0 (B6.Cg-Ikbkg^tm1.1Mpa Tg(Vil1-cre)997Gum)	colitis	J:175865
\Ikbkg^tm1Dwb/\Ikbkg^tm1Dwb (Not Specified)	abnormal chemokine secretion	J:136353
	abnormal humoral immune response	J:136353
	decreased interleukin-6 secretion	J:136353
	decreased interleukin-12b secretion	J:136353
	decreased susceptibility to endotoxin shock	J:136353
	decreased tumor necrosis factor secretion	J:136353
\Ikbkg^tm1Mak/Y (involves: 129P2/OlaHsd * C57BL/6)	increased interleukin-6 secretion	J:61666
\Ikbkg^tm1Mka/\Ikbkg⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	erythroderma	J:63054
	small spleen	J:63054
	small thymus	J:63054
\Ikbkg^tm1Mpa/Y (involves: C57BL/6)	decreased interleukin-6 secretion	J:63055
\Ikbkg^tm1Mpa/Y (involves: C57BL/6)	decreased tumor necrosis factor secretion	J:63055
\Ikbkg^tm1Mpa/\Ikbkg⁺ (involves: C57BL/6)	skin inflammation	J:63055
\Ikzf1^m1Btlr/\Ikzf1^m1Btlr (C57BL/6J-Ikzf1^m1Btlr)	abnormal natural killer cell mediated cytotoxicity	J:265249
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265249
	decreased CD8-positive, naive alpha-beta T cell number	J:265249
	enhanced humoral immune response	J:265249
	increased B-1 B cell number	J:265249
	increased CD4-positive, alpha-beta T cell number	J:265249
	increased CD8-positive, alpha-beta T cell number	J:265249
	increased central memory CD4-positive, alpha-beta T cell number	J:265249
	increased central memory CD8 positive, alpha-beta T cell number	J:265249
	increased effector memory CD4-positive, alpha-beta T cell number	J:265249
	increased IgG level	J:265249
	increased response to antigen	J:265249
	increased single-positive T cell number	J:265249
	increased T cell number	J:265249
\Ikzf1^m2Btlr/\Ikzf1^m2Btlr (C57BL/6J-Ikzf1^m2Btlr)	decreased B cell number	J:265250
	decreased CD4-positive, alpha-beta T cell number	J:265250
	decreased CD8-positive, naive alpha-beta T cell number	J:265250
	decreased single-positive T cell number	J:265250
	decreased T cell number	J:265250
	increased CD8-positive, alpha-beta T cell number	J:265250
	increased central memory CD4-positive, alpha-beta T cell number	J:265250
	increased central memory CD8 positive, alpha-beta T cell number	J:265250
	increased effector memory CD4-positive, alpha-beta T cell number	J:265250
	increased effector memory CD8-positive, alpha-beta T cell number	J:265250
	increased single-positive T cell number	J:265250
\Ikzf1^m3Btlr/\Ikzf1^m3Btlr (C57BL/6J-Ikzf1^m3Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265251
	increased B-1 B cell number	J:265251
	increased CD8-positive, alpha-beta T cell number	J:265251
	increased single-positive T cell number	J:265251
	increased T cell number	J:265251
\Ikzf1^plstc/\Ikzf1⁺ (C57BL/6JSfdAnu-Ikzf1^plstc)	abnormal B cell differentiation	J:84569
	abnormal lymphopoiesis	J:84569
	abnormal T cell differentiation	J:84569
	decreased double-negative T cell number	J:84569
	decreased double-positive T cell number	J:84569
	decreased mature B cell number	J:84569
	decreased pre-B cell number	J:84569
	decreased thymocyte number	J:84569
	increased pro-B cell number	J:84569
	increased T cell derived lymphoma incidence	J:84569
	myeloid hyperplasia	J:84569
\Ikzf1^plstc/\Ikzf1^plstc (C57BL/6JSfdAnu-Ikzf1^plstc)	abnormal granulocyte differentiation	J:84569
	abnormal lymphopoiesis	J:84569
	abnormal macrophage differentiation	J:84569
	abnormal myelopoiesis	J:84569
	absent pro-B cells	J:84569
	absent T cells	J:84569
	arrested B cell differentiation	J:84569
	decreased granulocyte number	J:84569
	increased macrophage cell number	J:84569
	thymus hypoplasia	J:84569
\Ikzf1^tm1(Pax5)Mbu/\Ikzf1⁺ \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:118111
\Ikzf1^tm1(Pax5)Mbu/\Ikzf1^tm1(Pax5)Mbu (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:80815
	abnormal dendritic cell morphology	J:80815
	abnormal T cell differentiation	J:80815
\Ikzf1^tm1(Pax5)Mbu/\Ikzf1^tm1(Pax5)Mbu \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell differentiation	J:80815
	arrested T cell differentiation	J:80815
	increased B cell number	J:80815
	increased early pro-B cell number	J:80815
	thymus hypoplasia	J:80815
\Ikzf1^{tm1.1(Pax5)Mbu}/\Ikzf1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:80815
	decreased double-positive T cell number	J:118111
	enlarged lymph nodes	J:118111
	enlarged spleen	J:118111
	enlarged thymus	J:118111
	increased B cell number	J:80815
	increased pro-B cell number	J:80815
	increased T cell derived lymphoma incidence	J:118111
	thymus hypoplasia	J:118111
\Ikzf1^{tm1.1(Pax5)Mbu}/\Ikzf1⁺ \Tcf3^tm1Mbu/\Tcf3^tm1Mbu \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129P2/OlaHsd * C57BL/10 * CBA/Ca)	abnormal immunoglobulin heavy chain V(D)J recombination	J:137719
	immune system phenotype	J:137719
\Ikzf1^tm1.1Smale/\Ikzf1^tm1.1Smale (B6.Cg-Ikzf1^tm1.1Smale)	decreased B cell number	J:208211
	decreased B-1a cell number	J:208211
	decreased B-1b cell number	J:208211
	decreased DN1 thymic pro-T cell number	J:208211
	decreased immature B cell number	J:208211
	decreased mature B cell number	J:208211
	decreased pre-B cell number	J:208211
	immune system phenotype	J:208211
	thymus hypoplasia	J:208211
\Ikzf1^tm1Kast/\Ikzf1^tm1Kast (involves: 129S2/SvPas)	abnormal B cell activation	J:82813
	abnormal B cell differentiation	J:82813
	decreased B cell number	J:82813
	decreased B cell proliferation	J:82813
	decreased B-1a cell number	J:82813
	decreased B-1b cell number	J:82813
	decreased IgG3 level	J:82813
	decreased spleen germinal center number	J:82813
\Ikzf1^tm1Kge/\Ikzf1⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal lymph node cortex morphology	J:29355
	abnormal lymph node medulla morphology	J:29355
	abnormal T cell differentiation	J:29355
	abnormal thymocyte activation	J:29355
	abnormal thymus lobule morphology	J:29355
	abnormal thymus medulla morphology	J:29355
	decreased spleen red pulp amount	J:29355
	enlarged cervical lymph nodes	J:29355
	enlarged mesenteric lymph nodes	J:29355
	enlarged thymus	J:29355
	increased spleen white pulp amount	J:29355
	increased T cell proliferation	J:29355
	lymph node hyperplasia	J:29355
	spleen hyperplasia	J:29355
	thymus cortex hypoplasia	J:29355
\Ikzf1^tm1Kge/\Ikzf1⁺ (involves: 129S4/SvJae * BALB/c)	abnormal lymph node cortex morphology	J:29355
	abnormal lymph node medulla morphology	J:29355
	abnormal T cell differentiation	J:29355
	abnormal thymocyte activation	J:29355
	abnormal thymus lobule morphology	J:29355
	abnormal thymus medulla morphology	J:29355
	decreased spleen red pulp amount	J:29355
	enlarged cervical lymph nodes	J:29355
	enlarged mesenteric lymph nodes	J:29355
	enlarged thymus	J:29355
	increased spleen white pulp amount	J:29355
	increased T cell proliferation	J:29355
	lymph node hyperplasia	J:29355
	spleen hyperplasia	J:29355
	thymus cortex hypoplasia	J:29355
\Ikzf1^tm1Kge/\Ikzf1^tm1Kge (involves: 129S4/SvJae * C57BL/6)	abnormal eosinophil morphology	J:20671
	abnormal immune system organ morphology	J:20671
	abnormal NK cell morphology	J:20671
	abnormal spleen morphology	J:20671
	abnormal thymus cortex morphology	J:20671
	abnormal thymus morphology	J:20671
	absent axillary lymph nodes	J:20671
	absent B cells	J:20671
	absent cervical lymph nodes	J:20671
	absent inguinal lymph nodes	J:20671
	absent mesenteric lymph nodes	J:20671
	absent Peyer's patches	J:20671
	absent pre-B cells	J:20671
	arrested T cell differentiation	J:20671
	decreased gamma-delta intraepithelial T cell number	J:20671
	enlarged spleen	J:20671
	increased basophil cell number	J:20671
	increased susceptibility to bacterial infection	J:20671
	intermingled spleen red and white pulp	J:20671
	lung inflammation	J:20671
	thymus hypoplasia	J:20671
\Ikzf1^tm1Kge/\Ikzf1^tm1Kge (involves: 129S4/SvJae * BALB/c)	abnormal eosinophil morphology	J:20671
	abnormal immune system organ morphology	J:20671
	abnormal NK cell morphology	J:20671
	abnormal spleen morphology	J:20671
	abnormal thymus cortex morphology	J:20671
	abnormal thymus morphology	J:20671
	absent axillary lymph nodes	J:20671
	absent B cells	J:20671
	absent cervical lymph nodes	J:20671
	absent inguinal lymph nodes	J:20671
	absent mesenteric lymph nodes	J:20671
	absent Peyer's patches	J:20671
	absent pre-B cells	J:20671
	arrested T cell differentiation	J:20671
	decreased gamma-delta intraepithelial T cell number	J:20671
	enlarged spleen	J:20671
	increased basophil cell number	J:20671
	increased susceptibility to bacterial infection	J:20671
	intermingled spleen red and white pulp	J:20671
	lung inflammation	J:20671
	thymus hypoplasia	J:20671
\Ikzf1^tm2.1Smale/\Ikzf1^tm2.1Smale (B6.Cg-Ikzf1^tm2.1Smale)	abnormal lymphopoiesis	J:208211
	abnormal peripheral lymph node morphology	J:208211
	abnormal T cell differentiation	J:208211
	absent inguinal lymph nodes	J:208211
	absent NK cells	J:208211
	absent Peyer's patches	J:208211
	decreased B cell number	J:208211
	decreased DN2 thymocyte number	J:208211
	decreased DN3 thymocyte number	J:208211
	decreased double-negative T cell number	J:208211
	decreased double-positive T cell number	J:208211
	decreased immature B cell number	J:208211
	decreased mature B cell number	J:208211
	decreased plasmacytoid dendritic cell number	J:208211
	decreased pre-pro B cell number	J:208211
	immune system phenotype	J:208211
	increased gamma-delta T cell number	J:208211
	increased pre-B cell number	J:208211
	thymus cortex hypoplasia	J:208211
	thymus hypoplasia	J:208211
\Ikzf1^tm2Kge/\Ikzf1^tm2Kge (involves: 129S4/SvJae)	abnormal dendritic cell number	J:37317
	abnormal splenic cell ratio	J:37317
	abnormal T cell differentiation	J:208211, J:37317
	abnormal thymus development	J:37317
	absent axillary lymph nodes	J:37317
	absent B cells	J:208211, J:37317
	absent B-1a cells	J:37317
	absent cervical lymph nodes	J:37317
	absent inguinal lymph nodes	J:37317
	absent mesenteric lymph nodes	J:37317
	absent NK cells	J:208211, J:37317
	absent Peyer's patches	J:37317
	absent pre-B cells	J:37317
	absent pro-B cells	J:37317
	decreased double-positive T cell number	J:37317
	decreased gamma-delta intraepithelial T cell number	J:37317
	decreased granulocyte number	J:37317
	decreased mature gamma-delta T cell number	J:37317
	decreased plasmacytoid dendritic cell number	J:208211
	decreased splenocyte number	J:37317
	increased T cell proliferation	J:37317
	thymus hypoplasia	J:37317
\Ikzf1^tm3.1Mbu/\Ikzf1^tm3.1Mbu \Cd79a^tm1(cre)Reth/\Cd79a⁺ \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6 * SJL)	decreased pro-B cell number	J:209928
\Ikzf1^tm3.1Mbu/\Ikzf1^tm3.1Mbu \Il7r^{tm1.1(icre)Hrr}/\Il7r⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	increased T cell derived lymphoma incidence	J:209928
\Ikzf1^tm3Kge/\Ikzf1^tm3Kge \Tg(CD2-icre)4Kio/? (involves: C57BL/10 * CBA/Ca)	abnormal B cell physiology	J:209927
	impaired B cell migration	J:209927
	increased T cell derived lymphoma incidence	J:209927
\Ikzf1^tm3Kge/\Ikzf1^tm3Kge \Tg(CD19-cre/ERT2)1Cgn/? (Not Specified)	abnormal B cell apoptosis	J:209927
	absent pre-B cells	J:209927
	decreased pre-B cell number	J:209927
\Ikzf2^tm1.1Etms/\Ikzf2^tm1.1Etms \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal regulatory T cell physiology	J:160098
\Ikzf3^{tm1(KOMP)Vlcg}/\Ikzf3^{tm1(KOMP)Vlcg} (C57BL/6N-Ikzf3^{tm1(KOMP)Vlcg}/Rbrc)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Ikzf3^tm1Kge/\Ikzf3^tm1Kge (involves: 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:50626
	abnormal spleen marginal zone morphology	J:50626
	abnormal type III hypersensitivity reaction	J:81805
	autoimmune response	J:81805
	decreased B cell number	J:81805
	decreased IgG2b level	J:50626
	decreased IgG3 level	J:50626
	decreased IgM level	J:50626
	decreased naive B cell number	J:81805
	enlarged spleen	J:50626
	glomerulonephritis	J:81805
	increased anti-double stranded DNA antibody level	J:81805
	increased anti-histone antibody level	J:81805
	increased anti-nuclear antigen antibody level	J:81805
	increased anti-single stranded DNA antibody level	J:81805
	increased autoantibody level	J:81805, J:50626
	increased B cell proliferation	J:50626
	increased IgE level	J:50626
	increased IgG1 level	J:50626
	increased IgG2a level	J:50626
	increased pre-B cell number	J:50626
	increased spleen germinal center number	J:50626
	increased T cell proliferation	J:50626
\Ikzf3^tm1Kge/\Ikzf3^tm1Kge (involves: 129S4/SvJae)	decreased marginal zone B cell number	J:69477
\Ikzf3^tm1Kge/\Ikzf3^tm1Kge (involves: 129S4/SvJae)	increased follicular B cell number	J:69477
\Ikzf4^tm1.1Etms/\Ikzf4^tm1.1Etms (Not Specified)	chronic inflammation	J:294549
	decreased T cell proliferation	J:295208
	immune system phenotype	J:295208
	increased susceptibility to experimental autoimmune encephalomyelitis	J:295208
\Ikzf4^tm1Djr/\Ikzf4^tm1Djr \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	chronic inflammation	J:294549
\Ikzf5^{tm1(KOMP)Wtsi}/\Ikzf5^{tm1(KOMP)Wtsi} (C57BL/6N-Ikzf5^{tm1(KOMP)Wtsi}/Rbrc)	increased large unstained cell number	J:211773
\Il1a^tm1Yiw/\Il1a^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased circulating interleukin-1 alpha level	J:47429
	decreased interleukin-1 beta secretion	J:47429
\Il1a^tm1Yiw/\Il1a^tm1Yiw \Il1b^tm1Yiw/\Il1b^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased circulating interleukin-1 alpha level	J:47429
	decreased circulating interleukin-1 beta level	J:47429
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:165513
	decreased susceptibility to type IV hypersensitivity reaction	J:165513
\Il1a^tm1Yiw/\Il1a^tm1Yiw \Il1b^tm1Yiw/\Il1b^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	impaired neutrophil recruitment	J:50775
\Il1a^tm1Yiw/\Il1a^tm1Yiw \Il1b^tm1Yiw/\Il1b^tm1Yiw \Tg(KRT14-CASP1)1Miz/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	dermatitis	J:78602
\Il1a^tm1Yiw/\Il1a^tm1Yiw \Nlrp1a^Neut1/\Nlrp1a^Neut1 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:191055
	increased neutrophil cell number	J:191055
\Il1b^tm1Dch/\Il1b^tm1Dch (involves: 129S2/SvPas)	decreased interleukin-1 beta secretion	J:33465
	decreased susceptibility to type IV hypersensitivity reaction	J:33465
	immune system phenotype	J:189777
	increased susceptibility to bacterial infection	J:112400
\Il1b^tm1Lvp/\Il1b^tm1Lvp (involves: 129S7/SvEvBrd * C57BL/6)	abnormal interleukin-6 secretion	J:27234
	abnormal lymphocyte physiology	J:67001
	decreased acute inflammation	J:27234
	decreased circulating interleukin-1 beta level	J:27234
	decreased inflammatory response	J:27234
	decreased interferon-gamma secretion	J:67001
	decreased interleukin-2 secretion	J:67001
	decreased interleukin-4 secretion	J:67001
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:67001
\Il1b^tm1Lvp/\Il1b^tm1Lvp (involves: 129S7/SvEvBrd)	abnormal macrophage physiology	J:136368
	decreased interleukin-1 beta secretion	J:136368
	decreased susceptibility to Togaviridae infection	J:52841
	decreased susceptibility to Togaviridae infection induced morbidity/mortality	J:52841
	decreased susceptibility to viral infection	J:135243
	decreased tumor necrosis factor secretion	J:82394
	increased susceptibility to bacterial infection induced morbidity/mortality	J:136368
\Il1b^tm1Lvp/\Il1b^tm1Lvp (129S7/SvEvBrd-Il1b^tm1Lvp)	immune system phenotype	J:173245
\Il1b^tm1Yiw/\Il1b^tm1Yiw (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased circulating interleukin-1 beta level	J:47429
\Il1f10^tm1Gpa/\Il1f10^tm1Gpa (C.129-Il1f10^tm1Gpa)	immune system phenotype	J:260118
\Il1r1^{em1(IMPC)Ccpcz}/\Il1r1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Il1r1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Il1r1^em1Qizh/\Il1r1^em1Qizh (C57BL/6-Il1r1^em1Qizh)	increased circulating interleukin-6 level	J:338375
	increased circulating tumor necrosis factor level	J:338375
	increased susceptibility to induced arthritis	J:338375
\Il1r1^tm1Imx/\Il1r1^tm1Imx (involves: 129 * C57BL/6)	decreased circulating interleukin-6 level	J:43088
	increased susceptibility to bacterial infection	J:58851
	osteomyelitis	J:58851
\Il1r1^tm1Imx/\Il1r1^tm1Imx (involves: 129S7/SvEvBrd)	abnormal neutrophil physiology	J:113110
\Il1r1^tm1Imx/\Il1r1^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	abnormal neutrophil physiology	J:112999
	decreased susceptibility to experimental autoimmune uveoretinitis	J:115094
\Il1r1^tm1Imx/\Il1r1^tm1Imx (B6.129S7-Il1r1^tm1Imx/J)	decreased circulating interleukin-6 level	J:125570
	decreased circulating interleukin-18 level	J:125570
	decreased interleukin-6 secretion	J:148779, J:125570
	decreased tumor necrosis factor secretion	J:125570
	increased circulating interleukin-1 beta level	J:125570
	increased circulating interleukin-18 level	J:125570
	increased susceptibility to bacterial infection	J:125570
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125570
	increased susceptibility to induced arthritis	J:125570
	sepsis	J:125570
\Il1r1^tm1Imx/\Il1r1^tm1Imx (B6.129S7-Il1r1^tm1Imx)	immune system phenotype	J:173245
\Il1r1^tm1Imx/\Il1r1^tm1Imx \Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	abnormal chemokine level	J:126652
	decreased interleukin-6 secretion	J:115094
	decreased susceptibility to experimental autoimmune uveoretinitis	J:115094
	impaired neutrophil recruitment	J:126652
	increased susceptibility to bacterial infection	J:58851
	interstitial pneumonia	J:126652
	lung inflammation	J:126652
	osteomyelitis	J:58851
\Il1r1^tm1Imx/\Il1r1^tm1Imx \Vsig4^tm1Gne/\Vsig4^tm1Gne (B6.Cg-Il1r1^tm1Imx Vsig4^tm1Gne)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:281762
	decreased T helper 1 cell number	J:281762
	decreased T-helper 17 cell number	J:281762
	increased susceptibility to induced colitis	J:281762
\Il1r1^tm1Quan/\Il1r1^tm1Quan (involves: C57BL/6)	abnormal inflammatory response	J:219864
\Il1r1^tm1Quan/\Il1r1^tm1Quan (involves: C57BL/6)	abnormal microglial cell activation	J:219864
\Il1r1^tm1Quan/\Il1r1^tm1Quan \Lyz2^tm1(cre)Ifo/\Lyz2^tm1(cre)Ifo (involves: 129P2/OlaHsd * C57BL/6)	abnormal inflammatory response	J:219864
	abnormal microglial cell activation	J:219864
\Il1r1^tm1Quan/\Il1r1^tm1Quan \Tg(Tek-cre)12Flv/0 (involves: C3H * C57BL/6)	abnormal inflammatory response	J:219864
	abnormal microglial cell activation	J:219864
\Il1r1^tm1Roml/\Il1r1^tm1Roml (involves: 129S1/Sv * C57BL/6)	decreased circulating interleukin-6 level	J:42373
	decreased circulating serum amyloid protein level	J:42373
	decreased interleukin-6 secretion	J:42373
	decreased susceptibility to type IV hypersensitivity reaction	J:42373
	increased susceptibility to bacterial infection	J:42373
\Il1r1^tm1Roml/\Il1r1^tm1Roml (NOD.Cg-Il1r1^tm1Roml)	decreased susceptibility to autoimmune diabetes	J:87251
\Il1r1^tm1Roml/\Il1r1^tm1Roml (C.Cg-Il1r1^tm1Roml)	decreased eosinophil cell number	J:82863
	decreased immunoglobulin level	J:82863
	decreased T cell number	J:82863
	decreased T cell proliferation	J:82863
\Il1r1^tm1Roml/\Il1r1^tm1Roml (involves: 129S1/Sv * BALB/c)	impaired neutrophil chemotaxis	J:124226
\Il1r1^tm1Roml/\Il1r1^tm1Roml (involves: 129S1/Sv)	decreased neutrophil cell number	J:193548
\Il1r1^tm1Roml/\Il1r1^tm1Roml (involves: 129S1/Sv)	decreased susceptibility to induced arthritis	J:120707
\Il1r1^tm1Roml/\Il1r1^tm1Roml \Mefv^{tm5.1(MEFV)Chae}/\Mefv^{tm5.1(MEFV)Chae} (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:172117
	increased interleukin-1 beta secretion	J:172117
\Il1r1^tm1Roml/\Il1r1^tm1Roml \Nlrp1a^Neut1/\Nlrp1a^Neut1 (involves: 129S1/Sv * C57BL/6)	abnormal leukocyte cell number	J:191055
	abnormal leukopoiesis	J:191055
	decreased eosinophil cell number	J:191055
	decreased lymphocyte cell number	J:191055
	decreased monocyte cell number	J:191055
	immune system phenotype	J:191055
	increased susceptibility to Riboviria infection	J:191055
\Il1r1^tm1Roml/\Il1r1^tm1Roml \Nlrp3^tm1Hhf/\Nlrp3⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * C57BL/6)	skin inflammation	J:150054
\Il1r2^tm1.2Epi/\Il1r2^tm1.2Epi (involves: BALB/cJ * C57BL/6J * C57BL/6NTac)	abnormal CD8-positive, alpha-beta T cell number	J:347877
	abnormal T cell physiology	J:347877
	increased CD4-positive, alpha-beta T cell number	J:347877
	increased circulating interleukin-1 alpha level	J:347877
	increased circulating interleukin-6 level	J:347877
	increased inflammatory response	J:347877
\Il1r2^tm1Yiw/\Il1r2^tm1Yiw (B6.129P2-Il1r2^tm1Yiw)	abnormal macrophage physiology	J:274653
	immune system phenotype	J:274653
	increased macrophage cytokine production	J:274653
	increased susceptibility to induced arthritis	J:274653
\Il1r2^tm1Yiw/\Il1r2^tm1Yiw \Il1rn^tm1Yiw/\Il1rn^tm1Yiw (B6.129-Il1r2^tm1Yiw Il1rn^tm1Yiw)	increased circulating tumor necrosis factor level	J:274653
\Il1rap^tm1Roml/\Il1rap^tm1Roml (involves: 129S1/Sv)	decreased interleukin-6 secretion	J:68065
\Il1rl1^tm1Anjm/\Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal eosinophil physiology	J:61108
	abnormal interleukin secretion	J:61108
	abnormal T-helper 2 physiology	J:61108
	decreased interleukin-4 secretion	J:61108
	decreased interleukin-5 secretion	J:61108
	granulomatous inflammation	J:61108
\Il1rl1^tm1Anjm/\Il1rl1^tm1Anjm (involves: 129P2/OlaHsd)	decreased eosinophil cell number	J:159464
\Il1rl1^tm1Anjm/\Il1rl1^tm1Anjm (involves: 129P2/OlaHsd)	decreased IgE level	J:159464
\Il1rl1^tm1Anjm/\Il1rl1^tm1Anjm (C.129P2-Il1rl1^tm1Anjm)	increased susceptibility to induced pancreatitis	J:184801
\Il1rl1^tm1Brl/\Il1rl1^tm1Brl (involves: 129S/SvEv * C57BL/6)	abnormal response to infection	J:63507
	decreased interleukin-5 secretion	J:63507
	increased eosinophil cell number	J:63507
\Il1rl2^tm1Hblu/\Il1rl2^tm1Hblu (involves: 129 * C57BL/6)	abnormal dendritic cell physiology	J:296074
\Il1rl2^tm1Hblu/\Il1rl2^tm1Hblu (involves: 129 * C57BL/6)	abnormal macrophage activation involved in immune response	J:296074
\Il1rl2^tm1Hblu/\Il1rl2^tm1Hblu (involves: 129)	abnormal lymph node morphology	J:193548
	decreased gamma-delta T cell number	J:193548
	decreased interleukin-9 secretion	J:256437
	decreased interleukin-17 secretion	J:193548
	decreased leukocyte cell number	J:193548
	decreased macrophage cell number	J:193548
	decreased neutrophil cell number	J:193548
	decreased susceptibility to induced colitis	J:256437
	increased regulatory T cell number	J:256437
\Il1rn^tm1.1Cga/\Il1rn^tm1.1Cga \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (D1.Cg-Il1rn^tm1.1Cga Lyz2^tm1(cre)Ifo)	abnormal chemokine secretion	J:162760
	increased interferon-gamma secretion	J:162760
	increased interleukin-1 beta secretion	J:162760
	increased interleukin-6 secretion	J:162760
	increased interleukin-17 secretion	J:162760
	increased susceptibility to induced arthritis	J:162760
	increased T cell proliferation	J:162760
\Il1rn^tm1Dih/\Il1rn⁺ (involves: 129S/SvEv * C57BL/6J)	decreased susceptibility to bacterial infection	J:36387
\Il1rn^tm1Dih/\Il1rn⁺ (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to endotoxin shock	J:36387
\Il1rn^tm1Dih/\Il1rn^tm1Dih (involves: 129S/SvEv * C57BL/6J)	decreased circulating interleukin-1 level	J:36387
	decreased susceptibility to bacterial infection	J:36387
	increased acute inflammation	J:61600, J:88605
	increased circulating interleukin-6 level	J:61600
	increased circulating serum amyloid protein level	J:61600
	increased susceptibility to endotoxin shock	J:36387
\Il1rn^tm1Nick/\Il1rn⁺ (involves: 129P2/OlaHsd * MF1)	aortitis	J:59410
\Il1rn^tm1Nick/\Il1rn^tm1Nick (involves: 129P2/OlaHsd * MF1)	aortitis	J:59410
	chronic inflammation	J:59410
\Il1rn^tm1Nick/\Il1rn^tm1Nick (involves: 129P2/OlaHsd * MF1 * BALB/cAnNHsd)	aortitis	J:89034
	immune system phenotype	J:89034
	skin inflammation	J:89034
\Il1rn^tm1Nick/\Il1rn^tm1Nick (involves: BALB/cAnNHsd)	aortitis	J:89034
	rheumatoid arthritis	J:89034
	skin inflammation	J:89034
\Il1rn^tm1Nick/\Il1rn^tm1Nick (involves: C57BL/6)	immune system phenotype	J:89034
\Il1rn^tm1Nick/\Il1rn^tm1Nick (involves: BALB/cAnNHsd * C57BL/6)	aortitis	J:89034
	immune system phenotype	J:89034
	rheumatoid arthritis	J:89034
\Il1rn^tm1Sush/\Il1rn^tm1Sush (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:97684
	abnormal dendritic cell differentiation	J:97684
	abnormal dendritic cell number	J:97684
	abnormal immune system organ morphology	J:97684
	abnormal T-helper 1 cell morphology	J:97684
	abnormal T-helper 2 cell morphology	J:97684
	granulomatous inflammation	J:97684
\Il1rn^tm1Yiw/\Il1rn^tm1Yiw (C.129-Il1rn^tm1Yiw)	increased interleukin-17 secretion	J:143719
\Il1rn^tm1Yiw/\Il1rn^tm1Yiw (C.129-Il1rn^tm1Yiw)	rheumatoid arthritis	J:143719
\Il1rn^tm1Yiw/\Il1rn^tm1Yiw \Il17a^tm1Yiw/\Il17a⁺ (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	decreased susceptibility to induced arthritis	J:83408
\Il2^m1/\Il2^m1 (MRL/MpJ)	abnormal T cell activation	J:75331
\Il2^tm1.1Flv/\Il2^tm1.1Flv (NOD/ShiLtJ-Il2^tm1.1Flv)	abnormal susceptibility to autoimmune disorder	J:150823
\Il2^tm1.1Kasm/\Il2^tm1.1Kasm \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/? (involves: 129S/SvEv * C57BL/6)	decreased circulating interleukin-17 level	J:190168
	immune system phenotype	J:190168
\Il2^tm1Hor/\Il2⁺ (NOD.129P2(B6)-Il2^tm1Hor/DvsJ)	increased susceptibility to autoimmune diabetes	J:120349
\Il2^tm1Hor/\Il2^tm1Hor (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:39981, J:39989, J:15573
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:39981, J:15223
	abnormal class switch recombination	J:15573
	abnormal cytotoxic T cell physiology	J:39981
	abnormal gamma-delta intraepithelial T cell morphology	J:15223
	abnormal level of surface class II molecules	J:15223
	abnormal lymphocyte cell number	J:15223
	abnormal lymphocyte morphology	J:37220
	abnormal lymphocyte physiology	J:15223
	abnormal susceptibility to Riboviria infection	J:26861
	abnormal T-helper 1 cell differentiation	J:37220
	abnormal thymocyte activation	J:37220, J:39989
	colitis	J:37220, J:29999, J:15223
	decreased cytotoxic T cell cytolysis	J:15573, J:26198, J:26861
	decreased double-negative T cell number	J:15223
	decreased double-positive T cell number	J:37220
	decreased splenocyte proliferation	J:79241
	decreased T cell proliferation	J:39989, J:26198
	enlarged lymph nodes	J:15223
	enlarged mesenteric lymph nodes	J:29999
	enlarged spleen	J:15223
	impaired natural killer cell mediated cytotoxicity	J:15573
	increased B cell proliferation	J:16662
	increased double-negative T cell number	J:37220
	increased IgA level	J:15223
	increased IgE level	J:16662
	increased IgG1 level	J:39989, J:15223, J:16662
	increased IgG2a level	J:16662
	increased IgG2b level	J:16662
	increased length of allograft survival	J:26198
	increased pre-B cell number	J:16662
	increased pro-B cell number	J:16662
	increased single-positive T cell number	J:37220
	increased T cell proliferation	J:15223, J:16662
	lymph node hyperplasia	J:16662
\Il2^tm1Hor/\Il2^tm1Hor (C.129P2-Il2^tm1Hor)	abnormal lymphocyte morphology	J:29799
	abnormal regulatory T cell physiology	J:112603
	abnormal spleen morphology	J:29799
	enlarged lymph nodes	J:29799
	heart inflammation	J:29799
	increased B cell proliferation	J:29799
	increased germinal center B cell number	J:29799
	increased IgG level	J:29799
	increased inflammatory response	J:29799
	increased plasma cell number	J:29799
	increased spleen red pulp amount	J:29799
	increased susceptibility to autoimmune hemolytic anemia	J:29799
	increased T cell proliferation	J:29799
	liver inflammation	J:29799
	lung inflammation	J:29799
	pancreas inflammation	J:29799
	spleen hyperplasia	J:29799
\Il2^tm1Hor/\Il2^tm1Hor (B6.129P2-Il2^tm1Hor)	immune system phenotype	J:125748
	increased activated T cell number	J:28924
	increased CD4-positive, alpha-beta T cell number	J:28924
	increased CD8-positive, alpha-beta T cell number	J:28924
	increased T cell number	J:125748
	increased T cell proliferation	J:28924
\Il2^tm1Hor/\Il2^tm1Hor (C3.129P2-Il2^tm1Hor)	increased CD4-positive, alpha-beta T cell number	J:28924
\Il2^tm1Hor/\Il2^tm1Hor (C3.129P2-Il2^tm1Hor)	increased CD8-positive, alpha-beta T cell number	J:28924
\Il2^tm1Hor/\Il2^tm1Hor (B6.129P2-Il2^tm1Hor/J)	abnormal circulating cytokine level	J:190168
	abnormal response to transplant	J:113547
	abnormal T cell activation	J:190168
	abnormal T cell proliferation	J:190168
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:131774
	decreased circulating interferon-gamma level	J:190168
	decreased circulating interleukin-4 level	J:190168
	decreased circulating interleukin-13 level	J:190168
	decreased regulatory T cell number	J:113547
	enlarged lymph nodes	J:113547
	increased CD4-positive, alpha-beta T cell number	J:131774
	increased splenocyte number	J:131774
	increased susceptibility to autoimmune disorder	J:113547
	lacrimal gland inflammation	J:125129
	large intestinal inflammation	J:125129
	salivary gland inflammation	J:125129
\Il2^tm1Hor/\Il2^tm1Hor (involves: 129P2/OlaHsd)	increased regulatory T cell number	J:208318
\Il2^tm1Hor/\Il2^tm1Hor (involves: 129P2/OlaHsd * C57BL/6J)	increased circulating interleukin-17 level	J:120176
\Il2^tm1Hor/\Il2^tm1Hor (involves: 129P2/OlaHsd * C57BL/6J)	increased T-helper 17 cell number	J:120176
\Il2^tm1Hor/\Il2^tm1Hor \Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal susceptibility to Riboviria infection	J:26861
	decreased cytotoxic T cell cytolysis	J:26861
	decreased IgG level	J:16662, J:26861
	increased B cell proliferation	J:16662
	increased pre-B cell number	J:16662
	increased pro-B cell number	J:16662
	increased T cell proliferation	J:16662
\Il2^tm1Hor/\Il2^tm1Hor \Rag2^tm1Fwa/\Rag2⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	colitis	J:29999
	enlarged mesenteric lymph nodes	J:29999
\Il2^tm1Hor/\Il2^tm1Hor \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	immune system phenotype	J:29999
\Il2^tm1Hor/\Il2^tm1Hor \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Tcra5CC7,Tcrb5CC7)IWep/0 (involves: 129P2/OlaHsd * C57BL/10)	abnormal T cell number	J:120176
	increased T-helper 17 cell number	J:120176
\Il2^tm1Hor/\Il2^tm1Hor \Tcrb^tm1Mom/\Tcrb^tm1Mom (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:135589
\Il2^tm1Hor/\Il2^tm1Hor \Tg(DO11.10)10Dlo/? (C.Cg-Il2^tm1Hor Tg(DO11.10)10Dlo)	abnormal regulatory T cell physiology	J:88349
	increased activated T cell number	J:88349
	increased T cell proliferation	J:88349
\Il2^tm1Hor/\Il2^tm1Hor \Tg(Pgk1-HA)1.1Vbo/? \Tg(Tcra/Tcrb)1Vbo/? (C.Cg-Il2^tm1Hor Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)	abnormal regulatory T cell physiology	J:112603
	decreased regulatory T cell number	J:112603
	increased regulatory T cell number	J:112603
\Il2ra^M1J/\Il2ra^M1J (involves: 129S4/SvJae * C57BL/6)	abnormal regulatory T cell physiology	J:268677
\Il2ra^{tm1b(EUCOMM)Wtsi}/\Il2ra^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Il2ra^{tm1b(EUCOMM)Wtsi}/Orl)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
\Il2ra^tm1Dw/\Il2ra^tm1Dw (involves: 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:64279
	abnormal lymph organ size	J:64279
	abnormal T cell morphology	J:64279
	abnormal T cell physiology	J:64279
	colitis	J:64279
	enlarged lymph nodes	J:64279
	enlarged spleen	J:64279
	increased IgA level	J:64279
	increased IgG1 level	J:64279
	increased IgG2a level	J:64279
	increased IgG2b level	J:64279
	increased IgG level	J:64279
	increased lymphocyte cell number	J:64279
	increased memory T cell number	J:64279
\Il2ra^tm1Dw/\Il2ra^tm1Dw (B6.129S4-Il2ra^tm1Dw)	abnormal regulatory T cell physiology	J:125748
	abnormal T cell activation	J:125748
	lymphoid hyperplasia	J:125748
\Il2ra^tm1Dw/\Il2ra^tm1Dw (B6.129S4-Il2ra^tm1Dw/J)	lacrimal gland inflammation	J:125129
	large intestinal inflammation	J:125129
	lung inflammation	J:125129
	salivary gland inflammation	J:125129
\Il2ra^tm1Dw/\Il2ra^tm1Dw \Tg(CD2-Ccdc86)1Hfuj/? (B6.Cg-Il2ra^tm1Dw Tg(CD2-Ccdc86)1Hfuj)	immune system phenotype	J:151722
	increased activated T cell number	J:151722
\Il2ra^tm1Dw/\Il2ra^tm1Dw \Tg(Pgk1-HA)1.1Vbo/? \Tg(Tcra/Tcrb)1Vbo/? (C.Cg-Il2ra^tm1Dw Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)	abnormal regulatory T cell physiology	J:112603
	decreased regulatory T cell number	J:112603
	increased regulatory T cell number	J:112603
\Il2rb^m1Btlr/\Il2rb^m1Btlr (C57BL/6J-Il2rb^m1Btlr)	decreased B cell number	J:267694
	decreased CD4-positive, alpha-beta T cell number	J:267694
	decreased CD8-positive, naive alpha-beta T cell number	J:267694
	increased effector memory CD4-positive, alpha-beta T cell number	J:267694
	increased effector memory CD8-positive, alpha-beta T cell number	J:267694
\Il2rb^m2Btlr/\Il2rb^m2Btlr (C57BL/6J-Il2rb^m2Btlr)	increased IgE level	J:272832
\Il2rb^M3Btlr/\Il2rb^M3Btlr (C57BL/6J-Il2rb^M3Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272833
	abnormal T cell morphology	J:272833
	decreased CD8-positive, alpha-beta T cell number	J:272833
	decreased central memory CD8 positive, alpha-beta T cell number	J:272833
	decreased NK cell number	J:272833
	decreased NK T cell number	J:272833
	increased CD4-positive, alpha-beta T cell number	J:272833
	increased IgM level	J:272833
\Il2rb^tm1Mak/\Il2rb^tm1Mak (either: (involves: 129P2/OlaHsd) or (involves: 129S2/SvPas))	abnormal B cell activation	J:25940
	abnormal mononuclear cell morphology	J:25940
	abnormal T cell activation	J:25940
	decreased B cell number	J:25940
	decreased double-positive T cell number	J:25940
	decreased memory T cell number	J:25940
	enlarged lymph nodes	J:25940
	enlarged spleen	J:25940
	increased activated T cell number	J:25940
	increased anti-nuclear antigen antibody level	J:25940
	increased CD4-positive, alpha-beta T cell number	J:25940
	increased CD8-positive, alpha-beta T cell number	J:25940
	increased granulocyte number	J:25940
	increased IgE level	J:25940
	increased IgG1 level	J:25940
	increased neutrophil cell number	J:25940
	increased plasma cell number	J:25940
	increased susceptibility to autoimmune hemolytic anemia	J:25940
	thymus hypoplasia	J:25940
\Il2rb^tm1Mak/\Il2rb^tm1Mak (B6.129-Il2rb^tm1Mak)	abnormal lymphocyte morphology	J:113547
	abnormal response to transplant	J:113547
	abnormal spleen periarteriolar lymphoid sheath morphology	J:113547
	abnormal T cell activation	J:113547
	decreased regulatory T cell number	J:113547
	decreased T cell proliferation	J:113547
	enlarged lymph nodes	J:113547
	enlarged spleen	J:113547
	increased anti-double stranded DNA antibody level	J:113547
	increased susceptibility to autoimmune hemolytic anemia	J:113547
\Il2rb^tm1Mak/\Il2rb^tm1Mak (C.129-Il2rb^tm1Mak)	abnormal immune system organ morphology	J:113547
	abnormal lymphocyte morphology	J:113547
	abnormal marginal zone B cell morphology	J:113547
	abnormal spleen periarteriolar lymphoid sheath morphology	J:113547
	abnormal T cell activation	J:113547
	abnormal T cell clonal deletion	J:113547
	decreased CD8-positive, alpha-beta T cell number	J:113547
	decreased T cell proliferation	J:113547
	enlarged lymph nodes	J:113547
	enlarged spleen	J:113547
	increased anti-double stranded DNA antibody level	J:113547
	increased susceptibility to autoimmune hemolytic anemia	J:113547
	liver inflammation	J:113547
\Il2rb^tm1Mak/\Il2rb^tm1Mak (D2.129-Il2rb^tm1Mak)	abnormal T cell clonal deletion	J:113547
\Il2rb^tm1Mak/\Il2rb^tm1Mak \Lck^tm1Mak/\Lck^tm1Mak (involves: 129)	absent uterine NK cells	J:134589
\Il2rb^tm1Mak/\Il2rb^tm1Mak \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129 * 129S/SvEv)	decreased NK cell number	J:142654
\Il2rg^tm1.1Asin/\Il2rg^tm1Wjl \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:190889
	decreased CD8-positive, alpha-beta T cell number	J:190889
\Il2rg^tm1.1Asin/\Il2rg^tm1Wjl \Tg(Cd8a-cre)B8Asin/0 (involves: 129S4/SvJae C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:190889
	decreased CD8-positive, alpha-beta T cell number	J:190889
	decreased NK T cell number	J:190889
	decreased regulatory T cell number	J:190889
\Il2rg^tm1.1Asin/\Il2rg^tm1Wjl \Tg(Cd8a-cre)B8Asin/0 \Tg(LCKprBCL2)36Sjk/0 (involves: 129S4/SvJae C57BL/6)	decreased NK T cell number	J:190889
\Il2rg^tm1.1Flv/Y \Rag2^tm1.1Flv/\Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:168303
	increased susceptibility to bacterial infection	J:168303
\Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Csf2/Il3^{tm1.1(CSF2,IL3)Flv}/\Csf2/Il3^{tm1.1(CSF2,IL3)Flv} \Rag2^tm1.1Flv/\Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNCr * BALB/cAnNTac)	abnormal response to transplant	J:168302
\Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Rag2^tm1.1Flv/\Rag2^tm1.1Flv (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:168303
	increased susceptibility to bacterial infection	J:168303
\Il2rg^tm1.1Flv/\Il2rg^tm1.1Flv \Rag2^tm1.1Flv/\Rag2^tm1.1Flv \Thpo^{tm1.1(TPO)Flv}/\Thpo^{tm1.1(TPO)Flv} (involves: 129S4/SvJae * BALB/cAnNTac)	abnormal response to transplant	J:168301
\Il2rg^tm1Cgn/Y (involves: 129 * CB20)	abnormal alpha-beta intraepithelial T cell morphology	J:22521
	abnormal class switch recombination	J:22521
	abnormal gamma-delta T cell differentiation	J:111821
	abnormal leukocyte morphology	J:22521
	abnormal thymocyte activation	J:22521
	absent gamma-delta intraepithelial T cell	J:111821
	absent gamma-delta T cells	J:111821
	absent NK cells	J:22521
	absent Peyer's patches	J:22521
	absent spleen germinal center	J:22521
	decreased IgE level	J:22521
	decreased IgM level	J:22521
	decreased mature B cell number	J:22521
	decreased plasma cell number	J:22521
	decreased pre-B cell number	J:22521
	decreased spleen white pulp amount	J:22521
	decreased T cell number	J:22521
	decreased T cell proliferation	J:22521
	impaired natural killer cell mediated cytotoxicity	J:22521
	spleen hypoplasia	J:22521
	thymus hypoplasia	J:111821, J:22521
\Il2rg^tm1Cgn/Y \Rag2^tm1Fwa/\Rag2^tm1Fwa (B6.129-Rag2^tm1Fwa Il2rg^tm1Cgn)	absent B cells	J:132257
	absent NK cells	J:132257
	absent T cells	J:132257
\Il2rg^tm1Cgn/\Il2rg^tm1Cgn (involves: 129 * CB20)	abnormal alpha-beta intraepithelial T cell morphology	J:22521
	abnormal class switch recombination	J:22521
	abnormal leukocyte morphology	J:22521
	abnormal thymocyte activation	J:22521
	absent NK cells	J:22521
	absent Peyer's patches	J:22521
	absent spleen germinal center	J:22521
	decreased IgE level	J:22521
	decreased IgM level	J:22521
	decreased mature B cell number	J:22521
	decreased plasma cell number	J:22521
	decreased pre-B cell number	J:22521
	decreased spleen white pulp amount	J:22521
	decreased T cell number	J:22521
	decreased T cell proliferation	J:22521
	impaired natural killer cell mediated cytotoxicity	J:22521
	spleen hypoplasia	J:22521
	thymus hypoplasia	J:22521
\Il2rg^tm1Cgn/\Il2rg^tm1Cgn \Kit^tm1.1Bsm/\Kit^tm1.1Bsm (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	arrested T cell differentiation	J:90485
\Il2rg^tm1Cgn/\Il2rg^tm1Cgn \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal interleukin secretion	J:142654
	decreased NK cell number	J:142654
	increased susceptibility to bacterial infection	J:142654
\Il2rg^tm1Krf/\Il2rg^tm1Krf (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))	decreased thymocyte number	J:114561
\Il2rg^tm1Krf/\Il2rg^tm1Krf \Tg(BCL2/IGH)1Tjd/0 (either: (involves: 129P2/OlaHsd * C3H/He * C57BL/6) or (involves: 129P2/OlaHsd * C3H/He * C57BL/6 * FVB/N))	decreased thymocyte number	J:114561
\Il2rg^tm1Krf/\Il2rg^tm1Krf \Tg(Igh-Pim1)1Brn/0 (either: (involves: 129P2/OlaHsd * C57BL/6 * CBA) or (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N))	decreased thymocyte number	J:114561
\Il2rg^tm1Sug/Y (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S6/SvEvTac * C57BL/6))	abnormal immune serum protein physiology	J:31167
	abnormal immune system cell morphology	J:31167
	abnormal immune system organ morphology	J:31167
	abnormal immunoglobulin level	J:31167
	abnormal myelopoiesis	J:31167
	abnormal splenic cell ratio	J:31167
	absent NK cells	J:31167
	absent spleen white pulp	J:31167
	arrested B cell differentiation	J:31167
	decreased IgG3 level	J:31167
	decreased IgG level	J:31167
	decreased lymphocyte cell number	J:31167
	decreased T cell number	J:31167
	decreased thymocyte number	J:31167
	enlarged Peyer's patches	J:31167
	enlarged spleen	J:31167
	increased macrophage cell number	J:31167
	increased monocyte cell number	J:31167
	increased neutrophil cell number	J:31167
	small lymph nodes	J:31167
	small thymus	J:31167
	thymus cortex hypoplasia	J:31167
	thymus hypoplasia	J:31167
\Il2rg^tm1Sug/\Il2rg^tm1Sug (B6.129-Il2rg^tm1Sug)	absent uterine NK cells	J:116952
\Il2rg^tm1Wjl/Y (involves: 129S4/SvJae * C57BL/6)	abnormal B cell number	J:108209
	abnormal basophil physiology	J:24117
	abnormal CD4-positive, alpha beta T cell morphology	J:108209
	abnormal cell-mediated immunity	J:108209
	abnormal gut-associated lymphoid tissue morphology	J:24117
	abnormal immune serum protein physiology	J:108209
	abnormal immune system organ morphology	J:108209
	abnormal lymphocyte morphology	J:108209
	abnormal mast cell physiology	J:24117
	abnormal mesenteric lymph node morphology	J:24117
	abnormal thymocyte activation	J:24117
	absent gamma-delta intraepithelial T cell	J:24117
	absent gamma-delta T cells	J:24117
	absent NK cells	J:24117
	cecum inflammation	J:24117
	decreased CD8-positive, alpha-beta T cell number	J:24117
	decreased double-negative T cell number	J:24117
	decreased double-positive T cell number	J:24117
	decreased immature B cell number	J:24117
	decreased immunoglobulin level	J:24117
	decreased interferon-gamma secretion	J:24117
	decreased interleukin-2 secretion	J:24117
	decreased interleukin-4 secretion	J:24117
	decreased single-positive T cell number	J:24117
	decreased T cell proliferation	J:24117
	impaired natural killer cell mediated cytotoxicity	J:24117
	small lymph nodes	J:24117
	small thymus	J:24117
	small thymus cortex	J:24117
	spleen hyperplasia	J:24117
	spleen hypoplasia	J:24117
	thymus hyperplasia	J:108209
\Il2rg^tm1Wjl/Y \Crlf2^tm1Wjl/\Crlf2^tm1Wjl (involves: 129S4/SvJae * C57BL/6)	thymus hypoplasia	J:108209
\Il2rg^tm1Wjl/Y \Prkdc^scid/\Prkdc^scid (NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/Sz)	abnormal immune system organ morphology	J:109833
	abnormal response to transplant	J:109833, J:140388
	abnormal splenic cell ratio	J:109833
	abnormal thymus morphology	J:109833
	decreased CD4-positive, alpha-beta T cell number	J:109833
	decreased CD8-positive, alpha-beta T cell number	J:109833
	decreased immature B cell number	J:109833
	decreased immunoglobulin level	J:109833
	decreased leukocyte cell number	J:109833
	decreased mature B cell number	J:109833
	decreased NK cell number	J:109833
	decreased spleen B cell follicle number	J:109833
	lymph node hypoplasia	J:109833
	small lymph nodes	J:109833
\Il2rg^tm1Wjl/Y \Rag1^tm1Mom/\Rag1^tm1Mom (NOD.Cg-Rag1^tm1Mom Il2rg^tm1Wjl/SzJ)	abnormal adaptive immunity	J:140388
	abnormal innate immunity	J:140388
	abnormal response to transplant	J:140388
	abnormal spleen morphology	J:140388
	abnormal thymus morphology	J:140388
	absent NK T cells	J:140388
	absent thymus cortex	J:140388
	absent thymus medulla	J:140388
	decreased macrophage cell number	J:140388
	decreased spleen B cell follicle number	J:140388
	thymus cyst	J:140388
\Il2rg^tm1Wjl/\Il2rg^tm1Wjl (B6.129S4-Il2rg^tm1Wjl/J)	abnormal dendritic cell physiology	J:123902
	abnormal splenic cell ratio	J:123902
	decreased myeloid dendritic cell number	J:123902
\Il2rg^tm1Wjl/\Il2rg^tm1Wjl \Prkdc^scid/\Prkdc^scid (NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/Sz)	abnormal immune system organ morphology	J:109833
	abnormal response to transplant	J:109833
	abnormal splenic cell ratio	J:109833
	abnormal thymus morphology	J:109833
	decreased CD4-positive, alpha-beta T cell number	J:109833
	decreased CD8-positive, alpha-beta T cell number	J:109833
	decreased immature B cell number	J:109833
	decreased immunoglobulin level	J:109833
	decreased leukocyte cell number	J:109833
	decreased mature B cell number	J:109833
	decreased NK cell number	J:109833
	decreased spleen B cell follicle number	J:109833
	lymph node hypoplasia	J:109833
	small lymph nodes	J:109833
	thymus cyst	J:109833
\Il2rg^tm1Wjl/\Il2rg^tm1Wjl \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * 129S4/SvJae)	abnormal interferon secretion	J:140483
	absent NK cells	J:140483
	absent T cells	J:140483
	increased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
\Il2rg^tm1Wjl/\Il2rg^tm1Wjl \Tg(CD2-Ccdc86)1Hfuj/? (B6.Cg-Il2rg^tm1Wjl Tg(CD2-Ccdc86)1Hfuj)	decreased CD4-positive, alpha-beta T cell number	J:151722
	decreased CD8-positive, alpha-beta T cell number	J:151722
	decreased regulatory T cell number	J:151722
	decreased splenocyte number	J:151722
	immune system phenotype	J:151722
\Il2rg^tm2Cgn/Y \Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased NK cell number	J:132257
\Il3^tm1Glli/\Il3^tm1Glli (either: (involves: 129S2/SvPas * BALB/c) or (involves: 129S2/SvPas * C57BL/6))	abnormal mast cell differentiation	J:80500
	decreased susceptibility to type IV hypersensitivity reaction	J:80640
	increased susceptibility to parasitic infection	J:80500
\Il3^tm1Glli/\Il3^tm1Glli \Kit^W/\Kit^W-v (involves: 129S2/SvPas * C57BL/6 * WB)	increased susceptibility to parasitic infection	J:80500
\Il3ra^m1/\Il3ra^m1 (A/J)	abnormal leukopoiesis	J:23971
\Il4/Il13^tm3Anjm/\Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:89095
	abnormal splenocyte physiology	J:72587
	abnormal susceptibility to infection	J:113543
	abnormal T-helper 2 physiology	J:89095
	decreased IgE level	J:113543, J:72587
	decreased IgG1 level	J:72587
	decreased IgG level	J:89095
	decreased susceptibility to parasitic infection	J:72587
	granulomatous inflammation	J:113543
	increased eosinophil cell number	J:113543
	increased susceptibility to parasitic infection	J:113543, J:89095
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
\Il4/Il13^tm3Anjm/\Il4/Il13^tm3Anjm (C.129P2/OlaHsd-Il4/Il13^tm3Anjm)	abnormal interleukin-4 secretion	J:91403
	decreased IgE level	J:91403
	decreased interferon-gamma secretion	J:91403
	decreased interleukin-5 secretion	J:91403
	decreased interleukin-13 secretion	J:91403
	decreased susceptibility to autoimmune disorder	J:91403
	increased IgG2a level	J:91403
\Il4/Il13^tm3Anjm/\Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * BALB/c)	abnormal splenocyte physiology	J:60609
	abnormal susceptibility to infection	J:60609, J:131994
	decreased IgG1 level	J:178986
	decreased inflammatory response	J:60609, J:165513
	ileum inflammation	J:60609
	increased susceptibility to parasitic infection	J:60609
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
\Il4/Il13^tm3Anjm/\Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:89095
	abnormal splenocyte physiology	J:72587
	abnormal susceptibility to infection	J:113543
	abnormal T-helper 2 physiology	J:89095
	decreased IgE level	J:113543, J:72587
	decreased IgG1 level	J:72587
	decreased IgG level	J:89095
	decreased susceptibility to parasitic infection	J:72587
	granulomatous inflammation	J:113543
	increased eosinophil cell number	J:113543
	increased susceptibility to parasitic infection	J:113543, J:89095
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
\Il4/Il13^tm3Anjm/\Il4/Il13^tm3Anjm (C.129P2/OlaHsd-Il4/Il13^tm3Anjm)	abnormal interleukin-4 secretion	J:91403
	decreased IgE level	J:91403
	decreased interferon-gamma secretion	J:91403
	decreased interleukin-5 secretion	J:91403
	decreased interleukin-13 secretion	J:91403
	decreased susceptibility to autoimmune disorder	J:91403
	increased IgG2a level	J:91403
\Il4/Il13^tm3Anjm/\Il4/Il13^tm3Anjm (involves: 129P2/OlaHsd * BALB/c)	abnormal splenocyte physiology	J:60609
	abnormal susceptibility to infection	J:60609, J:131994
	decreased IgG1 level	J:178986
	decreased inflammatory response	J:60609, J:165513
	ileum inflammation	J:60609
	increased susceptibility to parasitic infection	J:60609
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
\Il4^tm1(CD2)Irvr/\Il4⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:111440
\Il4^tm1(CD2)Mmrs/\Il4^tm1(CD2)Mmrs (involves: 129)	decreased basophil cell number	J:181313
	decreased IgE level	J:178986
	decreased IgG1 level	J:178986
	decreased interleukin-4 secretion	J:181313
\Il4^tm1.1Wep/\Il4⁺ (C.129P2-Il4^tm1.1Wep)	decreased IgE level	J:138827
\Il4^tm1.1Wep/\Il4⁺ \Stat6^tm1Gru/\Stat6^tm1Gru (C.129-Stat6^tm1Gru Il4^tm1.1Wep)	abnormal T-helper 2 cell differentiation	J:138827
	decreased IgE level	J:138827
	impaired eosinophil recruitment	J:138827
\Il4^tm1.1Wep/\Il4^tm1.1Wep (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-4 secretion	J:67964
\Il4^tm1.1Wep/\Il4^tm1.1Wep (C.129P2-Il4^tm1.1Wep)	abnormal T-helper 2 cell differentiation	J:138827
	decreased IgE level	J:138827
	impaired eosinophil recruitment	J:138827
\Il4^tm1.1Wep/\Il4^tm1.1Wep \Stat6^tm1Gru/\Stat6^tm1Gru (C.129-Stat6^tm1Gru Il4^tm1.1Wep)	abnormal T-helper 2 cell differentiation	J:138827
	decreased IgE level	J:138827
	impaired eosinophil recruitment	J:138827
\Il4^tm1Cgn/\Il4^tm1Cgn (B6.Cg-Il4^tm1Cgn)	abnormal humoral immune response	J:89095
\Il4^tm1Cgn/\Il4^tm1Cgn (B6.Cg-Il4^tm1Cgn)	abnormal T-helper 2 physiology	J:89095
\Il4^tm1Cgn/\Il4^tm1Cgn (NOD.129P2-Il4^tm1Cgn)	decreased susceptibility to autoimmune disorder	J:95105
\Il4^tm1Cgn/\Il4^tm1Cgn (NOD.129P2-Il4^tm1Cgn)	increased susceptibility to autoimmune disorder	J:95105
\Il4^tm1Cgn/\Il4^tm1Cgn (NOD.Cg-H2^b Il4^tm1Cgn)	lacrimal gland inflammation	J:105803
\Il4^tm1Cgn/\Il4^tm1Cgn (NOD.Cg-H2^b Il4^tm1Cgn)	salivary gland inflammation	J:105803
\Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * NOD)	abnormal cytokine secretion	J:85924
\Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * NOD)	decreased IgG1 level	J:85924
\Il4^tm1Cgn/\Il4^tm1Cgn (either: NOD.129-Il4^tm1Cgn or (involves: 129 * NOD))	autoimmune response	J:85924
	insulitis	J:85924
\Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:704
	decreased IgE level	J:704
	decreased IgG1 level	J:704
	granulomatous inflammation	J:113543
\Il4^tm1Cgn/\Il4^tm1Cgn (MRL.129P2-Il4^tm1Cgn)	lacrimal gland inflammation	J:132514
\Il4^tm1Cgn/\Il4^tm1Cgn (B6.129P2-Il4^tm1Cgn/J)	immune system phenotype	J:160119, J:44346
\Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)	decreased IgE level	J:39600
	decreased IgG1 level	J:39600
\Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * A/WySn * C57BL/10SnSg * Swiss)	decreased IgG1 level	J:119207
	increased IgG2a level	J:119207
\Il4^tm1Cgn/\Il4^tm1Cgn \Ndfip1^{Gt(RRD002)Byg}/\Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd)	esophageal inflammation	J:205692
	increased CD4-positive, alpha-beta T cell number	J:205692
	increased eosinophil cell number	J:205692
	increased inflammatory response	J:205692
	increased interleukin-2 secretion	J:205692
	increased neutrophil cell number	J:205692
	increased T cell number	J:205692
	lung inflammation	J:205692
\Il4^tm1Cgn/\Il4^tm1Cgn \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (NOD.Cg-Il4^tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased susceptibility to autoimmune diabetes	J:85924
	insulitis	J:85924
\Il4^tm1Kopf/\Il4^tm1Kopf (involves: 129S2/SvPas * C57BL/6)	abnormal response to infection	J:14593
	decreased IgE level	J:14593
	decreased IgG1 level	J:14593
	decreased interleukin-3 secretion	J:14593
	decreased interleukin-4 secretion	J:14593
	decreased interleukin-5 secretion	J:14593
	decreased interleukin-10 secretion	J:14593
	increased IgG level	J:14593
\Il4^tm1Kopf/\Il4^tm1Kopf (involves: 129S2/SvPas)	decreased eosinophil cell number	J:113065
	decreased IgE level	J:113065
	decreased interleukin-5 secretion	J:113065
\Il4^tm1Kopf/\Il4^tm1Kopf \Lyn^tm1Ard/\Lyn^tm1Ard (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal circulating complement protein level	J:161523
	decreased B cell number	J:161523
	decreased IgE level	J:161523
	decreased IgG1 level	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgG2a level	J:161523
	increased IgG2b level	J:161523
	increased IgM level	J:161523
	increased mast cell number	J:161523
\Il4^tm1Lky/\Il4⁺ \Lat^tm1.1Mal/\Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:151840
\Il4^tm1Lky/\Il4^tm1Lky \Itk^tm1Litt/\Itk^tm1Litt (involves: 129S4/SvJae * BALB/c * C57BL/6J)	abnormal cytokine secretion	J:129883
	abnormal response to infection	J:129883
	abnormal T-helper 2 physiology	J:129883
	immune system phenotype	J:129883
\Il4^tm1Nnt/\Il4^tm1Nnt (C57BL/6-Il4^tm1Nnt/J)	abnormal microglial cell morphology	J:125605
	abnormal T-helper 2 physiology	J:37196
	CNS inflammation	J:125605
	decreased IgE level	J:37196
	decreased IgG1 level	J:37196
	decreased IgM level	J:37196
	decreased interleukin-4 secretion	J:37196
	decreased interleukin-5 secretion	J:37196
	decreased interleukin-10 secretion	J:120556, J:37196
	granulomatous inflammation	J:37196
	increased IgA level	J:37196
	increased interferon-gamma secretion	J:120556, J:37196
	stomach inflammation	J:120556
\Il4^tm1Nnt/\Il4^tm1Nnt (involves: C57BL/6)	abnormal interleukin-4 secretion	J:91403
\Il4^tm1Nnt/\Il4^tm1Nnt (involves: C57BL/6)	decreased susceptibility to autoimmune disorder	J:91403
\Il4^tm1Rao/\Il4^tm1Rao (involves: 129S6/SvEvTac * C57BL/6)	abnormal mast cell physiology	J:78089
	abnormal T-helper 2 physiology	J:78089
	decreased interleukin-4 secretion	J:78089
	decreased interleukin-13 secretion	J:78089
\Il4^tm2.1Kubo/\Il4^tm2.1Kubo (B6.Cg-Il4^tm2.1Kubo)	decreased IgE level	J:167446
	decreased IgG1 level	J:167446
	decreased interleukin-4 secretion	J:167446
	impaired eosinophil recruitment	J:167446
	increased IgG2c level	J:167446
	increased interleukin-5 secretion	J:167446
	increased interleukin-13 secretion	J:167446
\Il4^tm2Nnt/\Il4^tm2Nnt (BALB/c-Il4^tm2Nnt/J)	abnormal dendritic cell antigen presentation	J:141937
	abnormal dendritic cell differentiation	J:141937
	decreased IgE level	J:31486
	decreased IgG1 level	J:31486
	decreased interleukin-5 secretion	J:141937
	decreased interleukin-13 secretion	J:141937
	decreased susceptibility to autoimmune disorder	J:141937
	increased interferon-gamma secretion	J:141937
\Il4^tm2Nnt/\Il4^tm2Nnt (BALB/c-Il4^tm2Nnt)	abnormal splenocyte physiology	J:60609
	abnormal susceptibility to infection	J:60609
	ileum inflammation	J:60609
	increased susceptibility to parasitic infection	J:60609
	increased susceptibility to parasitic infection induced morbidity/mortality	J:60609
\Il4^tm2Nnt/\Il4^tm2Nnt \Tgfb1^tm1Doe/\Tgfb1^tm1Doe (C.Cg-Tgfb1^tm1Doe Il4^tm2Nnt)	liver inflammation	J:69346
\Il4^tm3.1Kubo/\Il4^tm3.1Kubo (B6.Cg-Il4^tm3.1Kubo)	decreased interleukin-4 secretion	J:167446
\Il4ppq^NZB/Slc/\Il4ppq^NZW/Slc (involves: NZB/Slc * NZW/Slc)	abnormal cytokine secretion	J:117863
\Il4ra^M1Btlr/\Il4ra^M1Btlr (C57BL/6J-Il4ra^M1Btlr)	decreased IgE level	J:267558
\Il4ra^M2Btlr/\Il4ra^M2Btlr (C57BL/6J-Il4ra^M2Btlr)	decreased IgE level	J:272804
\Il4ra^tm1Fbb/\Il4ra^tm1Fbb (involves: BALB/c)	abnormal susceptibility to infection	J:55526
\Il4ra^tm1Fbb/\Il4ra^tm1Fbb (involves: BALB/cJ)	abnormal circulating cytokine level	J:133518
	abnormal circulating interferon-gamma level	J:133518
	abnormal cytokine secretion	J:114751
	abnormal immune system physiology	J:114751
	abnormal macrophage physiology	J:114751
	decreased T-helper 2 cell number	J:172134
	granulomatous inflammation	J:114751
	impaired macrophage chemotaxis	J:114751
	increased circulating interleukin-4 level	J:133518
	increased susceptibility to infection	J:114751
	increased susceptibility to parasitic infection	J:114751
	liver inflammation	J:114751
\Il4ra^tm1Fbb/\Il4ra^tm2Fbb \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * BALB/c)	abnormal immune system physiology	J:114751
	abnormal macrophage physiology	J:114751
	decreased susceptibility to parasitic infection	J:114751
	granulomatous inflammation	J:114751
	increased susceptibility to parasitic infection	J:114751
	liver inflammation	J:114751
\Il4ra^tm1Sz/\Il4ra^tm1Sz (BALB/c-Il4ra^tm1Sz/J)	abnormal microglial cell morphology	J:125605
	abnormal susceptibility to infection	J:131994
	abnormal T-helper 2 physiology	J:43656
	decreased IgE level	J:43656
	decreased IgG1 level	J:43656
	decreased interleukin-4 secretion	J:43656
	decreased interleukin-5 secretion	J:43656
	decreased interleukin-10 secretion	J:43656
	increased IgG2a level	J:43656
\Il4ra^tm1Sz/\Il4ra^tm1Sz (BALB/c-Il4ra^tm1Sz)	increased IgG2a level	J:110429
\Il4ra^tm1Sz/\Il4ra^tm1Sz (BALB/c-Il4ra^tm1Sz)	increased susceptibility to parasitic infection	J:110429
\Il4ra^tm1Sz/\Il4ra^tm1Sz \Il7r^tm1.1Asin/\Il7r^tm1Imx \Tg(Cd8a-cre)B8Asin/0 (involves: 129S7/SvEvBrd BALB/cJ * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
\Il4ra^tm1Tch/\Il4ra^tm1Tch (involves: 129X1/SvJ * BALB/c)	abnormal immune serum protein physiology	J:86215
	abnormal T-helper 2 cell morphology	J:86215
	decreased T cell proliferation	J:86215
	increased IgE level	J:86215
	increased IgG level	J:86215
	respiratory system inflammation	J:86215
\Il4ra^tm2Tch/\Il4ra^tm2Tch (C.129X1-Il4ra^tm2Tch)	abnormal T-helper 2 physiology	J:152376
	increased circulating interleukin-4 level	J:152376
	increased eosinophil cell number	J:152376
	increased IgE level	J:152376
	increased monocyte cell number	J:152376
	increased susceptibility to type I hypersensitivity reaction	J:152376
	respiratory system inflammation	J:152376
\Il4ra^tm2Tch/\Il4ra^tm2Tch \Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/? (B6.Cg-Il4ra^tm2Tch Tg(Scgb1a1-rtTA,tetO-IL13)1Eli)	increased eosinophil cell number	J:152376
	respiratory system inflammation	J:152376
\Il4ra^tm3.1Tch/\Il4ra^tm3.1Tch (C.129X1-Il4ra^tm3.1Tch)	abnormal macrophage activation involved in immune response	J:160806
	increased IgE level	J:160806
	increased interleukin-4 secretion	J:160806
	increased susceptibility to type I hypersensitivity reaction	J:160806
\Il5^{tm1.1(icre)Lky}/\Il5⁺ (C57BL/6-Il5^{tm1.1(icre)Lky})	decreased circulating interleukin-5 level	J:206097
\Il5^tm1Anjm/\Il5^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:113543
	abnormal mast cell physiology	J:113543
	abnormal susceptibility to infection	J:113543
	decreased eosinophil cell number	J:113543
	decreased IgE level	J:113543
	granulomatous inflammation	J:113543
	increased susceptibility to parasitic infection	J:113543
\Il5^tm1Anjm/\Il5^tm1Anjm \Il9^tm1Anjm/\Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:113543
	abnormal interleukin level	J:113543
	abnormal mast cell morphology	J:113543
	abnormal mast cell physiology	J:113543
	abnormal susceptibility to infection	J:113543
	decreased eosinophil cell number	J:113543
	decreased IgE level	J:113543
	granulomatous inflammation	J:113543
	increased susceptibility to parasitic infection	J:113543
\Il5^tm1Kopf/\Il5^tm1Kopf (C57BL/6-Il5^tm1Kopf/J)	increased eosinophil cell number	J:30867
\Il5^tm1Kopf/\Il5^tm1Kopf (C57BL/6-Il5^tm1Kopf)	granulomatous inflammation	J:107418
	increased interferon-gamma secretion	J:107418
	increased lymphocyte cell number	J:30641
	increased neutrophil cell number	J:30641
\Il5^tm1Ktk/\Il5⁺ (B6.129S4-Il5^tm1Ktk)	decreased interleukin-5 secretion	J:180790
\Il5^tm1Ktk/\Il5^tm1Ktk (B6.129S4-Il5^tm1Ktk)	abnormal B-1 B cell morphology	J:180790
\Il5^tm1Ktk/\Il5^tm1Ktk (B6.129S4-Il5^tm1Ktk)	decreased interleukin-5 secretion	J:180790
\Il5^tm2Anjm/\Il5^tm2Anjm \Il9^tm1Anjm/\Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:113543
	abnormal interleukin level	J:113543
	abnormal susceptibility to infection	J:113543
	granulomatous inflammation	J:113543
	increased eosinophil cell number	J:113543
	increased susceptibility to parasitic infection	J:113543
\Il5^tm3Anjm/\Il5^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	granulomatous inflammation	J:113543
\Il5^tm3Anjm/\Il5^tm3Anjm \Il9^tm1Anjm/\Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	granulomatous inflammation	J:113543
\Il5ra^tm1Ktk/\Il5ra^tm1Ktk (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:33140
	abnormal eosinophil cell number	J:33140
	abnormal immune system physiology	J:33140
	abnormal lymphopoiesis	J:33140
	abnormal T cell differentiation	J:33140
	decreased CD4-positive, alpha-beta T cell number	J:33140
	decreased IgA level	J:33140
	decreased IgG3 level	J:33140
	decreased IgM level	J:33140
	decreased immunoglobulin level	J:33140
	increased susceptibility to parasitic infection	J:33140
\Il5ra^tm1Ktk/\Il5ra^tm1Ktk (B6.129P2-Il5ra^tm1Ktk)	abnormal B-1 B cell morphology	J:89849
	decreased B cell proliferation	J:89849
	decreased B-1 B cell number	J:89849
	decreased IgA level	J:89849
	decreased IgG1 level	J:89849
	decreased IgG3 level	J:89849
	decreased IgM level	J:89849
\Il5ra^tm1Ktk/\Il5ra^tm1Ktk \Lyn^tm1Tya/\Lyn^tm1Tya (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system organ morphology	J:91089
	abnormal spleen B cell corona morphology	J:91089
	abnormal spleen white pulp morphology	J:91089
	decreased B-1 B cell number	J:91089
	enlarged lymph nodes	J:91089
	enlarged spleen	J:91089
	glomerulonephritis	J:91089
	increased anti-double stranded DNA antibody level	J:91089
	increased IgA level	J:91089
	increased IgM level	J:91089
	increased immunoglobulin level	J:91089
\Il6^tm1.1Jho/\Il6^tm1.1Jho \Tg(GFAP-cre)8Gtm/0 (involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * CBA)	microgliosis	J:211914
\Il6^tm1Kopf/\Il6⁺ \Prdm1^tm1Clme/\Prdm1^tm1Clme \Tg(Itgax-cre)1-1Reiz/0 (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:178876
\Il6^tm1Kopf/\Il6⁺ \Tg(ED-L2-IL1RN/IL1B)#Tcw/? (B6.Cg-Il6^tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)	esophageal inflammation	J:180282
\Il6^tm1Kopf/\Il6^tm1Kopf (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:17360
	abnormal microglial cell morphology	J:79142
	abnormal T cell differentiation	J:17360
	decreased cytotoxic T cell cytolysis	J:17360
	decreased T cell number	J:17360
	increased susceptibility to bacterial infection	J:17360
	increased susceptibility to induced colitis	J:79073
	increased susceptibility to Poxviridae infection	J:17360
\Il6^tm1Kopf/\Il6^tm1Kopf (B6.129S2-Il6^tm1Kopf/J)	abnormal interleukin-6 secretion	J:109359
	decreased interferon-gamma secretion	J:123351
	decreased pro-B cell number	J:117320
	decreased susceptibility to induced arthritis	J:208213
	increased interleukin-4 secretion	J:123351
\Il6^tm1Kopf/\Il6^tm1Kopf (involves: 129S2/SvPas)	abnormal inflammatory response	J:160966
	abnormal T cell physiology	J:159479
	decreased interleukin-17 secretion	J:159479
	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
\Il6^tm1Kopf/\Il6^tm1Kopf \Il6st^tm1Ern/\Il6st^tm1Ern (involves: 129S1/Sv * 129S2/SvPas)	decreased susceptibility to endotoxin shock	J:168781
	immune system phenotype	J:139226
\Il6^tm1Kopf/\Il6^tm1Kopf \Inpp5d^tm1Rkh/\Inpp5d^tm1Rkh (involves: 129 * C57BL/6)	abnormal lymphopoiesis	J:117320
	abnormal myelopoiesis	J:117320
	decreased pro-B cell number	J:117320
\Il6^tm1Kopf/\Il6^tm1Kopf \Junb^tm3Wag/\Junb^tm3Wag \Tg(KRT5-cre)1Tak/0 (involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)	immune system phenotype	J:155575
	skin inflammation	J:155575
\Il6^tm1Kopf/\Il6^tm1Kopf \Tank^tm1Aki/\Tank^tm1Aki (involves: 129/Sv * 129S2/SvPas * C57BL/6)	immune system phenotype	J:151757
\Il6^tm1Kopf/\Il6^tm1Kopf \Tg(ED-L2-IL1RN/IL1B)#Tcw/? (B6.Cg-Il6^tm1Kopf Tg(ED-L2-IL1RN/IL1B)#Tcw)	esophageal inflammation	J:180282
\Il6^tm1Kopf/\Il6^tm1Kopf \Tg(Rorc-EGFP)1Ebe/? (involves: 129S2/SvPas * C57BL/6)	abnormal effector T cell morphology	J:137020
\Il6^tm1Mur/\Il6^tm1Mur (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:25684
	immune system phenotype	J:25684
	increased susceptibility to bacterial infection	J:25684
\Il6^tm1Mur/\Il6^tm1Mur (involves: 129/Sv * C57BL/6)	abnormal interferon level	J:40579
	abnormal lymphocyte cell number	J:40579
	absent NK cells	J:40579
	brain inflammation	J:40579
	increased susceptibility to parasitic infection	J:40579
\Il6^tm1Mur/\Il6^tm1Mur (B6.129P2(B6)-Il6^tm1Mur)	abnormal inflammatory response	J:85581
	abnormal microglial cell morphology	J:85581
	abnormal microglial cell physiology	J:85581
	abnormal osteoclast differentiation	J:65093
	abnormal osteoclast physiology	J:65093
\Il6^tm1Poli/\Il6^tm1Poli (involves: 129S/SvEv * MF1)	abnormal macrophage physiology	J:79314
	abnormal neutrophil physiology	J:79314
	abnormal osteoclast physiology	J:17249
	abnormal T-helper 1 cell morphology	J:79314
	abnormal T-helper 1 physiology	J:79314
	abnormal T-helper 2 physiology	J:79314
	decreased circulating interleukin-12 level	J:79314
	decreased IgA level	J:79314
	decreased IgE level	J:79314
	immune system phenotype	J:17249
	increased circulating interleukin-10 level	J:79314
	increased IgG2a level	J:79314
	increased susceptibility to fungal infection	J:79314
\Il6^tm1Poli/\Il6^tm1Poli (involves: 129S/SvEv * C57BL/6)	decreased inflammatory response	J:68063
\Il6^tm1Poli/\Il6^tm1Poli (involves: 129S/SvEv * C57BL/6)	impaired neutrophil recruitment	J:68063
\Il6^tm1Poli/\Il6^tm1Poli (CAnNCrl.129S(Cg)-Il6^tm1Poli)	abnormal B cell proliferation	J:42869
	abnormal immune system physiology	J:96706
	decreased inflammatory response	J:42869
\Il6ra^{tm1.1(IL6R)Csk}/\Il6ra^{tm1.1(IL6R)Csk} (involves: 129S6/SvEvTac * C57BL/6)	abnormal circulating serum amyloid protein level	J:207264
\Il6ra^{tm1.1(IL6R)Csk}/\Il6ra^{tm1.1(IL6R)Csk} \Tg(H2-L-IL6)40Csk/0 (involves: 129S6/SvEvTac * C57BL/6)	enlarged lymph nodes	J:207264
	enlarged spleen	J:207264
	increased plasma cell number	J:207264
	increased spleen weight	J:207264
	increased spleen white pulp amount	J:207264
\Il6ra^tm1.1Drew/\Il6ra^tm1.1Drew \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: C57BL/6 * C57BL/6N * SJL)	immune system phenotype	J:160966
\Il6ra^tm1.1Drew/\Il6ra^tm1.1Drew \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: C57BL/6 * C57BL/6N * SJL)	decreased acute inflammation	J:160966
\Il6ra^tm1.1Jcbr/\Il6ra^tm1.1Jcbr \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-1 beta level	J:188445
	decreased circulating tumor necrosis factor level	J:188445
	decreased susceptibility to parasitic infection	J:188445
\Il6ra^tm1.1Jcbr/\Il6ra^tm1.1Jcbr \Tg(Alb1-cre)7Gsc/0 (involves: C57BL/6 * FVB/N)	decreased circulating interleukin-1 beta level	J:188445
	decreased circulating tumor necrosis factor level	J:188445
	decreased susceptibility to parasitic infection	J:188445
	increased circulating interleukin-6 level	J:166367
	increased circulating tumor necrosis factor level	J:166367
\Il6ra^tm1.2Drew/\Il6ra^tm1.2Drew (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	abnormal inflammatory response	J:160966
\Il6ra^tm1.2Jcbr/\Il6ra^tm1.2Jcbr (involves: C57BL/6)	decreased circulating interleukin-1 beta level	J:188445
	decreased circulating tumor necrosis factor level	J:188445
	decreased susceptibility to parasitic infection	J:188445
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:188445
	liver inflammation	J:202764
\Il6ra^tm1Saj/\Il6ra^tm1Saj (involves: 129P2/OlaHsd * C57BL/6J)	abnormal CD4-positive, alpha-beta T cell physiology	J:159479
\Il6st^tm1Ard/\Il6st^tm1Ard (involves: 129S1/Sv * C57BL/6)	abnormal leukocyte cell number	J:110742
	abnormal thrombopoiesis	J:110742
	cecum inflammation	J:79555
	conjunctivitis	J:79555
	decreased IgA level	J:79555
	decreased IgG level	J:79555
	decreased immunoglobulin level	J:79555
	increased inflammatory response	J:79555
	increased susceptibility to induced colitis	J:79073
	increased susceptibility to parasitic infection	J:79555
\Il6st^tm1Ern/\Il6st^tm1Ern (involves: 129S1/Sv * C57BL/6)	abnormal inflammatory response	J:139226
	decreased susceptibility to induced colitis	J:79073
	enlarged spleen	J:79073
	increased osteoclast cell number	J:87612
	increased susceptibility to induced arthritis	J:142883
	stomach inflammation	J:87206
\Il6st^tm1Ern/\Il6st^tm1Ern (involves: 129S1/Sv)	increased circulating interleukin-6 level	J:168781
	increased interleukin-6 secretion	J:168781
	increased neutrophil cell number	J:168781
	increased susceptibility to endotoxin shock	J:168781
\Il6st^tm1Ern/\Il6st^tm1Ern \Stat1^tm1Rds/\Stat1^tm1Rds (involves: 129S1/Sv)	abnormal inflammatory response	J:139226
\Il6st^tm1Ern/\Il6st^tm1Ern \Stat3^tm1Aki/\Stat3⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	decreased circulating interleukin-6 level	J:168781
	decreased susceptibility to endotoxin shock	J:168781
	immune system phenotype	J:100160, J:142883, J:139226
\Il6st^tm1Ern/\Il6st^tm1Ern \Tg(RP11-H2112)5Trme/0 (involves: 129S1/Sv * C57BL/6J * DBA/2J)	abnormal spleen size	J:234656
\Il6st^tm1Ern/\Il6st^tm1Ern \Tg(RP11-H2112)9Trme/0 (involves: 129S1/Sv * C57BL/6J * DBA/2J)	abnormal spleen size	J:234656
\Il6st^tm1Ern/\Il6st^tm1Ern \Tirap^tm1.1Pjh/\Tirap^tm1.1Pjh (involves: 129S1/Sv)	decreased circulating interleukin-6 level	J:168781
	decreased susceptibility to endotoxin shock	J:168781
\Il6st^tm1Kish/\Il6st^tm1Kish (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:75419
\Il6st^tm1Kish/\Il6st^tm1Kish (involves: 129P2/OlaHsd * CD-1)	abnormal bone marrow development	J:88710
	abnormal osteoclast differentiation	J:88710
	abnormal osteoclast morphology	J:88710
	abnormal osteoclast physiology	J:88710
	increased osteoclast cell number	J:88710
\Il6st^tm1Thir/\Il6st^tm1Thir (Not Specified)	abnormal B cell physiology	J:59922
	abnormal dendritic cell antigen presentation	J:113335
	decreased interleukin-4 secretion	J:59922
	enlarged axillary lymph nodes	J:59922
	enlarged cervical lymph nodes	J:59922
	enlarged inguinal lymph nodes	J:59922
	enlarged mesenteric lymph nodes	J:59922
	increased B cell number	J:59922
	increased CD4-positive, alpha-beta T cell number	J:59922
	increased CD8-positive, alpha-beta T cell number	J:59922
	increased IgG2a level	J:59922
	increased IgG2b level	J:59922
	increased interferon-gamma secretion	J:59922
	lymph node hyperplasia	J:59922
	spleen hyperplasia	J:59922
\Il6st^tm1Thir/\Il6st^tm1Thir (involves: 129 * C57BL/6)	abnormal T cell activation	J:133059
	abnormal T cell clonal deletion	J:133059
	abnormal thymocyte activation	J:133059
	decreased double-positive T cell number	J:133059
	increased activated T cell number	J:133059
	increased anti-double stranded DNA antibody level	J:133059
	increased anti-nuclear antigen antibody level	J:133059
	increased anti-single stranded DNA antibody level	J:133059
	increased autoantibody level	J:133059
	increased double-negative T cell number	J:133059
	increased IgA level	J:133059
	increased IgG1 level	J:133059
	increased IgG2a level	J:133059
	increased IgG2b level	J:133059
	increased neutrophil cell number	J:133059
	increased single-positive T cell number	J:133059
	rheumatoid arthritis	J:133059
\Il6st^tm1Thir/\Il6st^tm1Thir \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:133059
\Il6st^tm1Thir/\Il6st^tm1Thir \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129 * C57BL/6 * DBA)	abnormal negative T cell selection	J:133059
\Il6st^tm1Wme/\Il6st^tm1Wme (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:67677
	abnormal T cell differentiation	J:67677
	abnormal thrombopoiesis	J:67677
	decreased thymocyte number	J:67677
	increased IgE level	J:67677
	increased IgG level	J:67677
	increased leukocyte cell number	J:67677
\Il6st^tm2Thir/\Il6st^tm2Thir (Not Specified)	abnormal dendritic cell antigen presentation	J:113335
	decreased B-1a cell number	J:59922
	decreased IgG1 level	J:59922
	decreased IgG2a level	J:59922
	decreased IgG2b level	J:59922
	decreased interferon-gamma secretion	J:59922
	increased IgM level	J:59922
\Il6st^tm3Thir/\Il6st^tm3Thir (Not Specified)	decreased IgA level	J:59922
	decreased IgG2a level	J:59922
	decreased IgG2b level	J:59922
\Il7^hlb368/\Il7^hlb368 (C57BL/6J-Il7^hlb368/J)	abnormal T cell subpopulation ratio	J:118450
	absent axillary lymph nodes	J:118450
	absent cervical lymph nodes	J:118450
	absent mesenteric lymph nodes	J:118450
	absent Peyer's patches	J:118450
	absent popliteal lymph nodes	J:118450
	decreased leukocyte cell number	J:82961, J:118450
	decreased T cell number	J:118450
	small inguinal lymph nodes	J:118450
	small spleen	J:118450
	small thymus	J:118450
	spleen hypoplasia	J:118450
	thymus hypoplasia	J:118450
\Il7^m1Jyen/\Il7^m1Jyen (involves: C3H * C57BL/6)	abnormal myeloid leukocyte morphology	J:136470
	decreased B cell number	J:136470
	decreased single-positive T cell number	J:136470
	lymph node hypoplasia	J:136470
	spleen hypoplasia	J:136470
	thymus hypoplasia	J:136470
\Il7^tm1.1Mysl/\Il7⁺ (B6.129P2(Cg)-Il7^tm1.1Mysl)	decreased T cell number	J:200544
\Il7^tm1.1Mysl/\Il7⁺ (B6.129P2(Cg)-Il7^tm1.1Mysl)	small lymph nodes	J:200544
\Il7^tm1.1Mysl/\Il7^tm1.1Mysl (B6.129P2(Cg)-Il7^tm1.1Mysl)	abnormal mesenteric lymph node morphology	J:200544
	arrested B cell differentiation	J:200544
	decreased T cell number	J:200544
	decreased thymocyte number	J:200544
	immune system phenotype	J:200544
	small lymph nodes	J:200544
	thymus hypoplasia	J:200544
\Il7^tm1Dnax/\Il7^tm1Dnax (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	absent lymph nodes	J:24165
	absent Peyer's patches	J:24165
	arrested B cell differentiation	J:24165
	decreased lymphocyte cell number	J:24165
	decreased spleen weight	J:24165
	decreased thymus weight	J:24165
	small spleen	J:24165
	small thymus	J:24165
	spleen hypoplasia	J:24165
	thymus hypoplasia	J:24165
\Il7^tm1Dnax/\Il7^tm1Dnax (involves: 129P2/OlaHsd)	decreased thymocyte number	J:64861
\Il7^tm1Dnax/\Il7^tm1Dnax \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	decreased NK cell number	J:132257
\Il7^tm1Hms/\Il7^tm1Hms (involves: 129S6/SvEvTac)	spleen hypoplasia	J:43971
\Il7^tm1Hms/\Il7^tm1Hms (involves: 129S6/SvEvTac)	thymus hypoplasia	J:43971
\Il7^tm2.1Iku/\Il7^tm2.1Iku \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA)	abnormal B cell differentiation	J:190615
	abnormal NK T cell physiology	J:190615
	decreased B cell number	J:190615
	decreased double-negative T cell number	J:190615
	decreased lymphocyte cell number	J:190615
	decreased NK T cell number	J:190615
	decreased T cell number	J:190615
	immune system phenotype	J:190615
\Il7r^tm1.1Asin/\Il7r^tm1Imx \Tg(Cd4-cre)1Cwi/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:190889
\Il7r^tm1.1Asin/\Il7r^tm1Imx \Tg(Cd8a-cre)B8Asin/0 (involves: 129S7/SvEvBrd C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
\Il7r^tm1Abra/\Il7r^tm1Abra (B6.129S4-Il7r^tm1Abra)	abnormal CD4-positive, alpha-beta T cell physiology	J:125360
	abnormal T cell differentiation	J:125360
	abnormal T cell proliferation	J:125360
	decreased B cell number	J:125360
	decreased CD4-positive, alpha-beta T cell number	J:125360
	decreased CD8-positive, alpha-beta T cell number	J:125360
	decreased memory T cell number	J:125360
	decreased thymocyte number	J:125360
	increased double-positive T cell number	J:125360
\Il7r^tm1Iku/\Il7r^tm1Iku (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:34658
	abnormal gamma-delta T cell differentiation	J:34658
	abnormal T cell subpopulation ratio	J:34658
	absent mature gamma-delta T cells	J:34658
	absent Peyer's patches	J:45633
	decreased B-1 B cell number	J:34658
	decreased double-positive T cell number	J:34658
	decreased immature B cell number	J:34658
	decreased leukocyte cell number	J:34658
	decreased lymphocyte cell number	J:34658
	decreased mature B cell number	J:34658
	decreased T cell number	J:34658
	immune system phenotype	J:34658
	increased double-negative T cell number	J:34658
	small thymus	J:34658
	spleen hypoplasia	J:34658
	thymus hypoplasia	J:34658
\Il7r^tm1Imx/\Il7r^tm1Imx (involves: 129P3/J * 129S7/SvEvBrd)	arrested B cell differentiation	J:21135
	arrested T cell differentiation	J:21135
	decreased B cell number	J:21135
	decreased T cell number	J:21135
	lymph node hypoplasia	J:21135
	spleen hypoplasia	J:21135
	thymus hypoplasia	J:21135
\Il7r^tm1Imx/\Il7r^tm1Imx (B6.129S7-Il7r^tm1Imx)	abnormal T cell differentiation	J:125360
	decreased double-positive T cell number	J:125360
	decreased thymocyte number	J:125360
\Il7r^tm1Imx/\Il7r^tm1Imx (involves: 129S7/SvEvBrd)	decreased thymocyte number	J:64861
\Il7r^tm1Imx/\Il7r^tm1Imx \Tg(Lck-Il7r)1676Trma/? (involves: 129S7/SvEvBrd * C57BL/6 * SJL)	decreased T cell proliferation	J:66400
	decreased thymocyte number	J:66400
	increased thymocyte apoptosis	J:66400
\Il7r^tm2Iku/\Il7r^tm2Iku \Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:193283
	abnormal CD8-positive, alpha-beta T cell differentiation	J:193283
	abnormal T cell morphology	J:193283
	decreased NK T cell number	J:193283
	increased B cell number	J:193283
	increased gamma-delta T cell number	J:193283
	increased thymocyte number	J:193283
\Il7r^tm2Iku/\Il7r^tm2Iku \Tg(Cd4-cre)1Cwi/? \Tg(H2-K-BCL2)1Josd/? (involves: 129S6/SvEvTac * C57BL/6 * C3H * DBA/2)	immune system phenotype	J:193283
\Il9^tm1Anjm/\Il9^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:82881
	abnormal response to infection	J:82881
	granulomatous inflammation	J:82881, J:113543
	increased susceptibility to parasitic infection	J:82881
\Il9^tm1Anjm/\Il9^tm1Anjm (involves: C57BL/6)	abnormal cytokine secretion	J:115764
\Il9^tm1Anjm/\Il9^tm1Anjm (involves: C57BL/6)	immune system phenotype	J:115764
\Il9^tm1Flv/\Il9^tm1Flv (BALB/c-Il9^tm1Flv)	increased susceptibility to parasitic infection	J:208730
\Il9r^tm1Jcrd/\Il9r^tm1Jcrd (involves: C57BL/6)	abnormal regulatory T cell physiology	J:151907
	immune system phenotype	J:115764
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151907
	increased T-helper 1 cell number	J:151907
\Il10^tm1.1Roer/\Il10^tm1.1Roer (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:94537
	abnormal hypersensitivity reaction	J:94537
	abnormal innate immunity	J:94537
	increased susceptibility to bacterial infection	J:94537
	intestinal inflammation	J:94537
\Il10^tm1.1Roer/\Il10^tm1.1Roer (involves: 129P2/OlaHsd)	abnormal myeloid leukocyte morphology	J:151551
	decreased circulating interleukin-10 level	J:151551
	increased B cell number	J:151551
	increased myeloid dendritic cell number	J:151551
	increased plasma cell number	J:151551
	increased susceptibility to endotoxin shock	J:151551
	increased T cell number	J:151551
	spleen hyperplasia	J:151551
\Il10^tm1Cgn/\Il10^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:35020
	abnormal immune system physiology	J:35020
	abnormal interferon level	J:35020, J:107077, J:125760
	abnormal interleukin level	J:35020, J:107077, J:51636
	abnormal Langerhans cell physiology	J:51636
	abnormal leukocyte morphology	J:35020
	abnormal level of surface class II molecules	J:15222
	abnormal lymphocyte cell number	J:35020
	abnormal myelopoiesis	J:15222
	abnormal response to infection	J:15222
	abnormal tumor necrosis factor level	J:107077, J:51636
	abnormal type IV hypersensitivity reaction	J:35510
	cecum inflammation	J:35020
	chronic inflammation	J:15222
	colitis	J:68476
	decreased length of allograft survival	J:44346
	decreased spleen iron level	J:15222
	decreased spleen red pulp amount	J:15222
	decreased T cell proliferation	J:125760
	immune system phenotype	J:107077, J:15222
	increased CD4-positive, alpha-beta T cell number	J:35020
	increased granulocyte number	J:35020, J:15222
	increased IgE level	J:62283
	increased IgG1 level	J:62283
	increased IgG2a level	J:62283
	increased interferon-gamma secretion	J:15222
	increased susceptibility to parasitic infection	J:123927
	increased susceptibility to type IV hypersensitivity reaction	J:51636
	increased thymus weight	J:107077
	intestinal inflammation	J:35020, J:107077, J:15222
	large intestinal inflammation	J:35020
	small intestinal inflammation	J:35020
	thymus hyperplasia	J:107077
\Il10^tm1Cgn/\Il10^tm1Cgn (involves: 129P2/OlaHsd)	abnormal cytokine secretion	J:117122
	abnormal inflammatory response	J:117122
	increased circulating interleukin-12 level	J:118833
	increased circulating tumor necrosis factor level	J:118833
	increased susceptibility to endotoxin shock	J:117122, J:118833
	intestinal inflammation	J:113376
\Il10^tm1Cgn/\Il10^tm1Cgn (B6.129P2-Il10^tm1Cgn/J)	abnormal chemokine level	J:157787
	abnormal cytokine level	J:157787, J:139972
	abnormal regulatory T cell physiology	J:125748
	cecum inflammation	J:157787
	increased circulating interferon-gamma level	J:157787
	increased circulating interleukin-1 alpha level	J:157787
	increased circulating interleukin-1 beta level	J:157787, J:139972
	increased circulating interleukin-2 level	J:157787
	increased circulating interleukin-6 level	J:157787, J:139972
	increased circulating interleukin-12 level	J:157787
	increased circulating interleukin-17 level	J:157787
	increased circulating tumor necrosis factor level	J:157787
	increased susceptibility to induced colitis	J:157787
	increased susceptibility to parasitic infection	J:157787
	large intestinal inflammation	J:149347
\Il10^tm1Cgn/\Il10^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6 * DBA/1)	colitis	J:84100
\Il10^tm1Cgn/\Il10^tm1Cgn (involves: 129P2/OlaHsd * 129S/SvEv)	colitis	J:59872
\Il10^tm1Cgn/\Il10^tm1Cgn (B10.129P2(B6)-Il10^tm1Cgn/J)	decreased length of allograft survival	J:44346
\Il10^tm1Cgn/\Il10^tm1Cgn (B6.129P2-Il10^tm1Cgn)	abnormal circulating interleukin-6 level	J:191723
\Il10^tm1Cgn/\Il10^tm1Cgn (B6.129P2-Il10^tm1Cgn)	abnormal circulating interleukin-12b level	J:191723
\Il10^tm1Cgn/\Il10^tm1Cgn \Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 cell differentiation	J:111712
	increased interferon-gamma secretion	J:111712
\Il10^tm1Cgn/\Il10^tm1Cgn \Il12b^tm1Jm/\Il12b^tm1Jm (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	abnormal T-helper 2 cell differentiation	J:111712
	increased interleukin-13 secretion	J:111712
\Il10^tm1Cgn/\Il10^tm1Cgn \Il27ra^tm1Mak/\Il27ra^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 physiology	J:136179
	abnormal T-helper 2 physiology	J:136179
	colitis	J:136179
	decreased interferon-gamma secretion	J:136179
	decreased susceptibility to induced colitis	J:136179
	increased interleukin-13 secretion	J:136179
\Il10^tm1Cgn/\Il10^tm1Cgn \Nfil3^tm1Look/\Nfil3^tm1Look (involves: 129P2/OlaHsd * 129X1/SvJ)	colitis	J:209365
	increased interleukin-12 secretion	J:209365
\Il10^tm1Cgn/\Il10^tm1Cgn \Nfil3^tm1Pbro/\Nfil3^tm1Pbro (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	colitis	J:209365
	increased interleukin-12 secretion	J:209365
\Il10^tm1Cgn/\Il10^tm1Cgn \Rps6ka4^tm1Jsca/\Rps6ka4^tm1Jsca \Rps6ka5^tm1Jsca/\Rps6ka5^tm1Jsca (B6.Cg-Il10^tm1Cgn Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca)	decreased interleukin-10 secretion	J:139576
	increased interleukin-6 secretion	J:139576
	increased interleukin-12a secretion	J:139576
	increased interleukin-12b secretion	J:139576
	increased tumor necrosis factor secretion	J:139576
\Il10^tm1Cgn/\Il10^tm1Cgn \Tg(MUC1)79.24Gend/0 (B6.Cg-Il10^tm1Cgn Tg(MUC1)79.24Gend)	large intestinal inflammation	J:149347
\Il10^tm1Cgn/\Il10^tm1Cgn \Tg(Vil1-cre)997Gum/? \Tlr5^tm1.1Gewr/\Tlr5^tm1.1Gewr (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac * SJL)	colitis	J:229155
\Il10^tm1Cgn/\Il10^tm1Cgn \Tlr5^tm1.1Gewr/\Tlr5^tm1.1Gewr (involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NTac)	colitis	J:229155
\Il10^tm1Cgn/\Il10^tm1Cgn \Vdr^tm1Mbd/\Vdr^tm1Mbd (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:107077
	abnormal cytokine level	J:107077
	abnormal lymph node cell ratio	J:107077
	abnormal splenic cell ratio	J:107077
	abnormal thymus corticomedullary boundary morphology	J:107077
	abnormal thymus involution	J:107077
	absent spleen white pulp	J:107077
	colitis	J:107077
	decreased lymphocyte cell number	J:107077
	decreased T cell proliferation	J:107077
	enlarged mesenteric lymph nodes	J:107077
	enlarged spleen	J:107077
	increased macrophage cell number	J:107077
	increased neutrophil cell number	J:107077
	increased spleen red pulp amount	J:107077
	increased T cell apoptosis	J:107077
	intestinal inflammation	J:107077
	thymus hypoplasia	J:107077
\Il10^tm1Keny/\Il10⁺ \Nfil3^tm1.1Kubo/\Nfil3^tm1.1Kubo (involves: 129 * C57BL/6)	decreased interleukin-10 secretion	J:172134
\Il10^tm1Mhry/\Il10^tm1Mhry (involves: 129P2/OlaHsd * C57BL/6)	intestinal inflammation	J:117628
\Il10^tm1Roer/\Il10^tm1Roer \Foxp3^{tm4(YFP/icre)Ayr}/Y (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal regulatory T cell physiology	J:134513
	abnormal type IV hypersensitivity reaction	J:134513
	colitis	J:134513
	decreased interleukin-10 secretion	J:134513
	lung inflammation	J:134513
\Il10^tm1Roer/\Il10^tm1Roer \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal cytokine secretion	J:94537
	abnormal hypersensitivity reaction	J:94537
	abnormal lymph node morphology	J:94537
	increased susceptibility to parasitic infection	J:94537
	intestinal inflammation	J:94537
	liver inflammation	J:94537
	peritoneal inflammation	J:94537
\Il10^tm2Roer/\Il10^tm2Roer \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:117122
	abnormal inflammatory response	J:117122
	increased susceptibility to endotoxin shock	J:117122
\Il10^tm2Roer/\Il10^tm2Roer \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal inflammatory response	J:117122
	increased susceptibility to endotoxin shock	J:117122
\Il10ra^m1Jskg/\Il10ra^m1Jskg (B6.Cg-Il10ra^m1Jskg)	colitis	J:146644
\Il10ra^NZW/\Il10ra⁺ ((NZB x NZW)F1)	increased anti-chromatin antibody level	J:102087
\Il10ra^NZW/\Il10ra⁺ ((NZB x NZW)F1)	increased IgG level	J:102087
\Il10ra^tm1.1Jack/\Il10ra^tm1.1Jack \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal chemokine level	J:157787
	abnormal cytokine level	J:157787
	increased circulating interferon-gamma level	J:157787
	increased circulating interleukin-1 alpha level	J:157787
	increased circulating interleukin-1 beta level	J:157787
	increased circulating interleukin-2 level	J:157787
	increased circulating interleukin-12 level	J:157787
	increased circulating interleukin-17 level	J:157787
	increased circulating tumor necrosis factor level	J:157787
	increased susceptibility to parasitic infection	J:157787
\Il10ra^tm1.1Jack/\Il10ra^tm1.1Jack \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)	immune system phenotype	J:157787
\Il10ra^tm1.1Tlg/\Il10ra^tm1.1Tlg \Tg(Cd4-cre)1Cwi/? (B6.Cg-Tg(Cd4-cre)1Cwi Il10ra^tm1.1Tlg)	abnormal lymphocyte cell number	J:189797
	abnormal regulatory T cell number	J:189797
	autoimmune response	J:189797
	decreased splenocyte proliferation	J:189797
	decreased T cell number	J:189797
	immune system phenotype	J:189797
\Il10ra^tm1.2Jack/\Il10ra^tm1.2Jack (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)	abnormal chemokine level	J:157787
	abnormal cytokine level	J:157787
	cecum inflammation	J:157787
	increased circulating interferon-gamma level	J:157787
	increased circulating interleukin-1 alpha level	J:157787
	increased circulating interleukin-1 beta level	J:157787
	increased circulating interleukin-2 level	J:157787
	increased circulating interleukin-6 level	J:157787
	increased circulating interleukin-12 level	J:157787
	increased circulating interleukin-17 level	J:157787
	increased circulating tumor necrosis factor level	J:157787
	increased susceptibility to induced colitis	J:157787
	increased susceptibility to parasitic infection	J:157787
\Il10ra^{tm1b(KOMP)Wtsi}/\Il10ra^{tm1b(KOMP)Wtsi} (C57BL/6N-Il10ra^{tm1b(KOMP)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Il10rb^tm1Agt/\Il10rb^tm1Agt (involves: 129S2/SvPas * C57BL/6)	abnormal granulocyte differentiation	J:45917
	abnormal lymph node medullary cord morphology	J:45917
	abnormal mesenteric lymph node morphology	J:45917
	abnormal spleen morphology	J:45917
	colitis	J:134156
	increased interferon-gamma secretion	J:134156
	increased interleukin-17 secretion	J:134156
	increased leukocyte cell number	J:45917
	increased spleen weight	J:45917
	large intestinal inflammation	J:45917
	spleen hyperplasia	J:45917
\Il10rb^tm1Agt/\Il10rb^tm1Agt \Tg(Cd4-TGFBR2)16Flv/? (involves: 129S2/SvPas * C3H * C57BL/6)	abnormal cytokine level	J:134156
	abnormal cytokine secretion	J:134156
	colitis	J:134156
	increased circulating interferon-gamma level	J:134156
	increased circulating interleukin-6 level	J:134156
	increased circulating tumor necrosis factor level	J:134156
	increased interferon-gamma secretion	J:134156
	increased interleukin-17 secretion	J:134156
	increased tumor necrosis factor secretion	J:134156
	liver inflammation	J:134156
	lung inflammation	J:134156
	proctitis	J:134156
\Il11^tm2.1Moto/\Il11^tm2.1Moto \Tg(BGLAP-cre)1Clem/0 (involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/NJ)	abnormal circulating interleukin level	J:345337
\Il11ra1^tm1Gos/\Il11ra1^tm1Gos (involves: 129S2/SvPas * C57BL/6J)	immune system phenotype	J:48920
\Il11ra1^tm1Gos/\Il11ra1^tm1Gos (involves: 129S2/SvPas * C57BL/6J * CD-1)	abnormal NK cell differentiation	J:93811
	abnormal uterine NK cell morphology	J:93811
\Il11ra1^tm1Wehi/\Il11ra1^tm1Wehi (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:42921, J:79073
\Il11ra1^tm1Wehi/\Il11ra1^tm1Wehi \Il6^tm1Kopf/\Il6^tm1Kopf (involves: 129/Sv * C57BL/6)	increased susceptibility to induced colitis	J:79073
\Il12a^m1Btlr/\Il12a^m1Btlr (C57BL/6J-Il12a^m1Btlr)	increased susceptibility to Herpesvirales infection	J:267667
\Il12a^tm1Cab/\Il12a^tm1Cab (involves: 129S4/SvJae * C57BL/6)	decreased circulating interferon-gamma level	J:54482
	decreased circulating interleukin-12 level	J:54482
\Il12a^tm1Cab/\Il12a^tm1Cab (B6.129S4-Il12a^tm1Cab)	abnormal NK cell physiology	J:79552
\Il12a^tm1Cab/\Il12a^tm1Cab (B6.129S4-Il12a^tm1Cab)	decreased circulating interferon-gamma level	J:79552
\Il12a^tm1Cab/\Il12a^tm1Cab \Il23a^tm1.1Thak/\Il23a^tm1.1Thak (B6.Cg-Il12a^tm1Cab Il23a^tm1.1Thak)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:143970
\Il12a^tm1Jm/\Il12a^tm1Jm (129S1/Sv-Il12a^tm1Jm)	abnormal CD4-positive, alpha-beta T cell physiology	J:34164
	decreased susceptibility to type IV hypersensitivity reaction	J:34164
	increased susceptibility to parasitic infection	J:34164
\Il12a^tm1Jm/\Il12a^tm1Jm (B6.129S1-Il12a^tm1Jm)	immune system phenotype	J:120806
\Il12a^tm1Jm/\Il12a^tm1Jm (C.129S1-Il12a^tm1Jm)	impaired natural killer cell mediated cytotoxicity	J:125611
\Il12a^tm1Jm/\Il12a^tm1Jm (involves: 129S1/Sv)	abnormal NK cell physiology	J:139001
\Il12a^tm1Jm/\Il12a^tm1Jm \Il12b^tm1Jm/\Il12b^tm1Jm (B6.129S1-Il12a^tm1Jm Il12b^tm1Jm)	impaired natural killer cell mediated cytotoxicity	J:125611
\Il12a^tm1Jm/\Il12a^tm1Jm \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * 129S1/Sv * 129S6/SvEvTac)	abnormal interferon secretion	J:140483
	decreased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
\Il12b^tm1Jm/\Il12b^tm1Jm (B6.129S1-Il12b^tm1Jm/J)	abnormal CD8-positive, alpha-beta T cell physiology	J:111568
	abnormal granulocyte physiology	J:111568
	abnormal lymphocyte physiology	J:120806
	abnormal macrophage physiology	J:111568
	abnormal NK cell physiology	J:120806
	decreased circulating interferon-gamma level	J:120806
	decreased interleukin-17 secretion	J:111568
	decreased susceptibility to type IV hypersensitivity reaction	J:120806
	increased susceptibility to bacterial infection	J:120806
\Il12b^tm1Jm/\Il12b^tm1Jm (129S1/Sv-Il12b^tm1Jm)	abnormal CD4-positive, alpha-beta T cell physiology	J:34164
	decreased susceptibility to type IV hypersensitivity reaction	J:34164
	increased susceptibility to parasitic infection	J:34164
\Il12b^tm1Jm/\Il12b^tm1Jm (involves: 129S1/SvImJ)	abnormal T-helper 1 physiology	J:46514
	decreased interferon-gamma secretion	J:46514
	impaired natural killer cell mediated cytotoxicity	J:46514
\Il12b^tm1Jm/\Il12b^tm1Jm (involves: 129S1/Sv)	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
\Il12b^tm1Jm/\Il12b^tm1Jm \Il18^tm1Aki/\Il18^tm1Aki (involves: 129P2/OlaHsd * 129S1/SvImJ)	abnormal T-helper 1 physiology	J:46514
	decreased interferon-gamma secretion	J:46514
	impaired natural killer cell mediated cytotoxicity	J:46514
\Il12b^tm1Jm/\Il12b^tm1Jm \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * 129S1/Sv)	abnormal chemokine secretion	J:140483
	abnormal interferon secretion	J:140483
	increased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
\Il12b^tm1Jm/\Il12b^tm1Jm \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S1/Sv * C57BL/6J)	small intestinal inflammation	J:108572
\Il12rb1^tm1Jm/\Il12rb1^tm1Jm (involves: 129S1/Sv * C57BL/6J)	abnormal lymphocyte physiology	J:42105
	decreased circulating interferon-gamma level	J:42105
	decreased interferon-gamma secretion	J:42105
\Il12rb1^tm1Jm/\Il12rb1^tm1Jm \Tg(Rorc-EGFP)1Ebe/? (involves: 129S1/Sv * C57BL/6)	abnormal effector T cell morphology	J:137020
\Il12rb2^Ifnm-d/\Il12rb2^Ifnm-d \Tlr4^lps-del/\Tlr4^lps-del (C57BL/10ScCr)	abnormal dendritic cell physiology	J:91014
	abnormal granulocyte physiology	J:91014
	abnormal immune cell physiology	J:91014
	abnormal macrophage physiology	J:91014
	abnormal NK cell physiology	J:91014
	decreased interferon-gamma secretion	J:91014, J:70821
	increased interleukin-4 secretion	J:91014
	increased susceptibility to bacterial infection	J:91014, J:70821
\Il12rb2^tm1Jm/\Il12rb2^tm1Jm (either: (involves: 129S1/Sv * BALB/cByJ) or (involves: 129S1/Sv * C57BL/6J))	abnormal lymphocyte physiology	J:65891
	abnormal NK cell physiology	J:65891
\Il12rb2^tm1Jm/\Il12rb2^tm1Jm (B6;129S1-Il12rb2^tm1Jm/J)	abnormal B cell activation	J:106805
	abnormal T cell activation	J:106805
	glomerulonephritis	J:106805
	increased anti-nuclear antigen antibody level	J:106805
	increased circulating interleukin-12 level	J:120061
	increased interleukin-6 secretion	J:106805
	liver inflammation	J:106805
	lymphoid hyperplasia	J:106805
	parotid gland inflammation	J:106805
	salivary gland inflammation	J:106805
	submandibular gland inflammation	J:106805
\Il13^{tm1(YFP/cre)Lky}/\Il13⁺ \Il4^tm1(CD2)Mmrs/\Il4⁺ \Gt(ROSA)26Sor^tm1(DTA)Lky/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	decreased eosinophil cell number	J:178986
	increased susceptibility to parasitic infection	J:178986
\Il13^tm1.1Anjm/\Il13^tm1.1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 2 cell differentiation	J:67965
	decreased circulating interleukin-13 level	J:67965
	decreased IgE level	J:67965
	decreased interleukin-4 secretion	J:67965
	decreased interleukin-5 secretion	J:67965
	decreased interleukin-10 secretion	J:67965
	decreased T-helper 2 cell number	J:67965
	increased IgG2b level	J:67965
	increased IgM level	J:67965
	increased interferon-gamma secretion	J:67965
\Il13^tm1.1Anjm/\Il13^tm1.1Anjm (C.129P2-Il13^tm1.1Anjm)	abnormal dendritic cell antigen presentation	J:141937
	abnormal dendritic cell differentiation	J:141937
	decreased IgE level	J:91403
	decreased interleukin-5 secretion	J:141937
	decreased interleukin-13 secretion	J:141937, J:91403
	decreased susceptibility to autoimmune disorder	J:141937, J:91403
	increased IgG2a level	J:91403
	increased interferon-gamma secretion	J:141937
\Il13^tm1.1Anjm/\Il13^tm1.1Anjm \Tg(DO11.10)10Dlo/0 (involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:91403
	decreased interleukin-13 secretion	J:91403
\Il13^tm1Anjm/\Il13⁺ \Il4^tm1.1Wep/\Il4⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	decreased interleukin-4 secretion	J:69099
\Il13^tm1Anjm/\Il13^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal interleukin secretion	J:82881
	decreased eosinophil cell number	J:82881
	decreased interleukin-4 secretion	J:82881
	decreased interleukin-5 secretion	J:82881
	decreased interleukin-9 secretion	J:82881
	granulomatous inflammation	J:82881, J:113543
	increased susceptibility to parasitic infection	J:113543
\Il13^tm1Anjm/\Il13^tm1Anjm (C.129P2-Il13^tm1Anjm)	decreased interleukin-4 secretion	J:69099
\Il13^tm1Anjm/\Il13^tm1Anjm (C.129P2-Il13^tm1Anjm)	decreased interleukin-13 secretion	J:69099
\Il13^tm1Anjm/\Il13^tm1Anjm \Il5^tm3Anjm/\Il5^tm3Anjm (involves: 129P2/OlaHsd * C57BL/6)	granulomatous inflammation	J:113543
	increased susceptibility to parasitic infection	J:113543
\Il13^tm2Anjm/\Il13^tm2Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal splenocyte physiology	J:72587
	abnormal T-helper 2 physiology	J:89095
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:60609
	immune system phenotype	J:72587
	increased susceptibility to parasitic infection	J:89095
\Il13^tm2Anjm/\Il13^tm2Anjm (C.129P2(B6)-Il13^tm2Anjm)	abnormal response to transplant	J:110188
	abnormal type I hypersensitivity reaction	J:123772
	increased length of allograft survival	J:110188
	increased susceptibility to type I hypersensitivity reaction	J:123772
\Il13^tm2Anjm/\Il13^tm2Anjm (involves: 129)	abnormal T-helper 2 cell differentiation	J:67965
	decreased circulating interleukin-13 level	J:67965
	decreased IgE level	J:67965
	decreased interleukin-4 secretion	J:67965
	decreased interleukin-5 secretion	J:67965
	decreased interleukin-10 secretion	J:67965
	decreased T-helper 2 cell number	J:67965
	increased IgG2b level	J:67965
	increased IgM level	J:67965
	increased interferon-gamma secretion	J:67965
\Il13^tm2Anjm/\Il13^tm2Anjm (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal chemokine level	J:131994
	abnormal macrophage physiology	J:176092
	abnormal susceptibility to infection	J:131994
	decreased susceptibility to bacterial infection	J:176092
	decreased susceptibility to parasitic infection	J:60609
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:60609
	impaired eosinophil recruitment	J:126675
	impaired neutrophil recruitment	J:105813
\Il13^tm2Anjm/\Il13^tm2Anjm (B6.129P2-Il13^tm2Anjm)	abnormal antigen presentation	J:131969
	abnormal leukocyte physiology	J:131969
	decreased macrophage cell number	J:131969
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:131969
\Il13^tm3.1Anjm/\Il13⁺ \Il1rl1^tm1Anjm/\Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	decreased eosinophil cell number	J:159464
\Il13^tm3.1Anjm/\Il13⁺ \Il17rb^tm1Anjm/\Il17rb^tm1Anjm (involves: BALB/c * C57BL/6)	decreased eosinophil cell number	J:159464
\Il13^tm3.1Anjm/\Il13⁺ \Il17rb^tm1Anjm/\Il17rb^tm1Anjm \Il1rl1^tm1Anjm/\Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	decreased eosinophil cell number	J:159464
\Il13ra1^tm1Twy/Y (C.Cg-Il13ra1^tm1Twy)	abnormal response to infection	J:130488
	abnormal T-helper 2 physiology	J:130488
	decreased IgE level	J:130488
	decreased susceptibility to parasitic infection	J:130488
	increased CD4-positive, alpha-beta T cell number	J:130488
	increased circulating interleukin-5 level	J:130488
	increased eosinophil cell number	J:130488
	increased IgA level	J:130488
	increased IgG1 level	J:130488
	increased IgG3 level	J:130488
	increased T-helper 2 cell number	J:130488
\Il13ra1^tm1Zagh/\Il13ra1^tm1Zagh (involves: BALB/c * C57BL/6)	abnormal thymus development	J:183111
	impaired myelopoiesis	J:183111
\Il13ra2^tm1Gru/\Il13ra2^tm1Gru (C.Cg-Il13ra2^tm1Gru)	abnormal macrophage physiology	J:82376
	decreased circulating interleukin-13 level	J:82376
	decreased interleukin-4 secretion	J:82376
	decreased susceptibility to endotoxin shock	J:82376
	increased IgA level	J:82376
	increased IgE level	J:82376
	increased IgG2a level	J:82376
	increased IgG2b level	J:82376
	increased interferon-gamma secretion	J:82376
	increased interleukin-10 secretion	J:82376
\Il15^m1Hwata/\Il15^m1Hwata (Not Specified)	abnormal interleukin secretion	J:184570
	abnormal NK T cell number	J:184570
	decreased interferon-gamma secretion	J:184570
	decreased NK cell number	J:184570
	decreased NK T cell number	J:184570
\Il15^tm1.1Iku/\Il15⁺ (B6.Cg-Il15^tm1.1Iku)	immune system phenotype	J:206571
\Il15^tm1Imx/\Il15⁺ \Myc^tm1Atp/\Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased memory T cell number	J:132730
\Il15^tm1Imx/\Il15^tm1Imx (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:95221
	abnormal cytokine secretion	J:97620
	abnormal immune system morphology	J:60915
	abnormal immune system physiology	J:60915
	abnormal lymphocyte morphology	J:60915
	abnormal susceptibility to infection	J:60915
	absent uterine NK cells	J:84009
	decreased CD8-positive, alpha-beta T cell number	J:113408, J:60915
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:155298
	decreased dendritic cell number	J:97620
	decreased IgG level	J:97620
	decreased IgM level	J:97620
	decreased immunoglobulin level	J:97620
	decreased interferon-gamma secretion	J:97620
	decreased interleukin-12 secretion	J:97620
	decreased memory T cell number	J:132730
	decreased NK cell number	J:132730, J:142654, J:60915
	decreased regulatory T cell number	J:208318
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:84009
	decreased susceptibility to type IV hypersensitivity reaction	J:87137
	impaired natural killer cell mediated cytotoxicity	J:97620
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:97038
	increased susceptibility to parasitic infection	J:97620
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:60915
	small lymph nodes	J:60915
\Il15^tm1Imx/\Il15^tm1Imx (C57BL/6-Il15^tm1Imx)	abnormal dendritic cell physiology	J:123902
\Il15^tm1Imx/\Il15^tm1Imx (C57BL/6-Il15^tm1Imx/Tac)	abnormal CD8-positive, alpha-beta T cell differentiation	J:111786
	abnormal thymus cell ratio	J:111786
	decreased CD8-positive, alpha-beta T cell number	J:111786
\Il15^tm1Imx/\Il15^tm1Imx \Il7r^tm1.1Asin/\Il7r^tm1Imx \Tg(Cd8a-cre)B8Asin/0 (involves: 129S7/SvEvBrd C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:190889
\Il15^tm1Imx/\Il15^tm1Imx \Itk^tm1Litt/\Itk^tm1Litt (involves: 129S4/SvJae * C57BL/6)	abnormal thymus cell ratio	J:111786
\Il15^tm1Imx/\Il15^tm1Imx \Itk^tm1Ljb/\Itk^tm1Ljb (involves: 129 * C57BL/6 * C57BL/10)	decreased CD8-positive, alpha-beta T cell number	J:113408
\Il15^tm1Imx/\Il15^tm1Imx \Myc^tm1Atp/\Myc⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased memory T cell number	J:132730
	decreased NK cell number	J:132730
\Il15^tm1Imx/\Il15^tm1Imx \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	decreased NK cell number	J:132257
\Il15^tm1Imx/\Il15^tm1Imx X/\Yaa (BXSB.B6-Il15^tm1Imx/Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
\Il15ra^tm1.1Nsl/\Il15ra^tm1.1Nsl (involves: 129X1/SvJ * C57BL/6)	abnormal T cell apoptosis	J:73738
	decreased CD8-positive, alpha-beta T cell number	J:73738
	decreased memory T cell number	J:73738
	decreased NK cell number	J:73738
	decreased NK T cell number	J:73738
	decreased single-positive T cell number	J:73738
	increased CD4-positive, alpha-beta T cell number	J:73738
	increased thymocyte apoptosis	J:73738
	lymph node hypoplasia	J:73738
\Il15ra^tm1.1Nsl/\Il15ra^tm1.1Nsl (B6.129X1-Il15ra^tm1.1Nsl)	abnormal T cell activation	J:92705
	abnormal T cell proliferation	J:92705
	increased interleukin-2 secretion	J:92705
	increased T cell proliferation	J:92705
\Il15ra^tm1.1Nsl/\Il15ra^tm1.1Nsl \Tg(TcrAND)53Hed/? (involves: 129X1/SvJ * C57BL/6 * SJL)	increased T cell proliferation	J:92705
\Il15ra^tm1Ama/\Il15ra^tm1Ama (involves: 129X1/SvJ)	abnormal NK cell physiology	J:119213
	decreased CD8-positive, alpha-beta T cell number	J:142570
	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:155298
	decreased memory T cell number	J:142570
	decreased NK cell number	J:119213, J:142570
	decreased NK T cell number	J:142570
	decreased T cell proliferation	J:142570
	impaired natural killer cell mediated cytotoxicity	J:142570
\Il15ra^tm1Ama/\Il15ra^tm2.1Ama \Lyz2^tm1(cre)Ifo/0 \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	abnormal immune system physiology	J:155298
	decreased CD8-positive, alpha-beta T cell number	J:155298
	decreased memory T cell number	J:155298
	decreased NK cell number	J:155298
\Il15ra^tm1Ama/\Il15ra^tm2.1Ama \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)	abnormal immune system physiology	J:155298
	abnormal NK cell differentiation	J:155298
	abnormal NK cell physiology	J:155298
	decreased CD8-positive, alpha-beta T cell number	J:155298
	decreased memory T cell number	J:155298
	decreased NK cell number	J:155298
\Il15ra^tm1Ama/\Il15ra^tm2.1Ama \Tg(Itgax-cre)1-1Reiz/0 (involves: 129X1/SvJ * C57BL/6J * CBA)	abnormal NK cell differentiation	J:155298
	abnormal NK cell physiology	J:155298
	abnormal T cell subpopulation ratio	J:155298
	decreased CD8-positive, alpha-beta T cell number	J:155298
	decreased memory T cell number	J:155298
	decreased NK cell number	J:155298
\Il15ra^tm1Ama/\Il15ra^tm2.1Ama \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	decreased CD8-positive, gamma-delta intraepithelial T cell number	J:155298
\Il15ra^tm1Wjl/\Il15ra^tm1Wjl (involves: 129 * C57BL/6)	abnormal T cell physiology	J:142570
	decreased CD8-positive, alpha-beta T cell number	J:142570
	decreased memory T cell number	J:142570
	decreased NK cell number	J:142570
	decreased NK T cell number	J:142570
	decreased T cell proliferation	J:142570
\Il16^tm1Korn/\Il16^tm1Korn (either: B6.129X1-Il16^tm1Korn or C.129X1-Il16^tm1Korn)	abnormal T cell physiology	J:97739
\Il17a/Il17f^tm1.1Impr/\Il17a/Il17f^tm1.1Impr (involves: C57BL/6)	abnormal effector T cell morphology	J:187400
	absent gamma-delta T cells	J:187400
	decreased interleukin-17 secretion	J:187400
	immune system phenotype	J:187400, J:189794
	increased gamma-delta T cell number	J:187400
	increased T cell proliferation	J:187400
\Il17a/Il17f^tm1.1Impr/\Il17a/Il17f^tm1.1Impr (involves: C57BL/6)	abnormal effector T cell morphology	J:187400
	absent gamma-delta T cells	J:187400
	decreased interleukin-17 secretion	J:187400
	immune system phenotype	J:187400, J:189794
	increased gamma-delta T cell number	J:187400
	increased T cell proliferation	J:187400
\Il17a^em1(IMPC)Mbp/\Il17a^em1(IMPC)Mbp (C57BL/6N-Il17a^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Il17a^tm1Cdon/\Il17a^tm1Cdon (involves: C57BL/6)	chronic inflammation	J:136279
	decreased CD4-positive, alpha-beta T cell number	J:136279
	decreased IgG1 level	J:136279
	decreased IgG2a level	J:136279
	decreased IgG2b level	J:136279
	decreased IgM level	J:136279
	decreased interleukin-17 secretion	J:136279
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:136279
	increased susceptibility to induced colitis	J:136279
\Il17a^tm1Yiw/\Il17a^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6J)	decreased IgG level	J:79127
	decreased immunoglobulin level	J:79127
	decreased interferon-gamma secretion	J:79127
	decreased susceptibility to type IV hypersensitivity reaction	J:79127
\Il17a^tm1Yiw/\Il17a^tm1Yiw (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	abnormal interleukin level	J:79127
	abnormal Langerhans cell physiology	J:79127
	decreased IgE level	J:79127
	decreased IgG1 level	J:79127
	decreased immunoglobulin level	J:79127
	decreased susceptibility to type IV hypersensitivity reaction	J:79127
\Il17a^tm1Yiw/\Il17a^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:143719
\Il17a^tm1Yiw/\Il17a^tm1Yiw (involves: 129P2/OlaHsd)	abnormal immune system physiology	J:144710
	decreased neutrophil cell number	J:193548
	increased gamma-delta T cell number	J:193548
\Il17a^tm1Yiw/\Il17a^tm1Yiw (B6.129P2-Il17a^tm1Yiw)	increased susceptibility to infection induced morbidity/mortality	J:160680
\Il17a^tm1Yiw/\Il17a^tm1Yiw \Il1rn^tm1Yiw/\Il1rn^tm1Yiw (involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)	decreased susceptibility to induced arthritis	J:83408
\Il17a^tm1Yiw/\Il17a^tm1Yiw \Il17f^tm1Yiw/\Il17f^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:143719
\Il17a^tm1Yiw/\Il17a^tm1Yiw \Il17f^tm1Yiw/\Il17f^tm1Yiw \Il1rn^tm1Yiw/\Il1rn^tm1Yiw (involves: 129 * BALB/c)	rheumatoid arthritis	J:143719
\Il17a^tm1Yiw/\Il17a^tm1Yiw \Il17f^tm2Yiw/\Il17f^tm2Yiw (involves: 129P2/OlaHsd * BALB/c)	decreased IgG3 level	J:143719
	enlarged submandibular lymph nodes	J:143719
	increased IgG1 level	J:143719
	increased IgG2a level	J:143719
	increased IgG2b level	J:143719
	increased susceptibility to bacterial infection	J:143719
	nasal inflammation	J:143719
\Il17a^tm1Yiw/\Il17a^tm1Yiw \Il17f^tm2Yiw/\Il17f^tm2Yiw (B6.129P2-Il17a^tm1Yiw Il17f^tm2Yiw)	decreased IgG3 level	J:143719
	enlarged submandibular lymph nodes	J:143719
	increased IgG1 level	J:143719
	increased IgG2a level	J:143719
	increased IgG2b level	J:143719
	increased susceptibility to infection induced morbidity/mortality	J:160680
\Il17a^tm1Yiw/\Il17a^tm1Yiw \Tg(CD2-Rorc)#Staka/0 (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to autoimmune disorder	J:230700
\Il17b^em1Cya/\Il17b^em1Cya (C57BL/6-Il17b^em1Cya)	abnormal cytokine level	J:339366
	increased macrophage cytokine production	J:339366
	increased neutrophil cell number	J:339366
	increased susceptibility to induced colitis	J:339366
\Il17b^{Gt(371C12)Cmhd}/\Il17b^{Gt(371C12)Cmhd} (B6.129-Il17b^{Gt(371C12)Cmhd})	abnormal chemokine secretion	J:229778
	abnormal interleukin secretion	J:229778
	decreased interleukin-4 secretion	J:229778
	increased eosinophil cell number	J:229778
	increased interleukin-1 beta secretion	J:229778
	increased interleukin-5 secretion	J:229778
	increased interleukin-6 secretion	J:229778
	increased interleukin-13 secretion	J:229778
	increased susceptibility to bacterial infection	J:229778
	increased susceptibility to induced colitis	J:229778
	increased T-helper 2 cell number	J:229778
	increased tumor necrosis factor secretion	J:229778
\Il17b^{Gt(371C12)Cmhd}/\Il17b^{Gt(371C12)Cmhd} \Il25^tm1.1Cdon/\Il25^tm1.1Cdon (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	immune system phenotype	J:229778
\Il17c^tm1.1Cdon/\Il17c^tm1.1Cdon (involves: 129S6/SvEvTac)	decreased CD4-positive, alpha-beta T cell number	J:177650
	decreased interferon-gamma secretion	J:177650
	decreased interleukin-17 secretion	J:177650
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177650
\Il17c^tm1Lex/\Il17c^tm1Lex (B6.129S5-Il17c^tm1Lex)	immune system phenotype	J:178967
\Il17f^tm1Awai/\Il17f⁺ (involves: 129S6/SvEvTac * C57BL/6)	decreased interleukin-17 secretion	J:144710
\Il17f^tm1Awai/\Il17f^tm1Awai (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:144710
	decreased interleukin-17 secretion	J:144710
\Il17f^tm1Cdon/\Il17f^tm1Cdon (involves: C57BL/6)	chronic inflammation	J:136279
	decreased acute inflammation	J:136279
	decreased interleukin-17 secretion	J:136279
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:136279
	decreased susceptibility to induced colitis	J:136279
	increased IgG2a level	J:136279
\Il17f^tm1Yiw/\Il17f^tm1Yiw (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:143719
\Il17f^tm1Yiw/\Il17f^tm1Yiw \Il1rn^tm1Yiw/\Il1rn^tm1Yiw (involves: 129 * BALB/c)	rheumatoid arthritis	J:143719
\Il17ra^tm1.2Kurs/\Il17ra^tm1.2Kurs (involves: 129S4/SvJae * BALB/cJ * C57BL/6 * SJL)	abnormal interleukin secretion	J:196483
	increased CD4-positive, alpha-beta T cell number	J:196483
	increased gamma-delta T cell number	J:196483
	increased interleukin-6 secretion	J:196483
	increased interleukin-17 secretion	J:196483
	increased T-helper 17 cell number	J:196483
	skin inflammation	J:196483
\Il17ra^tm1Koll/\Il17ra^tm1Koll (involves: 129 * C57BL/6)	abnormal granulocyte differentiation	J:71097
	abnormal interleukin-5 secretion	J:139080
	abnormal interleukin-13 secretion	J:139080
	decreased inflammatory response	J:139080
	decreased neutrophil cell number	J:71097
	impaired neutrophil recruitment	J:71097
	increased susceptibility to infection	J:71097
\Il17ra^tm1Koll/\Il17ra^tm1Koll (involves: 129)	abnormal T-helper 2 cell differentiation	J:158594
	decreased interleukin-9 secretion	J:158594
	decreased interleukin-17 secretion	J:177650
	impaired neutrophil recruitment	J:136279
\Il17rb^tm1Anjm/\Il17rb^tm1Anjm (BALB/c-Il17rb^tm1Anjm)	decreased eosinophil cell number	J:159464
	decreased IgE level	J:159464
	increased susceptibility to parasitic infection	J:159464
\Il17rb^tm1Anjm/\Il17rb^tm1Anjm \Il1rl1^tm1Anjm/\Il1rl1^tm1Anjm (involves: 129P2/OlaHsd * BALB/c)	decreased eosinophil cell number	J:159464
	decreased IgE level	J:159464
	increased susceptibility to parasitic infection	J:159464
\Il17rb^tm1Bud/\Il17rb^tm1Bud (B6.129-Il17rb^tm1Bud)	decreased inflammatory response	J:139080
	decreased interleukin-5 secretion	J:139080
	decreased interleukin-13 secretion	J:139080
\Il17rb^tm1Lex/\Il17rb^tm1Lex (C.129-Il17rb^tm1Lex)	abnormal chemokine secretion	J:159874
	abnormal osteoclast differentiation	J:159874
	decreased interleukin-5 secretion	J:159874
	decreased interleukin-6 secretion	J:159874
\Il17rb^tm1Tgi/\Il17rb⁺ (Not Specified)	decreased susceptibility to induced colitis	J:229778
\Il17rb^tm1Tgi/\Il17rb^tm1Tgi (B6.Cg-Il17rb^tm1Tgi)	abnormal interleukin secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:184570
	decreased interleukin-13 secretion	J:184570
	decreased interleukin-17 secretion	J:184570
	decreased NK T cell number	J:184570
\Il17rb^tm1Tgi/\Il17rb^tm1Tgi (C.Cg-Il17rb^tm1Tgi)	abnormal interleukin secretion	J:184570
	decreased interleukin-5 secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:184570
	decreased interleukin-13 secretion	J:184570
	decreased interleukin-17 secretion	J:184570
\Il17rb^tm1Tgi/\Il17rb^tm1Tgi (Not Specified)	decreased susceptibility to induced colitis	J:229778
\Il17rc^em1(IMPC)Mbp/\Il17rc^em1(IMPC)Mbp (C57BL/6NCrl-Il17rc^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Il17rc^tm1Lex/\Il17rc^tm1Lex (involves: C57BL/6)	abnormal chemokine level	J:159874
	decreased inflammatory response	J:159874
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:159874
	increased interleukin-17 secretion	J:159874
\Il17re^tm1Lex/\Il17re^tm1Lex (B6.129S5-Il17re^tm1Lex)	increased susceptibility to induced colitis	J:178967
\Il17re^tm1Sdl/\Il17re^tm1Sdl (involves: C57BL/6)	increased susceptibility to bacterial infection	J:178966
\Il17re^tm1Sdl/\Il17re^tm1Sdl (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:178966
\Il18^tm1Aki/\Il18^tm1Aki (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:112400
	abnormal T-helper 1 physiology	J:46514
	decreased circulating interferon-gamma level	J:46514
	decreased circulating interleukin-18 level	J:122588, J:46514
	decreased interferon-gamma secretion	J:46514
	impaired natural killer cell mediated cytotoxicity	J:46514
	increased susceptibility to bacterial infection	J:112400
\Il18^tm1Aki/\Il18^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal microglial cell morphology	J:122031
\Il18^tm1Aki/\Il18^tm1Aki (C.129P2-Il18^tm1Aki)	stomach inflammation	J:120594
\Il18^tm1Aki/\Il18^tm1Aki (B6.129P2-Il18^tm1Aki)	impaired neutrophil chemotaxis	J:125285
	increased susceptibility to bacterial infection	J:125285
	increased susceptibility to induced colitis	J:173245
\Il18^tm1Aki/\Il18^tm1Aki \Il1b^tm1Dch/\Il1b^tm1Dch (involves: 129P2/OlaHsd * 129S2/SvPas)	increased susceptibility to bacterial infection	J:112400
\Il18^tm1Aki/\Il18^tm1Aki \Nlrp1a^Neut1/\Nlrp1a^Neut1 (involves: 129P2/OlaHsd * C57BL/6)	abnormal inflammatory response	J:191055
	increased neutrophil cell number	J:191055
	myocarditis	J:191055
\Il18^tm1Aki/\Il18^tm1Aki \Tg(KRT14-CASP1)1Miz/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased IgE level	J:78602
	decreased IgG1 level	J:78602
	immune system phenotype	J:78602
\Il18^tm1Khe/\Il18^tm1Khe (involves: 129P2/OlaHsd)	abnormal T cell morphology	J:62263
	decreased circulating interferon-gamma level	J:62263
	decreased circulating interleukin-18 level	J:62263
	decreased susceptibility to endotoxin shock	J:62263
	increased circulating tumor necrosis factor level	J:62263
\Il18^tm1Khe/\Il18^tm1Khe (B6.129P2-Il18^tm1Khe)	abnormal cytokine level	J:138759
	decreased circulating interferon-gamma level	J:138759
	decreased circulating interleukin-6 level	J:138759
	decreased circulating interleukin-18 level	J:138759
	decreased interferon-gamma secretion	J:138759
	decreased susceptibility to bacterial infection	J:138759
	decreased tumor necrosis factor secretion	J:138759
	increased dendritic cell number	J:138759
	increased macrophage cell number	J:138759
	increased NK cell number	J:138759
\Il18^tm1Liew/\Il18^tm1Liew (involves: 129P2/OlaHsd * CD-1)	abnormal interferon level	J:86621
	abnormal interleukin level	J:86621
	abnormal tumor necrosis factor level	J:86621
	increased susceptibility to bacterial infection	J:86621
	increased susceptibility to parasitic infection	J:86621
	sepsis	J:86621
\Il18bp^{tm1(KOMP)Vlcg}/\Il18bp^{tm1(KOMP)Vlcg} (C57BL/6-Il18bp^{tm1(KOMP)Vlcg})	abnormal NK cell differentiation	J:255309
	decreased interferon-gamma secretion	J:255309
	decreased KLRG1-positive NK cell number	J:255309
	decreased mature NK cell number	J:255309
	decreased NK cell number	J:255309
	increased circulating interferon-gamma level	J:255309
	increased immature NK cell number	J:255309
\Il18bp^{tm1.1(KOMP)Vlcg}/\Il18bp^{tm1.1(KOMP)Vlcg} (involves: C57BL/6N)	abnormal circulating chemokine level	J:261967
	abnormal lymph node morphology	J:261967
	abnormal macrophage activation involved in immune response	J:261967
	abnormal phagocyte morphology	J:261967
	abnormal spleen morphology	J:261967
	enlarged spleen	J:261967
	immune system phenotype	J:261967
	increased B cell number	J:261967
	increased circulating interferon-gamma level	J:261967
	increased circulating interleukin-18 level	J:261967
	increased macrophage cell number	J:261967
	increased monocyte cell number	J:261967
\Il18r1^tm1Aki/\Il18r1^tm1Aki (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal T-helper 1 physiology	J:70298
	decreased interferon-gamma secretion	J:70298
	impaired natural killer cell mediated cytotoxicity	J:70298
\Il18rap^tm1Yeh/\Il18rap^tm1Yeh (Not Specified)	abnormal cytokine secretion	J:98417
\Il18rap^tm1Yeh/\Il18rap^tm1Yeh (Not Specified)	abnormal leukocyte physiology	J:98417
\Il19^tm2Vlcg/\Il19^tm2Vlcg (B6.Cg-Il19^tm2Vlcg)	decreased interleukin-6 secretion	J:229575
	decreased interleukin-10 secretion	J:229575
	decreased interleukin-13 secretion	J:229575
	immune system phenotype	J:229575
	increased interferon-gamma secretion	J:229575
	increased interleukin-1 beta secretion	J:229575
	increased interleukin-6 secretion	J:229575
	increased interleukin-12 secretion	J:229575
	increased susceptibility to colitis induced morbidity/mortality	J:229575
	increased susceptibility to induced colitis	J:229575
	increased tumor necrosis factor secretion	J:229575
\Il20^tm1Lex/\Il20^tm1Lex (B6;129S5-Il20^tm1Lex/Mmucd)	abnormal type IV hypersensitivity reaction	J:171883
\Il20ra^tm1.1Misc/\Il20ra^tm1.1Misc (involves: C57BL/6)	abnormal osteoclast differentiation	J:177783
\Il20rb^tm1Uwe/\Il20rb^tm1Uwe (B6.129P2-Il20rb^tm1Uwe)	abnormal cytotoxic T cell physiology	J:143497
	abnormal T-helper 1 physiology	J:143497
	decreased interleukin-4 secretion	J:143497
	decreased interleukin-10 secretion	J:143497
	increased interferon-gamma secretion	J:143497
	increased interleukin-2 secretion	J:143497
	increased memory T cell number	J:143497
	increased T cell proliferation	J:143497
\Il20rb^tm1Uwe/\Il20rb^tm1Uwe (C.129P2-Il20rb^tm1Uwe)	increased susceptibility to type IV hypersensitivity reaction	J:143497
\Il21^tm1Lex/\Il21^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal gamma-delta T cell morphology	J:123351
	abnormal interleukin level	J:123351
	abnormal T cell differentiation	J:123351
	decreased CD4-positive, alpha-beta T cell number	J:123351
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:123351
	increased susceptibility to experimental autoimmune encephalomyelitis	J:137377
\Il21^tm1Lex/\Il21^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:137867
	abnormal CD4-positive, alpha-beta T cell physiology	J:137867
	abnormal germinal center B cell physiology	J:137867
	abnormal spleen germinal center morphology	J:137867
	decreased germinal center B cell number	J:137867
	decreased IgG1 level	J:137867
	decreased spleen germinal center number	J:137867
\Il21^tm1Llit/\Il21^tm1Llit (involves: 129 * C57BL/6J)	abnormal class switch recombination	J:114783
\Il21^tm1Llit/\Il21^tm1Llit (involves: 129 * C57BL/6J)	increased IgE level	J:114783
\Il21r^tm1Day/\Il21r^tm1Day (involves: BALB/c * C57BL/6)	abnormal CD4-positive T cell differentiation	J:136955, J:123352
	abnormal dendritic cell physiology	J:144708
	abnormal Langerhans cell physiology	J:144708
	abnormal memory T cell physiology	J:76043
	abnormal NK cell physiology	J:76043
	abnormal plasmacytoid dendritic cell physiology	J:144708
	abnormal T cell activation	J:76043
	abnormal T cell physiology	J:76043
	abnormal thymocyte activation	J:76043
	decreased CD4-positive, alpha-beta T cell number	J:123352
	decreased cytotoxic T cell cytolysis	J:76043
	decreased IgE level	J:144708
	decreased IgG1 level	J:76043, J:144708
	decreased IgG2a level	J:144708
	decreased IgG2b level	J:76043
	decreased interferon-gamma secretion	J:144708
	decreased interleukin-4 secretion	J:144708
	decreased interleukin-13 secretion	J:144708
	decreased interleukin-17 secretion	J:123352
	decreased susceptibility to type IV hypersensitivity reaction	J:144708
	impaired natural killer cell mediated cytotoxicity	J:76043
	increased IgE level	J:76043
	increased interferon-gamma secretion	J:76043, J:123352
\Il21r^tm1Day/\Il21r^tm1Day (C57BL/6-Il21r^tm1Day)	abnormal susceptibility to infection	J:111712
	abnormal T-helper 2 physiology	J:111712
	decreased IgG1 level	J:111712
	decreased IgG2b level	J:111712
	decreased interleukin-4 secretion	J:111712
	decreased interleukin-13 secretion	J:111712
	decreased interleukin-21 secretion	J:111712
\Il21r^tm1Kopf/\Il21r^tm1Kopf (involves: 129/Sv * BALB/c)	abnormal immunoglobulin level	J:137508
	abnormal lymphocyte physiology	J:137508
	decreased IgA level	J:137508
	decreased IgG1 level	J:137508
	immune system phenotype	J:137377
	impaired eosinophil recruitment	J:137508
	increased IgE level	J:137508
\Il21r^tm1Kopf/\Il21r^tm1Kopf (B6.129-Il21r^tm1Kopf)	abnormal immune system morphology	J:137508
	abnormal immune system physiology	J:137508
	abnormal immunoglobulin level	J:137508
	abnormal leukocyte physiology	J:137508
	abnormal lymphocyte physiology	J:137508
	abnormal T-helper 1 physiology	J:137508
	abnormal T-helper 2 physiology	J:137508
	decreased basophil cell number	J:137508
	decreased eosinophil cell number	J:137508
	decreased granulocyte number	J:137508
	decreased IgA level	J:137508
	decreased IgG1 level	J:137508
	granulomatous inflammation	J:137508
	impaired eosinophil recruitment	J:137508
	increased IgE level	J:137508
	increased susceptibility to experimental autoimmune encephalomyelitis	J:137377
\Il21r^tm1Wjl/\Il21r^tm1Wjl (involves: 129 * C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:95221
	abnormal immunoglobulin level	J:80474
	decreased cytotoxic T cell cytolysis	J:95221
	decreased IgG1 level	J:80474
	decreased IgG2a level	J:80474
	decreased IgG2b level	J:80474
	decreased IgG3 level	J:80474
	decreased interleukin-17 secretion	J:124293
	increased IgE level	J:80474
\Il21r^tm1Wjl/\Il21r^tm1Wjl (NOD.Cg-Il21r^tm1Wjl)	abnormal CD4-positive T cell differentiation	J:139075
	decreased interleukin-17 secretion	J:139075
	decreased susceptibility to autoimmune diabetes	J:139075
	decreased T cell proliferation	J:139075
\Il21r^tm1Wjl/\Il21r^tm1Wjl \Il4^tm1Cgn/\Il4^tm1Cgn (involves: 129 * C57BL/6)	abnormal immunoglobulin level	J:80474
	abnormal lymph node germinal center morphology	J:80474
	decreased IgA level	J:80474
	decreased IgG1 level	J:80474
	decreased IgG2a level	J:80474
	decreased IgG2b level	J:80474
	decreased IgG3 level	J:80474
	decreased IgM level	J:80474
\Il21r^tm1Wjl/\Il21r^tm1Wjl X/\Yaa (BXSB.129(Cg)-Il21r^tm1Wjl/Dcr)	decreased susceptibility to systemic lupus erythematosus	J:144484
\Il22^{tm1.1(icre)Stck}/\Il22^{tm1.1(icre)Stck} (involves: 129X1/SvJ * C57BL/6N)	increased susceptibility to bacterial infection	J:220074
\Il22^tm1.1Lex/\Il22^tm1.1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:118261
	ear inflammation	J:118261
\Il22^tm1.1Lex/\Il22^tm1.1Lex (involves: 129S5/SvEvBrd)	abnormal circulating cytokine level	J:179011
	colitis	J:161073
	decreased circulating interleukin-1 alpha level	J:179011
	decreased circulating interleukin-12 level	J:179011
	decreased circulating interleukin-12b level	J:179011
	decreased circulating tumor necrosis factor level	J:179011
	increased circulating interleukin-17 level	J:179011
	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
	increased susceptibility to fungal infection	J:179011
	lung inflammation	J:179011
\Il22^tm1Flv/\Il22⁺ (B6.Cg-Il22^tm1Flv)	increased susceptibility to endotoxin shock	J:126103
\Il22^tm1Flv/\Il22^tm1Flv (B6.Cg-Il22^tm1Flv)	increased susceptibility to endotoxin shock	J:126103
\Il22^tm1Flv/\Il22^tm1Flv (B6.Cg-Il22^tm1Flv)	liver inflammation	J:126103
\Il22^tm1Flv/\Il22^tm1Flv (involves: 129/Sv * C57BL/6)	increased susceptibility to induced colitis	J:189217
\Il22^tm1Jcrd/\Il22^tm1Jcrd (B6.Cg-Il22^tm1Jcrd)	immune system phenotype	J:155038
\Il22^tm1Jcrd/\Il22^tm1Jcrd (Not Specified)	decreased neutrophil cell number	J:193548
\Il22^tm1Jcrd/\Il22^tm1Jcrd (Not Specified)	increased interleukin-17 secretion	J:193548
\Il22ra2^tm2Vlcg/\Il22ra2^tm2Vlcg (B6.Cg-Il22ra2^tm2Vlcg)	colitis	J:189217
\Il23a^tm1.1Thak/\Il23a^tm1.1Thak (C57BL/6-Il23a^tm1.1Thak)	decreased interferon-gamma secretion	J:143970
	decreased interleukin-17 secretion	J:143970
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:143970
	decreased T cell proliferation	J:143970
\Il23a^tm1Dnax/\Il23a^tm1Dnax (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:95542
	decreased interleukin-17 secretion	J:95542
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:95542
\Il23a^tm1Dnax/\Il23a^tm1Dnax (B6.Cg-Il23a^tm1Dnax)	abnormal CD8-positive, alpha-beta T cell physiology	J:111568
	abnormal granulocyte physiology	J:111568
	abnormal interleukin level	J:111568
	abnormal macrophage physiology	J:111568
\Il23a^tm1Dnax/\Il23a^tm1Dnax (Not Specified)	decreased gamma-delta T cell number	J:193548
	decreased interleukin-17 secretion	J:193548
	decreased leukocyte cell number	J:193548
	decreased neutrophil cell number	J:193548
	decreased T cell number	J:193548
\Il23a^tm1Gdy/\Il23a⁺ (B6.Cg-Il23a^tm1Gdy)	increased susceptibility to induced colitis	J:139557
\Il23a^tm1Gdy/\Il23a^tm1Gdy (B6.Cg-Il23a^tm1Gdy)	increased susceptibility to induced colitis	J:139557
\Il23a^tm1Ngh/\Il23a^tm1Ngh (involves: 129S/SvEv * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:88235
	abnormal CD8-positive, alpha beta T cell morphology	J:88235
	abnormal memory T cell physiology	J:88235
	decreased IgA level	J:88235
	decreased IgG2a level	J:88235
	decreased immunoglobulin level	J:88235
\Il23a^tm1Ngh/\Il23a^tm1Ngh (involves: 129 * C57BL/6)	abnormal circulating interleukin level	J:216867
	abnormal memory T cell physiology	J:120806
	decreased activated T cell number	J:120806
	decreased susceptibility to induced colitis	J:216867
	granulomatous inflammation	J:120806
	increased circulating interleukin-17 level	J:216867
	increased susceptibility to bacterial infection	J:120806
\Il23a^tm1Ngh/\Il23a^tm1Ngh (involves: 129)	increased susceptibility to bacterial infection induced morbidity/mortality	J:161073
\Il23r^tm1.1Kuch/\Il23r^tm1.1Kuch (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:151907
\Il23r^tm1.1Kuch/\Il23r^tm1.1Kuch (involves: C57BL/6)	decreased interleukin-9 secretion	J:151907
\Il23r^tm1.1Ngh/\Il23r^tm1.1Ngh (involves: C57BL/6)	abnormal circulating interleukin level	J:216867
	decreased susceptibility to induced colitis	J:216867
	increased circulating interleukin-17 level	J:216867
\Il23r^tm1.1Ngh/\Il23r^tm1.1Ngh \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	abnormal circulating interleukin level	J:216867
	decreased interleukin-17 secretion	J:216867
\Il23r^tm1Dnax/\Il23r^tm1Dnax (C57BL/6-Il23r^tm1Dnax)	immune system phenotype	J:111568
\Il23r^tm1Kuch/\Il23r^tm1Kuch (C57BL/6-Il23r^tm1Kuch)	abnormal CD4-positive T cell differentiation	J:148248
	abnormal CD4-positive, alpha-beta T cell physiology	J:148248
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:148248
\Il25^tm1.1Cdon/\Il25^tm1.1Cdon (involves: 129S6/SvEvTac)	abnormal chemokine secretion	J:229778
	abnormal interleukin secretion	J:229778
	decreased eosinophil cell number	J:229778
	decreased interleukin-1 beta secretion	J:229778
	decreased interleukin-4 secretion	J:229778, J:158594
	decreased interleukin-5 secretion	J:229778, J:158594
	decreased interleukin-9 secretion	J:158594
	decreased interleukin-13 secretion	J:229778, J:158594
	decreased susceptibility to bacterial infection	J:229778
	decreased susceptibility to induced colitis	J:229778
	decreased T-helper 2 cell number	J:229778
	decreased tumor necrosis factor secretion	J:229778
	increased susceptibility to type I hypersensitivity reaction	J:158594
	lung inflammation	J:158594
\Il25^tm1Anjm/\Il25^tm1Anjm (involves: 129P2/OlaHsd * C57BL/6)	abnormal interleukin secretion	J:123748
	abnormal mesenteric lymph node morphology	J:123748
	decreased eosinophil cell number	J:123748
	decreased interleukin-5 secretion	J:123748
	decreased interleukin-13 secretion	J:123748
	increased IgE level	J:123748
	increased susceptibility to parasitic infection	J:123748
\Il25^tm1Cdon/\Il25^tm1Cdon \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6N * SJL)	decreased susceptibility to induced colitis	J:229778
\Il25^tm1Dart/\Il25^tm1Dart (C57BL/6-Il25^tm1Dart)	abnormal interferon level	J:123808
	abnormal interleukin level	J:123808
	abnormal response to infection	J:123808
	decreased IgG2a level	J:123808
	increased susceptibility to parasitic infection	J:123808
	intestinal inflammation	J:123808
\Il25^tm1Dart/\Il25^tm1Dart (involves: C57BL/6)	abnormal interleukin level	J:125296
	increased susceptibility to experimental autoimmune encephalomyelitis	J:125296
	increased T cell number	J:125296
\Il27^{tm1b(EUCOMM)Wtsi}/\Il27^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Il27^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta memory T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
\Il27^tm1Cua/\Il27^tm1Cua (C57BL/6-Il27^tm1Cua)	abnormal CD4-positive T cell differentiation	J:147706
	increased susceptibility to experimental autoimmune encephalomyelitis	J:147706
	increased susceptibility to type IV hypersensitivity reaction	J:147706
\Il27^tm1Lex/\Il27^tm1Lex (involves: 129S/SvEvBrd)	increased circulating interleukin-12b level	J:187660
	increased interferon-gamma secretion	J:187660
	increased susceptibility to parasitic infection induced morbidity/mortality	J:187660
\Il27ra^tm1Fjs/\Il27ra^tm1Fjs (B6.Cg-Il27ra^tm1Fjs)	abnormal T-helper 1 physiology	J:94856
	decreased susceptibility to bacterial infection	J:94856
	increased lymphocyte cell number	J:94856
\Il27ra^tm1Mak/\Il27ra^tm1Mak (B6.129P2-Il27ra^tm1Mak)	abnormal T-helper 1 physiology	J:116610, J:89509
	decreased circulating interferon-gamma level	J:116610
	decreased interferon-gamma secretion	J:116610, J:89509
	decreased susceptibility to experimental autoimmune uveoretinitis	J:116610
	immune system phenotype	J:88618
	increased circulating interferon-gamma level	J:88618
	increased circulating interleukin-1 beta level	J:88618
	increased circulating interleukin-4 level	J:88618
	increased circulating interleukin-6 level	J:88618
	increased circulating interleukin-12 level	J:88618
	increased circulating tumor necrosis factor level	J:88618
	increased interferon-gamma secretion	J:88618
	increased interleukin-4 secretion	J:88618
	increased susceptibility to bacterial infection	J:89509
	increased susceptibility to parasitic infection	J:89509
	increased T cell proliferation	J:89509
\Il27ra^tm1Mak/\Il27ra^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to induced arthritis	J:151552
\Il31^tm1.1Snak/\Il31^tm1.1Snak (B6N(Cg)-Il31^tm1.1Snak)	immune system phenotype	J:263831
\Il31ra^tm1Jagr/\Il31ra^tm1Jagr (involves: 129S5/SvEvBrd)	immune system phenotype	J:91124
\Il31ra^tm1Ngh/\Il31ra^tm1Ngh (C57BL/6-Il31ra^tm1Ngh)	spleen hypoplasia	J:123111
\Il31ra^tm1Ngh/\Il31ra^tm1Ngh (involves: C57BL/6)	abnormal interleukin level	J:123198
	abnormal macrophage physiology	J:123198
	granulomatous inflammation	J:123198
	increased IgE level	J:123198
	increased susceptibility to parasitic infection	J:123198
	increased T cell proliferation	J:123198
\Il33^{tm1(KOMP)Vlcg}/\Il33^{tm1(KOMP)Vlcg} (C57BL/6-Il33^{tm1(KOMP)Vlcg})	impaired macrophage chemotaxis	J:232676
\Il33^tm1Aki/\Il33^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal T-helper 2 physiology	J:182160
	decreased eosinophil cell number	J:182160
	decreased IgE level	J:182160
	immune system phenotype	J:182160
	increased susceptibility to parasitic infection	J:182160
\Il33^tm1Amgn/\Il33^tm1Amgn (B6.129-Il33^tm1Amgn)	abnormal immune cell physiology	J:192531
	decreased lymphocyte cell number	J:192531
	increased susceptibility to parasitic infection	J:192531
\Il33^tm1Snak/\Il33^tm1Snak (involves: C57BL/6 * CBA)	decreased inflammatory response	J:165513
	decreased interleukin-1 alpha secretion	J:165513
	decreased interleukin-1 beta secretion	J:165513
	decreased interleukin-6 secretion	J:165513
	decreased susceptibility to endotoxin shock	J:165513
	immune system phenotype	J:165513
	increased susceptibility to induced colitis	J:165513
	lung inflammation	J:165513
\Il33^{tm2.1(IL33)Arte}/\Il33^{tm2.1(IL33)Arte} (involves: BALB/c * BALB/cJBomTac)	immune system phenotype	J:227003
\Il34^{tm1b(EUCOMM)Wtsi}/\Il34^{tm1b(EUCOMM)Wtsi} (involves: BALB/cJ * C57BL/6N)	abnormal microglial cell morphology	J:187643
	absent Langerhans cell	J:187643
	decreased dendritic cell number	J:187643
	decreased interferon-gamma secretion	J:187643
	decreased Langerhans cell number	J:187643
	decreased susceptibility to fungal infection	J:187643
	decreased susceptibility to type IV hypersensitivity reaction	J:187643
	immune system phenotype	J:187643
	increased susceptibility to Flaviviridae infection	J:187643
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:187643
	lymph node hypoplasia	J:187643
\Il36a^tm1Yiw/\Il36a^tm1Yiw (B6.129P2-Il36a^tm1Yiw)	abnormal cytokine level	J:263315
\Il36a^tm1Yiw/\Il36a^tm1Yiw (B6.129P2-Il36a^tm1Yiw)	immune system phenotype	J:263315
\Il36g^tm1Lex/\Il36g^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal interleukin level	J:264077
	abnormal macrophage morphology	J:264077
	abnormal tumor necrosis factor level	J:264077
	decreased alveolar macrophage number	J:264077
	increased CD11b-high dendritic cell number	J:264077
	increased macrophage apoptosis	J:264077
	increased susceptibility to Orthomyxoviridae infection	J:264077
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:264077
\Il36g^tm1Lex/\Il36g^tm1Lex (involves: 129S5/SvEvBrd)	decreased CD4-positive, alpha-beta T cell number	J:256437
	decreased interleukin-9 secretion	J:256437
	decreased susceptibility to induced colitis	J:256437
	impaired neutrophil recruitment	J:280917
	increased CD4-positive, alpha-beta T cell number	J:256437
	increased regulatory T cell number	J:256437
	increased susceptibility to Herpesvirales infection	J:280917
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:280917
\Il36g^tm1Lex/\Il36g^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal cytokine level	J:296074
	abnormal macrophage activation involved in immune response	J:296074
	impaired macrophage phagocytosis	J:296074
	increased susceptibility to bacterial infection	J:296074
	increased susceptibility to bacterial infection induced morbidity/mortality	J:296074
\Il36rn^tm1Hblu/\Il36rn⁺ \Tg(KRT14-Il1f6)1Hblu/? (involves: 129 * C57BL/6 * DBA/2)	skin inflammation	J:126327
\Il36rn^tm1Hblu/\Il36rn^tm1Hblu (C.129(B6)-Il36rn^tm1Hblu)	increased susceptibility to chemically induced skin inflammation	J:260118
\Il36rn^tm1Hblu/\Il36rn^tm1Hblu \Tg(KRT14-Il1f6)1Hblu/? (involves: 129 * C57BL/6 * DBA/2)	skin inflammation	J:126327
\Il36rn^tm1Kopf/\Il36rn^tm1Kopf (B6.129S5-Il36rn^tm1Kopf)	dermatitis	J:193548
	increased leukocyte cell number	J:193548
	increased neutrophil cell number	J:193548
\Ilf2^tm1Pnk/\Ilf2⁺ (involves: C57BL/6)	immune system phenotype	J:161086
\Ilf3^tm1.1Itl/\Ilf3^tm1.1Itl (Not Specified)	increased susceptibility to Adenoviridae infection	J:167126
\Ilf3^tm1Pnk/\Ilf3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:161086
\Ilk^tm1Star/\Ilk^tm1Star \Tg(KRT14-cre)1Amc/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	skin inflammation	J:172934
\Ilk^tm1Star/\Ilk^tm1Star \Tg(NPHS2-cre)295Lbh/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	tubulointerstitial nephritis	J:129286, J:129244
\Ilk^tm1Star/\Ilk^tm2Star \Tg(Acp5-cre)1Star/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast physiology	J:197593
	increased osteoclast cell number	J:197593
\Im1^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:46394
\Im2^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
\Im2^Bioz:BP1/\Im2^Bioz:BP1 (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:65671
\Im3^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:46394
\Im4^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
\Im5^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
\Im6^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
\Im7^Bioz:BP1/? (involves: Bioz:BP1 * Bioz:MP1)	abnormal humoral immune response	J:37251
\Imebt1^DU6/? (involves: DU6 * DUKs)	increased spleen weight	J:99475
\Imh1^NZB/\Imh1^NZB (involves: NZB * NZW)	increased IgM level	J:26266
\Imh1^NZB/\Imh1^NZB (involves: NZB * NZW)	increased susceptibility to systemic lupus erythematosus	J:26266
\Imh1^NZB/\Imh1^NZW (involves: NZB * NZW)	increased IgM level	J:26266
\Imh1^NZB/\Imh1^NZW (involves: NZB * NZW)	increased susceptibility to systemic lupus erythematosus	J:22353
\Imm1^NZW/\Imm1^NZB (involves: NZB * NZW)	abnormal immune system physiology	J:26266
\Imm1^NZW/\Imm1^NZW (involves: NZB * NZW)	abnormal immune system physiology	J:26266
\Immp2l^{Tg(HLA-A/H2-D)2Enge}/? ((C57BL/6 x CBA)F1)	abnormal cytotoxic T cell physiology	J:31937
	abnormal negative T cell selection	J:31937
	abnormal positive T cell selection	J:31937
\Impact^{em1(IMPC)Ccpcz}/\Impact^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Impact^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Impdh1^tm1Bmi/\Impdh1^tm1Bmi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune system cell morphology	J:85443
	decreased T cell proliferation	J:85443
\Impdh1^tm1Bmi/\Impdh1^tm1Bmi \Impdh2^tm1Bmi/\Impdh2⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytotoxic T cell physiology	J:85443
	abnormal immune system cell morphology	J:85443
	abnormal lymphopoiesis	J:85443
	decreased splenocyte proliferation	J:85443
	decreased T cell proliferation	J:85443
\Impdh2^tm1Bmi/\Impdh2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal lymphocyte cell number	J:86045
\Impg1^em1Visu/\Impg1^em1Visu \Impg2^em1Visu/\Impg2^em1Visu (involves: C57BL/6J * DBA/2)	microgliosis	J:288311
\Impg2^em1Visu/\Impg2^em1Visu (involves: C57BL/6J * DBA/2)	microgliosis	J:288311
\Imraq1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	increased IgG level	J:100370
\Imraq2^DBA/2J/? \Imraq3^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	increased IgG level	J:100370
\Imrfq1^C57BL/6J/? \Imrfq2^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	increased IgG level	J:100370
\In(2a;Itch)18H/\In(2a;Itch)18H (involves: 101/H * C3H/HeH)	abnormal alveolar macrophage morphology	J:24934
	chronic inflammation	J:24934
	immune system phenotype	J:205692
	increased inflammatory response	J:45910
	increased spleen red pulp amount	J:24934
	interstitial pneumonia	J:24934
	lung inflammation	J:24934
	lymph node hyperplasia	J:24934
\Inava^tm1.1Itl/\Inava^tm1.1Itl (involves: 129S6/SvEvTac * C57BL/6NTac)	increased susceptibility to bacterial infection	J:257317
	increased susceptibility to induced colitis	J:257317
\Inca1^tm1Cmt/\Inca1^tm1Cmt (involves: 129 * C57BL/6N)	abnormal spleen B cell follicle morphology	J:175667
	abnormal spleen morphology	J:175667
	abnormal spleen white pulp morphology	J:175667
	increased IgA level	J:175667
\Ing1^{Gt(OST206270)Lex}/\Ing1^{Gt(OST206270)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased thymocyte number	J:118602
	increased thymocyte apoptosis	J:118602
\Ing1^tm1Avg/\Ing1^tm1Avg (involves: 129S1/Sv * C57BL/6)	enlarged spleen	J:105658
\Ing2^tm1.1Ccha/\Ing2^tm1.1Ccha (involves: 129 * C57BL/6J * FVB/N)	spleen hyperplasia	J:167311
\Ing4^em1(IMPC)Tcp/\Ing4^em1(IMPC)Tcp (C57BL/6NCrl-Ing4^em2(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
\Ing4^Gt(XG370)Byg/\Ing4^Gt(XG370)Byg (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine level	J:161381
	increased circulating interleukin-6 level	J:161381
	increased interleukin-6 secretion	J:161381
\Ing5^tm1.1Avo/\Ing5^tm1.1Avo (B6.Cg-Ing5^tm1.1Avo)	spleen hypoplasia	J:345308
\Inha^tm1Bay/\Inha^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	chronic liver inflammation	J:20450
\Inhbb^tm1Jae/\Inhbb^tm1Jae (either: (129S4/SvJae-Inhbb^tm1Jae) or (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	increased incidence of corneal inflammation	J:16995
\Inmt^em1(IMPC)Mbp/\Inmt^em1(IMPC)Mbp (C57BL/6N-Inmt^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Ino80^tm1.1Schg/\Ino80⁺ \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6J)	increased T cell derived lymphoma incidence	J:221224
\Inpp1^{tm1a(KOMP)Wtsi}/\Inpp1^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased susceptibility to bacterial infection	J:213427
\Inpp4b^tm1.1Jva/\Inpp4b^tm1.1Jva (B6.129-Inpp4b^tm1.1Jva)	abnormal osteoclast differentiation	J:177648
	abnormal osteoclast morphology	J:177648
	increased osteoclast cell number	J:177648
\Inpp5d^el20/\Inpp5d^el20 (B6.129-Inpp5d^el20)	abnormal lymphocyte cell number	J:173266
	decreased lymphocyte cell number	J:173266
	decreased pre-B cell number	J:173266
	decreased thymocyte number	J:173266
	enlarged spleen	J:173266
	increased circulating interleukin-6 level	J:173266
	increased IgG2a level	J:173266
	increased IgM level	J:173266
	increased immunoglobulin level	J:173266
	increased macrophage cell number	J:173266
	small thymus	J:173266
\Inpp5d^m1Anu/\Inpp5d^m1Anu (C57BL/6JAnu-Inpp5d^m1Anu)	lung inflammation	J:104190
\Inpp5d^m1Btlr/\Inpp5d^m1Btlr (C57BL/6J-Inpp5d^m1Btlr)	abnormal B cell differentiation	J:140987
	abnormal eosinophil physiology	J:140987
	abnormal neutrophil physiology	J:140987
	decreased cytotoxic T cell cytolysis	J:140987
	enlarged spleen	J:140987
	enlarged thymus	J:140987
	impaired natural killer cell mediated cytotoxicity	J:140987
\Inpp5d^m2Btlr/\Inpp5d^m2Btlr (C57BL/6J-Inpp5d^m2Btlr)	decreased B cell number	J:216053
\Inpp5d^M3Btlr/\Inpp5d⁺ (C57BL/6J-Inpp5d^M3Btlr)	decreased NK cell number	J:254907
\Inpp5d^m4Btlr/\Inpp5d^m4Btlr (C57BL/6J-Inpp5d^m4Btlr)	increased interferon-beta secretion	J:272854
\Inpp5d^m4Btlr/\Inpp5d^m4Btlr (C57BL/6J-Inpp5d^m4Btlr)	increased tumor necrosis factor secretion	J:272854
\Inpp5d^m5Btlr/\Inpp5d^m5Btlr (C57BL/6J-Inpp5d^m5Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272856
	abnormal lymphocyte morphology	J:272856
	abnormal T cell differentiation	J:272856
	decreased alpha-beta T cell number	J:272856
	decreased B cell number	J:272856
	decreased CD4-positive, alpha-beta T cell number	J:272856
	decreased CD8-positive, alpha-beta T cell number	J:272856
	decreased CD8-positive, naive alpha-beta T cell number	J:272856
	decreased NK cell number	J:272856
	increased B-1 B cell number	J:272856
	increased CD8-positive, alpha-beta T cell number	J:272856
	increased central memory CD8 positive, alpha-beta T cell number	J:272856
	increased effector memory CD4-positive, alpha-beta T cell number	J:272856
	increased effector memory CD8-positive, alpha-beta T cell number	J:272856
\Inpp5d^tm1.1Wgk/\Inpp5d^tm1.1Wgk (involves: 129S6/SvEvTac * C57BL/6J)	abnormal leukocyte physiology	J:94861
	abnormal mononuclear cell differentiation	J:94861
	abnormal NK cell morphology	J:95215
	decreased susceptibility to graft versus host disease	J:95215, J:94861
	increased dendritic cell number	J:94861
	increased monocyte cell number	J:94861
	increased NK cell number	J:95215
\Inpp5d^tm1Dmt/\Inpp5d^tm1Dmt (involves: 129P2/OlaHsd)	abnormal leukocyte physiology	J:77739
	decreased B cell number	J:77739
	enlarged lymph nodes	J:77739
	enlarged spleen	J:77739
	increased leukocyte cell number	J:77739
\Inpp5d^tm1Dmt/\Inpp5d^tm1Dmt (B6.129P2/OlaHsd-Inpp5d^tm1Dmt)	decreased lymphocyte cell number	J:173266
	decreased pre-B cell number	J:173266
	increased circulating interleukin-6 level	J:173266
\Inpp5d^tm1Rav/\Inpp5d^tm1.1Rav \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen marginal zone macrophage morphology	J:119256
	absent marginal zone B cells	J:119256
	enlarged spleen	J:119256
\Inpp5d^tm1Rav/\Inpp5d^tm1Rav \Cd79a^tm1(cre)Reth/\Cd79a⁺ \Tg(IghAb36-65)1Wys/0 (involves: 129 * BALB/c * C57BL/6 * FVB/N)	abnormal B cell anergy	J:178833
	abnormal B cell negative selection	J:178833
	decreased B cell number	J:178833
	increased autoantibody level	J:178833
	increased plasma cell number	J:178833
\Inpp5d^tm1Rav/\Inpp5d^tm1Rav \Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:122796
	abnormal humoral immune response	J:122796
	abnormal interferon level	J:122796
	abnormal interleukin secretion	J:122796
	abnormal lymph node germinal center morphology	J:122796
	decreased susceptibility to parasitic infection	J:122796
\Inpp5d^tm1Rkh/\Inpp5d^tm1Rkh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal granulocyte differentiation	J:48193
	abnormal lymphopoiesis	J:48193
	abnormal macrophage chemotaxis	J:48193
	abnormal monocyte differentiation	J:48193
	decreased lymphocyte cell number	J:48193
	increased monocyte cell number	J:48193
	increased neutrophil cell number	J:48193
	increased spleen weight	J:48193
	spleen hyperplasia	J:48193
\Inpp5d^tm1Rkh/\Inpp5d^tm1Rkh (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal interleukin level	J:173301
	abnormal myelopoiesis	J:117320
	decreased pro-B cell number	J:117320
	ileum inflammation	J:173301
	increased circulating interleukin-6 level	J:117320
	intestinal inflammation	J:173301
\Inpp5d^tm1Rkh/\Inpp5d^tm1Rkh (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD4-positive, alpha-beta T cell physiology	J:110864
	abnormal CD8-positive, alpha-beta T cell physiology	J:110864
	abnormal cell-mediated immunity	J:110864
	abnormal macrophage chemotaxis	J:110864
	abnormal osteoclast differentiation	J:78771
	abnormal osteoclast morphology	J:78771
	abnormal osteoclast physiology	J:78771
	abnormal T cell physiology	J:110864
	enhanced B cell migration	J:110864
	increased circulating interleukin-6 level	J:78771
	increased mast cell degranulation	J:120426
	increased osteoclast cell number	J:78771
\Inpp5d^tm1Rkh/\Inpp5d^tm1Rkh \Rag1^tm1(GFP)Imku/\Rag1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal lymphopoiesis	J:117320
\Inpp5d^tm1Wgk/\Inpp5d^tm1.1Wgk \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Inpp5d^tm1Wgk/Inpp5d^tm1.1Wgk Tg(Mx1-cre)1Cgn)	abnormal leukocyte physiology	J:144110
	abnormal myeloid leukocyte morphology	J:144110
\Inpp5d^tm1Wgk/\Inpp5d^tm1Wgk \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Inpp5d^tm1Wgk Tg(Mx1-cre)1Cgn)	decreased susceptibility to graft versus host disease	J:144110
\Inpp5k^em1(IMPC)H/\Inpp5k⁺ (C57BL/6NTac-Inpp5k^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Ins1^tm1Jja/\Ins1^tm1Jja (NOD.129S2-Ins1^tm1Jja)	decreased susceptibility to autoimmune diabetes	J:85309
\Ins1^tm1Jja/\Ins1^tm1Jja \Ins2^tm1Jja/\Ins2^tm1Jja \Tg(Ins2Y16A)1Ell/0 (NOD.Cg-Ins1^tm1Jja Ins2^tm1Jja Tg(Ins2Y16A)1Ell)	decreased susceptibility to autoimmune diabetes	J:98583
	salivary gland inflammation	J:98583
\Ins1^tm1Jja/\Ins1^tm1Jja \Ins2^tm1Jja/\Ins2^tm1Jja \Tg(Ins2Y16A)3Ell/0 (NOD.Cg-Ins1^tm1Jja Ins2^tm1Jja Tg(Ins2Y16A)3Ell)	decreased anti-insulin autoantibody level	J:98583
	decreased susceptibility to autoimmune diabetes	J:98583
	salivary gland inflammation	J:98583
\Ins1^tm1Jja/\Ins1^tm1Jja \Ins2^tm1Mnt/\Ins2^tm1Mnt \Tg(Aire-cre)1Mnt/0 (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal immune system physiology	J:152798
	abnormal interferon-gamma secretion	J:152798
	abnormal T cell physiology	J:152798
	increased anti-insulin autoantibody level	J:152798
	pancreas inflammation	J:152798
\Ins1^tm1Jja/\Ins1^tm1Jja \Tg(Ins2Y16A)1Ell/0 (NOD.Cg-Ins1^tm1Jja Tg(Ins2Y16A)1Ell)	increased susceptibility to autoimmune diabetes	J:98583
\Ins1^tm1Jja/\Ins1^tm1Jja \Tg(Ins2Y16A)3Ell/0 (NOD.Cg-Ins1^tm1Jja Tg(Ins2Y16A)3Ell)	autoimmune response	J:98583
\Ins2^Akita/\Ins2⁺ (C57BL/6-Ins2^Akita/J)	abnormal microglial cell morphology	J:99412
	abnormal response to transplant	J:76224
	increased leukocyte cell number	J:99412
\Ins2^Akita/\Ins2⁺ \Prf1^tm1Sdz/\Prf1^tm1Sdz \Rag1^tm1Mom/\Rag1^tm1Mom (NOD.Cg-Rag1^tm1Mom Ins2^Akita Prf1^tm1Sdz)	absent mature B cells	J:138005
	absent T cells	J:138005
	increased granulocyte number	J:138005
	increased macrophage cell number	J:138005
	increased monocyte cell number	J:138005
\Ins2^C95S/\Ins2⁺ (C3HeB/FeJ-Ins2^C95S)	increased susceptibility to autoimmune diabetes	J:122098
\Ins2^C95S/\Ins2^C95S (C3HeB/FeJ-Ins2^C95S)	increased susceptibility to autoimmune diabetes	J:122098
\Ins2^tm1Jja/\Ins2^tm1Jja (NOD.129S2-Ins2^tm1Jja)	increased anti-insulin autoantibody level	J:85309
\Ins2^tm1Jja/\Ins2^tm1Jja (NOD.129S2-Ins2^tm1Jja)	insulitis	J:85309
\Ins2^tm1Jja/\Ins2^tm1Jja \Tg(Ins2Y16A)3Ell/0 (NOD.Cg-Ins2^tm1Jja Tg(Ins2Y16A)3Ell)	autoimmune response	J:98583
	increased anti-insulin autoantibody level	J:98583
\Insr^m1Btlr/\Insr^m1Btlr (C57BL/6J-Insr^m1Btlr)	increased susceptibility to induced colitis	J:267534
\Insr^tm1Khn/\Insr^tm1Khn \Lepr^tm1.1Chua/\Lepr^tm1.1Chua \Tg(Pomc1-cre)16Lowl/0 (involves: 129 * 129S4/SvJae * 129S6/SvEvTac * C57BL/6J * FVB/N)	liver inflammation	J:192274
	ovary inflammation	J:192274
	white adipose tissue inflammation	J:192274
\Insyn2b^em1(IMPC)J/\Insyn2b^em1(IMPC)J (C57BL/6NJ-Insyn2b^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Invs^inv/\Invs^inv (FVB/N-Invs^inv)	abnormal spleen morphology	J:48533
\Invs^inv/\Invs^inv (FVB/N-Invs^inv)	spleen hypoplasia	J:48533
\Ip6k2^tm1.1Snyd/\Ip6k2^tm1.1Snyd (B6.129-Ip6k2^tm1.1Snyd)	abnormal B cell physiology	J:212482
\Ipo7^em1(IMPC)Mbp/\Ipo7⁺ (C57BL/6N-Ipo7^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Ipp^{tm1.1(KOMP)Vlcg}/\Ipp^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ipp^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Iqce^{tm1b(EUCOMM)Hmgu}/\Iqce^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Iqce^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Iqcm^em1(IMPC)Tcp/\Iqcm⁺ (C57BL/6NCrl-Iqcm^em1(IMPC)Tcp/Cmmr)	increased monocyte cell number	J:211773
\Iqcm^em1(IMPC)Tcp/\Iqcm^em1(IMPC)Tcp (C57BL/6NCrl-Iqcm^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
\Iqgap1^{tm1b(EUCOMM)Wtsi}/\Iqgap1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Iqgap1^{tm1b(EUCOMM)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Irag1^{em1(IMPC)Ccpcz}/\Irag1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Irag1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Irak1^tm1.1Pcoh/? (involves: 129P2/OlaHsd)	decreased interferon-alpha secretion	J:205798
\Irak1^tm1.1Pcoh/? (involves: 129P2/OlaHsd)	immune system phenotype	J:205798
\Irak1^tm1.1Pcoh/? \Irak2^tm1.1Pcoh/? (involves: 129P2/OlaHsd * C57BL/6)	decreased interferon-alpha secretion	J:205798
\Irak1^tm1Jth/Y (B6.Cg-Irak1^tm1Jth)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:82302
\Irak1^tm1Jth/Y \Irak2^tm1Aki/\Irak2^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:136290
	abnormal macrophage physiology	J:136290
	decreased susceptibility to endotoxin shock	J:136290
\Irak1^tm1Jth/Y \Tg(Myh6-Tnf)1Brgi/? (involves: 129/Sv * C57BL/6J * SJL)	myocarditis	J:84829
\Irak1^tm1Jth/\Irak1^tm1Jth (B6.Cg-Irak1^tm1Jth)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:82302
\Irak1^tm1Jth/\Irak1^tm1Jth \Tg(Myh6-Tnf)1Brgi/? (involves: 129/Sv * C57BL/6J * SJL)	myocarditis	J:84829
\Irak2^tm1.1Pcoh/? (involves: C57BL/6)	decreased interferon-alpha secretion	J:205798
\Irak2^tm1Aki/\Irak2^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal macrophage physiology	J:136290
\Irak2^tm1Aki/\Irak2^tm1Aki (involves: 129/Sv * C57BL/6)	decreased susceptibility to endotoxin shock	J:136290
\Irak2^tm1Jth/\Irak2^tm1Jth (involves: 129 * C57BL/6)	abnormal chemokine level	J:149258
	decreased circulating interleukin-6 level	J:149258
	decreased circulating tumor necrosis factor level	J:149258
	decreased interleukin-6 secretion	J:149258
	decreased susceptibility to endotoxin shock	J:149258
	decreased tumor necrosis factor secretion	J:149258
\Irak3^tm1Flv/\Irak3^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal immune system morphology	J:78189
	abnormal inflammatory response	J:78189
	abnormal innate immunity	J:78189
	abnormal osteoclast physiology	J:98035
	abnormal Peyer's patch morphology	J:78189
	enlarged Peyer's patches	J:78189
	increased interleukin-6 secretion	J:78189
	increased interleukin-12b secretion	J:78189
	increased neutrophil cell number	J:78189
	increased osteoclast cell number	J:98035
	increased susceptibility to endotoxin shock	J:78189
	increased tumor necrosis factor secretion	J:78189
\Irak3^tm1Flv/\Irak3^tm1Flv (NOD.129S1(B6)-Irak3^tm1Flv)	abnormal dendritic cell physiology	J:229884
	abnormal professional antigen presenting cell physiology	J:229884
	abnormal T cell activation	J:229884
	abnormal T cell differentiation	J:229884
	increased anti-insulin autoantibody level	J:229884
	increased effector memory T-helper cell number	J:229884
	increased susceptibility to autoimmune diabetes	J:229884
	insulitis	J:229884
\Irak4^{em1(IMPC)Ccpcz}/\Irak4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Irak4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Irak4^m1Btlr/\Irak4^m1Btlr (C57BL/6J-Irak4^m1Btlr)	decreased tumor necrosis factor secretion	J:133271
\Irak4^m1Btlr/\Irak4^m1Btlr \Ptpn6^m1Btlr/\Ptpn6^m1Btlr (C57BL/6J-Ptpn6^m1Btlr Irak4^m1Btlr)	immune system phenotype	J:142845
\Irak4^m1Btlr/\Irak4^m1Btlr \Ticam1^Lps2/\Ticam1^Lps2 (involves: C57BL/6J)	decreased tumor necrosis factor secretion	J:187583
\Irak4^tm1Aki/\Irak4^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:125729
	decreased B cell proliferation	J:125729
	decreased interferon-alpha secretion	J:125729
	decreased interleukin-6 secretion	J:125729
	decreased interleukin-12b secretion	J:125729
	decreased susceptibility to endotoxin shock	J:125729
	decreased tumor necrosis factor secretion	J:125729
	immune system phenotype	J:125729
\Irak4^tm1Gram/\Irak4^tm1Gram (involves: BALB/c)	abnormal chemokine secretion	J:121912
\Irak4^tm1Gram/\Irak4^tm1Gram (involves: BALB/c)	abnormal cytokine secretion	J:121912
\Irak4^tm1Lix/\Irak4^tm1Lix (involves: C57BL/6)	abnormal chemokine secretion	J:125732
	decreased acute inflammation	J:125732
	decreased circulating interleukin-6 level	J:125732
	decreased circulating tumor necrosis factor level	J:125732
	decreased interferon-alpha secretion	J:125732
	decreased interferon-beta secretion	J:125732
	decreased interleukin-6 secretion	J:125732
	decreased susceptibility to endotoxin shock	J:125732
	decreased tumor necrosis factor secretion	J:125732
\Irak4^tm1Yeh/\Irak4^tm1Yeh (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine level	J:76098
	abnormal cytokine secretion	J:76098
	abnormal macrophage physiology	J:76098
	abnormal NK cell physiology	J:76098
	decreased B cell proliferation	J:76098
	decreased circulating interferon-gamma level	J:76098
	decreased circulating interleukin-1 level	J:76098
	decreased circulating interleukin-6 level	J:76098
	decreased circulating tumor necrosis factor level	J:76098
	decreased interleukin-6 secretion	J:76098
	decreased susceptibility to endotoxin shock	J:76098
	decreased tumor necrosis factor secretion	J:76098
	increased susceptibility to bacterial infection	J:76098
\Irak4^tm2Aki/\Irak4^tm2Aki (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:125729
	decreased B cell proliferation	J:125729
	decreased interferon-alpha secretion	J:125729
	decreased interleukin-6 secretion	J:125729
	decreased interleukin-12b secretion	J:125729
	decreased susceptibility to endotoxin shock	J:125729
	decreased tumor necrosis factor secretion	J:125729
	immune system phenotype	J:125729
\Irav1^C57BL/J/\Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cell-mediated immunity	J:122129
\Irav1^C57BL/J/\Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cytokine secretion	J:122129
\Irav1^DBA/2J/\Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cell-mediated immunity	J:122129
\Irav1^DBA/2J/\Irav1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal cytokine secretion	J:122129
\Ireb2^tm1.2Mwh/\Ireb2^tm1.2Mwh (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)	decreased spleen iron level	J:103414
\Ireb2^tm1Mwh/\Ireb2^tm1Mwh (involves: 129P2/OlaHsd * C57BL/6J)	decreased spleen iron level	J:105124
\Ireb2^tm1Roua/\Ireb2^tm1Roua (B6.Cg-Ireb2^tm1Roua)	decreased spleen iron level	J:176655
\Irf1^M1Btlr/\Irf1⁺ (C57BL/6J-Irf1^M1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:162995
	decreased NK cell number	J:162995
	immune system phenotype	J:162995
	impaired natural killer cell mediated cytotoxicity	J:162995
	increased susceptibility to Herpesvirales infection	J:162995
\Irf1^M1Btlr/\Irf1^M1Btlr (C57BL/6J-Irf1^M1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:162995
	decreased interferon-alpha secretion	J:162995
	decreased interferon-beta secretion	J:162995
	decreased NK cell number	J:162995
	immune system phenotype	J:162995
	impaired natural killer cell mediated cytotoxicity	J:162995
	increased susceptibility to Herpesvirales infection	J:162995
\Irf1^m2Btlr/\Irf1^m2Btlr (C57BL/6J-Irf1^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:267675
	decreased NK cell number	J:267675
	increased B-1 B cell number	J:267675
	increased CD4-positive, alpha-beta T cell number	J:267675
\Irf1^M3Btlr/\Irf1^M3Btlr (C57BL/6J-Irf1^M3Btlr)	decreased CD8-positive, alpha-beta T cell number	J:267677
\Irf1^M3Btlr/\Irf1^M3Btlr (C57BL/6J-Irf1^M3Btlr)	increased CD4-positive, alpha-beta T cell number	J:267677
\Irf1^tm1Cwe/\Irf1^tm1Cwe (involves: 129/Sv * C57BL/6)	abnormal cytokine level	J:110672
	abnormal immune system morphology	J:21235
	abnormal immune system physiology	J:43086
	abnormal immunoglobulin level	J:101427
	abnormal macrophage physiology	J:43086
	abnormal splenocyte morphology	J:21235
	abnormal T cell morphology	J:21235, J:36025
	abnormal thymus cell ratio	J:36025
	decreased CD8-positive, alpha-beta T cell number	J:21235
	decreased circulating interleukin-2 level	J:110672
	decreased susceptibility to induced arthritis	J:43086
	increased circulating interferon-gamma level	J:110672
	increased circulating interleukin-3 level	J:110672
	increased circulating interleukin-4 level	J:110672
	increased circulating interleukin-5 level	J:110672
	increased circulating interleukin-6 level	J:110672
	increased susceptibility to Poxviridae infection	J:101427
	increased T-helper 2 cell number	J:110672
\Irf1^tm1Cwe/\Irf1^tm1Cwe (involves: 129)	abnormal circulating interleukin-4 level	J:84367
	abnormal circulating interleukin-10 level	J:84367
	abnormal cytokine level	J:84367
	abnormal T cell proliferation	J:84367
	decreased circulating interferon-gamma level	J:84367
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:84367
	increased circulating interleukin-5 level	J:84367
	increased circulating interleukin-6 level	J:84367
	increased circulating interleukin-13 level	J:84367
\Irf1^tm1Mak/\Irf1^tm1Mak (either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))	abnormal response to infection	J:64286
	abnormal T cell number	J:64286
	decreased CD8-positive, alpha-beta T cell number	J:64286
	immune system phenotype	J:64286
	increased CD4-positive, alpha-beta T cell number	J:64286
	increased double-positive T cell number	J:64286
\Irf1^tm1Mak/\Irf1^tm1Mak (B6.129S2-Irf1^tm1Mak/J)	abnormal lymphocyte physiology	J:91927
\Irf1^tm1Mak/\Irf1^tm1Mak (B6.129S2-Irf1^tm1Mak/J)	decreased interferon-gamma secretion	J:91927
\Irf2^tm1Mak/\Irf2^tm1Mak (either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2))	abnormal immune system physiology	J:64286
	abnormal response to infection	J:64286
	decreased B cell proliferation	J:64286
	decreased IgG2a level	J:64286
	decreased mature B cell number	J:64286
	decreased T cell number	J:64286
	immune system phenotype	J:64286
\Irf2^tm1Mak/\Irf2^tm1Mak (involves: 129S2/SvPas * C57BL/6)	dermatitis	J:66034
	enlarged inguinal lymph nodes	J:66034
	increased memory T cell number	J:66034
	lymph node hyperplasia	J:66034
\Irf3^em1(IMPC)Mbp/\Irf3^em1(IMPC)Mbp (C57BL/6N-Irf3^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
\Irf3^tm1Ttg/\Irf3^tm1Ttg (involves: 129S/SvEv * C57BL/6J)	abnormal circulating interferon level	J:98127
\Irf3^tm1Ttg/\Irf3^tm1Ttg (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to Picornaviridae infection	J:98127
\Irf3^tm1Ttg/\Irf3^tm1Ttg \Irf7^tm1Ttg/\Irf7^tm1Ttg (involves: 129P2/OlaHsd * 129S/SvEv)	decreased interferon-beta secretion	J:158969
	decreased interleukin-1 beta secretion	J:158969
	increased susceptibility to bacterial infection	J:158969
	increased susceptibility to Herpesvirales infection	J:158969
	increased susceptibility to Paramyxoviridae infection	J:158969
\Irf3^tm1Ttg/\Irf3^tm1Ttg \Irf9^tm1Ttg/\Irf9^tm1Ttg (involves: 129S/SvEv * C57BL/6J)	abnormal cytokine secretion	J:98127
\Irf3^tm1Ttg/\Irf3^tm1Ttg \Sting1^em1Jmin/\Sting1^em1Jmin (involves: 129S/SvEv * C57BL/6N)	decreased single-positive T cell number	J:251372
	lung inflammation	J:251372
\Irf4^em1(IMPC)Mbp/\Irf4^em1(IMPC)Mbp (C57BL/6N-Irf4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Irf4^m1Btlr/\Irf4^m1Btlr (C57BL/6J-Irf4^m1Btlr)	abnormal B cell activation	J:160882
	decreased IgG level	J:160882
	decreased IgM level	J:160882
\Irf4^m1Btlr/\Irf4^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
\Irf4^M2Btlr/\Irf4⁺ (C57BL/6J-Irf4^M2Btlr)	abnormal B cell activation	J:234245
	decreased IgG level	J:234245
	decreased IgM level	J:234245
\Irf4^M2Btlr/\Irf4^M2Btlr (C57BL/6J-Irf4^M2Btlr)	abnormal B cell activation	J:234245
	decreased IgG level	J:234245
	decreased IgM level	J:234245
\Irf4^tm1.1Rdf/\Irf4^tm1.1Rdf (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	abnormal B cell differentiation	J:112643
	abnormal B cell physiology	J:112643
	absent spleen germinal center	J:112643
	decreased B cell proliferation	J:112643
	decreased IgG1 level	J:112643
\Irf4^tm1Mak/\Irf4^tm1Mak (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:42683
	abnormal immune system cell morphology	J:42683
	abnormal immune system physiology	J:42683
	abnormal lymph node morphology	J:42683
	abnormal spleen morphology	J:42683
	absent lymph node germinal center	J:42683
	absent plasma cells	J:42683
	absent spleen germinal center	J:42683
	arrested B cell differentiation	J:42683
	decreased B cell proliferation	J:42683
	decreased dendritic cell number	J:91043
	decreased immunoglobulin level	J:42683
	decreased T cell proliferation	J:42683
	enlarged lymph nodes	J:42683
	enlarged spleen	J:42683
	immune system phenotype	J:169863
	increased lymphocyte cell number	J:42683
	increased susceptibility to Riboviria infection	J:42683
\Irf4^tm1Mak/\Irf4^tm1Mak (B6.129P2-Irf4^tm1Mak)	abnormal CD4-positive, alpha beta T cell morphology	J:78909
	abnormal T-helper 1 cell differentiation	J:78909
	increased susceptibility to bacterial infection	J:78909
\Irf4^tm1Mak/\Irf4^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	decreased plasmacytoid dendritic cell number	J:97716
	increased susceptibility to bacterial infection	J:81744
\Irf4^tm1Rdf/\Irf4^tm1.1Rdf (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	immune system phenotype	J:112643
\Irf4^tm1Rdf/\Irf4^tm1.1Rdf (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	abnormal B cell physiology	J:112643
\Irf5^{tm1e(EUCOMM)Wtsi}/\Irf5^{tm1e(EUCOMM)Wtsi} (C57BL/6N-Irf5^{tm1e(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta memory T cell number	J:211773
	decreased leukocyte cell number	J:211773
\Irf5^tm1Ttg/\Irf5^tm1Ttg (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 physiology	J:97567
	decreased circulating interleukin-6 level	J:97567
	decreased circulating interleukin-12b level	J:97567
	decreased circulating tumor necrosis factor level	J:97567
	decreased susceptibility to bacterial infection	J:97567
	immune system phenotype	J:182658
\Irf5^tm1Ttg/\Irf5^tm1Ttg (B6.129P2-Irf5^tm1Ttg)	abnormal response to infection	J:182658
	decreased interferon-alpha secretion	J:182658
	decreased interleukin-6 secretion	J:182658
	decreased tumor necrosis factor secretion	J:182658
	immune system phenotype	J:182658
\Irf7^m1Btlr/\Irf7⁺ (C57BL/6J-Irf7^m1Btlr)	decreased interferon-alpha secretion	J:159358
\Irf7^m1Btlr/\Irf7⁺ (C57BL/6J-Irf7^m1Btlr)	decreased interferon-beta secretion	J:159358
\Irf7^m1Btlr/\Irf7^m1Btlr (C57BL/6J-Irf7^m1Btlr)	decreased interferon-alpha secretion	J:159358
\Irf7^m1Btlr/\Irf7^m1Btlr (C57BL/6J-Irf7^m1Btlr)	decreased interferon-beta secretion	J:159358
\Irf7^M2Btlr/\Irf7⁺ (C57BL/6J-Irf7^M2Btlr)	decreased circulating interferon-beta level	J:217798
\Irf7^M2Btlr/\Irf7^M2Btlr (C57BL/6J-Irf7^M2Btlr)	decreased circulating interferon-beta level	J:217798
\Irf7^tm1Ttg/\Irf7^tm1Ttg (involves: 129P2/OlaHsd)	abnormal interferon level	J:97662
	abnormal T cell physiology	J:97662
	increased susceptibility to Herpesvirales infection	J:97662
	increased susceptibility to Picornaviridae infection	J:97662
\Irf7^tm1Ttg/\Irf7^tm1Ttg (B6.129P2-Irf7^tm1Ttg)	increased susceptibility to Orthomyxoviridae infection	J:233979
\Irf7^tm1Ttg/\Irf7^tm1Ttg (B6.129P2-Irf7^tm1Ttg)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:233979
\Irf8^M1Btlr/\Irf8^M1Btlr (C57BL/6J-Irf8^M1Btlr)	abnormal interferon secretion	J:166600
	decreased macrophage cell number	J:166600
	decreased monocyte cell number	J:166600
	increased neutrophil cell number	J:166600
\Irf8^m2Btlr/\Irf8^m2Btlr (C57BL/6J-Irf8^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:274937
\Irf8^m2Btlr/\Irf8^m2Btlr (C57BL/6J-Irf8^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:274937
\Irf8^myls/\Irf8⁺ (involves: BXH2/TyJ * C57BL/6)	increased B cell number	J:168923
	increased B-1b cell number	J:168923
	increased follicular B cell number	J:168923
	increased transitional stage B cell number	J:168923
\Irf8^myls/\Irf8^myls (involves: BALB/cJ * BXH2/TyJ-Irf8^myls)	abnormal myelopoiesis	J:97931
	enlarged spleen	J:97931
\Irf8^myls/\Irf8^myls \Slc11a1^r/\Slc11a1^r (BXH2/TyJ)	abnormal myelopoiesis	J:97931
	decreased interferon-gamma secretion	J:97931
	decreased interleukin-12 secretion	J:97931
	enlarged spleen	J:97931
	increased susceptibility to bacterial infection	J:97931
\Irf8^myls/\Irf8^myls \Slc11a1^r/\Slc11a1^r (involves: BXH2/TyJ * C57BL/6J)	increased susceptibility to bacterial infection	J:97931
\Irf8^myls/\Irf8^myls \Slc11a1^r/\Slc11a1^r (involves: BALB/cJ * BXH2/TyJ)	increased susceptibility to bacterial infection	J:97931
\Irf8^myls/\Irf8^myls \Slc11a1^r/\Slc11a1^r (involves: BXH2/TyJ * C3H/HeJ)	enlarged spleen	J:97931
	increased susceptibility to bacterial infection	J:97931
\Irf8^myls/\Irf8^myls \Slc11a1^r/\Slc11a1^s (involves: BXH2/TyJ * C57BL/6J)	increased susceptibility to bacterial infection	J:97931
\Irf8^myls/\Irf8^myls \Slc11a1^r/\Slc11a1^s (involves: BALB/cJ * BXH2/TyJ)	increased susceptibility to bacterial infection	J:97931
\Irf8^myls/\Irf8^myls \Slc11a1^s/\Slc11a1^s (involves: BALB/cJ * BXH2/TyJ)	increased susceptibility to bacterial infection	J:97931
\Irf8^tm1Hor/\Irf8^tm1Hor (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal cytotoxic T cell physiology	J:36038
	abnormal plasma cell number	J:36038
	decreased B cell number	J:36038
	decreased interferon-gamma secretion	J:36038
	decreased lymphocyte cell number	J:36038
	decreased T cell number	J:36038
	enlarged lymph nodes	J:36038
	hepatosplenomegaly	J:36038
	increased B cell number	J:36038
	increased granulocyte number	J:36038
	increased immunoglobulin level	J:36038
	increased leukocyte cell number	J:36038
	increased lymphocyte cell number	J:36038
	increased macrophage cell number	J:36038
	increased mature B cell number	J:36038
	increased spleen red pulp amount	J:36038
	increased spleen weight	J:36038
	increased susceptibility to Riboviria infection	J:36038
	spleen hyperplasia	J:36038
\Irf8^tm1Hor/\Irf8^tm1Hor (B6.129P2-Irf8^tm1Hor)	decreased follicular B cell number	J:168923
	increased B-1b cell number	J:168923
	increased marginal zone B cell number	J:168923
\Irf8^tm1Hor/\Irf8^tm1Hor (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:181366
\Irf8^tm1Hor/\Irf8^tm1Hor \Irf4^tm1Mak/\Irf4^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:84577
	abnormal pre-B cell morphology	J:84577
	absent B cells	J:84577
	arrested B cell differentiation	J:84577
	decreased dendritic cell number	J:97716
	decreased IgM level	J:84577
	decreased lymphocyte cell number	J:84577
	decreased plasmacytoid dendritic cell number	J:97716
	decreased T cell number	J:84577
	increased pre-B cell number	J:84577
\Irf9^M1Btlr/\Irf9⁺ (C57BL/6J-Irf9^M1Btlr)	increased circulating interferon-beta level	J:236674
\Irf9^M1Btlr/\Irf9^M1Btlr (C57BL/6J-Irf9^M1Btlr)	increased circulating interferon-beta level	J:236674
\Irf9^tm1Ttg/\Irf9^tm1Ttg (B6.Cg-Irf9^tm1Ttg)	decreased interferon-alpha secretion	J:97662
\Irf9^tm1Ttg/\Irf9^tm1Ttg (either: (involves: C57BL/6 * CBA * ICR) or (involves: A/J * C57BL/6 * CBA))	increased susceptibility to viral infection	J:77456
\Irgc^em1(IMPC)Tcp/\Irgc^em1(IMPC)Tcp (C57BL/6N-Irgc^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
\Irgm1^tm1Gat/\Irgm1^tm1Gat (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:87535
	increased circulating interferon-gamma level	J:87535
	increased circulating interleukin-12 level	J:87535
	increased susceptibility to bacterial infection	J:87535
	increased susceptibility to parasitic infection	J:87535
\Irgm2^em1Myam/\Irgm2^em1Myam (C57BL/6-Irgm2^em1Myam)	increased susceptibility to parasitic infection	J:308470
\Irgm2^em1Myam/\Irgm2^em1Myam (C57BL/6-Irgm2^em1Myam)	increased susceptibility to parasitic infection induced morbidity/mortality	J:308470
\Irs1^Sml/\Irs1^Sml (C3.Cg-Irs1^Sml H2^b/GrsrJ)	increased osteoclast cell number	J:163661
\Irs1^tm1Mfw/\Irs1^tm1Mfw \Irs2^tm2Mfw/\Irs2^tm2Mfw \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	increased susceptibility to autoimmune diabetes	J:137845
\Irs1^tm1Tka/\Irs1^tm1Tka (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:61479
\Irs1^tm1Tka/\Irs1^tm1Tka (involves: C57BL/6 * CBA)	abnormal osteoclast physiology	J:61479
\Irs1^tm2Tka/\Irs1^tm2Tka \Irs2^tm2Tka/\Irs2^tm2Tka \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)	increased susceptibility to autoimmune diabetes	J:137846
\Is(14)1Rdf \Is(14)2Rdf/\Del(14Trim13-Dleu2)4Rdf \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
\Is(14)1Rdf \Is(14)5Rdf/\Del(14Trim13-Rnaseh2b)6Rdf \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal lymphopoiesis	J:179879
	increased B cell number	J:179879
\Is(14)1Rdf/\Is(14)1Rdf \Is(14)5Rdf/\Is(14)5Rdf \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal lymphopoiesis	J:179879
	increased B cell number	J:179879
\Isg15^tm1Kpk/\Isg15^tm1Kpk (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:100028
\Isg20^em1Cya/\Isg20^em1Cya \Tg(Cdh16-cre)91Igr/0 (involves: C57BL/6N * ICR)	kidney inflammation	J:343183
\Isl1^Drsh/\Isl1⁺ (C3HeB/FeJ-Isl1^Drsh)	increased susceptibility to otitis media	J:202214
\Isl1^tm1(cre)Sev/\Isl1⁺ \Pax9^tm1Rbal/\Pax9^tm1.1Hpt (involves: 129 * C57BL/6J)	ectopic thymus	J:311535
	thymus hypoplasia	J:311535
\Ism1^{em1(IMPC)Ccpcz}/\Ism1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ism1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Isy1^em1(IMPC)J/\Isy1⁺ (C57BL/6NJ-Isy1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Itch^tm1.1Alta/\Itch^tm1.1Alta \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immunoglobulin level	J:204685
	abnormal interleukin secretion	J:204685
	abnormal lymph organ size	J:204685
	abnormal lymphopoiesis	J:204685
	abnormal regulatory T cell physiology	J:204685
	abnormal T-helper 2 cell differentiation	J:204685
	abnormal T-helper 2 physiology	J:204685
	decreased CD4-positive, alpha-beta T cell number	J:204685
	dermatitis	J:204685
	enlarged lymph nodes	J:204685
	enlarged spleen	J:204685
	immune system phenotype	J:204685
	increased CD4-positive, alpha-beta T cell number	J:204685
	increased CD8-positive, alpha-beta T cell number	J:204685
	increased eosinophil cell number	J:204685
	increased IgA level	J:204685
	increased IgE level	J:204685
	increased IgG1 level	J:204685
	increased inflammatory response	J:204685
	increased interleukin-4 secretion	J:204685
	increased interleukin-5 secretion	J:204685
	increased interleukin-10 secretion	J:204685
	increased interleukin-13 secretion	J:204685
	increased interleukin-17 secretion	J:204685
	increased leukocyte cell number	J:204685
	increased regulatory T cell apoptosis	J:204685
	increased regulatory T cell number	J:204685
	lung inflammation	J:204685
\Itch^tm1.1Alta/\Itch^tm1.1Alta \Gt(ROSA)26Sor^tm1Hjf/\Gt(ROSA)26Sor⁺ \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:204685
	increased inflammatory response	J:204685
\Itch^{tm1b(EUCOMM)Hmgu}/\Itch^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Itch^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Itfg2^{Gt(OST215121)Lex}/\Itfg2^{Gt(OST215121)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal B cell activation	J:205951
	abnormal humoral immune response	J:205951
	abnormal splenocyte physiology	J:205951
	decreased B cell number	J:205951
	decreased IgE level	J:205951
	decreased IgG1 level	J:205951
	decreased IgG2a level	J:205951
	decreased IgG2b level	J:205951
	decreased IgG3 level	J:205951
	decreased lymphocyte cell number	J:205951
	decreased spleen germinal center number	J:205951
	decreased T follicular helper cell number	J:205951
	immune system phenotype	J:205951
	increased B cell number	J:205951
	spleen hyperplasia	J:205951
\Itga2b^tm1Tlr/\Itga2b^tm1Tlr (either: (involves: 129S1/Sv * 129X1/SvJ * BALB/c) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	enlarged spleen	J:63961
\Itga3^tm1Son/\Itga3^tm1Son \Krt14^tm1(cre)Wbm/\Krt14⁺ (involves: 129P2/OlaHsd * FVB/N)	skin inflammation	J:145988
\Itga3^tm1Son/\Itga3^tm1Son \Tg(KRT5-cre)5132Jlj/? (involves: 129P2/OlaHsd * C57BL/6 * DBA)	skin inflammation	J:145988
\Itga4^tm1Mgin/\Itga4^tm1Mgin (B6.129-Itga4^tm1Mgin)	abnormal B cell physiology	J:106471
	abnormal lymphocyte physiology	J:106471
	abnormal T cell physiology	J:106471
	decreased monocyte cell number	J:106471
	decreased Peyer's patch number	J:106471
	impaired macrophage chemotaxis	J:106471
\Itga4^tm1Mshi/\Itga4^tm1Mshi (C57BL/6-Itga4^tm1Mshi)	abnormal cellular extravasation	J:144092
	abnormal leukocyte adhesion	J:144092
	abnormal leukocyte migration	J:144092
	abnormal mononuclear cell morphology	J:144092
	decreased B cell number	J:144092
	decreased lymphocyte cell number	J:144092
	decreased T cell number	J:144092
	small Peyer's patches	J:144092
\Itga4^tm1Tpa/\Itga4^tm1Tpa \Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJaeSor * C57BL/6 * CBA)	abnormal B cell differentiation	J:86861
	decreased CD4-positive, alpha-beta T cell number	J:86861
	increased leukocyte cell number	J:86861
\Itga5^tm1Hyn/\Itga5⁺ \Nisch^edsn/\Nisch⁺ (C3H.Cg-Nisch^edsn Itga5^tm1Hyn)	increased susceptibility to otitis media	J:244907
\Itga5^tm1Hyn/\Itga5⁺ \Nisch^edsn/\Nisch^edsn (C3H.Cg-Nisch^edsn Itga5^tm1Hyn)	increased susceptibility to otitis media	J:244907
\Itga6^tm1Son/\Itga6^tm1Son (involves: 129P2/OlaHsd * FVB)	abnormal lymph node morphology	J:50235
	abnormal T cell physiology	J:50235
	decreased T cell number	J:50235
\Itga9^tm1Des/\Itga9^tm1Des (involves: 129S4/SvJae * C57BL/6)	abnormal lymph circulation	J:63038
\Itgad^tm1.1Zimm/\Itgad^tm1.1Zimm (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:130908
	abnormal macrophage physiology	J:130908
	abnormal susceptibility to infection	J:130908
	decreased susceptibility to parasitic infection	J:130908
	increased circulating interleukin-12 level	J:130908
	increased spleen weight	J:130908
	increased susceptibility to bacterial infection	J:130908
\Itgad^tm1Bll/\Itgad^tm1Bll (B6.129S7-Itgad^tm1Bll)	abnormal lymphocyte cell number	J:90954
	abnormal T cell activation	J:90954
	abnormal T cell subpopulation ratio	J:90954
	decreased CD4-positive, alpha-beta T cell number	J:90954
	decreased T cell proliferation	J:90954
	increased CD8-positive, alpha-beta T cell number	J:90954
\Itgae^{tm1b(EUCOMM)Wtsi}/\Itgae^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Itgae^{tm1b(EUCOMM)Wtsi}/H)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
\Itgae^tm1Cmp/\Itgae^tm1Cmp (involves: 129S2/SvPas * BALB/c)	decreased lymphocyte cell number	J:55333
	decreased T cell number	J:55333
\Itgal^em1(IMPC)H/\Itgal^em1(IMPC)H (C57BL/6NTac-Itgal^em1(IMPC)H/H)	increased spleen weight	J:211773
\Itgal^tm1.1Mshi/\Itgal^tm1.1Mshi (involves: C57BL/6)	abnormal diapedesis	J:168533
	abnormal leukocyte adhesion	J:168533
	abnormal leukocyte migration	J:168533
	decreased lymphocyte cell number	J:168533
	enhanced leukocyte tethering or rolling	J:168533
	small lymph nodes	J:168533
\Itgal^tm1Bll/\Itgal⁺ (involves: 129S7/SvEvBrd)	abnormal CD4-positive, alpha-beta T cell physiology	J:267548
\Itgal^tm1Bll/\Itgal^tm1Bll (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal cellular extravasation	J:83226
	abnormal leukocyte adhesion	J:83226
	abnormal leukocyte migration	J:83226
	increased eosinophil cell number	J:83226
	increased leukocyte cell number	J:83226
	increased monocyte cell number	J:83226
	increased neutrophil cell number	J:83226
\Itgal^tm1Bll/\Itgal^tm1Bll (B6.129S7-Itgal^tm1Bll)	abnormal leukocyte adhesion	J:100242
	abnormal leukocyte tethering or rolling	J:100242
	decreased T cell proliferation	J:90954
	impaired natural killer cell mediated cytotoxicity	J:90954
	increased leukocyte cell number	J:100242
	increased neutrophil cell number	J:100242
\Itgal^tm1Bll/\Itgal^tm1Bll (B6.129S7-Itgal^tm1Bll/J)	abnormal inflammatory response	J:113463
\Itgal^tm1Bll/\Itgal^tm1Bll (involves: 129S7/SvEvBrd)	abnormal CD4-positive, alpha-beta T cell physiology	J:267548
	abnormal cellular extravasation	J:141063
	abnormal leukocyte adhesion	J:141063
	abnormal neutrophil physiology	J:141063
\Itgal^tm1Hlz/\Itgal^tm1Hlz (involves: 129P2/OlaHsd)	abnormal cellular extravasation	J:99286
	abnormal humoral immune response	J:99286
	abnormal leukocyte adhesion	J:99286
	abnormal T cell activation	J:99286
	decreased cytotoxic T cell cytolysis	J:99286
	decreased lymphocyte cell number	J:99286
	decreased neutrophil cell number	J:99286
	spleen hyperplasia	J:99286
\Itgal^tm1Hogg/\Itgal^tm1Hogg (involves: 129P2/OlaHsd)	abnormal leukocyte adhesion	J:82587
	abnormal leukocyte migration	J:82587
	abnormal lymph node morphology	J:82587
	decreased B cell number	J:82587
	decreased CD4-positive, alpha-beta T cell number	J:82587
	decreased CD8-positive, alpha-beta T cell number	J:82587
	decreased lymphocyte cell number	J:82587
	enlarged spleen	J:82587
	increased CD4-positive, alpha-beta T cell number	J:82587
	increased CD8-positive, alpha-beta T cell number	J:82587
	small lymph nodes	J:82587
\Itgal^tm1Mak/\Itgal⁺ (B6.129P2-Itgal^tm1Mak)	decreased susceptibility to endotoxin shock	J:123460
\Itgal^tm1Mak/\Itgal^tm1Mak (B6.129P2-Itgal^tm1Mak)	decreased susceptibility to endotoxin shock	J:123460
	impaired natural killer cell mediated cytotoxicity	J:110889
	increased circulating interleukin-2 level	J:123460
	increased circulating interleukin-10 level	J:123460
	increased circulating tumor necrosis factor level	J:123460
\Itgal^tm1Wpfl/\Itgal^tm1Wpfl (involves: 129)	abnormal cytotoxic T cell physiology	J:37160
	abnormal leukocyte physiology	J:37160
	abnormal lymphocyte physiology	J:37160
	immune system phenotype	J:37160
	lymph node hyperplasia	J:37160
\Itgam^m1Btlr/\Itgam⁺ (C57BL/6J-Itgam^m1Btlr)	abnormal dendritic cell number	J:236681
	decreased macrophage cell number	J:236681
	decreased neutrophil cell number	J:236681
	increased plasmacytoid dendritic cell number	J:236681
\Itgam^m1Btlr/\Itgam^m1Btlr (C57BL/6J-Itgam^m1Btlr)	abnormal dendritic cell number	J:236681
	decreased macrophage cell number	J:236681
	decreased neutrophil cell number	J:236681
	increased plasmacytoid dendritic cell number	J:236681
\Itgam^m2Btlr/\Itgam^m2Btlr (C57BL/6J-Itgam^m2Btlr)	decreased CD11b-high dendritic cell number	J:272532
\Itgam^m3Btlr/\Itgam^m3Btlr (C57BL/6J-Itgam^m3Btlr)	decreased CD11b-high dendritic cell number	J:272533
\Itgam^tm1Bll/\Itgam^tm1Bll (B6.129S7-Itgam^tm1Bll)	abnormal leukocyte adhesion	J:100242
	abnormal lymphocyte cell number	J:90954
	abnormal T cell activation	J:90954
	abnormal T cell subpopulation ratio	J:90954
	decreased CD4-positive, alpha-beta T cell number	J:90954
	decreased T cell proliferation	J:90954
	increased CD8-positive, alpha-beta T cell number	J:90954
	increased leukocyte cell number	J:100242
	increased neutrophil cell number	J:100242
	increased susceptibility to bacterial infection	J:94855
\Itgam^tm1Bll/\Itgam^tm1Bll (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal cellular extravasation	J:83226
	abnormal leukocyte adhesion	J:83226
	abnormal leukocyte migration	J:83226
	abnormal neutrophil physiology	J:39092
	decreased eosinophil cell number	J:83226
	impaired neutrophil phagocytosis	J:39092
\Itgam^tm1Myd/\Itgam^tm1Myd (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal leukocyte adhesion	J:38052
	impaired neutrophil phagocytosis	J:38052
	increased eosinophil cell number	J:38052
	increased neutrophil cell number	J:38052
\Itgam^tm1Myd/\Itgam^tm1Myd (involves: 129S4/SvJae * C57BL/6)	decreased neutrophil cell number	J:103873
\Itgam^tm1Myd/\Itgam^tm1Myd (B6.129S4-Itgam^tm1Myd)	abnormal inflammatory response	J:113463
	abnormal neutrophil morphology	J:113463
	abnormal neutrophil physiology	J:113463
\Itgam^tm1Myd/\Itgam^tm1Myd (involves: 129S4/SvJae)	impaired leukocyte tethering or rolling	J:198197
\Itgam^tm1Myd/\Itgam^tm1Myd (involves: 129S4/SvJae)	impaired neutrophil phagocytosis	J:155479
\Itgam^tm1Myd/\Itgam^tm1Myd \Syk^tm1Tyb/\Syk^tm1.2Tara \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)	impaired granulocyte bactericidal activity	J:155479
\Itgam^tm1Rws/\Itgam^tm1Rws (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:65847
\Itgav^tm1Blb/\Itgav^tm1Blb \Itgb1^tm1Ref/\Itgb1^tm1Ref \Itgb2^tm2Bay/\Itgb2^tm2Bay \Itgb7^tm1Cgn/\Itgb7^tm1Cgn \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)	abnormal cellular extravasation	J:134784
	abnormal dendritic cell physiology	J:134784
	immune system phenotype	J:134784
\Itgav^tm2Hyn/\Itgav^tm2.1Hyn \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB)	colitis	J:125508
	impaired macrophage phagocytosis	J:125508
	increased autoantibody level	J:125508
\Itgav^tm2Hyn/\Itgav^tm2.1Hyn \Tg(Nes-cre)1Kln/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB * SJL)	increased susceptibility to bacterial infection induced morbidity/mortality	J:94376
\Itgav^tm2Hyn/\Itgav^tm2.1Hyn \Tg(Tek-cre)1Ywa/? (involves: 129S2/SvPas * C57BL/6 * FVB * SJL)	abnormal dendritic cell differentiation	J:125508
	abnormal immune system morphology	J:125508
	abnormal immune system physiology	J:125508
	abnormal interferon level	J:125508
	abnormal interleukin level	J:125508
	abnormal leukocyte morphology	J:125508
	abnormal tumor necrosis factor level	J:125508
	colitis	J:125508
	decreased regulatory T cell number	J:125508
	enlarged mesenteric lymph nodes	J:125508
	enlarged Peyer's patches	J:125508
	impaired macrophage phagocytosis	J:125508
	increased autoantibody level	J:125508
	increased inflammatory response	J:125508
	increased regulatory T cell number	J:125508
	large intestinal inflammation	J:125508
\Itgax^M1Btlr/\Itgax⁺ (C57BL/6J-Itgax^M1Btlr)	decreased dendritic cell number	J:236684
\Itgax^M1Btlr/\Itgax⁺ (C57BL/6J-Itgax^M1Btlr)	increased plasmacytoid dendritic cell number	J:236684
\Itgax^M1Btlr/\Itgax^M1Btlr (C57BL/6J-Itgax^M1Btlr)	decreased dendritic cell number	J:236684
\Itgax^M1Btlr/\Itgax^M1Btlr (C57BL/6J-Itgax^M1Btlr)	increased plasmacytoid dendritic cell number	J:236684
\Itgax^{tm1.1(HBEGF)Ktak}/\Itgax⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal response to infection	J:162397
\Itgax^tm1Bll/\Itgax^tm1Bll (B6.129S7-Itgax^tm1Bll)	decreased interferon-gamma secretion	J:122187
	decreased interleukin-17 secretion	J:122187
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:122187
	decreased tumor necrosis factor secretion	J:122187
	increased interleukin-2 secretion	J:122187
	increased interleukin-12 secretion	J:122187
	increased susceptibility to bacterial infection	J:94855
	increased T cell proliferation	J:122187
\Itgb1^tm1Ref/\Itgb1^tm1Ref \Tg(KRT5-cre)5132Jlj/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J)	skin inflammation	J:65038
\Itgb2^M1Btlr/\Itgb2^M1Btlr (C57BL/6J-Itgb2^M1Btlr)	abnormal NK cell differentiation	J:139559
	decreased interferon-gamma secretion	J:139559
	immune system phenotype	J:139559
\Itgb2^m2Btlr/\Itgb2^m2Btlr (C57BL/6J-Itgb2^m2Btlr)	increased interferon-beta secretion	J:265125
\Itgb2^m3Btlr/\Itgb2^m3Btlr (C57BL/6J-Itgb2^m3Btlr)	abnormal cytotoxic T cell cytolysis	J:265126
	decreased B cell number	J:265126
	decreased CD4-positive, alpha-beta T cell number	J:265126
	decreased CD8-positive, alpha-beta T cell number	J:265126
	decreased dendritic cell number	J:265126
	decreased IgG level	J:265126
	decreased macrophage cell number	J:265126
	decreased neutrophil cell number	J:265126
	decreased single-positive T cell number	J:265126
	impaired humoral immune response	J:265126
	impaired natural killer cell mediated cytotoxicity	J:265126
	increased dendritic cell number	J:265126
	increased effector memory CD4-positive, alpha-beta T cell number	J:265126
	increased IgE level	J:265126
	increased NK T cell number	J:265126
\Itgb2^M4Btlr/\Itgb2^M4Btlr (C57BL/6J-Itgb2^M4Btlr)	abnormal T cell differentiation	J:272843
\Itgb2^M4Btlr/\Itgb2^M4Btlr (C57BL/6J-Itgb2^M4Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:272843
\Itgb2^m5Btlr/\Itgb2^m5Btlr (C57BL/6J-Itgb2^m5Btlr)	increased B-1b cell number	J:272844
\Itgb2^tm1.1Arte/\Itgb2^tm1.1Arte (involves: C57BL/6NTac)	abnormal T cell physiology	J:202261
	decreased T cell proliferation	J:202261
	enlarged spleen	J:202261
	increased B cell number	J:202261
	increased dendritic cell number	J:202261
	increased neutrophil cell number	J:202261
	increased T cell number	J:202261
	lymph node hypoplasia	J:202261
\Itgb2^tm1Bay/\Itgb2^tm1Bay (involves: 129S7/SvEvBrd)	decreased inflammatory response	J:13599
	increased granulocyte number	J:13599
	increased leukocyte cell number	J:13599, J:32126
	increased lymphocyte cell number	J:13599
\Itgb2^tm1Bay/\Itgb2^tm1Bay (involves: 129S7/SvEvBrd * PL/J)	abnormal cytokine level	J:109598
	abnormal spleen morphology	J:32126
	abnormal T cell activation	J:109598
	dermatitis	J:109598, J:32126
	enlarged lymph nodes	J:32126
	increased basophil cell number	J:32126
	increased eosinophil cell number	J:32126
	increased interferon-gamma secretion	J:109598
	increased leukocyte cell number	J:32126
	increased lymphocyte cell number	J:32126
	increased monocyte cell number	J:32126
	increased neutrophil cell number	J:32126
	increased T cell number	J:109598
	increased T-helper 1 cell number	J:109598
	myeloid hyperplasia	J:32126
\Itgb2^tm1Bay/\Itgb2^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal spleen red pulp morphology	J:13599
	myeloid hyperplasia	J:13599
\Itgb2^tm1Bay/\Itgb2^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J * PL/J)	dermatitis	J:84126
\Itgb2^tm1Bay/\Itgb2^tm1Bay \Psrs1^PL/J/\Psrs1^PL/J (B6.Cg-(D10Mit126-D10Mit38) Itgb2^tm1Bay)	rheumatoid arthritis	J:134251
\Itgb2^tm1Bay/\Itgb2^tm1Bay \Psrs1^PL/J/\Psrs1^PL/J (B6.Cg-(D10Mit75-D10Mit271) Itgb2^tm1Bay)	rheumatoid arthritis	J:134251
\Itgb2^tm1Bay/\Itgb2^tm2Bay (PL.129S7-Itgb2^tm1Bay Itgb2^tm2Bay)	dermatitis	J:84126
\Itgb2^tm1Bay/\Itgb2^tm2Bay (involves: 129S7/SvEvBrd * C57BL/6J * PL/J)	dermatitis	J:84126
\Itgb2^tm2Bay/\Itgb2^tm2Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal immune system cell morphology	J:48542
	abnormal leukocyte physiology	J:48542
	abnormal lymph organ size	J:48542
	abnormal neutrophil morphology	J:48542
	abnormal neutrophil physiology	J:48542
	abnormal T cell proliferation	J:48542
	conjunctivitis	J:48542
	dermatitis	J:48542
	enlarged lymph nodes	J:48542
	enlarged spleen	J:48542
	increased circulating interleukin-3 level	J:48542
	increased circulating interleukin-6 level	J:48542
	increased IgA level	J:48542
	increased IgG level	J:48542
	increased IgM level	J:48542
	increased immunoglobulin level	J:48542
	increased inflammatory response	J:48542
	increased leukocyte cell number	J:48542
	increased lymphocyte cell number	J:48542
	increased monocyte cell number	J:48542
	increased neutrophil cell number	J:48542
	increased susceptibility to bacterial infection	J:48542
	myeloid hyperplasia	J:48542
\Itgb2^tm2Bay/\Itgb2^tm2Bay (involves: 129S7/SvEvBrd)	decreased T cell proliferation	J:90954
\Itgb2^tm2Bay/\Itgb2^tm2Bay (B6.129S7-Itgb2^tm2Bay)	abnormal leukocyte adhesion	J:83226
	abnormal leukocyte migration	J:83226
	decreased susceptibility to bacterial infection	J:94855
	increased eosinophil cell number	J:83226
	increased leukocyte cell number	J:83226
	increased lymphocyte cell number	J:83226
	increased monocyte cell number	J:83226
	increased neutrophil cell number	J:83226
\Itgb2^tm2Bay/\Itgb2^tm2Bay (involves: 129S7/SvEvBrd * C57BL/6)	decreased acute inflammation	J:112286
	impaired neutrophil recruitment	J:112286
	increased neutrophil cell number	J:112286
\Itgb2^tm2Bay/\Itgb2^tm2Bay (PL.129S7-Itgb2^tm2Bay)	decreased susceptibility to type IV hypersensitivity reaction	J:109598
\Itgb2l^tm1Jhws/\Itgb2l^tm1Jhws (involves: 129/Sv * C57BL/6)	immune system phenotype	J:118477
\Itgb3^tm1Hyn/\Itgb3^tm1.1Wlbcr \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal osteoclast differentiation	J:224675
	abnormal osteoclast morphology	J:224675
	decreased osteoclast cell number	J:224675
\Itgb3^tm1Hyn/\Itgb3^tm1.1Wlbcr \Tg(Pf4-icre)Q3Rsko/0 (involves: 129S2/SvPas * C57BL/6)	enlarged spleen	J:224675
\Itgb3^tm1Hyn/\Itgb3^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	abnormal macrophage physiology	J:119666
	dermatitis	J:52262
	enlarged spleen	J:52262
	impaired macrophage chemotaxis	J:119666
	increased monocyte cell number	J:119666
	myositis	J:119666
\Itgb3^tm1Hyn/\Itgb3^tm1Hyn (involves: 129S2/SvPas)	abnormal osteoclast morphology	J:60672
	abnormal osteoclast physiology	J:60672
	decreased macrophage cell number	J:96049
	increased osteoclast cell number	J:60672
\Itgb3^tm1Hyn/\Itgb3^tm1Hyn (involves: 129S2/SvPas * BALB/c)	immune system phenotype	J:131241
	increased IgG level	J:131241
\Itgb4^tm1Son/\Itgb4^tm1Son (129P2/OlaHsd-Itgb4^tm1Son)	immune system phenotype	J:33713
\Itgb4^tm2Son/\Itgb4^tm2Son \Tg(KRT14-cre)8Brn/0 (involves: 129P2/OlaHsd * FVB/N)	ear inflammation	J:96543
\Itgb5^{tm1a(EUCOMM)Wtsi}/\Itgb5^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Itgb5^{tm1a(EUCOMM)Wtsi}/Ics)	increased leukocyte cell number	J:165965
\Itgb6^{em1(IMPC)Ccpcz}/\Itgb6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Itgb6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Itgb6^tm1Des/\Itgb6^tm1Des (involves: 129S4/SvJae * C57BL/6J)	respiratory system inflammation	J:33139
\Itgb6^tm1Des/\Itgb6^tm1Des (involves: 129S4/SvJae)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
	decreased Langerhans cell number	J:120085
\Itgb6^tm1Des/\Itgb6^tm1Des (involves: 129S4/SvJae * C57BL/6 * SJL)	respiratory system inflammation	J:51592
\Itgb6^tm1Des/\Itgb6^tm1Des \Mmp12^tm1Sds/\Mmp12^tm1Sds (involves: 129/Sv * 129T2/SvEms)	lung inflammation	J:89578
\Itgb6^tm1Des/\Itgb6^tm1Des \Tg(SFTPC-ITGB6)1Des/? (involves: 129S4/SvJae * C57BL/6 * SJL)	respiratory system inflammation	J:51592
\Itgb7^tm1Cgn/\Itgb7^tm1Cgn (involves: C57BL/6)	abnormal gut-associated lymphoid tissue morphology	J:34306
	abnormal immune system morphology	J:34306
	abnormal immune system physiology	J:34306
	abnormal lymphocyte physiology	J:34306
	abnormal Peyer's patch follicle morphology	J:34306
	abnormal response to infection	J:62733
	abnormal uterine NK cell morphology	J:44813
	decreased B cell number	J:34306
	decreased CD4-positive, alpha-beta T cell number	J:34306
	decreased eosinophil cell number	J:62733
	decreased mast cell number	J:62733
	immune system phenotype	J:111227
	impaired leukocyte tethering or rolling	J:34306
	increased susceptibility to parasitic infection	J:90262
	increased uterine NK cell number	J:44813
	small Peyer's patches	J:34306
\Itgb7^tm1Cgn/\Itgb7^tm1Cgn (C57BL/6-Itgb7^tm1Cgn/J)	abnormal leukocyte migration	J:127413
\Itgb7^tm1Cgn/\Itgb7^tm1Cgn (C57BL/6-Itgb7^tm1Cgn/J)	colitis	J:127413
\Itgb7^tm1Cgn/\Itgb7^tm1Cgn \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * C57BL/6)	abnormal inflammatory response	J:136667
	autoimmune arthritis	J:136667
\Itgb7^tm1Mshi/\Itgb7^tm1Mshi (involves: C57BL/6)	abnormal leukocyte adhesion	J:127413
	abnormal leukocyte migration	J:127413
	colitis	J:127413
	small Peyer's patches	J:127413
\Itk^m1Btlr/\Itk^m1Btlr (C57BL/6J-Itk^m1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236673
	abnormal CD8-positive, alpha-beta T cell physiology	J:236673
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236673
	increased IgE level	J:236673
\Itk^m2Btlr/\Itk^m2Btlr (C57BL/6J-Itk^m2Btlr)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254826
	decreased CD8-positive, alpha-beta memory T cell number	J:254826
	decreased CD8-positive, naive alpha-beta T cell number	J:254826
	increased B cell number	J:254826
	increased central memory CD4-positive, alpha-beta T cell number	J:254826
	increased central memory CD8 positive, alpha-beta T cell number	J:254826
	increased effector memory CD4-positive, alpha-beta T cell number	J:254826
\Itk^tm1Lex/\Itk^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased CD4-positive, alpha-beta T cell number	J:103485
	decreased CD8-positive, alpha-beta T cell number	J:103485
	increased B cell number	J:103485
\Itk^tm1Litt/\Itk^tm1Litt (involves: 129S4/SvJae * C57BL/6J)	decreased B cell number	J:31230
	decreased CD4-positive, alpha-beta T cell number	J:31230
	decreased T cell number	J:31230
	decreased T cell proliferation	J:31230
	immune system phenotype	J:31230
\Itk^tm1Litt/\Itk^tm1Litt (involves: 129S4/SvJae)	decreased T cell proliferation	J:54449
\Itk^tm1Litt/\Itk^tm1Litt (involves: 129S4/SvJae)	increased susceptibility to parasitic infection	J:54449
\Itk^tm1Litt/\Itk^tm1Litt (involves: 129S4/SvJae * C57BL/6)	abnormal CD8-positive, alpha-beta T cell differentiation	J:111786
	abnormal thymus cell ratio	J:111786
	decreased CD8-positive, alpha-beta T cell number	J:111786
\Itk^tm1Litt/\Itk^tm1Litt (B6.129S4-Itk^tm1Litt)	abnormal positive T cell selection	J:141390
	abnormal T cell morphology	J:141390
	decreased interleukin-2 secretion	J:141390
	decreased T cell number	J:141390
	decreased T cell proliferation	J:141390
	increased double-negative T cell number	J:141390
\Itk^tm1Litt/\Itk^tm1Litt \Tg(DO11.10)10Dlo/0 (involves: 129S4/SvJae * BALB/c * C3H * C57BL/6J)	abnormal T-helper 2 physiology	J:129883
\Itk^tm1Litt/\Itk^tm1Litt \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2J)	abnormal positive T cell selection	J:31230
	decreased CD4-positive, alpha-beta T cell number	J:31230
	increased double-positive T cell number	J:31230
\Itk^tm1Litt/\Itk^tm1Litt \Tg(TcrAND)53Hed/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal lymphocyte morphology	J:31230
	decreased CD4-positive, alpha-beta T cell number	J:31230
	increased double-negative T cell number	J:31230
\Itk^tm1Litt/\Itk^tm1Litt \Txk^tm1Pls/\Txk^tm1Pls (involves: 129S4/SvJae * 129S6/SvEvTac)	decreased CD4-positive, alpha-beta T cell number	J:54449
	decreased single-positive T cell number	J:54449
	decreased T cell proliferation	J:54449
	increased susceptibility to parasitic infection	J:54449
\Itk^tm1Litt/\Itk^tm1Litt \Vav1^tm2Bbd/\Vav1^tm2Bbd (B6.129-Itk^tm1Litt Vav1^tm2Bbd)	abnormal CD4-positive T cell differentiation	J:141390
	abnormal CD8-positive, alpha-beta T cell differentiation	J:141390
	abnormal positive T cell selection	J:141390
	abnormal T cell morphology	J:141390
	abnormal T cell physiology	J:141390
	decreased CD4-positive, alpha-beta T cell number	J:141390
	decreased CD8-positive, alpha-beta T cell number	J:141390
	decreased double-positive T cell number	J:141390
	decreased T cell number	J:141390
	decreased thymocyte number	J:141390
	increased B cell number	J:141390
	increased T cell apoptosis	J:141390
\Itk^tm1Ljb/\Itk^tm1Ljb (B6.129-Itk^tm1Ljb)	abnormal NK T cell morphology	J:120689
\Itk^tm1Ljb/\Itk^tm1Ljb (B6.129-Itk^tm1Ljb)	decreased NK T cell number	J:120689
\Itk^tm1Ljb/\Itk^tm1Ljb (involves: 129 * C57BL/6)	abnormal T cell activation	J:48231
	decreased CD4-positive, alpha-beta T cell number	J:48231
	decreased interleukin-2 secretion	J:48231
\Itk^tm1Ljb/\Itk^tm1Ljb (B10.129-Itk^tm1Ljb)	abnormal CD8-positive, alpha-beta T cell differentiation	J:113408
	abnormal CD8-positive, alpha-beta T cell physiology	J:113408
	abnormal gamma-delta T cell morphology	J:148531
	decreased CD4-positive, alpha-beta T cell number	J:123795
	decreased interferon-gamma secretion	J:148531
	increased CD8-positive, alpha-beta T cell number	J:113408, J:123795
	increased germinal center B cell number	J:148531
	increased IgE level	J:148531
	increased interferon-gamma secretion	J:113408
	increased interleukin-4 secretion	J:148531
	increased interleukin-10 secretion	J:148531
	increased interleukin-13 secretion	J:148531
	increased mature gamma-delta T cell number	J:148531
	increased memory T cell number	J:113408
\Itk^tm1Ljb/\Itk^tm1Ljb \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(Tcra5CC7,Tcrb5CC7)IWep/? (involves: 129 * C57BL/10)	abnormal CD4-positive T cell differentiation	J:93606
	decreased interferon-gamma secretion	J:93606
	decreased interleukin-4 secretion	J:93606
	decreased interleukin-5 secretion	J:93606
	decreased interleukin-10 secretion	J:93606
\Itk^tm1Ljb/\Itk^tm1Ljb \Tcrd^tm1Mom/\Tcrd^tm1Mom (involves: 129 * C57BL/6 * C57BL/10)	immune system phenotype	J:148531
\Itk^tm1Ljb/\Itk^tm1Ljb \Tg(Tcra2B4)1Mmd/? \Tg(Tcrb2B4)1Mmd/? (involves: C3H/HeJ * C57BL/6 * C57BL/10)	decreased CD4-positive, alpha-beta T cell number	J:123795
\Itk^tm1Ljb/\Itk^tm1Ljb \Tg(Tcra5CC7,Tcrb5CC7)IWep/? (involves: 129 * C57BL/10)	decreased CD4-positive, alpha-beta T cell number	J:123795
\Itk^tm1Ljb/\Itk^tm1Ljb \Tg(TcraTcrb)1100Mjb/? (involves: 129 * C57BL/6 * C57BL/10)	immune system phenotype	J:113408
\Itk^tm1Ljb/\Itk^tm1Ljb \Txk^tm1Pls/\Txk^tm1Pls (B6.129-Txk^tm1Pls Itk^tm1Ljb)	abnormal CD8-positive, alpha-beta T cell physiology	J:113408
	increased CD8-positive, alpha-beta T cell number	J:113408
	increased interferon-gamma secretion	J:113408
	increased memory T cell number	J:113408
\Itln1^em1Cya/\Itln1^em1Cya (involves: C57BL/6)	abnormal cytokine level	J:282124
	abnormal osteoclast physiology	J:282124
	increased circulating interleukin-1 alpha level	J:282124
	increased circulating interleukin-6 level	J:282124
	increased circulating interleukin-10 level	J:282124
	increased circulating tumor necrosis factor level	J:282124
	increased osteoclast cell number	J:282124
\Itm2c^em1Nutt/\Itm2c^em1Nutt \Prdm1^tm1Nutt/\Prdm1⁺ (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:265892
\Itpkb^T-less/\Itpkb^T-less (C57BL/6-Itpkb^T-less)	abnormal T cell physiology	J:89286
\Itpkb^T-less/\Itpkb^T-less (C57BL/6-Itpkb^T-less)	arrested T cell differentiation	J:89286
\Itpkb^tm1Ssch/\Itpkb^tm1Ssch (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal thymocyte activation	J:86257
	abnormal thymus involution	J:86257
	absent CD4-positive, alpha-beta T cells	J:86257
	absent CD8-positive, alpha-beta T cells	J:86257
	absent T cells	J:86257
	absent thymus medulla	J:86257
	arrested T cell differentiation	J:86257
	decreased IgG1 level	J:86257
	decreased IgG2a level	J:86257
	decreased IgG2b level	J:86257
	decreased IgG level	J:86257
	increased double-positive T cell number	J:86257
	increased susceptibility to parasitic infection	J:86257
\Itpkb^tm1Ssch/\Itpkb^tm1Ssch \Itpkc^tm1Ssch/\Itpkc^tm1Ssch (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal thymocyte activation	J:86257
	absent CD4-positive, alpha-beta T cells	J:86257
	absent CD8-positive, alpha-beta T cells	J:86257
	arrested T cell differentiation	J:86257
\Ity2^C57BL/6J/\Ity2^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:45962
\Ity2^MOLF/EiJ/\Ity2^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:126552, J:45962
\Ity2a^MOLF/EiJ/\Ity2a^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:126552
\Ity2b^MOLF/EiJ/\Ity2b^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:126552
\Ity3^C57BL/6J/\Ity3^C57BL/6J (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:45962
\Ity3^C57BL/6J/\Ity3^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	decreased susceptibility to bacterial infection	J:45962
\Ity3^MOLF/EiJ/\Ity3^MOLF/EiJ (involves: C57BL/6J * MOLF/Ei)	increased susceptibility to bacterial infection	J:126552, J:45962
\Ity3^MOLF/EiJ/\Ity3^MOLF/EiJ (B6.MOLF-Slc11a1^r Ity3^MOLF/EiJ)	abnormal cytokine secretion	J:108692
\Jade2^em1(IMPC)Tcp/\Jade2^em1(IMPC)Tcp (C57BL/6N-Jade2^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
\Jag2^tm1Grid/\Jag2^tm1Grid (involves: 129S1/Sv * C57BL/6J)	abnormal gamma-delta T cell differentiation	J:46930
	abnormal thymus medulla morphology	J:46930
	abnormal thymus morphology	J:46930
	decreased gamma-delta T cell number	J:46930
\Jagn1^{tm1c(EUCOMM)Hmgu}/\Jagn1^{tm1c(EUCOMM)Hmgu} \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6N * C57BL/10 * CBA/Ca)	abnormal neutrophil morphology	J:214828
	abnormal neutrophil physiology	J:214828
	impaired neutrophil chemotaxis	J:214828
	impaired neutrophil recruitment	J:214828
	increased susceptibility to fungal infection	J:214828
\Jak1^M1Mhda/\Jak1⁺ (C3HeB/FeJ-Jak1^M1Mhda)	abnormal plasma cell morphology	J:199153
	ear inflammation	J:199153
	enlarged spleen	J:199153
	increased anti-nuclear antigen antibody level	J:199153
	increased IgA level	J:199153
	increased IgG1 level	J:199153
	increased IgG2a level	J:199153
	increased IgM level	J:199153
	increased immunoglobulin level	J:199153
	increased plasma cell number	J:199153
	skin inflammation	J:199153
\Jak1^tm1Rds/\Jak1^tm1Rds (involves: 129)	abnormal B cell differentiation	J:47300
	abnormal lymphopoiesis	J:47300
	abnormal T cell differentiation	J:47300
	arrested B cell differentiation	J:47300
	decreased B cell number	J:47300
	decreased thymocyte number	J:47300
	increased double-negative T cell number	J:47300
	small thymus	J:47300
\Jak2^{tm1(JAK2)Argr}/\Jak2⁺ \Dppa3^tm1(cre)Peli/\Dppa3⁺ (involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6)	increased leukocyte cell number	J:233169
	increased spleen weight	J:233169
\Jak2^{tm1(JAK2)Argr}/\Jak2⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	decreased leukocyte cell number	J:164539
	enlarged spleen	J:164539
	increased leukocyte cell number	J:164539
\Jak2^tm1.1Ble/\Jak2⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal cytokine level	J:257910
	enlarged spleen	J:257910
	increased granulocyte number	J:257910
	increased leukocyte cell number	J:257910
	increased neutrophil cell number	J:257910
\Jak2^tm1.1Jlvl/\Jak2^tm1.1Jlvl (involves: 129S2/SvPas * C57BL/6)	abnormal spleen morphology	J:163497
	decreased spleen white pulp amount	J:163497
	enlarged spleen	J:163497
	increased granulocyte number	J:163497
	increased leukocyte cell number	J:163497
	increased lymphocyte cell number	J:163497
	increased monocyte cell number	J:163497
	increased spleen red pulp amount	J:163497
\Jak2^tm1.2Ble/\Jak2⁺ (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal spleen morphology	J:160883
	abnormal spleen red pulp morphology	J:160883
	enlarged spleen	J:160883
	increased leukocyte cell number	J:160883
\Jak2^tm1.2Ble/\Jak2⁺ \Picalm^tm1.1Tmae/\Picalm^tm1.1Tmae \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL)	decreased CD4-positive, alpha-beta T cell number	J:220728
	decreased CD8-positive, alpha-beta T cell number	J:220728
\Jak2^tm1Mohi/\Jak2⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal spleen red pulp morphology	J:183821
	abnormal spleen white pulp morphology	J:183821
	decreased B cell number	J:183821
	enlarged spleen	J:183821
	increased leukocyte cell number	J:183821
	increased neutrophil cell number	J:183821
	increased spleen red pulp amount	J:183821
	increased spleen weight	J:183821
	myeloid hyperplasia	J:183821
	spleen fibrosis	J:183821
\Jak2^tm1Mohi/\Jak2^tm1Mohi \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal spleen red pulp morphology	J:183821
	abnormal spleen white pulp morphology	J:183821
	decreased B cell number	J:183821
	decreased spleen white pulp amount	J:183821
	enlarged spleen	J:183821
	increased leukocyte cell number	J:183821
	increased neutrophil cell number	J:183821
	increased spleen red pulp amount	J:183821
	increased spleen weight	J:183821
	myeloid hyperplasia	J:183821
	spleen fibrosis	J:183821
\Jak2^tm2.1Jlvl/\Jak2⁺ \Tg(Vav1-cre)#Cgp/0 (involves: 129S2/SvPas * C57BL/6NTac)	abnormal myelopoiesis	J:202234
	decreased B cell number	J:202234
	enlarged spleen	J:202234
	increased granulocyte number	J:202234
	increased leukocyte cell number	J:202234
	increased spleen weight	J:202234
	myeloid hyperplasia	J:202234
	spleen fibrosis	J:202234
\Jak2^tm2.2Jlvl/\Jak2⁺ (involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac * SJL)	enlarged spleen	J:202234
	increased leukocyte cell number	J:202234
\Jak3^bfy/\Jak3^bfy (C57BL/6JSfdAnu-Jak3^bfy/AnuApb)	abnormal lymphopoiesis	J:104190
	abnormal T cell subpopulation ratio	J:104190
	decreased B cell number	J:104190
	decreased lymphocyte cell number	J:104190
	decreased T cell number	J:104190
	decreased thymocyte number	J:104190
	small thymus	J:104190
\Jak3^em1(IMPC)Mbp/\Jak3⁺ (C57BL/6N-Jak3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Jak3^m1Btlr/\Jak3^m1Btlr (C57BL/6J-Jak3^m1Btlr)	abnormal T cell subpopulation ratio	J:217795
	decreased IgG level	J:217795
	decreased NK cell number	J:217795
	decreased response to antigen	J:217795
	decreased single-positive T cell number	J:217795
	decreased T cell number	J:217795
	impaired humoral immune response	J:217795
	increased effector memory CD4-positive, alpha-beta T cell number	J:217795
	increased effector memory CD8-positive, alpha-beta T cell number	J:217795
	increased IgE level	J:217795
	increased neutrophil cell number	J:217795
	increased single-positive T cell number	J:217795
	increased susceptibility to Herpesvirales infection	J:217795
\Jak3^m1J/\Jak3^m1J (B6.Cg-Crb1⁺ Jak3^m1J/Boc)	decreased spleen weight	J:265859
	decreased thymus weight	J:265859
	small spleen	J:265859
	small thymus	J:265859
\Jak3^M1Pgrs/\Jak3⁺ (involves: C57BL/6J * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:185217
\Jak3^M1Pgrs/\Jak3^M1Pgrs (involves: C57BL/6J * C57BL/10J)	absent B cells	J:185217
	decreased B cell number	J:185217
	decreased interferon-gamma secretion	J:185217
	decreased NK cell number	J:185217
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:185217
	enlarged spleen	J:185217
	increased CD4-positive, alpha-beta T cell number	J:185217
	increased CD8-positive, alpha-beta T cell number	J:185217
	increased susceptibility to bacterial infection	J:185217
	increased susceptibility to bacterial infection induced morbidity/mortality	J:185217
	small thymus	J:185217
\Jak3^M1Pgrs/\Jak3^tm1Ljb (involves: 129S4/SvJae * C57BL/6J * C57BL/10J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:185217
\Jak3^m2Btlr/\Jak3^m2Btlr (C57BL/6J-Jak3^m2Btlr)	increased B cell number	J:217796
\Jak3^m2Btlr/\Jak3^m2Btlr (C57BL/6J-Jak3^m2Btlr)	increased memory B cell number	J:217796
\Jak3^m3Btlr/\Jak3^m3Btlr (C57BL/6J-Jak3^m3Btlr)	abnormal T cell subpopulation ratio	J:225935
	decreased B cell number	J:225935
	decreased B-1 B cell number	J:225935
	decreased IgG level	J:225935
	decreased immature B cell number	J:225935
	decreased mature B cell number	J:225935
	decreased memory B cell number	J:225935
	decreased NK cell number	J:225935
	decreased single-positive T cell number	J:225935
	decreased T cell number	J:225935
	impaired humoral immune response	J:225935
	increased effector memory CD8-positive, alpha-beta T cell number	J:225935
	increased macrophage cell number	J:225935
	increased myeloid dendritic cell number	J:225935
\Jak3^m4Btlr/\Jak3^m4Btlr (C57BL/6J-Jak3^m4Btlr)	increased CD4-positive, alpha-beta T cell number	J:272398
\Jak3^M5Btlr/\Jak3^M5Btlr (C57BL/6J-Jak3^M5Btlr)	decreased NK T cell number	J:272399
\Jak3^m6Btlr/\Jak3^m6Btlr (C57BL/6J-Jak3^m6Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272400
	decreased IgG level	J:272400
	impaired humoral immune response	J:272400
	increased CD4-positive, alpha-beta T cell number	J:272400
\Jak3^M7Btlr/\Jak3^M7Btlr (C57BL/6J-Jak3^M7Btlr)	abnormal CD4-positive T cell differentiation	J:272401
\Jak3^m8Btlr/\Jak3^m8Btlr (C57BL/6J-Jak3^m8Btlr)	decreased B cell number	J:274939
	decreased B-1 B cell number	J:274939
	decreased B-2 B cell number	J:274939
	decreased CD4-positive, alpha-beta T cell number	J:274939
	decreased CD8-positive, alpha-beta T cell number	J:274939
	decreased CD8-positive, naive alpha-beta T cell number	J:274939
	decreased dendritic cell number	J:274939
	decreased IgG level	J:274939
	decreased IgM level	J:274939
	decreased response to antigen	J:274939
	decreased T cell number	J:274939
	impaired humoral immune response	J:274939
	increased B-1b cell number	J:274939
	increased effector memory CD4-positive, alpha-beta T cell number	J:274939
\Jak3^tm1Flv/\Jak3^tm1Flv (involves: 129S1/Sv)	abnormal T cell proliferation	J:95794
	arrested B cell differentiation	J:95794
	decreased CD8-positive, alpha-beta T cell number	J:95794
	enlarged spleen	J:95794
	increased CD4-positive, alpha-beta T cell number	J:95794
	small lymph nodes	J:95794
	thymus hypoplasia	J:95794
\Jak3^tm1Jni/\Jak3^tm1Jni \Crlf2^tm1Jni/\Crlf2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:89031
	decreased B cell number	J:89031
\Jak3^tm1Ljb/\Jak3⁺ (involves: 129S4/SvJae)	abnormal leukocyte morphology	J:56629
	decreased lymphocyte cell number	J:56629
	increased leukocyte cell number	J:56629
	increased monocyte cell number	J:56629
	increased neutrophil cell number	J:56629
\Jak3^tm1Ljb/\Jak3^tm1Ljb (involves: 129S4/SvJae * C57BL/6)	abnormal B cell morphology	J:29722
	abnormal immune system physiology	J:29722
	abnormal leukocyte physiology	J:90510
	abnormal lymphocyte physiology	J:90510
	abnormal response to infection	J:29722
	abnormal splenic cell ratio	J:29722
	abnormal T cell activation	J:29722
	arrested B cell differentiation	J:29722
	decreased IgG level	J:29722
	decreased immature B cell number	J:29722
	decreased mature B cell number	J:29722
	decreased T cell proliferation	J:29722
	lymph node hypoplasia	J:29722
	small lymph nodes	J:29722
	small Peyer's patches	J:29722
	small thymus	J:29722
	spleen hypoplasia	J:29722
	thymus hypoplasia	J:29722
\Jak3^tm1Ljb/\Jak3^tm1Ljb (involves: 129S4/SvJae)	abnormal leukocyte morphology	J:56629
	abnormal myelopoiesis	J:56629
	abnormal spleen morphology	J:56629
	abnormal spleen white pulp morphology	J:56629
	abnormal T cell activation	J:128694, J:56629
	abnormal T cell differentiation	J:64861
	abnormal T cell physiology	J:128694
	abnormal thymus cell ratio	J:128694
	absent B cells	J:128694
	absent lymph nodes	J:128694
	chronic inflammation	J:56629
	decreased lymphocyte cell number	J:56629
	decreased T cell proliferation	J:128694
	decreased thymocyte number	J:64861
	enlarged spleen	J:56629
	increased leukocyte cell number	J:56629
	increased monocyte cell number	J:56629
	increased neutrophil cell number	J:56629
	thymus hypoplasia	J:128694
\Jak3^tm1Ljb/\Jak3^tm1Ljb (B6;129S4-Jak3^tm1Ljb/J)	abnormal dendritic cell differentiation	J:123902
	abnormal dendritic cell morphology	J:123902
	abnormal dendritic cell physiology	J:123902
	abnormal splenic cell ratio	J:123902
	decreased CD4-positive, alpha-beta T cell number	J:123902
	decreased CD8-positive, alpha-beta T cell number	J:123902
	decreased myeloid dendritic cell number	J:123902
\Jak3^tm1Ljb/\Jak3^tm1Ljb \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal splenic cell ratio	J:56629
	immune system phenotype	J:56629
\Jak3^tm1Ljb/\Jak3^tm1Ljb \Tg(Lck-Jak3)1Ljb/0 (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)	absent B cells	J:128694
	absent lymph nodes	J:128694
	decreased T cell proliferation	J:128694
	immune system phenotype	J:128694
\Jak3^tm1Ljb/\Jak3^tm1Ljb \Tg(Lck-Jak3)2Ljb/0 (involves: 129S4/SvJae * C3H * C57BL/6)	abnormal T cell activation	J:56629
	enlarged spleen	J:56629
	immune system phenotype	J:56629
	increased leukocyte cell number	J:56629
\Jak3^tm1Ljb/\Jak3^tm1Ljb \Tg(Lck-Jak3)2Ljb/0 (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/10)	abnormal T cell activation	J:128694
	abnormal T cell physiology	J:128694
	absent B cells	J:128694
	absent lymph nodes	J:128694
	decreased T cell proliferation	J:128694
	immune system phenotype	J:128694
\Jak3^tm1Tks/\Jak3⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte physiology	J:31231
\Jak3^tm1Tks/\Jak3^tm1Tks (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:31231
	abnormal CD4-positive, alpha beta T cell morphology	J:31231
	abnormal lymphopoiesis	J:31231
	abnormal mesenteric lymph node morphology	J:31231
	abnormal spleen periarteriolar lymphoid sheath morphology	J:31231
	abnormal spleen white pulp morphology	J:31231
	abnormal T cell morphology	J:31231
	abnormal T cell number	J:31231
	abnormal T cell physiology	J:31231
	abnormal thymus cortex morphology	J:31231
	abnormal thymus corticomedullary boundary morphology	J:31231
	abnormal thymus medulla morphology	J:31231
	absent Hassall's corpuscle	J:31231
	absent lymph nodes	J:31231
	absent NK cells	J:31231
	decreased B cell number	J:31231
	decreased pre-B cell number	J:31231
	decreased thymocyte number	J:31231
	small spleen	J:31231
	small thymus medulla	J:31231
	spleen hypoplasia	J:31231
	thymus cortex hypoplasia	J:31231
	thymus hypoplasia	J:31231
\Jak3^wil/\Jak3^wil (C57BL/6JSfdAnu-Jak3^wil/Anu)	arrested B cell differentiation	J:104190
	decreased CD8-positive, alpha-beta T cell number	J:104190
	decreased leukocyte cell number	J:104190
	large intestinal inflammation	J:104190
\Jak3^X887Y/\Jak3^X887Y (Not Specified)	abnormal immune system organ morphology	J:112658
	abnormal lymph node morphology	J:112658
	abnormal lymphocyte morphology	J:112658
	abnormal spleen morphology	J:112658
	abnormal thymus morphology	J:112658
\Jak3^X887Y/\Jak3^X887Y \Trdc^tm1Mal/\Trdc^tm1Mal (involves: C57BL/6)	immune system phenotype	J:112658
\Jakmip2^em1(IMPC)J/\Jakmip2^em1(IMPC)J (C57BL/6NJ-Jakmip2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Jam3^tm1Lex/\Jam3^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	decreased neutrophil cell number	J:145994
	increased granulocyte number	J:145994
\Jam3^tm1Rha/\Jam3^tm1Rha (involves: 129P2/OlaHsd * C57BL/6)	increased granulocyte number	J:121841
	increased susceptibility to bacterial infection	J:121841
	lung inflammation	J:121841
\Jam3^tm1Rha/\Jam3^tm1Rha \Tg(Tek-Jam3)1Maal/? (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)	immune system phenotype	J:121841
\Jarid2^jumonji/\Jarid2^jumonji (C.129P2-Jarid2^jumonji)	abnormal splenic cell ratio	J:42772
	abnormal thymus cell ratio	J:42772
	spleen hypoplasia	J:42772
	thymus hypoplasia	J:42772
\Jarid2^jumonji/\Jarid2^jumonji (either: B6.129P2-Jarid2^jumonji or D2.129P2-Jarid2^jumonji)	spleen hypoplasia	J:42772
	thymus hypoplasia	J:42772
\Jchain^Mat1/? \Miju^C3HeB/FeJ/\Miju^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	increased IgA level	J:91062
\Jchain^tm1Jse/\Jchain^tm1Jse (involves: 129X1/SvJ)	abnormal B cell physiology	J:75843
\Jchain^tm1Jse/\Jchain^tm1Jse (involves: 129X1/SvJ)	increased IgA level	J:34042, J:75843
\Jchain^tm1Jse/\Jchain^tm1Jse (C.129X1-Jchain^tm1Jse)	decreased susceptibility to Herpesvirales infection	J:62298
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:62298
	increased susceptibility to parasitic infection	J:140515
\Jchain^tm1Tl/\Jchain^tm1Tl (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal humoral immune response	J:71355
	decreased IgG level	J:71355
	decreased IgM level	J:71355
	increased IgA level	J:71355
\Jchain^tm2(Myc)Tl/\Jchain^tm2(Myc)Tl (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal humoral immune response	J:71355
\Jchain^tm3Tl/\Jchain⁺ (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:56158
	abnormal immune cell physiology	J:49168
	decreased IgM level	J:49168, J:56158
	decreased plasma cell number	J:49168
	impaired complement classical pathway	J:49168
	increased IgA level	J:56158
	increased susceptibility to bacterial infection	J:56158
\Jchain^tm3Tl/\Jchain^tm3Tl (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:56158
	abnormal immune cell physiology	J:49168
	decreased IgG level	J:49168
	decreased IgM level	J:49168, J:56158
	decreased plasma cell number	J:49168, J:56158
	impaired complement classical pathway	J:49168
	increased IgA level	J:49168, J:56158
	increased susceptibility to bacterial infection	J:56158
\Jdp2^tm1Aki/\Jdp2^tm1Aki (Not Specified)	abnormal neutrophil physiology	J:191061
	abnormal osteoclast differentiation	J:191061
	abnormal osteoclast morphology	J:191061
	increased susceptibility to bacterial infection	J:191061
	increased susceptibility to fungal infection	J:191061
\Jmjd4^{em1(IMPC)Wtsi}/\Jmjd4^{em1(IMPC)Wtsi} (C57BL/6N-Jmjd4^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Jmjd6^tm1Gbf/\Jmjd6^tm1Gbf (C57BL/6-Ptdsr^tm1Gbf)	abnormal macrophage activation involved in immune response	J:98905
	small thymus	J:102098
	thymus hypoplasia	J:102098
\Jmjd8^em1Kaso/\Jmjd8^em1Kaso (C57BL/6-Jmjd8^em1Kaso)	decreased circulating interleukin-1 beta level	J:319518
\Jmjd8^em1Kaso/\Jmjd8^em1Kaso (C57BL/6-Jmjd8^em1Kaso)	decreased inflammatory response	J:319518
\Jph4^tm1Hta/\Jph4^tm1Hta (involves: 129S4/SvJae * C57BL/6J)	abnormal interleukin level	J:230995
	abnormal T cell activation	J:230995
\Jun^em1(IMPC)Mbp/\Jun⁺ (C57BL/6N-Jun^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Jun^tm1Rsjo/\Jun^tm1Rsjo \Tg(KRT14-cre)8Brn/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	increased incidence of corneal inflammation	J:84743
\Jun^tm4Wag/\Jun^tm4Wag \Junb^tm3Wag/\Junb^tm3Wag \Tg(Krt1-5-cre/ERT)1Ipc/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	autoimmune arthritis	J:116380
	increased inflammatory response	J:116380
	skin inflammation	J:116380
\Jun^tm4Wag/\Jun^tm4Wag \Tg(Sftpc-cre)1Blh/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal cytokine level	J:179883
	abnormal tumor necrosis factor level	J:179883
	lung inflammation	J:179883
\Junb^{tm1b(EUCOMM)Hmgu}/\Junb⁺ (C57BL/6N-Junb^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
\Junb^tm3Wag/\Junb^tm3Wag \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast morphology	J:88126
\Junb^tm3Wag/\Junb^tm3Wag \Meox2^tm1(cre)Sor/\Meox2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)	abnormal osteoclast differentiation	J:88126
	decreased osteoclast cell number	J:88126
\Junb^tm3Wag/\Junb^tm3Wag \Tg(KRT5-cre)1Tak/0 (involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)	dermatitis	J:155575
	glomerulonephritis	J:155575
	increased anti-histone antibody level	J:155575
	increased circulating interleukin-6 level	J:155575
	increased IgE level	J:155575
	increased inflammatory response	J:155575
	increased interleukin-6 secretion	J:155575
	increased plasma cell number	J:155575
	increased susceptibility to systemic lupus erythematosus	J:155575
	tubulointerstitial nephritis	J:155575
\Jund^tm1Mya/\Jund^tm1Mya (either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))	abnormal T-helper 2 physiology	J:89085
	immune system phenotype	J:53906
	increased susceptibility to endotoxin shock	J:65879
	increased T cell proliferation	J:89085
	liver inflammation	J:65879
\Jup^tm1.1Glr/\Jup^tm1.1Glr \A1cf^{Tg(Myh6-cre/Esr1)1Jmk}/\A1cf⁺ (involves: 129S6/SvEvTac C57BL/6 * FVB/N * SJL)	abnormal interleukin level	J:170618
	heart inflammation	J:170618
\Kash5^em1(IMPC)J/\Kash5^em1(IMPC)J (C57BL/6NJ-Kash5^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Kat5^tm1Jwl/\Kat5⁺ \Tg(IghMyc)22Bri/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)	abnormal B cell physiology	J:125164
\Kat6a^tm1.1Glac/\Kat6a^tm1.1Glac (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:148955
	decreased immature B cell number	J:148955
	decreased pre-B cell number	J:148955
	decreased pro-B cell number	J:148955
	decreased spleen weight	J:148955
	decreased thymus weight	J:148955
	spleen hypoplasia	J:148955
	thymus hypoplasia	J:148955
\Kat6a^tm1Avo/\Kat6a⁺ (involves: 129 * BALB/c * FVB/N)	small thymus	J:188772
\Kat6a^tm1Avo/\Kat6a^tm1Avo (involves: 129/Sv * BALB/c * FVB/N)	abnormal thymus development	J:108453
	absent spleen	J:108453
	athymia	J:188772
	decreased double-negative T cell number	J:108453
	small thymus	J:108453, J:188772
	thymus hypoplasia	J:108453
\Kat6a^tm1Iki/\Kat6a^tm1Iki (Not Specified)	abnormal myelopoiesis	J:108699
\Kat6a^tm1Iki/\Kat6a^tm1Iki (Not Specified)	decreased B cell number	J:108699
\Kat6a^tm2.2Avo/\Kat6a⁺ \Tbx1^tm1Bld/\Tbx1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	small thymus	J:188772
\Kat8^em1(IMPC)Mbp/\Kat8⁺ (C57BL/6N-Kat8^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Kat14^{tm1a(KOMP)Wtsi}/\Kat14^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased susceptibility to bacterial infection	J:213427
\Katnal1^em1(IMPC)Tcp/\Katnal1⁺ (C57BL/6NCrl-Katnal1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Katnal1^em1(IMPC)Tcp/\Katnal1^em1(IMPC)Tcp (C57BL/6NCrl-Katnal1^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Katnal2^em1(IMPC)Tcp/\Katnal2^em1(IMPC)Tcp (C57BL/6N-Katnal2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
\Kbtbd3^{em1(IMPC)Ccpcz}/\Kbtbd3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kbtbd3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased neutrophil cell number	J:211773
\Kbtbd11^{em1(IMPC)Wtsi}/\Kbtbd11^{em1(IMPC)Wtsi} (C57BL/6N-Kbtbd11^{em1(IMPC)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Kcna1^mceph/\Kcna1^mceph (BALB/cByJ-Kcna1^mceph/J)	ear inflammation	J:119491
\Kcna1^mceph/\Kcna1^mceph (BALB/cByJ-Kcna1^mceph/J)	eye inflammation	J:119491
\Kcna1^tm1Tem/\Kcna1^tm1Tem (involves: 129S7/SvEvBrd * BALB/cByJ * C3HeB/FeJ)	ear inflammation	J:119491
	eye inflammation	J:119491
\Kcna5^tm1Hket/\Kcna5^tm1Hket (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	abnormal microglial cell morphology	J:116545
\Kcna10^em3(IMPC)Mbp/\Kcna10⁺ (C57BL/6N-Kcna10^em3(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Kcnab2^em1(IMPC)Mbp/\Kcnab2^em1(IMPC)Mbp (C57BL/6NCrl-Kcnab2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Kcne1^{tm1b(EUCOMM)Hmgu}/\Kcne1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Kcne1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Kcne2^{tm1a(EUCOMM)Wtsi}/\Kcne2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Kcne2^{tm1a(EUCOMM)Wtsi})	decreased spleen iron level	J:230226
	stomach inflammation	J:230226
\Kcne3^tm1Gwab/\Kcne3^tm1Gwab (involves: C57BL/6)	increased inflammatory response	J:210381
\Kcnh8^em1(IMPC)Mbp/\Kcnh8^em1(IMPC)Mbp (C57BL/6N-Kcnh8^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Kcnip1^em1(IMPC)H/\Kcnip1^em1(IMPC)H (C57BL/6N-Kcnip1^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
\Kcnj8^gnite/\Kcnj8^gnite (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:126658, J:105543
\Kcnj8^mydy/\Kcnj8^mydy (involves: C57BL/6J)	increased susceptibility to endotoxin shock	J:126658
\Kcnj8^mydy/\Kcnj8^mydy (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection	J:126658
\Kcnj8^slmbr/\Kcnj8^slmbr (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:126658, J:105543
\Kcnj8^sltr/\Kcnj8^sltr (involves: C57BL/6J)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:126658, J:105543
\Kcnj8^sltr/\Kcnj8^sltr (involves: C57BL/6J)	increased susceptibility to Riboviria infection	J:105543
\Kcnj8^sos/\Kcnj8^sos (C57BL/6J-Kcnj8^sos)	increased susceptibility to endotoxin shock	J:149353
\Kcnj9^{tm1b(EUCOMM)Hmgu}/\Kcnj9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Kcnj9^{tm1b(EUCOMM)Hmgu}/H)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Kcnj10^{tm1b(KOMP)Wtsi}/\Kcnj10⁺ (C57BL/6N-Kcnj10^{tm1b(KOMP)Wtsi}/H)	decreased basophil cell number	J:211773
\Kcnk13^em1(IMPC)H/\Kcnk13^em1(IMPC)H (involves: C57BL/6NTac)	abnormal microglial cell morphology	J:256020
	abnormal microglial cell physiology	J:256020
\Kcnk13^em1(IMPC)H/\Kcnk13^em1(IMPC)H (C57BL/6N-Kcnk13^em1(IMPC)H/H)	increased basophil cell number	J:211773
	increased monocyte cell number	J:211773
\Kcnmb4^em1(IMPC)Mbp/\Kcnmb4^em1(IMPC)Mbp (C57BL/6N-Kcnmb4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Kcnn4^{em1(IMPC)Ccpcz}/\Kcnn4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kcnn4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
\Kcnn4^tm1Jemn/\Kcnn4^tm1Jemn (involves: 129S1/Sv * C57BL/6J)	abnormal T cell physiology	J:94478
\Kcnn4^tm1Rklr/\Kcnn4^tm1Rklr (involves: 129S/SvEv * C57BL/6)	enlarged spleen	J:148910
	increased spleen iron level	J:148910
	increased spleen weight	J:148910
\Kcnt1^em1(IMPC)Mbp/\Kcnt1^em1(IMPC)Mbp (C57BL/6N-Kcnt1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Kcnt2^em1(IMPC)Mbp/\Kcnt2^em1(IMPC)Mbp (C57BL/6N-Kcnt2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Kctd1^em1(IMPC)J/\Kctd1^em1(IMPC)J (C57BL/6NJ-Kctd1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Kctd9^em1Beij/\Kctd9^em1Beij (BALB/c-Kctd9^em1Beij)	abnormal immature NK cell morphology	J:281803
	abnormal NK cell differentiation	J:281803
	abnormal NK cell physiology	J:281803
	decreased mature NK cell number	J:281803
	decreased susceptibility to Coronaviridae infection	J:281803
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:281803
	impaired natural killer cell mediated cytotoxicity	J:281803
	increased immature NK cell number	J:281803
	increased NK cell number	J:281803
\Kdelr1^em1Btlr/\Kdelr1^em1Btlr (involves: C57BL/6J * C57BL/6JJcl)	decreased lymphocyte cell number	J:224970
\Kdelr1^em1Btlr/\Kdelr1^em1Btlr \Tg(Gt(ROSA)26Sor-Kdelr1)#Btlr/0 (C57BL/6J-Kdelr1^em1Btlr Tg(Gt(ROSA)26Sor-Kdelr1)#Btlr)	abnormal lymphocyte morphology	J:224970
\Kdelr1^m1Btlr/\Kdelr1^m1Btlr (C57BL/6J-Kdelr1^m1Btlr)	abnormal lymphocyte morphology	J:224970
	abnormal response to infection	J:224970
	abnormal T cell differentiation	J:224970
	absent NK T cells	J:224970
	decreased B cell number	J:224970
	decreased CD4-positive, alpha-beta T cell number	J:224970, J:158794
	decreased CD8-positive, alpha-beta T cell number	J:224970, J:158794
	decreased follicular B cell number	J:224970
	decreased lymphocyte cell number	J:224970
	decreased transitional stage T1 B cell number	J:224970
	decreased transitional stage T2 B cell number	J:224970
	immune system phenotype	J:224970
	increased marginal zone B cell number	J:224970
	increased susceptibility to Riboviria infection	J:224970
	thymus hypoplasia	J:158794
\Kdm1a^{tm1(NCOM)Mfgc}/\Kdm1a⁺ (C57BL/6N-Kdm1a^{tm1(NCOM)Mfgc}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	small spleen	J:211773
\Kdm1a^tm1.1Sho/\Kdm1a^tm1.1Sho \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	decreased leukocyte cell number	J:201572
\Kdm1a^tm1.1Sho/\Kdm1a^tm1.1Sho \Tg(Mx1-cre)1Cgn/? (involves: 129 * C57BL/6 * CBA/Ca)	decreased granulocyte number	J:201572
	decreased neutrophil cell number	J:201572
\Kdm3a^em1(IMPC)Mbp/\Kdm3a^em1(IMPC)Mbp (C57BL/6N-Kdm3a^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
	small spleen	J:211773
\Kdm4c^{tm1a(KOMP)Wtsi}/\Kdm4c⁺ (C57BL/6N-Kdm4c^{tm1a(KOMP)Wtsi}/Wtsi)	increased B cell number	J:165965
\Kdm5a^tm1.1Kael/\Kdm5a^tm1.1Kael (involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)	increased neutrophil cell number	J:137185
\Kdm6a^tm1.1Afst/\Kdm6a^tm1.1Afst \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac)	abnormal granulocyte morphology	J:196401
	decreased leukocyte cell number	J:196401
	enlarged spleen	J:196401
	increased B cell number	J:196401
	increased spleen weight	J:196401
\Kdm6a^tm1Cdcn/Y \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6J CBA)	enlarged spleen	J:263565
	increased granulocyte number	J:263565
	increased monocyte cell number	J:263565
	increased neutrophil cell number	J:263565
\Kdm6a^tm1Cdcn/Y \Tg(CAG-cre/Esr1)5Amc/0 \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas C57BL/6J * CBA * FVB/N)	enlarged spleen	J:263565
	increased monocyte cell number	J:263565
	increased neutrophil cell number	J:263565
\Kdm6a^tm1Cdcn/\Kdm6a^tm1Cdcn \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6J CBA)	enlarged spleen	J:263565
	increased granulocyte number	J:263565
	increased monocyte cell number	J:263565
	increased neutrophil cell number	J:263565
\Kdm6b^tm1Aki/\Kdm6b^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal response to infection	J:164690
\Kdm6b^tm1Aki/\Kdm6b^tm1Aki (involves: 129X1/SvJ * C57BL/6)	impaired eosinophil recruitment	J:164690
\Kdm8^{tm1a(EUCOMM)Wtsi}/\Kdm8⁺ (C57BL/6N-Kdm8^{tm1a(EUCOMM)Wtsi}/Ics)	increased B cell number	J:165965
\Kdr^tm1.1Jamb/\Kdr^tm1.1Jamb (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymphangiogenesis	J:154336
	lymphatic vessel hyperplasia	J:154336
\Kdr^tm1.1Jamb/\Kdr^tm1.1Jamb \Tg(KRT14-cre)1Efu/0 (involves: 129S1/Sv * 129X1/SvJ * ICR)	lymphatic vessel hyperplasia	J:154336
\Kdr^tm1.1Jamb/\Kdr^tm1.1Jamb \Tg(Pax6-cre,GFP)1Pgr/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR)	abnormal lymphatic vessel morphology	J:154336
	lymphatic vessel hyperplasia	J:154336
\Kdr^tm1Jrt/\Kdr⁺ \Tmem204^tm1.1Ali/\Tmem204^tm1.1Ali (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)	abnormal lymphatic vessel smooth muscle morphology	J:159519
	enlarged lymphatic vessel	J:159519
\Kdr^tm1Ykub/\Kdr^tm1Ykub (Not Specified)	enlarged lymphatic vessel	J:217533
\Kdr^tm1Ykub/\Kdr^tm1Ykub (Not Specified)	lymphatic vessel hyperplasia	J:217533
\Kera^tm1Cyl/\Kera^tm1Cyl (involves: 129S6/SvEvTac)	abnormal inflammatory response	J:128992
\Kera^tm1Cyl/\Kera^tm1Cyl (involves: 129S6/SvEvTac)	decreased neutrophil cell number	J:128992
\Khdrbs1^tm1Rchd/\Khdrbs1^tm1Rchd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal bone marrow development	J:115775
\Khsrp^tm1.1Cyc/\Khsrp^tm1.1Cyc (B6.Cg-Khsrp^tm1.1Cyc)	decreased susceptibility to Herpesvirales infection	J:175084
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:175084
	increased interferon-beta secretion	J:175084
\Kif1c^{Ltxs1-DBA/2NCr}/\Kif1c^{Ltxs1-DBA/2NCr} (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
\Kif1c^{Ltxs1-DBA/2NCr}/\Kif1c^{Ltxs1-DBA/2NCr} \Ltxs2^DBA/2NCr/\Ltxs2^DBA/2NCr \Ltxs3^DBA/2NCr/\Ltxs3^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
\Kif1c^Ltxs1/\Kif1c⁺ (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:49726
\Kif1c^Ltxs1/\Kif1c^Ltxs1 (involves: C3H/HeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:49726
\Kif1c^{Orch3-BALB/cByJ}/\Kif1c^{Orch3-BALB/cByJ} (involves: BALB/cByJ * DBA/2)	testis inflammation	J:35331
\Kif1c^{Orch3-BALB/cByJ}/\Kif1c^Orch3-DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
\Kif1c^Orch3-DBA/2J/\Kif1c^Orch3-DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
\Kif5c^tm1dIcs/\Kif5c⁺ (C57BL/6N-Kif5c^tm1dIcs/Ics)	decreased lymphocyte cell number	J:211773
\Kif5c^tm1dIcs/\Kif5c⁺ (C57BL/6N-Kif5c^tm1dIcs/Ics)	increased eosinophil cell number	J:211773
\Kif9^em1(IMPC)Mbp/\Kif9^em1(IMPC)Mbp (C57BL/6N-Kif9^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Kif13b^{tm1b(EUCOMM)Wtsi}/\Kif13b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Kif13b^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Kif15^em1Lium/\Kif15^em1Lium (C57BL/6-Kif15^em1Lium)	decreased spleen white pulp amount	J:336767
	increased CD8-positive, alpha-beta T cell number	J:336767
	increased spleen red pulp amount	J:336767
	increased spleen weight	J:336767
	intermingled spleen red and white pulp	J:336767
\Kif16b^{em1(IMPC)Ccpcz}/\Kif16b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kif16b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Kif27^{Gt(OST441915)Lex}/\Kif27^{Gt(OST441915)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:185566
	maxillary sinus inflammation	J:185566
\Kifbp^{tm1a(KOMP)Wtsi}/\Kifbp^{tm1a(KOMP)Wtsi} (C57BL/6N-Kifbp^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Kiss1r^{tm1.1(KOMP)Vlcg}/\Kiss1r^{tm1.1(KOMP)Vlcg} (C57BL/6N-Kiss1r^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
	increased thymus weight	J:211773
\Kiss1r^tm1.1Lex/\Kiss1r⁺ (involves: 129S4/SvJae)	decreased eosinophil cell number	J:181650
\Kiss1r^tm1.1Lex/\Kiss1r⁺ (involves: 129S4/SvJae)	decreased lymphocyte cell number	J:181650
\Kiss1r^tm1.1Lex/\Kiss1r^tm1.1Lex (involves: 129S4/SvJae)	decreased basophil cell number	J:181650
	decreased lymphocyte cell number	J:181650
	decreased monocyte cell number	J:181650
	decreased neutrophil cell number	J:181650
	increased spleen weight	J:181650
	increased thymus weight	J:181650
\Kiss1r^tm1Gstn/\Kiss1r^tm1Gstn (involves: 129P2/OlaHsd)	increased thymus weight	J:102113
\Kit^tm1.1Bsm/\Kit^tm1.1Bsm (involves: 129S1/Sv * BALB/c * C57BL/6J * FVB/N)	abnormal mast cell physiology	J:61141
	decreased mast cell number	J:61141
\Kit^tm1.1Bsm/\Kit^tm1.1Bsm (B6.129S1-Kit^tm1.1Bsm)	immune system phenotype	J:90485
\Kit^tm1Ber/\Kit^tm1Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased mast cell number	J:89602
	immune system phenotype	J:89602
\Kit^tm1Bpr/\Kit^tm1Bpr (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	decreased mast cell number	J:100778
\Kit^tm1Bsm/\Kit^tm1Bsm (involves: 129S1/Sv * C57BL/6J)	decreased mast cell number	J:61141
\Kit^tm2Ber/\Kit^tm2Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased mast cell number	J:89602
	immune system phenotype	J:89602
\Kit^tm2Bsm/\Kit⁺ (involves: 129X1/SvJ * C57BL/6J)	increased mast cell degranulation	J:83616
\Kit^tm2Bsm/\Kit⁺ (involves: 129X1/SvJ * C57BL/6J)	increased mast cell number	J:83616
\Kit^tm3.1Bsm/\Kit^tm3.1Bsm (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:90485
	abnormal mast cell physiology	J:90485
	abnormal T cell differentiation	J:90485
	decreased B cell number	J:90485
	decreased mast cell number	J:90485
	immune system phenotype	J:90485
\Kit^tm3.1Bsm/\Kit^tm3.1Bsm (B6.129S1-Kit^tm3.1Bsm)	spleen hypoplasia	J:146561
\Kit^tm3Ber/\Kit^tm3Ber (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	arrested B cell differentiation	J:89602
	decreased mast cell number	J:89602
	enlarged spleen	J:89602
	increased B cell number	J:89602
	spleen hyperplasia	J:89602
\Kit^tm4.1Bsm/\Kit⁺ (involves: 129S1/Sv * C57BL/6J * FVB/N)	enlarged spleen	J:188434
	increased mast cell number	J:188434
	spleen hyperplasia	J:188434
\Kit^W-37J/\Kit⁺ (involves: C57BL/6 * C57BL/6J)	decreased mast cell number	J:27513
\Kit^W-37J/\Kit^W (involves: C57BL/6 * C57BL/6J * WB)	abnormal mast cell physiology	J:27513
\Kit^W-37J/\Kit^W (involves: C57BL/6 * C57BL/6J * WB)	decreased mast cell number	J:27513
\Kit^W-42J/\Kit⁺ (involves: C57BL/6 * C57BL/6J * WB)	decreased mast cell number	J:27513
\Kit^W-42J/\Kit^W (involves: C57BL/6 * C57BL/6J * WB)	abnormal mast cell physiology	J:27513
\Kit^W-42J/\Kit^W (involves: C57BL/6 * C57BL/6J * WB)	decreased mast cell number	J:27513
\Kit^W-Btlr/\Kit^W-Btlr (C57BL/6J-Kit^W-Btlr)	decreased mast cell number	J:133270
\Kit^W-f/\Kit^W-f (involves: C3H/HePas)	decreased mast cell number	J:27513
\Kit^W-Jic/\Kit⁺ (involves: C57BL/6)	decreased mast cell number	J:27513
\Kit^W-Jic/\Kit^W (involves: C57BL/6 * WB)	abnormal mast cell physiology	J:27513
\Kit^W-Jic/\Kit^W (involves: C57BL/6 * WB)	decreased mast cell number	J:27513
\Kit^W-n/\Kit^W-n (Not Specified)	decreased mast cell number	J:12107
\Kit^W-n/\Kit^W (involves: WB)	abnormal mast cell physiology	J:27513
\Kit^W-n/\Kit^W (involves: WB)	decreased mast cell number	J:27513
\Kit^W-sh/\Kit^W-sh (involves: 101/H * C3H/HeH)	decreased mast cell degranulation	J:157470
	decreased mast cell number	J:145444
	increased susceptibility to parasitic infection	J:163761
\Kit^W-sh/\Kit^W-sh (involves: C57BL/6J)	decreased susceptibility to type I hypersensitivity reaction	J:197334
\Kit^W-sh/\Kit^W-sh (B6.Cg-Kit^W-sh/HNihrJaeBsmGlliJ)	decreased susceptibility to type I hypersensitivity reaction	J:275367
\Kit^W-sh/\Kit^W-sh \Lyn^tm1Ard/\Lyn^tm1Ard (involves: 101 * 129P2/OlaHsd * C3H/HeH)	abnormal circulating complement protein level	J:161523
	decreased B cell number	J:161523
	glomerulonephritis	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgE level	J:161523
	increased IgG2b level	J:161523
	increased IgM level	J:161523
\Kit^W-v/\Kit⁺ (involves: C57BL * C57BL/6)	decreased mast cell number	J:27513
\Kit^W-vkd/\Kit^W-vkd (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * WB)	abnormal B cell differentiation	J:79128
	abnormal T cell differentiation	J:79128
	decreased B cell number	J:79128
	decreased thymocyte number	J:79128
\Kit^W/\Kit⁺ \Tg(PGK1-KITLG*220)441Daw/0 (involves: C3H/HeJ)	decreased mast cell number	J:32600
\Kit^W/\Kit^W-v (involves: C57BL/6 * WB)	abnormal response to transplant	J:6084
\Kit^W/\Kit^W-v ((WB/ReJ x C57BL/6J-Kit^W-v/J)F1-Kit^W/Kit^W-v/J)	abnormal interferon level	J:131785
	abnormal interleukin level	J:131785
	decreased inflammatory response	J:131785
	immune system phenotype	J:125656
	impaired neutrophil recruitment	J:123463
	kidney inflammation	J:113500
\Kit^W/\Kit^W-v (involves: C57BL/6)	decreased basophil cell number	J:178942
	decreased mast cell number	J:178942
	immune system phenotype	J:178942
\Kit^W/\Kit^W-v ((WB Kit^W x B6.Cg-Kit^W-v)F1)	decreased susceptibility to induced arthritis	J:178942
\Kit^W/\Kit^W-v ((WB Kit^W x B6.Cg-Kit^W-v)F1)	decreased susceptibility to type I hypersensitivity reaction	J:197334
\Kit^W/\Kit^W \Tg(PDGFB-EPO)321Zbz/? (involves: C3H * C57BL/6)	abnormal B cell differentiation	J:79128
	abnormal T cell differentiation	J:79128
	decreased B cell number	J:79128
	decreased thymocyte number	J:79128
\Kit^Wads/\Kit^Wads (C57BL/6J-Kit^Wads)	decreased mast cell number	J:96391
\Kitl^Sl-con/\Kitl^Sl-con (either: (involves: C3H/HeJ) or (involves: C3H/HeN))	increased mast cell number	J:23593
\Kitl^Sl-d/\Kitl⁺ (either: (involves: C57BL/6 * DBA/2J) or (involves: C3H * C57BL/6 * DBA/2J * WC))	decreased mast cell number	J:6084
\Kitl^Sl/\Kitl⁺ (either: (involves: C3H * WC) or (involves: C3H * C57BL/6 * DBA/2J * WC))	decreased mast cell number	J:6084
\Kitl^Sl/\Kitl⁺ \Tg(PGK1-KITLG*220)441Daw/0 (involves: C3H)	decreased mast cell number	J:32600
\Kitl^Sl/\Kitl^Sl-d (involves: C57BL/6 * WC)	dermatitis	J:5758
	stomach inflammation	J:2777
	thymus atrophy	J:5758
\Kitl^Sl/\Kitl^Sl-d (involves: C3H * C57BL/6 * DBA/2J * WC)	abnormal response to transplant	J:6084
\Kitl^Sl/\Kitl^Sl-d (involves: C3H * C57BL/6 * DBA/2J * WC)	decreased mast cell number	J:6084
\Kitl^Sl/\Kitl^Sl-d ((WC/ReJ Kitl^Sl x B6.D2-Kitl^Sl-d/J)F1-Kitl^Sl/Kitl^Sl-d/J)	abnormal osteoclast morphology	J:111273
\Kitl^tm1.1Sjm/\Kitl^tm2.1Sjm \Lepr^tm2(cre)Rck/\Lepr⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/Ka * SJL)	enlarged spleen	J:180431
	spleen hyperplasia	J:180431
\Kitl^tm1.1Sjm/\Kitl^tm2.1Sjm \Lepr^tm2(cre)Rck/\Lepr⁺ \Tg(Tek-cre)12Flv/0 (involves: 129S6/SvEvTac * C3H * C57BL/6 * C57BL/Ka * SJL)	spleen hyperplasia	J:180431
\Kitl^tm1Pbes/\Kitl^tm1Pbes (involves: 129S1/Sv * C57BL/6J)	decreased mast cell number	J:50150
\Kitl^tm2.1Pbes/\Kitl^tm2.1Pbes (involves: 129S1/Sv * C57BL/6J * FVB/N)	increased mast cell number	J:157170
\Kitl^tm3.1Pbes/\Kitl^tm3.1Pbes (involves: 129S1/Sv * C57BL/6J * FVB/N)	decreased double-negative T cell number	J:157170
	decreased double-positive T cell number	J:157170
	decreased mast cell number	J:157170
	decreased T cell number	J:157170
	decreased thymocyte number	J:157170
\Kl^ecalc1/\Kl^ecalc1 (involves: C3H/HeH * C57BL/6J)	lung inflammation	J:229255
\Kl^kl/\Kl^kl (either: C.Cg-Kl^kl or (involves: C3H/HeJ * C57BL/6J))	abnormal leukocyte cell number	J:44109
	decreased osteoclast cell number	J:44109
	thymus atrophy	J:44109
\Kl^kl/\Kl^kl (involves: C3H/HeJ * C57BL/6J)	decreased B cell number	J:80503
\Kl^kl/\Kl^kl (involves: C3H/HeJ * C57BL/6J)	decreased osteoclast cell number	J:80503
\Kl^kl/\Kl^kl (involves: C3H/J * C57BL/6J)	abnormal osteoclast morphology	J:56666
\Kl^kl/\Kl^kl \Tnfrsf11b^tm1Khs/\Tnfrsf11b⁺ (involves: 129P2/OlaHsd * C3H * C57BL/6)	decreased B cell number	J:80503
\Kl^m1Anu/\Kl^m1Anu (C57BL/6NCrlAnu-Kl^m1Anu)	abnormal spleen morphology	J:104190
\Kl^m1Anu/\Kl^m1Anu (C57BL/6NCrlAnu-Kl^m1Anu)	small spleen	J:104190
\Klf1^Nan/\Klf1⁺ (either: B6.Cg-Klf1^Nan or WB.Cg-Klf1^Nan)	increased spleen weight	J:162530
\Klf1^Nan/\Klf1⁺ (involves: 101/H * C3H/HeH * PT)	enlarged spleen	J:13933
\Klf1^Nan/\Klf1⁺ (involves: 101/H * C3H/HeH * PT)	increased spleen iron level	J:13933
\Klf2^tm1Ling/\Klf2^tm1Ling (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:51402
\Klf2^tm1Mlkn/\Klf2^tm1Mlkn \Tg(VAV1-cre)1Graf/0 (Not Specified)	absent T cells	J:127228
\Klf2^tm2Ling/\Klf2^tm2Ling \Lyz2^tm1(cre)Ifo/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased Ly6C low monocyte number	J:239509
\Klf2^tm2Ling/\Klf2^tm2Ling \Tg(Cd4-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:151604
	decreased T cell number	J:151604
	increased IgE level	J:151604
	increased IgG1 level	J:151604
	increased interleukin-4 secretion	J:151604
	increased single-positive T cell number	J:151604
\Klf3^{Gt(CH0516)Wtsi}/\Klf3^{Gt(CH0516)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	increased leukocyte cell number	J:206507
	increased spleen weight	J:206507
\Klf3^{Gt(XS0187)Wtsi}/\Klf3^{Gt(XS0187)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	increased leukocyte cell number	J:206507
	increased spleen weight	J:206507
\Klf3^m1Cmhd/\Klf3⁺ (involves: C3H/HeJ * C57BL/6J)	increased spleen weight	J:206507
\Klf4^tm1Khk/\Klf4^tm1Khk \Lyz2^tm1(cre)Ifo/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased Ly6C low monocyte number	J:239509
\Klf4^tm1Khk/\Klf4^tm1Khk \Tg(Pax6-cre,GFP)1Pgr/0 (involves: 129S6/SvEvTac * FVB/N)	blepharitis	J:117671
\Klf5^Gt(XB751)Byg/\Klf5⁺ (B6.129P2-Klf5^Gt(XB751)Byg)	abnormal response to infection	J:136125
\Klf5^M1Btlr/\Klf5^M1Btlr (C57BL/6J-Klf5^M1Btlr)	increased susceptibility to induced colitis	J:265229
\Klf5^tm1Jaw/\Klf5^tm1Jaw \Tg(Pax6-cre,GFP)1Pgr/0 (involves: FVB)	lacrimal gland inflammation	J:175263
\Klf13^tm1Coll/\Klf13^tm1Coll (involves: 129S/SvEv)	decreased leukocyte cell number	J:136545
	decreased lymphocyte cell number	J:136545
	enlarged spleen	J:136545
	spleen hyperplasia	J:136545
\Klf13^tm1Kren/\Klf13^tm1Kren (B6.129-Klf13^tm1Kren)	abnormal immune system cell morphology	J:145839
	abnormal immune system organ morphology	J:145839
	abnormal spleen morphology	J:145839
	abnormal T cell number	J:145839
	decreased splenocyte apoptosis	J:145839
	decreased thymocyte apoptosis	J:145839
	decreased thymocyte number	J:145839
	increased double-positive T cell number	J:145839
	increased splenocyte number	J:145839
	increased thymocyte number	J:145839
	spleen hyperplasia	J:145839
	thymus hyperplasia	J:145839
\Klf15^tm1Jain/\Klf15^tm1Jain (involves: 129X1/SvJ)	blood vessel inflammation	J:203920
\Klf15^tm1Jain/\Klf15^tm1Jain (involves: 129X1/SvJ)	increased macrophage cell number	J:203920
\Klf16^em1(IMPC)J/\Klf16⁺ (C57BL/6NJ-Klf16^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Klhdc2^{tm1b(EUCOMM)Hmgu}/\Klhdc2⁺ (C57BL/6N-Klhdc2^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Klhdc7b^em1(IMPC)H/\Klhdc7b^em1(IMPC)H (C57BL/6N-Klhdc7b^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Klhdc10^tm1Hijo/\Klhdc10^tm1Hijo (B6J.B6N-Klhdc10^tm1Hijo)	decreased circulating interleukin-6 level	J:251158
	decreased inflammatory response	J:251158
	decreased interleukin-6 secretion	J:251158
\Klhl1^{em1(IMPC)Ccpcz}/\Klhl1^{em1(IMPC)Ccpcz} (C57BL/6N-Klhl1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Klhl6^{em1(IMPC)Ccpcz}/\Klhl6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Klhl6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased T cell number	J:211773
	increased T-helper cell number	J:211773
	small spleen	J:211773
\Klhl6^m1Anu/\Klhl6^m1Anu (C57BL/6JAnu-Klhl6^m1Anu)	decreased B cell number	J:104190
	decreased mature B cell number	J:104190
	increased immature B cell number	J:104190
\Klhl6^m1Btlr/\Klhl6^m1Btlr (C57BL/6J-Klhl6^m1Btlr)	decreased B cell number	J:265167
	decreased central memory CD4-positive, alpha-beta T cell number	J:265167
	increased B-1b cell number	J:265167
	increased CD4-positive, alpha-beta T cell number	J:265167
	increased single-positive T cell number	J:265167
	increased T cell number	J:265167
\Klhl6^m2Btlr/\Klhl6^m2Btlr (C57BL/6J-Klhl6^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265168
	increased CD4-positive, alpha-beta T cell number	J:265168
	increased single-positive T cell number	J:265168
	increased T cell number	J:265168
\Klhl6^M3Btlr/\Klhl6^M3Btlr (C57BL/6J-Klhl6^M3Btlr)	increased alpha-beta T cell number	J:267699
	increased B-1a cell number	J:267699
	increased CD4-positive, alpha-beta T cell number	J:267699
	increased CD8-positive, alpha-beta T cell number	J:267699
\Klhl6^m4Btlr/\Klhl6^m4Btlr (C57BL/6J-Klhl6^m4Btlr)	increased B-1 B cell number	J:272394
\Klhl6^M5Btlr/\Klhl6^M5Btlr (C57BL/6J-Klhl6^M5Btlr)	increased B-1 B cell number	J:272395
\Klhl6^m6Btlr/\Klhl6^m6Btlr (C57BL/6J-Klhl6^m6Btlr)	increased alpha-beta T cell number	J:272396
\Klhl6^m6Btlr/\Klhl6^m6Btlr (C57BL/6J-Klhl6^m6Btlr)	increased CD4-positive, alpha-beta T cell number	J:272396
\Klhl6^M7Btlr/\Klhl6^M7Btlr (C57BL/6J-Klhl6^M7Btlr)	abnormal B cell differentiation	J:272397
\Klhl6^M8Btlr/\Klhl6^M8Btlr (C57BL/6J-Klhl6^M8Btlr)	decreased B cell number	J:274963
	increased CD4-positive, alpha-beta T cell number	J:274963
	increased T cell number	J:274963
\Klhl6^tm1Sato/\Klhl6^tm1Sato (either: (involves: 129T2/SvEms) or (involves: BALB/c) or (involves: CD-1))	abnormal adaptive immunity	J:101363
	abnormal B cell differentiation	J:101363
	abnormal lymph node germinal center morphology	J:101363
	abnormal spleen morphology	J:101363
	decreased B cell number	J:101363
	decreased follicular B cell number	J:101363
	decreased spleen weight	J:101363
	spleen hypoplasia	J:101363
\Klhl14^tm1.1Jyw/\Klhl14⁺ (involves: C57BL/6)	decreased B-1a cell number	J:263511
	immune system phenotype	J:263511
	increased B-1b cell number	J:263511
\Klhl22^em1Cya/\Klhl22^em1Cya (C57BL/6N-Klhl22^em1Cya/Cya)	decreased interferon-gamma secretion	J:297538
\Klhl22^em1Cya/\Klhl22^em1Cya (C57BL/6N-Klhl22^em1Cya/Cya)	decreased tumor necrosis factor secretion	J:297538
\Klhl29^{tm1b(EUCOMM)Hmgu}/\Klhl29⁺ (C57BL/6N-Klhl29^{tm1b(EUCOMM)Hmgu}/Ics)	increased large unstained cell number	J:211773
\Klk4^{tm1.1(KOMP)Vlcg}/\Klk4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Klk4^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Klk5^em1Mer/\Klk5^em1Mer (BALB/c-Klk5^em1Mer)	abnormal acute inflammation	J:344772
\Klk6^tm1Gsot/\Klk6⁺ (involves: C57BL/6)	decreased inflammatory response	J:270051
\Klk6^tm1Gsot/\Klk6⁺ (involves: C57BL/6)	decreased susceptibility to chemically induced skin inflammation	J:270051
\Klk6^tm1Gsot/\Klk6^tm1Gsot (involves: C57BL/6)	abnormal cytokine level	J:270051
	decreased inflammatory response	J:270051
	decreased susceptibility to chemically induced skin inflammation	J:270051
\Klk6^tm1Gsot/\Klk6^tm1Gsot \Spink5^tm1Drh/\Spink5^tm1Drh (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:289877
	decreased inflammatory response	J:289877
\Klk8^{em1(IMPC)Ccpcz}/\Klk8^{em1(IMPC)Ccpcz} (C57BL/6N-Klk8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
\Klk10^{em1(IMPC)Ccpcz}/\Klk10^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Klk10^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged thymus	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
\Klk11^{em1(IMPC)Ccpcz}/\Klk11^{em1(IMPC)Ccpcz} (C57BL/6N-Klk11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Klra1^tm1.1Wyok/\Klra1^tm1.1Wyok (involves: BALB/cJ * C57BL/6NTac)	abnormal natural killer cell mediated cytotoxicity	J:252851
\Klra5^tm1.1Cgbr/\Klra5^tm1.1Cgbr (involves: C57BL/6 * SJL)	immune system phenotype	J:169142
\Klra5^tm1.2Glec/\Klra5^tm1.2Glec (involves: C57BL/6)	immune system phenotype	J:201231
\Klra8^Cmv1-del/\Klra8^Cmv1-r ((BXD8/TyJ x C57BL/6)F1)	decreased susceptibility to Herpesvirales infection	J:79093
\Klra8^Cmv1-del/\Klra8^Cmv1-s ((BXD8/TyJ x BALB/c)F1)	increased susceptibility to Herpesvirales infection	J:79093
\Klra8^Cmv1-del/\Klra8^Cmv1-s ((BXD8/TyJ x DBA/2)F1)	increased susceptibility to Herpesvirales infection	J:79093
\Klra8^Cmv1-r/\Klra8^Cmv1-r (C.B6-Klra8^Cmv1-r)	decreased IgG1 level	J:97203
	decreased IgG2a level	J:97203
	decreased IgG2b level	J:97203
	decreased IgG3 level	J:97203
	decreased IgG level	J:97203
	decreased interleukin-4 secretion	J:97203
	decreased susceptibility to Herpesvirales infection	J:22486, J:79093
	increased circulating interferon-gamma level	J:97203
	increased IgM level	J:97203
	increased susceptibility to infection induced morbidity/mortality	J:97203
	increased susceptibility to parasitic infection	J:97203
\Klra15^tm1.1Apma/\Klra15^tm1.1Apma (B6.129-Klra15^tm1.1Apma)	impaired natural killer cell mediated cytotoxicity	J:189106
\Klra17^tm1.1Apma/\Klra17^tm1.1Apma (involves: 129S1/Sv * 129X1/SvJ)	abnormal plasmacytoid dendritic cell physiology	J:152288
	abnormal response to infection	J:152288
	decreased circulating interferon-alpha level	J:152288
	decreased circulating interleukin-12 level	J:152288
	decreased interferon-alpha secretion	J:152288
	decreased interleukin-12 secretion	J:152288
	increased plasmacytoid dendritic cell number	J:152288
	increased susceptibility to Herpesvirales infection	J:152288
\Klrb1^{tm1b(EUCOMM)Wtsi}/\Klrb1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Klrb1^{tm1b(EUCOMM)Wtsi}/Ieg)	decreased leukocyte cell number	J:211773
	increased follicular B cell number	J:211773
\Klrb1b^tm1.1Apma/\Klrb1b^tm1.1Apma (B6.Cg-Klrb1b^tm1.1Apma)	abnormal NK cell physiology	J:222057
\Klrc1^tm1Mmka/\Klrc1^tm1Mmka (B6.129-Klrc1^tm1Mmka)	decreased CD8-positive, alpha-beta T cell number	J:222503
	decreased tumor necrosis factor secretion	J:222503
	immune system phenotype	J:222503
	increased interferon-gamma secretion	J:222503
	increased interleukin-2 secretion	J:222503
	increased susceptibility to Adenoviridae infection	J:222503
	increased susceptibility to Orthomyxoviridae infection	J:222503
	increased tumor necrosis factor secretion	J:222503
	liver inflammation	J:222503
	lung inflammation	J:222503
\Klrd1^tm1.1Lll/\Klrd1^tm1.1Lll (B6.129X1-Klrd1^tm1.1Lll)	immune system phenotype	J:167730
\Klre1^tm1Tgi/\Klre1^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:92262
\Klrg2^em1(IMPC)H/\Klrg2^em1(IMPC)H (C57BL/6NTac-Klrg2^em1(IMPC)H/H)	enlarged spleen	J:211773
\Klrk1^em1(IMPC)Mbp/\Klrk1^em1(IMPC)Mbp (C57BL/6NCrl-Klrk1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Klrk1^tm1.1Bpol/\Klrk1^tm1.1Bpol (C57BL/6-Klrk1^tm1.1Bpol)	abnormal NK cell differentiation	J:151878
	abnormal NK cell physiology	J:151878
	decreased B cell number	J:151878
	decreased susceptibility to Herpesvirales infection	J:151878
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:151878
	decreased T cell number	J:151878
	impaired natural killer cell mediated cytotoxicity	J:151878
	increased interferon-gamma secretion	J:151878
	spleen hypoplasia	J:151878
\Klrk1^tm1Dhr/\Klrk1^tm1Dhr (involves: C57BL/6 * CD-1)	impaired natural killer cell mediated cytotoxicity	J:134509
\Klrk1^tm1Dhr/\Klrk1^tm1Dhr (B6.Cg-Klrk1^tm1Dhr/J)	increased natural killer cell mediated cytotoxicity	J:221188
\Klrk1^tm2.1Bpol/\Klrk1^tm2.1Bpol (Not Specified)	abnormal NK cell differentiation	J:215590
\Klrk1^tm2.1Bpol/\Klrk1^tm2.1Bpol (Not Specified)	decreased susceptibility to Herpesvirales infection	J:215590
\Kmt2a^tm1(AFF1)Ksy/\Kmt2a⁺ (involves: 129S1/Sv * C57BL/6 * FVB)	abnormal lymphocyte morphology	J:110241
	enlarged spleen	J:110241
	increased leukocyte cell number	J:110241
	increased monocyte cell number	J:110241
	increased neutrophil cell number	J:110241
	increased pro-B cell number	J:110241
	lymphoid hyperplasia	J:110241
	myeloid hyperplasia	J:110241
\Kmt2a^{tm1(MLL1/ERT)Divo}/? (involves: 129S4/SvJae * C57BL/6)	enlarged spleen	J:189329
	myeloid hyperplasia	J:189329
\Kmt2a^{tm1.1(Sh3gl1)Lcc}/\Kmt2a⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	enlarged lymph nodes	J:205605
	enlarged spleen	J:205605
	myeloid hyperplasia	J:205605
\Kmt2a^tm1.1Erns/\Kmt2a^tm1.1Erns \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:147265
\Kmt2a^tm1.1Erns/\Kmt2a^tm1.1Erns \Tg(Lck-cre)1Cwi/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	immune system phenotype	J:147265
\Kmt2a^tm1Brad/\Kmt2a^tm1Brad \Commd10^{Tg(Vav1-icre)A2Kio}/? (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	decreased pre-B cell number	J:149811
\Kmt2a^tm1Clgr/\Kmt2a⁺ (B6.129-Kmt2a^tm1Clgr)	abnormal myelopoiesis	J:115001
\Kmt2a^tm1Sjk/\Kmt2a⁺ (involves: 129S2/SvPas * C3H * C57BL/6)	decreased B cell number	J:29958
\Kmt2a^tm1Thr/\Kmt2a⁺ \Mllt3^tm2Thr/\Mllt3⁺ \Tg(Lck-cre)1Thr/? (involves: 129S/SvEv)	abnormal spleen red pulp morphology	J:100794
	abnormal spleen white pulp morphology	J:100794
	enlarged spleen	J:100794
	increased T cell derived lymphoma incidence	J:100794
\Kmt2a^{tm2(MLLT3)Thr}/\Kmt2a⁺ (involves: 129P2/OlaHsd)	enlarged spleen	J:56340
\Kmt2a^{tm2(MLLT3)Thr}/\Kmt2a^{tm2(MLLT3)Thr} (involves: 129P2/OlaHsd * C57BL/6 * FVB)	increased leukocyte cell number	J:110241
	increased neutrophil cell number	J:110241
	increased pro-B cell number	J:110241
\Kmt2a^tm2Sjk/\Kmt2a⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	abnormal spleen morphology	J:95914
	enlarged spleen	J:95914
	increased leukocyte cell number	J:95914
	increased spleen red pulp amount	J:95914
	myeloid hyperplasia	J:95914
\Kmt2d^tm1.1Kaig/\Kmt2d⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased germinal center B cell number	J:228913
	increased spleen germinal center size	J:228913
\Kmt2d^tm1.1Kaig/\Kmt2d^tm1.1Kaig \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:228913
	decreased B cell number	J:228913
	decreased follicular B cell number	J:228913
	decreased IgG1 level	J:228913
	decreased IgM level	J:228913
	decreased mature B cell number	J:228913
	immune system phenotype	J:228913
	increased B cell proliferation	J:228913
	increased germinal center B cell number	J:228913
	increased spleen germinal center number	J:228913
	increased spleen germinal center size	J:228913
\Kmt2d^tm1.1Kaig/\Kmt2d^tm1.1Kaig \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:228913
\Kmt2d^{tm1.2(IMPC)Wtsi}/\Kmt2d⁺ (C57BL/6N-Kmt2d^{tm1.2(IMPC)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Kmt2e^tm1.1Hjf/\Kmt2e⁺ (B6.129P2-Kmte^tm1.1Hjf)	decreased thymocyte number	J:145579
	spleen hypoplasia	J:145579
	thymus hypoplasia	J:145579
\Kmt2e^tm1.1Hjf/\Kmt2e^tm1.1Hjf (B6.129P2-Kmte^tm1.1Hjf)	abnormal lymphopoiesis	J:145579
	decreased B cell number	J:145579
	decreased double-negative T cell number	J:145579
	decreased double-positive T cell number	J:145579
	decreased leukocyte cell number	J:145579
	decreased macrophage cell number	J:145579
	decreased pre-B cell number	J:145579
	decreased pro-B cell number	J:145579
	decreased T cell number	J:145579
	decreased thymocyte number	J:145579
	immune system phenotype	J:145579
	small lymph nodes	J:145579
	small spleen	J:145579
	small thymus	J:145579
	spleen hypoplasia	J:145579
	thymus hypoplasia	J:145579
\Kmt2e^tm1Apa/\Kmt2e^tm1Apa (129S6/SvEvTac-Kmt2e^tm1Apa)	abnormal granulocyte differentiation	J:145445
	abnormal neutrophil differentiation	J:145445
	abnormal neutrophil physiology	J:145445
	blepharitis	J:145445
	increased susceptibility to bacterial infection	J:145445
\Kmt2e^tm1Nik/\Kmt2e^tm1Nik (B6.Cg-Kmte^tm1Nik)	decreased NK cell number	J:145449
	decreased NK T cell number	J:145449
	increased neutrophil cell number	J:145449
\Kmt5b^tm1Jnw/\Kmt5b^tm1Jnw \Kmt5c^tm1.1Jnw/\Kmt5c^tm1.1Jnw \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129/Sv * C57BL/6J * C57BL/10 * CBA/Ca)	abnormal class switch recombination	J:139510
	abnormal lymphopoiesis	J:139510
	decreased B cell number	J:139510
	decreased double-positive T cell number	J:139510
	immune system phenotype	J:139510
\Knl1^{tm1c(EUCOMM)Hmgu}/\Knl1^{tm1c(EUCOMM)Hmgu} \Tg(GFAP-cre)25Mes/0 (involves: 129S4/SvJaeSor * C57BL/6N * FVB/N)	microgliosis	J:278483
\Knop1^{tm1b(EUCOMM)Wtsi}/\Knop1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Knop1^{tm1b(EUCOMM)Wtsi}/Bay)	increased spleen weight	J:211773
\Kpna2^em1(IMPC)Mbp/\Kpna2⁺ (C57BL/6N-Kpna2^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
\Kpna4^tm1Bdr/\Kpna4^tm1Bdr (B6.Cg-Kpna4^tm1Bdr)	increased susceptibility to Orthomyxoviridae infection	J:302003
\Kprp^tm1Msug/\Kprp⁺ (involves: C57BL/6)	increased IgE level	J:286659
\Kprp^tm1Msug/\Kprp⁺ (involves: C57BL/6)	increased susceptibility to chemically induced skin inflammation	J:286659
\Kptn^{tm1a(EUCOMM)Wtsi}/\Kptn^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	increased susceptibility to bacterial infection	J:200082
\Kras^tm1.1Khai/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA/J)	enlarged spleen	J:276349
	increased leukocyte cell number	J:276349
\Kras^tm1Mok/\Kras⁺ \Nras^tm1Mok/\Nras⁺ (involves: 129S/SvEv * C57BL/6 * DBA/2)	abnormal lymphatic vessel morphology	J:159024
\Kras^tm2Tyj/\Kras⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
\Kras^tm2Tyj/\Kras⁺ (involves: 129S2/SvPas)	increased T cell derived lymphoma incidence	J:68981
\Kras^tm2Tyj/\Kras⁺ \Trp53^tm1Tyj/\Trp53⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
\Kras^tm2Tyj/\Kras⁺ \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
\Kras^tm3Tyj/\Kras⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:68981
\Kras^tm3Tyj/\Kras⁺ (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:68981
\Kras^tm3Tyj/\Kras⁺ \Mir21a^tm1.1Eno/\Mir21a^tm1.1Eno (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:164198
\Kras^tm3Tyj/\Kras^tm3Tyj (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:237900
\Kras^tm4.1Bbd/\Kras⁺ (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N)	enlarged spleen	J:223433
\Kras^tm4.1Bbd/\Kras^tm4.1Bbd (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N)	decreased CD8-positive, alpha-beta T cell number	J:223433
	enlarged spleen	J:223433
	increased basophil cell number	J:223433
	increased eosinophil cell number	J:223433
	increased leukocyte cell number	J:223433
	increased neutrophil cell number	J:223433
	spleen vascular congestion	J:223433
\Kras^tm4Tyj/\Kras⁺ (involves: 129S4/SvJae)	increased regulatory T cell number	J:154046
\Kras^tm4Tyj/\Kras⁺ \Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/\Gt(ROSA)26Sor⁺ \Tg(Flt3-cre)#Ccb/0 (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)	decreased B cell number	J:247853
	decreased double-negative T cell number	J:247853
	decreased double-positive T cell number	J:247853
	decreased T cell number	J:247853
	hepatosplenomegaly	J:247853
	increased dendritic cell number	J:247853
	increased leukocyte cell number	J:247853
	increased monocyte cell number	J:247853
	thymus atrophy	J:247853
\Kras^tm4Tyj/\Kras⁺ \Krt19^{tm1(cre/ERT)Ggu}/\Krt19⁺ \Pten^tm2Mak/\Pten^tm2Mak (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)	lung inflammation	J:254370
\Kras^tm4Tyj/\Kras⁺ \Lrrc17^tm1Nik/\Lrrc17⁺ \Srpk2^tm1Nik/\Srpk2⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)	increased leukocyte cell number	J:161558
\Kras^tm4Tyj/\Kras⁺ \Pggt1b^tm1Mbrg/\Pggt1b⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:122107
	decreased lymphocyte cell number	J:122107
	increased neutrophil cell number	J:122107
\Kras^tm4Tyj/\Kras⁺ \Pten^tm1Hwu/\Pten^tm1Hwu \Scgb1a1^{tm1.1(cre)Fjd}/\Scgb1a1⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	lung inflammation	J:131721
\Kras^tm4Tyj/\Kras⁺ \Stk11^tm1.2Rdp/\Stk11^tm1.2Rdp (involves: 129S4/SvJae * 129S6/SvEvTac)	increased macrophage cell number	J:197037
\Kras^tm4Tyj/\Kras⁺ \Tg(MUC1)79.24Gend/0 (involves: 129S4/SvJae * C57BL/6)	decreased interferon-gamma secretion	J:154046
	increased IgG level	J:154046
	increased IgM level	J:154046
	increased regulatory T cell number	J:154046
\Kras^tm4Tyj/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)	abnormal myelopoiesis	J:88163
	enlarged spleen	J:88163
	increased granulocyte number	J:88163
	increased leukocyte cell number	J:88163
	increased lymphoblastic lymphoma incidence	J:88163
	increased spleen red pulp amount	J:88163
	lymphoid hyperplasia	J:88163
	myeloid hyperplasia	J:88163
\Kras^tm4Tyj/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal myelopoiesis	J:87429
	enlarged spleen	J:87429, J:115071
	increased leukocyte cell number	J:87429
	increased monocyte cell number	J:87429
	increased splenocyte proliferation	J:87429
	myeloid hyperplasia	J:87429
\Kras^tm4Tyj/\Kras⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6J * CBA/J)	enlarged spleen	J:276349
\Kras^tm4Tyj/\Kras⁺ \Tg(Scgb1a1-cre)1Kkw/? (involves: 129 * C57BL/6 * FVB/N)	increased inflammatory response	J:107260
\Kras^tm4Tyj/\Kras⁺ \Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm (B6.129-Kras^tm4Tyj Tgfbr2^tm1.2Hlm)	abnormal myeloid leukocyte morphology	J:177379
	increased B cell number	J:177379
	increased T cell number	J:177379
\Kras^tm4Tyj/\Kras⁺ \Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Ptf1a^{tm1.1(cre)Cvw}/\Ptf1a⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)	enlarged spleen	J:116129
\Kras^tm4Tyj/\Kras⁺ \Trp53^tm2Tyj/\Trp53⁺ (involves: 129S4/SvJae)	lung inflammation	J:191425
\Kras^tm4Tyj/\Kras⁺ \Trp53^tm2Tyj/\Trp53⁺ \Tg(Pdx1-cre)6Tuv/0 (involves: 129S4/SvJae * C57BL/6 * FVB/N)	increased T cell derived lymphoma incidence	J:98936
\Kras^tm4Tyj/\Kras^tm4Tyj \Trim33^tm1Los/\Trim33^tm1Los \Tg(Pdx1-cre)89.1Dam/0 (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)	pancreas inflammation	J:151781
\Kremen1^{em1(IMPC)Ccpcz}/\Kremen1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Kremen1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Krt1^{em1(IMPC)Ccpcz}/\Krt1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Krt1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased NK cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased spleen weight	J:211773
\Krt1^tm1Tmm/\Krt1^tm1Tmm (involves: 129 * C57BL/6)	abnormal circulating interleukin level	J:200244
	abnormal interleukin secretion	J:200244
	increased circulating interleukin-18 level	J:200244
\Krt2^{tm1a(KOMP)Wtsi}/\Krt2^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	skin inflammation	J:214772
\Krt5^{tm1.1(KOMP)Vlcg}/\Krt5⁺ (C57BL/6N-Krt5^{tm1.1(KOMP)Vlcg}/Tcp)	abnormal lymph node morphology	J:211773
\Krt8^{tm1b(EUCOMM)Hmgu}/\Krt8⁺ (C57BL/6N-Krt8^{tm1b(EUCOMM)Hmgu}/Ics)	increased neutrophil cell number	J:211773
\Krt8^tm1Rgo/\Krt8^tm1Rgo (involves: 129S2/SvPas * C57BL/6 * FVB/N)	chronic inflammation	J:86719, J:98058
	enlarged spleen	J:22116
\Krt10^tm1Tmm/\Krt10⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6))	increased susceptibility to infection	J:31853
\Krt18^tm1Tmm/\Krt18⁺ (involves: 129P2/OlaHsd)	liver inflammation	J:309021
\Krt18^tm1Tmm/\Krt18^tm1Tmm (involves: 129P2/OlaHsd)	liver inflammation	J:309021
\Krt27^{em1(IMPC)Ccpcz}/\Krt27^{em1(IMPC)Ccpcz} (C57BL/6N-Krt27^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Krt28^{em1(IMPC)Ccpcz}/\Krt28^{em1(IMPC)Ccpcz} (C57BL/6N-Krt28^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Krt33a^{em1(IMPC)Ccpcz}/\Krt33a^{em1(IMPC)Ccpcz} (C57BL/6N-Krt33a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Krt33a^Plsh-3Btlr/\Krt33a⁺ (C57BL/6J-Krt33a^Plsh-3Btlr)	immune system phenotype	J:145290
\Krt33b^{em1(IMPC)Ccpcz}/\Krt33b^{em1(IMPC)Ccpcz} (C57BL/6N-Krt33b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
\Krt34^{em1(IMPC)Ccpcz}/\Krt34^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Krt34^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Krt72^{em1(IMPC)Ccpcz}/\Krt72^{em1(IMPC)Ccpcz} (C57BL/6N-Krt72^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Krt76^{tm1a(KOMP)Wtsi}/\Krt76^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	skin inflammation	J:232539
\Krtap7-1^{em1(IMPC)Ccpcz}/\Krtap7-1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Krtap7-1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Krtap8-1^{em1(IMPC)Ccpcz}/\Krtap8-1^{em1(IMPC)Ccpcz} (C57BL/6N-Krtap8-1^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
\Krtap9-5^{em1(IMPC)Ccpcz}/\Krtap9-5^{em1(IMPC)Ccpcz} (C57BL/6N-Krtap9-5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Ksr1^tm1Shaw/\Ksr1^tm1Shaw (Not Specified)	decreased susceptibility to induced arthritis	J:140520
\Ksr1^tm1Shaw/\Ksr1^tm1Shaw (Not Specified)	decreased T cell proliferation	J:75739
\Ksr1^tm1Shaw/\Ksr1^tm1Shaw \Tg(DO11.10)10Dlo/0 (involves: BALB/c * C3H * C57BL/6)	abnormal CD4-positive T cell differentiation	J:75739
	decreased interleukin-2 secretion	J:75739
	decreased T cell proliferation	J:75739
\Ky^em1(IMPC)J/\Ky⁺ (C57BL/6NJ-Ky^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\L3mbtl1^tm1.1Haho/\L3mbtl1^tm1.1Haho (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:166180
\Lacc1^em1Arkr/\Lacc1^em1Arkr (C57BL/6NTac-Lacc1^em1Arkr)	abnormal macrophage physiology	J:244365
	decreased circulating interleukin-1 beta level	J:244365
	decreased susceptibility to endotoxin shock	J:244365
\Lacc1^em2Arkr/\Lacc1^em2Arkr (C57BL/6NTac-Lacc1^em2Arkr)	abnormal macrophage physiology	J:244365
	decreased circulating interleukin-1 beta level	J:244365
	decreased susceptibility to endotoxin shock	J:244365
\Lacc1^em3Arkr/\Lacc1^em3Arkr (C57BL/6NTac-Lacc1^em3Arkr)	abnormal macrophage physiology	J:244365
	increased circulating interleukin-1 beta level	J:244365
	increased susceptibility to endotoxin shock	J:244365
\Lacc1^em4Arkr/\Lacc1^em4Arkr (C57BL/6NTac-Lacc1^em4Arkr)	abnormal macrophage physiology	J:244365
	increased circulating interleukin-1 beta level	J:244365
	increased susceptibility to endotoxin shock	J:244365
\Lacc1^{tm1a(KOMP)Wtsi}/\Lacc1^{tm1a(KOMP)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal macrophage morphology	J:244365
	abnormal macrophage physiology	J:244365
	decreased circulating tumor necrosis factor level	J:244365
	decreased interleukin-1 beta secretion	J:244365
	increased circulating interleukin-1 beta level	J:244365
	increased susceptibility to endotoxin shock	J:244365
\Lag3^tm1Daav/\Lag3⁺ \Tg(Foxp3-EGFP/cre)1cJbs/0 (NOD.Cg-Lag3^tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)	decreased susceptibility to autoimmune diabetes	J:260063
\Lag3^tm1Daav/\Lag3^tm1Daav \Tg(Foxp3-EGFP/cre)1cJbs/0 (NOD.Cg-Lag3^tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)	abnormal CD8-positive, alpha-beta T cell physiology	J:260063
	abnormal effector T cell number	J:260063
	abnormal interleukin level	J:260063
	abnormal tumor necrosis factor level	J:260063
	decreased susceptibility to autoimmune diabetes	J:260063
\Lag3^tm1Doi/\Lag3^tm1Doi (involves: 129S2/SvPas * C57BL/6)	abnormal NK cell physiology	J:32509
	abnormal T cell physiology	J:89653
	enlarged spleen	J:89653
	increased CD4-positive, alpha-beta T cell number	J:89653
	increased CD8-positive, alpha-beta T cell number	J:89653
	increased single-positive T cell number	J:89653
\Lage3^em1(IMPC)Tcp/\Lage3^em1(IMPC)Tcp (C57BL/6N-Lage3^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
\Lair1^tm1.1Jco/\Lair1^tm1.1Jco (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:180203
	decreased CD8-positive, alpha-beta T cell number	J:180203
	decreased IgG1 level	J:180203
	decreased thymocyte number	J:180203
	increased activated T cell number	J:180203
	increased B cell number	J:180203
	increased CD4-positive, alpha-beta memory T cell number	J:180203
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:180203
	increased CD8-positive, alpha-beta memory T cell number	J:180203
	increased dendritic cell number	J:180203
	increased eosinophil cell number	J:180203
	increased marginal zone B cell number	J:180203
\Lair1^tm1Jco/\Lair1^tm1Jco \Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	decreased IgG2a level	J:180203
	decreased IgG2b level	J:180203
\Lama2^dy/\Lama2^dy (involves: 129P1/ReJ)	increased IgG level	J:102959
\Lama2^dy/\Lama2^dy (involves: 129P1/ReJ)	increased IgM level	J:102959
\Lama2^tm1Eeng/\Lama2^tm1Eeng (involves: 129S1/Sv)	myositis	J:170192
\Lama2^tm1Stk/\Lama2^tm1Stk (involves: 129P2/OlaHsd * BALB/c)	abnormal thymus corticomedullary boundary morphology	J:61802
	abnormal thymus physiology	J:61802
	decreased double-positive T cell number	J:61802
	decreased T cell number	J:61802
	thymus cortex hypoplasia	J:61802
\Lama3^tm1.1Grsb/\Lama3^tm1.1Grsb (involves: C57BL/6)	abnormal chemokine level	J:235712
	abnormal tumor necrosis factor level	J:235712
	increased alveolar macrophage number	J:235712
	lung inflammation	J:235712
\Lama3^tm1Arte/\Lama3^tm1Arte \Tg(KRT14-cre/ERT)20Efu/0 (involves: C57BL/6 * CD-1)	skin inflammation	J:240054
\Lama4^{tm1.1(KOMP)Vlcg}/\Lama4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Lama4^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
\Lama5^b2b2966.1Clo/\Lama5^b2b2966.1Clo (C57BL/6J-Lama5^b2b2966.1Clo)	thymus hypoplasia	J:175213
\Lama5^tm1Lsor/\Lama5^tm1Lsor \Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * SJL)	abnormal marginal zone B cell physiology	J:198783
	decreased marginal zone B cell number	J:198783
	decreased transitional stage T2 B cell number	J:198783
	increased B cell number	J:198783
	increased IgM level	J:198783
	increased transitional stage T1 B cell number	J:198783
\Lama5^tm2Jhm/\Lama5^tm1Jhm \Tg(NPHS2-cre)295Lbh/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL)	tubulointerstitial nephritis	J:185850
\Lamb2^tm1Jrs/\Lamb2^tm1Jrs (involves: 129S1/Sv * 129X1/SvJ)	glomerulonephritis	J:23783
\Lamc2^jeb/\Lamc2^jeb (129X1/SvJ-Lamc2^jeb)	ear inflammation	J:158873
\Lamp1^em1(IMPC)Mbp/\Lamp1^em1(IMPC)Mbp (C57BL/6N-Lamp1^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	small spleen	J:211773
\Lamp2^tm1Psa/\Lamp2^tm1Psa (either: (involves: 129P2/OlaHsd * 129/Sv * C57BL/6J) or (involves: 129P2/OlaHsd * 129/Sv))	abnormal thymus morphology	J:64151
	intermingled spleen red and white pulp	J:64151
\Lamp3^em1(IMPC)Tcp/\Lamp3^em1(IMPC)Tcp (C57BL/6N-Lamp3^em1(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
\Lamp3^em1Damme/\Lamp3^em1Damme (involves: C57BL/6N)	increased macrophage cell number	J:324174
\Lancl1^tm1.1Pfw/\Lancl1^tm1.1Pfw (involves: 129 * C57BL/6)	brain inflammation	J:214805
\Lancl2^{tm2a(KOMP)Wtsi}/\Lancl2^{tm2a(KOMP)Wtsi} (involves: C57BL/6N)	decreased macrophage cell number	J:250673
	decreased regulatory T cell number	J:250673
	decreased susceptibility to bacterial infection	J:250673
\Lancl2^{tm2c(KOMP)Wtsi}/\Lancl2^{tm2c(KOMP)Wtsi} \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: C57BL/6N)	decreased macrophage cell number	J:250673
	decreased regulatory T cell number	J:250673
	decreased susceptibility to bacterial infection	J:250673
\Lao1^tm1Oka/\Lao1^tm1Oka (involves: 129S2/SvPas * C57BL/6J)	abnormal interleukin level	J:260668
	increased susceptibility to bacterial infection	J:260668
	increased susceptibility to bacterial infection induced morbidity/mortality	J:260668
	mastitis	J:260668
\Lap3^tm1Klr/\Lap3^tm1Klr (involves: 129 * C57BL/6)	immune system phenotype	J:119392
\Laptm5^tm1Jow/\Laptm5^tm1Jow (C57BL/6-Laptm5^tm1Jow)	abnormal T cell activation	J:137841
	abnormal type IV hypersensitivity reaction	J:137841
	immune system phenotype	J:137841
	increased interleukin-2 secretion	J:137841
	increased T cell proliferation	J:137841
\Laq1^MRL/\Laq1^MRL (involves: C57BL/6 * MRL)	increased susceptibility to autoimmune disorder	J:45708
\Lar^SAMP1/? (involves: C57BL/10 * SAMP1)	abnormal humoral immune response	J:1953
\Large1^myd/\Large1^myd (MYD/Le-Os +/+ Large^myd/J)	myositis	J:5670
\Large1^myd/\Large1^myd (B6C3Fe a/a-Large1^myd/J)	myositis	J:27793
\Larp1^em1(IMPC)Mbp/\Larp1⁺ (C57BL/6N-Larp1^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Lat2^tm1Mal/\Lat2^tm1Mal (involves: 129S2/SvPas)	abnormal mast cell physiology	J:93950
\Lat2^tm1Mal/\Lat2^tm1Mal (B6.129S2-Lat2^tm1Mal)	increased anti-nuclear antigen antibody level	J:126321
\Lat2^tm1Mal/\Lat2^tm1Mal \Lime1^tm1.1Mal/\Lime1^tm1.1Mal (involves: 129 * C57BL/6)	increased anti-nuclear antigen antibody level	J:126321
\Lat2^tm1Wz/\Lat2^tm1Wz (involves: C57BL/6)	abnormal mast cell physiology	J:93951
\Lat2^tm1Wz/\Lat2^tm1Wz (B6.Cg-Lat2^tm1Wz)	abnormal CD8-positive, alpha-beta T cell physiology	J:116157
	abnormal cytokine secretion	J:116157
	abnormal T cell physiology	J:116157
	increased anti-double stranded DNA antibody level	J:116157
	increased autoantibody level	J:116157
	increased T cell proliferation	J:116157
	spleen hyperplasia	J:116157
\Lat2^tm1Wz/\Lat2^tm1Wz (Not Specified)	abnormal T cell physiology	J:181866
	decreased interleukin-12 secretion	J:181866
	increased circulating interleukin-6 level	J:181866
	increased circulating tumor necrosis factor level	J:181866
	increased interferon-gamma secretion	J:181866
	increased interleukin-10 secretion	J:181866
	increased mast cell degranulation	J:181866
	increased susceptibility to endotoxin shock	J:181866
\Lat2^tm2Wz/\Lat2^tm2Wz \Tg(Lck-cre)548Jxm/0 (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:116157
	enlarged spleen	J:116157
	increased activated T cell number	J:116157
	increased anti-double stranded DNA antibody level	J:116157
\Lat2^tm3.1Wz/\Lat2^tm3.1Wz (B6.Cg-Lat2^tm3.1Wz)	abnormal T cell physiology	J:181866
	enlarged spleen	J:181866
	immune system phenotype	J:181866
	increased interferon-gamma secretion	J:181866
	increased mast cell degranulation	J:181866
	increased memory T cell number	J:181866
	increased susceptibility to endotoxin shock	J:181866
\Lat^tm1.1Lov/\Lat^tm1.1Lov (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:116157, J:77099
	abnormal CD8-positive, alpha beta T cell morphology	J:77099
	abnormal cytokine secretion	J:77099
	abnormal double-negative T cell morphology	J:77099
	abnormal immunoglobulin level	J:77099
	abnormal lymph organ size	J:77099
	abnormal T cell differentiation	J:77099
	abnormal T cell physiology	J:77099
	decreased double-positive T cell number	J:77099
	decreased T cell proliferation	J:77099
	decreased thymocyte number	J:77099
	enlarged lymph nodes	J:116157, J:77099
	enlarged spleen	J:116157, J:77099
	increased activated T cell number	J:77099
	increased anti-double stranded DNA antibody level	J:116157
	increased anti-nuclear antigen antibody level	J:77099
	increased autoantibody level	J:77099
	increased IgE level	J:77099
	increased IgG1 level	J:77099
	increased IgM level	J:77099
	increased T cell proliferation	J:77099
	small thymus	J:77099
	spleen hyperplasia	J:116157
\Lat^tm1.1Lov/\Lat^tm1.1Lov \Lat2^tm1Wz/\Lat2^tm1Wz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:116157
	enlarged lymph nodes	J:116157
	enlarged spleen	J:116157
	increased anti-double stranded DNA antibody level	J:116157
	spleen hyperplasia	J:116157
\Lat^tm1.1Mal/\Lat^tm1.1Mal (involves: 129S2/SvPas)	abnormal B cell activation	J:77098
	abnormal gamma-delta T cell differentiation	J:77098
	abnormal immune serum protein physiology	J:77098
	abnormal immune system organ morphology	J:77098
	abnormal lymph node germinal center morphology	J:125722
	abnormal lymph node secondary follicle morphology	J:125722
	abnormal lymphocyte morphology	J:77098
	abnormal spleen periarteriolar lymphoid sheath morphology	J:125722
	abnormal T cell selection	J:77098
	abnormal T cell subpopulation ratio	J:77098
	abnormal T-helper 2 physiology	J:125722
	chronic inflammation	J:77098
	decreased double-positive T cell number	J:77098
	enlarged lymph nodes	J:77098
	enlarged spleen	J:77098
	glomerulonephritis	J:125722
	increased anti-chromatin antibody level	J:125722
	increased anti-erythrocyte antigen antibody level	J:125722
	increased anti-nuclear antigen antibody level	J:125722
	increased B cell number	J:77098
	increased CD4-positive, alpha-beta T cell number	J:125722, J:77098
	increased eosinophil cell number	J:77098
	increased IgE level	J:125722, J:77098
	increased IgG1 level	J:262891, J:125722, J:77098
	increased IgM level	J:125722
	increased inflammatory response	J:262891
	increased interferon-gamma secretion	J:77098
	increased interleukin-4 secretion	J:77098
	increased memory T cell number	J:77098
	increased plasma cell number	J:125722
	increased spleen germinal center number	J:125722
	increased spleen weight	J:262891
	increased susceptibility to autoimmune hemolytic anemia	J:125722
	increased T cell proliferation	J:77098
	increased T-helper 2 cell number	J:77098
	kidney inflammation	J:262891
	liver inflammation	J:125722
	lung inflammation	J:125722
	pancreas inflammation	J:262891
	phlebitis	J:262891
	salivary gland inflammation	J:262891
	spleen hyperplasia	J:77098
	thymus hypoplasia	J:77098
\Lat^tm1.1Mal/\Lat^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal T cell proliferation	J:131351
	abnormal T-helper 2 physiology	J:131351
\Lat^tm1.1Mal/\Lat^{tm6.1(HBEGF/EGFP)Mal} (involves: 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:151840
\Lat^tm1Bpay/\Lat^tm1Bpay (involves: 129S2/SvPas)	abnormal T cell differentiation	J:103904
	arrested T cell differentiation	J:103904
	decreased double-negative T cell number	J:103904
	decreased T cell number	J:103904
	decreased thymocyte number	J:103904
	immune system phenotype	J:103904
	small thymus	J:103904
\Lat^tm1Les/\Lat^tm1.1Wz (involves: C57BL/6)	abnormal effector T cell morphology	J:147946
\Lat^tm1Les/\Lat^tm1.1Wz \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal effector T cell morphology	J:147946
	abnormal T cell differentiation	J:147946
	abnormal T cell physiology	J:147946
	decreased CD4-positive, alpha-beta T cell number	J:147946
	decreased CD8-positive, alpha-beta T cell number	J:147946
	decreased regulatory T cell number	J:147946
	decreased thymocyte number	J:147946
	increased double-positive T cell number	J:147946
	increased gamma-delta T cell number	J:147946
	small thymus	J:147946
\Lat^tm1Les/\Lat^tm1.2Wz (involves: C57BL/6 * FVB/N)	absent T cells	J:147946
\Lat^tm1Les/\Lat^tm1.2Wz (involves: C57BL/6 * FVB/N)	arrested T cell differentiation	J:147946
\Lat^tm1Les/\Lat^tm1Les (Not Specified)	abnormal T cell morphology	J:54059
	arrested T cell differentiation	J:116964, J:54059
	decreased double-negative T cell number	J:54059
	decreased T cell number	J:54059
	decreased thymocyte number	J:54059
	small thymus	J:54059
\Lat^tm1Les/\Lat^tm1Les \Lat2^tm1Wz/\Lat2^tm1Wz (involves: C57BL/6)	abnormal mast cell physiology	J:93951
\Lat^tm1Les/\Lat^tm1Les \Lcp2^{tm5(Lat/Lcp2)Gak}/\Lcp2^{tm5(Lat/Lcp2)Gak} (involves: 129S1/Sv * 129X1/SvJ)	arrested T cell differentiation	J:147721
	decreased double-positive T cell number	J:147721
\Lat^tm1Les/\Lat^tm1Les \Tg(CD2-LAT2)1Wz/0 (Not Specified)	abnormal B cell physiology	J:116964
	abnormal interferon secretion	J:116964
	abnormal interleukin secretion	J:116964
	abnormal leukocyte physiology	J:116964
	abnormal single-positive T cell number	J:116964
	abnormal spleen periarteriolar lymphoid sheath morphology	J:116964
	abnormal T cell differentiation	J:116964
	decreased double-positive T cell number	J:116964
	enlarged spleen	J:116964
	increased IgG1 level	J:116964
	increased IgM level	J:116964
	increased interleukin-4 secretion	J:116964
	increased interleukin-10 secretion	J:116964
	small thymus	J:116964
	spleen hyperplasia	J:116964
\Lat^tm2.1Lov/\Lat^tm2.1Lov (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:77695
	decreased T cell number	J:77695
	small thymus	J:77695
\Lat^tm2.1Mal/\Lat^tm2.1Mal (involves: 129S2/SvPas)	abnormal B cell activation	J:94074
	abnormal B cell differentiation	J:94074
	abnormal gamma-delta T cell differentiation	J:94074
	abnormal immune system organ morphology	J:94074
	abnormal lymphocyte morphology	J:94074
	abnormal lymphopoiesis	J:94074
	abnormal mature gamma-delta T cell morphology	J:94074
	abnormal plasma cell morphology	J:94074
	abnormal spleen morphology	J:94074
	abnormal spleen periarteriolar lymphoid sheath morphology	J:94074
	abnormal spleen white pulp morphology	J:94074
	abnormal T cell activation	J:94074
	abnormal T-helper 2 cell morphology	J:94074
	abnormal thymocyte activation	J:94074
	absent CD4-positive, alpha-beta T cells	J:94074
	absent CD8-positive, alpha-beta T cells	J:94074
	arrested T cell differentiation	J:94074
	decreased double-positive T cell number	J:94074
	enlarged lymph nodes	J:94074
	enlarged spleen	J:94074
	increased B cell number	J:94074
	increased IgE level	J:94074
	increased IgG1 level	J:94074
	increased immunoglobulin level	J:94074
	increased interleukin-4 secretion	J:94074
	increased mature gamma-delta T cell number	J:94074
	thymus hypoplasia	J:94074
\Lat^tm2.1Mal/\Lat^tm2.1Mal \Lat2^tm1Mal/\Lat2^tm1Mal (involves: 129S2/SvPas)	abnormal mast cell physiology	J:93950
\Lat^tm3.1Mal/\Lat^tm3.1Mal (involves: 129S2/SvPas)	abnormal gamma-delta T cell differentiation	J:94074
	abnormal lymph node cell ratio	J:94074
	abnormal splenic cell ratio	J:94074
	abnormal thymocyte activation	J:94074
	abnormal thymus cell ratio	J:94074
	absent CD4-positive, alpha-beta T cells	J:94074
	absent CD8-positive, alpha-beta T cells	J:94074
	absent mature gamma-delta T cells	J:94074
	arrested T cell differentiation	J:94074
	decreased double-positive T cell number	J:94074
	decreased T cell number	J:94074
	increased T cell number	J:94074
\Lat^tm4.1Mal/\Lat^tm4.1Mal (involves: 129P2/OlaHsd)	abnormal gamma-delta T cell differentiation	J:94074
	abnormal lymph node cell ratio	J:94074
	abnormal lymphocyte morphology	J:94074
	abnormal splenic cell ratio	J:94074
	abnormal thymocyte activation	J:94074
	abnormal thymus cell ratio	J:94074
	absent CD4-positive, alpha-beta T cells	J:94074
	absent CD8-positive, alpha-beta T cells	J:94074
	absent mature gamma-delta T cells	J:94074
	arrested T cell differentiation	J:94074
	decreased double-positive T cell number	J:94074
	decreased T cell number	J:94074
\Lat^tm4.1Mal/\Lat^tm4.1Mal \Tg(LckF505)3073Rmp/? (involves: 129P2/OlaHsd C57BL/6 * DBA/2)	abnormal T-helper 2 physiology	J:151840
	increased CD4-positive, alpha-beta T cell number	J:151840
	increased IgE level	J:151840
	increased IgG1 level	J:151840
	increased interleukin-4 secretion	J:151840
	spleen hyperplasia	J:151840
\Lat^tm4.1Mal/\Lat^tm4.1Mal \Trdc^tm1Mal/\Trdc^tm1Mal (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:112658
\Lat^tm4.1Mal/\Lat^{tm6.1(HBEGF/EGFP)Mal} (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal T-helper 2 physiology	J:151840
\Lat^tm5.1Mal/\Lat^tm5.1Mal (involves: C57BL/6)	arrested T cell differentiation	J:152363
\Lat^{tm6.1(HBEGF/EGFP)Mal}/? \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraH-Y,TcrbH-Y)1Pas/? (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal T cell physiology	J:138401
\Lat^{tm6.1(HBEGF/EGFP)Mal}/\Lat^{tm6.1(HBEGF/EGFP)Mal} (involves: 129S2/SvPas * C57BL/6)	abnormal T cell activation	J:151840
	abnormal T-helper 2 physiology	J:151840
	decreased interferon-gamma secretion	J:151840
\Lat^{tm8.1(CD2,-ECFP)Mal}/\Lat^{tm8.1(CD2,-ECFP)Mal} (involves: 129S2/SvPas * C57BL/6)	abnormal lymphocyte morphology	J:152149
	abnormal T cell receptor delta chain V(D)J recombination	J:152149
	abnormal T cell receptor gamma chain V-J recombination	J:152149
	arrested T cell differentiation	J:152149
	increased double-negative T cell number	J:152149
\Lat^tm9Mal/\Lat^tm9Mal (involves: C57BL/6)	abnormal B cell number	J:205441
	abnormal immune system morphology	J:205441
	abnormal immune system physiology	J:205441
	abnormal lymphopoiesis	J:205441
	increased T-helper 2 cell number	J:205441
\Lat^tm9Mal/\Lat^tm9Mal \Carmil2^bas/\Carmil2^bas (involves: C3HeB/FeJ * C57BL/6)	immune system phenotype	J:205441
\Lax1^tm1Wz/\Lax1^tm1Wz (involves: C57BL/6)	abnormal B cell calcium ion homeostasis	J:98403
	abnormal B cell physiology	J:98403
	abnormal spleen germinal center morphology	J:98403
	abnormal splenic cell ratio	J:98403
	abnormal T cell activation	J:98403
	abnormal T cell physiology	J:98403
	increased IgE level	J:98403
	increased IgG1 level	J:98403
	increased IgG2a level	J:98403
\Layn^em1Romd/\Layn^em1Romd \Tg(Cd8a-cre,-GFP)1Yzo/0 (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:302853
	immune system phenotype	J:302853
\Lbca1^C57BL/6Igc/\Lbca1^C57BL/6Igc (involves: BALB/cIgc * C57BL/6Igc)	abnormal B cell activation	J:139348
	increased B cell proliferation	J:139348
\Lbca2^BALB/cIgc/\Lbca2^C57BL/6Igc (involves: BALB/cIgc * C57BL/6Igc)	abnormal B cell activation	J:139348
	increased B cell proliferation	J:139348
\Lbca2^C57BL/6Igc/\Lbca2^C57BL/6Igc (involves: BALB/cIgc * C57BL/6Igc)	abnormal B cell activation	J:139348
	increased B cell proliferation	J:139348
\Lbp^{tm1b(EUCOMM)Hmgu}/\Lbp^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lbp^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
	increased spleen weight	J:211773
\Lbp^tm1Buru/\Lbp^tm1Buru (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune serum protein physiology	J:44878
	decreased tumor necrosis factor secretion	J:44878
\Lbp^tm1Buru/\Lbp^tm1Buru (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	decreased susceptibility to type I hypersensitivity reaction	J:67090
\Lbp^tm1Buru/\Lbp^tm1Buru (B6.129-Lbp^tm1Buru)	abnormal acute inflammation	J:129411
	abnormal chemokine level	J:129411
	abnormal innate immunity	J:129411
	abnormal neutrophil physiology	J:129411
	abnormal tumor necrosis factor secretion	J:129411
\Lbp^tm1Jack/\Lbp^tm1Jack (involves: 129P2/OlaHsd * BALB/c)	increased susceptibility to bacterial infection	J:43514
\Lbr^em1(IMPC)Tcp/\Lbr^em1(IMPC)Tcp (C57BL/6N-Lbr^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Lbr^Gt(XE569)Byg/\Lbr^Gt(XE569)Byg (involves: 129P2/OlaHsd * C57BL/6Cr)	abnormal granulocyte differentiation	J:138854
	abnormal granulocyte morphology	J:138854
	abnormal lymphocyte morphology	J:138854
	abnormal neutrophil morphology	J:138854
	enlarged lymph nodes	J:138854
\Lbr^ic-2J/\Lbr^ic-2J (involves: A/J)	abnormal immune system cell morphology	J:80915
\Lbr^ic-3J/\Lbr^ic-3J (involves: A/J)	abnormal immune system cell morphology	J:80915
\Lbr^ic-J/\Lbr⁺ (C57BL/6J-Lbr^ic-J)	abnormal granulocyte morphology	J:80915
\Lbr^ic-J/\Lbr⁺ ((NZW/LacJ x C57BL/6J-Lbr^ic-J/J)F1)	abnormal neutrophil morphology	J:234168
	enlarged spleen	J:234168
	increased anti-chromatin antibody level	J:234168
	increased anti-nuclear antigen antibody level	J:234168
	increased autoantibody level	J:234168
	increased susceptibility to systemic lupus erythematosus	J:234168
\Lbr^ic-J/\Lbr⁺ \Tm7sf2^tm1Fdp/\Tm7sf2^tm1Fdp (involves: 129S4/SvJae * C57BL/6)	abnormal spleen morphology	J:143838
\Lbr^ic-J/\Lbr^ic-J (C57BL/6J-Lbr^ic-J)	abnormal eosinophil morphology	J:80915
	abnormal lymphocyte morphology	J:80915
	abnormal neutrophil morphology	J:80915
\Lbr^ic-J/\Lbr^ic-J (involves: 129S4/SvJae * C57BL/6)	abnormal neutrophil differentiation	J:143838
\Lbr^ic-J/\Lbr^ic-J (involves: 129S4/SvJae * C57BL/6)	abnormal spleen morphology	J:143838
\Lbr^ic-J/\Lbr^lym3 (C57BL/6-Lbr^ic-J/Lbr^lym3)	decreased leukocyte cell number	J:180355
\Lbr^ic-J/\Lbr^lym3 (C57BL/6-Lbr^ic-J/Lbr^lym3)	decreased lymphocyte cell number	J:180355
\Lbr^lym3/\Lbr⁺ (C57BL/6-Lbr^lym3)	abnormal neutrophil morphology	J:180355
\Lbr^lym3/\Lbr^lym3 (C57BL/6-Lbr^lym3)	abnormal B cell physiology	J:180355
	abnormal lymphocyte cell number	J:180355
	abnormal lymphocyte morphology	J:180355
	abnormal neutrophil morphology	J:180355
	abnormal T cell physiology	J:180355
	decreased B cell number	J:180355
	decreased CD4-positive, alpha-beta T cell number	J:180355
	decreased CD8-positive, alpha-beta T cell number	J:180355
	decreased leukocyte cell number	J:180355
	decreased lymphocyte cell number	J:180355
	decreased T cell number	J:180355
	decreased T cell proliferation	J:180355
	lymph node hypoplasia	J:180355
	spleen hypoplasia	J:180355
	thymus hypoplasia	J:180355
\Lbw2^NZB/BlScr/\Lbw2^NZB/BlScr (involves: NZB * NZW)	glomerulonephritis	J:45708
	increased anti-chromatin antibody level	J:98150
	increased autoantibody level	J:98150
	increased spleen weight	J:98150
\Lbw2^NZB/BlScr/\Lbw2^NZW/LacScr (involves: NZB * NZW)	glomerulonephritis	J:20991
	increased anti-chromatin antibody level	J:98150
	increased autoantibody level	J:98150
\Lbw2^NZW/LacScr/\Lbw2^NZW/LacScr (involves: NZB * NZW)	decreased autoantibody level	J:98150
	decreased IgG level	J:98150
	decreased IgM level	J:98150
\Lbw4^NZW/LacScr/? (involves: C57BL/6J * NZM2410/Aeg)	decreased immunoglobulin level	J:52863
\Lbw5^NZW/LacScr/\Lbw5^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
\Lbw5^NZW/LacScr/\Lbw5^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
\Lbw6^NZW/LacScr/\Lbw6^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
\Lbw7^NZB/BlScr/\Lbw7^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
\Lbw7^NZB/BlScr/\Lbw7^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to systemic lupus erythematosus	J:20991
\Lbw8^NZB/BlScr/\Lbw8^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to autoimmune disorder	J:20991
\Lbw8^NZB/BlScr/\Lbw8^NZW/LacScr (involves: NZB/BlScr * NZW/LacScr)	increased susceptibility to autoimmune disorder	J:20991
\Lck^m1Btlr/\Lck^m1Btlr (C57BL/6J-Lck^m1Btlr)	abnormal CD4-positive T cell differentiation	J:144695
	abnormal CD8-positive, alpha-beta T cell differentiation	J:144695
	decreased CD4-positive, alpha-beta T cell number	J:144695
	decreased CD8-positive, alpha-beta T cell number	J:144695
	decreased cytotoxic T cell cytolysis	J:144695
	thymus atrophy	J:144695
	thymus hypoplasia	J:144695
\Lck^m2Btlr/\Lck^m2Btlr (C57BL/6J-Lck^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:203759
	decreased CD8-positive, alpha-beta T cell number	J:203759
	decreased IgG level	J:203759
\Lck^m3Btlr/\Lck^m3Btlr (C57BL/6J-Lck^m3Btlr)	abnormal T cell subpopulation ratio	J:217863
	decreased single-positive T cell number	J:217863
	increased activated T cell number	J:217863
	increased single-positive T cell number	J:217863
\Lck^tm1.1Litt/\Lck^tm1.1Litt (Not Specified)	abnormal immunoglobulin level	J:152472
	abnormal lymphocyte morphology	J:152472
	abnormal thymus morphology	J:152472
\Lck^tm1Dbs/\Lck^tm1Dbs (involves: C3H * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:114660
	abnormal CD8-positive, alpha beta T cell morphology	J:114660
	abnormal double-negative T cell morphology	J:114660
	abnormal T cell differentiation	J:114660
	decreased T cell number	J:114660
	decreased T cell proliferation	J:114660
	decreased thymocyte number	J:114660
\Lck^tm1Dbs/\Lck^tm1Dbs \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C3H * C57BL/6 * DBA/2J)	abnormal positive T cell selection	J:114660
	abnormal T cell differentiation	J:114660
	arrested T cell differentiation	J:114660
\Lck^tm1Dbs/\Lck^tm1Dbs \Tg(TcraTcrb)425Cbn/0 (involves: C3H * C57BL/6)	abnormal positive T cell selection	J:114660
	arrested T cell differentiation	J:114660
\Lck^tm1Dbs/\Lck^tm1Dbs \Tg(TcraTcrb)1100Mjb/0 (involves: C3H * C57BL/6)	abnormal positive T cell selection	J:114660
	decreased T cell proliferation	J:114660
\Lck^tm1Litt/\Lck^tm1.1Litt \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129X1/SvJ)	abnormal regulatory T cell physiology	J:152472
	decreased regulatory T cell number	J:152472
	decreased T cell proliferation	J:152472
	enlarged lymph nodes	J:152472
	increased regulatory T cell number	J:152472
	increased T cell number	J:152472
\Lck^tm1Mak/\Lck^tm1Mak (involves: 129S2/SvPas)	abnormal alpha-beta intraepithelial T cell morphology	J:112977
	abnormal double-negative T cell morphology	J:110847
	abnormal lymphocyte morphology	J:1119
	abnormal single-positive T cell number	J:37062
	abnormal T cell morphology	J:110847
	abnormal thymocyte activation	J:110847
	decreased CD4-positive, alpha-beta T cell number	J:37940
	decreased CD8-positive, alpha-beta T cell number	J:37940
	decreased double-positive T cell number	J:1119, J:110847
	decreased gamma-delta intraepithelial T cell number	J:112977, J:37940
	decreased gamma-delta T cell number	J:37062
	decreased IgG1 level	J:1119
	decreased T cell number	J:1119, J:37062
	decreased thymocyte number	J:1119
	increased IgG2a level	J:1119
	increased IgG3 level	J:1119
	increased IgM level	J:1119
	thymus atrophy	J:1119
	thymus hypoplasia	J:37062, J:37940
\Lck^tm1Mak/\Lck^tm1Mak (B6.129S2-Lck^tm1Mak)	abnormal intraepithelial T cell morphology	J:111646
	abnormal intraepithelial T cell number	J:111646
	abnormal T cell differentiation	J:111646
	decreased cytotoxic T cell cytolysis	J:111646
	decreased gamma-delta intraepithelial T cell number	J:111646
\Lck^tm1Mak/\Lck^tm1Mak \Rag1^tm1Mom/\Rag1⁺ \Tg(Lck-FynY528F)5525Cjg/0 (involves: 129S2/SvPas 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:37062
	decreased T cell number	J:37062
\Lcmt1^{em1(IMPC)Rbrc}/\Lcmt1⁺ (C57BL/6NJcl-Lcmt1^{em1(IMPC)Rbrc}/Rbrc)	increased large unstained cell number	J:211773
	increased spleen weight	J:211773
\Lcn2^tm1Aade/\Lcn2^tm1Aade (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to bacterial infection	J:95107
	sepsis	J:95107
\Lcn2^tm1Aade/\Lcn2^tm1Aade (B6.129P2-Lcn2^tm1Aade)	increased spleen weight	J:169355
\Lcn2^tm1Mak/\Lcn2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to bacterial infection	J:106079
\Lcn2^tm1Mrgr/\Lcn2^tm1Mrgr (129(B6)-Lcn2^tm1Mrgr)	abnormal mast cell physiology	J:173490
	abnormal myelopoiesis	J:173490
	decreased thymocyte apoptosis	J:173490
	increased B cell number	J:173490
	increased leukocyte cell number	J:173490
	increased lymphocyte cell number	J:173490
	increased macrophage cell number	J:173490
	increased monocyte cell number	J:173490
	increased neutrophil cell number	J:173490
	increased splenocyte number	J:173490
	myeloid hyperplasia	J:173490
	spleen hyperplasia	J:173490
	thymus hyperplasia	J:173490
\Lcn2^tm1Mrgr/\Lcn2^tm1Mrgr (B6.129-Lcn2^tm1Mrgr)	abnormal mast cell physiology	J:173490
\Lcn2^tm1Mrgr/\Lcn2^tm1Mrgr (involves: 129 * C57BL/6)	abnormal mast cell physiology	J:173490
\Lcn10^{tm1.1(KOMP)Vlcg}/\Lcn10^{tm1.1(KOMP)Vlcg} (C57BL/6N-Lcn10^{tm1.1(KOMP)Vlcg}/MbpMmucd)	increased susceptibility to endotoxin shock	J:359002
\Lcp1^tm1Erjb/\Lcp1^tm1Erjb (involves: 129X1/SvJ)	abnormal macrophage physiology	J:161042
	abnormal neutrophil physiology	J:161042
	decreased interleukin-1 secretion	J:161042
	immune system phenotype	J:161042
	increased susceptibility to bacterial infection	J:161042
\Lcp2^m1Khoe/\Lcp2^m1Khoe (C57BL/6J-Lcp2^m1Khoe)	abnormal NK cell physiology	J:196519
\Lcp2^m1Khoe/\Lcp2^m1Khoe (C57BL/6J-Lcp2^m1Khoe)	impaired natural killer cell mediated cytotoxicity	J:196519
\Lcp2^tm1.1Wz/\Lcp2^tm1.1Wz (B6.Cg-Lcp2^tm1.1Wz)	abnormal effector T cell morphology	J:150304
	abnormal T cell differentiation	J:150304
	abnormal T cell subpopulation ratio	J:150304
	decreased CD4-positive, alpha-beta T cell number	J:150304
	decreased CD8-positive, alpha-beta T cell number	J:150304
	decreased double-negative T cell number	J:150304
	decreased interleukin-2 secretion	J:150304
	decreased T cell number	J:150304
	decreased T cell proliferation	J:150304
	decreased thymocyte number	J:150304
	immune system phenotype	J:150304
	increased double-negative T cell number	J:150304
	lymph node hypoplasia	J:150304
	small thymus	J:150304
\Lcp2^tm1.1Wz/\Lcp2^tm1.1Wz \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:150304
\Lcp2^tm1Gak/\Lcp2^tm2Gak \Tg(Pf4-icre)Q3Rsko/0 \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphatic vessel morphology	J:162815
	abnormal Peyer's patch morphology	J:162815
\Lcp2^tm1Gak/\Lcp2^tm2Gak \Tg(VAV1-cre)1Graf/0 \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphatic vessel morphology	J:162815
\Lcp2^tm1Geha/\Lcp2^tm1Geha (involves: 129S4/SvJae)	decreased interferon-gamma secretion	J:131621
	impaired natural killer cell mediated cytotoxicity	J:131621
	increased NK cell number	J:131621
\Lcp2^tm2Gak/\Lcp2^tm2Gak \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:107467
	decreased T cell apoptosis	J:107467
	increased CD8-positive, alpha-beta T cell number	J:107467
	increased gamma-delta T cell number	J:107467
	thymus hypoplasia	J:107467
\Lcp2^tm3Gak/\Lcp2^tm3Gak (involves: 129S6/SvEvTac * C57BL/6)	abnormal double-negative T cell morphology	J:132995
	abnormal negative T cell selection	J:132995
	abnormal T cell activation	J:132995
	abnormal T cell subpopulation ratio	J:132995
	decreased NK T cell number	J:132995
\Lcp2^tm3Gak/\Lcp2^tm3Gak (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal negative T cell selection	J:132995
\Lcp2^tm3Gak/\Lcp2^tm3Gak \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S6/SvEvTac * C57BL/6 * DBA/2J)	abnormal negative T cell selection	J:132995
	immune system phenotype	J:132995
	increased CD8-positive, alpha-beta T cell number	J:132995
	increased double-positive T cell number	J:132995
\Lcp2^tm3Gak/\Lcp2^tm3Gak \Tg(TcrAND)53Hed/? (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal positive T cell selection	J:132995
	abnormal thymocyte activation	J:132995
\Lcp2^tm3Gak/\Lcp2^tm4Gak (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	immune system phenotype	J:132995
\Lcp2^tm4Gak/\Lcp2^tm4Gak (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal double-negative T cell morphology	J:132995
	abnormal negative T cell selection	J:132995
	abnormal T cell activation	J:132995
	abnormal T cell subpopulation ratio	J:132995
	decreased NK T cell number	J:132995
\Lcp2^tm4Gak/\Lcp2^tm4Gak (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal negative T cell selection	J:132995
\Lcp2^tm4Gak/\Lcp2^tm4Gak \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S6/SvEvTac * C57BL/6 * DBA * FVB/N)	abnormal negative T cell selection	J:132995
	increased double-positive T cell number	J:132995
\Lcp2^tm4Gak/\Lcp2^tm4Gak \Tg(TcrAND)53Hed/? (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal positive T cell selection	J:132995
	abnormal thymocyte activation	J:132995
\Lcp2^{tm5(Lat/Lcp2)Gak}/\Lcp2^{tm5(Lat/Lcp2)Gak} (involves: 129S1/Sv * 129X1/SvJ)	abnormal thymocyte activation	J:147721
	arrested T cell differentiation	J:147721
	decreased double-positive T cell number	J:147721
	decreased single-positive T cell number	J:147721
	thymus hypoplasia	J:147721
\Lcp2^twm/\Lcp2^twm (C57BL/6JSfdAnu-Lcp2^twm/Anu)	abnormal double-positive T cell morphology	J:104190
	abnormal negative T cell selection	J:104190
	abnormal positive T cell selection	J:104190
	abnormal T cell physiology	J:104190
	arrested T cell differentiation	J:104190
	autoimmune response	J:104190
	decreased T cell number	J:104190
	decreased thymocyte number	J:104190
	increased IgE level	J:104190
	increased IgG level	J:104190
\Lctlp1^DBA/1J/\Lctlp1^DBA/1J (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
\Lctlp1^DBA/1J/\Lctlp1^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
\Lctlp1^FVB/NJ/\Lctlp1^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:122919
\Lctlp2^DBA/1J/\Lctlp2^DBA/1J (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
\Lctlp2^DBA/1J/\Lctlp2^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased CD8-positive, alpha-beta T cell number	J:122919
\Lctlp2^FVB/NJ/\Lctlp2^FVB/NJ (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:122919
\Ldb3^{tm2b(EUCOMM)Hmgu}/\Ldb3⁺ (C57BL/6N-Ldb3^{tm2b(EUCOMM)Hmgu}/Bay)	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
\Ldha^a-m1Neu/\Ldha^a-m1Neu (involves: 101/El * C3H/El)	abnormal leukocyte morphology	J:132674
	increased neutrophil cell number	J:132674
	increased spleen weight	J:132674
	spleen hyperplasia	J:132674
\Ldlr^Hlb301/\Ldlr⁺ (C57BL/6J-Ldlr^Hlb301/J)	increased macrophage derived foam cell number	J:82961
\Ldlr^Hlb301/\Ldlr^Hlb301 (C57BL/6J-Ldlr^Hlb301/J)	increased macrophage derived foam cell number	J:82961
\Ldlr^tm1Her/\Ldlr^tm1Her (involves: 129S7/SvEvBrd * C57BL/6)	abnormal microglial cell morphology	J:116493
	liver inflammation	J:175559
\Ldlr^tm1Her/\Ldlr^tm1Her (B6.129S7-Ldlr^tm1Her)	abnormal microglial cell morphology	J:137264
	decreased circulating interleukin-10 level	J:130794
	increased circulating interleukin-1 beta level	J:137264
	increased circulating interleukin-6 level	J:137264
	increased circulating tumor necrosis factor level	J:137264
\Ldlr^tm1Her/\Ldlr^tm1Her \Lrp1^tm2Her/\Lrp1^tm2Her \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	impaired macrophage phagocytosis	J:137404
\Ldlr^tm1Her/\Ldlr^tm1Her \Lrp1^tm2Her/\Lrp1^tm2Her \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)	abnormal microglial cell physiology	J:144185
\Ldlr^tm1Her/\Ldlr^tm1Her \Mapkapk2^tm1Mgl/\Mapkapk2^tm1Mgl (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal macrophage derived foam cell morphology	J:142788
	decreased macrophage cell number	J:142788
\Ldlr^tm1Her/\Ldlr^tm1Her \Olr1^tm1Meht/\Olr1^tm1Meht (involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)	increased circulating interleukin-10 level	J:130794
\Ldlr^tm1Her/\Ldlr^tm1Her \Pfn1^tm1Wit/\Pfn1⁺ (B6.129S-Ldlr^tm1Her Pfn1^tm1Wit)	impaired macrophage chemotaxis	J:140294
\Ldlr^tm1Her/\Ldlr^tm1Her \Soat1^tm1Far/\Soat1^tm1Far (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J)	skin inflammation	J:61147
\Ldlr^tm1Her/\Ldlr^tm1Her \Tbx21^tm1Glm/\Tbx21^tm1Glm (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	abnormal interleukin secretion	J:96110
	decreased IgG level	J:96110
	decreased interferon-gamma secretion	J:96110
	increased IgM level	J:96110
\Ldlr^tm1Her/\Ldlr^tm1Her \Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (B6.129-Ldlr^tm1Her Tcra-J^tm1Tgi)	decreased interferon-gamma secretion	J:140276
\Ldlr^tm1Her/\Ldlr^tm1Her \Tg(H2-K-AKR1B1)1Tj/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	abnormal macrophage physiology	J:100916
\Ldlr^tm1Her/\Ldlr^tm1Her \Tlr2^tm1Kir/\Tlr2^tm1Kir (B6.129-Tlr2^tm1Kir Ldlr^tm1Her)	abnormal cellular extravasation	J:131783
	decreased tumor necrosis factor secretion	J:131783
\Ldlr^tm1Her/\Ldlr^tm1Her \Vwf^tm1Wgr/\Vwf^tm1Wgr (B6.129S-Vwf^tm1Wgr Ldlr^tm1Her)	impaired leukocyte tethering or rolling	J:106677
\Ldlrad3^em1Diam/\Ldlrad3^em1Diam (C57BL/6-Ldlrad3^em1Diam)	decreased susceptibility to Togaviridae infection	J:300132
\Ldlrad3^em1Diam/\Ldlrad3^em2Diam (C57BL/6-Ldlrad3^em1Diam Ldlrad3^em2Diam)	decreased susceptibility to Togaviridae infection	J:300132
\Ldlrad3^em2Diam/\Ldlrad3^em2Diam (C57BL/6-Ldlrad3^em2Diam)	decreased susceptibility to Togaviridae infection	J:300132
\Ldlrad4^{tm1b(EUCOMM)Wtsi}/\Ldlrad4^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ldlrad4^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased monocyte cell number	J:211773
\Lect2^tm1Ymg/\Lect2^tm1Ymg (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine secretion	J:90961
	abnormal leukocyte physiology	J:90961
	increased T cell apoptosis	J:90961
	increased T cell number	J:90961
	liver inflammation	J:90961
\Lef1^{tm1.1(KOMP)Vlcg}/\Lef1⁺ (C57BL/6N-Lef1^{tm1.1(KOMP)Vlcg}/Ucd)	increased monocyte cell number	J:211773
\Lef1^tm1Hhx/\Lef1^tm1Hhx \Tcf7^tm1Cle/\Tcf7^tm1Cle \Gt(ROSA)26Sor^tm2Sho/\Gt(ROSA)26Sor⁺ \Tg(GZMB-cre)1Jcb/0 (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal memory T cell physiology	J:189838
	decreased CD8-positive, alpha-beta T cell number	J:189838
	decreased tumor necrosis factor secretion	J:189838
\Lef1^tm1Rug/\Lef1^tm1Rug (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:18378
\Lefty2^tm2Hmd/\Lefty2^tm2Hmd (involves: 129P2/OlaHsd * C57BL/6)	accessory spleen	J:70483
\Lemd2^em1(IMPC)Bay/\Lemd2⁺ (C57BL/6N-Lemd2^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Lep^m1Yst/\Lep^m1Yst (C57BL/6J-Lep^m1Yst)	increased macrophage cell number	J:167736
\Lep^ob/\Lep^ob (involves: C57BL/6J)	abnormal osteoclast differentiation	J:60001
\Lep^ob/\Lep^ob (B6.Cg-Lep^ob/J)	decreased NK cell number	J:117826
\Lep^ob/\Lep^ob (B6.Cg-Lep^ob/J)	lung inflammation	J:115772
\Lep^ob/\Lep^ob (B6.Cg-Lep^ob/OlaHsd)	abnormal acute inflammation	J:124815
	abnormal chemokine secretion	J:124815
	increased interleukin-6 secretion	J:124815
	increased susceptibility to endotoxin shock	J:124815
	liver inflammation	J:124815
\Lep^ob/\Lep^ob (involves: STOCK Mlph^ln a Tgfa^wa1 Cdh23^v Ednrb^s)	abnormal microglial cell physiology	J:115569
	decreased circulating tumor necrosis factor level	J:115569
\Lep^ob/\Lep^ob (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:164339
	decreased splenocyte number	J:164339
	decreased T cell proliferation	J:164339
\Lep^ob/\Lep^ob (B6.Cg-Lep^ob/JRj)	liver inflammation	J:277927
\Lep^ob/\Lep^ob \Serpine1^tm1Mlg/\Serpine1^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal tumor necrosis factor level	J:70695
\Lep^{tm1b(EUCOMM)Hmgu}/\Lep^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lep^{tm1b(EUCOMM)Hmgu}/Bay)	decreased spleen weight	J:211773
\Lepr^db-5J/\Lepr^db-5J (NOD/ShiLt-Lepr^db-5J)	abnormal CD4-positive, alpha beta T cell morphology	J:118304
	abnormal CD8-positive, alpha beta T cell morphology	J:118304
	pancreas inflammation	J:118305
	periinsulitis	J:118305
\Lepr^db-lb/\Lepr^db-lb (C57BL/6NCrl-Lepr^db-lb/Crl)	white adipose tissue inflammation	J:171755
\Lepr^db-Pas/\Lepr^db-Pas (involves: DW/Pas)	enlarged spleen	J:174584
\Lepr^db/\Lepr^db (involves: C57BLKS/J)	increased susceptibility to autoimmune diabetes	J:7005
\Lepr^db/\Lepr^db (B6.Cg-Dock7^m +/+ Lepr^db/J)	abnormal chemokine level	J:115772
	abnormal interleukin level	J:115772
	abnormal leukocyte morphology	J:115772
	decreased leukocyte cell number	J:115772
	increased circulating interleukin-6 level	J:115772
	increased neutrophil cell number	J:115772
	lung inflammation	J:115772
\Lepr^db/\Lepr^db (BKS.Cg-Dock7^m +/+ Lepr^db/OlaHsd)	abnormal acute inflammation	J:124815
	abnormal chemokine secretion	J:124815
	increased interleukin-6 secretion	J:124815
	increased susceptibility to endotoxin shock	J:124815
	liver inflammation	J:124815
\Lepr^db/\Lepr^db (involves: C57BL/6)	abnormal osteoclast differentiation	J:60001
\Lepr^db/\Lepr^db (B6.BKS(D)-Lepr^db/JOrlRj)	liver inflammation	J:277927
\Lepr^db/\Lepr^db (BKS.Cg-Dock7^m +/+ Lepr^db)	kidney inflammation	J:346348
\Lepr^m7Btlr/\Lepr^m7Btlr (C57BL/6J-Lepr^m7Btlr)	decreased response to antigen	J:236685
\Lepr^m7Btlr/\Lepr^m7Btlr (C57BL/6J-Lepr^m7Btlr)	increased IgE level	J:236685
\Lepr^m8Btlr/\Lepr^m8Btlr (C57BL/6J-Lepr^m8Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:267679
	increased effector memory CD4-positive, alpha-beta T cell number	J:267679
	increased effector memory CD8-positive, alpha-beta T cell number	J:267679
\Lepr^tm1.1Rll/\Lepr⁺ (129P3/J-Lepr^tm1.1Rll)	increased susceptibility to parasitic infection	J:172012
\Lepr^tm1.1Rll/\Lepr^tm1.1Rll (129P3/J-Lepr^tm1.1Rll)	increased susceptibility to parasitic infection	J:172012
\Lepr^{tm1b(EUCOMM)Wtsi}/\Lepr^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Lepr^{tm1b(EUCOMM)Wtsi}/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Lepr^tm4Mgmj/\Lepr^tm4Mgmj (B6.Cg-Lepr^tm4Mgmj)	decreased CD4-positive, alpha-beta T cell number	J:164339
	decreased splenocyte number	J:164339
	decreased T cell proliferation	J:164339
\Leprot^tm1.2Damj/\Leprot^tm1.2Damj (involves: 129S2/SvPas * C57BL/6N * FVB/N)	decreased cytokine level	J:349250
	decreased inflammatory response	J:349250
\Lgals1^tm1Rob/\Lgals1^tm1Rob (involves: 129S/SvEv)	increased interferon-gamma secretion	J:123416
	increased interleukin-2 secretion	J:123416
	increased susceptibility to experimental autoimmune encephalomyelitis	J:123416
\Lgals1^tm1Rob/\Lgals1^tm1Rob (involves: 129S/SvEv * 129S1/SvImJ * DBA/2J)	abnormal cytokine secretion	J:130208
\Lgals2^tm1.1Cfg/\Lgals2^tm1.1Cfg (involves: C57BL/6)	abnormal immune system physiology	J:217719
	decreased neutrophil cell number	J:217719
	enhanced humoral immune response	J:217719
	increased CD4-positive, alpha-beta T cell number	J:217719
	increased CD8-positive, alpha-beta T cell number	J:217719
	increased IgG2b level	J:217719
	increased IgG3 level	J:217719
	increased leukocyte cell number	J:217719
	increased lymphocyte cell number	J:217719
	increased spleen red pulp amount	J:217719
	increased susceptibility to type IV hypersensitivity reaction	J:217719
	increased T cell number	J:217719
\Lgals3^tm1Ftl/\Lgals3^tm1Ftl (B6.129S2-Lgals3^tm1Ftl)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:109126
	abnormal dendritic cell physiology	J:109126
	abnormal interferon secretion	J:109126
	abnormal response to infection	J:109126
	brain inflammation	J:109126
	decreased macrophage cell number	J:109126
	increased IgG level	J:109126
	increased interleukin-12b secretion	J:109126
	increased susceptibility to parasitic infection	J:109126
	lung inflammation	J:109126
	small intestinal inflammation	J:109126
\Lgals3^tm1Ftl/\Lgals3^tm1Ftl (involves: 129S2/SvPas * C57BL/6)	abnormal leukocyte physiology	J:60741
	abnormal macrophage physiology	J:60741
	abnormal monocyte morphology	J:60741
	decreased lymphocyte cell number	J:60741
	decreased macrophage cell number	J:313172, J:60741
	decreased monocyte cell number	J:60741
	increased eosinophil cell number	J:60741
	increased macrophage apoptosis	J:60741
	peritoneal inflammation	J:60741
\Lgals3^tm1Ftl/\Lgals3^tm1Ftl (involves: 129S2/SvPas * CD-1)	liver inflammation	J:221030
\Lgals3^tm1Poi/\Lgals3^tm1Poi (involves: 129/Sv * C57BL/6 * SJL)	abnormal macrophage physiology	J:131971
	impaired macrophage chemotaxis	J:131971
	impaired macrophage phagocytosis	J:131407
	impaired neutrophil recruitment	J:131407
	increased interleukin-6 secretion	J:131407
	increased susceptibility to bacterial infection	J:131407
	increased tumor necrosis factor secretion	J:131407
	lung inflammation	J:131407
	sepsis	J:131407
\Lgals3^tm1Poi/\Lgals3^tm1Poi (involves: 129/Sv * C57BL/6 * MF1 * SJL)	decreased granulocyte number	J:110422
\Lgals3bp^tm1Megt/\Lgals3bp^tm1Megt (involves: 129P2/OlaHsd * C57BL/Ka)	increased circulating interferon-gamma level	J:94936
	increased circulating interleukin-12 level	J:94936
	increased susceptibility to endotoxin shock	J:94936
	increased tumor necrosis factor secretion	J:94936
\Lgals8^{tm1(KOMP)Vlcg}/\Lgals8^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal lymphangiogenesis	J:235778
	decreased susceptibility to Herpesvirales infection	J:235778
\Lgals9^tm1.1Cfg/\Lgals9^tm1.1Cfg (involves: C57BL/6)	abnormal lymph node germinal center morphology	J:217719
	abnormal Peyer's patch morphology	J:217719
	enhanced humoral immune response	J:217719
	increased B cell proliferation	J:217719
	increased lymphocyte cell number	J:217719
	increased neutrophil cell number	J:217719
	increased spleen germinal center size	J:217719
	lymph node hyperplasia	J:217719
	spleen hyperplasia	J:217719
	thymus hyperplasia	J:217719
\Lgals9^tm1Glp/\Lgals9^tm1Glp (B6.129S6-Lgals9^tm1Glp)	decreased regulatory T cell number	J:132889
	increased susceptibility to induced arthritis	J:132889
	increased T-helper 1 cell number	J:132889
\Lgmn^tm1Cptr/\Lgmn^tm1Cptr (B6.129S6-Lgmn^tm1Cptr)	abnormal adaptive immunity	J:155339
	decreased interleukin-6 secretion	J:155339
	decreased interleukin-12b secretion	J:155339
	decreased tumor necrosis factor secretion	J:155339
	enlarged spleen	J:172774
\Lgmn^tm1Ihn/\Lgmn^tm1Ihn (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:143886
	abnormal NK cell physiology	J:143886
	dark spleen	J:143886
	immune system phenotype	J:143886
	increased circulating tumor necrosis factor level	J:143886
	increased lymphocyte cell number	J:143886
	increased spleen weight	J:143886
\lgr/\lgr (Not Specified)	eye inflammation	J:13879
\Lgr4^{Gt(LST020)Byg}/\Lgr4^{Gt(LST020)Byg} (involves: 129P2/OlaHsd * C57BL/6)	increased incidence of corneal inflammation	J:134299
\Lgr5^{em1(IMPC)Kmpc}/\Lgr5⁺ (C57BL/6NTac-Lgr5^{em1(IMPC)Kmpc}/Kmpc)	increased CD8-positive, CD25-positive alpha-beta T cell number	J:211773
	increased CD11b-high dendritic cell number	J:211773
\Lgr6^{em1(IMPC)Ccpcz}/\Lgr6^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Lgr6^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased lymphocyte cell number	J:211773
\Lhcgr^{tm1(KOMP)Vlcg}/\Lhcgr^{tm1(KOMP)Vlcg} (C57BL/6N-Lhcgr^{tm1(KOMP)Vlcg}/Nju)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	small spleen	J:211773
	small thymus	J:211773
\Lhcgr^tm1Hht/\Lhcgr^tm1Hht (involves: 129S7/SvEvBrd * C57BL/6J)	enlarged spleen	J:105533
	epididymis inflammation	J:105533
	prostate gland inflammation	J:105533
	reproductive system inflammation	J:105533
\Lhx5^{em1(IMPC)Ccpcz}/\Lhx5⁺ (C57BL/6N-Lhx5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased leukocyte cell number	J:211773
\Lif^tm1Cgre/\Lif^tm1Cgre (involves: MF1)	abnormal macrophage morphology	J:96965
	increased eosinophil cell number	J:96965
	increased uterine NK cell number	J:96965
\Lif^tm1Phb/\Lif⁺ (involves: 129S2/SvPas * C57BL/6 * DBA/2)	decreased T cell proliferation	J:77410
\Lif^tm1Phb/\Lif^tm1Phb (involves: 129S2/SvPas * C57BL/6 * DBA/2)	decreased T cell proliferation	J:77410
\Lif^tm1Stw/\Lif^tm1Stw (involves: 129S1/Sv * C57BL/6)	increased acute inflammation	J:119777
\Lif^tm1Stw/\Lif^tm1Stw (involves: 129S1/Sv * C57BL/6)	increased circulating interleukin-1 beta level	J:119777
\Lif^tm1Stw/\Lif^tm1Stw (involves: 129S1/Sv * BALB/c)	decreased interleukin-10 secretion	J:136940
	decreased leukocyte cell number	J:136940
	increased circulating interleukin-6 level	J:136940
	increased circulating serum amyloid protein level	J:136940
	increased circulating tumor necrosis factor level	J:136940
	increased susceptibility to bacterial infection induced morbidity/mortality	J:136940
	increased susceptibility to endotoxin shock	J:136940
\Lif^tm1Stw/\Lif^tm1Stw (involves: 129S1/Sv * MF1)	abnormal osteoclast differentiation	J:137646
	abnormal osteoclast morphology	J:137646
	abnormal osteoclast physiology	J:137646
	increased osteoclast cell number	J:137646
\Lifr^tm1Imx/\Lifr^tm1Imx (involves: 129P3/J * 129S7/SvEvBrd * C57BL/6)	increased osteoclast cell number	J:25253
\Lig1^tm1Dwm/\Lig1^tm1Dwm (involves: 129P2/OlaHsd)	enlarged spleen	J:75962
\Lig1^tm3Dwm/\Lig1^tm3Dwm (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen physiology	J:77902
	abnormal thymus physiology	J:77902
	enlarged spleen	J:77902
\Lig4^{em1(IMPC)Ccpcz}/\Lig4⁺ (C57BL/6NCrl-Lig4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Lig4^m1Btlr/\Lig4^m1Btlr (C57BL/6J-Lig4^m1Btlr)	decreased B cell number	J:267684
	decreased CD4-positive, alpha-beta T cell number	J:267684
	decreased CD8-positive, naive alpha-beta T cell number	J:267684
	decreased IgD level	J:267684
	decreased IgG level	J:267684
	impaired humoral immune response	J:267684
	increased CD8-positive, alpha-beta T cell number	J:267684
	increased central memory CD8 positive, alpha-beta T cell number	J:267684
	increased effector memory CD4-positive, alpha-beta T cell number	J:267684
	increased NK cell number	J:267684
\Lig4^m2Btlr/\Lig4^m2Btlr (C57BL/6J-Lig4^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:267692
\Lig4^m2Btlr/\Lig4^m2Btlr (C57BL/6J-Lig4^m2Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:267692
\Lig4^tiny/\Lig4^tiny (C57BL/6-Lig4^tiny)	absent CD8-positive, alpha-beta T cells	J:104190
	decreased B cell number	J:122725
	decreased lymphocyte cell number	J:122725
\Lig4^tm1Fwa/\Lig4^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:50865
	abnormal lymphopoiesis	J:50865
	abnormal T cell differentiation	J:63078
	arrested B cell differentiation	J:63078
	arrested T cell differentiation	J:50865
	decreased thymocyte number	J:63078
	small thymus	J:50865
\Lig4^tm1Fwa/\Lig4^tm1Fwa \Tg(Cr2-cre)3Cgn/0 \Xrcc4^tm2Fwa/\Xrcc4^tm2Fwa (involves: 129S6/SvEvTac)	abnormal class switch recombination	J:126758
\Lig4^tm1Fwa/\Lig4^tm1Fwa \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S6/SvEvTac * 129S7/SvEvBrd)	decreased thymocyte number	J:63078
	increased B cell number	J:63078
\Lig4^tm2.1Fwa/\Lig4^tm2.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell activation	J:157574
	abnormal B cell differentiation	J:157574
	abnormal immune system cell morphology	J:157574
	abnormal immune system morphology	J:157574
	abnormal immune system organ morphology	J:157574
	abnormal immune system physiology	J:157574
	abnormal lymphocyte cell number	J:157574
	abnormal regulatory T cell morphology	J:157574
	abnormal T cell activation	J:157574
	abnormal T cell differentiation	J:157574
	abnormal T cell receptor beta chain V(D)J recombination	J:157574
	abnormal T cell receptor V(D)J recombination	J:157574
	abnormal thymus morphology	J:157574
	decreased B cell number	J:157574
	decreased CD4-positive, alpha-beta T cell number	J:157574
	decreased CD8-positive, alpha-beta T cell number	J:157574
	decreased double-negative T cell number	J:157574
	decreased double-positive T cell number	J:157574
	decreased IgA level	J:157574
	decreased IgG2b level	J:157574
	decreased IgG3 level	J:157574
	decreased IgG level	J:157574
	decreased IgM level	J:157574
	decreased immunoglobulin level	J:157574
	decreased interferon-gamma secretion	J:157574
	decreased interleukin-13 secretion	J:157574
	decreased spleen weight	J:157574
	decreased splenocyte number	J:157574
	decreased T cell proliferation	J:157574
	decreased thymocyte number	J:157574
	decreased thymus weight	J:157574
	increased anti-chromatin antibody level	J:157574
	increased anti-double stranded DNA antibody level	J:157574
	increased T cell apoptosis	J:157574
	increased T cell derived lymphoma incidence	J:157574
	intestinal inflammation	J:157574
	liver inflammation	J:157574
	small spleen	J:157574
	small thymus	J:157574
\Lig4^tm3.1Fwa/\Lig4^tm3.1Fwa \Tg(Cr2-cre)3Cgn/0 (Not Specified)	abnormal class switch recombination	J:157537
\Lilrb4a^tm1Eol/\Lilrb4a^tm1Eol (B6.129P2-Lilrb4a^tm1Eol)	abnormal cellular extravasation	J:129969
	abnormal cytokine level	J:129969
	abnormal immune system cell morphology	J:129969
	abnormal immune system physiology	J:129969
	abnormal interferon level	J:129969
	abnormal interleukin level	J:129969
	abnormal leukocyte physiology	J:129969
	decreased IgE level	J:129969
	increased inflammatory response	J:129969
	increased macrophage cell number	J:129969
	increased mast cell degranulation	J:129969
	increased plasma cell number	J:129969
\Lilrb4a^tm1Hrk/\Lilrb4a^tm1Hrk (involves: 129/Sv * BALB/c)	abnormal mast cell physiology	J:70491
	increased mast cell degranulation	J:70491
	increased susceptibility to type I hypersensitivity reaction	J:70491
\Lilrb4a^tm1Ttk/\Lilrb4a^tm1Ttk (B6.129X1-Lilrb4a^tm1Ttk)	abnormal dendritic cell antigen presentation	J:141234
\Lilrb4a^tm1Ttk/\Lilrb4a^tm1Ttk (B6.129X1-Lilrb4a^tm1Ttk)	increased susceptibility to graft versus host disease	J:141234
\Limd1^em1(IMPC)H/\Limd1^em1(IMPC)H (C57BL/6NTac-Limd1^em1(IMPC)H/H)	increased basophil cell number	J:211773
\Limd1^tm1Gdl/\Limd1^tm1Gdl (involves: 129X1/SvJ)	abnormal macrophage physiology	J:118130
	abnormal osteoclast cell number	J:118130
	abnormal osteoclast physiology	J:118130
\Lime1^tm1.1Mal/\Lime1^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:126321
\Lime1^tm1.1Mal/\Lime1^tm1.1Mal \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraH-Y,TcrbH-Y)1Pas/? (B6.Cg-Rag2^tm1Fwa Lime1^tm1.1Mal Tg(TcraH-Y,TcrbH-Y)1Pas)	abnormal CD4-positive T cell differentiation	J:126321
	increased CD4-positive, alpha-beta T cell number	J:126321
\Limk2^{Gt(OST80053)Lex}/\Limk2^{Gt(OST80053)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	increased incidence of corneal inflammation	J:192231
\Limk2^whe/\Limk2^whe (B6.Cg-Lep^ob Limk2^whe/GrsrJ)	increased incidence of corneal inflammation	J:127016
\Lipa^{tm1c(EUCOMM)Hmgu}/\Lipa^{tm1c(EUCOMM)Hmgu} \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1^{Tg(Alb-cre)21Mgn} (involves: C57BL/6J * C57BL/6N * C57BL/6NTac)	liver inflammation	J:270182
\Lipa^tm1Hodu/\Lipa^tm1Hodu (involves: 129P2/OlaHsd * CF-1)	abnormal alveolar macrophage morphology	J:101217
	abnormal Kupffer cell morphology	J:68812
	abnormal spleen morphology	J:49674, J:68812
	chronic inflammation	J:101217
	enlarged mesenteric lymph nodes	J:68812
	enlarged spleen	J:68812
	hepatosplenomegaly	J:68812
	increased spleen weight	J:49674, J:68812
	lung inflammation	J:101217
\Lipt1^em1(IMPC)Bay/\Lipt1⁺ (C57BL/6N-Lipt1^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Listr1^BALB/cByJ/? (involves: BALB/cByJ * C57BL/6ByJ)	decreased susceptibility to bacterial infection	J:68879
\Listr1^BALB/cByJ/? \Listr2^C57BL/6ByJ/? (involves: BALB/cByJ * C57BL/6ByJ)	decreased susceptibility to bacterial infection	J:68879
\Listr2^C57BL/6ByJ/? (involves: BALB/cByJ * C57BL/6ByJ)	decreased susceptibility to bacterial infection	J:68879
\Litaf^tm1.1Ics/\Litaf^tm1.1Ics (Not Specified)	impaired macrophage chemotaxis	J:186411
\Litaf^tm1.1Ics/\Litaf^tm1.1Ics (Not Specified)	increased macrophage cell number	J:186411
\Litaf^tm1Samr/\Litaf^tm1Samr (involves: 129S4/SvJae)	abnormal cytokine secretion	J:113750
\Litaf^tm1Samr/\Litaf^tm1Samr (involves: 129S4/SvJae)	decreased susceptibility to endotoxin shock	J:113750
\ll/\ll X/\Yaa (BXSB/MpJScr-ll)	abnormal monocyte morphology	J:10973
	decreased anti-nuclear antigen antibody level	J:10973
	decreased CD4-positive, alpha-beta T cell number	J:10973
	decreased IgG level	J:10973
	decreased susceptibility to autoimmune disorder	J:10973
	increased T cell derived lymphoma incidence	J:10973
\Lmb1^C57BL/6Scr/\Lmb1^C57BL/6Scr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
\Lmb1^C57BL/6Scr/\Lmb1^C57BL/6Scr (MRL.Cg-Lmb1^C57BL/6Scr Fas^lpr)	increased CD8-positive, alpha-beta T cell number	J:125557
	increased double-negative T cell number	J:125557
	increased spleen weight	J:125557
\Lmb1^C57BL/6Scr/\Lmb1^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
\Lmb1^MRL/MpScr/\Lmb1^MRL/MpScr (B6.MRL-Lmb1^MRL/MpScr Fas^lpr)	enlarged lymph nodes	J:125557
\Lmb2^C57BL/6Scr/\Lmb2^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
\Lmb2^MRL/MpScr/\Lmb2^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
	increased anti-double stranded DNA antibody level	J:45708
\Lmb2^MRL/MpScr/\Lmb2^MRL/MpScr (B6.MRL-Lmb2^MRL/MpScr Fas^lpr)	decreased double-negative T cell number	J:125557
\Lmb4^MRL/MpScr/\Lmb4^MRL/MpScr (involves: C57BL/6-Fas^lpr * MRL-Fas^lpr)	enlarged lymph nodes	J:45708
	enlarged spleen	J:45708
\Lmb4^MRL/MpScr/\Lmb4^MRL/MpScr (B6.MRL-Lmb4^MRL/MpScr Fas^lpr)	enlarged lymph nodes	J:125557
\Lmbr1l^em1Btlr/\Lmbr1l^em1Btlr (C57BL/6J-Lmbr1l^em1Btlr)	abnormal alpha-beta T cell morphology	J:274568
	abnormal B cell differentiation	J:274568
	abnormal cytotoxic T cell physiology	J:274568
	abnormal lymphocyte morphology	J:274568
	decreased CD4-positive, alpha-beta T cell number	J:274568
	decreased IgD level	J:274568
	decreased IgG level	J:274568
	decreased IgM level	J:274568
	decreased leukocyte cell number	J:274568
	decreased lymphocyte cell number	J:274568
	decreased monocyte cell number	J:274568
	decreased T cell number	J:274568
	impaired humoral immune response	J:274568
	impaired natural killer cell mediated cytotoxicity	J:274568
	increased IgM level	J:274568
\Lmbr1l^m1Btlr/\Lmbr1l^m1Btlr (C57BL/6J-Lmbr1l^m1Btlr)	abnormal CD4-positive T cell differentiation	J:274568
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274568
	abnormal cytotoxic T cell physiology	J:274568
	abnormal T cell differentiation	J:274568
	decreased CD4-positive, alpha-beta T cell number	J:274568
	decreased CD8-positive, alpha-beta T cell number	J:274568
	decreased CD8-positive, naive alpha-beta T cell number	J:274568
	decreased dendritic cell number	J:274568
	decreased IgE level	J:274568
	decreased IgG level	J:274568
	decreased IgM level	J:274568
	decreased NK cell number	J:274568
	decreased NK T cell number	J:274568
	decreased T cell number	J:274568
	impaired humoral immune response	J:274568
	impaired natural killer cell mediated cytotoxicity	J:274568
	increased B-1 B cell number	J:274568
	increased central memory CD8 positive, alpha-beta T cell number	J:274568
	increased effector memory CD4-positive, alpha-beta T cell number	J:274568
	increased macrophage cell number	J:274568
	increased neutrophil cell number	J:274568
\Lmbr1l^m2Btlr/\Lmbr1l^m2Btlr (C57BL/6J-Lmbr1l^m2Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:274857
\Lmna^Dhe/\Lmna⁺ (B6(D2)-Lmna^Dhe/TyGrsrJ)	abnormal peritoneal macrophage morphology	J:188496
\Lmna^Dhe/\Lmna⁺ (B6(D2)-Lmna^Dhe/TyGrsrJ)	increased susceptibility to otitis media	J:188496
\Lmna^tm1.1Otin/\Lmna^tm1.1Otin (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:177632
	small thymus	J:177632
\Lmna^tm1.1Otin/\Lmna^tm1.1Otin (involves: 129P2/OlaHsd * C57BL/6NTac)	keratoconjunctivitis sicca	J:261974
\Lmna^tm1Stw/\Lmna^tm1Stw (involves: 129S1/Sv)	small spleen	J:58702
\Lmna^tm1Stw/\Lmna^tm1Stw (involves: 129S1/Sv)	thymus atrophy	J:58702
\Lmo2^tm2(cre)Thr/\Lmo2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased granulocyte number	J:155870
\Lmo2^tm2(cre)Thr/\Lmo2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased monocyte cell number	J:155870
\Lmo2^tm2(cre)Thr/\Lmo2⁺ \Kmt2a^tm1Thr/\Kmt2a⁺ \Mllt1^tm1Thr/\Mllt1⁺ (involves: 129S/SvEv)	abnormal spleen red pulp morphology	J:100794
	abnormal spleen white pulp morphology	J:100794
	enlarged spleen	J:84518, J:100794
\Lmo2^tm3Thr/\Lmo2^tm4Thr \Cd19^tm1(cre)Thr/\Cd19⁺ (involves: 129S/SvEv)	immune system phenotype	J:86869
\Lmo2^tm3Thr/\Lmo2^tm4Thr \Rag1^tm1(cre)Thr/\Rag1⁺ (involves: 129S/SvEv)	immune system phenotype	J:86869
\Lmo2^tm3Thr/\Lmo2^tm4Thr \Tg(Lck-cre)1Thr/0 (involves: 129S/SvEv)	immune system phenotype	J:86869
\Lmo4^tm1Slp/\Lmo4^tm1Slp \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal acute inflammation	J:282740
	abnormal gut-associated lymphoid tissue morphology	J:282740
	abnormal lymphocyte physiology	J:282740
	abnormal lymphopoiesis	J:282740
	decreased Peyer's patch number	J:282740
	increased susceptibility to bacterial infection	J:282740
\Lmo4^tm1Slp/\Lmo4^tm1Slp \Yeats4^em1Zfa/\Yeats4^em1Zfa \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal acute inflammation	J:282740
	abnormal lymphocyte physiology	J:282740
	abnormal lymphopoiesis	J:282740
	increased susceptibility to bacterial infection	J:282740
\Lmod3^em1(IMPC)Mbp/\Lmod3⁺ (C57BL/6N-Lmod3^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Lmod3^em1(IMPC)Mbp/\Lmod3^em1(IMPC)Mbp (C57BL/6N-Lmod3^em1(IMPC)Mbp/Ucd)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased neutrophil cell number	J:211773
\Lmr1^BALB/c/\Lmr1^BALB/c (involves: BALB/c * C57BL/6J)	increased susceptibility to parasitic infection	J:40874
\Lmr1^BALB/c/\Lmr1^BALB/c \Lmr30^C57BL/6/\Lmr30^BALB/c (involves: BALB/c * C57BL/6)	increased susceptibility to parasitic infection	J:57691
\Lmr1^BALB/c/\Lmr1^BALB/c \Lmr30^C57BL/6/\Lmr30^C57BL/6 (involves: BALB/c * C57BL/6)	increased susceptibility to parasitic infection	J:57691
\Lmr1^BALB/c/\Lmr1^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
\Lmr1^C57BL/6J/\Lmr1^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
\Lmr2^BALB/c/\Lmr2^BALB/c (involves: BALB/c * C57BL/6J)	increased susceptibility to parasitic infection	J:40874
\Lmr2^BALB/c/\Lmr2^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
\Lmr2^C57BL/6J/\Lmr2^C57BL/6J (involves: BALB/c * C57BL/6J)	decreased susceptibility to parasitic infection	J:40874
\Lmr3^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	abnormal tumor necrosis factor level	J:82715
	enlarged spleen	J:82715
	increased IgE level	J:82715
\Lmr3^BALB/cHeA/\Lmr3^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
\Lmr3^BALB/cHeA/\Lmr3^CcS5/Dem (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
\Lmr4^BALB/cHeA/? \Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	abnormal tumor necrosis factor level	J:82715
\Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	abnormal interleukin level	J:82715
	abnormal tumor necrosis factor level	J:82715
	increased IgE level	J:82715
\Lmr5^CcS5/Dem/\Lmr5^CcS5/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-12 level	J:108764
\Lmr7^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	decreased splenocyte proliferation	J:108764
\Lmr7^CcS5/Dem/? (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:82715
\Lmr8^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
\Lmr8^BALB/cHeA/\Lmr8^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
\Lmr8^BALB/cHeA/\Lmr8^CcS20/Dem (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
\Lmr9^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
\Lmr9^BALB/cHeA/\Lmr9^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
\Lmr9^CcS20/Dem/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
\Lmr9^CcS20/Dem/\Lmr9^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
\Lmr10^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
\Lmr10^CcS20/Dem/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
\Lmr11^BALB/cHeA/\Lmr11^BALB/cHeA \Lmr8^CcS20/Dem/\Lmr8^CcS20/Dem (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
\Lmr11^BALB/cHeA/\Lmr11^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
\Lmr11^CcS20/Dem/\Lmr11^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-6 level	J:108764
\Lmr12^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
\Lmr12^BALB/cHeA/\Lmr12^BALB/cHeA \Lmr14^BALB/cHeA/\Lmr14^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased circulating tumor necrosis factor level	J:108764
\Lmr12^BALB/cHeA/\Lmr12^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-4 level	J:108764
\Lmr12^CcS16/Dem/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
\Lmr12^CcS16/Dem/\Lmr12^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-4 level	J:108764
\Lmr12^CcS16/Dem/\Lmr12^CcS16/Dem \Lmr19^BALB/cHeA/\Lmr19^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
\Lmr13^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	decreased IgE level	J:82717
\Lmr13^CcS16/Dem/\Lmr13^CcS16/Dem \Lmr14^CcS16/Dem/\Lmr14^CcS16/Dem (involves: BALB/cHeA * STS/A)	decreased circulating tumor necrosis factor level	J:108764
\Lmr14^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
\Lmr14^BALB/cHeA/\Lmr14^BALB/cHeA \Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82715
\Lmr14^BALB/cHeA/\Lmr14^BALB/cHeA \Lmr5^BALB/cHeA/\Lmr5^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
\Lmr14^BALB/cHeA/\Lmr14^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interferon-gamma level	J:108764
\Lmr14^CcS16/Dem/? (involves: BALB/cHeA * STS/A)	enlarged spleen	J:82716
\Lmr14^CcS16/Dem/\Lmr14^CcS16/Dem (involves: BALB/cHeA * STS/A)	increased circulating interferon-gamma level	J:108764
\Lmr14^CcS16/Dem/\Lmr14^CcS16/Dem \Lmr5^BALB/cHeA/? (involves: BALB/cHeA * STS/A)	increased IgE level	J:82715
\Lmr14^CcS16/Dem/\Lmr14^CcS16/Dem \Lmr5^BALB/cHeA/\Lmr5^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased IgE level	J:82717
\Lmr14^CcS16/Dem/\Lmr14^CcS16/Dem \Lmr5^CcS5/Dem/\Lmr5^CcS5/Dem (involves: BALB/cHeA * STS/A)	increased circulating interleukin-12 level	J:108764
\Lmr15^BALB/cHeA/\Lmr15^CcS16/Dem (involves: BALB/cHeA * STS/A)	decreased circulating interferon-gamma level	J:108764
\Lmr15^CcS16/Dem/\Lmr15^CcS16/Dem (involves: BALB/cHeA * STS/A)	decreased circulating interferon-gamma level	J:108764
\Lmr16^STS/A/\Lmr16^STS/A \Lmr18^BALB/cHeA/\Lmr18^BALB/cHeA (involves: BALB/cHeA * STS/A)	spleen hyperplasia	J:108764
\Lmr17^BALB/cHeA/\Lmr17^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating tumor necrosis factor level	J:108764
\Lmr17^CcS20/Dem/\Lmr17^CcS20/Dem (involves: BALB/cHeA * STS/A)	increased circulating tumor necrosis factor level	J:108764
\Lmr17^CcS20/Dem/\Lmr17^CcS20/Dem \Lmr3^BALB/cHeA/\Lmr3^BALB/cHeA (involves: BALB/cHeA * STS/A)	increased circulating interferon-gamma level	J:108764
\Lmr18^BALB/cHeA/\Lmr18^BALB/cHeA (involves: BALB/cHeA * STS/A)	decreased splenocyte proliferation	J:108764
\Lmr18^BALB/cHeA/\Lmr18^CcS20/Dem (involves: BALB/cHeA * STS/A)	decreased splenocyte proliferation	J:108764
\Lmrq1^BALB/cAnSim/\Lmrq1^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
\Lmrq2^BALB/cAnSim/\Lmrq2^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
\Lmrq3^BALB/cAnSim/\Lmrq3^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
\Lmrq4^BALB/cAnSim/\Lmrq4^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
\Lmrq4^C57BL/10Sn/\Lmrq4^C57BL/10Sn (C.B10-(D11Mit2-D11Mit29))	decreased susceptibility to parasitic infection	J:40624
\Lmrq5^BALB/cAnNSim/\Lmrq5^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
\Lmrq6^BALB/cAnSim/\Lmrq6^C57BL/10Sn (involves: BALB/cAnNSim * C57BL/10J)	decreased susceptibility to parasitic infection	J:40624
\Lncucc1^em1Bwu/\Lncucc1^em1Bwu (C57BL/6-Lncucc1^em1Bwu)	abnormal susceptibility to colitis induced morbidity/mortality	J:340220
\Lncucc1^em1Bwu/\Lncucc1^em1Bwu (C57BL/6-Lncucc1^em1Bwu)	increased susceptibility to induced colitis	J:340220
\Lnx1^tm1Lex/\Lnx1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased B-1b cell number	J:171883
\Loricrin^{tm1.1(KOMP)Vlcg}/\Loricrin⁺ (C57BL/6N-Loricrin^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Loricrin^{tm1.1(KOMP)Vlcg}/\Loricrin^{tm1.1(KOMP)Vlcg} (C57BL/6N-Loricrin^{tm1.1(KOMP)Vlcg}/Ucd)	increased spleen weight	J:211773
\Loricrin^tm1Der/\Loricrin^tm1Der (FVB.129S7-Loricrin^tm1Der)	erythroderma	J:65187
\Lox^tm1.1Khki/\Lox^tm1.1Khki (involves: C57BL/6)	increased lymphocyte cell number	J:264295
\Loxl2^tm1.2Acan/\Loxl2^tm1.2Acan (Not Specified)	decreased inflammatory response	J:220689
\Lpar2^tm1Dgen/\Lpar2^tm1Dgen (B6.Cg-Lpar2^tm1Dgen)	abnormal dendritic cell physiology	J:184061
	decreased interleukin-10 secretion	J:184061
	increased IgE level	J:184061
	increased interleukin-13 secretion	J:184061
	increased susceptibility to type I hypersensitivity reaction	J:184061
	increased tumor necrosis factor secretion	J:184061
	lung inflammation	J:184061
\Lpar4^tm1Sati/Y (involves: C57BL/6)	abnormal cellular extravasation	J:253134
	immune system phenotype	J:253134
	lymphangiectasis	J:167262
\Lpar4^tm1Sati/\Lpar4⁺ (involves: C57BL/6)	abnormal cellular extravasation	J:253134
\Lpar4^tm1Sati/\Lpar4^tm1Sati (involves: C57BL/6)	abnormal cellular extravasation	J:253134
	immune system phenotype	J:253134
	lymphangiectasis	J:167262
\Lpar6^tm1.1Sati/\Lpar6^tm1.1Sati (involves: C57BL/6 * C57BL/6NJcl * CBA)	abnormal cellular extravasation	J:253134
	immune system phenotype	J:253134
\Lpin2^{tm1b(KOMP)Wtsi}/\Lpin2^{tm1b(KOMP)Wtsi} (C57BL/6N-Lpin2^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
\Lpin2^tm1Reue/\Lpin2^tm1Reue (involves: C57BL/6J)	immune system phenotype	J:189894
\Lpin3^{tm1b(KOMP)Wtsi}/\Lpin3^{tm1b(KOMP)Wtsi} (C57BL/6N-Lpin3^{tm1b(KOMP)Wtsi}/Ucd)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Lpn1^NZB/\Lpn1^NZB (involves: NZB * NZW)	kidney inflammation	J:6026
\Lpn1^NZB/\Lpn1^NZW (involves: NZB * NZW)	kidney inflammation	J:6026
\Lpn2^NZB/\Lpn2^NZW (involves: NZB * NZW)	kidney inflammation	J:6026
\Lpn2^NZW/\Lpn2^NZW (involves: NZB * NZW)	kidney inflammation	J:6026
\Lpo^em1Zlu/\Lpo^em1Zlu (involves: C57BL/6 * SJL)	aortitis	J:307289
	arteritis	J:307289
	blood vessel inflammation	J:307289
	cardiovalvulitis	J:307289
	gallbladder inflammation	J:307289
	glomerulonephritis	J:307289
	increased inflammatory response	J:307289
	intestinal inflammation	J:307289
	liver inflammation	J:307289
	lung inflammation	J:307289
	mastitis	J:307289
	myocarditis	J:307289
	myositis	J:307289
	pancreas inflammation	J:307289
	stomach inflammation	J:307289
\Lppl1^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	abnormal leukocyte physiology	J:90647
\Lprm3^MRL/MpJ/\Lprm3^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	glomerulonephritis	J:44625
\Lprm4^MRL/MpJ/\Lprm4^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	enlarged spleen	J:44625
\Lprm5^MRL/MpJ/\Lprm5^MRL/MpJ (involves: C3H/HeJ-Fas^lpr * MRL/MpJ-Fas^lpr)	abnormal humoral immune response	J:44625
\Lptl1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	abnormal tumor necrosis factor level	J:90647
\Lptl1^DBA/2J/\Lptl1^DBA/2J \Lptl2^DBA/2J/\Lptl2^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal tumor necrosis factor level	J:90647
\Lptl2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	abnormal tumor necrosis factor level	J:90647
\Lpxn^{tm1b(EUCOMM)Hmgu}/\Lpxn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lpxn^{tm1b(EUCOMM)Hmgu}/Wtsi)	abnormal plasma cell differentiation	J:305662
	decreased IgM level	J:305662
	immune system phenotype	J:305662
\Lratd2^{em1(IMPC)Ccpcz}/\Lratd2^{em1(IMPC)Ccpcz} (C57BL/6N-Lratd2^{em1(IMPC)Ccpcz}/Ccpcz)	decreased eosinophil cell number	J:211773
	increased B-2 B cell number	J:211773
\Lrba^em1Btlr/\Lrba^em1Btlr (C57BL/6J-Lrba^em1Btlr)	increased susceptibility to induced colitis	J:274652
\Lrba^em2Btlr/\Lrba^em2Btlr (C57BL/6J-Lrba^em2Btlr)	increased susceptibility to induced colitis	J:274652
\Lrba^em3Btlr/\Lrba^em3Btlr (C57BL/6J-Lrba^em3Btlr)	increased susceptibility to induced colitis	J:274652
\Lrba^{Gt(OST69142)Lex}/\Lrba^{Gt(OST69142)Lex} (involves: 129 * 129S5/SvEvBrd)	abnormal NK cell physiology	J:237187
	decreased susceptibility to graft versus host disease	J:237187
	impaired natural killer cell mediated cytotoxicity	J:237187
	increased length of allograft survival	J:237187
	increased regulatory T cell number	J:237187
\Lrba^m1Btlr/\Lrba^m1Btlr (C57BL/6J-Lrba^m1Btlr)	increased susceptibility to induced colitis	J:274652
\Lrba^m2Btlr/\Lrba^m2Btlr (C57BL/6J-Lrba^m2Btlr)	increased susceptibility to induced colitis	J:274652
\Lrch1^em1Hwa/\Lrch1^em1Hwa (Not Specified)	abnormal cellular extravasation	J:238772
	immune system phenotype	J:238772
	increased susceptibility to experimental autoimmune encephalomyelitis	J:238772
\Lrdm1^MRL/MpJ/? (involves: CAST/Ei * MRL/MpJ-Fas^lpr/J)	kidney inflammation	J:3304
\Lrdm2^MRL/MpJ/? (involves: CAST/Ei * MRL/MpJ-Fas^lpr/J)	kidney inflammation	J:3304
\Lrfn2^{Tg(CD2-Myb/en)5Kmw}/\Lrfn2⁺ (involves: C57BL/10 * CBA)	abnormal lymph node morphology	J:125805
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
\Lrfn2^{Tg(CD2-Myb/en)5Kmw}/\Lrfn2⁺ \Tg(H2-K-Myc)1Brn/? (involves: C57BL/10 * CBA * FVB/N)	abnormal lymph node morphology	J:125805
	enlarged lymph nodes	J:125805
	enlarged spleen	J:125805
	lymph node hemorrhage	J:125805
	lymph node necrosis	J:125805
	spleen hyperplasia	J:125805
\Lrfn2^{Tg(CD2-Myb/en)5Kmw}/\Lrfn2^{Tg(CD2-Myb/en)5Kmw} (involves: C57BL/10 * CBA)	abnormal thymus cortex morphology	J:126456
	abnormal thymus medulla morphology	J:126456
	decreased CD8-positive, alpha-beta T cell number	J:126456
	decreased double-negative T cell number	J:126456
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
	small spleen	J:126456
	small thymus	J:126456
\Lrfn2^tm1.1Jaru/\Lrfn2^tm1.1Jaru (B6.129P2(Cg)-Lrfn2^tm1.1Jaru)	decreased granulocyte number	J:301285
	decreased leukocyte cell number	J:301285
	decreased lymphocyte cell number	J:301285
\Lrig1^m1Anu/\Lrig1^m1Anu (C57BL/NCrlAnu-Lrig1^m1Anu)	immune system phenotype	J:104190
\Lrig1^{tm1a(EUCOMM)Wtsi}/\Lrig1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased susceptibility to bacterial infection	J:213427
\Lrig2^tm1.1Hhed/\Lrig2^tm1.1Hhed (involves: 129 * C57BL/6 * FVB/N)	increased inflammatory response	J:205929
\Lrig3^{em1(IMPC)Ccpcz}/\Lrig3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Lrig3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Lrp1^tm2Her/\Lrp1^tm2Her \Tg(Camk2a-cre)T29-1Stl/0 (involves: 129S7/SvEvBrd * BALB/c * C57BL)	brain inflammation	J:167724
\Lrp2^b2b2671Clo/\Lrp2^b2b2671Clo (C57BL/6J-Lrp2^b2b2671Clo)	thymus hypoplasia	J:175213
\Lrp3^em1Cya/\Lrp3^em1Cya (C57BL/6N-Lrp3^em1Cya/Cya)	increased susceptibility to induced arthritis	J:345338
\Lrp3^em1Cya/\Lrp3^em1Cya (C57BL/6N-Lrp3^em1Cya/Cya)	osteoarthritis	J:345338
\Lrp5^tm1Grw/\Lrp5^tm1Grw (involves: 129S1/Sv * 129X1/SvJ)	decreased osteoclast cell number	J:104382
\Lrp6^tm1Arma/\Lrp6^tm1Arma (C57BL/6-Lrp6^tm1Arma)	liver inflammation	J:225450
\Lrp12^em1Gpt/\Lrp12^em1Gpt \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6JGpt * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:338432
	enhanced leukocyte migration	J:338432
	immune system phenotype	J:338432
	increased susceptibility to induced colitis	J:338432
	increased T cell number	J:338432
\Lrrc3^{tm1b(EUCOMM)Hmgu}/\Lrrc3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lrrc3^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
\Lrrc4c^tm1Lex/\Lrrc4c^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased circulating interleukin-6 level	J:171883
\Lrrc8a^tm1.1Geha/\Lrrc8a^tm1.1Geha (B6.129S1(Cg)-Lrrc8a^tm1.1Geha)	abnormal B cell differentiation	J:211308
	abnormal T cell differentiation	J:211308
	abnormal T cell physiology	J:211308
	abnormal T cell selection	J:211308
	abnormal thymus apoptosis	J:211308
	abnormal thymus medulla morphology	J:211308
	abnormal thymus morphology	J:211308
	abnormal thymus physiology	J:211308
	absent thymus corticomedullary boundary	J:211308
	decreased B cell number	J:211308
	decreased CD4-positive, alpha-beta T cell number	J:211308
	decreased CD8-positive, alpha-beta T cell number	J:211308
	decreased DN2 thymocyte number	J:211308
	decreased DN3 thymocyte number	J:211308
	decreased DN4 thymocyte number	J:211308
	decreased double-negative T cell number	J:211308
	decreased double-positive T cell number	J:211308
	decreased immature B cell number	J:211308
	decreased marginal zone B cell number	J:211308
	decreased pre-B cell number	J:211308
	decreased T cell number	J:211308
	decreased T cell proliferation	J:211308
	decreased thymocyte number	J:211308
	decreased transitional stage B cell number	J:211308
	increased IgG2a level	J:211308
	increased pro-B cell number	J:211308
	increased regulatory T cell number	J:211308
	increased thymocyte apoptosis	J:211308
	small spleen	J:211308
	small thymus	J:211308
	small thymus cortex	J:211308
	thymus hypoplasia	J:211308
\Lrrc8b^em1Bcgen/\Lrrc8b^em1Bcgen (C57BL/6N-Lrrc8b^em1Bcgen)	immune system phenotype	J:288504
\Lrrc8c^em1(IMPC)Mbp/\Lrrc8c^em1(IMPC)Mbp (C57BL/6N-Lrrc8c^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\Lrrc8d^em1Bcgen/\Lrrc8d^em1Bcgen (C57BL/6N-Lrrc8d^em1Bcgen)	immune system phenotype	J:288504
\Lrrc8e^em1Bcgen/\Lrrc8e^em1Bcgen (C57BL/6N-Lrrc8e^em1Bcgen)	abnormal circulating cytokine level	J:288504
	decreased circulating interferon-beta level	J:288504
	decreased circulating tumor necrosis factor level	J:288504
	decreased interferon-beta secretion	J:288504
	increased susceptibility to viral infection	J:288504
	increased susceptibility to viral infection induced morbidity/mortality	J:288504
\Lrrc17^{em1(IMPC)Ccpcz}/\Lrrc17^{em1(IMPC)Ccpcz} (C57BL/6N-Lrrc17^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Lrrc17^tm1Nik/\Lrrc17⁺ \Nf1^tm1Par/\Nf1^tm1Par \Srpk2^tm1Nik/\Srpk2⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased leukocyte cell number	J:161558
\Lrrc19^tm1Ryag/\Lrrc19^tm1Ryag (involves: C57BL/6J * C57BL/6NTac)	decreased circulating interleukin-6 level	J:271376
	decreased circulating tumor necrosis factor level	J:271376
	increased susceptibility to bacterial infection	J:271376
\Lrrc25^em1Cya/\Lrrc25^em1Cya (C57BL/6J-Lrrc25^em1Cya/Cya)	abnormal tumor necrosis factor level	J:270157
\Lrrc25^em1Cya/\Lrrc25^em1Cya (C57BL/6J-Lrrc25^em1Cya/Cya)	heart inflammation	J:270157
\Lrrc30^{em1(IMPC)Rbrc}/\Lrrc30^{em1(IMPC)Rbrc} (C57BL/6NJcl-Lrrc30^{em1(IMPC)Rbrc}/Rbrc)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Lrrc32^tm1.1Hfuj/\Lrrc32^tm1.1Hfuj \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * DBA/2)	abnormal regulatory T cell physiology	J:204761
	immune system phenotype	J:204761
\Lrrc55os^em1Caox/\Lrrc55os^em1Caox (C57BL/6-Lrrc55os^em1Caox)	decreased circulating interferon-beta level	J:293325
	immune system phenotype	J:293325
	increased susceptibility to Riboviria infection	J:293325
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:293325
\Lrrc56^em1(IMPC)Tcp/\Lrrc56^em1(IMPC)Tcp (C57BL/6N-Lrrc56^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Lrrk1^tm1.1Smo/\Lrrk1^tm1.1Smo (involves: 129S/Sv)	abnormal osteoclast physiology	J:208677
\Lrrk1^tm1.1Smo/\Lrrk1^tm1.1Smo (involves: 129S/Sv)	increased osteoclast cell number	J:208677
\Lrrk1^{tm1b(KOMP)Wtsi}/\Lrrk1^{tm1b(KOMP)Wtsi} (C57BL/6N-Lrrk1^{tm1b(KOMP)Wtsi}/H)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Lrrk2^tm1.1Cai/\Lrrk2⁺ \Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-SNCAA53T)E2Cai/0 (involves: 129X1/SvJ C57BL/6)	microgliosis	J:156512
\Lrrk2^tm1.1Cai/\Lrrk2^tm1.1Cai (involves: 129X1/SvJ * C57BL/6)	microgliosis	J:156512
\Lrrk2^tm2.1Shn/\Lrrk2^tm2.1Shn (involves: 129 * C57BL/6)	kidney inflammation	J:160542
\Lrrtm1^em1(IMPC)Mbp/\Lrrtm1^em1(IMPC)Mbp (C57BL/6N-Lrrtm1^em1(IMPC)Mbp/Ucd)	increased monocyte cell number	J:211773
\Lrrtm2^em1(IMPC)Mbp/\Lrrtm2^em1(IMPC)Mbp (C57BL/6N-Lrrtm2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Lse/\Lse⁺ (B6C3Fe a/a-Lse/J)	keratoconjunctivitis sicca	J:338204
\Lsm3^em1Caox/\Lsm3^em1Caox (involves: C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection	J:262834
	decreased susceptibility to Riboviria infection	J:262834
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:262834
	increased circulating interferon-alpha level	J:262834
	increased circulating interferon-beta level	J:262834
	increased circulating interleukin-6 level	J:262834
\Lsm8^em1(IMPC)Mbp/\Lsm8⁺ (C57BL/6N-Lsm8^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Lsm14a^{tm1b(KOMP)Wtsi}/\Lsm14a⁺ (C57BL/6N-Lsm14a^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
\Lsp1^tm1Jejb/\Lsp1^tm1Jejb (involves: 129S1/Sv * 129X1/SvJ)	abnormal cellular extravasation	J:96022
	abnormal immune system morphology	J:64219
	abnormal leukocyte physiology	J:68128
	abnormal lymphopoiesis	J:64219
	impaired neutrophil chemotaxis	J:68128
	increased macrophage cell number	J:64219
\Lsr1^A/J/? (involves: A/J * C57BL/6J)	increased susceptibility to bacterial infection	J:7345
\Lsr1^C57BL/6J/? (involves: A/J * C57BL/6J)	decreased susceptibility to bacterial infection	J:7345
\Lss^{tm1b(KOMP)Wtsi}/\Lss⁺ (C57BL/6N-Lss^{tm1b(KOMP)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
\Lst1^{tm1(KOMP)Vlcg}/\Lst1^{tm1(KOMP)Vlcg} (C57BL/6N-Lst1^{tm1(KOMP)Vlcg})	immune system phenotype	J:235700
	increased susceptibility to Orthomyxoviridae infection	J:235700
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:235700
\Lta4h^tm1Bhk/\Lta4h^tm1Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	decreased acute inflammation	J:58985
	decreased susceptibility to type I hypersensitivity reaction	J:58985
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (involves: 129)	abnormal humoral immune response	J:31129
	abnormal spleen marginal zone morphology	J:31129
	abnormal spleen morphology	J:31129
	absent lymph nodes	J:31129
	absent Peyer's patches	J:31129
	decreased IgA level	J:31129
	decreased T cell number	J:31129
	increased B cell number	J:31129
	increased leukocyte cell number	J:31129
	increased susceptibility to parasitic infection	J:31129
	increased susceptibility to Poxviridae infection	J:31129
	increased susceptibility to Riboviria infection	J:31129
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (involves: 129/Sv * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	decreased susceptibility to parasitic infection	J:37696
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (B6.129-Lta/Tnf^tm1Eug)	decreased circulating interferon-gamma level	J:115034
	decreased IgG1 level	J:115034
	decreased IgG2a level	J:115034
	decreased IgG3 level	J:115034
	decreased interferon-gamma secretion	J:115034
	decreased susceptibility to induced arthritis	J:115034
	impaired macrophage phagocytosis	J:115034
	increased IgM level	J:115034
	increased susceptibility to bacterial infection	J:115034
	increased susceptibility to bacterial infection induced morbidity/mortality	J:115034
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (involves: 129 * C57BL/6J)	increased spleen weight	J:112797
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (involves: 129)	abnormal humoral immune response	J:31129
	abnormal spleen marginal zone morphology	J:31129
	abnormal spleen morphology	J:31129
	absent lymph nodes	J:31129
	absent Peyer's patches	J:31129
	decreased IgA level	J:31129
	decreased T cell number	J:31129
	increased B cell number	J:31129
	increased leukocyte cell number	J:31129
	increased susceptibility to bacterial infection	J:31129
	increased susceptibility to Poxviridae infection	J:31129
	increased susceptibility to Riboviria infection	J:31129
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (involves: 129/Sv * C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	decreased susceptibility to parasitic infection	J:37696
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (B6.129-Lta/Tnf^tm1Eug)	decreased circulating interferon-gamma level	J:115034
	decreased IgG1 level	J:115034
	decreased IgG2a level	J:115034
	decreased IgG3 level	J:115034
	decreased interferon-gamma secretion	J:115034
	decreased susceptibility to induced arthritis	J:115034
	impaired macrophage phagocytosis	J:115034
	increased IgM level	J:115034
	increased susceptibility to bacterial infection	J:115034
	increased susceptibility to bacterial infection induced morbidity/mortality	J:115034
\Lta/Tnf^tm1Eug/\Lta/Tnf^tm1Eug (involves: 129 * C57BL/6J)	increased spleen weight	J:112797
\Lta/Tnf^tm1Fda/\Lta/Tnf^tm1Fda (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
\Lta/Tnf^tm1Fda/\Lta⁺ (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
\Lta/Tnf^tm1Fda/\Lta/Tnf^tm1Fda (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
\Lta/Tnf^tm1Fda/\Tnf⁺ (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to endotoxin shock	J:39519
	decreased tumor necrosis factor secretion	J:39519
	increased susceptibility to bacterial infection	J:39519
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (C57BL/6J-Lta/Tnf^tm1Jods)	abnormal spleen morphology	J:43602
	abnormal spleen white pulp morphology	J:43602
	absent lymph nodes	J:43602
	absent Peyer's patches	J:43602
	decreased immunoglobulin level	J:43602
	enlarged spleen	J:43602
	increased leukocyte cell number	J:43602
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	abnormal spleen white pulp morphology	J:78229
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:47428
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (involves: C57BL/6)	abnormal gamma-delta T cell morphology	J:169863
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (C57BL/6J-Lta/Tnf^tm1Jods)	abnormal spleen morphology	J:43602
	absent lymph nodes	J:43602
	absent Peyer's patches	J:43602
	decreased immunoglobulin level	J:43602
	enlarged spleen	J:43602
	increased leukocyte cell number	J:43602
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	abnormal spleen white pulp morphology	J:78229
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (C57BL/6-Lta/Tnf^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:47428
\Lta/Tnf^tm1Jods/\Lta/Tnf^tm1Jods (involves: C57BL/6)	abnormal gamma-delta T cell morphology	J:169863
\Lta^hlb382/\Lta^hlb382 (C57BL/6J-Lta^hlb382/J)	abnormal immune system organ morphology	J:134498
	absent lymph nodes	J:134498
	absent marginal zone B cells	J:134498
	absent mesenteric lymph nodes	J:134498
	absent Peyer's patches	J:134498
	absent spleen germinal center	J:134498
	absent spleen marginal zone	J:134498
	decreased NK cell number	J:134498
	decreased transitional stage B cell number	J:134498
	increased B-1b cell number	J:134498
	increased leukocyte cell number	J:82961
	liver inflammation	J:134498
	lung inflammation	J:134498
\Lta^{tm1.1(KOMP)Vlcg}/\Lta^{tm1.1(KOMP)Vlcg} (C57BL/6N-Lta^{tm1.1(KOMP)Vlcg}/Ucd)	decreased monocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Lta^tm1.1Sned/\Lta^tm1.1Sned (B6.129-Lta^tm1.1Sned)	abnormal circulating tumor necrosis factor level	J:109621
	abnormal class switch recombination	J:109621
	abnormal humoral immune response	J:109621
	abnormal immune system morphology	J:109621
	abnormal lymphopoiesis	J:109621
	absent Peyer's patches	J:109621
	decreased spleen white pulp amount	J:109621
	enlarged spleen	J:109621
	increased susceptibility to bacterial infection induced morbidity/mortality	J:109621
\Lta^tm1Dch/\Lta^tm1Dch (B6.129S2-Lta^tm1Dch)	abnormal class switch recombination	J:80616
	abnormal cytokine secretion	J:95222
	abnormal immune serum protein physiology	J:80616
	abnormal mucosa-associated lymphoid tissue morphology	J:95222
	abnormal spleen morphology	J:80616
	absent Peyer's patches	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased IgM level	J:80616
	increased leukocyte cell number	J:80616
\Lta^tm1Dch/\Lta^tm1Dch (involves: 129S2/SvPas * C57BL/6)	abnormal class switch recombination	J:109621
	abnormal humoral immune response	J:39746
	abnormal leukocyte cell number	J:17976
	abnormal lymph node morphology	J:17976
	abnormal lymph node primary follicle morphology	J:109621
	abnormal spleen morphology	J:17976, J:39746
	abnormal spleen periarteriolar lymphoid sheath morphology	J:17976
	absent axillary lymph nodes	J:17976
	absent cervical lymph nodes	J:17976
	absent inguinal lymph nodes	J:17976
	absent mesenteric lymph nodes	J:17976, J:39746
	absent Peyer's patches	J:17976
	absent popliteal lymph nodes	J:17976
	absent spleen marginal zone	J:17976
	decreased interferon-gamma secretion	J:109621
	decreased spleen white pulp amount	J:109621
	decreased T cell number	J:17976
	decreased tumor necrosis factor secretion	J:109621
	increased B cell number	J:17976
	increased leukocyte cell number	J:17976
\Lta^tm1Dch/\Lta^tm1Dch (B6.129S2-Lta^tm1Dch/J)	abnormal lymph organ development	J:73100
\Lta^tm1Dch/\Lta^tm1Dch (involves: 129S2/SvPas)	abnormal lymphocyte morphology	J:173115
	abnormal thymus epithelium morphology	J:173115
	abnormal thymus medulla morphology	J:173115
	small thymus medulla	J:173115
\Lta^tm1Dch/\Lta^tm1Dch \Rorc^tm2Litt/\Rorc⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal gut-associated lymphoid tissue morphology	J:91566
\Lta^tm1Dch/\Lta^tm1Dch \Tg(Igk-Lta/Ltb)4Cys/0 (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal lymph organ development	J:73100
	abnormal spleen morphology	J:73100
	immune system phenotype	J:73100
\Lta^tm1Dch/\Lta^tm1Dch \Tnfsf14^tm1Lpc/\Tnfsf14^tm1Lpc (involves: 129S2/SvPas * 129X1/SvJ)	abnormal lymphocyte morphology	J:173115
	abnormal thymus epithelium morphology	J:173115
	small thymus medulla	J:173115
\Lta^tm1Jods/\Lta^tm1Jods (C57BL/6-Lta^tm1Jods)	abnormal immune system organ morphology	J:47428
	abnormal spleen morphology	J:47428
	abnormal spleen white pulp morphology	J:78229
	absent peripheral lymph nodes	J:47428
	absent Peyer's patches	J:47428
	increased lymphocyte cell number	J:47428
\Lta^tm1Jods/\Lta^tm1Jods (involves: C57BL/6)	abnormal thymus epithelium morphology	J:125864
\Lta^tm1Tab/\Lta^tm1Tab (either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * CF-1))	abnormal humoral immune response	J:28061
	absent lymph nodes	J:28061
	absent Peyer's patches	J:28061
	absent spleen marginal zone	J:28061
	decreased IgA level	J:28061
	decreased spleen white pulp amount	J:28061
	increased IgM level	J:28061
	increased leukocyte cell number	J:28061
	increased spleen weight	J:28061
\Lta^tm1Tab/\Lta^tm1Tab (involves: 129S2/SvPas * C57BL/6)	decreased tumor necrosis factor secretion	J:109621
\Lta^tm1Tab/\Lta^tm1Tab (B6.129S2-Lta^tm1Tab)	decreased susceptibility to parasitic infection	J:121070
\Ltb4r1^tm1Adl/\Ltb4r1^tm1Adl (involves: 129S4/SvJae * C57BL/6)	abnormal leukocyte adhesion	J:63873
	abnormal leukocyte migration	J:63873
	abnormal macrophage physiology	J:63873
	abnormal neutrophil physiology	J:63873
	impaired eosinophil recruitment	J:63873
	impaired neutrophil chemotaxis	J:63873
\Ltb4r1^tm1Bodd/\Ltb4r1^tm1Bodd (involves: 129S4/SvJaeSor * C57BL/6)	decreased susceptibility to autoimmune disorder	J:108446
\Ltb4r1^tm1Bodd/\Ltb4r1^tm1Bodd (involves: 129S4/SvJaeSor)	decreased susceptibility to induced arthritis	J:131779
\Ltb4r1^tm1Bodd/\Ltb4r1^tm1Bodd (either: (involves: 129S4/SvJaeSor * BALB/c ) or (involves: 129S4/SvJaeSor * C57BL/6))	decreased susceptibility to induced arthritis	J:163271
	impaired neutrophil chemotaxis	J:163271
\Ltb4r1^tm1Tksh/\Ltb4r1^tm1Tksh (B6.Cg-Ltb4r1^tm1Tksh)	abnormal cytokine secretion	J:118995
	decreased eosinophil cell number	J:118995
	decreased IgE level	J:118995
	decreased susceptibility to type I hypersensitivity reaction	J:197334
	lung inflammation	J:118995
\Ltb4r1^tm1Tksh/\Ltb4r1^tm1Tksh (C.Cg-Ltb4r1^tm1Tksh)	abnormal mast cell physiology	J:133998
\Ltb4r1^tm1Tksh/\Ltb4r1^tm1Tksh (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	abnormal granulocyte physiology	J:118995
\Ltb4r2^tm1Bodd/\Ltb4r2^tm1Bodd (involves: 129S4/SvJaeSor * C57BL/6)	decreased susceptibility to induced arthritis	J:163271
	immune system phenotype	J:163271
\Ltb4r2^tm1Tksh/\Ltb4r2^tm1Tksh (C.Cg-Ltb4r2^tm1Tksh)	abnormal mast cell physiology	J:133998
\Ltb4r2^tm1Tksh/\Ltb4r2^tm1Tksh (B6.Cg-Ltb4r2^tm1Tksh)	decreased susceptibility to type I hypersensitivity reaction	J:197334
\Ltb/Tnf/Lta^tm1Dvk/\Ltb/Tnf/Lta^tm1Dvk (involves: C57BL/6)	decreased spleen white pulp amount	J:109621
\Ltb/Tnf/Lta^tm1Dvk/\Ltb/Tnf/Lta^tm1Dvk (B6.Cg-Ltb/Tnf/Lta^tm1Dvk)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent axillary lymph nodes	J:80616
	absent brachial lymph nodes	J:80616
	absent inguinal lymph nodes	J:80616
	absent lymph nodes	J:80616
	absent mesenteric lymph nodes	J:80616
	absent Peyer's patches	J:80616
	absent popliteal lymph nodes	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616
\Ltb/Tnf/Lta^tm1Dvk/\Ltb/Tnf/Lta^tm1Dvk (involves: C57BL/6)	decreased spleen white pulp amount	J:109621
\Ltb/Tnf/Lta^tm1Dvk/\Ltb/Tnf/Lta^tm1Dvk (B6.Cg-Ltb/Tnf/Lta^tm1Dvk)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent axillary lymph nodes	J:80616
	absent brachial lymph nodes	J:80616
	absent inguinal lymph nodes	J:80616
	absent lymph nodes	J:80616
	absent mesenteric lymph nodes	J:80616
	absent Peyer's patches	J:80616
	absent popliteal lymph nodes	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616
\Ltb/Tnf/Lta^tm1Dvk/\Ltb/Tnf/Lta^tm1Dvk (involves: C57BL/6)	decreased spleen white pulp amount	J:109621
\Ltb/Tnf/Lta^tm1Dvk/\Ltb/Tnf/Lta^tm1Dvk (B6.Cg-Ltb/Tnf/Lta^tm1Dvk)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent axillary lymph nodes	J:80616
	absent brachial lymph nodes	J:80616
	absent inguinal lymph nodes	J:80616
	absent lymph nodes	J:80616
	absent mesenteric lymph nodes	J:80616
	absent Peyer's patches	J:80616
	absent popliteal lymph nodes	J:80616
	absent spleen germinal center	J:80616
	absent spleen marginal zone	J:80616
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616
\Ltb/Tnf^tm1.1Dvk/\Ltb/Tnf^tm1.1Dvk (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal mesenteric lymph node morphology	J:58981
	abnormal spleen morphology	J:58981
	absent axillary lymph nodes	J:58981
	absent brachial lymph nodes	J:58981
	absent cervical lymph nodes	J:58981
	absent follicular dendritic cells	J:58981
	absent germinal center B cells	J:58981
	absent inguinal lymph nodes	J:58981
	absent peripheral lymph nodes	J:58981
	absent Peyer's patches	J:58981
	absent popliteal lymph nodes	J:58981
	absent spleen marginal zone	J:58981
	intermingled spleen red and white pulp	J:58981
\Ltb/Tnf^tm1.1Dvk/\Ltb/Tnf^tm1.1Dvk (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal mesenteric lymph node morphology	J:58981
	abnormal spleen morphology	J:58981
	absent axillary lymph nodes	J:58981
	absent brachial lymph nodes	J:58981
	absent cervical lymph nodes	J:58981
	absent follicular dendritic cells	J:58981
	absent germinal center B cells	J:58981
	absent inguinal lymph nodes	J:58981
	absent peripheral lymph nodes	J:58981
	absent Peyer's patches	J:58981
	absent popliteal lymph nodes	J:58981
	absent spleen marginal zone	J:58981
	intermingled spleen red and white pulp	J:58981
\Ltb^tm1Flv/\Ltb^tm1Flv (involves: 129S1/Sv * C57BL/6J)	abnormal humoral immune response	J:39746
	abnormal mesenteric lymph node morphology	J:39746
	abnormal spleen morphology	J:39746
	abnormal spleen red pulp morphology	J:39746
	abnormal spleen white pulp morphology	J:39746
	absent peripheral lymph nodes	J:39746
	absent Peyer's patches	J:39746
	decreased IgA level	J:39746
\Ltb^tm1Kpf/\Ltb^tm1Kpf (B6.129P2-Ltb^tm1Kpf)	abnormal class switch recombination	J:80616
	abnormal spleen morphology	J:80616
	absent spleen marginal zone	J:80616
	colitis	J:158663
	decreased IgG level	J:80616
	decreased spleen B cell follicle number	J:80616
	decreased spleen white pulp amount	J:80616
	increased IgM level	J:80616
	increased leukocyte cell number	J:80616
	increased susceptibility to bacterial infection	J:80616, J:158663
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158663
\Ltb^tm1Kpf/\Ltb^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mesenteric lymph node morphology	J:58981, J:42508
	abnormal spleen follicular dendritic cell network	J:42508
	abnormal spleen germinal center morphology	J:42508
	abnormal spleen marginal zone morphology	J:42508
	abnormal spleen morphology	J:58981, J:42508
	abnormal spleen red pulp morphology	J:42508
	absent axillary lymph nodes	J:42508
	absent brachial lymph nodes	J:42508
	absent cervical lymph nodes	J:58981
	absent follicular dendritic cells	J:58981
	absent inguinal lymph nodes	J:42508
	absent Peyer's patches	J:42508
	absent popliteal lymph nodes	J:42508
	absent spleen marginal zone	J:58981
	decreased spleen white pulp amount	J:109621
	increased lymphocyte cell number	J:42508
\Ltb^tm1Kpf/\Ltb^tm1Kpf \Tnfsf14^tm1Kpf/\Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	abnormal mesenteric lymph node morphology	J:77250
	abnormal spleen morphology	J:77250
	absent axillary lymph nodes	J:77250
	absent brachial lymph nodes	J:77250
	absent inguinal lymph nodes	J:77250
	absent lymph nodes	J:77250
	absent Peyer's patches	J:77250
	absent popliteal lymph nodes	J:77250
\Ltb^tm1Krn/\Ltb^tm1Krn (C57BL/6-Ltb^tm1Krn)	abnormal humoral immune response	J:78229
	abnormal mesenteric lymph node morphology	J:78229
	abnormal spleen morphology	J:78229
	absent cervical lymph nodes	J:78229
	absent peripheral lymph nodes	J:78229
	absent Peyer's patches	J:78229
	decreased IgG1 level	J:78229
	decreased IgG2a level	J:78229
	increased IgM level	J:78229
	increased susceptibility to parasitic infection	J:78229
	spleen hyperplasia	J:78229
\Ltbp1^{tm1a(EUCOMM)Wtsi}/\Ltbp1⁺ (B6JTyr;B6N-Ltbp1^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:175295
\Ltbp3^{em1(IMPC)Ccpcz}/\Ltbp3⁺ (C57BL/6NCrl-Ltbp3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Ltbp3^tm1Bdvc/\Ltbp3^tm1Bdvc (involves: 129S6/SvEvTac)	osteoarthritis	J:76213, J:79920
\Ltbp4^em1(IMPC)Tcp/\Ltbp4^em1(IMPC)Tcp (C57BL/6NCrl-Ltbp4^em1(IMPC)Tcp/Tcp)	decreased basophil cell number	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
\Ltbp4^{Gt(U3Cre)1Vmel}/\Ltbp4^{Gt(U3Cre)1Vmel} (B6.129S2-Ltbp4^{Gt(U3Cre)1Vmel})	colitis	J:78819
	enlarged spleen	J:78819
	proctitis	J:78819
\Ltbr^m1Btlr/\Ltbr^m1Btlr (C57BL/6J-Ltbr^m1Btlr)	abnormal B cell physiology	J:212068
\Ltbr^m1Btlr/\Ltbr^m1Btlr (C57BL/6J-Ltbr^m1Btlr)	abnormal humoral immune response	J:212068
\Ltbr^m2Btlr/\Ltbr^m2Btlr (C57BL/6J-Ltbr^m2Btlr)	abnormal humoral immune response	J:254823
\Ltbr^m2Btlr/\Ltbr^m2Btlr (C57BL/6J-Ltbr^m2Btlr)	abnormal IgG level	J:254823
\Ltbr^m3Btlr/\Ltbr^m3Btlr (C57BL/6J-Ltbr^m3Btlr)	impaired natural killer cell mediated cytotoxicity	J:264642
\Ltbr^m3Btlr/\Ltbr^m3Btlr (C57BL/6J-Ltbr^m3Btlr)	increased NK T cell number	J:264642
\Ltbr^m4Btlr/\Ltbr^m4Btlr (C57BL/6J-Ltbr^m4Btlr)	decreased alpha-beta T cell number	J:264820
	decreased CD4-positive, alpha-beta T cell number	J:264820
	decreased CD8-positive, alpha-beta T cell number	J:264820
	decreased NK cell number	J:264820
	decreased single-positive T cell number	J:264820
	increased B cell number	J:264820
	increased B-1 B cell number	J:264820
\Ltbr^tm1.1Thhe/\Ltbr^tm1.1Thhe \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal macrophage physiology	J:183109
\Ltbr^tm1Avt/\Ltbr^tm1Avt \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	increased susceptibility to bacterial infection	J:158663
\Ltbr^tm1Avt/\Ltbr^tm1Avt \Tg(Lck-cre)I57Jxm/0 (Not Specified)	immune system phenotype	J:158663
\Ltbr^tm1Avt/\Ltbr^tm1Avt \Tg(Rorc-cre)1Litt/0 (Not Specified)	abnormal chemokine level	J:158663
	decreased neutrophil cell number	J:158663
	increased susceptibility to bacterial infection	J:158663
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158663
\Ltbr^tm1Avt/\Ltbr^tm1Avt \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	decreased neutrophil cell number	J:158663
	increased susceptibility to bacterial infection	J:158663
\Ltbr^tm1Kpf/\Ltbr^tm1Kpf (involves: 129P2/OlaHsd)	abnormal gamma-delta T cell morphology	J:169863
	abnormal immune system morphology	J:48837
	abnormal immune system organ morphology	J:48837
	abnormal immune system physiology	J:48837
	abnormal spleen B cell follicle morphology	J:48837
	abnormal spleen morphology	J:48837
	abnormal spleen periarteriolar lymphoid sheath morphology	J:48837
	absent marginal zone B cells	J:48837
	absent peripheral lymph nodes	J:48837
	absent Peyer's patches	J:48837
	decreased IgE level	J:86810
	decreased interleukin-17 secretion	J:169863
	enlarged spleen	J:48837
	immune system phenotype	J:169863
	increased B cell number	J:48837
	increased lymphocyte cell number	J:48837
	increased T cell number	J:48837
\Ltbr^tm1Kpf/\Ltbr^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen white pulp amount	J:109621
\Ltbr^tm1Kpf/\Ltbr^tm1Kpf (B6.129P2-Ltbr^tm1Kpf)	decreased neutrophil cell number	J:158663
\Ltbr^tm1Kpf/\Ltbr^tm1Kpf \Tg(Lck-Tnfsf14)24Yxf/? (B6.Cg-Ltbr^tm1Kpf Tg(Lck-Tnfsf14)24Yxf)	immune system phenotype	J:128976
\Ltbr^tm1Mmat/\Ltbr^tm1Mmat (involves: C57BL/6 * CBA)	abnormal lymphocyte morphology	J:173115
	abnormal spleen morphology	J:173115
	abnormal thymus epithelium morphology	J:173115
	abnormal thymus medulla morphology	J:173115
	absent follicular dendritic cells	J:173115
	absent mesenteric lymph nodes	J:173115
	absent spleen germinal center	J:173115
	small thymus medulla	J:173115
\Ltbr^tm1Mmat/\Ltbr^tm1Mmat \Tnfsf11^tm1Pngr/\Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal thymus epithelium morphology	J:173115
\Ltc4s^tm1Blam/\Ltc4s^tm1Blam (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:110309
	respiratory system inflammation	J:88647
\Ltc4s^tm1Blam/\Ltc4s^tm1Blam (involves: 129S7/SvEvBrd * BALB/c)	abnormal hypersensitivity reaction	J:87909
	abnormal type I hypersensitivity reaction	J:87909
\Ltc4s^tm1Blam/\Ltc4s^tm1Blam (C.129S7-Ltc4s^tm1Blam)	autoimmune response	J:182213
\Ltc4s^tm1Blam/\Ltc4s^tm1Blam (B6.129S7-Ltc4s^tm1Blam)	decreased susceptibility to type I hypersensitivity reaction	J:197334
\Ltf^tm1Omc/\Ltf^tm1Omc (either: 129S/SvEv or (involves: 129S/SvEv * C57BL/6))	decreased spleen iron level	J:81005
\Ltn1^{tm1b(EUCOMM)Hmgu}/\Ltn1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ltn1^{tm1b(EUCOMM)Hmgu}/Ccpcz)	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
\Ltv1^em1(IMPC)J/\Ltv1⁺ (C57BL/6NJ-Ltv1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Ltxs2^BALB/cAnPt/\Ltxs2^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
\Ltxs2^DBA/2NCr/\Ltxs2^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
\Ltxs3^BALB/cAnPt/\Ltxs3^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
\Ltxs3^DBA/2NCr/\Ltxs3^DBA/2NCr (involves: BALB/cAnPt * DBA/2NCr)	decreased susceptibility to infection	J:103336
\Luc7l^em1(IMPC)Mbp/\Luc7l^em1(IMPC)Mbp (C57BL/6N-Luc7l^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Lum^tm1Wwk/\Lum^tm1Wwk (involves: 129P2/OlaHsd)	abnormal inflammatory response	J:128992
\Lum^tm1Wwk/\Lum^tm1Wwk (involves: 129P2/OlaHsd)	decreased neutrophil cell number	J:128992
\Lxw1^BXSB/Scr/? (involves: BXSB/Scr * NZW/LacScr)	increased anti-chromatin antibody level	J:86924
\Lxw2^NZW/LacScr/\Lxw2^NZW/LacScr (involves: BXSB/Scr * NZW/LacScr)	glomerulonephritis	J:86924
\Lxw3^NZW/LacScr/? (involves: BXSB/Scr * NZW/LacScr)	increased anti-chromatin antibody level	J:86924
\Lxw5^BXSB/Scr/\Lxw5^BXSB/Scr (involves: BXSB/Scr * NZW/LacScr)	enlarged spleen	J:86924
\Lxw5^NZW/LacScr/\Lxw5^BXSB/Scr (involves: BXSB/Scr * NZW/LacScr)	enlarged spleen	J:86924
\Lxw6^NZW/LacScr/\Lxw6^NZW/LacScr (involves: BXSB/Scr * NZW/LacScr)	enlarged spleen	J:86924
\Ly6a^tm1Pmf/\Ly6a^tm1Pmf (B6.129P2-Ly6a^tm1Pmf)	abnormal immunoglobulin level	J:42594
	abnormal myeloid leukocyte morphology	J:81387
	abnormal T cell proliferation	J:42594
	decreased granulocyte number	J:81387
	decreased monocyte cell number	J:81387
	increased lymphocyte cell number	J:81387
\Ly6a^tm1Pmf/\Ly6a^tm1Pmf (C.129P2-Ly6a^tm1Pmf)	abnormal osteoclast differentiation	J:83409
\Ly6a^tm1Pmf/\Ly6a^tm1Pmf (C.129P2-Ly6a^tm1Pmf)	decreased osteoclast cell number	J:83409
\Ly6a^{tm2(RUNX1)Grau}/\Ly6a⁺ (involves: 129X1/SvJ * C57BL/6J)	abnormal spleen B cell follicle morphology	J:93408
	enlarged spleen	J:93408
	increased leukocyte cell number	J:93408
	increased neutrophil cell number	J:93408
	myeloid hyperplasia	J:93408
\Ly6e^{tm1c(EUCOMM)Hmgu}/\Ly6e^{tm1c(EUCOMM)Hmgu} \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (B6.Cg-Ly6e^{tm1c(EUCOMM)Hmgu} Commd10^{Tg(Vav1-icre)A2Kio})	abnormal mononuclear cell morphology	J:291868
	decreased B cell number	J:291868
	decreased CD4-positive, alpha-beta T cell number	J:291868
	decreased dendritic cell number	J:291868
	decreased inflammatory response	J:291868
	decreased macrophage cell number	J:291868
	decreased neutrophil cell number	J:291868
	decreased NK cell number	J:291868
	increased susceptibility to Coronaviridae infection	J:291868
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:291868
\Ly6g^{tm2621(cre)Arte}/\Ly6g^{tm2621(cre)Arte} (involves: C57BL/6)	immune system phenotype	J:227159
\Ly9^tm1Mckn/\Ly9^tm1Mckn (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:105482
	abnormal T-helper 2 cell morphology	J:105482
	decreased T cell proliferation	J:105482
\Ly75^tm1Mnz/\Ly75^tm1Mnz (Not Specified)	abnormal CD8-positive, alpha beta T cell morphology	J:97290
\Ly75^tm1Mnz/\Ly75^tm1Mnz (Not Specified)	abnormal cytotoxic T cell physiology	J:97289
\Ly86^{tm1a(KOMP)Wtsi}/\Ly86⁺ (C57BL/6N-Ly86^{tm1a(KOMP)Wtsi}/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Ly86^{tm1a(KOMP)Wtsi}/\Ly86^{tm1a(KOMP)Wtsi} (C57BL/6N-Ly86^{tm1a(KOMP)Wtsi}/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Ly86^tm1Kmiy/\Ly86^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell proliferation	J:109720
	decreased IgG2b level	J:137066
	decreased IgG3 level	J:137066
	increased IgG level	J:109720
	increased IgM level	J:109720
\Ly96^m1Btlr/\Ly96^m1Btlr (C57BL/6J-Ly96^m1Btlr)	decreased interleukin-1 beta secretion	J:265259
	decreased macrophage apoptosis	J:265259
	decreased tumor necrosis factor secretion	J:265259
\Ly96^tm1Kmiy/\Ly96^tm1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune cell physiology	J:92494
	abnormal macrophage physiology	J:92494
	decreased B cell proliferation	J:92494
	decreased interleukin-6 secretion	J:92494
	decreased susceptibility to endotoxin shock	J:92494
	decreased tumor necrosis factor secretion	J:92494
	impaired neutrophil recruitment	J:92479
	increased susceptibility to bacterial infection	J:92494
\Lyar^{Gt(RRG292)Byg}/\Lyar^{Gt(RRG292)Byg} \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:263530
\Lyg1^{tm1(KOMP)Vlcg}/\Lyg1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased CD4-positive, alpha-beta T cell number	J:256594
	decreased CD8-positive, alpha-beta T cell number	J:256594
	decreased interferon-gamma secretion	J:256594
\Lyl1^tm1Fsky/\Lyl1^tm1Fsky (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:116300
	arrested B cell differentiation	J:116300
	decreased B cell number	J:116300
	decreased pro-B cell number	J:116300
\Lyn^m1Anu/\Lyn^m1Anu (C57BL/6JAnu-Lyn^m1Anu)	decreased B cell number	J:195155
\Lyn^M1Btlr/\Lyn⁺ (C57BL/6J-Lyn^M1Btlr)	decreased B cell number	J:214511
\Lyn^M1Btlr/\Lyn⁺ (C57BL/6J-Lyn^M1Btlr)	increased neutrophil cell number	J:214511
\Lyn^M1Btlr/\Lyn^M1Btlr (C57BL/6J-Lyn^M1Btlr)	decreased B cell number	J:214511
\Lyn^M1Btlr/\Lyn^M1Btlr (C57BL/6J-Lyn^M1Btlr)	increased neutrophil cell number	J:214511
\Lyn^m2Anu/\Lyn^m2Anu (C57B/6JAnu-Lyn^m2Anu/AnuApb)	decreased mature B cell number	J:104190
\Lyn^m2Anu/\Lyn^m2Anu (C57B/6JAnu-Lyn^m2Anu/AnuApb)	increased immature B cell number	J:104190
\Lyn^M2Btlr/\Lyn⁺ (C57BL/6J-Lyn^M2Btlr)	decreased IgG level	J:217146
	decreased IgM level	J:217146
	impaired humoral immune response	J:217146
\Lyn^M2Btlr/\Lyn^M2Btlr (C57BL/6J-Lyn^M2Btlr)	decreased IgG level	J:217146
	decreased IgM level	J:217146
	impaired humoral immune response	J:217146
\Lyn^M3Btlr/\Lyn⁺ (C57BL/6J-Lyn^M3Btlr)	decreased T cell number	J:236679
	increased B-1 B cell number	J:236679
	increased dendritic cell number	J:236679
	increased macrophage cell number	J:236679
\Lyn^M3Btlr/\Lyn^M3Btlr (C57BL/6J-Lyn^M3Btlr)	decreased T cell number	J:236679
	increased B-1 B cell number	J:236679
	increased dendritic cell number	J:236679
	increased macrophage cell number	J:236679
\Lyn^m4Btlr/\Lyn^m4Btlr (C57BL/6J-Lyn^m4Btlr)	decreased IgG level	J:272816
\Lyn^m4Btlr/\Lyn^m4Btlr (C57BL/6J-Lyn^m4Btlr)	impaired humoral immune response	J:272816
\Lyn^mld4/\Lyn^mld4 (involves: C57BL/6)	abnormal B cell activation	J:144799
	abnormal B cell morphology	J:144799
	abnormal myelopoiesis	J:144799
	decreased follicular B cell number	J:144799
	decreased marginal zone B cell number	J:144799
	decreased transitional stage B cell number	J:144799
	glomerulonephritis	J:144799
	increased anti-double stranded DNA antibody level	J:144799
	increased IgE level	J:144799
	increased IgM level	J:144799
	increased macrophage cell number	J:144799
	increased neutrophil cell number	J:144799
	increased T cell number	J:144799
	peritoneal inflammation	J:144799
	spleen hypoplasia	J:144799
\Lyn^mld4/\Lyn^mld4 \Mpl^tm1Wsa/\Mpl^tm1Wsa (B6.129S1-Mpl^tm1Wsa)	decreased leukocyte cell number	J:144799
\Lyn^tm1.1Calo/\Lyn^tm1.1Calo \Myd88^tm1Defr/\Myd88^tm1Defr \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:200745
\Lyn^tm1.1Calo/\Lyn^tm1.1Calo \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal circulating chemokine level	J:200745
	abnormal circulating cytokine level	J:200745
	abnormal dendritic cell physiology	J:200745
	abnormal leukocyte physiology	J:200745
	abnormal T cell activation	J:200745
	enlarged lymph nodes	J:200745
	enlarged spleen	J:200745
	glomerulonephritis	J:200745
	increased activated T cell number	J:200745
	increased autoantibody level	J:200745
	increased circulating interferon-gamma level	J:200745
	increased circulating interleukin-1 beta level	J:200745
	increased circulating interleukin-6 level	J:200745
	increased circulating interleukin-12 level	J:200745
	increased circulating interleukin-17 level	J:200745
	increased circulating tumor necrosis factor level	J:200745
	increased dendritic cell number	J:200745
	increased granulocyte number	J:200745
	increased inflammatory response	J:200745
	increased leukocyte cell number	J:200745
	increased monocyte cell number	J:200745
	increased plasma cell number	J:200745
	increased T cell number	J:200745
	liver inflammation	J:200745
	lung inflammation	J:200745
	lymph node hyperplasia	J:200745
	myeloid hyperplasia	J:200745
	skin inflammation	J:200745
\Lyn^tm1Ard/\Lyn⁺ \Ptpn6^me-v/\Ptpn6⁺ \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
\Lyn^tm1Ard/\Lyn⁺ \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
\Lyn^tm1Ard/\Lyn^tm1Ard (involves: 129P2/OlaHsd)	abnormal circulating complement protein level	J:161523
	abnormal level of surface class II molecules	J:161523
	decreased spleen red pulp amount	J:72269
	decreased spleen white pulp amount	J:72269
	enlarged spleen	J:72269
	glomerulonephritis	J:161523
	increased anti-double stranded DNA antibody level	J:161523
	increased anti-nuclear antigen antibody level	J:161523
	increased basophil cell number	J:161523
	increased IgA level	J:161523
	increased IgE level	J:161523
	increased IgG2b level	J:161523
	increased IgM level	J:161523
	increased mast cell number	J:161523
	increased neutrophil cell number	J:72269
\Lyn^tm1Ard/\Lyn^tm1Ard (B6.129P2-Lyn^tm1Ard)	abnormal B cell activation	J:144799
	abnormal B cell morphology	J:144799
	abnormal myelopoiesis	J:144799
	decreased follicular B cell number	J:144799
	decreased marginal zone B cell number	J:144799
	decreased transitional stage B cell number	J:144799
	glomerulonephritis	J:144799
	increased anti-double stranded DNA antibody level	J:144799
	increased anti-nuclear antigen antibody level	J:144799
	increased T cell number	J:144799
	peritoneal inflammation	J:144799
	spleen hypoplasia	J:144799
\Lyn^tm1Ard/\Lyn^tm1Ard \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:110531
	abnormal B cell negative selection	J:110531
	abnormal mature B cell morphology	J:110531
	absent B-1 B cells	J:110531
	increased IgM level	J:110531
\Lyn^{tm1b(EUCOMM)Hmgu}/\Lyn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Lyn^{tm1b(EUCOMM)Hmgu}/H)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
\Lyn^tm1Mhi/\Lyn^tm1Mhi (involves: 129S1/Sv)	decreased spleen weight	J:72269
\Lyn^tm1Mhi/\Lyn^tm1Mhi (involves: 129S1/Sv)	increased neutrophil cell number	J:72269
\Lyn^tm1Sor/\Lyn^tm1Sor (involves: 129S4/SvJae)	decreased B cell number	J:42037
	decreased mature B cell number	J:42037
	enlarged lymph nodes	J:42037
	enlarged spleen	J:42037
	increased anti-double stranded DNA antibody level	J:42037
	increased B cell proliferation	J:42037
\Lyn^tm1Sor/\Lyn^tm1Sor (B6.129S4-Lyn^tm1Sor)	abnormal inflammatory response	J:113463
\Lyn^tm1Sor/\Lyn^tm1Sor (involves: 129S4/SvJaeSor)	abnormal chemokine level	J:80658
	abnormal circulating chemokine level	J:200745
	abnormal circulating cytokine level	J:200745
	abnormal dendritic cell physiology	J:200745
	abnormal macrophage physiology	J:80658
	abnormal microglial cell physiology	J:80658
	decreased B cell number	J:200745
	decreased follicular B cell number	J:146161
	decreased marginal zone B cell number	J:146161
	decreased mature B cell number	J:146161
	decreased transitional stage B cell number	J:146161
	glomerulonephritis	J:146161, J:200745
	increased anti-double stranded DNA antibody level	J:146161
	increased autoantibody level	J:200745
	increased B cell proliferation	J:146161
	increased circulating interferon-gamma level	J:200745
	increased circulating interleukin-6 level	J:200745
	increased circulating interleukin-12 level	J:200745
	increased circulating interleukin-17 level	J:200745
	increased IgA level	J:146161
	increased IgM level	J:146161
	increased plasma cell number	J:200745
	liver inflammation	J:146161
	myeloid hyperplasia	J:146161
	spleen hyperplasia	J:146161
\Lyn^tm1Sor/\Lyn^tm1Sor (involves: 129S4/SvJaeSor * C57BL/6)	decreased B cell number	J:71174
	decreased B-1 B cell number	J:71174
	decreased mature B cell number	J:71174
	enlarged spleen	J:71174
	glomerulonephritis	J:71174
	increased anti-double stranded DNA antibody level	J:71174
	increased B cell proliferation	J:71174
	increased IgA level	J:71174
	increased IgG1 level	J:71174
	increased IgG2b level	J:71174
	increased IgG level	J:71174
	increased IgM level	J:71174
	increased susceptibility to systemic lupus erythematosus	J:71174
\Lyn^tm1Tya/\Lyn^tm1Tya (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:29751
	abnormal class switch recombination	J:29751
	abnormal spleen morphology	J:29751
	decreased B cell number	J:29751
	decreased B cell proliferation	J:29751
	decreased lymphocyte cell number	J:29751
	enlarged lymph nodes	J:29751
	enlarged spleen	J:29751
	glomerulonephritis	J:29751
	increased anti-double stranded DNA antibody level	J:29751
	increased IgA level	J:29751
	increased IgM level	J:29751
	increased immunoglobulin level	J:29751
	increased spleen white pulp amount	J:29751
	small Peyer's patches	J:29751
\Lyn^weeb/\Lyn^weeb (C57BL/6-Lyn^weeb)	decreased follicular B cell number	J:146161
	decreased marginal zone B cell number	J:146161
	decreased mature B cell number	J:146161
	decreased transitional stage B cell number	J:146161
	disorganized spleen B cell follicle	J:146161
	glomerulonephritis	J:146161
	increased anti-double stranded DNA antibody level	J:146161
	increased B cell proliferation	J:146161
	increased IgM level	J:146161
	liver inflammation	J:146161
	spleen hyperplasia	J:146161
\Lynf1^C57BL/10J/\Lynf1^C57BL/10J \Lynf3^C57BL/10J/\Lynf3^C57BL/10J (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
\Lynf2^C57BL/10J/\Lynf2^C57BL/10J \Lynf3^C57BL/10J/\Lynf3^C57BL/10J (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
\Lynf2^O20/A/\Lynf2^O20/A (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
\Lynf4^C57BL/10J/\Lynf4^C57BL/10J (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
\Lynf4^C57BL/10J/\Lynf4^O20/A (involves: B10.O20 * O20/A)	abnormal acute inflammation	J:128728
\Lypd8^tm2Ktak/\Lypd8^tm2Ktak (B6.Cg-Lypd8^tm2Ktak)	increased susceptibility to colitis induced morbidity/mortality	J:232706
\Lypd8^tm2Ktak/\Lypd8^tm2Ktak (B6.Cg-Lypd8^tm2Ktak)	increased susceptibility to induced colitis	J:232706
\Lyset^em1Janc/\Lyset^em1Janc (C57BL/6J-Tmem251^em1Janc)	decreased susceptibility to viral infection	J:330704
\Lyset^em1Janc/\Lyset^em2Janc (C57BL/6J-Tmem251^em1Janc Tmem251^em2Janc)	decreased susceptibility to viral infection	J:330704
\Lyset^em2Janc/\Lyset^em2Janc (C57BL/6J-Tmem251^em2Janc)	decreased susceptibility to viral infection	J:330704
\Lyst^bg-2Btlr/\Lyst^bg-2Btlr (C57BL/6J-Lyst^bg-2Btlr)	abnormal NK cell physiology	J:133617
\Lyst^bg-2Btlr/\Lyst^bg-2Btlr (C57BL/6J-Lyst^bg-2Btlr)	increased susceptibility to Herpesvirales infection	J:133617
\Lyst^bg-2J/\Lyst^bg-2J (C3.Cg-Lyst^bg-2J/J)	abnormal susceptibility to infection	J:147940
\Lyst^bg-2J/\Lyst^bg-2J (C3.Cg-Lyst^bg-2J/J)	decreased susceptibility to fungal infection	J:147940
\Lyst^bg-5Btlr/\Lyst⁺ (C57BL/6J-Lyst^bg-5Btlr)	impaired macrophage phagocytosis	J:217864
\Lyst^bg-5Btlr/\Lyst^bg-5Btlr (C57BL/6J-Lyst^bg-5Btlr)	impaired macrophage phagocytosis	J:217864
\Lyst^bg-6Btlr/\Lyst^bg-6Btlr (C57BL/6J-Lyst^bg-6Btlr)	increased susceptibility to Herpesvirales infection	J:220065
\Lyst^bg-Btlr/\Lyst^bg-Btlr (C57BL/6J-Lyst^bg-Btlr)	abnormal NK cell physiology	J:133616
	increased susceptibility to bacterial infection	J:133616
	increased susceptibility to Herpesvirales infection	J:133616
\Lyst^bg-grey/\Lyst^bg-grey (C57BL/6-Lyst^bg-grey)	abnormal dermal mast cell morphology	J:106442
\Lyst^bg-J/\Lyst^bg-J (C57BL/6J-Lyst^bg-J/J)	abnormal granulocyte morphology	J:34814
	abnormal neutrophil morphology	J:34814
	decreased macrophage cell number	J:34814
	impaired natural killer cell mediated cytotoxicity	J:34814
\Lyst^bg-J/\Lyst^bg-J \Prkdc^scid/\Prkdc^scid (B6.Cg-Lyst^bg-J Prkdc^scid/Sz)	abnormal complement pathway	J:34814
	abnormal granulocyte morphology	J:34814
	abnormal level of surface class II molecules	J:34814
	abnormal lymph node morphology	J:34814
	abnormal neutrophil morphology	J:34814
	abnormal Peyer's patch morphology	J:34814
	abnormal spleen white pulp morphology	J:34814
	abnormal thymus morphology	J:34814
	decreased B cell number	J:34814
	decreased CD4-positive, alpha-beta T cell number	J:34814
	decreased CD8-positive, alpha-beta T cell number	J:34814
	decreased immunoglobulin level	J:34814
	decreased lymphocyte cell number	J:34814
	decreased pre-B cell number	J:34814
	decreased T cell number	J:34814
	impaired natural killer cell mediated cytotoxicity	J:34814
	increased eosinophil cell number	J:34814
	increased granulocyte number	J:34814
	increased macrophage cell number	J:34814
	increased monocyte cell number	J:34814
	increased neutrophil cell number	J:34814
	increased NK cell number	J:34814
	small Peyer's patches	J:34814
	small thymus	J:34814
	spleen hypoplasia	J:34814
	thymus cyst	J:34814
\Lyst^bg-Lac/\Lyst^bg-Lac (CBA/CaLac-Lyst^bg-Lac)	absent NK T cells	J:29745
\Lyst^bg/\Lyst^bg (B6.C3Rl-Lyst^bg)	abnormal eosinophil morphology	J:5078
	abnormal lymphocyte morphology	J:5078
	abnormal neutrophil morphology	J:5078
	alveolitis	J:110157
	decreased cytotoxic T cell cytolysis	J:6692
	impaired natural killer cell mediated cytotoxicity	J:6302, J:6213
\Lyst^bg/\Lyst^bg (B6.C3Rl-Lyst^bg/J)	abnormal NK cell physiology	J:6801
\Lyst^bg/\Lyst^bg (B6.C3Rl-Lyst^bg/J)	increased susceptibility to parasitic infection	J:6946
\Lyst^bg/\Lyst^bg \Prkdc^scid/\Prkdc^scid (Not Specified)	increased susceptibility to infection	J:4752
\Lyve1^{tm1.1(EGFP/cre)Cys}/\Lyve1⁺ \Sphk1^tm2Cgh/\Sphk1^tm2Cgh \Sphk2^tm1.1Cgh/\Sphk2^tm1.1Cgh (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal leukocyte migration	J:156826
	abnormal lymph node morphology	J:156826
	abnormal lymphatic vessel morphology	J:156826
	abnormal lymphocyte cell number	J:156826
	abnormal Peyer's patch T cell area morphology	J:156826
	decreased B cell number	J:156826
	decreased splenocyte number	J:156826
	decreased T cell number	J:156826
	immune system phenotype	J:156826
\Lyve1^tm1Dgjk/\Lyve1^tm1Dgjk (involves: 129 * C57BL/6)	immune system phenotype	J:117678
\Lyve1^tm1Lhua/\Lyve1^tm1Lhua (B6.129S1-Lyve1^tm1Lhua)	abnormal lymph circulation	J:117713
\Lyve1^tm1Lhua/\Lyve1^tm1Lhua (B6.129S1-Lyve1^tm1Lhua)	lymphangiectasis	J:117713
\Lyz2^tm1(cre)Ifo/0 \Nup85^tm1.1Yter/\Nup85^tm1.1Yter (involves: 129P2/OlaHsd * C57BL/6)	decreased macrophage cell number	J:292726
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:172024
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Nfkbiz^tm1.1Muta/\Nfkbiz^tm1.1Muta (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:194832
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Nsd3^tm1.1Caox/\Nsd3^tm1.1Caox (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL)	decreased macrophage cytokine production	J:251909
	increased susceptibility to Riboviria infection	J:251909
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:251909
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Pdcd10^tm1Wami/\Pdcd10^tm1Wami (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal neutrophil morphology	J:256076
	abnormal neutrophil physiology	J:256076
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Pikfyve^{tm1b(EUCOMM)Hmgu}/\Pikfyve^{tm1b(EUCOMM)Hmgu} (involves: 129P2/OlaHsd * C57BL/6N)	abnormal alveolar macrophage morphology	J:244776
	decreased alveolar macrophage number	J:244776
	decreased regulatory T cell number	J:244776
	immune system phenotype	J:244776
	increased eosinophil cell number	J:244776
	increased interleukin-4 secretion	J:244776
	increased interleukin-13 secretion	J:244776
	increased susceptibility to type I hypersensitivity reaction	J:244776
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Rnf217^tm1.1Fudi/\Rnf217^tm1.1Fudi (involves: 129P2/OlaHsd)	decreased spleen iron level	J:315675
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ \Selenow^{tm1c(EUCOMM)Wtsi}/\Selenow^{tm1c(EUCOMM)Wtsi} (B6.Cg-Selenow^{tm1c(EUCOMM)Wtsi} Lyz2^tm1(cre)Ifo)	abnormal osteoclast differentiation	J:317012
\Lyz2^tm1(cre)Ifo/\Lyz2⁺ \St18^{tm1c(KOMP)Wtsi}/\St18^{tm1c(KOMP)Wtsi} (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	immune system phenotype	J:298828
	increased circulating interleukin-1 beta level	J:298828
	increased inflammatory response	J:298828
\Lyz2^tm1(cre)Ifo/\Lyz2^tm1(cre)Ifo \Nrros^tm1Wouy/\Nrros^tm1Wouy (involves: 129P2/OlaHsd)	abnormal cellular extravasation	J:209569
	increased susceptibility to experimental autoimmune encephalomyelitis	J:209569
\Lyz2^{tm1(HBEGF)Mtka}/\Lyz2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal alveolar macrophage morphology	J:145285
\Lyz2^tm1.1Graf/\Lyz2^tm1.1Graf (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased inflammatory response	J:82642
\Lztr1^em2Tumg/\Lztr1⁺ (C57BL/6J-Lztr1^em2Tumg)	abnormal lymphatic vessel morphology	J:361054
\Lztr1^em2Tumg/\Lztr1⁺ (C57BL/6J-Lztr1^em2Tumg)	enlarged spleen	J:361054
\Lztr1^em2Tumg/\Lztr1^em2Tumg (C57BL/6J-Lztr1^em2Tumg)	abnormal lymphatic vessel morphology	J:361054
\m1Hefl/\m1Hefl (C3HeB/FeJ-m1Hefl)	decreased B cell number	J:137446
X/\m1Nish (involves: BALB/c * C57BL/6N)	absent B cells	J:204833
	absent Peyer's patches	J:204833
	decreased NK cell number	J:204833
X/\m1Nish (involves: C57BL/6N)	abnormal B cell differentiation	J:204833
	abnormal NK cell differentiation	J:204833
	absent B cells	J:204833
	absent B-1 B cells	J:204833
	absent B-2 B cells	J:204833
	absent Peyer's patches	J:204833
	decreased B cell number	J:204833
	decreased B-1 B cell number	J:204833
	decreased IgG level	J:204833
	decreased IgM level	J:204833
	decreased immature B cell number	J:204833
	decreased NK cell number	J:204833
	decreased T cell proliferation	J:204833
	immune system phenotype	J:204833
	small lymph nodes	J:204833
\m1Nish/\m1Nish⁺ (involves: BALB/c * C57BL/6N)	immune system phenotype	J:204833
\m1Nish/\m1Nish⁺ (involves: C57BL/6N)	immune system phenotype	J:204833
\m2Hefl/\m2Hefl (C3HeB/FeJ-m2Hefl)	absent B cells	J:137446
\m2Hefl/\m2Hefl (C3HeB/FeJ-m2Hefl)	absent T cells	J:137446
\m3Hefl/\m3Hefl (C3HeB/FeJ-m3Hefl)	decreased CD8-positive, alpha-beta T cell number	J:137446
\m3Hefl/\m3Hefl (C3HeB/FeJ-m3Hefl)	decreased NK cell number	J:137446
\m4Hefl/\m4Hefl (C3HeB/FeJ-m4Hefl)	decreased T cell number	J:137446
\m5Hefl/\m5Hefl (C3HeB/FeJ-m5Hefl)	decreased T cell number	J:137446
\M6pr^em1(IMPC)Mbp/\M6pr^em1(IMPC)Mbp (C57BL/6N-M6pr^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\M7321Wlst/\M7321Wlst⁺ (involves: 129S1/SvImJ * C57BL/6J)	abnormal thrombopoiesis	J:189491
\M7324Wlst/\M7324Wlst⁺ (involves: 129S1/SvImJ * C57BL/6J)	abnormal thrombopoiesis	J:189491
\M7325Wlst/\M7325Wlst⁺ (involves: 129S1/SvImJ * C57BL/6J)	abnormal thrombopoiesis	J:189491
\m12137Asr/\m12137Asr⁺ (C57BL/6J-m12137Asr)	decreased osteoclast cell number	J:132290
\Macroh2a1^tm1.1Oxbo/\Macroh2a1^tm1.1Oxbo (B6.Cg-Macroh2a1^tm1.1Oxbo)	decreased B cell number	J:293382
	decreased neutrophil cell number	J:293382
	increased eosinophil cell number	J:293382
	increased lymphocyte cell number	J:293382
\Macroh2a1^tm1Peh/\Macroh2a1^tm1Peh \Macroh2a2^tm1.1Peh/\Macroh2a2^tm1.1Peh (129S6.Cg-Macroh2a2^tm1.1Peh Macroh2a1^tm1Peh)	blepharitis	J:220524
\Macroh2a2^{em1(IMPC)Hmgu}/\Macroh2a2^{em1(IMPC)Hmgu} (C57BL/6NCrl-Macroh2a2^{em1(IMPC)Hmgu}/Ieg)	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Mad2l1^tm1Sorg/\Mad2l1⁺ (involves: 129S2/SvPas * C57BL/6)	increased spleen germinal center number	J:62829
\Madcam1^tm1.2Nwag/\Madcam1^tm1.2Nwag (B6.129P2-Madcam1^tm1.2Nwag)	abnormal B cell physiology	J:169739
	decreased B cell number	J:169739
	decreased IgA level	J:169739
	decreased plasma cell number	J:169739
	increased plasma cell number	J:169739
	small Peyer's patches	J:169739
\Maea^Gt(XG702)Byg/\Maea^Gt(XG702)Byg (involves: 129P2/OlaHsd * C57BL/6J)	decreased macrophage cell number	J:114865
\Maf^em1(IMPC)Mbp/\Maf⁺ (C57BL/6N-Maf^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Maf^Ofl/\Maf^Ofl (either: 102/ElH or C3H/HeH)	tubular nephritis	J:82475
\Maf^tm1Glm/\Maf^tm1Glm (involves: 129/Sv * BALB/c)	decreased interleukin-4 secretion	J:78382
\Mafb^tm1Jeng/\Mafb^tm1Jeng (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:111415
\Mafg^tm1Jeng/\Mafg^tm1Jeng \Mafk^tm1Jeng/\Mafk^tm1Jeng (involves: 129S1/Sv * 129X1/SvJ)	enlarged spleen	J:61142
\Mag^{tm1.1(KOMP)Vlcg}/\Mag^{tm1.1(KOMP)Vlcg} (C57BL/6N-Mag^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Mag^tm1Rod/\Mag^tm1Rod (involves: 129S1/Sv * 129X1/SvJ)	increased B cell proliferation	J:217719
\Maged1^tm1.1Urfm/\Maged1^tm1.1Urfm (involves: 129P2/OlaHsd)	abnormal tumor necrosis factor level	J:157549
\Magi2^tm1Key/\Magi2^tm1Key (involves: 129S4/SvJae)	tubulointerstitial nephritis	J:213553
\Magix^{em1(IMPC)Hmgu}/Y (C57BL/6NCrl-Magix^{em1(IMPC)Hmgu}/Ieg)	decreased leukocyte cell number	J:211773
\Magt1^{Gt(IST13422E1)Tigm}/Y (involves: C57BL/6N)	abnormal B cell morphology	J:260923
	decreased plasma cell number	J:260923
	decreased T cell number	J:260923
	increased B cell number	J:260923
	increased B cell proliferation	J:260923
	increased marginal zone B cell number	J:260923
\Malat1^tm1.2Dlsp/\Malat1^tm1.2Dlsp (B6J.Cg-Malat1^tm1.2Dlsp)	brain inflammation	J:239375
\Malt1^m1Btlr/\Malt1⁺ (C57BL/6J-Malt1^m1Btlr)	impaired humoral immune response	J:221474
\Malt1^m1Btlr/\Malt1^m1Btlr (C57BL/6J-Malt1^m1Btlr)	impaired humoral immune response	J:221474
\Malt1^m2Btlr/\Malt1⁺ (C57BL/6J-Malt1^m2Btlr)	decreased IgM level	J:224671
\Malt1^m2Btlr/\Malt1⁺ (C57BL/6J-Malt1^m2Btlr)	impaired humoral immune response	J:224671
\Malt1^m2Btlr/\Malt1^m2Btlr (C57BL/6J-Malt1^m2Btlr)	decreased IgG level	J:224671
	decreased IgM level	J:224671
	impaired humoral immune response	J:224671
\Malt1^m3Btlr/\Malt1⁺ (C57BL/6J-Malt1^m3Btlr)	decreased IgM level	J:224672
\Malt1^m3Btlr/\Malt1⁺ (C57BL/6J-Malt1^m3Btlr)	impaired humoral immune response	J:224672
\Malt1^m3Btlr/\Malt1^m3Btlr (C57BL/6J-Malt1^m3Btlr)	decreased IgG level	J:224672
	decreased IgM level	J:224672
	impaired humoral immune response	J:224672
\Malt1^tm1Mak/\Malt1^tm1Mak (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:111706
	decreased IgG level	J:109545
	decreased IgM level	J:109545
	decreased T cell proliferation	J:109545
\Malt1^tm1Vmd/\Malt1^tm1Vmd (involves: C57BL/6N)	abnormal B cell differentiation	J:86770
	abnormal double-negative T cell morphology	J:86770
	abnormal immune system morphology	J:86770
	abnormal spleen marginal zone morphology	J:86770
	abnormal T cell differentiation	J:86770
	abnormal T cell proliferation	J:86770
	absent B-1a cells	J:86770
	decreased immunoglobulin level	J:86770
	decreased interleukin-2 secretion	J:86770
\Maml1^tm1Mkit/\Maml1^tm1Mkit (involves: 129P2/OlaHsd * C57BL/6)	decreased marginal zone B cell number	J:122286
	decreased thymocyte number	J:122286
	increased double-negative T cell number	J:122286
\Mamld1^{tm1.1(NCOM)Mfgc}/Y (C57BL/6N-Mamld1^{tm1.1(NCOM)Mfgc}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Man2a1^tm1Jxm/\Man2a1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immune serum protein physiology	J:74579
	abnormal immune system physiology	J:74579
	abnormal self tolerance	J:74579
	abnormal spleen morphology	J:74579
	enlarged spleen	J:41621
	glomerulonephritis	J:74579
	immune system phenotype	J:74579
	increased IgA level	J:74579
	increased IgG level	J:74579
	increased IgM level	J:74579
	increased memory T cell number	J:74579
	liver inflammation	J:74579
	lung inflammation	J:74579
\Man2a1^tm1Jxm/\Man2a1^tm1Jxm \Rag1^tm1Mom/\Rag1^tm1Mom (B6.129-Rag1^tm1Mom Man2a1^tm1Jxm)	kidney inflammation	J:124348
\Man2b1^tm1Psa/\Man2b1^tm1Psa (involves: 129 * C57BL/6J)	abnormal Kupffer cell morphology	J:56659
\Man2b1^tm1Psa/\Man2b1^tm1Psa (involves: 129 * C57BL/6J)	abnormal spleen red pulp morphology	J:56659
\Man2b2^{tm1b(KOMP)Wtsi}/\Man2b2^{tm1b(KOMP)Wtsi} (C57BL/6N-Man2b2^{tm1b(KOMP)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Man2c1^tm1.1Tbec/\Man2c1^tm1.1Tbec (B6N.129P2-Man2c1^tm1.1Tbec)	abnormal microglial cell activation	J:205550
\Manba^tm1Khf/\Manba^tm1Khf (B6.129-Manba^tm1Khf)	abnormal Kupffer cell morphology	J:105427
\Map2k3^tm1Flv/\Map2k3^tm1Flv (involves: 129S1/Sv)	abnormal CD4-positive, alpha-beta T cell physiology	J:85266
\Map2k3^tm1Flv/\Map2k3^tm1Flv (involves: 129S1/Sv)	decreased T cell apoptosis	J:85266
\Map2k3^tm1Flv/\Map2k3^tm1Flv (B6.129S1-Map2k3^tm1Flv)	increased susceptibility to bacterial infection	J:124327
\Map2k6^tm1Flv/\Map2k6^tm1Flv (involves: 129S1/Sv)	abnormal thymocyte apoptosis	J:85266
\Map2k6^tm1Ina/\Map2k6^tm1Ina \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal thymus cell ratio	J:100093
\Map3k1^tm1Glj/\Map3k1^tm1Glj (involves: 129S/SvEv)	heart inflammation	J:78068
\Map3k1^tm1Glj/\Map3k1^tm1Glj (involves: 129S/SvEv)	immune system phenotype	J:62909
\Map3k2^tm1Bisu/\Map3k2^tm1Bisu (Not Specified)	abnormal cytokine secretion	J:78072
	abnormal T cell activation	J:78072
	increased T cell proliferation	J:78072
\Map3k3^tm1Bisu/\Map3k3^tm2Bisu \Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal T cell physiology	J:145923
	abnormal T cell proliferation	J:145923
	decreased CD4-positive, alpha-beta T cell number	J:145923
	decreased CD8-positive, alpha-beta T cell number	J:145923
	spleen hypoplasia	J:145923
\Map3k3^tm1Kuro/\Map3k3^tm1Kuro \Tg(Lck-cre)1Jtak/0 (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:147103
	decreased CD8-positive, alpha-beta T cell number	J:147103
	decreased double-positive T cell number	J:147103
	decreased interferon-gamma secretion	J:147103
	decreased interleukin-2 secretion	J:147103
	decreased single-positive T cell number	J:147103
	decreased T cell proliferation	J:147103
	decreased thymocyte number	J:147103
	increased double-negative T cell number	J:147103
\Map3k4^tm1Flv/\Map3k4^tm1Flv (involves: 129S6/SvEvTac * C57BL/6)	abnormal T-helper 1 physiology	J:90112
	decreased interferon-gamma secretion	J:90112
\Map3k5^tm1Hijo/\Map3k5^tm1Hijo (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:251158
\Map3k7^tm1.1Gkl/\Map3k7^tm1.1Gkl \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-10 level	J:211916
	decreased interleukin-10 secretion	J:211916
	increased circulating interleukin-1 beta level	J:211916
	increased circulating tumor necrosis factor level	J:211916
	increased inflammatory response	J:211916
	increased interleukin-1 beta secretion	J:211916
	increased interleukin-6 secretion	J:211916
	increased interleukin-10 secretion	J:211916
	increased susceptibility to endotoxin shock	J:211916
	increased tumor necrosis factor secretion	J:211916
\Map3k7^tm1Aki/\Map3k7^tm1Aki \Tg(Alb1-cre)7Gsc/0 (involves: 129P2/OlaHsd * FVB/N)	liver inflammation	J:160521
\Map3k7^tm1Aki/\Map3k7^tm1Aki \Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd)	abnormal spleen morphology	J:112837
	abnormal T cell activation	J:112837
	absent regulatory T cells	J:112837
	colitis	J:112837
	decreased CD4-positive, alpha-beta T cell number	J:112837
	decreased CD8-positive, alpha-beta T cell number	J:112837
	decreased single-positive T cell number	J:112837
	decreased T cell number	J:112837
	decreased T cell proliferation	J:112837
	enlarged lymph nodes	J:112837
	enlarged spleen	J:112837
	increased memory T cell number	J:112837
	spleen hyperplasia	J:112837
\Map3k7^tm1Aki/\Map3k7^tm1Aki \Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:238318
	abnormal CD4-positive, alpha-beta T cell physiology	J:238318
	abnormal cytokine level	J:238318
	abnormal intraepithelial T cell number	J:238318
	abnormal regulatory T cell number	J:238318
	abnormal regulatory T cell physiology	J:238318
	abnormal T cell morphology	J:238318
	colitis	J:238318
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:238318
	decreased NK T cell number	J:238318
	increased CD4-positive, alpha-beta T cell number	J:238318
	increased gamma-delta intraepithelial T cell number	J:238318
	increased interferon-gamma secretion	J:238318
	increased interleukin-17 secretion	J:238318
\Map3k7^tm1Zjc/\Map3k7^tm1Zjc \Tg(Lck-cre)548Jxm/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:111794
	decreased CD8-positive, alpha-beta T cell number	J:111794
	decreased T cell number	J:111794
	increased thymocyte apoptosis	J:111794
\Map3k8^M1Btlr/\Map3k8⁺ (C57BL/6J-Map3k8^M1Btlr)	abnormal tumor necrosis factor secretion	J:140986
\Map3k8^M1Btlr/\Map3k8⁺ (C57BL/6J-Map3k8^M1Btlr)	decreased tumor necrosis factor secretion	J:140986
\Map3k8^M1Btlr/\Map3k8^M1Btlr (C57BL/6J-Map3k8^M1Btlr)	abnormal response to infection	J:140986
	decreased interferon-alpha secretion	J:140986
	decreased interferon-beta secretion	J:140986
	decreased interleukin-1 beta secretion	J:140986
	decreased interleukin-6 secretion	J:140986
	decreased tumor necrosis factor secretion	J:140986
	impaired natural killer cell mediated cytotoxicity	J:140986
	increased interleukin-12b secretion	J:140986
\Map3k8^m2Btlr/\Map3k8^m2Btlr (C57BL/6J-Map3k8^m2Btlr)	abnormal response to infection	J:212899
\Map3k8^m3Btlr/\Map3k8⁺ (C57BL/6J-Map3k8^m3Btlr)	decreased macrophage cytokine production	J:224668
\Map3k8^m3Btlr/\Map3k8⁺ (C57BL/6J-Map3k8^m3Btlr)	decreased tumor necrosis factor secretion	J:224668
\Map3k8^m3Btlr/\Map3k8^m3Btlr (C57BL/6J-Map3k8^m3Btlr)	decreased macrophage cytokine production	J:224668
\Map3k8^m3Btlr/\Map3k8^m3Btlr (C57BL/6J-Map3k8^m3Btlr)	decreased tumor necrosis factor secretion	J:224668
\Map3k8^M4Btlr/\Map3k8⁺ (C57BL/6J-Map3k8^M4Btlr)	decreased tumor necrosis factor secretion	J:254880
\Map3k8^M4Btlr/\Map3k8^M4Btlr (C57BL/6J-Map3k8^M4Btlr)	decreased tumor necrosis factor secretion	J:254880
\Map3k8^tm1.2Gkl/\Map3k8^tm1.2Gkl (involves: 129 * C57BL/6J * FVB/N)	decreased tumor necrosis factor secretion	J:193546
\Map3k8^tm1Pnt/\Map3k8^tm1Pnt (involves: 129S1/Sv * C57BL/6J)	decreased susceptibility to endotoxin shock	J:66503
	decreased tumor necrosis factor secretion	J:66503
	immune system phenotype	J:66503
\Map3k8^tm1Pnt/\Map3k8^tm1Pnt (involves: 129S1/Sv)	immune system phenotype	J:142340, J:196528
\Map3k8^tm1Pnt/\Map3k8^tm1Pnt \Nfkb1^tm1Sley/\Nfkb1^tm1Sley (involves: 129S1/Sv * 129S4/SvJae)	decreased circulating interleukin-12b level	J:196528
	decreased interleukin-12b secretion	J:196528
	decreased tumor necrosis factor secretion	J:196528
\Map3k8^tm1Pnt/\Map3k8^tm1Pnt \Tnf^tm2Gkl/\Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	increased CD8-positive, alpha-beta T cell number	J:108572
	increased single-positive T cell number	J:108572
	small intestinal inflammation	J:108572
\Map3k8^tm1Sley/\Map3k8^tm1Sley \Nfkb1^tm1Sley/\Nfkb1^tm1Sley (involves: 129S4/SvJae)	decreased tumor necrosis factor secretion	J:196528
\Map3k8^tm1Tmat/\Map3k8^tm1Tmat (involves: 129S/SvEv * C57BL/6)	abnormal cytokine secretion	J:92844
	abnormal dendritic cell antigen presentation	J:92844
	decreased IgE level	J:92844
	decreased IgG1 level	J:92844
	increased IgG2a level	J:92844
	increased T cell proliferation	J:92844
\Map3k9^em1(IMPC)Mbp/\Map3k9^em1(IMPC)Mbp (C57BL/6N-Map3k9^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Map3k10^tm1Dsd/\Map3k10^tm1Dsd \Map3k11^tm1Rjd/\Map3k11^tm1Rjd (involves: 129 * 129S6/SvEvTac * C57BL/6J)	abnormal circulating chemokine level	J:177426
	abnormal circulating cytokine level	J:177426
	abnormal response to infection	J:177426
\Map3k10^tm1Dsd/\Map3k10^tm1Dsd \Map3k11^tm2.1Rjd/\Map3k11^tm2.1Rjd (involves: 129 * C57BL/6J)	abnormal circulating chemokine level	J:177426
	abnormal circulating cytokine level	J:177426
	abnormal response to infection	J:177426
\Map3k14^aly/\Map3k14⁺ \Relb^{Tg(H2-K1/GH1)106Bri}/\Relb⁺ (involves: C57BL/6 * C57BL/6J)	decreased circulating interferon-gamma level	J:120659
	decreased NK T cell number	J:120659
	decreased Peyer's patch number	J:120659
	small Peyer's patches	J:120659
\Map3k14^aly/\Map3k14^aly (involves: C57BL/6J)	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:87993, J:128211
	abnormal dendritic cell antigen presentation	J:128211
	abnormal dendritic cell physiology	J:128211
	abnormal immune system morphology	J:147681
	abnormal immune system physiology	J:147681
	abnormal NK T cell morphology	J:120659
	abnormal T cell activation	J:38580
	abnormal thymus corticomedullary boundary morphology	J:87993
	abnormal thymus medulla morphology	J:87993
	absent Peyer's patches	J:120659
	bile duct inflammation	J:48224
	decreased circulating interferon-gamma level	J:120659
	decreased circulating interleukin-4 level	J:120659
	decreased dendritic cell number	J:128211
	decreased IgE level	J:135748
	decreased mast cell number	J:135748
	decreased NK T cell number	J:120659
	decreased regulatory T cell number	J:128211
	increased eosinophil cell number	J:135748
	increased inflammatory response	J:38580, J:48224
	increased susceptibility to parasitic infection	J:135748
	kidney inflammation	J:38580
	lacrimal gland inflammation	J:38580
	liver inflammation	J:48224
	lung inflammation	J:48224
	pancreas inflammation	J:48224
	small thymus	J:147681
	thymus cyst	J:147681
\Map3k14^aly/\Map3k14^aly (involves: AEJ/GnRk * C57BL/6J)	abnormal immune system morphology	J:54529
	abnormal lymphocyte morphology	J:16865
	abnormal lymphopoiesis	J:16865
	abnormal spleen primary B follicle morphology	J:54529
	absent follicular dendritic cells	J:54529
	absent lymph nodes	J:16865, J:54529
	absent Peyer's patches	J:16865, J:54529
	absent spleen marginal zone	J:54529
	absent thymus corticomedullary boundary	J:16865, J:54529
	decreased B cell number	J:54529
	decreased IgA level	J:16865, J:54529
	decreased IgG level	J:16865, J:54529
	decreased IgM level	J:16865, J:54529
	decreased spleen B cell follicle number	J:16865
	increased length of allograft survival	J:16865
\Map3k14^aly/\Map3k14^aly (C57BL/6J-Map3k14^aly)	absent lymph nodes	J:16865
\Map3k14^aly/\Map3k14^aly (C57BL/6J-Map3k14^aly)	increased susceptibility to infection	J:16865
\Map3k14^m1Btlr/\Map3k14^m1Btlr (C57BL/6J-Map3k14^m1Btlr)	abnormal B cell activation	J:152065
	absent lymph nodes	J:152065
	arrested B cell differentiation	J:152065
	decreased B cell number	J:152065
	decreased IgG level	J:152065
\Map3k14^m1Btlr/\Map3k14^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	arrested B cell differentiation	J:185495
	decreased IgG level	J:185495
\Map3k14^tm1.1Gne/\Map3k14^tm1.1Gne \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac)	decreased B cell number	J:280549
\Map3k14^tm1.1Gne/\Map3k14^tm1.1Gne \Otub1^{tm1c(EUCOMM)Hmgu}/\Otub1^{tm1c(EUCOMM)Hmgu} \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * C57BL/6NTac)	immune system phenotype	J:280549
\Map3k14^tm1.2Gne/\Map3k14^tm1.2Gne (B6(Cg)-Map3k14^tm1.2Gne)	abnormal B cell physiology	J:240453
	abnormal spleen marginal zone morphology	J:240453
	abnormal thymus cell ratio	J:240453
	absent inguinal lymph nodes	J:240453
	absent Peyer's patches	J:240453
	absent popliteal lymph nodes	J:240453
	decreased B cell number	J:240453
	decreased B-2 B cell number	J:240453
	decreased follicular B cell number	J:240453
	decreased germinal center B cell number	J:240453
	decreased IgA level	J:240453
	decreased marginal zone B cell number	J:240453
	decreased transitional stage T1 B cell number	J:240453
	decreased transitional stage T2 B cell number	J:240453
	small axillary lymph nodes	J:240453
	small brachial lymph nodes	J:240453
\Map3k14^tm1Rds/\Map3k14^tm1Rds (involves: 129/Sv * C57BL/6)	abnormal spleen morphology	J:68125
	abnormal thymus morphology	J:68125
	absent axillary lymph nodes	J:68125
	absent cervical lymph nodes	J:68125
	absent inguinal lymph nodes	J:68125
	absent lymph nodes	J:68125
	absent mesenteric lymph nodes	J:68125
	absent Peyer's patches	J:68125
	absent popliteal lymph nodes	J:68125
	decreased IgA level	J:68125
	decreased IgG2b level	J:68125
	decreased immunoglobulin level	J:68125
\Map3k14^tm1Rds/\Map3k14^tm1Rds (involves: 129)	abnormal class switch recombination	J:188560
\Map4k1^m1Anu/\Map4k1^m1Anu (C57BL/6NCrlAnu-Map4k1^m1Anu)	immune system phenotype	J:104190
\Map4k1^tm1Ssaw/\Map4k1^tm1Ssaw (B6.Cg-Map4k1^tm1Ssaw)	abnormal dendritic cell antigen presentation	J:150295
	abnormal dendritic cell physiology	J:150295
	increased interleukin-1 beta secretion	J:150295
	increased interleukin-6 secretion	J:150295
	increased interleukin-12 secretion	J:150295
	increased tumor necrosis factor secretion	J:150295
\Map4k1^tm1Tht/\Map4k1^tm1Tht (B6.129S7-Map4k1^tm1Tht)	increased susceptibility to experimental autoimmune encephalomyelitis	J:116613
\Map4k1^tm1Tht/\Map4k1^tm1Tht (involves: 129S7/SvEvBrd)	abnormal cytokine secretion	J:116613
	abnormal humoral immune response	J:116613
	increased T cell proliferation	J:116613
\Map4k3^{Gt(RRO270)Byg}/\Map4k3^{Gt(RRO270)Byg} (involves: 129P2/OlaHsd)	abnormal interleukin secretion	J:177642
	abnormal T-helper 1 cell differentiation	J:177642
	abnormal T-helper 2 cell differentiation	J:177642
	abnormal T-helper 17 cell differentiation	J:177642
	decreased IgG1 level	J:177642
	decreased IgG2a level	J:177642
	decreased IgG2b level	J:177642
	decreased IgG3 level	J:177642
	decreased IgM level	J:177642
	decreased immunoglobulin level	J:177642
	decreased interferon-gamma secretion	J:177642
	decreased interleukin-2 secretion	J:177642
	decreased interleukin-4 secretion	J:177642
	decreased interleukin-17 secretion	J:177642
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177642
	decreased T cell proliferation	J:177642
	immune system phenotype	J:177642
\Map4k5^{Gt(OST218153)Lex}/\Map4k5^{Gt(OST218153)Lex} (B6;129S5-Map4k5^{Gt(OST218153)Lex}/Ieg)	increased CD4-positive, alpha-beta T cell number	J:82809
	increased IgG1 level	J:82809
\Map7^mshi/\Map7^mshi (involves: BALB/cBy)	decreased length of allograft survival	J:37165
\Mapk1^tm1.1Hed/\Mapk1^tm1.1Hed \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T cell subpopulation ratio	J:113280
	decreased CD4-positive, alpha-beta T cell number	J:113280
	decreased CD8-positive, alpha-beta T cell number	J:113280
\Mapk1^tm1Gela/\Mapk1^tm1Gela \H2az2^{Tg(Wnt1-cre)11Rth}/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)	abnormal thymus morphology	J:144862
\Mapk1^tm1Gela/\Mapk1^tm1Gela \Mapk3^tm1Gela/\Mapk3⁺ \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)	abnormal thymus morphology	J:144862
\Mapk1^tm1Gela/\Mapk1^tm1Gela \Mapk3^tm1Gela/\Mapk3^tm1Gela \H2az2^{Tg(Wnt1-cre)11Rth}/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J)	athymia	J:144862
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Mapk3^tm1Gpg/\Mapk3^tm1Gpg \Tg(Cd4-cre)1Cwi/0 (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal positive T cell selection	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Mapk3^tm1Gpg/\Mapk3^tm1Gpg \Tg(Cd4-cre)1Cwi/0 \Tg(TcrAND)53Hed/0 (involves: 129/Sv * C57BL/6 * DBA/2 * SJL)	abnormal positive T cell selection	J:113280
	abnormal T cell subpopulation ratio	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Mapk3^tm1Gpg/\Mapk3^tm1Gpg \Tg(Lck-cre)1Cwi/0 (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal T cell proliferation	J:113280
	decreased thymocyte number	J:113280
	increased double-positive T cell number	J:113280
	small thymus	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Mapk3^tm1Gpg/\Mapk3^tm1Gpg \Tg(TcraTcrb)1100Mjb/0 (involves: 129/Sv * C57BL/6)	decreased thymocyte number	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal positive T cell selection	J:113280
	decreased CD4-positive, alpha-beta T cell number	J:113280
	decreased CD8-positive, alpha-beta T cell number	J:113280
	increased double-positive T cell number	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T cell subpopulation ratio	J:113280
	decreased double-positive T cell number	J:113280
	decreased T cell proliferation	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Tg(Lck-cre)1Cwi/0 \Tg(TcrAND)53Hed/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal positive T cell selection	J:113280
	abnormal T cell subpopulation ratio	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Tg(TcrAND)53Hed/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal double-positive T cell morphology	J:113280
	abnormal positive T cell selection	J:113280
\Mapk1^tm1Hed/\Mapk1^tm1Hed \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	decreased thymocyte number	J:113280
\Mapk1^tm2Moga/\Mapk1^tm2Moga \Mapk3^tm1Gpg/\Mapk3^tm1Gpg \Tg(Mx1-cre)1Cgn/? (involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * CBA)	abnormal pro-B cell differentiation	J:134528
	abnormal pro-B cell morphology	J:134528
	decreased pre-B cell number	J:134528
\Mapk3^m1Btlr/\Mapk3^m1Btlr (C57BL/6J-Mapk3^m1Btlr)	decreased interleukin-1 beta secretion	J:221481
\Mapk3^tm1Gela/\Mapk3^tm1Gela (either: 129(Cg)-Mapk3^tm1Gela or B6.129-Mapk3^tm1Gela)	abnormal cytokine secretion	J:107504
	increased susceptibility to experimental autoimmune encephalomyelitis	J:107504
\Mapk3^tm1Gpg/\Mapk3^tm1Gpg (involves: 129)	decreased T cell number	J:58468
\Mapk3^tm1Gpg/\Mapk3^tm1Gpg (involves: 129)	decreased T cell proliferation	J:58468
\Mapk8^tm1Flv/\Mapk8^tm1Flv (involves: 129S1/Sv)	abnormal cytokine secretion	J:51510
	abnormal T-helper 1 cell differentiation	J:51510
	increased T cell proliferation	J:51510
\Mapk8^tm1Rjd/\Mapk8^tm1Rjd \Mapk9^tm2.1Rjd/\Mapk9^tm2.1Rjd \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6J.Cg-Lyz2^tm1(cre)Ifo Mapk9^tm2.1Rjd Mapk8^tm1Rjd)	abnormal chemokine level	J:192551
	abnormal circulating chemokine level	J:192551
	abnormal circulating cytokine level	J:192551
	abnormal macrophage differentiation	J:192551
	abnormal macrophage physiology	J:192551
	decreased inflammatory response	J:192551
	decreased macrophage cell number	J:192551
	decreased macrophage cytokine production	J:192551
	impaired macrophage chemotaxis	J:192551
\Mapk8^tm1Wag/\Mapk8⁺ \Mapk9^tm1Mka/\Mapk9⁺ (involves: 129)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
\Mapk8^tm1Wag/\Mapk8⁺ \Mapk9^tm1Mka/\Mapk9^tm1Mka (involves: 129)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
\Mapk8^tm1Wag/\Mapk8^tm1Wag (involves: 129P2/OlaHsd)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
\Mapk8^tm1Wag/\Mapk8^tm1Wag \Mapk9^tm1Mka/\Mapk9⁺ (involves: 129)	abnormal T cell activation	J:78190
	decreased T cell apoptosis	J:78190
	decreased T cell proliferation	J:78190
\Mapk9^tm1Flv/\Mapk9^tm1Flv (involves: 129S2/SvPas)	abnormal T-helper 1 cell differentiation	J:50628
\Mapk9^tm1Flv/\Mapk9^tm1Flv \Tnf^tm2Gkl/\Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	immune system phenotype	J:108572
	small intestinal inflammation	J:108572
\Mapk9^tm1Mka/\Mapk9^tm1Mka (either: (involves: 129S2/SvPas) or (involves: 129S1/Sv * 129X1/SvJ))	abnormal T cell activation	J:78129
	decreased T cell apoptosis	J:78129
	decreased T cell proliferation	J:78129
\Mapk11^tm1Jda/\Mapk11^tm1Jda (B6.Cg-Mapk11^tm1Jda)	immune system phenotype	J:165966
\Mapk11^tm1Jda/\Mapk11^tm1Jda \Mapk14^tm1Jda/\Mapk14^tm1Jda (involves: 129 * C57BL/6)	abnormal T-helper 1 cell differentiation	J:165966
	abnormal T-helper 2 cell differentiation	J:165966
	abnormal T-helper 17 cell differentiation	J:165966
	decreased interferon-gamma secretion	J:165966
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:165966
	decreased susceptibility to induced arthritis	J:165966
	decreased T cell proliferation	J:165966
	decreased tumor necrosis factor secretion	J:165966
	increased interleukin-10 secretion	J:165966
\Mapk11^tm1Jsca/\Mapk11^tm1Jsca (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:107771
\Mapk11^tm1Jsca/\Mapk11^tm1Jsca \Tnf^tm2Gkl/\Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	autoimmune arthritis	J:107771
	ileum inflammation	J:107771
\Mapk14^tm1Jda/\Mapk14^tm1Jda (B6.Cg-Mapk14^tm1Jda)	abnormal T-helper 1 physiology	J:146088
	decreased interferon-alpha secretion	J:146088
	decreased interferon-gamma secretion	J:146088
	decreased T cell proliferation	J:146088
	increased double-negative T cell number	J:146088
\Mapkapk2^tm1.2Gkl/\Mapkapk2^tm1.2Gkl (involves: BALB/cJ * C57BL/6)	decreased circulating tumor necrosis factor level	J:262876
	decreased tumor necrosis factor secretion	J:262876
\Mapkapk2^{tm1b(EUCOMM)Hmgu}/\Mapkapk2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mapkapk2^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
\Mapkapk2^tm1Mgl/\Mapkapk2^tm1Mgl (involves: 129P2/OlaHsd * C57BL/6J)	abnormal cytokine level	J:59678
	abnormal macrophage derived foam cell morphology	J:142788
	decreased circulating tumor necrosis factor level	J:59678
	decreased susceptibility to endotoxin shock	J:59678
	increased spleen germinal center size	J:59678
\Mapkapk2^tm1Mgl/\Mapkapk2^tm1Mgl (involves: 129S * C57BL/6)	decreased interferon-gamma secretion	J:76161
	decreased tumor necrosis factor secretion	J:76161
	impaired macrophage phagocytosis	J:76161
	increased interleukin-1 beta secretion	J:76161
	increased susceptibility to bacterial infection	J:76161
	increased susceptibility to bacterial infection induced morbidity/mortality	J:76161
\Mapkapk2^tm1Mgl/\Mapkapk2^tm1Mgl (involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:117668
\Mapkapk2^tm1Mgl/\Mapkapk2^tm1Mgl \Mapkapk3^tm1.1Lex/\Mapkapk3^tm1.1Lex (involves: 129P2/OlaHsd * 129S/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:117668
\Mapkapk2^tm1Mgl/\Mapkapk2^tm1Mgl \Tnf^tm2Gkl/\Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	granulomatous inflammation	J:108572
	immune system phenotype	J:108572
	small intestinal inflammation	J:108572
\Mapkapk3^{em1(IMPC)Ccpcz}/\Mapkapk3^{em1(IMPC)Ccpcz} (C57BL/6N-Mapkapk3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Mapkapk3^tm1.1Lex/\Mapkapk3^tm1.1Lex (involves: 129S/SvEvBrd * C57BL/6)	immune system phenotype	J:117668
\Mapkbp1^{tm1b(EUCOMM)Hmgu}/\Mapkbp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mapkbp1^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
\Mapt^tm1(EGFP)Klt/\Mapt^tm1(EGFP)Klt \Tg(MAPT)8cPdav/? (involves: 129S4/SvJae * C57BL/6 * Swiss Webster)	abnormal spleen B cell follicle morphology	J:174270
	abnormal spleen B cell follicle shape	J:174270
	abnormal spleen red pulp morphology	J:174270
	increased spleen B cell follicle size	J:174270
\Mapt^{tm2.1(FUS)Neas}/\Mapt⁺ (B6J.129P2(129S)-Mapt^{tm2.1(FUS)Neas})	microgliosis	J:232167
\Mapt^{tm3.1(FUS)Neas}/\Mapt⁺ (B6J.129P2(129S)-Mapt^{tm3.1(FUS)Neas})	microgliosis	J:232167
\Mar1^tm1Wtg/\Mar1⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:68024
\Mar1^tm1Wtg/\Mar1⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal somatic hypermutation frequency	J:68024
\Mar1^tm1Wtg/\Mar1^tm1Wtg (involves: 129S6/SvEvTac * C57BL/6)	abnormal somatic hypermutation frequency	J:68024
\Marchf1^tm1.1Sish/\Marchf1^tm1.1Sish (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell physiology	J:119918
	abnormal dendritic cell antigen presentation	J:201198, J:157516
	abnormal dendritic cell morphology	J:119918
	abnormal level of surface class II molecules	J:119918
	abnormal T cell differentiation	J:201198
	decreased interleukin-12 secretion	J:157516
	decreased regulatory T cell number	J:201198
	decreased tumor necrosis factor secretion	J:157516
	immune system phenotype	J:201198
\Marchf2^em1Cnu/\Marchf2^em1Cnu (C57BL/6-Marchf2^em1Cnu)	decreased susceptibility to bacterial infection	J:297482
	decreased susceptibility to viral infection	J:297482
	increased circulating interferon-beta level	J:297482
	increased circulating interleukin-6 level	J:297482
	increased circulating interleukin-12 level	J:297482
	increased circulating tumor necrosis factor level	J:297482
	increased interleukin-6 secretion	J:297482
	increased interleukin-12 secretion	J:297482
	increased susceptibility to bacterial infection induced morbidity/mortality	J:297482
	increased susceptibility to endotoxin shock	J:297482
\Marchf3^em1Hbsh/\Marchf3^em1Hbsh (involves: C57BL/6J)	abnormal circulating cytokine level	J:267641
\Marchf3^em1Hbsh/\Marchf3^em1Hbsh (involves: C57BL/6J)	increased susceptibility to infection induced morbidity/mortality	J:267641
\Marchf3^{tm1b(EUCOMM)Hmgu}/\Marchf3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Marchf3^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Marchf5^tm1.1Ygi/\Marchf5^tm1.1Ygi \Tg(Emx1-cre)#Ito/0 (involves: C57BL/6)	increased microglial cell activation	J:284572
\Marchf5^{tm1a(EUCOMM)Wtsi}/\Marchf5⁺ (C57BL/6-Marchf5^{tm1a(EUCOMM)Wtsi})	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:225000
	increased circulating interferon-beta level	J:225000
	increased circulating interleukin-6 level	J:225000
\Marchf6^{tm1b(EUCOMM)Hmgu}/\Marchf6^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Marchf6^{tm1b(EUCOMM)Hmgu}/Ccpcz)	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased T-helper cell number	J:211773
\Marchf7^{Gt(ROSABetageo)1Summ}/\Marchf7⁺ (involves: BALB/c)	abnormal cytokine secretion	J:96167
	abnormal interleukin level	J:96167
	increased interleukin-10 secretion	J:96167
	increased T cell proliferation	J:96167
\Marchf7^{Gt(ROSABetageo)1Summ}/\Marchf7^{Gt(ROSABetageo)1Summ} (involves: BALB/c)	abnormal cytokine secretion	J:96167
	abnormal interleukin level	J:96167
	increased interleukin-10 secretion	J:96167
	increased T cell proliferation	J:96167
\Marchf8^{em2(IMPC)Ccpcz}/\Marchf8^{em2(IMPC)Ccpcz} (C57BL/6N-Marchf8^{em2(IMPC)Ccpcz}/Ccpcz)	decreased eosinophil cell number	J:211773
\Marchf8^tm1.1Lkle/\Marchf8^tm1.1Lkle (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:236611
\Marchf9^{tm1a(EUCOMM)Wtsi}/\Marchf9^{tm1a(EUCOMM)Wtsi} (Not Specified)	decreased B cell number	J:165965
\Marcksl1^tm1Fsh/\Marcksl1^tm1Fsh (involves: 129S4/SvJae)	abnormal macrophage physiology	J:115146
\Marco^tm1Ktry/\Marco^tm1Ktry (B6.129S6-Marco^tm1Ktry)	abnormal macrophage physiology	J:115081
	abnormal spleen marginal zone morphology	J:122271
	impaired macrophage phagocytosis	J:115081
	increased inflammatory response	J:115081
	increased susceptibility to bacterial infection	J:115081, J:122271
\Marco^tm1Ktry/\Marco^tm1Ktry \Msr1^tm1Csk/\Msr1^tm1Csk (B6.129-Marco^tm1Ktry Msr1^tm1Csk)	abnormal macrophage physiology	J:122271
	abnormal spleen marginal zone morphology	J:122271
	increased IgM level	J:122271
	increased susceptibility to bacterial infection	J:122271
\Marco^tm1Spt/\Marco^tm1Spt (C57BL/6-Marco^tm1Spt)	abnormal dendritic cell chemotaxis	J:204315
	abnormal dendritic cell physiology	J:204315
	increased interferon-gamma secretion	J:204315
\Marif1^C57BL/10J/\Marif1^C57BL/10J (involves: O20/A * NXT-10/Dem)	abnormal immune serum protein physiology	J:90251
	decreased interleukin-12 secretion	J:90251
	decreased tumor necrosis factor secretion	J:90251
\Marif2^C57BL/10J/\Marif2^C57BL/10J (involves: O20/A * NXT-10/Dem)	abnormal immune serum protein physiology	J:90251
	decreased interleukin-12 secretion	J:90251
	increased tumor necrosis factor secretion	J:90251
\Marif3^C57BL/10J/\Marif3^C57BL/10J (involves: O20/A * NXT-10/Dem)	increased interleukin-12 secretion	J:90251
\Mark2^tm1Hpw/\Mark2^tm1Hpw (involves: 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:68830
	abnormal humoral immune response	J:68830
	abnormal immune system physiology	J:68830
	abnormal spleen B cell follicle morphology	J:68830
	decreased B cell proliferation	J:68830
	decreased IgG3 level	J:68830
	decreased IgM level	J:68830
	enlarged lymph nodes	J:68830
	enlarged spleen	J:68830
	glomerulonephritis	J:68830
	increased B cell number	J:68830
	increased B cell proliferation	J:68830
	increased interferon-gamma secretion	J:68830
	increased interleukin-4 secretion	J:68830
	increased spleen weight	J:68830
	kidney inflammation	J:68830
	lung inflammation	J:68830
	lymph node hyperplasia	J:68830
	salivary gland inflammation	J:68830
	spleen hyperplasia	J:68830
\Mark4^em1(IMPC)Mbp/\Mark4^em1(IMPC)Mbp (C57BL/6N-Mark4^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Marveld2^tm1.1Sria/\Marveld2^tm1.1Sria (involves: 129X1/SvJ * C57BL/6J)	increased spleen weight	J:201580
\Marveld3^{em1(IMPC)Ccpcz}/\Marveld3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Marveld3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Masp1^tm1Tefu/\Masp1^tm1Tefu (B6.129S4-Masp1^tm1Tefu)	impaired complement alternative pathway	J:177350
\Masp1^tm1Tefu/\Masp1^tm1Tefu (B6.129S4-Masp1^tm1Tefu)	impaired lectin complement pathway	J:134537
\Masp2^tm1Tefu/\Masp2^tm1Tefu (involves: 129 * C57BL/6)	abnormal complement pathway	J:140667
\Masp2^tm1Wjsc/\Masp2^tm1Wjsc (B6.129P2-Masp2^tm1Wjsc)	impaired lectin complement pathway	J:172218
\Mast4^m1Anu/\Mast4^m1Anu (C57BL/6NCrlAnu-Mast4^m1Anu)	immune system phenotype	J:104190
\Mat1a^tm1Jmm/\Mat1a^tm1Jmm (involves: 129/Sv * C57BL/6)	liver inflammation	J:69408
\Matn1^tm1Ref/\Matn1^tm1Ref \Matn2^tm1Asz/\Matn2^tm1Asz \Matn3^tm1Asz/\Matn3^tm1Asz \Matn4^tm1.1Asz/\Matn4^tm1.1Asz (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased double-positive T cell number	J:237230
	increased granulocyte number	J:237230
\Matn3^tm1Brd/\Matn3^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6)	osteoarthritis	J:112002
\Matr3^em1Tcp/\Matr3^em1Tcp (C57BL/6J-Matr3^em1Tcp)	increased microglial cell activation	J:298091
\Mavs^tm1Aki/\Mavs^tm1Aki (Not Specified)	abnormal cytokine secretion	J:124405
	abnormal response to infection	J:124405
	decreased circulating interleukin-6 level	J:124405
	decreased interferon-alpha secretion	J:124405
	decreased interferon-beta secretion	J:124405
	decreased interleukin-6 secretion	J:124405
	increased susceptibility to Picornaviridae infection	J:124405
\Mavs^tm1Aki/\Mavs^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:130954
	decreased circulating interferon-alpha level	J:130954
	decreased circulating interferon-beta level	J:130954
	decreased circulating interferon-gamma level	J:130954
	decreased circulating interleukin-6 level	J:130954
	decreased IgG1 level	J:130954
	decreased IgG2a level	J:130954
	decreased IgG level	J:130954
	decreased interferon-beta secretion	J:130954
	decreased interleukin-12b secretion	J:130954
\Mavs^tm1Aki/\Mavs^tm1Aki (involves: C57BL/6)	immune system phenotype	J:132662
\Mavs^tm1Aki/\Mavs^tm1Aki (involves: 129S/SvEv * C57BL/6)	abnormal circulating interferon level	J:162888
	abnormal dendritic cell physiology	J:162888
	abnormal macrophage physiology	J:162888
	brain inflammation	J:162888
	CNS inflammation	J:162888
	decreased CD4-positive, alpha-beta T cell number	J:162888
	decreased CD8-positive, alpha-beta T cell number	J:162888
	decreased interferon-beta secretion	J:162888
	enlarged spleen	J:162888
	immune system phenotype	J:162888
	increased circulating interferon-gamma level	J:162888
	increased circulating interleukin-6 level	J:162888
	increased circulating tumor necrosis factor level	J:162888
	increased dendritic cell number	J:162888
	increased IgG2a level	J:162888
	increased IgG level	J:162888
	increased IgM level	J:162888
	increased susceptibility to Flaviviridae infection	J:162888
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:162888
\Mavs^tm1Aki/\Mavs^tm1Aki \Ifna6^tm1Aki/\Ifna6⁺ (involves: 129P2/OlaHsd)	abnormal alveolar macrophage morphology	J:124340
	abnormal macrophage morphology	J:124340
	abnormal myeloid dendritic cell morphology	J:124340
	decreased interferon-alpha secretion	J:124340
\Mavs^tm1Aki/\Mavs^tm1Aki \Ticam1^tm1Aki/\Ticam1^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:130954
	decreased circulating interferon-alpha level	J:130954
	decreased circulating interferon-beta level	J:130954
	decreased circulating interferon-gamma level	J:130954
	decreased circulating interleukin-6 level	J:130954
	decreased circulating interleukin-12b level	J:130954
	decreased cytotoxic T cell cytolysis	J:130954
	decreased IgG1 level	J:130954
	decreased IgG2a level	J:130954
	decreased IgG level	J:130954
	decreased interferon-beta secretion	J:130954
	decreased interleukin-12b secretion	J:130954
\Mavs^tm1Camb/\Mavs^tm1Camb (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell calcium ion homeostasis	J:180356
	decreased B cell proliferation	J:180356
	decreased interleukin-12 secretion	J:180356
	decreased tumor necrosis factor secretion	J:180356
\Mavs^tm1Itl/\Mavs^tm1Itl \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	increased inflammatory response	J:181257
	myocarditis	J:181257
	myositis	J:181257
	skin inflammation	J:181257
	stomach inflammation	J:181257
\Mavs^tm1Tsc/\Mavs^tm1Tsc (Not Specified)	decreased interferon-beta secretion	J:136289
\Mavs^tm1Tsse/\Mavs^tm1Tsse \Tg(PVR)1Kkst/0 (involves: 129 * C57BL/6 * ICR)	abnormal interferon-alpha secretion	J:179625
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:179625
\Mavs^tm1Zjc/\Mavs⁺ (involves: 129/Sv * C57BL/6)	abnormal innate immunity	J:110905
\Mavs^tm1Zjc/\Mavs⁺ (involves: 129/Sv * C57BL/6)	increased susceptibility to Riboviria infection	J:110905
\Mavs^tm1Zjc/\Mavs^tm1Zjc (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:110905
	abnormal innate immunity	J:110905
	abnormal macrophage physiology	J:110905
	increased susceptibility to Riboviria infection	J:110905
\Mavs^tm1Zjc/\Mavs^tm1Zjc (B6.Cg-Mavs^tm1Zjc)	abnormal circulating interferon level	J:243916
\Mavs^tm1Zjc/\Mavs^tm1Zjc \Rnaseh2a^tm1Crh/\Rnaseh2a^tm1Crh (Not Specified)	abnormal innate immunity	J:232933
\Mb21d2^em1(IMPC)Mbp/\Mb21d2^em1(IMPC)Mbp (C57BL/6N-Mb21d2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\Mbd2^tm1Bh/\Mbd2^tm1Bh (NOD.129P2(B6)-Mbd2^tm1Bh)	abnormal CD4-positive, alpha-beta T cell physiology	J:323838
	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:323838
	abnormal effector T cell morphology	J:323838
	enlarged lymph nodes	J:323838
	enlarged spleen	J:323838
	increased T cell proliferation	J:323838
	increased T-helper 1 cell number	J:323838
	increased T-helper 2 cell number	J:323838
	insulitis	J:323838
	salivary gland inflammation	J:323838
\Mbd3^tm2Bh/\Mbd3^tm2Bh \Tg(Vil1-cre)20Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	increased susceptibility to induced colitis	J:167984
\Mbd5^{tm1b(EUCOMM)Wtsi}/\Mbd5⁺ (C57BL/6N-Mbd5^{tm1b(EUCOMM)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Mbip^em1(IMPC)J/\Mbip⁺ (C57BL/6NJ-Mbip^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Mbis1^NOD/ShiLt/\Mbis1^NOD/ShiLt (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
\Mbis2^BALB/c/\Mbis2^BALB/c (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
\Mbis2^BALB/c/\Mbis2^NOD/ShiLt (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
\Mbis3^BALB/c/? (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
\Mbis4^NOD/ShiLt/\Mbis4^NOD/ShiLt (involves: BALB/c * NOD/Lt)	increased susceptibility to bacterial infection	J:75276
\Mbl1^tm1.1Mnz/\Mbl1^tm1.1Mnz (B6.129-Mbl1^tm1.1Mnz)	immune system phenotype	J:84540
\Mbl1^tm1Kata/\Mbl1^tm1Kata (involves: 129S4/SvJae * C57BL/6J)	decreased circulating tumor necrosis factor level	J:90437
\Mbl1^tm1Kata/\Mbl1^tm1Kata \Mbl2^tm1Kata/\Mbl2^tm1Kata (involves: 129 * C57BL/6)	abnormal B cell number	J:97686
	abnormal circulating interleukin-6 level	J:98124
	abnormal circulating tumor necrosis factor level	J:98124
	decreased germinal center B cell number	J:97686
	decreased macrophage cell number	J:98124
	decreased monocyte cell number	J:98124
	impaired macrophage phagocytosis	J:97686, J:98124
	increased B-1 B cell number	J:97686
	increased susceptibility to bacterial infection	J:98124
\Mbl1^tm1Kata/\Mbl1^tm1Kata \Mbl2^tm1Kata/\Mbl2^tm1Kata (involves: 129 * C57BL/6J)	abnormal complement pathway	J:106351
	abnormal response to infection	J:106352
	increased susceptibility to bacterial infection	J:106353
\Mbl1^tm1Rala/\Mbl1^tm1Rala (involves: 129X1/SvJ * C57BL/6J)	abnormal immunoglobulin level	J:145279
	decreased IgG2b level	J:145279
	decreased IgM level	J:145279
	increased IgG1 level	J:145279
	increased IgG2a level	J:145279
	increased IgG3 level	J:145279
	increased susceptibility to parasitic infection	J:145279
\Mboat2^em1(IMPC)Mbp/\Mboat2^em1(IMPC)Mbp (C57BL/6N-Mboat2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Mboat7^{tm1b(KOMP)Wtsi}/\Mboat7⁺ (C57BL/6N-Mboat7^{tm1b(KOMP)Wtsi}/H)	increased lymphocyte cell number	J:211773
\Mbp^shi/\Mbp^shi (C3Fe.SWV-Mbp^shi/J)	decreased susceptibility to Picornaviridae infection	J:41447
\Mbp^shi/\Mbp^shi (C3Fe.SWV-Mbp^shi/J)	immune system phenotype	J:41447
\Mbp^shi/\Mbp^shi (involves: BALB/c * C3HeB/Fe * SWV)	increased interferon-gamma secretion	J:48412
	increased interleukin-2 secretion	J:48412
	increased interleukin-4 secretion	J:48412
	increased susceptibility to experimental autoimmune encephalomyelitis	J:48412
	increased T cell proliferation	J:48412
\Mbtps1^wrt/\Mbtps1^wrt (C57BL/6J-Mbtps1^wrt)	decreased cytotoxic T cell cytolysis	J:94077
	decreased susceptibility to bacterial infection	J:123123
	increased interleukin-1 beta secretion	J:146454
	increased interleukin-6 secretion	J:146454
	increased susceptibility to Herpesvirales infection	J:94077, J:123123
	increased susceptibility to induced colitis	J:146454
\Mc2r^tm1Dchi/\Mc2r^tm1Dchi (B6.129P2-Mc2r^tm1Dchi)	increased spleen weight	J:127445
\Mc2r^tm1Dchi/\Mc2r^tm1Dchi (B6.129P2-Mc2r^tm1Dchi)	increased thymus weight	J:127445
\Mc3r^tm1Butl/\Mc3r^tm1Butl (B6.Cg-Mc3r^tm1Butl)	increased inflammatory response	J:178147
\Mc4r^tm1Dhu/\Mc4r^tm1Dhu (involves: 129S4/SvJae * C57BL/6J)	decreased osteoclast cell number	J:97566
\Mc4r^tm1Lowl/\Mc4r^tm1Lowl (involves: 129S4/SvJae * C57BL/6J)	increased circulating interleukin-6 level	J:177386
	liver inflammation	J:177386
	white adipose tissue inflammation	J:177386
\Mc4r^tm1Matsu/\Mc4r^tm1Matsu (C57BL/6J-Mc4r^tm1Matsu)	liver inflammation	J:285412
\Mcam^tm1Lex/\Mcam^tm1Lex (involves: 129S/SvEvBrd)	abnormal cytokine level	J:193167
	abnormal response to infection	J:193167
	decreased macrophage cytokine production	J:193167
\Mcat^tm1.1Ssmi/\Mcat^tm1.1Ssmi \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129P2/OlaHsd C57BL/6 * C57BL/6J * CBA)	abnormal immune system organ morphology	J:192213
	abnormal myelopoiesis	J:192213
	decreased leukocyte cell number	J:192213
	decreased lymphocyte cell number	J:192213
	enlarged spleen	J:192213
\Mcemp1^em1Jngj/\Mcemp1^em1Jngj (C57BL/6-Mcemp1^em1Jngj)	abnormal mast cell differentiation	J:335318
\Mcemp1^em1Jngj/\Mcemp1^em1Jngj (C57BL/6-Mcemp1^em1Jngj)	abnormal type I hypersensitivity reaction	J:335318
\Mcidas^em2(IMPC)Tcp/\Mcidas^em2(IMPC)Tcp (C57BL/6NCrl-Mcidas^em2(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
\Mcl1^em1(IMPC)Mbp/\Mcl1⁺ (C57BL/6N-Mcl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Mcl1^tm1Dmta/\Mcl1⁺ \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (B6.Cg-Mcl1^tm1Dmta Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte})	decreased germinal center B cell number	J:166069
	decreased memory B cell number	J:166069
\Mcl1^tm1Dmta/\Mcl1⁺ \Tg(Aicda-cre)9Mbu/0 (B6.Cg-Mcl1^tm1Dmta Tg(Aicda-cre)9Mbu)	decreased germinal center B cell number	J:166069
	decreased memory B cell number	J:166069
\Mcl1^tm1Dmta/\Mcl1^tm1Dmta \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (B6.Cg-Mcl1^tm1Dmta Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte})	abnormal B cell differentiation	J:166069
	absent germinal center B cells	J:166069
	absent memory B cells	J:166069
	decreased naive B cell number	J:166069
\Mcl1^tm1Dmta/\Mcl1^tm1Dmta \Tg(Aicda-cre)9Mbu/0 (B6.Cg-Mcl1^tm1Dmta Tg(Aicda-cre)9Mbu)	absent germinal center B cells	J:166069
	absent memory B cells	J:166069
	decreased IgG1 level	J:166069
	immune system phenotype	J:166069
\Mcl1^tm1Yen/\Mcl1^tm1Yen (B6.129-Mcl1^tm1Yen)	abnormal CD8-positive, alpha-beta T cell physiology	J:146246
	abnormal double-positive T cell morphology	J:146246
	decreased CD8-positive, alpha-beta T cell number	J:146246
	decreased double-negative T cell number	J:146246
	decreased single-positive T cell number	J:146246
\Mcl1^tm1Yen/\Mcl1^tm1Yen \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal double-positive T cell morphology	J:146246
	decreased CD8-positive, alpha-beta T cell number	J:146246
\Mcl1^tm1Yen/\Mcl1^tm1Yen \Tg(TcraTcrb)425Cbn/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal double-positive T cell morphology	J:146246
	decreased CD4-positive, alpha-beta T cell number	J:146246
\Mcl1^tm1Ywh/\Mcl1^tm1Ywh \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal neutrophil physiology	J:137502
	decreased granulocyte number	J:137502
	decreased neutrophil cell number	J:137502
	immune system phenotype	J:137502
	impaired neutrophil recruitment	J:137502
	increased eosinophil cell number	J:137502
\Mcl1^tm1Ywh/\Mcl1^tm1Ywh \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:137400
	decreased CD8-positive, alpha-beta T cell number	J:137400
	decreased T cell number	J:137400
	increased double-positive T cell number	J:137400
	increased T cell apoptosis	J:137400
\Mcl1^tm1Ywh/\Mcl1^tm1Ywh \Tg(Lck-cre)548Jxm/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * CBA)	abnormal T cell differentiation	J:137400
	decreased CD4-positive, alpha-beta T cell number	J:137400
	decreased CD8-positive, alpha-beta T cell number	J:137400
	decreased double-negative T cell number	J:137400
	decreased double-positive T cell number	J:137400
	decreased T cell number	J:137400
	increased T cell apoptosis	J:137400
	thymus hypoplasia	J:137400
\Mcl1^tm2Sjk/\Mcl1^tm3Sjk \Tg(Lck-cre)1Cwi/0 (involves: 129X1/SvJ * C57BL/6 * DBA/2)	arrested T cell differentiation	J:86906
	decreased double-negative T cell number	J:86906
	decreased double-positive T cell number	J:86906
	decreased T cell number	J:86906
	decreased thymocyte number	J:86906
	increased T cell apoptosis	J:86906
\Mcl1^tm2Sjk/\Mcl1^tm3Sjk \Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	decreased B cell number	J:86906
	decreased T cell number	J:86906
\Mcl1^tm3Sjk/\Mcl1^tm3Sjk \Tg(Cpa3-cre)3Glli/0 (involves: 129X1/Sv * C57BL/6)	decreased basophil cell number	J:179080
	decreased inflammatory response	J:179080
	decreased mast cell number	J:179080
	decreased susceptibility to type I hypersensitivity reaction	J:179080
\Mclr^RF/J/\Mclr^SWR/J (involves: RF/J * SWR/J)	increased T cell derived lymphoma incidence	J:9614
\Mclr^SWR/J/\Mclr^SWR/J (involves: RF/J * SWR/J)	increased T cell derived lymphoma incidence	J:9614
\Mcm2^{Gt(AB0178)Wtsi}/\Mcm2⁺ \Mcm4^chaos3/\Mcm4^chaos3 (involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)	increased T cell derived lymphoma incidence	J:165667
\Mcm2^{tm1(cre/ERT2)Scpr}/\Mcm2^{tm1(cre/ERT2)Scpr} (involves: 129S6/SvEvTac)	enlarged spleen	J:141493
\Mcm3ap^tm1Imku/\Mcm3ap^tm1Imku \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal germinal center B cell physiology	J:88276
	abnormal memory B cell number	J:88276
	abnormal spleen germinal center morphology	J:88276
	decreased B cell number	J:88276
	decreased B cell proliferation	J:88276
	decreased germinal center B cell number	J:88276
	decreased IgG level	J:88276
\Mcm4^chaos3/\Mcm4^chaos3 (involves: C57BL/6J)	increased T cell derived lymphoma incidence	J:165667
\Mcm4^Sdla/\Mcm4⁺ (involves: C57BL/6)	decreased DN1 thymic pro-T cell number	J:194117
	enlarged lymph nodes	J:194117
	enlarged spleen	J:194117
\Mcoln1^tm1Sasl/\Mcoln1^tm1Sasl (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage physiology	J:189070
\Mcoln2^{tm1e.1(KOMP)Wtsi}/\Mcoln2^{tm1e.1(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	abnormal chemokine level	J:239875
	abnormal chemokine secretion	J:239875
	abnormal innate immunity	J:239875
	impaired macrophage chemotaxis	J:239875
	impaired neutrophil chemotaxis	J:239875
\Mcph1^{Tg(HLA-A2.1)1Enge}/\Mcph1⁺ (involves: C57BL/6)	abnormal immune tolerance	J:52612
\Mcph1^{Tg(HLA-A2.1)1Enge}/\Mcph1⁺ (NOD.B6-Mcph1^{Tg(HLA-A2.1)1Enge})	increased susceptibility to autoimmune diabetes	J:109851
\Mcph1^{Tg(HLA-A2.1)1Enge}/\Mcph1^{Tg(HLA-A2.1)1Enge} (NOD.B6-Mcph1^{Tg(HLA-A2.1)1Enge})	immune system phenotype	J:109851
	increased susceptibility to autoimmune diabetes	J:109851
\Mcph1^tm1.2Kali/\Mcph1^tm1.2Kali (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal T cell physiology	J:156371
\Mcph1^{tm1a(EUCOMM)Wtsi}/\Mcph1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased B cell number	J:213427
\Mcpt1^tm1Hrpm/\Mcpt1^tm1Hrpm (involves: 129P2/OlaHsd * MF1)	abnormal mast cell morphology	J:93795
	decreased circulating tumor necrosis factor level	J:93616
	increased susceptibility to parasitic infection	J:93616, J:93795
\Mcpt4^tm1Mabr/\Mcpt4^tm1Mabr (involves: 129X1/SvJ * C57BL/6J)	abnormal mast cell physiology	J:84839
\Mcpt8^{tm1.1(HBEGF)Hkar}/\Mcpt8^{tm1.1(HBEGF)Hkar} (B6.Cg-Mcpt8^{tm1.1(HBEGF)Hkar})	decreased basophil cell number	J:163761
	immune system phenotype	J:163761
	increased susceptibility to parasitic infection	J:163761
\Mcr^C57BL/10J/\Mcr^NC (involves: C57BL/10J * NC)	cutaneous mastocytosis	J:8804
\Mcr^NC/\Mcr^NC (involves: C57BL/10J * NC)	cutaneous mastocytosis	J:8804
\Mcts1^em1(IMPC)Mbp/Y (C57BL/6N-Mcts1^em1(IMPC)Mbp/Ucd)	enlarged spleen	J:211773
\Mdc1^{Gt(OST441263)Lex}/\Mdc1^{Gt(OST441263)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal class switch recombination	J:137341
	small spleen	J:137341
	small thymus	J:137341
\Mdfic^em1Nlh/\Mdfic^em2Nlh (C57BL/6J-Mdfic^em1Nlh/Mdfic^em2Nlh)	abnormal lymph circulation	J:326462
	abnormal lymphatic vessel morphology	J:326462
\Mdga2^{Tg(Prnp-PFN1*G118V)838Kiaei}/\Mdga2⁺ (involves: C57BL/6N)	microgliosis	J:241428
\Mdk^tm1Tmu/\Mdk^tm1Tmu (129S2-Mdk^tm1Tmu)	tubular nephritis	J:93637
\Mdk^tm1Tmu/\Mdk^tm1Tmu (B6.129S2-Mdk^tm1Tmu)	abnormal macrophage chemotaxis	J:102069
	decreased macrophage cell number	J:102069
	impaired neutrophil chemotaxis	J:102069
\Mdm2^tm1.1Ypz/\Mdm2^tm1.1Ypz \Tg(IghMyc)22Bri/0 (B6.Cg-Mdm2^tm1.1Ypz Tg(IghMyc)22Bri)	enlarged lymph nodes	J:164200
	enlarged Peyer's patches	J:164200
	enlarged thymus	J:164200
	spleen hyperplasia	J:164200
\Mdm2^tm1Bay/\Mdm2^tm1Mep (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell differentiation	J:81065
	decreased double-negative T cell number	J:81065
	decreased double-positive T cell number	J:81065
	decreased granulocyte number	J:81065
	decreased immature B cell number	J:81065
	decreased leukocyte cell number	J:81065
	decreased lymphocyte cell number	J:81065
	decreased neutrophil cell number	J:81065
	decreased spleen weight	J:81065
	decreased T cell number	J:81065
	decreased thymocyte number	J:81065
	decreased thymus weight	J:81065
	spleen hypoplasia	J:81065
	thymus hypoplasia	J:81065
\Mdm2^tm1Glo/\Mdm2⁺ \Mdm4^tm1Glo/\Mdm4⁺ (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:123661
	spleen atrophy	J:123661
	spleen hypoplasia	J:123661
	thymus atrophy	J:123661
	thymus hypoplasia	J:123661
\Mdm2^tm1Glo/\Mdm2⁺ \Trp53^tm2Wahl/\Trp53^tm2Wahl (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:174375
	small thymus	J:174375
	spleen atrophy	J:174375
\Mdm2^tm1Mep/\Mdm2^tm1.1Mep (involves: 129S7/SvEvBrd * C57BL/6 * FVB)	decreased spleen weight	J:81065
	decreased thymus weight	J:81065
\Mdm2^tm2.1Snj/\Mdm2^tm2.1Snj (involves: 129S4/SvJae * C57BL/6)	decreased thymocyte apoptosis	J:189297
	enlarged spleen	J:189297
	increased T cell derived lymphoma incidence	J:189297
\Mdm2^tm3.1Snj/\Mdm2^tm3.1Snj (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:189297
\Mdm4^m1Btlr/\Mdm4^m1Btlr (C57BL/6J-Mdm4^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265262
	decreased single-positive T cell number	J:265262
	increased CD4-positive, alpha-beta T cell number	J:265262
	increased single-positive T cell number	J:265262
\Mdm4^m2Btlr/\Mdm4^m2Btlr (C57BL/6J-Mdm4^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272830
\Mdm4^m2Btlr/\Mdm4^m2Btlr (C57BL/6J-Mdm4^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:272830
\Mdm4^tm1.1Wahl/\Mdm4^tm1.1Wahl (involves: 129S/Sv * C57BL/6)	decreased thymocyte apoptosis	J:150341
	increased leukocyte cell number	J:150341
\Me1^em1(IMPC)Tcp/\Me1^em1(IMPC)Tcp (C57BL/6NCrl-Me1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Mecom^Jbo/\Mecom⁺ (C3N.C-Mecom^Jbo)	abnormal neutrophil differentiation	J:113445
	immune system phenotype	J:113445
	increased susceptibility to otitis media	J:113445
	respiratory system inflammation	J:113445
\Mecom^Jbo/\Mecom⁺ (involves: BALB/c)	increased susceptibility to otitis media	J:250208
\Mecom^tm1Aspe/\Mecom^tm1Aspe (involves: 129S6/SvEvTac * C57BL/6)	increased leukocyte cell number	J:178429
\Mecom^tm2.2Aspe/\Mecom^tm2.2Aspe (involves: 129 * C57BL/6J * FVB/N)	abnormal immune system organ morphology	J:213829
	decreased B cell number	J:213829
	decreased leukocyte cell number	J:213829
\Mecp2^tm1.1Bird/Y \Sqle^Sum3-Jus/\Sqle⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	dermatitis	J:198551
\Mecp2^tm1.1Bird/Y \Sum2^M1Jus/\Sum2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	dermatitis	J:198551
	eye inflammation	J:198551
\Mecp2^tm1.1Bird/Y \Sum4^M1Jus/\Sum4⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	dermatitis	J:198551
	eye inflammation	J:198551
\Mecp2^tm1.1Bird/Y \Sum5^M1Jus/\Sum5⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	eye inflammation	J:198551
\Med18^{tm1a(EUCOMM)Wtsi}/\Med18⁺ (C57BL/6N-Med18^{tm1a(EUCOMM)Wtsi}/H)	decreased leukocyte cell number	J:165965
\Med19^{tm1c(EUCOMM)Wtsi}/\Med19^{tm1c(EUCOMM)Wtsi} \Tg(Adipoq-icre/ERT2)1Soff/0 (involves: C57BL/6J * C57BL/6N)	white adipose tissue inflammation	J:298822
\Med20^em1(IMPC)J/\Med20⁺ (C57BL/6NJ-Med20^em1(IMPC)J/J)	decreased leukocyte cell number	J:211773
\Med28^{tm1.1(KOMP)Vlcg}/\Med28⁺ (C57BL/6N-Med28^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Mef2b^tm2Rdf/\Mef2b⁺ \Tg(Cr2-cre)3Cgn/0 (involves: C57BL/6)	abnormal mature B cell morphology	J:265465
	enlarged lymph nodes	J:265465
	enlarged mesenteric lymph nodes	J:265465
	enlarged spleen	J:265465
	increased germinal center B cell number	J:265465
\Mef2c^tm1Jjs/\Mef2c^tm1Jjs \Mir223^tm1Fcam/\Mir223^tm1Fcam \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * C57BL/6)	abnormal neutrophil differentiation	J:140009
	abnormal neutrophil physiology	J:140009
	increased neutrophil cell number	J:140009
\Mefv^tm1Bhk/\Mefv^tm1Bhk (129S6/SvEvTac-Mefv^tm1Bhk)	immune system phenotype	J:192443
	increased interleukin-1 beta secretion	J:192443
	increased interleukin-18 secretion	J:192443
\Mefv^tm1Chae/\Mefv^tm1Chae (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	decreased macrophage apoptosis	J:82763
	increased inflammatory response	J:82763
	increased susceptibility to endotoxin shock	J:82763
\Mefv^{tm3.1(MEFV)Chae}/\Mefv^{tm3.1(MEFV)Chae} (B6.129S6-Mefv^{tm3.1(MEFV)Chae})	autoimmune arthritis	J:172117
	dermatitis	J:172117
	increased inflammatory response	J:172117
	increased leukocyte cell number	J:172117
\Mefv^{tm4.1(MEFV)Chae}/\Mefv^{tm4.1(MEFV)Chae} (B6.129S6-Mefv^{tm4.1(MEFV)Chae})	autoimmune arthritis	J:172117
	dermatitis	J:172117
	increased inflammatory response	J:172117
	increased leukocyte cell number	J:172117
\Mefv^{tm5.1(MEFV)Chae}/\Mefv^{tm5.1(MEFV)Chae} (B6.129S6-Mefv^{tm5.1(MEFV)Chae})	abnormal cytokine secretion	J:172117
	abnormal spleen germinal center morphology	J:172117
	autoimmune arthritis	J:172117
	decreased B cell number	J:172117
	decreased interleukin-3 secretion	J:172117
	decreased lymphocyte cell number	J:172117
	decreased T cell number	J:172117
	dermatitis	J:172117
	enlarged lymph nodes	J:172117
	enlarged spleen	J:172117
	increased circulating interleukin-1 beta level	J:172117
	increased circulating interleukin-6 level	J:172117
	increased circulating tumor necrosis factor level	J:172117
	increased granulocyte number	J:172117
	increased inflammatory response	J:172117
	increased interferon-gamma secretion	J:172117
	increased interleukin-1 alpha secretion	J:172117
	increased interleukin-1 beta secretion	J:172117
	increased interleukin-2 secretion	J:172117
	increased interleukin-4 secretion	J:172117
	increased interleukin-5 secretion	J:172117
	increased interleukin-9 secretion	J:172117
	increased interleukin-10 secretion	J:172117
	increased interleukin-12 secretion	J:172117
	increased interleukin-12b secretion	J:172117
	increased interleukin-13 secretion	J:172117
	increased interleukin-17 secretion	J:172117
	increased leukocyte cell number	J:172117
	increased macrophage cell number	J:172117
	increased monocyte cell number	J:172117
	increased neutrophil cell number	J:172117
	joint inflammation	J:172117
	liver inflammation	J:172117
	skin inflammation	J:172117
\Mefv^{tm5.1(MEFV)Chae}/\Mefv^{tm5.1(MEFV)Chae} \Nlrp3^tm1Tsc/\Nlrp3^tm1Tsc (involves: 129S6/SvEvTac * C57BL/6)	increased inflammatory response	J:172117
	increased interleukin-1 beta secretion	J:172117
\Mefv^{tm5.1(MEFV)Chae}/\Mefv^{tm5.1(MEFV)Chae} \Pycard^tm1Tno/\Pycard^tm1Tno (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	decreased interleukin-1 beta secretion	J:172117
	immune system phenotype	J:172117
\Mefv^{tm5.1(MEFV)Chae}/\Mefv^{tm5.1(MEFV)Chae} \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:172117
	increased circulating interleukin-1 beta level	J:172117
	increased circulating interleukin-6 level	J:172117
	increased circulating tumor necrosis factor level	J:172117
	increased inflammatory response	J:172117
	increased interferon-gamma secretion	J:172117
	increased interleukin-1 beta secretion	J:172117
	increased interleukin-2 secretion	J:172117
	increased interleukin-4 secretion	J:172117
	increased interleukin-5 secretion	J:172117
	increased interleukin-9 secretion	J:172117
	increased interleukin-10 secretion	J:172117
	increased interleukin-12 secretion	J:172117
	increased interleukin-13 secretion	J:172117
	increased interleukin-17 secretion	J:172117
\Megf8^b2b1702.2Clo/\Megf8^b2b1702.2Clo (C57BL/6J-Megf8^b2b1702.2Clo)	spleen hypoplasia	J:175213
	thymus hypoplasia	J:175213
\Megf8^hlb611/\Megf8^hlb611 (involves: C57BL/6J)	absent spleen	J:146805
\Megf8^hlb611/\Megf8^hlb611 (involves: C57BL/6J)	accessory spleen	J:146805
\Megf8^hlb611/\Megf8^hlb611 (involves: C57BL/6J * C3H/HeJ)	absent spleen	J:146957
\Megf8^hlb611/\Megf8^hlb611 (involves: C57BL/6J * C3H/HeJ)	accessory spleen	J:146957
\Meis3^{tm1b(EUCOMM)Hmgu}/\Meis3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Meis3^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Men1^tm1.2Zqw/\Men1^tm1.2Zqw \Pgr^tm2(cre)Lyd/\Pgr⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased uterine NK cell number	J:322043
\Men1^tm1Ctre/\Men1⁺ (either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))	pancreas inflammation	J:67128
\Meox2^tm1(cre)Sor/\Meox2⁺ \Procr^tm2Cte/\Procr^tm2Cte (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * Black Swiss * C57BL/6)	decreased circulating fibrinogen level	J:119529
	increased circulating C-reactive protein level	J:119529
\Meox2^tm1(cre)Sor/\Meox2⁺ \Slc40a1^tm2Nca/\Slc40a1^tm2Nca (involves: 129S4/SvJae * 129S6/SvEvTac)	increased spleen iron level	J:129846
\Meox2^tm1(cre)Sor/\Meox2⁺ \Tg(CAG-lacZ,-FUSR521G,-EGFP)682Gyu/0 (involves: 129S4/SvJaeSor C57BL/6)	microgliosis	J:216672
\Meox2^tm1(cre)Sor/\Meox2⁺ \Tg(CAG-lacZ,-FUS,-EGFP)629Gyu/0 (involves: 129S4/SvJaeSor * C57BL/6)	microgliosis	J:216672
\Mep1a^tm1Bond/\Mep1a^tm1Bond (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal chemokine level	J:145685
	abnormal circulating interleukin-1 beta level	J:145037
	abnormal cytokine level	J:145037, J:145685
	abnormal leukocyte physiology	J:145037
	abnormal tumor necrosis factor level	J:145037
	increased circulating interleukin-1 beta level	J:145685
	increased circulating interleukin-6 level	J:145685
	increased susceptibility to induced colitis	J:145685
	urinary bladder inflammation	J:145037
\Mep1b^tm1Bond/\Mep1b^tm1Bond (B6.129-Mep1b^tm1Bond)	immune system phenotype	J:145037
\Mep1b^tm1Bond/\Mep1b^tm1Bond (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased inflammatory response	J:132021
\Mepe^tm1Tbrw/\Mepe^tm1Tbrw (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast morphology	J:81218
\Mertk^nmf12/\Mertk^nmf12 (involves: C57BL/6J)	abnormal tumor necrosis factor level	J:175587
\Mertk^tm1Gkm/\Mertk^tm1Gkm (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	increased circulating tumor necrosis factor level	J:53423
	increased susceptibility to endotoxin shock	J:53423
	increased tumor necrosis factor secretion	J:53423
\Mertk^tm1Gkm/\Mertk^tm1Gkm (NOD.129P2-Mertk^tm1Gkm)	abnormal mononuclear cell morphology	J:147153
	decreased susceptibility to autoimmune diabetes	J:147153
	decreased T cell number	J:147153
	increased T cell apoptosis	J:147153
	insulitis	J:147153
\Mertk^tm1Gkm/\Mertk^tm1Gkm (B6.129P2-Mertk^tm1Gkm)	decreased autoantibody level	J:136377
\Mertk^tm1Gkm/\Mertk^tm1Gkm (B6.129P2-Mertk^tm1Gkm)	decreased susceptibility to graft versus host disease	J:136377
\Mertk^tm1Gkm/\Mertk^tm1Gkm \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (NOD.Cg-Mertk^tm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased double-positive T cell number	J:147153
	increased CD8-positive, alpha-beta T cell number	J:147153
	increased T cell apoptosis	J:147153
\Mertk^tm1Grl/\Mertk^tm1Grl (involves: 129P2/OlaHsd)	enlarged spleen	J:54681
\Mesp1^tm2(cre)Ysa/\Mesp1⁺ \Tbx1^tm1Bld/\Tbx1^tm3Bld (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	athymia	J:112457
	thymus hypoplasia	J:112457
\Mesp1^tm2(cre)Ysa/\Mesp1⁺ \Tbx1^tm1Bld/\Tbx1^tm5Bld (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	athymia	J:112457
\Met^tm1Gvw/\Met⁺ (involves: 129 * C57BL/6J)	glomerulonephritis	J:94722
\Met^tm2Gvw/\Met⁺ (involves: 129 * C57BL/6J)	glomerulonephritis	J:94722
\Met^tm4Gvw/\Met⁺ (involves: 129 * C57BL/6J)	glomerulonephritis	J:94722
\Metap1^em1(IMPC)Tcp/\Metap1⁺ (C57BL/6NCrl-Metap1^em1(IMPC)Tcp/Cmmr)	small spleen	J:211773
\Metrn^em1(IMPC)Mbp/\Metrn^em1(IMPC)Mbp (C57BL/6NCrl-Metrn^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Metrnl^{tm1d(KOMP)Wtsi}/\Metrnl^{tm1d(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased IgG level	J:268270
	increased IgM level	J:268270
	increased susceptibility to endotoxin shock	J:268270
	kidney inflammation	J:268270
	liver inflammation	J:268270
	uterus inflammation	J:268270
\Mettl4^em1Dfel/\Mettl4^em1Dfel (involves: 129/Sv * C57BL/6N)	decreased leukocyte cell number	J:278437
	enlarged spleen	J:278437
\Mettl5^{em1(IMPC)Hmgu}/\Mettl5^{em1(IMPC)Hmgu} (C57BL/6N-Mettl5^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
\Mettl14^em1(IMPC)Tcp/\Mettl14⁺ (C57BL/6NCrl-Mettl14^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Mettl23^{em1(IMPC)Hmgu}/\Mettl23^{em1(IMPC)Hmgu} (C57BL/6NCrl-Mettl23^{em1(IMPC)Hmgu}/Ieg)	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Mettl25^em1(IMPC)Bay/\Mettl25^em1(IMPC)Bay (C57BL/6N-Mettl25^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
\Mex3b^tm1.1Mbld/\Mex3b^tm1.1Mbld \Plekha5^{Tg(AMH-cre)1Flor}/\Plekha5⁺ (involves: C57BL/6 * SJL)	increased anti-sperm antibody level	J:213588
\Mex3b^tm1.2Mbld/\Mex3b^tm1.2Mbld (involves: C57BL/6 * CBA)	impaired macrophage phagocytosis	J:213588
\Mex3c^tm1Aki/\Mex3c^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal cytokine secretion	J:208870
	decreased interferon-beta secretion	J:208870
	decreased interleukin-6 secretion	J:208870
	decreased interleukin-12 secretion	J:208870
\Mexis^tm1.1Pton/\Mexis^tm1.1Pton (involves: C57BL/6)	increased macrophage derived foam cell number	J:264834
\Mfap2^{tm1a(KOMP)Wtsi}/\Mfap2^{tm1a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased B cell number	J:236092
	decreased leukocyte cell number	J:236092
	decreased neutrophil cell number	J:236092
	increased B cell number	J:236092
	increased macrophage cell number	J:236092
	increased monocyte cell number	J:236092
	increased myeloid dendritic cell number	J:236092
	increased splenocyte number	J:236092
\Mfap2^tm1Mech/\Mfap2^tm1Mech (involves: 129X1/SvJ)	decreased macrophage cell number	J:203960
\Mfap2^tm1Mech/\Mfap2^tm1Mech (involves: 129X1/SvJ)	decreased monocyte cell number	J:203960
\Mfap2^tm1Mech/\Mfap2^tm1Mech \Mfap5^tm1Mech/\Mfap5^tm1Mech (involves: 129X1/SvJ)	decreased monocyte cell number	J:203960
	decreased neutrophil cell number	J:203960
	immune system phenotype	J:203960
\Mfap4^{tm1b(NCOM)Mfgc}/\Mfap4^{tm1b(NCOM)Mfgc} (C57BL/6N-Mfap4^{tm1b(NCOM)Mfgc}/Tcp)	enlarged lymph nodes	J:211773
\Mfap5^tm1Mech/\Mfap5^tm1Mech (Not Specified)	decreased neutrophil cell number	J:203960
\Mfap5^tm1Mech/\Mfap5^tm1Mech (Not Specified)	immune system phenotype	J:203960
\Mfge8^{Gt(KST227)Byg}/\Mfge8^{Gt(KST227)Byg} (B6.129P2-Mfge8^{Gt(KST227)Byg})	enlarged spleen	J:98314
	impaired macrophage phagocytosis	J:98314
\Mfge8^{Gt(KST227)Byg}/\Mfge8^{Gt(KST227)Byg} (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:107106
	impaired macrophage phagocytosis	J:107106
	mastitis	J:107106
\Mfge8^tm1Mcu/\Mfge8^tm1Mcu (involves: 129X1/SvJ * C57BL/6NCr)	enlarged spleen	J:123138
\Mfge8^tm1Mcu/\Mfge8^tm1Mcu \Tg(RIP1-Tag)2Dh/? (involves: 129X1/SvJ * C57BL/6J * C57BL/6NCr * DBA/2J)	decreased Langerhans cell number	J:123138
\Mfge8^tm1Osa/\Mfge8^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:90633
	enlarged spleen	J:90633
	impaired macrophage phagocytosis	J:90633
	increased anti-double stranded DNA antibody level	J:225063
	increased spleen B cell follicle size	J:90633
	increased spleen weight	J:90633
	increased spleen white pulp amount	J:90633
	spleen hyperplasia	J:90633
\Mfge8^tm1Osa/\Mfge8^tm1Osa (B6.129-Mfge8^tm1Osa)	immune system phenotype	J:187181
\Mfge8^tm1Osa/\Mfge8^tm1Osa \Timd4^tm1Osa/\Timd4^tm1Osa (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	impaired macrophage phagocytosis	J:187181
	increased anti-double stranded DNA antibody level	J:187181
	increased anti-nuclear antigen antibody level	J:187181
\Mfge8^tm1Shur/\Mfge8^tm1Shur (B6.129-Mfge8^tm1Shur)	spermatic granuloma	J:145962
\Mfn1^tm2Dcc/\Mfn1^tm2Dcc \Mfn2^tm3Dcc/\Mfn2^tm3Dcc \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * C57BL/6J * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:339075
\Mfng^{em1(IMPC)Ccpcz}/\Mfng^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mfng^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
\Mfng^tm1.1Cfg/\Mfng^tm1.1Cfg (involves: C57BL/6)	decreased macrophage cell number	J:217719
	decreased mature B cell number	J:217719
	decreased neutrophil cell number	J:217719
	increased B cell number	J:217719
	increased B cell proliferation	J:217719
	increased lymphocyte cell number	J:217719
\Mfng^tm1Cjg/\Mfng^tm1Cjg (B6.Cg-Mfng^tm1Cjg)	abnormal marginal zone B cell morphology	J:146621
\Mfsd1^em1(IMPC)Tcp/\Mfsd1⁺ (C57BL/6N-Mfsd1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Mfsd1^em1(IMPC)Tcp/\Mfsd1^em1(IMPC)Tcp (C57BL/6N-Mfsd1^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Mfsd1^{tm1a(KOMP)Wtsi}/\Mfsd1^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	enlarged spleen	J:280713
\Mfsd2a^tm1Dls/\Mfsd2a^tm1Dls (B6.Cg-Mfsd2a^tm1Dls)	abnormal microglial cell activation	J:234197
\Mfsd2b^{tm1a(KOMP)Wtsi}/\Mfsd2b^{tm1a(KOMP)Wtsi} (C57BL/6-Mfsd2b^{tm1a(KOMP)Wtsi})	decreased B cell number	J:250123
	decreased leukocyte cell number	J:250123
	decreased T cell number	J:250123
	enlarged spleen	J:250123
	increased susceptibility to type I hypersensitivity reaction	J:250123
\Mfsd6^tm1Ryosh/\Mfsd6^tm1Ryosh (B6.129S2-Mfsd6^tm1Ryosh)	abnormal leukocyte physiology	J:260694
	immune system phenotype	J:260694
	increased length of allograft survival	J:260694
\Mfsd8^{tm1a(EUCOMM)Hmgu}/\Mfsd8^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal spleen morphology	J:211608
	CNS inflammation	J:211608
	microgliosis	J:211608
\Mfsd10^{tm1.1(KOMP)Vlcg}/\Mfsd10^{tm1.1(KOMP)Vlcg} (C57BL/6N-Mfsd10^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Mgat2^tm1.1Jxm/\Mgat2^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal B cell differentiation	J:80661
	decreased T cell number	J:80661
	enlarged lymph nodes	J:80661
	enlarged spleen	J:80661
	glomerulonephritis	J:80661
\Mgat4b^tm1.1Jxm/\Mgat4b^tm1.1Jxm (B6.129-Mgat4b^tm1.1Jxm)	decreased neutrophil cell number	J:212313
\Mgat4b^tm1.1Jxm/\Mgat4b^tm1.1Jxm (B6.129-Mgat4b^tm1.1Jxm)	increased leukocyte cell number	J:212313
\Mgat4d^{tm1b(KOMP)Wtsi}/\Mgat4d^{tm1b(KOMP)Wtsi} (C57BL/6N-Mgat4d^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Mgat5^tm1Jwd/\Mgat5^tm1Jwd (involves: 129S1/Sv * 129X1/SvJ)	abnormal inflammatory response	J:60960
	abnormal leukocyte physiology	J:94864
	abnormal T cell physiology	J:60960
	decreased interleukin-2 secretion	J:94864
	decreased interleukin-4 secretion	J:94864
	increased interleukin-10 secretion	J:94864
	increased tumor necrosis factor secretion	J:94864
\Mgat5b^tm1.1Cfg/\Mgat5b^tm1.1Cfg (involves: 129S6/SvEvTac)	decreased pre-B cell number	J:217719
	enhanced humoral immune response	J:217719
	increased IgG2b level	J:217719
\Mgat5b^tm1Nta/\Mgat5b^tm1Nta (Not Specified)	brain inflammation	J:199165
\Mgl2^{tm1.1(HBEGF/EGFP)Aiwsk}/\Mgl2⁺ (involves: C57BL/6 * FVB/N)	abnormal immune system physiology	J:201044
	abnormal lymph node size	J:201044
	abnormal T-helper 2 cell morphology	J:201044
	decreased B cell number	J:201044
	decreased CD4-positive, alpha-beta T cell number	J:201044
	decreased CD8-positive, alpha-beta T cell number	J:201044
	decreased dendritic cell number	J:201044
	decreased interleukin-4 secretion	J:201044
	decreased Langerhans cell number	J:201044
	increased susceptibility to parasitic infection	J:201044
\Mgmt^tm1Mse/\Mgmt^tm1Mse (involves: 129S/SvEv)	increased T cell derived lymphoma incidence	J:47642
\Mgmt^tm1Mse/\Mgmt^tm1Mse \Mlh1^tm1Mse/\Mlh1^tm1Mse (involves: 129S/SvEv)	increased T cell derived lymphoma incidence	J:47642
\Mgrn1^em1(IMPC)Tcp/\Mgrn1⁺ (C57BL/6NCrl-Mgrn1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Mgrn1^em1(IMPC)Tcp/\Mgrn1^em1(IMPC)Tcp (C57BL/6NCrl-Mgrn1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Mgst2^em1(IMPC)Mbp/\Mgst2^em1(IMPC)Mbp (C57BL/6N-Mgst2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Mical2^em1(IMPC)Tcp/\Mical2^em1(IMPC)Tcp (C57BL/6NCrl-Mical2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Mical3^em1(IMPC)J/\Mical3^em1(IMPC)J (C57BL/6NJ-Mical3^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Micu1^em#Fink/\Micu1^em#Fink (C57BL/6N-Micu1^em#Fink)	decreased B cell number	J:238984
	decreased follicular B cell number	J:238984
	increased B cell apoptosis	J:238984
\Micu1^em#Fink/\Micu1^em#Fink \Smdt1^em1Fink/\Smdt1⁺ (involves: C57BL/6J * C57BL/6N * CBA)	decreased B cell number	J:238984
\Micu1^tm1bNarl/\Micu1⁺ (C57BL/6N-Micu1^tm1bNarl/Narl)	decreased monocyte cell number	J:211773
\Mid2^{tm1b(KOMP)Wtsi}/Y (C57BL/6N-Mid2^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Mideas^em1Shmc/\Mideas^em1Shmc (C57BL/6J-Mideas^em1Shmc)	immune system phenotype	J:291786
\Mif^tm1Dvd/\Mif^tm1Dvd (involves: 129S4/SvJae * C57BL/6)	decreased circulating tumor necrosis factor level	J:52300
	decreased susceptibility to bacterial infection	J:52300
	decreased susceptibility to endotoxin shock	J:52300
	increased interleukin-4 secretion	J:52300
	increased susceptibility to parasitic infection	J:52300
\Mif^tm1Mky/\Mif^tm1Mky (C.129-Mif^tm1Mky)	abnormal cytokine secretion	J:106380
	abnormal inflammatory response	J:106380
	decreased eosinophil cell number	J:106380
\Miga2^{tm1a(KOMP)Wtsi}/\Miga2^{tm1a(KOMP)Wtsi} (C57BL/6N-Miga2^{tm1a(KOMP)Wtsi}/Mmucd)	abnormal CD4-positive, alpha beta T cell morphology	J:339075
\Miga2^{tm1a(KOMP)Wtsi}/\Miga2^{tm1a(KOMP)Wtsi} \Pnp2^em1Smoc/\Pnp2^em1Smoc (C57BL/6-Miga2^{tm1a(KOMP)Wtsi} Pnp2^em1Smoc)	abnormal CD4-positive, alpha-beta T cell physiology	J:339075
\Miga2^{tm1c(KOMP)Wtsi}/\Miga2^{tm1c(KOMP)Wtsi} \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Miga2^{tm1c(KOMP)Wtsi} Tg(Cd4-cre)1Cwi)	abnormal CD4-positive, alpha-beta T cell physiology	J:339075
	abnormal immune system morphology	J:339075
	immune system phenotype	J:339075
\Miju^C3HeB/FeJ/\Miju^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	increased IgA level	J:91062
\Milr1^tm1Shib/\Milr1^tm1Shib (involves: C57BL/6N)	decreased mast cell degranulation	J:161854
\Milr1^tm1Shib/\Milr1^tm1Shib (involves: C57BL/6N)	increased susceptibility to type I hypersensitivity reaction	J:161854
\Minar1^em1(IMPC)Tcp/\Minar1^em1(IMPC)Tcp (C57BL/6NCrl-Minar1^em1(IMPC)Tcp/Tcp)	abnormal thymus morphology	J:211773
\Mink1^em1(IMPC)Tcp/\Mink1^em1(IMPC)Tcp (C57BL/6N-Mink1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Mipep^tm1.1Yhig/\Mipep^tm1.1Yhig \Tg(Adipoq-cre)1Evdr/0 (involves: C57BL/6J * C57BL/6N * FVB/NJ)	decreased T cell number	J:365489
	increased cytokine level	J:365489
	increased granulocyte number	J:365489
	increased inflammatory response	J:365489
	increased macrophage cell number	J:365489
	increased monocyte cell number	J:365489
	increased spleen weight	J:365489
	white adipose tissue inflammation	J:365489
\Mir10b^em1Rosay/\Mir10b^em1Rosay (C57BL/6J-Mir10b^em1Rosay)	large intestinal inflammation	J:342486
\Mir21a^tm1.1Mer/\Mir21a^tm1.1Mer (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal cytokine level	J:179235
	abnormal cytokine secretion	J:179235
	abnormal interferon level	J:179235
	abnormal interleukin level	J:179235
	decreased interleukin-4 secretion	J:179235
	increased interferon-gamma secretion	J:179235
	increased interleukin-12 secretion	J:179235
	increased susceptibility to type I hypersensitivity reaction	J:179235
\Mir21a^tm1.1Mer/\Mir21a^tm1.1Mer (B6.129S1-Mir21a^tm1.1Mer)	increased susceptibility to type IV hypersensitivity reaction	J:179235
\Mir27a^em1Bge/\Mir27a^em1Bge (C57BL/6-Mir27a^em1Bge)	abnormal macrophage physiology	J:267961
\Mir27a^em1Bge/\Mir27a^em1Bge (C57BL/6-Mir27a^em1Bge)	decreased susceptibility to bacterial infection	J:267961
\Mir33^tm1.1Koho/\Mir33^tm1.1Koho (involves: C57BL/6)	abnormal macrophage physiology	J:165420
\Mir34a^tm1.1Pisc/\Mir34a^tm1.1Pisc \Mirc21^tm1.1Pisc/\Mirc21^tm1.1Pisc \Mirc34^tm1.1Pisc/\Mirc34^tm1.1Pisc (involves: 129S4/SvJae * C57BL/6 * C57BL/6J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:256929
	nasal inflammation	J:256929
\Mir34a^tm1.2Arte/\Mir34a^tm1.2Arte (involves: C57BL/6N)	abnormal immune system cell morphology	J:221990
\Mir34a^tm1.2Arte/\Mir34a^tm1.2Arte (involves: C57BL/6N)	increased B cell number	J:221990
\Mir100^em1Nju/\Mir100^em1Nju \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: C57BL/6 * DBA)	liver inflammation	J:281439
\Mir122^tm1.1Apts/\Mir122^tm1.1Apts (involves: 129 * C57BL/6)	increased circulating interleukin-6 level	J:190066
	increased macrophage cell number	J:190066
	increased monocyte cell number	J:190066
	liver inflammation	J:190066
\Mir122^tm1.1Kgh/\Mir122^tm1.1Kgh (involves: 129S1/Sv * 129X1/SvJ)	increased circulating interleukin-6 level	J:190067
	liver inflammation	J:190067
\Mir122^tm1.2Kgh/\Mir122^tm1.2Kgh \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	increased circulating interleukin-6 level	J:190067
	increased interleukin-6 secretion	J:190067
	increased monocyte cell number	J:190067
	increased neutrophil cell number	J:190067
	increased tumor necrosis factor secretion	J:190067
	liver inflammation	J:190067
\Mir125a^tm1Smoc/\Mir125a^tm1Smoc (involves: C57BL/6)	abnormal regulatory T cell physiology	J:224880
	decreased regulatory T cell number	J:224880
	immune system phenotype	J:224880
	increased interferon-gamma secretion	J:224880
	increased interleukin-17 secretion	J:224880
	increased susceptibility to experimental autoimmune encephalomyelitis	J:224880
\Mir126a^tm2.1Smoc/\Mir126a^tm2.1Smoc \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6J * C57BL/6N * DBA/2)	decreased T-helper 2 cell number	J:355195
	dermatitis	J:355195
	enlarged spleen	J:355195
	increased T-helper 1 cell number	J:355195
	increased T-helper 17 cell number	J:355195
\Mir139^em1Jwli/\Mir139^em1Jwli (C57BL/6J-Mir139^em1Jwli)	abnormal cytokine level	J:248779
	increased susceptibility to colitis induced morbidity/mortality	J:280467, J:248779
	increased susceptibility to induced colitis	J:248779
\Mir140^tm1.1Asah/\Mir140^tm1.1Asah (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	increased susceptibility to induced arthritis	J:160358
	osteoarthritis	J:160358
\Mir142^tm1.1Sbel/\Mir142^tm1.1Sbel (involves: C57BL/6N)	decreased eosinophil cell number	J:227228
	decreased leukocyte cell number	J:227228
	decreased lymphocyte cell number	J:227228
	decreased monocyte cell number	J:227228
\Mir142^tm1Teyo/\Mir142^tm1Teyo (involves: C57BL/6)	decreased mast cell degranulation	J:211850
\Mir142hg^{Gt(IST11580H2)Tigm}/\Mir142hg^{Gt(IST11580H2)Tigm} (involves: C57BL/6N)	abnormal dendritic cell differentiation	J:207516
	abnormal dendritic cell morphology	J:207516
	decreased dendritic cell number	J:207516
	enlarged spleen	J:207516
	immune system phenotype	J:207516
	increased dendritic cell number	J:207516
	increased neutrophil cell number	J:207516
\Mir144/Mir451a^tm1.1Mjwe/\Mir144/Mir451a^tm1.1Mjwe (Not Specified)	increased spleen weight	J:163250
	spleen hyperplasia	J:163250
\Mir144/Mir451a^tm1.1Mjwe/\Mir144/Mir451a^tm1.1Mjwe (Not Specified)	increased spleen weight	J:163250
	spleen hyperplasia	J:163250
\Mir144/Mir451a^tm1.2Doca/\Mir144/Mir451a^tm1.2Doca (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)	enlarged spleen	J:163418
\Mir144/Mir451a^tm1.2Doca/\Mir144/Mir451a^tm1.2Doca (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)	enlarged spleen	J:163418
\Mir146^tm1.1Bal/\Mir146^tm1.1Bal (involves: C57BL/6)	abnormal lymphopoiesis	J:167922
	abnormal regulatory T cell physiology	J:167922
	decreased interferon-gamma secretion	J:167922
	decreased leukocyte cell number	J:173230
	decreased lymphocyte cell number	J:173230
	decreased monocyte cell number	J:173230
	enlarged spleen	J:173230
	increased regulatory T cell number	J:167922
	increased spleen weight	J:173230
	increased T cell derived lymphoma incidence	J:173230
	myeloid hyperplasia	J:167922, J:173230
\Mir146^tm1.1Bal/\Mir146^tm1.1Bal (involves: C57BL/6 * FVB/N)	abnormal immune system physiology	J:173671
	abnormal immune tolerance	J:173671
	abnormal macrophage physiology	J:173671
	abnormal T cell activation	J:173671
	increased circulating interleukin-1 beta level	J:173671
	increased circulating interleukin-6 level	J:173671
	increased circulating interleukin-10 level	J:173671
	increased circulating tumor necrosis factor level	J:173671
	increased interleukin-1 beta secretion	J:173671
	increased interleukin-6 secretion	J:173671
	increased macrophage nitric oxide production	J:173671
	increased susceptibility to bacterial infection induced morbidity/mortality	J:173671
	increased susceptibility to endotoxin shock	J:173671
	increased tumor necrosis factor secretion	J:173671
	myeloid hyperplasia	J:173671
\Mir146^tm1.1Bal/\Mir146^tm1.1Bal \Tifab^tm1.1Dsta/\Tifab^tm1.1Dsta (involves: 129 * C57BL/6 * C57BL/6J)	decreased lymphocyte cell number	J:229024
	decreased neutrophil cell number	J:229024
\Mir146^tm1.1Lfl/\Mir146^tm1.1Lfl \Ighg1^tm1(cre)Cgn/\Ighg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased germinal center B cell number	J:266124
	increased T follicular helper cell number	J:266124
\Mir146^tm1.1Lfl/\Mir146^tm1.1Lfl \Mir146b^tm1.1Lfl/\Mir146b^tm1.1Lfl \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	increased germinal center B cell number	J:266124
	increased IgG level	J:266124
	increased T follicular helper cell number	J:266124
\Mir146^tm1.1Lfl/\Mir146^tm1.1Lfl \Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	increased germinal center B cell number	J:266124
	increased T follicular helper cell number	J:266124
\Mir146^tm1.1Lfl/\Mir146^tm1.1Lfl \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:266124
\Mir146^tm1.1Lfl/\Mir146^tm1.1Lfl \Tg(Cr2-cre)3Cgn/0 (involves: C57BL/6)	increased anti-double stranded DNA antibody level	J:266124
	increased germinal center B cell number	J:266124
	increased IgG1 level	J:266124
	increased IgG level	J:266124
	increased plasma cell number	J:266124
	increased T follicular helper cell number	J:266124
\Mir146^tm2.1Bal/\Mir146^tm2.1Bal (involves: 129S1/Sv * C57BL/6 * FVB/N)	abnormal immune system physiology	J:173671
	abnormal immune tolerance	J:173671
	abnormal macrophage physiology	J:173671
	abnormal spleen B cell follicle morphology	J:173671
	abnormal T cell activation	J:173671
	decreased lymphocyte cell number	J:173671
	decreased monocyte cell number	J:173671
	enlarged lymph nodes	J:173671
	enlarged spleen	J:173671
	immune system phenotype	J:173671
	increased acute inflammation	J:173671
	increased anti-double stranded DNA antibody level	J:173671
	increased circulating interleukin-1 beta level	J:173671
	increased circulating interleukin-6 level	J:173671
	increased circulating interleukin-10 level	J:173671
	increased circulating tumor necrosis factor level	J:173671
	increased interleukin-1 beta secretion	J:173671
	increased interleukin-6 secretion	J:173671
	increased macrophage nitric oxide production	J:173671
	increased spleen germinal center number	J:173671
	increased spleen germinal center size	J:173671
	increased spleen weight	J:173671
	increased susceptibility to bacterial infection induced morbidity/mortality	J:173671
	increased susceptibility to endotoxin shock	J:173671
	increased tumor necrosis factor secretion	J:173671
	myeloid hyperplasia	J:173671
\Mir146b^tm1.1Lfl/\Mir146b^tm1.1Lfl \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:266124
\Mir147^tm1.2Xyn/\Mir147^tm1.2Xyn (involves: C57BL/6)	immune system phenotype	J:332925
\Mir148a^tm2942.1Arte/\Mir148a^tm2942.1Arte \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal plasmablast number	J:307366
	decreased IgA level	J:307366
	decreased IgG level	J:307366
	decreased IgM level	J:307366
	decreased plasma cell number	J:307366
	impaired humoral immune response	J:307366
	increased memory B cell number	J:307366
\Mir148a^tm2942.1Arte/\Mir148a^tm2942.1Arte \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal B cell physiology	J:307366
	abnormal plasmablast number	J:307366
	decreased plasma cell number	J:307366
	impaired humoral immune response	J:307366
	increased plasma cell number	J:307366
\Mir148a^tm2942.2Arte/\Mir148a^tm2942.2Arte (involves: C57BL/6 * FVB/N)	abnormal B cell physiology	J:307366
	decreased plasma cell number	J:307366
\Mir149^em1Ydw/\Mir149^em1Ydw (C57BL/6J-Mir149^em1Ydw)	increased susceptibility to endotoxin shock	J:294318
\Mir150^tm1Rsky/\Mir150^tm1Rsky (involves: C57BL/6)	decreased B-2 B cell number	J:127234
	increased B-1 B cell number	J:127234
	increased IgA level	J:127234
	increased IgG1 level	J:127234
	increased IgG2b level	J:127234
	increased IgM level	J:127234
\Mir155^tm1.1Brd/\Mir155^tm1.1Brd (B6.Cg-Mir155^tm1.1Brd Tyr^c-Brd)	abnormal CD4-positive, alpha beta T cell morphology	J:121095
	abnormal CD4-positive, alpha-beta T cell physiology	J:121095
	abnormal dendritic cell physiology	J:121095
	abnormal T-helper 1 cell morphology	J:121095
	decreased IgG1 level	J:121095
	immune system phenotype	J:121095
	increased susceptibility to bacterial infection	J:121095
	increased T-helper 2 cell number	J:121095
\Mir155^tm1.1Brd/\Mir155^tm1.1Brd (B6.129S7-Mir155^tm1.1Brd)	decreased regulatory T cell number	J:146268
\Mir155^tm1.1Rsky/\Mir155^tm1.1Rsky (involves: 129 * C57BL/6)	abnormal B cell physiology	J:121084
	abnormal cytokine secretion	J:121084
	abnormal germinal center B cell physiology	J:121084
	abnormal humoral immune response	J:121084
	abnormal T cell physiology	J:121084
	decreased germinal center B cell number	J:121084
\Mir155^tm1.1Rsky/\Mir155^tm1.1Rsky (B6.Cg-Mir155^tm1Rsky/J)	abnormal T cell physiology	J:226678
	abnormal T-helper 17 cell differentiation	J:226678
	decreased effector memory T-helper cell number	J:226678
	decreased interleukin-6 secretion	J:226678
	decreased regulatory T cell number	J:226678
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226678
	decreased T-helper 17 cell number	J:226678
\Mir155^tm1Brd/\Mir155^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell physiology	J:121095
	abnormal class switch recombination	J:121095
	abnormal cytokine secretion	J:121095
	decreased IgM level	J:121095
	immune system phenotype	J:121095
	intestinal inflammation	J:121095
	lung inflammation	J:121095
\Mir155^tm1Rsky/\Mir155^tm1Rsky (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:121084
	abnormal gut-associated lymphoid tissue morphology	J:121084
	abnormal humoral immune response	J:121084
	abnormal immune system morphology	J:121084
	abnormal immune system physiology	J:121084
	abnormal Peyer's patch germinal center morphology	J:121084
	decreased interferon-gamma secretion	J:121084
	decreased interleukin-4 secretion	J:121084
	decreased spleen germinal center number	J:121084
	decreased spleen germinal center size	J:121084
	decreased tumor necrosis factor secretion	J:121084
	increased interleukin-10 secretion	J:121084
\Mir155^tm1Rsky/\Mir155^tm1Rsky (involves: 129 * C57BL/6)	abnormal class switch recombination	J:136224
\Mir181d^tm1.1Oers/\Mir181d^tm1.1Oers (involves: C57BL/6)	immune system phenotype	J:212571
\Mir181d^tm1.1Oers/\Mir181d^tm1.1Oers (involves: C57BL/6)	increased T cell number	J:212571
\Mir204^tm1.2Dic/\Mir204^tm1.2Dic \Mir211^tm1.2Dic/\Mir211^tm1.2Dic (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	increased susceptibility to induced arthritis	J:345335
\Mir205hg^tm1.1Oers/\Mir205hg^tm1.1Oers (B6(Cg)-Mir205hg^tm1.1Oers)	small thymus	J:278363
\Mir210^tm1.1Wtsi/\Mir210^tm1.1Wtsi (involves: C57BL/6J * C57BL/6N)	decreased germinal center B cell number	J:205868
	immune system phenotype	J:205868
	increased anti-chromatin antibody level	J:205868
	increased anti-double stranded DNA antibody level	J:205868
	increased anti-nuclear antigen antibody level	J:205868
\Mir216a^em1Uf/\Mir216a^em1Uf (C57BL/6-Mir216a^em1Uf)	increased susceptibility to induced pancreatitis	J:278847
\Mir216a^em2Uf/\Mir216a^em2Uf (C57BL/6-Mir216a^em2Uf)	increased susceptibility to induced pancreatitis	J:278847
\Mir216b^em1Uf/\Mir216b^em1Uf (C57BL/6-Mir216b^em1Uf)	increased susceptibility to induced pancreatitis	J:278847
\Mir217^em1Uf/\Mir217^em1Uf (C57BL/6-Mir217^em1Uf)	increased susceptibility to induced pancreatitis	J:278847
\Mir217^em2Uf/\Mir217^em2Uf (C57BL/6-Mir217^em2Uf)	increased susceptibility to induced pancreatitis	J:278847
\Mir223^tm1Fcam/\Mir223^tm1Fcam (involves: 129S4/SvJae * C57BL/6)	abnormal granulocyte physiology	J:140009
	abnormal neutrophil differentiation	J:140009
	abnormal neutrophil physiology	J:140009
	increased acute inflammation	J:140009
	increased granulocyte number	J:140009
	increased neutrophil cell number	J:140009
	lung inflammation	J:140009
\Mir301^tm1Yoli/\Mir301^tm1Yoli (involves: C57BL/6J)	abnormal response to transplant	J:237900
\Mir338^em1Zchn/\Mir338^em1Zchn (C57BL/6-Mir338^em1Zchn)	decreased osteoclast cell number	J:285968
\Mir378b^em#Yoo/\Mir378b^em#Yoo (C57BL/6J-Mir378b^em#Yoo)	abnormal chemokine secretion	J:307588
	abnormal susceptibility to bacterial infection	J:307588
	decreased interferon-gamma secretion	J:307588
	decreased interleukin-12 secretion	J:307588
	decreased tumor necrosis factor secretion	J:307588
\Mir425^em1Nju/\Mir425⁺ (involves: C57BL/6)	increased tumor necrosis factor secretion	J:280159
\Mir451a^tm1.2Doca/\Mir451a^tm1.2Doca (involves: 129P2/OlaHsd * 129S4/SvJaeSor * BALB/cJ)	enlarged spleen	J:163418
\Mir451a^tm1Eno/\Mir451a^tm1Eno (involves: C57BL/6)	enlarged spleen	J:163251
\Mir497^em1Hgyu/\Mir497^em1Hgyu (C57BL/6-Mir497^em1Hgyu)	increased susceptibility to induced colitis	J:357958
\Mir511^em1Clib/\Mir511^em1Clib (C57BL/6J-Mir511^em1Clib)	abnormal macrophage physiology	J:345580
\Mir511^em1Clib/\Mir511^em1Clib (C57BL/6J-Mir511^em1Clib)	decreased susceptibility to induced colitis	J:345580
\Mir592^em1Jzhan/\Mir592^em1Jzhan (Not Specified)	abnormal microglial cell morphology	J:323615
\Mirc1^tm1.1Aven/\Mirc1^tm1.1Aven (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased alpha-beta T cell number	J:223213
	decreased B cell number	J:223213
	decreased pre-B cell number	J:223213
	decreased pro-B cell number	J:223213
	increased B cell apoptosis	J:223213
	small spleen	J:223213
\Mirc1^tm1.2Tyj/\Mirc1^tm1.2Tyj (involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL)	abnormal B cell differentiation	J:134861
	decreased pre-B cell number	J:134861
	increased B cell apoptosis	J:134861
\Mirc1^tm1.3Tyj/\Mirc1^tm1.3Tyj (involves: 129S4/SvJae * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:134861
	decreased pre-B cell number	J:134861
	increased B cell apoptosis	J:134861
\Mirc1^tm1Tyj/\Mirc1^tm1Tyj \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA * SJL)	abnormal immunoglobulin heavy chain V(D)J recombination	J:134861
	decreased pre-B cell number	J:134861
	increased B cell apoptosis	J:134861
\Mirc1^tm2.1Aven/\Mirc1^tm2.1Aven (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased B cell number	J:223213
\Mirc1^tm2.1Aven/\Mirc1^tm2.1Aven \Tg(IghMyc)22Bri/? (involves: 129S4/SvJae * C57BL/6 * SJL/J)	abnormal pre-B cell morphology	J:223213
	increased B cell apoptosis	J:223213
\Mirc1^tm3.1Aven/\Mirc1^tm3.1Aven (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased alpha-beta T cell number	J:223213
	decreased B cell number	J:223213
	decreased pre-B cell number	J:223213
	decreased pro-B cell number	J:223213
	increased B cell apoptosis	J:223213
	small spleen	J:223213
\Mirc11^tm1Rdhl/\Mirc11^tm1Rdhl (B6.129-Mirc11^tm1Rdhl)	abnormal B cell differentiation	J:243248
	immune system phenotype	J:243248
	impaired myelopoiesis	J:243248
	increased B cell number	J:243248
	increased follicular B cell number	J:243248
	increased immature B cell number	J:243248
	increased mature B cell number	J:243248
	increased plasma cell number	J:243248
	increased pre-pro B cell number	J:243248
	increased pro-B cell number	J:243248
	increased transitional stage T1 B cell number	J:243248
\Mirc13^tm1.1Mtm/\Mirc13^tm1.1Mtm (Not Specified)	abnormal macrophage activation involved in immune response	J:256444
\Mirc14^tm1.1Ankr/\Mirc14^tm1.1Ankr (involves: C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:196134
	abnormal NK T cell morphology	J:196134
	abnormal T cell differentiation	J:196134
	decreased double-positive T cell number	J:196134
	decreased interferon-gamma secretion	J:196134
	decreased interleukin-4 secretion	J:196134
	decreased interleukin-13 secretion	J:196134
	decreased NK T cell number	J:196134
	immune system phenotype	J:196134
	increased CD4-positive, alpha-beta T cell number	J:196134
\Mirc14^tm1.1Czc/\Mirc14^tm1.1Czc \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ (either: (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor * C57BL/6))	decreased double-positive T cell number	J:188125
	thymus hypoplasia	J:188125
\Mirc14^tm1.1Flv/\Mirc14^tm1.1Flv \Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA/2 * SJL)	immune system phenotype	J:203157
\Mirc14^tm1.1Flv/\Mirc14^tm1.1Flv \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2 * SJL)	decreased NK T cell number	J:203157
\Mirc14^tm1.2Czc/\Mirc14^tm1.2Czc (either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))	decreased B cell number	J:188125
	decreased DN3 thymocyte number	J:188125
	decreased double-positive T cell number	J:188125
	decreased germinal center B cell number	J:188125
	decreased thymocyte number	J:188125
	increased CD4-positive, alpha-beta T cell number	J:188125
	increased marginal zone B cell number	J:188125
\Mirc14^tm1.2Flv/\Mirc14^tm1.2Flv (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	abnormal T cell differentiation	J:203157
	abnormal T cell physiology	J:203157
	abnormal T cell receptor V(D)J recombination	J:203157
	decreased B cell number	J:203157
	decreased CD4-positive, alpha-beta T cell number	J:203157
	decreased CD8-positive, alpha-beta T cell number	J:203157
	decreased DN1 thymic pro-T cell number	J:203157
	decreased double-positive T cell number	J:203157
	decreased NK T cell number	J:203157
	decreased T cell proliferation	J:203157
	decreased thymocyte apoptosis	J:203157
	decreased thymocyte number	J:203157
\Mirc14^tm1.2Flv/\Mirc14^tm1.2Flv \Mirc15^tm1.2Flv/\Mirc15^tm1.2Flv (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	decreased B cell number	J:203157
	decreased immature B cell number	J:203157
	decreased pre-B cell number	J:203157
	increased pro-B cell number	J:203157
\Mirc14^tm1.2Flv/\Mirc14^tm1.2Flv \Tg(Cd4-TcraDN32D3)1Aben/0 (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	abnormal NK T cell physiology	J:203157
	decreased NK T cell number	J:203157
\Mirc14^tm1.2Flv/\Mirc14^tm1.2Flv \Tg(LCKprBCL2L1)12Sjk/0 (involves: C57BL/6 * C57BL/6N * FVB/N * SJL)	decreased NK T cell number	J:203157
\Mirc15^tm1.2Czc/\Mirc15^tm1.2Czc (either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))	immune system phenotype	J:188125
\Mirc16^tm1.2Czc/\Mirc16^tm1.2Czc (either: (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6))	immune system phenotype	J:188125
	increased CD8-positive, alpha-beta T cell number	J:188125
\Mirc19^tm1.2Arte/\Mirc19^tm1.2Arte (involves: C57BL/6N)	immune system phenotype	J:200865
\Mirc27^em1Hhzg/\Mirc27^em1Hhzg \Tg(Vav1-cre)#Cgp/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)	immune system phenotype	J:320883
\Mirc29^tm1.1Cwh/\Mirc29^tm1.1Cwh (involves: 129X1/SvJ)	immune system phenotype	J:189763
\Mirc30^em1Hhzg/\Mirc30^em1Hhzg \Tg(Vav1-cre)#Cgp/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)	abnormal NK cell morphology	J:320883
	increased B cell number	J:320883
	increased pre-B cell number	J:320883
	increased pro-B cell number	J:320883
	increased spleen weight	J:320883
\Mirc30^tm1.2Rdf/\Mirc30^tm1.2Rdf (involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)	abnormal B cell proliferation	J:156946
	increased B cell number	J:156946
	increased B-1a cell number	J:156946
	increased spleen white pulp amount	J:156946
\Mirc32^tm1.1Jtm/\Mirc32^tm1.1Jtm \Tg(Myh11-cre,-EGFP)2Mik/? (B6.Cg-Mirc32^tm1.1Jtm Tg(Myh11-cre,-EGFP)2Mik)	increased susceptibility to induced colitis	J:214382
\Mirc32^tm1.1Jtm/\Mirc32^tm1.1Jtm \Twist2^tm1(cre)Dor/\Twist2⁺ (B6.129(Cg)-Twist2^{tm1.1(cre)Dor} Mirc32^tm1.1Jtm)	increased susceptibility to induced colitis	J:214382
\Mirc32^tm1.2Jtm/\Mirc32^tm1.2Jtm (B6.129(Cg)-Mirc32^tm1.2Jtm)	increased susceptibility to induced colitis	J:214382
\Mirc33^tm1.1Cwh/\Mirc33^tm1.1Cwh (involves: 129X1/SvJ)	abnormal T cell morphology	J:189763
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:189763
	increased interferon-gamma secretion	J:189763
	increased interleukin-17 secretion	J:189763
	increased T-helper 1 cell number	J:189763
	lymph node hypoplasia	J:189763
	lymphoid hypoplasia	J:189763
	spleen hypoplasia	J:189763
	thymus hypoplasia	J:189763
\Mirc33^tm1Bdes/\Mirc33^tm1Bdes (Not Specified)	abnormal thymus involution	J:180783
\Mirc40^tm1Jzb/\Mirc40^tm1Jzb (Not Specified)	increased microglial cell activation	J:244554
\Misp^em2Nsas/\Misp^em2Nsas (FVB/NJcl-Misp^em2Nsas)	abnormal interleukin level	J:333842
\Misp^em2Nsas/\Misp^em2Nsas (FVB/NJcl-Misp^em2Nsas)	increased susceptibility to induced colitis	J:333842
\Mitf^mi-di/\Mitf^mi-di ((PT x C3H/HeH)F1)	abnormal spleen germinal center morphology	J:8196
	abnormal spleen morphology	J:8196
	abnormal spleen red pulp morphology	J:8196
	abnormal spleen white pulp morphology	J:8196
\Mitf^mi-ew/\Mitf^mi-ew \Tfe3^tm1Est/\Tfe3^tm1Est (either: (involves: 129/Sv * 129S1/Sv * C57BL/6Bn * NAW) or (involves: 129S1/Sv * C57BL/6Bn * C57BL/6J * NAW))	abnormal osteoclast morphology	J:89821
\Mitf^Mi-Or/\Mitf^Mi-Or (involves: 101/Rl * C3H/Rl)	abnormal osteoclast morphology	J:30149
	abnormal osteoclast physiology	J:30149
	decreased osteoclast cell number	J:30149
	increased osteoclast cell number	J:30149
\Mitf^mi-tg/\Mitf^mi-tg (B6.Cg-Mitf^mi-tg)	abnormal mast cell physiology	J:53161
\Mitf^mi-vga9/\Mitf^mi-vga9 \Tfe3^tm1Est/\Tfe3^tm1Est (either: (involves: 129/Sv * 129S1/Sv * C57BL/6 * CBA) or (involves: 129S1/Sv * C57BL/6 * C57BL/6J * CBA))	abnormal osteoclast morphology	J:89821
\Mitf^mi-vit/\Mitf^mi-vit (C57BL/6J-Mitf^mi-vit)	abnormal Langerhans cell physiology	J:102101
\Mitf^Mi/\Mitf^Mi (Not Specified)	abnormal osteoclast morphology	J:5046
	decreased mast cell number	J:6889
	increased osteoclast cell number	J:5046
\Mitf^Mi/\Mitf^Mi (B6.Cg-Mitf^Mi)	abnormal mast cell physiology	J:53161
\Mitf^Mi/\Mitf^Mi (involves: C57BL/6J)	abnormal osteoclast morphology	J:89821
\Mitf^Mi/\Mitf^Mi \Tfe3^tm1Est/\Tfe3^tm1Est (either: (involves: 129/Sv * 129S1/Sv * C57BL/6J) or (involves: 129S1/Sv * C57BL/6J))	abnormal osteoclast morphology	J:89821
\Mitf^{Tg(Tff3-Tmem207)2Tamo}/\Mitf⁺ (involves: C57BL/6)	kidney inflammation	J:244533
\Mki67^em1(IMPC)Mbp/\Mki67^em1(IMPC)Mbp (C57BL/6NCrl-Mki67^em1(IMPC)Mbp/MbpMmucd)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Mki67^em1Dfis/\Mki67^em1Dfis (involves: C57BL/6J)	immune system phenotype	J:304800
\Mkrn2^{tm1b(KOMP)Wtsi}/\Mkrn2^{tm1b(KOMP)Wtsi} (C57BL/6N-Mkrn2^{tm1b(KOMP)Wtsi}/Wtsi)	decreased dendritic epidermal T cell number	J:211773
\Mks1^hlb614/\Mks1^hlb614 (involves: C3H * C57BL/6)	absent spleen	J:167534
\Mks1^hlb614/\Mks1^hlb614 (involves: C3H * C57BL/6)	accessory spleen	J:167534
\Mlf1^tm1Swm/\Mlf1^tm1Swm (involves: 129 * C57BL/6)	decreased splenocyte apoptosis	J:266833
\Mlf1^tm1Swm/\Mlf1^tm1Swm (involves: 129 * C57BL/6)	increased B cell number	J:266833
\Mlh1^m1Btlr/\Mlh1^m1Btlr (C57BL/6J-Mlh1^m1Btlr)	abnormal humoral immune response	J:265206
\Mlh1^m1Btlr/\Mlh1^m1Btlr (C57BL/6J-Mlh1^m1Btlr)	increased IgM level	J:265206
\Mlh1^m2Btlr/\Mlh1^m2Btlr (C57BL/6J-Mlh1^m2Btlr)	abnormal humoral immune response	J:265207
	decreased IgE level	J:265207
	increased IgM level	J:265207
\Mlh1^m3Btlr/\Mlh1^m3Btlr (C57BL/6J-Mlh1^m3Btlr)	abnormal humoral immune response	J:265208
	decreased IgE level	J:265208
	increased IgM level	J:265208
\Mlh1^{tm1b(EUCOMM)Hmgu}/\Mlh1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mlh1^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
\Mlh1^tm1Mse/\Mlh1^tm1Mse (involves: 129S/SvEv)	increased T cell derived lymphoma incidence	J:47642
\Mlh1^tm1Rak/\Mlh1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:53451
\Mlh1^tm1Rak/\Mlh1^tm1Rak (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:53451
\Mlh1^tm1Rak/\Mlh1^tm1Rak (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)	increased T cell derived lymphoma incidence	J:153684
\Mlkl^{em1(IMPC)Ccpcz}/\Mlkl^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mlkl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Mlkl^em1Jhan/\Mlkl^em1Jhan (involves: C57BL/6)	abnormal macrophage physiology	J:204622
\Mlkl^em1Jhan/\Mlkl^em1Jhan (involves: C57BL/6)	immune system phenotype	J:204622
\Mlkl^m1Btlr/\Mlkl⁺ (C57BL/6J-Mlkl^m1Btlr)	decreased inflammatory response	J:225934
\Mlkl^m1Btlr/\Mlkl^m1Btlr (C57BL/6J-Mlkl^m1Btlr)	decreased inflammatory response	J:225934
\Mlkl^m2Btlr/\Mlkl⁺ (C57BL/6J-Mlkl^m2Btlr)	decreased inflammatory response	J:234252
\Mlkl^m2Btlr/\Mlkl^m2Btlr (C57BL/6J-Mlkl^m2Btlr)	decreased inflammatory response	J:234252
\Mlkl^m3Btlr/\Mlkl⁺ (C57BL/6J-Mlkl^m3Btlr)	decreased inflammatory response	J:234251
\Mlkl^m3Btlr/\Mlkl^m3Btlr (C57BL/6J-Mlkl^m3Btlr)	decreased inflammatory response	J:234251
\Mlkl^tm1.1Wsa/\Mlkl^tm1.1Wsa \Otulin^{tm1c(EUCOMM)Hmgu}/\Otulin^{tm1c(EUCOMM)Hmgu} \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	dermatitis	J:312394
\Mllt6^em1(IMPC)Tcp/\Mllt6^em1(IMPC)Tcp (C57BL/6NCrl-Mllt6^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Mllt10^em1(IMPC)Mbp/\Mllt10⁺ (C57BL/6N-Mllt10^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Mlph^ln-Btlr/\Mlph^ln-Btlr (C57BL/6J-Mlph^ln-Btlr)	immune system phenotype	J:133625
\Mlrrq^DBA/2/\Mlrrq^DBA/2 (C.D2-Mtv7^DBA/2)	decreased susceptibility to parasitic infection	J:41574
\Mmab^{em1(IMPC)Hmgu}/\Mmab⁺ (C57BL/6NCrl-Mmab^{em1(IMPC)Hmgu}/Ieg)	abnormal spleen morphology	J:211773
\Mmachc^{tm1.1(NCOM)Mfgc}/\Mmachc⁺ (C57BL/6N-Mmachc^{tm1.1(NCOM)Mfgc}/Tcp)	enlarged lymph nodes	J:211773
\Mmd^tm1Beij/\Mmd^tm1Beij (Not Specified)	abnormal macrophage differentiation	J:304637
	decreased susceptibility to induced arthritis	J:304637
	increased macrophage apoptosis	J:304637
	small inguinal lymph nodes	J:304637
\Mme^tm1Cge/\Mme^tm1Cge (B6.129S4-Mme^tm1Cge)	dermatitis	J:66854
\Mme^tm1Cge/\Mme^tm1Cge (B6.129S4-Mme^tm1Cge)	increased susceptibility to type I hypersensitivity reaction	J:66854
\Mmgt2^{tm1b(EUCOMM)Wtsi}/\Mmgt2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Mmgt2^{tm1b(EUCOMM)Wtsi}/Bay)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
\Mmp1a^tm1Otin/\Mmp1a^tm1Otin (involves: 129P2/OlaHsd * C57BL/6J)	abnormal interleukin secretion	J:198586
	decreased inflammatory response	J:198586
	increased interferon-gamma secretion	J:198586
	increased interleukin-1 alpha secretion	J:198586
	increased interleukin-2 secretion	J:198586
	increased interleukin-17 secretion	J:198586
\Mmp2^em1(IMPC)Mbp/\Mmp2^em1(IMPC)Mbp (C57BL/6N-Mmp2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Mmp2^tm1Ito/\Mmp2^tm1Ito (involves: 129P2/OlaHsd * C57BL/6J)	abnormal inflammatory response	J:46091
	brain inflammation	J:94099
	decreased inflammatory response	J:46091
	increased susceptibility to experimental autoimmune encephalomyelitis	J:94099
\Mmp2^tm1Ito/\Mmp2^tm1Ito (involves: 129P2/OlaHsd)	autoimmune arthritis	J:121780
\Mmp2^tm1Ito/\Mmp2^tm1Ito (involves: 129P2/OlaHsd)	decreased osteoclast cell number	J:121780
\Mmp2^tm1Ito/\Mmp2^tm1Ito \Timp1^tm1Pds/\Timp1^tm1Pds (either: (involves: 129S4/SvJae) or (involves: C57BL/6))	decreased susceptibility to bacterial infection	J:94836
\Mmp2^tm1Ito/\Mmp2^tm1Ito \Timp3^tm1Osya/\Timp3^tm1Osya (involves: 129P2/OlaHsd * C57BL/6)	aortitis	J:193744
\Mmp3^tm1Mrl/\Mmp3^tm1Mrl (either: (129S7/SvEvBrd X B10.RIII)N2 or ((involves: 129S7/SvEvBrd * C57BL/6) X B10.RIII)N2)	autoimmune arthritis	J:46038
	joint inflammation	J:46038
	osteoarthritis	J:46038
\Mmp3^tm1Mrl/\Mmp3^tm1Mrl (either: 129S7/SvEvBrd or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal CD4-positive, alpha-beta T cell physiology	J:93706
	increased susceptibility to bacterial infection	J:93706
\Mmp3^tm1Mrl/\Mmp3^tm1Mrl (involves: 129S7/SvEvBrd * C57BL/10ScSn * RIII)	abnormal lymphocyte physiology	J:55723
	decreased susceptibility to type IV hypersensitivity reaction	J:55723
\Mmp3^tm1Mrl/\Mmp3^tm1Mrl (involves: 129S7/SvEvBrd)	immune system phenotype	J:124841
\Mmp3^tm1Mrl/\Mmp3^tm1Mrl \Timp1^tm1Pds/\Timp1^tm1Pds (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:94836
\Mmp7^tm1Lmm/\Mmp7^tm1Lmm (involves: 129S1/Sv * 129X1/SvJ)	decreased susceptibility to bacterial infection	J:153651
\Mmp7^tm1Lmm/\Mmp7^tm1Lmm (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:55723
\Mmp7^tm1Lmm/\Mmp7^tm1Lmm (B6.129-Mmp7^tm1Lmm)	increased interleukin-1 beta secretion	J:149388
\Mmp7^tm1Lmm/\Mmp7^tm1Lmm (B6.129-Mmp7^tm1Lmm)	increased susceptibility to induced colitis	J:149388
\Mmp7^tm1Lmm/\Mmp7^tm1Lmm (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:124841
	decreased tumor necrosis factor secretion	J:124841
	impaired macrophage chemotaxis	J:124841
\Mmp7^tm1Lmm/\Mmp7^tm1Lmm \Timp1^tm1Pds/\Timp1^tm1Pds (involves: 129S4/SvJae)	decreased susceptibility to bacterial infection	J:94836
\Mmp8^tm1Otin/\Mmp8^tm1Otin (involves: 129X1/SvJ * C57BL/6J)	abnormal inflammatory response	J:86393
	chronic inflammation	J:86393
	increased susceptibility to bacterial infection	J:97118
\Mmp8^tm1Otin/\Mmp8^tm1Otin (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:113463
\Mmp8^tm1Otin/\Mmp8^tm1Otin (involves: 129X1/SvJ)	immune system phenotype	J:148442
\Mmp8^tm1Otin/\Mmp8^tm1Otin \Mmp9^tm1Tvu/\Mmp9^tm1Tvu (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	immune system phenotype	J:113463
\Mmp9^tm1Arnd/\Mmp9^tm1Arnd (involves: 129P2/OlaHsd)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:58833
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (involves: 129S6/SvEvTac)	abnormal chemokine level	J:84293
	abnormal dendritic cell physiology	J:84293
	abnormal Langerhans cell physiology	J:76157
	decreased dendritic cell number	J:84293
	decreased IgE level	J:84293
	decreased inflammatory response	J:84293
	increased circulating interferon-beta level	J:148442
	increased circulating interferon-gamma level	J:148442
	increased susceptibility to Picornaviridae infection	J:148442
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:148442
	myocarditis	J:148442
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (FVB.129S6-Mmp9^tm1Tvu)	abnormal neutrophil physiology	J:104644
	decreased susceptibility to induced colitis	J:104644
	immune system phenotype	J:104644
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (129S6/SvEvTac-Mmp9^tm1Tvu)	immune system phenotype	J:113463
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (involves: 129/Sv * 129S6/SvEvTac)	decreased circulating interleukin-10 level	J:55723
	increased susceptibility to type IV hypersensitivity reaction	J:55723
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (involves: 129S6/SvEvTac * CD-1)	impaired myelopoiesis	J:149957
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (involves: 129S6/SvEvTac * C57BL/6)	abnormal chemokine level	J:88065
	abnormal cytokine secretion	J:88065
	abnormal leukocyte morphology	J:88065
	abnormal response to infection	J:126519
	decreased interferon-gamma secretion	J:88065
	increased eosinophil cell number	J:88065
	increased IgE level	J:88065
	increased interferon-gamma secretion	J:88065
	increased interleukin-4 secretion	J:88065
	increased interleukin-5 secretion	J:88065
	increased interleukin-13 secretion	J:88065
	increased lymphocyte cell number	J:88065
	increased macrophage cell number	J:88065
	increased monocyte cell number	J:88065
	increased T cell proliferation	J:88065
	increased T-helper 2 cell number	J:88065
	lung inflammation	J:88065
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (FVB.129S6(Cg)-Mmp9^tm1Tvu/J)	decreased susceptibility to Flaviviridae infection	J:153406
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (FVB.129S6(Cg)-Mmp9^tm1Tvu/J)	decreased susceptibility to Flaviviridae infection induced morbidity/mortality	J:153406
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu (C3N.129S6-Mmp9^tm1Tvu)	decreased susceptibility to bacterial infection	J:150311
	decreased susceptibility to induced arthritis	J:150311
	joint inflammation	J:150311
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu \Tg(SOD1G93A)1Gur/0 (involves: 129S6/SvEvTac C57BL/6 * CD-1 * SJL)	decreased tumor necrosis factor secretion	J:141587
\Mmp9^tm1Tvu/\Mmp9^tm1Tvu \Timp1^tm1Pds/\Timp1^tm1Pds (involves: 129S4/SvJae * 129S6/SvEvTac)	immune system phenotype	J:94836
\Mmp10^tm1Jkmg/\Mmp10^tm1Jkmg (B6.129X1-Mmp10^tm1Jkmg)	increased susceptibility to bacterial infection	J:153651
\Mmp10^tm1Jkmg/\Mmp10^tm1Jkmg (B6.129X1-Mmp10^tm1Jkmg)	lung inflammation	J:153651
\Mmp11^{tm1b(EUCOMM)Hmgu}/\Mmp11^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mmp11^{tm1b(EUCOMM)Hmgu}/Ics)	increased monocyte cell number	J:211773
\Mmp12^tm1Sds/\Mmp12^tm1Sds (involves: 129X1/SvJ)	abnormal macrophage physiology	J:32902
\Mmp12^tm1Sds/\Mmp12^tm1Sds \Timp1^tm1Pds/\Timp1^tm1Pds (either: (involves: 129S4/SvJae) or (involves: C57BL/6))	decreased susceptibility to bacterial infection	J:94836
\Mmp13^{em1(IMPC)Ccpcz}/\Mmp13^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mmp13^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Mmp14^tm1Hbh/\Mmp14^tm1Hbh (involves: 129P2/OlaHsd * Black Swiss)	abnormal osteoclast physiology	J:57969, J:86538
	autoimmune arthritis	J:57969
\Mmp14^tm1Ktry/\Mmp14^tm1Ktry (involves: 129X1/SvJ)	abnormal dendritic cell physiology	J:138782
\Mmp15^{tm1b(KOMP)Wtsi}/\Mmp15^{tm1b(KOMP)Wtsi} (C57BL/6N-Mmp15^{tm1b(KOMP)Wtsi}/Bay)	absent lymph nodes	J:211773
	athymia	J:211773
	enlarged spleen	J:211773
\Mmp19^tm1Rase/\Mmp19^tm1Rase (B6.129P2-Mmp19^tm1Rase)	abnormal cytokine level	J:137128
	abnormal T cell activation	J:137128
	abnormal T cell differentiation	J:137128
	decreased CD4-positive, alpha-beta T cell number	J:137128
	decreased CD8-positive, alpha-beta T cell number	J:137128
	decreased inflammatory response	J:137128
	decreased susceptibility to type IV hypersensitivity reaction	J:137128
	decreased T cell proliferation	J:137128
	increased double-positive T cell number	J:137128
\Mmp20^{em1(IMPC)Ccpcz}/\Mmp20^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mmp20^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
\Mmp24^tm1Otin/\Mmp24^tm1Otin (involves: 129P2/OlaHsd * C57BL/6J)	abnormal mast cell degranulation	J:153230
	increased mast cell degranulation	J:153230
\Mmp25^em1(IMPC)J/\Mmp25^em1(IMPC)J (C57BL/6NJ-Mmp25^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Mmp25^{Gt(IST14198E10)Tigm}/\Mmp25^{Gt(IST14198E10)Tigm} (involves: C57BL/6N)	abnormal circulating cytokine level	J:347009
	abnormal macrophage activation involved in immune response	J:347009
	abnormal neutrophil physiology	J:347009
	decreased circulating interleukin-1 alpha level	J:347009
	decreased susceptibility to endotoxin shock	J:347009
	increased IgG level	J:347009
\Mmp28^tm1Mani/\Mmp28^tm1Mani (B6.129X1-Mmp28^tm1Mani)	abnormal chemokine secretion	J:145912
	abnormal cytokine secretion	J:145912
	abnormal macrophage chemotaxis	J:145912
	decreased susceptibility to bacterial infection	J:145912
	impaired neutrophil recruitment	J:145912
	increased interleukin-6 secretion	J:145912
	increased tumor necrosis factor secretion	J:145912
\Mmrn1^{tm1b(EUCOMM)Hmgu}/\Mmrn1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mmrn1^{tm1b(EUCOMM)Hmgu}/Cnrm)	increased large unstained cell number	J:211773
\Mmut^tm1Cpv/\Mmut^tm1Cpv (involves: 129S/SvEv * C57BL/6 * FVB/N)	tubulointerstitial nephritis	J:147313
\Mmut^tm1Cpv/\Mmut^tm1Cpv \Tg(Alb-Mut)#Cpv/0 (involves: C57BL/6)	tubulointerstitial nephritis	J:200689
\Mnx1^tm1Jhk/\Mnx1^tm1Jhk (involves: 129P2/OlaHsd)	immune system phenotype	J:57314
\Mnx1^tm4(cre)Tmj/\Mnx1⁺ \Tardbp^tm1.1Ckjs/\Tardbp^tm1.2Cjks (involves: 129S1/Sv * C57BL/6J)	increased microglial cell activation	J:190254
\Mocos^em2(IMPC)Ics/\Mocos^em2(IMPC)Ics (involves: C57BL/6N)	kidney inflammation	J:336718
	tubulointerstitial nephritis	J:336718
\Mog^tm1(cre)Gkl/\Mog^tm1(cre)Gkl \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (C57BL/6-Mog^tm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch)	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
\Mog^tm1Dpd/\Mog^tm1Dpd (B6.129S2-Mog^tm1Dpd)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:85155
\Mog^tm1Dpd/\Mog^tm1Dpd (B6.129S2-Mog^tm1Dpd)	immune system phenotype	J:85155
\Mog^tm1Dpd/\Mog^tm1Dpd \Rag2^tm1Cgn/\Rag2^tm1Cgn \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
\Mog^tm1Dpd/\Mog^tm1Dpd \Tg(H2-K^b-Tcra,-Tcrb)1640Kurs/0 (SJL.Cg-Mog^tm1Dpd Tg(H2-K^b-Tcra,-Tcrb)1640Kurs)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:149511
\Mog^tm1Dpd/\Mog^tm1Dpd \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas * C57BL/6)	CNS inflammation	J:151335
	increased susceptibility to experimental autoimmune encephalomyelitis	J:151335
\Mog^tm1Reid/\Mog^tm1Reid (B6.129S1/Sv-Mog^tm1Reid)	increased susceptibility to experimental autoimmune encephalomyelitis	J:86663
\Mog^tm1Reid/\Mog^tm1Reid (129/Sv-Mog^tm1Reid)	abnormal cytokine secretion	J:86663
	abnormal T-helper 1 physiology	J:86663
	increased interleukin-2 secretion	J:86663
	increased interleukin-6 secretion	J:86663
	increased susceptibility to experimental autoimmune encephalomyelitis	J:86663
	increased T cell proliferation	J:86663
\Mogs^{tm1(KOMP)Vlcg}/\Mogs⁺ (C57BL/6N-Mogs^{tm1(KOMP)Vlcg}/Bay)	absent lymph nodes	J:211773
	enlarged thymus	J:211773
\Mol1^BALB/cByJ/\Mol1^BALB/cByJ (involves: BALB/cByJ * C57BL/6ByJ)	decreased B cell proliferation	J:58921
\Mol2^DBA/2N/\Mol2^DBA/2N (involves: BALB/cAnFcr * DBA/2N)	increased inflammatory response	J:58921
\Morc2a^{em1(IMPC)Wtsi}/\Morc2a^{em1(IMPC)Wtsi} (C57BL/6N-Morc2a^{em1(IMPC)Wtsi}/WtsiOulu)	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	athymia	J:239583
	blood in lymph vessels	J:239583
	small thymus	J:239583
\Morc3^{tm1b(EUCOMM)Hmgu}/\Morc3⁺ (C57BL/6N-Morc3^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Morc4^em1(IMPC)Mbp/Y (C57BL/6N-Morc4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Morc4^em1(IMPC)Mbp/\Morc4^em1(IMPC)Mbp (C57BL/6N-Morc4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Morf4l1^tm1Kto/\Morf4l1^tm1Kto (involves: 129S7/SvEvBrd)	spleen vascular congestion	J:97640
\Morrbid^em1Flv/\Morrbid⁺ (C57BL/6N-Morrbid^em1Flv)	decreased eosinophil cell number	J:236609
	decreased Ly6C high monocyte number	J:236609
	decreased neutrophil cell number	J:236609
\Morrbid^em1Flv/\Morrbid^em1Flv (C57BL/6N-Morrbid^em1Flv)	abnormal eosinophil physiology	J:236609
	abnormal leukocyte physiology	J:236609
	abnormal myelopoiesis	J:236609
	abnormal neutrophil physiology	J:236609
	decreased eosinophil cell number	J:236609
	decreased Ly6C high monocyte number	J:236609
	decreased Ly6C low monocyte number	J:236609
	decreased neutrophil cell number	J:236609
	immune system phenotype	J:236609
	increased susceptibility to bacterial infection	J:236609
	increased susceptibility to bacterial infection induced morbidity/mortality	J:236609
\mpc253H/\mpc253H (involves: BALB/c * C3H/HeH * C57BL/6J)	colitis	J:234901
\Mpdk2^C57BL/6J/\Mpdk2^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
\Mpdk2^CAST/Ei/\Mpdk2^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
\Mpdk7^C57BL/6J/\Mpdk7^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
\Mpdk7^CAST/Ei/\Mpdk7^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
\Mpdk8^C57BL/6J/\Mpdk8^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
\Mpdk8^CAST/Ei/\Mpdk8^CAST/Ei (involves: C57BL/6J * CAST/Ei)	bile duct inflammation	J:99468
\Mpeg1^tm1Pod/\Mpeg1⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
\Mpeg1^tm1Pod/\Mpeg1⁺ (129X1/SvJ-Mpeg1^tm1Pod)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
\Mpeg1^tm1Pod/\Mpeg1^tm1Pod (involves: 129X1/SvJ * C57BL/6)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
\Mpeg1^tm1Pod/\Mpeg1^tm1Pod (129X1/SvJ-Mpeg1^tm1Pod)	abnormal susceptibility to infection induced morbidity/mortality	J:269474
\Mpg^tm1Lds/\Mpg^tm1Lds (involves: 129P2/OlaHsd * C57BL/6)	autoimmune response	J:118148
\Mpg^tm1Lds/\Mpg^tm1Lds (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:118148
\Mpg^tm1Lds/\Mpg^tm1Lds (involves: 129P2/OlaHsd)	immune system phenotype	J:47993
\Mpg^tm1Rhe/\Mpg^tm1Rhe (involves: 129P2/OlaHsd * C57BL/6J)	increased CD4-positive, alpha-beta T cell number	J:70603
\Mpig6b^{tm1.1(KOMP)Vlcg}/\Mpig6b^{tm1.1(KOMP)Vlcg} (C57BL/6N-Mpig6b^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Mpig6b^tm1.1Arte/\Mpig6b^tm1.1Arte (involves: C57BL/6NTac)	abnormal spleen red pulp morphology	J:201266
	enlarged spleen	J:201266
	spleen fibrosis	J:201266
\Mpl^{em1(IMPC)Ccpcz}/\Mpl⁺ (C57BL/6NCrl-Mpl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Mpl^{em1(IMPC)Ccpcz}/\Mpl^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mpl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Mpl^hlb219/\Mpl^hlb219 (C57BL/6J-Mpl^hlb219/J)	abnormal circulating cytokine level	J:146577
	decreased leukocyte cell number	J:146577
	enlarged spleen	J:146577
\Mpl^tm1Mwm/\Mpl^tm1Mwm (B6;129S2)	immune system phenotype	J:83264
\Mpl^tm1Wsa/\Mpl^tm1Wsa (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:32131
\Mpl^tm1Wsa/\Mpl^tm1Wsa (involves: 129S1/Sv)	abnormal circulating chemokine level	J:162629
\Mpl^tm1Wsa/\Mpl^tm1Wsa \Myb^Plt3/\Myb⁺ (involves: 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:89601
\Mpl^tm1Wsa/\Mpl^tm1Wsa \Myb^Plt3/\Myb^Plt3 (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:89601
	abnormal spleen morphology	J:89601
	abnormal thrombopoiesis	J:89601
	decreased spleen B cell follicle size	J:89601
	increased spleen red pulp amount	J:89601
\Mpl^tm1Wsa/\Mpl^tm1Wsa \Myb^Plt4/\Myb⁺ (involves: 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:89601
\Mpl^tm1Wsa/\Mpl^tm1Wsa \Myb^Plt4/\Myb^Plt4 (involves: 129S1/Sv * C57BL/6)	abnormal spleen morphology	J:89601
	abnormal thrombopoiesis	J:89601
	decreased leukocyte cell number	J:89601
	decreased spleen B cell follicle size	J:89601
	increased spleen red pulp amount	J:89601
\Mpl^tm1Wsa/\Mpl^tm1Wsa \Suz12^{Gt(Betageo)1Khe}/\Suz12⁺ (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:136262
	increased leukocyte cell number	J:136262
	increased lymphocyte cell number	J:136262
\Mpl^tm1Wsa/\Mpl^tm1Wsa \Suz12^Plt8/\Suz12⁺ (B6.Cg-Mpl^tm1Wsa Suz12^Plt8)	abnormal thrombopoiesis	J:136262
	increased leukocyte cell number	J:136262
	increased lymphocyte cell number	J:136262
\Mpl^tm2.1Wsa/\Mpl^tm2.1Wsa \Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	enlarged spleen	J:208120
\Mpnd^em1(IMPC)J/\Mpnd^em1(IMPC)J (C57BL/6NJ-Mpnd^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Mpo^tm1Lus/\Mpo^tm1Lus (involves: 129X1/SvJ * C57BL/6J)	abnormal neutrophil physiology	J:67586
	decreased inflammatory response	J:102688
	increased monocyte cell number	J:67586
	increased susceptibility to experimental autoimmune encephalomyelitis	J:102965
	increased susceptibility to fungal infection	J:67586
	sepsis	J:126649
\Mpo^tm1Lus/\Mpo^tm1Lus (B6.129X1-Mpo^tm1Lus)	abnormal neutrophil physiology	J:112488
\Mpo^tm1Mae/\Mpo^tm1Mae (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:53993
\Mpo^tm1Mae/\Mpo^tm1Mae (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to fungal infection	J:53993
\Mpp1^{em1(IMPC)Ccpcz}/\Mpp1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mpp1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased T-helper cell number	J:211773
\Mpp1^tm1Ahc/\Mpp1^tm1Ahc (B6.129-Mpp1^tm1Ahc)	abnormal neutrophil physiology	J:154749
\Mpp1^tm1Ahc/\Mpp1^tm1Ahc (B6.129-Mpp1^tm1Ahc)	impaired neutrophil chemotaxis	J:154749
\Mpped2^em1(IMPC)J/\Mpped2^em1(IMPC)J (C57BL/6NJ-Mpped2^em1(IMPC)J/J)	increased leukocyte cell number	J:211773
\Mptx2^em1Yoxi/\Mptx2^em1Yoxi (C57BL/6J-Mptx2^em1Yoxi)	increased susceptibility to bacterial infection	J:326562
\Mpv17l2^{tm1.1(KOMP)Mbp}/\Mpv17l2^{tm1.1(KOMP)Mbp} (C57BL/6N-Mpv17l2^{tm1.1(KOMP)Mbp}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Mpz^tm1Msch/\Mpz⁺ (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:82432
	abnormal macrophage chemotaxis	J:67581
	abnormal T-helper 1 physiology	J:82432
	increased monocyte cell number	J:82432
\Mpz^tm1Msch/\Mpz⁺ (involves: 129S7/SvEvBrd)	increased macrophage cell number	J:133028
\Mpz^tm1Msch/\Mpz⁺ (B6.129S7-Mpz^tm1Msch)	autoimmune response	J:59319
\Mpz^tm1Msch/\Mpz⁺ \Rag1^tm1Mom/\Rag1^tm1Mom (B6.129S7-Mpz^tm1Msch Rag1^tm1Mom)	absent CD4-positive, alpha-beta T cells	J:59319
	absent CD8-positive, alpha-beta T cells	J:59319
\Mpz^tm1Msch/\Mpz⁺ \Tcra^tm1Mjo/\Tcra^tm1Mjo (involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6)	decreased T cell number	J:59319
\Mpzl2^tm1Lex/\Mpzl2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:171883
	increased CD8-positive, alpha-beta T cell number	J:171883
\Mpzl3^rc/\Mpzl3^rc (C57BL/6J-Mpzl3^rc/J)	abnormal spleen morphology	J:93038
	dermatitis	J:93038
	liver inflammation	J:93038
\Mpzl3^tm1(KOMP)Mbp/\Mpzl3^tm1(KOMP)Mbp (C57BL/6-Tyr^c-Brd Mpzl3^tm1(KOMP)Mbp)	seborrheic dermatitis	J:210832
	skin inflammation	J:210832
\Mr1^tm1Gfn/\Mr1^tm1Gfn (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal B cell physiology	J:113083
	abnormal T cell number	J:113083
\Mr1^tm1Gfn/\Mr1^tm1Gfn (B6.129P2-Mr1^tm1Gfn)	increased susceptibility to experimental autoimmune encephalomyelitis	J:112657
\Mr1^tm1Gfn/\Mr1^tm1Gfn (involves: 129P2/OlaHsd)	abnormal susceptibility to bacterial infection	J:276912
\Mras^{Gt(OST108223)Lex}/\Mras^{Gt(OST108223)Lex} (B6;129S5-Mras^{Gt(OST108223)Lex}/Ieg)	decreased B cell number	J:82809
\Mrc1^tm1Mnz/\Mrc1^tm1Mnz (involves: 129P2/OlaHsd)	abnormal macrophage physiology	J:124290
\Mrc1^tm1Mnz/\Mrc1^tm1Mnz (B6.129P2-Mrc1^tm1Mnz)	decreased susceptibility to parasitic infection	J:194065
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:194065
	decreased T cell number	J:194065
	increased granulocyte number	J:194065
\Mrc1^tm1Mnz/\Mrc1^tm1Mnz \Mrc2^tm1Cmi/\Mrc2^tm1Cmi (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:124290
\Mre11a^tm1.1Rchd/\Mre11a^tm1.1Rchd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:184053
\Mreg^{tm1b(EUCOMM)Hmgu}/\Mreg^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Mreg^{tm1b(EUCOMM)Hmgu}/Kmpc)	abnormal lymph node morphology	J:211773
\Mrfap1^tm1Kto/\Mrfap1^tm1Kto (involves: 129S7/SvEvBrd * C57BL/6J)	immune system phenotype	J:92967
\Mrgprb2^em1(IMPC)Tcp/\Mrgprb2^em1(IMPC)Tcp (C57BL/6NCrl-Mrgprb2^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
\Mrgprb2^em1Xzd/\Mrgprb2^em1Xzd (C57BL/6-Mrgprb2^em1Xzd)	decreased inflammatory response	J:219209
	decreased mast cell degranulation	J:219209
	immune system phenotype	J:219209
\Mri1^em1(IMPC)Bay/\Mri1^em1(IMPC)Bay (C57BL/6N-Mri1^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
\Mroh8^{em1(IMPC)Ccpcz}/\Mroh8^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Mroh8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Mrpl12^em1(IMPC)Tcp/\Mrpl12⁺ (C57BL/6NCrl-Mrpl12^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Mrps22^{tm1.1(KOMP)Vlcg}/\Mrps22⁺ (B6N(Cg)-Mrps22^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
\Mrs2^em1Muma/\Mrs2^em1Muma (B6.Cg-Mrs2^em1Muma)	decreased susceptibility to endotoxin shock	J:298361
\Ms4a1^tm1Msn/\Ms4a1^tm1Msn (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:48688
\Ms4a1^tm1Tft/\Ms4a1^tm1Tft (involves: 129 * C57BL/6)	abnormal B cell calcium ion homeostasis	J:88933
	abnormal B cell number	J:88933
	abnormal B cell physiology	J:88933
	decreased B-1 B cell number	J:88933
	immune system phenotype	J:88933
	increased transitional stage B cell number	J:88933
\Ms4a2^tm1Chr/\Ms4a2^tm1Chr (involves: 129S1/Sv * 129X1/SvJ)	abnormal mast cell physiology	J:53106
	decreased susceptibility to type I hypersensitivity reaction	J:53106
\Ms4a2^tm1Knt/\Ms4a2^tm1Knt (involves: 129 * BALB/c)	abnormal cytokine secretion	J:47138
	abnormal mast cell physiology	J:47138
	decreased susceptibility to type I hypersensitivity reaction	J:47138
\Ms4a2^tm1Knt/\Ms4a2^tm1Knt \Tg(SV40/HTLV-FCER1A)1Bhk/0 (involves: 129 * BALB/c)	abnormal cytokine secretion	J:47138
	abnormal mast cell physiology	J:47138
	decreased susceptibility to type I hypersensitivity reaction	J:47138
\Ms4a4a^em1Wwz/\Ms4a4a^em1Wwz (C57BL/6NCrl-Ms4a4a^em1Wwz)	abnormal macrophage physiology	J:296429
	decreased eosinophil cell number	J:296429
	decreased interleukin-4 secretion	J:296429
	decreased interleukin-13 secretion	J:296429
	impaired eosinophil recruitment	J:296429
\Ms4a6d^em1Cya/\Ms4a6d^em1Cya (involves: C57BL/6)	decreased susceptibility to endotoxin shock	J:342776
\Ms4a6d^em1Ywch/\Ms4a6d^em1Ywch (C57BL/6-Ms4a6d^em1Ywch)	decreased susceptibility to endotoxin shock	J:342776
\Ms4a6d^em2Ywch/\Ms4a6d^em2Ywch (C57BL/6-Ms4a6d^em2Ywch)	decreased susceptibility to endotoxin shock	J:342776
\Ms4a7^em1.1Jddl/\Ms4a7^em1.1Jddl (B6.Cg-Ms4a7^em1.1Jddl)	abnormal macrophage physiology	J:347975
	decreased circulating tumor necrosis factor level	J:347975
	decreased cytokine level	J:347975
	decreased interleukin-1 beta secretion	J:347975
	decreased macrophage cell number	J:347975
\Ms4a7^em1Jddl/\Ms4a7^em1Jddl \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.Cg-Lyz2^tm1(cre)Ifo Ms4a7^em1Jddl)	decreased circulating tumor necrosis factor level	J:347975
	decreased cytokine level	J:347975
\Ms4a8a^em1(IMPC)Tcp/\Ms4a8a^em1(IMPC)Tcp (C57BL/6NCrl-Ms4a8a^em1(IMPC)Tcp/Cmmr)	increased monocyte cell number	J:211773
\Ms4a12^em1(IMPC)Mbp/\Ms4a12^em1(IMPC)Mbp (C57BL/6N-Ms4a12^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Msantd3^em1(IMPC)J/\Msantd3^em1(IMPC)J (C57BL/6NJ-Msantd3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Msh2^tm1Htr/\Msh2^tm1Htr (either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))	increased T cell derived lymphoma incidence	J:27469
\Msh2^tm1Htr/\Msh2^tm1Htr (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:80893
	abnormal inflammatory response	J:80893
	abnormal somatic hypermutation frequency	J:155454
	decreased IgG1 level	J:80893
	decreased IgG3 level	J:80893
	immune system phenotype	J:47993
	increased T cell derived lymphoma incidence	J:45433
\Msh2^tm1Htr/\Msh2^tm1Htr (involves: 129P2/OlaHsd * FVB)	increased T cell derived lymphoma incidence	J:45433
\Msh2^tm1Htr/\Msh2^tm1Htr \Pcna^tm1Jcbs/\Pcna^tm1Jcbs (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454
\Msh2^tm1Mak/\Msh2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:28397
\Msh2^tm1Mak/\Msh2^tm1Mak (C57BL/6NTac-Msh2^tm1Mak)	abnormal class switch recombination	J:326431
\Msh2^tm1Mak/\Msh2^tm1Mak (C57BL/6NTac-Msh2^tm1Mak)	abnormal somatic hypermutation frequency	J:326431
\Msh2^tm1Rak/\Msh2^tm1Rak (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:56764
\Msh2^tm1Rak/\Msh2^tm1Rak (involves: 129P2/OlaHsd)	decreased mature B cell number	J:56764
\Msh2^tm1Wed/\Msh2^tm1Wed (involves: C57BL/6)	abnormal class switch recombination	J:86278
\Msh2^tm1Wed/\Msh2^tm1Wed (involves: C57BL/6)	decreased IgG level	J:86278
\Msh2^tm1Whl/\Msh2^tm1Whl (involves: 129P2/OlaHsd * C57BL/6J)	increased lymphoblastic lymphoma incidence	J:79016
\Msh2^tm1Whl/\Msh2^tm1Whl \Rb1^tm1Brd/\Rb1⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)	increased lymphoblastic lymphoma incidence	J:79016
\Msh5^{tm1b(EUCOMM)Wtsi}/\Msh5^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Msh5^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
\Msh6^m1Btlr/\Msh6^m1Btlr (C57BL/6J-Msh6^m1Btlr)	decreased IgE level	J:255208
\Msi2^em1(IMPC)Mbp/\Msi2^em1(IMPC)Mbp (C57BL/6N-Msi2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	small spleen	J:211773
\Msi2^{Gt(E035H03)Wrst}/\Msi2^{Gt(E035H03)Wrst} (B6.129P2-Msi2^{Gt(E035H03)Wrst})	abnormal myeloid leukocyte morphology	J:174870
	decreased B cell number	J:174870
	decreased CD4-positive, alpha-beta T cell number	J:174870
	decreased CD8-positive, alpha-beta T cell number	J:174870
	decreased DN2 thymocyte number	J:174870
	decreased DN3 thymocyte number	J:174870
	decreased double-negative T cell number	J:174870
	decreased double-positive T cell number	J:174870
	decreased granulocyte number	J:174870
	decreased immature B cell number	J:174870
	decreased leukocyte cell number	J:174870
	decreased macrophage cell number	J:174870
	decreased mature B cell number	J:174870
	decreased pre-B cell number	J:174870
	small spleen	J:174870
	small thymus	J:174870
	spleen hypoplasia	J:174870
	thymus hypoplasia	J:174870
\Msi2^tm1.1Cjl/\Msi2^tm1.1Cjl \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	decreased spleen weight	J:208349
	immune system phenotype	J:208349
	spleen hypoplasia	J:208349
\Mslnl^{tm1b(EUCOMM)Wtsi}/\Mslnl^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Mslnl^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased monocyte cell number	J:211773
\Msmb^tm1Xuan/\Msmb^tm1Xuan (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))	enlarged lymph nodes	J:96884
\Msmp^em1Jzx/\Msmp^em1Jzx (C57BL/6-Msmp^em1Jzx)	abnormal macrophage differentiation	J:311042
	decreased circulating interleukin-6 level	J:311042
	decreased circulating tumor necrosis factor level	J:311042
	liver inflammation	J:311042
\Msn^{tm1b(EUCOMM)Hmgu}/\Msn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Msn^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
\Msn^tm1Sts/Y (involves: 129S4/SvJae * C57BL/6)	decreased B cell number	J:189837
	decreased CD4-positive, alpha-beta T cell number	J:189837
	decreased eosinophil cell number	J:189837
	decreased lymphocyte cell number	J:189837
	decreased neutrophil cell number	J:189837
	impaired leukocyte migration	J:189837
\Msr1^tm1Csk/\Msr1^tm1Csk (involves: 129X1/SvJ * ICR)	increased interleukin-12 secretion	J:110433
	increased susceptibility to bacterial infection induced morbidity/mortality	J:39079
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:39079
\Msr1^tm1Csk/\Msr1^tm1Csk (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal macrophage physiology	J:91911
\Msr1^tm1Csk/\Msr1^tm1Csk (B6.129X1-Msr1^tm1Csk)	decreased interferon-beta secretion	J:251008
\Msr1^tm1Csk/\Msr1^tm1Csk \Scarf1^tm1Ishi/\Scarf1^tm1Ishi (involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6J)	abnormal macrophage physiology	J:91911
\Mst1^tm1Jab/\Mst1^tm1Jab (involves: 129P2/OlaHsd * Black Swiss)	abnormal macrophage physiology	J:46185
	immune system phenotype	J:46185
	increased susceptibility to induced colitis	J:46185
\Mst1r^Fv2-s/\Mst1r^Fv2-s (B6.DDD-Mst1r^Fv2-s)	enlarged spleen	J:5120
\Mst1r^Fv2-s/\Mst1r^Fv2-s (B6.DDD-Mst1r^Fv2-s)	increased susceptibility to Retroviridae infection	J:5120
\Mst1r^Fv2-s/\Mst1r^Fv2-s (either: A/Crgl or C57BL/Crgl)	decreased susceptibility to Retroviridae infection	J:167666
\Mst1r^Fv2-s/\Mst1r^Fv2-s (either: BALB/cCrgl or DBA/2Crgl or Swiss)	enlarged spleen	J:167666
	increased susceptibility to Retroviridae infection	J:167666
\Mst1r^Fv2-s/\Mst1r^Fv2-s (C3H/Crgl)	increased susceptibility to Retroviridae infection	J:167666
\Mst1r^tm1.1Sew/\Mst1r^tm1.1Sew (involves: 129/Ola * CD-1 * NIH Black Swiss)	abnormal macrophage physiology	J:75503
	abnormal type IV hypersensitivity reaction	J:75503
	increased acute inflammation	J:75503
	increased susceptibility to endotoxin shock	J:75503
\Mst1r^tm1Ber/\Mst1r^tm1Ber (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal macrophage physiology	J:76451
	abnormal type IV hypersensitivity reaction	J:76451
	immune system phenotype	J:76451
	increased inflammatory response	J:76451
	increased susceptibility to bacterial infection	J:76451
\Mst1r^tm1Sjd/\Mst1r⁺ (either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1) or (involves: 129 * NIH Black Swiss))	abnormal macrophage physiology	J:54903
	increased susceptibility to bacterial infection	J:54903
\Mst1r^{tm2(Mst1r)Sew}/\Mst1r^{tm2(Mst1r)Sew} (involves: 129P2/OlaHsd * Black Swiss * FVB/N)	decreased spleen weight	J:215969
	increased susceptibility to Retroviridae infection	J:215969
\Mst1r^{tm2(Mst1r)Sew}/\Mst1r^{tm2(Mst1r)Sew} (FVB.129P2(Cg)-Mst1r^{tm2(Mst1r*)Sew})	increased circulating interferon-gamma level	J:215969
	increased interferon-gamma secretion	J:215969
\Mstn^{em1(IMPC)Hmgu}/\Mstn^{em1(IMPC)Hmgu} (C57BL/6NCrl-Mstn^{em1(IMPC)Hmgu}/Ieg)	decreased spleen weight	J:211773
	enlarged spleen	J:211773
\Mstn^lean/\Mstn^lean (C57BL/6J-Mstn^lean)	abnormal circulating tumor necrosis factor level	J:146513
\Mstn^lean/\Mstn^lean (C57BL/6J-Mstn^lean)	decreased circulating tumor necrosis factor level	J:146513
\Msto1^em1(IMPC)Tcp/\Msto1⁺ (C57BL/6N-Msto1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Msx1^tm1Rilm/\Msx1⁺ \Pax9^tm1Rbal/\Pax9^tm1Rbal (involves: 129 * CD-1)	ectopic thymus	J:311535
	thymus hypoplasia	J:311535
\Msx2^tm1Rilm/\Msx2^tm1Rilm (either: (involves: 129S4/SvJae) or (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6J))	decreased osteoclast cell number	J:61509
\Mt1^tm1Bri/\Mt1^tm1Bri \Mt2^tm1Bri/\Mt2^tm1Bri (involves: 129S7/SvEvBrd)	abnormal microglial cell morphology	J:103102, J:53929
	abnormal microglial cell physiology	J:53929
	increased interleukin-1 beta secretion	J:103102
	increased interleukin-6 secretion	J:103102
	increased macrophage cell number	J:53929
	increased susceptibility to experimental autoimmune encephalomyelitis	J:103102
	increased tumor necrosis factor secretion	J:103102
\Mt1^tm1Bri/\Mt1^tm1Bri \Mt2^tm1Bri/\Mt2^tm1Bri (129S7/SvEvBrd-Mt1^tm1Bri Mt2^tm1Bri/J)	abnormal humoral immune response	J:110643
	abnormal lymphocyte physiology	J:110643
	abnormal microglial cell morphology	J:89429
	decreased B cell number	J:110643
	decreased T cell number	J:110643
	enlarged spleen	J:110643
	increased CD4-positive, alpha-beta T cell number	J:110643
	increased CD8-positive, alpha-beta T cell number	J:110643
	increased IgG level	J:110643
	increased IgM level	J:110643
	increased lymphocyte cell number	J:110643
	increased neutrophil cell number	J:120196
	increased plasma cell number	J:110643
	increased spleen weight	J:110643
	increased thymocyte apoptosis	J:57169
	kidney inflammation	J:126620
	lung inflammation	J:120196
	spleen hyperplasia	J:110643
\mt-Co1^m1Jiha (involves: C57BL/6J * M. m. domesticus)	heart inflammation	J:132659
\mt-Nd2^m1 (ALR/Lt)	decreased susceptibility to autoimmune diabetes	J:117602, J:97969
\Mta1^{em1(IMPC)Ccpcz}/\Mta1⁺ (C57BL/6NCrl-Mta1^{em1(IMPC)Ccpcz}/Ccpcz)	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Mta2^tm1.1Yzha/\Mta2^tm1.1Yzha (involves: 129S4/SvJae * C57BL/6 * FVB/N)	dermatitis	J:137101
	glomerulonephritis	J:137101
	increased anti-double stranded DNA antibody level	J:137101
	increased autoantibody level	J:137101
	increased circulating interferon-gamma level	J:137101
	increased circulating interleukin-2 level	J:137101
	increased circulating interleukin-4 level	J:137101
	increased susceptibility to systemic lupus erythematosus	J:137101
	increased T cell proliferation	J:137101
	liver inflammation	J:137101
	panniculitis	J:137101
	skin inflammation	J:137101
\Mta2^tm1Yzha/\Mta2^tm1Yzha \Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	immune system phenotype	J:137101
	increased T cell proliferation	J:137101
\Mtap^em1(IMPC)Mbp/\Mtap⁺ (C57BL/6N-Mtap^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Mtap^{Gt(RRK081)Byg}/\Mtap⁺ (129P2/OlaHsd-Mtap^{Gt(RRK081)Byg})	arteritis	J:123675
\Mtarc1^em1(IMPC)H/\Mtarc1^em1(IMPC)H (C57BL/6NTac-Mtarc1^em1(IMPC)H/H)	increased spleen weight	J:211773
\Mtbcq2^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	increased spleen weight	J:122125
\Mtch2^{tm1b(EUCOMM)Hmgu}/\Mtch2⁺ (C57BL/6N-Mtch2^{tm1b(EUCOMM)Hmgu}/Cnrm)	increased monocyte cell number	J:211773
\Mtdh^tm1.2Dsar/\Mtdh^tm1.2Dsar (either: B6.129(FVB)-Mtdh^tm1.2Dsar or (129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N))	decreased interleukin-1 beta secretion	J:216688
	decreased interleukin-6 secretion	J:216688
	decreased macrophage proliferation	J:216688
\Mtf1^Thyls-BALB/c/\Mtf1^Thyls-BALB/c (involves: BALB/c * MSM)	increased T cell derived lymphoma incidence	J:71358
\Mtf1^Thyls-BALB/c/\Mtf1^Thyls-MSM (involves: BALB/c * MSM)	increased T cell derived lymphoma incidence	J:85264, J:71358
\Mtf1^tm1Wsc/\Mtf1^tm1Wsc \Tg(Mx1-cre)1Cgn/0 \Tg(UBC-Mtf1)1Wsc/0 (involves: 129/Sv * C57BL/6 * CBA)	decreased leukocyte cell number	J:91119
	decreased lymphocyte cell number	J:91119
\Mtfmt^em1Heb/\Mtfmt⁺ (C57BL/6-Mtfmt^em1Heb)	decreased circulating interleukin-1 beta level	J:334467
\Mtfmt^em1Heb/\Mtfmt⁺ (C57BL/6-Mtfmt^em1Heb)	decreased inflammatory response	J:334467
\Mtgq4^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	increased spleen weight	J:122125
\Mthfd1^tm1.1Rzn/\Mthfd1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	decreased leukocyte cell number	J:199578
	decreased neutrophil cell number	J:199578
\Mtmr4^{tm1a(EUCOMM)Wtsi}/\Mtmr4⁺ (Not Specified)	decreased IgE level	J:165965
\Mtmr11^em1(IMPC)Tcp/\Mtmr11^em1(IMPC)Tcp (C57BL/6NCrl-Mtmr11^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Mtor^chino/\Mtor^chino (involves: C57BL/6JAnu)	decreased CD4-positive, alpha-beta T cell number	J:207898
	decreased splenocyte number	J:207898
	immune system phenotype	J:207898
\Mtor^chino/\Mtor^chino \Rasgrp1^m1Anu/\Rasgrp1^m1Anu (involves: C57BL/6JAnu * C57BL/6JSfdAnu * CBA/J)	immune system phenotype	J:207898
\Mtor^tm1.1Lgm/\Mtor^tm1.1Lgm (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:168600
\Mtor^tm1.2Koz/\Mtor^tm1.2Koz \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:150108
	abnormal T cell subpopulation ratio	J:150108
	abnormal thymus cell ratio	J:150108
	decreased interferon-gamma secretion	J:150108
	decreased interleukin-2 secretion	J:150108
	decreased interleukin-17 secretion	J:150108
	decreased T cell proliferation	J:150108
	decreased tumor necrosis factor secretion	J:150108
	increased regulatory T cell number	J:150108
\Mtor^tm1Lgm/\Mtor^tm1Lgm (involves: 129S1/Sv * C57BL/6)	abnormal B cell physiology	J:168600
	abnormal humoral immune response	J:168600
	abnormal T cell morphology	J:168600
	abnormal T cell physiology	J:168600
	decreased B cell number	J:168600
	decreased B cell proliferation	J:168600
	decreased double-positive T cell number	J:168600
	decreased follicular B cell number	J:168600
	decreased IgG level	J:168600
	decreased IgM level	J:168600
	decreased marginal zone B cell number	J:168600
	decreased monocyte cell number	J:168600
	decreased neutrophil cell number	J:168600
	decreased plasma cell number	J:168600
	decreased splenocyte apoptosis	J:168600
	decreased splenocyte proliferation	J:168600
	decreased thymocyte number	J:168600
	decreased transitional stage T1 B cell number	J:168600
	impaired B cell migration	J:168600
	increased CD4-positive, alpha-beta T cell number	J:168600
	increased CD8-positive, alpha-beta T cell number	J:168600
	small spleen	J:168600
\Mtss1^{Gt(CSC156)Byg}/\Mtss1^{Gt(CSC156)Byg} (B6.129P2-Mtss1^{Gt(CSC156)Byg})	abnormal B cell differentiation	J:186118
	abnormal B cell number	J:186118
	abnormal B cell physiology	J:186118
	decreased immature B cell number	J:186118
	enlarged spleen	J:186118
	increased inflammatory response	J:186118
	increased leukocyte cell number	J:186118
	increased pre-B cell number	J:186118
\Mtus1^{Gt(RRA048)Byg}/\Mtus1^{Gt(RRA048)Byg} (involves: 129P2/OlaHsd * C57BL/6)	glomerulonephritis	J:212144
	increased leukocyte cell number	J:212144
	increased lymphocyte cell number	J:212144
	increased susceptibility to systemic lupus erythematosus	J:212144
	insulitis	J:212144
	lymphoid hyperplasia	J:212144
	salivary gland inflammation	J:212144
\Mtv7^BALB/c/\Mtv7^BALB/c (involves: B10.Q * BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:27701
\Mtv7^BALB/c/\Mtv7^DBA/2 (involves: B10.Q * BALB/c * DBA/2)	decreased susceptibility to induced arthritis	J:27701
\Mtv7^DBA/2/\Mtv7^DBA/2 (C.D2-Mtv7^DBA/2)	decreased susceptibility to induced arthritis	J:27701
\Mtv8^em1Tvg/\Mtv8^em1Tvg (C57BL/6J-Mtv8^em1Tvg)	immune system phenotype	J:346992
\Mtx2^em1(IMPC)J/\Mtx2⁺ (C57BL/6NJ-Mtx2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Muc2^eey/\Muc2^eey (C57BL/6-Muc2^eey)	ileum inflammation	J:194148
	increased interferon-gamma secretion	J:194148
	increased interleukin-1 beta secretion	J:194148
	increased leukocyte cell number	J:194148
	increased susceptibility to induced colitis	J:194148
	increased tumor necrosis factor secretion	J:194148
\Muc2^keny/\Muc2^keny (C57BL/6JAnu-Muc2^keny/AnuApb)	enlarged lymph nodes	J:104190
\Muc2^M1Btlr/\Muc2⁺ (C57BL/6J-Muc2^M1Btlr)	increased susceptibility to induced colitis	J:150326
\Muc2^M1Btlr/\Muc2^M1Btlr (C57BL/6J-Muc2^M1Btlr)	increased susceptibility to induced colitis	J:150326
\Muc2^m2Btlr/? (C57BL/6J-Muc2^m2Btlr)	increased susceptibility to induced colitis	J:159359
\Muc2^m3Btlr/\Muc2^m3Btlr (C57BL/6J-Muc2^m3Btlr)	increased susceptibility to induced colitis	J:254906
\Muc2^tm1Avel/\Muc2^tm1Avel (involves: 129P2/OlaHsd * C57BL/6)	colitis	J:216831
	large intestinal inflammation	J:216831
\Muc2^wnn/\Muc2⁺ (C57BL/6-Muc2^wnn)	increased susceptibility to induced colitis	J:194148
\Muc2^wnn/\Muc2^wnn (C57BL/6-Muc2^wnn)	colitis	J:194148
	ileum inflammation	J:194148
	increased interferon-gamma secretion	J:194148
	increased interleukin-1 beta secretion	J:194148
	increased interleukin-13 secretion	J:194148
	increased leukocyte cell number	J:194148
	increased lymphocyte cell number	J:194148
	increased susceptibility to induced colitis	J:194148
	increased tumor necrosis factor secretion	J:194148
\Muc4^PWK/PhJ/\Muc4^PWK/PhJ (PWK/PhJ)	abnormal susceptibility to viral infection	J:287566
\Muc4^tm1Skb/\Muc4^tm1Skb (involves: 129 * C57BL/6J)	decreased susceptibility to colitis induced morbidity/mortality	J:234205
\Muc4^tm1Skb/\Muc4^tm1Skb (involves: 129 * C57BL/6J)	decreased susceptibility to induced colitis	J:234205
\Muc4^tm1Unc/\Muc4^tm1Unc (B6NTac.129(FVB)-Muc4^tm1Unc/Rand)	increased susceptibility to Coronaviridae infection	J:287566
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:287566
	increased susceptibility to Togaviridae infection	J:287566
\Muc5ac^tm1.1Evns/\Muc5ac^tm1.1Evns (B6.129S1-Muc5ac^tm1.1Evns)	increased circulating interferon-gamma level	J:177306
	increased susceptibility to parasitic infection	J:177306
\Muc5b^tm1.2Evns/\Muc5b^tm1.2Evns (B6.129S1-Muc5b^tm1.2Evns)	abnormal professional antigen presenting cell physiology	J:207159
	decreased interleukin-23 secretion	J:207159
	impaired macrophage phagocytosis	J:207159
	increased macrophage apoptosis	J:207159
	increased susceptibility to bacterial infection	J:207159
	increased susceptibility to bacterial infection induced morbidity/mortality	J:207159
	increased susceptibility to otitis media	J:207159
	respiratory system inflammation	J:207159
	sepsis	J:207159
\Muc13^tm1.1Mamg/\Muc13^tm1.1Mamg (involves: 129 * C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:313870
	increased susceptibility to induced colitis	J:313870
	large intestinal inflammation	J:313870
	small intestinal inflammation	J:313870
\Muc19^sld/\Muc19^sld (NFS/N-Muc19^sld)	increased susceptibility to autoimmune disorder	J:216958, J:20364
\Mug1^tm1Vln/\Mug1^tm1Vln (B.129P2-Mug1^tm1Vln)	abnormal cytokine level	J:57485
\Mug1^tm1Vln/\Mug1^tm1Vln (B.129P2-Mug1^tm1Vln)	liver inflammation	J:57485
\Mug1^tm2Vln/\Mug1^tm2Vln \Pzp^tm1Vln/\Pzp^tm1Vln (B.129P2-Pzp^tm1Vln Mug1^tm2Vln)	abnormal cytokine level	J:57485
	abnormal uterine NK cell morphology	J:117841
	liver inflammation	J:57485
\Mus81^tm1Esse/\Mus81⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased inflammatory response	J:222498
\Mus81^tm1Esse/\Mus81^tm1Esse (involves: 129P2/OlaHsd * C57BL/6J)	increased interleukin-1 beta secretion	J:222498
	lung inflammation	J:222498
\Mus81^tm1Raz/\Mus81^tm1Raz (involves: 129P2/OlaHsd)	immune system phenotype	J:91570
\Mx1^r/\Mx1^r (B6.A2G-Mx1^r)	abnormal susceptibility to infection	J:120938
\Mx1^r/\Mx1^r (B6.A2G-Mx1^r)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
\Mx1^r/\Mx1^r (C.A2G-Mx1^r)	decreased susceptibility to Orthomyxoviridae infection	J:23752
\Mx1^r/\Mx1^r (C.A2G-Mx1^r)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
\Mx1^r/\Mx1^r (A2G)	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
\Mx1^s1/\Mx1^s1 (BALB/c)	increased susceptibility to Orthomyxoviridae infection	J:23752
\Mx1^s1/\Mx1^s1 (C57BL/6)	abnormal peritoneal macrophage morphology	J:23752
	abnormal susceptibility to infection	J:120938
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:23752
\Mx1^s1/\Mx1^s1 \Tg(Hmgcr-MX1)LStae/? (involves: C57BL/6 * SJL)	decreased susceptibility to Orthomyxoviridae infection	J:128067
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:128067
	decreased susceptibility to Riboviria infection	J:128067
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:128067
\Mx1^s2/\Mx1^s2 (CBA/J)	increased susceptibility to Orthomyxoviridae infection	J:23752
\Mxd1^tm1Rne/\Mxd1^tm1Rne (involves: 129S4/SvJaeSor * C57BL/6)	abnormal B cell physiology	J:45945
	abnormal myeloid leukocyte morphology	J:45945
	immune system phenotype	J:45945
	increased granulocyte number	J:45945
\Mxd4^em1(IMPC)J/\Mxd4^em1(IMPC)J (C57BL/6NJ-Mxd4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Mxi1^tm1Rdp/\Mxi1^tm1Rdp (involves: 129/Sv * C57BL/6J * SJL)	abnormal lymphocyte morphology	J:48236
	enlarged spleen	J:48236
	increased spleen white pulp amount	J:48236
	increased T cell proliferation	J:48236
\Mxra8^em1Diam/\Mxra8⁺ (C57BL/6J-Mxra8^em1Diam)	decreased susceptibility to Togaviridae infection	J:280585
\Mxra8^em1Diam/\Mxra8^em1Diam (C57BL/6J-Mxra8^em1Diam)	abnormal cytokine level	J:280585
	decreased inflammatory response	J:280585
	decreased susceptibility to Togaviridae infection	J:280585
\Mxra8^em2Diam/\Mxra8^em2Diam (C57BL/6J-Mxra8^em2Diam)	decreased susceptibility to Togaviridae infection	J:280585
\Myb^boo/\Myb^boo (involves: C57BL/6)	abnormal B cell differentiation	J:167270
	abnormal leukocyte morphology	J:167270
	abnormal spleen morphology	J:167270
	decreased neutrophil cell number	J:167270
	decreased spleen white pulp amount	J:167270
	enlarged spleen	J:167270
	increased spleen red pulp amount	J:167270
\Myb^M303V/\Myb^M303V (involves: 129S1/SvlmJ * C57BL/6)	arrested B cell differentiation	J:96507
	arrested T cell differentiation	J:96507
	decreased B cell number	J:96507
	decreased eosinophil cell number	J:96507
	decreased single-positive T cell number	J:96507
	decreased thymocyte number	J:96507
\Myb^tm1.1Cgn/\Myb⁺ (involves: 129P2/OlaHsd * C57BL/6)	arrested B cell differentiation	J:127234
	decreased B-1 B cell number	J:127234
	decreased mature B cell number	J:127234
	decreased pre-B cell number	J:127234
\Myb^tm1Cgn/\Myb^tm1.1Cgn \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:91122
	decreased double-positive T cell number	J:91122
	thymus hypoplasia	J:91122
\Myb^tm1Cgn/\Myb^tm1Cgn \Tg(Lck-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	arrested T cell differentiation	J:91122
	decreased CD4-positive, alpha-beta T cell number	J:91122
	decreased CD8-positive, alpha-beta T cell number	J:91122
	decreased double-negative T cell number	J:91122
	decreased double-positive T cell number	J:91122
	decreased gamma-delta T cell number	J:91122
	thymus hypoplasia	J:91122
\Myb^tm1Cgn/\Myb^tm1Cgn \Tg(Lck-cre)548Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:91122
	decreased double-positive T cell number	J:91122
	thymus hypoplasia	J:91122
\Myb^tm1Epr/\Myb^tm1Epr \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:93481
	decreased CD4-positive, alpha-beta T cell number	J:93481
	decreased double-positive T cell number	J:93481
	increased CD8-positive, alpha-beta T cell number	J:93481
	thymus hypoplasia	J:93481
\Myb^tm1Epr/\Myb^tm1Epr \Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal double-negative T cell morphology	J:93481
	abnormal T cell differentiation	J:93481
	decreased double-positive T cell number	J:93481
	thymus hypoplasia	J:93481
\Myb^tm1Jof/\Myb^tm1Jof (involves: 129/Sv * C57BL/6)	abnormal B cell differentiation	J:85344
	abnormal double-negative T cell morphology	J:85344
	abnormal T cell differentiation	J:85344
	decreased thymocyte number	J:85344
\Myb^tm1Jof/\Myb^tm1Ssp (involves: 129/Sv * C57BL/6)	abnormal T cell differentiation	J:85344
\Myb^tm1Jof/\Myb^tm1Ssp (involves: 129/Sv * C57BL/6)	decreased thymocyte number	J:85344
\Myb^tm2.2Epr/\Myb^tm2.2Epr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:160189
\Mybl1^tm1Epr/\Mybl1^tm1Epr (involves: 129 * C57BL/6)	abnormal humoral immune response	J:67604
	abnormal spleen B cell follicle morphology	J:67604
	abnormal spleen marginal zone morphology	J:67604
	decreased B cell number	J:67604
	decreased IgG1 level	J:67604
	decreased IgG2a level	J:67604
	decreased IgG3 level	J:67604
	decreased spleen germinal center number	J:67604
	increased spleen red pulp amount	J:67604
	small spleen	J:67604
	spleen hypoplasia	J:67604
\Mybl2^tm1.1Epr/\Mybl2^tm1.1Epr \Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)	abnormal myelopoiesis	J:206816
	decreased B cell number	J:206816
	decreased leukocyte cell number	J:206816
	decreased lymphocyte cell number	J:206816
	decreased neutrophil cell number	J:206816
	decreased splenocyte number	J:206816
	decreased T cell number	J:206816
\Mybl2^tm1.1Jof/\Mybl2⁺ \Tg(Zp3-cre)3Mrt/0 (involves: 129S2/SvPas * C57BL/6 * FVB/N)	abnormal myelopoiesis	J:196804
	decreased leukocyte cell number	J:196804
	decreased neutrophil cell number	J:196804
	enlarged spleen	J:196804
	increased granulocyte number	J:196804
	increased leukocyte cell number	J:196804
	increased monocyte cell number	J:196804
	myeloid hyperplasia	J:196804
\Mybphl^{tm1a(KOMP)Wtsi}/\Mybphl^{tm1a(KOMP)Wtsi} (C57BL/6N-Mybphl^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Mybphl^{tm1b(KOMP)Wtsi}/\Mybphl^{tm1b(KOMP)Wtsi} (C57BL/6N-Mybphl^{tm1b(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
\Myc^{tm1.1(Nmyc1)Fwa}/\Myc^{tm1.1(Nmyc1)Fwa} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:62573
\Myc^tm1.1Cksn/\Myc^tm1.1Cksn (B6.129-Myc^tm1.1Cksn)	immune system phenotype	J:170508
\Myc^tm1Atp/\Myc⁺ (involves: 129P2/OlaHsd * FVB/N)	decreased T cell proliferation	J:73369
	lymph node hypoplasia	J:73369
	lymphoid hypoplasia	J:73369
	small lymphoid organs	J:73369
	spleen hypoplasia	J:73369
\Myc^tm1Atp/\Myc⁺ (B6.129P2-Myc^tm1Atp)	abnormal NK cell physiology	J:132730
	decreased memory T cell number	J:132730
	decreased T cell proliferation	J:132730
	immune system phenotype	J:132730
\Myc^tm1Atp/\Myc^tm2.1Atp (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	decreased T cell proliferation	J:73369
	immune system phenotype	J:73369
	lymph node hypoplasia	J:73369
	spleen hypoplasia	J:73369
\Myc^tm1Atp/\Myc^tm2.1Atp \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL)	immune system phenotype	J:73369
\Myc^tm1Lbox/\Myc⁺ (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	enlarged lymph nodes	J:97900
	enlarged spleen	J:97900
	increased B cell number	J:97900
	increased spleen weight	J:97900
\Myc^tm1Lbox/\Myc^tm1Lbox (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	decreased T cell number	J:97900
	enlarged lymph nodes	J:97900
	enlarged spleen	J:97900
	increased B cell apoptosis	J:97900
	increased B cell number	J:97900
	increased B cell proliferation	J:97900
	increased spleen weight	J:97900
\Myc^tm2.1Atp/\Myc⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	decreased T cell proliferation	J:73369
\Myc^tm2.1Atp/\Myc^tm2.1Atp \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * FVB/N * SJL)	immune system phenotype	J:73369
\Myc^tm2Fwa/\Myc^tm2Fwa \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac)	decreased B cell proliferation	J:67222
\Myc^tm3(Tcrb)Fwa/\Myc⁺ (involves: 129)	abnormal T cell receptor beta chain V(D)J recombination	J:131995
\Mycl^tm1.1Kmm/\Mycl^tm1.1Kmm (B6.129S6(C)-Mycl^tm1.1Kmm)	abnormal dendritic cell physiology	J:206430
	decreased dendritic cell number	J:206430
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:206430
\Myct1^em1(IMPC)Mbp/\Myct1^em1(IMPC)Mbp (C57BL/6N-Myct1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Myct1^em1Choi/\Myct1^em1Choi (involves: C57BL/6)	abnormal macrophage cell number	J:303692
	decreased regulatory T cell number	J:303692
	increased CD8-positive, alpha-beta T cell number	J:303692
\Myd88^lkd/\Myd88^lkd (C57BL/6-Myd88^lkd)	abnormal adaptive immunity	J:110094
	abnormal cell-mediated immunity	J:110094
	abnormal innate immunity	J:110094
	abnormal macrophage physiology	J:110094
	immune system phenotype	J:110094
\Myd88^m3Btlr/\Myd88^m3Btlr (C57BL/6J-Myd88^m3Btlr)	immune system phenotype	J:156848
\Myd88^M4Btlr/\Myd88⁺ (C57BL/6J-Myd88^M4Btlr)	decreased tumor necrosis factor secretion	J:254917
\Myd88^M4Btlr/\Myd88^M4Btlr (C57BL/6J-Myd88^M4Btlr)	decreased tumor necrosis factor secretion	J:254917
\Myd88^poc/\Myd88⁺ (C57BL/6-Myd88^poc)	immune system phenotype	J:110094
\Myd88^poc/\Myd88^poc (C57BL/6-Myd88^poc)	abnormal immune system physiology	J:110094
	abnormal macrophage physiology	J:110094
	immune system phenotype	J:110094
	increased susceptibility to bacterial infection	J:110094
	increased susceptibility to Herpesvirales infection	J:110094
\Myd88^poc/\Myd88^poc \Ptpn6^m1Btlr/\Ptpn6^m1Btlr (C57BL/6J-Ptpn6^m1Btlr Myd88^poc)	immune system phenotype	J:142845
\Myd88^tm1.1Defr/\Myd88^tm1.1Defr (B6.129P2(SJL)-Myd88^tm1.1Defr)	abnormal CD4-positive, alpha-beta T cell physiology	J:224849
	abnormal macrophage physiology	J:224849
	abnormal microglial cell physiology	J:224849
	decreased effector memory CD4-positive, alpha-beta T cell number	J:224849
	decreased interferon-gamma secretion	J:224849
	decreased leukocyte cell number	J:224849
	decreased macrophage cell number	J:224849
	decreased monocyte cell number	J:224849
	decreased neutrophil cell number	J:224849
	increased susceptibility to Coronaviridae infection	J:224849
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:224849
\Myd88^tm1.1Medz/\Myd88^tm1.1Medz \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:209373
\Myd88^tm1.1Medz/\Myd88^tm1.1Medz \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:209373
	abnormal memory T cell physiology	J:209373
	abnormal T-helper 1 physiology	J:209373
	abnormal T-helper 17 cell physiology	J:209373
\Myd88^tm1Aki/\Myd88^tm1Aki (Not Specified)	abnormal cytokine secretion	J:89257, J:88906
	abnormal dendritic cell physiology	J:96773
	abnormal macrophage physiology	J:96773
	abnormal NK cell physiology	J:88906
	abnormal NK T cell physiology	J:88906
	abnormal T cell physiology	J:96773
	decreased B cell proliferation	J:96773
	increased susceptibility to Herpesvirales infection	J:88906
\Myd88^tm1Aki/\Myd88^tm1Aki (B6.129P2-Myd88^tm1Aki)	abnormal chemokine secretion	J:102879
	abnormal cytokine secretion	J:116670, J:162707
	abnormal dendritic cell differentiation	J:139001
	abnormal dendritic cell physiology	J:116670, J:118954
	abnormal immune system physiology	J:121070
	abnormal innate immunity	J:162707
	abnormal macrophage physiology	J:116670
	abnormal NK cell physiology	J:139001
	abnormal response to infection	J:121070
	abnormal T cell physiology	J:97662
	bronchiolitis	J:162707
	decreased inflammatory response	J:123946
	decreased interferon-alpha secretion	J:97662
	decreased interferon-gamma secretion	J:116763, J:118954
	decreased interleukin-6 secretion	J:118954, J:121070
	decreased interleukin-12 secretion	J:116670
	decreased interleukin-12b secretion	J:116763, J:118954
	decreased susceptibility to parasitic infection	J:116763
	decreased tumor necrosis factor secretion	J:116670, J:116763, J:121070
	increased dendritic cell number	J:116763
	increased susceptibility to Coronaviridae infection	J:162707
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:162707
	increased susceptibility to Picornaviridae infection	J:97662
\Myd88^tm1Aki/\Myd88^tm1Aki (involves: 129P2/OlaHsd)	abnormal cytokine level	J:174941
	abnormal cytokine secretion	J:167340
	abnormal dendritic cell physiology	J:174941, J:137522
	abnormal interferon level	J:137522
	abnormal macrophage physiology	J:174941
	abnormal neutrophil physiology	J:145345
	abnormal tumor necrosis factor level	J:103464, J:124334
	decreased circulating tumor necrosis factor level	J:139030
	decreased interferon-alpha secretion	J:144400
	decreased interferon-gamma secretion	J:210086
	decreased interleukin-6 secretion	J:167340
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:105435
	increased IgA level	J:210086
	increased IgE level	J:115059
	increased IgG1 level	J:115059
	increased susceptibility to bacterial infection	J:210086
	increased susceptibility to induced colitis	J:167340
	increased susceptibility to Picornaviridae infection	J:137522
\Myd88^tm1Aki/\Myd88^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:141143
	abnormal cytokine secretion	J:117688
	abnormal dendritic cell physiology	J:122394
	abnormal macrophage physiology	J:141143, J:117688
	decreased IgG2b level	J:137066
	decreased IgG3 level	J:137066
	decreased IgG level	J:137066
	decreased interleukin-1 beta secretion	J:124226
	decreased interleukin-6 secretion	J:147023
	immune system phenotype	J:132662
\Myd88^tm1Aki/\Myd88^tm1Aki (C.129P2-Myd88^tm1Aki)	decreased susceptibility to induced arthritis	J:178054
\Myd88^tm1Aki/\Myd88^tm1Aki (B6.129-Myd88^tm1Aki)	abnormal susceptibility to bacterial infection	J:189854
	decreased interleukin-6 secretion	J:189854
	decreased tumor necrosis factor secretion	J:189854
\Myd88^tm1Aki/\Myd88^tm1Aki \Sh3bp2^tm1.1Ics/\Sh3bp2^tm1.1Ics (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:221901
\Myd88^tm1Aki/\Myd88^tm1Aki \Tank^tm1Aki/\Tank^tm1Aki (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	increased anti-double stranded DNA antibody level	J:151757
\Myd88^tm1Aki/\Myd88^tm1Aki \Tg(IghelMD4)4Ccg/0 \Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:115059
	increased B-1 B cell number	J:115059
\Myd88^tm1Aki/\Myd88^tm1Aki \Ticam1^tm1Aki/\Ticam1⁺ (B6.129P2-Myd88^tm1Aki Ticam1^tm1Aki)	decreased macrophage cytokine production	J:140485
	decreased macrophage nitric oxide production	J:140485
	increased susceptibility to parasitic infection	J:140485
	increased susceptibility to parasitic infection induced morbidity/mortality	J:140485
\Myd88^tm1Aki/\Myd88^tm1Aki \Ticam1^tm1Aki/\Ticam1^tm1Aki (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:174941
	abnormal macrophage physiology	J:174941
\Myd88^tm1Aki/\Myd88^tm1Aki \Ticam1^tm1Aki/\Ticam1^tm1Aki (B6.129P2-Myd88^tm1Aki Ticam1^tm1Aki)	decreased macrophage cytokine production	J:140485
	decreased macrophage nitric oxide production	J:140485
	increased susceptibility to parasitic infection	J:140485
	increased susceptibility to parasitic infection induced morbidity/mortality	J:140485
\Myd88^tm1Aki/\Myd88^tm1Aki \Tnfaip3^tm1.1Gvl/\Tnfaip3^tm1.1Gvl \Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	increased susceptibility to induced colitis	J:163410
\Myd88^tm1Aki/\Myd88^tm1Aki \Tnip1^tm1.1Pcoh/\Tnip1^tm1.1Pcoh (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:176826
\Myd88^tm1Aki/\Myd88^tm1Aki \Tradd^tm1.1Mpa/\Tradd^tm1.1Mpa (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased circulating tumor necrosis factor level	J:139030
\Myd88^tm1Defr/\Myd88^tm1Defr \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal NK cell physiology	J:139001
\Myd88^tm1Defr/\Myd88^tm1Defr \Tg(Itgax-cre)1-1Reiz/0 (B6.Cg-Myd88^tm1Defr Tg(Itgax-cre)1-1Reiz)	abnormal dendritic cell antigen presentation	J:139001
	abnormal dendritic cell differentiation	J:139001
	abnormal dendritic cell physiology	J:139001
	abnormal NK cell physiology	J:139001
	abnormal T-helper 1 cell differentiation	J:139001
	decreased circulating interleukin-6 level	J:139001
	decreased circulating interleukin-12b level	J:139001
	decreased IgG1 level	J:139001
	decreased IgG2b level	J:139001
	decreased IgG2c level	J:139001
\Myd88^tm1Defr/\Myd88^tm1Defr \Tnip1^tm1.2Ama/\Tnip1^tm1.2Ama \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)	immune system phenotype	J:205446
\Myd88^tm1Hlz/\Myd88^tm1Hlz (B6.129P2-Myd88^tm1Hlz)	abnormal chemokine level	J:188968
	decreased circulating interleukin-6 level	J:188968
	decreased circulating interleukin-10 level	J:188968
	decreased circulating interleukin-12b level	J:188968
	decreased interleukin-6 secretion	J:188968
	decreased interleukin-10 secretion	J:188968
	decreased neutrophil cell number	J:188968
	decreased tumor necrosis factor secretion	J:188968
\Myd88^tm1Hlz/\Myd88^tm1Hlz \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.129P2-Myd88^tm1Hlz Lyz2^tm1(cre)Ifo)	abnormal circulating chemokine level	J:188968
	decreased CXCL10 level	J:188968
	immune system phenotype	J:188968
	increased circulating tumor necrosis factor level	J:188968
\Mydgf^tm1Kcw/\Mydgf^tm1Kcw (BALB/c-Mydgf^tm1Kcw)	decreased inflammatory response	J:216795
\Myh1^{tm1b(KOMP)Wtsi}/\Myh1^{tm1b(KOMP)Wtsi} (C57BL/6N-Myh1^{tm1b(KOMP)Wtsi}/J)	decreased leukocyte cell number	J:211773
\Myh4^arl/\Myh4^arl (involves: C3H/HeH * C57BL/6J)	myositis	J:181892
\Myh6^tm1Jse/\Myh6⁺ \Tg(Myh6-TNNI3G203S)1Chs/0 (involves: 129X1/SvJ C57BL/6)	liver inflammation	J:153302
	lung inflammation	J:153302
\Myh9^tm1.1Dash/\Myh9⁺ (involves: 129S2/SvPas * C57BL/6 * C57BL/6J * CBA)	abnormal thrombopoiesis	J:204923
\Myh9^tm1.1Mjk/\Myh9⁺ (B6.129-Myh9^tm1.1Mjk)	abnormal neutrophil morphology	J:175367
\Myh9^tm1.1Mjk/\Myh9⁺ (B6.129-Myh9^tm1.1Mjk)	increased incidence of corneal inflammation	J:175367
\Myh9^tm1.1Mjk/\Myh9^tm1.1Mjk (B6.129-Myh9^tm1.1Mjk)	abnormal neutrophil morphology	J:175367
\Myh9^tm5Rsad/\Myh9^tm5Rsad (involves: 129S6/SvEvTac * C57BL/6J)	abnormal leukocyte migration	J:164684
	abnormal T cell physiology	J:164684
\Myh9^tm5Rsad/\Myh9^tm5Rsad \Tg(Lck-cre)#Nik/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)	abnormal CD8-positive, alpha-beta T cell physiology	J:164684
	abnormal leukocyte adhesion	J:164684
	abnormal leukocyte migration	J:164684
	abnormal lymph node cell ratio	J:164684
	abnormal T cell physiology	J:164684
	decreased CD8-positive, alpha-beta T cell number	J:164684
\Myh9^{tm6.1(EGFP/MYH9)Rsad}/\Myh9⁺ (involves: 129S4/SvJae BALB/cJ * C57BL/6)	abnormal neutrophil morphology	J:175367
\Myh9^tm7.1Rsad/\Myh9⁺ (involves: BALB/cJ)	abnormal neutrophil morphology	J:175367
\Myh9^tm7.1Rsad/\Myh9^tm7.1Rsad (involves: BALB/cJ)	abnormal neutrophil morphology	J:175367
\Myh10^tm7Rsad/\Myh10^tm7Rsad \Tg(Myh6-cre)2182Mds/0 (involves: 129S6/SvEvTac * C57BL/6J * FVB/N)	heart inflammation	J:170148
\Myh15^em1(IMPC)J/\Myh15^em1(IMPC)J (C57BL/6NJ-Myh15^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Myl3^{tm1a(EUCOMM)Hmgu}/\Myl3^{tm1a(EUCOMM)Hmgu} \Tg(Col2a1-cre)1Xya/0 (involves: C57BL/6J * C57BL/6N)	osteoarthritis	J:343166
\Myl3^{tm1a(EUCOMM)Hmgu}/\Myl3^{tm1a(EUCOMM)Hmgu} \Tg(Col2a1-cre/ERT)KA3Smac/0 (involves: C57BL/6J * C57BL/6N * FVB/N)	increased susceptibility to induced arthritis	J:343166
\Mylk^tm1Mzhu/\Mylk^tm1Mzhu \Tagln^{tm1(cre/ERT2)Feil}/? (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6)	small intestinal inflammation	J:141907
\Myo1d^em1Btlr/\Myo1d^em1Btlr (C57BL/6J-Myo1d^em1Btlr)	increased susceptibility to colitis induced morbidity/mortality	J:267525
\Myo1d^em1Btlr/\Myo1d^em1Btlr (C57BL/6J-Myo1d^em1Btlr)	increased susceptibility to induced colitis	J:267525
\Myo1d^m1Btlr/\Myo1d^m1Btlr (C57BL/6J-Myo1d^m1Btlr)	increased susceptibility to induced colitis	J:267525
\Myo1d^m1Btlr/\Myo1d^m2Btlr (C57BL/6J-Myo1d^m1Btlr/Myo1d^m2Btlr)	increased susceptibility to induced colitis	J:267525
\Myo1d^m2Btlr/\Myo1d^m2Btlr (C57BL/6J-Myo1d^m2Btlr)	increased susceptibility to induced colitis	J:267525
\Myo1d^m3Btlr/\Myo1d^m3Btlr (C57BL/6J-Myo1d^m3Btlr)	increased susceptibility to induced colitis	J:267525
\Myo1d^m4Btlr/\Myo1d^m4Btlr (C57BL/6J-Myo1d^m4Btlr)	increased susceptibility to induced colitis	J:267525
\Myo1f^tm1.1Flv/\Myo1f^tm1.1Flv (involves: 129S6/SvEvTac)	impaired neutrophil chemotaxis	J:113020
\Myo1g^tm1.2Mfk/\Myo1g^tm1.2Mfk (Not Specified)	abnormal B cell physiology	J:209304
	decreased B cell number	J:209304
	decreased tumor necrosis factor secretion	J:209304
	immune system phenotype	J:209304
	impaired B cell migration	J:209304
	increased B cell number	J:209304
\Myo1g^tm1.2Mfk/\Myo1g^tm1.2Mfk (involves: C57BL/6 * FVB/N * SJL)	abnormal T cell physiology	J:212451
\Myo1g^tm1.2Mfk/\Myo1g^tm1.2Mfk \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * FVB/N * SJL)	abnormal T cell physiology	J:212451
\Myo3b^{tm1b(EUCOMM)Hmgu}/\Myo3b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Myo3b^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
\Myo5a^d-2Btlr/\Myo5a^d-2Btlr (C57BL/6J-Myo5a^d-2Btlr)	immune system phenotype	J:133118
\Myo5a^d-Btlr/\Myo5a^d-Btlr (C57BL/6J-Myo5a^d-Btlr)	immune system phenotype	J:133117
\Myo5a^d-l20J/\Myo5a^d-l20J (involves: C57BL/6J)	immune system phenotype	J:111253
\Myo6^em1(IMPC)Tcp/\Myo6^em1(IMPC)Tcp (C57BL/6N-Myo6^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
\Myo9a^{tm1b(EUCOMM)Wtsi}/\Myo9a^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Myo9a^{tm1b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Myo9b^tm1.2Bah/\Myo9b^tm1.2Bah (B6.Cg-Myo9b^tm1.2Bah)	abnormal macrophage physiology	J:162326
	decreased leukocyte cell number	J:162326
	impaired macrophage chemotaxis	J:162326
\Myo18a^{tm1c(KOMP)Wtsi}/\Myo18a^{tm1c(KOMP)Wtsi} \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N)	immune system phenotype	J:277320
\Myoz1^{tm1b(EUCOMM)Hmgu}/\Myoz1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Myoz1^{tm1b(EUCOMM)Hmgu}/Ieg)	increased marginal zone B cell number	J:211773
\Mypn^em1(IMPC)J/\Mypn^em1(IMPC)J (C57BL/6NJ-Mypn^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\mypy/\mypy (C57BL/6J-mypy)	abnormal macrophage physiology	J:105543
	increased susceptibility to Herpesvirales infection	J:105543
	increased susceptibility to Riboviria infection	J:105543
\Mysm1^{tm1a(KOMP)Wtsi}/\Mysm1^{tm1a(KOMP)Wtsi} (Not Specified)	decreased B cell number	J:165965
	decreased leukocyte cell number	J:165965
	decreased mature B cell number	J:165965
	increased granulocyte number	J:165965
	increased IgG2b level	J:165965
	increased T cell number	J:165965
\Mysm1^{tm1b(KOMP)Wtsi}/\Mysm1^{tm1b(KOMP)Wtsi} \Tg(MMTV-cre)4Mam/0 (involves: 129 * C57BL/6N * FVB/N)	abnormal T cell differentiation	J:179287
	arrested B cell differentiation	J:179287
	decreased B cell number	J:179287
	decreased immature B cell number	J:179287
	decreased pre-B cell number	J:179287
	decreased pro-B cell number	J:179287
\Mzb1^tm1.2Rug/\Mzb1^tm1.2Rug (involves: 129S2/SvPas * BALB/cJ * C57BL/6 * SJL)	decreased pre-B cell number	J:211639
	immune system phenotype	J:211639
	impaired humoral immune response	J:211639
	increased pro-B cell number	J:211639
\Mzf1^tm1Ppp/\Mzf1^tm1Ppp (involves: 129)	abnormal bone marrow development	J:70407
\Mzf1^tm1Ppp/\Mzf1^tm1Ppp (involves: 129)	abnormal myelopoiesis	J:70407
\N4bp1^em1Vmd/\N4bp1^em1Vmd (C57BL/6N-N4bp1^em1Vmd)	decreased interleukin-6 secretion	J:297419
\N4bp1^em1Vmd/\N4bp1^em1Vmd (C57BL/6N-N4bp1^em1Vmd)	immune system phenotype	J:297419
\N4bp1^tm1.2Vmd/\N4bp1^tm1.2Vmd (involves: C57BL/6)	abnormal macrophage physiology	J:297419
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:297419
	increased activated T cell number	J:297419
	increased circulating interleukin-6 level	J:297419
	increased circulating tumor necrosis factor level	J:297419
	increased germinal center B cell number	J:297419
	increased interleukin-6 secretion	J:297419
	increased Ly6C high monocyte number	J:297419
	increased tumor necrosis factor secretion	J:297419
	lung inflammation	J:297419
\Naa10^em1(IMPC)Mbp/Y (C57BL/6NCrl-Naa10^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Naa10^em1(IMPC)Mbp/\Naa10^em1(IMPC)Mbp (C57BL/6NCrl-Naa10^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Naa16^em1(IMPC)J/\Naa16^em1(IMPC)J (C57BL/6NJ-Naa16^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Naa25^em1(IMPC)Tcp/\Naa25⁺ (C57BL/6NCrl-Naa25^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Naa35^em1(IMPC)J/\Naa35⁺ (C57BL/6NJ-Naa35^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Naa38^{em1(IMPC)Ccpcz}/\Naa38⁺ (C57BL/6N-Naa38^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Naaa^{tm1a(KOMP)Wtsi}/\Naaa^{tm1a(KOMP)Wtsi} (B6NTac;B6N-A^tm1Brd Naaa^{tm1a(KOMP)Wtsi}/WtsiH)	decreased susceptibility to type IV hypersensitivity reaction	J:258438
\Nabp2^tm1.1Kkha/\Nabp2^tm1.1Kkha \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:195140
\Nabp2^tm1.1Kkha/\Nabp2^tm1.1Kkha \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:195140
	increased thymocyte apoptosis	J:195140
\Nabp2^tm1.1Nfel/\Nabp2^tm1.2Nfel \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	immune system phenotype	J:190019
\Nabp2^tm1Schg/\Nabp2^tm1Schg (involves: 129S7/SvEvBrd * C57BL/6)	increased spleen red pulp amount	J:228558
\nad/\nad (C(D2)-nad)	abnormal bronchus-associated lymphoid tissue morphology	J:156089
\Nadsyn1^{tm1b(KOMP)Wtsi}/\Nadsyn1^{tm1b(KOMP)Wtsi} (C57BL/6N-Nadsyn1^{tm1b(KOMP)Wtsi}/Ucd)	enlarged spleen	J:211773
\Nagk^{tm1b(EUCOMM)Hmgu}/\Nagk^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nagk^{tm1b(EUCOMM)Hmgu}/H)	increased neutrophil cell number	J:211773
\Naglu^tm1Efn/\Naglu^tm1Efn (either: (involves: 129S/SvEv * C57BL/6) or (involves: C57BL/6))	abnormal Kupffer cell morphology	J:58950
	abnormal macrophage morphology	J:58950
\Naglu^tm1Efn/\Naglu^tm1Efn (involves: 129S/SvEv * C57BL/6J)	increased susceptibility to otitis media	J:129390
\Naip5^Lgn1-s/\Naip5^Lgn1-s (A/J)	increased susceptibility to bacterial infection	J:20633
\Naip5^m1Btlr/\Naip5^m1Btlr (C57BL/6J-Naip5^m1Btlr)	decreased interleukin-1 beta secretion	J:234250
\Naip5^m2Btlr/\Naip5⁺ (C57BL/6J-Naip5^m2Btlr)	decreased interleukin-1 beta secretion	J:234248
\Naip5^m2Btlr/\Naip5^m2Btlr (C57BL/6J-Naip5^m2Btlr)	decreased interleukin-1 beta secretion	J:234248
\Naip5^tm1Vnce/\Naip5^tm1Vnce (C57BL/6-Naip5^tm1Vnce)	decreased interleukin-1 beta secretion	J:141008
\Naipc^tm1.1Kmma/\Naipc^tm1.1Kmma (involves: BALB/cJ * C57BL/6)	decreased interleukin-1 beta secretion	J:222114
	decreased susceptibility to induced colitis	J:222114
\Naipc^tm1Kmma/\Naipc^tm1Kmma \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.Cg-Lyz2^tm1(cre)Ifo Naipc^tm1Kmma)	decreased susceptibility to induced colitis	J:222114
\Naipc^tm1Kmma/\Naipc^tm1Kmma \Tg(Vil1-cre)997Gum/0 (B6.Cg-Naipc^tm1Kmma Tg(Vil1-cre)997Gum)	decreased susceptibility to induced colitis	J:222114
\Nalcn^em1(IMPC)Mbp/\Nalcn⁺ (C57BL/6N-Nalcn^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Nampt^{Gt(RRR084)Byg}/\Nampt⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-6 secretion	J:194883
	decreased neutrophil cell number	J:194883
\Nampt^tm1Oleo/\Nampt^tm1Oleo \Tg(CD2-icre)4Kio/0 (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/10 * CBA/Ca)	decreased B cell number	J:141448
	decreased double-negative T cell number	J:141448
	decreased T cell number	J:141448
	thymus hypoplasia	J:141448
\Napa^{em1(IMPC)Ccpcz}/\Napa⁺ (C57BL/6NCrl-Napa^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Nat8f2^{tm1.1(KOMP)Vlcg}/\Nat8f2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nat8f2^{tm1.1(KOMP)Vlcg}/J)	enlarged lymph nodes	J:211773
\Nav1^em1(IMPC)Mbp/\Nav1^em1(IMPC)Mbp (C57BL/6N-Nav1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Nav2^em1(IMPC)Tcp/\Nav2^em1(IMPC)Tcp (C57BL/6NCrl-Nav2^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
\Naxe^{tm1b(EUCOMM)Hmgu}/\Naxe^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Naxe^{tm1b(EUCOMM)Hmgu}/Bay)	increased spleen weight	J:211773
\Nba4^NZB/\Nba4^NZB (involves: NZB * SWR)	glomerulonephritis	J:96060
	increased anti-double stranded DNA antibody level	J:96060
	increased anti-histone antibody level	J:96263
	increased anti-single stranded DNA antibody level	J:96060
	increased IgG3 level	J:96263
\Nba4^NZB/\Nba4^SWR (involves: NZB * SWR)	increased anti-histone antibody level	J:96263
\Nba4^NZB/\Nba4^SWR (involves: NZB * SWR)	increased IgG3 level	J:96263
\Nba5^NZB/\Nba5^NZB (C57BL/6-Nba5 Yaa)	glomerulonephritis	J:95829
\Nba5^NZB/\Nba5^NZB (C57BL/6-Nba5 Yaa)	increased susceptibility to type III hypersensitivity reaction	J:95829
\Nba8^NZB/\Nba8^NZB (involves: NZB * SWR)	glomerulonephritis	J:73097
\Nba10^NZB/? (involves: C57BL/6 * NZB * SB/Le)	glomerulonephritis	J:95829
	increased anti-chromatin antibody level	J:95829
	increased anti-double stranded DNA antibody level	J:95829
	increased susceptibility to type III hypersensitivity reaction	J:95829
\Nba10^NZB/\Nba10^NZB \Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6 * DBA/2J * NZB)	glomerulonephritis	J:134128
	increased anti-chromatin antibody level	J:134128
	increased anti-double stranded DNA antibody level	J:134128
	increased B cell number	J:134128
	increased IgG level	J:134128
	increased IgM level	J:134128
	increased marginal zone B cell number	J:134128
	increased susceptibility to systemic lupus erythematosus	J:134128
\Nba10^NZB/\Nba10^NZB \Tlr7^tm1Aki/Y X/\Yaa (B6.Cg-Nba10^NZB Tlr7^tm1Aki Yaa)	abnormal immune serum protein physiology	J:137656
	glomerulonephritis	J:137656
	increased anti-chromatin antibody level	J:137656
	increased monocyte cell number	J:137656
\Nba10^NZB/\Nba10^NZB X/\Yaa (C57BL/6-Nba2 Yaa)	abnormal immune serum protein physiology	J:137656
	glomerulonephritis	J:95829, J:137656
	increased anti-chromatin antibody level	J:137656
	increased anti-nuclear antigen antibody level	J:95829
	increased autoantibody level	J:137656
	increased monocyte cell number	J:137656, J:129409
	increased susceptibility to autoimmune disorder	J:95829
	increased susceptibility to type III hypersensitivity reaction	J:95829
\Nba11^NZB/\Nba11^NZB (involves: NZB * SWR)	glomerulonephritis	J:96263
\Nba11^NZB/\Nba11^SWR (involves: NZB * SWR)	glomerulonephritis	J:96263
\Nba12^NZB/\Nba12^NZB (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96263
\Nba12^NZB/\Nba12^SWR (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96263
\Nbeal2^gps/\Nbeal2^gps (129S1/SvImJ-Nbeal2^gps)	decreased neutrophil cell number	J:236370
\Nbeal2^{tm1a(EUCOMM)Wtsi}/\Nbeal2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Nbeal2^{tm1a(EUCOMM)Wtsi}/Wtsi)	enlarged spleen	J:220801
	increased inflammatory response	J:220801
	increased leukocyte cell number	J:211773
\Nbeal2^tm1Lex/\Nbeal2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	enlarged spleen	J:201413
\Nbn^em7Jpt/\Nbn^tm2Zqw \Tg(VAV1-cre)1Graf/0 (involves: 129P2/OlaHsd)	abnormal T cell morphology	J:277750
	absent mature B cells	J:277750
	decreased B cell number	J:277750
	decreased leukocyte cell number	J:277750
	decreased T cell number	J:277750
	decreased thymocyte number	J:277750
	increased CD8-positive, alpha-beta T cell number	J:277750
	increased pro-B cell number	J:277750
	increased T cell derived lymphoma incidence	J:277750
\Nbn^tm1Jpt/\Nbn^tm1Jpt (involves: 129S7/SvEvBrd)	immune system phenotype	J:75956
\Nbn^tm1Nus/\Nbn^tm2Nus \Tg(CD19-cre/ERT2)1Cgn/0 (Not Specified)	abnormal B cell physiology	J:96102
	decreased B cell proliferation	J:96102
	decreased IgG1 level	J:96102
	decreased IgG2a level	J:96102
	decreased IgG2b level	J:96102
	decreased IgG3 level	J:96102
	decreased IgG level	J:96102
\Nbn^tm1Xu/\Nbn^tm1Xu (Not Specified)	abnormal cell-mediated immunity	J:75272
	decreased CD4-positive, alpha-beta T cell number	J:75272
	decreased mature B cell number	J:75272
	decreased pre-B cell number	J:75272
	decreased T cell number	J:75272
	increased T cell derived lymphoma incidence	J:75272
	thymus hypoplasia	J:75272
\Nbn^tm1Zqw/\Nbn⁺ (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:86563
\Nbn^tm2Zqw/\Nbn^tm2Zqw \Tg(VAV1-cre)1Graf/0 (involves: 129P2/OlaHsd)	abnormal bone marrow development	J:251434
	decreased leukocyte cell number	J:251434
\Nbr1^tm1.1Jmos/\Nbr1^tm1.1Jmos \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129X1/SvJ * C57BL/6J)	abnormal T-helper 1 cell differentiation	J:165438
	abnormal T-helper 2 cell differentiation	J:165438
	decreased inflammatory response	J:165438
	decreased interferon-gamma secretion	J:165438
	decreased interleukin-4 secretion	J:165438
	decreased interleukin-5 secretion	J:165438
	decreased interleukin-13 secretion	J:165438
\Nbr1^tm1Whca/\Nbr1^tm1Whca (B6.129P2-Nbr1^tm1Whca)	abnormal osteoclast physiology	J:162412
\Nbwa1^NZB/? (involves: BALB/c * NZB * NZW)	increased anti-chromatin antibody level	J:88464
	increased anti-double stranded DNA antibody level	J:88464
	increased anti-single stranded DNA antibody level	J:88464
	increased susceptibility to systemic lupus erythematosus	J:88464
\Nbwa2^NZB/? (involves: BALB/c * NZB * NZW)	glomerulonephritis	J:88464
	increased IgG level	J:88464
	increased IgM level	J:88464
	increased susceptibility to systemic lupus erythematosus	J:88464
\Nbwa2^NZW/? (involves: BALB/c * NZB * NZW)	increased anti-double stranded DNA antibody level	J:88464
\Nbwa2^NZW/? (involves: BALB/c * NZB * NZW)	increased susceptibility to systemic lupus erythematosus	J:88464
\Ncam2^{tm1b(EUCOMM)Hmgu}/\Ncam2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ncam2^{tm1b(EUCOMM)Hmgu}/Orl)	increased eosinophil cell number	J:211773
\Ncapd2^em1Cya/\Ncapd2⁺ (C57BL/6N-Ncapd2^em1Cya)	decreased susceptibility to induced colitis	J:310248
\Ncaph2^nes/\Ncaph2^nes (C57BL/6JSfdAnu-Ncaph2^nes/Anu)	abnormal double-negative T cell morphology	J:123300
	abnormal splenic cell ratio	J:123300
	abnormal T cell morphology	J:123300
	abnormal thymus cell ratio	J:123300
	abnormal thymus cortex morphology	J:123300
	abnormal thymus corticomedullary boundary morphology	J:123300
	decreased CD8-positive, alpha-beta T cell number	J:123300
	decreased double-negative T cell number	J:123300
	decreased double-positive T cell number	J:123300
	decreased T cell number	J:123300
	decreased thymocyte number	J:123300
	thymus hypoplasia	J:123300
\Ncaph2^nes/\Ncaph2^nes \Tg(TcrHEL3A9)1Mmd/0 (C57BL/6-Ncaph2^nes Tg(TcrHEL3A9)1Mmd)	abnormal double-negative T cell morphology	J:123300
	abnormal thymus cell ratio	J:123300
	decreased double-positive T cell number	J:123300
\Nceh1^tm1Ishi/\Nceh1^tm1Ishi (B6.129S7-Nceh1^tm1Ishi)	abnormal macrophage physiology	J:152385
\Ncf1^em1(IMPC)Mbp/\Ncf1^em1(IMPC)Mbp (C57BL/6N-Ncf1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Ncf1^em1Nansh/\Ncf1^em1Nansh (involves: C57BL/6J)	immune system phenotype	J:329553
\Ncf1^m1J/\Ncf1^m1J (B6.Cg-Dock7^m +/+ Lepr^db/J)	abnormal macrophage physiology	J:83428
	decreased susceptibility to Orthomyxoviridae infection	J:145306
	impaired granulocyte bactericidal activity	J:83428
\Ncf1^tm1Hbd/\Ncf1^tm1Hbd (involves: 129)	abnormal neutrophil physiology	J:77597, J:74593
\Ncf1^tm1Hbd/\Ncf1^tm1Hbd (involves: 129)	granulomatous inflammation	J:74593
\Ncf1^tm1Hbd/\Ncf1^tm1Hbd (involves: C57BL/6)	immune system phenotype	J:118561
\Ncf1^tm1Shl/\Ncf1^tm1Shl (involves: 129S2/SvPas * C57BL/6J)	abnormal response to infection	J:28267
	increased acute inflammation	J:28267
	increased susceptibility to infection	J:28267
\Ncf1^tm1Shl/\Ncf1^tm1Shl (B6.129S2-Ncf1^tm1Shl)	abnormal inflammatory response	J:142617
\Ncf1^tm1Shl/\Ncf1^tm1Shl (B6.129S2-Ncf1^tm1Shl)	granulomatous inflammation	J:111142
\Ncf2^{tm1a(EUCOMM)Wtsi}/\Ncf2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Ncf2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
\Ncf2^{tm1b(EUCOMM)Wtsi}/\Ncf2⁺ (NZM2328.B6(Cg)-Ncf2^{tm1b(EUCOMM)Wtsi})	abnormal spleen germinal center morphology	J:260777
	increased activated T cell number	J:260777
	increased anti-double stranded DNA antibody level	J:260777
	increased B cell number	J:260777
	increased CD4-positive, alpha-beta memory T cell number	J:260777
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:260777
	increased CD8-positive, alpha-beta T cell number	J:260777
	increased follicular B cell number	J:260777
	increased germinal center B cell number	J:260777
	increased susceptibility to systemic lupus erythematosus	J:260777
	increased T cell number	J:260777
\Ncf2^{tm1b(EUCOMM)Wtsi}/\Ncf2^{tm1b(EUCOMM)Wtsi} (B6(Cg)-Ncf2^{tm1b(EUCOMM)Wtsi})	decreased CD8-positive, alpha-beta T cell number	J:260777
	increased susceptibility to fungal infection	J:260777
	lung inflammation	J:260777
\Ncf2^{tm1b(EUCOMM)Wtsi}/\Ncf2^{tm1b(EUCOMM)Wtsi} (NZM2328.B6(Cg)-Ncf2^{tm1b(EUCOMM)Wtsi})	abnormal spleen germinal center morphology	J:260777
	increased activated T cell number	J:260777
	increased anti-double stranded DNA antibody level	J:260777
	increased B cell number	J:260777
	increased follicular B cell number	J:260777
	increased germinal center B cell number	J:260777
	increased susceptibility to systemic lupus erythematosus	J:260777
	increased T cell number	J:260777
\Ncf4^tm1Pth/\Ncf4^tm2Pth (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:119217
	immune system phenotype	J:119217
	increased susceptibility to bacterial infection	J:119217
\Ncf4^tm2Pth/\Ncf4^tm2Pth (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:121820
	increased susceptibility to bacterial infection	J:121820
\Nckap1l^m1Btlr/\Nckap1l^m1Btlr (C57BL/6J-Nckap1l^m1Btlr)	decreased alpha-beta T cell number	J:272079
	decreased B cell number	J:272079
	decreased CD4-positive, alpha-beta T cell number	J:272079
	decreased CD8-positive, alpha-beta T cell number	J:272079
	decreased CD8-positive, naive alpha-beta T cell number	J:272079
	decreased central memory CD8 positive, alpha-beta T cell number	J:272079
	decreased NK cell number	J:272079
	increased alpha-beta T cell number	J:272079
	increased CD8-positive, alpha-beta T cell number	J:272079
	increased effector memory CD4-positive, alpha-beta T cell number	J:272079
	increased effector memory CD8-positive, alpha-beta T cell number	J:272079
\Nckap1l^m1Iri/\Nckap1l^m1Iri (involves: C57BL/6)	abnormal CD4-positive T cell differentiation	J:141377
	abnormal immune system organ morphology	J:141377
	abnormal lymphopoiesis	J:141377
	abnormal regulatory T cell number	J:141377
	abnormal thymus lobule morphology	J:141377
	decreased CD4-positive, alpha-beta T cell number	J:141377
	decreased CD8-positive, alpha-beta T cell number	J:141377
	decreased double-positive T cell number	J:141377
	decreased lymphocyte cell number	J:141377
	decreased mature B cell number	J:141377
	decreased mature gamma-delta T cell number	J:141377
	decreased T cell proliferation	J:141377
	heart inflammation	J:141377
	impaired macrophage phagocytosis	J:141377
	impaired neutrophil chemotaxis	J:141377
	impaired neutrophil phagocytosis	J:141377
	increased circulating interleukin-6 level	J:141377
	increased circulating interleukin-17 level	J:141377
	increased double-negative T cell number	J:141377
	increased interleukin-6 secretion	J:141377
	increased interleukin-17 secretion	J:141377
	increased leukocyte cell number	J:141377
	increased neutrophil cell number	J:141377
	increased tumor necrosis factor secretion	J:141377
	liver inflammation	J:141377
	lung inflammation	J:141377
	lymph node hypoplasia	J:141377
	spleen hyperplasia	J:141377
	thymus hypoplasia	J:141377
\Ncoa1^tm1Bwo/\Ncoa1^tm1Bwo (involves: 129 * C57BL/6J)	immune system phenotype	J:109522
\Ncoa2^em1(IMPC)Mbp/\Ncoa2⁺ (C57BL/6N-Ncoa2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Ncoa2^tm1.2Ipc/\Ncoa2^tm1.2Ipc (involves: 129S2/SvPas * C57BL/6J)	immune system phenotype	J:109522
\Ncoa3^tm1Jxu/\Ncoa3^tm1Jxu (involves: 129S6/SvEvTac * C57BL/6J)	abnormal B cell morphology	J:109522
	abnormal lymphopoiesis	J:109522
	abnormal spleen red pulp morphology	J:109522
	decreased splenocyte apoptosis	J:109522
	enlarged spleen	J:109522
	increased B cell number	J:109522
	increased B cell proliferation	J:109522
	increased CD4-positive, alpha-beta T cell number	J:109522
	increased CD8-positive, alpha-beta T cell number	J:109522
	increased leukocyte cell number	J:109522
	increased lymphocyte cell number	J:109522
	increased spleen germinal center size	J:109522
	increased T cell proliferation	J:109522
\Ncoa3^tm1Jxu/\Ncoa3^tm1Jxu (involves: 129S6/SvEvTac * C57BL/6)	decreased interleukin-1 beta secretion	J:120086
	increased circulating interleukin-1 beta level	J:120086
	increased circulating interleukin-6 level	J:120086
	increased circulating tumor necrosis factor level	J:120086
	increased interleukin-6 secretion	J:120086
	increased susceptibility to bacterial infection induced morbidity/mortality	J:120086
	increased susceptibility to endotoxin shock	J:120086
	increased tumor necrosis factor secretion	J:120086
\Ncoa5^{tm1.1(KOMP)Mbp}/\Ncoa5⁺ (C57BL/6N-Ncoa5^{tm1.1(KOMP)Mbp}/Tcp)	increased eosinophil cell number	J:211773
\Ncoa5^tm1Hxia/\Ncoa5⁺ (involves: 129 * C57BL/6)	chronic liver inflammation	J:207622
\Ncor1^tm1Rsd/\Ncor1^tm1Rsd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	arrested T cell differentiation	J:65417
	small thymus	J:65417
\Ncor2^tm1Rev/\Ncor2^tm1Rev (involves: 129/Sv * C57BL/6)	abnormal spleen morphology	J:202976
	enlarged spleen	J:202976
	increased osteoclast cell number	J:202976
\Ncr1^m1J/\Ncr1^m1J \Pepc^b/\Pepc^b \Ptprc^a/\Ptprc^a (B6.SJL-Ptprc^a Pepc^b/BoyJ)	abnormal interferon level	J:257226
	abnormal NK cell physiology	J:257226
	abnormal susceptibility to infection induced morbidity/mortality	J:257226
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:257226
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:257226
\Ncr1^noe/\Ncr1^noe (involves: C57BL/6J)	abnormal NK cell physiology	J:179728
	decreased CD4-positive, alpha-beta T cell number	J:179728
	decreased CD8-positive, alpha-beta memory T cell number	J:179728
	decreased CD8-positive, alpha-beta T cell number	J:179728
	decreased susceptibility to Herpesvirales infection	J:179728
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:179728
	increased NK cell number	J:179728
	increased susceptibility to bacterial infection	J:179728
\Ncr1^{tm1.1(icre)Viv}/\Ncr1^{tm1.1(icre)Viv} (involves: C57BL/6)	abnormal NK cell physiology	J:179728
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:179728
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:179728
\Ncr1^tm1Oman/\Ncr1^tm1Oman (involves: 129S1/Sv * 129X1/SvJ)	decreased NK cell number	J:112394
	impaired natural killer cell mediated cytotoxicity	J:112394
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:112394
\Ncr1^tm2.1Viv/\Ncr1⁺ (involves: C57BL/6)	immune system phenotype	J:186000
\Ncstn^tm1.1Akli/\Ncstn^tm1.1Akli \Tet2^tm1.1Iaai/\Tet2^tm1.1Iaai \Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	enlarged spleen	J:196407
	increased leukocyte cell number	J:196407
	myeloid hyperplasia	J:196407
\Ncstn^tm1.1Akli/\Ncstn^tm1.1Akli \Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA * SJL)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased leukocyte cell number	J:172442
	increased monocyte cell number	J:172442
	increased spleen red pulp amount	J:172442
\Ncstn^tm1.1Akli/\Ncstn^tm1.1Akli \Tg(VAV1-cre)1Graf/0 (involves: 129 * C57BL/6 * SJL)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased leukocyte cell number	J:172442
	increased monocyte cell number	J:172442
	increased spleen red pulp amount	J:172442
\Ncstn^tm1.1Akli/\Ncstn^tm1.1Akli \Tg(VAV1-cre)1Graf/0 (involves: 129)	abnormal splenocyte physiology	J:196407
	enlarged spleen	J:196407
\Ndfip1^{Gt(RRD002)Byg}/\Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell physiology	J:116617
	abnormal T-helper 2 physiology	J:116617
	dermatitis	J:116617
	increased activated T cell number	J:116617
	increased inflammatory response	J:116617
	increased spleen weight	J:116617
	increased T cell proliferation	J:116617
	lung inflammation	J:116617
\Ndfip1^{Gt(RRD002)Byg}/\Ndfip1^{Gt(RRD002)Byg} (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:205692
	increased activated T cell number	J:205692
	increased interleukin-2 secretion	J:205692
	increased T cell proliferation	J:205692
\Ndfip1^{Gt(RRD002)Byg}/\Ndfip1^{Gt(RRD002)Byg} \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6)	immune system phenotype	J:205692
\Ndfip1^kru/\Ndfip1^kru (involves: C57BL/6JSfdAnu)	immune system phenotype	J:188722
\Ndfip1^kru/\Ndfip1^kru (involves: C57BL/6JSfdAnu)	increased T-helper 2 cell number	J:188722
\Ndfip1^tm1.1Pmo/\Ndfip1^tm1.1Pmo \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	esophageal inflammation	J:205692
	increased activated T cell number	J:205692
	increased eosinophil cell number	J:205692
	skin inflammation	J:205692
\Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/\Ndor1⁺ \Rnpc3^{tm1c(EUCOMM)Wtsi}/\Rnpc3^{tm1c(EUCOMM)Wtsi} (involves: 129S/SvEv * C57BL/6 * C57BL/6N)	decreased leukocyte cell number	J:267519
	decreased lymphocyte cell number	J:267519
	decreased monocyte cell number	J:267519
	decreased thymus weight	J:267519
	esophageal inflammation	J:267519
	small intestinal inflammation	J:267519
	thymus atrophy	J:267519
	thymus cortex atrophy	J:267519
	thymus medulla atrophy	J:267519
\Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/\Ndor1⁺ \Rraga^tm2Dmsa/\Rraga^tm2Dmsa (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	decreased B cell number	J:213516
	enlarged spleen	J:213516
	increased monocyte cell number	J:213516
	myeloid hyperplasia	J:213516
\Ndrg2^tm1.1Hori/\Ndrg2^tm1.1Hori (B6.129-Ndrg2^tm1.1Hori)	abnormal microglial cell chemotaxis	J:214686
	decreased inflammatory response	J:214686
	decreased interleukin-6 secretion	J:214686
\Ndrg2^tm1Kmori/\Ndrg2⁺ (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	increased T cell derived lymphoma incidence	J:210264
\Ndrg2^tm1Kmori/\Ndrg2^tm1Kmori (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)	increased T cell derived lymphoma incidence	J:210264
\Ndrg3^em1(IMPC)Mbp/\Ndrg3⁺ (C57BL/6NCrl-Ndrg3^em1(IMPC)Mbp/Mmucd)	enlarged spleen	J:211773
\Ndst1^b2b2230Clo/\Ndst1^b2b2230Clo (C57BL/6J-Ndst1^b2b2230Clo)	thymus hypoplasia	J:175213
\Ndst1^tm1Je/\Ndst1^tm1Je \Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal leukocyte adhesion	J:100456
	abnormal leukocyte migration	J:100456
	decreased inflammatory response	J:100456
	impaired leukocyte tethering or rolling	J:100456
\Ndst2^tm1Lkj/\Ndst2^tm1Lkj (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal mast cell morphology	J:57121
	decreased mast cell degranulation	J:57121
	decreased mast cell histamine storage	J:57121
	decreased mast cell number	J:57121
	decreased mast cell protease storage	J:57121
\Ndst2^tm1Rls/\Ndst2^tm1Rls (Not Specified)	abnormal response to infection	J:57120
	decreased mast cell degranulation	J:57120
	decreased mast cell histamine storage	J:57120
	decreased mast cell protease storage	J:57120
\Ndst2^tm1Rls/\Ndst2^tm1Rls (B6.Cg-Ndst2^tm1Rls)	abnormal mast cell differentiation	J:142880
\Ndst2^tm1Rls/\Ndst2^tm1Rls (B6.Cg-Ndst2^tm1Rls)	decreased susceptibility to induced arthritis	J:142880
\Ndst3^tm1.1Grob/\Ndst3^tm1.1Grob (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	decreased CD8-positive, alpha-beta T cell number	J:138557
	decreased lymphocyte cell number	J:138557
\Ndufs4^tm1.1Rpa/\Ndufs4^tm1.1Rpa (involves: 129S4/SvJaeSor)	microgliosis	J:161393
\Ndufs4^tm1.1Rpa/\Ndufs4^tm1.1Rpa (B6.129S4-Ndufs4^tm1.1Rpa)	microgliosis	J:190475
\Ndufs4^tm1Rpa/\Ndufs4^tm1Rpa (B6.129S4-Ndufs4^tm1Rpa)	microgliosis	J:190475
\Ndufs4^tm1Rpa/\Ndufs4^tm1Rpa \Tg(Nes-cre)1Kln/0 (involves: 129S4/SvJaeSor * C57BL/6 * SJL)	microgliosis	J:161393
\Ndufs4^tm1Rpa/\Ndufs4^tm1Rpa \Tg(Nes-cre)1Kln/0 (B6.Cg-Tg(Nes-cre)1Kln Ndufs4^tm1Rpa)	microgliosis	J:190475
\Nectin4^em1Jaa/\Nectin4^em1Jaa (involves: C57BL/6N)	decreased susceptibility to type I hypersensitivity reaction	J:336809
\Nedd1^em1(IMPC)H/\Nedd1⁺ (C57BL/6NTac-Nedd1^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
\Nedd4^Gt(XA209)Byg/\Nedd4^Gt(XA209)Byg (involves: 129P2/OlaHsd)	abnormal T cell activation	J:143560
	decreased B cell number	J:143560
	decreased IgG1 level	J:143560
	decreased IgG2b level	J:143560
	decreased IgG3 level	J:143560
	decreased interleukin-2 secretion	J:143560
	decreased T cell proliferation	J:143560
	increased CD4-positive, alpha-beta T cell number	J:143560
	increased CD8-positive, alpha-beta T cell number	J:143560
	increased IgM level	J:143560
	increased T cell number	J:143560
\Nedd4^Gt(XB398)Byg/\Nedd4^Gt(XB398)Byg (involves: 129P2/OlaHsd)	decreased B cell number	J:143560
	decreased IgG1 level	J:143560
	decreased IgG2b level	J:143560
	decreased IgG3 level	J:143560
	decreased interleukin-2 secretion	J:143560
	decreased T cell proliferation	J:143560
	increased CD4-positive, alpha-beta T cell number	J:143560
	increased CD8-positive, alpha-beta T cell number	J:143560
	increased IgM level	J:143560
	increased T cell number	J:143560
\Nedd4^{tm2b(EUCOMM)Hmgu}/\Nedd4⁺ (C57BL/6N-Nedd4^{tm2b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Nedd4l^tm1.1Hkb/\Nedd4l^tm1.1Hkb \Tg(SFTPC-rtTA)5Jaw/0 \Tg(tetO-cre)1Jaw/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	lung inflammation	J:169296
\Nedd4l^tm1Shkr/\Nedd4l^tm1Shkr (involves: C57BL/6 * C57BL/6J)	increased neutrophil cell number	J:205657
	lung inflammation	J:205657
\Nedd4l^tm1Shkr/\Nedd4l^tm1Shkr (involves: 129 * C57BL/6 * C57BL/6J)	lung inflammation	J:205657
\Nedd9^m1Btlr/\Nedd9^m1Btlr (C57BL/6J-Nedd9^m1Btlr)	decreased B-1a cell number	J:267702
	decreased B-1b cell number	J:267702
	increased susceptibility to Herpesvirales infection	J:267702
\Nedd9^tm1Miku/\Nedd9^tm1Miku (B6.CBA-Nedd9^tm1Miku)	abnormal B cell number	J:116716
	abnormal follicular B cell physiology	J:116716
	abnormal leukocyte migration	J:116716
	abnormal T cell physiology	J:116716
	decreased lymphocyte cell number	J:116716
	decreased marginal zone B cell number	J:116716
	increased follicular B cell number	J:116716
	lymph node hypoplasia	J:116716
	spleen hypoplasia	J:116716
\Neil1^tm1Rsld/\Neil1^tm1Rsld (involves: 129S1/Sv * C57BL/6)	joint inflammation	J:106077
\Neil2^tm1.1Tkhz/\Neil2^tm1.1Tkhz (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl)	increased neutrophil cell number	J:225791
	lung inflammation	J:225791
\Neil3^tm1Bjor/\Neil3^tm1Bjor (involves: 129 * C57BL/6)	decreased microglial cell activation	J:180177
\Nek2^em1(IMPC)Tcp/\Nek2^em1(IMPC)Tcp (C57BL/6NCrl-Nek2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Nek7^M1Btlr/\Nek7⁺ (C57BL/6J-Nek7^M1Btlr)	abnormal macrophage physiology	J:226677
	decreased inflammatory response	J:226677
	decreased interleukin-1 beta secretion	J:226677
	decreased interleukin-18 secretion	J:226677
	immune system phenotype	J:226677
\Nek7^M1Btlr/\Nek7^M1Btlr (C57BL/6J-Nek7^M1Btlr)	abnormal macrophage physiology	J:226677
	decreased inflammatory response	J:226677
	decreased interleukin-1 beta secretion	J:226677
	decreased interleukin-18 secretion	J:226677
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226677
	immune system phenotype	J:226677
\Nek8^m1Btlr/\Nek8^m1Btlr (C57BL/6J-Nek8^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:267544
	decreased effector memory CD4-positive, alpha-beta T cell number	J:267544
	decreased effector memory CD8-positive, alpha-beta T cell number	J:267544
	increased CD4-positive, alpha-beta T cell number	J:267544
	increased susceptibility to induced colitis	J:267544
\Nek9^{tm1a(EUCOMM)Wtsi}/\Nek9⁺ (C57BL/6N-Nek9^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Nelfa^em1(IMPC)Tcp/\Nelfa⁺ (C57BL/6NCrl-Nelfa^em1(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
\Nell1^em1(IMPC)Mbp/\Nell1^em1(IMPC)Mbp (C57BL/6N-Nell1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
\Nemp1^em1(IMPC)Mbp/\Nemp1^em1(IMPC)Mbp (C57BL/6NCrl-Nemp1^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Nemp2^em1(IMPC)Tcp/\Nemp2^em1(IMPC)Tcp (C57BL/6N-Nemp2^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Neu1^a/\Neu1^a (SM/J)	abnormal Kupffer cell morphology	J:147881
\Neu1^tm1Adz/\Neu1^tm1Adz (either: (involves: 129S1/Sv * C57BL/6) or (involves: 129S1/Sv * NMRI))	abnormal Kupffer cell morphology	J:76937
	abnormal microglial cell morphology	J:76937
	enlarged spleen	J:76937
	spleen hyperplasia	J:76937
\Neurl2^{tm1.1(KOMP)Vlcg}/\Neurl2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Neurl2^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Neurl3^em1Luda/\Neurl3^em1Luda (B6N.Cg-Neurl3^em1Luda)	increased susceptibility to Riboviria infection	J:344721
\Neurl3^em1Luda/\Neurl3^em1Luda (B6N.Cg-Neurl3^em1Luda)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:344721
\Neurl4^em1(IMPC)Mbp/\Neurl4^em1(IMPC)Mbp (C57BL/6NCrl-Neurl4^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Nexmif^em1(IMPC)Tcp/Y (C57BL/6N-Nexmif^em1(IMPC)Tcp/Tcp)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
\Nexmif^em1(IMPC)Tcp/\Nexmif⁺ (C57BL/6N-Nexmif^em1(IMPC)Tcp/Tcp)	increased neutrophil cell number	J:211773
\Nf1^tm1.1Kest/\Nf1^{tm1c(KOMP)Wtsi} \Tg(Dhh-cre)1Mejr/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)	dermatitis	J:234172
\Nf1^{tm1c(KOMP)Wtsi}/\Nf1^{tm1c(KOMP)Wtsi} \Tg(Dhh-cre)1Mejr/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * FVB/N)	dermatitis	J:234172
\Nf1^tm1Fcr/\Nf1⁺ \Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Tg(Mx1-cre)1Cgn Nf1^tm1Fcr Pten^tm1Hwu)	abnormal spleen morphology	J:232645
	decreased B cell number	J:232645
	decreased lymphocyte cell number	J:232645
	decreased T cell number	J:232645
	enlarged spleen	J:232645
	increased granulocyte number	J:232645
	increased leukocyte cell number	J:232645
	increased macrophage cell number	J:232645
	increased monocyte cell number	J:232645
	increased spleen weight	J:232645
\Nf1^tm1Fcr/\Nf1^tm1Fcr (either: (involves: 129S/SvEv) or (involves: 129S/SvEv * C57BL/6J))	abnormal lymphatic vessel morphology	J:18048
\Nf1^tm1Fcr/\Nf1^tm1Par \Tg(Tek-cre)1Ywa/0 (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	abnormal spleen morphology	J:114455
	absent spleen germinal center	J:114455
	enlarged spleen	J:114455
	spleen fibrosis	J:114455
\Nf1^tm1Par/\Nf1^tm1Fcr \Tg(GFAP-cre)#Gtm/0 (involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal microglial cell morphology	J:165209
\Nf1^tm1Par/\Nf1^tm1Par \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal myeloid leukocyte morphology	J:90973
	abnormal myelopoiesis	J:90973
	abnormal spleen morphology	J:90973
	enlarged spleen	J:90973
	increased granulocyte number	J:90973
	increased leukocyte cell number	J:90973
	increased lymphocyte cell number	J:90973
	increased monocyte cell number	J:90973
	increased neutrophil cell number	J:90973
\Nf1^tm1Par/\Nf1^tm1Par \Tg(Prrx1-cre)1Cjt/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * SJL/J)	increased osteoclast cell number	J:193350
\Nf1^tm1Tyj/\Nf1⁺ (involves: 129S2/SvPas)	abnormal mast cell physiology	J:142439
\Nf1^tm1Tyj/\Nf1⁺ (involves: 129S2/SvPas)	increased mast cell degranulation	J:142439
\Nf1^tm1Tyj/\Nf1⁺ \Pak1^tm1Cher/\Pak1^tm1Cher (involves: 129S2/SvPas * C57BL/6)	abnormal mast cell physiology	J:142439
\Nf1^tm1Tyj/\Nf1⁺ \Trp53^tm1Tyj/\Trp53⁺ (involves: 129S2/SvPas * C57BL/6)	spleen hyperplasia	J:228258
\Nf2^tm1Gth/\Nf2^tm2Gth \Tg(Mpz-cre)2Brn/0 (involves: 129P2/OlaHsd * FVB/N)	increased susceptibility to otitis media	J:63264
\Nf2^tm2Gth/\Nf2^tm2Gth \Tg(Mpz-cre)1Brn/0 (involves: 129P2/OlaHsd * FVB/N)	increased susceptibility to otitis media	J:63264
\Nf2^tm2Gth/\Nf2^tm2Gth \Tg(Mpz-cre)2Brn/0 (involves: 129P2/OlaHsd * FVB/N)	increased susceptibility to otitis media	J:63264
\Nf2^tm2Gth/\Nf2^tm2Gth \Trp53^tm1Brn/\Trp53^tm1Brn (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:132943
\Nfam1^{em1(IMPC)Ccpcz}/\Nfam1^{em1(IMPC)Ccpcz} (C57BL/6N-Nfam1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Nfat5^tm1.1Itl/\Nfat5^tm1.1Itl \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac * FVB/N)	abnormal lymphatic vessel morphology	J:201429
\Nfat5^tm1.1Joar/\Nfat5^tm1.1Joar \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal T cell physiology	J:148271
\Nfat5^tm1Rao/\Nfat5^tm1Rao (B6.129-Nfat5^tm1Rao)	tubulointerstitial nephritis	J:88636
\Nfat5^tm1Snh/\Nfat5⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immunoglobulin level	J:91482
	decreased IgG level	J:91482
	decreased T cell proliferation	J:91482
	spleen hypoplasia	J:91482
	thymus hypoplasia	J:91482
\Nfatc1^tm1.1Fbs/\Nfatc1^tm1.1Fbs (C57BL/6-Nfatc1^tm1.1Fbs)	decreased interferon-gamma secretion	J:305649
	decreased interleukin-17 secretion	J:305649
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:305649
	decreased susceptibility to graft versus host disease	J:305649
	immune system phenotype	J:305649
	increased interleukin-2 secretion	J:305649
	increased regulatory T cell number	J:305649
\Nfatc1^tm1Glm/\Nfatc1^tm2Glm (chimera involves: 129S2/SvPas)	abnormal B cell physiology	J:78376
	abnormal immune system physiology	J:78376
	abnormal immunoglobulin level	J:78376
	abnormal interferon-gamma secretion	J:78376
	abnormal interleukin-2 secretion	J:78376
	abnormal lymphocyte cell number	J:78376
	abnormal lymphocyte physiology	J:78376
	abnormal T cell physiology	J:78376
	abnormal T-helper 2 physiology	J:78376
	decreased double-positive T cell number	J:78376
	decreased IgE level	J:78376
	decreased IgG1 level	J:78376
	decreased IgG2b level	J:78376
	decreased IgG3 level	J:78376
	decreased immunoglobulin level	J:78376
	decreased interleukin-4 secretion	J:78376
	decreased lymphocyte cell number	J:78376
	increased double-negative T cell number	J:78376
	increased IgA level	J:78376
	increased IgG2a level	J:78376
	increased IgM level	J:78376
	increased immunoglobulin level	J:78376
\Nfatc1^tm1Rao/\Nfatc1^tm1Rao \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c)	abnormal B cell calcium ion homeostasis	J:177319
	abnormal class switch recombination	J:177319
	abnormal marginal zone B cell physiology	J:177319
	decreased B cell number	J:177319
	decreased B cell proliferation	J:177319
	decreased B-1a cell number	J:177319
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:177319
	increased B cell apoptosis	J:177319
\Nfatc1^tm1Rao/\Nfatc1^tm1Rao \Nfatc2^tm1Rao/\Nfatc2^tm1Rao \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c)	abnormal B cell physiology	J:177319
	decreased interleukin-2 secretion	J:177319
\Nfatc1^tm1Rao/\Nfatc1^tm1Rao \Tg(Fcer2a-cre)5Mbu/0 (involves: C57BL/6 * CBA)	abnormal B cell physiology	J:177319
	abnormal class switch recombination	J:177319
	decreased B cell proliferation	J:177319
	decreased IgG2a level	J:177319
	decreased IgG3 level	J:177319
	decreased IgM level	J:177319
	decreased interleukin-2 secretion	J:177319
	increased IgM level	J:177319
	increased interleukin-10 secretion	J:177319
\Nfatc1^tm3Glm/\Nfatc1^tm3Glm \Sh3bp2^tm1Bjro/\Sh3bp2^tm1Bjro \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal osteoclast differentiation	J:144598
	decreased osteoclast cell number	J:144598
	liver inflammation	J:144598
	lung inflammation	J:144598
	lymph node inflammation	J:144598
	stomach inflammation	J:144598
\Nfatc1^tm3Glm/\Nfatc1^tm3Glm \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:144598
	decreased osteoclast cell number	J:144598
\Nfatc2^m1Anu/\Nfatc2^m1Anu (C57BL/6NCrlAnu-Nfatc2^m1Anu)	immune system phenotype	J:104190
\Nfatc2^tm1Glm/\Nfatc2^tm1Glm \Nfatc3^{tm1c(EUCOMM)Hmgu}/\Nfatc3^{tm1c(EUCOMM)Hmgu} \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6N * CBA)	decreased interleukin-2 secretion	J:346703
\Nfatc2^tm1Glm/\Nfatc2^tm1Glm \Nfatc3^tm1Glm/\Nfatc3^tm1Glm (involves: 129S2/SvPas)	abnormal lymph node morphology	J:51339
	abnormal lymphocyte cell number	J:51339
	blepharitis	J:51339
	decreased T cell number	J:51339
	enlarged spleen	J:51339
	increased B cell number	J:51339
	increased inflammatory response	J:51339
	increased T cell number	J:51339
	interstitial pneumonia	J:51339
\Nfatc2^tm1Rao/\Nfatc2^tm1Rao (B6.Cg-Nfatc2^tm1Rao)	abnormal mast cell physiology	J:78089
	decreased interleukin-4 secretion	J:78089
	decreased interleukin-13 secretion	J:78089
	decreased tumor necrosis factor secretion	J:78089
\Nfatc2^tm1Rao/\Nfatc2^tm1Rao \Nfatc3^tm1Grc/\Nfatc3^tm1Grc \Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal double-negative T cell morphology	J:141917
	abnormal T cell differentiation	J:141917
	increased T cell apoptosis	J:141917
\Nfatc2^tm1Srf/\Nfatc2^tm1Srf (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell number	J:110686
	abnormal B cell physiology	J:110686
	abnormal lymph node B cell domain morphology	J:110686
	abnormal lymphocyte physiology	J:110686
	abnormal spleen germinal center morphology	J:110686
	abnormal T cell physiology	J:110686
	abnormal thymus involution	J:110686
	enlarged spleen	J:110686
	enlarged thymus	J:110686
	increased activated T cell number	J:110686
	thymus hyperplasia	J:110686
\Nfatc2^tm1Srf/\Nfatc2^tm1Srf (involves: 129P2/OlaHsd)	abnormal immune system organ morphology	J:45252
	abnormal immune system physiology	J:45252
	abnormal interleukin secretion	J:45252
	abnormal lymph node morphology	J:45252
	abnormal T cell physiology	J:45252
	enlarged lymph nodes	J:45252
	enlarged spleen	J:45252
	increased B cell number	J:45252
	increased lymphocyte cell number	J:45252
	increased T cell number	J:45252
	lymph node hyperplasia	J:45252
\Nfatc2^tm1Srf/\Nfatc2^tm1Srf (B6.Cg-Nfatc2^tm1Srf)	abnormal CD4-positive, alpha-beta T cell physiology	J:86279
	abnormal T-helper 1 physiology	J:86279
	abnormal T-helper 2 physiology	J:86279
	decreased interferon-gamma secretion	J:86279
	increased IgE level	J:86279
	increased IgG1 level	J:86279
	increased immunoglobulin level	J:86279
	increased interleukin-4 secretion	J:86279
	increased interleukin-5 secretion	J:86279
\Nfatc2ip^em1(IMPC)Ics/\Nfatc2ip^em1(IMPC)Ics (C57BL/6N-Nfatc2ip^em1(IMPC)Ics/Ics)	increased eosinophil cell number	J:211773
\Nfatc2ip^tm1.1Glm/\Nfatc2ip^tm1.1Glm (either: B6.129-Nfatc2ip^tm1.1Glm or C.129-Nfatc2ip^tm1.1Glm)	abnormal interleukin secretion	J:157559
	abnormal leukocyte morphology	J:157559
	abnormal T-helper 2 physiology	J:157559
	decreased circulating interleukin-4 level	J:157559
	decreased interferon-gamma secretion	J:157559
	decreased interleukin-3 secretion	J:157559
	decreased interleukin-4 secretion	J:157559
	decreased interleukin-5 secretion	J:157559
	decreased interleukin-13 secretion	J:157559
	decreased mast cell number	J:157559
	decreased T-helper 2 cell number	J:157559
	increased susceptibility to parasitic infection	J:157559
\Nfatc3^tm1.1Grc/\Nfatc3^tm1.1Grc (involves: C57BL/6)	immune system phenotype	J:141917
\Nfatc3^tm1.1Grc/\Nfatc3^tm1.1Grc (involves: C57BL/6)	lymph node hypoplasia	J:141917
\Nfatc3^tm1Glm/\Nfatc3^tm1Glm \Tg(DO11.10)10Dlo/? (involves: 129S2/SvPas * BALB/c * C3H * C57BL/6)	decreased double-positive T cell number	J:50124
	increased double-negative T cell number	J:50124
	small thymus	J:50124
\Nfatc3^tm1Grc/\Nfatc3^tm1Grc \Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal T cell differentiation	J:141917
	decreased CD4-positive, alpha-beta T cell number	J:141917
	decreased CD8-positive, alpha-beta T cell number	J:141917
	decreased thymocyte number	J:141917
	increased double-negative T cell number	J:141917
	increased T cell apoptosis	J:141917
	lymph node hypoplasia	J:141917
	thymus hypoplasia	J:141917
\Nfe2^{em1(IMPC)Ccpcz}/\Nfe2⁺ (C57BL/6NCrl-Nfe2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Nfe2^tm1Sho/\Nfe2⁺ (C.129S4-Nfe2^tm1Sho)	enlarged spleen	J:125982
\Nfe2^tm1Sho/\Nfe2⁺ (C.129S4-Nfe2^tm1Sho)	increased susceptibility to Retroviridae infection	J:125982
\Nfe2^tm1Sho/\Nfe2^tm1Sho (involves: 129/Sv * 129S4/SvJae)	increased osteoclast cell number	J:111270
\Nfe2l1^tm1Jefc/\Nfe2l1^tm1Ywk \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129X1/SvJ * C57BL/6J)	liver inflammation	J:97188
\Nfe2l2^{em1(IMPC)Ccpcz}/\Nfe2l2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nfe2l2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Nfe2l2^tm1.1Sred/\Nfe2l2^tm1.1Sred \Tg(Scgb1a1-cre)1Grau/0 (involves: C57BL/6 * C57BL/6J)	decreased interleukin-1 beta secretion	J:191916
	decreased tumor necrosis factor secretion	J:191916
\Nfe2l2^tm1Mym/\Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * ICR)	abnormal macrophage physiology	J:118068
	decreased CD4-positive, alpha-beta T cell number	J:104016
	decreased T cell number	J:104016
	enlarged lymph nodes	J:104016
	glomerulonephritis	J:104016
	increased anti-double stranded DNA antibody level	J:104016
	increased anti-nuclear antigen antibody level	J:104016
	increased IgG level	J:104016
	increased IgM level	J:104016
	increased spleen weight	J:104016
	lung inflammation	J:118068
\Nfe2l2^tm1Mym/\Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to induced colitis	J:116676
\Nfe2l2^tm1Mym/\Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * CD-1)	increased acute inflammation	J:122813
\Nfe2l2^tm1Mym/\Nfe2l2^tm1Mym (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:150597
	increased circulating interleukin-6 level	J:136120
	increased circulating tumor necrosis factor level	J:136120
	increased susceptibility to experimental autoimmune uveoretinitis	J:150597
	liver inflammation	J:136120
\Nfe2l2^tm1Ywk/\Nfe2l2^tm1Ywk (involves: 129X1/SvJ)	abnormal spleen physiology	J:91407
	abnormal splenocyte physiology	J:91407
	decreased circulating interleukin-1 beta level	J:100106
	enlarged spleen	J:91407
	increased circulating interleukin-1 beta level	J:100106
	increased macrophage cell number	J:100106
	increased spleen weight	J:91407
	increased splenocyte apoptosis	J:91407
\Nfe2l2^tm1Ywk/\Nfe2l2^tm1Ywk (B6.129X1-Nfe2l2^tm1Ywk/J)	abnormal neutrophil physiology	J:233699
\Nfe2l2^tm1Ywk/\Nfe2l2^tm1Ywk (B6.129X1-Nfe2l2^tm1Ywk)	increased anti-double stranded DNA antibody level	J:165602
\Nfic^{em1(IMPC)Ccpcz}/\Nfic^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nfic^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
\Nfil3^{tm1.1(KOMP)Vlcg}/\Nfil3^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nfil3^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
\Nfil3^tm1.1Brad/\Nfil3⁺ (B6.Cg-Nfil3^tm1.1Brad)	decreased NK cell number	J:152774
\Nfil3^tm1.1Brad/\Nfil3^tm1.1Brad (B6.Cg-Nfil3^tm1.1Brad)	abnormal NK cell differentiation	J:152774
	decreased interferon-gamma secretion	J:152774
	decreased NK cell number	J:152774
	immune system phenotype	J:152774
	impaired natural killer cell mediated cytotoxicity	J:152774
	increased memory T cell number	J:152774
	increased NK T cell number	J:152774
\Nfil3^tm1.1Kubo/\Nfil3^tm1.1Kubo (B6.Cg-Nfil3^tm1.1Kubo)	abnormal interleukin secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:172134, J:184570
	decreased interleukin-13 secretion	J:172134, J:184570
	decreased interleukin-17 secretion	J:184570
	increased susceptibility to experimental autoimmune encephalomyelitis	J:172134
	increased susceptibility to induced colitis	J:172134
\Nfil3^tm1.2Kubo/\Nfil3^tm1.2Kubo \Tg(Itgax-cre)1-1Reiz/0 (involves: 129 * C57BL/6 * CBA)	immune system phenotype	J:334296
\Nfil3^tm1Look/\Nfil3^tm1Look (B6.129X1-Nfil3^tm1Look)	abnormal NK cell differentiation	J:155677
	decreased interferon-gamma secretion	J:155677
	decreased NK cell number	J:155677
	impaired natural killer cell mediated cytotoxicity	J:155677
\Nfil3^tm1Look/\Nfil3^tm1Look (involves: 129X1/SvJ)	immune system phenotype	J:209365
\Nfil3^tm1Pbro/\Nfil3^tm1Pbro (involves: 129S6/SvEvTac * C57BL/6)	abnormal class switch recombination	J:156521
	decreased IgE level	J:156521
	decreased IgG1 level	J:156521
	decreased interleukin-4 secretion	J:156521
	immune system phenotype	J:156521
\Nfil3^tm1Pbro/\Nfil3^tm1Pbro (B6.129S6-Nfil3^tm1Pbro)	abnormal circulating cytokine level	J:209365
	abnormal cytokine secretion	J:209365
	abnormal leukocyte morphology	J:209365
	abnormal plasma cell morphology	J:209365
	colitis	J:209365
	decreased NK cell number	J:209365
	increased circulating interferon-gamma level	J:209365
	increased circulating interleukin-10 level	J:209365
	increased circulating interleukin-12b level	J:209365
	increased circulating interleukin-17 level	J:209365
	increased circulating tumor necrosis factor level	J:209365
	increased interferon-gamma secretion	J:209365
	increased interleukin-10 secretion	J:209365
	increased interleukin-12b secretion	J:209365
	increased interleukin-17 secretion	J:209365
	increased macrophage cytokine production	J:209365
	increased T-helper 17 cell number	J:209365
	increased tumor necrosis factor secretion	J:209365
\Nfil3^tm1Pbro/\Nfil3^tm1Pbro \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:209365
\Nfkb1^M1Btlr/\Nfkb1⁺ (C57BL/6J-Nfkb1^M1Btlr)	decreased IgG level	J:216054
\Nfkb1^M1Btlr/\Nfkb1⁺ (C57BL/6J-Nfkb1^M1Btlr)	impaired humoral immune response	J:216054
\Nfkb1^M1Btlr/\Nfkb1^M1Btlr (C57BL/6J-Nfkb1^M1Btlr)	decreased IgG level	J:216054
\Nfkb1^M1Btlr/\Nfkb1^M1Btlr (C57BL/6J-Nfkb1^M1Btlr)	impaired humoral immune response	J:216054
\Nfkb1^m2Btlr/\Nfkb1⁺ (C57BL/6J-Nfkb1^m2Btlr)	abnormal humoral immune response	J:254822
	decreased central memory CD4-positive, alpha-beta T cell number	J:254822
	decreased effector memory CD4-positive, alpha-beta T cell number	J:254822
	decreased IgM level	J:254822
\Nfkb1^m2Btlr/\Nfkb1^m2Btlr (C57BL/6J-Nfkb1^m2Btlr)	abnormal humoral immune response	J:254822
	decreased CD8-positive, naive alpha-beta T cell number	J:254822
	decreased central memory CD4-positive, alpha-beta T cell number	J:254822
	decreased effector memory CD4-positive, alpha-beta T cell number	J:254822
	decreased IgE level	J:254822
	decreased IgG level	J:254822
	decreased IgM level	J:254822
	increased central memory CD8 positive, alpha-beta T cell number	J:254822
\Nfkb1^M3Btlr/\Nfkb1⁺ (C57BL/6J-Nfkb1^M3Btlr)	abnormal humoral immune response	J:254821
	decreased IgE level	J:254821
	decreased IgG level	J:254821
	increased central memory CD8 positive, alpha-beta T cell number	J:254821
\Nfkb1^M3Btlr/\Nfkb1^M3Btlr (C57BL/6J-Nfkb1^M3Btlr)	abnormal humoral immune response	J:254821
	decreased IgE level	J:254821
	decreased IgG level	J:254821
	increased central memory CD8 positive, alpha-beta T cell number	J:254821
	increased susceptibility to induced colitis	J:254821
\Nfkb1^M4Btlr/\Nfkb1^M4Btlr (C57BL/6J-Nfkb1^M4Btlr)	decreased B-1 B cell number	J:265169
\Nfkb1^M5Btlr/\Nfkb1^M5Btlr (C57BL/6J-Nfkb1^M5Btlr)	decreased B-1a cell number	J:272117
	decreased IgE level	J:272117
	decreased interleukin-1 beta secretion	J:272117
\Nfkb1^M6Btlr/\Nfkb1^M6Btlr (C57BL/6J-Nfkb1^M6Btlr)	decreased IgE level	J:272148
\Nfkb1^{tm1a(KOMP)Wtsi}/\Nfkb1^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Nfkb1^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:175295, J:165965
\Nfkb1^{tm1a(KOMP)Wtsi}/\Nfkb1^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased IgA level	J:213427
	decreased IgG1 level	J:213427
	decreased NK cell number	J:213427
	decreased regulatory T cell number	J:213427
	increased leukocyte cell number	J:213427
	increased susceptibility to bacterial infection	J:213427
	lymphoid hyperplasia	J:213427
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal (B6;129P-Nfkb1^tm1Bal/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:118907
	abnormal cytokine secretion	J:79107
	abnormal dendritic cell physiology	J:118907
	abnormal macrophage physiology	J:118907
	abnormal professional antigen presenting cell physiology	J:118907
	decreased susceptibility to autoimmune diabetes	J:118907
	immune system phenotype	J:118907
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:30268
	abnormal humoral immune response	J:37184
	abnormal Peyer's patch follicle morphology	J:77049
	abnormal Peyer's patch germinal center morphology	J:77049
	abnormal Peyer's patch T cell area morphology	J:77049
	cecum inflammation	J:67107
	decreased B cell proliferation	J:37184, J:30268
	decreased IgA level	J:37184
	decreased IgE level	J:37184
	decreased IgG1 level	J:37184
	decreased IgM level	J:30268
	decreased immunoglobulin level	J:37184
	decreased interleukin-6 secretion	J:37184
	decreased myeloid dendritic cell number	J:77049
	decreased Peyer's patch number	J:77049
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:37184
	increased susceptibility to bacterial infection	J:37184, J:67107
	increased susceptibility to bacterial infection induced morbidity/mortality	J:37184
	large intestinal inflammation	J:67107
	peritoneal inflammation	J:67107
	small Peyer's patches	J:77049
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal (involves: 129P2/OlaHsd)	decreased marginal zone B cell number	J:65246
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal (involves: 129P2/OlaHsd)	immune system phenotype	J:113514
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal (B6.Cg-Nfkb1^tm1Bal/J)	abnormal B cell physiology	J:113556
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal \Nfkb2^tm1Sbn/\Nfkb2^tm1Sbn (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal immune system organ morphology	J:45119
	abnormal macrophage physiology	J:45119
	abnormal osteoclast differentiation	J:45119
	abnormal spleen morphology	J:45119
	abnormal thymus cortex morphology	J:45119
	abnormal thymus medulla morphology	J:45119
	absent lymph nodes	J:45119
	absent spleen white pulp	J:45119
	arrested B cell differentiation	J:45119
	decreased B cell number	J:45119
	decreased CD4-positive, alpha-beta T cell number	J:45119
	decreased CD8-positive, alpha-beta T cell number	J:45119
	decreased dendritic cell number	J:45119
	decreased double-positive T cell number	J:45119
	decreased mature B cell number	J:45119
	decreased osteoclast cell number	J:45119
	decreased single-positive T cell number	J:45119
	decreased T cell number	J:45119
	increased granulocyte number	J:45119
	increased macrophage cell number	J:45119
	thymus hypoplasia	J:45119
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal \Rel^tm1Grd/\Rel^tm1Grd (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal immune system physiology	J:113514
	decreased interleukin-12 secretion	J:113514
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal \Rela^tm1Bal/\Rela⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	cecum inflammation	J:67107
	increased susceptibility to bacterial infection	J:67107
	large intestinal inflammation	J:67107
	peritoneal inflammation	J:67107
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal \Rela^tm1Bal/\Rela^tm1Bal (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal dendritic cell differentiation	J:113514
	decreased dendritic cell number	J:113514
\Nfkb1^tm1Bal/\Nfkb1^tm1Bal \Tg(Tnfsf13b)1Fma/? (B6.Cg-Nfkb1^tm1Bal Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	abnormal class switch recombination	J:113556
	decreased marginal zone B cell number	J:113556
	immune system phenotype	J:113556
	increased transitional stage B cell number	J:113556
\Nfkb1^tm1Brv/\Nfkb1^tm1Brv (involves: 129S1/Sv)	abnormal cytokine secretion	J:46912
	abnormal humoral immune response	J:46912
	abnormal inflammatory response	J:46912
	abnormal lymph organ size	J:46912
	abnormal lymphocyte physiology	J:46912
	decreased IgG3 level	J:46912
	decreased interleukin-2 secretion	J:46912
	decreased interleukin-4 secretion	J:46912
	decreased single-positive T cell number	J:46912
	decreased T cell proliferation	J:46912
	decreased tumor necrosis factor secretion	J:46912
	enlarged lymph nodes	J:46912
	enlarged spleen	J:46912
	increased B cell proliferation	J:46912
	increased IgE level	J:46912
	increased IgG1 level	J:46912
	increased immunoglobulin level	J:46912
	increased susceptibility to bacterial infection	J:46912
	liver inflammation	J:46912
	lung inflammation	J:46912
	myeloid hyperplasia	J:46912
\Nfkb1^tm1Brv/\Nfkb1^tm1Brv (involves: 129S1/Sv * C57BL/6)	decreased osteoclast cell number	J:44112
\Nfkb1^tm1Brv/\Nfkb1^tm1Brv \Nfkb2^tm1Brv/\Nfkb2⁺ (involves: 129S1/Sv * C57BL/6)	abnormal osteoclast differentiation	J:44112
	decreased osteoclast cell number	J:44112
\Nfkb1^tm1Brv/\Nfkb1^tm1Brv \Nfkb2^tm1Brv/\Nfkb2^tm1Brv (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:44112
	abnormal osteoclast differentiation	J:44112
	decreased interleukin-6 secretion	J:44112
	decreased osteoclast cell number	J:44112
	increased macrophage cell number	J:44112
\Nfkb1^tm1Sley/\Nfkb1^tm1Sley (involves: 129S4/SvJae * 129S8/SvEv)	abnormal inguinal lymph node morphology	J:142340
	absent inguinal lymph nodes	J:142340
	decreased circulating interleukin-2 level	J:142340
	decreased memory T cell number	J:142340
	decreased regulatory T cell number	J:142340
	decreased T cell proliferation	J:142340
	small inguinal lymph nodes	J:142340
\Nfkb1^tm1Sley/\Nfkb1^tm1Sley (involves: 129S4/SvJae * 129S8/SvEv * C57BL/6)	decreased memory T cell number	J:142340
	decreased NK T cell number	J:142340
	decreased regulatory T cell number	J:142340
\Nfkb1^tm1Sley/\Nfkb1^tm1Sley (involves: 129S4/SvJae)	decreased tumor necrosis factor secretion	J:196528
\Nfkb2^Lym1/\Nfkb2⁺ (BALB/c-Nfkb2^Lym1)	abnormal lymph node morphology	J:154812
	abnormal mesenteric lymph node morphology	J:154812
	abnormal spleen white pulp morphology	J:154812
	absent axillary lymph nodes	J:154812
	absent brachial lymph nodes	J:154812
	absent cervical lymph nodes	J:154812
	absent inguinal lymph nodes	J:154812
	absent Peyer's patches	J:154812
	decreased lymph node number	J:154812
	increased lymphocyte cell number	J:154812
	liver inflammation	J:154812
	lung inflammation	J:154812
\Nfkb2^Lym1/\Nfkb2⁺ (involves: BALB/c)	abnormal B cell differentiation	J:188560
\Nfkb2^Lym1/\Nfkb2⁺ \Otub1^{tm1c(EUCOMM)Hmgu}/\Otub1^{tm1c(EUCOMM)Hmgu} \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/6N)	immune system phenotype	J:280549
\Nfkb2^Lym1/\Nfkb2^Lym1 (involves: BALB/c)	abnormal class switch recombination	J:154812
	abnormal lymph node morphology	J:154812
	abnormal osteoclast differentiation	J:154812
	abnormal peripheral lymph node morphology	J:154812
	abnormal plasma cell differentiation	J:154812
	abnormal spleen follicular dendritic cell network	J:154812
	abnormal spleen periarteriolar lymphoid sheath morphology	J:154812
	abnormal spleen primary B follicle morphology	J:154812
	abnormal spleen white pulp morphology	J:154812
	abnormal T cell differentiation	J:154812
	abnormal thymus cell ratio	J:154812
	abnormal thymus physiology	J:154812
	abnormal thymus size	J:154812
	absent axillary lymph nodes	J:154812
	absent brachial lymph nodes	J:154812
	absent cervical lymph nodes	J:154812
	absent inguinal lymph nodes	J:154812
	absent mesenteric lymph nodes	J:154812
	absent Peyer's patches	J:154812
	autoimmune response	J:154812
	decreased B cell proliferation	J:154812
	decreased follicular B cell number	J:154812
	decreased IgA level	J:154812
	decreased IgG1 level	J:154812
	decreased IgG2b level	J:154812
	decreased IgM level	J:154812
	decreased immunoglobulin level	J:154812
	decreased lymph node number	J:154812
	decreased marginal zone B cell number	J:154812
	decreased mature B cell number	J:154812
	decreased transitional stage B cell number	J:154812
	enlarged spleen	J:154812
	increased CD4-positive, alpha-beta T cell number	J:154812
	increased CD8-positive, alpha-beta T cell number	J:154812
	increased double-negative T cell number	J:154812
	increased double-positive T cell number	J:154812
	increased spleen red pulp amount	J:154812
	increased spleen weight	J:154812
	increased transitional stage B cell number	J:154812
	liver inflammation	J:154812
	lung inflammation	J:154812
\Nfkb2^m2Btlr/\Nfkb2^m2Btlr (C57BL/6J-Nfkb2^m2Btlr)	increased B-1a cell number	J:221493
\Nfkb2^m3Btlr/\Nfkb2^m3Btlr (C57BL/6J-Nfkb2^m3Btlr)	abnormal B cell differentiation	J:274960
	abnormal CD4-positive T cell differentiation	J:274960
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274960
	abnormal T cell differentiation	J:274960
	decreased B cell number	J:274960
	decreased CD4-positive, alpha-beta T cell number	J:274960
	decreased effector memory CD8-positive, alpha-beta T cell number	J:274960
	decreased NK cell number	J:274960
	increased B-1 B cell number	J:274960
	increased CD4-positive, alpha-beta T cell number	J:274960
	increased CD8-positive, alpha-beta T cell number	J:274960
	increased CD8-positive, naive alpha-beta T cell number	J:274960
	increased T cell number	J:274960
\Nfkb2^M4Btlr/\Nfkb2^M4Btlr (C57BL/6J-Nfkb2^M4Btlr)	increased CD4-positive, alpha-beta T cell number	J:274961
	increased CD8-positive, alpha-beta T cell number	J:274961
	increased T cell number	J:274961
\Nfkb2^m5Btlr/\Nfkb2^m5Btlr (C57BL/6J-Nfkb2^m5Btlr)	increased B-1 B cell number	J:274962
\Nfkb2^tm1Brv/\Nfkb2^tm1Brv (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:43469
	abnormal lymph node B cell domain morphology	J:43469
	abnormal lymph node cortex morphology	J:43469
	abnormal lymphocyte cell number	J:43469
	abnormal T cell number	J:43469
	abnormal T cell subpopulation ratio	J:43469
	abnormal thymus corticomedullary boundary morphology	J:43469
	decreased double-positive T cell number	J:43469
	decreased spleen weight	J:43469
	enlarged lymph nodes	J:43469
	increased B cell proliferation	J:43469
	increased granulocyte number	J:43469
	increased interleukin-2 secretion	J:43469
	increased interleukin-4 secretion	J:43469
	increased interleukin-10 secretion	J:43469
	increased T cell proliferation	J:43469
	increased tumor necrosis factor secretion	J:43469
	intermingled spleen red and white pulp	J:43469
	spleen atrophy	J:43469
	spleen hypoplasia	J:43469
	thymus atrophy	J:43469
\Nfkb2^tm1Rsch/\Nfkb2^tm1Rsch (involves: 129P2/OlaHsd)	abnormal myeloid dendritic cell morphology	J:77049
	abnormal Peyer's patch follicle morphology	J:77049
	abnormal Peyer's patch germinal center morphology	J:77049
	abnormal Peyer's patch morphology	J:77049
	abnormal Peyer's patch T cell area morphology	J:77049
	decreased B cell number	J:77049
	decreased dendritic cell number	J:77049
	decreased myeloid dendritic cell number	J:77049
	increased plasmacytoid dendritic cell number	J:77049
	small Peyer's patches	J:77049
\Nfkb2^tm1Sbn/\Nfkb2^tm1Sbn (involves: 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:45437
	abnormal immunoglobulin level	J:45437
	abnormal lymphocyte cell number	J:45437
	abnormal metallophilic macrophage morphology	J:45437
	abnormal spleen B cell follicle morphology	J:45437
	abnormal spleen marginal zone macrophage morphology	J:45437
	abnormal spleen marginal zone morphology	J:45437
	abnormal spleen white pulp morphology	J:45437
	absent spleen germinal center	J:45437
	decreased B cell number	J:45437
	decreased IgA level	J:45437
	decreased IgG1 level	J:45437
	decreased IgG2a level	J:45437
	decreased IgG2b level	J:45437
	increased IgM level	J:45437
	increased susceptibility to parasitic infection	J:45437
	increased T cell number	J:45437
\Nfkb2^tm2Brv/\Nfkb2^tm2Brv (involves: 129S1/Sv * C57BL/6)	abnormal lymph node morphology	J:76380
	abnormal metallophilic macrophage morphology	J:76380
	abnormal spleen morphology	J:76380
	absent lymph node germinal center	J:76380
	absent spleen germinal center	J:76380
	absent spleen marginal zone	J:76380
	decreased B cell number	J:76380
	decreased B cell proliferation	J:76380
	decreased IgA level	J:76380
	decreased IgG1 level	J:76380
	decreased IgG3 level	J:76380
	increased CD4-positive, alpha-beta T cell number	J:76380
	increased CD8-positive, alpha-beta T cell number	J:76380
	increased IgG2a level	J:76380
	increased IgM level	J:76380
	increased splenocyte apoptosis	J:76380
\Nfkb2^tm2Brv/\Nfkb2^tm2Brv (involves: 129S1/Sv)	abnormal gamma-delta T cell morphology	J:169863
\Nfkb2^tm2Brv/\Nfkb2^tm2Brv (involves: 129S1/Sv)	decreased gamma-delta T cell number	J:169863
\Nfkb2^tm2Brv/\Nfkb2^tm2Brv \Tg(Tnfsf13b)1Fma/? (B6.Cg-Nfkb2^tm2Brv Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	absent spleen marginal zone	J:113556
	decreased marginal zone B cell number	J:113556
	immune system phenotype	J:113556
\Nfkb2^tm2Brv/\Nfkb2^tm2Brv \Traf3^tm1Bal/\Traf3^tm1Bal (involves: 129S1/Sv * 129S4/SvJae * C57BL/6)	immune system phenotype	J:124635
\Nfkb2^xdr/\Nfkb2^xdr (C57BL/6JSfdAnu-Nfkb2^xdr/Anu)	abnormal metallophilic macrophage morphology	J:79725
	abnormal peripheral lymph node morphology	J:79725
	abnormal spleen follicular dendritic cell network	J:79725
	abnormal spleen morphology	J:79725
	abnormal spleen secondary B follicle morphology	J:79725
	decreased B-2 B cell number	J:79725
	decreased follicular B cell number	J:79725
	decreased marginal zone B cell number	J:79725
	decreased mature B cell number	J:79725
	decreased transitional stage T2 B cell number	J:79725
	increased B-1 B cell number	J:79725
\Nfkb2^xdr/\Nfkb2^xdr (involves: C57BL/6JSfdAnu * C57BL/10Sg * C57BR/cd * NOD)	decreased B cell number	J:79725
\Nfkbia^tm1.1Kbp/\Nfkbia^tm1.1Kbp (involves: 129P2/OlaHsd * C57BL/6)	abnormal granulocyte morphology	J:97945
	increased granulocyte number	J:97945
\Nfkbia^tm1.1Pjc/\Nfkbia^tm1.1Pjc (involves: C57BL/6)	abnormal circulating cytokine level	J:163686
	abnormal T cell activation	J:163686
	abnormal T cell number	J:163686
	autoimmune response	J:163686
	chronic inflammation	J:163686
	decreased CD4-positive, alpha-beta T cell number	J:163686
	decreased CD8-positive, alpha-beta T cell number	J:163686
	increased activated T cell number	J:163686
	increased anti-insulin autoantibody level	J:163686
	increased anti-nuclear antigen antibody level	J:163686
	increased circulating interleukin-1 alpha level	J:163686
	increased circulating interleukin-17 level	J:163686
	increased circulating tumor necrosis factor level	J:163686
	increased double-positive T cell number	J:163686
	increased memory T cell number	J:163686
	increased susceptibility to bacterial infection induced morbidity/mortality	J:163686
	increased T cell apoptosis	J:163686
	increased T cell proliferation	J:163686
	increased thymocyte number	J:163686
\Nfkbia^tm1.1Smiy/\Nfkbia⁺ (B6.129-Nfkbia^tm1.1Smiy)	decreased B cell number	J:168977
	decreased follicular B cell number	J:168977
	decreased marginal zone B cell number	J:168977
	decreased transitional stage T2 B cell number	J:168977
	increased pro-B cell number	J:168977
	small Peyer's patches	J:168977
\Nfkbia^tm1.1Smiy/\Nfkbia^tm1.1Smiy (B6.129-Nfkbia^tm1.1Smiy)	abnormal B cell differentiation	J:168977
	abnormal marginal zone B cell morphology	J:168977
	decreased B cell number	J:168977
	decreased B cell proliferation	J:168977
	decreased B-2 B cell number	J:168977
	decreased CD4-positive, alpha-beta memory T cell number	J:168977
	decreased follicular B cell number	J:168977
	decreased IgA level	J:168977
	decreased IgG1 level	J:168977
	decreased IgG2b level	J:168977
	decreased marginal zone B cell number	J:168977
	decreased mature B cell number	J:168977
	decreased Peyer's patch number	J:168977
	decreased regulatory T cell number	J:168977
	decreased transitional stage T2 B cell number	J:168977
	increased activation-induced B cell apoptosis	J:168977
	increased immature B cell number	J:168977
	increased pre-B cell number	J:168977
	increased pro-B cell number	J:168977
	small Peyer's patches	J:168977
\Nfkbia^tm1Bal/\Nfkbia^tm1Bal (involves: 129S4/SvJae * C57BL/6J)	abnormal granulocyte differentiation	J:30058
	decreased double-positive T cell number	J:30058
	increased leukocyte cell number	J:30058
	spleen atrophy	J:30058
	thymus atrophy	J:30058
\Nfkbia^tm1Bal/\Nfkbia^tm1Bal \Nfkbie^tm1Syme/\Nfkbie^tm1Syme (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2)	abnormal B cell differentiation	J:88142
	abnormal T cell differentiation	J:88142
	decreased immature B cell number	J:88142
	decreased pre-B cell number	J:88142
	increased B cell apoptosis	J:88142
	increased T cell apoptosis	J:88142
\Nfkbia^tm1Fey/\Nfkbia^tm1Fey (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:110817
	abnormal humoral immune response	J:110817
	absent spleen germinal center	J:110817
	decreased double-negative T cell number	J:110817
	decreased T cell proliferation	J:110817
	decreased thymocyte number	J:110817
	increased B cell proliferation	J:110817
	increased IgA level	J:110817
	increased IgE level	J:110817
	increased IgG level	J:110817
	increased single-positive T cell number	J:110817
	small spleen	J:110817
	thymus atrophy	J:110817
\Nfkbia^tm1Stw/\Nfkbia^tm1Stw (involves: 129S1/Sv)	abnormal macrophage physiology	J:32527
	abnormal myelopoiesis	J:32527
	abnormal tumor necrosis factor level	J:32527
	dermatitis	J:32527
	increased macrophage cell number	J:32527
	increased monocyte cell number	J:32527
\Nfkbib^tm1.2Rsch/\Nfkbib^tm1.2Rsch (B6.129P2-Nfkbib^tm1.2Rsch)	abnormal cytokine secretion	J:176877
	abnormal immune system morphology	J:176877
	abnormal immune system physiology	J:176877
	abnormal interleukin-1 beta secretion	J:176877
	abnormal interleukin-6 secretion	J:176877
	abnormal tumor necrosis factor secretion	J:176877
	decreased B cell number	J:176877
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:176877
	increased macrophage cell number	J:176877
	increased marginal zone B cell number	J:176877
	increased memory T cell number	J:176877
\Nfkbib^tm1Bal/\Nfkbib^tm1Bal (B6.129S1-Nfkbib^tm1Bal)	decreased circulating interleukin-1 beta level	J:163302
	decreased circulating interleukin-6 level	J:163302
	decreased circulating tumor necrosis factor level	J:163302
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:163302
	decreased susceptibility to endotoxin shock	J:163302
	decreased susceptibility to induced arthritis	J:163302
	decreased tumor necrosis factor secretion	J:163302
\Nfkbid^m1Btlr/\Nfkbid^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	absent marginal zone B cells	J:185495
	decreased B cell proliferation	J:185495
	decreased B-1 B cell number	J:185495
	decreased B-1a cell number	J:185495
	decreased IgG1 level	J:185495
	decreased IgG3 level	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
	increased B cell apoptosis	J:185495
\Nfkbid^{tm1a(EUCOMM)Wtsi}/\Nfkbid⁺ (C57BL/6N-Nfkbid^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased B cell number	J:165965
\Nfkbid^{tm1a(EUCOMM)Wtsi}/\Nfkbid^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal class switch recombination	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
\Nfkbid^tm1Clay/\Nfkbid^tm1Clay (involves: 129S6/SvEvTac * C57BL/6)	abnormal NK cell physiology	J:132071
	abnormal thymocyte activation	J:132071
	decreased interferon-gamma secretion	J:132071
	decreased interleukin-2 secretion	J:132071
	decreased T cell proliferation	J:132071
\Nfkbid^tm1Ktak/\Nfkbid^tm1Ktak (involves: 129P2/OlaHsd * C57BL/6)	increased interferon-gamma secretion	J:113334
	increased interleukin-6 secretion	J:113334
	increased interleukin-12 secretion	J:113334
	increased interleukin-12b secretion	J:113334
	increased susceptibility to endotoxin shock	J:113334
	increased susceptibility to induced colitis	J:113334
\Nfkbie^tm1Syme/\Nfkbie^tm1Syme (either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal double-negative T cell morphology	J:88538
	increased IgG1 level	J:88538
	increased IgM level	J:88538
\Nfkbiz^tm1.1Muta/\Nfkbiz^tm1.1Muta \Tg(CAG-cre)13Miya/? (involves: C57BL/6)	dermatitis	J:194832
\Nfkbiz^tm1.1Muta/\Nfkbiz^tm1.1Muta \Tg(KRT5-cre)1Tak/? (involves: C3H * C57BL/6)	dermatitis	J:194832
\Nfkbiz^tm1.1Muta/\Nfkbiz^tm1.1Muta \Tg(Lck-cre)1Jtak/? (involves: C57BL/6)	immune system phenotype	J:194832
\Nfkbiz^tm1Aki/\Nfkbiz⁺ \Stat6^tm1Aki/\Stat6^tm1Aki (C.129P2-Stat6^tm1Aki Nfkbiz^tm1Aki)	skin inflammation	J:141704
\Nfkbiz^tm1Aki/\Nfkbiz^tm1Aki (involves: 129P2/OlaHsd)	abnormal cytokine secretion	J:91297
	abnormal immune system organ morphology	J:194832
	abnormal immune system physiology	J:194832
	abnormal leukocyte physiology	J:91297
	abnormal lymph node cell ratio	J:194832
	abnormal lymphocyte morphology	J:194832
	abnormal T-helper 1 cell morphology	J:194832
	abnormal tumor necrosis factor secretion	J:91297
	blepharitis	J:96363
	conjunctivitis	J:96363
	corneal limbitis	J:96363
	decreased interleukin-6 secretion	J:91297
	decreased interleukin-12 secretion	J:91297
	dermatitis	J:194832, J:91297
	enlarged lymph nodes	J:194832
	enlarged spleen	J:194832
	eye inflammation	J:96363
	increased immunoglobulin level	J:194832
	interstitial pneumonia	J:194832
	lacrimal gland inflammation	J:194832
	periocular dermatitis	J:194832
\Nfkbiz^tm1Aki/\Nfkbiz^tm1Aki (C.129P2-Nfkbiz^tm1Aki)	blepharitis	J:141704
	conjunctivitis	J:141704
	dermatitis	J:141704
	eye inflammation	J:141704
	increased IgE level	J:141704
	perioral dermatitis	J:141704
	skin inflammation	J:141704
\Nfkbiz^tm1Aki/\Nfkbiz^tm1Aki \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:194832
\Nfkbiz^tm1Aki/\Nfkbiz^tm1Aki \Stat6^tm1Aki/\Stat6^tm1Aki (C.129P2-Stat6^tm1Aki Nfkbiz^tm1Aki)	blepharitis	J:141704
	dermatitis	J:141704
	eye inflammation	J:141704
	skin inflammation	J:141704
\Nfkbiz^tm1Aki/\Nfkbiz^tm1Aki \Tnf^tm1Sek/\Tnf^tm1Sek (involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)	conjunctivitis	J:194832
	dermatitis	J:194832
\Nfkbiz^tm1Mamo/\Nfkbiz^tm1Mamo (involves: 129S7/SvEvBrd)	dermatitis	J:95040
\Nfkbiz^tm1Mamo/\Nfkbiz^tm1Mamo (involves: 129S7/SvEvBrd)	increased IgE level	J:95040
\Ngfr^tm1Jae/\Ngfr^tm1Jae (B6.129S4-Ngfr^tm1Jae)	abnormal Kupffer cell morphology	J:120368
\Ngfr^tm1Jae/\Ngfr^tm1Jae (B6.129S4-Ngfr^tm1Jae)	increased susceptibility to experimental autoimmune encephalomyelitis	J:112769
\Ngfr^tm1Jae/\Ngfr^tm1Jae (involves: 129S4/SvJae)	abnormal tumor necrosis factor level	J:157549
\Ngp^{tm1b(KOMP)Wtsi}/\Ngp^{tm1b(KOMP)Wtsi} (C57BL/6N-Ngp^{tm1b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
\Nhej1^tm1.1Ics/\Nhej1⁺ (involves: 129 * C57BL/6)	decreased thymocyte number	J:194422
\Nhej1^tm1.1Ics/\Nhej1^tm1.1Ics (involves: 129 * C57BL/6)	abnormal T cell receptor V(D)J recombination	J:194422
	decreased lymphocyte cell number	J:194422
	decreased NK T cell number	J:194422
	decreased thymocyte number	J:194422
	increased thymocyte apoptosis	J:194422
\Nhej1^tm1.1Ics/\Nhej1^tm1.1Ics \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	abnormal T cell receptor V(D)J recombination	J:194422
	decreased NK T cell number	J:194422
	decreased thymocyte apoptosis	J:194422
\Nhej1^tm1Fwa/\Nhej1^tm1Fwa (involves: 129)	abnormal class switch recombination	J:138774
	decreased IgG1 level	J:138774
	decreased IgG3 level	J:138774
	increased IgM level	J:138774
	spleen hypoplasia	J:138774
	thymus hypoplasia	J:138774
\Nhej1^tm1Fwa/\Nhej1^tm1Fwa \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129)	increased T cell derived lymphoma incidence	J:138774
\Nhej1^tm1Fwa/\Nhej1^tm1Fwa \Xrcc5^tm1Nus/\Xrcc5^tm1Nus (involves: 129S6/SvEvTac * C57BL/6)	athymia	J:236776
	small spleen	J:236776
\Nherf1^em1(IMPC)H/\Nherf1^em1(IMPC)H (C57BL/6NTac-Nherf1^em1(IMPC)H/H)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
\Nhlh1^{tm1b(KOMP)Wtsi}/\Nhlh1⁺ (C57BL/6N-Nhlh1^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
\Nhlh2^{tm1b(KOMP)Mbp}/\Nhlh2^{tm1b(KOMP)Mbp} (C57BL/6N-Nhlh2^{tm1b(KOMP)Mbp}/Tcp)	increased spleen weight	J:211773
\Nhsl2^em1(IMPC)Tcp/Y (C57BL/6N-Nhsl2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Nhsl2^em1(IMPC)Tcp/Y (C57BL/6N-Nhsl2^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
\Nhsl2^em1(IMPC)Tcp/\Nhsl2^em1(IMPC)Tcp (C57BL/6N-Nhsl2^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Niban1^{em1(IMPC)Ccpcz}/\Niban1^{em1(IMPC)Ccpcz} (C57BL/6N-Niban1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Niban3^em1(IMPC)Mbp/\Niban3^em1(IMPC)Mbp (C57BL/6N-Niban3^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Niban3^tm1Jyw/\Niban3^tm1Jyw (B6.Cg-Niban3^tm1Jyw)	abnormal B cell calcium ion homeostasis	J:282961
	abnormal B cell differentiation	J:282961
	abnormal class switch recombination	J:282961
	abnormal transitional stage B cell morphology	J:282961
	decreased B-1a cell number	J:282961
	decreased IgA level	J:282961
	decreased IgG2c level	J:282961
	enhanced humoral immune response	J:282961
	increased B cell number	J:282961
	increased B cell proliferation	J:282961
	increased follicular B cell number	J:282961
	increased IgG1 level	J:282961
	increased IgG3 level	J:282961
	increased IgG level	J:282961
	increased IgM level	J:282961
	increased transitional stage T2 B cell number	J:282961
\Nid2^{Gt(GST011)Byg}/\Nid2^{Gt(GST011)Byg} (involves: 129P2/OlaHsd)	osteoarthritis	J:229684
\Ninj1^tm1Gto/\Ninj1⁺ (B6.129P2-Ninj1^tm1Gto)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:209516
\Ninj1^tm1Gto/\Ninj1^tm1Gto (B6.129P2-Ninj1^tm1Gto)	abnormal leukocyte adhesion	J:209516
	abnormal leukocyte physiology	J:209516
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:209516
	impaired macrophage chemotaxis	J:209516
\Ninj2^em1Cqxu/\Ninj2^em1Cqxu (C57BL/6-Ninj2^em1Cqxu)	white adipose tissue inflammation	J:332575
\Nipal2^{em1(IMPC)Ccpcz}/\Nipal2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nipal2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Nipal3^tm1Pbfd/\Nipal3^tm1Pbfd (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	decreased IgM level	J:152829
	decreased NK cell number	J:152829
	increased IgA level	J:152829
	increased IgE level	J:152829
	increased IgG2a level	J:152829
	increased IgM level	J:152829
\Nipbl^{Gt(RRS564)Byg}/\Nipbl⁺ (involves: 129P2/OlaHsd * CD-1)	abnormal inflammatory response	J:154117
	eye inflammation	J:154117
\Nipbl^{Gt(RRS564)Byg}/\Nipbl⁺ (involves: 129P2/OlaHsd * C57BL/6J * CD-1)	abnormal chemokine level	J:297059
\Nipsnap3a^{tm1b(KOMP)Wtsi}/\Nipsnap3a^{tm1b(KOMP)Wtsi} (C57BL/6N-Nipsnap3a^{tm1b(KOMP)Wtsi}/Wtsi)	increased effector memory T-helper cell number	J:211773
\Nipsnap3b^em1(IMPC)J/\Nipsnap3b^em1(IMPC)J (C57BL/6NJ-Nipsnap3b^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Nisch^edsn/\Nisch^edsn (C3H.B6-Nisch^edsn)	increased susceptibility to otitis media	J:244907
\Nisch^edsn/\Nisch^V33A (involves: BALB/c * C3H/HeH * C57BL/6J)	increased susceptibility to otitis media	J:244907
\Nisch^{tm1b(EUCOMM)Hmgu}/\Nisch^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nisch^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
\Nisch^V33A/\Nisch^V33A (involves: BALB/c * C57BL/6J)	increased susceptibility to otitis media	J:244907
\Nkap^tm1.1Viss/Y \Tg(Lck-cre)1Cwi/0 (involves: 129S1/Sv * 129X1/SvJ)	arrested T cell differentiation	J:165961
	decreased CD4-positive, alpha-beta T cell number	J:165961
	decreased CD8-positive, alpha-beta T cell number	J:165961
	decreased DN4 thymocyte number	J:165961
	decreased double-positive T cell number	J:165961
	decreased thymocyte number	J:165961
	increased DN3 thymocyte number	J:165961
	thymus hypoplasia	J:165961
\Nkapd1^tm1.1Tak/\Nkapd1^tm1.1Tak \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6J * C57BL/10 * CBA/Ca)	abnormal B cell differentiation	J:350073
\Nkapd1^tm1.1Tak/\Nkapd1^tm1.1Tak \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C57BL/6 * C57BL/6J)	decreased leukocyte cell number	J:350073
	decreased lymphocyte cell number	J:350073
	small intestinal inflammation	J:350073
\Nkg7^{tm1.1(KOMP)Vlcg}/\Nkg7^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nkg7^{tm1.1(KOMP)Vlcg}/Ucd)	increased eosinophil cell number	J:211773
\Nkg7^{tm1.1(KOMP)Vlcg}/\Nkg7^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:301637
	abnormal mononuclear cell morphology	J:301637
	decreased CD4-positive, alpha-beta T cell number	J:301637
	decreased circulating interferon-gamma level	J:301637
	decreased circulating tumor necrosis factor level	J:301637
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:301637
	decreased T helper 1 cell number	J:301637
	increased susceptibility to parasitic infection induced morbidity/mortality	J:301637
\Nktcn1^C57BL/6J/\Nktcn1^C57BL/6J (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
\Nktcn1^C57BL/6J/\Nktcn1^C57BL/6J (NOD.B6-(D1Mit369-D1Mit155)(D6Mit105-D6Mit135))	abnormal T cell differentiation	J:137521
	increased NK T cell number	J:137521
\Nktcn1^C57BL/6J/\Nktcn1^NOD/ShiLt (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
\Nktcn2^C57BL/6J/\Nktcn2^C57BL/6J (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
\Nktcn2^C57BL/6J/\Nktcn2^NOD/ShiLt (involves: C57BL/6J * NOD.B6-(D6Mit105-D6Mit135))	increased NK T cell number	J:85376
\Nkx2-3^tm1Hha/\Nkx2-3^tm1Hha (involves: 129S4/SvJae * C57BL/6)	abnormal spleen primary B follicle morphology	J:54198
	abnormal splenic cell ratio	J:54198
	absent spleen	J:54198
	absent spleen marginal zone	J:54198
	decreased spleen white pulp amount	J:54198
	small spleen	J:54198
\Nkx2-3^tm1Hha/\Nkx2-3^tm1Hha (involves: 129S4/SvJae)	abnormal leukocyte migration	J:62129
	abnormal marginal zone B cell morphology	J:62129
	abnormal mesenteric lymph node morphology	J:62129
	abnormal metallophilic macrophage morphology	J:62129
	abnormal Peyer's patch follicle morphology	J:62129
	abnormal spleen marginal sinus morphology	J:62129
	abnormal spleen marginal zone macrophage morphology	J:62129
	abnormal spleen morphology	J:62129
	abnormal spleen periarteriolar lymphoid sheath morphology	J:62129
	absent marginal zone B cells	J:62129
	absent spleen marginal zone	J:62129
	decreased B cell number	J:62129
	decreased lymphocyte cell number	J:62129
	decreased Peyer's patch number	J:62129
	decreased spleen weight	J:62129
	decreased spleen white pulp amount	J:62129
	decreased T cell number	J:62129
	intermingled spleen red and white pulp	J:62129
	small Peyer's patches	J:62129
	small spleen	J:62129
\Nkx2-3^tm1Rph/\Nkx2-3^tm1Rph (involves: 129S1/Sv * C57BL/6)	abnormal gut-associated lymphoid tissue morphology	J:64018
	abnormal leukocyte migration	J:64018
	abnormal mesenteric lymph node morphology	J:64018
	abnormal metallophilic macrophage morphology	J:64018
	abnormal spleen B cell follicle morphology	J:64018
	abnormal spleen periarteriolar lymphoid sheath morphology	J:64018
	abnormal spleen red pulp morphology	J:64018
	absent spleen	J:64018
	absent spleen marginal zone	J:64018
	decreased CD4-positive, alpha-beta T cell number	J:64018
	decreased Peyer's patch number	J:64018
	decreased plasma cell number	J:64018
	increased leukocyte cell number	J:64018
	small Peyer's patches	J:64018
	small spleen	J:64018
	spleen atrophy	J:64018
\Nkx2-5^tm1(cre)Rjs/\Nkx2-5⁺ \Tbx1^tm1Bld/\Tbx1^tm3Bld (involves: 129S7/SvEvBrd * C57BL/6)	small thymus	J:91013
\Nkx2-5^tm1Wehi/\Nkx2-5⁺ (involves: 129P2/OlaHsd)	spleen hypoplasia	J:184521
\Nkx2-5^tm2(cre)Rph/\Nkx2-5⁺ \Pbx1^tm1.1Koss/\Pbx1^tm1.1Koss (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal spleen morphology	J:184521
	spleen hypoplasia	J:184521
\Nkx2-5^tm2(cre)Rph/\Nkx2-5^tm4Rph (involves: 129S1/Sv)	spleen hypoplasia	J:184521
\Nkx3-2^tm1.1Tlu/\Nkx3-2^tm1.1Tlu (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	absent spleen	J:55583
\Nkx3-2^tm1Bobh/\Nkx3-2^tm1Bobh (involves: 129P2/OlaHsd * C57BL/6)	absent spleen	J:57112
\Nkx3-2^tm1Tlu/\Nkx3-2^tm1Tlu (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	absent spleen	J:55583
\Nkx3-2^tm1Tno/\Nkx3-2^tm1Tno (involves: 129S4/SvJae * C57BL/6J)	absent spleen	J:77612
\Nle1^tm1Cba/\Nle1^tm1.1Cota \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S2/SvPas)	immune system phenotype	J:204063
\Nle1^tm1Cba/\Nle1^tm1.1Cota \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal immune system organ morphology	J:204063
	decreased granulocyte number	J:204063
	decreased macrophage cell number	J:204063
	decreased NK cell number	J:204063
	decreased T cell number	J:204063
	spleen hypoplasia	J:204063
	thymus hypoplasia	J:204063
\Nlgn3^{em1(IMPC)Rbrc}/Y (C57BL/6NJcl-Nlgn3^{em1(IMPC)Rbrc}/Rbrc)	increased eosinophil cell number	J:211773
\Nlk^tm1Tbo/\Nlk^tm1Tbo (129S1/Sv-Nlk^tm1Tbo)	abnormal bone marrow development	J:73353
	abnormal immune system organ morphology	J:73353
	decreased double-positive T cell number	J:73353
	decreased gamma-delta T cell number	J:73353
	decreased lymphocyte cell number	J:73353
	decreased NK cell number	J:73353
	decreased pro-B cell number	J:73353
	decreased thymocyte number	J:73353
	impaired myelopoiesis	J:73353
	small lymph nodes	J:73353
	spleen hypoplasia	J:73353
	thymus hypoplasia	J:73353
\Nlrc3^tm1Bhk/\Nlrc3^tm1Bhk (B6.129S6-Nlrc3^tm1Bhk)	increased circulating interleukin-6 level	J:187586
	increased circulating tumor necrosis factor level	J:187586
	increased monocyte cell number	J:187586
	increased susceptibility to endotoxin shock	J:187586
	increased tumor necrosis factor secretion	J:187586
\Nlrc4^em1Vnce/\Nlrc4^em1Vnce (C57BL/6-Nlrc4^em1Vnce)	decreased inflammatory response	J:294930
\Nlrc4^em1Vnce/\Nlrc4^em1Vnce (C57BL/6-Nlrc4^em1Vnce)	increased susceptibility to bacterial infection induced morbidity/mortality	J:294930
\Nlrc4^em1Vnce/\Nlrc4^em1Vnce \Nlrp3^tm1Vmd/\Nlrp3^tm1Vmd (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:294930
\Nlrc4^em2Vnce/\Nlrc4^em2Vnce (C57BL/6-Nlrc4^em2Vnce)	decreased inflammatory response	J:294930
\Nlrc4^em2Vnce/\Nlrc4^em2Vnce \Nlrp3^tm1Vmd/\Nlrp3^tm1Vmd (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:294930
\Nlrc4^em3Vnce/\Nlrc4^em3Vnce (C57BL/6-Nlrc4^em3Vnce)	immune system phenotype	J:294930
\Nlrc4^m1Btlr/\Nlrc4⁺ (C57BL/6J-Nlrc4^m1Btlr)	decreased interleukin-1 beta secretion	J:225933
\Nlrc4^m1Btlr/\Nlrc4^m1Btlr (C57BL/6J-Nlrc4^m1Btlr)	decreased interleukin-1 beta secretion	J:225933
\Nlrc4^tm1Gln/\Nlrc4^tm1Gln (involves: 129S5/SvEvBrd)	immune system phenotype	J:173245
\Nlrc4^tm1Gln/\Nlrc4^tm1Gln \Slc11a1^s/\Slc11a1^s (B6.129S5-Nlrc4^tm1Gln)	increased susceptibility to bacterial infection	J:124378
\Nlrc4^tm1Gne/\Nlrc4^tm1Gne (involves: C57BL/6N)	immune system phenotype	J:189256
\Nlrc4^tm1Nnz/\Nlrc4^tm1Nnz (involves: 129 * C57BL/6J)	abnormal macrophage physiology	J:112671, J:117251
\Nlrc4^tm1Nnz/\Nlrc4^tm1Nnz (involves: 129 * C57BL/6J)	increased susceptibility to bacterial infection	J:117251
\Nlrc4^tm1Vmd/\Nlrc4^tm1Vmd (C57BL/6N-Nlrc4^tm1Vmd)	decreased interleukin-1 beta secretion	J:91292
\Nlrc4^tm1Vmd/\Nlrc4^tm1Vmd (involves: C57BL/6N)	abnormal cytokine secretion	J:106976
\Nlrc4^tm1Vmd/\Nlrc4^tm1Vmd (involves: C57BL/6N)	abnormal response to infection	J:106976
\Nlrc4^tm1Vmd/\Nlrc4^tm1Vmd \Nlrp3^tm1Vmd/\Nlrp3^tm1Vmd (C57BL/6-Nlrp3^tm1Vmd Nlrc4^tm1Vmd)	decreased interleukin-1 beta secretion	J:160545
\Nlrc5^tm1.1Ggaur/\Nlrc5^tm1.1Ggaur (involves: BALB/cJ)	abnormal T cell physiology	J:184076
	decreased CD8-positive, alpha-beta T cell number	J:184076
	enlarged spleen	J:184076
	immune system phenotype	J:184076
\Nlrc5^tm1Aki/\Nlrc5^tm1Aki (Not Specified)	immune system phenotype	J:168788
\Nlrc5^tm1Itl/\Nlrc5^tm1Itl (C57BL/6-Nlrc5^tm1Itl)	decreased interferon-beta secretion	J:188857
	decreased interleukin-6 secretion	J:188857
	immune system phenotype	J:188857
\Nlrp1a^m1Btlr/\Nlrp1a^m1Btlr (C57BL/6J-Nlrp1a^m1Btlr)	decreased B cell number	J:265173
	decreased B-1 B cell number	J:265173
	decreased B-1b cell number	J:265173
	decreased B-2 B cell number	J:265173
	decreased CD8-positive, alpha-beta T cell number	J:265173
	decreased central memory CD8 positive, alpha-beta T cell number	J:265173
	decreased NK cell number	J:265173
	decreased single-positive T cell number	J:265173
	decreased T cell number	J:265173
	increased effector memory CD8-positive, alpha-beta T cell number	J:265173
	increased IgE level	J:265173
	increased macrophage apoptosis	J:265173
	increased tumor necrosis factor secretion	J:265173
\Nlrp1a^m2Btlr/\Nlrp1a^m2Btlr (C57BL/6J-Nlrp1a^m2Btlr)	decreased B cell number	J:265174
	decreased interleukin-1 beta secretion	J:265174
	decreased NK cell number	J:265174
	increased dendritic cell number	J:265174
	increased macrophage apoptosis	J:265174
	increased neutrophil cell number	J:265174
\Nlrp1a^Neut1/\Nlrp1a⁺ (C.B6-Nlrp1a^Neut1)	increased inflammatory response	J:191055
	liver inflammation	J:191055
	lung inflammation	J:191055
	meningitis	J:191055
	myocarditis	J:191055
	pancreas inflammation	J:191055
\Nlrp1a^Neut1/\Nlrp1a^Neut1 (C.B6-Nlrp1a^Neut1)	decreased lymphocyte cell number	J:191055
	decreased macrophage cell number	J:191055
	enlarged spleen	J:191055
	increased inflammatory response	J:191055
	increased macrophage cytokine production	J:191055
	increased neutrophil cell number	J:191055
	liver inflammation	J:191055
	lung inflammation	J:191055
	meningitis	J:191055
	myocarditis	J:191055
	pancreas inflammation	J:191055
\Nlrp1a^Neut1/\Nlrp1a^Neut1 \Pycard^tm1Vmd/\Pycard^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:191055
	increased neutrophil cell number	J:191055
\Nlrp1b^tm1Bhk/\Nlrp1b^tm1Bhk (129S6/SvEvTac-Nlrp1b^tm1Bhk)	abnormal macrophage physiology	J:189777
	decreased interleukin-1 alpha secretion	J:189777
	decreased interleukin-1 beta secretion	J:189777
\Nlrp2^tm1.2Itl/\Nlrp2^tm1.2Itl (involves: C57BL/6)	immune system phenotype	J:237496
\Nlrp3^m1Btlr/\Nlrp3^m1Btlr (C57BL/6J-Nlrp3^m1Btlr)	decreased interleukin-1 beta secretion	J:159357
\Nlrp3^m2Btlr/? (C57BL/6J-Nlrp3^m2Btlr)	abnormal interleukin-1 beta secretion	J:164865
\Nlrp3^m3Btlr/? (C57BL/6J-Nlrp3^m3Btlr)	abnormal interleukin-1 beta secretion	J:164866
\Nlrp3^m4Btlr/\Nlrp3^m4Btlr (involves: C57BL/6J)	decreased interleukin-1 beta secretion	J:171739
\Nlrp3^m5Btlr/\Nlrp3⁺ (C57BL/6J-Nlrp3^m5Btlr)	decreased interleukin-1 beta secretion	J:192651
\Nlrp3^m5Btlr/\Nlrp3^m5Btlr (C57BL/6J-Nlrp3^m5Btlr)	decreased interleukin-1 beta secretion	J:192651
\Nlrp3^M6Btlr/\Nlrp3⁺ (C57BL/6J-Nlrp3^M6Btlr)	decreased interleukin-1 beta secretion	J:216047
\Nlrp3^M6Btlr/\Nlrp3^M6Btlr (C57BL/6J-Nlrp3^M6Btlr)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226677
\Nlrp3^M7Btlr/\Nlrp3⁺ (C57BL/6J-Nlrp3^M7Btlr)	abnormal macrophage cytokine production	J:216048
\Nlrp3^M7Btlr/\Nlrp3⁺ (C57BL/6J-Nlrp3^M7Btlr)	decreased interleukin-1 beta secretion	J:216048
\Nlrp3^M7Btlr/\Nlrp3^M7Btlr (C57BL/6J-Nlrp3^M7Btlr)	abnormal macrophage cytokine production	J:216048
\Nlrp3^M7Btlr/\Nlrp3^M7Btlr (C57BL/6J-Nlrp3^M7Btlr)	decreased interleukin-1 beta secretion	J:216048
\Nlrp3^M8Btlr/\Nlrp3⁺ (C57BL/6J-Nlrp3^M8Btlr)	decreased interleukin-1 beta secretion	J:217294
\Nlrp3^M8Btlr/\Nlrp3^M8Btlr (C57BL/6J-Nlrp3^M8Btlr)	decreased interleukin-1 beta secretion	J:217294
\Nlrp3^M9Btlr/\Nlrp3⁺ (C57BL/6J-Nlrp3^M9Btlr)	decreased interleukin-1 beta secretion	J:220071
\Nlrp3^M9Btlr/\Nlrp3^M9Btlr (C57BL/6J-Nlrp3^M9Btlr)	decreased interleukin-1 beta secretion	J:220071
\Nlrp3^M10Btlr/\Nlrp3⁺ (C57BL/6J-Nlrp3^M10Btlr)	decreased interleukin-1 beta secretion	J:234254
\Nlrp3^M10Btlr/\Nlrp3^M10Btlr (C57BL/6J-Nlrp3^M10Btlr)	decreased interleukin-1 beta secretion	J:234254
\Nlrp3^M11Btlr/\Nlrp3^M11Btlr (C57BL/6J-Nlrp3^M11Btlr)	decreased interleukin-1 beta secretion	J:255211
\Nlrp3^m12Btlr/\Nlrp3^m12Btlr (C57BL/6J-Nlrp3^m12Btlr)	decreased interleukin-1 beta secretion	J:272150
\Nlrp3^tm1Bhk/\Nlrp3^tm1Bhk (involves: 129S6/SvEvTac)	decreased interleukin-1 beta secretion	J:189777
\Nlrp3^tm1Bhk/\Nlrp3^tm1Bhk (involves: 129S6/SvEvTac)	immune system phenotype	J:189777
\Nlrp3^tm1Bhk/\Nlrp3^tm1Bhk (B6.129S6-Nlrp3^tm1Bhk/J)	decreased interleukin-1 beta secretion	J:253629
\Nlrp3^tm1Bhk/\Nlrp3^tm1Bhk (B6.129S6-Nlrp3^tm1Bhk/J)	white adipose tissue inflammation	J:256504
\Nlrp3^tm1Flv/\Nlrp3^tm1Flv (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:113333
	decreased circulating interleukin-1 beta level	J:113333
	decreased circulating interleukin-18 level	J:113333
	decreased susceptibility to endotoxin shock	J:113333
	decreased susceptibility to type IV hypersensitivity reaction	J:113333
\Nlrp3^tm1Flv/\Nlrp3^tm1Flv (B6.129S5-Nlrp3^tm1Flv)	decreased interleukin-1 beta secretion	J:164725
\Nlrp3^tm1Flv/\Nlrp3^tm1Flv (involves: 129S5/SvEvBrd)	decreased susceptibility to induced colitis	J:173245
\Nlrp3^tm1Flv/\Nlrp3^tm1Flv \Slc11a1^s/\Slc11a1^s (B6.129S5-Nlrp3^tm1Flv)	increased susceptibility to bacterial infection	J:124378
\Nlrp3^tm1Flv/\Nlrp3^tm1Hhf \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * C57BL/6)	increased inflammatory response	J:150054
\Nlrp3^tm1Hhf/\Nlrp3⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal circulating chemokine level	J:150054
	abnormal circulating cytokine level	J:150054
	increased circulating interleukin-1 beta level	J:150054
	increased circulating interleukin-6 level	J:150054
	increased circulating interleukin-18 level	J:150054
	increased circulating tumor necrosis factor level	J:150054
	increased inflammatory response	J:150054
	increased leukocyte cell number	J:150054
	increased neutrophil cell number	J:150054
\Nlrp3^tm1Hhf/\Nlrp3⁺ \Rag1^tm1Mom/\Rag1^tm1Mom \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	absent B cells	J:150054
	absent T cells	J:150054
\Nlrp3^tm1Hhf/\Nlrp3⁺ \Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	skin inflammation	J:150054
\Nlrp3^tm1Hhf/\Nlrp3⁺ \Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	abnormal dendritic cell antigen presentation	J:150054
	abnormal dendritic cell physiology	J:150054
	abnormal macrophage physiology	J:150054
\Nlrp3^tm1Hhf/\Nlrp3⁺ \Tg(Zp3-cre)3Mrt/? (involves: 129/Sv * FVB/N)	increased inflammatory response	J:150054
	increased leukocyte cell number	J:150054
	increased neutrophil cell number	J:150054
\Nlrp3^tm1Tsc/\Nlrp3^tm1Tsc (C57BL/6-Nlrp3^tm1Tsc)	decreased interleukin-1 beta secretion	J:124226
\Nlrp3^tm1Tsc/\Nlrp3^tm1Tsc (involves: C57BL/6)	decreased interleukin-1 beta secretion	J:172117
\Nlrp3^tm1Vmd/\Nlrp3^tm1Vmd (involves: C57BL/6N)	abnormal cytokine secretion	J:106976
	abnormal response to infection	J:106976
	decreased susceptibility to endotoxin shock	J:106976
\Nlrp3^tm1Vmd/\Nlrp3^tm1Vmd (B6.B6N-Nlrp3^tm1Vmd)	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 beta secretion	J:193522
	decreased susceptibility to endotoxin shock	J:193522
	immune system phenotype	J:294930
\Nlrp3^tm1Wstr/\Nlrp3⁺ (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:150053
	abnormal dendritic cell physiology	J:150053
	abnormal lymph node morphology	J:150053
	abnormal macrophage physiology	J:150053
	abnormal spleen red pulp morphology	J:150053
	chronic inflammation	J:150053
	dermatitis	J:150053
	enlarged lymph nodes	J:150053
	enlarged spleen	J:150053
	increased activated T cell number	J:150053
	increased anti-double stranded DNA antibody level	J:150053
	increased interleukin-1 beta secretion	J:150053
	increased interleukin-17 secretion	J:150053
	increased interleukin-18 secretion	J:150053
	increased leukocyte cell number	J:150053
	increased susceptibility to type IV hypersensitivity reaction	J:150053
	increased T-helper 1 cell number	J:150053
\Nlrp3^tm2Hhf/\Nlrp3⁺ \Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	skin inflammation	J:150054
\Nlrp3^tm2Hhf/\Nlrp3⁺ \Tg(CAG-cre/Esr1)5Amc/? (involves: 129/Sv C57BL/6 * CBA)	abnormal dendritic cell physiology	J:150054
	abnormal macrophage physiology	J:150054
\Nlrp3^tm2Hhf/\Nlrp3^tm2Hhf \Vsig4^tm1Gne/\Vsig4^tm1Gne (B6.Cg-Nlrp3^tm2Hhf Vsig4^tm1Gne)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:281762
\Nlrp3^tm3.1Hhf/\Nlrp3⁺ (involves: 129)	abnormal circulating chemokine level	J:202147
	abnormal osteoclast differentiation	J:202147
	decreased circulating interleukin-5 level	J:202147
	decreased circulating interleukin-12b level	J:202147
	decreased lymphocyte cell number	J:202147
	immune system phenotype	J:202147
	increased circulating interleukin-1 beta level	J:202147
	increased circulating interleukin-3 level	J:202147
	increased circulating interleukin-4 level	J:202147
	increased circulating interleukin-6 level	J:202147
	increased circulating interleukin-9 level	J:202147
	increased circulating interleukin-13 level	J:202147
	increased circulating interleukin-18 level	J:202147
	increased circulating tumor necrosis factor level	J:202147
	increased granulocyte number	J:202147
	increased inflammatory response	J:202147
	increased interferon-gamma secretion	J:202147
	increased interleukin-1 beta secretion	J:202147
	increased lymphocyte cell number	J:202147
	increased monocyte cell number	J:202147
	increased neutrophil cell number	J:202147
	increased osteoclast cell number	J:202147
	joint inflammation	J:202147
	meningitis	J:202147
	osteomyelitis	J:202147
\Nlrp6^tm1Flv/\Nlrp6^tm1Flv (B6.Cg-Nlrp6^tm1Flv)	decreased circulating interleukin-18 level	J:173245
	decreased interleukin-18 secretion	J:173245
	enlarged Peyer's patches	J:173245
	increased B cell number	J:173245
	increased IgA level	J:173245
	increased IgG2c level	J:173245
	increased leukocyte cell number	J:173245
	increased susceptibility to induced colitis	J:173245
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:243487
\Nlrp6^tm1Macha/\Nlrp6^tm1Macha (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to induced colitis	J:173352
\Nlrp9b^em1Flv/\Nlrp9b^em1Flv (C57BL/6N-Nlrp9b^em1Flv)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:243487
\Nlrp9b^{tm1b(KOMP)Wtsi}/\Nlrp9b^{tm1b(KOMP)Wtsi} (C57BL/6N-Nlrp9b^{tm1b(KOMP)Wtsi}/H)	enlarged spleen	J:211773
\Nlrp10^tm1Seis/\Nlrp10^tm1Seis (involves: C57BL/6)	immune system phenotype	J:173245
\Nlrp10^tm1Seis/\Nlrp10^tm1Seis (B6.Cg-Nlrp10^tm1Seis)	abnormal adaptive immunity	J:183989
	abnormal dendritic cell physiology	J:183989
	abnormal T-helper 2 physiology	J:183989
	decreased dendritic cell number	J:183989
	decreased IgG1 level	J:183989
	decreased interferon-gamma secretion	J:183989
	decreased interleukin-17 secretion	J:183989
	decreased susceptibility to endotoxin shock	J:183989
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:183989
\Nlrp12^tm1Jpyt/\Nlrp12^tm1Jpyt (B6.Cg-Nlrp12^tm1Jpyt)	abnormal leukocyte migration	J:164725
	decreased neutrophil cell number	J:164725
	decreased susceptibility to type IV hypersensitivity reaction	J:164725
	impaired neutrophil chemotaxis	J:164725
\Nlrp12^tm1Jpyt/\Nlrp12^tm1Jpyt (Not Specified)	immune system phenotype	J:173245
\Nlrp12^tm1Tdk/\Nlrp12^tm1Tdk (B6.Cg-Nlrp12^tm1Tdk)	abnormal chemokine level	J:178951
	abnormal cytokine level	J:178951
	enlarged spleen	J:178951
	increased inflammatory response	J:178951
	increased susceptibility to induced colitis	J:178951
\Nlrx1^em1(IMPC)Mbp/\Nlrx1^em1(IMPC)Mbp (C57BL/6N-Nlrx1^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Nlrx1^tm1Jpyt/\Nlrx1^tm1Jpyt (involves: C57BL/6 * C57BL/6J)	abnormal macrophage physiology	J:173995
	abnormal neutrophil physiology	J:173995
	increased circulating interleukin-6 level	J:173995
	increased interferon-beta secretion	J:173995
	increased interleukin-1 beta secretion	J:173995
	increased interleukin-6 secretion	J:173995
	increased susceptibility to endotoxin shock	J:173995
	increased susceptibility to Orthomyxoviridae infection	J:173995
\Nme2^{Gt(69C10)Cmhd}/\Nme2^{Gt(69C10)Cmhd} (B6.129-Nme2^{Gt(69C10)Cmhd})	abnormal CD4-positive, alpha-beta T cell physiology	J:167387
	abnormal T-helper 1 physiology	J:167387
	abnormal T-helper 2 physiology	J:167387
	decreased interferon-gamma secretion	J:167387
	decreased interleukin-2 secretion	J:167387
	decreased interleukin-13 secretion	J:167387
	decreased tumor necrosis factor secretion	J:167387
	immune system phenotype	J:167387
\Nme5^tm1Lex/\Nme5^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	maxillary sinus inflammation	J:185566
	nasal inflammation	J:185566
\nmf4/\nmf4 (C57BL/6J-nmf4/J)	small spleen	J:78134
\nmf4/\nmf4 (C57BL/6J-nmf4/J)	thymus cortex atrophy	J:78134
\nmf356/\nmf356 (C57BL/6J-nmf356/J)	thymus atrophy	J:87349
\nmf370/\nmf370 (C57BL/6J-nmf370/J)	ear inflammation	J:87349
\nmf391/\nmf391 (C57BL/6J-nmf391/J)	ear inflammation	J:87349
\Nmi^em1Hhl/\Nmi^em1Hhl (C57BL/6-Nmi^em1Hhl)	decreased circulating interleukin-6 level	J:298909
	decreased circulating tumor necrosis factor level	J:298909
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:298909
	decreased susceptibility to endotoxin shock	J:298909
\Nmnat2^em1(IMPC)Mbp/\Nmnat2⁺ (C57BL/6N-Nmnat2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Nmnat3^Gt(3020)Tgen/\Nmnat3^Gt(3020)Tgen (involves: C57BL/6NCrlj * CBA/JNCrlj)	enlarged spleen	J:214107
	increased spleen iron level	J:214107
	increased spleen red pulp amount	J:214107
	increased spleen weight	J:214107
\Nmt1^tm1.1Poru/\Nmt1^tm1.1Poru \Nmt2^tm1.1Poru/\Nmt2^tm1.1Poru \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:226234
	abnormal CD8-positive, alpha beta T cell morphology	J:226234
	decreased circulating interferon-gamma level	J:226234
	decreased circulating interleukin-2 level	J:226234
	decreased circulating tumor necrosis factor level	J:226234
	decreased DN4 thymocyte number	J:226234
	decreased double-positive T cell number	J:226234
	decreased interferon-gamma secretion	J:226234
	decreased interleukin-2 secretion	J:226234
	decreased single-positive T cell number	J:226234
	decreased splenocyte proliferation	J:226234
	decreased susceptibility to endotoxin shock	J:226234
	decreased T cell number	J:226234
	decreased T cell proliferation	J:226234
	immune system phenotype	J:226234
	increased double-negative T cell number	J:226234
	increased gamma-delta T cell number	J:226234
	increased T cell apoptosis	J:226234
	small thymus medulla	J:226234
\Nmt1^tm1.1Poru/\Nmt1^tm1.1Poru \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:226234
	abnormal CD8-positive, alpha beta T cell morphology	J:226234
	decreased double-positive T cell number	J:226234
	decreased single-positive T cell number	J:226234
	decreased T cell number	J:226234
\Nmt2^tm1.1Poru/\Nmt2^tm1.1Poru \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	decreased double-positive T cell number	J:226234
	decreased single-positive T cell number	J:226234
	decreased T cell number	J:226234
\Nmu^tm1Sjab/\Nmu^tm1Sjab (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-6 level	J:142907
\Nnat^em1(IMPC)Mbp/\Nnat^em1(IMPC)Mbp (C57BL/6NCrl-Nnat^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Nnmt^em1(IMPC)Mbp/\Nnmt^em1(IMPC)Mbp (C57BL/6NCrl-Nnmt^em1(IMPC)Mbp/Mmucd)	enlarged spleen	J:211773
\Noa/\Noa⁺ (NOA)	cutaneous mastocytosis	J:43274
\Noa/\Noa⁺ (NOA)	increased IgE level	J:43274
\Noc2l^tm1.1Arte/\Noc2l^tm1.1Arte \Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal B cell morphology	J:216490
	abnormal T cell morphology	J:216490
	abnormal T cell proliferation	J:216490
	abnormal thymus cell ratio	J:216490
	abnormal thymus involution	J:216490
	abnormal thymus morphology	J:216490
	absent T cells	J:216490
	arrested T cell differentiation	J:216490
	decreased alpha-beta T cell number	J:216490
	decreased DN3 thymocyte number	J:216490
	decreased DN4 thymocyte number	J:216490
	decreased double-positive T cell number	J:216490
	decreased immature B cell number	J:216490
	decreased mature B cell number	J:216490
	decreased pre-B cell number	J:216490
	decreased pro-B cell number	J:216490
	decreased single-positive T cell number	J:216490
	increased thymocyte apoptosis	J:216490
	small thymus	J:216490
	spleen hypoplasia	J:216490
	thymus hypoplasia	J:216490
\Noc2l^tm1.1Arte/\Noc2l^tm1.1Arte \Trp53^tm1Brn/\Trp53^tm1Brn \Tg(CD2-icre)4Kio/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * CBA/Ca)	decreased pre-B cell number	J:216490
\Nod1^tm1Bert/\Nod1^tm1Bert (involves: C57BL/6)	immune system phenotype	J:117688
\Nod1^tm1Inoh/\Nod1^tm1Inoh (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:118808
	abnormal cytokine secretion	J:118808
	abnormal immune system physiology	J:118808
	abnormal macrophage physiology	J:132126, J:118808
	decreased interleukin-6 secretion	J:132126
	decreased tumor necrosis factor secretion	J:132126
\Nod1^tm1Inoh/\Nod1^tm1Inoh \Nod2^tm1Flv/\Nod2^tm1Flv (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:132126
	decreased interleukin-6 secretion	J:132126
	decreased tumor necrosis factor secretion	J:132126
	increased susceptibility to bacterial infection	J:132126
\Nod2^em1(IMPC)Mbp/\Nod2^em1(IMPC)Mbp (C57BL/6N-Nod2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Nod2^tm1Daph/\Nod2^tm1Daph (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:157879
\Nod2^tm1Flv/\Nod2^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal macrophage physiology	J:132126, J:96035
	abnormal susceptibility to infection	J:96035
	decreased IgG level	J:96035
	decreased interleukin-6 secretion	J:132126
	decreased susceptibility to endotoxin shock	J:96035
	decreased tumor necrosis factor secretion	J:132126
\Nod2^tm1Flv/\Nod2^tm1Flv (involves: 129S1/Sv)	abnormal response to infection	J:147177
	abnormal T-helper 1 physiology	J:147177
	impaired macrophage phagocytosis	J:147177
	impaired neutrophil phagocytosis	J:147177
	increased circulating interferon-gamma level	J:147177
	increased circulating interleukin-2 level	J:147177
	increased circulating tumor necrosis factor level	J:147177
	increased leukocyte cell number	J:147177
	increased neutrophil cell number	J:147177
	increased susceptibility to bacterial infection induced morbidity/mortality	J:147177
\Nod2^tm1Flv/\Nod2^tm1Flv (C.129S1-Nod2^tm1Flv)	decreased susceptibility to induced arthritis	J:178054
\Nod2^tm1Jhgt/\Nod2^tm1Jhgt (B6.Cg-Nod2^tm1Jhgt)	abnormal cytokine level	J:124575
	abnormal immune system morphology	J:124575
	abnormal immune system physiology	J:124575
	abnormal interferon level	J:124575
	abnormal interleukin level	J:124575
	abnormal lymph node B cell domain morphology	J:124575
	abnormal Peyer's patch morphology	J:124575
	abnormal response to infection	J:124575
	abnormal tumor necrosis factor level	J:124575
	enlarged Peyer's patches	J:124575
	increased CD4-positive, alpha-beta T cell number	J:124575
	increased double-negative T cell number	J:124575
	increased Peyer's patch number	J:124575
	increased susceptibility to induced colitis	J:124575
\Nod2^tm1Mka/\Nod2^tm1Mka (involves: C57BL/6)	abnormal cytokine level	J:96128
	abnormal macrophage morphology	J:96128
	increased interleukin-1 beta secretion	J:96128
	increased susceptibility to induced colitis	J:96128
\Nod2^tm1Pmu/\Nod2^tm1Pmu (involves: BALB/c * C57BL/6)	abnormal macrophage physiology	J:86264
\Nod2^tm1Pmu/\Nod2^tm1Pmu (involves: BALB/c * C57BL/6)	decreased susceptibility to endotoxin shock	J:86264
\Nod2^tm1Vmd/\Nod2^tm1Vmd (B6.129-Nod2^tm1Vmd)	abnormal cytokine secretion	J:106976
\Nodal^tm1.1Mku/\Nodal^tm2Mku \Tg(T-cre)1Lwd/0 (involves: 129S1/Sv * C3H * C57BL/6)	absent spleen	J:142430
	small spleen	J:142430
\Nodal^tm1.2Rob/\Nodal^tm3Rob (involves: 129S/SvEv * MF1)	small spleen	J:79098
\Nodal^tm1Hmd/\Nodal⁺ \Tg(Rr443-Lefty1,-lacZ)36Hmd/0 (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N) or (involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ))	small spleen	J:82703
\Nodal^tm1Hmd/\Nodal^tm1Hmd (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N) or (involves: 129S1/Sv * 129T2/SvEms * 129X1/SvJ))	abnormal spleen morphology	J:82703
	spleen hypoplasia	J:82703
\Nol3^em1(IMPC)Mbp/\Nol3^em1(IMPC)Mbp (C57BL/6N-Nol3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Nop53^tm2.1Asuz/\Nop53^tm2.1Asuz \Tg(Lck-cre)#Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	decreased thymocyte number	J:241062
\Nop53^tm2.1Asuz/\Nop53^tm2.1Asuz \Trp53^tm1Tyj/\Trp53^tm1Tyj \Tg(Lck-cre)#Jxm/0 (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte number	J:241062
\Nos1^tm1Plh/\Nos1^tm1Plh (involves: 129S4/SvJae)	abnormal leukocyte adhesion	J:55936
	abnormal neutrophil physiology	J:55936
	enhanced leukocyte tethering or rolling	J:55936
\Nos1^tm1Plh/\Nos1^tm1Plh (B6;129S4-Nos1^tm1Plh/J)	abnormal osteoclast differentiation	J:105612
\Nos1^tm1Plh/\Nos1^tm1Plh (B6.129S4-Nos1^tm1Plh/J)	decreased inflammatory response	J:103018
\Nos1^tm1Plh/\Nos1^tm1Plh \Nos2^tm1Mrl/\Nos2^tm1Mrl \Nos3^tm1Plh/\Nos3^tm1Plh (involves: 129S4/SvJae * 129S7/SvEvBrd)	abnormal osteoclast physiology	J:150159
	increased osteoclast cell number	J:150159
\Nos2^tm1Lau/\Nos2^tm1Lau (involves: 129P2/OlaHsd * C57BL/6)	abnormal adaptive immunity	J:90903
	abnormal immune system morphology	J:90903
	enlarged inguinal lymph nodes	J:90903
	immune system phenotype	J:64036, J:29677
	increased single-positive T cell number	J:90903
	increased susceptibility to bacterial infection	J:100513
	increased T cell proliferation	J:90903
	skin inflammation	J:64036
\Nos2^tm1Lau/\Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau)	abnormal osteoclast morphology	J:112399
\Nos2^tm1Lau/\Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau)	decreased susceptibility to induced colitis	J:87601
\Nos2^tm1Lau/\Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau/J)	abnormal inflammatory response	J:103018
\Nos2^tm1Lau/\Nos2^tm1Lau (B6.129P2-Nos2^tm1Lau/J)	decreased inflammatory response	J:103018
\Nos2^tm1Lau/\Nos2^tm1Lau (involves: 129P2/OlaHsd)	immune system phenotype	J:55936
\Nos2^tm1Liew/\Nos2^tm1Liew (involves: 129P2/Ola * MF1)	abnormal T-helper 1 physiology	J:25755
	decreased inflammatory response	J:25755
	decreased susceptibility to endotoxin shock	J:25755
	increased interferon-gamma secretion	J:25755
	increased susceptibility to parasitic infection	J:25755
	increased T cell proliferation	J:25755
\Nos2^tm1Liew/\Nos2^tm1Liew (involves: 129 * 129P2/OlaHsd)	immune system phenotype	J:118561
\Nos2^tm1Mrl/\Nos2^tm1Mrl (involves: 129S7/SvEvBrd)	abnormal eosinophil cell number	J:51635
	abnormal immune system physiology	J:51635
	abnormal macrophage physiology	J:120499
	decreased eosinophil cell number	J:51635
	decreased susceptibility to endotoxin shock	J:25511
	increased IgG2a level	J:51635
	increased inflammatory response	J:51635
	increased interferon-gamma secretion	J:51635
	increased susceptibility to bacterial infection	J:25511
\Nos2^tm1Mrl/\Nos2^tm1Mrl (involves: 129S7/SvEvBrd * C57BL/6)	increased length of allograft survival	J:54764
	pancreas inflammation	J:65562
\Nos2^tm1Mrl/\Nos2^tm1Mrl (B6.129S7-Nos2^tm1Mrl)	abnormal osteoclast differentiation	J:98070
	abnormal osteoclast morphology	J:98070
	abnormal response to infection	J:98070
	decreased osteoclast cell number	J:98070
\Nos2^tm1Mrl/\Nos2^tm1Mrl (involves: 129S7/SvEvBrd * PL/J)	increased susceptibility to experimental autoimmune encephalomyelitis	J:46192
\Nos3^em1(IMPC)Mbp/\Nos3^em1(IMPC)Mbp (C57BL/6N-Nos3^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Nos3^m1Btlr/\Nos3^m1Btlr (C57BL/6J-Nos3^m1Btlr)	increased susceptibility to induced colitis	J:225268
\Nos3^M2Btlr/\Nos3^M2Btlr (C57BL/6J-Nos3^M2Btlr)	increased susceptibility to induced colitis	J:272392
\Nos3^tm1Plh/\Nos3^tm1Plh (involves: 129S4/SvJae)	abnormal leukocyte adhesion	J:55936
	abnormal neutrophil physiology	J:55936
	enhanced leukocyte tethering or rolling	J:55936
\Nos3^tm1Plh/\Nos3^tm1Plh (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to bacterial infection	J:105005
\Nos3^tm1Plh/\Nos3^tm1Plh (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:105005
\Nos3^tm1Unc/\Nos3^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:36559
\Nos3^tm1Unc/\Nos3^tm1Unc (B6.129P2-Nos3^tm1Unc/J)	abnormal osteoclast physiology	J:129477
	increased inflammatory response	J:103018
	kidney inflammation	J:148626
\Notch1^tm1Agt/\Notch1^tm1Agt \Notch2^tm1Frad/\Notch2^tm1Frad \Tg(Mx1-cre)1Cgn/0 (involves: 129 * BALB/c * C57BL/6 * CBA)	abnormal T cell differentiation	J:125373
	arrested T cell differentiation	J:125373
\Notch1^tm1Agt/\Notch1^tm1Agt \Notch2^tm3Grid/\Notch2^tm3Grid \Tg(TcrAND)53Hed/? (involves: 129/Sv * 129S1/Sv * C57BL/6 * SJL)	abnormal humoral immune response	J:123631
	abnormal response to infection	J:123631
	decreased interleukin-4 secretion	J:123631
\Notch1^tm1Agt/\Notch1^tm1Agt \Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	abnormal B cell differentiation	J:125373
	abnormal T cell differentiation	J:125373, J:55400
	abnormal thymus cell ratio	J:55400, J:143472
	abnormal thymus morphology	J:55400
	decreased CD4-positive, alpha-beta T cell number	J:55400
	decreased CD8-positive, alpha-beta T cell number	J:55400
	decreased double-negative T cell number	J:55400
	decreased double-positive T cell number	J:55400
	decreased single-positive T cell number	J:55400
	decreased thymocyte number	J:55400
	increased immature B cell number	J:143472
	small thymus	J:55400
\Notch1^tm1Con/\Notch1⁺ (involves: 129S1/Sv * 129X1/SvJ * CD-1)	aortic valve inflammation	J:187551
\Notch1^tm2Pst/\Notch1^tm2Pst (B6.Cg-Notch1^tm2Pst)	abnormal T cell differentiation	J:131563
	decreased double-negative T cell number	J:131563
	decreased T cell number	J:131563
	decreased thymocyte number	J:131563
	increased T cell apoptosis	J:131563
\Notch1^tm2Rko/\Notch1^tm2Rko \Notch2^tm1Rko/\Notch2^tm1Rko \Notch3^{Gt(PST033)Byg}/\Notch3⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased spleen red pulp amount	J:172442
\Notch1^tm2Rko/\Notch1^tm2Rko \Notch2^tm1Rko/\Notch2^tm1Rko \Notch3^{Gt(PST033)Byg}/\Notch3^{Gt(PST033)Byg} \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)	abnormal spleen morphology	J:172442
	enlarged spleen	J:172442
	increased spleen red pulp amount	J:172442
\Notch1^tm2Rko/\Notch1^tm3(cre)Rko (involves: 129X1/SvJ * C57BL/6)	abnormal spleen morphology	J:171829
	chronic liver inflammation	J:171829
	enlarged spleen	J:171829
\Notch2^{Gt(betageo)1Byg}/\Notch2⁺ (B6.129P2-Notch2^{Gt(betageo)1Byg})	decreased marginal zone B cell number	J:146621
\Notch2^tm1.1Ecan/\Notch2⁺ (involves: 129 * 129S1/Sv * C57BL/6J)	abnormal osteoclast differentiation	J:230045
	abnormal osteoclast morphology	J:230045
	increased osteoclast cell number	J:230045
\Notch2^tm1.1Hhi/\Notch2^tm1.1Hhi \Tg(Cd8a-cre)1Itan/0 (involves: C57BL/6 * CBA)	abnormal CD8-positive, alpha-beta T cell physiology	J:141009
	abnormal cytotoxic T cell physiology	J:141009
	increased susceptibility to parasitic infection	J:141009
\Notch2^tm1.1Hhtg/\Notch2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal interleukin level	J:311038
	abnormal osteoclast differentiation	J:311038
	increased circulating interleukin-6 level	J:311038
	increased interleukin-6 secretion	J:311038
	increased osteoclast cell number	J:311038
\Notch2^tm1Frad/\Notch2^tm1Frad \Tg(Mx1-cre)1Cgn/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal B cell differentiation	J:125373
	absent marginal zone B cells	J:125373
\Notch2^tm1Yha/\Notch2⁺ (B6.129-Notch2^tm1Yha)	abnormal spleen marginal zone morphology	J:85379
	decreased B-1 B cell number	J:85379
	decreased marginal zone B cell number	J:85379
\Notch2^tm2.1Ecan/\Notch2^tm2.1Ecan \Tg(BGLAP-cre)1Clem/0 (involves: C57BL/6J * FVB/NJ)	increased osteoclast cell number	J:246017
\Notch2^tm2Hhi/\Notch2^tm1.1Hhi \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased marginal zone B cell number	J:83476
	immune system phenotype	J:83476
\Notch3^em1Ecan/\Notch3⁺ (C57BL/6J-Notch3^em1Ecan)	abnormal osteoclast differentiation	J:270682
\Notch3^em1Ecan/\Notch3⁺ (C57BL/6J-Notch3^em1Ecan)	increased osteoclast cell number	J:270682
\Notch3^{tm1.1(KOMP)Vlcg}/\Notch3^{tm1.1(KOMP)Vlcg} (C57BL/6N-Notch3^{tm1.1(KOMP)Vlcg}/Ucd)	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Notch3^tm1Khan/\Notch3^tm1Khan (involves: C57BL/6 * CBA)	decreased thymocyte number	J:98284
\Notch3^tm1Khan/\Notch3^tm1Khan (involves: C57BL/6 * CBA)	small thymus	J:98284
\Notum^em1(IMPC)Tcp/\Notum⁺ (C57BL/6NCrl-Notum^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
\Notum^{Gt(OST172035)Lex}/\Notum^{Gt(OST172035)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	chronic inflammation	J:274615
	increased leukocyte cell number	J:274615
	periodontium inflammation	J:266040
\Nox1^tm1.1Anrt/\Nox1^tm1.1Anrt \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * SJL)	colitis	J:194294
\Nox1^tm1Cyn/Y (involves: 129S1/Sv * 129X1/SvJ)	abnormal cytokine secretion	J:218649
\Nox4^em1(IMPC)Mbp/\Nox4^em1(IMPC)Mbp (C57BL/6N-Nox4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Nox4^tm1Syb/\Nox4^tm1Syb (involves: 129S4/SvJae)	decreased interleukin-1 beta secretion	J:298830
	decreased susceptibility to endotoxin shock	J:298830
	decreased tumor necrosis factor secretion	J:298830
\Noxa1^{em1(IMPC)Ccpcz}/\Noxa1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Noxa1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Npas2^em1(IMPC)Mbp/\Npas2^em1(IMPC)Mbp (C57BL/6N-Npas2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
\Npas3^tm1Mesu/\Npas3^tm1Mesu (B6.129S6-Npas3^tm1Mesu)	bronchiectasis	J:150793
\Npat^{tm1b(EUCOMM)Wtsi}/\Npat^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Npat^{tm1b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Npc1^m1N/\Npc1^m1N (involves: BALB/c)	abnormal alveolar macrophage morphology	J:204311
\Npc1^m1N/\Npc1^m1N (involves: BALB/c)	enlarged spleen	J:76733
\Npc1^m1N/\Npc1^m1N (BALB/cNctr-Npc1^m1N/J)	enlarged spleen	J:179744
	microgliosis	J:209834
	nasal inflammation	J:209834
\Npc1^m1N/\Npc1^m1N (involves: BALB/c * C57BL/6 * CBA)	increased microglial cell activation	J:144240
\Npc1^m1N/\Npc1^m1N (B6.C-Npc1^m1N)	microgliosis	J:157113
\Npc1^m1N/\Npc1^m1N (BALB/c-Npc1^m1N)	abnormal macrophage morphology	J:221855
	abnormal microglial cell activation	J:221855
	increased macrophage derived foam cell number	J:221855
	increased microglial cell activation	J:221855
\Npc1^m1N/\Npc1^m1N (involves: BALB/c * C3H/HeJ * C57BL/6J)	microgliosis	J:188345
\Npc1^m1N/\Npc1^m1N \Tg(PRNP-APPSweInd)8Dwst/0 (involves: BALB/c * C3H/HeJ * C57BL/6J)	microgliosis	J:188345
\Npc1^m1N/\Npc1^m1N \Tlr4^tm1Aki/\Tlr4^tm1Aki (involves: 129P2/OlaHsd * BALB/c)	abnormal cytokine secretion	J:118352
\Npc1^m1N/\Npc1^tm1.1Apl \Tg(CAG-cre/Esr1)5Amc/0 (B6J.Cg-Npc1^m1N/Npc1^tm1.1Apl Tg(CAG-cre/Esr1)5Amc)	microgliosis	J:176888
\Npc1^m1N/\Npc1^tm1.1Apl \Tg(Syn1-cre)671Jxm/0 (B6J.Cg-Npc1^m1N/Npc1^tm1.1Apl Tg(Syn1-cre)671Jxm)	microgliosis	J:176888
\Npc1^m1N/\Npc1^tm1.2Apl (B6.Cg-Npc1^m1N/Npc1^tm1.2Apl)	microgliosis	J:157113
\Npc1^nmf164/\Npc1^nmf164 (C57BL/6J-Npc1^nmf164/J)	enlarged spleen	J:179744
	increased macrophage derived foam cell number	J:179744
	increased microglial cell activation	J:179744
\Npc1^spm/\Npc1^spm (C57BLKS/J-Npc1^spm/J)	enlarged spleen	J:7245
\Npc1^spm/\Npc1^spm (C57BLKS/J-Npc1^spm/J)	increased macrophage derived foam cell number	J:7245
\Npc1^tm1.1Apl/\Npc1^tm1.2Apl \Tg(Pcp2-cre)2Mpin/0 (B6.Cg-Npc1^tm1.1Apl/Npc1^tm1.2Apl Tg(Pcp2-cre)2Mpin)	microgliosis	J:157113
\Npc1^tm1.1Dso/\Npc1^tm1.1Dso (B6.129-Npc1^tm1.1Dso)	abnormal macrophage morphology	J:221855
	abnormal microglial cell activation	J:221855
	increased macrophage cell number	J:221855
	increased macrophage derived foam cell number	J:221855
	increased microglial cell activation	J:221855
	microgliosis	J:221855
\Npc2^{Gt(LST105)Byg}/\Npc2^{Gt(LST105)Byg} (B6.129P2-Npc2^{Gt(LST105)Byg})	abnormal immune system morphology	J:125609
	abnormal immune system physiology	J:125609
\Npc2^tm1Plob/\Npc2^tm1Plob (involves: 129S1/Sv * C57BL/6)	decreased NK cell number	J:125609
\Npc2^tm1Plob/\Npc2^tm1Plob (C.129S1-Npc2^tm1Plob)	abnormal NK cell physiology	J:125609
	abnormal T cell physiology	J:125609
	decreased NK cell number	J:125609
\Npc2^tm1Plob/\Npc2^tm1Plob (involves: 129S1/Sv * BALB/c)	abnormal alveolar macrophage morphology	J:204311
\Npepps^tm1Klr/\Npepps^tm1Klr (involves: 129 * C57BL/6)	immune system phenotype	J:131502
\Npffr2^tm1.2Ics/\Npffr2^tm1.2Ics (involves: C57BL/6N)	abnormal macrophage activation involved in immune response	J:245025
	decreased macrophage cell number	J:245025
	decreased macrophage proliferation	J:245025
\Nphp3^pcy/\Nphp3^pcy (KK-Nphp3^pcy)	kidney inflammation	J:8302
\Nphp3^pcy/\Nphp3^pcy (either: D2.KK-Nphp3^pcy or (involves: DBA/2Fg * DBA/2J * KK))	kidney inflammation	J:11399
\Nphp3^pol/\Nphp3^pol (C57BL/6JSfdAnu-Nphp3^pol/Anu)	kidney inflammation	J:104190
\Npl^{Gt(OST15553)Lex}/\Npl^{Gt(OST15553)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	immune system phenotype	J:103485
\Npm1^tm1Gsva/\Npm1⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased B cell number	J:172071
	enlarged spleen	J:172071
	increased granulocyte number	J:172071
	increased leukocyte cell number	J:172071
	increased spleen weight	J:172071
\Npm1^tm1Hft/\Npm1⁺ (involves: 129)	abnormal granulocyte differentiation	J:194999
	abnormal spleen B cell follicle morphology	J:194999
	enlarged spleen	J:194999
	increased granulocyte number	J:194999
	increased leukocyte cell number	J:194999
	increased monocyte cell number	J:194999
	increased spleen weight	J:194999
	myeloid hyperplasia	J:194999
\Npm1^tm1Ppp/\Npm1⁺ (involves: 129S1/Sv * C57BL/6)	abnormal thrombopoiesis	J:101494
\Npr1^tm1Gar/\Npr1^tm1Gar (B6.129S7-Npr1^tm1Gar)	impaired neutrophil chemotaxis	J:70496
\Npr2^cn/\Npr2^cn (AKR/J)	small spleen	J:5109
\Npr3^tm1Unc/\Npr3^tm1Unc (involves: 129 * C57BL/6)	abnormal osteoclast morphology	J:56058
\Nprl3^tm1.1Drhi/\Nprl3^tm1.1Drhi (involves: 129P2/OlaHsd)	abnormal lymph organ development	J:183988
\Npsr1^{tm1b(KOMP)Wtsi}/\Npsr1^{tm1b(KOMP)Wtsi} (C57BL/6N-Npsr1^{tm1b(KOMP)Wtsi}/Rbrc)	increased eosinophil cell number	J:211773
\Npsr1^tm1Bhk/\Npsr1^tm1Bhk (either: (involves: 129S6/SvEvTac * BALB/c) or (involves: 129S6/SvEvTac * C57BL/6))	immune system phenotype	J:144688
\Npsr1^tm1Bhk/\Npsr1^tm1Bhk (129S/SvEv-Npsr1^tm1Bhk)	immune system phenotype	J:144688
\Npy1r^tm1.1Wpg/\Npy1r^tm1.1Wpg (involves: 129X1/SvJ * C57BL/6)	abnormal immune cell physiology	J:118850
	abnormal immune system organ morphology	J:118850
	abnormal immune system physiology	J:118850
	abnormal immunoglobulin level	J:118850
	abnormal inflammatory response	J:118850
	abnormal lymph node cell ratio	J:118850
	abnormal macrophage physiology	J:118850
	abnormal professional antigen presenting cell physiology	J:118850
	abnormal spleen morphology	J:118850
	abnormal splenic cell ratio	J:118850
	abnormal T cell activation	J:118850
	abnormal T cell number	J:118850
	abnormal T-helper 1 physiology	J:118850
	decreased B cell number	J:118850
	decreased CD8-positive, alpha-beta T cell number	J:118850
	decreased circulating interleukin-12 level	J:118850
	decreased circulating tumor necrosis factor level	J:118850
	decreased IgG2a level	J:118850
	decreased interferon-gamma secretion	J:118850
	decreased marginal zone B cell number	J:118850
	decreased mature B cell number	J:118850
	decreased susceptibility to type IV hypersensitivity reaction	J:118850
	decreased transitional stage B cell number	J:118850
	increased CD4-positive, alpha-beta T cell number	J:118850
	increased CD8-positive, alpha-beta T cell number	J:118850
	increased IgA level	J:118850
	increased IgG2b level	J:118850
	increased IgM level	J:118850
	increased immunoglobulin level	J:118850
	increased single-positive T cell number	J:118850
	small spleen	J:118850
\Npy2r^em1(IMPC)H/\Npy2r^em1(IMPC)H (C57BL/6N-Npy2r^em1(IMPC)H/H)	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Npy2r^tm1.1Hhz/\Npy2r^tm1.1Hhz (involves: 129X1/SvJ * BALB/cJ * C57BL/6)	decreased osteoclast cell number	J:84570
\Npy2r^tm1Hhz/\Npy2r^tm1Hhz (involves: 129X1/SvJ * C57BL/6)	decreased osteoclast cell number	J:97455
\Nqo2^tm1Akj/\Nqo2^tm1Akj (Not Specified)	abnormal lymphopoiesis	J:80549
\Nqo2^tm1Akj/\Nqo2^tm1Akj (Not Specified)	increased granulocyte number	J:80549
\Nr1d1^{tm1(KOMP)Vlcg}/\Nr1d1^{tm1(KOMP)Vlcg} (C57BL/6N-Nr1d1^{tm1(KOMP)Vlcg}/Bay)	decreased NK cell number	J:211773
\Nr1h2^tm1.1Gstr/\Nr1h2^tm1.1Gstr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased microglial cell activation	J:278794
\Nr1h2^tm1.1Gstr/\Nr1h2^tm1.1Gstr \Nr1h3^tm1.1Gstr/\Nr1h3^tm1.1Gstr (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased macrophage derived foam cell number	J:81790, J:234268
	lung inflammation	J:234268
\Nr1h2^tm1Djm/\Nr1h2^tm1Djm (involves: 129S6/SvEvTac * C57BL/6)	increased susceptibility to bacterial infection	J:81696
\Nr1h2^tm1Djm/\Nr1h2^tm1Djm \Nr1h3^tm1Djm/\Nr1h3^tm1Djm (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:125452
	increased susceptibility to bacterial infection	J:81696
\Nr1h3^tm1Djm/\Nr1h3^tm1Djm (involves: 129S6/SvEvTac * C57BL/6)	increased inflammatory response	J:158168
	increased susceptibility to bacterial infection	J:81696
\Nr1h3^tm1Wexi/\Nr1h3^tm1Wexi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased susceptibility to endotoxin shock	J:155709
\Nr1h4^tm1.1Mbj/\Nr1h4^tm1.1Mbj (B6N.B6-Nr1h4^tm1.1Mbj)	increased spleen weight	J:200842
\Nr1h4^tm1.1Mbj/\Nr1h4^tm1.1Mbj (B6N.B6-Nr1h4^tm1.1Mbj)	liver inflammation	J:200842
\Nr1h4^tm1Gonz/\Nr1h4^tm1Gonz (involves: 129X1/SvJ * C57BL/6)	liver inflammation	J:118204
\Nr2c2^tm1Amj/\Nr2c2^tm1Amj (B6.129-Nr2c2^tm1Amj)	decreased inflammatory response	J:169333
\Nr2f2^tm2.1Tsa/\Nr2f2^tm2.1Tsa \Rbpj^tm1Hon/\Rbpj^tm1Hon \Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6 * SJL)	decreased lymphatic vessel endothelial cell number	J:158959
\Nr2f2^tm2.1Tsa/\Nr2f2^tm2.1Tsa \Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6 * SJL)	decreased lymphatic vessel endothelial cell number	J:158959
\Nr3c1^tm1.1Jaci/\Nr3c1^tm1.1Jaci \Tg(Myh6-cre)2182Mds/0 (involves: C57BL/6 * FVB/N)	heart inflammation	J:201995
\Nr3c1^tm1.1Jda/\Nr3c1⁺ \Tg(Lck-cre)548Jxm/0 (B6.Cg-Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm)	decreased thymocyte apoptosis	J:189951
\Nr3c1^tm1.1Jda/\Nr3c1^tm1.1Jda \Rag2^tm1.1Cgn/\Rag2^tm1.1Cgn \Tg(Lck-cre)548Jxm/0 \Tg(TcrAND)53Hed/0 (B6.Cg-Rag2^tm1.1Cgn Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm Tg(TcrAND)53Hed)	decreased double-positive T cell number	J:189951
\Nr3c1^tm1.1Jda/\Nr3c1^tm1.1Jda \Tcra^tm1Mom/\Tcra^tm1Mom \Tg(Lck-cre)548Jxm/0 (B6.Cg-Tcra^tm1Mom Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm)	decreased double-positive T cell number	J:189951
\Nr3c1^tm1.1Jda/\Nr3c1^tm1.1Jda \Tg(Lck-cre)548Jxm/0 (B6.Cg-Nr3c1^tm1.1Jda Tg(Lck-cre)548Jxm)	abnormal humoral immune response	J:189951
	decreased CD4-positive, alpha-beta T cell number	J:189951
	decreased CD8-positive, alpha-beta T cell number	J:189951
	decreased double-positive T cell number	J:189951
	decreased single-positive T cell number	J:189951
	decreased thymocyte apoptosis	J:189951
	thymus hypoplasia	J:189951
\Nr3c1^tm1Dage/\Nr3c1⁺ (involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:147914
\Nr3c1^tm1Dage/\Nr3c1^tm1Dage (involves: 129P1/ReJ * C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:147914
	decreased CD4-positive, alpha-beta T cell number	J:147914
	decreased CD8-positive, alpha-beta T cell number	J:147914
	decreased macrophage cell number	J:147914
\Nr3c1^tm1Ljm/\Nr3c1^tm1Ljm (involves: 129S6/SvEvTac * C57BL/6)	abnormal thymocyte apoptosis	J:82174
\Nr3c1^tm2.1Gsc/\Nr3c1⁺ (B6.129P2-Nr3c1^tm2.1Gsc)	decreased T cell apoptosis	J:126427
\Nr3c1^tm2.1Gsc/\Nr3c1⁺ (B6.129P2-Nr3c1^tm2.1Gsc)	increased susceptibility to experimental autoimmune encephalomyelitis	J:137157
\Nr3c1^tm2.1Ljm/\Nr3c1^tm2.1Ljm \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal interleukin-6 secretion	J:197150
	abnormal monocyte cell number	J:197150
	increased interleukin-1 beta secretion	J:197150
\Nr3c1^tm2Gsc/\Nr3c1^tm2Gsc \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.129P2-Lyz2^tm1(cre)Ifo Nr3c1^tm2Gsc)	immune system phenotype	J:137157
\Nr3c1^tm2Gsc/\Nr3c1^tm2Gsc \Tg(Lck-cre)I57Jxm/0 (B6.Cg-Nr3c1^tm2Gsc Tg(Lck-cre)I57Jxm)	decreased T cell apoptosis	J:137157
	increased susceptibility to experimental autoimmune encephalomyelitis	J:137157
\Nr3c1^tm2Ljm/\Nr3c1^tm2Ljm \Tg(Lck-cre)548Jxm/? (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal interferon level	J:97484
	abnormal interleukin level	J:97484
	abnormal tumor necrosis factor level	J:97484
	cecum inflammation	J:97484
	increased susceptibility to endotoxin shock	J:97484
\Nr4a1^tm1Jmi/\Nr4a1^tm1Jmi (involves: 129S2/SvPas)	decreased B cell apoptosis	J:306652
	immune system phenotype	J:77686
	increased B cell proliferation	J:306652
\Nr4a1^tm1Jmi/\Nr4a1^tm1Jmi (involves: 129S2/SvPas * C57BL/6)	decreased Ly6C low monocyte number	J:239509
	increased susceptibility to endotoxin shock	J:239509
\Nr4a1^tm1Jmi/\Nr4a1^tm1Jmi \Nr4a3^tm1Omc/\Nr4a3^tm1Omc (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal leukopoiesis	J:121903
	abnormal myelopoiesis	J:121903
	abnormal spleen morphology	J:121903
	abnormal thymus morphology	J:121903
	decreased lymphocyte cell number	J:121903
	enlarged lymph nodes	J:121903
	enlarged spleen	J:121903
	increased eosinophil cell number	J:121903
	increased granulocyte number	J:121903
	increased leukocyte cell number	J:121903
	increased neutrophil cell number	J:121903
\Nr4a1^tm1Pcn/\Nr4a1^tm1Pcn \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:205658
\Nr4a1^tm1Pcn/\Nr4a1^tm1Pcn \Tg(Cr2-cre)3Cgn/0 (involves: 129)	increased B cell proliferation	J:306652
\Nr4a2^tm1.1Pcn/\Nr4a2⁺ \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal regulatory T cell morphology	J:205658
\Nr4a2^tm1.1Pcn/\Nr4a2^tm1.1Pcn \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal regulatory T cell morphology	J:205658
	abnormal T-helper 1 cell differentiation	J:205658
	abnormal T-helper 17 cell differentiation	J:205658
\Nr4a2^tm1.1Pcn/\Nr4a2^tm1.1Pcn \Tg(Lck-cre)1Jtak/0 (Not Specified)	abnormal regulatory T cell morphology	J:205658
	abnormal T-helper 1 cell differentiation	J:205658
	abnormal T-helper 17 cell differentiation	J:205658
	decreased regulatory T cell number	J:205658
	immune system phenotype	J:205658
	increased CD4-positive, alpha-beta T cell number	J:205658
	increased susceptibility to induced colitis	J:205658
	increased T-helper 1 cell number	J:205658
\Nr5a2^tm1Auw/\Nr5a2⁺ (involves: 129P2/OlaHsd)	increased susceptibility to induced colitis	J:123697
\Nr5a2^tm1Sjns/\Nr5a2^tm1Sjns \Tg(Vil1-cre/ERT2)23Syr/? (involves: 129/Sv * C57BL/6 * DBA/2 * SJL)	increased susceptibility to induced colitis	J:123697
\Nras^tm1.1Emfu/\Nras^tm1.1Emfu (involves: 129S1/Sv * FVB/N)	abnormal granulocyte differentiation	J:189834
	abnormal leukocyte cell number	J:189834
	abnormal thymus morphology	J:189834
	decreased monocyte cell number	J:189834
	decreased spleen weight	J:189834
	increased granulocyte number	J:189834
	increased T cell number	J:189834
\Nras^tm1Tyj/\Nras^tm1Tyj \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal myelopoiesis	J:174880
	enlarged spleen	J:204263, J:174880
	increased leukocyte cell number	J:204263
	increased monocyte cell number	J:204263
	increased neutrophil cell number	J:204263
	myeloid hyperplasia	J:204263
\Nrbp1^{tm3b(EUCOMM)Wtsi}/\Nrbp1⁺ (C57BL/6N-Nrbp1^{tm3b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
\Nrp1^tm1Ddg/\Nrp1^tm1Ddg (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:161856
\Nrp1^tm1Ddg/\Nrp1^tm1Ddg (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:161856
\Nrp2^tm1.2Mom/\Nrp2⁺ \Sema3f^tm1.2Ddg/\Sema3f⁺ (involves: 129P2/OlaHsd)	abnormal lymphatic vessel endothelial cell morphology	J:226501
\Nrp2^tm1.2Mom/\Nrp2^tm1.2Mom (involves: 129P2/OlaHsd)	abnormal lymphatic system physiology	J:226501
	abnormal lymphatic vessel endothelial cell morphology	J:226501
	abnormal lymphatic vessel morphology	J:226501
	lymphatic vessel hyperplasia	J:226501
\Nrp2^tm1Ddg/\Nrp2^tm1Ddg (involves: C57BL/6)	abnormal lymphangiogenesis	J:156869
\Nrros^tm1Lex/\Nrros^tm1Lex (B6.129S5-Nrros^tm1Lex)	decreased susceptibility to infection	J:209569
\Nrros^tm1Lex/\Nrros^tm1Lex (B6.129S5-Nrros^tm1Lex)	increased susceptibility to experimental autoimmune encephalomyelitis	J:209569
\Nrsn2^{em1(IMPC)Kmpc}/\Nrsn2^{em1(IMPC)Kmpc} (C57BL/6NTac-Nrsn2^{em1(IMPC)Kmpc}/Kmpc)	abnormal lymph node morphology	J:211773
\Nrtn^tm1Jmi/\Nrtn^tm1Jmi (involves: 129X1/SvJ * C57BL/6)	increased incidence of corneal inflammation	J:85753
\Nrtn^tm1Jmi/\Nrtn^tm1Jmi (involves: 129X1/SvJ * C57BL/6)	keratoconjunctivitis sicca	J:85753
\Nrxn1^{tm1b(KOMP)Wtsi}/\Nrxn1⁺ (C57BL/6N-Nrxn1^{tm1b(KOMP)Wtsi}/H)	increased neutrophil cell number	J:211773
\Nrxn1^{tm1b(KOMP)Wtsi}/\Nrxn1^{tm1b(KOMP)Wtsi} (C57BL/6N-Nrxn1^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Nsd3^{tm1b(EUCOMM)Hmgu}/\Nsd3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nsd3^{tm1b(EUCOMM)Hmgu}/H)	small spleen	J:211773
\Nsg1^{tm1.1(KOMP)Vlcg}/\Nsg1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Nsg1^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Nsl1^em1(IMPC)J/\Nsl1⁺ (C57BL/6NJ-Nsl1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Nsmaf^tm1Mkr/\Nsmaf^tm1Mkr (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:54972
\Nsmaf^tm1Mkr/\Nsmaf^tm1Mkr (involves: 129P2/OlaHsd)	immune system phenotype	J:54972
\Nsmaf^tm1Mkr/\Nsmaf^tm1Mkr (B6.129P2-Nsmaf^tm1Mkr)	decreased susceptibility to endotoxin shock	J:89524
\Nsmce1^{em1(IMPC)Wtsi}/\Nsmce1⁺ (C57BL/6N-Nsmce1^{em1(IMPC)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Nsmce2^tm2.1Ofc/\Nsmce2^tm2.1Ofc \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * C57BL/6 * SJL)	abnormal thymus physiology	J:227197
\Nsrp1^tm1.1Cdj/\Nsrp1^tm1.1Cdj \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal T cell number	J:306261
	decreased CD4-positive, alpha-beta T cell number	J:306261
	decreased CD8-positive, alpha-beta T cell number	J:306261
	immune system phenotype	J:306261
	increased memory T cell number	J:306261
	increased T cell apoptosis	J:306261
	increased T cell proliferation	J:306261
\Nss1^NOD/ShiLtJ/\Nss1^NOD/ShiLtJ (involves: C57BL/10 * NOD)	salivary gland inflammation	J:73932
\Nsun2^{tm1a(EUCOMM)Wtsi}/\Nsun2^{tm1a(EUCOMM)Wtsi} (B6JTyr;B6N-Nsun2^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus capsule morphology	J:239583
\Nsun5^{tm2b(EUCOMM)Wtsi}/\Nsun5^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Nsun5^{tm2b(EUCOMM)Wtsi}/J)	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased neutrophil cell number	J:211773
\Nsv1^C57BL/6J/? (involves: BALB/cBy * C57BL/6J)	increased susceptibility to viral infection	J:71216
\Nt5c3^em1(IMPC)Tcp/\Nt5c3^em1(IMPC)Tcp (C57BL/6NCrl-Nt5c3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Nt5e^em1(IMPC)Mbp/\Nt5e^em1(IMPC)Mbp (C57BL/6NCrl-Nt5e^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Ntan1^tm1Avar/\Ntan1^tm1Avar (involves: 129)	abnormal T cell physiology	J:62140
	decreased splenocyte proliferation	J:62140
	increased acute inflammation	J:62140
\Ntaq1^{tm1.1(KOMP)Vlcg}/\Ntaq1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ntaq1^{tm1.1(KOMP)Vlcg}/J)	increased leukocyte cell number	J:211773
\Ntn4^{tm1b(KOMP)Wtsi}/\Ntn4^{tm1b(KOMP)Wtsi} (C57BL/6N-Ntn4^{tm1b(KOMP)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
\Ntrk1^{tm1b(EUCOMM)Wtsi}/\Ntrk1⁺ (C57BL/6N-Ntrk1^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
\Ntrk1^tm1Tes/\Ntrk1^tm1Tes \Tg(Tuba1-cre)1Tes/0 (involves: 129S1/Sv)	abnormal mast cell physiology	J:93578
	increased B-1 B cell number	J:93578
	increased IgG1 level	J:93578
	increased IgG2a level	J:93578
	increased IgM level	J:93578
	increased immunoglobulin level	J:93578
\Nub1^{tm1b(EUCOMM)Hmgu}/\Nub1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nub1^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD4-negative NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD5-positive Ly6C-positive T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD11b-high dendritic cell number	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	enlarged spleen	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
\Nucb1^em1(IMPC)Mbp/\Nucb1^em1(IMPC)Mbp (C57BL/6NCrl-Nucb1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Nucb2^tm1.2Vdix/\Nucb2^tm1.2Vdix (involves: C57BL/6)	increased interleukin-1 beta secretion	J:270674
\Nucb2^tm1.2Vdix/\Nucb2^tm1.2Vdix (involves: C57BL/6)	increased tumor necrosis factor secretion	J:270674
\Nucks1^{tm1b(EUCOMM)Hmgu}/\Nucks1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Nucks1^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
	increased leukocyte cell number	J:211773
\Nudc^{tm1c(KOMP)Mbp}/\Nudc^{tm1c(KOMP)Mbp} \Tg(Rho-icre)1Ck/0 (involves: C57BL/6 * C57BL/6N * SJL)	increased microglial cell activation	J:346299
\Nudcd3^{em1(IMPC)Wtsi}/\Nudcd3^{em1(IMPC)Wtsi} (C57BL/6N-Nudcd3^{em1(IMPC)Wtsi}/Wtsi)	abnormal immunoglobulin light chain V-J recombination	J:351330
	abnormal T cell differentiation	J:351330
	abnormal T cell receptor V(D)J recombination	J:351330
	decreased NK T cell number	J:351330
	increased DN3 thymocyte number	J:351330
	increased double-negative T cell number	J:351330
	increased double-positive T cell number	J:351330
	increased IgE level	J:351330
	increased IgG2b level	J:351330
	increased IgM level	J:351330
	increased memory T cell number	J:351330
	increased pre-B cell number	J:351330
	thymus hypoplasia	J:351330
\Nudt1^tm1Tts/\Nudt1^tm1Tts \Ogg1^tm1Yun/\Ogg1^tm1Yun (involves: 129S/SvEv * C57BL/6JJcl)	microgliosis	J:193978
\Nudt2^{tm1a(EUCOMM)Wtsi}/\Nudt2^{tm1a(EUCOMM)Wtsi} (C57BL/6-Nudt2^{tm1a(EUCOMM)Wtsi})	immune system phenotype	J:315167
\Nudt7^em1Ejj/\Nudt7^em1Ejj (involves: C57BL/6N)	increased susceptibility to induced arthritis	J:266261
\Nudt7^em1Ejj/\Nudt7^em1Ejj (involves: C57BL/6N)	osteoarthritis	J:266261
\Nudt15^em1Maska/\Nudt15⁺ (C57BL/6-Nudt15^em1Maska)	decreased neutrophil cell number	J:285800
\Nudt15^em1Maska/\Nudt15^em1Maska (C57BL/6-Nudt15^em1Maska)	decreased neutrophil cell number	J:285800
\Nudt21^tm1.1Ejwpj/\Nudt21^tm1.1Ejwpj \Tg(Col1a1-cre/ERT2)1Crm/0 (involves: C57BL/6J * CBA/J)	increased acute inflammation	J:283035
\Nuggc^{em1(IMPC)Ccpcz}/\Nuggc^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nuggc^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Nuggc^tm1Diaz/\Nuggc^tm1Diaz \Edil3^{Tg(Sox2-cre)1Amc}/\Edil3⁺ (involves: C57BL/6 * C57BL/6J * CBA)	abnormal somatic hypermutation frequency	J:190402
	immune system phenotype	J:190402
\Nup35^m1Apb/\Nup35^m1Apb (involves: C57BL/6N)	abnormal macrophage morphology	J:235141
\Nup62cl^em1(IMPC)J/Y (C57BL/6NJ-Nup62cl^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Nup85^tm1.1Yter/\Nup85^tm1.1Yter \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	decreased Ly6C high monocyte number	J:292726
	decreased Ly6C low monocyte number	J:292726
	decreased macrophage cell number	J:292726
\Nup98^tm1Bmaf/\Nup98⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal level of surface class I molecules	J:110907
	abnormal level of surface class II molecules	J:110907
	abnormal MHC II cell surface expression on macrophages	J:110907
	decreased B cell number	J:110907
	decreased CD4-positive, alpha-beta T cell number	J:110907
	decreased IgG1 level	J:110907
	decreased IgG level	J:110907
	decreased T cell proliferation	J:110907
	increased T cell proliferation	J:110907
\Nup155^em1(IMPC)Mbp/\Nup155⁺ (C57BL/6NCrl-Nup155^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Nup210^enuI476T/\Nup210^enuI476T (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal alpha-beta T cell morphology	J:266693
	decreased CD4-positive, alpha-beta T cell number	J:266693
\Nup210^enuI476T/\Nup210^{tm1a(EUCOMM)Hmgu} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:266693
\Nup210^tm1.1Mdan/\Nup210^tm1.1Mdan (B6.Cg-Nup210^tm1.1Mdan)	abnormal CD4-positive, alpha-beta T cell number	J:282451
	abnormal CD4-positive, alpha-beta T cell physiology	J:282451
	abnormal lymphocyte morphology	J:282451
	abnormal T cell activation	J:282451
	decreased CD4-positive, alpha-beta T cell number	J:282451
	decreased leukocyte cell number	J:282451
	increased effector memory T-helper cell number	J:282451
\Nup210^{tm1b(EUCOMM)Hmgu}/\Nup210^{tm1b(EUCOMM)Hmgu} (involves: C57BL/6N)	decreased alpha-beta T cell number	J:266693
	decreased CD4-positive, alpha-beta T cell number	J:266693
	decreased CD8-positive, alpha-beta T cell number	J:266693
	decreased T cell number	J:266693
	immune system phenotype	J:266693
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:266693
	increased CD8-positive, alpha-beta T cell number	J:266693
	increased central memory CD8 positive, alpha-beta T cell number	J:266693
	increased T-helper 1 cell number	J:266693
\Nup210^tm1Mdan/\Nup210^tm1Mdan \Tg(Cd4-cre/ERT2)11Gnri/0 (involves: 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:282451
\Nus1^tm1Wcsa/\Nus1^tm1Wcsa \Tg(Cdh5-cre/ERT2)1Rha/0 (Not Specified)	abnormal jugular lymph sac morphology	J:230506
\Nwa2^NZW/LacJ/\Nwa2^NZW/LacJ (involves: BALB/cJ * NZW/LacJ)	increased anti-histone antibody level	J:35434
	increased anti-single stranded DNA antibody level	J:35434
\Nwd1^em2.1Sisa/\Nwd1^em2.1Sisa (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal Kupffer cell morphology	J:363603
	increased leukocyte cell number	J:363603
\Nwd2^{em1(IMPC)Ccpcz}/\Nwd2^{em1(IMPC)Ccpcz} (C57BL/6N-Nwd2^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD8-positive, naive alpha-beta T cell number	J:211773
\Nxn^{tm1b(EUCOMM)Wtsi}/\Nxn⁺ (C57BL/6N-Nxn^{tm1b(EUCOMM)Wtsi}/Ccpcz)	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Nxnl1^tm1.2Tlev/\Nxnl1^tm1.2Tlev (involves: BALB/c * BALB/cJ * C57BL/6)	microgliosis	J:186370
\Nxnl2^{em1(IMPC)Ccpcz}/\Nxnl2⁺ (C57BL/6NCrl-Nxnl2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Nxnl2^{em1(IMPC)Ccpcz}/\Nxnl2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Nxnl2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Oas1b^Flv-mr/\Oas1b^Flv-mr (MOLD/RkJ)	decreased susceptibility to Flaviviridae infection	J:3674
\Oas1b^Flv-r/\Oas1b^Flv-r (multiple strains)	decreased susceptibility to Flaviviridae infection	J:15009
\Oas1b^Flv-r/\Oas1b^Flv-r (C3.PRI-Oas1b^Flv-r)	decreased susceptibility to Flaviviridae infection	J:175365
\Oas1b^Flv-s/\Oas1b^Flv-s (multiple strains)	increased susceptibility to Flaviviridae infection	J:15009
\Oas1b^tm1.1Brin/\Oas1b^tm1.1Brin (involves: 129X1/SvJ * C57BL/6J)	decreased susceptibility to Flaviviridae infection	J:175365
\Oas1c^{em1(IMPC)Ccpcz}/\Oas1c^{em1(IMPC)Ccpcz} (C57BL/6N-Oas1c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Oasl1^tm1Yjk/\Oasl1^tm1Yjk (B6.129P2-Oasl1^tm1Yjk)	abnormal circulating interferon level	J:194467
	decreased susceptibility to Picornaviridae infection	J:194467
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:194467
\Obp2b^{em1(IMPC)Kmpc}/\Obp2b^{em1(IMPC)Kmpc} (C57BL/6NTac-Obp2b^{em1(IMPC)Kmpc}/Kmpc)	abnormal lymph node morphology	J:211773
\Oca2^p-3Btlr/\Oca2^p-3Btlr (C57BL/6J-Oca2^p-3Btlr)	abnormal NK cell physiology	J:133623
\Oca2^p-3Btlr/\Oca2^p-3Btlr (C57BL/6J-Oca2^p-3Btlr)	increased susceptibility to bacterial infection	J:133623
\Oca2^p-4Btlr/\Oca2^p-4Btlr (C57BL/6J-Oca2^p-4Btlr)	immune system phenotype	J:133624
\Oca2^p-4Btlr/\Oca2^p-4Btlr (C57BL/6J-Oca2^p-4Btlr)	increased susceptibility to bacterial infection	J:133624
\Oca2^p-8Btlr/\Oca2^p-8Btlr (C57BL/6J-Oca2^p-8Btlr)	increased susceptibility to induced colitis	J:264643
\Oca2^p-23DFiOD/\Oca2^p-x (Not Specified)	increased spleen weight	J:66645
\Oca2^p-30PUb/\Oca2^p-x (Not Specified)	increased spleen weight	J:89922
\Oca2^p-Btlr/\Oca2^p-Btlr (C57BL/6J-Oca2^p-Btlr)	immune system phenotype	J:133621
\Ociad1^em1(IMPC)J/\Ociad1^em1(IMPC)J (C57BL/6NJ-Ociad1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ociad1^tm1.1Msin/\Ociad1^tm1.1Msin (involves: BALB/cJ * C57BL/6NCrlj * CBA/JNCrlj)	decreased B cell number	J:279239
	decreased T cell number	J:279239
	enlarged spleen	J:279239
	increased granulocyte number	J:279239
	increased macrophage cell number	J:279239
	increased monocyte cell number	J:279239
	increased neutrophil cell number	J:279239
	increased spleen germinal center size	J:279239
\Ocln^{Gt(ROSA)39Tshi}/\Ocln^{Gt(ROSA)39Tshi} (involves: DBA/2)	stomach inflammation	J:110222
\Ocln^tm1Sts/\Ocln^tm1Sts (involves: 129S4/SvJae * C57BL/6)	stomach inflammation	J:99467
\Ocln^tm1Tshi/\Ocln^tm1Tshi (involves: C57BL/6 * DBA/2)	stomach inflammation	J:110222
\Ocln^tm2Sts/\Ocln^tm2Sts (involves: 129S4/SvJae * C57BL/6)	stomach inflammation	J:99467
\Ocstamp^{tm2a(KOMP)Wtsi}/\Ocstamp^{tm2a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	abnormal osteoclast morphology	J:233553
\Odad2^b2b227.1Clo/\Odad2^b2b227.1Clo (C57BL/6J-Odad2^b2b227.1Clo)	spleen hypoplasia	J:175213
\Odad2^em1(IMPC)Mbp/\Odad2^em1(IMPC)Mbp (C57BL/6N-Odad2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Odad3^b2b1885Clo/\Odad3^b2b1885Clo (C57BL/6J-Odad3^b2b1885Clo)	spleen hypoplasia	J:175213
\Odad3^{tm1b(EUCOMM)Hmgu}/\Odad3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Odad3^{tm1b(EUCOMM)Hmgu}/Cnrm)	abnormal spleen morphology	J:278798
	absent spleen	J:278798
	enlarged spleen	J:278798
\Odaph^{em1(IMPC)Ccpcz}/\Odaph^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Odaph^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Odf2^tm1.1Sats/\Odf2^tm1.2Sats \Tg(CAG-cre)13Miya/0 (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:181294
	increased susceptibility to otitis media	J:181294
	sinus inflammation	J:181294
\oed/\oed (STOCK pc-oed)	increased granulocyte number	J:5609
\oed/\oed (STOCK pc-oed)	increased leukocyte cell number	J:5609
\Ogdh^{tm1e(KOMP)Wtsi}/\Ogdh⁺ (C57BL/6N-Ogdh^{tm1e(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Ogg1^tm1Yun/\Ogg1^tm1Yun (involves: 129S/SvEv * C57BL/6JJcl)	microgliosis	J:193978
\Ogn^{tm1b(KOMP)Wtsi}/\Ogn^{tm1b(KOMP)Wtsi} (C57BL/6N-Ogn^{tm1b(KOMP)Wtsi}/J)	decreased leukocyte cell number	J:211773
\Ogt^tm1Gwh/Y \Tg(Lck-cre)548Jxm/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:93112
	decreased CD8-positive, alpha-beta T cell number	J:93112
	decreased double-positive T cell number	J:93112
	decreased T cell number	J:93112
	decreased thymocyte number	J:93112
	increased T cell apoptosis	J:93112
\oh/\oh (Not Specified)	increased macrophage cell number	J:5300
\Olah^em1Kedk/\Olah^em1Kedk (involves: C57BL/6)	abnormal macrophage morphology	J:353571
	abnormal macrophage physiology	J:353571
	decreased susceptibility to Orthomyxoviridae infection	J:353571
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:353571
	spleen hyperplasia	J:353571
\Olfm4^tm1Gpro/\Olfm4^tm1Gpro (involves: 129X1/SvJ * Black Swiss)	abnormal cytokine level	J:161279
	increased circulating interleukin-3 level	J:161279
	increased circulating interleukin-12 level	J:161279
	increased susceptibility to bacterial infection	J:161279
	stomach inflammation	J:161279
\Olr1^tm1Meht/\Olr1^tm1Meht (B6.129X1-Olr1^tm1Meht/Meht)	increased circulating interleukin-10 level	J:130794
\Oma1^tm1Otin/\Oma1^tm1Otin (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr)	granulomatous inflammation	J:184716
\Onecut1^tm1.1Mga/\Onecut1^tm1.1Mga \Tg(Pdx1-cre)89.1Dam/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)	pancreas inflammation	J:155058
\Opn3^em1(IMPC)Mbp/\Opn3^em1(IMPC)Mbp (C57BL/6NCrl-Opn3^em1(IMPC)Mbp/Mmucd)	decreased leukocyte cell number	J:211773
	increased basophil cell number	J:211773
\Oprl1^em1(IMPC)Mbp/\Oprl1^em1(IMPC)Mbp (C57BL/6N-Oprl1^em1(IMPC)Mbp/MbpMmucd)	enlarged spleen	J:211773
\Oprm1^tm1Lyu/\Oprm1⁺ (involves: Black Swiss)	increased splenocyte proliferation	J:39864
\Oprm1^tm1Lyu/\Oprm1^tm1Lyu (involves: Black Swiss)	increased splenocyte proliferation	J:39864
\Optn^tm1.2Jda/\Optn^tm1.2Jda (involves: 129S4/SvJae * C57BL/6J)	immune system phenotype	J:207113
\Optn^tm1.2Jda/\Optn^tm1.2Jda (B6.Cg-Optn^tm1.2Jda)	immune system phenotype	J:207113
\Or1e1c^em1(IMPC)Mbp/\Or1e1c^em1(IMPC)Mbp (C57BL/6NCrl-Or1e1c^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Or1e32^em1(IMPC)Mbp/\Or1e32^em1(IMPC)Mbp (C57BL/6NCrl-Or1e32^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Or9g4^em1(IMPC)Mbp/\Or9g4^em1(IMPC)Mbp (C57BL/6N-Or9g4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Orai1^Gt(XL922)Byg/\Orai1⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal mast cell physiology	J:130479
	decreased interferon-gamma secretion	J:130479
\Orai1^Gt(XL922)Byg/\Orai1^Gt(XL922)Byg (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal mast cell physiology	J:130479
	decreased interferon-gamma secretion	J:130479
	decreased interleukin-2 secretion	J:130479
	decreased susceptibility to type I hypersensitivity reaction	J:130479
\Orai1^tm1.1Hjm/\Orai1^tm1.1Hjm \Orai2^{tm1.1(KOMP)Vlcg}/\Orai2^{tm1.1(KOMP)Vlcg} \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Orai1^tm1.1Hjm Orai2^{tm1.1(KOMP)Vlcg})	abnormal CD4-positive helper T cell morphology	J:241365
	abnormal T cell physiology	J:241365
	decreased germinal center B cell number	J:241365
	decreased IgG level	J:241365
	decreased regulatory T cell number	J:241365
	decreased single-positive T cell number	J:241365
	immune system phenotype	J:241365
	lymph node hyperplasia	J:241365
	spleen hyperplasia	J:241365
\Orai1^tm1.1Hjm/\Orai1^tm1.1Hjm \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Orai1^tm1.1Hjm Tg(Cd4-cre)1Cwi)	abnormal T cell physiology	J:241365
\Orai1^tm1Rao/\Orai1⁺ (C57BL/6-Orai1^tm1Rao)	abnormal B cell activation	J:139730
\Orai1^tm1Rao/\Orai1⁺ (C57BL/6-Orai1^tm1Rao)	abnormal T cell activation	J:139730
\Orai1^tm1Rao/\Orai1^tm1Rao (involves: C57BL/6NTac * ICR)	abnormal B cell activation	J:139730
	abnormal cell-mediated immunity	J:139730
	abnormal cytokine secretion	J:139730
	abnormal mast cell physiology	J:139730
	abnormal T cell activation	J:139730
	abnormal thymocyte activation	J:139730
	blepharitis	J:139730
	decreased interferon-gamma secretion	J:139730
	decreased interleukin-2 secretion	J:139730
	decreased interleukin-4 secretion	J:139730
	decreased interleukin-10 secretion	J:139730
\Orai2^{tm1.1(KOMP)Vlcg}/\Orai2^{tm1.1(KOMP)Vlcg} (B6.Cg-Orai2^{tm1.1(KOMP)Vlcg})	abnormal macrophage physiology	J:241365
	abnormal T cell physiology	J:241365
\Orai2^tm1.1Itl/\Orai2^tm1.1Itl \Tg(Cma1-cre)#Roer/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N)	increased susceptibility to type I hypersensitivity reaction	J:278536
\Orai2^tm1.2Itl/\Orai2^tm1.2Itl (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6N)	abnormal mast cell physiology	J:278536
	increased mast cell degranulation	J:278536
\Orch4^BALB/cByJ/\Orch4^BALB/cByJ (involves: BALB/cByJ * DBA/2)	testis inflammation	J:35331
\Orch4^BALB/cByJ/\Orch4^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
\Orch4^DBA/2J/\Orch4^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
\Orch5^BALB/cByJ/\Orch5^BALB/cByJ (involves: BALB/cByJ * DBA/2)	testis inflammation	J:35331
\Orch5^BALB/cByJ/\Orch5^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
\Orch5^DBA/2J/\Orch5^DBA/2J (involves: BALB/cByJ * DBA/2)	decreased inflammatory response	J:35331
\Orgwq1^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
\Orgwq2^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
\Orgwq6^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
\Orgwq7^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
\Orgwq8^M16i/? (involves: CAST/Ei * M16i)	increased spleen weight	J:78471
\Orm2^em1Bcgen/\Orm2^em1Bcgen (involves: C57BL/6J)	liver inflammation	J:333118
\Orm2^{tm1(KOMP)Vlcg}/\Orm2^{tm1(KOMP)Vlcg} (C57BL/6N-Orm2^{tm1(KOMP)Vlcg}/Mmucd)	kidney inflammation	J:292194
\Ormdl1^em1Pdra/\Ormdl1^em1Pdra (C57BL/6J-Ormdl1^em1Pdra)	immune system phenotype	J:349248
\Ormdl1^em1Pdra/\Ormdl1^em1Pdra \Ormdl2^em1Pdra/\Ormdl2^em1Pdra (C57BL/6-Ormdl1^em1Pdra Ormdl2^em1Pdra)	immune system phenotype	J:349248
\Ormdl1^em1Pdra/\Ormdl1^em1Pdra \Ormdl3^em1Pdra/\Ormdl3^em1Pdra (C57BL/6-Ormdl1^em1Pdra Ormdl3^em1Pdra)	abnormal mast cell physiology	J:349248
\Ormdl2^em1Pdra/\Ormdl2^em1Pdra (C57BL/6-Ormdl2^em1Pdra)	immune system phenotype	J:349248, J:328837
\Ormdl2^em1Pdra/\Ormdl2^em1Pdra \Ormdl3^em1Pdra/\Ormdl3^em1Pdra (C57BL/6-Ormdl2^em1Pdra Ormdl3^em1Pdra)	abnormal mast cell physiology	J:328837
	abnormal type I hypersensitivity reaction	J:328837
	increased interleukin-4 secretion	J:328837
	increased interleukin-6 secretion	J:328837
	increased mast cell degranulation	J:328837
	increased tumor necrosis factor secretion	J:328837
\Ormdl3^em1Pdra/\Ormdl3^em1Pdra (C57BL/6-Ormdl3^em1Pdra)	abnormal mast cell physiology	J:328837
	abnormal type I hypersensitivity reaction	J:328837
	increased mast cell degranulation	J:328837
\Ormdl3^em1Quli/\Ormdl3^em1Quli (Not Specified)	abnormal spleen morphology	J:251260
	abnormal splenic cell ratio	J:251260
	small spleen	J:251260
\Os/\Os⁺ (ROP/GnLeJ)	glomerulonephritis	J:28323
\Osbp^em1(IMPC)Tcp/\Osbp⁺ (C57BL/6NCrl-Osbp^em1(IMPC)Tcp/Cmmr)	enlarged lymph nodes	J:211773
\Oscar^tm1Ywc/\Oscar^tm1Ywc (involves: 129P2/OlaHsd)	abnormal osteoclast differentiation	J:178250
\Oscar^tm1Ywc/\Oscar^tm1Ywc \Tyrobp^tm1Ttk/\Tyrobp^tm1Ttk (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:178250
	abnormal osteoclast morphology	J:178250
	abnormal osteoclast physiology	J:178250
	decreased osteoclast cell number	J:178250
\Osmr^tm1Mtan/\Osmr^tm1Mtan (B6.129S-Osmr^tm1Mtan)	increased circulating interleukin-10 level	J:214124
	increased circulating tumor necrosis factor level	J:214124
	increased inflammatory response	J:214124
	white adipose tissue inflammation	J:214124
\Ostm1^gl/\Ostm1^gl (GL/Le Edar^dl-J +/+ Ostm1^gl/J)	eye inflammation	J:13053
\Otc^em1(IMPC)Tcp/\Otc⁺ (C57BL/6NCrl-Otc^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
\Otc^spf-ash/Y (involves: C57BL/6)	increased susceptibility to parasitic infection	J:23205
\Otc^spf-ash/Y (B6EiC3Sn a/A-Otc^spf-ash/J)	increased susceptibility to endotoxin shock	J:108979
\Otop1^{em1(IMPC)Ccpcz}/\Otop1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Otop1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Otub1^{tm1c(EUCOMM)Hmgu}/\Otub1^{tm1c(EUCOMM)Hmgu} \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal B cell activation	J:280549
	abnormal follicular B cell morphology	J:280549
	decreased B-1 B cell number	J:280549
	decreased immature B cell number	J:280549
	decreased T cell number	J:280549
	enlarged spleen	J:280549
	increased anti-double stranded DNA antibody level	J:280549
	increased anti-nuclear antigen antibody level	J:280549
	increased B cell number	J:280549
	increased B-2 B cell number	J:280549
	increased circulating interleukin-6 level	J:280549
	increased IgA level	J:280549
	increased IgG2a level	J:280549
	increased IgG2b level	J:280549
	increased IgM level	J:280549
	increased immunoglobulin level	J:280549
	increased marginal zone B cell number	J:280549
	increased mature B cell number	J:280549
	increased susceptibility to autoimmune disorder	J:280549
	increased susceptibility to systemic lupus erythematosus	J:280549
\Otud1^em2Gpt/\Otud1^em2Gpt (C57BL/6-Otud1^em2Gpt)	abnormal innate immunity	J:287309
	decreased susceptibility to Herpesvirales infection	J:287309
	decreased susceptibility to Riboviria infection	J:287309
	increased circulating interferon-beta level	J:287309
	increased susceptibility to endotoxin shock	J:287309
\Otud3^em1Nju/\Otud3^em1Nju (involves: C57BL/6N)	abnormal chemokine secretion	J:294274
	decreased susceptibility to Riboviria infection	J:294274
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:294274
	increased interferon-beta secretion	J:294274
\Otud5^tm1Vmd/\Otud5^tm1Vmd \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T-helper 17 cell differentiation	J:219495
	decreased regulatory T cell number	J:219495
	decreased thymocyte number	J:219495
	immune system phenotype	J:219495
	increased circulating interleukin-17 level	J:219495
	increased interleukin-9 secretion	J:219495
	increased interleukin-17 secretion	J:219495
	increased interleukin-21 secretion	J:219495
	intestinal inflammation	J:219495
\Otud5^tm1Vmd/\Otud5^tm1Vmd \Tg(Vav1-cre)#Cgp/0 (involves: C57BL/6)	abnormal T-helper 17 cell differentiation	J:219495
\Otud6a^em1Smoc/\Otud6a^em1Smoc (C57BL/6J-Otud6a^em1Smoc)	abnormal innate immunity	J:345141
	decreased susceptibility to Herpesvirales infection	J:345141
	decreased susceptibility to Riboviria infection	J:345141
\Otud6a^{tm1(KOMP)Vlcg}/\Otud6a^{tm1(KOMP)Vlcg} (C57BL/6N-Otud6a^{tm1(KOMP)Vlcg}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Otud6b^{tm1b(EUCOMM)Wtsi}/\Otud6b⁺ (C57BL/6N-Otud6b^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased basophil cell number	J:211773
\Otud7b^{tm1(NCOM)Cmhd}/\Otud7b^{tm1(NCOM)Cmhd} (involves: C57BL/6N)	abnormal granulocyte physiology	J:209709
\Otud7b^tm1Dgen/\Otud7b^tm1Dgen (involves: 129 * C57BL/6)	decreased activation-induced B cell apoptosis	J:194553
	decreased susceptibility to bacterial infection	J:194553
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:194553
	increased B cell number	J:194553
	increased B cell proliferation	J:194553
	increased IgA level	J:194553
	lymphoid hyperplasia	J:194553
\Otulin^em1(IMPC)Bay/\Otulin⁺ (C57BL/6N-Otulin^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Otulin^em1Gvl/\Otulin^{tm1c(EUCOMM)Hmgu} \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)	dermatitis	J:312394
\Otulin^{tm1c(EUCOMM)Hmgu}/\Otulin^{tm1c(EUCOMM)Hmgu} \Tg(KRT14-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	dermatitis	J:312394
\Otulin^{tm1c(EUCOMM)Hmgu}/\Otulin^{tm1c(EUCOMM)Hmgu} \Tg(KRT14-cre)1Cgn/0 \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:312394
\Oxgr1^{tm1(KOMP)Vlcg}/\Oxgr1^{tm1(KOMP)Vlcg} (involves: BALB/c * C57BL/6NTac)	abnormal immune system physiology	J:198383
\Oxsr1^tm1.1Arte/\Oxsr1⁺ (involves: 129S/SvEvBrd)	abnormal dendritic cell morphology	J:191351
\Oxsr1^tm1.1Arte/\Oxsr1⁺ (involves: 129S/SvEvBrd)	abnormal dendritic cell physiology	J:191351
\P2rx2^tm1Ckn/\P2rx2^tm1Ckn \P2rx3^tm1Ckn/\P2rx3^tm1Ckn (involves: 129P2/OlaHsd * C57BL/6)	lung inflammation	J:86890
\P2rx4^tm1Ando/\P2rx4^tm1Ando (involves: 129S4/SvJae * BALB/c * C57BL/6)	abnormal neutrophil physiology	J:311564
\P2rx4^tm1Dgen/\P2rx4^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:145232
\P2rx5^tm1Lex/\P2rx5^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased CD8-positive, alpha-beta T cell number	J:82809
	increased NK cell number	J:82809
\P2rx7^tm1Gab/\P2rx7^tm1Gab (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * DBA/2))	abnormal interleukin-6 secretion	J:66835
	decreased interleukin-1 beta secretion	J:66835
	increased osteoclast cell number	J:84145
\P2rx7^tm1Gab/\P2rx7^tm1Gab (B6.129P2-P2rx7^tm1Gab/J)	abnormal mast cell physiology	J:190651
\P2rx7^tm1Ipch/\P2rx7^tm1Ipch (B6.Cg-P2rx7^tm1Ipch)	abnormal inflammatory response	J:101945
\P2rx7^tm1Ipch/\P2rx7^tm1Ipch (involves: 129)	immune system phenotype	J:97422
\P2rx7^tm1Ipch/\P2rx7^tm1Ipch (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:118561
\P2rx7^tm1Lex/\P2rx7^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:145020
\P2ry6^tm1.1Brob/\P2ry6^tm1.1Brob (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal macrophage physiology	J:169742
\P2ry6^tm1Jabo/\P2ry6^tm1Jabo \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: 129 * C57BL/6 * C57BL/6NTac)	decreased IgE level	J:179177
	decreased T cell apoptosis	J:179177
	increased eosinophil cell number	J:179177
	increased interferon-gamma secretion	J:179177
	increased interleukin-4 secretion	J:179177
	increased interleukin-5 secretion	J:179177
	increased interleukin-13 secretion	J:179177
	increased neutrophil cell number	J:179177
	increased T cell proliferation	J:179177
	lung inflammation	J:179177
\P2ry6^tm1Jabo/\P2ry6^tm1Jabo \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (B6.Cg-Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte} P2ry6^tm1Jabo)	increased eosinophil cell number	J:179177
	increased interferon-gamma secretion	J:179177
	increased interleukin-4 secretion	J:179177
	increased interleukin-5 secretion	J:179177
	increased interleukin-13 secretion	J:179177
	increased neutrophil cell number	J:179177
	lung inflammation	J:179177
\P2ry14^tm1.1Shbg/\P2ry14^tm1.1Shbg (involves: 129S6/SvEvTac * C57BL/6)	increased spleen weight	J:223427
\P4hb^tm1.1Geno/\P4hb^tm1.2Geno \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	decreased neutrophil cell number	J:197556
	impaired neutrophil recruitment	J:197556
\p23-ST1/\p23-ST1 (C57BL/6J-p23-ST1)	microgliosis	J:158278
\Paam1^MRL/MpJ/\Paam1^MRL/MpJ (involves: C3H/HeJ * MRL/MpJ)	increased susceptibility to autoimmune disorder	J:76107
\Paam2^MRL/MpJ/\Paam2^MRL/MpJ (involves: C3H/HeJ * MRL/MpJ)	increased susceptibility to autoimmune disorder	J:76107
\Pabir2^{em1(IMPC)Ccpcz}/Y (C57BL/6NCrl-Pabir2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Pabir2^{em1(IMPC)Ccpcz}/\Pabir2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pabir2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Pacsin1^{Gt(OST287788)Lex}/\Pacsin1^{Gt(OST287788)Lex} (B6.129S5-Pacsin1^{Gt(OST287788)Lex})	abnormal plasmacytoid dendritic cell physiology	J:187784
	decreased circulating interferon-alpha level	J:187784
	decreased interferon-alpha secretion	J:187784
	immune system phenotype	J:187784
\Pacsin3^tm1.2Bqu/\Pacsin3^tm1.2Bqu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	myositis	J:255013
\Padi2^tm1Lex/\Padi2^tm1Lex (B6.129S5-Padi2^tm1Lex)	abnormal mast cell physiology	J:190651
\Padi2^tm1Lex/\Padi2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	autoimmune response	J:190651
\Padi4^em1(IMPC)Mbp/\Padi4^em1(IMPC)Mbp (C57BL/6N-Padi4^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Padi4^tm1.1Kmow/\Padi4^tm1.1Kmow (involves: BALB/cJ * C57BL/6)	abnormal neutrophil physiology	J:174934
	decreased susceptibility to Orthomyxoviridae infection	J:174934
\Padi4^tm1.1Kmow/\Padi4^tm1.1Kmow \Tg(CMV-cre)1Cgn/0 (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:190651
\Padi4^tm1.1Ywan/\Padi4^tm1.1Ywan (involves: 129S4/SvJae)	abnormal neutrophil physiology	J:165718
	impaired neutrophil phagocytosis	J:165718
	increased susceptibility to bacterial infection	J:165718
\Pag1^tm1.1Tara/\Pag1^tm1.1Tara (C57BL/6-Pag1^tm1.1Tara)	immune system phenotype	J:159011
\Pag1^tm1Kplm/\Pag1^tm1Kplm (involves: 129P2/OlaHsd * C57BL/6)	increased thymocyte number	J:101365
\Pag1^tm1Tara/\Pag1^tm1Tara \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:159011
\Pah^em1(IMPC)Tcp/\Pah⁺ (C57BL/6NCrl-Pah^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
\Paip1^em1(IMPC)Tcp/\Paip1^em1(IMPC)Tcp (C57BL/6NCrl-Paip1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Pak1^tm1Cher/\Pak1^tm1Cher (B6.129S2-Pak1^tm1Cher)	abnormal mast cell physiology	J:142439
\Pak1^tm1Cher/\Pak1^tm1Cher (B6.129S2-Pak1^tm1Cher)	decreased mast cell degranulation	J:145444
\Pak5^em1(IMPC)Mbp/\Pak5^em1(IMPC)Mbp (C57BL/6N-Pak5^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Palm^tm1.2Kili/\Palm^tm1.2Kili \Tg(Ins2-VEGFC)#Pepr/0 (involves: C57BL/6N)	abnormal lymphangiogenesis	J:237034
\Palm^tm1.2Kili/\Palm^tm1.2Kili \Tg(RIP1-Tag)2Dh/0 \Tg(Ins2-VEGFC)#Pepr/0 (involves: C57BL/6J * C57BL/6N * DBA/2J)	abnormal lymphangiogenesis	J:237034
\Pals1^tm1Caw/\Pals1^tm1Caw \Tg(rx3-icre)1Mjam/0 (Not Specified)	microgliosis	J:184469
\Pals2^{em1(IMPC)Rbrc}/\Pals2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Pals2^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
\Pamr1^{em1(IMPC)Ccpcz}/\Pamr1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pamr1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Pan2^{tm1b(KOMP)Wtsi}/\Pan2^{tm1b(KOMP)Wtsi} (C57BL/6N-Pan2^{tm1b(KOMP)Wtsi}/Mhzh)	increased eosinophil cell number	J:211773
\Pan3^em1(IMPC)Tcp/\Pan3⁺ (C57BL/6N-Pan3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Pank1^tm1.1Suja/\Pank1^tm1.1Suja \Pank2^tm1.1Suja/\Pank2^tm1.1Suja (involves: 129S/SvEv * C57BL/6J * FVB/N)	decreased spleen weight	J:189609
	small spleen	J:189609
\Pank2^{em1(IMPC)Ccpcz}/\Pank2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pank2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Pank3^{tm1b(KOMP)Mbp}/\Pank3^{tm1b(KOMP)Mbp} (C57BL/6N-Pank3^{tm1b(KOMP)Mbp}/Bay)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Panx1^tm1.2Vmd/\Panx1^tm1.2Vmd (C57BL/6N-Panx1^tm1.2Vmd)	abnormal T cell physiology	J:173213
\Panx1^tm1.2Vmd/\Panx1^tm1.2Vmd (C57BL/6N-Panx1^tm1.2Vmd)	immune system phenotype	J:173213
\Panx2^{tm1b(KOMP)Wtsi}/\Panx2^{tm1b(KOMP)Wtsi} (C57BL/6N-Panx2^{tm1b(KOMP)Wtsi}/Ucd)	increased spleen weight	J:211773
\Panx3^{tm1c(KOMP)Wtsi}/\Panx3^{tm1c(KOMP)Wtsi} \Tg(Col2a1-cre)1Star/0 (involves: C3H * C57BL/6 * C57BL/6J * C57BL/6N)	decreased susceptibility to induced arthritis	J:233542
\Panx3^{tm1d(KOMP)Wtsi}/\Panx3^{tm1d(KOMP)Wtsi} (involves: BALB/cJ * C3H * C57BL/6 * C57BL/6N)	decreased susceptibility to induced arthritis	J:233542
\Pappa2^tm1Lex/\Pappa2^tm1Lex (C57BL/6-Pappa2^tm1Lex)	increased spleen weight	J:174887
\Papss2^bm/\Papss2^bm (involves: C57BL/6J * LDJ/Le)	autoimmune arthritis	J:166514
\Pard3^{tm1b(KOMP)Wtsi}/\Pard3⁺ (C57BL/6N-Pard3^{tm1b(KOMP)Wtsi}/H)	decreased basophil cell number	J:211773
\Parg^tm1Zqw/\Parg^tm1Zqw (involves: 129P2/OlaHsd * C57BL/6)	increased circulating tumor necrosis factor level	J:92244
	increased susceptibility to endotoxin shock	J:92244
\Parg^{tm2b(KOMP)Mbp}/\Parg⁺ (C57BL/6N-Parg^{tm2b(KOMP)Mbp}/J)	decreased leukocyte cell number	J:211773
\Parl^tm1.1Bdes/\Parl^tm1.1Bdes (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell morphology	J:116017
	decreased B cell number	J:116017
	decreased double-positive T cell number	J:116017
	decreased lymphocyte cell number	J:116017
	increased T cell apoptosis	J:116017
	spleen atrophy	J:116017
	thymus atrophy	J:116017
\Parl^tm1.1Bdes/\Parl^tm1.1Bdes (involves: 129P2/OlaHsd)	abnormal thymus apoptosis	J:269785
	microgliosis	J:269785
	spleen atrophy	J:269785
	thymus atrophy	J:269785
\Parl^tm1Bdes/\Parl^tm1Bdes \Tg(Nes-cre)1Kln/0 (involves: 129P2/OlaHsd * C57BL/6 * SJL)	abnormal thymus apoptosis	J:269785
	spleen atrophy	J:269785
	thymus atrophy	J:269785
\Parp1^{em1(IMPC)Ccpcz}/\Parp1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Parp1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Parp1^{tm1b(EUCOMM)Hmgu}/\Parp1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Parp1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased NK cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Parp1^tm1Jmdm/\Parp1^tm1Jmdm (involves: 129S2/SvPas * C57BL/6)	abnormal inflammatory response	J:117701
	abnormal leukocyte migration	J:117701
\Parp1^tm1Jmdm/\Parp1^tm1Jmdm (involves: 129S2/SvPas)	immune system phenotype	J:47993
\Parp1^tm1Zqw/\Parp1^tm1Zqw (involves: 129/Sv * C57BL/6)	decreased inflammatory response	J:94497
\Parp1^tm1Zqw/\Parp1^tm1Zqw (129S-Parp1^tm1Zqw/J)	abnormal microglial cell physiology	J:96548
\Parp1^tm1Zqw/\Parp1^tm1Zqw (129S-Parp1^tm1Zqw/J)	decreased inflammatory response	J:95418
\Parp1^tm1Zqw/\Parp1^tm1Zqw (involves: 129S2/SvPas)	immune system phenotype	J:146533
\Parp1^tm2Zqw/\Parp1^tm2Zqw (either: (involves: 129P2/OlaHsd * 129/Sv) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal inflammatory response	J:93479
	abnormal macrophage physiology	J:93479
	decreased circulating interleukin-1 beta level	J:93479
	decreased circulating tumor necrosis factor level	J:93479
	decreased inflammatory response	J:93479
	decreased susceptibility to endotoxin shock	J:93479
\Parp9^tm1.2Arte/\Parp9^tm1.2Arte (involves: C57BL/6N * FVB/N)	abnormal circulating interferon level	J:306337
	abnormal interferon secretion	J:306337
	abnormal response to infection	J:306337
\Parp12^{tm1.1(KOMP)Vlcg}/\Parp12^{tm1.1(KOMP)Vlcg} (C57BL/6N-Parp12^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Parp14^{Gt(OST415485)Lex}/\Parp14^{Gt(OST415485)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased B cell proliferation	J:146533
	decreased IgA level	J:146533
	decreased marginal zone B cell number	J:146533
	increased B cell apoptosis	J:146533
	increased B cell proliferation	J:146533
	increased follicular B cell number	J:146533
\Parva^{em1(IMPC)Ccpcz}/\Parva⁺ (C57BL/6NCrl-Parva^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Parvb^{tm1a(EUCOMM)Wtsi}/\Parvb^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Parvb^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased mature B cell number	J:165965
	decreased NK cell number	J:165965
	decreased T cell number	J:165965
\Patz1^tm1.1Welm/\Patz1^tm1.1Welm (involves: 129P2/OlaHsd)	abnormal T cell subpopulation ratio	J:158947
	decreased splenocyte number	J:158947
	decreased thymocyte number	J:158947
\Patz1^tm1.1Welm/\Patz1^tm1.1Welm \Tg(TcraTcrb)425Cbn/0 (involves: C57BL/6)	abnormal T cell subpopulation ratio	J:158947
	decreased CD8-positive, alpha-beta T cell number	J:158947
	increased CD4-positive, alpha-beta T cell number	J:158947
\Patz1^tm1.1Welm/\Patz1^tm1.1Welm \Tg(TcraTcrb)1100Mjb/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:158947
	decreased CD8-positive, alpha-beta T cell number	J:158947
	increased CD4-positive, alpha-beta T cell number	J:158947
\Patz1^tm1.2Welm/\Patz1^tm1.2Welm \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (B6.Cg-Patz1^tm1.2Welm Commd10^{Tg(Vav1-icre)A2Kio})	abnormal mast cell differentiation	J:209168
	decreased interleukin-6 secretion	J:209168
	immune system phenotype	J:209168
\Patz1^tm1.2Welm/\Patz1^tm1.2Welm \Tg(Cma1-cre)#Roer/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:209168
\Pawr^tm1Jmos/\Pawr^tm1Jmos (involves: 129/Sv * CD-1)	abnormal T-helper 2 physiology	J:85495
	enlarged spleen	J:85495
	increased B cell proliferation	J:85495
	increased lymphocyte cell number	J:85495
	increased T cell proliferation	J:85495
	spleen hyperplasia	J:85495
\Pax1^un-i/\Pax1⁺ (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	decreased CD4-positive, alpha-beta T cell number	J:100951
	decreased CD8-positive, alpha-beta T cell number	J:100951
	decreased thymocyte number	J:100951
\Pax1^un-i/\Pax1^un-i (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J))	decreased CD4-positive, alpha-beta T cell number	J:100951
	decreased CD8-positive, alpha-beta T cell number	J:100951
	decreased double-negative T cell number	J:100951
	decreased double-positive T cell number	J:100951
	decreased thymocyte number	J:100951
	increased double-negative T cell number	J:100951
\Pax1^un/\Pax1⁺ \Tcf3^tm1Cmu/\Tcf3^tm1Cmu (involves: 129P2/OlaHsd * C3H * C57BL/6)	abnormal T cell differentiation	J:103567
	abnormal T cell subpopulation ratio	J:103567
\Pax3^Sp-1H/\Pax3^Sp-1H (involves: 101/H * C3H/HeH * C57BL/6)	abnormal thymus morphology	J:88412
\Pax3^{tm1(FOXO1A)Gcg}/\Pax3⁺ (either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ * NMRI))	abnormal thymus lobule morphology	J:79365
	ectopic thymus	J:79365
\Pax5^m1Btlr/\Pax5^m1Btlr (C57BL/6J-Pax5^m1Btlr)	decreased B cell number	J:220072
	decreased IgA level	J:220072
	decreased IgG1 level	J:220072
	decreased IgG2a level	J:220072
	decreased IgG2b level	J:220072
	decreased IgG level	J:220072
	decreased IgM level	J:220072
	impaired humoral immune response	J:220072
	increased macrophage cell number	J:220072
	increased monocyte cell number	J:220072
	increased single-positive T cell number	J:220072
	increased T cell number	J:220072
\Pax5^m2Btlr/\Pax5⁺ (C57BL/6J-Pax5^m2Btlr)	decreased B-1b cell number	J:254824
\Pax5^m2Btlr/\Pax5^m2Btlr (C57BL/6J-Pax5^m2Btlr)	decreased B-1b cell number	J:254824
\Pax5^m2Btlr/\Pax5^m2Btlr (C57BL/6J-Pax5^m2Btlr)	increased B-1 B cell number	J:254824
\Pax5^m3Btlr/\Pax5⁺ (C57BL/6J-Pax5^m3Btlr)	decreased B cell number	J:254825
\Pax5^m3Btlr/\Pax5^m3Btlr (C57BL/6J-Pax5^m3Btlr)	abnormal humoral immune response	J:254825
	decreased B cell number	J:254825
	decreased B-1 B cell number	J:254825
	decreased IgG level	J:254825
	decreased IgM level	J:254825
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254825
	increased CD8-positive, alpha-beta memory T cell number	J:254825
\Pax5^m4Btlr/\Pax5^m4Btlr (C57BL/6J-Pax5^m4Btlr)	decreased IgD level	J:265140
\Pax5^M5Btlr/\Pax5^M5Btlr (C57BL/6J-Pax5^M5Btlr)	decreased IgD level	J:265141
\Pax5^{tm1b(EUCOMM)Wtsi}/\Pax5⁺ (C57BL/6N-Pax5^{tm1b(EUCOMM)Wtsi}/Ieg)	decreased leukocyte cell number	J:211773
	immune system phenotype	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
\Pax5^tm1Mbu/\Pax5^tm1Mbu (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:38813
	abnormal lymphopoiesis	J:38813
	absent B-2 B cells	J:113076
	absent mature B cells	J:113076
	arrested B cell differentiation	J:113076
	decreased B cell number	J:113076
	decreased B-1 B cell number	J:113076
	decreased immature B cell number	J:113076
	decreased immunoglobulin level	J:113076
	increased T cell number	J:113076
\Pax5^tm1Mbu/\Pax5^tm1Mbu (involves: 129S2/SvPas)	abnormal B cell physiology	J:123629
	abnormal immunoglobulin heavy chain V(D)J recombination	J:139510
	arrested B cell differentiation	J:75504
	enhanced B cell migration	J:123629
\Pax5^tm1Mbu/\Pax5^tm1Mbu (either: 129 or (involves: 129S2/SvPas * C57BL/6J))	abnormal late pro-B cell	J:21935
	abnormal lymphopoiesis	J:21935
	absent late pro-B cells	J:21935
	arrested B cell differentiation	J:21935
\Pax5^tm1Mbu/\Pax5^tm3Mbu \Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)	decreased mature B cell number	J:75504
\Pax5^tm3.1Mbu/\Pax5^tm3.1Mbu (involves: 129P2/OlaHsd * C57BL/6)	arrested B cell differentiation	J:75504
\Pax5^tm3Mbu/\Pax5⁺ \Tcf3^tm1(PBX1)Mlc/\Tcf3⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal pro-B cell morphology	J:226241
	arrested B cell differentiation	J:226241
	decreased immature B cell number	J:226241
\Pax5^tm4(CD2)Mbu/\Pax5^tm4(CD2)Mbu (B6.129P2-Pax5^tm4(CD2*)Mbu)	immune system phenotype	J:144100
\Pax5^tm5Mbu/\Pax5^tm5Mbu (B6.129P2-Pax5^tm5Mbu)	immune system phenotype	J:144100
\Pax5^tm6.1Mbu/\Pax5^tm6.1Mbu (B6.129P2-Pax5^tm6.1Mbu)	immune system phenotype	J:173158
\Pax6^Sey-4H/\Pax6⁺ (involves: 101/H * C3H/HeCrj * C3H/HeH)	increased susceptibility to induced pancreatitis	J:124276
\Pax7^{tm1.1(HBEGF,-EYFP)Mal}/\Pax7⁺ (involves: C57BL/6)	myositis	J:180899
\Pax9^tm1.1Hpt/\Pax9^tm1.1Hpt \Tg(Pgk1-cre)1Lni/? (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	abnormal thymus lobule morphology	J:125026
\Pax9^tm1Rbal/\Pax9^tm1Rbal (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	athymia	J:49857
\Pax9^tm1Rbal/\Pax9^tm1Rbal (involves: 129S1/Sv * 129X1/SvJ * CD-1)	ectopic thymus	J:311535
	thymus hypoplasia	J:311535
\Paxx^em1(IMPC)Mbp/\Paxx^em1(IMPC)Mbp (C57BL/6NCrl-Paxx^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Paxx^em1Spj/\Paxx^em1Spj (C57BL/6NTac-Paxx^em1Spj)	decreased B cell number	J:236776
	decreased CD4-positive, alpha-beta T cell number	J:236776
	decreased CD8-positive, alpha-beta T cell number	J:236776
	decreased follicular B cell number	J:236776
	decreased splenocyte number	J:236776
	decreased T cell number	J:236776
	decreased transitional stage B cell number	J:236776
	immune system phenotype	J:236776
	increased mature B cell number	J:236776
\Paxx^em1Spj/\Paxx^em1Spj \Nhej1^tm1Fwa/\Nhej1^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6NTac)	abnormal thymus involution	J:236776
	absent lymphocyte	J:236776
	athymia	J:236776
	decreased spleen weight	J:236776
	decreased splenocyte number	J:236776
	small spleen	J:236776
\Pbat1^BXSB/Slc/\Pbat1^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Pbat1^BXSB/Slc/\Pbat1^NZW/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Pbat2^BXSB/Slc/\Pbat2^BXSB/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Pbat2^BXSB/Slc/\Pbat2^NZW/Slc (involves: BXSB/Slc * NZW/Slc)	increased autoantibody level	J:49899
\Pbbcp1^C57BL/6J/? (involves: C57BL/6J * DBA/2J)	increased B cell number	J:74270
\Pbk^tm1Zgdo/\Pbk^tm1Zgdo (Not Specified)	decreased interleukin-6 secretion	J:176985
	increased interleukin-6 secretion	J:176985
	increased tumor necrosis factor secretion	J:176985
\Pbrm1^tm1Zhwa/\Pbrm1^tm1Zhwa \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal T-helper 2 cell differentiation	J:236906
	decreased T cell proliferation	J:236906
	immune system phenotype	J:236906
	increased interleukin-4 secretion	J:236906
	increased interleukin-10 secretion	J:236906
\Pbwg1.9^{M. m. castaneus}/? (involves: C57BL/6J * M. m. castaneus)	increased spleen weight	J:121981
\Pbx1^em1Dunw/\Pbx1^em1Dunw (C57BL/6J-Pbx1^em1Dunw)	ectopic thymus	J:320934
	spleen hypoplasia	J:320934
	thymus hypoplasia	J:320934
\Pbx1^tm1.1Koss/\Pbx1^tm1.1Koss \Tg(WT1-cre)AG11Dbdr/0 (involves: 129P2/OlaHsd * C57BL/6)	spleen hypoplasia	J:184521
\Pbx1^tm1.1Koss/\Pbx1^tm1.2Koss \Tmem163^{Tg(ACTB-cre)2Mrt}/0 (involves: 129P2/OlaHsd * FVB/N)	absent spleen	J:184521
\Pbx1^tm1Koss/\Pbx1^tm1Koss \Nkx2-5^tm2(cre)Rph/\Nkx2-5⁺ (involves: 129P2/OlaHsd * 129S1/Sv)	abnormal spleen mesenchyme morphology	J:184521
	abnormal spleen morphology	J:184521
	spleen hypoplasia	J:184521
\Pbx1^tm1Koss/\Pbx1^tm1Koss \Pbx2^tm1Mlc/\Pbx2⁺ \Nkx2-5^tm2(cre)Rph/\Nkx2-5⁺ (involves: 129P2/OlaHsd * 129S/Sv * 129S1/Sv)	abnormal spleen morphology	J:184521
	spleen hypoplasia	J:184521
\Pbx1^tm1Mlc/\Pbx1^tm1Mlc (involves: 129S6/SvEvTac * C57BL/6)	absent spleen	J:71996, J:70684
	ectopic thymus	J:71996
\Pbx1^tm1Mlc/\Pbx1^tm2.1Mlc (involves: 129S6/SvEvTac)	abnormal lymph node primary follicle morphology	J:132963
	decreased CD4-positive, alpha-beta T cell number	J:132963
	decreased CD8-positive, alpha-beta T cell number	J:132963
	decreased mature B cell number	J:132963
\Pbx1^tm1Mlc/\Pbx1^tm3.1Mlc \Tg(Tek-cre)1Ywa/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal spleen morphology	J:149799
	abnormal thymus morphology	J:149799
	decreased B cell number	J:149799
	decreased double-negative T cell number	J:149799
	decreased pre-B cell number	J:149799
	decreased pro-B cell number	J:149799
	decreased T cell number	J:149799
	small spleen	J:149799
	small thymus	J:149799
	spleen hypoplasia	J:149799
	thymus hypoplasia	J:149799
\Pbx2^tm1Mlc/\Pbx2^tm1Mlc (either: 129S/Sv or (involves: 129S/Sv * C57BL/6))	immune system phenotype	J:91079
\Pbx4^em2Hncs/\Pbx4^em2Hncs (involves: C57BL/6J * DBA * ICR)	decreased lymphocyte cell number	J:349843
	increased neutrophil cell number	J:349843
\Pbxip1^tm1Cya/\Pbxip1^tm1Cya \Tg(Col2a1-cre/ERT)KA3Smac/0 (involves: FVB/N)	osteoarthritis	J:270267
\Pcare^tm1Kpal/\Pcare^tm1Kpal (involves: C57BL/6J * C57BL/6NTac)	increased microglial cell activation	J:220866
\Pcd4ts1^DBA/2/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Pcd4ts2^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Pcd4ts3^BALB/c/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:83220
\Pcd8ts1^C57BL/6/? (involves: BALB/c * C3H * C57BL/6 * DBA/2)	increased CD8-positive, alpha-beta T cell number	J:83220
\Pcdh7^em1Ywc/\Pcdh7^em1Ywc (Not Specified)	decreased osteoclast cell number	J:298915
\Pcdha2^em1(IMPC)Tcp/\Pcdha2^em1(IMPC)Tcp (C57BL/6N-Pcdha2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Pcdhb13^em1(IMPC)Tcp/\Pcdhb13^em1(IMPC)Tcp (C57BL/6N-Pcdhb13^em1(IMPC)Tcp/Tcp)	decreased basophil cell number	J:211773
	enlarged lymph nodes	J:211773
\Pcdhg^em5Rwb/\Pcdhg^em5Rwb (C57BL/6J-Pcdhg^em5Rwb/Rwb)	microgliosis	J:285314
\Pcdhg^em41Rwb/\Pcdhg^em41Rwb (C57BL/6J-Pcdhg^em41Rwb/Rwb)	microgliosis	J:285314
\Pcdhg^tm1.1Tman/\Pcdhg^tm1.1Tman (involves: 129S4/SvJae * C57BL/6)	microgliosis	J:188341
\Pcgf2^{tm1b(KOMP)Mbp}/\Pcgf2⁺ (C57BL/6N-Pcgf2^{tm1b(KOMP)Mbp}/Tcp)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Pcgf2^tm1Hko/\Pcgf2^tm1Hko (involves: BALB/c * C57BL/6)	abnormal T-helper 2 physiology	J:71268
	decreased lymphocyte cell number	J:71268
	decreased thymocyte number	J:71268
\Pcgf3^{TgTn(sb-cHS4,Tyr)2349AOve}/\Pcgf3^{TgTn(sb-cHS4,Tyr)2349AOve} (FVB/N-Pcgf3^{TgTn(sb-cHS4,Tyr)2349AOve})	absent spleen	J:175597
\Pcid2^tm1Imku/\Pcid2^tm1Imku \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal spleen B cell follicle morphology	J:166080
	decreased follicular B cell number	J:166080
	decreased marginal zone B cell number	J:166080
	decreased mature B cell number	J:166080
\Pck2^em1(IMPC)Tcp/\Pck2^em1(IMPC)Tcp (C57BL/6N-Pck2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Pclaf^tm1.1Lkd/\Pclaf^tm1.1Lkd (involves: C57BL/6)	decreased leukocyte cell number	J:177782
	spleen hypoplasia	J:177782
	thymus hypoplasia	J:177782
\Pclaf^{tm1a(EUCOMM)Wtsi}/\Pclaf^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Pclaf^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased CD11b-high dendritic cell number	J:211773
	decreased dendritic cell number	J:211773
	decreased immature NK cell number	J:211773
	decreased plasmacytoid dendritic cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T cell number	J:211773
	increased CD11b-low dendritic cell number	J:211773
	increased dendritic cell number	J:211773
	increased mature NK cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased pro-B cell number	J:211773
\Pcm1^em1(IMPC)Tcp/\Pcm1^em1(IMPC)Tcp (C57BL/6NCrl-Pcm1^em1(IMPC)Tcp/Tcp)	decreased spleen weight	J:211773
	small spleen	J:211773
\Pcmt1^tm1Shs/\Pcmt1^tm1Shs (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:46228
\Pcna^tm1.1Mdsc/\Pcna^tm1.1Mdsc \Tg(Pcna*K164R)1Mdsc/0 (involves: FVB/N)	abnormal class switch recombination	J:141098
	abnormal somatic hypermutation frequency	J:141098
\Pcna^tm1Jcbs/\Pcna^tm1Jcbs (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:125916
\Pcna^tm1Jcbs/\Pcna^tm1Jcbs (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454, J:177630
\Pcna^tm1Jcbs/\Pcna^tm1Jcbs \Ung^tm1Tld/\Ung^tm1Tld (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454
\Pcolce2^tm1Ccb/\Pcolce2^tm1Ccb \Ppp1r16b^tm1Ccb/\Ppp1r16b^tm1Ccb (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:124347
\Pcsk1^tm1Dfs/\Pcsk1^tm1Dfs (involves: 129 * C57BL/6J)	abnormal peritoneal macrophage morphology	J:184882
	abnormal spleen marginal zone morphology	J:184882
	abnormal spleen white pulp morphology	J:184882
	abnormal T-helper 1 cell differentiation	J:184882
	decreased follicular dendritic cell number	J:184882
	decreased NK T cell number	J:184882
	decreased T cell number	J:184882
	enlarged spleen	J:184882
	increased circulating interferon-gamma level	J:184882
	increased circulating interleukin-1 beta level	J:184882
	increased circulating interleukin-6 level	J:184882
	increased circulating interleukin-10 level	J:184882
	increased circulating interleukin-12 level	J:184882
	increased circulating tumor necrosis factor level	J:184882
	increased interleukin-1 beta secretion	J:184882
	increased lymphocyte cell number	J:184882
	increased susceptibility to endotoxin shock	J:184882
	intermingled spleen red and white pulp	J:184882
\Pcsk5^vcc/\Pcsk5^vcc (involves: C57BL/6J)	abnormal thymus lobule morphology	J:136243
\Pcsk5^vcc/\Pcsk5^vcc (involves: C57BL/6J)	small thymus	J:136243
\Pcsk9^{em1(IMPC)Ccpcz}/\Pcsk9^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pcsk9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased T-helper cell number	J:211773
\Pctp^tm1Bor/\Pctp^tm1Bor (B6.129P2-Pctp^tm1Bor)	abnormal macrophage physiology	J:115284
\Pctp^tm1Bor/\Pctp^tm1Bor (B6.129P2-Pctp^tm1Bor)	increased macrophage apoptosis	J:115284
\Pcyt1a^tm1Irt/\Pcyt1a^tm1Irt \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * C57BL/6J)	abnormal immune cell physiology	J:65639
	abnormal macrophage physiology	J:65639
\Pdap1^em1Rkuhn/\Pdap1^em1Rkuhn \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	abnormal B cell physiology	J:298705
	abnormal class switch recombination	J:298705
	abnormal somatic hypermutation frequency	J:298705
	decreased germinal center B cell number	J:298705
	decreased mature B cell number	J:298705
	increased B cell apoptosis	J:298705
\Pdcd1^tm1.1Liux/\Pdcd1^tm1.1Liux (involves: C57BL/6)	decreased regulatory T cell number	J:190150
\Pdcd1^tm1.1Liux/\Pdcd1^tm1.1Liux (involves: C57BL/6)	increased T-helper 1 cell number	J:190150
\Pdcd1^tm1.1Liux/\Pdcd1^tm1.1Liux \Tg(MMTV-PyVT)634Mul/0 (involves: C57BL/6 * FVB/N)	decreased interleukin-17 secretion	J:190150
	decreased regulatory T cell number	J:190150
	decreased T-helper 2 cell number	J:190150
	decreased T-helper 17 cell number	J:190150
	increased interferon-gamma secretion	J:190150
	increased interleukin-2 secretion	J:190150
	increased T-helper 1 cell number	J:190150
	increased tumor necrosis factor secretion	J:190150
\Pdcd1^tm1.1Shr/\Pdcd1^tm1.1Shr (involves: C57BL/6)	decreased B-1 B cell number	J:153040
\Pdcd1^tm1.1Shr/\Pdcd1^tm1.1Shr (involves: C57BL/6)	increased regulatory T cell number	J:153040
\Pdcd1^tm1.1Shr/\Pdcd1^tm1.1Shr \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	abnormal immune tolerance	J:153040
	decreased T cell proliferation	J:153040
	increased susceptibility to autoimmune diabetes	J:153040
	increased T cell proliferation	J:153040
	insulitis	J:153040
	pancreas inflammation	J:153040
\Pdcd1^tm1Hon/\Pdcd1^tm1Hon (involves: 129S2/SvPas * C57BL/6)	abnormal immunoglobulin level	J:50688
	abnormal leukopoiesis	J:50688
	abnormal myelopoiesis	J:50688
	enlarged spleen	J:50688
	increased B cell number	J:50688
	increased B cell proliferation	J:50688
	increased B-1 B cell number	J:50688
	increased IgA level	J:50688
	increased IgG2b level	J:50688
	increased IgG3 level	J:50688
	increased lymphocyte cell number	J:50688
\Pdcd1^tm1Hon/\Pdcd1^tm1Hon (B6.129S2-Pdcd1^tm1Hon)	abnormal response to transplant	J:119356
	autoimmune arthritis	J:78802
	glomerulonephritis	J:78802
\Pdcd1^tm1Hon/\Pdcd1^tm1Hon (C.129S2(B6)-Pdcd1^tm1Hon)	increased autoantibody level	J:66979
\Pdcd1^tm1Hon/\Pdcd1^tm1Hon (involves: 129S2/SvPas)	abnormal T cell activation	J:222944
	increased IgA level	J:222944
	increased IgM level	J:222944
	increased inflammatory response	J:222944
	increased interferon-gamma secretion	J:222944
\Pdcd1^tm1Hon/\Pdcd1^tm1Hon \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:140751
\Pdcd1^tm1Hon/\Pdcd1^tm1Hon \Vsir^tm1Lex/\Vsir^tm1Lex (involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)	abnormal T cell activation	J:222944
	immune system phenotype	J:222944
	increased IgA level	J:222944
	increased IgM level	J:222944
	increased inflammatory response	J:222944
	increased interferon-gamma secretion	J:222944
	increased interleukin-17 secretion	J:222944
	increased tumor necrosis factor secretion	J:222944
\Pdcd1^tm1Hon/\Pdcd1^tm1Hon \Vsir^tm1Lex/\Vsir^tm1Lex \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:222944
\Pdcd1^tm1Llc/\Pdcd1^tm1Llc (involves: 129S5/SvEvBrd)	abnormal cytokine secretion	J:126829
	decreased CD8-positive, alpha-beta T cell number	J:126829
	increased susceptibility to experimental autoimmune encephalomyelitis	J:126829
\Pdcd1lg2^tm1.1Lex/\Pdcd1lg2^tm1.1Lex (involves: 129S5/SvEvBrd)	decreased CD8-positive, alpha-beta T cell number	J:126829
\Pdcd1lg2^tm1Dmp/\Pdcd1lg2^tm1Dmp (involves: 129X1/SvJ * 129S1/Sv * C57BL/6)	abnormal dendritic cell antigen presentation	J:84457
\Pdcd1lg2^tm1Dmp/\Pdcd1lg2^tm1Dmp (C.129-Pdcd1lg2^tm1Dmp)	abnormal cytokine secretion	J:99212
	abnormal cytotoxic T cell physiology	J:99212
	decreased IgG2a level	J:99212
	decreased T cell proliferation	J:99212
\Pdcd1lg2^tm1Shr/\Pdcd1lg2^tm1Shr (involves: 129/Sv * 129S4/SvJae)	increased IgG2a level	J:113851
	increased IgM level	J:113851
	increased susceptibility to parasitic infection	J:113851
\Pdcd1lg2^tm2Shr/\Pdcd1lg2^tm2Shr (C.B6-Pdcd1lg2^tm2Shr)	abnormal dendritic cell physiology	J:123785
	increased interferon-gamma secretion	J:123785
	increased interleukin-2 secretion	J:123785
\Pdcd1lg2^tm3Shr/\Pdcd1lg2^tm3Shr (involves: C57BL/6 * NOD/MrkTac)	abnormal CD8-positive, alpha-beta T cell physiology	J:123785
	increased CD4-positive, alpha-beta T cell number	J:123785
	increased CD8-positive, alpha-beta T cell number	J:123785
	increased susceptibility to autoimmune diabetes	J:123785
	insulitis	J:123785
	lymph node hyperplasia	J:123785
\Pdcd4^tm1Yhcn/\Pdcd4^tm1Yhcn (B6.129S6-Pdcd4^tm1Yhcn)	abnormal cytokine secretion	J:120583
	decreased susceptibility to autoimmune diabetes	J:120583
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:120583
\Pdcd6ip^{em1(IMPC)Hmgu}/\Pdcd6ip^{em1(IMPC)Hmgu} (C57BL/6N-Pdcd6ip^{em1(IMPC)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
\Pdcd6ip^em1(IMPC)Mbp/\Pdcd6ip^em1(IMPC)Mbp (C57BL/6NCrl-Pdcd6ip^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Pdcd10^tm1Kwhi/\Pdcd10^tm1.1Kwhi \Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/? (involves: C57BL/6 * CBA)	CNS inflammation	J:173947
\Pde2a^em1(IMPC)H/\Pde2a⁺ (C57BL/6NTac-Pde2a^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Pde4a^tm1Mct/\Pde4a^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:106828
\Pde4b^tm1Mct/\Pde4b⁺ \Pde4d^tm1Mct/\Pde4d^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil recruitment	J:94853
\Pde4b^tm1Mct/\Pde4b^tm1Mct (involves: 129X1/SvJ * C57BL/6)	decreased tumor necrosis factor secretion	J:76862
\Pde4b^tm1Mct/\Pde4b^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	decreased tumor necrosis factor secretion	J:106828
	impaired neutrophil chemotaxis	J:94853
	impaired neutrophil recruitment	J:94853
\Pde4b^tm1Mct/\Pde4b^tm1Mct \Pde4d^tm1Mct/\Pde4d⁺ (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil recruitment	J:94853
\Pde4d^tm1Mct/\Pde4d^tm1Mct (involves: 129P2/OlaHsd * C57BL/6)	abnormal tumor necrosis factor level	J:94853
	immune system phenotype	J:106828
	impaired neutrophil chemotaxis	J:94853
	impaired neutrophil recruitment	J:94853
\Pde7a^{Gt(Betageo-puro)1Yang}/\Pde7a^{Gt(Betageo-puro)1Yang} (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:86923
\Pde7b^tm1Pfi/\Pde7b^tm1Pfi (involves: 129 * C57BL/6)	immune system phenotype	J:322967
\Pdgfb^tm1Cbet/\Pdgfb^tm2Cbet \Tg(Tie1-cre)9Ref/0 (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal microglial cell morphology	J:89186
\Pdgfc^{tm1b(EUCOMM)Hmgu}/\Pdgfc⁺ (C57BL/6N-Pdgfc^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged spleen	J:211773
	increased CD4-negative, CD25-positive NK T cell number	J:211773
	increased granulocyte number	J:211773
	increased monocyte cell number	J:211773
\Pdgfra^{em1(IMPC)Ccpcz}/\Pdgfra⁺ (C57BL/6NCrl-Pdgfra^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased NK T cell number	J:211773
\Pdgfra^tm8Sor/\Pdgfra^tm8Sor \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (Not Specified)	small thymus	J:81153
\Pdgfra^tm8Sor/\Pdgfra^tm8Sor \Pdgfrb^tm1Mdt/\Pdgfrb^tm1Mdt \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: C57BL/6 * CBA)	abnormal thymus development	J:122584
	thymus hypoplasia	J:122584
\Pdgfra^tm12.1Sor/\Pdgfra⁺ (involves: 129 * C57BL/6)	abnormal immune system organ morphology	J:146617
\Pdgfrb^b2b2903Clo/\Pdgfrb^b2b2903Clo (C57BL/6J-Pdgfrb^b2b2903Clo)	thymus hypoplasia	J:175213
\Pdha2^em1(IMPC)Bay/\Pdha2^em1(IMPC)Bay (C57BL/6N-Pdha2^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Pdia6^em1Btlr/\Pdia6^m1Btlr (involves: C57BL/6J)	abnormal circulating cytokine level	J:288824
	abnormal T cell physiology	J:288824
	decreased B cell number	J:288824
	decreased double-negative T cell number	J:288824
	decreased double-positive T cell number	J:288824
	decreased follicular B cell number	J:288824
	decreased leukocyte cell number	J:288824
	decreased lymphocyte cell number	J:288824
	decreased monocyte cell number	J:288824
	decreased NK T cell number	J:288824
	decreased pre-B cell number	J:288824
	decreased transitional stage B cell number	J:288824
	increased marginal zone B cell number	J:288824
	increased marginal zone precursor B cell number	J:288824
	increased mature B cell number	J:288824
	spleen hypoplasia	J:288824
	thymus hypoplasia	J:288824
\Pdia6^m1Btlr/\Pdia6^m1Btlr (C57BL/6J-Pdia6^m1Btlr)	immune system phenotype	J:288824
\Pdia6^{tm1b(EUCOMM)Hmgu}/\Pdia6⁺ (C57BL/6N-Pdia6^{tm1b(EUCOMM)Hmgu}/Ieg)	decreased CD4-positive NK T cell number	J:211773
	enlarged lymph nodes	J:211773
\Pdik1l^em1(IMPC)Mbp/\Pdik1l^em1(IMPC)Mbp (C57BL/6NCrl-Pdik1l^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Pdk2^em1(IMPC)Mbp/\Pdk2^em1(IMPC)Mbp (C57BL/6N-Pdk2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Pdk4^tm1Tok/\Pdk4^tm1Tok (B6.129P2-Pdk4^tm1Tok)	abnormal osteoclast cell number	J:179789
	abnormal osteoclast differentiation	J:179789
	abnormal osteoclast morphology	J:179789
\Pdlim2^tm1Gru/\Pdlim2^tm1Gru (Not Specified)	abnormal T-helper 1 physiology	J:99108
	increased interferon-gamma secretion	J:99108
	increased susceptibility to bacterial infection	J:99108
\Pdlim7^em1(IMPC)Mbp/\Pdlim7^em1(IMPC)Mbp (C57BL/6N-Pdlim7^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Pdlim7^{Gt(OST445990)Lex}/\Pdlim7^{Gt(OST445990)Lex} (B6.129S5-Pdlim7^{Gt(OST445990)Lex})	increased lymphocyte cell number	J:209780
	increased monocyte cell number	J:209780
\Pdpk1^tm1.1Mlw/\Pdpk1^tm1.1Mlw \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	dermatitis	J:226194
\Pdpk1^tm1.1Mlw/\Pdpk1^tm1.1Mlw \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ (involves: 129X1/SvJ * C57BL/6)	abnormal regulatory T cell number	J:226194
	abnormal T cell physiology	J:226194
	dermatitis	J:226194
	enlarged lymph nodes	J:226194
	enlarged spleen	J:226194
\Pdpk1^tm1Dral/\Pdpk1^tm1Dral (B6.129P2-Pdpk1^tm1Dral)	small spleen	J:136089
\Pdpk1^tm1Mlw/\Pdpk1^tm1.1Daca \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * BALB/c * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:165626
	decreased NK T cell number	J:165626
	decreased T cell number	J:165626
\Pdpk1^tm1Mlw/\Pdpk1^tm1Mlw \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:165626
	abnormal NK T cell morphology	J:165626
	abnormal T cell differentiation	J:165626
	absent NK T cells	J:165626
	decreased NK T cell number	J:165626
	decreased T cell number	J:165626
	decreased T cell proliferation	J:165626
	immune system phenotype	J:165626
\Pdpn^tm1(cre)Mlkn/\Pdpn^tm1(cre)Mlkn (involves: 129S4/SvJae * C57BL/6)	abnormal lymphatic vessel morphology	J:162815
\Pdpn^tm1Mcws/\Pdpn⁺ (involves: 129S6/SvEvTac)	abnormal lymphatic vessel morphology	J:94978
\Pdpn^tm1Mcws/\Pdpn⁺ (involves: 129S6/SvEvTac)	lymphangiectasis	J:94978
\Pdpn^tm1Mcws/\Pdpn^tm1Mcws (involves: 129S6/SvEvTac)	abnormal lymph circulation	J:94978
	abnormal lymphatic vessel morphology	J:94978
	lymphangiectasis	J:94978
\Pdpn^tm2.1Mlkn/\Pdpn^tm2.1Mlkn \Rag1^tm1Mom/\Rag1^tm1Mom \Tg(Pdgfrb-cre)9Rha/0 (involves: 129S7/SvEvBrd * C57BL/6)	absent lymphocyte	J:205423
\Pdpn^tm2.1Mlkn/\Pdpn^tm2.1Mlkn \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	abnormal lymph node morphology	J:205423
	absent peripheral lymph nodes	J:205423
\Pdpn^tm2.1Mlkn/\Pdpn^tm2.1Mlkn \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129 C57BL/6)	abnormal lymphangiogenesis	J:235778
\Pdpn^tm2.1Mlkn/\Pdpn^tm2.1Mlkn \Tg(Pdgfrb-cre)9Rha/0 (involves: C57BL/6)	lymph node hemorrhage	J:205423
\Pdpr^{tm1b(EUCOMM)Wtsi}/\Pdpr^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Pdpr^{tm1b(EUCOMM)Wtsi}/Ics)	decreased large unstained cell number	J:211773
\Pdss2^kd/\Pdss2^kd (CBA/H-Pdss2^kd)	tubulointerstitial nephritis	J:197578
\Pdss2^kd/\Pdss2^kd (B6.CBACaH(CAST)-Pdss2^kd)	tubulointerstitial nephritis	J:101779
\Pdss2^tm1Dalg/\Pdss2^tm1Dalg \Tg(NPHS2-cre)295Lbh/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	tubulointerstitial nephritis	J:136670
\Pdx1^tm1Ted/\Pdx1⁺ (involves: 129P2/OlaHsd)	pancreas inflammation	J:82969
\Pdx1^tm1Ted/\Pdx1^tm1Ted (involves: 129P2/OlaHsd)	immune system phenotype	J:20779
\Pdxp^em1(IMPC)J/\Pdxp^em1(IMPC)J (C57BL/6NJ-Pdxp^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Pdzd8^{tm1b(EUCOMM)Wtsi}/\Pdzd8⁺ (C57BL/6N-Pdzd8^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased large unstained cell number	J:211773
\Pdzk1^{tm2b(EUCOMM)Wtsi}/\Pdzk1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Pdzk1^{tm2b(EUCOMM)Wtsi}/Wtsi)	abnormal lymphatic vessel morphology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
\Pdzph1^{em1(IMPC)Ccpcz}/\Pdzph1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pdzph1^{em1(IMPC)Ccpcz}/Ccpcz)	increased basophil cell number	J:211773
\Pebp1^em1(IMPC)Tcp/\Pebp1^em1(IMPC)Tcp (C57BL/6NCrl-Pebp1^em1(IMPC)Tcp/Tcp)	decreased eosinophil cell number	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Pecam1^tm1Mak/\Pecam1⁺ (D1.129P2-Pecam1^tm1Mak)	increased susceptibility to induced arthritis	J:106275
\Pecam1^tm1Mak/\Pecam1^tm1Mak (D1.129P2-Pecam1^tm1Mak)	abnormal leukocyte physiology	J:106275
	increased interferon-gamma secretion	J:106275
	increased susceptibility to induced arthritis	J:106275
	joint inflammation	J:106275
\Pecam1^tm1Mak/\Pecam1^tm1Mak (B6.129P2-Pecam1^tm1Mak)	abnormal cytokine secretion	J:95226
	liver inflammation	J:95226
	spleen vascular congestion	J:95226
\Pecam1^tm1Mak/\Pecam1^tm1Mak \Pitgp^C57BL/6/\Pitgp^C57BL/6 (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	peritoneal inflammation	J:144817
\Peli1^tm1.1Arte/\Peli1^tm1.1Arte (involves: C57BL/6N)	abnormal cytokine secretion	J:191578
	abnormal peripheral lymph node morphology	J:191578
	decreased interferon-alpha secretion	J:191578
	decreased interferon-beta secretion	J:191578
	decreased interleukin-6 secretion	J:191578
	decreased interleukin-10 secretion	J:191578
	decreased interleukin-12 secretion	J:191578
	decreased tumor necrosis factor secretion	J:191578
	enlarged lymph nodes	J:191578
	immune system phenotype	J:191578
	lymphoid hyperplasia	J:191578
\Peli1^{tm1b(EUCOMM)Wtsi}/\Peli1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Peli1^{tm1b(EUCOMM)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Peli1^tm1Tigm/\Peli1^tm1Tigm (involves: 129/Sv * C57BL/6)	decreased B cell proliferation	J:152781
	decreased circulating interferon-beta level	J:152781
	decreased circulating interleukin-6 level	J:152781
	decreased circulating interleukin-12b level	J:152781
	decreased circulating tumor necrosis factor level	J:152781
	decreased interleukin-12 secretion	J:152781
	decreased susceptibility to endotoxin shock	J:152781
	increased B cell apoptosis	J:152781
\Peli2^tm1.1Arte/\Peli2^tm1.1Arte (involves: C57BL/6)	abnormal circulating cytokine level	J:265431
	abnormal cytokine secretion	J:265431
	decreased circulating interleukin-1 beta level	J:265431
	decreased interleukin-1 beta secretion	J:265431
	decreased interleukin-18 secretion	J:265431
	increased macrophage apoptosis	J:265431
\Peli3^tm1.1Arte/\Peli3^tm1.1Arte (involves: C57BL/6NTac)	abnormal dendritic cell physiology	J:188556
	abnormal macrophage cytokine production	J:188556
	decreased susceptibility to Picornaviridae infection	J:188556
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:188556
\Penk-rs^tm1Pig/\Penk-rs^tm1Pig (B6.129-Penk-rs^tm1Pig)	abnormal T-helper 2 physiology	J:62435
	decreased T-helper 2 cell number	J:62435
	lung inflammation	J:62435
\Pepd^{tm1a(KOMP)Wtsi}/\Pepd^{tm1a(KOMP)Wtsi} (C57BL/6N-Pepd^{tm1a(KOMP)Wtsi}/Ucd)	decreased immature B cell number	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	decreased transitional stage T1 B cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased leukocyte cell number	J:211773
	increased memory CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker NK cell number	J:211773
\Pepd^{tm1b(KOMP)Wtsi}/\Pepd^{tm1b(KOMP)Wtsi} (C57BL/6N-Pepd^{tm1b(KOMP)Wtsi}/Ieg)	decreased B-1a cell number	J:211773
	decreased CD5-positive Ly6C-positive T cell number	J:211773
	decreased follicular B cell number	J:211773
	enlarged lymph nodes	J:211773
\Perp^tm1Att/\Perp^tm1Att (involves: 129S4/SvJae)	decreased thymocyte apoptosis	J:86549
\Perp^tm2Att/\Perp^tm2Att \Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S4/SvJae)	skin inflammation	J:167545
\Pex1^tm1.1Hrw/\Pex1^tm1.1Hrw (involves: C57BL/6NTac)	liver inflammation	J:278655
\Pex1^tm1.1Hrw/\Pex1^tm1.1Hrw (involves: C57BL/6NTac)	phlebitis	J:278655
\Pex5^tm1Pec/\Pex5^tm1Pec \Cnp^tm1(cre)Kan/\Cnp⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal inflammatory response	J:123503
	microgliosis	J:123503
\Pex7^tm1Nbra/\Pex7^tm1Nbra (involves: 129S/SvEv * C57BL/6)	liver inflammation	J:158845
\Pex7^tm1Rjaw/\Pex7^tm1Rjaw (Swiss)	abnormal osteoclast morphology	J:92346
\Pex26^{tm1.1(KOMP)Vlcg}/\Pex26⁺ (C57BL/6N-Pex26^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged spleen	J:211773
\Pfas^Sofa-2J/\Pfas⁺ (B6(Cg)-Pfas^Sofa-2J/GrsrJ)	abnormal transitional stage B cell morphology	J:223062
\Pfdn1^{Gt(GTR1.3)1Rul}/\Pfdn1^{Gt(GTR1.3)1Rul} (involves: 129)	abnormal B cell activation	J:137415
	abnormal B cell differentiation	J:137415
	abnormal B cell morphology	J:137415
	abnormal neutrophil morphology	J:137415
	abnormal spleen morphology	J:137415
	abnormal spleen red pulp morphology	J:137415
	abnormal spleen white pulp morphology	J:137415
	abnormal splenic cell ratio	J:137415
	abnormal T cell activation	J:137415
	abnormal thymus cell ratio	J:137415
	abnormal thymus morphology	J:137415
	decreased B-1 B cell number	J:137415
	decreased B-2 B cell number	J:137415
	decreased pre-B cell number	J:137415
	decreased thymus weight	J:137415
	sinus inflammation	J:137415
	small spleen	J:137415
	spleen hypoplasia	J:137415
	thymus hypoplasia	J:137415
\Pfkfb2^{tm1b(KOMP)Wtsi}/\Pfkfb2^{tm1b(KOMP)Wtsi} (C57BL/6N-Pfkfb2^{tm1b(KOMP)Wtsi}/Nju)	decreased neutrophil cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Pfkfb3^tm1.1Pec/\Pfkfb3^tm1.1Pec \Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA)	abnormal macrophage morphology	J:296552
	abnormal macrophage physiology	J:296552
\Pfkm^tm1Fbos/\Pfkm^tm1Fbos (involves: 129S6/SvEvTac * C57BL/6J)	enlarged spleen	J:152153
	increased spleen weight	J:152153
\Pgam1^tm1.1Hiko/\Pgam1^tm1.1Hiko \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:293746
	abnormal CD8-positive, alpha-beta T cell differentiation	J:293746
	abnormal effector T cell number	J:293746
	decreased acute inflammation	J:293746
	decreased CD4-positive, alpha-beta T cell number	J:293746
	decreased CD8-positive, alpha-beta T cell number	J:293746
	decreased interleukin-2 secretion	J:293746
	decreased NK T cell number	J:293746
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:293746
	decreased T-helper 2 cell number	J:293746
	decreased T-helper 17 cell number	J:293746
\Pgam5^{tm1d(EUCOMM)Wtsi}/\Pgam5^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal interleukin-1 beta secretion	J:240016
	abnormal macrophage activation involved in immune response	J:240016
	decreased interleukin-1 beta secretion	J:240016
\Pgap3^tm1.1Ymra/\Pgap3^tm1.1Ymra (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:181221
	abnormal T cell morphology	J:181221
	decreased T cell proliferation	J:181221
	immune system phenotype	J:181221
	increased susceptibility to experimental autoimmune encephalomyelitis	J:181221
	increased T cell proliferation	J:181221
\Pgap3^tm1.1Ymra/\Pgap3^tm1.1Ymra (B6.Cg-Pgap3^tm1.1Ymra)	abnormal T-helper 2 cell differentiation	J:203443
	decreased B cell proliferation	J:203443
	immune system phenotype	J:203443
	impaired macrophage phagocytosis	J:203443
	increased anti-double stranded DNA antibody level	J:203443
	increased anti-single stranded DNA antibody level	J:203443
	increased spleen germinal center number	J:203443
\Pgap3^tm1Ymra/\Pgap3^tm1Ymra \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:203443
\Pgap3^tm1Ymra/\Pgap3^tm1Ymra \Tg(Lck-cre)#Jxm/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:203443
\Pgap4^em1Osbir/\Pgap4^em1Osbir (involves: C57BL/6NSlc)	increased Ly6C-positive immature NK cell number	J:333707
	increased susceptibility to infection induced morbidity/mortality	J:333707
	increased susceptibility to prion infection	J:333707
\Pgbd1^em1(IMPC)Tcp/\Pgbd1^em1(IMPC)Tcp (C57BL/6NCrl-Pgbd1^em1(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Pgc^{em1(IMPC)Ccpcz}/\Pgc^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pgc^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Pgcka1^{em1(IMPC)Ccpcz}/\Pgcka1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pgcka1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Pgd^tm1.1Pse/\Pgd^tm1.1Pse \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal CD4-positive helper T cell morphology	J:313817
	abnormal regulatory T cell physiology	J:313817
	blepharitis	J:313817
	ear inflammation	J:313817
	enlarged lymph nodes	J:313817
	enlarged spleen	J:313817
	increased circulating interferon-gamma level	J:313817
	increased circulating interleukin-4 level	J:313817
	increased circulating interleukin-5 level	J:313817
	increased circulating interleukin-17 level	J:313817
	increased IgA level	J:313817
	increased IgD level	J:313817
	increased IgE level	J:313817
	increased IgG2a level	J:313817
	increased IgG3 level	J:313817
	increased IgM level	J:313817
	increased interferon-gamma secretion	J:313817
	increased susceptibility to type I hypersensitivity reaction	J:313817
	increased T cell number	J:313817
\Pgd^tm1.1Pse/\Pgd^tm1.1Pse \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal alpha-beta T cell morphology	J:306553
	abnormal CD8-positive, alpha beta T cell morphology	J:306553
	abnormal CD8-positive, alpha-beta T cell physiology	J:306553
	abnormal T cell differentiation	J:306553
	decreased CD4-positive, alpha-beta T cell number	J:306553
	decreased CD8-positive, alpha-beta T cell number	J:306553
\Pgd^tm1.1Pse/\Pgd^tm1.1Pse \Tg(Cd4-cre)1Cwi/0 \Tg(TcraTcrb)8Rest/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell physiology	J:306553
\Pgd^tm1.1Pse/\Pgd^tm1.1Pse \Tg(Cd4-cre)1Cwi/0 \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * DBA/2)	abnormal cytotoxic T cell physiology	J:306553
\Pgf^{em1(IMPC)Ccpcz}/\Pgf^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pgf^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK cell number	J:211773
\Pgf^tm1Pec/\Pgf^tm1Pec (involves: 129)	decreased susceptibility to type IV hypersensitivity reaction	J:81388
\Pgia1^BALB/cCrl/\Pgia1^DBA/2Crl (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
	increased susceptibility to autoimmune disorder	J:66460
\Pgia2^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
\Pgia3^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
\Pgia3^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
\Pgia4^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
\Pgia5^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
\Pgia6^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
\Pgia7^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
\Pgia8^DBA/2/\Pgia8^DBA/2 (C.D2-(D15Mit12-D15Mit267))	decreased susceptibility to induced arthritis	J:137478
\Pgia8^DBA/2/\Pgia8^DBA/2 (involves: BALB/c * DBA/2)	decreased interleukin-6 secretion	J:137478
	decreased susceptibility to induced arthritis	J:137478
	increased tumor necrosis factor secretion	J:137478
\Pgia8^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
\Pgia9^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
\Pgia9^DBA/2/\Pgia9^DBA/2 (C.D2-(D15Mit267-D15Mit41))	decreased susceptibility to induced arthritis	J:137478
\Pgia9^DBA/2/\Pgia9^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to induced arthritis	J:137478
	increased interleukin-6 secretion	J:137478
	increased tumor necrosis factor secretion	J:137478
\Pgia10^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
\Pgia10^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
\Pgia11^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased autoantibody level	J:66460
\Pgia12^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:66460
\Pgia13^C3H/HeJCr/\Pgia13^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to induced arthritis	J:65424
\Pgia14^C3H/HeJCr/\Pgia14^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to induced arthritis	J:65424
\Pgia15^C3H/HeJCr/\Pgia15^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to induced arthritis	J:65424
\Pgia16^C3H/HeJCr/\Pgia16^C3H/HeJCr (involves: C3H/HeJCr * C57BL/6)	increased susceptibility to autoimmune disorder	J:65424
\Pgia26^BALB/cCrl/? (involves: BALB/cCrl * DBA/2Crl)	increased inflammatory response	J:84150
\Pgia26^DBA/2Crl/? (involves: BALB/cCrl * DBA/2Crl)	abnormal inflammatory response	J:84150
\Pgia39^DBA/2Crl/? \Pgia6^BALB/cCrl/\Pgia6^DBA/2Crl (involves: BALB/cCrl * DBA/2Crl)	decreased inflammatory response	J:84150
\Pgia39^DBA/2Crl/\Pgia39^DBA/2Crl \Pgia6^DBA/2Crl/\Pgia6^DBA/2Crl (involves: BALB/cCrl * DBA/2Crl)	increased susceptibility to induced arthritis	J:84150
\Pgia39^DBA/2Crl/\Pgia39^DBA/2Crl \Pgia26^BALB/cCrl/\Pgia26^BALB/cCrl (involves: BALB/cCrl * DBA/2Crl)	increased susceptibility to induced arthritis	J:84150
\Pgis1^DBA/2/\Pgis1^DBA/2 (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
\Pgis1^DBA/2/\Pgis1^DBA/2 \Pgis2^BALB/c/\Pgis2^BALB/c (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
\Pgis1^DBA/2/\Pgis1^DBA/2 \Pgis2^BALB/c/\Pgis2^DBA/2 (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
\Pgis2^BALB/c/\Pgis2^BALB/c (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
\Pgis2^BALB/c/\Pgis2^DBA/2 (involves: BALB/c * DBA/2)	increased susceptibility to induced arthritis	J:107496
\Pglyrp1^tm1.1Lky/\Pglyrp1^tm1.1Lky (B6.129S4-Pglyrp1^tm1.1Lky)	abnormal neutrophil physiology	J:171412
	increased susceptibility to bacterial infection	J:171412
\Pglyrp1^tm1Rdz/\Pglyrp1^tm1Rdz (involves: 129S5/SvEvBrd)	abnormal neutrophil physiology	J:84680
	impaired granulocyte bactericidal activity	J:84680
	increased susceptibility to bacterial infection	J:84680
	increased susceptibility to bacterial infection induced morbidity/mortality	J:84680
\Pglyrp1^tm1Rdz/\Pglyrp1^tm1Rdz (C.129S-Pglyrp1^tm1Rdz)	increased susceptibility to induced arthritis	J:178054
\Pglyrp1^tm1Rdz/\Pglyrp1^tm1Rdz (involves: 129S5/SvEvBrd * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
\Pglyrp1^tm1Rdz/\Pglyrp1^tm1Rdz \Pglyrp2^tm1Rdz/\Pglyrp2^tm1Rdz (C.129S-Pglyrp1^tm1Rdz Pglyrp2^tm1Rdz)	decreased susceptibility to induced arthritis	J:178054
\Pglyrp2^tm1Lky/\Pglyrp2^tm1Lky (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage physiology	J:159600
	abnormal tumor necrosis factor level	J:159600
	decreased circulating interleukin-6 level	J:159600
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:159600
\Pglyrp2^tm1Rdz/\Pglyrp2^tm1Rdz (C.129S-Pglyrp2^tm1Rdz)	abnormal circulating chemokine level	J:178054
\Pglyrp2^tm1Rdz/\Pglyrp2^tm1Rdz (C.129S-Pglyrp2^tm1Rdz)	decreased susceptibility to induced arthritis	J:178054
\Pglyrp2^tm1Rdz/\Pglyrp2^tm1Rdz (involves: 129S/SvEv * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
\Pglyrp3^tm1Rdz/\Pglyrp3^tm1Rdz (C.129S-Pglyrp3^tm1Rdz)	immune system phenotype	J:178054
\Pglyrp3^tm1Rdz/\Pglyrp3^tm1Rdz (involves: 129S6/SvEvTac * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
\Pglyrp4^{em1(IMPC)Ccpcz}/\Pglyrp4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pglyrp4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small thymus	J:211773
\Pglyrp4^tm1Rdz/\Pglyrp4^tm1Rdz (C.129S-Pglyrp4^tm1Rdz)	immune system phenotype	J:178054
\Pglyrp4^tm1Rdz/\Pglyrp4^tm1Rdz (involves: 129S6/SvEvTac * BALB/c)	abnormal chemokine secretion	J:178053
	increased interleukin-6 secretion	J:178053
	increased susceptibility to induced colitis	J:178053
\Pgm3^{Gt(W037B08)Wrst}/\Pgm3^mld1 (involves: 129S1/Sv * C57BL/6)	abnormal T cell differentiation	J:125094
	absent follicular B cells	J:125094
	decreased B cell number	J:125094
	decreased leukocyte cell number	J:125094
	decreased T cell number	J:125094
	glomerulonephritis	J:125094
	increased pro-B cell number	J:125094
	increased spleen red pulp amount	J:125094
\Pgm3^mld1/\Pgm3^mld1 (C57BL/6-Pgm3^mld1)	abnormal thrombopoiesis	J:125094
	absent follicular B cells	J:125094
	decreased B cell number	J:125094
	decreased leukocyte cell number	J:125094
	increased pro-B cell number	J:125094
	increased spleen red pulp amount	J:125094
	increased spleen weight	J:125094
\Pgr^tm1Bwo/\Pgr^tm1Bwo (either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))	uterus inflammation	J:28980
\Pgr^tm1Bwo/\Pgr^tm1Bwo (involves: 129S7/SvEvBrd)	abnormal osteoclast morphology	J:145383
\Pgr^tm1Lyd/\Pgr^tm1Lyd (involves: 129S7/SvEvBrd)	abnormal cytokine secretion	J:130208
\Pgr^tm2(cre)Lyd/\Pgr⁺ \Cripto^tm2.2Mms/\Cripto^tm2.2Mms (involves: 129/Sv * C57BL/6N * CD-1)	endometrium inflammation	J:324146
\Pgrmc1^em1Ejho/\Pgrmc1^em1Ejho (involves: C57BL/6N)	liver inflammation	J:268130
\Pgrmc2^tm1.1Jjp/\Pgrmc2^tm1.1Jjp \Pgr^tm2(cre)Lyd/\Pgr⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased uterine NK cell number	J:247103
\Phactr1^em1(IMPC)Mbp/\Phactr1^em1(IMPC)Mbp (C57BL/6NCrl-Phactr1^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Phb1^em1(IMPC)H/\Phb1⁺ (C57BL/6NTac-Phb1^em1(IMPC)H/H)	increased large unstained cell number	J:211773
\Phc1^tm1Os/\Phc1^tm1Os (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:75707
	decreased spleen weight	J:43764
	decreased thymus weight	J:43764
\Phc2^tm1Hko/\Phc2^tm1Hko (B6.129-Phc2^tm1Hko)	immune system phenotype	J:100027
\Phex^Hyp-Duk/Y (involves: BALB/cAnBomUrd)	ear inflammation	J:132678
\Phex^Hyp-Duk/Y (involves: BALB/cAnBomUrd)	increased susceptibility to otitis media	J:132678
\Phex^Hyp/? (involves: C57BL/6J)	enthesitis	J:192371
\Phex^Mhdabap024/Y (C3HeB/FeJ-Phex^Mhdabap024)	decreased circulating C-reactive protein level	J:264682
\Phex^Ska1/\Phex^Ska1 (C57BL/6-Phex^Ska1)	abnormal osteoclast physiology	J:79953
\Phf6^em1Wencc/Y \Tg(Vav1-cre)#Cgp/0 (Not Specified)	abnormal effector T cell number	J:278804
	abnormal splenic cell ratio	J:278804
	abnormal thymus cell ratio	J:278804
	decreased CD4-positive, alpha-beta T cell number	J:278804
	decreased CD8-positive, alpha-beta T cell number	J:278804
	decreased double-negative T cell number	J:278804
	decreased lymphocyte cell number	J:278804
	enlarged spleen	J:278804
	immune system phenotype	J:278804
	increased B cell number	J:278804
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:278804
	increased pro-B cell number	J:278804
\Phf6^em1Wencc/\Phf6^em1Wencc \Tg(Vav1-cre)#Cgp/0 (Not Specified)	abnormal effector T cell number	J:278804
	abnormal splenic cell ratio	J:278804
	abnormal thymus cell ratio	J:278804
	decreased CD4-positive, alpha-beta T cell number	J:278804
	decreased CD8-positive, alpha-beta T cell number	J:278804
	decreased double-negative T cell number	J:278804
	decreased lymphocyte cell number	J:278804
	enlarged spleen	J:278804
	immune system phenotype	J:278804
	increased B cell number	J:278804
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:278804
	increased leukocyte cell number	J:278804
	increased pro-B cell number	J:278804
\Phf6^tm1.1Avo/Y \Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * SJL)	abnormal T cell differentiation	J:276228
	decreased DN2 thymocyte number	J:276228
	increased circulating interferon-alpha level	J:276228
	increased plasmacytoid dendritic cell number	J:276228
\Phf8^tm1dIcs/\Phf8^tm1dIcs (C57BL/6N-Phf8^tm1dIcs/Ics)	decreased lymphocyte cell number	J:211773
\Phf8^tm1dIcs/\Phf8^tm1dIcs (C57BL/6N-Phf8^tm1dIcs/Ics)	increased neutrophil cell number	J:211773
\Phf11d^m1H/\Phf11d^m1H (C3H.CAnNCrl(C3)-Phf11d^m1H)	abnormal inflammatory response	J:217094
\Phf19^tm1.1Ldc/\Phf19^tm1.1Ldc (Not Specified)	enlarged spleen	J:313068
\Phf20^Gt(XN131)Byg/\Phf20^Gt(XN131)Byg (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:228714
	decreased double-positive T cell number	J:228714
	decreased thymocyte number	J:228714
	increased double-negative T cell number	J:228714
	intermingled spleen red and white pulp	J:228714
	small spleen	J:228714
	small thymus	J:228714
	thymus hypoplasia	J:228714
\Phf20l1^em1(IMPC)Tcp/\Phf20l1^em1(IMPC)Tcp (C57BL/6N-Phf20l1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased spleen weight	J:211773
\Phip^{em1(IMPC)Wtsi}/\Phip⁺ (C57BL/6N-Phip^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Phka1^em1(IMPC)Tcp/Y (C57BL/6N-Phka1^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
\Phlda1^tm1Ywc/\Phlda1^tm1Ywc (involves: 129S1/Sv * C57BL/6J)	immune system phenotype	J:72947
\Phldb2^em1(IMPC)H/\Phldb2^em1(IMPC)H (C57BL/6NTac-Phldb2^em1(IMPC)H/H)	increased basophil cell number	J:211773
\Phlpp1^tm1.1Saco/\Phlpp1^tm1.1Saco (involves: 129 * C57BL/6)	immune system phenotype	J:231241
\Phlpp1^tm1.1Saco/\Phlpp1^tm1.1Saco \Phlpp2^{tm1d(EUCOMM)Hmgu}/\Phlpp2^{tm1d(EUCOMM)Hmgu} (involves: 129 * C57BL/6N)	decreased susceptibility to induced colitis	J:231241
\Phlpp2^{tm1d(EUCOMM)Hmgu}/\Phlpp2^{tm1d(EUCOMM)Hmgu} (involves: C57BL/6N)	immune system phenotype	J:231241
\Phrf1^em1(IMPC)Tcp/\Phrf1^em1(IMPC)Tcp (C57BL/6N-Phrf1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Phyh^{tm1b(EUCOMM)Wtsi}/\Phyh^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Phyh^{tm1b(EUCOMM)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Phyh^tm1Safe/\Phyh^tm1Safe (involves: 129P2/OlaHsd * 129X1/SvJ * Black Swiss * FVB/N)	liver inflammation	J:142512
\Pi4ka^m1Btlr/\Pi4ka^m1Btlr (C57BL/6J-Pi4ka^m1Btlr)	decreased macrophage apoptosis	J:265261
	decreased tumor necrosis factor secretion	J:265261
	increased interleukin-1 beta secretion	J:265261
\Pi4ka^m2Btlr/\Pi4ka^m2Btlr (C57BL/6J-Pi4ka^m2Btlr)	increased alpha-beta T cell number	J:272852
	increased CD4-positive, alpha-beta T cell number	J:272852
	increased central memory CD4-positive, alpha-beta T cell number	J:272852
\Pi4ka^{tm1b(EUCOMM)Wtsi}/\Pi4ka⁺ (C57BL/6N-Pi4ka^{tm1b(EUCOMM)Wtsi}/Tcp)	increased monocyte cell number	J:211773
\Pi4ka^tm2.1Arte/\Pi4ka⁺ \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6NTac)	abnormal spleen morphology	J:188779
\Pi16^{Gt(OST292194)Lex}/\Pi16^{Gt(OST292194)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal lymph node B cell domain morphology	J:94077
	abnormal spleen germinal center morphology	J:94077
	increased regulatory T cell number	J:94077
\Pi16^tm1.2Engl/\Pi16^tm1.2Engl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * SJL)	abnormal immune system physiology	J:244259
\Pias1^tm1Kes/\Pias1^tm1Kes (involves: 129S/Sv * C57BL/6)	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:92167
	increased susceptibility to bacterial infection induced morbidity/mortality	J:92167
	increased susceptibility to endotoxin shock	J:92167
\Pias4^tm1Rug/\Pias4^tm1Rug (involves: 129S2/SvPas * C57BL/6)	abnormal myelopoiesis	J:94291
\Picalm^tm1.1Tmae/\Picalm^tm1.1Tmae \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL)	decreased CD4-positive, alpha-beta T cell number	J:220728
	decreased CD8-positive, alpha-beta T cell number	J:220728
\Picalm^tm1.1Tmae/\Picalm^tm1.1Tmae \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA * SJL)	decreased CD4-positive, alpha-beta T cell number	J:220728
	decreased CD8-positive, alpha-beta T cell number	J:220728
	enlarged spleen	J:220728
\Picalm^tm1Towa/\Picalm^tm1Towa (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj)	abnormal B cell differentiation	J:185312
	decreased spleen B cell follicle number	J:185312
	enlarged spleen	J:185312
\Pierce1^{Gt(OST3440)Lex}/\Pierce1^{Gt(OST3440)Lex} (either: (involves: 129S5/SvEvBrd * C57BL/6J) or (involves: 129S5/SvEvBrd * C57BL/6J * FVB/N))	abnormal spleen morphology	J:252050
\Pierce1^{tm2b(EUCOMM)Wtsi}/\Pierce1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Pierce1^{tm2b(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Piezo1^tm2.1Apat/\Piezo1^tm2.1Apat \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA)	abnormal splenic cell ratio	J:229436
	dark spleen	J:229436
\Piga^tm1Tak/\Piga^tm1Tak \Tg(FES-cre)31Bsl/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/Ca)	abnormal T cell activation	J:162065
	abnormal T cell morphology	J:162065
	abnormal T cell physiology	J:162065
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:162065
\Pigr^tm1Fejo/\Pigr^tm1Fejo (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:57987
	abnormal immunoglobulin transcytosis	J:57987
	decreased IgA level	J:57987
	increased IgA level	J:57987
	increased IgG level	J:57987
\Pigr^tm1Fejo/\Pigr^tm1Fejo (involves: 129 * C57BL/6)	increased IgA level	J:140515
\Pigr^tm1Fejo/\Pigr^tm1Fejo (involves: 129 * C57BL/6)	increased susceptibility to parasitic infection	J:140515
\Pigr^tm1Ohw/\Pigr^tm1Ohw (involves: 129X1/SvJ * C57BL/6J)	decreased IgA level	J:58454
	increased IgA level	J:58454
	increased IgE level	J:58454
	increased IgG level	J:58454
\Pigr^tm1Ohw/\Pigr^tm1Ohw (B6.129X1-Pigr^tm1Ohw)	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:97824
	abnormal intraepithelial T cell number	J:97824
	abnormal lymphocyte physiology	J:97824
	decreased IgA level	J:108538
	decreased interferon-gamma secretion	J:108538
	decreased tumor necrosis factor secretion	J:108538
	increased IgA level	J:108538, J:97824
	increased susceptibility to bacterial infection	J:108538
\Pigr^tm1Ohw/\Pigr^tm1Ohw \Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J)	decreased lymphocyte cell number	J:97824
	immune system phenotype	J:97824
	increased IgA level	J:97824
\Pigr^tm1Rast/\Pigr^tm1Rast (C57BL/6-Pigr^tm1Rast)	abnormal immune system cell morphology	J:81984
	abnormal immunoglobulin level	J:81984
	abnormal immunoglobulin transcytosis	J:81984
	decreased IgA level	J:81984
	increased IgA level	J:81984
	increased IgG level	J:81984
\Pigv^b2b2859Clo/\Pigv^b2b2859Clo (C57BL/6J-Pigv^b2b2859Clo)	thymus hypoplasia	J:175213
\Pik3ap1^m1Btlr/\Pik3ap1^m1Btlr (involves: C57BL/6J)	arrested B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
\Pik3ap1^m2Btlr/\Pik3ap1^m2Btlr (C57BL/6J-Pik3ap1^m2Btlr)	decreased B-1a cell number	J:255271
	impaired humoral immune response	J:255271
	increased B-1b cell number	J:255271
	increased IgM level	J:255271
\Pik3ap1^M3Btlr/\Pik3ap1^M3Btlr (C57BL/6J-Pik3ap1^M3Btlr)	decreased B-1 B cell number	J:272019
\Pik3ap1^{tm1b(KOMP)Wtsi}/\Pik3ap1^{tm1b(KOMP)Wtsi} (C57BL/6N-Pik3ap1^{tm1b(KOMP)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Pik3ap1^tm1Kuro/\Pik3ap1^tm1Kuro (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:75075
	absent B-1a cells	J:84669
	decreased B cell number	J:84669
	decreased B cell proliferation	J:84669
	decreased follicular B cell number	J:84669
	decreased IgG2b level	J:75075
	decreased IgG3 level	J:75075
	decreased IgM level	J:75075
	decreased immunoglobulin level	J:75075
	decreased pre-B cell number	J:75075
	spleen hypoplasia	J:75075
\Pik3c2a^{Gt(OST288105)Lex}/\Pik3c2a^{Gt(OST288105)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	enlarged spleen	J:169710
	glomerulonephritis	J:169710
	immune system phenotype	J:169710
	increased anti-double stranded DNA antibody level	J:169710
	increased B cell number	J:169710
	increased CD4-positive, alpha-beta T cell number	J:169710
	increased CD8-positive, alpha-beta T cell number	J:169710
	increased granulocyte number	J:169710
	increased IgA level	J:169710
	increased IgG level	J:169710
	increased IgM level	J:169710
	increased leukocyte cell number	J:169710
	increased monocyte cell number	J:169710
	increased neutrophil cell number	J:169710
\Pik3c2a^{tm1b(EUCOMM)Hmgu}/\Pik3c2a⁺ (C57BL/6N-Pik3c2a^{tm1b(EUCOMM)Hmgu}/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
\Pik3c2a^tm1Bvan/\Pik3c2a⁺ (involves: C57BL/6)	abnormal thrombopoiesis	J:226344
\Pik3c3^tm1.1Flv/\Pik3c3^tm1.1Flv \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal T cell number	J:184753
	decreased CD4-positive, alpha-beta T cell number	J:184753
	decreased CD8-positive, alpha-beta T cell number	J:184753
\Pik3c3^tm1.1Flv/\Pik3c3^tm1.1Flv \Tg(Cd8a-cre)1Itan/0 (involves: C57BL/6 * C57BL/6N)	abnormal CD4-positive, alpha beta T cell morphology	J:184753
	abnormal CD8-positive, alpha beta T cell morphology	J:184753
	decreased CD4-positive, alpha-beta T cell number	J:184753
	decreased CD8-positive, alpha-beta T cell number	J:184753
	decreased lymphocyte cell number	J:184753
	immune system phenotype	J:184753
	increased T cell apoptosis	J:184753
\Pik3ca^tm1Jdo/\Pik3ca^tm1Jdo (B6.129S7(Cg)-Pik3ca^tm1Jdo)	abnormal lymphangiogenesis	J:122866
\Pik3ca^tm1Jdo/\Pik3ca^tm1Jdo (B6.129S7(Cg)-Pik3ca^tm1Jdo)	abnormal lymphatic vessel morphology	J:122866
\Pik3cd^em1.1Pls/\Pik3cd⁺ (Not Specified)	abnormal B cell differentiation	J:282486
	abnormal class switch recombination	J:282486
	abnormal follicular B cell physiology	J:282486
	abnormal gut-associated lymphoid tissue morphology	J:282486
	abnormal IgG1 level	J:282486
	abnormal immune tolerance	J:282486
	abnormal innate immunity	J:282486
	abnormal lymph node germinal center morphology	J:282486
	abnormal mesenteric lymph node morphology	J:282486
	abnormal Peyer's patch germinal center morphology	J:282486
	abnormal Peyer's patch morphology	J:282486
	abnormal plasmablast number	J:282486
	decreased B cell apoptosis	J:282486
	decreased CD4-positive, alpha-beta T cell number	J:282486
	decreased follicular B cell number	J:282486
	decreased leukocyte cell number	J:282486
	decreased naive B cell number	J:282486
	enlarged lymph nodes	J:282486
	enlarged spleen	J:282486
	impaired humoral immune response	J:282486
	increased activated T cell number	J:282486
	increased anti-double stranded DNA antibody level	J:282486
	increased anti-nuclear antigen antibody level	J:282486
	increased B cell proliferation	J:282486
	increased B-1a cell number	J:282486
	increased germinal center B cell number	J:282486
	increased IgA level	J:282486
	increased IgG level	J:282486
	increased IgM level	J:282486
	increased lymphocyte activation involved in immune response	J:282486
	increased lymphocyte cell number	J:282486
	increased marginal zone B cell number	J:282486
	increased plasma cell number	J:282486
	increased response to antigen	J:282486
	increased T follicular helper cell number	J:282486
	increased transitional stage B cell number	J:282486
	increased transitional stage T1 B cell number	J:282486
	lymph node hyperplasia	J:282486
	lymphoid hyperplasia	J:282486
	spleen hyperplasia	J:282486
\Pik3cd^{Gt(OST451938)Lex}/\Pik3cd^{Gt(OST451938)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	decreased IgG1 level	J:103485
	increased leukocyte cell number	J:103485
	increased lymphocyte cell number	J:103485
\Pik3cd^m1Btlr/\Pik3cd^m1Btlr (C57BL/6J-Pik3cd^m1Btlr)	abnormal humoral immune response	J:213049
\Pik3cd^m2Btlr/\Pik3cd⁺ (C57BL/6J-Pik3cd^m2Btlr)	decreased B-1 B cell number	J:236693
	decreased IgG level	J:236693
	decreased IgM level	J:236693
	decreased response to antigen	J:236693
\Pik3cd^m2Btlr/\Pik3cd^m2Btlr (C57BL/6J-Pik3cd^m2Btlr)	decreased B-1 B cell number	J:236693
	decreased B-1a cell number	J:236693
	decreased IgG level	J:236693
	decreased IgM level	J:236693
	decreased response to antigen	J:236693
	increased circulating interferon-alpha level	J:236693
	increased IgE level	J:236693
	increased response to antigen	J:236693
	increased susceptibility to Herpesvirales infection	J:236693
\Pik3cd^tm1.1Bvan/\Pik3cd^tm1.1Bvan (involves: 129P2/OlaHsd * BALB/c)	abnormal B cell differentiation	J:78412
	abnormal Peyer's patch germinal center morphology	J:78412
	absent spleen germinal center	J:78412
	decreased B-1 B cell number	J:78412
	decreased IgA level	J:78412
	decreased IgM level	J:78412
	decreased immunoglobulin level	J:78412
	increased neutrophil cell number	J:78412
	intestinal inflammation	J:78412
	spleen hypoplasia	J:78412
\Pik3cd^tm1Jni/\Pik3cd^tm1Jni (involves: 129P2/OlaHsd)	abnormal B cell calcium ion homeostasis	J:80614
	abnormal humoral immune response	J:80614
	absent B-1 B cells	J:80614
	absent spleen germinal center	J:80614
	decreased B cell number	J:80614
	decreased B cell proliferation	J:80614
	decreased immunoglobulin level	J:80614
	decreased mature B cell number	J:80614
	small lymph nodes	J:80614
	small spleen	J:80614
\Pik3cd^tm1Jni/\Pik3cd^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:124330
\Pik3cd^tm1Jni/\Pik3cd^tm1Jni \Pik3cg^tm1Pngr/\Pik3cg^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	abnormal NK cell differentiation	J:124330
	decreased cytotoxic T cell cytolysis	J:124330
	decreased interferon-gamma secretion	J:124330
	decreased NK cell number	J:124330
	decreased T cell number	J:124330
	spleen hypoplasia	J:124330
\Pik3cd^tm1Tnr/\Pik3cd^tm1Tnr (involves: 129S4/SvJae)	abnormal B cell physiology	J:113491
	abnormal humoral immune response	J:79133
	decreased B cell number	J:79133
	decreased B cell proliferation	J:113491, J:79133
	decreased B-1 B cell number	J:79133
	decreased B-2 B cell number	J:79133
	decreased IgG1 level	J:79133
	decreased IgG2a level	J:79133
	decreased IgG2b level	J:79133
	decreased IgG3 level	J:79133
	decreased IgM level	J:79133
	decreased marginal zone B cell number	J:79133
\Pik3cd^tm1Tnr/\Pik3cd^tm1Tnr (B6.129S4-Pik3cd^tm1Tnr)	decreased inflammatory response	J:134324
\Pik3cd^tm1Tnr/\Pik3cd^tm1Tnr (B6.129S4-Pik3cd^tm1Tnr)	decreased susceptibility to induced arthritis	J:134324
\Pik3cd^tm1Tnr/\Pik3cd^tm1Tnr \Pik3cg^tm1Pngr/\Pik3cg^tm1Pngr (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal T cell differentiation	J:125791
	abnormal T cell physiology	J:125791
	abnormal thymus lobule morphology	J:125791
	decreased CD4-positive, alpha-beta T cell number	J:125791
	decreased CD8-positive, alpha-beta T cell number	J:125791
	decreased double-positive T cell number	J:125791
	decreased lymphocyte cell number	J:125791
	decreased T cell number	J:125791
	small thymus	J:125791
	thymus hypoplasia	J:125791
\Pik3cd^tm1Tnr/\Pik3cd^tm1Tnr \Pik3cg^tm1Pngr/\Pik3cg^tm1Pngr (B6.129-Pik3cd^tm1Tnr Pik3cg^tm1Pngr)	decreased inflammatory response	J:134324
	decreased susceptibility to induced arthritis	J:134324
	impaired neutrophil chemotaxis	J:134324
	impaired neutrophil recruitment	J:134324
\Pik3cd^tm1Tnr/\Pik3cd^tm1Tnr \Pten^tm2.1Ppp/\Pten^tm2.1Ppp \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6)	abnormal class switch recombination	J:130950
	immune system phenotype	J:130950
	increased marginal zone B cell number	J:130950
\Pik3cd^tm1Tnr/\Pik3cd^tm1Tnr \Tg(BCL2)36Wehi/0 (involves: 129S4/SvJae * C57BL/6JWehi * SJL/JWehi)	decreased follicular B cell number	J:130950
\Pik3cd^tm2.1Tnr/\Pik3cd^tm2.1Tnr \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:164283
	increased IgE level	J:164283
\Pik3cd^tm2.1Tnr/\Pik3cd^tm2.1Tnr \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal adaptive immunity	J:164283
	abnormal humoral immune response	J:164283
	decreased CD4-positive, alpha-beta T cell number	J:164283
	decreased CD8-positive, alpha-beta T cell number	J:164283
	decreased germinal center B cell number	J:164283
	decreased IgG1 level	J:164283
	decreased spleen germinal center number	J:164283
	decreased spleen germinal center size	J:164283
	decreased T cell number	J:164283
	decreased T follicular helper cell number	J:164283
\Pik3cd^tm2.1Tnr/\Pik3cd^tm2.1Tnr \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal humoral immune response	J:164283
	decreased germinal center B cell number	J:164283
	decreased IgG1 level	J:164283
	decreased spleen germinal center number	J:164283
	decreased T follicular helper cell number	J:164283
\Pik3cg^tm1Dwu/\Pik3cg^tm1Dwu (Not Specified)	decreased immunoglobulin level	J:60348
\Pik3cg^tm1Dwu/\Pik3cg^tm1Dwu (Not Specified)	impaired neutrophil chemotaxis	J:60348
\Pik3cg^tm1Dwu/\Pik3cg^tm1Dwu (B6.Cg-Pik3cg^tm1Dwu)	abnormal CD8-positive, alpha-beta T cell physiology	J:131923
	abnormal response to infection	J:131923
	decreased CD8-positive, alpha-beta T cell number	J:131923
	immune system phenotype	J:131923
	increased susceptibility to Poxviridae infection	J:131923
\Pik3cg^tm1Dwu/\Pik3cg^tm1Dwu \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:131923
	abnormal response to infection	J:131923
	immune system phenotype	J:131923
\Pik3cg^tm1Ehi/\Pik3cg^tm1Ehi (Not Specified)	impaired macrophage chemotaxis	J:91945
\Pik3cg^tm1Ehi/\Pik3cg^tm1Ehi (Not Specified)	impaired neutrophil recruitment	J:91945
\Pik3cg^tm1Lste/\Pik3cg^tm1Lste (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil physiology	J:147259
	impaired neutrophil chemotaxis	J:147259
	impaired neutrophil recruitment	J:147259
\Pik3cg^tm1Lste/\Pik3cg^tm1Lste (involves: 129P2/OlaHsd)	impaired neutrophil chemotaxis	J:238900
\Pik3cg^tm1Pngr/\Pik3cg^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune cell physiology	J:60347
	abnormal neutrophil physiology	J:60347
	abnormal NK cell differentiation	J:124330
	abnormal T cell activation	J:60347
	abnormal T cell differentiation	J:60347
	abnormal T cell physiology	J:60347
	abnormal T-helper 2 physiology	J:60347
	decreased CD4-positive, alpha-beta T cell number	J:60347
	decreased cytotoxic T cell cytolysis	J:124330
	decreased interferon-gamma secretion	J:60347, J:124330
	decreased interleukin-2 secretion	J:60347
	decreased T cell proliferation	J:60347
	decreased thymocyte number	J:60347
	impaired neutrophil chemotaxis	J:60347
	impaired neutrophil recruitment	J:60347
	increased eosinophil cell number	J:60347
	increased monocyte cell number	J:60347
	increased neutrophil cell number	J:60347
	thymus hypoplasia	J:60347
\Pik3cg^tm1Pngr/\Pik3cg^tm1Pngr (B6.129P2-Pik3cg^tm1Pngr)	decreased inflammatory response	J:134324
	decreased susceptibility to induced arthritis	J:134324
	impaired neutrophil chemotaxis	J:134324
\Pik3cg^tm1Wym/\Pik3cg^tm1Wym (either: 129/Sv-Pik3cg^tm1Wym or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal leukocyte physiology	J:60349
	abnormal neutrophil physiology	J:60349
	impaired macrophage chemotaxis	J:60349
	impaired neutrophil chemotaxis	J:60349
	impaired neutrophil recruitment	J:60349
	increased neutrophil cell number	J:60349
	increased susceptibility to bacterial infection	J:60349
\Pik3cg^tm1Wym/\Pik3cg^tm1Wym (involves: 129S1/Sv * 129X1/SvJ)	abnormal neutrophil physiology	J:147259
	impaired neutrophil chemotaxis	J:238900
	impaired neutrophil recruitment	J:147259
\Pik3cg^tm2Ehi/\Pik3cg^tm2Ehi (Not Specified)	abnormal inflammatory response	J:124856
	abnormal macrophage physiology	J:124856
	decreased macrophage cell number	J:124856
	decreased neutrophil cell number	J:124856
	impaired macrophage chemotaxis	J:124856
	impaired neutrophil chemotaxis	J:124856
	increased interleukin-1 beta secretion	J:124856
	increased interleukin-6 secretion	J:124856
	increased leukocyte cell number	J:124856
	increased tumor necrosis factor secretion	J:124856
\Pik3ip1^m1Anu/\Pik3ip1^m1Anu (C57BL/6NCrlAnu-Pik3ip1^m1Anu)	immune system phenotype	J:104190
\Pik3r1^m1Btlr/\Pik3r1^m1Btlr (C57BL/6J-Pik3r1^m1Btlr)	decreased B cell number	J:254890
	decreased B-1a cell number	J:254890
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254890
	increased CD8-positive, alpha-beta memory T cell number	J:254890
\Pik3r1^M2Btlr/\Pik3r1⁺ (C57BL/6J-Pik3r1^M2Btlr)	decreased B-1 B cell number	J:254892
	decreased B-1a cell number	J:254892
	decreased B-1b cell number	J:254892
	decreased B-2 B cell number	J:254892
	decreased NK T cell number	J:254892
	increased B-1b cell number	J:254892
\Pik3r1^m3Btlr/\Pik3r1^m3Btlr (C57BL/6J-Pik3r1^m3Btlr)	increased B-1b cell number	J:272853
\Pik3r1^tm1Dfr/\Pik3r1^tm1Dfr (involves: 129S6/SvEvTac * C57BL/6)	arrested B cell differentiation	J:52229
	decreased B cell proliferation	J:52229
	decreased mature B cell number	J:52229
\Pik3r1^tm1Dfr/\Pik3r1^tm1Dfr (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:104166
	decreased immature B cell number	J:104166
	decreased mature B cell number	J:104166
	decreased pre-B cell number	J:104166
	increased pro-B cell number	J:104166
\Pik3r1^tm1Dfr/\Pik3r1^tm1Dfr \Plcg2^tm1Jni/\Plcg2^tm1Jni (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal B cell differentiation	J:104166
	arrested B cell differentiation	J:104166
	decreased immature B cell number	J:104166
	decreased mature B cell number	J:104166
	decreased pre-B cell number	J:104166
	immune system phenotype	J:104166
	increased B cell apoptosis	J:104166
\Pik3r1^tm1Tka/\Pik3r1^tm1Tka (involves: C57BL/6 * CBA)	abnormal B cell physiology	J:113491
	abnormal humoral immune response	J:52228
	decreased B cell number	J:52228
	decreased B cell proliferation	J:113491, J:52228
	decreased mature B cell number	J:52228
	decreased pre-B cell number	J:52228
	decreased pro-B cell number	J:52228
	increased susceptibility to bacterial infection	J:52228
\Pik3r1^tm2Dfr/\Pik3r1^tm2Dfr (either: C.129S6-Pik3r1^tm2Dfr or (involves: 129S6/SvEvTac * BALB/c * C57BL/6))	abnormal B cell differentiation	J:94077
\Pik3r4^tm1.1Mpnd/\Pik3r4^tm1.1Mpnd \Tg(ACTA1-cre)79Jme/0 (involves: 129S2/SvPas * C57BL/6J * C57BL/6N * SJL)	myositis	J:198770
\Pik3r5^tm1Lste/\Pik3r5^tm1Lste (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil chemotaxis	J:147259
	impaired neutrophil recruitment	J:147259
\Pik3r5^tm1Lste/\Pik3r5^tm1Lste (involves: 129P2/OlaHsd)	impaired neutrophil chemotaxis	J:238900
\Pik3r5^tm1Lste/\Pik3r5^tm1Lste (involves: 129P2/OlaHsd)	increased neutrophil cell number	J:238900
\Pik3r6^tm1.1Lste/\Pik3r6^tm1.1Lste (Not Specified)	abnormal neutrophil physiology	J:238900
	decreased granulocyte number	J:238900
	decreased lymphocyte cell number	J:238900
	immune system phenotype	J:238900
	increased neutrophil cell number	J:238900
\Pikfyve^{Gt(AT0926)Wtsi}/\Pikfyve^{Gt(AT0926)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:190368
	abnormal thymus morphology	J:190368
	spleen hypoplasia	J:190368
	thymus hypoplasia	J:190368
\Pikfyve^tm2.1Tssk/\Pikfyve^tm2.1Tssk \Tg(Vil1-cre)20Syr/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	intestinal inflammation	J:193689
\Pilra^tm1Osb/\Pilra^tm1Osb (B6.129-Pilra^tm1Osb)	abnormal leukocyte adhesion	J:191085
	abnormal neutrophil physiology	J:191085
	increased neutrophil cell number	J:191085
	increased susceptibility to bacterial infection induced morbidity/mortality	J:191085
	increased susceptibility to endotoxin shock	J:191085
\Pilrb1^tm1Pgh/\Pilrb1^tm1Pgh (involves: C57BL/6)	abnormal chemokine level	J:157763
	abnormal cytokine level	J:157763
	abnormal cytokine secretion	J:157763
	decreased circulating interleukin-1 beta level	J:157763
	decreased circulating interleukin-6 level	J:157763
	decreased circulating tumor necrosis factor level	J:157763
	decreased interleukin-1 beta secretion	J:157763
	decreased susceptibility to bacterial infection	J:157763
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:157763
	decreased tumor necrosis factor secretion	J:157763
	increased circulating interferon-gamma level	J:157763
	increased circulating interleukin-12 level	J:157763
	increased interferon-gamma secretion	J:157763
	increased interleukin-10 secretion	J:157763
	increased interleukin-12 secretion	J:157763
\Pim1^tm1Pwl/\Pim1^tm1Pwl (involves: 129P2/OlaHsd * BALB/c)	abnormal mast cell physiology	J:15259, J:14715
\Pim1^tm1Pwl/\Pim1^tm1Pwl \Pim2^tm1Brn/\Pim2^tm1Brn \Pim3^tm1Brn/\Pim3^tm1Brn (involves: 129P/Ola * FVB/N)	decreased B cell number	J:91592
	decreased B cell proliferation	J:91592
	decreased pre-B cell number	J:91592
	decreased pro-B cell number	J:91592
	decreased T cell proliferation	J:91592
	increased early pro-B cell number	J:91592
\Pim2^tm1.1Lex/\Pim2^tm1.1Lex (involves: 129S/SvEvBrd * C57BL/6)	decreased interleukin-6 secretion	J:166403
\Pim2^tm1Brn/\Pim2^tm1Brn (involves: 129P/Ola * FVB/N)	decreased T cell proliferation	J:91592
\Pink1^tm1Hbu/\Pink1^tm1Hbu (involves: 129S7/SvEvBrd * C57BL/6)	increased interleukin-1 beta secretion	J:169471
	increased interleukin-10 secretion	J:169471
	increased interleukin-12 secretion	J:169471
\Pip4k2c^{tm1b(KOMP)Wtsi}/\Pip4k2c^{tm1b(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	abnormal circulating chemokine level	J:234283
	abnormal T cell activation	J:234283
	chronic inflammation	J:234283
	chronic liver inflammation	J:234283
	decreased regulatory T cell number	J:234283
	increased CD4-positive, alpha-beta T cell number	J:234283
	increased CD8-positive, alpha-beta T cell number	J:234283
	increased circulating interferon-gamma level	J:234283
	increased circulating interleukin-2 level	J:234283
	increased circulating interleukin-4 level	J:234283
	increased circulating interleukin-10 level	J:234283
	increased circulating interleukin-12 level	J:234283
	increased circulating interleukin-12b level	J:234283
	increased IgG3 level	J:234283
	increased inflammatory response	J:234283
	increased interferon-gamma secretion	J:234283
	increased interleukin-17 secretion	J:234283
	increased T cell proliferation	J:234283
	increased T-helper cell number	J:234283
	intestinal inflammation	J:234283
	kidney inflammation	J:234283
	lung inflammation	J:234283
	salivary gland inflammation	J:234283
\Pip4p1^{em1(IMPC)Ccpcz}/\Pip4p1^{em1(IMPC)Ccpcz} (C57BL/6N-Pip4p1^{em1(IMPC)Ccpcz}/Ccpcz)	increased CD4-negative, CD25-positive NK T cell number	J:211773
\Pip5k1b^tm1Tssk/\Pip5k1b^tm1Tssk (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell physiology	J:97991
	increased susceptibility to type I hypersensitivity reaction	J:97991
\Pip5k1c^tm1.2Ref/\Pip5k1c^tm1.2Ref \Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6)	abnormal T cell physiology	J:164732
	decreased B cell number	J:164732
	decreased dendritic cell number	J:164732
	increased interferon-gamma secretion	J:164732
	increased interleukin-2 secretion	J:164732
	increased T cell proliferation	J:164732
\Pip^tm1Myal/\Pip^tm1Myal (involves: 129S/SvEv * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:202016
	arteritis	J:202016
	colitis	J:202016
	enlarged submandibular lymph nodes	J:202016
	enlarged thymus	J:202016
	enlarged thymus medulla	J:202016
\Pirb^em1Fgla/\Pirb^em1Fgla (C57BL/6-Pirb^em1Fgla)	decreased length of allograft survival	J:290663
\Pirb^tm1Ttk/\Pirb^tm1Ttk (involves: 129X1/SvJ)	abnormal B cell activation	J:76770
	abnormal dendritic cell differentiation	J:76770
	abnormal immune system cell morphology	J:76770
	abnormal leukocyte physiology	J:76770
	abnormal T cell physiology	J:76770
	abnormal T-helper 2 physiology	J:76770
	increased B cell proliferation	J:76770
	increased B-1 B cell number	J:76770
\Pitm1^C57BL/FaDk/\Pitm1^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitm1^C57BL/FaDk/\Pitm1^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitm2^C57BL/FaDk/\Pitm2^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitm2^C57BL/FaDk/\Pitm2^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitm3^C57BL/FaDk/\Pitm3^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitm3^C57BL/FaDk/\Pitm3^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitm4^C57BL/FaDk/\Pitm4^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitm4^C57BL/FaDk/\Pitm4^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:70033
\Pitpnm1^{tm1a(EUCOMM)Wtsi}/\Pitpnm1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	decreased leukocyte cell number	J:207051
\Pitx2^tm1Hmd/\Pitx2^tm1Hmd (involves: C3H * C57BL/6 * C57BL/6J)	small spleen	J:128475
\Pitx2^tm1Jfm/\Pitx2^tm1Jfm (involves: 129S4/SvJaeSor)	spleen hypoplasia	J:57674
\Pitx2^tm1Rsd/\Pitx2^tm1Rsd (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:57673
\Pitx2^tm3.1Jfm/\Pitx2^tm3.1Jfm (involves: 129S4/SvJaeSor)	small spleen	J:92872
\Pitx3^eyl/\Pitx3^eyl (involves: C3H/He * C57BL/6)	abnormal immunoglobulin level	J:156878
	decreased IgG3 level	J:156878
	decreased IgM level	J:156878
	decreased leukocyte cell number	J:156878
	increased CD4-positive, alpha-beta T cell number	J:156878
	increased CD8-positive, alpha-beta T cell number	J:156878
	increased granulocyte number	J:156878
\Pitx3^tm1.1Cai/\Pitx3⁺ \Tg(tetO-SNCAA53T)E2Cai/0 (involves: 129 C57BL/6J * FVB/N)	microgliosis	J:185958
\Pja2^tm1.2Afel/\Pja2^tm1.2Afel (involves: 129S6/SvEvTac * C57BL/6J)	kidney inflammation	J:345592
\Pja2^{tm1b(EUCOMM)Wtsi}/\Pja2⁺ (C57BL/6N-Pja2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Pja2^{tm1b(EUCOMM)Wtsi}/\Pja2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Pja2^{tm1b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Pkd1^{tm1b(EUCOMM)Hmgu}/\Pkd1⁺ (C57BL/6N-Pkd1^{tm1b(EUCOMM)Hmgu}/Bay)	increased neutrophil cell number	J:211773
\Pkd1^tm1Djmp/\Pkd1^tm1Djmp (involves: 129P2/OlaHsd * C57BL/6)	kidney inflammation	J:94582
\Pkd1^tm1Jzh/\Pkd1⁺ (either: (involves: 129S4/SvJae * C57BL/6) or (involves: 129S4/SvJae * BALB/c))	bile duct inflammation	J:52573
	kidney inflammation	J:52573
\Pkd2^tm1Dwo/\Pkd2^tm1Dwo (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	absent spleen	J:77401
\Pkhd1^tm1.1Ggg/\Pkhd1^tm1.1Ggg (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	bile duct inflammation	J:125113
\Pkhd1^tm1Som/\Pkhd1^tm1Som (involves: 129S/SvEv * C57BL/6)	enlarged spleen	J:131370
\Pkhd1l1^em1(IMPC)H/\Pkhd1l1^em1(IMPC)H (C57BL/6N-Pkhd1l1^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Pklr^char4/\Pklr^char4 (involves: A/J * C57BL/6)	decreased susceptibility to parasitic infection	J:141722, J:86735
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:141722
	enlarged spleen	J:86735
\Pklr^slc/\Pklr^slc (CBA/NSlc-Pklr^slc)	decreased susceptibility to parasitic infection	J:141722
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:141722
	enlarged spleen	J:30035
	increased susceptibility to bacterial infection induced morbidity/mortality	J:128518
\Pkn1^{tm1b(KOMP)Wtsi}/\Pkn1^{tm1b(KOMP)Wtsi} (C57BL/6N-Pkn1^{tm1b(KOMP)Wtsi}/H)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
\Pkn1^tm1Kik/\Pkn1^tm1Kik (B6.129P2-Pkn1^tm1Kik)	abnormal germinal center B cell physiology	J:193187
	abnormal somatic hypermutation frequency	J:193187
	decreased activation-induced B cell apoptosis	J:193187
	glomerulonephritis	J:193187
	immune system phenotype	J:193187
	increased anti-double stranded DNA antibody level	J:193187
	increased B cell proliferation	J:193187
	increased germinal center B cell number	J:193187
	increased IgG1 level	J:193187
	increased IgG2a level	J:193187
	increased IgG2b level	J:193187
	increased IgM level	J:193187
	increased spleen germinal center size	J:193187
	increased splenocyte number	J:193187
\Pkn3^tm1.1Mrl/\Pkn3⁺ \Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA/J)	enlarged spleen	J:216983
	enlarged thymus	J:216983
\Pkn3^tm1.1Mrl/\Pkn3^tm1.1Mrl \Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA/J)	enlarged spleen	J:216983
	enlarged thymus	J:216983
\Pknox1^{Gt(OST71835)Lex}/\Pknox1^{Gt(OST71835)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	decreased single-positive T cell number	J:103769
	increased double-negative T cell number	J:103769
	increased T cell apoptosis	J:103769
	thymus hypoplasia	J:103769
\Pknox1^tm1Ngc/\Pknox1⁺ \Tg(IghMyc)22Bri/0 (involves: C57BL * SJL)	decreased B cell apoptosis	J:192251
	increased B cell proliferation	J:192251
\Pknox1^tm2.1Fbla/\Pknox1^tm2.1Fbla \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd)	decreased pre-B cell number	J:192251
	increased pro-B cell number	J:192251
\Pknox2^{em1(IMPC)Ccpcz}/\Pknox2^{em1(IMPC)Ccpcz} (C57BL/6N-Pknox2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Pkp3^tm1.1Fvr/\Pkp3^tm1.1Fvr (involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)	dermatitis	J:136451
	enlarged lymph nodes	J:136451
\Pla1a^em1(IMPC)J/\Pla1a^em1(IMPC)J (C57BL/6NJ-Pla1a^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Pla1a^em1Appsc/\Pla1a^em1Appsc (C57BL/6J-Pla1a^em1Appsc)	abnormal interleukin level	J:333902
	decreased susceptibility to chemically induced skin inflammation	J:333902
	decreased susceptibility to induced arthritis	J:333902
	increased lymphocyte cell number	J:333902
\Pla2g2d^{tm1.1(KOMP)Vlcg}/\Pla2g2d^{tm1.1(KOMP)Vlcg} (C57BL/6N-Pla2g2d^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Pla2g2d^tm1.1Mhg/\Pla2g2d^tm1.1Mhg (B6.Cg-Pla2g2d^tm1.1Mhg)	immune system phenotype	J:197334
\Pla2g2d^tm1.1Mhg/\Pla2g2d^tm1.1Mhg (B6NCrSlc.Cg-Pla2g2d^tm1.1Mhg)	abnormal cytotoxic T cell physiology	J:229035
	abnormal dendritic cell migration	J:229035
	abnormal dendritic cell physiology	J:201008
	abnormal effector T cell morphology	J:201008
	decreased interleukin-6 secretion	J:201008
	decreased susceptibility to Coronaviridae infection	J:229035
	decreased susceptibility to Coronaviridae infection induced morbidity/mortality	J:229035
	decreased tumor necrosis factor secretion	J:201008
	immune system phenotype	J:201008
	increased CD4-positive, alpha-beta T cell number	J:229035, J:201008
	increased CD8-positive, alpha-beta T cell number	J:229035
	increased dendritic cell number	J:201008
	increased interferon-gamma secretion	J:229035
	increased susceptibility to type IV hypersensitivity reaction	J:201008
\Pla2g2e^tm1Mhg/\Pla2g2e^tm1Mhg (B6.Cg-Pla2g2e^tm1Mhg)	immune system phenotype	J:197334
\Pla2g2f^tm1Mhg/\Pla2g2f^tm1Mhg (B6.Cg-Pla2g2f^tm1Mhg)	immune system phenotype	J:197334
\Pla2g3^tm1Murm/\Pla2g3^tm1Murm (involves: 129S/SvEv * C57BL/6)	abnormal mast cell differentiation	J:197334
	abnormal mast cell morphology	J:197334
	decreased mast cell degranulation	J:197334
	decreased susceptibility to type I hypersensitivity reaction	J:197334
	ear inflammation	J:197334
\Pla2g4a^tm1Jvb/\Pla2g4a^tm1Jvb (involves: 129S4/SvJae)	abnormal mast cell differentiation	J:54619
\Pla2g4a^tm1Jvb/\Pla2g4a^tm1Jvb (involves: 129S4/SvJae)	increased mast cell degranulation	J:54619
\Pla2g4a^tm1Jvb/\Pla2g4a^tm1Jvb (involves: 129S4/SvJae * BALB/c)	immune system phenotype	J:110309
\Pla2g4a^tm1Tksh/\Pla2g4a^tm1Tksh (involves: 129P2/OlaHsd * C57BL/6J)	increased susceptibility to type I hypersensitivity reaction	J:39254
\Pla2g4a^tm1Tksh/\Pla2g4a^tm1Tksh (NOD.129P2(B6)-Pla2g4a^tm1Tksh)	abnormal macrophage physiology	J:99775
	insulitis	J:99775
\Pla2g4a^tm1Tksh/\Pla2g4a^tm1Tksh (B6.129P2-Pla2g4a^tm1Tksh)	abnormal cytokine level	J:107430
	decreased interferon-gamma secretion	J:107430
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:107430
	decreased tumor necrosis factor secretion	J:107430
	immune system phenotype	J:197334
\Pla2g4e^em1Murm/\Pla2g4e^em1Murm (C57BL/6NSlc-Pla2g4e^em1Murm)	increased susceptibility to chemically induced skin inflammation	J:333700
\Pla2g5^{em1(IMPC)Ccpcz}/\Pla2g5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Pla2g5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
\Pla2g5^tm1Jarm/\Pla2g5^tm1Jarm (involves: 129 * C57BL/6J)	abnormal macrophage physiology	J:89490
\Pla2g5^tm1Jarm/\Pla2g5^tm1Jarm (involves: 129 * C57BL/6J)	decreased acute inflammation	J:89490
\Pla2g5^tm1Jarm/\Pla2g5^tm1Jarm (involves: 129 * BALB/c)	impaired macrophage phagocytosis	J:110309
\Pla2g5^tm1Jarm/\Pla2g5^tm1Jarm (C.129-Pla2g5^tm1Jarm)	impaired macrophage phagocytosis	J:110309
\Pla2g5^tm1Jarm/\Pla2g5^tm1Jarm (involves: 129 * C57BL/6)	impaired macrophage phagocytosis	J:110309
\Pla2g5^tm1Jarm/\Pla2g5^tm1Jarm (B6.129-Pla2g5^tm1Jarm)	immune system phenotype	J:197334
\Pla2g5^tm1Jarm/\Pla2g5^tm1Jarm (B6.129-Pla2g5^tm1Jarm)	impaired macrophage phagocytosis	J:110309
\Pla2g6^m1Sein/\Pla2g6^m1Sein (C57BL/6JJcl-Pla2g6^m1Sein)	decreased double-positive T cell number	J:155328
\Pla2g7^tm1.1Mcap/\Pla2g7^tm1.1Mcap (B6.Cg-Pla2g7^tm1.1Mcap)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:228564
	increased susceptibility to bacterial infection	J:228564
\Pla2g10^Gt712Lex/\Pla2g10^Gt712Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal interleukin level	J:125607
	decreased CD4-positive, alpha-beta T cell number	J:125607
	decreased CD8-positive, alpha-beta T cell number	J:125607
	decreased eosinophil cell number	J:125607
	decreased IgE level	J:125607
	decreased inflammatory response	J:125607
	decreased T cell number	J:125607
\Pla2g10^tm1Kiku/\Pla2g10^tm1Kiku (B6.129P2-Pla2g10^tm1Kiku)	abnormal neutrophil physiology	J:155082
	decreased neutrophil cell number	J:155082
	immune system phenotype	J:197334
	impaired neutrophil chemotaxis	J:155082
\Pla2g15^tm1.1Jash/\Pla2g15^tm1.1Jash (involves: 129S1/Sv * C57BL/6)	abnormal macrophage morphology	J:111561
	abnormal macrophage physiology	J:111561
	abnormal spleen morphology	J:111561
	increased macrophage cell number	J:111561
	increased macrophage derived foam cell number	J:111561
	increased spleen weight	J:111561
\Pla2r1^tm1Itoh/\Pla2r1^tm1Itoh (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to endotoxin shock	J:44868
\Plaat3^em1(IMPC)Tcp/\Plaat3^em1(IMPC)Tcp (C57BL/6NCrl-Plaat3^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Plaat3^em1Ueda/\Plaat3^em1Ueda (C57BL/6NCrSlc-Plaat3^em1Ueda)	white adipose tissue inflammation	J:343807
\Plaat5^em1(IMPC)Tcp/\Plaat5^em1(IMPC)Tcp (C57BL/6N-Plaat5^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
\Plac8^tm1Bhk/\Plac8^tm1Bhk (involves: 129S6/SvEvTac * C57BL/6)	abnormal neutrophil physiology	J:145277
\Plac8^tm1Bhk/\Plac8^tm1Bhk (129S/SvEv-Plac8^tm1Bhk)	abnormal neutrophil physiology	J:145277
	increased leukocyte cell number	J:145277
	increased neutrophil cell number	J:145277
	increased susceptibility to bacterial infection	J:145277
\Plac9^{tm1b(EUCOMM)Hmgu}/\Plac9^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Plac9^{tm1b(EUCOMM)Hmgu}/H)	decreased neutrophil cell number	J:211773
\Plag1^{em1(IMPC)Hmgu}/\Plag1^{em1(IMPC)Hmgu} (C57BL/6N-Plag1^{em1(IMPC)Hmgu}/Ieg)	decreased CD8-positive, naive alpha-beta T cell number	J:211773
\Plat^tm1Mlg/\Plat^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:63134, J:82604
	immune system phenotype	J:17427
	increased macrophage cell number	J:63134
\Plat^tm1Mlg/\Plat^tm1Mlg (B6.Cg-Plat^tm1Mlg)	abnormal acute phase protein level	J:75303
	abnormal cytokine level	J:75303
	autoimmune arthritis	J:75303
	chronic joint inflammation	J:75303
\Plat^tm1Mlg/\Plat^tm1Mlg (involves: 129S2/SvPas)	abnormal microglial cell physiology	J:144185
\Plat^tm1Mlg/\Plat^tm1Mlg (B6.129S2-Plat^tm1Mlg/J)	abnormal susceptibility to Coronaviridae infection	J:288556
\Plat^tm1Mlg/\Plat^tm1Mlg (B6.129S2-Plat^tm1Mlg/J)	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:288556
\Plau^tm1.1Bug/\Plau^tm1.1Bug (involves: C57BL/6)	chronic inflammation	J:164542
	liver inflammation	J:164542
	trachea inflammation	J:164542
\Plau^{tm1b(EUCOMM)Wtsi}/\Plau^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Plau^{tm1b(EUCOMM)Wtsi}/H)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Plau^tm1Mlg/\Plau^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:63134, J:82604
	abnormal cell-mediated immunity	J:87817, J:95638
	abnormal macrophage physiology	J:17427
	abnormal neutrophil physiology	J:75573, J:91980
	impaired granulocyte bactericidal activity	J:91980
	impaired macrophage chemotaxis	J:63134
	impaired neutrophil phagocytosis	J:91980
	increased lymphocyte cell number	J:63134
	increased susceptibility to fungal infection	J:95637
	increased susceptibility to parasitic infection	J:87817
\Plau^tm1Mlg/\Plau^tm1Mlg (B6.Cg-Plau^tm1Mlg)	abnormal acute phase protein level	J:68083
	abnormal cytokine level	J:75303
	decreased inflammatory response	J:68083
	decreased susceptibility to induced arthritis	J:75303
	decreased T cell proliferation	J:75303
	impaired macrophage chemotaxis	J:68083
\Plau^tm1Mlg/\Plau^tm1Mlg (B6.129S2-Plau^tm1Mlg)	chronic inflammation	J:164542
	increased inflammatory response	J:164542
	liver inflammation	J:164542
	trachea inflammation	J:164542
\Plaur^tm1Jld/\Plaur^tm1Jld (involves: 129P2/OlaHsd * Black Swiss)	abnormal macrophage physiology	J:26874
\Plaur^tm1Jld/\Plaur^tm1Jld (B6.129P2-Plaur^tm1Jld)	chronic inflammation	J:164542
	increased inflammatory response	J:164542
	liver inflammation	J:164542
	trachea inflammation	J:164542
\Plaur^tm1Jld/\Plaur^tm1Jld \Tg(MSR1-Plau)1Ddi/0 (B6.Cg-Plaur^tm1Jld Tg(MSR1-Plau)1Ddi)	heart inflammation	J:113474
\Plaur^tm1Mlg/\Plaur^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal cytokine level	J:75573
	abnormal macrophage physiology	J:31253
	abnormal neutrophil physiology	J:75573, J:91980
	impaired neutrophil phagocytosis	J:91980
	increased susceptibility to bacterial infection	J:75573
\Plcb1^em1(IMPC)Mbp/\Plcb1⁺ (C57BL/6N-Plcb1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Plcb2^{tm1b(KOMP)Wtsi}/\Plcb2^{tm1b(KOMP)Wtsi} (C57BL/6N-Plcb2^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Plcb2^tm1Dwu/\Plcb2^tm1Dwu (involves: 129)	abnormal leukocyte physiology	J:41948
	decreased susceptibility to bacterial infection	J:41948
	decreased susceptibility to infection	J:41948
	decreased susceptibility to viral infection	J:41948
\Plcb2^tm1Dwu/\Plcb2^tm1Dwu \Plcb3^tm1Dwu/\Plcb3^tm1Dwu (involves: 129S1/Sv)	abnormal neutrophil physiology	J:60348
	increased immunoglobulin level	J:60348
\Plcd1^tm1.1Kfu/\Plcd1^tm1.1Kfu \Tg(KRT14-cre)1Amc/0 (involves: C57BL/6 * C57BL/6JJcl * CBA)	decreased B cell number	J:205633
	enlarged inguinal lymph nodes	J:205633
	increased circulating interleukin-17 level	J:205633
	increased granulocyte number	J:205633
	increased interleukin-17 secretion	J:205633
	increased NK T cell number	J:205633
	increased susceptibility to type IV hypersensitivity reaction	J:205633
\Plcd1^tm1Tta/\Plcd1^tm1Tta (involves: 129P2/OlaHsd)	abnormal granulocyte differentiation	J:205633
	decreased B cell number	J:205633
	enlarged axillary lymph nodes	J:205633
	enlarged inguinal lymph nodes	J:205633
	enlarged lymph nodes	J:205633
	enlarged spleen	J:205633
	increased circulating interleukin-17 level	J:205633
	increased granulocyte number	J:205633
	increased interleukin-17 secretion	J:205633
	increased leukocyte cell number	J:205633
\Plce1^em1(IMPC)Mbp/\Plce1^em1(IMPC)Mbp (C57BL/6N-Plce1^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Plcg1^tm1Gcrp/\Plcg1^tm1Rwen \Tg(Cd4-cre)1Cwi/0 (either: B6.Cg-Plcg1^tm1Gcrp/Plcg1^tm1Rwen Tg(Cd4-cre)1Cwi or (involves: 129X1/SvJ * C57BL/6 * DBA/2))	abnormal T cell activation	J:157757
	decreased regulatory T cell number	J:157757
	decreased T cell number	J:157757
	dermatitis	J:157757
	ear inflammation	J:157757
	increased anti-double stranded DNA antibody level	J:157757
	increased CD4-positive, alpha-beta T cell number	J:157757
	increased T cell proliferation	J:157757
	skin inflammation	J:157757
\Plcg1^tm1Gcrp/\Plcg1^tm1Rwen \Tg(Cd4-cre)1Cwi/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129X1/SvJ * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:157757
	decreased double-negative T cell number	J:157757
	increased CD8-positive, alpha-beta T cell number	J:157757
	increased double-positive T cell number	J:157757
	thymus hyperplasia	J:157757
\Plcg2^al/\Plcg2^al (involves: 129 * C57BL/6)	abnormal lymphatic vessel morphology	J:143529
\Plcg2^Ali5/\Plcg2⁺ (C3HeB/FeJ-Plcg2^Ali5)	abnormal B cell physiology	J:97930
	chronic inflammation	J:97930
	decreased B-2 B cell number	J:97930
	dermatitis	J:97930
	osteoarthritis	J:97930
\Plcg2^Ali5/\Plcg2⁺ (involves: C57BL/6J * C3HeB/FeJ-Plcg2^Ali5)	abnormal B cell physiology	J:97930
	glomerulonephritis	J:97930
	immune system phenotype	J:97930
\Plcg2^Ali5/\Plcg2⁺ \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S7/SvEvBrd * C3HeB/FeJ * C3HeB/FeJ-Plcg2^Ali5)	chronic inflammation	J:97930
	dermatitis	J:97930
	osteoarthritis	J:97930
\Plcg2^Ali5/\Plcg2^Ali5 (involves: C57BL/6J * C3HeB/FeJ-Plcg2^Ali5)	abnormal B cell physiology	J:97930
	chronic inflammation	J:97930
	decreased mature B cell number	J:97930
	decreased transitional stage B cell number	J:97930
	glomerulonephritis	J:97930
\Plcg2^Ali14/\Plcg2⁺ (C3HeB/FeJ-Plcg2^Ali14)	abnormal inflammatory response	J:166106
\Plcg2^em1Msasn/\Plcg2^em1Msasn (B6.Cg-Plcg2^em1Msasn/J)	impaired macrophage phagocytosis	J:308279
\Plcg2^m1Btlr/\Plcg2^m1Btlr (C57BL/6J-Plcg2^m1Btlr)	decreased IgM level	J:165702
\Plcg2^m1Btlr/\Plcg2^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	decreased IgM level	J:185495
	immune system phenotype	J:185495
\Plcg2^M2Btlr/\Plcg2⁺ (C57BL/6J-Plcg2^M2Btlr)	decreased tumor necrosis factor secretion	J:218966
\Plcg2^M2Btlr/\Plcg2^M2Btlr (C57BL/6J-Plcg2^M2Btlr)	decreased tumor necrosis factor secretion	J:218966
\Plcg2^M3Btlr/\Plcg2^M3Btlr (C57BL/6J-Plcg2^M3Btlr)	abnormal humoral immune response	J:265101
	decreased B-1a cell number	J:265101
	decreased IgM level	J:265101
\Plcg2^m4Btlr/\Plcg2^m4Btlr (C57BL/6J-Plcg2^m4Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:272862
\Plcg2^m4Btlr/\Plcg2^m4Btlr (C57BL/6J-Plcg2^m4Btlr)	increased effector memory CD8-positive, alpha-beta T cell number	J:272862
\Plcg2^tm1.1Kuro/\Plcg2^tm1.1Kuro (B6.Cg-Plcg2^tm1.1Kuro)	decreased interferon-gamma secretion	J:131621
\Plcg2^tm1.1Kuro/\Plcg2^tm1.1Kuro (B6.Cg-Plcg2^tm1.1Kuro)	impaired natural killer cell mediated cytotoxicity	J:131621
\Plcg2^tm1.1Kuro/\Plcg2^tm1.1Kuro (Not Specified)	abnormal B cell differentiation	J:131161
	abnormal NK cell physiology	J:187430
	increased pro-B cell number	J:131161
	spleen hyperplasia	J:131161
\Plcg2^tm1Ichi/\Plcg2^tm1Ichi (involves: 129 * C57BL/6)	abnormal lymphatic vessel morphology	J:143529
\Plcg2^tm1Jni/\Plcg2^tm1Jni (involves: 129P2/OlaHsd)	abnormal B cell calcium ion homeostasis	J:80614
	abnormal dendritic cell chemotaxis	J:157619
	abnormal dendritic cell morphology	J:157619
	abnormal dendritic cell physiology	J:157619
	arrested B cell differentiation	J:86373
	decreased B cell proliferation	J:80614
	decreased follicular B cell number	J:86373
	decreased mature B cell number	J:104166
	decreased susceptibility to induced arthritis	J:157619
	increased B cell apoptosis	J:86373
	increased pro-B cell number	J:104166
	increased transitional stage T2 B cell number	J:86373
\Plcg2^tm1Jni/\Plcg2^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:117023
	abnormal B cell physiology	J:117023
	abnormal osteoclast differentiation	J:114607
	decreased interferon-gamma secretion	J:100716
	decreased osteoclast cell number	J:114607
	impaired natural killer cell mediated cytotoxicity	J:100716
	increased B cell proliferation	J:117023
	increased pre-B cell number	J:117023
	increased susceptibility to Herpesvirales infection	J:100716
\Plcg2^tm1Jni/\Plcg2^tm1Jni \Tg(IghMyc)22Bri/0 (involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL)	enlarged lymph nodes	J:117023
\Plcg2^tm1Kuro/\Plcg2^tm1Kuro \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal humoral immune response	J:63744
	decreased B cell proliferation	J:63744
	decreased mature B cell number	J:63744
	decreased pre-B cell number	J:63744
	immune system phenotype	J:63744
	increased B-1a cell number	J:63744
	increased immature B cell number	J:63744
	increased pro-B cell number	J:63744
\Plcl2^tm1Tta/\Plcl2^tm1Tta (involves: 129P2/OlaHsd)	abnormal adaptive immunity	J:85960
	abnormal B cell calcium ion homeostasis	J:85960
	decreased B-1a cell number	J:85960
	decreased mature B cell number	J:85960
	increased anti-nuclear antigen antibody level	J:85960
	increased B cell proliferation	J:85960
	increased IgM level	J:85960
\Pld2^tm1.1Mjow/\Pld2^tm1.1Mjow (Not Specified)	abnormal neutrophil physiology	J:183062
\Pld3^em1Nemz/\Pld3^em1Nemz (C57BL/6J-Pld3^em1Nemz)	immune system phenotype	J:281205
\Pld3^em1Nemz/\Pld3^em1Nemz (C57BL/6J-Pld3^em1Nemz)	increased interleukin-6 secretion	J:281205
\Pld3^em1Nemz/\Pld3^em1Nemz \Pld4^tm1.2Nemz/\Pld4^tm1.2Nemz (B6.Cg-Pld3^em1Nemz Pld4^tm1.1Nemz)	abnormal circulating chemokine level	J:281205
	hemophagocytosis	J:281205
	increased circulating CXCL10 level	J:281205
	increased circulating interferon-gamma level	J:281205
	increased circulating tumor necrosis factor level	J:281205
	liver inflammation	J:281205
\Pld4^em1(IMPC)Mbp/\Pld4^em1(IMPC)Mbp (C57BL/6N-Pld4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
\Pld4^thss/\Pld4^thss (BALB/cJ-Pld4^thss/GrsrJ)	abnormal alpha-beta T cell morphology	J:278304
	abnormal immunoglobulin level	J:278304
	enlarged lymph nodes	J:278304
	enlarged spleen	J:278304
	increased anti-nuclear antigen antibody level	J:278304
	increased IgA level	J:278304
	increased IgE level	J:278304
	increased IgG2b level	J:278304
	increased IgG3 level	J:278304
	increased IgG level	J:278304
	increased IgM level	J:278304
	increased macrophage cell number	J:278304
	increased marginal zone B cell number	J:278304
	increased plasma cell number	J:278304
	increased plasmacytoid dendritic cell number	J:278304
	increased spleen germinal center number	J:278304
	lymph node hyperplasia	J:278304
	spleen hyperplasia	J:278304
\Pld4^tm1.1Nemz/\Pld4^tm1.1Nemz \Tg(Itgax-cre)1-1Reiz/0 (involves: 129 * C57BL/6 * C57BL/6J * CBA)	abnormal peritoneal macrophage morphology	J:281205
\Pld4^tm1.2Nemz/\Pld4^tm1.2Nemz (B6.129(Cg)-Pld4^tm1.1Nemz)	abnormal leukocyte cell number	J:281205
	abnormal peritoneal macrophage morphology	J:281205
	decreased B-1 B cell number	J:281205
	decreased NK T cell number	J:281205
	enlarged spleen	J:281205
	immune system phenotype	J:281205
	increased circulating CXCL10 level	J:281205
	increased circulating interferon-gamma level	J:281205
	increased marginal zone B cell number	J:281205
	increased monocyte cell number	J:281205
\Pld4^tm1.2Nemz/\Pld4^tm1.2Nemz \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129 * 129S7/SvEvBrd * C57BL/6J * FVB/N)	abnormal peritoneal macrophage morphology	J:281205
	decreased NK T cell number	J:281205
\Pld4^tm1.2Nemz/\Pld4^tm1.2Nemz \Tlr9^M7Btlr/\Tlr9^M7Btlr (involves: 129 * C57BL/6J * FVB/N)	immune system phenotype	J:281205
\Plec^tm3Gwi/\Plec^tm3Gwi (involves: 129P2/OlaHsd)	abnormal T cell physiology	J:104701
\Plec^tm3Gwi/\Plec^tm3Gwi (involves: 129P2/OlaHsd)	impaired macrophage chemotaxis	J:104701
\Plek2^tm1Pji/\Plek2^tm1Pji (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal granulocyte differentiation	J:257910
	enlarged spleen	J:257910
\Plek2^tm1Pji/\Plek2^tm1Pji \Jak2^tm1.1Ble/\Jak2⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal granulocyte differentiation	J:257910
	immune system phenotype	J:257910
\Plekha5^em1(IMPC)Tcp/\Plekha5^em1(IMPC)Tcp (C57BL/6NCrl-Plekha5^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	increased spleen weight	J:211773
\Plekha7^tm1.1Janc/\Plekha7^tm1.1Janc (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:227858
\Plekha7^tm1.1Janc/\Plekha7^tm1.1Janc (involves: C57BL/6)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:227858
\Plekhf1^tm1.1Caox/\Plekhf1^tm1.1Caox \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.Cg-Plekhf1^tm1.1Caox Lyz2^tm1(cre)Ifo)	abnormal cytokine secretion	J:277440
	abnormal macrophage physiology	J:277440
	decreased circulating interferon-beta level	J:277440
	decreased circulating interleukin-6 level	J:277440
	decreased circulating tumor necrosis factor level	J:277440
	increased susceptibility to bacterial infection	J:277440
	increased susceptibility to bacterial infection induced morbidity/mortality	J:277440
\Plekhg2^em1(IMPC)J/\Plekhg2^em1(IMPC)J (C57BL/6NJ-Plekhg2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Plekhm1^tm1.2Hzhao/\Plekhm1^tm1.2Hzhao (involves: 129S1/Sv * C57BL/6J)	abnormal osteoclast morphology	J:236517
	abnormal osteoclast physiology	J:236517
\Plekhm2^{tm1a(EUCOMM)Wtsi}/\Plekhm2^{tm1a(EUCOMM)Wtsi} (B6JTyr;B6N-Plekhm2^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:165965
\Plekhm2^{tm1a(EUCOMM)Wtsi}/\Plekhm2^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased susceptibility to bacterial infection	J:233985
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:233985
	increased leukocyte cell number	J:233985
\Plekho2^em1Lzhn/\Plekho2^em1Lzhn (C57BL/6-Plekho2^em1Lzhn)	decreased macrophage cell number	J:270531
	immune system phenotype	J:270531
	increased macrophage apoptosis	J:270531
\Plet1^tm1Cupe/\Plet1^tm1Cupe (Not Specified)	abnormal dendritic cell migration	J:271548
	abnormal dendritic cell number	J:271548
	increased dendritic cell number	J:271548
\Plg^tm1.1Fjc/\Plg^tm1.1Fjc (involves: C57BL/6 * C57BL/6JJcl)	enlarged lymph nodes	J:210802
	increased circulating fibrinogen level	J:210802
\Plg^tm1Dco/\Plg⁺ (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
\Plg^tm1Dco/\Plg^tm1Dco (involves: 129S2/SvPas * C57BL/6)	abnormal acute phase protein level	J:82604
\Plg^tm1Dco/\Plg^tm1Dco (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:80114
\Plg^tm1Dco/\Plg^tm1Dco (involves: 129S2/SvPas)	enlarged lymph nodes	J:210802
\Plg^tm1Dco/\Plg^tm1Dco (involves: 129S2/SvPas)	increased circulating fibrinogen level	J:210802
\Plg^tm1Jld/\Plg^tm1Jld (involves: 129P2/OlaHsd * NIH Black Swiss)	proctitis	J:39419
\Plg^tm1Jld/\Plg^tm1Jld (B6.129P2-Plg^tm1Jld)	conjunctivitis	J:46096
\Plg^tm1Jld/\Plg^tm1Jld (B6.129P2-Plg^tm1Jld)	eye inflammation	J:46096
\Plg^tm1Jld/\Plg^tm1Jld (involves: 129P2/OlaHsd * Black Swiss)	colitis	J:36591
\Plg^tm1Jld/\Plg^tm1Jld (B6.129P2-Plg^tm1Jld/J)	abnormal microglial cell physiology	J:141739
\Plgr1^BALB/cJ/\Plgr1^BALB/cJ (involves: BALB/cJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:138895
\Plgr1^BALB/cJ/\Plgr1^BALB/cJ (B6.C-Plgr1^BALB/cJ)	decreased susceptibility to bacterial infection	J:138895
\Plgr1^BALB/cJ/\Plgr1^C57BL/6J (involves: BALB/cJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:138895
\Plgr1^BALB/cJ/\Plgr1^C57BL/6J (B6.C-Plgr1^BALB/cJ)	decreased susceptibility to bacterial infection	J:138895
\Plgrkt^tm1Lmls/\Plgrkt⁺ (B6.Cg-Plgrkt^tm1Lmls)	dermatitis	J:282437
\Plgrkt^tm1Lmls/\Plgrkt^tm1Lmls (B6.Cg-Plgrkt^tm1Lmls)	abnormal macrophage physiology	J:282437
	dermatitis	J:282437
	impaired leukocyte migration	J:282437
	impaired macrophage chemotaxis	J:282437
\Plin2^tm1.1Asg/\Plin2^tm1.1Asg (B6.129S2(Cg)-Plin2^tm1.1Asg)	decreased inflammatory response	J:196302
\Plp1^jp-rsh/\Plp1⁺ (either: STOCK Rb(1.3)1Bnr or (involves: BALB/c * DBA/2 * STOCK Rb(1.3)1Bnr))	abnormal microglial cell morphology	J:604
\Plp1^jp-rsh/\Plp1^jp-rsh (involves: 101/H * C3H)	decreased susceptibility to Picornaviridae infection	J:41447
\Plp1^{tm1c(EUCOMM)Wtsi}/Y \Cnp^tm1(cre)Kan/\Cnp⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	increased T cell number	J:245100
	microgliosis	J:245100
\Plp1^tm1Kan/Y (involves: 129S1/Sv * 129X1/SvJ)	abnormal microglial cell morphology	J:48031
\Plp1^tm1Kan/Y (involves: 129S1/Sv * 129X1/SvJ)	microgliosis	J:245100
\Plp1^tm1Kan/Y (B6.129-Plp1^tm1Kan)	microgliosis	J:201143
\Plp1^tm1Kan/Y \Cnp^tm1(cre)Kan/\Cnp⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased T cell number	J:245100
	microgliosis	J:245100
\Plp1^tm1Kan/Y \Tspan2^tm1Hbw/\Tspan2^tm1Hbw (B6.Cg-Tspan2^tm1Hbw Plp1^tm1Kan)	brain inflammation	J:201143
	microgliosis	J:201143
\Plpp5^tm1(KOMP)Mbp/\Plpp5^tm1(KOMP)Mbp \Prdm1^tm1Nutt/\Prdm1⁺ (involves: C57BL/6 * C57BL/6N)	immune system phenotype	J:265892
\Plppr5^{em1(IMPC)Ccpcz}/\Plppr5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Plppr5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Pls1^tm1Fri/\Pls1^tm1Fri (B6.129-Pls1^tm1Fri)	increased susceptibility to colitis induced morbidity/mortality	J:216723
\Pls1^tm1Fri/\Pls1^tm1Fri (B6.129-Pls1^tm1Fri)	increased susceptibility to induced colitis	J:216723
\Plscr1^tm1Lex/\Plscr1^tm1Lex (129S/SvEvBrd-Plscr1^tm1Lex)	abnormal granulocyte differentiation	J:76790
	abnormal myelopoiesis	J:76790
	abnormal neutrophil differentiation	J:76790
	decreased granulocyte number	J:76790
	decreased neutrophil cell number	J:76790
\Plscr1^tm1Lex/\Plscr1^tm1Lex \Plscr3^tm1Sims/\Plscr3^tm1Sims (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal myelopoiesis	J:92404
\plt/\plt (involves: DDD/1)	abnormal immune system organ morphology	J:47819
	abnormal immune system physiology	J:47819
	abnormal leukocyte cell number	J:47819
	abnormal leukocyte migration	J:47819, J:47460
	abnormal lymph node T cell domain morphology	J:47819, J:47460
	abnormal peripheral lymph node morphology	J:47819
	abnormal spleen red pulp morphology	J:47460
	abnormal spleen white pulp morphology	J:47460
	decreased single-positive T cell number	J:15290
	decreased T cell number	J:47819
	increased memory T cell number	J:47460
	increased T cell number	J:47819
	lymph node hypoplasia	J:15290, J:47460
	small Peyer's patches	J:47460
\plt/\plt (C.DDD-plt)	abnormal T cell activation	J:119345
	decreased single-positive T cell number	J:119345
	increased length of allograft survival	J:119345
\plt/\plt (B6.DDD-plt)	abnormal leukocyte migration	J:93960
	abnormal thymus cortex morphology	J:93960
	immune system phenotype	J:93960
	small thymus medulla	J:93960
\plt/\plt (either: B6.DDD-plt or C.DDD-plt)	abnormal leukocyte migration	J:110910
	increased inflammatory response	J:110910
	increased susceptibility to autoimmune disorder	J:110910
	lacrimal gland inflammation	J:110910
	parotid gland inflammation	J:110910
	salivary gland inflammation	J:110910
	submandibular gland inflammation	J:110910
\Plvap^{tm1e(EUCOMM)Hmgu}/\Plvap^{tm1e(EUCOMM)Hmgu} \Tg(TIE2GFP)287Sato/0 (involves: C57BL/6N * FVB/N)	small spleen	J:203907
\Plxna1^tm1Kik/\Plxna1^tm1Kik (either: B6.Cg-Plxna1^tm1Kik or C.Cg-Plxna1^tm1Kik)	abnormal CD4-positive, alpha-beta T cell physiology	J:110786
	abnormal dendritic cell physiology	J:110786
\Plxna1^tm1Kik/\Plxna1^tm1Kik (Not Specified)	abnormal dendritic cell physiology	J:161856
\Plxna1^tm1Kik/\Plxna1^tm1Kik \Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6)	decreased T cell proliferation	J:161856
\Plxna1^tm1Tmj/\Plxna1^tm1Tmj (involves: 129S/SvEv)	abnormal lymphatic vessel endothelial cell morphology	J:226501
\Plxna1^tm1Tmj/\Plxna1^tm1Tmj (involves: 129S/SvEv)	abnormal lymphatic vessel morphology	J:226501
\Plxna2^tm1Hfu/\Plxna2^tm1Hfu (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal lymphatic vessel morphology	J:226501
\Plxna4^em1(IMPC)Mbp/\Plxna4^em1(IMPC)Mbp (C57BL/6NCrl-Plxna4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Plxnc1^em1(IMPC)Mbp/\Plxnc1^em1(IMPC)Mbp (C57BL/6N-Plxnc1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Plxnd1^b2b1863Clo/\Plxnd1^b2b1863Clo (C57BL/6J-Plxnd1^b2b1863Clo)	thymus hypoplasia	J:175213
\Plxnd1^b2b3150Clo/\Plxnd1^b2b3150Clo (C57BL/6J-Plxnd1^b2b3150Clo)	thymus hypoplasia	J:175213
\Plyid^HIGA/Nsc/\Plyid^HIGA/Nsc (involves: BALB/cA * HIGA/Nsc)	abnormal humoral immune response	J:91769
	increased IgA level	J:91769
\Pmaip1^tm1Ast/\Pmaip1^tm1Ast (C57BL/6-Pmaip1^tm1Ast)	abnormal NK cell morphology	J:123409
\Pmaip1^tm1Ast/\Pmaip1^tm1Ast (involves: C57BL/6)	immune system phenotype	J:132819
\Pmepa1^em1Akt/\Pmepa1^em1Akt (C57BL/6N-Pmepa1^em1Akt)	abnormal osteoclast differentiation	J:329578
	abnormal osteoclast physiology	J:329578
	decreased osteoclast cell number	J:329578
\Pml^{tm1(PML/RARA)Ley}/\Pml⁺ \Tg(CAG-cre/Esr1)5Amc/0 (involves: BALB/cJ C57BL/6 * CBA)	enlarged spleen	J:172024
\Pml^tm1.1Ews/\Pml^tm1.1Ews (involves: 129 * 129P2/OlaHsd)	increased T cell derived lymphoma incidence	J:262172
\Pml^tm1.1Ews/\Pml^tm1.1Ews \Tg(PML-RARA)556Kog/0 (FVB.Cg-Pml^tm1.1Ews Tg(PML-RARA)556Kog)	enlarged spleen	J:262172
	increased leukocyte cell number	J:262172
\Pml^tm1Ppp/\Pml⁺ \Trp53^tm3.1Glo/\Trp53⁺ (B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo)	hepatosplenomegaly	J:317504
	increased T cell derived lymphoma incidence	J:317504
\Pml^tm1Ppp/\Pml^tm1Ppp (involves: 129S7/SvEvBrd)	abnormal immune system cell morphology	J:46381
	abnormal myelopoiesis	J:46381
	decreased granulocyte number	J:46381
	decreased leukocyte cell number	J:46381
	increased susceptibility to bacterial infection	J:46381
\Pml^tm1Ppp/\Pml^tm1Ppp \Trp53^tm3.1Glo/\Trp53⁺ (B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo)	hepatosplenomegaly	J:317504
	increased T cell derived lymphoma incidence	J:317504
\Pmm2^{tm1b(EUCOMM)Hmgu}/\Pmm2⁺ (C57BL/6N-Pmm2^{tm1b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
\Pms2^tm1.1Wed/\Pms2^tm1.1Wed (involves: 129S6/SvEvTac * C57BL/6NCr)	abnormal class switch recombination	J:162378
	increased T cell derived lymphoma incidence	J:162378
\Pms2^tm1Lisk/\Pms2^tm1Lisk (involves: 129S2/SvPas)	abnormal class switch recombination	J:162378
\Pnliprp2^tm1Gru/\Pnliprp2^tm1Gru (involves: 129S2/SvPas * BALB/c)	decreased cytotoxic T cell cytolysis	J:51627
\Pnma8b^em1(IMPC)Tcp/\Pnma8b^em1(IMPC)Tcp (C57BL/6NCrl-Pnma8b^em1(IMPC)Tcp/Cmmr)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Pno1^tm1Jwu/\Pno1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:191966
\Pnp2^em1Smoc/\Pnp2^em1Smoc (C57BL/6J-Pnp2^em1Smoc)	immune system phenotype	J:339075
\Pnp^bata/\Pnp^bata (C57BL/6JSfdAnu-Pnp^bata)	decreased B cell proliferation	J:104190
	decreased marginal zone B cell number	J:104190
	increased T follicular helper cell number	J:104190
\Pnp^e/\Pnp^e (C57BL/6J-Pnp^e)	abnormal leukocyte physiology	J:39328
\Pnp^e/\Pnp^e (C57BL/6J-Pnp^e)	thymus hypoplasia	J:39328
\Pnp^f/\Pnp^f (involves: C3H/HeHa * C57BL/6J)	increased double-negative T cell number	J:522
\Pnp^f/\Pnp^f (C57BL/6J-Pnp^f)	abnormal leukocyte cell number	J:39328
	abnormal leukocyte physiology	J:39328
	decreased CD8-positive, alpha-beta T cell number	J:39328
	decreased double-positive T cell number	J:39328
	thymus hypoplasia	J:39328
\Pnp^g/\Pnp^g (involves: C57BL/6 * DBA/2J)	abnormal leukocyte cell number	J:39328
	abnormal leukocyte physiology	J:39328
	decreased CD8-positive, alpha-beta T cell number	J:39328
	decreased double-positive T cell number	J:39328
	increased double-negative T cell number	J:39328
	thymus hypoplasia	J:39328
\Pnp^M1Btlr/\Pnp^M1Btlr (C57BL/6J-Pnp^M1Btlr)	impaired humoral immune response	J:265147
\Pnp^M1Btlr/\Pnp^M1Btlr (C57BL/6J-Pnp^M1Btlr)	increased IgM level	J:265147
\Pnp^m2Btlr/\Pnp^m2Btlr (C57BL/6J-Pnp^m2Btlr)	decreased B-1a cell number	J:265150
	decreased B-2 B cell number	J:265150
	decreased CD4-positive, alpha-beta T cell number	J:265150
	decreased CD8-positive, naive alpha-beta T cell number	J:265150
	decreased T cell number	J:265150
	increased B-1b cell number	J:265150
	increased CD8-positive, alpha-beta memory T cell number	J:265150
	increased central memory CD4-positive, alpha-beta T cell number	J:265150
	increased central memory CD8 positive, alpha-beta T cell number	J:265150
	increased effector memory CD4-positive, alpha-beta T cell number	J:265150
	increased effector memory CD8-positive, alpha-beta T cell number	J:265150
\Pnp^tm1Cmr/\Pnp^tm1Cmr (involves: 129)	abnormal myelopoiesis	J:62870
	decreased CD4-positive, alpha-beta T cell number	J:62870
	decreased CD8-positive, alpha-beta T cell number	J:62870
	decreased cytotoxic T cell cytolysis	J:62870
	decreased double-positive T cell number	J:62870
	decreased single-positive T cell number	J:62870
	increased double-negative T cell number	J:62870
	increased pre-B cell number	J:62870
	increased thymocyte apoptosis	J:62870
\Pnpla5^em1(IMPC)Mbp/\Pnpla5^em1(IMPC)Mbp (C57BL/6N-Pnpla5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Podxl2^{tm1.1(KOMP)Vlcg}/\Podxl2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Podxl2^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Pofut1^tm2Pst/\Pofut1^tm1Pst \Shh^{tm2(cre/ERT2)Cjt}/\Shh⁺ (involves: 129/Sv * 129S6/SvEvTac * C57BL/6J * SJL)	lung inflammation	J:150051
\Polb^tm1.1Jbsw/\Polb⁺ (involves: 129/Sv * C57BL/6)	dermatitis	J:206872
	enlarged cervical lymph nodes	J:206872
	glomerulonephritis	J:206872
	increased anti-nuclear antigen antibody level	J:206872
	increased IgG level	J:206872
	lymph node inflammation	J:206872
	salivary gland inflammation	J:206872
\Polb^tm1.1Jbsw/\Polb^tm1.1Jbsw (involves: 129/Sv * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:206872
	abnormal somatic hypermutation frequency	J:206872
	abnormal spleen germinal center morphology	J:206872
	dermatitis	J:206872
	enlarged cervical lymph nodes	J:206872
	glomerulonephritis	J:206872
	increased anti-nuclear antigen antibody level	J:206872
	increased germinal center B cell number	J:206872
	increased IgG level	J:206872
	increased spleen germinal center number	J:206872
	increased splenocyte apoptosis	J:183837, J:206872
	increased susceptibility to systemic lupus erythematosus	J:206872
	increased T-helper 2 cell number	J:206872
	lymph node inflammation	J:206872
	salivary gland inflammation	J:206872
\Polb^{tm1a(KOMP)Wtsi}/\Polb^{tm1a(KOMP)Wtsi} (C57BL/6N-Polb^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal lymphatic vessel topology	J:239583
\Polb^tm1Rsky/\Polb^tm1Rsky \Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd * ICR)	immune system phenotype	J:67942
\Pold1^tm1.1Bdp/\Pold1^tm1.1Bdp (B6.129-Pold1^tm1.1Bdp)	increased T cell derived lymphoma incidence	J:153684
\Pold1^tm1.1Bdp/\Pold1^tm1.1Bdp \Pole^tm1.1Bdp/\Pole^tm1.1Bdp (B6.129-Pole^tm1.1Bdp Pold1^tm1.1Bdp)	increased T cell derived lymphoma incidence	J:153684
\Pold1^tm1.1Uchi/\Pold1^tm1.1Uchi (C57BL/6-Pold1^tm1.1Uchi)	enlarged thymus	J:144992
\Pold1^tm1Bdp/\Pold1^tm1Bdp (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:100685
\Pold1^tm1Uchi/\Pold1^tm1.1Uchi (C57BL/6-Pold1^tm1Uchi/Pold1^tm1.1Uchi)	enlarged thymus	J:144992
\Pold4^em1(IMPC)J/\Pold4^em1(IMPC)J (C57BL/6NJ-Pold4^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Pole2^em1(IMPC)Mbp/\Pole2⁺ (C57BL/6NCrl-Pole2^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Pole3^em1Tbo/\Pole3^em1Tbo (FVB-Pole3^em1Tbo)	decreased B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
\Pole3^em2Tbo/\Pole3^em2Tbo (FVB-Pole3^em2Tbo)	decreased B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
\Pole3^em3Tbo/\Pole3^em3Tbo (FVB-Pole3^em3Tbo)	abnormal thymus apoptosis	J:298827
	decreased B cell number	J:298827
	decreased DN4 thymocyte number	J:298827
	decreased double-positive T cell number	J:298827
	decreased gamma-delta T cell number	J:298827
	decreased immature B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased pre-B cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
	increased DN3 thymocyte number	J:298827
	increased thymocyte apoptosis	J:298827
	small spleen	J:298827
	small thymus	J:298827
\Pole3^em4Tbo/\Pole3^em4Tbo (FVB-Pole3^em4Tbo)	abnormal thymus apoptosis	J:298827
	decreased B cell number	J:298827
	decreased DN4 thymocyte number	J:298827
	decreased immature B cell number	J:298827
	decreased lymphocyte cell number	J:298827
	decreased pre-B cell number	J:298827
	decreased splenocyte number	J:298827
	decreased thymocyte number	J:298827
	increased DN3 thymocyte number	J:298827
	increased thymocyte apoptosis	J:298827
\Pole3^{tm1(KOMP)Vlcg}/\Pole3^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac * FVB)	decreased DN4 thymocyte number	J:298827
	increased DN3 thymocyte number	J:298827
\Pole4^{tm1(KOMP)Vlcg}/\Pole4^{tm1(KOMP)Vlcg} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N)	abnormal B cell differentiation	J:261973
	abnormal mesenteric lymph node morphology	J:261973
	abnormal spleen B cell follicle morphology	J:261973
	abnormal T cell differentiation	J:261973
	abnormal thymus morphology	J:261973
	absent thymus cortex	J:261973
	arrested B cell differentiation	J:261973
	athymia	J:261973
	decreased B cell number	J:261973
	decreased leukocyte cell number	J:261973
	decreased lymphocyte cell number	J:261973
	decreased single-positive T cell number	J:261973
	decreased spleen weight	J:261973
	increased double-negative T cell number	J:261973
	increased granulocyte number	J:261973
	increased monocyte cell number	J:261973
	increased T cell derived lymphoma incidence	J:261973
	small spleen	J:261973
\Pole4^{tm1(KOMP)Vlcg}/\Pole4^{tm1(KOMP)Vlcg} \Trp53^tm1Brd/\Trp53⁺ (involves: C57BL/6J * C57BL/6NTac)	decreased leukocyte cell number	J:261973
	decreased lymphocyte cell number	J:261973
	increased granulocyte number	J:261973
	increased monocyte cell number	J:261973
	increased T cell derived lymphoma incidence	J:261973
\Pole4^{tm1(KOMP)Vlcg}/\Pole4^{tm1(KOMP)Vlcg} \Trp53^tm1Brd/\Trp53^tm1Brd (involves: C57BL/6J * C57BL/6NTac)	immune system phenotype	J:261973
\Pole^tm1.1Bdp/\Pole^tm1.1Bdp (B6.129-Pole^tm1.1Bdp)	enlarged spleen	J:153684
\Polg^tm1.1Suom/\Polg^tm1.1Suom (involves: C57BL/6JOlaHsd)	brain inflammation	J:365276
	decreased circulating interferon-beta level	J:365276
	decreased circulating interferon-gamma level	J:365276
	increased circulating interleukin-6 level	J:365276
	increased susceptibility to Flaviviridae infection	J:365276
	liver inflammation	J:365276
\Polg^tm1Prol/\Polg^tm1Prol (involves: 129S7/SvEvBrd * C57BL/6J * ICR)	abnormal thymus involution	J:99764
\Polg^tm1Prol/\Polg^tm1Prol (B6J.129S7-Polg^tm1Prol)	abnormal lymphopoiesis	J:154187
	decreased double-positive T cell number	J:154187
	decreased immature B cell number	J:154187
	decreased lymphocyte cell number	J:154187
	decreased mature B cell number	J:154187
	decreased pre-B cell number	J:154187
	decreased pro-B cell number	J:154187
	decreased thymocyte number	J:154187
\Polh^tm1Crey/\Polh^tm1Crey (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:98037
\Polh^tm1Crey/\Polh^tm1Crey \Poli^d/\Poli^d (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:98037
\Polh^tm1Fmh/\Polh^tm1Fmh (involves: C57BL/6)	abnormal B cell physiology	J:99721
\Poli^d/\Poli^d \Polk^tm1Hohm/\Polk^tm1Hohm (involves: 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:105111
\Polk^tm1.1Rsky/\Polk^tm1.1Rsky (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	immune system phenotype	J:80212
\Polk^tm1Hohm/\Polk^tm1Hohm (involves: 129X1/SvJ * C57BL/6 * CBA)	immune system phenotype	J:105111
\Polk^tm1Hohm/\Polk^tm1Hohm (involves: C57BL/6 * CBA)	immune system phenotype	J:83202
\Poll^tm1Crey/\Poll^tm1Crey (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:75927
\Poll^tm1Crey/\Poll^tm1Crey (involves: 129P2/OlaHsd)	abnormal immunoglobulin heavy chain V(D)J recombination	J:113406
\Poll^tm1Crey/\Poll^tm1Crey (involves: 129P2/OlaHsd)	immune system phenotype	J:113406
\Poll^tm1Crey/\Poll^tm1Crey \Polm^tm1Crey/\Polm^tm1Crey (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:113406
	abnormal immunoglobulin heavy chain V(D)J recombination	J:113406
	abnormal immunoglobulin light chain V-J recombination	J:113406
	decreased B cell number	J:113406
\Polm^m1Btlr/\Polm^m1Btlr (C57BL/6J-Polm^m1Btlr)	decreased B cell number	J:272866
\Polm^m2Btlr/\Polm^m2Btlr (C57BL/6J-Polm^m2Btlr)	abnormal lymphocyte morphology	J:272867
\Polm^m2Btlr/\Polm^m2Btlr (C57BL/6J-Polm^m2Btlr)	decreased B cell number	J:272867
\Polm^tm1Abnd/\Polm^tm1Abnd (involves: 129/Sv * BALB/c)	abnormal B cell number	J:97782
\Polm^tm1Crey/\Polm^tm1Crey (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell proliferation	J:85190
	abnormal Peyer's patch morphology	J:85190
	decreased B cell number	J:75927, J:85190
	immune system phenotype	J:75927
	lymphoid hypoplasia	J:85190
\Polm^tm1Crey/\Polm^tm1Crey (involves: 129P2/OlaHsd)	abnormal immunoglobulin light chain V-J recombination	J:113406
\Polq^em1(IMPC)Mbp/\Polq^em1(IMPC)Mbp (C57BL/6N-Polq^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Polq^tm1Jcs/\Polq^tm1Jcs (involves: 129S4/SvJae * C57BL/6J)	abnormal somatic hypermutation frequency	J:103365
\Polq^tm1Jow/\Polq^tm1Jow (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	abnormal B cell physiology	J:101409
	abnormal somatic hypermutation frequency	J:101409
	decreased IgG1 level	J:101409
	decreased IgG level	J:101409
	decreased IgM level	J:101409
	decreased immunoglobulin level	J:101409
\Polq^tm2Jow/\Polq^tm2Jow (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal somatic hypermutation frequency	J:115989
\Polr1b^em1(IMPC)Tcp/\Polr1b⁺ (C57BL/6NCrl-Polr1b^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Polr2a^{tm1(cre/ERT2)Bbd}/\Polr2a⁺ \Rnf2^tm1Mvi/\Rnf2^tm1Mvi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * SJL)	decreased B cell number	J:130397
\Polr3a^em2(IMPC)Tcp/\Polr3a⁺ (C57BL/6NCrl-Polr3a^em2(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Polr3a^tm1Iwil/\Polr3a^tm1Iwil \Tg(CAG-cre/Esr1*)5Amc/0 (Not Specified)	increased microglial cell activation	J:364909
\Polrmt^em1(IMPC)Mbp/\Polrmt⁺ (C57BL/6N-Polrmt^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Pomc^{em1(IMPC)Rbrc}/\Pomc⁺ (C57BL/6NJcl-Pomc^{em1(IMPC)Rbrc}/Rbrc)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Pomc^tm1Low/\Pomc^tm1Low (involves: 129S2/SvPas * C57BL/6)	increased circulating interleukin-6 level	J:102955
	increased interleukin-6 secretion	J:102955
	increased splenocyte proliferation	J:102955
	increased tumor necrosis factor secretion	J:102955
\Pomk^{em1(IMPC)Hmgu}/\Pomk⁺ (C57BL/6NCrl-Pomk^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
\Pomt1^{Gt(OST194127)Lex}/\Pomt1⁺ (involves: 129S5/SvEvBrd * C57BL/6J)	decreased IgG level	J:103485
	increased neutrophil cell number	J:103485
\Pon2^Gt(XE661)Byg/\Pon2^Gt(XE661)Byg (B6.129P2-Pon2^Gt(XE661)Byg)	abnormal macrophage chemotaxis	J:116935
	abnormal macrophage physiology	J:116935
	increased susceptibility to bacterial infection	J:116935
\Pon3^tm1Dmsh/\Pon3^tm1Dmsh (B6J.129X1-Pon3^tm1Dmsh)	liver inflammation	J:234615
\Postn^tm1Sjc/\Postn^tm1Sjc (involves: C57BL/6)	periodontium inflammation	J:103753
\Postn^tm1Sjc/\Postn^tm1Sjc (B6.Cg-Postn^tm1Sjc)	increased osteoclast cell number	J:200192
\Pot1b^tm1.1Schg/\Pot1b^tm1.1Schg \Terc^tm1Rdp/\Terc⁺ (involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal granulocyte morphology	J:144553
	decreased granulocyte number	J:144553
	decreased leukocyte cell number	J:144553
\Pot1b^tm1.1Schg/\Pot1b^tm1.1Schg \Terc^tm1Rdp/\Terc^tm1Rdp (involves: 129/Sv * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal granulocyte morphology	J:144553
\Pou1f1^dw/\Pou1f1^dw (DW/J Pou1f1^dw)	decreased B cell number	J:110683
\Pou2af1^{tm1b(KOMP)Wtsi}/\Pou2af1^{tm1b(KOMP)Wtsi} (C57BL/6N-Pou2af1^{tm1b(KOMP)Wtsi}/Ucd)	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased neutrophil cell number	J:211773
\Pou2af1^tm1Pjln/\Pou2af1^tm1Pjln (C57BL/6-Pou2af1^tm1Pjln)	absent spleen germinal center	J:37085
	decreased B cell number	J:37085
	decreased IgA level	J:37085
	decreased IgG1 level	J:37085
	decreased IgG2a level	J:37085
	decreased IgG2b level	J:37085
	decreased IgG3 level	J:37085
	spleen hypoplasia	J:37085
\Pou2af1^tm1Pjln/\Pou2af1^tm1Pjln (involves: C57BL/6)	abnormal B cell differentiation	J:67362
	abnormal T-helper 1 physiology	J:123039
	abnormal T-helper 2 physiology	J:123039
	decreased B cell number	J:123039, J:67362
	decreased immature B cell number	J:67362
	decreased interferon-gamma secretion	J:123039
	decreased interleukin-2 secretion	J:123039
	decreased mature B cell number	J:67362
	decreased T cell number	J:123039
	increased B cell apoptosis	J:67362
	increased interleukin-4 secretion	J:123039
	increased interleukin-13 secretion	J:123039
	increased susceptibility to parasitic infection	J:123039
\Pou2af1^tm1Pjln/\Pou2af1^tm1Pjln \Tg(tetO-Pou2af1)1Pjln/0 \Tg(tTA)1Pjln/0 (involves: C57BL/6)	decreased B cell number	J:67362
	decreased immunoglobulin level	J:67362
	decreased mature B cell number	J:67362
	immune system phenotype	J:67362
\Pou2af1^tm1Pmt/\Pou2af1^tm1Pmt (involves: 129P2/OlaHsd * C57BL/6)	decreased immunoglobulin level	J:125114
\Pou2af1^tm1Pmt/\Pou2af1^tm1Pmt \Ikzf3^tm1Kge/\Ikzf3^tm1Kge (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	absent spleen germinal center	J:81805
	arrested B cell differentiation	J:81805
	decreased IgA level	J:81805
	decreased IgD level	J:81805
	decreased IgE level	J:81805
	decreased IgG level	J:81805
	decreased IgM level	J:81805
	decreased immunoglobulin level	J:81805
\Pou2af1^tm1Rgr/\Pou2af1^tm1Rgr (either: (involves: 129P2/OlaHsd) or (involves: 129S1/Sv))	abnormal B cell differentiation	J:114816, J:35785
	abnormal Peyer's patch germinal center morphology	J:35785
	abnormal pre-B cell morphology	J:114816
	absent lymph node germinal center	J:35785
	absent spleen germinal center	J:35785
	arrested B cell differentiation	J:114816
	decreased B cell number	J:114816
	decreased B cell proliferation	J:35785
	decreased IgA level	J:35785
	decreased IgE level	J:35785
	decreased IgG1 level	J:35785
	decreased IgG2a level	J:35785
	decreased IgG2b level	J:35785
	decreased IgG3 level	J:35785
	decreased IgG level	J:35785
	decreased immunoglobulin level	J:35785
	increased B cell proliferation	J:114816
	increased IgM level	J:35785
\Pou2af3^{tm1b(NCOM)Mfgc}/\Pou2af3^{tm1b(NCOM)Mfgc} (C57BL/6N-Pou2af3^{tm1b(NCOM)Mfgc}/Tcp)	decreased lymphocyte cell number	J:211773
	increased leukocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Pou2f2^tm1Bal/\Pou2f2⁺ (involves: 129S2/SvPas)	decreased IgG1 level	J:4555
	decreased IgM level	J:4555
	decreased mature B cell number	J:4555
\Pou2f2^tm1Bal/\Pou2f2^tm1Bal (involves: 129S2/SvPas * C57BL/6)	arrested B cell differentiation	J:88240
	decreased B cell number	J:88240
	decreased immunoglobulin level	J:88240
\Pou2f2^tm1Bal/\Pou2f2^tm1Bal (involves: 129S2/SvPas)	decreased IgG1 level	J:4555
	decreased IgM level	J:4555
	decreased mature B cell number	J:4555
\Pou2f2^tm1Lmc/\Pou2f2^tm1Lmc (involves: C57BL/6)	arrested B cell differentiation	J:88240
	decreased B cell number	J:88240
	decreased B-1 B cell number	J:88240
	decreased immunoglobulin level	J:88240
\Ppara^tm1Gonz/\Ppara^tm1Gonz (involves: 129S4/SvJae)	heart inflammation	J:63801
\Ppara^tm1Gonz/\Ppara^tm1Gonz (involves: 129S4/SvJae)	increased susceptibility to type IV hypersensitivity reaction	J:258438
\Ppard^tm1Dsvg/\Ppard^tm1Dsvg (involves: 129S2/SvPas * C57BL/6)	increased osteoclast cell number	J:219677
\Ppard^tm1Jps/\Ppard^tm1Jps (involves: 129/Sv * C57BL/6N)	skin inflammation	J:63040
\Pparg^tm1.1Gonz/\Pparg^tm1.1Gonz \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)	abnormal macrophage activation involved in immune response	J:168799
	abnormal peritoneal macrophage morphology	J:168799
	glomerulonephritis	J:168799
	impaired macrophage phagocytosis	J:168799
	increased anti-double stranded DNA antibody level	J:168799
	increased anti-nuclear antigen antibody level	J:168799
	increased anti-single stranded DNA antibody level	J:168799
	increased autoantibody level	J:168799
	increased IgG level	J:168799
	increased IgM level	J:168799
\Pparg^tm1.1Gonz/\Pparg^tm1.1Gonz \Tg(Mx1-cre)1Cgn/? (involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N)	abnormal macrophage physiology	J:75777
\Pparg^tm1Tka/\Pparg⁺ (involves: C57BL/6 * CBA)	abnormal bone marrow development	J:89250
\Pparg^tm1Tka/\Pparg⁺ (involves: C57BL/6 * CBA)	leukostasis	J:116269
\Pparg^tm1Tka/\Pparg⁺ (involves: C57BL/6 * CBA * ICR)	abnormal B cell physiology	J:58222
	abnormal humoral immune response	J:58222
	immune system phenotype	J:58222
	increased B cell proliferation	J:58222
	increased IgG level	J:58222
	increased IgM level	J:58222
	increased interferon-gamma secretion	J:58222
	increased interleukin-2 secretion	J:58222
	increased susceptibility to induced arthritis	J:58222
\Pparg^tm1Wwah/\Pparg⁺ (Not Specified)	immune system phenotype	J:71272
\Pparg^tm2Rev/\Pparg^tm2Rev \Tg(Cd4-cre)1Cwi/? (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal T-helper 17 cell differentiation	J:153358
	increased susceptibility to experimental autoimmune encephalomyelitis	J:153358
\Pparg^tm2Rev/\Pparg^tm2Rev \Tg(Krt1-15-cre/PGR)22Cot/? (involves: 129S4/SvJae C57BL/6 * SJL)	skin inflammation	J:150977
\Pparg^tm2Rev/\Pparg^tm2Rev \Tg(Tek-cre)1Ywa/? (involves: 129S4/SvJae * C57BL/6 * SJL)	abnormal osteoclast differentiation	J:160910
	abnormal osteoclast morphology	J:130475
	abnormal spleen morphology	J:130475
	abnormal splenocyte morphology	J:130475
	decreased osteoclast cell number	J:130475
	enlarged spleen	J:130475
	increased splenocyte number	J:130475
	skin inflammation	J:123403
\Pparg^tm2Rev/\Pparg^tm2Rev \Tg(Tek-cre)12Flv/? (B6.Cg-Pparg^tm2Rev Tg(Tek-cre)12Flv)	enlarged spleen	J:154216
\Ppargc1a^tm1Aztc/\Ppargc1a⁺ (C57BL/6-Ppargc1a^tm1Aztc)	increased thymus weight	J:82809
\Ppargc1a^tm1Brsp/\Ppargc1a⁺ (involves: 129 * FVB/N)	immune system phenotype	J:127403
\Ppargc1a^tm1Brsp/\Ppargc1a⁺ (involves: 129S4/SvJae * C57BL/6)	increased inflammatory response	J:264271
\Ppargc1a^tm1Brsp/\Ppargc1a^tm1Brsp (involves: 129 * FVB/N)	increased interleukin-6 secretion	J:127403
\Ppargc1a^tm1Brsp/\Ppargc1a^tm2Brsp \Tg(Myog-cre)1Eno/0 (involves: 129 * C57BL/6 * FVB/N)	increased circulating interleukin-6 level	J:127403
\Ppargc1a^tm2Brsp/\Ppargc1a⁺ \Tg(Myog-cre)1Eno/0 (involves: 129 * C57BL/6)	increased circulating interleukin-6 level	J:127403
\Ppargc1b^tm1.2Rev/\Ppargc1b^tm1.2Rev \Tg(Tek-cre)1Ywa/0 (involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)	abnormal osteoclast differentiation	J:160910
\Ppbp^{tm1(KOMP)Vlcg}/\Ppbp^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal leukocyte migration	J:198197
	abnormal leukocyte physiology	J:198197
	immune system phenotype	J:198197
\Ppbp^{tm1.1(KOMP)Vlcg}/\Ppbp^{tm1.1(KOMP)Vlcg} (C57BL/6N-Ppbp^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Ppfibp2^em1(IMPC)Tcp/\Ppfibp2^em1(IMPC)Tcp (C57BL/6NCrl-Ppfibp2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Ppia^em1(IMPC)Mbp/\Ppia^em1(IMPC)Mbp (C57BL/6NCrl-Ppia^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Ppia^tm1Lubn/\Ppia^tm1Lubn (129S6.129P2-Ppia^tm1Lubn)	abnormal CD4-positive, alpha-beta T cell physiology	J:93591
	blepharitis	J:93591
	heart inflammation	J:93591
	increased circulating interleukin-4 level	J:93591
	increased IgE level	J:93591
	increased IgG1 level	J:93591
	increased immunoglobulin level	J:93591
	increased inflammatory response	J:93591
	increased interleukin-2 secretion	J:93591
	increased interleukin-4 secretion	J:93591
	increased susceptibility to type I hypersensitivity reaction	J:93591
	increased T cell number	J:93591
	liver inflammation	J:93591
	pancreas inflammation	J:93591
	spleen hyperplasia	J:93591
\Ppic^em1Igc/\Ppic^em1Igc (C57BL/6-Ppic^em1Igc)	decreased NK cell number	J:321155
	increased transitional stage T1 B cell number	J:321155
	increased transitional stage T2 B cell number	J:321155
\Ppil1^em1(IMPC)Mbp/\Ppil1⁺ (C57BL/6N-Ppil1^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Ppl^{tm1b(KOMP)Wtsi}/\Ppl^{tm1b(KOMP)Wtsi} (C57BL/6N-Ppl^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
\Ppm1a^tm1.2Lavi/\Ppm1a^tm1.2Lavi (B.129(Cg)-Ppm1a^tm1.2Lavi)	increased acute inflammation	J:216372
\Ppm1d^tm1Lad/\Ppm1d^tm1Lad (involves: 129S7/SvEvBrd * C57BL/6)	chronic inflammation	J:74284
	decreased B cell proliferation	J:74284
	decreased CD8-positive, alpha-beta T cell number	J:74284
	decreased T cell proliferation	J:74284
	enlarged spleen	J:74284
	increased CD4-positive, alpha-beta T cell number	J:74284
	increased susceptibility to Orthomyxoviridae infection	J:74284
	lymphoid hyperplasia	J:74284
	myeloid hyperplasia	J:74284
	small thymus	J:74284
	spleen hyperplasia	J:74284
\Ppm1m^{tm2b(EUCOMM)Hmgu}/\Ppm1m^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Ppm1m^{tm2b(EUCOMM)Hmgu}/Bay)	decreased large unstained cell number	J:211773
\Ppm1n^em1(IMPC)Mbp/\Ppm1n^em1(IMPC)Mbp (C57BL/6N-Ppm1n^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Ppp1r8^tm1.1Itl/\Ppp1r8^tm1Ave \Tg(Alb1-cre)7Gsc/0 (involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6NTac * FVB/N)	liver inflammation	J:238108
\Ppp1r12a^tm1Mzhu/\Ppp1r12a^tm1Mzhu \Tg(Acta2-cre)#Xya/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	small intestinal inflammation	J:207752
\Ppp1r13b^tm1Suda/\Ppp1r13b^tm1Suda (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymph circulation	J:135686
	abnormal lymphatic vessel morphology	J:135686
\Ppp1r13b^tm1Suda/\Ppp1r13b^tm1Suda \Trp53^tm1Sia/\Trp53^tm1Sia (involves: various)	abnormal lymphatic vessel morphology	J:135686
\Ppp1r13l^wa3-J/\Ppp1r13l^wa3-J (BALB/cJ-Ppp1r13l^wa3-J/J)	heart inflammation	J:264272
\Ppp1r14c^tm1Uhl/\Ppp1r14c^tm1Uhl (B6;129S6-Ppp1r14c^tm1Uhl/J)	increased susceptibility to Coronaviridae infection	J:288523
\Ppp1r15a^tm1.1Ajf/\Ppp1r15a^tm1.1Ajf (involves: 129 * C57BL/6)	abnormal splenic cell ratio	J:106905
	increased spleen weight	J:106905
\Ppp1r17^em1(IMPC)H/\Ppp1r17^em1(IMPC)H (C57BL/6NTac-Ppp1r17^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Ppp1r18^em1Mgin/\Ppp1r18^em1Mgin (B6J.B6N-Ppp1r18^em1Mgin)	abnormal T cell physiology	J:331428
	decreased B cell number	J:331428
	decreased T cell number	J:331428
	immune system phenotype	J:331428
	impaired leukocyte migration	J:331428
	increased leukocyte cell number	J:331428
	increased neutrophil cell number	J:331428
	small spleen	J:331428
	spleen hypoplasia	J:331428
\Ppp1r18^em2Mgin/\Ppp1r18^em2Mgin (B6J.B6NHsd-Ppp1r18^em2Mgin)	immune system phenotype	J:331428
\Ppp1r18^em3Mgin/\Ppp1r18^em3Mgin (B6J.B6N-Ppp1r18^em3Mgin)	abnormal T cell physiology	J:331428
	decreased B cell number	J:331428
	decreased T cell number	J:331428
	immune system phenotype	J:331428
	impaired leukocyte migration	J:331428
	increased leukocyte cell number	J:331428
	increased neutrophil cell number	J:331428
	small spleen	J:331428
	spleen hypoplasia	J:331428
\Ppp2r1b^{tm1b(EUCOMM)Wtsi}/\Ppp2r1b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ppp2r1b^{tm1b(EUCOMM)Wtsi}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Ppp2r2b^{tm1b(KOMP)Wtsi}/\Ppp2r2b^{tm1b(KOMP)Wtsi} (C57BL/6N-Ppp2r2b^{tm1b(KOMP)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Ppp2r2d^em1(IMPC)Mbp/\Ppp2r2d^em1(IMPC)Mbp (C57BL/6N-Ppp2r2d^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Ppp2r2d^em1Gct/\Ppp2r2d^em1Gct \Tg(Lck-icre)3779Nik/0 (involves: C57BL/6 * DBA/2)	abnormal regulatory T cell physiology	J:308373
	increased interleukin-2 secretion	J:308373
\Ppp2r3c^tm1Imku/\Ppp2r3c^tm1Imku \Tg(CD19-cre/ERT2)1Cgn/? (involves: C57BL/6)	abnormal B cell activation	J:100706
	abnormal humoral immune response	J:100706
	decreased B cell number	J:100706
	decreased B cell proliferation	J:100706
	decreased B-1a cell number	J:100706
	decreased follicular B cell number	J:100706
	decreased immature B cell number	J:100706
	decreased mature B cell number	J:100706
	decreased pre-B cell number	J:100706
	decreased spleen germinal center size	J:100706
	decreased transitional stage B cell number	J:100706
	increased pro-B cell number	J:100706
	increased T cell number	J:100706
	increased transitional stage B cell number	J:100706
	small spleen	J:100706
\Ppp2r5a^em1(IMPC)Mbp/\Ppp2r5a^em1(IMPC)Mbp (C57BL/6N-Ppp2r5a^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Ppp2r5a^{Gt(IST13127C10)Tigm}/\Ppp2r5a^{Gt(IST13127C10)Tigm} (C57BL/6N-Ppp2r5a^{Gt(IST13127C10)Tigm})	enlarged mesenteric lymph nodes	J:254808
	enlarged spleen	J:254808
\Ppp2r5c^em1(IMPC)Mbp/\Ppp2r5c^em1(IMPC)Mbp (C57BL/6N-Ppp2r5c^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Ppp3ca^tm1Jse/\Ppp3ca^tm1Jse (either: (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6))	decreased interferon-gamma secretion	J:71750
	decreased interleukin-2 secretion	J:71750
	decreased interleukin-4 secretion	J:71750
	decreased T cell proliferation	J:71750
\Ppp3cb^{em1(IMPC)Ccpcz}/\Ppp3cb^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ppp3cb^{em1(IMPC)Ccpcz}/Ccpcz)	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
\Ppp3cb^M1Btlr/\Ppp3cb⁺ (C57BL/6J-Ppp3cb^M1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236670
	abnormal CD8-positive, alpha-beta T cell physiology	J:236670
	abnormal NK cell physiology	J:236670
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236670
\Ppp3cb^M1Btlr/\Ppp3cb^M1Btlr (C57BL/6J-Ppp3cb^M1Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236670
	abnormal CD8-positive, alpha-beta T cell physiology	J:236670
	abnormal NK cell physiology	J:236670
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236670
\Ppp3cb^m2Btlr/\Ppp3cb⁺ (C57BL/6J-Ppp3cb^m2Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236671
	abnormal CD8-positive, alpha-beta T cell physiology	J:236671
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236671
\Ppp3cb^m2Btlr/\Ppp3cb^m2Btlr (C57BL/6J-Ppp3cb^m2Btlr)	abnormal CD4-positive, alpha-beta T cell physiology	J:236671
	abnormal CD8-positive, alpha-beta T cell physiology	J:236671
	abnormal NK cell physiology	J:236671
	decreased response to antigen	J:236671
	increased CD8-positive, alpha-beta memory T cell proliferation	J:236671
\Ppp3cb^M3Btlr/\Ppp3cb⁺ (C57BL/6J-Ppp3cb^M3Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254889
\Ppp3cb^M3Btlr/\Ppp3cb⁺ (C57BL/6J-Ppp3cb^M3Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:254889
\Ppp3cb^M3Btlr/\Ppp3cb^M3Btlr (C57BL/6J-Ppp3cb^M3Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254889
	decreased CD8-positive, naive alpha-beta T cell number	J:254889
	increased central memory CD4-positive, alpha-beta T cell number	J:254889
	increased central memory CD8 positive, alpha-beta T cell number	J:254889
\Ppp3cb^M4Btlr/\Ppp3cb⁺ (C57BL/6J-Ppp3cb^M4Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254905
\Ppp3cb^M4Btlr/\Ppp3cb⁺ (C57BL/6J-Ppp3cb^M4Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:254905
\Ppp3cb^M4Btlr/\Ppp3cb^M4Btlr (C57BL/6J-Ppp3cb^M4Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254905
\Ppp3cb^M4Btlr/\Ppp3cb^M4Btlr (C57BL/6J-Ppp3cb^M4Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:254905
\Ppp3cb^m5Btlr/\Ppp3cb^m5Btlr (C57BL/6J-Ppp3cb^m5Btlr)	abnormal T cell morphology	J:272839
\Ppp3cb^m5Btlr/\Ppp3cb^m5Btlr (C57BL/6J-Ppp3cb^m5Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272839
\Ppp3cb^M6Btlr/\Ppp3cb^M6Btlr (C57BL/6J-Ppp3cb^M6Btlr)	abnormal lymphocyte morphology	J:272840
	decreased alpha-beta T cell number	J:272840
	decreased CD4-positive, alpha-beta T cell number	J:272840
	decreased CD8-positive, alpha-beta T cell number	J:272840
\Ppp3cb^tm1Jmk/\Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac * C57BL/6)	abnormal T cell differentiation	J:77729
	decreased single-positive T cell number	J:77729
	decreased T cell number	J:77729
	decreased T cell proliferation	J:77729
	decreased thymus weight	J:75775
	thymus hypoplasia	J:77729
\Ppp3cb^tm1Jmk/\Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac)	abnormal cytokine secretion	J:109586
\Ppp3cb^tm1Jmk/\Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac)	decreased T cell proliferation	J:109586
\Ppp3r1^tm2Grc/\Ppp3r1^tm2.1Grc \Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal lymph node cell ratio	J:89771
	abnormal positive T cell selection	J:89771
	abnormal splenic cell ratio	J:89771
\Ppp3r1^tm2Grc/\Ppp3r1^tm2Grc \Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	decreased thymocyte number	J:89771
	thymus hypoplasia	J:89771
\Ppp4c^tm1Tht/\Ppp4c^tm1Tht \Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal positive T cell selection	J:117684
	abnormal T cell activation	J:117684
	abnormal T cell differentiation	J:117684
	decreased CD4-positive, alpha-beta T cell number	J:117684
	decreased CD8-positive, alpha-beta T cell number	J:117684
	decreased double-positive T cell number	J:117684
	decreased single-positive T cell number	J:117684
	increased double-negative T cell number	J:117684
\Ppp4c^tm1Tht/\Ppp4c^tm1Tht \Tg(Lck-cre)548Jxm/0 \Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal positive T cell selection	J:117684
	decreased double-positive T cell number	J:117684
	decreased single-positive T cell number	J:117684
\Ppp4r3b^{tm1b(EUCOMM)Hmgu}/\Ppp4r3b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ppp4r3b^{tm1b(EUCOMM)Hmgu}/Ieg)	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Ppp5c^tm1.2Rhon/\Ppp5c^tm1.2Rhon (B6.129X1-Ppp5c^tm1.2Rhon)	enlarged spleen	J:178164
\Ppp5c^{tm1a(EUCOMM)Wtsi}/\Ppp5c^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased CD4-positive, alpha-beta T cell number	J:213427
	increased CD8-positive, alpha-beta T cell number	J:213427
	increased T cell number	J:213427
	lymphoid hyperplasia	J:213427
\Ppp6c^tm1Shma/\Ppp6c^tm1Shma \Tg(KRT14-cre/ERT)20Efu/0 (involves: C57BL/6 * CBA * CD-1)	increased susceptibility to chemically induced skin inflammation	J:231809
\Ppt1^tm1.1Dprc/\Ppt1^tm1.1Dprc (involves: 129S6/SvEvTac * BALB/cJ * C57BL/6)	abnormal microglial cell activation	J:213552
\Ppt1^tm1Aj/\Ppt1^tm1Aj (involves: 129S4/SvJae * C57BL/6)	abnormal spleen morphology	J:95522
\Ppt1^tm1Aj/\Ppt1^tm1Aj (involves: 129S4/SvJae * C57BL/6)	brain inflammation	J:95522
\Ppt1^tm1Hof/\Ppt1^tm1Hof (involves: 129S6/SvEvTac * C57BL/6J)	microgliosis	J:280337
\Ppt1^tm1Hof/\Ppt1^tm1Hof (involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	abnormal cytokine level	J:177265
	brain inflammation	J:177265
\Ppt2^tm1Hof/\Ppt2^tm1Hof (involves: 129S6/SvEvTac * C57BL/6J)	abnormal spleen morphology	J:86202
	decreased spleen B cell follicle number	J:86202
	enlarged spleen	J:86202
	increased macrophage cell number	J:86202
	increased spleen weight	J:86202
\Pram1^tm1Gak/\Pram1^tm1Gak (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal neutrophil physiology	J:95253
\Pramel1^em1(IMPC)Tcp/\Pramel1^em1(IMPC)Tcp (C57BL/6NCrl-Pramel1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Pramel12^em1(IMPC)Mbp/\Pramel12^em1(IMPC)Mbp (C57BL/6N-Pramel12^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Prap1^tm1Lex/\Prap1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal humoral immune response	J:171883
	increased immunoglobulin level	J:171883
\Prap1^tm1Lex/\Prap1^tm1Lex (B6.129S5-Prap1^tm1Lex)	increased circulating interleukin-2 level	J:304152
	increased circulating interleukin-4 level	J:304152
	increased circulating interleukin-12 level	J:304152
	increased inflammatory response	J:304152
	increased interleukin-12b secretion	J:304152
\Prcd^tm1Vya/\Prcd^tm1Vya (B6.Cg-Prcd^tm1Vya)	increased microglial cell activation	J:276708
\Prdm1^tm1.1Liz/\Prdm1^tm1.1Liz (involves: 129S/SvEv)	abnormal splenocyte physiology	J:163979
\Prdm1^tm1.1Liz/\Prdm1^tm1.1Liz (involves: 129S/SvEv)	absent plasma cells	J:196531
\Prdm1^tm1Clme/\Prdm1^tm1Clme \Tg(Itgax-cre)1-1Reiz/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	abnormal CD4-positive, alpha-beta T cell physiology	J:178876
	abnormal germinal center B cell physiology	J:178876
	abnormal immune system physiology	J:178876
	abnormal T follicular helper cell differentiation	J:178876
	increased anti-double stranded DNA antibody level	J:178876
	increased anti-nuclear antigen antibody level	J:178876
	increased autoantibody level	J:178876
	increased germinal center B cell number	J:178876
	increased IgG level	J:178876
	increased immunoglobulin level	J:178876
	increased interleukin-6 secretion	J:178876
	increased spleen germinal center number	J:178876
	increased splenocyte number	J:178876
	increased T follicular helper cell number	J:178876
	kidney inflammation	J:178876
\Prdm1^tm2.1Liz/\Prdm1^tm2.1Liz (involves: 129S/SvEv)	immune system phenotype	J:153979
\Prdm1^tm2.1Nutt/\Prdm1^tm2.1Nutt \Tg(Lck-cre)1Cwi/? (involves: C57BL/6)	increased susceptibility to Orthomyxoviridae infection	J:151858
\Prdm1^tm3.1Liz/\Prdm1^tm3.1Liz (involves: 129S/SvEv)	immune system phenotype	J:196531
\Prdm4^{tm1b(EUCOMM)Hmgu}/\Prdm4^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Prdm4^{tm1b(EUCOMM)Hmgu}/H)	absent spleen	J:211773
\Prdm8^{em1(IMPC)Wtsi}/\Prdm8⁺ (C57BL/6N-Prdm8^{em1(IMPC)Wtsi}/Wtsi)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Prdm8^{em1(IMPC)Wtsi}/\Prdm8^{em1(IMPC)Wtsi} (C57BL/6N-Prdm8^{em1(IMPC)Wtsi}/Wtsi)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Prdm11^tm1.1Ahl/\Prdm11^tm1.1Ahl (B6.129(C)-Prdm11^tm1.1Ahl)	abnormal humoral immune response	J:233986
	decreased CD4-positive, alpha-beta T cell number	J:233986
	decreased neutrophil cell number	J:233986
	increased B cell number	J:233986
	increased interferon-gamma secretion	J:233986
	increased interleukin-2 secretion	J:233986
\Prdm13^em1(IMPC)Tcp/\Prdm13^em1(IMPC)Tcp (C57BL/6NCrl-Prdm13^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	increased spleen weight	J:211773
\Prdm14^{tm1a(EUCOMM)Wtsi}/\Prdm14^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Prdm14^{tm1a(EUCOMM)Wtsi}/Bay)	increased effector memory T-helper cell number	J:211773
\Prdm16^{Gt(OST67423)Lex}/\Prdm16⁺ (involves: 129S5/SvEvBrd * C57BL/6J)	increased leukocyte cell number	J:103485
\Prdm16^tm1.1Brsp/\Prdm16^tm1.1Brsp \Tg(Adipoq-cre)1Evdr/0 (involves: 129/Sv * C57BL/6 * FVB/N)	increased macrophage cell number	J:208683
\Prdt1^CAST/EiJH/\Prdt1^CAST/EiJH (involves: CAST/Ei * NZW/OlaHsd)	decreased susceptibility to prion infection	J:80787
\Prdt1^NZW/OlaHsd/\Prdt1^NZW/OlaHsd (involves: CAST/Ei * NZW/OlaHsd)	increased susceptibility to prion infection	J:80787
\Prdt3^CAST/EiJH/\Prdt3^CAST/EiJH (involves: CAST/Ei * NZW/OlaHsd)	decreased susceptibility to prion infection	J:80787
\Prdt3^NZW/OlaHsd/\Prdt3^NZW/OlaHsd (involves: CAST/Ei * NZW/OlaHsd)	increased susceptibility to prion infection	J:80787
\Prdx1^flro/\Prdx1^flro (C57BL/10JAnu-Prdx1^flro/AnuApb)	abnormal lymphocyte morphology	J:104190
\Prdx1^tm1Rave/\Prdx1^tm1Rave (involves: 129S6/SvEvTac * C57BL/6)	abnormal NK T cell number	J:84677
	abnormal spleen morphology	J:84677
	enlarged spleen	J:84677
	impaired natural killer cell mediated cytotoxicity	J:84677
	increased spleen weight	J:84677
	increased T cell derived lymphoma incidence	J:84677
\Prdx2^tm1Yu/\Prdx2^tm1Yu (involves: 129S4/SvJae)	enlarged spleen	J:84271
	increased spleen red pulp amount	J:84271
	increased spleen weight	J:84271
\Prdx3^{Gt(Betageo-puro)711Lex}/\Prdx3^{Gt(Betageo-puro)711Lex} (involves: 129S5/SvEvBrd * C57BL/6)	lung inflammation	J:118595
\Prdx5^{tm1.1(KOMP)Vlcg}/\Prdx5^{tm1.1(KOMP)Vlcg} (involves: C57BL/6J * C57BL/6NTac)	immune system phenotype	J:271141
	increased circulating interleukin-12b level	J:271141
	increased circulating tumor necrosis factor level	J:271141
	increased interleukin-6 secretion	J:271141
	increased interleukin-12b secretion	J:271141
	increased tumor necrosis factor secretion	J:271141
\Prep^{Gt(RRM213)Byg}/\Prep⁺ (B6.129P2-Prep^{Gt(RRM213)Byg})	increased spleen weight	J:151643
\Prex1^tm1Dwu/\Prex1^tm1Dwu (Not Specified)	impaired neutrophil chemotaxis	J:102213
\Prex1^tm1Hcew/\Prex1^tm1Hcew (involves: 129P2/OlaHsd * C57BL/6)	impaired neutrophil chemotaxis	J:102214
	impaired neutrophil recruitment	J:102214
	increased neutrophil cell number	J:102214
\Prf1^m1Btlr/\Prf1^m1Btlr (C57BL/6J-Prf1^m1Btlr)	increased susceptibility to Herpesvirales infection	J:216044
\Prf1^m1Btlr/\Prf1^m1Btlr (C57BL/6J-Prf1^m1Btlr)	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:216044
\Prf1^tm1Clrk/\Prf1^tm1Clrk (involves: 129S7/SvEvBrd * C57BL/6)	decreased cytotoxic T cell cytolysis	J:21531
	immune system phenotype	J:21531
	increased susceptibility to Riboviria infection	J:21531
\Prf1^tm1Clrk/\Prf1^tm1Clrk (C.129S7(B6)-Prf1^tm1Clrk)	abnormal cytokine secretion	J:71576
	immune system phenotype	J:71576
	increased activated T cell number	J:71576
	increased interferon-gamma secretion	J:71576
	increased susceptibility to Riboviria infection	J:71576
	increased tumor necrosis factor secretion	J:71576
\Prf1^tm1Clrk/\Prf1^tm1Clrk (involves: 129S7/SvEvBrd * BALB/c * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
\Prf1^tm1Clrk/\Prf1^tm1Clrk \Tg(INS-Il10)#Sar/0 (involves: 129S7/SvEvBrd * BALB/c * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
\Prf1^tm1Sdz/\Prf1⁺ (NOD.B6-Prf1^tm1Sdz)	decreased susceptibility to autoimmune diabetes	J:43468
	insulitis	J:43468
	periinsulitis	J:43468
\Prf1^tm1Sdz/\Prf1⁺ (A.B6-Prf1^tm1Sdz)	impaired natural killer cell mediated cytotoxicity	J:211842
\Prf1^tm1Sdz/\Prf1^tm1Sdz (C57BL/6-Prf1^tm1Sdz)	abnormal inflammatory response	J:17986
	abnormal leukocyte physiology	J:17986
	abnormal NK cell physiology	J:113213
	decreased cytotoxic T cell cytolysis	J:17986
	impaired natural killer cell mediated cytotoxicity	J:17986
	increased interleukin-10 secretion	J:123934
	increased susceptibility to bacterial infection	J:123934
	increased susceptibility to infection	J:17986
	increased susceptibility to parasitic infection	J:81397
	increased susceptibility to Riboviria infection	J:17986
\Prf1^tm1Sdz/\Prf1^tm1Sdz (NOD.B6-Prf1^tm1Sdz)	decreased susceptibility to autoimmune diabetes	J:43468
	insulitis	J:43468
	periinsulitis	J:43468
\Prf1^tm1Sdz/\Prf1^tm1Sdz (C57BL/6-Prf1^tm1Sdz/J)	abnormal circulating cytokine level	J:92260
	abnormal cytotoxic T cell physiology	J:193137
	abnormal lymph node morphology	J:92260
	abnormal lymphocyte physiology	J:120427
	abnormal macrophage activation involved in immune response	J:92260
	abnormal spleen white pulp morphology	J:92260
	abnormal T cell activation	J:92260
	brain inflammation	J:92260, J:120427
	CNS inflammation	J:120427
	decreased circulating fibrinogen level	J:92260
	decreased cytotoxic T cell cytolysis	J:193137
	decreased interferon-gamma secretion	J:92260
	decreased leukocyte cell number	J:193137
	decreased neutrophil cell number	J:193137
	decreased NK cell degranulation	J:193137
	immune system phenotype	J:120427
	increased circulating interferon-alpha level	J:92260
	increased circulating interferon-gamma level	J:92260, J:193137
	increased circulating interleukin-1 beta level	J:193137
	increased circulating interleukin-6 level	J:92260, J:193137
	increased circulating interleukin-10 level	J:92260
	increased circulating interleukin-18 level	J:92260
	increased circulating tumor necrosis factor level	J:92260, J:193137
	increased spleen red pulp amount	J:92260
	increased susceptibility to Picornaviridae infection	J:120427
	increased susceptibility to Riboviria infection	J:92260, J:193137
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:92260
	increased susceptibility to viral infection induced morbidity/mortality	J:193137
	liver inflammation	J:92260
	lymph node inflammation	J:92260
	lymph node necrosis	J:92260
\Prf1^tm1Sdz/\Prf1^tm1Sdz (involves: BALB/c * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:73948
\Prf1^tm1Sdz/\Prf1^tm1Sdz (C.B6-Prf1^tm1Sdz)	increased T cell derived lymphoma incidence	J:77491
\Prf1^tm1Sdz/\Prf1^tm1Sdz (A.B6-Prf1^tm1Sdz)	impaired natural killer cell mediated cytotoxicity	J:211842
\Prf1^tm1Sdz/\Prf1^tm1Sdz \Rag1^tm1Mom/\Rag1^tm1Mom (NOD.Cg-Rag1^tm1Mom Prf1^tm1Sdz/SzJ)	abnormal response to transplant	J:91764
\Prf1^tm1Sdz/\Prf1^tm1Sdz X/\Yaa (BXSB.B6-Prf1^tm1Sdz/Dcr)	autoimmune response	J:179430
\Prf1^tm1Tsc/\Prf1⁺ (involves: 129S2/SvPas)	decreased cytotoxic T cell cytolysis	J:21731
\Prf1^tm1Tsc/\Prf1⁺ (involves: 129S2/SvPas)	impaired natural killer cell mediated cytotoxicity	J:21731
\Prf1^tm1Tsc/\Prf1^tm1Tsc (involves: 129S2/SvPas)	decreased cytotoxic T cell cytolysis	J:21731
	decreased susceptibility to bacterial infection	J:50903
	impaired natural killer cell mediated cytotoxicity	J:21731
\Prf1^tm1Tsc/\Prf1^tm1Tsc (129X1.129S2-Prf1^tm1Tsc)	abnormal NK cell physiology	J:126114
\Prf1^tm1Tsc/\Prf1^tm1Tsc (129X1.129S2-Prf1^tm1Tsc)	decreased T cell apoptosis	J:126114
\Prg2^tm1Nal/\Prg2^tm1Nal (involves: 129P2/OlaHsd * 129X1/SvJ)	abnormal eosinophil morphology	J:65655
	abnormal inflammatory response	J:65655
	respiratory system inflammation	J:65655
\Primpol^em1Nki/\Primpol^em1Nki (C57BL/6-Primpol^em1Nki)	abnormal somatic hypermutation frequency	J:242620
\Primpol^em1Nki/\Primpol^em1Nki (C57BL/6-Primpol^em1Nki)	immune system phenotype	J:242620
\Prkaa1^tm1Sbj/\Prkaa1^tm1Sbj (involves: 129)	increased spleen weight	J:147215
\Prkaa2^{tm1b(EUCOMM)Hmgu}/\Prkaa2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Prkaa2^{tm1b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
\Prkab1^em1(IMPC)Bay/\Prkab1^em1(IMPC)Bay (C57BL/6N-Prkab1^em1(IMPC)Bay/Bay)	increased spleen weight	J:211773
\Prkab1^{tm1b(KOMP)Wtsi}/\Prkab1⁺ (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Ccpcz)	decreased Ly6C-positive mature NK cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Prkab1^{tm1b(KOMP)Wtsi}/\Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Wtsi)	increased memory-marker CD4-negative NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
\Prkab1^{tm1b(KOMP)Wtsi}/\Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Prkab1^{tm1b(KOMP)Wtsi}/\Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Prkab1^{tm1b(KOMP)Wtsi}/\Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
\Prkab1^{tm1b(KOMP)Wtsi}/\Prkab1^{tm1b(KOMP)Wtsi} (involves: C57BL/6N)	enlarged spleen	J:236972
	increased spleen iron level	J:236972
	increased spleen red pulp amount	J:236972
	increased spleen weight	J:236972
\Prkab1^{tm1b(KOMP)Wtsi}/\Prkab1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkab1^{tm1b(KOMP)Wtsi}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Prkab1^tm1Eihl/\Prkab1^tm1Eihl (involves: C57BL/6)	decreased circulating interleukin-6 level	J:158295
\Prkab2^{tm1b(EUCOMM)Hmgu}/\Prkab2⁺ (C57BL/6N-Prkab2^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
\Prkag1^tm1.2Mfor/\Prkag1^tm1.2Mfor (involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac * FVB/N)	abnormal Kupffer cell morphology	J:167779
	enlarged spleen	J:167779
	increased spleen iron level	J:167779
	increased spleen red pulp amount	J:167779
\Prkag2^tm1.1Geno/\Prkag2^tm1.1Geno (B6J.129S(Cg)-Prkag2^tm1.1Geno)	abnormal inflammatory response	J:235379
	white adipose tissue inflammation	J:235379
\Prkag2^tm3.1Mrl/? (C57BL/6-Prkag2^tm3.1Mrl/Tac)	kidney inflammation	J:237375
\Prkar1a^tm2Gsm/\Prkar1a^tm2Gsm \Tg(Cr2-cre)3Cgn/0 (involves: 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:147785
\Prkar1b^tm1Gsm/\Prkar1b^tm1Gsm (Not Specified)	decreased inflammatory response	J:43080
\Prkcb^M1Btlr/\Prkcb⁺ (C57BL/6J-Prkcb^M1Btlr)	decreased IgM level	J:164864
\Prkcb^M1Btlr/\Prkcb^M1Btlr (C57BL/6J-Prkcb^M1Btlr)	decreased IgM level	J:164864
\Prkcb^M1Btlr/\Prkcb^M1Btlr (involves: C57BL/6J)	decreased IgM level	J:185495
\Prkcb^M1Btlr/\Prkcb^M1Btlr (involves: C57BL/6J)	immune system phenotype	J:185495
\Prkcb^M2Btlr/\Prkcb⁺ (C57BL/6J-Prkcb^M2Btlr)	decreased IgM level	J:217791
	decreased response to antigen	J:217791
	impaired humoral immune response	J:217791
\Prkcb^M2Btlr/\Prkcb^M2Btlr (C57BL/6J-Prkcb^M2Btlr)	decreased IgM level	J:217791
	decreased response to antigen	J:217791
	impaired humoral immune response	J:217791
\Prkcb^M3Btlr/\Prkcb⁺ (C57BL/6J-Prkcb^M3Btlr)	decreased IgM level	J:217793
	decreased response to antigen	J:217793
	impaired humoral immune response	J:217793
\Prkcb^M3Btlr/\Prkcb^M3Btlr (C57BL/6J-Prkcb^M3Btlr)	decreased IgM level	J:217793
	decreased response to antigen	J:217793
	impaired humoral immune response	J:217793
\Prkcb^M4Btlr/\Prkcb^M4Btlr (C57BL/6J-Prkcb^M4Btlr)	decreased B-1 B cell number	J:274860
	increased CD4-positive, alpha-beta T cell number	J:274860
	increased CD8-positive, alpha-beta T cell number	J:274860
	increased T cell number	J:274860
\Prkcb^M5Btlr/\Prkcb^M5Btlr (C57BL/6J-Prkcb^M5Btlr)	decreased IgM level	J:274861
\Prkcb^M5Btlr/\Prkcb^M5Btlr (C57BL/6J-Prkcb^M5Btlr)	impaired humoral immune response	J:274861
\Prkcb^M6Btlr/\Prkcb^M6Btlr (C57BL/6J-Prkcb^M6Btlr)	decreased B-1 B cell number	J:274862
\Prkcb^tilc/\Prkcb⁺ (involves: C57BL/6JSfdAnu)	abnormal humoral immune response	J:221236
	decreased IgG3 level	J:221236
	decreased IgM level	J:221236
\Prkcb^tilc/\Prkcb^tilc (C57BL/6JSfdAnu-Prkcb^tilc/AnuApb)	decreased IgM level	J:104190
\Prkcb^tilc/\Prkcb^tilc (involves: C57BL/6JSfdAnu)	abnormal humoral immune response	J:221236
	decreased B cell proliferation	J:221236
	decreased B-1a cell number	J:221236
	decreased IgG3 level	J:221236
	decreased IgM level	J:221236
	immune system phenotype	J:221236
\Prkcb^tm1Tara/\Prkcb⁺ (involves: 129)	abnormal humoral immune response	J:34818
	decreased IgG3 level	J:34818
	decreased IgM level	J:34818
\Prkcb^tm1Tara/\Prkcb^tm1Tara (involves: 129)	abnormal humoral immune response	J:34818
	decreased B cell number	J:34818
	decreased B cell proliferation	J:34818
	decreased B-1 B cell number	J:34818
	decreased B-1a cell number	J:34818
	decreased IgG3 level	J:34818
	decreased IgM level	J:34818
	immune system phenotype	J:34818
\Prkcd^M1Btlr/\Prkcd^M1Btlr (C57BL/6J-Prkcd^M1Btlr)	increased susceptibility to induced colitis	J:265145
\Prkcd^m2Btlr/\Prkcd^m2Btlr (C57BL/6J-Prkcd^m2Btlr)	enhanced humoral immune response	J:265146
	increased IgM level	J:265146
	increased NK cell number	J:265146
	increased susceptibility to induced colitis	J:265146
\Prkcd^tm1.1Chou/\Prkcd^tm1.1Chou (involves: C57BL/6 * C57BL/6NTac)	abnormal neutrophil physiology	J:217880
\Prkcd^tm1Kin/\Prkcd^tm1Kin (involves: 129P2/OlaHsd * C57BL/6)	abnormal immunoglobulin level	J:143854
	abnormal lymph node germinal center morphology	J:76135
	abnormal Peyer's patch germinal center morphology	J:76135
	abnormal plasma cell differentiation	J:143854
	enlarged lymph nodes	J:76135
	enlarged spleen	J:76135
	glomerulonephritis	J:76135
	increased acute inflammation	J:76135
	increased anti-chromatin antibody level	J:76135
	increased B cell number	J:76135
	increased B cell proliferation	J:76135, J:143854
	increased follicular B cell number	J:143854
	increased IgA level	J:76135, J:143854
	increased IgG1 level	J:76135, J:143854
	increased IgM level	J:143854
	increased interleukin-6 secretion	J:76135
	increased marginal zone B cell number	J:143854
	increased spleen germinal center number	J:76135
	increased transitional stage B cell number	J:143854
\Prkcd^tm1Msg/\Prkcd^tm1Msg (involves: 129X1/SvJ * C57BL/6J)	abnormal neutrophil physiology	J:91377
	decreased neutrophil cell number	J:91377
\Prkcd^tm1Qxu/\Prkcd^tm1Qxu (involves: 129P2/OlaHsd)	abnormal response to transplant	J:78680
\Prkcd^tm1Qxu/\Prkcd^tm1Qxu (involves: 129P2/OlaHsd * C57BL/6)	enlarged lymph nodes	J:76134
	enlarged spleen	J:76134
	immune system phenotype	J:76134
	increased anti-nuclear antigen antibody level	J:76134
	increased B cell apoptosis	J:76134
	increased B cell number	J:76134
	increased IgA level	J:76134
	increased IgG1 level	J:76134
	increased IgM level	J:76134
\Prkcd^tm1Qxu/\Prkcd^tm1Qxu \Tg(IghelMD4)4Ccg/0 \Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:76134
\Prkcd^tm1Qxu/\Prkcd^tm1Qxu \Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:76134
	abnormal B cell proliferation	J:76134
	abnormal self tolerance	J:76134
	abnormal spleen primary B follicle morphology	J:76134
	autoimmune response	J:76134
	decreased B cell number	J:76134
	immune system phenotype	J:76134
	increased spleen germinal center number	J:76134
\Prkce^m1Btlr/\Prkce^m1Btlr (C57BL/6J-Prkce^m1Btlr)	decreased dendritic cell number	J:267703
\Prkce^m1Btlr/\Prkce^m1Btlr (C57BL/6J-Prkce^m1Btlr)	decreased NK cell number	J:267703
\Prkce^tm1Bai/\Prkce^tm1Bai (Not Specified)	immune system phenotype	J:94663
\Prkce^tm1Bsca/\Prkce^tm1Bsca (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-1 beta level	J:103337
	decreased circulating tumor necrosis factor level	J:103337
	decreased macrophage apoptosis	J:103337
	decreased macrophage nitric oxide production	J:103337
	decreased T cell proliferation	J:103337
	increased susceptibility to bacterial infection	J:103337
\Prkce^tm1Ltg/\Prkce^tm1Ltg (involves: 129P2/OlaHsd * FVB/N)	decreased tumor necrosis factor secretion	J:86056
\Prkcg^tm1Stl/\Prkcg^tm1Stl (Not Specified)	decreased inflammatory response	J:25061
\Prkch^tm1.2Gasc/\Prkch^tm1.2Gasc (involves: C57BL/6 * FVB/N * SJL)	abnormal brachial lymph node morphology	J:186080
	abnormal cervical lymph node morphology	J:186080
	abnormal effector T cell morphology	J:186080
	abnormal lymph node morphology	J:186080
	decreased B cell number	J:186080
	decreased CD4-positive, alpha-beta T cell number	J:186080
	decreased CD8-positive, alpha-beta T cell number	J:186080
	decreased DN1 thymic pro-T cell number	J:186080
	decreased DN4 thymocyte number	J:186080
	decreased double-positive T cell number	J:186080
	decreased lymphocyte cell number	J:186080
	decreased T cell number	J:186080
	decreased T cell proliferation	J:186080
	enlarged axillary lymph nodes	J:186080
	enlarged cervical lymph nodes	J:186080
	enlarged inguinal lymph nodes	J:186080
	enlarged lymph nodes	J:186080
	increased B cell number	J:186080
	increased CD4-positive, alpha-beta T cell number	J:186080
	increased CD8-positive, alpha-beta T cell number	J:186080
	increased memory T cell number	J:186080
	increased T cell number	J:186080
	thymus hypoplasia	J:186080
\Prkch^tm1.2Gasc/\Prkch^tm1.2Gasc \Prkcq^tm1Litt/\Prkcq^tm1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)	abnormal positive T cell selection	J:186080
	decreased CD4-positive, alpha-beta T cell number	J:186080
	decreased CD8-positive, alpha-beta T cell number	J:186080
	decreased DN1 thymic pro-T cell number	J:186080
	decreased DN4 thymocyte number	J:186080
	decreased double-negative T cell number	J:186080
	decreased double-positive T cell number	J:186080
	decreased T cell proliferation	J:186080
	immune system phenotype	J:186080
\Prkci^tm1Rfar/\Prkci⁺ \Tg(Ckmm-cre)5Khn/? (involves: 129P2/OlaHsd * C57BL/6 * FVB)	increased susceptibility to autoimmune diabetes	J:123964
\Prkcq^m1Btlr/\Prkcq^m1Btlr (C57BL/6J-Prkcq^m1Btlr)	decreased IgG level	J:255214
\Prkcq^m1Btlr/\Prkcq^m1Btlr (C57BL/6J-Prkcq^m1Btlr)	impaired humoral immune response	J:255214
\Prkcq^m2Btlr/\Prkcq^m2Btlr (C57BL/6J-Prkcq^m2Btlr)	decreased IgG level	J:255216
\Prkcq^m2Btlr/\Prkcq^m2Btlr (C57BL/6J-Prkcq^m2Btlr)	impaired humoral immune response	J:255216
\Prkcq^tm1.1Bai/\Prkcq^tm1.1Bai (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell physiology	J:83733
	decreased interleukin-2 secretion	J:83733
	decreased T cell proliferation	J:83733
\Prkcq^tm1Litt/\Prkcq^tm1Litt (involves: 129P2/OlaHsd)	abnormal T cell activation	J:83922
	decreased interleukin-2 secretion	J:83922
	decreased T cell proliferation	J:83922, J:123989
	immune system phenotype	J:123989
\Prkcq^tm1Litt/\Prkcq^tm1Litt (B6.129P2-Prkcq^tm1Litt)	abnormal CD4-positive, alpha-beta T cell physiology	J:94285
	abnormal T-helper 1 cell differentiation	J:94285
	abnormal T-helper 2 physiology	J:94285
	decreased interferon-gamma secretion	J:129421, J:94285
	decreased interleukin-2 secretion	J:129421, J:94285
	decreased interleukin-4 secretion	J:129421, J:94285
	decreased interleukin-5 secretion	J:94285
	decreased interleukin-13 secretion	J:94285
	decreased interleukin-17 secretion	J:129421
	decreased splenocyte proliferation	J:129421
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:129421
	decreased T cell proliferation	J:94285
	immune system phenotype	J:94285
\Prkcq^tm1Litt/\Prkcq^tm1Litt (involves: 129P2/OlaHsd * C57BL/6)	abnormal effector T cell morphology	J:186080
	abnormal positive T cell selection	J:186080
	decreased CD4-positive, alpha-beta T cell number	J:186080
	decreased CD8-positive, alpha-beta T cell number	J:186080
	decreased DN1 thymic pro-T cell number	J:186080
	decreased NK T cell number	J:141128
	decreased T cell proliferation	J:186080
	immune system phenotype	J:141128
	increased T cell apoptosis	J:141128
\Prkcq^tm1Litt/\Prkcq^tm1Litt (either: (involves: 129/Sv * 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal response to infection	J:141930
	decreased T cell apoptosis	J:141930
	decreased T cell proliferation	J:141930
\Prkcq^tm1Litt/\Prkcq^tm1Litt \Tcra^tm1Mom/\Tcra^tm1Mom (involves: 129P2/OlaHsd * 129S2/SvPas)	decreased interleukin-4 secretion	J:135589
	decreased T cell proliferation	J:135589
	immune system phenotype	J:135589
\Prkcq^tm1Litt/\Prkcq^tm1Litt \Tg(DO11.10)10Dlo/0 (involves: 129 * BALB/c * C3H * C57BL/6)	decreased T cell apoptosis	J:141930
\Prkcq^tm1Litt/\Prkcq^tm1Litt \Tg(Lck-Notch3)#Issc/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	enlarged spleen	J:96010
	increased spleen weight	J:96010
\Prkcq^tm1Litt/\Prkcq^tm1Litt \Tg(LCKprBCL2L1)12Sjk/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased NK T cell number	J:141128
	immune system phenotype	J:141128
\Prkcq^tm1Litt/\Prkcq^tm1Litt \Tg(TcrLCMV)327Sdz/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal T cell anergy	J:123989
	decreased cytotoxic T cell cytolysis	J:123989
	decreased splenocyte proliferation	J:123989
	decreased T cell proliferation	J:123989
\Prkcz^tm1Jmos/\Prkcz^tm1Jmos (involves: 129P2/OlaHsd * 129/Sv)	abnormal Peyer's patch follicle morphology	J:72720
	abnormal Peyer's patch morphology	J:72720
	abnormal spleen marginal zone morphology	J:72720
	decreased B cell number	J:72720
	decreased spleen B cell follicle size	J:72720
	immune system phenotype	J:72720
	small Peyer's patches	J:72720
\Prkd1^{em2(IMPC)Wtsi}/\Prkd1⁺ (C57BL/6N-Prkd1^{em2(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Prkd2^{Gt(RRJ380)Byg}/\Prkd2^{Gt(RRJ380)Byg} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:166867
\Prkd2^tm1.1Daca/\Prkd2^tm1.1Daca (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:166867
	abnormal CD8-positive, alpha-beta T cell physiology	J:166867
	decreased IgG1 level	J:166867
	decreased IgM level	J:166867
	decreased interferon-gamma secretion	J:166867
	decreased interleukin-2 secretion	J:166867
	immune system phenotype	J:166867
\Prkd2^tm1.1Shoy/\Prkd2^tm1.1Shoy \Prkd3^tm1.1Shoy/\Prkd3^tm1.1Shoy \Tg(BCL2)25Wehi/0 \Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6 * C57BL/6JWehi * SJL/JWehi)	decreased thymocyte number	J:236298
\Prkd2^tm1.1Shoy/\Prkd2^tm1.1Shoy \Prkd3^tm1.1Shoy/\Prkd3^tm1.1Shoy \Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6)	decreased thymocyte number	J:236298
	small thymus medulla	J:236298
\Prkd2^tm1.1Shoy/\Prkd2^tm1.1Shoy \Prkd3^tm1.1Shoy/\Prkd3^tm1.1Shoy \Tg(Lck-cre)1Jtak/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6 * C57BL/6J * DBA/2J)	decreased thymocyte number	J:236298
	increased double-positive T cell number	J:236298
\Prkd2^tm1.1Shoy/\Prkd2^tm1.1Shoy \Prkd3^tm1.1Shoy/\Prkd3^tm1.1Shoy \Tg(Lck-cre)1Jtak/0 \Tg(TcraTcrb)425Cbn/0 (involves: 129 * BALB/c * C57BL/6)	decreased thymocyte number	J:236298
\Prkd2^tm1.1Shoy/\Prkd2^tm1.1Shoy \Prkd3^tm1.1Shoy/\Prkd3^tm1.1Shoy \Tg(Lck-cre)1Jtak/0 \Tg(TcraTcrb)1100Mjb/0 (involves: 129 * C57BL/6)	decreased thymocyte number	J:236298
\Prkd2^tm1.1Shoy/\Prkd2^tm1.1Shoy \Tg(Lck-cre)1Jtak/0 (involves: 129 * C57BL/6)	immune system phenotype	J:236298
\Prkdc^berty/\Prkdc^berty (C57BL/6JAnu-Prkdc^berty)	absent B cells	J:104190
\Prkdc^berty/\Prkdc^berty (C57BL/6JAnu-Prkdc^berty)	absent T cells	J:104190
\Prkdc^em2(IMPC)Ics/\Prkdc^em2(IMPC)Ics (C57BL/6N-Prkdc^em2(IMPC)Ics/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Prkdc^hanky/\Prkdc^hanky (either: C57BL/6JAnu or (involves: C57BL/6JAnu * CBA/CaJ))	cecum inflammation	J:104190
	colitis	J:104190
	decreased lymphocyte cell number	J:104190
	enlarged mesenteric lymph nodes	J:104190
	increased plasma cell number	J:104190
	interstitial pneumonia	J:104190
	liver inflammation	J:104190
	lymph node hyperplasia	J:104190
	myeloid hyperplasia	J:104190
\Prkdc^m1Anu/\Prkdc^m1Anu (C57BL/6JAnu-Prkdc^m1Anu)	abnormal lymphocyte morphology	J:104190
\Prkdc^m1Btlr/\Prkdc^m1Btlr (C57BL/6J-Prkdc^m1Btlr)	abnormal immune system physiology	J:178522
\Prkdc^m1Btlr/\Prkdc^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
\Prkdc^m2Btlr/\Prkdc^m2Btlr (C57BL/6J-Prkdc^m2Btlr)	abnormal B cell physiology	J:204502
	decreased B cell number	J:204502
	decreased CD4-positive, alpha-beta T cell number	J:204502
	decreased CD8-positive, alpha-beta T cell number	J:204502
	decreased IgG level	J:204502
	decreased IgM level	J:204502
\Prkdc^m3Btlr/\Prkdc^m3Btlr (C57BL/6J-Prkdc^m3Btlr)	decreased IgG level	J:224665
\Prkdc^m3Btlr/\Prkdc^m3Btlr (C57BL/6J-Prkdc^m3Btlr)	impaired humoral immune response	J:224665
\Prkdc^m4Btlr/\Prkdc^m4Btlr (C57BL/6J-Prkdc^m4Btlr)	decreased B cell number	J:255217
	increased B-1b cell number	J:255217
	increased neutrophil cell number	J:255217
\Prkdc^m5Btlr/\Prkdc^m5Btlr (C57BL/6J-Prkdc^m5Btlr)	increased alpha-beta T cell number	J:255220
\Prkdc^m5Btlr/\Prkdc^m5Btlr (C57BL/6J-Prkdc^m5Btlr)	increased CD4-positive, alpha-beta T cell number	J:255220
\Prkdc^m6Btlr/\Prkdc^m6Btlr (C57BL/6J-Prkdc^m6Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:255221
	increased alpha-beta T cell number	J:255221
	increased CD4-positive, alpha-beta T cell number	J:255221
	increased CD8-positive, alpha-beta T cell number	J:255221
\Prkdc^m7Btlr/\Prkdc^m7Btlr (C57BL/6J-Prkdc^m7Btlr)	abnormal humoral immune response	J:255223
	decreased IgG level	J:255223
	increased effector memory CD4-positive, alpha-beta T cell number	J:255223
\Prkdc^M8Btlr/\Prkdc⁺ (C57BL/6J-Prkdc^M8Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255224
\Prkdc^M8Btlr/\Prkdc^M8Btlr (C57BL/6J-Prkdc^M8Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255224
	increased CD4-positive, alpha-beta T cell number	J:255224
	increased plasmacytoid dendritic cell number	J:255224
\Prkdc^M9Btlr/\Prkdc⁺ (C57BL/6J-Prkdc^M9Btlr)	decreased B-1a cell number	J:255268
	decreased effector memory CD4-positive, alpha-beta T cell number	J:255268
	increased B cell number	J:255268
	increased B-1b cell number	J:255268
\Prkdc^M9Btlr/\Prkdc^M9Btlr (C57BL/6J-Prkdc^M9Btlr)	decreased B-1a cell number	J:255268
	decreased effector memory CD4-positive, alpha-beta T cell number	J:255268
	increased B cell number	J:255268
	increased B-1b cell number	J:255268
\Prkdc^M10Btlr/\Prkdc⁺ (C57BL/6J-Prkdc^M10Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255269
\Prkdc^M10Btlr/\Prkdc^M10Btlr (C57BL/6J-Prkdc^M10Btlr)	decreased CD8-positive, alpha-beta T cell number	J:255269
\Prkdc^M11Btlr/\Prkdc⁺ (C57BL/6J-Prkdc^M11Btlr)	enhanced humoral immune response	J:255270
\Prkdc^M11Btlr/\Prkdc⁺ (C57BL/6J-Prkdc^M11Btlr)	increased IgM level	J:255270
\Prkdc^M11Btlr/\Prkdc^M11Btlr (C57BL/6J-Prkdc^M11Btlr)	enhanced humoral immune response	J:255270
\Prkdc^M11Btlr/\Prkdc^M11Btlr (C57BL/6J-Prkdc^M11Btlr)	increased IgM level	J:255270
\Prkdc^m12Btlr/\Prkdc^m12Btlr (C57BL/6J-Prkdc^m12Btlr)	decreased B cell number	J:264708
	decreased B-1 B cell number	J:264708
	decreased CD4-positive, alpha-beta T cell number	J:264708
	decreased CD8-positive, alpha-beta T cell number	J:264708
	decreased CD8-positive, naive alpha-beta T cell number	J:264708
	decreased NK T cell number	J:264708
	decreased single-positive T cell number	J:264708
	decreased T cell number	J:264708
	increased central memory CD4-positive, alpha-beta T cell number	J:264708
	increased central memory CD8 positive, alpha-beta T cell number	J:264708
	increased effector memory CD4-positive, alpha-beta T cell number	J:264708
	increased NK cell number	J:264708
\Prkdc^m13Btlr/\Prkdc^m13Btlr (C57BL/6J-Prkdc^m13Btlr)	increased effector memory CD4-positive, alpha-beta T cell number	J:272441
\Prkdc^m14Btlr/\Prkdc^m14Btlr (C57BL/6J-Prkdc^m14Btlr)	abnormal CD4-positive T cell differentiation	J:272442
\Prkdc^M15Btlr/\Prkdc^M15Btlr (C57BL/6J-Prkdc^M15Btlr)	decreased B-1 B cell number	J:272445
\Prkdc^M16Btlr/\Prkdc^M16Btlr (C57BL/6J-Prkdc^M16Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272520
\Prkdc^m17Btlr/\Prkdc^m17Btlr (C57BL/6J-Prkdc^m17Btlr)	increased plasmacytoid dendritic cell number	J:272521
\Prkdc^m18Btlr/\Prkdc^m18Btlr (C57BL/6J-Prkdc^m18Btlr)	abnormal B cell differentiation	J:274730
	abnormal CD4-positive T cell differentiation	J:274730
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274730
	abnormal T cell differentiation	J:274730
	decreased alpha-beta T cell number	J:274730
	decreased B cell number	J:274730
	decreased B-1 B cell number	J:274730
	decreased CD4-positive, alpha-beta T cell number	J:274730
	decreased CD8-positive, alpha-beta T cell number	J:274730
	decreased CD8-positive, naive alpha-beta T cell number	J:274730
	increased CD4-positive, alpha-beta T cell number	J:274730
	increased CD8-positive, alpha-beta T cell number	J:274730
	increased central memory CD4-positive, alpha-beta T cell number	J:274730
	increased central memory CD8 positive, alpha-beta T cell number	J:274730
	increased effector memory CD4-positive, alpha-beta T cell number	J:274730
	increased effector memory CD8-positive, alpha-beta T cell number	J:274730
	increased T cell number	J:274730
\Prkdc^m19Btlr/\Prkdc^m19Btlr (C57BL/6J-Prkdc^m19Btlr)	abnormal B cell differentiation	J:274763
	abnormal CD4-positive T cell differentiation	J:274763
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274763
	abnormal T cell differentiation	J:274763
	decreased B cell number	J:274763
	decreased B-1 B cell number	J:274763
	decreased CD4-positive, alpha-beta T cell number	J:274763
	decreased CD8-positive, alpha-beta T cell number	J:274763
	decreased CD8-positive, naive alpha-beta T cell number	J:274763
	decreased T cell number	J:274763
	increased central memory CD4-positive, alpha-beta T cell number	J:274763
	increased central memory CD8 positive, alpha-beta T cell number	J:274763
	increased effector memory CD4-positive, alpha-beta T cell number	J:274763
	increased effector memory CD8-positive, alpha-beta T cell number	J:274763
	increased NK cell number	J:274763
\Prkdc^scid/\Prkdc^scid (C.BKa-Prkdc^scid)	abnormal humoral immune response	J:6958
	abnormal response to transplant	J:22026
	abnormal spleen white pulp morphology	J:6958
	abnormal thymus morphology	J:6958
	absent B cells	J:6958
	absent Peyer's patches	J:6958
	absent pre-B cells	J:6958
	absent thymus cortex	J:6958
	decreased B cell proliferation	J:6958
	decreased IgG level	J:6958
	decreased immunoglobulin level	J:6958, J:22026
	decreased leukocyte cell number	J:6958
	decreased T cell proliferation	J:6958
	immune system phenotype	J:22026
	increased length of allograft survival	J:6958, J:22026
	increased T cell derived lymphoma incidence	J:6958
	lymph node hypoplasia	J:6958
	lymphoid hypoplasia	J:6958
	salivary gland inflammation	J:21965
	small lymphoid organs	J:6958
	small thymus	J:6958
	thymus cyst	J:6958
\Prkdc^scid/\Prkdc^scid (NOD.Cg-Prkdc^scid)	abnormal lymph node morphology	J:109833, J:22026
	abnormal response to transplant	J:109833, J:22026
	abnormal spleen white pulp morphology	J:109833, J:22026
	abnormal thymus corticomedullary boundary morphology	J:22026
	abnormal thymus lobule morphology	J:22026
	decreased B cell number	J:22026
	decreased CD4-positive, alpha-beta T cell number	J:109833, J:22026
	decreased CD8-positive, alpha-beta T cell number	J:109833, J:22026
	decreased immunoglobulin level	J:22026
	decreased level of surface class I molecules	J:22026
	decreased lymphocyte cell number	J:22026
	decreased mature B cell number	J:109833
	decreased NK cell number	J:22026
	decreased pre-B cell number	J:22026
	decreased T cell number	J:22026
	impaired complement classical pathway	J:22026
	impaired natural killer cell mediated cytotoxicity	J:22026
	increased granulocyte number	J:22026
	increased length of allograft survival	J:22026
	increased macrophage cell number	J:22026
	increased T cell derived lymphoma incidence	J:109833, J:22026
	spleen hypoplasia	J:109833, J:22026
	thymus cyst	J:22026
\Prkdc^scid/\Prkdc^scid (B6.Cg-Prkdc^scid/Sz)	abnormal complement pathway	J:34814, J:22026
	abnormal level of surface class II molecules	J:34814
	abnormal lymph node B cell domain morphology	J:34814
	abnormal NK cell physiology	J:34814
	abnormal Peyer's patch morphology	J:34814
	abnormal spleen white pulp morphology	J:34814
	abnormal thymus morphology	J:34814
	decreased B cell number	J:34814
	decreased CD4-positive, alpha-beta T cell number	J:34814
	decreased CD8-positive, alpha-beta T cell number	J:34814
	decreased immunoglobulin level	J:34814
	decreased lymphocyte cell number	J:34814
	decreased pre-B cell number	J:34814
	decreased T cell number	J:34814
	increased eosinophil cell number	J:34814
	increased granulocyte number	J:34814
	increased macrophage cell number	J:34814
	increased monocyte cell number	J:34814
	increased neutrophil cell number	J:34814
	increased NK cell number	J:34814
	small Peyer's patches	J:34814
	small thymus	J:34814
	spleen hypoplasia	J:34814
	stomach inflammation	J:120556
	thymus cyst	J:34814
\Prkdc^scid/\Prkdc^scid (NOD.Cg-Prkdc^scid/J)	abnormal response to transplant	J:91764
\Prkdc^scid/\Prkdc^scid (involves: BALB/c * C57BL/6 * C57BL/Ka)	abnormal NK cell physiology	J:115033
\Prkdc^scid/\Prkdc^scid \Mcph1^{Tg(HLA-A2.1)1Enge}/\Mcph1⁺ (NOD.Cg-Mcph1^{Tg(HLA-A2.1)1Enge} Prkdc^scid/Dvs)	abnormal splenocyte morphology	J:91764
\Prkdc^scid/\Prkdc^scid \Rasa3^scat/\Rasa3^scat (involves: BALB/c * BALB/cBy * C57BL)	abnormal immune system morphology	J:186485
\Prkdc^scid/\Prkdc^scid \Sst1^C57BL/6J/\Sst1^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:93705
\Prkdc^scid/\Prkdc^scid \Tg(B2M)55Hpl/0 \Mcph1^{Tg(HLA-A2.1)1Enge}/\Mcph1⁺ (NOD.Cg-Mcph1^{Tg(HLA-A2.1)1Enge} Prkdc^scid Tg(B2M)55Hpl/Sz)	abnormal response to transplant	J:91764
\Prkdc^scid/\Prkdc^scid \Tg(CSF2)2Ygy/0 \Tg(IL3)1Ygy/0 (CB17.Cg-Prkdc^scid Tg(CSF2)2Ygy Tg(IL3)1Ygy)	abnormal response to transplant	J:94302
\Prkdc^scid/\Prkdc^scid \Tg(CSF2)2Ygy/0 \Tg(IL3)1Ygy/0 \Tg(KITLG)3Ygy/0 (CB17.Cg-Prkdc^scid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)	abnormal response to transplant	J:106416, J:94302
\Prkdc^scid/\Prkdc^scid \Tg(CSF2)2Ygy/0 \Tg(IL3)1Ygy/0 \Tg(KITLG)3Ygy/0 (NOD.Cg-Prkdc^scid Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)	abnormal response to transplant	J:107052
	decreased susceptibility to graft versus host disease	J:107052
\Prkdc^scid/\Prkdc^scid \Tg(HLA-DRA0101,HLA-DRB10101)1Dmz/\Tg(HLA-DRA0101,HLA-DRB10101)1Dmz (NOD.Cg-Tg(HLA-DRA0101,HLA-DRB10101)1Dmz Prkdc^scid/Gck)	abnormal professional antigen presenting cell morphology	J:126700
	absent T cells	J:126700
\Prkdc^scid/\Prkdc^scid \Tg(Ins2-Fasl)24Ach/0 (NOD.Cg-Prkdc^scid Tg(Ins2-Fasl)24Ach)	decreased susceptibility to autoimmune diabetes	J:81416
	increased susceptibility to autoimmune diabetes	J:81416
\Prkdc^scid/\Prkdc^scid \Tg(INS-Il10)#Sar/0 (NOD.Cg-Prkdc^scid Tg(INS-Il10)#Sar)	increased susceptibility to autoimmune diabetes	J:66103
\Prkdc^scid/\Prkdc^scid \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0 (NOD.Cg-Prkdc^scid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
	increased susceptibility to autoimmune diabetes	J:93553
\Prkdc^scid/\Prkdc^scid \Tg(Tcrb)93Vbo/0 (involves: Balb/c * C57BL/Ka * C57BL/Lia * CBA/BrA)	abnormal CD4-positive, alpha beta T cell morphology	J:111476
	abnormal CD8-positive, alpha beta T cell morphology	J:111476
	abnormal double-positive T cell morphology	J:111476
	abnormal single-positive T cell number	J:111476
	abnormal T cell differentiation	J:111476
\Prkdc^scid/\Prkdc^scid \Tg(TcrLCMV)327Sdz/? (NOD.Cg-Emv30^b Prkdc^scid Tg(TcrLCMV)327Sdz/DvsJ)	immune system phenotype	J:71050
\Prkdc^scid/\Prkdc^scid \Tgfb1^tm1Doe/\Tgfb1^tm1Doe (involves: 129 * C3H * CF-1)	decreased spleen weight	J:129629
\Prkdc^{Tg(INS-PDE2)5-1Lmb}/? (involves: FVB/N)	abnormal thymus morphology	J:108405
\Prkdc^tm1.1Bpcc/\Prkdc^tm1.1Bpcc (involves: 129 * C57BL/6)	abnormal immunoglobulin V(D)J recombination	J:171351
	arrested B cell differentiation	J:171351
	decreased CD4-positive, alpha-beta T cell number	J:171351
	decreased CD8-positive, alpha-beta T cell number	J:171351
	decreased double-negative T cell number	J:171351
	decreased double-positive T cell number	J:171351
	decreased gamma-delta T cell number	J:171351
	decreased granulocyte number	J:171351
	decreased leukocyte cell number	J:171351
	decreased lymphocyte cell number	J:171351
	decreased macrophage cell number	J:171351
	decreased mature B cell number	J:171351
	decreased T cell number	J:171351
	small lymphoid organs	J:171351
\Prkdc^tm1Fwa/\Prkdc^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	abnormal T cell receptor beta chain V(D)J recombination	J:50221
	abnormal T cell receptor V(D)J recombination	J:50221
	absent pre-B cells	J:50221
	arrested B cell differentiation	J:50221
	arrested T cell differentiation	J:50221
	decreased double-positive T cell number	J:50221
	decreased thymocyte number	J:50221
\Prkdc^tm1Fwa/\Prkdc^tm1Fwa (involves: 129S6/SvEvTac)	decreased splenocyte number	J:306598
\Prkdc^tm1Gcl/\Prkdc^tm1Gcl (involves: 129S1/Sv * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:53765
	abnormal lymph node morphology	J:53765
	abnormal spleen morphology	J:53765
	abnormal T cell receptor beta chain V(D)J recombination	J:53765
	abnormal T cell receptor delta chain V(D)J recombination	J:53765
	absent mature B cells	J:53765
	absent Peyer's patches	J:53765
	absent thymus corticomedullary boundary	J:53765
	arrested B cell differentiation	J:53765
	increased T cell derived lymphoma incidence	J:53765
	small lymph nodes	J:53765
	small Peyer's patches	J:53765
	small spleen	J:53765
	small thymus	J:53765
	thymus hypoplasia	J:53765
\Prkdc^tm1Gcl/\Prkdc^tm1Gcl (involves: 129S1/Sv)	decreased thymocyte apoptosis	J:126920
\Prkdc^tm1Get/\Prkdc^tm1Get (involves: 129S4/SvJae * Black Swiss)	abnormal B cell differentiation	J:50222
	abnormal immunoglobulin heavy chain V(D)J recombination	J:50222
	abnormal immunoglobulin light chain V-J recombination	J:50222
	abnormal T cell differentiation	J:50222
	abnormal T cell number	J:50222
	abnormal T cell receptor alpha chain V-J recombination	J:50222
	abnormal T cell receptor beta chain V(D)J recombination	J:50222
	abnormal T cell receptor delta chain V(D)J recombination	J:50222
	abnormal thymus corticomedullary boundary morphology	J:50222
	arrested B cell differentiation	J:50222
	arrested T cell differentiation	J:50222
	decreased IgM level	J:50222
	decreased single-positive T cell number	J:50222
	decreased spleen white pulp amount	J:50222
	increased double-negative T cell number	J:50222
	increased double-positive T cell number	J:50222
	increased NK cell number	J:50222
	small lymph nodes	J:50222
	spleen hypoplasia	J:50222
	thymus hypoplasia	J:50222
\Prkg1^{tm1b(KOMP)Wtsi}/\Prkg1^{tm1b(KOMP)Wtsi} (C57BL/6N-Prkg1^{tm1b(KOMP)Wtsi}/H)	enlarged spleen	J:211773
\Prkg1^tm2.1Naw/\Prkg1^tm2.1Naw (involves: 129S1/Sv * 129X1/SvJ)	enlarged spleen	J:134639
\Prl7d1^em1(IMPC)Tcp/\Prl7d1^em1(IMPC)Tcp (C57BL/6NCrl-Prl7d1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Prl7d1^em1Liga/\Prl7d1^em1Liga (involves: C57BL/6)	increased uterine NK cell number	J:288761
\Prl^tm1Hmn/\Prl^tm1Hmn (involves: 129S2/SvPas)	immune system phenotype	J:45243
\Prmt3^{tm1a(EUCOMM)Wtsi}/\Prmt3^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased CD4-positive, alpha-beta T cell number	J:213427
	increased CD8-positive, alpha-beta T cell number	J:213427
	increased incidence of corneal inflammation	J:213427
	increased T cell number	J:213427
\Prmt7^{tm1a(EUCOMM)Wtsi}/\Prmt7^{tm1a(EUCOMM)Wtsi} (B6JTyr;B6N-Prmt7^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus topology	J:239583
	blood in lymph vessels	J:239583
\Prmt9^em1Cya/\Prmt9^em1Cya \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	decreased susceptibility to viral infection	J:328263
	increased circulating interferon-beta level	J:328263
	increased interferon-beta secretion	J:328263
\Prnp/Prnd^tm1Aag/\Prnp/Prnd^tm1Aag (Not Specified)	immune system phenotype	J:89232
\Prnp/Prnd^tm1Aag/\Prnp/Prnd^tm1Aag (Not Specified)	immune system phenotype	J:89232
\Prnp^a/\Prnp^a (NZW)	increased susceptibility to prion infection	J:8918
\Prnp^b/\Prnp^b (I/LnJ)	decreased susceptibility to prion infection	J:8918
\Prnp^c/\Prnp^c (MAI/Pas)	decreased susceptibility to prion infection	J:90099
\Prnp^{em2.1(PrnpD178N)Jwat}/\Prnp^{em2.1(PrnpD178N)Jwat} (involves: 129S4/SvJae * C57BL/6)	dermatitis	J:361333
\Prnp^{em3.1(PrnpE200K)Jwat}/\Prnp^{em3.1(PrnpE200K)Jwat} (involves: 129S4/SvJae * C57BL/6)	dermatitis	J:361333
\Prnp^{tm1(PRNP)Tkit}/\Prnp^{tm1(PRNP)Tkit} (Not Specified)	decreased susceptibility to prion infection	J:86603
\Prnp^{tm1(PRNP)Tkit}/\Prnp^{tm1(PRNP)Tkit} (Not Specified)	increased susceptibility to prion infection	J:86603
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Lck-Prnp)33Cwe/0 (involves: 129S7/SvEvBrd * C57BL/6)	increased CD8-positive, alpha-beta T cell number	J:129512
	increased gamma-delta T cell number	J:129512
	thymus hypoplasia	J:129512
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Nefh-cre)22Jcol/? \Tg(Prnp)37Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	decreased susceptibility to prion infection	J:126424
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Nefh-cre)22Jcol/? \Tg(Prnp)46Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	decreased susceptibility to prion infection	J:74652
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(PRNP)35Jcol/\Tg(PRNP)35Jcol (involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)	increased susceptibility to prion infection	J:131494
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Prnp)37Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	increased susceptibility to prion infection	J:74652, J:126424
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(PRNP)45Jcol/\Tg(PRNP)45Jcol (involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N)	increased susceptibility to prion infection	J:131494
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Prnp)46Jcol/? (involves: 129/Sv * 129S7/SvEvBrd * C57BL/6 * FVB)	immune system phenotype	J:74652
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Prnp)4053Sbp/0 (involves: 129S7/SvEvBrd * FVB/N)	increased susceptibility to prion infection	J:136434
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(PRNP)23454Sbp/0 (involves: 129S7/SvEvBrd * FVB/N)	increased susceptibility to prion infection	J:236012
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Prnp)a19Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:32214
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Prnp)a20Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:32214
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Prnp)a20Cwe/0 (involves: 129S7/SvEvBrd * C57BL/6)	abnormal B cell morphology	J:129512
	abnormal T cell differentiation	J:129512
	decreased CD4-positive, alpha-beta T cell number	J:129512
	decreased CD8-positive, alpha-beta T cell number	J:129512
	decreased DN2 thymocyte number	J:129512
	decreased DN4 thymocyte number	J:129512
	decreased double-positive T cell number	J:129512
	decreased thymocyte number	J:129512
	increased DN3 thymocyte number	J:129512
	increased double-negative T cell number	J:129512
	increased gamma-delta T cell number	J:129512
	thymus atrophy	J:129512
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(Prnp)c35Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:32214
\Prnp^tm1Cwe/\Prnp^tm1Cwe \Tg(PrnpS170NN174T)1020Aag/0 (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to prion infection	J:143528
	microgliosis	J:143528
\Prnp^tm1Edin/\Prnp^tm1Edin (129P2/OlaHsd-Prnp^tm1Edin/EdinH)	abnormal susceptibility to prion infection	J:58820
\Prnp^tm1Lnq/\Prnp^tm1Lnq (involves: 129P2/OlaHsd * C57BL/6N)	decreased susceptibility to prion infection	J:154937
\Prnp^tm1Miy/\Prnp^tm1Miy (involves: 129S4/SvJae * C57BL/6)	decreased susceptibility to prion infection	J:69186
\Prnp^tm1Rcm/\Prnp^tm1Rcm (129P2/OlaHsd-Prnp^tm1Rcm)	abnormal susceptibility to prion infection	J:45908
\Prnp^tm1Tuzi/\Prnp⁺ (involves: 129P2/OlaHsd)	decreased susceptibility to prion infection	J:92302
\Prnp^tm1Tuzi/\Prnp⁺ \Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	immune system phenotype	J:92302
\Prnp^tm1Tuzi/\Prnp^tm2Edin (involves: 129P2/OlaHsd)	decreased susceptibility to prion infection	J:92302
\Prnp^tm1Tuzi/\Prnp^tm2Edin \Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	decreased susceptibility to prion infection	J:92302
\Prnp^{tm2(PRNP129M)Tkit}/\Prnp^{tm2(PRNP129M)Tkit} (Not Specified)	decreased susceptibility to prion infection	J:126777, J:105882
	increased susceptibility to prion infection	J:126777, J:105882
\Prnp^{tm2(PRNP129M)Tkit}/\Prnp^{tm2(PRNP129M)Tkit} \Tg(Prnp-PRNP*129M)1Tkit/? (Not Specified)	decreased susceptibility to prion infection	J:126777
	increased susceptibility to prion infection	J:126777
\Prnp^{tm2(PRNP129M)Tkit}/\Prnp^{tm3(PRNP129V)Tkit} (Not Specified)	decreased susceptibility to prion infection	J:105882
\Prnp^tm2Lnq/\Prnp^tm2Lnq (involves: 129P2/OlaHsd * C57BL/6N)	immune system phenotype	J:154937
\Prnp^tm2Tuzi/\Prnp⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:92302
\Prnp^tm2Tuzi/\Prnp⁺ \Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	decreased susceptibility to prion infection	J:92302
\Prnp^tm2Tuzi/\Prnp^tm2Edin (involves: 129P2/OlaHsd)	decreased susceptibility to prion infection	J:92302
\Prnp^tm2Tuzi/\Prnp^tm2Edin \Tg(CMV-cre)1Cgn/? (involves: 129P2/OlaHsd * BALB/cJ)	decreased susceptibility to prion infection	J:92302
\Prnp^{tm3(PRNP129V)Tkit}/\Prnp^{tm3(PRNP129V)Tkit} (Not Specified)	abnormal spleen morphology	J:126777
	decreased susceptibility to prion infection	J:126777, J:105882
	increased susceptibility to prion infection	J:126777
\Prnp^{tm3(PRNP129V)Tkit}/\Prnp^{tm3(PRNP129V)Tkit} \Tg(Prnp-PRNP*129V)139Tkit/? (Not Specified)	abnormal susceptibility to infection	J:126777
	decreased susceptibility to prion infection	J:105882
\Prnp^{tm3(PRNP129V)Tkit}/\Prnp^{tm3(PRNP129V)Tkit} \Tg(Prnp-PRNP*129V)144Tkit/? (Not Specified)	decreased susceptibility to prion infection	J:105882
\Prnp^{tm4(PRNP)Tkit}/\Prnp^{tm4(PRNP)Tkit} (Not Specified)	increased susceptibility to prion infection	J:105882
\Prnp^{tm4(PRNP)Tkit}/\Prnp^{tm4(PRNP)Tkit} \Tg(Prnp-PRNP)32Tkit/? (Not Specified)	increased susceptibility to prion infection	J:105882
\Prnp^{tm5(PRNP)TKit}/\Prnp^{tm5(PRNP)TKit} (Not Specified)	immune system phenotype	J:126777
\Prnp^{tm5(PRNP)TKit}/\Prnp^{tm5(PRNP)TKit} \Tg(Prnp-PRNP*)1Tkit/? (Not Specified)	decreased susceptibility to prion infection	J:126777
	increased susceptibility to prion infection	J:126777
\Prnr1^RIII/FaDk/\Prnr1^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:89558
\Prnr2^C57BL/FaDk/\Prnr2^C57BL/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:89558
\Prnr2^C57BL/FaDk/\Prnr2^RIII/FaDk (involves: C57BL/FaDk * RIII/FaDk)	decreased susceptibility to prion infection	J:89558
\Proc^tm1Fjc/\Proc^tm1Fjc (involves: 129S1/Sv * 129X1/SvJ * Swiss)	abnormal innate immunity	J:50527
	liver inflammation	J:50527
\Procr^tm1.1Pcl/\Procr^tm1.1Pcl (involves: 129S2/SvPas * C57BL/6)	bone marrow failure	J:225914
	enlarged spleen	J:225914
	increased circulating interleukin-6 level	J:225914
	increased spleen red pulp amount	J:225914
	increased spleen weight	J:225914
	increased splenocyte number	J:225914
	increased susceptibility to endotoxin shock	J:225914
\Proser2^{em1(IMPC)Ccpcz}/\Proser2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Proser2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Prox1^tm1Gco/\Prox1⁺ (involves: 129S1/Sv * 129X1/SvJ * NMRI)	abnormal lymph circulation	J:102652, J:57646
	abnormal lymphatic vessel morphology	J:102652
	increased inflammatory response	J:102652
	increased macrophage cell number	J:102652
\Prox1^tm1Gco/\Prox1⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymph circulation	J:57646
\Prox1^tm1Gco/\Prox1^tm1Gco (involves: 129S1/Sv * 129X1/SvJ * NMRI)	abnormal lymph organ development	J:57646
\Prox1^tm1Gco/\Prox1^tm2Gco \Tg(Tek-cre)1Ywa/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	absent lymphatic vessels	J:125507
\Prox1^tm1Gco/\Prox1^{tm5(GFP/cre)Gco} (involves: 129S1/Sv * 129X1/SvJ * NMRI)	decreased lymphatic vessel endothelial cell number	J:158959
\Prox1^tm2Gco/\Prox1⁺ \Tg(Tek-cre)1Ywa/0 (involves: 129S1/Sv * C57BL/6 * NMRI * SJL)	abnormal lymph circulation	J:102652
	abnormal lymphatic vessel morphology	J:102652
\Prox1^tm4.1Gco/\Prox1^tm4.1Gco (involves: 129S1/Sv * C57BL/10 * CBA/Ca)	decreased lymphatic vessel endothelial cell number	J:158959
\Prpf3^{tm1b(KOMP)Wtsi}/\Prpf3⁺ (C57BL/6N-Prpf3^{tm1b(KOMP)Wtsi}/Bay)	increased neutrophil cell number	J:211773
\Prph2^em1Sal/\Prph2⁺ (C57BL/6J-Prph2^em1Sal)	eye inflammation	J:342243
\Prph2^em1Sal/\Prph2^em1Sal (C57BL/6J-Prph2^em1Sal)	eye inflammation	J:342243
\Prph2^em1Sal/\Prph2^em1Sal (C57BL/6J-Prph2^em1Sal)	increased microglial cell activation	J:342243
\Prph2^Rd2/\Prph2^Rd2 (O20/A-Prph2^Rd2)	abnormal macrophage morphology	J:6432
\Prps1^{tm1b(EUCOMM)Wtsi}/\Prps1⁺ (C57BL/6N-Prps1^{tm1b(EUCOMM)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Prps2^{tm1a(KOMP)Wtsi}/Y (involves: C57BL/6N)	abnormal B cell physiology	J:214383
\Prps2^{tm1a(KOMP)Wtsi}/Y \Tg(IghMyc)22Bri/0 (involves: C57BL/6N * SJL)	abnormal B cell physiology	J:214383
	increased B cell apoptosis	J:214383
\Prr7^{tm1(KOMP)Vlcg}/\Prr7^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased CD4-positive, alpha-beta T cell number	J:237776
	immune system phenotype	J:237776
\Prr27^{tm1b(KOMP)Wtsi}/\Prr27^{tm1b(KOMP)Wtsi} (C57BL/6N-Prr27^{tm1b(KOMP)Wtsi}/Bay)	increased leukocyte cell number	J:211773
\Prr30^em1(IMPC)J/\Prr30^em1(IMPC)J (C57BL/6NJ-Prr30^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Prrg4^em1(IMPC)Mbp/\Prrg4^em1(IMPC)Mbp (C57BL/6NCrl-Prrg4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Prss3b^tm1.1Satom/\Prss3b⁺ (B6(FVB)-Prss3b^tm1.1Satom)	acute pancreas inflammation	J:267764
\Prss3b^tm1.1Satom/\Prss3b⁺ (B6(FVB)-Prss3b^tm1.1Satom)	chronic pancreas inflammation	J:267764
\Prss8^tm1.1Hum/\Prss8^tm1.2Hum \Tg(KRT14-cre)1Ipc/0 (involves: 129/Sv * C57BL/6 * FVB/N * SJL)	thymus medulla hypoplasia	J:100139
\Prss12^{em1(IMPC)Ccpcz}/\Prss12^{em1(IMPC)Ccpcz} (C57BL/6N-Prss12^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Prss16^tm1.1Mal/\Prss16⁺ \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraH-Y,TcrbH-Y)1Pas/? (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal positive T cell selection	J:148034
	decreased CD4-positive, alpha-beta T cell number	J:148034
	decreased single-positive T cell number	J:148034
	lymph node hypoplasia	J:148034
\Prss16^tm1.1Mal/\Prss16^tm1.1Mal (involves: 129S2/SvPas * C57BL/6)	abnormal professional antigen presenting cell morphology	J:148034
	abnormal thymus cortex morphology	J:148034
\Prss16^tm1.1Mal/\Prss16^tm1.1Mal \Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraH-Y,TcrbH-Y)1Pas/? (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	abnormal positive T cell selection	J:148034
	decreased CD4-positive, alpha-beta T cell number	J:148034
	decreased double-positive T cell number	J:148034
	decreased single-positive T cell number	J:148034
	lymph node hypoplasia	J:148034
	spleen hypoplasia	J:148034
	thymus hypoplasia	J:148034
\Prss16^tm1Cbo/\Prss16^tm1Cbo (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:94751
\Prss21^{em1(IMPC)Ccpcz}/\Prss21⁺ (C57BL/6N-Prss21^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Prss27^{tm1.1(NCOM)Mfgc}/\Prss27^{tm1.1(NCOM)Mfgc} (C57BL/6N-Prss27^{tm1.1(NCOM)Mfgc}/Tcp)	decreased monocyte cell number	J:211773
\Prss33^{em1(IMPC)Ccpcz}/\Prss33^{em1(IMPC)Ccpcz} (C57BL/6N-Prss33^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	small spleen	J:211773
\Prss34^tm1.1Hkar/\Prss34^tm1.1Hkar (involves: C57BL/6)	decreased inflammatory response	J:238924
\Prss34^tm1.1Hkar/\Prss34^tm1.1Hkar (involves: C57BL/6)	immune system phenotype	J:238924
\Prss35^{em1(IMPC)Ccpcz}/\Prss35^{em1(IMPC)Ccpcz} (C57BL/6N-Prss35^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Prss47^{em1(IMPC)Ccpcz}/\Prss47^{em1(IMPC)Ccpcz} (C57BL/6N-Prss47^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Prss48^{em1(IMPC)Ccpcz}/\Prss48^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Prss48^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Prss50^{tm1a(EUCOMM)Hmgu}/\Prss50^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Prss50^{tm1a(EUCOMM)Hmgu}/H)	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
\Prss53^{em3(IMPC)Wtsi}/\Prss53^{em3(IMPC)Wtsi} (C57BL/6N-Prss53^{em3(IMPC)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Prss54^{em1(IMPC)Ccpcz}/\Prss54^{em1(IMPC)Ccpcz} (C57BL/6N-Prss54^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
\Prss55^{em1(IMPC)Ccpcz}/\Prss55^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Prss55^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Prss56^em1(IMPC)J/\Prss56^em1(IMPC)J (C57BL/6NJ-Prss56^em1(IMPC)J/J)	decreased leukocyte cell number	J:211773
\Prss57^{em1(IMPC)Ccpcz}/\Prss57^{em1(IMPC)Ccpcz} (C57BL/6N-Prss57^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased NK T cell number	J:211773
	enlarged thymus	J:211773
\Prss57^tm1.1Gne/\Prss57^tm1.1Gne (C57BL/6N-Prss57^tm1.1Gne)	abnormal mast cell morphology	J:301479
	abnormal mast cell physiology	J:301479
	decreased mast cell histamine storage	J:301479
\Prss57^tm1Lex/\Prss57^tm1Lex (involves: 129S5/SvEvBrd)	abnormal mast cell physiology	J:301479
\Prtn3^tm1.1Hrlu/\Prtn3^tm1.1Hrlu (involves: C57BL/6)	abnormal neutrophil physiology	J:217636
\Prtn3^tm1.1Hrlu/\Prtn3^tm1.1Hrlu (involves: C57BL/6)	increased neutrophil cell number	J:217636
\Prxl2a^{tm1(KOMP)Vlcg}/\Prxl2a^{tm1(KOMP)Vlcg} (C57BL/6N-Prxl2a^{tm1(KOMP)Vlcg})	white adipose tissue inflammation	J:234040
\Psap^tm1Ggb/\Psap^tm1Ggb (involves: 129S/SvEv * C57BL/6J)	abnormal microglial cell physiology	J:121761
\Psap^tm1Ggb/\Psap^tm1Ggb (involves: 129S/SvEv * C57BL/6J)	dark spleen	J:121761
\Psap^tm1Juma/\Psap^tm1Juma (FVB.129S-Psap^tm1Juma)	abnormal microglial cell physiology	J:121761
\Psap^tm1Suz/\Psap^tm1Suz (involves: 129P2/OlaHsd)	abnormal macrophage morphology	J:113052
\Psap^tm1Suz/\Psap^tm1Suz (involves: 129P2/OlaHsd)	decreased spleen weight	J:106511
\Psap^tm2Ggb/\Psap^tm2Ggb (involves: 129S/SvEv * C57BL/6J)	CNS inflammation	J:137650
	kidney inflammation	J:137650
	microgliosis	J:198242
\Psap^tm2Suz/\Psap^tm2Suz (involves: 129S/SvEv * C57BL/6J)	abnormal macrophage morphology	J:78223
	CNS inflammation	J:78223
	microgliosis	J:198242
\Psap^tm4.1Ggb/\Psap^tm4.1Ggb (involves: 129S/SvEv * C57BL/6J)	microgliosis	J:198242
\Psca^{tm1b(EUCOMM)Hmgu}/\Psca^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Psca^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Pscr1^DBA/2/\Pscr1^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to bacterial infection	J:8914
\Pscr1^DBA/2/\Pscr1^DBA/2 \Pscr2^DBA/2/\Pscr2^DBA/2 \Pscr3^DBA/2/\Pscr3^DBA/2 (involves: C57BL/6 * DBA/2)	decreased susceptibility to bacterial infection	J:8914
\Pscr2^DBA/2/\Pscr2^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to bacterial infection	J:8914
\Pscr3^DBA/2/\Pscr3^DBA/2 (involves: BALB/c * DBA/2)	decreased susceptibility to bacterial infection	J:8914
\Psd^em1(IMPC)Mbp/\Psd^em1(IMPC)Mbp (C57BL/6NCrl-Psd^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Psen1^tm1.1Ruvi/\Psen1^tm1.1Ruvi \Tg(APP)8.9Btla/0 (involves: 129S2/SvPas * C57BL/6J)	microgliosis	J:187475
\Psen1^tm1Bdes/\Psen1⁺ \Psen2^tm1Bdes/\Psen2^tm1Bdes (involves: 129P2/OlaHsd)	abnormal T cell subpopulation ratio	J:91235
	arteritis	J:91235
	autoimmune response	J:91235
	chronic inflammation	J:91235
	dermatitis	J:91235
	enlarged lymph nodes	J:91235
	enlarged spleen	J:91235
	glomerulonephritis	J:91235
	increased anti-single stranded DNA antibody level	J:91235
	increased immunoglobulin level	J:91235
	increased incidence of corneal inflammation	J:91235
	increased inflammatory response	J:91235
	increased leukocyte cell number	J:91235
	increased susceptibility to autoimmune disorder	J:91235
	kidney inflammation	J:91235
	skin inflammation	J:91235
\Psen1^tm2Shn/\Psen1^tm4.1Shn \Psen2^tm1Haa/\Psen2^tm1Haa \Tg(Camk2a-cre)1Shn/0 (involves: 129 * 129S4/SvJae * C57BL/6 * C57BL/6J * CBA)	microgliosis	J:219929
\Psen2^{em1(IMPC)Ccpcz}/\Psen2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Psen2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Psip1^{Gt(betageo)1Hgs}/\Psip1^{Gt(betageo)1Hgs} (B6.129P2-Psip1^{Gt(betageo)1Hgs})	blepharitis	J:112975
	spleen atrophy	J:112975
\Psip1^{Gt(betageo)1Hgs}/\Psip1^{Gt(betageo)1Hgs} (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * MF1))	blepharitis	J:112975
	spleen atrophy	J:112975
\Psma8^em1(IMPC)Tcp/\Psma8^em1(IMPC)Tcp (C57BL/6N-Psma8^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
	small thymus	J:211773
\Psmb8^tm1Hjf/\Psmb8^tm1Hjf (either: 129P2/OlaHsd or (involves: 129P2/OlaHsd * C57BL/6))	decreased level of surface class I molecules	J:20012
	defective intracellular transport of class I molecules	J:20012
\Psmb8^tm1Hjf/\Psmb8^tm1Hjf (involves: 129P2/OlaHsd)	abnormal dendritic cell antigen presentation	J:180765
\Psmb8^tm1Hjf/\Psmb8^tm1Hjf (involves: 129P2/OlaHsd)	decreased level of surface class I molecules	J:180765
\Psmb8^tm1Hjf/\Psmb8^tm1Hjf \Tg(TcraTcrb)1100Mjb/? (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:107657
\Psmb9^tm1Stl/\Psmb9^tm1Stl (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:21549
	abnormal immune system physiology	J:21549
	decreased CD8-positive, alpha-beta T cell number	J:21549
	increased susceptibility to Orthomyxoviridae infection	J:21549
\Psmb10^tm1Mgro/\Psmb10^tm1Mgro (involves: 129S2/SvPas * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:125058
	abnormal cytotoxic T cell physiology	J:125058
	decreased CD8-positive, alpha-beta T cell number	J:125058
	decreased T cell proliferation	J:125058
\Psmb10^tm1Mgro/\Psmb10^tm1Mgro \Psmb9/Psmb8^tm1Klr/\Psmb9/Psmb8^tm1Klr (B6.129-Psmb10^tm1Mgro Psmb9/Psmb8^tm1Klr)	abnormal antigen presentation via MHC class I	J:180765
	abnormal B lymphocyte antigen presentation	J:180765
	abnormal dendritic cell antigen presentation	J:180765
	decreased CD8-positive, alpha-beta T cell number	J:180765
	decreased level of surface class I molecules	J:180765
\Psmb10^tm1Mgro/\Psmb10^tm1Mgro \Psmb9/Psmb8^tm1Klr/\Psmb9/Psmb8^tm1Klr (B6.129-Psmb10^tm1Mgro Psmb9/Psmb8^tm1Klr)	abnormal antigen presentation via MHC class I	J:180765
	abnormal B lymphocyte antigen presentation	J:180765
	abnormal dendritic cell antigen presentation	J:180765
	decreased CD8-positive, alpha-beta T cell number	J:180765
	decreased level of surface class I molecules	J:180765
\Psmb10^tm1Mgro/\Psmb10^Tub6 (involves: 129S2/SvPas * C3HeB/FeJ)	decreased NK cell number	J:261081
	decreased T cell number	J:261081
	increased granulocyte number	J:261081
\Psmb10^Tub6/\Psmb10⁺ (C3HeB/FeJ-Psmb10^Tub6)	abnormal T cell activation	J:261081
	decreased CD4-positive, alpha-beta T cell number	J:261081
	decreased CD8-positive, alpha-beta T cell number	J:261081
	decreased interferon-gamma secretion	J:261081
	decreased T cell number	J:261081
	increased susceptibility to bacterial infection induced morbidity/mortality	J:261081
\Psmb10^Tub6/\Psmb10^Tub6 (C3HeB/FeJ-Psmb10^Tub6)	absent lymph nodes	J:261081
	absent spleen white pulp	J:261081
	athymia	J:261081
	decreased B cell number	J:261081
	decreased immunoglobulin level	J:261081
	decreased leukocyte cell number	J:261081
	decreased NK cell number	J:261081
	decreased spleen red pulp amount	J:261081
	decreased T cell number	J:261081
	increased circulating interleukin-1 level	J:261081
	increased circulating interleukin-6 level	J:261081
	increased circulating tumor necrosis factor level	J:261081
	increased granulocyte number	J:261081
	increased inflammatory response	J:261081
	skin inflammation	J:261081
\Psmb10^Tub6/\Psmb10^Tub6 (B6.C3Fe-Psmb10^Tub6)	increased granulocyte number	J:261081
\Psmb10^Tub6/\Psmb10^Tub6 (C.C3Fe-Psmb10^Tub6)	increased granulocyte number	J:261081
\Psmb11^{em1(IMPC)Ccpcz}/\Psmb11^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Psmb11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased NK T cell number	J:211773
	increased T-helper cell number	J:211773
\Psmb11^{tm1(Psmb8)Khog}/\Psmb11⁺ (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:196156
\Psmb11^{tm1(Psmb8)Khog}/\Psmb11^{tm1(Psmb8)Khog} (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:196156
	abnormal self tolerance	J:196156
	abnormal T cell differentiation	J:196156
	abnormal T cell receptor V(D)J recombination	J:196156
	decreased CD8-positive, alpha-beta T cell number	J:196156
	decreased memory T cell number	J:196156
	increased T cell proliferation	J:196156
\Psmb11^{tm1(Psmb8)Khog}/\Psmb11^{tm1(Psmb8)Khog} \Psmb8^tm1Hjf/\Psmb8^tm1Hjf (involves: 129P2/OlaHsd * C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:196156
\Psmb11^{tm1.1(Psmb8)Khog}/\Psmb11^{tm1.1(Psmb8)Khog} \Psmb8^tm1Hjf/\Psmb8^tm1Hjf (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac)	abnormal T cell receptor V(D)J recombination	J:196156
	decreased CD8-positive, alpha-beta T cell number	J:196156
\Psmb11^tm1Smta/\Psmb11^tm1Smta (involves: C57BL/6 * CBA)	decreased CD8-positive, alpha-beta T cell number	J:121869
\Psmc4^tm1.1Ryot/\Psmc4^tm1.2Ryot \Tg(SLC18A3-cre)KMisa/0 (involves: C57BL/6 * C57BL/6N)	microgliosis	J:193770
\Psme2^tm1Yya/\Psme2^tm1Yya (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell physiology	J:58875
	decreased cytotoxic T cell cytolysis	J:58875
	defective assembly of class I molecules	J:58875
\Psme3^tm1Jjm/\Psme3^tm1Jjm (B6.129X1-Psme3^tm1Jjm)	decreased double-positive T cell number	J:88626
\Psme3^tm1Jjm/\Psme3^tm1Jjm (B6.129X1-Psme3^tm1Jjm)	increased susceptibility to fungal infection	J:88626
\Psme4^b2b1508Clo/\Psme4^b2b1508Clo (C57BL/6J-Psme4^b2b1508Clo)	thymus hypoplasia	J:175213
\Psmf1^{tm1c(EUCOMM)Hmgu}/\Psmf1^{tm1c(EUCOMM)Hmgu} \Tg(Pcp2-cre)GN135Gsat/0 (involves: C57BL/6J * C57BL/6N * FVB/N)	microgliosis	J:282431
\Pspc1^em1(IMPC)Mbp/\Pspc1^em1(IMPC)Mbp (C57BL/6N-Pspc1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Psph^{tm1a(EUCOMM)Hmgu}/\Psph^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Psph^{tm1a(EUCOMM)Hmgu}/Wtsi)	abnormal thymus morphology	J:239583
	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	athymia	J:239583
	blood in lymph vessels	J:239583
	spleen hypoplasia	J:239583
\Pstpip1^{em1(IMPC)Ccpcz}/\Pstpip1^{em1(IMPC)Ccpcz} (C57BL/6N-Pstpip1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased spleen weight	J:211773
	increased T-helper cell number	J:211773
\Pstpip1^tm1.1Dtg/\Pstpip1^tm1.1Dtg (involves: BALB/cJ * C57BL/6)	immune system phenotype	J:196002
\Pstpip1^tm1Spg/\Pstpip1^tm1Spg (involves: 129S/SvEv * C57BL/6)	abnormal immune system cell morphology	J:101977
	abnormal T cell physiology	J:101977
\Pstpip2^cmo/\Pstpip2^cmo (C.D2-Qa2)	chronic inflammation	J:1534
\Pstpip2^cmo/\Pstpip2^cmo (C.Cg-Pstpip2^cmo/J)	abnormal lymph node morphology	J:104476
	ear inflammation	J:104476
	enlarged spleen	J:104476
	osteomyelitis	J:104476, J:105410
\Pstpip2^em1(IMPC)Tcp/\Pstpip2^em1(IMPC)Tcp (C57BL/6NCrl-Pstpip2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Pstpip2^Lupo/\Pstpip2^Lupo (either: (involves: C3HeB/FeJ) or (involves: C3HeB/FeJ * C57BL/6J))	abnormal cytokine secretion	J:125785
	increased autoantibody level	J:125785
	increased IgE level	J:125785
	increased IgG1 level	J:125785
	increased IgG2a level	J:125785
	increased IgG level	J:125785
	skin inflammation	J:125785
\Pstpip2^Lupo/\Pstpip2^Lupo \Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S7/SvEvBrd * C3HeB/FeJ * C57BL/6J)	skin inflammation	J:125785
\Pstpip2^m1Bcs/\Pstpip2^m1Bcs (involves: C57BL/6)	abnormal inflammatory response	J:196534
	abnormal microglial cell morphology	J:196534
	autoimmune response	J:196534
	ear inflammation	J:196534
	skin inflammation	J:196534
\pta/\pta (C57BL/6J-pta)	thymus hypoplasia	J:94456
\Ptafr^tm1Tksh/\Ptafr^tm1Tksh (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:87866
	increased susceptibility to parasitic infection	J:87866
	increased susceptibility to type I hypersensitivity reaction	J:88505
\Ptafr^tm1Tksh/\Ptafr^tm1Tksh (C57BL/6-Ptafr^tm1Tksh)	decreased susceptibility to bacterial infection	J:88589
\Ptch1^tm1Bjw/\Ptch1^tm1Bjw \Tg(KRT14-cre)8Brn/0 (involves: 129T2/SvEms * FVB/N)	thymus hypoplasia	J:231264
\Ptch1^tm1Hahn/\Ptch1^tm1Hahn \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal double-negative T cell morphology	J:127207
	abnormal thymus lobule morphology	J:127207
	decreased B cell number	J:127207
	decreased double-positive T cell number	J:127207
	decreased immature B cell number	J:127207
	decreased lymphocyte cell number	J:127207
	decreased pre-B cell number	J:127207
	decreased transitional stage B cell number	J:127207
	increased B cell number	J:127207
	increased double-negative T cell number	J:127207
	increased mature B cell number	J:127207
	increased neutrophil cell number	J:127207
	increased single-positive T cell number	J:127207
	thymus hypoplasia	J:127207
\Ptch2^tm1Dgen/\Ptch2^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:101679
	increased neutrophil cell number	J:101679
\Ptch2^{tm3b(EUCOMM)Hmgu}/\Ptch2^{tm3b(EUCOMM)Hmgu} (C57BL/6N-Ptch2^{tm3b(EUCOMM)Hmgu}/Bay)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Ptchd1^{tm1b(KOMP)IcsOrl}/Y (C57BL/6N-Ptchd1^{tm1b(KOMP)IcsOrl}/Ics)	abnormal spleen morphology	J:211773
\Ptcra^tm1(icre)Hjf/\Ptcra^tm1(icre)Hjf (B6.129P2-Ptcra^tm1(icre)Hjf)	decreased DN4 thymocyte number	J:197923
	decreased double-positive T cell number	J:197923
	decreased thymocyte number	J:197923
\Ptcra^tm1.1Shoy/\Ptcra^tm1.1Shoy (involves: C57BL/6)	decreased double-positive T cell number	J:166147
	decreased T cell number	J:166147
	decreased thymocyte number	J:166147
	increased DN3 thymocyte number	J:166147
	increased gamma-delta T cell number	J:166147
	increased T cell number	J:166147
\Ptcra^tm1Bjf/\Ptcra⁺ (involves: 129X1/SvJ)	abnormal T cell differentiation	J:94338
	decreased double-negative T cell number	J:94338
	decreased single-positive T cell number	J:94338
\Ptcra^tm1Vbo/\Ptcra^tm1Vbo (involves: 129P2/OlaHsd * C57BL/6)	arrested T cell differentiation	J:91542
	increased double-negative T cell number	J:91542
\Ptcra^tm1Vbo/\Ptcra^tm1Vbo (involves: 129P2/OlaHsd)	abnormal double-positive T cell morphology	J:123569
	decreased DN4 thymocyte number	J:123569
	increased DN3 thymocyte number	J:123569
	thymus hypoplasia	J:123569
\Ptdss1^{tm1b(EUCOMM)Hmgu}/\Ptdss1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ptdss1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased large unstained cell number	J:211773
\Pten^tm1.1Gle/\Pten⁺ (involves: 129S6/SvEvTac * Black Swiss * FVB/N)	increased T cell derived lymphoma incidence	J:158751
\Pten^tm1.1Hwu/\Pten⁺ (involves: 129S4/SvJae * BALB/c)	lymphoid hyperplasia	J:110567
\Pten^tm1.2Mwst/\Pten⁺ (involves: 129S6/SvEvTac * Black Swiss * FVB/N)	increased T cell derived lymphoma incidence	J:158751
\Pten^tm1Engc/\Pten^tm1Engc (involves: CD-1)	abnormal microglial cell physiology	J:210487
\Pten^tm1Hwu/\Pten^tm1Hwu \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	abnormal alveolar macrophage morphology	J:148947
	abnormal cytokine level	J:148947
	abnormal macrophage chemotaxis	J:148947
	abnormal neutrophil physiology	J:148947, J:114699, J:145331
	decreased susceptibility to bacterial infection	J:148947
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:148947
	impaired neutrophil recruitment	J:148947
	increased susceptibility to bacterial infection	J:148947
	increased susceptibility to bacterial infection induced morbidity/mortality	J:148947
	lung inflammation	J:148947
\Pten^tm1Hwu/\Pten^tm1Hwu \Rps6kb1^tm1Gtho/\Rps6kb1^tm1Gtho \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)	enlarged spleen	J:169097
	enlarged thymus	J:169097
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0 \Tg(TPO-cre)1Shk/0 (involves: 129S4/SvJae * FVB/NCr * FVB/NJ)	abnormal thymus physiology	J:177181
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(CD2-icre)4Kio/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	enlarged thymus	J:216983
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Cdh5-cre)7Mlia/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N)	enlarged lymph nodes	J:135172
	enlarged spleen	J:135172
	enlarged thymus	J:135172
	increased leukocyte cell number	J:135172
	increased neutrophil cell number	J:135172
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(GZMB-cre)1Jcb/0 (involves: 129S4/SvJae * FVB/N)	abnormal CD8-positive, alpha-beta T cell physiology	J:164425
	decreased interleukin-2 secretion	J:164425
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	enlarged spleen	J:169097
	enlarged thymus	J:169097
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Mx1-cre)1Cgn/0 (BKS.Cg-Ptprc^b Thy1^a Tg(Mx1-cre)1Cgn Pten^tm1Hwu)	enlarged thymus	J:109085
	spleen hyperplasia	J:109085
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Tg(Mx1-cre)1Cgn Pten^tm1Hwu)	decreased B cell number	J:232645
	decreased lymphocyte cell number	J:232645
	decreased T cell number	J:232645
	enlarged spleen	J:232645
	increased granulocyte number	J:232645
	increased macrophage cell number	J:232645
	increased monocyte cell number	J:232645
	increased spleen weight	J:232645
\Pten^tm1Hwu/\Pten^tm1Hwu \Tg(Pbsn-cre)4Prb/0 (involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)	prostate gland inflammation	J:93902
	pyelonephritis	J:124208
\Pten^tm1Mak/\Pten⁺ (involves: 129P2/OlaHsd * C57BL/6J)	enlarged Peyer's patches	J:63478
\Pten^tm1Mak/\Pten⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased T cell derived lymphoma incidence	J:50437
\Pten^tm1Rps/\Pten⁺ (involves: 129S1/Sv * C57BL/6J)	abnormal lymph node B cell domain morphology	J:53065
	enlarged spleen	J:53065
	enlarged thymus	J:53065
	lymph node hyperplasia	J:53065
\Pten^tm2.1Gle/\Pten⁺ (involves: 129S6/SvEvTac * Black Swiss * FVB/N)	increased T cell derived lymphoma incidence	J:158751
\Pten^tm2.1Ppp/\Pten^tm2.1Ppp \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased germinal center B cell number	J:164283
	increased IgG1 level	J:164283
	increased T follicular helper cell number	J:164283
\Pten^tm2Mak/\Pten^tm2Mak \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129P2/OlaHsd * C57BL/6 * DBA)	liver inflammation	J:138099
\Ptf1a^tm1Pkwe/\Ptf1a^tm1Pkwe (involves: 129P2/OlaHsd * C57BL/6)	abnormal spleen morphology	J:51571
\Ptgdr2^tm1Byl/\Ptgdr2^tm1Byl (involves: C57BL/6J)	abnormal cytokine secretion	J:107519
\Ptgdr2^tm1Byl/\Ptgdr2^tm1Byl (involves: C57BL/6J)	increased eosinophil cell number	J:107519
\Ptgdr2^tm1Tasa/\Ptgdr2^tm1Tasa (involves: 129/Sv * BALB/c)	impaired eosinophil recruitment	J:130892
\Ptgdr2^tm1Tasa/\Ptgdr2^tm1Tasa (C.129-Ptgdr2^tm1Tasa)	abnormal chemokine level	J:131146
	abnormal inflammatory response	J:131146
	decreased IgE level	J:131146
	decreased inflammatory response	J:131146
	decreased susceptibility to type IV hypersensitivity reaction	J:131146
\Ptgdr2^tm1Tasa/\Ptgdr2^tm1Tasa (B6.129-Ptgdr2^tm1Tasa)	increased susceptibility to type I hypersensitivity reaction	J:197334
\Ptgdr^tm1Sna/\Ptgdr^tm1Sna (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage activation involved in immune response	J:243958
	brain inflammation	J:243958
	decreased microglial cell activation	J:243958
	increased CD4-positive, alpha-beta T cell number	J:243958
	increased interleukin-1 beta secretion	J:243958
	increased regulatory T cell number	J:243958
	increased susceptibility to Coronaviridae infection	J:243958
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:243958
	respiratory system inflammation	J:61023
\Ptgdr^tm1Sna/\Ptgdr^tm1Sna (B6.129P2-Ptgdr^tm1Sna/Sna)	abnormal dermal mast cell morphology	J:197334
	abnormal mast cell physiology	J:197334
	decreased mast cell degranulation	J:197334
	decreased mast cell histamine storage	J:197334
	decreased susceptibility to type I hypersensitivity reaction	J:197334
\Ptgds^tm1Mfg/\Ptgds^tm1Mfg (involves: C57BL/6)	immune system phenotype	J:98963
\Ptgds^tm1Ohy/\Ptgds^tm1Ohy (B6.129P2-Ptgds^tm1Ohy)	abnormal dermal mast cell morphology	J:197334
	decreased mast cell degranulation	J:197334
	decreased mast cell histamine storage	J:197334
	decreased susceptibility to type I hypersensitivity reaction	J:197334
	immune system phenotype	J:197334
\Ptger1^tm1Jdm/\Ptger1^tm1Jdm (DBA/1LacJ-Ptger1^tm1Jdm)	immune system phenotype	J:72198, J:78964
\Ptger1^tm1Sna/\Ptger1^tm1Sna (B6CrSlc.129P2-Ptger1^tm1Sna/Sna)	abnormal CD8-positive, alpha-beta T cell differentiation	J:128435
	abnormal cervical lymph node morphology	J:128435
	abnormal interferon-gamma secretion	J:128435
	abnormal lymph node morphology	J:128435
	abnormal response to infection	J:82750
	abnormal T-helper 1 cell differentiation	J:128435
	decreased susceptibility to type IV hypersensitivity reaction	J:128435
	immune system phenotype	J:128435, J:197334
\Ptger2^tm1.1Kand/\Ptger2^tm1.1Kand \Tg(ITGAM-cre)2781Gkl/0 (involves: C57BL/6 * CBA)	abnormal microglial cell physiology	J:202677
	decreased susceptibility to endotoxin shock	J:202677
\Ptger2^tm1Brey/\Ptger2^tm1Brey (involves: 129S6/SvEvTac * C57BL/6)	abnormal response to infection	J:120725
\Ptger2^tm1Brey/\Ptger2^tm1Brey (C.129S6-Ptger2^tm1Brey)	abnormal microglial cell physiology	J:97062
\Ptger2^tm1Brey/\Ptger2^tm1Brey (involves: 129S6/SvEvTac * BALB/c)	abnormal response to infection	J:164638
\Ptger2^tm1Rsz/\Ptger2^tm1Rsz (involves: 129S6/SvEvTac * C57BL/6)	abnormal osteoclast differentiation	J:77408
\Ptger2^tm1Sna/\Ptger2^tm1Sna (B6.129P2-Ptger2^tm1Sna/Sna)	immune system phenotype	J:197334
\Ptger2^tm2Bhk/\Ptger2^tm2Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:78964
\Ptger3^tm1Cof/\Ptger3^tm1Cof (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:78964
\Ptger3^tm1Sna/\Ptger3^tm1Sna (B6.129P2-Ptger3^tm1Sna/Sna)	abnormal response to infection	J:82750
\Ptger3^tm1Sna/\Ptger3^tm1Sna (B6.129P2-Ptger3^tm1Sna/Sna)	increased susceptibility to type I hypersensitivity reaction	J:197334
\Ptger4^tm1.1Matb/\Ptger4^tm1.1Matb \Tg(Myh6-cre)2182Mds/0 (involves: 129S6/SvEvTac * FVB/N)	heart inflammation	J:158439
\Ptger4^tm1Bhk/\Ptger4^tm1Bhk (involves: 129P2/OlaHsd * 129S/SvEv)	lymphangiectasis	J:44108
\Ptger4^tm1Bhk/\Ptger4^tm1Bhk (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal circulating interleukin-6 level	J:78964
	abnormal circulating serum amyloid protein level	J:78964
	abnormal cytokine level	J:78964
	abnormal macrophage physiology	J:78964
	decreased susceptibility to induced arthritis	J:78964
	immune system phenotype	J:78964
	rheumatoid arthritis	J:78964
\Ptger4^tm1Sna/\Ptger4^tm1Sna (involves: 129P2/OlaHsd * C57BL/6)	abnormal Langerhans cell physiology	J:83725
	abnormal osteoclast differentiation	J:63070
	abnormal osteoclast physiology	J:63070
	abnormal T cell activation	J:83725
	decreased interferon-gamma secretion	J:83725
	decreased susceptibility to type IV hypersensitivity reaction	J:83725
	decreased T cell proliferation	J:83725
	immune system phenotype	J:83725, J:197334
\Ptges2^tm1Kymm/\Ptges2^tm1Kymm (B6.Cg-Ptges2^tm1Kymm)	increased susceptibility to type I hypersensitivity reaction	J:197334
\Ptges^tm1.1Gaf/\Ptges^tm1.1Gaf \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * C57BL/6)	abnormal leukocyte physiology	J:210141
	increased leukocyte cell number	J:210141
\Ptges^tm1Aki/\Ptges^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal inflammatory response	J:91821
	chronic inflammation	J:91821
	impaired macrophage chemotaxis	J:91821
\Ptges^tm1Aki/\Ptges^tm1Aki (B6.129P2-Ptges^tm1Aki)	increased susceptibility to type I hypersensitivity reaction	J:197334
\Ptges^tm1Lpa/\Ptges^tm1Lpa (DBA/1LacJ-Ptges^tm1Lpa)	decreased inflammatory response	J:89960, J:90980
\Ptgfr^tm1Sna/\Ptgfr^tm1Sna (B6.129P2-Ptgfr^tm1Sna)	immune system phenotype	J:197334
\Ptgfrn^{em1(IMPC)Hmgu}/\Ptgfrn^{em1(IMPC)Hmgu} (C57BL/6NCrl-Ptgfrn^{em1(IMPC)Hmgu}/Ieg)	increased neutrophil cell number	J:211773
\Ptgir^tm1Sna/\Ptgir^tm1Sna (involves: 129P2/OlaHsd * C57BL/6)	decreased acute inflammation	J:42275
\Ptgir^tm1Sna/\Ptgir^tm1Sna (B6.129P2-Ptgir^tm1Sna/Sna)	immune system phenotype	J:197334
\Ptgis^em1(IMPC)Mbp/\Ptgis^em1(IMPC)Mbp (C57BL/6N-Ptgis^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Ptgs1^tm1Fun/\Ptgs1^tm1Fun (involves: 129S6/SvEvTac * C57BL/6)	decreased inflammatory response	J:97351
\Ptgs1^tm1Unc/\Ptgs1^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:29511
	enlarged spleen	J:60668
	increased susceptibility to endotoxin shock	J:75611
	increased susceptibility to induced colitis	J:158426, J:60668
\Ptgs1^tm1Unc/\Ptgs1^tm1Unc (B6.129P2-Ptgs1^tm1Unc)	decreased susceptibility to induced arthritis	J:110716
\Ptgs2^tm1.1Fun/\Ptgs2^tm1.1Fun (involves: 129S6/SvEvTac)	kidney inflammation	J:148699
\Ptgs2^tm1.1Wls/\Ptgs2^tm1.1Wls (B6.129-Ptgs2^tm1.1Wls)	increased susceptibility to endotoxin shock	J:156331
\Ptgs2^tm1Jed/\Ptgs2^tm1Jed (involves: 129S7/SvEvBrd)	immune system phenotype	J:29974
\Ptgs2^tm1Jed/\Ptgs2^tm1Jed (involves: 129S7/SvEvBrd)	pyelonephritis	J:29974
\Ptgs2^tm1Jed/\Ptgs2^tm1Jed (involves: 129S7/SvEvBrd * C57BL/6)	peritoneal inflammation	J:118171
\Ptgs2^tm1Jed/\Ptgs2^tm1Jed (involves: 129S7/SvEvBrd * CD-1)	abnormal response to infection	J:120725
\Ptgs2^tm1Unc/\Ptgs2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:124756
\Ptgs2^tm1Unc/\Ptgs2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:29510
	abnormal mesenteric lymph node morphology	J:29510
	immune system phenotype	J:29510
	peritoneal inflammation	J:29510
	spleen hyperplasia	J:29510
	tubulointerstitial nephritis	J:29510
\Ptgs2^tm1Unc/\Ptgs2^tm1Unc (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:124756
\Ptgs2^tm1Unc/\Ptgs2^tm1Unc (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to endotoxin shock	J:75611
	enlarged spleen	J:60668
	increased leukocyte cell number	J:60668
	increased susceptibility to induced colitis	J:158426, J:60668
	increased tumor necrosis factor secretion	J:108054
	peritoneal inflammation	J:60668
\Ptgs2^tm1Unc/\Ptgs2^tm1Unc (B6.129P2-Ptgs2^tm1Unc)	abnormal class switch recombination	J:140698
	abnormal memory B cell differentiation	J:140698
	abnormal response to infection	J:140698
	decreased IgG1 level	J:140698
	decreased IgG2a level	J:140698
	decreased IgG3 level	J:140698
	decreased susceptibility to induced arthritis	J:110716
	increased IgM level	J:140698
\Ptgs2^tm1Unc/\Ptgs2^tm2.1Hahe (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	increased susceptibility to induced colitis	J:158426
\Ptgs2^{tm2(Ptgs1)Fun}/\Ptgs2^{tm2(Ptgs1)Fun} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:118171
\Ptgs2^{tm2.1(Ptgs1)Fun}/\Ptgs2^{tm2.1(Ptgs1)Fun} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB)	abnormal macrophage physiology	J:118171
	kidney inflammation	J:118171
	peritoneal inflammation	J:118171
\Ptgs2os^tm1Scrp/\Ptgs2os^tm1Scrp (Not Specified)	abnormal chemokine level	J:325487
	decreased CCL3 level	J:325487
	decreased circulating CCL3 level	J:325487
	decreased circulating interleukin-6 level	J:325487
	decreased neutrophil cell number	J:325487
	increased interferon-beta secretion	J:325487
\Pth1r^{tm1a(EUCOMM)Hmgu}/\Pth1r^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Pth1r^{tm1a(EUCOMM)Hmgu}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
\Pth^tm1Dgo/\Pth^tm1Dgo (involves: 129S2/SvPas * C57BL/6J)	abnormal osteoclast morphology	J:76407
\Pth^tm1Dgo/\Pth^tm1Dgo (involves: 129S2/SvPas * C57BL/6J)	decreased osteoclast cell number	J:76407
\Pth^tm1Dgo/\Pth^tm1Dgo \Pthlh^tm1Hmk/\Pthlh^tm1Hmk (involves: 129S2/SvPas * C57BL/6J)	abnormal osteoclast morphology	J:76407
	decreased osteoclast cell number	J:76407
\Pthlh^tm1Ack/\Pthlh^tm1Ack \Tg(Col1a1-cre)1Ack/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal osteoclast morphology	J:100918
	decreased osteoclast cell number	J:100918
\Pthlh^tm1Ack/\Pthlh^tm1Hmk \Tg(LGB-cre)74Acl/0 (involves: 129 * C57BL/6 * CBA)	abnormal osteoclast morphology	J:86536
\Pthlh^tm1Hmk/\Pthlh⁺ (involves: 129S2/SvPas)	abnormal osteoclast morphology	J:100918
\Pthlh^tm1Hmk/\Pthlh^tm1Hmk (involves: 129S2/SvPas * C57BL/6J)	abnormal osteoclast morphology	J:76407
	decreased osteoclast cell number	J:76407
\Pthlh^tm1Hmk/\Pthlh^tm1Hmk \Pth1r^tm1Hmk/\Pth1r^tm2Hmk \Tg(Col2a1-PTHLH)1Ecw/0 (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * SJL)	abnormal bone marrow development	J:99641
\Pthlh^tm2Ack/\Pthlh^tm2Ack (involves: 129S2/SvPas * C57BL/6)	decreased osteoclast cell number	J:142669
\Ptk2b^tm1Schl/\Ptk2b^tm1Schl (involves: 129S1/Sv * 129X1/SvJ)	abnormal macrophage physiology	J:99741
	decreased acute inflammation	J:99741
	impaired macrophage chemotaxis	J:99741
\Ptn^tm1Tmu/\Ptn^tm1Tmu (B6.Cg-Ptn^tm1Tmu)	decreased macrophage cell number	J:102069
	impaired macrophage chemotaxis	J:102069
	impaired neutrophil recruitment	J:102069
\Ptp4a1^em2(IMPC)Tcp/\Ptp4a1^em2(IMPC)Tcp (C57BL/6NCrl-Ptp4a1^em2(IMPC)Tcp/Tcp)	small spleen	J:211773
\Ptp4a2^em1(IMPC)Tcp/\Ptp4a2^em1(IMPC)Tcp (C57BL/6N-Ptp4a2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Ptp4a2^{Gt(AQ0673)Wtsi}/\Ptp4a2^{Gt(AQ0673)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen weight	J:190411
\Ptp4a3^em1(IMPC)Mbp/\Ptp4a3^em1(IMPC)Mbp (C57BL/6N-Ptp4a3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Ptpmt1^tm2.1Ckq/\Ptpmt1^tm2.1Ckq \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	immune system phenotype	J:194929
\Ptpmt1^tm2.1Ckq/\Ptpmt1^tm2.1Ckq \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	immune system phenotype	J:194929
\Ptpmt1^tm2.1Ckq/\Ptpmt1^tm2.1Ckq \Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)	immune system phenotype	J:194929
\Ptpmt1^tm2.1Ckq/\Ptpmt1^tm2.1Ckq \Tg(VAV1-cre)1Graf/0 (involves: 129S6/SvEvTac * C57BL/6J * SJL)	small spleen	J:194929
	small thymus	J:194929
\Ptpn2^tm1.1Kry/\Ptpn2^tm1.1Kry \Tg(Col1a1-cre)1Kry/0 (involves: 129 * C57BL/6J * FVB)	abnormal osteoclast differentiation	J:183709
	abnormal osteoclast physiology	J:183709
\Ptpn2^tm1Mtr/\Ptpn2^tm1Mtr (involves: 129S4/SvJae * BALB/c)	abnormal B cell number	J:42595
	abnormal inflammatory response	J:90541
	abnormal spleen morphology	J:42595
	abnormal thymus involution	J:42595
	decreased B cell number	J:42595
	decreased double-positive T cell number	J:42595
	enlarged lymph nodes	J:42595
	enlarged spleen	J:42595
	increased B cell number	J:42595
	increased inflammatory response	J:90541
	increased interferon-gamma secretion	J:90541
	increased interleukin-12 secretion	J:90541
	increased macrophage cell number	J:42595
	increased mature B cell number	J:42595
	increased pre-B cell number	J:42595
	increased spleen red pulp amount	J:42595
	increased tumor necrosis factor secretion	J:90541
	lymph node hyperplasia	J:42595
	spleen hyperplasia	J:42595
\Ptpn2^tm1Mtr/\Ptpn2^tm1Mtr (C.129S4-Ptpn2^tm1Mtr)	abnormal lymph node morphology	J:186843
	abnormal negative T cell selection	J:186843
	abnormal positive T cell selection	J:186843
	abnormal T cell differentiation	J:186843
	abnormal T cell subpopulation ratio	J:186843
	decreased B cell number	J:186843
	decreased B-1 B cell number	J:186843
	decreased CD4-positive, alpha-beta T cell number	J:186843
	decreased double-positive T cell number	J:186843
	decreased follicular B cell number	J:186843
	decreased immature B cell number	J:186843
	decreased marginal zone B cell number	J:186843
	decreased mature B cell number	J:186843
	decreased single-positive T cell number	J:186843
	decreased T cell number	J:186843
	decreased thymocyte number	J:186843
	enlarged spleen	J:186843
	increased splenocyte number	J:186843
	thymus atrophy	J:186843
\Ptpn2^tm1Mtr/\Ptpn2^tm1Mtr (B6.129S4(C)-Ptpn2^tm1Mtr)	abnormal lymph node morphology	J:186843
	decreased B cell number	J:186843
	decreased B-1 B cell number	J:186843
	decreased CD4-positive, alpha-beta T cell number	J:186843
	decreased double-positive T cell number	J:186843
	decreased follicular B cell number	J:186843
	decreased immature B cell number	J:186843
	decreased marginal zone B cell number	J:186843
	decreased mature B cell number	J:186843
	decreased single-positive T cell number	J:186843
	decreased T cell number	J:186843
	decreased thymocyte number	J:186843
	thymus atrophy	J:186843
\Ptpn2^tm2.1Ttig/\Ptpn2^tm2.1Ttig (B6.Cg-Ptpn2^tm2.1Ttig)	abnormal negative T cell selection	J:186843
	abnormal positive T cell selection	J:186843
	abnormal T cell differentiation	J:186843
	abnormal T cell subpopulation ratio	J:186843
	decreased B cell number	J:186843
	decreased B-1 B cell number	J:186843
	decreased CD4-positive, alpha-beta T cell number	J:186843
	decreased double-positive T cell number	J:186843
	decreased follicular B cell number	J:186843
	decreased immature B cell number	J:186843
	decreased marginal zone B cell number	J:186843
	decreased mature B cell number	J:186843
	decreased single-positive T cell number	J:186843
	decreased thymocyte number	J:186843
	enlarged lymph nodes	J:186843
	thymus atrophy	J:186843
\Ptpn3^tm1Pdk/\Ptpn3^tm1Pdk \Ptpn4^{Gt(OST146128)Lex}/\Ptpn4^{Gt(OST146128)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:144351
\Ptpn4^{Gt(OST146128)Lex}/\Ptpn4^{Gt(OST146128)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:144351
\Ptpn4^tm1.1Oers/\Ptpn4^tm1.1Oers (B6.129S6-Ptpn4^tm1.1Oers)	immune system phenotype	J:138871
\Ptpn6^em1.1Shoy/\Ptpn6^em1.1Shoy (involves: C57BL/6)	decreased thymocyte number	J:236298
\Ptpn6^m1Amgn/\Ptpn6^m1Amgn (involves: C3H/HeSnJ * C57BL/6J * Swiss)	increased circulating interleukin-17 level	J:168664
\Ptpn6^m1Anu/\Ptpn6^m1Anu (C57BL/6JAnu-Ptpn6^m1Anu)	decreased IgM level	J:225105
\Ptpn6^m1Btlr/\Ptpn6^m1Btlr (C57BL/6J-Ptpn6^m1Btlr/Mmucd)	abnormal myeloid leukocyte morphology	J:142845
	decreased mature B cell number	J:142845
	decreased susceptibility to bacterial infection	J:142845
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:142845
	enlarged spleen	J:94077, J:142845
	increased anti-chromatin antibody level	J:142845
	increased IgM level	J:142845
	increased inflammatory response	J:94077
	increased neutrophil cell number	J:142845
	lung inflammation	J:142845
	salivary gland inflammation	J:142845
\Ptpn6^m3Btlr/\Ptpn6⁺ (C57BL/6J-Ptpn6^m3Btlr)	abnormal CD8-positive, alpha beta T cell morphology	J:234259
	decreased B cell number	J:234259
	decreased B-2 B cell number	J:234259
	decreased immature B cell number	J:234259
	decreased mature B cell number	J:234259
	increased B-1 B cell number	J:234259
	increased B-1a cell number	J:234259
	increased dendritic cell number	J:234259
	increased macrophage cell number	J:234259
\Ptpn6^m3Btlr/\Ptpn6^m3Btlr (C57BL/6J-Ptpn6^m3Btlr)	abnormal CD8-positive, alpha beta T cell morphology	J:234259
	decreased B cell number	J:234259
	decreased B-2 B cell number	J:234259
	decreased immature B cell number	J:234259
	decreased mature B cell number	J:234259
	increased B-1 B cell number	J:234259
	increased B-1b cell number	J:234259
	increased dendritic cell number	J:234259
	increased macrophage cell number	J:234259
\Ptpn6^m4Btlr/\Ptpn6^m4Btlr (C57BL/6J-Ptpn6^m4Btlr)	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:264807
	decreased CD8-positive, naive alpha-beta T cell number	J:264807
	increased B-1 B cell number	J:264807
	increased CD8-positive, alpha-beta memory T cell number	J:264807
	increased central memory CD8 positive, alpha-beta T cell number	J:264807
	increased effector memory CD4-positive, alpha-beta T cell number	J:264807
	increased effector memory CD8-positive, alpha-beta T cell number	J:264807
\Ptpn6^M5Btlr/\Ptpn6^M5Btlr (C57BL/6J-Ptpn6^M5Btlr)	decreased B cell number	J:265075
	decreased B-1 B cell number	J:265075
	decreased CD8-positive, naive alpha-beta T cell number	J:265075
	decreased IgD level	J:265075
	decreased IgM level	J:265075
	increased central memory CD8 positive, alpha-beta T cell number	J:265075
\Ptpn6^m6Btlr/\Ptpn6^m6Btlr (C57BL/6J-Ptpn6^m6Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272439
\Ptpn6^m6Btlr/\Ptpn6^m6Btlr (C57BL/6J-Ptpn6^m6Btlr)	abnormal T cell differentiation	J:272439
\Ptpn6^m7Btlr/\Ptpn6^m7Btlr (C57BL/6J-Ptpn6^m7Btlr)	abnormal T cell differentiation	J:272440
\Ptpn6^me-B2/\Ptpn6^me-B2 (involves: BALB/c)	abnormal circulating chemokine level	J:169850
	increased circulating interferon-gamma level	J:169850
	increased circulating interleukin-1 beta level	J:169850
	increased circulating interleukin-6 level	J:169850
	increased circulating interleukin-10 level	J:169850
	increased circulating serum amyloid protein level	J:169850
	increased IgG level	J:169850
	increased IgM level	J:169850
	increased neutrophil cell number	J:169850
	interstitial pneumonia	J:169850
	skin inflammation	J:169850
	small thymus	J:169850
\Ptpn6^me-v/\Ptpn6⁺ \Tg(IghelMD4)4Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal mature B cell morphology	J:110531
\Ptpn6^me-v/\Ptpn6^me-v (C57BL/6J-Ptpn6^me-v)	abnormal immunoglobulin level	J:7665
	abnormal inflammatory response	J:20845
	abnormal plasma cell morphology	J:14936
	abnormal T cell physiology	J:1661
	abnormal thymus development	J:16613
	chronic inflammation	J:20845
	decreased B cell number	J:113218
	decreased mature B cell number	J:7905
	increased plasma cell number	J:7905
	interstitial pneumonia	J:7531
	rheumatoid arthritis	J:20845
\Ptpn6^me/\Ptpn6^me (C57BL/6J-Ptpn6^me/J)	abnormal granulocyte morphology	J:5579
	abnormal humoral immune response	J:5579
	abnormal immune system cell morphology	J:5579
	abnormal leukocyte cell number	J:5579
	abnormal Peyer's patch morphology	J:5579
	abnormal thymus morphology	J:5579
	autoimmune response	J:5579
	enlarged spleen	J:5579
	increased granulocyte number	J:5579
	increased IgA level	J:5579
	increased IgG level	J:5579
	increased IgM level	J:5579
	increased immunoglobulin level	J:5579
	increased leukocyte cell number	J:5579
	increased monocyte cell number	J:5579
	small thymus	J:5579
\Ptpn6^me/\Ptpn6^me (involves: C3H/HeN * C57BL/6J * NFS)	increased autoantibody level	J:30994
	increased IgM level	J:30994
	increased splenocyte proliferation	J:30994
\Ptpn6^me/\Ptpn6^me (involves: C3HeB/FeJ * C57BL/6)	abnormal microglial cell morphology	J:72655
\Ptpn6^me/\Ptpn6^me (C3FeLe.B6 a/a-Ptpn6^me/J)	increased microglial cell activation	J:88807
\Ptpn6^me/\Ptpn6^me (either: (involves: C3H * C57BL/6J) or (involves: C57BL/6J * C57BL/6N))	lung inflammation	J:5999
	thymus atrophy	J:5999
\Ptpn9^tm1Dny/\Ptpn9^tm1Dny (B6.129-Ptpn9^tm1Dny)	abnormal T cell differentiation	J:118880
\Ptpn9^tm1Dny/\Ptpn9^tm1Dny (B6.129-Ptpn9^tm1Dny)	decreased T cell proliferation	J:118880
\Ptpn11^tm1.1Ics/\Ptpn11⁺ (involves: 129S2/SvPas * C57BL/6 * FVB/N)	enlarged spleen	J:216593
\Ptpn11^tm1Bgn/\Ptpn11⁺ (involves: 129S4/SvJae * C57BL/6J)	enlarged spleen	J:91609
	increased leukocyte cell number	J:91609
	increased lymphocyte cell number	J:91609
	increased neutrophil cell number	J:91609
	myeloid hyperplasia	J:91609
\Ptpn11^tm1Ckq/\Ptpn11⁺ \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	myeloid hyperplasia	J:177285
\Ptpn11^tm1Ckq/\Ptpn11⁺ \Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:177285
	increased lymphoblastic lymphoma incidence	J:177285
\Ptpn11^tm1Ckq/\Ptpn11⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA)	arrested B cell differentiation	J:177285
	enlarged spleen	J:177285
	increased leukocyte cell number	J:177285
	increased lymphoblastic lymphoma incidence	J:177285
	increased neutrophil cell number	J:177285
	increased spleen weight	J:177285
	myeloid hyperplasia	J:177285
\Ptpn11^tm1Gsf/\Ptpn11^tm1Gsf \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	increased acute inflammation	J:172422
	increased circulating interleukin-6 level	J:172422
	liver inflammation	J:172422
\Ptpn11^tm1Gsf/\Ptpn11^tm1Gsf \Stat3^tm1Vpo/\Stat3^tm1Vpo \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)	liver inflammation	J:172422
\Ptpn11^tm6Bgn/\Ptpn11⁺ \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S6/SvEvTac C57BL/6 * CBA)	abnormal leukopoiesis	J:148430
\Ptpn11^tm6Bgn/\Ptpn11⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal leukopoiesis	J:148430
	abnormal splenic cell ratio	J:148430
	enlarged spleen	J:148430
	increased granulocyte number	J:148430
	increased leukocyte cell number	J:148430
	increased monocyte cell number	J:148430
	intermingled spleen red and white pulp	J:148430
\Ptpn12^tm1Vei/\Ptpn12^tm1Vei \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Ptpn12^tm1Vei)	abnormal cytokine secretion	J:163910
	abnormal T cell physiology	J:163910
	decreased T cell proliferation	J:163910
\Ptpn12^tm1Vei/\Ptpn12^tm1Vei \Tg(Lck-cre)1Cwi/0 (B6.Cg-Ptpn12^tm1Vei Tg(Lck-cre)1Cwi)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:163910
\Ptpn13^tm1Gru/\Ptpn13^tm1Gru (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:118426
	abnormal cytokine secretion	J:118426
	decreased susceptibility to bacterial infection	J:118426
\Ptpn13^tm1Wjh/\Ptpn13^tm1Wjh (involves: 129P2/OlaHsd * C57BL/6)	increased T-helper 2 cell number	J:144351
\Ptpn13^tm1Wjh/\Ptpn13^tm1Wjh \Ptpn3^tm1Pdk/\Ptpn3^tm1Pdk \Ptpn4^{Gt(OST146128)Lex}/\Ptpn4^{Gt(OST146128)Lex} (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:144351
\Ptpn14^{Gt(RRR484)Byg}/\Ptpn14^{Gt(RRR484)Byg} (involves: 129P2/OlaHsd)	lymphatic vessel hyperplasia	J:169186
\Ptpn18^em1(IMPC)J/\Ptpn18^em1(IMPC)J (C57BL/6NJ-Ptpn18^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ptpn22^tm1.1Draw/\Ptpn22⁺ (involves: 129 * C57BL/6)	abnormal B cell differentiation	J:201448
	abnormal B cell morphology	J:201448
	abnormal B cell number	J:201448
	abnormal B cell physiology	J:201448
	abnormal T cell morphology	J:201448
	abnormal T cell number	J:201448
	abnormal T cell physiology	J:201448
	abnormal thymus morphology	J:201448
	autoimmune response	J:201448
	decreased B cell apoptosis	J:201448
	decreased follicular B cell number	J:201448
	decreased mature B cell number	J:201448
	enlarged spleen	J:201448
	increased anti-double stranded DNA antibody level	J:201448
	increased B cell number	J:201448
	increased B cell proliferation	J:201448
	increased CD4-positive, alpha-beta memory T cell number	J:201448
	increased double-positive T cell number	J:201448
	increased germinal center B cell number	J:201448
	increased IgG1 level	J:201448
	increased interleukin-2 secretion	J:201448
	increased regulatory T cell number	J:201448
	increased spleen germinal center size	J:201448
	increased T cell proliferation	J:201448
	increased transitional stage T1 B cell number	J:201448
	spleen hyperplasia	J:201448
	thymus hyperplasia	J:201448
\Ptpn22^tm1.1Draw/\Ptpn22^tm1.1Draw (involves: 129 * C57BL/6)	abnormal B cell activation	J:201448
	abnormal B cell differentiation	J:201448
	abnormal B cell morphology	J:201448
	abnormal B cell physiology	J:201448
	abnormal T cell differentiation	J:201448
	abnormal T cell morphology	J:201448
	abnormal T cell physiology	J:201448
	abnormal thymus morphology	J:201448
	autoimmune response	J:201448
	decreased B cell apoptosis	J:201448
	decreased follicular B cell number	J:201448
	decreased mature B cell number	J:201448
	enlarged spleen	J:201448
	glomerulonephritis	J:201448
	immune system phenotype	J:201448
	increased anti-double stranded DNA antibody level	J:201448
	increased anti-insulin autoantibody level	J:201448
	increased B cell number	J:201448
	increased B cell proliferation	J:201448
	increased double-positive T cell number	J:201448
	increased effector memory CD4-positive, alpha-beta T cell number	J:201448
	increased effector memory CD8-positive, alpha-beta T cell number	J:201448
	increased germinal center B cell number	J:201448
	increased IgE level	J:201448
	increased IgG1 level	J:201448
	increased IgG3 level	J:201448
	increased IgM level	J:201448
	increased inflammatory response	J:201448
	increased interleukin-2 secretion	J:201448
	increased regulatory T cell number	J:201448
	increased spleen germinal center size	J:201448
	increased T cell proliferation	J:201448
	increased transitional stage T1 B cell number	J:201448
	spleen hyperplasia	J:201448
	thymus hyperplasia	J:201448
\Ptpn22^tm1.1Kas/\Ptpn22^tm1.1Kas (involves: C57BL/6)	abnormal dendritic cell physiology	J:176519
	enlarged spleen	J:176519
	enlarged thymus	J:176519
	immune system phenotype	J:176519
	increased B cell proliferation	J:176519
	increased CD4-positive, alpha-beta T cell number	J:176519
	increased CD8-positive, alpha-beta T cell number	J:176519
	increased dendritic cell number	J:176519
	increased IgG2a level	J:176519
	increased IgG3 level	J:176519
	increased IgM level	J:176519
	increased interleukin-12 secretion	J:176519
	increased spleen germinal center number	J:176519
	increased spleen germinal center size	J:176519
	increased T cell number	J:176519
	increased T cell proliferation	J:176519
\Ptpn22^tm1.1Kas/\Ptpn22^tm1.1Kas \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	immune system phenotype	J:176519
\Ptpn22^tm1.1Kas/\Ptpn22^tm1.1Kas \Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:176519
	increased T cell proliferation	J:176519
\Ptpn22^tm1Achn/\Ptpn22^tm1Achn (involves: C57BL/6)	abnormal Peyer's patch germinal center morphology	J:90029
	abnormal T cell physiology	J:90029
	enlarged lymph nodes	J:90029
	enlarged spleen	J:90029
	increased B cell number	J:90029
	increased follicular B cell number	J:90029
	increased IgE level	J:90029
	increased IgG1 level	J:90029
	increased IgG2a level	J:90029
	increased spleen germinal center number	J:90029
\Ptpn22^tm2Achn/\Ptpn22^tm2Achn (involves: C57BL/6)	abnormal Peyer's patch germinal center morphology	J:90029
	abnormal T cell physiology	J:90029
	enlarged lymph nodes	J:90029
	enlarged spleen	J:90029
	increased B cell number	J:90029
	increased follicular B cell number	J:90029
	increased IgE level	J:90029
	increased IgG1 level	J:90029
	increased IgG2a level	J:90029
	increased spleen germinal center number	J:90029
\Ptpn22^tm2Achn/\Ptpn22^tm2Achn (B6.Cg-Ptpn22^tm2Achn)	abnormal double-positive T cell morphology	J:147129
	abnormal T cell activation	J:147129
	abnormal T cell subpopulation ratio	J:147129
	abnormal thymocyte activation	J:147129
	enlarged lymph nodes	J:147129
	increased memory T cell number	J:147129
\Ptpn22^tm2Achn/\Ptpn22^tm2Achn \Ptprc^tm1Weis/\Ptprc^tm1Weis (B6.Cg-Ptprc^tm1Weis Ptpn22^tm2Achn)	abnormal B cell activation	J:147129
	abnormal double-positive T cell morphology	J:147129
	abnormal follicular B cell physiology	J:147129
	abnormal lymphocyte cell number	J:147129
	abnormal T cell activation	J:147129
	abnormal T cell subpopulation ratio	J:147129
	abnormal thymocyte activation	J:147129
	decreased follicular B cell number	J:147129
	enlarged lymph nodes	J:147129
	glomerulonephritis	J:147129
	increased autoantibody level	J:147129
	increased memory T cell number	J:147129
	increased plasma cell number	J:147129
	increased transitional stage B cell number	J:147129
	liver inflammation	J:147129
	lung inflammation	J:147129
\Ptprc^loc/\Ptprc^loc (C57BL/6JSfdAnu-Ptprc^loc/AnuApb)	abnormal B cell number	J:104190
	abnormal double-positive T cell morphology	J:104190
	abnormal memory T cell number	J:104190
	abnormal T cell morphology	J:104190
	abnormal T cell selection	J:104190
	abnormal thymocyte activation	J:104190
	arrested T cell differentiation	J:104190
	decreased CD4-positive, alpha-beta T cell number	J:104190
	decreased CD8-positive, alpha-beta T cell number	J:104190
	decreased double-positive T cell number	J:104190
	decreased T cell number	J:104190
\Ptprc^ltng/\Ptprc^ltng (C57BL/6-Ptprc^ltng)	abnormal T cell differentiation	J:158876
	decreased CD4-positive, alpha-beta T cell number	J:158876
	decreased double-positive T cell number	J:158876
	thymus hypoplasia	J:158876
\Ptprc^ltng/\Ptprc^tm1Mak (involves: 129/Sv * C57BL/6)	abnormal T cell differentiation	J:158876
	decreased CD4-positive, alpha-beta T cell number	J:158876
	decreased double-positive T cell number	J:158876
	thymus hypoplasia	J:158876
\Ptprc^ltng/\Ptprc^tm1Mak \Tg(TcraTcrb)425Cbn/0 (involves: 129/Sv * BALB/c * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:158876
	thymus hypoplasia	J:158876
\Ptprc^m1Btlr/\Ptprc^m1Btlr (involves: C57BL/6J)	absent T cells	J:152064
\Ptprc^m1Smv/\Ptprc^m1Smv (involves: C57BL/6J * C57BL/10J)	abnormal CD4-positive T cell differentiation	J:214487
	abnormal CD8-positive, alpha-beta T cell differentiation	J:214487
	abnormal immune system cell morphology	J:214487
	abnormal immune system physiology	J:214487
	CNS inflammation	J:214487
	decreased DN4 thymocyte number	J:214487
	increased DN3 thymocyte number	J:214487
	increased double-negative T cell number	J:214487
	increased susceptibility to Herpesvirales infection	J:214487
\Ptprc^m2Btlr/\Ptprc^m2Btlr (C57BL/6J-Ptprc^m2Btlr)	abnormal humoral immune response	J:216796
	decreased B-1a cell number	J:216796
	decreased B-2 B cell number	J:216796
	decreased CD4-positive, alpha-beta memory T cell number	J:216796
	decreased CD8-positive, alpha-beta memory T cell number	J:216796
	decreased mature B cell number	J:216796
	decreased memory B cell number	J:216796
	decreased memory T cell number	J:216796
	decreased single-positive T cell number	J:216796
	increased B-1 B cell number	J:216796
	increased B-1b cell number	J:216796
	increased dendritic cell number	J:216796
	increased neutrophil cell number	J:216796
	increased single-positive T cell number	J:216796
\Ptprc^m3Btlr/\Ptprc^m3Btlr (C57BL/6J-Ptprc^m3Btlr)	decreased B cell number	J:254899
	decreased B-1a cell number	J:254899
	decreased B-2 B cell number	J:254899
	decreased CD8-positive, alpha-beta T cell number	J:254899
	increased B-1b cell number	J:254899
\Ptprc^m4Btlr/\Ptprc^m4Btlr (C57BL/6J-Ptprc^m4Btlr)	decreased B cell number	J:264808
	decreased CD4-positive, alpha-beta T cell number	J:264808
	decreased CD8-positive, alpha-beta T cell number	J:264808
	decreased CD8-positive, naive alpha-beta T cell number	J:264808
	decreased single-positive T cell number	J:264808
	decreased T cell number	J:264808
	increased B-1 B cell number	J:264808
	increased central memory CD4-positive, alpha-beta T cell number	J:264808
	increased central memory CD8 positive, alpha-beta T cell number	J:264808
	increased effector memory CD4-positive, alpha-beta T cell number	J:264808
	increased effector memory CD8-positive, alpha-beta T cell number	J:264808
\Ptprc^M5Btlr/\Ptprc^M5Btlr (C57BL/6J-Ptprc^M5Btlr)	increased alpha-beta T cell number	J:265143
\Ptprc^M6Btlr/\Ptprc^M6Btlr (C57BL/6J-Ptprc^M6Btlr)	decreased B-1a cell number	J:265186
	decreased B-1b cell number	J:265186
	decreased CD8-positive, naive alpha-beta T cell number	J:265186
	increased B-1 B cell number	J:265186
\Ptprc^m7Btlr/\Ptprc^m7Btlr (C57BL/6J-Ptprc^m7Btlr)	decreased alpha-beta T cell number	J:267486
	decreased B cell number	J:267486
	decreased CD4-positive, alpha-beta T cell number	J:267486
	decreased CD8-positive, alpha-beta T cell number	J:267486
	decreased CD8-positive, naive alpha-beta T cell number	J:267486
	decreased NK T cell number	J:267486
	increased B-1 B cell number	J:267486
	increased central memory CD4-positive, alpha-beta T cell number	J:267486
	increased central memory CD8 positive, alpha-beta T cell number	J:267486
	increased effector memory CD4-positive, alpha-beta T cell number	J:267486
	increased effector memory CD8-positive, alpha-beta T cell number	J:267486
\Ptprc^M8Btlr/\Ptprc^M8Btlr (C57BL/6J-Ptprc^M8Btlr)	increased B-1 B cell number	J:267487
\Ptprc^M8Btlr/\Ptprc^M8Btlr (C57BL/6J-Ptprc^M8Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:267487
\Ptprc^M9Btlr/\Ptprc^M9Btlr (C57BL/6J-Ptprc^M9Btlr)	abnormal B cell differentiation	J:272745
	abnormal CD8-positive, alpha beta T cell morphology	J:272745
	abnormal lymphocyte morphology	J:272745
	decreased B cell number	J:272745
	decreased NK cell number	J:272745
	increased CD8-positive, alpha-beta T cell number	J:272745
	increased effector memory CD4-positive, alpha-beta T cell number	J:272745
\Ptprc^M10Btlr/\Ptprc^M10Btlr (C57BL/6J-Ptprc^M10Btlr)	decreased B-1b cell number	J:272777
\Ptprc^M10Btlr/\Ptprc^M10Btlr (C57BL/6J-Ptprc^M10Btlr)	decreased IgE level	J:272777
\Ptprc^M11Btlr/\Ptprc^M11Btlr (C57BL/6J-Ptprc^M11Btlr)	abnormal B cell differentiation	J:274863
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274863
	increased B-1 B cell number	J:274863
\Ptprc^m12Btlr/\Ptprc^m12Btlr (C57BL/6J-Ptprc^m12Btlr)	decreased B cell number	J:274972
	decreased CD4-positive, alpha-beta T cell number	J:274972
	decreased CD8-positive, alpha-beta T cell number	J:274972
	decreased CD8-positive, naive alpha-beta T cell number	J:274972
	decreased central memory CD8 positive, alpha-beta T cell number	J:274972
	decreased effector memory CD4-positive, alpha-beta T cell number	J:274972
	decreased T cell number	J:274972
	increased B-1 B cell number	J:274972
\Ptprc^nim/\Ptprc^nim (C57BL/6JAnu-Ptprc^nim)	decreased B cell number	J:225105
	decreased leukocyte cell number	J:225105
	decreased T cell number	J:225105
\Ptprc^rain/\Ptprc^rain (C57BL/6JAnu-Ptprc^rain/AnuApb)	abnormal leukocyte morphology	J:104190
\Ptprc^strm/\Ptprc^strm (C57BL/6JAnu-Ptprc^strm/AnuApb)	decreased B cell number	J:104190
\Ptprc^strm/\Ptprc^strm (C57BL/6JAnu-Ptprc^strm/AnuApb)	decreased T cell number	J:104190
\Ptprc^tm1Holm/\Ptprc^tm1Holm (involves: 129/Sv * C57BL/6)	abnormal B cell number	J:33466
	abnormal lymphopoiesis	J:33466
	abnormal T cell differentiation	J:33466
	decreased CD4-positive, alpha-beta T cell number	J:33466
	decreased CD8-positive, alpha-beta T cell number	J:33466
	decreased double-positive T cell number	J:33466
	decreased T cell number	J:33466
	decreased thymocyte number	J:33466
	increased double-negative T cell number	J:33466
	spleen hyperplasia	J:33466
\Ptprc^tm1Holm/\Ptprc^tm1Holm \Tg(LckF505)2964Rmp/? (involves: 129/Sv C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:64671
	thymus hyperplasia	J:64671
\Ptprc^tm1Holm/\Ptprc^tm1Holm \Tg(LckF505)3073Rmp/? (involves: 129/Sv C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:64671
	thymus hyperplasia	J:64671
\Ptprc^tm1Mak/\Ptprc^tm1Mak (involves: 129/Sv * C57BL/6)	abnormal response to infection	J:13163
	abnormal T cell subpopulation ratio	J:13163
	arrested T cell differentiation	J:158876
	decreased B cell proliferation	J:13163
	decreased CD4-positive, alpha-beta T cell number	J:13163
	decreased CD8-positive, alpha-beta T cell number	J:13163
	decreased cytotoxic T cell cytolysis	J:13163
	decreased T cell number	J:13163
	decreased T cell proliferation	J:13163
	decreased thymocyte number	J:13163
	increased double-negative T cell number	J:13163
\Ptprc^tm1Mak/\Ptprc^tm1Mak (involves: 129)	abnormal osteoclast morphology	J:141275
	abnormal osteoclast physiology	J:141275
	decreased mast cell degranulation	J:110782
	decreased susceptibility to type I hypersensitivity reaction	J:110782
\Ptprc^tm1Mak/\Ptprc^tm1Mak (B6.Cg-Ptprc^tm1Mak)	abnormal CD4-positive, alpha-beta intraepithelial T cell morphology	J:111646
	abnormal intraepithelial T cell morphology	J:111646
	abnormal intraepithelial T cell number	J:111646
	abnormal NK cell physiology	J:109462
	abnormal T cell differentiation	J:111646
	decreased cytotoxic T cell cytolysis	J:111646
	decreased gamma-delta intraepithelial T cell number	J:111646
	increased T cell apoptosis	J:111646
\Ptprc^tm1Mak/\Ptprc^tm1Mak \Ptprj^tm1.2Weis/\Ptprj^tm1.2Weis (involves: 129/Sv * 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal B cell calcium ion homeostasis	J:131736
	abnormal cytokine secretion	J:131736
	abnormal follicular B cell morphology	J:131736
	abnormal myelopoiesis	J:131736
	decreased B cell number	J:131736
	impaired macrophage phagocytosis	J:131736
\Ptprc^tm1Mak/\Ptprc^tm1Mak \Ptprj^tm1.2Weis/\Ptprj^tm1.2Weis (B6.Cg-Ptprc^tm1Mak Ptprj^tm1.2Weis)	abnormal B cell differentiation	J:131736
	abnormal follicular B cell morphology	J:131736
	abnormal myelopoiesis	J:131736
	abnormal spleen morphology	J:131736
	abnormal transitional stage B cell morphology	J:131736
	decreased B cell number	J:131736
	decreased immature B cell number	J:131736
	decreased mature B cell number	J:131736
	liver inflammation	J:131736
	lung inflammation	J:131736
\Ptprc^tm1Mak/\Ptprc^tm1Mak \Tg(TcraTcrb)425Cbn/0 (involves: 129/Sv * BALB/c * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:158876
\Ptprc^tm1Tyb/\Ptprc^tm1Tyb (C.129S2-Ptprc^tm1Tyb)	abnormal positive T cell selection	J:57681
	abnormal T cell differentiation	J:57681
	abnormal T cell physiology	J:57681
	decreased CD4-positive, alpha-beta T cell number	J:57681
	decreased CD8-positive, alpha-beta T cell number	J:57681
	decreased double-positive T cell number	J:57681
	enlarged spleen	J:57681
	immune system phenotype	J:57681
	increased double-negative T cell number	J:57681
	thymus hypoplasia	J:57681
\Ptprc^tm1Tyb/\Ptprc^tm1Tyb (B6.129S2-Ptprc^tm1Tyb)	abnormal chemokine secretion	J:98190
	abnormal cytokine secretion	J:98190
	abnormal NK cell physiology	J:98190
	increased NK cell number	J:98190
\Ptprc^tm1Weis/\Ptprc⁺ (involves: 129X1/SvJ * C57BL/6)	increased anti-double stranded DNA antibody level	J:66501
	increased IgG2a level	J:66501
	increased susceptibility to autoimmune disorder	J:66501
\Ptprc^tm1Weis/\Ptprc^tm1Weis (involves: 129X1/SvJ * C57BL/6)	abnormal B cell activation	J:66501
	abnormal granulocyte differentiation	J:66501
	abnormal immune system organ morphology	J:66501
	abnormal leukocyte cell number	J:66501
	abnormal T cell activation	J:66501
	enlarged lymph nodes	J:66501
	enlarged spleen	J:66501
	glomerulonephritis	J:66501
	increased anti-double stranded DNA antibody level	J:66501
	increased B cell number	J:66501
	increased IgA level	J:66501
	increased IgG2a level	J:66501
	increased plasmacytoid dendritic cell number	J:66501
	increased spleen red pulp amount	J:66501
	increased spleen white pulp amount	J:66501
	increased susceptibility to autoimmune disorder	J:66501
	increased T cell number	J:66501
	lymph node hyperplasia	J:66501
\Ptprc^tm1Weis/\Ptprc^tm1Weis (B6.129X1-Ptprc^tm1Weis)	abnormal B cell activation	J:147129
	abnormal double-positive T cell morphology	J:147129
	abnormal follicular B cell physiology	J:147129
	abnormal T cell activation	J:147129
	abnormal T cell subpopulation ratio	J:147129
	abnormal thymocyte activation	J:147129
	decreased follicular B cell number	J:147129
	enlarged lymph nodes	J:147129
	immune system phenotype	J:109462
	increased memory T cell number	J:147129
	increased plasma cell number	J:147129
	increased transitional stage B cell number	J:147129
	liver inflammation	J:147129
	lung inflammation	J:147129
\Ptprcap^tm1Svn/\Ptprcap^tm1Svn (involves: C57BL/6)	enlarged lymph nodes	J:58712
\Ptprcap^tm1Svn/\Ptprcap^tm1Svn (involves: C57BL/6)	lymphoid hyperplasia	J:58712
\Ptprcap^tm1Tho/\Ptprcap^tm1Tho (involves: 129X1/SvJ)	immune system phenotype	J:58711
\Ptprcap^tm1Tkda/\Ptprcap^tm1Tkda (involves: 129X1/SvJ)	abnormal cytotoxic T cell physiology	J:48387
	decreased B cell proliferation	J:48387
	decreased T cell proliferation	J:48387
	immune system phenotype	J:48387
\Ptprd^{tm2a(KOMP)Wtsi}/\Ptprd^{tm2a(KOMP)Wtsi} (C57BL/6N-Ptprd^{tm2a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Ptpre^tm1Ael/\Ptpre^tm1Ael (involves: 129S6/SvEvTac * C57BL/6)	abnormal osteoclast differentiation	J:90031
	abnormal osteoclast physiology	J:90031
\Ptprf^tm1Wjh/\Ptprf^tm1Wjh (involves: 129P2/OlaHsd)	immune system phenotype	J:119456
\Ptprj^tm1.2Weis/\Ptprj^tm1.2Weis (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	abnormal B cell differentiation	J:131736
	abnormal splenic cell ratio	J:131736
	increased B-2 B cell number	J:131736
	increased marginal zone B cell number	J:131736
\Ptprn^tm1Aln/\Ptprn^tm1Aln (NOD.129S4-Ptprn^tm1Aln)	increased susceptibility to autoimmune diabetes	J:107161
\Ptprn^tm1Aln/\Ptprn^tm1Aln (NOD.129S4-Ptprn^tm1Aln)	insulitis	J:107161
\Ptprz1^{em1(IMPC)Ccpcz}/\Ptprz1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ptprz1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Ptprz1^tm1Mno/\Ptprz1^tm1Mno (B6.129-Ptprz1^tm1Mno)	decreased susceptibility to bacterial infection	J:85826
\Ptprz1^tm1Schl/\Ptprz1^tm1Schl (involves: 129 * Swiss Webster)	increased susceptibility to experimental autoimmune encephalomyelitis	J:79860
\Ptrh2^tm1.1Eruo/\Ptrh2^tm1.1Eruo (C57BL/6-Ptrh2^tm1.1Eruo)	decreased neutrophil cell number	J:131853
\Pts^{tm1b(EUCOMM)Wtsi}/\Pts⁺ (C57BL/6N-Pts^{tm1b(EUCOMM)Wtsi}/H)	increased large unstained cell number	J:211773
\Pttg1^{tm1b(EUCOMM)Wtsi}/\Pttg1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Pttg1^{tm1b(EUCOMM)Wtsi}/Tcp)	small spleen	J:211773
\Pttg1^tm1Sme/\Pttg1^tm1Sme (involves: 129S4/SvJae * C57BL/6)	abnormal immune system organ morphology	J:72267
	decreased IgG level	J:72267
	decreased IgM level	J:72267
	decreased immunoglobulin level	J:72267
	decreased spleen weight	J:72267
	increased T cell number	J:72267
	thymus hyperplasia	J:72267
\Ptx3^tm1Mant/\Ptx3^tm1Mant (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal dendritic cell physiology	J:85080
	abnormal macrophage physiology	J:85080
	abnormal professional antigen presenting cell physiology	J:85080
	abnormal T-helper 1 physiology	J:85080
	impaired macrophage phagocytosis	J:85080
	increased susceptibility to bacterial infection	J:85080
	increased susceptibility to fungal infection	J:85080
	lung inflammation	J:85080
\Ptx3^tm1Zuk/\Ptx3^tm1Zuk (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to Coronaviridae infection	J:188421
\Puf60^tm1.1Kmtsu/\Puf60⁺ \Trp53^tm1Sia/\Trp53^tm1Sia (involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj)	increased leukocyte cell number	J:233347
	increased spleen weight	J:233347
	increased T cell derived lymphoma incidence	J:233347
	increased thymus weight	J:233347
\Pura^tm1Kkh/\Pura^tm1Kkh (involves: 129)	abnormal spleen morphology	J:85759
	abnormal thymus morphology	J:85759
	decreased spleen weight	J:85759
	small spleen	J:85759
\Pvr^tm1Gbn/\Pvr^tm1Gbn (either: (involves: 129S2/SvPas) or (involves: 129S2/SvPas * BALB/c))	abnormal response to infection	J:123540
	decreased IgA level	J:123540
	decreased IgG1 level	J:123540
	decreased IgG2a level	J:123540
	decreased IgG2b level	J:123540
	decreased IgG level	J:123540
\Pvrig^em1(IMPC)Mbp/\Pvrig^em1(IMPC)Mbp (C57BL/6N-Pvrig^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Pvrig^tm1.2Sgng/\Pvrig^tm1.2Sgng (B6(Cg)-Pvrig^tm1.1Sgng)	abnormal CD8-positive, alpha-beta T cell physiology	J:324171
\Pvrig^tm1.2Sgng/\Pvrig^tm1.2Sgng (B6(Cg)-Pvrig^tm1.1Sgng)	abnormal T cell physiology	J:324171
\Pwwp3a^em1(IMPC)Tcp/\Pwwp3a^em1(IMPC)Tcp (C57BL/6NCrl-Pwwp3a^em1(IMPC)Tcp/Tcp)	small thymus	J:211773
\Pxdn^mhdakta048/\Pxdn^mhdakta048 (involves: C3HeB/FeJ * C57BL/6J)	eye inflammation	J:213336
\Pycard^tm1Ayaz/\Pycard^tm1Ayaz \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	decreased interleukin-1 alpha secretion	J:191239
	decreased interleukin-1 beta secretion	J:191239
	decreased interleukin-6 secretion	J:191239
	decreased tumor necrosis factor secretion	J:191239
\Pycard^tm1Flv/\Pycard^tm1Flv (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage physiology	J:113333
	decreased circulating interleukin-1 beta level	J:113333
	decreased circulating interleukin-18 level	J:113333, J:158969
	decreased interleukin-1 alpha secretion	J:113333
	decreased interleukin-1 beta secretion	J:113333
	decreased NK cell number	J:158969
	decreased susceptibility to endotoxin shock	J:113333
	decreased susceptibility to type IV hypersensitivity reaction	J:113333
	increased susceptibility to Herpesvirales infection	J:158969
\Pycard^tm1Flv/\Pycard^tm1Flv (B6.129S5-Pycard^tm1Flv)	enlarged Peyer's patches	J:173245
	increased IgA level	J:173245
	increased IgG2c level	J:173245
	increased susceptibility to induced colitis	J:173245
\Pycard^tm1Flv/\Pycard^tm1Flv \Slc11a1^s/\Slc11a1^s (B6.129S5-Pycard^tm1Flv)	increased susceptibility to bacterial infection	J:124378
\Pycard^tm1Nnz/\Pycard^tm1Nnz (involves: 129 * C57BL/6)	decreased interleukin-1 beta secretion	J:129871
\Pycard^tm1Nnz/\Pycard^tm1Nnz (involves: 129 * C57BL/6)	decreased interleukin-18 secretion	J:129871
\Pycard^tm1Tno/\Pycard^tm1Tno (involves: 129S4/SvJae * C57BL/6)	decreased interferon-gamma secretion	J:100807
	decreased interleukin-1 beta secretion	J:100807
	decreased interleukin-18 secretion	J:100807
	decreased susceptibility to endotoxin shock	J:100807
\Pycard^tm1Vmd/\Pycard^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	decreased inflammatory response	J:91292
	decreased interleukin-1 alpha secretion	J:91292
	decreased interleukin-1 beta secretion	J:91292
	decreased interleukin-18 secretion	J:91292
\Pycard^tm1Vmd/\Pycard^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ)	abnormal response to infection	J:106976
	decreased interleukin-1 beta secretion	J:124226, J:106976
	decreased interleukin-18 secretion	J:106976
\Pycard^tm1Vmd/\Pycard^tm1Vmd (B6.129-Pycard^tm1Vmd)	abnormal macrophage physiology	J:160545
	decreased circulating interleukin-1 beta level	J:193522
	decreased circulating interleukin-18 level	J:193522
	decreased interleukin-1 beta secretion	J:193522, J:160545
	decreased susceptibility to endotoxin shock	J:193522
	increased interferon-beta secretion	J:160545
	increased tumor necrosis factor secretion	J:160545
\Pycr2^m1J/\Pycr2^m1J (involves: C3H/HeJ * C57BL/6J)	decreased basophil cell number	J:308336
	decreased leukocyte cell number	J:308336
	decreased lymphocyte cell number	J:308336
\Pycr2^{tm1a(EUCOMM)Wtsi}/\Pycr2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Pycr2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased Ly6C low monocyte number	J:211773
	decreased monocyte cell number	J:211773
\Pygl^{tm1a(KOMP)Wtsi}/\Pygl^{tm1a(KOMP)Wtsi} (C57BL/6N-Pygl^{tm1a(KOMP)Wtsi})	liver inflammation	J:284765
\Pymr^129X1/SvJMs/\Pymr^NC/JicJcl (involves: 129X1/SvJMs * NC/JicJcl)	decreased susceptibility to parasitic infection	J:92924
\Pymr^NC/JicJcl/\Pymr^NC/JicJcl (involves: 129X1/SvJMs * NC/JicJcl)	increased susceptibility to parasitic infection	J:92924
\Pzp^tm1Vln/\Pzp^tm1Vln (involves: 129P2/OlaHsd * C57BL)	increased susceptibility to induced pancreatitis	J:28328
\Pzp^tm1Vln/\Pzp^tm1Vln (involves: 129P2/OlaHsd * C57BL)	pancreas inflammation	J:28328
\Pzp^tm1Vln/\Pzp^tm1Vln (B.129P2-Pzp^tm1Vln)	abnormal cytokine level	J:57485
\Pzp^tm1Vln/\Pzp^tm1Vln (B.129P2-Pzp^tm1Vln)	liver inflammation	J:57485
\Pzp^tm1Vln/\Pzp^tm1Vln (B6.129P2-Pzp^tm1Vln)	abnormal cytokine secretion	J:113532
\Qpct^tm1.1Gne/\Qpct^tm1.1Gne (C57BL/6N-Qpct^tm1.1Gne)	immune system phenotype	J:324112
\Qpct^tm1.1Gne/\Qpct^tm1.1Gne \Qpctl^tm1.1Gne/\Qpctl^tm1.1Gne (C57BL/6N-Qpctl^tm1.1Gne Qpct^tm1.1Gne)	decreased monocyte cell number	J:324112
\Qpctl^tm1.1Gne/\Qpctl^tm1.1Gne (C57BL/6N-Qpctl^tm1.1Gne)	decreased monocyte cell number	J:324112
\Qpctl^tm1.1Gne/\Qpctl^tm1.1Gne (C57BL/6N-Qpctl^tm1.1Gne)	increased monocyte cell number	J:324112
\Qprt^{Gt(OST337946)Lex}/\Qprt^{Gt(OST337946)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal cytokine level	J:282516
	abnormal macrophage morphology	J:282516
	abnormal macrophage physiology	J:282516
\Qrich1^b2b2404Clo/\Qrich1^b2b2404Clo (C57BL/6J-Qrich1^b2b2404Clo)	thymus hypoplasia	J:175213
\Qsox1^b2b2673Clo/\Qsox1^b2b2673Clo (C57BL/6J-Qsox1^b2b2673Clo)	spleen hypoplasia	J:175213
\Rab2a^em2(IMPC)Tcp/\Rab2a⁺ (C57BL/6NCrl-Rab2a^em2(IMPC)Tcp/Tcp)	increased spleen weight	J:211773
\Rab6b^{Gt(OST68543)Lex}/\Rab6b^{Gt(OST68543)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	immune system phenotype	J:103485
\Rab7^tm1.1Ale/\Rab7^tm1.1Ale \Tg(Cd4-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	abnormal T cell morphology	J:211733
	abnormal T cell physiology	J:211733
	abnormal T cell subpopulation ratio	J:211733
	decreased CD4-positive, alpha-beta T cell number	J:211733
	decreased CD8-positive, alpha-beta T cell number	J:211733
	decreased T cell number	J:211733
	decreased T cell proliferation	J:211733
\Rab7b^tm1Ciphe/\Rab7b^tm1Ciphe \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6N * CBA)	abnormal dendritic cell migration	J:321707
\Rab11a^tm1.1Ngao/\Rab11a^tm1.1Ngao \Tg(Vil1-cre)997Gum/0 (involves: 129S4/SvJae * C57BL/6J * SJL)	abnormal cytokine secretion	J:215917
	increased cytokine level	J:278932
	increased interleukin-1 beta secretion	J:215917
	increased interleukin-6 secretion	J:215917
	intestinal inflammation	J:215917
\Rab11a^tm1.1Ngao/\Rab11a^tm1.1Ngao \Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	increased interleukin-6 secretion	J:215917
\Rab11fip2^em1(IMPC)Mbp/\Rab11fip2^em1(IMPC)Mbp (C57BL/6NCrl-Rab11fip2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Rab13^tm1.1Ktg/\Rab13^tm1.1Ktg (involves: C57BL/6)	abnormal leukocyte adhesion	J:259093
	abnormal T cell physiology	J:259093
	decreased lymphocyte cell number	J:259093
	decreased lymphocyte chemotaxis	J:259093
	immune system phenotype	J:259093
	impaired leukocyte migration	J:259093
	lymphoid hypoplasia	J:259093
	small inguinal lymph nodes	J:259093
	small spleen	J:259093
\Rab19^{tm1b(EUCOMM)Hmgu}/\Rab19^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rab19^{tm1b(EUCOMM)Hmgu}/Ics)	decreased large unstained cell number	J:211773
	increased eosinophil cell number	J:211773
\Rab20^{tm1a(EUCOMM)Hmgu}/\Rab20^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal macrophage physiology	J:243883
\Rab26^em1Guwa/\Rab26^em1Guwa (Not Specified)	increased susceptibility to endotoxin shock	J:306921
\Rab27a^ash/\Rab27a^ash (involves: C3H/HeDiSn)	abnormal NK cell degranulation	J:111253
	decreased cytotoxic T cell cytolysis	J:111253, J:67600
	immune system phenotype	J:111253
	impaired natural killer cell mediated cytotoxicity	J:111253
\Rab27a^ash/\Rab27a^ash (B6.C3Sn-Rab27a^ash)	abnormal cytotoxic T cell physiology	J:193137
	decreased cytotoxic T cell cytolysis	J:193137
	decreased leukocyte cell number	J:193137
	decreased neutrophil cell number	J:193137
	decreased NK cell degranulation	J:193137
	increased circulating interferon-gamma level	J:193137
	increased circulating interleukin-1 beta level	J:193137
	increased circulating interleukin-6 level	J:193137
	increased circulating tumor necrosis factor level	J:193137
	increased susceptibility to Riboviria infection	J:193137
\Rab27a^cct/\Rab27a^cct (C57BL/6-Rab27a^cct)	abnormal neutrophil physiology	J:114299
\Rab27a^cct/\Rab27a^cct (C57BL/6-Rab27a^cct)	immune system phenotype	J:114299
\Rab32^{tm1c(KOMP)Wtsi}/\Rab32^{tm1c(KOMP)Wtsi} \Tg(Itgax-cre)1-1Reiz/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * CBA)	abnormal cytokine secretion	J:267497
	increased neutrophil cell number	J:267497
	increased susceptibility to bacterial infection	J:231298, J:267497
	increased susceptibility to colitis induced morbidity/mortality	J:267497
	increased susceptibility to induced colitis	J:267497
\Rab33b^em1Rmr/\Rab33b⁺ (involves: C57BL/6)	abnormal osteoclast differentiation	J:338833
	abnormal osteoclast morphology	J:338833
	increased osteoclast cell number	J:338833
\Rab33b^em1Rmr/\Rab33b^em1Rmr (involves: C57BL/6)	abnormal osteoclast morphology	J:338833
\Rab33b^em1Rmr/\Rab33b^em1Rmr (involves: C57BL/6)	increased osteoclast cell number	J:338833
\Rab39b^em1(IMPC)Tcp/Y (C57BL/6NCrl-Rab39b^em1(IMPC)Tcp/Tcp)	decreased spleen weight	J:211773
\Rab43^tm1.2Kmm/\Rab43^tm1.2Kmm (B6.129S(C)-Rab43^tm1.2Kmm)	abnormal dendritic cell antigen presentation	J:101977
\Rab44^em1Rbrc/\Rab44^em1Rbrc (Not Specified)	abnormal mast cell physiology	J:304506
\Rab44^em1Rbrc/\Rab44^em1Rbrc (Not Specified)	increased susceptibility to type I hypersensitivity reaction	J:304506
\Rabgap1^{tm1b(EUCOMM)Hmgu}/\Rabgap1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rabgap1^{tm1b(EUCOMM)Hmgu}/Ieg)	decreased effector memory T-helper cell number	J:211773
	enlarged spleen	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	small spleen	J:211773
\Rabgef1^tm1Glli/\Rabgef1^tm1Glli (either: (involves: 129P2/OlaHsd * 129S/SvEv) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal inflammatory response	J:91790
	abnormal mast cell morphology	J:91790
	chronic inflammation	J:91790
	cutaneous mastocytosis	J:91790
	increased IgE level	J:91790
	increased interleukin-6 secretion	J:91790
	increased tumor necrosis factor secretion	J:91790
\Rabgef1^tm2Glli/\Rabgef1^tm2Glli (WBB6F1)	increased interleukin-6 secretion	J:91790
\Rabgef1^tm2Glli/\Rabgef1^tm2Glli (WBB6F1)	increased tumor necrosis factor secretion	J:91790
\Rabggta^gm/\Rabggta⁺ (C57BL/6J-Rabggta^gm)	decreased cytotoxic T cell cytolysis	J:67600
\Rabggta^gm/\Rabggta^gm (C57BL/6J-Rabggta^gm)	decreased cytotoxic T cell cytolysis	J:67600
\Rabggta^{tm1.1(KOMP)Vlcg}/\Rabggta⁺ (C57BL/6N-Rabggta^{tm1.1(KOMP)Vlcg}/Nju)	decreased neutrophil cell number	J:211773
\Rabl3^xm/\Rabl3^em1Btlr (C57BL/6J-Rabl3^xm Rabl3^em1Btlr)	decreased leukocyte cell number	J:287198
	decreased lymphocyte cell number	J:287198
	spleen hypoplasia	J:287198
	thymus hypoplasia	J:287198
\Rabl3^xm/\Rabl3^xm (C57BL/6J-Rabl3^xm)	abnormal T cell morphology	J:287198
\Rabl3^xm/\Rabl3^xm (C57BL/6J-Rabl3^xm)	abnormal T cell number	J:287198
\Rac1^em1(IMPC)Mbp/\Rac1⁺ (C57BL/6N-Rac1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Rac1^tm1Djk/\Rac1^tm1.1Djk \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	decreased acute inflammation	J:83457
	decreased leukocyte cell number	J:83457
	decreased neutrophil cell number	J:83457
	impaired neutrophil chemotaxis	J:83457
	impaired neutrophil recruitment	J:83457
\Rac2^em1Shl/\Rac2⁺ (involves: C57BL/6)	abnormal neutrophil morphology	J:276213
	decreased alpha-beta T cell number	J:276213
	decreased CD4-positive, alpha-beta T cell number	J:276213
	decreased CD8-positive, alpha-beta T cell number	J:276213
	decreased leukocyte cell number	J:276213
	decreased lymphocyte cell number	J:276213
	decreased T cell number	J:276213
	increased neutrophil cell number	J:276213
\Rac2^m1Btlr/\Rac2⁺ (C57BL/6J-Rac2^m1Btlr)	decreased IgM level	J:221478
\Rac2^m1Btlr/\Rac2⁺ (C57BL/6J-Rac2^m1Btlr)	impaired humoral immune response	J:221478
\Rac2^m1Btlr/\Rac2^m1Btlr (C57BL/6J-Rac2^m1Btlr)	decreased IgM level	J:221478
\Rac2^m1Btlr/\Rac2^m1Btlr (C57BL/6J-Rac2^m1Btlr)	impaired humoral immune response	J:221478
\Rac2^M2Btlr/\Rac2⁺ (C57BL/6J-Rac2^M2Btlr)	decreased B-1 B cell number	J:231801
	decreased B-1a cell number	J:231801
	increased B-1b cell number	J:231801
\Rac2^M2Btlr/\Rac2^M2Btlr (C57BL/6J-Rac2^M2Btlr)	decreased B-1 B cell number	J:231801
	decreased B-1a cell number	J:231801
	increased B-1b cell number	J:231801
\Rac2^m3Btlr/\Rac2⁺ (C57BL/6J-Rac2^m3Btlr)	decreased B-1a cell number	J:236680
\Rac2^m3Btlr/\Rac2⁺ (C57BL/6J-Rac2^m3Btlr)	increased B-1 B cell number	J:236680
\Rac2^m3Btlr/\Rac2^m3Btlr (C57BL/6J-Rac2^m3Btlr)	decreased B cell number	J:236680
	decreased B-1a cell number	J:236680
	decreased IgM level	J:236680
	decreased response to antigen	J:236680
	increased B-1b cell number	J:236680
	increased neutrophil cell number	J:236680
\Rac2^M4Btlr/\Rac2⁺ (C57BL/6J-Rac2^M4Btlr)	abnormal cytotoxic T cell physiology	J:255273
	decreased alpha-beta T cell number	J:255273
	decreased CD4-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, naive alpha-beta T cell number	J:255273
	decreased IgG level	J:255273
	decreased IgM level	J:255273
	impaired humoral immune response	J:255273
	impaired natural killer cell mediated cytotoxicity	J:255273
	increased alpha-beta T cell number	J:255273
	increased CD8-positive, alpha-beta T cell number	J:255273
	increased central memory CD8 positive, alpha-beta T cell number	J:255273
	increased effector memory CD4-positive, alpha-beta T cell number	J:255273
	increased effector memory CD8-positive, alpha-beta T cell number	J:255273
	increased IgM level	J:255273
\Rac2^M4Btlr/\Rac2^M4Btlr (C57BL/6J-Rac2^M4Btlr)	abnormal cytotoxic T cell physiology	J:255273
	decreased alpha-beta T cell number	J:255273
	decreased CD4-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, alpha-beta T cell number	J:255273
	decreased CD8-positive, naive alpha-beta T cell number	J:255273
	decreased IgE level	J:255273
	decreased IgG level	J:255273
	decreased IgM level	J:255273
	impaired humoral immune response	J:255273
	impaired natural killer cell mediated cytotoxicity	J:255273
	increased alpha-beta T cell number	J:255273
	increased CD8-positive, alpha-beta T cell number	J:255273
	increased central memory CD4-positive, alpha-beta T cell number	J:255273
	increased central memory CD8 positive, alpha-beta T cell number	J:255273
	increased effector memory CD4-positive, alpha-beta T cell number	J:255273
	increased effector memory CD8-positive, alpha-beta T cell number	J:255273
\Rac2^M5Btlr/\Rac2⁺ (C57BL/6J-Rac2^M5Btlr)	increased CD8-positive, alpha-beta T cell number	J:255283
\Rac2^M5Btlr/\Rac2^M5Btlr (C57BL/6J-Rac2^M5Btlr)	decreased B-1a cell number	J:255283
	increased B-1b cell number	J:255283
	increased CD8-positive, alpha-beta T cell number	J:255283
\Rac2^tm1Mddw/\Rac2^tm1Mddw (involves: 129S/SvEv * C57BL/6)	abnormal granulocyte differentiation	J:53362
	abnormal neutrophil physiology	J:53362
	decreased leukocyte cell number	J:53362
	decreased neutrophil cell number	J:53362
	decreased T cell proliferation	J:119437
	impaired neutrophil chemotaxis	J:53362
	increased leukocyte cell number	J:53362
	increased neutrophil cell number	J:53362
	increased susceptibility to bacterial infection	J:53362
\Rac2^tm1Mddw/\Rac2^tm1Mddw (involves: 129S/SvEv)	abnormal neutrophil physiology	J:131305
\Rac2^tm1Mddw/\Rac2^tm1Mddw (B6.129S-Rac2^tm1Mddw)	abnormal neutrophil physiology	J:83457
\Rac2^tm1Mddw/\Rac2^tm1Mddw \Tg(TcrAND)53Hed/0 (involves: 129S/SvEv * C57BL/6 * SJL)	abnormal T cell activation	J:119437
	decreased circulating interleukin-2 level	J:119437
	decreased T cell proliferation	J:119437
\Racgap1^tm1Mahi/\Racgap1^tm1Mahi \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal B cell differentiation	J:137760
	abnormal myelopoiesis	J:137760
	decreased pro-B cell number	J:137760
	decreased transitional stage B cell number	J:137760
\Rad1^tm1.1Jcbs/\Rad1^tm1.1Jcbs (involves: 129P2/OlaHsd * 129S4/SvJaeSor)	immune system phenotype	J:169551
\Rad21^tm1.1Mmk/\Rad21^tm1.1Mmk \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:175827
	abnormal CD4-positive, alpha-beta T cell physiology	J:175827
	abnormal T cell differentiation	J:175827
	decreased CD4-positive, alpha-beta T cell number	J:175827
	decreased CD8-positive, alpha-beta T cell number	J:175827
	decreased double-positive T cell number	J:175827
\Rad23b^tm1Gvh/\Rad23b^tm1Gvh (involves: 129P2/OlaHsd * C57BL/6)	blepharitis	J:74288
	conjunctivitis	J:74288
\Rad50^tm1Flv/\Rad50^tm1Flv (involves: 129S6/SvEvTac * C57BL/6)	abnormal T-helper 2 physiology	J:94870
	decreased interleukin-4 secretion	J:94870
	decreased interleukin-5 secretion	J:94870
	decreased interleukin-13 secretion	J:94870
\Rad50^tm2.1Flv/\Rad50^tm2.1Flv (B6.129S6-Rad50^tm2.1Flv)	decreased interleukin-4 secretion	J:196154
	decreased interleukin-5 secretion	J:196154
	decreased interleukin-13 secretion	J:196154
\Rad50^tm2.1Flv/\Rad50^tm2.2Flv \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:165055
	abnormal T-helper 1 physiology	J:165055
	abnormal T-helper 2 physiology	J:165055
	decreased IgE level	J:165055
	decreased inflammatory response	J:165055
	decreased interferon-gamma secretion	J:165055
	decreased interleukin-4 secretion	J:165055
	decreased interleukin-5 secretion	J:165055
	decreased interleukin-13 secretion	J:165055
	immune system phenotype	J:165055
\Rad50^tm2Jpt/\Rad50^tm2Jpt (either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal immune system cell morphology	J:78820
	abnormal immune system organ morphology	J:78820
	abnormal spleen morphology	J:78820
	abnormal thymus morphology	J:78820
	decreased B cell number	J:78820
	decreased immature B cell number	J:78820
	decreased pre-B cell number	J:78820
	decreased T cell number	J:78820
	increased late pro-B cell number	J:78820
	increased macrophage cell number	J:78820
	increased T cell derived lymphoma incidence	J:78820
	spleen hyperplasia	J:78820
\Rad50^tm2Jpt/\Rad50^tm2Jpt (involves: 129S7/SvEvBrd * C57BL/6)	decreased double-negative T cell number	J:103922
	decreased macrophage cell number	J:103922
	decreased pro-B cell number	J:103922
\Rad50^tm2Jpt/\Rad50^tm2Jpt \Smc1a^tm1Mbk/\Smc1a^tm1Mbk (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6)	abnormal pro-B cell morphology	J:103922
	decreased double-negative T cell number	J:103922
	decreased macrophage cell number	J:103922
\Rad50^tm2Jpt/\Rad50^tm2Jpt \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:78820
	increased T cell derived lymphoma incidence	J:78820
\Rad50^tm3.1Flv/\Rad50^tm3.1Flv (B6.129S6-Rad50^tm3.1Flv)	decreased interleukin-4 secretion	J:196154
	decreased interleukin-5 secretion	J:196154
	decreased interleukin-13 secretion	J:196154
\Rad50^tm4.1Flv/\Rad50^tm4.1Flv (B6.129S6-Rad50^tm4.1Flv)	decreased interleukin-5 secretion	J:196154
	decreased interleukin-13 secretion	J:196154
	increased interleukin-4 secretion	J:196154
	increased interleukin-5 secretion	J:196154
	increased interleukin-13 secretion	J:196154
\Rad52^tm1Aps/\Rad52^tm1Aps (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:50357
\Rad54l^tm1Jhjh/\Rad54l^tm1Jhjh (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:39642
\Rad54l^tm1Jhjh/\Rad54l^tm1Jhjh (involves: 129P2/OlaHsd)	immune system phenotype	J:47993
\Radil^em1(IMPC)Tcp/\Radil^em1(IMPC)Tcp (C57BL/6NCrl-Radil^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Raet1d^em1Dhr/\Raet1d^em1Dhr \Raet1e^em1Dhr/\Raet1e^em1Dhr (involves: C57BL/6)	increased natural killer cell mediated cytotoxicity	J:221188
\Raf1^tm1.1Bgn/\Raf1⁺ (involves: 129S6/SvEvTac * C57BL/6NCr)	enlarged spleen	J:172034
	increased leukocyte cell number	J:172034
	increased monocyte cell number	J:172034
	increased neutrophil cell number	J:172034
\Rag1/Rag2^tm1Mnz/\Rag1/Rag2^tm1Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:90487
	abnormal double-positive T cell morphology	J:90487
	abnormal T cell morphology	J:90487
	decreased T cell number	J:90487
\Rag1/Rag2^tm1Mnz/\Rag1/Rag2^tm1Mnz (involves: 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:90487
	abnormal double-positive T cell morphology	J:90487
	abnormal T cell morphology	J:90487
	decreased T cell number	J:90487
\Rag1^coln/\Rag1^coln (C57BL/6JAnu-Rag1^coln/AnuApb)	absent B cells	J:104190
\Rag1^coln/\Rag1^coln (C57BL/6JAnu-Rag1^coln/AnuApb)	absent T cells	J:104190
\Rag1^em2Mvw/\Rag1^em2Mvw (A/J-Rag1^em2Mvw/MvwJ)	absent B cells	J:332675
	absent T cells	J:332675
	arrested B cell differentiation	J:332675
	arrested T cell differentiation	J:332675
\Rag1^em3Mvw/\Rag1^em3Mvw (129S1/SvImJ-Rag1^em3Mvw/MvwJ)	absent B cells	J:332675
	absent T cells	J:332675
	arrested B cell differentiation	J:332675
	arrested T cell differentiation	J:332675
\Rag1^m1Anu/\Rag1^m1Anu (C57BL/6NCrlAnu-Rag1^m1Anu)	decreased lymphocyte cell number	J:104190
\Rag1^m1Btlr/\Rag1^m1Btlr (C57BL/6J-Rag1^m1Btlr)	absent late pro-B cells	J:150635
	decreased CD4-positive, alpha-beta T cell number	J:150635
	decreased CD8-positive, alpha-beta T cell number	J:150635
\Rag1^m2Btlr/\Rag1^m2Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased B cell number	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	decreased T cell number	J:185495
\Rag1^m3Btlr/\Rag1^m3Btlr (C57BL/6J-Rag1^m3Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:272858
\Rag1^m4Btlr/\Rag1^m4Btlr (C57BL/6J-Rag1^m4Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272094
	abnormal T cell differentiation	J:272094
	decreased B cell number	J:272094
	decreased CD8-positive, naive alpha-beta T cell number	J:272094
	increased alpha-beta T cell number	J:272094
	increased CD8-positive, alpha-beta T cell number	J:272094
	increased central memory CD8 positive, alpha-beta T cell number	J:272094
\Rag1^tm1(cre)Thr/? \Shcbp1^{tm1c(EUCOMM)Wtsi}/\Shcbp1^{tm1c(EUCOMM)Wtsi} (involves: C57BL/6N)	immune system phenotype	J:212898
\Rag1^tm1(cre)Thr/\Rag1^tm1(cre)Thr (Not Specified)	abnormal lymphopoiesis	J:86869
\Rag1^tm1(cre)Thr/\Rag1^tm1(cre)Thr (Not Specified)	absent lymphocyte	J:86869
\Rag1^tm1(GFP)Imku/? \Zfp335^blt/\Zfp335^blt (involves: C57BL/6 * CBA)	abnormal CD4-positive T cell differentiation	J:214793
\Rag1^tm1(GFP)Imku/\Rag1^tm1(GFP)Imku (involves: C57BL/6 * CBA)	abnormal immunoglobulin V(D)J recombination	J:79416
\Rag1^tm1.1Sadu/\Rag1^tm1.1Sadu (involves: BALB/c)	arrested B cell differentiation	J:155473
\Rag1^tm1.1Sadu/\Rag1^tm1.1Sadu \Trdc^tm1Mal/\Trdc^tm1Mal \Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/\Gt(ROSA)26Sor⁺ (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	absent gamma-delta T cells	J:187400
	decreased gamma-delta T cell number	J:187400
	increased gamma-delta T cell number	J:187400
	small thymus	J:187400
\Rag1^tm1Bal/\Rag1^tm1Bal \Tg(TcraTcrb)1100Mjb/? (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:133645
	decreased CD4-positive, alpha-beta T cell number	J:133645
	increased CD8-positive, alpha-beta T cell number	J:133645
\Rag1^tm1Bal/\Rag1^tm1Bal \Tnfrsf1a^tm1.1Gkl/\Tnfrsf1a^tm1.1Gkl (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
\Rag1^tm1Bal/\Rag1^tm1Bal \Vav1^tm2Tyb/\Vav1^tm2Tyb (involves: 129S4/SvJae * 129S8/SvEv)	arrested T cell differentiation	J:113270
\Rag1^tm1Bal/\Rag1^tm1Bal \Vav1^tm2Tyb/\Vav1^tm2Tyb \Tg(TcrAND)53Hed/0 (involves: 129S4/SvJae * 129S8/SvEv * C57BL/6 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:113270
\Rag1^tm1Fwa/\Rag1^tm1Fwa (involves: 129)	abnormal B cell differentiation	J:86464
	abnormal T cell differentiation	J:86464
	decreased B cell number	J:86464
	increased double-negative T cell number	J:86464
	thymus hypoplasia	J:86464
\Rag1^tm1Jsek/\Rag1⁺ (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:146912
	abnormal immunoglobulin heavy chain V(D)J recombination	J:146912
	abnormal T cell differentiation	J:146912
	abnormal T cell receptor beta chain V(D)J recombination	J:146912
	decreased double-positive T cell number	J:146912
\Rag1^tm1Jsek/\Rag1^tm1Jsek (involves: 129S6/SvEvTac)	abnormal immunoglobulin heavy chain V(D)J recombination	J:146912
	abnormal immunoglobulin level	J:146912
	abnormal lymphopoiesis	J:146912
	abnormal T cell receptor beta chain V(D)J recombination	J:146912
	abnormal T cell receptor V(D)J recombination	J:146912
	absent immature B cells	J:146912
	absent mature B cells	J:146912
	arrested B cell differentiation	J:146912
	arrested T cell differentiation	J:146912
	decreased CD4-positive, alpha-beta T cell number	J:146912
	decreased CD8-positive, alpha-beta T cell number	J:146912
	decreased double-positive T cell number	J:146912
	decreased gamma-delta T cell number	J:146912
	increased double-negative T cell number	J:146912
	increased pro-B cell number	J:146912
	thymus hypoplasia	J:146912
\Rag1^tm1Jsek/\Rag1^tm1Jsek \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:146912
\Rag1^tm1Mom/\Rag1⁺ \Tg(LPV-TAg1135)11Tvd/0 (involves: 129/Sv * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
\Rag1^tm1Mom/\Rag1⁺ \Tg(LPV-TAg1135)11Tvd/0 \Tg(TcrLCMV)327Sdz/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
\Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S7/SvEvBrd * CD-1)	abnormal B cell differentiation	J:1934
	abnormal immunoglobulin V(D)J recombination	J:1934
	abnormal inguinal lymph node morphology	J:1934
	abnormal T cell differentiation	J:1934
	abnormal T cell morphology	J:1934
	abnormal T cell receptor V(D)J recombination	J:1934
	absent mature B cells	J:1934
	decreased IgM level	J:1934
	spleen hypoplasia	J:1934
	thymus hypoplasia	J:1934
\Rag1^tm1Mom/\Rag1^tm1Mom (B6.129S7-Rag1^tm1Mom)	decreased IgM level	J:78613
	decreased immunoglobulin level	J:111828
	dermatitis	J:111828
	ear inflammation	J:111828
	increased eosinophil cell number	J:111828
\Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased lymphocyte cell number	J:111874
	small thymus	J:111874
\Rag1^tm1Mom/\Rag1^tm1Mom (NOD.129S7(B6)-Rag1^tm1Mom)	abnormal level of surface class II molecules	J:109843
	decreased CD4-positive, alpha-beta T cell number	J:109843
	decreased CD8-positive, alpha-beta T cell number	J:109843
	decreased immunoglobulin level	J:109843
	decreased mature B cell number	J:109843
	impaired natural killer cell mediated cytotoxicity	J:109843
	increased granulocyte number	J:109843
	increased immature B cell number	J:109843
	increased macrophage cell number	J:109843
	increased NK cell number	J:109843
	spleen hypoplasia	J:109843
\Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S7/SvEvBrd * C57BL/6)	abnormal lymphatic vessel morphology	J:119344
	abnormal response to infection	J:119344
	autoimmune response	J:138466
	decreased neutrophil cell number	J:119344
	decreased susceptibility to induced colitis	J:194587
\Rag1^tm1Mom/\Rag1^tm1Mom (involves: 129S7/SvEvBrd)	abnormal double-negative T cell morphology	J:112990
	abnormal thymus epithelium morphology	J:125864
	decreased inflammatory response	J:94420
\Rag1^tm1Mom/\Rag1^tm1Mom \Prf1^tm1Sdz/\Prf1^tm1Sdz (NOD.Cg-Rag1^tm1Mom Prf1^tm1Sdz/Sz)	abnormal level of surface class II molecules	J:109843
	abnormal lymph node cortex morphology	J:109843
	abnormal response to transplant	J:109843
	abnormal spleen white pulp morphology	J:109843
	abnormal thymus cortex morphology	J:109843
	decreased CD4-positive, alpha-beta T cell number	J:109843
	decreased CD8-positive, alpha-beta T cell number	J:109843
	decreased immunoglobulin level	J:109843
	decreased mature B cell number	J:109843
	impaired natural killer cell mediated cytotoxicity	J:109843
	increased granulocyte number	J:109843
	increased immature B cell number	J:109843
	increased macrophage cell number	J:109843
	increased NK cell number	J:109843
	increased T cell derived lymphoma incidence	J:109843
	spleen hypoplasia	J:109843
	thymus hypoplasia	J:109843
\Rag1^tm1Mom/\Rag1^tm1Mom \Rasa3^scat/\Rasa3^scat (involves: 129S7/SvEvBrd * BALB/cBy)	abnormal immune system morphology	J:186485
\Rag1^tm1Mom/\Rag1^tm1Mom \Sh3bp2^tm1Bjro/\Sh3bp2^tm1Bjro (involves: 129S4/SvJae * 129S7/SvEvBrd * BALB/cJ * C57BL/6J)	abnormal osteoclast differentiation	J:117880
	increased circulating tumor necrosis factor level	J:117880
	increased inflammatory response	J:117880
\Rag1^tm1Mom/\Rag1^tm1Mom \Slc46a2^tm1Moki/\Slc46a2⁺ \Tg(TcraB12,TcrbB12)1Rest/0 (involves: 129 * C57BL/6)	arrested T cell differentiation	J:140121
	decreased double-positive T cell number	J:140121
	increased T cell apoptosis	J:140121
	thymus hypoplasia	J:140121
\Rag1^tm1Mom/\Rag1^tm1Mom \Tg(CAG-Lyn)#Paau/0 (involves: 129S7/SvEvBrd C57BL/6)	decreased inflammatory response	J:151886
\Rag1^tm1Mom/\Rag1^tm1Mom \Tg(Lck-Akt1E40K)E-3Pnt/0 (involves: 129S7/SvEvBrd C3H/He * C57BL/6)	increased double-positive T cell number	J:135903
	increased thymocyte number	J:135903
\Rag1^tm1Mom/\Rag1^tm1Mom \Tg(LPV-TAg1135)11Tvd/0 (involves: 129/Sv * C57BL/6 * DBA/2)	abnormal T cell receptor V(D)J recombination	J:47667
	increased T cell derived lymphoma incidence	J:47667
\Rag1^tm1Mom/\Rag1^tm1Mom \Tg(LPV-TAg1135)11Tvd/0 \Tg(TcrLCMV)327Sdz/0 (involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
\Rag1^tm1Mom/\Rag1^tm1Mom \Tg(Tcra,Tcrb)HRCAll/0 (B6.Cg-Rag1^tm1Mom Tg(Tcra,Tcrb)HRCAll)	abnormal T cell differentiation	J:131347
	abnormal T cell subpopulation ratio	J:131347
	absent CD4-positive, alpha-beta T cells	J:131347
	increased CD8-positive, alpha-beta T cell number	J:131347
\Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0 (NOD.Cg-Rag1^tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs)	increased susceptibility to autoimmune diabetes	J:94192
\Rag1^tm1Mom/\Rag1^tm1Mom \Tg(TcraBDC12-4.1)10Jos/0 \Tg(TcrbBDC12-4.1)82Gse/0 (involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)	decreased CD4-positive, alpha-beta T cell number	J:111874
	decreased lymphocyte cell number	J:111874
	decreased thymus weight	J:111874
	increased double-positive T cell number	J:111874
	increased susceptibility to autoimmune diabetes	J:111874
\Rag1^tm1Mom/\Rag1^tm1Mom \Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6)	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:54056
\Rag1^tm1Mom/\Rag1^tm1Mom \Tnfrsf25^tm1Mjo/\Tnfrsf25^tm1Mjo (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	abnormal T cell differentiation	J:84536
\Rag1^tm1Mom/\Rag1^tm1Mom \Tnfsf14^tm1Kpf/\Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)	decreased osteoclast cell number	J:294030
\Rag1^tm1Mom/\Rag1^tm1Mom \Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S7/SvEvBrd * C57BL)	increased T cell derived lymphoma incidence	J:141515
\Rag1^tm1Mom/\Rag1^tm1Mom \Trp53^tm1Brd/\Trp53^tm1Brd \Xrcc5^tm1Dbr/\Xrcc5^tm1Dbr (involves: 129S7/SvEvBrd * C57BL)	increased T cell derived lymphoma incidence	J:141515
\Rag1^tm1Mom/\Rag1^tm1Mom \Tyrobp^tm1.1Viv/\Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * C57BL/10)	abnormal osteoclast physiology	J:129304
\Rag1^tm1Mom/\Rag1^tm1Mom \Vtcn1^tm1Lpc/\Vtcn1^tm1Lpc (involves: 129S/SvEvBrd * 129S7/SvEvBrd * C57BL/6)	abnormal neutrophil differentiation	J:145712
	decreased susceptibility to bacterial infection	J:145712
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:145712
	increased neutrophil cell number	J:145712
	increased spleen weight	J:145712
\Rag2^m1Btlr/\Rag2^m1Btlr (C57BL/6J-Rag2^m1Btlr)	abnormal humoral immune response	J:203045
	decreased B cell number	J:203045
	decreased CD4-positive, alpha-beta T cell number	J:203045
	decreased IgG level	J:203045
	decreased IgM level	J:203045
\Rag2^tm1.1Cgn/\Rag2^tm1.1Cgn (C57BL/6-Rag2^tm1.1Cgn)	arrested B cell differentiation	J:72214
\Rag2^tm1.1Cgn/\Rag2^tm1.1Cgn (C57BL/6-Rag2^tm1.1Cgn)	arrested T cell differentiation	J:72214
\Rag2^tm1.1Cgn/\Rag2^tm1.1Cgn \Tg(HLA-DR2)#Lfug/0 \Tg(TCROb.1A12)#Lfug/0 (involves: C57BL/6 * DBA/2)	autoimmune response	J:134764
	CNS inflammation	J:134764
\Rag2^tm1.1Cgn/\Rag2^tm1.1Cgn \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:181257
\Rag2^tm1.1Desi/\Rag2^tm1.1Desi (involves: 129X1/SvJ * C57BL/6)	abnormal immunoglobulin V(D)J recombination	J:168974
\Rag2^tm1.1Desi/\Rag2^tm1.1Desi \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:168974
\Rag2^tm1.1Mss/\Rag2^tm1.1Mss (involves: 129S6/SvEvTac)	abnormal lymphopoiesis	J:171970
	abnormal pre-B cell morphology	J:171970
	decreased pre-B cell number	J:171970
	increased DN3 thymocyte number	J:171970
\Rag2^tm1.1Mss/\Rag2^tm1.1Mss \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129S6/SvEvTac)	increased T cell derived lymphoma incidence	J:170462
\Rag2^tm1Avla/\Rag2^tm1Avla (involves: 129/Sv * C57BL/6)	abnormal B cell physiology	J:122108
	abnormal immune system cell morphology	J:122108
	abnormal immune system organ morphology	J:122108
	abnormal lymph node morphology	J:122108
	abnormal lymphocyte physiology	J:122108
	abnormal spleen morphology	J:122108
	abnormal thymus morphology	J:122108
	absent Hassall's corpuscle	J:122108
	absent Peyer's patches	J:122108
	arrested B cell differentiation	J:122108
	arrested T cell differentiation	J:122108
	colitis	J:122108
	decreased double-positive T cell number	J:122108
	decreased IgA level	J:122108
	decreased IgG level	J:122108
	decreased lymphocyte cell number	J:122108
	decreased NK T cell number	J:122108
	decreased spleen white pulp amount	J:122108
	decreased T cell proliferation	J:122108
	erythroderma	J:122108
	small cervical lymph nodes	J:122108
	small inguinal lymph nodes	J:122108
	small lymph nodes	J:122108
	small spleen	J:122108
\Rag2^tm1Cgn/\Rag2^tm1.1Cgn \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal B cell activation	J:72214
	absent immature B cells	J:72214
	absent pre-B cells	J:72214
	arrested B cell differentiation	J:72214
	arrested T cell differentiation	J:72214
	decreased follicular B cell number	J:72214
	decreased marginal zone B cell number	J:72214
	decreased mature B cell number	J:72214
	increased plasma cell number	J:72214
\Rag2^tm1Cgn/\Rag2^tm1Cgn \Xrcc4^tm1Fwa/\Xrcc4^tm2Fwa \Tg(Cr2-cre)3Cgn/? (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6)	abnormal class switch recombination	J:150339
\Rag2^tm1Fwa/\Rag2⁺ \Tg(LPV-TAg1135)11Tvd/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
\Rag2^tm1Fwa/\Rag2⁺ \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	increased T cell derived lymphoma incidence	J:47667
\Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * MF1)	abnormal effector T cell morphology	J:1935
	abnormal immunoglobulin V(D)J recombination	J:1935
	abnormal spleen morphology	J:1935
	abnormal T cell receptor V(D)J recombination	J:1935
	absent mature B cells	J:1935
	arrested B cell differentiation	J:1935
	arrested T cell differentiation	J:1935
	decreased CD4-positive, alpha-beta T cell number	J:1935
	decreased CD8-positive, alpha-beta T cell number	J:1935
	decreased double-positive T cell number	J:1935
	decreased IgM level	J:1935
	increased granulocyte number	J:1935
	increased macrophage cell number	J:1935
	increased natural killer cell mediated cytotoxicity	J:1935
	increased susceptibility to infection	J:1935
	lymph node hypoplasia	J:1935
	spleen hypoplasia	J:1935
	thymus hypoplasia	J:1935
\Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv)	abnormal chemokine secretion	J:140483
	abnormal interferon secretion	J:140483
	abnormal macrophage physiology	J:140483
	abnormal response to transplant	J:116136
	abnormal T-helper 1 physiology	J:116136
	colitis	J:116136
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:140483
	decreased thymocyte number	J:114561
	increased susceptibility to bacterial infection	J:140483
	lung inflammation	J:140483
\Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * C57BL/6)	abnormal B cell morphology	J:81133
	arrested T cell differentiation	J:91542
	decreased double-negative T cell number	J:81133, J:91542
	decreased susceptibility to parasitic infection	J:64283
	decreased susceptibility to type IV hypersensitivity reaction	J:165513
	increased double-negative T cell number	J:91542
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Cd47^tm1Fpl/\Cd47^tm1Fpl \Il2rg^tm1Cgn/Y (involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)	absent peripheral lymph nodes	J:203904
	decreased CD4-positive, alpha-beta T cell number	J:203904
	decreased lymphocyte cell number	J:203904
	decreased susceptibility to graft versus host disease	J:203904
	increased activated T cell number	J:203904
	increased CD8-positive, alpha-beta T cell number	J:203904
	increased susceptibility to Retroviridae infection	J:203904
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Rr299391^tm1.1Fwa/\Rr299391^tm1.1Fwa (involves: 129P2/OlaHsd * 129S/SvEv)	abnormal T cell receptor delta chain V(D)J recombination	J:149413
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Sos1^tm1.1Les/\Sos1^tm1.1Les \Tg(Lck-cre)1Cwi/0 (involves: 129S/SvEv * C57BL/6)	abnormal T cell differentiation	J:174536
	decreased T cell proliferation	J:174536
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tbata^tm1Faf/\Tbata^tm1Faf (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	abnormal T cell differentiation	J:166065
	increased thymocyte number	J:166065
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tbx21^tm1Glm/\Tbx21^tm1Glm (involves: 129S/SvEv * 129S6/SvEvTac)	colitis	J:141481
	increased tumor necrosis factor secretion	J:141481
	large intestinal inflammation	J:141481
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tcra^Ln3Jae/\Tcra⁺ \Tcrb^Ln3Jae/\Tcrb⁺ (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:143006
	absent gamma-delta T cells	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	increased CD8-positive, alpha-beta T cell number	J:143006
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tcrb^Ln3Jae/\Tcrb⁺ (involves: 129S/SvEv * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:143006
	absent gamma-delta T cells	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	increased double-positive T cell number	J:143006
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Cd4-NPM/ALK)N1Ingh/0 (involves: 129S/SvEv * C57BL/6 * Swiss Webster)	increased DN3 thymocyte number	J:235890
	increased T cell derived lymphoma incidence	J:235890
	increased thymus tumor incidence	J:235890
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(DO11.10)10Dlo/0 (involves: 129S/SvEv * BALB/c * C3H * C57BL/6)	immune system phenotype	J:110446
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(EmuSR-tTa)83Bop/0 \Tg(tetO-Nfatct1)1Grc/0 (involves: 129S/SvEv C57BL/6J * CBA/J * FVB/N)	abnormal double-positive T cell morphology	J:141917
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Igh-Pim1)1Brn/0 (involves: 129S/SvEv * C57BL/6LiA * CBA)	decreased thymocyte number	J:114561
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Lck-Akt1)M-1Pnt/0 (involves: 129S/SvEv C3H/He * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:135903
	absent CD8-positive, alpha-beta T cells	J:135903
	increased double-positive T cell number	J:135903
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(LPV-TAg1135)11Tvd/0 (involves: 129S/SvEv * C57BL/6 * DBA/2)	increased T cell derived lymphoma incidence	J:47667
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Tcra5CC7,Tcrb5CC7)IWep/? \Themis^5AT161/\Themis^5AT161 (involves: 129S/SvEv * C57BL/6)	arrested T cell differentiation	J:151076
	increased double-positive T cell number	J:151076
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA/2)	abnormal CD4-positive T cell differentiation	J:125548
	abnormal positive T cell selection	J:125548
	decreased CD4-positive, alpha-beta T cell number	J:125548
	increased double-positive T cell number	J:125548
	thymus hyperplasia	J:125548
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraCN.B1,TcrbCN.B1)SM1Jen/0 (involves: 129S/SvEv * C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:162539
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S/SvEv * C57BL/6J * DBA/2J)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	abnormal CD8-positive, alpha-beta T cell physiology	J:125259
	abnormal cytotoxic T cell physiology	J:66565
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcraH-Y,TcrbH-Y)71Vbo/? \Themis^5AT161/\Themis^5AT161 (involves: 129S/SvEv * C57BL/6 * DBA/2)	decreased single-positive T cell number	J:151076
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcrHEL3A9)1Mmd/0 (involves: 129S/SvEv * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal double-positive T cell morphology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	abnormal thymus cell ratio	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Tg(TcrHEL3A9)1Mmd/0 \Tg(TLK2mHEL)2Ccg/0 (involves: 129S/SvEv * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
	thyroid gland inflammation	J:78309
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)	increased T cell derived lymphoma incidence	J:47667
\Rag2^tm1Fwa/\Rag2^tm1Fwa \Wdr1^rede/\Wdr1^rede (involves: 129S/SvEv * C57BL/6)	abnormal immune system physiology	J:134092
\Rag2^tm1Fwa/\Rag2^tm1Mao (involves: 129S/SvEv * C57BL/6)	abnormal B cell number	J:81837
	abnormal gamma-delta T cell differentiation	J:81837
	arrested B cell differentiation	J:81837
	arrested T cell differentiation	J:81837
	decreased double-negative T cell number	J:81837
	decreased immature B cell number	J:81837
	decreased mature B cell number	J:81837
	decreased pre-B cell number	J:81837
	increased immature B cell number	J:81837
	thymus hypoplasia	J:81837
\Rag2^tm1Libo/\Rag2^tm1Libo (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	abnormal B cell differentiation	J:84563
	abnormal B cell physiology	J:84563
	decreased B cell number	J:84563
	decreased monocyte cell number	J:84563
	decreased pre-B cell number	J:84563
\Rag2^tm1Mao/\Rag2^tm1Mao (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system cell morphology	J:81837
\Rag2^tm1Mao/\Rag2^tm1Mao (involves: 129 * C57BL/6)	abnormal B cell number	J:81837
	abnormal gamma-delta T cell differentiation	J:81837
	arrested B cell differentiation	J:81837
	arrested T cell differentiation	J:81837
	decreased double-negative T cell number	J:81837
	decreased immature B cell number	J:81837
	decreased mature B cell number	J:81837
	decreased pre-B cell number	J:81837
	increased immature B cell number	J:81837
	thymus hypoplasia	J:81837
\Rag2^tm1Tgi/\Rag2^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ)	abnormal Peyer's patch morphology	J:113641
	arrested B cell differentiation	J:113641
	arrested T cell differentiation	J:113641
	decreased B cell number	J:113641
	decreased double-positive T cell number	J:113641
	decreased thymocyte number	J:113641
\Rag2^tm2.1Desi/\Rag2^tm2.1Desi \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)	increased T cell derived lymphoma incidence	J:168974
\Rala^{tm1a(EUCOMM)Wtsi}/\Rala^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Rala^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Ralb^{tm1a(EUCOMM)Wtsi}/\Ralb^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Ralb^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Ramp1^tm1.1Tsuj/\Ramp1^tm1.1Tsuj (C.129S2-Ramp1^tm1.1Tsuj)	abnormal chemokine secretion	J:125974
	abnormal cytokine secretion	J:125974
	increased circulating interferon-gamma level	J:125974
	increased circulating interleukin-6 level	J:125974
	increased circulating tumor necrosis factor level	J:125974
\Ramp1^{tm1b(EUCOMM)Wtsi}/\Ramp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ramp1^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
\Ramp2^tm1Kmca/\Ramp2^tm1Kmca (involves: 129S6/SvEvTac * C57BL/6)	abnormal lymph organ development	J:130930
	abnormal lymphatic vessel morphology	J:130930
\Ranbp17^em1(IMPC)Tcp/\Ranbp17^em1(IMPC)Tcp (C57BL/6N-Ranbp17^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
\Rap1a^tm1Laaq/\Rap1a^tm1Laaq (either: B6.Cg-Rap1a^tm1Laaq or (involves: C57BL/6))	abnormal leukocyte migration	J:140471
	abnormal macrophage physiology	J:140471
	abnormal neutrophil physiology	J:140471
	immune system phenotype	J:140471
\Rap1a^tm1Tze/\Rap1a^tm1Tze (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:144145
	decreased interleukin-2 secretion	J:144145
	decreased T cell proliferation	J:144145
\Rap1gap2^m1Anu/\Rap1gap2^m1Anu (C57BL/6NCrlAnu-Rap1gap2^m1Anu)	immune system phenotype	J:104190
\Rap1gap^em1(IMPC)H/\Rap1gap^em1(IMPC)H (C57BL/6NTac-Rap1gap^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Rap1gds1^tm1Ytk/\Rap1gds1^tm1Ytk (involves: 129X1/SvJ * C57BL/6 * DBA)	abnormal thymus morphology	J:62244
	decreased thymocyte number	J:62244
	increased thymocyte apoptosis	J:62244
	small thymus	J:62244
\Rapgef2^tm1.1Hous/\Rapgef2^tm1.1Hous \Tg(Cd4-cre)1Cwi/0 (involves: 129S1/Sv * C57BL/6 * CBA)	immune system phenotype	J:165879
\Rapgef2^tm1.1Hous/\Rapgef2^tm1.1Hous \Tg(Cdh5-cre)7Mlia/0 (involves: 129S1/Sv * FVB/N)	immune system phenotype	J:165879
\Rapgef2^tm1.1Hous/\Rapgef2^tm1.1Hous \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	immune system phenotype	J:165879
\Rapgef2^tm1.1Hous/\Rapgef2^tm1.1Hous \Tg(VAV1-cre)1Graf/0 (involves: 129S1/Sv)	immune system phenotype	J:165879
\Rapgef3^tm1Skc/\Rapgef3^tm1Skc (Not Specified)	insulitis	J:201171
\Rapgef6^tm1.1Tkat/\Rapgef6^tm1.1Tkat (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:126164
\Rapgef6^tm1.1Tkat/\Rapgef6^tm1.1Tkat (involves: 129P2/OlaHsd)	enlarged spleen	J:218581
\Raph1^tm1.2Fbg/\Raph1^tm1.2Fbg (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine level	J:238262
	increased inflammatory response	J:238262
	increased susceptibility to bacterial infection	J:238262
	large intestinal inflammation	J:238262
\Rara^tm1.1Ybe/\Rara^tm1.1Ybe (involves: C57BL/6N)	abnormal lymphopoiesis	J:207485
\Rara^tm1Ipc/\Rara^tm1Ipc \Rarb^tm1Ipc/\Rarb^tm1Ipc (involves: 129S2/SvPas)	persistent cervical thymus	J:21034
\Rara^tm1Ipc/\Rara^tm1Ipc \Rarb^tm1Mma/\Rarb^tm1Mma (involves: 129S2/SvPas * C57BL/6)	abnormal thymus morphology	J:43344
	persistent cervical thymus	J:43344
\Rara^tm1Ipc/\Rara^tm1Ipc \Rarg^tm1Ipc/\Rarg^tm1Ipc (involves: 129S2/SvPas)	persistent cervical thymus	J:21034
\Rara^tm1Ipc/\Rara^tm1Ipc \Rarg^tm2Ipc/\Rarg^tm2Ipc (involves: 129S2/SvPas)	ectopic thymus	J:42773
\Rarres1^tm1.2Mhl/\Rarres1^tm1.2Mhl (involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)	abnormal B cell activation	J:324270
	abnormal B cell differentiation	J:324270
	abnormal B cell physiology	J:324270
	abnormal plasma cell differentiation	J:324270
	decreased B cell apoptosis	J:324270
	decreased spleen germinal center number	J:324270
	increased B cell proliferation	J:324270
\Rarres2^tm1Yktk/\Rarres2^tm1Yktk (B6.Cg-Rarres2^tm1Yktk)	decreased macrophage cell number	J:206120
\Rasa1^tm1Wid/\Rasa1^tm1Wid (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6N)	increased susceptibility to induced colitis	J:189241
\Rasa3^hlb381/\Rasa3^hlb381 (C57BL/6J-Rasa3^hlb381/J)	decreased leukocyte cell number	J:301035, J:221899
	enlarged spleen	J:221899
	increased spleen weight	J:301035
\Rasa3^scat/\Rasa3^scat (involves: BALB/cBy)	abnormal spleen morphology	J:186485
	decreased B cell number	J:186485
	decreased CD4-positive, alpha-beta T cell number	J:186485
	decreased CD8-positive, alpha-beta T cell number	J:186485
	decreased leukocyte cell number	J:186485
	decreased T cell number	J:186485
	enlarged spleen	J:186485
	increased spleen red pulp amount	J:186485
	pale spleen	J:186485
\Rasa3^scat/\Rasa3^scat (involves: BALB/cBy * BALB/cByJ)	decreased leukocyte cell number	J:301035
\Rasa3^scat/\Rasa3^scat (involves: BALB/cBy * BALB/cByJ)	increased spleen weight	J:301035
\Rasa3^tm1.1Llp/\Rasa3^tm1.1Llp \Tg(Mx1-cre)1Cgn/? (involves: 129S1/SvImJ * C57BL/6J * CBA/J)	bone marrow failure	J:301035
	decreased leukocyte cell number	J:301035
	increased spleen weight	J:301035
\Rasa4^tm1Ywh/\Rasa4^tm1Ywh (B6.129S6-Rasa4^tm1Ywh)	impaired macrophage phagocytosis	J:100455
\Rasa4^tm1Ywh/\Rasa4^tm1Ywh (B6.129S6-Rasa4^tm1Ywh)	increased susceptibility to bacterial infection	J:100455
\Rasal3^tm1.1Fuj/\Rasal3^tm1.1Fuj (involves: C57BL/6N * C57BL/6NCrlj * CBA/JNCrlj)	decreased circulating interferon-gamma level	J:229641
	decreased circulating interleukin-4 level	J:229641
	decreased interferon-gamma secretion	J:229641
	decreased interleukin-4 secretion	J:229641
	decreased NK T cell number	J:229641
	increased granulocyte number	J:229641
\Rasal3^{tm1b(EUCOMM)Hmgu}/\Rasal3^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rasal3^{tm1b(EUCOMM)Hmgu}/Orl)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Rasgrf2^tm1Esn/\Rasgrf2^tm1Esn (involves: 129S1/Sv * C57BL/10 * C57BR/cd)	decreased interleukin-2 secretion	J:128985
	decreased tumor necrosis factor secretion	J:128985
\Rasgrf2^tm1Esn/\Rasgrf2^tm1Esn \Vav1^tm1Tyb/\Vav1^tm1Tyb (involves: 129S1/Sv * 129S2/SvPas * C57BL/10 * C57BR/cd)	abnormal T cell physiology	J:128985
	decreased interleukin-2 secretion	J:128985
	decreased T cell proliferation	J:128985
	decreased tumor necrosis factor secretion	J:128985
\Rasgrp1^lag/\Rasgrp1^lag (involves: 129 * C57BL/6)	abnormal lymph node morphology	J:85189
	abnormal positive T cell selection	J:85189
	abnormal T cell physiology	J:85189
	decreased T cell proliferation	J:85189
	enlarged lymph nodes	J:85189
	enlarged spleen	J:85189
	glomerulonephritis	J:85189
	increased B cell number	J:85189
	increased IgG level	J:85189
	increased susceptibility to systemic lupus erythematosus	J:85189
	increased T cell number	J:85189
\Rasgrp1^m1Anu/\Rasgrp1⁺ (involves: C57BL/6JSfdAnu * CBA/J)	increased anti-nuclear antigen antibody level	J:207898
\Rasgrp1^m1Anu/\Rasgrp1^m1Anu (C57BL/6JSfdAnu-Rasgrp1^m1Anu)	abnormal T cell differentiation	J:104190
	autoimmune response	J:104190
\Rasgrp1^m1Anu/\Rasgrp1^m1Anu (involves: C57BL/6JSfdAnu * CBA/J)	abnormal CD4-positive, alpha beta T cell morphology	J:207898
	immune system phenotype	J:207898
	increased anti-nuclear antigen antibody level	J:207898
	increased effector memory CD4-positive, alpha-beta T cell number	J:207898
\Rasgrp1^m1Btlr/\Rasgrp1^m1Btlr (C57BL/6J-Rasgrp1^m1Btlr)	abnormal humoral immune response	J:265163
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265163
	decreased CD8-positive, naive alpha-beta T cell number	J:265163
	decreased IgM level	J:265163
	increased CD8-positive, alpha-beta memory T cell number	J:265163
	increased effector memory CD4-positive, alpha-beta T cell number	J:265163
	increased IgA level	J:265163
	increased IgE level	J:265163
	increased IgM level	J:265163
	increased NK cell number	J:265163
\Rasgrp1^m2Anu/\Rasgrp1^m2Anu (C57BL/6NCrlAnu-Rasgrp1^m2Anu)	immune system phenotype	J:104190
\Rasgrp1^m2Btlr/\Rasgrp1^m2Btlr (C57BL/6J-Rasgrp1^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265163
	decreased CD8-positive, alpha-beta T cell number	J:265163
	decreased CD8-positive, naive alpha-beta T cell number	J:265163
	decreased single-positive T cell number	J:265163
	decreased T cell number	J:265163
	increased central memory CD4-positive, alpha-beta T cell number	J:265163
	increased central memory CD8 positive, alpha-beta T cell number	J:265163
	increased effector memory CD4-positive, alpha-beta T cell number	J:265163
	increased effector memory CD8-positive, alpha-beta T cell number	J:265163
	increased NK cell number	J:265163
\Rasgrp1^m3Btlr/\Rasgrp1^m3Btlr (C57BL/6J-Rasgrp1^m3Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265255
	decreased CD8-positive, alpha-beta T cell number	J:265255
	decreased CD8-positive, naive alpha-beta T cell number	J:265255
	decreased single-positive T cell number	J:265255
	decreased T cell number	J:265255
	increased B cell number	J:265255
	increased B-1b cell number	J:265255
	increased central memory CD8 positive, alpha-beta T cell number	J:265255
	increased effector memory CD4-positive, alpha-beta T cell number	J:265255
	increased effector memory CD8-positive, alpha-beta T cell number	J:265255
	increased IgM level	J:265255
	increased neutrophil cell number	J:265255
	increased NK cell number	J:265255
\Rasgrp1^M4Btlr/\Rasgrp1^M4Btlr (C57BL/6J-Rasgrp1^M4Btlr)	abnormal T cell morphology	J:267490
\Rasgrp1^m5Btlr/\Rasgrp1^m5Btlr (C57BL/6J-Rasgrp1^m5Btlr)	increased NK cell number	J:272846
\Rasgrp1^tm1.1Wz/\Rasgrp1^tm1.1Wz (B6.Cg-Rasgrp1^tm1.1Wz)	abnormal CD4-positive T cell differentiation	J:225109
	abnormal CD8-positive, alpha-beta T cell differentiation	J:225109
	abnormal immune system cell morphology	J:225109
	abnormal immune system organ morphology	J:225109
	abnormal immune system physiology	J:225109
	abnormal immunoglobulin level	J:225109
	abnormal T cell differentiation	J:225109
	decreased single-positive T cell number	J:225109
	decreased T cell proliferation	J:225109
	enlarged spleen	J:225109
	immune system phenotype	J:225109
	increased autoantibody level	J:225109
	increased CD4-positive, alpha-beta memory T cell number	J:225109
	increased IgE level	J:225109
	increased IgG1 level	J:225109
	increased single-positive T cell number	J:225109
	increased spleen weight	J:225109
\Rasgrp1^tm1.1Wz/\Rasgrp1^tm1.1Wz \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6J * DBA/2J)	decreased single-positive T cell number	J:225109
	increased double-positive T cell number	J:225109
\Rasgrp1^tm1.1Wz/\Rasgrp1^tm1.1Wz \Tg(TcraTcrb)425Cbn/? (involves: C57BL/6 * BALB/c)	abnormal CD4-positive T cell differentiation	J:225109
\Rasgrp1^tm1Jstn/\Rasgrp1^tm1Jstn (involves: 129P3/J * C57BL/6J)	abnormal humoral immune response	J:108677
	decreased B cell number	J:108677
	decreased thymocyte number	J:108677
	enlarged spleen	J:108677
	increased immunoglobulin level	J:108677
	increased plasma cell number	J:108677
\Rasgrp1^tm1Jstn/\Rasgrp1^tm1Jstn (involves: 129P3/J)	abnormal CD4-positive, alpha beta T cell morphology	J:207898
	abnormal double-positive T cell morphology	J:207898
	decreased CD4-positive, alpha-beta T cell number	J:207898
	decreased CD8-positive, alpha-beta T cell number	J:207898
\Rasgrp1^tm1Jstn/\Rasgrp1^tm1Jstn \Rasgrp3^tm1Jstn/\Rasgrp3^tm1Jstn (involves: 129P3/J * C57BL/6J)	abnormal humoral immune response	J:108677
	decreased B cell number	J:108677
	decreased plasma cell number	J:108677
\Rasgrp2^tm1Amg/\Rasgrp2^tm1Amg (Not Specified)	abnormal neutrophil physiology	J:122618
\Rasgrp2^tm1Amg/\Rasgrp2^tm1Amg (Not Specified)	impaired neutrophil recruitment	J:122618
\Rasgrp3^{em1(IMPC)Wtsi}/\Rasgrp3^{em1(IMPC)Wtsi} (C57BL/6N-Rasgrp3^{em1(IMPC)Wtsi}/Wtsi)	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
\Rasgrp3^tm1Jstn/\Rasgrp3^tm1Jstn (involves: 129P3/J * C57BL/6J)	abnormal humoral immune response	J:108677
	decreased B cell number	J:108677
	decreased IgG1 level	J:108677
	decreased IgG2a level	J:108677
	decreased IgG level	J:108677
\Rasgrp4^tm1(cre)Rls/\Rasgrp4^tm1(cre)Rls (C57BL/6-Rasgrp4^tm1(cre)Rls)	decreased susceptibility to induced arthritis	J:186519
	decreased susceptibility to induced colitis	J:186519
\Rasgrp4^{tm1a(KOMP)Lste}/\Rasgrp4^{tm1a(KOMP)Lste} (involves: C57BL/6)	abnormal neutrophil physiology	J:186412
	impaired neutrophil chemotaxis	J:186412
\Rasgrp4^{tm1d(KOMP)Lste}/\Rasgrp4^{tm1d(KOMP)Lste} (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	abnormal neutrophil physiology	J:186412
	impaired neutrophil chemotaxis	J:186412
\Rassf1^tm1.2Brd/\Rassf1^tm1.2Brd (involves: 129S7/SvEvBrd * C57BL/6)	immune system phenotype	J:101369
\Rassf2^tm1Dlim/\Rassf2^tm1Dlim (B6.Cg-Rassf2^tm1Dlim)	abnormal myeloid leukocyte morphology	J:181952
	abnormal osteoclast differentiation	J:181952
	abnormal spleen red pulp morphology	J:181952
	abnormal thymus epithelium morphology	J:181952
	decreased B cell number	J:181952
	decreased CD4-positive, alpha-beta T cell number	J:181952
	decreased CD8-positive, alpha-beta T cell number	J:181952
	decreased leukocyte cell number	J:181952
	decreased osteoclast cell number	J:181952
	decreased spleen weight	J:181952
	decreased T cell number	J:181952
	decreased thymus weight	J:181952
	spleen hypoplasia	J:181952
	thymus hypoplasia	J:181952
\Rassf5^tm1Kina/\Rassf5⁺ (involves: C57BL/6 * CBA * ICR)	lymphoid hypoplasia	J:92670
\Rassf5^tm1Kina/\Rassf5^tm1Kina (involves: C57BL/6 * CBA * ICR)	abnormal B cell differentiation	J:92670
	abnormal dendritic cell physiology	J:92670
	abnormal leukocyte migration	J:92670
	abnormal lymph node cell ratio	J:92670
	abnormal lymph node cortex morphology	J:92670
	abnormal spleen red pulp morphology	J:92670
	abnormal thymus cell ratio	J:92670
	abnormal thymus corticomedullary boundary morphology	J:92670
	abnormal thymus medulla morphology	J:92670
	decreased thymocyte number	J:92670
	spleen hypoplasia	J:92670
\Rassf5^tm1Kina/\Rassf5^tm1Kina (B6.Cg-Rassf5^tm1Kina)	abnormal lymphocyte physiology	J:168749
	enlarged lymph nodes	J:168749
	enlarged spleen	J:168749
	glomerulonephritis	J:168749
	increased anti-double stranded DNA antibody level	J:168749
	increased B cell number	J:168749
	increased B cell proliferation	J:168749
	increased IgG level	J:168749
	increased memory T cell number	J:168749
	increased plasma cell number	J:168749
	increased T cell number	J:168749
	increased T cell proliferation	J:168749
\Raver1^{em1(IMPC)Hmgu}/\Raver1^{em1(IMPC)Hmgu} (C57BL/6NCrl-Raver1^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
\Rb1^tm1Dwg/\Rb1^tm1Dwg (involves: 129/Sv * C57BL/6)	abnormal macrophage morphology	J:105548
\Rb1^tm1Mlh/\Rb1^tm1Mlh (either: 129P2/OlaHsd-Rb1^tm1Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))	abnormal myelopoiesis	J:2498
\Rb1^tm1Tyj/\Rb1^tm1Tyj (involves: 129S2/SvPas)	abnormal macrophage differentiation	J:105548
\Rb1^tm2Mlh/\Rb1^tm2Mlh (either: 129P2/OlaHsd-Rb1^tm2Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))	abnormal myelopoiesis	J:2498
\Rb1cc1^tm1.1Guan/\Rb1cc1^tm1.1Guan \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:235399
\Rb1cc1^tm1.1Guan/\Rb1cc1^tm1.1Guan \Tg(BEST1-cre)1Jdun/0 (involves: 129P2/OlaHsd * C57BL/6)	microgliosis	J:282249
\Rb1cc1^tm1.1Guan/\Rb1cc1^tm1.1Guan \Tg(Tek-cre)12Flv/0 (B6.Cg-Rb1cc1^tm1.1Guan Tg(Tek-cre)12Flv)	abnormal myelopoiesis	J:167258
	increased neutrophil cell number	J:167258
\Rbbp4^em1(IMPC)Mbp/\Rbbp4⁺ (C57BL/6NCrl-Rbbp4^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Rbbp8^tm1Whl/\Rbbp8^tm1.1Thl \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor)	immune system phenotype	J:194603
\Rbl1^tm1Mru/\Rbl1^tm1Mru (involves: 129S4/SvJae * BALB/cJ)	abnormal inflammatory response	J:51060
\Rbl1^tm1Mru/\Rbl1^tm1Mru (involves: 129S4/SvJae * BALB/cJ)	abnormal spleen red pulp morphology	J:51060
\Rbm3^tm1Ttg/\Rbm3^tm1Ttg (involves: 129P2/OlaHsd)	immune system phenotype	J:174947
\Rbm4^{tm1a(EUCOMM)Hmgu}/\Rbm4⁺ (C57BL/6N-Rbm4^{tm1a(EUCOMM)Hmgu}/Cnrm)	decreased IgG2b level	J:165965
\Rbm7^em1Aki/\Rbm7^em1Aki (B6.Cg-Rbm7^em1Aki)	decreased monocyte cell number	J:288329
\Rbm10^em1(IMPC)Mbp/Y (C57BL/6NCrl-Rbm10^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
\Rbm10^em1(IMPC)Mbp/\Rbm10⁺ (C57BL/6NCrl-Rbm10^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Rbm15^tm1Dgg/\Rbm15^tm1.1Dgg \Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C57BL/6 * CBA * FVB/N)	abnormal B cell differentiation	J:120321
	decreased B cell number	J:120321
	decreased pre-B cell number	J:120321
	increased spleen red pulp amount	J:120321
\Rbm15^tm1Swm/\Rbm15^tm1Swm \Tg(Mx1-cre)1Cgn/0 (involves: 129X1/SvJ * C57BL/6 * CBA)	decreased leukocyte cell number	J:152262
	decreased lymphocyte cell number	J:152262
	decreased neutrophil cell number	J:152262
	increased spleen red pulp amount	J:152262
\Rbm20^em1(IMPC)Mbp/\Rbm20^em1(IMPC)Mbp (C57BL/6N-Rbm20^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Rbm22^em1(IMPC)Mbp/\Rbm22⁺ (C57BL/6NCrl-Rbm22^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Rbm38^tm1.1Xch/\Rbm38^tm1.1Xch (involves: C57BL/6 * FVB/N)	enlarged spleen	J:216929
\Rbm38^tm1.1Xch/\Rbm38^tm1.1Xch (involves: C57BL/6 * FVB/N)	increased spleen white pulp amount	J:216929
\Rbm38^tm1.1Xch/\Rbm38^tm1.1Xch \Trp53^tm1Tyj/\Trp53⁺ (involves: 129S2/SvPas * C57BL/6 * FVB/N)	abnormal spleen B cell follicle morphology	J:216929
\Rbm43^em1Brsp/\Rbm43^em1Brsp \Tg(Adipoq-cre)1Evdr/0 (B6.Cg-Rbm43^em1Brsp Tg(Adipoq-cre)1Evdr)	abnormal innate immunity	J:363192
	decreased inflammatory response	J:363192
\Rbp1^tm1Ipc/\Rbp1^tm1Ipc (involves: 129S2/SvPas)	increased granulocyte number	J:67762
\Rbp1^tm1Ipc/\Rbp1^tm1Ipc (involves: 129S2/SvPas)	increased neutrophil cell number	J:67762
\Rbpj^tm1Hon/\Rbpj^tm1Hon (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:76240
\Rbpj^tm1Hon/\Rbpj^tm1Hon \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA)	abnormal T-helper 2 cell differentiation	J:90018
\Rbpj^tm1Hon/\Rbpj^tm1Hon \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal cytokine secretion	J:125869
	decreased dendritic cell number	J:125869
\Rbpj^tm1Hon/\Rbpj^tm1Hon \Tg(Lck-cre)19Hhan/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA)	abnormal CD4-positive helper T cell morphology	J:168475
	abnormal immune system physiology	J:168475
	abnormal regulatory T cell physiology	J:168475
	immune system phenotype	J:168475
	increased macrophage cell number	J:168475
	increased single-positive T cell number	J:168475
	increased splenocyte number	J:168475
	increased T cell number	J:168475
	increased T cell proliferation	J:168475
\Rbpj^tm1Hon/\Rbpj^tm1Hon \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:99747
	abnormal lymphopoiesis	J:99747
	arrested T cell differentiation	J:125869, J:99747
	decreased dendritic cell number	J:125869
	decreased double-positive T cell number	J:99747
	decreased follicular dendritic cell number	J:125869
	decreased marginal zone B cell number	J:76240, J:99747
	decreased single-positive T cell number	J:99747
	decreased thymocyte number	J:99747
	increased B cell number	J:125869, J:99747
	increased double-negative T cell number	J:99747
	increased follicular B cell number	J:99747
	increased macrophage cell number	J:125869
	increased monocyte cell number	J:125869
	increased plasmacytoid dendritic cell number	J:125869
	small thymus	J:99747
\Rbpj^tm1Kyo/\Rbpj⁺ (involves: 129S2/SvPas * CD-1)	aortic valve inflammation	J:187551
\Rbpj^tm1Kyo/\Rbpj^tm1Kyo (involves: 129S2/SvPas)	abnormal humoral immune response	J:123631
	abnormal response to infection	J:123631
	decreased interleukin-4 secretion	J:123631
\Rc3h1^{Gt(CC0753)Wtsi}/\Rc3h1^{Gt(CC0753)Wtsi} (B6.129P2-Rc3h1^{Gt(CC0753)Wtsi})	chronic liver inflammation	J:199407
	ileum inflammation	J:199407
	intestinal inflammation	J:199407
\Rc3h1^san/\Rc3h1⁺ (involves: C57BL/6JSfdAnu)	abnormal lymph node germinal center morphology	J:189087
	abnormal lymph node morphology	J:189087
	abnormal T follicular helper cell physiology	J:189087
	enlarged lymph nodes	J:189087
	increased IgG level	J:189087
	increased spleen weight	J:189087
	increased T cell derived lymphoma incidence	J:189087
	increased T follicular helper cell number	J:189087
\Rc3h1^san/\Rc3h1^san (either: C57BL/6JSfdAnu-Rc3h1^san/Anu or (involves: C57BL/6JSfdAnu * CBA/Ca))	abnormal T cell differentiation	J:98938
	enlarged lymph nodes	J:98938
	glomerulonephritis	J:98938
	increased anti-double stranded DNA antibody level	J:98938
	increased anti-nuclear antigen antibody level	J:98938
	liver inflammation	J:98938
\Rc3h1^san/\Rc3h1^san (involves: C57BL/6JSfdAnu)	abnormal effector T cell morphology	J:199407
	abnormal intraepithelial T cell number	J:199407
	cecum inflammation	J:199407
	chronic liver inflammation	J:199407
	colitis	J:199407
	enlarged spleen	J:199407
	granulomatous inflammation	J:199407
	ileum inflammation	J:199407
	increased activated T cell number	J:199407
	increased CD4-positive, alpha-beta T cell number	J:199407
	increased circulating tumor necrosis factor level	J:196137
	increased T cell proliferation	J:199407
	lymphoid hyperplasia	J:199407
	small intestinal inflammation	J:199407
\Rc3h1^san/\Rc3h1^san \Rc3h2^tm1.2Cgv/\Rc3h2^tm1.2Cgv (involves: C57BL/6 * C57BL/6JSfdAnu)	increased circulating tumor necrosis factor level	J:196137
	increased inflammatory response	J:196137
	increased susceptibility to bacterial infection	J:196137
	increased T follicular helper cell number	J:196137
	kidney inflammation	J:196137
\Rc3h1^tm1.1Mass/\Rc3h1^tm1.1Mass \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL)	abnormal effector T cell morphology	J:177784
	enlarged spleen	J:177784
	increased B cell number	J:177784
	increased eosinophil cell number	J:177784
	increased regulatory T cell number	J:177784
	increased spleen weight	J:177784
\Rc3h1^tm1.1Mass/\Rc3h1^tm1.1Mass \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca * NZB * SJL)	abnormal B cell differentiation	J:177784
	abnormal effector T cell morphology	J:177784
	abnormal germinal center B cell physiology	J:177784
	abnormal spleen B cell follicle morphology	J:177784
	decreased B cell number	J:177784
	decreased IgA level	J:177784
	decreased IgG1 level	J:177784
	decreased IgG3 level	J:177784
	decreased immature B cell number	J:177784
	enlarged spleen	J:177784
	immune system phenotype	J:177784
	increased eosinophil cell number	J:177784
	increased IgG2b level	J:177784
	increased macrophage cell number	J:177784
	increased regulatory T cell number	J:177784
	increased spleen weight	J:177784
	increased splenocyte number	J:177784
	spleen hyperplasia	J:177784
\Rc3h1^tm1.1Mass/\Rc3h1^tm1.1Mass \Rc3h2^{tm1c(KOMP)Wtsi}/\Rc3h2^{tm1c(KOMP)Wtsi} \Tg(Cd4-cre)1Cwi/? (involves: C57BL/6N * DBA/2)	abnormal B cell number	J:196136
	abnormal immune system cell morphology	J:196136
	abnormal immune system organ morphology	J:196136
	abnormal immune system physiology	J:196136
	abnormal spleen B cell follicle morphology	J:196136
	abnormal spleen morphology	J:196136
	abnormal spleen periarteriolar lymphoid sheath morphology	J:196136
	decreased CD4-positive, alpha-beta T cell number	J:196136
	decreased CD8-positive, alpha-beta T cell number	J:196136
	decreased T cell number	J:196136
	enlarged lymph nodes	J:196136
	enlarged spleen	J:196136
	increased germinal center B cell number	J:196136
	increased T cell proliferation	J:196136
	increased T follicular helper cell number	J:196136
\Rc3h1^tm1.1Mass/\Rc3h1^tm1.1Mass \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * NZB * SJL)	immune system phenotype	J:177784
	increased CD8-positive, alpha-beta T cell number	J:177784
	increased eosinophil cell number	J:177784
	increased macrophage cell number	J:177784
\Rc3h1^tm1.2Cgv/\Rc3h1^san (involves: C57BL/6 * C57BL/6JSfdAnu)	increased CD4-positive, alpha-beta T cell number	J:196137
	increased T follicular helper cell number	J:196137
\Rc3h1^tm1.2Mass/\Rc3h1^tm1.2Mass (involves: C57BL/6 * CBA * NZB * SJL)	abnormal thymus development	J:177784
\Rc3h1^tm1.2Mass/\Rc3h1^tm1.2Mass (involves: C57BL/6 * CBA * CD-1 * NZB * SJL)	abnormal effector T cell morphology	J:177784
	enlarged spleen	J:177784
	immune system phenotype	J:177784
	increased spleen weight	J:177784
\Rc3h2^tm1.2Cgv/\Rc3h2^tm1.2Cgv (involves: C57BL/6)	immune system phenotype	J:196137
	increased macrophage cytokine production	J:196137
	increased tumor necrosis factor secretion	J:196137
\Rc3h2^{tm1a(KOMP)Wtsi}/\Rc3h2^{tm1a(KOMP)Wtsi} (involves: C57BL/6N * NMRI)	immune system phenotype	J:196136
\Rc3h2^{tm1c(KOMP)Wtsi}/\Rc3h2^{tm1c(KOMP)Wtsi} \Tg(Cd4-cre)1Cwi/? (involves: C57BL/6N * DBA/2)	immune system phenotype	J:196136
\Rcan1^tm1Fmc/\Rcan1^tm1Fmc (involves: 129S4/SvJae)	abnormal T cell apoptosis	J:85148
	abnormal T-helper 1 physiology	J:85148
	decreased IgG2a level	J:85148
	decreased interferon-gamma secretion	J:85148
	decreased T cell proliferation	J:85148
	increased susceptibility to endotoxin shock	J:152536
\Rcan1^tm1Jmol/\Rcan1^tm1Jmol \Rcan2^tm1Jmol/\Rcan2^tm1Jmol (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:109586
	abnormal cytokine secretion	J:109586
	decreased T cell proliferation	J:109586
\Rcan1^tm1Jmol/\Rcan1^tm1Jmol \Rcan2^tm1Jmol/\Rcan2^tm1Jmol \Ppp3cb^tm1Jmk/\Ppp3cb^tm1Jmk (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:109586
	abnormal CD4-positive, alpha-beta T cell physiology	J:109586
	abnormal CD8-positive, alpha beta T cell morphology	J:109586
	abnormal cytokine secretion	J:109586
	decreased T cell proliferation	J:109586
\Rcbtb2^tm1.1Xyw/\Rcbtb2⁺ (involves: C57BL/6 * CBA)	enlarged mesenteric lymph nodes	J:282928
\Rcbtb2^tm1.1Xyw/\Rcbtb2⁺ (involves: C57BL/6 * CBA)	enlarged spleen	J:282928
\Rcbtb2^tm1.1Xyw/\Rcbtb2^tm1.1Xyw (involves: C57BL/6 * CBA)	abnormal splenocyte physiology	J:282928
	enlarged mesenteric lymph nodes	J:282928
	enlarged spleen	J:282928
\Rcc1l^{tm1a(EUCOMM)Hmgu}/\Rcc1l⁺ (Not Specified)	decreased IgG1 level	J:165965
\Rdh7^{tm1c(KOMP)Wtsi}/\Rdh7^{tm1c(KOMP)Wtsi} \Tg(RARE-Hspa1b/lacZ)12Jrt/0 \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6J * C57BL/6N * CD-1 * SJL)	decreased lymphocyte cell number	J:279231
	decreased susceptibility to bacterial infection	J:279231
	immune system phenotype	J:279231
\Rdns/\Rdns⁺ (C57BL/6J-Rdns/GrsrJ)	increased susceptibility to otitis media	J:223062
\Rdur^em1Jiche/\Rdur^em1Jiche (Not Specified)	increased circulating interleukin-1 level	J:340209
	increased circulating interleukin-6 level	J:340209
	increased susceptibility to viral infection	J:340209
	increased susceptibility to viral infection induced morbidity/mortality	J:340209
\Recql4^tm1Abe/\Recql4^tm1Abe (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:85574
	decreased spleen white pulp amount	J:85574
	small thymus	J:85574
\Reep3^em1(IMPC)Tcp/\Reep3^em1(IMPC)Tcp (C57BL/6NCrl-Reep3^em1(IMPC)Tcp/Cmmr)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Reg3g^tm1.1Lvh/\Reg3g^tm1.1Lvh (B6.129-Reg3g^tm1.1Lvh)	immune system phenotype	J:177506
	increased IgA level	J:177506
	increased T-helper 1 cell number	J:177506
\Reg3g^{tm1a(KOMP)Wtsi}/\Reg3g^{tm1a(KOMP)Wtsi} (C57BL/6-Reg3g^{tm1a(KOMP)Wtsi})	increased susceptibility to Orthomyxoviridae infection	J:233979
\Rel^M1Btlr/\Rel⁺ (C57BL/6J-Rel^M1Btlr)	decreased IgE level	J:236682
	decreased IgG level	J:236682
	decreased IgM level	J:236682
	decreased response to antigen	J:236682
	increased CD4-positive, alpha-beta T cell number	J:236682
	increased T cell number	J:236682
\Rel^M1Btlr/\Rel^M1Btlr (C57BL/6J-Rel^M1Btlr)	decreased B-1 B cell number	J:236682
	decreased CD4-positive, alpha-beta T cell number	J:236682
	decreased CD8-positive, alpha-beta T cell number	J:236682
	decreased IgE level	J:236682
	decreased IgG level	J:236682
	decreased IgM level	J:236682
	decreased response to antigen	J:236682
	increased CD4-positive, alpha-beta T cell number	J:236682
	increased CD8-positive, alpha-beta T cell number	J:236682
	increased effector memory CD4-positive, alpha-beta T cell number	J:236682
	increased T cell number	J:236682
\Rel^M2Btlr/\Rel^M2Btlr (C57BL/6J-Rel^M2Btlr)	abnormal CD4-positive T cell differentiation	J:272778
	abnormal T cell differentiation	J:272778
	decreased alpha-beta T cell number	J:272778
	decreased B-1 B cell number	J:272778
	decreased CD4-positive, alpha-beta T cell number	J:272778
	decreased central memory CD4-positive, alpha-beta T cell number	J:272778
	decreased effector memory CD4-positive, alpha-beta T cell number	J:272778
\Rel^m3Btlr/\Rel^m3Btlr (C57BL/6J-Rel^m3Btlr)	decreased IgM level	J:272801
\Rel^m3Btlr/\Rel^m3Btlr (C57BL/6J-Rel^m3Btlr)	impaired humoral immune response	J:272801
\Rel^{tm1b(EUCOMM)Wtsi}/\Rel^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Rel^{tm1b(EUCOMM)Wtsi}/H)	decreased monocyte cell number	J:211773
\Rel^tm1Brv/\Rel^tm1Brv (involves: 129S1/Sv)	abnormal leukocyte physiology	J:46911
	abnormal macrophage morphology	J:46911
	abnormal macrophage physiology	J:46911
	abnormal spleen morphology	J:46911
	abnormal splenic cell ratio	J:46911
	abnormal T cell physiology	J:46911
	decreased IgG1 level	J:46911
	decreased IgG2b level	J:46911
	decreased IgG3 level	J:46911
	decreased IgG level	J:46911
	decreased spleen germinal center number	J:46911
	dermatitis	J:46911
	enlarged lymph nodes	J:46911
	enlarged spleen	J:46911
	impaired macrophage chemotaxis	J:46911
	increased IgA level	J:46911
	increased IgG2a level	J:46911
	increased IgM level	J:46911
	increased spleen B cell follicle size	J:46911
	increased susceptibility to bacterial infection	J:46911
\Rel^tm1Grd/\Rel⁺ (involves: 129S1/Sv * C57BL/6)	abnormal humoral immune response	J:28435
\Rel^tm1Grd/\Rel⁺ (involves: 129S1/Sv * C57BL/6)	decreased B cell proliferation	J:28435
\Rel^tm1Grd/\Rel^tm1Grd (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:37541, J:28435
	abnormal humoral immune response	J:28435
	abnormal macrophage physiology	J:37541
	decreased B cell proliferation	J:28435
	decreased IgG1 level	J:28435
	decreased IgG2a level	J:28435
	decreased IgG2b level	J:28435
	decreased IgG3 level	J:28435
	decreased IgM level	J:28435
	decreased susceptibility to parasitic infection	J:37541
	decreased T cell proliferation	J:28435
\Rel^tm1Grd/\Rel^tm1Grd (involves: 129S1/Sv)	immune system phenotype	J:113514
\Rel^tm1Grd/\Rel^tm1Grd \Rela^tm1Bal/\Rela^tm1Bal (B6.129S-Rel^tm1Grd Rela^tm1Bal)	abnormal monocyte differentiation	J:111325
	increased granulocyte number	J:111325
\Rel^tm1Hcl/\Rel⁺ (involves: 129S4/SvJae * C57BL/6)	decreased T cell proliferation	J:53513
\Rel^tm1Hcl/\Rel^tm1Hcl (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:79107, J:118907
	abnormal cytokine secretion	J:53513, J:79107
	abnormal dendritic cell physiology	J:118907
	abnormal macrophage physiology	J:118907
	abnormal memory B cell number	J:75621
	abnormal professional antigen presenting cell physiology	J:118907
	abnormal T-helper 1 cell differentiation	J:79107
	decreased B cell proliferation	J:75621
	decreased cytotoxic T cell cytolysis	J:53513
	decreased IgE level	J:58987
	decreased susceptibility to autoimmune diabetes	J:118907
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:79107
	decreased T cell proliferation	J:53513, J:79107
	immune system phenotype	J:53513, J:118907, J:58987
	increased eosinophil cell number	J:58987
\Rela^tm1Asba/\Rela^tm1Asba \Tg(Vil1-cre)997Gum/0 (involves: 129 * C57BL/6J * SJL)	increased susceptibility to induced colitis	J:131977
\Rela^tm1Bal/\Rela^tm1Bal (involves: 129S4/SvJae)	decreased marginal zone B cell number	J:65246
\Rela^tm1Bal/\Rela^tm1Bal (involves: 129S4/SvJae)	immune system phenotype	J:113514
\Rela^tm1Bal/\Rela^tm1Bal \Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (involves: 129S4/SvJae * C57BL/6)	abnormal spleen germinal center morphology	J:60742
	abnormal thymus morphology	J:60742
	decreased spleen white pulp amount	J:60742
	heart inflammation	J:60742
	liver inflammation	J:60742
	lung inflammation	J:60742
\Rela^tm1Mpa/\Rela^tm1Mpa \Tg(Alb1-cre)7Gsc/0 (involves: FVB/N)	increased susceptibility to endotoxin shock	J:137861
\Rela^tm1Rsch/\Rela^tm1Rsch \Ptf1a^tm1(cre)Hnak/? (involves: C57BL/6)	abnormal interleukin level	J:122194
	abnormal tumor necrosis factor level	J:122194
	lung inflammation	J:122194
	pancreas inflammation	J:122194
\Rela^tm1Rsch/\Rela^tm1Rsch \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal gamma-delta T cell morphology	J:169863
\Rela^tm1Rsch/\Rela^tm1Rsch \Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal gamma-delta T cell morphology	J:169863
	decreased interleukin-17 secretion	J:169863
	immune system phenotype	J:169863
	increased susceptibility to bacterial infection	J:169863
\Rela^tm1Yuo/\Rela^tm1Yuo (involves: 129S/SvEv)	abnormal lymphocyte physiology	J:63099
	decreased B cell proliferation	J:63099
	decreased double-positive T cell number	J:63099
	decreased IgA level	J:63099
	decreased IgG1 level	J:63099
	decreased T cell proliferation	J:63099
\Rela^tm2.1Gho/\Rela^tm2.1Gho (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen morphology	J:163663
	increased inflammatory response	J:163663
	increased neutrophil cell number	J:163663
	interstitial pneumonia	J:163663
	liver inflammation	J:163663
	lung inflammation	J:163663
	myositis	J:163663
\Rela^tm2.1Gho/\Rela^tm2.1Gho \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * 129S6/SvEvTac)	increased incidence of corneal inflammation	J:163663
	liver inflammation	J:163663
\Relb^shep/\Relb^shep (A;C-Relb^shep/GrsrJ)	liver inflammation	J:171971
\Relb^{Tg(H2-K1/GH1)106Bri}/\Relb⁺ (involves: C57BL/6)	decreased NK T cell number	J:120659
	decreased Peyer's patch number	J:120659
	small Peyer's patches	J:120659
\Relb^{Tg(H2-K1/GH1)106Bri}/\Relb^{Tg(H2-K1/GH1)106Bri} (C57BL/6-Relb^{Tg(H2-K1/GH1)106Bri})	abnormal antigen presentation	J:23081
	abnormal lymph node morphology	J:76450
	abnormal Peyer's patch morphology	J:76450
	absent thymus medulla	J:23081, J:76450
	decreased B cell number	J:76450
	decreased pre-B cell number	J:76450
	decreased T cell number	J:76450
	decreased T cell proliferation	J:76450
	enlarged spleen	J:76450
	glomerulonephritis	J:76450
	increased granulocyte number	J:23081, J:76450
	increased inflammatory response	J:23081, J:76450
	increased macrophage cell number	J:23081, J:76450
	liver inflammation	J:76450
	lung inflammation	J:76450
	skin inflammation	J:76450
\Relb^{Tg(H2-K1/GH1)106Bri}/\Relb^{Tg(H2-K1/GH1)106Bri} (involves: C57BL/6)	absent lymph nodes	J:120659
	absent Peyer's patches	J:120659
	decreased circulating interleukin-4 level	J:120659
	decreased NK T cell number	J:120659
	increased inflammatory response	J:120659
\Relb^tm1.1Fwei/\Relb^tm1.1Fwei \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:169863
\Relb^tm1.1Fwei/\Relb^tm1.1Fwei \Tg(Lck-cre)I57Jxm/0 (involves: ICR)	abnormal gamma-delta T cell morphology	J:169863
	decreased interleukin-17 secretion	J:169863
	immune system phenotype	J:169863
	increased susceptibility to bacterial infection	J:169863
\Relb^tm1Brv/\Relb^tm1Brv (involves: 129S2/SvPas * C57BL/6)	abnormal cell-mediated immunity	J:22675
	abnormal cytokine level	J:40630
	abnormal cytotoxic T cell physiology	J:40630
	abnormal humoral immune response	J:40630
	abnormal immune system organ morphology	J:22675
	abnormal immune system physiology	J:22675, J:40630
	abnormal immunoglobulin level	J:40630
	abnormal interferon level	J:40630
	abnormal interleukin level	J:40630
	abnormal lymph node morphology	J:22675
	abnormal macrophage physiology	J:40630
	abnormal mesenteric lymph node morphology	J:22675
	abnormal tumor necrosis factor level	J:40630
	decreased B cell proliferation	J:40630
	decreased dendritic cell number	J:22675
	decreased spleen white pulp amount	J:22675
	decreased susceptibility to type IV hypersensitivity reaction	J:22675
	decreased T cell number	J:22675
	epididymis inflammation	J:22675
	impaired neutrophil phagocytosis	J:40630
	increased IgE level	J:40630
	increased IgM level	J:40630
	increased spleen red pulp amount	J:22675
	increased spleen weight	J:22675
	increased susceptibility to bacterial infection	J:40630
	increased susceptibility to Riboviria infection	J:40630
	intestinal inflammation	J:22675
	liver inflammation	J:22675
	lung inflammation	J:22675
	myeloid hyperplasia	J:22675
	myositis	J:22675
	ovary inflammation	J:22675
	salivary gland inflammation	J:22675
	stomach inflammation	J:22675
	thymus atrophy	J:22675
	thymus hypoplasia	J:22675
\Relb^tm1Brv/\Relb^tm1Brv (either: (involves: 129S2/SvPas) or (involves: C57BL/6) or (involves: 129S2/SvPas * C57BL/6))	dermatitis	J:63950
	increased eosinophil cell number	J:63950
	lung inflammation	J:63950
\Relb^tm1Brv/\Relb^tm1Brv (involves: 129S2/SvPas)	abnormal gamma-delta T cell morphology	J:169863
	decreased dendritic cell number	J:85808
	spleen hyperplasia	J:85808
\Reln^em1(IMPC)Mbp/\Reln⁺ (C57BL/6N-Reln^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Relt^tm1Hlee/\Relt^tm1Hlee (Not Specified)	abnormal T cell morphology	J:266480
	immune system phenotype	J:266480
	increased T cell proliferation	J:266480
\Ren1^tm1Tkh/\Ren1^tm1Tkh (C57BL/6-Ren1^tm1Tkh)	kidney inflammation	J:110082
\Ret^tm2.1Cos/\Ret^tm2.1Cos (involves: 129S1/Sv)	immune system phenotype	J:195828
\Ret^tm6.1Vpa/\Ret^tm6.2Vpa \Tg(CD2-icre)4Kio/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)	immune system phenotype	J:195828
\Retn^tm1Laz/\Retn^tm1Laz \Tg(CD68-RETN)#Laz/? (involves: 129S6/SvEvTac * C57BL/6)	white adipose tissue inflammation	J:171262
\Retnla^tm1Mer/\Retnla^tm1Mer (C57BL/6-Retnla^tm1Mer)	abnormal chemokine secretion	J:144784
	decreased interleukin-5 secretion	J:144784
	decreased interleukin-6 secretion	J:144927
	decreased susceptibility to induced colitis	J:144784, J:144927
	impaired eosinophil recruitment	J:144784
	increased interleukin-10 secretion	J:144927
\Retnla^tm1Mer/\Retnla^tm1Mer (C.B6-Retnla^tm1Mer)	decreased susceptibility to induced colitis	J:144784, J:144927
\Retnla^tm1Mer/\Retnla^tm1Mer (involves: C57BL/6)	abnormal macrophage physiology	J:147863
	abnormal T-helper 2 physiology	J:147863
	increased IgE level	J:147863
	increased IgG1 level	J:147863
	increased interleukin-4 secretion	J:147863
	increased interleukin-5 secretion	J:147863
	increased interleukin-13 secretion	J:147863
\Retnlb^tm1Gdw/\Retnlb^tm1Gdw (involves: 129S/SvEv * C57BL/6)	decreased inflammatory response	J:114507
	decreased susceptibility to induced colitis	J:114507
\Retnlb^tm1Lex/\Retnlb^tm1Lex (FVB.129S5-Retnlb^tm1Lex)	abnormal CD4-positive, alpha-beta T cell physiology	J:235058
	decreased circulating interleukin-6 level	J:235058
	increased circulating interleukin-13 level	J:235058
	increased neutrophil cell number	J:235058
	liver inflammation	J:235058
	white adipose tissue inflammation	J:235058
\Retnlb^tm1Mer/\Retnlb^tm1Mer (involves: 129S1/Sv * C57BL/6)	decreased susceptibility to induced colitis	J:141524
	increased susceptibility to induced colitis	J:141524
\Retnlb^tm1Mer/\Retnlb^tm1Mer (involves: 129S1/Sv)	decreased IgG2a level	J:141446
	decreased interferon-gamma secretion	J:141446
	decreased susceptibility to parasitic infection	J:141446
	decreased tumor necrosis factor secretion	J:141446
	increased IgG1 level	J:141446
\Retreg2^{em2(IMPC)Ccpcz}/\Retreg2^{em2(IMPC)Ccpcz} (C57BL/6N-Retreg2^{em2(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Rev1^tm1.1Jow/\Rev1^tm1.1Jow (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:151700
\Rev1^tm1.1Jow/\Rev1^tm1.1Jow (involves: C57BL/6)	immune system phenotype	J:151700
\Rev1^tm1Ndew/\Rev1^tm1Ndew (involves: 129P2/OlaHsd * C57BL/6)	abnormal somatic hypermutation frequency	J:119176
	immune system phenotype	J:119176
	lymphoid hypoplasia	J:119176
\Rev3l^tm1.1Kunk/\Rev3l^tm1.1Kunk (involves: C57BL/6)	abnormal somatic hypermutation frequency	J:188723
\Rev3l^tm1.1Kunk/\Rev3l^tm1.1Kunk (involves: C57BL/6)	immune system phenotype	J:188723
\Rev3l^tm1Rsky/\Rev3l^tm1.1Rsky \Tg(Cr2-cre)3Cgn/? (involves: C57BL/6)	abnormal class switch recombination	J:146453
	abnormal somatic hypermutation frequency	J:146453
	decreased B cell proliferation	J:146453
	decreased germinal center B cell number	J:146453
	decreased IgG1 level	J:146453
\Rev3l^tm1Rwd/\Rev3l^tm2.1Rwd \Trp53^tm1Brd/\Trp53^tm1Brd \Tg(MMTV-cre)1Mam/0 (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)	increased T cell derived lymphoma incidence	J:158922
\Rexo2^{tm1b(EUCOMM)Wtsi}/\Rexo2⁺ (C57BL/6N-Rexo2^{tm1b(EUCOMM)Wtsi}/H)	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Rffl^{em1(IMPC)Ccpcz}/\Rffl^{em1(IMPC)Ccpcz} (C57BL/6N-Rffl^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Rfk^em1(IMPC)Mbp/\Rfk⁺ (C57BL/6NCrl-Rfk^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Rfk^tm1.1Jcbr/\Rfk^tm1.1Jcbr \Tg(Mx1-cre)1Cgn/? (involves: C57BL/6 * CBA)	decreased macrophage nitric oxide production	J:151999
\Rft1^{tm1b(KOMP)Wtsi}/\Rft1⁺ (C57BL/6N-Rft1^{tm1b(KOMP)Wtsi}/Bay)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased monocyte cell number	J:211773
\Rftn1^tm1Ayos/\Rftn1^tm1Ayos (B6.Cg-Rftn1^tm1Ayos)	abnormal CD4-positive T cell differentiation	J:150299
	decreased IgG2a level	J:150299
	decreased interferon-gamma secretion	J:150299
	decreased interleukin-4 secretion	J:150299
	decreased interleukin-17 secretion	J:150299
	decreased splenocyte number	J:150299
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:150299
\Rfx5^tm1.1Ifo/\Rfx5^tm1.1Ifo (involves: 129 * C57BL/6)	abnormal B lymphocyte antigen presentation	J:67941
	abnormal dendritic cell morphology	J:67941
	abnormal Kupffer cell morphology	J:67941
	abnormal level of surface class II molecules	J:67941
	abnormal MHC II cell surface expression on macrophages	J:67941
	abnormal thymus cortex morphology	J:67941
	decreased CD4-positive, alpha-beta T cell number	J:67941
	decreased IgG1 level	J:67941
	decreased IgM level	J:67941
	decreased single-positive T cell number	J:67941
\Rfx5^tm1Ifo/\Rfx5^tm1.1Ifo \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * C57BL/6 * C.B-20)	abnormal MHC II cell surface expression on macrophages	J:67924
\Rfx5^tm1Ifo/\Rfx5^tm1Ifo (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:282535
\Rfx7^tm1.1Ggaur/\Rfx7^tm1.1Ggaur \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal NK cell morphology	J:282535
	decreased NK cell number	J:282535
	small spleen	J:282535
\Rfx7^tm1.1Ggaur/\Rfx7^tm1.1Ggaur \Ncr1^{tm1.1(icre)Viv}/\Ncr1⁺ (involves: C57BL/6)	abnormal NK cell physiology	J:282535
	decreased NK cell number	J:282535
	increased susceptibility to viral infection	J:282535
\Rfx7^tm1.1Ggaur/\Rfx7^tm1.1Ggaur \Rptor^tm1.1Dmsa/\Rptor⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S/SvEv * C57BL/10 * CBA/Ca)	abnormal NK cell morphology	J:282535
	decreased NK cell number	J:282535
	small spleen	J:282535
\Rgcc^tm1Hrus/\Rgcc^tm1Hrus (involves: 129S6/SvEvTac * C57BL/6)	increased interleukin-2 secretion	J:279555
	increased T cell proliferation	J:279555
\Rgl1^em1(IMPC)Mbp/\Rgl1⁺ (C57BL/6N-Rgl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Rgs1^tm1Jhk/\Rgs1^tm1Jhk (B6.129P2-Rgs1^tm1Jhk)	abnormal B cell calcium ion homeostasis	J:90780
	abnormal dendritic cell physiology	J:89680
	abnormal spleen germinal center morphology	J:90780
	decreased plasma cell number	J:90780
	enhanced B cell migration	J:90780
	increased immunoglobulin level	J:90780
	increased marginal zone B cell number	J:90780
	small Peyer's patches	J:90780
\Rgs2^em1(IMPC)H/\Rgs2^em1(IMPC)H (C57BL/6NTac-Rgs2^em1(IMPC)H/H)	enlarged spleen	J:211773
\Rgs2^tm1Pngr/\Rgs2^tm1Pngr (involves: C57BL/6J)	abnormal T cell proliferation	J:77273
\Rgs3^tm1Ndul/\Rgs3^tm1Ndul (B6.129-Rgs3^tm1Ndul)	abnormal lymph node morphology	J:210195
	immune system phenotype	J:210195
	increased B cell number	J:210195
	increased CD4-positive, alpha-beta T cell number	J:210195
	increased CD8-positive, alpha-beta T cell number	J:210195
	increased susceptibility to type I hypersensitivity reaction	J:210195
	lung inflammation	J:210195
\Rgs4^em1(IMPC)H/\Rgs4^em1(IMPC)H (C57BL/6N-Rgs4^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased spleen weight	J:211773
\Rgs4^tm1Sdlk/\Rgs4^tm1Sdlk \Tg(Myh11-icre/ERT2)1Soff/? (involves: FVB/N)	abnormal macrophage chemotaxis	J:215588
\Rgs5^tm1Jhk/\Rgs5^tm1Jhk (involves: 129S/SvEv * C57BL/6)	decreased lymphocyte cell number	J:133897
\Rgs9^{em1(IMPC)Ccpcz}/\Rgs9^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Rgs9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Rgs10^tm1Ypl/\Rgs10^tm1Ypl (involves: 129S4/SvJae * C57BL/6J)	abnormal osteoclast differentiation	J:123167
	decreased osteoclast cell number	J:123167
\Rgs12^tm1.1Syy/\Rgs12^tm1.1Syy \Tg(Mx1-cre)1Cgn/0 (involves: 129 * C57BL/6 * CBA)	decreased osteoclast cell number	J:194057
\Rgs13^tm1.1Jhk/\Rgs13^tm1.1Jhk (involves: C57BL/6)	abnormal B cell differentiation	J:199530
	abnormal humoral immune response	J:199530
	abnormal spleen morphology	J:199530
	decreased B cell number	J:199530
	immune system phenotype	J:199530
	increased B cell number	J:199530
	increased germinal center B cell number	J:199530
	increased IgA level	J:199530
	increased IgG1 level	J:199530
	increased IgG2b level	J:199530
	increased IgG2c level	J:199530
	increased IgG3 level	J:199530
	increased IgM level	J:199530
	increased spleen germinal center number	J:199530
	increased spleen germinal center size	J:199530
\Rgs13^tm1Drue/\Rgs13^tm1Drue (B6.129S-Rgs13^tm1Drue)	abnormal mast cell physiology	J:130209
\Rgs13^tm1Drue/\Rgs13^tm1Drue (B6.129S-Rgs13^tm1Drue)	increased susceptibility to type I hypersensitivity reaction	J:130209
\Rgs14^tm1Lex/\Rgs14^tm1Lex (involves: 129S5/SvEvBrd)	immune system phenotype	J:103485
\Rgs16^tm1.1Drue/\Rgs16^tm1.1Drue (involves: C57BL/6)	abnormal T-helper 1 physiology	J:188966
	abnormal T-helper 2 physiology	J:188966
	granulomatous inflammation	J:188966
	increased interleukin-5 secretion	J:188966
	increased interleukin-10 secretion	J:188966
	increased interleukin-13 secretion	J:188966
	increased susceptibility to parasitic infection	J:188966
\Rgsc14/\Rgsc14⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased leukocyte cell number	J:133634
\Rgsc14/\Rgsc14⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased lymphocyte cell number	J:133634
\Rgsc15/\Rgsc15⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased leukocyte cell number	J:133634
\Rgsc15/\Rgsc15⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased lymphocyte cell number	J:133634
\Rgsc17/\Rgsc17⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	decreased leukocyte cell number	J:133634
\Rgsc17/\Rgsc17⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	decreased lymphocyte cell number	J:133634
\Rgsc142/\Rgsc142⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	increased T cell derived lymphoma incidence	J:133634
\Rgsc844/\Rgsc844⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	abnormal neutrophil physiology	J:133634
\Rgsc1045/\Rgsc1045⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	abnormal neutrophil physiology	J:133634
\Rgsc1354/\Rgsc1354⁺ (involves: C3H * C57BL/6JJcl)	abnormal neutrophil physiology	J:133634
\Rgsc1547/\Rgsc1547⁺ (involves: C3H * C57BL/6JJcl)	increased susceptibility to otitis media	J:133634
\Rhag^{em1(IMPC)Ccpcz}/\Rhag^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Rhag^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Rhbdd1^tm1.1Mfm/\Rhbdd1^tm1.1Mfm (involves: 129S/SvEv * C57BL/6J)	increased interleukin-6 secretion	J:346394
	increased susceptibility to endotoxin shock	J:346394
	increased tumor necrosis factor secretion	J:346394
\Rhbdd3^tm1Caox/\Rhbdd3^tm1Caox (B6.129S6-Rhbdd3^tm1Caox)	abnormal dendritic cell physiology	J:197348
	immune system phenotype	J:197348
	increased circulating interferon-gamma level	J:197348
	increased circulating interleukin-6 level	J:197348
	increased interferon-gamma secretion	J:197348
	increased interleukin-6 secretion	J:197348
	increased natural killer cell mediated cytotoxicity	J:197348
	increased NK cell number	J:197348
	liver inflammation	J:197348
\Rhbdf1^tm1.1Mfm/\Rhbdf1^tm1.1Mfm (involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6J)	small spleen	J:203951
	small thymus	J:203951
\Rhbdf2^cub/\Rhbdf2^cub (B6.Cg-Rhbdf2^cub)	white adipose tissue inflammation	J:82006
\Rhbdf2^m1Btlr/\Rhbdf2^m1Btlr (C57BL/6J-Rhbdf2^m1Btlr)	decreased tumor necrosis factor secretion	J:187583
\Rhbdf2^m1Btlr/\Rhbdf2^{tm1a(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	decreased tumor necrosis factor secretion	J:187583
\Rhbdf2^M2Btlr/\Rhbdf2⁺ (C57BL/6J-Rhbdf2^M2Btlr)	abnormal immune system physiology	J:213194
\Rhbdf2^M3Btlr/\Rhbdf2⁺ (C57BL/6J-Rhbdf2^M3Btlr)	abnormal immune system physiology	J:220064
\Rhbdf2^M3Btlr/\Rhbdf2^M3Btlr (C57BL/6J-Rhbdf2^M3Btlr)	abnormal immune system physiology	J:220064
\Rhbdf2^tm1.1Mfm/\Rhbdf2^tm1.1Mfm (B6.129S-Rhbdf2^tm1.1Mfm)	decreased circulating tumor necrosis factor level	J:179654
\Rhbdf2^tm1.1Mfm/\Rhbdf2^tm1.1Mfm (B6.129S-Rhbdf2^tm1.1Mfm)	decreased tumor necrosis factor secretion	J:179654
\Rhbdf2^{tm1a(KOMP)Wtsi}/\Rhbdf2^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	decreased tumor necrosis factor secretion	J:187583
\Rhbdf2^tm1Mak/\Rhbdf2^tm1Mak (B6.129P2-Rhbdf2^tm1Mak)	abnormal B cell physiology	J:179653
	abnormal immune serum protein physiology	J:179653
	decreased circulating tumor necrosis factor level	J:179653
	decreased susceptibility to infection induced morbidity/mortality	J:179653
	decreased tumor necrosis factor secretion	J:179653
	increased susceptibility to bacterial infection	J:179653
	increased susceptibility to bacterial infection induced morbidity/mortality	J:179653
\Rhbdf2^tm1Mak/\Rhbdf2^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal leukocyte physiology	J:221411
	abnormal microglial cell physiology	J:221411
	decreased tumor necrosis factor secretion	J:221411
\Rheb^tm1Pfw/\Rheb^tm1Pfw \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	immune system phenotype	J:150108
\Rho^tm2.1Kpal/\Rho^tm2.1Kpal (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)	microgliosis	J:194158
\Rhoa^tm1.1Tpal/\Rhoa⁺ \Tg(Cd4-cre/ERT2)11Gnri/0 (involves: C57BL/6)	increased regulatory T cell number	J:257764
	increased T cell proliferation	J:257764
	increased T follicular helper cell number	J:257764
\Rhobtb1^{em2(IMPC)Ccpcz}/\Rhobtb1^{em2(IMPC)Ccpcz} (C57BL/6N-Rhobtb1^{em2(IMPC)Ccpcz}/Ccpcz)	increased Ly6C-positive NK T cell number	J:211773
\Rhobtb3^{tm1a(KOMP)Wtsi}/\Rhobtb3^{tm1a(KOMP)Wtsi} (involves: C57BL/6N)	decreased spleen weight	J:226884
\Rhoc^tm1Mak/\Rhoc^tm1Mak (involves: 129P2/OlaHsd)	immune system phenotype	J:100482
\Rhof^tm1.2Dash/\Rhof^tm1.2Dash (involves: 129)	abnormal spleen marginal zone morphology	J:303076
	decreased marginal zone B cell number	J:303076
	immune system phenotype	J:303076
\Rhog^tm1Tnr/\Rhog^tm1Tnr (involves: 129)	abnormal CD4-positive, alpha-beta T cell physiology	J:87580
	abnormal leukocyte physiology	J:87580
	abnormal T-helper 2 physiology	J:87580
	increased B cell proliferation	J:87580
	increased immunoglobulin level	J:87580
\Rhoh^{tm1b(EUCOMM)Hmgu}/\Rhoh^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rhoh^{tm1b(EUCOMM)Hmgu}/Bay)	decreased leukocyte cell number	J:211773
\Rhoh^tm1Brak/\Rhoh^tm1Brak (involves: 129/Sv * C57BL/6)	abnormal double-negative T cell morphology	J:143161
	abnormal immune system organ morphology	J:143161
	abnormal lymphocyte cell number	J:143161
	abnormal splenic cell ratio	J:143161
	abnormal T cell proliferation	J:143161
	decreased CD4-positive, alpha-beta T cell number	J:143161
	decreased CD8-positive, alpha-beta T cell number	J:143161
	decreased double-positive T cell number	J:143161
	decreased single-positive T cell number	J:143161
	decreased T cell apoptosis	J:143161
	decreased T cell number	J:143161
	decreased T cell proliferation	J:143161
	increased double-negative T cell number	J:143161
	increased gamma-delta T cell number	J:143161
	increased NK cell number	J:143161
	increased NK T cell number	J:143161
	increased T cell number	J:143161
	increased T cell proliferation	J:143161
	spleen hypoplasia	J:143161
	thymus hypoplasia	J:143161
\Rhoh^tm1Brak/\Rhoh^tm1Brak \Itgb2^tm2Bay/\Itgb2^tm2Bay (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:143161
	decreased CD8-positive, alpha-beta T cell number	J:143161
	decreased double-positive T cell number	J:143161
	decreased single-positive T cell number	J:143161
	increased double-negative T cell number	J:143161
\Rhoh^tm1Brak/\Rhoh^tm1Brak \Tg(TcraTcrb)425Cbn/? (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:143161
	immune system phenotype	J:143161
\Rhoh^tm1Daw/\Rhoh^tm1Daw (involves: 129 * C57BL/6)	arrested T cell differentiation	J:113565
	decreased double-positive T cell number	J:113565
	decreased T cell number	J:113565
	thymus hypoplasia	J:113565
\Rhoh^tm1Hasu/\Rhoh^tm1Hasu (B6.Cg-Rhoh^tm1Hasu)	abnormal mast cell physiology	J:143491
	decreased mast cell degranulation	J:143491
	decreased susceptibility to type I hypersensitivity reaction	J:143491
	immune system phenotype	J:143491
\Rhs1^C57BL/6/\Rhs1^C57BL/6 (involves: BALB/c * C57BL/6)	decreased susceptibility to Herpesvirales infection	J:69352
\Ric1^{tm1a(EUCOMM)Hmgu}/\Ric1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Ric1^{tm1a(EUCOMM)Hmgu}/H)	decreased B cell number	J:165965
	decreased leukocyte cell number	J:165965
	decreased mature B cell number	J:165965
\Ric8b^{tm1b(EUCOMM)Hmgu}/\Ric8b⁺ (C57BL/6N-Ric8b^{tm1b(EUCOMM)Hmgu}/Cnrm)	increased basophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Rictor^tm1.1Klg/\Rictor^tm1.1Klg \Tg(Mx1-cre)1Cgn/0 (B6.Cg-Rictor^tm1.1Klg Tg(Mx1-cre)1Cgn)	abnormal double-negative T cell morphology	J:189736
	decreased DN1 thymic pro-T cell number	J:189736
	decreased DN2 thymocyte number	J:189736
	decreased DN3 thymocyte number	J:189736
	decreased DN4 thymocyte number	J:189736
	decreased double-positive T cell number	J:189736
	decreased single-positive T cell number	J:189736
	decreased T cell proliferation	J:189736
	decreased thymus weight	J:189736
	immune system phenotype	J:189736
	increased double-negative T cell number	J:189736
	thymus hypoplasia	J:189736
\Rictor^tm1.1Mnh/\Rictor^tm1.1Mnh \Tg(Fabp4-cre)1Rev/0 (B6.Cg-Rictor^tm1.1Mnh Tg(Fabp4-cre)1Rev)	increased spleen weight	J:150064
\Rif1^{Gt(XT0278)Wtsi}/\Rif1^{Gt(XT0278)Wtsi} (involves: 129P2/OlaHsd * CD-1 * MF1)	abnormal class switch recombination	J:195061
	decreased IgA level	J:195061
	decreased IgG1 level	J:195061
	decreased IgG2b level	J:195061
	decreased IgG3 level	J:195061
	decreased IgG level	J:195061
	immune system phenotype	J:195061
	increased susceptibility to bacterial infection	J:195061
\Rigi^tm1Aki/\Rigi^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:137522
\Rigi^tm1Aki/\Rigi^tm1Aki (involves: 129/Sv * C57BL/6 * ICR)	abnormal interferon level	J:137522
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:137522
\Rigi^tm1Zgwg/\Rigi^tm1Zgwg (involves: 129S1/Sv)	abnormal B cell differentiation	J:139016
	abnormal granulocyte morphology	J:139016
	abnormal granulocyte physiology	J:139016
	colitis	J:139868
	decreased Peyer's patch number	J:139868
	decreased T cell number	J:139868
	enlarged spleen	J:139016
	immune system phenotype	J:139016
	increased activated T cell number	J:139868
	increased granulocyte number	J:139016
	increased memory T cell number	J:139868
	increased susceptibility to induced colitis	J:139868
	small Peyer's patches	J:139868
\Rin3^{tm1.1(KOMP)Vlcg}/\Rin3^{tm1.1(KOMP)Vlcg} (involves: 129P2/OlaHsd * C57BL/6N)	abnormal osteoclast morphology	J:358899
\Rinl^tm1.1Boun/\Rinl^tm1.1Boun (B6.Cg-Rinl^tm1.1Boun)	abnormal susceptibility to Riboviria infection	J:346452
	enlarged spleen	J:346452
	immune system phenotype	J:346452
	increased B cell number	J:346452
	increased CD4-positive, alpha-beta T cell number	J:346452
	increased germinal center B cell number	J:346452
	increased splenocyte number	J:346452
	increased T follicular helper cell number	J:346452
\Rinl^tm1.1Boun/\Rinl^tm1.1Boun \Tg(TcraTcrb)425Cbn/0 (involves: C57BL/6)	abnormal T follicular helper cell differentiation	J:346452
	increased CD4-positive, alpha-beta T cell number	J:346452
	increased T follicular helper cell number	J:346452
\Riok2^{tm1c(KOMP)Wtsi}/\Riok2⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6N * C57BL/10 * CBA/Ca)	abnormal CD4-positive, alpha beta T cell morphology	J:305794
	abnormal CD4-positive, alpha-beta T cell physiology	J:305794
	abnormal circulating interleukin level	J:305794
	abnormal immune system morphology	J:305794
	abnormal interleukin secretion	J:305794
	decreased neutrophil cell number	J:305794
	increased monocyte cell number	J:305794
	increased NK T cell number	J:305794
\Riox1^tm1Qch/\Riox1^tm1Qch \Tg(Prrx1-cre)1Cjt/0 (involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * SJL/J)	decreased osteoclast cell number	J:224562
\Riox2^tm1Mtsun/\Riox2^tm1Mtsun (B6CrSlc.Cg-Riox2^tm1Mtsun)	abnormal circulating interferon-gamma level	J:201871
	abnormal circulating interleukin-4 level	J:201871
	abnormal immunoglobulin level	J:201871
	decreased eosinophil cell number	J:201871
	decreased inflammatory response	J:201871
	decreased macrophage cell number	J:201871
	decreased neutrophil cell number	J:201871
\Ripk1^tm1.1Vmd/\Ripk1^tm1.1Vmd (involves: C57BL/6N)	increased thymocyte apoptosis	J:209137
\Ripk1^tm1Led/\Ripk1^tm1Led (involves: 129S6/SvEvTac)	abnormal immune system organ morphology	J:46522
	abnormal leukocyte cell number	J:46522
	abnormal lymph node morphology	J:46522
	abnormal thymus morphology	J:46522
	decreased thymocyte number	J:46522
	increased spleen red pulp amount	J:46522
	lymph node inflammation	J:46522
	lymph node necrosis	J:46522
\Ripk2^tm1Cfl/\Ripk2^tm1Cfl (involves: 129S5/SvEvBrd)	abnormal macrophage physiology	J:107130
\Ripk2^tm1Flv/\Ripk2^tm1Flv (involves: 129S1/Sv)	abnormal cytokine secretion	J:75400
	abnormal T-helper 1 physiology	J:75400
	decreased interleukin-6 secretion	J:75400
	decreased T cell proliferation	J:75400
	decreased tumor necrosis factor secretion	J:75400
\Ripk2^tm1Flv/\Ripk2^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal macrophage physiology	J:132126
	decreased interleukin-6 secretion	J:132126
	decreased tumor necrosis factor secretion	J:132126
\Ripk2^tm1Flv/\Ripk2^tm1Flv \Tnip1^tm1.1Pcoh/\Tnip1^tm1.1Pcoh (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	enlarged lymph nodes	J:176826
	enlarged spleen	J:176826
\Ripk2^tm1Ghc/\Ripk2^tm1Ghc (involves: 129S4/SvJae * C57BL/6)	decreased IgG2a level	J:75401
	decreased interferon-gamma secretion	J:75401
	decreased T cell proliferation	J:75401
	increased susceptibility to infection	J:75401
\Ripk2^tm2Cfl/\Ripk2^tm2Cfl (involves: 129S5/SvEvBrd)	immune system phenotype	J:107130
\Ripk3^tm1Vmd/\Ripk3^tm1Vmd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6N)	immune system phenotype	J:87683
\Ripk3^tm1Vmd/\Ripk3^tm1Vmd (B6.129-Ripk3^tm1Vmd)	decreased inflammatory response	J:179279
\Ripk4^tm1Pmh/\Ripk4^tm1Pmh (involves: 129 * C57BL/6)	immune system phenotype	J:78593
\Ripply3^tm1Sjt/\Ripply3^tm1Sjt (involves: 129S1/Sv * C57BL/6)	abnormal thymus development	J:167713
	ectopic thymus	J:167713
	small thymus	J:167713
\Rit1^tm1.1Tumg/\Rit1⁺ (B6.Cg-Rit1^tm1.1Tumg)	enlarged spleen	J:277548
\Rlim^{em1(IMPC)Rbrc}/\Rlim⁺ (C57BL/6NJcl-Rlim^{em1(IMPC)Rbrc}/Rbrc)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Rmcf^r/\Rmcf^r (DBA/1J)	decreased susceptibility to Retroviridae infection	J:7108
\Rmcf^r/\Rmcf^r (DBA/2J)	decreased susceptibility to Retroviridae infection	J:7108
\Rmcf^r/\Rmcf^r (CBA/N)	decreased susceptibility to Retroviridae infection	J:7108
\Rmcf^s/\Rmcf^s (CBA/J)	increased susceptibility to Retroviridae infection	J:7108
\Rmcf^s/\Rmcf^s (C57L/J)	increased susceptibility to Retroviridae infection	J:7108
\Rmcf^s/\Rmcf^s (C57BR/cdJ)	increased susceptibility to Retroviridae infection	J:7108
\Rmp1^DBA/2J/\Rmp1^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to Poxviridae infection	J:28150
\Rmp2^DBA/2J/\Rmp2^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to Poxviridae infection	J:11032
\Rmp3^DBA/2J/\Rmp3^DBA/2J (involves: C57BL/6J * DBA/2J)	increased susceptibility to Poxviridae infection	J:11032
\Rmp4^C57BL/6NCr/\Rmp4^C57BL/6NCr (involves: C57BL/6NCr * DBA/2NCr)	decreased susceptibility to Poxviridae infection	J:29241
\Rmp5^C57BL/6NCr/\Rmp5^C57BL/6NCr (involves: C57BL/6NCr * DBA/2NCr)	decreased susceptibility to Poxviridae infection	J:3240
\Rmp6^C57BL/6NCr/\Rmp6^C57BL/6NCr (involves: C57BL/6NCr * DBA/2NCr)	decreased susceptibility to Poxviridae infection	J:3240
\Rmrp^{em1(IMPC)Ccpcz}/\Rmrp⁺ (C57BL/6NCrl-Rmrp^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Rnase4^em1Zpxu/\Rnase4^em1Zpxu (Not Specified)	increased susceptibility to induced colitis	J:354138
\Rnase4^em2Zpxu/\Rnase4^em2Zpxu \Tg(Vil1-cre)DNju/0 (involves: C57BL/6 * C57BL/6J)	increased susceptibility to induced colitis	J:354138
\Rnase6^em1(IMPC)Tcp/\Rnase6^em1(IMPC)Tcp (C57BL/6N-Rnase6^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
\Rnase11^em1(IMPC)Mbp/\Rnase11^em1(IMPC)Mbp (C57BL/6N-Rnase11^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	increased lymphocyte cell number	J:211773
	small spleen	J:211773
\Rnase12^em1(IMPC)Mbp/\Rnase12^em1(IMPC)Mbp (C57BL/6N-Rnase12^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Rnaseh2a^em1(IMPC)Tcp/\Rnaseh2a⁺ (C57BL/6NCrl-Rnaseh2a^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
\Rnaseh2a^tm1Crh/\Rnaseh2a^tm1Crh (Not Specified)	abnormal innate immunity	J:232933
\Rnaseh2a^tm1Crh/\Rnaseh2a^tm1Crh (Not Specified)	decreased susceptibility to Riboviria infection	J:232933
\Rnaseh2a^tm1Crh/\Rnaseh2a^tm1Crh \Sting1^tm1Gnb/\Sting1^tm1Gnb (involves: 129P2/OlaHsd)	immune system phenotype	J:232933
\Rnaseh2b^em1Anu/\Rnaseh2b⁺ \Tlr7^em2Anu/\Tlr7⁺ (C57BL/6NCrl-Rnaseh2b^em1Anu Tlr7^em2Anu)	abnormal immune system morphology	J:324448
	abnormal mature B cell morphology	J:324448
	increased autoantibody level	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased germinal center B cell number	J:324448
	increased plasma cell number	J:324448
	increased T follicular helper cell number	J:324448
\Rnaseh2b^{tm1a(EUCOMM)Wtsi}/\Rnaseh2b^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	thymus hypoplasia	J:186986
\Rnaseh2b^{tm1c(EUCOMM)Wtsi}/\Rnaseh2b^{tm1c(EUCOMM)Wtsi} \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL)	decreased B cell proliferation	J:186986
	immune system phenotype	J:186986
\Rnasel^tm1Slvm/\Rnasel^tm1Slvm (involves: 129P2/OlaHsd)	abnormal thymus morphology	J:44292
	decreased T cell apoptosis	J:44292
	enlarged thymus	J:44292
	increased susceptibility to Picornaviridae infection	J:44292
	thymus hyperplasia	J:44292
\Rnaset2b^{tm1b(EUCOMM)Hmgu}/\Rnaset2b^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rnaset2b^{tm1b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
\Rnd2^em1(IMPC)Mbp/\Rnd2^em1(IMPC)Mbp (C57BL/6NCrl-Rnd2^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Rnd3^{tm1b(EUCOMM)Hmgu}/\Rnd3⁺ (C57BL/6N-Rnd3^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
\Rnf2^tm1Mvi/\Rnf2^tm1Mvi \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * CBA)	abnormal B cell differentiation	J:130397
	decreased B cell number	J:130397
	decreased monocyte cell number	J:130397
\Rnf5^{tm1.1(KOMP)Vlcg}/\Rnf5⁺ (C57BL/6N-Rnf5^{tm1.1(KOMP)Vlcg}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Rnf5^{tm1.1(KOMP)Vlcg}/\Rnf5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Rnf5^{tm1.1(KOMP)Vlcg}/Ccpcz)	abnormal spleen morphology	J:211773
\Rnf8^{Gt(AS0574)Wtsi}/\Rnf8⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:161240
\Rnf8^{Gt(AS0574)Wtsi}/\Rnf8^{Gt(AS0574)Wtsi} (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:161240
	decreased B cell number	J:161240
	decreased CD4-positive, alpha-beta T cell number	J:161240
	decreased CD8-positive, alpha-beta T cell number	J:161240
	decreased double-negative T cell number	J:161240
	decreased double-positive T cell number	J:161240
	decreased IgG1 level	J:161240
	decreased IgG2b level	J:161240
	decreased IgG3 level	J:161240
	decreased immature B cell number	J:161240
	decreased pre-B cell number	J:161240
	decreased pro-B cell number	J:161240
	decreased splenocyte number	J:161240
	decreased T cell number	J:161240
	decreased thymocyte number	J:161240
	increased T cell derived lymphoma incidence	J:161240
	increased thymocyte apoptosis	J:161240
\Rnf8^{Gt(RRR260)Byg}/\Rnf8^{Gt(RRR260)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:161240
	decreased B cell number	J:161240
	decreased CD4-positive, alpha-beta T cell number	J:161240
	decreased CD8-positive, alpha-beta T cell number	J:161240
	decreased double-negative T cell number	J:161240
	decreased double-positive T cell number	J:161240
	decreased IgG1 level	J:161240
	decreased IgG2b level	J:161240
	decreased IgG3 level	J:161240
	decreased immature B cell number	J:161240
	decreased pre-B cell number	J:161240
	decreased pro-B cell number	J:161240
	decreased splenocyte number	J:161240
	decreased T cell number	J:161240
	decreased thymocyte number	J:161240
	increased T cell derived lymphoma incidence	J:161240
	increased thymocyte apoptosis	J:161240
\Rnf10^{tm1b(KOMP)Wtsi}/\Rnf10^{tm1b(KOMP)Wtsi} (C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Rnf10^{tm1b(KOMP)Wtsi}/\Rnf10^{tm1b(KOMP)Wtsi} (C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/H)	increased large unstained cell number	J:211773
\Rnf10^{tm1b(KOMP)Wtsi}/\Rnf10^{tm1b(KOMP)Wtsi} (C57BL/6N-Rnf10^{tm1b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Rnf19b^{em1(IMPC)Ccpcz}/\Rnf19b⁺ (C57BL/6N-Rnf19b^{em1(IMPC)Ccpcz}/Ccpcz)	increased eosinophil cell number	J:211773
\Rnf19b^tm1Jkorn/\Rnf19b^tm1Jkorn (B6.129S-Rnf19b^tm1Jkorn)	decreased interferon-gamma secretion	J:157393
\Rnf19b^tm1Jkorn/\Rnf19b^tm1Jkorn (B6.129S-Rnf19b^tm1Jkorn)	impaired natural killer cell mediated cytotoxicity	J:157393
\Rnf20^{Gt(RRJ249)Byg}/\Rnf20⁺ (involves: 129P2/OlaHsd)	abnormal leukocyte physiology	J:268221
	abnormal T cell physiology	J:268221
	enlarged spleen	J:268221
	increased interferon-gamma secretion	J:268221
	increased spleen weight	J:268221
	increased susceptibility to induced colitis	J:268221
	increased tumor necrosis factor secretion	J:268221
\Rnf31^tm1.1Kiwa/\Rnf31^tm1.1Kiwa \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj)	abnormal B-1 B cell morphology	J:201885
	abnormal humoral immune response	J:201885
	decreased B-1a cell number	J:201885
	decreased B-1b cell number	J:201885
	decreased IgA level	J:201885
	decreased IgG1 level	J:201885
	decreased IgG2a level	J:201885
	decreased IgG2b level	J:201885
	decreased IgG3 level	J:201885
	decreased IgM level	J:201885
	immune system phenotype	J:201885
\Rnf34^{tm1a(EUCOMM)Hmgu}/\Rnf34^{tm1a(EUCOMM)Hmgu} (C57BL/6NCrl-Rnf34^{tm1a(EUCOMM)Hmgu}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Rnf39^em1Zwei/\Rnf39^em1Zwei (involves: C57BL/6)	decreased susceptibility to Riboviria infection	J:357975
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:357975
	increased interferon-beta secretion	J:357975
	increased interleukin-6 secretion	J:357975
\Rnf40^tm1.1Sajo/\Rnf40^tm1.1Sajo \Tg(Car1-cre)5Flt/0 (involves: 129S2/SvPas * C57BL/6J)	decreased susceptibility to induced colitis	J:311838
\Rnf43^em1(IMPC)Tcp/\Rnf43^em1(IMPC)Tcp (C57BL/6NCrl-Rnf43^em1(IMPC)Tcp/Tcp)	enlarged spleen	J:211773
\Rnf43^em1Mage/\Rnf43^em1Mage (Not Specified)	immune system phenotype	J:276360
\Rnf43^em2Mage/\Rnf43^em2Mage (Not Specified)	immune system phenotype	J:276360
	increased interferon-gamma secretion	J:285428
	stomach inflammation	J:285428
\Rnf115^em1(IMPC)H/\Rnf115^em1(IMPC)H (C57BL/6N-Rnf115^em1(IMPC)H/H)	increased spleen weight	J:211773
\Rnf115^em1Gpt/\Rnf115^em1Gpt (C57BL/6JGpt-Rnf115^em1Gpt/Gpt)	decreased susceptibility to viral infection	J:297834
	decreased susceptibility to viral infection induced morbidity/mortality	J:297834
	increased circulating interferon-beta level	J:297834
	increased interferon-beta secretion	J:297834
	increased susceptibility to viral infection induced morbidity/mortality	J:297834
\Rnf122^em1Caox/\Rnf122^em1Caox (involves: C57BL/6J)	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:344769
	immune system phenotype	J:344769
	increased circulating interferon-alpha level	J:344769
	increased circulating interferon-beta level	J:344769
	increased circulating interleukin-6 level	J:344769
	increased interferon-alpha secretion	J:344769
	increased interferon-beta secretion	J:344769
	increased interleukin-6 secretion	J:344769
	increased tumor necrosis factor secretion	J:344769
\Rnf123^em1Nmea/\Rnf123^em1Nmea (NC/Jic-Rnf123^em1Nmea)	decreased susceptibility to parasitic infection	J:327312
\Rnf123^em1Nmea/\Rnf123^em1Nmea (NC/Jic-Rnf123^em1Nmea)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:327312
\Rnf123^em2Nmea/\Rnf123^em2Nmea (NC/Jic-Rnf123^em2Nmea)	decreased susceptibility to parasitic infection	J:327312
\Rnf123^em2Nmea/\Rnf123^em2Nmea (NC/Jic-Rnf123^em2Nmea)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:327312
\Rnf128^{tm1.1(KOMP)Vlcg}/Y (C57BL/6N-Rnf128^{tm1.1(KOMP)Vlcg}/Ccpcz)	increased effector memory T-helper cell number	J:211773
\Rnf128^tm1.1Flv/Y (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:153216
	abnormal peripheral T cell anergy	J:153216
	increased circulating interleukin-2 level	J:153216
	increased interferon-gamma secretion	J:153216
	increased T cell proliferation	J:153216
\Rnf128^tm1.1Flv/Y \Tg(TcraTcrb)425Cbn/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal peripheral T cell anergy	J:153216
	decreased T cell proliferation	J:153216
	increased circulating interleukin-2 level	J:153216
\Rnf128^tm1.1Flv/\Rnf128^tm1.1Flv (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:153216
	abnormal peripheral T cell anergy	J:153216
	increased circulating interleukin-2 level	J:153216
	increased interferon-gamma secretion	J:153216
	increased T cell proliferation	J:153216
\Rnf128^tm1.1Flv/\Rnf128^tm1.1Flv \Tg(TcraTcrb)425Cbn/0 (involves: 129S6/SvEvTac * BALB/c * C57BL/6)	abnormal peripheral T cell anergy	J:153216
	decreased T cell proliferation	J:153216
	increased circulating interleukin-2 level	J:153216
\Rnf128^tm1.2Cmse/\Rnf128^tm1.2Cmse (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:245025
\Rnf128^tm1Cdon/\Rnf128⁺ (involves: 129 * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:160681
\Rnf128^tm1Cdon/\Rnf128^tm1Cdon (involves: C57BL/6)	increased anti-double stranded DNA antibody level	J:160681
	increased interferon-gamma secretion	J:160681
	increased interleukin-2 secretion	J:160681
	increased interleukin-17 secretion	J:160681
	increased T cell proliferation	J:160681
\Rnf128^tm1Cdon/\Rnf128^tm1Cdon (involves: 129 * C57BL/6)	abnormal immune tolerance	J:160681
	abnormal interleukin secretion	J:160681
	abnormal regulatory T cell physiology	J:160681
	CNS inflammation	J:160681
	decreased interleukin-4 secretion	J:160681
	decreased interleukin-5 secretion	J:160681
	decreased interleukin-13 secretion	J:160681
	enlarged mesenteric lymph nodes	J:160681
	enlarged spleen	J:160681
	increased anti-double stranded DNA antibody level	J:160681
	increased IgG1 level	J:160681
	increased IgM level	J:160681
	increased interferon-gamma secretion	J:160681
	increased interleukin-2 secretion	J:160681
	increased interleukin-4 secretion	J:160681
	increased interleukin-17 secretion	J:160681
	increased interleukin-21 secretion	J:160681
	increased splenocyte proliferation	J:160681
	increased susceptibility to experimental autoimmune encephalomyelitis	J:160681
	lung inflammation	J:160681
\Rnf128^tm1Cdon/\Rnf128^tm1Cdon \Tg(TcraTcrb)425Cbn/0 (involves: 129 * BALB/c * C57BL/6)	abnormal immune tolerance	J:160681
	increased interferon-gamma secretion	J:160681
	increased interleukin-2 secretion	J:160681
	increased splenocyte proliferation	J:160681
\Rnf135^em1(IMPC)Tcp/\Rnf135^em1(IMPC)Tcp (C57BL/6NCrl-Rnf135^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Rnf139^{tm1(KOMP)Wtsi}/\Rnf139^{tm1(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	liver inflammation	J:231404
\Rnf144a^em1Smoc/\Rnf144a^em1Smoc (C57BL/6JSmoc-Rnf144a^em1Smoc/Smoc)	abnormal innate immunity	J:347002
	increased susceptibility to Herpesvirales infection	J:347002
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:347002
\Rnf144b^em1Cya/\Rnf144b^em1Cya (C57BL/6J-Rnf144b^em1Cya/Cya)	decreased susceptibility to Picornaviridae infection	J:357974
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:357974
	decreased susceptibility to Riboviria infection	J:357974
\Rnf146^tm1.1Rtpl/\Rnf146^tm1.1Rtpl \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	abnormal osteoclast differentiation	J:243612
	increased circulating tumor necrosis factor level	J:243612
	increased osteoclast cell number	J:243612
\Rnf148^{em1(IMPC)Ccpcz}/\Rnf148^{em1(IMPC)Ccpcz} (C57BL/6N-Rnf148^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Rnf149^em1Staa/\Rnf149^em1Staa (involves: BALB/c * C57BL/6)	increased leukocyte cell number	J:335358
	increased lymphocyte cell number	J:335358
	increased monocyte cell number	J:335358
	increased neutrophil cell number	J:335358
\Rnf168^{Gt(156B6)Cmhd}/\Rnf168^{Gt(156B6)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:198260
	abnormal T cell receptor delta chain V(D)J recombination	J:198260
	decreased gamma-delta T cell number	J:198260
	decreased IgG1 level	J:198260
	decreased IgG2a level	J:198260
	decreased IgG3 level	J:198260
	decreased IgG level	J:198260
	immune system phenotype	J:198260
	increased DN3 thymocyte number	J:198260
	increased double-negative T cell number	J:198260
\Rnf168^{Gt(405F11)Cmhd}/\Rnf168^{Gt(405F11)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal class switch recombination	J:198260
	abnormal T cell receptor delta chain V(D)J recombination	J:198260
	decreased gamma-delta T cell number	J:198260
	decreased IgG1 level	J:198260
	decreased IgG2a level	J:198260
	decreased IgG3 level	J:198260
	decreased IgG level	J:198260
	immune system phenotype	J:198260
	increased DN3 thymocyte number	J:198260
	increased double-negative T cell number	J:198260
\Rnf168^{tm2b(EUCOMM)Hmgu}/\Rnf168^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Rnf168^{tm2b(EUCOMM)Hmgu}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
\Rnf169^{tm1a(EUCOMM)Hmgu}/\Rnf169^{tm1a(EUCOMM)Hmgu} (B6NTac;B6N-Rnf169^{tm1a(EUCOMM)Hmgu}/H)	increased monocyte cell number	J:165965
\Rnf186^em1Ktak/\Rnf186^em1Ktak (involves: C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:258197
\Rnf186^em1Ktak/\Rnf186^em1Ktak (involves: C57BL/6 * DBA/2)	increased susceptibility to induced colitis	J:258197
\Rnf186^tm1Ktak/\Rnf186^tm1Ktak (involves: 129S4/SvJae * C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:258197
	increased susceptibility to induced colitis	J:258197
\Rnf208^{em1(IMPC)Ccpcz}/\Rnf208^{em1(IMPC)Ccpcz} (C57BL/6N-Rnf208^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
\Rnf216^{tm1b(EUCOMM)Wtsi}/\Rnf216^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Rnf216^{tm1b(EUCOMM)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Rnf223^{em1(IMPC)Ccpcz}/\Rnf223^{em1(IMPC)Ccpcz} (C57BL/6N-Rnf223^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Rnft2^{tm1b(EUCOMM)Hmgu}/\Rnft2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Rnft2^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Rnpepl1^em1(IMPC)Mbp/\Rnpepl1^em1(IMPC)Mbp (C57BL/6N-Rnpepl1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Ro60^tm1Woln/\Ro60⁺ (involves: 129S1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:84627
\Ro60^tm1Woln/\Ro60⁺ (involves: 129S1/Sv * C57BL/6)	increased IgG2a level	J:84627
\Ro60^tm1Woln/\Ro60^tm1Woln (involves: 129S1/Sv * C57BL/6)	glomerulonephritis	J:84627
	increased anti-chromatin antibody level	J:84627
	increased anti-double stranded DNA antibody level	J:84627
	increased anti-histone antibody level	J:84627
	increased anti-nuclear antigen antibody level	J:84627
	increased anti-single stranded DNA antibody level	J:84627
	increased IgG2a level	J:84627
	increased IgM level	J:84627
\Rock1^tm1Liao/\Rock1⁺ (C57BL/6-Rock1^tm1Liao)	abnormal leukocyte adhesion	J:135152
	abnormal leukocyte migration	J:135152
	impaired macrophage chemotaxis	J:135152
	impaired neutrophil recruitment	J:135152
\Rock1^tm1Sna/\Rock1^tm1Sna (B6N.129X1-Rock1^tm1Sna)	blepharitis	J:98250
\Rock2^tm1.1Itl/\Rock2⁺ \Tg(Tagln-cre)1Her/0 (B6.Cg-Rock2^tm1.1Itl Tg(Tagln-cre)1Her)	abnormal cytokine secretion	J:222206
\Ror1^{em1(IMPC)Ccpcz}/\Ror1⁺ (C57BL/6NCrl-Ror1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Rora^sg/\Rora^sg (involves: C57BL/6)	abnormal immune system organ morphology	J:2228
	abnormal immune system physiology	J:2228
	abnormal macrophage physiology	J:28095
	immune system phenotype	J:52105
	increased IgE level	J:135863
	increased interleukin-1 secretion	J:28095
	lung inflammation	J:135863
	spleen atrophy	J:2228
	thymus atrophy	J:2228
\Rorc^m1Btlr/\Rorc^m1Btlr (C57BL/6J-Rorc^m1Btlr)	decreased CD4-positive, alpha-beta T cell number	J:203039
\Rorc^m1Btlr/\Rorc^m1Btlr (C57BL/6J-Rorc^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:203039
\Rorc^m2Btlr/\Rorc^m2Btlr (C57BL/6J-Rorc^m2Btlr)	decreased IgM level	J:217792
	decreased response to antigen	J:217792
	impaired humoral immune response	J:217792
\Rorc^m3Btlr/\Rorc^m3Btlr (C57BL/6J-Rorc^m3Btlr)	abnormal CD4-positive, alpha beta T cell morphology	J:234257
	decreased B-2 B cell number	J:234257
	decreased CD4-positive, alpha-beta T cell number	J:234257
	decreased CD8-positive, naive alpha-beta T cell number	J:234257
	decreased IgG level	J:234257
	decreased IgM level	J:234257
	decreased response to antigen	J:234257
	impaired humoral immune response	J:234257
	increased B-1a cell number	J:234257
	increased B-1b cell number	J:234257
	increased CD8-positive, alpha-beta T cell number	J:234257
	increased effector memory CD4-positive, alpha-beta T cell number	J:234257
	increased effector memory CD8-positive, alpha-beta T cell number	J:234257
\Rorc^tm1.1Zsun/\Rorc^tm1.1Zsun (B6(129S4)-Rorc^tm1.1Zsun)	abnormal T-helper 17 cell differentiation	J:248565
	absent Peyer's patches	J:248565
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:248565
	small inguinal lymph nodes	J:248565
\Rorc^tm1Amj/\Rorc^tm1Amj (either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * DBA/2))	abnormal interleukin level	J:123351
	abnormal lymph organ development	J:64381
	abnormal splenic cell ratio	J:64381
	abnormal T cell physiology	J:64381
	absent lymph nodes	J:64381
	absent Peyer's patches	J:64381
	decreased CD4-positive, alpha-beta T cell number	J:64381
	decreased CD8-positive, alpha-beta T cell number	J:64381
	decreased double-positive T cell number	J:64381
	decreased T cell number	J:64381
	decreased thymus weight	J:64381
	enlarged spleen	J:64381
	increased double-negative T cell number	J:64381
	increased T cell apoptosis	J:64381
	thymus hypoplasia	J:64381
\Rorc^tm1Litt/\Rorc^tm1Litt (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell differentiation	J:248565
	abnormal T cell differentiation	J:128344, J:248565
	abnormal T cell morphology	J:248565
	abnormal T-helper 17 cell differentiation	J:248565
	absent lymph nodes	J:248565
	colitis	J:158663
	decreased CD4-positive, alpha-beta T cell number	J:248565
	decreased double-positive T cell number	J:248565
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:248565
	decreased thymocyte number	J:248565
	increased susceptibility to bacterial infection	J:158663
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158663
	increased thymocyte apoptosis	J:248565
\Rorc^tm1Litt/\Rorc^tm1Litt \Tcra-J^tm3.1Krg/\Tcra-J^tm3.1Krg (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal T cell differentiation	J:128344
\Rorc^tm2Litt/\Rorc^tm2Litt (involves: 129P2/OlaHsd)	abnormal CD4-positive, alpha-beta intraepithelial T cell morphology	J:91566
	abnormal CD8 positive, alpha-beta intraepithelial T cell morphology	J:91566
	abnormal gut-associated lymphoid tissue morphology	J:87395, J:91566
	abnormal lymph organ development	J:87395
	absent lymph nodes	J:87395
	absent Peyer's patches	J:87395
	decreased double-negative T cell number	J:91566
	decreased double-positive T cell number	J:87395
	decreased NK cell number	J:142654
	increased thymocyte apoptosis	J:87395
\Rosq1^DBA/1J/\Rosq1^DBA/1J (involves: DBA/1J * FVB/NJ)	abnormal neutrophil physiology	J:122919
\Rosq1^DBA/1J/\Rosq1^FVB/NJ (involves: DBA/1J * FVB/NJ)	abnormal neutrophil physiology	J:122919
\Rpa1^tm1Wed/\Rpa1⁺ (involves: 129/Sv * C57BL/6J * SJL)	increased lymphocyte cell number	J:99303
\Rpap3^em1(IMPC)Mbp/\Rpap3⁺ (C57BL/6N-Rpap3^em1(IMPC)Mbp/Ucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Rpap3^{tm1c(KOMP)Wtsi}/\Rpap3^{tm1c(KOMP)Wtsi} \Tg(Vil1-cre/ERT2)23Syr/0 (involves: C57BL/6N * DBA/2)	small intestinal inflammation	J:314346
\Rpe65^{tm1a(EUCOMM)Hmgu}/\Rpe65^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Rpe65^{tm1a(EUCOMM)Hmgu}/H)	decreased leukocyte cell number	J:165965
	increased leukocyte cell number	J:165965
\Rpe^em1(IMPC)Mbp/\Rpe⁺ (C57BL/6NCrl-Rpe^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Rpgrip1l^{tm1a(EUCOMM)Wtsi}/\Rpgrip1l^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Rpgrip1l^{tm1a(EUCOMM)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	absent spleen	J:239583
	spleen hypoplasia	J:239583
\Rpl12^em1(IMPC)Mbp/\Rpl12⁺ (C57BL/6NCrl-Rpl12^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Rpl13a^tm1.1Jesc/\Rpl13a^tm1.1Jesc (NOD.129S5(Cg)-Rpl13a^tm1.1Jesc)	decreased susceptibility to autoimmune diabetes	J:237822
\Rpl13a^tm1.1Mazu/\Rpl13a^tm1.1Mazu \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: C57BL/6)	abnormal cytokine level	J:194920
	abnormal macrophage chemotaxis	J:194920
	increased circulating tumor necrosis factor level	J:194920
\Rpl22^{Gt(GST000137)Lex}/\Rpl22^{Gt(GST000137)Lex} (involves: 129S5/SvEvBrd)	abnormal T cell differentiation	J:123569
	abnormal T cell number	J:123569
	arrested T cell differentiation	J:123569
	decreased CD4-positive, alpha-beta T cell number	J:123569
	decreased CD8-positive, alpha-beta T cell number	J:123569
	decreased double-negative T cell number	J:123569
	decreased T cell number	J:123569
	glomerulonephritis	J:123569
	increased T cell apoptosis	J:123569
	thymus hypoplasia	J:123569
\Rpl22^{Gt(YHB332)Byg}/\Rpl22^{Gt(YHB332)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus development	J:201164
	decreased B cell number	J:201164
	decreased T cell number	J:201164
\Rpl27a^Sfa/\Rpl27a⁺ (C57BL/6J-Rpl27a^Sfa)	decreased leukocyte cell number	J:174216
	small spleen	J:174216
	small thymus	J:174216
\Rpl38^Ts/\Rpl38⁺ (TSJ/Le)	increased susceptibility to otitis media	J:168509
\Rplp1^tm1.1Melt/\Rplp1^tm1.2Melt (Not Specified)	small thymus	J:218949
\Rprd1b^tm1Tshu/\Rprd1b^tm1Tshu \Tg(Vil1-cre)20Syr/0 (involves: C57BL/6 * DBA/2)	increased susceptibility to colitis induced morbidity/mortality	J:300857
\Rps6ka3^tm1.1Kry/\Rps6ka3⁺ (involves: 129X1/SvJ)	immune system phenotype	J:89403
\Rps6ka3^tm1.1Kry/\Rps6ka3^tm1.1Kry (involves: 129X1/SvJ)	immune system phenotype	J:89403
\Rps6ka4^tm1Jsca/\Rps6ka4^tm1Jsca \Rps6ka5^tm1Jsca/\Rps6ka5^tm1Jsca (Not Specified)	decreased T cell proliferation	J:124301
	spleen hypoplasia	J:124301
\Rps6ka4^tm1Jsca/\Rps6ka4^tm1Jsca \Rps6ka5^tm1Jsca/\Rps6ka5^tm1Jsca (B6.Cg-Rps6ka5^tm1Jsca Rps6ka4^tm1Jsca)	abnormal cytokine level	J:139576
	abnormal cytokine secretion	J:139576
	decreased circulating interleukin-10 level	J:139576
	decreased interleukin-10 secretion	J:139576
	increased circulating interleukin-6 level	J:139576
	increased circulating interleukin-12a level	J:139576
	increased circulating interleukin-12b level	J:139576
	increased circulating tumor necrosis factor level	J:139576
	increased interleukin-6 secretion	J:139576
	increased interleukin-12a secretion	J:139576
	increased interleukin-12b secretion	J:139576
	increased susceptibility to endotoxin shock	J:139576
	increased tumor necrosis factor secretion	J:139576
	skin inflammation	J:139576
\Rps9^tm1.1Geno/\Rps9^tm1.1Geno (involves: C57BL/6)	decreased leukocyte cell number	J:329922
\Rps9^tm1.1Geno/\Rps9^tm1.1Geno (involves: C57BL/6)	increased monocyte cell number	J:329922
\Rps12^em1.1Nbakr/\Rps12⁺ (involves: C57BL/6J * FVB/N)	decreased leukocyte cell number	J:338970
\Rps12^em1.1Nbakr/\Rps12⁺ (involves: C57BL/6J * FVB/N)	decreased spleen weight	J:338970
\Rps14^tm1.1Ble/\Rps14⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6NTac * CBA/J)	enlarged spleen	J:233322
\Rps14^tm1.1Ble/\Rps14⁺ \Tg(Mx1-cre)1Cgn/0 \Trp53^tm2.1Tyj/\Trp53⁺ (involves: 129S4/SvJae * C57BL/6J * C57BL/6NTac * CBA/J)	immune system phenotype	J:233322
\Rps19bp1^{tm1.1(KOMP)Wtsi}/\Rps19bp1⁺ (C57BL/6N-Rps19bp1^{tm1.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Rps27l^{Gt(IST11658B7)Tigm}/\Rps27l^{Gt(IST11658B7)Tigm} (C57BL/6-Rps27l^{Gt(IST11658B7)Tigm})	decreased spleen weight	J:223276
	decreased thymus weight	J:223276
	increased thymocyte apoptosis	J:223276
	thymus cortex hypoplasia	J:223276
\Rps27l^{Gt(IST11658B7)Tigm}/\Rps27l^{Gt(IST11658B7)Tigm} (involves: 129 * C57BL/6N)	spleen hypoplasia	J:223276
	thymus hypoplasia	J:223276
\Rps27l^{Gt(IST11658B7)Tigm}/\Rps27l^{Gt(IST11658B7)Tigm} \Trp53^tm1Tyj/\Trp53⁺ (involves: 129S2/SvPas * C57BL/6N)	enlarged lymph nodes	J:223276
	enlarged spleen	J:223276
	increased T cell derived lymphoma incidence	J:223276
\Rptor^tm1Ahir/\Rptor^tm1Ahir \Tg(Itgax-cre)1-1Reiz/0 (B6.Cg-Rptor^tm1Ahir Tg(Itgax-cre)1-1Reiz)	increased dendritic cell number	J:188676
	increased susceptibility to induced colitis	J:188676
\Rpusd2^{tm1b(KOMP)Wtsi}/\Rpusd2^{tm1b(KOMP)Wtsi} (C57BL/6N-Rpusd2^{tm1b(KOMP)Wtsi}/Bay)	increased spleen weight	J:211773
\Rr7^tm1.1Kio/\Rr7^tm1.1Kio (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:179326, J:164573
	immune system phenotype	J:164573
\Rr7^tm2.1Kio/\Rr7^tm2.1Kio (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:164573
	immune system phenotype	J:164573
\Rr7^tm3.1Kio/\Rr7⁺ (B6.129S4-Rr7^tm3.1Kio)	abnormal CD4-positive, alpha beta T cell morphology	J:179326
\Rr7^tm3.1Kio/\Rr7⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:179326
\Rr7^tm3.1Kio/\Rr7⁺ \Tg(CD2-icre)4Kio/0 (involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:179326
\Rr7^tm3.1Kio/\Rr7⁺ \Tg(Lck-cre)#Nik/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:179326
\Rr7^tm4.1Kio/\Rr7^tm4.1Kio (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:179326
\Rr7^tm5.1Kio/\Rr7^tm5.1Kio (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:179326
\Rr9^tm1.1Kubo/\Rr9^tm1.1Kubo (C57BL/6-Rr9^tm1.1Kubo)	decreased interleukin-13 secretion	J:167446
\Rr9^tm1.1Kubo/\Rr9^tm1.1Kubo (C57BL/6-Rr9^tm1.1Kubo)	immune system phenotype	J:167446
\Rr10^tm1.1Kubo/\Rr10^tm1.1Kubo (B6.Cg-Rr10^tm1.1Kubo)	immune system phenotype	J:167446
\Rr17^tm1.1Cdon/\Rr17^tm1.1Cdon (involves: 129S6/SvEvTac * C57BL/6)	decreased interleukin-17 secretion	J:181186
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:181186
	immune system phenotype	J:181186
	increased interleukin-17 secretion	J:181186
\Rr32^tm1.1Weav/\Rr32^tm1.1Weav (involves: C57BL/6)	decreased interferon-gamma secretion	J:208819
\Rr32^tm1.1Weav/\Rr32^tm1.1Weav (involves: C57BL/6)	immune system phenotype	J:208819
\Rr38^tm1.2Aafo/\Rr38⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	decreased thymocyte number	J:227747
	immune system phenotype	J:227747
\Rr38^tm1.2Aafo/\Rr38^tm1.2Aafo (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6)	abnormal thymus physiology	J:227747
	decreased CD4-positive, alpha-beta T cell number	J:227747
	decreased CD8-positive, alpha-beta T cell number	J:227747
	decreased double-positive T cell number	J:227747
	decreased single-positive T cell number	J:227747
	decreased thymocyte number	J:227747
	decreased thymus weight	J:227747
	immune system phenotype	J:227747
	increased DN3 thymocyte number	J:227747
	small thymus	J:227747
	thymus hypoplasia	J:227747
\Rr39^em1Ched/\Rr39^em1Ched (C57BL/6-Rr39^em1Ched)	decreased Ly6C low monocyte number	J:239509
\Rr39^em1Ched/\Rr39^em1Ched (C57BL/6-Rr39^em1Ched)	immune system phenotype	J:239509
\Rr79^em2Rtew/\Rr79^em2Rtew (C57BL/6J-Rr79^em2Rtew/J)	abnormal T cell activation	J:332957
	abnormal T cell physiology	J:332957
	abnormal T cell subpopulation ratio	J:332957
\Rr79^em2Rtew/\Rr79^em2Rtew \Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6J)	abnormal T cell activation	J:332957
\Rr94^tm3.1Litt/\Rr94⁺ \Rr112^tm4.1Litt/\Rr112⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	immune system phenotype	J:158962
\Rr94^tm3.1Litt/\Rr94⁺ \Tg(Cd4-cre)1Cwi/0 \Rr112^tm4.1Litt/\Rr112⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
\Rr94^tm3.1Litt/\Rr94^tm3.1Litt (involves: 129P2/OlaHsd * FVB/N)	immune system phenotype	J:158962
\Rr94^tm3.1Litt/\Rr94^tm3.1Litt \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased double-positive T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
\Rr94^tm3.2Litt/\Rr94⁺ \Rr112^tm4.1Litt/\Rr112⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N)	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
\Rr94^tm3.2Litt/\Rr94^tm3.2Litt (involves: 129P2/OlaHsd * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:158962
	abnormal double-positive T cell morphology	J:158962
	abnormal T cell differentiation	J:158962
	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	decreased double-positive T cell number	J:158962
	immune system phenotype	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
\Rr94^tm3.2Litt/\Rr94^tm3.2Litt \H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru (involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)	abnormal T cell subpopulation ratio	J:158962
	decreased CD4-positive, alpha-beta T cell number	J:158962
	immune system phenotype	J:158962
	increased CD8-positive, alpha-beta T cell number	J:158962
\Rr95^em1Pdi/\Rr95^em1Pdi (Not Specified)	immune system phenotype	J:333574
\Rr96^tm1.1Tich/\Rr96⁺ \Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129 129S4/SvJae * C57BL/6)	abnormal T cell differentiation	J:191711
\Rr96^tm1.1Tich/\Rr96⁺ \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor⁺ (involves: 129 129S4/SvJae * C57BL/6)	abnormal CD4-positive T cell differentiation	J:191711
\Rr96^tm1.1Tich/\Rr96^tm1.1Tich \Gt(ROSA)26Sor^{tm1(rtTAM2)Jae}/\Gt(ROSA)26Sor^{tm1(rtTAM2)Jae} (involves: 129 * 129S4/SvJae * C57BL/6)	abnormal T cell differentiation	J:191711
\Rr96^tm1.1Tich/\Rr96^tm1.1Tich \Tg(ACTB-tTS)1Mllo/? (involves: 129 * C57BL/6)	decreased double-positive T cell number	J:191711
\Rr96^tm1.1Yzo/\Rr96^tm1.1Yzo (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:130559
	increased CD4-positive, alpha-beta T cell number	J:130559
	increased double-positive T cell number	J:130559
\Rr96^tm1.1Yzo/\Rr96^tm1.1Yzo \H2-Ab1^b-tm1Gru/\H2-Ab1^b-tm1Gru (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal T cell differentiation	J:130559
\Rr96^tm1Yzo/\Rr96^tm1Yzo \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:130559
	increased double-positive T cell number	J:130559
\Rr96^tm1Yzo/\Rr96^tm1Yzo \Tg(Cd8a-cre,-GFP)1Yzo/? (involves: 129P2/OlaHsd)	increased double-positive T cell number	J:130559
\Rr96^tm2Litt/\Rr96⁺ \Zbtb7b^tm1.1Tani/\Zbtb7b^tm1.1Tani (involves: 129 * 129P2/OlaHsd * C57BL/6)	increased double-negative T cell number	J:141142
\Rr96^tm2Litt/\Rr96⁺ \Zbtb7b^tm1Itan/\Zbtb7b^tm1.1Tani (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal double-negative T cell morphology	J:141142
	decreased CD8-positive, alpha-beta T cell number	J:141142
\Rr96^tm2Litt/\Rr96^tm2Litt (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha beta T cell morphology	J:80690
\Rr96^tm2Litt/\Rr96^tm2Litt \Tfap4^tm1.1Litt/\Tfap4^tm1.1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:176461
\Rr97^tm3Welm/\Rr97^tm3Welm (involves: 129 * C57BL/6)	abnormal CD4-positive T cell differentiation	J:126027
	abnormal CD8-positive, alpha-beta T cell differentiation	J:126027
	abnormal dendritic cell morphology	J:126027
	abnormal double-positive T cell morphology	J:126027
	abnormal gamma-delta intraepithelial T cell morphology	J:126027
	abnormal T cell differentiation	J:126027
\Rr98^tm1Welm/\Rr98^tm1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:113136
\Rr99^tm1Litt/\Rr99^tm1Litt (either: (involves: 129P2/OlaHsd * AKR) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal CD8-positive, alpha beta T cell morphology	J:50624
\Rr100^tm2.1Welm/\Rr100⁺ (involves: 129P2/OlaHsd * AKR.1 * C57BL/6)	abnormal T cell differentiation	J:113136
\Rr100^tm2.1Welm/\Rr100^tm2.1Welm (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:113136
	abnormal T cell subpopulation ratio	J:113136
	decreased CD8-positive, alpha-beta T cell number	J:113136
	decreased double-positive T cell number	J:113136
	increased CD4-positive, alpha-beta T cell number	J:113136
\Rr100^tm2.1Welm/\Rr100^tm2.1Welm (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:158947
	decreased CD8-positive, alpha-beta T cell number	J:158947
	decreased double-positive T cell number	J:158947
	immune system phenotype	J:158947
	increased CD4-positive, alpha-beta T cell number	J:158947
\Rr100^tm2.1Welm/\Rr100^tm2.1Welm \Patz1^tm1.1Welm/\Patz1^tm1.1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:158947
\Rr100^tm2.1Welm/\Rr100^tm2.1Welm \Tcra^tm1Mom/\Tcra^tm1Mom (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal T cell morphology	J:113136
\Rr101^tm2Kio/\Rr101^tm2Kio (involves: 129S2/SvPas * C57BL/6 * DBA/2)	immune system phenotype	J:110530
\Rr104^tm1.2Mym/\Rr104^tm1.2Mym \Tg(Epo)458Mym/0 (involves: C57BL/6 DBA/2)	abnormal spleen morphology	J:231255
\Rr123^tm1.1Vbo/\Rr123^tm1.1Vbo (involves: 129S4/SvJae * C57BL/6 * FVB/N)	abnormal regulatory T cell morphology	J:191815
	immune system phenotype	J:191815
	increased regulatory T cell number	J:191815
\Rr148^tm1.1Fwa/\Rr148^tm1.1Fwa (involves: 129S6/SvEvTac)	abnormal B cell differentiation	J:101400
	arrested B cell differentiation	J:101400
	decreased immature B cell number	J:101400
	immune system phenotype	J:101400
	small spleen	J:101400
	spleen hypoplasia	J:101400
\Rr148^tm1.1Fwa/\Rr148^tm1.1Fwa \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * 129S6/SvEvTac)	abnormal B cell differentiation	J:101400
\Rr148^tm1Anbo/\Rr148^tm1Anbo (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal immunoglobulin heavy chain V(D)J recombination	J:136307
	decreased immature B cell number	J:136307
	decreased mature B cell number	J:136307
	decreased pre-B cell number	J:136307
\Rr148^tm1Fwa/\Rr148^tm1Fwa (129S6/SvEvTac-Rr148^tm1Fwa)	abnormal immature B cell morphology	J:101400
	absent B cells	J:101400
	absent Peyer's patches	J:101400
	arrested B cell differentiation	J:101400
	immune system phenotype	J:101400
	small spleen	J:101400
	spleen hypoplasia	J:101400
\Rr148^tm1Fwa/\Rr148^tm1Fwa \Rag2^tm1Fwa/\Rag2^tm1Fwa (involves: 129S/SvEv * 129S6/SvEvTac)	abnormal B cell differentiation	J:101400
\Rr148^tm2Anbo/\Rr148^tm2Anbo (involves: 129/Sv * C57BL/6 * FVB/N)	abnormal immunoglobulin heavy chain V(D)J recombination	J:136307
	decreased immature B cell number	J:136307
	decreased mature B cell number	J:136307
	decreased pre-B cell number	J:136307
\Rr152^tm2Cog/\Rr152⁺ (involves: 129S2/SvPas * C57BL/6)	decreased IgG1 level	J:90548
	decreased IgG2b level	J:90548
	decreased IgG3 level	J:90548
	decreased IgG level	J:90548
\Rr152^tm2Cog/\Rr152^tm2Cog (involves: 129S2/SvPas * C57BL/6)	decreased IgG1 level	J:90548
	decreased IgG2a level	J:90548
	decreased IgG2b level	J:90548
	decreased IgG3 level	J:90548
	decreased IgG level	J:90548
	increased pre-B cell number	J:90548
\Rr152^tm3.1Cog/\Rr152^tm3.1Cog (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal class switch recombination	J:71300
	decreased IgA level	J:71300
	decreased IgE level	J:71300
	decreased IgG2a level	J:71300
	decreased IgG2b level	J:71300
	decreased IgG3 level	J:71300
	decreased IgG level	J:71300
	decreased immunoglobulin level	J:71300
	immune system phenotype	J:71300
\Rr152^tm3Cog/\Rr152^tm3Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell morphology	J:71300
	abnormal class switch recombination	J:71300
	decreased IgA level	J:71300
	decreased IgE level	J:71300
	decreased IgG1 level	J:71300
	decreased IgG2a level	J:71300
	decreased IgG2b level	J:71300
	decreased IgG3 level	J:71300
	decreased IgG level	J:71300
	decreased IgM level	J:71300
	decreased immunoglobulin level	J:71300
	immune system phenotype	J:71300
\Rr152^tm5.1Cog/\Rr152^tm5.1Cog (involves: 129P2/OlaHsd * C57BL/6)	abnormal class switch recombination	J:164513
	abnormal somatic hypermutation frequency	J:164513, J:333348
	decreased IgA level	J:164513
	decreased IgE level	J:164513
	decreased IgG2b level	J:164513
	decreased IgG3 level	J:164513
	decreased IgM level	J:164513
\Rr155^tm1.1Erpi/\Rr155^tm1.1Erpi (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal immunoglobulin level	J:160101
	decreased IgG1 level	J:160101
	decreased IgG2a level	J:160101
	immune system phenotype	J:160101
\Rr156^tm6.1Cog/\Rr156^tm6.1Cog (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:165617
	decreased IgM level	J:165617
	immune system phenotype	J:165617
\Rr156^tm6Cog/\Rr156^tm6Cog (involves: 129P2/OlaHsd * C57BL/6)	decreased B cell number	J:165617
	decreased IgM level	J:165617
	immune system phenotype	J:165617
\Rr158^tm1(Igh)Xu/\Rr158^tm1(Igh)Xu (Not Specified)	abnormal immune system morphology	J:124407
	decreased B cell number	J:124407
	decreased immature B cell number	J:124407
	increased pre-B cell number	J:124407
\Rr158^tm1Cgn/\Rr158^tm1Cgn (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S2/SvPas * C57BL/6))	abnormal B cell differentiation	J:12574, J:64287
	decreased mature B cell number	J:64287
	increased mature B cell number	J:64287
	spleen hypoplasia	J:64287
\Rr158^tm2Cgn/\Rr158^tm2Cgn (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129S2/SvPas * C57BL/6))	abnormal B cell differentiation	J:12574
\Rr158^tm2Xu/\Rr158^tm2Xu (Not Specified)	decreased B cell number	J:124407
\Rr159^tm1.1Fwa/\Rr159⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:113715
\Rr159^tm1.1Fwa/\Rr159^tm1.1Fwa (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:113715
	decreased B cell number	J:113715
\Rr159^tm1Fwa/\Rr159⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased B cell number	J:113715
\Rr159^tm1Fwa/\Rr159^tm1Fwa (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:113715
	decreased B cell number	J:113715
\Rr160^tm1Wtg/\Rr160^tm1Wtg (involves: 129S6/SvEvTac * C57BL/6)	abnormal immunoglobulin level	J:134885
	abnormal mature B cell morphology	J:134885
	abnormal somatic hypermutation frequency	J:134885
	decreased follicular B cell number	J:134885
	increased transitional stage B cell number	J:134885
\Rr161^tm2.2Wtg/\Rr161^tm2.2Wtg (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:167472
	abnormal immunoglobulin V(D)J recombination	J:167472
	decreased B cell number	J:167472
	decreased pro-B cell number	J:167472
	increased pre-B cell number	J:167472
\Rr162^tm3.1Wtg/\Rr162^tm3.1Wtg (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)	abnormal immunoglobulin V(D)J recombination	J:172855
	immune system phenotype	J:172855
\Rr163^tm1Lfdn/\Rr163⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))	abnormal immune system physiology	J:31727
	immune system phenotype	J:31727
\Rr163^tm1Lfdn/\Rr163^tm1Lfdn (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CB20))	abnormal immune system physiology	J:31727
	immune system phenotype	J:31727
\Rr166^tm4.1Wtg/\Rr166^tm4.1Wtg (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)	abnormal B cell differentiation	J:193015
	abnormal B cell physiology	J:193015
	abnormal immunoglobulin level	J:193015
	abnormal immunoglobulin light chain V-J recombination	J:193015
	abnormal pre-B cell morphology	J:193015
\Rr169^tm2Rao/\Rr169⁺ (involves: 129S6/SvEvTac * C57BL/6J)	abnormal T-helper 1 cell differentiation	J:94039
\Rr169^tm2Rao/\Rr169^tm2Rao (involves: 129S6/SvEvTac * C57BL/6J)	abnormal T-helper 1 cell differentiation	J:94039
	increased susceptibility to parasitic infection	J:94039
\Rr170^tm1.1Iku/\Rr170^tm1.1Iku (B6.Cg-Rr170^tm1.1Iku)	decreased T cell number	J:333539
	decreased T cell proliferation	J:333539
	immune system phenotype	J:333539
	increased T cell apoptosis	J:333539
\Rr172^em1Kmm/\Rr172^em1Kmm \Rr253^em6Kmm/\Rr253^em6Kmm (C57BL/6J-Rr253^em6Kmm Rr172^em1Kmm)	decreased dendritic cell number	J:334296
	decreased monocyte cell number	J:334296
	immune system phenotype	J:334296
	increased dendritic cell number	J:334296
\Rr253^em1Kmm/\Rr253^em1Kmm (C57BL/6-Rr253^em1Kmm)	abnormal class switch recombination	J:316113
	abnormal effector T cell number	J:316113
	abnormal peritoneal macrophage morphology	J:316113
	abnormal spleen B cell follicle morphology	J:316113
	decreased B cell number	J:316113
	decreased mature NK cell number	J:316113
	decreased monocyte cell number	J:316113
	decreased plasmacytoid dendritic cell number	J:316113
	decreased spleen B cell follicle number	J:316113
	decreased spleen B cell follicle size	J:316113
	increased dendritic cell number	J:316113
	increased lymphocyte cell number	J:316113
	increased neutrophil cell number	J:316113
	increased NK cell number	J:316113
	increased susceptibility to viral infection induced morbidity/mortality	J:316113
	increased T cell number	J:316113
	spleen hypoplasia	J:316113
\Rr253^em3Kmm/\Rr253^em3Kmm (C57BL/6J-Rr253^em3Kmm)	decreased dendritic cell number	J:334296
\Rr253^em4Kmm/\Rr253^em4Kmm (C57BL/6J-Rr253^em4Kmm)	immune system phenotype	J:334296
\Rr253^em5Kmm/\Rr253^em5Kmm (C57BL/6J-Rr253^em5Kmm)	decreased dendritic cell number	J:334296
\Rr253^em5Kmm/\Rr253^em5Kmm (C57BL/6J-Rr253^em5Kmm)	increased dendritic cell number	J:334296
\Rr253^em6Kmm/\Rr253^em6Kmm (C57BL/6J-Rr253^em6Kmm)	abnormal T-helper 2 physiology	J:334296
	decreased dendritic cell number	J:334296
	decreased monocyte cell number	J:334296
	decreased plasmacytoid dendritic cell number	J:334296
	immune system phenotype	J:334296
	increased dendritic cell number	J:334296
	increased susceptibility to parasitic infection induced morbidity/mortality	J:334296
\Rr270^em1Mgn/\Rr270^em1Mgn (involves: CD-1)	abnormal embryonic lymph sac morphology	J:328045
\Rr308^tm1.1Fwa/\Rr308^tm1.1Fwa (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:82616, J:82395
\Rr308^tm1.1Fwa/\Rr308^tm1.1Fwa (involves: 129P2/OlaHsd)	abnormal T cell receptor alpha chain V-J recombination	J:82616
\Rr308^tm1Fwa/\Rr308^tm1Fwa (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:82616
\Rr308^tm1Fwa/\Rr308^tm1Fwa (involves: 129P2/OlaHsd)	abnormal T cell receptor alpha chain V-J recombination	J:82616
\Rr308^tm2Fwa/\Rr308^tm2Fwa (Not Specified)	abnormal T cell differentiation	J:82395
\Rr338^em1Jeng/\Rr338^em1Jeng (Not Specified)	abnormal T cell differentiation	J:232438
	abnormal T cell number	J:232438
	decreased CD4-positive, alpha-beta T cell number	J:232438
\Rr347^em1Prdns/\Rr347^em1Prdns (CBA/Ca-Rr347^em1Prdns)	absent Langerhans cell	J:281171
	decreased macrophage cell number	J:281171
	decreased microglial cell number	J:281171
	immune system phenotype	J:281171
	increased Ly6C low monocyte number	J:281171
\Rr364^tm1.1Aak/\Rr364^tm1.1Aak (129.129S2(Cg)-Rr364^tm1.1Aak)	abnormal class switch recombination	J:242276
	decreased IgG3 level	J:242276
	increased IgG2a level	J:242276
	increased IgG2b level	J:242276
\Rr381^em1Kap/\Rr381^em1Kap (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
\Rr381^em4Kap/\Rr381^em4Kap (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
\Rr381^em5Kap/\Rr381^em5Kap (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:333471
\Rr381^tm1.1Tani/\Rr381⁺ (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:131081
\Rr383^tm1Caob/\Rr383^tm1Caob (B6.Cg-Rr383^tm1Caob)	decreased osteoclast cell number	J:131132
\Rr386^em1Pdi/\Rr386^em1Pdi (involves: C57BL/6J)	immune system phenotype	J:333574
\Rr394^em1Bhao/\Rr394^em1Bhao (Not Specified)	abnormal T cell receptor alpha chain V-J recombination	J:333961
	decreased thymocyte number	J:333961
	increased DN3 thymocyte number	J:333961
\Rr395^em1Bhao/\Rr395^em1Bhao (Not Specified)	decreased double-positive T cell number	J:333961
	decreased thymocyte number	J:333961
	increased DN4 thymocyte number	J:333961
	increased thymocyte apoptosis	J:333961
\Rr149356^tm1.1Pf/\Rr149356^tm1.1Pf (either: 129P2/OlaHsd-Rr149356^tm1.1Pf or (involves: 129P2/OlaHsd * BALB/c))	abnormal T cell differentiation	J:34311
	abnormal thymus cortex morphology	J:34311
	abnormal thymus medulla morphology	J:34311
	abnormal thymus morphology	J:34311
	arrested T cell differentiation	J:34311
	decreased double-positive T cell number	J:34311
	decreased single-positive T cell number	J:34311
	decreased T cell number	J:34311
	decreased thymocyte number	J:34311
	increased double-negative T cell number	J:34311
	increased gamma-delta T cell number	J:34311
	lymph node hypoplasia	J:34311
\Rr149356^tm1Abnd/\Rr149356^tm1Abnd (involves: 129S1/Sv * 129X1/SvJ)	abnormal T cell differentiation	J:137580
	abnormal thymus morphology	J:137580
	arrested T cell differentiation	J:137580
	decreased double-positive T cell number	J:137580
	decreased single-positive T cell number	J:137580
	decreased T cell number	J:137580
	increased double-negative T cell number	J:137580
	increased gamma-delta T cell number	J:137580
	thymus hypoplasia	J:137580
\Rr149356^tm1Che/\Rr149356^tm1Che (involves: 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:106246, J:107306
	abnormal double-positive T cell morphology	J:106246, J:107306
\Rr149356^tm1Che/\Rr149356^tm1Che \Tcrd^tm1Mom/\Tcrd^tm1Mom \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:106246
	increased T cell derived lymphoma incidence	J:106246
\Rr149356^tm1Che/\Rr149356^tm1Che \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	abnormal double-negative T cell morphology	J:106246
	abnormal double-positive T cell morphology	J:106246
	increased T cell derived lymphoma incidence	J:106246
\Rr250409^tm1Lky/\Rr250409⁺ (involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)	decreased interleukin-4 secretion	J:125684
\Rr250409^tm1Lky/\Rr250409^tm1Lky (involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB)	abnormal response to infection	J:125684
	decreased IgE level	J:125684
	decreased interleukin-4 secretion	J:125684
	decreased interleukin-5 secretion	J:125684
	decreased interleukin-13 secretion	J:125684
	decreased susceptibility to parasitic infection	J:125684
\Rr250409^tm1Lky/\Rr250409^tm1Lky (involves: 129X1/SvJ * BALB/c)	decreased interleukin-4 secretion	J:167446
\Rr275254^tm2.1Dhr/\Rr275254^tm2.1Dhr (involves: 129S4/SvJae * C57BL/6)	abnormal gamma-delta T cell differentiation	J:75624
	abnormal T cell receptor gamma chain V-J recombination	J:75624
\Rr275254^tm2Dhr/\Rr275254^tm2Dhr (involves: 129S4/SvJae)	abnormal gamma-delta T cell differentiation	J:75624
\Rr275254^tm2Dhr/\Rr275254^tm2Dhr (involves: 129S4/SvJae)	abnormal T cell receptor gamma chain V-J recombination	J:75624
\Rr282726^tm1Dhr/\Rr282726^tm1Dhr (involves: 129S4/SvJae * C57BL/6)	abnormal gamma-delta T cell differentiation	J:75624
	abnormal T cell receptor gamma chain V-J recombination	J:75624
\Rr282729^tm1.1Iku/\Rr282729^tm1.1Iku (C57BL/6J-Rr316^tm1.1Iku)	abnormal T cell receptor gamma chain V-J recombination	J:288442
	decreased gamma-delta T cell number	J:288442
\Rr299391^tm1.1Fwa/\Rr299391⁺ (involves: 129P2/OlaHsd * FVB/N)	decreased T cell number	J:55401
	decreased thymocyte number	J:55401
\Rr299391^tm1.1Fwa/\Rr299391^tm1.1Fwa (involves: 129P2/OlaHsd * FVB/N)	decreased T cell number	J:55401
	decreased thymocyte number	J:55401
\Rragc^em1Efe/\Rragc⁺ (Not Specified)	abnormal B cell activation	J:320567
	abnormal B cell physiology	J:320567
	abnormal class switch recombination	J:320567
	decreased B cell proliferation	J:320567
	decreased germinal center B cell number	J:320567
	decreased IgG1 level	J:320567
	decreased IgM level	J:320567
	decreased plasma cell number	J:320567
	decreased spleen germinal center size	J:320567
	impaired humoral immune response	J:320567
\Rragc^em1Efe/\Rragc⁺ \Tg(Vav-BCL2)69Jad/0 (Not Specified)	decreased germinal center B cell number	J:320567
	decreased spleen germinal center size	J:320567
	decreased susceptibility to autoimmune disorder	J:320567
\Rras2^{em1(IMPC)Ccpcz}/\Rras2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Rras2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased NK cell number	J:211773
\Rras2^{Gt(OST361011)Lex}/\Rras2⁺ (involves: 129S5/SvEvBrd)	decreased B cell number	J:151653
	decreased follicular B cell number	J:151653
	decreased marginal zone B cell number	J:151653
	decreased memory T cell number	J:151653
	decreased spleen B cell follicle size	J:151653
	decreased spleen weight	J:151653
	decreased T cell number	J:151653
	spleen hypoplasia	J:151653
\Rras2^{Gt(OST361011)Lex}/\Rras2^{Gt(OST361011)Lex} (involves: 129S5/SvEvBrd)	abnormal B cell activation	J:151653
	abnormal B cell physiology	J:151653
	abnormal CD4-positive, alpha-beta T cell physiology	J:151653
	abnormal CD8-positive, alpha-beta T cell physiology	J:151653
	abnormal lymph node germinal center morphology	J:151653
	decreased B cell number	J:151653
	decreased B cell proliferation	J:151653
	decreased follicular B cell number	J:151653
	decreased marginal zone B cell number	J:151653
	decreased memory T cell number	J:151653
	decreased spleen B cell follicle size	J:151653
	decreased spleen weight	J:151653
	decreased T cell number	J:151653
	spleen hypoplasia	J:151653
\Rras2^{Gt(OST361011)Lex}/\Rras2^{Gt(OST361011)Lex} (B6.129S5-Rras2^{Gt(OST361011)Lex})	decreased B cell number	J:151653
	decreased memory T cell number	J:151653
	decreased T cell number	J:151653
\Rras^{Gt(OST24882)Lex}/\Rras^{Gt(OST24882)Lex} (B6;129S5-Rras^{Gt(OST24882)Lex}/Ieg)	decreased B cell number	J:82809
	increased CD4-positive, alpha-beta T cell number	J:82809
	increased CD8-positive, alpha-beta T cell number	J:82809
\Rras^tm1Itl/\Rras^tm1Itl (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	immune system phenotype	J:181730
\Rras^tm1Itl/\Rras^tm1Itl (involves: 129S6/SvEvTac * C57BL/6)	abnormal dendritic cell morphology	J:181730
	abnormal dendritic cell physiology	J:181730
\Rreb1^{tm1b(EUCOMM)Wtsi}/\Rreb1⁺ (C57BL/6N-Rreb1^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Rrm2b^{Gt(OST85254)Lex}/\Rrm2b^{Gt(OST85254)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	spleen atrophy	J:186071
	thymus atrophy	J:186071
\Rrm2b^tm1Ynak/\Rrm2b^tm1Ynak (involves: 129 * C57BL/6J)	abnormal mesenteric lymph node morphology	J:84841
	decreased spleen white pulp amount	J:84841
	thymus cortex hypoplasia	J:84841
\Rsad1^{tm1.1(KOMP)Vlcg}/\Rsad1⁺ (C57BL/6N-Rsad1^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
	small thymus	J:211773
\Rsad1^{tm1.1(KOMP)Vlcg}/\Rsad1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Rsad1^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
\Rsad2^tm1Aki/\Rsad2^tm1Aki (involves: 129/Sv * C57BL/6)	decreased circulating interferon-alpha level	J:169840
	decreased interferon-alpha secretion	J:169840
	decreased interferon-beta secretion	J:169840
\Rsad2^tm1Kchc/\Rsad2^tm1Kchc (B6.129-Rsad2^tm1Kchc)	abnormal T-helper 2 cell differentiation	J:148305
	decreased IgG1 level	J:148305
	decreased interleukin-4 secretion	J:148305
	decreased interleukin-5 secretion	J:148305
	decreased interleukin-13 secretion	J:148305
	increased interferon-gamma secretion	J:148305
\rsm1/\rsm1 (either: P/J or P/N)	abnormal cell-mediated immunity	J:8396
\Rsph9^em1Jwji/\Rsph9^em1Jwji (B6.Cg-Rsph9^em1Jwji)	increased microglial cell activation	J:294184
	microgliosis	J:294184
	sinus inflammation	J:294184
\Rspo1^{tm2b(KOMP)Wtsi}/\Rspo1^{tm2b(KOMP)Wtsi} (C57BL/6N-Rspo1^{tm2b(KOMP)Wtsi}/Ics)	increased lymphocyte cell number	J:211773
\Rtcb^{tm1c(KOMP)Wtsi}/\Rtcb^{tm1c(KOMP)Wtsi} \Tg(Fcer2a-cre)5Mbu/0 (involves: C57BL/6 * CBA * SJL)	abnormal B cell number	J:216740
	abnormal B cell physiology	J:216740
	abnormal plasma cell morphology	J:216740
	decreased IgM level	J:216740
\Rthyd1^NOD/MrkTac/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
\Rthyd2^B10.Br/SgSnJ/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
\Rthyd3^B10.Br/SgSnJ/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
\Rthyd5^NOD/MrkTac/? (involves: B10.Br/SgSnJ * NOD-H2^k)	abnormal T cell clonal deletion	J:94684
\Rtl5^em1Tmki/\Rtl5^em1Tmki \Rtl6^tm2.1Tmki/\Rtl6^tm2.1Tmki (involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)	abnormal inflammatory response	J:329352
	decreased susceptibility to endotoxin shock	J:329352
\Rtl5^tm1.1Tmki/\Rtl5^tm1.1Tmki (involves: C57BL/6NCrlj * CBA/JNCrlj)	immune system phenotype	J:329352
\Rtl5^tm1.1Tmki/\Rtl5^tm1.1Tmki \Rtl6^tm1.1Tmki/\Rtl6^tm1.1Tmki (involves: C57BL/6NCrlj * C57BL/6NSlc * CBA/JNCrlj)	abnormal inflammatory response	J:329352
\Rtl9^em2Tmki/\Rtl9^em2Tmki (C57BL/6N-Rtl9^em2Tmki)	abnormal innate immunity	J:343808
\Rtp4^em#Xzs/\Rtp4^em#Xzs (involves: C57BL/6)	decreased susceptibility to parasitic infection	J:293929
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:293929
	decreased susceptibility to viral infection	J:293929
\Rtraf^{tm1b(EUCOMM)Hmgu}/\Rtraf⁺ (C57BL/6N-Rtraf^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
\Rttn^em1(IMPC)Tcp/\Rttn⁺ (C57BL/6NCrl-Rttn^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Rubcn^em1Dgre/\Rubcn^em1Dgre (C57BL/6-Rubcn^em1Dgre)	abnormal macrophage physiology	J:261225
\Rubcn^em1Dgre/\Rubcn^em1Dgre (C57BL/6-Rubcn^em1Dgre)	immune system phenotype	J:261225
\Rubcn^em1Dgre/\Rubcn^em1Dgre (involves: C57BL/6 * C57BL/6N)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	abnormal spleen morphology	J:235399
	decreased circulating interleukin-10 level	J:235399
	glomerulonephritis	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased anti-nuclear antigen antibody level	J:235399
	increased autoantibody level	J:235399
	increased CD8-positive, alpha-beta T cell number	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased IgG level	J:235399
	increased lymphocyte cell number	J:235399
	increased monocyte cell number	J:235399
	increased neutrophil cell number	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
\Rubcn^em1Dgre/\Rubcn^em1Dgre \Tg(CAG-EGFP/Map1lc3b)53Nmz/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * C57BL/6NCrlj * DBA/2)	abnormal macrophage morphology	J:261225
	abnormal macrophage physiology	J:261225
\Rubcn^em1Dgre/\Rubcn^em1Dgre \Tg(CAG-EGFP/Map1lc3b)53Nmz/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal circulating chemokine level	J:235399
	abnormal macrophage physiology	J:235399
	decreased circulating interleukin-10 level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
\Runx1^{tm1(RUNX1)Gcg}/\Runx1^{tm1(RUNX1)Gcg} \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal granulocyte differentiation	J:106800
	abnormal myelopoiesis	J:106801
	abnormal T cell differentiation	J:106800
	decreased CD4-positive, alpha-beta T cell number	J:106800
	decreased double-positive T cell number	J:106800
	increased CD8-positive, alpha-beta T cell number	J:106800
	increased T cell derived lymphoma incidence	J:106800
\Runx1^{tm1(RUNX1/EVI1)Kmit}/\Runx1⁺ (involves: C57BL/6 * CBA)	abnormal myelopoiesis	J:118892
\Runx1^tm1Itan/\Runx1^tm1Itan (involves: 129P2/OlaHsd)	immune system phenotype	J:132661
\Runx1^tm1Soga/\Runx1^tm1.1Soga \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal B cell differentiation	J:88511
	abnormal T cell differentiation	J:88511
\Runx1^tm1Soga/\Runx1^tm1Soga \Stag2^tm1.1Soga/Y \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6N * CBA/J)	decreased leukocyte cell number	J:289000
\Runx1^tm1Spe/\Runx1⁺ (either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca))	increased T cell derived lymphoma incidence	J:80829
\Runx1^tm1Spe/\Runx1⁺ (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	decreased CD4-positive, alpha-beta T cell number	J:120100
\Runx1^tm1Spe/\Runx1^tm1Spe (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	impaired myelopoiesis	J:35115
\Runx1^tm1Tani/\Runx1^tm1Tani \Runx3^tm1Itan/\Runx3^tm1Itan \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:125959
\Runx1^tm1Tani/\Runx1^tm1Tani \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:125959
	abnormal CD8-positive, alpha-beta T cell differentiation	J:125959
	abnormal double-positive T cell morphology	J:125959
	decreased CD4-positive, alpha-beta T cell number	J:125959
\Runx1^tm1Tani/\Runx1^tm1Tani \Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd)	arrested T cell differentiation	J:125959
	decreased double-positive T cell number	J:125959
	decreased thymocyte number	J:125959
	increased double-negative T cell number	J:125959
\Runx1^tm1Toku/\Runx1⁺ \Runx3^tm1Itan/\Runx3^tm1Itan \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:131081
\Runx1^tm1Toku/\Runx1^tm1Toku (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:87697
	increased CD4-positive, alpha-beta T cell number	J:87697
	small thymus	J:87697
	thymus hypoplasia	J:87697
\Runx1^tm1Toku/\Runx1^tm1Toku \Runx3^tm1Itan/\Runx3⁺ \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:131081
	decreased CD8-positive, alpha-beta T cell number	J:131081
\Runx1^tm1Toku/\Runx1^tm1Toku \Runx3^tm1Itan/\Runx3^tm1Itan \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:131081
	decreased CD8-positive, alpha-beta T cell number	J:131081
\Runx1^tm1Toku/\Runx1^tm1Toku \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:131081
\Runx1^tm1Yg/\Runx1^tm1Yg (either: (involves: 129/Sv * 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))	abnormal leukopoiesis	J:125830
	abnormal T cell differentiation	J:125830
	abnormal thymus corticomedullary boundary morphology	J:125830
	abnormal thymus lobule morphology	J:125830
	decreased single-positive T cell number	J:125830
	decreased thymocyte number	J:125830
	increased double-positive T cell number	J:125830
	increased thymocyte apoptosis	J:125830
	small thymus	J:125830
	thymus cyst	J:125830
	thymus hypoplasia	J:125830
\Runx1^tm1Yg/\Runx1^tm1Yg \Tg(Lck-cre)1Jtak/? (either: (involves: 129/Sv * 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))	decreased T cell number	J:125830
\Runx1^{tm2(Runx1)Toku}/\Runx1^{tm2(Runx1)Toku} (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:87697
\Runx1^tm2.1Gss/\Runx1^tm2.1Gss (involves: 129S4/SvJae * C57BL/6)	abnormal leukocyte morphology	J:214025
	abnormal spleen white pulp morphology	J:214025
	decreased CD8-positive, alpha-beta T cell number	J:214025
	decreased immature B cell number	J:214025
	decreased pre-pro B cell number	J:214025
	enlarged spleen	J:214025
	increased granulocyte number	J:214025
	increased macrophage cell number	J:214025
	increased mature B cell number	J:214025
	increased monocyte cell number	J:214025
	increased pro-B cell number	J:214025
	myeloid hyperplasia	J:214025
\Runx1^tm2Buch/\Runx1^tm2Buch \Tg(Mx1-cre)1Cgn/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal immune system organ morphology	J:105709
	abnormal leukocyte morphology	J:105709
	abnormal lymph node size	J:105709
	abnormal thymus lobule morphology	J:105709
	decreased CD4-positive, alpha-beta T cell number	J:105709
	decreased CD8-positive, alpha-beta T cell number	J:105709
	decreased double-positive T cell number	J:105709
	decreased lymphocyte cell number	J:105709
	decreased mature B cell number	J:105709
	decreased spleen white pulp amount	J:105709
	decreased T cell number	J:105709
	decreased thymus weight	J:105709
	impaired myelopoiesis	J:105709
	increased mast cell number	J:105709
	increased monocyte cell number	J:105709
	increased neutrophil cell number	J:105709
	increased spleen red pulp amount	J:105709
	increased spleen weight	J:105709
	increased T cell derived lymphoma incidence	J:105709
	small Peyer's patches	J:105709
\Runx1^tm2Itan/\Runx1^tm2Itan (involves: 129P2/OlaHsd)	immune system phenotype	J:132661
\Runx1^{tm3(Runx3)Toku}/\Runx1^{tm3(Runx3)Toku} (involves: 129P2/OlaHsd)	abnormal thymus medulla morphology	J:98965
	decreased leukocyte cell number	J:98965
	decreased lymphocyte cell number	J:98965
	decreased thymocyte number	J:98965
	small spleen	J:98965
	small thymus	J:98965
	thymus hypoplasia	J:98965
\Runx1^tm3Dow/\Runx1⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:77129
\Runx1^tm3Itan/\Runx1^tm3Itan (involves: 129P2/OlaHsd * C57BL/6)	decreased leukocyte cell number	J:160791
\Runx1^tm3Itan/\Runx1^tm3Itan (involves: 129P2/OlaHsd)	abnormal axillary lymph node morphology	J:168918
	abnormal inguinal lymph node morphology	J:168918
	abnormal lymph organ development	J:168918
	abnormal Peyer's patch morphology	J:168918
	decreased CD4-positive, alpha-beta T cell number	J:168918
	decreased Peyer's patch number	J:168918
	decreased thymocyte number	J:168918
	small Peyer's patches	J:168918
\Runx1^tm3Spe/\Runx1^tm3Spe \Spi1^tm2.1Dgt/\Spi1^tm2.1Dgt \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	decreased B cell number	J:131217
	decreased thymus weight	J:131217
	increased granulocyte number	J:131217
	increased spleen weight	J:131217
\Runx1^tm3Spe/\Runx1^tm3Spe \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	arrested T cell differentiation	J:131217
	decreased B cell number	J:151639
	decreased double-negative T cell number	J:131217
	decreased thymus weight	J:131217
	increased double-negative T cell number	J:131217
	increased spleen weight	J:131217
\Runx1^tm3Spe/\Runx1^tm3Spe \Tg(VAV1-cre)1Graf/0 (involves: 129S4/SvJae)	decreased B cell number	J:145700
	decreased double-positive T cell number	J:145700
	decreased lymphocyte cell number	J:145700
	decreased thymocyte number	J:145700
	increased granulocyte number	J:145700
	increased monocyte cell number	J:145700
\Runx1^{tm4(Runx2)Toku}/\Runx1^{tm4(Runx2)Toku} (involves: 129P2/OlaHsd)	decreased leukocyte cell number	J:98965
\Runx1^tm4Spe/\Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
\Runx1^tm4Spe/\Runx1^tm4Spe (involves: 129/Sv * C57BL/6)	decreased leukocyte cell number	J:120100
	decreased lymphocyte cell number	J:120100
	increased monocyte cell number	J:120100
\Runx1^tm5Spe/\Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
\Runx1^tm6Spe/\Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
\Runx1^tm7Spe/\Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
\Runx1^tm8Spe/\Runx1⁺ (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:120100
\Runx1^tm8Spe/\Runx1^tm8Spe (involves: 129/Sv * C57BL/6)	lung inflammation	J:120100
\Runx2^tm1Kish/\Runx2⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged thymus	J:162258
\Runx2^tm1Kish/\Runx2^tm1Kish (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:59821, J:40783
	abnormal splenic cell ratio	J:53069
	decreased B cell number	J:53069
	decreased thymocyte number	J:40783
	enlarged spleen	J:53069
	increased granulocyte number	J:53069
\Runx3^tm1Itan/\Runx3^tm1Itan \Tg(Cd4-cre)1Cwi/0 (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:125953
	abnormal CD8-positive, alpha-beta T cell differentiation	J:125953
	decreased CD8-positive, alpha-beta T cell number	J:131081
	increased IgA level	J:125953
	lung inflammation	J:125953
\Runx3^tm1Litt/\Runx3^tm1Litt (involves: 129P2/OlaHsd)	abnormal CD8-positive, alpha-beta T cell differentiation	J:141144
\Runx3^tm1Litt/\Runx3^tm1Litt (involves: 129P2/OlaHsd)	abnormal double-positive T cell morphology	J:141144
\Runx3^tm1Yg/\Runx3^tm1Yg (either: (involves: 129S1/Sv * 129X1/SvJ * ICR) or (involves: 129S1/Sv * 129X1/SvJ * MF1))	abnormal cytokine level	J:93240
	abnormal dendritic cell differentiation	J:88424
	abnormal dendritic cell morphology	J:88424
	abnormal dendritic cell physiology	J:88424, J:100348
	abnormal inflammatory response	J:93240
	abnormal interferon level	J:93240
	abnormal interleukin level	J:93240
	abnormal mesenteric lymph node morphology	J:93240
	abnormal tumor necrosis factor level	J:93240
	absent Langerhans cell	J:88424
	colitis	J:93240
	increased dendritic cell number	J:88424, J:100348
	increased IgE level	J:100348
	intestinal inflammation	J:93240
	lung inflammation	J:88424
	small intestinal inflammation	J:93240
	stomach inflammation	J:93240
\Runx3^tm1Yg/\Runx3^tm1Yg (involves: 129S1/Sv * 129X1/SvJ)	abnormal CD8-positive, alpha beta T cell morphology	J:109584
\Runx3^tm2Yg/\Runx3^tm2Yg (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6 * ICR)	abnormal CD8-positive, alpha beta T cell morphology	J:109584
	abnormal dendritic cell differentiation	J:109584
\Runx3^tm3.1Yg/\Runx3^tm3.1Yg (Not Specified)	abnormal immune system physiology	J:224898
	absent Langerhans cell	J:224898
	intestinal inflammation	J:224898
\Ruvbl1^tm1.1Oxbk/\Ruvbl1^tm1.1Oxbk \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA/J * SJL)	bone marrow failure	J:220926
\Ruvbl2^M1Btlr/\Ruvbl2⁺ (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	decreased CD4-positive, alpha-beta T cell number	J:185495
	decreased CD8-positive, alpha-beta T cell number	J:185495
	decreased double-positive T cell number	J:185495
	decreased IgG1 level	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:185495
	increased thymocyte number	J:185495
\Rwdd1^{tm1b(KOMP)Wtsi}/\Rwdd1^{tm1b(KOMP)Wtsi} (C57BL/6N-Rwdd1^{tm1b(KOMP)Wtsi}/Wtsi)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased regulatory T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
\Rwdd2a^em1(IMPC)J/\Rwdd2a^em1(IMPC)J (C57BL/6NJ-Rwdd2a^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Rxfp2^{tm1a(EUCOMM)Wtsi}/\Rxfp2^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Rxfp2^{tm1a(EUCOMM)Wtsi}/Ieg)	decreased IgE level	J:165965
	increased monocyte cell number	J:165965
\Rxfp4^{tm1.1(KOMP)Vlcg}/\Rxfp4^{tm1.1(KOMP)Vlcg} (C57BL/6N-Rxfp4^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Rxra^pke/\Rxra^pke (C57BL/6J-Rxra^pke)	abnormal dendritic cell physiology	J:103186
	abnormal regulatory T cell physiology	J:103186
	abnormal T-helper 2 cell morphology	J:103186
\Rxra^tm1Ipc/\Rxra^tm4Ipc \Rxrb^tm1Mma/\Rxrb^tm1Pcn \Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S2/SvPas)	increased immunoglobulin level	J:102470
\Rxra^tm1Krc/\Rxra^tm1Krc \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)	abnormal macrophage activation involved in immune response	J:168799
	abnormal peritoneal macrophage morphology	J:168799
	glomerulonephritis	J:168799
	impaired macrophage phagocytosis	J:168799
	increased anti-double stranded DNA antibody level	J:168799
	increased anti-nuclear antigen antibody level	J:168799
	increased anti-single stranded DNA antibody level	J:168799
	increased autoantibody level	J:168799
	increased IgG level	J:168799
	increased IgM level	J:168799
\Rxra^tm2Ipc/\Rxra^tm4Ipc \Tg(KRT14-cre)1Ipc/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal Langerhans cell morphology	J:67149
	skin inflammation	J:67149
\Rxra^tm4Ipc/\Rxra^tm4Ipc \Rxrb^tm1Pcn/\Rxrb^tm1Pcn \Tg(KRT14-cre/ERT2)1Ipc/0 (involves: 129S2/SvPas)	dermatitis	J:102470
	ear inflammation	J:102470
	enlarged cervical lymph nodes	J:102470
	enlarged spleen	J:102470
	increased leukocyte cell number	J:102470
	lymph node hyperplasia	J:102470
\Ryk^em1(IMPC)Mbp/\Ryk⁺ (C57BL/6NCrl-Ryk^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
\Ryr1^{tm1b(EUCOMM)Hmgu}/\Ryr1⁺ (C57BL/6N-Ryr1^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
\Ryr2^{tm1(CAG-KRASG12V,-lacZ)Nobs}/\Ryr2^{tm1(CAG-KRASG12V,-lacZ)Nobs} \Trp53^tm1Sia/\Trp53^tm1Sia (involves: 129X1/SvJ * C57BL/6 * CBA)	myositis	J:117828
\Ryr2^tm1.1Hnis/\Ryr2^tm1.1Hnis (involves: C57BL/6)	abnormal mesenteric lymph node morphology	J:228787
	abnormal spleen white pulp morphology	J:228787
	enlarged mesenteric lymph nodes	J:228787
	immune system phenotype	J:228787
	increased spleen weight	J:228787
	increased thymus weight	J:228787
	large lymphoid organs	J:228787
	thymus cortex hyperplasia	J:228787
\S1pr1^tm1.1Cys/\S1pr1^tm1.1Cys (involves: 129P2/OlaHsd * C3H * C57BL/6)	abnormal B cell physiology	J:176118
	decreased B cell number	J:176118
	immune system phenotype	J:176118
\S1pr1^tm1.1Thla/\S1pr1^tm1.1Thla (B6.Cg-S1pr1^tm1.1Thla)	abnormal leukocyte migration	J:163389
	abnormal lymphocyte physiology	J:163389
	increased CD4-positive, alpha-beta T cell number	J:163389
	increased CD8-positive, alpha-beta T cell number	J:163389
\S1pr1^tm1Cys/\S1pr1^tm1Cys (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:176118
	decreased B cell number	J:176118
	immune system phenotype	J:176118
\S1pr1^tm1Jch/\S1pr1^tm1Jch \Tg(GFAP-cre)25Mes/? (involves: C57BL/6J * FVB/N)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:168824
\S1pr1^tm1Jch/\S1pr1^tm1Jch \Tg(Nes-cre)1Kln/0 (involves: C57BL/6J * SJL)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:168824
\S1pr1^tm1Jch/\S1pr1^tm1Jch \Tg(Syn1-cre)671Jxm/? (involves: C57BL/6J * CBA)	immune system phenotype	J:168824
\S1pr1^tm1Rlp/\S1pr1^tm1Rlp (involves: 129S6/SvEvTac)	abnormal NK cell differentiation	J:154069
\S1pr1^tm1Rlp/\S1pr1^tm1Rlp (involves: 129S6/SvEvTac)	decreased NK cell number	J:154069
\S1pr1^{tm3.1(tTA,-Arrb2)Rlp}/\S1pr1⁺ \Tg(tetO-HIST1H2BJ/GFP)47Efu/0 (involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N)	immune system phenotype	J:212772
\S1pr2^tm1Ajml/\S1pr2^tm1Ajml (involves: 129S5/SvEvBrd * C57BL/6)	abnormal spleen marginal zone morphology	J:154439
	increased germinal center B cell number	J:154439
	increased spleen germinal center number	J:154439
	increased spleen germinal center size	J:154439
	increased T cell number	J:154439
\S1pr2^tm1Rlp/\S1pr2^tm1Rlp (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen germinal center morphology	J:174313
	decreased B cell apoptosis	J:174313
	increased B cell number	J:174313
	increased B cell proliferation	J:174313
	increased germinal center B cell number	J:174313
	increased T cell number	J:174313
\S1pr3^tm1Jch/\S1pr3^tm1Jch (involves: 129S1/Sv * 129X1/SvJ)	abnormal cytokine level	J:133917
	decreased susceptibility to endotoxin shock	J:133917
	enlarged mesenteric lymph nodes	J:133917
\S1pr3^tm1Rlp/\S1pr3^tm1Rlp (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:91161
\S1pr4^tm1Lipp/\S1pr4^tm1Lipp (involves: 129X1/SvJ * C57BL/6J)	abnormal thrombopoiesis	J:179199
\S1pr5^tm1Club/\S1pr5^tm1Club (B6.129P2-S1pr5^tm1Club)	abnormal NK cell morphology	J:178789
	abnormal NK cell physiology	J:178789
	decreased NK cell number	J:178789
\S1pr5^tm1Jch/\S1pr5^tm1Jch (involves: 129P2/OlaHsd * C57BL/6)	abnormal NK cell differentiation	J:154069
\S100a3^em1(IMPC)Mbp/\S100a3^em1(IMPC)Mbp (C57BL/6NCrl-S100a3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\S100a4^tm1.1Abres/\S100a4^tm1.1Abres (B6.Cg-S100a4^tm1.1Abres)	abnormal eosinophil physiology	J:182865
	impaired macrophage chemotaxis	J:182865
\S100a9^tm1Hogg/\S100a9^tm1Hogg (involves: 129P2/OlaHsd * C57BL/6)	abnormal neutrophil morphology	J:82513
	abnormal neutrophil physiology	J:82513
	immune system phenotype	J:82513
\S100a9^tm1Nck/\S100a9^tm1Nck (B6.129P2-S100a9^tm1Nck)	decreased circulating tumor necrosis factor level	J:125179
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:125179
	decreased susceptibility to endotoxin shock	J:125179
	decreased susceptibility to fungal infection	J:209808
\S100a9^tm1Nck/\S100a9^tm1Nck (involves: 129P2/OlaHsd * C57BL/6)	abnormal cellular extravasation	J:81642
\Saa3^{tm1(KOMP)Vlcg}/\Saa3^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased circulating serum amyloid protein level	J:220630
\Sac3d1^tm1Hnaka/\Sac3d1⁺ (involves: 129P2/OlaHsd)	abnormal mast cell physiology	J:144601
\Sac3d1^tm1Hnaka/\Sac3d1^tm1Hnaka (involves: 129P2/OlaHsd)	abnormal B cell physiology	J:144601
	abnormal mast cell physiology	J:144601
	increased T cell proliferation	J:144601
	spleen hyperplasia	J:144601
	thymus hyperplasia	J:144601
\Sacs^em1(IMPC)Tcp/\Sacs^em1(IMPC)Tcp (C57BL/6NCrl-Sacs^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
\Sall3^{tm1.1(KOMP)Mbp}/\Sall3⁺ (C57BL/6NCrl-Sall3^{tm1.1(KOMP)Mbp}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Sall4^tm1Brd/\Sall4⁺ (involves: 129S7/SvEvBrd * C57BL/6J)	ear inflammation	J:117866
\Sall4^tm1Brd/\Sall4⁺ (involves: 129S7/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:117866
\Samd3^{tm1.1(HBEGF)Wfkr}/\Samd3⁺ (C57BL/6J-Samd3^{tm1.1(HBEGF)Wfkr})	abnormal NK cell differentiation	J:322359
	decreased memory T cell number	J:322359
	decreased NK cell number	J:322359
\Samd3^{tm1.1(HBEGF)Wfkr}/\Samd3^{tm1.1(HBEGF)Wfkr} (C57BL/6J-Samd3^{tm1.1(HBEGF)Wfkr})	decreased CD8-positive, alpha-beta memory T cell number	J:322359
	immune system phenotype	J:322359
\Samd8^tm1Jia/\Samd8^tm1Jia (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:220024
\Samd9l^tm1Homy/\Samd9l⁺ (involves: 129P2/OlaHsd)	abnormal myelopoiesis	J:202604
	abnormal neutrophil morphology	J:202604
	decreased neutrophil cell number	J:202604
	enlarged spleen	J:202604
	increased leukocyte cell number	J:202604
	increased susceptibility to Retroviridae infection	J:202604
\Samd9l^tm1Homy/\Samd9l^tm1Homy (involves: 129P2/OlaHsd)	abnormal myelopoiesis	J:202604
	abnormal neutrophil morphology	J:202604
	decreased neutrophil cell number	J:202604
	enlarged spleen	J:202604
	increased leukocyte cell number	J:202604
	increased susceptibility to Retroviridae infection	J:202604
\Samhd1^tm1.2Crs/\Samhd1^tm1.2Crs (involves: C57BL/6N * C57BL/6NTac)	increased susceptibility to Retroviridae infection	J:201909
\Samhd1^{tm1d(EUCOMM)Wtsi}/\Samhd1^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal response to infection	J:202757
	immune system phenotype	J:202757
\Samhd1^tm2.2Crs/\Samhd1^tm2.2Crs (involves: 129S6/SvEvTac * C57BL/6J)	increased susceptibility to Retroviridae infection	J:201909
\Samsn1^tm1Xyw/\Samsn1^tm1Xyw (B6.129P2-Samsn1^tm1Xyw)	abnormal dendritic cell physiology	J:158032
	abnormal T-helper 1 physiology	J:158032
	abnormal T-helper 2 physiology	J:158032
	increased B cell proliferation	J:158032
	increased B-1a cell number	J:158032
	increased circulating interferon-gamma level	J:158032
	increased IgG3 level	J:158032
	increased IgM level	J:158032
	increased interleukin-4 secretion	J:158032
	increased interleukin-12 secretion	J:158032
	increased T cell proliferation	J:158032
\Sap130^{tm1a(KOMP)Mbp}/\Sap130⁺ (C57BL/6N-Sap130^{tm1a(KOMP)Mbp}/Wtsi)	decreased leukocyte cell number	J:211773
\Sarm1^tm1.1Diam/\Sarm1^tm1.1Diam (involves: 129X1/SvJ * C57BL/6)	abnormal circulating tumor necrosis factor level	J:200140
	decreased microglial cell activation	J:200140
	immune system phenotype	J:200140, J:196200
	increased susceptibility to Flaviviridae infection	J:200140
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:200140
\Sarm1^tm1Aidi/\Sarm1^tm1Aidi (involves: 129X1/SvJ * C57BL/6J)	immune system phenotype	J:126083
\Sash3^tm1Hlz/\Sash3^tm1Hlz (B6.129P2-Sash3^tm1Hlz)	abnormal B cell morphology	J:102171
	abnormal B cell physiology	J:102171
	abnormal CD4-positive T cell differentiation	J:102171
	abnormal CD8-positive, alpha-beta T cell differentiation	J:102171
	abnormal humoral immune response	J:102171
	abnormal immune system organ morphology	J:102171
	abnormal inflammatory response	J:102171
	abnormal marginal zone B cell physiology	J:102171
	abnormal T cell morphology	J:102171
	decreased double-positive T cell number	J:102171
	decreased IgG1 level	J:102171
	decreased IgG2a level	J:102171
	decreased IgG level	J:102171
	decreased IgM level	J:102171
	decreased interferon-gamma secretion	J:102171
	decreased interleukin-2 secretion	J:102171
	decreased interleukin-4 secretion	J:102171
	decreased interleukin-10 secretion	J:102171
	decreased marginal zone B cell number	J:102171
	decreased Peyer's patch number	J:102171
	decreased T cell proliferation	J:102171
	decreased tumor necrosis factor secretion	J:102171
	increased length of allograft survival	J:102171
	lymphoid hypoplasia	J:102171
\Satb1^m1Anu/\Satb1⁺ (C57L/6JAnu-Satb1^m1Anu)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
\Satb1^m1Anu/\Satb1⁺ (C57L/6JAnu-Satb1^m1Anu)	abnormal CD8-positive, alpha beta T cell morphology	J:104190
\Satb1^m1Anu/\Satb1^m1Anu (C57L/6JAnu-Satb1^m1Anu)	abnormal CD4-positive, alpha beta T cell morphology	J:104190
\Satb1^m1Anu/\Satb1^m1Anu (C57L/6JAnu-Satb1^m1Anu)	abnormal CD8-positive, alpha beta T cell morphology	J:104190
\Satb1^tm1Kos/\Satb1^tm1Kos (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:61085
	abnormal T cell proliferation	J:61085
	arrested T cell differentiation	J:61085
	decreased thymocyte number	J:61085
	small lymph nodes	J:61085
	small spleen	J:61085
	small thymus	J:61085
\Satb1^tm2Kos/\Satb1^tm2Kos \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	absent regulatory T cells	J:252606
	increased anti-nuclear antigen antibody level	J:252606
	increased autoantibody level	J:252606
	increased susceptibility to autoimmune disorder	J:252606
	kidney inflammation	J:252606
	pancreas inflammation	J:252606
	salivary gland inflammation	J:252606
\Satb2^{tm1b(KOMP)Wtsi}/\Satb2⁺ (C57BL/6N-Satb2^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
\Saxo1^{tm1b(EUCOMM)Hmgu}/\Saxo1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Saxo1^{tm1b(EUCOMM)Hmgu}/Ics)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Saysd1^em1(IMPC)J/\Saysd1^em1(IMPC)J (C57BL/6NJ-Saysd1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Sbds^tm1Dats/\Sbds^tm1Dats \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: C57BL/6 * CD-1)	abnormal myeloid leukocyte morphology	J:158901
	abnormal neutrophil morphology	J:158901
	decreased B cell number	J:158901
	decreased leukocyte cell number	J:158901
	decreased lymphocyte cell number	J:158901
\Sbf1^em1(IMPC)Mbp/\Sbf1^em1(IMPC)Mbp (C57BL/6N-Sbf1^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Sbk1^{tm1b(EUCOMM)Wtsi}/\Sbk1⁺ (C57BL/6N-Sbk1^{tm1b(EUCOMM)Wtsi}/Bay)	decreased leukocyte cell number	J:211773
\Sbno1^{tm1b(EUCOMM)Hmgu}/\Sbno1⁺ (C57BL/6N-Sbno1^{tm1b(EUCOMM)Hmgu}/H)	increased leukocyte cell number	J:211773
\Sbno2^tm1.1Aki/\Sbno2^tm1.1Aki (involves: 129 * C57BL/6)	abnormal osteoclast morphology	J:202853
	abnormal osteoclast physiology	J:202853
	immune system phenotype	J:202853
\Sbsn^em1Ham/\Sbsn^em1Ham (C57BL/6N-Sbsn^em1Ham)	decreased interleukin-4 secretion	J:296400
	decreased susceptibility to type IV hypersensitivity reaction	J:296400
	immune system phenotype	J:296400
	increased susceptibility to type IV hypersensitivity reaction	J:296400
\Sbw1^NZB/BlScr/\Sbw1^NZB/BlScr (involves: NZB/BlScr * NZW/LacScr)	enlarged spleen	J:20991
\Sbw2^NZB/BlScr/\Sbw2^NZB/BlScr (involves: NZB * NZW)	enlarged spleen	J:20991
\Sbw2^NZB/BlScr/\Sbw2^NZW/LacScr (involves: NZB * NZW)	enlarged spleen	J:20991
\Scai^{tm1b(EUCOMM)Hmgu}/\Scai^{tm1b(EUCOMM)Hmgu} (involves: C57BL/6N * FVB/N)	immune system phenotype	J:240463
\Scara5^tm1Ktry/\Scara5^tm1Ktry (B6N.129X1-Scara5^tm1Ktry)	adipose tissue inflammation	J:195536
	increased anti-nuclear antigen antibody level	J:195536
	interstitial pneumonia	J:195536
	liver inflammation	J:195536
	lung inflammation	J:195536
	skin inflammation	J:195536
	urinary bladder inflammation	J:195536
\Scarb1^tm1.1Thh/\Scarb1^tm1.1Thh (B6.129X1-Scarb1^tm1.1Thh)	increased circulating interleukin-6 level	J:114663
\Scarb1^{tm1b(EUCOMM)Wtsi}/\Scarb1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Scarb1^{tm1b(EUCOMM)Wtsi}/Bay)	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Scarb1^tm1Thh/\Scarb1^tm1Thh \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (B6.Cg-Scarb1^tm1Thh Speer6-ps1^{Tg(Alb-cre)21Mgn})	increased circulating interleukin-6 level	J:114663
\Scarb2^em2(IMPC)Tcp/\Scarb2^em2(IMPC)Tcp (C57BL/6NCrl-Scarb2^em2(IMPC)Tcp/Tcp)	decreased monocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Scarb2^tm1Psa/\Scarb2^tm1Psa (involves: 129P2/OlaHsd * C57BL/6N)	microgliosis	J:216676
\Scarf1^tm1Tkms/\Scarf1^tm1Tkms (involves: C57BL/6)	abnormal B cell physiology	J:208237
	abnormal dendritic cell physiology	J:208237
	abnormal spleen morphology	J:208237
	enlarged spleen	J:208237
	glomerulonephritis	J:208237
	immune system phenotype	J:208237
	impaired macrophage phagocytosis	J:208237
	increased anti-histone antibody level	J:208237
	increased anti-nuclear antigen antibody level	J:208237
	increased anti-single stranded DNA antibody level	J:208237
	increased B cell number	J:208237
	increased CD4-positive, alpha-beta T cell number	J:208237
	increased IgG level	J:208237
	increased lymphocyte cell number	J:208237
	increased spleen germinal center size	J:208237
	increased susceptibility to systemic lupus erythematosus	J:208237
	increased T follicular helper cell number	J:208237
	skin inflammation	J:208237
\Scd1^ab-2J/\Scd1^ab-2J (DBA/1LacJ-Scd1^ab-2J/J)	granulomatous inflammation	J:62699
\Scd1^flk/\Scd1^flk (C57BL/6J-Scd1^flk)	increased susceptibility to bacterial infection	J:100424
\Scd2^swty/\Scd2^swty (C57BL/6JSfdAnu-Scd2^swty/Anu)	blepharitis	J:104190
\Scel^{em1(IMPC)Ccpcz}/\Scel^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Scel^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Scg5^em1(IMPC)Mbp/\Scg5^em1(IMPC)Mbp (C57BL/6NCrl-Scg5^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
\Scg5^tm1Led/\Scg5^tm1Led (either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * FVB) or (involves: 129S6/SvEvTac * C57BL/6))	spleen atrophy	J:53349
\Scgb1a1^tm1Abm/\Scgb1a1⁺ (involves: 129S1/Sv * 129X1/SvJ)	abnormal complement protein level	J:57504
\Scgb1a1^tm1Abm/\Scgb1a1⁺ (involves: 129S1/Sv * 129X1/SvJ)	increased IgA level	J:57504
\Scgb1a1^tm1Abm/\Scgb1a1^tm1Abm (involves: 129S1/Sv * 129X1/SvJ)	abnormal complement protein level	J:57504
	increased IgA level	J:57504
\Scgn^em1Ezb/\Scgn^em1Ezb (C57BL/6-Scgn^em1Ezb)	increased susceptibility to colitis induced morbidity/mortality	J:285572
\Scgn^em2Ezb/\Scgn^em2Ezb (C57BL/6-Scgn^em2Ezb)	increased susceptibility to colitis induced morbidity/mortality	J:285572
\Scin^tm1Glog/\Scin^tm1Glog \Tg(Acp5-cre)4Rda/0 (either: (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * CBA))	abnormal osteoclast differentiation	J:223220
	abnormal osteoclast morphology	J:223220
	abnormal osteoclast physiology	J:223220
\Scl2^C57BL/6J/\Scl2^C57BL/6J (involves: C57BL/6J * DBA/2J)	increased susceptibility to parasitic infection	J:12046
\Scmh1^tm1Yota/\Scmh1^tm1Yota (involves: 129X1/SvJ * C57BL/6)	decreased B cell number	J:194424
	decreased T cell number	J:194424
	myeloid hyperplasia	J:194424
\Scml4^em1(IMPC)J/\Scml4^em1(IMPC)J (C57BL/6NJ-Scml4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Scn3b^{tm1a(KOMP)Wtsi}/\Scn3b^{tm1a(KOMP)Wtsi} (C57BL/6N-Scn3b^{tm1a(KOMP)Wtsi}/Wtsi)	myositis	J:232539
\Scn8a^em1(IMPC)Bay/\Scn8a⁺ (C57BL/6N-Scn8a^em1(IMPC)Bay/BayMmucd)	increased spleen weight	J:211773
\Scn9a^tm1Dgen/\Scn9a^tm1Dgen (either: (involves: 129P2/OlaHsd * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * C57BL/6 * CD-1))	dermatitis	J:223425
\Sco1^{tm1c(KOMP)Wtsi}/\Sco1^{tm1c(KOMP)Wtsi} \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: C57BL/6 * C57BL/6N * DBA)	decreased leukocyte cell number	J:222036
	decreased spleen white pulp amount	J:222036
	increased spleen iron level	J:222036
	spleen atrophy	J:222036
\Scp2^tm1Kier/\Scp2^tm1Kier (involves: 129P2/OlaHsd * C57BL/6NCr)	liver inflammation	J:124895
\Scr/\Scr (involves: 101/H * C3H/HeH)	small thymus	J:3458
\Sctr^tm1Bkcc/\Sctr^tm1Bkcc (B6.129S7-Sctr^tm1Bkcc)	abnormal cytokine secretion	J:121376
	increased macrophage cell number	J:121376
	kidney inflammation	J:121376
\Scyl1^tm1.1Spel/\Scyl1^tm1.1Spel (involves: 129S6/SvEvTac * C57BL/6J)	microgliosis	J:192445
\Scyl1^tm1Spel/\Scyl1^tm1Spel \Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)	microgliosis	J:192445
\Scyl2^tm1.1Spel/\Scyl2^tm1.1Spel \Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	microgliosis	J:225808
\Scyl3^tm1.1Spel/\Scyl3^tm1.1Spel (involves: 129S6/SvEvTac * C57BL/6J)	immune system phenotype	J:262629
\Sdc1^tm1Cma/\Sdc1^tm1Cma (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	decreased susceptibility to bacterial infection	J:69845
\Sdc1^tm1Cma/\Sdc1^tm1Cma (either: C.Cg-Sdc1^tm1Cma or B6.Cg-Sdc1^tm1Cma)	increased inflammatory response	J:80682
\Sdc1^tm1Cma/\Sdc1^tm1Cma (B6.Cg-Sdc1^tm1Cma)	decreased susceptibility to bacterial infection	J:104294
\Sdc1^tm1Cma/\Sdc1^tm1Cma (B6.Cg-Sdc1^tm1Cma)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:104294
\Sdc1^tm1Cma/\Sdc1^tm1Cma (involves: 129S4/SvJae)	decreased IgG1 level	J:107378
	decreased interleukin-10 secretion	J:107378
	decreased interleukin-13 secretion	J:107378
	increased susceptibility to parasitic infection	J:107378
\Sdc4^{tm2b(KOMP)Wtsi}/\Sdc4^{tm2b(KOMP)Wtsi} (C57BL/6N-Sdc4^{tm2b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Sdhb^{tm1b(EUCOMM)Hmgu}/\Sdhb⁺ (C57BL/6N-Sdhb^{tm1b(EUCOMM)Hmgu}/Ieg)	decreased neutrophil cell number	J:211773
\seb/\seb (Him:OF1)	dermatitis	J:64455
	lymph node hyperplasia	J:20987
	lymph node inflammation	J:20987
	skin inflammation	J:8983
\Sec1^em1Cya/\Sec1^em1Cya (C57BL/6-Sec1^em1Cya)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:325740
\Sec22b^{tm1c(EUCOMM)Wtsi}/\Sec22b^{tm1c(EUCOMM)Wtsi} \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6N * CBA * SJL)	immune system phenotype	J:255769
\Sec23b^{Gt(AD0407)Wtsi}/\Sec23b^{Gt(AD0407)Wtsi} (B6J.129P2-Sec23b^{Gt(AD0407)Wtsi})	pancreas inflammation	J:186391
\Sec24b^em1(IMPC)Tcp/\Sec24b⁺ (C57BL/6NCrl-Sec24b^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Sec63^{tm1b(EUCOMM)Hmgu}/\Sec63⁺ (C57BL/6N-Sec63^{tm1b(EUCOMM)Hmgu}/Bay)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Secia1^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secia2^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secia3^FVB/NJ/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secia4^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secia5^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secia6^DBA/1J/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secia7^FVB/NJ/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secia8^FVB/NJ/? (involves: DBA/1J * FVB/NJ)	increased susceptibility to induced arthritis	J:123131
\Secisbp2^{tm1a(EUCOMM)Wtsi}/\Secisbp2⁺ (Not Specified)	increased NK cell number	J:165965
\Secisbp2^{tm1c(EUCOMM)Wtsi}/\Secisbp2^{tm1c(EUCOMM)Wtsi} (C57BL/6N-Secisbp2^{tm1a(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
\Sectm1a^em1Gcfa/\Sectm1a^em1Gcfa (C57BL/6-Sectm1a^em1Gcfa)	abnormal interleukin level	J:317204
	abnormal macrophage physiology	J:317204
	abnormal tumor necrosis factor level	J:317204
	heart inflammation	J:317204
	increased circulating interleukin-1 beta level	J:317204
	increased circulating interleukin-6 level	J:317204
	increased circulating tumor necrosis factor level	J:317204
	increased susceptibility to endotoxin shock	J:317204
\Sele^tm1Alb/\Sele^tm1Alb (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal spleen morphology	J:101979
	eye inflammation	J:101979
	increased susceptibility to bacterial infection	J:101979
\Sele^tm1Alb/\Sele^tm1Alb (involves: 129S7/SvEvBrd * C57BL/6)	increased neutrophil cell number	J:112286
\Sele^tm1Dmil/\Sele^tm1Dmil (involves: 129S4/SvJae * C57BL/6J)	abnormal leukocyte adhesion	J:113169
\Sele^tm1Hyn/\Sele^tm1Hyn \Sell^tm1Hyn/\Sell^tm1Hyn \Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased leukocyte cell number	J:57973
	increased monocyte cell number	J:57973
	increased neutrophil cell number	J:57973
\Sele^tm1Hyn/\Sele^tm1Hyn \Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas)	abnormal cytokine level	J:31626
	abnormal granulocyte differentiation	J:31626
	abnormal myelopoiesis	J:31626
	impaired leukocyte tethering or rolling	J:31626
	impaired neutrophil recruitment	J:31626
	increased circulating interleukin-3 level	J:31626
	increased eosinophil cell number	J:31626
	increased leukocyte cell number	J:31626
	increased lymphocyte cell number	J:31626
	increased monocyte cell number	J:31626
	increased neutrophil cell number	J:31626
	increased spleen red pulp amount	J:31626
	increased spleen weight	J:31626
	increased susceptibility to bacterial infection	J:31626
	spleen hyperplasia	J:31626
\Sele^tm1Hyn/\Sele^tm1Hyn \Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased leukocyte cell number	J:57973
	increased monocyte cell number	J:57973
	increased neutrophil cell number	J:57973
\Sele^tm1Roml/\Sele^tm1Roml (involves: 129S1/Sv * C57BL/6)	abnormal T cell physiology	J:113536
\Sele^tm1Roml/\Sele^tm1Roml (involves: 129S1/Sv)	abnormal T cell physiology	J:113536
\Sele^tm2Alb/\Sele^tm2Alb \Sell^tm2Alb/\Sell^tm2Alb \Selp^tm1Bay/\Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cellular extravasation	J:70682
	abnormal cervical lymph node morphology	J:70682
	abnormal spleen B cell follicle morphology	J:70682
	abnormal spleen B cell follicle shape	J:106550
	abnormal spleen morphology	J:70682
	decreased spleen B cell follicle number	J:106550
	enlarged lymph nodes	J:70682
	immune system phenotype	J:70682
	impaired leukocyte tethering or rolling	J:70682
	increased eosinophil cell number	J:70682
	increased leukocyte cell number	J:70682
	increased monocyte cell number	J:70682
	increased neutrophil cell number	J:106550, J:70682
	lung inflammation	J:70682
\Sele^tm2Alb/\Sele^tm2Alb \Selp^tm1Bay/\Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal leukocyte cell number	J:101979
	eye inflammation	J:101979
	increased neutrophil cell number	J:101979
	increased susceptibility to bacterial infection	J:101979
\Sele^tm2Alb/\Sele^tm2Alb \Selp^tm1Bay/\Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	abnormal cytokine secretion	J:70682
	abnormal lymph node germinal center morphology	J:70682
	abnormal lymph node secondary follicle morphology	J:70682
	abnormal neutrophil physiology	J:112286
	abnormal spleen B cell follicle morphology	J:70682
	decreased acute inflammation	J:112286
	decreased spleen B cell follicle number	J:70682
	enlarged lymph nodes	J:70682
	impaired leukocyte tethering or rolling	J:70682
	increased eosinophil cell number	J:70682
	increased leukocyte cell number	J:70682
	increased monocyte cell number	J:70682
	increased neutrophil cell number	J:70682, J:112286
\Sele^tm2Hyn/\Sele^tm2Hyn (involves: 129S2/SvPas * C57BL/6)	enhanced leukocyte tethering or rolling	J:57973
\Sele^tm2Hyn/\Sele^tm2Hyn (involves: 129S2/SvPas * C57BL/6)	impaired neutrophil recruitment	J:57973
\Sele^tm2Hyn/\Sele^tm2Hyn (B6.129S2-Sele^tm2Hyn)	abnormal type IV hypersensitivity reaction	J:121083
	decreased mast cell number	J:121083
	increased mast cell number	J:121083
\Selenbp1^tm1Hyama/\Selenbp1^tm1Hyama (C57BL/6-Selenbp1^tm1Hyama)	decreased spleen weight	J:202420
	increased thymus weight	J:202420
\Selenok^tm1.2Itl/\Selenok^tm1.2Itl (involves: BALB/cJ * C57BL/6)	abnormal circulating chemokine level	J:169169
	abnormal macrophage physiology	J:169169
	abnormal neutrophil physiology	J:169169
	abnormal T cell physiology	J:169169
	decreased interleukin-6 secretion	J:169169
	decreased T cell proliferation	J:169169
	decreased tumor necrosis factor secretion	J:169169
	impaired neutrophil chemotaxis	J:169169
	increased susceptibility to Flaviviridae infection	J:169169
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:169169
\Selenop^tm1Rfb/\Selenop^tm1Rfb (B6.129-Selenop^tm1Rfb)	increased susceptibility to parasitic infection	J:134536
\Selenow^em#Hwl/\Selenow^em#Hwl (C57BL/6-Selenow^em#Hwl)	abnormal osteoclast differentiation	J:317012
\Selenow^em#Hwl/\Selenow^em#Hwl (C57BL/6-Selenow^em#Hwl)	decreased osteoclast cell number	J:317012
\Sell^m1Btlr/\Sell^m1Btlr (C57BL/6J-Sell^m1Btlr)	decreased single-positive T cell number	J:217794
\Sell^m2Btlr/\Sell^m2Btlr (C57BL/6J-Sell^m2Btlr)	decreased response to antigen	J:231806
\Sell^m2Btlr/\Sell^m2Btlr (C57BL/6J-Sell^m2Btlr)	decreased single-positive T cell number	J:231806
\Sell^tm1.1Rpmc/\Sell^tm1.1Rpmc (involves: 129S1/Sv * C57BL/6J * FVB/N)	abnormal granulocyte physiology	J:249558
	abnormal neutrophil physiology	J:249558
	immune system phenotype	J:249558
	increased inflammatory response	J:249558
\Sell^tm1Alb/\Sell^tm1Alb (involves: 129S7/SvEvBrd * C57BL/6)	intermingled spleen red and white pulp	J:70682
\Sell^{tm1b(EUCOMM)Hmgu}/\Sell^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sell^{tm1b(EUCOMM)Hmgu}/H)	increased spleen weight	J:211773
\Sell^tm1Flv/\Sell⁺ (involves: C57BL/6 * NOD)	decreased susceptibility to autoimmune diabetes	J:88947
\Sell^tm1Flv/\Sell⁺ (involves: C57BL/6 * NOD)	pancreas inflammation	J:88947
\Sell^tm1Flv/\Sell⁺ (NOD.Cg-Sell^tm1Flv)	immune system phenotype	J:88974
\Sell^tm1Flv/\Sell^tm1Flv (involves: 129S2/SvPas * C57BL/6)	abnormal type IV hypersensitivity reaction	J:89253
\Sell^tm1Flv/\Sell^tm1Flv (involves: 129S2/SvPas * C57BL/6)	decreased activated T cell number	J:89253
\Sell^tm1Flv/\Sell^tm1Flv (involves: C57BL/6 * NOD)	decreased susceptibility to autoimmune disorder	J:88947
\Sell^tm1Flv/\Sell^tm1Flv (involves: C57BL/6 * NOD)	pancreas inflammation	J:88947
\Sell^tm1Flv/\Sell^tm1Flv (NOD.Cg-Sell^tm1Flv)	immune system phenotype	J:88974
\Sell^tm1Pest/\Sell⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal hypersensitivity reaction	J:112550
\Sell^tm1Pest/\Sell⁺ (involves: 129S4/SvJae * C57BL/6)	impaired leukocyte tethering or rolling	J:112550
\Sell^tm1Pest/\Sell^tm1Pest (involves: 129S4/SvJae)	abnormal hypersensitivity reaction	J:111233
	abnormal leukocyte adhesion	J:111233
	impaired leukocyte tethering or rolling	J:111233
	increased T cell proliferation	J:111233
\Sell^tm1Pest/\Sell^tm1Pest (involves: 129S4/SvJae * C57BL/6)	abnormal cell-mediated immunity	J:112550
	abnormal dendritic cell physiology	J:112550
	abnormal hypersensitivity reaction	J:112550
	abnormal leukocyte migration	J:112550
	abnormal splenic cell ratio	J:112550
	decreased T cell proliferation	J:112550
	enlarged spleen	J:112550
	immune system phenotype	J:112550
	impaired leukocyte tethering or rolling	J:112550
	lymph node hypoplasia	J:112550
	small popliteal lymph nodes	J:112550
\Sell^tm1Tft/\Sell^tm1Tft (involves: 129P2/OlaHsd * C57BL/6)	abnormal cellular extravasation	J:25005
	abnormal leukocyte migration	J:25005
	enlarged spleen	J:25005
	impaired leukocyte tethering or rolling	J:25005
\Sell^tm1Tft/\Sell^tm1Tft (B6.129-Sell^tm1Tft)	abnormal cellular extravasation	J:66107
\Sell^tm1Tft/\Sell^tm1Tft (B6.129-Sell^tm1Tft)	abnormal leukocyte migration	J:66107
\Sell^tm1Tft/\Sell^tm1Tft (B6.129P2-Sell^tm1Tft)	abnormal cellular extravasation	J:48271
	abnormal regulatory T cell number	J:141931
	abnormal regulatory T cell physiology	J:141931
	impaired leukocyte tethering or rolling	J:48271
	increased monocyte cell number	J:48271, J:142184
	lymph node hypoplasia	J:141931, J:142184
	spleen hyperplasia	J:141931
\Sell^tm2.1Tft/\Sell^tm2.1Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal neutrophil physiology	J:142184
	spleen hyperplasia	J:142184
\Sell^tm2Hyn/\Sell^tm2Hyn (involves: 129S2/SvPas * C57BL/6)	decreased monocyte cell number	J:57973
	immune system phenotype	J:106550
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
\Sell^tm2Hyn/\Sell^tm2Hyn (involves: 129S2/SvPas * BALB/c)	impaired leukocyte tethering or rolling	J:114317
\Sell^tm2Tft/\Sell^tm2.1Tft (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:142184
	abnormal neutrophil physiology	J:142184
	abnormal regulatory T cell number	J:141931
	abnormal regulatory T cell physiology	J:141931
	impaired leukocyte tethering or rolling	J:142184
\Sell^tm2Tft/\Sell^tm2Tft (involves: 129S1/Sv * 129X1/SvJ)	lymph node hypoplasia	J:142184
\Sell^tm2Tft/\Sell^tm2Tft (involves: 129S1/Sv * 129X1/SvJ)	spleen hyperplasia	J:142184
\Sell^tm3Hyn/\Sell^tm3Hyn \Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased leukocyte cell number	J:57973
	increased neutrophil cell number	J:57973
\Sell^tm4Hyn/\Sell^tm4Hyn \Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
\Selp^tm1.1Rpmc/\Selp^tm1.1Rpmc (B6.129S1-Selp^tm1.1Rpmc)	impaired leukocyte tethering or rolling	J:230041
\Selp^tm1Bay/\Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	abnormal leukocyte migration	J:24239
	abnormal spleen morphology	J:101979
	eye inflammation	J:101979
	increased leukocyte cell number	J:101979
	increased neutrophil cell number	J:101979, J:24239
	increased susceptibility to bacterial infection	J:101979
\Selp^tm1Bay/\Selp^tm1Bay (D1.129S7(B6J)-Selp^tm1Bay)	abnormal cytokine secretion	J:57086
	increased IgG level	J:57086
	increased susceptibility to induced arthritis	J:57086
\Selp^tm1Bay/\Selp^tm1Bay (B6.129S7-Selp^tm1Bay/J)	abnormal T cell physiology	J:113536
\Selp^tm1Bay/\Selp^tm1Bay (either: B6.129S7-Selp^tm1Bay or (involves: 129S7/SvEvBrd * C57BL/6))	abnormal leukocyte tethering or rolling	J:31374
	increased leukocyte cell number	J:31374
\Selp^tm1Bay/\Selp^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6)	increased neutrophil cell number	J:112286
\Selp^tm1Bay/\Selp^tm1Bay (B6.129S7-Selp^tm1Bay)	decreased mast cell number	J:121083
\Selp^tm1Bay/\Selp^tm1Bay (B6.129S7-Selp^tm1Bay)	decreased susceptibility to type IV hypersensitivity reaction	J:121083
\Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6J)	impaired leukocyte tethering or rolling	J:77329
	impaired neutrophil recruitment	J:77329
	increased neutrophil cell number	J:77329
\Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas)	impaired leukocyte tethering or rolling	J:29814
	impaired macrophage chemotaxis	J:29814
	increased neutrophil cell number	J:29814
\Selp^tm1Hyn/\Selp^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	impaired eosinophil recruitment	J:57973
	impaired leukocyte tethering or rolling	J:57973
	impaired neutrophil recruitment	J:57973
	increased eosinophil cell number	J:57973
	increased neutrophil cell number	J:57973
\Selp^tm2Hyn/\Selp^tm2Hyn (involves: 129S2/SvPas * C57BL/6J)	impaired leukocyte tethering or rolling	J:51068
	impaired neutrophil recruitment	J:51068
\Selplg^tm1Fur/\Selplg^tm1Fur (involves: 129/Sv * C57BL/6J * SJL)	impaired leukocyte tethering or rolling	J:75412
	impaired neutrophil chemotaxis	J:75412
	increased eosinophil cell number	J:75412
	increased neutrophil cell number	J:75412
\Selplg^tm1Rpmc/\Selplg^tm1Rpmc (involves: 129S1/Sv * C57BL/6J)	abnormal leukocyte adhesion	J:75829
	impaired leukocyte tethering or rolling	J:75829, J:138731
	increased eosinophil cell number	J:75829
	increased leukocyte cell number	J:75829
	increased lymphocyte cell number	J:75829
	increased neutrophil cell number	J:75829
\Selplg^tm1Rpmc/\Selplg^tm1Rpmc (involves: 129S1/Sv)	abnormal chemokine secretion	J:115682
\Selplg^tm1Rpmc/\Selplg^tm1Rpmc (involves: 129S1/Sv)	immune system phenotype	J:115682
\Selplg^tm2Rpmc/\Selplg^tm2Rpmc (B6.Cg-Selplg^tm2Rpmc)	impaired leukocyte tethering or rolling	J:138731
\Sema3a^tm1.1Tyag/\Sema3a^tm1.1Tyag (involves: C57BL/6 * CBA)	abnormal dendritic cell physiology	J:161856
	abnormal T cell physiology	J:161856
\Sema3f^tm1.2Ddg/\Sema3f^tm1.2Ddg (Not Specified)	abnormal lymphatic system physiology	J:226501
	abnormal lymphatic vessel endothelial cell morphology	J:226501
	abnormal lymphatic vessel morphology	J:226501
\Sema3f^tm1.2Ddg/\Sema3f^tm1.2Ddg \Sema3g^{tm1(KOMP)Vlcg}/\Sema3g^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal lymphatic vessel endothelial cell morphology	J:226501
	abnormal lymphatic vessel morphology	J:226501
	lymphatic vessel hyperplasia	J:226501
\Sema3g^{tm1(KOMP)Vlcg}/\Sema3g^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal lymphatic vessel morphology	J:226501
\Sema4a^tm1Kik/\Sema4a^tm1Kik (either: B6.Cg-Sema4a^tm1Kik or C.Cg-Sema4a^tm1Kik)	abnormal CD4-positive, alpha-beta T cell physiology	J:97027
	abnormal cytokine secretion	J:97027
	abnormal dendritic cell antigen presentation	J:97027
	abnormal T-helper 1 cell differentiation	J:97027
	decreased susceptibility to type IV hypersensitivity reaction	J:97027
\Sema4b^tm1Akum/\Sema4b^tm1Akum (either: B6.Cg-Sema4b^tm1Akum or C.Cg-Sema4b^tm1Akum)	abnormal immune system physiology	J:169386
	increased IgE level	J:169386
	increased IgG1 level	J:169386
\Sema4d^{tm1b(EUCOMM)Wtsi}/\Sema4d^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sema4d^{tm1b(EUCOMM)Wtsi}/H)	enlarged spleen	J:211773
\Sema4d^tm1Kik/\Sema4d^tm1Kik (involves: 129P2/OlaHsd * C57BL/6)	abnormal B-1 B cell morphology	J:66033
	abnormal immunoglobulin level	J:66033
	decreased B cell proliferation	J:66033
	decreased B-1a cell number	J:66033
	decreased CD4-positive, alpha-beta T cell number	J:66033
	decreased spleen germinal center size	J:66033
	decreased T cell number	J:66033
	increased B cell number	J:66033
\Sema4f^em1(IMPC)J/\Sema4f^em1(IMPC)J (C57BL/6NJ-Sema4f^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Sema5b^{tm1a(EUCOMM)Wtsi}/\Sema5b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Sema5b^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased T cell number	J:165965
\Sema6c^tm1Matl/\Sema6c^tm1Matl (Not Specified)	immune system phenotype	J:161856
\Sema6d^tm1Kik/\Sema6d^tm1Kik (Not Specified)	immune system phenotype	J:161856
\Senp1^tm1.1Wami/\Senp1^tm1.1Wami (involves: 129 * C57BL/6)	abnormal granulocyte differentiation	J:163428
\Senp1^tm1.1Wami/\Senp1^tm1.1Wami (involves: 129 * C57BL/6)	abnormal monocyte differentiation	J:163428
\Senp1^tm1Wami/\Senp1^tm1Wami \Tg(Fabp4-cre)#Abel/0 (B6.Cg-Senp1^tm1Wami Tg(Fabp4-cre)#Abel)	abnormal chemokine level	J:228009
	abnormal circulating cytokine level	J:228009
	abnormal cytokine level	J:228009
	increased anti-insulin autoantibody level	J:228009
	increased circulating C-reactive protein level	J:228009
	increased circulating interleukin-1 beta level	J:228009
	increased circulating interleukin-6 level	J:228009
	increased circulating tumor necrosis factor level	J:228009
	increased susceptibility to autoimmune diabetes	J:228009
	myocarditis	J:228009
	pancreas inflammation	J:228009
\Septin2^em1(IMPC)Tcp/\Septin2⁺ (C57BL/6NCrl-Septin2^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
\Septin5^{tm1b(EUCOMM)Hmgu}/\Septin5⁺ (C57BL/6N-Septin5^{tm1b(EUCOMM)Hmgu}/Rbrc)	small spleen	J:211773
\Septin7^tm1Mgl/\Septin7^tm1Mgl \Tg(CD2-icre)4Kio/0 (involves: 129P2/OlaHsd * C3H * C57BL/6 * C57BL/10 * CBA/Ca)	immune system phenotype	J:223786
\Septin9^tm2.1Emfu/\Septin9^tm2.1Emfu \Tg(Lck-cre)548Jxm/0 (involves: C57BL/6 * CBA)	abnormal T cell differentiation	J:205027
	decreased CD4-positive, alpha-beta memory T cell number	J:205027
	decreased CD4-positive, alpha-beta T cell number	J:205027
	decreased CD8-positive, alpha-beta memory T cell number	J:205027
	decreased CD8-positive, alpha-beta T cell number	J:205027
	decreased DN4 thymocyte number	J:205027
	decreased regulatory T cell number	J:205027
	decreased single-positive T cell number	J:205027
	decreased T cell number	J:205027
	decreased T cell proliferation	J:205027
	increased CD8-positive, alpha-beta memory T cell number	J:205027
	increased DN3 thymocyte number	J:205027
	increased double-negative T cell number	J:205027
\Septin9^tm2.1Emfu/\Septin9^tm2.1Emfu \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	decreased CD8-positive, alpha-beta T cell number	J:205027
\Serac1^em1(IMPC)Tcp/\Serac1^em1(IMPC)Tcp (C57BL/6NCrl-Serac1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Serf1^{tm1a(EUCOMM)Hmgu}/\Serf1^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Serf1^{tm1a(EUCOMM)Hmgu}/H)	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
\Serinc5^em1Spst/\Serinc5^em1Spst (C57BL/6-Serinc5^em1Spst)	immune system phenotype	J:291232
\Serpina1^em#Chmu/\Serpina1^em#Chmu (involves: C57BL/6J)	increased susceptibility to endotoxin shock	J:259615
\Serpina1^em#Chmu/\Serpina1^em#Chmu (involves: C57BL/6J)	respiratory system inflammation	J:259615
\Serpina3c^em1Smoc/\Serpina3c^em1Smoc (C57BL/6-Serpina3c^em1Smoc)	white adipose tissue inflammation	J:343846
\Serpina3g^tm1.1Arp/\Serpina3g^tm1.1Arp (involves: C57BL/6)	abnormal memory T cell morphology	J:189782
	abnormal response to infection	J:189782
	decreased CD8-positive, alpha-beta memory T cell number	J:189782
	decreased T cell proliferation	J:189782
\Serpina3g^tm1.1Arp/\Serpina3g^tm1.1Arp \Tg(TcrLCMV)#Sdz/0 (involves: C57BL/6 * DBA/2)	decreased T cell proliferation	J:189782
\Serpina3i^em1(IMPC)J/\Serpina3i^em1(IMPC)J (C57BL/6NJ-Serpina3i^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Serpina6^tm1Tew/\Serpina6^tm1Tew (involves: 129/SvEmcTer * C57BL/6N)	abnormal circulating cytokine level	J:112974
	abnormal cytokine level	J:112974
	increased susceptibility to endotoxin shock	J:112974
\Serpinb1a^tm1.1Cben/\Serpinb1a^tm1.1Cben (129S6/SvEvTac-Serpinb1a^tm1.1Cben)	abnormal chemokine secretion	J:125918
	abnormal circulating cytokine level	J:125918
	abnormal neutrophil physiology	J:125918
	decreased neutrophil cell number	J:125918
	impaired neutrophil chemotaxis	J:125918
	increased interleukin-1 beta secretion	J:125918
	increased susceptibility to bacterial infection	J:125918
	increased susceptibility to bacterial infection induced morbidity/mortality	J:125918
	increased tumor necrosis factor secretion	J:125918
	lung inflammation	J:125918
	sepsis	J:125918
\Serpinb2^tm1Dgi/\Serpinb2^tm1Dgi (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal leukocyte cell number	J:52283
	decreased lymphocyte cell number	J:52283
	decreased monocyte cell number	J:52283
	decreased neutrophil cell number	J:52283
	immune system phenotype	J:52283
\Serpinb2^tm2Dgi/\Serpinb2^tm2Dgi (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	abnormal leukocyte cell number	J:52283
	decreased lymphocyte cell number	J:52283
	decreased monocyte cell number	J:52283
	decreased neutrophil cell number	J:52283
	immune system phenotype	J:52283
\Serpinb3a^tm1Gsil/\Serpinb3a^tm1Gsil (C.129-Serpinb3a^tm1Gsil)	decreased susceptibility to type I hypersensitivity reaction	J:189949
\Serpinb9^{em1(IMPC)Ccpcz}/\Serpinb9^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Serpinb9^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased effector memory T-helper cell number	J:211773
\Serpinb9^tm1.1Pib/\Serpinb9^tm1.1Pib (involves: BALB/cJ * C57BL/6J)	abnormal dendritic cell antigen presentation	J:252016
	abnormal immune system morphology	J:252016
	abnormal immune system physiology	J:252016
	decreased cytotoxic T cell apoptosis	J:252016
	immune system phenotype	J:252016
\Serpinb9^tm1Arp/\Serpinb9^tm1Arp (involves: C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:113349
	abnormal cytotoxic T cell physiology	J:113349
	decreased cytotoxic T cell cytolysis	J:113349
	increased susceptibility to Riboviria infection	J:113349
\Serpinb9^tm1Arp/\Serpinb9^tm1Arp \Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6)	abnormal response to transplant	J:113349
\Serpinb10^em1(IMPC)Mbp/\Serpinb10^em1(IMPC)Mbp (C57BL/6NCrl-Serpinb10^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Serpinc1^tm1Dwr/\Serpinc1^tm1Dwr (involves: 129S1/Sv * 129X1/SvJ)	enlarged spleen	J:115658
	liver inflammation	J:115658
\Serpine1^em1(IMPC)Tcp/\Serpine1^em1(IMPC)Tcp (C57BL/6N-Serpine1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Serpine1^tm1.1Vlp/\Serpine1^tm1.1Vlp (involves: 129 * C57BL/6)	decreased susceptibility to endotoxin shock	J:229191
\Serpine1^tm1Mlg/\Serpine1^tm1Mlg (involves: 129S2/SvPas * C57BL/6)	abnormal acute inflammation	J:133227
	abnormal interleukin level	J:133227
	decreased circulating interleukin-6 level	J:133227
	glomerulonephritis	J:85989
	immune system phenotype	J:133227
	increased acute inflammation	J:133227
	increased granulocyte number	J:133227
	respiratory system inflammation	J:66093
\Serpine1^tm1Mlg/\Serpine1^tm1Mlg (B6.129S2-Serpine1^tm1Mlg/J)	heart inflammation	J:101486
	increased susceptibility to bacterial infection	J:124327
	increased susceptibility to Coronaviridae infection	J:288556
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:288556
\Serpine1^tm1Mlg/\Serpine1^tm1Mlg (involves: 129S2/SvPas)	decreased susceptibility to endotoxin shock	J:229191
\Serpine2^tm1Dmn/\Serpine2^tm1Dmn (B6.129P2-Serpine2^tm1Dmn)	abnormal acute phase protein level	J:121263
\Serpinf1^{tm1e.1(KOMP)Wtsi}/\Serpinf1^{tm1e.1(KOMP)Wtsi} (C57BL/6N-Serpinf1^{tm1e.1(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Serpini2^pq/\Serpini2^pq (involves: C57BL/6J)	abnormal B cell differentiation	J:115744
	abnormal pre-B cell morphology	J:115744
	abnormal pro-B cell morphology	J:115744
	decreased B cell number	J:115744
	decreased immature B cell number	J:115744
	decreased lymphocyte cell number	J:115744
	decreased pre-B cell number	J:115744
	decreased pro-B cell number	J:115744
	decreased T cell number	J:115744
	decreased thymocyte number	J:115744
	small spleen	J:115744
	small thymus	J:115744
	spleen hypoplasia	J:115744
	thymus hypoplasia	J:115744
\Sertad2^{Gt(OST98734)Lex}/\Sertad2^{Gt(OST98734)Lex} (B6.129S5-Sertad2^{Gt(OST98734)Lex})	abnormal macrophage physiology	J:194928
\Sertad3^em1Bcgen/\Sertad3^em1Bcgen (involves: C57BL/6N)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:300469
\Ses1a^C57BL/6J/\Ses1a^C57BL/6J (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:81412
\Ses1a^C57BL/6J/\Ses1a^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses1a^C57BL/6J/\Ses1a^C57BL/6J (129.B6-Ses1a^C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses1a^C57BL/6J/\Ses1a^C57BL/6J \Ses4^C57BL/6J/\Ses4^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses1a^C57BL/6J/\Ses1a^C57BL/6J \Ses5^C57BL/6J/\Ses5^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses1a^C57BL/6J/\Ses1a^C57BL/6J \Ses6^C57BL/6J/\Ses6^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses1b^C57BL/6J/\Ses1b^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses1b^C57BL/6J/\Ses1b^C57BL/6J (129.B6-Ses1b^C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses2^C57BL/6J/\Ses2^C57BL/6J (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:81412
\Ses3^C57BL/6J/\Ses3^C57BL/6J (involves: 129 * C57BL/6J)	decreased susceptibility to bacterial infection	J:81412
\Ses7^{129S6/SvEvTac}/\Ses7^C57BL/6J \Ses8^C57BL/6J/\Ses8^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses7^C57BL/6J/\Ses7^C57BL/6J \Ses8^C57BL/6J/\Ses8^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Ses9^C57BL/6J/\Ses9^C57BL/6J \Ses10^C57BL/6J/\Ses10^C57BL/6J (involves: 129S6/SvEvTac * C57BL/6J)	decreased susceptibility to bacterial infection	J:100367
\Sesn1^{tm1a(EUCOMM)Wtsi}/\Sesn1^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N)	abnormal class switch recombination	J:240602
	abnormal effector T cell number	J:240602
	decreased B cell number	J:240602
	enlarged spleen	J:240602
	increased immunoglobulin level	J:240602
	increased interferon-gamma secretion	J:240602
	increased interleukin-2 secretion	J:240602
	increased NK T cell number	J:240602
	increased single-positive T cell number	J:240602
	increased splenocyte number	J:240602
	increased T cell proliferation	J:240602
\Setd1a^{tm1a(EUCOMM)Wtsi}/\Setd1a⁺ (C57BL/6N-Setd1a^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Setd2^{tm1c(NCOM)Mfgc}/\Setd2^{tm1c(NCOM)Mfgc} \Tg(Lck-cre)#Zhu/0 (involves: C57BL/6 * SJL/J)	increased gamma-delta T cell number	J:243973
\Setd3^{tm1.1(NCOM)Mfgc}/\Setd3^{tm1.1(NCOM)Mfgc} (C57BL/6N-Setd3^{tm1.1(NCOM)Mfgc}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Setd3^{tm1.1(NCOM)Mfgc}/\Setd3^{tm1.1(NCOM)Mfgc} (involves: C57BL/6NCrl)	decreased susceptibility to Riboviria infection	J:293475
\Setd4^{tm1b(KOMP)Wtsi}/\Setd4^{tm1b(KOMP)Wtsi} (involves: C57BL/6N)	decreased macrophage cytokine production	J:304151
\Setd5^{tm1a(EUCOMM)Wtsi}/\Setd5⁺ (C57BL/6N-Setd5^{tm1a(EUCOMM)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
	enlarged lymphatic vessel	J:239583
	increased monocyte cell number	J:211773
	increased regulatory T cell number	J:211773
	small thymus	J:239583
\Setd7^tm1Frga/\Setd7⁺ (involves: 129 * C57BL/6)	abnormal spleen physiology	J:136558
\Setd7^tm1Frga/\Setd7^tm1Frga (involves: 129 * C57BL/6)	abnormal spleen physiology	J:136558
\Setdb2^tm1Desr/\Setdb2^tm1Desr (B6.Cg-Setdb2^tm1Desr)	abnormal response to infection	J:222611
	increased neutrophil cell number	J:222611
	increased susceptibility to bacterial infection	J:222611
\Setx^{tm1b(EUCOMM)Wtsi}/\Setx^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Setx^{tm1b(EUCOMM)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
\sevr/\sevr (C3H/HeJ-sevr/GrsrJ)	thymus atrophy	J:109437
\Sf3b1^tm1.1Mdf/\Sf3b1⁺ \Tet2^tm1.1Iaai/\Tet2^tm1.1Iaai \Tg(Mx1-cre)1Cgn/? (involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J)	abnormal myelopoiesis	J:234976
	decreased B cell number	J:234976
	enlarged spleen	J:234976
	increased granulocyte number	J:234976
\Sf3b1^tm1.1Mdf/\Sf3b1⁺ \Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJae * C57BL/6 * CBA/J)	abnormal myelopoiesis	J:234976
\Sf3b1^tm1Hko/\Sf3b1⁺ (Not Specified)	increased spleen red pulp amount	J:324276
\Sfmbt2^em1(IMPC)Mbp/\Sfmbt2⁺ (C57BL/6NCrl-Sfmbt2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Sfn^tm1Mak/\Sfn^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:168328
	abnormal spleen B cell follicle morphology	J:168328
	abnormal spleen morphology	J:168328
	absent spleen marginal zone	J:168328
	decreased B cell number	J:168328
	decreased B-1a cell number	J:168328
	decreased follicular B cell number	J:168328
	decreased IgG level	J:168328
	decreased IgM level	J:168328
	decreased marginal zone B cell number	J:168328
	immune system phenotype	J:168328
	increased B cell apoptosis	J:168328
	increased B cell proliferation	J:168328
	increased susceptibility to Riboviria infection	J:168328
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:168328
\Sfrp1^tm1Bsk/\Sfrp1^tm1Bsk (involves: 129S5/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:89547
	decreased lymphocyte cell number	J:89547
	decreased neutrophil cell number	J:89547
\Sfrp4^tm1.1Blan/\Sfrp4^tm1.1Blan (Not Specified)	increased osteoclast cell number	J:234467
\Sfrp4^tm1.1Lex/\Sfrp4^tm1.1Lex (Not Specified)	increased osteoclast cell number	J:234467
\Sftpa1^tm1Haw/\Sftpa1^tm1Haw (involves: 129/Sv * C57BL/6 * CD-1)	abnormal cytokine level	J:86024
	abnormal inflammatory response	J:85432
	abnormal interferon level	J:86024
	abnormal interleukin level	J:86024
	increased susceptibility to Orthomyxoviridae infection	J:86024
\Sftpa1^tm1Kor/\Sftpa1^tm1Kor (involves: 129P2/OlaHsd * NIH Black Swiss)	immune system phenotype	J:35250
	increased susceptibility to bacterial infection	J:120552, J:110382
	lung inflammation	J:110382
\Sftpa1^tm1Kor/\Sftpa1^tm1Kor (involves: 129P2/OlaHsd)	immune system phenotype	J:130958
\Sftpa1^tm1Kor/\Sftpa1^tm1Kor (involves: 129P2/OlaHsd)	lung inflammation	J:107841
\Sftpa1^tm1Kor/\Sftpa1^tm1Kor (involves: 129P2/OlaHsd * Black Swiss * C3H/HeN)	increased susceptibility to bacterial infection	J:130297
\Sftpa1^tm2Haw/\Sftpa1^tm2Haw \Sftpd^tm2Haw/\Sftpd^tm2Haw (involves: C57BL/6J * CD-1)	abnormal alveolar macrophage morphology	J:86022
	increased monocyte cell number	J:86022
\Sftpc^tm1Swg/\Sftpc^tm1Swg (either: 129 or (involves: 129 * Black Swiss))	conjunctivitis	J:82925
\Sftpd^tm1Haw/\Sftpd^tm1Haw (involves: C57BL/6J * CD-1)	abnormal alveolar macrophage morphology	J:98220, J:50147
\Sftpd^tm1Haw/\Sftpd^tm1Haw (involves: C57BL/6J * CD-1)	abnormal macrophage physiology	J:98220
\Sftpd^tm1Jhf/\Sftpd^tm1Jhf (involves: 129P2/OlaHsd * Black Swiss)	abnormal alveolar macrophage morphology	J:50436
	abnormal chemokine level	J:72681
	abnormal cytokine level	J:72681, J:62282
	abnormal macrophage morphology	J:62282, J:50436
	abnormal macrophage physiology	J:62282
	abnormal neutrophil physiology	J:72681
	increased macrophage cell number	J:62282, J:50436
	increased neutrophil cell number	J:72681
	increased susceptibility to Orthomyxoviridae infection	J:72681
	lung inflammation	J:62282, J:50436
\Sfxn4^{tm1b(KOMP)Wtsi}/\Sfxn4^{tm1b(KOMP)Wtsi} (C57BL/6N-Sfxn4^{tm1b(KOMP)Wtsi}/J)	decreased leukocyte cell number	J:211773
\Sgca^tm1Kcam/\Sgca^tm1Kcam (involves: 129S1/Sv * 129X1/SvJ)	heart inflammation	J:177563
\Sgca^tm1Kcam/\Sgca^tm1Kcam \Sgce^tm1Vinni/\Sgce^tm1Vinni (involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)	heart inflammation	J:177563
\Sgcb^tm1Oza/\Sgcb^tm1Oza (involves: 129S4/SvJae * C57BL/6J)	myositis	J:57590
\Sgce^em1(IMPC)H/\Sgce^em1(IMPC)H (C57BL/6N-Sgce^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
\Sgk3^fz-ica/\Sgk3^fz-ica (Swiss albino)	abnormal inflammatory response	J:107373
\sgl/\sgl (involves: C3H * C57BL/6J)	abnormal lymph node morphology	J:56826
\sgl/\sgl (involves: C3H * C57BL/6J)	conjunctivitis	J:56826
\Sgms1^tm1Jia/\Sgms1^tm1Jia (involves: C57BL/6)	abnormal cytokine level	J:201497
	abnormal cytokine secretion	J:201497
	decreased circulating interleukin-6 level	J:201497
	decreased circulating tumor necrosis factor level	J:201497
	decreased interleukin-6 secretion	J:201497
	decreased tumor necrosis factor secretion	J:201497
\Sgms2^tm1Jia/\Sgms2^tm1Jia (involves: 129 * C57BL/6)	abnormal macrophage morphology	J:162226
\Sgms2^tm1Jia/\Sgms2^tm1Jia (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:162192, J:162226
\Sgp5^NZB/? (involves: C57BL/6 * NZB * SB/Le)	abnormal immune serum protein physiology	J:95829
	glomerulonephritis	J:95829
	increased susceptibility to type III hypersensitivity reaction	J:95829
\Sgp5^NZB/\Sgp5^NZB (C57BL/6-Nba2 Yaa)	abnormal immune serum protein physiology	J:95829
\Sgpl1^{Gt(OST58278)Lex}/\Sgpl1^{Gt(OST58278)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal lymph node morphology	J:145159
	abnormal lymphopoiesis	J:145159
	abnormal osteoclast morphology	J:145159
	abnormal spleen periarteriolar lymphoid sheath morphology	J:145159
	decreased B cell number	J:145159
	decreased double-positive T cell number	J:145159
	decreased lymphocyte cell number	J:145159
	decreased neutrophil cell number	J:145159
	decreased pre-B cell number	J:145159
	decreased T cell number	J:145159
	increased CD4-positive, alpha-beta T cell number	J:145159
	increased CD8-positive, alpha-beta T cell number	J:145159
	increased granulocyte number	J:145159
	increased monocyte cell number	J:145159
	increased osteoclast cell number	J:145159
	lymph node hypoplasia	J:145159
	lymphoid hypoplasia	J:145159
	spleen hypoplasia	J:145159
	thymus cortex hypoplasia	J:145159
	thymus hypoplasia	J:145159
	thymus medulla hyperplasia	J:145159
\Sgpl1^{Gt(OST58278)Lex}/\Sgpl1^{tm1(SGPL1)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal immune system organ morphology	J:145159
	abnormal osteoclast morphology	J:145159
	decreased T cell number	J:145159
	thymus cortex hypoplasia	J:145159
	thymus medulla hyperplasia	J:145159
\Sgpl1^{Gt(ROSA)78Sor}/\Sgpl1^{Gt(ROSA)78Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
\Sgpl1^{Gt(ROSA)78Sor}/\Sgpl1^{Gt(ROSA)78Sor} (involves: 129S4/SvJaeSor * C57BL/6)	abnormal immune system physiology	J:187619
	abnormal leukocyte migration	J:187619
	abnormal T cell physiology	J:187619
	decreased lymphocyte cell number	J:187619
\Sgpl1^{tm1(SGPL1)Lex}/\Sgpl1^{tm1(SGPL1)Lex} (involves: 129S4/SvJae * 129S5/SvEvBrd * C57BL/6J)	abnormal immune system organ morphology	J:145159
	abnormal lymph node morphology	J:145159
	abnormal thymus lobule morphology	J:145159
	decreased B cell number	J:145159
	decreased CD4-positive, alpha-beta T cell number	J:145159
	decreased CD8-positive, alpha-beta T cell number	J:145159
	decreased lymphocyte cell number	J:145159
	decreased T cell number	J:145159
	increased single-positive T cell number	J:145159
\Sgpl1^tm1.2Npa/\Sgpl1^tm1.2Npa (involves: BALB/cJ * C57BL/6)	spleen hypoplasia	J:199525
\Sgsh^mps3a/\Sgsh^mps3a (involves: 129X1/SvJ * CD-1 * C57BL/6 * SJL)	enlarged spleen	J:72142
\Sgsm1^{tm1b(EUCOMM)Wtsi}/\Sgsm1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sgsm1^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
\Sh2b1^tm1Ayos/\Sh2b1^tm1Ayos (involves: C57BL/6)	immune system phenotype	J:78931
\Sh2b2^tm1Yeb/\Sh2b2^tm1Yeb (involves: C57BL/6)	abnormal B cell differentiation	J:88527
	increased B-1 B cell number	J:88527
	increased IgG3 level	J:88527
\Sh2b3^tm1Paw/\Sh2b3^tm1Paw (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal granulocyte differentiation	J:77248
	abnormal leukocyte cell number	J:77248
	abnormal monocyte differentiation	J:77248
	enlarged lymph nodes	J:77248
	enlarged spleen	J:77248
	increased B cell number	J:77248
	spleen fibrosis	J:77248
\Sh2b3^tm1Paw/\Sh2b3^tm1Paw (B6.129-Sh2b3^tm1Paw)	spleen hyperplasia	J:107464
\Sh2b3^tm1Paw/\Sh2b3^tm1Paw (involves: 129S1/Sv * 129X1/SvJ)	decreased B cell number	J:161643
	enlarged spleen	J:161643
	increased granulocyte number	J:161643
	increased leukocyte cell number	J:161643
	increased lymphocyte cell number	J:161643
	increased monocyte cell number	J:161643
	increased neutrophil cell number	J:161643
	myeloid hyperplasia	J:161643
\Sh2d1a^tm1.1Knic/Y \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	abnormal NK T cell physiology	J:196692
	decreased circulating interleukin-4 level	J:196692
	decreased interferon-gamma secretion	J:196692
	immune system phenotype	J:196692
\Sh2d1a^tm1.1Knic/\Sh2d1a^tm1.1Knic \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor⁺ \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0 (involves: 129S/SvEv * 129X1/SvJ * C57BL/6)	abnormal NK T cell physiology	J:196692
	decreased circulating interleukin-4 level	J:196692
	decreased interferon-gamma secretion	J:196692
	immune system phenotype	J:196692
\Sh2d1a^tm1Cpt/Y (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	abnormal immunoglobulin level	J:189126
	abnormal NK T cell physiology	J:189126
	decreased NK T cell number	J:189126
	increased susceptibility to Riboviria infection	J:97756
	increased T cell proliferation	J:97756
\Sh2d1a^tm1Cpt/Y (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell morphology	J:189126
	decreased germinal center B cell number	J:189126
	decreased IgE level	J:97756
	decreased IgG level	J:189126
	decreased NK T cell number	J:189126
	decreased susceptibility to parasitic infection	J:97756
	immune system phenotype	J:189126
\Sh2d1a^tm1Cpt/Y \Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)	decreased germinal center B cell number	J:189126
	decreased IgG level	J:189126
\Sh2d1a^tm1Cpt/\Sh2d1a⁺ (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine secretion	J:97756
\Sh2d1a^tm1Cpt/\Sh2d1a⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell proliferation	J:97756
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt (B6.129S4-Sh2d1a^tm1Cpt)	abnormal humoral immune response	J:97388
	absent NK T cells	J:97690
	decreased IgG1 level	J:97388
	decreased IgM level	J:97388
	decreased NK T cell number	J:97690
	decreased transitional stage B cell number	J:97690
	increased B cell number	J:97388
	increased IgG2a level	J:97388
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt (C.129S4-Sh2d1a^tm1Cpt)	decreased IgG level	J:97388
	decreased IgM level	J:97388
	decreased spleen germinal center number	J:97388
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt (involves: 129S4/SvJae * C57BL/6)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	abnormal immunoglobulin level	J:189126
	abnormal NK T cell physiology	J:189126
	decreased NK T cell number	J:189126
	increased susceptibility to Riboviria infection	J:97756
	increased T cell proliferation	J:97756
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt (involves: 129S4/SvJae * BALB/c)	abnormal cytokine secretion	J:97756
	abnormal germinal center B cell morphology	J:189126
	decreased germinal center B cell number	J:189126
	decreased IgE level	J:97756
	decreased IgG level	J:189126
	decreased NK T cell number	J:189126
	decreased susceptibility to parasitic infection	J:97756
	immune system phenotype	J:189126
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt (involves: 129S4/SvJae)	impaired natural killer cell mediated cytotoxicity	J:166054
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt \Sh2d1b1/Sh2d1b2^tm1.1Cpt/\Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: 129S4/SvJae * BALB/cJ)	impaired natural killer cell mediated cytotoxicity	J:166054
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt \Sh2d1b1/Sh2d1b2^tm1.1Cpt/\Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: 129S4/SvJae * BALB/cJ)	impaired natural killer cell mediated cytotoxicity	J:166054
\Sh2d1a^tm1Cpt/\Sh2d1a^tm1Cpt \Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c)	decreased germinal center B cell number	J:189126
	decreased IgG level	J:189126
\Sh2d1a^tm1Lyin/Y (involves: 129S2/SvPas * C57BL/6)	abnormal immune system physiology	J:97346
	chronic inflammation	J:97346
	decreased IgE level	J:97346
	decreased IgG level	J:97346
	decreased immunoglobulin level	J:97346
	increased CD8-positive, alpha-beta T cell number	J:97346
\Sh2d1a^tm1Lyin/\Sh2d1a^tm1Lyin (involves: 129S2/SvPas * C57BL/6)	abnormal immune system physiology	J:97346
	chronic inflammation	J:97346
	decreased IgE level	J:97346
	decreased IgG level	J:97346
	decreased immunoglobulin level	J:97346
	increased CD8-positive, alpha-beta T cell number	J:97346
\Sh2d1a^tm1Lyin/\Sh2d1a^tm1Lyin (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:110195
\Sh2d1a^tm1Pls/Y (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
	abnormal cytotoxic T cell physiology	J:187431
	abnormal long lived plasma cell morphology	J:157915
	abnormal NK T cell morphology	J:196692
	decreased CD4-positive, alpha-beta T cell number	J:157915
	decreased IgG level	J:157915
	decreased interleukin-21 secretion	J:157915
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls (either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * C57BL/6))	abnormal lymphocyte cell number	J:70032
	abnormal T-helper 1 cell morphology	J:70032
	abnormal T-helper 2 cell morphology	J:70032
	decreased IgE level	J:70032
	increased susceptibility to infection	J:70032
	increased susceptibility to parasitic infection	J:70032
	increased susceptibility to Riboviria infection	J:70032
	increased T cell proliferation	J:70032
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls (involves: BALB/c)	decreased susceptibility to parasitic infection	J:90484
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls (involves: 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:92740
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls (B6.129S6-Sh2d1a^tm1Pls)	abnormal CD4-positive, alpha-beta T cell physiology	J:93886
	abnormal NK cell physiology	J:187430
	decreased IgE level	J:93886
	decreased interferon-gamma secretion	J:187430
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls (involves: 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
	abnormal cytotoxic T cell physiology	J:187431
	abnormal long lived plasma cell morphology	J:157915
	abnormal NK T cell morphology	J:196692
	decreased CD4-positive, alpha-beta T cell number	J:157915
	decreased IgG level	J:157915
	decreased interleukin-21 secretion	J:157915
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls \Sh2d1b1^tm3Vei/\Sh2d1b1^tm3Vei (involves: 129S6/SvEvTac * C57BL/6)	abnormal NK cell physiology	J:187430
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls \Slamf6^tm1Lex/\Slamf6^tm1Lex (B6.129S-Slamf6^tm1Lex Sh2d1a^tm1Pls)	immune system phenotype	J:187429
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls \Slamf6^tm1Pls/\Slamf6^tm1Pls \Tg(TcraTcrb)1100Mjb/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J)	immune system phenotype	J:187431
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls \Tg(DO11.10)10Dlo/\Tg(DO11.10)10Dlo (involves: BALB/c * C3H * C57BL/6)	abnormal cytokine secretion	J:90484
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls \Tg(TcraTcrb)425Cbn/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:157915
\Sh2d1a^tm1Pls/\Sh2d1a^tm1Pls \Tg(TcraTcrb)1100Mjb/0 (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytotoxic T cell physiology	J:187431
	decreased cytotoxic T cell cytolysis	J:187431
	decreased interferon-gamma secretion	J:187431
\Sh2d1a^tm1Vei/\Sh2d1a^tm1Vei (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:93886
	abnormal memory T cell physiology	J:93886
	decreased IgE level	J:93886
\Sh2d1a^tm1Vei/\Sh2d1a^tm1Vei (B6.129-Sh2d1a^tm1Vei)	abnormal NK cell physiology	J:187430
\Sh2d1a^tm1Vei/\Sh2d1a^tm1Vei (B6.129-Sh2d1a^tm1Vei)	decreased interferon-gamma secretion	J:187430
\Sh2d1a^tm1Vei/\Sh2d1a^tm1Vei \Sh2d1b1^tm3Vei/\Sh2d1b1^tm3Vei (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal NK cell physiology	J:187430
\Sh2d1a^tm2.1Cpt/Y \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	decreased IgG level	J:189126
	decreased IgM level	J:189126
	immune system phenotype	J:189126
\Sh2d1a^tm2.1Cpt/\Sh2d1a^tm2.1Cpt \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal germinal center B cell physiology	J:189126
	abnormal humoral immune response	J:189126
	decreased IgG level	J:189126
	decreased IgM level	J:189126
	immune system phenotype	J:189126
\Sh2d1a^tm2.1Vei/\Sh2d1a^tm2.1Vei (involves: C57BL/6)	decreased germinal center B cell number	J:131618
	decreased IgE level	J:131618
	decreased IgG1 level	J:131618
	decreased IgG2a level	J:131618
	decreased IgG2b level	J:131618
	decreased IgG3 level	J:131618
	decreased IgM level	J:131618
	decreased NK T cell number	J:131618
\Sh2d1a^tm2Vei/\Sh2d1a^tm2Vei \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:131618
\Sh2d1a^tm2Vei/\Sh2d1a^tm2Vei \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased germinal center B cell number	J:131618
	decreased IgE level	J:131618
	decreased IgG1 level	J:131618
	decreased IgG2a level	J:131618
	decreased IgG2b level	J:131618
	decreased IgG3 level	J:131618
	decreased IgM level	J:131618
	decreased NK T cell number	J:131618
\Sh2d1a^tm2Vei/\Sh2d1a^tm2Vei \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6)	decreased germinal center B cell number	J:131618
	decreased IgE level	J:131618
	decreased IgG1 level	J:131618
	decreased IgG2a level	J:131618
	decreased IgG2b level	J:131618
	decreased IgG3 level	J:131618
	decreased IgM level	J:131618
	decreased NK T cell number	J:131618
\Sh2d1b1/Sh2d1b2^tm1.1Cpt/\Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: BALB/cJ)	decreased interferon-gamma secretion	J:166054
	impaired natural killer cell mediated cytotoxicity	J:166054
\Sh2d1b1/Sh2d1b2^tm1.1Cpt/\Sh2d1b1/Sh2d1b2^tm1.1Cpt (involves: BALB/cJ)	decreased interferon-gamma secretion	J:166054
	impaired natural killer cell mediated cytotoxicity	J:166054
\Sh2d1b1^tm1.1Cpt/\Sh2d1b1^tm1.1Cpt (involves: BALB/cJ * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:166054
\Sh2d1b1^tm1Vei/\Sh2d1b1^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	increased interferon-gamma secretion	J:110195
	increased natural killer cell mediated cytotoxicity	J:110195
\Sh2d1b1^tm2Vei/\Sh2d1b1^tm2Vei \Sh2d1b2^tm1Vei/\Sh2d1b2^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:145969
\Sh2d1b1^tm3Vei/\Sh2d1b1^tm3Vei (involves: C57BL/6)	abnormal NK cell physiology	J:187430
\Sh2d1b2^tm1.1Cpt/\Sh2d1b2^tm1.1Cpt (involves: BALB/cJ * C57BL/6)	impaired natural killer cell mediated cytotoxicity	J:166054
\Sh2d1b2^tm1Vei/\Sh2d1b2^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:145969
	increased natural killer cell mediated cytotoxicity	J:110195
\Sh2d2a^tm1Jbs/\Sh2d2a^tm1Jbs (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased interferon-gamma secretion	J:64938
	decreased interleukin-2 secretion	J:64938
	decreased T cell proliferation	J:64938
	immune system phenotype	J:64938
	increased interleukin-4 secretion	J:64938
\Sh2d3c^tm1Lex/\Sh2d3c^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal B cell physiology	J:161448
	abnormal humoral immune response	J:161448
	abnormal leukocyte migration	J:161448
	abnormal marginal zone B cell physiology	J:161448
	decreased IgG1 level	J:161448
	decreased IgG2b level	J:161448
	decreased IgG3 level	J:161448
	decreased IgM level	J:161448
	decreased interleukin-6 secretion	J:161448
	decreased marginal zone B cell number	J:161448
\Sh3bp2^tm1.1Ics/\Sh3bp2⁺ (involves: 129S2/SvPas * C57BL/6)	abnormal circulating cytokine level	J:221901
	abnormal macrophage physiology	J:221901
	increased susceptibility to bacterial infection	J:221901
	increased tumor necrosis factor secretion	J:221901
\Sh3bp2^tm1.1Ics/\Sh3bp2^tm1.1Ics (involves: 129S2/SvPas * C57BL/6)	abnormal circulating cytokine level	J:221901
	enlarged lymph nodes	J:221901
	increased circulating interleukin-6 level	J:221901
	increased circulating interleukin-12 level	J:221901
	increased circulating tumor necrosis factor level	J:221901
	increased inflammatory response	J:221901
	increased monocyte cell number	J:221901
	increased tumor necrosis factor secretion	J:221901
\Sh3bp2^tm1Bjro/\Sh3bp2⁺ (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal osteoclast differentiation	J:117880
	abnormal osteoclast physiology	J:117880
	immune system phenotype	J:117880
	increased osteoclast cell number	J:117880
\Sh3bp2^tm1Bjro/\Sh3bp2^tm1Bjro (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal B cell number	J:117880
	abnormal immune system organ morphology	J:117880
	abnormal macrophage physiology	J:117880
	abnormal osteoclast differentiation	J:117880
	abnormal osteoclast physiology	J:117880
	blepharitis	J:117880
	dermatitis	J:117880
	enlarged lymph nodes	J:117880
	increased circulating tumor necrosis factor level	J:117880
	increased inflammatory response	J:117880
	increased osteoclast cell number	J:117880
	increased spleen red pulp amount	J:117880
	joint inflammation	J:117880
	liver inflammation	J:117880
	lung inflammation	J:117880
	myositis	J:117880
	osteomyelitis	J:117880
	spinal cord inflammation	J:117880
	stomach inflammation	J:117880
\Sh3bp2^tm1Bjro/\Sh3bp2^tm1Bjro \Tnf^tm1Gkl/\Tnf^tm1Gkl (involves: 129S/SvEv * 129S4/SvJae * BALB/cJ * C57BL/6J)	abnormal osteoclast differentiation	J:117880
	immune system phenotype	J:117880
\Sh3bp2^tm1Geha/\Sh3bp2^tm1Geha (Not Specified)	abnormal B cell number	J:110319
	abnormal B cell physiology	J:110319
	decreased B cell proliferation	J:110319
	immune system phenotype	J:110319
	increased pre-B cell number	J:110319
\Sh3bp2^tm1Rtpl/\Sh3bp2^tm1Rtpl (B6.129P2-Sh3bp2^tm1Rtpl)	abnormal B cell number	J:121380
	abnormal marginal zone B cell physiology	J:121380
	abnormal spleen marginal zone morphology	J:121380
	decreased B cell proliferation	J:121380
	decreased B-1 B cell number	J:121380
	decreased IgA level	J:121380
	decreased IgG1 level	J:121380
	decreased IgG3 level	J:121380
	decreased IgM level	J:121380
	decreased immunoglobulin level	J:121380
	decreased pro-B cell number	J:121380
	decreased transitional stage B cell number	J:121380
	increased B cell apoptosis	J:121380
	increased marginal zone B cell number	J:121380
\Sh3bp2^tm1Rtpl/\Sh3bp2^tm1Rtpl (involves: 129P2/OlaHsd * C57BL/6)	abnormal circulating cytokine level	J:221901
	abnormal interleukin-6 secretion	J:221901
	abnormal macrophage physiology	J:221901
	decreased tumor necrosis factor secretion	J:221901
	impaired macrophage phagocytosis	J:221901
\Sh3glb2^{Gt(OST224737)Lex}/\Sh3glb2^{Gt(OST224737)Lex} (B6.129S5-Sh3glb2^{Gt(OST224737)Lex})	abnormal response to infection	J:246421
\Sh3kbp1^tm1Kuro/\Sh3kbp1^tm1Kuro \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6 * NZB)	abnormal B cell physiology	J:176805
	abnormal humoral immune response	J:176805
	abnormal lymphocyte cell number	J:176805
	decreased B cell number	J:176805
	decreased B-1a cell number	J:176805
	decreased follicular B cell number	J:176805
	decreased immature B cell number	J:176805
	decreased transitional stage T2 B cell number	J:176805
	decreased transitional stage T3 B cell number	J:176805
	immune system phenotype	J:176805
\Sh3kbp1^tm1Kuro/\Sh3kbp1^tm1Kuro \Cd79a^tm1(cre)Reth/\Cd79a⁺ \Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/? (involves: BALB/c * C57BL/6 * NZB)	decreased B-1a cell number	J:176805
	immune system phenotype	J:176805
\Sh3pxd2a^{tm1b(EUCOMM)Wtsi}/\Sh3pxd2a^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sh3pxd2a^{tm1b(EUCOMM)Wtsi}/Wtsi)	abnormal lymphatic vessel morphology	J:239583
	abnormal thymus topology	J:239583
	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
\Sh3pxd2b^nee/\Sh3pxd2b^nee (B10.Cg-H2^h4 Sh3pxd2b^nee/GrsrJ)	eye inflammation	J:262132
	hypopyon	J:262132
	increased susceptibility to otitis media	J:153369
\Sh3tc1^{tm1b(EUCOMM)Hmgu}/\Sh3tc1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sh3tc1^{tm1b(EUCOMM)Hmgu}/Orl)	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Sh3yl1^em1(IMPC)Mbp/\Sh3yl1^em1(IMPC)Mbp (C57BL/6NCrl-Sh3yl1^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
\Sh3yl1^tm1Syb/\Sh3yl1^tm1Syb (involves: C57BL/6N)	decreased interleukin-1 beta secretion	J:298830
	decreased susceptibility to endotoxin shock	J:298830
	decreased tumor necrosis factor secretion	J:298830
\Sharpin^cpdm-Dem/\Sharpin^cpdm-Dem (CBy.OcB3-Sharpin^cpdm-Dem)	abnormal immune system organ morphology	J:121810
	dermatitis	J:121810
	skin inflammation	J:121810
\Sharpin^cpdm/\Sharpin^cpdm (C57BL/KaLawRij-Sharpin^cpdm)	abnormal humoral immune response	J:53575
	abnormal immune system organ morphology	J:14539
	abnormal lymph node morphology	J:14539
	abnormal mesenteric lymph node morphology	J:53575
	abnormal peripheral lymph node morphology	J:53575
	abnormal spleen morphology	J:53575
	abnormal spleen white pulp morphology	J:31745, J:53575
	absent Peyer's patches	J:53575
	absent spleen B cell follicles	J:53575
	absent spleen germinal center	J:53575
	absent spleen marginal zone	J:53575
	cutaneous mastocytosis	J:31745, J:14539
	decreased B cell number	J:53575
	decreased CD4-positive, alpha-beta T cell number	J:53575
	decreased IgA level	J:53575
	decreased IgE level	J:31745, J:53575
	decreased IgG level	J:53575
	decreased immunoglobulin level	J:53575
	decreased T cell number	J:53575
	dermatitis	J:14539
	enlarged spleen	J:14539, J:53575
	esophageal inflammation	J:31745
	folliculitis	J:31745
	increased eosinophil cell number	J:31745, J:14539
	increased IgM level	J:53575
	joint inflammation	J:14539
	large lymphoid organs	J:31745
	lung inflammation	J:31745
	lymph node inflammation	J:31745
	stomach inflammation	J:31745
\Sharpin^cpdm/\Sharpin^cpdm (involves: C57BL/KaLawRij * FVB/NJ)	absent Peyer's patches	J:121810
	absent spleen B cell follicles	J:121810
	absent spleen germinal center	J:121810
	skin inflammation	J:121810
\Shc1^tm1Ravi/\Shc1^tm1Ravi \Tg(Lck-cre)1Cwi/? (involves: 129 * C57BL/6)	abnormal double-negative T cell morphology	J:78180
	decreased double-positive T cell number	J:78180
	decreased single-positive T cell number	J:78180
	thymus hypoplasia	J:78180
\Shcbp1^{tm1c(EUCOMM)Wtsi}/\Shcbp1^{tm1c(EUCOMM)Wtsi} \Tg(Lck-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:212898
	immune system phenotype	J:212898
\Shcbp1^{tm1d(EUCOMM)Wtsi}/\Shcbp1^{tm1d(EUCOMM)Wtsi} (involves: C57BL/6N * FVB/N)	decreased B cell number	J:212898
	decreased CD4-positive, alpha-beta T cell number	J:212898
	decreased macrophage cell number	J:212898
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:212898
	decreased T cell number	J:212898
	immune system phenotype	J:212898
\Shisa6^em1(IMPC)Tcp/\Shisa6^em1(IMPC)Tcp (C57BL/6N-Shisa6^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Shisal1^{em1(IMPC)Ccpcz}/\Shisal1^{em1(IMPC)Ccpcz} (C57BL/6N-Shisal1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Shld1^em1(IMPC)Mbp/\Shld1^em1(IMPC)Mbp (C57BL/6NCrl-Shld1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Shld1^em1Nus/\Shld1^em1Nus (involves: C57BL/6NCrl)	abnormal class switch recombination	J:307190
\Shmt2^em1(IMPC)Bay/\Shmt2⁺ (C57BL/6N-Shmt2^em1(IMPC)Bay/Bay)	increased spleen weight	J:211773
\sho/\sho (Not Specified)	small thymus	J:255
\Shprh^em1(IMPC)Tcp/\Shprh^em1(IMPC)Tcp (C57BL/6NCrl-Shprh^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
\Siae^tm1.2Avrk/\Siae^tm1.2Avrk (B6J.129(Cg)-Siae^tm1.2Avrk)	immune system phenotype	J:231437
\Siae^{tm1a(EUCOMM)Wtsi}/\Siae^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	immune system phenotype	J:231437
\Sials^MRL/MpJ/\Sials^MRL/MpJ (involves: C3H/HeJ * MRL/MpJ)	salivary gland inflammation	J:66636
\Sidt1^{tm1.1(KOMP)Vlcg}/\Sidt1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Sidt1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal lymph node morphology	J:211773
\Sidt2^tm1.1Hzha/\Sidt2^tm1.1Hzha (involves: 129S6/SvEvTac * C57BL/6J)	liver inflammation	J:236042
\Sigirr^tm1Lix/\Sigirr^tm1Lix (involves: 129S6/SvEvTac * BALB/c)	abnormal chemokine secretion	J:85151
	abnormal splenocyte proliferation	J:85151
	increased inflammatory response	J:85151
	increased susceptibility to endotoxin shock	J:85151
\Sigirr^tm1Mant/\Sigirr^tm1Mant (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal chemokine secretion	J:88907
	abnormal dendritic cell physiology	J:88907
	abnormal interleukin secretion	J:88907
	immune system phenotype	J:88907
	increased interleukin-6 secretion	J:88907
	increased susceptibility to induced colitis	J:88907
\Siglec1^{tm1(HBEGF)Mtka}/\Siglec1^{tm1(HBEGF)Mtka} \1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/? (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	abnormal dendritic cell physiology	J:123958
	abnormal immune system physiology	J:123958
	abnormal immune tolerance	J:123958
	abnormal macrophage physiology	J:123958
	abnormal metallophilic macrophage morphology	J:123958
	abnormal spleen marginal zone macrophage morphology	J:123958
\Siglec1^tm1Croc/\Siglec1^tm1Croc (B6.129-Siglec1^tm1Croc)	abnormal B cell number	J:105546
	abnormal T cell subpopulation ratio	J:105546
	decreased circulating interleukin-6 level	J:189854
	decreased circulating tumor necrosis factor level	J:189854
	decreased follicular B cell number	J:105546
	decreased IgM level	J:105546
	decreased interleukin-6 secretion	J:189854
	decreased interleukin-10 secretion	J:189854
	decreased interleukin-12 secretion	J:189854
	decreased tumor necrosis factor secretion	J:189854
	impaired macrophage phagocytosis	J:189854
	increased CD8-positive, alpha-beta T cell number	J:105546
	increased marginal zone B cell number	J:105546
	increased susceptibility to bacterial infection	J:189854
\Siglec1^tm2.1Croc/\Siglec1^tm2.1Croc (B6.129P2(C)-Siglec1^tm2.1Croc)	decreased circulating interleukin-6 level	J:189854
	decreased circulating tumor necrosis factor level	J:189854
	decreased susceptibility to bacterial infection	J:189854
	impaired macrophage phagocytosis	J:189854
\Siglec15^tm1Yohi/\Siglec15^tm1Yohi (B6.129S6-Siglec15^tm1Yohi)	abnormal osteoclast differentiation	J:193852
\Siglece^{tm1.1(SIGLEC16)Avrk}/\Siglece^{tm1.1(SIGLEC16)Avrk} (involves: C57BL/6)	abnormal cytokine level	J:264224
	decreased susceptibility to bacterial infection	J:264224
	increased circulating interleukin-6 level	J:264224
	increased circulating interleukin-12 level	J:264224
\Siglece^tm1Arte/\Siglece^tm1Arte (involves: C57BL/6)	abnormal macrophage physiology	J:195429
\Siglece^tm1Arte/\Siglece^tm1Arte (involves: C57BL/6)	abnormal neutrophil physiology	J:195429
\Siglece^tm1Croc/\Siglece^tm1Croc (B6.129P2-Siglece^tm1Croc)	abnormal macrophage physiology	J:195429
	abnormal neutrophil physiology	J:195429
\Siglecf^tm1.2Avrk/\Siglecf^tm1.2Avrk (B6.129(FVB)-Siglecf^tm1.2Avrk)	abnormal eosinophil differentiation	J:204811
	abnormal eosinophil physiology	J:204811
	immune system phenotype	J:204811
	increased eosinophil cell number	J:204811
	lung inflammation	J:204811
\Siglecg^M1Btlr/\Siglecg^M1Btlr (C57BL/6J-Siglecg^M1Btlr)	increased B-1 B cell number	J:265179
\Siglecg^m2Btlr/\Siglecg^m2Btlr (C57BL/6J-Siglecg^m2Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:265183
	increased B-1 B cell number	J:265183
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:265183
\Siglecg^M3Btlr/\Siglecg^M3Btlr (C57BL/6J-Siglecg^M3Btlr)	decreased B-2 B cell number	J:265185
	decreased IgM level	J:265185
	increased B-1 B cell number	J:265185
	increased B-1a cell number	J:265185
\Siglecg^M4Btlr/\Siglecg^M4Btlr (C57BL/6J-Siglecg^M4Btlr)	increased B-1 B cell number	J:272021
\Siglecg^M5Btlr/\Siglecg^M5Btlr (C57BL/6J-Siglecg^M5Btlr)	increased B-1a cell number	J:272022
\Siglecg^tm1Lnit/\Siglecg^tm1Lnit (involves: BALB/c)	abnormal plasma cell differentiation	J:123353
	autoimmune response	J:123353
	decreased IgG2a level	J:123353
	increased B-1 B cell number	J:123353
	increased B-1a cell number	J:123353
	increased B-1b cell number	J:123353
	increased IgM level	J:123353
\Siglecg^tm1Yliu/\Siglecg^tm1Yliu (C57BL/6-Siglecg^tm1Yliu)	increased B-1a cell number	J:130017
	increased IgM level	J:130017
	increased pre-B cell number	J:130017
\Siglech^tm1.1Cfg/\Siglech^tm1.1Cfg (involves: C57BL/6)	immune system phenotype	J:214874
\Siglech^tm1.1Cfg/\Siglech^tm1.1Cfg (involves: C57BL/6)	increased T cell proliferation	J:217719
\Siglech^tm1.1Cln/\Siglech⁺ \Tg(CLEC4C-HBEGF)956Cln/0 (involves: C57BL/6)	decreased plasmacytoid dendritic cell number	J:166504
\Siglech^tm1.1Ksat/\Siglech^tm1.1Ksat (B6.Cg-Siglech^tm1.1Ksat)	abnormal circulating cytokine level	J:179283
	abnormal dendritic cell antigen presentation	J:179283
	abnormal plasmacytoid dendritic cell physiology	J:179283
	abnormal regulatory T cell morphology	J:179283
	decreased circulating interferon-alpha level	J:179283
	decreased circulating interleukin-12b level	J:179283
	decreased plasmacytoid dendritic cell number	J:179283
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:179283
	decreased susceptibility to infection induced morbidity/mortality	J:179283
	decreased T-helper 17 cell number	J:179283
	increased circulating interferon-alpha level	J:179283
	increased circulating interleukin-12b level	J:179283
	increased T-helper 17 cell number	J:179283
\Sik2^tm1Lex/\Sik2^tm1Lex (involves: 129S/SvEvBrd)	increased inflammatory response	J:229999
\Sik3^{tm1a(EUCOMM)Hmgu}/\Sik3^{tm1a(EUCOMM)Hmgu} (C57BL/6N-Sik3^{tm1a(EUCOMM)Hmgu}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD5-positive gamma-delta T cell number	J:211773
	decreased early germinal center B cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased gamma-delta T cell number	J:211773
	decreased germinal center B cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased KLRG1-positive T-helper cell number	J:211773
	decreased Ly6C-positive mature NK cell number	J:211773
	decreased memory-marker CD4-negative NK T cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK cell number	J:211773
	decreased NK T cell number	J:211773
	decreased regulatory T cell number	J:211773
	decreased T cell number	J:211773
	decreased T-helper cell number	J:211773
	increased CD4-negative NK T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased eosinophil cell number	J:211773
	increased follicular B cell number	J:211773
	increased granulocyte number	J:211773
	increased KLRG1+ CD8 alpha-beta T cell number	J:211773
	increased KLRG1-positive CD4-negative NK T cell number	J:211773
	increased KLRG1-positive CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased KLRG1-positive T-helper cell number	J:211773
	increased Ly6C-positive NK T cell number	J:211773
	increased memory-marker gamma-delta T cell number	J:211773
	increased memory-marker NK cell number	J:211773
	increased NK cell number	J:211773
	increased plasmacytoid dendritic cell number	J:211773
\Sin3b^tm1.2Rdp/\Sin3b^tm1.2Rdp (involves: 129 * C57BL/6 * FVB/N * SJL)	abnormal granulocyte differentiation	J:154855
	decreased granulocyte number	J:154855
\Sinhcaf^tm1.2Hmd/\Sinhcaf^tm1.2Hmd (involves: 129 * C57BL/6)	spleen hypoplasia	J:313620
\Sipa1^tm1Nm/\Sipa1⁺ (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:97239
\Sipa1^tm1Nm/\Sipa1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased leukocyte cell number	J:97239
\Sipa1^tm1Nm/\Sipa1^tm1Nm (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:97239
	increased granulocyte number	J:97239
	increased leukocyte cell number	J:97239
	spleen hyperplasia	J:97239
\Sirpa^{tm1b(EUCOMM)Hmgu}/\Sirpa^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sirpa^{tm1b(EUCOMM)Hmgu}/Bay)	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Sirpa^tm1Nog/\Sirpa^tm1Nog (involves: 129P2/OlaHsd * C57BL/6)	abnormal Langerhans cell physiology	J:88694
	abnormal macrophage physiology	J:79592
	decreased T cell number	J:79592
\Sirt1^{tm1b(EUCOMM)Wtsi}/\Sirt1⁺ (C57BL/6N-Sirt1^{tm1b(EUCOMM)Wtsi}/H)	increased basophil cell number	J:211773
\Sirt1^tm1Fwa/\Sirt1^tm1Fwa (involves: 129/Sv * 129S6/SvEvTac)	immune system phenotype	J:85542
\Sirt1^tm1Mcby/\Sirt1^tm1Mcby (involves: 129)	decreased CD8-positive, alpha-beta T cell number	J:81010
	interstitial pneumonia	J:81010
	lung inflammation	J:81010
\Sirt1^tm1Mcby/\Sirt1^tm1Mcby (involves: 129S1/Sv * 129X1/SvJ * CD-1)	decreased CD8-positive, alpha-beta T cell number	J:81010
	glomerulonephritis	J:160869
	increased anti-nuclear antigen antibody level	J:160869
	increased immunoglobulin level	J:160869
	interstitial pneumonia	J:81010
	lung inflammation	J:81010
\Sirt1^tm1Mcby/\Sirt1^tm1Mcby (involves: 129S1/Sv * 129X1/SvJ)	increased autoantibody level	J:241633
\Sirt1^tm2.1Mcby/\Sirt1^tm2.1Mcby (involves: 129S1/Sv * 129X1/SvJ * CD-1)	enlarged spleen	J:180628
\Sirt3^tm1.1Fwa/\Sirt3^tm1.1Fwa (involves: 129S6/SvEvTac)	abnormal cytokine level	J:178653
	increased circulating interferon-gamma level	J:178653
	increased circulating interleukin-6 level	J:178653
	increased circulating interleukin-10 level	J:178653
	increased circulating interleukin-12 level	J:178653
	increased circulating tumor necrosis factor level	J:178653
	liver inflammation	J:178653
\Sirt6^tm1Fwa/\Sirt6^tm1Fwa (involves: 129S6/SvEvTac * 129X1/SvJ)	abnormal B cell differentiation	J:112817
	abnormal lymphopoiesis	J:112817
	colitis	J:112817
	decreased double-positive T cell number	J:112817
	decreased leukocyte cell number	J:112817
	spleen hypoplasia	J:112817
\Sirt6^tm2.1Cxd/\Sirt6^tm2.1Cxd (involves: 129S6/SvEvTac * NIH Black Swiss)	abnormal spleen physiology	J:167023
\Sirt6^tm2.2Cxd/\Sirt6^tm2.2Cxd (involves: 129S6/SvEvTac * FVB/N * NIH Black Swiss)	abnormal spleen physiology	J:167023
\Sirt7^tm1Evbo/\Sirt7^tm1Evbo (involves: 129/Sv * C57BL/6)	abnormal cytokine level	J:147652
	increased granulocyte number	J:147652
	increased interleukin-4 secretion	J:147652
	increased interleukin-12 secretion	J:147652
	increased interleukin-13 secretion	J:147652
\Sirt7^tm1Fwa/\Sirt7^tm1Fwa (involves: 129S1/Sv)	increased macrophage cell number	J:205529
\Sirt7^tm1Fwa/\Sirt7^tm1Fwa (involves: 129S1/Sv)	liver inflammation	J:205529
\Sit1^tm1Lsmn/\Sit1^tm1Lsmn (B6.Cg-Sit1^tm1Lsmn)	abnormal cytokine secretion	J:100408
	abnormal lymphocyte cell number	J:100408
	abnormal T cell differentiation	J:100408
	abnormal T-helper 1 cell differentiation	J:100408
	decreased CD4-positive, alpha-beta T cell number	J:100408
	decreased CD8-positive, alpha-beta T cell number	J:100408
	increased double-positive T cell number	J:100408
	increased interferon-gamma secretion	J:100408
	increased interleukin-2 secretion	J:100408
	increased mature gamma-delta T cell number	J:100408
	increased susceptibility to experimental autoimmune encephalomyelitis	J:100408
	increased T cell proliferation	J:100408
	increased tumor necrosis factor secretion	J:100408
	lymph node hypoplasia	J:100408
	thymus hyperplasia	J:100408
\Sit1^tm1Lsmn/\Sit1^tm1Lsmn \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal CD8-positive, alpha beta T cell morphology	J:100408
	abnormal positive T cell selection	J:100408
	abnormal T cell differentiation	J:100408
\Sit1^tm1Lsmn/\Sit1^tm1Lsmn \Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6)	abnormal positive T cell selection	J:100408
	abnormal T cell selection	J:100408
	thymus hypoplasia	J:100408
\Six1^em1(IMPC)Mbp/\Six1⁺ (C57BL/6N-Six1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	decreased leukocyte cell number	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Six1^tm1Kwk/\Six1^tm1Kwk (involves: 129P2/OlaHsd * C57BL/6)	athymia	J:104488
\Six1^tm1Mair/\Six1^tm1Mair (involves: 129S2/SvPas)	athymia	J:84417
\Ska1^{em1(IMPC)Ccpcz}/\Ska1⁺ (C57BL/6NCrl-Ska1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Skap1^Gt713Lex/\Skap1^Gt713Lex (B6.129S5-Skap1^Gt713Lex)	abnormal CD4-positive, alpha-beta T cell physiology	J:126545
	abnormal immune system physiology	J:126545
	abnormal T cell physiology	J:126545
	decreased interferon-gamma secretion	J:126545
	decreased interleukin-2 secretion	J:126545
	decreased T cell proliferation	J:126545
	immune system phenotype	J:126545
\Skap2^{Gt(VICTR20)21Lex}/\Skap2^{Gt(VICTR20)21Lex} (B6.129S5-Skap2^{Gt(VICTR20)21Lex})	abnormal B cell activation	J:101373
	abnormal dendritic cell antigen presentation	J:151350
	abnormal dendritic cell physiology	J:151350
	decreased B cell proliferation	J:101373
	decreased IgG2a level	J:101373
	decreased IgM level	J:101373
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:101373
\Skic8^em1(IMPC)Tcp/\Skic8⁺ (C57BL/6NCrl-Skic8^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
\Skida1^{tm1.1(KOMP)Wtsi}/\Skida1⁺ (C57BL/6N-Skida1^{tm1.1(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Skida1^{tm1.1(KOMP)Wtsi}/\Skida1^{tm1.1(KOMP)Wtsi} (C57BL/6N-Skida1^{tm1.1(KOMP)Wtsi}/Ucd)	enlarged thymus	J:211773
	small spleen	J:211773
\Skil^tm1Sis/\Skil⁺ (involves: C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:62174
\Skil^tm1Spw/\Skil^tm1Spw (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal immune system cell morphology	J:84554
	abnormal immune system organ morphology	J:84554
	decreased T cell proliferation	J:84554
	enlarged spleen	J:84554
\Skil^tm2Spw/\Skil^tm2Spw (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	decreased T cell proliferation	J:84554
	immune system phenotype	J:84554
\Skint1^m1Tac/\Skint1^m1Tac (FVB/NTac)	abnormal T cell differentiation	J:139711
\Skint1^m1Tac/\Skint1^m1Tac (FVB/NTac)	abnormal T cell morphology	J:139711
\Skint2^em2Htaka/\Skint2^em2Htaka (C57BL/6-Skint2^em2Htaka)	decreased dendritic epidermal T cell number	J:291989
\skp/\skp (CXB5/ByJ-skp/GrsrJ)	thymus atrophy	J:153578
\Skp2^tm1Kin/\Skp2^tm1Kin (involves: 129P2/OlaHsd)	abnormal immunoglobulin V(D)J recombination	J:168974
\Sla2^{em1(IMPC)Ccpcz}/\Sla2^{em1(IMPC)Ccpcz} (C57BL/6N-Sla2^{em1(IMPC)Ccpcz}/Ccpcz)	decreased NK cell number	J:211773
\Sla2^tm1Amch/\Sla2^tm1Amch (involves: 129)	immune system phenotype	J:169170
\Sla^tm1Weis/\Sla^tm1Weis (involves: 129 * C57BL/6)	abnormal double-positive T cell morphology	J:71804
\Sla^tm1Weis/\Sla^tm1Weis \Sla2^tm1Amch/\Sla2^tm1Amch (involves: 129)	abnormal dendritic cell differentiation	J:169170
	abnormal dendritic cell physiology	J:169170
	decreased interleukin-12 secretion	J:169170
	decreased tumor necrosis factor secretion	J:169170
\Sla^tm1Weis/\Sla^tm1Weis \Tg(DO11.10)10Dlo/0 (involves: 129 * BALB/c * C3H * C57BL/6)	abnormal positive T cell selection	J:71804
	abnormal T cell differentiation	J:71804
\Sla^tm1Weis/\Sla^tm1Weis \Zap70^tm1Weis/\Zap70^tm1Weis (involves: 129 * 129X1/SvJ * C57BL/6)	abnormal T cell differentiation	J:71804
	decreased CD4-positive, alpha-beta T cell number	J:71804
\Slamf1^tm1Cpt/\Slamf1^tm1Cpt (B6.129S4-Slamf1^tm1Cpt)	abnormal cytokine secretion	J:90484
	abnormal macrophage physiology	J:90484
	increased susceptibility to parasitic infection	J:90484
\Slamf1^tm1Cpt/\Slamf1^tm1Cpt (C.129S4-Slamf1^tm1Cpt)	abnormal cytokine secretion	J:90484
\Slamf1^tm1Cpt/\Slamf1^tm1Cpt (C.129S4-Slamf1^tm1Cpt)	abnormal macrophage physiology	J:90484
\Slamf1^tm1Cpt/\Slamf1^tm1Cpt \Tg(DO11.10)10Dlo/\Tg(DO11.10)10Dlo (involves: BALB/c * C3H * C57BL/6)	abnormal cytokine secretion	J:90484
\Slamf1^tm1Oono/\Slamf1^tm1Oono (B6.129-Slamf1^tm1Oono)	increased susceptibility to Paramyxoviridae infection	J:117810
\Slamf1^tm1Vei/\Slamf1^tm1Vei (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:133047, J:93886
\Slamf1^tm1Vei/\Slamf1^tm1Vei (involves: 129 * C57BL/6)	immune system phenotype	J:133047
\Slamf6^tm1Dhow/\Slamf6^tm1Dhow (involves: 129/Sv * C57BL/6)	abnormal neutrophil physiology	J:98995
	abnormal T-helper 2 physiology	J:98995
	decreased interleukin-4 secretion	J:98995
	decreased susceptibility to parasitic infection	J:98995
	impaired granulocyte bactericidal activity	J:98995
	increased circulating interleukin-12b level	J:98995
	increased circulating interleukin-16 level	J:98995
	increased circulating tumor necrosis factor level	J:98995
	increased susceptibility to bacterial infection	J:98995
	increased susceptibility to bacterial infection induced morbidity/mortality	J:98995
\Slamf6^tm1Lex/\Slamf6^tm1Lex (B6.129S5-Slamf6^tm1Lex)	immune system phenotype	J:187429
\Slamf6^tm1Pls/\Slamf6^tm1Pls \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * C57BL/6J)	immune system phenotype	J:187431
\Slamf7^tm1Vei/\Slamf7^tm1Vei (involves: 129S1/Sv * 129X1/SvJ)	impaired natural killer cell mediated cytotoxicity	J:145969
\Slamf8^tm1Mill/\Slamf8^tm1Mill (involves: BALB/c)	abnormal macrophage physiology	J:188963
\Slamf8^tm1Mill/\Slamf8^tm1Mill (involves: BALB/c)	increased susceptibility to bacterial infection	J:188963
\Slamf9^em1Isha/\Slamf9^em1Isha (involves: C57BL/6)	abnormal plasmacytoid dendritic cell physiology	J:279164
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:279164
	increased plasmacytoid dendritic cell number	J:279164
\Slc1a5^tm1Tac/\Slc1a5^tm1Tac (involves: 129S/SvEv * C57BL/6)	abnormal T cell physiology	J:254980
	abnormal T-helper 1 cell differentiation	J:254980
	abnormal T-helper 2 cell differentiation	J:254980
	abnormal T-helper 17 cell differentiation	J:254980
	decreased B cell number	J:254980
	decreased CD4-positive, alpha-beta memory T cell number	J:254980
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:254980
	decreased T helper 1 cell number	J:254980
	decreased T-helper 17 cell number	J:254980
	immune system phenotype	J:254980
	increased CD4-positive, alpha-beta T cell number	J:254980
\Slc2a4^tm1Mch/\Slc2a4⁺ (involves: 129/Sv * C57BL/6J * CD-1 * SJL)	heart inflammation	J:43650
\Slc2a5^{tm1b(EUCOMM)Wtsi}/\Slc2a5^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Slc2a5^{tm1b(EUCOMM)Wtsi}/Ieg)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Slc2a6^em1Kusu/\Slc2a6^em1Kusu (involves: C57BL/6JCrlj)	abnormal macrophage physiology	J:270487
	increased circulating tumor necrosis factor level	J:270487
	increased susceptibility to endotoxin shock	J:270487
\Slc2a9^tm1.2Thor/\Slc2a9^tm1.2Thor (involves: C57BL/6 * C57BL/6N)	kidney inflammation	J:153089
	tubulointerstitial nephritis	J:153089
\Slc2a10^G128E/\Slc2a10^G128E (C3HeB/FeJ-Slc2a10^G128E)	abnormal spleen morphology	J:161835
\Slc3a1^pbl/\Slc3a1^pbl (C3HeB/FeJ-Slc3a1^pbl)	tubulointerstitial nephritis	J:85461
\Slc3a1^pbl/\Slc3a1^pbl (involves: C3HeB/FeJ * MRL/MpJ)	kidney inflammation	J:85461
\Slc3a1^{tm1.1(KOMP)Vlcg}/\Slc3a1^{tm1.1(KOMP)Vlcg} (C57BL/6N-Slc3a1^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
	increased spleen weight	J:211773
\Slc3a2^tm1.1Merl/\Slc3a2⁺ \Tg(Vil1-cre)997Gum/0 (B6.Cg-Slc3a2^tm1.1Merl Tg(Vil1-cre)997Gum)	decreased susceptibility to induced colitis	J:173946
\Slc3a2^tm1.1Yait/\Slc3a2^tm1.1Yait \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6NCrSlc)	abnormal macrophage antigen presentation	J:188365
	abnormal macrophage differentiation	J:188365
	abnormal macrophage morphology	J:188365
	abnormal macrophage physiology	J:188365
	impaired macrophage phagocytosis	J:188365
\Slc4a1^tm1Ahc/\Slc4a1^tm1Ahc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal immune system organ morphology	J:35637
	enlarged spleen	J:35637
\Slc4a1^tm1Dmb/\Slc4a1^tm1Dmb (involves: 129S6/SvEvTac)	abnormal splenic cell ratio	J:145243
\Slc4a1^tm1Llp/\Slc4a1^tm1Llp (involves: 129S4/SvJae * C57BL/6J)	enlarged spleen	J:35487
\Slc4a1^tm1Phsl/\Slc4a1^tm1Phsl (involves: 129 * 129S6/SvEvTac * Black Swiss)	enlarged spleen	J:152245
\Slc4a2^tm1Ges/\Slc4a2^tm1Ges (involves: 129S6/SvEvTac)	abnormal osteoclast morphology	J:193823
\Slc4a2^tm1Ges/\Slc4a2^tm1Ges (involves: 129S6/SvEvTac)	abnormal osteoclast physiology	J:193823
\Slc4a2^tm2Ges/\Slc4a2^tm2Ges \Ctsk^tm1(cre)Ska/\Ctsk⁺ (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal osteoclast morphology	J:193823
	abnormal osteoclast physiology	J:193823
\Slc4a2^tm2Ges/\Slc4a2^tm2Ges \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal osteoclast morphology	J:193823
	abnormal osteoclast physiology	J:193823
\Slc4a4^tm1.1Slin/\Slc4a4^tm1.1Slin (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	enlarged spleen	J:186877
	increased spleen weight	J:186877
\Slc4a4^tm1Ges/\Slc4a4^tm1Ges (involves: 129S6/SvEvTac * Black Swiss)	decreased lymphocyte cell number	J:120867
	disorganized spleen B cell follicle	J:120867
	enlarged spleen	J:120867
	increased spleen red pulp amount	J:120867
	increased spleen white pulp amount	J:120867
\Slc4a10^{tm1b(KOMP)Wtsi}/\Slc4a10^{tm1b(KOMP)Wtsi} (C57BL/6N-Slc4a10^{tm1b(KOMP)Wtsi}/H)	small spleen	J:211773
\Slc5a2^m2Btlr/\Slc5a2^m2Btlr (C57BL/6J-Slc5a2^m2Btlr)	increased susceptibility to induced colitis	J:265117
\Slc5a2^m2Btlr/\Slc5a2^m2Btlr (C57BL/6J-Slc5a2^m2Btlr)	increased tumor necrosis factor secretion	J:265117
\Slc5a2^tm1Lex/\Slc5a2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased susceptibility to autoimmune diabetes	J:195941
\Slc5a6^tm1.1Said/\Slc5a6^tm1.1Said \Tg(Vil1-cre)997Gum/? (involves: C57BL/6)	immune system phenotype	J:194700
\Slc5a6^tm1.1Said/\Slc5a6^tm1.1Said \Tg(Vil1-cre/ERT2)23Syr/0 (involves: C57BL/6 * DBA/2)	cecum inflammation	J:307482
	small intestinal inflammation	J:307482
\Slc5a7^{tm1a(KOMP)Wtsi}/\Slc5a7^{tm1a(KOMP)Wtsi} (C57BL/6N-Slc5a7^{tm1a(KOMP)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Slc6a6^em1(IMPC)Mbp/\Slc6a6^em1(IMPC)Mbp (C57BL/6N-Slc6a6^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
\Slc6a8^tm1.2Lbar/Y (involves: 129 * 129S1/Sv * C57BL/6J * C57BL/6N)	microgliosis	J:238578
\Slc6a14^tm1Gana/\Slc6a14^tm1Gana (Not Specified)	abnormal circulating chemokine level	J:226105
	abnormal circulating cytokine level	J:226105
	decreased circulating interleukin-1 alpha level	J:226105
	decreased circulating interleukin-4 level	J:226105
\Slc6a14^tm1Gana/\Slc6a14^tm1Gana \Tg(MMTV-PyVT)634Mul/0 (Not Specified)	abnormal immunoglobulin level	J:226105
\Slc7a2^tm1Clm/\Slc7a2^tm1Clm (involves: 129S7/SvEvBrd * C57BL/6)	abnormal immune system physiology	J:69414
\Slc7a5^em1(IMPC)H/\Slc7a5⁺ (C57BL/6NTac-Slc7a5^em1(IMPC)H/H)	increased basophil cell number	J:211773
\Slc7a7^em1Lbu/\Slc7a7^em1Lbu (involves: 129/SvEv * C57BL/6)	abnormal spleen germinal center morphology	J:293773
	decreased lymphocyte cell number	J:293773
	decreased spleen weight	J:293773
	increased neutrophil cell number	J:293773
	increased spleen red pulp amount	J:293773
\Slc7a7^{Gt(OST41878)Lex}/\Slc7a7^{Gt(OST41878)Lex} (B6.129S-Slc7a7^{Gt(OST41878)Lex})	increased spleen weight	J:125847
\Slc7a9^tm1Nune/\Slc7a9^tm1Nune (involves: 129P2/OlaHsd * C57BL/6J)	tubulointerstitial nephritis	J:85462
\Slc7a11^m1Mtka/\Slc7a11^m1Mtka (C57BL/6-Slc7a11^m1Mtka)	abnormal dendritic cell physiology	J:159323
	abnormal macrophage physiology	J:159323
	immune system phenotype	J:159323
\Slc9a2^tm1Ges/\Slc9a2^tm1Ges (involves: 129X1/SvJ * Black Swiss)	stomach inflammation	J:65754
\Slc9a4^tm1Ges/\Slc9a4^tm1Ges (involves: 129S6/SvEvTac * Black Swiss)	stomach inflammation	J:98566
\Slc9a6^tm1Dgen/Y (B6.129P2-Slc9a6^tm1Dgen/J)	microgliosis	J:262453
\Slc9a8^m1Btlr/\Slc9a8^m1Btlr (C57BL/6J-Slc9a8^m1Btlr)	increased susceptibility to induced colitis	J:267481
\Slc9b1^em1(IMPC)Mbp/\Slc9b1^em1(IMPC)Mbp (C57BL/6N-Slc9b1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Slc11a1^em1(IMPC)Mbp/\Slc11a1^em1(IMPC)Mbp (C57BL/6N-Slc11a1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Slc11a1^r/\Slc11a1^r (C3H/HeJ-Slc11a1^r)	decreased susceptibility to bacterial infection	J:35004
\Slc11a1^r/\Slc11a1^r (129/Sv)	decreased susceptibility to bacterial infection	J:81412
\Slc11a1^r/\Slc11a1^s ((129/Sv x BALB/c)F1)	decreased susceptibility to bacterial infection	J:28278
\Slc11a1^s/\Slc11a1^r ((129/Sv x C57BL/6J)F1)	abnormal susceptibility to bacterial infection	J:81412
\Slc11a1^s/\Slc11a1^s (C57BL/6J)	increased susceptibility to bacterial infection	J:81412
\Slc11a1^s/\Slc11a1^s (BALB/c)	increased susceptibility to bacterial infection	J:28278
\Slc11a1^tm1Mcg/\Slc11a1^s (involves: 129S4/SvJae * BALB/c)	increased susceptibility to bacterial infection	J:28278
\Slc11a1^tm1Mcg/\Slc11a1^tm1Mcg (involves: 129S4/SvJae * BALB/c)	increased susceptibility to bacterial infection	J:28278
\Slc11a2^mk/\Slc11a2^mk (MK/ReJ)	increased spleen weight	J:5167
\Slc11a2^mk/\Slc11a2^mk (SEC.Cg-Slc11a2^mk)	increased spleen weight	J:5167
\Slc11a2^tm2Nca/\Slc11a2^tm2Nca \Tg(Vil1-cre)20Syr/? (involves: 129S6.129S4-Slc11a2^tm2Nca * C57BL/6 * DBA/2)	abnormal spleen morphology	J:98088
	decreased spleen iron level	J:98088
	enlarged spleen	J:98088
	increased spleen red pulp amount	J:98088
\Slc12a1^urehr3/\Slc12a1^urehr3 (involves: C3HeB/FeJ)	pyelitis	J:159994
\Slc12a1^urehr3/\Slc12a1^urehr3 (involves: C3HeB/FeJ)	pyelonephritis	J:159994
\Slc12a2^em1Dlp/\Slc12a2⁺ (involves: C57BL/6J * DBA/2J)	increased susceptibility to bacterial infection	J:285398
\Slc12a2^em1Dlp/\Slc12a2^em1Dlp (involves: C57BL/6J * DBA/2J)	increased lymphocyte cell number	J:285398
	increased susceptibility to bacterial infection	J:285398
	large intestinal inflammation	J:285398
\Slc12a5^em1(IMPC)Mbp/\Slc12a5⁺ (C57BL/6N-Slc12a5^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Slc13a3^{tm1b(KOMP)Wtsi}/\Slc13a3^{tm1b(KOMP)Wtsi} (C57BL/6N-Slc13a3^{tm1b(KOMP)Wtsi}/Ucd)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Slc13a5^{tm1b(EUCOMM)Hmgu}/\Slc13a5^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Slc13a5^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Slc14a1^tm1Ask/\Slc14a1^tm1Ask (involves: C57BL/6J * CD-1)	decreased spleen weight	J:125840
\Slc15a1^{em1(IMPC)Ccpcz}/\Slc15a1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Slc15a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Slc15a3^{tm1a(KOMP)Wtsi}/\Slc15a3^{tm1a(KOMP)Wtsi} (C57BL/6N-Slc15a3^{tm1a(KOMP)Wtsi})	abnormal myeloid dendritic cell morphology	J:210445
\Slc15a3^{tm1b(KOMP)Wtsi}/\Slc15a3^{tm1b(KOMP)Wtsi} (C57BL/6N-Slc15a3^{tm1b(KOMP)Wtsi}/H)	increased monocyte cell number	J:211773
\Slc15a4^m1Btlr/\Slc15a4^m1Btlr (C57BL/6J-Slc15a4^m1Btlr)	abnormal interferon secretion	J:166600
	decreased interleukin-6 secretion	J:166600
	decreased interleukin-12 secretion	J:166600
	decreased tumor necrosis factor secretion	J:166600
\Slc15a4^tm1Tkyo/\Slc15a4^tm1Tkyo (involves: C57BL/6)	abnormal circulating cytokine level	J:270965
	abnormal cytokine secretion	J:270965
	decreased circulating interleukin-1 beta level	J:270965
	decreased circulating interleukin-6 level	J:270965
	decreased interferon-beta secretion	J:270965
	decreased interleukin-1 beta secretion	J:270965
	decreased interleukin-6 secretion	J:270965
	decreased interleukin-12 secretion	J:270965
	decreased interleukin-12b secretion	J:270965
	decreased interleukin-15 secretion	J:270965
	decreased interleukin-18 secretion	J:270965
	decreased susceptibility to induced colitis	J:270965
	decreased tumor necrosis factor secretion	J:270965
\Slc17a1^em1(IMPC)J/\Slc17a1^em1(IMPC)J (C57BL/6NJ-Slc17a1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Slc17a8^em1(IMPC)Mbp/\Slc17a8^em1(IMPC)Mbp (C57BL/6N-Slc17a8^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Slc19a1^tm1Gold/\Slc19a1^tm1Gold (involves: 129/Sv * C57BL/6 * SJL)	abnormal lymphopoiesis	J:68666
	decreased lymphocyte cell number	J:68666
	small spleen	J:68666
	small thymus	J:68666
\Slc19a2^tm1Gelb/\Slc19a2^tm1Gelb (involves: 129X1/SvJ)	abnormal myelopoiesis	J:79974
\Slc19a3^tm1Said/\Slc19a3^tm1Said (involves: C57BL/6)	chronic liver inflammation	J:170952
\Slc19a3^tm1Said/\Slc19a3^tm1Said (involves: C57BL/6)	kidney inflammation	J:170952
\Slc20a1^tm1.1Lbek/\Slc20a1^tm1.1Lbek \Tg(Mx1-cre)1Cgn/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/6J * CBA)	enlarged spleen	J:194198
	increased leukocyte cell number	J:194198
	intermingled spleen red and white pulp	J:194198
	spleen hyperplasia	J:194198
\Slc20a1^tm1Lbek/\Slc20a1^tm1Lbek (involves: 129S2/SvPas * C57BL/6J)	abnormal spleen morphology	J:194198
	enlarged spleen	J:194198
	increased spleen weight	J:157997
\Slc20a2^{tm1a(EUCOMM)Wtsi}/\Slc20a2^{tm1a(EUCOMM)Wtsi} (C57BL/6NTac-Slc20a2^{tm1a(EUCOMM)Wtsi}/Ieg)	microgliosis	J:223197
\Slc22a4^tm1Atsu/\Slc22a4^tm1Atsu (involves: C57BL/6J)	intestinal inflammation	J:207006
\Slc22a6^tm1Dgen/\Slc22a6^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	increased thymus weight	J:101679
\Slc22a7^em1(IMPC)Tcp/\Slc22a7^em1(IMPC)Tcp (C57BL/6NCrl-Slc22a7^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Slc22a29^em1(IMPC)Mbp/\Slc22a29^em1(IMPC)Mbp (C57BL/6N-Slc22a29^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Slc23a4^{tm1a(KOMP)Wtsi}/\Slc23a4^{tm1a(KOMP)Wtsi} (C57BL/6N-2010107G12Rik^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Slc24a3^em#Ebje/\Slc24a3^em#Ebje (C57BL/6J-Slc24a3^em#Ebje)	increased susceptibility to induced colitis	J:308448
\Slc24a4^{tm1b(KOMP)Wtsi}/\Slc24a4⁺ (C57BL/6N-Slc24a4^{tm1b(KOMP)Wtsi}/H)	enlarged thymus	J:211773
\Slc25a17^Gt(XB686)Byg/\Slc25a17^Gt(XB686)Byg (involves: 129P2/OlaHsd * C57BL/6 * Swiss Webster)	abnormal Kupffer cell morphology	J:291257
	liver inflammation	J:291257
\Slc25a37^tm1.1Kapl/\Slc25a37^tm1.2Kapl \Speer6-ps1^{Tg(Alb-cre)21Mgn}/? (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * DBA)	enlarged spleen	J:173284
\Slc25a37^tm1.1Kapl/\Slc25a37^tm1.2Kapl \Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * CBA)	abnormal B cell morphology	J:173284
	abnormal lymphocyte morphology	J:173284
	abnormal spleen morphology	J:173284
	abnormal T cell morphology	J:173284
	enlarged spleen	J:173284
\Slc25a42^em1(IMPC)J/\Slc25a42⁺ (C57BL/6NJ-Slc25a42^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Slc25a46^atc/\Slc25a46^atc (B6.Cg-Slc25a46^atc)	decreased spleen weight	J:242350
	decreased thymus weight	J:242350
	microgliosis	J:242350
	spleen hypoplasia	J:242350
	thymus hypoplasia	J:242350
\Slc26a1^tm1Mark/\Slc26a1^tm1Mark (involves: 129X1/SvJ * CD-1)	kidney inflammation	J:158567
\Slc26a4^m2Btlr/\Slc26a4^m2Btlr (C57BL/6J-Slc26a4^m2Btlr)	increased susceptibility to induced colitis	J:236690
\Slc28a3^em1(IMPC)H/\Slc28a3^em1(IMPC)H (C57BL/6N-Slc28a3^em1(IMPC)H/H)	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
\Slc29a1^tm2Msg/\Slc29a1^tm2Msg \Epor^{tm1.1(EGFP/icre)Uk}/\Epor⁺ (involves: 129X1/SvJ * BALB/cJ)	decreased interleukin-6 secretion	J:244602
\Slc29a2^{Gt(OST207791)Lex}/\Slc29a2^{Gt(OST207791)Lex} (involves: 129S5/SvEvBrd)	decreased interleukin-6 secretion	J:203572
\Slc29a3^em1(IMPC)Mbp/\Slc29a3^em1(IMPC)Mbp (C57BL/6NCrl-Slc29a3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased spleen weight	J:211773
	small thymus	J:211773
\Slc29a3^{em1(IMPC)Wtsi}/\Slc29a3^{em1(IMPC)Wtsi} (C57BL/6N-Slc29a3^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Slc29a3^tm1Lex/\Slc29a3^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal macrophage morphology	J:179286
	abnormal macrophage physiology	J:179286
	enlarged lymph nodes	J:179286
	enlarged spleen	J:179286
	immune system phenotype	J:179286
	increased macrophage apoptosis	J:179286
	increased macrophage cell number	J:179286
	increased susceptibility to bacterial infection	J:179286
	increased susceptibility to bacterial infection induced morbidity/mortality	J:179286
	myeloid hyperplasia	J:179286
\Slc30a2^tm1Kgna/\Slc30a2^tm1Kgna (involves: 129 * C57BL/6)	abnormal macrophage physiology	J:264481
\Slc30a4^em1(IMPC)Tcp/\Slc30a4^em1(IMPC)Tcp (C57BL/6NCrl-Slc30a4^em1(IMPC)Tcp/Tcp)	small thymus	J:211773
\Slc30a4^lm/\Slc30a4^lm (C57BL/6J-Slc30a4^lm)	dermatitis	J:5911, J:7690
\Slc31a1^tm2Djt/\Slc31a1^tm2Djt \Tg(Vil1-cre)997Gum/0 (involves: 129 * C57BL/6 * FVB/N * SJL)	decreased spleen weight	J:129741
\Slc33a1^tm1.1Lpu/\Slc33a1⁺ (involves: 129S7/SvEvBrd * C57BL/6)	abnormal circulating cytokine level	J:211266
	abnormal cytokine secretion	J:211266
	abnormal T cell activation	J:211266
	brain inflammation	J:211266
	conjunctivitis	J:211266
	decreased B cell number	J:211266
	dermatitis	J:211266
	immune system phenotype	J:211266
	increased B cell number	J:211266
	increased circulating interleukin-17 level	J:211266
	increased circulating interleukin-18 level	J:211266
	increased inflammatory response	J:211266
	increased interferon-gamma secretion	J:211266
	increased interleukin-4 secretion	J:211266
	increased interleukin-17 secretion	J:211266
	increased neutrophil cell number	J:211266
	increased susceptibility to infection	J:211266
	microgliosis	J:211266
	preputial gland inflammation	J:211266
	prostate gland inflammation	J:211266
	salivary gland inflammation	J:211266
	stomach inflammation	J:211266
	urinary bladder inflammation	J:211266
\Slc35c1^tm1Cknr/\Slc35c1^tm1Cknr (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal leukocyte adhesion	J:121151
	abnormal lymph node primary follicle morphology	J:121151
	impaired leukocyte tethering or rolling	J:121151
	increased eosinophil cell number	J:121151
	increased leukocyte cell number	J:121151
	increased lymphocyte cell number	J:121151
	increased monocyte cell number	J:121151
	increased neutrophil cell number	J:121151
	lymph node hypoplasia	J:121151
\Slc37a2^em1(IMPC)Mbp/\Slc37a2^em1(IMPC)Mbp (C57BL/6NCrl-Slc37a2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
\Slc37a2^tm1Dgen/\Slc37a2^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6J)	abnormal macrophage physiology	J:311521
	increased interleukin-1 beta secretion	J:311521
	increased interleukin-6 secretion	J:311521
	increased susceptibility to endotoxin shock	J:311521
	increased tumor necrosis factor secretion	J:311521
\Slc37a4^tm1Jyc/\Slc37a4^tm1Jyc (involves: 129S4/SvJae * C57BL/6)	abnormal chemokine secretion	J:86005
	abnormal inflammatory response	J:86005
	abnormal myelopoiesis	J:86005
	abnormal neutrophil physiology	J:86005
	abnormal spleen morphology	J:86005
	absent spleen white pulp	J:86005
	decreased inflammatory response	J:86005
	decreased lymphocyte cell number	J:86005
	decreased neutrophil cell number	J:86005
	impaired neutrophil chemotaxis	J:86005
	small spleen	J:86005
\Slc38a2^{tm1a(KOMP)Wtsi}/\Slc38a2⁺ (C57BL/6N-Slc38a2^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Slc38a7^{em1(IMPC)Ccpcz}/\Slc38a7^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Slc38a7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Slc38a8^em1Cya/\Slc38a8^em1Cya (C57BL/6J-Slc38a8^em1Cya)	decreased susceptibility to viral infection	J:336781
\Slc38a8^em1Cya/\Slc38a8^em1Cya (C57BL/6J-Slc38a8^em1Cya)	decreased susceptibility to viral infection induced morbidity/mortality	J:336781
\Slc39a3^tm1Gka/\Slc39a3^tm1Gka (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:99161
	decreased double-positive T cell number	J:99161
	increased CD4-positive, alpha-beta T cell number	J:99161
\Slc39a5^tm1.1Gka/\Slc39a5^tm1.1Gka (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	increased susceptibility to induced pancreatitis	J:209760
\Slc39a5^tm1Gka/\Slc39a5^tm1Gka \Tg(Cela1-cre/ERT)1Lgdn/0 (involves: 129P2/OlaHsd * C57BL/6)	increased susceptibility to induced pancreatitis	J:209760
\Slc39a10^tm1.1Tfk/\Slc39a10^tm1.1Tfk \Tg(Foxn1-cre)8Ghr/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	increased thymocyte apoptosis	J:254216
	thymus hypoplasia	J:254216
\Slc40a1^ffe/\Slc40a1⁺ (either: (involves: 129X1/SvJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6J))	abnormal macrophage physiology	J:118592
\Slc40a1^Pcm/\Slc40a1⁺ (A.Cg-Slc40a1^Pcm)	abnormal spleen development	J:98335
	abnormal spleen physiology	J:98335
	decreased spleen iron level	J:98335
	increased splenocyte apoptosis	J:98335
	small spleen	J:98335
\Slc40a1^Pcm/\Slc40a1^Pcm (A.Cg-Slc40a1^Pcm)	abnormal spleen development	J:98335
	decreased spleen iron level	J:98335
	increased splenocyte apoptosis	J:98335
	small spleen	J:98335
\Slc40a1^tm1.1Mmfe/\Slc40a1⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen iron level	J:215585
\Slc40a1^tm1.1Mmfe/\Slc40a1^tm1.1Mmfe (involves: 129P2/OlaHsd * C57BL/6)	decreased spleen iron level	J:215585
\Slc40a1^tm1Nca/\Slc40a1⁺ (involves: 129S4/SvJae * 129S6/SvEvTac)	increased spleen iron level	J:129846
\Slc40a1^tm2Nca/\Slc40a1^tm2Nca \Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2)	decreased spleen iron level	J:129846
\Slc43a2^{Gt(258C1)Cmhd}/\Slc43a2^{Gt(258C1)Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	liver inflammation	J:237439
\Slc44a4^tm1.2Said/\Slc44a4^tm1.2Said (involves: BALB/cJ * C57BL/6J * C57BL/6N)	increased susceptibility to induced colitis	J:351314
\Slc46a2^tm1Moki/\Slc46a2^tm1Moki (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	thymus hypoplasia	J:140121
\Slc48a1^em1Ih/\Slc48a1^em1Ih (involves: 129 * C57BL/6J)	abnormal macrophage morphology	J:282829
	abnormal macrophage physiology	J:282829
	dark spleen	J:282829
	decreased macrophage cell number	J:282829
	enlarged spleen	J:282829
	increased spleen iron level	J:282829
\Slc51b^em1(IMPC)Mbp/\Slc51b^em1(IMPC)Mbp (C57BL/6NCrl-Slc51b^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Slc52a2^{tm1.1(KOMP)Vlcg}/\Slc52a2⁺ (C57BL/6N-Slc52a2^{tm1.1(KOMP)Vlcg}/Ucd)	enlarged lymph nodes	J:211773
\Slco1a5^tm1Lex/\Slco1a5^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	abnormal CD8-positive, alpha beta T cell morphology	J:103485
	increased B cell number	J:103485
\Slco4c1^{em1(IMPC)Ccpcz}/\Slco4c1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Slco4c1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Sle1^NZM2410/Aeg/\Sle1^NZM2410/Aeg \Sle3^NZM2410/Aeg/\Sle3^NZM2410/Aeg (B6;NZM-Sle1^NZM2410/Aeg Sle2^NZM2410/Aeg Sle3^NZM2410/Aeg/LmoJ)	abnormal marginal zone B cell physiology	J:138314
	increased marginal zone B cell number	J:138314
\Sle1^NZW/\Sle1^NZW \Sles1^NZW/\Sles1^NZW (involves: C57BL/6 * NZW)	abnormal T cell physiology	J:100678
	decreased susceptibility to systemic lupus erythematosus	J:100678
\Sle1^NZW/\Sle1^NZW \Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6 * DBA/2J * NZW)	glomerulonephritis	J:134128
	increased B cell number	J:134128
	increased IgG level	J:134128
	increased IgM level	J:134128
	increased marginal zone B cell number	J:134128
	increased susceptibility to systemic lupus erythematosus	J:134128
\Sle1a^C57BL/6J/\Sle1a^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
\Sle1a^NZM2410/J/\Sle1a^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
\Sle1b^C57BL/6J/\Sle1b^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
\Sle1b^NZM2410/J/\Sle1b^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
\Sle1c^C57BL/6J/\Sle1c^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
\Sle1c^NZB/\Sle1c^NZM2410/J (involves: C57BL/6J * NZB * NZM2410/J)	glomerulonephritis	J:145133
	increased autoantibody level	J:145133
\Sle1c^NZM2410/J/\Sle1c^NZM2410/J (involves: C57BL/6J * NZM2410/J)	increased anti-chromatin antibody level	J:67544
\Sle2^NZM2410/Aeg/\Sle2^NZM2410/Aeg (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:25006
\Sle3^NZM2410/Aeg/? (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
	increased IgG level	J:52863
	increased IgM level	J:52863
\Sle6^NZW/\Sle6^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sle7^BXSB/J/\Sle7^BXSB/J (involves: BXSB/J * C57BL/10Ola)	glomerulonephritis	J:60445
\Sle8^BXSB/J/\Sle8^BXSB/J (involves: BXSB/J * C57BL/10Ola)	glomerulonephritis	J:60445
\Sle9^BXSB/J/\Sle9^BXSB/J (involves: BXSB/J * C57BL/10Ola)	increased anti-nuclear antigen antibody level	J:60445
\Sle10^BXSB/J/\Sle10^BXSB/J (involves: BXSB/J * C57BL/10Ola)	enlarged lymph nodes	J:60445
\Sle11^BXSB/J/\Sle11^BXSB/J (involves: BXSB/J * C57BL/10Ola)	increased IgG3 level	J:60445
\Sle12^C57BL/6J/\Sle12^C57BL/6J (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
\Sle12^C57BL/6J/\Sle12^NZM2410/Aeg (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
\Sle12^NZM2410/Aeg/\Sle12^NZM2410/Aeg (involves: C57BL/6J * NZM2410/Aeg)	glomerulonephritis	J:52863
\Sle16^{129S6/SvEvTac}/? (involves: 129X1/Sv * C57BL/6)	abnormal immune serum protein physiology	J:93297
\Sle16^{129S6/SvEvTac}/\Sle16^{129S6/SvEvTac} (B6.129-Sle16^{129S6/SvEvTac})	increased autoantibody level	J:122132
	increased susceptibility to systemic lupus erythematosus	J:122132
\Sle17^{129S6/SvEvTac}/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune serum protein physiology	J:93297
\Sle18^C57BL/6/? (involves: 129X1/Sv * C57BL/6)	abnormal immune serum protein physiology	J:93297
\Sles1^C57BL/6/\Sles1^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sles1^C57BL/6/\Sles1^NZW (involves: C57BL/6 * NZW)	abnormal immune system physiology	J:57246
\Sles1^NZW/\Sles1^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
\Sles2^C57BL/6/\Sles2^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sles2^C57BL/6/\Sles2^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sles2^NZW/\Sles2^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
\Sles3^C57BL/6/\Sles3^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sles3^C57BL/6/\Sles3^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sles3^NZW/\Sles3^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
\Sles4^C57BL/6/\Sles4^C57BL/6 (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sles4^C57BL/6/\Sles4^NZW (involves: C57BL/6 * NZW)	increased susceptibility to systemic lupus erythematosus	J:57246
\Sles4^NZW/\Sles4^NZW (involves: C57BL/6 * NZW)	decreased susceptibility to systemic lupus erythematosus	J:57246
\Slfn1^tm1Aki/\Slfn1^tm1Aki (Not Specified)	immune system phenotype	J:158985, J:258797
\Slfn2^m1Btlr/\Slfn2^m1Btlr (C57BL/6J-Slfn2^m1Btlr)	abnormal leukocyte physiology	J:158985
	abnormal T cell activation	J:158985
	abnormal T cell proliferation	J:158985
	decreased CD4-positive, alpha-beta T cell number	J:158985
	decreased CD8-positive, alpha-beta T cell number	J:158985
	decreased monocyte cell number	J:158985
	decreased T cell proliferation	J:158985
	increased neutrophil cell number	J:158985
	increased susceptibility to bacterial infection	J:158985
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158985
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:158985
	increased susceptibility to Riboviria infection	J:158985
	increased T cell apoptosis	J:158985
\Slfn2^m2Btlr/\Slfn2^m2Btlr (C57BL/6J-Slfn2^m2Btlr)	decreased IgG level	J:234262
	decreased response to antigen	J:234262
	impaired humoral immune response	J:234262
\Slfn3^tm1Aki/\Slfn3^tm1Aki (Not Specified)	immune system phenotype	J:158985, J:258797
\Slfn4^{tm1c(EUCOMM)Wtsi}/\Slfn4^{tm1c(EUCOMM)Wtsi} \Gli1^{tm3(cre/ERT2)Alj}/\Gli1⁺ (involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * Swiss Webster)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:337060
	abnormal interleukin level	J:337060
	abnormal tumor necrosis factor level	J:337060
	decreased susceptibility to bacterial infection	J:337060
\Slfn5^tm1Aki/\Slfn5^tm1Aki (Not Specified)	immune system phenotype	J:258797
\Slfn8^tm1Aki/\Slfn8^tm1Aki (involves: 129X1/SvJ * C57BL/6)	decreased interferon-gamma secretion	J:258797
	decreased interleukin-1 beta secretion	J:258797
	decreased interleukin-6 secretion	J:258797
	decreased interleukin-17 secretion	J:258797
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:258797
	immune system phenotype	J:258797
\Slfn9^em1Liudp/\Slfn9^em1Liudp (C57BL/6-Slfn9^em1Liudp)	abnormal innate immunity	J:351319
\Slfn9^em1Liudp/\Slfn9^em1Liudp (C57BL/6-Slfn9^em1Liudp)	abnormal macrophage activation involved in immune response	J:351319
\Slfn14^em1Nvm/\Slfn14⁺ (C57BL/6J-Slfn14^em1Nvm)	enlarged spleen	J:325381
\Slfn14^em1Nvm/\Slfn14⁺ (C57BL/6J-Slfn14^em1Nvm)	increased spleen weight	J:325381
\Slitrk5^em1(IMPC)Mbp/\Slitrk5^em1(IMPC)Mbp (C57BL/6N-Slitrk5^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Slpd1^NZB/BlNJ/\Slpd1^NZB/BlNJ (involves: DBA/2J * NZB/BlNJ)	increased B cell proliferation	J:124364
\Slpi^tm1Ktak/\Slpi^tm1Ktak (B6.129P2-Slpi^tm1Ktak)	increased susceptibility to bacterial infection	J:132933
\Slpi^tm1Nkw/\Slpi^tm1Nkw (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:82214
	increased B cell proliferation	J:82214
	increased interleukin-6 secretion	J:82214
	increased susceptibility to endotoxin shock	J:82214
\Slu7^{tm1a(KOMP)Wtsi}/\Slu7⁺ (C57BL/6N-Slu7^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Slurp2^tm1Lex/\Slurp2^tm1Lex (involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:231067
\Slx4^{tm1a(EUCOMM)Wtsi}/\Slx4^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Slx4^{tm1a(EUCOMM)Wtsi})	abnormal lymphopoiesis	J:168567
	decreased leukocyte cell number	J:168567
\Smad2^tm3Rob/\Smad2^tm3Rob \Smad3^tm1Xfw/\Smad3^tm1Xfw (involves: 129/Sv * 129S/SvEv * C57BL/6 * ICR)	osteoarthritis	J:95374
\Smad3^em1(IMPC)H/\Smad3⁺ (C57BL/6NTac-Smad3^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
\Smad3^tm1Cxd/\Smad3^tm1Cxd (either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss))	abnormal immune system morphology	J:53510
	abnormal T cell activation	J:53510
	abnormal T cell physiology	J:53510
	abnormal thymus involution	J:53510
	colitis	J:53510
	enlarged lymph nodes	J:53510
	enlarged mesenteric lymph nodes	J:53510
	impaired neutrophil chemotaxis	J:53510
	increased inflammatory response	J:53510
	increased leukocyte cell number	J:53510
	increased monocyte cell number	J:53510
	increased neutrophil cell number	J:53510
	pancreas inflammation	J:53510
	small intestinal inflammation	J:53510
	small spleen	J:53510
	spleen hypoplasia	J:53510
	stomach inflammation	J:53510
	thymus hypoplasia	J:53510
\Smad3^tm1Cxd/\Smad3^tm1Cxd (B6.129S6-Smad3^tm1Cxd)	tubulointerstitial nephritis	J:102084
\Smad3^tm1Cxd/\Smad3^tm1Cxd (involves: 129S6/SvEvTac)	abnormal leukocyte physiology	J:59673
	decreased B cell apoptosis	J:140567
	osteoarthritis	J:68792
\Smad3^tm1Cxd/\Smad3^tm1Cxd (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive T cell differentiation	J:136955
\Smad3^tm1Par/\Smad3^tm1Par (129-Smad3^tm1Par/J)	abnormal circulating interleukin-6 level	J:175290
	abnormal cytokine secretion	J:175290
	decreased interleukin-6 secretion	J:175290
	increased inflammatory response	J:106572
\Smad3^tm1Xfw/\Smad3^tm1Xfw (involves: 129/Sv * C57BL/6)	abnormal B cell proliferation	J:53948
	abnormal cytokine secretion	J:53948
	abnormal T cell proliferation	J:53948
	immune system phenotype	J:53948
\Smad4^tm1.1Gsu/\Smad4^tm1.1Gsu \Ptf1a^{tm1.1(cre)Cvw}/\Ptf1a⁺ \Tg(MtTGFA)Lmb/0 (involves: 129S1/Sv * 129X1/SvJ * CD-1)	chronic pancreas inflammation	J:229184
\Smad4^tm2.1Cxd/\Smad4^tm2.1Cxd \Tg(Foxn1-cre)8Ghr/0 (B6.Cg-Smad4^tm2.1Cxd Tg(Foxn1-cre)8Ghr)	abnormal thymus physiology	J:138837
	small thymus	J:138837
\Smad4^tm2.1Cxd/\Smad4^tm2.1Cxd \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129S6/SvEvTac * C57BL/6J * CD-1)	decreased osteoclast cell number	J:211171
\Smad7^{Gt(YHC053)Byg}/\Smad7^{Gt(YHC053)Byg} (involves: 129P2/OlaHsd * C57BL/6J)	abnormal thymus morphology	J:212881
	thymus hypoplasia	J:212881
\Smad7^tm1.1Ink/\Smad7^tm1.1Ink \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal T-helper 1 cell differentiation	J:184670
	decreased activated T cell number	J:184670
	decreased interferon-gamma secretion	J:184670
	decreased interleukin-9 secretion	J:184670
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:184670
	decreased T cell proliferation	J:184670
	immune system phenotype	J:184670
\Smad7^tm1Rheu/\Smad7^tm1Rheu (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal class switch recombination	J:120714
	decreased B cell proliferation	J:120714
	increased B cell apoptosis	J:120714
\Smad9^tm3Jfm/\Smad9^tm3Jfm (involves: 129S4/SvJaeSor)	lung inflammation	J:150213
\Smap1^tm1.1Sata/\Smap1^tm1.1Sata (B6.Cg-Smap1^tm1.1Sata)	abnormal myelopoiesis	J:196385
	abnormal neutrophil morphology	J:196385
	enlarged spleen	J:196385
	increased neutrophil cell number	J:196385
\Smarca4^tm1.2Pcn/\Smarca4^tm1.2Pcn \Tg(Lck-cre)1Cwi/0 (Not Specified)	abnormal T cell morphology	J:144072
	decreased double-negative T cell number	J:144072
\Smarca4^tm1.2Pcn/\Smarca4^tm1.2Pcn \Tg(Lck-cre)1Cwi/0 \Tg(LCKprBCL2L1)12Sjk/0 (Not Specified)	abnormal T cell morphology	J:144072
	decreased double-positive T cell number	J:144072
	increased double-negative T cell number	J:144072
	increased thymocyte number	J:144072
\Smarca4^tm1.2Pcn/\Smarca4^tm1Mag \Tg(Lck-cre)1Cwi/? (involves: 129S/Sv * C57BL/6 * DBA/2)	abnormal T cell differentiation	J:85191
	absent CD8-positive, alpha-beta T cells	J:85191
	arrested T cell differentiation	J:85191
	decreased CD4-positive, alpha-beta T cell number	J:85191
	decreased double-negative T cell number	J:85191
	decreased double-positive T cell number	J:85191
	thymus hypoplasia	J:85191
\Smarca4^tm1.2Pcn/\Smarca4^tm1Mag \Tg(Lck-cre)1Cwi/? \Tg(LCKprBCL2)36Sjk/? (involves: 129S/Sv * C57BL/6 * DBA/2)	arrested T cell differentiation	J:85191
\Smarca4^tm1.2Pcn/\Smarca4^tm1Tich \Tg(Lck-cre)1Cwi/0 (involves: 129)	abnormal T cell morphology	J:144072
	decreased double-negative T cell number	J:144072
	decreased thymocyte number	J:144072
\Smarca4^tm1.2Pcn/\Smarca4^tm1Tich \Tg(Lck-cre)1Cwi/0 \Tg(LCKprBCL2L1)12Sjk/0 (involves: 129)	abnormal T cell morphology	J:144072
	decreased double-positive T cell number	J:144072
	increased double-negative T cell number	J:144072
	increased thymocyte number	J:144072
\Smarca4^tm1Tich/\Smarca4⁺ (involves: 129)	immune system phenotype	J:144072
\Smarca4^tm1Tich/\Smarca4⁺ \Tg(Lck-cre)1Cwi/0 (involves: 129)	decreased double-negative T cell number	J:144072
	decreased double-positive T cell number	J:144072
	decreased single-positive T cell number	J:144072
	decreased thymocyte number	J:144072
\Smarcad1^tm1Gos/\Smarcad1^tm1Gos (129S2/SvPas-Smarcad1^tm1Gos)	immune system phenotype	J:56661
\Smarcal1^tm1.1Cfbo/\Smarcal1^tm1.1Cfbo (either: B6.129-Smarcal1^tm1.1Cfbo or (involves: 129 * C57BL/6))	decreased B cell number	J:183899
\Smarcb1^{tm1b(EUCOMM)Hmgu}/\Smarcb1⁺ (C57BL/6N-Smarcb1^{tm1b(EUCOMM)Hmgu}/Bay)	decreased leukocyte cell number	J:211773
\Smarcb1^tm1Sho/\Smarcb1^tm3Sho \Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA)	abnormal lymph node morphology	J:80224
	abnormal spleen morphology	J:80224
	enlarged lymph nodes	J:80224
	enlarged spleen	J:80224
	increased eosinophil cell number	J:80224
	increased T cell derived lymphoma incidence	J:80224
\Smarcc1^tm2.1Rhs/\Smarcc1^tm2.1Rhs \Tg(Mx1-cre)1Cgn/0 (involves: BALB/c * C57BL/6 * CBA)	abnormal immature B cell morphology	J:184060
	abnormal immunoglobulin heavy chain V(D)J recombination	J:184060
	abnormal pre-B cell morphology	J:184060
	abnormal pro-B cell morphology	J:184060
	arrested B cell differentiation	J:184060
	decreased B cell number	J:184060
	decreased B cell proliferation	J:184060
	decreased early pro-B cell number	J:184060
	decreased follicular B cell number	J:184060
	decreased late pro-B cell number	J:184060
	decreased pro-B cell number	J:184060
	increased B cell apoptosis	J:184060
\Smarce1^tm1Tich/\Smarce1^tm2.1Tich \Gt(ROSA)26Sor^{tm3(CAG-flpo/ERT2)Alj}/\Gt(ROSA)26Sor⁺ \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	immune system phenotype	J:194195
\Smc3^{tm1a(EUCOMM)Wtsi}/\Smc3⁺ (involves: C57BL/6N)	increased T cell number	J:200082
\Smc5^{tm1b(KOMP)Wtsi}/\Smc5⁺ (C57BL/6N-Smc5^{tm1b(KOMP)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Smc6^tm1.1Arln/\Smc6^tm1.1Arln (involves: 129P2/OlaHsd * C57BL/6 * FVB)	decreased IgG2b level	J:220422
	increased leukocyte cell number	J:220422
\Smcr8^em1Btlr/\Smcr8^em1Btlr (C57BL/6J-Smcr8^em1Btlr)	enlarged lymph nodes	J:268243
	enlarged spleen	J:268243
	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased circulating interleukin-12b level	J:268243
	increased interleukin-6 secretion	J:268243
	increased susceptibility to induced colitis	J:268243
	increased tumor necrosis factor secretion	J:268243
\Smcr8^em1Btlr/\Smcr8^em1Btlr \Tlr3^tm1Flv/\Tlr3^tm1Flv \Tlr7^tm1Aki/\Tlr7^tm1Aki \Tlr9^tm1Aki/\Tlr9^tm1Aki (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6J)	immune system phenotype	J:268243
\Smcr8^em2Btlr/\Smcr8^em2Btlr (C57BL/6J-Smcr8^em2Btlr)	enlarged lymph nodes	J:268243
	enlarged spleen	J:268243
	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased circulating interleukin-12b level	J:268243
	increased interleukin-6 secretion	J:268243
	increased susceptibility to induced colitis	J:268243
	increased tumor necrosis factor secretion	J:268243
\Smcr8^m1Btlr/\Smcr8⁺ (C57BL/6J-Smcr8^m1Btlr)	increased susceptibility to induced colitis	J:268243
\Smcr8^m1Btlr/\Smcr8^m1Btlr (C57BL/6J-Smcr8^m1Btlr)	increased susceptibility to induced colitis	J:268243
\Smcr8^m1Btlr/\Smcr8^m1Btlr (C57BL/6J-Smcr8^m1Btlr)	increased tumor necrosis factor secretion	J:268243
\Smcr8^m2Btlr/\Smcr8^m2Btlr (C57BL/6J-Smcr8^m2Btlr)	increased susceptibility to induced colitis	J:268243
\Smcr8^m2Btlr/\Smcr8^m2Btlr (C57BL/6J-Smcr8^m2Btlr)	increased tumor necrosis factor secretion	J:268243
\Smcr8^m3Btlr/\Smcr8^m3Btlr (C57BL/6J-Smcr8^m3Btlr)	increased susceptibility to induced colitis	J:268243
\Smcr8^m3Btlr/\Smcr8^m3Btlr (C57BL/6J-Smcr8^m3Btlr)	increased tumor necrosis factor secretion	J:268243
\Smg1^{Gt(AG0297)Wtsi}/\Smg1⁺ (involves: 129P2/OlaHsd * C57BL/6)	chronic inflammation	J:193626
	decreased circulating interleukin-1 beta level	J:193626
	enlarged spleen	J:193626
	increased circulating interleukin-6 level	J:193626
\Smg6^em1(IMPC)Mbp/\Smg6⁺ (C57BL/6NCrl-Smg6^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Smg9^{tm1b(EUCOMM)Wtsi}/\Smg9^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Smg9^{tm1b(EUCOMM)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
\Smim3^tm1Anjm/\Smim3⁺ \Cd74^tm1Anjm/\Cd74⁺ \Lmo2^tm2(cre)Thr/\Lmo2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal mast cell morphology	J:155870
	decreased granulocyte number	J:155870
	decreased monocyte cell number	J:155870
\Smim20^em1(IMPC)J/\Smim20⁺ (C57BL/6NJ-Smim20^em1(IMPC)J/Mmjax)	immune system phenotype	J:350521
\Smim20^em1(IMPC)J/\Smim20^em1(IMPC)J (C57BL/6NJ-Smim20^em1(IMPC)J/Mmjax)	immune system phenotype	J:350521
\Smim23^em1(IMPC)Mbp/\Smim23^em1(IMPC)Mbp (C57BL/6N-Smim23^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Smoc1^{tm1b(EUCOMM)Wtsi}/\Smoc1⁺ (C57BL/6N-Smoc1^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased neutrophil cell number	J:211773
\Smoc1^{tm1b(EUCOMM)Wtsi}/\Smoc1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Smoc1^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Smpd1^tm1Esc/\Smpd1⁺ (involves: 129S1/Sv * C57BL/6J)	abnormal immune system cell morphology	J:70489
\Smpd1^tm1Esc/\Smpd1^tm1Esc (involves: 129S1/Sv * C57BL/6J)	abnormal granulocyte physiology	J:81982
	immune system phenotype	J:44401
	increased macrophage derived foam cell number	J:81982
	increased susceptibility to bacterial infection	J:81982
\Smpd1^tm1Wst/\Smpd1^tm1Wst (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:26748
	hepatosplenomegaly	J:26748
	increased macrophage derived foam cell number	J:26748
\Smpdl3b^{tm1a(EUCOMM)Wtsi}/\Smpdl3b^{tm1a(EUCOMM)Wtsi} (C57BL/6-Smpdl3b^{tm1a(EUCOMM)Wtsi})	abnormal chemokine secretion	J:224870
	abnormal circulating chemokine level	J:224870
	abnormal macrophage morphology	J:224870
	increased circulating interleukin-6 level	J:224870
	increased circulating interleukin-12b level	J:224870
	increased circulating tumor necrosis factor level	J:224870
	increased neutrophil cell number	J:224870
	increased susceptibility to endotoxin shock	J:224870
\Sms^{tm1a(EUCOMM)Wtsi}/Y (involves: C57BL/6 * C57BL/6N)	increased NK cell number	J:213427
\Sms^{tm1a(EUCOMM)Wtsi}/Y (involves: C57BL/6 * C57BL/6N)	increased NK T cell number	J:213427
\Smtn^tm1Gve/\Smtn^tm1Gve (involves: 129/Sv * C57BL/6)	intestinal inflammation	J:104648
\Smtn^tm1Gve/\Smtn^tm1Gve (involves: 129/Sv * C57BL/6)	sepsis	J:104648
\Smurf2^{Gt(RRA098)Byg}/\Smurf2^{Gt(RRA098)Byg} (involves: 129P2/OlaHsd * C57BL/6)	enlarged spleen	J:189320
\Smyd5^{tm1a(EUCOMM)Wtsi}/\Smyd5^{tm1a(EUCOMM)Wtsi} \Tg(Vil1-cre)997Gum/0 (B6.Cg-Smyd5^{tm1a(EUCOMM)Wtsi} Tg(Vil1-cre)997Gum)	decreased susceptibility to induced colitis	J:339411
\Snai2^tm1Look/\Snai2^tm1Look (involves: 129X1/SvJ * C57BL/6)	blepharitis	J:80652
	immune system phenotype	J:80652
\Snai2^tm2Grid/\Snai2⁺ \Snai3^tm1.2Jhws/\Snai3^tm1.2Jhws (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal thymus cortex morphology	J:204710
	abnormal thymus medulla morphology	J:204710
	decreased B cell number	J:204710
	disorganized spleen B cell follicle	J:204710
\Snai2^tm2Grid/\Snai2^tm2Grid (involves: 129S1/Sv)	abnormal T cell differentiation	J:78323
	blepharitis	J:48521
	conjunctivitis	J:48521
	decreased leukocyte cell number	J:78323
	small thymus	J:78323
\Snai2^tm2Grid/\Snai2^tm2Grid \Snai3^tm1.2Jhws/\Snai3⁺ (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal thymus cortex morphology	J:204710
	abnormal thymus medulla morphology	J:204710
	decreased B cell number	J:204710
	disorganized spleen B cell follicle	J:204710
	increased macrophage cell number	J:204710
	increased neutrophil cell number	J:204710
\Snai2^tm2Grid/\Snai2^tm2Grid \Snai3^tm1.2Jhws/\Snai3^tm1.2Jhws (involves: 129/Sv * 129S1/Sv * C57BL/6)	abnormal thymus cortex morphology	J:204710
	abnormal thymus involution	J:204710
	abnormal thymus medulla morphology	J:204710
	decreased B cell number	J:204710
	decreased double-positive T cell number	J:204710
	disorganized spleen B cell follicle	J:204710
	increased macrophage cell number	J:204710
	increased neutrophil cell number	J:204710
	increased single-positive T cell number	J:204710
	small spleen	J:204710
	small thymus	J:204710
	thymus fibrosis	J:204710
\Snai3^tm1.1Jhws/\Snai3^tm1.1Jhws \Tg(Lck-cre)548Jxm/0 (involves: 129/Sv * C57BL/6 * CBA)	immune system phenotype	J:204710
\Snca^em1(IMPC)H/\Snca^em1(IMPC)H (C57BL/6NTac-Snca^em1(IMPC)H/H)	increased spleen weight	J:211773
\Snca^tm1Rosl/\Snca^tm1Rosl (involves: 129X1/SvJ)	decreased susceptibility to bacterial infection	J:138194
\Snca^tm1Rosl/\Snca^tm1Rosl \Tg(Prnp-SNCA)7Vle/\Tg(Prnp-SNCA)7Vle (involves: 129X1/SvJ * C3H * C57BL/6)	abnormal response to infection	J:138194
\Snca^tm1Rosl/\Snca^tm1Rosl \Tg(Prnp-SNCAA53T)83Vle/\Tg(Prnp-SNCAA53T)83Vle (involves: 129X1/SvJ * C3H * C57BL/6)	increased susceptibility to bacterial infection	J:138194
\Snd1^em1(IMPC)Tcp/\Snd1⁺ (C57BL/6NCrl-Snd1^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	decreased spleen weight	J:211773
	increased neutrophil cell number	J:211773
	small thymus	J:211773
\Snd1^tm1.2Elws/\Snd1^tm1.2Elws (involves: C57BL/6)	immune system phenotype	J:324590
\Snhg15^tm1Nju/\Snhg15^tm1Nju (involves: C57BL/6J)	immune system phenotype	J:291983
\Snord50a/Snord50b^tm1.1Soen/\Snord50a/Snord50b^tm1.1Soen (B6.129P2-Snord50a/Snord50b^tm1.1Soen)	enlarged lymph nodes	J:206419
	enlarged spleen	J:206419
\Snord50a/Snord50b^tm1.1Soen/\Snord50a/Snord50b^tm1.1Soen (B6.129P2-Snord50a/Snord50b^tm1.1Soen)	enlarged lymph nodes	J:206419
	enlarged spleen	J:206419
\Snrk^tm1.1Hxu/\Snrk^tm1.1Hxu \Tg(Adipoq-cre)1Evdr/0 (B6.Cg-Snrk^tm1.1Hxu Tg(Adipoq-cre)1Evdr)	abnormal circulating chemokine level	J:257980
	brown adipose tissue inflammation	J:257980
	increased circulating interleukin-6 level	J:257980
	increased circulating tumor necrosis factor level	J:257980
	white adipose tissue inflammation	J:257980
\Snrnp40^em1Btlr/\Snrnp40^swp (C57BL/6J-Snrnp40^em1Btlr/Snrnp40^swp)	abnormal CD4-positive, alpha-beta T cell physiology	J:282417
	abnormal CD8-positive, alpha-beta T cell physiology	J:282417
	abnormal thymus development	J:282417
	decreased B cell number	J:282417
	decreased CD4-positive, alpha-beta T cell number	J:282417
	decreased CD8-positive, alpha-beta T cell number	J:282417
	decreased DN1 thymic pro-T cell number	J:282417
	decreased DN4 thymocyte number	J:282417
	decreased lymphocyte cell number	J:282417
	decreased monocyte cell number	J:282417
	decreased NK cell number	J:282417
	decreased T cell number	J:282417
	decreased T cell proliferation	J:282417
	immune system phenotype	J:282417
	impaired natural killer cell mediated cytotoxicity	J:282417
	increased central memory CD8 positive, alpha-beta T cell number	J:282417
	increased circulating interferon-beta level	J:282417
	increased circulating interferon-gamma level	J:282417
	increased circulating interleukin-6 level	J:282417
	increased circulating interleukin-12 level	J:282417
	increased circulating interleukin-17 level	J:282417
	increased circulating tumor necrosis factor level	J:282417
	increased effector memory CD8-positive, alpha-beta T cell number	J:282417
	increased susceptibility to viral infection	J:282417
	increased susceptibility to viral infection induced morbidity/mortality	J:282417
	small thymus	J:282417
	thymus hypoplasia	J:282417
\Snx8^tm1Hbsh/\Snx8^tm1Hbsh (Not Specified)	abnormal chemokine secretion	J:254306
	abnormal circulating chemokine level	J:254306
	abnormal dendritic cell physiology	J:254306
	abnormal macrophage physiology	J:254306
	decreased circulating CXCL10 level	J:254306
	decreased circulating tumor necrosis factor level	J:254306
	decreased CXCL10 secretion	J:254306
	decreased macrophage cytokine production	J:254306
	immune system phenotype	J:254306
	increased susceptibility to bacterial infection	J:254306
	increased susceptibility to bacterial infection induced morbidity/mortality	J:254306
\Snx8^{tm2a(EUCOMM)Hmgu}/\Snx8^{tm2a(EUCOMM)Hmgu} (C57BL/6N-Snx8^{tm2a(EUCOMM)Hmgu}/Wtsi)	increased leukocyte cell number	J:211773
\Snx10^em1Ael/\Snx10^em1Ael (involves: 129 * C57BL/6J * C57BL/6JOlaHsd)	abnormal osteoclast morphology	J:289051
	abnormal osteoclast physiology	J:289051
	decreased osteoclast cell number	J:289051
	osteomyelitis	J:289051
\Snx10^em2Ael/\Snx10^em2Ael (involves: 129 * C57BL/6J * C57BL/6JOlaHsd)	abnormal osteoclast morphology	J:289051
	abnormal osteoclast physiology	J:289051
	decreased osteoclast cell number	J:289051
	osteomyelitis	J:289051
\Snx10^{tm1a(EUCOMM)Raba}/\Snx10^{tm1a(EUCOMM)Raba} (involves: 129S4/SvJae * C57BL/6 * C57BL/6J)	abnormal osteoclast physiology	J:224711
\Snx13^{tm1b(EUCOMM)Hmgu}/\Snx13⁺ (C57BL/6N-Snx13^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Snx15^{tm1.1(KOMP)Vlcg}/\Snx15^{tm1.1(KOMP)Vlcg} (C57BL/6N-Snx15^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Snx20^tm1Lex/\Snx20^tm1Lex \Tg(Prm-cre)58Og/0 (involves: 129S/SvEvBrd * 129S4/SvJae)	immune system phenotype	J:131282
\Snx27^tm1Lslo/\Snx27^tm1Lslo (involves: 129P2/OlaHsd)	small spleen	J:171001
\Soat1^ald/\Soat1^ald (AKR/O)	thymus hyperplasia	J:12157
\Soat1^m1Anu/\Soat1^m1Anu (C57BL/6NCrlAnu-Soat1^m1Anu)	immune system phenotype	J:104190
\Soat1^tm1Far/\Soat1^tm1Far (involves: 129S4/SvJae * C57BL/6)	abnormal macrophage morphology	J:37049
\Socs1^tm1.1Ayr/\Socs1^tm1.1Ayr (involves: C57BL/6)	abnormal T cell physiology	J:226678
	decreased effector memory T-helper cell number	J:226678
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:226678
\Socs1^tm1Ayos/\Socs1^tm1Ayos \Foxp3^{tm4(YFP/icre)Ayr}/\Foxp3⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	blepharitis	J:167922
	conjunctivitis	J:167922
	dermatitis	J:167922
	increased regulatory T cell number	J:167922
\Socs1^tm1Ayos/\Socs1^tm1Ayos \Tg(Lck-cre)1Jtak/0 (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive T cell differentiation	J:132905
	abnormal CD4-positive, alpha-beta T cell physiology	J:132905
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:132905
\Socs1^tm1Ayos/\Socs1^tm1Ayos \Tg(Tek-cre)1Ywa/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	decreased CD4-positive, alpha-beta T cell number	J:132905
	increased CD8-positive, alpha-beta T cell number	J:132905
\Socs1^tm1Jni/\Socs1⁺ (Not Specified)	abnormal cytokine level	J:91651
\Socs1^tm1Jni/\Socs1⁺ (Not Specified)	abnormal interleukin level	J:91651
\Socs1^tm1Jni/\Socs1^tm1Jni (Not Specified)	abnormal cytokine secretion	J:57475
	abnormal T cell differentiation	J:57475
	decreased B cell number	J:57475
	decreased thymocyte number	J:57475
\Socs1^tm1Kish/\Socs1^tm1Kish (involves: 129P2/OlaHsd * C57BL/6J)	abnormal spleen morphology	J:51685
	abnormal spleen white pulp morphology	J:51685
	absent thymus corticomedullary boundary	J:51685
	decreased lymphocyte cell number	J:51685
\Socs1^tm1Kish/\Socs1^tm1Kish (B6.129P2-Socs1^tm1Kish)	abnormal lymphocyte physiology	J:69472
	increased activated T cell number	J:69472
	increased NK T cell number	J:69472
	liver inflammation	J:69472
	thymus atrophy	J:69472
\Socs1^tm1Kish/\Socs1^tm1Kish \Stat1^tm1Rds/\Stat1^tm1Rds (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:69472
	increased activated T cell number	J:69472
	liver inflammation	J:69472
	thymus atrophy	J:69472
\Socs1^tm1Kish/\Socs1^tm1Kish \Stat6^tm1Aki/\Stat6^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:69472
	increased activated T cell number	J:69472
	liver inflammation	J:69472
	thymus atrophy	J:69472
\Socs1^tm1Wehi/\Socs1^tm1Wehi (involves: 129S1/Sv * C57BL/6)	abnormal follicular B cell morphology	J:51281
	abnormal inflammatory response	J:57474
	abnormal lymph node B cell domain morphology	J:51281
	abnormal macrophage physiology	J:57474
	abnormal mature B cell morphology	J:51281
	abnormal Peyer's patch morphology	J:51281
	abnormal spleen white pulp morphology	J:57474
	decreased B cell number	J:51281
	decreased eosinophil cell number	J:51281
	decreased leukocyte cell number	J:57474
	decreased lymphocyte cell number	J:51281
	decreased pre-B cell number	J:51281
	decreased susceptibility to Togaviridae infection induced morbidity/mortality	J:57474
	heart inflammation	J:51281
	increased inflammatory response	J:72528
	increased spleen red pulp amount	J:51281
	liver inflammation	J:51281
	pancreas inflammation	J:51281
	small thymus	J:51281
	thymus cortex atrophy	J:57474, J:51281
\Socs1^tm1Wehi/\Socs1^tm3Wehi \Tg(Lck-cre)I57Jxm/0 (involves: 129P2/OlaHsd * C57BL/6 * ICR)	abnormal CD4-positive, alpha beta T cell morphology	J:83009
	abnormal CD8-positive, alpha beta T cell morphology	J:83009
	abnormal T cell activation	J:83009
	abnormal T cell differentiation	J:83009
	abnormal T cell subpopulation ratio	J:83009
	decreased B cell number	J:83009
	enlarged lymph nodes	J:83009
	enlarged thymus medulla	J:83009
	increased CD4-positive, alpha-beta T cell number	J:83009
	increased CD8-positive, alpha-beta T cell number	J:83009
	lymph node hyperplasia	J:83009
	thymus hyperplasia	J:83009
\Socs1^tm2Wehi/\Socs1^tm2Wehi (C57BL/6-Socs1^tm2Wehi)	absent spleen germinal center	J:72528
	glomerulonephritis	J:72528
	increased incidence of corneal inflammation	J:72528
	increased inflammatory response	J:72528
	intestinal inflammation	J:72528
	liver inflammation	J:72528
	myocarditis	J:72528
	myositis	J:72528
	pancreas inflammation	J:72528
	salivary gland inflammation	J:72528
	skin inflammation	J:72528
	thymus atrophy	J:72528
\Socs1^tm3.1Wehi/\Socs1^tm3.1Wehi (C57BL/6-Socs1^tm3.1Wehi)	abnormal inflammatory response	J:83009
\Socs1^tm3.1Wehi/\Socs1^tm3.1Wehi (C57BL/6-Socs1^tm3.1Wehi)	increased circulating interferon-gamma level	J:83009
\Socs2^tm1Wehi/\Socs2^tm1Wehi (involves: C57BL/6 * C57BL/6J)	abnormal circulating cytokine level	J:186227
	abnormal macrophage physiology	J:186227
	increased circulating interferon-gamma level	J:186227
	increased circulating interleukin-1 beta level	J:186227
	increased interferon-gamma secretion	J:186227
	increased interleukin-1 beta secretion	J:186227
	increased tumor necrosis factor secretion	J:186227
	liver inflammation	J:186227
\Socs3^tm1Ayos/\Socs3^tm1Ayos \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * C57BL/6)	decreased susceptibility to endotoxin shock	J:92040
\Socs3^tm1Jni/\Socs3⁺ (involves: 129P2/OlaHsd)	increased interleukin-2 secretion	J:128797
\Socs3^tm1Robb/\Socs3^tm1Robb (involves: C57BL/6)	enlarged spleen	J:145513
	increased neutrophil cell number	J:145513
	increased susceptibility to induced arthritis	J:145513
\Socs3^tm1Wsa/\Socs3^tm2Wsa \Lyz2^tm1(cre)Ifo/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:83645
\Socs3^tm1Wsa/\Socs3^tm2Wsa \Tg(Vav1-cre)1Awr/0 (involves: C57BL/6)	abnormal granulocyte differentiation	J:89785
	abnormal myelopoiesis	J:89785
	enlarged spleen	J:89785
	increased inflammatory response	J:89785
	increased neutrophil cell number	J:89785
	liver inflammation	J:89785
	lung inflammation	J:89785
	peritoneal inflammation	J:89785
\Socs4^m1Nch/\Socs4^m1Nch (C.C3Fe-Socs4^m1Nch)	abnormal chemokine secretion	J:241977
	abnormal T cell activation	J:241977
	decreased T cell number	J:241977
	immune system phenotype	J:241977
	increased interferon-gamma secretion	J:241977
	increased interleukin-1 secretion	J:241977
	increased interleukin-4 secretion	J:241977
	increased interleukin-5 secretion	J:241977
	increased interleukin-6 secretion	J:241977
	increased interleukin-12b secretion	J:241977
	increased interleukin-13 secretion	J:241977
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:241977
	increased T cell number	J:241977
\Socs4^m1Nch/\Socs4^m1Nch (C3H/He-Socs4^m1Nch)	immune system phenotype	J:241977
\Socs4^m1Nch/\Socs4^m1Nch (C3H/He-Socs4^m1Nch)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:241977
\Socs4^m1Nch/\Socs4^m1Nch (C6.C3Fe-Socs4^m1Nch)	immune system phenotype	J:241977
\Socs4^m1Nch/\Socs4^m1Nch (C6.C3Fe-Socs4^m1Nch)	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:241977
\Socs6^tm1Dlk/\Socs6^tm1Dlk (involves: C57BL/6)	immune system phenotype	J:77039
\Sod1^m1H/\Sod1^m1H (involves: C3H/HeH * C57BL/6J)	liver inflammation	J:219360
\Sod1^m1H/\Sod1^m1H (involves: C3H/HeH * C57BL/6J)	microgliosis	J:219360
\Sod1^tm1Leb/\Sod1^tm1Leb (involves: 129S7/SvEvBrd * C57BL/6)	blepharitis	J:219024
	increased circulating interleukin-6 level	J:219024
	increased circulating tumor necrosis factor level	J:219024
	increased interleukin-6 secretion	J:219024
	increased tumor necrosis factor secretion	J:219024
	Meibomian gland inflammation	J:219024
\Sod2^tm1Leb/\Sod2^tm1Leb (B6.129S7-Sod2^tm1Leb/J)	impaired myelopoiesis	J:36148
\Sod3^tm1Mrkl/\Sod3^tm1Mrkl (D1.129P2-Sod3^tm1Mrkl)	autoimmune arthritis	J:106273
	increased susceptibility to induced arthritis	J:106273
	increased tumor necrosis factor secretion	J:106273
\Sod3^tm1Svp/\Sod3^tm1Svp (involves: 129S6/SvEvTac * C57BL/6NTac)	decreased susceptibility to endotoxin shock	J:285340
\Son^em1.1Bcgen/\Son⁺ (B6(Cg)-Son^em1.1Bcgen)	abnormal B cell differentiation	J:347709
	abnormal naive B cell morphology	J:347709
	abnormal transitional stage B cell morphology	J:347709
	decreased follicular B cell number	J:347709
	decreased IgA level	J:347709
	decreased IgM level	J:347709
	decreased leukocyte cell number	J:347709
	decreased lymphocyte cell number	J:347709
	decreased monocyte cell number	J:347709
	decreased neutrophil cell number	J:347709
	decreased transitional stage T2 B cell number	J:347709
	increased marginal zone B cell number	J:347709
	increased pre-B cell number	J:347709
	increased transitional stage T1 B cell number	J:347709
\Sorbs1^tm1Krc/\Sorbs1^tm1Krc (B6.129-Sorbs1^tm1Krc)	decreased leukocyte cell number	J:121762
	decreased lymphocyte cell number	J:121762
	decreased monocyte cell number	J:121762
\Sord^{em1(IMPC)Ccpcz}/\Sord^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Sord^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Sort1^tm1Camo/\Sort1^tm1Camo (B6.129X1-Sort1^tm1Camo)	abnormal tumor necrosis factor level	J:157549
\Sos1^tm1.1Les/\Sos1^tm1.1Les \Tg(Lck-cre)1Cwi/0 (involves: 129 * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:174536
	decreased CD8-positive, alpha-beta T cell number	J:174536
	decreased DN4 thymocyte number	J:174536
	decreased double-negative T cell number	J:174536
	decreased double-positive T cell number	J:174536
	decreased gamma-delta T cell number	J:174536
	decreased T cell proliferation	J:174536
	decreased thymocyte number	J:174536
\Sos1^tm1.2Rak/\Sos1⁺ (involves: 129S/Sv * C57BL/6 * FVB/N * SJL)	enlarged spleen	J:171873
	increased leukocyte cell number	J:171873
	increased neutrophil cell number	J:171873
	increased spleen red pulp amount	J:171873
\Sostdc1^tm1Snd/\Sostdc1^tm1Snd (involves: C57BL/6)	decreased osteoclast cell number	J:216098
\Sox2^tm3(TK)Hoch/\Sox2⁺ (involves: 129S4/SvJae * C57BL/6)	stomach inflammation	J:177655
\Sox2^tm3(TK)Hoch/\Sox2⁺ (involves: 129S4/SvJae * C57BL/6)	tongue inflammation	J:177655
\Sox4^Igt4/\Del(13)36H (involves: 101/H * C3H/HeH * C57BL/6)	thymus hypoplasia	J:141688
\Sox4^tm1Cle/\Sox4^tm1Cle (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:32741
	absent pre-B cells	J:32741
	decreased pro-B cell number	J:32741
\Sox4^tm2Cle/\Sox4^tm2Cle (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:32741
	absent pre-B cells	J:32741
	decreased pro-B cell number	J:32741
\Sox9^{em1(cre/ERT2)Smoc}/\Sox9⁺ \Tnfsf18^em1Pwan/\Tnfsf18^em1Pwan (involves: C57BL/6J)	abnormal T cell activation	J:346395
	decreased CD8-positive, alpha-beta T cell number	J:346395
	decreased inflammatory response	J:346395
\Sox11^tm1.2Vlf/\Sox11⁺ \Sox4^tm1.1Vlf/\Sox4⁺ (involves: 129 * C57BL/6 * FVB/N)	small spleen	J:175338
\Sox11^tm1.2Vlf/\Sox11⁺ \Sox12^tm1.1Vlf/\Sox12^tm1.1Vlf \Sox4^tm1.1Vlf/\Sox4⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)	small spleen	J:175338
\Sox11^tm1.2Vlf/\Sox11^tm1.2Vlf (involves: 129 * C57BL/6)	absent spleen	J:175338
\Sox11^tm1Weg/\Sox11^tm1Weg (involves: 129S1/Sv * 129X1/SvJ)	absent spleen	J:92251
\Sox13^tm1Jskg/\Sox13⁺ (involves: C57BL/6)	decreased gamma-delta T cell number	J:117301
\Sox13^tm1Jskg/\Sox13^tm1Jskg (involves: C57BL/6)	decreased gamma-delta T cell number	J:117301
\Sox13^tm1Jskg/\Sox13^tm1Jskg (involves: C57BL/6)	increased T cell proliferation	J:117301
\Sox14^{em1(IMPC)Ccpcz}/\Sox14⁺ (C57BL/6N-Sox14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Sox14^{em1(IMPC)Ccpcz}/\Sox14^{em1(IMPC)Ccpcz} (C57BL/6N-Sox14^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
\Sox17^tm1Sjm/\Sox17^tm2Sjm \Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * C3H * C57BL/6 * C57BL/Ka * CBA)	decreased leukocyte cell number	J:123050
	spleen hypoplasia	J:123050
	thymus hypoplasia	J:123050
\Sox17^tm1Ysk/\Sox17⁺ (involves: 129S1/Sv * C57BL/6)	liver inflammation	J:194071
\Sox17^tm1Ysk/\Sox17⁺ (B6.129S1-Sox17^tm1Ysk)	gallbladder inflammation	J:241569
\Sox17^tm1Ysk/\Sox17⁺ (B6.129S1-Sox17^tm1Ysk)	liver inflammation	J:194071
\Sox17^tm2Sjm/\Sox17⁺ \Tg(Pdx1-cre)6Tuv/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	liver inflammation	J:241569
\Sox18^Ra-Op/\Sox18^Ra-Op (B6D2-Sox18^Ra-Op/J)	abnormal lymphatic vessel morphology	J:143564
\Sox18^tm1Koop/\Sox18^tm1Koop (B6.129-Sox18^tm1Koop)	abnormal lymphatic vessel morphology	J:143564
\Sox21^em1(IMPC)Mbp/\Sox21^em1(IMPC)Mbp (C57BL/6NCrl-Sox21^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Sp3^tm1Sus/\Sp3^tm1Sus (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:84837
	decreased CD4-positive, alpha-beta T cell number	J:84837
	small thymus	J:84837
\Sp4^tm1Sus/\Sp4^tm1Sus (involves: 129P2/OlaHsd * C57BL/6)	spleen hypoplasia	J:77894
\Sp4^tm1Sus/\Sp4^tm1Sus (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:77894
\Sp7^{em1(IMPC)Ccpcz}/\Sp7⁺ (C57BL/6NCrl-Sp7^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Sp110^em1Vnce/\Sp110^em1Vnce (C57BL/6J-Sp110^em1Vnce)	immune system phenotype	J:313901
\Sp140^em1Vnce/\Sp140^em1Vnce (C57BL/6J-Sp140^em1Vnce)	increased susceptibility to bacterial infection	J:313901
\Sp140^em1Vnce/\Sp140^em1Vnce (C57BL/6J-Sp140^em1Vnce)	increased susceptibility to bacterial infection induced morbidity/mortality	J:313901
\Spag11a^em1(IMPC)Mbp/\Spag11a^em1(IMPC)Mbp (C57BL/6NCrl-Spag11a^em1(IMPC)Mbp/Mmucd)	increased monocyte cell number	J:211773
\Spag11a^em2Mgef/\Spag11a⁺ (C57BL/6NJNcbs-Spag11a^em2Mgef)	epididymis inflammation	J:363226
\Spag11a^em2Mgef/\Spag11a^em2Mgef (C57BL/6NJNcbs-Spag11a^em2Mgef)	spermatic granuloma	J:363226
\Sparc^tm1Hwe/\Sparc^tm1Hwe (involves: 129S/SvEv * C57BL/6J)	abnormal osteoclast morphology	J:61480
	decreased osteoclast cell number	J:61480
	eye inflammation	J:52120
	vitreous body inflammation	J:52120
\Spata2^{tm1(KOMP)Vlcg}/\Spata2^{tm1(KOMP)Vlcg} (C57BL/6-Spata2^{tm1(KOMP)Vlcg})	increased inflammatory response	J:244164
\Spata2^{tm1.1(KOMP)Vlcg}/\Spata2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Spata2^{tm1.1(KOMP)Vlcg}/Ucd)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Spata24^{tm1b(EUCOMM)Wtsi}/\Spata24^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Spata24^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased neutrophil cell number	J:211773
\Spata31f3^{em1(IMPC)Ccpcz}/\Spata31f3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Spata31f3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged thymus	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
\spcy/\spcy (C57BL/6J-spcy)	abnormal innate immunity	J:94077
\Spdef^tm1Shiv/\Spdef^tm1Shiv (involves: 129S4/SvJae)	small intestinal inflammation	J:166876
\Spdef^tm1Shiv/\Spdef^tm1Shiv (involves: 129S4/SvJae)	stomach inflammation	J:166876
\Spdye4b^{tm3b(EUCOMM)Wtsi}/\Spdye4b^{tm3b(EUCOMM)Wtsi} (C57BL/6N-Spdye4b^{tm3b(EUCOMM)Wtsi}/Bay)	abnormal spleen morphology	J:211773
\Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ \Trmu^tm1Tomik/\Trmu^tm1Tomik (involves: C57BL/6 * DBA)	abnormal inflammatory response	J:235644
\Spef2^bgh/\Spef2^bgh (involves: 129S6/SvEvTac * C57BL/6J * C57BL/10J)	sinus inflammation	J:176695
\Speg^{tm1b(KOMP)Wtsi}/\Speg⁺ (C57BL/6N-Speg^{tm1b(KOMP)Wtsi}/Nju)	increased basophil cell number	J:211773
\Spen^tm1Hon/\Spen^tm1Hon (involves: 129P2/OlaHsd * C57BL/6J)	abnormal B cell differentiation	J:82332
\Spg11^em1(IMPC)J/\Spg11^em1(IMPC)J (C57BL/6NJ-Spg11^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Sphk1^tm1.1Cgh/\Sphk1^tm2Cgh \Sphk2^tm1.1Cgh/\Sphk2^tm1.1Cgh \Tg(Mx1-cre)1Cgn/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal immune serum protein physiology	J:120783
	abnormal NK cell differentiation	J:154069
	abnormal T cell differentiation	J:120783
	abnormal thymus cell ratio	J:120783
	decreased B cell number	J:120783
	decreased NK cell number	J:154069
	decreased T cell number	J:120783
	increased NK cell number	J:154069
\Sphk1^tm1Npa/\Sphk1^tm1Npa (BALB/c-Sphk1^tm1Npa)	increased B cell number	J:129314
\Sphk1^tm1Rlp/\Sphk1^tm1Rlp (involves: 129S6/SvEvTac)	abnormal cytokine level	J:133917
	decreased susceptibility to endotoxin shock	J:133917
	enlarged mesenteric lymph nodes	J:133917
\Sphk2^{Gt(NPX039)Byg}/\Sphk2^{Gt(NPX039)Byg} (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:102911
\Sphk2^tm1.1Stlp/\Sphk2^tm1.1Stlp (involves: BALB/c)	abnormal CD4-positive, alpha-beta T cell physiology	J:153014
\Sphk2^tm1Npa/\Sphk2^tm1Npa (BALB/c-Sphk2^tm1Npa)	abnormal B cell migration	J:129314
\Sphk2^tm1Npa/\Sphk2^tm1Npa (BALB/c-Sphk2^tm1Npa)	increased B cell number	J:129314
\Spi1^tm1.1Dgt/\Spi1^tm1.1Dgt (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:90331
	decreased B cell number	J:90331
	enlarged spleen	J:90331
	increased T cell derived lymphoma incidence	J:90331
	spleen hyperplasia	J:90331
\Spi1^tm1.2Nutt/\Spi1^tm1.2Nutt \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal granulocyte differentiation	J:98188
	abnormal spleen morphology	J:98188
	decreased B cell number	J:98188
	increased granulocyte number	J:98188
\Spi1^tm1.3Dgt/\Spi1^tm1.3Dgt (involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)	abnormal double-negative T cell morphology	J:106040
	abnormal T cell subpopulation ratio	J:106040
	arrested B cell differentiation	J:106040
	decreased B-1a cell number	J:106040
	decreased granulocyte number	J:106040
	decreased mature B cell number	J:106040
	decreased pre-B cell number	J:106040
	decreased pro-B cell number	J:106040
	decreased T cell number	J:106040
	decreased thymocyte number	J:106040
	increased B-1 B cell number	J:106040
	increased B-1b cell number	J:106040
	increased IgM level	J:106040
	increased lymphocyte cell number	J:106040
	increased T cell derived lymphoma incidence	J:106040
	increased T cell number	J:106040
	small thymus	J:106040
\Spi1^tm1.3Dgt/\Spi1^tm1.3Dgt (involves: 129 * BALB/c * C57BL/6)	abnormal spleen morphology	J:90331
	decreased B cell number	J:90331
	enlarged spleen	J:90331
	increased neutrophil cell number	J:90331
	increased spleen weight	J:90331
	increased T cell derived lymphoma incidence	J:90331
	spleen hyperplasia	J:90331
\Spi1^tm1Kast/\Spi1^tm1Kast (B6.129S2-Spi1^tm1Kast)	absent B cells	J:90543
\Spi1^tm1Kast/\Spi1^tm1Kast (B6.129S2-Spi1^tm1Kast)	failure of myelopoiesis	J:90543
\Spi1^tm1Ram/\Spi1^tm1Ram (involves: 129S2/SvPas)	decreased macrophage cell number	J:101493
\Spi1^tm1Ram/\Spi1^tm1Ram (involves: 129S2/SvPas * C57BL/6)	abnormal B cell number	J:36473
	abnormal macrophage differentiation	J:36473
	abnormal microglial cell morphology	J:116087
	abnormal neutrophil differentiation	J:36473
	abnormal T cell differentiation	J:36473
	abnormal T cell number	J:36473
	absent mature B cells	J:36473
	decreased CD4-positive, alpha-beta T cell number	J:36473
	decreased CD8-positive, alpha-beta T cell number	J:36473
	decreased double-positive T cell number	J:36473
	decreased macrophage cell number	J:36473
	decreased neutrophil cell number	J:36473
	decreased spleen red pulp amount	J:36473
	decreased thymocyte number	J:36473
	sepsis	J:36473
\Spi1^tm1Rpd/\Spi1^tm1Rpd (involves: 129/Sv * C57BL/6 * Black Swiss)	abnormal myelopoiesis	J:123079
	arrested B cell differentiation	J:123079
	enlarged spleen	J:123079
	impaired myelopoiesis	J:123079
\Spi1^tm1Sing/\Spi1⁺ \Spib^tm1Mcs/\Spib⁺ (involves: 129S/SvEv * 129X1/SvJ)	abnormal spleen germinal center morphology	J:88257
	decreased B cell proliferation	J:88257
\Spi1^tm1Sing/\Spi1⁺ \Spib^tm1Mcs/\Spib^tm1Mcs (involves: 129S/SvEv * 129X1/SvJ)	abnormal B cell differentiation	J:88257
	abnormal immature B cell morphology	J:88257
	absent spleen germinal center	J:88257
	decreased B cell number	J:88257
	decreased B cell proliferation	J:88257
	immune system phenotype	J:88257
	increased B cell apoptosis	J:88257
\Spi1^tm1Sing/\Spi1^tm1Sing (involves: 129S/SvEv)	abnormal B cell differentiation	J:20348
	abnormal granulocyte morphology	J:20348
	abnormal leukopoiesis	J:20348
	abnormal monocyte morphology	J:20348
	abnormal T cell differentiation	J:20348
\Spi1^tm3Dgt/\Spi1^tm3Dgt (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased B cell number	J:131217
	decreased double-negative T cell number	J:131217
	increased double-negative T cell number	J:131217
	increased granulocyte number	J:131217
\Spib^tm1Ksho/\Spib^tm1Ksho (involves: C57BL/6J)	abnormal Peyer's patch morphology	J:187649
\Spib^tm1Ksho/\Spib^tm1Ksho (involves: C57BL/6J)	increased susceptibility to bacterial infection	J:187649
\Spib^tm1Mcs/\Spib^tm1Mcs (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal immature B cell morphology	J:88257
	decreased B cell proliferation	J:88257
\Spib^tm1Mcs/\Spib^tm1Mcs (involves: 129S1/Sv * 129X1/SvJ)	abnormal humoral immune response	J:45245
	abnormal spleen B cell follicle morphology	J:45245
	abnormal spleen germinal center morphology	J:45245
	abnormal spleen white pulp morphology	J:45245
	decreased B cell proliferation	J:45245
	decreased IgG1 level	J:45245
	decreased IgG2a level	J:45245
	decreased IgG2b level	J:45245
	increased B cell apoptosis	J:45245
	increased IgM level	J:45245
\Spic^tm1.1Kmm/\Spic^tm1.1Kmm (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:143900
	impaired macrophage phagocytosis	J:143900
	increased spleen iron level	J:143900
	increased spleen weight	J:143900
\Spic^tm1Kmm/\Spic^tm1Kmm (involves: 129S6/SvEvTac * C57BL/6)	abnormal macrophage morphology	J:143900
	impaired macrophage phagocytosis	J:143900
	increased spleen iron level	J:143900
	increased spleen weight	J:143900
\Spin4^em1Jbn/Y (involves: C57BL/6J)	increased spleen weight	J:347154
\Spin4^em2Jbn/Y (involves: C57BL/6J)	increased spleen weight	J:347154
\Spink1^tm1Kymm/\Spink1^tm1Kymm (involves: C57BL/6NCrlj * CBA/JNCrlj)	small spleen	J:104647
\Spink2^{tm1.1(KOMP)Vlcg}/\Spink2^{tm1.1(KOMP)Vlcg} (C57BL/6N-Spink2^{tm1.1(KOMP)Vlcg}/Ucd)	increased basophil cell number	J:211773
\Spink5^m1Btlr/\Spink5^m1Btlr (involves: C57BL/6J)	increased neutrophil cell number	J:183755
\Spink5^tm2.1Hov/\Spink5^tm2.1Hov \Tg(KRT5-cre/ERT2)2Ipc/0 (involves: C57BL/6 * C57BL/6JRj * SJL)	abnormal lymph node B cell domain morphology	J:357366
	abnormal lymph node germinal center morphology	J:357366
	abnormal spleen marginal zone morphology	J:357366
	abnormal spleen morphology	J:357366
	abnormal thymus morphology	J:357366
	arrested T cell differentiation	J:357366
	decreased double-positive T cell number	J:357366
	decreased spleen B cell follicle number	J:357366
	enlarged lymph nodes	J:357366
	enlarged spleen	J:357366
	increased chemokine level	J:357366
	increased IgE level	J:357366
	increased neutrophil cell number	J:357366
	increased spleen white pulp amount	J:357366
	lymph node hyperplasia	J:357366
	myeloid hyperplasia	J:357366
	skin inflammation	J:357366
	small thymus	J:357366
	spleen hypoplasia	J:357366
	thymus atrophy	J:357366
	thymus cortex hypoplasia	J:357366
	thymus hypoplasia	J:357366
\Spink6^{em1(IMPC)Ccpcz}/\Spink6^{em1(IMPC)Ccpcz} (C57BL/6N-Spink6^{em1(IMPC)Ccpcz}/Ccpcz)	decreased Ly6C-positive immature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	increased Ly6C-positive mature NK cell number	J:211773
	increased monocyte cell number	J:211773
\Spink7^em1Cya/\Spink7^em1Cya (C57BL/6N-Spink7^em1Cya/Cya)	increased interleukin-1 beta secretion	J:310883
	increased interleukin-6 secretion	J:310883
	increased susceptibility to induced colitis	J:310883
\Spink13^{em1(IMPC)Ccpcz}/\Spink13^{em1(IMPC)Ccpcz} (C57BL/6N-Spink13^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Spink14^{tm1e(KOMP)Wtsi}/\Spink14^{tm1e(KOMP)Wtsi} (C57BL/6N-Spink14^{tm1e(KOMP)Wtsi}/Wtsi)	decreased immature NK cell number	J:211773
	decreased macrophage cell number	J:211773
	decreased mature NK cell number	J:211773
	decreased NK cell number	J:211773
	increased anti-nuclear antigen antibody level	J:211773
	increased memory-marker NK cell number	J:211773
\Spint1^tm2.1Hk/\Spint1^tm2.1Hk \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased susceptibility to induced colitis	J:179937
\Spir1^BALB/cOlaHsd/\Spir1^BALB/cOlaHsd (involves: BALB/cOlaHsd * CBA/CaOlaHsd)	decreased susceptibility to bacterial infection	J:84089
\Spir1^BALB/cOlaHsd/\Spir1^CBA/CaOlaHsd (involves: BALB/cOlaHsd * CBA/CaOlaHsd)	decreased susceptibility to bacterial infection	J:84089
\Spir1^CBA/CaOlaHsd/\Spir1^CBA/CaOlaHsd (involves: BALB/cOlaHsd * CBA/CaOlaHsd)	increased susceptibility to bacterial infection	J:84089
\Splq1^L6/\Splq1^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq1^L6/\Splq1^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq2^L6/\Splq2^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq2^L6/\Splq2^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq3^L6/\Splq3^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq4^L6/\Splq4^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq4^L6/\Splq4^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq5^L6/\Splq5^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq5^L6/\Splq5^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq6^L6/\Splq6^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq6^L6/\Splq6^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq7^L6/\Splq7^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq8^L6/\Splq8^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq8^L6/\Splq8^M16i (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splq9^L6/\Splq9^L6 (involves: L6 * M16i)	decreased spleen weight	J:87793
\Splwt1^LG/J/? (involves: LG/J * SM/J)	increased spleen weight	J:94605
\Spm1^C57BL/6/? (involves: C57BL/6 * NZB)	abnormal immune system organ morphology	J:59427
\Spmip2^{tm1b(EUCOMM)Hmgu}/\Spmip2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Spmip2^{tm1b(EUCOMM)Hmgu}/Bay)	abnormal spleen morphology	J:211773
\Spn^tm1Bam/\Spn^tm1Bam (involves: 129S4/SvJae * C57BL/6)	abnormal T cell physiology	J:29272
\Spn^tm1Bam/\Spn^tm1Bam (involves: 129S4/SvJae * C57BL/6)	increased T cell proliferation	J:29272, J:88252
\Spn^tm1Bam/\Spn^tm1Bam (B6;129S4-Spn^tm1Bam/J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:86932
\Spn^tm1Bam/\Spn^tm1Bam (B6;129S4-Spn^tm1Bam/J)	immune system phenotype	J:66401
\Spns2^tm1.1Nmoc/\Spns2^tm1.1Nmoc \Tg(Tek-cre)1Ywa/0 (involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * SJL)	abnormal B cell physiology	J:184558
	abnormal effector T cell morphology	J:184558
	abnormal T cell physiology	J:184558
	decreased CD4-positive, alpha-beta T cell number	J:184558
	decreased CD8-positive, alpha-beta T cell number	J:184558
	decreased mature B cell number	J:184558
	increased CD4-positive, alpha-beta T cell number	J:184558
	increased CD8-positive, alpha-beta T cell number	J:184558
\Spns2^tm1.2Nmoc/\Spns2^tm1.2Nmoc (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal B cell physiology	J:184558
	abnormal T cell physiology	J:184558
	decreased B-1 B cell number	J:184558
	decreased CD4-positive, alpha-beta T cell number	J:184558
	decreased CD8-positive, alpha-beta T cell number	J:184558
	decreased follicular B cell number	J:184558
	decreased immature B cell number	J:184558
	decreased leukocyte cell number	J:184558
	decreased mature B cell number	J:184558
	decreased transitional stage T1 B cell number	J:184558
	increased CD4-positive, alpha-beta T cell number	J:184558
	increased CD8-positive, alpha-beta T cell number	J:184558
	increased single-positive T cell number	J:184558
\Spns2^{tm1a(KOMP)Wtsi}/\Spns2^{tm1a(KOMP)Wtsi} (B6JTyr;B6N-Spns2^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:165965
\Spns2^{tm1a(KOMP)Wtsi}/\Spns2^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	abnormal humoral immune response	J:188933
	decreased B cell number	J:188933, J:213427
	decreased B-1 B cell number	J:188933
	decreased CD4-positive, alpha-beta T cell number	J:188933, J:213427
	decreased CD8-positive, alpha-beta T cell number	J:188933, J:213427
	decreased follicular B cell number	J:188933
	decreased IgG1 level	J:188933
	decreased IgG level	J:188933
	decreased leukocyte cell number	J:188933, J:213427
	decreased mature B cell number	J:213427
	decreased T cell number	J:213427
	immune system phenotype	J:188933
	increased CD4-positive, alpha-beta T cell number	J:188933
	increased CD8-positive, alpha-beta T cell number	J:188933
	increased granulocyte number	J:213427
	increased incidence of corneal inflammation	J:213427
	increased monocyte cell number	J:213427
	increased NK cell number	J:213427
	increased NK T cell number	J:213427
	increased susceptibility to bacterial infection	J:213427
\Spns2^{tm1b(KOMP)Wtsi}/\Spns2^{tm1b(KOMP)Wtsi} (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6N)	decreased B cell number	J:188933
	decreased CD4-positive, alpha-beta T cell number	J:188933
	decreased CD8-positive, alpha-beta T cell number	J:188933
	increased CD4-positive, alpha-beta T cell number	J:188933
	increased CD8-positive, alpha-beta T cell number	J:188933
\Spns2^{tm1b(KOMP)Wtsi}/\Spns2^{tm1b(KOMP)Wtsi} (B6Brd;B6Dnk;B6N-Tyr^c-Brd Spns2^{tm1b(KOMP)Wtsi}/WtsiH)	decreased leukocyte cell number	J:211773
\Spns2^{tm1c(KOMP)Wtsi}/\Spns2^{tm1c(KOMP)Wtsi} (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N)	immune system phenotype	J:188933
\Spns2^tm1Tni/\Spns2^tm1Tni (B6.Cg-Spns2^tm1Tni)	abnormal leukocyte cell number	J:225108
	abnormal mature B cell number	J:225108
	abnormal thymus morphology	J:225108
	decreased leukocyte cell number	J:225108
	decreased lymphocyte cell number	J:225108
	decreased monocyte cell number	J:225108
	decreased single-positive T cell number	J:225108
	decreased thymocyte number	J:225108
\Spns3^em1(IMPC)Tcp/\Spns3^em1(IMPC)Tcp (C57BL/6NCrl-Spns3^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
\Spnw1^DBA/2/\Spnw1^DBA/2 \Spnw4^DU6i/\Spnw4^DU6i (involves: DBA/2 * DU6i)	increased spleen weight	J:101006
\Spo11^tm1Mjn/\Spo11^tm1Mjn (involves: 129X1/SvJ * C57BL/6)	immune system phenotype	J:74754
\Spo11^{tm2b(KOMP)Wtsi}/\Spo11^{tm2b(KOMP)Wtsi} (C57BL/6N-Spo11^{tm2b(KOMP)Wtsi}/Bay)	abnormal spleen morphology	J:211773
	increased spleen weight	J:211773
\Spon2^tm1Mjb/\Spon2^tm1Mjb (involves: 129S6/SvEvTac * C57BL/6)	abnormal interleukin level	J:87393
	abnormal susceptibility to infection	J:87393
	abnormal tumor necrosis factor level	J:87393
\Spop^{tm1b(KOMP)Wtsi}/\Spop⁺ (C57BL/6N-Spop^{tm1b(KOMP)Wtsi}/Tcp)	enlarged lymph nodes	J:211773
	small thymus	J:211773
\Spp1^Ric-r/\Spp1⁺ (AKR/J)	decreased susceptibility to bacterial infection	J:5949
\Spp1^Ric-r/\Spp1⁺ (A/J)	decreased susceptibility to bacterial infection	J:5949
\Spp1^Ric-r/\Spp1⁺ (BALB/cJ)	decreased susceptibility to bacterial infection	J:5949
\Spp1^Ric-r/\Spp1⁺ (C57BL/6J)	decreased susceptibility to bacterial infection	J:5949
\Spp1^Ric-r/\Spp1⁺ (C57L/J)	decreased susceptibility to bacterial infection	J:5949
\Spp1^Ric-r/\Spp1⁺ (SWR/J)	decreased susceptibility to bacterial infection	J:5949
\Spp1^Ric-r/\Spp1⁺ (C3H/Rv)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:7240
\Spp1^Ric-r/\Spp1⁺ (C3H/Rv)	increased macrophage cell number	J:7240
\Spp1^Ric-s/\Spp1⁺ (A/HeJ)	increased susceptibility to bacterial infection	J:5949
\Spp1^Ric-s/\Spp1⁺ (C3H/HeJ)	increased susceptibility to bacterial infection	J:5949
\Spp1^Ric-s/\Spp1⁺ (C3H/HeN)	increased susceptibility to bacterial infection	J:5949
\Spp1^Ric-s/\Spp1⁺ (C3H/St)	increased susceptibility to bacterial infection	J:5949
\Spp1^Ric-s/\Spp1⁺ (CBA/J)	increased susceptibility to bacterial infection	J:5949
\Spp1^Ric-s/\Spp1⁺ (DBA/1J)	increased susceptibility to bacterial infection	J:5949
\Spp1^Ric-s/\Spp1⁺ (DBA/2J)	increased susceptibility to bacterial infection	J:5949
\Spp1^Ric-s/\Spp1⁺ (SJL/J)	increased susceptibility to bacterial infection	J:5949
\Spp1^tm1.1Dhd/\Spp1^tm1.1Dhd (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage morphology	J:237104
	abnormal osteoclast physiology	J:237104
	decreased osteoclast cell number	J:237104
\Spp1^tm1Blh/\Spp1⁺ (BKSW.129S6-Spp1^tm1Blh)	abnormal immune system physiology	J:113585
\Spp1^tm1Blh/\Spp1⁺ (involves: 129S6/SvEvTac * Black Swiss)	abnormal leukocyte migration	J:86531
\Spp1^tm1Blh/\Spp1^tm1Blh (involves: 129S6/SvEvTac * Black Swiss)	abnormal chemokine level	J:127389
	abnormal leukocyte migration	J:86531
	abnormal leukocyte physiology	J:86531
	abnormal macrophage chemotaxis	J:140014
	abnormal macrophage physiology	J:127389
	abnormal response to infection	J:103013
	abnormal susceptibility to infection	J:140014
	decreased circulating interleukin-6 level	J:127389
	decreased leukocyte cell number	J:86531
	decreased macrophage cell number	J:127389
	granulomatous inflammation	J:140014
	increased lymphocyte cell number	J:103050
\Spp1^tm1Blh/\Spp1^tm1Blh (B6.129S6-Spp1^tm1Blh)	abnormal microglial cell morphology	J:118432
	decreased susceptibility to experimental autoimmune uveoretinitis	J:116272
	granulomatous inflammation	J:116272
\Spp1^tm1Blh/\Spp1^tm1Blh (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:119298
	decreased dendritic cell number	J:119298
\Spp1^tm1Blh/\Spp1^tm1Blh (BKSW.129S6-Spp1^tm1Blh)	abnormal immune system physiology	J:113585
\Spp1^tm1Blh/\Spp1^tm1Blh (BKSW.129S6-Spp1^tm1Blh)	impaired macrophage chemotaxis	J:113585
\Spp1^tm1Rit/\Spp1^tm1Rit (involves: 129S7/SvEvBrd * C57BL/6)	abnormal inflammatory response	J:60284
	abnormal osteoclast physiology	J:68872, J:56353
	abnormal response to infection	J:60284
	decreased interferon-gamma secretion	J:60284
	decreased interleukin-12 secretion	J:60284
	decreased osteoclast cell number	J:115395
	decreased susceptibility to Herpesvirales infection	J:60284
	decreased susceptibility to type IV hypersensitivity reaction	J:60284
	increased interleukin-4 secretion	J:60284
	increased interleukin-10 secretion	J:60284
	increased osteoclast cell number	J:56353, J:56535
\Spp1^tm1Rit/\Spp1^tm1Rit (B6.129S7-Spp1^tm1Rit)	decreased acute inflammation	J:93915
	decreased interferon-gamma secretion	J:93915
	decreased tumor necrosis factor secretion	J:93915
\Sppl2a^chompB/\Sppl2a^chompB (involves: C57BL/6)	abnormal class switch recombination	J:194595
	abnormal humoral immune response	J:194595
	decreased activation-induced B cell apoptosis	J:194595
	decreased B cell proliferation	J:194595
	decreased follicular B cell number	J:194595
	decreased IgG1 level	J:194595
	decreased IgG2b level	J:194595
	decreased IgG3 level	J:194595
	decreased IgM level	J:194595
	decreased marginal zone B cell number	J:194595
	decreased mature B cell number	J:194595
	decreased myeloid dendritic cell number	J:194595
	decreased plasmacytoid dendritic cell number	J:194595
	decreased transitional stage T2 B cell number	J:194595
	immune system phenotype	J:194595
\Sppl2a^m1Anu/\Sppl2a^m1Anu (involves: C57BL/6JAnu)	abnormal immunoglobulin level	J:194663
	abnormal mature B cell morphology	J:194663
	abnormal transitional stage B cell morphology	J:194663
	decreased IgG1 level	J:194663
	decreased IgM level	J:194663
	decreased marginal zone B cell number	J:194663
	decreased transitional stage T2 B cell number	J:194663
	decreased transitional stage T3 B cell number	J:194663
\Sppl2a^m1Anu/\Sppl2a^m1Anu \Tg(Vav-BCL2)69Jad/? (involves: C57BL/6JAnu)	abnormal T cell number	J:194663
	decreased CD4-positive, alpha-beta T cell number	J:194663
	decreased double-negative T cell number	J:194663
	increased mature B cell number	J:194663
	increased plasmacytoid dendritic cell number	J:194663
\Sppl2a^m1Btlr/\Sppl2a^m1Btlr (C57BL/6J-Sppl2a^m1Btlr)	decreased IgG level	J:236687
\Sppl2a^m1Btlr/\Sppl2a^m1Btlr (C57BL/6J-Sppl2a^m1Btlr)	decreased response to antigen	J:236687
\Sppl2a^m2Btlr/\Sppl2a^m2Btlr (C57BL/6J-Sppl2a^m2Btlr)	decreased IgG level	J:236688
	decreased IgM level	J:236688
	decreased response to antigen	J:236688
\Sppl2a^tm1Basc/\Sppl2a^tm1Basc (involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl)	abnormal B cell calcium ion homeostasis	J:194664
	abnormal B cell physiology	J:194664
	arrested B cell differentiation	J:194664
	decreased B cell number	J:194664
	decreased B-1 B cell number	J:194664
	decreased B-2 B cell number	J:194664
	decreased follicular B cell number	J:194664
	decreased IgA level	J:194664
	decreased IgG1 level	J:194664
	decreased IgG2a level	J:194664
	decreased IgG2b level	J:194664
	decreased IgG3 level	J:194664
	decreased IgM level	J:194664
	decreased marginal zone B cell number	J:194664
	decreased mature B cell number	J:194664
	decreased Peyer's patch number	J:194664
	decreased T cell number	J:194664
	decreased transitional stage T2 B cell number	J:194664
	small Peyer's patches	J:194664
	small spleen	J:194664
\Sppl2a^tm1Basc/\Sppl2a^tm1Basc \Sppl2b^{Gt(Ayu21-T160)Imeg}/\Sppl2b^{Gt(Ayu21-T160)Imeg} (B6N.Cg-Sppl2a^tm1Basc Sppl2b^{Gt(Ayu21-T160)Imeg})	abnormal mature B cell morphology	J:213519
	decreased B cell number	J:213519
	decreased immunoglobulin level	J:213519
\Sppl2a^tm1Dgen/\Sppl2a^tm1Dgen (B6.129P2-Sppl2a^tm1Dgen)	decreased B cell number	J:194595
	decreased B-1 B cell number	J:194595
	decreased follicular B cell number	J:194595
	decreased IgA level	J:194595
	decreased IgG1 level	J:194595
	decreased IgG2b level	J:194595
	decreased IgG3 level	J:194595
	decreased IgM level	J:194595
	decreased myeloid dendritic cell number	J:194595
	decreased transitional stage T2 B cell number	J:194595
\Sppl2b^{Gt(Ayu21-T160)Imeg}/\Sppl2b^{Gt(Ayu21-T160)Imeg} (B6N.Cg-Sppl2b^{Gt(Ayu21-T160)Imeg})	immune system phenotype	J:213519
\Sppl3^tm1Itl/\Sppl3^em1Pomz \Ncr1^{tm1.1(icre)Viv}/\Ncr1⁺ (involves: 129S/SvEv * C57BL/6 * C57BL/6J)	abnormal NK cell differentiation	J:280182
	decreased mature NK cell number	J:280182
	decreased NK cell number	J:280182
	increased immature NK cell number	J:280182
\Sppl3^tm1Itl/\Sppl3^tm1Itl \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S/SvEv * C57BL/6 * C57BL/10 * CBA/Ca)	abnormal NK cell differentiation	J:280182
	decreased mature NK cell number	J:280182
	decreased NK cell number	J:280182
	immune system phenotype	J:280182
	impaired natural killer cell mediated cytotoxicity	J:280182
	increased immature NK cell number	J:280182
\Sppl3^tm1Itl/\Sppl3^tm1Itl \Ncr1^{tm1.1(icre)Viv}/\Ncr1⁺ (involves: 129S/SvEv * C57BL/6)	abnormal NK cell differentiation	J:280182
	abnormal NK cell physiology	J:280182
	decreased mature NK cell number	J:280182
	decreased NK cell number	J:280182
	impaired natural killer cell mediated cytotoxicity	J:280182
	increased immature NK cell number	J:280182
\Spr^em1(IMPC)H/\Spr⁺ (C57BL/6N-Spr^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Spred1^{em1(IMPC)Ccpcz}/\Spred1^{em1(IMPC)Ccpcz} (C57BL/6N-Spred1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK T cell number	J:211773
	increased spleen weight	J:211773
\Spred1^tm1.1Ayos/\Spred1^tm1.1Ayos (involves: 129 * C57BL/6 * SJL)	increased mast cell degranulation	J:186742
	increased mast cell number	J:186742
\Spred1^tm1Hiin/\Spred1^tm1Hiin (involves: C57BL/6)	abnormal cytokine secretion	J:95263
	abnormal eosinophil physiology	J:95263
	increased eosinophil cell number	J:95263
\Spred2^em1(IMPC)Mbp/\Spred2^em1(IMPC)Mbp (C57BL/6N-Spred2^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Spred3^em1(IMPC)Tcp/\Spred3⁺ (C57BL/6NCrl-Spred3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Sprol1^STS/A/? (involves: B10.O20/Dem * O20/A)	increased lymphocyte cell number	J:56029
\Spryd4^{em1(IMPC)Ccpcz}/\Spryd4^{em1(IMPC)Ccpcz} (C57BL/6N-Spryd4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Spta1^ihj/\Spta1^ihj (involves: HRS/J * LAH)	abnormal spleen morphology	J:105409
\Spta1^ihj/\Spta1^ihj (involves: HRS/J * LAH)	enlarged spleen	J:105409
\Spta1^sph-2Bc/\Spta1^sph-2Bc (involves: SELH)	dark spleen	J:7048
	enlarged spleen	J:7048
	increased leukocyte cell number	J:7048
\Spta1^sph-3J/\Spta1^sph-3J (NOD.Cg-H2^b Spta1^sph-3J)	decreased spleen iron level	J:157766
	enlarged spleen	J:157766
	increased spleen weight	J:157766
\Spta1^sph-4J/\Spta1^sph-4J (C57BL/6J-Spta1^sph-4J/Llp)	enlarged spleen	J:157766
\Spta1^sph-4J/\Spta1^sph-4J (C57BL/6J-Spta1^sph-4J/Llp)	increased spleen weight	J:157766
\Spta1^sph-Dem/\Spta1^sph-Dem (CcS3/Dem-Spta1^sph-Dem)	enlarged spleen	J:66966
\Spta1^sph-ha/\Spta1^sph-ha (involves: DBA/1J)	enlarged spleen	J:30699, J:14946
\Spta1^sph-ha/\Spta1^sph-ha (either: (B6.D1-Spta1^sph-ha x WB.D1-Spta1^sph-ha)F1 or (WB.D1-Spta1^sph-ha x B6.D1-Spta1^sph-ha)F1)	abnormal lymph node cell ratio	J:1967
	abnormal spleen morphology	J:6695
	abnormal splenic cell ratio	J:1967
	alveolitis	J:12830
	enlarged spleen	J:6695
	increased B cell number	J:1967
	increased B cell proliferation	J:1967
	increased CD4-positive, alpha-beta T cell number	J:1967
	increased CD8-positive, alpha-beta T cell number	J:1967
	increased IgA level	J:12830
	increased IgG level	J:12830
	increased leukocyte cell number	J:12830
	increased lymphocyte cell number	J:12830, J:1967
	increased monocyte cell number	J:12830
	increased neutrophil cell number	J:12830
	increased susceptibility to bacterial infection	J:12830
	increased T cell number	J:1967
	increased T cell proliferation	J:1967
	interstitial pneumonia	J:12830
	lymph node hyperplasia	J:12830, J:1967
\Spta1^sph-ha/\Spta1^sph-ha ((WB.D1-Spta1^sph-ha/Brk x B6.D1-Spta1^sph-ha/Brk)F1)	enlarged spleen	J:162532
\Spta1^sph/\Spta1^sph (either: (B6.C3-Spta1^sph x WB.C3-Spta1^sph)F1 or (WB.C3-Spta1^sph x B6.C3-Spta1^sph)F1)	abnormal spleen morphology	J:6695
	decreased susceptibility to parasitic infection	J:111131
	enlarged spleen	J:6695
\Spta1^sph/\Spta1^sph ((WB.C3-Spta1^sph x B6.C3-Spta1^sph)F1)	enlarged spleen	J:162532, J:44313
	glomerulonephritis	J:44313
	tubular nephritis	J:44313
\Sptb^ja/\Sptb^ja (129/Sv-Sptb^ja)	enlarged spleen	J:305
\Sptb^ja/\Sptb^ja ((WB.129-Sptb^ja/J x B6.129-Sptb^ja/J)F1)	enlarged spleen	J:162532, J:44313
	glomerulonephritis	J:44313
	increased spleen red pulp amount	J:44313
	tubular nephritis	J:44313
\Sptb^m1Jus/\Sptb^m1Jus (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:159750
\Sptbn4^qv/\Sptbn4^qv (either: (involves: BALB/c) or (involves: C57BL/10))	eye inflammation	J:167
\Sptlc2^tm1Yhir/\Sptlc2^tm1Yhir \Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6NTac)	abnormal spleen morphology	J:202954
	abnormal thymus morphology	J:202954
	decreased lymphocyte cell number	J:202954
	decreased spleen weight	J:202954
	decreased thymus weight	J:202954
	increased neutrophil cell number	J:202954
\Sptlc2^tm1Yhir/\Sptlc2^tm1Yhir \Tg(KRT5-cre)1Tak/0 (involves: C3H * C57BL/6)	abnormal dendritic epidermal T cell morphology	J:202388
	abnormal Langerhans cell morphology	J:202388
	abnormal Langerhans cell physiology	J:202388
	increased dendritic cell number	J:202388
	increased gamma-delta T cell number	J:202388
	increased T-helper 17 cell number	J:202388
	skin inflammation	J:202388
\Spw1^SWR/J/\Spw1^SWR/J \Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
\Spw2^SWR/J/? \Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
\Spw3^SWR/J/\Spw3^SWR/J \Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	increased spleen weight	J:139159
\Spw4^SWR/J/\Spw4^SWR/J \Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
\Spw5^SWR/J/\Spw5^SWR/J \Tg(CTSG-PML/RARA)135Ley/0 (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased spleen weight	J:139159
	increased spleen weight	J:139159
\Spz1^em1(IMPC)Mbp/\Spz1^em1(IMPC)Mbp (C57BL/6N-Spz1^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Sqstm1^tm1.1Sral/\Sqstm1⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:173755
	increased osteoclast cell number	J:173755
\Sqstm1^tm1.1Sral/\Sqstm1^tm1.1Sral (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:173755
	abnormal osteoclast morphology	J:173755
	increased osteoclast cell number	J:173755
\Sqstm1^tm1Jjw/\Sqstm1^tm1Jjw (involves: 129 * C57BL/6)	abnormal osteoclast differentiation	J:141179
\Sqstm1^tm1Jjw/\Sqstm1^tm1Jjw (involves: 129 * C57BL/6)	abnormal osteoclast physiology	J:141179
\Sqstm1^tm1Jmos/\Sqstm1^tm1Jmos (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal osteoclast differentiation	J:90010
	decreased interleukin-6 secretion	J:90010
	decreased osteoclast cell number	J:90010
\Sqstm1^tm1Keta/\Sqstm1^tm1Keta (involves: 129 * C57BL/6N)	abnormal osteoclast differentiation	J:264183
\Sqstm1^tm1Keta/\Sqstm1^tm1Keta (involves: 129 * C57BL/6N)	abnormal osteoclast physiology	J:264183
\Sra1^{tm1a(EUCOMM)Hmgu}/\Sra1^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6J * C57BL/6N)	decreased circulating tumor necrosis factor level	J:214131
\Src^tm1Sor/\Src^tm1Sor (either: 129S7/SvEvBrd-Src^tm1Sor or (involves: 129S7/SvEvBrd * C57BL/6J))	increased inflammatory response	J:67040
	periodontium inflammation	J:67040
\Srcr/\Srcr⁺ (BALB/c-Srcr/Cui)	abnormal innate immunity	J:83618
\Srd5a2^em1(IMPC)Mbp/\Srd5a2^em1(IMPC)Mbp (C57BL/6N-Srd5a2^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Srf^tm1Rmn/\Srf^tm1Rmn \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	athymia	J:144862
\Srf^tm2Nor/\Srf^tm2Nor \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd)	abnormal mature B cell morphology	J:124767
	absent marginal zone B cells	J:124767
	decreased B cell number	J:124767
	decreased B-1 B cell number	J:124767
\Srf^tm2Nor/\Srf^tm2Nor \Tg(Cd4-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6 * DBA/2)	decreased CD4-positive, alpha-beta T cell number	J:124767
	decreased CD8-positive, alpha-beta T cell number	J:124767
	decreased T cell number	J:124767
	decreased thymocyte number	J:124767
\Srfbp1^em1(IMPC)J/\Srfbp1⁺ (C57BL/6NJ-Srfbp1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Srgn^tm1Mabr/\Srgn^tm1Mabr (involves: 129X1/SvJ)	abnormal mast cell morphology	J:93338
\Srgn^tm1Mabr/\Srgn^tm1Mabr (involves: 129X1/SvJ)	decreased mast cell number	J:93338
\Sros1^em1Caox/\Sros1^em1Caox (involves: C57BL/6J)	abnormal circulating chemokine level	J:306407
	decreased susceptibility to bacterial infection	J:306407
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:306407
	increased circulating CXCL10 level	J:306407
\Srp14^em1(IMPC)Mbp/\Srp14⁺ (C57BL/6NCrl-Srp14^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Srpk3^{tm1b(KOMP)Wtsi}/Y (C57BL/6N-Srpk3^{tm1b(KOMP)Wtsi}/Ucd)	increased monocyte cell number	J:211773
\Srpx^tm1Hzi/\Srpx^tm1Hzi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymphocyte morphology	J:119999
	enlarged spleen	J:119999
	increased T cell derived lymphoma incidence	J:119999
\Srr^Rgsc34/\Srr⁺ (involves: C57BL/6JJcl * DBA/2JJcl)	abnormal neutrophil physiology	J:133634
\Srrt^tm1.1Thsn/\Srrt^tm1.2Thsn \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal thymus physiology	J:152729
	increased splenocyte apoptosis	J:152729
\Srsf2^tm1.1Oaw/\Srsf2⁺ \Tg(Mx1-cre)1Cgn/? (B6.Cg-Tg(Mx1-cre)1Cgn Srsf2^tm1.1Oaw)	abnormal myelopoiesis	J:221404
	abnormal neutrophil morphology	J:221404
	decreased B cell number	J:221404
	failure of myelopoiesis	J:221404
\Srsf2^tm1Xdfu/\Srsf2⁺ \Tg(Lck-cre)I57Jxm/? (involves: 129S4/SvJae * 129X1/SvJ * ICR)	decreased thymocyte number	J:88668
	decreased thymus weight	J:88668
\Srsf2^tm1Xdfu/\Srsf2^tm1Xdfu \Tg(Lck-cre)I57Jxm/? (involves: 129S4/SvJae * 129X1/SvJ * ICR)	abnormal spleen white pulp morphology	J:88668
	abnormal T cell differentiation	J:88668
	absent thymus corticomedullary boundary	J:88668
	decreased double-positive T cell number	J:88668
	decreased T cell number	J:88668
	decreased thymocyte number	J:88668
	increased double-negative T cell number	J:88668
	small thymus	J:88668
\Srsf2^tm1Xdfu/\Srsf2^tm1Xdfu \Tg(Mx1-cre)1Cgn/? (involves: 129S4/SvJae * C57BL/6J * CBA/J)	bone marrow failure	J:221404
\Srsf3^tm1Pjln/\Srsf3^tm1Pjln \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129P2/OlaHsd * BALB/c)	decreased B cell number	J:113645
	decreased pre-B cell number	J:113645
	decreased pro-B cell number	J:113645
\Srsf3^tm1Pjln/\Srsf3^tm1Pjln \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: BALB/c * C57BL/6 * DBA)	abnormal thymus development	J:205756
\Srsf5^em1Nju/\Srsf5^em1Nju (C57BL/6JGpt-Srsf5^em1Nju)	small spleen	J:311867
\Srxn1^tm1Mtol/\Srxn1^tm1Mtol (either: B6.129S2-Srxn1^tm1Mtol or (involves: 129S2/SvPasCrl * C57BL/6))	increased susceptibility to endotoxin shock	J:199277
\Ss18l1^em1Zqi/\Ss18l1⁺ (involves: C57BL/6)	increased microglial cell activation	J:278840
\Ss18l1^em1Zqi/\Ss18l1^em1Zqi (involves: C57BL/6)	increased microglial cell activation	J:278840
\Ss18l1^em2Zqi/\Ss18l1^em2Zqi (involves: C57BL/6)	increased microglial cell activation	J:278840
\Ssb^tm1Rjma/\Ssb^tm2.1Rjma \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S/SvEv * BALB/c)	arrested B cell differentiation	J:207687
	decreased B cell number	J:207687
	decreased IgG level	J:207687
	decreased IgM level	J:207687
	decreased spleen weight	J:207687
	immune system phenotype	J:207687
	small spleen	J:207687
\Ssbp2^tm1Lana/\Ssbp2^tm1Lana (involves: 129S/SvEv * C57BL/6)	arteritis	J:162035
	decreased lymphocyte cell number	J:162035
	increased pre-B cell number	J:162035
\Ssbp2^tm1Lana/\Ssbp2^tm1Lana \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6)	increased T cell derived lymphoma incidence	J:162035
	thymus hypoplasia	J:162035
\Ssh2^em1(IMPC)J/\Ssh2^em1(IMPC)J (C57BL/6NJ-Ssh2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ssial1^NOD/\Ssial1^NOD (involves: C57BL/6J * NOD)	periinsulitis	J:11442
\Ssial1^NOD/\Ssial1^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
\Ssial2^NOD/? (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
\Ssial3^NOD/\Ssial3^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
\Ssial4^C57BL/6/\Ssial4^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
\Ssial4^NOD/\Ssial4^NOD (involves: C57BL/6J * NOD)	salivary gland inflammation	J:75908
\Sspn^{tm1b(EUCOMM)Hmgu}/\Sspn^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sspn^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Ssr2^{tm1b(EUCOMM)Wtsi}/\Ssr2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ssr2^{tm1b(EUCOMM)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
\Sst1^C3HeB/FeJ/\Sst1^C3HeB/FeJ (involves: C3HeB/FeJ * C57BL/6J)	increased susceptibility to bacterial infection	J:63410
\Sst1^C3HeB/FeJ/\Sst1^C3HeB/FeJ (B6.C3-Sst1^C3HeB/FejKrmn/Mmnc)	increased susceptibility to bacterial infection	J:313901
	increased susceptibility to bacterial infection induced morbidity/mortality	J:313901
\Sst1^C3HeB/FeJ/\Sst1^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:63410
\Sst1^C57BL/6J/\Sst1^C57BL/6J (involves: C3HeB/FeJ * C57BL/6J)	decreased susceptibility to bacterial infection	J:63410, J:93705
\Sst^tm1Low/\Sst^tm1Low (B6.129P2-Sst^tm1Low)	immune system phenotype	J:126384
\Sstr2^em1(IMPC)Mbp/\Sstr2^em1(IMPC)Mbp (C57BL/6N-Sstr2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Sstr4^tm1Szo/\Sstr4^tm1Szo (B6.129P2-Sstr4^tm1Szo)	abnormal granulocyte morphology	J:152015
	abnormal neutrophil physiology	J:152015
	increased interferon-gamma secretion	J:152015
	increased interleukin-1 beta secretion	J:152015
	increased susceptibility to type IV hypersensitivity reaction	J:152015
	increased tumor necrosis factor secretion	J:152015
\Ssu2^{em1(IMPC)Ccpcz}/\Ssu2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ssu2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Ssu72^tm1Cwl/\Ssu72^tm1Cwl \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (B6.Cg-Ssu72^tm1Cwl Speer6-ps1^{Tg(Alb-cre)21Mgn})	liver inflammation	J:309624
\St3gal2^tm1Jxm/\St3gal2^tm1Jxm (Not Specified)	decreased T cell proliferation	J:217719
	increased spleen germinal center size	J:217719
	increased T cell number	J:217719
\St3gal4^tm1.1Jxm/\St3gal4^tm1.1Jxm (B6.129-St3gal4^tm1.1Jxm)	abnormal leukocyte tethering or rolling	J:117085
	abnormal response to infection	J:136946
\St3gal4^tm1.1Jxm/\St3gal4^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ)	abnormal leukocyte migration	J:189086
	decreased lymphocyte cell number	J:189086
	immune system phenotype	J:189086
\St3gal4^tm1.1Jxm/\St3gal4^tm1.1Jxm \St3gal6^tm1.1Jxm/\St3gal6^tm1.1Jxm (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal leukocyte migration	J:189086
	decreased lymphocyte cell number	J:189086
	impaired leukocyte tethering or rolling	J:189086
	impaired neutrophil recruitment	J:189086
	increased leukocyte cell number	J:189086
	increased neutrophil cell number	J:189086
\St3gal6^tm1.1Jxm/\St3gal6^tm1.1Jxm (B6.Cg-St3gal6^tm1.1Jxm)	immune system phenotype	J:189086
	impaired leukocyte tethering or rolling	J:189086
	impaired neutrophil recruitment	J:189086
\St6gal1^tm1Jlau/\St6gal1^tm1Jlau (129S4/SvJae-St6gal1^tm1Jlau)	abnormal neutrophil physiology	J:140702
	increased susceptibility to bacterial infection	J:140702
\St6gal1^tm1Jlau/\St6gal1^tm1Jlau (B6.129S4-St6gal1^tm1Jlau)	abnormal myelopoiesis	J:140547
	abnormal neutrophil physiology	J:140547
	increased neutrophil cell number	J:140547
	peritoneal inflammation	J:140547
\St6gal1^tm1Jxm/\St6gal1^tm1Jxm (involves: 129S1/Sv * 129X1/SvJ)	abnormal dendritic cell physiology	J:132991
	decreased marginal zone B cell number	J:132991
	decreased transitional stage B cell number	J:132991
	increased neutrophil cell number	J:140547
	peritoneal inflammation	J:140547
\St6galnac1^em1Len/\St6galnac1^em1Len (Not Specified)	increased susceptibility to colitis induced morbidity/mortality	J:324883
\St6galnac2^tm1.1Cfg/\St6galnac2^tm1.1Cfg (involves: 129S1/Sv * 129X1/SvJ)	decreased IgA level	J:217719
	increased B cell proliferation	J:217719
	increased pre-B cell number	J:217719
	increased spleen germinal center size	J:217719
\St6galnac3^em1Staka/\St6galnac3^em1Staka \St6galnac4^em1Staka/\St6galnac4^em1Staka (C57BL/6J-St6galnac3^em1Staka St6galnac4^em1Staka)	lymph node hemorrhage	J:340690
\St8sia1^tm1Kfk/\St8sia1^tm1Kfk (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:73818
	immune system phenotype	J:73818
	increased T cell proliferation	J:73818
\St8sia6^em1(IMPC)Mbp/\St8sia6^em1(IMPC)Mbp (C57BL/6N-St8sia6^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\St13^em1Gwzh/\St13^em1Gwzh \Tg(PRSS1/lacZ)#Gwzh/0 (Not Specified)	increased susceptibility to induced pancreatitis	J:345508
\St14^tm1Bug/\St14^tm1Bug (involves: 129P2/OlaHsd * Black Swiss)	decreased double-positive T cell number	J:87125
	increased thymocyte apoptosis	J:87125
\St14^tm2Bug/\St14^tm3Bug \Tg(MMTV-cre)4Mam/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * FVB/NJ * N:Black Swiss)	abnormal chemokine secretion	J:213072
	abnormal cytokine secretion	J:213072
	decreased CD4-positive, alpha-beta T cell number	J:213072
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:213072
	decreased CD8-positive, alpha-beta T cell number	J:213072
	decreased regulatory T cell number	J:213072
	increased anti-nuclear antigen antibody level	J:213072
	increased autoantibody level	J:213072
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:213072
	increased effector memory CD4-positive, alpha-beta T cell number	J:213072
	increased effector memory CD8-positive, alpha-beta T cell number	J:213072
	lacrimal gland inflammation	J:213072
	submandibular gland inflammation	J:213072
\St14^tm2Bug/\St14^tm3Bug \Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * SJL)	colitis	J:153070
\St14^tm3Bug/\St14^tm3Bug (involves: 129S6/SvEvTac)	immune system phenotype	J:213072
\Stag1^em1(IMPC)Mbp/\Stag1⁺ (C57BL/6N-Stag1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Stag2^tm1.1Soga/Y \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6J * C57BL/6N * CBA/J)	decreased B cell number	J:289000
	decreased leukocyte cell number	J:289000
	enlarged spleen	J:289000
	increased granulocyte number	J:289000
	increased monocyte cell number	J:289000
\Stam^tm2Sug/\Stam^tm2Sug \Stam2^tm1Sug/\Stam2^tm1Sug \Tg(Lck-cre)I57Jxm/0 (involves: 129S4/SvJae * C57BL/6 * ICR)	decreased T cell number	J:80617
	decreased T cell proliferation	J:80617
\Stambp^tm1Sug/\Stambp^tm1Sug (involves: 129S4/SvJae * C57BL/6)	immune system phenotype	J:72940
\Stard7^{tm1a(EUCOMM)Wtsi}/\Stard7⁺ (involves: C57BL/6N)	dermatitis	J:242746
	immune system phenotype	J:242746
	increased CD11b-high dendritic cell number	J:242746
	increased susceptibility to type I hypersensitivity reaction	J:242746
	lung inflammation	J:242746
\Stard13^{tm1a(KOMP)Wtsi}/\Stard13^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased susceptibility to bacterial infection	J:213427
	lymphoid hyperplasia	J:213427
\Stat1^fae/\Stat1^fae (C57BL/6JSfdAnu-Stat1^fae/Anu)	abnormal T cell activation	J:105311
	abnormal T-helper 2 physiology	J:105311
	increased IgG level	J:105311
\Stat1^m1Anu/\Stat1^m1Anu (C57BL/6JSfdAnu-Stat1^m1Anu)	abnormal response to infection	J:104190
\Stat1^m1Btlr/\Stat1^m1Btlr (C57BL/6J-Stat1^m1Btlr)	abnormal macrophage physiology	J:105543
	increased susceptibility to Herpesvirales infection	J:105543
	increased susceptibility to Riboviria infection	J:105543
\Stat1^m2Btlr/\Stat1^m2Btlr (C57BL/6J-Stat1^m2Btlr)	decreased interferon-gamma secretion	J:134096
	decreased NK cell degranulation	J:134096
	impaired natural killer cell mediated cytotoxicity	J:134096
	increased susceptibility to Herpesvirales infection	J:134096
\Stat1^m3Btlr/\Stat1^m3Btlr (C57BL/6J-Stat1^m3Btlr)	impaired natural killer cell mediated cytotoxicity	J:254835
\Stat1^m4Btlr/\Stat1^m4Btlr (C57BL/6J-Stat1^m4Btlr)	abnormal CD8-positive, naive alpha-beta T cell number	J:264800
	decreased B cell number	J:264800
	decreased B-1 B cell number	J:264800
	decreased CD8-positive, alpha-beta T cell number	J:264800
	decreased NK cell number	J:264800
	decreased single-positive T cell number	J:264800
	increased CD4-positive, alpha-beta T cell number	J:264800
	increased effector memory CD8-positive, alpha-beta T cell number	J:264800
	increased NK T cell number	J:264800
\Stat1^m5Btlr/\Stat1^m5Btlr (C57BL/6J-Stat1^m5Btlr)	abnormal CD4-positive T cell differentiation	J:274938
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274938
	abnormal T cell differentiation	J:274938
	decreased CD8-positive, naive alpha-beta T cell number	J:274938
	decreased cytotoxic T cell cytolysis	J:274938
	increased CD4-positive, alpha-beta T cell number	J:274938
	increased effector memory CD4-positive, alpha-beta T cell number	J:274938
	increased effector memory CD8-positive, alpha-beta T cell number	J:274938
	increased T cell number	J:274938
\Stat1^tm1Dlv/\Stat1^tm1Dlv (either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * C57BL/6 * CD-1))	abnormal leukocyte physiology	J:31325
	increased susceptibility to Coronaviridae infection	J:31325
	increased susceptibility to Riboviria infection	J:31325
\Stat1^tm1Dlv/\Stat1^tm1Dlv (B6.129-Stat1^tm1Dlv)	increased susceptibility to Herpesvirales infection	J:81243
\Stat1^tm1Dlv/\Stat1^tm1Dlv (B6.129-Stat1^tm1Dlv)	increased susceptibility to Togaviridae infection	J:81243
\Stat1^tm1Dlv/\Stat1^tm1Dlv (involves: 129S/SvEv)	abnormal MHC II cell surface expression on macrophages	J:130622
	decreased level of surface class I molecules	J:130622
	decreased susceptibility to endotoxin shock	J:130622
	immune system phenotype	J:99728
	increased circulating interferon-gamma level	J:130622
	increased susceptibility to bacterial infection	J:130622
	increased susceptibility to Riboviria infection	J:130622
\Stat1^tm1Dlv/\Stat1^tm1Dlv (B6.129S-Stat1^tm1Dlv)	abnormal NK cell physiology	J:79552
	impaired natural killer cell mediated cytotoxicity	J:79552
	increased circulating interferon-gamma level	J:79552
	increased circulating interleukin-12b level	J:79552
\Stat1^tm1Dlv/\Stat1^tm1Dlv \Tg(ANPEP)270Mmul/\Tg(ANPEP)270Mmul (involves: 129S/SvEv * ICR)	increased susceptibility to Coronaviridae infection	J:99728
\Stat1^tm1Dlv/\Stat1^tm1Dlv \Tg(ANPEP)861Mmul/\Tg(ANPEP)861Mmul (involves: 129S/SvEv * ICR)	increased susceptibility to Coronaviridae infection	J:99728
\Stat1^tm1Rds/\Stat1^tm1Rds (either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))	increased susceptibility to bacterial infection	J:31326
	increased susceptibility to Riboviria infection	J:31326
\Stat1^tm1Rds/\Stat1^tm1Rds (involves: 129)	increased susceptibility to Herpesvirales infection	J:81243
	increased susceptibility to Riboviria infection	J:66564
	increased susceptibility to Togaviridae infection	J:81243
\Stat1^tm1Rds/\Stat1^tm1Rds (129S6/SvEv-Stat1^tm1Rds/Tac)	abnormal macrophage physiology	J:136368
	abnormal osteoclast differentiation	J:131353
	bronchiolitis	J:286237
	decreased circulating interferon-gamma level	J:122801
	decreased interleukin-1 beta secretion	J:136368
	increased NK T cell number	J:122801
	increased susceptibility to Coronaviridae infection	J:286237
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286237
	lung inflammation	J:286237
	peritoneal inflammation	J:286237
	pleuritis	J:286237
\Stat1^tm1Rds/\Stat1^tm1Rds (B6.129-Stat1^tm1Rds)	increased osteoclast cell number	J:84894
\Stat1^tm1Rds/\Stat1^tm1Rds \Stat2^tm1Shnd/\Stat2^tm1Shnd (involves: 129/Sv * 129S1/Sv * 129X1/SvJ)	increased susceptibility to Riboviria infection	J:66564
\Stat1^tm1Rds/\Stat1^tm1Rds \Stat3^tm2Aki/\Stat3^tm2Aki \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	colitis	J:83280
	increased CD4-positive, alpha-beta T cell number	J:83280
	increased interferon-gamma secretion	J:83280
	increased interleukin-6 secretion	J:83280
	increased tumor necrosis factor secretion	J:83280
\Stat1^tm1Tdec/\Stat1^tm1Tdec (involves: 129P2/OlaHsd * BALB/c)	abnormal macrophage physiology	J:130622
	abnormal MHC II cell surface expression on macrophages	J:130622
	decreased susceptibility to endotoxin shock	J:130622
	increased susceptibility to bacterial infection	J:130622
	increased susceptibility to Riboviria infection	J:130622
\Stat1^tm1Uvin/\Stat1^tm1Uvin (involves: 129 * C57BL/6)	increased macrophage nitric oxide production	J:174863
\Stat1^tm2.1Uvin/\Stat1^tm2.1Uvin (B6.129P2-Stat1^tm2.1Uvin)	decreased susceptibility to endotoxin shock	J:209388
	immune system phenotype	J:209388
	increased susceptibility to bacterial infection	J:209388
	increased susceptibility to bacterial infection induced morbidity/mortality	J:209388
\Stat1^{tm2b(EUCOMM)Wtsi}/\Stat1^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Stat1^{tm2b(EUCOMM)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Stat2^m1Btlr/\Stat2^m1Btlr (C57BL/6J-Stat2^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265265
	decreased central memory CD8 positive, alpha-beta T cell number	J:265265
	decreased single-positive T cell number	J:265265
\Stat2^p117/\Stat2^p117 (C57BL/6J-Stat2^P117)	abnormal level of surface class II molecules	J:164049
	decreased dendritic cell number	J:164049
	decreased level of surface class I molecules	J:164049
	decreased plasmacytoid dendritic cell number	J:164049
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:164049
\Stat2^{tm1.1(STAT2)Diam}/\Stat2^{tm1.1(STAT2)Diam} (C57BL/6-Stat2^{tm1.1(STAT2)Diam})	increased susceptibility to Flaviviridae infection	J:261503
	increased susceptibility to Flaviviridae infection induced morbidity/mortality	J:261503
\Stat2^tm1Jdf/\Stat2^tm1Jdf \Tg(DO11.10)10Dlo/0 (C.Cg-Stat2^tm1Jdf Tg(DO11.10)10Dlo)	immune system phenotype	J:95855
\Stat2^tm1Shnd/\Stat2^tm1Shnd (involves: 129S1/Sv * 129X1/SvJ)	abnormal T cell differentiation	J:66564
	increased susceptibility to Riboviria infection	J:66564
\Stat3^tm1Aki/\Stat3^tm1Aki \Tg(Tek-cre)12Flv/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	abnormal interleukin level	J:123351
\Stat3^tm1Desi/\Stat3^tm1Desi (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to endotoxin shock	J:77307
\Stat3^tm1Dlv/\Stat3^tm1Dlv \Tg(Cd4-cre)1Cwi/? (involves: 129 * C57BL/6 * DBA/2)	abnormal CD4-positive T cell differentiation	J:124293
	abnormal gut-associated lymphoid tissue morphology	J:124293
	decreased interleukin-17 secretion	J:124293
	increased interferon-gamma secretion	J:124293
\Stat3^tm1Dlv/\Stat3^tm1Dlv \Tg(Csf1r-icre)1Jwp/0 (involves: 129P2/OlaHsd * C57BL/6 * FVB)	abnormal acute inflammation	J:156593
	abnormal inflammatory response	J:156593
	colitis	J:156593
	increased granulocyte number	J:156593
	increased macrophage cell number	J:156593
	increased T cell number	J:156593
\Stat3^tm1Dlv/\Stat3^tm1Dlv \Tg(MMTV-cre)4Mam/0 (involves: 129P2/OlaHsd * C57BL/6J * FVB)	decreased T-helper 17 cell number	J:120176
\Stat3^tm1Dnl/\Stat3^tm1Dlv (involves: C57BL/6)	decreased thymocyte number	J:87599
\Stat3^tm1Dnl/\Stat3^tm1Dlv (involves: C57BL/6)	increased thymocyte apoptosis	J:87599
\Stat3^tm1Flv/\Stat3^tm1Flv \Tg(Tek-cre)1Xyfu/0 (involves: C57BL/6)	abnormal cytokine secretion	J:86655
	increased susceptibility to endotoxin shock	J:86655
\Stat3^tm1Flv/\Stat3^tm1Flv \Tg(Tek-cre)12Flv/0 (involves: 129 * C3H * C57BL/6)	abnormal inflammatory response	J:81973
	abnormal innate immunity	J:81973
	abnormal T-helper 1 physiology	J:81973
	cecum inflammation	J:81973
	colitis	J:81973
	granulomatous inflammation	J:81973
	ileum inflammation	J:81973
	increased circulating interferon-gamma level	J:81973
	increased circulating tumor necrosis factor level	J:81973
	increased leukocyte cell number	J:81973
	intestinal inflammation	J:81973
	liver inflammation	J:81973
\Stat3^tm1Vpo/\Stat3^tm1Vpo \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CBA)	abnormal macrophage physiology	J:89194
	increased interleukin-6 secretion	J:89194
	increased tumor necrosis factor secretion	J:89194
\Stat3^tm1Vpo/\Stat3^tm2Vpo \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA * BALB/cAn)	abnormal macrophage physiology	J:89194
	increased interleukin-6 secretion	J:89194
	increased tumor necrosis factor secretion	J:89194
\Stat3^tm1Xyfu/\Stat3⁺ \Tg(Myh6-cre)2182Mds/0 (involves: 129S1/Sv * FVB/N)	increased susceptibility to endotoxin shock	J:86400
	increased tumor necrosis factor secretion	J:86400
\Stat3^tm1Xyfu/\Stat3^tm1.1Xyfu \Tg(Myh6-cre)2182Mds/0 (involves: 129S1/Sv * FVB/N)	increased susceptibility to endotoxin shock	J:86400
	increased tumor necrosis factor secretion	J:86400
\Stat3^tm1Xyfu/\Stat3^tm1.1Xyfu \Tg(Ttr-cre)10-3Xyfu/? (involves: 129S1/Sv * C57BL/6)	increased monocyte cell number	J:128719
	increased neutrophil cell number	J:128719
\Stat3^tm2Aki/\Stat3^tm2Aki (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal response to infection	J:122213
\Stat3^tm2Aki/\Stat3^tm2Aki \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	colitis	J:83280
	increased CD4-positive, alpha-beta T cell number	J:83280
	increased dendritic cell number	J:83280
	increased interferon-gamma secretion	J:83280
	increased interleukin-12 secretion	J:83280
	increased macrophage cell number	J:83280
\Stat3^tm2Aki/\Stat3^tm2Aki \Tg(KRT5-cre)1Tak/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	conjunctivitis	J:194832
	dermatitis	J:194832
	lacrimal gland inflammation	J:194832
\Stat3^tm2Aki/\Stat3^tm2Aki \Tg(Lck-cre)1Jtak/0 (involves: 129P2/OlaHsd)	decreased T cell proliferation	J:50443
	increased T cell apoptosis	J:50443
\Stat3^tm2Aki/\Stat3^tm2Aki \Tg(SFTPC-rtTA)5Jaw/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:87622
	lung inflammation	J:87622
\Stat3^tm2Aki/\Stat3^tm2Aki \Tlr4^tm1Aki/\Tlr4^tm1Aki \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	colitis	J:83280
	decreased interferon-gamma secretion	J:83280
	decreased susceptibility to endotoxin shock	J:83280
\Stat3^tm2Aki/\Stat3^tm2Aki \Tnf^tm1Sek/\Tnf^tm1Sek \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * CBA)	colitis	J:83280
	increased interferon-gamma secretion	J:83280
	increased interleukin-6 secretion	J:83280
	increased interleukin-12b secretion	J:83280
\Stat3^tm3Vpo/\Stat3^tm3Vpo (involves: C57BL/6 * CBA * BALB/cAn)	abnormal macrophage physiology	J:89194
\Stat4^ity14/\Stat4^ity14 (involves: 129S1/Sv * 129X1/SvJ)	decreased circulating interferon-gamma level	J:207092
	decreased interferon-gamma secretion	J:207092
	increased circulating interleukin-12 level	J:207092
	increased susceptibility to bacterial infection	J:207092
	increased susceptibility to bacterial infection induced morbidity/mortality	J:207092
\Stat4^ity14/\Stat4^tm1Gru (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)	increased susceptibility to bacterial infection induced morbidity/mortality	J:207092
\Stat4^tm1Gru/\Stat4^tm1Gru (involves: 129S2/SvPas * BALB/c)	abnormal lymphocyte physiology	J:34059
	abnormal NK cell physiology	J:34059
	abnormal T cell proliferation	J:34059
	abnormal T-helper 1 physiology	J:34059
	abnormal T-helper 2 physiology	J:34059
	decreased circulating interferon-gamma level	J:163843
	decreased interferon-gamma secretion	J:34059
	increased susceptibility to bacterial infection	J:163843
	increased susceptibility to bacterial infection induced morbidity/mortality	J:163843
\Stat4^tm1Gru/\Stat4^tm1Gru (NOD.129S2-Stat4^tm1Gru)	abnormal inflammatory response	J:90600
	decreased circulating interferon-gamma level	J:90600
	decreased circulating interleukin-2 level	J:90600
	decreased susceptibility to autoimmune diabetes	J:90600
\Stat4^tm1Gru/\Stat4^tm1Gru (C.129S2-Stat4^tm1Gru)	abnormal CD4-positive T cell differentiation	J:143729
	decreased circulating interferon-gamma level	J:90600
	decreased circulating interleukin-2 level	J:90600
\Stat4^tm1Gru/\Stat4^tm1Gru (involves: 129S2/SvPas)	abnormal cytokine secretion	J:112600
\Stat4^tm1Gru/\Stat4^tm1Gru \Tg(Ins2-GP)34-20Olds/0 (involves: 129S2/SvPas * BALB/c * C57BL/6)	abnormal susceptibility to autoimmune disorder	J:107047
\Stat4^tm1Gru/\Stat4^tm1Gru \Tg(Ins2-NP)25-3Olds/0 (involves: 129S2/SvPas * BALB/c * C57BL/6)	abnormal cytotoxic T cell physiology	J:107047
	decreased interferon-gamma secretion	J:107047
	decreased susceptibility to autoimmune diabetes	J:107047
	insulitis	J:107047
\Stat4^tm1Jni/\Stat4^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	abnormal NK cell physiology	J:79552
	decreased circulating interferon-gamma level	J:79552
	decreased susceptibility to autoimmune diabetes	J:96338
	increased interleukin-4 secretion	J:96338
\Stat4^tm1Jni/\Stat4^tm1Jni \Stat6^tm1Jni/\Stat6^tm1Jni (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	decreased interleukin-4 secretion	J:96338
	increased interferon-gamma secretion	J:96338
	increased susceptibility to autoimmune diabetes	J:96338
\Stat5a^tm1.1Wjl/\Stat5a^tm1.1Wjl \Stat5b^tm2.1Wjl/\Stat5b^tm2.1Wjl (involves: 129S6/SvEvTac * C57BL/6J * FVB/N)	abnormal leukocyte morphology	J:187325
	abnormal regulatory T cell physiology	J:187325
	abnormal T cell subpopulation ratio	J:187325
	decreased CD8-positive, alpha-beta T cell number	J:187325
	decreased NK cell number	J:187325
	decreased T cell proliferation	J:187325
	increased T cell apoptosis	J:187325
\Stat5a^tm1Jni/\Stat5a^tm1Jni \Stat5b^tm2Jni/\Stat5b^tm2Jni (either: (involves: 129P2/OlaHsd) or (involves: 129X1/SvJ))	abnormal myelopoiesis	J:77412
	decreased leukocyte cell number	J:77412
	decreased T cell number	J:77412
	increased neutrophil cell number	J:77412
\Stat5a^tm1Jni/\Stat5a^tm1Jni \Stat5b^tm2Jni/\Stat5b^tm2Jni (involves: 129 * C57BL/6)	abnormal mast cell differentiation	J:84889
	abnormal mast cell physiology	J:84889
	absent mast cells	J:84889
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:122463
\Stat5a^tm1Mam/\Stat5a^tm1Mam (C.129S6-Stat5a^tm1Mam)	abnormal mast cell differentiation	J:101855
	abnormal mast cell morphology	J:101855
	decreased mast cell number	J:101855
\Stat5a^tm1Mam/\Stat5a^tm1Mam (involves: 129S6/SvEvTac * C57BL/6)	decreased NK cell number	J:112035
	decreased splenocyte number	J:112035
	impaired natural killer cell mediated cytotoxicity	J:112035
\Stat5a^tm2Mam/\Stat5a^tm2Mam \Stat5b^tm1Mam/\Stat5b⁺ (involves: 129S6/SvEvTac)	abnormal lymphopoiesis	J:258967
\Stat5a^tm2Mam/\Stat5a^tm2Mam \Stat5b^tm1Mam/\Stat5b^tm1Mam \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)	increased circulating interleukin-17 level	J:120176
	increased interleukin-17 secretion	J:120176
\Stat5a^tm2Mam/\Stat5a^tm2Mam \Stat5b^tm1Mam/\Stat5b^tm1Mam \Tg(Lck-cre)I57Jxm/0 (involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)	abnormal acute inflammation	J:122463
	abnormal T cell subpopulation ratio	J:122463
	decreased CD8-positive, alpha-beta T cell number	J:122463
	enlarged spleen	J:122463
\Stat5a^tm2Mam/\Stat5a^tm2Mam \Stat5b^tm1Mam/\Stat5b^tm1Mam \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal leukopoiesis	J:155489
	abnormal neutrophil differentiation	J:155489
	abnormal neutrophil physiology	J:155489
	decreased leukocyte cell number	J:155489
	decreased lymphocyte cell number	J:155489
	decreased monocyte cell number	J:155489
	decreased neutrophil cell number	J:155489
\Stat5b^tm1Hwd/\Stat5b^tm1Hwd (involves: C57BL/6)	abnormal double-negative T cell morphology	J:112035
	abnormal lymphocyte cell number	J:112035
	abnormal lymphocyte morphology	J:112035
	decreased CD8-positive, alpha-beta T cell number	J:112035
	decreased NK cell number	J:112035
	decreased splenocyte number	J:112035
	decreased T cell proliferation	J:112035
	decreased thymocyte number	J:112035
	impaired natural killer cell mediated cytotoxicity	J:112035
\Stat5b^tm1Mam/\Stat5b^tm1Mam \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2)	increased circulating interleukin-17 level	J:120176
	increased interleukin-17 secretion	J:120176
\Stat5b^tm1Mam/\Stat5b^tm1Mam \Tg(Lck-cre)I57Jxm/0 (involves: 129 * 129S6/SvEvTac * C57BL/6 * ICR)	abnormal acute inflammation	J:122463
	abnormal T cell subpopulation ratio	J:122463
	decreased CD8-positive, alpha-beta T cell number	J:122463
	enlarged spleen	J:122463
\Stat5b^tm1Mam/\Stat5b^tm1Mam \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	abnormal leukopoiesis	J:155489
	abnormal neutrophil differentiation	J:155489
	abnormal neutrophil physiology	J:155489
	decreased leukocyte cell number	J:155489
	decreased lymphocyte cell number	J:155489
	decreased monocyte cell number	J:155489
	decreased neutrophil cell number	J:155489
\Stat6^tm1Aki/\Stat6^tm1Aki (involves: 129P2/OlaHsd)	abnormal T-helper 2 physiology	J:32561
	decreased B cell proliferation	J:32561
	decreased IgE level	J:32561
	decreased IgG1 level	J:32561
	decreased T cell proliferation	J:32561
	decreased T-helper 2 cell number	J:172134
	increased IgA level	J:32561
	increased IgG level	J:32561
\Stat6^tm1Aki/\Stat6^tm1Aki (C.129P2-Stat6^tm1Aki Nfkbiz^tm1Aki)	skin inflammation	J:141704
\Stat6^tm1Aki/\Stat6^tm1Aki \Tg(KRT14-CASP1)1Miz/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased IgE level	J:78602
	decreased IgG1 level	J:78602
	dermatitis	J:78602
	increased circulating interleukin-18 level	J:78602
\Stat6^tm1Gru/\Stat6⁺ \Tg(Scgb1a1-Il13)2Eli/? (involves: 129S2/SvPas * C57BL/6 * CBA)	respiratory system inflammation	J:132385
\Stat6^tm1Gru/\Stat6^tm1Gru (C.129S2-Stat6^tm1Gru/J)	abnormal CD4-positive T cell differentiation	J:204829
	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	abnormal humoral immune response	J:107370
	decreased IgA level	J:107370
	decreased IgG3 level	J:107370
	decreased IgM level	J:107370
	decreased interleukin-4 secretion	J:107370
	decreased susceptibility to Herpesvirales infection	J:107370
	increased interferon-gamma secretion	J:107370
	increased interleukin-2 secretion	J:107370
\Stat6^tm1Gru/\Stat6^tm1Gru (129S2/SvPas-Stat6^tm1Gru)	abnormal interleukin secretion	J:31932
	abnormal T-helper 2 cell differentiation	J:31932
	decreased IgE level	J:31932
	decreased interleukin-4 secretion	J:31932
	decreased interleukin-5 secretion	J:31932
	decreased T cell proliferation	J:31932
\Stat6^tm1Gru/\Stat6^tm1Gru (involves: 129S2/SvPas)	abnormal cytokine secretion	J:112600
\Stat6^tm1Gru/\Stat6^tm1Gru (involves: 129S2/SvPas * BALB/c)	abnormal acute inflammation	J:85386
	abnormal granulocyte physiology	J:85386
	abnormal macrophage physiology	J:85386
	immune system phenotype	J:85386
	impaired eosinophil chemotaxis	J:85386
	impaired neutrophil chemotaxis	J:85386
	increased circulating tumor necrosis factor level	J:85386
\Stat6^tm1Gru/\Stat6^tm1Gru (C.129S2-Stat6^tm1Gru)	abnormal circulating interleukin level	J:66222
	abnormal circulating interleukin-4 level	J:66222
	abnormal circulating interleukin-5 level	J:66222
	abnormal cytotoxic T cell physiology	J:65894
	abnormal immune serum protein physiology	J:66222
	abnormal immunoglobulin level	J:66222
	abnormal leukocyte migration	J:74497
	abnormal leukocyte physiology	J:74497
	decreased IgE level	J:74497, J:66222
	decreased IgG1 level	J:66222
	impaired eosinophil recruitment	J:66222
	increased IgG2a level	J:66222
\Stat6^tm1Jni/\Stat6^tm1Jni (involves: 129S/SvEv)	abnormal B cell physiology	J:32607
	abnormal B cell proliferation	J:32607
	abnormal class switch recombination	J:32607
	abnormal level of surface class II molecules	J:32607
	abnormal T-helper 1 cell differentiation	J:32607
	abnormal T-helper 2 cell differentiation	J:32607
	increased B cell apoptosis	J:146533
\Stat6^tm1Jni/\Stat6^tm1Jni (involves: 129S/SvEv * C57BL/6)	abnormal mast cell morphology	J:110429
	abnormal T-helper 1 cell differentiation	J:51096
	decreased IgE level	J:51096
	decreased IgG1 level	J:51096
	decreased interleukin-4 secretion	J:96338
	decreased susceptibility to autoimmune diabetes	J:96338
	increased IgE level	J:110429
	increased IgG1 level	J:110429
	increased IgG2a level	J:51096
	increased interferon-gamma secretion	J:51096, J:96338
	increased interleukin-12 secretion	J:51096
	increased susceptibility to parasitic infection	J:110429
\Stau2^em1(IMPC)Mbp/\Stau2^em1(IMPC)Mbp (C57BL/6N-Stau2^em1(IMPC)Mbp/MbpMmucd)	increased monocyte cell number	J:211773
\Steap3^fred/\Steap3^fred (C57BL/6-Steap3^fred)	enlarged spleen	J:145194
\Steap3^tm1.1Atel/\Steap3^tm1.1Atel (involves: C57BL/6)	abnormal spleen morphology	J:154356
	abnormal spleen red pulp morphology	J:154356
	decreased splenocyte apoptosis	J:154356
	increased spleen weight	J:154356
	increased spleen white pulp amount	J:154356
\Steap4^tm1Dgen/\Steap4^tm1Dgen (involves: 129P2/OlaHsd)	increased macrophage cell number	J:187736
\Stia1^NOD/ShiLtDoi/? (involves: C57BL/6J * NOD/LtDoi)	increased inflammatory response	J:70882
\Stia2^C57BL/6J/\Stia2^C57BL/6J (involves: C57BL/6J * NOD/LtDoi)	increased inflammatory response	J:70882
\Stia2^C57BL/6J/\Stia2^NOD/ShiLtDoi (involves: C57BL/6J * NOD/LtDoi)	increased inflammatory response	J:70882
\Stim1^em1(IMPC)Mbp/\Stim1⁺ (C57BL/6N-Stim1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Stim1^Sax/\Stim1⁺ (involves: C3HeB/FeJ * C57BL/6)	abnormal thrombopoiesis	J:127381
	enlarged spleen	J:127381
	immune system phenotype	J:127381
	increased spleen red pulp amount	J:127381
\Stim1^tm1.1Kuro/\Stim1⁺ (C57BL/6-Stim1^tm1.1Kuro)	decreased susceptibility to type I hypersensitivity reaction	J:130477
\Stim1^tm1.1Kuro/\Stim1^tm1.1Kuro (C57BL/6-Stim1^tm1.1Kuro)	abnormal cytokine secretion	J:130477
	abnormal interleukin secretion	J:130477
	decreased interleukin-6 secretion	J:130477
	decreased interleukin-13 secretion	J:130477
	decreased mast cell degranulation	J:130477
	decreased tumor necrosis factor secretion	J:130477
\Stim1^tm1.1Pg/\Stim1⁺ (involves: C57BL/6)	decreased Ly6C low monocyte number	J:285187
	decreased NK cell number	J:285187
	enlarged spleen	J:285187
	increased Ly6C high monocyte number	J:285187
\Stim1^tm1Kuro/\Stim1^tm1Kuro \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell calcium ion homeostasis	J:172608
	decreased B cell proliferation	J:172608
	decreased interleukin-10 secretion	J:172608
\Stim1^tm1Kuro/\Stim1^tm1Kuro \Stim2^tm1.1Kuro/\Stim2^tm1.1Kuro \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell calcium ion homeostasis	J:172608
	abnormal B cell physiology	J:172608
	decreased B cell proliferation	J:172608
	decreased interleukin-10 secretion	J:172608
	immune system phenotype	J:172608
	increased CD4-positive, alpha-beta T cell number	J:172608
	increased CD8-positive, alpha-beta T cell number	J:172608
	increased interferon-gamma secretion	J:172608
	increased interleukin-10 secretion	J:172608
	increased interleukin-17 secretion	J:172608
	increased regulatory T cell number	J:172608
	increased susceptibility to experimental autoimmune encephalomyelitis	J:172608
\Stim1^tm1Rao/\Stim1^tm1Rao \Stim2^tm1Rao/\Stim2^tm1Rao \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal B cell differentiation	J:133262
	abnormal CD4-positive, alpha-beta T cell physiology	J:133262
	abnormal granulocyte morphology	J:133262
	abnormal immune system morphology	J:133262
	abnormal immune system physiology	J:133262
	abnormal lymph organ size	J:133262
	abnormal T cell differentiation	J:133262
	blepharitis	J:133262
	decreased interferon-gamma secretion	J:133262
	decreased interleukin-2 secretion	J:133262
	decreased regulatory T cell number	J:133262
	decreased T cell proliferation	J:133262
	dermatitis	J:133262
	enlarged lymph nodes	J:133262
	enlarged spleen	J:133262
	increased germinal center B cell number	J:133262
	increased IgG1 level	J:133262
	increased lymphocyte cell number	J:133262
	increased spleen germinal center number	J:133262
\Stim1^tm1Rao/\Stim1^tm1Rao \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha-beta T cell physiology	J:133262
	decreased interleukin-2 secretion	J:133262
	increased lymphocyte cell number	J:133262
\Stim1^tm3Ics/\Stim1⁺ (involves: C57BL/6N)	decreased lymphocyte cell number	J:277842
	decreased NK T cell number	J:277842
	decreased regulatory T cell number	J:277842
	increased monocyte cell number	J:277842
	increased neutrophil cell number	J:277842
	increased spleen weight	J:277842
	myositis	J:277842
\Stim2^tm1.1Kuro/\Stim2^tm1.1Kuro \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6)	abnormal B cell calcium ion homeostasis	J:172608
	immune system phenotype	J:172608
\Stim2^tm1Rao/\Stim2^tm1Rao \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2 * SJL)	abnormal CD4-positive, alpha-beta T cell physiology	J:133262
	abnormal T-helper 1 physiology	J:133262
	abnormal T-helper 2 physiology	J:133262
	decreased interferon-gamma secretion	J:133262
	decreased interleukin-2 secretion	J:133262
	decreased interleukin-4 secretion	J:133262
\Sting1^em1Jmin/\Sting1⁺ (involves: C57BL/6N)	abnormal cytokine level	J:251372
	abnormal spleen morphology	J:251372
	decreased single-positive T cell number	J:251372
	enlarged spleen	J:251372
	increased circulating interleukin-10 level	J:251372
	increased circulating interleukin-13 level	J:251372
	increased circulating tumor necrosis factor level	J:251372
	increased IgM level	J:251372
	lung inflammation	J:251372
\Sting1^gt/\Sting1^gt (C57BL/6-Sting1^gt)	abnormal dendritic cell physiology	J:201167
	abnormal humoral immune response	J:201167
	abnormal immune cell physiology	J:201167
	abnormal macrophage physiology	J:201167
	abnormal plasmacytoid dendritic cell physiology	J:201167
	abnormal response to infection	J:168746
	decreased circulating interferon-alpha level	J:201167
	decreased circulating interferon-beta level	J:201167, J:168746
	increased susceptibility to Herpesvirales infection	J:201167
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:201167
\Sting1^gt/\Sting1^gt (involves: C57BL/6)	immune system phenotype	J:265023
\Sting1^gt/\Sting1^gt (involves: C57BL/6)	increased susceptibility to Retroviridae infection	J:265023
\Sting1^gt/\Sting1^gt (C57BL/6J-Sting1^gt/J)	abnormal interferon-beta secretion	J:354143
	abnormal level of surface class I molecules	J:363611
	abnormal MHC II cell surface expression on macrophages	J:363611
	abnormal response to infection	J:354143
	increased susceptibility to Retroviridae infection	J:354143
\Sting1^tm1Camb/\Sting1^tm1Camb (involves: C57BL/6N)	decreased circulating interferon-beta level	J:179270
	decreased circulating interleukin-6 level	J:179270
	immune system phenotype	J:179270
\Sting1^tm1Gnb/\Sting1^tm1Gnb (involves: 129P2/OlaHsd * C57BL/6)	abnormal innate immunity	J:141011
	abnormal susceptibility to Herpesvirales infection	J:141011
	increased susceptibility to Riboviria infection	J:141011
\Sting1^tm1Gnb/\Sting1^tm1Gnb (involves: 129P2/OlaHsd)	abnormal response to infection	J:168746
\Sting1^tm1Gnb/\Sting1^tm1Gnb \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:181257
\Stip1^tm1.2Mamp/\Stip1^tm1.2Mamp (involves: C57BL/6)	increased acute inflammation	J:201097
\Stk3^tm1.1Jav/\Stk3^tm1.1Jav (involves: 129 * C57BL/6)	immune system phenotype	J:153945
\Stk3^tm1.1Jav/\Stk3^tm1.1Jav \Stk4^tm1Kina/\Stk4^tm1Kina \Tg(Nkx2-1-cre)2Sand/? (involves: 129 * C57BL/6)	lung inflammation	J:197340
\Stk3^tm1.1Yy/\Stk3^tm1Yy \Stk4^tm1.1Yy/\Stk4^tm1.1Yy \Tg(CAG-cre/Esr1)5Amc/0 (involves: C57BL/6 CBA)	enlarged spleen	J:156541
\Stk4^{Gt(AJ0315)Wtsi}/\Stk4^{Gt(AJ0315)Wtsi} (B6.129P2-Stk4^{Gt(AJ0315)Wtsi})	abnormal memory T cell number	J:142674
	abnormal T cell differentiation	J:142674
	decreased CD4-positive, alpha-beta T cell number	J:142674
	decreased CD8-positive, alpha-beta T cell number	J:142674
	decreased spleen white pulp amount	J:142674
	increased interferon-gamma secretion	J:142674
	increased interleukin-2 secretion	J:142674
	increased interleukin-4 secretion	J:142674
	increased T cell apoptosis	J:142674
	increased T cell proliferation	J:142674
\Stk4^m1Btlr/\Stk4^m1Btlr (C57BL/6J-Stk4^m1Btlr)	abnormal humoral immune response	J:265233
	decreased B cell number	J:265233
	decreased CD4-positive, alpha-beta T cell number	J:265233
	decreased CD8-positive, alpha-beta T cell number	J:265233
	decreased IgD level	J:265233
	decreased single-positive T cell number	J:265233
	decreased T cell number	J:265233
	increased IgE level	J:265233
	increased IgM level	J:265233
	increased macrophage cell number	J:265233
	increased neutrophil cell number	J:265233
	increased NK cell number	J:265233
\Stk4^m2Btlr/\Stk4^m2Btlr (C57BL/6J-Stk4^m2Btlr)	decreased B-1 B cell number	J:265237
	decreased B-2 B cell number	J:265237
	decreased CD4-positive, alpha-beta T cell number	J:265237
	decreased CD8-positive, alpha-beta T cell number	J:265237
	decreased CD8-positive, naive alpha-beta T cell number	J:265237
	decreased IgD level	J:265237
	decreased single-positive T cell number	J:265237
	decreased T cell number	J:265237
	increased B-1b cell number	J:265237
	increased central memory CD4-positive, alpha-beta T cell number	J:265237
	increased central memory CD8 positive, alpha-beta T cell number	J:265237
	increased dendritic cell number	J:265237
	increased effector memory CD4-positive, alpha-beta T cell number	J:265237
	increased effector memory CD8-positive, alpha-beta T cell number	J:265237
	increased IgE level	J:265237
	increased macrophage cell number	J:265237
	increased neutrophil cell number	J:265237
	increased NK cell number	J:265237
\Stk4^m3Btlr/\Stk4^m3Btlr (C57BL/6J-Stk4^m3Btlr)	decreased CD4-positive, alpha-beta T cell number	J:265245
	decreased CD8-positive, alpha-beta T cell number	J:265245
	decreased single-positive T cell number	J:265245
	decreased T cell number	J:265245
\Stk4^m4Btlr/\Stk4^m4Btlr (C57BL/6J-Stk4^m4Btlr)	decreased CD11b-high dendritic cell number	J:272536
	decreased IgD level	J:272536
	decreased IgG level	J:272536
	impaired humoral immune response	J:272536
	increased B-1b cell number	J:272536
	increased dendritic cell number	J:272536
\Stk4^m5Btlr/\Stk4^m5Btlr (C57BL/6J-Stk4^m5Btlr)	abnormal CD4-positive T cell differentiation	J:272743
	abnormal T cell differentiation	J:272743
	decreased CD4-positive, alpha-beta T cell number	J:272743
	increased central memory CD4-positive, alpha-beta T cell number	J:272743
\Stk4^tm1.1Kina/\Stk4^tm1.1Kina (involves: C57BL/6)	abnormal B cell physiology	J:148791
	abnormal dendritic cell physiology	J:148791
	abnormal immune system organ morphology	J:148791
	abnormal leukocyte adhesion	J:148791
	abnormal leukocyte migration	J:148791
	abnormal marginal zone B cell morphology	J:148791
	abnormal Peyer's patch germinal center morphology	J:148791
	abnormal Peyer's patch T cell area morphology	J:148791
	abnormal spleen B cell follicle morphology	J:148791
	abnormal T cell physiology	J:148791
	decreased B cell number	J:148791
	decreased lymphocyte cell number	J:148791
	decreased marginal zone B cell number	J:148791
	decreased myeloid dendritic cell number	J:148791
	decreased spleen B cell follicle size	J:148791
	decreased T cell number	J:148791
	increased single-positive T cell number	J:148791
	increased T cell proliferation	J:148791
	thymus hyperplasia	J:148791
\Stk4^tm1.1Wtao/\Stk4^tm1.2Wtao \Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * SJL/J)	decreased CD4-positive, alpha-beta T cell number	J:152323
	decreased CD8-positive, alpha-beta T cell number	J:152323
	decreased T cell number	J:152323
	increased single-positive T cell number	J:152323
	increased thymocyte number	J:152323
\Stk4^tm1.2Wtao/\Stk4^tm1.2Wtao (involves: 129S4/SvJaeSor * 129S6/SvEvTac)	abnormal CD4-positive, alpha-beta T cell physiology	J:152323
	abnormal CD8-positive, alpha-beta T cell physiology	J:152323
	abnormal T cell physiology	J:152323
	decreased B cell number	J:152323
	decreased CD4-positive, alpha-beta T cell number	J:152323
	decreased CD8-positive, alpha-beta T cell number	J:152323
	decreased lymphocyte cell number	J:152323
	increased single-positive T cell number	J:152323
	increased thymocyte number	J:152323
\Stk4^tm1Dlim/\Stk4^tm1Dlim (Not Specified)	abnormal T cell physiology	J:155001
\Stk4^tm1Dlim/\Stk4^tm1Dlim (Not Specified)	decreased T cell number	J:155001
\Stk10^{em1(IMPC)Ccpcz}/\Stk10^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Stk10^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
\Stk10^tm1Hkar/\Stk10^tm1Hkar (involves: 129S1/Sv)	abnormal T cell physiology	J:60738
\Stk11^tm1.1Mlfr/\Stk11⁺ (involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)	enlarged spleen	J:104347
\Stk11^tm1.1Rdp/\Stk11^tm1.1Rdp \Tg(Pdx1-cre)89.1Dam/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N * ICR)	pancreas inflammation	J:134078
\Stk11^tm1.1Rdp/\Stk11^tm1.1Rdp \Tg(Sprr2f-cre)1Dcas/0 (involves: 129S6/SvEvTac * FVB/N)	peritoneal inflammation	J:158190
	sepsis	J:158190
\Stk11^tm1.1Sjm/\Stk11^tm1.1Sjm \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA * SJL)	decreased leukocyte cell number	J:165090
	thymus hypoplasia	J:165090
\Stk11^tm1Keis/\Stk11^tm1Keis \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	increased circulating interleukin-10 level	J:191723
\Stk17b^tm1Hed/\Stk17b^tm1Hed (involves: 129X1/SvJ * C57BL/6)	increased T cell proliferation	J:94685
\Stk17b^tm1Hed/\Stk17b^tm1Hed (B6.129X1-Stk17b^tm1Hed)	abnormal cytokine secretion	J:94685
	decreased double-positive T cell number	J:94685
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:94685
	increased CD4-positive, alpha-beta T cell number	J:94685
	increased interferon-gamma secretion	J:94685
	increased interleukin-2 secretion	J:94685
	increased memory T cell number	J:94685
	increased T cell proliferation	J:94685
	increased tumor necrosis factor secretion	J:94685
\Stk24^{Gt(AM0826)Wtsi}/\Stk24^{Gt(AM0826)Wtsi} (B6.129P2-Stk24^{Gt(AM0826)Wtsi})	abnormal neutrophil morphology	J:256076
	abnormal neutrophil physiology	J:256076
	immune system phenotype	J:256076
\Stk26^{tm1b(EUCOMM)Hmgu}/Y (C57BL/6N-Stk26^{tm1b(EUCOMM)Hmgu}/Ccpcz)	increased NK T cell number	J:211773
\Stk26^{tm1b(EUCOMM)Hmgu}/\Stk26^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Stk26^{tm1b(EUCOMM)Hmgu}/Ccpcz)	decreased monocyte cell number	J:211773
\Stk36^tm1Fjs/\Stk36^tm1Fjs (involves: 129S1/Sv * C57BL/6)	rhinitis	J:116391
	spleen atrophy	J:116391
	thymus atrophy	J:116391
\Stk36^tm1Lex/\Stk36^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:185566
\Stk38^{tm1b(KOMP)Wtsi}/\Stk38⁺ (C57BL/6N-Stk38^{tm1b(KOMP)Wtsi}/J)	increased leukocyte cell number	J:211773
\Stk38^tm1Hem/\Stk38⁺ (involves: 129P2/Ola * C57BL/6)	increased T cell derived lymphoma incidence	J:185408
\Stk38^tm1Hem/\Stk38^tm1Hem (involves: 129P2/Ola * C57BL/6)	abnormal T cell physiology	J:185408
	decreased thymocyte apoptosis	J:185408
	increased T cell derived lymphoma incidence	J:185408
\Stk38^tm1Xen/\Stk38^tm1Xen (involves: 129S5/SvEvBrd * C57BL/6)	immune system phenotype	J:224932
	increased circulating interleukin-6 level	J:224932
	increased circulating tumor necrosis factor level	J:224932
	increased interleukin-6 secretion	J:224932
	increased susceptibility to bacterial infection	J:224932
	increased susceptibility to bacterial infection induced morbidity/mortality	J:224932
	increased tumor necrosis factor secretion	J:224932
\Stoml1^em1(IMPC)Tcp/\Stoml1^em1(IMPC)Tcp (C57BL/6N-Stoml1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Stoml2^tm1Jmad/\Stoml2^tm1Jmad \Tg(Cd4-cre)1Cwi/0 (B6.Cg-Tg(Cd4-cre)1Cwi Stoml2^tm1Jmad)	immune system phenotype	J:187226
\Stra6^tm1Jwu/\Stra6^tm1Jwu (B6.129-Stra6^tm1Jwu)	immune system phenotype	J:211118
\Stra6l^{tm1b(KOMP)Wtsi}/\Stra6l^{tm1b(KOMP)Wtsi} (C57BL/6N-Stra6l^{tm1b(KOMP)Wtsi}/Ucd)	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Stub1^tm1Cpat/\Stub1^tm1Cpat (involves: 129S/SvEv * C57BL/6)	increased thymocyte apoptosis	J:86213
	thymus atrophy	J:86213
	thymus hypoplasia	J:86213
\Stx2^tm1Dcru/\Stx2^tm1Dcru (involves: 129X1/SvJ * C57BL/6J)	decreased susceptibility to induced colitis	J:110376
\Stx3^{Gt(EUCE320f12)1.1Hmgu}/\Stx3^{Gt(EUCE320f12)1.1Hmgu} (B6.129P2(129S4)-Stx3^{Gt(EUCE320f12)1.1Hmgu})	immune system phenotype	J:275367
\Stx3^{Gt(EUCE320f12)1.1Hmgu}/\Stx3^{Gt(EUCE320f12)1.1Hmgu} \Tg(Cma1-cre)ARoer/0 (B6.Cg-Stx3^{Gt(EUCE320f12)1.1Hmgu} Tg(Cma1-cre)ARoer)	abnormal mast cell degranulation	J:275367
	decreased mast cell degranulation	J:275367
	immune system phenotype	J:275367
\Stx3^{Gt(EUCE320f12)1.2Hmgu}/\Stx3⁺ (B6.129P2(Cg)-Stx3^{Gt(EUCE320f12)1.2Hmgu})	abnormal mast cell degranulation	J:275367
	immune system phenotype	J:275367
\Stx4a^tm1.1Radac/\Stx4a^tm1.1Radac (involves: 129S4/SvJaeSor * C57BL/6J)	immune system phenotype	J:275367
\Stx4a^tm1.1Radac/\Stx4a^tm1.1Radac \Tg(Cma1-cre)ARoer/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6J)	immune system phenotype	J:275367
\Stx4a^tm1.2Radac/\Stx4a⁺ (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6J)	immune system phenotype	J:275367
\Stx7^{em1(IMPC)Rbrc}/\Stx7^{em1(IMPC)Rbrc} (C57BL/6NJcl-Stx7^{em1(IMPC)Rbrc}/Rbrc)	abnormal thymus morphology	J:211773
	decreased large unstained cell number	J:211773
	small thymus	J:211773
\Stx11^em1(IMPC)Mbp/\Stx11^em1(IMPC)Mbp (C57BL/6N-Stx11^em1(IMPC)Mbp/MbpMmucd)	increased lymphocyte cell number	J:211773
\Stx11^tm1.2Ics/\Stx11^tm1.2Ics (involves: C57BL/6NTac)	abnormal cytotoxic T cell physiology	J:193137
	decreased cytotoxic T cell cytolysis	J:193137
	decreased leukocyte cell number	J:193137
	decreased neutrophil cell number	J:193137
	decreased NK cell degranulation	J:193137
	increased circulating interferon-gamma level	J:193137
	increased circulating interleukin-1 beta level	J:193137
	increased circulating interleukin-6 level	J:193137
	increased circulating tumor necrosis factor level	J:193137
	increased susceptibility to Riboviria infection	J:193137
\Stx11^tm1Bupa/\Stx11^tm1Bupa (B6.129-Stx11^tm1Bupa)	abnormal cell-mediated immunity	J:191103
	abnormal cytokine secretion	J:191103
	abnormal lymphocyte physiology	J:191103
	abnormal neutrophil physiology	J:191103
	impaired natural killer cell mediated cytotoxicity	J:191103
	increased interferon-gamma secretion	J:191103
	increased tumor necrosis factor secretion	J:191103
\Stxbp2^tm1Bdic/\Stxbp2⁺ (involves: 129S * C57BL/6)	decreased mast cell degranulation	J:188931
\Stxbp2^tm1Bdic/\Stxbp2⁺ (involves: 129S * C57BL/6)	decreased susceptibility to type I hypersensitivity reaction	J:188931
\sty/\sty (Not Specified)	small thymus	J:3675
\Styk1^tm1Twa/\Styk1^tm1Twa (C57BL/6N-Styk1^tm1Twa)	immune system phenotype	J:277150
\Styk1^tm1Twa/\Styk1^tm1Twa (B6J.B6N-Styk1^tm1Twa)	immune system phenotype	J:277150
\Styxl2^em1(IMPC)Mbp/\Styxl2^em1(IMPC)Mbp (C57BL/6N-Styxl2^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
\Sucnr1^tm1Dgen/\Sucnr1^tm1Dgen (B6.129P2-Sucnr1^tm1Dgen)	abnormal dendritic cell physiology	J:143337
	abnormal interleukin-2 secretion	J:143337
	abnormal Langerhans cell physiology	J:143337
	abnormal T cell activation	J:143337
	decreased T cell proliferation	J:143337
	increased length of allograft survival	J:143337
\Suco^{Gt(KST050)Byg}/\Suco^{Gt(KST050)Byg} (involves: 129P2/OlaHsd * C57BL/6 * CD-1)	abnormal osteoclast physiology	J:159823
	decreased osteoclast cell number	J:159823
\Sufu^{tm1b(KOMP)Wtsi}/\Sufu⁺ (C57BL/6N-Sufu^{tm1b(KOMP)Wtsi}/Ucd)	enlarged lymph nodes	J:211773
\Sugct^tm1.2Kald/\Sugct^tm1.2Kald (B6.Cg-Sugct^tm1.2Kald)	increased macrophage cell number	J:293423
	kidney inflammation	J:293423
	white adipose tissue inflammation	J:293423
\Sugp1^em1(IMPC)Mbp/\Sugp1⁺ (C57BL/6NCrl-Sugp1^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Sulf1^{Gt(OST352220)Lex}/\Sulf1^{Gt(OST352220)Lex} (involves: 129S5/SvEvBrd * C57BL/6N)	decreased susceptibility to bacterial infection	J:171883
\Sulf2^{em1(IMPC)Ccpcz}/\Sulf2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Sulf2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Sult1a1^{em1(IMPC)Ccpcz}/\Sult1a1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Sult1a1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Sumf1^{Gt(RST760)Byg}/\Sumf1^{Gt(RST760)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage morphology	J:120146
	abnormal microglial cell morphology	J:120146
	CNS inflammation	J:120146
	increased macrophage cell number	J:120146
\Sun1^{tm1b(EUCOMM)Wtsi}/\Sun1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Sun1^{tm1b(EUCOMM)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Sun2^{tm1b(EUCOMM)Hmgu}/\Sun2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Sun2^{tm1b(EUCOMM)Hmgu}/Bay)	increased large unstained cell number	J:211773
\Sun5^em1(IMPC)Mbp/\Sun5^em1(IMPC)Mbp (C57BL/6N-Sun5^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Supv3l1^tm2.1Jkl/\Supv3l1^tm2.2Jkl \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129P2/OlaHsd 129S4/SvJaeSor * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:144991
	decreased CD4-positive, alpha-beta T cell number	J:144991
	decreased CD8-positive, alpha-beta T cell number	J:144991
	decreased double-negative T cell number	J:144991
	decreased double-positive T cell number	J:144991
	increased macrophage derived foam cell number	J:144991
	lung inflammation	J:144991
	thymus atrophy	J:144991
	thymus hypoplasia	J:144991
\Supv3l1^tm2Jkl/\Supv3l1^tm2Jkl \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129P2/OlaHsd C57BL/6)	abnormal T cell differentiation	J:144991
	decreased CD4-positive, alpha-beta T cell number	J:144991
	decreased CD8-positive, alpha-beta T cell number	J:144991
	decreased double-negative T cell number	J:144991
	decreased double-positive T cell number	J:144991
	increased macrophage derived foam cell number	J:144991
	lung inflammation	J:144991
	thymus atrophy	J:144991
	thymus hypoplasia	J:144991
\Supv3l1^tm2Jkl/\Supv3l1^tm2Jkl \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	increased macrophage derived foam cell number	J:144991
	increased plasma cell number	J:144991
	interstitial pneumonia	J:144991
\Susd4^tm1Lex/\Susd4^tm1Lex (B6.129S5-Susd4^tm1Lex)	abnormal complement protein level	J:306852
	abnormal microglial cell morphology	J:306852
	increased microglial cell activation	J:306852
\Susd6^{tm1b(KOMP)Wtsi}/\Susd6^{tm1b(KOMP)Wtsi} (C57BL/6N-Susd6^{tm1b(KOMP)Wtsi}/Bay)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	enlarged spleen	J:211773
	increased lymphocyte cell number	J:211773
\Suv39h1^tm1Jnw/\Suv39h1^tm1Jnw (involves: 129)	abnormal T-helper 2 physiology	J:186702
\Suv39h1^tm1Jnw/\Suv39h1^tm1Jnw (involves: 129)	decreased susceptibility to type I hypersensitivity reaction	J:186702
\Suz12^Plt8/\Suz12⁺ (involves: 129 * C57BL/6)	increased leukocyte cell number	J:136262
\Suz12^Plt8/\Suz12⁺ (involves: 129 * C57BL/6)	increased lymphocyte cell number	J:136262
\Svep1^{tm1a(EUCOMM)Hmgu}/\Svep1^{tm1a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal lymphangiogenesis	J:244466
	abnormal lymphatic vessel morphology	J:244466
\Swap70^tm1Jess/\Swap70^tm1Jess (involves: 129T2/SvEms * 129X1/SvJ)	abnormal class switch recombination	J:71160
	decreased IgE level	J:71160
	increased autoantibody level	J:71160
\Swq6^C57BL/6J/\Swq6^CAST/EiJ (involves: C57BL/6J * CAST/EiJ)	increased spleen weight	J:117545
\Swq6^CAST/EiJ/\Swq6^CAST/EiJ (involves: C57BL/6J * CAST/EiJ)	increased spleen weight	J:117545
\Swqnd1^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	decreased spleen weight	J:122125
\Swqnd2^NMRI8/Fbn/? (involves: DBA/2OlaHsd * NMRI8/Fbn)	decreased spleen weight	J:122125
\Swrl1^NZB/\Swrl1^NZB (involves: NZB * SWR)	abnormal type II hypersensitivity reaction	J:73097
\Swrl1^NZB/\Swrl1^SWR (involves: NZB * SWR)	abnormal type II hypersensitivity reaction	J:73097
\Swrl1^SWR/\Swrl1^SWR (involves: NZB * SWR)	increased IgG3 level	J:96263
\Swrl2^NZB/\Swrl2^SWR (involves: NZB * SWR)	glomerulonephritis	J:73097
\Swrl2^SWR/\Swrl2^SWR (involves: NZB * SWR)	glomerulonephritis	J:73097
\Swrl2^SWR/\Swrl2^SWR (involves: NZB * SWR)	increased anti-single stranded DNA antibody level	J:96060
\Swrl3^NZB/\Swrl3^SWR (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96060
	increased anti-histone antibody level	J:96060
	increased anti-nuclear antigen antibody level	J:73097
\Swrl3^SWR/\Swrl3^SWR (involves: NZB * SWR)	increased anti-double stranded DNA antibody level	J:96060
	increased anti-histone antibody level	J:96060
	increased anti-nuclear antigen antibody level	J:73097
\Swt1^em1(IMPC)J/\Swt1^em1(IMPC)J (C57BL/6NJ-Swt1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Sycn^tm1Rja/\Sycn^tm1Rja (involves: 129P2/OlaHsd)	increased susceptibility to induced pancreatitis	J:74654
\Syk^m1Btlr/\Syk^m1Btlr (involves: C57BL/6J)	decreased B cell number	J:199281
	increased neutrophil cell number	J:199281
	increased tumor necrosis factor secretion	J:199281
\Syk^M2Btlr/\Syk⁺ (C57BL/6J-Syk^M2Btlr)	abnormal NK cell differentiation	J:231803
\Syk^M2Btlr/\Syk⁺ (C57BL/6J-Syk^M2Btlr)	decreased inflammatory response	J:231803
\Syk^M2Btlr/\Syk^M2Btlr (C57BL/6J-Syk^M2Btlr)	abnormal NK cell differentiation	J:231803
\Syk^M2Btlr/\Syk^M2Btlr (C57BL/6J-Syk^M2Btlr)	decreased inflammatory response	J:231803
\Syk^{tm1.1(cre)Fkfr}/\Syk^{tm1.1(cre)Fkfr} \Gt(ROSA)26Sor^tm1(EYFP)Cos/\Gt(ROSA)26Sor^tm1(EYFP)Cos (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphangiogenesis	J:159112
	decreased leukocyte cell number	J:159112
	increased leukocyte cell number	J:159112
\Syk^tm1.1Nns/\Syk^tm1.1Nns \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/10 * CBA/Ca)	abnormal lymphatic vessel morphology	J:181715
\Syk^tm1.1Nns/\Syk^tm1.1Nns \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd)	immune system phenotype	J:181715
\Syk^tm1.1Nns/\Syk^tm1.1Nns \Tg(CD2-icre)4Kio/0 (involves: C57BL/10 * CBA/Ca)	immune system phenotype	J:181715
\Syk^tm1.1Nns/\Syk^tm1.1Nns \Tg(Pf4-icre)Q3Rsko/0 (involves: C57BL/6)	abnormal lymphatic vessel endothelial cell morphology	J:181715
	abnormal lymphatic vessel morphology	J:181715
\Syk^tm1.1Nns/\Syk^tm1.1Nns \Tg(Tie1-cre)9Ref/0 \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * CBA/Ca)	abnormal lymphatic vessel morphology	J:181715
\Syk^tm1.1Tara/\Syk^tm1.1Tara (involves: 129P2/OlaHsd * C57BL/6)	arrested B cell differentiation	J:115080
	increased B cell proliferation	J:114816
\Syk^tm1.2Tara/\Syk^tm1.2Tara \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:208904
\Syk^tm1.2Tara/\Syk^tm1.2Tara \Tg(Itgax-cre)1-1Reiz/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:181715
\Syk^tm1Kuro/\Syk^tm1Kuro \Zap70^tm1Dlo/\Zap70^tm1Dlo \Cd79a^tm1(cre)Reth/? (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal pro-B cell differentiation	J:134528
\Syk^tm1Paw/\Syk^tm1Paw (involves: 129S1/Sv * 129X1/SvJ)	abnormal B cell differentiation	J:29797
	abnormal lymphangiogenesis	J:159112
	abnormal lymphatic vessel endothelium morphology	J:159112
	abnormal lymphatic vessel morphology	J:159112
	absent pre-B cells	J:29797
	decreased late pro-B cell number	J:29797
	enlarged lymphatic vessel	J:159112
	lymphatic vessel hyperplasia	J:159112
\Syk^tm1Tyb/\Syk^tm1.2Tara \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal neutrophil physiology	J:155479
	impaired granulocyte bactericidal activity	J:155479
\Syk^tm1Tyb/\Syk^tm1.2Tara \Tg(S100A8-cre,-EGFP)1Ilw/0 (involves: 129P2/OlaHsd * 129S2/SvPas * C3H * C57BL/6)	impaired granulocyte bactericidal activity	J:155479
\Syk^tm1Tyb/\Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6 * DBA/2)	abnormal T cell number	J:29796
	arrested B cell differentiation	J:29796
\Syk^tm1Tyb/\Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6)	abnormal osteoclast differentiation	J:89583
\Syk^tm1Tyb/\Syk^tm1Tyb (involves: 129S2/SvPas)	abnormal dendritic cell antigen presentation	J:147472
	abnormal neutrophil physiology	J:155479
	decreased tumor necrosis factor secretion	J:155479
	impaired granulocyte bactericidal activity	J:155479
	impaired neutrophil phagocytosis	J:155479
\Syk^tm1Tyb/\Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6J)	abnormal lymphatic vessel morphology	J:181715
\Syk^tm1Tyb/\Syk^tm1Tyb (involves: 129S2/SvPas * C57BL/6J)	decreased lymphatic vessel endothelial cell number	J:181715
\Syk^{tm2.1(ZAP70)Fkfr}/\Syk^{tm2.1(ZAP70)Fkfr} (B6.129-Syk^{tm2.1(ZAP70)Fkfr})	abnormal B cell physiology	J:188422
	abnormal neutrophil physiology	J:188422
	arrested B cell differentiation	J:188422
	decreased B cell number	J:188422
	decreased DN1 thymic pro-T cell number	J:188422
	decreased IgG1 level	J:188422
	decreased IgG2a level	J:188422
	decreased IgG2b level	J:188422
	decreased marginal zone B cell number	J:188422
	decreased mature B cell number	J:188422
	decreased transitional stage B cell number	J:188422
	decreased transitional stage T1 B cell number	J:188422
	decreased transitional stage T2 B cell number	J:188422
	glomerulonephritis	J:188422
	immune system phenotype	J:188422
	increased anti-insulin autoantibody level	J:188422
	increased B cell apoptosis	J:188422
	increased CD4-positive, alpha-beta memory T cell number	J:188422
	increased CD4-positive, alpha-beta T cell number	J:188422
	increased CD8-positive, alpha-beta memory T cell number	J:188422
	increased CD8-positive, alpha-beta T cell number	J:188422
	increased DN3 thymocyte number	J:188422
	increased IgM level	J:188422
\Syne1^tm1.1Mcn/\Syne1^tm1.1Mcn (involves: 129S4/SvJae * 129S6/SvEvTac * C57BL)	conjunctivitis	J:144757
\Syngr1^{em1(IMPC)Ccpcz}/\Syngr1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Syngr1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Syngr3^em1Pave/\Syngr3⁺ \Tg(Prnp-MAPTP301S)PS19Vle/0 (involves: C3H C57BL/6)	microgliosis	J:303506
\Synj1^{tm1b(EUCOMM)Wtsi}/\Synj1⁺ (C57BL/6N-Synj1^{tm1b(EUCOMM)Wtsi}/H)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased lymphocyte cell number	J:211773
\Synpo2^{tm1b(EUCOMM)Wtsi}/\Synpo2⁺ (C57BL/6N-Synpo2^{tm1b(EUCOMM)Wtsi}/Ics)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Syt7^tm1Nan/\Syt7^tm1Nan (involves: 129S1/Sv * C57BL/6)	increased anti-nuclear antigen antibody level	J:85201
	increased inflammatory response	J:85201
	increased susceptibility to autoimmune disorder	J:85201
	myositis	J:85201
\Sytl1^{tm1a(KOMP)Wtsi}/\Sytl1^{tm1a(KOMP)Wtsi} (involves: C57BL/6 * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:213427
	decreased IgG2b level	J:213427
	decreased mature B cell number	J:213427
	decreased T cell number	J:213427
	epididymis inflammation	J:213427
	increased regulatory T cell number	J:213427
	meningitis	J:213427
\Syvn1^tm1Tn/\Syvn1⁺ (D1.Cg-Syvn1^tm1Tn)	decreased susceptibility to induced arthritis	J:86009
\t^AE5/\t^AE5 (Not Specified)	abnormal spleen morphology	J:83862
	abnormal thymus cortex morphology	J:83862
	abnormal thymus morphology	J:83862
	decreased spleen white pulp amount	J:83862
	increased mast cell number	J:83862
	increased susceptibility to infection	J:83862
	thymus cortex hypoplasia	J:83862
\Tab2^tm2.1Aki/\Tab2^tm2.1Aki \Tab3^tm1Aki/\Tab3^tm1Aki \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:195289
	abnormal immune serum protein physiology	J:195289
	decreased B cell proliferation	J:195289
	decreased B-1a cell number	J:195289
	decreased circulating interleukin-6 level	J:195289
	decreased IgD level	J:195289
	decreased IgE level	J:195289
	decreased IgG level	J:195289
	decreased immunoglobulin level	J:195289
	decreased mature B cell number	J:195289
	decreased plasma cell number	J:195289
	increased B cell apoptosis	J:195289
\Tab2^tm2.1Aki/\Tab2^tm2.1Aki \Tab3^tm1Aki/\Tab3^tm1Aki \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:195289
\Tac4^tm1Albe/\Tac4^tm1Albe (B6.129P2-Tac4^tm1Albe)	increased pro-B cell number	J:166471
\Tacc3^tm1Jni/\Tacc3^tm1Jni (involves: 129P2/OlaHsd * C57BL/6)	decreased thymocyte number	J:74762
	small thymus	J:74762
\Tacr1^tm1Nge/\Tacr1^tm1Nge (involves: 129S4/SvJae)	abnormal humoral immune response	J:35529
\Tacr1^tm1Nge/\Tacr1^tm1Nge (involves: 129S4/SvJae * C57BL)	abnormal mast cell physiology	J:84660
\Tacr1^tm1Sph/\Tacr1^tm1Sph (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:46629
	joint inflammation	J:103700
\Taf4^tm1Idvd/\Taf4^tm1Idvd \Tg(KRT14-cre/ERT2)1Ipc/0 (involves: C57BL/6 * SJL)	chronic inflammation	J:124111
\Taf7^tm1.1Dss/\Taf7^tm1.2Dss \Tg(Cd8a*-cre)B8Asin/0 (involves: C57BL/6)	abnormal T cell differentiation	J:185745
	decreased CD4-positive, alpha-beta T cell number	J:185745
	decreased CD8-positive, alpha-beta T cell number	J:185745
	decreased double-positive T cell number	J:185745
	decreased single-positive T cell number	J:185745
	decreased T cell number	J:185745
	decreased T cell proliferation	J:185745
	decreased thymocyte number	J:185745
\Taf7^tm1.1Dss/\Taf7^tm1.2Dss \Tg(Lck-cre)1Cwi/0 (involves: C57BL/6)	abnormal T cell differentiation	J:185745
	abnormal thymus physiology	J:185745
	decreased CD4-positive, alpha-beta T cell number	J:185745
	decreased CD8-positive, alpha-beta T cell number	J:185745
	decreased double-positive T cell number	J:185745
	decreased thymocyte number	J:185745
	increased double-negative T cell number	J:185745
	small thymus	J:185745
\Taf15^em1(IMPC)Mbp/\Taf15^em1(IMPC)Mbp (C57BL/6NCrl-Taf15^em1(IMPC)Mbp/MbpMmucd)	increased lymphocyte cell number	J:211773
\Tagap1^em1(IMPC)Tcp/\Tagap1⁺ (C57BL/6N-Tagap1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Tagln2^em1(IMPC)Tcp/\Tagln2^em1(IMPC)Tcp (C57BL/6N-Tagln2^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged spleen	J:211773
	increased neutrophil cell number	J:211773
\Tagln2^tm1Cdj/\Tagln2^tm1Cdj (involves: 129S4/SvJae * C57BL/6)	abnormal cytotoxic T cell physiology	J:256656
	abnormal T cell physiology	J:256656
	immune system phenotype	J:256656
\Tagln2^tm1Cdj/\Tagln2^tm1Cdj \Tg(TcraTcrb)425Cbn/0 (involves: 129S4/SvJae * C57BL/6)	abnormal T cell activation	J:256656
\Tagln2^tm1Cdj/\Tagln2^tm1Cdj \Tg(TcraTcrb)1100Mjb/0 (involves: 129S4/SvJae * C57BL/6)	abnormal T cell activation	J:256656
\Tal1^Hpt/\Tal1⁺ (HPT/Le)	decreased leukocyte cell number	J:1780
\Tal1^tm1Por/\Tal1^tm1Por (involves: 129P2/OlaHsd)	increased spleen weight	J:139179
\Tal1^tm3Wehi/\Tal1^tm2Wehi \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal splenic cell ratio	J:81826
\Tank^tm1Aki/\Tank^tm1Aki (involves: 129/Sv * C57BL/6)	abnormal dendritic cell physiology	J:151757
	abnormal macrophage physiology	J:151757
	abnormal plasmacytoid dendritic cell physiology	J:151757
	glomerulonephritis	J:151757
	increased anti-double stranded DNA antibody level	J:151757
	increased anti-nuclear antigen antibody level	J:151757
	increased B cell proliferation	J:151757
	increased IgA level	J:151757
	increased IgG1 level	J:151757
	increased IgG2a level	J:151757
	increased IgG2b level	J:151757
	increased IgM level	J:151757
	increased interferon-alpha secretion	J:151757
	increased interleukin-6 secretion	J:151757
	increased mature B cell number	J:151757
	increased plasma cell number	J:151757
	increased tumor necrosis factor secretion	J:151757
	liver inflammation	J:151757
	lung inflammation	J:151757
	lymph node hyperplasia	J:151757
	spleen hyperplasia	J:151757
\Taok1^em1(IMPC)Tcp/\Taok1⁺ (C57BL/6NCrl-Taok1^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
\Tap1^m1Btlr/\Tap1^m1Btlr (C57BL/6J-Tap1^m1Btlr)	decreased CD8-positive, alpha-beta memory T cell number	J:254888
\Tap1^m1Btlr/\Tap1^m1Btlr (C57BL/6J-Tap1^m1Btlr)	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254888
\Tap1^m2Btlr/\Tap1^m2Btlr (C57BL/6J-Tap1^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:236697
\Tap1^m2Btlr/\Tap1^m2Btlr (C57BL/6J-Tap1^m2Btlr)	increased susceptibility to Herpesvirales infection	J:236697
\Tap1^rose/\Tap1^rose (C57BL/6JAnu-Tap1^rose/AnuApb)	decreased CD8-positive, alpha-beta T cell number	J:166104
\Tap1^tm1Arp/\Tap1^tm1Arp (involves: 129S2/SvPas * C57BL/6)	abnormal antigen presentation	J:122479
	abnormal dendritic cell antigen presentation	J:112436
	abnormal lymphocyte physiology	J:122479
	absent CD8-positive, alpha-beta T cells	J:3524
	decreased double-negative T cell number	J:3524
	decreased level of surface class I molecules	J:3524
	defective intracellular transport of class I molecules	J:3524
\Tap1^tm1Arp/\Tap1^tm1Arp (involves: 129S2/SvPas)	abnormal antigen presentation via MHC class I	J:64349
	abnormal dendritic cell antigen presentation	J:64349
	decreased CD8-positive, alpha-beta T cell number	J:64177, J:64349
	decreased cytotoxic T cell cytolysis	J:64349
	decreased level of surface class I molecules	J:64177, J:64349
	defective assembly of class I molecules	J:64177
	defective intracellular transport of class I molecules	J:64177
\Tap1^tm1Arp/\Tap1^tm1Arp (B6.129S2-Tap1^tm1Arp/J)	decreased CD8-positive, alpha-beta T cell number	J:123934
	decreased susceptibility to bacterial infection	J:123934
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:123934
	increased T-helper 1 cell number	J:123934
\Tap1^tm1Arp/\Tap1^tm1Arp X/\Yaa (BXSB.129S2(B6)-Tap1^tm1Arp/Dcr)	increased susceptibility to systemic lupus erythematosus	J:179430
\Tap1^tm1Hpl/\Tap1^tm1Hpl (either: (involves: 129S2/SvPas * 129/Ola) or (involves: 129S2/SvPas * FVB))	immune system phenotype	J:60782
\Tap2^jas/\Tap2^jas (C57BL/6JSfdAnu-Tap2^jas/AnuApb)	absent CD8-positive, alpha-beta T cells	J:104190
\Tap2^jas/\Tap2^jas (C57BL/6JSfdAnu-Tap2^jas/AnuApb)	decreased CD8-positive, alpha-beta T cell number	J:166104
\Tap2^m1Btlr/\Tap2^m1Btlr (C57BL/6J-Tap2^m1Btlr)	abnormal cytotoxic T cell physiology	J:159355
	abnormal NK cell physiology	J:159355
	absent CD8-positive, alpha-beta T cells	J:159355
	decreased level of surface class I molecules	J:159355
	defective assembly of class I molecules	J:159355
\Tap2^m2Btlr/\Tap2^m2Btlr (C57BL/6J-Tap2^m2Btlr)	decreased CD8-positive, alpha-beta T cell number	J:217145
\Tap2^m2Btlr/\Tap2^m2Btlr (C57BL/6J-Tap2^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:217145
\Tap2^m3Btlr/\Tap2^m3Btlr (C57BL/6J-Tap2^m3Btlr)	decreased CD8-positive, alpha-beta T cell number	J:254929
	decreased CD8-positive, naive alpha-beta T cell number	J:254929
	decreased effector memory CD4-positive, alpha-beta T cell number	J:254929
	decreased NK T cell number	J:254929
	increased CD4-positive, alpha-beta T cell number	J:254929
	increased central memory CD8 positive, alpha-beta T cell number	J:254929
\Tap2^M4Btlr/\Tap2^M4Btlr (C57BL/6J-Tap2^M4Btlr)	increased CD4-positive, alpha-beta T cell number	J:272847
\Tapbp^tm1Gjh/\Tapbp^tm1Gjh (involves: 129S2/SvPas)	abnormal antigen presentation via MHC class I	J:64349
	abnormal dendritic cell antigen presentation	J:64349
	abnormal NK cell physiology	J:64349
	decreased cytotoxic T cell cytolysis	J:64349
	decreased level of surface class I molecules	J:64349
	decreased T cell number	J:64349
\Tapbp^tm1Luc/\Tapbp^tm1Luc (involves: 129S6/SvEvTac * C57BL/6)	abnormal lymphocyte physiology	J:122479
\Tapbp^tm1Luc/\Tapbp^tm1Luc (involves: 129S6/SvEvTac)	abnormal antigen presentation via MHC class I	J:64177
	abnormal cytotoxic T cell physiology	J:64177
	decreased CD8-positive, alpha-beta T cell number	J:64177
	decreased level of surface class I molecules	J:64177
	defective assembly of class I molecules	J:64177
\Tapbp^tm1Luc/\Tapbp^tm1Luc \Tg(TcraTcrb)1100Mjb/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:64177
	abnormal CD8-positive, alpha beta T cell morphology	J:64177
	abnormal negative T cell selection	J:64177
	abnormal positive T cell selection	J:64177
	immune system phenotype	J:64177
\Tapbp^tm1Luc/\Tapbp^tm1Luc \Tg(TcraTcrb)1100Mjb/? (involves: 129S6/SvEvTac)	immune system phenotype	J:64177
\Tapr^BALB/c/? (involves: BALB/c * DBA/2)	abnormal inflammatory response	J:72894
\Tardbp^tm1.1Neas/\Tardbp^tm1.1Neas (B6(C3)-Tardbp^tm1.1Neas)	microgliosis	J:283769
\Tardbp^tm2.1Neas/\Tardbp^tm2.1Neas (B6(C3)-Tardbp^tm2.1Neas)	microgliosis	J:283769
\Tarm1^tm1Yiw/\Tarm1^tm1Yiw (involves: C57BL/6 * C57BL/6NSlc)	abnormal dendritic cell antigen presentation	J:301164
	abnormal dendritic cell differentiation	J:301164
	abnormal interleukin-6 secretion	J:301164
	abnormal lymphocyte physiology	J:301164
	abnormal tumor necrosis factor secretion	J:301164
	decreased B cell number	J:301164
	decreased CD4-positive, alpha-beta T cell number	J:301164
	decreased dendritic cell number	J:301164
	decreased IgG2a level	J:301164
	decreased IgG2b level	J:301164
	decreased IgG3 level	J:301164
	decreased interferon-gamma secretion	J:301164
	decreased interleukin-17 secretion	J:301164
	decreased susceptibility to induced arthritis	J:301164
	decreased T cell proliferation	J:301164
	decreased tumor necrosis factor secretion	J:301164
	immune system phenotype	J:301164
\Tars3^em1(IMPC)J/\Tars3^em1(IMPC)J (C57BL/6NJ-Tars3^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Tas2r131^em1(IMPC)Bay/\Tas2r131^em1(IMPC)Bay (C57BL/6N-Tas2r131^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Tas2r139^em1(IMPC)Mbp/\Tas2r139^em1(IMPC)Mbp (C57BL/6NCrl-Tas2r139^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Tasl^em1Bcgen/\Tasl^em1Bcgen (BALB/cJ-Tasl^em1Bcgen)	abnormal immune cell physiology	J:363059
	decreased interferon level	J:363059
	decreased susceptibility to systemic lupus erythematosus	J:363059
\Tasp1^tm1Jjdh/\Tasp1^tm1Jjdh \Tg(Mx1-cre)1Cgn/? (involves: 129X1/SvJ * C57BL/6 * CBA)	decreased double-positive T cell number	J:112159
	decreased thymocyte number	J:112159
	decreased thymus weight	J:112159
\Tax1bp1^tm1Ktj/\Tax1bp1^tm1Ktj (B6.129P2-Tax1bp1^tm1Ktj)	abnormal hypersensitivity reaction	J:131849
	abnormal leukocyte physiology	J:131849
	abnormal macrophage chemotaxis	J:131849
	abnormal neutrophil physiology	J:131849
	abnormal T cell physiology	J:131849
	cardiovalvulitis	J:131849
	increased interleukin-1 beta secretion	J:131849
	increased interleukin-2 secretion	J:131849
	increased tumor necrosis factor secretion	J:131849
	skin inflammation	J:131849
\tb/\tb (Not Specified)	abnormal thymus involution	J:12166
\Tbata^tm1Faf/\Tbata^tm1Faf (involves: 129P2/OlaHsd * C57BL/6)	abnormal thymus epithelium morphology	J:166065
	enlarged thymus	J:166065
	immune system phenotype	J:166065
	increased double-negative T cell number	J:166065
	increased thymocyte number	J:166065
	thymus hyperplasia	J:166065
\Tbc1d4^tm1.1Arte/\Tbc1d4^tm1.1Arte (involves: C57BL/6)	decreased spleen weight	J:169477
\Tbc1d4^{tm1b(EUCOMM)Hmgu}/\Tbc1d4^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tbc1d4^{tm1b(EUCOMM)Hmgu}/J)	decreased leukocyte cell number	J:211773
\Tbc1d7^em1(IMPC)Bay/\Tbc1d7⁺ (C57BL/6N-Tbc1d7^em1(IMPC)Bay/Bay)	abnormal lymph node morphology	J:211773
	enlarged spleen	J:211773
\Tbc1d8b^em1(IMPC)Bay/Y (C57BL/6N-Tbc1d8b^em1(IMPC)Bay/BayMmucd)	decreased spleen weight	J:211773
\Tbc1d10c^tm1.1Psou/\Tbc1d10c^tm1.2Psou \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: 129S2/SvPas * BALB/c * C57BL/6J)	abnormal B cell physiology	J:211913
	increased anti-double stranded DNA antibody level	J:211913
	increased IgG level	J:211913
	increased IgM level	J:211913
	increased susceptibility to systemic lupus erythematosus	J:211913
\Tbc1d10c^tm1.1Psou/\Tbc1d10c^tm1.2Psou \Tg(Lck-cre)#Nik/0 (involves: 129S2/SvPas * C57BL/6 * C57BL/6J * DBA/2)	immune system phenotype	J:211913
\Tbc1d10c^tm1.2Psou/\Tbc1d10c^tm1.2Psou (involves: 129S2/SvPas * C57BL/6J)	abnormal B cell physiology	J:211913
	abnormal response to infection	J:211913
	abnormal T cell activation	J:211913
	immune system phenotype	J:211913
	increased anti-double stranded DNA antibody level	J:211913
	increased IgG level	J:211913
	increased susceptibility to systemic lupus erythematosus	J:211913
	increased T cell proliferation	J:211913
\Tbc1d23^{Gt(BA0556)Wtsi}/\Tbc1d23^{Gt(BA0556)Wtsi} (B6.129P2-Tbc1d23^{Gt(BA0556)Wtsi})	abnormal tumor necrosis factor level	J:181861
	increased circulating interleukin-6 level	J:181861
	increased circulating tumor necrosis factor level	J:181861
	increased inflammatory response	J:181861
\Tbc1d32^b2b2284Clo/\Tbc1d32^b2b2284Clo (C57BL/6J-Tbc1d32^b2b2284Clo)	spleen hypoplasia	J:175213
\Tbk1^M1Btlr/\Tbk1⁺ (involves: C57BL/6J)	abnormal interferon secretion	J:188770
\Tbk1^M1Btlr/\Tbk1⁺ (involves: C57BL/6J)	abnormal macrophage physiology	J:188770
\Tbk1^tm1.1Lex/\Tbk1⁺ (involves: 129S4/SvJae * 129S5/SvEvBrd)	abnormal inflammatory response	J:166476
	decreased basophil cell number	J:166476
	decreased eosinophil cell number	J:166476
\Tbk1^tm1.1Lex/\Tbk1^tm1.1Lex (involves: 129S4/SvJae * 129S5/SvEvBrd)	abnormal cytokine level	J:166476
	abnormal cytokine secretion	J:166476
	abnormal inflammatory response	J:166476
	decreased interferon-beta secretion	J:166476
	decreased NK T cell number	J:166476
	increased circulating interleukin-1 beta level	J:166476
	increased circulating interleukin-6 level	J:166476
	increased circulating interleukin-10 level	J:166476
	increased circulating tumor necrosis factor level	J:166476
	increased IgA level	J:166476
	increased interleukin-6 secretion	J:166476
	increased monocyte cell number	J:166476
	increased NK T cell number	J:166476
	increased spleen weight	J:166476
	increased susceptibility to bacterial infection induced morbidity/mortality	J:166476
	increased susceptibility to endotoxin shock	J:166476
	increased tumor necrosis factor secretion	J:166476
	lymphoid hyperplasia	J:166476
	skin inflammation	J:166476
\Tbk1^tm1Aki/\Tbk1^tm1Aki \Tnf^tm1Sek/\Tnf^tm1Sek (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal cytotoxic T cell physiology	J:132662
	decreased cytotoxic T cell cytolysis	J:132662
	decreased IgG1 level	J:132662
	decreased IgG2a level	J:132662
	decreased IgG level	J:132662
	decreased interferon-gamma secretion	J:132662
\Tbk1^tm1Arte/\Tbk1^tm1Arte \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:188560
	abnormal class switch recombination	J:188560
	increased anti-double stranded DNA antibody level	J:188560
	increased anti-nuclear antigen antibody level	J:188560
	increased IgA level	J:188560
	increased IgM level	J:188560
	increased mature B cell number	J:188560
\Tbk1^tm1Arte/\Tbk1^tm1Arte \Map3k14^tm1Rds/\Map3k14^tm1Rds \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:188560
	abnormal immunoglobulin level	J:188560
\Tbkbp1^tm1Aki/\Tbkbp1^tm1Aki (Not Specified)	immune system phenotype	J:204786
\Tbkbp1^{tm1b(EUCOMM)Wtsi}/\Tbkbp1^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tbkbp1^{tm1b(EUCOMM)Wtsi}/H)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Tbp^tm1.1Ees/\Tbp^tm1.1Ees (B6.129X1(Cg)-Tbp^tm1.1Ees)	hemophagocytosis	J:77714
\Tbrg1^{tm1a(KOMP)Wtsi}/\Tbrg1^{tm1a(KOMP)Wtsi} (C57BL/6N-Tbrg1^{tm1a(KOMP)Wtsi})	enlarged spleen	J:225146
	increased marginal zone B cell number	J:225146
	increased spleen white pulp amount	J:225146
\Tbrs1^C57BL/6J/\Tbrs1^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
\Tbrs2^C57BL/6J/\Tbrs2^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
\Tbrs2^C57BL/6J/\Tbrs2^DBA/2J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
\Tbrs3^C57BL/6J/\Tbrs3^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
\Tbrs3^C57BL/6J/\Tbrs3^C57BL/6J \Tbrs4^C57BL/6J/\Tbrs4^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:83619
\Tbrs3^C57BL/6J/\Tbrs3^DBA/2J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:67658
\Tbrs4^C57BL/6J/\Tbrs4^C57BL/6J (involves: C57BL/6J * DBA/2J)	decreased susceptibility to bacterial infection	J:83619
\Tbs1^I/StSnEgYCit/\Tbs1^A/SnYCit (involves: A/SnYCit * I/StSnEgYCit)	decreased susceptibility to bacterial infection	J:80972
\Tbs2^I/StSnEgYCit/\Tbs2^A/SnYCit (involves: A/SnYCit * I/StSnEgYCit)	decreased susceptibility to bacterial infection	J:80972
\Tbx1^m1H/\Tbx1^m1H (involves: C3H/HeH * C57BL/6J)	small thymus	J:169366
\Tbx1^m1Jlk/\Tbx1^m1Jlk (129/Sv-Tbx1^m1Jlk)	athymia	J:146769
\Tbx1^m1Jlk/\Tbx1^tm1Bld (involves: 129)	athymia	J:146769
\Tbx1^tm1.1Dsr/\Tbx1^tm1.1Dsr (either: 129/Sv or (involves: 129/Sv * C57BL/6))	athymia	J:93588
\Tbx1^tm1Bem/\Tbx1⁺ (FVB.Cg-Tbx1^tm1Bem)	increased susceptibility to otitis media	J:91664
\Tbx1^tm1Bem/\Tbx1^tm1Bem (FVB.Cg-Tbx1^tm1Bem)	athymia	J:91664
\Tbx1^tm1Bem/\Tbx1^tm1Bem (FVB.Cg-Tbx1^tm1Bem)	thymus hypoplasia	J:91664
\Tbx1^tm1Bld/\Tbx1^tm1Bld (involves: 129S7/SvEvBrd)	abnormal lymphangiogenesis	J:159824
	abnormal lymphatic vessel morphology	J:159824
	athymia	J:146769
	lymphangiectasis	J:159824
\Tbx1^tm1Bld/\Tbx1^tm2.1Bem \Tfap2a^tm1(cre)Moon/\Tfap2a⁺ (either: (involves: 129/Sv * C57BL/6 * SJL) or (involves: 129/Sv * C57BL/6J * CBA * SJL))	athymia	J:154590
	thymus hypoplasia	J:154590
\Tbx1^tm1Bld/\Tbx1^tm3Bld \Tg(CAG-cre/Esr1)5Amc/0 (involves: 129S7/SvEvBrd C57BL/6 * CBA)	abnormal lymphangiogenesis	J:159824
	abnormal lymphatic vessel morphology	J:159824
\Tbx1^tm1Bld/\Tbx1^tm3Bld \Tg(Tek-cre)1Ywa/0 (involves: 129S7/SvEvBrd * C57BL/6 * SJL)	abnormal lymphangiogenesis	J:159824
	abnormal lymphatic vessel morphology	J:159824
\Tbx1^tm1Bld/\Tbx1^tm5Bld (involves: 129S7/SvEvBrd * C57BL/6)	athymia	J:112457
\Tbx1^tm1Dsr/\Tbx1^tm1Dsr (either: 129/Sv or (involves: 129/Sv * C57BL/6))	athymia	J:93588
\Tbx1^tm1Pa/\Tbx1^tm1Pa (either: (involves: 129) or (involves: 129 * C57BL/6) or (involves: 129 * C57BL/6 * Swiss Webster))	abnormal thymus development	J:70730
	athymia	J:70730
\Tbx1^tm2.1Bem/\Tbx1^tm2.2Bem \Foxg1^tm1(cre)Skm/\Foxg1⁺ (involves: 129 * C57BL/6J * SJL * Swiss Webster)	athymia	J:105980
\Tbx3^em1(IMPC)Mbp/\Tbx3⁺ (C57BL/6NCrl-Tbx3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
\Tbx20^em1(IMPC)Mbp/\Tbx20⁺ (C57BL/6N-Tbx20^em1(IMPC)Mbp/MbpMmucd)	increased neutrophil cell number	J:211773
\Tbx21^duane/\Tbx21^duane (C57BL/6-Tbx21^duane)	abnormal NK cell differentiation	J:154069
	absent NK T cells	J:154069
	decreased NK cell number	J:154069
	increased NK cell number	J:154069
\Tbx21^m1Btlr/\Tbx21^m1Btlr (C57BL/6J-Tbx21^m1Btlr)	increased CD8-positive, alpha-beta T cell number	J:267478
	increased effector memory CD8-positive, alpha-beta T cell number	J:267478
	increased IgM level	J:267478
\Tbx21^{tm1.1(flpe/ERT2)Gmld}/\Tbx21^{tm1.1(flpe/ERT2)Gmld} (involves: 129S2/SvPas * C57BL/6)	decreased interferon-gamma secretion	J:207104
\Tbx21^tm1Glm/\Tbx21⁺ (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytokine level	J:73833
	abnormal interleukin level	J:73832
	abnormal NK cell physiology	J:73833
	abnormal tumor necrosis factor level	J:73832
	decreased T helper 1 cell number	J:73833
\Tbx21^tm1Glm/\Tbx21^tm1Glm (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:73833
	abnormal cytokine level	J:73832
	abnormal immunoglobulin level	J:73833
	abnormal interleukin level	J:73832
	abnormal NK cell physiology	J:73833
	abnormal T-helper 1 cell differentiation	J:73833
	abnormal tumor necrosis factor level	J:73832
	decreased interferon-gamma secretion	J:73833
	decreased T helper 1 cell number	J:73833
	impaired natural killer cell mediated cytotoxicity	J:73833
	increased natural killer cell mediated cytotoxicity	J:73833
	increased susceptibility to parasitic infection	J:73833
	increased T-helper 2 cell number	J:73833
	respiratory system inflammation	J:73832
\Tbx21^tm1Glm/\Tbx21^tm1Glm (C.129S6-Tbx21^tm1Glm/J)	abnormal CD4-positive, alpha-beta T cell physiology	J:111932
	abnormal cytokine secretion	J:111932
	CNS inflammation	J:111932
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:111932
\Tbx21^tm1Glm/\Tbx21^tm1Glm (B6.129S6-Tbx21^tm1Glm)	abnormal CD4-positive T cell differentiation	J:143729
\Tbx21^tm1Glm/\Tbx21^tm1Glm (involves: 129S6/SvEvTac)	abnormal cytokine level	J:112600
	abnormal leukocyte migration	J:163822
	decreased CD4-positive, alpha-beta T cell number	J:163822
	decreased memory T cell number	J:163822
	increased interleukin-17 secretion	J:163822
	increased susceptibility to induced colitis	J:141481
\Tbx21^tm1Srnr/\Tbx21⁺ (involves: C57BL/6)	absent NK T cells	J:112679
\Tbx21^tm1Srnr/\Tbx21⁺ (involves: C57BL/6)	decreased NK cell number	J:112679
\Tbx21^tm1Srnr/\Tbx21^tm1Srnr (involves: C57BL/6)	abnormal T-helper 1 cell morphology	J:112679
\Tbx21^tm1Srnr/\Tbx21^tm1Srnr (involves: C57BL/6)	decreased NK T cell number	J:112679
\Tbx21^tm2Srnr/\Tbx21⁺ \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:174315
	increased susceptibility to Riboviria infection	J:174315
\Tbx21^tm2Srnr/\Tbx21^tm2Srnr \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:174315
	immune system phenotype	J:137655
	increased interleukin-2 secretion	J:174315
	increased interleukin-17 secretion	J:174315
	increased susceptibility to Riboviria infection	J:174315
	increased tumor necrosis factor secretion	J:174315
\Tbxa2r^tm1Cof/\Tbxa2r^tm1Cof (either: (involves: 129P2/OlaHsd * C57BL/6 * DBA/2) or (involves: 129P2/OlaHsd * 129S/SvEv))	immune system phenotype	J:52125
\Tbxa2r^tm1Sna/\Tbxa2r^tm1Sna (either: (involves: 129/Ola * BALB/c) or (involves: 129/Ola * C57BL/6))	abnormal cervical lymph node morphology	J:84085
	abnormal immune serum protein physiology	J:84085
	abnormal immune system organ morphology	J:84085
	abnormal immune system physiology	J:84085
	abnormal lymph node morphology	J:84085
	abnormal type I hypersensitivity reaction	J:84085
	enlarged lymph nodes	J:84085
	enlarged spleen	J:84085
\Tbxa2r^tm1Sna/\Tbxa2r^tm1Sna (B6.Cg-Tbxa2r^tm1Sna)	increased susceptibility to type I hypersensitivity reaction	J:197334
\Tbxas1^tm1Swl/\Tbxas1^tm1Swl (involves: 129P2/OlaHsd * BALB/c * C57BL/6J)	decreased inflammatory response	J:90922
\Tcaf2^{em1(IMPC)Ccpcz}/\Tcaf2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tcaf2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Tcaim^{tm1b(EUCOMM)Wtsi}/\Tcaim^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tcaim^{tm1b(EUCOMM)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Tcdel1^C57BL/6/\Tcdel1^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
\Tcdel1^NOD/ShiLtDoi/\Tcdel1^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
\Tcdel2^C57BL/6/\Tcdel2^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
\Tcdel2^NOD/ShiLtDoi/\Tcdel2^NOD/ShiLtDoi (involves: C57BL/6 * NOD/ShLtDoi * SJL)	decreased double-negative T cell number	J:97046
	increased double-positive T cell number	J:97046
\Tcea2^em1(IMPC)J/\Tcea2^em1(IMPC)J (C57BL/6NJ-Tcea2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Tceal3^em1(IMPC)Tcp/Y (C57BL/6NCrl-Tceal3^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Tcf3^tm1(PBX1)Mlc/\Tcf3⁺ \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:226241
	abnormal pro-B cell differentiation	J:226241
	abnormal pro-B cell morphology	J:226241
	arrested B cell differentiation	J:226241
	decreased B cell number	J:226241
	decreased immature B cell number	J:226241
	enlarged lymph nodes	J:226241
	enlarged spleen	J:226241
	increased leukocyte cell number	J:226241
\Tcf3^tm1(PBX1)Mlc/\Tcf3⁺ \Cd79a^tm1(cre)Reth/\Cd79a⁺ (involves: BALB/c * C57BL/6)	arrested B cell differentiation	J:226241
	decreased B cell number	J:226241
	decreased immature B cell number	J:226241
	enlarged lymph nodes	J:226241
	enlarged spleen	J:226241
	increased leukocyte cell number	J:226241
\Tcf3^tm1(PBX1)Mlc/\Tcf3⁺ \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * C57BL/6J * CBA/J)	arrested B cell differentiation	J:226241
	decreased B cell number	J:226241
	decreased immature B cell number	J:226241
	enlarged lymph nodes	J:226241
	enlarged spleen	J:226241
	increased leukocyte cell number	J:226241
\Tcf3^{tm1(TCF3/HLF)Homy}/\Tcf3⁺ \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:160392
	increased B cell number	J:160392
\Tcf3^tm1.1Mbu/\Tcf3⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:137719
\Tcf3^tm1Cmu/\Tcf3⁺ (either: 129P2/OlaHsd-Tcf3^tm1Cmu or (involves: 129P2/OlaHsd * FVB/N))	decreased B cell number	J:67011
\Tcf3^tm1Cmu/\Tcf3^tm1Cmu (either: 129P2/OlaHsd-Tcf3^tm1Cmu or (involves: 129P2/OlaHsd * FVB/N))	abnormal immunoglobulin heavy chain V(D)J recombination	J:67011
	abnormal immunoglobulin V(D)J recombination	J:67011
	abnormal T cell subpopulation ratio	J:67011
	decreased B cell number	J:67011
	decreased lymphocyte cell number	J:67011
\Tcf3^tm1Mbu/\Tcf3^tm1.2Mbu \Tg(Aicda-cre)9Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)	abnormal germinal center B cell morphology	J:137719
	decreased B cell number	J:137719
	decreased germinal center B cell number	J:137719
	immune system phenotype	J:137719
\Tcf3^tm1Mbu/\Tcf3^tm1.2Mbu \Tg(Fcer2a-cre)5Mbu/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)	abnormal germinal center B cell morphology	J:137719
	decreased B cell number	J:137719
	decreased germinal center B cell number	J:137719
	immune system phenotype	J:137719
	increased marginal zone B cell number	J:137719
\Tcf3^tm1Mbu/\Tcf3^tm1Mbu \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129P2/OlaHsd * C57BL/10 * CBA/Ca)	decreased pro-B cell number	J:137719
\Tcf3^tm1Mbu/\Tcf3^tm1Mbu \Tg(Ikzf1-Tcfe2a,-GFP)1Mbu/0 \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129P2/OlaHsd * C57BL * CBA)	immune system phenotype	J:137719
\Tcf3^tm1Wein/\Tcf3⁺ (either: (involves: 129/Sv * 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6J))	decreased B cell number	J:22134
\Tcf3^tm1Wein/\Tcf3⁺ (involves: 129S4/SvJaeSor)	abnormal B cell number	J:91042
\Tcf3^tm1Wein/\Tcf3⁺ (involves: 129S4/SvJaeSor)	decreased pre-B cell number	J:91042
\Tcf3^tm1Wein/\Tcf3^tm1Wein (either: (involves: 129 * 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6J))	abnormal B cell number	J:22134
	abnormal lymphocyte cell number	J:22134
	spleen atrophy	J:22134
\Tcf3^tm1Wein/\Tcf3^tm1Wein (involves: 129S4/SvJaeSor * C57BL/6)	enlarged thymus	J:44278
	increased T cell derived lymphoma incidence	J:44278
\Tcf3^tm1Wein/\Tcf3^tm3Zhu (involves: 129/Sv * 129S4/SvJaeSor * C57BL/6)	decreased pro-B cell number	J:47671
\Tcf3^tm1Xhsu/\Tcf3^tm1Xhsu (B6.129X1-Tcf3^tm1Xhsu)	immune system phenotype	J:132669
\Tcf3^tm1Xhsu/\Tcf3^tm1Xhsu (B6.129X1-Tcf3^tm1Xhsu)	increased B cell number	J:132669
\Tcf3^tm1Xhsu/\Tcf3^tm1Xhsu \Tg(Lck-Stat5b)1Mafa/0 (involves: 129X1/SvJ C57BL/6 * FVB/N)	increased B cell proliferation	J:132669
\Tcf3^tm1Zhu/\Tcf3^tm1Zhu (involves: 129)	decreased B cell number	J:47671
\Tcf3^tm1Zhu/\Tcf3^tm1Zhu (involves: 129 * C57BL/6J)	decreased double-positive T cell number	J:136143
	increased double-negative T cell number	J:136143
	increased single-positive T cell number	J:136143
	thymus hypoplasia	J:136143
\Tcf3^tm1Zhu/\Tcf3^tm2Zhu (involves: 129 * C57BL/6)	decreased B cell number	J:47671
\Tcf3^tm2Cmu/\Tcf3^tm2Cmu (involves: 129P2/OlaHsd)	abnormal lymphopoiesis	J:118827
	absent pre-B cells	J:118827
	absent pro-B cells	J:118827
	decreased dendritic cell number	J:118827
	decreased NK cell number	J:118827
\Tcf3^tm2Wein/\Tcf3^tm2Wein (Not Specified)	abnormal immune system morphology	J:47671
\Tcf3^tm2Wein/\Tcf3^tm2Wein (Not Specified)	increased T cell derived lymphoma incidence	J:47671
\Tcf3^tm2Zhu/\Tcf3^tm2Zhu (involves: 129 * C57BL/6)	decreased pre-B cell number	J:47671
\Tcf3^tm2Zhu/\Tcf3^tm2Zhu (involves: 129 * C57BL/6)	decreased pro-B cell number	J:47671
\Tcf3^tm3.1Cmu/\Tcf3^tm3.1Cmu (involves: 129S/SvEv * FVB/N)	abnormal B cell differentiation	J:153423
	abnormal immunoglobulin light chain V-J recombination	J:153423
	decreased pre-B cell number	J:153423
\Tcf3^tm3Zhu/\Tcf3^tm3Zhu (involves: 129/Sv * C57BL/6)	decreased B cell number	J:47671
\Tcf3^tm3Zhu/\Tcf3^tm3Zhu (involves: 129/Sv * C57BL/6)	immune system phenotype	J:47671
\Tcf3^tm4.1Cmu/\Tcf3^tm4.1Cmu (involves: 129S/SvEv * FVB/N)	abnormal immunoglobulin light chain V-J recombination	J:153423
	absent B cells	J:153423
	arrested B cell differentiation	J:153423
	decreased pro-B cell number	J:153423
\Tcf3^tm4Zhu/\Tcf3^tm4Zhu \Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	immune system phenotype	J:75746
\Tcf3^tm4Zhu/\Tcf3^tm4Zhu \Tg(Lck-cre)#Zhu/0 \Tg(TcrAND)53Hed/0 (involves: 129S4/SvJae * C57BL/6 * SJL)	immune system phenotype	J:75746
\Tcf3^tm5.1Cmu/\Tcf3^tm5.1Cmu (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:183781
\Tcf3^{tm6(Esr1)Zhu}/\Tcf3^{tm6(Esr1)Zhu} (involves: 129/Sv * C57BL/6)	abnormal immunoglobulin heavy chain V(D)J recombination	J:154788
	arrested B cell differentiation	J:154788
\Tcf4^tm1.1Hmb/\Tcf4⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased double-negative T cell number	J:136143
\Tcf4^tm1.1Hmb/\Tcf4^tm1.1Hmb (involves: 129P2/OlaHsd * C57BL/6J)	abnormal T cell differentiation	J:136143
	abnormal T cell physiology	J:136143
	immune system phenotype	J:136143
	increased double-negative T cell number	J:136143
\Tcf4^tm1Hmb/\Tcf4^tm1Zhu \Tg(Kit-cre)143Hmb/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:65236
	decreased double-positive T cell number	J:65236
	decreased thymocyte number	J:65236
	spleen hypoplasia	J:65236
\Tcf4^tm1Zhu/\Tcf4⁺ \Tcf3^tm1Wein/\Tcf3⁺ (involves: 129P2/OlaHsd)	decreased pro-B cell number	J:43324
\Tcf4^tm1Zhu/\Tcf4^tm1Zhu (involves: 129P2/OlaHsd * C57BL/6)	decreased pro-B cell number	J:43324
\Tcf7^{tm1a(EUCOMM)Wtsi}/\Tcf7^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Tcf7^{tm1a(EUCOMM)Wtsi}/Ics)	decreased CD4-positive, alpha-beta T cell number	J:165965
	decreased T cell number	J:165965
	increased B cell number	J:165965
\Tcf7^tm1Cle/\Tcf7^tm1Cle (involves: 129P2/OlaHsd)	abnormal memory T cell physiology	J:189838
	abnormal T cell differentiation	J:23255
	decreased CD8-positive, alpha-beta T cell number	J:189838
	decreased double-positive T cell number	J:23255
	decreased single-positive T cell number	J:23255
	decreased T cell number	J:23255
	increased osteoclast cell number	J:98430
	thymus cortex hypoplasia	J:23255
	thymus hypoplasia	J:23255
\Tcf7^tm2Cle/\Tcf7^tm2Cle (involves: 129P2/OlaHsd)	decreased double-positive T cell number	J:23255
	decreased single-positive T cell number	J:23255
	thymus hypoplasia	J:23255
\Tcf7l2^m1Btlr/\Tcf7l2^m1Btlr (C57BL/6J-Tcf7l2^m1Btlr)	increased susceptibility to induced colitis	J:267536
\Tcf12^m1Btlr/\Tcf12^m1Btlr (C57BL/6J-Tcf12^M1Btlr)	increased CD8-positive, alpha-beta T cell number	J:267564
\Tcf12^M2Btlr/\Tcf12^M2Btlr (C57BL/6J-Tcf12^M2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:267666
	increased CD8-positive, alpha-beta T cell number	J:267666
	increased effector memory CD4-positive, alpha-beta T cell number	J:267666
\Tcf12^M3Btlr/\Tcf12^M3Btlr (C57BL/6J-Tcf12^M3Btlr)	decreased B cell number	J:271971
	decreased CD4-positive, alpha-beta T cell number	J:271971
	increased CD8-positive, alpha-beta T cell number	J:271971
\Tcf12^m4Btlr/\Tcf12^m4Btlr (C57BL/6J-Tcf12^m4Btlr)	abnormal B cell morphology	J:271972
	abnormal T cell morphology	J:271972
	decreased CD4-positive, alpha-beta T cell number	J:271972
	increased CD8-positive, alpha-beta T cell number	J:271972
\Tcf12^tm1Zhu/\Tcf12⁺ \Tcf3^tm1Wein/\Tcf3⁺ (involves: 129S4/SvJaeSor)	decreased pro-B cell number	J:43324
\Tcf12^tm1Zhu/\Tcf12⁺ \Tcf3^tm4Zhu/\Tcf3^tm4Zhu \Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL)	abnormal T cell differentiation	J:75746
	increased double-negative T cell number	J:75746
	increased single-positive T cell number	J:75746
\Tcf12^tm1Zhu/\Tcf12⁺ \Tcf4^tm1Zhu/\Tcf4⁺ (involves: 129P2/OlaHsd * 129S7/SvEvBrd)	decreased pro-B cell number	J:43324
\Tcf12^tm1Zhu/\Tcf12^tm1Zhu (involves: 129/Sv * C57BL/6)	decreased pro-B cell number	J:43324
\Tcf12^tm1Zhu/\Tcf12^tm1Zhu (involves: 129S7/SvEvBrd)	arrested T cell differentiation	J:120411
\Tcf12^tm1Zhu/\Tcf12^tm1Zhu (involves: 129S7/SvEvBrd)	decreased thymocyte number	J:120411
\Tcf12^tm1Zhu/\Tcf12^tm1Zhu (involves: 129S7/SvEvBrd * C57BL/6J)	decreased double-positive T cell number	J:136143
	increased CD8-positive, alpha-beta T cell number	J:136143
	increased double-negative T cell number	J:136143
	thymus hypoplasia	J:136143
\Tcf12^tm1Zhu/\Tcf12^tm2Zhu (involves: 129S7/SvEvBrd)	arrested T cell differentiation	J:120411
\Tcf12^tm2Zhu/\Tcf12^tm2Zhu (Not Specified)	abnormal B cell differentiation	J:120411
	abnormal response to transplant	J:120411
	abnormal T cell differentiation	J:120411
	absent T cells	J:120411
	arrested T cell differentiation	J:120411
	decreased double-positive T cell number	J:120411
	decreased immature B cell number	J:120411
	decreased pre-B cell number	J:120411
	decreased pro-B cell number	J:120411
	decreased thymocyte number	J:120411
	increased double-negative T cell number	J:120411
	thymus hypoplasia	J:120411
\Tcf12^tm2Zhu/\Tcf12^tm2Zhu \Tg(TcrAND)53Hed/0 (involves: C57BL/6 * SJL)	abnormal CD4-positive, alpha beta T cell morphology	J:120411
	abnormal T cell subpopulation ratio	J:120411
	arrested T cell differentiation	J:120411
	increased T cell number	J:120411
\Tcf12^tm3Zhu/\Tcf12^tm3Zhu \Tcf3^tm4Zhu/\Tcf3^tm4Zhu \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJae * C57BL/6 * DBA/2)	abnormal CD8-positive, alpha beta T cell morphology	J:129171
	abnormal T cell differentiation	J:129171
	decreased CD4-positive, alpha-beta T cell number	J:129171
	increased CD8-positive, alpha-beta T cell number	J:129171
\Tcf12^tm3Zhu/\Tcf12^tm3Zhu \Tcf3^tm4Zhu/\Tcf3^tm4Zhu \Tg(Lck-cre)#Zhu/0 (involves: 129S4/SvJae * C57BL/6 * SJL/J)	decreased double-positive T cell number	J:129570
	decreased T cell number	J:129570
	increased double-negative T cell number	J:129570
	increased T cell proliferation	J:129570
	thymus hypoplasia	J:129570
\Tcf12^tm3Zhu/\Tcf12^tm3Zhu \Tg(Lck-cre)#Zhu/0 (involves: C57BL/6 * SJL/J)	decreased thymocyte number	J:129570
	increased CD8-positive, alpha-beta T cell number	J:129570
\Tcf21^em1(IMPC)Mbp/\Tcf21⁺ (C57BL/6NCrl-Tcf21^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Tcf21^tm1Eno/\Tcf21^tm1Eno (involves: 129 * Black Swiss)	abnormal spleen development	J:64068
\Tcf21^tm1Eno/\Tcf21^tm1Eno (involves: 129 * Black Swiss)	absent spleen	J:64068
\Tcf21^tm2Eno/\Tcf21^tm2Eno (involves: 129 * Black Swiss)	abnormal spleen development	J:64068
\Tcf21^tm2Eno/\Tcf21^tm2Eno (involves: 129 * Black Swiss)	absent spleen	J:64068
\Tcim^tm1Icle/\Tcim^tm1Icle (B6.129-Tcim^tm1Icle)	abnormal mononuclear cell morphology	J:217318
	increased eosinophil cell number	J:217318
	increased leukocyte cell number	J:217318
	increased lymphocyte cell number	J:217318
	increased monocyte cell number	J:217318
	increased neutrophil cell number	J:217318
	lymphoid hyperplasia	J:217318
	myeloid hyperplasia	J:217318
\Tcirg1^M1Jeau/\Tcirg1⁺ (either: (involves: C3H/HeJ * C57BL/6) or (involves: C3H/HeJ * C57BL/6 * FVB/N))	abnormal osteoclast morphology	J:196503
	abnormal osteoclast physiology	J:196503
	increased osteoclast cell number	J:196503
\Tcirg1^oc/\Tcirg1^oc (B6C3Fe a/a-Tcirg1^oc/J)	abnormal osteoclast morphology	J:7870
\Tcirg1^tm1.2Ywd/\Tcirg1^tm1.2Ywd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL)	abnormal macrophage physiology	J:150327
\Tcirg1^tm1Utku/\Tcirg1^tm1Utku (involves: 129X1/SvJ * C57BL/6)	abnormal immune serum protein physiology	J:92730
	abnormal immune system physiology	J:92730
	abnormal mesenteric lymph node morphology	J:92730
	abnormal peripheral lymph node morphology	J:92730
	abnormal Peyer's patch morphology	J:92730
	abnormal spleen B cell corona morphology	J:92730
	abnormal spleen morphology	J:92730
	abnormal spleen periarteriolar lymphoid sheath morphology	J:92730
	abnormal spleen red pulp morphology	J:92730
	abnormal spleen white pulp morphology	J:92730
	decreased B cell number	J:92730
	decreased lymphocyte cell number	J:92730
	decreased spleen B cell follicle size	J:92730
	decreased T cell number	J:92730
	increased granulocyte number	J:92730
	increased IgG1 level	J:92730
	increased IgG2a level	J:92730
	increased IgM level	J:92730
	increased immunoglobulin level	J:92730
	increased spleen germinal center number	J:92730
	thymus atrophy	J:92730
\Tcirg1^tm1Ypl/\Tcirg1^tm1Ypl (involves: 129S4/SvJae * C57BL/6J)	abnormal osteoclast physiology	J:58795
\Tcpm1^BALB/c/\Tcpm1^BALB/c (involves: BALB/c * C57BL/10)	abnormal effector T cell morphology	J:36255
\Tcpm1^BALB/c/\Tcpm1^C57BL/10Sn (involves: BALB/c * C57BL/10)	abnormal effector T cell morphology	J:36255
\Tcra-J^tm1Jpdv/\Tcra-J^tm1Jpdv (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:77518
\Tcra-J^tm1Kgwa/\Tcra-J^tm1Kgwa \Tg(Tcrb2B4)1Mmd/0 (involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6J)	abnormal T cell differentiation	J:50143
	increased double-positive T cell number	J:50143
\Tcra-J^tm1Slek/\Tcra-J^tm1Slek (involves: 129P2/OlaHsd)	abnormal T cell differentiation	J:101398
	decreased double-positive T cell number	J:101398
	decreased single-positive T cell number	J:101398
	increased double-negative T cell number	J:101398
	increased thymocyte number	J:101398
\Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (B6.129-Tcra-J^tm1Tgi)	decreased activated T cell number	J:99107
	decreased B cell number	J:99107
	decreased circulating interleukin-5 level	J:121037
	decreased IgE level	J:121037
	decreased IgG level	J:99107
	decreased susceptibility to induced arthritis	J:99107
	increased incidence of corneal inflammation	J:132503
	liver inflammation	J:135830
	lung inflammation	J:121037
\Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ)	decreased circulating interferon-gamma level	J:155199
	decreased interferon-gamma secretion	J:155199
	decreased susceptibility to bacterial infection	J:155199
\Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ * BALB/c)	abnormal eosinophil cell number	J:84720
	abnormal immune serum protein physiology	J:84720
	abnormal interleukin secretion	J:84720
	decreased IgE level	J:84720
	decreased interleukin-4 secretion	J:84720
	decreased interleukin-13 secretion	J:84720
	liver inflammation	J:105977
\Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	decreased NK T cell number	J:89695
	lung inflammation	J:89695
\Tcra-J^tm1Tgi/\Tcra-J^tm1Tgi (C.129-Tcra-J^tm1Tgi)	abnormal interleukin secretion	J:184570
	decreased interleukin-5 secretion	J:184570
	decreased interleukin-9 secretion	J:184570
	decreased interleukin-10 secretion	J:184570
	decreased interleukin-13 secretion	J:184570
	decreased interleukin-17 secretion	J:184570
\Tcra-J^tm2.3Krg/\Tcra-J^tm2.3Krg (involves: 129S/SvEv * C57BL/6)	abnormal T cell receptor alpha chain V-J recombination	J:147326
\Tcra-J^tm3.1Krg/\Tcra-J^tm3.1Krg (involves: 129S6/SvEvTac)	abnormal T cell differentiation	J:128344
\Tcra-J^tm4.1Krg/\Tcra-J^tm4.1Krg (involves: 129S6/SvEvTac)	abnormal T cell receptor alpha chain V-J recombination	J:147326
\Tcra-J^tm5Krg/\Tcra-J^tm5Krg (involves: 129S6/SvEvTac)	abnormal T cell receptor alpha chain V-J recombination	J:147326
\Tcra^Ln1Ogu/\Tcra⁺ (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:152041
	abnormal NK T cell morphology	J:152041
	abnormal T cell subpopulation ratio	J:152041
	decreased IgG2a level	J:152041
	decreased splenocyte number	J:152041
	decreased thymocyte number	J:152041
	increased IgG1 level	J:152041
	increased interferon-gamma secretion	J:152041
	increased interleukin-2 secretion	J:152041
	increased interleukin-4 secretion	J:152041
	increased interleukin-10 secretion	J:152041
	increased NK T cell number	J:152041
\Tcra^Ln1Ogu/\Tcra⁺ \Tcrb^Ln1Ogu/\Tcrb⁺ (involves: 129/Sv * C57BL/6)	abnormal T cell morphology	J:152069
\Tcra^Ln2Ogu/\Tcra⁺ \Tcrb^Ln2Ogu/\Tcrb⁺ (involves: 129/Sv * C57BL/6)	abnormal T cell morphology	J:152069
\Tcra^Ln3Jae/\Tcra⁺ (B6.Cg-Tcra^Ln3Jae)	abnormal double-negative T cell morphology	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	decreased double-positive T cell number	J:143006
	increased CD8-positive, alpha-beta T cell number	J:143006
	thymus hypoplasia	J:143006
\Tcra^Ln3Jae/\Tcra⁺ \Tcrb^Ln3Jae/\Tcrb⁺ (B6.Cg-Tcrb^Ln3Jae Tcra^Ln3Jae)	abnormal double-negative T cell morphology	J:143006
	abnormal T cell differentiation	J:143006
	absent gamma-delta T cells	J:143006
	decreased CD4-positive, alpha-beta T cell number	J:143006
	decreased double-positive T cell number	J:143006
	increased CD8-positive, alpha-beta T cell number	J:143006
	thymus hypoplasia	J:143006
\Tcra^tm1Cgn/\Tcra^tm1Cgn \Tg(Mx1-cre)1Cgn/0 (involves: 129S7/SvEvBrd * C57BL/6 * CBA)	abnormal CD4-positive, alpha beta T cell morphology	J:79298
	abnormal CD8-positive, alpha beta T cell morphology	J:79298
	abnormal memory T cell morphology	J:79298
	abnormal T cell morphology	J:79298
\Tcra^tm1Cgn/\Tcra^tm1Cgn \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:201417
\Tcra^tm1Cgn/\Tcra^tm1Mass \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal T cell physiology	J:201417
	increased T cell number	J:201417
\Tcra^tm1Mass/\Tcra⁺ \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	abnormal NK T cell morphology	J:201417
	decreased NK cell number	J:201417
	increased NK T cell number	J:201417
\Tcra^tm1Mass/\Tcra⁺ \Tg(Nes-cre)Wme/0 (involves: C57BL/6 * CBA)	abnormal positive T cell selection	J:201417
	decreased NK T cell number	J:201417
	decreased thymocyte number	J:201417
	increased double-negative T cell number	J:201417
\Tcra^tm1Mass/\Tcra^tm1Mass (involves: C57BL/6)	arrested T cell differentiation	J:201417
\Tcra^tm1Mjo/\Tcra⁺ (NOD.129P2-Tcra^tm1Mjo)	abnormal T cell physiology	J:108590
\Tcra^tm1Mjo/\Tcra⁺ (NOD.129P2-Tcra^tm1Mjo)	decreased susceptibility to autoimmune diabetes	J:108590
\Tcra^tm1Mjo/\Tcra⁺ (SJL.129P2-Tcra^tm1Mjo)	immune system phenotype	J:108590
\Tcra^tm1Mjo/\Tcra^tm1Mjo (involves: 129P2/OlaHsd * BALB/c)	abnormal immune system organ morphology	J:1292
	abnormal splenic cell ratio	J:1292
	abnormal T cell morphology	J:1292
	abnormal thymus cortex morphology	J:1292
	absent thymus medulla	J:1292
	enlarged thymus cortex	J:1292
	increased activated T cell number	J:111129
	increased anti-double stranded DNA antibody level	J:111129
	increased anti-nuclear antigen antibody level	J:111129
	increased autoantibody level	J:111129
	increased B cell number	J:111129
	increased IgE level	J:111129
	increased IgG1 level	J:111129
	increased immunoglobulin level	J:111129
	small Peyer's patches	J:1292
\Tcra^tm1Mjo/\Tcra^tm1Mjo (NOD.129P2-Tcra^tm1Mjo)	increased activated T cell number	J:52940
\Tcra^tm1Mjo/\Tcra^tm1Mjo (involves: 129P2/OlaHsd)	colitis	J:37699
	decreased T cell proliferation	J:110898
	enlarged mesenteric lymph nodes	J:110898
	enlarged spleen	J:110898
	increased activated T cell number	J:110898
	increased gamma-delta T cell number	J:110898
	increased T cell number	J:110898
	spleen hyperplasia	J:110898
\Tcra^tm1Mjo/\Tcra^tm1Mjo X/\Yaa (BXSB.129P2(Cg)-Tcra^tm1Mjo/Theo)	immune system phenotype	J:120153
\Tcra^tm1Mom/\Tcra/Tcrd^{tm1.1(Tcra)Rsky} \H2^b/\H2^b \Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal double-negative T cell morphology	J:131357
	abnormal double-positive T cell morphology	J:81564
	abnormal negative T cell selection	J:81564
	abnormal T cell differentiation	J:81564
	decreased double-positive T cell number	J:131357
	decreased thymocyte number	J:131357
\Tcra^tm1Mom/\Tcra/Tcrd^{tm1.1(Tcra)Rsky} \H2^d/\H2^d \Ptcra^tm1Vbo/\Ptcra^tm1Vbo \Tg(Tcrb)93Vbo/? (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal T cell differentiation	J:131357
	decreased thymocyte number	J:131357
\Tcra^tm1Mom/\Tcra^tm1Mom (involves: 129S2/SvPas)	absent T cells	J:88620
\Tcra^tm1Mom/\Tcra^tm1Mom (B6.129S2-Tcra^tm1Mom)	abnormal response to transplant	J:91742
	colitis	J:135597
	increased mature gamma-delta T cell number	J:135597
	increased susceptibility to bacterial infection	J:106241
\Tcra^tm1Mom/\Tcra^tm1Mom (involves: 129S2/SvPas * C57BL/6)	abnormal response to infection	J:119344
	arrested T cell differentiation	J:3206
	colitis	J:15221
	decreased CD4-positive, alpha-beta T cell number	J:3206
	decreased CD8-positive, alpha-beta T cell number	J:3206
	decreased IgG level	J:119344
	increased gamma-delta intraepithelial T cell number	J:15221
\Tcra^tm1Mom/\Tcra^tm1Mom \Tcra-J^tm1Kgwa/\Tcra-J^tm1Kgwa (involves: 129P2/OlaHsd * 129S2/SvPas * C3H/HeJ * C57BL/6J)	increased double-negative T cell number	J:50143
\Tcra^tm1Mom/\Tcra^tm1Mom \Tcrb^tm1Mom/\Tcrb^tm1Mom (involves: 129 * BALB/c * C57BL/6)	arrested T cell differentiation	J:3206
	decreased double-positive T cell number	J:3206
	thymus hypoplasia	J:3206
\Tcra^tm1Mom/\Tcra^tm1Mom \Tcrg^tm1.1Hish/\Tcrg^tm1.1Hish (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	absent gamma-delta T cells	J:135597
	colitis	J:135597
	impaired macrophage chemotaxis	J:135597
	impaired neutrophil recruitment	J:135597
\Tcra^tm1Mom/\Tcra^tm1Mom \Tg(CD19-Tnfsf7)#Rvl/0 (involves: 129P2/OlaHsd * C57BL/6)	absent T cells	J:88620
\Tcra^tm1Mom/\Tcra^tm1Mom \Tg(Lck-Akt1E40K)E-3Pnt/0 (involves: 129S2/SvPas C3H/He * C57BL/6)	arrested T cell differentiation	J:135903
\Tcra^tm1Mom/\Tcra^tm1Mom \Tg(TcraAV19AJ33)1Shima/? (involves: 129S2/SvPas * C57BL/6)	abnormal NK T cell morphology	J:140924
	abnormal NK T cell physiology	J:140924
\Tcra^tm1Mom/\Tcra^tm1Mom \Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	colitis	J:181257
	immune system phenotype	J:181257
	increased inflammatory response	J:181257
	myositis	J:181257
	skin inflammation	J:181257
\Tcra^tm1Slek/\Tcra^tm1Slek (Not Specified)	immune system phenotype	J:101719
\Tcrb^Ln3Jae/\Tcrb⁺ (B6.Cg-Tcrb^Ln3Jae)	abnormal double-negative T cell morphology	J:143006
\Tcrb^Ln3Jae/\Tcrb⁺ (B6.Cg-Tcrb^Ln3Jae)	absent gamma-delta T cells	J:143006
\Tcrb^tm1(Tcrb)Chb/\Tcrb^tm1(Tcrb)Chb (Not Specified)	abnormal double-negative T cell morphology	J:147947
	abnormal T cell morphology	J:147947
	decreased CD8-positive, alpha-beta T cell number	J:147947
	increased single-positive T cell number	J:147947
\Tcrb^tm1(Tcrb)Chb/\Tcrb^tm1Slek (Not Specified)	abnormal double-negative T cell morphology	J:147947
	abnormal T cell morphology	J:147947
	abnormal T cell receptor beta chain V(D)J recombination	J:147947
	decreased CD8-positive, alpha-beta T cell number	J:147947
	increased single-positive T cell number	J:147947
\Tcrb^tm1(Tcrb)Fwa/\Tcrb^tm1(Tcrb)Fwa (involves: 129)	abnormal T cell receptor beta chain V(D)J recombination	J:131995
\Tcrb^tm1Mom/\Tcrb⁺ \Tg(SOD1G93A)1Gur/0 (B6.Cg-Tcrb^tm1Mom Tg(SOD1G93A)1Gur/J)	abnormal microglial cell physiology	J:143173
\Tcrb^tm1Mom/\Tcrb^tm1Mom (involves: 129P2/OlaHsd * BALB/c)	arrested T cell differentiation	J:3206
	colitis	J:15221
	decreased CD4-positive, alpha-beta T cell number	J:3206
	decreased CD8-positive, alpha-beta T cell number	J:3206
	decreased double-positive T cell number	J:3206
	thymus hypoplasia	J:3206
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom (FVB.129P2-Tcrb^tm1Mom Tcrd^tm1Mom)	immune system phenotype	J:75915
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom (involves: 129P2/OlaHsd * C57BL/6)	abnormal response to infection	J:119344
	decreased IgG level	J:119344
	immune system phenotype	J:126867
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom (B6.129P2-Tcrb^tm1Mom Tcrd^tm1Mom/J)	abnormal transitional stage B cell morphology	J:187766
	decreased autoantibody level	J:187766
	decreased IgE level	J:125656
	decreased IgG1 level	J:125656
	decreased IgG level	J:125656, J:187766
	decreased plasma cell number	J:187766
	decreased T cell number	J:187766
	increased B cell number	J:187766
	increased follicular B cell number	J:187766
	increased IgM level	J:187766
	increased immature B cell number	J:187766
	increased marginal zone B cell number	J:187766
	increased mature B cell number	J:187766
	increased transitional stage T2 B cell number	J:187766
	increased transitional stage T3 B cell number	J:187766
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom (involves: 129 * BALB/c * C57BL/6)	absent CD4-positive, alpha-beta T cells	J:3206
	absent CD8-positive, alpha-beta T cells	J:3206
	arrested T cell differentiation	J:3206
	colitis	J:15221
	decreased double-positive T cell number	J:3206
	thymus hypoplasia	J:3206
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom (involves: 129P2/OlaHsd)	decreased IgA level	J:97824
	decreased lymphocyte cell number	J:97824
	immune system phenotype	J:97824
	increased T cell number	J:97824
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom \Igh-J^{tm2(3H9-VDJ)Mwg}/\Igh-J⁺ (B6.129P2-Tcrb^tm1Mom Igh-J^{tm2(3H9-VDJ)Mwg} Tcrd^tm1Mom)	increased anti-double stranded DNA antibody level	J:142389
	increased marginal zone B cell number	J:142389
	spleen hypoplasia	J:142389
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tcrd^tm1Mom/\Tcrd^tm1Mom \Traf3ip2^tm1.1Lix/\Traf3ip2^tm1.1Lix (B6.129-Tcrb^tm1Mom Traf3ip2^tm1.1Lix Tcrd^tm1Mom)	abnormal transitional stage B cell morphology	J:187766
	decreased IgG level	J:187766
	decreased T cell number	J:187766
	immune system phenotype	J:187766
	increased anti-chromatin antibody level	J:187766
	increased anti-double stranded DNA antibody level	J:187766
	increased anti-histone antibody level	J:187766
	increased autoantibody level	J:187766
	increased IgM level	J:187766
	increased immature B cell number	J:187766
	increased marginal zone B cell number	J:187766
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tg(H2-K-Cd86)7All/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell differentiation	J:112475
	abnormal B cell morphology	J:112475
	decreased B cell number	J:112475
\Tcrb^tm1Mom/\Tcrb^tm1Mom \Tg(KRT5-rtTA)1Glk/0 \Tg(tetO/CMV-Tslp)#Sfz/0 (involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N)	decreased IgE level	J:100506
	skin inflammation	J:100506
\Tcrb^tm1Slek/\Tcrb^tm1Slek (Not Specified)	immune system phenotype	J:119552
\Tcrb^tm1Slek/\Tcrb^tm5Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
\Tcrb^tm1Slek/\Tcrb^tm6Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
\Tcrb^tm2(Tcrb)Fwa/\Tcrb^tm3Slek (involves: 129)	abnormal T cell receptor beta chain V(D)J recombination	J:132446
\Tcrb^tm2Slek/\Tcrb^tm2Slek (Not Specified)	arrested T cell differentiation	J:119552
\Tcrb^tm2Slek/\Tcrb^tm2Slek (Not Specified)	decreased T cell number	J:119552
\Tcrb^tm2Slek/\Tcrb^tm2Slek \Trbv13-2^tm1(CD2)Zhu/\Trbv13-2^tm1(CD2)Zhu (involves: 129 * C57BL/6)	abnormal T cell differentiation	J:121608
\Tcrb^tm3.1Che/\Tcrb^tm3.1Che (involves: 129S4/SvJae)	immune system phenotype	J:120387
\Tcrb^tm3Che/\Tcrb^tm3Che (involves: 129S4/SvJae)	immune system phenotype	J:120387
\Tcrb^tm3Slek/\Tcrb^tm3Slek (Not Specified)	arrested T cell differentiation	J:119552
\Tcrb^tm3Slek/\Tcrb^tm3Slek (Not Specified)	decreased T cell number	J:119552
\Tcrb^tm4Slek/\Tcrb^tm4Slek (Not Specified)	immune system phenotype	J:119552
\Tcrb^tm5Slek/\Tcrb^tm5Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
\Tcrb^tm6Slek/\Tcrb^tm6Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
\Tcrb^tm7Slek/\Tcrb^tm7Slek (Not Specified)	abnormal T cell receptor beta chain V(D)J recombination	J:143738
\Tcrb^tm8.1Slek/\Tcrb^tm8.1Slek (Not Specified)	immune system phenotype	J:176070
\Tcrb^tm9.1Slek/\Tcrb^tm9.1Slek (Not Specified)	immune system phenotype	J:176070
\Tcrd-V1^tm1Kjk/\Tcrd-V1^tm1Kjk (involves: 129P2/OlaHsd * C57BL/6)	abnormal gamma-delta T cell differentiation	J:64863
	abnormal mature gamma-delta T cell morphology	J:64863
	abnormal T cell receptor delta chain V(D)J recombination	J:64863
	decreased gamma-delta intraepithelial T cell number	J:64863
\Tcrd-V1^tm1Kjk/\Tcrd-V1^tm1Kjk (B6.129P2-Tcrd-V1^tm1Kjk)	abnormal T cell receptor delta chain V(D)J recombination	J:128525
\Tcrd-V1^tm1Kjk/\Tcrd-V1^tm1Kjk (B6.129P2-Tcrd-V1^tm1Kjk)	decreased gamma-delta intraepithelial T cell number	J:128525
\Tcrd^tm1Mom/\Tcrd^tm1Mom (FVB.129P2-Tcrd^tm1Mom)	dermatitis	J:75915
\Tcrd^tm1Mom/\Tcrd^tm1Mom (FVB.129P2-Tcrd^tm1Mom)	increased susceptibility to type IV hypersensitivity reaction	J:75915
\Tcrd^tm1Mom/\Tcrd^tm1Mom (NOD.129P2-Tcrd^tm1Mom)	dermatitis	J:75915
\Tcrd^tm1Mom/\Tcrd^tm1Mom (B6.129P2-Tcrd^tm1Mom)	immune system phenotype	J:75915
\Tcrd^tm1Mom/\Tcrd^tm1Mom (either: (involves: 129P2/OlaHsd * BALB/cJ) or (involves: 129P2/OlaHsd * C57BL/6))	abnormal gamma-delta T cell differentiation	J:3865
	absent gamma-delta T cells	J:3865
\Tcrd^tm1Mom/\Tcrd^tm1Mom \Tcrg^tm2.1Dhr/\Tcrg^tm2.1Dhr (involves: 129 * C57BL/6)	abnormal T cell receptor gamma chain V-J recombination	J:75624
\Tcrd^tm1Mom/\Tcrd^tm1Mom \Tnf^tm2Gkl/\Tnf⁺ (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)	small intestinal inflammation	J:108572
\Tcrg^tm1.1Dhr/\Tcrg^tm1.1Dhr (involves: 129)	abnormal T cell receptor gamma chain V-J recombination	J:133974
\Tcrg^tm1.1Hish/\Tcrg^tm1.1Hish (involves: 129P2/OlaHsd * C57BL/6)	absent gamma-delta T cells	J:135597
\Tcrg^tm1Dhr/\Tcrg^tm1Dhr (involves: 129)	abnormal T cell receptor gamma chain V-J recombination	J:133974
\Tcrg^tm1Iku/\Tcrg^tm1Iku (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:39791
\Tcrg^tm1Scar/\Tcrg^tm1Scar (B6.Cg-Tcrg^tm1Scar)	abnormal immune system organ morphology	J:105477
	enlarged spleen	J:105477
	enlarged thymus	J:105477
	impaired granulocyte bactericidal activity	J:105477
	increased macrophage cell number	J:105477
	increased T cell number	J:105477
	spleen hyperplasia	J:105477
	thymus hyperplasia	J:105477
\Tcrg^tm2.1Dhr/\Tcrg^tm2.1Dhr (involves: 129S4/SvJae * C57BL/6)	abnormal gamma-delta T cell differentiation	J:75624
	abnormal T cell receptor gamma chain V-J recombination	J:75624
\Tdp1^em1(IMPC)Tcp/\Tdp1^em1(IMPC)Tcp (C57BL/6NCrl-Tdp1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Tdp2^tm1.1Huy/\Tdp2^tm1.1Huy (involves: 129P2/OlaHsd * CD-1)	abnormal immature B cell morphology	J:195301
	abnormal immune system organ morphology	J:195301
	abnormal lymphopoiesis	J:195301
	decreased double-positive T cell number	J:195301
	spleen atrophy	J:195301
	thymus atrophy	J:195301
\Tdrd3^{Gt(RRK474)Byg}/\Tdrd3^{Gt(RRK474)Byg} (involves: 129P2/OlaHsd)	abnormal B cell differentiation	J:210647
	abnormal B cell physiology	J:210647
\Tdrd7^nmf166/\Tdrd7^nmf166 (involves: C3H * C57BL/6J)	uveitis	J:169836
\Tec^tm1Welm/\Tec^tm1Welm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:66080
\Tecpr1^tm1Chsa/\Tecpr1^tm1Chsa (involves: 129S4/SvJae)	abnormal susceptibility to infection	J:198333
\Tedc1^em1(IMPC)Tcp/\Tedc1⁺ (C57BL/6NCrl-Tedc1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Teddm1a^em1(IMPC)Tcp/\Teddm1a^em1(IMPC)Tcp (C57BL/6N-Teddm1a^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
\Tekt1^{em1(IMPC)Ccpcz}/\Tekt1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tekt1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	small lymph nodes	J:211773
\Ten1^{em1(IMPC)Hmgu}/\Ten1^{em1(IMPC)Hmgu} (involves: C57BL/6NCrl)	abnormal cytokine secretion	J:365069
	abnormal thymus medulla morphology	J:365069
	bone marrow failure	J:365069
	increased inflammatory response	J:365069
	thymus atrophy	J:365069
	thymus cortex hypoplasia	J:365069
\Tenm4^em1(IMPC)Tcp/\Tenm4^em1(IMPC)Tcp (C57BL/6NCrl-Tenm4^em1(IMPC)Tcp/Tcp)	decreased spleen weight	J:211773
\Tent2^{em1(IMPC)Ccpcz}/\Tent2⁺ (C57BL/6NCrl-Tent2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Tent2^{em1(IMPC)Ccpcz}/\Tent2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tent2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Tent5a^{em1(IMPC)Ccpcz}/\Tent5a^{em1(IMPC)Ccpcz} (C57BL/6N-Tent5a^{em1(IMPC)Ccpcz}/Ccpcz)	decreased Ly6C-positive mature NK cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased granulocyte number	J:211773
	increased leukocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Tent5c^em1Adki/\Tent5c^em1Adki (involves: C57BL/6JTar * CBA/WTar)	decreased B cell proliferation	J:252302
\Tent5c^{tm1b(KOMP)Wtsi}/\Tent5c^{tm1b(KOMP)Wtsi} (C57BL/6N-Tent5c^{tm1b(KOMP)Wtsi}/Wtsi)	absent connection between subcutaneous lymph vessels and lymph sac	J:239583
	blood in lymph vessels	J:239583
\Terb1^{tm1b(KOMP)Mbp}/\Terb1⁺ (C57BL/6N-Terb1^{tm1b(KOMP)Mbp}/Ucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Terc^tm1Rdp/\Terc^tm1Rdp (involves: 129/Sv * C57BL/6J * SJL)	decreased B cell proliferation	J:60223
	decreased spleen B cell follicle number	J:60223
	decreased spleen germinal center number	J:60223
	decreased T cell proliferation	J:60223
	increased B cell apoptosis	J:60223
\Terf1^tm1.1Blas/\Terf1^tm1.1Blas \Tg(KRT5-cre)1Tak/0 (involves: 129 * C3H * C57BL/6 * SJL)	skin inflammation	J:152077
\Terf2ip^Gt(XD108)Byg/\Terf2ip⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased susceptibility to bacterial infection induced morbidity/mortality	J:163158
	decreased susceptibility to endotoxin shock	J:163158
\Tert^tm2.1Rdp/\Tert^tm2.1Rdp (involves: C57BL/6)	decreased spleen weight	J:167227
\Tert^tm2.1Rdp/\Tert^tm2.1Rdp (involves: C57BL/6)	spleen atrophy	J:167227
\Tespa1^tm1Smoc/\Tespa1^tm1Smoc (B6.129-Tespa1^tmSmoc)	abnormal T cell differentiation	J:186446
	abnormal thymus morphology	J:186446
	decreased CD4-positive, alpha-beta T cell number	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
	decreased interferon-gamma secretion	J:186446
	decreased interleukin-2 secretion	J:186446
	decreased regulatory T cell number	J:186446
	decreased T cell number	J:186446
	decreased T cell proliferation	J:186446
	increased memory T cell number	J:186446
	increased T cell proliferation	J:186446
	small thymus medulla	J:186446
\Tespa1^tm1Smoc/\Tespa1^tm1Smoc \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129 * C57BL/6 * DBA/2J)	decreased CD8-positive, alpha-beta T cell number	J:186446
\Tespa1^tm1Smoc/\Tespa1^tm1Smoc \Tg(TcraTcrb)425Cbn/0 (B6.Cg-Tespa1^tm1Smoc Tg(TcraTcrb)425Cbn)	abnormal T cell differentiation	J:186446
	decreased CD4-positive, alpha-beta T cell number	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
\Tespa1^tm1Smoc/\Tespa1^tm1Smoc \Tg(TcraTcrb)1100Mjb/0 (B6.Cg-Tespa1^tm1Smoc Tg(TcraTcrb)1100Mjb)	abnormal T cell differentiation	J:186446
	decreased CD4-positive, alpha-beta T cell number	J:186446
	decreased CD8-positive, alpha-beta T cell number	J:186446
\Tet1^tm1.1Gxu/\Tet1^tm1.1Gxu (involves: 129 * 129P2/OlaHsd * C57BL/6J)	decreased spleen iron level	J:315675
\Tet1^tm1.1Jae/\Tet1^tm1.1Jae (involves: 129S4/SvJae * C57BL/6)	decreased neutrophil cell number	J:175858
\Tet1^tm1.2Jae/\Tet1^tm1.2Jae \Tet2^tm1.1Iaai/\Tet2⁺ \Tet3^tm1.1Yzhg/\Tet3^tm1.1Yzhg \Tg(Rorc-cre)1Litt/0 (involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)	decreased effector memory T-helper cell number	J:333574
	immune system phenotype	J:333574
\Tet1^tm1.2Jae/\Tet1^tm1.2Jae \Tet2^tm1.1Iaai/\Tet2^tm1.1Iaai \Tet3^tm1.1Yzhg/\Tet3^tm1.1Yzhg \Tg(Rorc-cre)1Litt/0 (involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)	enlarged lymph nodes	J:333574
	enlarged spleen	J:333574
	increased susceptibility to autoimmune disorder	J:333574
\Tet2^{Gt(AN0709)Wtsi}/\Tet2⁺ (B6.129P2-Tet2^{Gt(AN0709)Wtsi})	abnormal monocyte differentiation	J:174052
	abnormal spleen morphology	J:174052
	enlarged spleen	J:174052
	increased B cell number	J:174052
	increased leukocyte cell number	J:174052
	increased monocyte cell number	J:174052
	liver inflammation	J:174052
\Tet2^{Gt(AN0709)Wtsi}/\Tet2^{Gt(AN0709)Wtsi} (B6.129P2-Tet2^{Gt(AN0709)Wtsi})	abnormal monocyte differentiation	J:174052
	abnormal spleen morphology	J:174052
	decreased pre-B cell number	J:174052
	decreased pro-B cell number	J:174052
	enlarged spleen	J:174052
	increased B cell number	J:174052
	increased DN1 thymic pro-T cell number	J:174052
	increased double-negative T cell number	J:174052
	increased leukocyte cell number	J:174052
	increased monocyte cell number	J:174052
	liver inflammation	J:174052
\Tet2^tm1.1Iaai/\Tet2⁺ \Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	increased leukocyte cell number	J:174053
	increased monocyte cell number	J:174053
\Tet2^tm1.1Iaai/\Tet2^tm1.1Iaai \Tg(Mx1-cre)1Cgn/0 (involves: 129S/SvEv * C57BL/6 * CBA)	abnormal myelopoiesis	J:234976
	decreased B cell number	J:234976
	enlarged spleen	J:234976
	increased granulocyte number	J:234976
\Tet2^tm1.1Iaai/\Tet2^tm1.1Iaai \Tg(VAV1-cre)1Graf/0 (involves: 129S/SvEv * C57BL/6)	abnormal myeloid leukocyte morphology	J:174053
	enlarged spleen	J:174053
	increased leukocyte cell number	J:174053
	increased monocyte cell number	J:174053
	increased spleen weight	J:174053
	myeloid hyperplasia	J:174053
\Tet2^tm1.1Mjxu/\Tet2⁺ (involves: 129 * C57BL/6)	enlarged spleen	J:178415
	increased leukocyte cell number	J:178415
	increased monocyte cell number	J:178415
	myeloid hyperplasia	J:178415
\Tet2^tm1.1Mjxu/\Tet2^tm1.1Mjxu (involves: 129 * C57BL/6)	enlarged spleen	J:178415
	increased leukocyte cell number	J:178415
	increased monocyte cell number	J:178415
	increased neutrophil cell number	J:178415
	myeloid hyperplasia	J:178415
\Tet2^tm1.2Rao/\Tet2^tm1.2Rao (involves: C57BL/6NTac)	abnormal myelopoiesis	J:175222
\Tet2^tm1.2Rao/\Tet2^tm1.2Rao (involves: C57BL/6NTac)	increased splenocyte number	J:175222
\Tet2^tm1Ics/\Tet2^tm1Ics \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 * CBA)	abnormal spleen morphology	J:174052
	decreased pre-B cell number	J:174052
	decreased pro-B cell number	J:174052
	enlarged spleen	J:174052
	increased B cell number	J:174052
	increased DN1 thymic pro-T cell number	J:174052
	increased double-negative T cell number	J:174052
	increased leukocyte cell number	J:174052
	increased monocyte cell number	J:174052
	increased spleen red pulp amount	J:174052
\Tex2^{tm1.1(KOMP)Vlcg}/\Tex2⁺ (C57BL/6N-Tex2^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Tex29^{tm1.1(KOMP)Vlcg}/\Tex29^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tex29^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Tex261^{tm1b(EUCOMM)Wtsi}/\Tex261^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tex261^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Tfap4^tm1.1Litt/\Tfap4^tm1.1Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	abnormal T cell differentiation	J:176461
	immune system phenotype	J:176461
\Tfeb^em1Xinli/\Tfeb^em1Xinli (involves: C57BL/6J)	increased susceptibility to bacterial infection induced morbidity/mortality	J:342735
\Tff2^tm1Blin/\Tff2^tm1Blin (involves: 129S7/SvEvBrd * C57BL/6)	abnormal adaptive immunity	J:105277
	abnormal innate immunity	J:105277
\Tff3^tm1Dkpy/\Tff3^tm1Dkpy (involves: 129S4/SvJae)	increased susceptibility to induced colitis	J:35882
\Tfpi2^tm1Dgen/\Tfpi2^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:301794
	increased circulating interleukin-6 level	J:301794
	increased circulating interleukin-10 level	J:301794
	increased interleukin-10 secretion	J:301794
	increased susceptibility to bacterial infection	J:301794
	increased susceptibility to bacterial infection induced morbidity/mortality	J:301794
\Tfpi^tm1Gjb/\Tfpi^tm1Gjb (involves: 129)	abnormal acute phase protein level	J:51137
\Tfr2^tm1.1Anro/\Tfr2^tm1.1Anro (129.Cg-Tfr2^tm1.1Anro)	increased spleen iron level	J:160785
\Tfr2^tm1.1Nsub/\Tfr2^tm1.1Nsub (involves: 129T2/SvEms * C57BL/6)	decreased spleen iron level	J:114330
\Tfr2^tm1.1Nsub/\Tfr2^tm1.1Nsub (involves: 129T2/SvEms)	increased spleen iron level	J:160785
\Tfr2^tm1Slu/\Tfr2^tm1Slu (involves: 129X1/SvJ * C57BL/6J)	decreased spleen iron level	J:78360
\Tfrc^tm1Nca/\Tfrc⁺ (either: (involves: 129S4/SvJae * 129S6/SvEvTac) or (involves: 129S4/SvJae * C57BL/6))	decreased spleen iron level	J:54107
\Tg(Ace2-ACE2)1Cqin/0 (involves: ICR)	alveolitis	J:141460
	increased susceptibility to Coronaviridae infection	J:141460, J:287631, J:288244
	interstitial pneumonia	J:141460, J:287631
	lymph node hemorrhage	J:141460
	lymph node necrosis	J:287631
	pyelitis	J:141460
	submandibular gland inflammation	J:141460
\Tg(Acp5-Adam8)#Rood/0 (involves: BALB/c * C57BL/6)	abnormal osteoclast differentiation	J:172936
	abnormal osteoclast morphology	J:172936
	increased osteoclast cell number	J:172936
\Tg(Acp5-Selenow)#Djeo/0 (involves: FVB/N)	abnormal osteoclast differentiation	J:317012
\Tg(Acp5-Selenow)#Djeo/0 (involves: FVB/N)	increased osteoclast cell number	J:317012
\Tg(ACTA1-Il15)10941Lsq/0 (involves: C3H * C57BL/6)	abnormal interleukin level	J:145611
\Tg(ACTA1-Il15)11650Lsq/0 (involves: C3H C57BL/6)	abnormal interleukin level	J:145611
\Tg(ACTA1-Il15)11650Lsq/0 (involves: C3H C57BL/6)	increased circulating interleukin-15 level	J:145611
\Tg(Acta2-cre/ERT2)#Pcn/0 \Tgfbr2^tm1Karl/\Tgfbr2^tm1Karl \Tg(H2-K-Fosl2,-EGFP)13Wag/0 (B6.Cg-Tgfbr2^tm1Karl Tg(Acta2-cre/ERT2)#Pcn Tg(H2-K-Fosl2,-EGFP)13Wag)	lung inflammation	J:238723
\Tg(Acta2-RAC1G12V)33Pjgc/\Tg(Acta2-RAC1G12V)33Pjgc (involves: C57BL/6 * FVB/N)	abnormal chemokine secretion	J:150015
	increased interleukin-6 secretion	J:150015
	increased tumor necrosis factor secretion	J:150015
\Tg(ACTB-eGFP,-RAMP1)#Afru/0 \Tg(Nes-cre)1Kln/0 (involves: C57BL/6J * SJL/J)	increased inflammatory response	J:120077
\Tg(ACTB-Eif4e)#Ppp/0 \Tg(IghMyc)22Bri/0 (involves: C57BL * SJL)	decreased B cell apoptosis	J:89878
\Tg(ACTB-Fpr2)#Jimw/0 (involves: FVB)	abnormal dendritic cell physiology	J:160074
\Tg(ACTB-Fpr2)#Jimw/0 (involves: FVB)	respiratory system inflammation	J:160074
\Tg(ACTB-Mgat3)2Nta/0 (involves: C57BL/6 * DBA/2)	decreased leukocyte cell number	J:80227
	decreased lymphocyte cell number	J:80227
	decreased neutrophil cell number	J:80227
	decreased spleen B cell follicle number	J:80227
	spleen atrophy	J:80227
\Tg(ACTB-TNFRSF6B)754Jwu/? (B6.Cg-Tg(Actb-TNFRSF6B)754Jwu)	abnormal CD4-positive, alpha beta T cell morphology	J:148162
	abnormal type IV hypersensitivity reaction	J:148162
	decreased leukocyte cell number	J:148162
	enlarged lymph nodes	J:148162
	enlarged spleen	J:148162
	increased anti-double stranded DNA antibody level	J:148162
	increased autoantibody level	J:148162
	increased B-1a cell number	J:148162
	increased IgE level	J:148162
	increased IgG1 level	J:148162
	increased IgG2b level	J:148162
	increased interleukin-4 secretion	J:148162
\Tg(Actb-Tnfsf4)1Nish/0 (B6.D2-Tg(Actb-Tnfsf4)1Nish)	abnormal cytokine secretion	J:80214
	increased susceptibility to type IV hypersensitivity reaction	J:80214
	increased T cell proliferation	J:80214
\Tg(Adipoq-Apol6)#Hsul/0 (C57BL/6J-Tg(Adipoq-Apol6)#Hsul)	white adipose tissue inflammation	J:344362
\Tg(Adipoq-cre)1Evdr/0 \Tg(CAG-Jmjd8)#Kaso/0 (involves: C57BL/6 * FVB/NJ)	white adipose tissue inflammation	J:319518
\Tg(AGER)#Eca/0 (C57BL/6J-Tg(AGER)#Eca)	lung inflammation	J:205092
\Tg(AGT)2-5Afu/0 (involves: C57BL/6)	heart inflammation	J:194606
\Tg(Alb1-GP33/H2-K^b)1Hpi/0 (B6.Cg-Tg(Alb1-GP33/H2-K^b)1Hpi)	abnormal cytotoxic T cell physiology	J:162605
	decreased cytotoxic T cell cytolysis	J:162605
\Tg(Alb1-GP33/H2-K^b)1Hpi/0 \Tg(Alb1-HBV)66Bri/0 (involves: C57BL/6 * C57BL/10 * DBA/2)	liver inflammation	J:162605
\Tg(Alb1-GP33/H2-K^b)1Hpi/0 \Tg(Alb1-HBV)66Bri/0 \Tg(TcrLCMV)318Sdz/0 (involves: C57BL/6 * C57BL/10 * DBA/2)	liver inflammation	J:162605
\Tg(Alb1-GP33/H2-K^b)1Hpi/0 \Tg(TcrLCMV)318Sdz/0 (involves: C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:162605
\Tg(Alb1-Myc)#Sst/0 \Tg(MtTGFA)Lmb/0 (involves: C57BL/6 * CBA * CD-1)	decreased NK cell number	J:176432
	increased NK T cell number	J:176432
\Tg(Alb1-Ren)1Unc/0 (involves: 129S6/SvEvTac * C57BL/6)	kidney inflammation	J:89252
\Tg(Alb1-Ren)2Unc/0 (involves: 129S6/SvEvTac * C57BL/6)	kidney inflammation	J:89252
\Tg(Alb1HBV)44Bri/0 (C57BL/6J-Tg(Alb1HBV)44Bri/J)	liver inflammation	J:223921
\Tg(Alb-PDGFC)#Jcam/0 (involves: C57BL/6)	chronic liver inflammation	J:211984
	enlarged spleen	J:211984
	increased circulating interleukin-6 level	J:211984
\Tg(Alb-PLG)1Dgi/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased susceptibility to bacterial infection	J:120780
\Tg(Alb-SND1)3aDsar/0 (involves: C57BL/6 * CBA)	chronic liver inflammation	J:242582
\Tg(Alb-TAg)#Arnd/0 ((C3Fe.Cg-Tg(Alb-TAg)#Arnd x C57BL/6N)F1)	abnormal immune system physiology	J:171880
\Tg(Amy1TAg)501Knw/0 (involves: C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:84288
\Tg(ANPEP)270Mmul/\Tg(ANPEP)270Mmul (involves: ICR)	immune system phenotype	J:99728
\Tg(ANPEP)861Mmul/\Tg(ANPEP)861Mmul (involves: ICR)	immune system phenotype	J:99728
\Tg(ANX6)2Agh/0 (FVB/N-Tg(ANX6)2Agh)	myocarditis	J:92579
\Tg(ANX6)2Agh/0 (FVB/N-Tg(ANX6)2Agh)	thymus cortex hypoplasia	J:92579
\Tg(aP2-SREBF1c)9884Reh/0 (involves: C57BL/6J * SJL)	abnormal abdominal lymph node morphology	J:50770
	decreased interleukin-6 secretion	J:249664
	decreased tumor necrosis factor secretion	J:249664
	enlarged spleen	J:50770
	liver inflammation	J:249664
\Tg(APCS-Ifng)5Imeg/0 (involves: C57BL/6 * DBA/2)	abnormal cytokine level	J:135124
	chronic liver inflammation	J:135124
	increased circulating interleukin-12 level	J:135124
	liver inflammation	J:16979
	myocarditis	J:135124
	pancreas inflammation	J:135124
\Tg(APCS-Tnfsf11)#aKhs/0 (C57BL/6J-Tg(APCS-Tnfsf11)#aKhs)	abnormal osteoclast morphology	J:264357
	enlarged thymus medulla	J:264357
	increased osteoclast cell number	J:264357
\Tg(APOA1)1Rub/\Tg(APOA1)1Rub (C57BL/6-Tg(APOA1)1Rub/J)	abnormal circulating interleukin-17 level	J:190966
\Tg(APOA1)1Rub/\Tg(APOA1)1Rub (C57BL/6-Tg(APOA1)1Rub/J)	abnormal spleen weight	J:190966
\Tg(APOC1)1Lmh/\Tg(APOC1)1Lmh (C57BL/6-Tg(APOC1)1Lmh)	dermatitis	J:65036
	enlarged spleen	J:65036
	folliculitis	J:65036
\Tg(APOC1)1Lmh/\Tg(APOC1)1Lmh (involves: C57BL/6)	dermatitis	J:135501
	increased IgE level	J:135501
	increased mast cell degranulation	J:135501
	skin inflammation	J:135501
\Tg(APOE-DGAT1)1Far/0 (involves: C57BL/6NHsd)	liver inflammation	J:124005
\Tg(APOE-DGAT2)1Far/0 (involves: C57BL/6NHsd)	liver inflammation	J:124005
\Tg(APOE-FGF23R176Q)#Ack/0 (involves: C57BL/6J CBA)	decreased osteoclast cell number	J:93981
\Tg(APOE-FGF23R176Q)#Ack/0 (involves: C57BL/6J CBA)	enthesitis	J:192371
\Tg(APP695)3Dbo/0 \Tg(PSEN1dE9)S9Dbo/0 (Not Specified)	abnormal microglial cell morphology	J:139070
\Tg(APPSWE)2576Kha/0 (involves: C57BL/6 * SJL)	microgliosis	J:159623
\Tg(APPswe,PSEN1dE9)85Dbo/0 (D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo)	microgliosis	J:227541
\Tg(APPSwFlLon,PSEN1M146LL286V)6799Vas/0 (involves: C57BL/6 * SJL)	brain inflammation	J:112949
\Tg(APPSwFlLon,PSEN1M146LL286V)6799Vas/? (involves: C57BL/6 * SJL)	increased microglial cell activation	J:208030
\Tg(ARR2/Pbsn-FGF8)3Prb/0 (involves: C57BL/6 * DBA/2)	increased inflammatory response	J:78918
\Tg(ARR2/Pbsn-FGF8)3Prb/0 (involves: C57BL/6 * DBA/2)	prostate gland inflammation	J:78918
\Tg(B2M)55Hpl/? \Tg(CD8aCD8b)57Scr/? \Tg(HLA-B)22Hpl/? (involves: C57BL/6 * C57BL/LiA * CBA)	abnormal cytotoxic T cell physiology	J:127813
\Tg(B2M,HLA-B27:05)56-3Trg/0 (involves: C57BL/6 SJL/J)	immune system phenotype	J:74451
\Tg(B19-RNAi:Il3)241Ckn/? (involves: BALB/cJ * C57BL/6J * FVB/N)	abnormal B cell differentiation	J:107618
	decreased interleukin-3 secretion	J:107618
	enlarged lymph nodes	J:107618
	enlarged spleen	J:107618
	increased pre-B cell number	J:107618
\Tg(BCL2)22Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell differentiation	J:93111
	abnormal B cell physiology	J:93111
	increased B cell number	J:93111
	increased susceptibility to autoimmune disorder	J:93111
\Tg(BCL2)22Wehi/0 (involves: C57BL/6J * C57BL/6JWehi)	increased B cell number	J:88565
\Tg(BCL2)22Wehi/0 \Tg(IghMyc)22Bri/0 (involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)	abnormal B cell morphology	J:69571
	abnormal pre-B cell morphology	J:69571
	enlarged lymph nodes	J:69571
	enlarged spleen	J:69571
	enlarged thymus	J:69571
	increased B cell number	J:69571
	increased leukocyte cell number	J:69571
	increased pre-B cell number	J:69571
\Tg(BCL2)25Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell differentiation	J:131912
	abnormal plasma cell differentiation	J:131912
	abnormal T cell physiology	J:93111
	increased T cell number	J:93111
\Tg(BCL2)36Wehi/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal B cell physiology	J:93111
	abnormal T cell physiology	J:93111
	increased B cell number	J:93111
	increased immunoglobulin level	J:93111
	increased susceptibility to autoimmune disorder	J:93111
	increased T cell derived lymphoma incidence	J:93111
	increased T cell number	J:93111
\Tg(BCL2)36Wehi/? (B6.Cg-Tg(BCL2)36Wehi/J)	abnormal B cell proliferation	J:90963
\Tg(BCL2)36Wehi/? (B6.Cg-Tg(BCL2)36Wehi/J)	decreased B cell apoptosis	J:90963
\Tg(BCL2/IGH)1Tjd/? (involves: C3H/He * C57BL/6)	abnormal B cell physiology	J:81147
	abnormal lymph node morphology	J:81147
	abnormal mononuclear cell differentiation	J:81147
	enlarged lymph nodes	J:81147
	enlarged spleen	J:81147
	increased B cell number	J:81147
	increased spleen white pulp amount	J:81147
	spleen hyperplasia	J:81147
\Tg(BCL2/IGH)#Jcre/0 \Tg(H2-K/Igh-Traf2)#Ywc/0 (involves: BALB/c C57BL/6 * CBA/J * FVB/N * SJL/J * SWR/J)	abnormal spleen marginal zone morphology	J:94116
	decreased B cell apoptosis	J:94116
	enlarged lymph nodes	J:94116
	enlarged spleen	J:94116
	increased B cell number	J:94116
	increased B-1a cell number	J:94116
	increased B-1b cell number	J:94116
	increased marginal zone B cell number	J:94116
	increased spleen weight	J:94116
\Tg(BCL2/IGH)M23Tjd/? (involves: C3H/He * C57BL/6)	abnormal B cell physiology	J:81147
	abnormal lymph node morphology	J:81147
	abnormal mononuclear cell differentiation	J:81147
	enlarged lymph nodes	J:81147
	enlarged spleen	J:81147
	increased B cell number	J:81147
	increased spleen white pulp amount	J:81147
	spleen hyperplasia	J:81147
\Tg(BLG-STAT5A)15Itb/0 (involves: FVB/N)	increased inflammatory response	J:80588
\Tg(C9orf72)500Lpwr/0 (FVB/NJ-Tg(C9orf72)500Lpwr)	microgliosis	J:239579
\Tg(CAG-ACE2)AC63Ctkt/0 (either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))	increased susceptibility to Coronaviridae infection	J:117824
\Tg(CAG-ACE2)AC70Ctkt/0 (either: (involves: BALB/c * C3H/HeJ * C57BL/6J) or (involves: C3H/HeJ * C57BL/6 * C57BL/6J))	abnormal cytokine level	J:117824
	increased susceptibility to Coronaviridae infection	J:117824
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:117824
	interstitial pneumonia	J:117824
\Tg(CAG-APP)0304Shoj/0 (involves: C3H * C57BL/6N)	abnormal circulating serum amyloid protein level	J:100977
\Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0 \Tg(Flt4-cre)44Ichi/0 (involves: 129P2/OlaHsd * C57BL/6J)	lymphatic vessel hyperplasia	J:159024
\Tg(CAG-Bgeo,-Hras1,-EGFP)#Ichi/0 \Tg(Tek-cre)12Flv/0 (involves: 129P2/OlaHsd * C3H * C57BL/6)	lymphatic vessel hyperplasia	J:159024
\Tg(CAG-Btc)2Ewo/0 (FVB/N-Tg(CAG-Btc)2Ewo)	increased spleen weight	J:103364
\Tg(CAG-Btc)4Ewo/0 (FVB/N-Tg(CAG-Btc)4Ewo)	increased spleen weight	J:103364
\Tg(CAG-C1qtnf6)#Yiw/0 (involves: C57BL/6JJcl)	abnormal complement protein level	J:227217
	decreased IgG level	J:227217
	decreased susceptibility to induced arthritis	J:227217
	impaired complement alternative pathway	J:227217
\Tg(CAG-cat,-Il18)#Thos/0 \Tg(SFTPC-rtTA)5Jaw/0 \Tg(tetO-cre)1Jaw/0 (involves: 129 * C57BL/6)	increased interferon-gamma secretion	J:147547
	interstitial pneumonia	J:147547
\Tg(CAG-cre/Esr1)5Amc/0 \Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm (involves: 129S6/SvEvTac C57BL/6 * CBA)	microgliosis	J:221181
\Tg(CAG-DPP4)4Yuzh/0 (C57BL/6-Tg(CAG-DPP4)4Yuzh)	abnormal circulating cytokine level	J:286175
	abnormal spleen morphology	J:286175
	brain inflammation	J:286175
	increased circulating interferon-gamma level	J:286175
	increased circulating interleukin-17 level	J:286175
	increased susceptibility to Coronaviridae infection	J:286175
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286175
	kidney inflammation	J:286175
	liver inflammation	J:286175
	lung inflammation	J:286175
\Tg(CAG-DPP4)52Ctkt/0 (involves: C3H/HeJ * C57BL/6J)	abnormal mononuclear cell morphology	J:227925
	brain inflammation	J:227925
	increased inflammatory response	J:227925
	increased microglial cell activation	J:227925
	increased susceptibility to Coronaviridae infection	J:227925, J:258199
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:227925, J:258199
	interstitial pneumonia	J:258199
	lung inflammation	J:227925
\Tg(CAG-dsRed2/RNAi:Tardbp)6Zxu/0 (involves: C57BL/6 * C57BL/6J * FVB/NJ * SJL)	microgliosis	J:207750
\Tg(CAG-Has2)99Nita/0 \Tg(MMTV-cre)4Mam/0 \Tg(MMTVneu)202Mul/0 (FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)	abnormal lymphatic vessel morphology	J:130531
	impaired macrophage chemotaxis	J:164205
	increased macrophage cell number	J:164205
\Tg(CAG-Has2)99Nita/0 \Tg(MMTVneu)202Mul/0 (FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)	abnormal lymphatic vessel morphology	J:130531
\Tg(CAG-LacZ,-ACVR1,-EGFP)35-1Mis/0 (involves: C57BL/6 DBA/2)	myositis	J:142253
\Tg(CAG-Lyn)#Paau/0 (B6.Cg-Tg(CAG-Lyn)#Paau)	skin inflammation	J:151886
\Tg(CAG-Ncoa6)71Hwl/0 (involves: FVB)	lung inflammation	J:80609
	spleen atrophy	J:80609
	thymus atrophy	J:80609
\Tg(CAG-Ncoa6)87Hwl/0 (involves: FVB)	lung inflammation	J:80609
	spleen atrophy	J:80609
	thymus atrophy	J:80609
\Tg(CAG-Ncoa6)104Hwl/0 (involves: FVB)	spleen atrophy	J:80609
\Tg(CAG-Ncoa6)104Hwl/0 (involves: FVB)	thymus atrophy	J:80609
\Tg(CAG-NRIP1)51Row/0 (involves: FVB/N)	lung inflammation	J:175885
\Tg(CAG-OVAL)916Jen/? (C57BL/6-Tg(CAG-OVAL)916Jen)	abnormal dendritic cell antigen presentation	J:91742
\Tg(CAG-OVAL)916Jen/? (C57BL/6-Tg(CAG-OVAL)916Jen)	decreased length of allograft survival	J:91742
\Tg(CAG-p35)1Miur/0 (involves: C57BL/6)	autoimmune response	J:126593
\Tg(CAG-p35)1Miur/0 \Tg(Mbp-cre)29Miur/0 (involves: C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:126593
\Tg(CAG-Pgam2)#Hiko/0 (involves: C57BL/6)	increased susceptibility to chemically induced skin inflammation	J:306793
\Tg(CAG-PGDS)1Groy/0 (involves: FVB/N)	abnormal cytokine secretion	J:107651
	abnormal lymph node morphology	J:107651
	decreased inflammatory response	J:107651
\Tg(CAG-PLA2G3)#aMurm/0 (Not Specified)	increased mast cell degranulation	J:197334
\Tg(CAG-PLA2G3)#aMurm/0 (Not Specified)	increased susceptibility to type I hypersensitivity reaction	J:197334
\Tg(CAG-Ptafr)1Tksh/0 (B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)	increased mast cell number	J:38639
\Tg(CAG-Ptafr)1Tksh/0 (B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)	increased susceptibility to endotoxin shock	J:38639
\Tg(CAG-Romo1)#Xiwa/0 (involves: C57BL/6J)	decreased monocyte cell number	J:367536
\Tg(CAG-Romo1)#Xiwa/0 (involves: C57BL/6J)	decreased neutrophil cell number	J:367536
\Tg(CAG-SPTLC1C133W)8EAmcc/0 (involves: C3H C57BL/6)	microgliosis	J:155748
\Tg(CAG-SYVN1)1Tn/? (D1.Cg-Tg(CAG-SYVN1)1Tn)	rheumatoid arthritis	J:86009
\Tg(Camk2a-cre)2Gsc/0 \Tg(H2-L^d)LoxNibl/0 (involves: C57BL/6 * FVB/N)	immune system phenotype	J:284394
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-APPSwInd)107Dbo/0 (involves: C3H/HeJ * C57BL/6 * CBA)	CNS inflammation	J:109829
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-APPSwInd)Dbo/0 (involves: C3H/HeJ * C57BL/6J)	microgliosis	J:236737
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-LRRK2)C77Cai/0 \Tg(tetO-SNCA*A53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-LRRK2)C7874Cai/0 \Tg(tetO-SNCA*A53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-LRRK2G2019S)E3Cai/0 \Tg(tetO-SNCAA53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-Mtor)#Atai/0 (involves: C57BL/6 DBA/2 * ICR)	microgliosis	J:211789
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-SNCA*A53T)E2Cai/0 (involves: C57BL/6)	microgliosis	J:156512
\Tg(Camk2a-tTA)1Mmay/0 \Tg(tetO-TARDBP)12Vle/0 (involves: C3H/HeJ * C57BL/6J)	microgliosis	J:170756
\Tg(CD2-Ccdc86)1Hfuj/? (B6.FVB-Tg(CD2-Ccdc86)1Hfuj)	abnormal T cell morphology	J:151722
\Tg(CD2-Ccdc86)1Hfuj/? (B6.FVB-Tg(CD2-Ccdc86)1Hfuj)	increased T cell apoptosis	J:151722
\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/\Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell (NOD/MrkTac-Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)	immune system phenotype	J:86540
\Tg(CD2-Ceacam1*4L)1Rsb/0 (involves: C57BL/6)	abnormal T cell physiology	J:116136
	decreased interleukin-2 secretion	J:116136
	decreased T cell number	J:116136
	decreased T cell proliferation	J:116136
\Tg(CD2-Ceacam14L)1Rsb/0 \Tg(TcraTcrb)425Cbn/0 (involves: BALB/c C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:116136
\Tg(CD2-Foxj1)#Stlp/0 (C57BL/6-Tg(CD2-Foxj1)#Stlp)	abnormal T cell physiology	J:122222
	decreased CD4-positive, alpha-beta T cell number	J:122222
	decreased CD8-positive, alpha-beta T cell number	J:122222
	immune system phenotype	J:122222
	increased single-positive T cell number	J:122222
	lymphoid hypoplasia	J:122222
\Tg(CD2-Ifngr2)1Pbro/? (B6.Cg-Tg(CD2-Ifngr2)1Pbro)	abnormal T-helper 1 cell differentiation	J:134448
	abnormal T-helper 1 physiology	J:134448
	decreased susceptibility to type IV hypersensitivity reaction	J:134448
	immune system phenotype	J:134448
	increased susceptibility to parasitic infection	J:134448
\Tg(CD2-Ifngr2)2Pbro/? (B6.Cg-Tg(CD2-Ifngr2)2Pbro)	abnormal T-helper 1 cell differentiation	J:134448
	abnormal T-helper 1 physiology	J:134448
	immune system phenotype	J:134448
	increased susceptibility to parasitic infection	J:134448
\Tg(CD2-Ifngr2)2Pbro/? (NOD.Cg-Tg(CD2-Ifngr2)2Pbro)	abnormal splenic cell ratio	J:81981
	abnormal T-helper 1 physiology	J:81981
	decreased interferon-gamma secretion	J:81981
	decreased interleukin-4 secretion	J:81981
	decreased tumor necrosis factor secretion	J:81981
	immune system phenotype	J:81981
	insulitis	J:81981
	myositis	J:81981
	ovary inflammation	J:81981
\Tg(CD2-LAT2)1Wz/0 (Not Specified)	abnormal CD8-positive, alpha-beta T cell physiology	J:116157
\Tg(CD2-Lmo2)#Thr/0 (involves: C57BL/6 * CBA)	enlarged spleen	J:102058
\Tg(CD2-Lmo2)#Thr/0 (involves: C57BL/6 * CBA)	enlarged thymus	J:102058
\Tg(CD2-Lrch1)#Liux/0 (involves: C57BL/6)	abnormal cellular extravasation	J:238772
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:238772
	immune system phenotype	J:238772
\Tg(CD2-Mir181d)38Oers/0 (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:212571
	decreased double-positive T cell number	J:212571
	decreased T cell number	J:212571
	immune system phenotype	J:212571
	thymus atrophy	J:212571
\Tg(CD2-Mir181d)38Oers/0 \Tg(TcraTcrb)425Cbn/0 (involves: C3H * C57BL/6)	decreased T cell number	J:212571
\Tg(CD2-Myb/en)2Kmw/? (involves: C57BL/10 * CBA)	abnormal single-positive T cell number	J:126456
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
	increased double-negative T cell number	J:126456
\Tg(CD2-Myb/en)2Kmw/\Tg(CD2-Myb/en)2Kmw (involves: C57BL/10 * CBA)	decreased double-positive T cell number	J:126456
	decreased T cell number	J:126456
	decreased T cell proliferation	J:126456
	increased double-negative T cell number	J:126456
	small spleen	J:126456
	small thymus	J:126456
\Tg(CD2-Nfat5)1Snh/0 (involves: BALB/c * C57BL/6)	abnormal cytotoxic T cell physiology	J:80066
	abnormal T cell differentiation	J:80066
	abnormal T cell physiology	J:80066
	decreased CD4-positive, alpha-beta T cell number	J:80066
	decreased CD8-positive, alpha-beta T cell number	J:80066
	decreased splenocyte proliferation	J:80066
	decreased T cell number	J:80066
	decreased T cell proliferation	J:80066
	spleen hypoplasia	J:80066
	thymus hypoplasia	J:80066
\Tg(CD2-Ppp2ca)#Gct/0 (involves: C57BL/6J)	abnormal T cell subpopulation ratio	J:184067
	enlarged lymph nodes	J:184067
	enlarged spleen	J:184067
	glomerulonephritis	J:184067
	increased germinal center B cell number	J:184067
	increased interleukin-17 secretion	J:184067
	increased neutrophil cell number	J:184067
\Tg(CD2-Rorc)#Staka/0 (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:236222
	abnormal susceptibility to Picornaviridae infection	J:236222
	abnormal T-helper 17 cell physiology	J:236222
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:230700
	decreased CD8-positive, alpha-beta T cell number	J:236222
	decreased IgG2c level	J:236222
	decreased IgG3 level	J:236222
	decreased IgG level	J:236222
	decreased interferon-gamma secretion	J:236222
	decreased interleukin-10 secretion	J:236222
	increased anti-nuclear antigen antibody level	J:230700
	increased autoantibody level	J:230700
	increased effector memory CD4-positive, alpha-beta T cell number	J:230700
	increased interferon-gamma secretion	J:236222
	increased interleukin-17 secretion	J:236222
	increased susceptibility to autoimmune disorder	J:230700
	lacrimal gland inflammation	J:230700
	lung inflammation	J:230700
	salivary gland inflammation	J:230700
\Tg(CD2-S1PR1)1Ejg/? (involves: C57BL/6 * DBA/2)	abnormal humoral immune response	J:96558
	abnormal lymphocyte chemotaxis	J:96558
	decreased activated T cell number	J:96558
	decreased susceptibility to type IV hypersensitivity reaction	J:96558
	decreased T cell proliferation	J:96558
	impaired leukocyte migration	J:96558
	increased activated T cell number	J:96558
	increased IgE level	J:96558
	increased T cell number	J:96558
\Tg(CD2-Sh2d1a)#Vei/0 (involves: 129S1/Sv * 129X1/SvJ)	increased natural killer cell mediated cytotoxicity	J:110195
\Tg(CD2-Sh2d1b1)#Vei/0 (B6.Cg-Tg(CD2-Sh2d1b1)#Vei)	decreased interferon-gamma secretion	J:110195
\Tg(CD2-Sh2d1b1)#Vei/0 (B6.Cg-Tg(CD2-Sh2d1b1)#Vei)	impaired natural killer cell mediated cytotoxicity	J:110195
\Tg(CD2-Sh2d1b2)#Vei/0 (B6.Cg-Tg(CD2-Sh2d1b2)#Vei)	impaired natural killer cell mediated cytotoxicity	J:110195
\Tg(Cd2-Smad7)#Chbe/0 (involves: C57BL/6)	abnormal T-helper 1 cell differentiation	J:184670
	decreased interleukin-9 secretion	J:184670
	decreased interleukin-10 secretion	J:184670
	decreased interleukin-17 secretion	J:184670
	increased interferon-gamma secretion	J:184670
	increased susceptibility to experimental autoimmune encephalomyelitis	J:184670
\Tg(CD2-Stat6V625AT626A)78Mhk/0 (involves: C3H * C57BL/6)	dermatitis	J:160119
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: C57BL/10)	abnormal positive T cell selection	J:113713
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: C57BL/10)	increased CD8-positive, alpha-beta T cell number	J:113713
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: C57BL/10 * CBA/Ca)	decreased CD8-positive, alpha-beta T cell number	J:113713
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 (involves: BALB/c * C57BL/10)	decreased CD8-positive, alpha-beta T cell number	J:113713
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N)	abnormal positive T cell selection	J:126026
	decreased CD4-positive, alpha-beta T cell number	J:126026
	increased CD8-positive, alpha-beta T cell number	J:126026
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 \Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 (involves: C57BL/6 C57BL/10)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
	enlarged lymph nodes	J:217939
	increased T cell number	J:217939
\Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0 \Tg(LCKprBCL2)36Sjk/0 (involves: C57BL/6 * C57BL/10)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
\Tg(CD2-Tgfbr2)1Grs/0 (C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)	enlarged lymph nodes	J:97523
	enlarged spleen	J:97523
	increased T cell proliferation	J:97523
\Tg(CD2-Tgfbr2)1Grs/? (C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)	abnormal CD8-positive, alpha beta T cell morphology	J:93665
	increased T cell derived lymphoma incidence	J:93665
	increased T cell proliferation	J:93665
\Tg(CD2-Zbtb7b)C8Rbo/? (involves: C57BL/6)	absent CD8-positive, alpha-beta T cells	J:97610
\Tg(CD2-Zbtb7b)C8Rbo/? (involves: C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:97610
\Tg(CD2-Zbtb7b)C8Rbo/? \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
\Tg(CD2-Zbtb7b)C8Rbo/? \Tg(TcrLCMV)327Sdz/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
\Tg(CD2-Zbtb7b)C8Rbo/? \Themis^tm1Lov/\Themis^tm1Lov (involves: 129)	abnormal T cell differentiation	J:151075
\Tg(Cd3d-Il5)NJ.1638Nal/? (involves: C57BL/6J * CBA/J)	abnormal eosinophil differentiation	J:123440
	abnormal spleen morphology	J:123440
	abnormal T cell number	J:123440
	enlarged lymph nodes	J:123440
	increased eosinophil cell number	J:123440
	increased leukocyte cell number	J:123440
	increased mature B cell number	J:123440
	increased monocyte cell number	J:123440
	increased neutrophil cell number	J:123440
	increased spleen weight	J:123440
	peritoneal inflammation	J:123440
\Tg(CD3E)26Cpt/\Tg(CD3E)26Cpt (involves: C57BL/6J * CBA/J)	abnormal thymus corticomedullary boundary morphology	J:81711
	absent NK cells	J:81711
	arrested T cell differentiation	J:81711
	decreased double-positive T cell number	J:54756
	decreased T cell number	J:54756
	decreased thymocyte number	J:81711
	decreased uterine NK cell number	J:134589
	thymus hypoplasia	J:54756
\Tg(Cd4-BCL2G101AD102A*D103A)AWnt/0 (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:217939
	abnormal mesenteric lymph node morphology	J:217939
	abnormal splenic cell ratio	J:217939
	abnormal T cell clonal deletion	J:217939
	abnormal T cell proliferation	J:217939
	abnormal T cell subpopulation ratio	J:217939
	decreased double-positive T cell number	J:217939
	decreased thymocyte apoptosis	J:217939
	enlarged lymph nodes	J:217939
	enlarged spleen	J:217939
	glomerulonephritis	J:217939
	increased activated T cell number	J:217939
	increased anti-nuclear antigen antibody level	J:217939
	increased autoantibody level	J:217939
	increased B cell number	J:217939
	increased central memory CD8 positive, alpha-beta T cell number	J:217939
	increased interferon-gamma secretion	J:217939
	increased regulatory T cell number	J:217939
	increased single-positive T cell number	J:217939
	increased susceptibility to autoimmune disorder	J:217939
	increased T cell number	J:217939
	kidney inflammation	J:217939
	liver inflammation	J:217939
	lung inflammation	J:217939
	lymphoid hyperplasia	J:217939
	skin inflammation	J:217939
\Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 (involves: C57BL/6 CBA/J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
\Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 \Tg(Nr4a1-EGFP/cre)820Khog/0 (involves: C57BL/6 C57BL/6J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
\Tg(Cd4-BCL2G101AD102AD103A)AWnt/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 C57BL/6J * DBA/2J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
\Tg(Cd4-CD4)2362Litt/0 (involves: C57BL/6 * SJL)	immune system phenotype	J:50435
\Tg(Cd4-CD4)2362Litt/0 \Tg(HLA-DR2)#Lfug/0 \Tg(TCROb.1A12)#Lfug/0 (involves: C57BL/6 * DBA/2 * SJL)	CNS inflammation	J:134764
	increased susceptibility to experimental autoimmune encephalomyelitis	J:134764
\Tg(CD4-CIITA)357Ccum/? (involves: C57BL/6 * C57BL/6J * SJL)	increased osteoclast cell number	J:233241
\Tg(Cd4-cre)1Cwi/? \Tg(TcraTcrb)425Cbn/? \Traf6^tm2Ywc/\Traf6^tm2Ywc (involves: C57BL/6 * DBA/2)	abnormal lymphocyte anergy	J:130882
	increased interleukin-2 secretion	J:130882
\Tg(Cd4-cre)1Cwi/0 \Trmt6^em1Hbgl/\Trmt6^em1Hbgl (involves: C57BL/6 * DBA/2J)	decreased CD4-positive, alpha-beta T cell number	J:336736
	decreased T cell proliferation	J:336736
\Tg(Cd4-cre)1Cwi/0 \Trmt61a^em1Hbgl/\Trmt61a^em1Hbgl (involves: C57BL/6 * DBA/2J)	abnormal CD4-positive T cell differentiation	J:336736
	abnormal T cell activation	J:336736
	colitis	J:336736
	decreased CD4-positive, alpha-beta T cell number	J:336736
	decreased CD8-positive, alpha-beta T cell number	J:336736
	decreased T cell proliferation	J:336736
	increased CD4-positive, alpha-beta T cell number	J:336736
	increased CD8-positive, alpha-beta T cell number	J:336736
\Tg(Cd4-DsRed)4Lt/0 (NOD/ShiLt-Tg(Cd4-DsRed)4Lt)	decreased susceptibility to autoimmune diabetes	J:127785
\Tg(Cd4-Dtx1)1Mzl/? (involves: C57BL/6)	abnormal T cell activation	J:151605
	abnormal thymocyte activation	J:151605
	decreased interleukin-2 secretion	J:151605
	decreased T cell proliferation	J:151605
\Tg(CD4-HIV)F21380Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(CD4-HIV)F21388Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(CD4-HIV)F21407Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(CD4-HIV)F26605Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(CD4-HIV)F26622Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(CD4-HIV)F26990Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(CD4-HIV)F27011Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(CD4-HIV)F27367Pjo/0 (involves: C3H * C57BL/6)	interstitial pneumonia	J:78756
	lymph node atrophy	J:78756
	spleen atrophy	J:78756
	thymus atrophy	J:78756
	tubular nephritis	J:78756
\Tg(Cd4-Il17rb)#Cdon/? (involves: C57BL/6)	abnormal T cell differentiation	J:158594
	decreased interferon-gamma secretion	J:158594
	increased eosinophil cell number	J:158594
	increased interleukin-5 secretion	J:158594
	increased interleukin-9 secretion	J:158594
	increased interleukin-13 secretion	J:158594
	increased susceptibility to type I hypersensitivity reaction	J:158594
	lung inflammation	J:158594
\Tg(CD4-Il17re)#Cdon/0 (involves: C57BL/6)	abnormal interleukin secretion	J:177650
	decreased interleukin-17 secretion	J:177650
	increased susceptibility to experimental autoimmune encephalomyelitis	J:177650
\Tg(Cd4-NPM/ALK)N1Ingh/0 (either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))	increased immunoglobulin level	J:82127
	increased lymphoblastic lymphoma incidence	J:82127
\Tg(Cd4-NPM/ALK)N1Ingh/0 (involves: C57BL/6 * Swiss Webster)	abnormal T cell differentiation	J:235890
	abnormal T cell morphology	J:235890
	increased DN3 thymocyte number	J:235890
	increased thymus tumor incidence	J:235890
\Tg(Cd4-NPM/ALK)N1Ingh/0 \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * Swiss Webster)	abnormal double-negative T cell morphology	J:235890
	abnormal thymus morphology	J:235890
	increased T cell derived lymphoma incidence	J:235890
\Tg(Cd4-TGFBR2)16Flv/? (involves: C3H * C57BL/6 * C57BL/10 * C57BR/cd)	abnormal T cell activation	J:97554
	abnormal T cell proliferation	J:97554
	abnormal thymus involution	J:97554
	colitis	J:97554
	decreased B cell number	J:97554
	glomerulonephritis	J:97554
	increased anti-nuclear antigen antibody level	J:97554
	increased IgA level	J:97554
	increased IgG1 level	J:97554
	increased IgG2a level	J:97554
	increased immunoglobulin level	J:97554
	increased inflammatory response	J:97554
	increased memory T cell number	J:97554
	liver inflammation	J:97554
	lung inflammation	J:97554
	lymph node hyperplasia	J:97554
	pancreas inflammation	J:97554
	spleen hyperplasia	J:97554
\Tg(Cd4-TGFBR2)16Flv/? (involves: C3H * C57BL/6)	abnormal CD8-positive, alpha-beta regulatory T cell morphology	J:134473
	abnormal T cell proliferation	J:134473
	colitis	J:134156
	increased interferon-gamma secretion	J:134156
	increased tumor necrosis factor secretion	J:134156
\Tg(Cd4-Zbtb16)1797Aben/? (C57BL/6-Tg(Cd4-Zbtb16)1797Aben)	decreased CD4-positive, alpha-beta T cell number	J:139690
	increased CD4-positive, alpha-beta memory T cell number	J:139690
	increased T-helper 2 cell number	J:139690
\Tg(Cd8aCd8b)3Erob/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:93004
	abnormal double-positive T cell morphology	J:93004
	decreased CD4-positive, alpha-beta T cell number	J:93004
	decreased double-negative T cell number	J:93004
	increased CD8-positive, alpha-beta T cell number	J:93004
\Tg(Cd8aCd8b)3Erob/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * DBA/2)	abnormal CD4-positive, alpha beta T cell morphology	J:93004
	abnormal CD8-positive, alpha-beta T cell differentiation	J:93004
	increased CD8-positive, alpha-beta T cell number	J:93004
\Tg(CD8aCD8b)57Scr/? (B6;SJL-Tg(CD8aCD8b)57Scr/J)	abnormal cytotoxic T cell physiology	J:92994
\Tg(CD8aCD8b)57Scr/? (B6;SJL-Tg(CD8aCD8b)57Scr/J)	abnormal effector T cell morphology	J:92994
\Tg(Cd8b1)46Erob/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal T cell subpopulation ratio	J:110916
	decreased T cell number	J:110916
	decreased thymocyte number	J:110916
\Tg(CD19)1Tft/0 (involves: C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:27236
\Tg(CD19)1Tft/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased B cell proliferation	J:27236
\Tg(CD19)1Tft/\Tg(CD19)1Tft (involves: C57BL/6 * C57BL/6J * SJL)	decreased B cell number	J:27236
	decreased IgG1 level	J:27236
	decreased IgG3 level	J:27236
	decreased immature B cell number	J:27236
	increased B cell proliferation	J:27236
	increased IgG2a level	J:27236
	increased IgG2b level	J:27236
	increased IgM level	J:27236
\Tg(CD19-Tnfsf7)#Rvl/0 (involves: C57BL/6)	abnormal metallophilic macrophage morphology	J:88620
	abnormal spleen marginal zone macrophage morphology	J:88620
	abnormal spleen marginal zone morphology	J:88620
	decreased B cell number	J:88620
	decreased mature B cell number	J:88620
	decreased transitional stage B cell number	J:88620
\Tg(CD46)2Gsv/0 (involves: C57BL/6 * FVB/N)	abnormal cell-mediated immunity	J:109895
	abnormal chemokine level	J:109895
	abnormal cytokine secretion	J:109895
	abnormal humoral immune response	J:109895
	abnormal response to transplant	J:113644
	decreased cytotoxic T cell cytolysis	J:109895
	increased susceptibility to Paramyxoviridae infection	J:109895
\Tg(CD46)373Zbz/\Tg(CD46)373Zbz (involves: C3H/He * C57BL/6)	immune system phenotype	J:160878
\Tg(Cd68-BCL2)526Medz/0 (involves: 129 * C57BL/6)	abnormal immune cell physiology	J:82809
\Tg(Cd68-BCL2)526Medz/0 (involves: 129 * C57BL/6)	increased inflammatory response	J:82809
\Tg(Cd68-BCL2)533Medz/0 (involves: 129 * C57BL/6)	abnormal immune system cell morphology	J:82809
\Tg(Cd68-BCL2)535Medz/0 (involves: 129 * C57BL/6)	abnormal dendritic cell physiology	J:211458
	decreased dendritic cell apoptosis	J:211458
	enlarged lymph nodes	J:82809
	enlarged spleen	J:82809
	increased inflammatory response	J:82809
\Tg(Cd68-Fem1a)1Seno/0 (C57BL/6-Tg(Cd68-Fem1a)1Seno)	abnormal susceptibility to induced colitis	J:228893
\Tg(Cd74-Nlrc4*)1Kyas/0 (involves: C57BL/6N)	abnormal spleen morphology	J:219652
	autoimmune arthritis	J:219652
	dermatitis	J:219652
	enlarged spleen	J:219652
	increased circulating interleukin-1 beta level	J:219652
	increased circulating interleukin-17 level	J:219652
	increased inflammatory response	J:219652
	increased interleukin-1 beta secretion	J:219652
	increased neutrophil cell number	J:219652
	increased splenocyte number	J:219652
	increased T cell number	J:219652
	joint inflammation	J:219652
	skin inflammation	J:219652
\Tg(Cd79b-TCL1A)BKTeit/0 (involves: C3H * C57BL/6)	abnormal lymph node morphology	J:79703
	abnormal spleen morphology	J:79703
	abnormal thymus morphology	J:79703
	decreased B cell apoptosis	J:79703
	decreased T cell apoptosis	J:79703
	enlarged lymph nodes	J:79703
	enlarged spleen	J:79703
	increased B cell proliferation	J:79703
	increased lymphocyte cell number	J:79703
	increased T cell proliferation	J:79703
\Tg(Cd152Ig)1Jbs/0 (involves: C3H * NOD)	increased susceptibility to autoimmune diabetes	J:35353
\Tg(CD207-Dta)312Dhka/? (FVB-Tg(CD207-Dta)312Dhka)	absent Langerhans cell	J:113309
\Tg(CD207-Dta)312Dhka/? (FVB-Tg(CD207-Dta)312Dhka)	increased susceptibility to type IV hypersensitivity reaction	J:113309
\Tg(Cebpb-tTA)5Bjd/0 \Tg(tetO-MYC,-OVAL)#Gtgm/0 (B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm)	abnormal immune tolerance	J:186226
\Tg(Cga-LHB/CGB)94Jhn/? (involves: C57BL/6 * SJL)	pyelonephritis	J:55157
\Tg(Cga-LHB/CGB)94Jhn/? (involves: C57BL/6 * SJL)	tubulointerstitial nephritis	J:55157
\Tg(Chst4-cre)1Hkwa/0 (involves: C3H/HeN * C57BL/6)	immune system phenotype	J:147714
\Tg(Ckm-APPSw)A2Lfa/0 (involves: C57BL/6 * SJL)	myositis	J:76338
\Tg(Ckm-APPSw)A6Lfa/0 (involves: C57BL/6 * SJL)	myositis	J:76338
\Tg(CKMM-tTA)A3Rhvh/0 \Tg(tetO-H2-K1)#Papl/0 (B6.Cg-Tg(CKMM-tTA)A3Rhvh Tg(tetO-H2-K1)#Papl)	abnormal cytokine level	J:205907
	increased anti-nuclear antigen antibody level	J:205907
	increased autoantibody level	J:205907
	myositis	J:205907
\Tg(CLEC4C-HBEGF)956Cln/0 (C57BL/6-Tg(CLEC4C-HBEGF)956Cln)	abnormal chemokine secretion	J:166504
	abnormal cytotoxic T cell physiology	J:166504
	abnormal NK cell physiology	J:166504
	abnormal NK T cell physiology	J:166504
	decreased CD8-positive, alpha-beta T cell number	J:166504
	decreased interferon-alpha secretion	J:166504
	decreased plasmacytoid dendritic cell number	J:166504
	decreased splenocyte number	J:166504
	impaired natural killer cell mediated cytotoxicity	J:166504
	increased interferon-gamma secretion	J:166504
	increased interleukin-12 secretion	J:166504
	increased susceptibility to Herpesvirales infection	J:166504
	small spleen	J:166504
\Tg(Cma1-cre)ARoer/0 \Tg(Kit*D814V)1Roer/0 (involves: C57BL/6)	colitis	J:169611
	increased mast cell number	J:169611
\Tg(Cma1-cre)ARoer/0 \Tg(Kit*D814V)3Roer/0 (involves: C57BL/6)	increased mast cell number	J:169611
\Tg(CMV-cre)1Cgn/0 \Tg(KitD814V)1Roer/0 (involves: BALB/cJ C57BL/6)	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
\Tg(CMV-cre)1Cgn/0 \Tg(KitD814V)3Roer/0 (involves: BALB/cJ C57BL/6)	increased mast cell number	J:169611
\Tg(CMV-cre)1Cgn/0 \Trp53^tm4Att/\Trp53⁺ (involves: 129S4/SvJae * BALB/cJ * C57BL/6J)	small thymus	J:217080
\Tg(CMV-IghvaD11)CCat/0 \Tg(CMV-IgkvaD11)BCat/0 (involves: C57BL/6 * SJL)	abnormal splenic cell ratio	J:79946
	increased splenocyte apoptosis	J:79946
\Tg(CMV-IghvaD11)DCat/0 \Tg(CMV-IgkvaD11)ACat/0 (involves: C57BL/6 * SJL)	abnormal splenic cell ratio	J:79946
	increased splenocyte apoptosis	J:79946
\Tg(CMV-SALL4_iB)#Chai/? (Not Specified)	abnormal leukocyte morphology	J:115037
	abnormal myelopoiesis	J:115037
	abnormal neutrophil morphology	J:115037
	decreased leukocyte cell number	J:115037
	decreased neutrophil cell number	J:115037
	myeloid hyperplasia	J:115037
\Tg(CMV-tTA)3Bjd/0 \Tg(tetO-Prkar1ax2as)1Stra/0 (involves: C57BL/6 NMRI * SJL)	abnormal lymph node morphology	J:94953
	pancreas inflammation	J:94953
\Tg(Cnp-EGFR)10Nrat/0 (involves: C57BL/6 * SJL)	increased mast cell number	J:95933
\Tg(Cnp-Gpr17)1Qrlu/0 (Not Specified)	microgliosis	J:154602
\Tg(Col1a1-cre)1Kry/0 \Vdr^tm2Ska/\Vdr^tm2Ska (involves: C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj * FVB/N)	abnormal osteoclast differentiation	J:196471
	decreased osteoclast cell number	J:196471
\Tg(Col1a1-Dkk1)1Hmk/? (B6.FVB-Tg(Col1a1-Dkk1)1Hmk)	abnormal osteoclast physiology	J:158620
	abnormal response to transplant	J:238121
	increased osteoclast cell number	J:158620
\Tg(Col1a1-FGF2,-Sapphire)203Mmh/\Tg(Col1a1-FGF2,-Sapphire)203Mmh (involves: FVB/N)	increased osteoclast cell number	J:159949
	osteoarthritis	J:240777
\Tg(Col1a1-Runx2)#Pmt/0 (involves: BALB/c * C57BL/6)	increased osteoclast cell number	J:167992
\Tg(Col1a1-TK*)#Rowe/0 (involves: CD-1)	decreased osteoclast cell number	J:112520, J:217781
\Tg(Col1a1-TK*)#Rowe/0 (involves: CD-1)	increased spleen weight	J:112520
\Tg(Col1a1-tTA)139Niss/0 \Tg(tetO-HTR4D100A)7Niss/0 (FVB/N-Tg(Col1a1-tTA)139Niss Tg(tetO-HTR4D100A)7Niss)	increased osteoclast cell number	J:131617
\Tg(Col2a1-cre/ERT2)1Dic/0 \Tgfbr1^tm1.1Karl/\Tgfbr1^tm1.1Karl (involves: 129 * C57BL/6)	osteoarthritis	J:271724
\Tg(Col2a1-Fgfr3/GH)BDor/0 (FVB/N-Tg(Col2a1-Fgfr3/GH)BDor)	abnormal osteoclast differentiation	J:50292
\Tg(Col2a1-Mir140)#Asah/0 (C57BL/6-Tg(Col2a1-Mir140)#Asah)	decreased susceptibility to induced arthritis	J:160358
\Tg(Col2a1-rtTA,tetO-COMP)2Jath/0 (C57BL/6-Tg(Col2a1-rtTA,tetO-COMP)2Jath)	increased inflammatory response	J:233238
\Tg(Col10a1-Tg*L2263P)1Rpbh/0 (Not Specified)	decreased osteoclast cell number	J:154052
\Tg(Col10a1-TgL2263P)1Rpbh/\Tg(Col10a1-TgL2263P)1Rpbh (Not Specified)	decreased osteoclast cell number	J:154052
\Tg(Comp-tTA)#Yeli/0 \Tg(tetO-DDR2)#Yeli/0 (Not Specified)	osteoarthritis	J:176308
\Tg(Cr2-cre)3Cgn/? \Xrcc4^tm1Fwa/\Xrcc4^tm2Fwa (involves: 129P2/OlaHsd * 129S6/SvEvTac)	abnormal class switch recombination	J:150339
\Tg(Crh)227.1Pbl/0 (involves: C57BL/6 * SJL)	decreased spleen weight	J:92996
\Tg(Crh)227.1Pbl/0 (involves: C57BL/6 * SJL)	decreased thymus weight	J:92996
\Tg(Csf1r-Tnfsf15,-EGFP)#Targ/0 (involves: C57BL/6)	increased interferon-gamma secretion	J:169462
\Tg(Csf1r-Tnfsf15,-EGFP)#Targ/0 (involves: C57BL/6)	small intestinal inflammation	J:169462
\Tg(CSF2)2Ygy/0 \Tg(IL3)1Ygy/0 \Tg(KITLG)3Ygy/0 (C.Cg-Tg(CSF2)2Ygy Tg(IL3)1Ygy Tg(KITLG)3Ygy)	abnormal response to transplant	J:107052
	decreased susceptibility to graft versus host disease	J:107052
\Tg(CSTG-NPM1/RARA)#Sjch/0 (involves: C57BL/6)	enlarged spleen	J:55196
\Tg(CSTG-NPM1/RARA)#Sjch/0 (involves: C57BL/6)	increased spleen red pulp amount	J:55196
\Tg(CTSG-NUMA1/RARA)#Skr/0 (involves: C57BL/6)	abnormal spleen morphology	J:88103
	abnormal spleen red pulp morphology	J:88103
	enlarged spleen	J:88103
	increased granulocyte number	J:88103
	increased leukocyte cell number	J:88103
	increased neutrophil cell number	J:88103
	increased spleen germinal center size	J:88103
	increased spleen white pulp amount	J:88103
\Tg(CTSG-PML/RARA)135Ley/? (Not Specified)	abnormal leukocyte cell number	J:77881
	abnormal spleen red pulp morphology	J:77881
	enlarged spleen	J:77881
	spleen hyperplasia	J:77881
\Tg(CTSG-PML/RARA)135Ley/? (involves: C3H * C57BL/6)	abnormal spleen red pulp morphology	J:59080
	enlarged spleen	J:59080
	immune system phenotype	J:59080
	increased leukocyte cell number	J:59080
\Tg(CTSG-PML/RARA)135Ley/0 \Tg(CTSG-RARA/PML)#Ley/0 (involves: C3H * C57BL/6)	abnormal spleen red pulp morphology	J:59080
	enlarged spleen	J:59080
	immune system phenotype	J:59080
	increased leukocyte cell number	J:59080
\Tg(CTSG-PML/RARA)135Ley/0 \Wbcc1^SWR/J/? (involves: C3H/HeJ * C57BL/6J * SWR/J)	decreased leukocyte cell number	J:139159
\Tg(CTSG-PML/RARA)135Ley/0 \Wbcc2^SWR/J/? (involves: C3H/HeJ * C57BL/6J * SWR/J)	increased leukocyte cell number	J:139159
\Tg(CTSG-PML/RARA)135Ley/0 \Wbcc3^SWR/J/? (involves: C3H/HeJ * C57BL/6J * SWR/J)	increased leukocyte cell number	J:139159
\Tg(CTSG-PML/RARA)6179Ppp/0 (Not Specified)	abnormal myelopoiesis	J:40373
	increased granulocyte number	J:40373
	increased leukocyte cell number	J:40373
\Tg(CTSG-PML/RARA)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:78201, J:40373
	increased granulocyte number	J:40373
	increased leukocyte cell number	J:40373
\Tg(CTSG-RARA/ZBTB16)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:65878
	enlarged spleen	J:65878
	myeloid hyperplasia	J:65878
\Tg(CTSG-RARA/ZBTB16)#Ppp/0 \Tg(CTSG-ZBTB16/RARA)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:65878
	increased leukocyte cell number	J:65878
\Tg(CTSG-ZBTB16/RARA)#Ppp/0 (Not Specified)	abnormal myelopoiesis	J:78201
\Tg(CTSG-ZBTB16/RARA)#Ppp/0 (Not Specified)	increased leukocyte cell number	J:65878, J:78201
\Tg(CTSG-ZBTB16/RARA)#Sjch/0 (involves: C57BL/6)	abnormal myelopoiesis	J:55196
	abnormal spleen morphology	J:55196
	abnormal spleen red pulp morphology	J:55196
	enlarged spleen	J:55196
	increased leukocyte cell number	J:55196
	myeloid hyperplasia	J:55196
\Tg(CYP1A1-PPARD)#Jfoe/0 (involves: C57BL/6J * CBA)	increased T cell proliferation	J:158907
\Tg(CYP1A1-PPARD)#Jfoe/0 (involves: C57BL/6J * CBA)	skin inflammation	J:158907
\Tg(Dct-Grm1)ESzc/0 (involves: C57BL/6J)	enlarged inguinal lymph nodes	J:83183
\Tg(Dct-Grm1)ESzc/0 (involves: C57BL/6J)	enlarged submandibular lymph nodes	J:83183
\Tg(DMD-APP)7Neve/0 (involves: C57BL/6 SJL)	abnormal microglial cell morphology	J:100978
\Tg(DMD-APP)18Neve/0 (involves: C57BL/6 SJL)	abnormal microglial cell morphology	J:100978
\Tg(DO11.10)10Dlo/? (involves: BALB/c * C3H * C57BL/6)	abnormal thymus physiology	J:70572
	decreased CD4-positive, alpha-beta T cell number	J:70572
	decreased double-positive T cell number	J:70572
\Tg(DO11.10)10Dlo/0 \Crlf2^tm1Wjl/\Crlf2^tm1Wjl (involves: 129 * BALB/c * C3H * C57BL/6)	decreased inflammatory response	J:107431
\Tg(DO11.10)10Dlo/? \Tox^tm1.1Kay/\Tox^tm1.1Kay (involves: 129S/Sv * BALB/c * C3H * C57BL/6)	arrested T cell differentiation	J:131287
	decreased T cell number	J:131287
\Tg(DPP4)2Nnag/0 (B6.Cg-Tg(DPP4)2Nnag)	abnormal cytokine level	J:286321
	increased susceptibility to Coronaviridae infection	J:286321
	lung inflammation	J:286321
\Tg(DPP4)2Nnag/0 \Tmprss2^{tm1(KOMP)Vlcg}/\Tmprss2^{tm1(KOMP)Vlcg} (involves: C57BL/6NCr * C57BL/6NTac * DBA)	abnormal cytokine secretion	J:283077
	decreased susceptibility to Coronaviridae infection	J:283077
\Tg(DUX4)1Maar/? (involves: C57BL/6J CBA/J)	increased incidence of corneal inflammation	J:195481
\Tg(ED-L2-IL1RN/IL1B)#Tcw/? (B6.Cg-Tg(ED-L2-IL1RN/IL1B)#Tcw)	abnormal interleukin level	J:180282
	enlarged spleen	J:180282
	esophageal inflammation	J:180282
	increased circulating interleukin-6 level	J:180282
	increased inflammatory response	J:180282
\Tg(EEF1A1-SHC1)1Ravi/? \Tg(Lck-cre)1Cwi/? (involves: 129 C57BL/6)	abnormal double-negative T cell morphology	J:78180
	decreased double-positive T cell number	J:78180
	decreased single-positive T cell number	J:78180
	thymus hypoplasia	J:78180
\Tg(EIF1AX-Il31ra)1Jagr/0 (involves: C3H * C57BL/6)	abnormal immune system physiology	J:91124
	abnormal leukopoiesis	J:91124
	conjunctivitis	J:91124
	cutaneous mastocytosis	J:91124
	decreased T cell number	J:91124
	dermatitis	J:91124
	enlarged lymph nodes	J:91124
	increased activated T cell number	J:91124
	increased B cell number	J:91124
	increased memory T cell number	J:91124
\Tg(Ela1-TAg)18Bri/0 (involves: C57BL/6 * SJL)	pancreas inflammation	J:107545
\Tg(Ela1-TAg)79Mjt/0 \Tg(MUC1)79.24Gend/0 (involves: C57BL/6 DBA/2)	immune system phenotype	J:64570
\Tg(Ela2a-Prss1,-GFP)1Dbs/0 (C57BL/6-Tg(Ela2a-Prss1,-GFP)1Dbs)	chronic pancreas inflammation	J:144663
	increased susceptibility to induced pancreatitis	J:144663
\Tg(Ela-KRASG12D)9Eps/0 (involves: C57BL/6 FVB)	increased regulatory T cell number	J:231759
\Tg(Ela-KRASG12D)9Eps/0 (involves: C57BL/6 FVB)	pancreas inflammation	J:231759
\Tg(Ela-KRASG12D)9Eps/0 \Tg(Mt1-TGFBR2)AM3Epb/0 (involves: C57BL/6 * FVB)	increased regulatory T cell number	J:231759
	pancreas inflammation	J:231759
\Tg(Ela-KRASG12D)9Eps/0 \Tgfbr1^tm1Bopa/\Tgfbr1⁺ (involves: 129S1/SvImJ C57BL/6 * FVB)	increased CD8-positive, alpha-beta T cell number	J:231759
\Tg(Emu-FGFR3)A5Wmk/0 (FVB/N-Tg(Emu-FGFR3)A5Wmk)	lymphoid hyperplasia	J:160845
\Tg(Emu-FGFR3)D3Wmk/0 (FVB/N-Tg(Emu-FGFR3)D3Wmk)	lymphoid hyperplasia	J:160845
\Tg(Emu-Pim1)64aBrn/0 (involves: C57BL/6LiA * CBA)	enlarged lymph nodes	J:79624
	enlarged spleen	J:79624
	enlarged thymus	J:79624
	increased T cell derived lymphoma incidence	J:79624
\Tg(Emu-TXLNA)1Amjr/0 (B6.Cg-Tg(Emu-TXLNA)1Amjr)	abnormal B cell physiology	J:117018
	enhanced humoral immune response	J:145185
	enlarged spleen	J:117018
	increased autoantibody level	J:117018
	increased B cell number	J:117018
	increased B-1 B cell number	J:117018
	increased B-2 B cell number	J:117018
	increased circulating interferon-alpha level	J:117018
	increased germinal center B cell number	J:117018
	increased IgA level	J:117018
	increased IgG2a level	J:117018
	increased IgM level	J:117018
	increased immunoglobulin level	J:117018
	increased marginal zone B cell number	J:117018
	increased plasma cell number	J:117018
	increased susceptibility to autoimmune disorder	J:117018, J:145185
	interstitial pneumonia	J:145185
	kidney inflammation	J:117018
	lacrimal gland inflammation	J:145185
	lymphoid hyperplasia	J:117018
	parotid gland inflammation	J:145185
	salivary gland inflammation	J:117018, J:145185
	submandibular gland inflammation	J:145185
\Tg(Emu-Zfp521)1Homy/0 (Not Specified)	abnormal B cell differentiation	J:160392
\Tg(Emu-Zfp521)1Homy/0 (Not Specified)	increased B cell number	J:160392
\Tg(EmuSR-HDAC9)1468Kpet/0 (involves: C57BL/6 * CBA)	abnormal lymphocyte physiology	J:237420
	abnormal spleen marginal zone morphology	J:237420
	enlarged spleen	J:237420
	increased B cell number	J:237420
	increased B cell proliferation	J:237420
\Tg(EmuSR-tTa)83Bop/0 \Tg(IghMyc)22Bri/0 \Tg(tetO-RNAi:Trp53)ASlowe/0 (involves: C57BL * C57BL/6 * FVB/N * SJL)	enlarged spleen	J:123006
\Tg(EmuSR-tTa)83Bop/\Tg(EmuSR-tTa)83Bop \Tg(tetO-NPM1/ALK,-luc)2Gde/0 (involves: FVB/N)	enlarged lymph nodes	J:160236
	enlarged spleen	J:160236
\Tg(EmuSR-tTa)83Bop/\Tg(EmuSR-tTa)83Bop \Tg(tetO-TPM3/ALK,-luc)2Gde/0 (involves: FVB/N)	enlarged lymph nodes	J:160236
	enlarged spleen	J:160236
\Tg(Eno2-Hgf)1Tnak/0 \Tg(SOD1G93A)^dl1Gur/0 (involves: C57BL/6 C57BL/6J * SJL/J)	microgliosis	J:128738
\Tg(Eno2-Hmox1)2Main/\Tg(Eno2-Hmox1)2Main (involves: C57BL/6J)	enlarged spleen	J:120240
\Tg(EPO33)72Ptc/0 (involves: C57BL/6J * SJL/J)	enlarged spleen	J:92650
\Tg(F2RL1)1Mslb/0 (involves: FVB/NCrl)	increased inflammatory response	J:79757
\Tg(F2RL1)1Mslb/0 (involves: FVB/NCrl)	respiratory system inflammation	J:79757
\Tg(Fabp1-cre)1Jig/0 \Vhl^tm1Jae/\Vhl^tm1Jae (involves: 129S4/SvJae * BALB/c * FVB/N)	decreased susceptibility to induced colitis	J:93476
\Tg(Fabp2-Arg1)1Wla/\Tg(Fabp2-Arg1)1Wla (involves: FVB)	abnormal B cell differentiation	J:80204
	abnormal Peyer's patch morphology	J:80204, J:80556
	decreased B cell number	J:80204
	decreased IgM level	J:80204
	decreased Peyer's patch number	J:80556
	decreased pre-B cell number	J:80204
	decreased spleen B cell follicle number	J:80204
	decreased spleen weight	J:80556
	decreased transitional stage B cell number	J:80204
	small Peyer's patches	J:80556
	small spleen	J:80204
\Tg(Fabp4-Angptl2)5Yo/0 (involves: C57BL/6)	abnormal macrophage chemotaxis	J:152387
	chronic inflammation	J:152387
	white adipose tissue inflammation	J:152387
\Tg(Fabp4-Apol6)#Hsul/0 (C57BL/6J-Tg(Fabp4-Apol6)#Hsul)	white adipose tissue inflammation	J:344362
\Tg(Fabp4-Phb*Y114F)#Smis/0 (Not Specified)	abnormal circulating chemokine level	J:227976
	abnormal circulating cytokine level	J:227976
	abnormal lymph node morphology	J:227976
	abnormal spleen morphology	J:227976
	enlarged lymph nodes	J:227976
	enlarged spleen	J:227976
	increased lymphocyte cell number	J:227976
\Tg(FCGR2A)11Mkz/0 \Tg(PF4)#Zcy/0 (involves: C57BL/6 * SJL)	increased acute inflammation	J:72220
\Tg(FCGR2A)11Mkz/\Tg(FCGR2A)11Mkz (involves: C57BL/6 * SJL)	abnormal macrophage physiology	J:136516
	autoimmune arthritis	J:136516
	glomerulonephritis	J:136516
	increased anti-histone antibody level	J:136516
	increased IgG2a level	J:136516
	increased susceptibility to induced arthritis	J:136516
	increased tumor necrosis factor secretion	J:136516
	interstitial pneumonia	J:136516
\Tg(Fga,Fgb,Fgg)1Unc/? (C57BL/6-Tg(Fga,Fgb,Fgg)1Unc)	increased circulating fibrinogen level	J:118353
\Tg(Fli1)1Ber/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)	increased thymocyte number	J:33052
\Tg(FOXJ1-ACE2)1Rba/0 (involves: C3H * C57BL/6)	decreased lymphocyte cell number	J:288386
	increased susceptibility to Coronaviridae infection	J:287092, J:288386
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:287092, J:288386
	interstitial pneumonia	J:288386
\Tg(Foxp3-HBEGF/EGFP)23.2Spar/0 (involves: C57BL/6NCrl)	decreased regulatory T cell number	J:125295
	enlarged lymph nodes	J:125295
	enlarged spleen	J:125295
	immune system phenotype	J:125295
	increased inflammatory response	J:125295
	increased spleen red pulp amount	J:125295
	increased spleen white pulp amount	J:125295
	increased susceptibility to type IV hypersensitivity reaction	J:125295
	insulitis	J:125295
	lung inflammation	J:125295
	lymph node hyperplasia	J:125295
	skin inflammation	J:125295
\Tg(Gfap-gp120)2Lms/0 (involves: C57BL/6 * SJL)	abnormal microglial cell morphology	J:146427
\Tg(Gfap-gp120)2Lms/0 (involves: C57BL/6 * SJL)	microgliosis	J:146427
\Tg(Gfap-gp120)10Lms/0 (involves: C57BL/6 * SJL)	microgliosis	J:146427
\Tg(Gfap-Ifna1)12Ilc/0 (involves: BALB/c * C57BL/6J)	CNS inflammation	J:68811
	decreased susceptibility to Riboviria infection	J:68811
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:68811
	meningoencephalitis	J:68811
\Tg(Gfap-Ifna1)39Ilc/0 (involves: BALB/c * C57BL/6J)	CNS inflammation	J:68811
\Tg(Gfap-Ifna1)39Ilc/0 (involves: BALB/c * C57BL/6J)	meningoencephalitis	J:68811
\Tg(Gfap-Il6)G16Lms/0 \Tg(Gfap-lacZ)1Lms/0 (involves: C57BL/6J * SJL)	immune system phenotype	J:125549
\Tg(Gfap-Il6)G369Lms/0 (involves: C57BL/6J * SJL)	immune system phenotype	J:125549
\Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/0 (involves: C57BL/6)	abnormal microglial cell activation	J:132679
\Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/0 (involves: C57BL/6)	abnormal microglial cell morphology	J:132679
\Tg(Gfap-TGFB1)64Lms/0 (involves: BALB/c * SJL)	immune system phenotype	J:27781
\Tg(Gfap-TGFB1)64Lms/\Tg(Gfap-TGFB1)64Lms (involves: BALB/c * SJL)	immune system phenotype	J:27781
\Tg(Gfap-TK)7.1Mvs/0 (involves: C57BL/10 * CBA * CFLP)	abnormal inflammatory response	J:104241
	brain inflammation	J:113202
	increased neutrophil cell number	J:104241
	small intestinal inflammation	J:104241
\Tg(Gfap-TNF)K21Gkl/0 (involves: C57BL/6 CBA)	CNS inflammation	J:106592
\Tg(GFAP-tTA)78Pop/0 \Tg(tetO-Ifng)184Pop/0 (B6.Cg-Tg(GFAP-tTA)78Pop Tg(tetO-Ifng)184Pop)	abnormal interferon-gamma secretion	J:109838
	CNS inflammation	J:109838
\Tg(GNB1L,TBX1,GP1BB,SEPT5)23Bem/0 (either: FVB-Tg(GNB1L,TBX1,GP1BB,SEPT5)23Bem or (involves: C57BL/6 * FVB))	abnormal thymus development	J:67796
	abnormal thymus lobule morphology	J:67796
	decreased thymocyte number	J:67796
	thymus hypoplasia	J:67796
\Tg(H2-Aa)26Dim/? \Tg(H2-Ab1)62Dim/? (B6.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)	abnormal antigen presentation via MHC class II	J:110897
	abnormal level of surface class II molecules	J:110897
	immune system phenotype	J:110897
	increased immunoglobulin level	J:110897
\Tg(H2-Aa)26Dim/? \Tg(H2-Ab1)62Dim/? (SJL.Cg-Tg(H2-Aa)26Dim Tg(H2-Ab1)62Dim)	abnormal level of surface class II molecules	J:110897
	immune system phenotype	J:110897
\Tg(H2-D-Il15)3304Clgr/? (FVB/N-Tg(H2-D-Il15)3304Clgr)	abnormal inflammatory response	J:67478
	abnormal lymphocyte physiology	J:67478
	abnormal T cell morphology	J:67478
	abnormal T cell subpopulation ratio	J:67478
	dermatitis	J:67478
	enlarged lymph nodes	J:67478
	enlarged spleen	J:67478
	increased lymphocyte cell number	J:67478
	increased memory T cell number	J:67478
	increased NK cell number	J:67478
	increased spleen white pulp amount	J:67478
\Tg(H2-D^b)2Bujf/0 (FVB/NPas-Tg(H2-D^b)2Bujf)	decreased susceptibility to Picornaviridae infection	J:18556
\Tg(H2-Ea)16Dim/? (involves: C57BL/6 * SJL)	increased immunoglobulin level	J:111128
\Tg(H2-Ea-G6pc2)69Tkay/? (NOD-Tg(H2-Ea-G6pc2)69Tkay)	abnormal CD4-positive, alpha-beta T cell physiology	J:117352
	abnormal CD8-positive, alpha beta T cell morphology	J:117352
	abnormal immune tolerance	J:117352
	decreased T cell proliferation	J:117352
	increased anti-insulin autoantibody level	J:117352
	increased susceptibility to autoimmune diabetes	J:117352
	insulitis	J:117352
\Tg(H2-Ea-HA)HACIIAjca/0 \Tg(Tcra/Tcrb)1Vbo/0 (C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo)	abnormal CD4-positive, alpha beta T cell morphology	J:209872
	abnormal circulating cytokine level	J:209872
	autoimmune arthritis	J:209872
	heart inflammation	J:209872
	increased circulating interleukin-6 level	J:209872
	increased IgG level	J:209872
	joint inflammation	J:209872
	kidney inflammation	J:209872
\Tg(H2-Ea-HA)HACIIAjca/0 \Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0 (C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)	abnormal CD4-positive, alpha beta T cell morphology	J:209872
	abnormal CD4-positive, alpha-beta T cell physiology	J:209872
	abnormal circulating cytokine level	J:209872
	autoimmune arthritis	J:209872
	decreased circulating interleukin-6 level	J:209872
	enlarged lymph nodes	J:209872
	immune system phenotype	J:209872
	increased circulating interleukin-17 level	J:209872
	increased IgG level	J:209872
	joint inflammation	J:209872
\Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6)	abnormal B cell morphology	J:81133
\Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6)	abnormal double-negative T cell morphology	J:81133
\Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6 * DBA/2)	increased pre-B cell number	J:171924
\Tg(H2-Ea-Il7)10Rhdr/0 (involves: C57BL/6 * DBA/2)	increased pro-B cell number	J:171924
\Tg(H2-Ea-Ins2)1Wehi/0 (NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)	abnormal T cell proliferation	J:100232
	immune system phenotype	J:100232
	salivary gland inflammation	J:100232
\Tg(H2-Ea-Ins2)1Wehi/\Tg(H2-Ea-Ins2)1Wehi (NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)	abnormal CD8-positive, alpha beta T cell morphology	J:117352
	decreased anti-insulin autoantibody level	J:117352
	decreased T cell proliferation	J:117352
	immune system phenotype	J:117352
\Tg(H2-Ea-LACK)1Ngkh/0 (C.Cg-Tg(H2-Ea-LACK)1Ngkh)	abnormal immune system physiology	J:181384
	abnormal T-helper 1 physiology	J:181384
	abnormal T-helper 2 physiology	J:181384
	decreased susceptibility to parasitic infection	J:181384
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:181384
	decreased T-helper 2 cell number	J:181384
	increased T-helper 1 cell number	J:181384
\Tg(H2-Ea-Tnfsf9)16Lpc/0 (involves: C57BL/6)	abnormal B cell physiology	J:132372
	abnormal lymph node B cell domain morphology	J:132372
	decreased B cell number	J:132372
	decreased IgG level	J:132372
	decreased spleen B cell follicle number	J:132372
	enlarged spleen	J:132372
	increased granulocyte number	J:132372
	increased lymphocyte cell number	J:132372
	increased macrophage cell number	J:132372
	increased memory T cell number	J:145439
	increased NK cell number	J:132372
	spleen hyperplasia	J:132372
\Tg(H2-Ea^d)5Lt/0 (NOD/ShiLt-Tg(H2-Ea^d)5Lt)	autoimmune response	J:36435
	decreased interferon-gamma secretion	J:36435
	decreased susceptibility to autoimmune diabetes	J:36435
	increased interleukin-4 secretion	J:36435
	periinsulitis	J:36435
\Tg(H2-Ea^d)12Lt/0 (NOD/ShiLt-Tg(H2-Ea^d)12Lt)	autoimmune response	J:36435
	decreased interferon-gamma secretion	J:36435
	decreased susceptibility to autoimmune diabetes	J:36435
	increased interleukin-4 secretion	J:36435
	insulitis	J:36435
\Tg(H2-K1-HLA-A)28Mpla/0 (B10.Cg-Tg(H2-K1-HLA-A)28Mpla)	choroid inflammation	J:67871
\Tg(H2-K1-HLA-A)28Mpla/0 (B10.Cg-Tg(H2-K1-HLA-A)28Mpla)	eye inflammation	J:67871
\Tg(H2-K-BCL2)1Josd/0 (involves: C57BL/6 * C57BL/Ka * C3H)	abnormal lymph organ size	J:80894
	enlarged lymph nodes	J:80894
	enlarged spleen	J:80894
	enlarged thymus	J:80894
	increased leukocyte cell number	J:80894
\Tg(H2-K-Cd86)7All/0 (involves: C57BL/6J * CBA)	abnormal B cell differentiation	J:112475
	decreased B cell number	J:112475
	increased CD4-positive, alpha-beta T cell number	J:112475
	increased CD8-positive, alpha-beta T cell number	J:112475
\Tg(H2-K-Cd86)7All/0 (B6.Cg-Tg(H2-K-Cd86)7All)	abnormal inflammatory response	J:112266
	decreased B cell number	J:112266
	decreased CD4-positive, alpha-beta T cell number	J:112266
	increased CD8-positive, alpha-beta T cell number	J:112266
	increased T cell number	J:112266
	lymph node hyperplasia	J:112266
	lymphoid hyperplasia	J:112266
\Tg(H2-K-Cd86)7All/0 (involves: BALB/c * C57BL/6 * CBA)	increased splenocyte number	J:112266
	lymph node hyperplasia	J:112266
	spleen hyperplasia	J:112266
\Tg(H2-K-Cd86)27All/0 (involves: C57BL/6J * CBA)	abnormal B cell differentiation	J:112475
\Tg(H2-K-Cd86)27All/0 (involves: C57BL/6J * CBA)	decreased B cell number	J:112475
\Tg(H2-K-Cd86)31All/0 (involves: C57BL/6J * CBA)	increased CD4-positive, alpha-beta T cell number	J:112475
\Tg(H2-K-Cd86)31All/0 (involves: C57BL/6J * CBA)	increased CD8-positive, alpha-beta T cell number	J:112475
\Tg(H2-K-DUSP5)21Wjl/0 (involves: C57BL/6J * CBA)	abnormal T cell number	J:138077
	decreased single-positive T cell number	J:138077
	decreased T cell proliferation	J:138077
	dermatitis	J:138077
	increased CD4-positive, alpha-beta T cell number	J:138077
	increased CD8-positive, alpha-beta T cell number	J:138077
	increased double-positive T cell number	J:138077
	increased plasma cell number	J:138077
	increased single-positive T cell number	J:138077
	skin inflammation	J:138077
\Tg(H2-K-Fosl1)1Wag/0 (involves: C57BL/6 * CBA)	enlarged spleen	J:64494
\Tg(H2-K-Fosl2,-EGFP)13Wag/0 (either: 129.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag or B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)	thymus fibrosis	J:139032
\Tg(H2-K-Fosl2,-EGFP)13Wag/0 (B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)	lung inflammation	J:238723
\Tg(H2-K-HLA-G,B2M)1Alm/0 (CBA/Ca-Tg(H2-K-HLA-G,B2M)1Alm/CmwJ)	abnormal cytotoxic T cell physiology	J:140016
	increased T cell proliferation	J:140016
\Tg(H2-K-Hmga1)#Lmsr/0 (involves: C57BL/6 * SJL)	increased leukocyte cell number	J:90252
\Tg(H2-K-IL6)2Srj/0 (B6.Cg-Tg(H2-K-IL6)2Srj)	abnormal granulocyte morphology	J:185153
	abnormal lymph node germinal center morphology	J:185153
	abnormal lymph node morphology	J:185153
	abnormal spleen germinal center morphology	J:185153
	abnormal spleen red pulp morphology	J:185153
	enlarged lymph nodes	J:185153
	enlarged spleen	J:185153
	increased IgG level	J:185153
	increased plasma cell number	J:185153
\Tg(H2-K-MC159/EGFP)13Fkmc/0 (involves: C57BL/6)	abnormal lymphopoiesis	J:138050
	decreased B cell apoptosis	J:138050
	decreased T cell apoptosis	J:138050
	enlarged spleen	J:138050
	immune system phenotype	J:138050
	increased B cell proliferation	J:138050
	increased follicular B cell number	J:138050
\Tg(H2-K-MC159/EGFP)13Fkmc/\Tg(H2-K-MC159/EGFP)13Fkmc (involves: C57BL/6)	increased anti-double stranded DNA antibody level	J:138050
	increased double-negative T cell number	J:138050
	increased IgG2b level	J:138050
	increased T cell number	J:138050
\Tg(H2-K-TcrbP14)128Mak/? (involves: C57BL/6 * C57L * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:111265
	abnormal T cell clonal deletion	J:111265
	abnormal T cell differentiation	J:111265
	increased CD8-positive, alpha-beta T cell number	J:111265
\Tg(H2-K^b-IL21)5Wjl/0 (involves: 129)	abnormal B cell differentiation	J:93740
	abnormal class switch recombination	J:93740
	decreased follicular B cell number	J:93740
	decreased marginal zone B cell number	J:93740
	decreased mature B cell number	J:93740
	decreased transitional stage T2 B cell number	J:93740
	increased B cell apoptosis	J:93740
	increased IgG1 level	J:93740
	increased IgM level	J:93740
	increased immature B cell number	J:93740
	increased transitional stage T1 B cell number	J:93740
\Tg(H2-K^b-Jak2V617F)2Shmd/0 (involves: C57BL/6 DBA/2)	abnormal spleen morphology	J:130189
	enlarged spleen	J:130189
	increased leukocyte cell number	J:130189
	increased neutrophil cell number	J:130189
	increased spleen red pulp amount	J:130189
	increased spleen weight	J:130189
	myeloid hyperplasia	J:130189
	spleen fibrosis	J:130189
\Tg(H2-K^b-Tcra,-Tcrb)1640Kurs/0 (SJL.FVB-Tg(H2-K^b-Tcra,-Tcrb)1640Kurs)	abnormal cytokine level	J:149511
	brain inflammation	J:149511
	CNS inflammation	J:149511
	increased autoantibody level	J:149511
	increased susceptibility to experimental autoimmune encephalomyelitis	J:149511
	increased T-helper 1 cell number	J:149511
	increased T-helper 17 cell number	J:149511
\Tg(H2-L-IL6)1Kish/\Tg(H2-L-IL6)1Kish (C57BL/6-Tg(H2-L-IL6)1Kish)	abnormal myelopoiesis	J:128016
	enlarged lymph nodes	J:128016, J:138762
	enlarged spleen	J:128016, J:138762
	glomerulonephritis	J:128016, J:138762
	increased IgG1 level	J:128016
	increased monocyte cell number	J:128016
	increased neutrophil cell number	J:128016
	increased plasma cell number	J:128016, J:138762
\Tg(H2-L-IL6)40Csk/0 (involves: C57BL/6)	enlarged lymph nodes	J:207264
	enlarged spleen	J:207264
	increased spleen weight	J:207264
\Tg(H2-L-IL6)46Kish/\Tg(H2-L-IL6)46Kish (C57BL/6-Tg(H2-L-IL6)46Kish)	enlarged axillary lymph nodes	J:40405
	enlarged mesenteric lymph nodes	J:40405
	glomerulonephritis	J:40405
	increased immunoglobulin level	J:40405
	increased plasma cell number	J:40405
\Tg(H2-L-IL6)46Kish/\Tg(H2-L-IL6)46Kish (involves: BALB/c * C57BL/6)	abnormal immune system organ morphology	J:40405
	abnormal lymph node morphology	J:40405
	enlarged mesenteric lymph nodes	J:40405
	increased IgA level	J:40405
	increased immunoglobulin level	J:40405
\Tg(H2-L-IL6)46Kish/\Tg(H2-L-IL6)46Kish (C.B6-Tg(H2-L-IL6)46Kish)	abnormal spleen trabecular artery morphology	J:177820
	abnormal spleen trabecular vein morphology	J:177820
	enlarged spleen	J:177820
	increased IgG1 level	J:74377
	increased IgG2b level	J:74377
	increased IgG level	J:74377
\Tg(H2-L^d)LoxNibl/0 (C57BL/6-Tg(H2-L^d)LoxNibl)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:284394
\Tg(H2-L^d)LoxNibl/0 (C57BL/6-Tg(H2-L^d)LoxNibl)	increased response to antigen	J:284394
\Tg(H2KePCC)2403Stoe/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
\Tg(H2KePCC)2403Stoe/? \Tg(TcraTcrbAD10)1Hed/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
	abnormal T cell anergy	J:92997
	decreased CD4-positive, alpha-beta T cell number	J:92997
\Tg(H2KmPCC)2939Stoe/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
\Tg(H2KmPCC)2939Stoe/0 \Tg(Tcra2B4)1Mmd/0 \Tg(Tcrb2B4)1Mmd/0 (involves: C3H/HeJ * C57BL/6 * SJL)	abnormal T cell differentiation	J:50143
	decreased T cell proliferation	J:50143
	decreased thymocyte number	J:50143
\Tg(H2KmPCC)2939Stoe/? \Tg(TcrAND)53Hed/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
	abnormal T cell anergy	J:92997
	decreased CD4-positive, alpha-beta T cell number	J:92997
\Tg(H2KmPCC)2939Stoe/? \Tg(TcraTcrbAD10)1Hed/? (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:92997
	abnormal T cell anergy	J:92997
	decreased CD4-positive, alpha-beta T cell number	J:92997
\Tg(HBB-Myc)#Cos/0 (involves: C57BL/6J * CBA/J)	abnormal immune system organ morphology	J:276641
\Tg(HBB-Myc)#Cos/0 (involves: C57BL/6J * CBA/J)	kidney inflammation	J:276641
\Tg(HBV)10Imeg/0 (involves: C57BL/6)	abnormal cytokine secretion	J:95283
\Tg(HBV)10Imeg/0 (involves: C57BL/6)	abnormal dendritic cell physiology	J:95283
\Tg(HBVX,-Myc)#Skp/\Tg(HBVX,-Myc)#Skp (Not Specified)	increased macrophage cell number	J:81098
\Tg(HCRT-tTA)1Ahky/0 \Tg(tetO-DTA)1Gfi/0 (B6.Cg-Tg(HCRT-tTA)1Ahky Tg(tetO-DTA)1Gfi)	increased microglial cell activation	J:211045
\Tg(HIV)26Aln/0 (involves: FVB/N)	kidney inflammation	J:90297
	myositis	J:90297
	uveitis	J:136652
\Tg(HLA-A2/H2-K)1Scr/? (involves: C57BL/6)	abnormal cytotoxic T cell physiology	J:127813
\Tg(HLA-A/H2-D/B2M)1Dvs/0 (NOD/ShiLtDvs-Tg(HLA-A/H2-D/B2M)1Dvs)	increased susceptibility to autoimmune diabetes	J:121685
\Tg(HLA-B27)1Trg/0 (involves: C57BL/6 * SJL/J)	immune system phenotype	J:74451
\Tg(HLA-B27)30-4Trg/? (involves: C57BL/6J * NOD)	decreased susceptibility to autoimmune diabetes	J:109851
\Tg(HLA-DQA1,HLA-DQB1)1Dv/0 \Tg(Ins2-CD80)3B7Flv/0 (B6.Cg-Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)	decreased susceptibility to autoimmune diabetes	J:59245
\Tg(HLA-DR2)#Lfug/0 \Tg(TCROb.1A12)#Lfug/0 (involves: C57BL/6 * DBA/2)	CNS inflammation	J:134764
	increased susceptibility to experimental autoimmune encephalomyelitis	J:134764
\Tg(HLA-DRA0101,HLA-DRB10101)1Dmz/\Tg(HLA-DRA0101,HLA-DRB10101)1Dmz (involves: C57BL/6 * C57BL/10Sn * SJL/J)	abnormal T cell physiology	J:108635
	increased autoantibody level	J:108635
	increased susceptibility to induced arthritis	J:108635
\Tg(Hmgcr-MX1)LStae/\Tg(Hmgcr-MX1)LStae (involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)	decreased susceptibility to Orthomyxoviridae infection	J:119783
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:119783
\Tg(HTT*)NXwy/0 (involves: FVB/NJ)	CNS inflammation	J:219890
\Tg(ICAM1)4Grom/? (involves: BALB/cAnNTac)	increased susceptibility to Picornaviridae infection	J:92607
\Tg(Igh3H9)41Mwg/? (involves: C57BL/6 * SJL)	abnormal B cell differentiation	J:119625
	decreased IgD level	J:119625
	increased anti-single stranded DNA antibody level	J:119625
\Tg(Igh*-Mir125b-1)5Toki/0 (Not Specified)	enlarged spleen	J:178816
\Tg(Igh*-Mir125b-1)116Toki/0 (Not Specified)	decreased B cell apoptosis	J:178816
	enlarged spleen	J:178816
	increased B cell number	J:178816
	increased T cell derived lymphoma incidence	J:178816
\Tg(Igh-3/Igh-6VD93)1241Ust/? (C57BL/6-Tg(Igh-3/Igh-6VD93)1241Ust)	abnormal B cell morphology	J:135209
	decreased pre-B cell number	J:135209
\Tg(Igh-3VD93)343Ust/? (involves: C57BL/6 * SJL)	abnormal B cell morphology	J:135209
\Tg(Igh-3VD93)343Ust/? (involves: C57BL/6 * SJL)	decreased pre-B cell number	J:135209
\Tg(Igh-6-Cd80)1Gjf/0 (involves: FVB)	abnormal CD4-positive, alpha-beta T cell physiology	J:44271
	abnormal humoral immune response	J:112474
	abnormal T cell activation	J:44271
	decreased B cell number	J:44271
	decreased immunoglobulin level	J:112474
\Tg(Igh-6-Cd80)1Gjf/0 (B6.Cg-Tg(Igh-6-Cd80)1Gjf)	abnormal T cell number	J:112266
\Tg(Igh-6-Cd80)1Gjf/0 (NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ)	abnormal B cell activation	J:131077
	abnormal CD8-positive, alpha-beta T cell physiology	J:131077
	abnormal level of surface class II molecules	J:131077
	decreased B cell number	J:131077
	decreased B-2 B cell number	J:131077
	decreased follicular B cell number	J:131077
	decreased IgG1 level	J:131077
	decreased IgG2b level	J:131077
	decreased IgG3 level	J:131077
	decreased IgM level	J:131077
	decreased immature B cell number	J:131077
	decreased immunoglobulin level	J:131077
	decreased mature B cell number	J:131077
	decreased susceptibility to autoimmune diabetes	J:131077
	insulitis	J:131077
\Tg(Igh-6-Cd86)1Akab/0 (involves: FVB)	abnormal CD4-positive, alpha-beta T cell physiology	J:44271
\Tg(Igh-6-Cd86)1Akab/0 (involves: FVB)	decreased B cell number	J:44271
\Tg(Igh-6/Igh-V125)2Jwt/0 \Tg(Igk-C/Igk-V125)1Jwt/0 (NOD.B6-Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)	abnormal B cell number	J:91865
	increased susceptibility to autoimmune diabetes	J:91865
	insulitis	J:91865
\Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)	decreased susceptibility to autoimmune diabetes	J:91865
\Tg(Igh-6/Igh-V281)3Jwt/0 (NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)	insulitis	J:91865
\Tg(Igh-Abl1)40Sco/0 (involves: C57BL/6JWehi * SJL/JWehi)	abnormal peripheral lymph node morphology	J:78204
	enlarged mesenteric lymph nodes	J:78204
	enlarged spleen	J:78204
\Tg(Igh-Abl1)40Sco/0 \Tg(IghMyc)22Bri/0 (involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)	enlarged mesenteric lymph nodes	J:78204
\Tg(Igh-HMGA2)#Cro/0 (FVB/N-Tg(Igh-HMGA2)#Cro)	abnormal splenic cell ratio	J:233225
	decreased B cell number	J:233225
	decreased IgG1 level	J:233225
	decreased IgG2a level	J:233225
	decreased IgG2b level	J:233225
	decreased IgG3 level	J:233225
	decreased response to antigen	J:233225
	decreased T cell number	J:233225
	enlarged lymph nodes	J:233225
	enlarged spleen	J:233225
	increased circulating interleukin-6 level	J:233225
	increased circulating tumor necrosis factor level	J:233225
	increased T cell number	J:233225
\Tg(Igh-HOX11)11Idd/0 (CD-1)	abnormal immunoglobulin V(D)J recombination	J:52782
	increased leukocyte cell number	J:52782
	myeloid hyperplasia	J:52782
	spleen hyperplasia	J:52782
\Tg(Igh-Lmp2a)ERlon/0 (involves: C57BL/6 * SJL)	abnormal B cell proliferation	J:129571
\Tg(Igh-Lmp2a)ERlon/0 (involves: C57BL/6 * SJL)	decreased B cell number	J:129571
\Tg(Igh-Maf)68Staka/0 (C57BL/6-Tg(Igh-Maf)68Staka)	abnormal spleen morphology	J:168074
	enlarged spleen	J:168074
	increased IgG level	J:168074
	increased IgM level	J:168074
	increased immunoglobulin level	J:168074
	increased plasma cell number	J:168074
\Tg(Igh-Maf)524Staka/0 (involves: C57BL/6 * C57BL/6J * DBA/2)	abnormal spleen morphology	J:168074
	enlarged spleen	J:168074
	increased IgG level	J:168074
	increased IgM level	J:168074
	increased immunoglobulin level	J:168074
	increased plasma cell number	J:168074
\Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0 (FVB/N-Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro)	abnormal B cell physiology	J:162077
	abnormal lymphopoiesis	J:162077
	abnormal spleen morphology	J:162077
	decreased IgG1 level	J:162077
	decreased IgG2a level	J:162077
	decreased IgG2b level	J:162077
	enlarged spleen	J:162077
	increased B cell proliferation	J:162077
	increased B-1a cell number	J:162077
	spleen hyperplasia	J:162077
\Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0 \Tg(Igh-V186.2-TCL1A)3Cro/0 (involves: C3H * C57BL/6 * FVB/N)	increased B-1a cell number	J:162077
	spleen hyperplasia	J:162077
\Tg(Igh-Mir155)8Cro/0 (involves: FVB/N)	abnormal lymphopoiesis	J:109591
	abnormal spleen B cell follicle morphology	J:109591
	decreased leukocyte cell number	J:109591
	decreased spleen white pulp amount	J:109591
	enlarged spleen	J:109591
	increased B cell number	J:109591
	increased B cell proliferation	J:109591
	increased lymphoblastic lymphoma incidence	J:109591
	increased pre-B cell number	J:109591
	increased spleen white pulp amount	J:109591
	intermingled spleen red and white pulp	J:109591
\Tg(Igh-Mir155)10Cro/0 (involves: FVB/N)	enlarged spleen	J:109591
\Tg(Igh-Mir210)#aKgcs/\Tg(Igh-Mir210)#aKgcs (B6.Cg-Tg(Igh-Mir210)#aKgcs)	abnormal class switch recombination	J:205868
	abnormal spleen marginal zone morphology	J:205868
	decreased IgA level	J:205868
	decreased IgG1 level	J:205868
	decreased IgG2a level	J:205868
	decreased IgG2b level	J:205868
	decreased IgG3 level	J:205868
	decreased marginal zone B cell number	J:205868
	decreased mature B cell number	J:205868
	decreased pre-B cell number	J:205868
	decreased pro-B cell number	J:205868
	immune system phenotype	J:205868
	increased B-1a cell number	J:205868
\Tg(Igh-Nfil3)#Kubo/0 (B6.Cg-Tg(Igh-Nfil3)#Kubo)	increased interleukin-3 secretion	J:172134
	increased interleukin-10 secretion	J:172134
	increased interleukin-13 secretion	J:172134
\Tg(Igh-Pim1)1Brn/0 (involves: C57BL/6LiA * CBA)	enlarged lymph nodes	J:79624
	enlarged spleen	J:79624
	enlarged thymus	J:79624
	increased T cell derived lymphoma incidence	J:79624
\Tg(Igh-ROR1)1Kip/0 (C57BL/6-Tg(Igh-ROR1)1Kip)	enlarged spleen	J:206368
	increased lymphocyte cell number	J:206368
	increased mature B cell number	J:206368
\Tg(Igh-ROR1)1Kip/0 \Tg(Igh-V186.2-TCL1A)3Cro/0 (B6.Cg-Tg(Igh-ROR1)1Kip Tg(Igh-V186.2-TCL1A)3Cro)	enlarged spleen	J:206368
	increased lymphocyte cell number	J:206368
	increased mature B cell number	J:206368
\Tg(Igh-TCL1A)1Ypek/0 (FVB/N-Tg(Igh-TCL1A)1Ypek)	abnormal circulating chemokine level	J:160184
	abnormal humoral immune response	J:160184
	abnormal lymphocyte physiology	J:160184
	decreased IgG1 level	J:160184
	decreased IgG2a level	J:160184
	decreased IgG2b level	J:160184
	decreased IgG3 level	J:160184
	decreased IgM level	J:160184
	enlarged spleen	J:160184
	increased circulating tumor necrosis factor level	J:160184
\Tg(Igh-V186.2-TCL1A)3Cro/0 (involves: C3H * C57BL/6)	abnormal B cell morphology	J:76574
	increased marginal zone B cell number	J:76574
	peritoneal inflammation	J:76574
	spleen hyperplasia	J:76574
\Tg(Igh-V-CD40lg)#Tsub/0 (C57BL/6-Tg(Igh-V-CD40lg)#Tsub)	glomerulonephritis	J:128824
	increased anti-double stranded DNA antibody level	J:128824
	increased anti-histone antibody level	J:128824
	increased anti-single stranded DNA antibody level	J:128824
\Tg(Igh-V-CD40lg)#Tsub/0 (involves: C57BL/6)	abnormal bronchus-associated lymphoid tissue morphology	J:89855
	colitis	J:89855
	enlarged lymph nodes	J:89855
	enlarged spleen	J:89855
	glomerulonephritis	J:89855
	increased autoantibody level	J:89855
	increased IgG level	J:89855
	increased IgM level	J:89855
	increased interferon-gamma secretion	J:89855
	increased splenocyte number	J:89855
	increased splenocyte proliferation	J:89855
\Tg(IGH@)SALed/0 (involves: C57BL/6 CD-1)	abnormal mature B cell morphology	J:131938
\Tg(IGH@yH1)2BJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin heavy chain V(D)J recombination	J:23827
	abnormal immunoglobulin level	J:23827
\Tg(IGH@yH1)2BJkbv/0 \Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
\Tg(IghelMD4)4Ccg/0 (involves: C3H/HeJ * C57BL/6)	decreased pre-B cell number	J:115059
\Tg(IghelMD4)4Ccg/0 (involves: C3H/HeJ * C57BL/6)	decreased pro-B cell number	J:115059
\Tg(IghelMD4)4Ccg/0 (involves: C57BL/6)	abnormal B cell activation	J:73608
	decreased pre-B cell number	J:115059
	decreased pro-B cell number	J:115059
\Tg(IghelMD4)4Ccg/0 (C57BL/6-Tg(IghelMD4)4Ccg)	abnormal B cell morphology	J:78308, J:109923, J:132538
	abnormal B-2 B cell morphology	J:132538
	abnormal germinal center B cell morphology	J:109923
	abnormal immature B cell morphology	J:109923
	abnormal mature B cell morphology	J:89156, J:109923
	abnormal plasma cell morphology	J:109923
	abnormal pro-B cell morphology	J:109923
	increased IgG2b level	J:132538
	increased IgM level	J:78308, J:132538
	increased immature B cell number	J:78308, J:132538
\Tg(IghelMD4)4Ccg/0 \Tg(KLK4mHEL)6Ccg/0 (NOD.B6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg/Dvs)	decreased B cell number	J:89156
\Tg(IghelMD4)4Ccg/0 \Tg(KLK4mHEL)6Ccg/0 (C57BL/6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg)	decreased B cell number	J:89156
\Tg(IghelMD4)4Ccg/? \Tg(KLK4mHEL)6Ccg/? (involves: C57BL/6)	arrested B cell differentiation	J:78307
	decreased mature B cell number	J:78307
	increased immature B cell number	J:78307
\Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (NOD.B6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg/Dvs)	abnormal B cell anergy	J:89156
	abnormal B cell clonal deletion	J:89156
	abnormal B cell morphology	J:89156
	decreased IgM level	J:89156
\Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (C57BL/6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg)	abnormal B cell anergy	J:89156, J:78308
	abnormal central B cell anergy	J:109923
	abnormal germinal center B cell morphology	J:109923
	abnormal immature B cell morphology	J:109923
	abnormal mature B cell morphology	J:109923
	abnormal plasma cell morphology	J:109923
	abnormal pro-B cell morphology	J:109923
	abnormal spleen B cell follicle morphology	J:109923
	decreased B cell number	J:89156
	decreased IgM level	J:89156, J:78308
\Tg(IghelMD4)4Ccg/0 \Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6)	abnormal B cell anergy	J:73608, J:132538
	abnormal B cell physiology	J:76134
	abnormal spleen primary B follicle morphology	J:76134
	decreased B cell number	J:76134
	decreased marginal zone B cell number	J:132538
\Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg (NOD.B6-Tg(IghelMD4)4Ccg/DvsJ)	abnormal mature B cell morphology	J:80859, J:89156
	abnormal T cell proliferation	J:80859
	decreased CD8-positive, alpha-beta T cell number	J:80859
	increased susceptibility to autoimmune diabetes	J:80859
\Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg (involves: C57BL/6)	decreased pre-B cell number	J:171924
\Tg(IghelMD4)4Ccg/\Tg(IghelMD4)4Ccg (involves: C57BL/6)	decreased pro-B cell number	J:171924
\Tg(IghH280)48Dvs/? (NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)	increased susceptibility to autoimmune diabetes	J:274578
\Tg(IghH280)48Dvs/? (NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)	insulitis	J:274578
\Tg(IghH280)48Dvs/? \Tg(IgkH280)934Dvs/? (NOD/ShiLtDvs-Tg(IghH280)48Dvs Tg(IgkH280)934Dvs/Dvs)	increased susceptibility to autoimmune diabetes	J:274578
\Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (involves: FVB/N)	abnormal B cell physiology	J:113109
\Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (involves: FVB/N)	immune system phenotype	J:113109
\Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0 (NOD.FVB-Tg(Ighm-Ctla4Ig/Cd80)1Jbs)	decreased susceptibility to autoimmune diabetes	J:113109
	immune system phenotype	J:113109
\Tg(IghMyc)22Bri/? (involves: C57BL * C57BL/6 * SJL)	enlarged spleen	J:121564
\Tg(IghMyc)22Bri/? (involves: C57BL * C57BL/6 * SJL)	increased lymphocyte cell number	J:121564
\Tg(IghMyc)22Bri/0 (involves: C57BL/6 * SJL)	abnormal lymphopoiesis	J:78177
	enlarged lymph nodes	J:78177
	enlarged spleen	J:78177
	enlarged thymus	J:78177
	increased leukocyte cell number	J:186117
	increased pre-B cell number	J:223213
\Tg(IghMyc)22Bri/0 (B6.Cg-Tg(IghMyc)22Bri/J)	enlarged lymph nodes	J:354285, J:164200
\Tg(IghMyc)22Bri/0 (B6.Cg-Tg(IghMyc)22Bri/J)	spleen hyperplasia	J:164200
\Tg(IghMyc)22Bri/0 (involves: C57BL/6N * SJL)	increased B cell apoptosis	J:214383
\Tg(IghMyc)22Bri/0 \Tg(Igk-V21-Bax)1967Bvn/0 (involves: C57BL/6 * FVB/N)	enlarged spleen	J:89049
	increased transitional stage B cell number	J:89049
\Tg(IghMyc)22Bri/0 \Xiap^tm1Hs/\Xiap^tm1Hs (B6.Cg-Xiap^tm1Hs Tg(IghMyc)22Bri)	decreased B cell proliferation	J:138979
	decreased leukocyte cell number	J:138979
	increased B cell apoptosis	J:138979
\Tg(IghMyc)186Brn/0 \Rpl24^Bst/\Rpl24⁺ (involves: C57BL/LiA * C57BLKS * CBA/BrA)	immune system phenotype	J:142390
\Tg(Igk-Lta/Ltb)4Cys/0 (involves: C57BL/6J * DBA/2J)	abnormal B cell morphology	J:73100
\Tg(Igk-Lta/Ltb)10Cys/0 (involves: C57BL/6J * DBA/2J)	abnormal B cell morphology	J:73100
\Tg(Igk-V21-Bax)1967Bvn/0 (involves: FVB/N)	abnormal plasma cell morphology	J:89049
	increased IgA level	J:89049
	increased IgE level	J:89049
	increased IgG1 level	J:89049
	increased IgG2a level	J:89049
	increased IgG level	J:89049, J:90901
	increased IgM level	J:89049
	increased immunoglobulin level	J:89049
	increased transitional stage B cell number	J:89049
\Tg(IGK@yK1)9.2CJkbv/0 (involves: 129P2/OlaHsd)	abnormal B cell morphology	J:23827
	abnormal immunoglobulin level	J:23827
	abnormal immunoglobulin light chain V-J recombination	J:23827
\Tg(IgkH280)934Dvs/? (NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)	increased susceptibility to autoimmune diabetes	J:274578
\Tg(IgkH280)934Dvs/? (NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)	insulitis	J:274578
\Tg(Igkv3-5-MYC)24Plbe/0 (C57BL/6J-Tg(Igkv3-5-MYC)DLoxP4Plbe/PlbeMmmh)	abnormal humoral immune response	J:131912
	abnormal immunoglobulin level	J:131912
	abnormal plasma cell differentiation	J:131912
	increased IgG1 level	J:131912
	increased IgG3 level	J:131912
	increased plasma cell number	J:131912
\Tg(Igl-2MOPC315)1275Ust/? (C57BL/6-Tg(Igl-2MOPC315)1275Ust)	abnormal B cell morphology	J:134666
	decreased IgM level	J:134666
	decreased immature B cell number	J:134666
\Tg(IGL-MYC)3Hm/0 (C57BL/6N-Tg(IGL-MYC)3Hm/Nci)	enlarged lymph nodes	J:65245
\Tg(Il1rn)1Dih/0 (involves: C57BL/6 * CBA)	decreased circulating interleukin-6 level	J:88605
	decreased circulating serum amyloid protein level	J:61600
	decreased inflammatory response	J:88605
	decreased susceptibility to endotoxin shock	J:36387
	decreased susceptibility to Herpesvirales infection	J:88605
	increased susceptibility to bacterial infection	J:36387
\Tg(Il1rn)1Dih/\Tg(Il1rn)1Dih (involves: C57BL/6 * CBA)	decreased susceptibility to endotoxin shock	J:36387
	increased circulating interleukin-1 level	J:36387
	increased susceptibility to bacterial infection	J:36387
\Tg(IL2-Il10)1Kro/0 (involves: C3H * C57BL/6)	abnormal cytokine secretion	J:41588
	decreased susceptibility to parasitic infection	J:41588
	increased susceptibility to bacterial infection	J:80569
\Tg(IL3,CSF2)C42Pnc/0 (involves: C57BL/6 * CBA)	immune system phenotype	J:219403
\Tg(ILK3mHEL)3Ccg/0 \Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6JSfd * C57BL/10Sg * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	insulitis	J:78309
\Tg(Ins1-Cat,Tyr)25Pne/0 (NOD.FVB-Tg(Ins1-Cat,Tyr)25Pne)	increased susceptibility to autoimmune diabetes	J:108415
\Tg(Ins1-Cd80)378Psoh/0 \Tg(Ins2-GP)#Psoh/0 \Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6 * DBA/2 * FVB/N)	insulitis	J:209714
	periinsulitis	J:209714
\Tg(Ins1-EGFP/GH1)14Hara/0 (NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)	increased susceptibility to autoimmune diabetes	J:127015
\Tg(Ins1-EGFP/GH1)14Hara/\Tg(Ins1-EGFP/GH1)14Hara (NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)	decreased susceptibility to autoimmune disorder	J:127015
	insulitis	J:127015
\Tg(Ins2Y16A)1Ell/0 (NOD-Tg(Ins2Y16A)1Ell)	increased susceptibility to autoimmune diabetes	J:98583
\Tg(Ins2Y16A)3Ell/0 (NOD-Tg(Ins2Y16A)3Ell)	increased susceptibility to autoimmune diabetes	J:98583
\Tg(Ins2-Ccl19)2Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:77238
\Tg(Ins2-Ccl21b)2Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:77238
\Tg(Ins2-CD80)3B7Flv/? (involves: C57BL/6 * CBA/Ca * NOD/Caj)	increased susceptibility to autoimmune diabetes	J:26618
	insulitis	J:26618
\Tg(Ins2-CD80)3B7Flv/0 \Tg(Ins2-H2-Ea^d,Ins2-H2-Eb1^b)187-7Bri/0 (involves: C57BL/6 * CBA/Ca * SJL)	increased susceptibility to autoimmune diabetes	J:93555
	insulitis	J:93555
\Tg(Ins2-CD80)3B7Flv/0 \Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA/Ca)	abnormal cytokine secretion	J:93555
	increased susceptibility to autoimmune diabetes	J:93555
\Tg(Ins2-CD86)12B70Flv/0 (involves: C57BL/6 * CBA/Ca)	abnormal cytokine secretion	J:93555
	decreased susceptibility to autoimmune diabetes	J:93555
	periinsulitis	J:93555
\Tg(Ins2-CD86)12B70Flv/0 \Tg(Ins2-H2-Ea^d,Ins2-H2-Eb1^b)187-7Bri/0 (involves: C57BL/6 * CBA/Ca * SJL)	abnormal cytokine secretion	J:93555
	increased susceptibility to autoimmune diabetes	J:93555
	insulitis	J:93555
\Tg(Ins2-CD86)12B70Flv/0 \Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA/Ca)	abnormal cytokine secretion	J:93555
	increased susceptibility to autoimmune diabetes	J:93555
\Tg(Ins2-Cd274)2Mdos/? (NOD/ShiLt-Tg(Ins2-Cd274)2Mdos)	increased susceptibility to autoimmune diabetes	J:118934
\Tg(Ins2-cre)5Lt/0 (NOD/ShiLt-Tg(Ins2-cre)5Lt)	increased susceptibility to autoimmune diabetes	J:127015
\Tg(Ins2-cre)5Lt/\Tg(Ins2-cre)5Lt (NOD/ShiLt-Tg(Ins2-cre)5Lt)	decreased susceptibility to autoimmune disorder	J:127015
	insulitis	J:127015
\Tg(Ins2-crmA)27Ngkh/? (NOD-Tg(Ins2-CrmA)27Ngkh)	increased susceptibility to autoimmune diabetes	J:132052
\Tg(Ins2-Cxcl13)1Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:110548
\Tg(Ins2-E3)1Dvs/? (NOD.Cg-Tg(Ins2-E3)1Dvs)	decreased susceptibility to autoimmune diabetes	J:68996
\Tg(Ins2-E3309)5Dvs/? (NOD/ShiLtDvs-Tg(Ins2-E3309)5Dvs/Dvs)	decreased susceptibility to autoimmune diabetes	J:83195
\Tg(Ins2-E3704)2Dvs/? (NOD/ShiLtDvs-Tg(Ins2-E3704)2Dvs)	decreased susceptibility to autoimmune diabetes	J:83195
\Tg(Ins2-E3734)3Dvs/0 (NOD/ShiLtDvs-Tg(Ins2-E3734)3Dvs/DvsJ)	decreased susceptibility to autoimmune diabetes	J:106340
\Tg(Ins2-E3734)4Dvs/? (NOD/ShiLtDvs-Tg(Ins2-E3734)4Dvs/DvsJ)	decreased susceptibility to autoimmune diabetes	J:106340
\Tg(Ins2-FasI246N)1Ach/0 (NOD-Tg(Ins2-FasI246N)1Ach)	decreased susceptibility to autoimmune diabetes	J:81416
\Tg(Ins2-FasI246N)1Ach/0 \Tg(Ins2-Fasl)24Ach/0 (NOD-Tg(Ins2-FasI246N)1Ach Tg(Ins2-Fasl)24Ach)	decreased susceptibility to autoimmune diabetes	J:81416
\Tg(Ins2-Fasl)24Ach/0 (NOD-Tg(Ins2-Fasl)24Ach/J)	increased susceptibility to autoimmune diabetes	J:78679, J:81416
\Tg(Ins2-GAD2)1Lt/0 (NOD/ShiLt-Tg(Ins2-GAD2)1Lt)	insulitis	J:100251
\Tg(Ins2-GAD2)2Lt/0 (NOD/ShiLt-Tg(Ins2-GAD2)2Lt)	abnormal cytokine secretion	J:100251
	decreased susceptibility to autoimmune diabetes	J:100251
	insulitis	J:100251
\Tg(Ins2-GP)34-20Olds/0 (involves: BALB/c * C57BL/6)	abnormal lymphocyte physiology	J:81287
	abnormal T cell physiology	J:81287
	increased susceptibility to autoimmune diabetes	J:81287
\Tg(Ins2-GP)#Psoh/0 (involves: C57BL/6)	insulitis	J:81285
\Tg(Ins2-GP)#Psoh/0 \Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6 * DBA/2)	abnormal B cell selection	J:81285
\Tg(Ins2-H2-Ea^d,Ins2-H2-Eb1^b)187-7Bri/0 (involves: C57BL/6 * SJL)	decreased susceptibility to autoimmune diabetes	J:93555
\Tg(Ins2-HA)165Bri/0 (B10.Cg- H2^d Tg(Ins2-HA)165Bri/ShrmJ)	abnormal CD4-positive, alpha-beta T cell physiology	J:86430
	decreased T cell proliferation	J:86430
	immune system phenotype	J:86430
\Tg(Ins2-HA)165Bri/0 \Tg(TcraCl4,TcrbCl4)1Shrm/0 (involves: BALB/c * C57BL/6 * C57BL/10 * DBA/2)	insulitis	J:99756
\Tg(Ins2-HA)165Bri/? \Tg(TcraCl4,TcrbCl4)1Shrm/? (involves: BALB/c * C57BL/6 * C57BL/10)	insulitis	J:99756
\Tg(Ins2-Iapp)6Soel/\Tg(Ins2-Iapp)6Soel (involves: FVB/N)	decreased susceptibility to autoimmune diabetes	J:130022
\Tg(Ins2-IAPP)RHFSoel/\Tg(Ins2-IAPP)RHFSoel (involves: FVB/N)	increased susceptibility to autoimmune diabetes	J:130022
\Tg(Ins2-Lta)#Flv/0 (involves: NOD)	insulitis	J:91820
	kidney inflammation	J:91820
	periinsulitis	J:91820
\Tg(Ins2-Lta)#Flv/0 (involves: C57BL/6)	insulitis	J:91820
	kidney inflammation	J:91820
	periinsulitis	J:91820
\Tg(Ins2-Lta)#Flv/0 (involves: C57BL/6 * CBA)	insulitis	J:127705
\Tg(Ins2-Lta)#Flv/0 (involves: C57BL/6 * CBA)	periinsulitis	J:127705
\Tg(Ins2-NP)25-3Olds/0 (involves: BALB/c * C57BL/6)	decreased susceptibility to autoimmune diabetes	J:81287
\Tg(Ins2-NP)25-3Olds/0 (involves: BALB/c * C57BL/6)	increased susceptibility to autoimmune diabetes	J:81287
\Tg(Ins2-OVA)59Wehi/? (involves: BALB/c * C57BL/6)	abnormal T cell activation	J:99560
\Tg(Ins2-OVA)59Wehi/? (involves: BALB/c * C57BL/6)	increased susceptibility to autoimmune diabetes	J:99560
\Tg(Ins2-OVA)307Wehi/? (involves: BALB/c * C57BL/6)	increased susceptibility to autoimmune diabetes	J:99560
\Tg(Ins2-OVA)307Wehi/0 \Tg(TcraTcrb)1100Mjb/0 (involves: C57BL/6 * C57BL/6JWehi)	autoimmune response	J:99451
\Tg(Ins2-TFRC/OVA)296Wehi/0 (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:98589
	abnormal leukocyte migration	J:98589
	decreased interferon-gamma secretion	J:122114
	increased susceptibility to autoimmune diabetes	J:122114
\Tg(Ins2-TFRC/OVA)296Wehi/0 \1700016L21Rik^{Tg(Itgax-HBEGF/EGFP)57Lan}/0 (involves: C57BL/6 * FVB)	decreased T cell proliferation	J:122114
\Tg(Ins2-TFRC/OVA)296Wehi/0 \Tg(TcraTcrb)425Cbn/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:135154
	increased double-positive T cell number	J:135154
\Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA * NOD)	immune system phenotype	J:91820
\Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA * NOD)	insulitis	J:91820
\Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6 * CBA)	insulitis	J:91820
\Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6)	decreased CD8-positive, alpha-beta T cell number	J:93555
\Tg(Ins2-Tnf)17Flv/0 (involves: C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:93555
\Tg(INS-Il10)#Sar/0 (involves: BALB/c)	pancreas inflammation	J:107927
\Tg(INS-Il10)#Sar/0 (involves: BALB/c)	periinsulitis	J:107927
\Tg(INS-Il10)#Sar/0 \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6J * NOD)	increased susceptibility to autoimmune diabetes	J:64051
\Tg(INS-Il10)#Sar/0 \Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6J * NOD)	increased susceptibility to autoimmune diabetes	J:64051
\Tg(INS-MT2A,Tyr)1Pne/0 (FVB-Tg(INS-MT2A,Tyr)1Pne)	abnormal response to transplant	J:95089
\Tg(ITGA2)1067Fmw/0 \Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1067Fmw/0 \Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1067Fmw/0 \Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1070Fmw/0 \Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1070Fmw/0 \Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1070Fmw/0 \Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1075Fmw/0 \Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1075Fmw/0 \Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA2)1075Fmw/0 \Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0794Fmw/0 \Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0794Fmw/0 \Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0794Fmw/0 \Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0844Fmw/0 \Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0844Fmw/0 \Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0844Fmw/0 \Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0858Fmw/0 \Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0858Fmw/0 \Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGA5)0858Fmw/0 \Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
	eye inflammation	J:30249
\Tg(ITGAL-Hhex)2Hro/0 (C3HeB/FeJ-Tg(ITGAL-Hhex)2Hro)	abnormal double-negative T cell morphology	J:80777
	abnormal thymus corticomedullary boundary morphology	J:80777
	decreased double-positive T cell number	J:80777
	decreased leukocyte cell number	J:80777
	decreased lymphocyte cell number	J:80777
	decreased T cell number	J:80777
	increased CD8-positive, alpha-beta T cell number	J:80777
	thymus hypoplasia	J:80777
\Tg(ITGAL-Ptprc^a)FRasch/\Tg(ITGAL-Ptprc^a)FRasch (involves: BALB/c * C57BL/6)	abnormal T cell differentiation	J:158876
\Tg(Itgam-FCAR)83Rcmo/0 (involves: C57BL/6 * NOD)	glomerulonephritis	J:120534
\Tg(Itgam-FCAR)83Rcmo/0 (involves: C57BL/6 * NOD)	increased IgA level	J:120534
\Tg(ITGAM-HBEGF/EGFP)34Lan/0 (involves: FVB/N)	abnormal macrophage morphology	J:95141
	decreased macrophage cell number	J:95141
	increased neutrophil cell number	J:95141
\Tg(ITGAM-HBEGF/EGFP)34Lan/0 (NOD.FVB-Tg(ITGAM-HBEGF/EGFP)34Lan/Jdk)	decreased macrophage cell number	J:137009
	immune system phenotype	J:137009
\Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh/0 (C57BL/6-Tg(Itgax-EGFP,-cre,-HBEGF,-luc)2Gjh)	abnormal susceptibility to infection	J:194800
	immune system phenotype	J:194800
	increased monocyte cell number	J:194800
	increased neutrophil cell number	J:194800
\Tg(Itgax-HBEGF/OVA/EGFP)1Garbi/0 (C57BL/6-Tg(Itgax-HBEGF/OVA/EGFP)1Garbi)	abnormal susceptibility to infection	J:194800
	decreased dendritic cell number	J:194800
	increased neutrophil cell number	J:194800
\Tg(Itgax-TGFBR2)1Flv/0 (C.Cg-Tg(Itgax-TGFBR2)1Flv)	abnormal immune system physiology	J:98953
	abnormal interferon level	J:98953
	abnormal NK cell differentiation	J:98953
	decreased susceptibility to parasitic infection	J:98953
	immune system phenotype	J:98953
	increased NK cell number	J:98953
\Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
\Tg(ITGB1)0840Fmw/0 (involves: C57BL/10 * CBA)	eye inflammation	J:30249
\Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
\Tg(ITGB1)0869Fmw/0 (involves: C57BL/10 * CBA)	eye inflammation	J:30249
\Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	dermatitis	J:30249
\Tg(ITGB1)0870Fmw/0 (involves: C57BL/10 * CBA)	eye inflammation	J:30249
\Tg(IVL-KLK5)#Hov/0 (involves: C57BL/6 * CBA)	abnormal circulating cytokine level	J:210758
	abnormal inguinal lymph node morphology	J:210758
	enlarged lymph nodes	J:210758
	enlarged spleen	J:210758
	erythroderma	J:210758
	increased activated T cell number	J:210758
	increased IgE level	J:210758
	lymph node inflammation	J:210758
	skin inflammation	J:210758
\Tg(JAK2V617F)FF1Rsko/0 \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 C57BL/10 * CBA/Ca)	abnormal myelopoiesis	J:134364
	abnormal spleen morphology	J:134364
	decreased B cell number	J:134364
	decreased T cell number	J:134364
	enlarged spleen	J:134364
	increased neutrophil cell number	J:134364
	spleen fibrosis	J:134364
\Tg(JAK2V617F)FF1Rsko/0 \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal myelopoiesis	J:134364
	abnormal spleen morphology	J:134364
	decreased B cell number	J:134364
	decreased T cell number	J:134364
	enlarged spleen	J:134364
	increased neutrophil cell number	J:134364
	spleen fibrosis	J:134364
\Tg(JAK2V617F)FF1Rsko/0 \Tg(Tek-cre)1Arnd/0 (involves: C57BL/6 CBA * DBA/2)	decreased T cell number	J:206659
	enlarged spleen	J:206659
	increased neutrophil cell number	J:206659
\Tg(K18-ACE2)2Prlmn/0 (involves: C57BL/6J * SJL/J)	increased susceptibility to Coronaviridae infection	J:283648
\Tg(K18-ACE2)2Prlmn/0 (involves: C57BL/6J * SJL/J)	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:283648
\Tg(K18-ACE2)2Prlmn/0 (B6.Cg-Tg(K18-ACE2)2Prlmn/J)	abnormal chemokine level	J:302313
	abnormal circulating chemokine level	J:294084
	abnormal circulating cytokine level	J:302313
	abnormal cytokine level	J:294084, J:302313
	abnormal interferon level	J:300960, J:302313
	abnormal interleukin level	J:300960, J:302313
	abnormal tumor necrosis factor level	J:300960, J:302313
	blood vessel inflammation	J:300960
	brain inflammation	J:294084
	bronchiolitis	J:302313
	conjunctivitis	J:294084
	cytokine storm	J:300960
	enhanced humoral immune response	J:302313
	increased circulating CXCL10 level	J:302313
	increased circulating interferon-gamma level	J:302313
	increased circulating interleukin-6 level	J:294084
	increased circulating interleukin-10 level	J:294084, J:302313
	increased circulating tumor necrosis factor level	J:294084
	increased CXCL10 level	J:300960
	increased IgG level	J:302313
	increased IgM level	J:302313
	increased leukocyte cell number	J:294084
	increased lymphocyte cell number	J:302313
	increased macrophage cell number	J:294084, J:302313
	increased neutrophil cell number	J:294084, J:300960, J:302313
	increased susceptibility to Coronaviridae infection	J:294084, J:300960, J:302313, J:296067
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:294084, J:300960
	increased susceptibility to Orthomyxoviridae infection	J:296067
	increased susceptibility to viral infection	J:296067
	increased susceptibility to viral infection induced morbidity/mortality	J:296067
	increased T cell number	J:300960
	interstitial pneumonia	J:300960, J:302313
	liver inflammation	J:300960
	lung inflammation	J:294084, J:302313
	meningitis	J:294084, J:302313
	meningoencephalitis	J:300960, J:296067
	microgliosis	J:294084
	rhinitis	J:300960
\Tg(KitD814V)1Roer/0 \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal mast cell morphology	J:169611
	colitis	J:169611
	enlarged spleen	J:169611
	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
	small intestinal inflammation	J:169611
\Tg(KitD814V)2Roer/0 \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal mast cell morphology	J:169611
	colitis	J:169611
	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
	small intestinal inflammation	J:169611
\Tg(KitD814V)3Roer/0 \Tg(Mx1-cre)1Cgn/0 (involves: C57BL/6 CBA)	abnormal mast cell morphology	J:169611
	colitis	J:169611
	enlarged spleen	J:169611
	increased mast cell number	J:169611
	large intestinal inflammation	J:169611
\Tg(KLK4mHEL)6Ccg/0 \Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
\Tg(KRT5-IKBKB)1Armz/0 (involves: C57BL/6 * DBA/2)	increased interleukin-1 alpha secretion	J:160072
	increased interleukin-6 secretion	J:160072
	increased tumor necrosis factor secretion	J:160072
\Tg(KRT5-IKBKB)2Armz/0 (involves: C57BL/6 * DBA/2)	abnormal cytokine level	J:160072
	abnormal immune serum protein physiology	J:160072
	abnormal melanophage morphology	J:160072
	dermatitis	J:160072
	increased circulating interferon-gamma level	J:160072
	increased circulating interleukin-1 alpha level	J:160072
	increased circulating interleukin-2 level	J:160072
	increased circulating interleukin-4 level	J:160072
	increased circulating interleukin-5 level	J:160072
	increased circulating interleukin-6 level	J:160072
	increased circulating interleukin-10 level	J:160072
	increased circulating tumor necrosis factor level	J:160072
	increased interleukin-1 alpha secretion	J:160072
	increased interleukin-6 secretion	J:160072
	increased tumor necrosis factor secretion	J:160072
\Tg(KRT5-Nfkbia)3Rto/0 \Tg(Krt5-Tnfr1)#Rsab/0 \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas C57BL/6 * CBA)	skin inflammation	J:208995
\Tg(KRT5-rtTA)1Glk/0 \Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0 (involves: FVB/N)	immune system phenotype	J:199558
\Tg(KRT5-rtTA)1Glk/0 \Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0 \Tg(tetO/CMV-Tslp)#Sfz/0 (involves: C3H * C57BL/6 * FVB/N)	increased T cell proliferation	J:199558
	respiratory system inflammation	J:199558
	skin inflammation	J:199558
\Tg(KRT5-rtTA)1Glk/0 \Tg(tetO-TGFB1C223SC225S)1Glk/0 (involves: FVB/N)	dermatitis	J:70670
	skin inflammation	J:70670
\Tg(KRT5-rtTA)1Glk/0 \Tg(tetO/CMV-Tslp)#Sfz/0 (involves: C3H * C57BL/6 * FVB/N)	abnormal cytokine level	J:100506
	abnormal lymph node morphology	J:100506
	conjunctivitis	J:100506
	decreased IgG2a level	J:100506
	dermatitis	J:100506
	enlarged lymph nodes	J:100506
	enlarged spleen	J:100506
	increased CD4-positive, alpha-beta T cell number	J:100506
	increased IgE level	J:100506
	increased IgG1 level	J:100506
\Tg(KRT5-rtTA)1Glk/0 \Tg(tetO/CMV-Tslp)#Sfz/0 (C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz)	abnormal B cell activation	J:182756
	increased autoantibody level	J:182756
	increased B cell proliferation	J:182756
	increased circulating interleukin-4 level	J:182756
	increased susceptibility to autoimmune hemolytic anemia	J:182756
\Tg(KRT5-rtTA)#Glk/0 \Tg(tetO-cre)1Jaw/0 \Wls^tm1.1Lan/\Wls^tm1.1Lan (involves: 129S6/SvEvTac * C57BL/6 * FVB/N)	cutaneous mastocytosis	J:204142
\Tg(KRT5-rtTA)#Glk/0 \Tg(tetO-S100a7a)#Yus/0 (involves: FVB/N)	abnormal chemokine secretion	J:168000
	increased interleukin-1 alpha secretion	J:168000
	increased tumor necrosis factor secretion	J:168000
\Tg(KRT5-TGFB1)F2020Xjw/0 (involves: C57BL/6 * DBA/2 * ICR)	abnormal Langerhans cell morphology	J:90118
	abnormal Langerhans cell physiology	J:90118
	cutaneous mastocytosis	J:90118
	decreased Langerhans cell number	J:90118
	skin inflammation	J:90118
\Tg(KRT5-tTA)1216Glk/0 \Tg(tetO-Il13)1Tazh/0 (B6.Cg-Tg(KRT5-tTA)1216Glk Tg(tetO-Il13)1Tazh)	cutaneous mastocytosis	J:150232
	dermatitis	J:150232
	increased IgE level	J:150232
	increased IgG1 level	J:150232
	increased interleukin-4 secretion	J:150232
	increased interleukin-13 secretion	J:150232
\Tg(KRT5-tTA)1216Glk/0 \Tg(tetO-LMNA*G608G,-EGFP)VF1-07Maer/0 (involves: FVB/N)	periodontium inflammation	J:145312
	skin inflammation	J:145312
\Tg(KRT5-tTA)1216Glk/0 \Tg(tetO-Tek)1Dmt/0 (involves: CD-1 * FVB/N)	abnormal interleukin secretion	J:147438
	increased interferon-gamma secretion	J:147438
	increased interleukin-12 secretion	J:147438
	increased interleukin-17 secretion	J:147438
	increased interleukin-23 secretion	J:147438
	skin inflammation	J:147438
\Tg(KRT5-tTA)1216Glk/0 \Tg(tetO-TGFB1C223SC225S)1Glk/0 (involves: FVB/N)	dermatitis	J:70670
	skin inflammation	J:70670
\Tg(Krt14-Angptl2)1Yo/0 (C.Cg-Tg(Krt14-Angptl2)1Yo)	skin inflammation	J:152387, J:181261
\Tg(KRT14-CASP1)1Miz/0 (involves: C57BL/6)	abnormal T cell physiology	J:78602
	decreased T cell number	J:78602
	dermatitis	J:78602, J:79706
	increased circulating interleukin-18 level	J:78602, J:79706
	increased IgE level	J:78602
	increased IgG1 level	J:78602
	increased neutrophil cell number	J:78602
	increased susceptibility to bacterial infection	J:79706
	increased susceptibility to bacterial infection induced morbidity/mortality	J:79706
\Tg(KRT14-cre)1Amc/0 \Trpv3^tm1.1Clph/\Trpv3^tm1.1Clph (involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA * Swiss Webster)	erythroderma	J:164741
\Tg(KRT14-FIGF)2Ali/0 (involves: FVB/N)	lymphatic vessel hyperplasia	J:137909, J:68138
\Tg(KRT14-FLT4/IGHG1)#Ali/0 (either: (involves: FVB/N) or (involves: BALB/c * DBA))	abnormal lymphatic vessel morphology	J:201429
	abnormal mononuclear phagocyte morphology	J:201429
\Tg(Krt14-Ifnk)#Cya/0 (C57BL/6N-Tg(Krt14-Ifnk)#Cya)	enlarged spleen	J:322130
\Tg(Krt14-Ifnk)#Cya/0 (C57BL/6N-Tg(Krt14-Ifnk)#Cya)	increased susceptibility to chemically induced skin inflammation	J:322130
\Tg(KRT14-Il1f6)1Hblu/? (involves: C57BL/6 * DBA/2)	abnormal chemokine level	J:126327
\Tg(KRT14-Il1f6)1Hblu/? (involves: C57BL/6 * DBA/2)	skin inflammation	J:126327
\Tg(KRT14-Il4)#Lsch/0 (involves: BALB/cBy * C57BL/6)	blepharitis	J:126285
	conjunctivitis	J:126285
	decreased IgG2a level	J:126285
	dermatitis	J:126285
	increased IgE level	J:126285
	increased IgG1 level	J:126285
	increased mast cell degranulation	J:126285
	increased susceptibility to bacterial infection	J:126285
	skin inflammation	J:126285
\Tg(KRT14-Il7)1Tsk/0 (FVB/N-Tg(KRT14-Il7)1Tsk)	blepharitis	J:42565
\Tg(KRT14-Il7)1Tsk/0 (FVB/N-Tg(KRT14-Il7)1Tsk)	skin inflammation	J:42565
\Tg(KRT14-Il7)1Tsk/\Tg(KRT14-Il7)1Tsk (FVB/N-Tg(KRT14-Il7)1Tsk)	skin inflammation	J:42565
\Tg(KRT14-Il18)#Knak/0 (C57BL/6-Tg(KRT14-Il18)#Knak)	abnormal T cell physiology	J:78602
	decreased T cell number	J:78602
	dermatitis	J:78602
	increased circulating interleukin-18 level	J:78602
	increased IgE level	J:78602
	increased IgG1 level	J:78602
	increased neutrophil cell number	J:78602
\Tg(Krt14-Rac1*G12V)#Mrnk/0 (involves: CBA/CaJ)	abnormal circulating interleukin level	J:237134
	joint inflammation	J:237134
	skin inflammation	J:237134
\Tg(KRT14-Tslp)1Pcn/0 (involves: C57BL/6 * SJL)	abnormal lymphocyte physiology	J:102470
	enlarged spleen	J:102470
	increased immunoglobulin level	J:102470
	lymph node hyperplasia	J:102470
\Tg(KRT14-Vegfa)3Dtm/0 (FVB/N-Tg(KRT14-Vegfa)3Dtm)	abnormal leukocyte adhesion	J:104245
	abnormal lymphatic vessel morphology	J:111924
	enhanced leukocyte tethering or rolling	J:104245
	enlarged lymph nodes	J:92643
	enlarged lymphatic vessel	J:92643
	increased macrophage cell number	J:111924
	increased mast cell number	J:104245
\Tg(KRT14-VEGFC*)1Ali/0 (involves: FVB/N)	lymphatic vessel hyperplasia	J:68138
\Tg(KRT14-Vegfd)1Ali/0 \Vegfc^tm1Ali/\Vegfc⁺ (involves: 129S1/Sv * 129X1/SvJ * FVB)	abnormal lymphatic vessel morphology	J:137909
\Tg(KRT14-VP16/NR1I2)13Sdub/? (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell number	J:258435
	abnormal CD8-positive, alpha beta T cell morphology	J:258435
	abnormal dendritic cell migration	J:258435
	abnormal innate immunity	J:258435
	decreased interleukin-1 beta secretion	J:258435
	dermatitis	J:258435
	enhanced humoral immune response	J:258435
	enlarged lymph nodes	J:258435
	increased dendritic cell number	J:258435
	increased effector memory T-helper cell number	J:258435
	increased gamma-delta T cell number	J:258435
	increased IgE level	J:258435
	increased IgG1 level	J:258435
	increased leukocyte cell number	J:258435
	skin inflammation	J:258435
\Tg(KRT18*R89C)22Rgo/0 (involves: FVB/N)	chronic liver inflammation	J:241700
\Tg(KRT18*R89C)30Rgo/0 (involves: FVB/N)	chronic liver inflammation	J:241700
\Tg(KRT18*R89C)50Rgo/0 (involves: FVB/N)	chronic liver inflammation	J:241700
\Tg(KRT18-DPP4)3Pbmj/0 (involves: C57BL/6J * SJL/J)	abnormal cytokine secretion	J:285467
	abnormal mononuclear cell morphology	J:286231
	brain inflammation	J:285467
	increased lymphocyte cell number	J:286231
	increased susceptibility to Coronaviridae infection	J:286231, J:285467
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:286231, J:285467
	interstitial pneumonia	J:286231
	lung inflammation	J:286231, J:285467
\Tg(LANA,vFLIP,vCYC)801Dtmr/? (involves: C57BL/6)	abnormal B cell activation	J:196403
	abnormal B cell differentiation	J:196403
	abnormal germinal center B cell physiology	J:196403
	abnormal marginal zone B cell morphology	J:196403
	abnormal marginal zone B cell physiology	J:196403
	abnormal spleen morphology	J:196403
	enlarged spleen	J:196403
	increased B cell proliferation	J:196403
	increased germinal center B cell number	J:196403
	increased IgG1 level	J:196403
	increased IgG3 level	J:196403
	increased marginal zone B cell number	J:196403
	increased mature B cell number	J:196403
	increased plasma cell number	J:196403
\Tg(Lck)4220Rmp/0 (involves: C57BL/6J * DBA/2)	increased T cell derived lymphoma incidence	J:88120
\Tg(Lck-Akt1)M-1Pnt/0 (involves: C3H/He C57BL/6)	decreased thymocyte number	J:73487
	enlarged spleen	J:73487
	increased double-negative T cell number	J:135903
	increased single-positive T cell number	J:135903
	increased T cell derived lymphoma incidence	J:73487
\Tg(Lck-Akt1E40K)E-3Pnt/0 (involves: C3H/He C57BL/6)	decreased thymocyte number	J:73487
	enlarged spleen	J:73487
	increased T cell derived lymphoma incidence	J:73487
\Tg(Lck-Akt1*E40K)E-3Pnt/0 (Not Specified)	abnormal T cell differentiation	J:144975
\Tg(Lck-Akt1*E40K)E-3Pnt/0 (Not Specified)	increased T cell derived lymphoma incidence	J:144975
\Tg(Lck-Akt2*)#Test/0 (Not Specified)	increased T cell derived lymphoma incidence	J:153923
\Tg(Lck-Bcl2l1)1Cant/? (B6.Cg-Tg(Lck-Bcl2l1)1Cant)	increased interleukin-2 secretion	J:77507
	increased memory T cell number	J:77507
	increased T cell proliferation	J:77507
\Tg(Lck-cre)1Cwi/0 (involves: C57BL/6 * DBA/2)	decreased thymocyte number	J:226234
\Tg(Lck-cre)548Jxm/? \Tgfb1^tm2.1Doe/\Tgfb1^tm2.1Doe (involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA)	abnormal immune system organ morphology	J:150024
	abnormal T cell activation	J:150024
	abnormal T cell subpopulation ratio	J:150024
	decreased spleen weight	J:150024
	decreased thymus weight	J:150024
	increased inflammatory response	J:150024
	increased interferon-gamma secretion	J:150024
	increased interleukin-2 secretion	J:150024
	lung inflammation	J:150024
	salivary gland inflammation	J:150024
	spleen hypoplasia	J:150024
	thymus hypoplasia	J:150024
\Tg(Lck-cre)548Jxm/? \Upf2^tm1Btp/\Upf2^tm1Btp (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal T cell receptor beta chain V(D)J recombination	J:134765
	decreased CD4-positive, alpha-beta T cell number	J:134765
	decreased CD8-positive, alpha-beta T cell number	J:134765
	decreased double-positive T cell number	J:134765
	thymus hypoplasia	J:134765
\Tg(Lck-cre)I57Jxm/? \Traf2^tm1Rbr/\Traf2^tm1Rbr (involves: C57BL/6 * ICR)	absent follicular B cells	J:132877
	absent marginal zone B cells	J:132877
	decreased mature B cell number	J:132877
\Tg(Lck-cre)I57Jxm/? \Traf3^tm1Rbr/\Traf3^tm1Rbr (involves: C57BL/6 * ICR * SJL)	abnormal T cell physiology	J:132877
	decreased CD4-positive, alpha-beta T cell number	J:132877
	decreased CD8-positive, alpha-beta T cell number	J:132877
\Tg(Lck-CrmA)1Hed/0 (involves: BALB/c * C57BL/6J)	decreased T cell apoptosis	J:100451
\Tg(Lck-CrmA)1Hed/0 (involves: BALB/c * C57BL/6J)	immune system phenotype	J:100451
\Tg(Lck-CrmA)1Hed/? (involves: BALB/c * C57BL/6J)	decreased thymocyte apoptosis	J:100451
\Tg(Lck-CrmA)1Hed/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (BALB/c * C57BL/6)	immune system phenotype	J:100451
\Tg(Lck-CrmA)1Hed/\Tg(Lck-CrmA)1Hed (involves: BALB/c * C57BL/6J)	immune system phenotype	J:100451
\Tg(Lck-Cxadr)1Jdgr/0 (FVB-Tg(Lck-Cxadr)1Jdgr)	abnormal T cell physiology	J:109884
	decreased T cell apoptosis	J:109884
	decreased T cell proliferation	J:109884
\Tg(Lck-FADD)1Hed/0 (involves: BALB/c * C57BL/6)	abnormal T cell proliferation	J:100451
	arrested T cell differentiation	J:100451
	decreased T cell number	J:100451
	decreased thymocyte number	J:100451
\Tg(Lck-FADD)1Hed/? (involves: BALB/c * C57BL/6)	abnormal T cell physiology	J:100451
	decreased thymocyte apoptosis	J:100451
	immune system phenotype	J:100451
\Tg(Lck-FADD)1Hed/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: BALB/c * C57BL/6J * C57L/J * DBA/2J)	immune system phenotype	J:100451
\Tg(Lck-FADD)1Hed/\Tg(Lck-FADD)1Hed (involves: BALB/c * C57BL/6)	abnormal T cell differentiation	J:100451
	decreased T cell number	J:100451
	decreased thymocyte number	J:100451
	immune system phenotype	J:100451
\Tg(Lck-Hhex)1Hro/0 (C3HeB/FeJ-Tg(Lck-Hhex)1Hro)	abnormal double-negative T cell morphology	J:80777
	decreased double-positive T cell number	J:80777
	decreased leukocyte cell number	J:80777
	decreased lymphocyte cell number	J:80777
	decreased T cell number	J:80777
	increased CD8-positive, alpha-beta T cell number	J:80777
	thymus hyperplasia	J:80777
\Tg(Lck-Id1)28Xhsu/0 (Not Specified)	increased T cell derived lymphoma incidence	J:58607
\Tg(Lck-Il31)1Jagr/0 (involves: C3H * C57BL/6)	abnormal immune system physiology	J:91124
	abnormal leukopoiesis	J:91124
	conjunctivitis	J:91124
	cutaneous mastocytosis	J:91124
	decreased T cell number	J:91124
	dermatitis	J:91124
	enlarged lymph nodes	J:91124
	increased activated T cell number	J:91124
	increased B cell number	J:91124
	increased memory T cell number	J:91124
\Tg(Lck-LMO1)11Sjk/0 \Tg(STIL-TAL1)A5.3Alpa/0 (involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)	abnormal inflammatory response	J:40868
	enlarged lymph nodes	J:40868
	enlarged spleen	J:40868
	enlarged thymus	J:40868
	increased leukocyte cell number	J:40868
	increased T cell derived lymphoma incidence	J:40868
\Tg(Lck-Map3k8)3456Ngc/? (involves: C3H/HeJ * C57BL/6J)	increased T cell derived lymphoma incidence	J:39450
\Tg(LCK-NFKBIA)5Dwb/0 (involves: C57BL/6 * DBA/2)	abnormal CD8-positive, alpha-beta T cell differentiation	J:93003
	decreased CD4-positive, alpha-beta T cell number	J:93003
	decreased CD8-positive, alpha-beta T cell number	J:93003
	decreased interleukin-2 secretion	J:93003
	decreased T cell proliferation	J:93003
	increased T cell apoptosis	J:93003
\Tg(LCK-NFKBIA)5Dwb/? (involves: BALB/c * C57BL/6 * DBA/2)	abnormal T-helper 1 physiology	J:145531
	decreased interferon-gamma secretion	J:145531
	decreased susceptibility to type I hypersensitivity reaction	J:145531
	decreased susceptibility to type IV hypersensitivity reaction	J:145531
\Tg(LCK-NFKBIA)5Dwb/? \Tg(Tcra,Tcrb)1Mcd/? (involves: BALB/c * C57BL/6 * DBA/2)	decreased interferon-gamma secretion	J:145531
\Tg(Lck-Notch3)#Issc/0 (involves: C57BL/6 * DBA/2)	abnormal T cell differentiation	J:63300
	enlarged lymph nodes	J:63300
	enlarged spleen	J:63300
	increased double-negative T cell number	J:63300
	increased lymphoblastic lymphoma incidence	J:63300
	increased T cell derived lymphoma incidence	J:96010
	increased thymocyte number	J:63300
	thymus hyperplasia	J:63300
\Tg(Lck-Socs3)1Kubo/0 (Not Specified)	abnormal CD4-positive T cell differentiation	J:132905
	decreased interleukin-2 secretion	J:128797
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:132905
	decreased T cell number	J:128797
	decreased T cell proliferation	J:128797
	decreased thymocyte number	J:128797
\Tg(Lck-Sox13)#Jskg/0 (involves: C57BL/6)	decreased double-positive T cell number	J:117301
	decreased T cell proliferation	J:117301
	decreased thymocyte number	J:117301
	increased thymocyte apoptosis	J:117301
\Tg(Lck-Stat5b*)1Mafa/0 (Not Specified)	decreased mature B cell number	J:132669
\Tg(Lck-Stat5b*)1Mafa/0 (Not Specified)	increased B cell proliferation	J:132669
\Tg(Lck-Stk17b)26.1Wals/? (B6.Cg-Tg(Lck-Stk17b)26.1Wals)	decreased CD4-positive, alpha-beta T cell number	J:149973
	decreased CD8-positive, alpha-beta T cell number	J:149973
	decreased single-positive T cell number	J:149973
	decreased thymocyte number	J:149973
	enlarged spleen	J:149973
	increased anti-nuclear antigen antibody level	J:149973
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:149973
	increased double-positive T cell number	J:149973
	increased interleukin-2 secretion	J:149973
	increased spleen weight	J:149973
	increased susceptibility to experimental autoimmune encephalomyelitis	J:149973
	increased T cell proliferation	J:149973
	spleen hyperplasia	J:149973
\Tg(Lck-Stk17b)26.1Wals/? \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * C57BL/10)	abnormal T cell differentiation	J:149973
	decreased CD8-positive, alpha-beta T cell number	J:149973
	decreased thymocyte number	J:149973
	increased CD8-positive, alpha-beta T cell number	J:149973
\Tg(Lck-Tal1)4709Led/0 (FVB/N-Tg(Lck-Tal1)4709Led)	abnormal thymus morphology	J:36076
	enlarged spleen	J:36076
	increased lymphoblastic lymphoma incidence	J:36076
\Tg(Lck-Tax)53Hall/0 (involves: C57BL/6)	enlarged lymph nodes	J:129531
	enlarged spleen	J:129531
	hepatosplenomegaly	J:129531
	increased susceptibility to fungal infection	J:129531
	increased T cell derived lymphoma incidence	J:129531
\Tg(Lck-Tnfsf4)1Nish/0 (B6.Cg-Tg(Lck-Tnfsf4)1Nish)	abnormal CD4-positive, alpha-beta T cell physiology	J:194882
	abnormal cytokine secretion	J:80214
	abnormal T cell subpopulation ratio	J:194882
	increased CD4-positive, alpha-beta T cell number	J:194882
	increased interleukin-13 secretion	J:194882
	increased regulatory T cell number	J:194882
	increased susceptibility to type IV hypersensitivity reaction	J:80214
	increased T cell proliferation	J:80214
	lung inflammation	J:194882
\Tg(Lck-Tnfsf4)1Nish/0 (C.Cg-Tg(Lck-Tnfsf4)1Nish)	abnormal CD4-positive, alpha-beta T cell physiology	J:194882
	increased CD4-positive, alpha-beta T cell number	J:194882
	increased interleukin-13 secretion	J:194882
	increased regulatory T cell number	J:194882
\Tg(Lck-TNFSF13)3919Mhah/0 (B6.Cg-Tg(Lck-TNFSF13)3919Mhah)	abnormal immune system organ morphology	J:94628
	abnormal mesenteric lymph node morphology	J:94628
	abnormal spleen morphology	J:94628
	decreased B cell apoptosis	J:94628
	enlarged mesenteric lymph nodes	J:94628
	enlarged Peyer's patches	J:94628
	increased B cell number	J:94628
	increased B-1 B cell number	J:94628
	increased CD4-positive, alpha-beta T cell number	J:94628
	increased CD8-positive, alpha-beta T cell number	J:94628
	increased IgA level	J:94628
	intermingled spleen red and white pulp	J:94628
	spleen hyperplasia	J:94628
\Tg(Lck-Tnfsf14)24Yxf/? (C57BL/6-Tg(Lck-Tnfsf14)24Yxf)	abnormal complement protein level	J:128976
	abnormal inflammatory response	J:128976
	abnormal lymph node cell ratio	J:129951
	abnormal T cell physiology	J:120962, J:129951
	colitis	J:129951
	glomerulonephritis	J:129951
	increased anti-double stranded DNA antibody level	J:129951
	increased anti-nuclear antigen antibody level	J:128976
	increased autoantibody level	J:129951
	increased IgA level	J:128976
	increased IgG level	J:128976
	increased spleen weight	J:129951
	increased T cell proliferation	J:129951
	intestinal inflammation	J:128976
	liver inflammation	J:129951
	lung inflammation	J:129951
	lymph node hyperplasia	J:129951
	myositis	J:129951
	small intestinal inflammation	J:120962
	spleen hyperplasia	J:129951
\Tg(Lck-Tnfsf15,-EGFP)#Targ/0 (involves: C57BL/6)	increased CD4-positive, alpha-beta memory T cell number	J:169462
	increased CD8-positive, alpha-beta memory T cell number	J:169462
	increased interferon-gamma secretion	J:169462
	increased interleukin-17 secretion	J:169462
	small intestinal inflammation	J:169462
\Tg(Lck-Tslp)1Chea/0 (B6.Cg-Tg(Lck-Tslp)1Chea)	enlarged lymph nodes	J:72982
	enlarged spleen	J:72982
	glomerulonephritis	J:72982
	increased anti-nuclear antigen antibody level	J:72982
	increased immunoglobulin level	J:72982
	increased spleen weight	J:72982
	liver inflammation	J:72982
	lung inflammation	J:72982
\Tg(Lck-VIPR2)1Ejg/0 (C57BL/6-Tg(Lck-VIPR2)1Ejg)	decreased interferon-gamma secretion	J:127974
	decreased susceptibility to type IV hypersensitivity reaction	J:127974
	increased eosinophil cell number	J:127974
	increased IgE level	J:127974
	increased IgG1 level	J:127974
	increased interleukin-4 secretion	J:127974
	increased interleukin-5 secretion	J:127974
	increased susceptibility to type I hypersensitivity reaction	J:127974
\Tg(Lck/Emu-Rftn1)1Ayos/? (involves: C57BL/6)	increased IgG1 level	J:150299
	increased IgG2a level	J:150299
	increased IgG3 level	J:150299
	increased IgM level	J:150299
	increased interferon-gamma secretion	J:150299
	increased interleukin-4 secretion	J:150299
	increased interleukin-17 secretion	J:150299
	increased susceptibility to experimental autoimmune encephalomyelitis	J:150299
	increased T cell proliferation	J:150299
\Tg(LckIl4)1315Dbl/0 (involves: C57BL/6J * DBA/2J)	abnormal osteoclast physiology	J:107359
	abnormal T cell activation	J:92453
	abnormal T cell differentiation	J:92453
	abnormal T cell number	J:92453
	abnormal thymocyte activation	J:92453
	abnormal thymus cell ratio	J:92453
	abnormal thymus morphology	J:92453
	absent CD8-positive, alpha-beta T cells	J:92453
	decreased CD4-positive, alpha-beta T cell number	J:92453
	decreased double-positive T cell number	J:92453
	increased CD4-positive, alpha-beta T cell number	J:92453
	increased CD8-positive, alpha-beta T cell number	J:92453
	increased double-negative T cell number	J:92453
	increased IgG2a level	J:92453
	increased interleukin-4 secretion	J:92453
	increased susceptibility to parasitic infection	J:92453
	thymus cortex hypoplasia	J:92453
	thymus hypoplasia	J:92453
\Tg(LckNotch1)9Erob/? (involves: C57BL/6 * CBA/J)	abnormal CD8-positive, alpha-beta T cell differentiation	J:93005
	abnormal thymus cell ratio	J:93005
	decreased CD4-positive, alpha-beta T cell number	J:93005
	increased CD8-positive, alpha-beta T cell number	J:93005
	increased T cell derived lymphoma incidence	J:93005
\Tg(LCKprBCL2)36Sjk/? (involves: C3H * C57BL/6)	abnormal T cell number	J:28635
	abnormal T cell subpopulation ratio	J:11548
	abnormal thymus cell ratio	J:11548
	decreased T cell apoptosis	J:11548
	increased CD8-positive, alpha-beta T cell number	J:11548
	increased T cell derived lymphoma incidence	J:28635
	increased T cell number	J:11548
\Tg(LCKprBCL2)36Sjk/0 (B6.Cg-Tg(LCKprBCL2)36Sjk)	abnormal CD4-positive, alpha-beta T cell number	J:217939
	abnormal T cell subpopulation ratio	J:217939
	increased regulatory T cell number	J:217939
\Tg(LCKprBCL2)36Sjk/0 (involves: C57BL/6 * CBA/J)	abnormal T cell clonal deletion	J:217939
\Tg(LCKprBCL2)36Sjk/0 (involves: C57BL/6 * CBA/J)	decreased thymocyte apoptosis	J:217939
\Tg(LCKprBCL2)36Sjk/0 \Tg(Nr4a1-EGFP/cre)820Khog/0 (involves: C57BL/6 * C57BL/6J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
\Tg(LCKprBCL2)36Sjk/0 \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: C57BL/6 * C57BL/6J * DBA/2J)	abnormal T cell clonal deletion	J:217939
	decreased thymocyte apoptosis	J:217939
\Tg(LCR-HBA2,LCR-HBB)1Cos/0 (involves: C57BL/6J CBA/J)	enlarged spleen	J:94193
\Tg(Ly6a-BCR/ABL1)IS1AIsg/0 (involves: C57BL/6J * CBA)	abnormal lymph node morphology	J:144382
	abnormal spleen morphology	J:144382
	increased leukocyte cell number	J:144382
	increased neutrophil cell number	J:144382
	increased spleen red pulp amount	J:144382
	increased spleen weight	J:144382
\Tg(Ly6a-BCR/ABL1)IS1BIsg/0 (involves: C57BL/6J * CBA)	abnormal lymph node morphology	J:144382
	abnormal spleen morphology	J:144382
	increased leukocyte cell number	J:144382
	increased neutrophil cell number	J:144382
	increased spleen red pulp amount	J:144382
	increased spleen weight	J:144382
\Tg(Ly6a-GCSAM)102AIsg/0 (involves: C57BL/6J * CBA)	abnormal spleen morphology	J:221238
	decreased B-1 B cell number	J:221238
	enlarged Peyer's patches	J:221238
	enlarged spleen	J:221238
	increased B cell proliferation	J:221238
	increased B-1 B cell number	J:221238
	increased IgG level	J:221238
	increased inflammatory response	J:221238
	increased spleen white pulp amount	J:221238
	lymphoid hyperplasia	J:221238
\Tg(Ly6a-SET/NUP214)2969Gcg/0 (involves: FVB/NJ)	abnormal B cell differentiation	J:142938
	decreased leukocyte cell number	J:142938
	decreased lymphocyte cell number	J:142938
	decreased pre-B cell number	J:142938
	decreased pro-B cell number	J:142938
	increased B cell apoptosis	J:142938
\Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0 (involves: C57BL/6J * CBA)	increased leukocyte cell number	J:144382
\Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0 (involves: C57BL/6J * CBA)	increased neutrophil cell number	J:144382
\Tg(Ly6e-MALT1)#Isg/0 (involves: C57BL/6 * CBA)	increased mature B cell number	J:185590
	increased pre-B cell number	J:185590
	increased pro-B cell number	J:185590
\Tg(LYZ-rtTA2SM2,tetO-ELAVL1)632Dkon/0 (B6.Cg-Tg(LYZ-rtTA2SM2,tetO-ELAVL1)632Dkon)	decreased susceptibility to induced colitis	J:184388
\Tg(Mbp-Pad2)28Fgm/0 (involves: CD-1)	abnormal tumor necrosis factor level	J:142650
\Tg(Mbp-SNCA)1Ema/0 (involves: C57BL/6 * DBA/2)	brain inflammation	J:207162
\Tg(MCL1)8Caig/0 (involves: C57BL/6 * SJL)	abnormal immature B cell morphology	J:50604
	abnormal leukocyte physiology	J:50604
	abnormal macrophage apoptosis	J:95913
	abnormal mast cell differentiation	J:50604
	abnormal monocyte differentiation	J:50604
	decreased B cell apoptosis	J:50604
	decreased splenocyte apoptosis	J:50604
	decreased T cell apoptosis	J:50604
	increased spleen white pulp amount	J:50604
	increased susceptibility to bacterial infection	J:95913
	increased T cell derived lymphoma incidence	J:69755
	increased thymocyte number	J:50604
	spleen hyperplasia	J:50604
\Tg(Mcpt8-cre)1Voeh/0 (involves: C57BL/6)	decreased basophil cell number	J:164432
	decreased inflammatory response	J:164432
	immune system phenotype	J:164432
\Tg(Mir125a)#Smoc/0 (involves: C57BL/6)	decreased interferon-gamma secretion	J:224880
\Tg(Mir125a)#Smoc/0 (involves: C57BL/6)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:224880
\Tg(ML5sHEL)5Ccg/0 (C57BL/6-Tg(ML5sHEL)5Ccg)	abnormal B cell anergy	J:78308
\Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6JSfd * CBA)	abnormal B cell anergy	J:78308
\Tg(ML5sHEL)5Ccg/0 (involves: C57BL/6JSfd * CBA)	abnormal T cell anergy	J:78308
\Tg(ML5sHEL)5Ccg/0 \Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
\Tg(ML5sHEL)5Ccg/0 \Tg(TcrHEL3A9)1Mmd/0 \Tg(TLK2mHEL)2Ccg/0 (involves: C57BL/6JSfd * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
	thyroid gland inflammation	J:78309
\Tg(MMTV-ENPP2)#Gbm/0 (FVB/N-Tg(MMTV-ENPP2)#Gbm)	mastitis	J:149661
\Tg(MMTV-Erbb2)9Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
\Tg(MMTV-Erbb2)9Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
\Tg(MMTV-Erbb2)10Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
\Tg(MMTV-Erbb2)10Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
\Tg(MMTV-Erbb2)12Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
\Tg(MMTV-Erbb2)12Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
\Tg(MMTV-Erbb2)17Pjo/0 (involves: BALB/c * C3H * C57BL/6)	enlarged spleen	J:72129
\Tg(MMTV-Erbb2)17Pjo/0 (involves: BALB/c * C3H * C57BL/6)	increased spleen red pulp amount	J:72129
\Tg(MMTV-LPAR1)2Gbm/\Tg(MMTV-LPAR1)2Gbm (FVB/N-Tg(MMTV-LPAR1)2Gbm)	mastitis	J:149661
\Tg(MMTV-LPAR1)7Gbm/\Tg(MMTV-LPAR1)7Gbm (FVB/N-Tg(MMTV-LPAR1)7Gbm)	mastitis	J:149661
\Tg(MMTV-LPAR1)#Gbm/\Tg(MMTV-LPAR1)#Gbm (FVB/N-Tg(MMTV-LPAR1)#Gbm)	mastitis	J:149661
\Tg(MMTV-LPAR2)3Gbm/\Tg(MMTV-LPAR2)3Gbm (FVB/N-Tg(MMTV-LPAR2)3Gbm)	mastitis	J:149661
\Tg(MMTV-LPAR2)6Gbm/\Tg(MMTV-LPAR2)6Gbm (FVB/N-Tg(MMTV-LPAR2)6Gbm)	mastitis	J:149661
\Tg(MMTV-LPAR2)#Gbm/\Tg(MMTV-LPAR2)#Gbm (FVB/N-Tg(MMTV-LPAR2)#Gbm)	mastitis	J:149661
\Tg(MMTV-LPAR3)3Gbm/\Tg(MMTV-LPAR3)3Gbm (FVB/N-Tg(MMTV-LPAR3)3Gbm)	mastitis	J:149661
\Tg(MMTV-LPAR3)#Gbm/\Tg(MMTV-LPAR3)#Gbm (FVB/N-Tg(MMTV-LPAR3)#Gbm)	mastitis	J:149661
\Tg(MMTV-PyVT)#Mul/0 (B6.FVB-Tg(MMTV-PyVT)#Mul)	abnormal circulating cytokine level	J:147923
	abnormal lymph node cell ratio	J:147923
	abnormal lymph node morphology	J:147923
	abnormal splenic cell ratio	J:147923
	abnormal T cell physiology	J:147923
	decreased B cell proliferation	J:147923
	decreased splenocyte proliferation	J:147923
	decreased T cell proliferation	J:147923
	enlarged spleen	J:147923
	increased circulating tumor necrosis factor level	J:147923
	increased regulatory T cell number	J:147923
	increased splenocyte number	J:147923
\Tg(MMTV-Scgb1a1)#Abm/0 (involves: C57BL/6 * SJL)	increased IgA level	J:57504
\Tg(Mpz-RAF1/ESR1)A668Ayld/0 (involves: C57BL/6J * CBA/J)	increased inflammatory response	J:182703
	increased macrophage cell number	J:182703
	increased mast cell number	J:182703
	increased neutrophil cell number	J:182703
	increased T cell number	J:182703
\Tg(Msmb-TAg)183-2Xuan/0 (involves: C57BL/6 * CBA)	enlarged lymph nodes	J:80313
\Tg(Msr1-MMP9)#Apar/0 (B6.Cg-Tg(Msr1-MMP9)#Apar)	abnormal macrophage physiology	J:136830
	decreased inflammatory response	J:129959
	immune system phenotype	J:136830
\Tg(MSR1-Plau)1Ddi/0 (involves: C57BL/6 * SJL)	heart inflammation	J:101486
\Tg(Mt1-Crry)26Quig/? (involves: CD-1)	abnormal inflammatory response	J:117777
\Tg(Mt1-IL6)28Gci/0 (involves: C57BL/6 * DBA/2)	abnormal spleen morphology	J:18424
	enlarged lymph nodes	J:18424
	enlarged spleen	J:177825, J:18424
	increased circulating interleukin-6 level	J:177825
	increased circulating serum amyloid protein level	J:177825
	increased granulocyte number	J:177825
	increased IgG1 level	J:18424
	increased IgG level	J:177825, J:18424
	increased leukocyte cell number	J:18424
	increased neutrophil cell number	J:18424
	increased plasma cell number	J:177825, J:18424
	increased plasmacytoid dendritic cell number	J:177825
\Tg(Mt1-TGFBR2*)AM3Epb/0 (involves: FVB/N)	pancreas inflammation	J:76993
\Tg(MT2A-TGFBR2)4Rser/0 (involves: C57BL/6 * DBA)	osteoarthritis	J:44579
\Tg(MtTGFA)42Lmb/\Tg(MtTGFA)42Lmb (involves: CD-1)	immune system phenotype	J:28452
\Tg(MUC1)79.24Gend/0 (involves: C57BL/6)	abnormal humoral immune response	J:128899
	increased IgG level	J:154046
	increased IgM level	J:154046
\Tg(Mup3-Plau)350-2Eps/? (C57BL/6-Tg(Mup3-Plau)350-2Eps)	increased interleukin-1 beta secretion	J:233146
	increased tumor necrosis factor secretion	J:233146
	liver inflammation	J:233146
\Tg(Mx1-cre)1Cgn/0 \Tg(Tal1-tTA)19Dgt/0 \Tg(tetO-BCR/ABL1)2Dgt/0 \TgTn(pb-sb-GrOnc)#aGsva/0 (involves: C57BL/6 * CBA/J * DBA/2 * FVB/N)	increased granulocyte number	J:227558
	increased leukocyte cell number	J:227558
\Tg(Mx1-cre)1Cgn/0 \Thoc5^tm1Tate/\Thoc5^tm1Tate (involves: C57BL/6 * CBA)	abnormal lymphopoiesis	J:169944
	decreased leukocyte cell number	J:169944
	decreased spleen weight	J:169944
\Tg(Mx1-cre)1Cgn/0 \Tnfrsf13c^tm2.1Mass/\Tnfrsf13c^tm2.1Mass (involves: C57BL/6 * CBA)	increased immature B cell number	J:170519
	increased pre-B cell number	J:170519
	increased pro-B cell number	J:170519
\Tg(Mx1-cre)1Cgn/0 \Traf2^tm1Rbr/\Traf2^tm1Rbr (involves: C57BL/6 * CBA)	abnormal spleen marginal zone morphology	J:93890
	abnormal spleen morphology	J:93890
	enlarged lymph nodes	J:93890
	enlarged spleen	J:93890
	increased B cell number	J:93890
	increased marginal zone B cell number	J:93890
\Tg(Mx1-cre)1Cgn/0 \U2af1^tm1.1Hev/\U2af1⁺ (involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6J * CBA/J)	decreased leukocyte cell number	J:267082
\Tg(Mx1-cre)1Cgn/0 \U2af1^tm1Mohi/\U2af1^tm1Mohi (involves: C57BL/6J * CBA/J)	bone marrow failure	J:308564
	decreased leukocyte cell number	J:308564
	decreased neutrophil cell number	J:308564
\Tg(Mx1-cre)1Cgn/0 \Zmiz1^{tm1c(EUCOMM)Hmgu}/\Zmiz1^{tm1c(EUCOMM)Hmgu} (involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA/J)	decreased B cell number	J:234445
	decreased NK cell number	J:234445
	decreased T cell number	J:234445
	thymus hypoplasia	J:234445
\Tg(Mx1-cre)1Cgn/0 \Znrf1^tm1Lchs/\Znrf1^tm1Lchs (involves: C57BL/6)	decreased susceptibility to endotoxin shock	J:250572
\Tg(Myh6*/tetO-Capn1)L3Gwd/0 (involves: FVB/N)	heart inflammation	J:133797
\Tg(Myh6-BAG3P209L)#Mswi/0 (involves: C57BL/6 DBA/2)	heart inflammation	J:234278
\Tg(Myh6-Grem2)1Akh/0 (involves: C57BL/6)	decreased inflammatory response	J:250034
\Tg(Myh6-Grem2)1Akh/0 (involves: C57BL/6)	decreased interleukin-10 secretion	J:250034
\Tg(Myh6-IGF1)34Pia/0 (FVB/N-Tg(Myh6-IGF1)34Pia)	increased spleen weight	J:35215
\Tg(Myh6-JUP)1Dpju/0 (FVB/N-Tg(Myh6-JUP)1Dpju)	heart inflammation	J:235770
\Tg(Myh6-Tnf)1Brgi/? (involves: C57BL/6J * SJL)	myocarditis	J:84829, J:100006
\Tg(Myh6-Tnf)2Brgi/? (involves: C57BL/6J * SJL)	myocarditis	J:84829, J:100006
\Tg(Myh6-Tnnt2*R92Q)2Lnwd/0 (involves: C57BL/6)	heart inflammation	J:56911
\Tg(Myh6-Tnnt2*R92Q)3Lnwd/0 (involves: C57BL/6)	heart inflammation	J:56911
\Tg(Myh6-tTA)6Smbf/0 \Tg(tetO-EDN1,-lacZ)9Mhus/0 (involves: C57BL/6 * CBA)	heart inflammation	J:131245
\Tg(Myh6-tTA)6Smbf/0 \Tg(tetO-HDAC5)1Eno/0 (involves: C3H C57BL/6 * CBA)	myocarditis	J:81967
\Tg(Myh6-tTA)6Smbf/0 \Tg(tetO-NOS2,-lacZ)240iMhus/0 (involves: C57BL/6 * CBA)	heart inflammation	J:132082
\Tg(Myh6-tTA)6Smbf/0 \Tg(tetO-Spp1)5Gad/0 (involves: C57BL/6 * CBA)	heart inflammation	J:194810
	myocarditis	J:194810
\Tg(Myl1-SOD1G93A)#Amu/0 (FVB/NJ-Tg(Myl1-SOD1G93A)#Amu)	increased microglial cell activation	J:143747
\Tg(Nlrp1b)1Die/0 (involves: 129S1/SvImJ * C57BL/6 * SJL)	abnormal macrophage physiology	J:99748
\Tg(Nr4a1-EGFP/cre)820Khog/0 (C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog)	immune system phenotype	J:172415
\Tg(OMP-SV40T)13Bse/0 (involves: C57BL/6 * SJL)	abnormal immune tolerance	J:54269
\Tg(Pcp2-TBP*)69Hmhl/0 (involves: FVB/N)	brain inflammation	J:174239
\Tg(PF4-tTA/VP16)42Kra/0 \Tg(tetO-Aurkb,lacZ)41Kra/0 (FVB/NJ-Tg(tetO-Aurkb,lacZ)41Kra Tg(PF4-tTA/VP16)42Kra)	abnormal thrombopoiesis	J:104239
\Tg(PF4MER)6Kra/? (FVB/N-Tg(PF4MER)6Kra)	enlarged spleen	J:35507
\Tg(Pgk1-HA)1.1Vbo/? \Tg(Tcra/Tcrb)1Vbo/? (involves: 129 * BALB/c * C57BL/6J * DBA/2J)	decreased CD4-positive, alpha-beta T cell number	J:125750
	increased double-positive T cell number	J:125750
	increased regulatory T cell number	J:125750
\Tg(Pgk1-HA)1.1Vbo/? \Tg(Tcra/Tcrb)1Vbo/? (C.Cg-Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo)	abnormal regulatory T cell physiology	J:112603
	increased regulatory T cell number	J:112603
\Tg(PGK1-KITLG220)441Daw/\Tg(PGK1-KITLG220)441Daw (C3H/HeJ-Tg(PGK1-KITLG*220)441Daw)	abnormal thymus morphology	J:32600
\Tg(Pim1-Il9)5Jcrd/0 (involves: BALB/c * FVB/N)	increased susceptibility to type I hypersensitivity reaction	J:100568
\Tg(Pim1-Il9)5Jcrd/0 (involves: FVB/N)	increased interleukin-5 secretion	J:115764
	increased susceptibility to type I hypersensitivity reaction	J:100568
	increased T cell derived lymphoma incidence	J:17848
\Tg(Pklr-HRASG12V)21Ak/0 (involves: C57BL/6 DBA/2)	abnormal thymus morphology	J:44803
\Tg(Pklr-HRASG12V)21Ak/0 (involves: C57BL/6 DBA/2)	enlarged thymus	J:44803
\Tg(Pklr-Myc)73Ak/0 (B6.Cg-Tg(Pklr-Myc)73Ak)	decreased NK T cell number	J:184496
\Tg(PLA2G2A)703Dsg/? (involves: C57BL/6 * C57BL/6J * SJL)	immune system phenotype	J:113573
\Tg(PLP1*)4Rsj/0 (involves: CD-1)	CNS inflammation	J:161344
\Tg(Plp1-Eif2ak3)18Pop/0 (C57BL/6J-Tg(Plp1-Eif2ak3)18Pop)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:238042
\Tg(Plp1-LMNB1)1108Qsp/0 (involves: FVB/N)	microgliosis	J:226169
\Tg(Plp1-SNCA)1Haa/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:96778
\Tg(PML-RARA)556Kog/? (involves: FVB/N)	abnormal neutrophil differentiation	J:39327
\Tg(PML-RARA)556Kog/0 (FVB/N-Tg(PML-RARA)556Kog)	enlarged spleen	J:262172
\Tg(PML-RARA)556Kog/0 (FVB/N-Tg(PML-RARA)556Kog)	increased leukocyte cell number	J:262172
\Tg(PMP22)C61Clh/0 (B6.Cg-Tg(PMP22)C61Clh)	increased macrophage cell number	J:158350
\Tg(Prdx6)153Pgn/0 (C57BL/6-Tg(Prdx6)153Pgn/Pgn)	abnormal macrophage physiology	J:86528
\Tg(PRG1)18Wlad/0 (involves: C57BL/6J * CBA/J)	decreased susceptibility to Picornaviridae infection	J:127826
	increased susceptibility to Picornaviridae infection	J:92990
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:92990
\Tg(PRG3)9Wlad/0 (involves: C57BL/6J * CBA/J)	increased susceptibility to Picornaviridae infection	J:92990, J:127826
\Tg(Prnp)4053Sbp/0 (involves: FVB/N)	increased susceptibility to prion infection	J:136434
\Tg(Prnp)a20Cwe/0 (Not Specified)	increased susceptibility to prion infection	J:130657, J:143528
\Tg(Prnp-APP)1Hmor/0 (B6.Cg-Tg(Prnp-APP)1Hmor)	microgliosis	J:159623
\Tg(Prnp-ATXN792Q)6529Als/Y (involves: C3H/HeJ C57BL/6J)	colitis	J:135615
\Tg(Prnp-FUS)WT3Cshw/0 (involves: C57BL/6 * Crl:CD-1(ICR))	microgliosis	J:189360
\Tg(Prnp-FUS)WT3Cshw/\Tg(Prnp-FUS)WT3Cshw (involves: C57BL/6 * Crl:CD-1(ICR))	microgliosis	J:189360
\Tg(Prnp-Immt/SOD1G93A)7Gmnf/\Tg(Prnp-Immt/SOD1G93A)7Gmnf (involves: C57BL/6 * CBA * SJL)	dermatitis	J:177846
\Tg(Prnp-ITM2B)1Ruvi/\Tg(Prnp-ITM2B)1Ruvi \Tg(Prnp-MAPTP301L)#Ruvi/\Tg(Prnp-MAPTP301L)#Ruvi (involves: C3HeB/FeJ * C57BL/6)	increased inflammatory response	J:197198
\Tg(Prnp-ITM2B)7Jckr/0 (C57BL/6-Tg(Prnp-ITM2B)7Jckr)	microgliosis	J:159279
\Tg(Prnp-MAPTP301L)JNPL3Hlmc/? (involves: C57BL/6 DBA/2)	eye inflammation	J:63887
\Tg(Prnp-MAPTR406W)21807Dwst/? (FVB/N-Tg(Prnp-MAPTR406W)21807Dwst)	microgliosis	J:95971
\Tg(Prnp-PFN1C71G)22Zxu/0 \Tg(Thy1-PFN1C71G)67Zxu/\Tg(Thy1-PFN1*C71G)67Zxu (involves: FVB/N)	microgliosis	J:235427
\Tg(Prnp-TARDBP)96Dwc/0 \Tg(Prnp-TARDBPQ331K)31Dwc/0 (involves: C3H C57BL/6)	microgliosis	J:239141
\Tg(Prnp-TARDBPQ331K)31Dwc/? (involves: C3H C57BL/6)	microgliosis	J:239141
\Tg(Prox1-EGFP)KY221Gsat/0 (involves: FVB/NTac)	abnormal lymphangiogenesis	J:235778
\Tg(Prox1-EGFP)KY221Gsat/0 (involves: FVB/NTac)	abnormal lymphatic vessel endothelial cell morphology	J:235778
\Tg(PRSS1/lacZ)#Gwzh/0 (Not Specified)	increased susceptibility to induced pancreatitis	J:345508
\Tg(Psp-Rbbp4)1Yoha/0 (involves: C57BL/6)	abnormal antigen presentation	J:141378
	abnormal T cell activation	J:141378
	increased autoantibody level	J:141378
	increased interferon-gamma secretion	J:141378
	increased interleukin-2 secretion	J:141378
	increased interleukin-18 secretion	J:141378
	increased marginal zone B cell number	J:141378
	increased susceptibility to autoimmune disorder	J:141378
	lacrimal gland inflammation	J:141378
	salivary gland inflammation	J:141378
\Tg(PTH-CCND1)PC2Anar/0 (FVB/N-Tg(PTH-CCND1)PC2Anar)	increased osteoclast cell number	J:69423
\Tg(PVR)1Kkst/0 (involves: ICR)	increased susceptibility to Picornaviridae infection	J:153943
\Tg(RIP1-Tag)5Dh/? (C3HeB/FeJ-Tg(RIP1-Tag)5Dh)	pancreas inflammation	J:80168
\Tg(Rr158-H2-Ea^d)1Flv/0 \Tg(Tcra1H3.1,Tcrb1H3.1)1Vire/0 (involves: C57BL/6 * SJL)	decreased double-positive T cell number	J:124574
	thymus hypoplasia	J:124574
\Tg(rv-CYCLIN)29Dlh/0 (involves: C57BL/6 * SJL)	lymphoid hyperplasia	J:62478
\Tg(rv-CYCLIN)29Dlh/0 (involves: C57BL/6 * SJL)	spleen hyperplasia	J:62478
\Tg(Scgb1a1-IL6)9Flv/0 (involves: C57BL/6 * CBA)	lung inflammation	J:128762, J:156430
\Tg(Scgb1a1-Il13)2Eli/? (involves: C57BL/6 * CBA)	abnormal leukocyte physiology	J:53612
\Tg(Scgb1a1-Il13)2Eli/? (involves: C57BL/6 * CBA)	respiratory system inflammation	J:53612
\Tg(Scgb1a1-Il17a)3Cdon/0 (C57BL/6-Tg(Scgb1a1-Il17a)3Cdon)	abnormal chemokine level	J:112600
\Tg(Scgb1a1-Il17a)3Cdon/0 (C57BL/6-Tg(Scgb1a1-Il17a)3Cdon)	lung inflammation	J:112600
\Tg(Scgb1a1-Il17f,GFP)1Cdon/? (C57BL/6-Tg(Scgb1a1-Il17f,GFP)1Cdon)	lung inflammation	J:136279
\Tg(Scgb1a1-Muc5b,-AcGFP)#Evns/0 (involves: C57BL/6J * C57BL/6N)	decreased susceptibility to bacterial infection	J:207159
\Tg(Scgb1a1-PLUNC)#Chuh/0 (involves: FVB/N)	decreased susceptibility to bacterial infection	J:171589
\Tg(Scgb1a1-rtTA)1Jaw/0 \Tg(tetO-Aimp1)29872Mcla/0 (involves: 129 * C57BL/6)	increased macrophage cell number	J:173904
\Tg(Scgb1a1-rtTA)1Jaw/0 \Tg(tetO-EGFRT790ML858R)19Kkw/0 (involves: 129 * C57BL/6 * FVB/N)	interstitial pneumonia	J:122849
\Tg(Scgb1a1-rtTA)1Jaw/0 \Tg(tetO-IL1B)KBry/0 (involves: 129 * C57BL/6)	abnormal chemokine level	J:107601, J:130523
	lung inflammation	J:107601, J:130523
\Tg(Scgb1a1-rtTA,-tTS,tetO-CHI3L1)1Eli/0 (Not Specified)	abnormal macrophage morphology	J:148490
	decreased T cell apoptosis	J:148490
	increased T-helper 2 cell number	J:148490
\Tg(Scgb1a1-rtTA,-tTS,tetO-TGFB1*)1Eli/0 (involves: C57BL/6)	lung inflammation	J:92469
\Tg(Scgb1a1-rtTA,tetO-Ifng)14Eli/0 (involves: C57BL/6 * CBA)	increased lymphocyte cell number	J:100854
	increased macrophage cell number	J:100854
	increased neutrophil cell number	J:100854
\Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * CBA)	abnormal T-helper 2 physiology	J:148490
\Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * CBA)	increased T-helper 2 cell number	J:148490
\Tg(Scgb1a1-Scnn1b)6608Bouc/0 (involves: C3H * C57BL/6)	bronchitis	J:91139
\Tg(Scgb1a1-Scnn1b)6608Bouc/0 (B6.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)	respiratory system inflammation	J:191673
\Tg(Scgb1a1-Scnn1b)6608Bouc/0 (C.Cg-Tg(Scgb1a1-Scnn1b)6608Bouc)	respiratory system inflammation	J:191673
\Tg(SERPINA1E342K)#Slcw/0 (involves: C57BL/6 ICR)	liver inflammation	J:149132
\Tg(SERPINA1-HBVX)1655Jtsb/0 (involves: C3H * C57BL/6 * ICR)	liver inflammation	J:90305
\Tg(SERPINA1-IGHG1/Il1rl1)423Zbz/? (involves: C3H * C57BL/6)	abnormal eosinophil physiology	J:63507
	abnormal response to infection	J:63507
	decreased interleukin-5 secretion	J:63507
	increased eosinophil cell number	J:63507
X/\Tg(SERPINC1-SV40)BPbr (involves: C57BL/6 * DBA/2)	increased macrophage cell number	J:84204
\Tg(SFTPC-DPP4)3Pbmj/0 (involves: C57BL/6J * SJL/J)	abnormal susceptibility to Coronaviridae infection	J:285467
\Tg(SFTPC-Il18)AThos/0 (B6N.Cg-Tg(SFTPC-Il18)AThos)	abnormal spleen morphology	J:147547
	enlarged spleen	J:147547
	increased interferon-gamma secretion	J:147547
	increased interleukin-13 secretion	J:147547
	lung inflammation	J:147547
\Tg(SFTPC-rtTA)2Jaw/0 \Tg(tetO-CTGF)#Swu/0 (involves: 129 * C57BL/6 * C57BL/6J)	lung inflammation	J:171151
\Tg(SFTPC-rtTA,tetO-Tnf)320-1Gwho/0 (involves: C57BL/6 * SJL)	abnormal B cell morphology	J:97297
	abnormal bronchus-associated lymphoid tissue morphology	J:97297
	abnormal CD4-positive, alpha beta T cell morphology	J:97297
	abnormal dendritic cell morphology	J:97297
	abnormal T cell morphology	J:97297
	increased CD8-positive, alpha-beta T cell number	J:97297
	increased lymphocyte cell number	J:97297
	increased neutrophil cell number	J:97297
	lung inflammation	J:97297
\Tg(SFTPC-Tnf)2Pva/0 (involves: C57BL/6 * DBA/2)	alveolitis	J:28120
\Tg(SFTPC-Tnf)2Pva/0 (involves: C57BL/6 * DBA/2)	interstitial pneumonia	J:28120
\Tg(Sirt1)ASrn/? (involves: C57BL/6 * CBA)	increased susceptibility to endotoxin shock	J:137868
\Tg(SOD1G93A)1Gur/0 (B6.Cg-Tg(SOD1G93A)1Gur/J)	abnormal spleen morphology	J:138237
	abnormal T cell physiology	J:138237
	decreased spleen weight	J:138237
	decreased splenocyte number	J:138237
\Tg(SOD1G93A)1Gur/0 (B6SJL-Tg(SOD1G93A)1Gur/J)	abnormal lymphocyte morphology	J:129215
	abnormal microglial cell morphology	J:165019, J:143173
	abnormal spleen morphology	J:138237
	abnormal splenic cell ratio	J:138237
	abnormal splenocyte morphology	J:138237
	CNS inflammation	J:110437
	decreased eosinophil cell number	J:129215
	decreased leukocyte cell number	J:129215
	decreased lymphocyte cell number	J:129215
	decreased monocyte cell number	J:129215
	decreased spleen weight	J:138237
	increased basophil cell number	J:129215
	microgliosis	J:146652, J:165019, J:110437, J:143173
	small spleen	J:138237
\Tg(SOD1G93A)^dl1Gur/0 (involves: C57BL/6 C57BL/6J * SJL/J)	microgliosis	J:128738
\Tg(SOD1H46R)LAra/0 (involves: C57BL/6 DBA/2)	microgliosis	J:221350
\Tg(SOD1H46RC111S)PAra/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:221350
\Tg(SOD1H46RC111S)PAra/\Tg(SOD1H46RC111S)PAra (involves: C57BL/6 * DBA/2)	microgliosis	J:221350
\Tg(SOD1H46RC111S)QAra/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:221350
\Tg(SOD1L126Z)45Dbo/0 (involves: C3H/HeJ C57BL/6J)	microgliosis	J:219482
\Tg(Stat3*)9199Alau/0 (involves: C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:210877
	abnormal T-helper 17 cell differentiation	J:210877
	decreased IgG1 level	J:210877
	decreased IgG3 level	J:210877
	increased IgE level	J:210877
	increased inflammatory response	J:210877
	increased neutrophil cell number	J:210877
	increased susceptibility to bacterial infection	J:210877
	increased susceptibility to bacterial infection induced morbidity/mortality	J:210877
	increased susceptibility to endotoxin shock	J:210877
	intestinal inflammation	J:210877
\Tg(SV40-Ahr)1Poe/0 (involves: C57BL/6 * CBA)	absent B-1a cells	J:82428
	decreased B-1 B cell number	J:82428
	decreased thymus weight	J:77977
	increased B-2 B cell number	J:82428
	increased mature B cell number	J:82428
	increased pre-B cell number	J:82428
	increased pro-B cell number	J:82428
\Tg(SV40-Igh-64C8)H3Hon/0 \Tg(SV40-Igk4C8)L1Hon/0 (involves: C57BL/6)	abnormal B cell clonal deletion	J:139864
	abnormal B cell number	J:139864
	increased anti-erythrocyte antigen antibody level	J:139864
\Tg(SV40-KLK7)1010Teg/0 (involves: C57BL/6J * CBA)	dermatitis	J:75714
\Tg(SV40-NRAS*G12D)1Sco/? (Not Specified)	increased T cell derived lymphoma incidence	J:125150
\Tg(SV40/HTLV-FCER1A)1Bhk/0 (involves: 129)	immune system phenotype	J:47138
\Tg(SV)419Bri/\Tg(SV)419Bri (C57BL/6J-Tg(SV)419Bri)	increased T cell derived lymphoma incidence	J:147031
\Tg(SV)427Bri/0 (C57BL/6J-Tg(SV)427Bri)	enlarged thymus	J:79096
\Tg(TARDBP)#Jpj/0 (involves: C3H * C57BL/6)	microgliosis	J:195184
\Tg(TARDBPA315T)#Jpj/0 (involves: C3H C57BL/6)	microgliosis	J:195184
\Tg(TARDBPG348C)#Jpj/0 (involves: C3H C57BL/6)	abnormal cytokine level	J:195184
\Tg(TARDBPG348C)#Jpj/0 (involves: C3H C57BL/6)	microgliosis	J:195184
\Tg(TCF3/HLF)1Mlc/0 (involves: FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:55022
	abnormal thymus involution	J:55022
	arrested T cell differentiation	J:55022
	decreased CD4-positive, alpha-beta T cell number	J:55022
	decreased CD8-positive, alpha-beta T cell number	J:55022
	decreased double-positive T cell number	J:55022
	decreased T cell number	J:55022
	decreased thymocyte number	J:55022
	increased T cell derived lymphoma incidence	J:55022
	thymus hypoplasia	J:55022
\Tg(Tcra2B4)1Mmd/? (involves: C3H/HeJ * C57BL/6)	abnormal thymus cell ratio	J:92992
	decreased CD4-positive, alpha-beta T cell number	J:92992
	decreased double-positive T cell number	J:92992
	decreased thymocyte number	J:92992
	increased double-negative T cell number	J:92992
\Tg(Tcra2C,Tcrb2C)1Dlo/? (involves: C57BL/6 * SJL)	abnormal CD8-positive, alpha beta T cell morphology	J:125259
\Tg(Tcra2C,Tcrb2C)1Dlo/? (involves: C57L * DBA/2 * SJL)	abnormal memory T cell physiology	J:95380
	decreased lymphocyte cell number	J:95380
	decreased thymocyte number	J:95380
	increased CD4-positive, alpha-beta T cell number	J:95380
	seborrheic dermatitis	J:95380
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:83278
	abnormal cytokine secretion	J:83278
	blepharitis	J:83278
	CNS inflammation	J:83278
	increased susceptibility to autoimmune disorder	J:83278
	increased susceptibility to experimental autoimmune encephalomyelitis	J:83278
\Tg(Tcra2D2,Tcrb2D2)1Kuch/? (involves: C57BL/6 * CD-1)	decreased interleukin-17 secretion	J:125296
\Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129P2/OlaHsd * C57BL/6)	abnormal T-helper 1 cell number	J:189919
	decreased interferon-gamma secretion	J:189919
	decreased interleukin-2 secretion	J:189919
	decreased interleukin-10 secretion	J:189919
	decreased T cell proliferation	J:189919
	decreased T-helper 2 cell number	J:189919
	decreased T-helper 17 cell number	J:189919
	increased interferon-gamma secretion	J:189919
	increased interleukin-6 secretion	J:189919
	increased interleukin-17 secretion	J:189919
	increased T cell apoptosis	J:189919
	increased T cell proliferation	J:189919
\Tg(Tcra5CC7,Tcrb5CC7)IWep/0 (involves: C57BL/6)	abnormal T cell activation	J:73608
\Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0 (involves: C57BL/6 * DBA/2)	abnormal positive T cell selection	J:125548
\Tg(Tcra,Tcrb)3Ayr/0 (involves: C57BL/6 * DBA/2)	abnormal lymphocyte anergy	J:80775
	abnormal positive T cell selection	J:125548
	decreased T cell proliferation	J:80775
\Tg(Tcra,Tcrb)24Efro/0 (D1.Cg-Tg(Tcra,Tcrb)24Efro)	abnormal cytokine secretion	J:104243
	abnormal T cell differentiation	J:104243
	autoimmune response	J:104243
	decreased T cell proliferation	J:104243
	increased autoantibody level	J:104243
	increased memory T cell number	J:104243
	increased susceptibility to autoimmune disorder	J:104243
	increased T cell proliferation	J:104243
\Tg(Tcra,Tcrb)HRCAll/0 (B6.Cg-Tg(Tcra,Tcrb)HRCAll)	abnormal T cell subpopulation ratio	J:131347
	decreased CD4-positive, alpha-beta T cell number	J:131347
	decreased cytotoxic T cell cytolysis	J:131347
	decreased interferon-gamma secretion	J:131347
	increased CD8-positive, alpha-beta T cell number	J:131347
\Tg(Tcra,Tcrb)HRVAll/0 (B6.Cg-Tg(Tcra,Tcrb)HRVAll)	abnormal T cell subpopulation ratio	J:131347
	decreased CD4-positive, alpha-beta T cell number	J:131347
	increased CD8-positive, alpha-beta T cell number	J:131347
\Tg(TcraAI4)1Dvs/0 (NOD-Tg(TcraAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
\Tg(TcraAI4)1Dvs/0 (NOD-Tg(TcraAI4)1Dvs)	increased susceptibility to autoimmune diabetes	J:93553
\Tg(TcraAI4)1Dvs/0 \Tg(TcrbAI4)1Dvs/0 (NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
	abnormal CD8-positive, alpha beta T cell morphology	J:94192
	abnormal cytotoxic T cell physiology	J:94192
	increased susceptibility to autoimmune diabetes	J:94192
\Tg(TcraAV19AJ33)1Shima/? (involves: 129S4/SvJae * C57BL/6)	abnormal NK T cell morphology	J:112657
	abnormal NK T cell physiology	J:112657
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:112657
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)	decreased susceptibility to autoimmune diabetes	J:87251
	increased activated T cell number	J:52940
	insulitis	J:52940
\Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: C57BL/6 * NOD * SJL)	decreased dendritic cell number	J:137009
	immune system phenotype	J:135214
	insulitis	J:137009
\Tg(TcraCl1,TcrbCl1)1Shrm/0 (B10.Cg-Thy1^a H2^d Tg(TcraCl1,TcrbCl1)1Shrm)	abnormal T cell subpopulation ratio	J:97745
\Tg(TcraCl4,TcrbCl4)1Shrm/? (B10.Cg-H2^d Tg(TcraCl4,TcrbCl4)1Shrm)	abnormal CD8-positive, alpha-beta T cell differentiation	J:99756
	abnormal T cell subpopulation ratio	J:99756
\Tg(TcraDN32D3)#Alhn/0 (involves: NOD)	decreased NK cell number	J:201417
	decreased thymocyte number	J:201417
	increased double-negative T cell number	J:201417
\Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6J * C57L/J * DBA/2J)	abnormal double-negative T cell morphology	J:79738
	abnormal T cell differentiation	J:79738, J:90776
	decreased thymocyte number	J:79738
	thymus hypoplasia	J:79738
\Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * DBA/2J)	abnormal cytotoxic T cell physiology	J:66565
\Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
\Tg(TcraH-Y,TcrbH-Y)71Vbo/? \Themis^tm1Gasc/\Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal negative T cell selection	J:151074
	abnormal positive T cell selection	J:151074
\Tg(TcraH-Y,TcrbH-Y)71Vbo/? \Themis^tm1Lov/\Themis^tm1Lov (involves: 129 * C57BL/6 * DBA/2)	abnormal negative T cell selection	J:151075
	abnormal positive T cell selection	J:151075
	decreased single-positive T cell number	J:151075
	increased double-positive T cell number	J:151075
\Tg(TcraH-Y,TcrbH-Y)71Vbo/0 \Tnfrsf25^tm1Mjo/\Tnfrsf25^tm1Mjo (involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)	abnormal negative T cell selection	J:84536
	abnormal thymus morphology	J:84536
	increased thymocyte number	J:84536
\Tg(TcrAND)53Hed/? (involves: A/WySnSg * C57BL/6 * C57BL/10SnSg * SJL)	abnormal positive T cell selection	J:85777
	abnormal T cell differentiation	J:85777
	abnormal T cell proliferation	J:85777
	abnormal T cell subpopulation ratio	J:85777
	abnormal thymocyte activation	J:85777
	decreased CD8-positive, alpha-beta T cell number	J:85777
	decreased double-positive T cell number	J:85777
	increased CD4-positive, alpha-beta T cell number	J:85777
\Tg(TcrAND)53Hed/? (involves: C57BL/6 * SJL)	abnormal lymph node cell ratio	J:124701
\Tg(TcrAND)53Hed/? (involves: C57BL/6 * SJL)	increased CD4-positive, alpha-beta T cell number	J:124701
\Tg(TcrAND)53Hed/? \Themis^tm1Gasc/\Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6 * SJL)	abnormal positive T cell selection	J:151074
	decreased CD4-positive, alpha-beta T cell number	J:151074
	decreased CD8-positive, alpha-beta T cell number	J:151074
	increased double-positive T cell number	J:151074
\Tg(TcrAND)53Hed/? \Themis^tm1Lov/\Themis^tm1Lov (involves: 129 * C57BL/6 * SJL)	abnormal positive T cell selection	J:151075
	decreased single-positive T cell number	J:151075
	increased double-positive T cell number	J:151075
\Tg(TcrAND)53Hed/? \Zbtb7b^tm1.1Rbo/\Zbtb7b^tm1.1Rbo (involves: C57BL/6 * SJL)	abnormal T cell differentiation	J:141145
\Tg(TcraR28,TcrbR28)KRNDim/0 (involves: C57BL/6 * NOD * SJL)	abnormal lymphocyte cell number	J:36815
	abnormal macrophage chemotaxis	J:36815
	abnormal T cell activation	J:36815
	abnormal T cell anergy	J:36815
	abnormal T cell clonal deletion	J:36815
	abnormal T cell proliferation	J:36815
	chronic joint inflammation	J:36815
	decreased CD4-positive, alpha-beta T cell number	J:36815
	decreased CD8-positive, alpha-beta T cell number	J:36815
	enlarged spleen	J:36815
	glomerulonephritis	J:36815
	impaired neutrophil recruitment	J:36815
	increased B cell number	J:36815
	increased IgG1 level	J:36815
	kidney inflammation	J:36815
	rheumatoid arthritis	J:36815
\Tg(TcraTcrb)8Rest/? (C57BL/6-Tg(TcraTcrb)8Rest)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:85058
	abnormal cytotoxic T cell physiology	J:85058
	increased interferon-gamma secretion	J:85058
\Tg(TcraTcrb)425Cbn/0 (involves: BALB/c * C57BL/6)	abnormal positive T cell selection	J:125548
\Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6)	abnormal positive T cell selection	J:87876
\Tg(TcraTcrb)425Cbn/? (involves: BALB/c * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:87876
\Tg(TcraTcrb)425Cbn/0 (involves: C57BL/6)	abnormal cytokine level	J:112600
\Tg(TcraTcrb)425Cbn/0 \Trim30a^tm1Yjk/\Trim30a^tm1Yjk (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	increased T cell proliferation	J:215171
\Tg(TcraTcrb)425Cbn/0 \Trip10^tm1.1Geha/\Trip10^tm1.1Geha (B6.Cg-Trip10^tm1.1Geha Tg(TcraTcrb)425Cbn)	abnormal effector T cell morphology	J:164363
	decreased CD4-positive, alpha-beta T cell number	J:164363
	immune system phenotype	J:164363
\Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6)	abnormal CD8-positive, alpha beta T cell morphology	J:92867
	abnormal cytotoxic T cell physiology	J:92867, J:133645
	abnormal positive T cell selection	J:92867, J:133645
	abnormal T cell clonal deletion	J:92867
	abnormal T cell subpopulation ratio	J:92867, J:133645
	decreased CD4-positive, alpha-beta T cell number	J:133645
	increased CD8-positive, alpha-beta T cell number	J:92867, J:133645
	increased T cell proliferation	J:92867
\Tg(TcraTcrb)1100Mjb/? (involves: C57BL/6 * MRL/Mp)	liver inflammation	J:72817
\Tg(TcraTcrb)1100Mjb/? \Themis^tm1Gasc/\Themis^tm1Gasc (involves: 129S6/SvEvTac * C57BL/6)	abnormal positive T cell selection	J:151074
	decreased CD8-positive, alpha-beta T cell number	J:151074
	increased double-positive T cell number	J:151074
\Tg(TcraTcrbNY4.1)1Pesa/0 (NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)	increased susceptibility to autoimmune diabetes	J:108768
\Tg(TcraTcrbNY4.1)1Pesa/0 (NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)	insulitis	J:108768
\Tg(TcraTcrbNY8.3)1Pesa/? (involves: C57BL/6 * NOD * SJL)	pancreas inflammation	J:44202
\Tg(TcraY1,TcrbY1)416Tev/0 (involves: C57BL/6J * DBA/2J)	abnormal immune tolerance	J:84288
\Tg(Tcrb)93Vbo/0 (involves: C57BL/LiA * CBA/BrA)	abnormal T cell morphology	J:93247
\Tg(Tcrb)93Vbo/0 (involves: C57BL/LiA * CBA/BrA)	abnormal T cell receptor beta chain V(D)J recombination	J:93247
\Tg(Tcrb)93Vbo/0 (involves: C57BL/6 * C57BL/LiA * CBA/BrA)	abnormal CD8-positive, alpha-beta T cell differentiation	J:66565
	abnormal cytotoxic T cell physiology	J:66565
	abnormal T cell clonal deletion	J:66565
\Tg(Tcrb)HRBAll/0 (B6.Cg-Tg(Tcrb)HRBAll)	immune system phenotype	J:131347
\Tg(Tcrb-TCF3/PBX1)19Gusa/0 (involves: C3H * C57BL/6 * C57BL/6J)	decreased thymocyte number	J:95693
\Tg(Tcrb-TCF3/PBX1)23Gusa/0 (involves: C3H * C57BL/6 * C57BL/6J)	decreased thymocyte number	J:95693
\Tg(TcrbAI4)1Dvs/0 (NOD-Tg(TcrbAI4)1Dvs)	abnormal CD4-positive, alpha beta T cell morphology	J:93553
\Tg(TcrbBL17)1Lmor/0 (involves: DBA/1J * SWR/J)	increased susceptibility to induced arthritis	J:134111
\Tg(TcrbBL17)1Lmor/\Tg(TcrbBL17)1Lmor (involves: DBA/1J * SWR/J)	increased susceptibility to induced arthritis	J:134111
\Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:73608
	abnormal interleukin secretion	J:73608
	abnormal T cell activation	J:73608
	increased T cell proliferation	J:73608
\Tg(TcrHEL3A9)1Mmd/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal double-positive T cell morphology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	abnormal thymus cell ratio	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
\Tg(TcrHEL3A9)1Mmd/0 \Tg(TLK2mHEL)2Ccg/0 (involves: C57BL/6 * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:78309
	abnormal CD4-positive, alpha-beta T cell physiology	J:78309
	abnormal T cell activation	J:78309
	abnormal T cell proliferation	J:78309
	decreased CD4-positive, alpha-beta T cell number	J:78309
	decreased double-positive T cell number	J:78309
	thyroid gland inflammation	J:78309
\Tg(TcrLCMV)1Aox/? (C57BL/6-Tg(TcrLCMV)1Aox)	abnormal cytotoxic T cell physiology	J:92228
	decreased CD8-positive, alpha-beta T cell number	J:92228
	decreased double-positive T cell number	J:92228
	increased CD4-positive, alpha-beta T cell number	J:92228
	increased double-negative T cell number	J:92228
	increased IgG level	J:92228
\Tg(TcrLCMV)2Aox/? (C57BL/6-Tg(TcrLCMV)2Aox)	abnormal cytotoxic T cell physiology	J:92228
	decreased CD8-positive, alpha-beta T cell number	J:92228
	decreased double-positive T cell number	J:92228
	increased CD4-positive, alpha-beta T cell number	J:92228
	increased double-negative T cell number	J:92228
\Tg(TcrLCMV)327Sdz/0 (involves: C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:77696
	decreased cytotoxic T cell cytolysis	J:77696
	decreased double-positive T cell number	J:77696
	decreased T cell proliferation	J:77696
	thymus hypoplasia	J:77696
\Tg(TcrLCMV)327Sdz/? (involves: C57BL/6 * DBA/2J)	abnormal T cell differentiation	J:97610
\Tg(TcrLCMV)327Sdz/? (involves: C57BL/6 * DBA/2J)	decreased CD4-positive, alpha-beta T cell number	J:97610
\Tg(TcrLCMV)327Sdz/\Tg(TcrLCMV)327Sdz (NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs)	autoimmune response	J:71050
\Tg(Tek-cre)1Ywa/0 \Thbd^tm2Rdr/\Thbd^tm2Wlr (involves: 129S2/SvPas * C57BL/6 * SJL)	abnormal acute phase protein level	J:71269
	increased circulating interleukin-6 level	J:71269
	increased spleen weight	J:71269
\Tg(Tek-cre)1Ywa/0 \Trp53^tm1Brn/\Trp53^tm1Brn (involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)	increased T cell derived lymphoma incidence	J:263520
\Tg(Tek-Jam3)1Maal/? (B6.Cg-Tg(Tek-Jam3)1Maal)	abnormal cellular extravasation	J:99020
	abnormal leukocyte adhesion	J:99020
	abnormal leukocyte physiology	J:99020
	impaired neutrophil chemotaxis	J:99020
	lung inflammation	J:99020
	peritoneal inflammation	J:99020
\Tg(Tek-Procr)1Cte/0 (B6.FVB-Tg(Tek-Procr)1Cte)	abnormal acute phase protein level	J:119637
	abnormal immune system physiology	J:119637
	abnormal inflammatory response	J:119637
\Tg(Tek-Tnf)5382Mcla/0 (B6.Cg-Tg(Tek-Tnf)5382Mcla)	chronic inflammation	J:71622
	chronic liver inflammation	J:71622
	decreased inflammatory response	J:71622
	kidney inflammation	J:71622
	lung inflammation	J:71622
\Tg(Tek-tTA)1Dmt/0 \Tg(tetO-Tek)1Dmt/0 (involves: CD-1)	abnormal spleen red pulp morphology	J:137745
	abnormal spleen white pulp morphology	J:137745
	enlarged spleen	J:137745
	increased eosinophil cell number	J:137745
	increased T cell number	J:137745
	skin inflammation	J:96718, J:137745
\Tg(tetO-BCR/ABL1)2Dgt/0 \Tg(MMTVtTA)1Mam/0 (involves: C57BL/6 * FVB/N * SJL)	enlarged lymph nodes	J:72377
	enlarged spleen	J:72377
	increased leukocyte cell number	J:72377
\Tg(tetO-BCR/ABL1)2Dgt/0 \Tg(Tal1-tTA)19Dgt/0 (involves: C57BL/6 * DBA/2 * FVB/N)	abnormal lymph node morphology	J:96511
	abnormal lymphopoiesis	J:96511
	abnormal spleen red pulp morphology	J:96511
	abnormal splenic cell ratio	J:96511
	enlarged spleen	J:96511
	increased leukocyte cell number	J:96511
	increased neutrophil cell number	J:96511
\Tg(tetO-BCR/ABL1)27Dgt/0 \Tg(MMTVtTA)1Mam/0 (involves: C57BL/6 * FVB/N * SJL)	enlarged lymph nodes	J:72377
	enlarged spleen	J:72377
	increased leukocyte cell number	J:72377
\Tg(tetO-MAP2K1)#Ahsa/? \Tg(CD2-rtTA)CRza/? (involves: C57BL/6 * C57BL/10 * CBA * SJL)	immune system phenotype	J:174339
	increased anti-double stranded DNA antibody level	J:174339
\Tg(tetO/CMV-CD200)1Rmgo/\Tg(tetO/CMV-CD200)1Rmgo (involves: C57BL/6)	abnormal dendritic cell physiology	J:134313
\Tg(TetOp-Polb/tTA)2Sbl/0 (B6.Cg-Tg(TetOp-Polb/tTA)2Sbl)	glomerulonephritis	J:152481
\Tg(TG-SV40)#Cled/0 (involves: C57BL/6J * DBA/2J)	spleen hypoplasia	J:209788
\Tg(TG-SV40)#Cled/0 (involves: C57BL/6J * DBA/2J)	thymus hypoplasia	J:209788
\Tg(TG-TSHR)51.9Smcl/? (involves: BALB/c * C57BL/6)	immune system phenotype	J:118100
\Tg(Tgfa)1Efu/0 (Not Specified)	ear inflammation	J:65045
\Tg(Th-SNCA)5Eric/\Tg(Th-SNCA)5Eric (involves: C57BL/6)	abnormal microglial cell physiology	J:140907
\Tg(THY1-APP)2Somm/0 (involves: C57BL/6J * DBA/2)	brain inflammation	J:44603
\Tg(Thy1-APP)3Somm/0 (involves: C57BL/6J * DBA/2)	brain inflammation	J:44603
\Tg(Thy1-APP)3Somm/0 (involves: C57BL/6J * DBA/2)	microgliosis	J:134832
\Tg(Thy1-AppR609DK612E)2Vln/0 (involves: C57BL * CBA/J)	abnormal microglial cell morphology	J:32213
\Tg(Thy1-AppR609DK612E)4Vln/0 (involves: FVB)	abnormal microglial cell morphology	J:32213
\Tg(Thy1-AppR609DK612E)6Vln/0 (involves: FVB)	abnormal microglial cell morphology	J:32213
\Tg(Thy1-APPDutch)#Jckr/0 (involves: C57BL/6J)	microgliosis	J:92796
\Tg(Thy1-APPSw)10Jiri/0 (involves: C3H * C57BL/6)	microgliosis	J:128647
\Tg(Thy1-APPSw)10Jiri/0 \Tg(Thy1-PSEN1M146V)#Jiri/0 (B6.Cg-Tg(Thy1-APPSw)10Jiri Tg(Thy1-PSEN1M146V)#Jiri)	microgliosis	J:156577
\Tg(Thy1-APPSwDutIowa)BWevn/0 (involves: C57BL/6)	abnormal microglial cell physiology	J:124911
\Tg(Thy1-APPSweLon)41Ema/0 (involves: C57BL/6 * DBA/2)	microgliosis	J:162842
\Tg(Thy1-cmyc)6Kio/0 (Not Specified)	increased T cell derived lymphoma incidence	J:129440
\Tg(Thy1-cmyc)6LKio/0 (Not Specified)	increased T cell derived lymphoma incidence	J:129440
\Tg(Thy1-Fcer2a)2431Putt/? (involves: BALB/c * C57BL/6)	abnormal immune system physiology	J:129296
	decreased IgE level	J:20421
	decreased IgG1 level	J:20421
	increased eosinophil cell number	J:20421
\Tg(Thy1-Fcer2a)2733Putt/? (involves: BALB/c * C57BL/6)	immune system phenotype	J:20421
\Tg(Thy1-FUS)1Dit/0 (B6.Cg-Tg(Thy1-FUS)1Dit)	microgliosis	J:287782
\Tg(Thy1-FUS)1Dit/0 \Tg(Thy1-TARDBP)4Singh/0 (involves: C57BL/6J DBA/2J * SJL/J)	microgliosis	J:287782
\Tg(Thy1-FUS)19Vlb/0 (B6.Cg-Tg(Thy1-FUS)19Vlb)	microgliosis	J:203550
\Tg(Thy1-MAPT)1Avil/\Tg(Thy1-MAPT)1Avil (involves: C57BL/6 * CBA)	microgliosis	J:201700
\Tg(Thy1-MAPTP301S)2541Godt/\Tg(Thy1-MAPTP301S)2541Godt (involves: C57BL/6J * CBA/Ca)	eye inflammation	J:108870
\Tg(Thy1-PSEN1M146V,-APPSwe)10Arte/\Tg(Thy1-PSEN1M146V,-APPSwe)10Arte (involves: C57BL/6 * CBA)	microgliosis	J:155410
\Tg(Thy1-Snca)1S13Putt/? (involves: C57BL/6)	microgliosis	J:177661
\Tg(Thy1-SNCA)61Ema/0 (involves: C57BL/6 * DBA/2)	abnormal microglial cell activation	J:238066
\Tg(Thy1-SNCA)61Ema/0 (involves: C57BL/6 * DBA/2)	abnormal microglial cell morphology	J:238066
\Tg(Thy1-Sncg)HvP36Putt/? (C57BL/6-Tg(Thy1-Sncg)HvP36Putt)	microgliosis	J:185793
\Tg(Thy1-TARDBP)4Singh/0 (involves: C57BL/6J * SJL/J)	microgliosis	J:157550
\Tg(Thy1-TARDBP)4Singh/\Tg(Thy1-TARDBP)4Singh (involves: C57BL/6J * SJL/J)	microgliosis	J:157550
\Tg(Thy1-TARDBP)6Singh/\Tg(Thy1-TARDBP)6Singh (involves: C57BL/6 * C57BL/6J * SJL)	microgliosis	J:157550
\Tg(Thy1-UBQLN2P497S)3Mont/? (involves: C3H C57BL/6 * C57BL/6J)	increased microglial cell activation	J:239510
\Tg(Thy1-UBQLN2P506T)6Mont/? (involves: C3H C57BL/6 * C57BL/6J)	decreased microglial cell activation	J:239510
\Tg(Thy1/THY1)T6Gsv/0 (involves: C57BL/10 * CBA)	abnormal mononuclear cell morphology	J:294621
	increased macrophage derived foam cell number	J:294621
	increased neutrophil cell number	J:294621
\Tg(Thy1/THY1)T12Gsv/0 (involves: C57BL/10 * CBA)	increased IgG level	J:133943
\Tg(Thy1/THY1)T12Gsv/0 (involves: C57BL/10 * CBA)	increased IgM level	J:133943
\Tg(Tk1-DPP4)27Ysj/0 (involves: C57BL/6 * FVB/N)	abnormal chemokine level	J:290259
	abnormal innate immunity	J:290259
	abnormal interleukin level	J:290259
	abnormal macrophage activation involved in immune response	J:290259
	abnormal tumor necrosis factor level	J:290259
	increased susceptibility to Coronaviridae infection	J:290259
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:290259
	lung inflammation	J:290259
\Tg(Tlr7)1Boll/0 (involves: C57BL/6)	abnormal circulating chemokine level	J:127600
	abnormal dendritic cell morphology	J:127600
	abnormal spleen morphology	J:127600
	autoimmune response	J:127600
	decreased spleen white pulp amount	J:127600
	enlarged spleen	J:127600
	glomerulonephritis	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased circulating interleukin-6 level	J:127600
	increased circulating tumor necrosis factor level	J:127600
	liver inflammation	J:127600
X/\Tg(Tlr7)6Boll (involves: C57BL/6)	abnormal B cell activation	J:127600
	abnormal B cell morphology	J:127600
	abnormal dendritic cell morphology	J:127600
	abnormal T cell activation	J:127600
	autoimmune response	J:127600
	decreased marginal zone B cell number	J:127600
	enlarged spleen	J:127600
	glomerulonephritis	J:127600
	increased anti-nuclear antigen antibody level	J:127600
	increased mature B cell number	J:127600
	increased splenocyte proliferation	J:127600
	liver inflammation	J:127600
	lung inflammation	J:127600
\Tg(TNF)197Gkl/0 (involves: C57BL/6 * CBA)	abnormal osteoclast differentiation	J:97992
	autoimmune arthritis	J:97992, J:92576
	increased osteoclast cell number	J:97992
\Tg(TNF)197Gkl/0 \Tnfrsf1a^tm1.1Gkl/\Tnfrsf1a^tm1.1Gkl (involves: 129 * C57BL/6 * CBA)	autoimmune arthritis	J:92470
\Tg(TNF)3647Gkl/0 (involves: C57BL/6 * CBA)	autoimmune arthritis	J:190204
\Tg(Tnf)6074Gkl/0 (involves: C57BL/6 * CBA)	abnormal microglial cell morphology	J:106592
\Tg(Tnf)6074Gkl/0 (involves: C57BL/6 * CBA)	brain inflammation	J:106592
\Tg(Tnf)6074Gkl/0 \Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6 * CBA)	CNS inflammation	J:106592
\Tg(TNFSF11)5516Edou/0 \Tnfsf11^tles/\Tnfsf11^tles (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	absent lymph nodes	J:233240
\Tg(TNFSF11)5519Edou/0 (involves: C57BL/6J * CBA/J)	increased osteoclast cell number	J:233240
\Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6 * DBA/2J)	abnormal B cell morphology	J:58798
	abnormal B cell physiology	J:58798
	abnormal spleen follicular dendritic cell network	J:58798
	abnormal spleen morphology	J:58798
	abnormal spleen periarteriolar lymphoid sheath morphology	J:58798
	abnormal T cell number	J:58798
	abnormal T cell physiology	J:58798
	abnormal T cell subpopulation ratio	J:58798
	enlarged lymph nodes	J:58798
	enlarged Peyer's patches	J:58798
	enlarged spleen	J:58798
	increased anti-double stranded DNA antibody level	J:58798
	increased anti-single stranded DNA antibody level	J:58798
	increased autoantibody level	J:58798
	increased B cell number	J:58798
	increased IgG level	J:58798
	increased IgM level	J:58798
	increased immunoglobulin level	J:58798
	increased lymphocyte cell number	J:58798
	increased marginal zone B cell number	J:58798
	increased mature B cell number	J:58798
	increased plasma cell number	J:58798
	increased spleen B cell follicle size	J:58798
	increased spleen germinal center size	J:58798
	increased T cell number	J:58798
\Tg(Tnfsf13b)1Fma/0 (B6.Cg-Tg(Tnfsf13b)1Fma)	abnormal B cell differentiation	J:73711
	abnormal B-1 B cell morphology	J:114782
	abnormal spleen germinal center morphology	J:114782
	abnormal spleen marginal zone morphology	J:114782
	increased autoantibody level	J:114782
	increased B cell number	J:114782
	increased B-1a cell number	J:114782
	increased B-1b cell number	J:114782
	increased IgA level	J:114782
	increased plasma cell number	J:114782
	kidney inflammation	J:73711
	salivary gland inflammation	J:73711
\Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6J * DBA/2J)	abnormal B cell differentiation	J:115788
\Tg(Tnfsf13b)1Fma/0 (involves: C57BL/6J * DBA/2J)	abnormal B-1 B cell morphology	J:115788
\Tg(Tnfsf13b)1Fma/? (B6.Cg-Tg(Tnfsf13b)1Fma)	abnormal B cell activation	J:113556
	abnormal marginal zone B cell physiology	J:113556
	abnormal spleen marginal zone morphology	J:113556
	glomerulonephritis	J:113556
	increased anti-double stranded DNA antibody level	J:113556
	increased B cell number	J:113556
	increased marginal zone B cell number	J:113556
	increased transitional stage B cell number	J:113556
\Tg(Tnfsf13b)1Fma/? \Tnfrsf13b^tm1Rjb/\Tnfrsf13b^tm1Rjb (B6.Cg-Tnfrsf13b^tm1Rjb Tg(Tnfsf13b)1Fma)	abnormal class switch recombination	J:113556
\Tg(Tnfsf13b)1Fma/? \Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (B6.Cg-Tnfrsf13c^tm1Mass Tg(Tnfsf13b)1Fma)	abnormal class switch recombination	J:113556
\Tg(Tnfsf13b)1Fma/0 \Tnfsf14^tm1Kpf/\Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)	abnormal spleen germinal center morphology	J:114782
	abnormal spleen marginal zone morphology	J:114782
	increased B cell number	J:114782
	increased IgA level	J:114782
	increased plasma cell number	J:114782
\Tg(Tnfsf13b)1Fma/\Tg(Tnfsf13b)1Fma (involves: C57BL/6 * DBA/2)	abnormal immunoglobulin level	J:178227
	increased B cell number	J:178227
	increased IgA level	J:178227
	increased IgM level	J:178227
	increased immunoglobulin level	J:178227
	increased marginal zone B cell number	J:178227
	increased transitional stage T2 B cell number	J:178227
	kidney inflammation	J:178227
\Tg(Tox)1Kay/? \Tox^tm1.1Kay/\Tox^tm1.1Kay (involves: 129S6/SvEvTac * C57BL/6)	abnormal T cell number	J:131287
\Tg(Trp53)1Srn/0 (involves: C57BL/6 * CBA)	increased thymocyte apoptosis	J:80311
\Tg(Trp53)1Srn/0 \Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte apoptosis	J:80311
\Tg(Trp53)bSrn/0 (involves: C57BL/6 * CBA)	increased thymocyte apoptosis	J:80311
\Tg(Trp53A135V)L3Ber/0 (involves: C57BL/6 * CD-1)	decreased spleen weight	J:73757
\Tg(Ttr-IGF1)1Sykr/0 (FVB/N-Tg(Ttr-IGF1)1Sykr)	increased spleen weight	J:157350
\Tg(Tyr-NRASQ61K)1Bee/? (involves: BALB/c C57BL/6J * DBA/2)	skin inflammation	J:98545
\Tg(Tyr-NRASQ61K)1Bee/? (involves: C57BL/6J DBA/2)	skin inflammation	J:98545
\Tg(UBC-scFv)2Nemz/0 (involves: C57BL/6 * DBA/2)	abnormal B cell differentiation	J:96759
	abnormal B cell morphology	J:96759
	abnormal B cell receptor editing	J:96759
	abnormal B-1 B cell morphology	J:96759
	abnormal immune tolerance	J:96759
	abnormal immunoglobulin level	J:96759
	abnormal mature B cell morphology	J:96759
	decreased mature B cell number	J:96759
	decreased splenocyte number	J:96759
	spleen hypoplasia	J:96759
\Tg(Umod*C147W)958Lura/0 (involves: FVB)	kidney inflammation	J:161532
\Tg(Vav1-Asxl1Y588X)#Fcy/0 (C57BL/6-Tg(Vav1-Asxl1Y588X)#Fcy)	abnormal neutrophil morphology	J:257690
	abnormal spleen morphology	J:257690
	decreased leukocyte cell number	J:257690
	decreased lymphocyte cell number	J:257690
	enlarged spleen	J:257690
	hepatosplenomegaly	J:257690
	increased leukocyte cell number	J:257690
	increased monocyte cell number	J:257690
	increased neutrophil cell number	J:257690
\Tg(VAV1-cre)1Graf/? \Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/? \Trip11^tm1.1Psmi/\Trip11^tm1.2Psmi (involves: 129/Sv * C57BL/6)	immune system phenotype	J:253969
\Tg(Vav1-ERG)#Jpim/0 (involves: C57BL/6)	abnormal thymus morphology	J:174808
	enlarged spleen	J:174808
	enlarged thymus	J:174808
\Tg(Vav1-JAK2V617F)AZjz/0 (involves: C57BL/6 DBA/2)	enlarged spleen	J:135993
	increased granulocyte number	J:135993
	increased leukocyte cell number	J:135993
	increased spleen weight	J:135993
	spleen fibrosis	J:135993
\Tg(Vav1-Lin28b)C3Apla/0 (involves: C57BL/6)	abnormal cytokine level	J:189197
	abnormal inflammatory response	J:189197
	abnormal T cell differentiation	J:189197
	abnormal thymus cell ratio	J:189197
	abnormal thymus cortex morphology	J:189197
	abnormal thymus corticomedullary boundary morphology	J:189197
	decreased CD4-positive, alpha-beta T cell number	J:189197
	decreased CD8-positive, alpha-beta T cell number	J:189197
	decreased double-positive T cell number	J:189197
	decreased leukocyte cell number	J:189197
	decreased lymphocyte cell number	J:189197
	decreased thymocyte number	J:189197
	enlarged lymph nodes	J:189197
	enlarged spleen	J:189197
	enlarged thymus medulla	J:189197
	increased CD8-positive, alpha-beta T cell number	J:189197
	increased effector memory CD4-positive, alpha-beta T cell number	J:189197
	increased effector memory CD8-positive, alpha-beta T cell number	J:189197
	increased eosinophil cell number	J:189197
	increased IgG level	J:189197
	increased neutrophil cell number	J:189197
	increased T cell derived lymphoma incidence	J:189197
	increased T cell proliferation	J:189197
\Tg(Vav1-NUP98/HOXD13)C1Apla/0 (FVB/N-Tg(Vav1-NUP98/HOXD13)C1Apla)	abnormal neutrophil morphology	J:107446
	decreased leukocyte cell number	J:107446
\Tg(Vav1-NUP98/HOXD13)G2Apla/0 (C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla)	abnormal neutrophil morphology	J:107446
	decreased leukocyte cell number	J:107446
	decreased lymphocyte cell number	J:107446
	decreased neutrophil cell number	J:107446
\Tg(Vav1-STAT5BN642H)726Biat/0 (C57BL/6NCrl-Tg(Vav1-STAT5BN642H)726Biat)	abnormal effector T cell number	J:257519
	abnormal lymph node morphology	J:257519
	abnormal spleen morphology	J:257519
	enlarged spleen	J:257519
	increased CD4-positive, alpha-beta T cell number	J:257519
	increased CD8-positive, alpha-beta T cell number	J:257519
	increased leukocyte cell number	J:257519
	increased T cell proliferation	J:257519
\Tg(Vav-BCL2)69Jad/0 (involves: C57BL/6J)	abnormal class switch recombination	J:88565
	abnormal lymphocyte cell number	J:88565
	abnormal somatic hypermutation frequency	J:88565
	abnormal spleen germinal center morphology	J:88565
	enlarged lymph nodes	J:88565
	enlarged spleen	J:88565
	glomerulonephritis	J:88565
	increased B cell number	J:88565
	increased CD4-positive, alpha-beta T cell number	J:88565
	increased CD8-positive, alpha-beta T cell number	J:88565
	increased spleen germinal center number	J:88565
	increased spleen germinal center size	J:88565
	increased T cell derived lymphoma incidence	J:88565
	increased T cell number	J:88565
\Tg(Vil1-cre)997Gum/? \Tlr4^lps-del/\Tlr4^lps-del \Tlr5^tm1.1Gewr/\Tlr5^tm1.1Gewr (involves: C57BL/6J * C57BL/6NTac * C57BL/10ScN * SJL)	large intestinal inflammation	J:229155
\Tg(Vil1-cre)997Gum/? \Tlr5^tm1.1Gewr/\Tlr5^tm1.1Gewr (involves: C57BL/6J * C57BL/6NTac * SJL/J)	enlarged spleen	J:229155
	increased interleukin-1 beta secretion	J:229155
	increased susceptibility to colitis induced morbidity/mortality	J:229155
	large intestinal inflammation	J:229155
\Tg(Vil1-cre)997Gum/0 \Tnfrsf11a^tm1.1Irw/\Tnfrsf11a^tm1.1Irw (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac * SJL)	abnormal Peyer's patch epithelium morphology	J:219915, J:226603
	abnormal Peyer's patch follicle morphology	J:226603
	abnormal Peyer's patch germinal center morphology	J:226603
	abnormal Peyer's patch morphology	J:226603
	abnormal Peyer's patch T cell area morphology	J:226603
	decreased IgA level	J:226603
	decreased plasma cell number	J:226603
\Tg(Vil-SLC3A2)HEMerl/0 (involves: FVB/N)	colitis	J:173946
	increased circulating tumor necrosis factor level	J:173946
	increased susceptibility to induced colitis	J:173946
\Tg(VIM-Tag)3Pau/0 (involves: C57BL/6 * SJL/J)	enlarged thymus	J:91542
	increased double-negative T cell number	J:91542
	thymus hyperplasia	J:91542
\Tg(VIM-Tag)3Pau/0 (either: (involves: C57BL/6 * CBA * SJL/J) or (involves: C57BL/6 * SJL/J))	glomerulonephritis	J:92226
\Tg(Wnt1)1Hev/0 \Zfp451^em1Ssli/\Zfp451^em1Ssli (involves: C57BL/6 * SJL)	abnormal macrophage morphology	J:338905
	decreased chemokine level	J:338905
\Tg^m3Btlr/\Tg^m3Btlr (C57BL/6J-Tg^m3Btlr)	decreased B cell number	J:265197
	decreased IgE level	J:265197
	increased susceptibility to induced colitis	J:265197
\Tg^m4Btlr/\Tg^m4Btlr (C57BL/6J-Tg^m4Btlr)	decreased B cell number	J:272522
	decreased B-2 B cell number	J:272522
	increased alpha-beta T cell number	J:272522
	increased B-1a cell number	J:272522
	increased CD4-positive, alpha-beta T cell number	J:272522
	increased CD8-positive, alpha-beta T cell number	J:272522
	increased central memory CD4-positive, alpha-beta T cell number	J:272522
	increased IgE level	J:272522
	increased macrophage cell number	J:272522
\Tg^M5Btlr/\Tg^M5Btlr (C57BL/6J-Tg^M5Btlr)	increased central memory CD4-positive, alpha-beta T cell number	J:272523
\Tg^m6Btlr/\Tg^m6Btlr (C57BL/6J-Tg^m6Btlr)	increased alpha-beta T cell number	J:272525
\tga/\tga (C57BL/6J-tga)	thymus hypoplasia	J:94456
\Tgfa^tm1Ard/\Tgfa^tm1Ard (involves: 129P2/OlaHsd * C57BL/6)	increased incidence of corneal inflammation	J:4606
\Tgfa^tm1Unc/\Tgfa^tm1Unc (involves: 129P2/OlaHsd * C57BL/6J)	immune system phenotype	J:4605
\Tgfa^wa1/\Tgfa^wa1 (Not Specified)	conjunctivitis	J:13115
\Tgfa^wa1/\Tgfa^wa1 (Not Specified)	keratoconjunctivitis	J:13115
\Tgfb1^{tm1(Tgfb3)Kul}/\Tgfb1^{tm1(Tgfb3)Kul} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell morphology	J:204892
	immune system phenotype	J:204892
	increased monocyte cell number	J:204892
	increased regulatory T cell number	J:204892
\Tgfb1^tm1Doe/\Tgfb1^tm1Doe (involves: 129S2/SvPas * CF-1)	abnormal inflammatory response	J:2892
	abnormal Peyer's patch germinal center morphology	J:2892
	brain inflammation	J:2892
	conjunctivitis	J:2892
	decreased Peyer's patch number	J:2892
	diaphragmitis	J:2892
	enlarged lymph nodes	J:2892
	eye inflammation	J:2892
	heart inflammation	J:2892
	increased leukocyte cell number	J:2892
	lacrimal gland inflammation	J:2892
	liver inflammation	J:2892
	lung inflammation	J:2892
	myositis	J:2892
	pancreas inflammation	J:2892
	salivary gland inflammation	J:2892
	skin inflammation	J:2892
	small spleen	J:2892
	stomach inflammation	J:2892
\Tgfb1^tm1Doe/\Tgfb1^tm1Doe (involves: 129S2/SvPas * BALB/c * CF-1)	heart inflammation	J:69346
	increased interferon-gamma secretion	J:69346
	liver inflammation	J:69346
	lung inflammation	J:69346
\Tgfb1^tm1Doe/\Tgfb1^tm1Doe (C.129S2-Tgfb1^tm1Doe)	decreased CD4-positive, alpha-beta T cell number	J:69346
	heart inflammation	J:69346
	increased CD4-positive, alpha-beta T cell number	J:69346
	increased interferon-gamma secretion	J:69346
	increased T-helper 1 cell number	J:69346
	liver inflammation	J:69346
\Tgfb1^tm1Doe/\Tgfb1^tm2.1Doe \Tg(Lck-cre)548Jxm/? (involves: 129S2/SvPas * 129S6/SvEvTac * Black Swiss * BALB/c * C57BL/6 * CBA)	lung inflammation	J:150024
	salivary gland inflammation	J:150024
\Tgfb1^tm1Jmu/\Tgfb1^tm1Jmu (involves: 129S6/SvEvTac * C57BL/6)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
	heart inflammation	J:120085
	liver inflammation	J:120085
	lung inflammation	J:120085
	pancreas inflammation	J:120085
	stomach inflammation	J:120085
\Tgfb1^tm1Jmu/\Tgfb1^tm1Jmu (involves: 129S6/SvEvTac * C57BL/6 * Swiss Webster)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
\Tgfb1^tm1N/\Tgfb1^tm1N (involves: 129S/SvEv)	abnormal immune system physiology	J:120085
	absent Langerhans cell	J:120085
	atrial endocarditis	J:50848
	increased inflammatory response	J:50848
	interstitial pneumonia	J:50848
	lymph node inflammation	J:50848
	myocarditis	J:50848
	pancreas inflammation	J:50848
	pericarditis	J:50848
	phlebitis	J:50848
	salivary gland inflammation	J:50848
\Tgfb1^tm1Rif/\Tgfb1^tm1Rif (Not Specified)	abnormal immune system physiology	J:141786
\Tgfb1^tm1Rif/\Tgfb1^tm1Rif (either: (involves: 129) or (involves: 129S/SvEv * C57BL/6))	absent Langerhans cell	J:142353
	cecum inflammation	J:142353
	heart inflammation	J:142353
	increased inflammatory response	J:142353
	large intestinal inflammation	J:142353
	lung inflammation	J:142353
	proctitis	J:142353
	small intestinal inflammation	J:142353
	stomach inflammation	J:142353
\Tgfb1^tm2Flv/\B9d2/Tgfb1^tm1Flv \Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
\Tgfb1^tm3.1Flv/\Tgfb1^tm3.1Flv \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD)	increased regulatory T cell number	J:196160
	increased T-helper 1 cell number	J:196160
\Tgfb1^tm3.1Flv/\Tgfb1^tm3.1Flv \Tg(Cd4-cre)1Cwi/0 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)	increased regulatory T cell number	J:196160
	increased susceptibility to autoimmune diabetes	J:196160
	increased T-helper 1 cell number	J:196160
\Tgfb2^tm1Doe/\Tgfb2^tm1Doe (involves: 129P2/OlaHsd * Black Swiss)	abnormal macrophage physiology	J:73681
\Tgfb3^{tm1.1(KOMP)Vlcg}/\Tgfb3⁺ (C57BL/6N-Tgfb3^{tm1.1(KOMP)Vlcg}/Tcp)	enlarged lymph nodes	J:211773
\Tgfbi^tm1Zhao/\Tgfbi^tm1Zhao (involves: 129 * C57BL/6J)	enlarged spleen	J:143036
\Tgfbi^tm1Zhao/\Tgfbi^tm1Zhao (involves: 129 * C57BL/6J)	increased B cell number	J:143036
\Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(Cd4-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	abnormal T cell activation	J:148747
	autoimmune response	J:148747
	liver inflammation	J:148747
\Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD)	increased inflammatory response	J:196160
\Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(Cd4-cre)1Cwi/0 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)	abnormal abdominal lymph node morphology	J:196160
	abnormal immune serum protein physiology	J:196160
	abnormal immune system morphology	J:196160
	abnormal immune system organ morphology	J:196160
	abnormal immune system physiology	J:196160
	abnormal interleukin secretion	J:196160
	abnormal spleen morphology	J:196160
	decreased interleukin-9 secretion	J:196160
	decreased interleukin-17 secretion	J:196160
	decreased regulatory T cell number	J:196160
	immune system phenotype	J:196160
	increased interferon-gamma secretion	J:196160
	increased interleukin-2 secretion	J:196160
	increased interleukin-21 secretion	J:196160
	increased regulatory T cell number	J:196160
	increased susceptibility to autoimmune diabetes	J:196160
	pancreas inflammation	J:196160
\Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(CD207-cre)1Dhka/? (involves: 129S6/SvEvTac * C57BL/6J * SJL/J)	decreased Langerhans cell number	J:126147
\Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tg(Foxp3-EGFP/cre)1cJbs/0 \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129S6/SvEvTac * C57BL/6 * NOD * SJL)	immune system phenotype	J:196160
	increased regulatory T cell number	J:196160
\Tgfbr2^tm1.2Hlm/\Tgfbr2^tm1.2Hlm \Tnfrsf4^tm2(cre)Nik/\Tnfrsf4⁺ \Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0 (involves: 129 * C57BL/6 * NOD * SJL)	immune system phenotype	J:196160
	increased susceptibility to autoimmune diabetes	J:196160
\Tgfbr2^tm1Karl/\Tgfbr2^tm1Karl \H2az2^{Tg(Wnt1-cre)11Rth}/\H2az2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	small thymus	J:96359
\Tgfbr2^tm1Karl/\Tgfbr2^tm1Karl \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)	eye inflammation	J:77844
	increased inflammatory response	J:77844
	liver inflammation	J:77844
	pancreas inflammation	J:77844
	small thymus	J:77844
	stomach inflammation	J:77844
\Tgfbr3^tm1Stv/\Tgfbr3^tm1Stv (involves: 129/Sv * C57BL/6)	abnormal spleen morphology	J:83727
\Tgfbr3^tm1Stv/\Tgfbr3^tm1Stv (involves: 129/Sv * C57BL/6)	decreased spleen white pulp amount	J:83727
\Tgif1^tm1.1Caw/\Tgif1^tm1.1Caw (B6.129S-Tgif1^tm1.1Caw)	abnormal cytokine level	J:198238
\Tgif1^tm1.1Caw/\Tgif1^tm1.1Caw (B6.129S-Tgif1^tm1.1Caw)	increased susceptibility to otitis media	J:198238
\Tgm2^tm1.1Rmgr/\Tgm2^tm1.1Rmgr (involves: 129S1/SvImJ * C57BL/6)	abnormal T cell physiology	J:95130
\Tgm2^tm1Gml/\Tgm2^tm1Gml (involves: C57BL/6)	decreased susceptibility to endotoxin shock	J:131975
	immune system phenotype	J:131975
	increased macrophage cell number	J:131975
\Tgm2^tm1Gml/\Tgm2^tm1Gml (involves: C57BL/6 * DBA/1LacJ)	abnormal thymus morphology	J:132254
\Tgm2^tm1Gml/\Tgm2^tm1Gml (involves: C57BL/6 * DBA/1LacJ)	impaired macrophage phagocytosis	J:132254
\Tgm6^em1Bge/\Tgm6^em1Bge (C57BL/6N-Tgm6^em1Bge)	increased susceptibility to bacterial infection	J:268324
\TgTn(pb-CAG-Gm614)#Cya/0 (involves: C57BL/6)	decreased B cell apoptosis	J:307345
	immune system phenotype	J:307345
	increased susceptibility to systemic lupus erythematosus	J:307345
\TgTn(pb-CAG-Gm40600)#Rew/0 (C57BL/6-TgTn(pb-CAG-Gm40600)#Rew)	abnormal plasmablast number	J:311878
	decreased B cell number	J:311878
	decreased IgA level	J:311878
	decreased IgE level	J:311878
	decreased IgG1 level	J:311878
	decreased IgG2b level	J:311878
	decreased IgG2c level	J:311878
	decreased IgG3 level	J:311878
	decreased IgG level	J:311878
	decreased IgM level	J:311878
	decreased plasma cell number	J:311878
	increased B cell number	J:311878
	increased IgA level	J:311878
	increased IgE level	J:311878
	increased IgG1 level	J:311878
	increased IgG2b level	J:311878
	increased IgG2c level	J:311878
	increased IgG3 level	J:311878
	increased IgG level	J:311878
	increased IgM level	J:311878
	increased plasma cell number	J:311878
\Thap4^em1Nvl/\Thap4^em1Nvl (C57BL/6JJcl-Thap4^em1Nvl)	increased thymus weight	J:350810
\Thbd^tm1.1Hlwu/\Thbd^tm1.1Hlwu \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (B6.129-Thbd^tm1.1Hlwu Lyz2^tm1(cre)Ifo)	decreased circulating interleukin-6 level	J:188879
	decreased circulating tumor necrosis factor level	J:188879
	decreased susceptibility to bacterial infection	J:188879
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:188879
	decreased tumor necrosis factor secretion	J:188879
\Thbd^tm1Wlr/\Thbd^tm1Wlr (B6.129S2-Thbd^tm1Wlr)	abnormal spleen morphology	J:111502
	decreased circulating tumor necrosis factor level	J:111502
	increased circulating interleukin-1 beta level	J:111502
	increased circulating interleukin-6 level	J:111502
	increased susceptibility to endotoxin shock	J:111502
\Thbd^tm1Wlr/\Thbd^tm2Rdr (involves: 129S2/SvPas * C57BL/6)	abnormal spleen morphology	J:111502, J:47676
\Thbd^tm2.1Emc/\Thbd^tm2.1Emc (involves: 129/Sv * BALB/c * C57BL/6)	abnormal leukocyte adhesion	J:118000
	abnormal leukocyte physiology	J:118000
	increased circulating interleukin-1 beta level	J:118000
	increased circulating tumor necrosis factor level	J:118000
	increased susceptibility to endotoxin shock	J:118000
\Thbd^tm2Emc/\Thbd^tm2Emc (either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))	abnormal leukocyte physiology	J:118000
\Thbs1^tm1Hyn/\Thbs1^tm1Hyn (either: (involves: 129S2/SvPas * 129/Sv) or (involves: 129S2/SvPas * C57BL/6))	increased eosinophil cell number	J:46182
	increased leukocyte cell number	J:46182
	increased lymphocyte cell number	J:46182
	increased monocyte cell number	J:46182
	increased neutrophil cell number	J:46182
	lung inflammation	J:46182, J:48446
	pancreas inflammation	J:48446
\Thbs1^tm1Hyn/\Thbs1^tm1Hyn (involves: 129S2/SvPas * C57BL/6)	decreased interferon-gamma secretion	J:153126
	decreased regulatory T cell number	J:153126
	increased anti-single stranded DNA antibody level	J:153126
	increased CD4-positive, alpha-beta T cell number	J:153126
	increased interleukin-17 secretion	J:153126
	lacrimal gland inflammation	J:153126
\Thbs1^tm1Hyn/\Thbs1^tm1Hyn \Thbs2^tm1Bst/\Thbs2^tm1Bst (involves: 129T2/SvEms * 129X1/SvJ)	impaired macrophage chemotaxis	J:78876
	lung inflammation	J:78876
\Thbs2^em1(IMPC)Mbp/\Thbs2^em1(IMPC)Mbp (C57BL/6NCrl-Thbs2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Thbs4^tm1Dgen/\Thbs4^tm1Dgen (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:301049
	increased macrophage cell number	J:301049
\Thbs4^tm1Olsa/\Thbs4^tm1Olsa (C57BL/6J-Thbs4^tm1Olsa)	decreased macrophage cell number	J:301049
\Thcr^BALB/cJ/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	decreased interferon-gamma secretion	J:86188
\Thcr^BALB/cJ/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	increased interleukin-4 secretion	J:86188
\Thcr^C57BL/10Sn/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	decreased interleukin-4 secretion	J:86188
\Thcr^C57BL/10Sn/? (involves: BALB/cJ * C57BL/10J * DBA/2J)	increased interferon-gamma secretion	J:86188
\Themis2^{tm1d(KOMP)Wtsi}/\Themis2^{tm1d(KOMP)Wtsi} (involves: 129S4/SvJae * C57BL/6 * C57BL/6N * SJL)	immune system phenotype	J:232061
\Themis^5AT161/\Themis^5AT161 (involves: C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:151076
	decreased CD8-positive, alpha-beta T cell number	J:151076
	decreased regulatory T cell number	J:151076
	decreased single-positive T cell number	J:151076
\Themis^m1Btlr/\Themis^m1Btlr (C57BL/6J-Themis^m1Btlr)	abnormal lymphocyte morphology	J:211400
	decreased B-1a cell number	J:211400
	decreased CD4-positive, alpha-beta T cell number	J:211400
	decreased CD8-positive, alpha-beta T cell number	J:211400
	immune system phenotype	J:211400
	impaired humoral immune response	J:211400
\Themis^m2Btlr/\Themis^m2Btlr (C57BL/6J-Themis^m2Btlr)	decreased CD4-positive, alpha-beta T cell number	J:236691
	decreased T cell number	J:236691
	increased CD8-positive, alpha-beta T cell number	J:236691
	increased effector memory CD4-positive, alpha-beta T cell number	J:236691
\Themis^m3Btlr/\Themis^m3Btlr (C57BL/6J-Themis^m3Btlr)	abnormal CD8-positive, alpha-beta cytotoxic T cell morphology	J:254834
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254834
	decreased CD8-positive, alpha-beta memory T cell number	J:254834
	decreased CD8-positive, naive alpha-beta T cell number	J:254834
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254834
	increased CD8-positive, alpha-beta memory T cell number	J:254834
	increased central memory CD4-positive, alpha-beta T cell number	J:254834
	increased central memory CD8 positive, alpha-beta T cell number	J:254834
	increased effector memory CD4-positive, alpha-beta T cell number	J:254834
\Themis^M4Btlr/\Themis^M4Btlr (C57BL/6J-Themis^M4Btlr)	decreased CD4-positive, alpha-beta T cell number	J:272849
\Themis^m5Btlr/\Themis^m5Btlr (C57BL/6J-Themis^m5Btlr)	abnormal CD4-positive T cell differentiation	J:274716
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274716
	abnormal T cell differentiation	J:274716
	decreased alpha-beta T cell number	J:274716
	decreased CD4-positive, alpha-beta T cell number	J:274716
	decreased CD8-positive, alpha-beta T cell number	J:274716
	decreased CD8-positive, naive alpha-beta T cell number	J:274716
	increased CD8-positive, alpha-beta memory T cell number	J:274716
	increased central memory CD4-positive, alpha-beta T cell number	J:274716
	increased central memory CD8 positive, alpha-beta T cell number	J:274716
	increased effector memory CD4-positive, alpha-beta T cell number	J:274716
	increased effector memory CD8-positive, alpha-beta T cell number	J:274716
	increased NK T cell number	J:274716
\Themis^Spotr/\Themis⁺ (C57BL/6-Themis^Spotr)	decreased CD4-positive, alpha-beta T cell number	J:152601
\Themis^Spotr/\Themis⁺ (C57BL/6-Themis^Spotr)	decreased CD8-positive, alpha-beta T cell number	J:152601
\Themis^Spotr/\Themis^Spotr (C57BL/6-Themis^Spotr)	abnormal T cell differentiation	J:152601
	decreased CD4-positive, alpha-beta T cell number	J:152601
	decreased CD8-positive, alpha-beta T cell number	J:152601
	small thymus medulla	J:152601
\Themis^tm1.1Hko/\Themis⁺ (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:152601
\Themis^tm1.1Hko/\Themis⁺ (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:152601
\Themis^tm1.1Hko/\Themis^tm1.1Hko (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:152601
	decreased CD8-positive, alpha-beta T cell number	J:152601
	decreased single-positive T cell number	J:152601
\Themis^tm1Gasc/\Themis^tm1Gasc (B6.129S-Themis^tm1Gasc)	abnormal memory T cell morphology	J:151074
	abnormal positive T cell selection	J:151074
	abnormal regulatory T cell morphology	J:151074
	abnormal thymus medulla morphology	J:151074
	decreased CD4-positive, alpha-beta T cell number	J:151074
	decreased CD8-positive, alpha-beta T cell number	J:151074
	decreased T cell proliferation	J:151074
	decreased thymocyte number	J:151074
	increased double-positive T cell number	J:151074
\Themis^tm1Hasu/\Themis⁺ (involves: C57BL/6 * CBA)	decreased CD4-positive, alpha-beta T cell number	J:153235
\Themis^tm1Hasu/\Themis⁺ (involves: C57BL/6 * CBA)	decreased CD8-positive, alpha-beta T cell number	J:153235
\Themis^tm1Hasu/\Themis^tm1Hasu (involves: C57BL/6 * CBA)	abnormal T cell differentiation	J:153235
	decreased CD4-positive, alpha-beta T cell number	J:153235
	decreased CD8-positive, alpha-beta T cell number	J:153235
	decreased splenocyte number	J:153235
	decreased thymocyte number	J:153235
	increased memory T cell number	J:153235
	increased T cell proliferation	J:153235
\Themis^tm1Lov/\Themis^tm1Lov (involves: 129)	abnormal negative T cell selection	J:151075
	abnormal T cell differentiation	J:151075
	decreased CD4-positive, alpha-beta T cell number	J:151075
	decreased CD8-positive, alpha-beta T cell number	J:151075
	decreased regulatory T cell number	J:151075
	decreased single-positive T cell number	J:151075
	increased memory T cell number	J:151075
\Thim^{Tg(Myh6-TGFB1)1Ljf}/\Thim⁺ (involves: C3HeB/FeJ)	increased T cell derived lymphoma incidence	J:59903
\thnh/\thnh (NOD.Cg-H2^b thnh/J)	folliculitis	J:142872
\Thnsl2^em1(IMPC)Tcp/\Thnsl2^em1(IMPC)Tcp (C57BL/6NCrl-Thnsl2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Thoc1^{em1(IMPC)Ccpcz}/\Thoc1⁺ (C57BL/6NCrl-Thoc1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Thoc6^em5(IMPC)Tcp/\Thoc6⁺ (C57BL/6NCrl-Thoc6^em5(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Thop1^em1(IMPC)Mbp/\Thop1^em1(IMPC)Mbp (C57BL/6NCrl-Thop1^em1(IMPC)Mbp/MbpMmucd)	decreased leukocyte cell number	J:211773
\Thop1^{Gt(CSG163)Byg}/\Thop1^{Gt(CSG163)Byg} (B6.129P2-Thop1^{Gt(CSG163)Byg})	decreased lymphocyte cell number	J:290567
	decreased susceptibility to infection	J:290567
	decreased susceptibility to infection induced morbidity/mortality	J:290567
	increased granulocyte number	J:290567
	increased monocyte cell number	J:290567
	increased susceptibility to experimental autoimmune encephalomyelitis	J:290567
\Thpo^tm1Mwm/\Thpo^tm1Mwm (involves: 129S2/SvPas * C57BL/6)	immune system phenotype	J:83262
\Thra^tm1Ffla/\Thra⁺ \Tg(Sycp1-cre)4Min/? (involves: 129/Sv * C57BL/6 * DBA/2)	decreased spleen weight	J:125353
\Thra^tm1Syc/\Thra⁺ (involves: 129S6/SvEvTac * C57BL/6J * NIH Black Swiss)	abnormal osteoclast physiology	J:217018
	decreased osteoclast cell number	J:217018
\Thra^tm2Jas/\Thra^tm2Jas (involves: 129)	abnormal osteoclast physiology	J:120899
\Thra^tm2Jas/\Thra^tm2Jas (involves: 129)	decreased osteoclast cell number	J:120899
\Thra^tm2Ven/\Thra^tm2Ven (involves: 129P2/OlaHsd * BALB/c)	abnormal osteoclast physiology	J:72959
\Thrb^tm1Olc/\Thrb^tm1Olc (involves: 129)	abnormal osteoclast physiology	J:120899
\Thrb^tm1Olc/\Thrb^tm1Olc (involves: 129)	increased osteoclast cell number	J:120899
\Thtpa^em1(IMPC)Tcp/\Thtpa^em1(IMPC)Tcp (C57BL/6NCrl-Thtpa^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Thyct1^C57BL/6J/\Thyct1^C57BL/6J \Thyct2^C57BL/6J/\Thyct2^C57BL/6J (involves: C57BL/6J * DBA/2J)	thymus hyperplasia	J:85261
\Thyct1^DBA/2J/\Thyct1^DBA/2J \Thyct2^DBA/2J/\Thyct2^DBA/2J (involves: C57BL/6J * DBA/2J)	thymus hypoplasia	J:85261
\Thyls2^MSM/\Thyls2^MSM (involves: BALB/c * MSM)	increased T cell derived lymphoma incidence	J:87704
\Thypr1^DBA/2J/? (involves: C57BL/6J * DBA/2J)	increased T cell proliferation	J:76931
\Thypr2^DBA/2J/? (involves: C57BL/6J * DBA/2J)	increased T cell proliferation	J:76931
\Tia1^tm1Andp/\Tia1^tm1Andp (C.129S2-Tia1^tm1Andp)	abnormal macrophage physiology	J:88770
	immune system phenotype	J:88770
	increased susceptibility to endotoxin shock	J:88770
\Tia1^tm1Andp/\Tia1^tm1Andp (B6.Cg-Tia1^tm1Andp)	autoimmune arthritis	J:88443
\Tia1^tm1Andp/\Tia1^tm1Andp \Zfp36^tm1Pjb/\Zfp36^tm1Pjb (B6.Cg-Tia1^tm1Andp Zfp36^tm1Pjb)	abnormal macrophage physiology	J:88443
	autoimmune arthritis	J:88443
	increased neutrophil cell number	J:88443
\Ticam1^Lps2/\Ticam1^Lps2 (involves: C57BL/6)	abnormal cytokine secretion	J:110201
	abnormal macrophage physiology	J:84896
	decreased circulating tumor necrosis factor level	J:86521
	decreased macrophage apoptosis	J:84896, J:92674
	decreased macrophage cytokine production	J:84896
	decreased macrophage nitric oxide production	J:84896
	decreased susceptibility to bacterial infection	J:86521, J:92674
	decreased susceptibility to endotoxin shock	J:84896
	decreased tumor necrosis factor secretion	J:84896
	increased susceptibility to Herpesvirales infection	J:84896
\Ticam1^Lps2/\Ticam1^Lps2 (C57BL/6J-Ticam1^Lps2)	abnormal circulating tumor necrosis factor level	J:138963
	abnormal cytokine secretion	J:167340
	decreased interleukin-6 secretion	J:167340
	decreased susceptibility to induced colitis	J:167340
	immune system phenotype	J:131353
\Ticam1^Lps2/\Ticam1^Lps2 (C57BL/6J-Ticam1^Lps2/J)	abnormal chemokine level	J:288471
	decreased CD8-positive, alpha-beta T cell number	J:288471
	decreased Ly6C low monocyte number	J:288471
	increased interferon-beta secretion	J:288471
	increased Ly6C high monocyte number	J:288471
	increased macrophage cell number	J:288471
	increased neutrophil cell number	J:288471
	increased plasmacytoid dendritic cell number	J:288471
	increased susceptibility to Coronaviridae infection	J:288471
	increased susceptibility to Coronaviridae infection induced morbidity/mortality	J:288471
\Ticam1^Lps2/\Ticam1^Lps2 \Myd88^tm1Aki/\Myd88^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:84896
	decreased tumor necrosis factor secretion	J:84896
\Ticam1^M2Btlr/\Ticam1⁺ (C57BL/6J-Ticam1^M2Btlr)	abnormal cytokine secretion	J:234240
	abnormal macrophage physiology	J:234240
	decreased macrophage cytokine production	J:234240
	decreased tumor necrosis factor secretion	J:234240
\Ticam1^M2Btlr/\Ticam1^M2Btlr (C57BL/6J-Ticam1^M2Btlr)	abnormal cytokine secretion	J:234240
	abnormal macrophage physiology	J:234240
	decreased macrophage cytokine production	J:234240
	decreased tumor necrosis factor secretion	J:234240
\Ticam1^M3Btlr/\Ticam1⁺ (C57BL/6J-Ticam1^M3Btlr)	decreased tumor necrosis factor secretion	J:255300
\Ticam1^M3Btlr/\Ticam1^M3Btlr (C57BL/6J-Ticam1^M3Btlr)	decreased tumor necrosis factor secretion	J:255300
\Ticam1^tm1Aki/\Ticam1^tm1Aki (involves: 129P2/OlaHsd)	abnormal B cell activation	J:174941
	abnormal B cell physiology	J:84679
	abnormal cytokine level	J:174941
	abnormal cytokine secretion	J:84679
	abnormal dendritic cell physiology	J:174941
	abnormal interleukin level	J:137522
	abnormal macrophage physiology	J:174941, J:84679
	abnormal microglial cell physiology	J:185198
	abnormal NK cell physiology	J:174941
	abnormal NK T cell physiology	J:174941
	decreased circulating interleukin-6 level	J:145306
	decreased splenocyte proliferation	J:84679
	decreased susceptibility to endotoxin shock	J:84679
	decreased susceptibility to Orthomyxoviridae infection	J:145306
	impaired macrophage phagocytosis	J:185198
\Ticam1^tm1Aki/\Ticam1^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine level	J:169158
	abnormal susceptibility to Poxviridae infection	J:162716
	decreased CD8-positive, alpha-beta T cell number	J:130954
	decreased circulating interferon-gamma level	J:130954
	decreased circulating interleukin-6 level	J:130954
	decreased circulating interleukin-12b level	J:130954
	decreased IgG2a level	J:130954
	decreased IgG level	J:130954
	decreased interferon-beta secretion	J:130954
	decreased interleukin-12b secretion	J:130954
	decreased susceptibility to type I hypersensitivity reaction	J:161445
	immune system phenotype	J:132662
	increased susceptibility to Picornaviridae infection	J:169158
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:169158
	myocarditis	J:169158
\Ticam1^tm1Aki/\Ticam1^tm1Aki (B6.129P2-Ticam1^tm1Aki)	abnormal cytokine level	J:144301
	abnormal response to infection	J:144301
	decreased circulating tumor necrosis factor level	J:144301
	decreased macrophage cytokine production	J:144301
	impaired neutrophil recruitment	J:144301
	increased susceptibility to bacterial infection	J:144301
\Ticam1^tm1Tsse/\Ticam1^tm1Tsse (B6.129-Ticam1^tm1Tsse)	impaired natural killer cell mediated cytotoxicity	J:118750
\Ticam1^tm1Tsse/\Ticam1^tm1Tsse \Tg(PVR)1Kkst/0 (involves: 129 * C57BL/6 * ICR)	abnormal interferon-alpha secretion	J:179625
	increased susceptibility to Picornaviridae infection	J:179625
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:179625
\Ticam2^M1Btlr/\Ticam2⁺ (C57BL/6J-Ticam2^M1Btlr)	decreased tumor necrosis factor secretion	J:215010
\Ticam2^M1Btlr/\Ticam2^M1Btlr (C57BL/6J-Ticam2^M1Btlr)	decreased tumor necrosis factor secretion	J:215010
\Ticam2^M2Btlr/\Ticam2⁺ (C57BL/6J-Ticam2^M2Btlr)	decreased interleukin-1 beta secretion	J:254908
\Ticam2^M2Btlr/\Ticam2^M2Btlr (C57BL/6J-Ticam2^M2Btlr)	decreased interleukin-1 beta secretion	J:254908
\Ticam2^M3Btlr/\Ticam2⁺ (C57BL/6J-Ticam2^M3Btlr)	decreased tumor necrosis factor secretion	J:254912
\Ticam2^M3Btlr/\Ticam2^M3Btlr (C57BL/6J-Ticam2^M3Btlr)	decreased tumor necrosis factor secretion	J:254912
\Ticam2^tm1Aki/\Ticam2^tm1Aki (involves: C57BL/6)	abnormal immune system physiology	J:86256
	decreased interleukin-6 secretion	J:86256
	increased susceptibility to Coronaviridae infection	J:270045
\Ticam2^tm1Btlr/\Ticam2^tm1Btlr (C57BL/6J-Ticam2^tm1Btlr)	abnormal interferon secretion	J:133619
\Ticam2^tm1Btlr/\Ticam2^tm1Btlr (C57BL/6J-Ticam2^tm1Btlr)	decreased tumor necrosis factor secretion	J:133619
\Tie1^tm1.1Scba/\Tie1^tm1.1Scba (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal lymphangiogenesis	J:158668
	abnormal lymphatic vessel morphology	J:158668
	lymphatic vessel hyperplasia	J:158668
\Tie1^tm1Geno/\Tie1^tm1Geno (involves: ICR)	abnormal lymphangiogenesis	J:159507
\Tie1^tm1Jpa/\Tie1^tm1Jpa (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymphangiogenesis	J:159507
\Tie1^tm1Scba/\Tie1^tm1Scba (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal lymph circulation	J:158668
	abnormal lymphangiogenesis	J:158668
	abnormal lymphatic vessel morphology	J:158668
	lymphatic vessel hyperplasia	J:158668
\Tifab^em1(IMPC)J/\Tifab^em1(IMPC)J (C57BL/6NJ-Tifab^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Tifab^tm1.1Dsta/\Tifab⁺ (involves: 129 * C57BL/6 * C57BL/6J)	enlarged spleen	J:229024
\Tifab^tm1.1Dsta/\Tifab^tm1.1Dsta (involves: 129 * C57BL/6 * C57BL/6J)	abnormal neutrophil morphology	J:229024
	decreased leukocyte cell number	J:229024
	decreased lymphocyte cell number	J:229024
	decreased monocyte cell number	J:229024
	decreased neutrophil cell number	J:229024
	enlarged spleen	J:229024
\Tigar^{Gt(EUCE0047g05)Hmgu}/\Tigar^{Gt(EUCE0047g05)Hmgu} (involves: 129P2/OlaHsd)	increased susceptibility to induced colitis	J:198650
\Tigar^tm1.1Khv/\Tigar^tm1.1Khv \Tg(CMV-cre)1Cgn/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * SJL)	increased susceptibility to induced colitis	J:198650
\Tigit^tm1Sdl/\Tigit^tm1Sdl (involves: C57BL/6)	abnormal professional antigen presenting cell physiology	J:168902
	decreased interleukin-10 secretion	J:168902
	immune system phenotype	J:209990
	increased susceptibility to experimental autoimmune encephalomyelitis	J:168902
	increased T cell proliferation	J:168902
\Tigit^tm1Sdl/\Tigit^tm1Sdl \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: C57BL/6)	decreased interleukin-10 secretion	J:168902
	increased susceptibility to experimental autoimmune encephalomyelitis	J:168902
\Timd2^{tm1(GAL4)Pdre}/\Timd2^{tm1(GAL4)Pdre} (C.129S4-Timd2^{tm1(GAL4)Pdre})	abnormal inflammatory response	J:125054
	abnormal interleukin secretion	J:125054
	increased eosinophil cell number	J:125054
	increased interferon-gamma secretion	J:125054
	increased lymphocyte cell number	J:125054
	increased tumor necrosis factor secretion	J:125054
\Timd4^tm1Kuch/\Timd4^tm1Kuch (C57BL/6-Timd4^tm1Kuch)	abnormal B cell physiology	J:160747
	abnormal macrophage physiology	J:160747
	increased anti-double stranded DNA antibody level	J:160747
	increased IgA level	J:160747
	increased IgG2a level	J:160747
	increased IgG2b level	J:160747
	increased interferon-gamma secretion	J:160747
	increased interleukin-17 secretion	J:160747
	increased splenocyte proliferation	J:160747
\Timd4^tm1Kuch/\Timd4^tm1Kuch (involves: C57BL/6)	abnormal circulating chemokine level	J:235399
	decreased circulating interleukin-10 level	J:235399
	increased anti-double stranded DNA antibody level	J:235399
	increased circulating interleukin-1 beta level	J:235399
	increased circulating interleukin-6 level	J:235399
	increased circulating interleukin-12b level	J:235399
	increased susceptibility to systemic lupus erythematosus	J:235399
\Timd4^tm1Osa/\Timd4^tm1Osa (involves: C57BL/6)	immune system phenotype	J:187181
\Timd4^tm1Osa/\Timd4^tm1Osa (involves: C57BL/6)	impaired macrophage phagocytosis	J:187181
\Timd4^tm1Wouy/\Timd4^tm1Wouy (involves: 129)	abnormal macrophage physiology	J:160304
	decreased tumor necrosis factor secretion	J:160304
	impaired macrophage phagocytosis	J:160304
	increased IgG2a level	J:160304
	increased leukocyte cell number	J:160304
	increased lymphocyte cell number	J:160304
	increased tumor necrosis factor secretion	J:160304
\Timd6^{tm1b(KOMP)Wtsi}/\Timd6⁺ (C57BL/6N-Timd6^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Timm13^em1(IMPC)Tcp/\Timm13⁺ (C57BL/6NCrl-Timm13^em1(IMPC)Tcp/Tcp)	abnormal spleen morphology	J:211773
	enlarged thymus	J:211773
\Timmdc1^{Gt(OST407011)Lex}/\Timmdc1⁺ (B6;129S5-Timmdc1^{Gt(OST407011)Lex}/Mmucd)	increased CD4-positive, alpha-beta T cell number	J:171883
\Timp1^tm1Pds/\Timp1^tm1Pds (involves: 129S4/SvJae)	decreased susceptibility to bacterial infection	J:94836
\Timp1^tm1Pds/\Timp1^tm1Pds (involves: C57BL/6)	decreased susceptibility to bacterial infection	J:94836
\Timp1^tm1Pds/\Timp1^tm1Pds (involves: 129S4/SvJae * C57BL/6)	increased neutrophil cell number	J:112941
	lung inflammation	J:112941
\Timp2^{em1(IMPC)Hmgu}/\Timp2^{em1(IMPC)Hmgu} (C57BL/6N-Timp2^{em1(IMPC)Hmgu}/Ieg)	increased follicular B cell number	J:211773
\Timp2^tm1Pds/\Timp2^tm1Pds (involves: 129S4/SvJae * C57BL/6)	increased neutrophil cell number	J:112941
\Timp3^tm1Osya/\Timp3^tm1Osya (B6.129P2-Timp3^tm1Osya)	aortitis	J:193744
\Timp3^tm1Rkho/\Timp3^tm1Rkho (B6.129-Timp3^tm1Rkho)	increased tumor necrosis factor secretion	J:92948
\Timp3^tm1Rkho/\Timp3^tm1Rkho (B6.129-Timp3^tm1Rkho)	liver inflammation	J:92948
\Timp3^tm1Rkho/\Timp3^tm1Rkho \Tnf^tm1Gkl/\Tnf^tm1Gkl (involves: 129 * 129S/SvEv * C57BL/6)	increased neutrophil cell number	J:112033
\Timp4^em1(IMPC)Mbp/\Timp4^em1(IMPC)Mbp (C57BL/6N-Timp4^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Tincr^{em1(IMPC)Ccpcz}/\Tincr^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tincr^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Tinf2^tm2.2Tdl/\Tinf2⁺ (involves: BALB/cJ * C57BL/6)	dermatitis	J:207367
	lymphoid hyperplasia	J:207367
	myeloid hyperplasia	J:207367
\Tiparp^{Gt(ROSA)79Sor}/\Tiparp^{Gt(ROSA)79Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
\Tiparp^{Gt(ROSA)79Sor}/\Tiparp^{Gt(ROSA)79Sor} (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6J)	abnormal thymus involution	J:250417
\Tiparp^{tm1b(EUCOMM)Wtsi}/\Tiparp^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tiparp^{tm1b(EUCOMM)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Tir2^BALB/cOlaHsd/\Tir2^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	abnormal immune serum protein physiology	J:40771
\Tir2^{C57BL/6JOlaHsd}/\Tir2^{C57BL/6JOlaHsd} (involves: A/JOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
\Tir2^{C57BL/6JOlaHsd}/\Tir2^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
\Tir2^{C57BL/6JOlaHsd}/\Tir2^{C57BL/6JOlaHsd} (A.B6-Tir2)	decreased susceptibility to parasitic infection	J:97672
\Tir2^{C57BL/6JOlaHsd}/\Tir2^{C57BL/6JOlaHsd} (A.B6-(D5Mit200-D5Mit10))	decreased susceptibility to parasitic infection	J:135428
\Tir3^BALB/cOlaHsd/\Tir3^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
\Tir3^{C57BL/6JOlaHsd}/\Tir3^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
\Tir3^{C57BL/6JOlaHsd}/\Tir3^{C57BL/6JOlaHsd} (A.B6-Tir3)	decreased susceptibility to parasitic infection	J:97672
\Tir3^{C57BL/6JOlaHsd}/\Tir3^{C57BL/6JOlaHsd} (A.B6-(D1Mit60-D1Mit217))	decreased susceptibility to parasitic infection	J:135428
\Tir4^{C57BL/6JOlaHsd}/? (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
\Tir4^{C57BL/6JOlaHsd}/\Tir4^{C57BL/6JOlaHsd} (involves: A/JOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
\Tir4^{C57BL/6JOlaHsd}/\Tir4^{C57BL/6JOlaHsd} (involves: BALB/cOlaHsd * C57BL/6JOlaHsd)	decreased susceptibility to parasitic infection	J:40771
\Tir4^{C57BL/6JOlaHsd}/\Tir4^{C57BL/6JOlaHsd} (A.B6-Tir1)	decreased susceptibility to parasitic infection	J:97672
\Tir4^{C57BL/6JOlaHsd}/\Tir4^{C57BL/6JOlaHsd} (A.B6-(D17Mit29-D17Mit11))	decreased susceptibility to parasitic infection	J:135428
\Tir9^C57BL/6/\Tir9^C57BL/6 (involves: C57BL/6 * DBA/2)	increased susceptibility to parasitic infection	J:84716
\Tir10^C57BL/6/\Tir10^C57BL/6 (involves: C57BL/6 * DBA/2)	increased susceptibility to parasitic infection	J:84716
\Tirap^m1Btlr/\Tirap^m1Btlr (C57BL/6J-Tirap^m1Btlr)	abnormal interferon secretion	J:133618
\Tirap^m1Btlr/\Tirap^m1Btlr (C57BL/6J-Tirap^m1Btlr)	decreased tumor necrosis factor secretion	J:133618
\Tirap^tm1Aki/\Tirap^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:111205
	abnormal level of surface class II molecules	J:111205
	decreased IgG3 level	J:137066
\Tirap^tm1Aki/\Tirap^tm1Aki (B6.129P2-Tirap^tm1Aki)	abnormal dendritic cell physiology	J:118954
	decreased interleukin-6 secretion	J:118954
	decreased interleukin-12b secretion	J:118954
\Tirap^tm1Medz/\Tirap^tm1Medz (involves: 129S1/Sv * C57BL/6)	abnormal dendritic cell physiology	J:96773
	abnormal macrophage physiology	J:96773
	decreased B cell proliferation	J:96773
\Tirap^tm1Medz/\Tirap^tm1Medz (involves: 129S1/Sv)	abnormal macrophage physiology	J:96018
\Tirap^tm1Medz/\Tirap^tm1Medz (involves: 129S1/Sv)	increased susceptibility to bacterial infection	J:96018
\Tk1^tm1Vnd/\Tk1^tm1Vnd (involves: 129P2/OlaHsd * C57BL/6)	arteritis	J:101669
	liver inflammation	J:101669
	lung inflammation	J:101669
	lymph node atrophy	J:101669
	small spleen	J:101669
	spleen hypoplasia	J:101669
	thyroid gland inflammation	J:101669
\Tkfc^{em1(IMPC)Ccpcz}/\Tkfc^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tkfc^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Tktl1^tm1Arte/\Tktl1^tm1Arte (C57BL/6-Tktl1^tm1Arte)	increased susceptibility to induced colitis	J:171154
\Tlag2^AKR/J/\Tlag2^C57L/J (involves: AKR/J * C57L/J)	increased T cell derived lymphoma incidence	J:74369
\Tlag2^AKR/J/\Tlag2^C57L/J \Tlag1^AKR/J/\Tlag1^AKR/J (involves: AKR/J * C57L/J)	increased T cell derived lymphoma incidence	J:74369
\Tle3^em1(IMPC)Mbp/\Tle3^em1(IMPC)Mbp (C57BL/6N-Tle3^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Tle4^em1(IMPC)Mbp/\Tle4^em1(IMPC)Mbp (C57BL/6NCrl-Tle4^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Tle4^tm1.2Dasw/\Tle4^tm1.2Dasw (B6.129S6(Cg)-Tle4^tm1.2Dasw)	abnormal lymphopoiesis	J:219243
	abnormal thymus morphology	J:219243
	decreased B cell number	J:219243
	decreased DN2 thymocyte number	J:219243
	decreased double-positive T cell number	J:219243
	decreased follicular B cell number	J:219243
	decreased leukocyte cell number	J:219243
	decreased lymphocyte cell number	J:219243
	decreased pre-pro B cell number	J:219243
	decreased spleen B cell follicle number	J:219243
	immune system phenotype	J:219243
	increased NK T cell number	J:219243
	increased thymocyte apoptosis	J:219243
	spleen hypoplasia	J:219243
	thymus atrophy	J:219243
	thymus hypoplasia	J:219243
\Tlf2^NOD/Smrf/? (involves: NOD/Smrf * NON/Lt)	increased CD8-positive, alpha-beta T cell number	J:49676
\Tlf^NOD/Smrf/? (involves: NOD/Smrf * NON/Lt)	increased CD4-positive, alpha-beta T cell number	J:49676
\Tll1^b2b2476Clo/\Tll1^b2b2476Clo (C57BL/6J-Tll1^b2b2476Clo)	thymus hypoplasia	J:175213
\Tln1^tm4.1Crit/\Tln1^tm4.1Crit \Tg(Mx1-cre)1Cgn/0 (involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:134784
\Tlr1^tm1Aki/\Tlr1^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:103395
	decreased interleukin-6 secretion	J:103395
	decreased tumor necrosis factor secretion	J:103395
\Tlr1^tm1Flv/\Tlr1^tm1Flv (involves: 129S1/Sv)	abnormal macrophage physiology	J:95726
	decreased immunoglobulin level	J:95726
	increased susceptibility to bacterial infection	J:95726
\Tlr2^lngd/\Tlr2^lngd (C57BL/6J-Tlr2^lngd)	abnormal macrophage physiology	J:94077
\Tlr2^lngd/\Tlr2^lngd (C57BL/6J-Tlr2^lngd)	increased susceptibility to bacterial infection	J:94077
\Tlr2^tm1Aki/\Tlr2^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal chemokine level	J:88174
	abnormal macrophage physiology	J:76115, J:95726
	abnormal tumor necrosis factor level	J:124334
	decreased immunoglobulin level	J:95726
	decreased interleukin-6 secretion	J:76115, J:88174
	decreased microglial cell activation	J:122551
	decreased susceptibility to Herpesvirales infection	J:88174
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:88174
	decreased tumor necrosis factor secretion	J:76115
	immune system phenotype	J:76115
	increased susceptibility to bacterial infection	J:95726
\Tlr2^tm1Aki/\Tlr2^tm1Aki (B6.129P2-Tlr2^tm1Aki)	abnormal dendritic cell physiology	J:118954
	abnormal interleukin level	J:118954
	decreased interleukin-6 secretion	J:118954
	decreased interleukin-12b secretion	J:118954
	decreased susceptibility to parasitic infection	J:116763
	increased T cell number	J:118954
\Tlr2^tm1Aki/\Tlr2^tm1Aki (involves: 129P2/OlaHsd)	abnormal cytokine secretion	J:70578
	abnormal leukocyte migration	J:171379
	abnormal macrophage physiology	J:103464, J:130138, J:70578
	abnormal osteoclast physiology	J:130138
	decreased circulating interleukin-1 beta level	J:119941
	decreased circulating tumor necrosis factor level	J:119941
	decreased inflammatory response	J:146111
	decreased interleukin-6 secretion	J:70578
	decreased interleukin-12 secretion	J:70578
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:146111
	decreased tumor necrosis factor secretion	J:103395, J:70578
	increased B cell apoptosis	J:135830
\Tlr2^tm1Aki/\Tlr2^tm1Aki (NOD.129P2-Tlr2^tm1Aki)	insulitis	J:124334
\Tlr2^tm1Aki/\Tlr2^tm1Aki (C.129P2-Tlr2^tm1Aki)	immune system phenotype	J:178054
\Tlr2^tm1Aki/\Tlr2^tm1Aki \Tlr4^tm1Aki/\Tlr4^tm1Aki (B6.129P2-Tlr2^tm1Aki Tlr4^tm1Aki)	abnormal chemokine secretion	J:102879
\Tlr2^tm1Aki/\Tlr2^tm1Aki \Tlr4^tm1Aki/\Tlr4^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:117688
	abnormal macrophage physiology	J:117688
	decreased IgG3 level	J:117688
\Tlr2^tm1Aki/\Tlr2^tm1Aki \Tlr6^tm1Aki/\Tlr6^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-6 secretion	J:70578
\Tlr2^tm1Kir/\Tlr2^tm1Kir (either: (involves: 129/Sv * C57BL/6) or (involves: 129/Sv * C57BL/6 * C57BL/6J))	abnormal innate immunity	J:85323
	abnormal macrophage physiology	J:85323
	decreased interleukin-6 secretion	J:85323
	decreased interleukin-10 secretion	J:85323
	decreased macrophage cytokine production	J:85323
	decreased macrophage nitric oxide production	J:85323
	increased susceptibility to bacterial infection	J:85323
\Tlr2^tm1Kir/\Tlr2^tm1Kir (Not Specified)	abnormal macrophage physiology	J:96018
\Tlr2^tm1Kir/\Tlr2^tm1Kir (Not Specified)	increased susceptibility to bacterial infection	J:96018
\Tlr2^tm1Kir/\Tlr2^tm1Kir (B6.129-Tlr2^tm1Kir)	abnormal cellular extravasation	J:171028
	abnormal cytokine secretion	J:121930
	decreased circulating tumor necrosis factor level	J:162168
	decreased interleukin-1 beta secretion	J:129871
	decreased interleukin-6 secretion	J:129871
	decreased splenocyte proliferation	J:121930
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:121930
	decreased tumor necrosis factor secretion	J:129871
	increased susceptibility to induced colitis	J:165105
\Tlr2^tm1Kir/\Tlr2^tm1Kir (involves: 129)	abnormal interleukin secretion	J:94463
	decreased interleukin-1 secretion	J:94463
	decreased interleukin-6 secretion	J:94463
	decreased tumor necrosis factor secretion	J:94463
	increased susceptibility to bacterial infection induced morbidity/mortality	J:147177
\Tlr2^tm1Kir/\Tlr2^tm1Kir \Tlr4^Lps-d/\Tlr4^Lps-d (C3.Cg-Tlr2^tm1Kir Tlr4^Lps-d)	abnormal macrophage physiology	J:121930
\Tlr3^M1Btlr/\Tlr3⁺ (C57BL/6J-Tlr3^M1Btlr)	decreased macrophage cytokine production	J:224670
\Tlr3^M1Btlr/\Tlr3⁺ (C57BL/6J-Tlr3^M1Btlr)	decreased tumor necrosis factor secretion	J:224670
\Tlr3^M1Btlr/\Tlr3^M1Btlr (C57BL/6J-Tlr3^M1Btlr)	decreased macrophage cytokine production	J:224670
\Tlr3^M1Btlr/\Tlr3^M1Btlr (C57BL/6J-Tlr3^M1Btlr)	decreased tumor necrosis factor secretion	J:224670
\Tlr3^M2Btlr/\Tlr3⁺ (C57BL/6J-Tlr3^M2Btlr)	decreased tumor necrosis factor secretion	J:254925
\Tlr3^M2Btlr/\Tlr3^M2Btlr (C57BL/6J-Tlr3^M2Btlr)	decreased tumor necrosis factor secretion	J:254925
\Tlr3^tm1Aki/\Tlr3^tm1Aki (involves: 129P2/OlaHsd)	abnormal dendritic cell physiology	J:114555
\Tlr3^tm1Aki/\Tlr3^tm1Aki (involves: 129P2/OlaHsd)	immune system phenotype	J:144400
\Tlr3^tm1Aki/\Tlr3^tm1Aki \Tlr7^tm1Aki/\Tlr7^tm1Aki (involves: 129P2/OlaHsd)	decreased interferon-alpha secretion	J:144400
\Tlr3^tm1Flv/\Tlr3^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal B cell physiology	J:72167
	abnormal macrophage physiology	J:72167
	decreased inflammatory response	J:72167
	immune system phenotype	J:72167
\Tlr3^tm1Flv/\Tlr3^tm1Flv (involves: C57BL/6)	abnormal macrophage physiology	J:86617
\Tlr3^tm1Flv/\Tlr3^tm1Flv (involves: C57BL/6)	immune system phenotype	J:86617
\Tlr3^tm1Flv/\Tlr3^tm1Flv (Not Specified)	abnormal cytokine secretion	J:88906
	abnormal NK cell physiology	J:88906
	abnormal NK T cell physiology	J:88906
	increased susceptibility to Herpesvirales infection	J:88906
\Tlr3^tm1Flv/\Tlr3^tm1Flv (involves: 129S1/Sv)	abnormal cytokine level	J:119967
	abnormal interferon level	J:119967
	abnormal interleukin level	J:119967
	abnormal tumor necrosis factor level	J:119967
	decreased susceptibility to Riboviria infection	J:136330
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:136330
	heart inflammation	J:119967
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:119967
\Tlr3^tm1Flv/\Tlr3^tm1Flv (B6.129S1-Tlr3^tm1Flv/Apb)	abnormal cytokine level	J:129533
	abnormal interleukin level	J:126415
	decreased interferon-beta secretion	J:251008
\Tlr3^tm1Flv/\Tlr3^tm1Flv (B6N.129S1-Tlr3^tm1Flv/J)	increased susceptibility to Coronaviridae infection	J:288471
\Tlr4^Lps-2Btlr/? (C57BL/6J-Tlr4^Lps-2Btlr)	decreased tumor necrosis factor secretion	J:147339
\Tlr4^Lps-2Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^Lps-2Btlr)	decreased interleukin-1 beta secretion	J:147339
\Tlr4^lps-2J/\Tlr4^lps-2J (BXD29-Tlr4^lps-2J/J)	abnormal inflammatory response	J:107391
\Tlr4^Lps-3Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^Lps-3Btlr)	decreased interferon-beta secretion	J:217295
\Tlr4^Lps-3Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^Lps-3Btlr)	decreased tumor necrosis factor secretion	J:217295
\Tlr4^Lps-3Btlr/\Tlr4^Lps-3Btlr (C57BL/6J-Tlr4^Lps-3Btlr)	decreased interferon-beta secretion	J:217295
\Tlr4^Lps-3Btlr/\Tlr4^Lps-3Btlr (C57BL/6J-Tlr4^Lps-3Btlr)	decreased tumor necrosis factor secretion	J:217295
\Tlr4^lps-4Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^lps-4Btlr)	decreased macrophage cytokine production	J:224664
\Tlr4^lps-4Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^lps-4Btlr)	decreased tumor necrosis factor secretion	J:224664
\Tlr4^lps-4Btlr/\Tlr4^lps-4Btlr (C57BL/6J-Tlr4^lps-4Btlr)	decreased macrophage apoptosis	J:224664
	decreased macrophage cytokine production	J:224664
	decreased tumor necrosis factor secretion	J:224664
\Tlr4^lps-5Btlr/\Tlr4^lps-5Btlr (C57BL/6J-Tlr4^lps-5Btlr)	decreased B cell number	J:224666
	decreased macrophage cytokine production	J:224666
	decreased memory B cell number	J:224666
	decreased tumor necrosis factor secretion	J:224666
\Tlr4^Lps-6Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^Lps-6Btlr)	decreased macrophage cytokine production	J:224667
\Tlr4^Lps-6Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^Lps-6Btlr)	decreased tumor necrosis factor secretion	J:224667
\Tlr4^Lps-6Btlr/\Tlr4^Lps-6Btlr (C57BL/6J-Tlr4^Lps-6Btlr)	decreased macrophage cytokine production	J:224667
\Tlr4^Lps-6Btlr/\Tlr4^Lps-6Btlr (C57BL/6J-Tlr4^Lps-6Btlr)	decreased tumor necrosis factor secretion	J:224667
\Tlr4^lps-7Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^Lps-7Btlr)	decreased interleukin-1 beta secretion	J:234239
	decreased macrophage cytokine production	J:234239
	decreased tumor necrosis factor secretion	J:234239
\Tlr4^lps-7Btlr/\Tlr4^lps-7Btlr (C57BL/6J-Tlr4^Lps-7Btlr)	decreased interleukin-1 beta secretion	J:234239
	decreased macrophage cytokine production	J:234239
	decreased tumor necrosis factor secretion	J:234239
\Tlr4^Lps-8Btlr/\Tlr4⁺ (C57BL/6J-Tlr4^Lps-8Btlr)	decreased interleukin-1 beta secretion	J:234241
	decreased macrophage cytokine production	J:234241
	decreased tumor necrosis factor secretion	J:234241
\Tlr4^Lps-8Btlr/\Tlr4^Lps-8Btlr (C57BL/6J-Tlr4^Lps-8Btlr)	decreased interleukin-1 beta secretion	J:234241
	decreased macrophage cytokine production	J:234241
	decreased tumor necrosis factor secretion	J:234241
\Tlr4^lps-Btlr/\Tlr4^lps-Btlr (C57BL/6J-Tlr4^lps-Btlr)	abnormal macrophage physiology	J:128416
\Tlr4^Lps-d/\Tlr4^Lps-d (involves: C3H/HeJ)	abnormal osteoclast differentiation	J:131353
	abnormal T-helper 2 physiology	J:96356
	abnormal tumor necrosis factor level	J:124334, J:114368
	increased susceptibility to bacterial infection	J:5721, J:51522, J:87807
	increased susceptibility to induced arthritis	J:96356
\Tlr4^Lps-d/\Tlr4^Lps-d (C3H/HeJ-Tlr4^Lps-d)	abnormal cytokine level	J:96680
	abnormal interleukin level	J:96680
	abnormal macrophage chemotaxis	J:122597
	abnormal microglial cell physiology	J:99051
	abnormal phagocyte morphology	J:125179
	abnormal spleen weight	J:37271
	abnormal susceptibility to infection	J:162716
	abnormal tumor necrosis factor level	J:96680
	immune system phenotype	J:209808
	increased circulating interleukin-6 level	J:37271
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:162716
	liver inflammation	J:135830
	lung inflammation	J:96680
\Tlr4^Lps-d/\Tlr4^Lps-d \Tg(IghelMD4)4Ccg/0 \Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6)	decreased B cell number	J:115059
	increased B-1 B cell number	J:115059
\Tlr4^lps-del/\Tlr4^lps-del (C57BL/10ScCr)	abnormal cytokine secretion	J:88996
	abnormal macrophage physiology	J:88996
	increased susceptibility to bacterial infection	J:51522, J:88996
\Tlr4^lps-del/\Tlr4^lps-del (C57BL/10ScN)	increased spleen weight	J:37271
\Tlr4^lps-del/\Tlr4^lps-del (involves: C57BL/10ScN)	abnormal tumor necrosis factor level	J:114368
	decreased interleukin-6 secretion	J:147023
	decreased interleukin-10 secretion	J:147023
\Tlr4^lps-hypo/\Tlr4^lps-hypo (B6.Cg-Tlr4^lps-hypo Cln8^mnd)	decreased susceptibility to bacterial infection	J:103167
\Tlr4^lps-n/\Tlr4^lps-n (C3H/HeN)	decreased acute inflammation	J:37271
	immune system phenotype	J:5557
	increased spleen weight	J:37271
\Tlr4^tm1.1Djh/\Tlr4^tm1.1Djh (involves: FVB/N)	decreased susceptibility to endotoxin shock	J:192520
\Tlr4^tm1Aki/\Tlr4^lps-2J (involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)	abnormal inflammatory response	J:107391
\Tlr4^tm1Aki/\Tlr4^tm1Aki (involves: 129P2/OlaHsd)	decreased circulating interleukin-6 level	J:145306
	decreased susceptibility to Orthomyxoviridae infection	J:145306
	increased susceptibility to bacterial infection	J:53519
\Tlr4^tm1Aki/\Tlr4^tm1Aki (involves: 129P2/OlaHsd * C57BL/6J)	abnormal acute inflammation	J:98224
	enlarged mesenteric lymph nodes	J:98224
	impaired neutrophil chemotaxis	J:98224
	increased susceptibility to bacterial infection	J:98224
\Tlr4^tm1Aki/\Tlr4^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal level of surface class II molecules	J:76115
	abnormal macrophage physiology	J:76115
	decreased B cell proliferation	J:76115
	decreased interleukin-6 secretion	J:76115
	decreased susceptibility to endotoxin shock	J:76115
	decreased tumor necrosis factor secretion	J:76115
	increased susceptibility to bacterial infection	J:111778
\Tlr4^tm1Aki/\Tlr4^tm1Aki (C.129P2-Tlr4^tm1Aki)	decreased susceptibility to induced arthritis	J:178054
\Tlr4^tm1Aki/\Tlr4^tm1Aki \Tlr5^tm1Flv/\Tlr5^tm1Flv (involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)	increased susceptibility to bacterial infection	J:111778
\Tlr5^tm1.1Gewr/\Tlr5^tm1.1Gewr \Tg(Itgax-cre,-EGFP)4097Ach/? (involves: C57BL/6J * C57BL/6NTac)	immune system phenotype	J:229155
\Tlr5^tm1Aki/\Tlr5^tm1Aki (B6.129P2-Tlr5^tm1Aki)	decreased interleukin-6 secretion	J:112391
	decreased interleukin-12b secretion	J:112391
	decreased susceptibility to bacterial infection	J:112391
	immune system phenotype	J:116763
\Tlr5^tm1Aki/\Tlr5^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:112671
\Tlr5^tm1Aki/\Tlr5^tm1Aki (involves: 129P2/OlaHsd)	enlarged spleen	J:229155
	increased interleukin-1 beta secretion	J:229155
	increased susceptibility to colitis induced morbidity/mortality	J:229155
\Tlr5^tm1Flv/\Tlr5^tm1Flv (involves: 129S1/Sv * C57BL/6)	abnormal cytokine secretion	J:111778
	abnormal dendritic cell physiology	J:111778
	abnormal response to transplant	J:111778
	decreased neutrophil cell number	J:111778
	increased susceptibility to autoimmune diabetes	J:158055
	increased susceptibility to bacterial infection	J:111778
	increased susceptibility to induced colitis	J:158055
	increased susceptibility to induced pancreatitis	J:158055
	lung inflammation	J:111778
\Tlr5^tm1Flv/\Tlr5^tm1Flv (involves: 129S1/Sv)	abnormal leukocyte migration	J:171379
\Tlr6^int/\Tlr6^int (C57BL/6-Tlr6^int)	abnormal adaptive immunity	J:110094
	abnormal cell-mediated immunity	J:110094
	abnormal innate immunity	J:110094
	abnormal macrophage physiology	J:110094
\Tlr6^m2Btlr/\Tlr6^m2Btlr (C57BL/6J-Tlr6^m2Btlr)	abnormal macrophage physiology	J:144166
\Tlr6^m2Btlr/\Tlr6^m2Btlr (C57BL/6J-Tlr6^m2Btlr)	decreased tumor necrosis factor secretion	J:144166
\Tlr6^m3Btlr/\Tlr6^m3Btlr (C57BL/6J-Tlr6^m3Btlr)	abnormal macrophage physiology	J:144167
\Tlr6^m3Btlr/\Tlr6^m3Btlr (C57BL/6J-Tlr6^m3Btlr)	decreased tumor necrosis factor secretion	J:144167
\Tlr6^m4Btlr/\Tlr6^m4Btlr (C57BL/6J-Tlr6^m4Btlr)	abnormal macrophage physiology	J:144168
\Tlr6^m4Btlr/\Tlr6^m4Btlr (C57BL/6J-Tlr6^m4Btlr)	decreased tumor necrosis factor secretion	J:144168
\Tlr6^tm1Aki/\Tlr6^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:70578
	abnormal macrophage physiology	J:70578
	decreased interleukin-6 secretion	J:70578
	decreased interleukin-12 secretion	J:70578
	decreased tumor necrosis factor secretion	J:70578
\Tlr7^em2Anu/Y (C57BL/6NCrl-Tlr7^em2Anu)	abnormal B cell physiology	J:324448
	abnormal macrophage physiology	J:324448
	abnormal Peyer's patch morphology	J:324448
	decreased B cell apoptosis	J:324448
	decreased B cell proliferation	J:324448
	enlarged spleen	J:324448
	increased anti-double stranded DNA antibody level	J:324448
	increased anti-nuclear antigen antibody level	J:324448
	increased anti-single stranded DNA antibody level	J:324448
	increased autoantibody level	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased circulating interferon-gamma level	J:324448
	increased circulating interleukin-6 level	J:324448
	increased circulating interleukin-10 level	J:324448
	increased circulating tumor necrosis factor level	J:324448
	increased effector memory CD4-positive, alpha-beta T cell number	J:324448
	increased susceptibility to systemic lupus erythematosus	J:324448
	increased T follicular helper cell number	J:324448
	liver inflammation	J:324448
	lung inflammation	J:324448
	lymph node inflammation	J:324448
\Tlr7^em2Anu/\Tlr7⁺ (C57BL/6NCrl-Tlr7^em2Anu)	abnormal mature B cell morphology	J:324448
	abnormal plasmacytoid dendritic cell physiology	J:324448
	decreased marginal zone B cell number	J:324448
	enlarged spleen	J:324448
	increased anti-double stranded DNA antibody level	J:324448
	increased anti-nuclear antigen antibody level	J:324448
	increased anti-single stranded DNA antibody level	J:324448
	increased autoantibody level	J:324448
	increased B cell number	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased circulating interferon-gamma level	J:324448
	increased circulating interleukin-6 level	J:324448
	increased circulating interleukin-10 level	J:324448
	increased circulating tumor necrosis factor level	J:324448
	increased germinal center B cell number	J:324448
	increased plasma cell number	J:324448
	increased spleen germinal center number	J:324448
	increased T follicular helper cell number	J:324448
	spleen hyperplasia	J:324448
\Tlr7^em2Anu/\Tlr7^em2Anu (C57BL/6NCrl-Tlr7^em2Anu)	abnormal mature B cell morphology	J:324448
	abnormal Peyer's patch morphology	J:324448
	abnormal plasmacytoid dendritic cell physiology	J:324448
	decreased leukocyte cell number	J:324448
	decreased marginal zone B cell number	J:324448
	enlarged spleen	J:324448
	glomerulonephritis	J:324448
	increased anti-nuclear antigen antibody level	J:324448
	increased anti-single stranded DNA antibody level	J:324448
	increased B cell number	J:324448
	increased CD4-positive, alpha-beta T cell number	J:324448
	increased effector memory CD4-positive, alpha-beta T cell number	J:324448
	increased germinal center B cell number	J:324448
	increased inflammatory response	J:324448
	increased plasma cell number	J:324448
	increased spleen germinal center number	J:324448
	increased susceptibility to systemic lupus erythematosus	J:324448
	increased T follicular helper cell number	J:324448
	liver inflammation	J:324448
	lung inflammation	J:324448
	lymph node inflammation	J:324448
	pancreas inflammation	J:324448
	salivary gland inflammation	J:324448
	spleen hyperplasia	J:324448
\Tlr7^rsq1/Y (C57BL/6J-Tlr7^rsq1)	abnormal macrophage physiology	J:128404
\Tlr7^rsq1/Y (C57BL/6J-Tlr7^rsq1)	decreased tumor necrosis factor secretion	J:128404
\Tlr7^rsq1/\Tlr7^rsq1 (C57BL/6J-Tlr7^rsq1)	abnormal macrophage physiology	J:128404
\Tlr7^rsq1/\Tlr7^rsq1 (C57BL/6J-Tlr7^rsq1)	decreased tumor necrosis factor secretion	J:128404
\Tlr7^rsq2/Y (C57BL/6J-Tlr7^rsq2)	abnormal macrophage physiology	J:140020
\Tlr7^rsq2/Y (C57BL/6J-Tlr7^rsq2)	decreased tumor necrosis factor secretion	J:140020
\Tlr7^tm1Aki/\Tlr7^tm1Aki (B6.129P2-Tlr7^tm1Aki)	abnormal dendritic cell physiology	J:118954
\Tlr7^tm1Aki/\Tlr7^tm1Aki (B6.129P2-Tlr7^tm1Aki)	decreased interleukin-12b secretion	J:118954
\Tlr7^tm1Aki/\Tlr7^tm1Aki (involves: 129P2/OlaHsd)	decreased interferon-alpha secretion	J:144400
\Tlr7^tm1Flv/Y (B6.129S1-Tlr7^tm1Flv)	decreased splenocyte proliferation	J:127600
\Tlr7^tm1Flv/Y (B6.129S1-Tlr7^tm1Flv)	increased marginal zone B cell number	J:127600
\Tlr7^tm1Flv/\Tlr7^tm1Flv (involves: 129S1/Sv)	decreased circulating interferon-alpha level	J:89257
\Tlr7^tm1Flv/\Tlr7^tm1Flv (B6.129S1-Tlr7^tm1Flv)	decreased anti-insulin autoantibody level	J:165267
	decreased IgG1 level	J:165267
	decreased IgG2a level	J:165267
	decreased IgG level	J:165267
	decreased IgM level	J:165267
\Tlr8/Tlr7^tm1Vlcg/\Tlr8/Tlr7^tm1Vlcg (B6.Cg-Tlr8/Tlr7^tm1Vlcg)	decreased anti-insulin autoantibody level	J:165267
	decreased follicular B cell number	J:165267
	increased marginal zone B cell number	J:165267
\Tlr8/Tlr7^tm1Vlcg/\Tlr7⁺ \Tlr8/Tlr7^tm1Vlcg/\Tlr8^tm1Vlcg (B6.Cg-Tlr8/Tlr7^tm1Vlcg Tlr8^tm1Vlcg)	abnormal spleen marginal zone morphology	J:165267
	decreased anti-insulin autoantibody level	J:165267
	decreased IgG level	J:165267
	decreased IgM level	J:165267
	decreased marginal zone B cell number	J:165267
	increased IgG level	J:165267
	increased IgM level	J:165267
	increased marginal zone B cell number	J:165267
\Tlr8/Tlr7^tm1Vlcg/\Tlr8/Tlr7^tm1Vlcg (B6.Cg-Tlr8/Tlr7^tm1Vlcg Tlr8^tm1Vlcg)	decreased anti-insulin autoantibody level	J:165267
	decreased follicular B cell number	J:165267
	increased marginal zone B cell number	J:165267
\Tlr8^tm1Vlcg/\Tlr8^tm1Vlcg (B6.129S1-Tlr8^tm1Vlcg)	abnormal spleen marginal zone morphology	J:165267
	decreased B-1a cell number	J:165267
	decreased B-1b cell number	J:165267
	decreased dendritic cell number	J:165267
	decreased IgG1 level	J:165267
	decreased marginal zone B cell number	J:165267
	enlarged spleen	J:165267
	glomerulonephritis	J:165267
	increased anti-double stranded DNA antibody level	J:165267
	increased anti-nuclear antigen antibody level	J:165267
	increased B-2 B cell number	J:165267
	increased circulating interleukin-12 level	J:165267
	increased IgG2a level	J:165267
	increased IgG level	J:165267
	increased IgM level	J:165267
	increased interleukin-6 secretion	J:165267
	increased spleen weight	J:165267
\Tlr9^M1Btlr/\Tlr9^M1Btlr (involves: C57BL/6)	abnormal cytokine secretion	J:88906
	abnormal macrophage physiology	J:88906
	abnormal NK cell physiology	J:88906
	abnormal NK T cell physiology	J:88906
	increased susceptibility to Herpesvirales infection	J:88906
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:88906
\Tlr9^M2Btlr/\Tlr9⁺ (C57BL/6J-Tlr9^M2Btlr)	abnormal macrophage physiology	J:128405
\Tlr9^M2Btlr/\Tlr9^M2Btlr (C57BL/6J-Tlr9^M2Btlr)	abnormal macrophage physiology	J:128405
\Tlr9^M2Btlr/\Tlr9^M2Btlr (C57BL/6J-Tlr9^M2Btlr)	increased susceptibility to Herpesvirales infection	J:128405
\Tlr9^m3Btlr/\Tlr9^m3Btlr (C57BL/6J-Tlr9^m3Btlr)	abnormal macrophage physiology	J:128406
\Tlr9^m3Btlr/\Tlr9^m3Btlr (C57BL/6J-Tlr9^m3Btlr)	decreased B cell proliferation	J:128406
\Tlr9^m4Btlr/\Tlr9⁺ (C57BL/6J-Tlr9^m4Btlr)	abnormal macrophage physiology	J:132489
	abnormal plasmacytoid dendritic cell physiology	J:132489
	decreased B cell proliferation	J:132489
\Tlr9^M5Btlr/? (C57BL/6J-Tlr9^M5Btlr)	abnormal macrophage physiology	J:147856
\Tlr9^M5Btlr/? (C57BL/6J-Tlr9^M5Btlr)	decreased tumor necrosis factor secretion	J:147856
\Tlr9^M5Btlr/\Tlr9⁺ (C57BL/6J-Tlr9^M5Btlr)	decreased interferon-alpha secretion	J:147856
\Tlr9^M5Btlr/\Tlr9⁺ (C57BL/6J-Tlr9^M5Btlr)	decreased interferon-beta secretion	J:147856
\Tlr9^m6Btlr/\Tlr9^m6Btlr (C57BL/6J-Tlr9^m6Btlr)	increased susceptibility to induced colitis	J:155728
\Tlr9^M7Btlr/\Tlr9⁺ (C57BL/6J-Tlr9^M7Btlr)	decreased tumor necrosis factor secretion	J:165701
\Tlr9^M7Btlr/\Tlr9^M7Btlr (C57BL/6J-Tlr9^M7Btlr)	decreased tumor necrosis factor secretion	J:165701
\Tlr9^M8Btlr/\Tlr9^M8Btlr (involves: C57BL/6J)	decreased interferon-gamma secretion	J:168138
\Tlr9^M9Btlr/\Tlr9⁺ (C57BL/6J-Tlr9^M9Btlr)	decreased tumor necrosis factor secretion	J:220063
\Tlr9^M9Btlr/\Tlr9^M9Btlr (C57BL/6J-Tlr9^M9Btlr)	decreased tumor necrosis factor secretion	J:220063
\Tlr9^tm1Aki/\Tlr9^tm1Aki (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell physiology	J:66049
	abnormal dendritic cell physiology	J:66049
	abnormal macrophage physiology	J:117688, J:66049
	abnormal T-helper 1 physiology	J:66049
	decreased inflammatory response	J:66049
	immune system phenotype	J:66049
\Tlr9^tm1Aki/\Tlr9^tm1Aki (involves: 129P2/OlaHsd * BALB/c * C57BL/6)	abnormal dendritic cell physiology	J:88244
\Tlr9^tm1Aki/\Tlr9^tm1Aki (B6.129P2-Tlr9^tm1Aki)	abnormal immune system physiology	J:121070
	abnormal response to infection	J:121070
	decreased interferon-alpha secretion	J:125611
	decreased interferon-beta secretion	J:125611
	decreased interleukin-12b secretion	J:125611, J:118954
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:105435
	decreased susceptibility to parasitic infection	J:116763
	decreased tumor necrosis factor secretion	J:121070
	impaired natural killer cell mediated cytotoxicity	J:125611
\Tlr9^tm1Aki/\Tlr9^tm1Aki (involves: 129P2/OlaHsd)	abnormal leukocyte migration	J:171379
\Tlr9^tm1Aki/\Tlr9^tm1Aki \Tg(IghelMD4)4Ccg/0 \Tg(KLK4mHEL)6Ccg/0 (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:115059
	increased B-1 B cell number	J:115059
\Tlr12^tm1Gho/\Tlr12^tm1Gho (Not Specified)	abnormal macrophage physiology	J:89754
\Tlr12^tm1Gho/\Tlr12^tm1Gho (Not Specified)	increased susceptibility to bacterial infection	J:89754
\Tlr13^m1Btlr/\Tlr13^m1Btlr (C57BL/6J-Tlr13^m1Btlr)	immune system phenotype	J:156849
\Tlsm1^AKR/JMs/\Tlsm1^AKR/JMs (involves: AKR/JMs * SL/Kh)	increased T cell derived lymphoma incidence	J:21741, J:41197, J:33016
\Tlsm1^AKR/JMs/\Tlsm1^SL/Kh (involves: AKR/JMs * SL/Kh)	increased T cell derived lymphoma incidence	J:21741, J:41197, J:33016
\tlss/\tlss (Not Specified)	enlarged mesenteric lymph nodes	J:169366
	enlarged spleen	J:169366
	enlarged thymus	J:169366
\Tlx1^{tm1.1(cre/ERT2)Rygo}/\Tlx1^{tm1.1(cre/ERT2)Rygo} (involves: C57BL/6 * C57BL/6JJcl * C57BL/6NSlc)	absent spleen	J:217489
\Tlx1^tm1Sjk/\Tlx1^tm1Sjk (involves: 129S2/SvPas)	abnormal spleen development	J:17695
	abnormal spleen mesenchyme morphology	J:17695
	absent spleen	J:17695
	increased leukocyte cell number	J:17695
	increased lymphocyte cell number	J:17695
	increased neutrophil cell number	J:17695
\Tlx1^tm1Thr/\Tlx1^tm1Thr (involves: 129P2/OlaHsd * MF1)	abnormal spleen development	J:28700
	absent spleen	J:28700
	increased splenocyte apoptosis	J:28700
\Tlx3^tm1Sjk/\Tlx3^tm1Sjk (involves: 129X1/SvJ)	immune system phenotype	J:60751
\Tm4sf19^em1Sjkm/\Tm4sf19^em1Sjkm (C57BL/6J-Tm4sf19^em1Sjkm)	abnormal osteoclast differentiation	J:343322
	abnormal osteoclast physiology	J:343322
\Tm4sf19^em2Sjkm/\Tm4sf19^em2Sjkm (C57BL/6J-Tm4sf19^em2Sjkm)	abnormal osteoclast differentiation	J:343322
	abnormal osteoclast physiology	J:343322
\Tm4sf20^em1(IMPC)Bay/\Tm4sf20^em1(IMPC)Bay (C57BL/6N-Tm4sf20^em1(IMPC)Bay/BayMmucd)	decreased spleen weight	J:211773
\Tm7sf2^{tm1b(KOMP)Wtsi}/\Tm7sf2^{tm1b(KOMP)Wtsi} (C57BL/6N-Tm7sf2^{tm1b(KOMP)Wtsi}/Orl)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Tm9sf2^em1(IMPC)Tcp/\Tm9sf2⁺ (C57BL/6N-Tm9sf2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Tmc6^tm1.1Les/\Tmc6^tm1.1Les (B6.129S6(Cg)-Tmc6^tm1.1Les)	decreased CD4-positive, alpha-beta T cell number	J:300461
\Tmc6^tm1.1Les/\Tmc6^tm1.1Les (B6.129S6(Cg)-Tmc6^tm1.1Les)	decreased CD8-positive, alpha-beta T cell number	J:300461
\Tmc7^em1(IMPC)Mbp/\Tmc7^em1(IMPC)Mbp (C57BL/6NCrl-Tmc7^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Tmc8^tm1.1Les/\Tmc8^tm1.1Les (B6.129S6(Cg)-Tmc8^tm1.1Les)	decreased CD4-positive, alpha-beta T cell number	J:300461
\Tmc8^tm1.1Les/\Tmc8^tm1.1Les (B6.129S6(Cg)-Tmc8^tm1.1Les)	decreased CD8-positive, alpha-beta T cell number	J:300461
\Tmcc2^em1(IMPC)Mbp/\Tmcc2⁺ (C57BL/6N-Tmcc2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Tmco1^em1(IMPC)J/\Tmco1⁺ (C57BL/6NJ-Tmco1^em1(IMPC)J/J)	increased leukocyte cell number	J:211773
\Tmem8b^em1(IMPC)Tcp/\Tmem8b⁺ (C57BL/6N-Tmem8b^em1(IMPC)Tcp/Tcp)	increased basophil cell number	J:211773
\Tmem30a^tm1.1Xjz/\Tmem30a^tm1.1Xjz \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6J * DBA)	liver inflammation	J:249038
\Tmem35a^{tm1.1(KOMP)Vlcg}/Y (B6(FVB)-Tmem35a^{tm1.1(KOMP)Vlcg})	spleen hyperplasia	J:244268
\Tmem41b^em1Cya/\Tmem41b⁺ (involves: C57BL/6)	decreased susceptibility to Coronaviridae infection	J:316472
\Tmem45a^em1(IMPC)Mbp/\Tmem45a^em1(IMPC)Mbp (C57BL/6N-Tmem45a^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Tmem60^{em1(IMPC)Ccpcz}/\Tmem60^{em1(IMPC)Ccpcz} (C57BL/6N-Tmem60^{em1(IMPC)Ccpcz}/Ccpcz)	decreased effector memory T-helper cell number	J:211773
\Tmem64^{Gt(SYA242)Byg}/\Tmem64^{Gt(SYA242)Byg} (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:198051
	decreased osteoclast cell number	J:198051
\Tmem74^em1(IMPC)Tcp/\Tmem74^em1(IMPC)Tcp (C57BL/6NCrl-Tmem74^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small thymus	J:211773
\Tmem79^ma/\Tmem79^ma (involves: C57BL/6JJcl * CBA/CaGr)	dermatitis	J:202316
\Tmem79^ma/\Tmem79^ma (B6.CBACaGr-Tmem79^ma/J)	blepharitis	J:202453
	dermatitis	J:202453
	increased IgE level	J:202453
	skin inflammation	J:202453
\Tmem86a^{tm1b(KOMP)Mbp}/\Tmem86a^{tm1b(KOMP)Mbp} (C57BL/6N-Tmem86a^{tm1b(KOMP)Mbp}/Kmpc)	abnormal lymph node morphology	J:211773
\Tmem100^{tm1e.1(KOMP)Wtsi}/\Tmem100⁺ (C57BL/6N-Tmem100^{tm1e.1(KOMP)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Tmem102^tm1.1Jyen/\Tmem102^tm1.1Jyen (B6.Cg-Tmem102^tm1.1Jyen)	abnormal leukocyte adhesion	J:200103
	impaired leukocyte migration	J:200103
\Tmem106a^em1Cheyy/\Tmem106a^em1Cheyy (B6.Cg-Tmem106a^em1Cheyy)	abnormal macrophage activation involved in immune response	J:345342
	immune system phenotype	J:345342
	increased circulating interferon-beta level	J:345342
	increased circulating interleukin-6 level	J:345342
	increased circulating tumor necrosis factor level	J:345342
	increased interleukin-6 secretion	J:345342
	increased susceptibility to endotoxin shock	J:345342
	increased tumor necrosis factor secretion	J:345342
\Tmem109^tm1Yamt/\Tmem109^tm1Yamt (B6.Cg-Tmem109^tm1Yamt)	decreased thymocyte apoptosis	J:157864
\Tmem115^{tm1(KOMP)Vlcg}/\Tmem115⁺ (C57BL/6N-Tmem115^{tm1(KOMP)Vlcg}/MbpMmucd)	decreased neutrophil cell number	J:211773
\Tmem116^{tm1b(EUCOMM)Hmgu}/\Tmem116^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tmem116^{tm1b(EUCOMM)Hmgu}/Ieg)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Tmem121b^em1(IMPC)Tcp/\Tmem121b^em1(IMPC)Tcp (C57BL/6NCrl-Tmem121b^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Tmem126a^{tm1a(EUCOMM)Wtsi}/\Tmem126a^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Tmem126a^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased T-helper cell number	J:211773
\Tmem127^{tm1(KOMP)Wtsi}/\Tmem127^{tm1(KOMP)Wtsi} (C57BL/6N-Tmem127^{tm1(KOMP)Wtsi}/Wtsi)	decreased B cell number	J:211773
	decreased B-2 B cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased effector memory CD8-positive, alpha-beta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	decreased KLRG1-positive T-helper cell number	J:211773
	decreased Ly6C high monocyte number	J:211773
	decreased memory-marker NK cell number	J:211773
	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	decreased NK cell number	J:211773
	decreased plasmacytoid dendritic cell number	J:211773
	increased alpha-beta T cell number	J:211773
	increased CD4-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, alpha-beta T cell number	J:211773
	increased CD8-positive, naive alpha-beta T cell number	J:211773
	increased KLRG1-positive NK cell number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased memory-marker NK cell number	J:211773
	increased T cell number	J:211773
\Tmem138^{tm1b(EUCOMM)Wtsi}/\Tmem138^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tmem138^{tm1b(EUCOMM)Wtsi}/BayMmucd)	increased spleen weight	J:211773
\Tmem150b^{em1(IMPC)Ccpcz}/\Tmem150b^{em1(IMPC)Ccpcz} (C57BL/6N-Tmem150b^{em1(IMPC)Ccpcz}/Ccpcz)	decreased eosinophil cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
\Tmem160^em1.1Bros/\Tmem160^em1.1Bros (involves: C57BL/6JRj * FVB/N)	abnormal cytokine level	J:328221
\Tmem178^tm1Lex/\Tmem178^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal osteoclast differentiation	J:228311
	abnormal osteoclast physiology	J:228311
	increased osteoclast cell number	J:228311
	increased susceptibility to induced arthritis	J:228311
\Tmem184b^{tm1.1(KOMP)Vlcg}/\Tmem184b^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tmem184b^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal lymph node morphology	J:211773
\Tmem204^tm1.1Ali/\Tmem204^tm1.1Ali (involves: BALB/c * C57BL/6)	abnormal lymphatic vessel smooth muscle morphology	J:159519
	enlarged lymphatic vessel	J:159519
\Tmem204^tm1Ali/\Tmem204^tm1Ali \Tg(Tie1-cre)9Ref/0 (involves: 129S1/Sv * 129X1/SvJ)	enlarged lymphatic vessel	J:159519
\Tmem209^em1(IMPC)Tcp/\Tmem209⁺ (C57BL/6NCrl-Tmem209^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Tmem219^{tm1(KOMP)Vlcg}/\Tmem219^{tm1(KOMP)Vlcg} (B6J.B6N-Tmem219^{tm1(KOMP)Vlcg})	immune system phenotype	J:236976
	increased eosinophil cell number	J:236976
	increased IgE level	J:236976
	increased interleukin-4 secretion	J:236976
	increased interleukin-13 secretion	J:236976
\Tmem219^{tm1(KOMP)Vlcg}/\Tmem219^{tm1(KOMP)Vlcg} \Tg(Scgb1a1-rtTA,tetO-Il13)1Eli/0 (involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)	lung inflammation	J:236976
\Tmem225^em1(IMPC)Mbp/\Tmem225^em1(IMPC)Mbp (C57BL/6N-Tmem225^em1(IMPC)Mbp/MbpMmucd)	small spleen	J:211773
\Tmem234^tm1Lex/\Tmem234^tm1Lex (B6;129S5-Tmem234^tm1Lex/Mmucd)	increased IgG2a level	J:171883
\Tmem237^{tm1b(EUCOMM)Hmgu}/\Tmem237⁺ (C57BL/6N-Tmem237^{tm1b(EUCOMM)Hmgu}/Ccpcz)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Tmem241^em1Blsg/\Tmem241^em1Blsg (involves: C57BL/6J)	lung inflammation	J:344360
\Tmem248^{tm1.1(KOMP)Vlcg}/\Tmem248^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tmem248^{tm1.1(KOMP)Vlcg}/Ucd)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased thymus weight	J:211773
	increased monocyte cell number	J:211773
	small spleen	J:211773
	small thymus	J:211773
\Tmem256^{tm1.1(KOMP)Vlcg}/\Tmem256^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tmem256^{tm1.1(KOMP)Vlcg}/Ucd)	increased monocyte cell number	J:211773
\Tmem258^{tm1.1(KOMP)Vlcg}/\Tmem258⁺ (involves: C57BL/6NTac)	increased susceptibility to colitis induced morbidity/mortality	J:240635
	increased susceptibility to induced colitis	J:240635
\Tmem263^em1Gww/\Tmem263^em1Gww (C57BL/6J-Tmem263^em1Gww)	decreased spleen weight	J:345905
\Tmem268^em1Cheyy/\Tmem268^em1Cheyy (involves: C57BL/6)	abnormal leukocyte adhesion	J:350812
	abnormal leukocyte physiology	J:350812
	abnormal macrophage physiology	J:350812
	abnormal monocyte cell number	J:350812
	abnormal neutrophil cell number	J:350812
	decreased macrophage cell number	J:350812
	immune system phenotype	J:350812
	impaired leukocyte migration	J:350812
	impaired macrophage phagocytosis	J:350812
	impaired neutrophil phagocytosis	J:350812
	increased chemokine level	J:350812
	increased circulating interferon-beta level	J:350812
	increased circulating tumor necrosis factor level	J:350812
	increased susceptibility to bacterial infection	J:350812
	increased susceptibility to bacterial infection induced morbidity/mortality	J:350812
\Tmem278^em1(IMPC)Mbp/\Tmem278^em1(IMPC)Mbp (C57BL/6N-Tmem278^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\Tmevp2^C57BL/10SnSg/\Tmevp2^C57BL/10SnSg (involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)	decreased susceptibility to Picornaviridae infection	J:54593
\Tmevp3^C57BL/10SnSg/\Tmevp3^C57BL/10SnSg (involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)	decreased susceptibility to Picornaviridae infection	J:54593
\Tmevp3^C57BL/10SnSg/\Tmevp3^SJL/J (involves: A/WySn * C57BL/10SnSg * SJL/J * Swiss)	decreased susceptibility to Picornaviridae infection	J:54593
\Tmprss2^{em1(IMPC)Ccpcz}/\Tmprss2^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tmprss2^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Tmprss2^{tm1(KOMP)Vlcg}/\Tmprss2^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal cytokine secretion	J:283077
	decreased susceptibility to Coronaviridae infection	J:283077
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:214427
	lung inflammation	J:214427
\Tmprss2^tm1Psn/\Tmprss2^tm1Psn (B6JRj.129S1-Tmprss2^tm1Psn)	decreased susceptibility to Orthomyxoviridae infection	J:287633
	decreased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:287633
\Tmprss2^tm1Psn/\Tmprss2^tm1Psn (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	decreased susceptibility to Orthomyxoviridae infection	J:244166
\Tmprss2^{tm2.1(ETV1)Sho}/\Tmprss2^{tm2.1(ETV1)Sho} (involves: C57BL/6 * DBA/2)	prostate gland inflammation	J:212219
\Tmprss6^msk/\Tmprss6^msk (C57BL/6J-Tmprss6^msk)	decreased spleen iron level	J:134446
\Tmprss6^{tm1b(EUCOMM)Wtsi}/\Tmprss6^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Tmprss6^{tm1b(EUCOMM)Wtsi}/Ics)	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased NK cell number	J:211773
	immune system phenotype	J:211773
	increased CD11b-high dendritic cell number	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased Ly6C-positive mature NK cell number	J:211773
\Tmprss6^tm1Dgen/\Tmprss6⁺ (B6.129P2-Tmprss6^tm1Dgen/Crl)	decreased spleen iron level	J:160248
\Tmprss6^tm1Dgen/\Tmprss6^tm1Dgen (B6.129P2-Tmprss6^tm1Dgen/Crl)	decreased spleen iron level	J:160248
	increased spleen weight	J:160248
\Tmprss15^{tm1a(KOMP)Wtsi}/\Tmprss15^{tm1a(KOMP)Wtsi} (C57BL/6N-Tmprss15^{tm1a(KOMP)Wtsi}/Wtsi)	increased leukocyte cell number	J:175295
\Tmub1^tm1Lex/\Tmub1^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased monocyte cell number	J:171883
\Tmub2^{tm1b(KOMP)Wtsi}/\Tmub2^{tm1b(KOMP)Wtsi} (C57BL/6N-Tmub2^{tm1b(KOMP)Wtsi}/Tcp)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Tnbs1^SJL/J/? (involves: C57BL/6J * SJL/J)	increased susceptibility to induced colitis	J:82095
\Tnbs2^SJL/J/? (involves: C57BL/6J * SJL/J)	increased interleukin-12b secretion	J:82095
\Tnbs2^SJL/J/? (involves: C57BL/6J * SJL/J)	increased susceptibility to induced colitis	J:82095
\Tnf^Bpsm1/\Tnf⁺ (involves: C57BL/6)	aortic valve inflammation	J:226052
	increased circulating tumor necrosis factor level	J:226052
	mitral valve inflammation	J:226052
	rheumatoid arthritis	J:226052
\Tnf^Bpsm1/\Tnf⁺ (C.Cg-Tnf^Bpsm1)	aortic valve inflammation	J:226052
	cardiovalvulitis	J:226052
	mitral valve inflammation	J:226052
\Tnf^Bpsm1/\Tnf⁺ \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	increased circulating tumor necrosis factor level	J:226052
\Tnf^Bpsm1/\Tnf^Bpsm1 (involves: C57BL/6)	accelerated temporomandibular joint osteoarthritis	J:226052
	aortic valve inflammation	J:226052
	increased circulating tumor necrosis factor level	J:226052
	mitral valve inflammation	J:226052
	rheumatoid arthritis	J:226052
\Tnf^Bpsm1/\Tnf^Bpsm1 \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6)	increased circulating tumor necrosis factor level	J:226052
\Tnf^em4Boui/\Tnf⁺ (C57BL/6-Tnf^em4Boui)	autoimmune arthritis	J:306876
	cardiovalvulitis	J:306876
	colitis	J:306876
	esophageal inflammation	J:306876
	ileum inflammation	J:306876
\Tnf^em5Boui/\Tnf⁺ \Tnfrsf1a^tm1Mak/\Tnfrsf1a⁺ (involves: 129S2/SvPas * C57BL/6)	autoimmune arthritis	J:306876
	cardiovalvulitis	J:306876
	colitis	J:306876
\Tnf^M1Btlr/\Tnf⁺ (C57BL/6J-Tnf^M1Btlr)	decreased follicular dendritic cell number	J:124642
\Tnf^M1Btlr/\Tnf⁺ (C57BL/6J-Tnf^M1Btlr)	immune system phenotype	J:124642
\Tnf^M1Btlr/\Tnf^M1Btlr (C57BL/6J-Tnf^M1Btlr)	decreased follicular dendritic cell number	J:124642
	immune system phenotype	J:124642
	increased susceptibility to bacterial infection	J:124642
\Tnf^M2Btlr/\Tnf⁺ (C57BL/6J-Tnf^M2Btlr)	decreased macrophage cytokine production	J:213047
\Tnf^M2Btlr/\Tnf⁺ (C57BL/6J-Tnf^M2Btlr)	decreased tumor necrosis factor secretion	J:213047
\Tnf^R8H/\Tnf^R8H (involves: I/St)	increased susceptibility to bacterial infection	J:114302
\Tnf^tm1.1Sned/\Tnf^tm1.1Sned \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:95684
\Tnf^tm1.1Sned/\Tnf^tm1.1Sned \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129 * 129P2/OlaHsd * C57BL/6)	abnormal chemokine secretion	J:95684
	decreased circulating tumor necrosis factor level	J:95684
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684
	increased susceptibility to bacterial infection	J:95684
\Tnf^tm1.1Sned/\Tnf^tm1.1Sned \Tg(Cd4-cre)1Cwi/0 (involves: 129 * C57BL/6 * DBA/2)	decreased circulating tumor necrosis factor level	J:95684
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684
	increased susceptibility to bacterial infection	J:95684
\Tnf^tm1.2Sned/\Tnf^tm1.2Sned (involves: 129/Sv * C57BL/6)	absent Peyer's patches	J:97783
	decreased susceptibility to bacterial infection	J:97783
	increased leukocyte cell number	J:97783
	increased susceptibility to parasitic infection	J:97783
\Tnf^tm1Gkl/\Tnf^tm1Gkl (involves: 129S/SvEv * C57BL/6)	abnormal inflammatory response	J:114740
	abnormal lymph node B cell domain morphology	J:40970
	abnormal lymphocyte physiology	J:114740
	abnormal macrophage physiology	J:114740
	abnormal mesenteric lymph node morphology	J:114740
	abnormal Peyer's patch follicle morphology	J:40970
	abnormal Peyer's patch morphology	J:40970
	abnormal spleen follicular dendritic cell network	J:42579
	abnormal spleen primary B follicle morphology	J:47673
	absent follicular dendritic cells	J:40970
	absent spleen germinal center	J:47673, J:114740
	decreased inflammatory response	J:56068
	decreased Peyer's patch number	J:40970
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114740
	decreased susceptibility to type IV hypersensitivity reaction	J:47673
	immune system phenotype	J:114740
	increased susceptibility to bacterial infection	J:47673, J:114740
\Tnf^tm1Gkl/\Tnf^tm1Gkl (involves: 129S/SvEv)	abnormal chemokine secretion	J:95684
	decreased circulating tumor necrosis factor level	J:95684
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684
	increased susceptibility to bacterial infection	J:95684
\Tnf^tm1Gkl/\Tnf^tm1Gkl (either: B6.129-Tnf^tm1Gkl or (involves: 129 * C57BL/6))	decreased Peyer's patch number	J:97783
	decreased susceptibility to bacterial infection	J:97783
	increased leukocyte cell number	J:97783
	increased lymphocyte cell number	J:97783
	increased neutrophil cell number	J:97783
	increased susceptibility to parasitic infection	J:97783
	small Peyer's patches	J:97783
\Tnf^tm1Gkl/\Tnf^tm1Gkl (involves: 129S/SvEv * C57BL/6J)	abnormal metallophilic macrophage morphology	J:124642
	abnormal Peyer's patch follicle morphology	J:124642
	abnormal Peyer's patch germinal center morphology	J:124642
	abnormal Peyer's patch morphology	J:124642
	abnormal Peyer's patch T cell area morphology	J:124642
	abnormal spleen follicular dendritic cell network	J:124642
	abnormal spleen marginal sinus morphology	J:124642
	abnormal spleen primary B follicle morphology	J:124642
	absent spleen germinal center	J:124642
	decreased Peyer's patch number	J:124642
	increased susceptibility to bacterial infection	J:124642
\Tnf^tm1Gkl/\Tnf^tm1Gkl \Tnfaip3^tm1Ama/\Tnfaip3^tm1Ama (involves: 129S/SvEv * C57BL/6J)	abnormal cytokine secretion	J:92694
	abnormal inflammatory response	J:92694
\Tnf^tm1Gkl/\Tnf^tm1Gkl \Tnfrsf1a^tm1.1Gkl/\Tnfrsf1a^tm1.1Gkl (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:92470
\Tnf^tm1Gkl/\Tnf^tm2Gkl (involves: 129S/SvEv * C57BL/6)	increased circulating tumor necrosis factor level	J:54056
	increased susceptibility to endotoxin shock	J:54056
	increased tumor necrosis factor secretion	J:54056
	rheumatoid arthritis	J:54056
\Tnf^tm1Jods/\Tnf^tm1Jods (involves: C57BL/6)	abnormal immune system physiology	J:98591
	abnormal lymph node primary follicle morphology	J:98591
	abnormal metallophilic macrophage morphology	J:98591
	abnormal Peyer's patch follicle morphology	J:43602
	abnormal Peyer's patch morphology	J:43602, J:98591
	abnormal spleen marginal sinus morphology	J:43602
	abnormal spleen primary B follicle morphology	J:43602, J:98591
	abnormal spleen white pulp morphology	J:43602, J:98591
	absent spleen germinal center	J:98591
	decreased follicular dendritic cell number	J:43602
	decreased Peyer's patch number	J:43602
	decreased susceptibility to endotoxin shock	J:98591
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:44545, J:98591
	increased leukocyte cell number	J:43602
	increased susceptibility to bacterial infection	J:115034, J:98170
	small Peyer's patches	J:43602
\Tnf^tm1Jods/\Tnf^tm1Jods (C57BL/6-Tnf^tm1Jods)	abnormal cytokine level	J:118417
\Tnf^tm1Jods/\Tnf^tm1Jods (C57BL/6-Tnf^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:118417
\Tnf^tm1Jods/\Tnf^tm1Jods (C57BL/6-Lta^tm1Jods)	abnormal spleen B cell follicle morphology	J:78229
\Tnf^tm1Jods/\Tnf^tm1Jods (C57BL/6-Lta^tm1Jods)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:47428
\Tnf^tm1Ljo/\Tnf⁺ (involves: 129S1/Sv)	increased susceptibility to bacterial infection	J:41992
\Tnf^tm1Ljo/\Tnf⁺ (involves: 129S1/Sv)	increased susceptibility to fungal infection	J:41992
\Tnf^tm1Ljo/\Tnf^tm1Ljo (involves: 129S1/Sv)	abnormal chemokine secretion	J:95684
	abnormal cytokine secretion	J:41992
	abnormal follicular dendritic cell physiology	J:41992
	abnormal susceptibility to infection	J:41992
	absent spleen germinal center	J:80616, J:41992
	decreased circulating tumor necrosis factor level	J:95684
	decreased IgG level	J:41992
	decreased spleen B cell follicle number	J:95684
	decreased spleen white pulp amount	J:80616
	decreased susceptibility to autoimmune disorder	J:95684
	decreased susceptibility to endotoxin shock	J:95684, J:41992
	increased susceptibility to bacterial infection	J:80616, J:95684, J:41992
	increased susceptibility to fungal infection	J:41992
\Tnf^tm1Ljo/\Tnf^tm1Ljo (either: B6.129-Tnf^tm1Ljo or (involves: 129 * C57BL/6))	abnormal Peyer's patch follicle morphology	J:97783
	abnormal Peyer's patch germinal center morphology	J:97783
	abnormal Peyer's patch T cell area morphology	J:97783
	absent follicular dendritic cells	J:97783
	decreased Peyer's patch number	J:97783
	decreased susceptibility to bacterial infection	J:97783
	increased leukocyte cell number	J:97783
	increased lymphocyte cell number	J:97783
	increased neutrophil cell number	J:97783
	increased susceptibility to parasitic infection	J:97783
	small Peyer's patches	J:97783
\Tnf^tm1Ljo/\Tnf^tm1Ljo (B6.129S1-Tnf^tm1Ljo)	lung inflammation	J:127028
\Tnf^tm1Ljo/\Tnf^tm1Ljo (involves: 129S1/Sv * C57BL/6)	abnormal lymph node cell ratio	J:127028
	abnormal neutrophil physiology	J:127028
	decreased immunoglobulin level	J:127028
	increased interferon-gamma secretion	J:127028
	increased neutrophil cell number	J:127028
	increased susceptibility to parasitic infection	J:127028
	lymph node hypoplasia	J:127028
	skin inflammation	J:127028
\Tnf^tm1Sek/\Tnf^tm1Sek (B6.Cg-Tnf^tm1Sek)	abnormal cytokine secretion	J:44841
	abnormal macrophage physiology	J:44841
	abnormal mesenteric lymph node morphology	J:44841
	abnormal Peyer's patch germinal center morphology	J:44841
	absent lymph node germinal center	J:44841
	absent spleen germinal center	J:44841
	decreased circulating interferon-gamma level	J:44841
	decreased circulating interleukin-1 alpha level	J:44841
	decreased circulating interleukin-1 beta level	J:44841
	decreased circulating interleukin-6 level	J:44841
	decreased susceptibility to endotoxin shock	J:44841
	immune system phenotype	J:44841
\Tnf^tm2.1Gkl/\Tnf^tm2.1Gkl \Tg(Fabp1-cre)1Jig/0 (involves: 129S/SvEv * FVB/N)	ileum inflammation	J:204557
	increased circulating tumor necrosis factor level	J:204557
	large intestinal inflammation	J:204557
	small intestinal inflammation	J:204557
\Tnf^tm2.1Gkl/\Tnf^tm2.1Gkl \Tg(Lck-cre)I57Jxm/0 (involves: 129S/SvEv * ICR)	small intestinal inflammation	J:108572
\Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * C57BL/6)	abnormal alpha-beta intraepithelial T cell morphology	J:136667
	abnormal CD4-positive, alpha-beta T cell physiology	J:136667
	abnormal CD8-positive, alpha beta T cell morphology	J:136667
	abnormal circulating chemokine level	J:204922
	abnormal T cell physiology	J:136667
	abnormal T cell subpopulation ratio	J:136667
	abnormal T-helper 17 cell physiology	J:204922
	autoimmune arthritis	J:92307, J:136667
	decreased inflammatory response	J:204922
	ileum inflammation	J:204922
	increased circulating tumor necrosis factor level	J:54056, J:204922
	increased dendritic cell number	J:204922
	intestinal inflammation	J:136667
	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:92307, J:54056, J:204922
\Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * C57BL/6 * SPRET/Ei)	autoimmune arthritis	J:92307
	small intestinal inflammation	J:92307
\Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * C57BL/6J)	abnormal cytotoxic T cell physiology	J:108572
	abnormal myelopoiesis	J:108572
	abnormal response to transplant	J:108572
	enlarged spleen	J:108572
	increased CD8-positive, alpha-beta T cell number	J:108572
	increased circulating tumor necrosis factor level	J:264147
	increased tumor necrosis factor secretion	J:264147
	small intestinal inflammation	J:108572
\Tnf^tm2Gkl/\Tnf⁺ (involves: 129S/SvEv * C57BL/6 * CBA)	autoimmune arthritis	J:131930
\Tnf^tm2Gkl/\Tnf⁺ (B6.129S-Tnf^tm2Gkl/Jarn)	abnormal CD4-positive, alpha-beta T cell physiology	J:145626
	abnormal CD8-positive, alpha beta T cell morphology	J:131978
	ileum inflammation	J:131978, J:145626
	increased CD4-positive, alpha-beta memory T cell number	J:145626
	increased CD4-positive, alpha-beta T cell number	J:145626
	increased interferon-gamma secretion	J:131978
	increased interleukin-2 secretion	J:145626
	increased tumor necrosis factor secretion	J:145626
\Tnf^tm2Gkl/\Tnf⁺ \Tnfrsf1a^tm2Gkl/\Tnfrsf1a^tm2Gkl \Tg(Col6a1-cre)1Gkl/? (involves: 129S/SvEv * C57BL/6 * CBA)	autoimmune arthritis	J:131930
	small intestinal inflammation	J:131930
\Tnf^tm2Gkl/\Tnf⁺ \Tnfrsf1b^tm1.1Gkl/\Tnfrsf1b^tm1.1Gkl \Tg(Col6a1-cre)1Gkl/0 (involves: 129S/SvEv * C57BL/6 * C57BL/6J * CBA)	increased circulating tumor necrosis factor level	J:264147
	increased tumor necrosis factor secretion	J:264147
	joint inflammation	J:264147
\Tnf^tm2Gkl/\Tnf⁺ \Tnfrsf1b^tm1.2Gkl/\Tnfrsf1b^tm1.2Gkl (involves: 129S/SvEv * C57BL/6 * C57BL/6J)	aortic valve inflammation	J:264147
	autoimmune arthritis	J:264147
	increased circulating tumor necrosis factor level	J:264147
	increased tumor necrosis factor secretion	J:264147
\Tnf^tm2Gkl/\Tnf⁺ \Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129S/SvEv * 129S2/SvPas * C57BL/6)	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:54056
\Tnf^tm2Gkl/\Tnf^tm2Gkl (involves: 129S/SvEv * C57BL/6)	cardiovalvulitis	J:226052
	increased circulating tumor necrosis factor level	J:54056
	rheumatoid arthritis	J:54056
	small intestinal inflammation	J:54056
	thymus hypoplasia	J:54056
\Tnf^tm2Gkl/\Tnf^tm2Gkl \Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)	increased circulating tumor necrosis factor level	J:54056
	increased tumor necrosis factor secretion	J:54056
\Tnf^tm2Jods/\Tnf^tm2Jods (involves: C57BL/6)	abnormal lymph node cell ratio	J:127028
	decreased immunoglobulin level	J:127028
	immune system phenotype	J:127028
	increased susceptibility to bacterial infection	J:98170
\Tnf^tm2Jods/\Tnf^tm2Jods (C57BL/6-Tnf^tm2Jods)	abnormal immune system physiology	J:98591
	abnormal lymph node primary follicle morphology	J:98591
	abnormal metallophilic macrophage morphology	J:98591
	abnormal Peyer's patch follicle morphology	J:98591
	abnormal spleen follicular dendritic cell network	J:98591
	abnormal spleen primary B follicle morphology	J:98591
	abnormal spleen white pulp morphology	J:98591
	decreased spleen germinal center number	J:98591
	decreased spleen germinal center size	J:98591
	decreased susceptibility to endotoxin shock	J:98591
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:98591
\Tnf^tm3Gkl/\Tnf^tm3Gkl (involves: 129S/SvEv * C57BL/6)	abnormal lymph node B cell domain morphology	J:114740
	abnormal lymphocyte physiology	J:114740
	abnormal mesenteric lymph node morphology	J:114740
	abnormal spleen primary B follicle morphology	J:114740
	absent follicular dendritic cells	J:114740
	absent spleen germinal center	J:114740
	autoimmune response	J:114740
	decreased circulating tumor necrosis factor level	J:114740
	decreased IgG1 level	J:114740
	decreased susceptibility to bacterial infection	J:114740
	decreased susceptibility to endotoxin shock	J:114740
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114740
	decreased tumor necrosis factor secretion	J:114740
\Tnf^tm3Gkl/\Tnf^tm3Gkl \Zfp36^tm1Pjb/\Zfp36^tm1Pjb (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:114740
	myeloid hyperplasia	J:114740
\Tnfaip3^m1Apb/\Tnfaip3^m1Apb (C57BL/6-Tnfaip3^m1Apb)	CNS inflammation	J:324062
	enlarged lymph nodes	J:324062
	increased effector memory T-helper cell number	J:324062
	increased macrophage cell number	J:324062
	increased microglial cell activation	J:324062
	uterus inflammation	J:324062
\Tnfaip3^tm1.1Gho/\Tnfaip3^tm1.1Gho (involves: C57BL/6J)	enlarged spleen	J:217021
\Tnfaip3^tm1.1Gho/\Tnfaip3^tm1.1Gho (involves: C57BL/6J)	immune system phenotype	J:217021
\Tnfaip3^tm1.1Gvl/\Tnfaip3^tm1.1Gvl \Tg(Vil1-cre)997Gum/0 (B6.Cg-Tnfaip3^tm1.1Gvl Tg(Vil1-cre)997Gum)	increased circulating interleukin-6 level	J:163410
	increased susceptibility to induced colitis	J:163410
\Tnfaip3^tm1.1Gvl/\Tnfaip3^tm1.1Gvl \Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak \Tg(Vil1-cre)997Gum/0 (involves: 129S2/SvPas * C57BL/6 * SJL)	decreased susceptibility to induced colitis	J:163410
	increased susceptibility to induced colitis	J:163410
\Tnfaip3^tm1Ama/\Tnfaip3^tm1Ama (involves: C57BL/6J)	abnormal cytokine secretion	J:92694
\Tnfaip3^tm1Ama/\Tnfaip3^tm1Ama (involves: C57BL/6J)	abnormal inflammatory response	J:92694
\Tnfaip3^tm1Ama/\Tnfaip3^tm1Ama (Not Specified)	increased granulocyte number	J:92931
	increased inflammatory response	J:92931
	increased lymphocyte cell number	J:92931
	increased macrophage cell number	J:92931
	intestinal inflammation	J:92931
	joint inflammation	J:92931
	kidney inflammation	J:92931
	liver inflammation	J:92931
\Tnfaip3^tm1Ama/\Tnfaip3^tm1Ama \Tnfrsf1a^tm1Imx/\Tnfrsf1a⁺ (involves: C57BL/6J)	abnormal inflammatory response	J:92694
\Tnfaip3^tm1Ama/\Tnfaip3^tm1Ama \Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (involves: C57BL/6J)	abnormal inflammatory response	J:92694
\Tnfaip3^tm1Homy/\Tnfaip3^tm1Homy \Tg(Mx1-cre)1Cgn/? (involves: 129S6/SvEvTac * C57BL/6J * CBA/J)	abnormal B cell number	J:212681
	abnormal circulating cytokine level	J:212681
	abnormal circulating interleukin level	J:212681
	abnormal myelopoiesis	J:212681
	abnormal spleen morphology	J:212681
	enlarged lymph nodes	J:212681
	increased circulating interferon-gamma level	J:212681
	increased circulating interleukin-1 beta level	J:212681
	increased circulating interleukin-6 level	J:212681
	increased circulating tumor necrosis factor level	J:212681
	liver inflammation	J:212681
	lung inflammation	J:212681
\Tnfaip3^tm2Ama/\Tnfaip3^tm2Ama \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell activation	J:163917
	abnormal B cell morphology	J:163917
	abnormal B-1a B cell morphology	J:163917
	decreased B cell apoptosis	J:163917
	decreased B cell number	J:163917
	increased autoantibody level	J:163917
	increased B cell number	J:163917
	increased B cell proliferation	J:163917
	increased germinal center B cell number	J:163917
	increased IgG level	J:163917
	increased IgM level	J:163917
	increased immature B cell number	J:163917
	increased immunoglobulin level	J:163917
	increased interleukin-6 secretion	J:163917
	increased plasma cell number	J:163917
	increased susceptibility to autoimmune disorder	J:163917
	increased T cell number	J:163917
\Tnfaip3^tm3.1Ama/\Tnfaip3^tm3.1Ama (C57BL/6J-Tnfaip3^tm3.1Ama)	abnormal chemokine secretion	J:203160
	decreased interleukin-6 secretion	J:203160
	enlarged spleen	J:203160
	increased B cell number	J:203160
	increased CD4-positive, alpha-beta T cell number	J:203160
	increased CD8-positive, alpha-beta T cell number	J:203160
	increased susceptibility to induced colitis	J:203160
	myeloid hyperplasia	J:203160
\Tnfaip3^tm4.1Ama/\Tnfaip3^tm4.1Ama (C57BL/6J-Tnfaip3^tm4.1Ama)	abnormal chemokine secretion	J:203160
	decreased interleukin-6 secretion	J:203160
	enlarged spleen	J:203160
	increased B cell number	J:203160
	increased CD4-positive, alpha-beta T cell number	J:203160
	increased CD8-positive, alpha-beta T cell number	J:203160
	increased susceptibility to induced colitis	J:203160
	myeloid hyperplasia	J:203160
\Tnfaip6^tm1Cful/\Tnfaip6^tm1Cful (involves: 129S6/SvEvTac * BALB/c)	decreased inflammatory response	J:193758
\Tnfaip8^{Gt(IST13629C1)Tigm}/\Tnfaip8^{Gt(IST13629C1)Tigm} (involves: C57BL/6N)	immune system phenotype	J:223320
	increased circulating interleukin-6 level	J:223320
	increased circulating interleukin-17 level	J:223320
	increased interleukin-1 beta secretion	J:223320
	increased interleukin-6 secretion	J:223320
	increased interleukin-17 secretion	J:223320
	increased neutrophil cell number	J:223320
	increased susceptibility to induced colitis	J:223320
	small spleen	J:223320
\Tnfaip8^{Gt(IST13629C1)Tigm}/\Tnfaip8^{Gt(IST13629C1)Tigm} \Tnfaip8l1^em1Huwa/\Tnfaip8l1^em1Huwa (involves: C57BL/6 * C57BL/6N)	colitis	J:342074
	decreased spleen weight	J:342074
	increased leukocyte cell number	J:342074
	increased T-helper 17 cell number	J:342074
\Tnfaip8l1^em1(IMPC)Mbp/\Tnfaip8l1^em1(IMPC)Mbp (C57BL/6N-Tnfaip8l1^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Tnfaip8l1^em1Huwa/\Tnfaip8l1^em1Huwa (C57BL/6-Tnfaip8l1^em1Huwa)	increased susceptibility to colitis induced morbidity/mortality	J:342074
	increased susceptibility to induced colitis	J:342074
\Tnfaip8l2^tm1Yhcn/\Tnfaip8l2^tm1Yhcn (129S6/SvEvTac-Tnfaip8l2^tm1Yhcn)	abnormal B cell activation	J:139785
	abnormal B cell physiology	J:139785
	abnormal CD4-positive, alpha-beta T cell physiology	J:139785
	abnormal cytotoxic T cell physiology	J:139785
	abnormal inflammatory response	J:139785
	abnormal leukocyte morphology	J:139785
	abnormal macrophage activation involved in immune response	J:139785
	abnormal myeloid dendritic cell morphology	J:139785
	abnormal spleen morphology	J:139785
	abnormal T cell apoptosis	J:139785
	chronic inflammation	J:139785
	decreased IgG2a level	J:139785
	decreased IgG2b level	J:139785
	enlarged spleen	J:139785
	increased B cell number	J:139785
	increased circulating interleukin-1 beta level	J:139785
	increased circulating interleukin-6 level	J:139785
	increased circulating interleukin-10 level	J:139785
	increased circulating interleukin-12 level	J:139785
	increased circulating tumor necrosis factor level	J:139785
	increased interferon-gamma secretion	J:139785
	increased interleukin-1 beta secretion	J:139785
	increased interleukin-2 secretion	J:139785
	increased interleukin-4 secretion	J:139785
	increased interleukin-6 secretion	J:139785
	increased interleukin-12 secretion	J:139785
	increased interleukin-17 secretion	J:139785
	increased spleen white pulp amount	J:139785
	increased susceptibility to endotoxin shock	J:139785
	increased T cell number	J:139785
	increased tumor necrosis factor secretion	J:139785
	intestinal inflammation	J:139785
	liver inflammation	J:139785
	lung inflammation	J:139785
	lymph node inflammation	J:139785
	spleen hyperplasia	J:139785
\Tnfrsf1a^{em1(IMPC)Ccpcz}/\Tnfrsf1a^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tnfrsf1a^{em1(IMPC)Ccpcz}/Ccpcz)	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased neutrophil cell number	J:211773
	increased NK cell number	J:211773
\Tnfrsf1a^tm1.1Gkl/\Tnfrsf1a⁺ (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
\Tnfrsf1a^tm1.1Gkl/\Tnfrsf1a^tm1.1Gkl (involves: 129/Sv * C57BL/6)	abnormal cytokine secretion	J:92470
	decreased susceptibility to bacterial infection	J:92470
	increased susceptibility to experimental autoimmune encephalomyelitis	J:92470
	liver inflammation	J:92470
\Tnfrsf1a^tm1.1Gkl/\Tnfrsf1a^tm1.1Gkl \Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129/Sv * C57BL/6)	liver inflammation	J:92470
\Tnfrsf1a^tm1Blt/\Tnfrsf1a⁺ (involves: 129P2/OlaHsd)	decreased circulating interleukin-6 level	J:210950
\Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system physiology	J:14424
	abnormal lymph node B cell domain morphology	J:40970
	abnormal Peyer's patch follicle morphology	J:40970
	abnormal Peyer's patch morphology	J:40970
	absent follicular dendritic cells	J:40970
	decreased IgG1 level	J:115225
	decreased interleukin-6 secretion	J:14424
	decreased Peyer's patch number	J:40970
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	increased susceptibility to bacterial infection	J:14424
	increased susceptibility to parasitic infection	J:114203
	increased susceptibility to type I hypersensitivity reaction	J:92307
\Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm1Blt (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	decreased susceptibility to bacterial infection	J:50903
\Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd)	impaired humoral immune response	J:210950
\Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm1Blt (involves: 129P2/OlaHsd)	increased susceptibility to bacterial infection induced morbidity/mortality	J:210950
\Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm1Blt \Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	abnormal lymph node cortex morphology	J:119206
	abnormal lymph node primary follicle morphology	J:119206
	abnormal lymph node secondary follicle morphology	J:119206
	absent lymph node germinal center	J:119206
	absent spleen germinal center	J:119206
	decreased IgG1 level	J:115225
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	immune system phenotype	J:119206
	increased susceptibility to parasitic infection	J:114203
	small Peyer's patches	J:119206
\Tnfrsf1a^tm1Blt/\Tnfrsf1a^tm2Gkl \Tg(Cr2-cre)3Cgn/0 (involves: 129P2/OlaHsd * 129S/SvEv)	immune system phenotype	J:113314
\Tnfrsf1a^tm1Imx/\Tnfrsf1a⁺ (involves: C57BL/6)	decreased circulating interleukin-6 level	J:210950
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	abnormal immune system physiology	J:45147
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (C57BL/6-Tnfrsf1a^tm1Imx)	decreased inflammatory response	J:45147
	decreased microglial cell number	J:112713
	decreased susceptibility to endotoxin shock	J:45147
	increased circulating tumor necrosis factor level	J:45147
	increased susceptibility to bacterial infection	J:45147
	lung inflammation	J:120174
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (C57BL/6-Tnfrsf1a^tm1Imx/J)	abnormal chemokine secretion	J:160543
	abnormal follicular dendritic cell morphology	J:160543
	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	decreased susceptibility to endotoxin shock	J:160543
	increased circulating tumor necrosis factor level	J:160543
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (involves: C57BL/6)	impaired humoral immune response	J:210950
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:210950
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx \Tg(Ins2-Cxcl13)1Cys/0 (involves: C57BL/6 * DBA/2)	abnormal lymph organ development	J:110548
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx \Tg(Thy1-APP)3Somm/0 (involves: C57BL/6 * C57BL/6J * DBA/2)	microgliosis	J:134832
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx \Tnfrsf1b^tm1Imx/\Tnfrsf1b^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	decreased inflammatory response	J:45147
	decreased microglial cell activation	J:33864
	decreased susceptibility to endotoxin shock	J:45147
	decreased susceptibility to experimental autoimmune uveoretinitis	J:115094
	decreased susceptibility to induced arthritis	J:120707
	increased circulating tumor necrosis factor level	J:45147
	increased susceptibility to bacterial infection	J:58851
	osteomyelitis	J:58851
\Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx \Tnfrsf1b^tm1Imx/\Tnfrsf1b^tm1Imx (B6.129S-Tnfrsf1b^tm1Imx Tnfrsf1a^tm1Imx/J)	decreased susceptibility to Coronaviridae infection	J:288523
\Tnfrsf1a^tm1Mak/\Tnfrsf1a⁺ (involves: 129S2/SvPas)	decreased circulating interleukin-6 level	J:210950
\Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6J * DBA/2J)	granulomatous inflammation	J:55889
\Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas * C57BL/6J * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
\Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak (involves: 129S2/SvPas)	abnormal spleen germinal center morphology	J:139030
	decreased circulating interleukin-6 level	J:138824
	decreased IgG level	J:139030
	decreased susceptibility to bacterial infection	J:4753, J:121930
	impaired humoral immune response	J:210950
	increased circulating tumor necrosis factor level	J:139030
	increased susceptibility to bacterial infection induced morbidity/mortality	J:4753, J:139030, J:210950
\Tnfrsf1a^tm1Mak/\Tnfrsf1a^tm1Mak \Tnip1^{Gt(E059E05)Wrst}/\Tnip1^{Gt(E059E05)Wrst} (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)	glomerulonephritis	J:180054
	increased neutrophil cell number	J:180054
	increased susceptibility to systemic lupus erythematosus	J:180054
	spleen hyperplasia	J:180054
\Tnfrsf1a^tm1Rsie/\Tnfrsf1a⁺ (B6.Cg-Tnfrsf1a^tm1Rsie)	increased circulating tumor necrosis factor level	J:160543
	increased interleukin-6 secretion	J:160543
	increased susceptibility to endotoxin shock	J:160543
\Tnfrsf1a^tm1Rsie/\Tnfrsf1a^tm1Rsie (B6.Cg-Tnfrsf1a^tm1Rsie)	abnormal chemokine secretion	J:160543
	abnormal follicular dendritic cell morphology	J:160543
	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-1 beta level	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	decreased susceptibility to endotoxin shock	J:160543
	increased circulating tumor necrosis factor level	J:160543
\Tnfrsf1a^tm2.1Rsie/\Tnfrsf1a⁺ (B6.Cg-Tnfrsf1a^tm2.1Rsie)	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-1 beta level	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	increased interleukin-6 secretion	J:160543
	increased susceptibility to endotoxin shock	J:160543
\Tnfrsf1a^tm2.1Rsie/\Tnfrsf1a⁺ (involves: 129S6/SvEvTac)	increased susceptibility to endotoxin shock	J:160543
\Tnfrsf1a^tm2.1Rsie/\Tnfrsf1a^tm2.1Rsie (B6.Cg-Tnfrsf1a^tm2.1Rsie)	abnormal chemokine secretion	J:160543
	abnormal macrophage physiology	J:160543
	decreased circulating interleukin-6 level	J:160543
	decreased interleukin-6 secretion	J:160543
	decreased susceptibility to endotoxin shock	J:160543
	increased circulating tumor necrosis factor level	J:160543
\Tnfrsf1a^{tm2b(EUCOMM)Wtsi}/\Tnfrsf1a^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Tnfrsf1a^{tm2b(EUCOMM)Wtsi}/H)	decreased monocyte cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Tnfrsf1b^{tm1a(EUCOMM)Wtsi}/\Tnfrsf1b^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Tnfrsf1b^{tm1a(EUCOMM)Wtsi}/Ics)	decreased T cell number	J:165965
\Tnfrsf1b^tm1Imx/\Tnfrsf1b^tm1Imx (involves: 129S7/SvEvBrd * C57BL/6)	increased circulating tumor necrosis factor level	J:45147
	increased inflammatory response	J:45147
	lung inflammation	J:120174
	microgliosis	J:112713
\Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (B6.129S2-Tnfrsf1b^tm1Mwm/J)	decreased interferon-gamma secretion	J:107039
	decreased interleukin-2 secretion	J:107039
	decreased T cell proliferation	J:107039
	immune system phenotype	J:288523
\Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6J)	abnormal immune system physiology	J:21815
	increased susceptibility to bacterial infection	J:21815
\Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6J * NOD)	decreased susceptibility to autoimmune diabetes	J:64051
	periinsulitis	J:64051
\Tnfrsf1b^tm1Mwm/\Tnfrsf1b^tm1Mwm (involves: 129S2/SvPas * C57BL/6)	decreased susceptibility to bacterial infection	J:50903
	increased susceptibility to experimental autoimmune encephalomyelitis	J:115225
	increased susceptibility to parasitic infection	J:114203
\Tnfrsf4^tm1Mfb/\Tnfrsf4^tm1Mfb (involves: 129P2/OlaHsd * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:59204
\Tnfrsf4^tm1Nik/\Tnfrsf4^tm1Nik (involves: 129S4/SvJae * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:64552
	abnormal T-helper 2 physiology	J:68588
	decreased susceptibility to type I hypersensitivity reaction	J:68588
	decreased T cell proliferation	J:58979, J:64552
	immune system phenotype	J:58979
\Tnfrsf8^tm1Mak/\Tnfrsf8^tm1Mak (involves: 129P2/OlaHsd * C57BL/6)	enlarged thymus	J:62854
	immune system phenotype	J:62854
	increased thymocyte number	J:62854
\Tnfrsf8^tm1Mak/\Tnfrsf8^tm1Mak (involves: C57BL/6)	decreased susceptibility to graft versus host disease	J:92723
\Tnfrsf9^em1Ygch/\Tnfrsf9^em1Ygch (NOD/ShiLtDvs-Tnfrsf9^em1Ygch)	abnormal T cell physiology	J:208927
	immune system phenotype	J:208927
	insulitis	J:208927
\Tnfrsf9^em2Ygch/\Tnfrsf9^em2Ygch (NOD/ShiLtDvs-Tnfrsf9^em2Ygch)	abnormal T cell physiology	J:208927
	immune system phenotype	J:208927
	insulitis	J:208927
\Tnfrsf9^m1Btlr/\Tnfrsf9^m1Btlr (C57BL/6J-Tnfrsf9^m1Btlr)	decreased CD8-positive, alpha-beta T cell number	J:265260
	decreased CD8-positive, naive alpha-beta T cell number	J:265260
	decreased single-positive T cell number	J:265260
	increased B cell number	J:265260
	increased effector memory CD4-positive, alpha-beta T cell number	J:265260
	increased effector memory CD8-positive, alpha-beta T cell number	J:265260
\Tnfrsf9^tm1Byk/\Tnfrsf9^tm1Byk (B6.Cg-Tnfrsf9^tm1Byk)	abnormal cytotoxic T cell physiology	J:83996
	decreased IgG2a level	J:83996
	decreased IgG3 level	J:83996
	decreased interferon-gamma secretion	J:83996
	decreased interleukin-2 secretion	J:83996
	decreased interleukin-4 secretion	J:83996
	increased T cell proliferation	J:83996
\Tnfrsf9^tm1Byk/\Tnfrsf9^tm1Byk (C.Cg-Tnfrsf9^tm1Byk)	abnormal cytotoxic T cell physiology	J:83722
	abnormal immunoglobulin level	J:83996
	decreased IgG2a level	J:83996
	decreased IgG3 level	J:83996
	decreased interferon-gamma secretion	J:83996
	decreased interleukin-2 secretion	J:83996
	decreased interleukin-4 secretion	J:83996
	decreased interleukin-12 secretion	J:83722
	increased IgA level	J:83722
	increased IgG2a level	J:83722
	increased IgG2b level	J:83722
	increased splenocyte proliferation	J:83722
	increased T cell proliferation	J:83996
\Tnfrsf9^tm1Lpc/\Tnfrsf9^tm1Lpc (B6.129-Tnfrsf9^tm1Lpc)	abnormal memory T cell physiology	J:145439
\Tnfrsf9^tm1Lpc/\Tnfrsf9^tm1Lpc (B6.129-Tnfrsf9^tm1Lpc)	immune system phenotype	J:145439
\Tnfrsf10b^tm1Wnt/\Tnfrsf10b^tm1Wnt (involves: 129S6/SvEvTac * C57BL/6)	abnormal innate immunity	J:94681
	abnormal interferon level	J:94681
	decreased susceptibility to Herpesvirales infection	J:94681
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:94681
	increased circulating interferon-gamma level	J:94681
	increased circulating interleukin-12b level	J:94681
	increased interleukin-12 secretion	J:94681
	increased NK cell number	J:94681
	increased tumor necrosis factor secretion	J:94681
\Tnfrsf10b^tm1Wsed/\Tnfrsf10b^tm1Wsed (involves: 129P2/OlaHsd)	enlarged thymus	J:96816
\Tnfrsf11a^del8/\Tnfrsf11a^del8 (involves: 129)	abnormal mesenteric lymph node morphology	J:111512
	decreased osteoclast cell number	J:111512
	enlarged spleen	J:111512
\Tnfrsf11a^tm1.1Pngr/\Tnfrsf11a^tm1.2Pngr \Tg(Gfap-cre)2Brn/0 (involves: 129 * C57BL/6 * C57BL/6NTac * FVB/N)	decreased susceptibility to endotoxin shock	J:155398
\Tnfrsf11a^tm1.1Pngr/\Tnfrsf11a^tm1.2Pngr \Tg(Nes-cre)1Kln/0 (involves: 129 * C57BL/6 * C57BL/6NTac * SJL)	decreased susceptibility to endotoxin shock	J:155398
\Tnfrsf11a^tm1.1Sral/\Tnfrsf11a⁺ (B6.129P2(Cg)-Tnfrsf11a^tm1.1Sral)	abnormal osteoclast differentiation	J:312215
	abnormal osteoclast physiology	J:312215
	increased osteoclast cell number	J:312215
\Tnfrsf11a^tm1.1Sral/\Tnfrsf11a^tm1.1Sral (B6.129P2(Cg)-Tnfrsf11a^tm1.1Sral)	abnormal osteoclast differentiation	J:312215
	decreased osteoclast cell number	J:312215
\Tnfrsf11a^tm1.2Pngr/\Tnfrsf11a^tm1.2Pngr (B6.Cg-Tnfrsf11a^tm1.2Pngr)	absent lymph nodes	J:155398
	decreased osteoclast cell number	J:155398
\Tnfrsf11a^tm1Imx/\Tnfrsf11a^tm1Imx (involves: 129 * C57BL/6)	abnormal osteoclast differentiation	J:57899
	absent lymph nodes	J:57899
	decreased B cell number	J:57899
	decreased mature B cell number	J:57899
	decreased osteoclast cell number	J:57899
	decreased Peyer's patch number	J:57899
	decreased spleen germinal center size	J:57899
	increased granulocyte number	J:57899
	increased neutrophil cell number	J:57899
	small Peyer's patches	J:57899
	spleen hyperplasia	J:57899
\Tnfrsf11a^tm1Imx/\Tnfrsf11a^tm1Imx (involves: 129)	abnormal negative T cell selection	J:125864
\Tnfrsf11a^tm1Imx/\Tnfrsf11a^tm1Imx (involves: 129)	abnormal thymus epithelium morphology	J:125864
\Tnfrsf11b^em1(IMPC)Mbp/\Tnfrsf11b^em1(IMPC)Mbp (C57BL/6N-Tnfrsf11b^em1(IMPC)Mbp/MbpMmucd)	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Tnfrsf11b^tm1Eac/\Tnfrsf11b^tm1Eac (involves: 129S4/SvJaeSor)	abnormal dendritic cell antigen presentation	J:67105
	abnormal immune system morphology	J:67105
	abnormal immune system physiology	J:67105
	abnormal immunoglobulin level	J:67105
	abnormal pro-B cell differentiation	J:67105
	increased B cell number	J:67105
	increased immature B cell number	J:67105
	increased pro-B cell number	J:67105
\Tnfrsf11b^tm1Khs/\Tnfrsf11b^tm1Khs (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:111153, J:48325
	abnormal osteoclast physiology	J:111153
	increased osteoclast cell number	J:80503
\Tnfrsf11b^tm1Wss/\Tnfrsf11b^tm1Wss (either: (involves: 129X1/SvJ * C57BL/6) or (involves: 129X1/SvJ * Black Swiss))	abnormal osteoclast morphology	J:47602
\Tnfrsf12a^tm1Biib/\Tnfrsf12a^tm1Biib (B6.129S4-Tnfrsf12a^tm1Biib)	abnormal chemokine secretion	J:126416
\Tnfrsf13b^tm1Cmac/\Tnfrsf13b^tm1Cmac (Not Specified)	enlarged spleen	J:91914
	immune system phenotype	J:92334
	increased B cell number	J:91914
\Tnfrsf13b^tm1Rjb/\Tnfrsf13b^tm1Rjb (involves: 129X1/SvJ * C57BL/6)	abnormal B cell activation	J:69474
	decreased IgA level	J:69474
	decreased IgM level	J:69474
	increased B cell number	J:69474
	increased B cell proliferation	J:69474
	increased spleen weight	J:69474
\Tnfrsf13b^tm1Rjb/\Tnfrsf13b^tm1Rjb (involves: 129X1/SvJ)	abnormal class switch recombination	J:95288
	decreased IgA level	J:95288
	decreased IgE level	J:95288
	decreased IgG1 level	J:95288
\Tnfrsf13b^tm1Vmd/\Tnfrsf13b^tm1Vmd (involves: C57BL/6)	abnormal immunoglobulin level	J:70172
	abnormal lymph node primary follicle morphology	J:70172, J:82331
	abnormal Peyer's patch follicle morphology	J:70172
	abnormal spleen morphology	J:70172
	abnormal spleen periarteriolar lymphoid sheath morphology	J:70172, J:82331
	abnormal spleen primary B follicle morphology	J:70172
	enlarged lymph nodes	J:70172, J:82331
	enlarged spleen	J:70172, J:82331
	glomerulonephritis	J:82331
	increased anti-double stranded DNA antibody level	J:82331
	increased anti-nuclear antigen antibody level	J:82331
	increased B cell number	J:70172, J:82331
	increased B cell proliferation	J:70172
	increased follicular B cell number	J:70172
	increased IgG1 level	J:70172
	increased marginal zone B cell number	J:70172
	increased mature B cell number	J:70172
	increased spleen germinal center size	J:70172
	increased spleen white pulp amount	J:70172
	increased transitional stage B cell number	J:70172
	kidney inflammation	J:82331
	liver inflammation	J:82331
\Tnfrsf13c^Bcmd1/\Tnfrsf13c^Bcmd1 (A/WySnJ)	abnormal lymphocyte physiology	J:92334
	decreased B cell proliferation	J:122315
	decreased IgG level	J:122315
	decreased interferon-gamma secretion	J:92334
	decreased T cell proliferation	J:92334
	increased length of allograft survival	J:92334
\Tnfrsf13c^m1Btlr/\Tnfrsf13c^m1Btlr (C57BL/6J-Tnfrsf13c^m1Btlr)	decreased B cell number	J:265247
\Tnfrsf13c^M2Btlr/\Tnfrsf13c^M2Btlr (C57BL/6J-Tnfrsf13c^M2Btlr)	decreased B cell number	J:265247
\Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (C57BL/6-Tnfrsf13c^tm1Mass)	abnormal B cell physiology	J:113556
	absent marginal zone B cells	J:92732
	arrested B cell differentiation	J:92732
	decreased B-2 B cell number	J:92732
	decreased IgG1 level	J:92732
	decreased IgG2a level	J:92732
	decreased IgG2b level	J:92732
	decreased IgG3 level	J:92732
	decreased IgG level	J:92732
	decreased IgM level	J:92732
	decreased mature B cell number	J:92732
\Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: C57BL/6)	decreased lymphocyte cell number	J:139293
\Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass (involves: C57BL/6)	decreased mature B cell number	J:139293
\Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass \Tg(BCL2)22Wehi/0 (involves: C57BL/6 * SJL)	immune system phenotype	J:92732
\Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass \Traf2^tm1Rbr/\Traf2^tm1Rbr (involves: C57BL/6)	decreased germinal center B cell number	J:172843
	decreased spleen germinal center size	J:172843
	immune system phenotype	J:172843
\Tnfrsf13c^tm1Mass/\Tnfrsf13c^tm1Mass \Traf3^tm1Rbr/\Traf3^tm1Rbr (involves: C57BL/6)	immune system phenotype	J:172843
\Tnfrsf13c^tm1Msc/\Tnfrsf13c^tm1Msc (involves: 129P2/OlaHsd * C57BL/6)	abnormal humoral immune response	J:92676
	absent marginal zone B cells	J:92676
	absent transitional stage B cells	J:92676
	decreased B cell number	J:92676
	decreased B-2 B cell number	J:92676
	decreased IgD level	J:92676
	decreased IgG1 level	J:92676
	decreased IgG level	J:92676
	decreased IgM level	J:92676
\Tnfrsf14^tm1Csj/\Tnfrsf14^tm1Csj (B6.Cg-Tnfrsf14^tm1Csj)	decreased interferon-gamma secretion	J:169369
	decreased interleukin-6 secretion	J:169369
	decreased interleukin-10 secretion	J:169369
	decreased susceptibility to induced colitis	J:169369
	decreased tumor necrosis factor secretion	J:169369
\Tnfrsf14^tm1Kpf/\Tnfrsf14^tm1Kpf (B6.129P2-Tnfrsf14^tm1Kpf)	abnormal T cell physiology	J:99456
	increased T cell proliferation	J:99456
\Tnfrsf14^tm1Kro/\Tnfrsf14^tm1Kro (C57BL/6-Tnfrsf14^tm1Kro)	decreased susceptibility to Herpesvirales infection	J:243038
\Tnfrsf14^tm1Wwhk/\Tnfrsf14^tm1Wwhk (B6.Cg-Tnfrsf14^tm1Wwhk)	decreased length of allograft survival	J:119356
\Tnfrsf17^tm1Kplm/\Tnfrsf17^tm1Kplm (involves: 129P2/OlaHsd * C57BL/6)	decreased plasma cell number	J:124543
\Tnfrsf18^tm1Ppp/\Tnfrsf18^tm1Ppp (involves: 129/Sv * C57BL/6)	abnormal T cell activation	J:77393
	immune system phenotype	J:77393
	increased interleukin-2 secretion	J:77393
	increased T cell apoptosis	J:77393
	increased T cell proliferation	J:77393
\Tnfrsf21^tm1Ddy/\Tnfrsf21^tm1Ddy (involves: 129S1/Sv * 129X1/SvJ)	abnormal T-helper 1 physiology	J:70594
	abnormal T-helper 2 physiology	J:70594
	increased B cell proliferation	J:109341
	increased IgG1 level	J:109341
	increased IgG2a level	J:109341
	increased IgG2b level	J:109341
	increased IgG3 level	J:109341
	increased IgM level	J:109341
	increased interleukin-4 secretion	J:70594
	increased interleukin-5 secretion	J:70594
	increased interleukin-10 secretion	J:70594
	increased interleukin-13 secretion	J:70594
	increased spleen germinal center size	J:109341
	increased T cell proliferation	J:70594
\Tnfrsf21^tm1Vmd/\Tnfrsf21^tm1Vmd (involves: C57BL/6)	abnormal cell-mediated immunity	J:72761
	abnormal T-helper 2 physiology	J:72761
	immune system phenotype	J:72761
	increased CD4-positive, alpha-beta T cell number	J:72761
	increased CD8-positive, alpha-beta T cell number	J:72761
	increased IgE level	J:72761
	increased IgG1 level	J:72761
	increased IgG2a level	J:72761
	increased IgM level	J:72761
	increased interferon-gamma secretion	J:72761
	increased interleukin-2 secretion	J:72761
	increased interleukin-4 secretion	J:72761
	increased T cell number	J:72761
	increased T cell proliferation	J:72761
\Tnfrsf25^tm1Mjo/\Tnfrsf25^tm1Mjo (involves: 129P2/OlaHsd)	abnormal negative T cell selection	J:84536
	decreased T cell apoptosis	J:84536
	enlarged thymus	J:84536
	increased thymocyte number	J:84536
\Tnfsf4^tm1Shr/\Tnfsf4^tm1Shr (involves: 129S4/SvJae)	abnormal cell-mediated immunity	J:59203
	abnormal dendritic cell antigen presentation	J:59203
	decreased interferon-gamma secretion	J:59203
	decreased interleukin-2 secretion	J:59203
	decreased interleukin-4 secretion	J:59203
	decreased susceptibility to type IV hypersensitivity reaction	J:59203
	decreased T cell proliferation	J:59203
	immune system phenotype	J:59203
\Tnfsf4^tm1Shr/\Tnfsf4^tm1Shr (NOD.129S4-Tnfsf4^tm1Shr)	decreased susceptibility to autoimmune diabetes	J:86926
\Tnfsf4^tm1Shr/\Tnfsf4^tm1Shr (C.129S4-Tnfsf4^tm1Shr)	abnormal cytokine secretion	J:59203
\Tnfsf4^tm1Shr/\Tnfsf4^tm1Shr (C.129S4-Tnfsf4^tm1Shr)	abnormal dendritic cell antigen presentation	J:59203
\Tnfsf4^tm1Sug/\Tnfsf4^tm1Sug (B6.129S4-Tnfsf4^tm1Sug)	abnormal cytokine secretion	J:80214
	decreased susceptibility to type IV hypersensitivity reaction	J:80214
	decreased T cell proliferation	J:80214
\Tnfsf8^tm1Pod/\Tnfsf8^tm1Pod (B6.129X1-Tnfsf8^tm1Pod)	decreased susceptibility to graft versus host disease	J:92723
\Tnfsf9^tm1Thw/\Tnfsf9^tm1Thw (involves: 129 * C57BL/6)	abnormal cytotoxic T cell physiology	J:76373
\Tnfsf9^tm1Thw/\Tnfsf9^tm1Thw (involves: 129 * C57BL/6)	immune system phenotype	J:76373
\Tnfsf10^tm1Mjs/\Tnfsf10^tm1Mjs (C.129-Tnfsf10^tm1Mjs)	abnormal negative T cell selection	J:82145
	decreased susceptibility to bacterial infection	J:87620
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:87620
	immune system phenotype	J:84838
	impaired natural killer cell mediated cytotoxicity	J:73948
	liver inflammation	J:87620
	thymus hyperplasia	J:84838, J:82145
\Tnfsf10^tm1Mjs/\Tnfsf10^tm1Mjs (B6.129-Tnfsf10^tm1Mjs)	abnormal negative T cell selection	J:82145
	immune system phenotype	J:84838
	increased IgG1 level	J:82145
	increased IgG2a level	J:82145
	increased interferon-gamma secretion	J:82145
	increased interleukin-2 secretion	J:82145
	increased susceptibility to autoimmune diabetes	J:82145
	increased susceptibility to experimental autoimmune encephalomyelitis	J:101672
	increased susceptibility to induced arthritis	J:82145
	thymus hyperplasia	J:82145
\Tnfsf10^tm1Sdg/\Tnfsf10^tm1Sdg (B6.129-Tnfsf10^tm1Sdg)	immune system phenotype	J:79085
\Tnfsf10^tm1Sdg/\Tnfsf10^tm1Sdg (involves: 129 * C57BL/6)	immune system phenotype	J:79085
\Tnfsf11^tles/\Tnfsf11^tles (involves: 129S6/SvEvTac * C57BL/6J)	absent lymph nodes	J:179743
	decreased osteoclast cell number	J:179743
	enlarged spleen	J:179743
	thymus hypoplasia	J:179743
\Tnfsf11^tles/\Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)	decreased osteoclast cell number	J:179743
\Tnfsf11^{tm1(TNFSF11)Kost}/\Tnfsf11^{tm1(TNFSF11)Kost} (involves: 129/Sv * Black Swiss)	abnormal osteoclast morphology	J:166279
\Tnfsf11^tm1.1Caob/\Tnfsf11^tm1.1Caob \Tg(Dmp1-cre)1Jqfe/0 (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB)	abnormal osteoclast cell number	J:177558
	decreased osteoclast cell number	J:177558
\Tnfsf11^tm1.1Caob/\Tnfsf11^tm1.1Caob \Tg(Prrx1-cre)1Cjt/0 (involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)	decreased osteoclast cell number	J:177558
\Tnfsf11^tm1.1Htaka/\Tnfsf11^tm1.2Htaka \Tg(Dmp1-cre)1Jqfe/0 (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * FVB/N)	decreased osteoclast cell number	J:177557
\Tnfsf11^tm1.2Htaka/\Tnfsf11⁺ (B6.Cg-Tnfsf11^tm1.2Htaka)	decreased osteoclast cell number	J:177557
\Tnfsf11^tm1.2Htaka/\Tnfsf11^tm1.2Htaka (B6.Cg-Tnfsf11^tm1.2Htaka)	decreased osteoclast cell number	J:177557
	increased spleen weight	J:177557
\Tnfsf11^tm1Pngr/\Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system morphology	J:52369
	abnormal immune system physiology	J:52369
	abnormal pro-B cell differentiation	J:52369
	absent mesenteric lymph nodes	J:52369
	absent peripheral lymph nodes	J:52369
	arrested T cell differentiation	J:52369
	decreased immature B cell number	J:52369
	decreased interferon-gamma secretion	J:52369
	decreased interleukin-2 secretion	J:52369
	decreased interleukin-4 secretion	J:52369
	decreased interleukin-5 secretion	J:52369
	decreased interleukin-6 secretion	J:52369
	decreased mature B cell number	J:52369
	decreased osteoclast cell number	J:52369
	decreased thymus weight	J:52369
	immune system phenotype	J:52369
	increased spleen weight	J:52369
	small Peyer's patches	J:52369
	thymus hypoplasia	J:52369
\Tnfsf11^tm1Pngr/\Tnfsf11^tm1Pngr (involves: 129P2/OlaHsd)	abnormal thymus epithelium morphology	J:173115
\Tnfsf11^tm1Ywc/\Tnfsf11⁺ (involves: 129P2/OlaHsd)	absent peripheral lymph nodes	J:65888
\Tnfsf11^tm1Ywc/\Tnfsf11^tm1Ywc (involves: 129P2/OlaHsd)	abnormal cervical lymph node morphology	J:65888
	abnormal spleen B cell follicle morphology	J:65888
	abnormal spleen marginal zone morphology	J:65888
	abnormal spleen morphology	J:65888
	abnormal splenic cell ratio	J:233265
	abnormal thymus cell ratio	J:233265
	absent cervical lymph nodes	J:65888
	absent mesenteric lymph nodes	J:65888
	absent peripheral lymph nodes	J:65888
	decreased Langerhans cell number	J:137471
	decreased osteoclast cell number	J:65888, J:64737
	decreased Peyer's patch number	J:233265
	decreased spleen white pulp amount	J:233265
	increased spleen red pulp amount	J:233265
	small Peyer's patches	J:233265
	small thymus medulla	J:233265
\Tnfsf12^tm1Ash/\Tnfsf12^tm1Ash (B6.129-Tnfsf12^tm1Ash)	abnormal cytokine secretion	J:104801
	abnormal immune system organ morphology	J:104801
	abnormal leukocyte morphology	J:104801
	decreased interleukin-10 secretion	J:104801
	enlarged lymph nodes	J:104801
	enlarged spleen	J:104801
	increased double-positive T cell number	J:104801
	increased interferon-gamma secretion	J:104801
	increased interleukin-12 secretion	J:104801
	increased memory T cell number	J:104801
	increased NK cell number	J:104801
	increased susceptibility to bacterial infection	J:104801
	increased T-helper 1 cell number	J:104801
\Tnfsf13^tm1Geha/\Tnfsf13^tm1Geha (involves: 129S4/SvJae)	abnormal class switch recombination	J:88910
	decreased IgA level	J:88910
	decreased IgM level	J:88910
	immune system phenotype	J:88910
	increased IgG level	J:88910
	increased memory T cell number	J:88910
	increased spleen germinal center number	J:88910
	increased spleen germinal center size	J:88910
\Tnfsf13^tm1Pod/\Tnfsf13⁺ (B6.Cg-Tnfsf13^tm1Pod)	decreased IgA level	J:141374
\Tnfsf13^tm1Pod/\Tnfsf13^tm1Pod (B6.Cg-Tnfsf13^tm1Pod)	abnormal interleukin secretion	J:141374
	decreased IgA level	J:141374
	decreased IgG2a level	J:141374
	decreased interleukin-10 secretion	J:141374
	decreased interleukin-17 secretion	J:141374
	decreased susceptibility to induced arthritis	J:141374
	increased IgG1 level	J:141374
	increased interferon-gamma secretion	J:141374
	increased interleukin-4 secretion	J:141374
	increased interleukin-5 secretion	J:141374
	increased interleukin-13 secretion	J:141374
	increased interleukin-17 secretion	J:141374
	increased T cell proliferation	J:141374
\Tnfsf13b^m1Anu/\Tnfsf13b^m1Anu (C57BL/6JAnu-Tnfsf13b^m1Anu/AnuApb)	abnormal B cell differentiation	J:104190
	decreased mature B cell number	J:104190
	increased immature B cell number	J:104190
\Tnfsf13b^M1Btlr/\Tnfsf13b⁺ (C57BL/6J-Tnfsf13b^M1Btlr)	decreased B cell number	J:220069
	decreased IgG level	J:220069
	decreased IgM level	J:220069
	impaired humoral immune response	J:220069
	increased single-positive T cell number	J:220069
	increased T cell number	J:220069
\Tnfsf13b^M1Btlr/\Tnfsf13b^M1Btlr (C57BL/6J-Tnfsf13b^M1Btlr)	decreased B cell number	J:220069
	decreased IgG level	J:220069
	decreased IgM level	J:220069
	impaired humoral immune response	J:220069
	increased single-positive T cell number	J:220069
	increased T cell number	J:220069
\Tnfsf13b^m2Btlr/\Tnfsf13b^m2Btlr (C57BL/6J-Tnfsf13b^m2Btlr)	decreased B cell number	J:220070
	decreased IgG level	J:220070
	impaired humoral immune response	J:220070
\Tnfsf13b^m3Btlr/\Tnfsf13b^m3Btlr (C57BL/6J-Tnfsf13b^m3Btlr)	abnormal lymphocyte morphology	J:272850
	decreased B cell number	J:272850
\Tnfsf13b^tm1Cleg/\Tnfsf13b^tm1Cleg (involves: 129S5/SvEvBrd)	abnormal B cell differentiation	J:71301
	abnormal B cell physiology	J:71301
	abnormal leukocyte morphology	J:71301
	abnormal lymph organ size	J:71301
	decreased follicular B cell number	J:71301
	decreased IgG level	J:71301
	decreased IgM level	J:71301
	decreased mature B cell number	J:71301
	decreased memory T cell number	J:71301
	increased T cell number	J:71301
	lymph node hypoplasia	J:71301
	spleen hypoplasia	J:71301
\Tnfsf13b^tm1Msc/\Tnfsf13b⁺ (involves: 129S2/SvPas * C57BL/6)	decreased immunoglobulin level	J:71681
\Tnfsf13b^tm1Msc/\Tnfsf13b^tm1Msc (involves: 129S2/SvPas * C57BL/6)	abnormal B cell differentiation	J:71681
	abnormal humoral immune response	J:71681
	abnormal lymph node B cell domain morphology	J:71681
	arrested B cell differentiation	J:71681
	decreased B cell number	J:71681
	decreased follicular B cell number	J:71681
	decreased immunoglobulin level	J:71681
	decreased marginal zone B cell number	J:71681
	decreased spleen weight	J:71681
\Tnfsf13b^tm1Msc/\Tnfsf13b^tm1Msc (involves: 129S2/SvPas)	decreased B cell number	J:138560
	decreased follicular B cell number	J:138560
	decreased T cell proliferation	J:92334
	decreased transitional stage B cell number	J:138560
	increased length of allograft survival	J:92334
\Tnfsf13b^tm1Msc/\Tnfsf13b^tm1Msc \Traf2^tm1Rbr/\Traf2^tm1Rbr (involves: 129S2/SvPas * C57BL/6)	absent follicular B cells	J:132877
	absent marginal zone B cells	J:132877
	decreased mature B cell number	J:132877
\Tnfsf14^tm1Ddy/\Tnfsf14^tm1Ddy (involves: 129S1/Sv * 129X1/SvJ)	abnormal cytotoxic T cell physiology	J:84366
	abnormal T cell activation	J:84366
	decreased T cell proliferation	J:84366
	immune system phenotype	J:84366
\Tnfsf14^tm1Kpf/\Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell subpopulation ratio	J:77250
	decreased cytotoxic T cell cytolysis	J:77250
	decreased interferon-gamma secretion	J:77250
	decreased interleukin-2 secretion	J:77250
	decreased interleukin-4 secretion	J:77250
	decreased interleukin-10 secretion	J:77250
	decreased splenocyte proliferation	J:77250
	decreased T cell proliferation	J:77250
\Tnfsf14^tm1Kpf/\Tnfsf14^tm1Kpf (involves: 129P2/OlaHsd)	abnormal gamma-delta T cell morphology	J:169863
\Tnfsf14^tm1Kpf/\Tnfsf14^tm1Kpf (B6.129P2-Tnfsf14^tm1Kpf)	abnormal osteoclast differentiation	J:294030
\Tnfsf14^tm1Lpc/\Tnfsf14^tm1Lpc (involves: 129X1/SvJ * C57BL/6)	abnormal cytotoxic T cell physiology	J:76414
	decreased cytotoxic T cell cytolysis	J:76414
	decreased inflammatory response	J:107803
	decreased interferon-gamma secretion	J:76414
	decreased tumor necrosis factor secretion	J:76414
\Tnfsf14^tm1Lpc/\Tnfsf14^tm1Lpc (B6.129X1-Tnfsf14^tm1Lpc)	immune system phenotype	J:158663
\Tnfsf14^tm1Wwh/\Tnfsf14^tm1Wwh (involves: 129 * C57BL/6)	increased length of allograft survival	J:75705
\Tnfsf15^tm1Cdon/\Tnfsf15^tm1Cdon (B6.129-Tnfsf15^tm1Cdon)	abnormal dendritic cell differentiation	J:136280
\Tnfsf15^tm1Cdon/\Tnfsf15^tm1Cdon (B6.129-Tnfsf15^tm1Cdon)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:136280
\Tnfsf15^tm1Hluo/\Tnfsf15^tm1Hluo (D1LacJ.129(B6)-Tnfsf15^tm1Hluo)	decreased B cell number	J:207029
	decreased germinal center B cell number	J:207029
	decreased IgG2a level	J:207029
	decreased IgG2b level	J:207029
	decreased IgG level	J:207029
	decreased plasma cell number	J:207029
	decreased susceptibility to induced arthritis	J:207029
	decreased T cell number	J:207029
	decreased T follicular helper cell number	J:207029
	immune system phenotype	J:207029
	lymph node hypoplasia	J:207029
\Tnfsf15^tm1Lex/\Tnfsf15^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	increased NK cell number	J:82809
\Tnik^m1Anu/\Tnik^m1Anu (C57BL/6NCrlAnu-Tnik^m1Anu/Anu)	immune system phenotype	J:104190
\Tnip1^{Gt(E059E05)Wrst}/\Tnip1^{Gt(E059E05)Wrst} (involves: 129P2/OlaHsd * C57BL/6)	decreased interleukin-12 secretion	J:180054
	decreased interleukin-12b secretion	J:180054
	enlarged lymph nodes	J:180054
	enlarged spleen	J:180054
	glomerulonephritis	J:180054
	increased anti-double stranded DNA antibody level	J:180054
	increased anti-nuclear antigen antibody level	J:180054
	increased IgA level	J:180054
	increased IgG1 level	J:180054
	increased IgG2b level	J:180054
	increased IgM level	J:180054
	increased neutrophil cell number	J:180054
	increased susceptibility to systemic lupus erythematosus	J:180054
	lymph node hyperplasia	J:180054
	spleen hyperplasia	J:180054
\Tnip1^m1Btlr/\Tnip1^m1Btlr (C57BL/6J-Tnip1^m1Btlr)	decreased B cell number	J:265175
	decreased B-2 B cell number	J:265175
	increased anti-double stranded DNA antibody level	J:265175
	increased B-1a cell number	J:265175
	increased B-1b cell number	J:265175
	increased dendritic cell number	J:265175
	increased IgA level	J:265175
	increased IgE level	J:265175
	increased macrophage cell number	J:265175
	increased susceptibility to induced colitis	J:265175
\Tnip1^tm1.1Pcoh/\Tnip1⁺ (involves: 129P2/OlaHsd * C57BL/6)	increased anti-double stranded DNA antibody level	J:176826
\Tnip1^tm1.1Pcoh/\Tnip1^tm1.1Pcoh (involves: 129P2/OlaHsd * C57BL/6)	abnormal complement pathway	J:176826
	abnormal effector T cell morphology	J:176826
	abnormal immune system morphology	J:176826
	abnormal Peyer's patch morphology	J:176826
	abnormal plasma cell morphology	J:176826
	abnormal spleen germinal center morphology	J:176826
	enlarged lymph nodes	J:176826
	enlarged spleen	J:176826
	glomerulonephritis	J:176826
	immune system phenotype	J:176826
	increased anti-double stranded DNA antibody level	J:176826
	increased anti-nuclear antigen antibody level	J:176826
	increased B cell number	J:176826
	increased B cell proliferation	J:176826
	increased germinal center B cell number	J:176826
	increased granulocyte number	J:176826
	increased IgA level	J:176826
	increased IgE level	J:176826
	increased IgG1 level	J:176826
	increased IgG2a level	J:176826
	increased IgG2b level	J:176826
	increased IgG3 level	J:176826
	increased IgG level	J:176826
	increased IgM level	J:176826
	increased immunoglobulin level	J:176826
	increased interleukin-6 secretion	J:176826
	increased interleukin-12b secretion	J:176826
	increased monocyte cell number	J:176826
	increased plasma cell number	J:176826
	increased spleen red pulp amount	J:176826
	increased spleen weight	J:176826
	increased spleen white pulp amount	J:176826
	increased T follicular helper cell number	J:176826
	increased tumor necrosis factor secretion	J:176826
\Tnip1^tm1.2Ama/\Tnip1^tm1.2Ama \Tg(Itgax-cre)1-1Reiz/0 (involves: C57BL/6 * C57BL/6J * CBA)	abnormal leukocyte morphology	J:205446
	enlarged lymph nodes	J:205446
	enlarged spleen	J:205446
	increased interleukin-6 secretion	J:205446
	increased interleukin-12 secretion	J:205446
	increased interleukin-23 secretion	J:205446
	increased memory T cell number	J:205446
	increased plasmacytoid dendritic cell number	J:205446
	increased tumor necrosis factor secretion	J:205446
\Tnip1^tm1.2Pcoh/\Tnip1^tm1.2Pcoh (involves: 129P2/OlaHsd * C57BL/6)	abnormal immune system morphology	J:176826
\Tnip1^{tm1b(EUCOMM)Hmgu}/\Tnip1^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tnip1^{tm1b(EUCOMM)Hmgu}/H)	decreased eosinophil cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased large unstained cell number	J:211773
	increased monocyte cell number	J:211773
	increased spleen weight	J:211773
\Tnip2^tm1.1Sley/\Tnip2^tm1.1Sley (involves: 129S4/SvJae * 129S8/SvEv * C57BL/6)	abnormal macrophage physiology	J:112395
	immune system phenotype	J:112395
\Tnip3^tm1Rds/\Tnip3^tm1Rds (involves: 129S6/SvEvTac)	immune system phenotype	J:122758
\Tnk2^em1(IMPC)Tcp/\Tnk2^em1(IMPC)Tcp (C57BL/6N-Tnk2^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Tnk2^tm1.2Npma/\Tnk2^tm1.2Npma (B6(Cg)-Tnk2^tm1.2Npma)	abnormal regulatory T cell number	J:341740
	abnormal T cell physiology	J:341740
	increased activated T cell number	J:341740
	increased circulating interferon-gamma level	J:341740
	increased circulating interleukin-2 level	J:341740
	increased effector memory CD8-positive, alpha-beta T cell number	J:341740
	increased interferon level	J:341740
	increased interleukin level	J:341740
\Tnr^{em1(IMPC)Rbrc}/\Tnr^{em1(IMPC)Rbrc} (C57BL/6NJcl-Tnr^{em1(IMPC)Rbrc}/Rbrc)	increased spleen weight	J:211773
\Tns1^tm1Efu/\Tns1^tm1Efu (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	tubulointerstitial nephritis	J:39202
\Tns2^nph/\Tns2^nph (involves: ICR)	enlarged lymph nodes	J:24698
\Tns2^nph/\Tns2^nph (involves: ICR)	glomerulonephritis	J:108691
\Tns3^Gt(XK294)Byg/\Tns3^Gt(XK294)Byg (involves: 129P2/OlaHsd * C57BL/6)	small spleen	J:96666
\Tnxb^{tm1b(EUCOMM)Hmgu}/\Tnxb^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tnxb^{tm1b(EUCOMM)Hmgu}/H)	enlarged spleen	J:211773
\Tob2^tm1Tya/\Tob2^tm1Tya (involves: 129S4/SvJae * C57BL/6)	abnormal osteoclast differentiation	J:134287
	abnormal osteoclast physiology	J:134287
	increased osteoclast cell number	J:134287
\Tollip^tm1Kbns/\Tollip^tm1Kbns (involves: C57BL/6)	decreased circulating interleukin-6 level	J:105514
	decreased interleukin-6 secretion	J:105514
	decreased tumor necrosis factor secretion	J:105514
\Tom1l2^Gt(XG909)Byg/\Tom1l2⁺ (involves: 129P2/OlaHsd * C57BL/6J)	enlarged spleen	J:133892
	increased susceptibility to infection	J:133892
\Tom1l2^Gt(XG909)Byg/\Tom1l2^Gt(XG909)Byg (involves: 129P2/OlaHsd * C57BL/6J)	abnormal humoral immune response	J:133892
	abnormal immune system physiology	J:133892
	abnormal inflammatory response	J:133892
	abnormal lymph node cell ratio	J:133892
	abnormal spleen B cell follicle morphology	J:133892
	abnormal spleen morphology	J:133892
	abnormal spleen periarteriolar lymphoid sheath morphology	J:133892
	abnormal splenic cell ratio	J:133892
	conjunctivitis	J:133892
	dark spleen	J:133892
	dermatitis	J:133892
	enlarged spleen	J:133892
	increased B cell number	J:133892
	increased CD4-positive, alpha-beta T cell number	J:133892
	increased CD8-positive, alpha-beta T cell number	J:133892
	increased inflammatory response	J:133892
	increased leukocyte cell number	J:133892
	increased spleen white pulp amount	J:133892
	increased susceptibility to bacterial infection	J:133892
	increased susceptibility to infection	J:133892
	increased T cell number	J:133892
	lymphoid hyperplasia	J:133892
\Tomm5^{Gt(OST44663)Lex}/\Tomm5^{Gt(OST44663)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	increased eosinophil cell number	J:186382
	lung inflammation	J:186382
	thymus atrophy	J:186382
\Tomm6^{tm1a(KOMP)Wtsi}/\Tomm6⁺ (C57BL/6N-Tomm6^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Tomm20^em1(IMPC)J/\Tomm20⁺ (C57BL/6NJ-Tomm20^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Top2a^em2(IMPC)Tcp/\Top2a⁺ (C57BL/6NCrl-Top2a^em2(IMPC)Tcp/Tcp)	small spleen	J:211773
	small thymus	J:211773
\Top2b^em1(IMPC)Mbp/\Top2b⁺ (C57BL/6NCrl-Top2b^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Top3b^tm1Jcw/\Top3b^tm1Jcw (involves: 129S6/SvEvTac * C57BL/6)	dermatitis	J:69405
	enlarged axillary lymph nodes	J:69405
	enlarged spleen	J:69405
	enlarged submandibular lymph nodes	J:69405
	glomerulonephritis	J:69405
	increased inflammatory response	J:69405
	pancreas inflammation	J:69405
	stomach inflammation	J:69405
\Tor1b^em1(IMPC)Mbp/\Tor1b^em1(IMPC)Mbp (C57BL/6NCrl-Tor1b^em1(IMPC)Mbp/MbpMmucd)	increased basophil cell number	J:211773
\Tox2^em1Cdon/\Tox2^em1Cdon (C57BL/6J-Tox2^em1Cdon)	abnormal T follicular helper cell differentiation	J:290926
\Tox2^em1Cdon/\Tox2^em1Cdon (C57BL/6J-Tox2^em1Cdon)	decreased germinal center B cell number	J:290926
\Tox^tm1.1Kay/\Tox^tm1.1Kay (involves: 129S6/SvEvTac)	abnormal CD4-positive T cell differentiation	J:131287
	abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology	J:131287
	abnormal CD8-positive, alpha beta T cell morphology	J:131287
	decreased CD4-positive, alpha-beta T cell number	J:131287
	decreased cytotoxic T cell cytolysis	J:131287
	decreased NK T cell number	J:131287
\Tox^tm1.1Kay/\Tox^tm1.1Kay (involves: 129S6/SvEvTac * C57BL/6)	abnormal positive T cell selection	J:164687
	abnormal spleen morphology	J:164687
	absent axillary lymph nodes	J:164687
	absent inguinal lymph nodes	J:164687
	absent mesenteric lymph nodes	J:164687
	absent popliteal lymph nodes	J:164687
	decreased NK cell number	J:164687
	decreased Peyer's patch number	J:164687
	small Peyer's patches	J:164687
\Tox^{tm1b(KOMP)Wtsi}/\Tox^{tm1b(KOMP)Wtsi} (C57BL/6N-Tox^{tm1b(KOMP)Wtsi}/Tcp)	increased spleen weight	J:211773
\Tox^tm1Kay/\Tox^tm1Kay \Tg(Lck-cre)1Cwi/0 (involves: 129S6/SvEvTac * C57BL/6)	abnormal CD4-positive T cell differentiation	J:164687
\Tpcn1^tm1.1Dren/\Tpcn1^tm1.1Dren \Tpcn2^tm1.1Dren/\Tpcn2^tm1.1Dren (Not Specified)	abnormal macrophage physiology	J:189070
\Tpcn2^{tm1b(EUCOMM)Hmgu}/\Tpcn2^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Tpcn2^{tm1b(EUCOMM)Hmgu}/H)	increased eosinophil cell number	J:211773
\Tph2^em1(IMPC)Mbp/\Tph2^em1(IMPC)Mbp (C57BL/6N-Tph2^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	increased eosinophil cell number	J:211773
\Tpi1^a-m6Neu/\Tpi1^a-m6Neu (involves: 101/El * C3H/El)	increased spleen weight	J:163223
\Tpi1^rbc19/\Tpi1^rbc19 (SJL-Tpi1^rbc19)	abnormal spleen red pulp morphology	J:263104
\Tpi1^rbc19/\Tpi1^rbc19 (SJL-Tpi1^rbc19)	enlarged spleen	J:263104
\Tpm4^Plt53/\Tpm4⁺ (BALB/c-Tpm4^Plt53)	abnormal thrombopoiesis	J:242938
\Tpm4^Plt53/\Tpm4^Plt53 (BALB/c-Tpm4^Plt53)	abnormal thrombopoiesis	J:242938
\Tpm4^Plt53/\Tpm4^Plt53 (BALB/c-Tpm4^Plt53)	increased lymphocyte cell number	J:242938
\Tpo^R479C/\Tpo^R479C (involves: ICR)	small spleen	J:112930
\Tpp2^{Gt(OST432061)Lex}/\Tpp2^{Gt(OST432061)Lex} (B6.129S5-Tpp2^{Gt(OST432061)Lex})	abnormal level of surface class I molecules	J:157195
\Tpp2^{Gt(OST432061)Lex}/\Tpp2^{Gt(OST432061)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal antigen presentation	J:157195
\Tpp2^tm1.1Gnie/\Tpp2^tm1.1Gnie (involves: 129S6/SvEvTac * C57BL/6)	abnormal cytotoxic T cell physiology	J:133572
	abnormal immune system cell morphology	J:133572
	abnormal immune system organ morphology	J:133572
	abnormal spleen morphology	J:133572
	abnormal splenic cell ratio	J:133572
	decreased CD8-positive, alpha-beta T cell number	J:133572
	decreased double-positive T cell number	J:133572
	decreased T cell number	J:133572
	enlarged spleen	J:133572
	increased double-negative T cell number	J:133572
	increased single-positive T cell number	J:133572
	increased spleen red pulp amount	J:133572
	increased T cell apoptosis	J:133572
	increased T cell number	J:133572
	thymus atrophy	J:133572
\Tpp2^tm1.1Gnie/\Tpp2^tm1.1Gnie (involves: 129S6/SvEvTac)	abnormal CD4-positive T cell differentiation	J:221205
	abnormal CD8-positive, alpha-beta T cell differentiation	J:221205
	abnormal lymphocyte physiology	J:221205
	decreased leukocyte cell number	J:221205
	enlarged lymph nodes	J:221205
	enlarged spleen	J:221205
	increased anti-nuclear antigen antibody level	J:221205
	increased autoantibody level	J:221205
	increased B cell number	J:221205
	increased memory T cell number	J:221205
\Tppp3^{em1(IMPC)Ccpcz}/\Tppp3⁺ (C57BL/6NCrl-Tppp3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased CD4-positive NK T cell number	J:211773
	increased memory-marker CD4-positive NK T cell number	J:211773
	increased NK T cell number	J:211773
\Tpsab1^m1/\Tpsab1^m1 (involves: C57BL/6J)	abnormal mast cell differentiation	J:142880
\Tpsab1^m1/\Tpsab1^m1 \Tpsb2^tm1(cre)Adch/\Tpsb2^tm1(cre)Adch (B6.Cg-Tpsb2^tm1(cre)Adch Tpsab1^m1)	abnormal mast cell differentiation	J:142880
	decreased susceptibility to induced arthritis	J:142880
\Tpsb2^tm1(cre)Adch/\Tpsb2^tm1(cre)Adch (B6.Cg-Tpsb2^tm1(cre)Adch)	increased susceptibility to bacterial infection	J:124554
\Tpsb2^tm1.1Mfg/\Tpsb2^tm1.1Mfg (B6.129-Tpsb2^tm1.1Mfg)	abnormal mast cell differentiation	J:142880
	decreased susceptibility to induced arthritis	J:142880
	impaired eosinophil recruitment	J:133373
	impaired neutrophil chemotaxis	J:142880
	increased susceptibility to parasitic infection	J:133373
\Tpsg1^tm1.2Rls/\Tpsg1^tm1.2Rls (involves: C57BL/6 * C57BL/6NTac)	decreased susceptibility to colitis induced morbidity/mortality	J:243813
	immune system phenotype	J:243813
\Tpx2^{Gt(D028B03)Wrst}/\Tpx2⁺ (involves: 129S2/SvPas * C57BL/6J)	abnormal splenocyte morphology	J:184948
	granulomatous inflammation	J:184948
\Tra2a^{tm2b(EUCOMM)Hmgu}/\Tra2a⁺ (C57BL/6N-Tra2a^{tm2b(EUCOMM)Hmgu}/Bay)	increased basophil cell number	J:211773
\Trabd2b^{em2(IMPC)Ccpcz}/\Trabd2b^{em2(IMPC)Ccpcz} (C57BL/6N-Trabd2b^{em2(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Tradd^tm1.1Mak/\Tradd⁺ (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))	decreased acute inflammation	J:138824
\Tradd^tm1.1Mak/\Tradd^tm1.1Mak (either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * FVB/N))	abnormal spleen follicular dendritic cell network	J:138824
	absent spleen germinal center	J:138824
	decreased acute inflammation	J:138824
	decreased circulating interleukin-6 level	J:138824
	decreased inflammatory response	J:138824
	decreased interleukin-6 secretion	J:138824
\Tradd^tm1.1Mpa/\Tradd^tm1.1Mpa (involves: C57BL/6)	decreased interferon-beta secretion	J:136289
\Tradd^tm1.1Mpa/\Tradd^tm1.1Mpa (involves: BALB/cJ * C57BL/6)	abnormal interleukin level	J:139030
	abnormal spleen germinal center morphology	J:139030
	decreased circulating tumor necrosis factor level	J:139030
	decreased IgG level	J:139030
	increased susceptibility to bacterial infection	J:139030
\Traf1^tm1Tsi/\Traf1^tm1Tsi (involves: 129S4/SvJae * C57BL/6)	abnormal lymph node cell ratio	J:72327
	immune system phenotype	J:72327
	increased lymphocyte cell number	J:72327
	increased T cell proliferation	J:72327
\Traf2^{tm1a(EUCOMM)Wtsi}/\Traf2⁺ (C57BL/6N-Traf2^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased alpha-beta T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
\Traf2^tm1Mak/\Traf2^tm1Mak (either: (involves: 129P2/OlaHsd * C57BL/6J) or (involves: 129P2/OlaHsd * BALB/c * C57BL/6J))	absent lymph node germinal center	J:44360
	absent spleen germinal center	J:44360
	decreased double-positive T cell number	J:44360
	decreased immature B cell number	J:44360
	decreased lymphocyte cell number	J:44360
	decreased thymocyte number	J:44360
	increased circulating tumor necrosis factor level	J:44360
	increased granulocyte number	J:44360
	increased thymocyte apoptosis	J:44360
	lymphoid hypoplasia	J:44360
	spleen atrophy	J:44360
	thymus atrophy	J:44360
\Traf3^m1Btlr/\Traf3^m1Btlr (C57BL/6J-Traf3^m1Btlr)	decreased mature B cell number	J:212064
\Traf3^m1Btlr/\Traf3^m1Btlr (C57BL/6J-Traf3^m1Btlr)	impaired humoral immune response	J:212064
\Traf3^m2Btlr/\Traf3^m2Btlr (C57BL/6J-Traf3^m2Btlr)	decreased IgG level	J:217797
\Traf3^m2Btlr/\Traf3^m2Btlr (C57BL/6J-Traf3^m2Btlr)	decreased response to antigen	J:217797
\Traf3^tm1Bal/\Traf3^tm1Bal (involves: 129S4/SvJae * C57BL/6J)	abnormal B cell differentiation	J:37065
	abnormal T cell physiology	J:37065
	decreased double-positive T cell number	J:37065
	decreased leukocyte cell number	J:37065
	decreased thymocyte number	J:37065
	spleen hypoplasia	J:37065
\Traf3^tm1Bshp/\Traf3^tm1Bshp \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)	abnormal adaptive immunity	J:124329
	abnormal immune system organ morphology	J:124329
	abnormal immune system physiology	J:124329
	abnormal leukocyte morphology	J:124329
	abnormal lymph node B cell domain morphology	J:124329
	abnormal spleen germinal center morphology	J:124329
	autoimmune response	J:124329
	decreased B cell apoptosis	J:124329
	decreased T cell number	J:124329
	enlarged lymph nodes	J:124329
	enlarged spleen	J:124329
	increased anti-double stranded DNA antibody level	J:124329
	increased B cell number	J:124329
	increased follicular B cell number	J:124329
	increased IgA level	J:124329
	increased IgG2a level	J:124329
	increased IgG2b level	J:124329
	increased IgG3 level	J:124329
	increased IgG level	J:124329
	increased IgM level	J:124329
	increased marginal zone B cell number	J:124329
	increased spleen white pulp amount	J:124329
	increased transitional stage B cell number	J:124329
\Traf3ip2^adjm/\Traf3ip2^adjm (KOR-Traf3ip2^adjm)	dermatitis	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (KOR-Traf3ip2^adjm)	increased IgE level	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (A.KOR-Traf3ip2^adjm)	dermatitis	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (A.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (B6.KOR-Traf3ip2^adjm)	dermatitis	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (B6.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (C.KOR-Traf3ip2^adjm)	dermatitis	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (C.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (AK.KOR-Traf3ip2^adjm)	dermatitis	J:162859
\Traf3ip2^adjm/\Traf3ip2^adjm (AK.KOR-Traf3ip2^adjm)	increased IgE level	J:162859
\Traf3ip2^{Gt(IST11484G7)Tigm}/\Traf3ip2^{Gt(IST11484G7)Tigm} (involves: C57BL/6N)	immune system phenotype	J:177650
\Traf3ip2^tm1.1Lix/\Traf3ip2^tm1.1Lix (involves: 129/Sv * BALB/c)	abnormal immune system morphology	J:93923
	abnormal immune system physiology	J:93923
	abnormal spleen B cell corona morphology	J:93923
	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	increased anti-double stranded DNA antibody level	J:93923
	increased anti-histone antibody level	J:93923
	increased anti-single stranded DNA antibody level	J:93923
	increased autoantibody level	J:93923
	increased B cell number	J:93923
	increased dendritic cell number	J:93923
	increased IgE level	J:93923
	increased IgG level	J:93923
	increased immunoglobulin level	J:93923
	increased inflammatory response	J:93923
	lymphoid hyperplasia	J:93923
	respiratory system inflammation	J:93923
\Traf3ip2^tm1.1Lix/\Traf3ip2^tm1.1Lix (C.129-Traf3ip2^tm1.1Lix)	blepharitis	J:138560
	enlarged submandibular lymph nodes	J:138560
	glomerulonephritis	J:138560
	increased autoantibody level	J:138560
	increased follicular B cell number	J:138560
	increased inflammatory response	J:138560
	increased marginal zone B cell number	J:138560
	increased transitional stage B cell number	J:138560
	kidney inflammation	J:138560
	lacrimal gland inflammation	J:138560
	parotid gland inflammation	J:138560
	stomatitis	J:138560
	submandibular gland inflammation	J:138560
\Traf3ip2^tm1.1Lix/\Traf3ip2^tm1.1Lix (B6.129-Traf3ip2^tm1.1Lix)	abnormal transitional stage B cell morphology	J:187766
	enlarged cervical lymph nodes	J:187766
	enlarged spleen	J:187766
	immune system phenotype	J:187766
	increased anti-chromatin antibody level	J:187766
	increased anti-double stranded DNA antibody level	J:187766
	increased anti-histone antibody level	J:187766
	increased anti-nuclear antigen antibody level	J:187766
	increased autoantibody level	J:187766
	increased B cell number	J:187766
	increased IgG1 level	J:187766
	increased IgG2c level	J:187766
	increased IgG level	J:187766
	increased immature B cell number	J:187766
	increased marginal zone B cell number	J:187766
	increased spleen weight	J:187766
	lymph node hyperplasia	J:187766
	spleen hyperplasia	J:187766
\Traf3ip2^tm1.1Lix/\Traf3ip2^tm1.1Lix \Tnfsf13b^tm1Msc/\Tnfsf13b^tm1Msc (involves: 129 * 129S2/SvPas * BALB/c)	decreased B cell number	J:138560
	decreased follicular B cell number	J:138560
	decreased mature B cell number	J:138560
	decreased transitional stage B cell number	J:138560
	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	increased autoantibody level	J:138560
\Traf3ip2^tm1Lix/\Traf3ip2^tm1.1Lix \Tg(CD19-cre/ERT2)1Cgn/0 (involves: 129/Sv * BALB/c)	enlarged lymph nodes	J:93923
	enlarged spleen	J:93923
	increased B cell number	J:93923
	increased dendritic cell number	J:93923
	increased immunoglobulin level	J:93923
\Traf3ip2^tm1Sbn/\Traf3ip2^tm1Sbn (either: B6.129-Traf3ip2^tm1Sbn or (involves: 129) or (involves: 129 * BALB/c))	abnormal cytokine secretion	J:144320
	decreased interleukin-6 secretion	J:144320
	decreased susceptibility to autoimmune disorder	J:144320
	impaired eosinophil recruitment	J:144320
	impaired macrophage chemotaxis	J:144320
	impaired neutrophil recruitment	J:144320
\Traf3ip2^tm1Sbn/\Traf3ip2^tm1Sbn (involves: 129 * C57BL/6)	decreased inflammatory response	J:191090
\Traf3ip3^{tm1a(KOMP)Wtsi}/\Traf3ip3^{tm1a(KOMP)Wtsi} (C57BL/6N-Traf3ip3^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:175295
\Traf3ip3^{tm1b(KOMP)Wtsi}/\Traf3ip3^{tm1b(KOMP)Wtsi} (involves: BALB/cJ * C57BL/6N)	abnormal T cell differentiation	J:226431
	decreased CD4-positive, alpha-beta memory T cell number	J:226431
	decreased CD8-positive, alpha-beta memory T cell number	J:226431
	decreased regulatory T cell number	J:226431
	decreased T cell number	J:226431
	decreased thymocyte number	J:226431
	immune system phenotype	J:226431
	increased double-positive T cell number	J:226431
	increased gamma-delta T cell number	J:226431
\Traf4^tm1Lind/\Traf4^tm1Lind (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:74252
	lung inflammation	J:74252
\Traf4^tm1Mrio/\Traf4^tm1Mrio (involves: 129X1/SvJ)	abnormal dendritic cell physiology	J:142780
\Traf4^tm1Mrio/\Traf4^tm1Mrio (involves: 129X1/SvJ)	immune system phenotype	J:142780
\Traf4^tm2Lind/\Traf4^tm2Lind (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:74252
	lung inflammation	J:74252
\Traf5^tm1Hna/\Traf5^tm1Hna (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	abnormal B cell proliferation	J:57114
	abnormal humoral immune response	J:57114
	abnormal T cell proliferation	J:57114
	decreased IgG1 level	J:57114
	decreased IgM level	J:57114
\Traf6^tm1.1Mpa/\Traf6^tm1.1Mpa \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased circulating interleukin-6 level	J:145306
\Traf6^tm1Jino/\Traf6^tm1Jino (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:77453
	decreased immature B cell number	J:77453
	decreased lymph node number	J:77453
\Traf6^tm1Mak/\Traf6^tm1Mak (involves: 129P3/J)	abnormal macrophage physiology	J:54467
	abnormal osteoclast morphology	J:54467
	abnormal osteoclast physiology	J:54467
	decreased B cell proliferation	J:54467
	decreased tumor necrosis factor secretion	J:54467
	enlarged spleen	J:54467
\Traf6^tm1Ywc/\Traf6^tm1Ywc (Not Specified)	abnormal dendritic cell differentiation	J:85808
	abnormal dendritic cell physiology	J:85808
	abnormal lymph node morphology	J:85808
	abnormal spleen morphology	J:85808
	absent spleen white pulp	J:85808
	decreased dendritic cell number	J:85808
	decreased interleukin-6 secretion	J:85808
	decreased interleukin-12 secretion	J:85808
	enlarged spleen	J:85808
	thymus atrophy	J:85808
\Traf6^{tm2a(EUCOMM)Wtsi}/\Traf6^{tm2a(EUCOMM)Wtsi} (C57BL/6N-Traf6^{tm2a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
\Traf6^tm2Ywc/\Traf6^tm2Ywc \Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	abnormal lymphocyte anergy	J:130882
	increased activated T cell number	J:130882
	increased memory T cell number	J:130882
\Traf7^em1(IMPC)Tcp/\Traf7⁺ (C57BL/6NCrl-Traf7^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Trafd1^tm1Ayos/\Trafd1^tm1Ayos (involves: 129 * C57BL/6J)	decreased susceptibility to Riboviria infection	J:144594
	increased circulating interleukin-6 level	J:144594
	increased interleukin-6 secretion	J:144594
	increased interleukin-12 secretion	J:144594
	increased susceptibility to endotoxin shock	J:144594
	increased tumor necrosis factor secretion	J:144594
\Traj18^em1Hwata/\Traj18^em1Hwata (C57BL/6-Traj18^em1Hwata)	abnormal cytokine secretion	J:256533
\Traj18^em1Hwata/\Traj18^em1Hwata (C57BL/6-Traj18^em1Hwata)	absent NK T cells	J:256533
\Traj18^em1Hwata/\Traj18^em1Hwata (C.B6-Traj18^em1Hwata)	abnormal cytokine secretion	J:256533
\Traj18^em1Hwata/\Traj18^em1Hwata (C.B6-Traj18^em1Hwata)	absent NK T cells	J:256533
\Traj18^tm1.1Kro/\Traj18^tm1.1Kro (involves: C57BL/6NTac)	abnormal circulating interleukin-4 level	J:232957
	abnormal interferon-gamma secretion	J:232957
	absent NK T cells	J:232957
	decreased inflammatory response	J:232957
\Traj33^em#Dig/\Traj33^em#Dig (involves: C57BL/6)	decreased T cell number	J:276912
\Traj33^em#Dig/\Traj33^em#Dig (involves: C57BL/6)	immune system phenotype	J:276912
\Trak1^{em1(IMPC)Ccpcz}/\Trak1⁺ (C57BL/6NCrl-Trak1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Trak2^em1(IMPC)Mbp/\Trak2^em1(IMPC)Mbp (C57BL/6N-Trak2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Trap1^em1(IMPC)Mbp/\Trap1^em1(IMPC)Mbp (C57BL/6N-Trap1^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	decreased monocyte cell number	J:211773
\Trap1^{Gt(E150H04)Wrst}/\Trap1^{Gt(E150H04)Wrst} (involves: 129P2/OlaHsd * C57BL/6)	decreased inflammatory response	J:226880
	spleen hyperplasia	J:226880
\Trappc1^em1(IMPC)Mbp/\Trappc1⁺ (C57BL/6NCrl-Trappc1^em1(IMPC)Mbp/Mmucd)	enlarged spleen	J:211773
\Trappc2l^em1(IMPC)Mbp/\Trappc2l^em1(IMPC)Mbp (C57BL/6N-Trappc2l^em1(IMPC)Mbp/Ucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Trappc8^em1(IMPC)Tcp/\Trappc8⁺ (C57BL/6NCrl-Trappc8^em1(IMPC)Tcp/Tcp)	increased eosinophil cell number	J:211773
	increased monocyte cell number	J:211773
\Trappc9^{tm1a(EUCOMM)Wtsi}/\Trappc9^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Trappc9^{tm1a(EUCOMM)Wtsi}/Wtsi)	blood in lymph vessels	J:239583
	decreased CD11b-low dendritic cell number	J:211773
	decreased gamma-delta T cell number	J:211773
	decreased KLRG1-positive NK cell number	J:211773
	increased CD11b-high dendritic cell number	J:211773
	increased Ly6C high monocyte number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased monocyte cell number	J:211773
\Trappc10^b2b2416Clo/\Trappc10^b2b2416Clo (Trappc10^b2b2416Clo)	thymus hypoplasia	J:175213
\Trat1^tm1Lsmn/\Trat1^tm1Lsmn (B6.129X1-Trat1^tm1Lsmn)	lymph node hypoplasia	J:108406
	spleen hypoplasia	J:108406
	thymus hypoplasia	J:108406
\Trbv13-2^tm1(CD2)Zhu/\Trbv13-2^tm1(CD2)Zhu (involves: 129 * C57BL/6)	abnormal T cell differentiation	J:121608
	immune system phenotype	J:121608
\Trbv13-2^tm1(CD2)Zhu/\Trbv13-2^tm1(CD2)Zhu (involves: 129 * C57BL/6 * SJL)	abnormal T cell differentiation	J:121608
\Trbv14^tm1Che/\Trbv14^tm1Che (involves: 129S4/SvJae)	decreased T cell number	J:92288
\Trbv14^tm2Che/\Trbv14^tm2Che (involves: 129S4/SvJae)	decreased T cell number	J:92288
\Trbv15^tm1Krg/\Trbv15^tm1Krg (involves: 129S/SvEv * C57BL/6)	immune system phenotype	J:95669
\Trdmt1^{Gt(OST19279)Lex}/\Trdmt1^{Gt(OST19279)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	decreased NK cell number	J:103485
\Treh^em1(IMPC)H/\Treh^em1(IMPC)H (C57BL/6N-Treh^em1(IMPC)H/H)	increased eosinophil cell number	J:211773
\Trem1^{tm1(KOMP)Vlcg}/\Trem1^{tm1(KOMP)Vlcg} (C57BL/6N-Trem1^{tm1(KOMP)Vlcg}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\Trem1^tm1.1Ahoru/\Trem1^tm1.1Ahoru (C57BL/6-Trem1^tm1.1Ahoru)	decreased monocyte cell number	J:191035
	decreased neutrophil cell number	J:191035
\Trem2^em2Bwef/\Trem2⁺ (involves: C57BL/6J * DBA/2J * FVB/N)	decreased macrophage cell number	J:242126
\Trem2^em2Bwef/\Trem2^em2Bwef (involves: C57BL/6J * DBA/2J * FVB/N)	decreased macrophage cell number	J:242126
	decreased macrophage proliferation	J:242126
	decreased microglial cell activation	J:242126
	impaired macrophage phagocytosis	J:242126
	increased circulating interleukin-6 level	J:242126
	increased circulating tumor necrosis factor level	J:242126
	increased macrophage apoptosis	J:242126
	increased susceptibility to endotoxin shock	J:242126
\Trem2^{tm1(KOMP)Vlcg}/\Trem2^{tm1(KOMP)Vlcg} (C57BL/6N-Trem2^{tm1(KOMP)Vlcg})	abnormal microglial cell physiology	J:239381
	decreased microglial cell activation	J:239381
\Trem2^tm1Cln/\Trem2^tm1Cln (B6.129P2-Trem2^tm1Cln)	abnormal interferon level	J:138057
	abnormal interleukin level	J:138057
	abnormal tumor necrosis factor level	J:138057
\Treml1^tm1Mcvic/\Treml1^tm1Mcvic (C57BL/6-Treml1^tm1Mcvic)	increased susceptibility to endotoxin shock	J:150578
\Treml1^tm1Mcvic/\Treml1^tm1Mcvic (C57BL/6-Treml1^tm1Mcvic)	increased tumor necrosis factor secretion	J:150578
\Treml4^tm1Ji/\Treml4^tm1Ji (B6(Cg)-Treml4^tm1Ji)	immune system phenotype	J:180744
\Trex1^{em1(IMPC)Ccpcz}/\Trex1⁺ (C57BL/6NCrl-Trex1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Trex1^{em1(IMPC)Ccpcz}/\Trex1^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Trex1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased lymphocyte cell number	J:211773
	decreased NK cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
	increased effector memory T-helper cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Trex1^em3Gpt/\Trex1^em3Gpt (C57BL/6JGpt-Trex1^em3Gpt)	enlarged spleen	J:330879
	increased circulating tumor necrosis factor level	J:330879
	increased spleen weight	J:330879
	increased susceptibility to autoimmune disorder	J:330879
\Trex1^tm1.1Fwpe/\Trex1⁺ (involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)	increased CD4-positive, alpha-beta T cell number	J:220965
\Trex1^tm1.1Fwpe/\Trex1^tm1.1Fwpe (involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)	abnormal immune system organ morphology	J:220965
	abnormal T cell activation	J:220965
	bronchiolitis	J:220965
	enlarged lymph nodes	J:220965
	enlarged spleen	J:220965
	glomerulonephritis	J:220965
	heart inflammation	J:220965
	increased anti-double stranded DNA antibody level	J:220965
	increased B cell number	J:220965
	increased CD4-positive, alpha-beta T cell number	J:220965
	increased IgG level	J:220965
	increased inflammatory response	J:220965
	increased plasma cell number	J:220965
	increased regulatory T cell number	J:220965
	increased spleen weight	J:220965
	increased splenocyte number	J:220965
	increased susceptibility to systemic lupus erythematosus	J:220965
	lacrimal gland inflammation	J:220965
	lymphoid hyperplasia	J:220965
	pancreas inflammation	J:220965
	salivary gland inflammation	J:220965
	tubulointerstitial nephritis	J:220965
\Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd)	abnormal interferon secretion	J:234263
	abnormal spleen marginal zone morphology	J:92264
	enlarged lymph nodes	J:92264
	enlarged spleen	J:92264
	heart inflammation	J:202757
	increased autoantibody level	J:202757
	increased spleen B cell follicle size	J:92264
	myocarditis	J:92264
	skin inflammation	J:202757
	thymus cortex hypoplasia	J:92264
\Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6)	dermatitis	J:181257
	folliculitis	J:181257
	glomerulonephritis	J:181257
	immune system phenotype	J:181257
	increased anti-nuclear antigen antibody level	J:181257
	increased IgG level	J:181257
	increased inflammatory response	J:181257
	increased susceptibility to systemic lupus erythematosus	J:181257
	kidney inflammation	J:181257
	myocarditis	J:181257
	myositis	J:181257
	skin inflammation	J:181257
	stomach inflammation	J:181257
\Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	heart inflammation	J:234263
	increased autoantibody level	J:234263
	increased inflammatory response	J:234263
	kidney inflammation	J:234263
	myositis	J:234263
	stomach inflammation	J:234263
\Trex1^tm1Tld/\Trex1^tm1Tld (involves: 129P2/OlaHsd * C57BL/6J)	dermatitis	J:243357
	increased susceptibility to autoimmune disorder	J:243357
\Trf^{em1(IMPC)Rbrc}/\Trf⁺ (C57BL/6NJcl-Trf^{em1(IMPC)Rbrc}/Rbrc)	increased large unstained cell number	J:211773
\Trgc1^tm1.2Dhr/\Trgc1^tm1.2Dhr (either: 129S4/SvJae or (involves: 129S4/SvJae * C57BL/6))	decreased gamma-delta T cell number	J:91304
\Tria4^STS/A/? (involves: BALB/c * STS/A)	abnormal leukocyte physiology	J:56029
\Tria5^STS/A/? (involves: BALB/cHeA * STS/A)	abnormal leukocyte physiology	J:56029
\Trib1^tm1Aki/\Trib1^tm1Aki (involves: 129P2/OlaHsd)	abnormal spleen red pulp morphology	J:196449
	decreased eosinophil cell number	J:196449
	decreased interleukin-12 secretion	J:126085
	decreased macrophage cell number	J:196449
	decreased spleen iron level	J:196449
	increased neutrophil cell number	J:196449
\Trib2^{Tg(Thy1-Trh/APP)2.1Ingm}/\Trib2⁺ \Tg(Thy1-APP)2.2Ingm/0 (involves: C57BL/6 * DBA/1)	microgliosis	J:176575
\Trib2^{Tg(Thy1-Trh/APP)2.1Ingm}/\Trib2^{Tg(Thy1-Trh/APP)2.1Ingm} (involves: C57BL/6 * DBA/1)	microgliosis	J:176575
\Trib2^tm1Lex/\Trib2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased B cell number	J:82809
	increased CD8-positive, alpha-beta T cell number	J:82809
\Trib3^tm1Tord/\Trib3^tm1Tord (involves: C57BL/6)	abnormal mast cell physiology	J:192615
\Trib3^tm1Tord/\Trib3^tm1Tord (involves: C57BL/6)	decreased mast cell degranulation	J:192615
\Tril^tm1.1Kaf/\Tril^tm1.1Kaf (involves: C57BL/6)	abnormal chemokine secretion	J:301765
	abnormal cytokine secretion	J:301765
	decreased interferon-beta secretion	J:301765
	decreased interleukin-6 secretion	J:301765
	decreased tumor necrosis factor secretion	J:301765
\Trim6^em1Raj/\Trim6^em1Raj (C57BL/6J-Trim6^em1Raj)	abnormal response to infection	J:326927
\Trim7^em1Jiew/\Trim7^em1Jiew (C57BL/6-Trim7^em1Jiew)	decreased susceptibility to Herpesvirales infection	J:292408
\Trim7^em1Jiew/\Trim7^em1Jiew (C57BL/6-Trim7^em1Jiew)	decreased susceptibility to viral infection	J:292408
\Trim8^tm1Hbsh/\Trim8^tm1Hbsh (involves: 129S6/SvEvTac)	abnormal chemokine secretion	J:251270
	abnormal circulating chemokine level	J:251270
	decreased interleukin-6 secretion	J:251270
	decreased tumor necrosis factor secretion	J:251270
	immune system phenotype	J:251270
	increased circulating interleukin-6 level	J:251270
	increased circulating tumor necrosis factor level	J:251270
	increased interferon-beta secretion	J:251270
	increased interleukin-6 secretion	J:251270
	increased macrophage cytokine production	J:251270
	increased susceptibility to bacterial infection	J:251270
	increased susceptibility to bacterial infection induced morbidity/mortality	J:251270
	increased susceptibility to endotoxin shock	J:251270
	increased tumor necrosis factor secretion	J:251270
\Trim9^{em1(IMPC)Ccpcz}/\Trim9^{em1(IMPC)Ccpcz} (C57BL/6N-Trim9^{em1(IMPC)Ccpcz}/Ccpcz)	decreased effector memory T-helper cell number	J:211773
	decreased spleen weight	J:211773
\Trim13^em1(IMPC)Tcp/\Trim13^em1(IMPC)Tcp (C57BL/6N-Trim13^em1(IMPC)Tcp/Tcp)	enlarged thymus	J:211773
\Trim13^tm1.1Jskg/\Trim13^tm1.1Jskg (B6.129S7(Cg)-Trim13^tm1.1Jskg)	abnormal circulating interferon level	J:243916
	decreased circulating interferon-beta level	J:243916
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:243916
	increased interferon-beta secretion	J:243916
\Trim14^em1Rfw/\Trim14^em1Rfw (involves: C57BL/6J)	decreased interferon-beta secretion	J:249057
	increased susceptibility to Herpesvirales infection	J:249057
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:249057
\Trim21^tm1Mwah/\Trim21⁺ (C57BL/6-Trim21^tm1Mwah)	dermatitis	J:151775
\Trim21^tm1Mwah/\Trim21^tm1Mwah (C57BL/6-Trim21^tm1Mwah)	abnormal interleukin level	J:151775
	abnormal T cell activation	J:151775
	abnormal tumor necrosis factor level	J:151775
	autoimmune response	J:151775
	dermatitis	J:151775
	enlarged lymph nodes	J:151775
	enlarged spleen	J:151775
	increased autoantibody level	J:151775
	increased inflammatory response	J:151775
\Trim25^tm1Mura/\Trim25⁺ \Usp15^L749R/\Usp15⁺ (involves: 129S1/SvImJ * 129S4/SvJae * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
\Trim25^tm1Mura/\Trim25^tm1Mura (involves: 129S4/SvJae)	decreased susceptibility to parasitic infection	J:259382
\Trim25^tm1Mura/\Trim25^tm1Mura (involves: 129S4/SvJae)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
\Trim27^{Gt(345D11)Cmhd}/\Trim27^{Gt(345D11)Cmhd} (B6.129-Trim27^{Gt(345D11)Cmhd})	abnormal T-helper 1 physiology	J:180433
	abnormal T-helper 2 physiology	J:180433
	immune system phenotype	J:180433
	increased interferon-gamma secretion	J:180433
	increased tumor necrosis factor secretion	J:180433
\Trim29^{tm1a(EUCOMM)Wtsi}/\Trim29^{tm1a(EUCOMM)Wtsi} (involves: C57BL/6N * C57BL/6NTac)	abnormal interferon secretion	J:349246
	abnormal tumor necrosis factor level	J:349246
	decreased interleukin level	J:349246
	decreased susceptibility to Picornaviridae infection	J:349246
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:349246
	increased interferon level	J:349246
	increased interferon-alpha secretion	J:349246
	increased interferon-beta secretion	J:349246
\Trim29^{tm1c(EUCOMM)Wtsi}/\Trim29^{tm1c(EUCOMM)Wtsi} \Tg(Myh6-cre)2182Mds/0 (involves: C57BL/6J * C57BL/6N * C57BL/6NTac)	abnormal tumor necrosis factor level	J:349246
	decreased inflammatory response	J:349246
	decreased interleukin level	J:349246
	decreased susceptibility to Picornaviridae infection	J:349246
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:349246
	increased interferon level	J:349246
	increased interferon-gamma secretion	J:349246
	increased T cell proliferation	J:349246
\Trim30a^tm1Yjk/\Trim30a^tm1Yjk (B6.129P2-Trim30a^tm1Yjk)	abnormal CD4-positive, alpha-beta T cell physiology	J:215171
	abnormal T cell subpopulation ratio	J:215171
	increased CD4-positive, alpha-beta T cell number	J:215171
	increased T cell proliferation	J:215171
\Trim31^em1Cya/\Trim31^em1Cya (involves: C57BL/6)	abnormal circulating cytokine level	J:243237
	decreased susceptibility to induced colitis	J:243237
	increased circulating interleukin-1 beta level	J:243237
	increased Ly6C high monocyte number	J:243237
	increased neutrophil cell number	J:243237
\Trim33^em1(IMPC)Tcp/\Trim33⁺ (C57BL/6N-Trim33^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Trim33^tm1Los/\Trim33^tm1Los \Tg(Cd4-cre)1Cwi/0 (involves: 129S2/SvPas * C57BL/6 * DBA/2)	immune system phenotype	J:149449
\Trim35^em1Smoc/\Trim35^em1Smoc (C57BL/6J-Trim35^em1Smoc)	decreased circulating interferon-beta level	J:303214
	decreased macrophage cytokine production	J:303214
	increased susceptibility to Orthomyxoviridae infection	J:303214
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:303214
\Trim37^{Gt(RRO307)Byg}/\Trim37^{Gt(RRO307)Byg} (B6J.129P2-Trim37^{Gt(RRO307)Byg})	enlarged spleen	J:232482
\Trim38^{tm1(KOMP)Vlcg}/\Trim38^{tm1(KOMP)Vlcg} (involves: C57BL/6N)	increased circulating interferon-alpha level	J:239773
	increased circulating interferon-beta level	J:239773
	increased circulating interleukin-6 level	J:239773
	increased circulating tumor necrosis factor level	J:239773
	increased susceptibility to bacterial infection	J:239773
	increased susceptibility to bacterial infection induced morbidity/mortality	J:239773
	increased susceptibility to infection induced morbidity/mortality	J:239773
\Trim39^{tm1b(EUCOMM)Hmgu}/\Trim39^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Trim39^{tm1b(EUCOMM)Hmgu}/H)	decreased monocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Trim40^em1Caox/\Trim40^em1Caox (involves: C57BL/6J)	abnormal immune system physiology	J:255265
	abnormal macrophage physiology	J:255265
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:255265
\Trim41^tm1Caox/\Trim41^tm1Caox (B6.Cg-Trim41^tm1Caox)	abnormal innate immunity	J:340065
	abnormal tumor necrosis factor level	J:340065
	decreased circulating interferon-beta level	J:340065
	decreased circulating interleukin-6 level	J:340065
	decreased interferon level	J:340065
	decreased interleukin level	J:340065
	increased susceptibility to bacterial infection	J:340065
	increased susceptibility to bacterial infection induced morbidity/mortality	J:340065
	increased susceptibility to Herpesvirales infection	J:340065
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:340065
	increased susceptibility to Riboviria infection	J:340065
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:340065
\Trim45^{tm1a(KOMP)Wtsi}/\Trim45^{tm1a(KOMP)Wtsi} (B6Brd;B6Dnk;B6N-Trim45^{tm1a(KOMP)Wtsi} Tyr^c-Brd/Wtsi)	blood in lymph vessels	J:239583
\Trim46^em1(IMPC)J/\Trim46^em1(IMPC)J (C57BL/6NJ-Trim46^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Trim50^{tm1b(KOMP)Wtsi}/\Trim50^{tm1b(KOMP)Wtsi} (C57BL/6N-Trim50^{tm1b(KOMP)Wtsi}/BayMmucd)	decreased spleen weight	J:211773
\Trim55^tm1Slbt/\Trim55^tm1Slbt (involves: 129 * C57BL/6)	decreased susceptibility to Coronaviridae infection	J:268979
\Trim56^{tm1a(EUCOMM)Wtsi}/\Trim56^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Trim56^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased regulatory T cell number	J:211773
\Trim58^em1(IMPC)Mbp/\Trim58^em1(IMPC)Mbp (C57BL/6N-Trim58^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Trim58^tm2313.1Arte/\Trim58^tm2313.1Arte \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	increased susceptibility to induced colitis	J:279270
\Trim58^tm2313.2Arte/\Trim58^tm2313.2Arte (involves: BALB/cJ * C57BL/6N)	increased susceptibility to induced colitis	J:279270
\Trim65^em1Cya/\Trim65^em1Cya (involves: C57BL/6)	decreased circulating interferon-alpha level	J:240099
	decreased circulating interferon-beta level	J:240099
	decreased interferon-alpha secretion	J:240099
	decreased interferon-beta secretion	J:240099
	increased susceptibility to Picornaviridae infection	J:240099
	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:240099
\Trim65^em2Cya/\Trim65^em2Cya (involves: C57BL/6)	decreased interferon-beta secretion	J:240099
\Trim65^em3Cya/\Trim65^em3Cya (involves: C57BL/6)	decreased interferon-beta secretion	J:240099
\Trio^em1(IMPC)H/\Trio⁺ (C57BL/6NTac-Trio^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Trip6^{tm1b(EUCOMM)Hmgu}/\Trip6⁺ (C57BL/6N-Trip6^{tm1b(EUCOMM)Hmgu}/Bay)	enlarged spleen	J:211773
\Trip10^tm1.1Geha/\Trip10^tm1.1Geha (B6.129S1-Trip10^tm1.1Geha)	abnormal spleen germinal center morphology	J:164363
	abnormal T cell physiology	J:164363
	decreased IgE level	J:164363
	decreased IgG level	J:164363
	decreased spleen germinal center number	J:164363
	decreased spleen germinal center size	J:164363
	decreased susceptibility to type IV hypersensitivity reaction	J:164363
\Trip13^{tm1.1(KOMP)Vlcg}/\Trip13^{tm1.1(KOMP)Vlcg} (C57BL/6N-Trip13^{tm1.1(KOMP)Vlcg}/Ucd)	increased leukocyte cell number	J:211773
\Trmq1^C57BL/6J/\Trmq1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
\Trmq1^DBA/2J/\Trmq1^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
\Trmq2^C57BL/6J/\Trmq2^C57BL/6J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
\Trmq2^C57BL/6J/\Trmq2^DBA/2J (involves: C57BL/6J * DBA/2J)	abnormal CD4-positive, alpha beta T cell morphology	J:77603
\Trmq3^DBA/1J/\Trmq3^FVB/N (involves: DBA/1J * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:116665
\Trmq3^FVB/N/? (involves: DBA/1J * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:94347
\Trmq3^FVB/N/? (involves: DBA/1J * FVB/N)	abnormal T cell proliferation	J:94347
\Trmq3^FVB/N/\Trmq3^FVB/N (involves: DBA/1J * FVB/N)	abnormal CD4-positive, alpha beta T cell morphology	J:116665
\Trmq4^RIIIS/J/\Trmq4^RIIIS/J \Trmq5^RIIIS/J/\Trmq5^RIIIS/J (involves: B10.RIII * RIIIS/J)	abnormal CD4-positive, alpha beta T cell morphology	J:95848
\Trmt2a^{tm2b(EUCOMM)Wtsi}/\Trmt2a^{tm2b(EUCOMM)Wtsi} (C57BL/6N-Trmt2a^{tm2b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Trp53^Bbl/\Trp53⁺ (C57BL/6JSfdAnu-Trp53^Bbl/Anu)	increased T cell derived lymphoma incidence	J:104190
\Trp53^bhy/\Trp53⁺ (C57BL/6JSfdAnu-Trp53^bhy/Anu)	increased T cell derived lymphoma incidence	J:104190
\Trp53^tm1.1Awbr/\Trp53^tm1.1Awbr (involves: C57BL/6)	decreased thymocyte apoptosis	J:173271
	increased pro-B cell number	J:169434
	increased T cell derived lymphoma incidence	J:173271
\Trp53^tm1.1Manf/\Trp53^tm1.1Manf (Not Specified)	abnormal abdominal lymph node morphology	J:201153
	abnormal spleen morphology	J:201153
	abnormal spleen white pulp morphology	J:201153
	abnormal thymus morphology	J:201153
	decreased neutrophil cell number	J:201153
	small spleen	J:201153
	small thymus	J:201153
\Trp53^tm1.1Manf/\Trp53^tm1.1Manf (involves: C57BL/6J)	abnormal abdominal lymph node morphology	J:201153
	abnormal spleen morphology	J:201153
	abnormal spleen white pulp morphology	J:201153
	abnormal thymus morphology	J:201153
	decreased neutrophil cell number	J:201153
	small spleen	J:201153
	small thymus	J:201153
\Trp53^tm1.1Thst/\Trp53⁺ (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	spleen hyperplasia	J:198482
\Trp53^tm1.1Thst/\Trp53^tm1.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	decreased thymocyte apoptosis	J:198482
	immune system phenotype	J:198482
	increased T cell derived lymphoma incidence	J:198482
	spleen hyperplasia	J:198482
\Trp53^tm1.1Tldo/\Trp53^tm1.1Tldo (involves: 129S2/SvPas * BALB/c * C57BL/6)	increased thymocyte apoptosis	J:199308
\Trp53^tm1.1Umol/\Trp53^tm1.1Umol (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
\Trp53^tm1.1Wgu/\Trp53^tm1.1Wgu (involves: 129S6/SvEvTac * C57BL/6)	decreased thymocyte apoptosis	J:186159
\Trp53^tm1.2Awbr/\Trp53⁺ (involves: C57BL/6)	abnormal lymphocyte morphology	J:173271
	abnormal Peyer's patch morphology	J:173271
	increased inflammatory response	J:173271
	liver inflammation	J:173271
\Trp53^tm1.2Awbr/\Trp53^tm1.2Awbr (involves: C57BL/6)	abnormal lymphocyte morphology	J:173271
	abnormal Peyer's patch morphology	J:173271
	adipose tissue inflammation	J:173271
	decreased thymocyte apoptosis	J:173271
	enlarged spleen	J:173271
	increased circulating interferon-gamma level	J:173271
	increased circulating interleukin-3 level	J:173271
	increased circulating interleukin-5 level	J:173271
	increased circulating interleukin-6 level	J:173271
	increased circulating tumor necrosis factor level	J:173271
	increased inflammatory response	J:173271
	increased splenocyte proliferation	J:173271
	increased T cell derived lymphoma incidence	J:173271
	liver inflammation	J:173271
	lung inflammation	J:173271
\Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S7/SvEvBrd)	abnormal thymus physiology	J:175018
\Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S7/SvEvBrd)	decreased thymocyte apoptosis	J:186159
\Trp53^tm1Brd/\Trp53^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:126497
\Trp53^tm1Brd/\Trp53^tm1Brd \Tg(Lck-cre)1Cwi/0 (involves: 129S7/SvEvBrd)	increased T cell derived lymphoma incidence	J:157041
\Trp53^tm1Brd/\Trp53^tm1Brd \Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)	increased T cell derived lymphoma incidence	J:109585
\Trp53^tm1Brd/\Trp53^tm1Brd \Trp73^tm2Mak/\Trp73^tm2Mak (involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte apoptosis	J:157905
\Trp53^tm1Brd/\Trp53^tm1Ldo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:73757
\Trp53^tm1Brd/\Trp53^tm8Xu (involves: 129S7/SvEvBrd)	decreased leukocyte cell number	J:170216
\Trp53^tm1Gev/\Trp53^tm1Gev (involves: 129P2/OlaHsd * C57BL/6)	increased T cell derived lymphoma incidence	J:99305
\Trp53^tm1Glo/\Trp53^tm1Glo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:61683
\Trp53^tm1Glo/\Trp53^tm1Glo (involves: 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte apoptosis	J:172038
\Trp53^tm1Glo/\Trp53^tm4Glo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:171821
\Trp53^tm1Holl/\Trp53^tm7.1Xu (involves: 129P2/OlaHsd)	decreased thymocyte apoptosis	J:160414
\Trp53^tm1Ldo/\Trp53⁺ (involves: 129S7/SvEvBrd * C57BL/6)	decreased spleen weight	J:73757
\Trp53^tm1Ldo/\Trp53⁺ (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:73757
\Trp53^tm1Sia/\Trp53^tm1Sia (involves: C57BL/6 * CBA)	increased T cell derived lymphoma incidence	J:36762
\Trp53^tm1Sia/\Trp53^tm1Sia (involves: C57BL/6NCrlj * CBA/JNCrlj)	increased leukocyte cell number	J:233347
	increased spleen weight	J:233347
	increased T cell derived lymphoma incidence	J:233347
	increased thymus weight	J:233347
\Trp53^tm1Thst/\Trp53⁺ (involves: 129S1/Sv * 129X1/SvJ)	spleen hyperplasia	J:198482
\Trp53^tm1Thst/\Trp53^tm1.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	spleen hyperplasia	J:198482
\Trp53^tm1Thst/\Trp53^tm1Thst (involves: 129S1/Sv * 129X1/SvJ)	decreased thymocyte apoptosis	J:198482
	increased T cell derived lymphoma incidence	J:198482
\Trp53^tm1Tyj/\Trp53⁺ (involves: 129S2/SvPas)	decreased thymocyte apoptosis	J:158953
\Trp53^tm1Tyj/\Trp53⁺ (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte apoptosis	J:80311
\Trp53^tm1Tyj/\Trp53⁺ \Trp63^tm1Fmc/\Trp63⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
\Trp53^tm1Tyj/\Trp53⁺ \Trp73^tm1Fmc/\Trp73⁺ (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
\Trp53^tm1Tyj/\Trp53⁺ \Xrcc2^tm1Pmc/\Xrcc2^tm1Pmc (involves: 129S1/Sv * 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:111068
\Trp53^tm1Tyj/\Trp53^tm1.1Umol (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
\Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:87501, J:17728
\Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas)	decreased splenocyte apoptosis	J:195018
	decreased T cell apoptosis	J:109354
	decreased thymocyte apoptosis	J:158953, J:195018, J:126920
	increased T cell derived lymphoma incidence	J:251434, J:221224, J:88120, J:95316
\Trp53^tm1Tyj/\Trp53^tm1Tyj (involves: 129S2/SvPas * C57BL/6 * CBA)	decreased thymocyte apoptosis	J:80311
\Trp53^tm1Tyj/\Trp53^tm1Tyj \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca)	abnormal interleukin secretion	J:305794
\Trp53^tm1Tyj/\Trp53^tm1Tyj \Riok2^{tm1c(KOMP)Wtsi}/\Riok2⁺ \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca)	immune system phenotype	J:305794
\Trp53^tm1Tyj/\Trp53^tm1Tyj \Xrcc2^tm1Pmc/\Xrcc2^tm1Pmc (involves: 129S1/Sv * 129S2/SvPas * C57BL/6)	increased T cell derived lymphoma incidence	J:111068
\Trp53^tm1Tyj/\Trp53^tm1Tyj \Xrcc4^tm1Fwa/\Xrcc4^tm1Fwa (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal lymphopoiesis	J:61973
\Trp53^tm1Tyj/\Trp53^tm2.1Tyj (involves: 129S2/SvPas * 129S4/SvJae)	increased T cell derived lymphoma incidence	J:95316
\Trp53^tm1Tyj/\Trp53^tm2.1Umol (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
\Trp53^tm1Tyj/\Trp53^tm3.1Tyj (involves: 129S2/SvPas * 129S4/SvJae)	increased T cell derived lymphoma incidence	J:95316
\Trp53^tm1Xu/\Trp53^tm1Xu (involves: 129S4/SvJae)	abnormal thymocyte apoptosis	J:86185
\Trp53^tm1Yjc/\Trp53^tm1Yjc (B6.129S1-Trp53^tm1Yjc)	abnormal spleen marginal zone morphology	J:195018
	abnormal spleen white pulp morphology	J:195018
	decreased splenocyte apoptosis	J:195018
	enlarged spleen	J:195018
	immune system phenotype	J:195018
\Trp53^tm2.1Snj/\Trp53^tm2.1Snj (involves: 129S4/SvJae * C57BL/6)	abnormal thymus physiology	J:175018
\Trp53^tm2.1Thst/\Trp53^tm2.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	increased T cell derived lymphoma incidence	J:282255
\Trp53^tm2.1Umol/\Trp53^tm2.1Umol (involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)	increased T cell derived lymphoma incidence	J:228632
\Trp53^tm2.1Wgu/\Trp53^tm2.1Wgu (involves: 129S6/SvEvTac * C57BL/6)	decreased thymocyte apoptosis	J:186159
\Trp53^tm2Thst/\Trp53^tm2.1Thst (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	increased T cell derived lymphoma incidence	J:282255
\Trp53^tm2Wahl/\Trp53^tm2Wahl (involves: 129S4/SvJae * C57BL/6)	decreased leukocyte cell number	J:174375
	decreased spleen red pulp amount	J:174375
\Trp53^tm2Xu/\Trp53^tm2Xu (involves: 129S6/SvEvTac)	decreased T cell apoptosis	J:109354
\Trp53^tm2Xu/\Trp53^tm2Xu (involves: 129S6/SvEvTac)	decreased T cell proliferation	J:109354
\Trp53^tm3.1Glo/\Trp53⁺ (B6.129S7-Trp53^tm3.1Glo)	hepatosplenomegaly	J:317504
	increased leukocyte cell number	J:317504
	increased T cell derived lymphoma incidence	J:317504
\Trp53^tm3.1Holl/\Trp53^tm3.1Holl (Not Specified)	increased thymocyte apoptosis	J:191183
\Trp53^tm4Glo/\Trp53^tm4Glo (involves: 129S7/SvEvBrd * C57BL/6)	increased T cell derived lymphoma incidence	J:171821
\Trp53^tm4Xu/\Trp53^tm4Xu (Not Specified)	increased T cell derived lymphoma incidence	J:126497
\Trp53^tm6Xu/\Trp53^tm6Xu \Tg(Lck-cre)1Cwi/0 (involves: 129S4/SvJae)	increased T cell derived lymphoma incidence	J:157041
\Trp53^tm7.1Xu/\Trp53⁺ (Not Specified)	abnormal thymus physiology	J:160414
\Trp53^tm7.1Xu/\Trp53^tm7.1Xu (Not Specified)	abnormal thymus physiology	J:160414
\Trp53^tm7.1Xu/\Trp53^tm7.1Xu (Not Specified)	decreased thymocyte apoptosis	J:160414
\Trp53bp1^{Gt(OST94324)Lex}/\Trp53bp1^{Gt(OST94324)Lex} (involves: 129S5/SvEvBrd)	abnormal T cell differentiation	J:83164
	decreased mature B cell number	J:83164
	decreased T cell number	J:83164
	small thymus	J:83164
	thymus hypoplasia	J:83164
\Trp53bp1^m2Btlr/\Trp53bp1^m2Btlr (C57BL/6J-Trp53bp1^m2Btlr)	decreased B cell number	J:254841
	decreased CD8-positive, naive alpha-beta T cell number	J:254841
	decreased IgD level	J:254841
	decreased IgG level	J:254841
	impaired humoral immune response	J:254841
	increased central memory CD4-positive, alpha-beta T cell number	J:254841
\Trp53bp1^m3Btlr/\Trp53bp1^m3Btlr (C57BL/6J-Trp53bp1^m3Btlr)	decreased IgD level	J:254848
\Trp53bp1^m4Btlr/\Trp53bp1^m4Btlr (C57BL/6J-Trp53bp1^m4Btlr)	decreased IgD level	J:254852
\Trp53bp1^m5Btlr/\Trp53bp1^m5Btlr (C57BL/6J-Trp53bp1^m5Btlr)	decreased IgD level	J:272848
\Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc (involves: 129 * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:82512
	increased double-negative T cell number	J:82512
	increased T cell derived lymphoma incidence	J:82512
	thymus hypoplasia	J:82512
\Trp53bp1^tm1Jc/\Trp53bp1^tm1Jc (involves: 129)	abnormal class switch recombination	J:194603, J:231089, J:307190
\Trp53bp2^tm1Cdlo/\Trp53bp2⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal T cell physiology	J:146764
\Trp53bp2^tm1Cdlo/\Trp53bp2⁺ \Tg(EmuSR-tTa)83Bop/0 \Tg(tetO-MYC)36aBop/0 (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	increased T cell derived lymphoma incidence	J:146764
\Trp53bp2^tm1Xlu/\Trp53bp2⁺ (involves: 129S6/SvEvTac * C57BL/6J)	increased T cell derived lymphoma incidence	J:108701
\Trp53bp2^tm1Xlu/\Trp53bp2^tm1Xlu (C.129S6-Trp53bp2^tm1Xlu)	small thymus	J:240594
\Trp53inp1^tm1Acar/\Trp53inp1^tm1Acar (involves: 129/Sv * C57BL/6)	increased susceptibility to induced colitis	J:118867
	large intestinal inflammation	J:118867
\Trp53inp2^em1(IMPC)Mbp/\Trp53inp2^em1(IMPC)Mbp (C57BL/6N-Trp53inp2^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Trp63^tm1Fmc/\Trp63⁺ \Trp73^tm1Fmc/\Trp73⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
\Trp63^tm2Brd/\Trp63⁺ (involves: 129S7/SvEvBrd)	enlarged lymph nodes	J:100483
	increased susceptibility to infection	J:100483
	kidney inflammation	J:100483
	uterine cervix inflammation	J:100483
\Trp73^em1(IMPC)H/\Trp73⁺ (C57BL/6NTac-Trp73^em1(IMPC)H/H)	decreased spleen weight	J:211773
\Trp73^tm1Fmc/\Trp73⁺ (involves: 129S4/SvJae * C57BL/6)	increased T cell derived lymphoma incidence	J:98958
\Trp73^tm1Fmc/\Trp73^tm1Fmc (involves: 129S4/SvJae)	chronic inflammation	J:60896
	conjunctivitis	J:60896
	increased susceptibility to bacterial infection	J:60896
	increased susceptibility to otitis media	J:60896
	rhinitis	J:60896
	sinus inflammation	J:60896
\Trp73^tm1Mak/\Trp73⁺ (involves: 129P2/OlaHsd * C57BL/6J)	increased T cell derived lymphoma incidence	J:142848
\Trp73^tm1Mak/\Trp73^tm1Mak (involves: 129P2/OlaHsd * C57BL/6J)	increased T cell derived lymphoma incidence	J:142848
\Trp73^tm2Mak/\Trp73^tm2Mak (either: B6.129P2-Trp73^tm2Mak or (involves: 129P2/OlaHsd * C57BL/6J))	increased thymocyte apoptosis	J:157905
\Trpa1^tm1Jul/\Trpa1⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal acute inflammation	J:115886
\Trpc1^em1(IMPC)H/\Trpc1^em1(IMPC)H (C57BL/6N-Trpc1^em1(IMPC)H/H)	increased spleen weight	J:211773
\Trpc3^tm1.2Akon/\Trpc3^tm1.2Akon (involves: 129S/SvEv)	immune system phenotype	J:190105
\Trpm2^tm1.1Alp/\Trpm2^tm1.1Alp (B6.129P2-Trpm2^tm1.1Alp)	decreased circulating interferon-gamma level	J:174397
	decreased circulating interleukin-12 level	J:174397
	decreased circulating interleukin-12b level	J:174397
	decreased interferon-gamma secretion	J:174397
	decreased interleukin-12 secretion	J:174397
	increased susceptibility to bacterial infection	J:174397
	increased susceptibility to bacterial infection induced morbidity/mortality	J:174397
\Trpm2^tm1Lhj/\Trpm2^tm1Lhj (Not Specified)	abnormal macrophage morphology	J:202791
\Trpm2^tm1Lhj/\Trpm2^tm1Lhj (Not Specified)	abnormal macrophage physiology	J:202791
\Trpm2^tm1Yamo/\Trpm2^tm1Yamo (involves: 129S4/SvJae * C57BL/6J)	abnormal interferon level	J:137676
	abnormal interleukin level	J:137676
	abnormal leukocyte physiology	J:137676
	abnormal macrophage physiology	J:137676
	decreased inflammatory response	J:137676
	impaired neutrophil recruitment	J:137676
\Trpm4^tm1.1Knt/\Trpm4^tm1.1Knt (Not Specified)	abnormal dendritic cell physiology	J:140991
\Trpm4^tm1.1Knt/\Trpm4^tm1.1Knt (Not Specified)	decreased dendritic cell number	J:140991
\Trpm4^tm1.1Knt/\Trpm4^tm1.1Knt \Trpm5^tm1Csz/\Trpm5^tm1Csz (involves: 129S1/Sv * 129X1/SvJ)	abnormal dendritic cell physiology	J:140991
	decreased dendritic cell number	J:140991
\Trpm4^tm1.1Mfre/\Trpm4^tm1.1Mfre (involves: 129S1/Sv * 129X1/SvJ * BALB/cJ)	increased susceptibility to type I hypersensitivity reaction	J:118679
\Trpm7^tm1Agry/\Trpm7⁺ (involves: 129)	increased susceptibility to type IV hypersensitivity reaction	J:205665
\Trpm7^tm1Clph/\Trpm7^tm1.1Clph \Tg(Lck-cre)548Jxm/0 (involves: 129S4/SvJae * C57BL/6 * CBA)	abnormal T cell differentiation	J:140630
	abnormal T cell physiology	J:140630
	abnormal thymus cell ratio	J:140630
	abnormal thymus corticomedullary boundary morphology	J:140630
	abnormal thymus medulla morphology	J:140630
	abnormal thymus morphology	J:140630
	decreased T cell number	J:140630
	decreased thymocyte number	J:140630
\Trps1^m1Anu/\Trps1^m1Anu (C57BL/6NCrlAnu-Trps1^m1Anu)	immune system phenotype	J:104190
\Trpv1^tm1Jul/\Trpv1^tm1Jul (involves: 129X1/SvJ * C57BL/6)	decreased susceptibility to endotoxin shock	J:104828
\Trpv1^tm1Jul/\Trpv1^tm1Jul (B6.129X1-Trpv1^tm1Jul)	abnormal chemokine secretion	J:154624
	increased interleukin-6 secretion	J:154624
	increased tumor necrosis factor secretion	J:154624
	kidney inflammation	J:154624
\Trpv2^tm1Mijc/\Trpv2^tm1Mijc (involves: 129S6/SvEvTac * C57BL/6)	impaired macrophage chemotaxis	J:158505
	impaired macrophage phagocytosis	J:158505
	increased susceptibility to bacterial infection	J:158505
	increased susceptibility to bacterial infection induced morbidity/mortality	J:158505
\Trpv3^Nh/\Trpv3⁺ (involves: DS)	dermatitis	J:42153
\Trpv3^Nh/\Trpv3⁺ (involves: DS)	increased susceptibility to bacterial infection	J:42153
\Trpv3^tm1.2Clph/\Trpv3^tm1.2Clph (involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * C57BL/6J * CBA)	erythroderma	J:164741
\Trpv5^Hcalc1/\Trpv5⁺ (involves: C3H/HeH * C57BL/6J)	kidney inflammation	J:196612
\Trpv5^Hcalc1/\Trpv5^Hcalc1 (involves: C3H/HeH * C57BL/6J)	kidney inflammation	J:196612
\Trpv5^m1Btlr/\Trpv5^m1Btlr (C57BL/6J-Trpv5^m1Btlr)	increased susceptibility to induced colitis	J:192586
\Trpv5^m1Btlr/\Trpv5^m1Btlr (C57BL/6J-Trpv5^m1Btlr)	intestinal inflammation	J:192586
\Trpv5^tm1Bind/\Trpv5^tm1Bind (involves: 129 * C57BL/6)	increased osteoclast cell number	J:86949
\Try10^em1(IMPC)J/\Try10^em1(IMPC)J (C57BL/6NJ-Try10^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Ts(16C-tel)1Cje/0 (involves: C57BL/6J * Rb(11.16)2H * Rb(16.17)32Lub)	abnormal spleen B cell follicle morphology	J:174270
	abnormal spleen B cell follicle shape	J:241597
	abnormal spleen red pulp morphology	J:174270
	increased spleen B cell follicle size	J:241597
\Ts(17¹⁶)65Dn/0 (involves: C3H/HeJ * C57BL/6J * DBA/2J)	abnormal spleen B cell follicle morphology	J:174270
	abnormal spleen B cell follicle shape	J:174270
	abnormal spleen red pulp morphology	J:174270
	increased spleen B cell follicle size	J:174270
\Tsc1^{em1(IMPC)Ccpcz}/\Tsc1⁺ (C57BL/6NCrl-Tsc1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Tsc22d2^em1(IMPC)Tcp/\Tsc22d2^em1(IMPC)Tcp (C57BL/6NCrl-Tsc22d2^em1(IMPC)Tcp/Cmmr)	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Tsc22d3^tm1.2Efmd/Y (Not Specified)	abnormal susceptibility to autoimmune disorder	J:201728
	abnormal T cell subpopulation ratio	J:201728
	immune system phenotype	J:201728
	increased interferon-gamma secretion	J:201728
	increased interleukin-17 secretion	J:201728
	increased susceptibility to type IV hypersensitivity reaction	J:201728
\Tsc22d3^tm1.2Hum/Y (involves: 129S1/SvImJ)	abnormal thymus cell ratio	J:223992
	decreased DN3 thymocyte number	J:223992
	decreased thymus weight	J:223992
	increased DN4 thymocyte number	J:223992
\Tshr^hyt/\Tshr^hyt (CBy.RF-Tshr^hyt/J)	decreased B cell number	J:111014
\Tshr^hyt/\Tshr^hyt (CBy.RF-Tshr^hyt/J)	increased pro-B cell number	J:111014
\Tsil^{Tg(Myc)12ALvn}/\Tsil^{Tg(Myc)12ALvn} (involves: C57BL/6 * SJL/J)	increased double-positive T cell number	J:33857
\Tsiq1^BALB/cOla/\Tsiq1^BALB/cOla (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
\Tsiq1^BALB/cOla/\Tsiq1^BALB/cOla \Tsiq2^BALB/cOla/\Tsiq2^BALB/cOla \Tsiq3^BALB/cOla/\Tsiq3^C57BL/6Ola (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
\Tsiq2^BALB/cOla/\Tsiq2^BALB/cOla (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
\Tsiq3^BALB/cOla/\Tsiq3^C57BL/6Ola (involves: BALB/cOla * C57BL/6Ola)	increased interleukin-4 secretion	J:99489
\Tslp^{tm1(KOMP)Vlcg}/\Tslp^{tm1(KOMP)Vlcg} (involves: C57BL/6 * C57BL/6NTac)	abnormal immune system physiology	J:187770
	abnormal immunoglobulin level	J:187770
	abnormal T-helper 2 cell differentiation	J:187770
	decreased acute inflammation	J:187770
	decreased circulating interleukin-4 level	J:187770
	increased interferon-gamma secretion	J:187770
	respiratory system inflammation	J:187770
\Tslp^tm1.1Pcn/\Tslp^tm1.1Pcn \Tg(KRT14-cre)1Ipc/0 (involves: 129 * C57BL/6 * SJL)	decreased eosinophil cell number	J:146511
	decreased IgE level	J:146511
	decreased lymphocyte cell number	J:146511
\Tslp^tm1Mak/\Tslp^tm1Mak (B6.Cg-Tslp^tm1Mak)	colitis	J:175844
\Tslp^tm1Mak/\Tslp^tm1Mak (B6.Cg-Tslp^tm1Mak)	immune system phenotype	J:175844
\Tslp^tm1Sfz/\Tslp^tm1Sfz (C.129(Cg)-Tslp^tm1Sfz)	immune system phenotype	J:199558
\Tslp^tm1Sfz/\Tslp^tm1Sfz (involves: 129)	abnormal interleukin secretion	J:197193
	abnormal T-helper 2 physiology	J:197193
	increased interleukin-5 secretion	J:197193
	increased interleukin-13 secretion	J:197193
\Tsn^{Gt(OST63223)Lex}/\Tsn^{Gt(OST63223)Lex} (involves: 129S5/SvEvBrd * C57BL/6J)	immune system phenotype	J:85466
\Tspan2^tm1Hbw/\Tspan2^tm1Hbw (C57BL/6-Tspan2^tm1Hbw)	microgliosis	J:201143
\Tspan9^em1Tshu/\Tspan9^em1Tshu (C57BL/6-Tspan9^em1Tshu)	abnormal macrophage morphology	J:307067
	abnormal neutrophil morphology	J:307067
	decreased neutrophil cell number	J:307067
\Tspan32^em1(IMPC)Mbp/\Tspan32^em1(IMPC)Mbp (C57BL/6N-Tspan32^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Tspan32^{Gt(pMS-1)1Jmt}/\Tspan32^{Gt(pMS-1)1Jmt} (involves: 129S1/Sv)	increased T cell proliferation	J:78033
\Tspan33^tm1Stsa/\Tspan33^tm1Stsa (involves: 129S1/Sv * 129X1/SvJ)	abnormal spleen morphology	J:143158
	abnormal splenic cell ratio	J:143158
	enlarged spleen	J:143158
	increased monocyte cell number	J:143158
\Tspo^tm1.1Guwu/\Tspo^tm1.1Guwu (involves: C57BL/6)	increased NK cell number	J:219189
\Tssk5^{tm1.1(KOMP)Vlcg}/\Tssk5^{tm1.1(KOMP)Vlcg} (C57BL/6N-Tssk5^{tm1.1(KOMP)Vlcg}/J)	decreased leukocyte cell number	J:211773
\Tst^{tm1(KOMP)Vlcg}/\Tst^{tm1(KOMP)Vlcg} (C57BL/6N-Tst^{tm1(KOMP)Vlcg}/Ucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Tstd1^em1(IMPC)J/\Tstd1^em1(IMPC)J (C57BL/6NJ-Tstd1^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ttc7^fsn-Jic/\Ttc7^fsn-Jic (C3.INT-Ttc7^fsn-Jic)	decreased spleen white pulp amount	J:115742
	decreased thymus weight	J:115742
	increased spleen red pulp amount	J:115742
	increased spleen weight	J:115742
	liver inflammation	J:115742
\Ttc7^fsn/\Ttc7^fsn (CByJ.A-Ttc7^fsn)	enlarged spleen	J:29200, J:30519
	small thymus	J:29200
	thymus cortex hypoplasia	J:29200
\Ttc7^fsn/\Ttc7^fsn (involves: A/J)	stomach inflammation	J:2777
\Ttc7^fsn/\Ttc7^fsn (involves: A/J * BALB/cByJ)	increased dendritic epidermal T cell number	J:14506
\Ttc7^fsn/\Ttc7^fsn (involves: A/J * BALB/cByJ)	increased Langerhans cell number	J:14506
\Ttc7^hea/\Ttc7^hea (CFO)	enlarged spleen	J:7515
\Ttc7^hea/\Ttc7^hea (CFO)	increased leukocyte cell number	J:7515
\Ttc9^tm1Vcl/\Ttc9⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	thymus hyperplasia	J:241703
\Ttc9^tm1Vcl/\Ttc9^tm1Vcl (involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)	increased spleen weight	J:241703
	increased thymus weight	J:241703
	thymus hyperplasia	J:241703
\Ttc28^{tm1b(EUCOMM)Hmgu}/\Ttc28^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ttc28^{tm1b(EUCOMM)Hmgu}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Ttc39aos1^em1Bcgen/\Ttc39aos1^em1Bcgen (involves: C57BL/6N)	increased cytokine level	J:307097
	increased susceptibility to induced pancreatitis	J:307097
\Ttc39aos1^tm1Kaf/\Ttc39aos1^tm1Kaf (C57BL/6-Ttc39aos1^tm1Kaf)	increased susceptibility to endotoxin shock	J:234649
\Tti1^em1(IMPC)J/\Tti1⁺ (C57BL/6NJ-Tti1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Tti2^{tm1b(KOMP)Wtsi}/\Tti2⁺ (C57BL/6N-Tti2^{tm1b(KOMP)Wtsi}/Ics)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Ttk^em1(IMPC)J/\Ttk⁺ (C57BL/6NJ-Ttk^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Ttll1^{Gt(OST372941)Lex}/\Ttll1^{Gt(OST372941)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	increased susceptibility to otitis media	J:186050
	rhinitis	J:186050
\Ttll1^tm1Seto/\Ttll1^tm1Seto (involves: 129S/SvEv * C57BL/6)	rhinosinusitis	J:161297
\Ttll11^{em1(IMPC)Ccpcz}/\Ttll11^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Ttll11^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Ttn^mdm/\Ttn^mdm (Not Specified)	myositis	J:14016
\Ttn^tm1.1Isrd/\Ttn^tm1.1Isrd (involves: 129S2/SvPas * C57BL/6)	myositis	J:165576
\Tub^tub/\Tub^tub (C57BL/6J-Tub^tub)	abnormal Langerhans cell physiology	J:13772
\Tubal3^em1(IMPC)J/\Tubal3^em1(IMPC)J (C57BL/6NJ-Tubal3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Tulp4^{tm1a(KOMP)Wtsi}/\Tulp4⁺ (involves: C57BL/6N * C57BL/6NRj)	absent connection between subcutaneous lymph vessels and lymph sac	J:344151
	immune system phenotype	J:344151
\Tulp4^{tm1a(KOMP)Wtsi}/\Tulp4^{tm1a(KOMP)Wtsi} (involves: C57BL/6N * C57BL/6NRj)	abnormal thymus topology	J:344151
\Tusc2^tm1Avi/\Tusc2⁺ (involves: 129S1/Sv * C57BL/6J)	arteritis	J:119985
	glomerulonephritis	J:119985
	increased anti-nuclear antigen antibody level	J:119985
	increased susceptibility to autoimmune disorder	J:119985
\Tusc2^tm1Avi/\Tusc2^tm1Avi (involves: 129S1/Sv * C57BL/6J)	abnormal NK cell differentiation	J:119985
	arteritis	J:119985
	decreased interleukin-15 secretion	J:119985
	decreased NK cell number	J:119985
	glomerulonephritis	J:119985
	increased anti-nuclear antigen antibody level	J:119985
	increased leukocyte cell number	J:119985
	increased susceptibility to autoimmune disorder	J:119985
\Tusc2^tm1Avi/\Tusc2^tm1Avi (involves: 129S1/Sv)	arteritis	J:309768
	chronic inflammation	J:309768
	decreased T cell proliferation	J:309768
	decreased thymocyte number	J:309768
	increased macrophage cell number	J:309768
	increased monocyte cell number	J:309768
	increased susceptibility to autoimmune disorder	J:309768
\Tvp23b^em3Eetr/\Tvp23b^em3Eetr (C57BL/6J-Tvp23b^em3Eetr)	increased susceptibility to induced colitis	J:340685
\Tvp23b^m1Btlr/\Tvp23b^m1Btlr (C57BL/6J-Tvp23b^m1Btlr)	increased susceptibility to induced colitis	J:340685
\Twist2^tm1(cre)Dor/\Twist2^tm1(cre)Dor (involves: 129/Sv * 129X1/SvJ)	abnormal interleukin level	J:81485
	abnormal spleen morphology	J:81485
	abnormal spleen white pulp morphology	J:81485
	abnormal thymus cortex morphology	J:81485
	abnormal thymus medulla morphology	J:81485
	abnormal thymus morphology	J:81485
	abnormal tumor necrosis factor level	J:81485
	thymus atrophy	J:81485
\Twsg1^tm1Nosa/\Twsg1^tm1Nosa (involves: 129P2/OlaHsd * C57BL/6)	abnormal B cell differentiation	J:82738
	abnormal spleen development	J:82738
	abnormal thymus development	J:82738
	decreased double-positive T cell number	J:82738
	decreased immature B cell number	J:82738
	decreased lymphocyte cell number	J:82738
	decreased pre-B cell number	J:82738
	decreased pro-B cell number	J:82738
	decreased spleen white pulp amount	J:82738
	decreased splenocyte number	J:82738
	decreased thymocyte number	J:82738
	increased granulocyte number	J:82738
	increased monocyte cell number	J:82738
	increased single-positive T cell number	J:82738
	increased thymocyte apoptosis	J:82738
	thymus atrophy	J:82738
\Txk^tm1Pls/\Txk^tm1Pls (involves: 129S6/SvEvTac)	abnormal cytokine secretion	J:54449
\Txk^tm1Pls/\Txk^tm1Pls (involves: 129S6/SvEvTac)	increased susceptibility to parasitic infection	J:54449
\Txlna^{tm1b(EUCOMM)Hmgu}/\Txlna⁺ (C57BL/6N-Txlna^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
\Txlna^{tm1b(EUCOMM)Hmgu}/\Txlna^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Txlna^{tm1b(EUCOMM)Hmgu}/H)	increased large unstained cell number	J:211773
	increased lymphocyte cell number	J:211773
\Txndc2^tm1Lex/\Txndc2^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	decreased circulating interleukin-6 level	J:103485
\Txnip^tm1Yu/\Txnip^tm1Yu (involves: 129)	abnormal mesenteric lymph node morphology	J:96677
	abnormal NK cell morphology	J:96677
	abnormal NK cell physiology	J:96677
	decreased CD8-positive, alpha-beta T cell number	J:96677
	decreased NK cell number	J:96677
	decreased NK T cell number	J:96677
	increased lymphocyte cell number	J:96677
	increased regulatory T cell number	J:96677
	increased T cell proliferation	J:96677
\Txnl1^em1(IMPC)Tcp/\Txnl1^em1(IMPC)Tcp (C57BL/6NCrl-Txnl1^em1(IMPC)Tcp/Tcp)	increased monocyte cell number	J:211773
\Tyk2^E775K/\Tyk2^E775K (B10.D1-H2^q/SgJ)	abnormal T-helper 1 physiology	J:69051
	decreased IgG1 level	J:69051
	decreased IgG2a level	J:69051
	decreased IgG level	J:69051
	decreased interferon-gamma secretion	J:69051, J:120304
	decreased susceptibility to induced arthritis	J:69051
	increased circulating interleukin-12 level	J:120304
	increased susceptibility to parasitic infection	J:120304
\Tyk2^tm1Biat/\Tyk2^tm1Biat (involves: 129P2/OlaHsd * C57BL/6)	abnormal response to infection	J:116703
	decreased interferon-gamma secretion	J:65408
	decreased macrophage nitric oxide production	J:65408
	increased susceptibility to Herpesvirales infection	J:116703
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:116703
	increased susceptibility to Riboviria infection	J:65408
	increased susceptibility to viral infection induced morbidity/mortality	J:65408
\Tyk2^tm1Biat/\Tyk2^tm1Biat (B6NCrl.129P2-Tyk2^tm1Biat)	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:187818
\Tyk2^tm1Biat/\Tyk2^tm1Biat (B6NCrl.129P2-Tyk2^tm1Biat)	increased susceptibility to Riboviria infection induced morbidity/mortality	J:187818
\Tyk2^tm1Shmd/\Tyk2^tm1Shmd (involves: 129P2/OlaHsd)	abnormal splenocyte physiology	J:65409
	abnormal T cell differentiation	J:65409
	abnormal T cell physiology	J:65409
	decreased interferon-gamma secretion	J:65409
\Tyk2^{tm2b(EUCOMM)Hmgu}/\Tyk2^{tm2b(EUCOMM)Hmgu} (C57BL/6N-Tyk2^{tm2b(EUCOMM)Hmgu}/Ieg)	decreased plasmacytoid dendritic cell number	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Tyk2^tm3.1Biat/\Tyk2^tm3.1Biat (B6NCrl.129P2(C)-Tyk2^tm3.1Biat)	increased susceptibility to Picornaviridae infection induced morbidity/mortality	J:187818
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:187818
\Tymp^tm1Akiy/\Tymp^tm1Akiy \Upp1^tm1Akiy/\Upp1^tm1Akiy (involves: 129X1/SvJ)	brain inflammation	J:78036
\Tyro3^{em1(IMPC)Ccpcz}/\Tyro3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Tyro3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
	increased eosinophil cell number	J:211773
\Tyrobp^tm1.1Viv/\Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * C57BL/6)	decreased uterine NK cell number	J:100668
\Tyrobp^tm1.1Viv/\Tyrobp^tm1.1Viv (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)	decreased susceptibility to type IV hypersensitivity reaction	J:64764
	impaired natural killer cell mediated cytotoxicity	J:64764
	increased dendritic cell number	J:64764
\Tyrobp^tm1.1Viv/\Tyrobp^tm1.1Viv (B6.129P2-Tyrobp^tm1.1Viv)	abnormal microglial cell morphology	J:95232
	abnormal myelopoiesis	J:95232
	abnormal osteoclast physiology	J:129304, J:95232
\Tyrobp^tm1Lll/\Tyrobp^tm1Lll (involves: 129P2/OlaHsd * C57BL/6)	abnormal osteoclast differentiation	J:89583
	decreased interferon-gamma secretion	J:64763
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:64763
	decreased T cell proliferation	J:64763
	immune system phenotype	J:64763
	impaired natural killer cell mediated cytotoxicity	J:64763
	increased dendritic cell number	J:64763
	increased natural killer cell mediated cytotoxicity	J:64763
\Tyrobp^tm1Lll/\Tyrobp^tm1Lll (B6.129P2-Tyrobp^tm1Lll)	abnormal NK T cell physiology	J:147867
\Tyrobp^tm1Lll/\Tyrobp^tm1Lll (B6.129P2-Tyrobp^tm1Lll)	decreased interferon-gamma secretion	J:147867
\Tyrobp^tm1Lll/\Tyrobp^tm1Lll (involves: 129P2/OlaHsd)	decreased susceptibility to induced arthritis	J:158811
\Tyrobp^tm1Ttk/\Tyrobp^tm1Ttk (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:110786
	abnormal osteoclast morphology	J:81823
	abnormal osteoclast physiology	J:81823
\Tyrobp^tm1Ttk/\Tyrobp^tm1Ttk (B6.129P2-Tyrobp^tm1Ttk)	increased anti-double stranded DNA antibody level	J:177613
	increased autoantibody level	J:177613
	increased B cell proliferation	J:177613
	increased germinal center B cell number	J:177613
	increased IgG2a level	J:177613
	increased IgG3 level	J:177613
	increased interleukin-6 secretion	J:177613
	increased spleen germinal center number	J:177613
	increased spleen germinal center size	J:177613
\Tyrobp^tm1Viv/\Tyrobp^tm1Viv (B6.129P2-Tyrobp^tm1Viv)	increased susceptibility to Herpesvirales infection	J:124749
\U2af2^em1(IMPC)J/\U2af2⁺ (C57BL/6NJ-U2af2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\U90926^em1Dnkv/\U90926^em1Dnkv (C57BL6/J-U90926^em1Dnkv)	increased circulating interleukin-6 level	J:340649
	increased susceptibility to bacterial infection induced morbidity/mortality	J:340649
	increased susceptibility to endotoxin shock	J:340649
\Uaca^tm1Kiy/\Uaca^tm1Kiy (B6.129P2-Uaca^tm1Kiy)	abnormal Kupffer cell morphology	J:157049
	decreased dendritic cell number	J:157049
	increased tumor necrosis factor secretion	J:157049
	liver inflammation	J:157049
	lung inflammation	J:157049
\Ubash3b^tm1Jni/\Ubash3b^tm1Jni \Ubash3a^tm1Jni/\Ubash3a^tm1Jni (Not Specified)	abnormal cytokine secretion	J:89761
	increased mature B cell number	J:89761
	increased splenocyte number	J:89761
	increased susceptibility to experimental autoimmune encephalomyelitis	J:89761
	increased T cell proliferation	J:89761
\Ubd^{tm1b(EUCOMM)Wtsi}/\Ubd^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Ubd^{tm1b(EUCOMM)Wtsi}/Ccpcz)	abnormal thymus morphology	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	increased CD4-positive, CD25-positive NK T cell number	J:211773
	small thymus	J:211773
\Ubd^tm1Smwe/\Ubd^tm1Smwe (B6.129S6-Ubd^tm1Smwe)	abnormal lymphocyte physiology	J:110321
\Ubd^tm1Smwe/\Ubd^tm1Smwe (B6.129S6-Ubd^tm1Smwe)	increased susceptibility to bacterial infection	J:110321
\Ube2b^{tm1b(EUCOMM)Wtsi}/\Ube2b⁺ (C57BL/6N-Ube2b^{tm1b(EUCOMM)Wtsi}/Ics)	decreased basophil cell number	J:211773
	decreased neutrophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Ube2i^em1(IMPC)J/\Ube2i⁺ (C57BL/6NJ-Ube2i^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Ube2j1^tm1.2Hpl/\Ube2j1^tm1.2Hpl (involves: BALB/cJ * C57BL/6 * C57BL/6N * SJL)	immune system phenotype	J:218292
\Ube2j2^{em1(IMPC)Rbrc}/\Ube2j2^{em1(IMPC)Rbrc} (C57BL/6NJcl-Ube2j2^{em1(IMPC)Rbrc}/Rbrc)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
\Ube2n^{em1(IMPC)Ccpcz}/\Ube2n⁺ (C57BL/6N-Ube2n^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Ube2n^{Gt(OST374154)Lex}/\Ube2n⁺ (involves: 129S5/SvEvBrd * C57BL/6)	abnormal leukocyte physiology	J:120846
	abnormal macrophage physiology	J:120846
	decreased B cell proliferation	J:120846
	decreased susceptibility to endotoxin shock	J:120846
	decreased T cell proliferation	J:120846
\Ube2n^tm1Aki/\Ube2n^tm1Aki \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal macrophage physiology	J:112287
\Ube2s^tm1.1Smoc/\Ube2s^tm1.1Smoc (involves: C57BL/6)	abnormal macrophage physiology	J:306461
	decreased susceptibility to Herpesvirales infection	J:306461
	decreased susceptibility to Picornaviridae infection	J:306461
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:306461
	decreased susceptibility to Riboviria infection	J:306461
	increased circulating interferon-alpha level	J:306461
	increased circulating interferon-beta level	J:306461
	increased circulating interleukin-6 level	J:306461
	increased circulating tumor necrosis factor level	J:306461
	increased interferon level	J:306461
	increased interferon-beta secretion	J:306461
\Ube2u^{tm1e.1(KOMP)Wtsi}/\Ube2u^{tm1e.1(KOMP)Wtsi} (C57BL/6N-Ube2u^{tm1e.1(KOMP)Wtsi}/H)	increased basophil cell number	J:211773
\Ube2w^{tm1d(EUCOMM)Wtsi}/\Ube2w^{tm1d(EUCOMM)Wtsi} (involves: 129 * C57BL/6N)	increased neutrophil cell number	J:230053
\Ube3b^{Gt(RRJ142)Byg}/\Ube3b^{Gt(RRJ142)Byg} (involves: 129P2/OlaHsd * CBA/Ca)	eye inflammation	J:203652
	lymphangiectasis	J:203652
\Ube3c^{tm1b(EUCOMM)Hmgu}/\Ube3c^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ube3c^{tm1b(EUCOMM)Hmgu}/Rbrc)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Ube3c^{tm1b(EUCOMM)Hmgu}/\Ube3c^{tm1b(EUCOMM)Hmgu} (C57BL/6NCrl-Ube3c^{tm1b(EUCOMM)Hmgu}/Rbrc)	decreased CD4-negative NK T cell number	J:211773
	decreased CD5-positive Ly6C-positive T cell number	J:211773
	decreased Ly6C-positive immature NK cell number	J:211773
	decreased Ly6C-positive NK T cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
\Ube4a^em1(IMPC)Tcp/\Ube4a^em1(IMPC)Tcp (C57BL/6N-Ube4a^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Ubl4b^{em1(IMPC)Ccpcz}/\Ubl4b^{em1(IMPC)Ccpcz} (C57BL/6N-Ubl4b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Ubl7^em1Fanm/\Ubl7^em1Fanm (involves: C57BL/6J)	increased susceptibility to Orthomyxoviridae infection	J:349835
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:349835
	increased susceptibility to Riboviria infection	J:349835
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:349835
\Ubox5^{tm1b(EUCOMM)Hmgu}/\Ubox5^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Ubox5^{tm1b(EUCOMM)Hmgu}/Tcp)	increased neutrophil cell number	J:211773
\Ubqln4^em1(IMPC)Mbp/\Ubqln4^em1(IMPC)Mbp (C57BL/6NCrl-Ubqln4^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Ubr7^em1(IMPC)Tcp/\Ubr7^em1(IMPC)Tcp (C57BL/6NCrl-Ubr7^em1(IMPC)Tcp/Tcp)	increased leukocyte cell number	J:211773
\Ubtf^em1(IMPC)Mbp/\Ubtf⁺ (C57BL/6NCrl-Ubtf^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Ubxn11^em1(IMPC)J/\Ubxn11^em1(IMPC)J (C57BL/6NJ-Ubxn11^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Uchl3^tm1Tilg/\Uchl3^tm1Tilg (involves: 129S1/Sv * C57BL/6)	immune system phenotype	J:61093
\Ucp2^tm1Rcq/\Ucp2^tm1Rcq (involves: 129X1/SvJ * C57BL/6J)	abnormal macrophage physiology	J:66262
	decreased susceptibility to bacterial infection	J:66262
	decreased susceptibility to infection induced morbidity/mortality	J:66262
	decreased susceptibility to parasitic infection	J:66262
\Uevld^{tm1a(EUCOMM)Wtsi}/\Uevld^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Uevld^{tm1a(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Ufl1^{tm1c(EUCOMM)Wtsi}/\Ufl1^{tm1c(EUCOMM)Wtsi} \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ (involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N)	decreased granulocyte number	J:238253
	decreased leukocyte cell number	J:238253
	decreased lymphocyte cell number	J:238253
	decreased monocyte cell number	J:238253
\Ugcg^em1(IMPC)H/\Ugcg⁺ (C57BL/6NTac-Ugcg^em1(IMPC)H/H)	decreased lymphocyte cell number	J:211773
\Ugcg^em1(IMPC)H/\Ugcg⁺ (C57BL/6NTac-Ugcg^em1(IMPC)H/H)	increased neutrophil cell number	J:211773
\Uggt1^{tm1a(KOMP)Wtsi}/\Uggt1⁺ (involves: C57BL/6N)	abnormal susceptibility to Picornaviridae infection	J:244058
	decreased susceptibility to Picornaviridae infection	J:244058
	decreased susceptibility to Picornaviridae infection induced morbidity/mortality	J:244058
\Ugt8a^tm1Pop/\Ugt8a^tm1Pop (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:78426
\Uhrf1^{tm1a(EUCOMM)Wtsi}/\Uhrf1⁺ (Not Specified)	increased NK cell number	J:165965
\Uhrf2^{tm1b(EUCOMM)Wtsi}/\Uhrf2^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Uhrf2^{tm1b(EUCOMM)Wtsi}/Tcp)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Uimc1^tm1.2Amj/\Uimc1^tm1.2Amj (involves: BALB/cJ * C57BL/6)	increased T cell derived lymphoma incidence	J:191827
\Ulk1^tm1.1Thsn/\Ulk1^tm1.1Thsn (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	increased spleen weight	J:139213
\Ulk1^tm1.1Thsn/\Ulk1^tm1.1Thsn (involves: 129S1/Sv * 129X1/SvJ)	immune system phenotype	J:235399
\Ulk3^em2(IMPC)Tcp/\Ulk3^em2(IMPC)Tcp (C57BL/6NCrl-Ulk3^em2(IMPC)Tcp/Tcp)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
\Ulk4^tm1Lex/\Ulk4^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6J)	increased susceptibility to otitis media	J:185566
	maxillary sinus inflammation	J:185566
	nasal inflammation	J:185566
\Umod^em1Duf/\Umod⁺ (C57BL/6J-Umod^em1Duf)	kidney inflammation	J:252597
\Umod^tm1.1Rvt/\Umod⁺ (either: B6J.129-Umod^tm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))	kidney inflammation	J:242593
\Umod^tm1.1Rvt/\Umod^tm1.1Rvt (either: B6J.129-Umod^tm1.1Rvt or (involves: 129S1/Sv * 129X1/SvJ))	kidney inflammation	J:242593
\Umod^tm1Xrw/\Umod^tm1Xrw (involves: 129S6/SvEvTac)	increased susceptibility to bacterial infection	J:95431
\Unc13d^Jinx/\Unc13d^Jinx (C57BL/6J-Unc13d^Jinx/Mmucd)	abnormal cytokine secretion	J:119974
	abnormal macrophage physiology	J:105543
	abnormal NK cell physiology	J:119974
	absent lymph node germinal center	J:119974
	decreased cytotoxic T cell cytolysis	J:119974
	enlarged spleen	J:119974
	hemophagocytosis	J:119974
	increased CD8-positive, alpha-beta T cell number	J:119974
	increased monocyte cell number	J:119974
	increased neutrophil cell number	J:119974
	increased susceptibility to Herpesvirales infection	J:105543, J:119974
	increased susceptibility to Riboviria infection	J:105543, J:119974
\Unc80^em1(IMPC)Tcp/\Unc80⁺ (C57BL/6N-Unc80^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Unc93b1^3d/\Unc93b1^3d (C57BL/6J-Unc93b1^3d)	abnormal antigen presentation via MHC class I	J:105484
	abnormal antigen presentation via MHC class II	J:105484
	abnormal circulating interferon level	J:105484
	abnormal dendritic cell antigen presentation	J:105484
	abnormal macrophage physiology	J:105484
	abnormal tumor necrosis factor secretion	J:105484
	decreased interleukin-12b secretion	J:105484
	increased circulating tumor necrosis factor level	J:105484
	increased susceptibility to bacterial infection	J:105484
	increased susceptibility to Herpesvirales infection	J:105484
\Unc93b1^3d/\Unc93b1^3d (C57BL/6-Unc93b1^3d)	abnormal dendritic cell antigen presentation	J:159599
	abnormal dendritic cell morphology	J:159599
	decreased interleukin-6 secretion	J:159599
	decreased interleukin-12b secretion	J:159599
\Unc93b1^{tm1(KOMP)Vlcg}/\Unc93b1^{tm1(KOMP)Vlcg} (involves: C57BL/6NTac)	abnormal dendritic cell antigen presentation	J:211069
	abnormal dendritic cell morphology	J:211069
	abnormal dendritic cell physiology	J:211069
	abnormal tumor necrosis factor level	J:211069
	decreased circulating interleukin-6 level	J:211069
	decreased circulating interleukin-12b level	J:211069
\Unc93b1^tm1.1Kmiy/\Unc93b1^tm1.1Kmiy (involves: 129P2/OlaHsd * C57BL/6)	abnormal cytokine secretion	J:174308
	abnormal T-helper 1 cell differentiation	J:174308
	abnormal T-helper 17 cell differentiation	J:174308
	decreased B cell proliferation	J:174308
	decreased interferon-alpha secretion	J:174308
	decreased interleukin-12b secretion	J:174308
	decreased marginal zone B cell number	J:174308
	decreased tumor necrosis factor secretion	J:174308
	enlarged spleen	J:174308
	glomerulonephritis	J:174308
	increased anti-nuclear antigen antibody level	J:174308
	increased autoantibody level	J:174308
	increased B cell number	J:174308
	increased B cell proliferation	J:174308
	increased CD4-positive, alpha-beta memory T cell number	J:174308
	increased IgG2a level	J:174308
	increased IgG2b level	J:174308
	increased interferon-alpha secretion	J:174308
	increased interleukin-12b secretion	J:174308
	increased memory T cell number	J:174308
	increased spleen weight	J:174308
	increased T-helper 1 cell number	J:174308
	increased T-helper 17 cell number	J:174308
	increased tumor necrosis factor secretion	J:174308
	liver inflammation	J:174308
\Ung^tm1Tld/\Ung^tm1Tld (Not Specified)	abnormal class switch recombination	J:79590
	decreased IgG3 level	J:79590
	enlarged lymph nodes	J:85353
	enlarged spleen	J:85353
	enlarged thymus	J:85353
	increased IgM level	J:79590
	lymphoid hyperplasia	J:85353
	spleen hyperplasia	J:85353
\Ung^tm1Tld/\Ung^tm1Tld (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:306598
\Ung^tm1Tld/\Ung^tm1Tld (involves: 129P2/OlaHsd)	abnormal somatic hypermutation frequency	J:155454
\Uox^em1Cli/\Uox^em1Cli (C57BL/6J-Uox^em1Cli)	abnormal cytokine level	J:271949
\Uox^em1Cli/\Uox^em1Cli (C57BL/6J-Uox^em1Cli)	kidney inflammation	J:271949
\Uoxⁱⁿ/\Uoxⁱⁿ (involves: C57BL/6J * DBA/2J)	chronic inflammation	J:70677
\Uox^tm1Bay/\Uox^tm1Bay (involves: 129S7/SvEvBrd * C57BL/6J)	tubulointerstitial nephritis	J:16490
\Upf2^tm1Btp/\Upf2^tm1Btp \Lyz2^tm1(cre)Ifo/? (involves: 129P2/OlaHsd * C57BL/6 * CBA)	immune system phenotype	J:134765
\Upf2^tm1Btp/\Upf2^tm1Btp \Tg(Mx1-cre)1Cgn/0 (involves: 129P2/OlaHsd * C57BL/6 * CBA)	abnormal B cell number	J:134765
	decreased granulocyte number	J:134765
	decreased T cell proliferation	J:134765
\Upf3b^em1(IMPC)Tcp/Y (C57BL/6NCrl-Upf3b^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	small thymus	J:211773
\Upf3b^em1(IMPC)Tcp/\Upf3b^em1(IMPC)Tcp (C57BL/6NCrl-Upf3b^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	small thymus	J:211773
\Upk1a^em2Mgef/\Upk1a^em2Mgef (C57BL/6NJNcbs-Upk1a^em2Mgef)	epididymis inflammation	J:345207
	increased susceptibility to bacterial infection	J:345207
	liver inflammation	J:345207
	lung inflammation	J:345207
	tubulointerstitial nephritis	J:345207
	urinary bladder inflammation	J:345207
\Uqcrb^{tm1b(EUCOMM)Wtsi}/\Uqcrb⁺ (C57BL/6N-Uqcrb^{tm1b(EUCOMM)Wtsi}/Ieg)	increased leukocyte cell number	J:211773
\Urah^plt2/\Urah^plt2 (C57BL/6-Urah^plt2)	abnormal NK cell morphology	J:267227
	decreased CD8-positive, alpha-beta T cell number	J:267227
	increased T cell proliferation	J:267227
\Uri1^tm1.1Ndj/\Uri1^tm1.1Ndj \Alb^{tm1(cre/ERT2)Mtz}/\Alb⁺ (B6.Cg-Alb^{tm1(cre/ERT2)Mtz} Uri1^tm1.1Ndj)	liver inflammation	J:217463
\Uros^tm1Cged/\Uros^tm1Cged (involves: 129S2/SvPas)	enlarged spleen	J:105776
\Uros^tm1Cged/\Uros^tm1Cged (involves: 129S2/SvPas)	increased spleen red pulp amount	J:105776
\Uros^tm2Rjde/\Uros^tm3Rjde (involves: 129S6/SvEvTac * C57BL/6)	enlarged spleen	J:132542
	increased spleen iron level	J:132542
\Usp4^tm1Xilu/\Usp4^tm1Xilu (B6.129-Usp4^tm1Xilu)	increased splenocyte apoptosis	J:173192
\Usp4^tm1Xilu/\Usp4^tm1Xilu (B6.129-Usp4^tm1Xilu)	increased thymocyte apoptosis	J:173192
\Usp5^{tm1a(EUCOMM)Hmgu}/\Usp5⁺ (C57BL/6N-Usp5^{tm1a(EUCOMM)Hmgu}/Wtsi)	decreased leukocyte cell number	J:211773
\Usp12^{tm1a(EUCOMM)Hmgu}/\Usp12^{tm1a(EUCOMM)Hmgu} (Not Specified)	decreased CD8-positive, alpha-beta T cell number	J:165965
	decreased IgA level	J:165965
\Usp13^em1Nmw/\Usp13^em1Nmw (B6.Cg-Usp13^em1Nmw)	increased interleukin-1 beta secretion	J:285981
	increased interleukin-6 secretion	J:285981
	increased susceptibility to bacterial infection	J:285981
	increased tumor necrosis factor secretion	J:285981
	lung inflammation	J:285981
\Usp15^em1Peih/\Usp15^em1Peih (involves: C57BL/6)	abnormal macrophage physiology	J:306461
\Usp15^L749R/\Usp15⁺ (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
\Usp15^L749R/\Usp15⁺ (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
\Usp15^L749R/\Usp15^L749R (involves: 129S1/SvImJ * C57BL/6J)	abnormal T-helper 1 physiology	J:259382
	decreased susceptibility to bacterial infection	J:259382
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:259382
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
	decreased susceptibility to parasitic infection	J:259382
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
	immune system phenotype	J:259382
\Usp15^L749R/\Usp15^tm1Pgrs (involves: 129S1/SvImJ * C57BL/6J)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
\Usp15^{tm1b(EUCOMM)Wtsi}/\Usp15^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Usp15^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Usp15^tm1Pgrs/\Usp15^tm1Pgrs (Not Specified)	decreased susceptibility to experimental autoimmune encephalomyelitis	J:259382
\Usp15^tm1Pgrs/\Usp15^tm1Pgrs (Not Specified)	decreased susceptibility to parasitic infection induced morbidity/mortality	J:259382
\Usp16^{tm1b(EUCOMM)Hmgu}/\Usp16⁺ (C57BL/6N-Usp16^{tm1b(EUCOMM)Hmgu}/Nju)	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
\Usp17lc^tm1Khb/\Usp17lc⁺ (either: 129-Usp17lc^tm1Khb or (involves: 129S/SvEv * C57BL/6J))	decreased regulatory T cell number	J:191761
	increased B cell number	J:191761
	increased CD4-positive, alpha-beta T cell number	J:191761
	increased CD8-positive, alpha-beta T cell number	J:191761
	increased thymus weight	J:191761
\Usp18^ity9/\Usp18^ity9 (involves: 129S1/SvImJ * C57BL/6)	abnormal lymphocyte morphology	J:163843
	decreased circulating interferon-gamma level	J:163843
	decreased interferon-gamma secretion	J:163843
	decreased leukocyte cell number	J:163843
	increased circulating interleukin-6 level	J:163843
	increased interleukin-6 secretion	J:163843
	increased susceptibility to bacterial infection	J:163843
	increased susceptibility to bacterial infection induced morbidity/mortality	J:163843
	increased susceptibility to endotoxin shock	J:163843
\Usp18^ity9/\Usp18^tm1Dez (involves: 129 * C57BL/6 * FVB/N)	increased susceptibility to bacterial infection	J:163843
\Usp18^ity9/\Usp18^tm1Dez (involves: 129 * C57BL/6 * FVB/N)	increased susceptibility to bacterial infection induced morbidity/mortality	J:163843
\Usp18^tm1Dez/\Usp18^tm1Dez (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal cytokine level	J:214425
	decreased circulating interferon-alpha level	J:214425
	decreased circulating interferon-beta level	J:214425
	decreased circulating interferon-gamma level	J:214425
	decreased susceptibility to Coronaviridae infection	J:214425
\Usp20^em1Dalin/\Usp20^em1Dalin (involves: C57BL/6)	abnormal circulating chemokine level	J:274572
	decreased circulating interferon-beta level	J:274572
	decreased circulating interleukin-6 level	J:274572
	decreased interferon-beta secretion	J:274572
	decreased tumor necrosis factor secretion	J:274572
	increased susceptibility to Herpesvirales infection	J:274572
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:274572
\Usp21^tm1.1Jhy/\Usp21^tm1.1Jhy (B6.129S7(Cg)-Usp21^tm1.1Jhy)	abnormal interferon level	J:208320
	decreased susceptibility to Riboviria infection	J:208320
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:208320
	enlarged spleen	J:208320
	increased circulating interferon-alpha level	J:208320
	increased circulating interferon-beta level	J:208320
	increased macrophage cell number	J:208320
	increased neutrophil cell number	J:208320
	increased spleen weight	J:208320
	increased splenocyte number	J:208320
\Usp21^{tm1a(EUCOMM)Wtsi}/\Usp21^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Usp21^{tm1a(EUCOMM)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Usp22^{tm1b(KOMP)Wtsi}/\Usp22⁺ (C57BL/6N-Usp22^{tm1b(KOMP)Wtsi}/Wtsi)	increased monocyte cell number	J:211773
\Usp25^{Gt(RRS805)Byg}/\Usp25^{Gt(RRS805)Byg} (involves: 129P2/OlaHsd)	decreased interferon-gamma secretion	J:188557
	increased interleukin-6 secretion	J:188557
	increased neutrophil cell number	J:188557
	increased susceptibility to experimental autoimmune encephalomyelitis	J:188557
	lung inflammation	J:188557
\Usp28^{Gt(EUCE0037g10)Hmgu}/\Usp28^{Gt(EUCE0037g10)Hmgu} (involves: 129P2/OlaHsd * C57BL/6J)	decreased spleen weight	J:215354
	decreased splenocyte number	J:215354
	immune system phenotype	J:215354
\Usp32^{em1(IMPC)Mhzh}/\Usp32⁺ (C57BL/6N-Usp32^{em1(IMPC)Mhzh}/Mhzh)	decreased neutrophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Usp38^em1Cya/\Usp38^em1Cya (C57BL/6-Usp38^em1Cya)	lung inflammation	J:321973
\Usp42^{tm2a(EUCOMM)Wtsi}/\Usp42^{tm2a(EUCOMM)Wtsi} (involves: C57BL/6 * C57BL/6N)	increased CD4-positive, alpha-beta T cell number	J:213427
	increased T cell number	J:213427
\Usp45^em1(IMPC)H/\Usp45^em1(IMPC)H (C57BL/6NTac-Usp45^em1(IMPC)H/H)	decreased neutrophil cell number	J:211773
\Usp49^em1Gpt/\Usp49^em1Gpt (involves: C57BL/6NGpt)	decreased susceptibility to Herpesvirales infection	J:285681
	decreased susceptibility to Herpesvirales infection induced morbidity/mortality	J:285681
	immune system phenotype	J:285681
	increased circulating interferon-beta level	J:285681
	increased circulating interleukin-6 level	J:285681
	increased interferon-beta secretion	J:285681
	increased interleukin-6 secretion	J:285681
\Usp54^{tm1b(KOMP)Wtsi}/\Usp54^{tm1b(KOMP)Wtsi} (C57BL/6N-Usp54^{tm1b(KOMP)Wtsi}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Utp4^em1(IMPC)J/\Utp4⁺ (C57BL/6NJ-Utp4^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Uvrag^{Tn(pb-Act-RFP)1.100107015-HRAZhu}/\Uvrag^{Tn(pb-Act-RFP)1.100107015-HRAZhu} (involves: FVB/NJ)	abnormal interleukin level	J:219546
	abnormal tumor necrosis factor level	J:219546
	heart inflammation	J:219546
\Uxs1^tm1Lex/\Uxs1⁺ (B6;129S5-Uxs1^tm1Lex/Mmucd)	abnormal humoral immune response	J:171883
\Uxs1^tm1Lex/\Uxs1⁺ (B6;129S5-Uxs1^tm1Lex/Mmucd)	increased IgG1 level	J:171883
\Vamp2^tm1Sud/\Vamp2^tm1Sud (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:131926
\Vamp3^tm1Jpes/\Vamp3^tm1Jpes (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	immune system phenotype	J:131926
\Vamp4^{em1(IMPC)Ccpcz}/\Vamp4^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Vamp4^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Vamp8^{Gt(OST20346)Lex}/\Vamp8^{Gt(OST20346)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	abnormal mast cell physiology	J:131926
\Vamp8^tm1Hong/\Vamp8^tm1Hong (involves: 129P2/OlaHsd * C57BL/6)	abnormal dendritic cell physiology	J:131528
	abnormal type I hypersensitivity reaction	J:133439
	decreased mast cell degranulation	J:133439
	immune system phenotype	J:133439
\Varc/\Varc⁺ (C3H/HeJ-Varc/J)	increased susceptibility to otitis media	J:241135
\Varc/\Varc⁺ (C3OuJ.C3-Varc/Kjn)	increased susceptibility to otitis media	J:241135
\Vav1^m1Anu/\Vav1^m1Anu (C57BL/6JAnu-Vav1^m1Anu)	increased T cell number	J:104190
\Vav1^m1Btlr/\Vav1^m1Btlr (C57BL/6J-Vav1^m1Btlr)	abnormal humoral immune response	J:265128
	decreased B-1 B cell number	J:265128
	decreased CD4-positive, alpha-beta T cell number	J:265128
	decreased CD8-positive, alpha-beta T cell number	J:265128
	decreased CD8-positive, naive alpha-beta T cell number	J:265128
	decreased IgD level	J:265128
	decreased IgG level	J:265128
	decreased single-positive T cell number	J:265128
	decreased T cell number	J:265128
	increased central memory CD4-positive, alpha-beta T cell number	J:265128
	increased central memory CD8 positive, alpha-beta T cell number	J:265128
	increased effector memory CD4-positive, alpha-beta T cell number	J:265128
	increased IgM level	J:265128
\Vav1^m2Btlr/\Vav1^m2Btlr (C57BL/6J-Vav1^m2Btlr)	decreased B-1 B cell number	J:265130
\Vav1^M3Btlr/\Vav1^M3Btlr (C57BL/6J-Vav1^M3Btlr)	decreased IgG level	J:272527
\Vav1^M3Btlr/\Vav1^M3Btlr (C57BL/6J-Vav1^M3Btlr)	impaired humoral immune response	J:272527
\Vav1^M4Btlr/\Vav1^M4Btlr (C57BL/6J-Vav1^M4Btlr)	abnormal CD4-positive T cell differentiation	J:272528
	abnormal CD8-positive, alpha-beta T cell differentiation	J:272528
	abnormal T cell differentiation	J:272528
	decreased B-1 B cell number	J:272528
	decreased CD4-positive, alpha-beta T cell number	J:272528
	decreased CD8-positive, naive alpha-beta T cell number	J:272528
	increased central memory CD4-positive, alpha-beta T cell number	J:272528
	increased central memory CD8 positive, alpha-beta T cell number	J:272528
	increased effector memory CD4-positive, alpha-beta T cell number	J:272528
	increased effector memory CD8-positive, alpha-beta T cell number	J:272528
\Vav1^M5Btlr/\Vav1^M5Btlr (C57BL/6J-Vav1^M5Btlr)	decreased CD8-positive, alpha-beta T cell number	J:272529
\Vav1^tm1Tyb/\Vav1^tm1Tyb (involves: 129S2/SvPas * 129S8/SvEv)	abnormal T cell physiology	J:113270
	decreased CD4-positive, alpha-beta T cell number	J:113270
	decreased double-negative T cell number	J:113270
	decreased T cell proliferation	J:113270
\Vav1^tm1Tyb/\Vav1^tm1Tyb (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:113270
	abnormal negative T cell selection	J:113270
\Vav1^tm1Tyb/\Vav1^tm1Tyb (involves: 129S2/SvPas)	abnormal double-negative T cell morphology	J:79323
	abnormal T cell physiology	J:86654, J:79323
	decreased double-positive T cell number	J:79323
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:79323
	decreased T cell proliferation	J:86654
	decreased thymocyte number	J:86654
	thymus hypoplasia	J:79323
\Vav1^tm1Tyb/\Vav1^tm1Tyb (C.129S2-Vav1^tm1Tyb)	abnormal negative T cell selection	J:79323
\Vav1^tm1Tyb/\Vav1^tm1Tyb (involves: 129S2/SvPas * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:79323
	abnormal T cell physiology	J:128985
	decreased interleukin-2 secretion	J:128985
	decreased T cell proliferation	J:128985
	decreased tumor necrosis factor secretion	J:128985
\Vav1^tm1Tyb/\Vav1^tm1Tyb (either: (involves: 129S4/SvJae * 129S8/SvEv) or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))	abnormal CD8-positive, alpha-beta T cell physiology	J:190087
	abnormal immune system physiology	J:190087
	abnormal interleukin-2 secretion	J:190087
	abnormal lymphocyte cell number	J:190087
	abnormal T cell number	J:190087
	decreased double-positive T cell number	J:190087
	increased DN2 thymocyte number	J:190087
	increased DN3 thymocyte number	J:190087
	increased double-negative T cell number	J:190087
\Vav1^tm1Tyb/\Vav1^tm1Tyb \Vav2^tm1Kdf/\Vav2^tm1Kdf (involves: 129S1/Sv * 129S2/SvPas)	decreased B cell proliferation	J:86654
	decreased double-negative T cell number	J:86654
	decreased double-positive T cell number	J:86654
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:86654
	decreased T cell number	J:86654
	decreased T cell proliferation	J:86654
	decreased thymocyte number	J:86654
\Vav1^tm1Tyb/\Vav1^tm1Tyb \Vav2^tm1Kdf/\Vav2^tm1Kdf \Vav3^tm1Swat/\Vav3^tm1Swat (involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	abnormal B cell calcium ion homeostasis	J:86654
	abnormal humoral immune response	J:86654
	abnormal T cell physiology	J:86654
	arrested B cell differentiation	J:86654
	arrested T cell differentiation	J:86654
	decreased B cell proliferation	J:86654
	decreased double-positive T cell number	J:86654
	decreased follicular B cell number	J:86654
	decreased IgG1 level	J:86654
	decreased IgG2b level	J:86654
	decreased IgG3 level	J:86654
	decreased IgM level	J:86654
	decreased immunoglobulin level	J:86654
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased marginal zone B cell number	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:86654
	decreased T cell number	J:86654
	decreased T cell proliferation	J:86654
	decreased thymocyte number	J:86654
	decreased transitional stage T2 B cell number	J:86654
	increased immature B cell number	J:86654
	increased transitional stage T1 B cell number	J:86654
\Vav1^tm1Tyb/\Vav1^tm1Tyb \Vav2^tm1Kdf/\Vav2^tm1Kdf \Vav3^tm1Swat/\Vav3^tm1Swat (involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac)	abnormal macrophage physiology	J:145345
	abnormal neutrophil physiology	J:145345
	abnormal NK cell physiology	J:187430
	decreased interleukin-10 secretion	J:145345
	decreased tumor necrosis factor secretion	J:145345
\Vav1^tm1Tyb/\Vav1^tm1Tyb \Vav2^tm1Tnr/\Vav2^tm1Tnr (involves: 129P2/OlaHsd * 129S2/SvPas)	abnormal B cell calcium ion homeostasis	J:69807
	decreased B cell number	J:69807
	decreased B cell proliferation	J:69807
	decreased CD4-positive, alpha-beta T cell number	J:69807
	decreased CD8-positive, alpha-beta T cell number	J:69807
	decreased follicular B cell number	J:69807
	decreased immature B cell number	J:69807
	decreased mature B cell number	J:69807
\Vav1^tm1Tyb/\Vav1^tm1Tyb \Vav3^tm1Swat/\Vav3^tm1Swat (involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)	decreased B cell proliferation	J:86654
	decreased double-negative T cell number	J:86654
	decreased double-positive T cell number	J:86654
	decreased interferon-gamma secretion	J:86654
	decreased interleukin-2 secretion	J:86654
	decreased mature B cell number	J:86654
	decreased single-positive T cell number	J:86654
	decreased T cell number	J:86654
	decreased T cell proliferation	J:86654
\Vav1^tm2Bbd/\Vav1^tm2Bbd (involves: 129S1/Sv * 129X1/SvJ * CD-1)	abnormal T cell activation	J:47596
	abnormal T cell differentiation	J:47596
	decreased B-1 B cell number	J:47596
	decreased CD4-positive, alpha-beta T cell number	J:47596
	decreased CD8-positive, alpha-beta T cell number	J:47596
	decreased interleukin-2 secretion	J:47596
	decreased T cell proliferation	J:47596
	immune system phenotype	J:47596
	thymus hypoplasia	J:47596
\Vav1^tm2Bbd/\Vav1^tm2Bbd (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell number	J:55647
	abnormal lymph node cell ratio	J:69806
	abnormal response to infection	J:55647
	abnormal splenic cell ratio	J:69806
	abnormal T cell differentiation	J:47596
	abnormal T cell number	J:47596
	decreased B cell proliferation	J:55647, J:69806
	decreased B-1 B cell number	J:55647
	decreased CD4-positive, alpha-beta T cell number	J:47596
	decreased CD8-positive, alpha-beta T cell number	J:47596
	decreased IgG1 level	J:55647
	decreased IgG2a level	J:55647
	decreased IgG3 level	J:69806
	decreased IgG level	J:55647
	increased double-negative T cell number	J:47596
	increased transitional stage B cell number	J:69806
\Vav1^tm2Bbd/\Vav1^tm2Bbd (B6.129-Vav1^tm2Bbd)	abnormal CD4-positive T cell differentiation	J:141390
	abnormal positive T cell selection	J:141390
	abnormal T cell physiology	J:141390
	decreased double-positive T cell number	J:141390
	decreased interleukin-4 secretion	J:71161
	decreased NK T cell number	J:71161
	decreased T cell number	J:141390
	immune system phenotype	J:71161
	impaired natural killer cell mediated cytotoxicity	J:71161
\Vav1^tm2Bbd/\Vav1^tm2Bbd \Vav2^tm1Kdf/\Vav2^tm1Kdf (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal B cell activation	J:69806
	abnormal B cell differentiation	J:69806
	abnormal lymph node cell ratio	J:69806
	abnormal splenic cell ratio	J:69806
	abnormal T cell differentiation	J:69806
	decreased B cell number	J:69806
	decreased B cell proliferation	J:69806
	decreased B-1 B cell number	J:69806
	decreased CD8-positive, alpha-beta T cell number	J:69806
	decreased IgG1 level	J:69806
	decreased IgG2b level	J:69806
	decreased IgG3 level	J:69806
	decreased IgM level	J:69806
	decreased immunoglobulin level	J:69806
	decreased mature B cell number	J:69806
	decreased T cell number	J:69806
	thymus hypoplasia	J:69806
\Vav1^tm2Tyb/\Vav1^tm2Tyb (involves: 129S4/SvJae * 129S8/SvEv)	abnormal T cell physiology	J:113270
	decreased CD4-positive, alpha-beta T cell number	J:113270
	decreased double-negative T cell number	J:113270
	decreased T cell proliferation	J:113270
\Vav1^tm2Tyb/\Vav1^tm2Tyb (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd)	abnormal CD4-positive, alpha beta T cell morphology	J:113270
	abnormal negative T cell selection	J:113270
\Vav1^tm4Tyb/\Vav1^tm4Tyb (either: 129S8.129S4-Vav1^tm4Tyb or (involves: 129S4/SvJae * 129S8/SvEv * C57BL/10 * C57BR/cd))	abnormal CD4-positive, alpha-beta T cell physiology	J:190087
	abnormal CD8-positive, alpha-beta T cell physiology	J:190087
	abnormal immune serum protein physiology	J:190087
	abnormal immune system physiology	J:190087
	abnormal interleukin-2 secretion	J:190087
	abnormal lymphocyte cell number	J:190087
	abnormal T cell number	J:190087
	abnormal T cell physiology	J:190087
	increased circulating interferon-gamma level	J:190087
	increased DN2 thymocyte number	J:190087
	increased DN3 thymocyte number	J:190087
\Vav2^tm1Kdf/\Vav2^tm1Kdf (involves: 129S1/Sv * C57BL/6)	decreased B cell proliferation	J:69806
	decreased IgG3 level	J:69806
	decreased mature B cell number	J:69806
\Vav2^tm1Kdf/\Vav2^tm1Kdf \Vav3^tm1Swat/\Vav3^tm1Swat (involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)	immune system phenotype	J:86654
\Vav2^tm1Tnr/\Vav2^tm1Tnr (involves: 129P2/OlaHsd)	abnormal class switch recombination	J:69807
	decreased B cell number	J:69807
	decreased B cell proliferation	J:69807
	decreased IgG1 level	J:69807
	decreased IgG2b level	J:69807
	decreased IgG3 level	J:69807
	decreased IgM level	J:69807
	decreased spleen germinal center number	J:69807
\Vcam1^tm1Dmil/\Vcam1^tm1Dmil (either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6))	increased monocyte cell number	J:69597
\Vcam1^tm1Dmil/\Vcam1^tm1Dmil (C.129S4-Vcam1^tm1Dmil)	increased B cell number	J:69597
	increased leukocyte cell number	J:69597
	increased monocyte cell number	J:69597
	increased T cell number	J:69597
\Vcam1^tm2Flv/\Vcam1^tm3Flv \Tg(Tek-cre)12Flv/0 (involves: 129S1/Sv * C3H * C57BL/6)	abnormal CD4-positive, alpha-beta T cell physiology	J:68147
	abnormal CD8-positive, alpha-beta T cell physiology	J:68147
	abnormal lymphocyte physiology	J:68147
	abnormal splenic cell ratio	J:107447
	decreased B cell number	J:68147
	decreased CD4-positive, alpha-beta T cell number	J:68147
	decreased CD8-positive, alpha-beta T cell number	J:68147
	decreased immature B cell number	J:68147
	impaired B cell migration	J:68147
	increased immature B cell number	J:68147
	increased leukocyte cell number	J:107447, J:68147
	spleen hyperplasia	J:107447
\Vcam1^tm2Roml/\Vcam1^tm2Roml \Tg(Mx1-cre)1Cgn/? (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal humoral immune response	J:68148
	decreased B cell number	J:68148
	decreased mature B cell number	J:68148
	decreased transitional stage B cell number	J:68148
	increased B cell number	J:68148
	increased immature B cell number	J:68148
	increased mature B cell number	J:68148
	increased transitional stage B cell number	J:68148
\Vcan^em2(IMPC)Mbp/\Vcan⁺ (C57BL/6NCrl-Vcan^em2(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Vcp^tm1Itl/\Vcp⁺ (B6.129S-Vcp^tm1Itl)	abnormal osteoclast differentiation	J:166230
\Vcp^tm1Itl/\Vcp⁺ (B6.129S-Vcp^tm1Itl)	increased osteoclast cell number	J:166230
\Vdac2^tm1.1Ehyc/\Vdac2^tm1.1Ehyc \Bak1^tm1Thsn/\Bak1^tm1Thsn \Tg(Lck-cre)1Cwi/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)	immune system phenotype	J:220951
\Vdac2^tm1.1Ehyc/\Vdac2^tm1.1Ehyc \Bax^tm2Sjk/\Bax^tm2Sjk \Tg(Lck-cre)1Cwi/? (involves: 129X1/SvJ * C57BL/6 * DBA/2)	decreased thymocyte number	J:220951
	small thymus	J:220951
\Vdac2^tm1.1Ehyc/\Vdac2^tm1.1Ehyc \Tg(Lck-cre)1Cwi/? (involves: 129X1/SvJ * C57BL/6 * DBA/2)	abnormal thymocyte apoptosis	J:220951
	decreased thymocyte number	J:220951
	small thymus	J:220951
\Vdr^tm1Gcm/\Vdr^tm1Gcm \Tg(Col2a1-cre)1Bhr/? (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)	decreased osteoclast cell number	J:117377
\Vdr^tm1Mbd/\Vdr^tm1Mbd (involves: 129S4/SvJae * C57BL/6)	abnormal interleukin level	J:107077
	abnormal tumor necrosis factor level	J:107077
	immune system phenotype	J:107077
	increased susceptibility to induced colitis	J:130511
	increased thymus weight	J:107077
	intestinal inflammation	J:107077
	thymus hyperplasia	J:107077
\Vdr^tm1Rge/\Vdr^tm1Rge (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	abnormal macrophage physiology	J:134827
	decreased susceptibility to parasitic infection	J:134827
\Vdr^tm1Ska/\Vdr^tm1Ska (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal macrophage chemotaxis	J:112519
	decreased splenocyte proliferation	J:112519
	decreased susceptibility to autoimmune diabetes	J:112519
	dermatitis	J:111828
\Vdr^tm1Ska/\Vdr^tm1Ska (NOD.Cg-Vdr^tm1Ska/CmatJ)	abnormal chemokine secretion	J:127787
	abnormal dendritic cell differentiation	J:127787
	abnormal interleukin-1 secretion	J:127787
	abnormal T cell number	J:127787
	decreased interleukin-6 secretion	J:127787
	decreased regulatory T cell number	J:127787
	increased susceptibility to autoimmune diabetes	J:127787
\Vdr^tm2Ska/\Vdr^tm2Ska (involves: C57BL/6NCrlj * CBA/JNCrlj)	ear inflammation	J:111828
\Vegfa^tm1.1Nagy/\Vegfa^tm1.1Nagy (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphatic vessel morphology	J:64090
\Vegfa^tm1Pec/\Vegfa^tm1Pec (involves: 129S1/Sv * 129X1/SvJ)	abnormal thymus morphology	J:81698
	athymia	J:81698
	decreased lymphocyte cell number	J:81698
	ectopic thymus	J:81698
	thymus hypoplasia	J:81698
\Vegfa^tm2Gne/\Vegfa^tm2Gne \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd)	decreased inflammatory response	J:107682
\Vegfa^tm2Gne/\Vegfa^tm2Gne \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129/Sv * 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:148597
\Vegfa^tm2Gne/\Vegfa^tm2Gne \Tg(SFTPC-cre)#Mliu/0 (involves: 129/Sv * ICR)	lung inflammation	J:158566
\Vegfc^tm1Ali/\Vegfc⁺ (involves: 129S1/Sv * 129X1/SvJ * ICR)	abnormal lymph circulation	J:87394
	lymphatic vessel hypoplasia	J:87394
\Vegfc^tm1Ali/\Vegfc⁺ (involves: 129S1/Sv * 129X1/SvJ)	lymphatic vessel hypoplasia	J:137909
\Vegfc^tm1Ali/\Vegfc⁺ \Tg(KRT14-FIGF)2Ali/0 (involves: 129S1/Sv * 129X1/SvJ * FVB/N)	lymphatic vessel hyperplasia	J:137909
\Vegfc^tm1Ali/\Vegfc^tm1Ali (involves: 129S1/Sv * 129X1/SvJ * ICR)	absent lymphatic vessels	J:87394
\Vegfc^tm1Ali/\Vegfc^tm1Ali (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphangiogenesis	J:137909
	abnormal lymphatic vessel morphology	J:137909
\Vegfd^{em1(IMPC)Ccpcz}/\Vegfd^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Vegfd^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Vegfd^tm1Hrl/Y (involves: 129S/SvEv * Swiss)	immune system phenotype	J:153734
\Vegfd^tm1Mach/\Vegfd^tm1Mach \Vegfc^tm1Ali/\Vegfc^tm1Ali (involves: 129S1/Sv * 129X1/SvJ)	abnormal lymphangiogenesis	J:137909
	abnormal lymphatic vessel morphology	J:137909
\Vezf1^tm1Stmn/\Vezf1⁺ (B6.129-Vezf1^tm1Stmn)	abnormal lymphatic vessel morphology	J:99326
\Vhl^tm1Jae/\Vhl^tm1Jae \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJae)	increased inflammatory response	J:107682
\Vhl^tm1Jae/\Vhl^tm1Jae \Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 (involves: 129S4/SvJae * CD-1)	decreased lymphocyte cell number	J:186085
	enlarged spleen	J:186085
\Vhl^tm1Mcs/\Vhl^tm1Mcs (involves: 129S4/SvJae * C57BL/6 * FVB/N)	dark spleen	J:130780
	decreased spleen white pulp amount	J:130780
	increased leukocyte cell number	J:130780
	increased spleen red pulp amount	J:130780
	increased spleen weight	J:130780
\Vim^tm1Cba/\Vim^tm1Cba (involves: 129S2/SvPas * C57BL/6)	abnormal cellular extravasation	J:129405
	abnormal leukocyte adhesion	J:129405
	abnormal leukocyte migration	J:129405
	abnormal leukocyte tethering or rolling	J:129405
	immune system phenotype	J:125280
\Vip^tm1Clw/\Vip^tm1Clw (involves: 129S/Sv * C57BL/6)	lung inflammation	J:132313
\Vipr2^tm1Ajh/\Vipr2^tm1Ajh (B6.129P2-Vipr2^tm1Ajh)	abnormal cytokine secretion	J:72933
	decreased IgE level	J:72933
	decreased interleukin-4 secretion	J:72933
	decreased susceptibility to type I hypersensitivity reaction	J:72933
	increased interferon-gamma secretion	J:72933
	increased interleukin-2 secretion	J:72933
	increased susceptibility to type IV hypersensitivity reaction	J:72933
\Vkorc1l1^em1(IMPC)J/\Vkorc1l1^em1(IMPC)J (C57BL/6NJ-Vkorc1l1^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Vldlr^em1(IMPC)Mbp/\Vldlr^em1(IMPC)Mbp (C57BL/6N-Vldlr^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
\Vms1^A/J/\Vms1^A/J (involves: A/J * C57BL/10SnSg)	myocarditis	J:121574
\Vnn1^tm1Pna/\Vnn1^tm1Pna (involves: 129P2/OlaHsd)	immune system phenotype	J:65449
\Vnn3^{em1(IMPC)Ccpcz}/\Vnn3^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Vnn3^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Vpreb1a^tm1Ilm/\Vpreb1a⁺ \Vpreb1b^tm1Ilm/\Vpreb1b^tm3Ilm (involves: 129P2/OlaHsd * C57BL/6)	immune system phenotype	J:104211
\Vpreb1a^tm1Ilm/\Vpreb1a^tm1Ilm (involves: 129P2/OlaHsd * C57BL/6)	abnormal pre-B cell morphology	J:53512
	arrested B cell differentiation	J:53512
	immune system phenotype	J:53512
\Vpreb1a^tm1Ilm/\Vpreb1a^tm1Ilm (B6.129P2-Vpreb1a^tm1Ilm)	decreased pre-B cell number	J:104211
\Vpreb1a^tm1Ilm/\Vpreb1a^tm1Ilm (B6.129P2-Vpreb1a^tm1Ilm)	increased pre-B cell number	J:104211
\Vpreb1a^tm1Ilm/\Vpreb1a^tm1Ilm \Vpreb1b^tm1Ilm/\Vpreb1b⁺ (involves: 129P2/OlaHsd * C57BL/6)	decreased mature B cell number	J:104211
	decreased pre-B cell number	J:104211
	increased pre-B cell number	J:104211
\Vpreb1a^tm1Ilm/\Vpreb1a^tm1Ilm \Vpreb1b^tm1Ilm/\Vpreb1b^tm1Ilm (B6.129P2-Vpreb1a^tm1Ilm Vpreb1b^tm1Ilm)	abnormal B cell differentiation	J:67609
	abnormal immature B cell morphology	J:67609
	abnormal splenic cell ratio	J:67609
	decreased B-1a cell number	J:67609
	decreased IgG level	J:67609
	decreased mature B cell number	J:67609
	decreased pre-B cell number	J:67609
	immune system phenotype	J:67609
	increased pre-B cell number	J:67609
\Vpreb1b^tm3Ilm/\Vpreb1b^tm3Ilm (B6.129P2-Vpreb1b^tm3Ilm)	immune system phenotype	J:104211
\Vps4a^{tm1b(EUCOMM)Hmgu}/\Vps4a⁺ (C57BL/6N-Vps4a^{tm1b(EUCOMM)Hmgu}/Bay)	enlarged spleen	J:211773
	increased spleen weight	J:211773
\Vps13a^{tm1b(EUCOMM)Wtsi}/\Vps13a^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Vps13a^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased plasmacytoid dendritic cell number	J:211773
	decreased T-helper cell number	J:211773
\Vps13b^em1(IMPC)Tcp/\Vps13b^em1(IMPC)Tcp (C57BL/6N-Vps13b^em1(IMPC)Tcp/Tcp)	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	small spleen	J:211773
\Vps13b^tm1.2Ics/\Vps13b^tm1.2Ics (involves: C57BL/6N)	eye inflammation	J:296007
\Vps33a^em2(IMPC)Tcp/\Vps33a⁺ (C57BL/6NCrl-Vps33a^em2(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
	increased spleen weight	J:211773
\Vps33b^tm1.1Arte/\Vps33b^tm1.1Arte \Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/\Gt(ROSA)26Sor⁺ (involves: C57BL/6 * C57BL/6J)	decreased dendritic cell number	J:222766
	decreased lymphocyte cell number	J:222766
	enlarged spleen	J:222766
	increased macrophage cell number	J:222766
	increased monocyte cell number	J:222766
	increased neutrophil cell number	J:222766
\Vps35^tm1.1Mjff/\Vps35^tm1.1Mjff (B6.Cg-Vps35^tm1.1Mjff)	microgliosis	J:303283
\Vps54^wr/\Vps54^wr (involves: C57BL/6J * C57BL/Fa)	increased microglial cell activation	J:181019
\Vrk3^em1(IMPC)Mbp/\Vrk3^em1(IMPC)Mbp (C57BL/6NCrl-Vrk3^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Vsig4^tm1Gne/\Vsig4^tm1Gne (involves: C57BL/6N)	increased susceptibility to bacterial infection	J:138691
\Vsig4^tm1Gne/\Vsig4^tm1Gne (C57BL/6-Vsig4^tm1Gne)	abnormal macrophage physiology	J:281762
	decreased susceptibility to induced colitis	J:281762
	increased circulating interleukin-1 beta level	J:281762
	increased interleukin-1 beta secretion	J:281762
	increased susceptibility to experimental autoimmune encephalomyelitis	J:281762
	increased T-helper 1 cell number	J:281762
	increased T-helper 17 cell number	J:281762
\Vsig10^{em1(IMPC)Wtsi}/\Vsig10^{em1(IMPC)Wtsi} (C57BL/6N-Vsig10^{em1(IMPC)Wtsi}/Wtsi)	increased leukocyte cell number	J:211773
\Vsir^tm1Lex/\Vsir^tm1Lex (involves: 129S5/SvEvBrd * C57BL/6)	abnormal T cell activation	J:222944
	increased IgA level	J:222944
	increased IgM level	J:222944
	increased inflammatory response	J:222944
	increased interferon-gamma secretion	J:222944
	increased interleukin-17 secretion	J:222944
\Vsir^tm1Lex/\Vsir^tm1Lex \Tg(Tcra2D2,Tcrb2D2)1Kuch/0 (involves: 129S5/SvEvBrd * C57BL/6)	increased susceptibility to experimental autoimmune encephalomyelitis	J:222944
\Vstm5^em1Cdj/\Vstm5^em1Cdj (Not Specified)	decreased interleukin-2 secretion	J:267548
\Vstm5^em1Cdj/\Vstm5^em1Cdj (Not Specified)	immune system phenotype	J:267548
\Vtcn1^tm1Lpc/\Vtcn1^tm1Lpc (B6.129S-Vtcn1^tm1Lpc)	abnormal myelopoiesis	J:145712
	decreased susceptibility to bacterial infection	J:145712
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:145712
	increased neutrophil cell number	J:145712
\Vtcn1^tm1Mak/\Vtcn1^tm1Mak (C.Cg-Vtcn1^tm1Mak)	decreased interleukin-4 secretion	J:112130
	decreased susceptibility to parasitic infection	J:112130
	increased interferon-gamma secretion	J:112130
\Vtcn1^tm1Xxz/\Vtcn1^tm1Xxz (involves: 129S4/SvJae * BALB/c * C57BL/6)	increased CD4-positive, alpha-beta T cell number	J:177612
	increased interleukin-17 secretion	J:177612
	increased susceptibility to autoimmune diabetes	J:177612
	increased susceptibility to experimental autoimmune encephalomyelitis	J:177612
	increased T-helper 1 cell number	J:177612
	increased T-helper 17 cell number	J:177612
\Vwf^tm1.1Geno/\Vwf⁺ (involves: C57BL/6)	increased acute inflammation	J:250145
\Vwf^tm1.1Geno/\Vwf^tm1.1Geno (involves: C57BL/6)	increased acute inflammation	J:250145
\Vwf^tm1Wgr/\Vwf^tm1Wgr (B6.129S2-Vwf^tm1Wgr)	increased susceptibility to bacterial infection	J:140334
\Vwf^tm1Wgr/\Vwf^tm1Wgr (B6.129S2-Vwf^tm1Wgr)	increased susceptibility to experimental autoimmune encephalomyelitis	J:140334
\Wac^{tm2b(EUCOMM)Wtsi}/\Wac⁺ (C57BL/6N-Wac^{tm2b(EUCOMM)Wtsi}/Wtsi)	decreased eosinophil cell number	J:211773
	increased Ly6C low monocyte number	J:211773
	increased monocyte cell number	J:211773
\Was^tm1Itl/Y (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
\Was^tm1Itl/\Was^tm1Itl (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
\Was^tm1Kas/\Was^tm1Kas (involves: 129/Sv * C57BL/6)	decreased B cell number	J:87875
	decreased double-positive T cell number	J:87875
	decreased lymphocyte cell number	J:87875
	decreased T cell number	J:87875
	lymphoid hypoplasia	J:87875
	thymus hypoplasia	J:87875
\Was^tm1Sbs/Y (involves: 129S6/SvEvTac)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased monocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
\Was^tm1Sbs/Y (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgA level	J:182528
	increased IgE level	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
\Was^tm1Sbs/\Was^tm1Sbs (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	colitis	J:48836
	decreased B cell number	J:48836
	decreased lymphocyte cell number	J:48836
	decreased T cell number	J:48836
	decreased T cell proliferation	J:48836
	immune system phenotype	J:48836
	increased neutrophil cell number	J:48836
\Was^tm1Sbs/\Was^tm1Sbs (involves: C57BL/6 * CBA)	abnormal B cell physiology	J:95909
\Was^tm1Sbs/\Was^tm1Sbs (involves: 129S/SvEv)	abnormal cytokine secretion	J:86835
	abnormal mast cell morphology	J:86835
	abnormal mast cell physiology	J:86835
	abnormal osteoclast differentiation	J:90542
	abnormal osteoclast physiology	J:90542
\Was^tm1Sbs/\Was^tm1Sbs (involves: BALB/c)	abnormal dendritic cell antigen presentation	J:84131
	decreased T cell proliferation	J:84131
	immune system phenotype	J:84131
\Was^tm1Sbs/\Was^tm1Sbs (involves: 129S6/SvEvTac)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal double-negative T cell morphology	J:125309
	abnormal double-positive T cell morphology	J:125309
	abnormal lymphocyte morphology	J:153247
	abnormal thymocyte activation	J:125309
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased monocyte cell number	J:153247
	increased splenocyte number	J:153247
	spleen hyperplasia	J:153247
\Was^tm1Sbs/\Was^tm1Sbs (129S6/SvEvTac-Was^tm1Sbs/J)	glomerulonephritis	J:180407
	increased IgA level	J:180407
	increased IgM level	J:180407
\Was^tm1Sbs/\Was^tm1Sbs (involves: 129S6/SvEvTac * C57BL/6)	abnormal B cell physiology	J:182528
	decreased marginal zone B cell number	J:182528
	decreased mature B cell number	J:182528
	increased anti-chromatin antibody level	J:182528
	increased anti-double stranded DNA antibody level	J:182528
	increased anti-single stranded DNA antibody level	J:182528
	increased autoantibody level	J:182528
	increased germinal center B cell number	J:182528
	increased IgA level	J:182528
	increased IgE level	J:182528
	increased IgM level	J:182528
	increased plasma cell number	J:182528
\Was^tm1Sbs/\Was^tm1Sbs \Wasl^tm2Sbs/\Wasl^tm2Sbs \Tg(Lck-cre)1Cwi/? (involves: 129S6/SvEvTac * C57BL/6)	abnormal double-negative T cell morphology	J:125309
	abnormal double-positive T cell morphology	J:125309
	abnormal thymocyte activation	J:125309
	colitis	J:125309
	decreased regulatory T cell number	J:125309
	decreased single-positive T cell number	J:125309
	decreased T cell number	J:125309
	decreased thymocyte number	J:125309
	increased single-positive T cell number	J:125309
\Was^tm2Itl/Y (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
\Was^tm2Itl/\Was^tm2Itl (Not Specified)	abnormal dendritic cell morphology	J:153247
	abnormal dendritic cell physiology	J:153247
	abnormal lymphocyte morphology	J:153247
	decreased NK cell number	J:153247
	decreased T cell number	J:153247
	decreased T cell proliferation	J:153247
	increased anti-double stranded DNA antibody level	J:153247
	increased B cell number	J:153247
	increased follicular B cell number	J:153247
	increased leukocyte cell number	J:153247
	increased splenocyte number	J:153247
\Wasl^tm1.1Ttha/\Wasl^tm1.1Ttha \Tg(KRT14-cre)1Amc/0 (involves: C57BL/6 * C57BL/6N * CBA)	abnormal circulating chemokine level	J:271857
	dermatitis	J:271857
	increased circulating interleukin-1 alpha level	J:271857
	increased circulating interleukin-6 level	J:271857
	increased circulating interleukin-17 level	J:271857
	increased circulating tumor necrosis factor level	J:271857
	increased susceptibility to bacterial infection	J:271857
	skin inflammation	J:271857
\Wbcq1^C57BLKS/J/\Wbcq1^C57BLKS/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq1^C57BLKS/J/\Wbcq1^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq2^C57BLKS/J/\Wbcq2^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq2^C57BLKS/J/\Wbcq2^SM/J \Wbcq3^C57BLKS/J/\Wbcq3^C57BLKS/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq2^SM/J/\Wbcq2^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq2^SM/J/\Wbcq2^SM/J \Wbcq3^C57BLKS/J/\Wbcq3^C57BLKS/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq3^C57BLKS/J/\Wbcq3^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq3^SM/J/\Wbcq3^SM/J (involves: C57BLKS/J * SM/J)	increased leukocyte cell number	J:102636
\Wbcq4^NZW/LacJ/\Wbcq4^NZW/LacJ (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
\Wbcq4^NZW/LacJ/\Wbcq4^SM/J (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
\Wbcq5^NZW/LacJ/\Wbcq5^NZW/LacJ (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
\Wbcq6^NZW/LacJ/\Wbcq6^NZW/LacJ (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
\Wbcq6^SM/J/\Wbcq6^SM/J (involves: NZW/LacJ * SM/J)	increased leukocyte cell number	J:102636
\Wbp1^em1(IMPC)Tcp/\Wbp1^em1(IMPC)Tcp (C57BL/6NCrl-Wbp1^em1(IMPC)Tcp/Cmmr)	increased monocyte cell number	J:211773
\Wbp1l^{tm2a(EUCOMM)Hmgu}/\Wbp1l^{tm2a(EUCOMM)Hmgu} (involves: C57BL/6N)	abnormal pre-B cell morphology	J:284781
	decreased B cell number	J:284781
	decreased B-1 B cell number	J:284781
	decreased pre-B cell number	J:284781
	decreased pro-B cell number	J:284781
	immune system phenotype	J:284781
	increased dendritic cell number	J:284781
	increased marginal zone B cell number	J:284781
\Wbp2^{tm2a(EUCOMM)Wtsi}/\Wbp2^{tm2a(EUCOMM)Wtsi} (C57BL/6N-Wbp2^{tm2a(EUCOMM)Wtsi}/Cnrm)	increased leukocyte cell number	J:165965
\Wbp11^em1Gcha/\Wbp11⁺ (involves: C57BL/6J * FVB/N)	ectopic thymus	J:300837
\Wdfy3^em1(IMPC)Mbp/\Wdfy3⁺ (C57BL/6N-Wdfy3^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Wdfy4^em1Jkln/\Wdfy4^em1Jkln (C57BL/6J-Wdfy4^em1Jkln)	decreased dendritic cell number	J:326216
\Wdfy4^em1Jkln/\Wdfy4^em1Jkln (C57BL/6J-Wdfy4^em1Jkln)	immune system phenotype	J:326216
\Wdr1^Gt(XN462)Byg/\Wdr1^rede (involves: 129P2/OlaHsd * C57BL/6)	ear inflammation	J:134092
	skin inflammation	J:134092
\Wdr1^rede/\Wdr1^rede (Not Specified)	increased inflammatory response	J:85113
\Wdr1^rede/\Wdr1^rede (C57BL/6-Wdr1^rede)	abnormal myelopoiesis	J:134092
	abnormal osteoclast physiology	J:134092
	abnormal thrombopoiesis	J:134092
	ear inflammation	J:134092
	impaired neutrophil chemotaxis	J:134092
	increased neutrophil cell number	J:134092
	increased osteoclast cell number	J:134092
	skin inflammation	J:134092
\Wdr27^{em1(IMPC)Ccpcz}/\Wdr27^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Wdr27^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Wdr37^{tm1a(KOMP)Wtsi}/\Wdr37^{tm1a(KOMP)Wtsi} (C57BL/6N-Wdr37^{tm1a(KOMP)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Wdr41^m1Btlr/\Wdr41^m1Btlr (C57BL/6J-Wdr41^m1Btlr)	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased circulating interleukin-12b level	J:268243
	increased susceptibility to induced colitis	J:268243
	increased tumor necrosis factor secretion	J:268243
\Wdr41^m2Btlr/\Wdr41^m2Btlr (C57BL/6J-Wdr41^m2Btlr)	increased CD4-positive, alpha-beta T cell number	J:268243
	increased CD8-positive, alpha-beta T cell number	J:268243
	increased tumor necrosis factor secretion	J:268243
\Wdr45^em1Wrst/Y (involves: C57BL/6N * FVB)	increased leukocyte cell number	J:307284
\Wdr59^{tm1b(EUCOMM)Wtsi}/\Wdr59⁺ (C57BL/6N-Wdr59^{tm1b(EUCOMM)Wtsi}/Wtsi)	decreased leukocyte cell number	J:211773
\Wdr62^em1(IMPC)Tcp/\Wdr62^em1(IMPC)Tcp (C57BL/6NCrl-Wdr62^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Wdr83^tm1Guwo/\Wdr83⁺ (involves: C57BL/6)	kidney inflammation	J:153983
\Wdr89^m1Anu/\Wdr89^m1Anu (C57BL/6NCrlAnu-Wdr89^m1Anu)	immune system phenotype	J:104190
\Wfdc1^tm1Bcm/\Wfdc1^tm1Bcm (involves: 129S7/SvEvBrd * C57BL/6)	decreased susceptibility to Orthomyxoviridae infection	J:216357
\Wfdc2^em1(IMPC)H/\Wfdc2⁺ (C57BL/6NTac-Wfdc2^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
\Wfdc2^tm1.1Ohbo/\Wfdc2^tm1.1Ohbo (involves: C57BL/6NCrlj * CBA/JNCrlj)	abnormal cytokine level	J:282576
	lung inflammation	J:282576
\Wfdc15a^em1Ohbo/\Wfdc15a^em1Ohbo (involves: Slc:ICR)	testis inflammation	J:360881
\Whrn^wi/\Whrn^wi (involves: C57BL/6J * STOCK a Tyrp1^b Myo5a^d Oca2^p Ednrb^s)	decreased leukocyte cell number	J:5538
	decreased thymus weight	J:5037
\Why1^MOLF/EiJ/? (involves: C57BL/6J * MOLF/Ei)	increased interleukin-6 secretion	J:131437
\Why2^MOLF/EiJ/? (involves: C57BL/6J * MOLF/Ei)	decreased interleukin-6 secretion	J:131437
\Wipf1^tm1Geha/\Wipf1^tm1Geha (involves: 129S6/SvEvTac)	abnormal T cell physiology	J:74719
	decreased T cell proliferation	J:74719
	decreased thymocyte number	J:74719
	increased B cell proliferation	J:74719
	increased IgE level	J:74719
	increased IgM level	J:74719
	thymus hypoplasia	J:74719
\Wipf1^tm1Geha/\Wipf1^tm1Geha (involves: 129S6/SvEvTac * C57BL/6)	abnormal alpha-beta T cell morphology	J:116168
	abnormal lymph node B cell domain morphology	J:116168
	abnormal lymphopoiesis	J:116168
	abnormal Peyer's patch T cell area morphology	J:116168
	abnormal spleen morphology	J:116168
	abnormal thymus morphology	J:116168
	colitis	J:116168
	decreased B cell number	J:116168
	decreased follicular B cell number	J:116168
	decreased lymphocyte cell number	J:116168
	decreased marginal zone B cell number	J:116168
	decreased spleen white pulp amount	J:116168
	decreased thymus weight	J:116168
	enlarged spleen	J:116168
	glomerulonephritis	J:116168
	increased autoantibody level	J:116168
	increased granulocyte number	J:116168
	increased IgA level	J:116168
	increased monocyte cell number	J:116168
	increased spleen red pulp amount	J:116168
	interstitial pneumonia	J:116168
	joint inflammation	J:116168
	lung inflammation	J:116168
\Wls^tm1.1Arte/\Wls^tm1.1Arte \Krt14^tm1(cre)Wbm/\Krt14⁺ (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:202499
	abnormal T cell physiology	J:202499
	abnormal T cell subpopulation ratio	J:202499
	cutaneous mastocytosis	J:202499
	decreased double-positive T cell number	J:202499
	decreased gamma-delta T cell number	J:202499
	decreased T cell number	J:202499
	decreased thymus weight	J:202499
	increased double-negative T cell number	J:202499
	increased macrophage cell number	J:202499
	increased neutrophil cell number	J:202499
	increased T cell proliferation	J:202499
	skin inflammation	J:202499
	small thymus medulla	J:202499
	thymus atrophy	J:202499
	thymus hypoplasia	J:202499
\Wls^tm1.1Arte/\Wls^tm1.1Arte \Tg(Foxn1-cre)1Tbo/0 (involves: C57BL/6)	immune system phenotype	J:202499
\Wnt1^tm1Brd/\Wnt1^tm1Brd (involves: 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte number	J:75999
\Wnt1^tm1Brd/\Wnt1^tm1Brd \Wnt4^tm1Amc/\Wnt4^tm1Amc (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J)	decreased thymocyte number	J:75999
\Wnt2b^{tm1b(EUCOMM)Wtsi}/\Wnt2b^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Wnt2b^{tm1b(EUCOMM)Wtsi}/Tcp)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
	small spleen	J:211773
\Wnt3a^{em1(IMPC)Ccpcz}/\Wnt3a⁺ (C57BL/6NCrl-Wnt3a^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	increased eosinophil cell number	J:211773
\Wnt4^{em1(IMPC)Hmgu}/\Wnt4⁺ (C57BL/6NCrl-Wnt4^{em1(IMPC)Hmgu}/Ieg)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Wnt4^tm1Amc/\Wnt4^tm1Amc (involves: 129S1/Sv)	decreased thymocyte number	J:75999
\Wnt5a^b2b3077.1Clo/\Wnt5a^b2b3077.1Clo (C57BL/6J-Wnt5a^b2b3077.1Clo)	thymus hypoplasia	J:175213
\Wrn^b2b3121.1Clo/\Wrn^b2b3121.1Clo (C57BL/6J-Wrn^b2b3121.1Clo)	thymus hypoplasia	J:175213
\Wrn^{em1(IMPC)Ccpcz}/\Wrn^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Wrn^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Wrn^tm1Led/\Wrn^tm1Led (involves: 129S6/SvEvTac * Black Swiss)	heart inflammation	J:106446
	increased susceptibility to infection	J:106446
\Wrn^tm1Lgu/\Wrn^tm1Lgu (B6J.Cg-Wrn^tm1Lgu)	increased osteoclast cell number	J:213181
\Wrnip1^{tm1a(EUCOMM)Wtsi}/\Wrnip1^{tm1a(EUCOMM)Wtsi} (C57BL/6N-Wrnip1^{tm1a(EUCOMM)Wtsi}/Cnrm)	decreased T cell number	J:165965
\Wsb1^tm1.1Jszh/\Wsb1^tm1.1Jszh \Ubc^{em1(cre/ERT2)Smoc}/\Ubc⁺ (involves: C57BL/6J * C57BL/6N)	decreased inflammatory response	J:358004
\Wt1^tm1Jae/\Wt1^tm1Jae (involves: 129S4/SvJae * C57BL/6 * MF1)	abnormal spleen development	J:56651
	absent spleen	J:56651
	increased splenocyte apoptosis	J:56651
\Wt1^tm1Mlh/\Wt1⁺ (involves: 129P2/OlaHsd * C57BL/6)	glomerulonephritis	J:135449
\Wt1^tm1Mlh/\Wt1⁺ (129P2/OlaHsd-Wt1^tm1Mlh)	glomerulonephritis	J:135449
\Wt1^tm1Mlh/\Wt1⁺ (involves: 129P2/OlaHsd * C57BL/6 * MF1)	glomerulonephritis	J:135449
\Wwc1^tm1Arsc/\Wwc1^tm1Arsc \Wwc2^tm1.1Arte/\Wwc2^tm1.1Arte \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: 129 * C57BL/6 * C57BL/6J * DBA)	liver inflammation	J:305034
\Wwox^em1Mald/\Wwox^em1Mald (FVB/N-Wwox^em1Mald)	microgliosis	J:339564
\Wwox^tm1.1Mald/\Wwox^tm1.1Mald (involves: C57BL/6 * FVB/N)	abnormal thymus cortex morphology	J:155406
	decreased leukocyte cell number	J:155406
	decreased spleen weight	J:155406
	decreased thymus weight	J:155406
	small spleen	J:155406
	spleen atrophy	J:155406
\Wwox^tm1Ria/\Wwox⁺ (involves: 129X1/SvJ * C57BL/6)	enlarged spleen	J:120064
\Wwox^tm1Ria/\Wwox^tm1Ria (involves: 129X1/SvJ * C57BL/6J)	abnormal osteoclast physiology	J:138140
\Wwp2^tm1.1Yyiw/\Wwp2^tm1.1Yyiw (involves: 129S/SvEv * C57BL/6 * FVB/N)	immune system phenotype	J:228707
	increased circulating interferon-beta level	J:228707
	increased circulating interleukin-6 level	J:228707
	increased circulating tumor necrosis factor level	J:228707
\Wwtr1^tm1Benj/\Wwtr1^tm1Benj (129S6/SvEvTac-Wwtr1^tm1Benj)	intestinal inflammation	J:125326
\Wwtr1^tm1Benj/\Wwtr1^tm1Benj (129S6/SvEvTac-Wwtr1^tm1Benj)	lung inflammation	J:125326
\Wwtr1^tm1Benj/\Wwtr1^tm1Benj (129S-Wwtr1^tm1Benj/J)	intestinal inflammation	J:156586
\Wwtr1^tm1Benj/\Wwtr1^tm1Benj (129S-Wwtr1^tm1Benj/J)	lung inflammation	J:156586
\Wwtr1^tm1Hku/\Wwtr1^tm1Hku (involves: 129 * C57BL/6 * ICR)	alveolitis	J:164957
\Wwtr1^tm1Hku/\Wwtr1^tm1Hku (involves: 129 * C57BL/6 * ICR)	lung inflammation	J:164957
\Wwtr1^tm1Whun/\Wwtr1^tm1Whun (either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6))	tubular nephritis	J:119488
\Xaf1^em2.1Cya/\Xaf1^em2.1Cya (C57BL/6J-Xaf1^em2.1Cya)	abnormal tumor necrosis factor level	J:344340
	decreased circulating CXCL10 level	J:344340
	decreased circulating interferon-beta level	J:344340
	decreased macrophage cytokine production	J:344340
	immune system phenotype	J:344340
	increased susceptibility to Riboviria infection	J:344340
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:344340
\Xbp1^{tm1a(EUCOMM)Wtsi}/\Xbp1⁺ (C57BL/6N-Xbp1^{tm1a(EUCOMM)Wtsi}/Ics)	decreased IgG1 level	J:165965
	decreased T cell number	J:165965
\Xbp1^{tm1b(EUCOMM)Wtsi}/\Xbp1⁺ (C57BL/6N-Xbp1^{tm1b(EUCOMM)Wtsi}/Ics)	decreased large unstained cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Xbp1^tm2Glm/\Xbp1⁺ \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)	small intestinal inflammation	J:188627
\Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Defa6-icre)1Rsb/0 (involves: 129S6/SvEvTac * C57BL/6)	small intestinal inflammation	J:206084
\Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Nes-cre)1Kln/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	decreased susceptibility to prion infection	J:131028
\Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL)	increased susceptibility to bacterial infection	J:188627
	increased susceptibility to induced colitis	J:188627
	small intestinal inflammation	J:188627
\Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	small intestinal inflammation	J:206084
\Xbp1^tm2Glm/\Xbp1^tm2Glm \Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	small intestinal inflammation	J:206084
\Xbp1^tm2Glm/\Xbp1^tm2Glm \Tnfrsf1a^tm1Imx/\Tnfrsf1a^tm1Imx \Tg(Vil1-cre)997Gum/0 (involves: 129S6/SvEvTac * C57BL/6 * SJL)	small intestinal inflammation	J:206084
\Xbp1^tm3Glm/\Xbp1^tm3Glm \Tg(Vil1-cre/ERT2)23Syr/0 (involves: 129S6/SvEvTac * C57BL/6 * DBA/2)	small intestinal inflammation	J:188627
\Xcl1^tm1.1Dnax/\Xcl1^tm1.1Dnax (either: (involves: 129/Sv * BALB/c) or (involves: 129/Sv * C57BL/6))	abnormal immune system morphology	J:176844
	autoimmune response	J:176844
	decreased dendritic cell number	J:176844
	decreased regulatory T cell number	J:176844
	heart inflammation	J:176844
	increased dendritic cell number	J:176844
	increased inflammatory response	J:176844
	lacrimal gland inflammation	J:176844
	liver inflammation	J:176844
	salivary gland inflammation	J:176844
	stomach inflammation	J:176844
\Xcl1^tm1Rakr/\Xcl1^tm1Rakr (B6.129-Xcl1^tm1Rakr)	decreased cytotoxic T cell cytolysis	J:155297
\Xcl1^tm1Rakr/\Xcl1^tm1Rakr (B6.129-Xcl1^tm1Rakr)	immune system phenotype	J:155297
\Xcl1^tm1Rakr/\Xcl1^tm1Rakr \Tg(TcraTcrb)1100Mjb/0 (involves: 129/Sv * C57BL/6)	abnormal CD8-positive, alpha-beta T cell physiology	J:155297
	decreased cytotoxic T cell cytolysis	J:155297
	decreased interferon-gamma secretion	J:155297
	decreased T cell number	J:155297
\Xcr1^tm1Dgen/\Xcr1^tm1Dgen (B6.129P2-Xcr1^tm1Dgen/J)	abnormal dendritic cell physiology	J:155297
\Xcr1^tm1Dgen/\Xcr1^tm1Dgen (B6.129P2-Xcr1^tm1Dgen/J)	immune system phenotype	J:155297
\Xcr1^{tm2(HBEGF/Venus)Ksho}/\Xcr1⁺ (involves: C57BL/6 * C57BL/6J)	abnormal antigen presentation	J:204851
	abnormal CD8-positive, alpha-beta T cell physiology	J:204851
	decreased dendritic cell number	J:204851
	decreased interferon-gamma secretion	J:204851
	decreased susceptibility to bacterial infection	J:204851
	immune system phenotype	J:204851
\Xdh^tm1.1Takni/\Xdh^tm1.1Takni (involves: C57BL/6)	abnormal peritoneal macrophage morphology	J:281671
\Xdh^tm1Fink/\Xdh^tm1Fink (involves: 129X1/SvJ * C57BL/6J)	tubulointerstitial nephritis	J:166326
\Xiap^tm1Hs/\Xiap^tm1Hs (B6.129P2-Xiap^tm1Hs)	immune system phenotype	J:138979
\Xkrx^{tm1b(EUCOMM)Wtsi}/\Xkrx^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Xkrx^{tm1b(EUCOMM)Wtsi}/Wtsi)	increased anti-nuclear antigen antibody level	J:211773
\Xpa^tm1Tnka/\Xpa^tm1Tnka (involves: C57BL/6 * CBA)	abnormal immune system physiology	J:35054
	abnormal Langerhans cell physiology	J:35054
	abnormal lymphocyte physiology	J:55739
	abnormal NK cell physiology	J:55739
	increased NK cell number	J:55739
\Xpnpep1^{tm1a(KOMP)Wtsi}/\Xpnpep1^{tm1a(KOMP)Wtsi} (C57BL/6N-Xpnpep1^{tm1a(KOMP)Wtsi}/Wtsi)	abnormal thymus morphology	J:239583
	blood in lymph vessels	J:239583
	increased gamma-delta T cell number	J:211773
	increased NK cell number	J:211773
\Xpo5^em1(IMPC)Mbp/\Xpo5⁺ (C57BL/6NCrl-Xpo5^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Xpr1^Sxv/\Xpr1^Sxv (M. spretus)	increased susceptibility to Retroviridae infection	J:7951
\Xrcc4^tm1Fwa/\Xrcc4^tm1Fwa (involves: 129P2/OlaHsd * C57BL/6)	thymus hypoplasia	J:65218
\Xrcc5^{em1(IMPC)Ccpcz}/\Xrcc5^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Xrcc5^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	decreased CD4-positive NK T cell number	J:211773
	decreased CD4-positive, alpha-beta T cell number	J:211773
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:211773
	decreased CD8-positive, alpha-beta T cell number	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	decreased effector memory T-helper cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased memory-marker CD4-positive NK T cell number	J:211773
	decreased NK T cell number	J:211773
	decreased T-helper cell number	J:211773
	immune system phenotype	J:211773
	increased effector memory CD8-positive, alpha-beta T cell number	J:211773
	increased effector memory T-helper cell number	J:211773
	small spleen	J:211773
	small thymus	J:211773
\Xrcc5^m1Btlr/\Xrcc5^m1Btlr (C57BL/6J-Xrcc5^m1Btlr)	abnormal B cell differentiation	J:274736
	abnormal CD8-positive, alpha-beta T cell differentiation	J:274736
	abnormal T cell differentiation	J:274736
	decreased B-2 B cell number	J:274736
	decreased CD4-positive, alpha-beta T cell number	J:274736
	decreased CD8-positive, alpha-beta T cell number	J:274736
	decreased CD8-positive, naive alpha-beta T cell number	J:274736
	decreased T cell number	J:274736
	increased B-1a cell number	J:274736
	increased B-1b cell number	J:274736
	increased CD4-positive, alpha-beta T cell number	J:274736
	increased dendritic cell number	J:274736
	increased effector memory CD4-positive, alpha-beta T cell number	J:274736
	increased effector memory CD8-positive, alpha-beta T cell number	J:274736
	increased neutrophil cell number	J:274736
\Xrcc5^tm1Dbr/\Xrcc5^tm1Dbr (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:34834
	absent T cells	J:34834
	arrested B cell differentiation	J:34834
	arrested T cell differentiation	J:34834
	increased double-negative T cell number	J:34834
	lymph node hypoplasia	J:34834
	thymus hypoplasia	J:34834
\Xrcc5^tm1Dbr/\Xrcc5^tm1Dbr \Lig4^tm1Fwa/\Lig4^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6)	abnormal lymphocyte morphology	J:80467
\Xrcc5^tm1Nus/\Xrcc5^tm1Nus (involves: 129S1/Sv * 129X1/SvJ)	abnormal class switch recombination	J:120658
	abnormal humoral immune response	J:120658
	spleen hypoplasia	J:108657
	thymus hypoplasia	J:108657
\Xrcc6^avon/\Xrcc6^avon (involves: C57BL/6JAnu)	decreased B cell number	J:104190
\Xrcc6^avon/\Xrcc6^avon (involves: C57BL/6JAnu)	decreased T cell number	J:104190
\Xrcc6^tm1Fwa/\Xrcc6^tm1Fwa (involves: 129S6/SvEvTac * C57BL/6J)	abnormal B cell differentiation	J:44361
	abnormal B cell morphology	J:44361
	abnormal T cell differentiation	J:44361
	abnormal T cell morphology	J:44361
	absent immature B cells	J:44361
	absent mature B cells	J:44361
	absent pre-B cells	J:44361
	arrested B cell differentiation	J:44361
	decreased IgM level	J:44361
	decreased single-positive T cell number	J:44361
	decreased thymocyte number	J:44361
	increased double-positive T cell number	J:44361
	increased T cell derived lymphoma incidence	J:44361
\Xrcc6^tm1Gcl/\Xrcc6^tm1Gcl (involves: 129S1/Sv * C57BL/6)	abnormal B cell differentiation	J:108657
	abnormal immune system organ morphology	J:108657
	absent mature B cells	J:108657
	decreased spleen white pulp amount	J:108657
	small lymph nodes	J:108657
	small spleen	J:108657
	small thymus	J:108657
	spleen hypoplasia	J:108657
	thymus hypoplasia	J:108657
\Xylt1^npo/\Xylt1^npo (involves: C57BL/6J * FVB/NJ)	abnormal osteoclast differentiation	J:205339
X/\Yaa ((NZB x BXSB)F1)	abnormal immune cell physiology	J:6235
	abnormal lymph node morphology	J:6235
	enlarged lymph nodes	J:6235
	increased anti-erythrocyte antigen antibody level	J:6235
	increased anti-nuclear antigen antibody level	J:6235
	increased autoantibody level	J:6235
	increased spleen weight	J:6235
	increased susceptibility to autoimmune disorder	J:6235
X/\Yaa ((SJL/J x BXSB)F1)	enlarged lymph nodes	J:6235
X/\Yaa ((SJL/J x BXSB)F1)	increased susceptibility to autoimmune disorder	J:6235
X/\Yaa ((C57BL/6J x BXSB)F1)	enlarged lymph nodes	J:6235
X/\Yaa ((C57BL/6J x BXSB)F1)	increased susceptibility to autoimmune disorder	J:6235
X/\Yaa (involves: BXSB * NZB)	enlarged lymph nodes	J:6235
X/\Yaa (involves: BXSB * NZB)	increased susceptibility to autoimmune disorder	J:6235
X/\Yaa (BXSB/MpJ)	abnormal B cell differentiation	J:108760
	abnormal lymph node morphology	J:6235
	abnormal spleen B cell follicle morphology	J:179430
	abnormal T cell subpopulation ratio	J:179430
	enlarged lymph nodes	J:6235
	glomerulonephritis	J:6235
	increased anti-erythrocyte antigen antibody level	J:6235
	increased anti-nuclear antigen antibody level	J:179430
	increased circulating interleukin-21 level	J:93740
	increased IgG1 level	J:179430, J:93740
	increased IgG2a level	J:179430
	increased IgG2b level	J:179430
	increased IgG3 level	J:93740
	increased monocyte cell number	J:7308
	increased plasma cell number	J:108760
	increased spleen weight	J:6235
	increased splenocyte number	J:179430
	increased susceptibility to autoimmune disorder	J:108760, J:6235
X/\Yaa ((NZW x SB)F1)	abnormal immune serum protein physiology	J:7276
	glomerulonephritis	J:7276
	increased susceptibility to autoimmune disorder	J:7276
X/\Yaa ((NZW x BXSB)F1)	abnormal immune serum protein physiology	J:7276
X/\Yaa ((NZW x BXSB)F1)	increased susceptibility to autoimmune disorder	J:7276
X/\Yaa (BXSB/MpJScr)	decreased CD4-positive, alpha-beta T cell number	J:10973
	glomerulonephritis	J:10973
	increased anti-nuclear antigen antibody level	J:10973
	increased IgG level	J:10973
	increased monocyte cell number	J:10973
	increased susceptibility to autoimmune disorder	J:10973
X/\Yaa ((NZB x B6.SB/Le-Yaa)F1)	increased monocyte cell number	J:129409
X/\Yaa (B6.SB-Yaa/J)	decreased marginal zone B cell number	J:127600
X/\Yaa (B6.SB-Yaa/J)	increased splenocyte proliferation	J:127600
\Yaa2^BXSB/J/? (involves: BXSB/J * C57BL/10Ola)	kidney inflammation	J:49868
\Yaa3^BXSB/J/? (involves: BXSB/J * C57BL/10Ola)	kidney inflammation	J:49868
\Yaa4^BXSB/J/? (involves: BXSB/J * C57BL/10Ola)	kidney inflammation	J:49868
\Yaail^NZW/Ola/? (involves: C57BL/6Ola * NZW/Ola)	glomerulonephritis	J:52110
\Yaail^NZW/Ola/? (involves: C57BL/6Ola * NZW/Ola)	increased anti-double stranded DNA antibody level	J:52110
\Yap1^M1Btlr/\Yap1^M1Btlr (C57BL/6J-Yap1^M1Btlr)	increased susceptibility to induced colitis	J:267549
\Yap1^tm1.1Dupa/\Yap1^tm1.1Dupa \Tg(Vil1-cre)997Gum/0 (involves: 129P2/OlaHsd * C57BL/6J * SJL)	increased susceptibility to induced colitis	J:165471
\Ydjc^{tm1(KOMP)Wtsi}/\Ydjc^{tm1(KOMP)Wtsi} (C57BL/6N-Ydjc^{tm1(KOMP)Wtsi}/Wtsi)	increased effector memory T-helper cell number	J:211773
	increased germinal center B cell number	J:211773
\Yeats4^em1Zfa/\Yeats4^em1Zfa \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6 * C57BL/10 * CBA/Ca)	abnormal acute inflammation	J:282740
	abnormal gut-associated lymphoid tissue morphology	J:282740
	abnormal interleukin secretion	J:282740
	abnormal lymphocyte physiology	J:282740
	abnormal lymphopoiesis	J:282740
	decreased interferon-gamma secretion	J:282740
	decreased interleukin-5 secretion	J:282740
	decreased interleukin-12 secretion	J:282740
	decreased lymphocyte cell number	J:282740
	decreased Peyer's patch number	J:282740
	increased susceptibility to bacterial infection	J:282740
\Yipf6^em1(IMPC)Mbp/\Yipf6^em1(IMPC)Mbp (C57BL/6N-Yipf6^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	increased monocyte cell number	J:211773
\Yipf6^M1Btlr/Y (C57BL/6J-Yipf6^M1Btlr/Mmucd)	colitis	J:187584
\Yipf6^M1Btlr/Y (C57BL/6J-Yipf6^M1Btlr/Mmucd)	increased susceptibility to induced colitis	J:187584
\Yipf6^M1Btlr/\Yipf6^M1Btlr (C57BL/6J-Yipf6^M1Btlr/Mmucd)	colitis	J:187584
\Yipf6^M1Btlr/\Yipf6^M1Btlr (C57BL/6J-Yipf6^M1Btlr/Mmucd)	increased susceptibility to induced colitis	J:187584
\Ykt6^em1(IMPC)J/\Ykt6⁺ (C57BL/6NJ-Ykt6^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Yod1^em1Smoc/\Yod1^em1Smoc (C57BL/6JSmoc-Yod1^em1Smoc/Smoc)	abnormal macrophage physiology	J:350806
	decreased circulating fibrinogen level	J:350806
	increased circulating interleukin-1 beta level	J:350806
	increased inflammatory response	J:350806
	increased interleukin-1 beta secretion	J:350806
	increased macrophage cytokine production	J:350806
	increased susceptibility to bacterial infection	J:350806
	increased susceptibility to bacterial infection induced morbidity/mortality	J:350806
\Yod1^tm1bNarl/\Yod1^tm1bNarl (C57BL/6N-Yod1^tm1bNarl/Narl)	decreased lymphocyte cell number	J:211773
\Yod1^tm1bNarl/\Yod1^tm1bNarl (C57BL/6N-Yod1^tm1bNarl/Narl)	increased neutrophil cell number	J:211773
\Ythdf3^em1(IMPC)Mbp/\Ythdf3^em1(IMPC)Mbp (C57BL/6N-Ythdf3^em1(IMPC)Mbp/MbpMmucd)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Ythdf3^em1Caox/\Ythdf3^em1Caox (involves: C57BL/6J)	abnormal macrophage physiology	J:276397
	decreased susceptibility to Riboviria infection	J:276397
	decreased susceptibility to Riboviria infection induced morbidity/mortality	J:276397
	immune system phenotype	J:276397
\Ywhaz^{tm1b(EUCOMM)Hmgu}/\Ywhaz⁺ (C57BL/6N-Ywhaz^{tm1b(EUCOMM)Hmgu}/Tcp)	enlarged lymph nodes	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Yy1^tm3.1Yshi/\Yy1⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)	immune system phenotype	J:208226
\Yy2^em1(IMPC)Mbp/\Yy2^em1(IMPC)Mbp (C57BL/6NCrl-Yy2^em1(IMPC)Mbp/Mmucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Zap70^m1Btlr/\Zap70^m1Btlr (involves: C57BL/6J)	abnormal class switch recombination	J:185495
	abnormal humoral immune response	J:167119
	absent CD4-positive, alpha-beta T cells	J:167119
	absent CD8-positive, alpha-beta T cells	J:167119
	decreased IgG level	J:185495
	decreased T cell number	J:185495
	immune system phenotype	J:167119, J:185495
\Zap70^m1Saka/\Zap70^m1Saka (involves: BALB/c)	abnormal lymph node cell ratio	J:154166
	abnormal positive T cell selection	J:154166, J:86607
	abnormal splenic cell ratio	J:154166
	abnormal T cell clonal deletion	J:154166
	abnormal T cell differentiation	J:86607
	abnormal T cell selection	J:86607
	abnormal thymocyte activation	J:154166
	abnormal thymus cell ratio	J:154166
	chronic joint inflammation	J:86607
	decreased CD4-positive, alpha-beta T cell number	J:154166, J:86607
	decreased CD8-positive, alpha-beta T cell number	J:154166, J:86607
	decreased interleukin-2 secretion	J:154166
	decreased regulatory T cell number	J:154166
	decreased T cell proliferation	J:154166, J:86607
	increased activated T cell number	J:154166
	increased autoantibody level	J:86607
	increased B cell number	J:86607
	increased immunoglobulin level	J:86607
	increased interleukin-17 secretion	J:154166
	increased memory T cell number	J:154166
	increased susceptibility to induced arthritis	J:154166
	lung inflammation	J:86607
	rheumatoid arthritis	J:86607
\Zap70^m1Saka/\Zap70^m1Saka \Tg(DO11.10)10Dlo/0 (involves: BALB/c * C3H * C57BL/6)	decreased T cell number	J:86607
	decreased T cell proliferation	J:86607
\Zap70^m1Saka/\Zap70^m1Saka \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: BALB/c * C57BL/6J * DBA/2J)	abnormal positive T cell selection	J:86607
	autoimmune arthritis	J:86607
\Zap70^m1Saka/\Zap70^tm1Dlo (involves: 129P2/OlaHsd * BALB/c)	autoimmune arthritis	J:86607
\Zap70^m1Saka/\Zap70^tm2.1Weis (involves: 129S4/SvJae * BALB/c)	abnormal T cell clonal deletion	J:154166
	decreased susceptibility to induced arthritis	J:154166
\Zap70^m2Btlr/\Zap70^m2Btlr (involves: C57BL/6J)	decreased T cell number	J:174837
\Zap70^m3Btlr/\Zap70^m3Btlr (C57BL/6J-Zap70^m3Btlr)	decreased IgG level	J:225043
\Zap70^m3Btlr/\Zap70^m3Btlr (C57BL/6J-Zap70^m3Btlr)	impaired humoral immune response	J:225043
\Zap70^m4Btlr/\Zap70^m4Btlr (C57BL/6J-Zap70^m4Btlr)	decreased CD4-positive, alpha-beta T cell number	J:236698
	decreased CD8-positive, alpha-beta T cell number	J:236698
	decreased T cell number	J:236698
\Zap70^m5Btlr/\Zap70^m5Btlr (C57BL/6J-Zap70^m5Btlr)	abnormal humoral immune response	J:254830
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254830
	decreased CD8-positive, alpha-beta T cell number	J:254830
	decreased CD8-positive, naive alpha-beta T cell number	J:254830
	decreased IgG level	J:254830
	increased B cell number	J:254830
	increased central memory CD4-positive, alpha-beta T cell number	J:254830
	increased central memory CD8 positive, alpha-beta T cell number	J:254830
	increased effector memory CD4-positive, alpha-beta T cell number	J:254830
\Zap70^m6Btlr/\Zap70^m6Btlr (C57BL/6J-Zap70^m6Btlr)	abnormal humoral immune response	J:254831
	decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254831
	decreased CD8-positive, alpha-beta T cell number	J:254831
	decreased CD8-positive, naive alpha-beta T cell number	J:254831
	decreased IgG level	J:254831
	increased B cell number	J:254831
	increased central memory CD4-positive, alpha-beta T cell number	J:254831
	increased central memory CD8 positive, alpha-beta T cell number	J:254831
	increased effector memory CD4-positive, alpha-beta T cell number	J:254831
\Zap70^m6Hefl/\Zap70^m6Hefl (C3HeB/FeJ-Zap70^m6Hefl)	abnormal humoral immune response	J:137446
	abnormal T cell differentiation	J:137446
	decreased CD4-positive, alpha-beta T cell number	J:137446
	decreased CD8-positive, alpha-beta T cell number	J:137446
	decreased T cell number	J:137446
	immune system phenotype	J:137446
	increased IgE level	J:137446
	increased IgG1 level	J:137446
\Zap70^m6Hefl/\Zap70^tm1Weis (involves: 129X1/SvJ * C3HeB/FeJ * C57BL/10 * DBA/2)	decreased T cell number	J:137446
	increased IgE level	J:137446
\Zap70^m7Btlr/\Zap70^m7Btlr (C57BL/6J-Zap70^m7Btlr)	abnormal humoral immune response	J:254832
	decreased IgG level	J:254832
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:254832
	increased central memory CD8 positive, alpha-beta T cell number	J:254832
\Zap70^m8Btlr/\Zap70^m8Btlr (C57BL/6J-Zap70^m8Btlr)	decreased CD8-positive, naive alpha-beta T cell number	J:272864
\Zap70^m8Btlr/\Zap70^m8Btlr (C57BL/6J-Zap70^m8Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:272864
\Zap70^mrtle/\Zap70^mrtle (C57BL/6JSfdAnu-Zap70^mrtle/Apb)	abnormal positive T cell selection	J:104190
	abnormal T cell subpopulation ratio	J:104190
	absent T cells	J:104190
	arrested T cell differentiation	J:104190
	decreased T cell number	J:104190
\Zap70^mrtle/\Zap70^mrtle (involves: C57BL/6JSfdAnu)	abnormal double-positive T cell morphology	J:211510
	abnormal regulatory T cell number	J:211510
	decreased CD4-positive, alpha-beta T cell number	J:211510
	decreased CD8-positive, alpha-beta T cell number	J:211510
	increased double-positive T cell number	J:211510
\Zap70^mrtle/\Zap70^rps (involves: C57BL/6 * C57BL/6JSfdAnu)	abnormal CD4-positive, alpha beta T cell morphology	J:211510
	abnormal double-positive T cell morphology	J:211510
	abnormal regulatory T cell number	J:211510
	decreased CD4-positive, alpha-beta T cell number	J:211510
	decreased CD8-positive, alpha-beta T cell number	J:211510
	increased double-positive T cell number	J:211510
\Zap70^mur/\Zap70^mur (C57BL/6Apb-Zap70^mur/ApbH)	abnormal T cell activation	J:104190
	abnormal T cell physiology	J:104190
	decreased T cell number	J:104190
	increased IgG2b level	J:104190
\Zap70^st/\Zap70^st (involves: C57BL/6)	abnormal T cell physiology	J:41170
	arrested T cell differentiation	J:41170
	decreased T cell number	J:41170
	thymus hypoplasia	J:41170
\Zap70^st/\Zap70^tm1Dlo (involves: C57BL/6)	arrested T cell differentiation	J:41170
\Zap70^tm1.1Mmal/\Zap70^tm1.1Mmal (B6.129P2-Zap70^tm1.1Mmal)	immune system phenotype	J:71099
\Zap70^tm1.1Mmal/\Zap70^tm1.1Mmal \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J)	immune system phenotype	J:71099
\Zap70^tm1.1Mmal/\Zap70^tm1.1Mmal \Tg(TcrLCMV)327Sdz/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2)	abnormal cytokine secretion	J:71099
	abnormal T cell proliferation	J:71099
	immune system phenotype	J:71099
\Zap70^tm1Dlo/\Zap70^tm1Dlo (involves: 129P2/OlaHsd)	increased double-positive T cell number	J:97610
\Zap70^tm1Weis/\Zap70^tm1Weis (involves: 129X1/SvJ * C57BL/6J)	abnormal lymph node cell ratio	J:74974
	abnormal splenic cell ratio	J:74974
	abnormal T cell differentiation	J:74974
	arrested T cell differentiation	J:74974
	small lymph nodes	J:74974
\Zap70^tm2.1Mmal/\Zap70^tm2.1Mmal (B6.129P2-Zap70^tm2.1Mmal)	immune system phenotype	J:71099
\Zap70^tm2.1Mmal/\Zap70^tm2.1Mmal \Tg(TcraH-Y,TcrbH-Y)71Vbo/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J)	abnormal lymph node cell ratio	J:71099
	abnormal T cell morphology	J:71099
	abnormal thymus cell ratio	J:71099
	immune system phenotype	J:71099
\Zap70^tm2.1Mmal/\Zap70^tm2.1Mmal \Tg(TcrLCMV)327Sdz/0 (involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2)	abnormal T cell morphology	J:71099
	immune system phenotype	J:71099
\Zap70^tm2.1Weis/\Zap70^tm2.1Weis (B6.129S4-Zap70^tm2.1Weis)	abnormal CD8-positive, alpha-beta T cell differentiation	J:154166
	abnormal thymus cell ratio	J:154166
	decreased CD4-positive, alpha-beta T cell number	J:154166
	decreased CD8-positive, alpha-beta T cell number	J:154166
\Zap70^tm2.1Weis/\Zap70^tm2.1Weis (C.129S4-Zap70^tm2.1Weis)	abnormal lymph node cell ratio	J:154166
	abnormal positive T cell selection	J:154166
	abnormal regulatory T cell physiology	J:154166
	abnormal splenic cell ratio	J:154166
	abnormal T cell clonal deletion	J:154166
	abnormal thymocyte activation	J:154166
	abnormal thymus cell ratio	J:154166
	decreased CD4-positive, alpha-beta T cell number	J:154166
	decreased CD8-positive, alpha-beta T cell number	J:154166
	decreased interleukin-2 secretion	J:154166
	decreased regulatory T cell number	J:154166
	decreased T cell proliferation	J:154166
	immune system phenotype	J:154166
	increased activated T cell number	J:154166
	increased interleukin-17 secretion	J:154166
	increased memory T cell number	J:154166
\Zap70^tm2.1Weis/\Zap70^tm2.1Weis \Tg(DO11.10)10Dlo/? (involves: 129S4/SvJae * BALB/c * C3H * C57BL/6)	abnormal positive T cell selection	J:154166
\Zap70^tm2.1Weis/\Zap70^tm2.1Weis \Tg(TcraH-Y,TcrbH-Y)71Vbo/? (involves: 129S4/SvJae * C57BL/6J * DBA/2J)	abnormal positive T cell selection	J:154166
	abnormal T cell clonal deletion	J:154166
\Zbp1^tm1.1Jreh/\Zbp1^tm1.1Jreh (involves: C57BL/6 * C57BL/6N)	increased susceptibility to Herpesvirales infection	J:252669
\Zbp1^tm1Aki/\Zbp1^tm1Aki (involves: C57BL/6)	immune system phenotype	J:132662
\Zbtb1^m1Btlr/\Zbtb1^m1Btlr (involves: C3H/HeN * C57BL/6J)	abnormal B cell differentiation	J:178820
	abnormal immune system physiology	J:178820
	abnormal T cell differentiation	J:178820
	abnormal thymus morphology	J:178820
	decreased B cell number	J:178820
	decreased CD4-positive, alpha-beta T cell number	J:178820
	decreased CD8-positive, alpha-beta T cell number	J:178820
	decreased DN2 thymocyte number	J:178820
	decreased DN3 thymocyte number	J:178820
	decreased DN4 thymocyte number	J:178820
	decreased double-positive T cell number	J:178820
	decreased follicular B cell number	J:178820
	decreased NK cell number	J:178820
	decreased T cell number	J:178820
	decreased transitional stage B cell number	J:178820
	immune system phenotype	J:178820
	increased B cell number	J:178820
	thymus hypoplasia	J:178820
\Zbtb1^m2Btlr/\Zbtb1^m2Btlr (C57BL/6J-Zbtb1^m2Btlr)	abnormal CD8-positive, alpha-beta T cell differentiation	J:272845
\Zbtb1^m2Btlr/\Zbtb1^m2Btlr (C57BL/6J-Zbtb1^m2Btlr)	increased central memory CD8 positive, alpha-beta T cell number	J:272845
\Zbtb7a^tm1Ppp/\Zbtb7a^tm1Ppp (B6.129S1-Zbtb7a^tm1Ppp)	abnormal lymphopoiesis	J:121576
	abnormal response to transplant	J:121576
	decreased B cell number	J:121576
	decreased pro-B cell number	J:121576
\Zbtb7a^tm1Ppp/\Zbtb7a^tm2Ppp \Tg(Mx1-cre)1Cgn/0 (involves: 129S1/Sv * C57BL/6 * CBA)	abnormal B cell differentiation	J:121576
	abnormal double-positive T cell morphology	J:121576
	abnormal response to transplant	J:121576
	decreased B cell number	J:121576
	decreased leukocyte cell number	J:121576
	immune system phenotype	J:121576
\Zbtb7b^hd/\Zbtb7b^hd (involves: 129/Sv * BALB/c * C3H * C57BL/6)	abnormal CD4-positive T cell differentiation	J:48734
	absent CD4-positive, alpha-beta T cells	J:48734
	increased CD8-positive, alpha-beta T cell number	J:48734
\Zbtb7b^hpls/\Zbtb7b^hpls (involves: C57BL/6JAnu)	abnormal humoral immune response	J:104190
\Zbtb7b^hpls/\Zbtb7b^hpls (involves: C57BL/6JAnu)	decreased CD4-positive, alpha-beta T cell number	J:104190
\Zbtb7b^tm1.1Rbo/\Zbtb7b^tm1.1Rbo (Not Specified)	abnormal CD8-positive, alpha-beta T cell number	J:141145
	abnormal T cell differentiation	J:141145
	decreased CD4-positive, alpha-beta T cell number	J:141145
\Zbtb7b^tm1.1Skok/\Zbtb7b^tm1.1Skok (involves: 129/Sv * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:169841
\Zbtb7b^tm1.1Tani/\Zbtb7b^tm1.1Tani (involves: 129 * C57BL/6)	increased double-negative T cell number	J:141142
\Zbtb7b^tm1Itan/\Zbtb7b^tm1.1Tani (involves: 129 * C57BL/6)	abnormal CD4-positive, alpha beta T cell morphology	J:141142
	abnormal CD4-positive, alpha-beta T cell physiology	J:141142
	decreased CD4-positive, alpha-beta T cell number	J:141142
	increased CD8-positive, alpha-beta T cell number	J:141142
	increased double-negative T cell number	J:141142
\Zbtb7b^tm1Itan/\Zbtb7b^tm2Itan (involves: 129 * C57BL/6)	decreased CD4-positive, alpha-beta T cell number	J:141142
	increased CD8-positive, alpha-beta T cell number	J:141142
	increased double-negative T cell number	J:141142
\Zbtb7b^tm1Litt/\Zbtb7b^tm1.2Litt (involves: C57BL/6)	abnormal double-positive T cell morphology	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
	increased CD8-positive, alpha-beta T cell number	J:141144
	increased interferon-gamma secretion	J:141144
\Zbtb7b^tm2Litt/\Zbtb7b^tm1.2Litt (involves: 129P2/OlaHsd)	decreased CD4-positive, alpha-beta T cell number	J:141144
\Zbtb7b^tm2Litt/\Zbtb7b^tm1.2Litt \Tg(Lck-cre)1Cwi/? (involves: 129P2/OlaHsd * C57BL/6)	abnormal T cell differentiation	J:141144
	decreased CD4-positive, alpha-beta T cell number	J:141144
\Zbtb7b^tm2Litt/\Zbtb7b^tm2Litt (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)	absent CD4-positive, alpha-beta T cells	J:141519
\Zbtb7b^tm4.1Itan/\Zbtb7b^tm4.1Itan (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:193321
\Zbtb7b^tm4.1Itan/\Zbtb7b^tm4.1Itan (Not Specified)	increased CD8-positive, alpha-beta T cell number	J:193321
\Zbtb7b^tm6.1Itan/\Zbtb7b^tm6.1Itan \Tg(Cd4-cre)1Cwi/? (involves: C57BL/6 * DBA/2)	decreased CD8-positive, alpha-beta T cell number	J:195348
\Zbtb7b^tm6.1Itan/\Zbtb7b^tm6.1Itan \Tg(Cd8a-cre)1Itan/? (involves: C57BL/6)	immune system phenotype	J:195348
\Zbtb7b^tm7Itan/\Zbtb7b^tm7Itan (Not Specified)	decreased CD4-positive, alpha-beta T cell number	J:195348
\Zbtb16^em1(IMPC)Mbp/\Zbtb16^em1(IMPC)Mbp (C57BL/6NCrl-Zbtb16^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Zbtb16^lu/\Zbtb16^lu (B6.C3-Zbtb16^lu/J)	decreased NK T cell number	J:139690
\Zbtb17^tm1Cksn/\Zbtb17^tm1Cksn \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (B6.Cg-Zbtb17^tm1Cksn Commd10^{Tg(Vav1-icre)A2Kio})	arrested T cell differentiation	J:170508
	decreased DN1 thymic pro-T cell number	J:170508
	decreased DN2 thymocyte number	J:170508
	decreased DN3 thymocyte number	J:170508
	decreased double-negative T cell number	J:170508
	decreased gamma-delta T cell number	J:170508
	decreased T cell number	J:170508
	decreased thymocyte number	J:170508
	increased T cell apoptosis	J:170508
	thymus hypoplasia	J:170508
\Zbtb17^tm1Cksn/\Zbtb17^tm1Cksn \Tg(Lck-cre)548Jxm/0 (B6.Cg-Zbtb17^tm1Cksn Tg(Lck-cre)548Jxm)	immune system phenotype	J:170508
\Zbtb32^tm1Iho/\Zbtb32^tm1Iho (involves: BALB/c)	abnormal cytokine secretion	J:94944
\Zbtb32^tm1Iho/\Zbtb32^tm1Iho (involves: BALB/c)	increased T cell proliferation	J:94944
\Zbtb32^tm1Iho/\Zbtb32^tm1Iho (involves: C57BL/6)	increased T cell proliferation	J:94944
\Zbtb32^tm2Ppp/\Zbtb32^tm2Ppp (involves: 129S1/Sv)	abnormal cytokine secretion	J:95119
\Zbtb32^tm2Ppp/\Zbtb32^tm2Ppp (involves: 129S1/Sv)	increased T cell proliferation	J:95119
\Zbtb38^em1Dbhat/\Zbtb38^em1Dbhat \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (involves: C57BL/6J * C57BL/6N * C57BL/10 * CBA/Ca)	immune system phenotype	J:296556
\Zbtb42^em1(IMPC)Mbp/\Zbtb42^em1(IMPC)Mbp (C57BL/6NCrl-Zbtb42^em1(IMPC)Mbp/Mmucd)	enlarged lymph nodes	J:211773
\Zbtb46^{tm1(HBEGF)Mnz}/\Zbtb46⁺ (C57BL/6-Zbtb46^{tm1(HBEGF)Mnz})	abnormal memory T cell physiology	J:189122
	abnormal response to infection	J:189122
	abnormal T-helper 1 physiology	J:189122
	decreased dendritic cell number	J:189122
	immune system phenotype	J:189122
	increased monocyte cell number	J:189122
	increased neutrophil cell number	J:189122
	increased susceptibility to parasitic infection	J:189122
\Zbtb46^tm1Kmm/\Zbtb46^tm1Kmm (129S/SvEv-Zbtb46^tm1Kmm)	abnormal dendritic cell physiology	J:184205
\Zbtb46^tm1Kmm/\Zbtb46^tm1Kmm (129S/SvEv-Zbtb46^tm1Kmm)	immune system phenotype	J:184205
\Zbtb46^tm2.1Mnz/\Zbtb46^tm2.1Mnz (involves: C57BL/6)	abnormal dendritic cell morphology	J:191314
	abnormal lymphangiogenesis	J:191314
	decreased dendritic cell number	J:191314
	enlarged lymph nodes	J:191314
	increased dendritic cell number	J:191314
	lymph node hyperplasia	J:191314
\Zc2hc1b^{em1(IMPC)Ccpcz}/\Zc2hc1b^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Zc2hc1b^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Zc2hc1c^{em1(IMPC)Ccpcz}/\Zc2hc1c^{em1(IMPC)Ccpcz} (C57BL/6N-Zc2hc1c^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal thymus morphology	J:211773
	enlarged thymus	J:211773
\Zc3h7ait^em1Caox/\Zc3h7ait^em1Caox (C57BL/6J-Zc3h7ait^em1Caox)	abnormal interferon secretion	J:282488
	abnormal macrophage activation involved in immune response	J:282488
	decreased circulating interferon-alpha level	J:282488
	decreased circulating interferon-beta level	J:282488
	decreased circulating interleukin-6 level	J:282488
	decreased interferon-alpha secretion	J:282488
	decreased interferon-beta secretion	J:282488
	decreased interleukin-6 secretion	J:282488
	immune system phenotype	J:282488
	increased susceptibility to Riboviria infection	J:282488
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:282488
\Zc3h7b^em1(IMPC)J/\Zc3h7b^em1(IMPC)J (C57BL/6NJ-Zc3h7b^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Zc3h8^{em1(IMPC)Ccpcz}/\Zc3h8⁺ (C57BL/6N-Zc3h8^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	decreased CD8-positive, naive alpha-beta T cell number	J:211773
	enlarged spleen	J:211773
\Zc3h11a^em1(IMPC)Mbp/\Zc3h11a⁺ (C57BL/6NCrl-Zc3h11a^em1(IMPC)Mbp/Mmucd)	abnormal thymus morphology	J:211773
\Zc3h12a^tm1Aki/\Zc3h12a^tm1Aki (involves: 129X1/SvJ * C57BL/6)	abnormal acute inflammation	J:147868
	abnormal class switch recombination	J:147868
	enlarged lymph nodes	J:147868
	enlarged spleen	J:147868
	granulomatous inflammation	J:147868
	increased anti-double stranded DNA antibody level	J:147868
	increased anti-nuclear antigen antibody level	J:147868
	increased IgA level	J:147868
	increased IgG1 level	J:147868
	increased IgG2a level	J:147868
	increased IgG2b level	J:147868
	increased IgG3 level	J:147868
	increased IgM level	J:147868
	increased immunoglobulin level	J:147868
	increased interferon-gamma secretion	J:147868
	increased interleukin-6 secretion	J:147868
	increased interleukin-12b secretion	J:147868
	increased leukocyte cell number	J:147868
	increased memory T cell number	J:147868
	increased plasma cell number	J:147868
\Zc3h12a^{tm1c(EUCOMM)Hmgu}/\Zc3h12a^{tm1c(EUCOMM)Hmgu} \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6N)	increased inflammatory response	J:304105
\Zc3h12a^{tm1c(EUCOMM)Hmgu}/\Zc3h12a^{tm1c(EUCOMM)Hmgu} \Speer6-ps1^{Tg(Alb-cre)21Mgn}/\Speer6-ps1⁺ (involves: C57BL/6 * C57BL/6N * DBA)	bile duct inflammation	J:304105
	enlarged spleen	J:304105
	granulomatous inflammation	J:304105
	increased anti-nuclear antigen antibody level	J:304105
	increased autoantibody level	J:304105
	increased IgG level	J:304105
	increased IgM level	J:304105
	liver inflammation	J:304105
\Zc3h12a^tm1Fum/\Zc3h12a^tm1Fum (C57BL/6-Zc3h12a^tm1Fum)	abnormal chemokine secretion	J:176866
	abnormal circulating chemokine level	J:176866
	enlarged lymph nodes	J:176866
	enlarged spleen	J:176866
	increased circulating tumor necrosis factor level	J:176866
	increased interleukin-1 beta secretion	J:176866
	increased interleukin-6 secretion	J:176866
	increased tumor necrosis factor secretion	J:176866
\Zc3h12b^em1(IMPC)Tcp/\Zc3h12b^em1(IMPC)Tcp (C57BL/6NCrl-Zc3h12b^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Zc3h12c^em1(IMPC)Tcp/\Zc3h12c^em1(IMPC)Tcp (C57BL/6NCrl-Zc3h12c^em1(IMPC)Tcp/Tcp)	decreased lymphocyte cell number	J:211773
	enlarged lymph nodes	J:211773
	increased neutrophil cell number	J:211773
\Zc3h12c^{tm2c(EUCOMM)Hmgu}/\Zc3h12c^{tm2c(EUCOMM)Hmgu} \Cd19^tm1(cre)Cgn/\Cd19⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	immune system phenotype	J:277714
\Zc3h12c^{tm2c(EUCOMM)Hmgu}/\Zc3h12c^{tm2c(EUCOMM)Hmgu} \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)	enlarged lymph nodes	J:277714
	increased B cell number	J:277714
	increased CD4-positive, alpha-beta T cell number	J:277714
	increased effector memory CD8-positive, alpha-beta T cell number	J:277714
	increased immature B cell number	J:277714
	increased marginal zone B cell number	J:277714
\Zc3h12c^{tm2c(EUCOMM)Hmgu}/\Zc3h12c^{tm2c(EUCOMM)Hmgu} \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6N * DBA/2)	immune system phenotype	J:277714
\Zc3h12c^{tm2d(EUCOMM)Hmgu}/\Zc3h12c^{tm2d(EUCOMM)Hmgu} (involves: 129S4/SvJaeSor * C57BL/6N)	abnormal lymph node cortex morphology	J:277714
	abnormal lymph node primary follicle morphology	J:277714
	decreased CD8-positive, alpha-beta T cell number	J:277714
	decreased germinal center B cell number	J:277714
	decreased macrophage cell number	J:277714
	enlarged lymph nodes	J:277714
	immune system phenotype	J:277714
	increased B cell number	J:277714
	increased CD4-positive, alpha-beta T cell number	J:277714
	increased circulating interferon-gamma level	J:277714
	increased effector memory CD4-positive, alpha-beta T cell number	J:277714
	increased IgA level	J:277714
	increased IgG level	J:277714
	increased IgM level	J:277714
	increased immature B cell number	J:277714
	increased marginal zone B cell number	J:277714
	increased splenocyte number	J:277714
	increased T cell number	J:277714
\Zc3h12d^{tm1b(EUCOMM)Hmgu}/\Zc3h12d^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Zc3h12d^{tm1b(EUCOMM)Hmgu}/Orl)	decreased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Zc3h12d^tm1Tom/\Zc3h12d^tm1Tom (B6.Cg-Zc3h12d^tm1Tom)	immune system phenotype	J:209383
	increased interleukin-6 secretion	J:209383
	increased interleukin-10 secretion	J:209383
	increased susceptibility to experimental autoimmune encephalomyelitis	J:209383
	increased T cell proliferation	J:209383
	increased T-helper 17 cell number	J:209383
\Zc3hav1l^{tm1b(EUCOMM)Wtsi}/\Zc3hav1l^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Zc3hav1l^{tm1b(EUCOMM)Wtsi}/Tcp)	increased eosinophil cell number	J:211773
\Zcchc3^em1Hbsh/\Zcchc3^em1Hbsh (involves: C57BL/6)	abnormal innate immunity	J:271802
	decreased circulating CXCL10 level	J:271802
	decreased circulating interferon-beta level	J:271802
	decreased circulating interleukin-6 level	J:271802
	increased susceptibility to Herpesvirales infection	J:271802
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:271802
	increased susceptibility to Poxviridae infection induced morbidity/mortality	J:271802
\Zcchc4^em1(IMPC)Bay/\Zcchc4^em1(IMPC)Bay (C57BL/6N-Zcchc4^em1(IMPC)Bay/Bay)	abnormal lymph node morphology	J:211773
\Zcchc17^{em1(IMPC)Hmgu}/\Zcchc17^{em1(IMPC)Hmgu} (C57BL/6NCrl-Zcchc17^{em1(IMPC)Hmgu}/Ieg)	increased spleen weight	J:211773
\Zcrb1^{em1(IMPC)Ccpcz}/\Zcrb1⁺ (C57BL/6NCrl-Zcrb1^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Zcwpw1^em1(IMPC)Tcp/\Zcwpw1^em1(IMPC)Tcp (C57BL/6N-Zcwpw1^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Zdbf2^em1(IMPC)J/\Zdbf2^em1(IMPC)J (C57BL/6NJ-Zdbf2^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Zdhhc1^tm1Yyiw/\Zdhhc1^tm1Yyiw (involves: 129S6/SvEvTac)	abnormal circulating cytokine level	J:284987
	decreased circulating interferon-alpha level	J:284987
	decreased circulating interferon-beta level	J:284987
	decreased circulating interleukin-6 level	J:284987
	decreased circulating tumor necrosis factor level	J:284987
	immune system phenotype	J:284987
	increased susceptibility to Herpesvirales infection	J:284987
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:284987
\Zdhhc2^em1Eko/\Zdhhc2^em1Eko (C57BL/6-Zdhhc2^em1Eko)	abnormal cytokine level	J:303593
	abnormal interferon level	J:303593
	abnormal interleukin level	J:303593
	abnormal plasmacytoid dendritic cell physiology	J:303593
	abnormal T cell activation	J:303593
	abnormal tumor necrosis factor level	J:303593
	decreased dendritic epidermal T cell number	J:303593
	decreased leukocyte cell number	J:303593
	decreased plasmacytoid dendritic cell number	J:303593
	decreased susceptibility to chemically induced skin inflammation	J:303593
	increased alpha-beta T cell number	J:303593
	increased gamma-delta T cell number	J:303593
\Zdhhc9^tm1Lex/Y (involves: 129S5/SvEvBrd * C57BL/6)	abnormal leukocyte physiology	J:231488
\Zdhhc11^{tm1.1(KOMP)Vlcg}/\Zdhhc11^{tm1.1(KOMP)Vlcg} (involves: C57BL/6NTac)	decreased circulating interleukin-6 level	J:310891
	decreased susceptibility to endotoxin shock	J:310891
	decreased susceptibility to viral infection	J:310891
\Zdhhc13^skc4/\Zdhhc13^skc4 (involves: 129S6/SvEvTac * C3H * C57BL/6)	abnormal Kupffer cell morphology	J:161519
	decreased leukocyte cell number	J:161519
	enlarged spleen	J:161519
	increased neutrophil cell number	J:161519
\Zeb1^m1Btlr/\Zeb1^m1Btlr (involves: C57BL/6J)	abnormal B cell differentiation	J:185495
	abnormal class switch recombination	J:185495
	abnormal memory B cell physiology	J:185495
	absent marginal zone B cells	J:185495
	decreased B cell proliferation	J:185495
	decreased B-1 B cell number	J:185495
	decreased B-1a cell number	J:185495
	decreased B-1b cell number	J:185495
	decreased double-positive T cell number	J:185495
	decreased germinal center B cell number	J:185495
	decreased IgG1 level	J:185495
	decreased IgG level	J:185495
	decreased IgM level	J:185495
	decreased NK cell number	J:185495
	immune system phenotype	J:185495
	increased single-positive T cell number	J:185495
	increased thymocyte number	J:185495
\Zeb1^m2Btlr/\Zeb1^m2Btlr (C57BL/6J-Zeb1^m2Btlr)	impaired humoral immune response	J:221490
\Zeb1^tm1Yhi/\Zeb1^tm1Yhi (B6.129P2-Zeb1^tm1Yhi)	abnormal T cell differentiation	J:39865
	abnormal T cell subpopulation ratio	J:39865
	abnormal thymus development	J:39865
	decreased CD8-positive, alpha-beta T cell number	J:39865
	decreased double-positive T cell number	J:39865
	decreased lymphocyte cell number	J:39865
	decreased splenocyte number	J:39865
	decreased T cell number	J:39865
	decreased thymocyte number	J:39865
	lymph node hypoplasia	J:39865
	small thymus	J:39865
	thymus hypoplasia	J:39865
\Zeb1^tm1Yhi/\Zeb1^tm1Yhi (either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR))	increased T cell derived lymphoma incidence	J:139194
\Zeb1^tm2Yhi/\Zeb1^tm2Yhi (B6.129-Zeb1^tm2Yhi)	decreased thymocyte number	J:45575
\Zeb1^tm2Yhi/\Zeb1^tm2Yhi (B6.129-Zeb1^tm2Yhi)	thymus hypoplasia	J:45575
\Zeb1^Tw/\Zeb1⁺ (B6.Cg-Zeb1^Tw)	decreased leukocyte cell number	J:177274
	decreased lymphocyte cell number	J:177274
	decreased neutrophil cell number	J:177274
	small spleen	J:177274
	small thymus	J:177274
\Zfand2b^tm1Otin/\Zfand2b⁺ (involves: 129S7/SvEvBrd * C57BL/6)	increased granulocyte number	J:233169
\Zfand2b^tm1Otin/\Zfand2b^tm1Otin (involves: 129S7/SvEvBrd * C57BL/6)	abnormal myeloid leukocyte morphology	J:233169
	decreased lymphocyte cell number	J:233169
	enlarged spleen	J:233169
	increased granulocyte number	J:233169
	increased leukocyte cell number	J:233169
	increased lymphocyte cell number	J:233169
	increased spleen weight	J:233169
\Zfand3^em1(IMPC)J/\Zfand3^em1(IMPC)J (C57BL/6NJ-Zfand3^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Zfand6^em1(IMPC)Mbp/\Zfand6^em1(IMPC)Mbp (C57BL/6N-Zfand6^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Zfat^{em1(IMPC)Ccpcz}/\Zfat⁺ (C57BL/6NCrl-Zfat^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
	abnormal thymus morphology	J:211773
	enlarged spleen	J:211773
	enlarged thymus	J:211773
\Zfat^tm2.1Sawa/\Zfat^tm2.1Sawa \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6JJcl * C57BL/6NCrSlc * DBA/2)	abnormal CD4-positive, alpha-beta T cell physiology	J:187164
	abnormal CD8-positive, alpha-beta T cell differentiation	J:187164
	decreased CD4-positive, alpha-beta T cell number	J:187164
	decreased CD8-positive, alpha-beta T cell number	J:187164
	decreased interleukin-2 secretion	J:187164
	decreased T cell proliferation	J:187164
	immune system phenotype	J:187164
	increased T cell apoptosis	J:187164
\Zfp14^tm1Xch/\Zfp14⁺ (involves: C57BL/6)	chronic pancreas inflammation	J:331393
	increased inflammatory response	J:331393
	lymph node hyperplasia	J:331393
	spleen hyperplasia	J:331393
	thymus hyperplasia	J:331393
\Zfp14^tm1Xch/\Zfp14^tm1Xch (involves: C57BL/6)	chronic pancreas inflammation	J:331393
	increased inflammatory response	J:331393
	lymph node hyperplasia	J:331393
	spleen hyperplasia	J:331393
	thymus hyperplasia	J:331393
\Zfp30^em1Snpk/\Zfp30^em1Snpk (C57BL/6J-Zfp30^em1Snpk/Mmnc)	immune system phenotype	J:300801
\Zfp35^tm1Naka/\Zfp35^tm1Naka (either: B6.Cg-Zfp35^tm1Naka or C.Cg-Zfp35^tm1Naka)	abnormal T-helper 2 cell differentiation	J:153828
	increased circulating interleukin-4 level	J:153828
	increased circulating interleukin-5 level	J:153828
	increased circulating interleukin-13 level	J:153828
	increased eosinophil cell number	J:153828
\Zfp36^{tm1(KOMP)Vlcg}/\Zfp36⁺ (C57BL/6N-Zfp36^{tm1(KOMP)Vlcg}/Nju)	increased leukocyte cell number	J:211773
\Zfp36^tm1Pjb/\Zfp36^tm1Pjb (Not Specified)	abnormal thymus cortex morphology	J:33986
	abnormal thymus medulla morphology	J:33986
	autoimmune arthritis	J:33986
	conjunctivitis	J:33986
	dermatitis	J:33986
	enlarged lymph nodes	J:33986
	enlarged spleen	J:33986
	heart inflammation	J:33986
	increased leukocyte cell number	J:33986
	liver inflammation	J:33986
	spleen hyperplasia	J:33986
	thymus hypoplasia	J:33986
\Zfp36^tm1Pjb/\Zfp36^tm1Pjb (B6.Cg-Zfp36^tm1Pjb)	abnormal macrophage physiology	J:88443
	autoimmune arthritis	J:88443
	blood vessel inflammation	J:214114
	decreased lymphocyte cell number	J:214114
	increased granulocyte number	J:214114
	increased monocyte cell number	J:214114
	increased neutrophil cell number	J:214114
\Zfp36^tm2.1Pjb/\Zfp36^tm2.1Pjb (involves: C57BL/6)	decreased inflammatory response	J:229078
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:229078
	decreased susceptibility to induced arthritis	J:229078
\Zfp36^tm4.1Pjb/\Zfp36^tm4.1Pjb \Lyz2^tm1(cre)Ifo/\Lyz2⁺ (involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)	alveolitis	J:188677
	autoimmune arthritis	J:188677
	enlarged lymph nodes	J:188677
	enlarged spleen	J:188677
	increased circulating tumor necrosis factor level	J:188677
	increased inflammatory response	J:188677
	increased spleen weight	J:188677
	increased susceptibility to endotoxin shock	J:188677
\Zfp36l1^tm1.1Tnr/\Zfp36l1^tm1.1Tnr \Zfp36l2^tm1.1Tnr/\Zfp36l2^tm1.1Tnr \Tg(CD2-icre)4Kio/0 (involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL)	abnormal thymus development	J:162388
	enlarged lymph nodes	J:162388
	enlarged spleen	J:162388
	increased T cell derived lymphoma incidence	J:162388
	thymus atrophy	J:162388
\Zfp36l2^tm2Pjb/\Zfp36l2^tm2Pjb (involves: 129S7/SvEvBrd * C57BL/6)	decreased leukocyte cell number	J:152911
	decreased neutrophil cell number	J:152911
	decreased splenocyte number	J:152911
\Zfp91^em1(IMPC)Tcp/\Zfp91⁺ (C57BL/6N-Zfp91^em1(IMPC)Tcp/Tcp)	enlarged lymph nodes	J:211773
\Zfp106^{tm1a(KOMP)Wtsi}/\Zfp106^{tm1a(KOMP)Wtsi} (involves: C57BL/6Brd * C57BL/6Dnk * C57BL/6N)	microgliosis	J:229162
\Zfp119a^{tm1b(EUCOMM)Hmgu}/\Zfp119a^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Zfp119a^{tm1b(EUCOMM)Hmgu}/Ieg)	increased leukocyte cell number	J:211773
\Zfp131^tm1.1Mytk/\Zfp131^tm1.1Mytk \Tg(Cd4-cre)1Cwi/0 (involves: C57BL/6 * C57BL/6N * DBA/2)	abnormal T cell subpopulation ratio	J:271921
	abnormal thymocyte activation	J:271921
	decreased CD4-positive, alpha-beta T cell number	J:271921
	decreased CD8-positive, alpha-beta T cell number	J:271921
	decreased T cell number	J:271921
	decreased T cell proliferation	J:271921
	immune system phenotype	J:271921
\Zfp131^tm1.1Mytk/\Zfp131^tm1.2Mytk \Tg(Lck-cre)1Jtak/0 (involves: C57BL/6N * FVB/N)	abnormal double-negative T cell morphology	J:271921
	abnormal T cell differentiation	J:271921
	arrested T cell differentiation	J:271921
	decreased CD4-positive, alpha-beta T cell number	J:271921
	decreased CD8-positive, alpha-beta T cell number	J:271921
	decreased DN2 thymocyte number	J:271921
	decreased DN3 thymocyte number	J:271921
	decreased DN4 thymocyte number	J:271921
	decreased double-negative T cell number	J:271921
	decreased double-positive T cell number	J:271921
	decreased T cell proliferation	J:271921
	decreased thymocyte number	J:271921
\Zfp148^tm1.1Jmer/\Zfp148^tm1.1Jmer \Tg(Vil1-cre)997Gum/0 (involves: C57BL/6 * C57BL/6J * SJL)	increased inflammatory response	J:198847
	increased susceptibility to bacterial infection	J:198847
	increased susceptibility to bacterial infection induced morbidity/mortality	J:198847
\Zfp148^tm1Djl/\Zfp148^tm1Djl (involves: 129)	increased susceptibility to induced colitis	J:107441
\Zfp160^{tm1b(EUCOMM)Wtsi}/\Zfp160^{tm1b(EUCOMM)Wtsi} (C57BL/6N-Zfp160^{tm1b(EUCOMM)Wtsi}/BayMmucd)	decreased spleen weight	J:211773
\Zfp207^{tm1b(EUCOMM)Hmgu}/\Zfp207⁺ (C57BL/6N-Zfp207^{tm1b(EUCOMM)Hmgu}/H)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Zfp236^em1(IMPC)Mbp/\Zfp236⁺ (C57BL/6NCrl-Zfp236^em1(IMPC)Mbp/Mmucd)	abnormal spleen morphology	J:211773
	enlarged spleen	J:211773
\Zfp260^{tm1b(NCOM)Mfgc}/\Zfp260⁺ (C57BL/6N-Zfp260^{tm1b(NCOM)Mfgc}/Tcp)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Zfp281^em1(IMPC)Mbp/\Zfp281⁺ (C57BL/6N-Zfp281^em1(IMPC)Mbp/MbpMmucd)	abnormal spleen morphology	J:211773
	small spleen	J:211773
\Zfp292^em1Zfa/\Zfp292^em1Zfa (involves: C57BL/6)	increased susceptibility to bacterial infection	J:259392
\Zfp292^em1Zfa/\Zfp292^em1Zfa (involves: C57BL/6)	increased susceptibility to bacterial infection induced morbidity/mortality	J:259392
\Zfp318^m1Anu/\Zfp318⁺ (C57BL/6JAnu-Zfp318^m1Anu)	decreased IgD level	J:207375
\Zfp318^m1Anu/\Zfp318⁺ (C57BL/6JAnu-Zfp318^m1Anu)	increased IgM level	J:207375
\Zfp318^m1Anu/\Zfp318^m1Anu (C57BL/6JAnu-Zfp318^m1Anu)	abnormal B cell number	J:104190
	abnormal follicular B cell physiology	J:207375
	abnormal marginal zone B cell physiology	J:207375
	decreased IgD level	J:207375, J:104190
	increased IgM level	J:207375, J:104190
	increased mature B cell number	J:207375
\Zfp318^M1Btlr/\Zfp318⁺ (C57BL/6J-Zfp318^M1Btlr)	decreased IgD level	J:218965
\Zfp318^M1Btlr/\Zfp318^M1Btlr (C57BL/6J-Zfp318^M1Btlr)	decreased IgD level	J:218965
\Zfp318^tm1.1Jhws/\Zfp318^tm1.1Jhws \Commd10^{Tg(Vav1-icre)A2Kio}/\Commd10⁺ (B6.Cg-Zfp318^tm1.1Jhws Tg^Vav1-creA2Kio)	decreased IgD level	J:215815
	decreased transitional stage T2 B cell number	J:215815
	increased IgM level	J:215815
\Zfp318^tm1Hhag/\Zfp318^tm1Hhag (involves: 129 * C57BL/6)	decreased IgD level	J:207375
\Zfp318^tm1Hhag/\Zfp318^tm1Hhag (involves: 129 * C57BL/6)	increased IgM level	J:207375
\Zfp335^blt/\Zfp335^blt (involves: C57BL/6)	abnormal CD4-positive T cell differentiation	J:214793
	abnormal CD8-positive, alpha-beta T cell differentiation	J:214793
	abnormal T cell differentiation	J:214793
	decreased B cell number	J:214793
	decreased CD4-positive, alpha-beta memory T cell number	J:214793
	decreased CD4-positive, alpha-beta T cell number	J:214793
	decreased CD8-positive, alpha-beta memory T cell number	J:214793
	decreased CD8-positive, alpha-beta T cell number	J:214793
	decreased NK T cell number	J:214793
	decreased regulatory T cell number	J:214793
	decreased single-positive T cell number	J:214793
\Zfp354a^em1(IMPC)Mbp/\Zfp354a^em1(IMPC)Mbp (C57BL/6NCrl-Zfp354a^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Zfp366^b2b2834Clo/\Zfp366^b2b2834Clo (C57BL/6J-Zfp366^b2b2834Clo)	thymus hypoplasia	J:175213
\Zfp398^em1(IMPC)Mbp/\Zfp398^em1(IMPC)Mbp (C57BL/6NCrl-Zfp398^em1(IMPC)Mbp/Mmucd)	increased basophil cell number	J:211773
\Zfp420^{tm1b(EUCOMM)Hmgu}/\Zfp420^{tm1b(EUCOMM)Hmgu} (C57BL/6N-Zfp420^{tm1b(EUCOMM)Hmgu}/Bay)	increased lymphocyte cell number	J:211773
\Zfp467^{tm1.1(KOMP)Vlcg}/\Zfp467^{tm1.1(KOMP)Vlcg} (B6(Cg)-Zfp467^{tm1.1(KOMP)Vlcg})	abnormal osteoclast physiology	J:302865
	increased osteoclast cell number	J:302865
\Zfp469^em1(IMPC)Mbp/\Zfp469^em1(IMPC)Mbp (C57BL/6N-Zfp469^em1(IMPC)Mbp/MbpMmucd)	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
\Zfp474^{em1(IMPC)Ccpcz}/\Zfp474^{em1(IMPC)Ccpcz} (C57BL/6N-Zfp474^{em1(IMPC)Ccpcz}/Ccpcz)	decreased lymphocyte cell number	J:211773
	increased eosinophil cell number	J:211773
	increased neutrophil cell number	J:211773
\Zfp488^em1(IMPC)Bay/\Zfp488^em1(IMPC)Bay (C57BL/6N-Zfp488^em1(IMPC)Bay/Bay)	abnormal spleen morphology	J:211773
\Zfp503^em1(IMPC)Mbp/\Zfp503⁺ (C57BL/6N-Zfp503^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
	increased basophil cell number	J:211773
\Zfp513^em1(IMPC)J/\Zfp513^em1(IMPC)J (C57BL/6NJ-Zfp513^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Zfp521^tm1Nohk/\Zfp521^tm1Nohk (B6J.Cg-Zfp521^tm1Nohk)	decreased spleen weight	J:214267
\Zfp521^tm1Nohk/\Zfp521^tm1Nohk (B6J.Cg-Zfp521^tm1Nohk)	decreased thymus weight	J:214267
\Zfp574^em1Btlr/\Zfp574^em1Btlr (C57BL/6J-Zfp574^em1Btlr)	abnormal B cell physiology	J:354285
	abnormal class switch recombination	J:354285
	abnormal humoral immune response	J:354285
	decreased B cell number	J:354285
	decreased B cell proliferation	J:354285
	decreased B-1 B cell number	J:354285
	decreased IgA level	J:354285
	decreased IgG1 level	J:354285
	decreased IgG2a level	J:354285
	decreased IgG2b level	J:354285
	decreased IgG level	J:354285
	decreased IgM level	J:354285
	decreased immunoglobulin level	J:354285
	decreased leukocyte cell number	J:354285
	decreased lymphocyte cell number	J:354285
	decreased monocyte cell number	J:354285
	decreased neutrophil cell number	J:354285
	decreased T cell number	J:354285
	increased B cell apoptosis	J:354285
\Zfp574^em1Btlr/\Zfp574^em1Btlr \Tg(IghMyc)22Bri/0 (B6.Cg-Zfp574^em1Btlr Tg(IghMyc)22Bri)	decreased pre-B cell number	J:354285
\Zfp574^em3Btlr/\Zfp574^em3Btlr \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/\Ndor1⁺ (B6.Cg-Ndor1^{Tg(UBC-cre/ERT2)1Ejb} Zfp574^em3Btlr)	decreased B cell number	J:354285
\Zfp574^em3Btlr/\Zfp574^em3Btlr \Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/\Ndor1⁺ \Tg(IghMyc)22Bri/0 (B6.Cg-Ndor1^{Tg(UBC-cre/ERT2)1Ejb} Zfp574^em3Btlr Tg(IghMyc)22Bri)	decreased B cell number	J:354285
\Zfp574^m1Btlr/\Zfp574^m1Btlr (C57BL/6J-Zfp574^m1Btlr)	abnormal humoral immune response	J:354285
	abnormal T cell physiology	J:354285
	decreased B cell number	J:354285
\Zfp593^em1(IMPC)J/\Zfp593^em1(IMPC)J (C57BL/6NJ-Zfp593^em1(IMPC)J/Mmjax)	decreased leukocyte cell number	J:211773
\Zfp595^{tm1b(KOMP)Wtsi}/\Zfp595^{tm1b(KOMP)Wtsi} (C57BL/6N-Zfp595^{tm1b(KOMP)Wtsi}/Bay)	decreased eosinophil cell number	J:211773
	decreased leukocyte cell number	J:211773
	decreased lymphocyte cell number	J:211773
\Zfp616^{tm1b(KOMP)Wtsi}/\Zfp616^{tm1b(KOMP)Wtsi} (C57BL/6N-Zfp616^{tm1b(KOMP)Wtsi}/Wtsi)	increased KLRG1-positive T-helper cell number	J:211773
\Zfp629^em1(IMPC)Tcp/\Zfp629^em1(IMPC)Tcp (C57BL/6N-Zfp629^em1(IMPC)Tcp/Tcp)	small spleen	J:211773
\Zfp638^em1(IMPC)J/\Zfp638⁺ (C57BL/6NJ-Zfp638^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Zfp639^tm1.2Jaty/\Zfp639^tm1.2Jaty (involves: 129 * BALB/cJ * C57BL/6 * SJL)	decreased susceptibility to Retroviridae infection	J:305874
	immune system phenotype	J:305874
\Zfp644^m1Anu/\Zfp644^m1Anu (C57BL/6NCrlAnu-Zfp644^m1Anu)	immune system phenotype	J:104190
\Zfp683^{Gt(OST314703)Lex}/\Zfp683^{Gt(OST314703)Lex} (B6.129S5-Zfp683^{Gt(OST314703)Lex})	abnormal NK T cell morphology	J:187727
	abnormal susceptibility to infection	J:187727
	decreased NK T cell number	J:187727
	immune system phenotype	J:187727
	increased interferon-gamma secretion	J:187727
\Zfp760^{tm1a(EUCOMM)Hmgu}/\Zfp760⁺ (C57BL/6N-Zfp760^{tm1a(EUCOMM)Hmgu}/Ieg)	decreased IgE level	J:165965
\Zfp871^{tm1a(EUCOMM)Wtsi}/\Zfp871⁺ (C57BL/6N-Zfp871^{tm1a(EUCOMM)Wtsi}/BayMmucd)	liver inflammation	J:317166
	spleen hyperplasia	J:317166
	thymus hyperplasia	J:317166
\Zfp950^{Gt(ROSA)76Sor}/\Zfp950^{Gt(ROSA)76Sor} (involves: 129S4/SvJaeSor)	kidney inflammation	J:117491
\Zfpm1^tm1.1Esv/\Zfpm1^tm1.1Esv (involves: 129S6/SvEvTac * C57BL/6)	abnormal spleen morphology	J:156475
	increased granulocyte number	J:156475
	increased neutrophil cell number	J:156475
	increased spleen red pulp amount	J:156475
	increased spleen weight	J:156475
\Zfpm1^tm1.1Geab/\Zfpm1^tm1.1Geab (Not Specified)	abnormal circulating chemokine level	J:162629
	decreased spleen white pulp amount	J:156393
	enlarged spleen	J:156393
	increased monocyte cell number	J:156393
	increased neutrophil cell number	J:156393
	increased spleen weight	J:156393
	spleen hypoplasia	J:156393
\Zftraf1^em1(IMPC)H/\Zftraf1^em1(IMPC)H (C57BL/6NTac-Zftraf1^em1(IMPC)H/H)	decreased eosinophil cell number	J:211773
\Zfx^tm1.1Reiz/Y \Tg(Mx1-cre)1Cgn/0 (involves: 129S6/SvEvTac * C57BL/6 * CBA)	decreased lymphocyte cell number	J:149654
\Zfx^tm1.1Reiz/Y \Tg(Tek-cre)12Flv/0 (involves: 129S6/SvEvTac * C3H * C57BL/6)	decreased mature B cell number	J:149654
	decreased T cell number	J:149654
\Zfyve1^em1Hbsh/\Zfyve1^em1Hbsh (C57BL/6J-Zfyve1^em1Hbsh)	decreased susceptibility to viral infection	J:292942
\Zfyve1^em1Hbsh/\Zfyve1^em1Hbsh (C57BL/6J-Zfyve1^em1Hbsh)	decreased susceptibility to viral infection induced morbidity/mortality	J:292942
\Zfyve16^{tm2a(KOMP)Wtsi}/\Zfyve16^{tm2a(KOMP)Wtsi} (C57BL/6N-Zfyve16^{tm2a(KOMP)Wtsi})	decreased B cell number	J:302014
	decreased B cell proliferation	J:302014
	increased T cell number	J:302014
\Zg16^tm1Lex/\Zg16^tm1Lex (B6.129S-Zg16^tm1Lex)	increased circulating interferon-gamma level	J:239095
	increased circulating interleukin-6 level	J:239095
	increased susceptibility to bacterial infection	J:239095
\Zic2^iso/\Zic2^iso (involves: C3H/HeH * C57BL/6)	abnormal spleen morphology	J:268103
	abnormal spleen size	J:268103
	absent spleen	J:268103
\Zic3^tm1Bca/Y (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:75951
\Zic3^tm1Bca/\Zic3⁺ (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:75951
\Zic3^tm1Bca/\Zic3^tm1Bca (involves: 129S7/SvEvBrd * C57BL/6)	spleen hypoplasia	J:75951
\Zkscan3^tm1.2Itl/\Zkscan3^tm1.2Itl (B6.Cg-Zkscan3^tm1.2Itl)	abnormal response to infection	J:318724
\Zkscan7^em1(IMPC)Mbp/\Zkscan7^em1(IMPC)Mbp (C57BL/6N-Zkscan7^em1(IMPC)Mbp/MbpMmucd)	abnormal lymph node morphology	J:211773
	abnormal spleen morphology	J:211773
	enlarged lymph nodes	J:211773
	enlarged spleen	J:211773
\Zmpste24^tm1Otin/\Zmpste24^tm1Otin (involves: 129P2/Ola * C57BL/6)	abnormal thymus corticomedullary boundary morphology	J:76209
	thymus hypoplasia	J:76209
\Zmym2^em1(IMPC)J/\Zmym2⁺ (C57BL/6NJ-Zmym2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Zmynd10^{tm1(KOMP)Wtsi}/\Zmynd10^{tm1(KOMP)Wtsi} (involves: C57BL/6J * C57BL/6N)	lung inflammation	J:261915
\Zmynd11^{em1(IMPC)Wtsi}/\Zmynd11^{em1(IMPC)Wtsi} (C57BL/6N-Zmynd11^{em1(IMPC)Wtsi}/WtsiIeg)	blood in lymph vessels	J:239583
\Zmynd12^em1(IMPC)J/\Zmynd12^em1(IMPC)J (C57BL/6NJ-Zmynd12^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Znfx1^em1Xua/\Znfx1^em1Xua (involves: C57BL/6J)	abnormal macrophage physiology	J:345967
	abnormal response to infection	J:282875
	decreased circulating interferon-gamma level	J:345967
	decreased circulating interleukin-12 level	J:345967
	decreased circulating tumor necrosis factor level	J:345967
	decreased interferon-alpha secretion	J:282875
	decreased interferon-beta secretion	J:282875
	decreased macrophage cytokine production	J:282875
	impaired macrophage phagocytosis	J:345967
	increased susceptibility to bacterial infection	J:345967
	increased susceptibility to Riboviria infection	J:282875
\Znhit2^em1(IMPC)J/\Znhit2⁺ (C57BL/6NJ-Znhit2^em1(IMPC)J/Mmjax)	increased leukocyte cell number	J:211773
\Znhit6^em1(IMPC)Mbp/\Znhit6⁺ (C57BL/6N-Znhit6^em1(IMPC)Mbp/Ucd)	abnormal lymph node morphology	J:211773
	enlarged lymph nodes	J:211773
\Zp3r^{em1(IMPC)Ccpcz}/\Zp3r^{em1(IMPC)Ccpcz} (C57BL/6NCrl-Zp3r^{em1(IMPC)Ccpcz}/Ccpcz)	abnormal spleen morphology	J:211773
\Zranb1^em1Shios/\Zranb1^em1Shios (involves: C57BL/6)	increased susceptibility to colitis induced morbidity/mortality	J:333468
\Zranb1^{tm1c(EUCOMM)Hmgu}/\Zranb1^{tm1c(EUCOMM)Hmgu} \Tg(Cd4-cre)1Cwi/0 (involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)	immune system phenotype	J:235701
\Zranb1^{tm1c(EUCOMM)Hmgu}/\Zranb1^{tm1c(EUCOMM)Hmgu} \Tg(Itgax-cre)1-1Reiz/0 (involves: 129S4/SvJaeSor * C57BL/6N * CBA)	abnormal dendritic cell physiology	J:235701
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:235701
	decreased T helper 1 cell number	J:235701
	decreased T-helper 17 cell number	J:235701
	immune system phenotype	J:235701
\Zranb1^{tm1d(EUCOMM)Hmgu}/\Zranb1^{tm1d(EUCOMM)Hmgu} (involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)	decreased CD4-positive, alpha-beta T cell number	J:235701
	decreased circulating interferon-gamma level	J:235701
	decreased circulating interleukin-17 level	J:235701
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:235701
	decreased T helper 1 cell number	J:235701
	decreased T-helper 17 cell number	J:235701
	immune system phenotype	J:235701
\Zrsr2^em1(IMPC)Mbp/Y (C57BL/6N-Zrsr2^em1(IMPC)Mbp/MbpMmucd)	decreased lymphocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Zscan10^{Gt(285B6)1.1Cmhd}/\Zscan10^{Gt(285B6)1.1Cmhd} (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)	abnormal IgG level	J:221010
	abnormal T cell subpopulation ratio	J:221010
	decreased spleen weight	J:221010
	decreased T cell number	J:221010
	increased B cell number	J:221010
	increased CD4-positive, CD25-positive, alpha-beta regulatory T cell number	J:221010
	increased IgG1 level	J:221010
	increased IgG2b level	J:221010
	increased mature NK cell number	J:221010
\Zswim1^{tm1b(KOMP)Mbp}/\Zswim1^{tm1b(KOMP)Mbp} (C57BL/6N-Zswim1^{tm1b(KOMP)Mbp}/Nju)	decreased lymphocyte cell number	J:211773
	decreased monocyte cell number	J:211773
	increased basophil cell number	J:211773
	increased eosinophil cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased monocyte cell number	J:211773
	increased neutrophil cell number	J:211773
\Zup1^em1Lisi/\Zup1^em1Lisi (involves: C57BL/6J)	abnormal macrophage physiology	J:350802
	increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality	J:350802
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:350802

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 03/25/2025 MGI 6.24